A2
aortic second sound
ABGs
arterial blood gases
ACE
angiotensin converting 
enzyme
AF
atrial fibrillation
AIDS
acquired immunodeficiency 
syndrome
ALS
amyotrophic lateral 
sclerosis
ANA
antinuclear antibody
ARDS
adult respiratory distress 
syndrome
bid
two times daily
biw
twice a week
bp
blood pressure
BUN
blood urea nitrogen
CAPD
continuous ambulatory 
peritoneal dialysis
CBC
complete blood count
CF
complement fixation
CHF
congestive heart failure
CLL
chronic lymphocytic 
leukemia
CML
chronic myeloid 
leukemia
CMV
cytomegalovirus
CNS
central nervous system
CPK
creatine phosphokinase
CSF
cerebrospinal fluid
CT
computed tomography
CVP
central venous pressure
CXR
chest x-ray
DIC
disseminated intravascular 
coagulation
DVT
deep venous thrombosis
Dx
diagnosis
EBV
Epstein-Barr virus
ECG
electrocardiogram
EEG
electroencephalogram
ELISA enzyme-linked
immunosorbent assay
EMG
electromyogram
ENT
ear, nose, and throat
EOM
extraocular movement
ESR
erythrocyte sedimentation 
rate
FDA
US Food and Drug 
Administration
FEV1
forced expiratory volume 
in first second
GRF
glomerular filtration rate
GI
gastrointestinal
G6PD
glucose-6-phosphate
dehydrogenase
Hb
hemoglobin
Hct
hematocrit
HDL
high-density lipoprotein
HIV
human immunodeficiency 
virus
hs
at bedtime
HSV
herpes simplex virus
Hx
history
ICU
intensive care unit
IFN
interferon
Ig
immunoglobulin
IL
interleukin
IM
intramuscular
IV
intravenous
IVC
inferior vena cava
IVP
intravenous pyelogram
GLOSSARY
18th Edition
TM
M A N U A L  O F
M E D I C I N E
EDITORS
Dan L. Longo, MD
Professor of Medicine, Harvard Medical School; 
Senior Physician, Brigham and Women’s Hospital; 
Deputy Editor, New England Journal of Medicine, 
Boston, Massachusetts; Adjunct Investigator, 
National Institute on Aging, National Institutes of Health, 
Bethesda, Maryland
Anthony S. Fauci, MD, ScD(HON)
Chief, Laboratory of Immunoregulation; 
Director, National Institute of Allergy and Infectious Diseases, 
National Institutes of Health, Bethesda, Maryland
Dennis L. Kasper, MD, MA(HON)
William Ellery Channing Professor of Medicine, Professor of 
Microbiology and Molecular Genetics, Harvard Medical School; 
Director, Channing Laboratory, Department of Medicine, Brigham 
and Women’s Hospital, Boston, Massachusetts
Stephen L. Hauser, MD
Robert A. Fishman Distinguished Professor and Chairman, 
Department of Neurology, University of California, San Francisco, 
San Francisco, California
J. Larry Jameson, MD, PhD
Robert G. Dunlop Professor of Medicine; Dean, University 
of Pennsylvania Perelman School of Medicine; Executive 
Vice-President, University of Pennsylvania Health System, 
Philadelphia, Pennsylvania
Joseph Loscalzo, MD, PhD
Hersey Professor of the Theory and Practice of Medicine, Harvard 
Medical School; Chairman, Department of Medicine; 
Physician-in-Chief, Brigham and Women’s Hospital, Boston, 
Massachusetts
EDITORS
Dan L. Longo, MD
Anthony S. Fauci, MD
Dennis L. Kasper, MD
Stephen L. Hauser, MD
J. Larry Jameson, MD, PhD
Joseph Loscalzo, MD, PhD
New York  Chicago  San Francisco  Lisbon  London  Madrid  Mexico City  
Milan  New Delhi  San Juan  Seoul  Singapore  Sydney  Toronto
18th Edition
TM
M A N U A L  O F
M E D I C I N E
Copyright © 2013, 2009, 2005, 2002, 1998, 1995, 1991, 1988 by The McGraw-Hill
Companies, Inc. All rights reserved. Except as permitted under the United States
Copyright Act of 1976, no part of this publication may be reproduced or distributed 
in any form or by any means, or stored in a database or retrieval system, without the 
prior written permission of the publisher.
ISBN: 978-0-07-180830-9
MHID: 0-07-180830-2
The material in this eBook also appears in the print version of this title: ISBN: 978-0-07-174519-2,    
MHID: 0-07-174519-X.
All trademarks are trademarks of their respective owners. Rather than put a 
trademark symbol after every occurrence of a trademarked name, we use names in an 
editorial fashion only, and to the beneﬁ t of the trademark owner, with no intention of 
infringement of the trademark. Where such designations appear in this book, they 
have been printed with initial caps.
McGraw-Hill eBooks are available at special quantity discounts to use as 
premiums and sales promotions, or for use in corporate training programs. To contact a 
representative please e-mail us at bulksales@mcgraw-hill.com.
NOTE: Dr. Fauci’s work as editor and author was performed outside the scope of his 
employment as a U.S. government employee. This work represents his personal and 
professional views and not necessarily those of the U.S. government.
This book was set in Minion Pro by Cenveo Publisher Services. The editors were 
James F. Shanahan and Kim J. Davis. The production supervisor was Catherine H. 
Saggese; project management was provided by Vastavikta Sharma, Cenveo Publisher 
Services. The designer was Alan Barnett; the cover designer was Anthony Landi. RR 
Donnelly was printer and binder.
International Edition ISBN 978-0-07-179290-5; MHID 0-07-179290-2.
Copyright © 2013. Exclusive rights by The McGraw-Hill Companies, Inc., for 
manufacture and export. This book cannot be re-exported from the country to which 
it is consigned by McGraw-Hill. The International Edition is not available in North 
America.
TERMS OF USE
This is a copyrighted work and The McGraw-Hill Companies, Inc. (“McGraw-Hill”) 
and its licensors reserve all rights in and to the work. Use of this work is subject 
to these terms. Except as permitted under the Copyright Act of 1976 and the right 
to store and retrieve one copy of the work, you may not decompile, disassemble, 
reverse engineer, reproduce, modify, create derivative works based upon, transmit, 
distribute, disseminate, sell, publish or sublicense the work or any part of it without 
McGraw-Hill’s prior consent. You may use the work for your own noncommercial 
and personal use; any other use of the work is strictly prohibited. Your right to use the 
work may be terminated if you fail to comply with these terms.
THE WORK IS PROVIDED “AS IS.” McGRAW-HILL AND ITS LICENSORS 
MAKE NO GUARANTEES OR WARRANTIES AS TO THE ACCURACY, 
ADEQUACY OR COMPLETENESS OF OR RESULTS TO BE OBTAINED 
FROM USING THE WORK, INCLUDING ANY INFORMATION THAT CAN BE 
ACCESSED THROUGH THE WORK VIA HYPERLINK OR OTHERWISE, 
AND EXPRESSLY DISCLAIM ANY WARRANTY, EXPRESS OR IMPLIED, 
INCLUDING BUT NOT LIMITED TO IMPLIED WARRANTIES OF 
MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. 
McGraw-Hill and its licensors do not warrant or guarantee that the functions contained 
in the work will meet your requirements or that its operation will be uninterrupted or 
error free. Neither McGraw-Hill nor its licensors shall be liable to you or anyone 
else for any inaccuracy, error or omission, regardless of cause, in the work or for any 
damages resulting therefrom. McGraw-Hill has no responsibility for the content of any 
information accessed through the work. Under no circumstances shall 
McGraw-Hill and/or its licensors be liable for any indirect, incidental, special, punitive, 
consequential or similar damages that result from the use of or inability to use the 
work, even if any of them has been advised of the possibility of such damages. This 
limitation of liability shall apply to any claim or cause whatsoever whether such 
claim or cause arises in contract, tort or otherwise.
v
Contributors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . xiii
Preface . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . xv
Acknowledgments . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . xvii
SECTION 1
Care of the Hospitalized Patient
1 Initial Evaluation and Admission Orders for 
the General Medicine Patient . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1
2 Electrolytes/Acid-Base Balance . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3
3 Diagnostic Imaging in Internal Medicine  . . . . . . . . . . . . . . . . . . . . . . 26
4 Procedures Commonly Performed by Internists . . . . . . . . . . . . . . . . . 30
5 Principles of Critical Care Medicine . . . . . . . . . . . . . . . . . . . . . . . . . . 35
6 Pain and Its Management  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 40
7 Assessment of Nutritional Status . . . . . . . . . . . . . . . . . . . . . . . . . . . . 46
8 Enteral and Parenteral Nutrition . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 49
9 Transfusion and Pheresis Therapy . . . . . . . . . . . . . . . . . . . . . . . . . . . 51
10 Palliative and End-of-Life Care . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 54
SECTION 2
Medical Emergencies
11 Cardiovascular Collapse and Sudden Death . . . . . . . . . . . . . . . . . . . . 65
12 Shock . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 69
13 Sepsis and Septic Shock . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 74
14 Acute Pulmonary Edema  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 78
15 Acute Respiratory Distress Syndrome  . . . . . . . . . . . . . . . . . . . . . . . . 80
16 Respiratory Failure . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 83
17 Confusion, Stupor, and Coma . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 86
18 Stroke  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 93
19 Subarachnoid Hemorrhage . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 103
20 Increased Intracranial Pressure and Head Trauma . . . . . . . . . . . . . . 105
21 Spinal Cord Compression . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 112
22 Hypoxic-Ischemic Encephalopathy . . . . . . . . . . . . . . . . . . . . . . . . . . 114
23 Status Epilepticus  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 116
CONTENTS
vi
CONTENTS
24 Diabetic Ketoacidosis and Hyperosmolar Coma . . . . . . . . . . . . . . . . 118
25 Hypoglycemia . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 122
26 Infectious Disease Emergencies . . . . . . . . . . . . . . . . . . . . . . . . . . . . 125
27 Oncologic Emergencies . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 133
28 Anaphylaxis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 138
29 Bites, Venoms, Stings, and Marine Poisonings  . . . . . . . . . . . . . . . . . 139
30 Hypothermia and Frostbite . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 151
31 Altitude Illness . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 155
32 Poisoning and Drug Overdose  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 159
33 Bioterrorism . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 191
SECTION 3
Common Patient Presentations
34 Fever, Hyperthermia, and Rash . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 209
35 Generalized Fatigue . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 214
36 Weight Loss . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 218
37 Chest Pain . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 221
38 Palpitations  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 225
39 Dyspnea . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 226
40 Cyanosis  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 229
41 Cough and Hemoptysis  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 231
42 Edema . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 235
43 Abdominal Pain  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 239
44 Nausea, Vomiting, and Indigestion . . . . . . . . . . . . . . . . . . . . . . . . . . 244
45 Dysphagia  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 248
46 Diarrhea, Constipation, and Malabsorption . . . . . . . . . . . . . . . . . . . . 253
47 Gastrointestinal Bleeding . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 261
48 Jaundice and Evaluation of Liver Function . . . . . . . . . . . . . . . . . . . . 266
49 Ascites  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 275
50 Lymphadenopathy and Splenomegaly  . . . . . . . . . . . . . . . . . . . . . . . 278
51 Anemia and Polycythemia  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 283
52 Azotemia and Urinary Abnormalities  . . . . . . . . . . . . . . . . . . . . . . . . 287
53 Pain and Swelling of Joints . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 294
54 Back and Neck Pain . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 298
55 Headache . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 307
CONTENTS
vii
56 Syncope . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 316
57 Dizziness and Vertigo . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 320
58 Acute Visual Loss and Double Vision  . . . . . . . . . . . . . . . . . . . . . . . . 324
59 Weakness and Paralysis  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 328
60 Tremor and Movement Disorders . . . . . . . . . . . . . . . . . . . . . . . . . . . 332
61 Aphasia  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 335
62 Sleep Disorders . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 337
SECTION 4
Ophthalmology and Otolaryngology
63 Common Disorders of Vision and Hearing  . . . . . . . . . . . . . . . . . . . . 343
64 Sinusitis, Pharyngitis, Otitis, and Other 
Upper Respiratory Tract Infections . . . . . . . . . . . . . . . . . . . . . . . . . . 353
SECTION 5
Dermatology
65 General Examination of the Skin  . . . . . . . . . . . . . . . . . . . . . . . . . . . 363
66 Common Skin Conditions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 367
SECTION 6
Hematology and Oncology
67 Examination of Blood Smears and Bone Marrow . . . . . . . . . . . . . . . 375
68 Red Blood Cell Disorders . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 377
69 Leukocytosis and Leukopenia  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 384
70 Bleeding and Thrombotic Disorders . . . . . . . . . . . . . . . . . . . . . . . . . 387
71 Cancer Chemotherapy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 395
72 Myeloid Leukemias, Myelodysplasia, and 
Myeloproliferative Syndromes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 403
73 Lymphoid Malignancies . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 414
74 Skin Cancer . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 428
75 Head and Neck Cancer . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 432
76 Lung Cancer . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 433
77 Breast Cancer  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 441
78 Tumors of the Gastrointestinal Tract  . . . . . . . . . . . . . . . . . . . . . . . . 447
79 Genitourinary Tract Cancer . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 460
80 Gynecologic Cancer . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 464
81 Prostate Hyperplasia and Carcinoma . . . . . . . . . . . . . . . . . . . . . . . . 469
82 Cancer of Unknown Primary Site . . . . . . . . . . . . . . . . . . . . . . . . . . . 473
83 Paraneoplastic Endocrine Syndromes  . . . . . . . . . . . . . . . . . . . . . . . 477
84 Neurologic Paraneoplastic Syndromes . . . . . . . . . . . . . . . . . . . . . . . 480
SECTION 7
Infectious Diseases
85 Diagnosis of Infectious Diseases . . . . . . . . . . . . . . . . . . . . . . . . . . . 485
86 Antibacterial Therapy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 496
87 Health Care–Associated Infections . . . . . . . . . . . . . . . . . . . . . . . . . . 505
88 Infections in the Immunocompromised Host  . . . . . . . . . . . . . . . . . . 511
89 Infective Endocarditis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 521
90 Intraabdominal Infections . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 532
91 Infectious Diarrheas . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 536
92 Sexually Transmitted and Reproductive Tract Infections . . . . . . . . . . 551
93 Infections of the Skin, Soft Tissues, Joints, and Bones . . . . . . . . . . . 569
94 Pneumococcal Infections . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 580
95 Staphylococcal Infections . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 584
96 Streptococcal/Enterococcal Infections, Diphtheria, and 
Other Infections Caused by Corynebacteria and 
Related Species . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 592
97 Meningococcal and Listerial Infections  . . . . . . . . . . . . . . . . . . . . . . 603
98 Infections Caused by Haemophilus, Bordetella, 
Moraxella, and HACEK Group Organisms . . . . . . . . . . . . . . . . . . . . . 608
99 Diseases Caused by Gram-Negative Enteric Bacteria, 
Pseudomonas, and Legionella . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 615
100 Infections Caused by Miscellaneous Gram-Negative Bacilli . . . . . . . 627
101 Anaerobic Infections  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 635
102 Nocardiosis and Actinomycosis . . . . . . . . . . . . . . . . . . . . . . . . . . . . 644
103 Tuberculosis and Other Mycobacterial Infections . . . . . . . . . . . . . . . 649
104 Lyme Disease and Other Nonsyphilitic Spirochetal Infections  . . . . . 663
105 Rickettsial Diseases . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 670
106 Mycoplasma Infections  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 680
107 Chlamydial Infections . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 681
108 Herpesvirus Infections . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 685
109 Cytomegalovirus and Epstein-Barr Virus Infections  . . . . . . . . . . . . . 694
110 Influenza and Other Viral Respiratory Diseases  . . . . . . . . . . . . . . . . 699
viii
CONTENTS
111 Rubeola, Rubella, Mumps, and Parvovirus Infections . . . . . . . . . . . . 708
112 Enteroviral Infections . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 714
113 Insect- and Animal-Borne Viral Infections  . . . . . . . . . . . . . . . . . . . . 718
114 HIV Infection and AIDS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 728
115 Fungal Infections . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 744
116 Pneumocystis Infections  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 759
117 Protozoal Infections . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 763
118 Helminthic Infections and Ectoparasite Infestations . . . . . . . . . . . . . 778
SECTION 8
Cardiology
119 Physical Examination of the Heart . . . . . . . . . . . . . . . . . . . . . . . . . . 795
120 Electrocardiography . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 800
121 Noninvasive Examination of the Heart . . . . . . . . . . . . . . . . . . . . . . . 805
122 Congenital Heart Disease in the Adult  . . . . . . . . . . . . . . . . . . . . . . . 811
123 Valvular Heart Disease . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 815
124 Cardiomyopathies and Myocarditis  . . . . . . . . . . . . . . . . . . . . . . . . . 822
125 Pericardial Disease . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 828
126 Hypertension  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 834
127 Metabolic Syndrome  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 842
128 ST-Segment Elevation Myocardial Infarction (STEMI) . . . . . . . . . . . . 844
129 Unstable Angina and Non-ST-Elevation Myocardial Infarction  . . . . . 855
130 Chronic Stable Angina  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 858
131 Bradyarrhythmias . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 864
132 Tachyarrhythmias . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 867
133 Heart Failure and Cor Pulmonale . . . . . . . . . . . . . . . . . . . . . . . . . . . 879
134 Diseases of the Aorta . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 887
135 Peripheral Vascular Disease . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 890
136 Pulmonary Hypertension . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 895
SECTION 9
Pulmonology
137 Respiratory Function and Pulmonary Diagnostic Procedures . . . . . . 899
138 Asthma . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 907
139 Environmental Lung Diseases  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 911
140 Chronic Obstructive Pulmonary Disease . . . . . . . . . . . . . . . . . . . . . . 915
CONTENTS
ix
 141 Pneumonia, Bronchiectasis, and Lung Abscess . . . . . . . . . . . . . . . . 920
 142 Pulmonary Thromboembolism and Deep-Vein Thrombosis  . . . . . . . 929
 143 Interstitial Lung Disease  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 933
 144 Diseases of the Pleura and Mediastinum . . . . . . . . . . . . . . . . . . . . . 939
 145 Disorders of Ventilation  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 945
 146 Sleep Apnea . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 947
SECTION 10
Nephrology
147 Approach to the Patient With Renal Disease  . . . . . . . . . . . . . . . . . . 949
 148 Acute Renal Failure  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 954
 149 Chronic Kidney Disease and Uremia  . . . . . . . . . . . . . . . . . . . . . . . . 960
 150 Dialysis  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 963
 151 Renal Transplantation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 965
 152 Glomerular Diseases  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 968
 153 Renal Tubular Disease  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 978
 154 Urinary Tract Infections and Interstitial Cystitis  . . . . . . . . . . . . . . . . 986
 155 Renovascular Disease  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 991
156 Nephrolithiasis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 998
157 Urinary Tract Obstruction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1001
SECTION 11
Gastroenterology
158 Peptic Ulcer and Related Disorders  . . . . . . . . . . . . . . . . . . . . . . . . 1005
159 Inflammatory Bowel Diseases  . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1011
160 Colonic and Anorectal Diseases . . . . . . . . . . . . . . . . . . . . . . . . . . . 1016
161 Cholelithiasis, Cholecystitis, and Cholangitis  . . . . . . . . . . . . . . . . . 1021
162 Pancreatitis  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1026
163 Acute Hepatitis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1032
164 Chronic Hepatitis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1039
165 Cirrhosis and Alcoholic Liver Disease . . . . . . . . . . . . . . . . . . . . . . . 1051
166 Portal Hypertension . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1057
SECTION 12
Allergy, Clinical Immunology, and Rheumatology
167 Diseases of Immediate-Type Hypersensitivity  . . . . . . . . . . . . . . . . 1061
168 Primary Immune Deficiency Diseases  . . . . . . . . . . . . . . . . . . . . . . 1066
x
CONTENTS
169 SLE, RA, and Other Connective Tissue Diseases . . . . . . . . . . . . . . . 1070
170 Vasculitis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1078
171 Ankylosing Spondylitis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1082
172 Psoriatic Arthritis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1085
173 Reactive Arthritis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1087
174 Osteoarthritis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1089
175 Gout, Pseudogout, and Related Diseases . . . . . . . . . . . . . . . . . . . . 1091
176 Other Musculoskeletal Disorders . . . . . . . . . . . . . . . . . . . . . . . . . . 1096
177 Sarcoidosis  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1100
178 Amyloidosis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1102
SECTION 13
Endocrinology and Metabolism
179 Disorders of the Anterior Pituitary and Hypothalamus . . . . . . . . . . 1105
180 Diabetes Insipidus and SIADH  . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1113
181 Thyroid Gland Disorders . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1116
182 Adrenal Gland Disorders . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1126
183 Obesity . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1134
184 Diabetes Mellitus . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1137
185 Disorders of the Male Reproductive System  . . . . . . . . . . . . . . . . . 1144
186 Disorders of the Female Reproductive System  . . . . . . . . . . . . . . . 1150
187 Hypercalcemia and Hypocalcemia . . . . . . . . . . . . . . . . . . . . . . . . . 1159
188 Osteoporosis and Osteomalacia . . . . . . . . . . . . . . . . . . . . . . . . . . . 1167
189 Hypercholesterolemia and Hypertriglyceridemia  . . . . . . . . . . . . . . 1172
190 Hemochromatosis, Porphyrias, and Wilson’s Disease . . . . . . . . . . . 1180
SECTION 14
Neurology
191 The Neurologic Examination . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1187
192 Neuroimaging . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1197
193 Seizures and Epilepsy  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1199
194 Dementia . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1212
195 Parkinson’s Disease . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1221
196 Ataxic Disorders . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1227
197 ALS and Other Motor Neuron Diseases . . . . . . . . . . . . . . . . . . . . . . 1231
198 Autonomic Nervous System Disorders . . . . . . . . . . . . . . . . . . . . . . 1235
CONTENTS
xi
199 Trigeminal Neuralgia, Bell’s Palsy, and Other 
Cranial Nerve Disorders . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1243
200 Spinal Cord Diseases . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1251
201 Tumors of the Nervous System  . . . . . . . . . . . . . . . . . . . . . . . . . . . 1257
202 Multiple Sclerosis (MS)  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1262
203 Acute Meningitis and Encephalitis . . . . . . . . . . . . . . . . . . . . . . . . . 1270
204 Chronic Meningitis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1283
205 Peripheral Neuropathies Including 
Guillain-Barré Syndrome (GBS)  . . . . . . . . . . . . . . . . . . . . . . . . . . . 1292
206 Myasthenia Gravis (MG) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1302
207 Muscle Diseases  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1306
SECTION 15
Psychiatry and Substance Abuse
208 Psychiatric Disorders . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1315
209 Psychiatric Medications . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1324
210 Eating Disorders . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1333
211 Alcoholism . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1336
212 Narcotic Abuse . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1340
SECTION 16
Disease Prevention and Health Maintenance
213 Routine Disease Screening  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1345
214 Immunization and Recommendations for Travelers  . . . . . . . . . . . . 1350
215 Cardiovascular Disease Prevention  . . . . . . . . . . . . . . . . . . . . . . . . 1361
216 Prevention and Early Detection of Cancer  . . . . . . . . . . . . . . . . . . . 1365
217 Smoking Cessation  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1372
218 Women’s Health . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1375
SECTION 17
Adverse Drug Reactions
219 Adverse Drug Reactions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1379
SECTION 18
Laboratory Values
220 Laboratory Values of Clinical Importance . . . . . . . . . . . . . . . . . . . . 1393
Index  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1451
xii
CONTENTS
xiii
ASSOCIATE EDITORS
GERHARD P. BAUMANN, MD
Professor of Medicine Emeritus
Division of Endocrinology, Metabolism, and Molecular Medicine
Northwestern University Feinberg School of Medicine
Chicago, Illinois
S. ANDREW JOSEPHSON, MD
Assistant Professor of Neurology, Director, Neurohospitalist Program
University of California, San Francisco
San Francisco, California
CAROL A. LANGFORD, MD, MHS
Director, Center for Vasculitis Care and Research
Department of Rheumatic and Immunologic Diseases
Cleveland Clinic
Cleveland, Ohio
LEONARD S. LILLY, MD
Professor of Medicine
Harvard Medical School
Chief, Brigham and Women’s/Faulkner Cardiology
Brigham and Women’s Hospital
Boston, Massachusetts
DAVID B. MOUNT, MD
Assistant Professor of Medicine
Harvard Medical School
Associate Physician, Renal Division, Brigham and Women’s Hospital
Staff Physician, Renal Division, VA Boston Healthcare System
Boston, Massachusetts
EDWIN K. SILVERMAN, MD, PhD
Associate Professor of Medicine
Chief, Channing Division of Network Medicine
Department of Medicine, Brigham and Women’s Hospital
Harvard Medical School
Boston, Massachusetts
CONTRIBUTORS
SECTION 00
xiv
Infectious Diseases
NEERAJ K. SURANA, MD, PhD
Instructor in Pediatrics
Harvard Medical School
Assistant in Medicine
Boston Children’s Hospital
Boston, Massachusetts
Numbers indicate the chapters written or co-written by the contributor.
GERHARD P. BAUMANN, MD
1, 3, 4, 7, 8, 24, 25, 30, 32, 35, 36, 127, 179–190, 210, 213, 218, 220
ANTHONY S. FAUCI, MD
28, 33, 48, 49, 53, 65, 66, 114, 161–178
STEPHEN L. HAUSER, MD
6, 17–23, 54–63, 84, 191–209, 211, 212, 217
J. LARRY JAMESON, MD, PhD
1, 3, 4, 7, 8, 24, 25, 30, 32, 35, 36, 127, 179–190, 210, 213, 218, 220
S. ANDREW JOSEPHSON, MD
6, 17–23, 54–63, 84, 191–209, 211, 212, 217
DENNIS L. KASPER, MD
13, 26, 29, 31, 34, 64, 85–113, 115–118, 141, 154, 214
CAROL A. LANGFORD, MD
28, 33, 48, 49, 53, 65, 66, 114, 161–178
LEONARD S. LILLY, MD
11, 12, 14, 37, 38, 40, 119–126, 128–136, 215
DAN L. LONGO, MD
9, 10, 27, 43–47, 50, 51, 67–83, 158–160, 216
JOSEPH LOSCALZO, MD, PhD
5, 11, 12, 14–16, 37–42, 52, 119–126, 128–153, 155–157, 215
DAVID B. MOUNT, MD
42, 52, 147–153, 155–157
EDWIN K. SILVERMAN, MD, PhD
5, 15, 16, 39, 41, 137–146
NEERAJ K. SURANA, MD
13, 26, 29, 31, 34, 64, 85–113, 115–118, 141, 154, 214
xiv
CONTRIBUTORS
xv
Harrison’s Principles of Internal Medicine (HPIM) provides a comprehensive 
body of information important to an understanding of the biological and 
clinical aspects of quality patient care. It remains the premier medical text-
book for students and clinicians. With the rapidly expanding base of medi-
cal knowledge and the time constraints associated with heavy patient-care 
responsibilities in modern health care settings, it is not always possible to 
read a comprehensive account of diseases and their presentations, clinical 
manifestations, and treatments before or even immediately after encoun-
tering the patient. It was for these reasons, among others, that in 1988 the 
Editors first condensed the clinical portions of HPIM into a pocket-sized 
volume, Harrison’s Manual of Medicine. Similar to the prior seven editions, 
this new edition of the Manual, drawn from the 18th edition of HPIM, pres-
ents the key features of the diagnosis, clinical manifestations, and treatment 
of the major diseases that are likely to be encountered on a medical service.
The Editors stress that the Manual should not substitute for in-depth anal-
ysis of the clinical problem, but should serve as a ready source of well-crafted 
and informative summaries that will be useful “on-the-spot” and that will 
prepare the reader for a more in-depth analysis drawn from more extensive 
reading at a later time. The Manual has met with increasing popularity over 
the years; its popularity and value relate in part to its abbreviated format, 
which has proven to be extremely useful for initial diagnosis, brief descrip-
tion of pathogenesis, and outline of management in time-restricted clinical 
settings. The book’s full-color format will increase the speed with which 
readers can locate and use information within its chapters. The Manual has 
been written for easy and seamless reference to the full text of the 18th edition 
of HPIM, and the Editors recommend that the full textbook—or Harrison’s 
Online—be consulted as soon as time allows. As with previous editions, 
this latest edition of the Manual attempts to keep up with the continual and 
sometimes rapid evolution of internal medicine practices. In this regard, 
every chapter has received a close review and has been updated from the 
prior edition, with substantial revisions and new chapters provided where 
appropriate. The format of the book has been further streamlined to reflect 
more use of abbreviated text, with use of numerous tables and graphics to 
help guide understanding and decisions at the point of care. In full recogni-
tion of the important role of digital information delivery in alleviating the 
increasing time demands put on clinicians, the 18th edition of the Manual has 
also been made available in portable format for the smartphone and tablet.
We would like to thank our friend and colleague Eugene Braunwald, MD 
for his many contributions and years of wise advice in shaping the Manual 
and indeed all the publications in the Harrison’s family.
PREFACE
This page intentionally left blank 
The Editors and McGraw-Hill wish to thank their editorial staff whose as-
sistance and patience made this edition come out in a timely manner:
From the Editors’ offices: Pat Duffey; Gregory K. Folkers; Julie B. McCoy; 
Elizabeth Robbins, MD; Marie E. Scurti; Kristine Shontz; and Stephanie 
Tribuna.
From McGraw-Hill: James F. Shanahan, Kim J. Davis, and Catherine H. 
Saggese.
The Editors also wish to acknowledge contributors to past editions of this 
Manual, whose work formed the basis for many of the chapters herein: Eugene 
Braunwald, MD; Joseph B. Martin, MD, PhD; Kurt Isselbacher, MD; Jean 
Wilson, MD; Tamar F. Barlam, MD; Daryl R. Gress, MD; Michael Sneller, MD; 
John W. Engstrom, MD; Kenneth Tyler, MD; Sophia Vinogradov, MD; Dan B. 
Evans, MD; Punit Chadha, MD; Glenn Chertow, MD; and James Woodrow 
Weiss, MD.
ACKNOWLEDGMENTS
xvii
NOTICE
Medicine is an ever-changing science. As new research and clinical 
experience broaden our knowledge, changes in treatment and drug 
therapy are required. The authors and the publisher of this work have 
checked with sources believed to be reliable in their efforts to provide 
information that is complete and generally in accord with the standards 
accepted at the time of publication. However, in view of the possibility 
of human error or changes in medical sciences, neither the authors 
nor the publisher nor any other party who has been involved in the 
preparation or publication of this work warrants that the information 
contained herein is in every respect accurate or complete, and they 
disclaim all responsibility for any errors or omissions or for the results 
obtained from use of the information contained in this work. Readers 
are encouraged to confirm the information contained herein with other 
sources. For example and in particular, readers are advised to check the 
product information sheet included in the package of each drug they 
plan to administer to be certain that the information contained in this 
work is accurate and that changes have not been made in the recom-
mended dose or in the contraindications for administration. This 
recommendation is of particular importance in connection with new 
or infrequently used drugs.
1
CHAPTER 1
Initial Evaluation and Admission Orders 
for the General Medicine Patient
Pts are admitted to the hospital when (1) they present the physician with a 
complex diagnostic challenge that cannot be safely or efficiently performed 
in the outpatient setting; or (2) they are acutely ill and require inpatient 
diagnostic tests, interventions, and treatments. The decision to admit a pt 
includes identifying the optimal clinical service (e.g., medicine, urology, 
neurology), the level of care (observation, general floor, telemetry, ICU), 
and necessary consultants. Admission should always be accompanied by 
clear communication with the pt and family, both to obtain information 
and to outline the anticipated events in the hospital. Pts often have multiple 
physicians, and based on the nature of the clinical problems, they should 
be contacted to procure relevant medical history and to assist with clinical 
care during or after admission. Electronic health records promise to 
facilitate the communication of medical information among physicians, 
hospitals, and other medical care providers.
The scope of illnesses cared for by internists is enormous. During a single 
day on a typical general medical service, it is not unusual for physicians, espe-
cially residents in training, to admit ten pts with ten different diagnoses affect-
ing ten different organ systems. Given this diversity of disease, it is important 
to be systematic and consistent in the approach to any new admission.
Physicians are often concerned about making errors of commission. 
Examples would include prescribing an improper antibiotic for a pt with 
pneumonia or miscalculating the dose of heparin for a pt with new deep 
venous thrombosis (DVT). However, errors of omission are also common 
and can result in pts being denied life-saving interventions. Simple exam-
ples include: not checking a lipid panel for a pt with coronary heart disease, 
not prescribing an angiotensin-converting enzyme (ACE) inhibitor to a 
diabetic with documented albuminuria, or forgetting to give a pt with an 
osteoporotic hip fracture calcium, vitamin D, and an oral bisphosphonate.
Inpatient medicine typically focuses on the diagnosis and treatment of 
acute medical problems. However, most pts have multiple medical problems 
affecting different organ systems, and it is equally important to prevent 
nosocomial complications. Prevention of common hospital complications, 
such as DVT, peptic ulcers, line infections, falls, delirium, and pressure 
ulcers, is an important aspect of the care of all general medicine pts.
A consistent approach to the admission process helps to ensure compre-
hensive and clear orders that can be written and implemented in a timely 
manner. Several mnemonics serve as useful reminders when writing admis-
sion orders. A suggested checklist for admission orders is shown below; it 
SECTION 1
Care of the  Hospitalized Patient
SECTION 1
2
Care of the  Hospitalized Patient
2
includes several interventions targeted to prevent common nosocomial com-
plications. Computerized order entry systems are also useful when designed 
to prompt structured sets of admission orders. However, these should not be 
used to the exclusion of orders tailored for the needs of an individual pt.
Checklist mnemonic: ADMIT VITALS AND PHYSICAL EXAM
• Admit to: service (Medicine, Oncology, ICU); provide status (acute or 
observation).
• Diagnosis: state the working diagnosis prompting this particular 
hospitalization.
• MD: name the attending, resident, intern, student, primary care MD, and 
consultants.
• Isolation requirements: state respiratory or contact isolation and reason 
for order.
• Telemetry: state indications for telemetry and specify monitor parameters.
• Vital signs (VS): frequency of VS; also specify need for pulse oximetry 
and orthostatic VS.
• IV access and IV fluid or TPN orders (Chap. 2).
• Therapists: respiratory, speech, physical, and/or occupational therapy needs.
• Allergies: also specify type of adverse reaction.
• Labs: blood count, chemistries, coagulation tests, type & screen, UA, 
special tests.
• Studies: CT scans (also order contrast), ultrasounds, angiograms, endos-
copies, etc.
• Activity: weight bear/ambulating instructions, fall/seizure precautions 
and restraints.
• Nursing Orders: call intern if (x/y/z), also order I/Os, daily weights, and 
blood glucose.
• Diet: include NPO orders and tube feeding. State whether to resume diet 
after tests.
• Peptic ulcer prevention: proton-pump inhibitor or misoprostol for high-
risk pts.
• Heparin or other modality (warfarin, compression boots, support hose) 
for DVT prophylaxis.
• Yank all Foley catheters and nonessential central lines to prevent iatro-
genic infections.
• Skin care: prevent pressure sores with heel guards, air mattresses, and RN 
wound care.
• Incentive spirometry: prevent atelectasis and hospital-acquired pneumonia.
• Calcium, vitamin D, and bisphosphonates if steroid use, bone fracture, or 
osteoporosis.
• ACE inhibitor and aspirin: use for nearly all pts with coronary disease or 
diabetes.
• Lipid panel: assess and treat all cardiac and vascular pts for hyperlipidemia.
• ECG: for nearly every pt >50 years at the time of admission.
• X-rays: chest x-ray, abdominal series; evaluate central lines and endotra-
cheal tubes.
• Advance directives: Full code or DNR; specify whether to rescind for any 
procedures.
• Medications: be specific with your medication orders.
CHAPTER 2
3
Electrolytes/Acid-Base Balance
3
It may be helpful to remember the medication mnemonic “Stat DRIP” for 
different routes of administration (stat, daily, round-the-clock, IV, and prn 
medications). For the sake of cross-covering colleagues, provide relevant 
prn orders for acetaminophen, diphenhydramine, stool softeners or laxa-
tives, and sleeping pills. Specify any stat medications since routine medica-
tion orders entered as “once daily” may not be dispensed until the following 
day unless ordered as stat or “first dose now.”
CHAPTER 2
Electrolytes/Acid-Base Balance
SODIUM
Disturbances of sodium concentration [Na+] result in most cases from 
abnormalities of H2O homeostasis, which change the relative ratio of 
Na+ to H2O. Disorders of Na+ balance per se are, in contrast, associated 
with changes in extracellular fluid volume, either hypo- or hypervolemia. 
Maintenance of the “effective circulating volume” is achieved in large part 
by changes in urinary sodium excretion, whereas H2O balance is achieved 
by changes in both H2O intake and urinary H2O excretion (Table 2-1). 
Confusion can result from the coexistence of defects in both H2O and Na+ 
balance. For example, a hypovolemic pt may have an appropriately low 
urinary Na+ due to increased renal tubular reabsorption of filtered NaCl; 
a concomitant increase in circulating arginine vasopressin (AVP)—part of 
the defense of effective circulating volume (Table 2-1)—will cause the renal 
retention of ingested H2O and the development of hyponatremia.
� HYPONATREMIA
This is defined as a serum [Na+] <135 mmol/L and is among the most com-
mon electrolyte abnormalities encountered in hospitalized pts. Symptoms 
include nausea, vomiting, confusion, lethargy, and disorientation; if severe 
(<120 mmol/L) and/or abrupt, seizures, central herniation, coma, or death 
may result (see Acute Symptomatic Hyponatremia, below). Hyponatremia is 
almost always the result of an increase in circulating AVP and/or increased 
renal sensitivity to AVP; a notable exception is in the setting of low solute 
intake (“beer potomania”), wherein a markedly reduced urinary solute 
excretion is inadequate to support the excretion of sufficient free H2O. 
The serum [Na+] by itself does not yield diagnostic information regard-
ing total-body Na+ content; hyponatremia is primarily a disorder of H2O 
homeostasis. Pts with hyponatremia are thus categorized diagnostically 
into three groups, depending on their clinical volume status: hypovolemic, 
euvolemic, and hypervolemic hyponatremia (Fig. 2-1). All three forms of 
hyponatremia share an exaggerated, “nonosmotic” increase in circulating 
AVP, in the setting of reduced serum osmolality. Notably, hyponatremia is 
often multifactorial; clinically important nonosmotic stimuli that can cause 
a release of AVP and increase the risk of hyponatremia include drugs, pain, 
nausea, and strenuous exercise.
4
SECTION 1
Care of the  Hospitalized Patient
4
Laboratory investigation of a pt with hyponatremia should include a 
measurement of serum osmolality to exclude “pseudohyponatremia” due 
to hyperlipidemia or hyperproteinemia. Serum glucose also should be mea-
sured; serum Na+ falls by 1.4 mM for every 100-mg/dL increase in glucose, 
due to glucose-induced H2O efflux from cells. Hyperkalemia may suggest 
adrenal insufficiency or hypoaldosteronism; increased blood urea nitrogen 
(BUN) and creatinine may suggest a renal cause. Urine electrolytes and 
osmolality are also critical tests in the initial evaluation of hyponatremia. 
In particular, a urine Na+ <20 meq/L is consistent with hypovolemic hypo-
natremia in the clinical absence of a “hypervolemic,” Na+-avid syndrome 
such as congestive heart failure (CHF) (Fig. 2-1). Urine osmolality <100 
mosmol/kg is suggestive of polydipsia or, in rare cases, of decreased solute 
intake; urine osmolality >400 mosmol/kg suggests that AVP excess is play-
ing a more dominant role, whereas intermediate values are more consistent 
with multifactorial pathophysiology (e.g., AVP excess with a component of 
polydipsia). Finally, in the right clinical setting, thyroid, adrenal, and pitu-
itary function should also be tested.
Hypovolemic Hyponatremia 
Hypovolemia from both renal and extrarenal causes is associated with 
hyponatremia. Renal causes of hypovolemia include primary adrenal insuf-
ficiency and hypoaldosteronism, salt-losing nephropathies (e.g., reflux 
nephropathy, nonoliguric acute tubular necrosis), diuretics, and osmotic 
diuresis. Random “spot” urine Na+ is typically >20 meq/L in these cases but 
may be <20 meq/L in diuretic-associated hyponatremia if tested long after 
TABLE 2-1  OSMOREGULATION VERSUS VOLUME REGULATION
Osmoregulation
Volume Regulation
What is sensed
Plasma osmolality
“Effective” circulating volume
Sensors
Hypothalamic 
osmoreceptors
Carotid sinus
Afferent arteriole
Atria
Effectors
AVP
Sympathetic nervous system
Thirst
Renin-angiotensin-aldosterone system
ANP/BNP
AVP
What is affected
Urine osmolality
Urinary sodium excretion
H2O intake
Vascular tone
Note: See text for details. 
Abbreviations: ANP, atrial natriuretic peptide; AVP, arginine vasopressin; BNP, brain 
natriuretic peptide.
Source: Adapted from Rose BD, Black RM (eds): Manual of Clinical Problems in Nephrology.
Boston, Little Brown, 1988; with permission.
5
Assessment of Volume Status
UNa >20
UNa <20
UNa >20
UNa >20
UNa <20
Hypovolemia
• Total body water ↓
• Total body sodium ↓↓
Hypervolemia
• Total body water ↑↑
• Total body sodium ↑
Euvolemia (no edema)
• Total body water ↑
• Total body sodium ←→
Renal losses
Diuretic excess
Mineral corticoid deficiency
Salt-losing deficiency
Bicarbonaturia with
 renal tubal acidosis and
 metabolic alkalosis
Ketonuria
Osmotic diuresis
Cerebral salt wasting
 syndrome
Extrarenal losses
Vomiting
Diarrhea
Third spacing of fluids
Burns
Pancreatitis
Trauma
Glucocorticoid deficiency
Hypothyroidism
Stress
Drugs
Syndrome of inappropriate
 antidiuretic hormone
 secretion
Acute or chronic
 renal failure
Nephrotic syndrome
Cirrhosis
Cardiac failure
FIGURE 2-1 The diagnostic approach to hyponatremia. See text for details. [From S Kumar, T Berl: Diseases of water metabolism, in Atlas of Diseases of the 
Kidney, RW Schrier (ed). Philadelphia, Current Medicine, Inc, 1999; with permission.]
SECTION 1
6
Care of the  Hospitalized Patient
administration of the drug. Nonrenal causes of hypovolemic hyponatremia 
include GI loss (e.g., vomiting, diarrhea, tube drainage) and integumentary 
loss (sweating, burns); urine Na+ is typically <20 meq/L in these cases.
Hypovolemia causes profound neurohumoral activation, inducing  systems 
that preserve effective circulating volume, such as the renin-angioten-
sin-aldosterone axis (RAA), the sympathetic nervous system, and AVP 
(Table 2-1). The increase in circulating AVP serves to increase the retention 
of ingested free H2O, leading to hyponatremia. The optimal treatment of 
hypovolemic hyponatremia is volume administration, generally as isotonic 
crystalloid, i.e., 0.9% NaCl (“normal saline”). If the history suggests that 
hyponatremia has been “chronic,” i.e., present for 48 h, care should be taken 
to avoid overcorrection (see below), which can easily occur as AVP levels 
plummet in response to volume-resuscitation; if necessary, the administra-
tion of desmopressin (DDAVP) and free water can reinduce or arrest the 
correction of hyponatremia (see below).
Hypervolemic Hyponatremia 
The edematous disorders (CHF, hepatic cirrhosis, and nephrotic syndrome) 
are often associated with mild to moderate degrees of hyponatremia ([Na+] = 
125–135 mmol/L); occasionally, pts with severe CHF or cirrhosis may present 
with serum [Na+] <120 mmol/L. The pathophysiology is similar to that 
in hypovolemic hyponatremia, except that “effective circulating volume” 
is decreased due to the specific etiologic factors, i.e., cardiac dysfunction, 
peripheral vasodilation in cirrhosis, and hypoalbuminemia in nephrotic 
syndrome. The degree of hyponatremia is an indirect index of the associ-
ated neurohumoral activation (Table 2-1) and an important prognostic 
indicator in hypervolemic hyponatremia.
Management consists of treatment of the underlying disorder (e.g., 
afterload reduction in heart failure, large-volume paracentesis in cirrhosis, 
immunomodulatory therapy in some forms of nephrotic syndrome), Na+ 
restriction, diuretic therapy, and, in some pts, H2O restriction. Vasopressin 
antagonists (e.g., tolvaptan and conivaptan) are also effective in normalizing 
hyponatremia associated with both cirrhosis and CHF.
Euvolemic Hyponatremia 
The syndrome of inappropriate ADH secretion (SIADH) characterizes most 
cases of euvolemic hyponatremia. Other causes of euvolemic hyponatremia 
include hypothyroidism and secondary adrenal insufficiency due to pitu-
itary disease; notably, repletion of glucocorticoid levels in the latter may 
cause a rapid drop in circulating AVP levels and overcorrection of serum 
[Na+] (see below).
Common causes of SIADH include pulmonary disease (e.g., pneumonia, 
tuberculosis, pleural effusion) and central nervous system (CNS) diseases 
(e.g., tumor, subarachnoid hemorrhage, meningitis); SIADH also occurs 
with malignancies (e.g., small cell carcinoma of the lung) and drugs (e.g., 
selective serotonin reuptake inhibitors, tricyclic antidepressants, nicotine, 
vincristine, chlorpropamide, carbamazepine, narcotic analgesics, anti-
psychotic drugs, cyclophosphamide, ifosfamide). Optimal treatment of 
euvolemic hyponatremia includes treatment of the underlying disorder. 
CHAPTER 2
7
Electrolytes/Acid-Base Balance
H2O restriction to <1 L/d is a cornerstone of therapy, but may be ineffective 
or poorly tolerated. However, vasopressin antagonists are predictably effec-
tive in normalizing serum [Na+] in SIADH. Alternatives include the coad-
ministration of loop diuretics to inhibit the countercurrent mechanism and 
reduce urinary concentration, combined with oral salt tablets to abrogate 
diuretic-induced salt loss and attendant hypovolemia.
Acute Symptomatic Hyponatremia 
Acute symptomatic hyponatremia is a medical emergency; a sudden drop 
in serum [Na+] can overwhelm the capacity of the brain to regulate cell vol-
ume, leading to cerebral edema, seizures, and death. Women, particularly 
premenopausal women, are particularly prone to such sequelae; neuro-
logic consequences are comparatively rare in male pts. Many of these pts 
develop hyponatremia from iatrogenic causes, including hypotonic fluids 
in the postoperative period, prescription of a thiazide diuretic, colonoscopy 
preparation, or intraoperative use of glycine irrigants. Polydipsia with an 
associated cause of increased AVP may also cause acute hyponatremia, as 
can increased H2O intake in the setting of strenuous exercise, e.g., a mara-
thon. The recreational drug Ecstasy [methylenedioxymethamphetamine 
(MDMA)] can cause acute hyponatremia, rapidly inducing both AVP 
release and increased thirst.
Severe symptoms may occur at relatively modest levels of serum [Na+], 
e.g., in the mid-120s. Nausea and vomiting are common premonitory symp-
toms of more severe sequelae. An important concomitant is respiratory fail-
ure, which may be hypercapnic due to CNS depression or normocapnic due 
to neurogenic, noncardiogenic pulmonary edema; the attendant hypoxia 
amplifies the impact of hyponatremic encephalopathy.
Hyponatremia
TREATMENT
Three considerations are critical in the therapy of hyponatremia. First, 
the presence, absence, and/or severity of symptoms determine the 
urgency of therapy (see above for acute symptomatic hyponatremia). 
Second, pts with hyponatremia that has been present for >48 h (“chronic 
hyponatremia”) are at risk for osmotic demyelination syndrome, typically 
central pontine myelinolysis, if serum Na+ is corrected by >10–12 mM 
within the first 24 h and/or by >18 mM within the first 48 h. Third, 
the response to interventions, such as hypertonic saline or vasopressin 
antagonists, can be highly unpredictable, such that frequent monitoring 
of serum Na+ (every 2–4 h) is imperative.
Treatment of acute symptomatic hyponatremia should include hyper-
tonic saline to acutely increase serum Na+ by 1–2 mM/h to a total 
increase of 4–6 mM; this increase is typically sufficient to alleviate acute 
symptoms, after which corrective guidelines for “chronic” hyponatremia 
are appropriate (see below). A number of equations and algorithms have 
been developed to estimate the required rate of hypertonic solution; one 
popular approach is to calculate a “Na+ deficit,” where the Na+ deficit = 
0.6 × body weight × (target [Na+] – starting [Na+]). Regardless of the
SECTION 1
8
Care of the  Hospitalized Patient
method used to determine the rate of administered hypertonic saline, 
the increase in serum [Na+] can be highly unpredictable, as the under-
lying physiology rapidly changes; serum [Na+] should be monitored 
every 2–4 h during and after treatment with hypertonic saline. The 
administration of supplemental O2 and ventilatory support can also be 
critical in acute hyponatremia, if pts develop acute pulmonary edema 
or hypercapnic respiratory failure. IV loop diuretics will help treat acute 
pulmonary edema and will also increase free H2O excretion by interfer-
ing with the renal countercurrent multiplier system. It is noteworthy that 
vasopressin antagonists do not have a role in the management of acute 
hyponatremia.
The rate of correction should be comparatively slow in chronic hypona-
tremia (<10–12 mM in the first 24 h and <18 mM in the first 48 h), so 
as to avoid osmotic demyelination syndrome. Vasopressin antagonists 
are highly effective in SIADH and in hypervolemic hyponatremia due to 
heart failure or cirrhosis. Should pts overcorrect serum [Na+] in response 
to vasopressin antagonists, hypertonic saline, or isotonic saline (in chronic 
hypovolemic hyponatremia), hyponatremia can be safely reinduced or 
stabilized by the administration of the vasopressin agonist DDAVP and 
the administration of free H2O, typically IV D5W; again, close monitoring 
of the response of serum [Na+] is essential to adjust therapy.
� HYPERNATREMIA 
This is rarely associated with hypervolemia, where the association is typi-
cally iatrogenic, e.g., administration of hypertonic sodium bicarbonate. More 
commonly, hypernatremia is the result of a combined H2O and volume 
deficit, with losses of H2O in excess of Na+. Elderly individuals with reduced 
thirst and/or diminished access to fluids are at the highest risk of hyperna-
tremia due to decreased free H2O intake. Common causes of renal H2O loss 
are osmotic diuresis secondary to hyperglycemia, postobstructive diuresis, 
or drugs (radiocontrast, mannitol, etc.); H2O diuresis occurs in central or 
nephrogenic diabetes insipidus (DI) (Chap. 51). In pts with hypernatremia 
due to renal loss of H2O, it is critical to quantify ongoing daily losses in addi-
tion to calculation of the baseline H2O deficit (Table 2-2).
Hypernatremia
TREATMENT
The approach to correction of hypernatremia is outlined in Table 2-2. 
As with hyponatremia, it is advisable to correct the H2O deficit slowly 
to avoid neurologic compromise, decreasing the serum [Na+] over 
48–72 h. Depending on the blood pressure or clinical volume status, 
it may be appropriate to initially treat with hypotonic saline solu-
tions (1/4 or 1/2 normal saline); blood glucose should be monitored 
in pts treated with large volumes of D5W, should hyperglycemia 
ensue. Calculation of urinary electrolyte-free H2O clearance is help-
ful to estimate daily, ongoing loss of free H2O in pts with nephrogenic 
or central DI (Table 2-2). Other forms of therapy may be helpful in
CHAPTER 2
9
Electrolytes/Acid-Base Balance
selected cases of hypernatremia. Pts with central DI may respond 
to the administration of intranasal DDAVP. Stable pts with nephro-
genic DI due to lithium may reduce their polyuria with amiloride 
(2.5–10 mg/d) or hydrochlorothiazide (12.5–50 mg/d) or both in 
combination. These diuretics are thought to increase proximal H2O 
reabsorption and decrease distal solute delivery, thus reducing polyuria; 
amiloride may also decrease entry of lithium into principal cells in the 
distal nephron by inhibiting the amiloride-sensitive epithelial sodium 
channel (ENaC). Notably, however, most pts with lithium-induced 
nephrogenic DI can adequately accommodate by increasing their H2O 
intake. Occasionally, nonsteroidal anti-inflammatory drugs (NSAIDs) 
have also been used to treat polyuria associated with nephrogenic DI, 
reducing the negative effect of local prostaglandins on urinary concen-
tration; however, the nephrotoxic potential of NSAIDs typically makes 
them a less attractive therapeutic option.
POTASSIUM
Since potassium (K+) is the major intracellular cation, discussion of disor-
ders of K+ balance must take into consideration changes in the exchange 
of intra- and extracellular K+ stores. (Extracellular K+ constitutes <2% of 
total-body K+ content.) Insulin, β2-adrenergic agonists, and alkalosis tend to 
promote K+ uptake by cells; acidosis, insulinopenia, or acute hyperosmolality 
TABLE 2-2 CORRECTION OF HYPERNATREMIA
H2O Deficit
1.  Estimate total-body water (TBW): 50–60% body weight (kg) depending on 
body composition
2.  Calculate free-water deficit: [(Na+ 140)/140] × TBW
3.  Administer deficit over 48–72 h
Ongoing H2O Losses
4.  Calculate free-water clearance, CeH2O:
C H O
V 1 U
U
S
e
2
H
Na
K
Na
−
1
V
⎛
1
⎝
⎜
⎛
⎜⎝
⎜
⎞
⎠
⎟
⎞
⎟⎠
⎟
where V is urinary volume, UNa is urinary [Na+], UK is urinary [K+], and SNa 
is serum [Na+].
Insensible Losses
5.  ~10 mL/kg per day: less if ventilated, more if febrile
Total
6.  Add components to determine H2O deficit and ongoing H2O loss; correct the 
H2O deficit over 48–72 h and replace daily H2O loss.
SECTION 1
10
Care of the  Hospitalized Patient
(e.g., after treatment with mannitol or D50W) promote the efflux or 
reduced uptake of K+. A corollary is that tissue necrosis and the attendant 
release of K+ can cause severe hyperkalemia, particularly in the setting of 
acute kidney injury. Hyperkalemia due to rhabdomyolysis is thus particu-
larly common, due to the enormous store of K+ in muscle; hyperkalemia 
may also be prominent in tumor lysis syndrome.
The kidney plays a dominant role in K+ excretion. Although K+ is trans-
ported along the entire nephron, it is the principal cells of the connecting 
segment and cortical collecting duct that play a dominant role in K+ excre-
tion. Apical Na+ entry into principal cells via the amiloride-sensitive epithe-
lial Na+ channel (ENaC) generates a lumen-negative potential difference, 
which drives passive K+ exit through apical K+ channels. This relationship 
is key to the bedside understanding of potassium disorders. For example, 
decreased distal delivery of Na+ tends to blunt the ability to excrete K+, leading 
to hyperkalemia. Abnormalities in the RAA can cause both hypo- and 
hyperkalemia; aldosterone has a major influence on potassium excretion, 
increasing the activity of ENaC channels and thus amplifying the driving 
force for K+ secretion across the luminal membrane of principal cells.
� HYPOKALEMIA 
Major causes of hypokalemia are outlined in Table 2-3. Atrial and ventricular 
arrhythmias are the most serious health consequences of hypokalemia. Pts with 
concurrent Mg deficit and/or digoxin therapy are at a particularly increased risk 
of arrhythmias. Other clinical manifestations include muscle weakness, which 
may be profound at serum [K+] <2.5 mmol/L, and, if hypokalemia is sustained, 
hypertension, ileus, polyuria, renal cysts, and even renal failure.
The cause of hypokalemia is usually obvious from history, physical exam-
ination, and/or basic laboratory tests. However, persistent hypokalemia may 
require a more thorough, systematic evaluation (Fig. 2-2). Initial laboratory 
evaluation should include electrolytes, BUN, creatinine, serum osmolality, 
Mg2+, and Ca2+, a complete blood count, and urinary pH, osmolality, 
creatinine, and electrolytes. Serum and urine osmolality are required for 
TABLE 2-3 CAUSES OF HYPOKALEMIA
I.  Decreased intake
A.  Starvation
B.  Clay ingestion
II.  Redistribution into cells
A.  Acid-base
1.  Metabolic alkalosis
B.  Hormonal
1.  Insulin
2.  Increased β2-adrenergic sympathetic activity: post–myocardial 
infarction, head injury
CHAPTER 2
11
Electrolytes/Acid-Base Balance
3.  β2-Adrenergic agonists: bronchodilators, tocolytics
4.  α-Adrenergic antagonists
5.  Thyrotoxic periodic paralysis
6.  Downstream stimulation of Na+/K+-ATPase: theophylline, caffeine
C.  Anabolic state
1.  Vitamin B12 or folic acid administration (red blood cell production)
2.  Granulocyte-macrophage colony-stimulating factor (white blood cell 
production)
3.  Total parenteral nutrition
D.  Other
1.  Pseudohypokalemia
2.  Hypothermia
3.  Familial hypokalemic periodic paralysis
4.  Barium toxicity: systemic inhibition of “leak” K+ channels
III.  Increased loss
A.  Nonrenal
1.  Gastrointestinal loss (diarrhea)
2.  Integumentary loss (sweat)
B.  Renal
1.  Increased distal flow and distal Na+ delivery: diuretics, osmotic diuresis, 
salt-wasting nephropathies
2.  Increased secretion of potassium
a.  Mineralocorticoid excess: primary hyperaldosteronism [aldosterone-
producing adenomas (APAs)], primary or unilateral adrenal 
hyperplasia (PAH or UAH), idiopathic hyperaldosteronism (IHA) due 
to bilateral adrenal hyperplasia and adrenal carcinoma, familial 
hyperaldosteronism (FH-I, FH-II, congenital adrenal hyperplasias), 
secondary hyperaldosteronism (malignant hypertension, 
renin-secreting tumors, renal artery stenosis, hypovolemia), 
Cushing’s syndrome, Bartter’s syndrome, Gitelman’s syndrome 
b.  Apparent mineralocorticoid excess: genetic deficiency of 
11β-dehydrogenase-2 (syndrome of apparent mineralocorticoid 
excess), inhibition of 11β-dehydrogenase-2 (glycyrrhetinic/
glycyrrhizinic acid and/or carbenoxolone; licorice, food products, 
drugs), Liddle’s syndrome [genetic activation of epithelial Na+
channels (ENaC)]
c.   Distal delivery of nonreabsorbed anions: vomiting, nasogastric 
suction, proximal renal tubular acidosis, diabetic ketoacidosis, 
glue sniffing (toluene abuse), penicillin derivatives (penicillin, 
nafcillin, dicloxacillin, ticarcillin, oxacillin, and carbenicillin)
3.  Magnesium deficiency, amphotericin B, Liddle’s syndrome
TABLE 2-3 CAUSES OF HYPOKALEMIA (CONTINUED)
12
FIGURE 2-2 The diagnostic approach to hypokalemia. See text for details. BP, blood pressure; DKA, diabetic ketoacidosis; FHPP, familial hypokalemic pe-
riodic paralysis; FH-I, familial hyperaldosteronism type I; GI, gastrointestinal; HTN, hypertension; PA, primary aldosteronism; RAS, renal artery stenosis; 
RST, renin-secreting tumor; RTA, renal tubular acidosis; SAME, syndrome of apparent mineralocorticoid excess; TTKG, transtubular potassium gradient. 
[From Mount DB, Zandi-Nejad K: Disorders of potassium balance, in The Kidney, 8th ed, BM Brenner (ed). Philadelphia, Saunders, 2008; with permission.]
<15 mmol/day OR <15 mmol/g Cr
>15 mmol/g Cr OR >15 mmol/day
Renal loss
TTKG
↑ Distal K+ secretion
↑ Tubular flow
 
-Osmotic diuresis
BP and/or Volume
Extrarenal loss/remote renal loss
Metabolic acidosis
 - GI K+ loss
Normal
 -Profuse sweating
Metabolic alkalosis
 -Remote diuretic use
 -Remote vomiting or stomach drainage
 -Profuse sweating
Non-reabsorbable anions other than
HCO3–
 -Hippurate
 -Penicillins
Metabolic acidosis
 
-Proximal RTA
 
-Distal RTA
 
-DKA
 
-Amphotericin B
 
-Acetazolamide
Acid-base status
Low OR normal
Acid-base status
Variable
Aldosterone
High
Low
High
High
Low
High
Normal
Cortisol
Renin
Urine K+
Pseudohypokalemia?
Emergency?
Hypokalemia (Serum K+<3.5 mmol/l)
Move to therapy
Clear evidence of transcellular shift
No further workup
Treat accordingly
Clear evidence of low intake
History, physical examination & basic laboratory tests
Treat accordingly and re-evaluate
Yes
Yes
Yes
Yes
No
No
No
No
-Insulin excess
-β2-adrenergic agonists
-FHPP
-Hyperthyroidism
-Barium intoxication
-Theophylline
-Chloroquine
>4
>20
>0.20
<0.15
<10
<2
Metabolic alkalosis
Urine Ca/Cr
(molar ratio)
-Vomiting
-Chloride
-Diarrhea
-Loop diuretic
-Bartter’s syndrome
-Thiazide diuretic
-Gitelman’s syndrome
Urine Cl– (mmol/l)
-RAS
-RST
-Malignant HTN
-PA
-FH-I
-Cushing’s
syndrome
-Liddle’s syndrome
-Licorice
-SAME
Electrolytes/Acid-Base Balance
CHAPTER 2
13
calculation of the transtubular K+ gradient (TTKG), which should be <3 in 
the presence of hypokalemia (see also Hyperkalemia). Further tests such as 
urinary Mg2+ and Ca2+ and/or plasma renin and aldosterone levels may be 
necessary in specific cases.
Hypokalemia
TREATMENT
Hypokalemia can generally be managed by correction of the underlying 
disease process (e.g., diarrhea) or withdrawal of an offending medica-
tion (e.g., loop or thiazide diuretic), combined with oral KCl supplemen-
tation. However, hypokalemia is refractory to correction in the presence 
of Mg deficiency, which also should be corrected when present; renal 
wasting of both cations may be particularly prominent after renal tubu-
lar injury, e.g., from cisplatin nephrotoxicity. If loop or thiazide diuretic 
therapy cannot be discontinued, a distal tubular K-sparing agent, such as 
amiloride or spironolactone, can be added to the regimen. Angiotensin-
converting enzyme (ACE) inhibition in pts with CHF attenuates 
diuretic-induced hypokalemia and protects against cardiac arrhythmia. 
If hypokalemia is severe (<2.5 mmol/L) and/or if oral supplementation 
is not feasible or tolerated, IV KCl can be administered through a central 
vein with cardiac monitoring in an intensive care setting, at rates that 
should not exceed 20 mmol/h. KCl should always be administered in 
saline solutions, rather than dextrose; the dextrose-induced increase in 
insulin can acutely exacerbate hypokalemia.
� HYPERKALEMIA 
Causes are outlined in Table 2-4; in most cases, hyperkalemia is due to 
decreased renal K+ excretion. However, increases in dietary K+ intake can 
have a major effect in susceptible pts, e.g., diabetics with hyporeninemic 
hypoaldosteronism and chronic kidney disease. Drugs that impact on 
the renin-angiotensin-aldosterone axis are also a major cause of hyper-
kalemia, particularly given recent trends to coadminister these agents, e.g., 
spironolactone or angiotensin receptor blockers with an ACE inhibitor in 
cardiac and/or renal disease.
The first priority in the management of hyperkalemia is to assess the 
need for emergency treatment (ECG changes and/or K+ ≥6.0 mM). This 
should be followed by a comprehensive workup to determine the cause 
(Fig. 2-3). History and physical examination should focus on medica-
tions (e.g., ACE inhibitors, NSAIDs, trimethoprim/sulfamethoxazole), 
diet and dietary supplements (e.g., salt substitute), risk factors for 
acute kidney failure, reduction in urine output, blood pressure, and 
volume status. Initial laboratory tests should include electrolytes, BUN, 
creatinine, serum osmolality, Mg2+, and Ca2+, a complete blood count, 
and urinary pH, osmolality, creatinine, and electrolytes. A urine [Na+] 
<20 meq/L suggests that distal Na+ delivery is a limiting factor in K+ 
excretion; volume repletion with 0.9% saline or treatment with furo-
semide may then be effective in reducing serum [K+] by increasing distal 
Na+ delivery. Serum and urine osmolality are required for calculation of 
SECTION 1
14
Care of the  Hospitalized Patient
TABLE 2-4 CAUSES OF HYPERKALEMIA
I.  “Pseudo” hyperkalemia
A.  Cellular efflux: thrombocytosis, erythrocytosis, leukocytosis, in vitro 
hemolysis
B.  Hereditary defects in red cell membrane transport
II.  Intra- to extracellular shift
A.  Acidosis
B.  Hyperosmolality; radiocontrast, hypertonic dextrose, mannitol
C.  β-adrenergic antagonists (noncardioselective agents)
D.  Digoxin and related glycosides (yellow oleander, foxglove, bufadienolide)
E.  Hyperkalemic periodic paralysis
F.  Lysine, arginine, and ε-aminocaproic acid (structurally similar, positively 
charged)
G.  Succinylcholine; thermal trauma, neuromuscular injury, disuse atrophy, 
mucositis, or prolonged immobilization
H.  Rapid tumor lysis
III.  Inadequate excretion
A.  Inhibition of the renin-angiotensin-aldosterone axis; ↑ risk of hyper-
kalemia when used in combination
1.  Angiotensin-converting enzyme (ACE) inhibitors
2.  Renin inhibitors: aliskiren [in combination with ACE inhibitors or 
angiotensin receptor blockers (ARBs)]
3.  ARBs
4.  Blockade of the mineralocorticoid receptor: spironolactone, epler-
enone, drospirenone
5.  Blockade of ENaC: amiloride, triamterene, trimethoprim, pentamidine, 
nafamostat
B.  Decreased distal delivery
1.  Congestive heart failure
2.  Volume depletion
C.  Hyporeninemic hypoaldosteronism
1.  Tubulointerstitial diseases: systemic lupus erythematosus (SLE), sickle 
cell anemia, obstructive uropathy
2.  Diabetes, diabetic nephropathy
3.  Drugs: nonsteroidal anti-inflammatory drugs, cyclooxygenase 2 
(COX-2) inhibitors, beta blockers, cyclosporine, tacrolimus
4.  Chronic kidney disease, advanced age
5.  Pseudohypoaldosteronism type II: defects in WNK1 or WNK4 kinases
CHAPTER 2
15
Electrolytes/Acid-Base Balance
the TTKG. The expected values of the TTKG are largely based on his-
toric data: <3 in the presence of hypokalemia and >7–8 in the presence 
of hyperkalemia.
TTKG
OSM
OSM
urine
serum
r
serum
urine
= [
]
K +
[
]
K +
Hyperkalemia
TREATMENT
The most important consequence of hyperkalemia is altered cardiac 
conduction, with the risk of bradycardic cardiac arrest. Figure 2-4 
shows serial ECG patterns of hyperkalemia; ECG manifestations of 
hyperkalemia should be considered a true medical emergency and 
treated urgently. However, ECG changes of hyperkalemia are notori-
ously insensitive, particularly in pts with chronic kidney disease; given 
these limitations, pts with significant hyperkalemia (K+ ≥6–6.5 mmol/L) 
in the absence of ECG changes should also be aggressively managed.
Urgent management of hyperkalemia constitutes a 12-lead ECG, 
admission to the hospital, continuous cardiac monitoring, and immediate 
treatment. Treatment of hyperkalemia is divided into three categories: 
TABLE 2-4 CAUSES OF HYPERKALEMIA (CONTINUED)
D.  Renal resistance to mineralocorticoid
1.   Tubulointerstitial diseases: SLE, amyloidosis, sickle cell anemia, 
obstructive uropathy, post-acute tubular necrosis
2.   Hereditary: pseudohypoaldosteronism type I: defects in the 
mineralocorticoid receptor or ENaC
E.  Advanced renal insufficiency with low GFR
1.  Chronic kidney disease
2.  End-stage renal disease
3.  Acute oliguric kidney injury
F.  Primary adrenal insufficiency
1.  Autoimmune: Addison’s disease, polyglandular endocrinopathy
2.   Infectious: HIV, cytomegalovirus, tuberculosis, disseminated fungal 
infection
3.  Infiltrative: amyloidosis, malignancy, metastatic cancer
4.  Drug-associated: heparin, low-molecular-weight heparin
5.  Hereditary: adrenal hypoplasia congenita, congenital lipoid adrenal 
hyperplasia, aldosterone synthase deficiency
6.  Adrenal hemorrhage or infarction, including in antiphospholipid 
syndrome
16
FIGURE 2-3 The diagnostic approach to hyperkalemia. See text for details. ACE-I, angiotensin converting enzyme inhibitor; acute GN, acute glomerulonephritis;
ARB, angiotensin II receptor blocker; ECG, electrocardiogram; ECV, effective circulatory volume; GFR, glomerular filtration rate; LMW heparin, low-molecular-weight
heparin; NSAIDs, nonsteroidal anti-inflammatory drugs; PHA, pseudohypoaldosteronism; SLE, systemic lupus erythematosus; TTKG, transtubular potassium gradient. 
[From Mount DB, Zandi-Nejad K: Disorders of potassium balance, in The Kidney, 8th ed, BM Brenner (ed). Philadelphia, Saunders, 2008; with permission.]
<5
Drugs
-Amiloride
-Spironolactone
-Triamterene
-Trimethoprim
-Pentamidine
-Eplerenone
-Drospirenone
-Calcineurin
 inhibitors
Other causes
-Tubulointerstitial
 diseases
-Urinary tract
 obstruction
-PHA type I
-PHA type II
-Sickle cell disease
-Renal transplant
-SLE
Hyperkalemia (Serum K+ ≥5.5 mmol/l)
History, physical examination
& basic laboratory tests
Decreased urinary K+ excretion (<40 mmol/day)
Urine electrolytes
TTKG
Evidence of increased
potassium load
Urine Na+
<25 mmol/L
Reduced tubular flow
Reduced distal K+ secretion (GFR >20 ml/min)
Advanced kidney failure
(GFR ≤20 ml/min)
Reduced ECV
TTKG < 8
(Tubular resistance)
TTKG ≥8
Low aldosterone
Renin 
9α-Fludrocortisone
Treat accordingly
and re-evaluate 
Pseudohyperkalemia?
Evidence of
transcellular shift
No further action
K+ ≥6.0 or ECG changes
Emergency therapy
Yes
Yes
Decreased distal
Na+ delivery
Yes
Treat accordingly
and re-evaluate
-Hypertonicity (e.g., mannitol)
-Hyperglycemia
-Succinylcholine
-ε-aminocaproic acid
-Digoxin
-β-blockers
-Metabolic acidosis (non-organic)
-Arginine or lysine infusion
-Hyperkalemic periodic paralysis
-↓Insulin
-Exercise
Yes
No
No
No
No
>8
High
Low
-Primary adrenal insufficiency
-Isolated aldosterone deficiency
-Heparin/LMW heparin
-ACE-I/ARB
-Ketoconazole
-Diabetes mellitus
-Acute GN
-Tubulointerstitial diseases
-PHA type II
-NSAIDs
-β-Blockers
Electrolytes/Acid-Base Balance
CHAPTER 2
17
(1) antagonism of the cardiac effects of hyperkalemia, (2) rapid reduc-
tion in [K+] by redistribution into cells, and (3) removal of K+ from the 
body. Treatment of hyperkalemia is summarized in Table 2-5.
ACID-BASE DISORDERS (FIG. 2-5)
Regulation of normal pH (7.35–7.45) depends on both the lungs and kid-
neys. By the Henderson-Hasselbalch equation, pH is a function of the ratio 
of HCO3
– (regulated by the kidney) to Pco2 (regulated by the lungs). The 
HCO3 /Pco2 relationship is useful in classifying disorders of acid-base bal-
ance. Acidosis is due to gain of acid or loss of alkali; causes may be meta-
bolic (fall in serum HCO3
–) or respiratory (rise in Pco2). Alkalosis is due to 
loss of acid or addition of base and is either metabolic (↑ serum [HCO3
–]) 
or respiratory (↓ Pco2 ).
To limit the change in pH, metabolic disorders evoke an immediate com-
pensatory response in ventilation; full renal compensation for respiratory 
disorders is a slower process, such that “acute” compensations are of lesser 
magnitude than “chronic” compensations. Simple acid-base disorders con-
sist of one primary disturbance and its compensatory response. In mixed 
disorders, a combination of primary disturbances is present.
Normal
Mild
hyperkalemia
Moderate
hyperkalemia
Severe
hyperkalemia
FIGURE 2-4 Diagrammatic ECGs at normal and high serum K. Peaked T waves 
(precordial leads) are followed by diminished R wave, wide QRS, prolonged P-R, loss 
of P wave, and ultimately a sine wave.
18
TABLE 2-5 TREATMENT OF HYPERKALEMIA
Mechanism
Therapy
Dose
Onset
Duration
Comments
Stabilize membrane 
potential
Calcium
10% Ca gluconate, 10 mL 
over 10 min
1–3 min
30–60 min
Repeat in 5 min if persistent electrocardiographic 
changes; avoid in digoxin toxicity.
Cellular K+ uptake
Insulin
10 U R with 50 mL of 
D50, if blood sugar <250
30 min
4–6 h
Can repeat in 15 min; initiate D10W IV at 50–75 mL/h 
to avoid rebound hypoglycemia.
β2-agonist
Nebulized albuterol, 
10–20 mg in 4 mL saline
30 min
2–4 h
Can be synergistic/additive to insulin; should not be 
used as sole therapy; use with caution in cardiac 
disease; may cause tachycardia/hyperglycemia.
K+ removal
Kayexalate
30–60 g PO in 20% 
sorbitol
1–2 h
4–6 h
May cause ischemic colitis and colonic necrosis, 
particularly in enema form and postoperative state.
Furosemide
20–250 mg IV
15 min
4–6 h
Depends on adequate renal response/function.
Hemodialysis
Immediate
Efficacy depends on pretreatment of hyperkalemia 
(with attendant decrease in serum K+), the dialyzer 
used, blood flow and dialysate flow rates, duration, 
and serum to dialysate K+ gradient.
19
Electrolytes/Acid-Base Balance
CHAPTER 2
The cause of simple acid-base disorders is usually obvious from his-
tory, physical examination, and/or basic laboratory tests. Initial laboratory 
evaluation depends on the dominant acid-base disorder, but for metabolic 
acidosis and alkalosis this should include electrolytes, BUN, creatinine, 
albumin, urinary pH, and urinary electrolytes. An arterial blood gas (ABG) 
is not always required for pts with a simple acid-base disorder, e.g., mild 
metabolic acidosis in the context of chronic renal failure. However, con-
comitant ABG and serum electrolytes are necessary to fully evaluate more 
complex acid-base disorders. The compensatory response should be esti-
mated from the ABG; Winter’s formula [PaCO2 = (1.5 × [HCO3
–]) + 8 ± 2] is 
particularly useful for assessing the respiratory response to metabolic acidosis. 
The anion gap should also be calculated; the anion gap = [Na+] – ([HCO3
–]+
[Cl–]) = unmeasured anions – unmeasured cations. The anion gap should 
50
45
40
35
30
25
20
15
10
0
10
20
30
40
50
60
70
80
90
100
7.7
7.6
7.5
pH = 7.4
7.3
7.2
7.1
7.0
6.9
6.8
Bicarbonate, mmol/L
1
4
8
12
Pco2 , mmHg
Pco2 , kPa
Ac resp alk
Chr
resp alk
Ac & chr
met alk
Chr
resp acid
Ac resp acid
Ac & chr
met acid
Normal
range
FIGURE 2-5 Nomogram showing bands for uncomplicated respiratory or metabolic 
acid-base disturbances in intact subjects. Each confidence band represents the mean 
±2 SD for the compensatory response of normal subjects or pts to a given primary 
disorder. Ac, acute; chr, chronic; resp, respiratory; met, metabolic; acid, acidosis; alk, 
alkalosis. (From Levinsky NG: HPIM-12, p. 290; modified from Arbus GS: Can Med 
Assoc J 109:291, 1973.)
20
SECTION 1
Care of the  Hospitalized Patient
be adjusted for changes in the concentration of albumin, a dominant 
unmeasured anion; the “adjusted anion gap” = anion gap + ~2.5 × (4 – 
albumin mg/dL). Other supportive tests will elucidate the specific form of 
anion-gap acidosis (see below).
� METABOLIC ACIDOSIS 
The low HCO3
– in metabolic acidosis results from the addition of acids 
(organic or inorganic) or from a loss of HCO3
–; causes of metabolic acidosis 
are classically categorized by presence or absence of an increase in the anion 
gap (Table 2-6). Increased anion-gap acidosis (>12 mmol/L) is due to addition 
of acid (other than HCl) and unmeasured anions to the body. Common causes 
include ketoacidosis [diabetes mellitus (DKA), starvation, alcohol], lactic aci-
dosis, poisoning (salicylates, ethylene glycol, and methanol), and renal failure.
Rare and newly appreciated causes of anion-gap acidosis include d-lactic 
acidosis, propylene glycol toxicity, and 5-oxoprolinuria (also known as 
pyroglutamic aciduria). d-Lactic acidosis (an increase in the d-enantiomer 
of lactate) can occur in pts with removal, disease, or bypass of the short 
bowel, leading to increased delivery of carbohydrates to colon. Intestinal 
overgrowth of organisms that metabolize carbohydrate to d-lactate results 
in d-lactic acidosis; a wide variety of neurologic symptoms can ensue, with 
resolution following treatment with appropriate antibiotics to change the 
intestinal flora. Propylene glycol is a common solvent for IV preparations 
of a number of drugs, most prominently lorazepam. Pts receiving high rates 
of these drugs may develop a hyperosmolar anion-gap metabolic acidosis, 
due mostly to increased lactate, often accompanied by acute kidney failure. 
Pyroglutamic aciduria (5-oxoprolinuria) is a high anion-gap acidosis caused 
by dysfunction of the γ-glutamyl cycle that replenishes intracellular glutathi-
one; 5-oxoproline is an intermediate product of the cycle. Hereditary defects 
in the γ-glutamyl cycle are associated with 5-oxoprolinuria; acquired defects 
occur in the context of acetaminophen therapy, due to derepression of the 
cycle by reduced glutathione and overproduction of 5-oxoproline. Resolution 
occurs after withdrawal of acetaminophen; treatment with N-acetyl cysteine 
to replenish glutathione stores may hasten recovery.
The differentiation of the various anion-gap acidoses depends on the 
clinical scenario and routine laboratory tests (Table 2-6) in conjunc-
tion with measurement of serum lactate, ketones, toxicology screens (if 
ethylene glycol or methanol ingestion are suspected), and serum osmolality. 
d-Lactic acidosis can be diagnosed by a specific assay for the d-enantiomer; 
5-oxoprolinuria can be diagnosed by the clinical scenario and confirmed 
by gas chromatographic/mass spectroscopic (GC/MS) analysis of urine, a 
widely available pediatric screening test for inborn errors of metabolism 
(typically “urine for organic acids”).
Pts with ethylene glycol, methanol, or propylene glycol toxicity may have an 
“osmolar gap,” defined as a >10-mosm/kg difference between calculated and 
measured serum osmolality. Calculated osmolality = 2 × Na+ + glucose/18 + 
BUN/2.8. Of note, pts with alcoholic ketoacidosis and lactic acidosis may also 
exhibit a modest elevation in the osmolar gap; pts may alternatively metabo-
lize ethylene glycol or methanol to completion by presentation, with an 
increased anion gap and no increase in the osmolar gap. However, the rapid 
21
TABLE 2-6 METABOLIC ACIDOSIS
Non-Anion-Gap Acidosis
Anion-Gap Acidosis
Cause
Clue
Cause
Clue
Diarrhea enterostomy
RF
RTA
Proximal
Distal—hypokalemic
Distal—hyperkalemic
Distal—hyporeninemic
hypoaldosteronism
Dilutional
Ureterosigmoidostomy
Hyperalimentation
Acetazolamide, NH4Cl, lysine HCl, 
arginine HCl, sevelamer-HCl
Hx; ↑ K+ Drainage
Early chronic kidney disease
↓ K+, presence of other proximal 
tubular defects (Fanconi Syndrome)
↓ K+; hypercalciuria; UpH >5.5
↑ K+; nl PRA/aldo; UpH >5.5
↑ K+; ↓ PRA/aldo; UpH <5.5
Massive volume expansion with saline
Obstructed ileal loop
Amino acid infusion
Hx of administration of these agents
DKA
RF
Lactic acidosis
(L-lactate)
Alcoholic ketoacidosis
Starvation
Salicylates
Methanol
Ethylene glycol
D-lactic acidosis
Propylene glycol
Pyroglutamic aciduria, 
5-oxoprolinuria
Hyperglycemia, ketones
Late chronic kidney disease
Clinical setting + ↑ serum lactate
Hx; weak + ketones; + osm gap
Hx; mild acidosis; + ketones
Hx; tinnitus; high serum level; + ketones; + lactate
Large AG; concomitant respiratory alkalosis; 
retinitis; + toxic screen; + osm gap
RF; CNS symptoms; + toxic screen; crystalluria; 
+ osm gap
Small-bowel disease; prominent neuro symptoms
IV infusions, e.g., lorazepam; + osm gap; RF
Large AG; chronic acetaminophen
Abbreviations: AG, anion gap; CNS, central nervous system; DKA, diabetic ketoacidosis; osm gap, osmolar gap; PRA, plasma renin activity; RF, renal failure; RTA, renal tubular 
acidosis; UpH, urinary pH.
SECTION 1
22
Care of the  Hospitalized Patient
availability of a measured serum osmolality may aid in the urgent assessment 
and management of pts with these medical emergencies.
Normal anion-gap acidosis can result from HCO3
– loss from the GI 
tract. Diarrhea is by far the most common cause, but other GI conditions 
associated with external losses of bicarbonate-rich fluids may lead to large 
alkali losses—e.g., in ileus secondary to intestinal obstruction, in which 
liters of alkaline fluid may accumulate within the intestinal lumen. Various 
forms of kidney disease are associated with non-anion-gap acidosis due to 
reduced tubular reabsorption of filtered bicarbonate and/or reduced excre-
tion of ammonium (NH4
+). The early stages of progressive renal disease are 
frequently associated with a non-anion-gap acidosis, with development of 
an anion-gap component in more advanced renal failure. Non-anion-gap 
acidosis is also seen in renal tubular acidosis or in the context of tubulointer-
stitial injury, e.g., after acute tubular necrosis, allergic interstitial nephritis, or 
urinary tract obstruction. Finally, non-anion-gap acidosis due to exogenous 
acid loads may occur after rapid volume expansion with saline-containing 
solutions, the administration of NH4Cl (a component of cough syrup), lysine 
HCl, or treatment with the phosphate binder sevelamer hydrochloride.
Calculation of the urinary anion gap may be helpful in the evaluation 
of hyperchloremic metabolic acidosis, along with a measurement of urine 
pH. The urinary anion gap is defined as urinary ([Na+] + [K+]) – [Cl–] = 
[unmeasured anions] – [unmeasured cations]); the NH4
+ ion is the major 
unmeasured urinary cation in metabolic acidosis, wherein the urinary 
anion gap should be strongly negative. A negative anion gap thus suggests 
GI losses of bicarbonate, with appropriate renal response and increased 
NH4
+ excretion; a positive anion gap suggests altered urinary acidification, 
as seen in renal failure or distal renal tubular acidoses. An important caveat 
is that the rapid renal excretion of unmeasured anions in anion-gap acido-
sis, classically seen in DKA, may reduce the serum anion gap and generate 
a positive value for the urinary anion gap, despite the adequate excretion of 
urinary NH4
+; this may lead to misdiagnosis as a renal tubular acidosis.
Metabolic Acidosis 
TREATMENT
Treatment of metabolic acidosis depends on the cause and severity. 
DKA responds to insulin therapy and aggressive hydration; close atten-
tion to serum [K+] and administration of KCl is essential, given that 
the correction of insulinopenia can cause profound hypokalemia. The 
administration of alkali in anion-gap acidoses is controversial and is 
rarely appropriate in DKA. It is reasonable to treat severe lactic acidosis 
with IV HCO3
– at a rate sufficient to maintain a pH >7.20; treatment of 
moderate lactic acidosis with HCO3
– is controversial. IV HCO3 is how-
ever appropriate to reduce acidosis in d-lactic acidosis, ethylene glycol 
and methanol toxicity, and 5-oxoprolinuria.
Chronic metabolic acidosis should be treated when HCO3
– is <18–20 
mmol/L. In pts with chronic kidney disease, there is some evidence that aci-
dosis promotes protein catabolism and may worsen bone disease. Sodium 
citrate may be more palatable than oral NaHCO3, although the former
CHAPTER 2
23
Electrolytes/Acid-Base Balance
should be avoided in pts with advanced renal insufficiency, as it augments 
aluminum absorption. Oral therapy with NaHCO3 usually begins with 650 
mg tid and is titrated upward to maintain serum [HCO3
–].
� METABOLIC ALKALOSIS 
Metabolic alkalosis is due to a primary increase in serum [HCO3
–], distin-
guished from chronic respiratory acidosis—with a compensatory increase in 
renal HCO3
– reabsorption—by the associated increase in arterial pH (normal 
or decreased in chronic respiratory acidosis). Administered, exogenous alkali 
(HCO3
–, acetate, citrate, or lactate) may cause alkalosis if the normal capacity 
to excrete HCO3
– is reduced or if renal HCO3
– reabsorption is enhanced. A 
recently resurgent problem is “milk alkali syndrome,” a triad of hypercal-
cemia, metabolic alkalosis, and acute renal failure due to ingested calcium 
carbonate, typically taken for the treatment or prevention of osteoporosis.
Metabolic alkalosis is primarily caused by renal retention of HCO3
– and 
is due to a variety of underlying mechanisms. Pts are typically separated 
into two major subtypes: Cl–-responsive and Cl–-resistant. Measurement 
of urine Cl– affords this separation in the clinical setting (Fig. 2-6). The 
 quintessential causes of Cl–-responsive alkalosis are GI-induced from 
Urine [Cl-]
>20 meg/L
<20 meg/L
Chloride-responsive alkaloses
Gastric fluid loss
Diuretics*
Posthypercapnea
Villous adenoma
Congenital chloridorrhea
Nonreabsorbable anion delivery
Chloride-unresponsive alkaloses
Urine K+
Laxative abuse
Severe K+ depletion
<30 meg/L
>30 meg/L
Plasma renin
Primary aldosteronism,
bilateral adrenal 
hyperplasia, Liddle’s 
syndrome, GRA, licorice
High
Low
Low/normal
Blood pressure
Bartter’s or Gitelman’s
syndrome, or 
diuretic abuse
Renovascular HTN
JGA tumor
Malignant or
accelerated HTN
High
Plasma cortisol
Cushing’s
syndrome
High
High unilateral
renal vein renin
Yes
No
Normal
*After diuretic therapy
FIGURE 2-6 The diagnostic approach to metabolic alkalosis. See text for details. 
GRA, glucocorticoid-remediable aldosteronism; HTN, hypertension; JGA, juxtaglo-
merular apparatus. [Modified from Dubose TD: Disorders of acid-base balance, in 
The Kidney, 8th ed, BM Brenner (ed). Philadelphia, Saunders, 2008; with permission.]
SECTION 1
24
Care of the  Hospitalized Patient
vomiting or gastric aspiration through a nasogastric tube, and renal-
induced from diuretic therapy. Hypovolemia, chloride deficiency, activation 
of the renin-angiotensin-aldosterone axis, and hypokalemia play interrelated 
roles in the maintenance of this hypochloremic or “contraction” alkalosis. 
The various syndromes of true or apparent mineralocorticoid excess cause 
Cl–-resistant metabolic alkalosis (Fig. 2-6); most of these pts are hypokale-
mic, volume-expanded, and/or hypertensive.
Common forms of metabolic alkalosis are generally diagnosed from the his-
tory, physical examination, and/or basic laboratory tests. ABGs will help deter-
mine whether an elevated [HCO3
–] is reflective of metabolic alkalosis or chronic 
respiratory acidosis; ABGs are required for the diagnosis of mixed acid-base dis-
orders. Measurement of urinary electrolytes will aid in separating Cl–-responsive 
and Cl–-resistant forms. Urinary [Na+] may thus be >20 meq/L in Cl–-responsive 
alkalosis despite the presence of hypovolemia; however, urinary [Cl–] will be very 
low. Notably, urinary [Cl–] may be variable in pts with diuretic-associated alka-
losis, depending on the temporal relationship to diuretic administration. Other 
diagnostic tests—e.g., plasma renin, aldosterone, cortisol—may be appropriate 
in Cl–-resistant forms with high urinary [Cl–] (Fig. 2-6).
Metabolic Alkalosis 
TREATMENT
The acid-base disorder in Cl–-responsive alkalosis will typically respond 
to saline infusion; however, the associated hypokalemia should also be 
corrected. Pts with true or apparent mineralocorticoid excess require 
specific treatment of the underlying disorder. For example, hyperactive 
amiloride-sensitive ENaC channels cause Liddle’s syndrome, which can 
respond to therapy with amiloride and related drugs; pts with hyperal-
dosteronism may in turn respond to blockade of the mineralocorticoi-
dreceptor with spironolactone or eplerenone. Finally, severe alkalosis 
in the critical care setting may require treatment with acidifying agents 
such as acetazolamide or HCl.
� RESPIRATORY ACIDOSIS 
Respiratory acidosis is characterized by CO2 retention due to ventilatory 
failure. Causes include sedatives, stroke, chronic pulmonary disease, airway 
obstruction, severe pulmonary edema, neuromuscular disorders, and cardio-
pulmonary arrest. Symptoms include confusion, asterixis, and obtundation.
Respiratory Acidosis
TREATMENT
The goal is to improve ventilation through pulmonary toilet and 
reversal of bronchospasm. Intubation or noninvasive positive pressure 
ventilation (NPPV) may be required in severe acute cases. Acidosis due 
to hypercapnia is usually mild; however, combined respiratory and 
metabolic acidosis may cause a profound reduction in pH. Respiratory 
acidosis may accompany low tidal volume ventilation in ICU pts and 
may require metabolic “overcorrection” to maintain a neutral pH.
CHAPTER 2
25
Electrolytes/Acid-Base Balance
� RESPIRATORY ALKALOSIS 
Excessive ventilation causes a primary reduction in CO2 and ↑ pH in pneu-
monia, pulmonary edema, interstitial lung disease, and asthma. Pain and 
psychogenic causes are common; other etiologies include fever, hypoxemia, 
sepsis, delirium tremens, salicylates, hepatic failure, mechanical overven-
tilation, and CNS lesions. Pregnancy is associated with a mild respiratory 
alkalosis. Severe respiratory alkalosis may acutely cause seizures, tetany, 
cardiac arrhythmias, or loss of consciousness.
Respiratory Alkalosis
TREATMENT
Treatment should be directed at the underlying disorders. In psycho-
genic cases, sedation or a rebreathing bag may be required.
� “MIXED” DISORDERS 
In many circumstances, more than a single acid-base disturbance exists. 
Examples include combined metabolic and respiratory acidosis with car-
diogenic shock; metabolic alkalosis and anion-gap acidosis in pts with 
vomiting and diabetic ketoacidosis; and anion-gap metabolic acidosis with 
respiratory alkalosis in pts with salicylate toxicity. The diagnosis may be 
clinically evident and/or suggested by relationships between the Pco2 and 
[HCO3
–] that diverge from those found in simple disorders. For example, 
the Pco2 in a pt with metabolic acidosis and respiratory alkalosis will be 
considerably less than that predicted from the [HCO3
–] and Winter’s for-
mula [Paco2 = (1.5 × [HCO3
–]) + 8 + 2].
In “simple” anion-gap acidosis, the anion gap increases in proportion 
to the fall in [HCO3
–]. A lesser drop in serum [HCO3
–] than in the anion 
gap suggests a coexisting metabolic alkalosis. Conversely, a proportionately 
larger drop in [HCO3
–] than in the anion gap suggests the presence of a 
mixed anion-gap and non-anion-gap metabolic acidosis. Notably, however, 
these interpretations assume 1:1 relationships between unmeasured anions 
and the fall in [HCO3
–], which are not uniformly present in individual pts or 
as acidoses evolve. For example, volume resuscitation of pts with DKA will 
typically increase glomerular filtration and the urinary excretion of ketones, 
resulting in a decrease in the anion gap in the absence of a supervening 
non-anion-gap acidosis.
For a more detailed discussion, see Mount DB: Fluid and 
Electrolyte Disturbances, Chap. 45, p. 341; and DuBose TD 
Jr: Acidosis and Alkalosis, Chap. 47, p. 363, in HPIM-18. See 
also Mount DB, Zandi-Nejad K: Disorders of potassium bal-
ance, in The Kidney, 9th ed, BM Brenner (ed). Philadelphia, 
Saunders, 2011; and Ellison DH, Berl T: Clinical practice. 
The syndrome of inappropriate antidiuresis. N Engl J Med 
356:2064, 2007.
SECTION 1
26
Care of the  Hospitalized Patient
CHAPTER 3
Diagnostic Imaging in 
Internal Medicine
Clinicians have a wide array of radiologic modalities at their disposal to 
aid them in noninvasive diagnosis. Despite the introduction of highly 
specialized imaging modalities, radiologic tests such as chest radiographs 
and ultrasound continue to serve a vital role in the diagnostic approach to 
pt care. At most institutions, CT is available on an emergent basis and is 
invaluable for initial evaluation of pts with trauma, stroke, suspected CNS 
hemorrhage, or ischemic stroke. MRI and related techniques (MR angiog-
raphy, functional MRI, MR spectroscopy) provide remarkable resolution 
of many tissues including the brain, vascular system, joints, and most large 
organs. Radionuclide scans including PET (positron emission tomography) 
can provide functional assessment of organs or specific regions within 
organs. Combination of PET with MRI or CT scanning provides highly 
informative images of the location and configuration of metabolically active 
lesions, such as cancers.
This chapter will review the indications and utility of the most commonly 
utilized radiologic studies used by internists.
� CHEST RADIOGRAPHY (FIG. 3-1)
• Can be obtained quickly and should be part of the standard evaluation 
for pts with cardiopulmonary complaints.
• Is able to identify life-threatening conditions such as pneumothorax, intra-
peritoneal air, pulmonary edema, pneumonia, and aortic dissection.
• Is most often normal in a pt with an acute pulmonary embolus.
• Should be repeated in 4–6 weeks in a pt with an acute pneumonic process 
to document resolution of the radiographic infiltrate.
• Is used in conjunction with the physical exam to support the diagnosis of 
congestive heart failure. Radiographic findings supporting the diagnosis 
of heart failure include cardiomegaly, cephalization, Kerley B lines, and 
pleural effusions.
• Should be obtained daily in intubated pts to examine endotracheal tube 
position and the possibility of barotrauma.
• Helps to identify alveolar or airspace disease. Radiographic features of such 
diseases include inhomogeneous, patchy opacities and air-bronchograms.
• Helps to document the free-flowing nature of pleural effusions. Decubitus 
views should be obtained to exclude loculated pleural fluid prior to 
attempts to extract such fluid.
� ABDOMINAL RADIOGRAPHY
• Should be the initial imaging modality in a pt with suspected bowel 
obstruction. Signs of small-bowel obstruction on plain radiographs 
include multiple air-fluid levels, absence of colonic distention, and a 
“stepladder” appearance of small-bowel loops.
27
CHAPTER 3
Diagnostic Imaging in Internal Medicine
FIGURE 3-1 Normal chest radiograph-review of anatomy. 1. Trachea. 2. Carina. 
3. Right atrium. 4. Right hemi-diaphragm. 5. Aortic knob. 6. Left hilum. 7. Left ven-
tricle. 8. Left hemi-diaphragm (with stomach bubble). 9. Retrosternal clear space. 
10. Right ventricle. 11. Left hemi-diaphragm (with stomach bubble). 12. Left upper 
lobe bronchus.
SECTION 1
28
Care of the  Hospitalized Patient
• Should not be performed with barium enhancement when perforated 
bowel, portal venous gas, or toxic megacolon is suspected.
• Is used to evaluate the size of bowel:
 
1.  Normal small bowel is <3 cm in diameter.
 
2.  Normal caliber of the cecum is up to 9 cm, with the rest of the large 
bowel up to 6 cm in diameter.
� ULTRASOUND
• Is more sensitive and specific than CT scanning in evaluating for the 
presence of gallstone disease.
• Can readily identify the size of the kidneys in a pt with renal insuffi-
ciency and can exclude the presence of hydronephrosis.
• Can expeditiously evaluate for the presence of peritoneal fluid in a pt 
with blunt abdominal trauma.
• Is used in conjunction with Doppler studies to evaluate for the presence 
of arterial atherosclerotic disease.
• Is used to evaluate cardiac valves and wall motion.
• Should be used to localize loculated pleural and peritoneal fluid prior to 
draining such fluid.
• Can determine the size of thyroid nodules and guide fine-needle aspira-
tion biopsy.
• Can determine the size and location of enlarged lymph nodes, especially 
in superficial locations such as in the neck.
• Is the modality of choice for assessing known or suspected scrotal pathology.
• Should be the first imaging modality utilized when evaluating the ovaries.
� COMPUTED TOMOGRAPHY
• CT delivers a substantially higher radiation dose than conventional radi-
ography; it should therefore be used judiciously.
• CT of the brain should be the initial radiographic modality in evaluating 
a pt with a potential stroke.
• Is highly sensitive for diagnosing an acute subarachnoid hemorrhage 
and, in the acute setting, is more sensitive than MRI.
• CT of the brain is an essential test in evaluating a pt with mental status 
changes to exclude entities such as intracranial bleeding, mass effect, 
subdural or epidural hematomas, and hydrocephalus.
• Is better than MRI for evaluating osseous lesions of the skull and spine.
• CT of the chest should be considered in the evaluation of a pt with chest 
pain to rule out entities such as pulmonary embolus or aortic dissection.
• CT of the chest is essential for evaluating lung nodules to assess for the 
presence of thoracic lymphadenopathy.
• CT, with high-resolution cuts through the lungs, is the imaging modality 
of choice for evaluating the lung interstitium in a pt with interstitial lung 
disease.
• Can be used to evaluate for presence of pleural and pericardial fluid and 
to localize loculated effusions.
• Is useful in a pt with unexplained abdominal pain to evaluate for condi-
tions such as appendicitis, mesenteric ischemia or infarction, diverticulitis, 
or pancreatitis.
29
Diagnostic Imaging in Internal Medicine
CHAPTER 3
• CT of the abdomen is also the test of choice for evaluating for nephro-
lithiasis in a pt with renal colic.
• Is the test of choice for evaluating for the presence of an abscess in the 
chest or abdomen.
• In conjunction with abdominal radiography, CT can help identify the 
cause of bowel obstruction.
• Can identify abdominal conditions such as intussusception and volvulus 
in a pt with abdominal pain.
• Is the imaging modality of choice for evaluating the retroperitoneum.
• Should be obtained expeditiously in a pt with abdominal trauma to 
evaluate for the presence of intraabdominal hemorrhage and to assess 
injury to abdominal organs.
� MAGNETIC RESONANCE IMAGING
• Is more useful than CT in the evaluation of ischemic infarction, dementia, 
mass lesions, demyelinating diseases, and most nonosseous spinal 
disorders.
• Provides excellent imaging of large joints including the knee, hip, and 
shoulder.
• Can be used, often with CT or angiography, to assess possible dissecting 
aortic aneurysms and congenital anomalies of the cardiovascular system.
• Cardiac MRI is proving useful to evaluate cardiac wall motion and for 
assessing cardiac muscle viability in ischemic heart disease.
• Is preferable to CT for evaluating adrenal masses such as pheochromo-
cytoma and for helping to distinguish benign and malignant adrenal 
masses.
• Is preferable to CT for evaluating pituitary lesions and parasellar 
pathology.
� RADIONUCLIDE IMAGING
• Radionuclides can be used in the form of radioactive ions (iodide, gal-
lium, thallium) or radiolabeled substances with affinity for specific 
 tissues (radiopharmaceuticals, e.g., bisphosphonates, sestamibi, octreotide, 
metaiodobenzylguanidine [MIBG], iodocholesterol, etc.), or in the form of 
fluorodeoxyglucose for PET scanning. 
• Radionuclide scintigraphy can be combined/merged with CT or MRI for 
precise anatomic localization of the radionuclide-imaged tissue.
• Tomographic radionuclide scintigraphy (single photon emission com-
puted tomography, SPECT) is analogous to CT, using radionuclide emis-
sions instead of x-rays. It permits visualization of sequential slices that can 
be computer-manipulated to yield a three-dimensional reconstruction.
• PET is very useful for detection of metabolically active tissues, such as 
cancers and their metastases, and has largely supplanted older modalities 
of radionuclide scanning (e.g., gallium scintigraphy).
• Radionuclide scans frequently ordered by the general internist are: 
1. Bone scan to identify metastatic disease in bone or osteomyelitis
2. Sestamibi scans for preoperative localization of parathyroid adenomas
3.  Thyroid scans (technetium or iodine) to identify hot or cold thyroid 
nodules
SECTION 1
30
Care of the  Hospitalized Patient
• Specialized radionuclide scans include thallium or sestamibi myocardial 
perfusion scans, pulmonary ventilation/perfusion scans, octreotide 
scans for neuroendocrine tumors, MIBG scans for pheochromocytoma, 
iodocholesterol scans for adrenocortical adenomas, and whole-body 
radioiodine scans for disseminated thyroid cancer.
• Radioiodine scanning of the thyroid can be used to obtain quantitative 
information on iodine uptake by the thyroid, which is useful to differen-
tiate subacute thyroiditis from Graves’ disease.
CHAPTER 4
Procedures Commonly
Performed by Internists
Internists perform a wide range of medical procedures, although prac-
tices vary widely among institutions and by specialty. Internists, nurses, 
or other ancillary health care professionals perform venipuncture for 
blood testing, arterial puncture for blood gases, endotracheal intuba-
tion, and flexible sigmoidoscopy, and insert IV lines, nasogastric (NG) 
tubes, and urinary catheters. These procedures are not covered here, but 
require skill and practice to minimize pt discomfort and potential com-
plications. Here, we review more invasive diagnostic and therapeutic 
procedures performed by internists—thoracentesis, lumbar puncture, 
and paracentesis. Many additional procedures are performed by spe-
cialists and require additional training and credentialing, including the 
following:
• Allergy—skin testing, rhinoscopy
• Cardiology—stress testing, echocardiograms, coronary catheterization, 
angioplasty, stent insertion, pacemakers, electrophysiology testing and 
ablation, implantable defibrillators, cardioversion
• Endocrinology—thyroid biopsy, dynamic hormone testing, bone den-
sitometry
• Gastroenterology—upper and lower endoscopy, esophageal manometry, 
endoscopic retrograde cholangiopancreatography, stent insertion, endo-
scopic ultrasound, liver biopsy
• Hematology/Oncology—bone marrow biopsy, stem cell transplant, lymph 
node biopsy, plasmapheresis
• Pulmonary—intubation and ventilator management, bronchoscopy
• Renal—kidney biopsy, dialysis
• Rheumatology—joint aspiration
Increasingly, ultrasound, CT, and MRI are being used to guide invasive 
procedures, and flexible fiberoptic instruments are extending the reach into 
the body. For most invasive medical procedures, including those reviewed 
below, informed consent should be obtained in writing before beginning 
the procedure.
31
Procedures Commonly Performed by Internists
CHAPTER 4
THORACENTESIS
Drainage of the pleural space can be performed at the bedside. Indications 
for this procedure include diagnostic evaluation of pleural fluid, removal of 
pleural fluid for symptomatic relief, and instillation of sclerosing agents in 
pts with recurrent, usually malignant pleural effusions.
� PREPARATORY WORK 
Familiarity with the components of a thoracentesis tray is a prerequisite 
to performing a thoracentesis successfully. Recent PA and lateral chest 
radiographs with bilateral decubitus views should be obtained to document 
the free-flowing nature of the pleural effusion. Loculated pleural effusions 
should be localized by ultrasound or CT prior to drainage.
� TECHNIQUE 
A posterior approach is the preferred means of accessing pleural fluid. 
Comfortable positioning is a key to success for both pt and physician. The 
pt should sit on the edge of the bed, leaning forward with the arms abducted 
onto a pillow on a bedside stand. Pts undergoing thoracentesis frequently 
have severe dyspnea, and it is important to assess if they can maintain this 
positioning for at least 10 min. The entry site for the thoracentesis is based 
on the physical exam and radiographic findings. Percussion of dullness is 
utilized to ascertain the extent of the pleural effusion with the site of entry 
being the first or second highest interspace in this area. The entry site for 
the thoracentesis is at the superior aspect of the rib, thus avoiding the inter-
costal nerve, artery, and vein, which run along the inferior aspect of the rib 
(Fig. 4-1).
The site of entry should be marked with a pen to guide the thoracentesis. 
The skin is then prepped and draped in a sterile fashion with the operator 
FIGURE 4-1 In thoracentesis, the needle is passed over the top of the rib to avoid 
the neurovascular bundle. (From LG Gomella, SA Haist: Clinician’s Pocket Reference, 
11th ed. New York, McGraw-Hill, 2007.)
2
1
Pleura
Lung tissue
Local
anesthetic
Rib
Effusion
Neurovascular bundle
(nerve, artery, vein)
SECTION 1
32
Care of the  Hospitalized Patient
observing sterile technique at all times. A small-gauge needle is used to 
anesthetize the skin, and a larger-gauge needle is used to anesthetize down 
to the superior aspect of the rib. The needle should then be directed over 
the upper margin of the rib to anesthetize down to the parietal pleura. 
The pleural space should be entered with the anesthetizing needle, all the 
while using liberal amounts of lidocaine.
A dedicated thoracentesis needle with an attached syringe should next 
be utilized to penetrate the skin. This needle should be advanced to the 
superior aspect of the rib. While maintaining gentle negative pressure, the 
needle should be slowly advanced into the pleural space. If a diagnostic 
tap is being performed, aspiration of only 30–50 mL of fluid is necessary 
before termination of the procedure. If a therapeutic thoracentesis is being 
performed, a three-way stopcock is utilized to direct the aspirated pleural 
fluid into collection bottles or bags. No more than 1 L of pleural fluid 
should be withdrawn at any given time, as quantities >1–1.5 L can result in 
re-expansion pulmonary edema.
After all specimens have been collected, the thoracentesis needle should 
be withdrawn and the needle site occluded for at least 1 min.
� SPECIMEN COLLECTION 
The diagnostic evaluation of pleural fluid depends on the clinical situa-
tion. All pleural fluid samples should be sent for cell count and differen-
tial, Gram stain, and bacterial cultures. LDH and protein determinations 
should also be made to differentiate between exudative and transudative 
pleural effusions. The pH should be determined if empyema is a diagnostic 
consideration. Other studies on pleural fluid include mycobacterial 
and fungal cultures, glucose, triglyceride level, amylase, and cytologic 
 determination.
� POSTPROCEDURE 
A postprocedural chest radiograph should be obtained to evaluate for a 
pneumothorax, and the pt should be instructed to notify the physician if 
new shortness of breath develops.
LUMBAR PUNCTURE
Evaluation of CSF is essential for the diagnosis of suspected meningeal 
infection, subarachnoid hemorrhage, leptomeningeal neoplastic disease, 
and noninfectious meningitis. Relative contraindications to LP include local 
skin infection in the lumbar area, suspected spinal cord mass lesion, and a 
suspected intracranial mass lesion. Any bleeding diathesis should also be 
corrected prior to performing LP to prevent the possible occurrence of an 
epidural hematoma. A functional platelet count >50,000/μL and an INR 
<1.5 are advisable to perform LP safely.
� PREPARATORY WORK 
Familiarity with the components of a lumbar puncture tray is a prerequisite 
to performing LP successfully. In pts with focal neurologic deficits or with 
evidence of papilledema on physical exam, a CT scan of the head should be 
obtained prior to performing LP.
33
CHAPTER 4
Procedures Commonly Performed by Internists
� TECHNIQUE 
Proper positioning of the pt is important to ensure a successful LP. Two dif-
ferent pt positions can be used: the lateral decubitus position and the sitting 
position. Most routine LPs should be performed using the lateral decubitus 
position (Fig. 4-2). The sitting position may be preferable in obese pts. 
With either position, the pt should be instructed to flex the spine as much 
as possible. In the lateral decubitus position, the pt is instructed to assume 
the fetal position with the knees flexed toward the abdomen. In the sitting 
position, the pt should bend over a bedside table with the head resting on 
folded arms.
The entry site for an LP is below the level of the conus medullaris, which 
extends to L1-L2 in most adults. Thus, either the L3-L4 or L4-L5 interspace 
can be utilized as the entry site. The posterior superior iliac crest should 
be identified and the spine palpated at this level. This represents the L3-L4 
interspace, with the other interspaces referenced from this landmark. The 
midpoint of the interspace between the spinous processes represents the 
entry point for the thoracentesis needle. This entry site should be marked 
with a pen to guide the LP. The skin is then prepped and draped in a ster-
ile fashion with the operator observing sterile technique at all times. A 
small-gauge needle is then used to anesthetize the skin and subcutaneous 
tissue. The spinal needle should be introduced perpendicular to the skin in 
the midline and should be advanced slowly. The needle stylette should be 
withdrawn frequently as the spinal needle is advanced. As the needle enters 
the subarachnoid space, a “popping” sensation can sometimes be felt. If 
bone is encountered, the needle should be withdrawn to just below the skin 
and then redirected more caudally. Once CSF begins to flow, the opening 
pressure can be measured. This should be measured in the lateral decubitus 
position with the pt shifted to this position if the procedure was begun with 
the pt in the sitting position. After the opening pressure is measured, the 
CSF should be collected in a series of specimen tubes for various tests. At a 
minimum, a total of 10–15 mL of CSF should be collected in the different 
specimen tubes.
Once the required spinal fluid is collected, the stylette should be replaced 
and the spinal needle removed.
FIGURE 4-2 Proper positioning of a pt in the lateral decubitus position. Note that 
the shoulders and hips are in a vertical plane; the torso is perpendicular to the bed. 
[From RP Simon et al (eds): Clinical Neurology, 7th ed. New York, McGraw-Hill, 2009.]
Level of the iliac crests
L3–L4 interspace
SECTION 1
34
Care of the  Hospitalized Patient
� SPECIMEN COLLECTION 
Diagnostic evaluation of CSF is based on the clinical scenario. In general, 
spinal fluid should always be sent for cell count with differential, protein, 
glucose, and bacterial cultures. Other specialized studies that can be 
obtained on CSF include viral cultures, fungal and mycobacterial cultures, 
VDRL, cryptococcal antigen, oligoclonal bands, and cytology.
� POSTPROCEDURE 
To reduce the chance of a post-LP headache, the pt should be instructed 
to lie prone for at least 3 h. If a headache does develop, bedrest, hydration, 
and oral analgesics are often helpful. If an intractable post-LP headache 
ensues, the pt may have a persistent CSF leak. In this case, consultation 
with an anesthesiologist should be considered for the placement of a 
blood patch.
PARACENTESIS
Removal and analysis of peritoneal fluid is invaluable in evaluating pts with 
new-onset ascites or ascites of unknown etiology. It is also requisite in pts 
with known ascites who have a decompensation in their clinical status. 
Relative contraindications include bleeding diathesis, prior abdominal sur-
gery, distended bowel, or known loculated ascites.
� PREPARATORY WORK 
Prior to performing a paracentesis, any severe bleeding diathesis should be 
corrected. Bowel distention should also be relieved by placement of a naso-
gastric tube, and the bladder should also be emptied before beginning the 
procedure. If a large-volume paracentesis is being performed, large vacuum 
bottles with the appropriate connecting tubing should be obtained.
� TECHNIQUE 
Proper pt positioning greatly improves the ease with which a paracentesis 
can be performed. The pt should be instructed to lie supine with the head 
of the bed elevated to 45°. This position should be maintained for ~15 
min to allow ascitic fluid to accumulate in the dependent portion of the 
 abdomen.
The preferred entry site for paracentesis is a midline puncture halfway 
between the pubic symphysis and the umbilicus; this correlates with 
the location of the relatively avascular linea alba. The midline puncture 
should be avoided if there is a previous midline surgical scar, as neovascu-
larization may have occurred. Alternative sites of entry include the lower 
quadrants, lateral to the rectus abdominis, but caution should be used 
to avoid collateral blood vessels that may have formed in pts with portal 
hypertension.
The skin is prepped and draped in a sterile fashion. The skin, the sub-
cutaneous tissue, and the abdominal wall down to the peritoneum should 
be infiltrated with an anesthetic agent. The paracentesis needle with an 
attached syringe is then introduced in the midline perpendicular to the 
skin. To prevent leaking of ascitic fluid, “Z-tracking” can sometimes be 
helpful: after penetrating the skin, the needle is inserted 1–2 cm before 
35
Principles of Critical Care Medicine
CHAPTER 5
advancing further. The needle is then advanced slowly while continuous 
aspiration is performed. As the peritoneum is pierced, the needle will “give” 
noticeably. Fluid should flow freely into the syringe soon thereafter. For a 
diagnostic paracentesis, removal of 50 mL of ascitic fluid is adequate. For 
a large-volume paracentesis, direct drainage into large vacuum containers 
using connecting tubing is a commonly utilized option.
After all samples have been collected, the paracentesis needle should be 
removed and firm pressure applied to the puncture site.
� SPECIMEN COLLECTION 
Peritoneal fluid should be sent for cell count with differential, Gram stain, 
and bacterial cultures. Albumin measurement of ascitic fluid is also neces-
sary for calculating the serum–ascitic albumin gradient. Depending on the 
clinical scenario, other studies that can be obtained include mycobacterial 
cultures, amylase, adenosine deaminase, triglycerides, and cytology.
� POSTPROCEDURE 
The pt should be monitored carefully after paracentesis and should be 
instructed to lie supine in bed for several hours. If persistent fluid leakage 
occurs, continued bedrest with pressure dressings at the puncture site can 
be helpful. For pts with hepatic dysfunction undergoing large-volume 
paracentesis, the sudden reduction in intravascular volume can precipi-
tate hepatorenal syndrome. Administration of 25 g IV albumin following 
large-volume paracentesis has been shown to decrease the incidence of 
postprocedure renal failure. Finally, if the ascites fluid analysis shows 
evidence of spontaneous bacterial peritonitis, then antibiotics (directed 
toward gram-negative gut bacteria) and IV albumin should be adminis-
tered as soon as possible.
For a more detailed discussion, see Robbins E, Hauser SL: 
Technique of Lumbar Puncture, Chap. e46, and the Clinical 
Procedure Tutorial videos in Chaps. e54–e57 in HPIM-18.
CHAPTER 5
Principles of Critical Care Medicine
� INITIAL EVALUATION OF THE CRITICALLY ILL PATIENT
Initial care of critically ill pts must often be performed rapidly and before a 
thorough medical history has been obtained. Physiologic stabilization begins 
with the principles of advanced cardiovascular life support and frequently 
involves invasive techniques such as mechanical ventilation and renal replace-
ment therapy to support organ systems that are failing. A variety of severity-of-
illness scoring systems, such as APACHE (acute physiology and chronic health 
evaluation), have been developed. Although these tools are useful for ensuring 
similarity among groups of pts involved in clinical trials or in quality assurance 
SECTION 1
36
Care of the  Hospitalized Patient
monitoring, their relevance to individual pts is less clear. These scoring systems 
are not typically used to guide clinical management.
� SHOCK
Shock, which is characterized by multisystem end-organ hypoperfusion and 
tissue hypoxia, is a frequent problem requiring ICU admission. A variety of 
clinical indicators of shock exist, including reduced mean arterial pressure, 
tachycardia, tachypnea, cool extremities, altered mental status, oliguria, and 
lactic acidosis. Although hypotension is usually observed in shock, there is 
not a specific blood pressure threshold that is used to define it. Shock can 
result from decreased cardiac output, decreased systemic vascular resis-
tance, or both. The three main categories of shock are hypovolemic, car-
diogenic, and high cardiac output/low systemic vascular resistance. Clinical 
evaluation can be useful to assess the adequacy of cardiac output, with nar-
row pulse pressure, cool extremities, and delayed capillary refill suggestive 
of reduced cardiac output. Indicators of high cardiac output (e.g., widened 
pulse pressure, warm extremities, and rapid capillary refill) associated with 
shock suggest reduced systemic vascular resistance. Reduced cardiac output 
can be due to intravascular volume depletion (e.g., hemorrhage) or cardiac 
dysfunction. Intravascular volume depletion can be assessed through the 
jugular venous pressure, changes in right atrial pressure with spontaneous 
respirations, or changes in pulse pressure during positive pressure mechani-
cal ventilation. Reduced systemic vascular resistance is often caused by 
sepsis, but high cardiac output hypotension is also seen in pancreatitis, liver 
failure, burns, anaphylaxis, peripheral arteriovenous shunts, and thyro-
toxicosis. Early resuscitation of septic and cardiogenic shock may improve 
survival; objective assessments such as echocardiography and/or invasive 
vascular monitoring should be used to complement clinical evaluation and 
minimize end-organ damage. The approach to the pt in shock is outlined 
in Fig. 5-1.
� MECHANICAL VENTILATORY SUPPORT
Critically ill pts often require mechanical ventilation. During initial 
resuscitation, standard principles of advanced cardiovascular life sup-
port should be followed. Mechanical ventilation should be considered for 
acute hypoxemic respiratory failure, which may occur with cardiogenic 
shock, pulmonary edema (cardiogenic or noncardiogenic), or pneumonia. 
Mechanical ventilation should also be considered for treatment of ventila-
tory failure, which can result from an increased load on the respiratory 
system—often manifested by lactic acidosis or decreased lung compli-
ance. Mechanical ventilation may decrease respiratory work, improve 
arterial oxygenation with improved tissue O2 delivery, and reduce acido-
sis. Reduction in mean arterial pressure after institution of mechanical 
ventilation commonly occurs due to reduced venous return from positive 
pressure ventilation, reduced endogenous catecholamine secretion, and 
administration of drugs used to facilitate intubation. Since hypovolemia 
often contributes to postintubation hypotension, IV volume administra-
tion should be considered. The major types of respiratory failure are 
discussed in Chap. 16.
37
CHAPTER 5
Principles of Critical Care Medicine
The Mechanically Ventilated Patient
TREATMENT
Many pts receiving mechanical ventilation require treatment for pain 
(typically with opiates) and for anxiety (typically with benzodiazepines, 
which also have the benefit of providing amnesia). Less commonly, 
neuromuscular blocking agents are required to facilitate ventilation 
when there is extreme dyssynchrony between the pt’s respiratory efforts 
and the ventilator that cannot be corrected with manipulation of the
Inotropes, afterload
reduction
Antibiotics, EGDT, low-dose
steroids, activated protein C
Heart is “full”
(cardiogenic shock)
Evaluate for myocardial
ischemia
Cold, clammy
extremities
Warm, bounding
extremities
High cardiac output
No improvement
What does not fit?
Adrenal crisis, right heart syndrome,
pericardial disease
Consider echocardiogram,
invasive vascular monitoring
Consider echocardiogram,
invasive vascular monitoring
Septic shock,
liver failure
Low cardiac output
JVP, crackles
JVP, orthostasis
Intravenous fluids
May
convert
to
SHOCK
Heart is “empty”
(hypovolemic shock)
FIGURE 5-1 Approach to pt in shock. EGDT, early goal directed therapy; JVP, jugular 
venous pulse.
SECTION 1
38
Care of the  Hospitalized Patient
ventilator settings; aggressive sedation is required during treatment 
with neuromuscular blockers. Neuromuscular blocking agents should 
be used with caution because a myopathy associated with prolonged 
weakness can result.
Weaning from mechanical ventilation should be considered when 
the disease process prompting intubation has improved. Daily screen-
ing of intubated pts for weaning potential should be performed. Stable 
oxygenation (at low PEEP levels), intact cough and airway reflexes, and 
lack of requirement for vasopressor agents are required before consider-
ing a trial of weaning from mechanical ventilation. The most effective 
approach for weaning is usually a spontaneous breathing trial, which 
involves 30–120 min of breathing without significant ventilatory sup-
port. Either an open T-piece breathing system or minimal amounts 
of ventilatory support (pressure support to overcome resistance of the 
endotracheal tube and/or low levels of CPAP) can be used. Failure of a 
spontaneous breathing trial has occurred if tachypnea (respiratory rate 
>35 breaths/min for >5 min), hypoxemia (O2 saturation <90%), tachy-
cardia (>140 beats/min or 20% increase from baseline), bradycardia 
(20% reduction from baseline), hypotension (<90 mmHg), hyperten-
sion (>180 mmHg), increased anxiety, or diaphoresis develop. At the 
end of the spontaneous breathing trial, the rapid shallow breathing index 
(RSBI or f/VT), which is calculated as respiratory rate in breaths/min
divided by tidal volume in liters, can be used to predict weanability. 
A f/VT <105 at the end of the spontaneous breathing test warrants a trial 
of extubation. Daily interruption of sedative infusions in conjunction 
with spontaneous breathing trials can limit excessive sedation and 
shorten the duration of mechanical ventilation. Despite careful weaning 
protocols, up to 10% of pts develop respiratory distress after extubation 
and may require reintubation.
� MULTIORGAN SYSTEM FAILURE
Multiorgan system failure is a syndrome defined by the simultaneous 
dysfunction or failure of two or more organs in pts with critical illness. 
Multiorgan system failure is a common consequence of systemic inflam-
matory conditions (e.g., sepsis, pancreatitis, and trauma). To meet the 
criteria for multiorgan system failure, organ failure must persist for >24 h. 
Prognosis worsens with increased duration of organ failure and increased 
number of organ systems involved.
� MONITORING IN THE ICU
With critical illness, close and often continuous monitoring of multiple 
organ systems is required. In addition to pulse oximetry, frequent arte-
rial blood gas analysis can reveal evolving acid-base disturbances and 
assess the adequacy of ventilation. Intra-arterial pressure monitoring is 
frequently performed to follow blood pressure and to provide arterial blood 
gases and other blood samples. Pulmonary artery (Swan-Ganz) catheters 
can provide pulmonary artery pressure, cardiac output, systemic vascular 
resistance, and oxygen delivery measurements. However, no morbidity or 
39
CHAPTER 5
Principles of Critical Care Medicine
mortality benefit from pulmonary artery catheter use has been demon-
strated, and rare but significant complications from placement of central 
venous access (e.g., pneumothorax, infection) or the pulmonary artery 
catheter (e.g., cardiac arrhythmias, pulmonary artery rupture) can result. 
Thus, routine pulmonary artery catheterization in critically ill pts is not 
recommended.
For intubated pts receiving volume-controlled modes of mechanical 
ventilation, respiratory mechanics can be followed easily. The peak air-
way pressure is regularly measured by mechanical ventilators, and the 
plateau pressure can be assessed by including an end-inspiratory pause. 
The inspiratory airway resistance is calculated as the difference between 
the peak and plateau airway pressures (with adjustment for flow rate). 
Increased airway resistance can result from bronchospasm, respiratory 
secretions, or a kinked endotracheal tube. Static compliance of the respi-
ratory system is calculated as the tidal volume divided by the gradient 
in airway pressure (plateau pressure minus PEEP). Reduced respiratory 
system compliance can result from pleural effusions, pneumothorax, 
pneumonia, pulmonary edema, or auto-PEEP (elevated end-expiratory 
pressure related to insufficient time for alveolar emptying before the next 
inspiration).
� PREVENTION OF CRITICAL ILLNESS COMPLICATIONS
Critically ill pts are prone to a number of complications, including the 
 following:
• Sepsis—Often related to the invasive monitoring performed of critically 
ill pts.
• Anemia—Usually due to chronic inflammation as well as iatrogenic 
blood loss. A conservative approach to providing blood transfusions is 
recommended unless pts have active hemorrhage.
• Deep-vein thrombosis—May occur despite standard prophylaxis with 
SC heparin or lower extremity sequential compression devices and may 
occur at the site of central venous catheters. Low-molecular-weight 
heparins (e.g., enoxaparin) are more effective for high-risk pts than is 
unfractionated heparin.
• GI bleeding—Stress ulcers of the gastric mucosa frequently develop in 
pts with bleeding diatheses, shock, or respiratory failure, necessitating 
prophylactic acid neutralization in such pts.
• Acute renal failure—A frequent occurrence in ICU pts, exacerbated by 
nephrotoxic medications and hypoperfusion. The most common etiol-
ogy is acute tubular necrosis. Low-dose dopamine treatment does not 
protect against the development of acute renal failure.
• Inadequate nutrition and hyperglycemia—Enteral feeding, when pos-
sible, is preferred over parenteral nutrition, since the parenteral route 
is associated with multiple complications including hyperglycemia, 
cholestasis, and sepsis. The utility of tight glucose control in the ICU is 
controversial. 
• ICU-acquired weakness—Neuropathies and myopathies have been 
described—typically after at least one week of ICU care. These complica-
tions are especially common in sepsis.
40
SECTION 1
Care of the  Hospitalized Patient
� NEUROLOGIC DYSFUNCTION IN CRITICALLY ILL PATIENTS
A variety of neurologic problems can develop in critically ill pts. Most ICU pts 
develop delirium, which is characterized by acute changes in mental status, 
inattention, disorganized thinking, and an altered level of consciousness. Use 
of dexmedetomidine was associated with less ICU delirium than midazolam, 
one of the conventional sedatives. Less common but important neurologic 
complications include anoxic brain injury, stroke, and status epilepticus.
� LIMITATION OR WITHDRAWAL OF CARE
Withholding or withdrawing care commonly occurs in the ICU. Technological 
advances have allowed many pts to be maintained in the ICU with little 
or no chance of recovery. Increasingly, pts, families, and caregivers have 
acknowledged the ethical validity to withhold or withdraw care when the 
pt or surrogate decision-maker determines that the pt’s goals for care are no 
longer achievable with the clinical situation.
For a more detailed discussion, see Kress JP, Hall JB: 
Approach to the Patient With Critical Illness, Chap. 267, 
p. 2196, in HPIM-18.
CHAPTER 6
Pain and Its Management
Pain
APPROACH TO THE
PATIENT
Pain is the most common symptom that brings a pt to a physician’s 
attention. Management depends on determining its cause, alleviating 
triggering and potentiating factors, and providing rapid relief whenever 
possible. Pain may be of somatic (skin, joints, muscles), visceral, or neu-
ropathic (injury to nerves, spinal cord pathways, or thalamus) origin. 
Characteristics of each are summarized in Table 6-1.
NEUROPATHIC PAIN Definitions: neuralgia: pain in the distribution 
of a single nerve, as in trigeminal neuralgia; dysesthesia: spontaneous, 
unpleasant, abnormal sensations; hyperalgesia and hyperesthesia: exagger-
ated responses to nociceptive or touch stimulus, respectively; allodynia: 
perception of light mechanical stimuli as painful, as when vibration 
evokes painful sensation. Reduced pain perception is called hypalgesia or, 
when absent, analgesia. Causalgia is continuous severe burning pain with 
indistinct boundaries and accompanying sympathetic nervous system 
dysfunction (sweating; vascular, skin, and hair changes—sympathetic 
dystrophy) that occurs after injury to a peripheral nerve.
Sensitization refers to a lowered threshold for activating primary noci-
ceptors following repeated stimulation in damaged or inflamed tissues; 
41
CHAPTER 6
Pain and Its Management
inflammatory mediators play a role. Sensitization contributes to tender-
ness, soreness, and hyperalgesia (as in sunburn).
Referred pain results from the convergence of sensory inputs from 
skin and viscera on single spinal neurons that transmit pain signals to 
the brain. Because of this convergence, input from deep structures is 
mislocalized to a region of skin innervated by the same spinal segment.
CHRONIC PAIN The problem is often difficult to diagnose, and pts may 
appear emotionally distraught. Several factors can cause, perpetuate, 
or exacerbate chronic pain: (1) painful disease for which there is no 
cure (e.g., arthritis, cancer, migraine headaches, diabetic neuropathy); 
(2) neural factors initiated by a bodily disease that persist after the 
disease has resolved (e.g., damaged sensory or sympathetic nerves); 
(3) psychological conditions. Pay special attention to the medical history 
and to depression. Major depression is common, treatable, and poten-
tially fatal (suicide).
� PATHOPHYSIOLOGY: ORGANIZATION OF PAIN PATHWAYS
Pain-producing (nociceptive) sensory stimuli in skin and viscera activate 
peripheral nerve endings of primary afferent neurons, which synapse on 
second-order neurons in spinal cord or medulla (Fig. 6-1). These second-
order neurons form crossed ascending pathways that reach the thalamus 
and are projected to the somatosensory cortex. Parallel ascending neurons 
TABLE 6-1 CHARACTERISTICS OF SOMATIC AND NEUROPATHIC PAIN
Somatic pain
Nociceptive stimulus usually evident
Usually well localized
Similar to other somatic pains in pt’s experience
Relieved by anti-inflammatory or narcotic analgesics
Visceral pain
Most commonly activated by inflammation
Pain poorly localized and usually referred
Associated with diffuse discomfort, e.g., nausea, bloating
Relieved by narcotic analgesics
Neuropathic pain
No obvious nociceptive stimulus
Associated evidence of nerve damage, e.g., sensory impairment, weakness
Unusual, dissimilar from somatic pain, often shooting or electrical quality
Only partially relieved by narcotic analgesics, may respond to antidepressants 
or anticonvulsants
SECTION 1
42
Care of the  Hospitalized Patient
connect with brainstem nuclei and ventrocaudal and medial thalamic 
nuclei. These parallel pathways project to the limbic system and underlie 
the emotional aspect of pain. Pain transmission is regulated at the dorsal 
horn level by descending bulbospinal pathways that contain serotonin, 
norepinephrine, and several neuropeptides.
Agents that modify pain perception may act by reducing tissue inflam-
mation (NSAIDs, prostaglandin synthesis inhibitors), interfering with pain 
transmission (narcotics), or enhancing descending modulation (narcotics 
Spinal 
cord
Medulla
Midbrain
Spinothalamic
tract
Hypothalamus
A
B
SS
Thalamus
C
F
Injury
FIGURE 6-1 Pain transmission and modulatory pathways. A. Transmission system 
for nociceptive messages. Noxious stimuli activate the sensitive peripheral ending of 
the primary afferent nociceptor by the process of transduction. The message is then 
transmitted over the peripheral nerve to the spinal cord, where it synapses with cells 
of origin of the major ascending pain pathway, the spinothalamic tract. The mes-
sage is relayed in the thalamus to the anterior cingulate (C), frontal insular (F), and 
somatosensory cortex (SS). B. Pain-modulation network. Inputs from frontal cortex 
and hypothalamus activate cells in the midbrain that control spinal pain-transmission 
cells via cells in the medulla.
43
CHAPTER 6
Pain and Its Management
and antidepressants). Anticonvulsants (gabapentin, carbamazepine) may be 
effective for aberrant pain sensations arising from peripheral nerve injury.
Pain ( Table 6-2 )
TREATMENT
ACUTE SOMATIC PAIN 
• Moderate pain: usually treated effectively with nonnarcotic analgesics, 
e.g., aspirin, acetaminophen, and NSAIDs, which inhibit cyclooxyge-
nase (COX) and, except for acetaminophen, have anti-inflammatory 
actions, especially at high dosages. Particularly effective for headache 
and musculoskeletal pain.
• Parenteral ketorolac is sufficiently potent and rapid in onset to sup-
plant opioids for many pts with acute severe pain.
• Narcotic analgesics in oral or parenteral form can be used for more 
severe pain. These are the most effective drugs available; the opioid 
antagonist naloxone should be readily available when narcotics are 
used in high doses or in unstable pts.
• Pt-controlled analgesia (PCA) permits infusion of a baseline dose 
plus self-administered boluses (activated by press of a button) as 
needed to control pain.
CHRONIC PAIN 
• Develop an explicit treatment plan including specific and realistic 
goals for therapy, e.g., getting a good night’s sleep, being able to go 
shopping, or returning to work. 
• A multidisciplinary approach that utilizes medications, counseling, 
physical therapy, nerve blocks, and even surgery may be required to 
improve quality of life.
• Psychological evaluation is key; behaviorally based treatment para-
digms are frequently helpful. 
• Some pts may require referral to a pain clinic; for others, pharmaco-
logic management alone can provide significant help.
• Tricyclic antidepressants are useful in management of chronic pain 
from many causes, including headache, diabetic neuropathy, posther-
petic neuralgia, chronic low back pain, and central post-stroke pain.
• Anticonvulsants or antiarrhythmics benefit pts with neuropathic pain 
and little or no evidence of sympathetic dysfunction (e.g., diabetic 
neuropathy, trigeminal neuralgia).
• The long-term use of opioids is accepted for pain due to malignant 
disease, but is controversial for chronic pain of nonmalignant origin. 
When other approaches fail, long-acting opioid compounds such as 
levorphanol, methadone, sustained-release morphine, or transdermal 
fentanyl may be considered for these pts.
For a more detailed discussion, see Rathmell HP, Fields HL: 
Pain: Pathophysiology and Management, Chap. 11, p. 93, 
in HPIM-18.
44
TABLE 6-2 DRUGS FOR RELIEF OF PAIN
Generic Name
Dose, mg
Interval
Comments
Nonnarcotic analgesics: usual doses and intervals 
Acetylsalicylic acid
650 PO
q4h
Enteric-coated preparations available
Acetaminophen
650 PO
q4h
Side effects uncommon
Ibuprofen
400 PO
q4–6h
Available without prescription
Naproxen
250–500 PO
q12h
Delayed effects may be due to long half-life
Fenoprofen
200 PO
q4–6h
Contraindicated in renal disease
Indomethacin
25–50 PO
q8h
Gastrointestinal side effects common
Ketorolac
15–60 IM/IV
q4–6h
Available for parenteral use
Celecoxib
100–200 PO
q12–24h
Useful for arthritis
Valdecoxib
10–20 PO
q12–24h
Removed from U.S. market in 2005
Generic Name
Parenteral 
Dose, mg
PO Dose, mg
Comments
Narcotic analgesics: usual doses and intervals
Codeine
30–60 q4h
30–60 q4h
Nausea common
Oxycodone
—
5–10 q4–6h
Usually available with acetaminophen or aspirin
Morphine
5 q4h
30 q4h
Morphine sustained release
—
15–60 bid to tid
Oral slow-release preparation
Hydromorphone
1–2 q4h
2–4 q4h
Shorter acting than morphine sulfate
Levorphanol
2 q6–8h
4 q6–8h
Longer acting than morphine sulfate; absorbed well PO
Methadone
5-10 q6–8h
5–20 q6–8h
Delayed sedation due to long half-life; therapy should not be initiated with >40 mg/
day and dose escalation should be made no more frequently than every 3 days
45
Meperidine
50–100 
q3–4h
300 q4h
Poorly absorbed PO; normeperidine a toxic metabolite; routine use of this agent is 
not recommended
Butorphanol
—
1–2 q4h
Intranasal spray
Fentanyl
25–100 μg/h
—
72-h transdermal patch
Tramadol
—
50–100 q4–6h
Mixed opioid/adrenergic action
Generic Name
Uptake Blockade
Sedative
Potency
Anticholinergic 
Potency
Orthostatic
Hypotension
Cardiac 
Arrhythmia
Ave. Dose, 
mg/d
Range, 
mg/d
5-HT
NE
Antidepressantsa
Doxepin
++
+
High
Moderate
Moderate
Less
200
75–400
Amitriptyline
++++
++
High
Highest
Moderate
Yes
150
25–300
Imipramine
++++
++
Moderate
Moderate
High
Yes
200
75–400
Nortriptyline
+++
++
Moderate
Moderate
Low
Yes
100
40–150
Desipramine
+++
++++
Low
Low
Low
Yes
150
50–300
Venlafaxine
+++
++
Low
None
None
No
150
75–400
Duloxetine
+++
+++
Low
None
None
No
40
30–60
Generic Name
PO Dose, mg
Interval
Generic Name
PO Dose, mg
Interval
Anticonvulsants and antiarrhythmicsa
Phenytoin
300
Daily/qhs
Clonazepam
1
q6h
Carbamazepine
200–300
q6h
Gabapentinb
600–1200
q8h
Oxcarbazepine
300
bid
Pregabalin
150–600
bid
aAntidepressants, anticonvulsants, and antiarrhythmics have not been approved by the U.S. Food and Drug Administration (FDA) for the treatment of pain.
bGabapentin in doses up to 1800 mg/d is FDA approved for postherpetic neuralgia.
Abbreviations: 5-HT, serotonin; NE, norepinephrine.
SECTION 1
46
Care of the  Hospitalized Patient
Calculate BEE
• BEE (men) = 66.47 + (13.75 x W) + (5.00 x H) – (6.76 x A) kcal/d
• BEE (women) = 655.10 + (9.56 x W) + (1.85 x H) – (4.68 x A) kcal/d
Account for the stress of illness
• BEE x 1.1 for patients without significant physiologic stress
• BEE x 1.4 for patients with marked stress, such as sepsis or trauma
24-hour energy goal for feeding
FIGURE 7-1 Basal energy expenditure (BEE) calculation in kcal/d, estimated by the 
Harris and Benedict formula. A, age in years; H, height in cm; W, Weight in kg.
CHAPTER 7
Assessment of Nutritional Status
Stability of body weight requires that energy intake and expenditures are 
balanced over time. The major categories of energy output are resting 
energy expenditure (REE) and physical activity; minor sources include the 
energy cost of metabolizing food (thermic effect of food or specific dynamic 
action) and shivering thermogenesis. The average energy intake is about 
2800 kcal/d for men and about 1800 kcal/d for women, though these esti-
mates vary with age, body size, and activity level. Basal energy expenditure 
(BEE), measured in kcal/d, may be estimated by the Harris and Benedict 
formula (Fig. 7-1).
Dietary reference intakes (DRI) and recommended dietary allow-
ances (RDA) have been defined for many nutrients, including 9 essential 
amino acids, 4 fat-soluble and 10 water-soluble vitamins, several minerals, 
fatty acids, choline, and water (Tables 73-1 and 73-2, pp. 590 and 591, 
in HPIM-18). The usual water requirements are 1.0–1.5 mL/kcal energy 
expenditure in adults, with adjustments for excessive losses. The RDA for 
protein is 0.6 g/kg ideal body weight, representing 15% of total caloric 
intake. Fat should constitute ≤30% of calories, and saturated fat should 
be <10% of calories. At least 55% of calories should be derived from 
carbohydrates.
� MALNUTRITION
Malnutrition results from inadequate intake or abnormal gastrointestinal 
assimilation of dietary calories, excessive energy expenditure, or altered 
metabolism of energy supplies by an intrinsic disease process.
47
CHAPTER 7
Assessment of Nutritional Status
Both outpatients and inpatients are at risk for malnutrition if they meet 
one or more of the following criteria:
• Unintentional loss of >10% of usual body weight in the preceding 
3 months
• Body weight <90% of ideal for height (Table 7-1)
• Body mass index (BMI: weight/height2 in kg/m2) <18.5
Two forms of severe malnutrition can be seen: marasmus, which refers 
to generalized starvation that occurs in the setting of chronically decreased 
energy intake, and kwashiorkor, which refers to selective protein malnutri-
tion due to decreased protein intake and catabolism in the setting of acute, 
life-threatening illnesses or chronic inflammatory disorders. Aggressive 
TABLE 7-1 IDEAL WEIGHT FOR HEIGHT
Men
Women
Heighta
Weighta
Height
Weight
Height
Weight
Height
Weight
145
51.9
166
64.0
140
44.9
161
56.9
146
52.4
167
64.6
141
45.4
162
57.6
147
52.9
168
65.2
142
45.9
163
58.3
148
53.5
169
65.9
143
46.4
164
58.9
149
54.0
170
66.6
144
47.0
165
59.5
150
54.5
171
67.3
145
47.5
166
60.1
151
55.0
172
68.0
146
48.0
167
60.7
152
55.6
173
68.7
147
48.6
168
61.4
153
56.1
174
69.4
148
49.2
169
62.1
154
56.6
175
70.1
149
49.8
155
57.2
176
70.8
150
50.4
156
57.9
177
71.6
151
51.0
157
58.6
178
72.4
152
51.5
158
59.3
179
73.3
153
52.0
159
59.9
180
74.2
154
52.5
160
60.5
181
75.0
155
53.1
161
61.1
182
75.8
156
53.7
162
61.7
183
76.5
157
54.3
163
62.3
184
77.3
158
54.9
164
62.9
185
78.1
159
55.5
165
63.5
186
78.9
160
56.2
aValues are expressed in cm for height and kg for weight. To obtain height in inches, divide by 
2.54. To obtain weight in pounds, multiply by 2.2.
Source: Adapted from GL Blackburn et al.: Nutritional and metabolic assessment of the hospi-
talized patient. J Parenter Enteral Nutr 1:11, 1977; with permission.
SECTION 1
48
Care of the  Hospitalized Patient
nutritional support is indicated in kwashiorkor to prevent infectious com-
plications and poor wound healing.
Etiology 
The major etiologies of malnutrition are starvation, stress from surgery or 
severe illness, and mixed mechanisms. Starvation results from decreased 
dietary intake (from poverty, chronic alcoholism, anorexia nervosa, fad 
diets, severe depression, neurodegenerative disorders, dementia, or strict 
vegetarianism; abdominal pain from intestinal ischemia or pancreatitis; or 
anorexia associated with AIDS, disseminated cancer, heart failure, or renal 
failure) or decreased assimilation of the diet (from pancreatic insufficiency; 
short bowel syndrome; celiac disease; or esophageal, gastric, or intestinal 
obstruction). Contributors to physical stress include fever, acute trauma, 
major surgery, burns, acute sepsis, hyperthyroidism, and inflammation as 
occurs in pancreatitis, collagen vascular diseases, and chronic infectious 
diseases such as tuberculosis or AIDS opportunistic infections. Mixed 
mechanisms occur in AIDS, disseminated cancer, chronic obstructive 
pulmonary disease, chronic liver disease, Crohn’s disease, ulcerative colitis, 
and renal failure.
Clinical Features
• General—weight loss, temporal and proximal muscle wasting, decreased 
skin-fold thickness
• Skin, hair, and nails—easily plucked hair (protein); sparse hair (protein, 
biotin, zinc); coiled hair, easy bruising, petechiae, and perifollicular hem-
orrhages (vit. C); “flaky paint” rash of lower extremities (zinc); hyper-
pigmentation of skin in exposed areas (niacin, tryptophan); spooning of 
nails (iron)
• Eyes—conjunctival pallor (anemia); night blindness, dryness, and Bitot 
spots (vit. A); ophthalmoplegia (thiamine)
• Mouth and mucous membranes—glossitis and/or cheilosis (riboflavin, 
niacin, vit. B12, pyridoxine, folate), diminished taste (zinc), inflamed and 
bleeding gums (vit. C)
• Neurologic—disorientation (niacin, phosphorus); confabulation, cerebel-
lar gait, or past pointing (thiamine); peripheral neuropathy (thiamine, 
pyridoxine, vit. E); lost vibratory and position sense (vit. B12)
• Other—edema (protein, thiamine), heart failure (thiamine, phosphorus), 
hepatomegaly (protein)
Laboratory findings in protein malnutrition include a low serum albumin, 
low total iron-binding capacity, and anergy to skin testing. Specific vitamin 
deficiencies also may be present.
For a more detailed discussion, see Dwyer J: Nutritional 
Requirements and Dietary Assessment, Chap. 73, p. 588; 
Russell RM and Suter PM: Vitamin and Trace Mineral 
Deficiency and Excess, Chap. 74, p. 594; and Heimberger DC: 
Malnutrition and Nutritional Assessment, Chap. 75, p. 605 in 
HPIM-18.
49
CHAPTER 8
Enteral and Parenteral Nutrition
CHAPTER 8
Enteral and Parenteral Nutrition
Nutritional support should be initiated in pts with malnutrition or in those 
at risk for malnutrition (e.g., conditions that preclude adequate oral feeding 
or pts in catabolic states, such as sepsis, burns, or trauma). An approach for 
deciding when to use various types of specialized nutrition support (SNS) 
is summarized in Fig. 8-1.
Does the patient require
  total parenteral nutrition?
Is disease process likely to cause nutritional impairment?
Does the patient have PCM or is at risk for PCM?
Would preventing or treating the malnutrition with
 SNS improve the prognosis and quality of life?
What are the fluid, energy, mineral,
 and vitamin requirements and can
 these be provided enterally?
Can requirements be met
  through oral foods and
  liquid supplements?
Keep under
   surveillance
   with frequent
   calorie counts
   and clinical
   assessment
Request feeding tube
Needed for
   several weeks
Needed for 
   months or years
Nasally
   inserted tube
Percutaneously
   inserted tube
Request CVC, PICC
   or peripheral catheter
   plus enteral nutrition
Request
  CVC or PICC
Need for
   several
   weeks
Need for 
   months
   or years
Tunneled
   external catheter
   or subcutaneous
   infusion port 
Subclavian
   catheter or
   PICC
Risks and discomfort of SNS
 outweigh potential benefits.
 Explain issue to patient or
 legal surrogate. Support patient
 with general comfort measures
 including oral food and liquid
 supplements if desired. 
Yes
Yes
Yes
No
Yes
Yes
Yes
No
No
No
ALGORITHM FOR IMPLEMENTATION OF SNS
FIGURE 8-1 Decision-making for the implementation of specialized nutrition support 
(SNS). CVC, central venous catheter; PCM, protein-calorie malnutrition; PICC, 
peripherally inserted central catheter. (Adapted from chapter in Harrison’s Principles 
of Internal Medicine, 16e, by Lyn Howard, MD.)
SECTION 1
50
Care of the  Hospitalized Patient
Enteral therapy refers to feeding via the gut, using oral supplements or 
infusion of formulas via various feeding tubes (nasogastric, nasoduodenal, 
gastrostomy, jejunostomy, or combined gastrojejunostomy). Parenteral ther-
apy refers to the infusion of nutrient solutions into the bloodstream via a 
peripherally inserted central catheter (PICC), a centrally inserted external-
ized catheter, or a centrally inserted tunneled catheter or subcutaneous port. 
When feasible, enteral nutrition is the preferred route because it sustains 
the digestive, absorptive, and immunologic functions of the GI tract, and 
because it minimizes the risk of fluid and electrolyte imbalance. Parenteral 
nutrition is often indicated in severe pancreatitis, necrotizing enterocolitis, 
prolonged ileus, and distal bowel obstruction.
� ENTERAL NUTRITION
The components of a standard enteral formula are as follows:
• Caloric density: 1 kcal/mL
• Protein: ~14% cals; caseinates, soy, lactalbumin
•  Fat: ~30% cals; corn, soy, safflower oils
•  Carbohydrate: ~60% cals; hydrolyzed corn starch, maltodextrin, sucrose
• Recommended daily intake of all minerals and vitamins in ≥1500 kcal/d
• Osmolality (mosmol/kg): ~300
However, modification of the enteral formula may be required based on 
various clinical indications and/or associated disease states. After elevation 
of the head of the bed and confirmation of correct tube placement, con-
tinuous gastric infusion is initiated using a half-strength diet at a rate of 
25–50 mL/h. This can be advanced to full strength as tolerated to meet the 
energy target. The major risks of enteral tube feeding are aspiration, diar-
rhea, electrolyte imbalance, warfarin resistance, sinusitis, and esophagitis.
� PARENTERAL NUTRITION
The components of parenteral nutrition include adequate fluid (30 mL/kg 
body weight/24 h for adults, plus any abnormal loss); energy from glucose, 
amino acids, and lipid solutions; nutrients essential in severely ill pts, such 
as glutamine, nucleotides, and products of methionine metabolism; and 
electrolytes, vitamins, and minerals. The risks of parenteral therapy include 
mechanical complications from insertion of the infusion catheter, catheter 
sepsis, fluid overload, hyperglycemia, hypophosphatemia, hypokalemia, 
acid-base and electrolyte imbalance, cholestasis, metabolic bone disease, 
and micronutrient deficiencies.
The following parameters should be monitored in all pts receiving 
supplemental nutrition, whether enteral or parenteral:
• Fluid balance (weight, intake vs. output)
• Glucose, electrolytes, BUN (daily until stable, then 2× per week)
• Serum creatinine, albumin, phosphorus, calcium, magnesium, Hb/Hct, 
WBC (baseline, then 2× per week)
• INR (baseline, then weekly)
• Micronutrient tests as indicated
� SPECIFIC MICRONUTRIENT DEFICIENCY
Appropriate therapies for micronutrient deficiencies are outlined in Table 8-1.
51
CHAPTER 9
Transfusion and Pheresis Therapy
TABLE 8-1 THERAPY FOR COMMON VITAMIN AND MINERAL DEFICIENCIES
Nutrient
Therapy
Vitamin Aa,b,c
60 mg PO, repeated 1 and 14 days later if ocular changes; 
30 mg for ages 6–11 months
15 mg PO qd × 1 month if chronic malabsorption
Vitamin C
200 mg PO qd
Vitamin Da,d
Encourage sun exposure if possible
50,000 units PO once weekly for 4–8 weeks, then 
400–800 units PO qd
Substantially higher dose may be required in chronic 
malabsorption
Vitamin Ea
800–1200 mg PO qd
Vitamin Ka
10 mg IV × 1
1–2 mg PO qd or 1–2 mg IV weekly in chronic malabsorption
Thiamineb
100 mg IV qd × 7 days, followed by 10 mg PO qd
Niacin
100–200 mg PO tid for 5 days
Pyridoxine
50 mg PO qd, 100–200 mg PO qd if deficiency related to 
medication
Zincb,c
60 mg PO bid
aAssociated with fat malabsorption.
bAssociated with chronic alcoholism; always replete thiamine before carbohydrates in alcoholics 
to avoid precipitation of acute thiamine deficiency.
cAssociated with protein-calorie malnutrition.
dTherapy must be monitored by serum calcium measurements.
For a more detailed discussion, see Russell RM and Suter 
PM: Vitamin and Trace Mineral Deficiency and Excess, 
Chap. 74, p. 594; and Bistrian BR and Driscoll DF: Enteral and 
Parenteral Nutrition Therapy, Chap. 76, p. 612, HPIM-18. 
CHAPTER 9
Transfusion and Pheresis Therapy
TRANSFUSIONS
� WHOLE BLOOD TRANSFUSION
Indicated when acute blood loss is sufficient to produce hypovolemia, 
whole blood provides both oxygen-carrying capacity and volume expan-
sion. In acute blood loss, hematocrit may not accurately reflect degree of 
blood loss for 48 h until fluid shifts occur.
SECTION 1
52
Care of the  Hospitalized Patient
� RED BLOOD CELL TRANSFUSION
Indicated for symptomatic anemia unresponsive to specific therapy or 
requiring urgent correction. Packed red blood cell (RBC) transfusions may 
be indicated in pts who are symptomatic from cardiovascular or pulmonary 
disease when Hb is between 70 and 90 g/L (7 and 9 g/dL). Transfusion is 
usually necessary when Hb is <70 g/L (<7 g/dL). One unit of packed RBCs 
raises the Hb by approximately 10 g/L (1 g/dL). In the setting of acute 
hemorrhage, packed RBCs, fresh-frozen plasma (FFP), and platelets in an 
approximate ratio of 3:1:10 units are an adequate replacement for whole 
blood. Removal of leukocytes reduces risk of alloimmunization and trans-
mission of cytomegalovirus. Washing to remove donor plasma reduces 
risk of allergic reactions. Irradiation prevents graft-versus-host disease in 
immunocompromised recipients by killing alloreactive donor lymphocytes. 
Avoid related donors.
Other Indications
(1) Hypertransfusion therapy to block production of defective cells, e.g., 
thalassemia, sickle cell anemia; (2) exchange transfusion—hemolytic disease 
of newborn, sickle cell crisis; (3) transplant recipients—decreases rejection 
of cadaveric kidney transplants.
Complications (See Table 9-1)
(1) Transfusion reaction—immediate or delayed, seen in 1–4% of transfu-
sions; IgA-deficient pts at particular risk for severe reaction; (2) infection—
bacterial (rare); hepatitis C, 1 in 1,800,000 transfusions; HIV transmission, 
1 in 2,300,000; (3) circulatory overload; (4) iron overload—each unit contains 
200–250 mg iron; hemochromatosis may develop after 100 U of RBCs (less 
in children), in absence of blood loss; iron chelation therapy with deferox-
amine indicated; (5) graft-versus-host disease; (6) alloimmunization.
� AUTOLOGOUS TRANSFUSION
Use of pt’s own stored blood avoids hazards of donor blood; also useful 
in pts with multiple RBC antibodies. Pace of autologous donation may be 
accelerated using erythropoietin (50–150 U/kg SC three times a week) in 
the setting of normal iron stores.
� RED CELL EXCHANGE
The main goal of red cell exchange transfusions is to remove sickle cells and 
replace them with normal red cells to interrupt the vicious cycle of sickling, 
stasis, vasoocclusion, and hypoxia that propagate sickle cell crises. The 
usual target is 70% hemoglobin A.
� PLATELET TRANSFUSION
Prophylactic transfusions usually reserved for platelet count <10,000/μL 
(<20,000/μL in acute leukemia). One unit elevates the count by about 
10,000/μL if no platelet antibodies are present as a result of prior transfu-
sions. Efficacy assessed by 1-h and 24-h posttransfusion platelet counts. 
HLA-matched single-donor platelets may be required in pts with platelet 
alloantibodies.
53
CHAPTER 9
Transfusion and Pheresis Therapy
� TRANSFUSION OF PLASMA COMPONENTS
Fresh frozen plasma (FFP) is a source of coagulation factors, fibrinogen, 
antithrombin, and proteins C and S. It is used to correct coagulation factor 
deficiencies, rapidly reverse warfarin effects, and treat thrombotic throm-
bocytopenic purpura (TTP). Cryoprecipitate is a source of fibrinogen, 
factor VIII, and von Willebrand factor; it may be used when recombinant 
factor VIII or factor VIII concentrates are not available.
THERAPEUTIC HEMAPHERESIS
Hemapheresis is removal of a cellular or plasma constituent of blood; the 
specific procedure is referred to by the blood fraction removed.
TABLE 9-1 RISKS OF TRANSFUSION COMPLICATIONS
Frequency, Episodes: Unit
Reactions
Febrile (FNHTR)
1–4:100
Allergic
1–4:100
Delayed hemolytic
1:1000
TRALI
1:5000
Acute hemolytic
1:12,000
Fatal hemolytic
1:100,000
Anaphylactic
1:150,000
Infectionsa
Hepatitis B
1:220,000
Hepatitis C
1:1,800,000
HIV-1, HIV-2
1:2,300,000
HTLV-I, HTLV-II
1:2,993,000
Malaria
1:4,000,000
Other complications
RBC allosensitization
1:100
HLA allosensitization
1:10
Graft-versus-host disease 
Rare
aInfectious agents rarely associated with transfusion, theoretically possible, or of unknown 
risk include West Nile virus, hepatitis A virus, parvovirus B-19, Babesia microti (babesiosis), 
Borrelia burgdorferi (Lyme disease), Anaplasma phagocytophilum (human granulocytic ehrli-
chiosis), Trypanosoma cruzi (Chagas’ disease), Treponema pallidum, and human herpesvirus 8.
Abbreviations: FNHTR, febrile nonhemolytic transfusion reaction; HTLV, human T lymphotropic 
virus; RBC, red blood cell; TRALI, transfusion-related acute lung injury.
SECTION 1
54
Care of the  Hospitalized Patient
� LEUKAPHERESIS
Removal of WBCs; most often used in acute leukemia, esp. acute myeloid 
leukemia (AML) in cases complicated by marked elevation (>100,000/μL) 
of the peripheral blast count, to lower risk of leukostasis (blast-mediated 
vasoocclusive events resulting in central nervous system or pulmonary 
infarction, hemorrhage). Leukapheresis is replacing bone marrow aspiration 
to obtain hematopoietic stem cells. After treatment with a chemotherapeutic 
agent and granulocyte-macrophage colony-stimulating factor, hematopoi-
etic stem cells are mobilized from marrow to the peripheral blood; such cells 
are leukapheresed and then used for hematopoietic reconstitution after high-
dose myeloablative therapy. A third emerging medical use of leukapheresis is 
to harvest lymphocytes to use as adoptive immunotherapy.
� PLATELETPHERESIS
Used in some pts with thrombocytosis associated with myeloproliferative 
disorders with bleeding and/or thrombotic complications. Other treatments 
are generally used first. Plateletpheresis also enhances platelet yield from 
blood donors.
� PLASMAPHERESIS
Indications
(1) Hyperviscosity states—e.g., Waldenström’s macroglobulinemia; (2) TTP; 
(3) immune-complex and autoantibody disorders—e.g., Goodpasture’s syn-
drome, rapidly progressive glomerulonephritis, myasthenia gravis; possibly 
Guillain-Barré, systemic lupus erythematosus, idiopathic thrombocytopenic 
purpura; (4) cold agglutinin disease, cryoglobulinemia. In plasma exchange, 
abnormal proteins are removed and normal plasma or plasma components 
are replaced; useful in TTP to remove anti-ADAMTS13 antibody and pro-
vide normal ADAMTS13 levels.
For a more detailed discussion, see Dzieczkowski JS, 
Anderson KC: Transfusion Biology and Therapy, Chap. 113, 
p. 951, in HPIM-18.
CHAPTER 10
Palliative and End-of-Life Care
In 2008, 2,473,000 people died in the United States; death rates are declining. 
Heart disease and cancer are the two leading causes of death and together 
account for nearly half of all deaths. About 70% of deaths occur in people 
who have a condition that is known to be leading to their death; thus, 
planning for terminal care is relevant and important. An increasing fraction 
of deaths are occurring in hospices or at home rather than in the hospital.
Optimal care depends on a comprehensive assessment of pt needs 
in all four domains affected by illness: physical, psychological, social, 
55
Palliative and End-of-Life Care
CHAPTER 10
and spiritual. A variety of assessment tools are available to assist in the 
process.
Communication and continuous assessment of management goals are 
key components to addressing end-of-life care. Physicians must be clear 
about the likely outcome of the illness(es) and provide an anticipated 
schedule with goals and landmarks in the care process. When the goals of 
care have changed from cure to palliation, that transition must be clearly 
explained and defended. Seven steps are involved in establishing goals:
1. Ensure that the medical information is as complete as possible and 
understood by all relevant parties.
2. Explore the pt’s goals while making sure the goals are achievable.
3. Explain the options.
4. Show empathy as the pt and the family adjust to changing expectations.
5. Make a plan with realistic goals.
6. Follow through with the plan.
7. Review and revise the plan periodically as the pt’s situation changes.
� ADVANCE DIRECTIVES 
About 70% of pts lack decision-making capacity in their final days. Advance 
directives define ahead of time the level of intervention the pt is willing to 
accept. Two types of legal documents can be used: the advance directive, 
in which specific instructions from the pt may be made known; and the 
durable attorney for health care, in which a person is designated as hav-
ing the pt’s authority to make health decisions on the pt’s behalf. Forms 
are available free of charge from the National Hospice and Palliative Care 
Organization (www.nhpco.org). Physicians also should complete these 
forms for themselves.
� PHYSICAL SYMPTOMS AND THEIR MANAGEMENT 
The most common physical and psychological symptoms among terminally 
ill pts are shown in Table 10-1. Studies of pts with advanced cancer have 
shown that pts experience an average of 11.5 symptoms.
Pain 
Pain is noted in 36–90% of terminally ill pts. The various types of pain and 
their management are discussed in Chap. 6.
Constipation
Constipation is noted in up to 87% of terminally ill pts. Medications that 
commonly contribute to constipation include opioids used to manage pain 
and dyspnea and tricyclic antidepressants with their anticholinergic effects. 
Inactivity, poor diet, and hypercalcemia may contribute. GI tract obstruc-
tion also may play a role in some settings.
Interventions
Improved physical activity (if possible), adequate hydration; 
opioid effects can be antagonized by the μ-opioid receptor blocker methyln-
altrexone (8–12 mg SC daily); rule out surgically correctable obstruction; 
laxatives and stool softeners (Table 10-2).
SECTION 1
56
Care of the  Hospitalized Patient
TABLE 10-1  COMMON PHYSICAL AND PSYCHOLOGICAL SYMPTOMS 
OF TERMINALLY ILL PATIENTS
Physical Symptoms
Psychological Symptoms
Pain
Anxiety
Fatigue and weakness
Depression
Dyspnea
Hopelessness
Insomnia
Meaninglessness
Dry mouth
Irritability
Anorexia
Impaired concentration
Nausea and vomiting
Confusion
Constipation
Delirium
Cough
Loss of libido
Swelling of arms or legs
Itching
Diarrhea
Dysphagia
Dizziness
Fecal and urinary incontinence
Numbness/tingling in hands/feet
Nausea
Up to 70% of pts with advanced cancer have nausea. Nausea may result 
from uremia, liver failure, hypercalcemia, bowel obstruction, severe consti-
pation, infection, gastroesophageal reflux disease, vestibular disease, brain 
metastases, medications (cancer chemotherapy, antibiotics, nonsteroidal 
anti-inflammatory drugs, opioids, proton pump inhibitors), and radiation 
therapy.
Interventions
Treatment should be tailored to the cause. Offending medi-
cations should be stopped. Underlying conditions should be alleviated, if 
possible. If decreased bowel motility is suspected, metoclopramide may 
help. Nausea from cancer chemotherapy agents can generally be prevented 
with glucocorticoids and serotonin receptor blockers like ondansetron or 
dolasetron. Aprepitant is useful in controlling nausea from highly emeto-
genic agents like cisplatin. Vestibular nausea may respond to antihistamines 
(meclizine) or anticholinergics (scopolamine). Anticipatory nausea may be 
prevented with a benzodiazepine such as lorazepam. Haloperidol is some-
times useful when the nausea does not have a single specific cause.
Dyspnea
Up to 75% of dying pts experience dyspnea. Dyspnea exerts perhaps the 
greatest adverse effect on the pt, often even more distressing than pain. 
57
CHAPTER 10
Palliative and End-of-Life Care
It may be caused by parenchymal lung disease, infection, effusions, pul-
monary emboli, pulmonary edema, asthma, or compressed airway. While 
many of the causes may be treated, often the underlying cause cannot be 
reversed.
Interventions
Underlying causes should be reversed, where possible, as long 
as the intervention is not more unpleasant (e.g., repeated thoracenteses) than 
the dyspnea. Most often the treatment is symptomatic (Table 10-3).
Fatigue 
Fatigue is nearly a universal symptom in terminally ill pts. It is often a direct 
consequence of the disease process (and the cytokines produced in response 
to that process) and may be complicated by inanition, dehydration, anemia, 
infection, hypothyroidism, and drug effects. Depression may also contrib-
ute to fatigue. Functional assessments include the Karnofsky performance 
TABLE 10-2 MEDICATIONS FOR THE MANAGEMENT OF CONSTIPATION
Intervention
Dose
Comment
Stimulant laxatives
These agents directly stimulate 
peristalsis and may reduce 
colonic absorption of water.
Work in 6–12 h.
Prune juice
120–240 mL/d
Senna (Senokot)
2–8 tablets PO bid
Bisacodyl
5–15 mg/d PO, PR
Osmotic laxatives 
These agents are not 
absorbed. They attract and 
retain water in the 
gastrointestinal tract.
Lactulose
15–30 mL PO q4–8h
Lactulose may cause 
flatulence and bloating.
Magnesium 
hydroxide (Milk of 
Magnesia)
15–30 mL/d PO
Lactulose works in 1 day, 
magnesium products in 6 h.
Magnesium citrate
125–250 mL/d PO
Stool softeners 
These agents work by 
increasing water secretion 
and as detergents, increasing 
water penetration into the 
stool.
Work in 1–3 days.
Sodium docusate 
(Colace)
300–600 mg/d PO
Calcium docusate
300–600 mg/d PO
Suppositories and 
enemas
Bisacodyl
10–15 PR qd
Sodium phosphate 
enema
PR qd
Fixed dose, 4.5 oz, Fleet’s.
SECTION 1
58
Care of the  Hospitalized Patient
TABLE 10-3 MEDICATIONS FOR THE MANAGEMENT OF DYSPNEA
Intervention
Dose
Comments
Weak opioids
For pts with mild dyspnea
Codeine (or codeine 
with 325 mg 
acetaminophen)
30 mg PO q4h
For opioid-naïve pts
Hydrocodone
5 mg PO q4h
Strong opioids 
For opioid-naïve pts with 
moderate to severe dyspnea
Morphine
5–10 mg PO q4h
For pts already taking 
opioids for pain or other 
symptoms
30–50% of baseline 
opioid dose q4h
Oxycodone
5–10 mg PO q4h
Hydromorphone
1–2 mg PO q4h
Anxiolytics
Give a dose every hour until 
the pt is relaxed, then 
provide a dose for 
maintenance
Lorazepam
0.5–2.0 mg PO/SL/IV 
qh then q4–6h
Clonazepam
0.25–2.0 mg PO q12h
Midazolam
0.5 mg IV q15min
status or the Eastern Cooperative Oncology Group system based on how 
much time the pt spends in bed each day: 0, normal activity; 1, symptomatic 
without being bedridden; 2, in bed <50% of the day; 3, in bed >50% of the 
day; 4, bedbound.
Interventions
Modest exercise and physical therapy may reduce muscle 
wasting and depression and improve mood; discontinue medications that 
worsen fatigue, if possible; glucocorticoids may increase energy and enhance 
mood; dextroamphetamine (5–10 mg/d) or methylphenidate (2.5–5 mg/d) 
in the morning may enhance energy levels but should be avoided at night 
because they may produce insomnia; modafinil and l-carnitine have shown 
some early promise.
Depression
Up to 75% of terminally ill pts experience depression. The inexperienced 
physician may feel that depression is an appropriate response to terminal 
illness; however, in a substantial fraction of pts the depression is more 
intense and disabling than usual. Pts with a previous history of depression 
are at greater risk. A number of treatable conditions can cause depression-
like symptoms including hypothyroidism, Cushing’s syndrome, electrolyte 
abnormalities (e.g., hypercalcemia), and drugs including dopamine block-
ers, interferon, tamoxifen, interleukin 2, vincristine, and glucocorticoids.
59
CHAPTER 10
Palliative and End-of-Life Care
Interventions
Dextroamphetamine or methylphenidate (see above); sero-
tonin reuptake inhibitors such as fluoxetine, paroxetine, and citalopram; 
modafinil 100 mg/d; pemoline 18.75 mg in the a.m. and at noon.
Delirium
Delirium is a global cerebral dysfunction associated with altered cognition 
and consciousness; it is frequently preceded by anxiety. Unlike dementia, 
it is of sudden onset, is characterized by fluctuating consciousness and 
inattention, and may be reversible. It is generally manifested in the hours 
before death. It may be caused by metabolic encephalopathy in renal or liver 
failure, hypoxemia, infection, hypercalcemia, paraneoplastic syndromes, 
dehydration, constipation, urinary retention, and central nervous system 
spread of cancer. It is also a common medication side effect; offending 
agents include those commonly used in dying pts including opioids, glu-
cocorticoids, anticholinergics, antihistamines, antiemetics, and benzodiaz-
epines. Early recognition is key because the pt should be encouraged to use 
the periods of lucidity for final communication with loved ones. Day-night 
reversal with changes in mentation may be an early sign.
Interventions
Stop any and all unnecessary medications that may have this 
side effect; provide a calendar, clock, newspaper, or other orienting signals; 
gently correct hallucinations or cognitive mistakes; pharmacologic inter-
ventions are shown in Table 10-4.
� CARE DURING THE LAST HOURS 
The clinical course of a dying pt may largely be predictable. Figure 10-1 
shows common and uncommon changes during the last days of life. 
TABLE 10-4 MEDICATIONS FOR THE MANAGEMENT OF DELIRIUM
Interventions
Dose
Neuroleptics
Haloperidol
0.5–5 mg q2–12h, PO/IV/SC/IM
Thioridazine
10–75 mg q4–8h, PO
Chlorpromazine
12.5–50 mg q4–12h, PO/IV/IM
Atypical neuroleptics
Olanzapine
2.5–5 mg qd or bid, PO
Risperidone
1–3 mg q12h, PO
Anxiolytics
Lorazepam
0.5–2 mg q1–4h, PO/IV/IM
Midazolam
1–5 mg/h continuous infusion, IV/SC
Anesthetics
Propofol
0.3–2.0 mg/h continuous infusion, IV
SECTION 1
60
Care of the  Hospitalized Patient
Common clinical
course
Uncommon clinical
course
Normal
Sleepy
Lethargic
Obtunded
Seizures
Myoclonic jerks
Delirium
Hallucinations
Tremulous
Confused
Restless
Semicomatose
Comatose
Death
CLINICAL COURSES FOR TERMINALLY ILL
PATIENTS
FIGURE 10-1 Common and uncommon clinical courses in the last days of terminally 
ill pts. (Adapted from FD Ferris et al: Module 4: Palliative care, in Comprehensive Guide 
for the Care of Persons with HIV Disease. Toronto: Mt. Sinai Hospital and Casey Hospice, 
1995, www.cpsonline.info/content/resources/hivmodule/module4complete.pdf.)
Informing families that these changes might occur can help minimize the 
distress that they cause. In particular, the physician needs to be sensitive to 
the sense of guilt and helplessness that family members feel. They should 
be reassured that the illness is taking its course and their care of the pt is 
not at fault in any way. The pt stops eating because they are dying; they are 
not dying because they have stopped eating. Families and caregivers should 
be encouraged to communicate directly with the dying pt whether or not 
the pt is unconscious. Holding the pt’s hand may be a source of comfort to 
both the pt and the family member/caregiver. Table 10-5 provides a listing 
61
CHAPTER 10
Palliative and End-of-Life Care
TABLE 10-5  MANAGING CHANGES IN THE PATIENT’S CONDITION 
DURING THE FINAL DAYS AND HOURS
Changes in 
the Patient’s 
Condition
Potential
Complication
Family’s 
Possible
Reaction and 
Concern
Advice and Intervention
Profound
fatigue
Bedbound with 
development of 
pressure ulcers 
that are prone to 
infection, malodor, 
and pain, and 
joint pain
Pt is lazy and 
giving up.
Reassure family and 
caregivers that terminal 
fatigue will not respond to 
interventions and should 
not be resisted.
Use an air mattress if 
necessary.
Anorexia
None
Pt is giving 
up; pt will 
suffer from 
hunger and 
will starve to 
death.
Reassure family and 
caregivers that the pt is 
not eating because he or 
she is dying; not eating 
at the end of life does not 
cause suffering or death.
Forced feeding, whether 
oral, parenteral, or enteral, 
does not reduce symptoms 
or prolong life.
Dehydration
Dry mucosal 
membranes (see 
below)
Pt will suffer 
from thirst 
and die of 
dehydration.
Reassure family and 
caregivers that dehydration 
at the end of life does not 
cause suffering because pts 
lose consciousness before 
any symptom distress.
IV hydration can worsen 
symptoms of dyspnea by 
pulmonary edema and 
peripheral edema as well 
as prolong dying process.
Dysphagia
Inability to 
swallow oral 
medications 
needed for 
palliative care
Do not force oral intake.
Discontinue unnecessary 
medications that may have 
been continued, including 
antibiotics, diuretics, anti-
depressants, and laxatives.
If swallowing pills is 
difficult, convert essential 
medications (analgesics, 
antiemetics, anxiolytics, 
and psychotropics) to oral 
solutions, buccal, sublingual, 
or rectal administration.
(continued )
SECTION 1
62
Care of the  Hospitalized Patient
“Death 
rattle”—
noisy
breathing
Pt is choking 
and
suffocating.
Reassure the family and 
caregivers that this is 
caused by secretions in 
the oropharynx and the pt 
is not choking.
Reduce secretions with 
scopolamine (0.2–0.4 mg 
SC q4h or 1–3 patches 
q3d).
Reposition pt to permit 
drainage of secretions.
Do not suction. Suction 
can cause pt and family 
discomfort and is usually 
ineffective.
Apnea, 
Cheyne-
Stokes
respirations, 
dyspnea
Pt is 
suffocating.
Reassure family and 
caregivers that unconscious 
pts do not experience 
suffocation or air hunger.
Apneic episodes are 
frequently a premorbid 
change.
Opioids or anxiolytics may 
be used for dyspnea.
Oxygen is unlikely to 
relieve dyspneic symptoms 
and may prolong the dying 
process.
Urinary or 
fecal
incontinence
Skin breakdown 
if days until death
Pt is dirty, 
malodorous, 
and
physically
repellent.
Remind family and 
caregivers to use universal 
precautions.
Potential 
transmission of 
infectious agents 
to caregivers
Frequent changes 
of bedclothes and 
bedding.
Use diapers, urinary 
catheter, or rectal tube 
if diarrhea or high urine 
output.
TABLE 10-5  MANAGING CHANGES IN THE PATIENT’S CONDITION 
DURING THE FINAL DAYS AND HOURS (CONTINUED)
Changes in 
the Patient’s 
Condition
Potential
Complication
Family’s 
Possible
Reaction and 
Concern
Advice and Intervention
63
CHAPTER 10
Palliative and End-of-Life Care
Agitation or 
delirium
Day/night
reversal
Pt is in 
horrible pain 
and going to 
have a 
horrible
death.
Reassure family and 
caregivers that agitation 
and delirium do not 
necessarily connote 
physical pain.
Hurt self or 
caregivers
Depending on the prognosis 
and goals of treatment, 
consider evaluating for 
causes of delirium and 
modify medications.
Manage symptoms 
with haloperidol, 
chlorpromazine, diazepam, 
or midazolam.
Dry mucosal 
membranes
Cracked lips, 
mouth sores, and 
candidiasis can 
also cause pain.
Pt may be 
malodorous, 
physically
repellent.
Use baking soda 
mouthwash or 
saliva preparation 
q15–30min.
Odor
Use topical nystatin for 
candidiasis.
Coat lips and nasal 
mucosa with petroleum 
jelly q60–90min.
Use ophthalmic lubricants 
q4h or artificial tears 
q30min.
of some changes in the pt’s condition in the final hours and advice on how 
to manage the changes.
Additional resources for managing terminally ill pts may be found at the 
following websites: www.epec.net, www.eperc.mcw.edu, www.capc.org, and 
www.nhpco.org.
For a more detailed discussion, see Emanuel EJ: Palliative 
and End-of-Life Care, Chap. 9, p. 67, in HPIM-18.
TABLE 10-5  MANAGING CHANGES IN THE PATIENT’S CONDITION 
DURING THE FINAL DAYS AND HOURS (CONTINUED)
Changes in 
the Patient’s 
Condition
Potential
Complication
Family’s 
Possible
Reaction and 
Concern
Advice and Intervention
This page intentionally left blank 
65
CHAPTER 11
Cardiovascular Collapse and 
Sudden Death
Unexpected cardiovascular collapse and death most often result from 
ventricular fibrillation in pts with acute or chronic atherosclerotic coro-
nary artery disease. Other common etiologies are listed in Table 11-1. 
Arrhythmic causes may be provoked by electrolyte disorders (primarily 
hypokalemia), hypoxemia, acidosis, or massive sympathetic discharge, as 
may occur in CNS injury. Immediate institution of cardiopulmonary resus-
citation (CPR) followed by advanced life support measures (see below) is 
mandatory. Ventricular fibrillation, or asystole, without institution of CPR 
within 4–6 min is usually fatal.
SECTION 2
Medical Emergencies
TABLE 11-1 CARDIAC ARREST AND SUDDEN CARDIAC DEATH
Structural Associations and Causes
I. 
Coronary heart disease (chronic, or acute coronary syndromes)
II. Myocardial hypertrophy (e.g., hypertrophic cardiomyopathy)
III. Dilated cardiomyopathy
IV. Inflammatory (e.g., myocarditis) and infiltrative disorders
V. Valvular heart diseases
VI. Electrophysiologic abnormalities (e.g., Wolff-Parkinson-White syndrome)
VII.  Inherited disorders associated with electrophysiological abnormalities 
(e.g., congenital long QT syndromes, right ventricular dysplasia, Brugada 
syndrome, catecholaminergic polymorphic ventricular tachycardia)
Functional Contributing Factors 
I. 
Transient ischemia
II. Low cardiac output states (heart failure, shock)
III. Systemic metabolic abnormalities
 
A. Electrolyte imbalance (e.g., hypokalemia)
 
B. Hypoxemia, acidosis
IV. Neurologic disturbances (e.g., CNS injury)
V. Toxic responses
 
A. Proarrhythmic drug effects
 
B. Cardiac toxins (e.g., cocaine, digitalis intoxication)
SECTION 2
66
Medical Emergencies
� MANAGEMENT OF CARDIAC ARREST
Basic life support (BLS) must commence immediately (Fig. 11-1):
1. Phone emergency line (e.g., 911); retrieve automated external defibrillator 
(AED) if quickly available.
2. If respiratory stridor is present, assess for aspiration of a foreign body 
and perform Heimlich maneuver.
3. Perform chest compressions (depressing sternum 4–5 cm) at rate of 100 
per min without interruption. A second rescuer should attach and utilize 
AED if available.
B
C
A
FIGURE 11-1 Major steps in cardiopulmonary resuscitation. A. Begin cardiac 
compressions at 100 compressions/min. B. Confirm that victim has an open airway. 
C. Trained rescuers begin mouth-to-mouth resuscitation if advanced life support 
equipment is not available. (Modified from J Henderson, Emergency Medical Guide, 
4th ed, New York, McGraw-Hill, 1978.)
CHAPTER 11 
67
Cardiovascular Collapse and Sudden Death 
4. If second trained rescuer available, tilt pt’s head backward, lift chin, and 
begin mouth-to-mouth respiration (pocket mask is preferable to prevent 
transmission of infection), while chest compressions continue. The lungs 
should be inflated twice in rapid succession for every 30 chest com-
pressions. For untrained lay rescuers, chest compression only, without 
ventilation, is recommended until advanced life support capability arrives.
5. As soon as resuscitation equipment is available, begin advanced life 
support with continued chest compressions and ventilation. Although 
performed as simultaneously as possible, defibrillation (≥300 J monopha-
sic, or 120–150 J biphasic) takes highest priority (Fig. 11-2), followed by 
placement of IV access and intubation. 100% O2 should be administered 
VENTRICULAR FIBRILLATION OR PULSELESS
VENTRICULAR TACHYCARDIA
Immediate defibrillation within 5 minutes of onset;
60-90 seconds of CPR before defibrillation for delay ≥5 minutes
If return of circulation fails
5 cycles of CPR followed by repeat shock; repeat sequence
twice if needed
If return of circulation fails
If return of
circulation fails
If return of
circulation fails
Continue CPR, Intubate, I.V. Access
Epinephrine, 1 mg I.V. -or- Vasopressin, 40 units I.V; follow with
repeat defibrillation at maximum energy within 30-60 seconds
as required; repeat epinephrine
Epinephrine, ↑ dose
NaHCO3, 1 mEq/kg (↑ K+)
Antiarrhythmics
Amiodarone: 150 mg
over 10 min, 1 mg/min
Lidocaine: 1.5 mg/kg;
repeat in 3-5 min
Defibrillate, CPR:  Drug –Shock –Drug –Shock
Magnesium sulfate:
1-2 gm I.V. (polymorphic VT)
Procainamide: 30 mg/min,
to 17 mg/kg (limited use-see text)
FIGURE 11-2 Management of cardiac arrest. The algorithm of ventricular fibrilla-
tion or hypotensive ventricular tachycardia begins with defibrillation attempts. If that 
fails, it is followed by epinephrine or vasopressin and then antiarrhythmic drugs. 
CPR, cardiopulmonary resuscitation. [Modified from Myerburg R. and Castellanos A. 
Chap. 23, HPIM-18.]
SECTION 2
68
Medical Emergencies
by endotracheal tube or, if rapid intubation cannot be accomplished, by 
bag-valve-mask device; respirations should not be interrupted for more 
than 30 s while attempting to intubate.
6. Initial IV access should be through the antecubital vein, but if drug 
administration is ineffective, a central line (internal jugular or subcla-
vian) should be placed. IV NaHCO3 should be administered only if there 
is persistent severe acidosis (pH <7.15) despite adequate ventilation. 
Calcium is not routinely administered but should be given to pts with 
known hypocalcemia, those who have received toxic doses of calcium 
channel antagonists, or if acute hyperkalemia is thought to be the trig-
gering event for resistant ventricular fibrillation.
7. The approach to cardiovascular collapse caused by bradyarrhythmias, 
asystole, or pulseless electrical activity is shown in Fig. 11-3.
8. Therapeutic hypothermia (cooling to 32–34ºC for 12–24 h) should be 
considered for unconscious survivors of cardiac arrest.
� FOLLOW-UP
If cardiac arrest resulted from ventricular fibrillation in initial hours of 
an acute MI, follow-up is standard post-MI care (Chap. 128). For other 
Bradyarrhythmia/Asystole
Pulseless Electrical Activity
CPR, intubate, I.V. access
Confirm asystole
Assess blood flow
Identify and treat causes
• Hypoxia
• Hyper-/hypokalemia
• Severe acidosis
• Drug overdose
• Hypothermia
• Hypovolemia
• Hypoxia
• Tamponade
• Pneumothorax
• Hypothermia
• Pulmonary embolus
• Drug overdose
• Hyperkalemia
• Severe acidosis
• Massive acute M.I.
Epinephrine
1 mg I.V. (repeat)
Atropine
1 mg I.V. (repeat)
Sodium bicarbonate
1 mEq/kg I.V.
—
—
Pacing—External or pacing wire
FIGURE 11-3 The algorithms for bradyarrhythmia/asystole (left) or pulseless elec-
trical activity (right) are dominated first by continued life support and a search for 
reversible causes. CPR, cardiopulmonary resuscitation; MI, myocardial infarction. 
[Modified from Myerburg R. and Castellanos A. Chap. 23, HPIM-18.]
CHAPTER 12
69
Shock
survivors of a ventricular fibrillation arrest, further assessment, including 
evaluation of coronary anatomy, and left ventricular function, is typically 
recommended. In absence of a transient or reversible cause, placement of 
an implantable cardioverter defibrillator is usually indicated.
For a more detailed discussion, see Myerburg RJ, Castellanos A: 
Cardiovascular Collapse, Cardiac Arrest, and Sudden Cardiac 
Death, Chap. 273, p. 2238, in HPIM-18.
CHAPTER 12
Shock
� DEFINITION
Condition of severe impairment of tissue perfusion leading to cellular 
injury and dysfunction. Rapid recognition and treatment are essential to 
prevent irreversible organ damage and death. Common causes are listed in 
Table 12-1.
� CLINICAL MANIFESTATIONS
• Hypotension (mean arterial bp <60 mmHg), tachycardia, tachypnea, 
pallor, restlessness, and altered sensorium.
• Signs of intense peripheral vasoconstriction, with weak pulses and cold 
clammy extremities. In distributive (e.g., septic) shock, vasodilatation 
predominates and extremities are warm.
• Oliguria (<20 mL/h) and metabolic acidosis common.
• Acute lung injury and acute respiratory distress syndrome (ARDS; see 
Chap. 15) with noncardiogenic pulmonary edema, hypoxemia, and dif-
fuse pulmonary infiltrates.
Shock
APPROACH TO THE
PATIENT
Obtain history for underlying causes, including cardiac disease (coronary 
disease, heart failure, pericardial disease), recent fever or infection lead-
ing to sepsis, drug effects (e.g., excess diuretics or antihypertensives), 
conditions leading to pulmonary embolism (Chap. 142), potential 
sources of bleeding.
� PHYSICAL EXAMINATION
Jugular veins are flat in oligemic or distributive (septic) shock; jugular venous 
distention (JVD) suggests cardiogenic shock; JVD in presence of paradoxical 
pulse (Chap. 119) may reflect cardiac tamponade (Chap. 125). Check for 
asymmetry of pulses (aortic dissection—Chap. 134). Assess for evidence of 
SECTION 2
70
Medical Emergencies
heart failure (Chap. 133), murmurs of aortic stenosis, acute mitral or aortic 
regurgitation, ventricular septal defect. Tenderness or rebound in abdomen 
may indicate peritonitis or pancreatitis; high-pitched bowel sounds suggest 
intestinal obstruction. Perform stool guaiac to rule out GI bleeding.
Fever and chills typically accompany septic shock. Sepsis may not cause 
fever in elderly, uremic, or alcoholic pts. Skin lesions may suggest specific 
pathogens in septic shock: petechiae or purpura (Neisseria meningitidis or 
Haemophilus influenzae), ecthyma gangrenosum (Pseudomonas aerugi-
nosa), generalized erythroderma (toxic shock due to Staphylococcus aureus 
or Streptococcus pyogenes).
� LABORATORY
Obtain hematocrit, WBC, electrolytes, platelet count, PT, PTT, DIC screen, 
electrolytes. Arterial blood gas usually shows metabolic acidosis (in septic 
shock, respiratory alkalosis precedes metabolic acidosis). If sepsis sus-
pected, draw blood cultures, perform urinalysis, and obtain Gram stain and 
cultures of sputum, urine, and other suspected sites.
Obtain ECG (myocardial ischemia or acute arrhythmia), chest x-ray 
(heart failure, tension pneumothorax, pneumonia). Echocardiogram is 
often helpful (cardiac tamponade, left/right ventricular dysfunction, aortic 
dissection).
TABLE 12-1 COMMON FORMS OF SHOCK
Oligemic shock
 Hemorrhage
  Volume depletion (e.g., vomiting, diarrhea, diuretic overusage, 
ketoacidosis)
 Internal sequestration (ascites, pancreatitis, intestinal obstruction)
Cardiogenic shock
 Myopathic (acute MI, dilated cardiomyopathy)
  Mechanical (acute mitral regurgitation, ventricular septal defect, severe 
aortic stenosis)
 Arrhythmic
Extracardiac obstructive shock
 Pericardial tamponade
 Massive pulmonary embolism
 Tension pneumothorax
Distributive shock (profound decrease in systemic vascular tone)
 Sepsis
 Toxic overdoses
 Anaphylaxis
 Neurogenic (e.g., spinal cord injury)
 Endocrinologic (Addison’s disease, myxedema)
CHAPTER 12
71
Shock
Central venous pressure or pulmonary capillary wedge (PCW) pressure 
measurements may be necessary to distinguish between different categories 
of shock (Table 12-2): Mean PCW <6 mmHg suggests oligemic or distribu-
tive shock; PCW >20 mmHg suggests left ventricular failure. Cardiac output 
(thermodilution) is decreased in cardiogenic and oligemic shock, and usu-
ally increased initially in septic shock.
Shock (See Fig. 12-1).
TREATMENT
Aimed at rapid improvement of tissue hypoperfusion and respiratory 
impairment:
• Serial measurements of bp (intraarterial line preferred), heart rate, 
continuous ECG monitor, urine output, pulse oximetry, blood studies: 
Hct, electrolytes, creatinine, BUN, ABGs, pH, calcium, phosphate, lac-
tate, urine Na concentration (<20 mmol/L suggests volume depletion). 
Consider monitoring of CVP and/or pulmonary artery pressure/ 
PCW pressures in pts with ongoing blood loss or suspected cardiac 
dysfunction.
• Insert Foley catheter to monitor urine flow.
• Assess mental status frequently.
• Augment systolic bp to >100 mmHg: (1) place in reverse Trendelenburg 
position; (2) IV volume infusion (500- to 1000-mL bolus), unless car-
diogenic shock suspected (begin with normal saline or Ringer’s lactate, 
then whole blood, or packed RBCs, if anemic); continue volume 
replacement as needed to restore vascular volume.
• Add vasoactive drugs after intravascular volume is optimized; 
administer vasopressors (Table 12-3) if systemic vascular resistance 
(SVR) is decreased (begin with norepinephrine [preferred] or dopa-
mine; for persistent hypotension add phenylephrine or vasopressin).
TABLE 12-2 PHYSIOLOGIC CHARACTERISTICS OF FORMS OF SHOCK
Type of Shock
CVP and 
PCWP
Cardiac
Output
Systemic
Vascular 
Resistance
Venous O2
Saturation
Hypovolemic
↓
↓
↑
↓
Cardiogenic
↑
↓
↑
↓
Septic
Hyperdynamic
↓↑
↑
↓
↑
Hypodynamic
↓↑
↓
↓
↑↓
Traumatic
↓
↓↑
↑↓
↓
Neurogenic
↓
↓
↓
↓
Hypoadrenal
↓↑
↓
=↓
↓
Abbreviations: CVP, central venous pressure; PCWP, pulmonary capillary wedge pressure.
SECTION 2
72
Medical Emergencies
• If CHF present, add inotropic agents (usually dobutamine) (Table 12-3); 
aim to maintain cardiac index >2.2(L/m2)/min [>4.0(L/m2)/min in 
septic shock].
• Administer 100% O2; intubate with mechanical ventilation if Po2 <70 
mmHg.
• If severe metabolic acidosis present (pH <7.15), administer NaHCO3.
• Identify and treat underlying cause of shock. Cardiogenic shock in 
acute MI is discussed in Chap. 128. Emergent coronary revasculariza-
tion may be lifesaving if persistent ischemia is present.
Monitor CI deterioration
Maintain optimal PCWP*
• Crystalloid
• Blood (Hct ≥30)
Hypotension and/or Tachycardia
• Airway control
• Assure ventilation
• Augment circulation
  (crystalloid +/– blood)
Consider cardiac dysfunction
or tamponade
• ECHO
• Treat appropriately
VS Unstable
HR >120 and/or SBP<90
VS Normalized
Definitive W/U
Insert PAC
VS unstable or acidosis worsens
Central monitoring
CVP <15
CVP >15
CI <3.5; 15< PCWP <20
Administer crystalloid +/– blood
   • Hct >30
   • CVP >15
Administer 500 mL crystalloid
boluses until preload     maximal CI
(Starling’s curve)
CI <3.5; PCWP <15
Administer crystalloid
+/– blood
PCWP >15, Hct >30
*
*
CI <3.5; PCWP >20
• Inotrope as indicated
• Consider ECHO
FIGURE 12-1 An algorithm for the resuscitation of the pt in shock. *Monitor SVO2,
SVRI, and RVEDVI as additional markers of correction for perfusion and hypovolemia. 
Consider age-adjusted CI. SVO2, saturation of hemoglobin with O2 in venous blood; 
SVRI, systemic vascular resistance index; RVEDVI, right-ventricular end-diastolic vol-
ume index. CI, cardiac index in (L/min) per m2; CVP, central venous pressure; ECHO, 
echocardiogram; Hct, hematocrit; HR, heart rate; PAC, pulmonary artery catheter; 
PCWP, pulmonary capillary wedge pressure in mmHg; SBP, systolic blood pressure; 
VS, vital signs; W/U, work up.
CHAPTER 12
73
Shock
SEPTIC SHOCK (SEE CHAP. 13)
TABLE 12-3 VASOPRESSORS USED IN SHOCK STATESa
Drug
Dose
Notes
Dopamine
1–2 μg/kg per min
Facilitates diuresis
2–10 μg/kg per min
Positive inotropic and chrono-
tropic effects; may increase 
O2 consumption as well as O2
delivery; use may be limited by 
tachycardia
10–20 μg/kg per min
Generalized vasoconstriction 
(decrease renal perfusion)
Norepinephrine
0.5–30 μg/min
Potent vasoconstrictor; moderate 
inotropic effect; in septic shock 
is thought to increase tissue 
O2 consumption as well as O2
delivery; may be chosen over 
dopamine in sepsis due to less 
chronotropic and adverse effects; 
may be useful in cardiogenic 
shock with reduced SVR but 
should generally be reserved for 
refractory hypotension
Dobutamine
2–20 μg/kg per min
Primarily for cardiogenic shock 
(Chap. 128): positive inotrope; 
lacks vasoconstrictor activity; 
most useful when only mild 
hypotension present and avoid-
ance of tachycardia desired
Phenylephrine
40–180 μg/min
Potent vasoconstrictor without 
inotropic effect; may be useful in 
distributive (septic) shock
Vasopressin
0.01–0.04 U/min
Occasionally used in refrac-
tory septic (distributive) shock; 
restores vascular tone in 
vasopressin-deficient states 
(e.g., sepsis)
aIsoproterenol not recommended in shock states because of potential hypotension and 
arrhythmogenic effects.
Abbreviation: SVR, systemic vascular resistance.
For a more detailed discussion, see Maier RV: Approach to 
the Patient With Shock, Chap. 270, p. 2215, and Hochman JS, 
Ingbar DH: Cardiogenic Shock and Pulmonary Edema, 
Chap. 272, p. 2232, in HPIM-18.
SECTION 2
74
Medical Emergencies
CHAPTER 13
Sepsis and Septic Shock
� DEFINITIONS
• Systemic inflammatory response syndrome (SIRS)—Two or more of the 
following:
 
–  Fever (oral temperature >38°C) or hypothermia (oral temperature 
<36°C)
 
–  Tachypnea (>24 breaths/min)
 
–  Tachycardia (>90 beats/min)
 
–  Leukocytosis (>12,000/μL), leukopenia (<4000/μL), or >10% bands; 
may have a noninfectious etiology
• Sepsis—SIRS with a proven or suspected microbial etiology
• Severe sepsis—Sepsis with one or more signs of organ dysfunction
• Septic shock—Sepsis with hypotension (arterial blood pressure <90 mmHg 
or 40 mmHg below pt’s normal blood pressure for at least 1 h despite 
fluid resuscitation) or need for vasopressors to maintain systolic blood 
pressure ≥90 mmHg or mean arterial pressure ≥70 mmHg
� ETIOLOGY
• Blood cultures are positive in 20–40% of sepsis cases and in 40–70% of 
septic shock cases. 
• A single bacterial species accounts for ~70% of isolates in positive blood 
cultures; the remainder are fungal or polymicrobial.
� EPIDEMIOLOGY
• The incidence of severe sepsis and septic shock in the United States 
continues to increase, with >700,000 cases each year contributing to 
>200,000 deaths.
• Invasive bacterial infections are a prominent cause of death around the 
world, especially among young children.
• Sepsis-related incidence and mortality rates increase with age and 
preexisting comorbidity, with two-thirds of cases occurring in pts with 
significant underlying disease.
• The increasing incidence of sepsis is attributable to the aging of the 
population, longer survival of pts with chronic diseases, a relatively 
high frequency of sepsis among AIDS pts, and medical treatments that 
circumvent host defenses (e.g., immunosuppressive agents, indwelling 
catheters, and mechanical devices).
� PATHOPHYSIOLOGY
Local and Systemic Host Responses
• Hosts have numerous receptors that recognize highly conserved micro-
bial molecules (e.g., lipopolysaccharide, lipoproteins, double-stranded 
RNA), triggering the release of cytokines and other host molecules 
CHAPTER 13
75
Sepsis and Septic Shock
that increase blood flow and neutrophil migration to the infected site, 
enhance local vascular permeability, and elicit pain.
• Many local and systemic control mechanisms diminish cellular responses 
to microbial molecules, including intravascular thrombosis (which pre-
vents spread of infection and inflammation) and an increase in anti-
inflammatory cytokines (e.g., IL-4 and IL-10).
Organ Dysfunction and Shock
• Widespread vascular endothelial injury is believed to be the major 
mechanism for multiorgan dysfunction.
• Septic shock is characterized by compromised oxygen delivery to tissues 
followed by a vasodilatory phase (a decrease in peripheral vascular resis-
tance despite increased levels of vasopressor catecholamines).
� CLINICAL FEATURES
• Hyperventilation
• Encephalopathy (disorientation, confusion)
• Acrocyanosis and ischemic necrosis of peripheral tissues (e.g., digits) due 
to hypotension and DIC
• Skin: hemorrhagic lesions, bullae, cellulitis, pustules. Skin lesions may 
suggest specific pathogens—e.g., petechiae and purpura suggest Neisseria 
meningitidis, and ecthyma gangrenosum suggests Pseudomonas aeruginosa.
• Gastrointestinal: nausea, vomiting, diarrhea, ileus, cholestatic jaundice
Major Complications
• Cardiopulmonary manifestations
 
–  Ventilation-perfusion mismatch, increased alveolar capillary perme-
ability, increased pulmonary water content, and decreased pulmonary 
compliance impede oxygen exchange and lead to acute respiratory 
distress syndrome (progressive diffuse pulmonary infiltrates and arte-
rial hypoxemia) in ~50% of pts.
 
–  Hypotension: Normal or increased cardiac output and decreased sys-
temic vascular resistance distinguish septic shock from cardiogenic 
and hypovolemic shock.
 
–  The ejection fraction is decreased, but ventricular dilatation allows 
maintenance of a normal stroke volume.
• Adrenal insufficiency: May be difficult to diagnose in critically ill pts.
• Renal manifestations: oliguria or polyuria, azotemia, proteinuria, and 
renal failure due to acute tubular necrosis
• Coagulopathy: thrombocytopenia
• Neurologic manifestations: polyneuropathy with distal motor weakness in 
prolonged sepsis
• Immunosuppression: Pts may have reactivation of HSV, CMV, or VZV.
Laboratory Findings
• CBC: leukocytosis with a left shift, thrombocytopenia
• Coagulation: prolonged thrombin time, decreased fibrinogen, presence 
of D-dimers, suggestive of DIC. With DIC, platelet counts usually fall 
below 50,000/μL.
SECTION 2
76
Medical Emergencies
• Chemistries: metabolic acidosis, elevated anion gap, elevated lactate 
levels
• LFTs: transaminitis, hyperbilirubinemia, azotemia, hypoalbuminemia
� DIAGNOSIS
Definitive diagnosis requires isolation of the microorganism from blood 
or a local site of infection. Culture of infected cutaneous lesions may help 
establish the diagnosis.
Sepsis and Septic Shock
TREATMENT
Pts in whom sepsis is suspected must be managed expeditiously, if 
possible within 1 h of presentation.
1. Antibiotic treatment: See Table 13-1.
2. Removal or drainage of a focal source of infection
a. Remove indwelling intravascular catheters; replace Foley and other 
drainage catheters; drain local sources of infection.
b. Rule out sinusitis in pts with nasal intubation.
c. Image the chest, abdomen, and/or pelvis to evaluate for abscess.
3. Hemodynamic, respiratory, and metabolic support
a. Initiate treatment with 1–2 L of normal saline administered over 
1–2 h, keeping the central venous pressure at 8–12 cmH2O, urine 
output at >0.5 mL/kg per hour, and mean arterial blood pressure at 
>65 mmHg. Add vasopressor therapy if needed.
b. If hypotension does not respond to fluid replacement therapy, 
hydrocortisone (50 mg IV q6h) should be given. If clinical improve-
ment results within 24–48 h, most experts would continue hydro-
cortisone treatment for 5–7 days.
c. Maintain oxygenation with ventilator support as indicated. Recent 
studies favor the use of low tidal volumes—typically 6 mL/kg of 
ideal body weight—provided the plateau pressure is ≤30 cmH2O.
d. Erythrocyte transfusion is recommended when the blood hemoglo-
bin level decreases to ≤7 g/dL, with a target level of 9 g/dL.
4. Recombinant activated protein C (aPC) has been approved for treat-
ment of severe sepsis or septic shock in pts with APACHE II scores of 
≥25 prior to aPC infusion; however, given the increased risk of severe 
bleeding and uncertain performance in clinical practice, many experts 
are awaiting the results of additional trials before recommending fur-
ther use of aPC.
5. General support: Nutritional supplementation should be given to 
pts with prolonged sepsis (i.e., that lasting >2–3 days), with available 
evidence suggesting an enteral delivery route. Prophylactic heparin 
should be administered to prevent deep-venous thrombosis if no 
active bleeding or coagulopathy is present. Insulin should be used to 
maintain the blood glucose concentration below ~150 mg/dL.
CHAPTER 13
77
Sepsis and Septic Shock
TABLE 13-1  INITIAL ANTIMICROBIAL THERAPY FOR SEVERE SEPSIS WITH 
NO OBVIOUS SOURCE IN ADULTS WITH NORMAL RENAL 
FUNCTION
Clinical Condition
Antimicrobial Regimens (IV Therapy)
Immunocompetent
adult
The many acceptable regimens include 
(1) piperacillin-tazobactam (3.375 g q4–6h); 
(2) imipenem-cilastatin (0.5 g q6h) or meropenem 
(1 g q8h); or (3) cefepime (2 g q12h). If the pt is 
allergic to β-lactam agents, use ciprofloxacin 
(400 mg q12h) or levofloxacin (500–750 mg q12h) 
plus clindamycin (600 mg q8h). Vancomycin 
(15 mg/kg q12h) should be added to each of the 
above regimens. 
Neutropenia
(<500 neutrophils/μL)
Regimens include (1) imipenem-cilastatin 
(0.5 g q6h) or meropenem (1 g q8h) or cefepime 
(2 g q8h); (2) piperacillin-tazobactam (3.375 g q4h) 
plus tobramycin (5–7 mg/kg q24h). Vancomycin 
(15 mg/kg q12h) should be added if the pt has an 
indwelling vascular catheter, has received quinolone 
prophylaxis, or has received intensive chemotherapy 
that produces mucosal damage; if staphylococci are 
suspected; if the institution has a high incidence of 
MRSA infections; or if there is a high prevalence of 
MRSA isolates in the community. Empirical antifun-
gal therapy with an echinocandin (for caspofungin: 
a 70-mg loading dose, then 50 mg daily) or a lipid 
formulation of amphotericin B should be added if 
the pt is hypotensive or has been receiving broad-
spectrum antibacterial drugs.
Splenectomy
Cefotaxime (2 g q6–8h) or ceftriaxone (2 g q12h) 
should be used. If the local prevalence of 
cephalosporin-resistant pneumococci is high, add 
vancomycin. If the pt is allergic to β-lactam drugs, 
vancomycin (15 mg/kg q12h) plus either moxiflox-
acin (400 mg q24h) or levofloxacin (750 mg q24h) 
or aztreonam (2 g q8h) should be used.
IV drug user
Vancomycin (15 mg/kg q12h)
AIDS
Cefepime (2 g q8h) or piperacillin-tazobactam 
(3.375 g q4h) plus tobramycin (5–7 mg/kg q24h) 
should be used. If the pt is allergic to β-lactam
drugs, ciprofloxacin (400 mg q12h) or levofloxacin 
(750 mg q12h) plus vancomycin (15 mg/kg q12h) 
plus tobramycin should be used.
Abbreviation: MRSA, methicillin-resistant Staphylococcus aureus.
Sources: Adapted in part from WT Hughes et al: Clin Infect Dis 25:551, 1997; and DN Gilbert 
et al: The Sanford Guide to Antimicrobial Therapy, 2009.
SECTION 2
78
Medical Emergencies
� PROGNOSIS
In all, 20–35% of pts with severe sepsis and 40–60% of pts with septic shock 
die within 30 days, and further deaths occur within 6 months. Prognostic 
stratification systems (e.g., APACHE II) can estimate the risk of dying of 
severe sepsis.
� PREVENTION
Nosocomial infections cause most episodes of severe sepsis and septic 
shock in the United States. Measures to reduce those infections could 
reduce the incidence of sepsis.
CHAPTER 14
Acute Pulmonary Edema
Life-threatening, acute development of alveolar lung edema due to one or 
more of the following:
1. Elevation of hydrostatic pressure in the pulmonary capillaries (left heart 
failure, mitral stenosis)
2. Specific precipitants (Table 14-1), resulting in cardiogenic pulmonary 
edema in pts with previously compensated heart failure or without previ-
ous cardiac history
3. Increased permeability of pulmonary alveolar-capillary membrane 
(noncardiogenic pulmonary edema). For common causes, see Table 14-2.
For a more detailed discussion, see Munford RS: Severe 
Sepsis and Septic Shock, Chap. 271, p. 2223, in HPIM-18.
TABLE 14-1 PRECIPITANTS OF ACUTE PULMONARY EDEMA
Acute tachy- or bradyarrhythmia
Infection, fever
Acute MI
Severe hypertension
Acute mitral or aortic regurgitation
Increased circulating volume (Na+ ingestion, blood transfusion, pregnancy)
Increased metabolic demands (exercise, hyperthyroidism)
Pulmonary embolism
Noncompliance (sudden discontinuation) of chronic CHF medications
CHAPTER 14
79
Acute Pulmonary Edema
� PHYSICAL FINDINGS
Pt appears severely ill, often diaphoretic, sitting bolt upright, tachypneic, 
cyanosis may be present. Bilateral pulmonary rales; third heart sound may 
be present. Frothy, blood-tinged sputum may occur.
� LABORATORY
Early arterial blood gases show reductions of both Pao2 and Paco2. With 
progressive respiratory failure, hypercapnia develops with acidemia. CXR 
shows pulmonary vascular redistribution, diffuse haziness in lung fields 
with perihilar “butterfly” appearance.
Acute Pulmonary Edema
TREATMENT
Immediate, aggressive therapy is mandatory for survival. The following 
measures should be instituted as simultaneously as possible for cardio-
genic pulmonary edema:
1. Administer 100% O2 by mask to achieve Pao2 >60 mmHg; if inad-
equate, use positive-pressure ventilation by face or nasal mask, and if 
necessary, proceed to endotracheal intubation.
2. Reduce preload:
a. Seat pt upright to reduce venous return, if not hypotensive.
b. Intravenous loop diuretic (e.g., furosemide, initially 0.5–1.0 mg/kg); 
use lower dose if pt does not take diuretics chronically.
c. Nitroglycerin (sublingual 0.4 mg × 3 q5min) followed by 5–10 μg/
min IV if needed. 
d. Morphine 2–4 mg IV (repetitively); assess frequently for hypoten-
sion or respiratory depression; naloxone should be available to 
reverse effects of morphine if necessary.
e. Consider ACE inhibitor if pt is hypertensive, or in setting of acute 
MI with heart failure.
TABLE 14-2  COMMON CAUSES OF NONCARDIOGENIC PULMONARY EDEMA
Direct Injury to Lung
Chest trauma, pulmonary contusion
Pneumonia
Aspiration
Oxygen toxicity
Smoke inhalation
Pulmonary embolism, reperfusion
Hematogenous Injury to Lung
Sepsis
Multiple transfusions
Pancreatitis
IV drug use, e.g., heroin
Nonthoracic trauma
Cardiopulmonary bypass
Possible Lung Injury Plus Elevated Hydrostatic Pressures
High altitude pulmonary edema
Reexpansion pulmonary edema
Neurogenic pulmonary edema
SECTION 2
80
Medical Emergencies
f. Consider nesiritide (2-μg/kg bolus IV followed by 0.01 μg/kg 
per min) for refractory symptoms—do not use in acute MI or 
cardiogenic shock.
3. Inotropic agents are indicated in cardiogenic pulmonary edema 
and severe LV dysfunction: dopamine, dobutamine, milrinone (see 
Chap. 12).
4. The precipitating cause of cardiogenic pulmonary edema (Table 14-1) 
should be sought and treated, particularly acute arrhythmias or infec-
tion. For refractory pulmonary edema associated with persistent 
cardiac ischemia, early coronary revascularization may be life-saving. 
For noncardiac pulmonary edema, identify and treat/remove cause 
(Table 14-2).
For a more detailed discussion, see Schwartzstein RM: 
Dyspnea, Chap. 33, p. 277; and Hochman JS, Ingbar D: 
Cardiogenic Shock and Pulmonary Edema, Chap. 272, p. 2232, 
in HPIM-18.
CHAPTER 15
Acute Respiratory Distress 
Syndrome
� DEFINITION AND ETIOLOGY
Acute respiratory distress syndrome (ARDS) develops rapidly and includes 
severe dyspnea, diffuse pulmonary infiltrates, and hypoxemia; it typi-
cally causes respiratory failure. Key diagnostic criteria for ARDS include 
(1) diffuse bilateral pulmonary infiltrates on chest x-ray (CXR); (2) Pao2 
(arterial partial pressure of oxygen in mmHg)/Fio2 (inspired O2 fraction) 
≤200 mmHg; and (3) absence of elevated left atrial pressure (pulmonary 
capillary wedge pressure ≤18 mmHg). Acute lung injury is a related but 
milder syndrome, with less profound hypoxemia (Pao2/Fio2 ≤300 mmHg), 
that can develop into ARDS. Although many medical and surgical condi-
tions can cause ARDS, most cases (>80%) result from sepsis, bacterial 
pneumonia, trauma, multiple transfusions, gastric acid aspiration, and drug 
overdose. Individuals with more than one predisposing factor have a greater 
risk of developing ARDS. Other risk factors include older age, chronic alco-
hol abuse, metabolic acidosis, and overall severity of critical illness.
� CLINICAL COURSE AND PATHOPHYSIOLOGY
There are three phases in the natural history of ARDS:
1. Exudative phase—Characterized by alveolar edema and leukocytic 
inflammation, with subsequent development of hyaline membranes from 
CHAPTER 15
81
Acute Respiratory Distress Syndrome 
diffuse alveolar damage. The alveolar edema is most prominent in the 
dependent portions of the lung; this causes atelectasis and reduced lung 
compliance. Hypoxemia, tachypnea, and progressive dyspnea develop, 
and increased pulmonary dead space can also lead to hypercarbia. CXR 
reveals bilateral, diffuse alveolar and interstitial opacities. The differen-
tial diagnosis is broad, but common alternative etiologies to consider are 
cardiogenic pulmonary edema, pneumonia, and alveolar hemorrhage. 
Unlike cardiogenic pulmonary edema, the CXR in ARDS rarely shows 
cardiomegaly, pleural effusions, or pulmonary vascular redistribution. 
The exudative phase duration is typically up to 7 days in length and usu-
ally begins within 12–36 h after the inciting insult.
2. Proliferative phase—This phase typically lasts from approximately days 
7 to 21 after the inciting insult. Although most pts recover, some will 
develop progressive lung injury and evidence of pulmonary fibrosis. 
Even among pts who show rapid improvement, dyspnea and hypoxemia 
often persist during this phase.
3. Fibrotic phase—Although the majority of pts recover within 3–4 weeks 
of the initial pulmonary injury, some experience progressive fibrosis, 
necessitating prolonged ventilatory support and/or supplemental O2. 
Increased risk of pneumothorax, reductions in lung compliance, and 
increased pulmonary dead space are observed during this phase.
ARDS
TREATMENT
Progress in recent therapy has emphasized the importance of general 
critical care of pts with ARDS in addition to lung protective ventilator 
strategies. General care requires treatment of the underlying medical 
or surgical problem that caused lung injury, minimizing iatrogenic 
complications (e.g., procedure-related), prophylaxis to prevent venous 
thromboembolism and GI hemorrhage, prompt treatment of infections, 
and adequate nutritional support. An algorithm for the initial manage-
ment of ARDS is presented in Fig. 15-1.
MECHANICAL VENTILATORY SUPPORT Pts with ARDS typically require 
mechanical ventilatory support due to hypoxemia and increased work 
of breathing. A substantial improvement in outcomes from ARDS 
occurred with the recognition that mechanical ventilator–related over-
distention of normal lung units with positive pressure can produce or 
exacerbate lung injury, causing or worsening ARDS. Currently recom-
mended ventilator strategies limit alveolar distention but maintain 
adequate tissue oxygenation.
It has been clearly shown that low tidal volumes (≤6 mL/kg predicted 
body weight) provide reduced mortality compared with higher tidal 
volumes (12 mL/kg predicted body weight). In ARDS, alveolar col-
lapse can occur due to alveolar/interstitial fluid accumulation and loss 
of surfactant, thus worsening hypoxemia. Therefore, low tidal volumes 
are combined with the use of positive end-expiratory pressure (PEEP) 
at levels that strive to minimize alveolar collapse and achieve adequate
SECTION 2
82
Medical Emergencies
oxygenation with the lowest Fio2. Use of PEEP levels higher than 
required to optimize oxygenation has not been proven to be of ben-
efit. Measurement of esophageal pressures to estimate transpulmonary 
pressure may help to identify an optimal level of PEEP. Other tech-
niques that may improve oxygenation while limiting alveolar distention 
include extending the time of inspiration on the ventilator (inverse ratio 
ventilation) and placing the pt in the prone position. However, these 
approaches are not of proven benefit in reducing mortality from ARDS.
ANCILLARY THERAPIES Pts with ARDS have increased pulmonary vas-
cular permeability leading to interstitial and alveolar edema. Therefore, 
they should receive IV fluids only as needed to achieve adequate cardiac 
output and tissue O2 delivery as assessed by urine output, acid-base sta-
tus, and arterial pressure. There is not convincing evidence currently to 
support the use of glucocorticoids or nitric oxide in ARDS.
� OUTCOMES
Mortality from ARDS has declined with improvements in general critical 
care treatment and with the introduction of low tidal volume ventilation. 
Current mortality from ARDS is 26–44%, with most deaths due to sepsis 
and nonpulmonary organ failure. Increased risk of mortality from ARDS is 
associated with advanced age, preexisting organ dysfunction (e.g., chronic 
INITIAL MANAGEMENT OF ARDS
Oxygenate
Minimize acidosis
Diuresis
Goals and Limits:
Tidal volume ≤ 6 ml/kg PBW 
Plateau pressure ≤ 30 cmH2O
RR ≤ 35 bpm
FIO2 ≤ 0.6
PEEP ≤ 10 cmH2O
SpO2 88 – 95%
MAP ≥ 65 mmHg
Avoid hypoperfusion
pH ≥ 7.30
RR ≤ 135 bpm
Initiate
volume/pressure-limited
ventilation
FIGURE 15-1 Algorithm for the initial management of ARDS. Clinical trials have 
provided evidence-based therapeutic goals for a step-wise approach to the early 
mechanical ventilation, oxygenation, correction of acidosis and diuresis of critically 
ill pts with ARDS.
CHAPTER 16
83
Respiratory Failure
liver disease, chronic alcohol abuse, chronic immunosuppression, and 
chronic renal disease), and direct lung injury (e.g., pneumonia, pulmonary 
contusion, and aspiration) compared with indirect lung injury (e.g., sepsis, 
trauma, and pancreatitis). Most surviving ARDS pts do not have significant 
long-term pulmonary disability.
For a more detailed discussion, see Levy BD, Choi AMK: 
Acute Respiratory Distress Syndrome, Chap. 268, p. 2205, 
in HPIM-18.
CHAPTER 16
Respiratory Failure
� DEFINITION AND CLASSIFICATION OF RESPIRATORY FAILURE
Respiratory failure is defined as inadequate gas exchange due to malfunc-
tion of one or more components of the respiratory system.
There are two main types of acute respiratory failure: hypoxemic and 
hypercarbic. Hypoxemic respiratory failure is defined by arterial O2 satura-
tion <90% while receiving an inspired O2 fraction >0.6. Acute hypoxemic 
respiratory failure can result from pneumonia, pulmonary edema (cardio-
genic or noncardiogenic), and alveolar hemorrhage. Hypoxemia results 
from ventilation-perfusion mismatch and intrapulmonary shunting.
Hypercarbic respiratory failure is characterized by respiratory acidosis 
with pH <7.30. Hypercarbic respiratory failure results from decreased min-
ute ventilation and/or increased physiologic dead space. Common condi-
tions associated with hypercarbic respiratory failure include neuromuscular 
diseases, such as myasthenia gravis, and respiratory diseases associated 
with respiratory muscle fatigue, such as asthma and chronic obstructive 
pulmonary disease (COPD). In acute hypercarbic respiratory failure, Paco2 
is typically >50 mmHg. With acute-on-chronic respiratory failure, as is 
often seen with COPD exacerbations, considerably higher Paco2 values 
may be observed. The degree of respiratory acidosis, the pt’s mental status, 
and the pt’s degree of respiratory distress are better indicators of the need 
for mechanical ventilation than a specific Paco2 level in acute-on-chronic 
respiratory failure. Two other types of respiratory failure are commonly 
considered: (1) perioperative respiratory failure related to atelectasis; and 
(2) hypoperfusion of respiratory muscles related to shock.
� MODES OF MECHANICAL VENTILATION
Respiratory failure often requires treatment with mechanical ventila-
tion. There are two general classes of mechanical ventilation: noninvasive 
ventilation (NIV) and conventional mechanical ventilation. NIV, admin-
istered through a tightly fitting nasal or full-face mask, is widely used in 
SECTION 2
84
Medical Emergencies
acute-on-chronic respiratory failure related to COPD exacerbations. NIV 
typically involves a preset positive pressure applied during inspiration and 
a lower pressure applied during expiration; it is associated with fewer com-
plications such as nosocomial pneumonia than conventional mechanical 
ventilation through an endotracheal tube. However, NIV is contraindicated 
in cardiopulmonary arrest, severe encephalopathy, severe GI hemorrhage, 
hemodynamic instability, unstable coronary artery disease, facial surgery 
or trauma, upper airway obstruction, inability to protect the airway, and 
inability to clear secretions.
Most pts with acute respiratory failure require conventional mechanical 
ventilation via a cuffed endotracheal tube. The goal of mechanical ventila-
tion is to optimize oxygenation while avoiding ventilator-induced lung 
injury. Various modes of conventional mechanical ventilation are com-
monly used; different modes are characterized by a trigger (what the venti-
lator senses to initiate a machine-delivered breath), a cycle (what determines 
the end of inspiration), and limiting factors (operator-specified values for 
key parameters that are monitored by the ventilator and not allowed to 
be exceeded). Three of the common modes of mechanical ventilation are 
described below; additional information is provided in Table 16-1.
• Assist-control ventilation: The trigger for a machine delivered breath is the 
pt’s inspiratory effort, which causes a synchronized breath to be delivered. 
If no effort is detected over a prespecified time interval, a timer-triggered 
machine breath is delivered. Assist control is volume-cycled with an 
operator-determined tidal volume. Limiting factors include the minimum 
respiratory rate, which is specified by the operator; pt efforts can lead to 
higher respiratory rates. Other limiting factors include the airway pressure 
limit, which is also set by the operator. Because the pt will receive a full 
tidal breath with each inspiratory effort, tachypnea due to nonrespiratory 
drive (such as pain) can lead to respiratory alkalosis. In pts with airflow 
obstruction (e.g., asthma or COPD), auto-PEEP can develop.
• Synchronized intermittent mandatory ventilation (SIMV): As with 
assist-control, SIMV is volume-cycled, with similar limiting factors. 
As with assist-control, the trigger for a machine-delivered breath can 
be either pt effort or a specified time interval. However, if the pt’s next 
inspiratory effort occurs before the time interval for another mandatory 
breath has elapsed, only their spontaneous respiratory effort (without 
machine support) is delivered. Thus, the number of machine-delivered 
breaths is limited in SIMV, allowing pts to exercise their inspiratory 
muscles between assisted breaths.
• Pressure-support ventilation (PSV): PSV is triggered by the pt’s inspira-
tory effort. The cycle of PSV is determined by the inspiratory flow rate. 
Because a specific respiratory rate is not provided, this mode of ventila-
tion may be combined with SIMV to ensure that an adequate respiratory 
rate is achieved in pts with respiratory depression.
Other modes of ventilation may be appropriate in specific clinical situa-
tions; for example, pressure-control ventilation is helpful to regulate airway 
pressures in pts with barotrauma or in the postoperative period from 
thoracic surgery.
TABLE 16-1  CLINICAL CHARACTERISTICS OF COMMONLY USED MODES OF MECHANICAL VENTILATION
Ventilator Mode
Independent Variables 
(Set by User)
Dependent Variables 
(Monitored by User)
Trigger/Cycle 
Limit
Advantages
Disadvantages
ACMV (assist-control 
mandatory 
ventilation)
FIO2
Peak airway pressure 
ABG
Minute Ventilation
Pt/timer
Timer backup
Not useful for weaning
Tidal volume
Ventilator rate
Level of PEEP
Inspiratory flow pattern
Peak inspiratory flow
Pressure limit
Plateau pressure
Mean airway pressure
I/E ratio
Pressure limit
Pt-vent synchrony
Pt controls minute 
ventilation
Potential for dangerous respira-
tory alkalosis
SIMV (synchronized
intermittent
mandatory 
ventilation)
Same as for ACMV
Same as for ACMV
Same as for 
ACMV
Timer backup is 
useful for weaning
Comfort from 
spontaneous breaths
Potential dyssynchrony
PSV (pressure-
support ventilation)
FIO2
Inspiratory pressure level
PEEP
Pressure limit
Tidal volume
Respiratory Rate
Minute Ventilation
Inspiratory flow
Pressure limit
Assures synchrony
Good for weaning
No timer backup; may result in 
hypoventilation
NIV
(noninvasive
ventilation)
Inspiratory and 
expiratory pressure levels
FIO2
Tidal Volume
Respiratory Rate
I/E Ratio
Minute Ventilation
Pressure limit
Inspiratory flow
Pt control
Discomfort and bruising from mask
Leaks are common
Hypoventilation
Abbreviations: I/E, inspiration/expiration; FIO2, inspired O2; PEEP, positive end-expiratory pressure.
85
SECTION 2
86
Medical Emergencies
� MANAGEMENT OF MECHANICALLY VENTILATED PATIENTS
General care of mechanically ventilated pts is reviewed in Chap. 5, along 
with weaning from mechanical ventilation. A cuffed endotracheal tube is 
often used to provide positive pressure ventilation with conditioned gas. 
A protective ventilation approach is generally recommended, including 
the following elements: (1) target tidal volume of approximately 6 mL/kg 
of ideal body weight; (2) avoid plateau pressures >30 cm H2O; (3) use 
the lowest fraction of inspired oxygen (FIo2) to maintain arterial oxygen 
saturation ≥90%; and (4) apply PEEP to maintain alveolar patency while 
avoiding overdistention. After an endotracheal tube has been in place for an 
extended period of time, tracheostomy should be considered, primarily to 
improve pt comfort and management of respiratory secretions. No absolute 
time frame for tracheostomy placement exists, but pts who are likely to 
require mechanical ventilatory support for >2 weeks should be considered 
for a tracheostomy.
A variety of complications can result from mechanical ventilation. 
Barotrauma—overdistention and damage of lung tissue—typically occurs 
at high airway pressures (>50 cm H2O). Barotrauma can cause pneumome-
diastinum, subcutaneous emphysema, and pneumothorax; pneumothorax 
typically requires treatment with tube thoracostomy. Ventilator-associated 
pneumonia is a major complication in intubated pts; common pathogens 
include Pseudomonas aeruginosa and other gram-negative bacilli, as well as 
Staphylococcus aureus.
For a more detailed discussion, see Celli BR: Mechanical 
Ventilatory Support, Chap. 269, p. 2210; and Kress JP and 
Hall JB: Approach to the Patient With Critical Illness, Chap. 
267, p. 2196, in HPIM-18.
CHAPTER 17
Confusion, Stupor, and Coma
Disorders of Consciousness
APPROACH TO THE
PATIENT
Disorders of consciousness are common; these always signify a disorder 
of the nervous system. Assessment should determine whether there is 
a change in level of consciousness (drowsy, stuporous, comatose) and/
or content of consciousness (confusion, perseveration, hallucinations). 
Confusion is a lack of clarity in thinking with inattentiveness; delirium 
is used to describe an acute confusional state; stupor, a state in which 
vigorous stimuli are needed to elicit a response; coma, a condition of 
unresponsiveness. Pts in such states are usually seriously ill, and etio-
logic factors must be assessed (Tables 17-1 and 17-2). 
CHAPTER 17
87
Confusion, Stupor, and Coma
TABLE 17-1 COMMON ETIOLOGIES OF DELIRIUM
Toxins
Prescription medications: especially those with anticholinergic properties, 
narcotics, and benzodiazepines
Drugs of abuse: alcohol intoxication and alcohol withdrawal, opiates, 
ecstasy, LSD, GHB, PCP, ketamine, cocaine
Poisons: inhalants, carbon monoxide, ethylene glycol, pesticides
Metabolic conditions
Electrolyte disturbances: hypoglycemia, hyperglycemia, hyponatremia, 
hypernatremia, hypercalcemia, hypocalcemia, hypomagnesemia
Hypothermia and hyperthermia
Pulmonary failure: hypoxemia and hypercarbia
Liver failure/hepatic encephalopathy
Renal failure/uremia
Cardiac failure
Vitamin deficiencies: B12, thiamine, folate, niacin
Dehydration and malnutrition
Anemia
Infections
Systemic infections: urinary tract infections, pneumonia, skin and soft tis-
sue infections, sepsis
CNS infections: meningitis, encephalitis, brain abscess
Endocrinologic conditions
Hyperthyroidism, hypothyroidism
Hyperparathyroidism
Adrenal insufficiency
Cerebrovascular disorders
Global hypoperfusion states
Hypertensive encephalopathy
Focal ischemic strokes and hemorrhages: especially nondominant parietal 
and thalamic lesions
Autoimmune disorders
CNS vasculitis
Cerebral lupus
Seizure-related disorders
Nonconvulsive status epilepticus
Intermittent seizures with prolonged postictal states
Neoplastic disorders
Diffuse metastases to the brain
(continued)
SECTION 2
88
Medical Emergencies
TABLE 17-1 COMMON ETIOLOGIES OF DELIRIUM (CONTINUED)
Gliomatosis cerebri
Carcinomatous meningitis
Hospitalization
Terminal end-of-life delirium
Abbreviations: CNS, central nervous system; GHB, γ-hydroxybutyrate; LSD, lysergic acid 
diethylamide; PCP, phencyclidine.
� DELIRIUM
Delirium is a clinical diagnosis made at the bedside; a careful history and 
physical exam are necessary, focusing on common etiologies of delirium, 
especially toxins and metabolic conditions. Observation will usually reveal 
an altered level of consciousness or a deficit of attention. Attention can be 
assessed through a simple bedside test of digits forward—pts are asked to 
repeat successively longer random strings of digits beginning with two dig-
its in a row; a digit span of four digits or less usually indicates an attentional 
deficit unless hearing or language barriers are present. Delirium is vastly 
underrecognized, especially in pts presenting with a quiet, hypoactive state.
A cost-effective approach to the evaluation of delirium allows the history and 
physical exam to guide tests. No single algorithm will fit all pts due to the large 
number of potential etiologies, but one step-wise approach is shown in Table 17-2.
Management of the delirious pt begins with treatment of the under-
lying inciting factor (e.g., pts with systemic infections should be given 
appropriate antibiotics, and electrolyte disturbances judiciously corrected). 
Relatively simple methods of supportive care can be quite effective, such 
as frequent reorientation by staff, preservation of sleep-wake cycles, and 
attempting to mimic the home environment as much as possible. Chemical 
restraints exacerbate delirium and should be used only when necessary to 
protect pt or staff from possible injury; antipsychotics at low dose are usu-
ally the treatment of choice.
� COMA (SEE TABLE 17-3)
Because coma demands immediate attention, the physician must employ an 
organized approach. Almost all instances of coma can be traced to widespread 
abnormalities of the bilateral cerebral hemispheres or to reduced activity of the 
reticular activating system in the brainstem.
History 
Pt should be aroused, if possible, and questioned regarding use of insulin, 
narcotics, anticoagulants, other prescription drugs, suicidal intent, recent 
trauma, headache, epilepsy, significant medical problems, and preceding 
symptoms. Witnesses and family members should be interviewed, often by 
phone. History of sudden headache followed by loss of consciousness suggests 
intracranial hemorrhage; preceding vertigo, nausea, diplopia, ataxia, hemi-
sensory disorder suggest basilar insufficiency; chest pain, palpitations, and 
faintness suggest a cardiovascular cause.
CHAPTER 17
89
Confusion, Stupor, and Coma
TABLE 17-2 STEPWISE EVALUATION OF A PATIENT WITH DELIRIUM
Initial evaluation
History with special attention to medications (including over-the-counter 
and herbals)
General physical examination and neurologic examination
Complete blood count
Electrolyte panel including calcium, magnesium, phosphorus
Liver function tests, including albumin
Renal function tests
First-tier further evaluation guided by initial evaluation
Systemic infection screen
Urinalysis and culture
Chest radiograph
Blood cultures
Electrocardiogram
Arterial blood gas
Serum and/or urine toxicology screen (perform earlier in young persons)
Brain imaging with MRI with diffusion and gadolinium (preferred) or CT
Suspected CNS infection: lumbar puncture after brain imaging
Suspected seizure-related etiology: electroencephalogram (EEG) (if high 
suspicion, should be performed immediately)
Second-tier further evaluation
Vitamin levels: B12, folate, thiamine
Endocrinologic laboratories: thyroid-stimulating hormone (TSH) and free T4;
cortisol
Serum ammonia
Sedimentation rate
Autoimmune serologies: antinuclear antibodies (ANA), complement levels; 
p-ANCA, c-ANCA
Infectious serologies: rapid plasmin reagin (RPR); fungal and viral serologies 
if high suspicion; HIV antibody
Lumbar puncture (if not already performed)
Brain MRI with and without gadolinium (if not already performed)
Abbreviations: c-ANCA, cytoplasmic antineutrophil cytoplasmic antibody; p-ANCA, 
perinuclear antineutrophil cytoplasmic antibody.
Immediate Assessment 
Acute respiratory and cardiovascular problems should be attended to 
prior to the neurologic assessment. Vital signs should be evaluated, and 
appropriate support initiated. Thiamine, glucose, and naloxone should be 
administered if the etiology of coma is not immediately apparent. Blood 
SECTION 2
90
Medical Emergencies
TABLE 17-3 DIFFERENTIAL DIAGNOSIS OF COMA
1.  Diseases that cause no focal or lateralizing neurologic signs, usually with 
normal brainstem functions; CT scan and cellular content of the CSF are 
normal
 
a. Intoxications: alcohol, sedative drugs, opiates, etc.
 b.  Metabolic disturbances: anoxia, hyponatremia, hypernatremia, hyper-
calcemia, diabetic acidosis, nonketotic hyperosmolar hyperglycemia, 
hypoglycemia, uremia, hepatic coma, hypercarbia, Addisonian crisis, 
hypo- and hyperthyroid states, profound nutritional deficiency
 c.  Severe systemic infections: pneumonia, septicemia, typhoid fever, 
malaria, Waterhouse-Friderichsen syndrome
 d. Shock from any cause
 e. Postseizure states, status epilepticus, subclinical epilepsy
 f.   Hypertensive encephalopathy, eclampsia
 g. Severe hyperthermia, hypothermia
 h. Concussion
 i.  Acute hydrocephalus
2.  Diseases that cause meningeal irritation with or without fever, and with 
an excess of WBCs or RBCs in the CSF, usually without focal or lateralizing 
cerebral or brainstem signs; CT or MRI shows no mass lesion
 a.  Subarachnoid hemorrhage from ruptured aneurysm, arteriovenous 
malformation, trauma
 b. Acute bacterial meningitis
 c.  Viral encephalitis
 d.  Miscellaneous: fat embolism, cholesterol embolism, carcinomatous and 
lymphomatous meningitis, etc.
3.  Diseases that cause focal brainstem or lateralizing cerebral signs, with or 
without changes in the CSF; CT and MRI are abnormal
 a.  Hemispheral hemorrhage (basal ganglionic, thalamic) or infarction (large 
middle cerebral artery territory) with secondary brainstem compression
 b. Brainstem infarction due to basilar artery thrombosis or embolism
 c. Brain abscess, subdural empyema
 d. Epidural and subdural hemorrhage, brain contusion
 e. Brain tumor with surrounding edema
 f.  Cerebellar and pontine hemorrhage and infarction
 g. Widespread traumatic brain injury
 h. Metabolic coma (see above) with preexisting focal damage
 i.     Miscellaneous: Cortical vein thrombosis, herpes simplex encephalitis, 
multiple cerebral emboli due to bacterial endocarditis, acute hemorrhagic 
leukoencephalitis, acute disseminated (postinfectious) encephalomyelitis, 
thrombotic thrombocytopenic purpura, cerebral vasculitis, gliomatosis 
cerebri, pituitary apoplexy, intravascular lymphoma, etc.
Abbreviations: CSF, cerebrospinal fluid; RBCs, red blood cells; WBCs, white blood cells.
CHAPTER 17
91
Confusion, Stupor, and Coma
should be drawn for glucose, electrolytes, calcium, and renal (BUN, cre-
atinine) and hepatic (ammonia, transaminases) function; also screen for 
presence of alcohol and other toxins, and obtain blood cultures if infection 
is suspected. Arterial blood-gas analysis is helpful in pts with lung disease 
and acid-base disorders. Fever, especially with petechial rash, suggests 
meningitis. Examination of CSF is essential in diagnosis of meningitis and 
encephalitis; lumbar puncture should not be deferred if meningitis is a 
possibility, but CT scan should be obtained first to exclude a mass lesion. 
Empirical antibiotic and glucocorticoid coverage for meningitis may be 
instituted until CSF results are available. Fever with dry skin suggests heat 
shock or intoxication with anticholinergics. Hypothermia suggests myx-
edema, intoxication, sepsis, exposure, or hypoglycemia. Marked hyperten-
sion occurs with increased intracranial pressure (ICP) and hypertensive 
encephalopathy.
Neurologic Examination 
Focus on establishing pt’s best level of function and uncovering signs that 
enable a specific diagnosis. Comatose pt’s best motor and sensory function 
should be assessed by testing reflex responses to noxious stimuli; carefully 
note any asymmetric responses, which suggest a focal lesion. Multifocal 
myoclonus indicates that a metabolic disorder is likely; intermittent twitch-
ing may be the only sign of a seizure.
Responsiveness
Stimuli of increasing intensity are applied to gauge the degree of unre-
sponsiveness and any asymmetry in sensory or motor function. Motor 
responses may be purposeful or reflexive. Spontaneous flexion of elbows 
with leg extension, termed decortication, accompanies severe damage to 
contralateral hemisphere above midbrain. Internal rotation of the arms with 
extension of elbows, wrists, and legs, termed decerebration, suggests damage 
to midbrain or diencephalon. These postural reflexes occur in profound 
encephalopathic states.
Pupillary Signs 
In comatose pts, equal, round, reactive pupils exclude mid-brain damage 
as cause and suggest a metabolic abnormality. Pinpoint pupils occur in 
narcotic overdose (except meperidine, which can cause midsize pupils), 
pontine damage, hydrocephalus, or thalamic hemorrhage; the response to 
naloxone and presence of reflex eye movements (usually intact with drug 
overdose) can distinguish these. A unilateral, enlarged, often oval, poorly 
reactive pupil is caused by midbrain lesions or compression of third cranial 
nerve, as occurs in transtentorial herniation. Bilaterally dilated, unreactive 
pupils indicate severe bilateral midbrain damage, anticholinergic overdose, 
or ocular trauma.
Ocular Movements 
Examine spontaneous and reflex eye movements. Intermittent horizontal 
divergence is common in drowsiness. Slow, to-and-fro horizontal movements 
SECTION 2
92
Medical Emergencies
suggest bihemispheric dysfunction. Conjugate eye deviation to one side 
indicates damage to the pons on the opposite side or a lesion in the frontal 
lobe on the same side (“The eyes look toward a hemispheral lesion and away 
from a brainstem lesion”). An adducted eye at rest with impaired ability 
to turn eye laterally indicates an abducens (VI) nerve palsy, common in 
raised ICP or pontine damage. The eye with a dilated, unreactive pupil is 
often abducted at rest and cannot adduct fully due to third nerve dysfunc-
tion, as occurs with transtentorial herniation. Vertical separation of ocular 
axes (skew deviation) occurs in pontine or cerebellar lesions. Doll’s head 
maneuver (oculocephalic reflex) and cold caloric–induced eye movements 
allow diagnosis of gaze or cranial nerve palsies in pts who do not move 
their eyes purposefully. Doll’s head maneuver is tested by observing eye 
movements in response to lateral rotation of head (this should not be per-
formed in pts with possible neck injury); full conjugate movement of eyes 
occurs in bihemispheric dysfunction. In comatose pts with intact brainstem 
function, raising head to 60° above the horizontal and irrigating external 
auditory canal with cool water causes tonic deviation of gaze to side of 
irrigated ear (“cold calorics”). In conscious pts, it causes nystagmus, vertigo, 
and emesis.
Respiratory Patterns 
Respiratory pattern may suggest site of neurologic damage. Cheyne-Stokes 
(periodic) breathing occurs in bihemispheric dysfunction and is common 
in metabolic encephalopathies. Respiratory patterns composed of gasps or 
other irregular breathing patterns are indicative of lower brainstem damage; 
such pts usually require intubation and ventilatory assistance.
Radiologic Examination 
Lesions causing raised ICP commonly cause impaired consciousness. CT or 
MRI scan of the brain is often abnormal in coma but may not be diagnostic; 
appropriate therapy should not be postponed while awaiting a CT or MRI 
scan. Pts with disordered consciousness due to high ICP can deteriorate 
rapidly; emergent CT study is necessary to confirm presence of mass effect 
and to guide surgical decompression. CT scan is normal in some pts with 
subarachnoid hemorrhage; the diagnosis then rests on clinical history com-
bined with RBCs or xanthochromia in spinal fluid. CT, MR, or conventional 
angiography may be necessary to establish basilar artery stroke as cause of 
coma in pts with brainstem signs. The EEG is useful in metabolic or drug-
induced states but is rarely diagnostic; exceptions are coma due to seizures 
or herpes virus encephalitis.
� BRAIN DEATH
This results from total cessation of cerebral function while somatic func-
tion is maintained by artificial means and the heart continues to pump. 
It is legally and ethically equivalent to cardiorespiratory death. The pt is 
unresponsive to all forms of stimulation (widespread cortical destruc-
tion), brainstem reflexes are absent (global brainstem damage), and 
there is complete apnea (destruction of the medulla). Demonstration of 
apnea requires that the Pco2 be high enough to stimulate respiration, 
CHAPTER 18
93
Stroke
while Po2 and bp are maintained. EEG is isoelectric at high gain. The 
absence of deep tendon reflexes is not required because the spinal cord 
may remain functional. Special care must be taken to exclude drug 
toxicity and hypothermia prior to making a diagnosis of brain death. 
Diagnosis should be made only if the state persists for some agreed-
upon period, usually 6–24 h.
For a more detailed discussion, see Josephson SA, Miller BL: 
Confusion and Delirium, Chap. 25, p. 196, in HPIM-18. and 
Ropper AH: Coma, Chap. 274, p. 2247, in HPIM-18.
CHAPTER 18
Stroke
Sudden onset of a neurologic deficit from a vascular mechanism: 85% are 
ischemic; 15% are primary hemorrhages [subarachnoid (Chap. 19) and 
intraparenchymal]. An ischemic deficit that resolves rapidly is termed 
a transient ischemic attack (TIA); 24 h is a commonly used boundary 
between TIA and stroke whether or not a new infarction has occurred, 
although most TIAs last between 5 and 15 min. Recently proposed new 
definitions classify all brain infarctions as strokes regardless of dura-
tion of symptoms. Stroke is the leading cause of neurologic disability 
in adults; 200,000 deaths annually in the United States. Much can be 
done to limit morbidity and mortality through prevention and acute 
intervention.
� PATHOPHYSIOLOGY
Ischemic stroke is most often due to embolic occlusion of large cerebral 
vessels; source of emboli may be heart, aortic arch, or other arterial lesions 
such as the carotid arteries. Small, deep ischemic lesions are most often 
related to intrinsic small-vessel disease (lacunar strokes). Low-flow strokes 
are seen with severe proximal stenosis and inadequate collaterals challenged 
by systemic hypotensive episodes. Hemorrhages most frequently result 
from rupture of aneurysms or small vessels within brain tissue. Variability 
in stroke recovery is influenced by collateral vessels, blood pressure, 
and the specific site and mechanism of vessel occlusion; if blood flow is 
restored prior to significant cell death, the pt may experience only transient 
symptoms, i.e., a TIA.
� CLINICAL FEATURES
Ischemic Stroke 
Abrupt and dramatic onset of focal neurologic symptoms is typical of 
ischemic stroke. Pts may not seek assistance on their own because they 
are rarely in pain and may lose appreciation that something is wrong 
SECTION 2
94
Medical Emergencies
(anosognosia). Symptoms reflect the vascular territory involved (Table 18-1). 
Transient monocular blindness (amaurosis fugax) is a particular form 
of TIA due to retinal ischemia; pts describe a shade descending over the 
visual field.
TABLE 18-1 ANATOMIC LOCALIZATION IN STROKE
Signs and Symptoms
Cerebral Hemisphere, Lateral Aspect (Middle Cerebral A.)
Hemiparesis
Hemisensory deficit
Motor aphasia (Broca’s)—hesitant speech with word-finding difficulty and 
preserved comprehension
Sensory aphasia (Wernicke’s)—anomia, poor comprehension, jargon speech
Unilateral neglect, apraxias
Homonymous hemianopia or quadrantanopia
Gaze preference with eyes deviated toward side of lesion
Cerebral Hemisphere, Medial Aspect (Anterior Cerebral A.)
Paralysis of foot and leg with or without paresis of arm
Cortical sensory loss over leg
Grasp and sucking reflexes
Urinary incontinence
Gait apraxia
Cerebral Hemisphere, Posterior Aspect (Posterior Cerebral A.)
Homonymous hemianopia
Cortical blindness
Memory deficit
Dense sensory loss, spontaneous pain, dysesthesias, choreoathetosis
Brainstem, Midbrain (Posterior Cerebral A.)
Third nerve palsy and contralateral hemiplegia
Paralysis/paresis of vertical eye movement
Convergence nystagmus, disorientation
Brainstem, Pontomedullary Junction (Basilar A.)
Facial paralysis
Paresis of abduction of eye
Paresis of conjugate gaze
Hemifacial sensory deficit
CHAPTER 18
95
Stroke
Lacunar Syndromes (Small-Vessel Strokes) 
Most common are:
• Pure motor hemiparesis of face, arm, and leg (internal capsule or pons)
• Pure sensory stroke (ventral thalamus)
• Ataxic hemiparesis (pons or internal capsule)
• Dysarthria—clumsy hand (pons or genu of internal capsule).
Intracranial Hemorrhage 
Vomiting and drowsiness occur in some cases, and headache in about one-
half. Signs and symptoms are often not confined to a single vascular terri-
tory. Etiologies are diverse but hypertension-related is the most common 
(Table 18-2). Hypertensive hemorrhages typically occur in the following 
locations:
• Putamen: Contralateral hemiparesis often with homonymous hemianopia.
• Thalamus: Hemiparesis with prominent sensory deficit.
• Pons: Quadriplegic, “pinpoint” pupils, impaired horizontal eye movements.
• Cerebellum: Headache, vomiting, gait ataxia.
A neurologic deficit that evolves gradually over 5–30 min strongly suggests 
intracerebral bleeding.
Stroke
TREATMENT
Principles of management are outlined in Fig. 18-1. Stroke needs to 
be distinguished from potential mimics, including seizure, migraine, 
tumor, and metabolic derangements. 
•  Imaging. After initial stabilization, an emergency noncontrast head 
CT scan is necessary to differentiate ischemic from hemorrhagic 
stroke. With large ischemic strokes, CT abnormalities are usually 
evident within the first few hours, but small infarcts can be difficult to 
visualize by CT. CT or MR angiography (CTA/MRA) and perfusion
TABLE 18-1 ANATOMIC LOCALIZATION IN STROKE (CONTINUED)
Brainstem, Pontomedullary Junction (Basilar A.)
Horner’s syndrome
Diminished pain and thermal sense over half body (with or without face)
Ataxia
Brainstem, Lateral Medulla (Vertebral A.)
Vertigo, nystagmus
Horner’s syndrome (miosis, ptosis, decreased sweating)
Ataxia, falling toward side of lesion
Impaired pain and thermal sense over half body with or without face
SECTION 2
96
Medical Emergencies
TABLE 18-2  CAUSES OF INTRACRANIAL HEMORRHAGE
Cause
Location
Comments
Head trauma
Intraparenchymal: 
frontal lobes, 
anterior temporal 
lobes;
subarachnoid
Coup and contrecoup injury during 
brain deceleration
Hypertensive
hemorrhage
Putamen, globus 
pallidus, thalamus, 
cerebellar
hemisphere, pons
Chronic hypertension produces 
hemorrhage from small (~100 μm) 
vessels in these regions
Transformation 
of prior ischemic 
infarction
Basal ganglion, 
subcortical
regions, lobar
Occurs in 1–6% of ischemic 
strokes with predilection for large 
hemispheric infarctions
Metastatic brain 
tumor
Lobar
Lung, choriocarcinoma, melanoma, 
renal cell carcinoma, thyroid, atrial 
myxoma
Coagulopathy
Any
Uncommon cause; often associated 
with prior stroke or underlying 
vascular anomaly
Drug
Lobar, 
subarachnoid
Cocaine, amphetamine, phenylpropa-
nolamine
Arteriovenous
malformation
Lobar, intraventric-
ular, subarachnoid
Risk is ~2–4% per year for bleeding
Aneurysm
Subarachnoid, 
intraparenchymal, 
rarely subdural
Mycotic and nonmycotic forms of 
aneurysms
Amyloid angi-
opathy
Lobar
Degenerative disease of intracranial 
vessels; linkage to Alzheimer’s 
disease, rare in pts <60 years
Cavernous 
angioma
Intraparenchymal
Multiple cavernous angiomas linked 
to mutations in KRIT1, CCM2, and 
PDCD10 genes
Dural arteriove-
nous fistula
Lobar, 
subarachnoid
Produces bleeding by venous 
hypertension
Capillary 
telangiectasias
Usually brainstem
Rare cause of hemorrhage
may help reveal vascular occlusions and tissue at risk for infarction. 
Diffusion-weighted MRI has a high sensitivity for identifying isch-
emic stroke even minutes after onset.
ACUTE ISCHEMIC STROKE Treatments designed to reverse or lessen 
tissue infarction include: (1) medical support, (2) thrombolysis and 
endovascular techniques, (3) antiplatelet agents, (4) anticoagulation, 
and (5) neuroprotection.
CHAPTER 18
97
Stroke
MEDICAL SUPPORT Optimize perfusion in ischemic penumbra sur-
rounding the infarct. 
•  Blood pressure should never be lowered precipitously (exacerbates the 
underlying ischemia), and only in the most extreme situations should 
gradual lowering be undertaken (e.g., malignant hypertension with 
bp > 220/120 or, if thrombolysis planned, bp > 185/110 mmHg). 
•  Intravascular volume should be maintained with isotonic fluids as 
volume restriction is rarely helpful. Osmotic therapy with mannitol 
may be necessary to control edema in large infarcts, but isotonic 
volume must be replaced to avoid hypovolemia. 
•  In cerebellar infarction (or hemorrhage), rapid deterioration can 
occur from brainstem compression and hydrocephalus, requiring 
neurosurgical intervention.
FIGURE 18-1 Medical management of stroke and TIA. Rounded boxes are diagno-
ses; rectangles are interventions. Numbers are percentages of stroke overall. ABCs, 
airway, breathing, circulation; BP, blood pressure; CEA, carotid endarterectomy; ICH, 
intracerebral hemorrhage; SAH, subarachnoid hemorrhage; TIA, transient ischemic 
attack.
ALGORITHM FOR STROKE AND TIA MANAGEMENT
Stroke or TIA
ABCs, glucose
Ischemic stroke/ 
TIA, 85%
Hemorrhage 
15%
Consider thrombolysis/ 
thrombectomy
Consider BP 
lowering
Obtain brain 
imaging
Establish cause
Establish cause
Atrial 
fibrillation, 
17%
Carotid 
disease, 
4%
Aneurysmal 
SAH, 4%
Hyperten-
sive ICH, 7%
Other, 
64%
Other, 
4%
Consider 
warfarin
Consider 
CEA or 
stent
Clip or coil 
(Chap. 19)
Consider 
surgery
Treat 
specific 
cause
Treat 
specific 
cause
Deep venous thrombosis prophylaxis
Physical, occupational, speech therapy
Evaluate for rehab, discharge planning
Secondary prevention based on disease
SECTION 2
98
Medical Emergencies
TABLE 18-3  ADMINISTRATION OF INTRAVENOUS RECOMBINANT TISSUE 
PLASMINOGEN ACTIVATOR (rtPA) FOR ACUTE ISCHEMIC 
STROKE (AIS)a
Indication
Contraindication
Clinical diagnosis of stroke
Sustained BP >185/110 mmHg despite 
treatment
Onset of symptoms to time 
of drug administration ≤3 h
Platelets <100,000; HCT <25%; glucose <50 
or >400 mg/dL
CT scan showing no hemor-
rhage or edema of >1/3 of 
the MCA territory
Use of heparin within 48 h and prolonged PTT, 
or elevated INR
Rapidly improving symptoms
Age ≥18 years
Consent by pt or surrogate
Prior stroke or head injury within 3 months; 
prior intracranial hemorrhage
Major surgery in preceding 14 days
Minor stroke symptoms
Gastrointestinal bleeding in preceding 21 days
Recent myocardial infarction
Coma or stupor
Administration of rtPA
Intravenous access with two peripheral IV lines (avoid arterial or central line 
placement)
Review eligibility for rtPA
Administer 0.9 mg/kg IV (maximum 90 mg) IV as 10% of total dose by bolus, 
followed by remainder of total dose over 1 h
Frequent cuff blood pressure monitoring
No other antithrombotic treatment for 24 h
For decline in neurologic status or uncontrolled blood pressure, stop infusion, 
give cryoprecipitate, and reimage brain emergently
Avoid urethral catheterization for ≥ 2 h
aSee Activase (tissue plasminogen activator) package insert for complete list of contraindica-
tions and dosing.
Abbreviations:  BP, blood pressure; HCT, hematocrit; INR, international normalized ratio; MCA, 
middle cerebral artery; PTT, partial thromboplastin time.
THROMBOLYSIS AND ENDOVASCULAR TECHNIQUES
•  Ischemic deficits of <3 h duration, with no hemorrhage by CT cri-
teria, may benefit from thrombolytic therapy with IV recombinant 
tissue plasminogen activator (Table 18-3). 
•  Based on recent data, IV rtPA is used in some centers for deficits of 
3–4.5 h duration, but is not yet approved for this window in the U.S. 
and Canada.
CHAPTER 18
99
Stroke
•  Ischemic stroke from large-vessel intracranial occlusion results in 
high rates of morbidity and mortality; pts with such occlusions may 
benefit from intraarterial thrombolysis (<6 h duration) or embolec-
tomy (<8 h duration) administered at the time of an urgent cerebral 
angiogram at specialized centers. 
ANTIPLATELET AGENTS
•  Aspirin (up to 325 mg/d) is safe and has a small but definite benefit 
in acute ischemic stroke.
ANTICOAGULATION
•  Trials do not support the use of heparin or other anticoagulants 
acutely for pts with acute stroke.
NEUROPROTECTION
•  Hypothermia is effective in coma following cardiac arrest but has 
not been adequately studied in pts with stroke. Other neuroprotec-
tive agents have shown no benefit in human trials despite promising 
animal data.
STROKE CENTERS AND REHABILITATION
•  Pt care in comprehensive stroke units followed by rehabilitation 
services improves neurologic outcomes and reduces mortality.
ACUTE INTRACEREBRAL HEMORRHAGE
•  Noncontrast head CT will confirm diagnosis. 
•  Rapidly identify and correct any coagulopathy. 
•  Nearly 50% of pts die; prognosis is determined by volume and loca-
tion of hematoma. 
•  Stuporous or comatose pts generally are treated presumptively for 
elevated ICP. Treatment for edema and mass effect with osmotic 
agents may be necessary; glucocorticoids not helpful.
•  Neurosurgical consultation should be sought for possible urgent 
evacuation of cerebellar hematoma; in other locations, data do not 
support surgical intervention.
� EVALUATION: DETERMINING THE CAUSE OF STROKE
Although initial management of acute ischemic stroke or TIA does not depend 
on the etiology, establishing a cause is essential to reduce risk of recurrence 
(Table 18-4); particular attention should be on atrial fibrillation and carotid 
atherosclerosis as these etiologies have proven secondary prevention strategies. 
Nearly 30% of strokes remain unexplained despite extensive evaluation.
Clinical examination should be focused on the peripheral and cervi-
cal vascular system. Routine studies include CXR and ECG, urinalysis, 
CBC/platelets, electrolytes, glucose, ESR, lipid profile, PT, PTT, and 
serologic tests for syphilis. If a hypercoagulable state is suspected, further 
studies of coagulation are indicated.
Imaging evaluation may include brain MRI (compared with CT, 
increased sensitivity for small infarcts of cortex and brainstem); MR or 
SECTION 2
100
Medical Emergencies
TABLE 18-4 CAUSES OF ISCHEMIC STROKE
Common Causes
Uncommon Causes
Thrombosis
Lacunar stroke (small vessel)
Large vessel thrombosis
Dehydration
Embolic occlusion
Artery-to-artery
Carotid bifurcation
Aortic arch
Arterial dissection
Cardioembolic
Atrial fibrillation
Mural thrombus
Myocardial infarction
Dilated cardiomyopathy
Valvular lesions
Mitral stenosis
Mechanical valve
Bacterial endocarditis
Paradoxical embolus
Atrial septal defect
Patent foramen ovale
Atrial septal aneurysm
Spontaneous echo contrast 
Hypercoagulable disorders
Protein C deficiency
Protein S deficiency
Antithrombin III deficiency
Antiphospholipid syndrome
Factor V Leiden mutationa
Prothrombin G20210 mutationa
Systemic malignancy
Sickle cell anemia 
β-Thalassemia
Polycythemia vera
Systemic lupus erythematosus
Homocysteinemia
Thrombotic thrombocytopenic purpura
Disseminated intravascular coagulation
Dysproteinemias
Nephrotic syndrome
Inflammatory bowel disease
Oral contraceptives
Venous sinus thrombosisb
Fibromuscular dysplasia 
Vasculitis
Systemic vasculitis [PAN, granuloma-
tosis with polyangiitis (Wegener’s), 
Takayasu’s, giant cell arteritis]
Primary CNS vasculitis
Meningitis (syphilis, tuberculosis, 
fungal, bacterial, zoster)
Cardiogenic
Mitral valve calcification
Atrial myxoma
Intracardiac tumor
Marantic endocarditis
Libman-Sacks endocarditis
Subarachnoid hemorrhage vasospasm
Drugs: cocaine, amphetamine 
Moyamoya disease
Eclampsia
aChiefly cause venous sinus thrombosis.
bMay be associated with any hypercoagulable disorder.
Abbreviations: CNS, central nervous system; PAN, polyarteritis nodosa.
CHAPTER 18
101
Stroke
CT angiography (evaluate patency of intracranial vessels and extracranial 
carotid and vertebral vessels); noninvasive carotid tests (“duplex” stud-
ies, combine ultrasound imaging of the vessel with Doppler evaluation of 
blood flow characteristics); or cerebral angiography (“gold standard” for 
evaluation of intracranial and extracranial vascular disease). For suspected 
cardiogenic source, cardiac echocardiogram with attention to right-to-left 
shunts, and 24-h Holter or long-term cardiac event monitoring indicated.
� PRIMARY AND SECONDARY PREVENTION OF STROKE
Risk Factors 
Atherosclerosis is a systemic disease affecting arteries throughout the body. 
Multiple factors including hypertension, diabetes, hyperlipidemia, and family 
history influence stroke and TIA risk (Table 18-5). Cardioembolic risk fac-
tors include atrial fibrillation, MI, valvular heart disease, and cardiomyopathy. 
Hypertension and diabetes are also specific risk factors for lacunar stroke 
and intraparenchymal hemorrhage. Smoking is a potent risk factor for all 
vascular mechanisms of stroke. Identification of modifiable risk factors and 
prophylactic interventions to lower risk is probably the best approach to stroke 
overall.
TABLE 18-5 RISK FACTORS FOR STROKE
Risk Factor
Relative
Risk
Relative Risk 
Reduction with 
Treatment
Number Needed to Treata
Primary 
Prevention
Secondary 
Prevention
Hypertension
2–5
38%
100–300
50–100
Atrial fibrillation
1.8–2.9
68% warfarin, 
21% aspirin
20–83
13
Diabetes
1.8–6
No proven effect
Smoking
1.8
50% at 1 year,
baseline risk 
at 5 years post 
cessation
Hyperlipidemia
1.8–2.6
16–30%
560
230
Asymptomatic 
carotid stenosis
2.0
53%
85
N/A
Symptomatic 
carotid stenosis 
(70–99%)
65% at 2 years
N/A
12
Symptomatic 
carotid stenosis 
(50–69%)
29% at 5 years
N/A
77
aNumber needed to treat to prevent one stroke annually. Prevention of other cardiovascular 
outcomes is not considered here.
Abbreviations: N/A, not applicable.
SECTION 2
102
Medical Emergencies
Antiplatelet Agents 
Platelet antiaggregation agents can prevent atherothrombotic events, 
including TIA and stroke, by inhibiting the formation of intraarterial 
platelet aggregates. Aspirin (50–325 mg/d) inhibits thromboxane A2, a 
platelet aggregating and vasoconstricting prostaglandin. Aspirin, clopido-
grel (blocks the platelet ADP receptor), and the combination of aspirin plus 
extended-release dipyridamole (inhibits platelet uptake of adenosine) are 
the antiplatelet agents most commonly used. In general, antiplatelet agents 
reduce new stroke events by 25–30%. Every pt who has experienced an 
atherothrombotic stroke or TIA and has no contraindication should take 
an antiplatelet agent regularly because the average annual risk of another 
stroke is 8–10%. The choice of aspirin, clopidogrel, or dipyridamole plus 
aspirin must balance the fact that the latter are more effective than aspirin 
but the cost is higher.
Embolic Stroke 
In pts with atrial fibrillation, the choice between anticoagulant or aspirin 
prophylaxis is determined by age and risk factors; the presence of any risk 
factor tips the balance in favor of anticoagulation (Table 18-6). 
Anticoagulation Therapy for Noncardiogenic Stroke 
Data do not support the use of long-term warfarin for preventing athero-
thrombotic stroke for either intracranial or extracranial cerebrovascular 
disease.
Carotid Revascularization 
Carotid endarterectomy benefits many pts with symptomatic severe (>70%) 
carotid stenosis; the relative risk reduction is ~65%. However, if the periop-
erative stroke rate is >6% for any surgeon, the benefit is lost. Endovascular 
stenting is an emerging option; there remains controversy as to who should 
receive a stent or undergo endarterectomy. Surgical results in pts with 
asymptomatic carotid stenosis are less robust, and medical therapy for reduc-
tion of atherosclerosis risk factors plus antiplatelet medications is generally 
recommended in this group.
TABLE 18-6  CONSENSUS RECOMMENDATION FOR ANTITHROMBOTIC 
PROPHYLAXIS IN ATRIAL FIBRILLATION
CHADS2 Scorea
Recommendation
0
Aspirin or no antithrombotic
1
Aspirin or warfarin INR 2.5
>1
Warfarin INR 2.5
aCHADS2 score calculated as follows: 1 point for age > 75 years, 1 point for hypertension, 
1 point for congestive heart failure, 1 point for diabetes, and 2 points for stroke or TIA; sum of 
points is the total CHADS2 score.
Source: Modified from DE Singer et al: Chest 133:546S, 2008; with permission.
CHAPTER 19
103
Subarachnoid Hemorrhage
For a more detailed discussion, see Smith WS, English JD, 
Johnston SC: Cerebrovascular Diseases, Chap. 370, p. 3270, 
in HPIM-18.
CHAPTER 19
Subarachnoid Hemorrhage
Excluding head trauma, the most common cause of subarachnoid hem-
orrhage (SAH) is rupture of an intracranial (saccular) aneurysm; other 
etiologies include bleeding from a vascular malformation (arteriovenous 
malformation or dural arterial-venous fistula), infective (mycotic) aneurysms, 
and extension into the subarachnoid space from a primary intracerebral 
hemorrhage. Approximately 2% of the population harbor aneurysms, and 
25,000–30,000 cases of aneurysmal rupture producing SAH occur each year 
in the United States; rupture risk for aneurysms <10 mm in size is 0.1% per 
year; for unruptured aneurysms, the surgical morbidity risk far exceeds the 
percentage.
� CLINICAL PRESENTATION
Sudden, severe headache, often with transient loss of consciousness at 
onset; vomiting is common. Bleeding may injure adjacent brain tissue and 
produce focal neurologic deficits. A progressive third nerve palsy, usually 
involving the pupil, along with headache suggests posterior communicating 
artery aneurysm. In addition to dramatic presentations, aneurysms can 
undergo small ruptures with leaks of blood into the subarachnoid space 
(sentinel bleeds). The initial clinical manifestations of SAH can be graded 
using established scales (Table 19-1); prognosis for good outcome falls as 
the grade increases.
� INITIAL EVALUATION
• Noncontrast CT is the initial study of choice and usually demonstrates 
the hemorrhage if obtained within 72 h. LP is required for diagnosis of 
suspected SAH if the CT is nondiagnostic; xanthochromia of the spinal 
fluid is seen within 6–12 h after rupture and lasts for 1–4 weeks.
• Cerebral angiography is necessary to localize and define the anatomic 
details of the aneurysm and to determine if other unruptured aneurysms 
exist; angiography should be performed as soon as possible after the 
diagnosis of SAH is made.
• ECG may reveal ST-segment and T-wave changes similar to those asso-
ciated with cardiac ischemia; caused by circulating catecholamines and 
excessive discharge of sympathetic neurons. A reversible cardiomyopa-
thy producing shock or congestive heart failure may result.
• Studies of coagulation and platelet count should be obtained, and rapid 
correction should ensue if SAH is documented.
SECTION 2
104
Medical Emergencies
Subarachnoid Hemorrhage
TREATMENT
ANEURYSM REPAIR
• Early aneurysm repair prevents rerupture.
• The International Subarachnoid Aneurysm Trial (ISAT) demon-
strated improved outcomes with endovascular therapy compared to 
surgery; however, some aneurysms have a morphology not amenable 
to endovascular treatment, and therefore surgery is still an important 
treatment option for some pts.
MEDICAL MANAGEMENT
• Closely follow serum electrolytes and osmolality; hyponatremia 
(“cerebral salt wasting”) frequently develops several days after SAH, 
and supplemental oral salt plus IV normal saline or hypertonic saline 
may be used to overcome renal losses.
• Anticonvulsants may be begun until the aneurysm is treated, although 
most experts reserve this therapy only for pts in whom a seizure has 
occurred.
• Blood pressure should be carefully controlled, while preserving cere-
bral blood flow, in order to decrease the risk of rerupture until the 
aneurysm is repaired.
• All pts should have pneumatic compression stockings applied to 
prevent pulmonary embolism; unfractionated heparin administered 
subcutaneously for deep-vein thrombosis prophylaxis can be initiated 
immediately following endovascular treatment and within days 
following craniotomy and surgical clipping.
TABLE 19-1 GRADING SCALES FOR SUBARACHNOID HEMORRHAGE
Grade
Hunt-Hess Scale
World Federation of 
Neurosurgical Societies 
(WFNS) Scale
1
Mild headache, normal mental status, 
no cranial nerve or motor findings
GCSa score 15, no motor 
deficits
2
Severe headache, normal mental sta-
tus, may have cranial nerve deficit
GCS score 13–14, no motor 
deficits
3
Somnolent, confused, may have cra-
nial nerve or mild motor deficit
GCS score 13–14, with motor 
deficits
4
Stupor, moderate to severe motor 
deficit, may have intermittent reflex 
posturing
GCS score 7–12, with or with-
out motor deficits
5
Coma, reflex posturing or flaccid
GCS score 3–6, with or with-
out motor deficits
aGlasgow Coma Scale: See Table 20-2.
CHAPTER 20
105
HYDROCEPHALUS
• Severe hydrocephalus may require urgent placement of a ventricular 
catheter for external CSF drainage; some pts will require permanent 
shunt placement.
• Deterioration of a SAH pt in the first hours to days should prompt 
repeat CT scanning to evaluate ventricular size.
VASOSPASM
• The leading cause of mortality and morbidity following initial rupture; 
may develop by day 4 and continue through day 14, leading to focal 
ischemia and possibly stroke.
• Medical treatment with the calcium channel antagonist nimodipine 
(60 mg PO q4h) improves outcome, probably by preventing ischemic 
injury rather than reducing the risk of vasospasm. 
• Cerebral perfusion can be improved in symptomatic vasospasm by 
increasing mean arterial pressure with vasopressor agents such as phen-
ylephrine or norepinephrine, and intravascular volume can be expanded 
with crystalloid, augmenting cardiac output and reducing blood viscos-
ity by reducing the hematocrit; this so-called “triple-H” (hypertension, 
hemodilution, and hypervolemic) therapy is widely used. 
• If  symptomatic vasospasm persists despite optimal medical therapy, 
intra-arterial vasodilators and angioplasty of the cerebral vessels can 
be effective.
For a more detailed discussion, see Hemphill JC III, Smith WS, 
and Gress DR: Neurologic Critical Care, Including Hypoxic-
Ischemic Encephalopathy and Subarachnoid Hemorrhage. 
Chap. 275, p. 2254, in HPIM-18.
CHAPTER 20
Increased Intracranial 
Pressure and Head Trauma
INCREASED INTRACRANIAL PRESSURE
A limited volume of extra tissue, blood, CSF, or edema can be added to 
the intracranial contents without raising the intracranial pressure (ICP). 
Clinical deterioration or death may follow increases in ICP that shift intra-
cranial contents, distort vital brainstem centers, or compromise cerebral 
perfusion. Cerebral perfusion pressure (CPP), defined as the mean arterial 
pressure (MAP) minus the ICP, is the driving force for circulation across 
capillary beds of the brain; decreased CPP is a fundamental mechanism of 
secondary ischemic brain injury and constitutes an emergency that requires 
Increased ICP and Head Trauma
SECTION 2
106
Medical Emergencies
A
B
D
C
FIGURE 20-1 Types of cerebral herniation. A. uncal; B. central; C. transfalcial; 
D. foraminal.
immediate attention. In general, ICP should be maintained at <20 mmHg 
and CPP should be maintained at ≥60 mmHg.
� CLINICAL FEATURES
Elevated ICP may occur in a wide range of disorders including head trauma, 
intracerebral hemorrhage, subarachnoid hemorrhage (SAH) with hydro-
cephalus, and fulminant hepatic failure.
Symptoms of high ICP include drowsiness, headache (especially a constant 
ache that is worse upon awakening), nausea, emesis, diplopia, and blurred vision. 
Papilledema and sixth nerve palsies are common. If not controlled, then cerebral 
hypoperfusion, pupillary dilation, coma, focal neurologic deficits, posturing, 
abnormal respirations, systemic hypertension, and bradycardia may result.
Masses that cause raised ICP also distort midbrain and diencephalic 
anatomy, leading to stupor and coma. Brain tissue is pushed away from 
the mass against fixed intracranial structures and into spaces not normally 
occupied. Posterior fossa masses, which may initially cause ataxia, stiff 
neck, and nausea, are especially dangerous because they can both compress 
vital brainstem structures and cause obstructive hydrocephalus.
Herniation syndromes (Fig. 20-1) include:
• Uncal: Medial temporal lobe displaced through the tentorium, compress-
ing the third cranial nerve and pushing the cerebral peduncle against the 
tentorium, leading to ipsilateral pupillary dilation, contralateral hemipa-
resis, and posterior cerebral artery compression.
CHAPTER 20
107
Increased ICP and Head Trauma
TABLE 20-1  STEPWISE APPROACH TO TREATMENT OF ELEVATED 
INTRACRANIAL PRESSURE*
Insert ICP monitor—ventriculostomy versus parenchymal device general 
goals: maintain ICP <20 mmHg and CPP ≥60 mmHg For ICP >20–25 mmHg 
for >5 min:
1. Drain CSF via ventriculostomy (if in place)
2. Elevate head of the bed; midline head position
3.  Osmotherapy—mannitol 25–100 g q4h as needed (maintain serum 
osmolality <320 mosmol) or hypertonic saline (30 mL, 23.4% NaCl bolus)
4.  Glucocorticoids—dexamethasone 4 mg q6h for vasogenic edema from 
tumor, abscess (avoid glucocorticoids in head trauma, ischemic and hem-
orrhagic stroke)
5.  Sedation (e.g., morphine, propofol, or midazolam); add neuromuscular 
paralysis if necessary (pt will require endotracheal intubation and 
mechanical ventilation at this point, if not before)
6.  Hyperventilation—to PaCO2 30–35 mmHg
7.  Pressor therapy—phenylephrine, dopamine, or norepinephrine to maintain 
adequate MAP to ensure CPP ≥ 60 mmHg (maintain euvolemia to minimize 
deleterious systemic effects of pressors)
8.  Consider second-tier therapies for refractory elevated ICP
a.  High-dose barbiturate therapy (“pentobarb coma”)
b.  Aggressive hyperventilation to PaCO2 <30 mmHg
c.  Hypothermia
d.  Hemicraniectomy
*Throughout ICP treatment algorithm, consider repeat head CT to identify mass lesions 
amenable to surgical evacuation.
Abbreviations: CPP, cerebral perfusion pressure; CSF, cerebrospinal fluid; MAP, mean arterial 
pressure; PaCO2, arterial partial pressure of carbon dioxide.
• Central: Downward displacement of the thalamus through the tento-
rium; miotic pupils and drowsiness are early signs.
• Transfalcial: Cingulate gyrus displaced under the midline falx, leading to 
anterior cerebral artery compression.
• Foraminal: Cerebellar tonsils displaced into the foramen magnum, causing 
medullary compression and respiratory arrest.
Increased Intracranial Pressure
TREATMENT
• A number of different interventions may lower ICP, and ideally the 
selection of treatment will be based on the underlying mechanism 
responsible for the elevated ICP (Table 20-1).
• With hydrocephalus, the principal cause of elevated ICP is impaired 
CSF drainage; in this setting, ventricular drainage of CSF is likely to be 
sufficient.
SECTION 2
108
Medical Emergencies
• If cytotoxic edema is responsible, as in head trauma or stroke, use of 
osmotic diuretics such as mannitol or hypertonic saline is an appropri-
ate early step.
• Elevated ICP may cause tissue ischemia; resulting vasodilatation can 
lead to a cycle of worsening ischemia. Paradoxically, administration 
of vasopressor agents to increase mean arterial pressure may actually 
lower ICP by increasing perfusion; therefore, hypertension should be 
treated carefully, if at all.
• Free water should be restricted.
• Fever should be treated aggressively.
• Hyperventilation is best used for only short periods of time until a 
more definitive treatment can be instituted.
• ICP monitoring is an important tool to guide medical and surgical 
decisions in selected pts with cerebral edema (Fig. 20-2).
After stabilization and initiation of the above therapies, a CT scan (or 
MRI, if feasible) is performed to delineate the cause of the elevated ICP. 
Emergency surgery is sometimes necessary to decompress the intracra-
nial contents in cerebellar stroke with edema, surgically accessible tumor, 
and subdural or epidural hemorrhage.
HEAD TRAUMA
Almost 10 million head injuries occur annually in the United States, about 
20% of which are serious enough to cause brain damage.
Ventriculostomy
Fiberoptic
intraparenchymal
ICP monitor
Brain tissue
oxygen probe
Lateral ventricle
FIGURE 20-2 Intracranial pressure and brain tissue oxygen monitoring. A ventricu-
lostomy allows for drainage of cerebrospinal fluid to treat elevated intracranial pres-
sure (ICP). Fiberoptic ICP and brain tissue oxygen monitors are usually secured using 
a screwlike skull bolt. Cerebral blood flow and microdialysis probes (not shown) may 
be placed in a manner similar to the brain tissue oxygen probe.
CHAPTER 20
109
� CLINICAL FEATURES
Head trauma can cause immediate loss of consciousness. If transient and 
accompanied by a short period of amnesia, it is called concussion. Prolonged 
alterations in consciousness may be due to parenchymal, subdural, or epi-
dural hematoma or to diffuse shearing of axons in the white matter. Skull 
fracture should be suspected in pts with CSF rhinorrhea, hemotympanum, 
and periorbital or mastoid ecchymoses. Glasgow Coma Scale (Table 20-2) 
useful for grading severity of brain injury.
Head Injury
APPROACH TO THE
PATIENT
Medical personnel caring for head injury pts should be aware that: 
• Spinal injury often accompanies head injury and care must be taken to 
prevent compression of the spinal cord due to instability of the spinal 
column.
• Intoxication is a frequent accompaniment of traumatic brain injury; 
when appropriate, testing should be carried out for drugs and alcohol.
• Accompanying systemic injuries, including ruptures of abdominal 
organs, may produce vascular collapse or respiratory compromise 
requiring immediate attention.
MINOR CONCUSSIVE INJURY The pt with minor head injury who is alert 
and attentive after a short period of unconsciousness (<1 min) may have 
headache, dizziness, faintness, nausea, a single episode of emesis, diffi-
culty with concentration, or slight blurring of vision. Such pts have usually 
sustained a concussion and are expected to have a brief amnestic period. 
Increased ICP and Head Trauma
TABLE 20-2 GLASGOW COMA SCALE FOR HEAD INJURY
Eye opening (E)
Verbal response (V)
Spontaneous
4
Oriented
5
To loud voice
3
Confused, disoriented
4
To pain
2
Inappropriate words
3
Nil
1
Incomprehensible sounds
2
Nil
1
Best motor response (M)
Obeys
6
Localizes
5
Withdraws (flexion)
4
Abnormal flexion posturing
3
Extension posturing
2
Nil
1
Note: Coma score = E + M + V. Pts scoring 3 or 4 have an 85% chance of dying or remain-
ing vegetative, while scores >11 indicate only a 5–10% likelihood of death or vegetative state 
and 85% chance of moderate disability or good recovery. Intermediate scores correlate with 
proportional chances of recovery.
SECTION 2
110
Medical Emergencies
TABLE 20-3 GUIDELINES FOR MANAGEMENT OF CONCUSSION IN SPORTS
Severity of Concussion
Grade 1: Transient confusion, no loss of consciousness (LOC), all symptoms 
resolve within 15 min.
Grade 2: Transient confusion, no LOC, but concussive symptoms or mental 
status abnormalities persist longer than 15 min.
Grade 3: Any LOC, either brief (seconds) or prolonged (minutes).
On-Site evaluation
1. Mental status testing
a. Orientation—time, place, person, circumstances of injury
b. Concentration—digits backward, months of year in reverse order
c.  Memory—names of teams, details of contest, recent events, recall of 
three words and objects at 0 and 5 min
2. Finger-to-nose with eyes open and closed
3. Pupillary symmetry and reaction
4. Romberg and tandem gait
5.  Provocative testing—40-yard sprint, 5 push ups, 5 sit ups, 5 knee bends 
(development of dizziness, headaches, or other symptoms is abnormal)
Management guidelines
Grade 1: Remove from contest. Examine immediately and at 5-min 
intervals. May return to contest if exam clears within 15 min. A second 
grade 1 concussion eliminates player for 1 week, with return contingent 
upon normal neurologic assessment at rest and with exertion.
Grade 2: Remove from contest, cannot return for at least 1 week. Examine at fre-
quent intervals on sideline. Formal neurologic exam the next day. If headache or 
other symptoms persist for 1 week or longer, CT or MRI scan is indicated. After 
1 full asymptomatic week, repeat neurologic assessment at rest and with exercise 
before cleared to resume play. A second grade 2 concussion eliminates player for 
at least 2 weeks following complete resolution of symptoms at rest or with exer-
tion. If imaging shows abnormality, player is removed from play for the season.
Grade 3: Transport by ambulance to emergency department if still unconscious 
or worrisome signs are present; cervical spine stabilization may be indicated. 
Neurologic exam and, when indicated, CT or MRI scan will guide subsequent 
management. Hospital admission indicated when signs of pathology are present 
or if mental status remains abnormal. If findings are normal at the time of the 
initial medical evaluation, the athlete may be sent home, but daily exams as an 
outpatient are indicated. A brief (LOC for seconds) grade 3 concussion eliminates 
player for 1 week, and a prolonged (LOC for minutes) grade 3 concussion for 
2 weeks, following complete resolution of symptoms. A second grade 
3 concussion should eliminate player from sports for at least 1 month following 
resolution of symptoms. Any abnormality on CT or MRI scans should result in 
termination of the season for the athlete, and return to play at any future time 
should be discouraged.
Source: Modified from Quality Standards Subcommittee of the American Academy of 
Neurology: The American Academy of Neurology Practice Handbook. The American Academy 
of Neurology, St. Paul, MN, 1997.
CHAPTER 20
111
After several hours of observation, these pts can be accompanied home 
and observed for a day by family or friends. Persistent severe headache 
and repeated vomiting are usually benign if the neurologic exam remains 
normal, but in such situations radiologic studies should be obtained and 
hospitalization is justified.
Timing of return to contact sports depends on the severity of concus-
sion and examination; this common sense approach is not guided by 
adequate data (Table 20-3).
Older age, two or more episodes of vomiting, >30 min of retrograde 
or persistent anterograde amnesia, seizure, and concurrent drug or alco-
hol intoxication are sensitive (but not specific) indicators of intracranial 
hemorrhage that justify CT scanning; it is appropriate to be more liberal 
in obtaining CT scans in children.
INJURY OF INTERMEDIATE SEVERITY Pts who are not comatose but who 
have persistent confusion, behavioral changes, subnormal alertness, 
extreme dizziness, or focal neurologic signs such as hemiparesis should 
be hospitalized and have a CT scan. A cerebral contusion or subdural 
hematoma is often found. Pts with intermediate head injury require medi-
cal observation to detect increasing drowsiness, respiratory dysfunc-
tion, pupillary enlargement, or other changes in the neurologic exam. 
Abnormalities of attention, intellect, spontaneity, and memory tend to 
return to normal weeks or months after the injury, although some cogni-
tive deficits may be persistent.
SEVERE INJURY Pts who are comatose from onset require immediate 
neurologic attention and often resuscitation. After intubation (with care 
taken to avoid deforming the cervical spine), the depth of coma, pupillary 
size and reactivity, limb movements, and Babinski responses are assessed. 
As soon as vital functions permit and cervical spine x-rays and a CT scan 
have been obtained, the pt should be transported to a critical care unit. 
CT scan may be normal in comatose pts with axonal shearing lesions in 
cerebral white matter.
The finding of an epidural or subdural hematoma or large intracere-
bral hemorrhage requires prompt decompressive surgery in otherwise 
salvageable pts. Subsequent treatment is probably best guided by direct 
measurement of ICP. The use of prophylactic anticonvulsants has been 
recommended but supportive data is limited.
For a more detailed discussion, see Hemphill JC Smith 
WS Gress DR: Neurologic Critical Care, Including Hypoxic-
Ischemic Encephalopathy and Subarachnoid Hemorrhage, 
Chap. 275, p. 2254; Ropper AH: Concussion and Other 
Head Injuries, Chap. 378, p. 3377; and Ropper AH: Coma, 
Chap. 274, p. 2247; in HPIM-18.
Increased ICP and Head Trauma
SECTION 2
112
Medical Emergencies
CHAPTER 21
Spinal Cord Compression
Spinal Cord Compression
APPROACH TO THE
PATIENT
Initial symptoms, focal neck or back pain, may evolve over days to 
weeks. These are followed by various combinations of paresthesias, 
sensory loss, motor weakness, and sphincter disturbance evolving over 
hours to several days. Partial lesions may selectively involve one or more 
tracts and may be limited to one side of the cord. In severe or abrupt 
cases, areflexia reflecting spinal shock may be present, but hyperreflexia 
supervenes over days to weeks. With thoracic lesions, a sensory level to 
pain may be present on the trunk, indicating localization to the cord at 
that dermatomal level.
In any pt who presents with spinal cord symptoms, the first prior-
ity is to exclude treatable compression by a mass. Compression is 
more likely to be preceded by warning signs of neck or back pain, 
bladder disturbances, and sensory symptoms prior to development 
of weakness; noncompressive etiologies such as infarction and hem-
orrhage are more likely to produce myelopathy without antecedent 
symptoms.
MRI with gadolinium, centered on the clinically suspected level, is 
the initial diagnostic procedure. (CT myelography may be helpful in 
pts who have contraindications to MRI.) It is often useful to image the 
entire spine to search for additional clinically silent lesions. Infectious 
etiologies, unlike tumor, often cross the disc space to involve adjacent 
vertebral bodies.
� NEOPLASTIC SPINAL CORD COMPRESSION
Occurs in 3–5% of pts with cancer; epidural tumor may be the initial 
manifestation of malignancy. Most neoplasms are epidural in origin and 
result from metastases to the adjacent spinal bones. Almost any malignant 
tumor can metastasize to the spinal column with lung, breast, prostate, 
kidney, lymphoma, and plasma cell dyscrasia being particularly frequent. 
The thoracic cord is most commonly involved; exceptions include prostate 
and ovarian tumors, which preferentially involve the lumbar and sacral 
segments from spread through veins in the anterior epidural space. The 
most common presenting symptom is localized back pain and tenderness 
followed by symptoms of neurologic compromise. Urgent MRI is indicated 
when the diagnosis is suspected; up to 40% of pts with neoplastic cord 
compression at one level are found to have asymptomatic epidural disease 
elsewhere, so the entire spine should be imaged. Plain radiographs will miss 
15–20% of metastatic vertebral lesions.
CHAPTER 21
113
Spinal Cord Compression
Neoplastic Spinal Cord Compression
TREATMENT
• Glucocorticoids to reduce edema (dexamethasone, up to 40 mg daily) 
can be administered before the imaging study if the clinical suspicion 
is high, and continued at a lower dose until radiotherapy (generally 
3000 cGy administered in 15 daily fractions) is completed.
• Early surgery, either decompression by laminectomy or vertebral body 
resection, should be considered as a recent clinical trial indicated that sur-
gery followed by radiotherapy is more effective than radiotherapy alone 
for pts with a single area of spinal cord compression by extradural tumor.
• Time is of the essence in treatment; fixed motor deficits (paraplegia or 
quadriplegia) once established for >12 h do not usually improve, and 
beyond 48 h the prognosis for substantial motor recovery is poor.
• Biopsy is needed if there is no history of underlying malignancy; a 
simple systemic workup including chest imaging, mammography, 
measurement of prostate-specific antigen (PSA), and abdominal CT 
may reveal the diagnosis.
� SPINAL EPIDURAL ABSCESS
Presents as a triad of pain, fever, and progressive limb weakness. Aching 
pain is almost always present, either over the spine or in a radicular pattern. 
The duration of pain prior to presentation is generally <2 weeks but may be 
several months or longer. Fever is usually present along with elevated white 
blood cell count, sedimentation rate, and C-reactive protein. Risk factors 
include an impaired immune status (diabetes mellitus, HIV, renal failure, 
alcoholism, malignancy), intravenous drug abuse, and infections of the 
skin or other soft tissues. Most cases are due to Staphylococcus aureus; other 
important causes include gram-negative bacilli, Streptococcus, anaerobes, 
fungi, and tuberculosis (Pott’s disease).
MRI localizes the abscess. Lumbar puncture (LP) is required only if 
encephalopathy or other clinical signs raise the question of associated 
meningitis, a feature found in <25% of cases. The level of the LP should be 
planned to minimize risk of meningitis due to passage of the needle through 
infected tissue.
Spinal Epidural Abscess
TREATMENT
• Decompressive laminectomy with debridement combined with long-
term antibiotic treatment. 
• Surgical evacuation is unlikely to improve deficits of more than several 
days’ duration.
• Broad-spectrum antibiotics should be started empirically before sur-
gery and then modified on the basis of culture results and continued 
for at least 4 weeks.
• With prompt diagnosis and treatment, up to two-thirds of pts experi-
ence significant recovery.
SECTION 2
114
Medical Emergencies
CHAPTER 22
Hypoxic-Ischemic
Encephalopathy
Results from lack of delivery of oxygen to the brain because of hypotension 
or respiratory failure. Most common causes are MI, cardiac arrest, shock, 
asphyxiation, paralysis of respiration, and carbon monoxide or cyanide 
poisoning. In some circumstances, hypoxia may predominate. Carbon 
monoxide and cyanide poisoning are termed histotoxic hypoxia since they 
cause a direct impairment of the respiratory chain.
� CLINICAL MANIFESTATIONS
Mild degrees of pure hypoxia (e.g., at high altitude) cause impaired judgment, 
inattentiveness, motor incoordination, and, at times, euphoria. However, with 
hypoxia-ischemia, such as occurs with circulatory arrest, consciousness is lost 
within seconds. If circulation is restored within 3–5 min, full recovery may 
occur, but with longer periods permanent cerebral damage usually results. It 
may be difficult to judge the precise degree of hypoxia-ischemia, and some 
pts make a relatively full recovery even after 8–10 min of global ischemia. The 
distinction between pure hypoxia and hypoxia-ischemia is important, since a 
Pao2 as low as 2.7 kPa (20 mmHg) can be well tolerated if it develops gradu-
ally and normal blood pressure is maintained, but short durations of very low 
or absent cerebral circulation may result in permanent impairment.
Clinical examination at different time points after an insult (especially 
cardiac arrest) helps to assess prognosis (Fig. 22-1). The prognosis is better 
for pts with intact brainstem function, as indicated by normal pupillary 
light responses, intact oculocephalic (doll’s eyes) reflexes, and oculoves-
tibular (caloric) and corneal reflexes. Absence of these reflexes and the 
presence of persistently dilated pupils that do not react to light are grave 
prognostic signs. A uniformly dismal prognosis is conveyed by the absence 
of a pupillary light reflex or absence of a motor response to pain on day 3 
following the injury. Bilateral absence of the cortical somatosensory evoked 
� SPINAL EPIDURAL HEMATOMA
Hemorrhage into the epidural (or subdural) space causes acute focal or radicu-
lar pain followed by variable signs of a spinal cord disorder. Therapeutic anti-
coagulation, trauma, tumor, or blood dyscrasia are predisposing conditions; 
rarely complication of LP or epidural anesthesia. Treatment consists of prompt 
reversal of any underlying bleeding disorder and surgical decompression.
For a more detailed discussion, see Gucalp R and Dutcher J:
Oncologic Emergencies, Chap. 276, p. 2266; and Hauser SL
and Ropper AH: Diseases of the Spinal Cord, Chap. 377, 
p. 3366, in HPIM-18.
CHAPTER 22
115
Hypoxic-Ischemic Encephalopathy 
Coma
Brain death
testing
Yes
Yes
Yes
Yes
Yes
Day 1–3
Serum NSE > 33 μg/L∗
Day 3
Absent pupil or corneal
reflexes; extensor or absent
motor response
Indeterminate outcome
FPR
0%
(0–8.8)
FPR
0.7%
(0–3.7)
FPR
0%
(0–3)
FPR
0%
(0–3)
Poor
outcome
Poor
outcome
Poor
outcome
Poor
outcome
or
or
or
or
no
Day 1–3
SSEP
absent N20 responses∗
Day 1
Myoclonus, status epilepticus
No brainstem reflexes at
 any time (pupil, cornea, 
oculocephalic, cough)
Exclude major confounders
PROGNOSTICATION ALGORITHM OF OUTCOME
FIGURE 22-1 Prognostication of outcome in comatose survivors of cardiopulmonary 
resuscitation. Numbers in parentheses are 95% confidence intervals. Confounders 
could include use of sedatives or neuromuscular blocking agents, hypothermia ther-
apy, organ failure, or shock. Tests denoted with an asterisk (*) may not be available 
in a timely and standardized manner. SSEP, somatosensory evoked potentials; NSE, 
neuron-specific enolase; FPR, false-positive rate. [From EFM Wijdicks et al: Practice 
parameter: Prediction of outcome in comatose survivors after cardiopulmonary 
resuscitation (an evidence-based review). Neurology 67:203, 2006; with permission.]
potentials (SSEP) in the first several days also conveys a poor prognosis, 
as does a very elevated serum level (>33 μg/L) of the biochemical marker 
neuron-specific enolase (NSE). Usefulness of SSEP and NSE often limited: 
difficult to obtain in a timely fashion; need for expert interpretation (SSEP); 
and lack of standardization (NSE measurements). Whether administration 
of mild hypothermia after cardiac arrest will alter the usefulness of these 
clinical and electrophysiologic predictors is unknown.
SECTION 2
116
Medical Emergencies
For a more detailed discussion, see Hemphill JC III, Smith 
WS, Gress DR: Neurologic Critical Care, Including Hypoxic-
Ischemic Encephalopathy and Subarachnoid Hemorrhage, 
Chap. 275, p. 2254, in HPIM-18.
CHAPTER 23
Status Epilepticus
Defined as continuous seizures or repetitive, discrete seizures with impaired 
consciousness in the interictal period. The duration of seizure activity to 
meet the definition has traditionally been 15–30 min. A more practical 
definition is any situation requiring the acute use of anticonvulsants; in 
generalized convulsive status epilepticus (GCSE), this is typically when 
seizures last >5 min.
Long-term consequences include persistent coma or vegetative state, 
dementia, visual agnosia, parkinsonism, choreoathetosis, ataxia, myoclo-
nus, seizures, and an amnestic state. Delayed postanoxic encephalopathy is 
an uncommon phenomenon in which pts appear to make an initial recov-
ery following an insult and then have a relapse with a progressive course 
often characterized by widespread demeylination on imaging studies.
Hypoxic-Ischemic Encephalopathy
TREATMENT
• Initial treatment is directed at restoring normal cardiorespiratory 
function. This includes securing a clear airway, ensuring adequate 
oxygenation and ventilation, and restoring cerebral perfusion, whether 
by cardiopulmonary resuscitation, fluids, pressors, or cardiac pacing.
• Mild hypothermia (33°C), initiated as early as possible and contin-
ued for 12–24 h, may improve outcome in pts who remain comatose 
after cardiac arrest, based on trials in pts whose initial rhythm was 
primarily ventricular fibrillation or pulseless ventricular tachycar-
dia. Potential complications include coagulopathy and an increased 
risk of infection.
• Anticonvulsants are not usually given prophylactically but may be 
used to control seizures.
• Posthypoxic myoclonus can be controlled with clonazepam 
(1.5–10 mg/d) or valproate (300–1200 mg/d) in divided doses.
• Myoclonic status epilepticus within 24 h after a hypoxic-ischemic 
insult portends a universally poor prognosis, even if seizures are 
controlled.
• Severe carbon monoxide intoxication may be treated with hyper-
baric oxygen.
CHAPTER 23
117
Status Epilepticus
� CLINICAL FEATURES
Has numerous subtypes: GCSE (e.g., persistent, generalized electrographic 
seizures, coma, and tonic-clonic movements), and nonconvulsive status 
epilepticus (e.g., persistent absence seizures or focal seizures, confusion, or 
partially impaired consciousness, and minimal motor abnormalities). GCSE 
is obvious when overt convulsions are present, but after 30–45 min of unin-
terrupted seizures, the signs may become increasingly subtle (mild clonic 
movements of the fingers; fine, rapid movements of the eyes; or paroxysmal 
episodes of tachycardia, pupillary dilatation, and hypertension). EEG may 
be the only method of diagnosis with these subtle signs; therefore, if a pt 
remains comatose after a seizure, EEG should be performed to exclude 
ongoing status epilepticus. GCSE is life-threatening when accompanied by 
cardiorespiratory dysfunction, hyperthermia, and metabolic derangements 
such as acidosis (from prolonged muscle activity). Irreversible neuronal 
injury may occur from persistent seizures, even when a pt is paralyzed from 
neuromuscular blockade.
� ETIOLOGY
Principal causes of GCSE are antiepileptic drug withdrawal or noncompli-
ance, metabolic disturbances, drug toxicity, CNS infections, CNS tumors, 
refractory epilepsy, and head trauma.
FIGURE 23-1 Pharmacologic treatment of generalized tonic-clonic status epilepticus 
in adults. The horizontal gray bars indicate the approximate duration of drug infusions. 
IV, intravenous; PE, phenytoin equivalents.
Lorazepam 0.1–0.15 mg/kg IV over 1–2 min
(repeat x 1 if no response after 5 min)
Additional emergent drug therapy
may not be required if seizures
stop and the etiology of status
epilepticus is rapidly corrected 
Fosphenytoin 20 mg/kg PE IV 150 mg/min
or phenytoin 20 mg/kg IV 50 mg/min
Fosphenytoin 7–10 mg/kg PE IV 150 mg/min
or phenytoin 7–10 mg/kg IV 50 mg/min
Consider valproate
25 mg/kg IV
Phenobarbital 20 mg/kg IV 60 mg/min
Phenobarbital 10 mg/kg IV 60 mg/min
IV anesthesia with propofol or
midazolam or pentobarbital
Consider valproate
25 mg/kg IV in pts.
normally taking
valproate and who may 
be subtherapeutic
Seizures continuing
Seizures continuing
Seizures continuing
No immediate access to ICU
Admit 
to ICU
TREATMENT OF GENERALIZED TONIC-CLONIC STATUS EPILEPTICUS IN ADULTS
SECTION 2
118
Medical Emergencies
For a more detailed discussion, see Lowenstein DH: Seizures 
and Epilepsy, Chap. 369, p. 3251, in HPIM-18.
CHAPTER 24
Diabetic Ketoacidosis and 
Hyperosmolar Coma
Diabetic ketoacidosis (DKA) and hyperglycemic hyperosmolar state (HHS) 
are acute complications of diabetes mellitus (DM). DKA is seen primarily in 
individuals with type 1 DM and HHS in individuals with type 2 DM. Both 
disorders are associated with absolute or relative insulin deficiency, volume 
depletion, and altered mental status. The metabolic similarities and differ-
ences in DKA and HHS are summarized in Table 24-1.
DIABETIC KETOACIDOSIS
� ETIOLOGY 
DKA results from insulin deficiency with a relative or absolute increase 
in glucagon and may be caused by inadequate insulin administration, 
infection (pneumonia, urinary tract infection, gastroenteritis, sepsis), 
infarction (cerebral, coronary, mesenteric, peripheral), surgery, trauma, 
Status Epilepticus
TREATMENT
GCSE is a medical emergency and must be treated immediately. 
• First attend to any acute cardiorespiratory problems or hyperthermia.
• Perform a brief medical and neurologic exam, establish venous 
access, and send labs to screen for metabolic abnormalities includ-
ing anticonvulsant levels if pt has a history of epilepsy.
• Anticonvulsant therapy should then begin without delay (Fig. 23-1) 
• In parallel, it is essential to determine the cause of the seizures to 
prevent recurrence and treat any underlying abnormalities.
The treatment of nonconvulsive status epilepticus is somewhat less 
urgent since the ongoing seizures are not accompanied by the severe 
metabolic disturbances of GCSE; however, evidence points to local 
cellular injury in the region of the seizure focus, so the condition 
should be treated as promptly as possible using the general approach 
for GCSE.
� PROGNOSIS
The mortality rate is 20% in GCSE, and the incidence of permanent neuro-
logic sequelae is 10–5 0%.
CHAPTER 24
119
Diabetic Ketoacidosis and Hyperosmolar Coma
drugs (cocaine), or pregnancy. A common precipitating scenario is the pt 
with type 1 DM who erroneously stops administering insulin because of 
anorexia/lack of food intake caused by a minor illness, followed by lipolysis 
and progressive ketosis leading to DKA. 
� CLINICAL FEATURES 
The initial symptoms of DKA include anorexia, nausea, vomiting, poly-
uria, and thirst. Abdominal pain, altered mental function, or frank coma 
may ensue. Classic signs of DKA include Kussmaul respirations and an 
acetone odor on the pt’s breath. Volume depletion can lead to dry mucous 
membranes, tachycardia, and hypotension. Fever and abdominal tender-
ness may also be present. Laboratory evaluation reveals hyperglycemia, 
ketosis (β-hydroxybutyrate > acetoacetate), and metabolic acidosis (arterial 
pH 6.8–7.3) with an increased anion gap (Table 24-1). The fluid deficit is 
often 3–5 L and can be greater. Despite a total-body potassium deficit, the 
serum potassium at presentation may be normal or mildly high as a result 
of acidosis. Similarly, phosphate may be normal at presentation despite 
total body phosphate depletion. Leukocytosis, hypertriglyceridemia, and 
hyperlipoproteinemia are common. Hyperamylasemia is usually of salivary 
origin but may suggest a diagnosis of pancreatitis. The measured serum 
TABLE 24-1  LABORATORY VALUES IN DIABETIC KETOACIDOSIS (DKA) 
AND HYPERGLYCEMIC HYPEROSMOLAR STATE (HHS) 
(REPRESENTATIVE RANGES AT PRESENTATION)
DKA
HHS
Glucose,a mmol/L (mg/dL)
13.9–33.3 (250–600)
33.3–66.6 
(600–1200)c
Sodium, meq/L
125–135
135–145
Potassium,a meq/L
Normal to ↑b
Normal
Magnesiuma
Normalb
Normal
Chloridea
Normal
Normal
Phosphatea
Normal to ↓b
Normal
Creatinine, μmol/L (mg/dL)
Slightly ↑
Moderately ↑
Osmolality (mOsm/mL)
300–320
330–380
Plasma ketonesa
++++
±
Serum bicarbonate,a meq/L
<15 meq/L
Normal to slightly ↓
Arterial pH
6.8–7.3
>7.3
Arterial PCO2,a mmHg
20–30
Normal
Anion gapa
[Na – (Cl + HCO3)], meq/L
↑
Normal to slightly ↑
aLarge changes occur during treatment of DKA.
bAlthough plasma levels may be normal or high at presentation, total-body stores are usually 
depleted.
cLarge changes occur during treatment
SECTION 2
120
Medical Emergencies
TABLE 24-2 MANAGEMENT OF DIABETIC KETOACIDOSIS
1.  Confirm diagnosis ( plasma glucose, positive serum ketones, metabolic 
acidosis).
2.  Admit to hospital; intensive-care setting may be necessary for frequent 
monitoring or if pH <7.00 or unconscious.
3.  Assess: Serum electrolytes (K+, Na+, Mg2+, Cl–, bicarbonate, phosphate) 
Acid-base status—pH, HCO3–, PCO2, β-hydroxybutyrate Renal function 
(creatinine, urine output)
4.  Replace fluids: 2–3 L of 0.9% saline over first 1–3 h (10–15 mL/kg per 
hour); subsequently, 0.45% saline at 150–300 mL/h; change to 5% 
glucose and 0.45% saline at 100–200 mL/h when plasma glucose reaches 
14 mmol/L (250 mg/dL).
5.  Administer short-acting insulin: IV (0.1 units/kg) or IM (0.3 units/kg), then 
0.1 units/kg per hour by continuous IV infusion; increase 2- to 3-fold if 
no response by 2–4 h. If initial serum potassium is <3.3 meq/L, do not 
administer insulin until the potassium is corrected to >3.3 meq/L. If the 
initial serum potassium is >5.2 meq/L, do not supplement K+ until the 
potassium is corrected.
6.  Assess pt: What precipitated the episode (noncompliance, infection, 
trauma, infarction, cocaine)? Initiate appropriate workup for precipitating 
event (cultures, chest x-ray, ECG).
7.  Measure capillary glucose every 1–2 h; measure electrolytes (especially 
K+, bicarbonate, phosphate) and anion gap every 4 h for first 24 h.
8.  Monitor blood pressure, pulse, respirations, mental status, fluid intake 
and output every 1–4 h.
9.  Replace K+: 10 meq/h when plasma K+ <5.0–5.2 meq/L, ECG normal, 
urine flow and normal creatinine documented; administer 40–80 meq/h 
when plasma K+ <3.5 meq/L or if bicarbonate is given.
10.  Continue above until pt is stable, glucose goal is 150–250 mg/dL, 
and acidosis is resolved. Insulin infusion may be decreased to 
0.05–0.1 units/kg per hour.
11.  Administer intermediate or long-acting insulin as soon as pt is eating. 
Allow for overlap in insulin infusion and SC insulin injection.
Abbreviations: ECG, electrocardiogram.
Source: Adapted from M Sperling, in Therapy for Diabetes Mellitus and Related Disorders,
American Diabetes Association, Alexandria, VA, 1998; and AE Kitabchi et al: Diabetes Care 
29:2739, 2006.
sodium is reduced as a consequence of osmotic fluid shifts due to hyper-
glycemia [1.6-meq reduction for each 5.6-mmol/L (100-mg/dL) rise in the 
serum glucose].
Diabetic Ketoacidosis
TREATMENT
The management of DKA is outlined in Table 24-2.
CHAPTER 24
121
Diabetic Ketoacidosis and Hyperosmolar Coma
HYPERGLYCEMIC HYPEROSMOLAR STATE
� ETIOLOGY 
Relative insulin deficiency and inadequate fluid intake are the underlying 
causes of HHS. Hyperglycemia induces an osmotic diuresis that leads to 
profound intravascular volume depletion. HHS is often precipitated by a 
serious, concurrent illness such as myocardial infarction or sepsis and com-
pounded by conditions that impede access to water.
� CLINICAL FEATURES 
Presenting symptoms include polyuria, thirst, and altered mental state, rang-
ing from lethargy to coma. Notably absent are symptoms of nausea, vomit-
ing, and abdominal pain and the Kussmaul respirations characteristic of 
DKA. The prototypical pt is an elderly individual with a several week history 
of polyuria, weight loss, and diminished oral intake. The laboratory features 
are summarized in Table 24-1. In contrast to DKA, acidosis and ketonemia 
are usually not found; however, a small anion gap may be due to lactic acidosis, 
and moderate ketonuria may occur from starvation. Prerenal azotemia is 
typically present. Although the measured serum sodium may be normal or 
slightly low, the corrected serum sodium is usually increased [add 1.6 meq 
to measured sodium for each 5.6-mmol/L (100-mg/dL) rise in the serum 
glucose]. HHS, even when adequately treated, has a significant mortality rate 
(up to 15%), which is in part explained by comorbidities and pt age.
Hyperglycemic Hyperosmolar State
TREATMENT
The precipitating problem should be sought and treated. Sufficient IV 
fluids (1–3 L of 0.9% normal saline over the first 2–3 h) must be given to 
stabilize the hemodynamic status. The calculated free water deficit (usually 
9–10 L) should be reversed over the next 1–2 days, using 0.45% saline ini-
tially then 5% dextrose in water. Overly rapid fluid replacement should be 
avoided to prevent worsening of neurologic status. Potassium repletion is 
usually necessary. The plasma glucose may drop precipitously with hydra-
tion alone, though insulin therapy with an IV bolus of 0.1 units/kg followed 
by a constant infusion rate (0.1 units/kg per hour) is usually required. If the 
serum glucose does not fall, the insulin infusion rate should be doubled. 
Glucose should be added to IV fluid and the insulin infusion rate decreased 
when the plasma glucose falls to 13.9 mmol/L (250 mg/dL). The insulin 
infusion should be continued until the pt has resumed eating and can be 
transitioned to a subcutaneous insulin regimen.
For a more detailed discussion, see Powers AC: Diabetes 
Mellitus, Chap. 344, p. 2968, in HPIM-18.
SECTION 2
122
Medical Emergencies
CHAPTER 25
Hypoglycemia
Glucose is an obligate metabolic fuel for the brain. Hypoglycemia should be 
considered in any pt with confusion, altered level of consciousness, or seizures. 
Counterregulatory responses to hypoglycemia include insulin suppression and 
the release of catecholamines, glucagon, growth hormone, and cortisol.
The laboratory diagnosis of hypoglycemia is usually defined as a 
plasma glucose level <2.5–2.8 mmol/L (<45–50 mg/dL), although the 
absolute glucose level at which symptoms occur varies among individuals. 
For this reason, Whipple’s triad should be present: (1) symptoms consis-
tent with hypoglycemia, (2) a low plasma glucose concentration measured 
by a method capable of accurately measuring low glucose levels (not a 
glucose monitor), and (3) relief of symptoms after the plasma glucose 
level is raised.
� ETIOLOGY
Hypoglycemia occurs most commonly as a result of treating pts with dia-
betes mellitus. Additional factors to be considered in any pt with hypogly-
cemia are listed below.
1. Drugs: insulin, insulin secretagogues (especially chlorpropamide, repa-
glinide, nateglinide), alcohol, high doses of salicylates, sulfonamides, 
pentamidine, quinine, quinolones
2. Critical illness: hepatic, renal, or cardiac failure; sepsis; prolonged starvation
3. Hormone deficiencies: adrenal insufficiency, hypopituitarism (particu-
larly in young children)
4. Insulinoma (pancreatic β cell tumor), β cell hyperplasia (nesidioblastosis; 
congenital or after gastric or bariatric surgery)
5. Other rare etiologies: Non–β cell tumors (large mesenchymal or epithelial 
tumors producing an incompletely processed IGF-II, other nonpancre-
atic tumors), antibodies to insulin or the insulin receptor, inherited enzy-
matic defects such as hereditary fructose intolerance and galactosemia.
� CLINICAL FEATURES
Symptoms of hypoglycemia can be divided into autonomic (adrenergic: pal-
pitations, tremor, and anxiety; cholinergic: sweating, hunger, and paresthe-
sia) and neuroglycopenic (behavioral changes, confusion, fatigue, seizure, 
loss of consciousness, and, if hypoglycemia is severe and prolonged, death). 
Signs of autonomic discharge, such as tachycardia, elevated systolic blood 
pressure, pallor, and diaphoresis are typically present in a pt with hypogly-
cemia awareness but may be absent in a pt with pure neuroglycopenia.
Recurrent hypoglycemia shifts thresholds for the autonomic symptoms 
and counterregulatory responses to lower glucose levels, leading to hypo-
glycemic unawareness. Under these circumstances, the first manifestation 
of hypoglycemia is neuroglycopenia, placing pts at risk of being unable to 
treat themselves.
CHAPTER 25
123
Hypoglycemia
� DIAGNOSIS
Diagnosis of the hypoglycemic mechanism is critical for choosing a treat-
ment that prevents recurrent hypoglycemia (Fig. 25-1). Urgent treatment 
is often necessary in pts with suspected hypoglycemia. Nevertheless, blood 
should be drawn at the time of symptoms, whenever possible before the 
administration of glucose, to allow documentation of the glucose level. 
If the glucose level is low and the cause of hypoglycemia is unknown, 
additional assays should be performed on blood obtained at the time of a 
low plasma glucose. These should include insulin, proinsulin, C-peptide, 
sulfonylurea levels, cortisol, and ethanol. In the absence of documented 
spontaneous hypoglycemia, overnight fasting or food deprivation during 
observation in the outpatient setting will sometimes elicit hypoglycemia 
and allow diagnostic evaluation. An extended (up to 72 h) fast under careful 
FIGURE 25-1 Diagnostic approach to a pt with suspected hypoglycemia based on 
a history of symptoms, a low plasma glucose concentration, or both. AB+, positive 
for antibodies against insulin or the insulin receptor; SU+, positive for sulfonylurea.
ALGORITHM APPROACH TO PATIENT
Suspected/Documented Hypoglycemia
Diabetes
No diabetes
Clinical clues
• Drugs
• Organ failure
• Sepsis
• Hormone 
deficiencies
• Non-β-cell tumor
• Previous gastric     
surgery
Apparently healthy
Fasting glucose
<55 mg/dL
≥55 mg/dL
↑ C-peptide
↓ C-peptide
Mixed meal
Insulinoma
Autoimmune
Sulfonylurea
Exogenous
insulin
Whipple’s
triad
No Whipple’s
triad
History
Strong
Weak
Extended fast
Glucose
Adjust regimen
Document
improvement and 
monitor
Likely factitious
Reactive
hypoglycemia
Hypoglycemia
excluded
<55 mg/dL
≥55 mg/dL
↑ Insulin, Whipple’s triad
SU+
Ab+
Provide adequate
glucose, treat
underlying cause
Treated with
• Insulin
• Sulfonylurea
• Other secretagogue
SECTION 2
124
Medical Emergencies
TABLE 25-1 DIAGNOSTIC INTERPRETATION OF HYPOGLYCEMIA
Diagnosis
Glucose, 
mmol/L
(mg/dL)
Insulin, 
μU/mL
C-
Peptide, 
pmol/L
Proinsulin, 
pmol/L
Urine or 
Plasma 
Sulfonylurea
Nonhypoglycemic ≥2.2 (≥40)
<3
<200
<5
No
Insulinoma
≤2.5 (≤45)
≥3
≥200
≥5
No
Exogenous insulin ≤2.5 (≤45)
≥3a
<200
<5
No
Sulfonylurea
≤2.5 (≤45)
≥3
≥200
≥5
Yes
Non-insulin
mediated
≤2.5 (≤45)
<3
<200
<5
No
aOften very high.
For a more detailed discussion, see Cryer PE, Davis SN: 
Hypoglycemia, Chap. 345, p. 3003, in HPIM-18.
supervision in the hospital may otherwise be required—the test should be 
terminated if plasma glucose drops below 2.5 mmol/L (45 mg/dL) and the 
pt has symptoms.
Interpretation of fasting test results is shown in Table 25-1.
Hypoglycemia
TREATMENT
The syndrome of hypoglycemic unawareness in pts with diabetes mel-
litus is reversible after as little as 2 weeks of scrupulous avoidance of 
hypoglycemia. This involves a shift of glycemic thresholds for sym-
pathetic autonomic symptoms back to higher glucose concentrations.
Acute therapy of hypoglycemia requires administration of oral glu-
cose or, if unavailable, rapidly absorbable sugar (e.g., fruit juice), or 
25 g of a 50% solution IV followed by a constant infusion of 5% or 10% 
dextrose if parenteral therapy is necessary. Hypoglycemia from sulfo-
nylureas is often prolonged, requiring treatment and monitoring for 
24 h or more. SC or IM glucagon can be used in diabetics. Prevention 
of recurrent hypoglycemia requires treatment of the underlying cause of 
hypoglycemia, including discontinuation or dose reduction of offend-
ing drugs, treatment of critical illnesses, replacement of hormonal 
deficiencies, and surgery of insulinomas or other tumors. Diazoxide or 
octreotide therapy can be used to control hypoglycemia in inoperable 
metastatic insulinoma or nesidioblastosis. Treatment of other forms 
of hypoglycemia is dietary, with avoidance of fasting and ingestion of 
frequent small meals.  
CHAPTER 26
125
Infectious Disease Emergencies
CHAPTER 26
Infectious Disease Emergencies
Infectious Disease Emergencies
APPROACH TO THE
PATIENT
• Acutely ill febrile pts require emergent attention and must be appro-
priately evaluated and treated at presentation to improve outcome. A 
quick assessment of general appearance provides a subjective sense of 
whether the pt is septic or toxic.
• History: Although presenting symptoms are frequently nonspecific, 
the physician should elicit the following elements of a directed his-
tory to help identify risk factors for particular infections:
– Onset and duration of symptoms, changes in severity or rate of 
progression over time
– Host factors (e.g., alcoholism, IV drug use) and comorbid condi-
tions (e.g., asplenia, diabetes, HIV infection)
– Potential nidus for invasive infection (e.g., recent URI or influ-
enza, trauma, burn, surgery, foreign body)
– Exposure history (e.g., travel, pets, diet, medication use, vaccina-
tion history, sick contacts, menstruation history, sexual contacts)
• Physical examination: A complete physical examination should be 
performed, with particular attention to general appearance, vital 
signs, skin and soft tissue exam, and neurologic evaluation (including 
mental status).
• Diagnostic workup: should be initiated rapidly, preferably before anti-
biotics are given
– Bloodwork: cultures, CBC with differential, electrolytes, BUN, 
creatinine, LFTs, blood smear examination (for parasitic or tick-
borne diseases), buffy coat
– CSF cultures if meningitis is possible. If focal neurologic signs, 
papilledema, or abnormal mental status is noted, administer anti-
biotics after blood culture samples are obtained, perform brain 
imaging, and then consider LP.
– CT or MRI to evaluate focal abscesses; cultures of wounds or 
scraping of skin lesions as indicated 
– No diagnostic procedure should delay treatment for more than 
minutes.
• Treatment: Empirical antibiotic therapy (Table 26-1) is critical. 
– Adjunctive therapy (e.g., glucocorticoids or IV immunoglobulin) 
may reduce morbidity and mortality rates for specific conditions. 
Dexamethasone for bacterial meningitis must be given before or 
with the first dose of antibiotic. 
TABLE 26-1 COMMON INFECTIOUS DISEASE EMERGENCIES
Clinical
Syndrome
Possible
Etiologies
Treatment
Comments
Sepsis without a clear focus
Septic shock
Pseudomonas spp., gram-negative 
enteric bacilli, Staphylococcus spp., 
Streptococcus spp.
Vancomycin (1 g q12h) plus
Gentamicin (5 mg/kg per day) 
plus either 
Piperacillin/tazobactam
(3.375 g q4h)
or
Cefepime (2 g q12h)
Adjust treatment when culture data become 
available. Drotrecogin alfa (activated)a or low-
dose hydrocortisone and fludrocortisoneb may 
improve outcome in pts with septic shock.
Overwhelming post- 
splenectomy sepsis
Streptococcus pneumoniae, 
Haemophilus influenzae, Neisseria 
meningitidis
Ceftriaxone (2 g q12h) plus
Vancomycin (1 g q12h)
If a β-lactam–sensitive strain is identified, 
vancomycin can be discontinued.
Babesiosis
Babesia microti (U.S.), B. divergens
(Europe)
Either:
Clindamycin (600 mg tid) 
plus
Quinine (650 mg tid)
or:
Atovaquone (750 mg q12h) plus
Azithromycin (500-mg loading 
dose, then 250 mg/d)
Atovaquone and azithromycin are as effective as 
clindamycin and quinine and are associated with 
fewer side effects. Treatment with doxycycline 
(100 mg bid c) for potential co-infection with 
Borrelia burgdorferi or Anaplasma spp. may be 
prudent.
126
Sepsis with Skin Findings
Meningococcemia
N. meningitidis
Penicillin (4 mU q4h)
or
Ceftriaxone (2 g q12h)
Consider protein C replacement in fulminant 
meningococcemia.
Rocky Mountain spot-
ted fever (RMSF)
Rickettsia rickettsii
Doxycycline (100 mg bid)
If both meningococcemia and RMSF are being 
considered, use ceftriaxone (2 g q12h) plus
doxycycline (100 mg bidc) or chloramphenicol 
alone (50–75 mg/kg per day in four divided 
doses). If RMSF is diagnosed, doxycycline is the 
proven superior agent.
Purpura fulminans
S. pneumoniae, H. influenzae, 
N. meningitidis
Ceftriaxone (2 g q12h) plus
Vancomycin (1 g q12h)
If a β-lactam–sensitive strain is identified, 
vancomycin can be discontinued.
Erythroderma: toxic 
shock syndrome
Group A Streptococcus, 
Staphylococcus aureus
Vancomycin (1 g q12h) plus
Clindamycin (600 mg q8h)
If a penicillin- or oxacillin-sensitive strain is iso-
lated, these agents are superior to vancomycin 
(penicillin, 2 mU q4h; or oxacillin, 2 g q4h). The 
site of toxigenic bacteria should be debrided; 
IV immunoglobulin can be used in severe cases.d
Sepsis with Soft Tissue Findings
Necrotizing fasciitis
Group A Streptococcus, 
mixed aerobic/anaerobic flora, 
CA-MRSAe
Vancomycin (1 g q12h) plus
Clindamycin (600 mg q8h) plus
Gentamicin (5 mg/kg per day)
Urgent surgical evaluation is critical. If a penicillin- 
or oxacillin-sensitive strain is isolated, these 
agents are superior to vancomycin (penicillin, 
2 mU q4h; or oxacillin, 2 g q4h).
(continued)
127
TABLE 26-1 COMMON INFECTIOUS DISEASE EMERGENCIES (CONTINUED)
Clinical
Syndrome
Possible
Etiologies
Treatment
Comments
Sepsis with soft tissue findings
Clostridial myonecrosis
Clostridium perfringens
Penicillin (2 mU q4h) plus
Clindamycin (600 mg q8h)
Urgent surgical evaluation is critical.
Neurologic infections
Bacterial meningitis
S. pneumoniae,
N. meningitidis
Ceftriaxone (2 g q12h) 
plus
Vancomycin (1 g q12h)
If a β-lactam–sensitive strain is identified, 
vancomycin can be discontinued. If the pt is 
>50 years old or has comorbid disease, add 
ampicillin (2 g q4h) for Listeria coverage. 
Dexamethasone (10 mg q6h × 4 days) improves 
outcome in adult pts with meningitis (especially 
pneumococcal) and cloudy CSF, positive CSF 
Gram’s stain, or a CSF leukocyte count >1000/mL.
Brain abscess, sup-
purative intracranial 
infections
Streptococcus spp., Staphylococcus 
spp., anaerobes, gram-negative 
bacilli
Vancomycin (1 g q12h) plus
Metronidazole (500 mg q8h) plus
Ceftriaxone (2 g q12h)
Urgent surgical evaluation is critical. If a penicillin- 
or oxacillin-sensitive strain is isolated, these 
agents are superior to vancomycin (penicillin, 
4 mU q4h; or oxacillin, 2 g q4h).
Cerebral malaria
Plasmodium falciparum
Artesunate (2.4 mg/kg IV at 0, 
12, and 24 h; then once daily)f
or
Quinine (IV loading dose of 20 mg 
salt/kg; then 10 mg/kg q8h) plus
Doxycycline (100 mg IV q12h)
Do not use glucocorticoids. Use IV quinidine if 
IV quinine is not available. During IV quinidine 
treatment, blood pressure and cardiac function 
should be monitored continuously and blood glu-
cose monitored periodically.
128
Spinal epidural abscess Staphylococcus
spp., gram-negative bacilli
Vancomycin (1 g q12h) plus
Ceftriaxone (2 g q24h)
Surgical evaluation is essential. If a penicillin- or 
oxacillin-sensitive strain is isolated, these agents 
are superior to vancomycin (penicillin, 4 mU q4h; 
or oxacillin, 2 g q4h).
Focal infections
Acute bacterial 
endocarditis
S. aureus, β-hemolytic streptococci, 
HACEK group,g Neisseria spp.,
S. pneumoniae
Ceftriaxone (2 g q12h) plus
Vancomycin (1 g q12h)
Adjust treatment when culture data become 
available. Surgical evaluation is essential.
aDrotrecogin alfa (activated) is administered at a dose of 24 μg/kg per hour for 96 h. It has been approved for use in pts with severe sepsis and a high risk of death as defined by 
an Acute Physiology and Chronic Health Evaluation II (APACHE II) score of ≥25 and/or multiorgan failure.
bHydrocortisone (50-mg IV bolus q6h) with fludrocortisone (50-μg tablet daily for 7 days) may improve outcomes of severe sepsis, particularly in the setting of relative adrenal 
insufficiency.
cTetracyclines can be antagonistic in action to β-lactam agents. Adjust treatment as soon as the diagnosis is confirmed.
dThe optimal dose of IV immunoglobulin has not been determined, but the median dose in observational studies is 2 g/kg (total dose administered over 1–5 days).
eCommunity-acquired methicillin-resistant S. aureus.
fIn the United States, artesunate must be obtained by the Centers for Disease Control and Prevention. For pts diagnosed with severe malaria, full doses of parenteral antimalarial 
treatment should be started with whichever recommended antimalarial agent is first available.
gHaemophilus aphrophilus, H. paraphrophilus, H. parainfluenzae, Aggregatibacter ( formerly Actinobacillus) actinomycetemcomitans, Cardiobacterium hominis, Eikenella corrodens,
and Kingella kingae.
129
SECTION 2
130
Medical Emergencies
� SPECIFIC PRESENTATIONS (TABLE 26-1)
Sepsis without an Obvious Focus of Primary Infection
1. Septic shock: A primary site of infection may not be evident initially.
2. Overwhelming infection in asplenic pts
a. Most infections occur within 2 years after splenectomy, with ~50% 
mortality.
b. Encapsulated organisms cause the majority of infections; Streptococcus 
pneumoniae is the most common isolate.
3. Babesiosis: A history of recent travel to endemic areas raises the possibil-
ity of this diagnosis.
a. Nonspecific symptoms occur 1–4 weeks after a tick bite and can prog-
ress to renal failure, acute respiratory failure, and DIC.
b. Asplenia, age >60 years, underlying immunosuppressive conditions, 
infection with the European strain Babesia divergens, and co-infection 
with Borrelia burgdorferi (Lyme disease) or Anaplasma phagocytophilum 
are risk factors for severe disease.
4. Tularemia and plague can produce typhoidal or septic syndromes with 
mortality rates ~30% and should be considered in the appropriate epide-
miologic setting.
5. Viral hemorrhagic fevers: zoonotic viral illness from animal reservoirs 
or arthropod vectors (e.g., Lassa fever in Africa, hantavirus hemorrhagic 
fever with renal syndrome in Asia, Ebola and Marburg virus infections 
in Africa, and yellow fever in Africa and South America). Dengue is the 
most common arboviral disease worldwide; dengue hemorrhagic fever 
is the more severe form, with a triad of hemorrhagic manifestations, 
plasma leakage, and platelet counts <100,000/μL. Mortality is 10–20% 
but approaches 40% if dengue shock syndrome develops. Supportive care 
and volume replacement therapy are life-saving.
Sepsis with Skin Manifestations
1. Maculopapular rashes: usually not emergent but can occur in early 
meningococcemia or rickettsial disease
2. Petechiae: warrant urgent attention when accompanied by hypotension 
or a toxic appearance
a. Meningococcemia: Young children and their household contacts are 
at greatest risk; outbreaks occur in schools, day-care centers, and mili-
tary barracks.
 
  i.  Petechiae begin at ankles, wrists, axillae, and mucosal surfaces and 
progress to purpura and DIC.
 
  ii.  Other symptoms include headache, nausea, myalgias, altered 
mental status, and meningismus.
 
iii.  Mortality rates are 50–60%; early treatment initiation may be 
life-saving.
b. Rocky Mountain spotted fever: A history of a tick bite and/or travel or 
outdoor activity can often be ascertained.
 
i.  Rash appears by day 3 (but never develops in 10–15% of pts). Blanching 
macules become hemorrhagic, starting at wrists and ankles and spread-
ing to legs and trunk (centripetal spread), then palms and soles. 
CHAPTER 26
131
Infectious Disease Emergencies
 
ii.  Other symptoms include headache, malaise, myalgias, nausea, 
vomiting, and anorexia. In severe cases, hypotension, encephalitis, 
and coma can ensue.
c. Other rickettsial diseases: Mediterranean spotted fever (Africa, south-
western and south-central Asia, southern Europe) is characterized by 
an inoculation eschar at the site of the tick bite and has a mortality rate 
of ~50%. Epidemic typhus occurs in louse-infested areas, usually in a 
setting of poverty, war, or natural disaster; mortality rates are 10–15%. 
In scrub typhus (southeastern Asia and western Pacific), the etiologic 
organism is found in areas of heavy scrub vegetation (e.g., riverbanks); 
1–35% of pts die.
3 Purpura fulminans: cutaneous manifestation of DIC with large ecchy-
motic areas and hemorrhagic bullae. It is associated primarily with 
Neisseria meningitidis but can also be associated with S. pneumoniae and 
Haemophilus influenzae in asplenic pts.
4. Ecthyma gangrenosum: hemorrhagic vesicles with central necrosis and 
ulceration and a rim of erythema seen in pts with septic shock due to 
Pseudomonas aeruginosa or Aeromonas hydrophila
5. Bullous or hemorrhagic lesions: can be caused by Escherichia coli and 
organisms in the genus Vibrio (V. vulnificus and other noncholera vibrios 
from seawater or contaminated raw shellfish), Aeromonas, and Klebsiella, 
particularly in pts with liver disease 
6. Erythroderma: diffuse sunburn-like rash, often associated with toxic 
shock syndrome (TSS, defined by clinical criteria of hypotension, multi-
organ failure, fever, and rash) in acutely ill pts; more common in staphy-
lococcal TSS than streptococcal TSS 
Sepsis with a Soft Tissue/Muscle Primary Focus
1. Necrotizing fasciitis: characterized by extensive necrosis of the SC tissue 
and fascia; typically caused by group A streptococci
a.  Exam is notable for high fever and pain out of proportion to physical 
findings; the infected area is red, hot, shiny, and exquisitely tender. 
Lessening of pain in the absence of treatment is an ominous sign that 
represents destruction of peripheral nerves.
b.  Risk factors: trauma, varicella, childbirth, and comorbid conditions 
(e.g., diabetes, peripheral vascular disease, IV drug use)
c.  Mortality rates are ~100% without surgery, >70% in the setting of TSS, 
and 15–34% overall.
2. Clostridial myonecrosis: often associated with trauma or surgery, with 
massive necrotizing gangrene developing within hours of onset
a.  Spontaneous cases are associated with Clostridium septicum infection 
and underlying malignancy.
b.  Pain and toxic appearance are out of proportion to physical findings. 
Pts are apathetic and may have a sense of impending doom.
c.  Skin overlying the affected area is mottled, bronze-brown in color, 
and edematous. Crepitus may be present. Bullous lesions may drain 
serosanguineous fluid with a mousy or sweet odor.
d.  Mortality rates are 12% for myonecrosis of extremities, 63% for myo-
necrosis of the trunk, and >65% for spontaneous myonecrosis.
SECTION 2
132
Medical Emergencies
Neurologic Infections with or without Septic Shock
1. Bacterial meningitis: Most cases in adults are caused by S. pneumoniae 
(30–50%) or N. meningitidis (10–35%).
a.  Classic triad of headache, meningismus, and fever in only one-half to 
two-thirds of pts
b.  Blood cultures positive in 50–70% of pts
c.  Predictors of a poor outcome include meningitis due to S. pneumoniae, 
coma, respiratory distress, hypotension, CSF protein >2.5 g/L, CSF 
glucose <10 mg/dL, peripheral WBC count <5000/μL, and serum Na+ 
<135 mmol/L.
2. Brain abscess: often present without systemic signs. Presentations are 
more consistent with a space-occupying lesion in the brain.
a.  70% of pts have headache and/or altered mental status, 50% have focal 
neurologic signs, and 25% have papilledema.
b.  Lesions arise from contiguous foci (e.g., sinusitis or otitis) or hema-
togenous infection (e.g., endocarditis).
c.  >50% of cases are polymicrobial, involving both aerobic (primarily 
streptococcal) and anaerobic organisms.
d.  Mortality is low, but morbidity is high (30–55%).
3. Intracranial and spinal epidural abscesses (ICEAs and SEAs): ICEAs are 
rare in the United States, but SEAs are on the rise. Both are more com-
mon in areas with limited access to health care.
a.  ICEAs are typically polymicrobial and present as fever, mental status 
changes, and neck pain.
b.  SEAs are typically due to hematogenous seeding (with staphylococci 
most commonly isolated) and present as fever, localized spinal tender-
ness, and back pain.
4. Cerebral malaria: should be urgently considered in pts who have recently 
traveled to endemic areas and present with a febrile illness and neuro-
logic signs 
a.  Fulminant Plasmodium falciparum infection is associated with fever 
>40°C, hypotension, jaundice, ARDS, and bleeding. Nuchal rigidity 
and photophobia are rare.
b.  Unrecognized infection results in a 20–30% mortality rate.
Focal Syndromes with a Fulminant Course
1. Rhinocerebral mucormycosis: presents as low-grade fever, dull sinus 
pain, diplopia, impaired mental status, chemosis, proptosis, hard-palate 
lesions that respect the midline, and dusky or necrotic nasal turbinates; 
generally occurs in pts with immunocompromising conditions
2. Acute bacterial endocarditis: presents as fever, fatigue, and malaise 
within 2 weeks of infection and is associated with rapid valvular destruc-
tion, pulmonary edema, and myocardial abscesses
a.  Etiologies include Staphylococcus aureus, S. pneumoniae, Listeria 
monocytogenes, Haemophilus spp., and streptococci of group A, B, or G.
b.  Although Janeway lesions (hemorrhagic macules on the palms or 
soles) can be seen, other embolic phenomena (e.g., petechiae, Roth’s 
spots, splinter hemorrhages) are less common. 
CHAPTER 27
133
Oncologic Emergencies
c.  Features can include rapid valvular destruction, pulmonary edema, 
hypotension, myocardial abscesses, conduction abnormalities and 
arrhythmias, large friable vegetations, and major arterial emboli with 
tissue infarction.
d.  Mortality rates are 10–40%.
3. Inhalational anthrax: of increasing concern, given the potential of 
Bacillus anthracis as a bioterrorism agent 
a.  Clinical symptoms are nonspecific, but chest x-rays show mediastinal 
widening, pulmonary infiltrates, and pleural effusions.
b.  Hemorrhagic meningitis occurs in 38% of pts.
c.  Urgent antimicrobial therapy is needed, ideally with a multidrug regi-
men in the prodromal period.
4. Avian influenza (H5N1): occurs primarily in Southeast Asia after expo-
sure to poultry. Pts can rapidly develop bilateral pneumonia, ARDS, and 
multiorgan failure, culminating in death. Human-to-human transmis-
sion is rare.
5. Hantavirus pulmonary syndrome: occurs primarily following rodent 
exposure in rural areas of the southwestern United States, Canada, and 
South America.
a.  A nonspecific viral prodrome can rapidly progress to pulmonary 
edema, respiratory failure, myocardial depression, and death.
b.  In an appropriate epidemiologic setting, the early onset of thrombocy-
topenia may distinguish this syndrome from other febrile illnesses.
For a more detailed discussion, see Barlam TF, Kasper DL: 
Approach to the Acutely Ill Infected Febrile Patient, Chap. 
121, p. 1023, in HPIM-18.
CHAPTER 27
Oncologic Emergencies
Emergencies in the cancer pt may be classified into three categories: effects 
from tumor expansion, metabolic or hormonal effects mediated by tumor 
products, and treatment complications.
STRUCTURAL/OBSTRUCTIVE ONCOLOGIC EMERGENCIES
The most common problems are superior vena cava syndrome; pericar-
dial effusion/tamponade; spinal cord compression; seizures (Chap. 193) 
and/or increased intracranial pressure; and intestinal, urinary, or biliary 
obstruction. The last three conditions are discussed in Chap. 276 in 
HPIM-18.
SECTION 2
134
Medical Emergencies
� SUPERIOR VENA CAVA SYNDROME
Obstruction of the superior vena cava reduces venous return from the head, 
neck, and upper extremities. About 85% of cases are due to lung cancer; 
lymphoma and thrombosis of central venous catheters are also causes. Pts 
often present with facial swelling, dyspnea, and cough. In severe cases, the 
mediastinal mass lesion may cause tracheal obstruction. Dilated neck veins 
and increased collateral veins on anterior chest wall are noted on physical 
exam. Chest x-ray (CXR) documents widening of the superior mediasti-
num; 25% of pts have a right-sided pleural effusion.
Superior Vena Cava Syndrome
TREATMENT
Radiation therapy is the treatment of choice for non-small cell lung 
cancer; addition of chemotherapy to radiation therapy is effective in 
small cell lung cancer and lymphoma. Symptoms recur in 10–30% and 
can be palliated by venous stenting. Clotted central catheters producing 
this syndrome should be removed and anticoagulation therapy initiated.
� PERICARDIAL EFFUSION/TAMPONADE
Accumulation of fluid in the pericardium impairs filling of the heart 
and decreases cardiac output. Most commonly seen in pts with lung or 
breast cancers, leukemias, or lymphomas, pericardial tamponade may also 
develop as a late complication of mediastinal radiation therapy (constrictive 
pericarditis). Common symptoms are dyspnea, cough, chest pain, orthop-
nea, and weakness. Pleural effusion, sinus tachycardia, jugular venous 
distention, hepatomegaly, and cyanosis are frequent physical findings. 
Paradoxical pulse, decreased heart sounds, pulsus alternans, and friction 
rub are less common with malignant than nonmalignant pericardial dis-
ease. Echocardiography is diagnostic; pericardiocentesis may show serous 
or bloody exudate, and cytology usually shows malignant cells.
Pericardial Effusion/Tamponade
TREATMENT
Drainage of fluid from the pericardial sac may be lifesaving until a definitive 
surgical procedure (pericardial stripping or window) can be performed.
� SPINAL CORD COMPRESSION
Primary spinal cord tumors occur rarely, and cord compression is most 
commonly due to epidural metastases from vertebral bodies involved with 
tumor, especially from prostate, lung, breast, lymphoma, and myeloma pri-
maries. Pts present with back pain, worse when recumbent, with local ten-
derness. Loss of bowel and bladder control may occur. On physical exam, 
pts have a loss of sensation below a horizontal line on the trunk, called 
a sensory level, which usually corresponds to one or two vertebrae below 
the site of compression. Weakness and spasticity of the legs and hyperac-
tive reflexes with upgoing toes on Babinski testing are often noted. Spine 
radiographs may reveal erosion of the pedicles (winking owl sign), lytic or 
sclerotic vertebral body lesions, and vertebral collapse. Collapse alone is not 
CHAPTER 27
135
Oncologic Emergencies
a reliable indicator of tumor; it is a common manifestation of a more com-
mon disease, osteoporosis. MRI can visualize the cord throughout its length 
and define the extent of tumor involvement.
Spinal Cord Compression (See Fig. 27-1)
TREATMENT
Radiation therapy plus dexamethasone, 4 mg IV or PO q4h, is successful 
in arresting and reversing symptoms in about 75% of pts who are diag-
nosed while still ambulatory. Surgery results in better recovery rates but 
may be extensive (vertebral body resection with spine stabilization). Only 
10% of pts made paraplegic by the tumor recover the ability to ambulate.
EMERGENT PARANEOPLASTIC SYNDROMES
Most paraneoplastic syndromes have an insidious onset (Chap. 83). 
Hypercalcemia, syndrome of inappropriate antidiuretic hormone secretion 
(SIADH), and adrenal insufficiency may present as emergencies.
� HYPERCALCEMIA
The most common paraneoplastic syndrome, hypercalcemia occurs in about 
10% of cancer pts, particularly those with lung, breast, head and neck, and 
kidney cancer and myeloma. Bone resorption mediated by parathyroid 
FIGURE 27-1 Management of cancer pts with back pain. 
Symptomatic
therapy
Back Pain
Neurologic exam
Plain spine x-ray
High-dose
dexamethasone
MRI of spine
Bone metastases but
no epidural metastases
Symptomatic therapy ±
radiation therapy
Epidural metastases
No metastases
Surgery followed by
radiation therapy or
radiation therapy alone
Symptomatic
therapy
Pain crescendo pattern
Lhermitte’s sign
Pain aggravated with cough,
Valsalva, and recumbency
Abnormal
Normal
Normal
Suspicious for
myelopathy
SECTION 2
136
Medical Emergencies
hormone–related protein is the most common mechanism; interleukin 1 
(IL-1), IL-6, tumor necrosis factor, and transforming growth factor β may 
act locally in tumor-involved bone. Pts usually present with nonspecific 
symptoms: fatigue, anorexia, constipation, weakness. Hypoalbuminemia 
associated with malignancy may make symptoms worse for any given serum 
calcium level because more calcium will be free rather than protein bound.
Hypercalcemia
TREATMENT
Saline hydration, antiresorptive agents (e.g., pamidronate, 60–90 mg IV 
over 4 h, or zoledronate, 4–8 mg IV), and glucocorticoids usually lower 
calcium levels significantly within 1–3 days. Treatment effects usually last 
several weeks. Treatment of the underlying malignancy is also important.
� SIADH
Induced by the action of arginine vasopressin produced by certain tumors 
(especially small cell cancer of the lung), SIADH is characterized by hypona-
tremia, inappropriately concentrated urine, and high urine sodium excretion 
in the absence of volume depletion. Most pts with SIADH are asymptomatic. 
When serum sodium falls to <115 meq/L, pts may experience anorexia, 
depression, lethargy, irritability, confusion, weakness, and personality changes.
SIADH
TREATMENT
Water restriction controls mild forms. Demeclocycline (150–300 mg PO 
tid or qid) inhibits the effects of vasopressin on the renal tubule but has 
a slow onset of action (1 week). Treatment of the underlying malignancy 
is also important. If the pt has mental status changes with sodium levels 
<115 meq/L, normal saline infusion plus furosemide to increase free 
water clearance may provide more rapid improvement. Rate of cor-
rection should not exceed 0.5–1 meq/L per h. More rapid change can 
produce fluid shifts that lead to brain damage.
� ADRENAL INSUFFICIENCY
The infiltration of the adrenals by tumor and their destruction by hemor-
rhage are the two most common causes. Symptoms such as nausea, vomiting, 
anorexia, and orthostatic hypotension may be attributed to progressive cancer 
or to treatment side effects. Certain treatments (e.g., ketoconazole, aminoglu-
tethimide) may directly interfere with steroid synthesis in the adrenal.
Adrenal Insufﬁ ciency
TREATMENT
In emergencies, a bolus of 100 mg IV hydrocortisone is followed by 
a continuous infusion of 10 mg/h. In nonemergent but stressful cir-
cumstances, 100–200 mg/d oral hydrocortisone is the beginning dose, 
tapered to maintenance of 15–37.5 mg/d. Fludrocortisone (0.1 mg/d) 
may be required in the presence of hyperkalemia.
CHAPTER 27
137
Oncologic Emergencies
TREATMENT COMPLICATIONS
Complications from treatment may occur acutely or emerge only many years 
after treatment. Toxicity may be either related to the agents used to treat the 
cancer or from the response of the cancer to the treatment (e.g., leaving a per-
foration in a hollow viscus or causing metabolic complications such as tumor 
lysis syndrome). Several treatment complications present as emergencies. 
Fever and neutropenia and tumor lysis syndrome will be discussed here; others 
are discussed in Chap. 276 in HPIM-18.
� FEVER AND NEUTROPENIA
Many cancer pts are treated with myelotoxic agents. When peripheral 
blood granulocyte counts are <1000/μL, the risk of infection is substantially 
increased (48 infections/100 pts). A neutropenic pt who develops a fever 
(>38°C) should undergo physical exam with special attention to skin lesions, 
mucous membranes, IV catheter sites, and perirectal area. Two sets of blood 
cultures from different sites should be drawn and a CXR performed, and any 
additional tests should be guided by findings from the history and physical 
exam. Any fluid collections should be tapped, and urine and/or fluids should 
be examined under the microscope for evidence of infection.
Fever and Neutropenia
TREATMENT
After cultures are obtained, all pts should receive IV broad-spectrum anti-
biotics (e.g., ceftazidime, 1 g q8h). If an obvious infectious site is found, 
the antibiotic regimen is designed to cover organisms that may cause the 
infection. Usually therapy should be started with an agent or agents that 
cover both gram-positive and -negative organisms. If the fever resolves, 
treatment should continue until neutropenia resolves. Persistence of 
febrile neutropenia after 7 days should lead to addition of amphotericin 
B (or another broad spectrum antifungal agent) to the antibiotic regimen.
� TUMOR LYSIS SYNDROME
When rapidly growing tumors are treated with effective chemotherapy 
regimens, the dying tumor cells can release large amounts of nucleic acid 
breakdown products (chiefly uric acid), potassium, phosphate, and lactic 
acid. The phosphate elevations can lead to hypocalcemia. The increased 
uric acid, especially in the setting of acidosis, can precipitate in the renal 
tubules and lead to renal failure. The renal failure can exacerbate the 
hyperkalemia.
Tumor Lysis Syndrome
TREATMENT
Prevention is the best approach. Maintain hydration with 3 L/d of saline, 
keep urine pH > 7.0 with bicarbonate administration, and start allopu-
rinol, 300 mg/m2 per day, 24 h before starting chemotherapy. Once che-
motherapy is given, monitor serum electrolytes every 6 h. If after 24 h, 
uric acid (>8 mg/dL) and serum creatinine (>1.6 mg/dL) are elevated,
SECTION 2
138
Medical Emergencies
rasburicase (recombinant urate oxidase), 0.2 mg/kg IV daily, may lower 
uric acid levels. If serum potassium is >6.0 meq/L and renal failure 
ensues, hemodialysis may be required. Maintain normal calcium levels.
For a more detailed discussion, see Finberg R: Infections in 
Patients With Cancer, Chap. 86, p. 712; Jameson JL, Longo 
DL: Paraneoplastic Syndromes: Endocrinologic/Hematologic, 
Chap. 100, p. 826, and Gucalp R, Dutcher J: Oncologic 
Emergencies, Chap. 276, p. 2266, in HPIM-18.
CHAPTER 28
Anaphylaxis
� DEFINITION
A life-threatening systemic hypersensitivity reaction to contact with an aller-
gen; it may appear within minutes of exposure to the offending substance. 
Manifestations include respiratory distress, pruritus, urticaria, mucous mem-
brane swelling, gastrointestinal disturbances (including nausea, vomiting, 
abdominal pain, and diarrhea), and vascular collapse. Virtually any allergen 
may trigger an anaphylactic reaction, but among the more common agents are 
proteins such as antisera, hormones, pollen extracts, Hymenoptera venom, and 
foods; drugs (especially antibiotics); and diagnostic agents such as IV contrast 
material. Atopy does not seem to predispose to anaphylaxis from penicillin or 
venom exposures. Anaphylactic transfusion reactions are covered in Chap. 9.
� CLINICAL PRESENTATION
Time to onset is variable, but symptoms usually occur within seconds to 
minutes of exposure to the offending antigen:
• Respiratory: mucous membrane swelling, hoarseness, stridor, wheezing
• Cardiovascular: tachycardia, hypotension
• Cutaneous: pruritus, urticaria, angioedema
� DIAGNOSIS
Made by obtaining history of exposure to offending substance with subse-
quent development of characteristic complex of symptoms.
Anaphylaxis
TREATMENT
Mild symptoms such as pruritus and urticaria can be controlled by admin-
istration of 0.3–0.5 mL of 1:1000 (1.0 mg/mL) epinephrine SC or IM, with 
repeated doses as required at 5- to 20-min intervals for a severe reaction.
An IV infusion should be initiated for administration of 2.5 mL of 
1:10,000 epinephrine solution at 5- to 10-min intervals, and volume 
expanders such as normal saline, and vasopressor agents, e.g., dopa-
mine, if intractable hypotension occurs.
CHAPTER 29 
139
Bites, Venoms, Stings, and Marine Poisonings 
Epinephrine provides both α- and β-adrenergic effects, resulting in 
vasoconstriction and bronchial smooth-muscle relaxation. Beta blockers 
are relatively contraindicated in persons at risk for anaphylactic reactions.
The following should also be used as necessary:
• Antihistamines such as diphenhydramine 50–100 mg IM or IV
• Nebulized albuterol or aminophylline 0.25–0.5 g IV for bronchospasm
• Oxygen
• Glucocorticoids (medrol 0.5–1.0 mg/kg IV); not useful for acute 
manifestations but may help alleviate later recurrence of hypotension, 
bronchospasm, or urticaria.
• For antigenic material injected into an extremity consider: use of a 
tourniquet proximal to the site, 0.2 mL of 1:1000 epinephrine into the 
site, removal of an insect stinger if present.
� PREVENTION
Avoidance of offending antigen, where possible; skin testing and desensiti-
zation to materials such as penicillin and Hymenoptera venom, if necessary. 
Individuals should wear an informational bracelet and have immediate 
access to an unexpired epinephrine kit.
For a more detailed discussion, see Austen KF: Allergies, 
Anaphylaxis, and Systemic Mastocytosis, Chap. 317, p. 2707, 
in HPIM-18.
CHAPTER 29
Bites, Venoms, Stings, 
and Marine Poisonings
MAMMALIAN BITES
• Each year, there are ~300 dog and cat bites per 100,000 population in the 
United States, with most bites inflicted by pet animals.
• The microflora of bite wounds typically reflects the oral flora of the bit-
ing animal.
• Bites from many different animals can transmit rabies and tularemia.
� DOG BITES
• Epidemiology: Dogs bite ≥4.7 million people per year, causing 80% of all 
animal bites; 15–20% of dog bites become infected.
• Bacteriology: includes aerobic and anaerobic organisms, such as 
β-hemolytic streptococci; Eikenella corrodens; Capnocytophaga canimorsus; 
and Pasteurella, Staphylococcus, Actinomyces, and Fusobacterium species 
SECTION 2
140
Medical Emergencies
• Clinical Features: typically manifest within 8–24 h after the bite as local 
cellulitis with purulent, sometimes foul-smelling discharge. Systemic 
spread (e.g., bacteremia, endocarditis, brain abscess) can occur. C. cani-
morsus infection can present as sepsis syndrome, DIC, and renal failure, 
particularly in pts who are splenectomized, have hepatic dysfunction, or 
are otherwise immunosuppressed.
� CAT BITES
• Epidemiology: Cat bites and scratches result in infection in >50% of cases. 
• Bacteriology: includes organisms similar to those involved in dog bites. 
Pasteurella multocida and Bartonella henselae, the agent of cat-scratch 
disease, are important cat-associated pathogens. 
• Clinical Features: P. multocida infections can cause rapidly advanc-
ing inflammation and purulent discharge within a few hours after the 
bite. Dissemination (e.g., bacteremia, pneumonia) may occur. Because 
of deep tissue penetration by narrow, sharp feline incisors, cat bites are 
more likely than dog bites to cause septic arthritis or osteomyelitis.
� OTHER NONHUMAN MAMMALIAN BITES
• Old World monkeys (Macaca species): Bites may transmit herpes B virus 
(Herpesvirus simiae), which can cause CNS infections with high mortal-
ity rates.
• Seals, walruses, polar bears: Bites may cause a chronic suppurative infec-
tion known as seal finger, which is probably due to Mycoplasma species.
• Small rodents (and their predators): Bites may transmit rat-bite fever, 
caused by Streptobacillus moniliformis (in the United States) or Spirillum 
minor (in Asia). 
– Rat-bite fever occurs after the initial wound has healed, a feature 
distinguishing it from an acute bite-wound infection. 
• S. moniliformis infections manifest 3–10 days after the bite as fever, 
chills, myalgias, headache, and severe migratory arthralgias followed by a 
maculopapular rash involving the palms and soles. Disease can progress 
to metastatic abscesses, endocarditis, meningitis, and pneumonia. 
– Haverhill fever is an S. moniliformis infection acquired from contami-
nated milk or drinking water and has manifestations similar to those 
described above.
 
•  S. minor infections cause local pain, purple swelling at the bite site, 
and associated lymphangitis and regional lymphadenopathy 1–4 
weeks after the bite, with evolution into a nonspecific systemic illness. 
� HUMAN BITES
• Epidemiology: Human bites become infected 10–15% of the time. 
–  Occlusional injuries are inflicted by actual biting; clenched-fist injuries 
result when the fist of one individual strikes the teeth of another and 
are particularly prone to serious infection.
–  Clenched-fist injuries are more common and typically result in more 
serious infections (e.g., septic arthritis, tenosynovitis).
• Bacteriology: See Table 29-1.
TABLE 29-1 MANAGEMENT OF WOUND INFECTIONS FOLLOWING ANIMAL AND HUMAN BITES
Biting
Species
Commonly Isolated 
Pathogens
Preferred Antibiotic(s)a
Alternative in Penicillin-
Allergic Pt
Prophylaxis 
Advised for 
Early Uninfected 
Wounds
Other Considerations
Dog
Staphylococcus 
aureus, Pasteurella 
multocida, anaerobes,
Capnocytophaga cani-
morsus
Amoxicillin/clavulanate 
(250–500 mg PO tid) 
or ampicillin/sulbactam 
(1.5–3.0 g IV q6h)
Clindamycin (150–300 mg PO 
qid) plus either TMP-SMX (1 DS 
tablet PO bid) or ciprofloxacin 
(500 mg PO bid)
Sometimesb
Consider rabies prophylaxis.
Cat
P. multocida, S. aureus,
anaerobes
Amoxicillin/clavulanate 
or ampicillin/sulbactam 
as above
Clindamycin plus TMP-SMX as 
above or a fluoroquinolone
Usually
Consider rabies prophylaxis. 
Carefully evaluate for joint/
bone penetration.
Human, 
occlusional
Viridans streptococci, 
S. aureus, Haemophilus 
influenzae, anaerobes
Amoxicillin/clavulanate 
or ampicillin/sulbactam 
as above
Erythromycin (500 mg PO qid) 
or a fluoroquinolone
Always
Examine for tendon, nerve, 
or joint involvement.
Human, 
clenched-
fist
As for occlusional plus 
Eikenella corrodens
Ampicillin/sulbactam as 
above or imipenem 
(500 mg q6h)
Cefoxitinc
Always
Examine for tendon, nerve, 
or joint involvement.
Monkey
As for human bite
As for human bite
As for human bite
Always
For macaque monkeys, 
consider B virus prophylaxis 
with acyclovir.
(continued)
141
TABLE 29-1 MANAGEMENT OF WOUND INFECTIONS FOLLOWING ANIMAL AND HUMAN BITES (CONTINUED)
Biting
Species
Commonly Isolated 
Pathogens
Preferred Antibiotic(s)a
Alternative in Penicillin-
Allergic Pt
Prophylaxis 
Advised for 
Early Uninfected 
Wounds
Other Considerations
Snake
Pseudomonas
aeruginosa, Proteus 
spp., Bacteroides 
fragilis, Clostridium 
spp.
Ampicillin/sulbactam
as above
Clindamycin plus TMP-SMX as 
above or a fluoroquinolone
Sometimes, 
especially with 
venomous
snakes
Antivenin for venomous 
snake bite
Rodent
Streptobacillus
moniliformis, Leptospira 
spp., P. multocida
Penicillin VK (500 mg 
PO qid)
Doxycycline (100 mg PO bid)
Sometimes
—
aAntibiotic choices should be based on culture data when available. These suggestions for empirical therapy need to be tailored to individual circumstances and local conditions. 
IV regimens should be used for hospitalized pts. A single IV dose of antibiotics may be given to pts who will be discharged after initial management.
bProphylactic antibiotics are suggested for severe or extensive wounds, facial wounds, and crush injuries; when bone or joint may be involved; and when comorbidity is present (see text).
cMay be hazardous in pts with immediate-type hypersensitivity reaction to penicillin.
Abbreviations: DS, double-strength; TMP-SMX, trimethoprim-sulfamethoxazole.
142
CHAPTER 29 
143
Bites, Venoms, Stings, and Marine Poisonings 
Mammalian Bites
TREATMENT
• Wound management: Wound closure is controversial in bite injuries. 
After thorough cleansing, facial wounds are usually sutured for cosmetic 
reasons and because the abundant facial blood supply lessens the risk of 
infection. For wounds elsewhere on the body, many authorities do not 
attempt primary closure, preferring instead to irrigate the wound copi-
ously, debride devitalized tissue, remove foreign bodies, and approximate 
the margins. Delayed primary closure may be undertaken after the risk 
of infection has passed. Puncture wounds due to cat bites should be left 
unsutured because of the high rate at which they become infected.
• Antibiotic therapy: See Table 29-1. Antibiotics are typically given for 
3–5 days as prophylaxis or for 10–14 days as treatment for established 
infections.
• Other prophylaxis: Rabies prophylaxis (passive immunization with 
rabies immune globulin and active immunization with rabies vac-
cine) should be given in consultation with local and regional public 
health authorities. A tetanus booster for pts immunized previously but 
not boosted within 5 years should be considered, as should primary 
immunization and tetanus immune globulin administration for pts 
not previously immunized against tetanus.
VENOMOUS SNAKEBITES
• Epidemiology: Worldwide, 1.2–5.5 million snakebites are sustained each 
year, with 421,000–1,841,000 envenomations and 20,000–94,000 deaths. 
–  Bite rates are highest in temperate and tropical climates where popula-
tions subsist by manual agriculture. 
–  Differentiation of venomous from nonvenomous snake species can be 
difficult; color pattern is notoriously misleading.
• Clinical Features: Snake venoms are complex mixtures of enzymes and 
other substances that promote vascular leaking, cause tissue necrosis, 
affect the coagulation cascade, inhibit peripheral nerve impulses, and 
impair organ function.
–  Specific presentations differ somewhat with the particular snake species.
–  Systemic symptoms may include hypotension, pulmonary edema, hemor-
rhage, altered mental status, or paralysis (including muscles of respiration).
• Prognosis: The overall mortality rate for venomous snakebite is <1% 
among U.S. victims who receive antivenom; most U.S. snakebite-related 
deaths are caused by eastern and western diamondback rattlesnakes.
Venomous Snakebites
TREATMENT
FIELD MANAGEMENT
• Get the victim to definitive care as soon as possible.
• Splint a bitten extremity and keep it at heart level to lessen bleeding 
and discomfort.
SECTION 2
144
Medical Emergencies
• Avoid incisions into the bite wound, cooling, consultation with tradi-
tional healers, tourniquets, and electric shock.
• If the offending snake is reliably identified and known to be primarily 
neurotoxic, pressure immobilization (wrapping of the entire limb in a 
bandage at a pressure of 40–70 mmHg for upper limbs or 55–70 mmHg 
for lower limbs) may be used. The victim must be carried to medical 
care, as walking will disperse venom from the bite site regardless of its 
anatomic location.
HOSPITAL MANAGEMENT
• Monitor vital signs, cardiac rhythm, urine output, and O2 saturation 
closely, and watch for evidence of cranial nerve dysfunction (e.g., ptosis), 
which may precede difficulty swallowing or respiratory insufficiency.
• Note the level of swelling and the circumference of the affected limb 
every 15 min until swelling has stabilized.
• Treat shock initially with isotonic saline (20–40 mL/kg IV); if hypoten-
sion persists, try 5% albumin (10–20 mL/kg IV) and vasopressors.
• Begin the search for appropriate, specific antivenom early in all cases 
of known venomous snakebite. In the United States, round-the-clock 
assistance is available from regional poison control centers.
1. Any evidence of systemic envenomation (systemic symptoms or 
signs, laboratory abnormalities) and significant, progressive local 
findings (e.g., swelling that crosses a joint or involves more than half 
of the bitten limb) are indications for antivenom administration.
2. Treating physicians should seek advice from snakebite experts 
regarding indications and dosing of antivenom. The duration of 
antivenom administration depends on the offending snake species, 
but multiple doses are not effective in reversing bite responses that 
have already been established (e.g., renal failure, established paraly-
sis, necrosis).
3. Worldwide, antivenom quality varies; rates of anaphylactoid reac-
tion can exceed 50%, prompting some authorities to recommend 
pretreatment with IV antihistamines (diphenhydramine, 1 mg/kg 
to a maximum of 100 mg; and cimetidine, 5–10 mg/kg to a maxi-
mum of 300 mg) or even a prophylactic SC or IM dose of epineph-
rine (0.01 mg/kg, up to 0.3 mg). CroFab, an antivenom used in the 
United States against North American pit viper species, poses a low 
risk of allergy elicitation.
4. A trial of acetylcholinesterase inhibitors should be undertaken for 
pts with objective evidence of neurologic dysfunction, as this treat-
ment may cause neurologic improvement in pts bitten by snakes 
with postsynaptic neurotoxins.
• Elevate the bitten extremity once antivenom administration has been 
initiated.
• Update tetanus immunization.
• Observe pts for muscle-compartment syndrome.
CHAPTER 29 
145
Bites, Venoms, Stings, and Marine Poisonings 
• Observe pts with signs of envenomation in the hospital for at least 
24 h. Pts with “dry” bites should be watched for at least 8 h because 
symptoms are commonly delayed.
MARINE ENVENOMATIONS
• Much of the management of envenomation by marine creatures is support-
ive in nature. Specific marine antivenom can be used when appropriate.
� INVERTEBRATES
• Etiology: Injuries from cnidocysts (stinging cells) of hydroids, fire coral, 
jellyfish, Portuguese man-of-wars, and sea anemones cause similar clini-
cal symptoms that differ in severity. Other invertebrates (e.g., sea sponges, 
annelid worms, sea urchins) have spines that can inflict painful stings.
• Clinical Features: Pain (prickling, burning, and throbbing), pruritus, 
and paresthesia develop immediately at the site of the bite. Neurologic, 
GI, renal, cardiovascular, respiratory, rheumatologic, and ocular symp-
toms have been described.
Marine Invertebrate Envenomations
TREATMENT
• Decontaminate the skin immediately with vinegar (5% acetic acid). 
Rubbing alcohol (40–70% isopropanol), baking soda, papain (unsea-
soned meat tenderizer), lemon or lime juice, household ammonia, 
olive oil, or sugar may be effective, depending on the species of the 
stinging creature.
• Shaving the skin may help remove remaining nematocysts.
• After decontamination, topical anesthetics, antihistamines, or steroid 
lotions may be helpful.
• Narcotics may be necessary for persistent pain.
• Muscle spasms may respond to diazepam (2–5 mg titrated upward as 
needed) or IV 10% calcium gluconate (5–10 mL).
� VERTEBRATES
• Etiology: Many marine vertebrates, including stingrays, scorpionfish 
(e.g., lionfish and stonefish), marine catfish, and horned venomous 
sharks are capable of envenomating humans.
• Clinical Features: depend on the offending fish
–  Stingrays: represent both an envenomation and a traumatic wound. 
The venom causes immediate, intense pain that may last up to 48 h. 
The wound often becomes ischemic and heals poorly. Systemic effects 
can include weakness, dysrhythmias, hypotension, paralysis, and rare 
deaths.
–  Stonefish: Because of the neuromuscular toxicity of the venom, stings 
may be life-threatening, and death may occur within 6–8 h. Local pain 
is immediate and intense and may last for days. Systemic effects are 
similar to those of stingray envenomations.
SECTION 2
146
Medical Emergencies
Marine Vertebrate Envenomations
TREATMENT
• Immerse the affected part immediately in nonscalding hot water 
(113°F/45°C) for 30–90 min or until there is significant pain relief. 
Repeated hot-water therapy may help with recurrent pain.
• Explore, debride, and vigorously irrigate the wound after local/regional 
anesthetics are given.
• Antivenom is available for stonefish and serious scorpionfish enven-
omations. In the United States, contact the nearest regional poison 
control center for assistance.
• Leave wounds to heal by secondary intention or to be treated by 
delayed primary closure.
• Update tetanus immunization.
• Consider empirical antibiotics to cover Staphylococcus and Streptococcus 
species for serious wounds or envenomations in immunocompromised 
hosts. Coverage should be broadened to include Vibrio species if the 
wound is primarily closed.
MARINE POISONINGS
� CIGUATERA
• Epidemiology: the most common fish-associated nonbacterial food 
poisoning in the United States, with most cases occurring in Florida and 
Hawaii 
– Almost exclusively involves tropical and semitropical marine coral 
fish common in the Indian Ocean, the South Pacific, and the 
Caribbean Sea
– 75% of non-Hawaiian cases involve barracuda, snapper, jack, or 
grouper. 
• Pathogenesis: Ciguatera syndrome is associated with at least five toxins 
that originate in photosynthetic dinoflagellates and accumulate in the 
food chain. Three major ciguatoxins—CTX-1, -2, and -3—are found 
in the flesh and viscera of ciguateric fish, are typically unaffected by 
external factors (e.g., heat, cold, freeze-drying, gastric acid), and do not 
generally affect the fish (e.g., odor, color, or taste).
• Clinical Features: Virtually all pts are affected within 24 h; most 
experience symptoms within 2–6 h. The diagnosis is made on clinical 
grounds.
– Symptoms can be numerous (>150 reported) and include diarrhea, 
vomiting, abdominal pain, neurologic signs (e.g., paresthesias, weak-
ness, fasciculations, ataxia), maculopapular or vesicular rash, and 
hemodynamic instability. 
– A pathognomonic symptom—reversal of hot and cold tactile perception—
develops within 3–5 days and can last for months. 
– Death is rare.
CHAPTER 29 
147
Bites, Venoms, Stings, and Marine Poisonings 
Ciguatera Poisoning
TREATMENT
• Therapy is supportive and based on symptoms. 
• Cool showers, hydroxyzine (25 mg PO q6–8h), or amitriptyline 
(25 mg PO bid) may ameliorate pruritus and dysesthesias. 
• During recovery, the pt should avoid ingestion of fish, shellfish, fish 
oils, fish or shellfish sauces, alcohol, nuts, and nut oils.
� PARALYTIC SHELLFISH POISONING
• Etiology: induced by ingestion of contaminated filter-feeding organisms 
(e.g., clams, oysters, scallops, mussels) that concentrate water-soluble, 
heat- and acid-stable chemical toxins 
– The best-characterized and most frequently identified paralytic shell-
fish toxin is saxitoxin.
– Paralytic shellfish toxins cannot be destroyed by ordinary cooking.
• Clinical Features: Oral paresthesias (initially tingling and burning, later 
numbness) develop within minutes to hours after ingestion of contami-
nated shellfish and progress to involve the neck and distal extremities. 
Flaccid paralysis and respiratory insufficiency may follow 2–12 h later. 
Paralytic Shellﬁ sh Poisoning
TREATMENT
• If pts present within hours of ingestion, gastric lavage and stomach 
irrigation with 2 L of a 2% sodium bicarbonate solution may be of 
benefit, as may administration of activated charcoal (50–100 g) and 
non-magnesium-based cathartics (e.g., sorbitol, 20–50 g). 
• The pt should be monitored for respiratory paralysis for at least 24 h.
� SCOMBROID
• Etiology: histamine intoxication due to bacterial decomposition of inad-
equately preserved or refrigerated scombroid fish (e.g., tuna, mackerel, 
saury, needlefish, wahoo, skipjack, and bonito)
– This syndrome can also occur with nonscombroid fish (e.g., sardines, 
herring, dolphinfish, amberjack, and bluefish).
– Affected fish typically have a sharply metallic or peppery taste but may 
be normal in appearance and flavor.
– Because of uneven distribution of decay within the fish, not all people 
who eat an affected fish will become ill. 
• Clinical Features: Within 15–90 min of ingestion, pts present with flush-
ing (exacerbated by ultraviolet exposure), pruritus, urticaria, angioneu-
rotic edema, bronchospasm, GI symptoms, and hypotension. 
– Symptoms generally resolve within 8–12 h.
– May be worse in pts concurrently taking isoniazid because of inhibi-
tion of GI tract histaminase
SECTION 2
148
Medical Emergencies
Scombroid Poisoning
TREATMENT
• Treatment consists of antihistamine (H1 or H2) administration.
• If bronchospasm is severe, an inhaled bronchodilator or injected epi-
nephrine may be used.
ARTHROPOD BITES AND STINGS
� TICK BITES  AND TICK PARALYSIS
• Epidemiology: Ticks are important carriers of vector-borne diseases 
(e.g., Lyme disease, babesiosis, anaplasmosis, ehrlichiosis) in the United 
States.
• Etiology: While ticks feed on blood from their hosts, their secretions 
may produce local reactions, transmit diverse pathogens, induce a febrile 
illness, or cause paralysis. Soft ticks attach for <1 h; hard ticks can feed 
for >1 week.
• Clinical Features: Except for tick-borne diseases, most manifestations of 
tick bites are self-limited following tick removal.
– Tick-induced fever, associated with headache, nausea, and malaise, 
usually resolves ≤36 h after the tick is removed.
– Tick paralysis is an ascending flaccid paralysis due to a toxin in tick saliva 
that causes neuromuscular block and decreased nerve conduction.
• Weakness begins in the lower extremities ≤6 days after the tick’s 
attachment and ascends symmetrically, causing complete paralysis 
of the extremities and cranial nerves.
• Deep tendon reflexes are decreased or absent, but sensory exami-
nation and LP yield normal findings. 
• Tick removal results in improvement within hours; failure to 
remove the tick may lead ultimately to respiratory paralysis and 
death.
Tick Bites and Tick Paralysis
TREATMENT
• Ticks should be removed with forceps applied close to the point of 
attachment.
• The site of attachment should be disinfected. 
• Tick removal within 36 h of attachment usually prevents transmission of 
the agents of Lyme disease, babesiosis, anaplasmosis, and ehrlichiosis.
� SPIDER BITES
Recluse Spider Bites 
Epidemiology: Brown recluse spiders occur mainly in the southern 
and midwestern United States, and their close relatives are found in the 
Americas, Africa, and the Middle East. These spiders only infrequently bite 
humans, typically if threatened or pressed against the skin.
CHAPTER 29 
149
Bites, Venoms, Stings, and Marine Poisonings 
Clinical Features
• Most bites by the brown recluse spider result in only minor injury with 
edema and erythema, although severe necrosis of the skin and SC tissue 
and systemic hemolysis may occur.
• Within hours, the site of the bite becomes painful and pruritic, with 
central induration surrounded by zones of ischemia and erythema.
• Fever and other nonspecific systemic symptoms may develop within 
3 days of the bite.
• Lesions typically resolve within 2–3 days, but severe cases can leave a 
large ulcer and a depressed scar that take months or years to heal. 
• Deaths are rare and are due to hemolysis and renal failure.
Recluse Spider Bites
TREATMENT
• Initial management includes RICE (rest, ice, compression, elevation); 
administration of analgesics, antihistamines, antibiotics, and tetanus 
prophylaxis should be undertaken as indicated.
• Immediate surgical excision of the wound is detrimental and should 
be avoided.
Widow Spider Bites 
Epidemiology: Black widow spiders, recognized by a red hourglass mark-
ing on a shiny black ventral abdomen, are most abundant in the southeast-
ern United States. Other Latrodectus species are present in other temperate 
and subtropical parts of the world. 
Pathogenesis: Female widow spiders produce a potent neurotoxin that 
binds irreversibly to nerves and causes release and depletion of acetylcho-
line and other neurotransmitters from presynaptic terminals. 
Clinical Features
• Within 60 min, painful cramps spread from the bite site to large muscles 
of the extremities and trunk. 
• Extreme abdominal muscular rigidity and pain may mimic peritonitis, 
but the abdomen is nontender. 
• Other features are similar to that of acetylcholine overdose (e.g., excessive 
salivation, lacrimation, urination, and defecation; GI upset; and emesis). 
• Although pain may subside within the first 12 h, it can recur for weeks.
• Respiratory arrest, cerebral hemorrhage, or cardiac failure may occur.
Widow Spider Bites
TREATMENT
• Treatment consists of RICE and tetanus prophylaxis. 
• Because of questionable efficacy and the risk of anaphylaxis and serum 
sickness, antivenom use should be reserved for severe cases involving 
respiratory arrest, refractory hypertension, seizures, or pregnancy.
SECTION 2
150
Medical Emergencies
SCORPION STINGS
Epidemiology: Only ~30 of the ~1000 species of scorpions produce poten-
tially lethal venoms, causing >5000 deaths worldwide each year. Among 
scorpions in the United States, only the bark scorpion (Centruroides sculp-
turatus or C. exilicauda) produces a potentially lethal venom. 
Clinical Features: The severity of symptoms depends on the particular 
scorpion species. For the U.S. bark scorpion, symptoms progress to maxi-
mal severity in ~5 h and typically subside within 1–2 days. 
 
•  Bark scorpion: Swelling generally is not apparent, and tapping on 
the affected area (the tap test) can accentuate pain, paresthesia, and 
hyperesthesia. Cranial nerve dysfunction and skeletal muscle hyper-
excitability develop within hours. Complications include tachycardia, 
arrhythmias, hypertension, hyperthermia, rhabdomyolysis, acidosis, 
and occasional fatal respiratory arrests. 
 
•  Outside the United States, scorpion envenomations can cause mas-
sive release of endogenous catecholamines with hypertensive crises, 
arrhythmias, pulmonary edema, and myocardial damage.
Scorpion Stings
TREATMENT
• Stings of nonlethal species require at most ice packs, analgesics, or 
antihistamines.
• In severe envenomations, aggressive supportive care should include 
pressure dressings and cold packs to decrease the absorption of venom. 
• A continuous IV infusion of midazolam helps control agitation and 
involuntary muscle movements.
• C. sculpturatus antivenom is available as an investigational drug only 
in Arizona and has not been approved by the FDA. The benefit of 
scorpion antivenom has not been established in controlled trials.
HYMENOPTERA STINGS
Epidemiology: The hymenoptera include bees, wasps, hornets, yellow 
jackets, and ants. About 100 deaths from hymenoptera stings occur annu-
ally in the United States, nearly all due to allergic reactions to venoms. An 
estimated 0.4–4.0% of the U.S. population exhibits immediate-type hyper-
sensitivity to insect stings.
Clinical Features 
• Uncomplicated stings cause pain, a wheal-and-flare reaction, and local 
edema that subside within hours.
• Multiple stings (e.g., from wasps, hornets, ants) can lead to vomiting, 
diarrhea, generalized edema, dyspnea, hypotension, rhabdomyolysis, 
renal failure, and death.
• Large (>10-cm) local reactions progressing over 1–2 days are not 
uncommon; while they resemble cellulitis, they are in fact hypersensitivity 
reactions. Such reactions recur on subsequent exposure but are seldom 
accompanied by anaphylaxis.
CHAPTER 30
151
Hypothermia and Frostbite
• Serious reactions occur within 10 min (and rarely >5 h) after the sting 
and include upper airway edema, bronchospasm, hypotension, shock, 
and death.
Hymenoptera Stings
TREATMENT
• Stingers embedded in skin should be removed promptly by grasping 
with forceps or scraping with a blade or fingernail.
• The site should be disinfected and ice packs applied to slow the spread 
of venom. 
• Elevation of the bite site and administration of analgesics, oral antihis-
tamines, and topical calamine lotion may ease symptoms.
• Large local reactions may require a short course of glucocorticoids.
• Anaphylaxis is treated with epinephrine hydrochloride (0.3–0.5 mL 
of a 1:1000 solution, given SC q20–30min as needed). For profound 
shock, epinephrine (2–5 mL of a 1:10,000 solution by slow IV 
push) is indicated. Pts should be observed for 24 h for recurrent 
anaphylaxis.
• Pts with a history of allergy to insect stings should carry a sting kit and 
seek medical attention immediately after the kit is used. Adults with a 
history of anaphylaxis should undergo desensitization.
For a more detailed discussion, see Madoff LC, Pereyra F: 
Infectious Complications of Bites, Chap. e24 in HPIM-18; 
and Auerbach PS, Norris RL: Disorders Caused by Venomous 
Snakebites and Marine Animal Exposures, Chap. 396, 
p. 3566; and Pollack RJ: Ectoparasite Infestations and 
Arthropod Bites and Stings, Chap. 397, p. 3576, in HPIM-18.
CHAPTER 30
Hypothermia and Frostbite
HYPOTHERMIA
Hypothermia is defined as a core body temperature of ≤35°C and is classi-
fied as mild (32.2°–35°C), moderate (28°–32.2°C), or severe (<28°C).
� ETIOLOGY 
Most cases occur during the winter in cold climates, but hypothermia may 
occur in mild climates and is usually multifactorial. Heat is generated in 
most tissues of the body and is lost by radiation, conduction, convection, 
evaporation, and respiration. Factors that impede heat generation and/or 
increase heat loss lead to hypothermia (Table 30-1).
SECTION 2
152
Medical Emergencies
TABLE 30-1 RISK FACTORS FOR HYPOTHERMIA
Age extremes
Elderly
Neonates
Environmental exposure
Occupational
Sports-related
Inadequate clothing
Immersion
Toxicologic and pharmacologic
Ethanol
Phenothiazines
Barbiturates
Anesthetics
Neuromuscular blockers
Antidepressants
Insufficient fuel
Malnutrition
Marasmus
Kwashiorkor
Endocrine
Diabetes mellitus
Hypoglycemia
Hypothyroidism
Adrenal insufficiency
Hypopituitarism
Neurologic
Cerebrovascular accident
Hypothalamic disorders
Parkinson’s disease
Spinal cord injury
Multisystem
Trauma
Sepsis
Shock
Hepatic or renal failure
Burns and exfoliative dermatologic disorders
Immobility or debilitation
� CLINICAL FEATURES 
Acute cold exposure causes tachycardia, increased cardiac output, peripheral 
vasoconstriction, and increased peripheral vascular resistance, tachypnea, 
increased skeletal muscle tone, shivering, and dysarthria. As body temperature 
drops below 32°C, cardiac conduction becomes impaired, the heart rate slows, 
and cardiac output decreases. Atrial fibrillation with slow ventricular response 
is common. Other ECG changes include Osborn (J) waves. Additional mani-
festations of hypothermia include volume depletion, hypotension, increased 
blood viscosity (which can lead to thrombosis), coagulopathy, thrombocyto-
penia, DIC, acid-base disturbances, and bronchospasm. CNS abnormalities 
are diverse and can include ataxia, amnesia, hallucinations, hyporeflexia, and 
(in severe hypothermia) an isoelectric EEG. Hypothermia may mask other 
concurrent disorders, such as an acute abdomen, drug toxicity, or spinal cord 
injury. Hypothermia in the ICU setting (sepsis, etc.) is a poor prognostic sign.
� DIAGNOSIS 
Hypothermia is confirmed by measuring the core temperature, preferably 
at two sites. Since oral thermometers are usually calibrated only as low as 
34.4°C, the exact temperature of a pt whose initial reading is <35°C should 
be determined with a rectal thermocouple probe inserted to ≥15 cm and 
not adjacent to cold feces. Simultaneously, an esophageal probe should be 
placed 24 cm below the larynx.
CHAPTER 30
153
Hypothermia and Frostbite
Hypothermia
TREATMENT
Cardiac monitoring and supplemental oxygen should be instituted, along 
with attempts to limit further heat loss. Mild hypothermia is managed by 
passive external rewarming and insulation. The pt should be placed in a 
warm environment and covered with blankets to allow endogenous heat 
production to restore normal body temperature. With the head also cov-
ered, the rate of rewarming is usually 0.5°–2.0°C/h. Active rewarming is 
necessary for moderate to severe hypothermia, cardiovascular instability, 
age extremes, CNS dysfunction, endocrine insufficiency, or hypothermia 
due to complications from systemic disorders. Active rewarming may 
be external (forced-air heating blankets, radiant heat sources, and hot 
packs) or internal (by inspiration of heated, humidified oxygen warmed to 
40°–45°C, by administration of IV fluids warmed to 40°–42°C, or by 
peritoneal or pleural lavage with dialysate or saline warmed to 40°–45°C). 
The most efficient active internal rewarming techniques are extracorpo-
real rewarming by hemodialysis and cardiopulmonary bypass. External 
rewarming may cause a fall in blood pressure by relieving peripheral vaso-
constriction. Volume should be repleted with warmed isotonic solutions; 
lactated Ringer’s solution should be avoided because of impaired lactate 
metabolism in hypothermia. If sepsis is a possibility, empirical broad-
spectrum antibiotics should be administered after sending blood cultures. 
Atrial arrhythmias usually require no specific treatment. Ventricular 
fibrillation is often refractory. Only a single sequence of 3 defibrillation 
attempts (2 J/kg) should be attempted when the temperature is <30°C; 
defibrillation can be reattempted after the temperature has risen above 
30°C. Since it is sometimes difficult to distinguish profound hypothermia 
from death, cardiopulmonary resuscitation efforts and active internal 
rewarming should continue until the core temperature is >32°C or cardio-
vascular status has been stabilized.
FROSTBITE
Frostbite occurs when the tissue temperature drops below 0°C. Clinically, 
it is most practical to classify frostbite as superficial (involves skin only) or 
deep (involves deep tissues, muscle, and bone). Classically, frostbite is ret-
rospectively graded like a burn (first- to fourth-degree) once the resultant 
pathology is demarcated over time.
� CLINICAL FEATURES 
The initial presentation of frostbite can be deceptively benign. The symp-
toms always include a sensory deficit affecting light touch, pain, and 
temperature perception. Deep frostbitten tissue can appear waxy, mottled, 
yellow, or violaceous-white. Favorable presenting signs include some 
warmth or sensation with normal color. Hemorrhagic vesicles reflect a 
serious injury to the microvasculature and indicate third-degree frostbite. 
Differential diagnosis of frostbite includes frostnip (superficial freezing of 
skin without tissue destruction) as well as chilblain (pernio) and immersion 
(trench) foot, both of which occur at temperatures above freezing.
SECTION 2
154
Medical Emergencies
Frostbite
TREATMENT
A treatment protocol for frostbite is summarized in Table 30-2. Frozen 
tissue should be rapidly and completely thawed by immersion in cir-
culating water at 37°–40°C. Thawing should not be terminated pre-
maturely due to pain from reperfusion; ibuprofen, 400 mg, should be 
given, and parenteral narcotics are often required. If cyanosis persists 
after rewarming, the tissue compartment pressures should be monitored 
carefully. Pts with parts showing no flow on 99mTc scintiscan may be 
candidates for tissue plasminogen activator (tPA).
TABLE 30-2 TREATMENT FOR FROSTBITE
Before Thawing
During Thawing
After Thawing
Remove from 
environment
Consider parenteral 
analgesia and ketorolac
Gently dry and protect part; 
elevate; pledgets between 
toes, if macerated
Prevent partial 
thawing and 
refreezing
Administer ibuprofen, 
400 mg PO
If clear vesicles are intact, 
aspirate sterilely; if broken, 
debride and dress with 
antibiotic or sterile aloe 
vera ointment
Stabilize core 
temperature and 
treat hypothermia
Immerse part in 
37°–40°C (99°–104°F) 
(thermometer-
monitored) circulating 
water containing an 
antiseptic soap until 
distal flush (10–45 min)
Leave hemorrhagic vesicles 
intact to prevent desicca-
tion and infection
Protect frozen 
part—no friction 
or massage
Encourage pt to gently 
move part
Continue ibuprofen 400 
mg PO (12 mg/kg per day) 
q8–12h
Address medical or 
surgical conditions
If pain is refractory, 
reduce water 
temperature to 
35°–37°C (95°–99°F) 
and administer 
parenteral narcotics
Consider tetanus and 
streptococcal prophylaxis; 
elevate part
Hydrotherapy at 37°C 
(99°F)
Consider phenoxybenza-
mine or thrombolysis in 
severe cases
For a more detailed discussion, see Danzl DF: Hypothermia 
and Frostbite, Chap. 19, p. 165, in HPIM-18.
CHAPTER 31
155
Altitude Illness
CHAPTER 31
Altitude Illness
HIGH-ALTITUDE ILLNESS
� EPIDEMIOLOGY
• Altitude illness is likely to occur at >2500 m and has occurred even at 
1500–2500 m.
• 100 million persons travel to high-altitude locations each year.
� CLINICAL SYNDROMES
Acute Mountain Sickness (AMS), Including HACE
AMS represents a clinical continuum of neurologic disease, of which high-
altitude cerebral edema (HACE) is the most severe form.
• Risk factors: rate of ascent, history of high-altitude illness, exertion
– Lack of physical fitness is not a risk factor.
– Exposure to high altitude within the preceding 2 months may be protective.
– Pts >50 years old may be less likely to develop AMS than younger pts.
• Pathophysiology: Although the exact mechanisms remain unknown, 
hypoxic cerebral vasodilatation and altered permeability of the blood-
brain barrier contribute to cerebral edema in AMS.
• Clinical manifestations
– Nonspecific symptoms (headache, nausea, fatigue, and dizziness) with 
a paucity of physical findings, developing 6–12 h after ascent to a high 
altitude
– HACE: encephalopathy whose hallmarks are ataxia and altered con-
sciousness with diffuse cerebral involvement but generally without 
focal neurologic deficits
 
•  Retinal hemorrhages and, less commonly, papilledema may be seen.
 
•  Retinal hemorrhages occur frequently at ≥5000 m irrespective of 
the presence of symptoms of AMS or HACE.
• Prevention: Gradual ascent with acclimation is the best measure to pre-
vent AMS.
– At >3000 m, a graded ascent of ≤300 m each day is recommended.
– Taking an extra day for acclimation after 3 days of gain in sleeping 
altitude is helpful.
– Pharmacologic prophylaxis is warranted when the pt has a history of 
AMS or when flight to a high-altitude location is required.
 
•  Acetazolamide (125–250 mg PO bid) or dexamethasone (8 mg/d in 
divided doses), administered 1 day before ascent and continued for 
2–3 days, is effective.
 
• Gingko biloba is ineffective for prevention of AMS.
SECTION 2
156
Medical Emergencies
Acute Mountain Sickness
TREATMENT
See Table 31-1.
• Prognosis: With AMS, the pt may reascend gradually to a higher alti-
tude after symptoms abate. In HACE, reascent after a few days is not 
advisable.
TABLE 31-1 MANAGEMENT OF ALTITUDE ILLNESS
Condition
Management
Acute mountain sickness 
(AMS), milda
Discontinuation of ascent
Treatment with acetazolamide (250 mg q12h)
Descentb
AMS, moderatea
Immediate descent for worsening symptoms
Use of low-flow oxygen if available
Treatment with acetazolamide (250 mg q12h) 
and/or dexamethasone (4 mg q6h)c
Hyperbaric therapyd
High-altitude cerebral 
edema (HACE)
Immediate descent or evacuation
Administration of oxygen (2–4 L/min)
Treatment with dexamethasone (8 mg PO/IM/IV; 
then 4 mg q6h)
Hyperbaric therapy if descent is not possible
High-altitude pulmonary 
edema (HAPE)
Immediate descent or evacuation
Minimization of exertion while pt is kept warm
Administration of oxygen (4–6 L/min) to bring 
O2 saturation to >90%
Adjunctive therapy with nifedipinee (30 mg, 
extended-release, q12h)
Hyperbaric therapy if descent is not possible
aCategorization of cases as mild or moderate is a subjective judgment based on the severity 
of headache and the presence and severity of other manifestations (nausea, fatigue, dizziness, 
insomnia).
bNo fixed altitude is specified; the pt should descend to a point below that at which symptoms 
developed.
cAcetazolamide treats and dexamethasone masks symptoms. For prevention (as opposed to 
treatment), acetazolamide (125–250 mg q12h) or—when acetazolamide is contraindicated, 
as in sulfa allergy—dexamethasone (4 mg q12h) may be used.
dIn hyperbaric therapy, the pt is placed in a portable altitude chamber or bag to simulate 
descent.
eNifedipine (30 mg, extended-release, q12h) is also effective for the prevention of HAPE, as is 
salmeterol (125 mg inhaled bid), tadalafil (10 mg bid), or dexamethasone (8 mg bid).
CHAPTER 31
157
Altitude Illness
High-Altitude Pulmonary Edema (HAPE)
HAPE is primarily a pulmonary problem and not necessarily preceded by AMS.
• Risk factors: rapid rate of ascent, history of HAPE, respiratory tract 
infections, cold environmental temperatures, male sex, abnormalities 
of the cardiopulmonary circulation leading to pulmonary hypertension 
(e.g., patent foramen ovale, mitral stenosis, 1° pulmonary hypertension)
• Pathophysiology: noncardiogenic pulmonary edema characterized by 
patchy pulmonary vasoconstriction that leads to overperfusion in some 
areas. Hypoxia-induced impairment of nitric oxide release may play a role 
in vasoconstriction.
• Clinical manifestations: reduction in exercise tolerance greater than 
that expected at the given altitude; dry, persistent cough with blood-
tinged sputum; tachypnea and tachycardia at rest
– Chest x-rays may reveal patchy or localized opacities or streaky inter-
stitial edema. 
– Kerley B lines or a bat-wing appearance typically is not seen.
• Prevention
– Gradual ascent with acclimation is the best measure to prevent HAPE.
– Pharmacologic prophylaxis with sustained-release nifedipine (30 mg 
PO qd or bid) is effective for pts who have a history of HAPE or who 
must ascend rapidly.
High-Altitude Pulmonary Edema
TREATMENT
See Table 31-1.
• Prognosis: Pts may reascend slowly a few days after symptoms resolve. 
The architecture of the lung is well preserved, with rapid reversibility of 
abnormalities.
Other High-Altitude Problems
• Sleep impairment
– Increased periodic breathing and changes in sleep architecture (e.g., 
increased time in lighter sleep stages) lead to poor-quality sleep.
– Acetazolamide (125 mg PO qhs) decreases hypoxemic episodes and 
alleviates sleeping disruptions caused by excessive periodic breathing.
• GI issues: abdominal bloating, distension, and excessive flatus can result 
from decreased atmospheric pressure. Diarrhea is not associated with 
high altitude but may indicate bacterial or parasitic infection, which is 
common in many high-altitude locations in the developing world. 
• High-altitude cough: Hypoxia and bronchoconstriction (due to cold 
and exercise) lead to a debilitating cough that is sometimes severe 
enough to cause rib fractures, especially above 5000 m. 
• High-altitude neurologic events unrelated to “altitude illness”: Even 
without other symptoms of AMS, transient ischemic attacks, strokes, 
subarachnoid hemorrhage, transient global amnesia, delirium, and cra-
nial nerve palsies can occur, particularly in pts with few traditional risk 
factors for these conditions.
SECTION 2
158
Medical Emergencies
� PREEXISTING MEDICAL CONDITIONS
Few medical conditions influence susceptibility to altitude illness, and no 
evidence-based guidelines exist regarding the advisability of high-altitude 
travel by pts with these conditions.
• Cardiac disease: Pts with ischemic heart disease, previous myocardial 
infarction, angioplasty, and/or bypass surgery should have an exercise 
treadmill test. A strongly positive treadmill test is a contraindication for 
high-altitude trips. Pts with poorly controlled arrhythmias also should 
avoid high-altitude travel.
• Asthma: Severely asthmatic pts should be cautioned against ascending to 
high altitudes.
• Pregnancy: Although there are no relevant data, it is unadvisable for 
pregnant women to travel to altitudes >3000 m, given the steep drops in 
oxygen saturation at these altitudes.
• Sickle cell disease: High altitude is one of the rare environmental expo-
sures that occasionally provoke a crisis in persons with the sickle cell 
trait, even at 2500 m.
• Diabetes mellitus: Trekking at high altitudes may enhance sugar uptake. 
Pts taking insulin may require lower doses on trekking/climbing days 
than on rest days.
• Chronic lung disease: Pts with preexisting pulmonary hypertension 
should be discouraged from ascending to high altitudes. If such travel is 
necessary, treatment with sustained-release nifedipine (20 mg PO bid) 
should be considered.
• Chronic kidney disease: Acetazolamide should be avoided by pts with 
preexisting metabolic acidosis and by pts with a glomerular filtration rate 
(GFR) ≤10 mL/min; the dose of acetazolamide should be adjusted if the 
GFR is ≤50 mL/min.
DECOMPRESSION SICKNESS (DCS)
DCS is caused by the formation of bubbles from dissolved inert gas (usu-
ally nitrogen) during or after ascent (decompression) from a compressed 
gas dive.
• Incidence: 1:10,000 recreational dives. Risk factors are deeper and longer 
dives and too rapid of an ascent.
• Pathophysiology: Bubbles may form within tissues themselves, leading 
to symptoms by mechanical distraction of pain-sensitive or functionally-
important structures. Bubbles also appear in the venous circulation 
where they can incite inflammatory and coagulation cascades, damage 
endothelium, activate formed elements of blood such as platelets, and 
cause symptomatic vascular obstruction (also in arterial beds when a 
patent foramen ovale is present).
• Clinical manifestations: Most cases present with mild symptoms of 
pain, fatigue, and minor neurologic illnesses such as patchy paresthe-
sias. Pulmonary and cardiovascular manifestations can be life-threatening 
including dyspnea, chest pain, arrhythmia, coagulopathy, and hypotension. 
• Diagnosis 
– Based on integration of findings and examination of the dive profile 
while correlating relationship of symptoms temporally to the dive.
CHAPTER 32 
159
Poisoning and Drug Overdose 
Decompression Sickness
TREATMENT
Horizontal positioning to prevent bubble entry into the cerebral circula-
tion, IV fluids, and 100% oxygen. Definitive treatment with hyperbaric 
oxygen administered in a compression chamber with stepwise decom-
pression over variable periods adjusted to treatment response . If recovery 
is complete, diving can be resumed after a period of at least 1 month; if 
residual symptoms exist, diving is discouraged.
For a more detailed discussion, see Basnyat B, Tabin G: 
Altitude Illness, Chap. e51; and Bennett MH, Mitchell SJ: 
Hyperbaric and Diving Medicine, Chap. e52 in HPIM-18.
CHAPTER 32
Poisoning and Drug 
Overdose
Poisoning refers to the development of dose-related harmful effects fol-
lowing exposure to chemicals, drugs, or other xenobiotics. Overdosage is 
exposure to excessive amounts of a substance normally intended for con-
sumption (a pharmaceutical) or an illicit drug. Chemical exposures result 
in an estimated 5 million requests in the United States for medical advice 
or treatment each year, and about 5% of victims require hospitalization. 
Overall mortality is low (<1% of exposures); suicide attempts account for 
most serious or fatal poisonings (1–2% mortality). Up to 30% of psychiatric 
admissions are prompted by attempted suicide via overdosage.
Carbon monoxide is the leading cause of death from poisoning. 
Acetaminophen toxicity is the most common pharmaceutical agent caus-
ing fatalities. Other drug-related fatalities are commonly due to analgesics, 
antidepressants, sedative-hypnotics, neuroleptics, stimulants and street drugs, 
cardiovascular drugs, anticonvulsants, antihistamines, and asthma therapies. 
Nonpharmaceutical agents implicated in fatal poisoning include alcohols and 
glycols, gases and fumes, cleaning substances, pesticides, and automotive prod-
ucts. The diagnosis of poisoning or drug overdose must be considered in any  pt 
who presents with coma, seizure, or acute renal, hepatic, or bone marrow failure.
DIAGNOSIS
The correct diagnosis can usually be reached by history, physical exam, 
and routine and toxicologic laboratory evaluation. All available sources 
should be used to determine the exact nature of the ingestion or exposure. 
The history should include the time, route, duration, and circumstances 
(location, surrounding events, and intent) of exposure; name of chemical(s) 
involved, time of onset, nature, and severity of symptoms; relevant past 
SECTION 2
160
Medical Emergencies
medical and psychiatric history. The Physicians Desk Reference, regional 
poison control centers, and local/hospital pharmacies may be useful for 
identification of ingredients and potential effects of toxins.
The diagnosis of poisoning in cases of unknown etiology primarily relies 
on pattern recognition. The first step is a physical exam with initial focus on 
the pulse, blood pressure, respiratory rate, temperature, and neurologic sta-
tus and then characterization of the overall physiologic state as stimulated, 
depressed, discordant, or normal (Table 32-1).
Examination of the eyes (for nystagmus, pupil size, and reactivity), neu-
romuscular status (for tremors, dyskinesia, rigidity, dystonia), abdomen (for 
bowel activity and bladder size), and skin (for burns, bullae, color, warmth, 
moisture, pressure sores, and puncture marks) may narrow the diagnosis to a 
particular disorder. The pt should also be examined for evidence of trauma and 
underlying illnesses. When the history is unclear, all orifices should be exam-
ined for the presence of chemical burns and drug packets. The odor of breath 
or vomitus and the color of nails, skin, or urine may provide diagnostic clues.
Initial laboratory studies should include glucose, serum electrolytes, serum 
osmolality, BUN/creatinine, LFTs, PT/PTT, and ABGs. An increased anion-
gap metabolic acidosis is characteristic of advanced methanol, ethylene glycol, 
and salicylate intoxication, but can occur with other agents and in any poison-
ing that results in hepatic, renal, or respiratory failure; seizures; or shock. An 
increased osmolal gap—the difference between the measured serum osmolal-
ity (determined by freezing point depression) and that calculated from the 
serum sodium, glucose, and BUN of >10 mmol/L—suggests the presence of 
a low-molecular-weight solute such as an alcohol, glycol, ketone, unmeasured 
electrolyte, or sugar. Ketosis suggests acetone, isopropyl alcohol, or salicylate 
poisoning. Hypoglycemia may be due to poisoning with β-adrenergic blockers, 
ethanol, insulin, oral hypoglycemic agents, quinine, and salicylates, whereas 
hyperglycemia can occur in poisoning with acetone, β-adrenergic agonists, 
calcium channel blockers, iron, theophylline, or the rodenticide Vacor. 
Radiologic studies should include a chest x-ray to exclude aspiration or 
ARDS. Radiopaque densities may be visible on abdominal x-rays. Head CT 
or MRI is indicated in stuporous or comatose pts to exclude structural lesions 
or subarachnoid hemorrhage, and LP should be performed when CNS infec-
tion is suspected. The ECG can be helpful in pointing to a poisoning agent: 
Bradycardia and A–V block may occur with poisoning by α-adrenergic ago-
nists, antiarrhythmic agents, beta blockers, calcium channel blockers, cholin-
ergic agents (carbamate and organophosphate insecticides), cardiac glycosides, 
lithium, or tricyclic antidepressants. QRS- and QT-interval prolongation 
may be seen with antidepressant and other membrane-active drug exposure. 
Ventricular tachyarrhythmias may be observed with exposure to cardiac 
glycosides, fluoride, methylxanthines, sympathomimetics, antidepressants, 
and agents that cause hyperkalemia or potentiate the effects of endogenous 
catecholamines (e.g., chloral hydrate, aliphatic and halogenated hydrocarbons). 
Toxicologic analysis of urine and blood (and occasionally of gastric contents 
and chemical samples) may be useful to confirm or rule out suspected poison-
ing. Although rapid screening tests for a limited number of drugs of abuse are 
available, comprehensive screening tests require 2–6 h for completion, and 
immediate management must be based on the history, circumstantial evidence, 
TABLE 32-1 DIFFERENTIAL DIAGNOSIS OF POISONING BASED ON PHYSIOLOGIC STATE 
Stimulated
Depressed
Discordant
Normal
Sympathetics Sympathomimetics
Ergot alkaloids
Methylxanthines
Monoamine oxidase inhibitors
Thyroid hormones
Anticholinergics
Antihistamines
Antiparkinsonian agents
Antipsychotics
Antispasmodics
Belladonna alkaloids
Cyclic antidepressants
Muscle relaxants
Mushrooms and plants
Hallucinogens
Cannabinoids (marijuana)
LSD and analogues
Mescaline and analogues
Mushrooms
Phencyclidine and analogues
Withdrawal syndromes
Barbiturates
Sympatholytics
α1-Adrenergic antagonists
α2-Adrenergic agonists
ACE inhibitors
Angiotensin receptor blockers
Antipsychotics
β-Adrenergic blockers
Calcium channel blockers
Cardiac glycosides
Cyclic antidepressants
Cholinergics
Acetylcholinesterase inhibitors
Muscarinic agonists
Nicotinic agonists
Opioids
Analgesics
GI antispasmodics
Heroin
Sedative-hypnotics
Alcohols
Anticonvulsants
Barbiturates
Asphyxiants
Cytochrome oxidase inhibitors
Inert gases
Irritant gases
Methemoglobin inducers
Oxidative phosphorylation 
inhibitors
AGMA inducers
Alcohol (ketoacidosis)
Ethylene glycol
Iron
Methanol
Salicylate
Toluene
CNS syndromes
Extrapyramidal reactions
Hydrocarbon inhalation
Isoniazid
Lithium
Neuroleptic malignant syndrome
Serotonin syndrome
Strychnine
Nontoxic exposure
Psychogenic illness
Toxic time bombs
Slow absorption
Anticholinergics
Carbamazepine
Concretion formers
Extended-release phenytoin 
sodium capsules (Dilantin 
Kapseals)
Drug packets
Enteric-coated pills
Diphenoxylate-atropine (Lomotil)
Opioids
Salicylates
Sustained-release pills
Valproate
Slow distribution
Cardiac glycosides
Lithium
Heavy metals
Salicylate
161
(continued)
TABLE 32-1 DIFFERENTIAL DIAGNOSIS OF POISONING BASED ON PHYSIOLOGIC STATE (CONTINUED)
Stimulated
Depressed
Discordant
Normal
Benzodiazepines
Ethanol
Opioids
Sedative-hypnotics
Sympatholytics
Benzodiazepines
GABA precursors
Muscle relaxants
Other agents
GHB products
Membrane-active agents
Amantadine
Antiarrhythmics
Antihistamines
Antipsychotics
Carbamazepine
Cyclic antidepressants
Local anesthetics
Opioids (some)
Orphenadrine
Quinoline antimalarials
Valproate
Toxic metabolite
Acetaminophen
Carbon tetrachloride
Cyanogenic glycosides
Ethylene glycol
Methanol
Methemoglobin inducers
Mushroom toxins
Organophosphate insecticides
Paraquat
Metabolism disruptors
Antineoplastic agents
Antiviral agents
Colchicine
Hypoglycemic agents
Immunosuppressive agents
MAO inhibitors
Heavy metals
Salicylate
Warfarin
Abbreviations: ACE, angiotensin-converting enzyme; AGMA, anion-gap metabolic acidosis; CNS, central nervous system; GABA, γ-aminobutyric acid; GHB, γ-hydroxybutyrate; GI, 
gastrointestinal; LSD, lysergic acid diethylamide; MAO, monoamine oxidase.
162
CHAPTER 32 
163
Poisoning and Drug Overdose 
physical exam, and routine ancillary tests. Quantitative analysis is useful for 
poisoning with acetaminophen, acetone, alcohols (including ethylene glycol), 
antiarrhythmics, anticonvulsants, barbiturates, digoxin, heavy metals, lithium, 
salicylate, and theophylline, as well as for carboxyhemoglobin and methemo-
globin. Results can often be available within an hour.
The response to antidotes may be useful for diagnostic purposes. 
Resolution of altered mental status and abnormal vital signs within minutes 
of IV administration of dextrose, naloxone, or flumazenil is virtually diag-
nostic of hypoglycemia, narcotic poisoning, and benzodiazepine intoxica-
tion, respectively. The prompt reversal of acute dystonic (extrapyramidal) 
symptoms following an IV dose of benztropine or diphenhydramine con-
firms a drug etiology. Although physostigmine reversal of both central and 
peripheral manifestations of anticholinergic poisoning is diagnostic, it may 
cause arousal in  pts with CNS depression of any etiology.
Poisoning and Drug Overdose
TREATMENT
Goals of therapy include support of vital signs, prevention of further absorp-
tion, enhancement of elimination, administration of specific antidotes, and 
prevention of reexposure. Fundamentals of poisoning management are 
listed in Table 32-2. When the type of poison is unknown or uncertain, 
blood and urine specimens for toxicologic studies should be obtained if 
possible before treatment is started. Treatment is usually initiated before 
routine and toxicologic data are known. All symptomatic  pts need large-
bore IV access, supplemental O2, cardiac monitoring, continuous observa-
tion, and, if mental status is altered, 100 mg thiamine (IM or IV), 1 ampule 
of 50% dextrose in water, and 4 mg of naloxone along with specific antidotes 
as indicated. Unconscious  pts should be intubated. Activated charcoal may 
be given PO or via a large-bore gastric tube; gastric lavage requires an oro-
gastric tube. Severity of poisoning determines the management. Admission 
to an ICU is indicated for  pts with severe poisoning (coma, respiratory 
depression, hypotension, cardiac conduction abnormalities, arrhythmias, 
hypothermia or hyperthermia, seizures); those needing close monitoring, 
antidotes, or enhanced elimination therapy; and those with progressive 
clinical deterioration or significant underlying medical problems. Suicidal  
pts require constant observation by qualified personnel.
SUPPORTIVE CARE Airway protection is mandatory. Gag reflex alone is 
not a reliable indicator of the need for intubation. Intubation is required 
in all pts with CNS depression or seizures to prevent aspiration of gastric 
contents. Need for O2 supplementation and ventilatory support can be 
assessed by measurement of ABGs. Drug-induced pulmonary edema is 
usually secondary to hypoxia, but myocardial depression may contribute. 
Measurement of pulmonary artery pressure may be necessary to establish 
etiology. Electrolyte imbalances should be corrected as soon as possible.
Adequate cardiovascular function and organ perfusion is necessary 
for elimination of toxin and pt recovery. If hypotension is unresponsive 
to volume expansion, pressors such as norepinephrine, epinephrine or 
dopamine may be required. In severe cases, intra-aortic balloon pump or
SECTION 2
164
Medical Emergencies
TABLE 32-2 FUNDAMENTALS OF POISONING MANAGEMENT
Supportive Care
Airway protection
Treatment of seizures
Oxygenation/ventilation
Correction of temperature abnormalities
Treatment of arrhythmias
Correction of metabolic derangements
Hemodynamic support
Prevention of secondary complications
Prevention of Further Poison Absorption
Gastrointestinal decontamination
Decontamination of other sites
Gastric lavage
Eye decontamination
Activated charcoal
Skin decontamination
Whole-bowel irrigation
Body cavity evacuation
Dilution
Endoscopic/surgical removal
Enhancement of Poison Elimination
Multiple-dose activated charcoal 
Extracorporeal removal 
Diuresis
Hemodialysis 
Alteration of urinary pH
Hemoperfusion 
Chelation
Hemofiltration 
Plasmapheresis 
Exchange transfusion 
Hyperbaric oxygenation
Administration of Antidotes
Neutralization by antibodies
Metabolic antagonism
Neutralization by chemical binding
Physiologic antagonism
Prevention of Reexposure
Adult education
Notification of regulatory agencies
Child-proofing
Psychiatric referral
other mechanical perfusion assists may be considered. Supraventricular 
tachycardia (SVT) with hypertension and CNS excitation is almost 
always due to sympathetic, anticholinergic, or hallucinogenic stimulation 
or to drug withdrawal. Treatment is indicated if associated with hemo-
dynamic instability, chest pain, or ischemia on ECG. Treatment with 
combined α and β blockers or combinations of β blocker and vasodilator 
is indicated in severe sympathetic hyperactivity. Physostigmine is useful 
for hyperactivity due to an anticholinergic overdose. SVT without hyper-
tension usually responds to fluid administration.
CHAPTER 32 
165
Poisoning and Drug Overdose 
Ventricular tachycardia (VT) can be caused by sympathetic stimula-
tion, myocardial membrane destabilization, or metabolic derangements. 
Lidocaine and phenytoin are generally safe. Sodium bicarbonate should 
be the agent given first for VT of toxicologic origin. Drugs that prolong 
the QT interval (quinidine, procainamide) should not be used in VT due 
to tricyclic antidepressant overdose. Magnesium sulfate and overdrive 
pacing (by isoproterenol or a pacemaker) may be useful for torsades 
de pointes. Arrhythmias may be resistant to therapy until underlying 
acid-base and electrolyte derangements, hypoxia, and hypothermia are 
corrected. It is acceptable to observe hemodynamically stable pts without 
pharmacologic intervention.
Seizures are best treated with γ-aminobutyric acid agonists such as 
benzodiazepines or barbiturates. Barbiturates should be given only after 
intubation. Seizures caused by isoniazid overdose may respond only to 
large doses of pyridoxine IV. Seizures from beta blockers or tricyclic 
antidepressants may require phenytoin and benzodiazepines.
PREVENTION OF POISON ABSORPTION Whether to perform GI decon-
tamination, and which procedure to use, depends on the time since 
ingestion; the existing and predicted toxicity of the ingestant; the avail-
ability, efficacy, and contraindications of the procedure; and the nature, 
severity, and risk of complications. The efficacy of activated charcoal 
and gastric lavage decreases with time, and there are insufficient data 
to support or exclude a beneficial effect when they are used >1 h after 
ingestion. Activated charcoal has comparable or greater efficacy, fewer 
contraindications and complications, and is less invasive than gastric 
lavage and is the preferred method of GI decontamination in most 
situations.
Activated charcoal is prepared as a suspension in water, either alone 
or with a cathartic. It is given orally via a nippled bottle (for infants), or 
via a cup, straw, or small-bore nasogastric tube. The recommended dose 
is 1 g/kg body weight, using 8 mL of diluent per gram of charcoal if a 
premixed formulation is not available. Charcoal may inhibit absorption 
of other orally administered agents and is contraindicated in pts with 
corrosive ingestion.
When indicated, gastric lavage is performed using a 28F orogastric 
tube in children and a 40F orogastric tube in adults. Saline or tap water 
may be used in adults or children. (Use saline in infants.) Place pt in 
Trendelenburg and left lateral decubitus position to minimize aspiration 
(occurs in 10% of pts). Repeated administration of fluid (5 mL/kg) 
followed by aspiration results in progressive removal of gastric 
content. Lavage is contraindicated in pts resisting the procedure, 
and with ingested corrosives and petroleum distillate hydrocarbons 
because of risk of aspiration-induced pneumonia and gastroesophageal 
perforation. 
Syrup of ipecac, once the most commonly used decontamination 
procedure, has no role in the hospital setting and is no longer recom-
mended for the management of poisoning. 
TABLE 32-3 PATHOPHYSIOLOGIC FEATURES AND TREATMENT OF SPECIFIC TOXIC SYNDROMES AND POISONINGS
Physiologic 
Condition, Causes
Examples
Mechanism of Action
Clinical Features
Specific Treatments
Stimulated
Sympathetics (see also HPIM-18 Chap. 394)
Sympathomimetics
α1-Adrenergic
agonists (deconges-
tants): phenylephrine, 
phenylpropanolamine
Stimulation of central 
and peripheral sympa-
thetic receptors directly 
or indirectly (by pro-
moting the release or 
inhibiting the reuptake 
of norepinephrine and 
sometimes dopamine)
Physiologic stimulation 
(HPIM-18 Table e50-2); 
reflex bradycardia can occur 
with selective α1 agonists; 
β agonists can cause hypo-
tension and hypokalemia.
Phentolamine, a nonselective α1-adrenergic
receptor antagonist, for severe hypertension due 
to α1-adrenergic agonists; propranolol, a non-
selective β blocker, for hypotension and tachy-
cardia due to β2 agonists; labetalol, a β blocker 
with α-blocking activity, or phentolamine with 
esmolol, metoprolol, or other cardioselective 
β blocker for hypertension with tachycardia due to 
nonselective agents (β blockers, if used alone, can 
exacerbate hypertension and vasospasm due to 
unopposed a stimulation); benzodiazepines; propofol.
β2-Adrenergic agonists 
(bronchodilators): alb-
uterol, terbutaline
Nonspecific adrenergic 
agonists: amphetamines, 
cocaine, ephedrine
Ergot alkaloids
Ergotamine, methyser-
gide, bromocriptine, 
pergolide
Stimulation and inhibi-
tion of serotonergic and 
α-adrenergic receptors; 
stimulation of dopamine 
receptors
Physiologic stimulation 
(HPIM-18 Table e50-2); 
formication; vasospasm with 
limb (isolated or generalized), 
myocardial, and cerebral isch-
emia progressing to gangrene 
or infarction; hypotension, 
bradycardia, and involuntary 
movements can also occur.
Nitroprusside or nitroglycerine for severe vaso-
spasm; prazosin (an α1 blocker), captopril, nife-
dipine, and cyproheptadine (a serotonin receptor 
antagonist) for mild to moderate limb ischemia; 
dopamine receptor antagonists (antipsychotics) for 
hallucinations and movement disorders.
166
(continued)
Methylxanthines
Caffeine, theophylline
Inhibition of adenosine 
synthesis and adenosine 
receptor antagonism; 
stimulation of epine 
phrine and norepineph-
rine release; inhibition 
of phosphodiesterase 
resulting in increased 
intracellular cyclic ade-
nosine and guanosine 
monophosphate
Physiologic stimulation 
(HPIM-18 Table e50-2); 
pronounced gastrointestinal 
symptoms and β agonist 
effects (see above). Toxicity 
occurs at lower drug levels 
in chronic poisoning than in 
acute poisoning.
Propranolol, a nonselective β blocker, for tachy-
cardia with hypotension; any β blocker for 
supraventricular or ventricular tachycardia without 
hypotension; elimination enhanced by multiple-
dose charcoal, hemoperfusion, and hemodialysis; 
indications for hemoperfusion or hemodialysis 
include unstable vital signs, seizures, and a the-
ophylline level of 80–100 μg/mL after acute 
overdose and 40–60 μg/mL with chronic 
exposure.
Monoamine oxidase 
inhibitors
Phenelzine, tranylcy-
promine, selegiline
Inhibition of monoamine 
oxidase resulting in 
impaired metabolism of 
endogenous catechol-
amines and exogenous 
sympathomimetic 
agents
Delayed or slowly progres-
sive physiologic stimulation 
(HPIM-18 Table e50-2); 
terminal hypotension and 
bradycardia in severe cases.
Short-acting agents (e.g., nitroprusside, esmolol) 
for severe hypertension and tachycardia; direct-
acting sympathomimetics (e.g., norepinephrine, 
epinephrine) for hypotension and bradycardia.
167
TABLE 32-3 PATHOPHYSIOLOGIC FEATURES AND TREATMENT OF SPECIFIC TOXIC SYNDROMES AND POISONINGS (CONTINUED)
Physiologic 
Condition, Causes
Examples
Mechanism of Action
Clinical Features
Specific Treatments
Anticholinergics
Antihistamines
Diphenhydramine, 
doxylamine, pyrilamine
Inhibition of central and 
postganglionic para-
sympathetic muscarinic 
cholinergic receptors. 
At high doses, amanta-
dine, diphenhydramine, 
orphenadrine, pheno-
thiazines, and tricyclic 
antidepressants have 
additional nonanticho-
linergic activity (see 
below).
Physiologic stimulation 
(HPIM-18 Table e50-2); dry 
skin and mucous mem-
branes, decreased bowel 
sounds, flushing, and uri-
nary retention; myoclonus 
and picking activity. Central 
effects may occur without 
significant autonomic 
dysfunction.
Physostigmine, an acetylcholinesterase inhibi-
tor (see below) for delirium, hallucinations, and 
neuromuscular hyperactivity. Contraindications 
include nonanticholinergic cardiovascular toxicity 
(e.g., cardiac conduction abnormalities, hypoten-
sion, and ventricular arrhythmias).
Antiparkinsonian
agents
Amantadine, trihexy-
phenidyl
Antipsychotics
Chlorpromazine, olan-
zapine, quetiapine, 
thioridazine
Antispasmotics
Clidinium, dicyclomine
Belladonna alkaloids
Atropine, hyoscyamine, 
scopolamine
Cyclic 
antidepressants
Amitriptyline, doxepin, 
imipramine
Muscle relaxants
Cyclobenzaprine, 
orphenadrine
Mushrooms and 
plants
Amanita muscaria
and A. pantherina,
henbane, jimson weed, 
nightshade
168
Depressed
Sympatholytics
α2-Adrenergic
agonists
Clonidine, guanabenz, 
tetrahydrozoline and 
other imidazoline 
decongestants, 
tizanidine and other 
imidazoline muscle 
relaxants
Stimulation of 
α2-adrenergic recep-
tors leading to inhibition 
of CNS sympathetic 
outflow; activity at non-
adrenergic imidazoline 
binding sites also con-
tributes to CNS effects.
Physiologic depression 
(HPIM-18 Table e50-2), 
miosis. Transient initial 
hypertension may be seen.
Dopamine and norepinephrine for hypotension. 
Atropine for symptomatic bradycardia. Naloxone 
for CNS depression (inconsistently effective).
Antipsychotics
Chlorpromazine, 
clozapine, haloperidol, 
risperidone, 
thioridazine
Inhibition of α-adrenergic, 
dopaminergic, 
histaminergic, muscarinic, 
and serotonergic 
receptors. Some agents 
also inhibit sodium, 
potassium, and calcium 
channels.
Physiologic depression 
(HPIM-18 Table e50-2), 
miosis, anticholinergic effects 
(see above), extrapyramidal 
reactions (see below), 
tachycardia. Cardiac 
conduction delays (increased 
PR, QRS, JT, and QT intervals) 
with ventricular tachydys-
rhythmias, including torsades 
des pointes, can sometimes 
develop.
Sodium bicarbonate and lidocaine for ventricular 
tachydysrhythmias associated with QRS prolonga-
tion. Magnesium, isoproterenol, and overdrive 
pacing for torsades de pointes. Avoid class IA, IC, 
and III antiarrhythmics. IV lipid emulsion therapy 
may be beneficial in some cases.
169
(continued)
TABLE 32-3 PATHOPHYSIOLOGIC FEATURES AND TREATMENT OF SPECIFIC TOXIC SYNDROMES AND POISONINGS (CONTINUED)
Physiologic 
Condition, Causes
Examples
Mechanism of Action
Clinical Features
Specific Treatments
Depressed
β-Adrenergic
blockers
Cardioselective (β1)
blockers: atenolol, 
esmolol, metoprolol
Nonselective (β1 and 
β2) blockers: nadolol, 
propranolol, timolol
Partial β agonists: 
acebutolol, pindolol
α1 Antagonists: carve-
dilol, labetalol
Membrane-active
agents: acebutolol, 
propranolol, sotalol
Inhibition of 
β-adrenergic receptors 
(class II antiarrhythmic 
effect). Some agents 
have activity at addi-
tional receptors or have 
membrane effects (see 
below).
Physiologic depression 
(HPIM-18 Table e50-2), 
atrioventricular block, hypo-
glycemia, hyperkalemia, 
seizures. Partial agonists 
can cause hypertension and 
tachycardia. Sotalol can 
cause increased QT interval 
and ventricular tachydys-
rhythmias. Onset may be 
delayed after sotalol and 
sustained-release formula-
tion overdose.
Glucagon and calcium for hypotension and 
symptomatic bradycardia. Atropine, isoproter-
enol, amrinone, dopamine, dobutamine, epi-
nephrine, and norepinephrine may sometimes 
be effective. High-dose insulin (with glucose 
and potassium to maintain euglycemia and nor-
mokalemia), electrical pacing, and mechanical 
cardiovascular support for refractory cases.
Calcium channel 
blockers
Diltiazem, nifedipine 
and other dihydro-
pyridine derivatives, 
verapamil
Inhibition of slow 
(type L) cardiovascular 
calcium channels 
(class IV antiarrhythmic 
effect).
Physiologic depression 
(HPIM-18 Table e50-2), 
atrioventricular block, organ 
ischemia and infarction, 
hyperglycemia, seizures. 
Calcium and glucagon for hypotension and 
symptomatic bradycardia. Dopamine, epinephrine, 
norepinephrine, atropine, and isoproterenol are 
less often effective but can be used adjunctively. 
Amrinone, high-dose insulin (with glucose and
170
Hypotension is usually 
due to decreased vascular 
resistance rather than to 
decreased cardiac output. 
Onset may be delayed for 
≥12 h after overdose of sus-
tained-release formulations.
potassium to maintain euglycemia and normo-
kalemia), IV lipid emulsion therapy, electrical 
pacing, and mechanical cardiovascular support 
for refractory cases.
Cardiac glycosides
Digoxin, endogenous 
cardioactive steroids, 
foxglove and other 
plants, toad skin 
secretions
(Bufonidae sp.)
Inhibition of cardiac Na+,
K+-ATPase membrane 
pump.
Physiologic depression 
(HPIM-18 Table e50-2); 
gastrointestinal, psychiat-
ric, and visual symptoms; 
atrioventricular block with or 
without concomitant supra-
ventricular tachyarrhythmia; 
ventricular tachyarrhythmias. 
Hyperkalemia in acute poison-
ing. Toxicity occurs at lower 
drug levels in chronic poison-
ing than in acute poisoning.
Digoxin-specific antibody fragments for hemo-
dynamically compromising dysrhythmias, 
Mobitz II or third-degree atrioventricular block, 
hyperkalemia (>5.5 meq/L; in acute poisoning 
only). Temporizing measures include atropine, 
dopamine, epinephrine, phenytoin, and external 
cardiac pacing for bradydysrhythmias and mag-
nesium, lidocaine, or phenytoin for ventricular 
tachydysrhythmias. Internal cardiac pacing and 
cardioversion can increase ventricular irritability 
and should be reserved for refractory cases.
(continued)
171
TABLE 32-3 PATHOPHYSIOLOGIC FEATURES AND TREATMENT OF SPECIFIC TOXIC SYNDROMES AND POISONINGS (CONTINUED)
Physiologic 
Condition, Causes
Examples
Mechanism of Action
Clinical Features
Specific Treatments
Depressed
Cyclic antidepres-
sants
Amitriptyline, doxepin, 
imipramine
Inhibition of α-adrenergic 
dopaminergic, GABA-
ergic, histaminergic, 
muscarinic, and seroto-
nergic receptors; inhibi-
tion of sodium channels 
(see membrane-active 
agents); inhibition of nor-
epinephrine and serotonin 
reuptake.
Physiologic depression 
(HPIM-18 Table e50-2), 
seizures, tachycardia, cardiac 
conduction delays (increased 
PR, QRS, JT, and QT inter-
vals; terminal QRS right axis 
deviation) with aberrancy 
and ventricular tachydys-
rhythmias. Anticholinergic 
toxidrome (see above).
Hypertonic sodium bicarbonate (or hypertonic 
saline) and lidocaine for ventricular tachydys-
rhythmias associated with QRS prolongation. 
Use of phenytoin is controversial. Avoid class IA, 
IC, and III antiarrhythmics.
Cholinergics
Acetylcholinesterase
inhibitors
Carbamate insecti-
cides (aldicarb, car-
baryl, propoxur) and 
medicinals (neostig-
mine, physostigmine, 
tacrine); nerve gases 
(sarin, soman, tabun, 
VX) organophosphate 
insecticides (diazinon, 
chlorpyrifos-ethyl, 
malathion)
Inhibition of acetylcho-
linesterase leading to 
increased synaptic ace-
tylcholine at muscarinic 
and nicotinic cholinergic 
receptor sites
Physiologic depression 
(HPIM-18 Table e50-2). 
Muscarinic signs and symp-
toms: seizures, excessive 
secretions (lacrimation, 
salivation, bronchorrhea and 
wheezing, diaphoresis), and 
increased bowel and bladder 
activity with nausea, vomit-
ing, diarrhea, abdominal 
cramps, and incontinence
Atropine for muscarinic signs and symptoms. 
Pralidoxime (2-PAM), a cholinesterase reactivator, 
for nicotinic signs and symptoms due to 
organophosphates, nerve gases, or an unknown 
anticholinesterase.
172
Muscarinic agonists
Nicotinic agonists
Bethanecol, mush-
rooms (Boletus,
Clitocybe, Inocybe
spp.), pilocarpine
Lobeline, nicotine 
(tobacco)
Stimulation of CNS and 
postganglionic para-
sympathetic cholinergic 
(muscarinic) receptors
Stimulation of pregan-
glionic sympathetic and 
parasympathetic and 
striated muscle (neu-
romuscular junction) 
cholinergic (nicotine) 
receptors
of feces and urine. Nicotinic 
signs and symptoms: 
hypertension, tachycardia, 
muscle cramps, fas-
ciculations, weakness, and 
paralysis. Death is usually 
due to respiratory failure. 
Cholinesterase activity in 
plasma and red cells <50% 
of normal in acetylcholines-
terase inhibitor poisoning.
Sedative-hypnotics (see also HPIM-18 Chap. 393)
Anticonvulsants
Carbamazepine, 
ethosuximide, felb-
amate, gabapentin, 
lamotrigine, levetirace-
tam, oxcarbazepine, 
phenytoin, tiagabine, 
topiramate, valproate, 
zonisamide
Potentiation of the inhibi-
tory effects of GABA by 
binding to the neuronal 
GABA-A chloride channel 
receptor complex and 
increasing the frequency 
or duration of chloride 
channel opening in 
response to GABA stimu-
lation. Baclofen and, to
Physiologic depression 
(HPIM-18 Table e50-2), nys-
tagmus. Delayed absorption 
can occur with carbamaze-
pine, phenytoin, and valpro-
ate. Myoclonus, seizures, 
hypertension, and tachyar-
rhythmias can occur with 
baclofen, carbamazepine, 
and orphenadrine.
Benzodiazepines, barbiturates or propofol for 
seizures. Elimination of phenobarbital and pos-
sibly other long-acting agents enhanced by 
multiple-dose charcoal. 
Hemodialysis and hemoperfusion may be indi-
cated for severe poisoning by some agents (see 
Extracorporeal Removal, in text). 
(continued)
173
TABLE 32-3 PATHOPHYSIOLOGIC FEATURES AND TREATMENT OF SPECIFIC TOXIC SYNDROMES AND POISONINGS (CONTINUED)
Physiologic 
Condition, Causes
Examples
Mechanism of Action
Clinical Features
Specific Treatments
Cholinergics
Barbiturates
Short-acting: butabar-
bital, pentobarbital, 
secobarbital
Long-acting: pheno-
barbital, primidone
some extent, GHB act 
at the GABA-B rector 
complex; meprobamate, 
its metabolite cariso-
prodol, felbamate, and 
orphenadrine antagonize 
N-methyl-D-aspartate 
NMDA excitatory 
receptors; ethosuximide, 
valproate, and 
zonisamide decrease 
conduction through 
T-type calcium channels; 
valproate decreases 
GABA degradation, 
and tiagabine blocks 
GABA reuptake; carba-
mazepine, lamotrigine, 
oxcarbazepine, 
phenytoin, topiramate, 
valproate, and 
zonisamide slow the 
See above and below for treatment of anticho-
linergic and sodium channel (membrane) 
blocking effects.
Benzodiazepines
Ultrashort-acting: 
estazolam, midazolam, 
temazepam, triazolam
Short-acting: alpra-
zolam, flunitrazepam, 
lorazepam, oxazepam
Long-acting: chlordiaz-
epoxide, clonazepam, 
diazepam, flurazepam
Tachyarrhythmias can also 
occur with chloral hydrate. 
AGMA, hypernatremia, 
hyperosmolality, hyperam-
monemia, chemical hepa-
titis, and hypoglycemia can 
be seen in valproate poison-
ing. Carbamazepine and 
oxcarbazepine may produce 
hyponatremia from SIADH.
174
Pharmacologically
related agents: 
zaleplon, zolpidem
rate of recovery of inac-
tivated sodium channels. 
Some agents also have 
α2 agonist, anticho-
linergic, and sodium 
channel-blocking activity 
(see above and below).
GABA precursors
γ-Hydroxybutyrate 
(sodium oxybate; 
GHB), γ-butyrolactone
(GBL), 1,4-butanediol.
Some agents can cause 
anticholinergic and sodium 
channel (membrane) block-
ing effects (see above and 
below).
Muscle relaxants
Baclofen, carisopro-
dol, cyclobenzaprine, 
etomidate, metaxa-
lone, methocarbamol, 
orphenadrine, propofol, 
tizanidine and other 
imidazoline muscle 
relaxants.
Other agents
Chloral hydrate, eth-
chlorvynol, glutethi-
mide, meprobamate, 
methaqualone, 
methyprylon.
175
(continued)
TABLE 32-3 PATHOPHYSIOLOGIC FEATURES AND TREATMENT OF SPECIFIC TOXIC SYNDROMES AND POISONINGS (CONTINUED)
Physiologic 
Condition, Causes
Examples
Mechanism of Action
Clinical Features
Specific Treatments
Discordant
Asphyxiants
Cytochrome oxidase 
inhibitors
Carbon monoxide, cya-
nide, hydrogen sulfide
Inhibition of mitochron-
drial cytochrome oxi-
dase, thereby blocking 
electron transport and 
oxidative metabolism. 
Carbon monoxide also 
binds to hemoglobin and 
myoglobin and prevents 
oxygen binding, trans-
port, and tissue uptake 
(binding to hemoglobin 
shifts the oxygen disso-
ciation curve to the left).
Signs and symptoms 
of hypoxia with initial 
physiologic stimulation and 
subsequent depression 
(HPIM-18 Table e50-2); lac-
tic acidosis; normal PO2 and
calculated oxygen saturation 
but decreased oxygen satu-
ration by co-oximetry (that 
measured by pulse oximetry 
is falsely elevated but is 
less than normal and less 
than the calculated value). 
Headache and nausea 
are common with carbon 
monoxide. Sudden collapse 
may occur with cyanide and 
hydrogen sulfide exposure. 
A bitter almond breath odor 
may be noted with cyanide 
ingestion, and hydrogen sul-
fide smells like rotten eggs.
High-dose oxygen. Inhaled amyl nitrite and IV 
sodium nitrite and sodium thiosulfate (Lilly 
cyanide antidote kit) for coma, metabolic 
acidosis, and cardiovascular dysfunction in 
cyanide poisoning. Amyl and sodium nitrite 
(without thiosulfate) for similar toxicity in 
hydrogen sulfide poisoning. Hyperbaric oxygen 
for moderate to severe carbon monoxide 
poisoning and for cyanide or hydrogen sulfide 
poisoning unresponsive to other measures. 
176
Methemoglobin
inducers
Aniline derivatives, 
dapsone, local anes-
thetics, nitrates, 
nitrites, nitrogen 
oxides, nitro- and 
nitroso hydrocarbons, 
phenazopyridine, pri-
maquine-type antima-
larials, sulfonamides.
Oxidation of hemoglobin 
iron from ferrous (Fe2+)
to ferric (Fe3+) state pre-
vents oxygen binding, 
transport, and tissue 
uptake (methemoglo-
binemia shifts oxygen 
dissociation curve to the 
left). Oxidation of hemo-
globin protein causes 
hemoglobin precipitation 
and hemolytic anemia 
(manifest as Heinz bod-
ies and “bite cells” on 
peripheral blood smear).
Signs and symptoms of 
hypoxia with initial physio-
logic stimulation and subse-
quent depression (HPIM-18 
Table e50-2), gray-brown 
cyanosis unresponsive to 
oxygen at methemoglobin 
fractions >15–20%, head-
ache, lactic acidosis (at 
methemoglobin fractions 
>45%), normal PO2  and 
calculated oxygen satura-
tion but decreased oxygen 
saturation and increased 
methemoglobin fraction 
by co-oximetry (oxygen 
saturation by pulse oximetry 
may be falsely increased or 
decreased but is less than 
normal and less than the 
calculated value).
High-dose oxygen. Intravenous methylene blue 
for methemoglobin fraction >30%, symptomatic 
hypoxia, or ischemia (contraindicated in G6PD 
deficiency). Exchange transfusion and hyperbaric 
oxygen for severe or refractory cases.
177
(continued)
TABLE 32-3 PATHOPHYSIOLOGIC FEATURES AND TREATMENT OF SPECIFIC TOXIC SYNDROMES AND POISONINGS (CONTINUED)
Physiologic 
Condition, Causes
Examples
Mechanism of Action
Clinical Features
Specific Treatments
Discordant
AGMA inducers
Ethylene glycol
Ethylene glycol causes 
CNS depression and 
increased serum 
osmolality. Metabolites 
(primarily glycolic acid) 
cause AGMA, CNS 
depression, and renal 
failure. Precipitation of 
oxalic acid metabolite 
as calcium salt in tis-
sues and urine results 
in hypocalcemia, tissue 
edema, and crystalluria.
Initial ethanol-like intoxi-
cation, nausea, vomiting, 
increased osmolar gap, 
calcium oxalate crystalluria. 
Delayed AGMA, back pain, 
renal failure. Coma, sei-
zures, hypotension, ARDS in 
severe cases.
Gastric aspiration for recent ingestions. Sodium 
bicarbonate to correct acidemia. Thiamine, folinic 
acid, magnesium, and high-dose pyridoxine to 
facilitate metabolism. Ethanol or fomepizole for 
AGMA, crystalluria or renal dysfunction, ethylene 
glycol level >3 mmol/L (>20 mg/dL), and for 
ethanol-like intoxication or increased osmolal 
gap if level not readily obtainable. Hemodialysis 
for persistent AGMA, lack of clinical improvement, 
and renal dysfunction. Hemodialysis also useful 
for enhancing ethylene glycol elimination and 
shortening duration of treatment when ethylene 
glycol level >8 mmol/L (>50 mg/dL).
AGMA inducers
Iron
Hydration of ferric (Fe3+)
ion generates H+. Non-
transferrin-bound iron 
catalyzes formation 
of free radicals that 
cause mitochondrial 
injury, lipid peroxidation, 
increased capillary per-
meability, vasodilation, 
and organ toxicity.
Initial nausea, vomiting, 
abdominal pain, diarrhea. 
AGMA, cardiovascular and 
CNS depression, hepatitis, 
coagulopathy, and seizures 
in severe cases. Radiopaque 
iron tablets may be seen on 
abdominal x-ray.
Whole-bowel irrigation for large ingestions. 
Endoscopy and gastrostomy if clinical toxicity 
and large number of tablets still visible on x-ray. 
IV hydration. Sodium bicarbonate for acidemia. 
IV deferoxamine for systemic toxicity, iron level 
>90 μmol/L (>500 g/dL).
178
Methanol
Methanol causes 
ethanol-like CNS 
depression and 
increased serum 
osmolality. Formic acid 
metabolite causes AGMA 
and retinal toxicity.
Initial ethanol-like intoxi-
cation, nausea, vomiting, 
increased osmolar gap. 
Delayed AGMA, visual 
(clouding, spots, blindness) 
and retinal (edema, hyper-
emia) abnormalities. Coma, 
seizures, cardiovascular 
depression in severe cases. 
Possible pancreatitis.
Gastric aspiration for recent ingestions. Sodium 
bicarbonate to correct acidemia. High-dose 
folinic acid or folate to facilitate metabolism. 
Ethanol or fomepizole for AGMA, visual symp-
toms, methanol level >6 mmol/L (>20 mg/dL), 
and for ethanol-like intoxication or increased 
osmolal gap if level not readily obtainable. 
Hemodialysis for persistent AGMA, lack of 
clinical improvement, and renal dysfunction. 
Hemodialysis also useful for enhancing methanol 
elimination and shortening duration of treatment 
when methanol level >15 mmol/L (>50 mg/dL).
Salicylate
Increased sensitivity of 
CNS respiratory center 
to changes in PO2 and 
Pco2 stimulates respira-
tion. Uncoupling of oxi-
dative phosphorylation, 
inhibition of Krebs cycle 
enzymes, and stimula-
tion of carbohydrate 
and lipid metabolism 
generate unmeasured 
endogenous anions and 
cause AGMA.
Initial nausea, vomiting, 
hyperventilation, alkalemia, 
alkaluria. Subsequent alka-
lemia with both respiratory 
alkalosis and AGMA, and 
paradoxical aciduria. Late 
acidemia with CNS and 
respiratory depression. 
Cerebral and pulmonary 
edema in severe cases. 
Hypoglycemia, hypocal-
cemia, hypokalemia, and 
seizures can occur.
IV hydration and supplemental glucose. Sodium 
bicarbonate to correct acidemia. Alkaline diure-
sis for systemic toxicity. Hemodialysis for coma, 
cerebral edema, seizures, pulmonary edema, 
renal failure, progressive acid-base disturbances 
or clinical toxicity, salicylate level >7 mmol/L 
(>100 mg/dL) following acute overdose.
179
(continued)
TABLE 32-3 PATHOPHYSIOLOGIC FEATURES AND TREATMENT OF SPECIFIC TOXIC SYNDROMES AND POISONINGS (CONTINUED)
Physiologic 
Condition, Causes
Examples
Mechanism of Action
Clinical Features
Specific Treatments
Discordant
CNS syndromes
Extrapyramidal 
reactions
Antipsychotics (see 
above), some cyclic 
antidepressants and 
antihistamines.
Decreased CNS dopa-
minergic activity with 
relative excess of 
cholinergic activity.
Akathisia, dystonia, 
parkinsonism
Oral or parenteral anticholinergic agent such as 
benztropine or diphenhydramine.
Isoniazid
Interference with acti-
vation and supply of 
pyridoxal-5-phosphate, 
a cofactor for glutamic 
acid decarboxylase, 
which converts glutamic 
acid to GABA, results 
in decreased levels of 
this inhibitory CNS neu-
rotransmitter; complex-
ation with and depletion 
of pyridoxine itself; 
inhibition of nicotine-
adenine dinucleotide 
dependent lactate and
Nausea, vomiting, agitation, 
confusion; coma, respiratory 
depression, seizures, lactic 
and ketoacidosis in severe 
cases.
High-dose IV pyridoxine (vitamin B6) for agitation, 
confusion, coma, and seizures. Diazepam or 
barbiturates for seizures.
180
hydroxybutyrate dehy-
drogenases resulting in 
substrate accumulation.
Lithium
Interference with cell 
membrane ion transport, 
adenylate cyclase and 
Na+, K+-ATPase activity, 
and neurotransmitter 
release.
Nausea, vomiting, diarrhea, 
ataxia, choreoathetosis, 
encephalopathy, hyper-
reflexia, myoclonus, 
nystagmus, nephrogenic 
diabetes insipidus, falsely 
elevated serum chloride 
with low anion gap, tachy-
cardia. Coma, seizures, 
arrhythmias, hyperthermia, 
and prolonged or permanent 
encephalopathy and move-
ment disorders in severe 
cases. Delayed onset after 
acute overdose, particularly 
with delayed-release for-
mations. Toxicity occurs at 
lower drug levels in chronic 
poisoning than in acute 
poisoning.
Whole-bowel irrigation for large inges-
tions. IV hydration. Hemodialysis for coma, 
seizures, severe, progressive, or persistent 
encephalopathy or neuromuscular dysfunction, 
peak lithium level >8 meq/L following acute 
overdose.
181
(continued)
TABLE 32-3 PATHOPHYSIOLOGIC FEATURES AND TREATMENT OF SPECIFIC TOXIC SYNDROMES AND POISONINGS (CONTINUED)
Physiologic 
Condition, Causes
Examples
Mechanism of Action
Clinical Features
Specific Treatments
Discordant
Serotonin syndrome
Amphetamines, 
cocaine, dextrometho-
rphan, meperidine, 
MAO inhibitors, selec-
tive serotonin (5HT) 
reuptake inhibitors, tri-
cyclic antidepressants, 
tramadol, triptans, 
tryptophan.
Promotion of serotonin 
release, inhibition of 
serotonin reuptake, or 
direct stimulation of 
CNS and peripheral 
serotonin receptors 
(primarily 5HT-1a and 
5HT-2), alone or in 
combination.
Altered mental status (agi-
tation, confusion, mutism, 
coma, seizures), neuromus-
cular hyperactivity (hyper-
reflexia, myoclonus, rigidity, 
tremors), and autonomic 
dysfunction (abdominal pain, 
diarrhea, diaphoresis, fever, 
flushing, labile hyperten-
sion, mydriasis, tearing, 
salivation, tachycardia). 
Complications include 
hyperthermia, lactic acido-
sis, rhabdomyolysis, and 
multisystem organ failure.
Serotonin receptor antagonists such as cyprohep-
tadine, discontinue offending agent(s).
Membrane-active
agents
Amantadine, antiar-
rhythmics (class I and 
III agents; some β
blockers), antipsychot-
ics (see above), anti-
histamines (particularly 
Blockade of fast sodium 
membrane channels 
prolongs phase 0 (depo-
larization) of the cardiac 
action potential, which 
prolongs the QRS duration 
QRS and JT prolongation (or 
both) with hypotension, ven-
tricular tachyarrhythmias, 
CNS depression, seizures. 
Anti-cholinergic effects with 
amantadine, antihistamines, 
Hypertonic sodium bicarbonate (or hypertonic 
saline) for cardiac conduction delays and mono-
morphic ventricular tachycardia. Lidocaine 
for monomorphic ventricular tachycardia 
(except when due to class Ib antiarrhythmics). 
Magnesium, isoproterenol, and overdrive pacing 
182
diphenhydramine), 
carbamazepine, local 
anesthetics (including 
cocaine), opioids 
(meperidine, propoxy-
phene), orphenadrine, 
quinoline antimalarials 
(chloroquine, hydroxy-
chloroquine, quinine), 
cyclic antidepressants 
(see above).
and promotes reentrant 
(monomorphic) ventricu-
lar tachycardia. Class Ia, 
Ic, and III antiarrhythmics 
also block potassium 
channels during phases 
2 and 3 (repolarization) 
of the action potential, 
prolonging the JT inter-
val and promoting early 
after-depolarizations and 
polymorphic (torsades des 
pointes) ventricular tachy-
cardia. Similar effects 
on neuronal membrane 
channels cause CNS 
dysfunction. Some agents 
also block α-adrenergic 
and cholinergic receptors 
or have opioid effects 
(see above and HPIM-18 
Chap. 393).
carbamazepine, disopyramide, 
antipsychotics, and cyclic 
antidepressants (see above). 
Opioid effects with meperi-
dine and propoxy phene 
(see HPIM-18 Chap. 393). 
Cinchonism (hearing loss, 
tinnitus, nausea, vomiting, 
vertigo, ataxia, headache, 
flushing, diaphoresis) and 
blindness with quinoline 
antimalarials.
for polymorphic ventricular tachycardia. 
Physostigmine for anticholinergic effects (see 
above). Naloxone for opioid effects (see HPIM-
18 Chap. 393). Extracorporeal removal for some 
agents (see text).
Abbreviations: AGMA, anion-gap metabolic acidosis; ARDS, adult respiratory distress syndrome; ATPase, adenosine triphosphatase, CNS, central nervous system; 5-HT, 5-hydroxytrypta-
mine (serotonin); GABA, γ-aminobutyric acid; G6PD, glucose-6-phosphate dehydrogenase; MAO, monoamine oxidase; SIADH, syndrome of inappropriate antidiuretic hormone secretion, VX, 
extremely toxic persistent nerve agent (no common chemical name).
183
TABLE 32-4 HEAVY METALS
Main Sources
Metabolism
Toxicity
Diagnosis
Treatment
Arsenic
Smelting and micro-
electronics industries; 
wood preservatives, 
pesticides, herbi-
cides, fungicides; 
contaminant of deep-
water wells; folk 
remedies; and coal; 
incineration of these 
products
Organic arsenic (arseno-
betaine, arsenocholine) 
is ingested in seafood 
and fish, but is nontoxic; 
inorganic arsenic is read-
ily absorbed (lung and GI); 
sequesters in liver, spleen, 
kidneys, lungs, and GI tract; 
residues persist in skin, hair, 
and nails; biomethylation 
results in detoxification, but 
this process saturates.
Acute arsenic poisoning 
results in necrosis of intes-
tinal mucosa with hemor-
rhagic gastroenteritis, fluid 
loss, hypotension, delayed 
cardiomyopathy, acute tubu-
lar necrosis, and hemolysis.
Chronic arsenic exposure 
causes diabetes, vasospasm, 
peripheral vascular insuffi-
ciency and gangrene, periph-
eral neuropathy, and cancer 
of skin, lung, liver (angiosar-
coma), bladder, and kidney.
Lethal dose: 120–200 mg 
(adults); 2 mg/kg 
(children).
Nausea, vomiting, diarrhea, 
abdominal pain, delirium, 
coma, seizures; garlicky odor 
on breath; hyperkeratosis, 
hyperpigmentation, exfoliative 
dermatitis, and Mees’ lines 
(transverse white striae of the 
fingernails); sensory and motor 
polyneuritis, distal weakness. 
Radiopaque sign on abdominal 
x-ray; ECG–QRS broadening, 
QT prolongation, ST depression, 
T-wave flattening; 24-h urinary 
arsenic >67 μmol/d or 50 μg/d; 
(no seafood for 24 h); if recent 
exposure, serum arsenic 
>0.9 μmol/L (7 μg/dL). High 
arsenic in hair or nails.
If acute ingestion, gastric 
lavage, activated charcoal 
with a cathartic. Supportive 
care in ICU.
Dimercaprol 3–5 mg/kg IM 
q4h × 2 days; q6h × 1 day, 
then q12h × 10 days; alter-
native: oral succimer.
184
Cadmium
Metal-plating, pig-
ment, smelting, 
battery, and plastics 
industries; tobacco; 
incineration of these 
products; ingestion 
of food that con-
centrates cadmium 
(grains, cereals).
Absorbed through inges-
tion or inhalation; bound by 
metallothionein, filtered at 
the glomerulus, but reab-
sorbed by proximal tubules 
(thus, poorly excreted). 
Biologic half-life: 10–30 y. 
Binds cellular sulfhydryl 
groups, competes with zinc, 
calcium for binding sites. 
Concentrates in liver and 
kidneys.
Acute cadmium inhalation 
causes pneumonitis after 
4–24 h; acute ingestion 
causes gastroenteritis. 
Chronic exposure causes 
anosmia, yellowing of 
teeth, emphysema, minor 
LFT elevations, microcytic 
hypochromic anemia unre-
sponsive to iron therapy, 
proteinuria, increased urinary 
β2-microglobulin, calciuria, 
leading to chronic renal 
failure, osteomalacia, and 
fractures.
With inhalation: pleuritic chest 
pain, dyspnea, cyanosis, fever, 
tachycardia, nausea, noncardio-
genic pulmonary edema. With 
ingestion: nausea, vomiting, 
cramps, diarrhea. Bone pain, frac-
tures with osteomalacia. If recent 
exposure, serum cadmium >500 
nmol/L (5 μg/dL). Urinary cadmium 
>100 nmol/L (10 μg/g creatinine) 
and/or urinary β2-microglobulin 
>750 μg/g creatinine (but urinary 
β2-microglobulin also increased 
in other renal diseases such as 
pyelonephritis).
There is no effective treat-
ment for cadmium poison-
ing (chelation not useful; 
dimercaprol can exacerbate 
nephrotoxicity).
Avoidance of further expo-
sure, supportive therapy, 
vitamin D for osteomalacia.
Lead
Manufacturing of 
auto batteries, lead 
crystal, ceramics, 
fishing weights, etc.; 
demolition or sand-
ing of lead-painted 
houses, bridges; 
stained glass making, 
plumbing, soldering;
Absorbed through inges-
tion or inhalation; organic 
lead (e.g., tetraethyl lead) 
absorbed dermally. In blood, 
95–99% sequestered in 
RBCs—thus, must measure 
lead in whole blood (not 
serum). Distributed widely in 
soft tissue, with half-life 
Acute exposure with blood 
lead levels (BPb) of 
>60–80 μg/dL can cause 
impaired neurotransmis-
sion and neuronal cell death 
(with central and peripheral 
nervous system effects); 
Aimpaired hematopoiesis and 
renal tubular dysfunction.
Abdominal pain, irritability, 
lethargy, anorexia, anemia, 
Fanconi’s syndrome, pyuria, 
azotemia in children with 
blood lead level (BPb) 
>80 μg/dL; may also see 
epiphyseal plate “lead lines” on 
long bone x-rays. Convulsions, 
coma at BPb >120 μg/dL.
Identification and correction 
of exposure sources is critical. 
In some U.S. states, screening 
and reporting to local health 
boards of children with BPb 
>10 μg/dL and workers with 
BPb >40 μg/dL is required. In 
the highly exposed individual 
with symptoms, chelation
(continued)
185
TABLE 32-4 HEAVY METALS (CONTINUED)
Main Sources
Metabolism
Toxicity
Diagnosis
Treatment
Lead
environmental
exposure to paint 
chips, house dust (in 
homes built before 
1975), firing ranges 
(from bullet dust), 
food or water from 
improperly glazed 
ceramics, lead pipes; 
contaminated herbal 
remedies, candies; 
exposure to the 
combustion of leaded 
fuels.
~30 days; 15% of dose 
sequestered in bone with 
half-life of >20 years. 
Excreted mostly in urine, 
but also appears in other 
fluids including breast milk. 
Interferes with mitochondrial 
oxidative phosphorylation, 
ATPases, calcium-dependent 
messengers; enhances oxi-
dation and cell apoptosis.
At higher levels of exposure 
(e.g., BPb >80–120 μg/
dL), acute encephalopathy 
with convulsions, coma, and 
death may occur. Subclinical 
exposures in children (BPb 
25–60 μg/dL) are associated 
with anemia; mental retarda-
tion; and deficits in language, 
motor function, balance, 
hearing, behavior, and school 
performance. Impairment of 
IQ appears to occur at even 
lower levels of exposure with 
no measurable threshold 
above the limit of detection 
in most assays of 1 μg/dL.
In adults, chronic subclinical 
exposures (BPb >40 μg/dL) 
are associated with an 
Noticeable neurodevelopmental 
delays at BPb of 40–80 μg/dL; 
may also see symptoms associ-
ated with higher BPb levels. In 
the U.S., screening of all chil-
dren when they begin to crawl 
(~6 months) is recommended 
by the CDC; source identifica-
tion and intervention is begun 
if the BPb >10 μg/dL. In adults, 
acute exposure causes similar 
symptoms as in children as 
well as headaches, arthralgias, 
myalgias, depression, impaired 
short-term memory, loss of 
libido. Physical exam may 
reveal a “lead line” at the 
gingiva-tooth border, pallor, 
wrist drop, and cognitive dys-
function (e.g., declines on the
is recommended with oral 
DMSA (succimer); if acutely 
toxic, hospitalization and IV or 
IM chelation with edetate cal-
cium disodium (CaEDTA) may 
be required, with the addition 
of dimercaprol to prevent 
worsening of encephalopathy. 
It is uncertain whether chil-
dren with asymptomatic 
lead exposure (e.g., BPb 
20–40 μg/dL) benefit from 
chelation. Correction of 
dietary deficiencies in iron, 
calcium, magnesium, and 
zinc will lower lead absorp-
tion and may also improve 
toxicity. Vitamin C is a weak 
but natural chelating agent. 
Calcium supplements
186
increased risk of anemia, 
demyelinating peripheral 
neuropathy (mainly motor), 
impairments of reaction 
time, hypertension, ECG 
conduction delays, interstitial 
nephritis and chronic 
renal failure, diminished 
sperm counts, spontaneous 
abortions.
mini-mental status exam); lab 
tests may reveal a normocytic, 
normochromic anemia, baso-
philic stippling, an elevated 
blood protoporphyrin level (free 
erythrocyte or zinc), and motor 
delays on nerve conduction. In 
the U.S., OSHA requires regular 
testing of lead-exposed workers 
with removal if BPb >40 μg/
dL. New guidelines have been 
proposed recommending moni-
toring of cumulative exposure 
parameters (Kosnett, 2007).
(1200 mg at bedtime) have 
been shown to lower blood 
lead levels in pregnant 
women.
Mercury
Metallic, mercurous, 
and mercuric mer-
cury (Hg, Hg+, Hg2+)
exposures occur 
in some chemical, 
metal-processing, 
electrical-equipment, 
automotive indus-
tries; they are also in 
thermometers, dental 
amalgams, batteries.
Elemental mercury (Hg) is 
not well absorbed; however, 
it will volatilize into highly 
absorbable vapor. Inorganic 
mercury is absorbed 
through the gut and skin. 
Organic mercury is well 
absorbed through inhalation 
and ingestion. Elemental 
and organic mercury cross
Acute inhalation of Hg vapor 
causes pneumonitis and 
noncardiogenic pulmonary 
edema leading to death, 
CNS symptoms, and 
polyneuropathy.
Chronic high exposure 
causes CNS toxicity (mercu-
rial erethism, see Diagnosis); 
Chronic exposure to metallic 
mercury vapor produces a 
characteristic intention tremor 
and mercurial erethism:
excitability, memory loss, 
insomnia, timidity, and delirium 
(“mad as a hatter” —hat 
makers used mercury in the 
manufacturing process). On 
neurobehavioral tests: 
decreased motor speed, visual
Treat acute ingestion of 
mercuric salts with induced 
emesis or gastric lavage and 
polythiol resins (to bind mer-
cury in the GI tract). Chelate 
with dimercaprol (up to 
24 mg/kg per day IM in 
divided doses), DMSA 
(succimer), or penicillamine, 
with 5-day courses separated 
(continued)
187
TABLE 32-4 HEAVY METALS (CONTINUED)
Main Sources
Metabolism
Toxicity
Diagnosis
Treatment
Mercury
Mercury is dispersed 
by waste incinera-
tion. Environmental 
bacteria convert 
inorganic to organic 
mercury, which then 
bioconcentrates up 
the aquatic food 
chain to contaminate 
tuna, swordfish, and 
other pelagic fish.
the blood-brain barrier 
and placenta. Mercury is 
excreted in urine and feces 
and has a half-life in blood 
of ~60 days; however, 
deposits will remain in the 
kidney and brain for years. 
Exposure to mercury stimu-
lates the kidney to produce 
metallothionein, which 
provides some detoxification 
benefit. Mercury binds sulf-
hydryl groups and interferes 
with a wide variety of criti-
cal enzymatic processes.
lower exposures impair 
renal function, motor speed, 
memory, coordination. 
Acute ingestion of inorganic 
mercury causes gastroenteri-
tis, the nephritic syndrome, or 
acute renal failure, hyperten-
sion, tachycardia, and cardio-
vascular collapse, with death 
at a dose of 10–42 mg/kg.
Ingestion of organic mer-
cury causes gastroenteritis, 
arrhythmias, and lesions in 
the basal ganglia, gray matter, 
and cerebellum at doses 
>1.7 mg/kg.
scanning, verbal and visual 
memory, visuomotor 
coordination. 
Children exposed to mercury in 
any form may develop acro dynia
(“pink disease”): flushing, itching, 
swelling, tachycardia, hyperten-
sion, excessive salivation or per-
spiration, irritability, weakness, 
morbilliform rashes, desquama-
tion of palms and soles.
Toxicity from elemental or inor-
ganic mercury exposure begins 
when blood levels are >180 
nmol/L (3.6 μg/dL) and urine 
levels >0.7 μmol/L (15 μg/dL). 
by several days of rest. If 
renal failure occurs, treat  
with peritoneal dialysis, 
hemodialysis, or extra-cor-
poreal regional complexing 
hemodialysis and succimer.
Chronic inorganic mercury 
poisoning is best treated with 
N-acetyl penicillamine.
188
High exposure during preg-
nancy causes derangement 
of fetal neuronal migration 
resulting in severe mental 
retardation. 
Mild exposures during preg-
nancy (from fish consump-
tion) are associated with 
declines in neurobehavioral 
performance in offspring.
Dimethylmercury, a com-
pound only found in research 
labs, is “supertoxic”—a few 
drops of exposure via skin 
absorption or inhaled vapor 
can cause severe cerebellar 
degeneration and death.
Exposures that ended years ago 
may result in a >20-μg increase 
in 24-h urine after a 2-g dose of 
succimer.
Organic mercury exposure is 
best measured by levels in blood 
(if recent) or hair (if chronic); 
CNS toxicity in children may 
derive from fetal exposures 
associated with maternal hair 
Hg > 30 nmol/g (6 μg/g).
Abbreviations: ATPase, adenosine triphosphatase; CDC, Centers for Disease Control and Prevention; CNS, central nervous system; DMSA, dimercaptosuccinic acid; ECG, electro-
cardiogram; GI, gastrointestinal; ICU, intensive care unit; IQ, intelligence quotient; LFT, liver function tests; OSHA, Occupational Safety and Health Administration; RBC, red blood cell.
189
SECTION 2
190
Medical Emergencies
Whole-bowel irrigation may be useful with ingestions of foreign bod-
ies, drug packets, slow-release medications, and heavy metals. Electrolyte/
polyethylene glycol solution (e.g., Golytely, Colyte) is given orally or by 
gastric tube up to a rate of 2 L/h. Cathartic salts (magnesium citrate) and 
saccharides (sorbitol, mannitol) promote evacuation of the rectum but 
have not been shown to of benefit in poison decontamination. Dilution 
of corrosive acids and alkali is accomplished by having the pt drink 5 mL 
water per kg body weight. Endoscopy or surgical intervention may be 
required in large foreign-body ingestion, concretions of ingested material 
(heavy metals, lithium, salicylate, or sustained-release tablets), and when 
ingested drug packets leak or rupture.
Skin and eyes are decontaminated by washing with copious amounts 
of water or saline.
ENHANCEMENT OF ELIMINATION Activated charcoal in repeated doses 
of 1 g/kg q2–4h is useful for ingestions of drugs with enteral circula-
tion such as carbamazepine, dapsone, diazepam, digoxin, glutethimide, 
meprobamate, methotrexate, phenobarbital, phenytoin, salicylate, the-
ophylline, and valproic acid.
Forced urinary alkalinization enhances the elimination of chloro-
phenoxyacetic acid herbicides, chlorpropamide, diflunisal, fluoride, 
methotrexate, phenobarbital, sulfonamides, and salicylates through ion-
ization and inhibition of tubular reabsorption. Sodium bicarbonate, 1–2 
ampules per liter of 0.45% NaCl, is given at a rate sufficient to maintain 
urine pH ≥7.5 and urine output at 3–6 mL/kg per h. Acid diuresis is no 
longer recommended.
Hemodialysis may be useful in severe poisoning due to barbiturates, 
bromide, chloral hydrate, ethanol, ethylene glycol, isopropyl alco-
hol, lithium, heavy metals, methanol, procainamide, and salicylate. 
Peritoneal dialysis is less effective. Hemoperfusion may be indicated for 
chloramphenicol, disopyramide, and hypnotic-sedative overdose, but 
is no longer widely available. Exchange transfusion removes poisons 
affecting red blood cells (arsine, sodium chlorate causing hemolysis, 
methemoglobinemia, sulfhemoglobinemia).
The features of specific toxic syndromes and approaches to treatment are 
summarized in Table 32-3. The features of selected heavy metal toxicity 
and approaches to treatment are summarized in Table 32-4. Readers are 
encouraged to contact poison control centers for additional information 
(www.aapcc.org/DNN/).
For a more detailed discussion, see Hu H: Heavy Metal 
Poisoning, Chap. e49 and Mycyk MB: Poisoning and Drug 
Overdosage, Chap. e50; in HPIM-18.
CHAPTER 33 
191
Bioterrorism
CHAPTER 33
Bioterrorism
MICROBIAL BIOTERRORISM
Microbial bioterrorism refers to the use of microbial pathogens as weapons 
of terror that target civilian populations. A primary goal of bioterrorism is 
not necessarily to produce mass casualties but to destroy the morale of a 
society through creating fear and uncertainty. The events of September 11, 
2001, followed by the anthrax attacks through the U.S. Postal Service, illus-
trate the vulnerability of the American public to terrorist attacks, including 
those that use microbes. The key to combating bioterrorist attacks is a 
highly functioning system of public health surveillance and education that 
rapidly identifies and effectively contains the attack.
Agents of microbial bioterrorism may be used in their natural form 
or may be deliberately modified to maximize their deleterious effect. 
Modifications that increase the deleterious effect of a biologic agent 
include genetic alteration of microbes to produce antimicrobial resistance, 
creation of fine-particle aerosols, chemical treatment to stabilize and 
prolong infectivity, and alteration of the host range through changes in 
surface protein receptors. Certain of these approaches fall under the cat-
egory of weaponization, a term that describes the processing of microbes 
or toxins in a manner that enhances their deleterious effect after release. 
The key features that characterize an effective biologic weapon are sum-
marized in Table 33-1.
The U.S. Centers for Disease Control and Prevention (CDC) has clas-
sified microbial agents that could potentially be used in bioterrorism 
TABLE 33-1 KEY FEATURES OF BIOLOGIC AGENTS USED AS BIOWEAPONS
1. High morbidity and mortality
2. Potential for person-to-person spread
3. Low infective dose and highly infectious by aerosol
4. Lack of rapid diagnostic capability
5. Lack of universally available effective vaccine
6. Potential to cause anxiety
7. Availability of pathogen and feasibility of production
8. Environmental stability
9. Database of prior research and development
10. Potential to be “weaponized”
Source: From L Borio et al: JAMA 287:2391, 2002; with permission.
SECTION 2
192
Medical Emergencies
attacks into three categories: A, B, and C (Table 33-2). Category A 
agents are the highest-priority pathogens. They pose the greatest 
risk to national security because they (1) can be easily disseminated 
or transmitted from person to person, (2) are associated with high 
case-fatality rates, (3) have potential to cause significant public panic 
and social disruption, and (4) require special action and public health 
preparedness.
TABLE 33-2 CDC CATEGORY A, B, AND C AGENTS
Category A
Anthrax (Bacillus anthracis)
Botulism (Clostridium botulinum toxin)
Plague (Yersinia pestis)
Smallpox (Variola major)
Tularemia (Francisella tularensis)
Viral hemorrhagic fevers
Arenaviruses: Lassa, New World (Machupo, Junin, Guanarito, and Sabia)
Bunyaviridae: Crimean-Congo, Rift Valley
Filoviridae: Ebola, Marburg
Category B
Brucellosis (Brucella spp.)
Epsilon toxin of Clostridium perfringens
Food safety threats (e.g., Salmonella spp., Escherichia coli 0157:H7,
Shigella)
Glanders (Burkholderia mallei  )
Melioidosis (B. pseudomallei )
Psittacosis (Chlamydia psittaci )
Q fever (Coxiella burnetii  )
Ricin toxin from Ricinus communis (castor beans)
Staphylococcal enterotoxin B
Typhus fever (Rickettsia prowazekii  )
Viral encephalitis [alphaviruses (e.g., Venezuelan, eastern, and western 
equine encephalitis)]
Water safety threats (e.g., Vibrio cholerae, Cryptosporidium parvum)
Category C
Emerging infectious diseases threats such as Nipah, hantavirus, SARS 
coronavirus, and pandemic influenza.
Abbreviations: SARS, severe acute respiratory syndrome.
Source: Centers for Disease Control and Prevention and the National Institute of Allergy and 
Infectious Diseases.
CHAPTER 33 
193
Bioterrorism
� CATEGORY A AGENTS
Anthrax (Bacillus Anthracis)
Anthrax as a Bioweapon Anthrax in many ways is the prototypic bioweapon. 
Although it is only rarely spread by person-to-person contact, it has many of 
the other features of an ideal biologic weapon listed in Table 33-1. The poten-
tial impact of anthrax as a bioweapon is illustrated by the apparent accidental 
release in 1979 of anthrax spores from a Soviet bioweapons facility in Sverdlosk, 
Russia. As a result of this atmospheric release of anthrax spores, at least 77 cases 
of anthrax (of which 66 were fatal) occurred in individuals within an area 4 
km downwind of the facility. Deaths were noted in livestock up to 50 km from 
the facility. The interval between probable exposure and onset of symptoms 
ranged from 2 to 43 days, with the majority of cases occurring within 2 weeks. 
In September of 2001 the American public was exposed to anthrax spores deliv-
ered through the U.S. Postal Service. There were 22 confirmed cases: 11 cases of 
inhaled anthrax (5 died) and 11 cases of cutaneous anthrax (no deaths). Cases 
occurred in individuals who opened contaminated letters as well as in postal 
workers involved in processing the mail.
Microbiology and Clinical Features (See also Chaps. 138 and 221, HPIM-18)
• Anthrax is caused by infections with B. anthracis, a gram-positive, non-
motile, spore-forming rod that is found in soil and predominantly causes 
disease in cattle, goats, and sheep.
• Spores can remain viable for decades in the environment and be difficult 
to destroy with standard decontamination procedures. These properties 
make anthrax an ideal bioweapon.
• Naturally occurring human infection generally results from exposure to 
infected animals or contaminated animal products.
There are three major clinical forms of anthrax:
1. Gastrointestinal anthrax is rare and is unlikely to result from a bioterror-
ism event.
2. Cutaneous anthrax follows introduction of spores through an opening in 
the skin. The lesion begins as a papule followed by the development of a 
black eschar. Prior to the availability of antibiotics, about 20% of cutane-
ous anthrax cases were fatal.
3. Inhalation anthrax is the form most likely to result in serious illness and 
death in a bioterrorism attack. It occurs following inhalation of spores that 
become deposited in the alveolar spaces. The spores are phagocytosed by 
alveolar macrophages and are transported to regional lymph nodes where 
they germinate. Following germination, rapid bacterial growth and toxin 
production occur. Subsequent hematologic dissemination leads to cardio-
vascular collapse and death. The earliest symptoms are typically those of a 
viral-like prodrome with fever, malaise, and abdominal/chest symptoms 
that rapidly progress to a septic shock picture. Widening of the mediasti-
num and pleural effusions are typical findings on chest radiography. Once 
considered 100% fatal, experience from the Sverdlosk and U.S. Postal out-
breaks indicate that with prompt initiation of appropriate antibiotic therapy, 
survival may be >50%. Awareness of the possibility of the diagnosis of 
anthrax is critical to the prompt initiation of therapy.
SECTION 2
194
Medical Emergencies
Anthrax (See Table 33-3)
TREATMENT
Anthrax can be successfully treated if the disease is promptly recog-
nized and appropriate antibiotic therapy is initiated.
• Penicillin, ciprofloxacin, and doxycycline are currently licensed for the 
treatment of anthrax.
• Clindamycin and rifampin have in vitro activity against the organism 
and may be used as part of the treatment regimen.
• Pts with inhalation anthrax are not contagious and do not require 
special isolation procedures.
Vaccination and Prevention
• Currently there is a single vaccine licensed for use, produced from a 
cell-free culture supernatant of an attenuated strain of B. anthracis (Stern 
strain).
• Current recommendation for postexposure prophylaxis is 60 days of 
antibiotics (see Table 33-1); recent animal studies have suggested that 
postexposure vaccination may be of some additional benefit.
Plague (Yersinia Pestis) (See also Chap. 100)
Plague as a Bioweapon Although plague lacks the environmental stability of 
anthrax, the highly contagious nature of the infection and the high mortality 
rate make it a potentially important agent of bioterrorism. As a bioweapon, 
plague would likely be delivered via an aerosol leading to primary pneu-
monic plague. In such an attack, person-to-person transmission of plague 
via respiratory aerosol could lead to large numbers of secondary cases.
Microbiology and Clinical Features See Chap. 100.
Plague See Table 33-3 and Chap. 100.
TREATMENT
Smallpox (Variola major and V. minor) (See also Chaps. 183 and 221, HPIM-18)
Smallpox as a Bioweapon Smallpox as a disease was globally eradicated by 
1980 through a worldwide vaccination program. However, with the cessa-
tion of smallpox immunization programs in the United States in 1972 (and 
worldwide in 1980), close to half the U.S. population is fully susceptible 
to smallpox today. Given the infectious nature and the 10–30% mortality 
of smallpox in unimmunized individuals, the deliberate release of virus 
could have devastating effects on the population. In the absence of effective 
containment measures, an initial infection of 50–100 persons in a first gen-
eration of cases could expand by a factor of 10 to 20 with each succeeding 
generation. These considerations make smallpox a formidable bioweapon.
Microbiology and Clinical Features The disease smallpox is caused by one 
of two closely related double-strand DNA viruses, V. major and V. minor. 
Both viruses are members of the Orthopoxvirus genus of the Poxviridae 
family. Infection with V. minor is generally less severe, with low mortality 
rates; thus, V. major is the only one considered as a potential bioweapon. 
TABLE 33-3 CLINICAL SYNDROMES, PREVENTION, AND TREATMENT STRATEGIES FOR DISEASES CAUSED BY CATEGORY A AGENTS
Agent
Clinical Syndrome
Incubation
Period
Diagnosis
Treatment
Prophylaxis
Bacillus
anthracis
(anthrax)
Cutaneous lesion
1–12 days
Culture, Gram 
stain, PCR, 
Wright stain of 
peripheral smear
Postexposure
Anthrax 
vaccine
adsorbed
Papule to eschar
Ciprofloxacin, 500 mg, PO 
bid × 60 d or
Recombinant
protective
antigen
vaccines are 
under study
Inhalational disease
1–60 days
Doxycycline, 100 mg 
PO bid × 60 d or
Fever, malaise, chest and 
abdominal discomfort
Amoxicillin, 500 mg PO q8h, likely to 
be effective if strain penicillin 
sensitive
Pleural effusion, widened 
mediastinum on chest 
x-ray
Active disease:
Ciprofloxacin, 400 mg IV q12h or
Doxycycline, 100 mg IV q12h plus
Clindamycin, 900 mg IV q8h and/or 
rifampin, 300 mg IV q12h; switch to 
PO when stable × 60 d total
Antitoxin strategies:
Neutralizing monoclonal and polyclonal 
antibodies are under study
195
(continued)
TABLE 33-3 CLINICAL SYNDROMES, PREVENTION, AND TREATMENT STRATEGIES FOR DISEASES CAUSED BY CATEGORY A AGENTS (CONTINUED)
Agent
Clinical Syndrome
Incubation
Period
Diagnosis
Treatment
Prophylaxis
Yersinia pestis 
(pneumonic
plague)
Fever, cough, dyspnea, 
hemoptysis
1–6 days
Culture, Gram stain, 
direct fluorescent 
antibody, PCR
Gentamicin, 2.0 mg/kg IV loading 
then 1.7 mg/kg q8h IV or
Doxycycline, 100 mg PO 
bid (ciprofloxacin may 
also be active)
Infiltrates and 
consolidation on chest 
x-ray
Streptomycin, 1.0 g q12h IM or IV
Formalin-fixed vaccine 
(FDA licensed; not 
available)
Alternatives include doxycycline, 
100 mg bid PO or IV; chlorampheni-
col, 500 mg qid PO or IV
Variola major 
(smallpox)
Fever, malaise, headache, 
backache, emesis
7–17 days
Culture, PCR, electron 
microscopy
Supportive measures; consideration 
for cidofovir, anti-vaccinia 
immunoglobulin
Vaccinia immunization
Maculopapular to 
vesicular to pustular skin 
lesions
Francisella 
tularensis
(tularemia)
Fever, chills, malaise, 
myalgia, chest 
discomfort, dyspnea, 
headache, skin rash, 
pharyngitis, conjunctivitis
1–14 days
Gram stain, culture, 
immunohistochemistry, 
PCR
Streptomycin, 1 g IM bid or
Doxycycline, 100 mg PO 
bid × 14 days or
Gentamicin, 5 mg/kg per day div q8h 
IV for 14 days or
Ciprofloxacin, 500 mg 
PO bid × 14 days
Hilar adenopathy on 
chest x-ray
Doxycycline, 100 mg IV bid or
Chloramphenicol, 15 mg/kg up to 
1 gm IV qid or
Ciprofloxacin, 400 mg IV bid
196
Viral
hemorrhagic 
fevers
Fever, myalgia, rash, 
encephalitis, prostration
2–21 days
RT-PCR, serologic 
testing for antigen or 
antibody
Supportive measures
No known 
chemoprophylaxis
Viral isolation by CDC 
or U.S. Army Medical 
Research Institute of 
Infectious Diseases 
(USAMRIID)
Ribavirin 30 mg/kg up to 2 g × 1, 
followed by 16 mg/kg IV up to 
1 g q6h for 4 days, followed by 
8 mg/kg IV up to 0.5 g q8h × 6 days
Consideration for 
ribavirin in high-risk 
situations
Botulinum toxin 
(Clostridium
botulinum)
Dry mouth, blurred 
vision, ptosis, weakness, 
dysarthria, dysphagia, 
dizziness, respiratory 
failure, progressive 
paralysis, dilated pupils
12–72 h
Mouse bioassay, toxin 
immunoassay
Supportive measures including 
ventilation, HBAT equine antitoxin 
from the CDC Emergency Operations 
Center, 770-488-7100
Administration of 
antitoxin
Abbreviations: CDC, Centers for Disease Control and Prevention; FDA, U.S. Food and Drug Administration; HBAT, heptavalent botulinum antitoxin; PCR, polymerase chain reaction; 
RT-PCR, reverse transcriptase PCR.
197
SECTION 2
198
Medical Emergencies
Infection with V. major typically occurs following contact with an infected 
person from the time that a maculopapular rash appears through scabbing 
of the pustular lesions. Infection is thought to occur from inhalation of 
virus-containing saliva droplets from oropharyngeal lesions. Contaminated 
clothing or linen can also spread infection. About 12–14 days following ini-
tial exposure the pt develops high fever, malaise, vomiting, headache, back 
pain, and a maculopapular rash that begins on the face and extremities and 
spreads to the trunk. The skin lesions evolve into vesicles that eventually 
become pustular with scabs. The oral mucosa also develops macular lesions 
that progress to ulcers. Smallpox is associated with a 10–30% mortality. 
Historically, about 5–10% of naturally occurring cases manifest as highly 
virulent atypical forms, classified as hemorrhagic and malignant. These are 
difficult to recognize due to their atypical manifestations. Both forms have 
similar onset of a severe prostrating illness characterized by high fever, 
severe headache, and abdominal and back pain. In the hemorrhagic form, 
cutaneous erythema develops followed by petechiae and hemorrhage into 
the skin and mucous membranes. In the malignant form, confluent skin 
lesions develop but never progress to the pustular stage. Both of these forms 
are often fatal, with death occurring in 5–6 days.
Smallpox
TREATMENT
Treatment is supportive. There is no licensed specific antiviral therapy 
for smallpox; however, certain candidate drugs look promising in pre-
clinical testing in animal models. Smallpox is highly infectious to close 
contacts; pts who are suspected cases should be handled with strict 
isolation procedures.
Vaccination and Prevention Smallpox is a preventable disease following 
immunization with vaccinia. Past and current experience indicates that the 
smallpox vaccine is associated with a very low incidence of severe compli-
cations (see Table 221-4, p. 1775, HPIM-18). The current dilemma facing 
our society regarding assessment of the risk/benefit of smallpox vaccina-
tion is that, while the risks of vaccination are known, the risk of someone 
deliberately and effectively releasing smallpox into the general population 
is unknown. Given the rare, but potentially severe complications associated 
with smallpox vaccination using the currently available vaccine together 
with the current level of threat, it has been decided by public health authori-
ties that vaccination of the general population is not indicated.
Tularemia (Francisella Tularensis) (See also Chap. 100)
Tularemia as a Bioweapon Tularemia has been studied as a biologic agent 
since the mid-twentieth century. Reportedly, both the United States and the 
former Soviet Union had active programs investigating this organism as a 
possible bioweapon. It has been suggested that the Soviet program extended 
into the era of molecular biology and that some strains of F. tularensis 
may have been genetically engineered to be resistant to commonly used 
antibiotics. F. tularensis is extremely infectious and can cause significant 
CHAPTER 33 
199
Bioterrorism
morbidity and mortality. These facts make it reasonable to consider this 
organism as a possible bioweapon that could be disseminated by either 
aerosol or contamination of food or drinking water.
Microbiology and Clinical Features See Chap. 100.
Tularemia See Table 33-3 and Chap. 100.
TREATMENT
Viral Hemorrhagic Fevers (See also Chap. 113)
Hemorrhagic Fever Viruses as Bioweapons Several of the hemorrhagic fever 
viruses have been reported to have been weaponized by the former Soviet 
Union and the United States. Nonhuman primate studies indicate that 
infection can be established with very few virions and that infectious aero-
sol preparations can be produced.
Microbiology and Clinical Features See Chap. 113.
Viral Hemorrhagic Fevers See Table 33-3 and Chap. 113.
TREATMENT
Botulinum Toxin (Clostridium botulinum) (See also Chap. 101)
Botulinum Toxin as a Bioweapon In a bioterrorism attack, botulinum toxin 
would likely be dispersed as an aerosol or used to contaminate food. 
Contamination of the water supply is possible, but the toxin would likely 
be degraded by chlorine used to purify drinking water. The toxin can also 
be inactivated by heating food to >85°C for >5 min. The United States, the 
former Soviet Union, and Iraq have all acknowledged studying botulinum 
toxin as a potential bioweapon. Unique among the Category A agents for 
not being a live organism, botulinum toxin is one of the most potent and 
lethal toxins known to man. It has been estimated that 1 g of toxin is suf-
ficient to kill 1 million people if adequately dispersed.
Microbiology and Clinical Features See Chap. 101.
Botulinum Toxin See Table 33-3 and Chap. 101.
TREATMENT
� CATEGORY B AND C AGENTS (SEE TABLE 33-2)
Category B agents are the next highest priority and include agents that are 
moderately easy to disseminate, produce moderate morbidity and low mor-
tality, and require enhanced diagnostic capacity.
Category C agents are the third highest priority agents in the biodefense 
agenda. These agents include emerging pathogens, such as SARS (severe 
acute respiratory syndrome) coronavirus or a pandemic influenza virus, to 
which the general population lacks immunity. Category C agents could be 
engineered for mass dissemination in the future. It is important to note that 
these categories are empirical, and, depending on future circumstances, the 
priority ratings for a given microbial agent may change.
SECTION 2
200
Medical Emergencies
� PREVENTION AND PREPAREDNESS
As indicated above, a diverse array of agents have the potential to be used 
against a civilian population in a bioterrorism attack. The medical profes-
sion must maintain a high index of suspicion that unusual clinical presen-
tations or clustering of rare diseases may not be a chance occurrence, but 
rather the first sign of a bioterrorism attack. Possible early indicators of a 
bioterrorism attack could include:
• The occurrence of rare diseases in healthy populations
• The occurrence of unexpectedly large numbers of a rare infection
• The appearance in an urban population of an infectious disease that is 
usually confined to rural settings
Given the importance of rapid diagnosis and early treatment for many 
of these diseases, it is important that the medical care team report any sus-
pected cases of bioterrorism immediately to local and state health authori-
ties and/or the CDC (888-246-2675).
CHEMICAL BIOTERRORISM
The use of chemical warfare agents (CWAs) as weapons of terror against 
civilian populations is a potential threat that must be addressed by public 
health officials and the medical profession. The use of both nerve agents 
and sulfur mustard by Iraq against Iranian military and Kurdish civilians 
and the sarin attacks in 1994–1995 in Japan underscore this threat.
A detailed description of the various CWAs can be found in Chap. 222, 
HPIM-18, and on the CDC website at www.bt.cdc.gov/agent/agentlistchem.
asp. In this section only vesicants and nerve agents will be discussed, as 
these are considered the most likely agents to be used in a terrorist attack.
� VESICANTS (SULFUR MUSTARD, NITROGEN MUSTARD, LEWISITE)
Sulfur mustard is the prototype for this group of CWAs and was first used 
on the battlefields of Europe in World War I. This agent constitutes both 
a vapor and liquid threat to exposed epithelial surfaces. The organs most 
commonly affected are the skin, eyes, and airways. Exposure to large 
quantities of sulfur mustard can result in bone marrow toxicity. Sulfur 
mustard dissolves slowly in aqueous media such as sweat or tears, but once 
dissolved it forms reactive compounds that react with cellular proteins, 
membranes, and importantly DNA. Much of the biologic damage from this 
agent appears to result from DNA alkylation and cross-linking in rapidly 
dividing cells in the corneal epithelium, skin, bronchial mucosal epithelium, 
GI epithelium, and bone marrow. Sulfur mustard reacts with tissue within 
minutes of entering the body.
Clinical Features 
The topical effects of sulfur mustard occur in the skin, airways, and eyes. 
Absorption of the agent may produce effects in the bone marrow and GI 
tract (direct injury to the GI tract may occur if sulfur mustard is ingested in 
contaminated food or water).
• Skin: erythema is the mildest and earliest manifestation; involved areas of 
skin then develop vesicles that coalesce to form bullae; high-dose expo-
sure may lead to coagulation necrosis within bullae.
CHAPTER 33 
201
Bioterrorism
• Airways: initial and, with mild exposures, the only airway manifestations 
are burning of the nares, epistaxis, sinus pain, and pharyngeal pain. With 
exposure to higher concentrations, damage to the trachea and lower 
airways may occur, producing laryngitis, cough, and dyspnea. With large 
exposures, necrosis of the airway mucosa occurs leading to pseudomem-
brane formation and airway obstruction. Secondary infection may occur 
due to bacterial invasion of denuded respiratory mucosa.
• Eyes: the eyes are the most sensitive organ to injury by sulfur mustard. 
Exposure to low concentrations may produce only erythema and irritation. 
Exposure to higher concentrations produces progressively more severe 
conjunctivitis, photophobia, blepharospasm pain, and corneal damage.
• GI tract manifestations include nausea and vomiting, lasting up to 24 h.
• Bone marrow suppression, with peaks at 7–14 days following exposure, 
may result in sepsis due to leukopenia.
Sulfur Mustard
TREATMENT
Immediate decontamination is essential to minimize damage. Immediately 
remove clothing and gently wash skin with soap and water. Eyes should 
be flushed with copious amounts of water or saline. Subsequent medical 
care is supportive. Cutaneous vesicles should be left intact. Larger bul-
lae should be debrided and treated with topical antibiotic preparations. 
Intensive care similar to that given to severe burn pts is required for pts 
with severe exposure. Oxygen may be required for mild/moderate respi-
ratory exposure. Intubation and mechanical ventilation may be necessary 
for laryngeal spasm and severe lower airway damage. Pseudomembranes 
should be removed by suctioning; bronchodilators are of benefit for bron-
chospasm. The use of granulocyte colony-stimulating factor and/or stem 
cell transplantation may be effective for severe bone marrow suppression.
� NERVE AGENTS
The organophosphorus nerve agents are the deadliest of the CWAs and work 
by inhibiting synaptic acetylcholinesterase, creating an acute cholinergic crisis. 
The “classic” organophosphorus nerve agents are tabun, sarin, soman, cyclosa-
rin, and VX. All agents are liquid at standard temperature and pressure. With 
the exception of VX, all these agents are highly volatile, and the spilling of even 
a small amount of liquid agent represents a serious vapor hazard.
Mechanism
Inhibition of acetylcholinesterase accounts for the major life-threatening 
effects of these agents. At the cholinergic synapse, the enzyme acetylcho-
linesterase functions as a “turn off” switch to regulate cholinergic synaptic 
transmission. Inhibition of this enzyme allows released acetylcholine to 
accumulate, resulting in end-organ overstimulation and leading to what is 
clinically referred to as cholinergic crisis.
Clinical Features 
The clinical manifestations of nerve agent exposure are identical for vapor 
and liquid exposure routes. Initial manifestations include miosis, blurred 
SECTION 2
202
Medical Emergencies
vision, headache, and copious oropharyngeal secretions. Once the agent 
enters the bloodstream (usually via inhalation of vapors) manifestations 
of cholinergic overload include nausea, vomiting, abdominal cramping, 
muscle twitching, difficulty breathing, cardiovascular instability, loss of 
consciousness, seizures, and central apnea. The onset of symptoms fol-
lowing vapor exposure is rapid (seconds to minutes). Liquid exposure to 
nerve agents results in differences in speed of onset and order of symptoms. 
Contact of a nerve agent with intact skin produces localized sweating fol-
lowed by localized muscle fasciculations. Once in the muscle, the agent 
enters the circulation and causes the symptoms described above.
Nerve Agents
TREATMENT
Since nerve agents have a short circulating half-life, improvement should 
be rapid if exposure is terminated and supportive care and appropriate 
antidotes are given. Thus, the treatment of acute nerve agent poisoning 
involves decontamination, respiratory support, antidotes.
1. Decontamination: Procedures are the same as those described above 
for sulfur mustard.
2. Respiratory support: Death from nerve agent exposure is usually due to 
respiratory failure. Ventilation will be complicated by increased airway 
resistance and secretions. Atropine should be given before mechanical 
ventilation is instituted.
3. Antidotal therapy (see Table 33-4):
a. Atropine: Generally the preferred anticholinergic agent of choice 
for treating acute nerve agent poisoning. Atropine rapidly reverses 
cholinergic overload at muscarinic synapses but has little effect at 
nicotinic synapses. Thus, atropine can rapidly treat the life-threat-
ening respiratory effects of nerve agents but will probably not help 
neuromuscular effects. The field loading dose is 2–6 mg IM, with 
repeat doses given every 5–10 min until breathing and secretions 
improve. In the mildly affected pt with miosis and no systemic 
symptoms, atropine or homoatropine eye drops may suffice.
b. Oxime therapy: Oximes are nucleophiles that help restore normal 
enzyme function by reactivating the cholinesterase whose active 
site has been occupied and bound by the nerve agent. The oxime 
available in the United States is 2-pralidoxime chloride (2-PAM Cl). 
Treatment with 2-PAM may cause blood pressure elevation.
c. Anticonvulsant: Seizures caused by nerve agents do not respond 
to the usual anticonvulsants such as phenytoin, phenobarbital, 
carbamazepine, valproate, and lamotrigine. The only class of drugs 
known to have efficacy in treating nerve agent–induced seizures 
are the benzodiazepines. Diazepam is the only benzodiazepine 
approved by the U.S. Food and Drug Administration for the 
treatment of seizures (although other benzodiazepines have been 
shown to work well in animal models of nerve agent–induced 
seizures).
TABLE 33-4  ANTIDOTE RECOMMENDATIONS FOLLOWING EXPOSURE TO NERVE AGENTS
Antidotes
Patient Age
Mild/Moderate Effectsa
Severe Effectsb
Other Treatment
Infants
(0–2 yrs)
Atropine: 0.05 mg/kg IM, or
0.02 mg/kg IV; and
2-PAM chloride: 15 mg/kg 
IM or IV slowly
Atropine: 0.1 mg/kg IM, or 0.02 mg/kg IV; 
and
2-PAM chloride: 25 mg/kg IM, or
15 mg/kg IV slowly
Assisted ventilation after antidotes for severe exposure.
Child
(2–10 yrs)
Atropine: 1 mg IM, or
0.02 mg/kg IV; and 2-PAM chloridec:
15 mg/kg IM or IV slowly
Atropine: 2 mg IM, or 0.02 mg/kg IV; 
and 2-PAM chloridec: 25 mg/kg IM, or
15 mg/kg IV slowly
Repeat atropine (2 mg IM, or 1 mg IM for infants) at 5- to 
10-min intervals until secretions have diminished and 
breathing is comfortable or airway resistance has returned to 
near normal.
Adolescent
(>10 yrs)
Atropine: 2 mg IM, or 0.02 mg/kg 
IV; and 2-PAM chloridec: 15 mg/kg 
IM or IV slowly
Atropine: 4 mg IM, or 0.02 mg/kg IV; 
and 2-PAM chloridec: 25 mg/kg IM, or
15 mg/kg IV slowly
Adult
Atropine: 2–4 mg IM or IV; and
2-PAM chloride: 600 mg IM, or
15 mg/kg IV slowly
Atropine: 6 mg IM; and
2-PAM chloride: 1800 mg IM, or
15 mg/kg IV slowly
Phentolamine for 2-PAM-induced hypertension: (5 mg IV for 
adults; 1 mg IV for children).
Diazepam for convulsions: (0.2–0.5 mg IV for infants <5 years: 
1 mg IV for children >5 years; 5 mg IV for adults).
Elderly, frail
Atropine: 1 mg IM; and 2-PAM 
chloride: 10 mg/kg IM, or
5–10 mg/kg IV slowly
Atropine: 2–4 mg IM; and 2-PAM chloride: 
25 mg/kg IM, or 5–10 mg/kg IV slowly
aMild/moderate effects include localized sweating, muscle fasciculations, nausea, vomiting, weakness, dyspnea.
cIf calculated dose exceeds the adult IM dose, adjust accordingly.
Source: State of New York, Department of Health.
bSevere effects include unconsciousness, convulsions, apnea, flaccid paralysis.
Note: 2-PAM chloride is pralidoxime chloride or protopam chloride.
203
SECTION 2
204
Medical Emergencies
RADIATION BIOTERRORISM
Nuclear or radiation-related devices represent a third category of weapon 
that could be used in a terrorism attack. There are two major types of attacks 
that could occur. The first is the use of radiologic dispersal devices that 
cause the dispersal of radioactive material without detonation of a nuclear 
explosion. Such devices could use conventional explosives to disperse radio-
nuclides. The second, and less probable, scenario would be the use of actual 
nuclear weapons by terrorists against a civilian target. In addition to weap-
onization, detrimental human exposure has also resulted from unintentional 
breaches in radiation containment. The consequences of radiation sickness 
remain the same for accidental exposure as they do for deliberate release. 
� TYPES OF RADIATION
Alpha radiation consists of heavy, positively charged particles containing 
two protons and two neutrons. Due to their large size, alpha particles have 
limited penetrating power. Cloth and human skin can usually prevent alpha 
particles from penetrating into the body. If alpha particles are internalized, 
they can cause significant cellular damage.
Beta radiation consists of electrons and can travel only short distances in tis-
sue. Plastic layers and clothing can stop most beta particles. Higher energy beta 
particles can cause injury to the basal stratum of skin similar to a thermal burn.
Gamma radiation and x-rays are forms of electromagnetic radiation 
discharged from the atomic nucleus. Sometimes referred to as penetrating 
radiation, both gamma and x-rays easily penetrate matter and are the prin-
ciple type of radiation to cause whole-body exposure (see below).
Neutron particles are heavy and uncharged; often emitted during a 
nuclear detonation. Their ability to penetrate tissues is variable, depending 
upon their energy. They are less likely to be generated in various scenarios 
of radiation bioterrorism.
The commonly used units of radiation are the rad and the gray. The rad is 
the energy deposited within living matter and is equal to 100 ergs/g of tissue. 
The rad has been replaced by the SI unit of the gray (Gy). 100 rad = 1 Gy.
� TYPES OF EXPOSURE
Whole-body exposure represents deposition of radiation energy over the 
entire body. Alpha and beta particles have limited penetration power and 
do not cause significant whole-body exposure unless they are internal-
ized in large amounts. Whole-body exposure from gamma rays, x-rays, or 
high-energy neutron particles can penetrate the body, causing damage to 
multiple tissues and organs.
External contamination results from fallout of radioactive particles landing 
on the body surface, clothing, and hair. This is the dominant form of contami-
nation likely to occur in a terrorist strike that utilizes a dispersal device. The 
most likely contaminants would emit alpha and beta radiation. Alpha particles 
do not penetrate the skin and thus would produce minimal systemic damage. 
Beta emitters can cause significant cutaneous burns. Gamma emitters not 
only cause cutaneous burns but can also cause significant internal damage.
Internal contamination will occur when radioactive material is inhaled, 
is ingested, or is able to enter the body via a disruption in the skin. The 
CHAPTER 33 
205
Bioterrorism
respiratory tract is the main portal of entrance for internal contamination, 
and the lung is the organ at greatest risk. Radioactive material entering the 
GI tract will be absorbed according to its chemical structure and solubility. 
Penetration through the skin usually occurs when wounds or burns have 
disrupted the cutaneous barrier. Absorbed radioactive materials will travel 
throughout the body. Liver, kidney, adipose tissue, and bone tend to bind 
and retain radioactive material more than do other tissues.
Localized exposure results from close contact between highly radioactive 
material and a part of the body, resulting in discrete damage to the skin and 
deeper structures.
� ACUTE RADIATION SICKNESS
Radiation interactions with atoms can result in ionization and free radical 
formation that damages tissue by disrupting chemical bonds and molecular 
structures in the cell, including DNA. Radiation can lead to cell death; cells 
that recover may have DNA mutations that pose a higher risk for malignant 
transformation. Cell sensitivity to radiation damage increases as replication 
rate increases. Bone marrow and mucosal surfaces in the GI tract have high 
mitotic activity and thus are significantly more prone to radiation damage 
than slowly dividing tissues such as bone and muscle. Acute radiation sick-
ness (ARS) can develop following exposure of all or most of the human body 
to ionizing radiation. The clinical manifestations of ARS reflect the dose and 
type of radiation as well as the parts of the body that are exposed.
Clinical Features 
ARS produces signs and symptoms related to damage of three major organ 
systems: GI tract, bone marrow, and neurovascular. The type and dose of 
radiation and the part of the body exposed will determine the dominant 
clinical picture.
• There are four major stages of ARS:
1. Prodrome occurs between hours to 4 days after exposure and 
lasts from hours to days. Manifestations include nausea, vomiting, 
anorexia, and diarrhea.
2. The latent stage follows the prodrome and is associated with minimal 
or no symptoms. It most commonly lasts up to 2 weeks, but can last as 
long as 6 weeks.
3. Illness follows the latent stage.
4. Death or recovery is the final stage of ARS.
• The higher the radiation dose, the shorter and more severe the stage.
• At low radiation doses (0.7–4 Gy), bone marrow suppression occurs and 
constitutes the main illness. The pt may develop bleeding or infection 
secondary to thrombocytopenia and leukopenia. The bone marrow will 
generally recover in most pts. Care is supportive (transfusion, antibiotics, 
colony-stimulating factors).
• With exposure to 6–8 Gy, the clinical picture is more complicated; the 
bone marrow may not recover and death will ensue. Damage to the GI 
mucosa producing diarrhea, hemorrhage, sepsis, fluid and electrolyte 
imbalance may occur and complicate the clinical picture.
SECTION 2
206
Medical Emergencies
• Whole-body exposure to >10 Gy is usually fatal. In addition to severe 
bone marrow and GI tract damage, a neurovascular syndrome charac-
terized by vascular collapse, seizures, and death may occur (especially at 
doses >20 Gy).
Acute Radiation Sickness
TREATMENT
Treatment of ARS is largely supportive (Fig. 33-1).
1. Persons contaminated either externally or internally should be decon-
taminated as soon as possible. Contaminated clothes should be removed; 
showering or washing the entire skin and hair is very important. A 
radiation detector should be used to check for residual contamination. 
Decontamination of medical personnel should occur following emer-
gency treatment and decontamination of the pt.
2. Treatment for the hematopoietic system includes appropriate ther-
apy for neutropenia and infection, transfusion of blood products as 
needed, and hematopoietic growth factors. The value of bone marrow 
transplantation in this situation is unknown.
Management
   • Treat trauma
   • Antiemetics
   • Consider initial viral prophylaxis
   • Supportive care in reverse isolation environment
   • Consider colony stimulating factors, stem cell
      transfusion, etc.
   • Note areas of erythema, fever, weight loss, mucositis
   • Psychological support
   • If needed—treatment of internal contamination
   • If needed—antibiotics
Tests
   • Frequent CBC with differential
   • Consider tissue, blood typing (HLA)
   • Chromosomal analysis
   • Biologic dosimetry
Management
   • Treat trauma
   • Close observation
   • Outpatient management
   • Home care instructions
   • If needed—treatment of
     internal contamination
Tests
   • Frequent CBC with
     differential and platelets
Radiation Dose
< 2 Gy
> 2 Gy
Gastrointestinal
syndrome (> 6 Gy) 
Cardiovascular and
neurovascular
syndrome (> 20 Gy) 
Hematopoietic
syndrome
Mainly mild
prodrome
ALGORITHM/GENERAL GUIDELINES
FIGURE 33-1 General guidelines for treatment of radiation casualties. CBC, complete 
blood count.
CHAPTER 33 
207
Bioterrorism
3. Partial or total parenteral nutrition is appropriate supportive therapy 
for pts with significant injury to the GI mucosa.
4. Treatment of internal radionuclide contamination is aimed at reduc-
ing absorption and enhancing elimination of the ingested material 
(Table 223-2, p. 1794, HPIM-18).
a. Clearance of the GI tract may be achieved by gastric lavage, emetics, or 
purgatives, laxatives, ion exchange resins, and aluminum-containing 
antacids.
b. Administration of blocking agents is aimed at preventing the 
entrance of radioactive materials into tissues (e.g., potassium iodide, 
which blocks the uptake of radioactive iodine by the thyroid).
c. Diluting agents decrease the absorption of the radionuclide (e.g., water 
in the treatment of tritium contamination).
d. Mobilizing agents are most effective when given immediately; 
however, they may still be effective for up to 2 weeks following 
exposure. Examples include antithyroid drugs, glucocorticoids, 
ammonium chloride, diuretics, expectorants, and inhalants. All of 
these should induce the release of radionuclides from tissues.
e. Chelating agents bind many radioactive materials, after which the 
complexes are excreted from the body.
For a more detailed discussion, see Lane HC, Fauci AS: 
Microbial Bioterrorism, Chap. 221, p. 1768; Hurst CG, 
Newmark J, Romano JA: Chemical Terrorism, Chap. 222, 
p. 1779; and Tochner ZA, Glatstein E: Radiation Terrorism, 
Chap. 223, p. 1788, in HPIM-18.
This page intentionally left blank 
209
CHAPTER 34
Fever, Hyperthermia, 
and Rash
� DEFINITIONS 
• Temperature: The hypothalamic thermoregulatory center balances excess 
heat production from metabolic activity in muscle and liver with heat 
dissipation from the skin and lungs to maintain a normal body tem-
perature of 36.8° ± 0.4°C (98.2° ± 0.7°F), with diurnal variation (lower in 
a.m., higher in p.m.).
• Fever: an elevation of body temperature (>37.2°C/98.9°F in the morning 
and >37.7°C/99.9°F in the evening) in conjunction with an increase in 
the hypothalamic set point 
• Fever of unknown origin (FUO): generally refers to temperatures >38.3°C 
(>101°F) on several occasions over a defined period, with unrevealing 
investigations into its cause. FUO can be classified further into several 
categories:
 
–  Classic FUO: fever lasting >3 weeks where 3 outpt visits, 3 days in the 
hospital, or 1 week of “intelligent and invasive” ambulatory investiga-
tion does not elucidate a cause
 
–  Nosocomial FUO: at least 3 days of investigation and 2 days of culture 
incubation failing to elucidate a cause of fever in a hospitalized pt with 
no infection on admission
 
–  Neutropenic FUO: at least 3 days of investigation and 2 days of cul-
ture incubation failing to elucidate a cause of fever in a pt whose 
neutrophil count is <500/μL or is expected to fall to that level within 
1–2 days
 
–  HIV-associated FUO: fever in an HIV-infected pt, lasting >4 weeks for 
outpatients or >3 days for hospitalized pts, where appropriate inves-
tigation (including 2 days’ incubation of cultures) does not reveal a 
cause
• Hyperpyrexia: temperatures >41.5°C (>106.7°F) that can occur with 
severe infections but more commonly occur with CNS hemorrhages 
• Hyperthermia: an uncontrolled increase in body temperature that 
exceeds the body’s ability to lose heat without a change in the 
hypothalamic set point. Hyperthermia does not involve pyrogenic 
molecules.
• Pyrogen: any fever-causing substance, including exogenous pyrogens 
(e.g., microbial toxins, lipopolysaccharide, superantigens) and pyrogenic 
cytokines (e.g., IL-1, IL-6, TNF)
SECTION 3
Common Patient Presentations
SECTION 3
210
Common Patient Presentations
FEVER
• Pathogenesis: The hypothalamic set point increases, causing peripheral 
vasoconstriction (i.e., heat conservation). The pt feels cold as a result of 
blood shunting to the internal organs. Mechanisms of heat production 
(e.g., shivering, increased hepatic thermogenesis) help to raise the body 
temperature to the new set point. Increases in peripheral prostaglan-
din E2 account for the nonspecific myalgias and arthralgias that often 
accompany fever. When the set point is lowered again by resolution or 
treatment of fever, processes of heat loss (e.g., peripheral vasodilation 
and sweating) commence.
• Etiology Most fevers are associated with self-limited infections (usually 
viral) and have causes that are easily identified.
Fever
APPROACH TO THE
PATIENT
• History: A meticulous history is essential, with particular attention 
to the chronology of events (e.g., in the case of rash: the site of onset 
and the direction and rate of spread; see below) and the relation of 
symptoms to medications, pet exposure, sick contacts, sexual contacts, 
travel, trauma, and the presence of prosthetic materials. 
• Physical examination: A thorough physical examination should 
be performed. A consistent site for taking temperatures should 
be used. Temperature–pulse dissociations (relative bradycardia) 
should be noted, if present (sometimes present, for example, with 
typhoid fever, brucellosis, leptospirosis, factitious fever). Close 
attention should be paid to any rash, with precise definition of its 
salient features.
1. Lesion type (e.g., macule, papule, nodule, vesicle, pustule, purpura, 
ulcer; see Chap. 65 for details), configuration (e.g., annular or tar-
get), arrangement, distribution (e.g., central or peripheral)
2. Classification of rash
a. Centrally distributed maculopapular eruptions (e.g., viral exan-
thems, exanthematous drug-induced eruptions)
b. Peripheral eruptions (e.g., Rocky Mountain spotted fever, sec-
ondary syphilis, bacterial endocarditis)
c. Confluent desquamative erythemas (e.g., toxic shock syndrome)
d. Vesiculobullous eruptions (e.g., varicella, primary HSV infec-
tion, ecthyma gangrenosum)
e. Urticaria-like eruptions: in the presence of fever, usually due to 
urticarial vasculitis caused by serum sickness, connective-tissue 
disease, infection (hepatitis B virus, enteroviral, or parasitic 
infection), or malignancy (particularly lymphoma)
f. Nodular eruptions (e.g., disseminated fungal infection, ery-
thema nodosum, Sweet’s syndrome)
g. Purpuric eruptions (e.g., meningococcemia, viral hemorrhagic 
fever, disseminated gonococcemia)
CHAPTER 34
211
Fever, Hyperthermia, and Rash 
h. Eruptions with ulcers or eschars (e.g., rickettsial diseases, tulare-
mia, anthrax)
• Laboratory tests: CBC with differential, ESR, and C-reactive protein; 
other tests as indicated by history and physical exam
Fever
TREATMENT
• The use of antipyretics is not contraindicated in common viral or bac-
terial infections and can relieve symptoms without slowing resolution 
of infection. Withholding of antipyretics may be useful, however, in 
evaluating the effectiveness of a particular antibiotic or in diagnosing 
conditions with temperature–pulse dissociations or relapsing fevers 
(e.g., infection with Plasmodium or Borrelia species).
• Treatment of fever in pts with preexisting impairment of cardiac, pul-
monary, or CNS function is recommended to reduce oxygen demand. 
• Aspirin, NSAIDs, and glucocorticoids are effective antipyretics. 
Acetaminophen is preferred because it does not mask signs of inflam-
mation, does not impair platelet function, and is not associated with 
Reye’s syndrome.
• Hyperpyretic pts should be treated with cooling blankets in addition 
to oral antipyretics.
FEVER OF UNKNOWN ORIGIN
• Etiology: The likely etiologies differ with the category of FUO. 
 
– Classic FUO: Etiologies to consider include:
 
•  Infection—e.g., extrapulmonary tuberculosis; EBV, CMV, or HIV 
infection; occult abscesses; endocarditis; fungal disease. Infections 
remain a leading diagnosable cause of FUO, accounting for ~25% of 
cases in recent studies.
 
•  Neoplasm—e.g., colon cancer
 
•  Miscellaneous noninfectious inflammatory diseases—e.g., systemic 
rheumatologic disease, vasculitis, granulomatous disease. In pts >50 
years old, giant-cell arteritis accounts for 15–20% of FUO cases.
 
•  Miscellaneous diseases—e.g., pulmonary embolism, hereditary 
fever syndromes, drug fever, factitious fevers
 
–  Nosocomial FUO: More than 50% of cases are due to infection 
(e.g., infected foreign bodies or catheters, Clostridium difficile colitis, 
sinusitis). Noninfectious causes (e.g., drug fever, pulmonary embolism, 
acalculous cholecystitis) account for ~25% of cases.
 
–  Neutropenic FUO: More than 50–60% of pts with febrile neutropenia 
are infected, and 20% are bacteremic. Candida and Aspergillus infec-
tions are common.
 
–  HIV-associated FUO: More than 80% of pts are infected, with the 
specific infectious etiology dependent on the extent of immunosup-
pression and the geographic region. Drug fever and lymphoma are 
also possible etiologies.
SECTION 3
212
Common Patient Presentations
FUO
APPROACH TO THE
PATIENT
The workup must consider the pt’s country of origin, recent and remote 
travel, environmental exposures associated with hobbies, and pets. An 
approach to diagnosis of FUO is illustrated in Fig. 34-1. 
+
–
Laboratory Testing
Physical exam
Directed exam
CT of chest, abdomen, pelvis with
IV or PO contrast; colonoscopy
+
–
Potentially diagnostic cluesa
No potentially diagnostic cluea
+
–
Needle biopsyb, invasive testingc
No diagnosis
Steroids
Empirical therapyd
Colchicine, NSAIDs
Anti-TB therapy,
antimicrobial
therapy
Watchful waiting
Diagnosis
Specific therapy
Fever > 38°C (100.4°F) x 3 weeks; 1 week of “intelligent and invasive investigation”
CBC, Diff, smear, ESR, CRP, urinalysis, liver function tests, muscle enzymes, VDRL,
HIV, CMV, EBV, ANA, RF, SPEP, PPD, control skin tests, creatinine, electrolytes, Ca,
Fe, transferrin, TIBC, vitamin B12; acute/convalescent serum set aside
Cultures: Blood, urine, sputum, fluids as appropriate
Repeat history
67Ga scan, 111In PMN scan, FDG PET scan
a“Potentially diagnostic clues,” as outlined by de Kleijn and colleagues (1997, Part II), may be key findings in 
the history, localizing signs, or key symptoms. bNeedle biopsy of liver as well as any other tissue indicated 
by “potentially diagnostic clues.” cInvasive testing could involve laparoscopy. dEmpirical therapy is a last 
resort, given the good prognosis of most patients with FUO persisting without a diagnosis.
FIGURE 34-1 Approach to the patient with classic FUO. ANA, antinuclear antibody; CBC, com-
plete blood count; CMV, cytomegalovirus; CRP, C-reactive protein; CT, computed tomography; 
Diff, differential; EBV, Epstein-Barr virus; ESR, erythrocyte sedimentation rate; FDG, fluorodeoxy-
glucose F18; NSAIDs, nonsteroidal anti-inflammatory drugs; PET, positron emission tomography; 
PMN, polymorphonuclear leukocyte; PPD, purified protein derivative; RF, rheumatoid factor; 
SPEP, serum protein electrophoresis; TB, tuberculosis; TIBC, total iron-binding capacity; VDRL, 
Venereal Disease Research Laboratory test.
CHAPTER 34
213
Fever, Hyperthermia, and Rash 
FUO
TREATMENT
The emphasis in pts with classic FUO is on continued observation and 
examination, with the avoidance of “shotgun” empirical therapy. 
• Vital-sign instability, neutropenia, and immunosuppressive conditions 
may prompt earlier empirical anti-infective therapies.
• The use of glucocorticoids and NSAIDs should be avoided unless 
infection has been largely ruled out and unless inflammatory disease 
is both probable and debilitating or threatening.
Prognosis: When no underlying source of FUO is identified after pro-
longed observation (>6 months), the prognosis is generally good. 
HYPERTHERMIA
• Etiology: Exogenous heat exposure (e.g., heat stroke) and endogenous 
heat production (e.g., drug-induced hyperthermia, malignant hyperther-
mia) are two mechanisms by which hyperthermia can result in danger-
ously high internal temperatures.
 
–  Heat stroke: thermoregulatory failure in association with a warm envi-
ronment; can be categorized as exertional (e.g., due to exercise in high 
heat or humidity) or nonexertional (typically occurring in either very 
young or elderly individuals during heat waves)
 
–  Drug-induced hyperthermia: caused by drugs such as monoamine 
oxidase inhibitors (MAOIs), tricyclic antidepressants, amphetamines, 
and cocaine and other illicit agents
 
–  Malignant hyperthermia: hyperthermic and systemic response (e.g., 
muscle rigidity, rhabdomyolysis, cardiovascular instability) in pts with 
a genetic abnormality that causes a rapid increase in intracellular cal-
cium in response to inhalational anesthetics or succinylcholine. This 
rare condition is often fatal.
 
–  Neuroleptic malignant syndrome: caused by use of neuroleptic agents 
(e.g., haloperidol) or withdrawal of dopaminergic drugs and char-
acterized by “lead-pipe” muscle rigidity, extrapyramidal side effects, 
autonomic dysregulation, and hyperthermia
 
–  Serotonin syndrome: caused by selective serotonin reuptake inhibitors 
(SSRIs), MAOIs, and other serotonergic drugs. Serotonin syndrome can 
be distinguished clinically from neuroleptic malignant syndrome by the 
presence of diarrhea, tremor, and myoclonus rather than lead-pipe rigidity.
• Clinical Features: high core temperature in association with an appro-
priate history (heat exposure, certain drug treatments) and dry skin, 
hallucinations, delirium, pupil dilation, muscle rigidity, and/or elevated 
levels of creatine phosphokinase 
• Diagnosis: It can be difficult to distinguish fever from hyperthermia. 
The clinical history is often most useful (e.g., a history of heat expo-
sure or treatment with drugs that interfere with thermoregulation).
 
–  Hyperthermic pts have hot, dry skin; antipyretic agents do not lower 
the body temperature. 
SECTION 3
214
Common Patient Presentations
 
–  Febrile pts can have cold skin (as a result of vasoconstriction) or hot, 
moist skin; antipyretics usually result in some lowering of the body 
temperature.
Hyperthermia
TREATMENT
• Physical cooling by external physical means (e.g., sponging, fans, cool-
ing blankets, ice baths) or internal cooling (e.g., gastric or peritoneal 
lavage with iced saline). In extreme cases, hemodialysis or cardiopul-
monary bypass with cooling of blood may be necessary.
• IV fluids, given the risk of dehydration
• Pharmacologic agents can be used, as appropriate.
 
–  Malignant hyperthermia, neuroleptic malignant syndrome, and 
drug-induced hyperthermia should be treated with dantrolene 
(1–2.5 mg/kg IV q6h for at least 24–48 h); dantrolene may also be 
helpful in serotonin syndrome and thyrotoxicosis.
 
–  Neuroleptic malignant syndrome also may be treated with 
bromocriptine, levodopa, amantadine, or nifedipine or by induc-
tion of muscle paralysis with curare and pancuronium.
 
–  Tricyclic antidepressant overdose may be treated with physostigmine.
For a more detailed discussion, see Kaye KM, Kaye ET: Atlas 
of Rashes Associated With Fever, Chap. e7 and Dinarello CA, 
Porat R: Fever and Hyperthermia, Chap. 16, p. 143; Kaye ET, 
Kaye KM: Fever and Rash, Chap. 17, p. 148; and Gelfand JA, 
Callahan MV: Fever of Unknown Origin, Chap. 18, p. 158, in 
HPIM-18.
CHAPTER 35
Generalized Fatigue
Fatigue is one of the most common complaints related by pts. It usually refers 
to nonspecific sense of a low energy level, or the feeling that near exhaus-
tion is reached after relatively little exertion. Fatigue should be distinguished 
from true neurologic weakness, which describes a reduction in the normal 
power of one or more muscles (Chap. 59). It is not uncommon for pts, 
especially the elderly, to present with generalized failure to thrive, which 
may include components of fatigue and weakness, depending on the cause.
� CLINICAL MANIFESTATIONS
Because the causes of generalized fatigue are numerous, a thorough his-
tory, review of systems (ROS), and physical examination are paramount 
to narrow the focus to likely causes. The history and ROS should focus on 
CHAPTER 35
215
Generalized Fatigue
the temporal onset of fatigue and its progression. Has it lasted days, weeks, 
or months? Activities of daily living, exercise, eating habits/appetite, sexual 
practices, and sleep habits should be reviewed. Features of depression or 
dementia should be sought. Travel history and possible exposures to infec-
tious agents should be reviewed, along with the medication list. The ROS 
may elicit important clues as to organ system involvement. The past medical 
history may elucidate potential precursors to the current presentation, such 
as previous malignancy or cardiac problems. The physical exam should 
specifically assess weight and nutritional status, lymphadenopathy, hepato-
splenomegaly, abdominal masses, pallor, rash, heart failure, new murmurs, 
painful joints or trigger points, and evidence of weakness or neurologic 
abnormalities. A finding of true weakness or paralysis should prompt con-
sideration of neurologic disorders (Chap. 59).
� DIFFERENTIAL DIAGNOSIS
Determining the cause of fatigue can be one of the most challenging 
diagnostic problems in medicine because the differential diagnosis is very 
broad, including infection, malignancy, cardiac disease, endocrine disor-
ders, neurologic disease, depression, or serious abnormalities of virtually 
any organ system, as well as side effects of many medications (Table 35-1). 
Symptoms of fever and weight loss will focus attention on infectious causes, 
whereas symptoms of progressive dyspnea might point toward cardiac, 
pulmonary, or renal causes. A presentation that includes arthralgia suggests 
the possibility of a rheumatologic disorder. A previous malignancy, thought 
to be cured or in remission, may have recurred or metastasized widely. A 
previous history of valvular heart disease or cardiomyopathy may identify 
a condition that has decompensated. Treatment for Graves’ disease may 
have resulted in hypothyroidism. Changes in medication should always be 
pursued, whether discontinued or recently started. Almost any new medi-
cation has the potential to cause fatigue. However, a temporal association 
with a new medication should not eliminate other causes, as many pts may 
have received new medications in an effort to address their complaints. 
Medications and their dosages should be carefully assessed, especially in 
elderly pts, in whom polypharmacy and inappropriate or misunderstood 
dosing is a frequent cause of fatigue. The time course for presentation is 
also valuable. Indolent presentations over months to years are more likely 
to be associated with slowly progressive organ failure or endocrinopathies, 
whereas a more rapid course over weeks to months suggests infection or 
malignancy.
� LABORATORY TESTING
Laboratory testing and imaging should be guided by the history and 
physical exam. However, a CBC with differential, electrolytes, BUN, 
creatinine, glucose, calcium, and LFTs are useful in most pts with undif-
ferentiated fatigue, as these tests will rule out many causes and may 
provide clues to unsuspected disorders. Similarly, a CXR is useful to 
evaluate many possible disorders rapidly, including heart failure, pulmo-
nary disease, or occult malignancy that may be detected in the lungs or 
bony structures. Subsequent testing should be based on the initial results 
and clinical assessment of the likely differential diagnoses. For example, 
SECTION 3
216
Common Patient Presentations
a finding of anemia would dictate the need to assess whether it has 
features of iron deficiency or hemolysis, thereby narrowing potential 
causes. Hyponatremia might be caused by SIADH, hypothyroidism, adre-
nal insufficiency, or medications or by underlying cardiac, pulmonary, 
liver, or renal dysfunction. An elevated WBC count would raise the pos-
sibility of infection or malignancy. Thus, the approach is generally one of 
gathering information in a serial but cost-effective manner to narrow the 
differential diagnosis progressively.
TABLE 35-1 POTENTIAL CAUSES OF GENERALIZED FATIGUE
Disease Category
Examples
Infection
HIV, TB, Lyme disease, endocarditis, 
hepatitis, sinusitis, fungal, Epstein-Barr 
virus (EBV), malaria (chronic phase)
Inflammatory disease
RA, polymyalgia rheumatica, chronic 
fatigue syndrome, fibromyalgia, sarcoidosis
Cancer
Lung, GI, breast, prostate, leukemia, 
lymphoma, metastases
Psychiatric
Depression, alcoholism, chronic anxiety
Metabolic
Hypothyroidism, hyperthyroidism, diabetes 
mellitus, Addison’s disease, hyperparathy-
roidism, hypogonadism, hypopituitarism 
(TSH, ACTH, growth hormone deficiency), 
McArdle’s disease
Electrolyte imbalance
Hypercalcemia, hypokalemia, hyponatre-
mia, hypomagnesemia,
Nutrition, vitamin deficiency
Starvation, obesity, iron deficiency, 
vitamin B12, folic acid deficiency, vitamin 
C deficiency (scurvy), thiamine deficiency 
(beriberi)
Neurologic
Multiple sclerosis, myasthenia gravis, 
dementia
Cardiac
Heart failure, CAD, valvular disease, 
cardiomyopathy
Pulmonary
COPD, pulmonary hypertension, chronic 
pulmonary emboli, sarcoidosis
Sleep disturbances
Sleep apnea, insomnia, restless leg 
syndrome
Gastrointestinal
Celiac disease, Crohn’s, ulcerative colitis, 
chronic hepatitis, cirrhosis
Hematologic
Anemia
Renal
Renal failure
Medication
Sedatives, antihistamines, narcotics, β
blockers, and many other medications
CHAPTER 35
217
Generalized Fatigue
Generalized Fatigue
TREATMENT
Treatment should be based on the diagnosis, if known. Many conditions, 
such as metabolic, nutritional, or endocrine disorders, can be corrected 
quickly by appropriate treatment of the underlying causes. Specific 
treatment can also be initiated for many infections, such as TB, sinus-
itis, or endocarditis. Pts with chronic conditions such as COPD, heart 
failure, renal failure, or liver disease may benefit from interventions 
that enhance organ function or correct associated metabolic problems, 
and it may be possible to gradually improve physical conditioning. In 
pts with cancer, fatigue may be caused by chemotherapy or radiation 
and may resolve with time; treatment of associated anemia, nutritional 
deficiency, hyponatremia, or hypercalcemia may increase energy levels. 
Replacement therapy in endocrine deficiencies typically results in 
improvement. Treatment of depression or sleep disorders, whether a 
primary cause of fatigue or secondary to a medical disorder, may be ben-
eficial. Withdrawal of medications that potentially contribute to fatigue 
should be considered, recognizing that other medications may need to 
be substituted for the underlying condition. In elderly pts, appropriate 
medication dose adjustments (typically lowering the dose) and restrict-
ing the regimen to only essential drugs may improve fatigue.
CHRONIC FATIGUE SYNDROME
Chronic fatigue syndrome (CFS) is characterized by debilitating fatigue 
and several associated physical, constitutional, and neuropsychological 
complaints. The majority of pts (~75%) are women, generally 30–45 
years old. The CDC has developed diagnostic criteria for CFS based upon 
symptoms and the exclusion of other illnesses (Table 35-2). The cause 
is uncertain, although clinical manifestations often follow an infectious 
illness (Q fever, Lyme disease, mononucleosis or another viral illness). 
Many studies have attempted, without success, to link CFS to infec-
tion with EBV, a retrovirus (including a murine leukemia virus–related 
retrovirus), or an enterovirus. Physical or psychological stress is also 
often identified as a precipitating factor. Depression is present in half to 
two-thirds of pts, and some experts believe that CFS is fundamentally a 
psychiatric disorder.
CFS remains a diagnosis of exclusion, and no laboratory test can establish 
the diagnosis or measure its severity. CFS does not appear to progress but 
typically has a protracted course. The median annual recovery rate is 5% 
(range, 0–31%) with an improvement rate of 39% (range, 8–63%).
The management of CFS commences with acknowledgement by the phy-
sician that the pt’s daily functioning is impaired. The pt should be informed 
of the current understanding of CFS (or lack thereof) and be offered gen-
eral advice about disease management. NSAIDs alleviate headache, diffuse 
pain, and feverishness. Antihistamines or decongestants may be helpful 
for symptoms of rhinitis and sinusitis. Although the pt may be averse to 
psychiatric diagnoses, features of depression and anxiety may justify treat-
ment. Nonsedating antidepressants improve mood and disordered sleep 
SECTION 3
218
Common Patient Presentations
and may attenuate the fatigue. Cognitive behavioral therapy (CBT) and 
graded exercise therapy (GET) have been found to be effective treatment 
strategies in some pts.
TABLE 35-2  CDC CRITERIA FOR DIAGNOSIS OF CHRONIC 
FATIGUE SYNDROME
A case of chronic fatigue syndrome is defined by the presence of:
I.  Clinically evaluated, unexplained, persistent or relapsing fatigue that is of 
new or definite onset; is not the result of ongoing exertion; is not alleviated 
by rest; and results in substantial reduction of previous levels of occupa-
tional, educational, social, or personal activities; and
2.  Four or more of the following symptoms that persist or recur during six or 
more consecutive months of illness and that do not predate the fatigue:
• Impaired memory or concentration
• Sore throat that is frequent or recurring
• Tender cervical or axillary nodes
• Muscle pain
• Multi-joint pain without redness or swelling
• Headaches of a new pattern or severity
• Unrefreshing sleep
• Postexertional malaise lasting ≥ 24 h
Abbreviation: CDC, Centers for Disease Control and Prevention.
Source: www.cdc.gov/cfs/toolkit/
For a more detailed discussion, see Aminoff MJ: Weakness 
and Paralysis, Chap. 22, p. 181; Czeisler CA, Winkelman 
JW, Richardson GS: Sleep Disorders, Chap. 27, p. 213; 
Robertson RG, Jameson LJ: Involuntary Weight Loss, 
Chap. 80, p. 641; Bleijenberg G, van der Meer JWM: 
Chronic Fatigue Syndrome, Chap. 389, p. 3519; Reus VI: 
Mental Disorders, Chap. 391, p. 3529, in HPIM-18. 
CHAPTER 36
Weight Loss
Significant unintentional weight loss in a previously healthy individual 
is often a harbinger of underlying systemic disease. The routine medical 
history should always include inquiry about changes in weight. Rapid fluc-
tuations of weight over days suggest loss or gain of fluid, whereas long-term 
changes usually involve loss of tissue mass. Loss of 5% of body weight over 
6–12 months should prompt further evaluation. Gradual weight loss is 
CHAPTER 36
219
Weight Loss
physiologic in persons over age 80, but this demographic group also has a 
high risk for malignancy or other serious illness.
� ETIOLOGY
The principal causes of involuntary weight loss can be assigned to four 
categories: (1) malignant neoplasms, (2) chronic inflammatory or infectious 
diseases, (3) metabolic disorders, or (4) psychiatric disorders (Table 36-1). 
In older persons the most common causes of weight loss are depression, 
TABLE 36-1 CAUSES OF WEIGHT LOSS
Cancer
Endocrine and metabolic causes
Hyperthyroidism
Diabetes mellitus
Pheochromocytoma
Adrenal insufficiency
Gastrointestinal disorders
Malabsorption
Obstruction
Peptic ulcer
Inflammatory bowel disease
Pancreatitis
Pernicious anemia
Cardiac disorders
Chronic ischemia
Chronic congestive heart failure
Respiratory disorders
Emphysema
Chronic obstructive pulmonary
disease
Renal insufficiency
Rheumatologic disease
Infections
HIV
Tuberculosis
Parasitic infection
Subacute bacterial endocarditis
Medications
Sedatives
Antibiotics
Nonsteroidal anti-inflammatory
drugs
Serotonin reuptake inhibitors
Metformin
Levodopa
ACE inhibitors
Other drugs
Disorders of the mouth and teeth
Caries
Dysgeusia
Age-related factors 
Physiologic changes
Decreased taste and smell
Functional disabilities
Neurologic causes
Stroke
Parkinson’s disease
Neuromuscular disorders
Dementia
Social causes
Isolation
Economic hardship
Psychiatric and behavioral causes
Depression
Anxiety
Bereavement
Alcoholism
Eating disorders
Increased activity or exercise
Idiopathic
SECTION 3
220
Common Patient Presentations
TABLE 36-2  SCREENING TESTS FOR EVALUATION OF INVOLUNTARY 
WEIGHT LOSS
Initial testing
 CBC
Electrolytes, calcium, glucose
 Renal and liver function tests
 Urinalysis
 Thyroid-stimulating hormone
 Chest x-ray
 Recommended cancer screening
Additional testing
HIV test
Upper and/or lower gastrointestinal 
endoscopy
Abdominal CT scan or MRI
Chest CT scan
cancer, and benign gastrointestinal disease. Lung and GI cancers are the 
most common malignancies in pts presenting with weight loss. In younger 
individuals, diabetes mellitus, hyperthyroidism, anorexia nervosa, and 
infection, especially with HIV, should be considered.
� CLINICAL FEATURES
Before extensive evaluation is undertaken, it is important to confirm that 
weight loss has occurred (up to 50% of claims of weight loss cannot be sub-
stantiated). In the absence of documentation, changes in belt notch size or 
the fit of clothing may help to determine loss of weight.
The history should include questions about fever, pain, shortness of 
breath or cough, palpitations, and evidence of neurologic disease. A 
history of GI symptoms should be obtained, including difficulty eating, 
dysgeusia, dysphagia, anorexia, nausea, and change in bowel habits. Travel 
history, use of cigarettes, alcohol, and all medications should be reviewed, 
and pts should be questioned about previous illness or surgery as well as 
diseases in family members. Risk factors for HIV should be assessed. Signs 
of depression, evidence of dementia, and social factors, including isola-
tion, loneliness, and financial issues that might affect food intake, should 
be considered.
Physical examination should begin with weight determination and docu-
mentation of vital signs. The skin should be examined for pallor, jaundice, 
turgor, surgical scars, and stigmata of systemic disease. Evaluation for oral 
thrush, dental disease, thyroid gland enlargement, and adenopathy and for 
respiratory, cardiac, or abdominal abnormalities should be performed. All 
men should have a rectal examination, including the prostate; all women 
should have a pelvic examination; and both should have testing of the stool 
for occult blood. Neurologic examination should include mental status 
assessment and screening for depression.
Initial laboratory evaluation is shown in Table 36-2, with appropriate 
treatment based on the underlying cause of the weight loss. If an etiology 
of weight loss is not found, careful clinical follow-up, rather than persistent 
undirected testing, is reasonable. The absence of abnormal laboratory tests 
is a favorable prognostic sign.
CHAPTER 37
221
Chest Pain
For a more detailed discussion, see Robertson RG, Jameson 
JL: Involuntary Weight Loss, Chap. 80, p. 641, in HPIM-18. 
CHAPTER 37
Chest Pain
There is little correlation between the severity of chest pain and the seri-
ousness of its cause. The range of disorders that cause chest discomfort is 
shown in Table 37-1.
Weight Loss
TREATMENT
Treatment of weight loss should be directed at correcting the underlying 
physical cause or social circumstance. In specific situations, nutritional 
supplements and medications (megestrol acetate, dronabinol, or growth 
hormone) may be effective for stimulating appetite or increasing weight.
TABLE 37-1  DIFFERENTIAL DIAGNOSES OF PATIENTS ADMITTED 
TO HOSPITAL WITH ACUTE CHEST PAIN RULED NOT 
MYOCARDIAL INFARCTION 
Diagnosis
Percentage
Gastroesophageal diseasea
42
 Gastroesophageal reflux
 Esophageal motility disorders
 Peptic ulcer
 Gallstones
Ischemic heart disease
31
Chest wall syndromes
28
Pericarditis
4
Pleuritis/pneumonia
2
Pulmonary embolism
2
Lung cancer
1.5
Aortic aneurysm
1
Aortic stenosis
1
Herpes zoster
1
aIn order of frequency.
Source: Fruergaard P et al: Eur Heart J 17:1028, 1996.
SECTION 3
222
Common Patient Presentations
� POTENTIALLY SERIOUS CAUSES
The differential diagnosis of chest pain is shown in Figs. 37-1 and 37-2. It 
is useful to characterize the chest pain as (1) new, acute, and ongoing; (2) 
recurrent, episodic; and (3) persistent, e.g., for days at a time.
Costochondral
or chest wall
pain
Localized; sharp/stabbing or
persistent/dull pain, reproduced
by pressure over the painful area
Likely Etiology
Symptoms and Signs
Cervical or
thoracic spine
disease with
nerve root
compression
Sharp pain, may be in
radicular distribution;
exacerbated by movement
of neck, back
Esophageal or
gastric pain
(Chap. 159)
Associated with dysphagia or
gastric regurgitation; may be
worsened by aspirin/alcohol
ingestion/certain foods/supine
position; often relieved by
antacids
Biliary pain
(Chap. 162)
Intolerance of fatty foods;
right upper quadrant
tenderness also present
Myocardial
ischemia*
(Chap. 130)
Precipitated by exertion or
emotional arousal; ECG
(or Holter monitor) during pain
shows ST segment shifts; pain
relieved quickly ( < 5 min ) by
sublingual TNG
FIGURE 37-1 Differential diagnosis of recurrent chest pain. *If myocardial ischemia 
suspected, also consider aortic valve disease (Chap. 123) and hypertrophic obstruc-
tive cardiomyopathy (Chap. 124) if systolic murmur present.
Description
of pain
Background
history
Key Physical
findings
Consider
Confirmatory
tests
Oppressive,
constrictive,
or squeezing; may
radiate to arm(s),
neck, back
Less severe, similar
pain on exertion; +
coronary risk factors
Diaphoresis, pallor;
S4 common;
S3 less common
"Tearing" or
"ripping"; may
travel from 
anterior chest
to mid-back
Hypertension or
Marfan syndrome
(Chap. 169)
Weak, asymmetric
peripheral pulses;
possible diastolic
murmur of aortic 
insufficiency
(Chap. 123)
• CXR – widened
  mediastinal silhouette
• MRI, CT, or transeso-
  phageal echogram:
  intimal flap visualized
• Aortic angiogram:
  definitive diagnosis
Crushing, sharp,
pleuritic; relieved
by sitting forward
Recent upper respiratory
tract infection, or other
conditions which
predispose to pericarditis
(Chap. 125)
Pericardial friction rub
(usually 3 components,
best heard by sitting
patient forward)
• ECG: diffuse ST
  elevation and PR
  segment depression
• Echogram: pericardial
  effusion often
  visualized
Pleuritic, sharp;
possibly
accompanied by
cough/hemoptysis
Recent surgery
or other
immobilization
Tachypnea;
possible pleural
friction rub
•
   lung scan:  V/Q
  mismatch
• Pulmonary
  angiogram: arterial
  luminal filling defects
• CXR: radiolucency
  within pleural space;
  poss. collapse of
  adjacent lung
  segment; if tension
  pneumothorax,
  mediastinum is
  shifted to opp. side
• CXR:
  pneumo-
  mediastinum
• Esophageal
  endoscopy is
  diagnostic
• Serial ECGs
• Serial cardiac
  markers
  (esp. troponins,CK)
Very sharp,
pleuritic
Recent chest
trauma, or history
of chronic
obstructive lung
disease
Tachypnea;
breath sounds &
hyperresonance
over affected
lung field
Intense substernal
and epigastric;
accompanied
by vomiting ±
hematemesis
Recent recurrent
vomiting/retching
Subcutaneous
emphysema;
audible crepitus
adjacent to
the sternum
Rupture of
esophagus
Acute
pneumothorax
(Chap. 144)
Pulmonary
embolism
(Chap. 142)
Acute pericarditis
(Chap. 125)
Aortic dissection
(Chap. 134)
Acute myocardial
infarction
(Chaps. 128 and 129)
Normal D-dimer makes
diagnosis unlikely
CT angiography or
 . .
•
FIGURE 37-2 Differential diagnosis of acute chest pain.
223
SECTION 3
224
Common Patient Presentations
Myocardial Ischemia Angina Pectoris 
Substernal pressure, squeezing, constriction, with radiation typically to left 
arm; usually on exertion, especially after meals or with emotional arousal. 
Characteristically relieved by rest and nitroglycerin.
Acute Myocardial Infarction (Chaps. 128 and 129)
Similar to angina but usually more severe, of longer duration (≥30 min), 
and not immediately relieved by rest or nitroglycerin. S3 and S4 common.
Pulmonary Embolism (Chap. 142)
May be substernal or lateral, pleuritic in nature, and associated with hemop-
tysis, tachycardia, and hypoxemia.
Aortic Dissection (Chap. 134)
Very severe, in center of chest, a sharp “ripping” quality, radiates to back, 
not affected by changes in position. May be associated with weak or absent 
peripheral pulses.
Mediastinal Emphysema 
Sharp, intense, localized to substernal region; often associated with audible 
crepitus.
Acute Pericarditis (Chap. 125)
Usually steady, crushing, substernal; often has pleuritic component aggravated 
by cough, deep inspiration, supine position, and relieved by sitting upright; 
one-, two-, or three-component pericardial friction rub often audible.
Pleurisy
Due to inflammation; less commonly tumor and pneumothorax. Usually 
unilateral, knifelike, superficial, aggravated by cough and respiration.
� LESS SERIOUS CAUSES
Costochondral Pain 
In anterior chest, usually sharply localized, may be brief and darting or a 
persistent dull ache. Can be reproduced by pressure on costochondral and/
or chondrosternal junctions. In Tietze’s syndrome (costochondritis), joints 
are swollen, red, and tender.
Chest Wall Pain 
Due to strain of muscles or ligaments from excessive exercise or rib fracture 
from trauma; accompanied by local tenderness.
Esophageal Pain 
Deep thoracic discomfort; may be accompanied by dysphagia and regurgitation.
Emotional Disorders 
Prolonged ache or dartlike, brief, flashing pain; associated with fatigue, 
emotional strain.
CHAPTER 38
225
Palpitations
� OTHER CAUSES
(1) Cervical disk disease; (2) osteoarthritis of cervical or thoracic spine; 
(3) abdominal disorders: peptic ulcer, hiatus hernia, pancreatitis, biliary 
colic; (4) tracheobronchitis, pneumonia; (5) diseases of the breast (inflam-
mation, tumor); (6) intercostal neuritis (herpes zoster).
Chest Pain
APPROACH TO THE
PATIENT
A meticulous history of the behavior of pain, what precipitates it and 
what relieves it, aids diagnosis of recurrent chest pain. Fig. 37-2 presents 
clues to diagnosis and workup of acute, life-threatening chest pain.
An ECG is key to the initial evaluation to rapidly distinguish pts with 
acute ST-elevation MI, who typically warrant immediate reperfusion 
therapies (Chap. 128).
For a more detailed discussion, see Lee TH: Chest Discomfort, 
Chap. 12, p. 102, in HPIM-18.
CHAPTER 38
Palpitations
Palpitations represent an intermittent or sustained awareness of the heartbeat, 
often described by the pt as a thumping, pounding, or fluttering sensation in 
the chest. The symptom may reflect a cardiac etiology, an extracardiac cause 
[hyperthyroidism, use of stimulants (e.g., caffeine, cocaine)], or a high cat-
echolamine state (e.g., exercise, anxiety, pheochromocytoma). Contributory 
cardiac dysrhythmias include atrial or ventricular premature beats or, when 
sustained and regular, supraventricular or ventricular tachyarrhythmias 
(Chap. 132). Irregular sustained palpitations are often due to atrial fibrillation. 
Asking the pt to “tap out” the sense of palpitation can help distinguish regular 
from irregular rhythms.
Palpitations
APPROACH TO THE
PATIENT
Palpitations are often benign but may represent an important dysrhyth-
mia if associated with hemodynamic compromise (lightheadedness, 
syncope, angina, dyspnea) or if found in pts with preexisting CAD, 
ventricular dysfunction, hypertrophic cardiomyopathy, aortic stenosis, 
or other valvular disease.
Helpful diagnostic studies include electrocardiography (if symptoms 
present at time of recording), exercise testing (if exertion typically 
SECTION 3
226
Common Patient Presentations
precipitates the sense of palpitation or if underlying CAD is suspected), 
and echocardiography (if structural heart disease is suspected). If symp-
toms are episodic, ambulatory electrocardiographic monitoring can be 
diagnostic, including use of a Holter monitor (24–48 h of monitoring), 
event/loop monitor (for 2–4 weeks), or implantable loop monitor (for 
1–2 years). Helpful laboratory studies may include testing for hypokale-
mia, hypomagnesemia, and/or hyperthyroidism. 
For pts with benign atrial or ventricular premature beats in the 
absence of structural heart disease, therapeutic strategies include reduc-
tion of ethanol and caffeine intake, reassurance, and consideration of 
beta-blocker therapy for symptomatic suppression. Treatment of more 
serious dysrhythmias is presented in Chaps. 131 and 132.
For a more detailed discussion, see Loscalzo J: Palpitations, 
Chap. 37, p. 295, in HPIM-18.
CHAPTER 39
Dyspnea
� DEFINITION
Dyspnea, a subjective experience of uncomfortable breathing, is a symp-
tom that often results from increased work of inhalation and exhala-
tion. Assessment begins by determining the quality and intensity of the 
discomfort. Dyspnea typically results from cardiopulmonary problems 
that cause an increased drive to breathe, an increased work of breath-
ing, and/or stimulation of specific receptors in the heart, lungs, or 
vasculature. 
� CAUSES
Respiratory System Dyspnea
• Airway disease: Asthma and COPD are common causes of dyspnea asso-
ciated with increased work of breathing. Bronchospasm can cause chest 
tightness and hyperventilation. Hypoxemia and hypercapnia can result 
from ventilation-perfusion mismatch. 
• Chest wall disorders: Chest wall stiffness (e.g., kyphoscoliosis) and neu-
romuscular weakness (e.g., myasthenia gravis) cause increased work of 
breathing.
• Lung parenchymal disorders: Interstitial lung diseases (Chap. 143) cause 
reduced lung compliance and increased work of breathing. Ventilation-
perfusion mismatch and pulmonary fibrosis may lead to hypoxemia. 
Stimulation of lung receptors can cause hyperventilation. 
CHAPTER 39
227
Dyspnea
Cardiovascular System Dyspnea
• Left heart disorders: Elevations of left-ventricular end-diastolic and pul-
monary capillary wedge pressures lead to dyspnea related to stimulation of 
pulmonary receptors and hypoxemia from ventilation-perfusion mismatch. 
• Pulmonary vascular disorders: Pulmonary emboli, primary pulmonary 
arterial hypertension, and pulmonary vasculitis stimulate pulmonary 
receptors via increased pulmonary artery pressures. Hyperventilation 
and hypoxemia also may contribute to dyspnea. 
• Pericardial diseases: Constrictive pericarditis and pericardial tamponade 
cause increased intracardiac and pulmonary arterial pressures, leading to 
dyspnea. 
Dyspnea with Normal Respiratory and Cardiovascular Systems
Anemia can cause dyspnea, especially with exertion. Obesity is associated 
with dyspnea due to high cardiac output and impaired ventilatory function. 
Deconditioning may contribute as well. 
Dyspnea (See Fig. 39-1)
APPROACH TO THE
PATIENT
History: Obtain description of discomfort, including the impact of posi-
tion, infections, and environmental exposures. Orthopnea is commonly 
observed in congestive heart failure (CHF). Nocturnal dyspnea is seen 
in CHF and asthma. Intermittent dyspnea suggests myocardial ischemia, 
asthma, or pulmonary embolism. 
Physical examination: Assess increased work of breathing indicated by 
accessory ventilatory muscle use. Determine if chest movement is sym-
metric. Use percussion (dullness or hyperresonance) and auscultation 
(decreased or adventitious breath sounds) to assess the lungs. Cardiac 
exam should note jugular venous distention, heart murmurs, and S3 or 
S4 gallops. Clubbing can relate to interstitial lung disease or lung cancer. 
To evaluate exertional dyspnea, reproduce the dyspnea with observation 
while assessing pulse oximetry. 
Radiographic studies: Chest radiograph should be obtained as initial 
evaluation. Chest CT can be used subsequently to assess lung parenchyma 
(e.g., emphysema or interstitial lung disease) and pulmonary embolism. 
Laboratory studies: ECG should be obtained; echocardiography can assess 
left ventricular dysfunction, pulmonary hypertension, and valvular disease. 
Pulmonary function tests to consider include spirometry, lung volumes, and 
diffusing capacity. Methacholine challenge testing can assess for asthma in 
subjects with normal spirometry. Cardiopulmonary exercise testing can 
determine whether pulmonary or cardiac disease limits exercise capacity. 
Dyspnea
TREATMENT
Ideally, treatment involves correcting the underlying problem that 
caused dyspnea. Supplemental oxygen is required for significant oxygen 
desaturation at rest or with exertion. Pulmonary rehabilitation is help-
ful in COPD.
SECTION 3
228
Common Patient Presentations
Pulmonary Edema
Cardiogenic pulmonary edema results from cardiac abnormalities 
that cause increased pulmonary venous pressure leading to interstitial 
edema; with greater pressures, alveolar edema and pleural effusions 
develop. Symptoms include exertional dyspnea and orthopnea. Physical 
examination can reveal S3 gallop, elevated jugular venous pressure, and 
peripheral edema. Chest radiographs show prominent vascular mark-
ings in the upper lung zones. With increased severity, CXRs demon-
strate perihilar alveolar opacities progressing to diffuse parenchymal 
abnormalities.
Noncardiogenic pulmonary edema results from damage to the pulmonary 
capillary lining. Hypoxemia relates to intrapulmonary shunt; decreased 
ALGORITHM FOR THE EVALUATION OF THE PATIENT WITH DYSPNEA
History
Quality of sensation, timing, positional disposition
Persistent vs intermittent
Physical Exam
General appearance: Speak in full sentences? Accessory muscles? Color?
Vital Signs: Tachypnea? Pulsus paradoxus? Oximetry-evidence of desaturation?
Chest: Wheezes, rales, rhonchi, diminished breath sounds? Hyperinflated?
Cardiac exam: JVP elevated? Precordial impulse? Gallop? Murmur?
Extremities: Edema? Cyanosis?
At this point, diagnosis may be evident—if not, proceed to further evaluation
Chest radiograph
Assess cardiac size, evidence of CHF
Assess for hyperinflation
Assess for pneumonia, interstitial lung disease, pleural effusions
Suspect low cardiac output, 
myocardial ischemia, or 
pulmonary vascular disease
Suspect respiratory pump or gas 
exchange abnormality
Suspect high 
cardiac output
ECG and echocardiogram to 
assess left ventricular function 
and pulmonary artery 
pressure
Pulmonary function testing—if diffusing 
capacity reduced, consider CT 
angiogram to assess for interstitial lung 
disease and pulmonary embolism
Hematocrit, 
thyroid function 
tests
If diagnosis still uncertain, obtain cardiopulmonary exercise test
FIGURE 39-1 An algorithm for the evaluation of the pt with dyspnea. JVP, jugular 
venous pulse; CHF, congestive heart failure; ECG, electrocardiogram. (Adapted from 
RM Schwartzstein, D Feller-Kopman, in Primary Cardiology, 2nd ed. E Braunwald, 
L Goldman (eds): Philadelphia, Saunders, 2003.)
CHAPTER 40
229
Cyanosis
CHAPTER 40
Cyanosis
Bluish discoloration of the skin and/or mucous membranes is usually due to 
elevated quantity of reduced hemoglobin [>40 g/L (>4 g/dL)] in the capil-
lary blood vessels. Findings are most apparent in the lips, nail beds, ears, 
and malar eminences.
� CENTRAL CYANOSIS
Results from arterial desaturation or presence of an abnormal hemoglobin. 
Usually evident when arterial saturation is ≤85%, or ≤75% in dark-skinned 
individuals. Etiologies include:
1. Impaired pulmonary function: Poorly ventilated alveoli or impaired 
oxygen diffusion; most frequent in pneumonia, pulmonary edema, and 
chronic obstructive pulmonary disease (COPD); in COPD with cyanosis, 
polycythemia is often present.
2. Anatomic vascular shunting: Shunting of desaturated venous blood into 
the arterial circulation may result from congenital heart disease or pul-
monary AV fistula.
3. Decreased inspired O2: Cyanosis may develop in ascents to altitudes 
>4000 m (>13,000 ft).
4. Abnormal hemoglobins: Methemoglobinemia, sulfhemoglobinemia, 
and mutant hemoglobins with low oxygen affinity (see Chap. 104, 
HPIM-18).
� PERIPHERAL CYANOSIS
Occurs with normal arterial O2 saturation with increased extraction of O2 
from capillary blood caused by decreased localized blood flow. Contributors 
include vasoconstriction due to cold exposure, decreased cardiac output 
pulmonary compliance is observed. Clinical impact can range from mild dys-
pnea to severe respiratory failure. Normal intracardiac pressures are typically 
observed. Etiologies may be direct injury (e.g., aspiration, smoke inhalation, 
pneumonia, oxygen toxicity, or chest trauma), indirect injury (e.g., sepsis, 
pancreatitis, and leukoagglutination reactions), or pulmonary vascular 
(e.g., high altitude and neurogenic pulmonary edema). Chest radiograph 
typically shows normal heart size and diffuse alveolar infiltrates; pleural effu-
sions are atypical. Hypoxemia in noncardiogenic pulmonary edema often 
requires treatment with high concentrations of oxygen. 
For a more detailed discussion, see Schwartzstein RM: 
Dyspnea, Chap. 33, p. 277, HPIM-18.
SECTION 3
230
Common Patient Presentations
(e.g., in shock, Chap. 12), heart failure (Chap. 133), and peripheral vascular 
disease (Chap. 135) with arterial obstruction or vasospasm (Table 40-1). 
Local (e.g., thrombophlebitis) or central (e.g., constrictive pericarditis) 
venous hypertension intensifies cyanosis.
Cyanosis
APPROACH TO THE
PATIENT
• Inquire about duration (cyanosis since birth suggests congenital heart 
disease) and exposures (drugs or chemicals that result in abnormal 
hemoglobins).
• Differentiate central from peripheral cyanosis by examining nailbeds, 
lips, and mucous membranes. Peripheral cyanosis is most intense in 
nailbeds and may resolve with gentle warming of extremities.
• Check for clubbing, i.e., selective enlargement of the distal segments 
of fingers and toes, due to proliferation of connective tissue. Clubbing
TABLE 40-1 CAUSES OF CYANOSIS
Central Cyanosis
Decreased arterial oxygen saturation
Decreased atmospheric pressure—high altitude
Impaired pulmonary function
Alveolar hypoventilation
Uneven relationships between pulmonary ventilation and perfusion 
(perfusion of hypoventilated alveoli)
Impaired oxygen diffusion
Anatomic shunts
Certain types of congenital heart disease
Pulmonary arteriovenous fistulas
Multiple small intrapulmonary shunts
Hemoglobin with low affinity for oxygen
Hemoglobin abnormalities
Methemoglobinemia—hereditary, acquired
Sulfhemoglobinemia—acquired
Carboxyhemoglobinemia (not true cyanosis)
Peripheral Cyanosis
Reduced cardiac output
Cold exposure
Redistribution of blood flow from extremities
Arterial obstruction
Venous obstruction
CHAPTER 41
231
Cough and Hemoptysis
 
may be hereditary, idiopathic, or acquired in association with lung 
cancer, infective endocarditis, bronchiectasis, or hepatic cirrhosis. 
Combination of clubbing and cyanosis is frequent in congenital 
heart disease and occasionally in pulmonary disease (lung abscess, 
pulmonary AV shunts, but not with uncomplicated obstructive lung 
disease).
• Examine chest for evidence of pulmonary disease, pulmonary edema, 
or murmurs associated with congenital heart disease.
• If cyanosis is localized to an extremity, evaluate for peripheral vascular 
obstruction.
• Obtain arterial blood gas to measure systemic O2 saturation. Repeat 
while pt inhales 100% O2; if saturation fails to increase to >95%, intra-
vascular shunting of blood bypassing the lungs is likely (e.g., right-to-
left intracardiac shunts).
• Evaluate for abnormal hemoglobins (e.g., hemoglobin electrophoresis, 
spectroscopy, measurement of methemoglobin level).
For a more detailed discussion, see Loscalzo J: Hypoxia and 
Cyanosis, Chap. 35, p. 287, in HPIM-18.
CHAPTER 41
Cough and Hemoptysis
COUGH
� ETIOLOGY
Acute cough, which is defined as duration <21 days, is usually related to respira-
tory infection, aspiration, or inhalation of respiratory irritants. Subacute cough 
(present for 3–8 weeks) is often related to persistent inflammation from a tra-
cheobronchitis episode. Chronic cough (>8 weeks in duration) can be caused 
by many pulmonary and cardiac diseases. Chronic bronchitis related to cigarette 
smoking is a common cause. If the chest radiograph and physical examination 
are unremarkable, other common causes of chronic cough include cough-
variant asthma, gastroesophageal reflux disease (GERD), postnasal drip related 
to sinus disease, and medications including angiotensin-converting enzyme 
(ACE) inhibitors. Irritation of tympanic membranes and chronic eosinophilic 
bronchitis also can cause chronic cough with a normal chest radiograph. 
Ineffective cough can predispose to serious respiratory infections due to diffi-
culty clearing lower respiratory secretions; abnormal airway secretions (e.g., due 
to bronchiectasis) or tracheomalacia can contribute. Weakness or pain limiting 
abdominal and intercostal muscle use also can lead to ineffective cough.
SECTION 3
232
Common Patient Presentations
� CLINICAL ASSESSMENT 
Key historic issues include triggers for onset of cough, determinants of 
increased or decreased cough, and sputum production. Symptoms of naso-
pharyngeal disease should be assessed, including postnasal drip, sneezing, 
and rhinorrhea. GERD may be suggested by heartburn, hoarseness, and 
frequent eructation. Cough-variant asthma is suggested by noting the rela-
tionship of cough onset to asthmatic triggers. Usage of ACE inhibitors, but 
not angiotensin receptor blockers, can cause cough long after treatment is 
initiated. 
On physical examination, signs of cardiopulmonary diseases should 
be assessed, including adventitious lung sounds and digital clubbing. 
Examination of the nasal passages, posterior pharyngeal wall, auditory 
canals, and tympanic membranes should be performed.
Laboratory evaluation should include chest radiography. Spirometry with 
bronchodilator testing can assess for reversible airflow obstruction. With 
normal spirometry, methacholine challenge testing can be used to assess for 
asthma. Sputum should be sent for routine bacterial and possibly mycobacte-
rial cultures. Sputum cytology can reveal malignant cells in lung cancer and 
eosinophils in eosinophilic bronchitis. Esophageal pH probes can be used to 
assess for GERD. Chest CT should be considered in pts with normal chest 
radiographs who fail to improve with treatment. Evaluation of hemoptysis is 
discussed below. 
Chronic Cough
TREATMENT
In pts with chronic cough and a normal chest x-ray, empiric treatment 
is directed at the most likely cause based on the history and physical 
examination. If treatment directed at one empiric cause fails, empiric 
treatment of an alternative etiology can be considered. Postnasal drip 
treatment may include antihistamines, nasal corticosteroids, and/
or antibiotics. GERD can be treated with antacids, type 2 histamine 
blockers, or proton pump inhibitors. Cough-variant asthma is treated 
with inhaled glucocorticoids and as-needed inhaled beta agonists. Pts 
on ACE inhibitors should be given a 1-month trial of discontinuing 
this medication. Chronic eosinophilic bronchitis often improves with 
inhaled glucocorticoid treatment. Symptomatic treatment of cough can 
include narcotics such as codeine; however, somnolence, constipation, 
and addiction can result. Dextromethorphan and benzonatate have 
fewer side effects but reduced efficacy.
HEMOPTYSIS
� ETIOLOGY 
Hemoptysis, expectoration of blood from the respiratory tract, must 
be differentiated from expectorated blood originating from the naso-
pharynx and gastrointestinal tract. Acute bronchitis is the most com-
mon cause of hemoptysis in the U.S.; tuberculosis is the leading cause 
worldwide. 
CHAPTER 41
233
Cough and Hemoptysis
Hemoptysis originating from the alveoli is known as diffuse alveolar hem-
orrhage (DAH). DAH can be caused by inflammatory diseases including 
Wegener’s granulomatosis, systemic lupus erythematosus, and Goodpasture’s 
disease. Within the first 100 days after bone marrow transplant, inflammatory 
DAH can cause severe hypoxemia. Noninflammatory DAH usually results from 
inhalational injuries from toxic exposures, such as smoke inhalation or cocaine. 
Hemoptysis most commonly originates from small- to medium-sized 
bronchi. Since the bleeding source is usually bronchial arteries, there is 
potential for rapid blood loss. Airway hemoptysis is often caused by viral or 
bacterial bronchitis. Pts with bronchiectasis have increased risk of hemoptysis. 
Pneumonia can cause hemoptysis, especially if cavitation (e.g., tuberculosis) 
and/or necrotizing pneumonia (e.g., Klebsiella pneumoniae and Staphylococcus 
aureus) develop. Paragonimiasis, a helminthic infection common in pts from 
Southeast Asia and China, can cause hemoptysis and must be differentiated 
from tuberculosis. Although only 10% of lung cancer pts have hemoptysis at 
diagnosis, cancers developing in central airways (e.g., squamous cell carci-
noma, small cell carcinoma, and carcinoid tumors) often cause hemoptysis. 
Cancers that metastasize to the lungs can cause hemoptysis less commonly.
Pulmonary vascular sources of hemoptysis include congestive heart 
failure, which usually causes pink, frothy sputum. Pulmonary embolism 
with infarction and pulmonary arteriovenous malformations are additional 
pulmonary vascular etiologies to consider. 
� CLINICAL ASSESSMENT 
The approaches to assess and treat hemoptysis are shown in Fig. 41-1. 
History should determine whether the bleeding source is likely the respira-
tory tract or an alternative source (e.g., nasopharynx, upper GI tract). The 
quantity of expectorated blood should be estimated, as it influences the 
urgency of evaluation and treatment. Massive hemoptysis, variably defined 
as 200–600 mL within 24 h, requires emergent care. The presence of puru-
lent or frothy secretions should be assessed. History of previous hemoptysis 
episodes and cigarette smoking should be ascertained. Fever and chills 
should be assessed as potential indicators of acute infection. Recent inhala-
tion of illicit drugs and other toxins should be determined. 
Physical examination should include assessment of the nares for epistaxis, 
and evaluation of the heart and lungs. Pedal edema could indicate conges-
tive heart failure if symmetric, and deep-vein thrombosis with pulmonary 
embolism if asymmetric. Clubbing could indicate lung cancer or bronchiec-
tasis. Assessment of vital signs and oxygen saturation can provide informa-
tion about hemodynamic stability and respiratory compromise. 
Radiographic evaluation with a chest x-ray should be performed. Chest 
CT may be helpful to assess for bronchiectasis, pneumonia, lung cancer, and 
pulmonary embolism. Laboratory studies include a complete blood count 
and coagulation studies; renal function and urinalysis should be assessed, 
with additional blood tests including ANCA, anti-GBM, and ANA if diffuse 
alveolar hemorrhage is suspected. Sputum should be sent for Gram’s stain 
and routine culture as well as AFB smear and culture. 
Bronchoscopy is often required to complete the evaluation. In massive 
hemoptysis, rigid bronchoscopy may be necessary. 
Quantify amount
of bleeding
History and
physical exam
Patient with Hemoptysis
Mild
Moderate
Massive
Rule out other sources:
• Oropharynx
• Gastrointestinal tract
No risk factors*
Risk factors* or
recurrent bleeding
Treat underlying disease
(usually infection)
CT scan if
unrevealing, bronchoscopy
Bleeding
continues
Treat underlying disease
CT scan
Bronchoscopy
CXR, CBC, coagulation
studies, UA, creatinine
Secure airway
Treat underlying disease
Persistent bleeding
*Risk Factors: smoking, age >40
Bleeding stops
Embolization or
resection
FIGURE 41-1 An algorithm for the evaluation of hemoptysis. CBC, complete blood count; CT, computed tomography; CXR, chest x-ray; UA, urinalysis. (From
Kritek P and Fanta C: HPIM-18.)
234
CHAPTER 42
235
Edema
Hemoptysis
TREATMENT
As shown in Fig. 41-1, massive hemoptysis may require endotracheal 
intubation and mechanical ventilation to provide airway stabilization. If 
the source of bleeding can be identified, isolating the bleeding lung with 
an endobronchial blocker or double-lumen endotracheal tube is optimal. 
Pts should be positioned with the bleeding side down. If bleeding persists, 
bronchial arterial embolization by angiography may be beneficial; how-
ever, risk of spinal artery embolization is an important potential adverse 
event. As a last resort, surgical resection can be considered to stop the 
bleeding. Cough suppression, typically with narcotics, is desirable. 
For a more detailed discussion, see Kritek P, Fanta C: Cough 
and Hemoptysis, Chap. 34, p. 282, in HPIM-18.
CHAPTER 42
Edema
� DEFINITION
Soft tissue swelling due to abnormal expansion of interstitial fluid volume. 
Edema fluid is a plasma transudate that accumulates when movement of fluid 
from vascular to interstitial space is favored. Since detectable generalized edema 
in the adult reflects a gain of ≥3 L, renal retention of salt and water is necessary 
for edema to occur. Distribution of edema can be an important guide to cause.
Localized Edema 
Limited to a particular organ or vascular bed; easily distinguished from general-
ized edema. Unilateral extremity edema is usually due to venous or lymphatic 
obstruction (e.g., deep venous thrombosis, tumor obstruction, primary lymph-
edema). Stasis edema of a paralyzed lower extremity also may occur. Allergic 
reactions (“angioedema”) and superior vena caval obstruction are causes of 
localized facial edema. Bilateral lower-extremity edema may have localized 
causes, e.g., inferior vena caval obstruction, compression due to ascites, abdom-
inal mass. Ascites (fluid in peritoneal cavity) and hydrothorax (in pleural space) 
also may present as isolated localized edema, due to inflammation or neoplasm.
Generalized Edema 
Soft tissue swelling of most or all regions of the body. Bilateral lower-
extremity swelling, more pronounced after standing for several hours, and 
pulmonary edema are usually cardiac in origin. Periorbital edema noted 
on awakening often results from renal disease and impaired Na excretion. 
SECTION 3
236
Common Patient Presentations
Ascites and edema of lower extremities and scrotum are frequent in cirrho-
sis, nephrotic syndrome, or CHF. 
In CHF, diminished cardiac output and arterial underfilling result in 
both decreased renal perfusion and increased venous pressure with resul-
tant renal Na retention due to renal vasoconstriction, intrarenal blood flow 
redistribution, direct Na-retentive effects of norepinephrine and angioten-
sin II, and secondary hyperaldosteronism.
In cirrhosis, arteriovenous shunts and peripheral vasodilation lower renal 
perfusion, resulting in Na retention. Ascites accumulates when increased 
intrahepatic vascular resistance produces portal hypertension. As in heart 
failure, the effects of excess intrarenal and circulating norepinephrine, 
angiotensin II, and aldosterone lead to renal Na retention and worsening 
edema. Reduced serum albumin and increased abdominal pressure also 
promote lower-extremity edema.
In acute or chronic renal failure, edema occurs if Na intake exceeds kidneys’ 
ability to excrete Na secondary to marked reductions in glomerular filtration. 
Severe hypoalbuminemia [<25 g/L (2.5 g/dL)] of any cause (e.g., nephrotic 
TABLE 42-1 DRUGS ASSOCIATED WITH EDEMA FORMATION
Nonsteroidal anti-inflammatory drugs
Antihypertensive agents
Direct arterial/arteriolar vasodilators
Hydralazine
Clonidine
Methyldopa
Guanethidine
Minoxidil
Calcium channel antagonists
α-Adrenergic antagonists
Thiazolidinediones
Steroid hormones
Glucocorticoids
Anabolic steroids
Estrogens
Progestins
Cyclosporine
Growth hormone
Immunotherapies
Interleukin 2
OKT3 monoclonal antibody
Source: From GM Chertow, in E Braunwald, L Goldman (eds): Cardiology for the Primary Care 
Physician, 2nd ed. Philadelphia, Saunders, 2003.
CHAPTER 42
237
Edema
syndrome, nutritional deficiency, chronic liver disease) may lower plasma 
oncotic pressure, promoting fluid transudation into interstitium; lowering of 
effective blood volume stimulates renal Na retention and causes edema.
Less common causes of generalized edema: idiopathic edema, a syndrome 
of recurrent rapid weight gain and edema in women of reproductive age; 
hypothyroidism, in which myxedema is typically located in the pretibial 
region; drugs (Table 42-1).
Edema
TREATMENT
Primary management is to identify and treat the underlying cause of 
edema (Fig. 42-1).
yes
yes
yes
yes
Edema
• Severe malnutrition
• Cirrhosis (Chap. 165)
• Nephrotic syndrome
• Heart failure (Chap. 133)
• Renal failure (Chap. 148)
Consider:
• Drug-induced (steroids, estrogens, vasodilators)
• Hypothyroidism (Chap. 181)
• Venous or lymphatic obstruction 
  (Chap. 135)
• Local injury (thermal, immune,
   infectious, mechanical)
?
albumin <
2.5 g/dL
?
JVD or
  CO
?
Azotemia
or active
urine
sediment
?
Localized
no
no
no
no
FIGURE 42-1 Diagnostic approach to edema. CO, cardiac output; JVD, jugular 
venous distention. (From Chap. 49: HMOM-17.)
SECTION 3
238
Common Patient Presentations
Dietary Na restriction (<500 mg/d) may prevent further edema formation. 
Bed rest enhances response to salt restriction in CHF and cirrhosis. Supportive 
stockings and elevation of edematous lower extremities help to mobilize inter-
stitial fluid. If severe hyponatremia (<132 mmol/L) is present, water intake 
also should be reduced (<1500 mL/d). Diuretics (Table 42-2) are indicated 
for marked peripheral edema, pulmonary edema, CHF, inadequate dietary 
salt restriction. Complications are listed in Table 42-3. Weight loss by diuret-
ics should be limited to 1–1.5 kg/d. Distal (“potassium sparing”) diuretics or 
metolazone may be added to loop diuretics for enhanced effect. Note that 
intestinal edema may impair absorption of oral diuretics and reduce effective-
ness. When desired weight is achieved, diuretic doses should be reduced.
TABLE 42-2 DIURETICS FOR EDEMA
Drug
Usual Dose
Comments
Loop (May be administered PO or IV)
Furosemide
20–120 mg qd 
or bid
Short-acting; potent; effective with 
low GFR
Bumetanide
0.5–2 mg qd 
or bid
Better oral absorption than furose-
mide, but shorter duration of action
Torsemide
20– 200 mg qd
Better oral absorption than 
furosemide, longer duration of action
Distal, K-Losing
Hydrochlorothiazide 12.5–25 mg qd
Causes hypokalemia; need GFR >25 
mL/min
Chlorthalidone
12.5–25 mg qd 
Long-acting (up to 72 h); hypokalemia 
Metolazone
1–5 mg qd
Long-acting; hypokalemia; effective 
with low GFR, especially when com-
bined with a loop diuretic
Distal, K-Sparing
Spironolactone
12.5–100 mg qd Hyperkalemia; acidosis; blocks 
aldosterone; gynecomastia, impo-
tence, amenorrhea; onset takes 
2–3 days; avoid use in renal failure or 
in combination with ACE inhibitors or 
potassium supplement
Eplerenone
Amiloride
25–50 mg qd
5–10 mg qd 
or bid
Similar side effects to spironolactone, 
but more specific for mineralocor-
ticoid receptor; lower incidence of 
gynecomastia and amenorrhea
Hyperkalemia; once daily; less potent 
than spironolactone
Triamterene
100 mg bid
Hyperkalemia; less potent than 
spironolactone; renal stones
Abbreviations: ACE, angiotensin-converting enzyme; GFR, glomerular filtration rate.
Source: From Chap. 49, HMOM-17.
CHAPTER 43
239
Abdominal Pain
In CHF (Chap. 133), avoid overdiuresis because it may bring a fall in 
cardiac output and prerenal azotemia. Avoid diuretic-induced hypokalemia, 
which predisposes to digitalis toxicity.
In cirrhosis and other hepatic causes of edema, spironolactone is the 
initial diuretic of choice but may produce acidosis and hyperkalemia. 
Thiazides or small doses of loop diuretics may also be added. However, 
renal failure may result from volume depletion. Overdiuresis may result 
in hyponatremia, hypokalemia, and alkalosis, which may worsen hepatic 
encephalopathy (Chap. 165).
TABLE 42-3 COMPLICATIONS OF DIURETICS
Common
Uncommon
Volume depletion
Interstitial nephritis (thiazides, furosemide)
Prerenal azotemia
Pancreatitis (thiazides)
Potassium depletion
Loss of hearing (loop diuretics)
Hyponatremia (thiazides)
Anemia, leukopenia, thrombocytopenia (thiazides)
Metabolic alkalosis
Hypercholesterolemia
Hyperglycemia (thiazides)
Hyperkalemia (K-sparing)
Hypomagnesemia
Hyperuricemia
Hypercalcemia (thiazides)
GI complaints
Rash (thiazides)
Source: From Chap. 49, HMOM-17.
For a more detailed discussion, see Braunwald E, Loscalzo 
J: Edema, Chap. 36, p. 290, in HPIM-18.
CHAPTER 43
Abdominal Pain
Numerous causes, ranging from acute, life-threatening emergencies to 
chronic functional disease and disorders of several organ systems, can gen-
erate abdominal pain. Evaluation of acute pain requires rapid assessment 
of likely causes and early initiation of appropriate therapy. A more detailed 
and time-consuming approach to diagnosis may be followed in less acute 
situations. Table 43-1 lists the common causes of abdominal pain.
SECTION 3
240
Common Patient Presentations
Abdominal Pain
APPROACH TO THE
PATIENT
History: History is of critical diagnostic importance. Physical exam 
may be unrevealing or misleading, and laboratory and radiologic exams 
delayed or unhelpful.
TABLE 43-1 COMMON ETIOLOGIES OF ABDOMINAL PAIN
Mucosal or muscle inflammation in hollow viscera: Peptic disease (ulcers, 
erosions, inflammation), hemorrhagic gastritis, gastroesophageal reflux, appen-
dicitis, diverticulitis, cholecystitis, cholangitis, inflammatory bowel diseases 
(Crohn’s, ulcerative colitis), infectious gastroenteritis, mesenteric lymphadeni-
tis, colitis, cystitis, or pyelonephritis
Visceral spasm or distention: Intestinal obstruction (adhesions, tumor, 
intussusception), appendiceal obstruction with appendicitis, strangulation of 
hernia, irritable bowel syndrome (muscle hypertrophy and spasm), acute biliary 
obstruction, pancreatic ductal obstruction (chronic pancreatitis, stone), ureteral 
obstruction (kidney stone, blood clot), fallopian tubes (tubal pregnancy)
Vascular disorders: Mesenteric thromboembolic disease (arterial or venous), 
arterial dissection or rupture (e.g., aortic aneurysm), occlusion from external 
pressure or torsion (e.g., volvulus, hernia, tumor, adhesions, intussusception), 
hemoglobinopathy (esp. sickle cell disease)
Distention or inflammation of visceral surfaces: Hepatic capsule (hepati-
tis, hemorrhage, tumor, Budd-Chiari syndrome, Fitz-Hugh-Curtis syndrome), 
renal capsule (tumor, infection, infarction, venous occlusion), splenic capsule 
(hemorrhage, abscess, infarction), pancreas (pancreatitis, pseudocyst, abscess, 
tumor), ovary (hemorrhage into cyst, ectopic pregnancy, abscess)
Peritoneal inflammation: Bacterial infection (perforated viscus, pelvic inflam-
matory disease, infected ascites), intestinal infarction, chemical irritation, 
pancreatitis, perforated viscus (esp. stomach and duodenum), reactive inflam-
mation (neighboring abscess, incl. diverticulitis, pleuropulmonary infection or 
inflammation), serositis (collagen-vascular diseases, familial Mediterranean 
fever), ovulation (mittelschmerz).
Abdominal wall disorders: Trauma, hernias, muscle inflammation or infec-
tion, hematoma (trauma, anticoagulant therapy), traction from mesentery (e.g., 
adhesions)
Toxins: Lead poisoning, black widow spider bite
Metabolic disorders: Uremia, ketoacidosis (diabetic, alcoholic), Addisonian 
crisis, porphyria, angioedema (C1 esterase deficiency), narcotic withdrawal
Neurologic disorders: Herpes zoster, tabes dorsalis, causalgia, compression 
or inflammation of spinal roots, (e.g., arthritis, herniated disk, tumor, abscess), 
psychogenic
Referred pain: From heart, lungs, esophagus, genitalia (e.g., cardiac ischemia, 
pneumonia, pneumothorax, pulmonary embolism, esophagitis, esophageal 
spasm, esophageal rupture)
CHAPTER 43
241
Abdominal Pain
CHARACTERISTIC FEATURES OF ABDOMINAL PAIN
Duration and Pattern: These provide clues to nature and severity, 
although acute abdominal crisis may occasionally present insidiously 
or on a background of chronic pain.
Type and location provide a rough guide to nature of disease. Visceral 
pain (due to distention of a hollow viscus) localizes poorly and is often 
perceived in the midline. Intestinal pain tends to be crampy; when 
originating proximal to the ileocecal valve, it usually localizes above 
and around the umbilicus. Pain of colonic origin is perceived in the 
hypogastrium and lower quadrants. Pain from biliary or ureteral 
obstruction often causes pts to writhe in discomfort. Somatic pain 
(due to peritoneal inflammation) is usually sharper and more precisely 
localized to the diseased region (e.g., acute appendicitis; capsular dis-
tention of liver, kidney, or spleen), exacerbated by movement, causing 
pts to remain still. Pattern of radiation may be helpful: right shoulder 
(hepatobiliary origin), left shoulder (splenic), midback (pancreatic), 
flank (proximal urinary tract), groin (genital or distal urinary tract).
Factors that precipitate or relieve pain: Ask about its relationship to 
eating (e.g., upper GI, biliary, pancreatic, ischemic bowel disease), 
defecation (colorectal), urination (genitourinary or colorectal), 
respiratory (pleuropulmonary, hepatobiliary), position (pancre-
atic, gastroesophageal reflux, musculoskeletal), menstrual cycle/
menarche (tuboovarian, endometrial, including endometriosis), 
exertion (coronary/intestinal ischemia, musculoskeletal), medi-
cation or specific foods (motility disorders, food intolerance, 
gastroesophageal reflux, porphyria, adrenal insufficiency, keto-
acidosis, toxins), and stress (motility disorders, nonulcer dyspepsia, 
irritable bowel syndrome).
Associated symptoms: Look for fevers/chills (infection, inflamma-
tory disease, infarction), weight loss (tumor, inflammatory disease, 
malabsorption, ischemia), nausea/vomiting (obstruction, infection, 
inflammatory disease, metabolic disease), dysphagia/odynophagia 
(esophageal), early satiety (gastric), hematemesis (esophageal, gastric, 
duodenal), constipation (colorectal, perianal, genitourinary), jaundice 
(hepatobiliary, hemolytic), diarrhea (inflammatory disease, infection, 
malabsorption, secretory tumors, ischemia, genitourinary), dysuria/
hematuria/vaginal or penile discharge (genitourinary), hematochezia 
(colorectal or, rarely, urinary), skin/joint/eye disorders (inflammatory 
disease, bacterial or viral infection).
Predisposing factors: Inquire about family history (inflammatory 
disease, tumors, pancreatitis), hypertension and atherosclerotic dis-
ease (ischemia), diabetes mellitus (motility disorders, ketoacidosis), 
connective tissue disease (motility disorders, serositis), depression 
(motility disorders, tumors), smoking (ischemia), recent smoking 
cessation (inflammatory disease), ethanol use (motility disorders, 
hepatobiliary, pancreatic, gastritis, peptic ulcer disease).
SECTION 3
242
Common Patient Presentations
Physical examination: Evaluate abdomen for prior trauma or surgery, 
current trauma; abdominal distention, fluid, or air; direct, rebound, 
and referred tenderness; liver and spleen size; masses, bruits, altered 
bowel sounds, hernias, arterial masses. Rectal examination assesses 
presence and location of tenderness, masses, blood (gross or occult). 
Pelvic examination in women is essential. General examination: eval-
uate for evidence of hemodynamic instability, acid-base disturbances, 
nutritional deficiency, coagulopathy, arterial occlusive disease, stig-
mata of liver disease, cardiac dysfunction, lymphadenopathy, and 
skin lesions.
Routine laboratory and radiologic studies: Choices depend on clinical 
setting (esp. severity of pain, rapidity of onset) and may include 
complete blood count, serum electrolytes, coagulation parameters, 
serum glucose, and biochemical tests of liver, kidney, and pancre-
atic function; chest x-ray to determine the presence of diseases 
involving heart, lung, mediastinum, and pleura; electrocardiogram 
is helpful to exclude referred pain from cardiac disease; plain 
abdominal radiographs to evaluate bowel displacement, intestinal 
distention, fluid and gas pattern, free peritoneal air, liver size, and 
abdominal calcifications (e.g., gallstones, renal stones, chronic 
pancreatitis).
Special studies: These include abdominal ultrasonography (to visu-
alize biliary ducts, gallbladder, liver, pancreas, and kidneys); CT 
to identify masses, abscesses, evidence of inflammation (bowel 
wall thickening, mesenteric “stranding,” lymphadenopathy), aortic 
aneurysm; barium contrast radiographs (barium swallow, upper 
GI series, small-bowel follow-through, barium enema); upper 
GI endoscopy, sigmoidoscopy, or colonoscopy; cholangiography 
(endoscopic, percutaneous, or via MRI), angiography (direct or via 
CT or MRI), and radionuclide scanning. In selected cases, percu-
taneous biopsy, laparoscopy, and exploratory laparotomy may be 
required.
ACUTE, CATASTROPHIC ABDOMINAL PAIN
Intense abdominal pain of acute onset or pain associated with syncope, 
hypotension, or toxic appearance necessitates rapid yet orderly evaluation. 
Consider obstruction, perforation, or rupture of hollow viscus; dissec-
tion or rupture of major blood vessels (esp. aortic aneurysm); ulceration; 
abdominal sepsis; ketoacidosis; and adrenal crisis.
� BRIEF HISTORY AND PHYSICAL EXAMINATION 
Historic features of importance include age; time of onset of the pain; 
activity of the pt when the pain began; location and character of the pain; 
radiation to other sites; presence of nausea, vomiting, or anorexia; tempo-
ral changes; changes in bowel habits; and menstrual history. Physical exam 
should focus on the pt’s overall appearance [writhing in pain (ureteral 
CHAPTER 43
243
Abdominal Pain
lithiasis) vs. still (peritonitis, perforation)], position (a pt leaning forward 
may have pancreatitis or gastric perforation into the lesser sac), presence 
of fever or hypothermia, hyperventilation, cyanosis, bowel sounds, direct 
or rebound abdominal tenderness, pulsating abdominal mass, abdominal 
bruits, ascites, rectal blood, rectal or pelvic tenderness, and evidence 
of coagulopathy. Useful laboratory studies include hematocrit (may be 
normal with acute hemorrhage or misleadingly high with dehydration), 
WBC with differential count, arterial blood gases, serum electrolytes, 
BUN, creatinine, glucose, lipase or amylase, and UA. Females of reproduc-
tive age should have a pregnancy test. Radiologic studies should include 
supine and upright abdominal films (left lateral decubitus view if upright 
unobtainable) to evaluate bowel caliber and presence of free peritoneal 
air, cross-table lateral film to assess aortic diameter; CT (when available) 
to detect evidence of bowel perforation, inflammation, solid organ infarc-
tion, retroperitoneal bleeding, abscess, or tumor. Abdominal paracentesis 
(or peritoneal lavage in cases of trauma) can detect evidence of bleeding 
or peritonitis. Abdominal ultrasound (when available) reveals evidence of 
abscess, cholecystitis, biliary or ureteral obstruction, or hematoma and is 
used to determine aortic diameter.
� DIAGNOSTIC STRATEGIES 
The initial decision point is based on whether the pt is hemodynamically 
stable. If not, one must suspect a vascular catastrophe such as a leaking 
abdominal aortic aneurysm. Such pts receive limited resuscitation and 
move immediately to surgical exploration. If the pt is hemodynamically 
stable, the next decision point is whether the abdomen is rigid. Rigid abdo-
mens are most often due to perforation or obstruction. The diagnosis can 
generally be made by a chest and plain abdominal radiograph.
If the abdomen is not rigid, the causes may be grouped based on whether 
the pain is poorly localized or well localized. In the presence of poorly local-
ized pain, one should assess whether an aortic aneurysm is possible. If so, 
a CT scan can make the diagnosis; if not, early appendicitis, early obstruc-
tion, mesenteric ischemia, inflammatory bowel disease, pancreatitis, and 
metabolic problems are all in the differential diagnosis.
Pain localized to the epigastrium may be of cardiac origin or due to 
esophageal inflammation or perforation, gastritis, peptic ulcer disease, 
biliary colic or cholecystitis, or pancreatitis. Pain localized to the right 
upper quadrant includes those same entities plus pyelonephritis or nephro-
lithiasis, hepatic abscess, subdiaphragmatic abscess, pulmonary embolus, 
or pneumonia, or it may be of musculoskeletal origin. Additional consid-
erations with left upper quadrant localization are infarcted or ruptured 
spleen, splenomegaly, and gastric or peptic ulcer. Right lower quadrant 
pain may be from appendicitis, Meckel’s diverticulum, Crohn’s disease, 
diverticulitis, mesenteric adenitis, rectus sheath hematoma, psoas abscess, 
ovarian abscess or torsion, ectopic pregnancy, salpingitis, familial fever 
syndromes, uterolithiasis, or herpes zoster. Left lower quadrant pain may 
be due to diverticulitis, perforated neoplasm, or other entities previously 
mentioned.
SECTION 3
244
Common Patient Presentations
 Acute, Catastrophic Abdominal Pain
TREATMENT
IV fluids, correction of life-threatening acid-base disturbances, and 
assessment of need for emergent surgery are the first priority; careful 
follow-up with frequent reexamination (when possible, by the same 
examiner) is essential. Relieve the pain. The use of narcotic analgesia 
is controversial. Traditionally, narcotic analgesics were withheld pend-
ing establishment of diagnosis and therapeutic plan, since masking of 
diagnostic signs may delay needed intervention. However, evidence that 
narcotics actually mask a diagnosis is sparse.
For a more detailed discussion, see Silen W: Abdominal Pain, 
Chap. 13, p. 108, in HPIM-18.
CHAPTER 44
Nausea, Vomiting, and 
Indigestion
NAUSEA AND VOMITING
Nausea refers to the imminent desire to vomit and often precedes or accom-
panies vomiting. Vomiting refers to the forceful expulsion of gastric contents 
through the mouth. Retching refers to labored rhythmic respiratory activity 
that precedes emesis. Regurgitation refers to the gentle expulsion of gastric 
contents in the absence of nausea and abdominal diaphragmatic muscular 
contraction. Rumination refers to the regurgitation, rechewing, and reswal-
lowing of food from the stomach.
� PATHOPHYSIOLOGY 
Gastric contents are propelled into the esophagus when there is relax-
ation of the gastric fundus and gastroesophageal sphincter followed by a 
rapid increase in intraabdominal pressure produced by contraction of the 
abdominal and diaphragmatic musculature. Increased intrathoracic pres-
sure results in further movement of the material to the mouth. Reflex eleva-
tion of the soft palate and closure of the glottis protect the nasopharynx 
and trachea and complete the act of vomiting. Vomiting is controlled by 
two brainstem areas, the vomiting center and chemoreceptor trigger zone. 
Activation of the chemoreceptor trigger zone results in impulses to the 
vomiting center, which controls the physical act of vomiting.
� ETIOLOGY 
Nausea and vomiting are manifestations of a large number of disorders 
(Table 44-1).
CHAPTER 44
245
Nausea, Vomiting, and Indigestion 
� EVALUATION 
The history, including a careful drug history, and the timing and character 
of the vomitus can be helpful. For example, vomiting that occurs predomi-
nantly in the morning is often seen in pregnancy, uremia, and alcoholic 
TABLE 44-1 CAUSES OF NAUSEA AND VOMITING
Intraperitoneal
Extraperitoneal
Medications/
Metabolic Disorders
Obstructing disorders
Pyloric obstruction
Small bowel obstruction
Colonic obstruction
Superior mesenteric 
artery syndrome
Enteric infections
Viral
Bacterial
Inflammatory diseases
Cholecystitis
Pancreatitis
Appendicitis
Hepatitis
Altered sensorimotor 
function
Gastroparesis
Intestinal pseudo-
obstruction
Gastroesophageal reflux
Chronic idiopathic 
nausea
Functional vomiting
Cyclic vomiting 
syndrome
Biliary colic
Abdominal irradiation
Cardiopulmonary disease
Cardiomyopathy
Myocardial infarction
Labyrinthine disease
Motion sickness
Labyrinthitis
Malignancy
Intracerebral disorders
Malignancy
Hemorrhage
Abscess
Hydrocephalus
Psychiatric illness
Anorexia and bulimia 
nervosa
Depression
Postoperative vomiting
Drugs
Cancer
chemotherapy
Antibiotics
Cardiac
antiarrhythmics
Digoxin
Oral hypoglycemics
Oral contraceptives
Endocrine/metabolic
disease
Pregnancy
Uremia
Ketoacidosis
Thyroid and 
parathyroid disease
Adrenal 
insufficiency
Toxins
Liver failure
Ethanol
SECTION 3
246
Common Patient Presentations
gastritis; feculent emesis implies distal intestinal obstruction or gastrocolic 
fistula; projectile vomiting suggests increased intracranial pressure; vomit-
ing during or shortly after a meal may be due to psychogenic causes or 
peptic ulcer disease. Associated symptoms may also be helpful: vertigo and 
tinnitus in Ménière’s disease, relief of abdominal pain with vomiting in 
peptic ulcer, and early satiety in gastroparesis. Plain radiographs can sug-
gest diagnoses such as intestinal obstruction. The upper GI series assesses 
motility of the proximal GI tract as well as the mucosa. Other studies may 
be indicated, such as gastric emptying scans (diabetic gastroparesis) and CT 
scan of the brain.
� COMPLICATIONS 
Rupture of the esophagus (Boerhaave’s syndrome), hematemesis from a 
mucosal tear (Mallory-Weiss syndrome), dehydration, malnutrition, den-
tal caries and erosions, metabolic alkalosis, hypokalemia, and aspiration 
pneumonitis.
Nausea and Vomiting
TREATMENT
Treatment is aimed at correcting the specific cause. The effective-
ness of antiemetic medications depends on etiology of symptoms, pt 
responsiveness, and side effects. Antihistamines such as meclizine and 
dimenhydrinate are effective for nausea due to inner ear dysfunction. 
Anticholinergics such as scopolamine are effective for nausea associated 
with motion sickness. Haloperidol and phenothiazine derivatives such as 
prochlorperazine are often effective in controlling mild nausea and vom-
iting, but sedation, hypotension, and parkinsonian symptoms are com-
mon side effects. Selective dopamine antagonists such as metoclopramide 
may be superior to the phenothiazines in treating severe nausea and vom-
iting and are particularly useful in treatment of gastroparesis. IV meto-
clopramide may be effective as prophylaxis against nausea when given 
before chemotherapy. Ondansetron and granisetron, serotonin receptor 
blockers, and glucocorticoids are used for treating nausea and vomiting 
associated with cancer chemotherapy. Aprepitant, a neurokinin receptor 
blocker, is effective at controlling nausea from highly emetic drugs like 
cisplatin. Erythromycin is effective in some pts with gastroparesis.
INDIGESTION
Indigestion is a nonspecific term that encompasses a variety of upper 
abdominal complaints including heartburn, regurgitation, and dyspepsia 
(upper abdominal discomfort or pain). These symptoms are overwhelm-
ingly due to gastroesophageal reflux disease (GERD).
� PATHOPHYSIOLOGY 
GERD occurs as a consequence of acid reflux into the esophagus from the 
stomach, gastric motor dysfunction, or visceral afferent hypersensitivity. A 
wide variety of situations promote GERD: increased gastric contents (from 
a large meal, gastric stasis, or acid hypersecretion), physical factors (lying 
CHAPTER 44
247
Nausea, Vomiting, and Indigestion 
down, bending over), increased pressure on the stomach (tight clothes, 
obesity, ascites, pregnancy), and loss (usually intermittent) of lower esopha-
geal sphincter tone (diseases such as scleroderma, smoking, anticholiner-
gics, calcium antagonists). Hiatal hernia also promotes acid flow into the 
esophagus.
� NATURAL HISTORY 
Heartburn is reported once monthly by 40% of Americans and daily by 
7%. Functional dyspepsia is defined as >3 months of dyspepsia without 
an organic cause. Functional dyspepsia is the cause of symptoms in 60% 
of pts with dyspeptic symptoms. However, peptic ulcer disease from either 
Helicobacter pylori infection or ingestion of nonsteroidal anti-inflammatory 
drugs (NSAIDs) is present in 15% of cases.
In most cases, the esophagus is not damaged, but 5% of pts develop 
esophageal ulcers and some form strictures; 8–20% develop glandular 
epithelial cell metaplasia, termed Barrett’s esophagus, which can progress to 
adenocarcinoma.
Extraesophageal manifestations include asthma, laryngitis, chronic 
cough, aspiration pneumonitis, chronic bronchitis, sleep apnea, dental car-
ies, halitosis, and hiccups.
� EVALUATION 
The presence of dysphagia, odynophagia, unexplained weight loss, recur-
rent vomiting leading to dehydration, occult or gross bleeding, or a 
palpable mass or adenopathy are “alarm” signals that demand directed 
radiographic, endoscopic, and surgical evaluation. Pts without alarm fea-
tures are generally treated empirically. Individuals >45 years can be tested 
for the presence of H. pylori. Pts positive for the infection are treated to 
eradicate the organism. Pts who fail to respond to H. pylori treatment, 
those >45 years old, and those with alarm factors generally undergo upper 
GI endoscopy.
Indigestion
TREATMENT
Weight reduction; elevation of the head of the bed; and avoidance of 
large meals, smoking, caffeine, alcohol, chocolate, fatty food, citrus 
juices, and NSAIDs may prevent GERD. Antacids are widely used. 
Clinical trials suggest that proton pump inhibitors (omeprazole) are 
more effective than histamine receptor blockers (ranitidine) in pts 
with or without esophageal erosions. H. pylori eradication regimens 
are discussed in Chap. 158. Motor stimulants like metoclopramide 
and erythromycin may be useful in a subset of pts with postprandial 
distress.
Surgical techniques (Nissen fundoplication, Belsey procedure) 
work best in young individuals whose symptoms have improved 
on proton pump inhibitors and who otherwise may require lifelong 
therapy. They can be used in the rare pts who are refractory to medi-
cal management. Clinical trials have not documented the superiority 
of one over another.
SECTION 3
248
Common Patient Presentations
For a more detailed discussion, see Hasler WL: Nausea, 
Vomiting, and Indigestion, Chap. 39, p. 301, in HPIM-18.
CHAPTER 45
Dysphagia
DYSPHAGIA
Dysphagia is difficulty moving food or liquid through the mouth, pharynx, 
and esophagus. The pt senses swallowed material sticking along the path. 
Odynophagia is pain on swallowing. Globus pharyngeus is the sensation of a 
lump lodged in the throat, with swallowing unaffected.
� PATHOPHYSIOLOGY 
Dysphagia is caused by two main mechanisms: mechanical obstruction 
or motor dysfunction. Mechanical causes of dysphagia can be luminal 
(e.g., large food bolus, foreign body), intrinsic to the esophagus (e.g., 
inflammation, webs and rings, strictures, tumors), or extrinsic to the 
esophagus (e.g., cervical spondylitis, enlarged thyroid or mediastinal 
mass, vascular compression). The motor function abnormalities that 
cause dysphagia may be related to defects in initiating the swallowing 
reflex (e.g., tongue paralysis, lack of saliva, lesions affecting sensory 
components of cranial nerves X and XI), disorders of the pharyngeal 
and esophageal striated muscle (e.g., muscle disorders such as polymyo-
sitis and dermatomyositis, neurologic lesions such as myasthenia gravis, 
polio, or amyotrophic lateral sclerosis), and disorders of the esophageal 
smooth muscle (e.g., achalasia, scleroderma, myotonic dystrophy).
Dysphagia
APPROACH TO THE
PATIENT
History can provide a presumptive diagnosis in about 80% of pts. 
Difficulty only with solids implies mechanical dysphagia. Difficulty 
with both solids and liquids may occur late in the course of mechanical 
dysphagia but is an early sign of motor dysphagia. Pts can sometimes 
pinpoint the site of food sticking. Weight loss out of proportion to the 
degree of dysphagia may be a sign of underlying malignancy. Hoarseness 
may be related to involvement of the larynx in the primary disease pro-
cess (e.g., neuromuscular disorders), neoplastic disruption of the recur-
rent laryngeal nerve, or laryngitis from gastroesophageal reflux.
Physical exam may reveal signs of skeletal muscle, neurologic, or 
oropharyngeal diseases. Neck exam can reveal masses impinging on 
the esophagus. Skin changes might suggest the systemic nature of the 
underlying disease (e.g., scleroderma).
CHAPTER 45
249
Dysphagia
Dysphagia is nearly always a symptom of organic disease rather than 
a functional complaint. If oropharyngeal dysphagia is suspected, video-
fluoroscopy of swallowing may be diagnostic. Mechanical dysphagia can 
be evaluated by barium swallow and esophagogastroscopy with endo-
scopic biopsy. Barium swallow and esophageal motility studies can show 
the presence of motor dysphagia. An algorithm outlining an approach to 
the pt with dysphagia is shown in Fig. 45-1.
� OROPHARYNGEAL DYSPHAGIA 
Pt has difficulty initiating the swallow; food sticks at the level of the 
suprasternal notch; nasopharyngeal regurgitation and aspiration may be 
present.
Causes include the following: for solids only, carcinoma, aberrant ves-
sel, congenital or acquired web (Plummer-Vinson syndrome in iron defi-
ciency), cervical osteophyte; for solids and liquids, cricopharyngeal bar 
(e.g., hypertensive or hypotensive upper esophageal sphincter), Zenker’s 
diverticulum (outpouching in the posterior midline at the intersection of 
the pharynx and the cricopharyngeus muscle), myasthenia gravis, glucocor-
ticoid myopathy, hyperthyroidism, hypothyroidism, myotonic dystrophy, 
amyotrophic lateral sclerosis, multiple sclerosis, Parkinson’s disease, stroke, 
bulbar palsy, pseudobulbar palsy.
� ESOPHAGEAL DYSPHAGIA 
Food sticks in the mid or lower sternal area; can be associated with 
regurgitation, aspiration, odynophagia. Causes include the following: for 
solids only, lower esophageal ring (Schatzki’s ring—symptoms are usually 
intermittent), peptic stricture (heartburn accompanies this), carcinoma, 
lye stricture; for solids and liquids, diffuse esophageal spasm (occurs with 
chest pain and is intermittent), scleroderma (progressive and occurs with 
heartburn), achalasia (progressive and occurs without heartburn).
NONCARDIAC CHEST PAIN
Of pts presenting with chest pain, 30% have an esophageal source rather 
than angina. History and physical exam often cannot distinguish cardiac 
from noncardiac pain. Exclude cardiac disease first. Causes include the 
following: gastroesophageal reflux disease, esophageal motility disorders, 
peptic ulcer disease, gallstones, psychiatric disease (anxiety, panic attacks, 
depression).
� EVALUATION 
Consider a trial of antireflux therapy (omeprazole); if no response, 24-h 
ambulatory luminal pH monitoring; if negative, esophageal manometry 
may show motor disorder. Trial of imipramine, 50 mg PO qhs, may be 
worthwhile. Consider psychiatric evaluation in selected cases.
ESOPHAGEAL MOTILITY DISORDERS
Pts may have a spectrum of manometric findings ranging from nonspecific 
abnormalities to defined clinical entities.
Dysphagia
Oropharyngeal dysphagia
Esophageal dysphagia
Propulsive
Propulsive
Structural
Structural
Odynophagia
Solid and liquid
dysphagia
Solid dysphagia
Myogenic
• Cerebral vascular
 accident 
• Parkinson’s
• Amyotropic lateral
 sclerosis
• Brainstem tumor
• Guillain-Barré
• Huntington’s chorea
• Post-polio syndrome
• Multiple sclerosis
• Cerebral palsy
• Zenker’s diverticulum
• Neoplasm
• Cervical web
• Cricopharyngeal bar
• Osteophytes
• Congenital abnormalities
• Post head and neck surgery
• Chemotherapy mucositis
• Radiation
• Corrosive injury
• Infection
Dysphagia localized
to chest or
neck, food impaction
Dysphagia localized
to neck, nasal
regurgitation, aspiration,
associated ENT symptoms
Neurogenic
• Myasthenia gravis
• Polymyositis
• Mixed connective
 tissue disorders
• Oculopharyngeal
 muscular
 dystrophy
• Paraneoplastic
 syndrome
• Myotonic dystrophy
• Sarcoidosis
• GERD with weak
 peristalsis
• Achalasia
 (primary and
 secondary)
• Diffuse
 esophageal
 spasm
• Scleroderma
Intermittent
• Schatzki ring
• Esophageal web 
Progressive
• Neoplasm
Variable
• Peptic stricture
• Eosinophilic
 esophagitis
• Hiatal hernia
• Extrinsic compression
• Surgical stenosis
• Radiation esophagitis
• Ringed esophagus
• Congenital esophageal
 stenosis
• Pill esophagitis
• Infectious
 esophagitis
• Caustic injury
• Chemotherapy
 mucositis
• Sclerotherapy
• Crohn’s disease
• Behcet’s syndrome
• Bullous pemphygoid
• Lichen planus
APPROACH TO THE PATIENT WITH DYSPHAGIA
FIGURE 45-1 Approach to the pt with dysphagia. Etiologies in bold print are the most common. ENT, ear, nose, and throat; GERD, gastroesophageal reflux disease.
250
CHAPTER 45
251
Dysphagia
� ACHALASIA 
Motor obstruction caused by hypertensive lower esophageal sphincter 
(LES), incomplete relaxation of LES, or loss of peristalsis in smooth-muscle 
portion of esophagus. Causes include the following: primary (idiopathic) 
or secondary due to Chagas’ disease, lymphoma, carcinoma, chronic idio-
pathic intestinal pseudoobstruction, ischemia, neurotropic viruses, drugs, 
toxins, radiation therapy, postvagotomy.
� EVALUATION 
Chest x-ray shows absence of gastric air bubble. Barium swallow shows 
dilated esophagus with distal beaklike narrowing and air-fluid level. 
Endoscopy is done to rule out cancer, particularly in persons >50 years. 
Manometry shows normal or elevated LES pressure, decreased LES relax-
ation, absent peristalsis.
Achalasia
TREATMENT
Pneumatic balloon dilatation is effective in 85%, with 3–5% risk of 
perforation or bleeding. Injection of botulinum toxin at endoscopy 
to relax LES is safe and effective, but effects last only ~12 months. 
Myotomy of LES (Heller procedure) is effective, but 10–30% of 
pts develop gastroesophageal reflux. Nifedipine, 10–20 mg, or iso-
sorbide dinitrate, 5–10 mg SL ac, may avert need for dilatation or 
surgery. Sildenafil may also augment swallow-induced relaxation of 
the LES.
� SPASTIC DISORDERS 
Diffuse esophageal spasm involves multiple spontaneous and swallow-
induced contractions of the esophageal body that are of simultaneous onset 
and long duration and are recurrent. Causes include the following: primary 
(idiopathic) or secondary due to gastroesophageal reflux disease, emotional 
stress, diabetes, alcoholism, neuropathy, radiation therapy, ischemia, or col-
lagen vascular disease.
An important variant is nutcracker esophagus: high-amplitude 
(>180 mmHg) peristaltic contractions; particularly associated with chest 
pain or dysphagia, but correlation between symptoms and manometry 
is inconsistent. Condition may resolve over time or evolve into diffuse 
spasm; associated with increased frequency of depression, anxiety, and 
somatization.
� EVALUATION 
Barium swallow shows corkscrew esophagus, pseudodiverticula, and 
diffuse spasm. Manometry shows spasm with multiple simultaneous 
esophageal contractions of high amplitude and long duration. In nutcracker 
esophagus, the contractions are peristaltic and of high amplitude. If heart 
disease has been ruled out, edrophonium, ergonovine, or bethanechol can 
be used to provoke spasm.
SECTION 3
252
Common Patient Presentations
Spastic Disorders
TREATMENT
Anticholinergics are usually of limited value; nitrates (isosorbide dini-
trate, 5–10 mg PO ac) and calcium antagonists (nifedipine, 10–20 mg 
PO ac) are more effective. Those refractory to medical management 
may benefit from balloon dilatation. Rare pts require surgical interven-
tion: longitudinal myotomy of esophageal circular muscle. Treatment of 
concomitant depression or other psychological disturbance may help.
� SCLERODERMA 
Atrophy of the esophageal smooth muscle and fibrosis can make the 
esophagus aperistaltic and lead to an incompetent LES with attendant reflux 
esophagitis and stricture. Treatment of gastroesophageal reflux disease is 
discussed in Chap. 44.
ESOPHAGEAL INFLAMMATION
� VIRAL ESOPHAGITIS 
Herpesviruses I and II, varicella-zoster virus, and cytomegalovirus (CMV) can 
all cause esophagitis; particularly common in immunocompromised pts (e.g., 
AIDS). Odynophagia, dysphagia, fever, and bleeding are symptoms and signs. 
Diagnosis is made by endoscopy with biopsy, brush cytology, and culture.
Viral Esophagitis
TREATMENT
Disease is usually self-limited in the immunocompetent person; viscous 
lidocaine can relieve pain; in prolonged cases and in immunocompro-
mised hosts, herpes and varicella esophagitis are treated with acyclovir, 
5–10 mg/kg IV q8h for 10–14 d, then 200–400 mg PO 5 times a day for a 
week or valacyclovir 1 g PO tid for 7 days. CMV is treated with ganciclovir, 
5 mg/kg IV q12h, until healing occurs, which may take weeks. Oral valgan-
ciclovir (900 mg bid) is an effective alternative to parenteral treatment. In 
nonresponders, foscarnet, 90 mg/kg IV q12h for 21 days, may be effective.
� CANDIDA ESOPHAGITIS
In immunocompromised hosts, or those with malignancy, diabetes, hypo-
parathyroidism, hemoglobinopathy, systemic lupus erythematosus, cor-
rosive esophageal injury, candidal esophageal infection may present with 
odynophagia, dysphagia, and oral thrush (50%). Diagnosis is made on 
endoscopy by identifying yellow-white plaques or nodules on friable red 
mucosa. Characteristic hyphae are seen on KOH stain. In pts with AIDS, 
the development of symptoms may prompt an empirical therapeutic trial.
Candida Esophagitis
TREATMENT
Oral nystatin (100,000 U/mL), 5 mL q6h, or clotrimazole, 10-mg tablet 
sucked q6h, is effective. In immunocompromised hosts, fluconazole, 
200 mg PO on day 1 followed by 100 mg daily for 1–2 weeks, is treatment of
CHAPTER 46
253
Diarrhea, Constipation, and Malabsorption
choice; alternatives include itraconazole, 200 mg PO bid, or ketoconazole, 
200–400 mg PO daily; long-term maintenance therapy is often required. 
Poorly responsive pts may respond to higher doses of fluconazole (400 mg/d) 
or to amphotericin, 10–15 mg IV q6h for a total dose of 300–500 mg.
� PILL-RELATED ESOPHAGITIS 
Doxycycline, tetracycline, aspirin, nonsteroidal anti-inflammatory drugs, 
KCl, quinidine, ferrous sulfate, clindamycin, alprenolol, and alendronate 
can induce local inflammation in the esophagus. Predisposing factors 
include recumbency after swallowing pills with small sips of water and ana-
tomic factors impinging on the esophagus and slowing transit.
Pill-Related Esophagitis
TREATMENT
Withdraw offending drug, use antacids, and dilate any resulting stricture.
� EOSINOPHILIC ESOPHAGITIS 
Mucosal inflammation with eosinophils with submucosal fibrosis can 
be seen especially in pts with food allergies. This diagnosis relies on the 
presence of symptoms of esophagitis with the appropriate findings on 
esophageal biopsy. Eotaxin 3, an eosinophil chemokine, has been impli-
cated in its etiology. IL-5 and TARC (thymus and activation-related 
chemokine) levels may be elevated. Treatment involves a 12-week course 
of swallowed fluticasone (440 μg bid) using a metered-dose inhaler.
� OTHER CAUSES OF ESOPHAGITIS IN AIDS 
Mycobacteria, Cryptosporidium, Pneumocystis, idiopathic esophageal ulcers, 
and giant ulcers (possible cytopathic effect of HIV) can occur. Ulcers may 
respond to systemic glucocorticoids.
For a more detailed discussion, see Hirano I, Kahrilas PJ: 
Dysphagia, Chap. 38, p. 297; and Kahrilas PJ, Hirano I: 
Diseases of the Esophagus, Chap. 292, p. 2427, in HPIM-18.
CHAPTER 46
Diarrhea, Constipation, and 
Malabsorption
NORMAL GASTROINTESTINAL FUNCTION
� ABSORPTION OF FLUID AND ELECTROLYTES 
Fluid delivery to the GI tract is 8–10 L/d, including 2 L/d ingested; most is 
absorbed in small bowel. Colonic absorption is normally 0.05–2 L/d, with 
capacity for 6 L/d if required. Intestinal water absorption passively follows 
active transport of Na+, Cl–, glucose, and bile salts. Additional transport 
SECTION 3
254
Common Patient Presentations
mechanisms include Cl–/HCO3
– exchange, Na+/H+ exchange, H+, K+, Cl–, 
and HCO3
– secretion, Na+-glucose cotransport, and active Na+ transport 
across the basolateral membrane by Na+,K+-ATPase.
� NUTRIENT ABSORPTION
1. Proximal small intestine: iron, calcium, folate, fats (after hydrolysis of tri-
glycerides to fatty acids by pancreatic lipase and colipase), proteins (after 
hydrolysis by pancreatic and intestinal peptidases), carbohydrates (after 
hydrolysis by amylases and disaccharidases); triglycerides absorbed as 
micelles after solubilization by bile salts; amino acids and dipeptides 
absorbed via specific carriers; sugars absorbed by active transport.
2. Distal small intestine: vitamin B12, bile salts, water.
3. Colon: water, electrolytes.
� INTESTINAL MOTILITY 
Allows propulsion of intestinal contents from stomach to anus and 
separation of components to facilitate nutrient absorption. Propulsion is 
controlled by neural, myogenic, and hormonal mechanisms; mediated by 
migrating motor complex, an organized wave of neuromuscular activity 
that originates in the distal stomach during fasting and migrates slowly 
down the small intestine. Colonic motility is mediated by local peristalsis to 
propel feces. Defecation is effected by relaxation of internal anal sphincter 
in response to rectal distention, with voluntary control by contraction of 
external anal sphincter.
DIARRHEA
� PHYSIOLOGY 
Formally defined as fecal output >200 g/d on low-fiber (western) diet; also 
frequently used to connote loose or watery stools. Mediated by one or more 
of the following mechanisms:
� OSMOTIC DIARRHEA 
Nonabsorbed solutes increase intraluminal oncotic pressure, causing out-
pouring of water; usually ceases with fasting; stool osmolal gap > 40 (see 
below). Causes include disaccharidase (e.g., lactase) deficiencies, pancreatic 
insufficiency, bacterial overgrowth, lactulose or sorbitol ingestion, poly-
valent laxative abuse, celiac or tropical sprue, and short bowel syndrome. 
Lactase deficiency can be either primary (more prevalent in blacks and 
Asians, usually presenting in early adulthood) or secondary (from viral, bac-
terial, or protozoal gastroenteritis, celiac or tropical sprue, or kwashiorkor).
� SECRETORY DIARRHEA 
Active ion secretion causes obligatory water loss; diarrhea is usually watery, 
often profuse, unaffected by fasting; stool Na+ and K+ are elevated with 
osmolal gap <40. Causes include viral infections (e.g., rotavirus, Norwalk 
virus), bacterial infections (e.g., cholera, enterotoxigenic Escherichia coli, 
Staphylococcus aureus), protozoa (e.g., Giardia, Isospora, Cryptosporidium), 
AIDS-associated disorders (including mycobacterial and HIV-induced), 
medications (e.g., theophylline, colchicine, prostaglandins, diuretics), 
Zollinger-Ellison syndrome (excess gastrin production), vasoactive intestinal 
CHAPTER 46
255
Diarrhea, Constipation, and Malabsorption
peptide (VIP)-producing tumors, carcinoid tumors (histamine and sero-
tonin), medullary thyroid carcinoma (prostaglandins and calcitonin), sys-
temic mastocytosis, basophilic leukemia, distal colonic villous adenomas 
(direct secretion of potassium-rich fluid), collagenous and microscopic 
colitis, and choleraic diarrhea (from ileal malabsorption of bile salts).
� EXUDATIVE DIARRHEA 
Inflammation, necrosis, and sloughing of colonic mucosa; may include com-
ponent of secretory diarrhea due to prostaglandin release by inflammatory 
cells; stools usually contain polymorphonuclear leukocytes as well as occult 
or gross blood. Causes include bacterial infections [e.g., Campylobacter, 
Salmonella, Shigella, Yersinia, invasive or enterotoxigenic E. coli, Vibrio para-
haemolyticus, Clostridium difficile colitis (frequently antibiotic-induced)], 
colonic parasites (e.g., Entamoeba histolytica), Crohn’s disease, ulcerative 
proctocolitis, idiopathic inflammatory bowel disease, radiation enterocolitis, 
cancer chemotherapeutic agents, and intestinal ischemia.
� ALTERED INTESTINAL MOTILITY 
Alteration of coordinated control of intestinal propulsion; diarrhea often 
intermittent or alternating with constipation. Causes include diabetes 
mellitus, adrenal insufficiency, hyperthyroidism, collagen-vascular 
diseases, parasitic infestations, gastrin and VIP hypersecretory states, 
amyloidosis, laxatives (esp. magnesium-containing agents), antibiotics 
(esp. erythromycin), cholinergic agents, primary neurologic dysfunction 
(e.g., Parkinson’s disease, traumatic neuropathy), fecal impaction, diver-
ticular disease, and irritable bowel syndrome. Blood in intestinal lumen is 
cathartic, and major upper GI bleeding leads to diarrhea from increased 
motility.
� DECREASED ABSORPTIVE SURFACE 
Usually arises from surgical manipulation (e.g., extensive bowel resection 
or rearrangement) that leaves inadequate absorptive surface for fat and 
carbohydrate digestion and fluid and electrolyte absorption; occurs sponta-
neously from enteroenteric fistulas (esp. gastrocolic).
� EVALUATION HISTORY 
Diarrhea must be distinguished from fecal incontinence, change in stool 
caliber, rectal bleeding, and small, frequent, but otherwise normal stools. 
Careful medication history is essential. Alternating diarrhea and constipa-
tion suggests fixed colonic obstruction (e.g., from carcinoma) or irritable 
bowel syndrome. A sudden, acute course, often with nausea, vomiting, and 
fever, is typical of viral and bacterial infections, diverticulitis, ischemia, 
radiation enterocolitis, or drug-induced diarrhea and may be the initial 
presentation of inflammatory bowel disease. More than 90% of acute diar-
rheal illnesses are infectious in etiology. A longer (>4 weeks), more insidi-
ous course suggests malabsorption, inflammatory bowel disease, metabolic 
or endocrine disturbance, pancreatic insufficiency, laxative abuse, ischemia, 
neoplasm (hypersecretory state or partial obstruction), or irritable bowel 
syndrome. Parasitic and certain forms of bacterial enteritis can also produce 
chronic symptoms. Particularly foul-smelling or oily stool suggests fat 
SECTION 3
256
Common Patient Presentations
malabsorption. Fecal impaction may cause apparent diarrhea because only 
liquids pass partial obstruction. Several infectious causes of diarrhea are 
associated with an immunocompromised state (Table 46-1).
� PHYSICAL EXAMINATION 
Signs of dehydration are often prominent in severe, acute diarrhea. Fever 
and abdominal tenderness suggest infection or inflammatory disease but 
are often absent in viral enteritis. Evidence of malnutrition suggests chronic 
course. Certain signs are frequently associated with specific deficiency 
states secondary to malabsorption (e.g., cheilosis with riboflavin or iron 
deficiency, glossitis with B12, folate deficiency). Questions to address in pts 
with chronic diarrhea are shown in Table 46-2.
TABLE 46-1 INFECTIOUS CAUSES OF DIARRHEA IN PATIENTS WITH AIDS
Nonopportunistic Pathogens
Opportunistic Pathogens
Shigella
Protozoa
Salmonella
Cryptosporidium
Campylobacter
Isospora belli
Entamoeba histolytica
Microsporidia
Chlamydia
Blastocystis hominis
Neisseria gonorrhoeae
Viruses
Treponema pallidum and other spirochetes
Cytomegalovirus
Giardia lamblia
Herpes simplex
Adenovirus
HIV
Bacteria
Mycobacterium avium complex
TABLE 46-2  PHYSICAL EXAMINATION IN PATIENTS WITH CHRONIC 
DIARRHEA
1.  Are there general features to suggest malabsorption or inflammatory bowel 
disease (IBD) such as anemia, dermatitis herpetiformis, edema, or clubbing?
2.  Are there features to suggest underlying autonomic neuropathy or 
collagen-vascular disease in the pupils, orthostasis, skin, hands, or joints?
3. Is there an abdominal mass or tenderness?
4.  Are there any abnormalities of rectal mucosa, rectal defects, or altered 
anal sphincter functions?
5.  Are there any mucocutaneous manifestations of systemic disease such as 
dermatitis herpetiformis (celiac disease), erythema nodosum (ulcerative 
colitis), flushing (carcinoid), or oral ulcers for IBD or celiac disease?
CHAPTER 46
257
Diarrhea, Constipation, and Malabsorption
� STOOL EXAMINATION 
Culture for bacterial pathogens, examination for leukocytes, measurement 
of C. difficile toxin, and examination for ova and parasites are important 
components of evaluation of pts with severe, protracted, or bloody diarrhea. 
Presence of blood (fecal occult blood test) or leukocytes (Wright’s stain) 
suggests inflammation (e.g., ulcerative colitis, Crohn’s disease, infection, 
or ischemia). Gram’s stain of stool can be diagnostic of Staphylococcus, 
Campylobacter, or Candida infection. Steatorrhea (determined with Sudan 
III stain of stool sample or 72-h quantitative fecal fat analysis) suggests mal-
absorption or pancreatic insufficiency. Measurement of Na+ and K+ levels 
in fecal water helps to distinguish osmotic from other types of diarrhea; 
osmotic diarrhea is implied by stool osmolal gap > 40, where stool osmolal 
gap = osmolserum [2 × (Na+ + K+)stool].
� LABORATORY STUDIES 
Complete blood count may indicate anemia (acute or chronic blood loss or 
malabsorption of iron, folate, or B12), leukocytosis (inflammation), eosino-
philia (parasitic, neoplastic, and inflammatory bowel diseases). Serum 
levels of calcium, albumin, iron, cholesterol, folate, B12, vitamin D, and 
carotene; serum iron-binding capacity; and prothrombin time can provide 
evidence of intestinal malabsorption or maldigestion.
� OTHER STUDIES 
D-Xylose absorption test is a convenient screen for small-bowel absorptive 
function. Small-bowel biopsy is especially useful for evaluating intestinal 
malabsorption. Specialized studies include Schilling test (B12 malabsorp-
tion), lactose H2 breath test (carbohydrate malabsorption), [14C]xylose and 
lactulose H2 breath tests (bacterial overgrowth), glycocholic breath test (ileal 
malabsorption), triolein breath test (fat malabsorption), and bentiromide 
and secretin tests (pancreatic insufficiency). Sigmoidoscopy or colonoscopy 
with biopsy is useful in the diagnosis of colitis (esp. pseudomembranous, 
ischemic, microscopic); it may not allow distinction between infectious 
and noninfectious (esp. idiopathic ulcerative) colitis. Barium contrast x-ray 
studies may suggest malabsorption (thickened bowel folds), inflammatory 
bowel disease (ileitis or colitis), tuberculosis (ileocecal inflammation), neo-
plasm, intestinal fistula, or motility disorders.
Diarrhea
TREATMENT
An approach to the management of acute diarrheal illnesses is shown 
in Fig. 46-1. Symptomatic therapy includes vigorous rehydration (IV 
or with oral glucose-electrolyte solutions), electrolyte replacement, 
binders of osmotically active substances (e.g., kaolin-pectin), and 
opiates to decrease bowel motility (e.g., loperamide, diphenoxylate); 
opiates may be contraindicated in infectious or inflammatory causes 
of diarrhea. An approach to the management of chronic diarrhea is 
shown in Fig. 46-2.
SECTION 3
258
Common Patient Presentations
MALABSORPTION SYNDROMES
Intestinal malabsorption of ingested nutrients may produce osmotic diarrhea, 
steatorrhea, or specific deficiencies (e.g., iron; folate; B12; vitamins A, D, E, and K). 
Table 46-3 lists common causes of intestinal malabsorption. Protein-losing 
enteropathy may result from several causes of malabsorption; it is associated 
with hypoalbuminemia and can be detected by measuring stool α1-antitrypsin 
or radiolabeled albumin levels. Therapy is directed at the underlying disease.
CONSTIPATION
Defined as decrease in frequency of stools to <1 per week or difficulty in 
defecation; may result in abdominal pain, distention, and fecal impaction, 
with consequent obstruction or, rarely, perforation. Constipation is a fre-
quent and often subjective complaint. Contributory factors may include 
inactivity, low-fiber diet, and inadequate allotment of time for defecation.
History and
  physical exam
Moderate
  (activities altered)
Mild
  (unrestricted)
Observe
Resolves
Persists*
Severe
  (incapacitated)
Institute fluid and electrolyte replacement
Antidiarrheal
  agents
Resolves
Persists*
Stool microbiology
  studies
Pathogen found
Fever ≥38.5°C, bloody stools,   fecal WBCs,
  immunocompromised or elderly host
Evaluate and
  treat accordingly
Acute Diarrhea
Likely noninfectious
Likely infectious
Yes†
No
Yes†
No
Select specific
  treatment
Empirical
  treatment + further
  evaluation
FIGURE 46-1 Algorithm for the management of acute diarrhea. Before evaluation, 
consider empiric RX with (*) metronidazole and with (†) quinolone. 
CHAPTER 46
259
Diarrhea, Constipation, and Malabsorption
Exclude iatrogenic problem:
medication, surgery
Blood
pr
Colonoscopy
+ biopsy
Features, e.g.,
stool, suggest
malabsorption
Small bowel:
Imaging, biopsy,
aspirate
Pain aggravated
before bm, relieved
with bm, sense
incomplete evacuation
Suspect IBS
Limited screen for
organic disease
No blood,
features of
malabsorption
Consider
functional
diarrhea
Dietary exclusion,
e.g., lactose,
sorbitol
Chronic Diarrhea
A
FIGURE 46-2 Algorithm for the management of chronic diarrhea based on ac-
companying symptoms or features (A) or based on a limited screening for organic 
disease (B). pr, per rectum; bm, bowel movement; IBS, irritable bowel syndrome; Hb, 
hemoglobin; Alb, albumin; MCV, mean corpuscular volume; MCH, mean corpuscular 
hemoglobin; OSM, osmolality. (Reprinted from M Camilleri: Clin Gastrol Hepatol. 
2:198, 2004.)
Limited screen for organic disease
Chronic diarrhea
B
Stool vol, OSM, pH;
Laxative screen;
Hormonal screen
Persistent
chronic diarrhea
Titrate Rx to 
speed of transit
Opioid Rx +
follow-up
Low K+
Screening tests
all normal
Normal and
stool fat
<14 g/day
Full gut transit
Low Hb, Alb; abnormal MCV,
MCH; excess fat in stool
Small bowel: X-ray,
biopsy, aspirate;
stool 48-h fat
Colonoscopy +
biopsy
Stool fat >20 g/day
Pancreatic function
� SPECIFIC CAUSES 
Altered colonic motility due to neurologic dysfunction (diabetes mellitus, 
spinal cord injury, multiple sclerosis, Chagas’ disease, Hirschsprung’s 
disease, chronic idiopathic intestinal pseudoobstruction, idiopathic megaco-
lon), scleroderma, drugs (esp. anticholinergic agents, opiates, aluminum- or 
SECTION 3
260
Common Patient Presentations
calcium-based antacids, calcium channel blockers, iron supplements, sucral-
fate), hypothyroidism, Cushing’s syndrome, hypokalemia, hypercalcemia, 
dehydration, mechanical causes (colorectal tumors, diverticulitis, volvu-
lus, hernias, intussusception), and anorectal pain (from fissures, hemor-
rhoids, abscesses, or proctitis) leading to retention, constipation, and fecal 
impaction.
Constipation
TREATMENT
A management approach is shown in Fig. 46-3. In absence of iden-
tifiable cause, constipation may improve with reassurance, exercise, 
increased dietary fiber, bulking agents (e.g., psyllium), and increased 
fluid intake. Specific therapies include removal of bowel obstruc-
tion (fecalith, tumor), discontinuance of nonessential hypomotility 
agents (esp. aluminum-or calcium-containing antacids, opiates), or 
substitution of magnesium-based antacids for aluminum-based ant-
acids. For symptomatic relief, magnesium-containing agents or other 
cathartics are occasionally needed. With severe hypo- or dysmotility 
or in presence of opiates, osmotically active agents (e.g., oral lactulose, 
intestinal polyethylene glycol–containing lavage solutions) and oral or 
rectal emollient laxatives (e.g., docusate salts) and mineral oil are most 
effective.
TABLE 46-3 COMMON CAUSES OF MALABSORPTION
Maldigestion: Chronic pancreatitis, cystic fibrosis, pancreatic carcinoma
Bile salt deficiency: Cirrhosis, cholestasis, bacterial overgrowth (blind loop 
syndromes, intestinal diverticula, hypomotility disorders), impaired ileal 
reabsorption (resection, Crohn’s disease), bile salt binders (cholestyramine, 
calcium carbonate, neomycin)
Inadequate absorptive surface: Massive intestinal resection, gastrocolic 
fistula, jejunoileal bypass
Lymphatic obstruction: Lymphoma, Whipple’s disease, intestinal 
lymphangiectasia
Vascular disease: Constrictive pericarditis, right-sided heart failure, 
mesenteric arterial or venous insufficiency
Mucosal disease: Infection (esp. Giardia, Whipple’s disease, tropical sprue), 
inflammatory diseases (esp. Crohn’s disease), radiation enteritis, eosinophilic 
enteritis, ulcerative jejunitis, mastocytosis, tropical sprue, infiltrative disor-
ders (amyloidosis, scleroderma, lymphoma, collagenous sprue, microscopic 
colitis), biochemical abnormalities (gluten-sensitive enteropathy, disacchari-
dase deficiency, hypogammaglobulinemia, abetalipoproteinemia, amino acid 
transport deficiencies), endocrine disorders (diabetes mellitus, hypoparathy-
roidism, adrenal insufficiency, hyperthyroidism, Zollinger-Ellison syndrome, 
carcinoid syndrome)
CHAPTER 47
261
Gastrointestinal Bleeding
FIGURE 46-3 Algorithm for the management of chronic constipation. 
Clinical and basic laboratory tests
Bloods, chest and abd x-ray
Exclude mechanical obstruction, e.g., colonoscopy
Colonic transit
Consider functional
  bowel disease
Known
  disorder
Rx
No known underlying disorder
Anorectal manometry and balloon expulsion
Slow colonic transit
Normal
Rectoanal angle measurement,
  defecation proctography?
Appropriate Rx: Rehabilitation
  program, surgery, or other
Chronic Constipation
Normal
Abnormal
For a more detailed discussion, see Camilleri M, Murray 
JA: Diarrhea and Constipation, Chap. 40, p. 308; and 
Binder HJ: Disorders of Absorption, Chap. 294, p. 2460, in
HPIM-18.
CHAPTER 47
Gastrointestinal Bleeding
PRESENTATION
1. Hematemesis: Vomiting of blood or altered blood (“coffee grounds”) 
indicates bleeding proximal to ligament of Treitz.
2. Melena: Altered (black) blood per rectum (>100 mL blood required 
for one melenic stool) usually indicates bleeding proximal to ligament 
of Treitz but may be as distal as ascending colon; pseudomelena may 
SECTION 3
262
Common Patient Presentations
be caused by ingestion of iron, bismuth, licorice, beets, blueberries, 
charcoal.
3. Hematochezia: Bright red or maroon rectal bleeding usually implies 
bleeding beyond ligament of Treitz but may be due to rapid upper GI 
bleeding (>1000 mL).
4. Positive fecal occult blood test with or without iron deficiency.
5. Symptoms of blood loss: e.g., light-headedness or shortness of breath.
� HEMODYNAMIC CHANGES 
Orthostatic drop in BP >10 mmHg usually indicates >20% reduction in 
blood volume (± syncope, light-headedness, nausea, sweating, thirst).
� SHOCK 
BP <100 mmHg systolic usually indicates <30% reduction in blood volume 
(± pallor, cool skin).
� LABORATORY CHANGES 
Hematocrit may not reflect extent of blood loss because of delayed equili-
bration with extravascular fluid. Mild leukocytosis and thrombocytosis. 
Elevated blood urea nitrogen is common in upper GI bleeding.
� ADVERSE PROGNOSTIC SIGNS 
Age >60, associated illnesses, coagulopathy, immunosuppression, presenta-
tion with shock, rebleeding, onset of bleeding in hospital, variceal bleeding, 
endoscopic stigmata of recent bleeding [e.g., “visible vessel” in ulcer base 
(see below)].
UPPER GI BLEEDING
� CAUSES 
Common
Peptic ulcer (accounts for ~50%), gastropathy [alcohol, aspirin, nonsteroi-
dal anti-inflammatory drugs (NSAIDs), stress], esophagitis, Mallory-Weiss 
tear (mucosal tear at gastroesophageal junction due to retching), gastro-
esophageal varices.
Less Common 
Swallowed blood (nosebleed); esophageal, gastric, or intestinal neo-
plasm; anticoagulant and fibrinolytic therapy; hypertrophic gastropathy 
(Ménétrier’s disease); aortic aneurysm; aortoenteric fistula (from aortic 
graft); arteriovenous malformation; telangiectases (Osler-Rendu-Weber 
syndrome); Dieulafoy lesion (ectatic submucosal vessel); vasculitis; con-
nective tissue disease (pseudoxanthoma elasticum, Ehlers-Danlos syn-
drome); blood dyscrasias; neurofibroma; amyloidosis; hemobilia (biliary 
origin).
� EVALUATION 
After hemodynamic resuscitation (see below and Fig. 47-1).
• History and physical examination: Drugs (increased risk of upper and 
lower GI tract bleeding with aspirin and NSAIDs), prior ulcer, bleeding 
Acute Upper GI Bleeding
ICU for 1-2 days;
ward for 2-3 days
Ligation + IV
vasoactive drug
(e.g., octreotide)
Esophageal varices
Ulcer
Mallory-Weiss tear
Clean base
Discharge
No IV PPI
or endoscopic
therapy
Active bleeding
or visible vessel
ICU for 1 day;
ward for 2 days
IV PPI therapy
+ endoscopic
therapy
Adherent clot
Ward for 3 days
IV PPI therapy
+/– endoscopic
therapy
Flat,
pigmented spot
No IV PPI
or endoscopic
therapy
Ward for 3 days
Active
bleeding
No active
bleeding
No
endoscopic
therapy
Discharge
Endoscopic
therapy
Ward for
1-2 days
FIGURE 47-1 Suggested algorithm for pts with acute upper GI bleeding. Recommendations on level of care and time of discharge assume pt is stabilized without 
further bleeding or other concomitant medical problems. ICU, intensive care unit; PPI, proton pump inhibitor. 
263
SECTION 3
264
Common Patient Presentations
history, family history, features of cirrhosis or vasculitis, etc. Hyperactive 
bowel sounds favor upper GI source.
• Nasogastric aspirate for gross blood, if source (upper versus lower) not 
clear from history; may be falsely negative in up to 16% of pts if bleeding 
has ceased or duodenum is the source. Testing aspirate for occult blood 
is meaningless.
• Upper endoscopy: Accuracy >90%; allows visualization of bleeding site 
and possibility of therapeutic intervention; mandatory for suspected 
varices, aortoenteric fistulas; permits identification of “visible vessel” 
(protruding artery in ulcer crater), which connotes high (~50%) risk of 
rebleeding.
• Upper GI barium radiography: Accuracy ~80% in identifying a lesion, 
though does not confirm source of bleeding; acceptable alternative to 
endoscopy in resolved or chronic low-grade bleeding.
• Selective mesenteric arteriography: When brisk bleeding precludes iden-
tification of source at endoscopy.
• Radioisotope scanning (e.g., 99Tc tagged to red blood cells or albumin); 
used primarily as screening test to confirm bleeding is rapid enough 
for arteriography to be of value or when bleeding is intermittent and of 
unclear origin.
LOWER GI BLEEDING
� CAUSES 
Anal lesions (hemorrhoids, fissures), rectal trauma, proctitis, colitis (ulcer-
ative colitis, Crohn’s disease, infectious colitis, ischemic colitis, radia-
tion), colonic polyps, colonic carcinoma, angiodysplasia (vascular ectasia), 
diverticulosis, intussusception, solitary ulcer, blood dyscrasias, vasculitis, 
connective tissue disease, neurofibroma, amyloidosis, anticoagulation.
� EVALUATION (SEE BELOW AND FIG. 47-2)
• History and physical examination.
• In the presence of hemodynamic changes, perform upper endoscopy fol-
lowed by colonoscopy. In the absence of hemodynamic changes, perform 
anoscopy and either flexible sigmoidoscopy or colonoscopy: Exclude 
hemorrhoids, fissure, ulcer, proctitis, neoplasm.
• Colonoscopy: Often test of choice, but may be impossible if bleeding is 
massive.
• Barium enema: No role in active bleeding.
• Arteriography: When bleeding is severe (requires bleeding rate >0.5 mL /min; 
may require prestudy radioisotope bleeding scan as above); defines site of 
bleeding or abnormal vasculature.
• Surgical exploration (last resort).
� BLEEDING OF OBSCURE ORIGIN 
Often small-bowel source. Consider small-bowel enteroclysis x-ray (careful 
barium radiography via peroral intubation of small bowel), Meckel’s scan, 
enteroscopy (small-bowel endoscopy), or exploratory laparotomy with 
intraoperative enteroscopy.
CHAPTER 47
265
Gastrointestinal Bleeding
Hemodynamic
instability
Site identified;
bleeding stops
Angiography
Obscure bleeding
work-up
Flexible
sigmoidoscopy
(colonoscopy if
iron-deficiency
anemia, familial
colon cancer, or
copious bleeding)*
Bleeding persists
Surgery
Acute Lower
GI Bleeding
No hemodynamic
instability
Age  ≥ 40 yrs
Upper endoscopy
Age < 40 yrs
Colonoscopy
Colonoscopy†
Site identified;
bleeding persists
Site not identified;
bleeding persists
FIGURE 47-2 Suggested algorithm for pts with acute lower gastrointestinal bleeding. 
*Some suggest colonoscopy for any degree of rectal bleeding in pts <40 years as well. 
†If massive bleeding does not allow time for colonic lavage, proceed to angiography.
Upper and Lower GI Bleeding
TREATMENT
• Venous access with large-bore IV (14–18 gauge); central venous line for 
major bleed and pts with cardiac disease; monitor vital signs, urine output, 
Hct (fall may lag). Gastric lavage of unproven benefit but clears stomach 
before endoscopy. Iced saline may lyse clots; room-temperature tap water 
may be preferable. Intubation may be required to protect airway.
• Type and cross-match blood (6 units for major bleed).
• Surgical standby when bleeding is massive.
• Support blood pressure with isotonic fluids (normal saline); albumin and 
fresh-frozen plasma in cirrhotics. Packed red blood cells when available 
(whole blood if massive bleeding); maintain Hct >25–30. Fresh-frozen 
plasma and vitamin K (10 mg SC or IV) in cirrhotics with coagulopathy.
SECTION 3
266
Common Patient Presentations
• IV calcium (e.g., up to 10–20 mL 10% calcium gluconate IV over 
10–15 min) if serum calcium falls (due to transfusion of citrated 
blood). Empirical drug therapy (antacids, H2 receptor blockers, 
omeprazole) of unproven benefit.
• Specific measures: Varices: octreotide (50-μg bolus, 50-μg/h infusion 
for 2–5 days), Sengstaken-Blakemore tube tamponade, endoscopic 
sclerosis, or band ligation; propranolol or nadolol in doses sufficient to 
cause beta blockade reduces risk of recurrent or initial variceal bleed-
ing (do not use in acute bleed) (Chap. 166); ulcer with visible vessel 
or active bleeding: endoscopic bipolar, heater-probe, or laser coagula-
tion or injection of epinephrine; gastritis: embolization or vasopres-
sin infusion of left gastric artery; GI telangiectases: ethinylestradiol/
norethisterone (0.05/1.0 mg PO qd) may prevent recurrent bleeding, 
particularly in pts with chronic renal failure; diverticulosis: mesenteric 
arteriography with intra-arterial vasopressin; angiodysplasia: colono-
scopic bipolar or laser coagulation, may regress with replacement of 
stenotic aortic valve.
• Indications for emergency surgery: Uncontrolled or prolonged bleeding, 
severe rebleeding, aortoenteric fistula. For intractable variceal bleeding, 
consider transjugular intrahepatic portosystemic shunt (TIPS).
For a more detailed discussion, see Laine L: Gastrointestinal 
Bleeding, Chap. 41, p. 320, in HPIM-18.
CHAPTER 48
Jaundice and Evaluation 
of Liver Function
� JAUNDICE
Definition
Yellow skin pigmentation caused by elevation in serum bilirubin level 
(also termed icterus); often more easily discernible in sclerae. Scleral 
icterus becomes clinically evident at a serum bilirubin level of ≥51 μmol/L 
(≥3 mg/dL); yellow skin discoloration also occurs with elevated serum caro-
tene levels but without pigmentation of the sclerae.
Bilirubin Metabolism 
Bilirubin is the major breakdown product of hemoglobin released from 
senescent erythrocytes. Initially, it is bound to albumin, transported into 
the liver, conjugated to a water-soluble form (glucuronide) by glucuronosyl 
CHAPTER 48
267
Jaundice and Evaluation of Liver Function 
transferase, excreted into the bile, and converted to urobilinogen in the 
colon. Urobilinogen is mostly excreted in the stool; a small portion is 
reabsorbed and excreted by the kidney. Bilirubin can be filtered by the 
kidney only in its conjugated form (measured as the “direct” fraction); 
thus, increased direct serum bilirubin level is associated with bilirubinuria. 
Increased bilirubin production and excretion (even without hyperbilirubi-
nemia, as in hemolysis) produce elevated urinary urobilinogen levels.
Etiology 
Hyperbilirubinemia occurs as a result of (1) overproduction; (2) impaired 
uptake, conjugation, or excretion of bilirubin; (3) regurgitation of uncon-
jugated or conjugated bilirubin from damaged hepatocytes or bile ducts 
(Table 48-1).
TABLE 48-1 CAUSES OF ISOLATED HYPERBILIRUBINEMIA
I. Indirect hyperbilirubinemia
A. Hemolytic disorders
1. Inherited
a. Spherocytosis, elliptocytosis
b.  Glucose-6-phosphate dehydrogenase and pyruvate kinase 
deficiencies
c. Sickle cell anemia
2. Acquired
a. Microangiopathic hemolytic anemias
b. Paroxysmal nocturnal hemoglobinuria
c. Spur cell anemia
d. Immune hemolysis
e. Parasitic infections 
1. Malaria
2. Babesiosis
B. Ineffective erythropoiesis
1. Cobalamin, folate, thalassemia, and severe iron deficiencies
C. Drugs
1. Rifampicin, probenecid, ribavirin
D. Inherited conditions
1. Crigler-Najjar types I and II
2. Gilbert’s syndrome
II. Direct hyperbilirubinemia
A. Inherited conditions
1. Dubin-Johnson syndrome
2. Rotor’s syndrome
SECTION 3
268
Common Patient Presentations
Evaluation 
The initial steps in evaluating the pt with jaundice are to determine whether (1) 
hyperbilirubinemia is conjugated or unconjugated, and (2) other biochemical 
liver tests are abnormal (Figs. 48-1 and 48-2, Tables 48-2 and 48-3). Essential 
clinical examination includes history (especially duration of jaundice, pruritus, 
associated pain, risk factors for parenterally transmitted diseases, medications, 
ethanol use, travel history, surgery, pregnancy, presence of any accompanying 
symptoms), physical examination (hepatomegaly, tenderness over liver, palpable 
gallbladder, splenomegaly, gynecomastia, testicular atrophy, other stigmata of 
chronic liver disease), blood liver tests (see below), and complete blood count.
History (focus on medication/drug exposure)
    Physical examination
    Lab tests: Bilirubin with fractionation,
    ALT, AST, alkaline phosphatase,
      prothrombin time, and albumin
Isolated elevation
  of the bilirubin
Indirect
  hyperbilirubinemia
  (direct < 15%)
See Table 48-1
Direct
  hyperbilirubinemia
    (direct > 15%)
    See Table 48-1
Drugs
    Rifampicin
    Probenecid
Inherited disorders
    Dubin-Johnson
      syndrome
    Rotor's syndrome
1. Viral serologies
        Hepatitis A IgM
        Hepatitis B surface
            antigen and core
            antibody (IgM)
        Hepatitis C RNA
2. Toxicology screen
      Acetaminophen level
3. Ceruloplasmin (if
      patient < 40
      years of age)
4. ANA, SMA, LKM, SPEP
Inherited disorders
    Gilbert's syndrome
    Crigler-Najjar syndromes
Hemolytic disorders
Ineffective erythropoiesis
Bilirubin and other
  liver tests elevated
Hepatocellular pattern:
  ALT/AST elevated out
  of proportion to
  alkaline phosphatase
  See Table 48-2
Cholestatic pattern:
  Alkaline phosphatase
  out of proportion
  ALT/AST
  See Table 48-3
Dilated ducts
Extrahepatic
  cholestasis
CT/ERCP
Liver biopsy
Liver biopsy
MRCP/Liver biopsy
Results
negative
Results
negative
Additional virologic testing
    CMV DNA, EBV capsid
      antigen
    Hepatitis D antibody
      (if indicated)
    Hepatitis E IgM
      (if indicated)
Results
negative
AMA
positive
Serologic testing
    AMA
    Hepatitis serologies
    Hepatitis A, CMV, EBV
Review drugs (see Table 48-3)
Ultrasound
Ducts not dilated
Intrahepatic
 cholestasis
ALGORITHM FOR PATIENT WITH JAUNDICE
FIGURE 48-1 Evaluation of the pt with jaundice. ALT, alanine aminotransferase; 
AMA, antimitochondrial antibody; ANA, antinuclear antibody; AST, aspartate ami-
notransferase; CMV, cytomegalovirus; EBV, Epstein-Barr virus; LKM, liver-kidney 
microsomal antibody; MRCP, magnetic resonance cholangiopancreatography; SMA, 
smooth-muscle antibody; SPEP, serum protein electrophoresis.
CHAPTER 48
269
Jaundice and Evaluation of Liver Function 
Gilbert’s Syndrome 
Impaired conjugation of bilirubin due to reduced bilirubin UDP glucuro-
nosyl transferase activity. Results in mild unconjugated hyperbilirubinemia, 
almost always <103 μmol/L (<6 mg/dL). Affects 3–7% of the population; 
males/females 2–7:1.
� BLOOD TESTS OF LIVER FUNCTION
Used to detect presence of liver disease (Fig. 48-2), discriminate among 
different types of liver disease (Table 48-4), gauge the extent of known liver 
damage, and follow response to treatment.
Bilirubin
Provides indication of hepatic uptake, metabolic (conjugation) and excre-
tory functions; conjugated fraction (direct) distinguished from unconju-
gated by chemical assay (Table 48-1).
EVALUATION OF ABNORMAL LIVER TESTS
Suspected Liver Disease
Abnormal liver tests
Acute
< 6 months
Chronic
> 6 months
Diagnostic
evaluation
1. lgM Anti-HAV
2. HBsAg
3. lgM Anti-HBc
4. Anti-HCV
5. ANA, SMA
6. Monospot,
    heterophile
7. Ceruloplasmin
8. Alcohol history
9. Drug history
Diagnostic
evaluation
1. AMA
2. Drug history
3. Ultrasound/MRI
4. MRCP/ERCP
Liver biopsy in acute liver disease:
Reserved for patients in whom the 
diagnosis remains unclear despite 
medical evaluation
Liver biopsy in chronic liver disease: 
Often valuable for diagnosis as well 
as staging and grading liver disease
Diagnostic
evaluation
1. HBsAg
2. Anti-HCV
3. Fe saturation,
    ferritin
4. Ceruloplasmin
5. α1AT
6. ANA, SMA
7. Ultrasound
8. Alcohol history
Diagnostic
evaluation
1. Drug history
2. AMA
3. P-ANCA
4. Ultrasound
5. MRCP/ERCP
Hepatic: ⇑⇑ALT
Mixed: ↑ALT,
             ↑AlkP
Cholestatic:
   ⇑⇑AlkP,
   ⇑⇑GGT,
   ↑ALT
Hepatic: ⇑⇑ALT
Mixed: ↑ALT,
             ↑AlkP
Cholestatic:
   ⇑⇑AlkP,
   ⇑⇑GGT,
   ↑ALT
FIGURE 48-2 Algorithm for evaluation of abnormal liver tests.
SECTION 3
270
Common Patient Presentations
TABLE 48-2  HEPATOCELLULAR CONDITIONS THAT MAY PRODUCE 
JAUNDICE
Viral hepatitis
Hepatitis A, B, C, D, and E
Epstein-Barr virus
Cytomegalovirus
Herpes simplex
Alcohol
Drug toxicity
Predictable, dose-dependent, (e.g., acetaminophen)
Unpredictable, idiosyncratic, (e.g., isoniazid)
Environmental toxins
Vinyl chloride
Jamaica bush tea—pyrrolizidine alkaloids
Kava Kava
Wild mushrooms—Amanita phalloides or A. verna
Wilson’s disease
Autoimmune hepatitis
Aminotransferases (Transaminases) 
Aspartate aminotransferase (AST; SGOT) and alanine aminotransferase 
(ALT; SGPT); sensitive indicators of liver cell injury; greatest elevations 
seen in hepatocellular necrosis (e.g., viral hepatitis, toxic or ischemic liver 
injury, acute hepatic vein obstruction), occasionally with sudden, complete 
biliary obstruction (e.g., from gallstone); milder abnormalities in choles-
tatic, cirrhotic, and infiltrative disease; poor correlation between degree of 
liver cell damage and level of aminotransferases; ALT more specific measure 
of liver injury, since AST also found in striated muscle and other organs; 
ethanol-induced liver injury usually produces modest increases with more 
prominent elevation of AST than ALT.
Alkaline Phosphatase
Sensitive indicator of cholestasis, biliary obstruction (enzyme increases 
more quickly than serum bilirubin), and liver infiltration; mild elevations 
in other forms of liver disease; limited specificity because of wide tissue 
distribution; elevations also seen in normal childhood, pregnancy, and bone 
diseases; tissue-specific isoenzymes can be distinguished by fractionation or 
by differences in heat stability (liver enzyme activity stable under conditions 
that destroy bone enzyme activity).
5′-Nucleotidase (5′-NT)
Pattern of elevation in hepatobiliary disease similar to alkaline phosphatase; 
has greater specificity for liver disorders; used to determine whether liver 
CHAPTER 48
271
Jaundice and Evaluation of Liver Function 
TABLE 48-3 CHOLESTATIC CONDITIONS THAT MAY PRODUCE JAUNDICE
I. Intrahepatic
A. Viral hepatitis
1. Fibrosing cholestatic hepatitis—hepatitis B and C
2. Hepatitis A, Epstein-Barr virus, cytomegalovirus
B. Alcoholic hepatitis
C. Drug toxicity
1. Pure cholestasis—anabolic and contraceptive steroids
2. Cholestatic hepatitis—chlorpromazine, erythromycin estolate
3. Chronic cholestasis—chlorpromazine and prochlorperazine
D.   Primary biliary cirrhosis
E. Primary sclerosing cholangitis
F.   Vanishing bile duct syndrome
1. Chronic rejection of liver transplants
2. Sarcoidosis
3. Drugs
G. Inherited
1. Progressive familial intrahepatic cholestasis
2. Benign recurrent cholestasis
H. Cholestasis of pregnancy
I.    Total parenteral nutrition
J.    Nonhepatobiliary sepsis
K. Benign postoperative cholestasis
L. Paraneoplastic syndrome
M.  Venoocclusive disease
N. Graft-versus-host disease
O. Infiltrative disease
1. TB
2. Lymphoma
3. Amyloidosis
II. Extrahepatic
A. Malignant
1. Cholangiocarcinoma
2. Pancreatic cancer
3. Gallbladder cancer
4. Ampullary cancer
5. Malignant involvement of the porta hepatis lymph nodes
(continued)
SECTION 3
272
Common Patient Presentations
TABLE 48-3  CHOLESTATIC CONDITIONS THAT MAY PRODUCE JAUNDICE 
(CONTINUED)
B. Benign
1. Choledocholithiasis
2. Postoperative biliary structures
3. Primary sclerosing cholangitis
4. Chronic pancreatitis
5. AIDS cholangiopathy
6. Mirizzi syndrome
7. Parasitic disease (ascariasis)
is source of elevation in serum alkaline phosphatase, esp. in children, preg-
nant women, pts with possible concomitant bone disease.
γ-Glutamyltranspeptidase (GGT) 
Correlates with serum alkaline phosphatase activity. Elevation is less spe-
cific for cholestasis than alkaline phosphatase or 5′-NT.
TABLE 48-4 LIVER TEST PATTERNS IN HEPATOBILIARY DISORDERS
Type of Disorder
Bilirubin
Aminotransferases
Hemolysis/Gilbert’s 
syndrome
Normal to 86 μmol/L 
(5 mg/dL)
Normal
85% due to indirect 
fractions
No bilirubinuria
Acute hepatocellular 
necrosis (viral and drug 
hepatitis, hepatotoxins, 
acute heart failure)
Both fractions may be 
elevated
Elevated, often >500 IU 
ALT >AST
Peak usually follows 
aminotransferases
Bilirubinuria
Chronic hepatocellular 
disorders
Both fractions may be 
elevated
Elevated, but usually 
<300 IU
Bilirubinuria
Alcoholic hepatitis
Both fractions may be 
elevated
AST:ALT > 2 suggests 
alcoholic hepatitis or 
cirrhosis
Cirrhosis
Bilirubinuria
Intra- and extra-hepatic 
cholestasis
Both fractions may be 
elevated
Normal to moderate 
elevation
(Obstructive jaundice)
Bilirubinuria
Rarely >500 IU
Infiltrative diseases (tumor, 
granulomata); partial bile 
duct obstruction
Usually normal
Normal to slight 
elevation
CHAPTER 48
273
Jaundice and Evaluation of Liver Function 
Coagulation Factors (See also Chap. 70)
Measure of clotting factor activity; prolongation results from clotting factor 
deficiency or inactivity; all clotting factors except factor VIII are synthe-
sized in the liver, and deficiency can occur rapidly from widespread liver 
disease as in hepatitis, toxic injury, or cirrhosis; single best acute measure 
of hepatic synthetic function; helpful in Dx and prognosis of acute liver 
disease. Clotting factors II, VII, IX, X function only in the presence of 
the fat-soluble vitamin K; PT prolongation from fat malabsorption distin-
guished from hepatic disease by rapid and complete response to vitamin K 
replacement.
Albumin
Decreased serum levels result from decreased hepatic synthesis (chronic 
liver disease or prolonged malnutrition) or excessive losses in urine or stool; 
insensitive indicator of acute hepatic dysfunction, since serum half-life is 
2–3 weeks; in pts with chronic liver disease, degree of hypoalbuminemia 
correlates with severity of liver dysfunction.
Globulin
Mild polyclonal hyperglobulinemia often seen in chronic liver diseases; 
marked elevation frequently seen in autoimmune chronic active hepatitis.
TABLE 48-4  LIVER TEST PATTERNS IN HEPATOBILIARY DISORDERS 
(CONTINUED)
Alkaline Phosphatase
Albumin
Prothrombin Time
Normal
Normal
Normal
Normal to <3 times normal 
elevation
Normal
Usually normal. If >5 × 
above control and not 
corrected by parenteral 
vitamin K, suggests 
poor prognosis
Normal to <3 times normal 
elevation
Often decreased
Often prolonged
Fails to correct with 
parenteral vitamin K
Normal to <3 times normal 
elevation 
Often decreased
Often prolonged
Fails to correct with 
parenteral vitamin K
Elevated, often >4 times 
normal elevation
Normal, unless 
chronic
Normal
If prolonged, will 
correct with parenteral 
vitamin K
Elevated, often >4 times 
normal elevation
Fractionate, or confirm liver 
origin with 5′ nucleotidase or 
γ glutamyl transpeptidase
Normal
Normal
SECTION 3
274
Common Patient Presentations
Ammonia
Elevated blood levels result from deficiency of hepatic detoxification path-
ways and portal-systemic shunting, as in fulminant hepatitis, hepatotoxin 
exposure, and severe portal hypertension (e.g., from cirrhosis); elevation of 
blood ammonia does not correlate well with hepatic function or the pres-
ence or degree of acute encephalopathy.
� HEPATOBILIARY IMAGING PROCEDURES
Ultrasonography (US) 
Rapid, noninvasive examination of abdominal structures; no radiation expo-
sure; relatively low cost, equipment portable; images and interpretation strongly 
dependent on expertise of examiner; particularly valuable for detecting biliary 
duct dilatation and gallbladder stones (>95%); much less sensitive for intraductal 
stones (~60%); most sensitive means of detecting ascites; moderately sensitive 
for detecting hepatic masses but excellent for discriminating solid from cystic 
structures; useful in directing percutaneous needle biopsies of suspicious lesions; 
Doppler US useful to determine patency and flow in portal, hepatic veins and 
portal-systemic shunts; imaging improved by presence of ascites but severely 
hindered by bowel gas; endoscopic US less affected by bowel gas and is sensitive 
for determination of depth of tumor invasion through bowel wall.
CT
Particularly useful for detecting, differentiating, and directing percutaneous 
needle biopsy of abdominal masses, cysts, and lymphadenopathy; imaging 
enhanced by intestinal or intravenous contrast dye and unaffected by intes-
tinal gas; somewhat less sensitive than US for detecting stones in gallbladder 
but more sensitive for choledocholithiasis; may be useful in distinguishing 
certain forms of diffuse hepatic disease (e.g., fatty infiltration, iron overload).
MRI
Most sensitive detection of hepatic masses and cysts; allows easy differentia-
tion of hemangiomas from other hepatic tumors; most accurate noninvasive 
means of assessing hepatic and portal vein patency, vascular invasion by 
tumor; useful for monitoring iron, copper deposition in liver (e.g., in hemo-
chromatosis, Wilson’s disease). Magnetic resonance cholangiopancreatogra-
phy (MRCP) can be useful for visualizing the head of the pancreas and the 
pancreatic and biliary ducts.
Radionuclide Scanning 
Using various radiolabeled compounds, different scanning methods allow 
sensitive assessment of biliary excretion (HIDA, PIPIDA, DISIDA scans), 
parenchymal changes (technetium sulfur colloid liver/spleen scan), and 
selected inflammatory and neoplastic processes (gallium scan); HIDA and 
related scans particularly useful for assessing biliary patency and excluding 
acute cholecystitis in situations where US is not diagnostic; CT, MRI, and 
colloid scans have similar sensitivity for detecting liver tumors and metas-
tases; CT and combination of colloidal liver and lung scans sensitive for 
detecting right subphrenic (suprahepatic) abscesses.
CHAPTER 49
275
Ascites
Cholangiography
Most sensitive means of detecting biliary ductal calculi, biliary tumors, scle-
rosing cholangitis, choledochal cysts, fistulas, and bile duct leaks; may be 
performed via endoscopic (transampullary) or percutaneous (transhepatic) 
route; allows sampling of bile and ductal epithelium for cytologic analysis 
and culture; allows placement of biliary drainage catheter and stricture 
dilatation; endoscopic route (ERCP) permits manometric evaluation of 
sphincter of Oddi, sphincterotomy, and stone extraction.
Angiography
Most accurate means of determining portal pressures and assessing patency 
and direction of flow in portal and hepatic veins; highly sensitive for detect-
ing small vascular lesions and hepatic tumors (esp. primary hepatocellular 
carcinoma); “gold standard” for differentiating hemangiomas from solid 
tumors; most accurate means of studying vascular anatomy in preparation 
for complicated hepatobiliary surgery (e.g., portal-systemic shunting, biliary 
reconstruction) and determining resectability of hepatobiliary and pancre-
atic tumors. Similar anatomic information (but not intravascular pressures) 
can often be obtained noninvasively by CT- and MR-based techniques.
Percutaneous Liver Biopsy 
Most accurate in disorders causing diffuse changes throughout the liver; 
subject to sampling error in focal infiltrative disorders such as metastasis; 
should not be the initial procedure in the Dx of cholestasis.
For a more detailed discussion, see Pratt DS, Kaplan MM: 
Jaundice, Chap. 42, p. 324; Ghany M, Hoofnagle JH: 
Approach to the Patient With Liver Disease, Chap 301, 
p. 2520; and Pratt DS, Kaplan MM: Evaluation of Liver 
Function, Chap. 302, p. 2527, in HPIM-18.
CHAPTER 49
Ascites
� DEFINITION
Accumulation of fluid within the peritoneal cavity. Small amounts may be 
asymptomatic; increasing amounts cause abdominal distention and discomfort, 
anorexia, nausea, early satiety, heartburn, flank pain, and respiratory distress.
� DETECTION
Physical Examination 
Bulging flanks, fluid wave, shifting dullness, “puddle sign” (dullness over 
dependent abdomen with pt on hands and knees). May be associated with 
penile or scrotal edema, umbilical or inguinal herniation, pleural effusion. 
SECTION 3
276
Common Patient Presentations
Evaluation should include rectal and pelvic examination, assessment of 
liver and spleen. Palmar erythema and spider angiomata seen in cirrho-
sis. Periumbilical nodule (Sister Mary Joseph’s nodule) suggests metastatic 
disease from a pelvic or GI tumor.
Ultrasonography/CT
Very sensitive; able to distinguish fluid from cystic masses.
� EVALUATION
Diagnostic paracentesis (50–100 mL) essential. Routine evaluation includes 
gross inspection, protein, albumin, glucose, cell count and differential, 
Gram’s and acid-fast stains, culture, cytology; in selected cases check amylase, 
LDH, triglycerides, culture for tuberculosis (TB). Rarely, laparoscopy or even 
exploratory laparotomy may be required. Ascites due to CHF (e.g., pericardial 
constriction) may require evaluation by right-sided heart catheterization.
Differential Diagnosis 
More than 90% of cases due to cirrhosis, neoplasm, CHF, TB.
Diseases of peritoneum: Infections (bacterial, tuberculous, fungal, para-
sitic), neoplasms, connective tissue disease, miscellaneous (Whipple’s dis-
ease, familial Mediterranean fever, endometriosis, starch peritonitis, etc.).
Diseases not involving peritoneum: Cirrhosis, CHF, Budd-Chiari 
syndrome, hepatic venoocclusive disease, hypoalbuminemia (nephrotic 
syndrome, protein-losing enteropathy, malnutrition), miscellaneous 
(myxedema, ovarian diseases, pancreatic disease, chylous ascites).
Pathophysiologic Classification Using Serum-Ascites 
Albumin Gradient (SAAG)
Difference in albumin concentrations between serum and ascites as a reflec-
tion of imbalances in hydrostatic pressures and can be used to differentiate 
between potential causes of ascites (Fig. 49-1). 
< 1.1 g/dL
Ascitic protein ≥ 2.5 g/dL
Cirrhosis
Late Budd-Chiari syndrome
Massive liver metastases
≥ 1.1 g/dL
Congestive heart failure/
constrictive pericarditis
Early Budd-Chiari syndrome
IVC obstruction
Sinusoidal obstruction
syndrome
Biliary leak
Nephrotic syndrome
Pancreatitis
Peritoneal carcinomatosis
Tuberculosis
Ascitic protein < 2.5 g/dL
SAAG
FIGURE 49-1 Algorithm for the diagnosis of ascites according to the serum-ascites 
albumin gradient (SAAG). IVC, inferior vena cava.
CHAPTER 49
277
Ascites
� CIRRHOTIC ASCITES
Pathogenesis 
Contributing factors: (1) portal hypertension, (2) hypoalbuminemia, 
(3) hepatic lymph, (4) renal sodium retention–secondary to hyperaldoste-
ronism, increased sympathetic nervous system activity (renin-angiotensin 
production). Initiating event may be peripheral arterial vasodilation 
triggered by endotoxin and cytokines and mediated by nitric oxide.
Cirrhotic Ascites
TREATMENT
Maximum mobilization ~700 mL/d (peripheral edema may be mobilized 
faster).
1. Rigid salt restriction (<2 g Na/d).
2. For moderate ascites, diuretics usually necessary; spironolactone 
100–200 mg/d PO (can be increased to 400 mg/d if low-sodium diet 
is confirmed and fluid not mobilized); furosemide 40–80 mg/d PO or 
IV may be added if necessary (greater risk of hepatorenal syndrome, 
encephalopathy), can increase to maximum of 120–160 mg/d until 
effect achieved or complication occurs.
3. Monitor weight, urinary Na and K, serum electrolytes, and creatinine. 
If ascites is still present with the above measures this is defined as 
refractory ascites. Treatment modalities include:
a. Repeated large-volume paracentesis (5 L) with IV infusions of 
albumin (10 g/L ascites removed).
b. Consider transjugular intrahepatic portosystemic shunt (TIPS). 
While TIPS manages the ascites, it has not been found to improve 
survival and is often associated with encephalopathy.
Prognosis for pts with cirrhotic ascites is poor with <50% survival 
2 years after onset of ascites. Consider liver transplantation in appropri-
ate candidates with the onset of ascites (Chap. 165).
� COMPLICATIONS
Spontaneous Bacterial Peritonitis 
Suspect in cirrhotic pt with ascites and fever, abdominal pain, worsening ascites, 
ileus, hypotension, worsening jaundice, or encephalopathy; low ascitic protein 
concentration (low opsonic activity) is predisposing factor. Diagnosis suggested 
by ascitic fluid PMN cell count >250/μL; confirmed by positive culture (usually 
Escherichia coli and other gut bacteria; however, gram-positive bacteria includ-
ing Streptococcus viridans, Staphylococcus aureus, and Enterococcus spp. also can 
be found). Initial treatment: Cefotaxime 2 g IV q8h. Risk is increased in pts with 
variceal bleeding and prophylaxis against spontaneous bacterial peritonitis is 
recommended when a pt presents with upper GI bleeding.
Hepatorenal Syndrome (HRS) 
Functional renal failure without renal pathology; occurs in 10% of pts with 
advanced cirrhosis or acute liver failure. Thought to result from altered 
renal hemodynamics. Two types: type 1 HRS–decrease in renal function 
SECTION 3
278
Common Patient Presentations
within 1–2 weeks of presentation; type 2 HRS–associated with a rise in 
serum creatinine but is associated with a better outcome. Often seen in pts 
with refractory ascites. Treatment: midodrine along with octreotide and IV 
albumin. For either type 1 or 2 HRS, prognosis is poor in the absence of 
liver transplantation.
For a more detailed discussion, see Corey KE, Friedman 
LS: Abdominal Swelling and Ascites, Chap. 43, p. 330; 
and Bacon BR: Cirrhosis and Its Complications, Chap. 308, 
p. 2592, in HPIM-18.
CHAPTER 50
Lymphadenopathy and 
Splenomegaly
LYMPHADENOPATHY
Exposure to antigen through a break in the skin or mucosa results in anti-
gen being taken up by an antigen-presenting cell and carried via lymphatic 
channels to the nearest lymph node. Lymph channels course throughout the 
body except for the brain and the bones. Lymph enters the node through the 
afferent vessel and leaves through an efferent vessel. As antigen-presenting 
cells pass through lymph nodes, they present antigen to lymphocytes 
residing there. Lymphocytes in a node are constantly being replaced by 
antigen-naïve lymphocytes from the blood. They are retained in the node 
via special homing receptors. B cells populate the lymphoid follicles in the 
cortex; T cells populate the paracortical regions. When a B cell encounters 
an antigen to which its surface immunoglobulin can bind, it stays in the fol-
licle for a few days and forms a germinal center where the immunoglobulin 
gene is mutated in an effort to make an antibody with higher affinity for the 
antigen. The B cell then migrates to the medullary region, differentiates into 
a plasma cell, and secretes immunoglobulin into the efferent lymph.
When a T cell in the node encounters an antigen it recognizes, it prolifer-
ates and joins the efferent lymph. The efferent lymph laden with antibodies 
and T cells specific for the inciting antigen passes through several nodes on its 
way to the thoracic duct, which drains lymph from most of the body. From the 
thoracic duct, lymph enters the bloodstream at the left subclavian vein. Lymph 
from the head and neck and the right arm drains into the right subclavian vein. 
From the bloodstream, the antibody and T cells localize to the site of infection.
Lymphadenopathy may be caused by infections, immunologic diseases, 
malignancies, lipid storage diseases, or other disorders of uncertain etiology 
(e.g., sarcoidosis, Castleman’s disease; Table 50-1). The two major mecha-
nisms of lymphadenopathy are hyperplasia, in response to immunologic or 
infectious stimuli, and infiltration, by cancer cells or lipid- or glycoprotein-
laden macrophages.
CHAPTER 50
279
Lymphadenopathy and Splenomegaly 
TABLE 50-1 DISEASES ASSOCIATED WITH LYMPHADENOPATHY
1. Infectious diseases
a.  Viral—infectious mononucleosis syndromes (EBV, CMV), infectious 
hepatitis, herpes simplex, herpesvirus 6, varicella-zoster virus, rubella, 
measles, adenovirus, HIV, epidemic keratoconjunctivitis, vaccinia, 
herpesvirus 8
b.  Bacterial—streptococci, staphylococci, cat-scratch disease, brucel-
losis, tularemia, plague, chancroid, melioidosis, glanders, tuberculosis, 
atypical mycobacterial infection, primary and secondary syphilis, 
diphtheria, leprosy
c.  Fungal—histoplasmosis, coccidioidomycosis, paracoccidioidomycosis
d. Chlamydial—lymphogranuloma venereum, trachoma
e. Parasitic—toxoplasmosis, leishmaniasis, trypanosomiasis, filariasis
f.  Rickettsial—scrub typhus, rickettsialpox, Q fever
2. Immunologic diseases
a. Rheumatoid arthritis
b. Juvenile rheumatoid arthritis
c. Mixed connective tissue disease
d. Systemic lupus erythematosus
e. Dermatomyositis
f.   Sjögren’s syndrome
g. Serum sickness
h.  Drug hypersensitivity—diphenylhydantoin, hydralazine, allopurinol, 
primidone, gold, carbamazepine, etc.
i.   Angioimmunoblastic lymphadenopathy
j.   Primary biliary cirrhosis
k. Graft-versus-host disease
l.   Silicone-associated
m.  Autoimmune lymphoproliferative syndrome
3. Malignant diseases
a.  Hematologic—Hodgkin’s disease, non-Hodgkin’s lymphomas, acute 
or chronic lymphocytic leukemia, hairy cell leukemia, malignant 
histiocytosis, amyloidosis
b. Metastatic—from numerous primary sites
4. Lipid storage diseases—Gaucher’s, Niemann-Pick, Fabry, Tangier
5. Endocrine diseases—hyperthyroidism
6. Other disorders
a. Castleman’s disease (giant lymph node hyperplasia)
b. Sarcoidosis
c. Dermatopathic lymphadenitis
d. Lymphomatoid granulomatosis
(continued)
SECTION 3
280
Common Patient Presentations
Lymphadenopathy
APPROACH TO THE
PATIENT
HISTORY Age, occupation, animal exposures, sexual orientation, sub-
stance abuse history, medication history, and concomitant symptoms 
influence diagnostic workup. Adenopathy is more commonly malignant 
in origin in those over age 40. Farmers have an increased incidence 
of brucellosis and lymphoma. Male homosexuals may have AIDS-
associated adenopathy. Alcohol and tobacco abuse increase risk of 
malignancy. Phenytoin may induce adenopathy. The concomitant pres-
ence of cervical adenopathy with sore throat or with fever, night sweats, 
and weight loss suggests particular diagnoses (mononucleosis in the 
former instance, Hodgkin’s disease in the latter).
PHYSICAL EXAMINATION Location of adenopathy, size, node texture, 
and the presence of tenderness are important in differential diagnosis. 
Generalized adenopathy (three or more anatomic regions) implies sys-
temic infection or lymphoma. Subclavian or scalene adenopathy is always 
abnormal and should be biopsied. Nodes >4 cm should be biopsied 
immediately. Rock-hard nodes fixed to surrounding soft tissue are usu-
ally a sign of metastatic carcinoma. Tender nodes are most often benign.
LABORATORY TESTS Usually lab tests are not required in the setting of 
localized adenopathy. If generalized adenopathy is noted, an excisional 
node biopsy should be performed for diagnosis, rather than a panoply 
of laboratory tests.
Lymphadenopathy
TREATMENT
Pts over age 40, those with scalene or supraclavicular adenopathy, those 
with lymph nodes >4 cm in diameter, and those with hard nontender 
nodes should undergo immediate excisional biopsy. In younger pts with
TABLE 50-1  DISEASES ASSOCIATED WITH LYMPHADENOPATHY (CONTINUED)
e. Histiocytic necrotizing lymphadenitis (Kikuchi’s disease)
f.  Sinus histiocytosis with massive lymphadenopathy (Rosai-Dorfman 
disease)
g. Mucocutaneous lymph node syndrome (Kawasaki’s disease)
h. Histiocytosis X
i. Familial Mediterranean fever
j. Severe hypertriglyceridemia
k. Vascular transformation of sinuses
l. Inflammatory pseudotumor of lymph node
m. Congestive heart failure
Abbreviations: CMV, cytomegalovirus; EBV, Epstein-Barr virus.
CHAPTER 50
281
Lymphadenopathy and Splenomegaly 
smaller nodes that are rubbery in consistency or tender, a period of 
observation for 7–14 days is reasonable. Empirical antibiotics are not 
indicated. If the nodes shrink, no further evaluation is necessary. If they 
enlarge, excisional biopsy is indicated.
SPLENOMEGALY
Just as the lymph nodes are specialized to fight pathogens in the tissues, 
the spleen is the lymphoid organ specialized to fight bloodborne patho-
gens. It has no afferent lymphatics. The spleen has specialized areas like 
the lymph node for making antibodies (follicles) and amplifying antigen-
specific T cells (periarteriolar lymphatic sheath, or PALS). In addition, it 
has a well-developed reticuloendothelial system for removing particles and 
antibody-coated bacteria. The flow of blood through the spleen permits it to 
filter pathogens from the blood and to maintain quality control over eryth-
rocytes (RBCs)—those that are old and nondeformable are destroyed, and 
intracellular inclusions (sometimes including pathogens such as Babesia 
and Plasmodium) are culled from the cells in a process called pitting. Under 
certain conditions, the spleen can generate hematopoietic cells in place of 
the marrow.
The normal spleen is about 12 cm in length and 7 cm in width and is not 
normally palpable. Dullness from the spleen can be percussed between the 
ninth and eleventh ribs with the pt lying on the right side. Palpation is best 
performed with the pt supine with knees flexed. The spleen may be felt as 
it descends when the pt inspires. Physical diagnosis is not sensitive. CT or 
ultrasound are superior tests.
Spleen enlargement occurs by three basic mechanisms: (1) hyperplasia 
or hypertrophy due to an increase in demand for splenic function (e.g., 
hereditary spherocytosis where demand for removal of defective RBCs is 
high or immune hyperplasia in response to systemic infection or immune 
diseases); (2) passive vascular congestion due to portal hypertension; and 
(3) infiltration with malignant cells, lipid- or glycoprotein-laden macro-
phages, or amyloid (Table 50-2). Massive enlargement, with spleen palpable 
>8 cm below the left costal margin, usually signifies a lymphoproliferative 
or myeloproliferative disorder.
Peripheral blood RBC count, white blood cell count, and platelet count 
may be normal, decreased, or increased depending on the underlying 
disorder. Decreases in one or more cell lineages could indicate hyper-
splenism, increased destruction. In cases with hypersplenism, the spleen 
is removed and the cytopenia is generally reversed. In the absence of 
hypersplenism, most causes of splenomegaly are diagnosed on the basis 
of signs and symptoms and laboratory abnormalities associated with 
the underlying disorder. Splenectomy is rarely performed for diagnostic 
purposes.
Individuals who have had splenectomy are at increased risk of sepsis 
from a variety of organisms including pneumococcus and Haemophilus 
influenzae. Vaccines for these agents should be given before splenectomy 
is performed. Splenectomy compromises the immune response to these 
T-independent antigens.
SECTION 3
282
Common Patient Presentations
TABLE 50-2  DISEASES ASSOCIATED WITH SPLENOMEGALY GROUPED 
BY PATHOGENIC MECHANISM
Enlargement Due to Increased Demand for Splenic Function
Reticuloendothelial system hyperplasia 
(for removal of defective erythrocytes)
Spherocytosis
Early sickle cell anemia
Ovalocytosis
Thalassemia major
Hemoglobinopathies
Paroxysmal nocturnal 
hemoglobinuria
Pernicious anemia
Immune hyperplasia
Response to infection (viral, bacte-
rial, fungal, parasitic)
Infectious mononucleosis
AIDS
Viral hepatitis
Cytomegalovirus
Subacute bacterial endocarditis
Bacterial septicemia
Congenital syphilis
Splenic abscess
Tuberculosis
Histoplasmosis
Malaria
Leishmaniasis
Trypanosomiasis
Ehrlichiosis
Disordered immunoregulation
Rheumatoid arthritis 
(Felty’s syndrome)
Systemic lupus erythematosus
Collagen vascular diseases
Serum sickness
Immune hemolytic anemias
Immune thrombocytopenias
Immune neutropenias
Drug reactions
Angioimmunoblastic
lymphadenopathy
Sarcoidosis
Thyrotoxicosis (benign lymphoid 
hypertrophy)
Interleukin 2 therapy
Extramedullary hematopoiesis
Myelofibrosis
Marrow damage by toxins, 
radiation, strontium
Marrow infiltration by tumors, 
leukemias, Gaucher’s disease
Enlargement Due to Abnormal Splenic or Portal Blood Flow
Cirrhosis
Hepatic vein obstruction
Portal vein obstruction, intrahepatic or 
extrahepatic
Cavernous transformation of the 
portal vein
Splenic vein obstruction
Splenic artery aneurysm
Hepatic schistosomiasis
Congestive heart failure
Hepatic echinococcosis
Portal hypertension (any cause 
including the above): “Banti’s disease”
CHAPTER 51
283
Anemia and Polycythemia
For a more detailed discussion, see Henry PH, Longo DL: 
Enlargement of Lymph Nodes and Spleen, Chap. 59, p. 465, 
in HPIM-18.
TABLE 50-2  DISEASES ASSOCIATED WITH SPLENOMEGALY GROUPED 
BY PATHOGENIC MECHANISM (CONTINUED)
Infiltration of the Spleen
Intracellular or extracellular depositions
Amyloidosis
Gaucher’s disease
Niemann-Pick disease
Tangier disease
Hurler’s syndrome and other 
mucopolysaccharidoses
Hyperlipidemias
Benign and malignant cellular 
infiltrations
Leukemias (acute, chronic, 
lymphoid, myeloid, monocytic)
Lymphomas
Hodgkin’s disease
Myeloproliferative syndromes 
(e.g., polycythemia vera, essential 
thrombocytosis)
Angiosarcomas
Metastatic tumors (melanoma is 
most common)
Eosinophilic granuloma
Histiocytosis X
Hamartomas
Hemangiomas, fibromas, 
lymphangiomas
Splenic cysts
Unknown Etiology
Idiopathic splenomegaly
Berylliosis
Iron-deficiency anemia
CHAPTER 51
Anemia and Polycythemia
ANEMIA
According to World Health Organization criteria, anemia is defined as 
blood hemoglobin (Hb) concentration <130 g/L (<13 g/dL) or hematocrit 
(Hct) <39% in adult males; Hb <120 g/L (<12 g/dL) or Hct <37% in adult 
females.
Signs and symptoms of anemia are varied, depending on the level of ane-
mia and the time course over which it developed. Acute anemia is nearly 
always due to blood loss or hemolysis. In acute blood loss, hypovolemia 
SECTION 3
284
Common Patient Presentations
dominates the clinical picture; hypotension and decreased organ perfusion 
are the main issues. Symptoms associated with more chronic onset vary 
with the age of the pt and the adequacy of blood supply to critical organs. 
Moderate anemia is associated with fatigue, loss of stamina, breathlessness, 
and tachycardia. The pt’s skin and mucous membranes may appear pale. If 
the palmar creases are lighter in color than the surrounding skin with the 
fingers extended, Hb level is often <80 g/L (8 g/dL). In pts with coronary 
artery disease, anginal episodes may appear or increase in frequency and 
severity. In pts with carotid artery disease, lightheadedness or dizziness 
may develop.
A physiologic approach to anemia diagnosis is based on the understand-
ing that a decrease in circulating red blood cells (RBCs) can be related to 
either inadequate production of RBCs or increased RBC destruction or loss. 
Within the category of inadequate production, erythropoiesis can be either 
ineffective, due to an erythrocyte maturation defect (which usually results 
in RBCs that are too small or too large), or hypoproliferative (which usually 
results in RBCs of normal size, but too few of them).
Basic evaluations include (1) reticulocyte index (RI), and (2) review of 
blood smear and RBC indices [chiefly mean corpuscular volume (MCV)] 
(Fig. 51-1).
The RI is a measure of RBC production. The reticulocyte count is 
corrected for the Hct level and for early release of marrow reticulocytes into 
the circulation, which leads to an increase in the lifespan of the circulat-
ing reticulocyte beyond the usual 1 day. Thus, RI = (% reticulocytes × pt 
Hct/45%) × (1/shift correction factor). The shift correction factor varies with 
the Hct: 1.5 for Hct = 35%, 2 for Hct = 25%, 2.5 for Hct = 15%. RI < 2–2.5% 
implies inadequate RBC production for the particular level of anemia; RI > 
2.5% implies excessive RBC destruction or loss.
If the anemia is associated with a low RI, RBC morphology helps dis-
tinguish a maturation disorder from hypoproliferative marrow states. 
Cytoplasmic maturation defects such as iron deficiency or Hb synthesis 
problems produce smaller RBCs, MCV < 80; nuclear maturation defects 
such as B12 and folate deficiency and drug effects produce larger RBCs, 
MCV >100. In hypoproliferative marrow states, RBCs are generally normal 
in morphology but too few are produced. Bone marrow examination is 
often helpful in the evaluation of anemia but is done most frequently to 
diagnose hypoproliferative marrow states.
Other laboratory tests indicated to evaluate particular forms of anemia 
depend on the initial classification based on the pathophysiology of the 
defect. These are discussed in more detail in Chap. 68.
POLYCYTHEMIA (ERYTHROCYTOSIS)
Polycythemia is an increase above the normal range of RBCs in the circula-
tion. Concern that the Hb level may be abnormally high should be triggered 
at a level of 170 g/L (17 g/dL) in men and 150 g/L (15 g/dL) in women. 
Polycythemia is usually found incidentally at routine blood count. Relative 
erythrocytosis, due to plasma volume loss (e.g., severe dehydration, burns), 
CHAPTER 51
285
Anemia and Polycythemia
does not represent a true increase in total RBC mass. Absolute erythrocyto-
sis is a true increase in total RBC mass.
� CAUSES 
Polycythemia vera (a clonal myeloproliferative disorder), erythropoietin-
producing neoplasms (e.g., renal cancer, cerebellar hemangioma), chronic 
hypoxemia (e.g., high altitude, pulmonary disease), carboxyhemoglobin 
excess (e.g., smokers), high-affinity hemoglobin variants, Cushing’s syn-
drome, androgen excess. Polycythemia vera is distinguished from second-
ary polycythemia by the presence of splenomegaly, leukocytosis, thrombo-
cytosis, and elevated vitamin B12 levels, and by decreased erythropoietin 
levels. An approach to evaluate polycythemic pts is shown in Fig. 51-2.
Hemolysis/
hemorrhage
Blood loss
Intravascular
hemolysis
Metabolic defect
Membrane
abnormality
Hemoglobinopathy
Immune destruction
Fragmentation
hemolysis
Hypoproliferative
Marrow damage
• Infiltration/fibrosis
• Aplasia
Iron deficiency
 Stimulation
• Inflammation
• Metabolic defect
• Renal disease
Maturation disorder
Cytoplasmic defects
• Iron deficiency
• Thalassemia
• Sideroblastic
  anemia
Nuclear defects
• Folate deficiency
• Vitamin B12 deficiency
• Drug toxicity
• Refractory anemia
Normocytic
normochromic
Micro or
macrocytic
Red cell
morphology
Index < 2.5
Index ≥ 2.5
Anemia
CBC, reticulocyte
count
ALGORITHM OF THE PHYSIOLOGIC CLASSIFICATION OF ANEMIA
FIGURE 51-1 The physiologic classification of anemia. CBC, complete blood count. 
SECTION 3
286
Common Patient Presentations
� COMPLICATIONS 
Hyperviscosity (with diminished O2 delivery) with risk of ischemic organ 
injury and thrombosis (venous or arterial) are most common.
Polycythemia
TREATMENT
Phlebotomy recommended for Hct ≥ 55%, regardless of cause, to low-
normal range.
Dx: Relative
  erythrocytosis
Measure RBC mass
Measure serum
  EPO levels
Measure arterial
  O2 saturation
elevated
elevated
Dx:   O2 affinity
  hemoglobinopathy
increased
elevated
normal
Dx: Polycythemia
  vera
Confirm
JAK-2
mutation
smoker?
normal
normal
Dx: Smoker’s
  polycythemia
normal
Increased Hct or hgb
low
low
Diagnostic evaluation for
  heart or lung disease,
  e.g., COPD, high altitude,
  AV or intracardiac shunt
Measure hemoglobin
  O2 affinity
Measure
  carboxyhemoglobin
  levels
Search for tumor as source of EPO
    IVP/renal ultrasound (renal Ca or cyst)
    CT of head (cerebellar hemangioma)
    CT of pelvis (uterine leiomyoma)
    CT of abdomen (hepatoma)
no
yes
AN APPROACH TO DIAGNOSING PATIENTS WITH POLYCYTHEMIA
FIGURE 51-2 An approach to the differential diagnosis of pts with an elevated 
hemoglobin (possible polycythemia). AV, atrioventricular; COPD, chronic obstructive 
pulmonary disease; EPO, erythropoietin; Hct, hematocrit; IVP, intravenous pyelogram; 
RBC, red blood cell.
For a more detailed discussion, see Adamson JW, Longo DL: 
Anemia and Polycythemia, Chap. 57, p. 448, in HPIM-18.
CHAPTER 52
287
Azotemia and Urinary Abnormalities 
CHAPTER 52
Azotemia and Urinary 
Abnormalities
� ABNORMALITIES OF RENAL FUNCTION, AZOTEMIA
Azotemia is the retention of nitrogenous waste products excreted by the 
kidney. Increased levels of blood urea nitrogen (BUN) [>10.7 mmol/L 
(>30 mg/dL)] and creatinine [>133 μmol/L (>1.5 mg/dL)] are ordinarily indic-
ative of impaired renal function. Renal function can be estimated by deter-
mining the clearance of creatinine (CLcr) (normal >100 mL/min); this can be 
directly measured from a 24-h urine collection using the following equation:
Creatinine clearance (mL/min) = (uCr × uV)/(sCr × 1440)
1. Where uCr is urine creatinine in mg/dL
2. Where sCr is serum creatinine in mg/dL
3. Where uV is 24-h urine volume in mL
4. Where 1440 represents number of minutes in 24 h
The “adequacy” or “completeness” of the collection is estimated by the 
urinary volume and creatinine content; creatinine is produced from muscle 
and excreted at a relatively constant rate. For a 20- to 50-year-old man, 
creatinine excretion should be 18.5–25.0 mg/kg body weight; for a woman 
of the same age, it should be 16.5–22.4 mg/kg body weight. For example, 
an 80-kg man should excrete between ~1500 and 2000 mg of creatinine in 
an “adequate” collection. Creatinine excretion is also influenced by age and 
muscle mass. Notably, creatinine is an imperfect measure of glomerular 
filtration rate (GFR), since it is both filtered by glomeruli and secreted 
by proximal tubular cells; the relative contribution of tubular secretion 
increases with advancing renal dysfunction, such that creatinine clearance 
will provide an overestimate of the “true” GFR in pts with chronic kidney 
disease. Isotopic markers that are filtered and not secreted (e.g., iothal-
amate) provide more accurate estimates of GFR.
A formula that allows for an estimate of creatinine clearance in men that 
accounts for age-related decreases in GFR, body weight, and sex has been 
derived by Cockcroft-Gault:
Creatinine clearance (mL/min) 
= (140 age) × lean body weight (kg)/plasma creatinine (mg/dL) × 72
This value should be multiplied by 0.85 for women.
GFR may also be estimated using serum creatinine–based equations 
derived from the Modification of Diet in Renal Disease Study. This “eGFR” 
is now reported with serum creatinine by most clinical laboratories in the 
United States and is the basis for the National Kidney Foundation classifica-
tion of chronic kidney disease (Table 52-1).
SECTION 3
288
Common Patient Presentations
Manifestations of impaired renal function include volume overload, hyper-
tension, electrolyte abnormalities (e.g., hyperkalemia, hypocalcemia, hyper-
phosphatemia), metabolic acidosis, and hormonal disturbances (e.g., 
insulin resistance, functional vitamin D deficiency, secondary hyperpara-
thyroidism). When severe, the symptom complex of “uremia” may develop, 
encompassing one or more of the following symptoms and signs: anorexia, 
dysgeusia, nausea, vomiting, lethargy, confusion, asterixis, pleuritis, peri-
carditis, enteritis, pruritus, sleep and taste disturbance, nitrogenous fetor.
An approach to the pt with azotemia is shown in Fig. 52-1.
� ABNORMALITIES OF URINE VOLUME
Oliguria
This refers to reduced urine output, usually defined as <400 mL/d. 
Oligoanuria refers to a more marked reduction in urine output, i.e., 
<100 mL/d. Anuria indicates the complete absence of urine output. 
Oliguria most often occurs in the setting of volume depletion and/or renal 
hypoperfusion, resulting in “prerenal azotemia” and acute renal failure 
(Chap. 148). Anuria can be caused by complete bilateral urinary tract 
obstruction; a vascular catastrophe (dissection or arterial occlusion); renal 
vein thrombosis; renal cortical necrosis; severe acute tubular necrosis; 
nonsteroidal anti-inflammatory drugs, angiotensin-converting enzyme 
(ACE) inhibitors, and/or angiotensin receptor blockers; and hypovolemic, 
cardiogenic, or septic shock. Oliguria is never normal, since at least 400 mL 
of maximally concentrated urine must be produced to excrete the obligate 
daily osmolar load.
Polyuria 
Polyuria is defined as a urine output >3 L/d. It is often accompanied by 
nocturia and urinary frequency and must be differentiated from other more 
common conditions associated with lower urinary tract pathology and 
TABLE 52-1  THE CLASSIFICATION OF CHRONIC KIDNEY DISEASE 
(NATIONAL KIDNEY FOUNDATION GUIDELINES)
Kidney Damage 
Stage
Description
eGFR (mL/min 
per 1.73 m2)
0
With risk factors for CKDa
>90
1
With evidence of kidney damageb
>90
2
Mild decrease in GFR
60–89
3
Moderate decrease in GFR
30–59
4
Severe decrease in GFR
15–29
5
Kidney failure
<15
aDiabetes, high blood pressure, family history, older age, African ancestry.
bAbnormal urinalysis, hematuria, proteinuria, albuminuria.
Abbreviations: CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; GFR, 
glomerular filtration rate.
CHAPTER 52
289
Azotemia and Urinary Abnormalities 
urinary urgency or frequency (e.g., cystitis, prostatism). It is often accom-
panied by hypernatremia (Chap. 2). Polyuria (Table 52-2) can occur as a 
response to a solute load (e.g., hyperglycemia) or to an abnormality in argi-
nine vasopressin [AVP; also known as antidiuretic hormone (ADH)] action. 
Diabetes insipidus is termed central if due to the insufficient hypothalamic 
production of AVP and nephrogenic if the result of renal insensitivity to the 
action of AVP. Excess fluid intake can lead to polyuria, but primary polydipsia 
rarely results in changes in plasma osmolality unless urinary diluting capacity 
is impaired. Tubulointerstitial diseases, lithium therapy, and resolving acute 
tubular necrosis or urinary tract obstruction can be associated with nephro-
genic diabetes insipidus, which is more rarely caused by mutations in the V2 
AVP receptor or the AVP-regulated water channel, aquaporin 2.
The approach to the pt with polyuria is shown in Fig. 52-2.
FIGURE 52-1 Approach to the pt with azotemia. FeNa, fractional excretion of sodium; 
GBM, glomerular basement membrane; RBC, red blood cell; WBC, white blood cell.  
(From Lin J and Denker BM: HPIM-18.)
AZOTEMIA
Urinalysis and
Renal ultrasound
Hydronephrosis
Renal size parenchyma
Urinalysis
Urologic evaluation
Relieve obstruction
Small kidneys, thin cortex,
  bland sediment,
  isosthenuria
  <3.5 g protein/24 h
Normal size kidneys
Intact parenchyma
Bacteria
Pyelonephritis
Chronic Renal Failure
Symptomatic treatment
  delay progression
If end-stage, prepare
  for dialysis
Normal
  urinalysis
 with oliguria
Abnormal
  urinalysis
WBC, casts
  eosinophils
Interstitial
  nephritis
Red blood
  cells
Renal artery
  or vein
  occlusion
Urine
  electrolytes
Muddy brown
  casts,
  amorphous
  sediment
  + protein
RBC casts
Proteinuria
Angiogram
FeNa <1%
U osmolality > 500 mosmol
FeNa >1%
U osmolality < 350 mosmol
Renal biopsy
Prerenal Azotemia
Volume contraction,
  cardiac failure,
  vasodilatation, drugs,
  sepsis, renal
  vasoconstriction,
  impaired autoregulation
Acute Tubular Necrosis
Glomerulonephritis
  or vasculitis
Immune complex,
  anti-GBM disease
EVALUATION OF AZOTEMIA
Acute Renal Failure
SECTION 3
290
Common Patient Presentations
� ABNORMALITIES OF URINE COMPOSITION
Proteinuria
This is the hallmark of glomerular disease. Levels up to 150 mg/d are con-
sidered within normal limits. Typical measurements are semiquantitative, 
using a moderately sensitive dipstick that estimates protein concentra-
tion; therefore, the degree of hydration may influence the dipstick protein 
determination. Most commercially available urine dipsticks detect albumin 
and do not detect smaller proteins, such as light chains, that require testing 
with sulfosalicylic acid. More sensitive assays can in turn be used to detect 
microalbuminuria, an important screening tool for diabetic nephropathy. 
A urine albumin to creatinine ratio >30 mg/g defines the presence of micro-
albuminuria.
Formal assessment of urinary protein excretion requires a 24-h urine 
protein collection (see “Abnormalities of Renal Function, Azotemia,” 
above). The ratio of protein to creatinine in a random, “spot” urine can also 
provide a rough estimate of protein excretion; for example, a protein/creati-
nine ratio of 3.0 correlates to ~3.0 g of proteinuria per day.
Urinary protein excretion rates between 500 mg/d and 3 g/d are nonspe-
cific and can be seen in a variety of renal diseases (including hypertensive 
nephrosclerosis, interstitial nephritis, vascular disease, and other primary 
renal diseases with little or no glomerular involvement). Transient, lesser 
degrees of proteinuria (500 mg/d to 1.5 g/d) may be seen after vigor-
ous exercise, changes in body position, fever, or congestive heart failure. 
Protein excretion rates >3 g/d are termed nephrotic range proteinuria in 
that they may be accompanied by hypoalbuminemia, hypercholesterol-
emia, and edema (the nephrotic syndrome). Nephrotic syndrome can 
be associated with a variety of extrarenal complications (Chap. 152). 
Massive degrees of proteinuria (>10 g/d) can be seen with minimal change 
TABLE 52-2 MAJOR CAUSES OF POLYURIA
Excessive fluid intake
Nephrogenic diabetes insipidus
 Primary polydipsia
 Lithium exposure
 Iatrogenic (IV fluids)
 Urinary tract obstruction
Therapeutic
 Papillary necrosis
 Diuretic agents
 Reflux nephropathy
Osmotic diuresis
 Interstitial nephritis
 Hyperglycemia
 Hypercalcemia
 Azotemia
Central diabetes insipidus
 Mannitol
 Tumor
 Radiocontrast
 Postoperative
 Head trauma
 Basilar meningitis
 Neurosarcoidosis
CHAPTER 52
291
Azotemia and Urinary Abnormalities 
FIGURE 52-2 Approach to the pt with polyuria. ADH, antidiuretic hormone; ATN, 
acute tubular necrosis. (From Lin J and Denker BM: HPIM-18.)
Urine osmolality
< 250 mosmol
History, low
  serum sodium
Water
  deprivation
  test or
  ADH level
Solute diuresis
    Glucose, mannitol,
      radiocontrast, urea
      (from high protein
      feeding), 
      medullary cystic
      diseases, resolving ATN,
      or obstruction, diuretics
Primary polydipsia
  Psychogenic
  Hypothalamic disease
  Drugs (thioridazine,
    chlorpromazine,
    anticholinergic agents)
Central DI (vasopressin-sensitive)
  posthypophysectomy, trauma,
  supra- or intrasellar tumor / cyst
  histiocystosis or granuloma,
  encroachment by aneurysm,
  Sheehan's syndrome, infection,
  Guillain-Barré, fat embolus,
  empty sella
Nephrogenic DI (vasopressin-insensitive)
Acquired tubular diseases: pyelonephritis, analgesic nephropathy,
  multiple myeloma, amyloidosis, obstruction, sarcoidosis,
  hypercalcemia, hypokalemia, Sjögren’s syndrome, sickle
  cell anemia
Drugs or toxins: lithium, demeclocycline, methoxyflurane, ethanol,
  diphenylhydantoin, propoxyphene, amphotericin
Congenital: hereditary, polycystic or medullary cystic disease
> 300 mosmol
EVALUATION OF POLYURIA
Diabetes insipidus (DI)
Polyuria (>3 L/24 h)
disease, primary focal segmental sclerosis (FSGS), membranous nephropa-
thy, collapsing glomerulopathy (a subtype of primary FSGS), and HIV-
associated nephropathy.
Pharmacologic inhibition of ACE or blockade of angiotensin II should 
be employed to reduce proteinuria; successful reduction of proteinuria 
decreases the rate of progression to end-stage renal disease in diabetic 
SECTION 3
292
Common Patient Presentations
nephropathy and other glomerulopathies. Specific therapy for a variety of 
causes of nephrotic syndrome is discussed in Chap. 152.
Hematuria
Gross hematuria refers to the presence of frank blood in the urine and is 
more characteristic of lower urinary tract disease and/or bleeding diatheses 
than intrinsic renal disease (Table 52-3). Cyst rupture in polycystic kidney 
disease and postpharyngitic flares of IgA nephropathy are exceptions. 
Microscopic hematuria [>1–2 red blood cells (RBCs) per high-powered 
field] accompanied by proteinuria, hypertension, and an active urinary 
sediment (the “nephritic syndrome”) is most likely related to an inflamma-
tory glomerulonephritis, classically poststreptococcal glomerulonephritis 
(Chap. 152).
Free hemoglobin and myoglobin are detected by dipstick; a negative urinary 
sediment with strongly heme-positive dipstick is characteristic of either hemo-
lysis or rhabdomyolysis, which can be differentiated by clinical history and lab-
oratory testing. RBC casts are not a sensitive finding but when seen are highly 
specific for glomerulonephritis. Specificity of urinalysis can be enhanced by 
examining urine with a phase contrast microscope capable of detecting dys-
morphic red cells (“acanthocytes”) associated with glomerular disease.
The approach to the pt with hematuria is shown in Fig. 52-3.
TABLE 52-3 MAJOR CAUSES OF HEMATURIA
Lower Urinary Tract
Bacterial cystitis
Interstitial cystitis
Urethritis (infectious or inflammatory)
Passed or passing kidney stone
Transitional cell carcinoma of bladder or structures proximal to it
Squamous cell carcinoma of bladder (e.g., following schistosomiasis)
Upper Urinary Tract
Renal cell carcinoma
Age-related renal cysts
Other neoplasms (e.g., oncocytoma, hamartoma)
Acquired renal cystic disease
Congenital cystic disease, including autosomal dominant form
Glomerular diseases
Interstitial renal diseases, including interstitial nephritis
Nephrolithiasis
Pyelonephritis
Renal infarction
Hypercalciuria
Hyperuricosuria
CHAPTER 52
293
Azotemia and Urinary Abnormalities 
Pyuria
This may accompany hematuria in inflammatory glomerular diseases. 
Isolated pyuria is most commonly observed in association with an infec-
tion of the upper or lower urinary tract. Pyuria may also occur with allergic 
interstitial nephritis (often with a preponderance of eosinophils), transplant 
rejection, and noninfectious, nonallergic tubulointerstitial diseases, includ-
ing atheroembolic renal disease. The finding of “sterile” pyuria (i.e., urinary 
white blood cells without bacteria) in the appropriate clinical setting should 
raise suspicion of renal tuberculosis.
Hematuria
Proteinuria (>500 mg/24 h),
Dysmorphic RBCs or RBC casts
Pyuria, WBC casts
Urine culture
Urine eosinophils
Serologic and
  hematologic
  evaluation: blood
  cultures, anti-GBM
  antibody, ANCA,
  complement levels,
  cryoglobulins,
  hepatitis B and C
  serologies, VDRL,
  HIV, ASLO
Hemoglobin electrophoresis
Urine cytology
UA of family members
24 h urinary calcium/uric acid
IVP +/- Renal
ultrasound
As indicated: retrograde
  pyelography or
  arteriogram,
  or cyst aspiration
Cystoscopy
Urogenital biopsy
and evaluation
Renal CT scan
Renal biopsy of
mass/lesion
Follow periodic
  urinalysis
Renal biopsy
EVALUATION OF HEMATURIA
FIGURE 52-3 Approach to the pt with hematuria. ANCA, antineutrophil cytoplasmic 
antibody; ASLO, antistreptolysin O; CT, computed tomography; GBM, glomerular 
basement membrane; IVP, intravenous pyelography; RBC, red blood cell; UA, urinaly-
sis; VDRL, Venereal Disease Research Laboratory; WBC, white blood cell. (From Lin J 
and Denker BM: HPIM-18.)
SECTION 3
294
Common Patient Presentations
For a more detailed discussion, see Lin J, Denker BM: 
Azotemia and Urinary Abnormalities, Chap. 44, p. 334, in 
HPIM-18.
CHAPTER 53
Pain and Swelling of Joints
Musculoskeletal complaints are extremely common in outpatient medical 
practice and are among the leading causes of disability and absenteeism 
from work. Pain in the joints must be evaluated in a uniform, thorough, and 
logical fashion to ensure the best chance of accurate diagnosis and to plan 
appropriate follow-up testing and therapy. Joint pain and swelling may be 
manifestations of disorders affecting primarily the musculoskeletal system 
or may reflect systemic disease. 
� INITIAL ASSESSMENT OF A MUSCULOSKELETAL COMPLAINT 
(SEE FIG. 53-1)
1. Articular versus nonarticular. Is the pain located in a joint or in a 
periarticular structure such as soft tissue or muscle?
2. Inflammatory versus noninflammatory. Inflammatory disease is suggested 
by local signs of inflammation (erythema, warmth, swelling); systemic 
features (morning stiffness, fatigue, fever, weight loss); or laboratory 
evidence of inflammation (thrombocytosis, elevated ESR or C-reactive 
protein).
3. Acute (≤6 weeks) versus chronic.
4. Localized versus systemic.
� HISTORIC FEATURES
• Age, sex, race, and family history
• Symptom onset (abrupt or gradual), evolution (chronic constant, inter-
mittent, migratory, additive), and duration (acute versus chronic)
• Number and distribution of involved structures: monarticular (one 
joint), oligoarticular (2–3 joints), polyarticular (>3 joints); symmetry
• Other articular features: morning stiffness, effect of movement, features 
that improve/worsen Sx
• Extraarticular Sx: e.g., fever, rash, weight loss, visual change, dyspnea, 
diarrhea, dysuria, numbness, weakness
• Recent events: e.g., trauma, drug administration, travel, other illnesses
� PHYSICAL EXAMINATION
Complete examination is essential: particular attention to skin, mucous 
membranes, nails (may reveal characteristic pitting in psoriasis), eyes. 
Careful and thorough examination of involved and uninvolved joints and 
periarticular structures; this should proceed in an organized fashion from 
CHAPTER 53
295
Pain and Swelling of Joints
Nonarticular condition
Consider
• Trauma/fracture
• Fibromyalgia
• Polymyalgia rheumatica
• Bursitis
• Tendinitis
Is complaint > 6 wk?
Acute
Chronic
Consider
• Acute arthritis
  • Infectious arthritis
  • Gout
  • Pseudogout
  • Reactive arthritis
• Initial presentation
  of chronic arthritis
Is inflammation present?
1. Is there prolonged morning stiffness?
2. Is there soft tissue swelling?
3. Are there systemic symptoms?
4. Is the ESR or CRP elevated?
Chronic
inflammatory
arthritis
How many
joints involved?
Are DIP, CMC1, hip or
knee joints involved?
Chronic inflammatory
mono/oligoarthritis
Consider
• Indolent infection
• Psoriatic arthritis
• Reactive arthritis
• Pauciarticular JA
Chronic inflammatory
polyarthritis
Is involvement
symmetric?
Are PIP, MCP, or
MTP joints
involved?
Consider
• Psoriatic arthritis
• Reactive arthritis
Rheumatoid
arthritis
Osteoarthritis
No
Yes
Yes
No
Yes
No
Yes
No
Yes
No
Yes
>3
1– 3
Unlikely to be osteoarthritis
Consider
• Osteonecrosis
• Charcot arthritis
Chronic
noninflammatory
arthritis
Unlikely to be rheumatoid arthritis
Consider
  • SLE
  • Scleroderma
  • Polymyositis
Initial rheumatic history and physical
exam to determine
1. Is it articular?
2. Is it acute or chronic?
3. Is inflammation present?
4. How many/which joints are involved?
Is it articular?
Musculoskeletal Complaint
No
ALGORITHM FOR MUSCULOSKELETAL COMPLAINTS
FIGURE 53-1 Algorithm for the diagnosis of musculoskeletal complaints. An 
approach to formulating a differential diagnosis (shown in italics). CMC, carpo-
metacarpal; CRP, C-reactive protein; DIP, distal interphalangeal; ESR, erythrocyte 
sedimentation rate; JA, juvenile arthritis; MCP, metacarpophalangeal; MTP, meta-
tarsophalangeal; PIP, proximal interphalangeal; SLE, systemic lupus erythematosus.
head to foot or from extremities inward toward axial skeleton; special 
attention should be paid to identifying the presence or absence of:
• Warmth and/or erythema
• Swelling
SECTION 3
296
Common Patient Presentations
INTERPRETATION OF SYNOVIAL FLUID ASPIRATION
Strongly consider synovial fluid aspiration
and analysis if there is
• Monarthritis (acute or chronic)
• Trauma with joint effusion
• Monarthritis in a patient with chronic polyarthritis
• Suspicion of joint infection, crystal-induced arthritis, or hemarthrosis
Analyze fluid for
• Appearance, viscosity
• WBC count, differential
• Gram stain, culture, and
  sensitivity (if indicated)
• Crystal identification
  by polarized microscopy
Inflammatory or
noninflammatory
articular condition
Consider
• Trauma or mechanical
  derangement
• Coagulopathy
• Neuropathic arthropathy
• Other
Is the WBC > 2000/μL?
Consider other
inflammatory
or septic arthritides
• Gram stain, culture
  mandatory
Is the % PMNs > 75%?
Are crystals present?
Consider
noninflammatory
articular conditions
• Osteoarthritis
• Trauma
• Other
Is the WBC > 50,000/μL?
Crystal identification for
specific diagnosis
• Gout
• Pseudogout
Probable inflammatory arthritis
Possible septic arthritis
Consider inflammatory
or septic arthritis
Is the effusion
hemorrhagic?
No
Yes
No
Yes
No
Yes
Yes
No
Yes
No
FIGURE 53-2 Algorithmic approach to the use and interpretation of synovial fluid aspi-
ration and analysis. PMNs, polymorphonuclear leukocytes; WBC, white blood cell count.
CHAPTER 53
297
Pain and Swelling of Joints
• Synovial thickening
• Subluxation, dislocation, joint deformity
• Joint instability
• Limitations to active and passive range of motion
• Crepitus
• Periarticular changes
• Muscular changes including weakness, atrophy
� LABORATORY INVESTIGATIONS
Additional evaluation usually indicated for monarticular, traumatic, inflam-
matory, or chronic conditions or for conditions accompanied by neurologic 
changes or systemic manifestations.
• For all evaluations: include CBC, ESR, or C-reactive protein
• Where there are suggestive clinical features, include: rheumatoid factor, 
ANA, antineutrophilic cytoplasmic antibodies (ANCA), antistreptolysin 
O titer, Lyme antibodies
• Where systemic disease is present or suspected: renal/hepatic function 
tests, UA
• Uric acid: useful only when gout diagnosed and therapy contemplated
• CPK, aldolase: consider with muscle pain, weakness
• Synovial fluid aspiration and analysis: always indicated for acute mon-
arthritis or when infectious or crystal-induced arthropathy is suspected. 
Should be examined for (1) appearance, viscosity; (2) cell count and 
differential (suspect septic joint if WBC count > 50,000/μL); (3) crystals 
using polarizing microscope; (4) Gram’s stain, cultures (Fig. 53-2).
� DIAGNOSTIC IMAGING
Conventional radiography using plain x-rays is a valuable tool in the 
diagnosis and staging of articular disorders (Table 53-1).
Additional imaging procedures, including ultrasound, radionuclide scin-
tigraphy, CT, and MRI, may be helpful in selected clinical settings.
� SPECIAL CONSIDERATIONS IN THE ELDERLY PATIENT
The evaluation of joint and musculoskeletal disorders in the elderly pt pres-
ents a special challenge given the frequently insidious onset and chronicity 
of disease in this age group, the confounding effect of other medical 
TABLE 53-1  APPLICATIONS FOR CONVENTIONAL RADIOGRAPHY IN 
ARTICULAR DISEASE
Trauma
Suspected chronic joint or bone infection
Progressive joint disability
Monarticular involvement
Baseline assessment of a chronic articular process
When therapeutic alterations are considered (such as for rheumatoid 
arthritis)
SECTION 3
298
Common Patient Presentations
CHAPTER 54
Back and Neck Pain
LOW BACK PAIN
The cost of low back pain (LBP) in the United States is ~$100 billion annually. 
Back symptoms are the most common cause of disability in those <45 years; 
LBP is the second most common cause of visiting a physician in the United 
States; ~1% of the United States population is disabled because of back pain.
� TYPES OF LOW BACK PAIN
• Local pain—caused by stretching of pain-sensitive structures that com-
press or irritate nerve endings; pain (i.e., tears, stretching) located near 
the affected part of the back.
• Pain referred to the back—abdominal or pelvic origin; back pain unaf-
fected by routine movements.
• Pain of spine origin—restricted to the back or referred to lower limbs 
or buttock. Diseases of upper lumbar spine refer pain to upper lumbar 
region, groin, or anterior thighs. Diseases of lower lumbar spine refer 
pain to buttocks, posterior thighs, or rarely the calves or feet.
• Radicular back pain—radiates from spine to leg in specific nerve root terri-
tory. Coughing, sneezing, lifting heavy objects, or straining may elicit pain.
• Pain associated with muscle spasm—diverse causes; accompanied by taut 
paraspinal muscles and abnormal posture.
� EXAMINATION 
Include abdomen, pelvis, and rectum to search for visceral sources of pain. 
Inspection may reveal scoliosis or muscle spasm. Palpation may elicit pain 
over a diseased spine segment. Pain from hip may be confused with spine 
pain; manual internal/external rotation of leg at hip (knee and hip in flex-
ion) reproduces the hip pain.
Straight leg raising (SLR) sign—elicited by passive flexion of leg at the 
hip with pt in supine position; maneuver stretches L5/S1 nerve roots and 
sciatic nerve passing posterior to the hip; SLR sign is positive if maneuver 
conditions, and the increased variability of many diagnostic tests in the 
geriatric population. Although virtually all musculoskeletal conditions may 
afflict the elderly, certain disorders are especially frequent. Special attention 
should be paid to identifying the potential rheumatic consequences of 
intercurrent medical conditions and therapies when evaluating the geriatric 
pt with musculoskeletal complaints.
For a more detailed discussion, see Cush JJ, Lipsky 
PE: Approach to Articular and Musculoskeletal Disorders, 
Chap. 331, p. 2818, in HPIM-18.
CHAPTER 54
299
Back and Neck Pain
reproduces the pain. Crossed SLR sign—positive when SLR on one leg 
reproduces symptoms in opposite leg or buttocks; nerve/nerve root lesion 
is on the painful side. Reverse SLR sign—passive extension of leg backwards 
with pt standing; maneuver stretches L2–L4 nerve roots, lumbosacral 
plexus, and femoral nerve passing anterior to the hip.
Neurologic exam—search for focal atrophy, weakness, reflex loss, dimin-
ished sensation in a dermatomal distribution. Findings with radiculopathy 
are summarized in Table 54-1.
TABLE 54-1 LUMBOSACRAL RADICULOPATHY—NEUROLOGIC FEATURES
Lumbosacral 
Nerve Roots
Examination Findings
Pain
Distribution
Reflex
Sensory
Motor
L2a
—
Upper 
anterior
thigh
Psoas (hip 
flexion)
Anterior
thigh
L3a
—
Lower 
anterior
thigh
Psoas (hip 
flexion)
Anterior
thigh, knee
Anterior
knee
Quadriceps (knee 
extension)
Thigh adduction
L4a
Quadriceps
(knee)
Medial
calf
Quadriceps (knee 
extension)b
Thigh adduction
Tibialis anterior 
(foot dorsiflexion)
Knee, medial 
calf
Anterolateral 
thigh
L5c
—
Dorsal 
surface—
foot
Peroneii (foot 
eversion)b
Lateral calf, 
dorsal foot, 
posterolat-
eral thigh, 
buttocks
Lateral 
calf
Tibialis anterior 
(foot dorsiflexion)
Gluteus medius 
(hip abduction)
Toe dorsiflexors
S1c
Gastrocnemius/
soleus (ankle)
Plantar
surface—
foot
Lateral 
aspect—
foot
Gastrocnemius/
soleus (foot plan-
tar flexion)b
Abductor hallucis 
(toe flexors)b
Gluteus maximus 
(hip extension)
Bottom foot, 
posterior
calf, poste-
rior thigh, 
buttocks
aReverse straight leg–raising sign present—see “Examination of the Back.”
bThese muscles receive the majority of innervation from this root.
cStraight leg–raising sign present—see “Examination of the Back.”
SECTION 3
300
Common Patient Presentations
� LABORATORY EVALUATION 
“Routine” laboratory studies and lumbar spine x-rays are rarely needed for 
acute LBP (<3 months) but indicated when risk factors for serious underly-
ing disease are present (Table 54-2). MRI and CT-myelography are tests of 
choice for anatomic definition of spine disease. Electromyography (EMG) 
and nerve conduction studies useful for functional assessment of peripheral 
nervous system.
� ETIOLOGY 
Lumbar Disk Disease 
Common cause of low back and leg pain; usually at L4-L5 or L5-S1 levels. 
Dermatomal sensory loss, reduction or loss of deep tendon reflexes, or 
myotomal pattern of weakness more informative than pain pattern for 
localization. Usually unilateral; can be bilateral with large central disk 
herniations compressing multiple nerve roots and causing cauda equina 
syndrome (Chap. 200).
Indications for lumbar disk surgery: 
• Progressive motor weakness on exam or progressive nerve root injury 
demonstrated on EMG
• Cauda equina syndrome or spinal cord compression usually indicated by 
abnormal bowel or bladder function 
TABLE 54-2  ACUTE LOW BACK PAIN: RISK FACTORS FOR AN IMPORTANT 
STRUCTURAL CAUSE
History
Pain worse at rest or at night
Prior history of cancer
History of chronic infection (esp. lung, urinary tract, skin)
History of trauma
Incontinence
Age >70 years
Intravenous drug use
Glucocorticoid use
History of a rapidly progressive neurologic deficit
Examination
Unexplained fever
Unexplained weight loss
Percussion tenderness over the spine
Abdominal, rectal, or pelvic mass
Patrick’s sign or heel percussion sign
Straight leg or reverse straight leg–raising signs
Progressive focal neurologic deficit
CHAPTER 54
301
Back and Neck Pain
Incapacitating nerve root pain despite conservative treatment for at least 
6–8 weeks: Trials indicate surgery leads to more rapid pain relief but no dif-
ference at 1–2 years compared with nonsurgical treatment.
Spinal Stenosis 
A narrowed spinal canal producing neurogenic claudication, i.e., back, but-
tock, and/or leg pain induced by walking or standing and relieved by sitting. 
Symptoms are usually bilateral. Unlike vascular claudication, symptoms are 
provoked by standing without walking. Unlike lumbar disk disease, symp-
toms are relieved by sitting. Focal neurologic deficits common; severe neu-
rologic deficits (paralysis, incontinence) rare. Stenosis results from acquired 
(75%), congenital, or mixed acquired/congenital factors. 
• Symptomatic treatment adequate for mild disease
• Surgery indicated when medical therapy does not allow for activities 
of daily living or if focal neurologic signs are present. Most pts treated 
surgically experience relief of back and leg pain; 25% develop recurrent 
stenosis within 7–10 years.
Trauma 
Low back strain or sprain used to describe minor, self-limited injuries 
associated with LBP. Vertebral fractures from trauma result in anterior 
wedging or compression of vertebral bodies; burst fractures involv-
ing vertebral body and posterior spine elements can occur. Neurologic 
impairment common with vertebral fractures; early surgical interven-
tion indicated. CT scans used to screen for spine disease in moderate to 
severe trauma; superior to routine x-rays for bony disease. Most common 
cause of nontraumatic fracture is osteoporosis; others are osteomalacia, 
hyperparathyroidism, hyperthyroidism, multiple myeloma, or metastatic 
carcinoma.
Spondylolisthesis
Slippage of anterior spine forward, leaving posterior elements behind; 
L4-L5 > L5-S1 levels; can produce LBP or radiculopathy/cauda equina 
syndrome (Chap. 200).
Osteoarthritis (Spondylosis) 
Back pain induced by spine movement and associated with stiffness. 
Increases with age; radiologic findings do not correlate with severity of 
pain. Osteophytes or combined disc-osteophytes may cause or contribute 
to central spinal canal stenosis, lateral recess stenosis, or neural foraminal 
narrowing.
Vertebral Metastases 
Back pain most common neurologic symptom in pts with systemic cancer 
and may be presenting complaint; pain typically not relieved by rest. 
Metastatic carcinoma, multiple myeloma, and lymphomas frequently involve 
spine. MRI or CT-myelography demonstrates vertebral body metastasis; disk 
space is spared.
SECTION 3
302
Common Patient Presentations
Vertebral Osteomyelitis 
Back pain unrelieved by rest; focal spine tenderness, elevated ESR. Primary 
source of infection is usually lung, urinary tract, or skin; IV drug abuse a 
risk factor. Destruction of the vertebral bodies and disk space common. 
Lumbar spinal epidural abscess presents as back pain and fever; exam may 
be normal or show radicular findings, spinal cord involvement, or cauda 
equina syndrome. Extent of abscess best defined by MRI.
Lumbar Adhesive Arachnoiditis 
May follow inflammation within subarachnoid space; fibrosis results in 
clumping of nerve roots, best seen by MRI; treatment is unsatisfactory.
Immune Disorders 
Ankylosing spondylitis, rheumatoid arthritis, Reiter’s syndrome, psoriatic 
arthritis, and chronic inflammatory bowel disease. Ankylosing spondylitis—
typically male <40 years with nocturnal back pain and morning stiffness, 
elevated ESR and presence of HLA-B27; pain unrelieved by rest but improves 
with exercise.
Osteoporosis
Loss of bone substance resulting from hyperparathyroidism, chronic glu-
cocorticoid use, immobilization, other medical disorders, or increasing age 
(particularly in females). Sole manifestation may be back pain exacerbated 
by movement. Can also occur in the upper back.
Visceral Diseases (Table 54-3)
Pelvis refers pain to sacral region, lower abdomen to mid-lumbar region, 
upper abdomen to lower thoracic or upper lumbar region. Local signs are 
absent; normal movements of the spine are painless. A contained rupture of 
an abdominal aortic aneurysm may produce isolated back pain.
TABLE 54-3 VISCERAL CAUSES OF LOW BACK PAIN
Stomach (posterior wall)—gallbladder—gallstones
Pancreas—tumor, cyst, pancreatitis
Retroperitoneal—hemorrhage, tumor, pyelonephritis
Vascular—abdominal aortic aneurysm, renal artery and vein thrombosis
Colon—colitis, diverticulitis, neoplasm
Uterosacral ligaments—endometriosis, carcinoma
Uterine malposition
Menstrual pain
Neoplastic infiltration of nerves
Radiation neurosis of tumors/nerves
Prostate—carcinoma, prostatitis
Kidney—renal stones, inflammatory disease, neoplasm, infection
CHAPTER 54
303
Back and Neck Pain
Other
Chronic LBP with no clear cause; psychiatric disorders, substance abuse 
may be associated.
Low Back Pain
TREATMENT
ACUTE LOW BACK PAIN (ALBP)
• Pain of <3 months’ duration.
• When leg pain absent, prognosis is excellent; full recovery in 85%. 
• Management controversial; few well-controlled clinical trials exist. 
• If “risk factors” (Table 54-2) are absent, initial treatment is symptom-
atic and no diagnostic tests necessary. 
• Clinical trials do not show benefit from bed rest >2 days. Possible ben-
efits of early activity—cardiovascular conditioning, disk and cartilage 
nutrition, bone and muscle strength, increased endorphin levels.
• A short course of lumbar spinal manipulation or physical therapy is a 
reasonable option.
• Proof lacking to support acupuncture, ultrasound, diathermy, transcu-
taneous electrical nerve stimulation, biofeedback, magnets, traction, 
or electrical stimulation.
• Self-application of ice or heat or use of shoe insoles is optional given 
low cost and risk.
• Spine infections, fractures, tumors, or rapidly progressive neurologic 
deficits require urgent diagnostic evaluation.
• Drug treatment of ALBP includes NSAIDs and acetaminophen 
(Chap. 6). 
• Muscle relaxants (cyclobenzaprine) may be useful but sedation is a 
common side effect. 
• Opioids are not clearly superior to NSAIDs or acetaminophen for ALBP. 
• No evidence to support oral or injected epidural glucocorticoids. 
CHRONIC LOW BACK PAIN (CLBP)
• Pain lasting >12 weeks; differential diagnosis includes most conditions 
described above. 
• CLBP causes can be clarified by neuroimaging and EMG/nerve con-
duction studies; diagnosis of radiculopathy secure when results con-
cordant with findings on neurologic exam. Treatment should not be 
based on neuroimaging alone: up to one-third of asymptomatic young 
adults have a herniated lumbar disk by CT or MRI.
• Management is not amenable to a simple algorithmic approach. 
Treatment based on identification of underlying cause; when specific 
cause not found, conservative management necessary. 
• Drug treatment and comfort measures similar to those described for 
ALBP. 
• Evidence supports the use of exercise therapy; effective in returning 
some pts to work, diminishing pain, and improving walking distances. 
• Cognitive-behavioral therapy may have some use; long-term results 
unclear.
SECTION 3
304
Common Patient Presentations
• Alternative therapies including spinal manipulation, acupuncture, and 
massage are frequently tried; trials are mixed as to their effectiveness.
• Some pts report short-term pain relief with percutaneous electrical 
nerve stimulation, but a recent evidence-based guideline failed to 
show efficacy.
• Epidural glucocorticoids and facet joint injections are not effective in 
the absence of radiculopathy.
• Surgical intervention for chronic LBP without radiculopathy is contro-
versial, and clinical trials do not support its use.
NECK AND SHOULDER PAIN
Usually arises from diseases of the cervical spine and soft tissues of the 
neck; typically precipitated by movement and may be accompanied by focal 
tenderness and limitation of motion.
� ETIOLOGY 
Trauma to the Cervical Spine 
Trauma to the cervical spine (fractures, subluxation) places the spine at 
risk for compression; immediate immobilization of the neck is essential to 
minimize movement of unstable cervical spine segments.
Whiplash injury is due to trauma (usually automobile accidents) causing 
cervical musculoligamentous injury due to hyperflexion or hyperextension. 
This diagnosis is not applied to pts with fractures, disk herniation, head 
injury, focal neurologic findings, or altered consciousness.
Cervical Disk Disease 
Herniation of a lower cervical disk is a common cause of neck, shoulder, 
arm, or hand pain or tingling. Neck pain (worse with movement), stiffness, 
and limited range of neck motion are common. With nerve root compres-
sion, pain may radiate into a shoulder or arm. Extension and lateral rotation 
of the neck narrows the intervertebral foramen and may reproduce radicu-
lar symptoms (Spurling’s sign). In young individuals, acute radiculopathy 
from a ruptured disk is often traumatic. Subacute radiculopathy is less likely 
to be related to a specific traumatic incident and may involve both disk 
disease and spondylosis. Clinical features of cervical nerve root lesions are 
summarized in Table 54-4.
Cervical Spondylosis 
Osteoarthritis of the cervical spine may produce neck pain that 
radiates into the back of the head, shoulders, or arms; can also be 
source of headaches in the posterior occipital region. A combined 
radiculopathy and myelopathy may occur. An electrical sensation 
elicited by neck flexion and radiating down the spine from the neck 
(Lhermitte’s symptom) usually indicates spinal cord involvement. MRI 
or CT-myelography can define the anatomic abnormalities, and EMG 
and nerve conduction studies can quantify the severity and localize the 
levels of nerve root injury.
TABLE 54-4 CERVICAL RADICULOPATHY—NEUROLOGIC FEATURES
Cervical Nerve 
Roots
Examination Findings
Pain Distribution
Reflex
Sensory
Motor
C5
Biceps
Over lateral deltoid
Supraspinatusa (initial arm abduction)
Infraspinatusa (arm external rotation)
Deltoida (arm abduction)
Biceps (arm flexion)
Lateral arm, medial scapula
C6
Biceps
Thumb, index fingers
Radial hand/forearm
Biceps (arm flexion)
Pronator teres (internal forearm rotation)
Lateral forearm, thumb, index 
finger
C7
Triceps
Middle fingers
Dorsum forearm
Tricepsa (arm extension)
Wrist extensorsa
Extensor digitoruma (finger extension)
Posterior arm, dorsal forearm, 
lateral hand
C8
Finger flexors
Little finger
Medial hand and forearm
Abductor pollicis brevis (abduction D1)
First dorsal interosseous (abduction D2)
Abductor digiti minimi (abduction D5)
4th and 5th fingers, medial 
forearm
T1
Finger flexors
Axilla and medial arm
Abductor pollicis brevis (abduction D1)
First dorsal interosseous (abduction D2)
Abductor digiti minimi (abduction D5)
Medial arm, axilla
aThese muscles receive the majority of innervation from this root.
305
SECTION 3
306
Common Patient Presentations
Other Causes of Neck Pain 
Includes rheumatoid arthritis of the cervical apophyseal joints, ankylosing 
spondylitis, herpes zoster (shingles), neoplasms metastatic to the cervical 
spine, infections (osteomyelitis and epidural abscess), and metabolic bone 
diseases. Neck pain may also be referred from the heart with coronary artery 
ischemia (cervical angina syndrome).
Thoracic Outlet 
An anatomic region containing the first rib, the subclavian artery and vein, 
the brachial plexus, the clavicle, and the lung apex. Injury may result in pos-
ture- or movement-induced pain around the shoulder and supraclavicular 
region. True neurogenic thoracic outlet syndrome is uncommon and results 
from compression of the lower trunk of the brachial plexus by an anoma-
lous band of tissue; treatment consists of surgical division of the band. 
Arterial thoracic outlet syndrome results from compression of the subclavian 
artery by a cervical rib; treatment is with thrombolysis or anticoagulation, 
and surgical excision of the cervical rib. Disputed thoracic outlet syndrome 
includes a large number of pts with chronic arm and shoulder pain of 
unclear cause; surgery is controversial, and treatment is often unsuccessful.
Brachial Plexus and Nerves 
Pain from injury to the brachial plexus or peripheral nerves can mimic pain 
of cervical spine origin. Neoplastic infiltration can produce this syndrome, 
as can postradiation fibrosis (pain less often present). Acute brachial neuritis 
consists of acute onset of severe shoulder or scapular pain followed over days 
by weakness of proximal arm and shoulder girdle muscles innervated by the 
upper brachial plexus; onset often preceded by an infection or immunization.
Shoulder
If signs of radiculopathy are absent, differential diagnosis includes mechani-
cal shoulder pain (tendinitis, bursitis, rotator cuff tear, dislocation, adhe-
sive capsulitis, and cuff impingement under the acromion) and referred 
pain [subdiaphragmatic irritation, angina, Pancoast (apical lung) tumor]. 
Mechanical pain is often worse at night, associated with shoulder tender-
ness, and aggravated by abduction, internal rotation, or extension of the arm.
Neck and Shoulder Pain
TREATMENT
• Indications for cervical disk surgery are similar to those for lum-
bar disk; however, with cervical disease, an aggressive approach is 
indicated if spinal cord injury is threatened. 
NECK PAIN WITHOUT RADICULOPATHY
• Spontaneous improvement is expected for most acute neck pain.
• Symptomatic treatment of neck pain includes analgesic medications. 
• If not related to trauma, supervised exercise appears to be effective.
• No valid clinical evidence to support cervical fusion or cervical disc 
arthroplasty.
CHAPTER 55
307
Headache
• No evidence to support radiofrequency neurotomy or cervical facet 
injections.
NECK PAIN WITH RADICULOPATHY
• Natural history is favorable and many will improve without specific 
therapy.
• NSAIDs, with or without muscle relaxants are appropriate initial 
therapy.
• Soft cervical collars are modestly helpful in limiting movements that 
exacerbate pain. 
• Cervical spondylosis with bony, compressive cervical radiculopathy is 
generally treated with surgical decompression to interrupt the pro-
gression of neurologic signs. 
• Surgical options for cervical herniated disks consist of anterior cervi-
cal discectomy alone, laminectomy with discectomy, discectomy with 
fusion, and disk arthroplasty. The cumulative risk of subsequent radic-
ulopathy or myelopathy at cervical segments adjacent to the fusion is 
~3% per year. 
• Indications for surgery include a progressive radicular motor deficit, 
pain that limits function and fails to respond to conservative manage-
ment, or spinal cord compression.
For more detailed discussion, see Engstrom JW, Deyo RA: 
Back and Neck Pain, Chap. 15, p. 129, in HPIM-18.
CHAPTER 55
Headache
Headache
APPROACH TO THE
PATIENT
Headache is among the most common reasons that pts seek medical 
attention. Headache can be either primary or secondary (Table 55-1). 
First step—distinguish serious from benign etiologies. Symptoms that 
raise suspicion for a serious cause are listed in Table 55-2. Intensity of 
head pain rarely has diagnostic value; most pts who present to emergency 
ward with worst headache of their lives have migraine. Headache loca-
tion can suggest involvement of local structures (temporal pain in giant 
cell arteritis, facial pain in sinusitis). Ruptured aneurysm (instant onset), 
cluster headache (peak over 3–5 min), and migraine (onset over minutes 
to hours) differ in time to peak intensity. Provocation by environmental 
factors suggests a benign cause.
SECTION 3
308
Common Patient Presentations
Complete neurologic exam is important in the evaluation of headache. If 
exam is abnormal or if serious underlying cause is suspected, an imaging study 
(CT or MRI) is indicated as a first step. Lumbar puncture (LP) is required 
when meningitis (stiff neck, fever) or subarachnoid hemorrhage (after nega-
tive imaging) is a possibility. The psychological state of the pt should also be 
evaluated since a relationship exists between pain and depression.
� MIGRAINE
A benign and recurring syndrome of headache associated with other symp-
toms of neurologic dysfunction in varying admixtures. Second to tension-type 
as most common cause of headache; afflicts ~15% of women and 6% of men 
annually. Diagnostic criteria for migraine are listed in Table 55-3. Onset usu-
ally in childhood, adolescence, or early adulthood; however, initial attack may 
occur at any age. Family history often positive. Women may have increased 
sensitivity to attacks during menstrual cycle. Classic triad: premonitory visual 
(scotoma or scintillations), sensory, or motor symptoms; unilateral throbbing 
headache; and nausea and vomiting. Most pts do not have visual aura or other 
TABLE 55-2  HEADACHE SYMPTOMS THAT SUGGEST A SERIOUS 
UNDERLYING DISORDER
“Worst” headache ever
First severe headache
Subacute worsening over days or weeks
Abnormal neurologic examination
Fever or unexplained systemic signs
Vomiting that precedes headache
Pain induced by bending, lifting, cough
Pain that disturbs sleep or presents immediately upon awakening
Known systemic illness
Onset after age 55
Pain associated with local tenderness, e.g., region of temporal artery
TABLE 55-1 COMMON CAUSES OF HEADACHE
Primary Headache
Secondary Headache
Type
%
Type
%
Tension-type
69
Systemic infection
63
Migraine
16
Head injury
4
Idiopathic stabbing
2
Vascular disorders
1
Exertional
1
Subarachnoid hemorrhage
<1
Cluster
0.1
Brain tumor
0.1
Source: After J Olesen et al: The Headaches. Philadelphia, Lippincott, Williams & Wilkins, 2005.
CHAPTER 55
309
Headache
premonitory symptoms and are therefore referred to as having “common 
migraine.” Photo- and phonophobia common. Vertigo may occur. Focal neu-
rologic disturbances without headache or vomiting (migraine equivalents) may 
also occur. An attack lasting 4–72 h is typical, as is relief after sleep. Attacks may 
be triggered by glare, bright lights, sounds, hunger, stress, physical exertion, 
hormonal fluctuations, lack of sleep, alcohol, or other chemical stimulation.
Migraine
TREATMENT
• Three approaches to migraine treatment: nonpharmacologic (such as 
the avoidance of pt-specific triggers; information for pts is available at 
www.achenet.org); drug treatment of acute attacks (Tables 55-4 and 
55-5); and prophylaxis (Table 55-6). 
• Drug treatment necessary for most migraine pts, but avoidance or 
management of environmental triggers is sufficient for some. 
• General principles of pharmacologic treatment: 
• Response rates vary from 50—70%.
• Initial drug choice is empirical—influenced by age, coexisting ill-
nesses, and side effect profile.
• Efficacy of prophylactic treatment may take several months to 
assess with each drug.
• When an acute attack requires additional medication 60 min after 
the first dose, then the initial drug dose should be increased for 
subsequent attacks. 
• Mild to moderate acute migraine attacks often respond to over-the-
counter (OTC) NSAIDs when taken early in the attack. 
• Triptans are widely used also but many have recurrence of pain after 
initial relief. 
• There is less frequent headache recurrence when using ergots, but 
more frequent side effects. 
• For prophylaxis, tricyclic antidepressants are a good first choice for 
young people with difficulty falling asleep; verapamil is often a first 
choice for prophylaxis in the elderly.
TABLE 55-3 SIMPLIFIED DIAGNOSTIC CRITERIA FOR MIGRAINE
Repeated attacks of headache lasting 4–72 h in pts with a normal physical 
examination, no other reasonable cause for the headache, and:
At least 2 of the following features:
Plus at least 1 of the following 
features:
Unilateral pain
Nausea/vomiting
Throbbing pain
Photophobia and phonophobia
Aggravation by movement
Moderate or severe intensity
Source: Adapted from the International Headache Society Classification (Headache 
Classification Committee of the International Headache Society, 2004).
SECTION 3
310
Common Patient Presentations
TABLE 55-4 TREATMENT OF ACUTE MIGRAINE
Drug
Trade Name
Dosage
Simple Analgesics
Acetaminophen, 
aspirin, caffeine
Excedrin
Migraine
Two tablets or caplets q6h 
(max 8 per day)
NSAIDs
Naproxen
Aleve, Anaprox, 
generic
220–550 mg PO bid
Ibuprofen
Advil, Motrin, 
generic
400 mg PO q3–4h
Tolfenamic acid
Clotam Rapid
200 mg PO. May repeat ×1 after 1–2 h
5-HT1 Agonists
Oral
Ergotamine
Ergomar
One 2-mg sublingual tablet at onset 
and q½h (max 3 per day, 5 per week)
Ergotamine 1 mg, 
caffeine 100 mg
Ercaf, Wigraine
One or two tablets at onset, then one 
tablet q½h (max 6 per day, 10 per week)
Naratriptan
Amerge
2.5-mg tablet at onset; may repeat 
once after 4 h
Rizatriptan
Maxalt
5- or 10-mg tablet at onset; may 
repeat after 2 h (max 30 mg/d)
Maxalt-MLT
Sumatriptan
Imitrex
50- or 100-mg tablet at onset; may 
repeat after 2 h (max 200 mg/d)
Frovatriptan
Frova
2.5-mg tablet at onset, may repeat 
after 2 h (max 5 mg/d)
Almotriptan
Axert
12.5-mg tablet at onset, may repeat 
after 2 h (max 25 mg/d)
Eletriptan
Relpax
40 or 80 mg
Zolmitriptan
Zomig
2.5-mg tablet at onset; may repeat 
after 2 h (max 10 mg/d)
Zomig Rapimelt
Nasal
Dihydroergotamine Migranal Nasal 
Spray
Prior to nasal spray, the pump must 
be primed 4 times; 1 spray (0.5 mg) 
is administered, followed in 15 min 
by a second spray
Sumatriptan
Imitrex Nasal 
Spray
5- or 20-mg intranasal spray as 
4 sprays of 5 mg or a single 20-mg 
spray (may repeat once after 2 h, not 
to exceed a dose of 40 mg/d)
Zolmitriptan
Zomig
5-mg intranasal spray as one spray 
(may repeat once after 2 h, not to 
exceed a dose of 10 mg/d)
CHAPTER 55
311
Headache
TABLE 55-4 TREATMENT OF ACUTE MIGRAINE (CONTINUED)
Drug
Trade Name
Dosage
Parenteral
Dihydroergotamine DHE-45
1 mg IV, IM, or SC at onset and q1h 
(max 3 mg/d, 6 mg per week)
Sumatriptan
Imitrex 
Injection
6 mg SC at onset (may repeat 
once after 1 h for max of 2 doses 
in 24 h)
Dopamine Antagonists
Oral
Metoclopramide
Reglan,a
generica
5–10 mg/d
Prochlorperazine
Compazine,a
generica
1–25 mg/d
Parenteral
Chlorpromazine
Generica
0.1 mg/kg IV at 2 mg/min; 
max 35 mg/d
Metoclopramide
Reglan,a
generic
10 mg IV
Prochlorperazine
Compazine,a
generica
10 mg IV
Other
Oral
Acetaminophen, 
325 mg, plus
dichloralphena-
zone, 100 mg, 
plus isomethep-
tene, 65 mg
Midrin, 
Duradrin, 
generic
Two capsules at onset followed by 
1 capsule q1h (max 5 capsules)
Nasal
Butorphanol
Stadola
1 mg (1 spray in 1 nostril), may repeat 
if necessary in 1–2 h
Parenteral
Narcotics
Generica
Multiple preparations and dosages; 
see Table 6-2
aNot all drugs are specifically indicated by the FDA for migraine. Local regulations and 
guidelines should be consulted.
Note: Antiemetics (e.g., domperidone 10 mg or ondansetron 4 or 8 mg) or prokinetics 
(e.g., metoclopramide 10 mg) are sometimes useful adjuncts.
Abbreviations: NSAIDs, nonsteroidal anti-inflammatory drugs; 5-HT, 5-hydroxytryptamine.
SECTION 3
312
Common Patient Presentations
TABLE 55-5  CLINICAL STRATIFICATION OF ACUTE SPECIFIC MIGRAINE 
TREATMENTS
Clinical Situation
Treatment Options
Failed NSAIDS/analgesics
First tier
Sumatriptan 50 mg or 100 mg PO
Almotriptan 12.5 mg PO
Rizatriptan 10 mg PO
Eletriptan 40 mg PO
Zolmitriptan 2.5 mg PO
Slower effect/better tolerability
Naratriptan 2.5 mg PO
Frovatriptan 2.5 mg PO
Infrequent headache
Ergotamine 1–2 mg PO
Dihydroergotamine nasal spray 
2 mg
Early nausea or difficulties taking tablets
Zolmitriptan 5 mg nasal spray
Sumatriptan 20 mg nasal spray
Rizatriptan 10 mg MLT wafer
Headache recurrence
Ergotamine 2 mg (most effective 
PR/usually with caffeine)
Naratriptan 2.5 mg PO
Almotriptan 12.5 mg PO
Eletriptan 40 mg
Tolerating acute treatments poorly
Naratriptan 2.5 mg
Almotriptan 12.5 mg
Early vomiting
Zolmitriptan 5 mg nasal spray
Sumatriptan 25 mg PR
Sumatriptan 6 mg SC
Menses-related headache
Prevention
Ergotamine PO at night
Estrogen patches
Treatment
Triptans
Dihydroergotamine nasal spray
Very rapidly developing symptoms
Zolmitriptan 5 mg nasal spray
Sumatriptan 6 mg SC
Dihydroergotamine 1 mg IM
CHAPTER 55
313
Headache
TABLE 55-6 PREVENTIVE TREATMENTS IN MIGRAINEa
Drug
Dose
Selected Side Effects
Pizotifenb
0.5–2 mg qd
Weight gain
Drowsiness
Beta blocker
 Propranolol
40–120 mg bid
Reduced energy
Tiredness
Postural symptoms
Contraindicated in asthma
Tricyclics
 Amitriptyline
 Dothiepin
 Nortriptylinec
10–75 mg at night
25–75 mg at night
25–75 mg at night
Drowsiness
Anticonvulsants
 Topiramate
25–200 mg/d
Paresthesias
Cognitive symptoms
Weight loss
Glaucoma
Caution with nephrolithiasis
 Valproate
400–600 mg bid
Drowsiness
Weight gain
Tremor
Hair loss
Fetal abnormalities
Hematologic or liver abnormalities
 Gabapentin
900–3600 mg qd
Dizziness
Sedation
Serotonergic drugs
 Methysergide
1–4 mg qd
Drowsiness
Leg cramps
Hair loss
Retroperitoneal fibrosis (1-month 
drug holiday is required every 
6 months)
 Flunarizineb
5–15 mg qd
Drowsiness
Weight gain
Depression
Parkinsonism
(continued)
SECTION 3
314
Common Patient Presentations
Tension-Type Headache 
Common in all age groups. Pain is described as bilateral tight, bandlike 
discomfort. May persist for hours or days; usually builds slowly. 
• Pain can be managed generally with simple analgesics such as acetamin-
ophen, aspirin, or NSAIDs. 
• Often related to stress; responds to behavioral approaches including 
relaxation. 
• Amitriptyline may be helpful for chronic (>15 days per month) tension-
type headache prophylaxis.
Cluster Headache 
Rare form of primary headache; population frequency 0.1%. Characterized 
by episodes of recurrent, deep, unilateral, retroorbital searing pain. 
Unilateral lacrimation and nasal and conjunctival congestion may be 
present. Visual complaints, nausea, or vomiting are rare. Unlike migraine, 
pts with cluster tend to move about during attacks. A core feature is 
periodicity. Typically, daily bouts of one to two attacks of relatively short-
duration unilateral pain for 8–10 weeks a year; usually followed by a 
pain-free interval that averages a little less than a year. Alcohol provokes 
attacks in 70%. 
• Prophylaxis with verapamil (40–80 mg twice daily to start), lithium 
(400–800 mg/d), prednisone (60 mg/d for 7 days followed by a taper 
over 21 days), or ergotamine (1–2 mg suppository 1–2 h before expected 
attack).
• High-flow oxygen (10–12 L/min for 15–20 min) or sumatriptan (6 mg 
SC or 20-mg nasal spray) is useful for the acute attack. 
• Deep-brain stimulation of the posterior hypothalamic gray matter is 
successful for refractory cases as is the less-invasive approach of occipital 
nerve stimulation.
TABLE 55-6 PREVENTIVE TREATMENTS IN MIGRAINEa (CONTINUED)
Drug
Dose
Selected Side Effects
No convincing evidence from controlled trials
 Verapamil
Controlled trials demonstrate no effect
 Nimodipine
 Clonidine
  SSRIs: fluoxetine
aCommonly used preventives are listed with typical doses and common side effects. Not all 
listed medicines are approved by the FDA; local regulations and guidelines should be consulted.
bNot available in the United States.
cSome pts may only need a total dose of 10 mg, although generally 1–1.5 mg/kg body 
weight is required.
CHAPTER 55
315
Headache
Post-Concussion Headache 
Common following motor vehicle collisions, other head trauma; severe 
injury or loss of consciousness often not present. Symptoms of headache, 
dizziness, vertigo, impaired memory, poor concentration, irritability; 
typically remits after several weeks to months. Neurologic examination and 
neuroimaging studies normal. Not a functional disorder; cause unknown 
and treatment usually not satisfactory.
Lumbar Puncture Headache 
Typical onset within 48 h after LP; follows 10–30% of LPs. Positional: 
onset when pt sits or stands, relief by lying flat. Most cases remit spon-
taneously in ≤1 week. Oral or IV caffeine (500 mg IV over 2 hours) suc-
cessful in 85%; epidural blood patch effective immediately in refractory 
cases.
Cough Headache 
Transient severe head pain with coughing, bending, lifting, sneezing, or 
stooping; lasts for several minutes; men > women. Usually benign, but pos-
terior fossa mass lesion in some pts; therefore consider brain MRI.
Indomethacin-Responsive Headaches 
A diverse set of disorders that respond often exquisitely to indomethacin 
includes:
• Paroxysmal hemicrania: Frequent unilateral, severe, short-lasting epi-
sodes of headache that are often retroorbital and associated with auto-
nomic phenomena such as lacrimation and nasal congestion.
• Hemicrania continua: Moderate and continuous unilateral pain associ-
ated with fluctuations of severe pain that may be associated with auto-
nomic features.
• Primary stabbing headache: Stabbing pain confined to the head or rarely 
the face lasting from 1 to many seconds or minutes.
• Primary cough headache
• Primary exertional headache: Has features similar to cough headache and 
migraine; usually precipitated by any form of exercise.
� FACIAL PAIN
Most common cause of facial pain is dental; triggered by hot, cold, 
or sweet foods. Exposure to cold repeatedly induces dental pain. Trigeminal 
neuralgia consists of paroxysmal, electric shock–like episodes of pain in the 
distribution of trigeminal nerve; occipital neuralgia presents as lancinat-
ing occipital pain. These disorders are discussed in Chap. 199.
For a more detailed discussion, see Goadsby PJ, Raskin NH: 
Headache, Chap. 14, p. 112, in HPIM-18.
SECTION 3
316
Common Patient Presentations
CHAPTER 56
Syncope
Syncope is a transient, self-limited loss of consciousness and postural tone 
due to reduced cerebral blood flow. It may occur suddenly, without warn-
ing, or may be preceded by presyncopal symptoms such as lightheaded-
ness or faintness, weakness, fatigue, nausea, dimming vision, ringing in 
ears, or sweating. The syncopal pt appears pale and has a faint, rapid, 
or irregular pulse. Breathing may be almost imperceptible; transient 
myoclonic or clonic movements may occur. Recovery of consciousness is 
prompt if pt is maintained in a horizontal position and cerebral perfusion 
is restored.
Syncope
APPROACH TO THE
PATIENT
The cause may be apparent only at the time of the event, leaving few, if 
any, clues when the pt is seen by the physician. Other disorders must 
be distinguished from syncope, including seizures, vertebrobasilar 
ischemia, hypoxemia, and hypoglycemia (see below). First consider 
serious underlying etiologies; among these are massive internal hem-
orrhage, myocardial infarction (can be painless), and cardiac arrhyth-
mias. In elderly pts, a sudden faint without obvious cause should raise 
the question of complete heart block or a tachyarrhythmia. Loss of 
consciousness in particular situations, such as during venipuncture 
or micturition, suggests a benign abnormality of vascular tone. The 
position of the pt at the time of the syncopal episode is important; 
syncope in the supine position is unlikely to be vasovagal and suggests 
arrhythmia or seizure. Medications must be considered, including 
nonprescription drugs or health store supplements, with particular 
attention to recent changes. Symptoms of impotence, bowel and blad-
der difficulties, disturbed sweating, or an abnormal neurologic exam 
suggest a primary neurogenic cause. An algorithmic approach is pre-
sented in Fig. 56-1.
� ETIOLOGY
Syncope is usually due to a neurally mediated disorder, orthostatic hypoten-
sion, or an underlying cardiac condition (Table 56-1). Not infrequently the 
cause is multifactorial.
Neurocardiogenic (Vasovagal and Vasodepressor) Syncope 
The common faint, experienced by normal persons, accounts for approxi-
mately half of all episodes of syncope. It is frequently recurrent and may be 
provoked by hot or crowded environment, alcohol, fatigue, pain, hunger, 
prolonged standing, or stressful situations.
CHAPTER 56
317
Syncope
Postural (Orthostatic) Hypotension 
Sudden rising from a recumbent position or standing quietly are precipitating 
circumstances. Cause of syncope in 30% of elderly; polypharmacy with antihy-
pertensive or antidepressant drugs often a contributor; physical deconditioning 
may also play a role. Also occurs with autonomic nervous system disorders, 
either peripheral (diabetes, nutritional, or amyloid polyneuropathy) or central 
(multiple system atrophy, Parkinson’s disease). Some cases are idiopathic.
� DIFFERENTIAL DIAGNOSIS
Seizures
The differential diagnosis is often between syncope and a generalized sei-
zure. Syncope is more likely if the event was provoked by acute pain or anxi-
ety or occurred immediately after arising from a lying or sitting position; 
seizures are typically not related to posture. Pts with syncope often describe 
a stereotyped transition from consciousness to unconsciousness that 
develops over a few seconds. Seizures occur either very abruptly without a 
transition or are preceded by premonitory symptoms such as an epigastric 
rising sensation, perception of odd odors, or racing thoughts. Pallor is seen 
during syncope; cyanosis is usually seen during a seizure. The duration of 
unconsciousness is usually very brief (i.e., seconds) in syncope and more 
prolonged (i.e., >5 min) in a seizure. Injury from falling and incontinence 
are common in seizure, rare in syncope. Whereas tonic-clonic movements 
are the hallmark of a generalized seizure, myoclonic and other movements 
also occur in 90% of syncopal episodes and eyewitnesses will often have a 
difficult time distinguishing between the two etiologies.
Syncope
Normal history 
and physical
examination
History, physical
exam, ECG suggest
cardiac disease
Examination
reveals orthostatic
hypotension
Review
medication
Abnormal
neurologic exam
Normal
neurologic exam
Echocardiogram,
24-hr Holter monitor,
stress test, other
cardiac testing
as indicated 
Tilt testing
if severe
or recurrent
Reflex
syncope
Consider
postganglionic
autonomic
insufficiency
Peripheral
neuropathy (consider
diabetic, nutritional,
amyloid, etc.)
Central nervous
system findings
Consider multiple
system atrophy
FIGURE 56-1 Approach to the pt with syncope.
SECTION 3
318
Common Patient Presentations
TABLE 56-1 CAUSES OF SYNCOPE
A. NEURALLY MEDIATED SYNCOPE
Vasovagal syncope
  Provoked fear, pain, anxiety, intense emotion, sight of blood, unpleasant 
sights and odors, orthostatic stress
Situational reflex syncope
 Pulmonary
   Cough syncope, wind instrument player’s syncope, weightlifter’s 
syncope, “mess trick”a and “fainting lark,”b sneeze syncope, airway 
instrumentation
 Urogenital
   Postmicturition syncope, urogenital tract instrumentation, prostatic 
massage
 Gastrointestinal
   Swallow syncope, glossopharyngeal neuralgia, esophageal stimulation, 
gastrointestinal tract instrumentation, rectal examination, defecation 
syncope
 Cardiac
   Swallow syncope, glossopharyngeal neuralgia, esophageal stimulation, 
gastrointestinal tract instrumentation, rectal examination, defecation 
syncope
 Carotid sinus
   Carotid sinus sensitivity, carotid sinus massage
 Ocular
   Ocular pressure, ocular examination, ocular surgery
B. ORTHOSTATIC HYPOTENSION
Primary autonomic failure due to idiopathic central and peripheral neurode-
generative diseases—the “synucleinopathies”
 Lewy body diseases
   Parkinson’s disease
   Lewy body dementia
   Pure autonomic failure
 Multiple system atrophy (Shy-Drager syndrome)
Secondary autonomic failure due to autonomic peripheral neuropathies
 Diabetes
 Hereditary amyloidosis (familial amyloid polyneuropathy)
  Primary amyloidosis (AL amyloidosis; immunoglobulin light chain 
associated)
  Hereditary sensory and autonomic neuropathies (HSAN) (especially type 
III—familial dysautonomia)
 Idiopathic immune-mediated autonomic neuropathy
CHAPTER 56
319
Syncope
TABLE 56-1 CAUSES OF SYNCOPE (CONTINUED)
B. ORTHOSTATIC HYPOTENSION
 Autoimmune autonomic ganglionopathy
 Sjögren’s syndrome
 Paraneoplastic autonomic neuropathy
 HIV neuropathy
Postprandial hypotension
Iatrogenic (drug-induced)
Volume depletion
C. CARDIAC SYNCOPE
Arrhythmias
 Sinus node dysfunction
 Atrioventricular dysfunction
 Supraventricular tachycardias
 Ventricular tachycardias
 Inherited channelopathies
Cardiac structural disease
 Valvular disease
 Myocardial ischemia
 Obstructive and other cardiomyopathies
 Atrial myxoma
 Pericardial effusions and tamponade
aHyperventilation for 1 minute, followed by sudden chest compression.
bHyperventilation (20 breaths) in a squatting position, rapid rise to standing, then Valsalva.
Hypoglycemia
Severe hypoglycemia is usually due to a serious disease. Hunger is a pre-
monitory feature that is not typical in syncope. The glucose level at the time 
of a spell is diagnostic.
Cataplexy 
Abrupt partial or complete loss of muscular tone triggered by strong emo-
tions; occurs in 60–75% of narcolepsy pts. Unlike syncope, consciousness is 
maintained throughout the attacks. No premonitory symptoms. 
Psychiatric Disorders
Apparent loss of consciousness can be present in generalized anxiety, panic 
disorders, major depression, and somatization disorder. Frequently resem-
bles presyncope, although the symptoms are not accompanied by prodromal 
symptoms and are not relieved by recumbency. Attacks can often be repro-
duced by hyperventilation and have associated symptoms of panic attacks 
such as a feeling of impending doom, air hunger, palpitations, and tingling of 
SECTION 3
320
Common Patient Presentations
the fingers and perioral region. Such pts are rarely injured despite numerous 
falls. There are no clinically significant hemodynamic changes.
Syncope
TREATMENT
Therapy is determined by the underlying cause. 
• Pts with neurally mediated syncope should be instructed to avoid situ-
ations or stimuli that provoke attacks.
• Drug therapy may be necessary for resistant neurally medicated 
syncope. β-adrenergic antagonists (metoprolol 25–50 mg twice daily; 
atenolol 25–50 mg/d; or nadolol 10–20 mg twice daily; all starting 
doses) are the most widely used agents; serotonin reuptake inhibitors 
(paroxetine 20–40 mg/d, or sertraline 25–50 mg/d) and bupropion SR 
(150 mg/d) are also effective.
• Pts with orthostatic hypotension should first be treated with removal 
of vasoactive medications. Then consider nonpharmacologic (pt edu-
cation regarding moves from supine to upright, increasing fluids and 
salt in diet) and finally pharmacologic methods such as the mineralo-
corticoid fludrocortisone acetate and vasoconstricting agents such as 
midodrine and pseudoephedrine.
Management of refractory orthostatic hypotension is discussed in 
Chap. 198.
For a more detailed discussion, see Freeman R: Syncope, 
Chap. 20, p. 171, in HPIM-18.
CHAPTER 57
Dizziness and Vertigo
Dizziness or Vertigo
APPROACH TO THE
PATIENT
The term dizziness is used by pts to describe a variety of head sensations 
or gait unsteadiness. With a careful history, distinguishing between 
faintness (presyncope; Chap. 56) and vertigo (an illusory or hallucina-
tory sense of movement of the body or the environment, most often a 
feeling of spinning) is usually possible.
When the meaning of dizziness is uncertain, provocative tests to 
reproduce the symptoms may be helpful. Valsalva maneuver, hyper-
ventilation, or postural changes leading to orthostasis may reproduce 
faintness. Rapid rotation in a swivel chair is a simple provocative test to 
reproduce vertigo. 
CHAPTER 57
321
Dizziness and Vertigo
Benign positional vertigo is identified by the Dix-Hallpike maneuver 
to elicit vertigo and the characteristic nystagmus; the pt begins in a sitting 
position with head turned 45 degrees; holding the back of the head, exam-
iner gently lowers pt to supine position with head extended backward 
20 degrees and observes for nystagmus; after 30 s the pt is raised to sitting 
position and after 1 min rest the maneuver is repeated on other side. 
If a central cause for the vertigo is suspected (e.g., signs of peripheral 
vertigo are absent or other neurologic abnormalities are present), then 
prompt evaluation for central pathology is required. The initial test 
is usually an MRI scan of the posterior fossa. Distinguishing between 
central and peripheral etiologies can be accomplished with vestibular 
function tests, including videonystagmography and simple bedside 
exams including the head impulse test (rapid, small amplitude head rota-
tions while pt instructed to fixate on the examiner’s face; if peripheral, a 
catch-up saccade is seen at the end of the rotation) and dynamic visual 
acuity (measure acuity at rest and with head rotated back and forth 
by examiner; a drop in acuity of more than one line on a near card or 
Snellen chart indicates vestibular dysfunction).
� FAINTNESS
Faintness is usually described as light-headedness followed by visual blur-
ring and postural swaying along with a feeling of warmth, diaphoresis, and 
nausea. It is a symptom of insufficient blood, oxygen, or, rarely, glucose 
supply to the brain. It can occur prior to a syncopal event of any etiology 
(Chap. 56) and with hyperventilation or hypoglycemia. Lightheadedness 
can rarely occur during an aura before a seizure. Chronic lightheadedness 
is a common somatic complaint with depression.
� VERTIGO
Usually due to a disturbance in the vestibular system; abnormalities in the 
visual or somatosensory systems may also contribute to vertigo. Frequently 
accompanied by nausea, postural unsteadiness, and gait ataxia; may be pro-
voked or worsened by head movement.
Physiologic vertigo results from unfamiliar head movement (seasickness) 
or a mismatch between visual-proprioceptive-vestibular system inputs 
(height vertigo, visual vertigo during motion picture chase scenes). True 
vertigo almost never occurs as a presyncopal symptom.
Pathologic vertigo may be caused by a peripheral (labyrinth or eighth 
nerve) or central CNS lesion. Distinguishing between these causes is the 
essential first step in diagnosis (Table  57-1) as central lesions require urgent 
imaging, usually with MRI.
Peripheral Vertigo 
Usually severe, accompanied by nausea and emesis. Tinnitus, a feeling of 
ear fullness, or hearing loss may occur. A characteristic jerk nystagmus is 
almost always present. The nystagmus does not change direction with a 
change in direction of gaze; it is usually horizontal with a torsional compo-
nent and has its fast phase away from the side of the lesion. It is inhibited 
by visual fixation. The pt senses spinning motion away from the lesion and 
SECTION 3
322
Common Patient Presentations
tends to have difficulty walking, with falls towards the side of the lesion, 
particularly in the darkness or with eyes closed. No other neurologic abnor-
malities are present.
Acute prolonged vertigo may be caused by infection, trauma, or ischemia. 
Often no specific etiology is found, and the nonspecific term acute laby-
rinthitis (or vestibular neuritis) is used to describe the event. Acute bilateral 
labyrinthine dysfunction is usually due to drugs (aminoglycoside antibi-
otics), alcohol, or a neurodegenerative disorder. Recurrent labyrinthine 
dysfunction with signs and symptoms of cochlear disease is usually due to 
Ménière’s disease (recurrent vertigo accompanied by tinnitus and deafness). 
Positional vertigo is usually precipitated by a recumbent head position. 
Benign paroxysmal positional vertigo (BPPV) of the posterior semicircular 
canal is particularly common; the pattern of nystagmus is distinctive. BPPV 
may follow trauma but is usually idiopathic; it generally abates spontane-
ously after weeks or months. Vestibular schwannomas of the eighth cranial 
nerve (acoustic neuroma) usually present as hearing loss and tinnitus, 
sometimes accompanied by facial weakness and sensory loss due to involve-
ment of cranial nerves VII and V. Psychogenic vertigo should be suspected 
in pts with chronic incapacitating vertigo who also have agoraphobia, panic 
attacks, a normal neurologic exam, and no nystagmus.
TABLE 57-1 FEATURES OF PERIPHERAL AND CENTRAL VERTIGO
Sign or Symptom
Peripheral (Labyrinth 
or Vestibular Nerve)
Central (Brainstem 
or Cerebellum)
Direction of associated 
nystagmus
Unidirectional; fast 
phase opposite lesiona
Bidirectional
(direction-changing) or 
unidirectional
Purely horizontal 
nystagmus without 
torsional component
Uncommon
May be present
Purely vertical or purely 
torsional nystagmus
Never presentb
May be present
Visual fixation
Inhibits nystagmus
No inhibition
Tinnitus and/or deafness
Often present
Usually absent
Associated central 
nervous system 
abnormalities
None
Extremely common 
(e.g., diplopia, hiccups, 
cranial neuropathies, 
dysarthria)
Common causes
Benign paroxysmal 
positional vertigo, 
infection (labyrinthitis), 
vestibular neuritis, 
Ménière’s disease, 
labyrinthine ischemia, 
trauma, toxin
Vascular, demyelinating, 
neoplasm
aIn Ménière’s disease, the direction of the fast phase is variable.
bCombined vertical-torsional nystagmus suggests benign paroxysmal positional vertigo.
CHAPTER 57
323
Dizziness and Vertigo
Central Vertigo 
Identified by associated brainstem or cerebellar signs such as dysarthria, 
diplopia, dysphagia, hiccups, other cranial nerve abnormalities, weakness, 
or limb ataxia; depending on the cause, headache may be present. The 
nystagmus can take almost any form (i.e., vertical or multidirectional) 
but is often purely horizontal without a torsional component and changes 
direction with different directions of gaze. Central nystagmus is not inhib-
ited by fixation. Central vertigo may be chronic, mild, and is usually not 
TABLE 57-2 TREATMENT OF VERTIGO
Agenta
Doseb
Antihistamines
 Meclizine
 Dimenhydrinate
 Promethazine
25–50 mg 3 times daily
50 mg 1–2 times daily
25 mg 2–3 times daily (can also be given 
rectally and IM)
Benzodiazepines
 Diazepam
 Clonazepam
2.5 mg 1–3 times daily
0.25 mg 1–3 times daily
Anticholinergic
 Scopolamine transdermalc
Patch
Physical therapy
 Repositioning maneuversd
 Vestibular rehabilitation
Other
  Diuretics and/or low-
sodium (1 g/d) diete
 Antimigraine drugsf
 Methylprednisoloneg
100 mg daily days 1–3; 80 mg daily days 
4–6; 60 mg daily days 7–9; 40 mg daily 
days 10–12; 20 mg daily days 13–15; 10 
mg daily days 16–18, 20, 22
Selective serotonin reuptake 
inhibitorsh
aAll listed drugs are approved by the U.S. Food and Drug Administration, but most are not 
approved for the treatment of vertigo.
bUsual oral (unless otherwise stated) starting dose in adults; a higher maintenance dose can 
be reached by a gradual increase.
cFor motion sickness only.
dFor benign paroxysmal positional vertigo.
eFor Ménière’s disease.
fFor vestibular migraine.
gFor acute vestibular neuritis (started within three days of onset).
hFor psychosomatic vertigo.
SECTION 3
324
Common Patient Presentations
accompanied by tinnitus or hearing loss. It may be due to vascular, demy-
elinating, or neoplastic disease. Vertigo may be a manifestation of migraine 
or, rarely, of temporal lobe epilepsy.
Vertigo
TREATMENT
• Treatment of acute vertigo consists of vestibular suppressant drugs for 
short-term relief (Table 57-2). They may hinder central compensa-
tion, prolonging the duration of symptoms, and therefore should be 
used sparingly.
• Vestibular rehabilitation promotes central adaptation processes and 
may habituate motion sensitivity and other symptoms of psychoso-
matic dizziness.
• BPPV may respond dramatically to repositioning exercises such as the 
Epley procedure designed to empty particulate debris from the poste-
rior semicircular canal (www.youtube.com/watch?v=pa6t-Bpg494). 
• For vestibular neuritis, antiviral medications are of no proven benefit 
unless herpes zoster oticus is present. Some data suggest that gluco-
corticoids improve the likelihood of recovery in vestibular neuritis.
• Ménière’s disease may respond to a low-salt diet (1 g/d) or to a diuretic. 
Otolaryngology referral is recommended.
• Recurrent episodes of migraine-associated vertigo should be treated 
with antimigraine therapy (Chap. 55). 
For a more detailed discussion, see Walker MF, Daroff RB: 
Dizziness, and Vertigo, Chap. 21, p. 178, in HPIM-18.
CHAPTER 58
Acute Visual Loss and 
Double Vision
Acute Visual Loss or Double Vision
APPROACH TO THE
PATIENT
Accurate measurement of visual acuity in each eye (with glasses) is of 
primary importance. Additional assessments include testing of pupils, 
eye movements, ocular alignment, and visual fields. Slit-lamp examina-
tion can exclude corneal infection, trauma, glaucoma, uveitis, and cata-
ract. Ophthalmoscopic exam to inspect the optic disc and retina often 
requires pupillary dilation using 1% tropicamide and 2.5% phenyleph-
rine; risk of provoking an attack of narrow-angle glaucoma is remote.
CHAPTER 58
325
Acute Visual Loss and Double Vision 
OPTIC NERVE OR RETINA
Central
scotoma
Arcuate
scotoma
Altitudinal
field
defect
Centrocecal
scotoma
Generalized
constriction
(AION; retinal artery branch
occlusion; optic neuritis)
(Optic neuritis; toxic, nutritional,
or hereditary optic neuropathy)
OPTIC CHIASM
Bitemporal
hemianopia
Left
Right
Right homonymous
hemianopia
Superior right
quadrantopia
("Pie in the Sky")
Macular
sparing
(Bilateral visual
cortex lesions)
(AION, glaucoma, branch retinal
artery or vein occlusion)
(Optic neuritis;
macular degeneration)
(Papilledema,
retinitis pigmentosa)
RETRO-CHIASMAL PATHWAY
(Optic chiasm
compression by
pituitary tumor,
meningioma)
(Lesion of left optic
radiations in
temporal lobe)
(Lesion of left optic tract,
lateral geniculate
body, optic radiations,
or visual cortex)
FIGURE 58-1 Deficits in visual fields caused by lesions affecting visual pathways.
Visual field mapping by finger confrontation localizes lesions in the 
visual pathway (Fig. 58-1); formal testing using a perimeter may be nec-
essary. The goal is to determine whether the lesion is anterior to, at, or 
posterior to the optic chiasm. A scotoma confined to one eye is caused by 
an anterior lesion affecting the optic nerve or globe; swinging flashlight 
test may reveal an afferent pupil defect. History and ocular exam are 
usually sufficient for diagnosis. If a bitemporal hemianopia is present, 
lesion is located at optic chiasm (e.g., pituitary adenoma, meningioma).
SECTION 3
326
Common Patient Presentations
Homonymous visual field loss signals a retrochiasmal lesion affecting 
the optic tract, lateral geniculate body, optic radiations, or visual cortex 
(e.g., stroke, tumor, abscess). Neuroimaging is recommended for any pt 
with a bitemporal or homonymous hemianopia.
� TRANSIENT OR SUDDEN VISUAL LOSS
Amaurosis fugax (transient monocular blindness; a TIA of the retina) usually 
occurs from a retinal embolus often arising from severe ipsilateral carotid ste-
nosis. Prolonged occlusion of the central retinal artery results in classic fundus 
appearance of a milky, infarcted retina with cherry red fovea. Any pt with com-
promise of the retinal circulation should be evaluated promptly for stroke risk 
factors (e.g., carotid atheroma, heart disease, atrial fibrillation). Occipital cortex 
lesions can be confused with amaurosis fugax because many pts mistakenly 
ascribe symptoms to their left or right eye, when in fact they are occurring in 
the left or right hemifield of both eyes. Interruption of blood flow to the visual 
cortex causes sudden graying of vision, occasionally with flashing lights or 
other symptoms that mimic migraine. The history may be the only guide to the 
correct diagnosis. Pts should be questioned about the precise pattern and dura-
tion of visual loss and other neurologic symptoms, especially those of posterior 
circulation dysfunction such as diplopia, vertigo, numbness, or weakness.
Malignant systemic hypertension can cause visual loss from exudates, 
hemorrhages, cotton-wool spots (focal nerve fiber layer infarcts), and optic 
disc edema.
In central or branch retinal vein occlusion, the fundus exam reveals 
engorged, phlebitic veins with extensive retinal hemorrhages.
In age-related macular degeneration, characterized by extensive drusen 
and scarring of the pigment epithelium, leakage of blood or fluid from 
subretinal neovascular membranes can produce sudden central visual loss.
Flashing lights and floaters may indicate a fresh vitreous detachment. 
Separation of the vitreous from the retina is a frequent involutional event in 
the elderly. It is not harmful unless it creates sufficient traction to produce 
a retinal detachment. Vitreous hemorrhage may occur in diabetic pts from 
retinal neovascularization.
Papilledema refers to optic disc edema from raised intracranial pressure. 
Transient visual obscurations are common, but visual acuity is not affected unless 
the papilledema is severe, long-standing, or accompanied by macular exudates 
or hemorrhage. Enlarged blind spots and peripheral constriction are typical. 
Neuroimaging should be obtained to exclude an intracranial mass. If negative, 
an LP is required to confirm elevation of the intracranial pressure. Pseudotumor 
cerebri (idiopathic intracranial hypertension) is a diagnosis of exclusion. Most 
pts are young, female, and obese; some are found to have occult cerebral venous 
sinus thrombosis. Treatment is with acetazolamide, repeated LPs, and weight 
loss; some pts require lumboperitoneal shunting to prevent blindness.
Optic neuritis is a common cause of monocular optic disc swelling and visual 
loss. If site of inflammation is retrobulbar, fundus will appear normal on initial 
exam. The typical pt is female, age 15–45, with pain provoked by eye move-
ments. Glucocorticoids, typically IV methylprednisolone (1 g daily for 3 days) 
followed by oral prednisone (1 mg/kg daily for 11 days), may hasten recovery in 
CHAPTER 58
327
Acute Visual Loss and Double Vision 
severely affected pts but make no difference in final acuity (measured 6 months 
after the attack). If an MR scan shows multiple demyelinating lesions, treatment 
for multiple sclerosis (Chap. 202) should be considered. Optic neuritis involv-
ing both eyes simultaneously or sequentially suggests neuromyelitis optica.
Anterior ischemic optic neuropathy (AION) is an infarction of the optic 
nerve head due to inadequate perfusion via the posterior ciliary arteries. 
Pts have sudden visual loss, often noted on awakening, and painless swell-
ing of the optic disc. It is important to differentiate between nonarteritic 
(idiopathic) AION and arteritic AION. There is no treatment for nonar-
teritic AION. In contrast, arteritic AION is caused by giant cell (tempo-
ral) arteritis and requires immediate glucocorticoid therapy to prevent 
blindness; temporal artery biopsy establishes the diagnosis. The ESR and 
C-reactive protein should be checked in any elderly pt with acute optic disc 
swelling or symptoms suggestive of polymyalgia rheumatica (associated 
with arteritic AION).
� DOUBLE VISION (DIPLOPIA)
First step: clarify whether diplopia persists in either eye after covering the 
opposite eye; if it does the diagnosis is monocular diplopia usually caused 
by disease intrinsic to the eye with no dire implications for the pt.
If pt has diplopia while being examined, motility testing will usually reveal 
an abnormality in ocular excursions. However, if the degree of angular sepa-
ration between the double images is small, the limitation of eye movements 
may be subtle and difficult to detect. In this situation, the cover test is use-
ful. While the pt is fixating upon a distant target, one eye is covered while 
observing the other eye for a movement of redress as it takes up fixation. 
If none is seen, the procedure is repeated with the other eye. With genuine 
diplopia, this test should reveal ocular malalignment, especially if the head is 
turned or tilted in the position that gives rise to the worst symptoms.
Common causes of diplopia are summarized in Table 58-1. The physical 
findings in isolated ocular motor nerve palsies are:
• CN III: Ptosis and deviation of the eye down and outwards, causing 
vertical and horizontal diplopia. A dilated pupil suggests direct compres-
sion of the third nerve; if present, the possibility of an aneurysm of the 
posterior communicating artery must be considered urgently.
• CN IV: Vertical diplopia with cyclotorsion; the affected eye is slightly 
elevated, and limitation of depression is seen when the eye is held in 
adduction. The pt may assume a head tilt to the opposite side (e.g., left 
head tilt in right fourth nerve paresis).
• CN VI: Horizontal diplopia with crossed eyes; the affected eye cannot 
abduct.
Isolated ocular motor nerve palsies often occur in pts with hypertension 
or diabetes. They usually resolve spontaneously over several months.
The development of multiple ocular motor nerve palsies, or diffuse oph-
thalmoplegia, raises the possibility of myasthenia gravis. In this disease, the 
pupils are always normal. Systemic weakness may be absent. Multiple ocular 
motor nerve palsies should be investigated with neuroimaging focusing on 
the cavernous sinus, superior orbital fissure, and orbital apex where all three 
nerves are in close proximity. Diplopia that cannot be explained by a single 
SECTION 3
328
Common Patient Presentations
ocular motor nerve palsy may also be caused by carcinomatous or fungal 
meningitis, Graves’ disease, Guillain-Barré syndrome (especially the Miller 
Fisher variant), or Tolosa-Hunt syndrome.
TABLE 58-1 COMMON CAUSES OF DIPLOPIA
Brainstem stroke (skew deviation, nuclear or fascicular palsy)
Microvascular infarction (III, IV, VI nerve palsy)
Tumor (brainstem, cavernous sinus, superior orbital fissure, orbit)
Multiple sclerosis (internuclear ophthalmoplegia, ocular motor nerve palsy)
Aneurysm (III nerve)
Raised intracranial pressure (VI nerve)
Postviral inflammation
Meningitis (bacterial, fungal, granulomatosis, neoplastic)
Carotid-cavernous fistula or thrombosis
Herpes zoster
Tolosa-Hunt syndrome
Wernicke-Korsakoff syndrome
Botulism
Myasthenia gravis
Guillain-Barré or Fisher syndrome
Graves’ disease
Orbital pseudotumor
Orbital myositis
Trauma
Orbital cellulitis
For a more detailed discussion, see Horton JC: Disorders of 
the Eye, Chap. 28, p. 224, in HPIM-18.
CHAPTER 59
Weakness and Paralysis
Weakness or Paralysis
APPROACH TO THE
PATIENT
Weakness is a reduction of power in one or more muscles. Paralysis 
indicates weakness that is so severe that the muscle cannot be contracted 
at all, whereas paresis refers to weakness that is mild or moderate. The 
prefix hemi- refers to one half of the body, para- to both legs, and quadri- 
to all four limbs. The suffix -plegia signifies severe weakness or paralysis.
CHAPTER 59
329
Weakness and Paralysis
TABLE 59-1 SIGNS THAT DISTINGUISH THE ORIGIN OF WEAKNESS
Sign
Upper Motor 
Neuron
Lower Motor 
Neuron
Myopathic
Atrophy
None
Severe
Mild
Fasciculations
None
Common
None
Tone
Spastic
Decreased
Normal/decreased
Distribution of 
weakness
Pyramidal/regional Distal/segmental
Proximal
Tendon reflexes
Hyperactive
Hypoactive/
absent
Normal/hypoactive
Babinski sign
Present
Absent
Absent
TABLE 59-2 COMMON CAUSES OF WEAKNESS 
Upper Motor Neuron
Cortex: ischemia; hemorrhage; intrinsic mass lesion (primary or metastatic 
cancer, abscess); extrinsic mass lesion (subdural hematoma); degenerative 
(amyotrophic lateral sclerosis)
Subcortical white matter/internal capsule: ischemia; hemorrhage; intrinsic 
mass lesion (primary or metastatic cancer, abscess); immunologic (multiple 
sclerosis); infectious (progressive multifocal leukoencephalopathy)
Brainstem: ischemia; immunologic (multiple sclerosis)
Spinal cord: extrinsic compression (cervical spondylosis, metastatic cancer, 
epidural abscess); immunologic (multiple sclerosis, transverse myelitis); 
infectious (AIDS-associated myelopathy, HTLV-I–associated myelopathy, 
tabes dorsalis); nutritional deficiency (subacute combined degeneration)
Motor Unit
Spinal motor neuron: degenerative (amyotrophic lateral sclerosis); infectious 
(poliomyelitis)
Spinal root: compressive (degenerative disc disease); immunologic (Guillain-
Barré syndrome); infectious (AIDS-associated polyradiculopathy, Lyme disease)
Peripheral nerve: metabolic (diabetes mellitus, uremia, porphyria); toxic 
(ethanol, heavy metals, many drugs, diphtheria); nutritional (B12 deficiency); 
inflammatory (polyarteritis nodosa); hereditary (Charcot-Marie-Tooth); 
immunologic (paraneoplastic, paraproteinemia); infectious (AIDS-associated 
polyneuropathies and mononeuritis multiplex); compressive (entrapment)
Neuromuscular junction: immunologic (myasthenia gravis); toxic (botulism, 
aminoglycosides)
Muscle: inflammatory (polymyositis, inclusion body myositis); degenerative 
(muscular dystrophy); toxic (glucocorticoids, ethanol, AZT); infectious 
(trichinosis); metabolic (hypothyroid, periodic paralyses); congenital (central 
core disease)
SECTION 3
330
Common Patient Presentations
TABLE 59-3  CLINICAL DIFFERENTIATION OF WEAKNESS ARISING FROM 
DIFFERENT AREAS OF THE NERVOUS SYSTEM
Location of Lesion
Pattern of Weakness
Associated Signs
Upper motor neuron
Cerebral cortex
Hemiparesis (face and 
arm predominantly, or 
leg predominantly)
Hemisensory loss, seizures, 
homonymous hemianopia 
or quadrantanopia, aphasia, 
apraxias, gaze preference
Internal capsule
Hemiparesis (face, arm, 
leg may be equally 
affected)
Hemisensory deficit; 
homonymous hemianopia 
or quadrantanopia
Brainstem
Hemiparesis (arm and 
leg; face may not be 
involved at all)
Vertigo, nausea and vomit-
ing, ataxia and dysarthria, 
eye movement abnormalities, 
cranial nerve dysfunction, 
altered level of conscious-
ness, Horner’s syndrome
Spinal cord
Quadriparesis if mid-
cervical or above
Sensory level; bowel and 
bladder dysfunction
Paraparesis if low 
cervical or thoracic
Hemiparesis below 
level of lesion (Brown-
Séquard)
Contralateral pain/
temperature loss below 
level of lesion
Motor unit
Spinal motor 
neuron
Diffuse weakness, may 
involve control of speech 
and swallowing
Muscle fasciculations and 
atrophy; no sensory loss
Spinal root
Radicular pattern of 
weakness
Dermatomal sensory loss; 
radicular pain common with 
compressive lesions
Peripheral nerve
 Polyneuropathy
Distal weakness, usually 
feet more than hands; 
usually symmetric
Distal sensory loss, usually 
feet more than hands
 Mononeuropathy Weakness in distribution 
of single nerve
Sensory loss in distribution 
of single nerve
Neuromuscular
junction
Fatigable weakness, 
usually with ocular 
involvement producing 
diplopia and ptosis
No sensory loss; no reflex 
changes
Muscle
Proximal weakness
No sensory loss; diminished 
reflexes only when severe; 
may have muscle tenderness
CHAPTER 59
331
Weakness and Paralysis
FIGURE 59-1 An algorithm for the initial workup of a pt with weakness. CT, com-
puted tomography; EMG, electromyography; LMN, lower motor neuron; MRI, mag-
netic resonance imaging; NCS, nerve conduction studies; UMN, upper motor neuron.
Hemiparesis
UMN signs
Cerebral signs
Brain CT
or MRI
†
Proximal
Restricted
Paraparesis
Quadriparesis
Monoparesis
Distal
LMN signs*
Alert
UMN signs
LMN signs*
UMN signs
LMN signs*
EMG and NCS
UMN pattern
LMN pattern
Myopathic pattern
Anterior horn,
  root, or peripheral
  nerve disease
Muscle or
  neuromuscular
  junction disease
* or signs of myopathy
† If no abnormality detected, consider spinal MRI.
‡ If no abnormality detected, consider myelogram or brain MRI.
No
Yes
No
Yes
Spinal MRI
‡
DISTRIBUTION OF WEAKNESS
Increased fatigability or limitation in function due to pain or articular 
stiffness is often confused with weakness by pts. Increased time is some-
times required for full power to be exerted, and this bradykinesia may be 
misinterpreted as weakness. Severe proprioceptive sensory loss may also 
lead to complaints of weakness because adequate feedback information 
about the direction and power of movements is lacking. Finally, apraxia, 
a disorder of planning and initiating a skilled or learned movement, is 
sometimes mistaken for weakness.
The history should focus on the tempo of development of weakness, 
presence of sensory and other neurologic symptoms, medication history, 
predisposing medical conditions, and family history.
Weakness or paralysis is typically accompanied by other neurologic abnor-
malities that help to indicate the site of the responsible lesion (Table 59-1). It 
is important to distinguish weakness arising from disorders of upper motor 
neurons (i.e., motor neurons in the cerebral cortex and their axons that 
descend through the subcortical white matter, internal capsule, brainstem, 
and spinal cord) from disorders of the motor unit (i.e., lower motor neurons 
in the ventral horn of the spinal cord and their axons in the spinal roots and 
peripheral nerves, neuromuscular junction, and skeletal muscle).
SECTION 3
332
Common Patient Presentations
Table 59-2 lists common causes of weakness by the primary site of 
pathology. Table 59-3 summarizes patterns with lesions of different parts 
of the nervous system.
An algorithm for the initial workup of weakness is shown in Fig. 59-1.
For a more detailed discussion, see Aminoff MJ: Weakness 
and Paralysis, Chap. 22, p. 181, in HPIM-18.
CHAPTER 60
Tremor and Movement 
Disorders
Movement Disorders
APPROACH TO THE
PATIENT
Divided into akinetic rigid forms, with muscle rigidity and slowness of 
movement, and hyperkinetic forms, with involuntary movements. In 
both types, preservation of strength is the rule. Most movement disor-
ders arise from disruption of basal ganglia circuits; common causes are 
degenerative diseases (hereditary and idiopathic), drug-induced, organ 
system failure, CNS infection, and ischemia. Clinical features of the vari-
ous movement disorders are summarized below.
� BRADYKINESIA 
Inability to initiate changes in activity or perform ordinary volitional move-
ments rapidly and easily. There is a slowness of movement and a paucity of 
automatic motions such as eye blinking and arm swinging while walking. 
Usually due to Parkinson’s disease or other causes of parkinsonism (Chap. 195).
� TREMOR 
Rhythmic oscillation of a part of the body due to intermittent muscle 
contractions, usually involving the distal limbs and less commonly the 
head, tongue, or jaw. A coarse tremor at rest, 4–5 beats/s, is usually due 
to Parkinson’s disease. A fine postural tremor of 8–10 beats/s may be an 
exaggeration of normal physiologic tremor or indicate familial essential 
tremor. An intention tremor, most pronounced during voluntary move-
ment towards a target, is found with cerebellar pathway disease.
� ESSENTIAL TREMOR (ET) 
This is the most common movement disorder. The tremor of ET must 
be distinguished from early Parkinson’s disease (Table 60-1). The patho-
physiology of ET is unknown. Approximately 50% of cases have a positive 
family history with autosomal dominant inheritance; LINGO1 was recently 
CHAPTER 60
333
Tremor and Movement Disorders 
identified in some early onset familial cases. Many pts with ET have mild 
symptoms and require no treatment. 
• When activities of daily living such as eating and writing are impaired, 
therapy with propranolol (20–80 mg/d) or primidone (12.5–750 mg/d) 
leads to benefit in 50% of pts. 
• Surgical therapies targeting the thalamus may be effective in refractory cases.
� DYSTONIA 
Consists of sustained or repetitive involuntary muscle contractions, fre-
quently causing twisting movements and abnormal posture. Dystonias may 
be generalized or focal.
Focal dystonias are common and include blepharospasm of the eyelids; 
spasmodic dysphonia involving the vocal cords; oromandibular dystonia 
of the face, lips, tongue, and jaw; cervical dystonia of the neck musculature 
(torticollis); and limb dystonias that are often task-specific such as writer’s 
cramp, playing a musical instrument (musician’s cramp), or putting in golf 
(yips).
Idiopathic torsional dystonia is a predominantly childhood-onset form 
of generalized dystonia with an autosomal dominant pattern of inheritance 
that mainly affects Ashkenazi Jewish families; most are linked to a mutation 
in the DYT1 gene on chromosome 9. Other generalized dystonias occur as 
a consequence of drugs such as antiemetics, neuroleptics, and treatments 
for Parkinson’s disease.
• Therapy for focal dystonias usually involves botulinum toxin injections 
into the affected musculature.
• All forms of dystonia may respond to anticholinergic medications (e.g., 
trihexyphenidyl 20–120 mg/d), baclofen, or tetrabenazine.
• Surgical therapies, including deep brain stimulation (DBS), may be effec-
tive in refractory cases.
� CHOREOATHETOSIS 
A combination of chorea (rapid, graceful, dance-like movements) and ath-
etosis (slow, distal, writhing movements). The two usually exist together, 
though one may be more prominent. Choreic movements are the pre-
dominant involuntary movements in rheumatic (Sydenham’s) chorea and 
Huntington’s disease. Systemic lupus erythematosus is the most common 
TABLE 60-1  ADVANCED EXAMINATION PEARLS: DIFFERENTIATING 
ESSENTIAL TREMOR FROM PARKINSONIAN TREMOR
Essential Tremor
Parkinsonian Tremor
Speed
5–10 Hz
4–6 Hz
Symmetry
Bilateral
Usually asymmetric
Most common component
Postural
Rest
Other parkinsonian symptoms
Absent
Present
Helped with alcohol
Usually
Rarely
Family history
Present often
Usually absent
SECTION 3
334
Common Patient Presentations
systemic disorder that causes chorea, but it can also be seen in pts with 
hyperthyroidism, various autoimmune disorders, infections including HIV, 
metabolic alterations, and in association with a wide variety of medications. 
Hemiballismus is a violent form of chorea that comprises wild, flinging 
movements on one side of the body; the most common cause is a lesion 
(often infarct or hemorrhage) of the subthalamic nucleus. Athetosis is 
prominent in some forms of cerebral palsy. Chronic neuroleptic use may 
lead to tardive dyskinesia, in which choreoathetotic movements are usually 
restricted to the buccal, lingual, and mandibular areas.
� HUNTINGTON’S DISEASE (HD) 
This is a progressive, fatal, autosomal dominant disorder characterized by 
motor, behavioral, and cognitive dysfunction. Onset is typically between 
the ages of 25 and 45 years. Rapid, nonpatterned, semipurposeful, invol-
untary choreiform movements are the hallmark feature; dysarthria, gait 
disturbance, and oculomotor abnormalities also occur. In late stages, chorea 
becomes less prominent, and the picture is dominated by dystonia, rigidity, 
bradykinesia, myoclonus, and spasticity. HD pts eventually develop behav-
ioral and cognitive disturbances that can be a major source of disability. HD 
is inherited as an autosomal dominant disorder and is caused by an expan-
sion in the number of polyglutamine (CAG) repeats in the coding sequence 
of the HTT gene on chromosome 4 encoding the protein huntingtin.
• Treatment involves a multidisciplinary approach with medical, neuro-
psychiatric, social, and genetic counseling for pts and their families. 
• Dopamine-blocking agents may control the chorea; tetrabenazine may 
cause secondary parkinsonism
• Depression and anxiety should be treated with appropriate antidepres-
sant and antianxiety drugs
• Psychosis can be treated with atypical neuroleptic agents. 
• No disease-modifying agents currently exist.
� TICS 
Brief, rapid, recurrent, and seemingly purposeless stereotyped muscle con-
tractions. Gilles de la Tourette syndrome (TS) is a neurobehavioral, multiple 
tic disorder that may involve motor tics (especially twitches of the face, 
neck, and shoulders) and vocal tics (grunts, words, coprolalia, echolalia). 
Pts may experience an irresistible urge to express tics but characteristically 
can voluntarily suppress them for short periods of time. Onset is usually 
between 2 and 15 years of age, and tics often lessen or even disappear in 
adulthood. 
• Drug treatment is only indicated when tics are disabling and interfere 
with quality of life. 
• Therapy is generally initiated with clonidine, starting at low dose, or 
guanfacine (0.5–2 mg/d). If these agents are not effective, neuroleptics 
may be used.
� MYOCLONUS 
Rapid (<100 ms), brief, shocklike, jerky, movements that are usually mul-
tifocal. Like asterixis, often indicates a diffuse encephalopathy. Following 
cardiac arrest, diffuse cerebral hypoxia may produce multifocal myoclonus. 
CHAPTER 61
335
Aphasia
Spinal cord injury can also cause myoclonus. Myoclonus occurs in normal 
individuals when waking up or falling asleep. 
• Treatment of myoclonus, indicated only when function is impaired, 
consists of treating the underlying condition or removing an offending 
agent.
• Drug therapies include valproic acid (800–3000 mg/d), piracetam 
(8–20 g/d), clonazepam (2–15 mg/d), or primidone (500–1000 mg/d). 
Levetiracetam may be particularly effective.
� ASTERIXIS 
Brief, arrhythmic interruptions of sustained voluntary muscle contraction, 
usually observed as a brief lapse of posture of wrists in dorsiflexion with 
arms outstretched; “negative myoclonus.” This “liver flap” may be seen in 
any encephalopathy related to drug intoxication, organ system failure, or 
CNS infection. 
Therapy is correction of the underlying disorder. 
For a more detailed discussion, see Olanow CW, Schapira 
AHV: Parkinson’s Disease and Other Movement Disorders, 
Chap. 372, p. 3317, in HPIM-18.
CHAPTER 61
Aphasia
Aphasias are disturbances in the comprehension or production of spoken 
or written language. Clinical examination should assess spontaneous speech 
(fluency), comprehension, repetition, naming, reading, and writing. A 
classification scheme is presented in Table 61-1. In nearly all right-handed 
individuals and many left-handed pts, language localization is in the left 
hemisphere.
� CLINICAL FEATURES
Wernicke’s Aphasia 
Although speech sounds grammatical, melodic, and effortless (fluent), it 
is  virtually incomprehensible due to errors in word usage, structure, and 
tense and the presence of paraphasic errors and neologisms (“jargon”). 
Comprehension of written and spoken material is severely impaired, as 
are reading, writing, and repetition. The pt usually seems unaware of the 
deficit. Associated symptoms can include parietal lobe sensory deficits and 
homonymous hemianopia. Motor disturbances are rare.
Lesion is located in posterior perisylvian region. Most common cause 
is embolism to the inferior division of dominant middle cerebral artery 
(MCA); less commonly intracerebral hemorrhage, severe head trauma, or 
tumor is responsible.
SECTION 3
336
Common Patient Presentations
Broca’s Aphasia 
Speech output is sparse (nonfluent), slow, labored, interrupted by many word-
finding pauses, and usually dysarthric; output may be reduced to a grunt or 
single word. Naming and repetition also impaired. Most pts have severe writ-
ing impairment. Comprehension of written and spoken language is relatively 
preserved. The pt is often aware of and visibly frustrated by deficit. With large 
lesions, a dense hemiparesis may occur, and eyes may deviate toward side of 
lesion. More commonly, lesser degrees of contralateral face and arm weakness 
are present. Sensory loss is rarely found, and visual fields are intact.
Lesion involves dominant inferior frontal gyrus (Broca’s area), although 
cortical and subcortical areas along superior sylvian fissure and insula 
are often involved. Commonly caused by vascular lesions involving the 
superior division of the MCA; less commonly due to tumor, intracerebral 
hemorrhage, or abscess.
Global Aphasia
All aspects of speech and language are impaired. Pt cannot read, write, or 
repeat and has poor auditory comprehension. Speech output is minimal and 
nonfluent. Hemiplegia, hemisensory loss, and homonymous hemianopia are 
TABLE 61-1  CLINICAL FEATURES OF APHASIAS AND RELATED CONDITIONS
Comprehension
Repetition
of Spoken 
Language
Naming
Fluency
Wernicke’s
Impaired
Impaired
Impaired
Preserved or 
increased
Broca’s
Preserved 
(except grammar)
Impaired
Impaired
Decreased
Global
Impaired
Impaired
Impaired
Decreased
Conduction
Preserved
Impaired
Impaired
Preserved
Nonfluent (motor) 
transcortical
Preserved
Preserved
Impaired
Impaired
Fluent (sensory) 
transcortical
Impaired
Preserved
Impaired
Preserved
Isolation
Impaired
Echolalia
Impaired
No purposeful 
speech
Anomic
Preserved
Preserved
Impaired
Preserved 
except for 
word-finding
pauses
Pure word 
deafness
Impaired only for 
spoken language
Impaired
Preserved Preserved
Pure alexia
Impaired only for 
reading
Preserved
Preserved Preserved
CHAPTER 62
337
Sleep Disorders
usually present. Syndrome represents the combined dysfunction of Wernicke’s 
and Broca’s areas, usually resulting from proximal occlusion of MCA supply-
ing dominant hemisphere (less commonly hemorrhage, trauma, or tumor).
Conduction Aphasia
Speech output is fluent but paraphasic, comprehension of spoken language 
is intact, and repetition is severely impaired, as are naming and writing. 
Lesion spares, but functionally disconnects, Wernicke’s and Broca’s areas. 
Most cases are embolic, involving supramarginal gyrus of dominant parietal 
lobe, dominant superior temporal lobe, or arcuate fasciculus.
� LABORATORY EVALUATION
CT scan or MRI usually identifies the location and nature of the causative 
lesion.
Aphasia
TREATMENT
• Speech therapy may be helpful in treatment of certain types of aphasia. 
• When the lesion is caused by a stroke, recovery of language function 
generally peaks within 2–6 months, after which time further progress 
is limited.
For a more detailed discussion, see Mesulam M-M: Aphasia, 
Memory Loss, and Other Focal Cerebral Disorders, Chap. 26, 
p. 202 in HPIM-18.
CHAPTER 62
Sleep Disorders
Disorders of sleep are among the most common problems seen by clinicians. 
More than one-half of adults experience at least intermittent sleep distur-
bances, and 50–70 million Americans suffer from a chronic sleep disturbance.
Sleep Disorders
APPROACH TO THE
PATIENT
Pts may complain of (1) difficulty in initiating and maintaining sleep 
(insomnia); (2) excessive daytime sleepiness, fatigue, or tiredness; (3) 
behavioral phenomena occurring during sleep [sleepwalking, rapid 
eye movement (REM) behavioral disorder, periodic leg movements of 
sleep, etc.]; or (4) circadian rhythm disorders associated with jet lag, 
shift work, and delayed sleep phase syndrome. A careful history of sleep 
habits and reports from the sleep partner (e.g., heavy snoring, falling 
asleep while driving) are a cornerstone of diagnosis. Pts with excessive
SECTION 3
338
Common Patient Presentations
sleepiness should be advised to avoid all driving until effective therapy 
has been achieved. Completion of a day-by-day sleep-work-drug log for 
at least 2 weeks is often helpful. Work and sleep times (including day-
time naps and nocturnal awakenings) as well as drug and alcohol use, 
including caffeine and hypnotics, should be noted each day. Objective 
sleep laboratory recording is necessary to evaluate specific disorders 
such as sleep apnea and narcolepsy.
� INSOMNIA
Insomnia, or the complaint of inadequate sleep, may be subdivided into 
difficulty falling asleep (sleep onset insomnia), frequent or sustained awaken-
ings (sleep maintenance insomnia), early morning awakenings (sleep offset 
insomnia), or persistent sleepiness/fatigue despite sleep of adequate duration 
(nonrestorative sleep). An insomnia complaint lasting one to several nights is 
termed transient insomnia and is typically due to situational stress or a change 
in sleep schedule or environment (e.g., jet lag). Short-term insomnia lasts from 
a few days up to 3 weeks; it is often associated with more protracted stress such 
as recovery from surgery or short-term illness. Long-term (chronic) insomnia 
lasts for months or years and, in contrast to short-term insomnia, requires a 
thorough evaluation for underlying causes. Chronic insomnia is often a wax-
ing and waning disorder, with spontaneous or stress-induced exacerbations.
All insomnias can be exacerbated and perpetuated by behaviors that are 
not conducive to initiating or maintaining sleep. Inadequate sleep hygiene is 
characterized by a behavior pattern prior to sleep, and/or a bedroom envi-
ronment, that is not conducive to sleep. In preference to hypnotic medica-
tions, the pt should attempt to avoid stressful activities before bed, reserve 
the bedroom environment for sleeping, and maintain regular rising times.
Adjustment Insomnia (Acute Insomnia) 
Acute insomnia can occur after a change in the sleeping environment (e.g., 
in an unfamiliar hotel or hospital bed) or before or after a significant life 
event or anxiety-provoking situation. Treatment is symptomatic, with inter-
mittent use of hypnotics and resolution of the underlying stress. 
Psychophysiologic Insomnia 
These pts are preoccupied with a perceived inability to sleep adequately at 
night. Rigorous attention should be paid to sleep hygiene and correction of 
counterproductive, arousing behaviors before bedtime. Behavioral thera-
pies are the treatment of choice.
Drugs and Medications 
Caffeine is probably the most common pharmacologic cause of insomnia. 
Alcohol and nicotine can also interfere with sleep, despite the fact that many 
pts use these agents to relax and promote sleep. A number of prescribed 
medications, including antidepressants, sympathomimetics, and glucocorti-
coids, can produce insomnia. In addition, severe rebound insomnia can result 
from the acute withdrawal of hypnotics, especially following use of high doses 
CHAPTER 62
339
Sleep Disorders
of benzodiazepines with a short half-life. For this reason, doses of hypnotics 
should be low to moderate and prolonged drug tapering is encouraged.
Movement Disorders 
Pts with restless legs syndrome (RLS) complain of creeping dysesthesias deep 
within the calves or feet associated with an irresistible urge to move the 
affected limbs; symptoms are typically worse at night. Iron deficiency and 
renal failure can cause secondary RLS. One-third of pts have multiple affected 
family members. Treatment is with dopaminergic drugs (pramipexole 0.25–
0.5 mg daily at 8 p.m. or ropinirole 0.5–4.0 mg daily at 8 p.m.). Periodic limb 
movements of sleep (PLMS) consists of stereotyped extensions of the great toe 
and dorsiflexion of the foot recurring every 20–40 s during non-REM sleep. 
Treatment options include dopaminergic medications or benzodiazepines.
Other Neurologic Disorders 
A variety of neurologic disorders produce sleep disruption through both 
indirect, nonspecific mechanisms (e.g., neck or back pain) or by impair-
ment of central neural structures involved in the generation and control 
of sleep itself. Common disorders to consider include dementia from any 
cause, epilepsy, Parkinson’s disease, and migraine.
Psychiatric Disorders 
Approximately 80% of pts with mental disorders complain of impaired 
sleep. The underlying diagnosis may be depression, mania, an anxiety dis-
order, or schizophrenia.
Medical Disorders 
In asthma, daily variation in airway resistance results in marked increases 
in asthmatic symptoms at night, especially during sleep. Treatment of 
asthma with theophylline-based compounds, adrenergic agonists, or glu-
cocorticoids can independently disrupt sleep. Inhaled glucocorticoids that 
do not disrupt sleep may provide a useful alternative to oral drugs. Cardiac 
ischemia is also associated with sleep disruption; the ischemia itself may 
result from increases in sympathetic tone as a result of sleep apnea. Pts may 
present with complaints of nightmares or vivid dreams. Paroxysmal noctur-
nal dyspnea can also occur from cardiac ischemia that causes pulmonary 
congestion exacerbated by the recumbent posture. Chronic obstructive pul-
monary disease, cystic fibrosis, hyperthyroidism, menopause, gastroesopha-
geal reflux, chronic renal failure, and liver failure are other causes.
Insomnia
TREATMENT
INSOMNIA WITHOUT IDENTIFIABLE CAUSE Primary insomnia is a diag-
nosis of exclusion. 
• Treatment directed toward behavior therapies for anxiety and negative 
conditioning; pharmacotherapy and/or psychotherapy for mood/anxi-
ety disorders; an emphasis on good sleep hygiene; and intermittent 
hypnotics for exacerbations of insomnia. 
SECTION 3
340
Common Patient Presentations
• Cognitive therapy emphasizes understanding the nature of normal 
sleep, the circadian rhythm, the use of light therapy, and visual imag-
ery to block unwanted thought intrusions.
• Behavioral modification involves bedtime restriction, set schedules, 
and careful sleep environment practices. 
• Judicious use of benzodiazepine receptor agonists with short half-lives 
can be effective; options include zaleplon (5–20 mg), zolpidem (5–10 mg), 
triazolam (0.125–0.25 mg), eszopiclone (1–3 mg). Limit use to 2–4 weeks 
maximum for acute insomnia or intermittent use for chronic. 
� DISORDERS OF EXCESSIVE DAYTIME SLEEPINESS
Differentiation of sleepiness from subjective complaints of fatigue may be 
difficult. Quantification of daytime sleepiness can be performed in a sleep 
laboratory using a multiple sleep latency test (MSLT), the repeated daytime 
measurement of sleep latency under standardized conditions. Common 
causes are summarized in Table 62-1.
Sleep Apnea Syndromes 
Respiratory dysfunction during sleep is a common cause of excessive daytime 
sleepiness and/or disturbed nocturnal sleep, affecting an estimated 2–5 million 
individuals in the United States. Episodes may be due to occlusion of the air-
way (obstructive sleep apnea), absence of respiratory effort (central sleep apnea), 
or a combination of these factors (mixed sleep apnea). Obstruction is exacer-
bated by obesity, supine posture, sedatives (especially alcohol), nasal obstruc-
tion, and hypothyroidism. Sleep apnea is particularly prevalent in overweight 
men and in the elderly and is undiagnosed in 80–90% of affected individuals. 
Treatment consists of correction of the above factors, positive airway pressure 
devices, oral appliances, and sometimes surgery (Chap. 146).
Narcolepsy
A disorder of excessive daytime sleepiness and intrusion of REM-related sleep 
phenomena into wakefulness (cataplexy, hypnagogic hallucinations, and sleep 
paralysis). Cataplexy, the abrupt loss of muscle tone in arms, legs, or face, is 
precipitated by emotional stimuli such as laughter or sadness. Symptoms of nar-
colepsy (Table 62-2) typically begin in the second decade, although the onset 
ranges from ages 5–50. The prevalence is 1 in 4000. Narcolepsy has a genetic 
basis; almost all narcoleptics with cataplexy are positive for HLA DQB1*0602. 
Hypothalamic neurons containing the neuropeptide hypocretin (orexin) 
regulate the sleep/wake cycle and loss of these cells, possibly due to autoim-
munity, has been implicated in narcolepsy. Diagnosis is made with sleep studies 
confirming a short daytime sleep latency and a rapid transition to REM sleep.
Narcolepsy
TREATMENT
• Somnolence is treated with modafinil (200–400 mg/d given as a 
single dose). 
• Older stimulants such as methylphenidate (10 mg bid to 20 mg qid) 
or dextroamphetamine (10 mg bid) are alternatives, particularly in 
refractory pts. 
TABLE 62-1  EVALUATION OF THE PATIENT WITH THE COMPLAINT OF EXCESSIVE DAYTIME SOMNOLENCE
Findings on History and Physical 
Examination
Diagnostic Evaluation
Diagnosis
Therapy
Obesity, snoring, hypertension
Polysomnography with 
respiratory monitoring
Obstructive sleep apnea
Continuous positive airway pressure; ENT surgery 
(e.g., uvulopalatopharyngoplasty); dental appliance; 
pharmacologic therapy (e.g., protriptyline); weight 
loss
Cataplexy, hypnogogic hallucinations, 
sleep paralysis, family history
Polysomnography with 
multiple sleep latency 
testing
Narcolepsy-cataplexy 
syndrome
Stimulants (e.g., modafinil, methylphenidate); REM-
suppressant antidepressants (e.g., protriptyline); 
genetic counseling
Restless legs, disturbed sleep, 
predisposing medical condition 
(e.g., iron deficiency or renal failure)
Assessment for predispos-
ing medical conditions
Restless legs syndrome
Treatment of predisposing condition, if possible; 
dopamine agonists (e.g., pramipexole, ropinirole)
Disturbed sleep, predisposing medical 
conditions (e.g., asthma), and/or 
predisposing medical therapies 
(e.g., theophylline)
Sleep-wake diary recording Insomnias (see text)
Treatment of predisposing condition and/or change in 
therapy, if possible; behavioral therapy; short-acting 
benzodiazepine receptor agonist (e.g., zolpidem)
Abbreviations: EMG, electromyogram; ENT, ears, nose, throat; REM, rapid eye movement.
341
SECTION 3
342
Common Patient Presentations
• Cataplexy, hypnagogic hallucinations, and sleep paralysis respond to 
the tricyclic antidepressants protriptyline (10–40 mg/d) and clomip-
ramine (25–50 mg/d) and to the selective serotonin uptake inhibitor 
fluoxetine (10–20 mg/d). Alternatively, γ-hydroxybutyrate (GHB) 
given at bedtime, and 4 h later, is effective in reducing daytime cata-
plectic episodes. 
• Adequate nocturnal sleep time and the use of short naps are other use-
ful preventative measures.
� CIRCADIAN RHYTHM SLEEP DISORDERS 
Insomnia or hypersomnia may occur in disorders of sleep timing rather than 
sleep generation. Such conditions may be (1) organic—due to a defect in the 
hypothalamic circadian pacemaker or its input from entraining stimuli, or 
(2) environmental—due to a disruption of exposure to entraining stimuli 
(light/dark cycle). Examples of the latter include jet-lag disorder and shift 
work. Shift work sleepiness can be treated with modafinil (200 mg, taken 
30–60 min before the start of each night shift) as well as properly timed 
exposure to bright light. Safety programs should promote education about 
sleep and increase awareness of the hazards associated with night work.
Delayed sleep phase syndrome is characterized by late sleep onset and 
awakening with otherwise normal sleep architecture. Bright-light photo-
therapy in the morning hours or melatonin therapy during the evening 
hours may be effective. 
 Advanced sleep phase syndrome moves sleep onset to the early evening 
hours with early morning awakening. These pts may benefit from bright-
light phototherapy during the evening hours. Some autosomal dominant 
cases result from mutations in a gene (PER2) involved in regulation of the 
circadian clock.
For a more detailed discussion, see Czeisler CA, Winkleman 
JW, Richardson GS: Sleep Disorders, Chap. 27, p. 213, in 
HPIM-18.
TABLE 62-2  PREVALENCE OF SYMPTOMS IN NARCOLEPSY
Symptom
Prevalence, %
Excessive daytime somnolence
100
Disturbed sleep
87
Cataplexy
76
Hypnagogic hallucinations
68
Sleep paralysis
64
Memory problems
50
Source: Modified from TA Roth, L Merlotti in SA Burton et al (eds). Narcolepsy 3rd International 
Symposium: Selected Symposium Proceedings, Chicago, Matrix Communications, 1989.
343
CHAPTER 63
Common Disorders 
of Vision and Hearing
DISORDERS OF THE EYE
Eye Disorders
APPROACH TO THE
PATIENT
The history and examination permit accurate diagnosis of most eye 
disorders without need for laboratory or imaging studies. The essential 
ocular exam includes assessment of the visual acuity, pupil reactions, eye 
movements, eye alignment, visual fields, and intraocular pressure. The 
lids, conjunctiva, cornea, anterior chamber, iris, and lens are examined 
with a slit lamp. The fundus is viewed with an ophthalmoscope.
Acute visual loss or double vision in a pt with quiet, uninflamed eyes 
often signifies a serious ocular or neurologic disorder and should be man-
aged emergently (Chap. 58). Paradoxically, the occurrence of a red eye, 
even if painful, has less dire implications as long as visual acuity is spared.
� SPECIFIC DISORDERS
Red or Painful Eye 
Common causes are listed in Table 63-1.
Minor Trauma This may result in corneal abrasion, subconjunctival hemor-
rhage, or foreign body. The integrity of the corneal epithelium is assessed by 
placing a drop of fluorescein in the eye and looking with a slit lamp (using 
cobalt-blue light) or a blue penlight. The conjunctival fornices should be 
searched carefully for foreign bodies by pulling the lower lid down and 
everting the upper lid.
Minor Trauma 
TREATMENT
• Chemical splashes and foreign bodies are treated by copious saline 
irrigation. 
• Foreign body can be removed with a moistened cotton-tipped applica-
tor after a drop of topical anesthetic
• Corneal abrasions may require application of a topical antibiotic, a 
mydriatic agent (1% cyclopentolate), and an eye patch.
SECTION 4
Ophthalmology and 
Otolaryngology
SECTION 4
344
Ophthalmology and Otolaryngology
344
Infection Infection of the eyelids and conjunctiva (blepharoconjunctivitis) 
produces redness and irritation but should not cause visual loss or pain. 
Adenovirus is the most common viral cause of “pink eye.” It produces a 
thin, watery discharge, whereas bacterial infection causes a more mucopu-
rulent exudate. On slit-lamp exam one should confirm that the cornea is not 
affected, by observing that it remains clear and lustrous. Corneal infection 
(keratitis) is a more serious condition than blepharoconjunctivitis because 
it can cause scarring, perforation, and permanent visual loss. Worldwide, 
the two leading causes of blindness from keratitis are trachoma from chla-
mydial infection and vitamin A deficiency from malnutrition; in the United 
States, contact lenses play a major role. A dendritic pattern of corneal fluo-
rescein staining is pathognomonic of herpes simplex keratitis but is seen in 
only a minority of cases.
TABLE 63-1 CAUSES OF A RED OR PAINFUL EYE
Blunt or penetrating trauma
Chemical exposure
Corneal abrasion
Foreign body
Contact lens (overuse or infection)
Corneal exposure (5th, 7th nerve palsy, ectropion)
Subconjunctival hemorrhage
Blepharitis
Conjunctivitis (infectious or allergic)
Corneal ulcer
Herpes keratitis
Herpes zoster ophthalmicus
Keratoconjunctivitis sicca (dry eye)
Dacryocystitis
Episcleritis
Scleritis
Anterior uveitis (iritis or iridocyclitis)
Endophthalmitis
Acute angle-closure glaucoma
Medicamentosus
Pinguecula
Pterygium
Proptosis (retrobulbar mass, orbital cellulitis, Graves’ ophthalmopathy, orbital 
pseudotumor, carotid-cavernous fistula)
345
CHAPTER 63
Common Disorders of Vision and Hearing
345
Infection
TREATMENT
• Strict handwashing and broad-spectrum topical antibiotics for blepha-
roconjunctivitis (sulfacetamide 10%, polymyxin-bacitracin-neomycin, 
or trimethoprim-polymyxin). 
• Keratitis requires empirical antibiotics (usually topical and subcon-
junctival) pending culture results from corneal scrapings.
• Herpes keratitis is treated with topical antiviral agents, cycloplegics, 
and oral acyclovir.
Inflammation Eye inflammation, without infection, can produce episcleritis, 
scleritis, or uveitis (iritis or iridocyclitis). Most cases are idiopathic, but some 
occur in conjunction with autoimmune disease. There is no discharge. A 
ciliary flush results from injection of deep conjunctival and episcleral ves-
sels near the corneal limbus. The diagnosis of uveitis hinges on the slit-lamp 
observation of inflammatory cells floating in the aqueous humor of the ante-
rior chamber or deposited on the corneal endothelium (keratic precipitates).
Inﬂ ammation
TREATMENT
• Mydriatic agents (to reduce pain and prevent the formation of syn-
echiae), NSAIDs, and topical glucocorticoids. (Note: prolonged treat-
ment with ocular glucocorticoids can cause cataract and glaucoma.)
Acute Angle-Closure Glaucoma This is a rare but frequently misdiagnosed 
cause of a red, painful eye. Because the anterior chamber is shallow, aqueous 
outflow via the anterior chamber angle becomes blocked by the peripheral 
iris. Intraocular pressure rises abruptly, causing ocular pain, injection, cor-
neal edema, obscurations, headache, nausea, and blurred vision. The key 
diagnostic step is measurement of the intraocular pressure during an attack.
Acute Angle-Closure Glaucoma
TREATMENT
• The acute attack is broken by constricting the pupil with a drop of 
pilocarpine and by lowering the intraocular pressure with acetazol-
amide (PO or IV), topical beta blockers, prostaglandin analogues, and 
α2-adrenergic agonists. 
• If these measures fail, laser therapy can be used to create a hole in the 
peripheral iris to relieve papillary block.
Chronic Visual Loss 
Most common causes are listed in Table 63-2.
Cataract A cloudy lens sufficient to reduce vision, due principally to aging. 
The formation of cataract occurs more rapidly in pts with a history of ocular 
SECTION 4
346
Ophthalmology and Otolaryngology
trauma, uveitis, or diabetes mellitus. Radiation and glucocorticoid treat-
ment can induce a cataract as a side effect. It is treated by surgical extraction 
and replacement with an artificial intraocular lens.
Glaucoma
An insidious optic neuropathy that leads to slowly progressive 
visual loss, usually associated with elevated intraocular pressure. Angle closure 
accounts for only a few cases; most pts have open angles and no identifiable 
cause for their pressure elevation. The diagnosis is made by document-
ing arcuate (nerve fiber bundle) scotomas on visual field exam, observing 
“cupping” of the optic disc (Fig. 63-1), and measuring intraocular pressure.
TABLE 63-2 CAUSES OF CHRONIC, PROGRESSIVE VISUAL LOSS
Cataract
Glaucoma
Macular degeneration
Diabetic retinopathy
Optic nerve or optic chiasm tumor
Intraocular tumor
Retinitis pigmentosa
Epiretinal membrane
Macular hole
FIGURE 63-1 Glaucoma results in “cupping” as the neural rim is destroyed and the 
central cup becomes enlarged and excavated. The cup-to-disc ratio is about 0.7/1.0 
in this pt. 
347
Glaucoma
TREATMENT
• Topical adrenergic agonists, cholinergic agonists, beta blockers, pros-
taglandin analogues, and oral carbonic anhydrase inhibitors (to lower 
intraocular pressure) are used for treatment. 
• Laser treatment of the trabecular meshwork in the anterior chamber 
angle improves aqueous outflow from the eye. 
• If medical and laser treatments fail, a surgical filter (trabeculectomy) 
or valve must be placed.
Macular Degeneration  This occurs in both a “dry” and “wet” form. In the 
dry form, clumps of extracellular material, called drusen, are deposited 
beneath the retinal pigment epithelium (Fig. 63-2). As they accumulate, 
vision is slowly lost. In the wet form, neovascular proliferation occurs 
beneath the retinal pigment epithelium. Bleeding from these neovascular 
vessels can cause sudden, central visual loss in the elderly, although usu-
ally blurring of vision is more gradual. Macular exam shows drusen and 
subretinal hemorrhage.
Macular Degeneration
TREATMENT
• Treatment with vitamins C and E, beta carotene, and zinc may retard 
dry macular degeneration. 
FIGURE 63-2 Age-related macular degeneration begins with the accumulation of 
drusen within the macula. They appear as scattered yellow subretinal deposits. 
CHAPTER 63
Common Disorders of Vision and Hearing
SECTION 4
348
Ophthalmology and Otolaryngology
• Wet macular degeneration can be treated with vascular endothelial 
growth factor antagonists directly injected into the vitreous cavity on 
a monthly basis.
Diabetic Retinopathy A leading cause of blindness in the United States. 
Appears in most pts years after onset of diabetes. Background diabetic 
retinopathy consists of intraretinal hemorrhage, exudates, nerve fiber layer 
infarcts (cotton-wool spots), and macular edema. Proliferative diabetic reti-
nopathy is characterized by ingrowth of neovascular vessels on the retinal 
surface, causing blindness from vitreous hemorrhage, retinal detachment, 
and glaucoma (Fig. 63-3).
Diabetic Retinopathy
TREATMENT
• All diabetics should be examined regularly by an ophthalmologist for 
surveillance of diabetic retinopathy. 
• Neovascularization is treated by panretinal laser photocoagulation to 
prevent complications.
Tumors Tumors of the optic nerve or chiasm are comparatively rare, but 
often escape detection because they produce insidious visual loss and few 
physical findings, except for optic disc pallor. Pituitary tumor is the most 
common lesion. It causes bitemporal or monocular visual loss. Melanoma 
is the most common primary tumor of the eye itself.
FIGURE 63-3 Diabetic retinopathy results in scattered hemorrhages, yellow exu-
dates, and neovascularization. This pt has neovascular vessels proliferating from the 
optic disc, requiring urgent pan retinal laser photocoagulation. 
CHAPTER 63
349
Common Disorders of Vision and Hearing
Tumors
TREATMENT
• Large pituitary tumors producing chiasm compression are removed 
transsphenoidally.
• In some cases, small tumors can be observed or controlled pharmaco-
logically (e.g., bromocriptine for prolactinoma).
HEARING DISORDERS
Nearly 10% of the adult population has some hearing loss; up to one-third 
of individuals over the age of 65 have hearing loss of sufficient magnitude to 
require a hearing aid. Hearing loss can result from disorders of the auricle, 
external auditory canal, middle ear, inner ear, or central auditory pathways. 
In general, lesions in the auricle, external auditory canal, or middle ear cause 
conductive hearing losses, while lesions in the inner ear or eighth nerve cause 
sensorineural hearing losses.
Hearing Impairment
APPROACH TO THE
PATIENT
The goal is to determine (1) the nature of the hearing impairment (senso-
rineural vs. conductive vs. mixed), (2) the severity of the impairment, (3) 
the anatomy of the impairment, and (4) the etiology. Ascertain onset (sud-
den vs. insidious), progression (rapid vs. slow), and whether symptoms 
are unilateral or bilateral. Ask about tinnitus, vertigo, imbalance, aural 
fullness, otorrhea, headache, and facial or other cranial nerve symptoms. 
Prior head trauma, exposure to ototoxins, occupational or recreational 
noise exposure, or family history of hearing impairment also important.
Exam should include the auricle, external ear canal, and tympanic 
membrane. The external ear canal of the elderly is often dry and fragile; 
it is preferable to clean cerumen with wall-mounted suction and ceru-
men loops and to avoid irrigation. Inspect the nose, nasopharynx, cranial 
nerves, and upper respiratory tract. Unilateral serous effusion should 
prompt a fiberoptic exam of the nasopharynx to exclude neoplasm.
The Weber and Rinne tests differentiate conductive from sensorineural 
hearing losses. Rinne test: the tines of a vibrating tuning fork (512 Hz) are 
held near the opening of the external auditory canal, and then the stem is 
placed on the mastoid process. Normally, and with sensorineural hearing 
loss, air conduction is louder than bone conduction; however, with conduc-
tive hearing loss, bone conduction is louder. Weber test: the stem of a vibrat-
ing tuning fork is placed on the forehead in the midline. With a unilateral 
conductive hearing loss, the tone is perceived in the affected ear; with a uni-
lateral sensorineural hearing loss, the tone is perceived in the unaffected ear.
� LABORATORY EVALUATION
Audiologic Assessment Pure tone audiometry assesses hearing acuity for 
pure tones. Speech recognition requires greater synchronous neural firing 
than necessary for appreciation of pure tones; clarity of hearing is tested in 
SECTION 4
350
Ophthalmology and Otolaryngology
speech audiometry. Tympanometry measures impedance of middle ear to 
sound; useful in diagnosis of middle-ear effusions. Otoacoustic emissions 
(OAE), measured with microphones inserted in external auditory canal, 
indicate that outer hair cells of the organ of Corti are intact; useful to 
assess auditory thresholds and distinguish sensory from neural hearing 
loss. Electrocochleography measures earliest evoked potentials generated 
in cochlea and auditory nerve; useful in diagnosis of Ménière’s disease. 
Brainstem auditory evoked responses (BAER) localize site of sensorineural 
hearing loss.
Imaging Studies CT of temporal bone with fine 0.3–0.6 mm cuts can define 
the caliber of the external auditory canal, integrity of the ossicular chain, 
presence of middle ear or mastoid disease, inner-ear malformations, and 
bone erosion (chronic otitis media and cholesteatoma). MRI superior to 
CT for imaging of retrocochlear structures including cerebellopontine angle 
(vestibular schwannoma) and brainstem.
� CAUSES OF HEARING LOSS (FIG. 63-4)
Conductive Hearing Loss 
May result from obstruction of the external auditory canal by cerumen, 
debris, and foreign bodies; swelling of the lining of the canal; atresia of the 
ear canal; neoplasms of the canal; perforations of the tympanic membrane; 
disruption of the ossicular chain, as occurs with necrosis of the long pro-
cess of the incus in trauma or infection; otosclerosis; and fluid, scarring, or 
neoplasms in the middle ear. Hearing loss with otorrhea most likely due to 
otitis media or cholesteatoma.
Cholesteatoma, i.e., stratified squamous epithelium in the middle ear or 
mastoid, is a benign, slowly growing lesion that destroys bone and normal 
ear tissue. A chronically draining ear that fails to respond to appropriate 
antibiotic therapy suggests cholesteatoma; surgery is required.
Conductive hearing loss with a normal ear canal and intact tympanic 
membrane suggests ossicular pathology. Fixation of the stapes from otoscle-
rosis is a common cause of low-frequency conductive hearing loss; onset is 
between the late teens to the forties. In women, the hearing loss is often first 
noticeable during pregnancy. A hearing aid or a surgical stapedectomy can 
provide auditory rehabilitation.
Eustachian tube dysfunction is common and may predispose to acute otitis 
media (AOM) or serous otitis media (SOM). Trauma, AOM, or chronic otitis 
media are the usual factors responsible for tympanic membrane perforation. 
While small perforations often heal spontaneously, larger defects usually 
require surgical tympanoplasty (>90% effective). Otoscopy is usually suf-
ficient to diagnose AOM, SOM, chronic otitis media, cerumen impaction, 
tympanic membrane perforation, and eustachian tube dysfunction.
Sensorineural Hearing Loss 
Damage to hair cells of the organ of Corti may be caused by intense noise, 
viral infections, ototoxic drugs (e.g., salicylates, quinine and its analogues, 
aminoglycoside antibiotics, diuretics such as furosemide and ethacrynic 
FIGURE 63-4 An algorithm for the approach to hearing loss. AOM, acute otitis media; HL, hearing loss; SNHL, sensorineural hearing loss; SOM, serous otitis 
media; TM, tympanic membrane; *, CT scan of temporal bone; †, MRI scan. 
Hearing Loss
History
Otologic examination
Cerumen impaction
TM perforation
Cholesteatoma
SOM
AOM
External auditory
  canal atresia/
  stenosis
Eustachian tube
  dysfunction
Tympanosclerosis
Pure tone and
speech audiometry
Conductive HL
Impedance audiometry
Mixed HL
SNHL
abnormal
Impedance audiometry
Acute
Asymmetric/symmetric
Chronic
normal
Otosclerosis
Cerumen
  impaction
Ossicular
  fixation
Cholesteatoma*
Temporal bone
  trauma*
Inner ear
  dehiscence or
  “third window”
AOM
SOM
TM perforation*
Eustachian tube
  dysfunction
Cerumen
  impaction
Cholesteatoma*
Temporal bone
  trauma*
Ossicular
  discontinuity*
Middle ear tumor*
abnormal
normal
AOM
TM perforation*
Cholesteatoma*
Temporal bone
  trauma*
Middle ear tumors*
    glomus
      tympanicum
    glomus jugulare
Stapes gusher
   syndrome*
Inner ear
  malformation*
Otosclerosis
Temporal bone
  trauma*
Inner ear
  dehiscence or
  “third window”
CNS infection†
Tumors†
    Cerebellopontine
      angle
    CNS
Stroke†
Trauma*
Symmetric
Asymmetric
Inner ear
  malformation*
Presbycusis
Noise exposure
Radiation therapy
MRI/BAER
abnormal
normal
Endolymphatic hydrops
Labyrinthitis*
Perilymphatic fistula*
Radiation therapy
Labyrinthitis*
Inner ear malformations*
Cerebellopontine angle tumors
    Arachnoid cyst; facial nerve tumor;
    lipoma; meningioma; vestibular schwannoma
Multiple sclerosis†
abnormal
normal
351
SECTION 4
352
Ophthalmology and Otolaryngology
acid, and chemotherapeutic agents such as cisplatin), fractures of the tem-
poral bone, meningitis, cochlear otosclerosis, Ménière’s disease, and aging. 
Congenital malformations of the inner ear may cause hearing loss in some 
adults. Genetic predisposition alone or in concert with environmental influ-
ences may also be responsible.
Presbycusis (age-associated hearing loss) is the most common cause of 
sensorineural hearing loss in adults. In early stages, symmetric high fre-
quency hearing loss is typical; with progression, the hearing loss involves 
all frequencies. The hearing impairment is associated with loss in clarity. 
Hearing aids provide limited rehabilitation; cochlear implants are treatment 
of choice for severe cases.
Ménière’s disease is characterized by episodic vertigo, fluctuating sensori-
neural hearing loss, tinnitus, and aural fullness. It is caused by an increase in 
endolymphatic fluid pressure due to endolymphatic sac dysfunction. Low-
frequency, unilateral sensorineural hearing impairment is usually present. 
MRI should be obtained to exclude retrocochlear pathology such as cerebel-
lopontine angle tumor or demyelinating disorder. Therapy directed toward 
control of vertigo; a low-salt diet (2g/d), diuretics, a short course of gluco-
corticoids, and intratympanic gentamicin may be useful. For unresponsive 
cases, endolymphatic sac decompression, labyrinthectomy, and vestibular 
nerve section abolish rotatory vertigo. There is no effective therapy for 
hearing loss, tinnitus, or aural fullness.
Vestibular schwannomas present with asymmetric hearing impairment, 
tinnitus, imbalance (rarely vertigo); cranial neuropathy (trigeminal or facial 
nerve) may accompany larger tumors.
Sensorineural hearing loss may also result from any neoplastic, vascu-
lar, demyelinating, infectious (including HIV), or degenerative disease or 
trauma affecting the central auditory pathways.
Tinnitus 
Defined as the perception of a sound when there is no sound in the environ-
ment. It may have a buzzing, roaring, or ringing quality and may be pulsatile 
(synchronous with the heartbeat). Tinnitus is often associated with either 
a conductive or sensorineural hearing loss and may be the first symptom 
of a serious condition such as a vestibular schwannoma. Pulsatile tinnitus 
requires evaluation of the vascular system of the head to exclude vascular 
tumors such as glomus jugulare tumors, aneurysms, arteriovenous fistulae, 
and stenotic arterial lesions; it may also occur with SOM.
Hearing Loss
TREATMENT
• Hearing aids have been improved to provide greater fidelity and 
miniaturized so that they can be placed entirely within the ear canal, 
reducing the stigma associated with their use. 
• Digital hearing aids can be individually programmed, and multiple 
and directional microphones at the ear level may be helpful in noisy 
surroundings. 
353
Upper Respiratory Tract Infections
CHAPTER 64
For a more detailed discussion, see Horton JC: Disorders of the 
Eye, Chap. 28, p. 224; and Lalwani AK: Disorders of Hearing, 
Chap. 30, p. 248, in HPIM-18.
• If the hearing aid provides inadequate rehabilitation, cochlear implants 
can be effective.
• Treatment of tinnitus is problematic. Relief of the tinnitus may be 
obtained by masking it with background music. Hearing aids are also 
helpful in tinnitus suppression, as are tinnitus maskers, devices that 
present a sound to the affected ear that is more pleasant to listen to 
than the tinnitus. Antidepressants have also shown some benefit.
• Hard-of-hearing individuals often benefit from a reduction in unnec-
essary noise to enhance the signal-to-noise ratio. Speech comprehen-
sion is aided by lip-reading; the face of the speaker should be well 
illuminated and easily seen.
� PREVENTION
Conductive hearing losses may be prevented by prompt antibiotic therapy 
for AOM and by ventilation of the middle ear with tympanostomy tubes 
in middle-ear effusions lasting ≥12 weeks. Loss of vestibular function and 
deafness due to aminoglycoside antibiotics can largely be prevented by 
monitoring of serum peak and trough levels.
Ten million Americans have noise-induced hearing loss, and 20 million 
are exposed to hazardous noise in their employment. Noise-induced 
hearing loss can be prevented by avoidance of exposure to loud noise 
or by regular use of ear plugs or fluid-filled muffs to attenuate intense 
sound.
CHAPTER 64
Sinusitis, Pharyngitis, 
Otitis, and Other 
Upper Respiratory 
Tract Infections
• Upper respiratory tract infections (URIs) are among the leading causes 
of lost time from work or school.
• Distinguishing pts with primary viral URI from those with primary bac-
terial URI is difficult since the signs and symptoms are the same.
• URIs are often treated with antibiotics even though bacteria cause only 
25% of cases. Inappropriate prescribing of antibiotics for URIs is a 
SECTION 4
354
Ophthalmology and Otolaryngology
leading cause of antibiotic resistance in common community-acquired 
pathogens such as Streptococcus pneumoniae.
NONSPECIFIC URIs
• Definition: Nonspecific URIs (the “common cold”) have no prominent 
localizing features.
• Etiology: A wide variety of viruses (e.g., rhinoviruses, coronaviruses, 
parainfluenza viruses, influenza viruses, adenoviruses) can cause non-
specific URIs. 
• Clinical manifestations: an acute, mild, self-limited catarrhal syndrome, 
typically characterized by rhinorrhea, nasal congestion, cough, and sore 
throat
 
– Hoarseness, malaise, sneezing, and fever are more variable.
 
– The median duration of symptoms is ~1 week (range, 2–10 days). 
• Treatment: Symptom-based treatment (e.g., with decongestants, NSAIDs, 
dextromethorphan, throat lozenges) is typically all that is required. 
 
–  Because secondary bacterial URI complicates only 0.5–2% of colds, 
antibiotics are not indicated.
 
–  Purulent nasal and throat secretions are poor predictors of bacterial 
infection.
SINUS INFECTIONS
• Rhinosinusitis is an inflammatory condition most commonly involving 
the maxillary sinus; next, in order of frequency, are the ethmoid, frontal, 
and sphenoid sinuses.
• Sinusitis accounts for millions of visits to primary care physicians each 
year and is the fifth most common diagnosis for which antibiotics are 
prescribed.
� ACUTE SINUSITIS
• Definition: sinusitis of <4 weeks’ duration
• Etiology: Infectious and noninfectious causes lead to sinus ostial 
obstruction and retention of mucus.
 
–  Infectious causes include viruses (e.g., rhinovirus, parainfluenza 
virus, influenza virus) and bacteria [e.g., S. pneumoniae, nontypable 
Haemophilus influenzae, and (in children) Moraxella catarrhalis]. 
• In immunocompromised pts, fungi (e.g., Rhizopus, Mucor, and 
occasionally Aspergillus) can be involved.
• Nosocomial cases are often polymicrobial and involve Staphylococcus 
aureus and gram-negative bacilli.
 
–  Noninfectious causes include allergic rhinitis, barotrauma, and expo-
sure to chemical irritants.
• Clinical manifestations: Common manifestations include nasal drain-
age, congestion, facial pain or pressure, and headache.
 
– Tooth pain and halitosis can be associated with bacterial sinusitis.
 
–  Pain localizes to the involved sinus and is often worse when the pt 
bends over or is supine. 
355
 
–  Advanced frontal sinusitis can present as “Pott’s puffy tumor”: swell-
ing and pitting edema over the frontal bone from a communicating 
subperiosteal abscess. 
 
–  Life-threatening complications include meningitis, epidural abscess, 
and brain abscess.
• Diagnosis: It is difficult to distinguish viral from bacterial sinusitis clini-
cally, although viral cases greatly outnumber bacterial cases.
 
–  Only 40–50% of pts with symptoms of >10 days’ duration, purulent 
nasal drainage, nasal obstruction, and facial pain have bacterial sinusitis. 
 
–  If fungal sinusitis is a consideration, biopsies of involved areas should 
be performed. 
 
–  Except in nosocomial cases, sinus CT or radiography is not recom-
mended for acute sinusitis. Nosocomial sinusitis should be confirmed 
by sinus CT, with sinus aspirates sent for culture and susceptibility 
testing (ideally before antimicrobial therapy is initiated).
Acute Sinusitis
TREATMENT
• Most pts improve without antibiotic therapy. 
• For pts with mild to moderate symptoms, treatment should focus on 
symptom relief and facilitation of sinus drainage (e.g., oral and topical 
decongestants, nasal saline lavage). 
• Pts without improvement after 10 days or with severe disease at pre-
sentation should be given antibiotics.
– See Table 64-1 for recommended regimens for adults. 
– Up to 10% of pts do not respond to initial antimicrobial therapy; 
consultation with an otolaryngologist about possible sinus aspira-
tion and/or lavage should be considered in these cases.
• Surgery should be considered for pts with severe disease, intracranial 
complications, or invasive fungal sinusitis. 
� CHRONIC SINUSITIS
• Definition: sinusitis of >12 weeks’ duration
• Etiology: commonly associated with bacterial or fungal infection
• Chronic bacterial sinusitis: Impaired mucociliary clearance leads to 
repeated infections as opposed to one persistent infection. 
 
–  Pts have constant nasal congestion and sinus pressure, with periods of 
increased severity. 
 
–  Sinus CT can define the extent of disease, detect an underlying ana-
tomic defect or obstructing process, and assess response to treatment. 
 
–  Endoscopy-derived tissue samples for histology and culture should be 
obtained to guide treatment. 
 
–  Repeated courses of antibiotics are required, often for 3–4 weeks at a 
time. Adjunctive measures include intranasal administration of gluco-
corticoids, sinus irrigation, and surgical evaluation. 
Upper Respiratory Tract Infections
CHAPTER 64
SECTION 4
356
Ophthalmology and Otolaryngology
TABLE 64-1  GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF SELECTED 
UPPER RESPIRATORY TRACT INFECTIONS IN ADULTSa
Syndrome, Diagnostic 
Criteria
Treatment Recommendations
Acute sinusitisb
  Moderate symptoms 
(e.g., nasal puru-
lence/congestion or 
cough) for >10 d or
  Severe symptoms 
of any duration, 
including unilateral/
focal facial swelling 
or tooth pain
Initial therapy
  Amoxicillin, 500 mg PO tid or 875 mg PO bid
Penicillin allergy
 TMP-SMX, 1 DS tablet PO bid for 10–14 d
Exposure to antibiotics within 30 d or >30% 
prevalence of penicillin-resistant S. pneumoniae
  Amoxicillin/clavulanate (extended-release), 
2000 mg PO bid; or
  Antipneumococcal fluoroquinolone 
(e.g., levofloxacin, 500 mg PO qd)
Recent treatment failure
  Amoxicillin/clavulanate (extended-release), 
2000 mg PO bid; or
  Amoxicillin, 1500 mg bid, plus clindamycin, 
300 mg PO qid; or
  Antipneumococcal fluoroquinolone 
(e.g., levofloxacin, 500 mg PO qd)
Acute otitis mediac
  Mild to moderate 
severity
Initial therapy
  Observation alone (antibiotic therapy deferred 
for 48–72 h and management limited to 
symptom relief) 
  Mild to moderate 
severity after 
observation period
  Amoxicillin, 2 g PO qd in divided doses (bid or tid); or
  Cefdinir, 600 mg PO qd in 1 dose or divided 
doses (bid); or
  Cefuroxime, 500 mg PO bid; or
  Azithromycin, 500 mg PO on day 1 followed 
by 250 mg PO qd for 4 d
Antibiotic exposure within 30 d c or recent treatment 
failure c,d
  Amoxicillin, 875 mg PO bid, plus clavulanate, 
125 mg PO bid; or
  Ceftriaxone, 1 g IV/IM qd for 3 d; or
  Clindamycin, 300 mg PO tid
Severe disease
  Middle-ear effusion 
and acute onset of 
signs and symptoms
Initial therapy
  Amoxicillin, 875 mg PO bid, plus clavulanate, 
125 mg PO bid; or
Ceftriaxone, 1 g IV/IM qd for 3 d
357
TABLE 64-1  GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF SELECTED 
UPPER RESPIRATORY TRACT INFECTIONS IN ADULTSa
of middle-ear inflamma-
tion, including tempera-
ture ≥39.0°C (102°F) 
or moderate to severe 
otalgia
Antibiotic exposure within 30 d c or recent treatment 
failure c,d
  Ceftriaxone, 1 g IV/IM qd for 3 d; or
  Clindamycin, 300 mg PO tid; or
Consider tympanocentesis with culture
Acute pharyngitisb
  Clinical suspicion of 
streptococcal phar-
yngitis (e.g., fever, 
tonsillar swelling, 
exudate, enlarged/
tender anterior cervi-
cal lymph nodes, 
absence of cough or 
coryza)e with:
  History of rheumatic 
fever or
  Documented house-
hold exposure or
  Positive rapid strep 
screen
Initial therapy
Penicillin VK, 500 mg PO tid; or
Amoxicillin, 500 mg PO bid; or
Erythromycin, 250 mg PO qid; or
Benzathine penicillin G, single dose of 1.2 million 
units IM
aFor detailed information on diagnosis and treatment in children, see Tables 31-1, 31-2, 
and 31-3 in HPIM-18.
bUnless otherwise specified, the duration of therapy is generally 10 d, with appropriate 
follow-up.
cThe duration of therapy is 5–7 d (10 d for pts with severe disease).
dFailure to improve and/or clinical worsening after 48–72 h of observation or treatment.
eSome organizations support treating adults who have these symptoms and signs without 
administering a rapid streptococcal antigen test.
Abbreviations: DS, double-strength; TMP-SMX, trimethoprim-sulfamethoxazole.
Sources: Rosenfeld RM et al: Otolaryngol Head Neck Surg 137(3 Suppl):S1, 2007; American 
Academy of Pediatrics Subcommittee on Management of Sinusitis and Committee on Quality 
Improvement: Pediatrics 108:798, 2001; American Academy of Pediatrics Subcommittee on 
Management of Acute Otitis Media: Pediatrics 113:1451, 2004; RJ Cooper et al: Ann Intern 
Med 134:509, 2001; and B Schwartz et al: Pediatrics 101:171, 1998.
Upper Respiratory Tract Infections
CHAPTER 64
 (CONTINUED)
• Chronic fungal sinusitis: a noninvasive disease in immunocompetent 
hosts, typically due to Aspergillus species and dematiaceous molds. 
Recurrence is common.
 
–  Mild, indolent disease is usually cured with endoscopic surgery and 
without antifungal agents. 
 
–  Unilateral disease with a mycetoma (fungus ball) in the sinus is treated 
with surgery and—if bony erosion has occurred—antifungal agents. 
SECTION 4
358
Ophthalmology and Otolaryngology
 
–  Allergic fungal sinusitis, seen in pts with nasal polyps and asthma, 
presents as pansinusitis and thick, eosinophil-laden mucus with the 
consistency of peanut butter.
 INFECTIONS OF THE EAR AND MASTOID
� EXTERNAL EAR INFECTIONS
In the absence of local or regional adenopathy, consider noninfectious 
causes of inflammation, among which trauma, insect bites, and environ-
mental exposures are more commonly implicated than are autoimmune 
diseases (e.g., lupus) or vasculitides [e.g., granulomatosis with polyangiitis 
(Wegener’s)].
• Auricular cellulitis: Tenderness, erythema, swelling, and warmth of the 
external ear, particularly the lobule, follow minor trauma. Treat with 
warm compresses and antibiotics active against S. aureus and strepto-
cocci (e.g., dicloxacillin).
• Perichondritis: Infection of the perichondrium of the auricular cartilage 
follows minor trauma (e.g., ear piercing). The infection may closely 
resemble auricular cellulitis, although the lobule is less often involved in 
perichondritis.
 
–  Treatment requires systemic antibiotics active against the most common 
etiologic agents, Pseudomonas aeruginosa and S. aureus, and typically 
consists of an antipseudomonal penicillin or a penicillinase-resistant 
penicillin (e.g., nafcillin) plus an antipseudomonal quinolone (e.g., cip-
rofloxacin). Surgical drainage may be needed; resolution can take weeks. 
 
–  If perichondritis fails to respond to adequate therapy, consider nonin-
fectious inflammatory etiologies (e.g., relapsing polychondritis).
• Otitis externa: a collection of diseases involving primarily the auditory 
meatus and resulting from a combination of heat and retained moisture, 
with desquamation and maceration of the epithelium of the outer ear 
canal. All forms are predominantly bacterial in origin; P. aeruginosa and 
S. aureus are the most common pathogens.
 
–  Acute localized otitis externa: furunculosis in the outer third of the 
ear canal, usually due to S. aureus. Treatment consists of an oral anti-
staphylococcal penicillin (e.g., dicloxacillin), with surgical drainage in 
cases of abscess formation.
 
–  Acute diffuse otitis externa (swimmer’s ear): infection in macerated, 
irritated canals that is typically due to P. aeruginosa and is character-
ized by severe pain, erythema, and swelling of the canal and white 
clumpy discharge from the ear. Treatment includes cleansing of the 
canal to remove debris and use of topical antibiotics (e.g., preparations 
with neomycin and polymyxin), with or without glucocorticoids to 
reduce inflammation.
 
–  Chronic otitis externa: erythematous, scaling, pruritic, nonpainful 
dermatitis that usually arises from persistent drainage from a chronic 
middle-ear infection, other causes of repeated irritation, or rare 
chronic infections such as tuberculosis or leprosy. Treatment consists 
of identifying and eliminating the offending process; successful reso-
lution is frequently difficult.
359
 
–  Malignant or necrotizing otitis externa: a slowly progressive infection 
characterized by purulent otorrhea, an erythematous swollen ear and 
external canal, and severe otalgia out of proportion to exam findings, 
with granulation tissue present in the posteroinferior wall of the canal, 
near the junction of bone and cartilage
• This potentially life-threatening disease, which occurs primarily in 
elderly diabetic or immunocompromised pts, can involve the base 
of the skull, meninges, cranial nerves, and brain.
• P. aeruginosa is the most common etiologic agent, but other 
gram-negative bacilli, S. aureus, Staphylococcus epidermidis, and 
Aspergillus have been reported. 
• A biopsy specimen of the granulation tissue (or of deeper tissues) 
should be obtained for culture. 
• Treatment involves systemic antibiotics for 6–8 weeks and consists 
of antipseudomonal agents (e.g., piperacillin, ceftazidime) with 
an aminoglycoside or a fluoroquinolone; antibiotic drops active 
against Pseudomonas, combined with glucocorticoids, are used as 
adjunctive therapies.
• Recurs in up to 20% of cases. Aggressive glycemic control in dia-
betic pts helps with treatment and prevention of recurrence.
� MIDDLE-EAR INFECTIONS
Eustachian tube dysfunction, often in association with URIs, causes inflam-
mation with a sterile transudate. Viral or bacterial superinfection often 
occurs.
• Acute otitis media: typically follows a viral URI, which can directly cause 
viral otitis media or predispose to bacterial otitis media 
 
–  Etiology: S. pneumoniae is isolated in up to 35% of cases; nontypable 
H. influenzae and M. catarrhalis are other common causes of bacte-
rial otitis media. Concern is increasing about community-acquired 
methicillin-resistant S. aureus (MRSA) as an emerging etiologic agent. 
Viruses (e.g., RSV, influenza virus, rhinovirus, enterovirus) have been 
recovered either alone or with bacteria in up to 40% of cases.
 
–  Clinical manifestations: The tympanic membrane is immobile, ery-
thematous, bulging, or retracted and can perforate spontaneously. 
• Other findings may include otalgia, otorrhea, decreased hearing, 
fever, and irritability.
• In isolation, erythema of the tympanic membrane is nonspecific as 
it is common in association with inflammation of the upper respira-
tory mucosa.
 
–  Treatment: Most cases of mild to moderate disease resolve within 
1 week without specific treatment. Relief of symptoms with analgesic 
agents and NSAIDs typically suffices. 
• Indications for antibiotic therapy and treatment regimens are listed 
in Table 64-1.
• Antibiotic prophylaxis and surgical interventions offer little benefit 
in recurrent acute otitis media.
• Serous otitis media: Also known as otitis media with effusion, this con-
dition can persist for weeks (e.g., acute effusions) or months (e.g., after 
Upper Respiratory Tract Infections
CHAPTER 64
SECTION 4
360
Ophthalmology and Otolaryngology
an episode of acute otitis media) without signs of infection and is associ-
ated with significant hearing loss in the affected ear.
 
–  The majority of cases resolve spontaneously within 3 months without 
antibiotic therapy.
 
–  Antibiotic therapy or myringotomy with tympanostomy tubes is 
reserved for pts with bilateral effusions that have persisted for at least 
3 months and are associated with bilateral hearing loss.
• Chronic otitis media: persistent or recurrent purulent otorrhea with 
tympanic membrane perforation, usually associated with conductive 
hearing loss 
 
–  Inactive disease, characterized by a central perforation of the tympanic 
membrane, is treated with repeated courses of topical antibiotic drops 
during periods of drainage.
 
–  Active disease involves formation of a cholesteatoma that may enlarge 
and ultimately lead to erosion of bone, meningitis, and brain abscess; 
surgical treatment is required. 
• Mastoiditis: accumulation of purulent exudate in the mastoid air cells 
that erodes surrounding bones and causes abscess-like cavities
 
–  Pts have pain, erythema, and mastoid process swelling causing displace-
ment of the pinna along with the signs and symptoms of otitis media. 
 
–  Rare complications include subperiosteal abscess, deep neck abscess, 
and septic thrombosis of the lateral sinus. 
 
–  Broad-spectrum empirical IV antibiotic regimens targeting 
S. pneumoniae, H. influenzae, and M. catarrhalis can be narrowed once 
culture results are available; mastoidectomy is reserved for compli-
cated cases or pts in whom medical management fails.
INFECTIONS OF THE PHARYNX AND ORAL CAVITY
• Sore throat is the most common presenting symptom and one of the 
most common reasons for ambulatory care visits by adults and children.
� ACUTE PHARYNGITIS
• Etiology: Respiratory viruses are the most common identifiable cause, 
although ~30% of cases have no etiology identified.
 
–  Viruses: Rhinoviruses and coronaviruses cause ~20% and ~5% of 
cases, respectively; influenza virus, parainfluenza virus, HSV, cox-
sackievirus, EBV, and HIV are other important viral causes.
 
–  Bacteria: Group A Streptococcus (GAS) accounts for 5–15% of adult 
cases. Fusobacterium necrophorum is increasingly identified as a 
cause of pharyngitis in adolescents and is isolated nearly as often as 
GAS. Other bacterial causes include streptococci of groups C and G, 
Neisseria gonorrhoeae, Corynebacterium diphtheriae, and anaerobic 
bacteria.
• Clinical manifestations: Specific signs and symptoms sometimes sug-
gest that one etiology is more likely than another.
 
–  Respiratory viruses: Symptoms usually are not severe and are associ-
ated with coryza without fever, tender cervical lymphadenopathy, or 
pharyngeal exudates.
 
–  Influenza virus and adenovirus: evidenced by severe exudative phar-
yngitis with fever
361
 
–  HSV: presents as pharyngeal inflammation and exudates with vesicles 
and ulcers on the palate
 
–  Coxsackievirus (herpangina): characterized by small vesicles on the 
soft palate and uvula that form shallow white ulcers
 
–  EBV and CMV: present as exudative pharyngitis in association with 
other signs of infectious mononucleosis
 
–  HIV: associated with fever, acute pharyngitis, myalgias, malaise, and 
sometimes a maculopapular rash
 
–  Streptococci: Presentation ranges from mild disease to profound 
pharyngeal pain, fever, chills, abdominal pain, and a hyperemic pha-
ryngeal membrane with tonsillar hypertrophy and exudates; coryzal 
symptoms are absent.
 
–  Other bacteria: often present as exudative pharyngitis without other 
specific findings
• Diagnosis: The primary goal of diagnostic testing is to identify cases of 
GAS pharyngitis.
 
–  Rapid antigen-detection tests for GAS offer good specificity 
(>90%) but variable sensitivity (65–90%); throat cultures are not 
routinely recommended for adults in the setting of negative rapid 
testing.
 
–  Other bacterial causes may be missed on routine testing if specific 
cultures are not requested.
 
–  If HIV is being considered, testing for HIV RNA should be performed.
• Treatment: Antibiotic therapy for GAS infection is outlined in Table 64-1 
and is recommended to prevent the development of rheumatic fever.
 
–  Symptom-based treatment of viral pharyngitis is generally sufficient.
 
–  Specific antiviral therapy may be helpful in selected cases of influenza 
and HSV infection.
� ORAL INFECTIONS
Oral-labial herpesvirus infections and oropharyngeal candidiasis are dis-
cussed in Chaps. 108 and 115, respectively.
INFECTIONS OF THE LARYNX AND EPIGLOTTIS
• Laryngitis: Acute laryngitis is a common syndrome caused by nearly 
all the major respiratory viruses and by some bacteria (e.g., GAS, 
C. diphtheriae, and M. catarrhalis). Chronic cases of infectious laryngitis 
are much less common in developed countries than in low-income coun-
tries and are caused by Mycobacterium tuberculosis, endemic fungi (e.g., 
Histoplasma, Blastomyces, Coccidioides), and Cryptococcus.
 
–  Pts are hoarse, exhibit reduced vocal pitch or aphonia, and have coryzal 
symptoms. 
 
–  Treatment of acute laryngitis consists of humidification, voice rest, 
and—if GAS is cultured—antibiotic administration. Treatment of 
chronic laryngitis depends on the pathogen, whose identification usu-
ally requires biopsy with culture.
• Epiglottitis: acute, rapidly progressive cellulitis of the epiglottis and adja-
cent structures that can result in complete—and sometimes fatal—airway 
obstruction 
Upper Respiratory Tract Infections
CHAPTER 64
SECTION 4
362
Ophthalmology and Otolaryngology
 
–  Epiglottitis is caused by GAS, S. pneumoniae, Haemophilus parainflu-
enzae, and S. aureus; pediatric cases due to H. influenzae type b are 
now rare because of vaccination.
 
–  Symptoms include fever, severe sore throat, and systemic toxicity, and 
pts often drool while sitting forward. Examination may reveal respira-
tory distress, inspiratory stridor, and chest wall retractions. 
 
–  Direct visualization in the exam room (i.e., with a tongue blade) 
should not be performed, given the risk of complete airway obstruc-
tion. Direct fiberoptic laryngoscopy in a controlled environment (e.g., 
an operating room) may be performed for diagnosis, procurement of 
specimens for culture, and placement of an endotracheal tube. 
 
–  Treatment focuses on protection of the airway. After blood and epi-
glottis samples are obtained for cultures, IV antibiotics active against
H. influenzae (e.g., ampicillin/sulbactam or a second- or third-generation 
cephalosporin) should be given for 7–10 days.
INFECTIONS OF DEEP NECK STRUCTURES
These infections, which include Ludwig’s angina, Lemierre’s syndrome, and 
retropharyngeal abscess, are discussed in Chap. 101.
For a more detailed discussion, see Rubin MA et al: Pharyngitis, 
Sinusitis, Otitis, and Other Upper Respiratory Tract Infections, 
Chap. 31, p. 255, in HPIM-18.
363
CHAPTER 65
General Examination 
of the Skin
As dermatologic evaluation relies heavily on the objective cutaneous 
appearance, physical examination is often performed prior to taking a 
complete history in pts presenting with a skin problem. A differential diag-
nosis can usually be generated on the basis of a thorough examination with 
precise descriptions of the skin lesion(s) and narrowed with pertinent facts 
from the history. Laboratory or diagnostic procedures are then used, when 
appropriate, to clarify the diagnosis.
PHYSICAL EXAMINATION
Examination of skin should take place in a well-illuminated room with pt 
completely disrobed. Helpful ancillary equipment includes a hand lens and a 
pocket flashlight to provide peripheral illumination of lesions. An ideal exam-
ination includes evaluation of the skin, hair, nails and mucous membranes. 
The examination often begins with an assessment of the entire skin viewed at 
a distance, which is then narrowed down to focus on the individual lesions.
� DISTRIBUTION
As illustrated in Fig. 65-1, the distribution of skin lesions can provide 
valuable clues to the identification of the disorder: generalized (systemic 
diseases); sun-exposed (SLE, photoallergic, phototoxic, polymorphous light 
eruption, porphyria cutanea tarda); dermatomal (herpes zoster); extensor 
surfaces (elbows and knees in psoriasis); flexural surfaces (antecubital and 
popliteal fossae in atopic dermatitis).
� ARRANGEMENT AND SHAPE
Can describe individual or multiple lesions: Linear (contact dermatitis such 
as poison ivy); annular—“ring-shaped” lesion (erythema chronicum migrans, 
erythema annulare centrificum, tinea corporis); iris or target lesion—two or 
three concentric circles of differing hue (erythema multiforme); nummular—
“coin-shaped” (nummular eczema); morbilliform—“measles-like” with small 
confluent papules coalescing into unusual shapes (measles, drug eruption); 
herpetiform—grouped vesicles, papules, or erosions (herpes simplex).
� PRIMARY LESIONS 
Cutaneous changes caused directly by disease process (Table 65-1).
� SECONDARY LESIONS 
Changes in area of primary pathology often due to secondary events, e.g., 
scratching, secondary infection, bleeding (Table 65-2).
SECTION 5
Dermatology
SECTION 5
364
Dermatology
� OTHER DESCRIPTIVE TERMS 
Color, e.g., violaceous, erythematous; physical characteristics, e.g., warm, 
tender; sharpness of edge, surface contour—flat-topped, pedunculated (on 
a stalk), verrucous (wartlike), umbilicated (containing a central depression).
HISTORY
A complete history should be obtained, with special attention being paid to 
the following points:
1.  Evolution of the lesion—site of onset, manner in which eruption pro-
gressed or spread, duration, periods of resolution or improvement in 
chronic eruptions
2.  Symptoms associated with the eruption—itching, burning, pain, numbness; 
what has relieved symptoms; time of day when symptoms are most severe
3. Current or recent medications—both prescription and over-the-counter
4. Associated systemic symptoms (e.g., malaise, fatigue, arthralgias)
5. Ongoing or previous illnesses
Acne
vulgaris
Acne rosacea
Xanthelasma
Perleche
Seborrheic
dermatitis
Seborrheic
dermatitis
Seborrheic
dermatitis
Tinea pedis
Tinea pedis
Verruca plantaris
Atopic
dermatitis
Hand
eczema
Epidermal
inclusion
cyst
Lichen
planus
Pityriasis
rosea
Acne
vulgaris
Psoriasis
Psoriasis
Psoriasis
Psoriasis
Herpes
zoster
Skin tags
Seborrheic
keratoses
Senile
angioma
Keratosis
pilaris
Verrucae
vulgaris
Asteatotic
eczema
Lichen
simplex
chronicus
Atopic
dermatitis
Tinea or
Candida
cruris
Actinic
keratoses
Dermatofibroma
Statis ulcer
Statis dermatitis
Actinic
keratoses
Basal cell
carcinoma
Contact
dermatitis
Skin tags
Melasma
Herpes labialis
D
C
A
B
Leukoplakia
Squamous cell
carcinoma
Oral hairy
leukoplakia
Geographic
tongue
Aphthous
stomatitis
Lichen
planus
Perianal lesions
     Hemorrhoids
      Condyloma
      accuminata
     Herpes simplex
     Dermatitis
     Vitiligo
Dyshidrotic
eczema
Folliculitis
FIGURE 65-1 The distribution of some common dermatologic diseases and lesions. 
CHAPTER 65
365
General Examination of the Skin
365
TABLE 65-1 DESCRIPTION OF PRIMARY SKIN LESIONS
Macule: A flat, colored lesion, <2 cm in diameter, not raised above the 
surface of the surrounding skin. A “freckle,” or ephelid, is a prototype 
pigmented macule.
Patch: A large (>2 cm) flat lesion with a color different from the surrounding 
skin. This differs from a macule only in size.
Papule: A small, solid lesion, <0.5 cm in diameter, raised above the surface 
of the surrounding skin and hence palpable (e.g., a closed comedone, or 
whitehead, in acne).
Nodule: A larger (0.5–5.0 cm), firm lesion raised above the surface of the 
surrounding skin. This differs from a papule only in size (e.g., a dermal 
nevomelanocytic nevus).
Tumor: A solid, raised growth >5 cm in diameter.
Plaque: A large (>1 cm), flat-topped, raised lesion; edges may either be 
distinct (e.g., in psoriasis) or gradually blend with surrounding skin (e.g., in 
eczematous dermatitis).
Vesicle: A small, fluid-filled lesion, <0.5 cm in diameter, raised above the 
plane of surrounding skin. Fluid is often visible, and the lesions are trans-
lucent [e.g., vesicles in allergic contact dermatitis caused by Toxicodendron
(poison ivy)].
Pustule: A vesicle filled with leukocytes. Note: The presence of pustules 
does not necessarily signify the existence of an infection.
Bulla: A fluid-filled, raised, often translucent lesion >0.5 cm in diameter.
Wheal: A raised, erythematous, edematous papule or plaque, usually 
representing short-lived vasodilatation and vasopermeability.
Telangiectasia: A dilated, superficial blood vessel.
6. History of allergies
7. Presence of photosensitivity
8. Review of systems
9. Family history
10. Social, sexual, or travel history
ADDITIONAL DIAGNOSTIC PROCEDURES
� SKIN BIOPSY 
Minor surgical procedure. Choice of site very important.
� POTASSIUM HYDROXIDE PREPARATION 
Useful for detection of dermatophyte or yeast. Scale is collected from advanc-
ing edge of a scaling lesion by gently scraping with side of a microscope slide 
or a scalpel blade. Nail lesions are best sampled by trimming back nail and 
scraping subungual debris. A drop of 10–20% potassium hydroxide is added 
to slide, and coverslip is applied. The slide may be gently heated and exam-
ined under microscope. This technique can be utilized to identify hyphae 
in dermatophyte infections, pseudohyphae and budding yeast in Candida 
infections, and “spaghetti and meatballs” yeast forms in tinea versicolor.
SECTION 5
366
Dermatology
� TZANCK PREPARATION 
Useful for determining presence of herpes viruses (herpes simplex virus or 
herpes zoster virus). Optimal lesion to sample is an early vesicle. Lesion is 
gently unroofed with no. 15 scalpel blade, and base of vesicle is gently scraped 
with belly of blade (keep blade perpendicular to skin surface to prevent lacer-
ation). Scrapings are transferred to slide and stained with Wright’s or Giemsa 
stain. A positive preparation has multinucleated giant cells. Culture or immu-
nofluorescence testing must be performed to identify the specific virus.
� DIASCOPY 
Assesses whether a lesion blanches with pressure. Done by pressing a magni-
fying lens or microscope slide on lesion and observing changes in vascularity. 
For example, hemangiomas will usually blanch; purpuric lesions will not.
� WOOD’S LIGHT EXAMINATION 
Useful for detecting bacterial or fungal infection or accentuating features of 
some skin lesions.
� PATCH TESTS 
To document cutaneous sensitivity to specific antigen.
TABLE 65-2 DESCRIPTION OF SECONDARY SKIN LESIONS
Lichenification: A distinctive thickening of the skin that is characterized by 
accentuated skin-fold markings.
Scale: Excessive accumulation of stratum corneum.
Crust: Dried exudate of body fluids that may be either yellow (i.e., serous 
crust) or red (i.e., hemorrhagic crust).
Erosion: Loss of epidermis without an associated loss of dermis.
Ulcer: Loss of epidermis and at least a portion of the underlying dermis.
Excoriation: Linear, angular erosions that may be covered by crust and are 
caused by scratching.
Atrophy: An acquired loss of substance. In the skin, this may appear as a 
depression with intact epidermis (i.e., loss of dermal or subcutaneous tissue) 
or as sites of shiny, delicate, wrinkled lesions (i.e., epidermal atrophy).
Scar: A change in the skin secondary to trauma or inflammation. Sites 
may be erythematous, hypopigmented, or hyperpigmented depending on 
their age or character. Sites on hair-bearing areas may be characterized by 
destruction of hair follicles.
For a more detailed discussion, see Lawley TJ, Yancey KB: 
Approach to the Patient With a Skin Disorder, Chap. 51, p. 
389, in HPIM-18.
367
Common Skin Conditions
CHAPTER 66
CHAPTER 66
Common Skin Conditions
PAPULOSQUAMOUS DISORDERS
Disorders exhibiting papules and scale.
� PSORIASIS 
A chronic, recurrent disorder. Classic lesion is a well-marginated, 
erythematous plaque with silvery-white surface scale. Distribution 
includes extensor surfaces (i.e., knees, elbows, and buttocks); may also 
involve palms and scalp (particularly anterior scalp margin). Associated 
findings include psoriatic arthritis (Chap. 172) and nail changes 
(onycholysis, pitting or thickening of nail plate with accumulation of 
subungual debris).
Psoriasis
TREATMENT
Maintain cutaneous hydration; topical glucocorticoids; topical vitamin D 
analogue (calcipotriol) and retinoid (tazarotene); UV light (PUVA when 
UV used in combination with psoralens); for severe disease methotrexate 
or cyclosporine; acitretin can also be used but is teratogenic. Alefacept 
(dimeric fusion protein: LFA-3/Fc human IgG1), or ustekinumab (human 
monoclonal antibody that blocks IL-12 and IL-23) can be considered for 
chronic, moderate to severe plaque psoriasis. Etanercept (dimeric fusion 
protein: TNF receptor/Fc human IgG1), infliximab, and adalimumab 
(monoclonal antibodies directed against TNF) are approved for psoriatic 
arthritis and psoriasis.
� PITYRIASIS ROSEA 
A self-limited condition lasting 3–8 weeks. Initially, there is a single 2- to 
6-cm annular salmon-colored patch (herald patch) with a peripheral rim 
of scale, followed in days to weeks by a generalized eruption involving the 
trunk and proximal extremities. Individual lesions are similar to but smaller 
than the herald patch and are arranged in symmetric fashion with long axis 
of each individual lesion along skin lines of cleavage. Appearance may be 
similar to that of secondary syphilis.
Pityriasis Rosea
TREATMENT
Disorder is self-limited, so treatment is directed at symptoms; oral anti-
histamines for pruritus; topical glucocorticoids; UV-B phototherapy in 
some cases.
SECTION 5
368
Dermatology
� LICHEN PLANUS 
Disorder of unknown cause; can follow administration of certain drugs and 
in chronic graft-versus-host disease; lesions are pruritic, polygonal, flat-
topped, and violaceous. Course is variable, but most pts have spontaneous 
remissions 6–24 months after onset of disease.
Lichen Planus
TREATMENT
Topical glucocorticoids.
ECZEMATOUS DISORDERS
� ECZEMA 
Eczema, or dermatitis, is a reaction pattern that presents with variable clinical and 
histologic findings; it is the final common expression for a number of disorders.
� ATOPIC DERMATITIS 
One aspect of atopic triad of hayfever, asthma, and eczema. Usually an 
intermittent, chronic, severely pruritic, eczematous dermatitis with scaly 
erythematous patches, vesiculation, crusting, and fissuring. Lesions are 
most commonly on flexures, with prominent involvement of antecubital 
and popliteal fossae; generalized erythroderma in severe cases.
Eczema and Atopic Dermatitis
TREATMENT
Avoidance of irritants; cutaneous hydration; topical glucocorti-
coids; treatment of infected lesions [often with Staphylococcus aureus 
(SA)—consider community-acquired methicillin-resistant strains 
(CA-MRSA)]. Systemic glucocorticoids only for severe exacerbations 
unresponsive to topical conservative therapy.
� ALLERGIC CONTACT DERMATITIS 
A delayed hypersensitivity reaction that occurs after cutaneous exposure 
to an antigenic substance. Lesions occur at site of contact and are vesicular, 
weeping, crusting; linear arrangement of vesicles is common. Most frequent 
allergens are resin from plants of the genus Toxicodendron (poison ivy, oak, 
sumac), nickel, rubber, and cosmetics.
Allergic Contact Dermatitis
TREATMENT
Avoidance of sensitizing agent; topical glucocorticoids; consideration of 
systemic glucocorticoids over 2–3 weeks for widespread disease.
� IRRITANT CONTACT DERMATITIS 
Inflammation of the skin due to direct injury by an exogenous agent. The 
most common area of involvement is the hands, where dermatitis is initi-
ated or aggravated by chronic exposure to water and detergents. Features 
may include skin dryness, cracking, erythema, edema.
369
Irritant Contact Dermatitis
TREATMENT
Avoidance of irritants; barriers (use of protective gloves); topical gluco-
corticoids; treatment of secondary bacterial or dermatophyte infection.
� SEBORRHEIC DERMATITIS 
A chronic noninfectious process characterized by erythematous patches 
with greasy yellowish scale. Lesions are generally on scalp, eyebrows, naso-
labial folds, axillae, central chest, and posterior auricular area.
Seborrheic Dermatitis
TREATMENT
Nonfluorinated topical glucocorticoids; shampoos containing coal tar, 
salicylic acid, or selenium sulfide.
INFECTIONS
� IMPETIGO 
A superficial infection of skin secondary to either S. aureus or group A 
β-hemolytic streptococci. The primary lesion is a superficial pustule that 
ruptures and forms a “honey-colored” crust. Tense bullae are associated 
with S. aureus infections (bullous impetigo). Lesions may occur anywhere 
but commonly involve the face. Impetigo and furunculosis (painful ery-
thematous nodule, or boil) have gained prominence because of increasing 
incidence of CA-MRSA.
Impetigo
TREATMENT
Gentle debridement of adherent crusts with soaks and topical antibiotics; 
appropriate oral antibiotics depending on organism (Chap. 86).
� ERYSIPELAS 
Superficial cellulitis, most commonly on face, characterized by a bright red, 
sharply demarcated, intensely painful, warm plaque. Because of superficial 
location of infection and associated edema, surface of plaque may exhibit a peau 
d’orange (orange peel) appearance. Most commonly due to infection with group 
A β-hemolytic streptococci, occurring at sites of trauma or other breaks in skin.
Erysipelas
TREATMENT
Appropriate antibiotics depending on organism (Chap. 86).
� HERPES SIMPLEX (SEE ALSO CHAP. 108)
Recurrent eruption characterized by grouped vesicles on an erythematous 
base that progress to erosions; often secondarily infected with staphylococci 
or streptococci. Infections frequently involve mucocutaneous surfaces 
Common Skin Conditions
CHAPTER 66
SECTION 5
370
Dermatology
around the oral cavity, genitals, or anus. Can also cause severe visceral 
disease including esophagitis, pneumonitis, encephalitis, and disseminated 
herpes simplex virus infection. Tzanck preparation of an unroofed early 
vesicle reveals multinucleated giant cells.
Herpes Simplex
TREATMENT
Will differ based on disease manifestations and level of immune com-
petence (Chap. 108); appropriate antibiotics for secondary infections, 
depending on organism.
� HERPES ZOSTER (SEE ALSO CHAP. 108)
Eruption of grouped vesicles on an erythematous base usually limited to a 
single dermatome (“shingles”); disseminated lesions can also occur, especially 
in immunocompromised pts. Tzanck preparation reveals multinucleated giant 
cells; indistinguishable from herpes simplex except by culture. Postherpetic 
neuralgia, lasting months to years, may occur, especially in the elderly.
Herpes Zoster
TREATMENT
Will differ based on disease manifestations and level of immune compe-
tence (Chap. 108).
� DERMATOPHYTE INFECTION 
Skin fungus, may involve any area of body; due to infection of stratum cor-
neum, nail plate, or hair. Appearance may vary from mild scaliness to florid 
inflammatory dermatitis. Common sites of infection include the foot (tinea 
pedis), nails (tinea unguium), groin (tinea cruris), or scalp (tinea capitis). 
Classic lesion of tinea corporis (“ringworm”) is an erythematous papu-
losquamous patch, often with central clearing and scale along peripheral 
advancing border. Hyphae are often seen on KOH preparation, although 
tinea capitis and tinea corporis may require culture or biopsy.
Dermatophyte Infection
TREATMENT
Depends on affected site and type of infection. Topical imidazoles, tri-
azoles, and allylamines may be effective. Haloprogin, undecylenic acid, 
ciclopirox olamine, and tolnaftate are also effective, but nystatin is not 
active against dermatophytes. Griseofulvin, 500 mg/d, if systemic therapy 
required. Itraconazole or terbinafine may be effective for nail infections.
� CANDIDIASIS 
Fungal infection caused by a related group of yeasts. Manifestations may be 
localized to the skin or rarely systemic and life-threatening. Predisposing 
factors include diabetes mellitus, cellular immune deficiencies, and HIV 
(Chap. 114). Frequent sites include the oral cavity, chronically wet macerated 
371
areas, around nails, intertriginous areas. Diagnosed by clinical pattern and 
demonstration of yeast on KOH preparation or culture.
Candidiasis
TREATMENT
(See also Chap. 115) Removal of predisposing factors; topical nystatin or 
azoles; systemic therapy reserved for immunosuppressed pts, unrespon-
sive chronic or recurrent disease; vulvovaginal candidiasis may respond 
to a single dose of fluconazole, 150 mg.
� WARTS 
Cutaneous neoplasms caused by human papilloma viruses (HPVs). Typically 
dome-shaped lesions with irregular filamentous surface. Propensity for the 
face, arms, and legs; often spread by shaving. HPVs are also associated with 
genital or perianal lesions and play a role in the development of cancer of 
the uterine cervix and external genitalia in females (Chap. 92).
Warts
TREATMENT
Cryotherapy with liquid nitrogen, keratinolytic agents (salicylic acid). For 
genital warts, application of podophyllin solution is effective but can be asso-
ciated with marked local reactions; topical imiquimod also has been used.
ACNE
� ACNE VULGARIS 
Usually a self-limited disorder of teenagers and young adults. Comedones 
(small cysts formed in hair follicles) are clinical hallmark; often accompanied by 
inflammatory lesions of papules, pustules, or nodules. May scar in severe cases.
Acne Vulgaris
TREATMENT
Careful cleaning and removal of oils; oral tetracycline or erythromycin; topical 
antibacterials (e.g., benzoyl peroxide), topical retinoic acid. Systemic isotreti-
noin only for unresponsive severe nodulocystic acne (risk of severe adverse 
events including teratogenicity and possible association with depression).
� ACNE ROSACEA 
Inflammatory disorder affecting predominantly the central face, rarely 
affecting pts <30 years of age. Tendency toward exaggerated flushing, with 
eventual superimposition of papules, pustules, and telangiectases. May lead 
to rhinophyma and ocular problems.
Acne Rosacea
TREATMENT
Oral tetracycline, 250–1000 mg/d; topical metronidazole and topical 
nonfluorinated glucocorticoids may be useful.
Common Skin Conditions
CHAPTER 66
SECTION 5
372
Dermatology
VASCULAR DISORDERS
� ERYTHEMA NODOSUM 
Septal panniculitis characterized by erythematous, warm, tender subcu-
taneous nodular lesions typically over anterior tibia. Lesions are usually 
flush with skin surface but are indurated and have appearance of an ery-
thematous/violaceous bruise. Lesions usually resolve spontaneously in 3–6 
weeks without scarring. Commonly seen in sarcoidosis, administration of 
certain drugs (esp. sulfonamides, oral contraceptives, and estrogens), and 
a wide range of infections including streptococcal and tubercular; may be 
idiopathic. 
Erythema Nodosum
TREATMENT
Identification and treatment/removal of underlying cause. NSAIDs for 
severe or recurrent lesions; systemic glucocorticoids are effective but 
dangerous if underlying infection is not appreciated.
� ERYTHEMA MULTIFORME 
A reaction pattern of skin consisting of a variety of lesions but most com-
monly erythematous papules and bullae. “Target” or “iris” lesion is char-
acteristic and consists of concentric circles of erythema and normal flesh-
colored skin, often with a central vesicle or bulla.
Distribution of lesions classically acral, esp. palms and soles. Three 
most common causes are drug reaction (particularly penicillins and sul-
fonamides) or concurrent herpetic or Mycoplasma infection. Can rarely 
affect mucosal surfaces and internal organs (erythema multiforme major or 
Stevens-Johnson syndrome).
Erythema Multiforme
TREATMENT
Provocative agent should be sought and eliminated if drug-related. In 
mild cases limited to skin, only symptomatic treatment is needed (anti-
histamines, NSAID). For Stevens-Johnson, systemic glucocorticoids 
have been used but are controversial; prevention of secondary infection 
and maintenance of nutrition and fluid/electrolyte balance are critical.
� URTICARIA 
A common disorder, either acute or chronic, characterized by evanescent 
(individual lesions lasting <24 h), pruritic, edematous, pink to erythema-
tous plaques with a whitish halo around margin of individual lesions. 
Lesions range in size from papules to giant coalescent lesions (10–20 cm in 
diameter). Often due to drugs, systemic infection, or foods (esp. shellfish). 
Food additives such as tartrazine dye (FD&C yellow no. 5), benzoate, or 
salicylates have also been implicated. If individual lesions last >24 h, con-
sider diagnosis of urticarial vasculitis.
373
Urticaria
TREATMENT
See Chap. 167.
� VASCULITIS 
Palpable purpura (nonblanching, elevated lesions) is the cutaneous hall-
mark of vasculitis. Other lesions include petechiae (esp. early lesions), 
necrosis with ulceration, bullae, and urticarial lesions (urticarial vasculitis). 
Lesions usually most prominent on lower extremities. Associations include 
infections, collagen-vascular disease, primary systemic vasculitides, malig-
nancy, hepatitis B and C, drugs (esp. thiazides), and inflammatory bowel 
disease. May occur as an idiopathic, predominantly cutaneous vasculitis.
Vasculitis
TREATMENT
Will differ based on cause. Pursue identification and treatment/elimina-
tion of an exogenous cause or underlying disease. If part of a systemic 
vasculitis, treat based on major organ-threatening features (Chap. 170). 
Immunosuppressive therapy should be avoided in idiopathic, predomi-
nantly cutaneous vasculitis as disease frequently does not respond and 
rarely causes irreversible organ system dysfunction.
CUTANEOUS DRUG REACTIONS
Cutaneous reactions are among the most frequent medication toxicities. 
These can have a wide range of severity and manifestations including 
urticaria, photosensitivity, erythema multiforme, fixed drug reactions, 
erythema nodosum, vasculitis, lichenoid reactions, bullous drug reac-
tions, Stevens-Johnson syndrome, and toxic epidermal necrolysis (TEN). 
Diagnosis is usually made by appearance and careful medication history.
Cutaneous Drug Reactions
TREATMENT
Withdrawal of the medication. Treatment based on nature and severity 
of cutaneous pathology.
For a more detailed discussion, see Lawley LP, McCall CO, 
Lawley TJ: Eczema, Psoriasis, Cutaneous Infections, Acne, and 
Other Common Skin Disorders, Chap. 52, p. 395; Shinkai K, 
Stern RS, Wintroub BU: Cutaneous Drug Reactions, Chap. 55, 
p. 432; and Bolognia JL, Braverman IM: Skin Manifestations of 
Internal Disease, Chap. 53, p. 405, in HPIM-18.
Common Skin Conditions
CHAPTER 66
This page intentionally left blank 
375
CHAPTER 67
Examination of Blood 
Smears and Bone Marrow
BLOOD SMEARS
� ERYTHROCYTE (RBC) MORPHOLOGY
• Normal: 7.5-μm diameter. Roughly the size of the nucleus of a small 
lymphocyte.
• Reticulocytes (Wright’s stain)—large, grayish-blue, admixed with pink 
(polychromasia).
• Anisocytosis—variation in RBC size; large cells imply delay in erythroid 
precursor DNA synthesis caused by folate or B12 deficiency or drug effect; 
small cells imply a defect in hemoglobin synthesis caused by iron defi-
ciency or abnormal hemoglobin genes.
• Poikilocytosis—abnormal RBC shapes; the following are examples:
1. Acanthocytes (spur cells)—irregularly spiculated; abetalipoprotein-
emia, severe liver disease, rarely anorexia nervosa.
2. Echinocytes (burr cells)—regularly shaped, uniformly distributed 
spiny projections; uremia, RBC volume loss.
3. Elliptocytes—elliptical; hereditary elliptocytosis.
4. Schistocytes (schizocytes)—fragmented cells of varying sizes and 
shapes; microangiopathic or macroangiopathic hemolytic anemia.
5. Sickled cells—elongated, crescentic; sickle cell anemias.
6. Spherocytes—small hyperchromic cells lacking normal central pallor; 
hereditary spherocytosis, extravascular hemolysis as in autoimmune 
hemolytic anemia, G6PD deficiency.
7. Target cells—central and outer rim staining with intervening ring of 
pallor; liver disease, thalassemia, hemoglobin C and sickle C diseases.
8. Teardrop cells—myelofibrosis, other infiltrative processes of marrow 
(e.g., carcinoma).
9. Rouleaux formation—alignment of RBCs in stacks; may be artifactual or 
due to paraproteinemia (e.g., multiple myeloma, macroglobulinemia).
� RBC INCLUSIONS
• Howell-Jolly bodies—1-μm-diameter basophilic cytoplasmic inclusion 
that represents a residual nuclear fragment, usually single; asplenic pts.
• Basophilic stippling—multiple, punctate basophilic cytoplasmic inclusions 
composed of precipitated mitochondria and ribosomes; lead poisoning, 
thalassemia, myelofibrosis.
SECTION 6
Hematology and Oncology
SECTION 6
376
Hematology and Oncology
• Pappenheimer (iron) bodies—iron-containing granules usually composed 
of mitochondria and ribosomes resemble basophilic stippling but also 
stain with Prussian blue; lead poisoning, other sideroblastic anemias.
• Heinz bodies—spherical inclusions of precipitated hemoglobin seen only 
with supravital stains, such as crystal violet; G6PD deficiency (after oxi-
dant stress such as infection, certain drugs), unstable hemoglobin variants.
• Parasites—characteristic intracytoplasmic inclusions; malaria, babesiosis.
� LEUKOCYTE INCLUSIONS AND NUCLEAR CONTOUR ABNORMALITIES
• Toxic granulations—dark cytoplasmic granules; bacterial infection.
• Döhle bodies—1- to 2-μm blue, oval cytoplasmic inclusions; bacterial 
infection, Chédiak-Higashi anomaly.
• Auer rods—eosinophilic, rodlike cytoplasmic inclusions; acute myeloid 
leukemia (some cases).
• Hypersegmentation—neutrophil nuclei contain more than the usual 2–4 
lobes; usually >5% have ≥5 lobes or a single cell with 7 lobes is adequate 
to make the diagnosis; folate or B12 deficiency, drug effects.
• Hyposegmentation—neutrophil nuclei contain fewer lobes than normal, 
either one or two: Pelger-Hüet anomaly, pseudo-Pelger-Hüet or acquired 
Pelger-Hüet anomaly in acute leukemia.
� PLATELET ABNORMALITIES
• Platelet clumping—an in vitro artifact—is often readily detectable on 
smear; can lead to falsely low platelet count by automated cell counters.
• Giant platelets—can be a sign of a very young platelet or increased platelet 
production or abnormal karyocyte maturation; if the platelets are >5-6 μm 
in diameter, they may not be counted as platelets by electronic counters.
BONE MARROW
Aspiration assesses cell morphology. Biopsy assesses overall marrow archi-
tecture, including degree of cellularity. Biopsy should precede aspiration to 
avoid aspiration artifact (mainly hemorrhage) in the specimen.
� INDICATIONS
Aspiration
Hypoproliferative or unexplained anemia, leukopenia, or thrombocytopenia, 
suspected leukemia or myeloma or marrow defect, evaluation of iron stores, 
workup of some cases of fever of unknown origin.
Special Tests 
Histochemical staining (leukemias), cytogenetic studies (leukemias, lympho-
mas), microbiology (bacterial, mycobacterial, fungal cultures), Prussian blue 
(iron) stain (assessment of iron stores, diagnosis of sideroblastic anemias).
Biopsy
Performed in addition to aspiration for pancytopenia (aplastic anemia), 
metastatic tumor, granulomatous infection (e.g., mycobacteria, brucel-
losis, histoplasmosis), myelofibrosis, lipid storage disease (e.g., Gaucher’s, 
Niemann-Pick), any case with “dry tap” on aspiration; evaluation of marrow 
cellularity. When biopsy and aspirate are both planned, the biopsy should 
CHAPTER 68 
377
Red Blood Cell Disorders
be performed first because of the risk of bleeding artifact from biopsy of an 
aspiration site.
Special Tests 
Histochemical staining (e.g., acid phosphatase for metastatic prostate car-
cinoma), immunoperoxidase staining (e.g., immunoglobulin or cell surface 
marker detection in multiple myeloma, leukemia, or lymphoma; lysozyme 
detection in monocytic leukemia), reticulin staining (increased in myelo-
fibrosis), microbiologic staining (e.g., acid-fast staining for mycobacteria).
� INTERPRETATION
Cellularity
Defined as percentage of space occupied by hematopoietic cells. The space that 
is not hematopoietic tissue is usually fat. Cellularity decreases with age after 
age 65 years from about 50% to 25–30% with a corresponding increase in fat.
Erythroid:Granulocytic (E:G) Ratio 
Normally about 1:2, the E:G ratio is decreased in acute and chronic infec-
tion, leukemoid reactions (e.g., chronic inflammation, metastatic tumor), 
acute and chronic myeloid leukemia, myelodysplastic disorders (“preleu-
kemia”), and pure red cell aplasia; increased in agranulocytosis, anemias 
with erythroid hyperplasia (megaloblastic, iron-deficiency, thalassemia, 
hemorrhage, hemolysis, sideroblastic), and erythrocytosis (excessive RBC 
production); normal in aplastic anemia (though marrow hypocellular), 
myelofibrosis (marrow hypocellular), multiple myeloma, lymphoma, ane-
mia of chronic disease. Some centers use the term M:E (myeloid to ery-
throid) ratio; normal value is 2:1 and increases with diseases that promote 
myeloid activity or inhibit erythroid activity and decreases with diseases 
that inhibit myeloid activity or promote erythroid activity.
For a more detailed discussion, see Adamson JW, Longo DL: 
Anemia and Polycythemia, Chap. 57, p. 448; Holland SM, 
Gallin JI: Disorders of Granulocytes and Monocytes, Chap. 
60, p. 472; Longo DL: Atlas of Hematology and Analysis of 
Peripheral Blood Smears, Chap. e17 in HPIM-18 .
CHAPTER 68
Red Blood Cell Disorders
Anemia is a common clinical problem in medicine. A physiologic approach 
(outlined in Chap. 51) provides the most efficient path to diagnosis and 
management. Anemias arise either because red blood cell (RBC) produc-
tion is inadequate or because RBC lifespan (normally 120 days) is shortened 
through loss from the circulation or destruction.
SECTION 6
378
Hematology and Oncology
HYPOPROLIFERATIVE ANEMIAS
These are the most common anemias. Usually the RBC morphology is 
normal and the reticulocyte index (RI) is low. Marrow damage, early iron 
deficiency, and decreased erythropoietin production or action may produce 
anemia of this type.
Marrow damage may be caused by infiltration of the marrow with tumor 
or fibrosis that crowds out normal erythroid precursors or by the absence of 
erythroid precursors (aplastic anemia) as a consequence of exposure to drugs, 
radiation, chemicals, viruses (e.g., hepatitis), autoimmune mechanisms, or 
genetic factors, either hereditary (e.g., Fanconi’s anemia) or acquired (e.g., 
paroxysmal nocturnal hemoglobinuria). Most cases of aplasia are idiopathic. 
The tumor or fibrosis that infiltrates the marrow may originate in the marrow 
(as in leukemia or myelofibrosis) or be secondary to processes originating 
outside the marrow (as in metastatic cancer or myelophthisis).
Early iron-deficiency anemia (or iron-deficient erythropoiesis) is associ-
ated with a decrease in serum ferritin levels (<15 μg/L), moderately elevated 
Microcytic
hypochromic
0
<15
>400
<30
<10
<10
>200
Microcytic/
hypochromic
Iron-
deficiency
anemia
0
<15
>380
<50
<20
<10
>100
NL
Iron-
deficient
erythropoiesis
1-3+
50-200
300-360
50-150
30-50
40-60
30-50
NL
Normal
0-1+
<20
>360
NL
NL
NL
NL
NL
Negative
iron
balance
Iron stores
Erythron iron
Marrow iron
stores
RBC
protoporphyrin
(μg/dL)
Saturation (%)
Marrow
sideroblasts (%)
RBC
morphology
TIBC (μg/dL)
SI (μg/dL)
Serum ferritin
(μg/L)
FIGURE 68-1 Measurements of marrow iron stores, serum ferritin, and total iron-
binding capacity (TIBC) are sensitive to early iron-store depletion. Iron-deficient eryth-
ropoiesis is recognized from additional abnormalities in the serum iron (SI), percent 
transferrin saturation, the pattern of marrow sideroblasts, and the red cell protopor-
phyrin level. Pts with iron-deficiency anemia demonstrate all the same abnormalities 
plus hypochromic microcytic anemia. (From RS Hillman, CA Finch: Red Cell Manual, 
7th. ed, Philadelphia, Davis, 1996, with permission.)
CHAPTER 68 
379
Red Blood Cell Disorders
total iron-binding capacity (TIBC) (>380 μg/dL), serum iron (SI) level 
<50 μg/dL, and an iron saturation of <30% but >10% (Fig. 68-1). RBC 
morphology is generally normal until iron deficiency is severe (see below).
Decreased stimulation of erythropoiesis can be a consequence of inad-
equate erythropoietin production [e.g., renal disease destroying the renal 
tubular cells that produce it or hypometabolic states (endocrine deficiency 
or protein starvation) in which insufficient erythropoietin is produced] or of 
inadequate erythropoietin action. The anemia of chronic disease is a com-
mon entity. It is multifactorial in pathogenesis: inhibition of erythropoietin 
production, inhibition of iron reutilization (which blocks the response to 
erythropoietin), and inhibition of erythroid colony proliferation by inflam-
matory cytokines (e.g., tumor necrosis factor, interferon γ). Hepcidin, a 
small iron-binding molecule produced by the liver during an acute-phase 
inflammatory response, may bind iron and prevent its reutilization in 
hemoglobin synthesis. The laboratory tests shown in Table 68-1 may assist 
in the differential diagnosis of hypoproliferative anemias. Measurement of 
hepcidin in the urine is not yet practical or widely available.
MATURATION DISORDERS
These result from either defective hemoglobin synthesis, leading to cyto-
plasmic maturation defects and small relatively empty red cells, or abnor-
mally slow DNA replication, leading to nuclear maturation defects and 
large full red cells. Defects in hemoglobin synthesis usually result from 
insufficient iron supply (iron deficiency) or decreased globin production 
(thalassemia) or are idiopathic (sideroblastic anemia). Defects in DNA 
synthesis are usually due to nutritional problems (vitamin B12 and folate 
deficiency), toxic (methotrexate or other cancer chemotherapeutic agent) 
exposure, or intrinsic marrow maturation defects (refractory anemia, 
myelodysplasia).
TABLE 68-1 DIAGNOSIS OF HYPOPROLIFERATIVE ANEMIAS
Tests
Iron
Deficiency
Inflammation
Renal
Disease
Hypometabolic
States
Anemia
Mild to 
severe
Mild
Mild to 
severe
Mild
MCV (fL)
60–90
80–90
90
90
Morphology
Normo-
microcytic
Normocytic
Normocytic
Normocytic
SI
<30
<50
Normal
Normal
TIBC
>360
<300
Normal
Normal
Saturation (%)
<10
10–20
Normal
Normal
Serum ferritin 
(μg/L)
<15
30–200
115–150
Normal
Iron stores
0
2–4+
1–4+
Normal
Abbreviations: MCV, mean corpuscular volume; SI, serum iron; TIBC, total iron-binding capacity.
SECTION 6
380
Hematology and Oncology
Laboratory tests useful in the differential diagnosis of the microcytic ane-
mias are shown in Table 68-2. Mean corpuscular volume (MCV) is generally 
60–80 fL. Increased lactate dehydrogenase (LDH) and indirect bilirubin lev-
els suggest an increase in RBC destruction and favor a cause other than iron 
deficiency. Iron status is best assessed by measuring SI, TIBC, and ferritin 
levels. Macrocytic MCVs are >94 fL. Folate status is best assessed by measur-
ing red blood cell folate levels. Vitamin B12 status is best assessed by measur-
ing serum B12, homocysteine, and methylmalonic acid levels. Homocysteine 
and methylmalonic acid levels are elevated in the setting of B12 deficiency.
ANEMIA DUE TO RBC DESTRUCTION OR ACUTE BLOOD LOSS
� BLOOD LOSS 
Trauma, GI hemorrhage (may be occult) are common causes; less common 
are genitourinary sources (menorrhagia, gross hematuria), internal bleed-
ing such as intraperitoneal from spleen or organ rupture, retroperitoneal, 
iliopsoas hemorrhage (e.g., in hip fractures). Acute bleeding is associated 
with manifestations of hypovolemia, reticulocytosis, macrocytosis; chronic 
bleeding is associated with iron deficiency, hypochromia, microcytosis.
� HEMOLYSIS 
Causes are listed in Table 68-3.
1. Intracellular RBC abnormalities—most are inherited enzyme defects 
[glucose-6-phosphate dehydrogenase (G6PD) deficiency > pyruvate 
kinase deficiency], hemoglobinopathies, sickle cell anemia and variants, 
thalassemia, unstable hemoglobin variants.
2. G6PD deficiency—leads to episodes of hemolysis precipitated by inges-
tion of drugs that induce oxidant stress on RBCs. These include 
TABLE 68-2 DIAGNOSIS OF MICROCYTIC ANEMIA
Tests
Iron
Deficiency
Inflammation
Thalassemia
Sideroblastic
Anemia
Smear
Micro/hypo
Normal micro/
hypo
Micro/hypo with 
targeting
Variable
SI
<30
<50
Normal to high
Normal to high
TIBC
>360
<300
Normal
Normal
Percent 
saturation
<10
10–20
30–80
30–80
Ferritin 
(μg/L)
<15
30–200
50–300
50–300
Hemoglobin
pattern on 
electropho-
resis
Normal
Normal
Abnormal with 
β thalassemia; 
can be normal 
with α
thalassemia
Normal
Abbreviations: SI, serum iron; TIBC, total iron-binding capacity.
CHAPTER 68 
381
Red Blood Cell Disorders
antimalarials (chloroquine), sulfonamides, analgesics (phenacetin), and 
other miscellaneous drugs (Table 68 -4).
3. Sickle cell anemia—characterized by a single-amino-acid change in β globin 
(valine for glutamic acid in the 6th residue) that produces a molecule of 
decreased solubility, especially in the absence of O2. Although anemia and 
chronic hemolysis are present, the major disease manifestations relate to 
vasoocclusion from misshapen sickled RBCs. Infarcts in lung, bone, spleen, 
retina, brain, and other organs lead to symptoms and dysfunction (Fig. 68-2).
4. Membrane abnormalities (rare)—spur cell anemia (cirrhosis, anorexia 
nervosa), paroxysmal nocturnal hemoglobinuria, hereditary spherocy-
tosis (increased RBC osmotic fragility, spherocytes), hereditary ellipto-
cytosis (causes mild hemolytic anemia).
5. Immunohemolytic anemia (positive Coombs’ test, spherocytes). Two 
types: (a) warm antibody (usually IgG)—idiopathic, lymphoma, chronic 
lymphocytic leukemia, systemic lupus erythematosus, drugs (e.g., meth-
yldopa, penicillins, quinine, quinidine, isoniazid, sulfonamides); and (b) 
cold antibody—cold agglutinin disease (IgM) due to Mycoplasma infec-
tion, infectious mononucleosis, lymphoma, idiopathic; paroxysmal cold 
hemoglobinuria (IgG) due to syphilis, viral infections.
6. Mechanical trauma (macro- and microangiopathic hemolytic anemias; 
schistocytes)—prosthetic heart valves, vasculitis, malignant hyperten-
sion, eclampsia, renal graft rejection, giant hemangioma, scleroderma, 
thrombotic thrombocytopenic purpura, hemolytic-uremic syndrome, 
disseminated intravascular coagulation, march hemoglobinuria (e.g., 
marathon runners, bongo drummers).
TABLE 68-3 CLASSIFICATION OF HEMOLYTIC ANEMIASa
Intracorpuscular Defects
Extracorpuscular Factors
Hereditary
Hemoglobinopathies
Enzymopathies
Membrane-cytoskeletal defects
Familial (atypical) hemolytic 
uremic syndrome
Acquired
Paroxysmal nocturnal 
hemoglobinuria (PNH)
Mechanical destruction 
(microangiopathic)
Toxic agents
Drugs
Infectious
Autoimmune
aHereditary causes correlate with intracorpuscular defects because these defects are due 
to inherited mutations. The one exception is PNH because the defect is due to an acquired 
somatic mutation. Similarly, acquired causes correlate with extracorpuscular factors because 
mostly these factors are exogenous. The one exception is familial hemolytic uremic syndrome 
(HUS; often referred to as atypical HUS) because here an inherited abnormality allows comple-
ment activation to be excessive, with bouts of production of membrane attack complex 
capable of destroying normal red cells.
SECTION 6
382
Hematology and Oncology
TABLE 68-4  DRUGS THAT CARRY RISK OF CLINICAL HEMOLYSIS IN 
PERSONS WITH G6PD DEFICIENCY
Definite Risk
Possible Risk
Doubtful Risk
Antimalarials
Primaquine
Dapsone/chlorpro-
guanila
Chloroquine
Quinine
Sulphonamides/
sulphones
Sulfamethoxazole
Others
Dapsone
Sulfasalazine
Sulfadimidine
Sulfisoxazole
Sulfadiazine
Antibacterial/
antibiotics
Cotrimoxazole
Nalidixic acid
Nitrofurantoin
Niridazole
Ciprofloxacin
Norfloxacin
Chloramphenicol
p-Aminosalicylic 
acid
Antipyretic/
analgesics
Acetanilide
Phenazopyridine
Acetylsalicylic acid 
high dose (>3 g/d)
Acetylsalicylic 
acid (<3 g/d)
Acetaminophen
Phenacetin
Other
Naphthalene
Methylene blue
Vitamin K 
analogues
Ascorbic acid >1 g
Rasburicase
Doxorubicin
Probenecid
aMarketed as Lapdap from 2003 to 2008.
Arterial PO2
  oxy Hbs (soluble)
Capillary venous PO2
 deoxy Hbs (polymerized)
Stiff, viscous sickle cell
Membrane changes Ca2+
 influx, K leakage
Capillary venule
occlusion
Shortened red cell survival
 (hemolytic anemia)
Microinfarction
Ischemic tissue pain
Ischemic organ malfunction
Autoinfarction of spleen
Anemia, Jaundice,
Gallstones, Leg ulcers
FIGURE 68-2 Pathophysiology of sickle cell crisis. 
CHAPTER 68 
383
Red Blood Cell Disorders
7. Direct toxic effect—infections (e.g., malaria, Clostridium perfringens 
toxin, toxoplasmosis).
8. Hypersplenism (pancytopenia may be present).
� LABORATORY ABNORMALITIES 
Elevated reticulocyte index, polychromasia and nucleated RBCs on smear; 
also spherocytes, elliptocytes, schistocytes, or target, spur, or sickle cells 
may be present depending on disorder; elevated unconjugated serum bili-
rubin and LDH, elevated plasma hemoglobin, low or absent haptoglobin; 
urine hemosiderin present in intravascular but not extravascular hemolysis, 
Coombs’ test (immunohemolytic anemias), osmotic fragility test (heredi-
tary spherocytosis), hemoglobin electrophoresis (sickle cell anemia, thalas-
semia), G6PD assay (best performed after resolution of hemolytic episode 
to prevent false-negative result).
Anemia
TREATMENT
GENERAL APPROACHES The acuteness and severity of the anemia deter-
mine whether transfusion therapy with packed RBCs is indicated. Rapid 
occurrence of severe anemia (e.g., after acute GI hemorrhage resulting 
in Hct <25%, following volume repletion) or development of angina or 
other symptoms is an indication for transfusion. Hct should increase 
3–4% [Hb by 10 g/L (1 g/dL)] with each unit of packed RBCs, assuming 
no ongoing losses. Chronic anemia (e.g., vitamin B12 deficiency), even 
when severe, may not require transfusion therapy if the pt is compen-
sated and specific therapy (e.g., vitamin B12) is instituted.
SPECIFIC DISORDERS
1. Iron deficiency: find and treat cause of blood loss, oral iron (e.g., FeSO4 
300 mg tid).
2. Folate deficiency: common in malnourished, alcoholics; less common 
now than before folate food supplementation; folic acid 1 mg PO qd 
(5 mg qd for pts with malabsorption).
3. Vitamin B12 deficiency: can be managed either with parenteral vitamin B12 
100 μg IM qd for 7 d, then 100–1000 μg IM per month or with 2 mg oral 
crystalline vitamin B12 per day. An inhaled formulation is also available.
4. Anemia of chronic disease: treat underlying disease; in uremia use 
recombinant human erythropoietin, 50–150 U/kg three times a week; 
role of erythropoietin in other forms of anemia of chronic disease is 
less clear; response more likely if serum erythropoietin levels are low. 
Target Hb 9–10 g/dL.
5. Sickle cell anemia: hydroxyurea 10–30 mg/kg per day PO increases 
level of HbF and prevents sickling, treat infections early, supplemental 
folic acid; painful crises treated with oxygen, analgesics (opioids), 
hydration, and hypertransfusion; consider allogeneic bone marrow 
transplantation in pts with increasing frequency of crises.
6. Thalassemia: transfusion to maintain Hb >90 g/L (>9 g/dL), folic 
acid, prevention of Fe overload with deferoxamine (parenteral) or
SECTION 6
384
Hematology and Oncology
 
deferasirox (oral) chelation; consider splenectomy and allogeneic bone 
marrow transplantation.
7. Aplastic anemia: antithymocyte globulin and cyclosporine leads to 
improvement in 70%, bone marrow transplantation in young pts with 
a matched donor.
8. Autoimmune hemolysis: glucocorticoids, sometimes immunosuppressive 
agents, danazol, plasmapheresis, rituximab.
9. G6PD deficiency: avoid agents known to precipitate hemolysis.
For a more detailed discussion, see Adamson JW, Chap. 
103; Benz EJ, Chap. 104; Hoffbrand AV, Chap. 105; Luzzato 
L, Chap. 106; Young NS, Chap. 107; pp. 844–897, in 
HPIM-18.
CHAPTER 69
Leukocytosis and Leukopenia
LEUKOCYTOSIS
Leukocytosis
APPROACH TO THE
PATIENT
Review smear (? abnormal cells present) and obtain differential count. 
The normal values for concentration of blood leukocytes are shown in 
Table 69-1.
� NEUTROPHILIA
Absolute neutrophil count (polys and bands) >10,000/μL. The pathophysi-
ology of neutrophilia involves increased production, increased marrow 
mobilization, or decreased margination (adherence to vessel walls).
TABLE 69-1 NORMAL VALUES FOR LEUKOCYTE CONCENTRATION IN BLOOD
Cell Type
Mean, cells/μL
95% Confidence 
Intervals, cells/μL
Total WBC, %
Neutrophil
3650
1830–7250
30–60%
Lymphocyte
2500
1500–4000
20–50%
Monocyte
430
200–950
2–10%
Eosinophil
150
0–700
0.3–5%
Basophil
30
0–150
0.6–1.8%
CHAPTER 69 
385
Leukocytosis and Leukopenia
Causes
(1) Exercise, stress; (2) infections—esp. bacterial; smear shows increased 
numbers of immature neutrophils (“left shift”), toxic granulations, Döhle 
bodies; (3) burns; (4) tissue necrosis (e.g., myocardial, pulmonary, renal 
infarction); (5) chronic inflammatory disorders (e.g., gout, vasculitis); (6) 
drugs (e.g., glucocorticoids, epinephrine, lithium); (7) cytokines [e.g., granu-
locyte colony-stimulating factor (G-CSF), granulocyte-macrophage colony-
stimulating factor (GM-CSF)]; (8) myeloproliferative disorders (Chap. 72); 
(9) metabolic (e.g., ketoacidosis, uremia); (10) other—malignant neoplasms, 
acute hemorrhage or hemolysis, after splenectomy.
� LEUKEMOID REACTION
Extreme elevation of leukocyte count (>50,000/μL) composed of mature 
and/or immature neutrophils.
Causes
(1) Infection (severe, chronic, e.g., tuberculosis), esp. in children; (2) hemo-
lysis (severe); (3) malignant neoplasms (esp. carcinoma of the breast, lung, 
kidney); (4) cytokines (e.g., G-CSF, GM-CSF). May be distinguished from 
chronic myeloid leukemia (CML) by measurement of the leukocyte alkaline 
phosphatase (LAP) level: elevated in leukemoid reactions, depressed in CML.
� LEUKOERYTHROBLASTIC REACTION
Similar to leukemoid reaction with addition of nucleated red blood cells 
(RBCs) and schistocytes on blood smear.
Causes
(1) Myelophthisis—invasion of the bone marrow by tumor, fibrosis, granu-
lomatous processes; smear shows “teardrop” RBCs; (2) myelofibrosis—same 
pathophysiology as myelophthisis, but the fibrosis is a primary marrow 
disorder; (3) hemorrhage or hemolysis (rarely, in severe cases).
� LYMPHOCYTOSIS
Absolute lymphocyte count >5000/μL.
Causes
(1) Infection—infectious mononucleosis, hepatitis, cytomegalovirus, rubella, 
pertussis, tuberculosis, brucellosis, syphilis; (2) endocrine disorders—thyro-
toxicosis, adrenal insufficiency; (3) neoplasms—chronic lymphocytic leuke-
mia (CLL), most common cause of lymphocyte count >10,000/μL.
� MONOCYTOSIS
Absolute monocyte count >800/μL.
Causes
(1) Infection—subacute bacterial endocarditis, tuberculosis, brucellosis, rick-
ettsial diseases (e.g., Rocky Mountain spotted fever), malaria, leishmaniasis; 
(2) granulomatous diseases—sarcoidosis, Crohn’s disease; (3) collagen vascular 
diseases—rheumatoid arthritis, systemic lupus erythematosus (SLE), poly-
arteritis nodosa, polymyositis, temporal arteritis; (4) hematologic diseases—
leukemias, lymphoma, myeloproliferative and myelodysplastic syndromes, 
hemolytic anemia, chronic idiopathic neutropenia; (5) malignant neoplasms.
SECTION 6
386
Hematology and Oncology
� EOSINOPHILIA
Absolute eosinophil count >500/μL.
Causes
(1) Drugs, (2) parasitic infections, (3) allergic diseases, (4) collagen vascular 
diseases, (5) malignant neoplasms, (6) hypereosinophilic syndromes.
� BASOPHILIA
Absolute basophil count >100/μL.
Causes
(1) Allergic diseases, (2) myeloproliferative disorders (esp. CML), (3) chronic 
inflammatory disorders (rarely).
LEUKOPENIA
Total leukocyte count <4300/μL.
� NEUTROPENIA
Absolute neutrophil count <2000/μL (increased risk of bacterial infec-
tion with count <1000/μL). The pathophysiology of neutropenia involves 
decreased production or increased peripheral destruction.
Causes
(1) Drugs—cancer chemotherapeutic agents are most common cause, also 
phenytoin, carbamazepine, indomethacin, chloramphenicol, penicillins, 
sulfonamides, cephalosporins, propylthiouracil, phenothiazines, captopril, 
methyldopa, procainamide, chlorpropamide, thiazides, cimetidine, allopu-
rinol, colchicine, ethanol, penicillamine, and immunosuppressive agents; 
(2) infections—viral (e.g., influenza, hepatitis, infectious mononucleosis, 
HIV), bacterial (e.g., typhoid fever, miliary tuberculosis, fulminant sepsis), 
malaria; (3) nutritional—B12, folate deficiencies; (4) benign—benign ethnic 
neutropenia (BEN) seen in up to 25% of blacks, no associated risk of infec-
tion; (5) hematologic diseases—cyclic neutropenia (q21d, with recurrent 
infections common), leukemia, myelodysplasia (preleukemia), aplastic ane-
mia, bone marrow infiltration (uncommon cause), Chédiak-Higashi syn-
drome; (6) hypersplenism—e.g., Felty’s syndrome, congestive splenomegaly, 
Gaucher’s disease; (7) autoimmune diseases—idiopathic, SLE, lymphoma 
(may see positive antineutrophil antibodies).
The Febrile, Neutropenic Patient
TREATMENT
(See Chap. 26) In addition to usual sources of infection, consider paranasal 
sinuses, oral cavity (including teeth and gums), anorectal region; empirical 
therapy with broad-spectrum antibiotics (e.g., ceftazidime) is indicated 
after blood and other appropriate cultures are obtained. Prolonged febrile 
neutropenia (>7 days) leads to increased risk of dis seminated fungal infec-
tions; requires addition of antifungal chemotherapy (e.g., amphotericin B). 
The duration of chemotherapy-induced neutropenia may be shortened by 
a few days by treatment with the cytokines GM-CSF or G-CSF.
CHAPTER 70 
387
Bleeding and Thrombotic Disorders 
� LYMPHOPENIA
Absolute lymphocyte count <1000/μL.
Causes
(1) Acute stressful illness—e.g., myocardial infarction, pneumonia, sepsis; 
(2) glucocorticoid therapy; (3) lymphoma (esp. Hodgkin’s disease); (4) 
immunodeficiency syndromes—ataxia telangiectasia and Wiskott-Aldrich 
and DiGeorge syndromes; (5) immunosuppressive therapy—e.g., antilym-
phocyte globulin, cyclophosphamide; (6) large-field radiation therapy (esp. 
for lymphoma); (7) intestinal lymphangiectasia (increased lymphocyte loss); 
(8) chronic illness—e.g., congestive heart failure, uremia, SLE, disseminated 
malignancies; (9) bone marrow failure/replacement—e.g., aplastic anemia, 
miliary tuberculosis.
� MONOCYTOPENIA
Absolute monocyte count <100/μL.
Causes
(1) Acute stressful illness, (2) glucocorticoid therapy, (3) aplastic anemia, (4) 
leukemia (certain types, e.g., hairy cell leukemia), (5) chemotherapeutic and 
immunosuppressive agents.
� EOSINOPENIA
Absolute eosinophil count <50/μL.
Causes
(1) Acute stressful illness, (2) glucocorticoid therapy.
For a more detailed discussion, see Holland SM, Gallin JI: 
Disorders of Granulocytes and Monocytes, Chap. 60, p. 472 ; 
in HPIM-18.
CHAPTER 70
Bleeding and Thrombotic 
Disorders
BLEEDING DISORDERS
Bleeding may result from abnormalities of (1) platelets, (2) blood ves-
sel walls, or (3) coagulation. Platelet disorders characteristically produce 
petechial and purpuric skin lesions and bleeding from mucosal surfaces. 
Defective coagulation results in ecchymoses, hematomas, and mucosal and, 
in some disorders, recurrent joint bleeding (hemarthroses).
SECTION 6
388
Hematology and Oncology
� PLATELET DISORDERS
Thrombocytopenia 
Normal platelet count is 150,000–350,000/μL. Thrombocytopenia is defined 
as a platelet count <100,000/μL. Bleeding time, a measurement of platelet 
function, is abnormally increased if platelet count <100,000/μL; injury or 
surgery may provoke excess bleeding. Spontaneous bleeding is unusual 
unless count <20,000/μL; platelet count <10,000/μL is often associated with 
serious hemorrhage. Bone marrow examination shows increased number 
of megakaryocytes in disorders associated with accelerated platelet destruc-
tion; decreased number in disorders of platelet production. Evaluation of 
thrombocytopenia is shown in Fig. 70-1.
Causes
(1) Production defects such as marrow injury (e.g., drugs, irradiation), 
marrow failure (e.g., aplastic anemia), marrow invasion (e.g., carcinoma, 
leukemia, fibrosis); (2) sequestration due to splenomegaly; (3) accelerated 
destruction—causes include:
• Drugs such as chemotherapeutic agents, thiazides, ethanol, estrogens, 
sulfonamides, quinidine, quinine, methyldopa.
• Heparin-induced thrombocytopenia is seen in 5% of pts receiving >5 days of 
therapy and is due to in vivo platelet aggregation often from anti–platelet 
Platelet count < 150,000/μL
Hemoglobin and white blood count
Normal
Abnormal
Bone marrow examination
Peripheral
blood smear
Platelets clumped: Redraw in
sodium citrate or heparin
Fragmented 
red blood cells
Normal RBC 
morphology; 
platelets normal or 
increased in size
Microangiopathic 
hemolytic anemias 
(e.g., DIC, TTP) 
Consider:
Drug-induced thrombocytopenia
Infection-induced thrombocytopenia
Idiopathic immune thrombocytopenia
Congenital thrombocytopenia
ALGORITHM FOR THROMBOCYTOPENIA EVALUATION
FIGURE 70-1 Algorithm for evaluating the thrombocytopenic pt.
CHAPTER 70 
389
Bleeding and Thrombotic Disorders 
factor 4 antibodies. Arterial and occasionally venous thromboses may 
result. Despite the low platelets, HIT is a hypercoagulable state.
• Autoimmune destruction by an antibody mechanism; may be idiopathic 
or associated with systemic lupus erythematosus (SLE), lymphoma, HIV.
• Idiopathic thrombocytopenic purpura (ITP) has two forms: an acute, self-
limited disorder of childhood requiring no specific therapy, and a chronic 
disorder of adults (esp. women 20–40 years). Chronic ITP may be due to 
autoantibodies to glycoprotein IIb-IIIa or glycoprotein Ib-IX complexes.
• Disseminated intravascular coagulation (DIC)—platelet consumption 
with coagulation factor depletion [prolonged prothrombin time (PT), 
partial thromboplastin time (PTT)] and stimulation of fibrinolysis 
[generation of fibrin split products (FSPs)]. Blood smear shows micro-
angiopathic hemolysis (schistocytes). Causes include infection (esp. 
meningococcal, pneumococcal, gram-negative bacteremias), extensive 
burns, trauma, or thrombosis; giant hemangioma, retained dead fetus, 
heat stroke, mismatched blood transfusion, metastatic carcinoma, acute 
promyelocytic leukemia.
• Thrombotic thrombocytopenic purpura (TTP)—rare disorder character-
ized by microangiopathic hemolytic anemia, fever, thrombocytopenia, 
renal dysfunction (and/or hematuria), and neurologic dysfunction 
caused by failure to cleave von Willebrand factor (vWF) normally.
• Hemorrhage with extensive transfusion.
Pseudothrombocytopenia 
Platelet clumping secondary to collection of blood in EDTA (0.3% of pts). 
Examination of blood smear establishes diagnosis.
Thrombocytosis 
Platelet count >350,000/μL. Either primary (essential thrombocytosis; 
Chap. 72) or secondary (reactive); latter secondary to severe hemorrhage, 
iron deficiency, surgery, after splenectomy (transient), malignant neoplasms 
(esp. Hodgkin’s disease, polycythemia vera), chronic inflammatory diseases 
(e.g., inflammatory bowel disease), recovery from acute infection, vitamin 
B12 deficiency, drugs (e.g., vincristine, epinephrine). Rebound thrombo-
cytosis may occur after marrow recovery from cytotoxic agents, alcohol, 
vitamin B12 replenishment. Primary thrombocytosis may be complicated by 
bleeding and/or thrombosis; secondary rarely causes hemostatic problems.
Disorders of Platelet Function 
Suggested by the finding of prolonged bleeding time with normal platelet 
count. Defect is in platelet adhesion, aggregation, or granule release. Causes 
include (1) drugs—aspirin, other nonsteroidal anti-inflammatory drugs, 
dipyridamole, clopidogrel or prasugrel, heparin, penicillins, esp. carbenicil-
lin, ticarcillin; (2) uremia; (3) cirrhosis; (4) dysproteinemias; (5) myelopro-
liferative and myelodysplastic disorders; (6) von Willebrand disease (vWD; 
see below); (7) cardiopulmonary bypass.
� HEMOSTATIC DISORDERS DUE TO BLOOD VESSEL WALL DEFECTS
Causes include (1) aging; (2) drugs—e.g., glucocorticoids (chronic therapy), 
penicillins, sulfonamides; (3) vitamin C deficiency; (4) TTP; (5) hemolytic 
SECTION 6
390
Hematology and Oncology
uremic syndrome; (6) Henoch-Schönlein purpura; (7) paraproteinemias; 
(8) hereditary hemorrhagic telangiectasia (Osler-Weber-Rendu disease).
� DISORDERS OF BLOOD COAGULATION
Congenital Disorders
1. Hemophilia A—incidence 1:5000; sex-linked recessive deficiency of factor 
VIII (low plasma factor VIII coagulant activity, but normal amount of factor 
VIII–related antigen—vWF). Laboratory features: elevated PTT, normal PT.
2. Hemophilia B (Christmas disease)—incidence 1:30,000, sex-linked reces-
sive, due to factor IX deficiency. Clinical and laboratory features similar 
to hemophilia A.
3. von Willebrand disease—most common inherited coagulation disorder 
(1:800–1000), usually autosomal dominant; primary defect is reduced 
synthesis or chemically abnormal factor VIII–related antigen produced 
by platelets and endothelium, resulting in abnormal platelet function.
Acquired Disorders
1. Vitamin K deficiency—impairs production of factors II (prothrombin), 
VII, IX, and X; vitamin K is a cofactor in the carboxylation of glutamate 
residues on prothrombin complex proteins; major source of vitamin K is 
dietary (esp. green vegetables), with minor production by gut bacteria. 
Laboratory features: elevated PT and PTT.
2. Liver disease—results in deficiencies of all clotting factors except VIII. 
Laboratory features: elevated PT, normal or elevated PTT.
3. Other disorders—DIC, fibrinogen deficiency (liver disease, L-asparaginase 
therapy, rattlesnake bites), other factor deficiencies, circulating anticoagulants 
(lymphoma, SLE, idiopathic), massive transfusion (dilutional coagulopathy).
Bleeding Disorders
TREATMENT
THROMBOCYTOPENIA CAUSED BY DRUGS Discontinue use of possible 
offending agents; expect recovery in 7–10 days. Platelet transfusions 
may be needed if platelet count <10,000/μL.
HEPARIN-INDUCED THROMBOCYTOPENIA Discontinue heparin promptly. 
A direct thrombin inhibitor such as lepirudin (0.4-mg/kg bolus, 0.15-
mg/kg per hour infusion; PTT target 1.5–2.5 × baseline) or argatroban 
(2-μg/kg per min infusion; PTT target 1.5–3 × baseline) should be used 
for treatment of thromboses. Do not use low-molecular-weight heparin 
(LMWH), as antibodies often cross-react.
CHRONIC ITP Prednisone, initially 1–2 mg/kg per day, then slow taper 
to keep the platelet count >60,000/μL. IV immunoglobulin (2 g/kg 
in divided doses over 2–5 days) to block phagocytic destruction may 
be useful. Rituximab is effective in pts refractory to glucocorticoids. 
Eltrombopag (50 mg PO qd) boosts platelet production and allows delay 
or avoidance of splenectomy. Splenectomy, danazol (androgen), or other 
agents (e.g., vincristine, cyclophosphamide, fludarabine) are indicated 
for refractory pts or those requiring >5–10 mg prednisone daily.
CHAPTER 70 
391
Bleeding and Thrombotic Disorders 
DIC Control of underlying disease most important; platelets, fresh-
frozen plasma (FFP) to correct clotting parameters. Heparin may be 
beneficial in pts with acute promyelocytic leukemia.
TTP Plasmapheresis and FFP infusions (plasma exchange), possibly IV 
IgG; recovery in two-thirds of cases. Plasmapheresis removes inhibitors of 
the vWF cleavage enzyme (ADAMTS13), and FFP replaces the enzyme.
DISORDERS OF PLATELET FUNCTION Remove or reverse underlying 
cause. Dialysis and/or cryoprecipitate infusions (10 bags/24 h) may be 
helpful for platelet dysfunction associated with uremia.
HEMOSTATIC DISORDERS Withdraw offending drugs, replace vitamin C, 
plasmapheresis, and plasma infusion for TTP.
HEMOPHILIA A Factor VIII replacement for bleeding or before surgical 
procedure; degree and duration of replacement depends on severity of 
bleeding. Give factor VIII (e.g., Recombinate) to obtain a 15% (for mild 
bleeding) to 50% (for severe bleeding) factor VIII level. The duration 
should range from a single dose of factor VIII to therapy bid for up to 2 
weeks. Dose is calculated as follows:
Factor VIII dose = (Target level – baseline level) × weight (kg) × 0.5 unit/kg
Up to 30% of pts may develop anti–factor VIII antibodies; activated 
factor VII or factor eight inhibitor bypass agent (FEIBA) may stop or 
prevent bleeding in these pts.
HEMOPHILIA B Recombinant factor IX (e.g., Benefix), FFP or factor IX 
concentrates (e.g., Proplex, Konyne). Because of the longer half-life, 
once-daily treatment is sufficient. Dose is calculated as follows:
Factor IX dose = (Target level – baseline level) × weight (kg) × 1 unit/kg
VON WILLEBRAND DISEASE Desmopressin (1-deamino-8-d-arginine 
vasopressin) increases release of vWF from endothelial stores in type 
1 vWD. It is given IV (0.3 μg/kg) or by nasal spray (2 squirts of 
1.5-mg/mL fluid in each nostril). For types 2A, 2M, and 3, cryopre-
cipitate (plasma product rich in factor VIII) or factor VIII concentrate 
(Humate-P, Koate HS) is used: up to 10 bags bid for 48–72 h, depending 
on the severity of bleeding.
VITAMIN K DEFICIENCY Vitamin K, 10 mg SC or slow IV.
LIVER DISEASE Fresh-frozen plasma.
THROMBOTIC DISORDERS
� HYPERCOAGULABLE STATE
Consider in pts with recurrent episodes of venous thrombosis [i.e., deep-
vein thrombosis (DVT), pulmonary embolism (PE)]. Causes include (1) 
venous stasis (e.g., pregnancy, immobilization); (2) vasculitis; (3) cancer 
and myeloproliferative disorders; (4) oral contraceptives; (5) lupus anti-
coagulant—antibody to platelet phospholipid, stimulates coagulation; 
SECTION 6
392
Hematology and Oncology
(6) heparin-induced thrombocytopenia; (7) deficiencies of endogenous 
anticoagulant factors—antithrombin III, protein C, protein S; (8) factor V 
Leiden—mutation in factor V (Arg → Glu at position 506) confers resistance 
to inactivation by protein C, accounts for 25% of cases of recurrent throm-
bosis; (9) prothrombin gene mutation—Glu → Arg at position 20210 results 
in increased prothrombin levels; accounts for about 6% of thromboses; 
(10) other—paroxysmal nocturnal hemoglobinuria, dysfibrinogenemias 
(abnormal fibrinogen).
The approach to the diagnosis of the pt with DVT and/or PE is discussed 
in Chap. 142.
Thrombotic Disorders
TREATMENT
Correct underlying disorder whenever possible; long-term warfarin 
therapy is otherwise indicated.
ANTICOAGULANT AGENTS
1. Heparin (Table 70-1)—enhances activity of antithrombin III; paren-
teral agent of choice. LMWH is the preparation of choice (enoxaparin 
or dalteparin). It can be administered SC, monitoring of the PTT is 
unnecessary, and it is less likely to induce antibodies and thrombocy-
topenia. The usual dose is 100 U/kg SC bid. Unfractionated heparin 
should be given only if LMWH is unavailable. In adults, the dose of 
unfractionated heparin is 25,000–40,000 U continuous IV infusion 
over 24 h following initial IV bolus of 5000 U; monitor by following 
PTT; should be maintained between 1.5 and 2 times upper normal 
limit. Prophylactic anticoagulation to lower risk of venous throm-
bosis recommended in some pts (e.g., postoperative, immobilized) 
(Table 70-1). Prophylactic doses of unfractionated heparin are 5000 U SC 
bid or tid. Major complication of unfractionated heparin therapy is hem-
orrhage—manage by discontinuing heparin; for severe bleeding, adminis-
ter protamine (1 mg/100 U heparin); results in rapid neutralization.
2. Warfarin (Coumadin)—vitamin K antagonist, decreases levels of fac-
tors II, VII, IX, X, and anticoagulant proteins C and S. Administered 
over 2–3 days; initial load of 5–10 mg PO qd followed by titration 
of daily dose to keep PT 1.5–2 times control PT or 2–3 times if the 
International Normalized Ratio (INR) method is used. Complications 
include hemorrhage, warfarin-induced skin necrosis (rare, occurs in 
persons deficient in protein C), teratogenic effects. Warfarin effect 
reversed by administration of vitamin K; FFP infused if urgent rever-
sal necessary. Numerous drugs potentiate or antagonize warfarin 
effect. Potentiating agents include chlorpromazine, chloral hydrate, 
sulfonamides, chloramphenicol, other broad-spectrum antibiotics, 
allopurinol, cimetidine, tricyclic antidepressants, disulfiram, laxatives, 
high-dose salicylates, thyroxine, clofibrate. Some pts who are sensi-
tive to warfarin effects have genetic defects metabolizing the drug. 
Antagonizing agents include vitamin K, barbiturates, rifampin, chole-
styramine, oral contraceptives, thiazides.
CHAPTER 70 
393
Bleeding and Thrombotic Disorders 
TABLE 70-1  ANTICOAGULANT THERAPY WITH LOW-MOLECULAR-WEIGHT 
AND UNFRACTIONATED HEPARIN
Clinical Indication
Heparin Dose and 
Schedule
Target 
PTTa
LMWH Dose 
and Scheduleb
Venous thrombosis pulmonary embolism
Treatment
5000 U IV bolus; 
1000–1500 U/h
2–2.5
100 U/kg SC bid
Prophylaxis
5000 U SC q8–12h
<1.5
100 U/kg SC bid
Acute myocardial infarction
With thrombolytic 
therapy
5000 U IV bolus; 1000 U/h
1.5–2.5
100 U/kg SC bid
With mural thrombus 8000 U SC q8h + warfarin
1.5–2.0
100 U/kg SC bid
Unstable angina
5000 U IV bolus; 1000 U/h
1.5–2.5
100 U/kg SC bid
Prophylaxis
General surgery
5000 U SC bid
<1.5
100 U/kg SC 
before and bid
Orthopedic surgery
10,000 U SC bid
1.5
100 U/kg SC 
before and bid
Medical pts with 
CHF, MI
10,000 U SC bid
1.5
100 U/kg SC bid
aTimes normal control; assumes PTT has been standardized to heparin levels so that 1.5–2.5 × 
normal equals 0.2–0.4 U/mL; if PTT is normal (27–35 s), start with 5000 U bolus 1300 U/h 
infusion monitoring PTT; if PTT at recheck is <50 s, rebolus with 5000 U and increase infusion 
by 100 U/h; if PTT at recheck is 50–60 s, increase infusion rate by 100 U/h; if PTT at recheck 
is 60–85 s, no change; if PTT at recheck is 85–100 s, decrease infusion rate 100 U/h; if PTT 
at recheck is 100–120 s, stop infusion for 30 min and decrease rate 100 U/h at restart; if 
PTT at recheck is >120 s, stop infusion for 60 min and decrease rate 200 U/h at restart.
bLMWH does not affect PTT, and PTT is not used to adjust dosage.
Abbreviations: CHF, congestive heart failure; LMWH, low-molecular-weight heparin; MI, 
myocardial infarction; PTT, partial thromboplastin time.
3. Fondaparinux—a pentapeptide that directly inhibits factor Xa. It is 
given at a dose of 2.5 mg SC daily for prophylaxis and 7.5 mg SC 
daily for treatment of thrombosis and does not require monitoring. 
Unlike the heparins, it does not bind to platelet factor 4 and does not 
elicit the antibodies that produce heparin-induced thrombocytopenia. 
Apixaban and rivaroxaban are oral factor Xa inhibitors. Apixaban 
(5 mg PO bid) as effective as warfarin in DVT and more effective in 
stroke prevention in atrial fibrillation (AF).
4. Argatroban and lepirudin—direct thrombin inhibitors. These agents are 
being compared to LMWH and are commonly used in pts with heparin-
induced thrombocytopenia. Both are monitored with the activated PTT. 
Dabigatran (150 mg PO bid) is an oral thrombin inhibitor and is non-
inferior to warfarin in both DVT and stroke prevention in AF.
SECTION 6
394
Hematology and Oncology
In-hospital anticoagulation is usually initiated with heparin for 4–10 
days, with subsequent maintenance on warfarin after an overlap of 3 days. 
Duration of therapy depends on underlying condition; calf DVT with clear 
precipitating cause, 3 months; proximal or idiopathic DVT or PE, 6–12 
months; recurrent idiopathic DVT, 12 months minimum; embolic disease 
with ongoing risk factor, long-term, indefinite. The new oral Xa and throm-
bin inhibitors are easier to use than warfarin but much more expensive.
FIBRINOLYTIC AGENTS Tissue plasminogen activators mediate clot lysis 
by activating plasmin, which degrades fibrin. Currently available versions 
include streptokinase, urokinase, anistreplase (acylated plasminogen 
streptokinase activator complex), and three modestly distinct forms of 
recombinant tissue plasminogen activator (tPA): alteplase, tenecteplase, 
and reteplase. Indications include treatment of DVT, with lower inci-
dence of postphlebitic syndrome (chronic venous stasis, skin ulceration) 
than with heparin therapy; massive PE, arterial embolic occlusion of 
an extremity, treatment of acute myocardial infarction (MI), unstable 
angina pectoris. Dosages for fibrinolytic agents: (1) tPA—for acute MI 
and massive PE (adult >65 kg), 10-mg IV bolus over 1–2 min, then 50 
mg IV over 1 h and 40 mg IV over next 2 h (total dose = 100 mg). tPA is 
slightly more effective but more expensive than streptokinase for treat-
ment of acute MI. (2) Streptokinase—for acute MI, 1.5 million IU IV over 
60 min; or 20,000 IU as a bolus intracoronary (IC) infusion, followed by 
2000 IU/min for 60 min IC. For PE or arterial or deep-vein thrombosis, 
250,000 IU over 30 min, then 100,000 IU/h for 24 h (PE) or 72 h (arterial 
or deep-vein thrombosis). (3) Urokinase—for PE, 4400 IU/kg IV over 10 
min, then 4400 (IU/kg)/h IV for 12 h.
Fibrinolytic therapy is usually followed by a period of anticoagulant 
therapy with heparin. Fibrinolytic agents are contraindicated in pts with 
(1) active internal bleeding; (2) recent (<2–3 months) cerebrovascular 
accident; (3) intracranial neoplasm, aneurysm, or recent head trauma.
ANTIPLATELET AGENTS Aspirin inhibits platelet function by blocking 
the ability of cyclooxygenase (COX-1) to synthesize thromboxane A2. 
The thienopyridines (ticlopidine and clopidogrel) inhibit ADP-induced 
platelet aggregation by blocking its receptor (P2Y12). Dipyridamole acts by 
inhibiting phosphodiesterase, which permits cAMP levels to increase and 
block activation. Glycoprotein IIb/IIIa (GPIIb/IIIa) antagonists block the 
integrin receptors on the platelet and prevent platelet aggregation. Three 
such agents are now in use: abciximab, an Fab antibody fragment that binds 
to the activated form of GPIIb/IIIa; eptifibatide, a cyclic heptapeptide that 
includes the KGD tripeptide motif that the GPIIb/IIIa receptor recognizes; 
and tirofiban, a tyrosine derivative that mimics the KGD motif.
Aspirin (160–325 mg/d) plus clopidogrel (400-mg loading dose then 
75 mg/d) may be beneficial in lowering incidence of arterial thrombotic 
events (stroke, MI) in high-risk pts. Antiplatelet agents are useful in 
preventing strokes, complications from percutaneous coronary inter-
ventions, and progression of unstable angina.
CHAPTER 71 
395
Cancer Chemotherapy
For a more detailed discussion, see Konkle BA: Bleeding 
and Thrombosis, Chap. 58, p. 457; Konkle BA: Disorders 
of Platelets and Vessel Wall, Chap. 115, p. 965; Arruda 
VR, High KA: Coagulation Disorders, Chap. 116, p. 973; 
Freedman JE, Loscalzo J: Arterial and Venous Thrombosis, 
Chap. 117, p. 983; and Weitz JI: Antiplatelet, Anticoagulant, 
and Fibrinolytic Drugs, Chap. 118, p. 988, in HPIM-18 .
CHAPTER 71
Cancer Chemotherapy
� BIOLOGY OF TUMOR GROWTH
Two essential features of cancer cells are uncontrolled growth and the ability 
to metastasize. The malignant phenotype of a cell is the end result of a series 
of genetic changes that remove safeguards restricting cell growth and induce 
new features that enable the cell to metastasize, including surface receptors 
for binding to basement membranes, enzymes to poke holes in anatomic 
barriers, cytokines to facilitate mobility, and angiogenic factors to develop a 
new vascular lifeline for nutrients and oxygen. These genetic changes usu-
ally involve increased or abnormal expression or activity of certain genes 
known as proto-oncogenes (often growth factors or their receptors, enzymes 
in growth pathways, or transcription factors), deletion or inactivation of 
tumor-suppressor genes, and defects in DNA repair enzymes. These genetic 
changes may occur by point mutation, gene amplification, gene rearrange-
ment, or epigenetic changes such as altered gene methylation.
Once cells are malignant, their growth kinetics are similar to those of 
normal cells but lack regulation. For unclear reasons, tumor growth kinet-
ics follow a Gompertzian curve: as the tumor mass increases, the fraction 
of dividing cells declines. Thus, by the time a cancer is large enough to be 
detected clinically, its growth fraction is often small. Unfortunately, tumor 
growth usually does not stop altogether before the tumor reaches a lethal 
tumor burden. Cancer cells proceed through the same cell-cycle stages as 
normal cycling cells: G1 (period of preparation for DNA synthesis), S (DNA 
synthesis), G2 (tetraploid phase preceding mitosis in which integrity of 
DNA replication is assessed), and M (mitosis). Some noncycling cells may 
remain in a G0, or resting, phase for long periods. Certain chemotherapeutic 
agents are specific for cells in certain phases of the cell cycle.
� DEVELOPMENT OF DRUG RESISTANCE
Drug resistance can be divided into de novo resistance or acquired resis-
tance. De novo resistance refers to the tendency of many of the most 
common solid tumors to be unresponsive to chemotherapeutic agents. In 
acquired resistance, tumors initially responsive to chemotherapy develop 
SECTION 6
396
Hematology and Oncology
TABLE 71-1 CURABILITY OF CANCERS WITH CHEMOTHERAPY
A. Advanced Cancers with Possible Cure
Acute lymphoid and acute myeloid leukemia (pediatric/adult)
Hodgkin’s disease (pediatric/adult)
Lymphomas—certain types (pediatric/adult)
Germ cell neoplasms
Embryonal carcinoma
Teratocarcinoma
Seminoma or dysgerminoma
Choriocarcinoma
Gestational trophoblastic neoplasia
Pediatric neoplasms
Wilms’ tumor
Embryonal rhabdomyosarcoma
Ewing’s sarcoma
Peripheral neuroepithelioma
Neuroblastoma
Small cell lung carcinoma
Ovarian carcinoma
B. Advanced Cancers Possibly Cured by Chemotherapy and Radiation
Squamous carcinoma (head and neck)
Squamous carcinoma (anus)
Breast carcinoma
Carcinoma of the uterine cervix
Non-small cell lung carcinoma (stage III)
Small cell lung carcinoma
C. Cancers Possibly Cured with Chemotherapy as Adjuvant to Surgery
Breast carcinoma
Colorectal carcinomaa
Osteogenic sarcoma
Soft tissue sarcoma
D.  Cancers Possibly Cured with “High-Dose” Chemotherapy with Stem 
Cell Support
Relapsed leukemias, lymphoid and myeloid
Relapsed lymphomas, Hodgkin’s and non-Hodgkin’s
Chronic myeloid leukemia
Multiple myeloma
E.  Cancers Responsive to Chemotherapy with Useful Palliation But 
Not Cure
Bladder carcinoma
CHAPTER 71 
397
Cancer Chemotherapy
TABLE 71-1  CURABILITY OF CANCERS WITH CHEMOTHERAPY 
(CONTINUED)
Chronic myeloid leukemia
Hairy cell leukemia
Chronic lymphocytic leukemia
Lymphoma—certain types
Multiple myeloma
Gastric carcinoma
Cervix carcinoma
Endometrial carcinoma
Soft tissue sarcoma
Head and neck cancer
Adrenocortical carcinoma
Islet-cell neoplasms
Breast carcinoma
Colorectal carcinoma
Renal carcinoma
F. Tumor Poorly Responsive in Advanced Stages to Chemotherapy
Pancreatic carcinoma
Biliary-tract neoplasms
Thyroid carcinoma
Carcinoma of the vulva
Non-small cell lung carcinoma
Prostate carcinoma
Melanoma
Hepatocellular carcinoma
Salivary gland cancer
aRectum also receives radiation therapy.
resistance during treatment, usually because resistant clones appear within 
tumor cell populations (Table 71-1).
Resistance can be specific to single drugs because of (1) defective trans-
port of the drug, (2) decreased activating enzymes, (3) increased drug 
inactivation, (4) increases in target enzyme levels, or (5) alterations in target 
molecules. Multiple drug resistance occurs in cells overexpressing the P 
glycoprotein, a membrane glycoprotein responsible for enhanced efflux of 
drugs from cells, but there are other mechanisms as well.
� CATEGORIES OF CHEMOTHERAPEUTIC AGENTS AND 
MAJOR TOXICITIES
A partial list of toxicities is shown in Table 71-2; some toxicities may apply 
only to certain members of a group of drugs.
SECTION 6
398
Hematology and Oncology
TABLE 71-2 TOXICITIES OF CANCER TREATMENTS
Agent
Toxicities
Alkylating agents
(add alkyl groups to N-7 or O-6 
of guanine)
Busulfan
Chlorambucil
Cyclophosphamide
Ifosfamide
Dacarbazine
Mechlorethamine
Nitrosoureas
Melphalan
Bendamustine
Nausea, vomiting, myelosuppression, 
sterility, alopecia, acute leukemia 
(rare), hemorrhagic cystitis, pulmonary 
fibrosis
Antimetabolites
(inhibit DNA or RNA synthesis)
5-Fluorouracil
Capecitabine
Fludarabine
Cladribine
Cytarabine
Methotrexate
Pemetrexed
Hydroxyurea
Pentostatin
Azathioprine
Thioguanine
Nausea, vomiting, myelosuppression, 
oral ulceration, hepatic toxicity, 
alopecia, neurologic symptoms
Tubulin poisons
(block tubule polymerization or 
depolymerization)
Vincristine
Vinblastine
Vinorelbine
Paclitaxel
Docetaxel
Cabazitaxel
Nab-paclitaxel
Estramustine
Ixabepilone
Nausea, vomiting, myelosuppression, 
vesicant effect, ileus, hypersensitivity 
reaction, peripheral neuropathy, SIADH
CHAPTER 71 
399
Cancer Chemotherapy
TABLE 71-2 TOXICITIES OF CANCER TREATMENTS (CONTINUED)
Agent
Toxicities
Topoisomerase inhibitors
(interfere with DNA unwinding/
repair)
Doxorubicin
Daunorubicin
Idarubicin
Epirubicin
Etoposide
Irinotecan
Topotecan
Mitoxantrone
Nausea, vomiting, myelosuppression, 
vesicant effect, cardiac failure, acute 
leukemia (rare)
Platinum compounds
(form DNA adducts, disrupt repair)
Cisplatin
Carboplatin
Oxaliplatin
Nausea, vomiting, myelosuppression, 
renal toxicity, neurotoxicity
Antibiotics
(diverse mechanisms)
Bleomycin
Dactinomycin
Mithramycin
Mitomycin
Nausea, vomiting, myelosuppression, 
cardiac toxicity, lung fibrosis, 
hypocalcemia, hypersensitivity 
reaction
Histone deacetylase inhibitors
Vorinostat
Romidepsin
Hormone and nuclear receptor targeting agents
Tamoxifen
Raloxifene
Anastrozole
Letrozole
Exemestane
Tretinoin
Bexarotene
Flutamide
Leuprolide
Diethylstilbestrol
Medroxyprogesterone
Nausea, vomiting, hot flashes, 
gynecomastia, impotence
(continued)
SECTION 6
400
Hematology and Oncology
TABLE 71-2 TOXICITIES OF CANCER TREATMENTS (CONTINUED)
Agent
Toxicities
Biologic agents
Interferon
Interleukin 2
Rituximab
Trastuzumab
Cetuximab
Panitumomab
Bevacizumab
Brentuximab vedotin
Gemtuzumab ozogamicin
Denileukin diftitox
Bortezomib
Imatinib
Dasatinib
Nilotinib
Gefitinib
Erlotinib
Sorafenib
Sunitinib
Everolimus
Temsirolimus
Nausea, vomiting, fever, chills, vascular 
leak, respiratory distress, skin rashes, 
edema
Radiation therapy
External beam (teletherapy)
Internal implants (brachytherapy)
Ibritumomab tiuxetan
Iodine-135 Tositumomab
Samarium-153 EDTMP
Strontium-89
Nausea, vomiting, myelosuppression, 
tissue damage, late second cancers, 
heart disease, sterility
Abbreviation: SIADH, syndrome of inappropriate antidiuretic hormone secretion.
� COMPLICATIONS OF THERAPY
While the effects of cancer chemotherapeutic agents may be exerted pri-
marily on the malignant cell population, virtually all currently employed 
regimens have profound effects on normal tissues as well. Every side effect 
of treatment must be balanced against potential benefits expected, and pts 
must always be fully apprised of the toxicities they may encounter. While 
CHAPTER 71 
401
Cancer Chemotherapy
the duration of certain adverse effects may be short-lived, others, such as 
sterility and the risk of secondary malignancy, have long-term implica-
tions; consideration of these effects is important in the use of regimens 
as adjuvant therapy. The combined toxicity of regimens involving radio-
therapy and chemotherapy is greater than that seen with each modality 
alone. Teratogenesis is a special concern in treating women of childbear-
ing years with radiation or chemotherapy. The most serious late toxicities 
are sterility (common; from alkylating agents), secondary acute leukemia 
(rare; from alkylating agents and topoisomerase inhibitors), secondary 
solid tumors (0.5–1%/year risk for at least 25 years after treatment; from 
radiation therapy), premature atherosclerosis (3-fold increased risk of fatal 
myocardial infarction; from radiation therapy that includes the heart), 
heart failure (rare; from anthracyclines, trastuzumab), and pulmonary 
fibrosis (rare; from bleomycin).
� MANAGEMENT OF ACUTE TOXICITIES
Nausea and Vomiting 
Mildly to moderately emetogenic agents—prochlorperazine, 5–10 mg PO or 
25 mg PR before chemotherapy; effects are enhanced by also administering 
dexamethasone, 10–20 mg IV. Highly emetogenic agents (such as cisplatin, 
mechlorethamine, dacarbazine, streptozocin)—ondansetron, 8 mg PO q6h 
the day before chemotherapy and IV at time of chemotherapy, plus dexa-
methasone, 20 mg IV at time of chemotherapy. Aprepitant (125 mg PO day 
1, 80 mg PO days 2, 3 with or without dexamethasone 8 mg), a substance P/
neurokinin 1 receptor blocker, decreases the risk of acute and delayed vomit-
ing from cisplatin.
Neutropenia
Colony-stimulating factors are often used where they have been shown 
to have little or no benefit. Specific indications for the use of granulocyte 
colony-stimulating factor or granulocyte-macrophage colony-stimulating 
factor are provided in Table 71-3.
Anemia
Quality of life is improved by maintaining Hb levels >90 g/L (9 g/dL). This 
is routinely done with packed red blood cell transfusions. Erythropoietin 
has the capacity to protect hypoxic cells from dying; its use has resulted in 
poorer tumor control and is generally discouraged. 
Thrombocytopenia 
Rarely, treatment may induce a decline in platelet counts. Platelet trans-
fusions are generally triggered at a platelet count of 10,000/μL in pts 
with solid tumors and at a platelet count of 20,000/μL in pts with acute 
leukemia. Newer oral thrombopoietin mimetics (e.g., eltrombopag) 
are promising but have not been widely tested in the setting of cancer 
chemotherapy.
SECTION 6
402
Hematology and Oncology
TABLE 71-3 INDICATIONS FOR THE CLINICAL USE OF G-CSF OR GM-CSF
Preventive uses
With the first cycle of chemotherapy (so-called primary CSF administration)
Not needed on a routine basis
Use if the probability of febrile neutropenia is ≥20%
Use if pt has preexisting neutropenia or active infection
Age >65 years treated for lymphoma with curative intent or other tumor 
treated by similar regimens
Poor performance status
Extensive prior chemotherapy
Dose-dense regimens in a clinical trial or with strong evidence of benefit
With subsequent cycles if febrile neutropenia has previously occurred 
(so-called secondary CSF administration)
Not needed after short-duration neutropenia without fever
Use if pt had febrile neutropenia in previous cycle
Use if prolonged neutropenia (even without fever) delays therapy
Therapeutic uses
Afebrile neutropenic pts
No evidence of benefit
Febrile neutropenic pts
No evidence of benefit
May feel compelled to use in the face of clinical deterioration from sepsis, 
pneumonia, or fungal infection, but benefit unclear
In bone marrow or peripheral blood stem cell transplantation
Use to mobilize stem cells from marrow
Use to hasten myeloid recovery
In acute myeloid leukemia
G-CSF of minor or no benefit
GM-CSF of no benefit and may be harmful
In myelodysplastic syndromes
Not routinely beneficial
Use intermittently in subset with neutropenia and recurrent infection
What dose and schedule should be used?
G-CSF: 5 mg/kg per day subcutaneously
GM-CSF: 250 mg/m2 per day subcutaneously
Peg-filgrastim: one dose of 6 mg 24 h after chemotherapy
When should therapy begin and end?
When indicated, start 24–72 h after chemotherapy
CHAPTER 72 
403
Myeloid Leukemias, Myelodysplasia
TABLE 71-3  INDICATIONS FOR THE CLINICAL USE OF G-CSF OR GM-CSF 
(CONTINUED)
Continue until absolute neutrophil count is 10,000/μL
Do not use concurrently with chemotherapy or radiation therapy
Abbreviations: G-CSF, granulocyte colony-stimulating factor; GM-CSF, granulocyte-macrophage 
colony-stimulating factor.
Source: From the American Society of Clinical Oncology.
For a more detailed discussion, see Sausville EA, Longo DL: 
Principles of Cancer Treatment, Chap. 85, p. 689, in HPIM-18.
CHAPTER 72
Myeloid Leukemias, 
Myelodysplasia, and 
Myeloproliferative Syndromes
ACUTE MYELOID LEUKEMIA (AML)
AML is a clonal malignancy of myeloid bone marrow precursors in which 
poorly differentiated cells accumulate in the bone marrow and circulation.
Signs and symptoms occur because of the absence of mature cells normally 
produced by the bone marrow, including granulocytes (susceptibility to infec-
tion) and platelets (susceptibility to bleeding). In addition, if large numbers of 
immature malignant myeloblasts circulate, they may invade organs and rarely 
produce dysfunction. There are distinct morphologic subtypes (Table 72-1) that 
have largely overlapping clinical features. Of note is the propensity of pts with 
acute promyelocytic leukemia (APL) (FAB M3) to develop bleeding and dis-
seminated intravascular coagulation, especially during induction chemotherapy, 
because of the release of procoagulants from their cytoplasmic granules.
Incidence and Etiology 
In the United States about 13,780 cases have occurred in 2012. AML accounts 
for about 80% of acute leukemias in adults. Etiology is unknown for the vast 
majority. Three environmental exposures increase the risk: chronic benzene 
exposure, radiation exposure, and prior treatment with alkylating agents 
(especially in addition to radiation therapy) and topoisomerase II inhibi-
tors (e.g., doxorubicin and etoposide). Chronic myeloid leukemia (CML), 
myelodysplasia, and myeloproliferative syndromes may all evolve into AML. 
Certain genetic abnormalities are associated with particular morphologic 
variants: t(15;17) with APL, inv(16) with eosinophilic leukemia; others 
occur in a number of types. Chromosome 11q23 abnormalities are often 
SECTION 6
404
Hematology and Oncology
TABLE 72-1 AML CLASSIFICATION SYSTEMS
World Health Organization Classificationa
AML with recurrent genetic abnormalities
 AML with t(8;21)(q22;q22);RUNX1-RUNX1T1b
 AML with inv(16)(p13.1;1q22) or t(16;16)(p13.1;q22);CBFB-MYH11b
 Acute promyelocytic leukemia with t(15;17)(q22;q12); PML-RARAb
 AML with t(9;11)(p22;q23); MLLT3-MLL
 AML with t(6;9)(p23;q34); DEK-NUP214
 AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1
 AML (megakaryoblastic) with t(1;22)(p13;q13); RBM15-MKL1
 Provisional entity: AML with mutated NPM1
 Provisional entity: AML with mutated CEBPA
AML with myelodysplasia-related changes
Therapy-related myeloid neoplasms
AML not otherwise specified
AML with minimal differentiation
AML without maturation
AML with maturation
Acute myelomonocytic leukemia
Acute monoblastic and monocytic leukemia
Acute erythroid leukemia
Acute megakaryoblastic leukemia
Acute basophilic leukemia
Acute panmyelosis with myelofibrosis
Myeloid sarcoma
Myeloid proliferations related to Down syndrome
Transient abnormal myelopoiesis
Myeloid leukemia associated with Down syndrome
Blastic plasmacytoid dendritic cell neoplasm
Acute leukemia of ambiguous lineage
Acute undifferentiated leukemia
Mixed phenotype acute leukemia with t(9;22)(q34;q11,20); BCR-ABL11
Mixed phenotype acute leukemia with t(v;11q23); MLL rearranged
Mixed phenotype acute leukemia, B/myeloid, NOS
Mixed phenotype acute leukemia, T/myeloid, NOS
Provisional entity: Natural killer (NK)-cell lymphoblastic leukemia/lymphoma
French-American-British (FAB) Classificationc
MO: Minimally differentiated leukemia
Ml: Myeloblastic leukemia without maturation
CHAPTER 72 
405
seen in leukemias developing after exposure to topoisomerase II inhibitors. 
Chromosome 5 or 7 deletions are seen in leukemias following radiation plus 
chemotherapy. The particular genetic abnormality has a strong influence 
on treatment outcome. Expression of MDR1 (multidrug resistance efflux 
pump) is common in older pts and adversely affects prognosis.
Clinical and Laboratory Features 
Initial symptoms of acute leukemia have usually been present for <3 
months; a preleukemic syndrome may be present in some 25% of pts with 
AML. Signs of anemia, pallor, fatigue, weakness, palpitations, and dys-
pnea on exertion are most common. White blood cell count (WBC) may 
be low, normal, or markedly elevated; circulating blast cells may or may 
not be present; with WBC >100 × 109 blasts per liter, leukostasis in lungs 
and brain may occur. Minor pyogenic infections of the skin are common. 
Thrombocytopenia leads to spontaneous bleeding, epistaxis, petechiae, 
conjunctival hemorrhage, gingival bleeding, and bruising, especially with 
platelet count <20,000/μL. Anorexia and weight loss are common; fever 
may be present.
Bacterial and fungal infection are common; risk is heightened with total 
neutrophil count <5000/μL, and breakdown of mucosal and cutaneous bar-
riers aggravates susceptibility; infections may be clinically occult in pres-
ence of severe leukopenia, and prompt recognition requires a high degree 
of clinical suspicion.
Hepatosplenomegaly occurs in about one-third of pts; leukemic meningi-
tis may present with headache, nausea, seizures, papilledema, cranial nerve 
palsies.
Metabolic abnormalities may include hyponatremia, hypokalemia, ele-
vated serum lactate dehydrogenase (LDH), hyperuricemia, and (rarely) 
lactic acidosis. With very high blast cell count in the blood, spurious 
hyperkalemia and hypoglycemia may occur (potassium released from and 
glucose consumed by tumor cells after the blood was drawn).
TABLE 72-1 AML CLASSIFICATION SYSTEMS (CONTINUED)
French-American-British (FAB) Classificationc
M2: Myeloblastic leukemia with maturation
M3: Hypergranular promyelocytic leukemia
M4: Myelomonocytic leukemia
M4Eo: Variant: Increase in abnormal marrow eosinophils
M5: Monocytic leukemia
M6: Erythroleukemia (DiGuglielmo’s disease)
M7: Megakaryoblastic leukemia
aFrom SH Swerdlow et al (eds): World Health Organization Classification of Tumours of 
Haematopoietic and Lymphoid Tissues. Lyon, IARC Press, 2008.
bDiagnosis is AML regardless of blast count.
cFrom JM Bennett et al: Ann Intern Med 103:620, 1985.
Abbreviation: AML, acute myeloid leukemia.
Myeloid Leukemias, Myelodysplasia
SECTION 6
406
Hematology and Oncology
Acute Myeloid Leukemia
TREATMENT
Leukemic cell mass at time of presentation may be 1011–1012 cells; 
when total leukemic cell numbers fall below ~109, they are no longer 
detectable in blood or bone marrow and pt appears to be in complete 
remission (CR). Thus aggressive therapy must continue past the point 
when initial cell bulk is reduced if leukemia is to be eradicated. Typical 
phases of chemotherapy include remission induction and postremission 
therapy, with treatment lasting about 1 year. Figure 72-1 outlines a treat-
ment algorithm. 
Supportive care with transfusions of red cells and platelets [from cyto-
megalovirus (CMV)-seronegative donors, if pt is a candidate for bone 
marrow transplantation] is very important, as are aggressive prevention, 
diagnosis, and treatment of infections. Colony-stimulating factors offer 
little or no benefit; some recommend their use in older pts and those 
with active infections. Febrile neutropenia should be treated with broad-
spectrum antibiotics (e.g., ceftazidime 1 g q8h); if febrile neutropenia 
persists beyond 7 days, amphotericin B should be added.
About 60–80% of pts will achieve initial remission when treated with 
cytarabine 100–200 (mg/m2)/d by continuous infusion for 7 days, and 
daunorubicin [45 (mg/m2)/d] or idarubicin [12–13 (mg/m2)/d] for 3 days. 
Addition of etoposide may improve CR duration. Half of treated pts enter 
CR with the first cycle of therapy, and another 25% require two cycles. 
About 10–30% of pts achieve 5-year disease-free survival and probable 
cure. Pts achieving a CR who have low risk of relapse [cells contain 
t(8;21) or inv(16)] receive 3–4 cycles of cytarabine. Those at high risk of 
relapse may be considered for allogeneic bone marrow transplantation.
Response to treatment after relapse is short, and prognosis for pts who 
have relapsed is poor. In APL, addition of trans-retinoic acid (tretinoin) 
to chemotherapy induces differentiation of the leukemic cells and may 
improve outcome. Arsenic trioxide also induces differentiation in APL cells.
Bone marrow transplantation from identical twin or human leukocyte 
antigen (HLA)-identical sibling is effective treatment for AML. Typical 
protocol uses high-dose chemotherapy ± total-body irradiation to 
ablate host marrow, followed by infusion of marrow from donor. Risks 
are substantial (unless marrow is from identical twin). Complications 
include graft-versus-host disease, interstitial pneumonitis, opportunis-
tic infections (especially CMV). Comparison between transplantation 
and high-dose cytarabine as postremission therapy has not produced a 
clear advantage for either approach. Up to 30% of otherwise end-stage 
pts with refractory leukemia achieve probable cure from transplanta-
tion; results are better when transplant is performed during remission. 
Results are best for children and young adults.
CHRONIC MYELOID LEUKEMIA (CML)
CML is a clonal malignancy usually characterized by splenomegaly and 
production of increased numbers of granulocytes; course is initially indo-
lent but eventuates in leukemic phase (blast crisis) that has a poorer prognosis 
Diagnosis AML
Induction therapy:
Daunorubicin + 
Cytarabine ±
Etoposide
Induction therapy:
Daunorubicin +
Cytarabine ±
Etoposide
Induction therapy:
Daunorubicin +
Cytarabine ±
Etoposide
Investigational
therapy
Investigational
therapy
Patient candidate for
allogeneic HSCT and
has suitable donor
Low risk 
Normal cytogenetics
(CEBPA mutation or
NPM1 mutation
without FLT3-ITD)
High risk 
Normal cytogenetics
(FLT3-ITD),
Others 
High risk
Cytogenetics
If CR,
Consolidation therapy:
High-dose cytarabine
or autologous HSCT
If CR,
Consolidation therapy:
Allogeneic HSCT
If CR,
consolidation
therapy:
Autologous HSCT
Either option
acceptable
If CR,
Investigational
therapy
Either option
acceptable
If CR,
Investigational
therapy
Yes:
Allogeneic
HSCT
No:
Investigational
therapy
Salvage
treatment
Either option
acceptable
Either option 
acceptable
Previously
untreated
Refractory or
relapsed
Induction therapy:
Daunorubicin + 
Cytarabine ±
Etoposide
If CR,
consolidation
therapy:
High-dose cytarabine
t (8;21) or inv (16)
407
FIGURE 72-1 Flow chart for the therapy of newly diagnosed acute myeloid leukemia. For all forms of AML except acute promyelocytic leukemia (APL), standard 
therapy includes a 7-day continuous infusion of cytarabine (100–200 mg/m2 per day) and a 3-day course of daunorubicin (60–90 mg/m2 per day) with or without 
3 days of etoposide (only with daunorubicin 60 mg/m2 per day) or novel therapies based on their predicted risk of relapse (i.e., risk-stratified therapy). Idarubicin 
(12–13 mg/m2 per day) could be used in place of daunorubicin (not shown). Patients who achieve complete remission undergo postremission consolidation
therapy, including sequential courses of high-dose cytarabine, autologous hematopoietic stem cell transplant (HSCT), allogeneic HSCT, or novel therapies, based 
on their predicted risk of relapse (i.e., risk-stratified therapy). Patients with APL (see text for treatment) usually receive tretinoin together with anthracycline-based 
chemotherapy for remission induction and then arsenic trioxide followed by consolidation with anthracycline-based chemotherapy and possibly maintenance with 
tretinoin. The role of cytarabine in APL induction and consolidation is controversial.
SECTION 6
408
Hematology and Oncology
than de novo AML; rate of progression to blast crisis is variable; overall 
survival averages 4 years from diagnosis.
Incidence and Etiology 
In the United States, about 5430 cases have occurred in the United States in 
2012. More than 90% of cases have a reciprocal translocation between chro-
mosomes 9 and 22, creating the Philadelphia (Ph) chromosome and a fusion 
gene product called BCR-ABL. (BCR is from 9, ABL from 22.) The chromo-
some abnormality appears in all bone marrow–derived cells except T cells. 
The protein made by the chimeric gene is 210 kDa in chronic phase and 190 
kDa in acute blast transformation. In some pts, the chronic phase is clinically 
silent and pts present with acute leukemia with the Ph chromosome.
Clinical and Laboratory Features 
Symptoms develop gradually; easy fatigability, malaise, anorexia, abdomi-
nal discomfort and early satiety from the large spleen, excessive sweating. 
Occasional pts are found incidentally based on elevated leukocyte count. 
WBC is usually >25,000/μL with the increase accounted for by granulocytes 
and their precursors back to the myelocyte stage; bands and mature forms 
predominate. Basophils may account for 10–15% of the cells in the blood. 
Platelet count is normal or increased. Anemia is often present. Neutrophil 
alkaline phosphatase score is low. Marrow is hypercellular with granulocytic 
hyperplasia. Marrow blast cell count is normal or slightly elevated. Serum 
levels of vitamin B12, B12-binding proteins, and LDH are elevated in pro-
portion to the WBC. With high blood counts, spurious hyperkalemia and 
hypoglycemia may be seen.
Natural History 
Chronic phase lasts 2–4 years. Accelerated phase is marked by anemia 
disproportionate to the disease activity or treatment. Platelet counts fall. 
Additional cytogenetic abnormalities appear. Blast cell counts increase. 
Usually within 6–8 months, overt blast crisis develops in which maturation 
ceases and blasts predominate. The clinical picture is that of acute leukemia. 
Half of the cases become AML, one-third have morphologic features of 
acute lymphoid leukemia, 10% are erythroleukemia, and the rest are undif-
ferentiated. Survival in blast crisis is often <4 months.
Chronic Myeloid Leukemia
TREATMENT
Criteria for response are provided in Table 72-2. Allogeneic bone mar-
row transplantation has the potential to cure the disease in chronic 
phase. However, the first treatment is imatinib, a molecule that inhibits 
the chimeric gene product’s tyrosine kinase activity. A daily oral dose of 
400 mg produces complete hematologic remission of >90% and cyto-
genetic remission in 76%. If a matched donor is available, it is best to 
transplant pts in complete remission. Several mechanisms of resistance 
to imatinib have emerged, and it is unlikely that it leads to permanent 
remissions when used alone; however, follow-up is not sufficient to draw 
firm conclusions.
CHAPTER 72 
409
Pts who no longer respond to imatinib may respond to other tyro-
sine kinase inhibitors such as dasatinib (100 mg PO qd) or nilotinib 
(400 mg PO bid). The T315I mutation in the BCR/ABL gene conveys 
resistance to all three kinase inhibitors. Allopurinol, 300 mg/d, prevents 
urate nephropathy. The only curative therapy for the disease is HLA-
matched allogeneic bone marrow transplantation. The optimal timing 
of transplantation is unclear, but transplantation in chronic phase is 
more effective than transplantation in accelerated phase or blast crisis. 
Transplantation appears most effective in pts treated within a year of 
diagnosis. Long-term disease-free survival may be obtained in 50–60% 
of transplanted pts. Infusion of donor lymphocytes can restore remission 
in relapsing pts. In pts without a matched donor, autologous transplanta-
tion may be helpful using peripheral blood stem cells. Treatment of pts 
in blast crisis with imatinib can obtain responses, but their durability has 
not been established.
MYELODYSPLASTIC SYNDROMES (MDS)
These are clonal abnormalities of marrow cells characterized by varying 
degrees of cytopenias affecting one or more cell lines. The World Health 
Organization (WHO) classification of myelodysplastic syndromes is shown 
in Table 72-3. Other terms that have been used to describe one or more of 
the entities include preleukemia and oligoblastic leukemia.
TABLE 72-2 RESPONSE CRITERIA IN CHRONIC MYELOID LEUKEMIA
Hematologic
 Complete responsea
White blood cell count <10,000/μL, normal
morphology
Normal hemoglobin and platelet counts
 Incomplete response White blood cell count ≥10,000/μL
Cytogenetic
Percentage of bone marrow metaphases 
with t(9;22)
 Complete response
0
 Partial response
≤35
 Minor response
36–85b
 No response
85–100
Molecular
Presence of BCR/ABL transcript by RT-PCR
 Complete response
None
 Incomplete response Any
aComplete hematologic response requires the disappearance of splenomegaly.
bUp to 15% normal metaphases are occasionally seen at diagnosis (when 30 metaphases 
are analyzed).
Abbreviation: RT-PCR, reverse transcriptase polymerase chain reaction.
Myeloid Leukemias, Myelodysplasia
TABLE 72-3 WORLD HEALTH ORGANIZATION (WHO) CLASSIFICATION OF MYELODYSPLASTIC SYNDROMES/NEOPLASMS
Name
WHO Estimated Proportion 
of Patients with MDS
Peripheral Blood: Key 
Features
Bone Marrow: Key Features
Refractory cytopenias with unilineage 
dysplasia (RCUD):
 Refractory anemia (RA)
10–20%
Anemia <1% of blasts
Unilineage erythroid dysplasia (in ≥10% of 
cells) <5% blasts
 Refractory neutropenia (RN)
<1%
Neutropenia <1% blasts
Unilineage granulocytic dysplasia 
<5% blasts
 Refractory thrombocytopenia (RT)
<1%
Thrombocytopenia <1% 
blasts
Unilineage megakaryocytic dysplasia <5% 
blasts
Refractory anemia with ring sideroblasts 
(RARS)
3–11%
Anemia
Unilineage erythroid dysplasia ≥15% of 
erythroid precursors are ring sideroblasts 
<5% blasts
No blasts
Refractory cytopenias with multilineage 
dysplasia (RCMD)
30%
Cytopenia(s) <1% blasts
Multilineage dysplasia ± ring sideroblasts 
<5% blasts
No Auer rods
No Auer rods
Refractory anemia with excess blasts, 
type 1 (RAEB-1)
40%
Cytopenia(s) <5% blasts
Unilineage or multilineage dysplasia
No Auer rods
Refractory anemia with excess blasts, type 
2 (RAEB-2)
Cytopenia(s) 5–19% blasts Unilineage or multilineage dysplasia 
10–19% blasts
± Auer rods
± Auer rods
410
411
MDS associated with isolated Del(5q) 
(Del(5q)
Uncommon
Anemia
Isolated 5q31 chromosome deletion
Normal or high platelet 
count
Anemia; hypolobated megakaryocytes
<1% blasts
<5% blasts
Childhood MDS, including refractory 
cytopenia of childhood (provisional) (RCC)
<1 %
Pancytopenia
<5% marrow blasts for RCC
Marrow usually hypocellular
MDS, unclassifiable (MDS-U)
?
Cytopenia
≤1% blasts
Does not fit other categories
Dysplasia
<5% blasts
If no dysplasia, MDS-associated karyotype
Note: If peripheral blood blasts are 2–4%, the diagnosis is RAEB-1 even if marrow blasts are <5%. If Auer rods are present, the WHO considers the diagnosis RAEB-2 if the blast 
proportion is <20% (even if <10%), AML if at least 20% blasts. For all subtypes, peripheral blood monocytes are <1 × 109/L. Bicytopenia may be observed in RCUD subtypes, but 
pancytopenia with unilineage marrow dysplasia should be classified as MDS-U. Therapy-related MDS (t-MDS), whether due to alkylating agents, topoisomerase II (t-MDS/t-AML) in 
the WHO classification of AML and precursor lesions. The listing in this table excludes MDS/myeloproliferative neoplasm overlap categories, such as chronic myelomonocytic leuke-
mia, juvenile myelomonocytic leukemia, and the provisional entity RARS with thrombocytosis.
Abbreviation: MDS, myelodysplastic syndrome.
SECTION 6
412
Hematology and Oncology
Incidence and Etiology 
About 3000 cases occur each year, mainly in persons >50 years old (median 
age, 68). As in AML, exposure to benzene, radiation, and chemotherapeutic 
agents may lead to MDS. Chromosome abnormalities occur in up to 80% of 
cases, including deletion of part or all of chromosomes 5, 7, and 9 (20 or 21 
less commonly) and addition of part or all of chromosome 8.
Clinical and Laboratory Features 
Symptoms depend on the affected lineages. 85% of pts are anemic, 50% have 
neutropenia, and about one-third have thrombocytopenia. The pathologic 
features of MDS are a cellular marrow with varying degrees of cytologic atypia 
including delayed nuclear maturation, abnormal cytoplasmic maturation, 
accumulation of ringed sideroblasts (iron-laden mitochondria surrounding 
the nucleus), uni- or bilobed megakaryocytes, micromegakaryocytes, and 
increased myeloblasts. Table 72-3 lists features used to identify distinct entities. 
Prognosis is defined by marrow blast %, karyotype, and lineages affected. The 
International Prognostic Scoring System is shown in Table 72-4.
Myelodysplastic Syndromes
TREATMENT
Allogeneic bone marrow transplantation is the only curative therapy 
and may cure 60% of those so treated. However, the majority of 
pts with MDS are too old to receive transplantation. 5-Azacytidine 
(75 mg/m2 daily × 7, q 4 weeks) can delay transformation to AML by 
8–10 months. Decitabine (15 mg/m2 by continuous IV infusion, q8h 
daily × 3, q 6 weeks) may induce responses lasting a median of 1 year in 
20% of pts. Lenalidomide (10 mg/d), a thalidomide analogue with fewer 
central nervous system effects, causes a substantial fraction of pts with 
the 5q– syndrome to become transfusion-independent. Pts with low 
erythropoietin levels may respond to erythropoietin, and a minority of 
pts with neutropenia respond to granulocyte colony-stimulating factor. 
Supportive care is the cornerstone of treatment.
MYELOPROLIFERATIVE SYNDROMES
The three major myeloproliferative syndromes are polycythemia vera, idio-
pathic myelofibrosis, and essential thrombocytosis. All are clonal disorders 
of hematopoietic stem cells and all are associated with a mutation in the 
JAK2 kinase (V617F) that results in activation of the kinase. The mutation is 
seen in 90% of pts with polycythemia vera and ~45% of pts with idiopathic 
myelofibrosis and essential thrombocytosis.
� POLYCYTHEMIA VERA
The most common myeloproliferative syndrome, this is characterized by an 
increase in red blood cell (RBC) mass, massive splenomegaly, and clinical 
manifestations related to increased blood viscosity, including neurologic 
symptoms (vertigo, tinnitus, headache, visual disturbances) and thromboses 
(myocardial infarction, stroke, peripheral vascular disease; uncommonly, 
CHAPTER 72 
413
mesenteric and hepatic). It must be distinguished from other causes of 
increased RBC mass (Chap. 51). This is most readily done by assaying 
serum erythropoietin levels. Polycythemia vera is associated with very 
low erythropoietin levels; in other causes of erythrocytosis, erythropoietin 
levels are high. Pts are effectively managed with phlebotomy. Some pts 
require splenectomy to control symptoms, and those with severe pruritus 
may benefit from psoralens and UV light. 20% develop myelofibrosis, <5% 
acute leukemia.
� IDIOPATHIC MYELOFIBROSIS
This rare entity is characterized by marrow fibrosis, myeloid metaplasia with 
extramedullary hematopoiesis, and splenomegaly. Evaluation of a blood 
smear reveals teardrop-shaped RBC, nucleated RBC, and some early granu-
locytic forms, including promyelocytes. However, many entities may lead 
to marrow fibrosis and extramedullary hematopoiesis, and the diagnosis of 
primary idiopathic myelofibrosis is made only when the many other potential 
causes are ruled out. The following diseases are in the differential diagnosis: 
CML, polycythemia vera, Hodgkin’s disease, cancer metastatic to the marrow 
(especially from breast and prostate), infection (particularly granulomatous 
infections), and hairy cell leukemia. Supportive therapy is generally used; 
novel inhibitors of JAK2 have shown activity in reducing splenomegaly; how-
ever, no study has yet shown a particular drug therapy to improve survival.
� ESSENTIAL THROMBOCYTOSIS
This is usually noted incidentally upon routine platelet count done in an 
asymptomatic person. Like myelofibrosis, many conditions can produce 
elevated platelet counts; thus, the diagnosis is one of exclusion. Platelet count 
must be >500,000/μL, and known causes of thrombocytosis must be ruled 
Myeloid Leukemias, Myelodysplasia
TABLE 72-4 INTERNATIONAL PROGNOSTIC SCORING SYSTEM (IPSS)
Score Value
Prognostic Variable
0
0.5
1
1.5
2
Bone marrow blasts (%)
<5%
5–10%
11–20%
21–30%
Karyotypea
Good
Intermediate
Poor
Cytopeniab (lineages 
affected)
0 or 1
2 or 3
Risk Group Scores
Score
Low
0
Intermediate-1
0.5–1
Intermediate-2
1.5–2
High
≥2.5
aGood, normal, -Y, del(5q), del (20q); poor, complex (≥3 abnormalities) or chromosome 
7 abnormalities; intermediate, all other abnormalities.
bCytopenias defined as Hb <100 g/L, platelet count <100,000/μL, absolute neutrophil count 
<1500/μL.
SECTION 6
414
Hematology and Oncology
CHAPTER 73
Lymphoid Malignancies
� DEFINITION 
Neoplasms of lymphocytes usually represent malignant counterparts of 
cells at discrete stages of normal lymphocyte differentiation. When bone 
marrow and peripheral blood involvement dominate the clinical picture, 
the disease is classified as a lymphoid leukemia. When lymph nodes and/
or other extranodal sites of disease are the dominant site(s) of involvement, 
the tumor is called a lymphoma. The distinction between lymphoma and 
leukemia is sometimes blurred; for example, small lymphocytic lymphoma 
and chronic lymphoid leukemia are tumors of the same cell type and are 
distinguished arbitrarily on the basis of the absolute number of peripheral 
blood lymphocytes (>5 × 109/L defines leukemia).
� CLASSIFICATION 
Historically, lymphoid tumors have had separate pathologic classifications 
based on the clinical syndrome—lymphomas according to the Rappaport, 
Kiel, or Working Formulation systems; acute leukemias according to the 
French-American-British (FAB) system; Hodgkin’s disease according to 
the Rye classification. Myelomas have generally not been subclassified by 
pathologic features of the neoplastic cells. The World Health Organization 
(WHO) has proposed a unifying classification system that brings together 
all lymphoid neoplasms into a single framework. Although the new system 
bases the definitions of disease entities on histology, genetic abnormalities, 
immunophenotype, and clinical features, its organization is based on cell of 
origin (B cell vs. T cell) and maturation stage (precursor vs. mature) of the 
tumor, features that are of limited value to the clinician. Table 73-1 lists 
the disease entities according to a more clinically useful schema based on 
the clinical manifestations and natural history of the diseases.
out including CML, iron deficiency, splenectomy, malignancy, infection, 
hemorrhage, polycythemia vera, myelodysplasia, and recovery from vitamin 
B12 deficiency. Although usually asymptomatic, pts should be treated if they 
develop migraine headache, transient ischemic attack, or other bleeding or 
thrombotic disease manifestations. Interferon α is effective therapy, as are 
anagrelide and hydroxyurea. Treatment should not be given just because the 
absolute platelet count is high in the absence of other symptoms.
For a more detailed discussion, see Young NS: Aplastic 
Anemia, Myelodysplasia, and Related Bone Marrow Failure 
Syndromes, Chap. 107, p. 887; Spivak JL: Polycythemia Vera 
and Other Myeloproliferative Diseases, Chap. 108, p. 898; 
and Wetzler M et al: Acute and Chronic Myeloid Leukemia, 
Chap. 109, p. 905, in HPIM-18.
415
TABLE 73-1 CLINICAL SCHEMA OF LYMPHOID NEOPLASMS
Chronic lymphoid leukemias/lymphomas
  Chronic lymphocytic leukemia/small lymphocytic lymphoma (99% B cell, 
1% T cell)
  Prolymphocytic leukemia (90% B cell, 10% T cell)
  Large granular lymphocyte leukemia [80% natural killer (NK) cell, 20% T cell]
  Hairy cell leukemia (99–100% B cell)
Indolent lymphoma
  Follicular center cell lymphoma, grades I and II (100% B cell)
  Lymphoplasmacytic lymphoma/Waldenström’s macroglobulinemia 
(100% B cell)
  Marginal zone lymphoma (100% B cell)
  Extranodal [mucosa-associated lymphatic tissue (MALT) lymphoma]
  Nodal (monocytoid B cell lymphoma)
   Splenic marginal zone lymphoma
  Cutaneous T cell lymphoma (mycosis fungoides) (100% T cell)
Aggressive lymphoma
  Diffuse large cell lymphoma (85% B cell, 15% T cell), includes immunoblastic
  Follicular center cell lymphoma, grade III (100% B cell)
  Mantle cell lymphoma (100% B cell)
  Primary mediastinal (thymic) large B cell lymphoma (100% B cell)
  Burkitt-like lymphoma (100% B cell)
  Peripheral T cell lymphoma (100% T cell)
  Angioimmunoblastic lymphoma (100% T cell)
  Angiocentric lymphoma (80% T cell, 20% NK cell)
  Intestinal T cell lymphoma (100% T cell)
  Anaplastic large cell lymphoma (70% T cell, 30% null cell)
Acute lymphoid leukemias/lymphomas
  Precursor lymphoblastic leukemia/lymphoma (80% T cell, 20% B cell)
  Burkitt’s leukemia/lymphoma (100% B cell)
  Adult T cell leukemia/lymphoma (100% T cell)
Plasma cell disorders (100% B cell)
  Monoclonal gammopathy of uncertain significance
  Solitary plasmacytoma
  Extramedullary plasmacytoma
  Multiple myeloma
  Plasma cell leukemia
Hodgkin’s disease (cell of origin mainly B cell)
  Lymphocyte predominant
 Nodular sclerosis
  Mixed cellularity
  Lymphocyte depleted
Lymphoid Malignancies
CHAPTER 73
SECTION 6
416
Hematology and Oncology
� INCIDENCE 
Lymphoid tumors are increasing in incidence. Nearly 116,000 cases have 
been diagnosed in 2012 in the United States (Fig. 73-1).
� ETIOLOGY 
The cause(s) for the vast majority of lymphoid neoplasms is unknown. The 
malignant cells are monoclonal and often contain numerous genetic abnor-
malities. Some genetic alterations are characteristic of particular histologic 
entities: t(8;14) in Burkitt’s lymphoma, t(14;18) in follicular lymphoma, 
t(11;14) in mantle cell lymphoma, t(2;5) in anaplastic large cell lymphoma, 
translocations or mutations involving bcl-6 on 3q27 in diffuse large cell 
lymphoma, and others. In most cases, translocations involve insertion of 
a distant chromosome segment into the antigen receptor genes (either 
immunoglobulin or T cell receptor) during the rearrangement of the gene 
segments that form the receptors.
Three viruses—Epstein-Barr virus (EBV), human herpesvirus 8 (HHV-8) 
(both herpes family viruses), and human T-lymphotropic virus type I 
(HTLV-I, a retrovirus)—may cause some lymphoid tumors. EBV has been 
strongly associated with African Burkitt’s lymphoma and the lymphomas 
that complicate immunodeficiencies (disease-related or iatrogenic). EBV 
has an uncertain relationship to mixed cellularity Hodgkin’s disease and 
angiocentric lymphoma. HHV-8 causes a rare entity, body cavity lym-
phoma, mainly in pts with AIDS. HTLV-I is associated with adult T cell 
leukemia/lymphoma. Both the virus and the disease are endemic to south-
western Japan and the Caribbean.
Gastric Helicobacter pylori infection is associated with gastric mucosa-
associated lymphoid tissue (MALT) lymphoma and perhaps gastric large 
cell lymphoma. Eradication of the infection produces durable remissions in 
about half of pts with gastric MALT lymphoma. MALT lymphomas of other 
sites are associated with either infection (ocular adnexae, Chlamydia psittaci; 
small intestine, Campylobacter jejuni; skin, Borrelia) or autoimmunity 
(salivary gland, Sjögren’s syndrome; thyroid gland, Hashimoto’s thyroiditis).
Inherited or acquired immunodeficiencies and autoimmune disorders 
predispose individuals to lymphoma. Lymphoma is 17 times more com-
mon in HIV-infected than in HIV-noninfected people. Lymphoma occurs 
with increased incidence in farmers and meat workers; Hodgkin’s disease is 
increased in wood workers.
� DIAGNOSIS AND STAGING 
Excisional biopsy is the standard diagnostic procedure; adequate tissue must 
be obtained. Tissue undergoes three kinds of studies: (1) light microscopy 
to discern the pattern of growth and the morphologic features of the malig-
nant cells, (2) flow cytometry for assessment of immunophenotype, and (3) 
genetic studies (cytogenetics, DNA extraction). Needle aspirates of nodal or 
extranodal masses are not adequate diagnostic procedures. Leukemia diag-
nosis and lymphoma staging include generous bilateral iliac crest bone mar-
row biopsies. Differential diagnosis of adenopathy is reviewed in Chap. 50.
Staging varies with the diagnosis. In acute leukemia, peripheral blood 
blast counts are most significant in assessing prognosis. In chronic 
Non-Hodgkin’s lymphoma subtypes
31% Diffuse large B cell lymphoma
22% Follicular lymphoma
7.6% MALT lymphoma
7.6% Mature T cell lymphoma
6.7% Small lymphocytic lymphoma
6% Mantle cell lymphoma
2.4% Mediastinal large B cell lymphoma
2.4% Anaplastic large cell lymphoma
2.4% Burkitt’s lymphoma
1.8% Nodal marginal zone lymphoma
1.7% Precursor T lymphoblastic lymphoma
1.2% Lymphoplasmacytic lymphoma
7.4% Others
Plasma cell
disorders
16%
Non-Hodgkin’s
lymphoma
62.4%
CLL
9%
ALL
3.8%
Hodgkin’s
disease
8.2%
FIGURE 73-1 Relative frequency of lymphoid malignancies. ALL, acute lymphoid leukemia; CLL, chronic lymphoid leukemia; MALT, mucosa-associated lymphoid 
tissue.
417
SECTION 6
418
Hematology and Oncology
leukemia, peripheral blood red blood cell (RBC) and platelet counts are 
most significant in assessing prognosis. Non-Hodgkin’s lymphomas have 
five clinical prognostic factors; indolent and aggressive lymphomas share 
three of these, advanced stage, high lactate dehydrogenase (LDH) levels, 
and age >60. In follicular lymphoma, the last two factors are Hb <120 g/L 
(<12 g/dL) and more than four nodal sites of involvement. In aggressive 
lymphoma, more than one extranodal site and performance status pre-
dict outcome. In myeloma, serum levels of paraprotein, creatinine, and 
β2-microglobulin levels predict survival.
CHRONIC LYMPHOID LEUKEMIAS/LYMPHOMAS
Most of these entities have a natural history measured in years. 
(Prolymphocytic leukemia is very rare and can be very aggressive.) Chronic 
lymphocytic leukemia is the most common entity in this group (~15,000 
cases/year in the U.S.) and the most common leukemia in the Western world.
� CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) 
Usually presents as asymptomatic lymphocytosis in pts >60 years. The 
malignant cell is a CD5+ B cell that looks like a normal small lymphocyte. 
Trisomy 12 is the most common genetic abnormality. Prognosis is related 
to stage; stage is determined mainly by the degree to which the tumor cells 
crowd out normal hematopoietic elements from the marrow (Table 73-2). 
Cells may infiltrate nodes and spleen as well as marrow. Nodal involvement 
may be related to the expression of an adhesion molecule that allows the 
cells to remain in the node rather than recirculate. Pts often have hypo-
gammaglobulinemia. Up to 20% have autoimmune antibodies that may 
produce autoimmune hemolytic anemia, thrombocytopenia, or red cell 
aplasia. Death is from infection, marrow failure, or intercurrent illnesses. In 
5%, the disease evolves to aggressive lymphoma (Richter’s syndrome) that 
is refractory to treatment.
TABLE 73-2 STAGING OF B CELL CLL AND RELATION TO SURVIVAL
Stage
Clinical Features
Median Survival, 
Years
RAI
0
Lymphocytosis
12
I
Lymphocytosis + adenopathy
9
II
Lymphocytosis + splenomegaly
7
III
Anemia
1–2
IV
Thrombocytopenia
1–2
BINET
A
No anemia/thrombocytopenia, <3 involved sites >10
B
No anemia/thrombocytopenia, >3 involved sites 5
C
Anemia and/or thrombocytopenia
2
CHAPTER 73 
419
Lymphoid Malignancies
Subsets of CLL may exist based on whether the immunoglobulin 
expressed by the tumor cell contains mutations (more indolent course, good 
prognosis) or retains the germ-line sequence (more aggressive course, poor 
response to therapy). Methods to distinguish the two subsets clinically are 
not well defined; CD38+ tumors may have poorer prognosis. The expres-
sion of ZAP-70, an intracellular tyrosine kinase normally present in T cells 
and aberrantly expressed in about 45% of CLL cases, may be a better way 
to define prognostic subsets. ZAP-70-positive cases usually need treatment 
within about 3–4 years from diagnosis; ZAP-70-negative cases usually don’t 
require treatment for 8–11 years.
Chronic Lymphocytic Leukemia
TREATMENT
Supportive care is generally given until anemia or thrombocytopenia 
develop. At that time, tests are indicated to assess the cause of the anemia 
or thrombocytopenia. Decreased RBC and/or platelet counts related to 
peripheral destruction may be treated with splenectomy or glucocorti-
coids without cytotoxic therapy in many cases. If marrow replacement is 
the mechanism, cytotoxic therapy is indicated. Fludarabine, 25 (mg/m2)/d 
IV × 5 days every 4 weeks, induces responses in about 75% of pts, com-
plete responses in half. Rituximab (375–500 mg/m2 day 1), fludarabine 
(25 mg/m2 days 2–4 on cycle 1 and 1–3 in subsequent cycles), plus cyclo-
phosphamide (250 mg/m2 with fludarabine) induces complete responses 
in nearly 70% of pts but the regimen is associated with significant myelo-
toxicity. Glucocorticoids increase the risk of infection without adding 
a substantial antitumor benefit. Monthly IV immunoglobulin (IVIg) 
significantly reduces risk of serious infection but is expensive and usu-
ally reserved for pts who have had a serious infection. Alkylating agents 
are also active against the tumor. Therapeutic intent is palliative in most 
pts. Young pts may be candidates for high-dose therapy and autologous 
or allogeneic hematopoietic cell transplantation; long-term disease-free 
survival has been noted. Mini-transplant, in which the preparative regi-
men is immunosuppressive but not myeloablative, may be less toxic and 
as active or more active in disease treatment than high-dose therapy. 
Monoclonal antibodies alemtuzumab (anti-CD52) and rituximab (anti-
CD20) also are active as single agents.
See Chaps. 110 and e21 in HPIM-18 for discussion of the rarer entities.
INDOLENT LYMPHOMAS
These entities have a natural history measured in years. Median survival 
is about 10 years. Follicular lymphoma is the most common indolent 
lymphoma, accounting for about one-third of all lymphoid malignancies.
� FOLLICULAR LYMPHOMA 
Usually presents with painless peripheral lymphadenopathy, often involving 
several nodal regions. “B symptoms” (fever, sweats, weight loss) occur in 
10%, less common than with Hodgkin’s disease. In about 25%, nodes wax 
SECTION 6
420
Hematology and Oncology
and wane before the pt seeks medical attention. Median age is 55 years. 
Disease is widespread at diagnosis in 85%. Liver and bone marrow are com-
monly involved extranodal sites.
The tumor has a follicular or nodular growth pattern reflecting the fol-
licular center origin of the malignant cell. The t(14;18) is present in 85% 
of cases, resulting in the overexpression of bcl-2, a protein involved in 
prevention of programmed cell death. The normal follicular center B cell 
is undergoing active mutation of the immunoglobulin variable regions in 
an effort to generate antibody of higher affinity for the selecting antigen. 
Follicular lymphoma cells also have a high rate of mutation that leads to the 
accumulation of genetic damage. Over time, follicular lymphomas acquire 
sufficient genetic damage (e.g., mutated p53) to accelerate their growth and 
evolve into diffuse large B cell lymphomas that are often refractory to treat-
ment. The majority of pts dying from follicular lymphoma have undergone 
histologic transformation. This transformation occurs at a rate of about 7% 
per year and is an attribute of the disease, not the treatment.
Follicular Lymphoma
TREATMENT
Only 15% of pts have localized disease, but the majority of these pts 
are curable with radiation therapy. Although many forms of treat-
ment induce tumor regression in advanced-stage pts, it is not clear 
that treatment of any kind alters the natural history of disease. No 
therapy, single-agent alkylators, nucleoside analogues (fludarabine, 
cladribine), combination chemotherapy, radiation therapy, and biologic 
agents [interferon (IFN) α, monoclonal antibodies such as rituximab 
(anti-CD20)] are all considered appropriate. More than 90% of pts are 
responsive to treatment; complete responses are seen in about 50–75% 
of pts treated aggressively. The median duration of remission of pts 
treated with cyclophosphamide, doxorubicin, vincristine, and predni-
sone (CHOP) + rituximab exceeds 6 years. Younger pts are being treated 
experimentally with high-dose therapy and autologous hematopoietic 
stem cells or mini-transplant. It is not yet clear whether this is curative. 
Radioimmunotherapy with isotopes guided by anti-CD20 antibody 
(ibritumomab tiuxetan, In-111; tositumomab, I-131) may produce dura-
ble responses. Combination chemotherapy with or without IFN mainte-
nance may prolong survival and delay or prevent histologic progression, 
especially in pts with poor prognostic features. Remissions appear to last 
longer with chemotherapy plus rituximab; some data suggest that the 
longer remissions are leading to improved survival.
See Chaps. 110 and e21 in HPIM-18 for discussion of the other indolent 
lymphomas.
AGGRESSIVE LYMPHOMAS
A large number of pathologic entities share an aggressive natural history; 
median survival untreated is 6 months, and nearly all untreated pts are dead 
within 1 year. Pts may present with asymptomatic adenopathy or symptoms 
CHAPTER 73 
421
Lymphoid Malignancies
referable to involvement of practically any nodal or extranodal site: medias-
tinal involvement may produce superior vena cava syndrome or pericardial 
tamponade; retroperitoneal nodes may obstruct ureters; abdominal masses 
may produce pain, ascites, or GI obstruction or perforation; central nervous 
system (CNS) involvement may produce confusion, cranial nerve signs, 
headache, seizures, and/or spinal cord compression; bone involvement may 
produce pain or pathologic fracture. About 45% of pts have B symptoms.
Diffuse large B cell lymphoma is the most common histologic diagnosis 
among the aggressive lymphomas, accounting for 35–45% of all lymphomas. 
Aggressive lymphomas together account for ~60% of all lymphoid tumors. 
About 85% of aggressive lymphomas are of mature B cell origin; 15% are 
derived from peripheral (postthymic) T cells.
Aggressive Lymphoma
APPROACH TO THE
PATIENT
Early diagnostic biopsy is critical. Pt workup is directed by symptoms 
and known patterns of disease. Pts with Waldeyer’s ring involvement 
should undergo careful evaluation of the GI tract. Pts with bone or bone 
marrow involvement should have a lumbar puncture to evaluate menin-
geal CNS involvement.
Aggressive Lymphomas
TREATMENT
Localized aggressive lymphomas are usually treated with four cycles of 
CHOP combination chemotherapy ± involved-field radiation therapy. 
About 85% of these pts are cured. CHOP + rituximab appears to be even 
more effective than CHOP + radiation therapy. The specific therapy 
used for pts with more advanced disease is controversial. Six cycles of 
CHOP + rituximab is the treatment of choice for advanced-stage dis-
ease. Outcome is influenced by tumor bulk (usually measured by LDH 
levels, stage, and number of extranodal sites) and physiologic reserve 
(usually measured by age and Karnofsky status) (Table 73-3). CHOP + 
rituximab cures about two-thirds of pts. The use of a sequential high-
dose chemotherapy regimen in pts with high-intermediate- and high-
risk disease has yielded long-term survival in about 75% of pts in some 
institutions. Other studies fail to confirm a role for high-dose therapy.
About 30–45% of pts not cured with initial standard combination 
chemotherapy may be salvaged with high-dose therapy and autologous 
hematopoietic stem cell transplantation.
Specialized approaches are required for lymphomas involving certain 
sites (e.g., CNS, stomach) or under certain complicating clinical circum-
stances (e.g., concurrent illness, AIDS). Lymphomas occurring in iatro-
genically immunosuppressed pts may regress when immunosuppressive 
medication is withheld. Lymphomas occurring post–allogeneic marrow 
transplant may regress with infusions of donor leukocytes.
Pts with rapidly growing bulky aggressive lymphoma may experience 
tumor lysis syndrome when treated (Chap. 27); prophylactic measures 
(hydration, urine alkalinization, allopurinol, rasburicase) may be lifesaving.
SECTION 6
422
Hematology and Oncology
ACUTE LYMPHOID LEUKEMIAS/LYMPHOMAS
� ACUTE LYMPHOBLASTIC LEUKEMIA AND LYMPHOBLASTIC LYMPHOMA 
These are more common in children than adults (~6000 total cases/year). 
The majority of cases have tumor cells that appear to be of thymic origin, 
and pts may have mediastinal masses. Pts usually present with recent 
onset of signs of marrow failure (pallor, fatigue, bleeding, fever, infection). 
Hepatosplenomegaly and adenopathy are common. Males may have testic-
ular enlargement reflecting leukemic involvement. Meningeal involvement 
may be present at diagnosis or develop later. Elevated LDH, hyponatremia, 
and hypokalemia may be present, in addition to anemia, thrombocytopenia, 
and high peripheral blood blast counts. The leukemic cells are more often 
FAB type L2 in adults than in children, where L1 predominates. Leukemia 
diagnosis requires at least 20% lymphoblasts in the marrow. Prognosis is 
adversely affected by high presenting white count, age >35 years, and the 
presence of t(9;22), t(1;19), and t(4;11) translocations. HOX11 expression 
identifies a more favorable subset of T cell acute lymphoblastic leukemia.
Acute Lymphoblastic Leukemia and Lymphoblastic 
Lymphoma
TREATMENT
Successful treatment requires intensive induction phase, CNS prophy-
laxis, and maintenance chemotherapy that extends for about 2 years. 
TABLE 73-3 INTERNATIONAL PROGNOSTIC INDEX FOR NHL
Five clinical risk factors:
 Age ≥60 years
 Serum lactate dehydrogenase levels elevated
 Performance status ≥2 (ECOG) or ≤70 (Karnofsky)
 Ann Arbor stage III or IV
>1 site of extranodal involvement
Pts are assigned a number for each risk factor they have
Pts are grouped differently based on the type of lymphoma
For diffuse large B cell lymphoma:
 0, 1 factor = low risk:
35% of cases; 5-year survival, 73%
 2 factors = low-intermediate risk:
27% of cases; 5-year survival, 51%
 3 factors = high-intermediate risk:
22% of cases; 5-year survival, 43%
 4, 5 factors = high risk:
16% of cases; 5-year survival, 26%
For diffuse large B cell lymphoma treated with R-CHOP:
 0 factor = very good:
10% of cases; 5-year survival, 94%
 1, 2 factors = good:
45% of cases; 5-year survival, 79%
 3, 4, 5 factors = poor:
45% of cases; 5-year survival, 55%
Abbreviations: ECOG, Eastern Cooperative Oncology Group; R-CHOP, rituximab, cyclophos-
phamide, doxorubicin, vincristine, prednisone.
CHAPTER 73 
423
Lymphoid Malignancies
Vincristine, L-asparaginase, cytarabine, daunorubicin, and prednisone 
are particularly effective agents. Intrathecal or high-dose systemic meth-
otrexate is effective CNS prophylaxis. Long-term survival of 60–65% of 
pts may be achieved. The role and timing of bone marrow transplanta-
tion in primary therapy is debated, but up to 30% of relapsed pts may be 
cured with salvage transplantation.
� BURKITT’S LYMPHOMA/LEUKEMIA 
This is also more common in children. It is associated with translocations 
involving the c-myc gene on chromosome 8 rearranging with immuno-
globulin heavy or light chain genes. Pts often have disseminated disease 
with large abdominal masses, hepatomegaly, and adenopathy. If a leukemic 
picture predominates, it is classified as FAB L3.
Burkitt’s Lymphoma/Leukemia
TREATMENT
Resection of large abdominal masses improves treatment outcome. 
Aggressive leukemia regimens that include vincristine, cyclophos-
phamide, 6-mercaptopurine, doxorubicin, and prednisone are active. 
CODOX-M and the BFM regimen are the most effective regimens. Cure 
may be achieved in 50–60%. The need for maintenance therapy is unclear. 
Prophylaxis against tumor lysis syndrome is important (Chap. 27).
� ADULT T CELL LEUKEMIA/LYMPHOMA (ATL) 
This is very rare; only a small fraction (~2%) of persons infected with 
HTLV-I go on to develop the disease. Some HTLV-I-infected pts develop 
spastic paraplegia from spinal cord involvement without developing cancer. 
The characteristic clinical syndrome of ATL includes high white count 
without severe anemia or thrombocytopenia, skin infiltration, hepatomegaly, 
pulmonary infiltrates, meningeal involvement, and opportunistic infections. 
The tumor cells are CD4+ T cells with cloven hoof- or flower-shaped nuclei. 
Hypercalcemia occurs in nearly all pts and is related to cytokines produced 
by the tumor cells.
Adult T Cell Leukemia/Lymphoma
TREATMENT
Aggressive therapy is associated with serious toxicity related to the 
underlying immunodeficiency. Glucocorticoids relieve hypercalcemia. 
The tumor is responsive to therapy, but responses are generally short-
lived. Zidovudine and IFN may be palliative in some pts.
PLASMA CELL DISORDERS
The hallmark of plasma cell disorders is the production of immunoglobulin 
molecules or fragments from abnormal plasma cells. The intact immuno-
globulin molecule, or the heavy chain or light chain produced by the abnor-
mal plasma cell clone, is detectable in the serum and/or urine and is called 
SECTION 6
424
Hematology and Oncology
the M (for monoclonal) component. The amount of the M component in 
any given pt reflects the tumor burden in that pt. In some, the presence of a 
clonal light chain in the urine (Bence Jones protein) is the only tumor prod-
uct that is detectable. M components may be seen in pts with other lym-
phoid tumors, nonlymphoid cancers, and noncancerous conditions such 
as cirrhosis, sarcoidosis, parasitic infestations, and autoimmune diseases.
� MULTIPLE MYELOMA 
A malignant proliferation of plasma cells in the bone marrow (notably not 
in lymph nodes). Nearly 22,000 new cases are diagnosed each year. Disease 
manifestations result from tumor expansion, local and remote actions of 
tumor products, and the host response to the tumor. About 70% of pts have 
bone pain, usually involving the back and ribs, precipitated by movement. 
Bone lesions are multiple, lytic, and rarely accompanied by an osteoblastic 
response. Thus, bone scans are less useful than radiographs. The production 
of osteoclast-activating cytokines by tumor cells leads to substantial calcium 
mobilization, hypercalcemia and symptoms related to it. Decreased synthesis 
and increased catabolism of normal immunoglobulins leads to hypogam-
maglobulinemia, and a poorly defined tumor product inhibits granulocyte 
migration. These changes create a susceptibility to bacterial infections, espe-
cially the pneumococcus, Klebsiella pneumoniae, and Staphylococcus aureus 
affecting the lung and Escherichia coli and other gram-negative pathogens 
affecting the urinary tract. Infections affect at least 75% of pts at some 
time in their course. Renal failure may affect 25% of pts; its pathogenesis is 
multifactorial—hypercalcemia, infection, toxic effects of light chains, urate 
nephropathy, dehydration. Neurologic symptoms may result from hyper-
viscosity, cryoglobulins, and rarely amyloid deposition in nerves. Anemia 
occurs in 80% related to myelophthisis and inhibition of erythropoiesis by 
tumor products. Clotting abnormalities may produce bleeding.
Diagnosis
Marrow plasmacytosis >10%, lytic bone lesions, and a serum and/or urine 
M component are the classic triad. Monoclonal gammopathy of uncertain 
significance (MGUS) is much more common than myeloma, affecting 
about 6% of people over age 70; in general, MGUS is associated with a 
level of M component <20 g/L, low serum β2-microglobulin, <10% marrow 
plasma cells, and no bone lesions. Lifetime risk of progression of MGUS to 
myeloma is about 25%.
Staging
Disease stage influences survival (Table 73-4).
Multiple Myeloma
TREATMENT
About 10% of pts have very slowly progressive disease and do not 
require treatment until the paraprotein levels rise above 50 g/L or 
progressive bone disease occurs. Pts with solitary plasmacytoma and 
extramedullary plasmacytoma are usually cured with localized radiation 
therapy. Supportive care includes early treatment of infections; control of
CHAPTER 73 
425
Lymphoid Malignancies
TABLE 73-4 MYELOMA STAGING SYSTEMS
Durie-Salmon Staging System
Stage
Criteria
Estimated
tumor burden, 
× 1012 cells/m2
I
All of the following:
1. Hemoglobin >100 g/L (>10 g/dL)
<0.6 (low)
2.  Serum calcium <3 mmol/L (<12 mg/dL)
3.  Normal bone x-ray or solitary lesion
4.  Low M-component production
a. IgG level <50 g/L (<5 g/dL)
b. IgA level <30 g/L (<3 g/dL)
c. Urine light chain <4 g/24 h
II
Fitting neither I nor III
0.6–1.20 
(intermediate)
III
One or more of the following:
1. Hemoglobin <85 g/L (<8.5 g/dL)
>1.20 (high)
2.  Serum calcium >3 mmol/L (>12 mg/dL)
3. Advanced lytic bone lesions
4. High M-component production
a. IgG level >70 g/L (>7 g/dL)
b. IgA level >50 g/L (>5 g/dL)
c. Urine light chains >12 g/24 h
Level
Stage
Median Survival, 
Months
Subclassification based on serum creatinine levels
A <177 μmol/L 
(<2 mg/dL)
IA
61
B >177 μmol/L 
(>2 mg/dL)
IIA, B
55
IIIA
30
IIIB
15
International Staging System
β2M <3.5, alb 
≥3.5
I (28%)
62
β2M <3.5, alb 
<3.5 or β2M = 
3.5–5.5
II (39%)
44
β2M >5.5
III (33%)
29
Note: β2M, serum β2-microglobulin in mg/L; alb, serum albumin in g/dL; (#), % pts presenting 
at each stage.
SECTION 6
426
Hematology and Oncology
hypercalcemia with glucocorticoids, hydration, and natriuresis; chronic 
administration of bisphosphonates to antagonize skeletal destruction; and 
prophylaxis against urate nephropathy and dehydration. Therapy aimed 
at the tumor is usually palliative. Initial therapy is usually one of several 
approaches, based on whether the pt is a candidate for high-dose therapy 
and autologous stem cell transplant. Transplant-eligible (avoid alkylating 
agents): thalidomide, 400 mg/d PO or 200 mg qhs, plus dexamethasone, 
40 mg/d on days 1–4 each month, with or without bortezomib or chemo-
therapy such as liposomal doxorubicin. Transplant-ineligible: melphalan, 
8 mg/m2 orally for 4–7 days every 4–6 weeks, plus prednisone. About 60% 
of pts have significant symptomatic improvement plus a 75% decline in 
the M component. Bortezomib also appears to improve response rates to 
melphalan. Experimental approaches using sequential high-dose pulses 
of melphalan plus two successive autologous stem cell transplants have 
produced complete responses in about 50% of pts <65 years. Long-term 
follow-up is required to see whether survival is enhanced. Palliatively 
treated pts generally follow a chronic course for 2–5 years, followed by an 
acceleration characterized by organ infiltration with myeloma cells and 
marrow failure. More aggressive treatment may produce median survival 
of 6 years. New approaches to salvage treatment include bortezomib, 
1.3 mg/m2 on days 1, 4, 8, and 11 every 3 weeks, often used with dexa-
methasone, vincristine, and/or liposomal doxorubicin. Lenalidomide is 
also active and increasingly used as maintenance therapy.
� HODGKIN’S DISEASE 
About 9000 new cases are diagnosed each year. Hodgkin’s disease (HD) is 
a tumor of Reed-Sternberg cells, aneuploid cells that usually express CD30 
and CD15 but may also express other B or T cell markers. Most tumors 
are derived from B cells in that immunoglobulin genes are rearranged but 
not expressed. Most of the cells in an enlarged node are normal lymphoid, 
plasma cells, monocytes, and eosinophils. The etiology is unknown, but 
the incidence in both identical twins is 99-fold increased over the expected 
concordance, suggesting a genetic susceptibility. Distribution of histologic 
subtypes is 75% nodular sclerosis, 20% mixed cellularity, with lymphocyte 
predominant and lymphocyte depleted representing about 5%.
Clinical Manifestations 
Usually presents with asymptomatic lymph node enlargement or with 
adenopathy associated with fever, night sweats, weight loss, and sometimes 
pruritus. Mediastinal adenopathy (common in nodular sclerosing HD) 
may produce cough. Spread of disease tends to be to contiguous lymph 
node groups. Superior vena cava obstruction or spinal cord compression 
may be presenting manifestation. Involvement of bone marrow and liver 
is rare.
Differential Diagnosis
• Infection—mononucleosis, viral syndromes, Toxoplasma, Histoplasma, 
primary tuberculosis
CHAPTER 73 
427
Lymphoid Malignancies
• Other malignancies—especially head and neck cancers
• Sarcoidosis—mediastinal and hilar adenopathy
Immunologic and Hematologic Abnormalities
• Defects in cell-mediated immunity (remains even after successful treat-
ment of lymphoma); cutaneous anergy; diminished antibody production 
to capsular antigens of Haemophilus and pneumococcus
• Anemia; elevated erythrocyte sedimentation rate; leukemoid reaction; 
eosinophilia; lymphocytopenia; fibrosis and granulomas in marrow
Staging
The Ann Arbor staging classification is shown in Table 73-5. Disease is 
staged by performing physical exam, chest x-ray, thoracoabdominal CT, 
bone marrow biopsy; ultrasound examinations, lymphangiogram. Staging 
laparotomy should be used, especially to evaluate the spleen, if pt has 
early-stage disease on clinical grounds and radiation therapy is being 
contemplated. Pathologic staging is unnecessary if the pt is treated with 
chemotherapy.
TABLE 73-5 THE ANN ARBOR STAGING SYSTEM FOR HODGKIN’S DISEASE
Stage
Definition
I
Involvement of a single lymph node region or lymphoid struc-
ture (e.g., spleen, thymus, Waldeyer’s ring)
II
Involvement of two or more lymph node regions on the same 
side of the diaphragm (the mediastinum is a single site; hilar 
lymph nodes should be considered “lateralized” and, when 
involved on both sides, constitute stage II disease)
III
Involvement of lymph node regions or lymphoid structures on 
both sides of the diaphragm
 III1
  Subdiaphragmatic involvement limited to spleen, splenic 
hilar nodes, celiac nodes, or portal nodes
 III2
  Subdiaphragmatic involvement includes paraaortic, iliac, or 
mesenteric nodes plus structures in III1
IV
Involvement of extranodal site(s) beyond that designated as “E”
 More than one extranodal deposit at any location
 Any involvement of liver or bone marrow
A
No symptoms
B
Unexplained weight loss of >10% of the body weight during 
the 6 months before staging investigation
Unexplained, persistent, or recurrent fever with temperatures 
>38°C during the previous month
Recurrent drenching night sweats during the previous month
E
Localized, solitary involvement of extralymphatic tissue, exclud-
ing liver and bone marrow
SECTION 6
428
Hematology and Oncology
Hodgkin’s Disease
TREATMENT
About 85% of pts are curable. Therapy should be performed by experi-
enced clinicians in centers with appropriate facilities. Most pts are clini-
cally staged and treated with chemotherapy alone or combined-modality 
therapy. Those with localized disease may be treated with radiation 
therapy alone. Those with stage II disease often receive either two or 
four cycles of ABVD plus involved-field radiation therapy or Stanford 
V, a combined-modality program using lower doses of chemotherapy. 
Those with stage III or IV disease receive six cycles of combination che-
motherapy, usually ABVD. Pts with any stage disease accompanied by a 
large mediastinal mass (greater than one-third the greatest chest diam-
eter) should receive combined-modality therapy with MOPP/ABVD or 
MOPP-ABV hybrid followed by mantle field radiation therapy. (Radiation 
plus ABVD is too toxic to the lung.) A persistently positive midtreatment 
positron emission tomography scan may be an index of risk of relapse and 
need for additional therapy. About one-half of pts (or more) not cured by 
their initial chemotherapy regimen may be rescued by high-dose therapy 
and autologous stem cell transplant. Brentuximab vedotin, an anti-CD30 
drug conjugate, has activity in patients relapsing after transplant.
With long-term follow-up, it has become clear that more pts are dying 
of late fatal toxicities related to radiation therapy (myocardial infarction, 
stroke, second cancers) than from HD. It may be possible to avoid radia-
tion exposure by using combination chemotherapy alone in early-stage 
disease as well as in advanced-stage disease.
CHAPTER 74
Skin Cancer
� MALIGNANT MELANOMA
Most dangerous cutaneous malignancy; high metastatic potential; poor 
prognosis with metastatic spread.
Incidence
Melanoma has been diagnosed in 76,250 people in the United States in 2011 
and caused 9180 deaths.
Predisposing Factors (Table 74-1)
Fair complexion, sun exposure, family history of melanoma, dysplastic nevus 
syndrome (autosomal dominant disorder with multiple nevi of distinctive 
For a more detailed discussion, see Longo DL: Malignancies of 
Lymphoid Cells, Chap. 110, p. 919; Munshi NC et al: Plasma 
Cell Disorders, Chap. 111, p. 936; and Chap. e21 in HPIM-18.
CHAPTER 74 
429
Skin Cancer
appearance and cutaneous melanoma, may be associated with 9p deletion), 
and presence of a giant congenital nevus. Blacks have a low incidence.
Prevention
Sun avoidance lowers risk. Sunscreens are not proven effective.
Types
1. Superficial spreading melanoma: Most common; begins with initial radial 
growth phase before invasion.
2. Lentigo maligna melanoma: Very long radial growth phase before inva-
sion, lentigo maligna (Hutchinson’s melanotic freckle) is precursor 
lesion, most common in elderly and in sun-exposed areas (esp. face).
3. Acral lentiginous: Most common form in darkly pigmented pts; occurs 
on palms and soles, mucosal surfaces, in nail beds and mucocutaneous 
junctions; similar to lentigo maligna melanoma but with more aggressive 
biologic behavior.
4. Nodular: Generally poor prognosis because of invasive growth from onset.
Biology 
About half of melanomas carry an activating somatic mutation in the BRAF 
gene, often a valine to glutamate substitution at amino acid 600 (V600E). 
N-ras is mutated in about 20% and rare pts have activating mutations in 
c-kit. These mutations have been targeted by therapeutic agents that appear 
to have antitumor activity.
Clinical Appearance 
Generally pigmented (rarely amelanotic); color of lesions varies, but red, 
white, and/or blue are common, in addition to brown and/or black. Suspicion 
should be raised by a pigmented skin lesion that is >6 mm in diameter, asym-
metric, has an irregular surface or border, or has variation in color.
Prognosis
Best with thin lesions without evidence of metastatic spread; with increas-
ing thickness or evidence of spread, prognosis worsens. Stage I and II 
TABLE 74-1 FACTORS ASSOCIATED WITH INCREASED RISK OF MELANOMA
Total body nevi (higher number = higher risk)
Family or personal history
Dysplastic nevi
Light skin/hair/eye color
Poor tanning ability
Freckling
UV exposure/sunburns/tanning booths
CDKN2A mutation
MC1R variants
SECTION 6
430
Hematology and Oncology
(primary tumor without spread) have 85% 5-year survival. Stage III (pal-
pable regional nodes with tumor) has a 50% 5-year survival when only one 
node is involved and 15–20% when four or more are involved. Stage IV 
(disseminated disease) has <5% 5-year survival.
Malignant Melanoma
TREATMENT
Early recognition and local excision for localized disease is best; 1- to 
2-cm margins are as effective as 4- to 5-cm margins and do not usually 
require skin grafting. Elective lymph node dissection offers no advantage 
in overall survival compared with deferral of surgery until clinical recur-
rence. Pts with stage II disease may have improved disease-free survival 
with adjuvant interferon-α 3 million units three times weekly for 12–18 
months. In one study, pts with stage III disease had improved survival with 
adjuvant IFN, 20 million units IV daily × 5 for 4 weeks, then 10 million 
units SC three times weekly for 11 months. This result was not confirmed 
in a second study. Metastatic disease may be treated with chemotherapy or 
immunotherapy. Vemurafenib 960 mg PO bid induces responses in about 
50% of pts with BRAF mutations. Median survival is about 16 months. The 
anti-CTLA4 antibody ipilimumab prolongs survival by about 4 months. 
Dacarbazine (250 mg/m2 IV daily × 5 q3w) plus tamoxifen (20 mg/m2 PO 
daily) may induce partial responses in one-quarter of pts. IFN and inter-
leukin 2 (IL-2) at maximum tolerated doses induce partial responses in 
15% of pts. Rare long remissions occur with IL-2. Temozolomide is an oral 
agent related to dacarbazine that has some activity. It can enter the central 
nervous system (CNS) and is being evaluated with radiation therapy for 
CNS metastases. No therapy for metastatic disease is curative. Vaccines and 
adoptive cellular therapies are being tested.
� BASAL CELL CARCINOMA (BCC)
Most common form of skin cancer; most frequently on sun-exposed skin, 
esp. face.
Predisposing Factors 
Fair complexion, chronic UV exposure, exposure to inorganic arsenic (i.e., 
Fowler’s solution or insecticides such as Paris green), or exposure to ionizing 
radiation.
Prevention
Avoidance of sun exposure and use of sunscreens lower risk.
Types 
Five general types: noduloulcerative (most common), superficial (mim-
ics eczema), pigmented (may be mistaken for melanoma), morpheaform 
(plaquelike lesion with telangiectasia—with keratotic is most aggressive), 
keratotic (basosquamous carcinoma).
Clinical Appearance 
Classically a pearly, translucent, smooth papule with rolled edges and sur-
face telangiectasia.
CHAPTER 74 
431
Skin Cancer
Basal Cell Carcinoma
TREATMENT
Local removal with electrodesiccation and curettage, excision, cryosur-
gery, or radiation therapy; metastases are rare but may spread locally. 
Exceedingly unusual for BCC to cause death. Locally advanced or meta-
static disease may respond to vismodegib, an inhibitor of the hedgehog 
pathway often activated in this disease.
� SQUAMOUS CELL CARCINOMA (SCC)
Less common than basal cell but more likely to metastasize.
Predisposing Factors 
Fair complexion, chronic UV exposure, previous burn or other scar (i.e., 
scar carcinoma), exposure to inorganic arsenic or ionizing radiation. 
Actinic keratosis is a premalignant lesion.
Types 
Most commonly occurs as an ulcerated nodule or a superficial erosion on 
the skin. Variants include:
1. Bowen’s disease: Erythematous patch or plaque, often with scale; non-
invasive; involvement limited to epidermis and epidermal appendages 
(i.e., SCC in situ).
2. Scar carcinoma: Suggested by sudden change in previously stable scar, 
esp. if ulceration or nodules appear.
3. Verrucous carcinoma: Most commonly on plantar aspect of foot; low-grade 
malignancy but may be mistaken for a common wart.
Clinical Appearance 
Hyperkeratotic papule or nodule or erosion; nodule may be ulcerated.
Squamous Cell Carcinoma
TREATMENT
Local excision and Mohs micrographic surgery are most common; radi-
ation therapy in selected cases. Metastatic disease may be treated with 
radiation therapy or with combination biologic therapy; 13-cis-retinoic 
acid 1 mg/d PO plus IFN 3 million units/d SC.
Prognosis
Favorable if secondary to UV exposure; less favorable if in sun-protected 
areas or associated with ionizing radiation.
� SKIN CANCER PREVENTION
Most skin cancer is related to sun exposure. Encourage pts to avoid the sun 
and use sunscreen.
For a more detailed discussion, see Urba WJ et al: Cancer of 
the Skin, Chap. 87, p. 723, in HPIM-18.
SECTION 6
432
Hematology and Oncology
CHAPTER 75
Head and Neck Cancer
Epithelial cancers may arise from the mucosal surfaces of the head and neck 
including the sinuses, oral cavity, nasopharynx, oropharynx, hypopharynx, 
and larynx. These tumors are usually squamous cell cancers. Thyroid cancer 
is discussed in Chap. 181.
� INCIDENCE AND EPIDEMIOLOGY
About 52,000 cases are diagnosed each year and 12,000 people die from the 
disease. Oral cavity, oropharynx, and larynx are the most frequent sites of 
primary lesions in the United States; nasopharyngeal primaries are more 
common in the Far East and Mediterranean countries. Alcohol and tobacco 
(including smokeless) abuse are risk factors. Human papillomavirus (usu-
ally types 16 and 18) is associated with some of these cancers.
� PATHOLOGY
Nasopharyngeal cancer in the Far East has a distinct histology, nonkera-
tinizing undifferentiated carcinoma with infiltrating lymphocytes called 
lymphoepithelioma, and a distinct etiology, Epstein-Barr virus. Squamous 
cell head and neck cancer may develop from premalignant lesions (eryth-
roplakia, leukoplakia), and the histologic grade affects prognosis. Pts who 
have survived head and neck cancer commonly develop a second cancer of 
the head and neck, lung, or esophagus, presumably reflecting the exposure 
of the upper aerodigestive mucosa to similar carcinogenic stimuli.
� GENETIC ALTERATIONS
Chromosomal deletions and mutations have been found in chromosomes 3p, 
9p, 17p, and 13q; mutations in p53 have been reported. Cyclin D1 may be 
overexpressed. Epidermal growth factor receptor is commonly overexpressed.
� CLINICAL PRESENTATION
Most occur in persons >50 years. Symptoms vary with the primary site. 
Nasopharynx lesions do not usually cause symptoms until late in the 
course and then cause unilateral serous otitis media or nasal obstruction 
or epistaxis. Oral cavity cancers present as nonhealing ulcers, sometimes 
painful. Oropharyngeal lesions also present late with sore throat or otalgia. 
Hoarseness may be an early sign of laryngeal cancer. Rare pts present with 
painless, rock-hard cervical or supraclavicular lymph node enlargement. 
Staging is based on size of primary tumor and involvement of lymph nodes. 
Distant metastases occur in <10% of pts.
Head and Neck Cancer
TREATMENT
Three categories of disease are common: localized, locally or region-
ally advanced, and recurrent or metastatic. Localized disease occurs in 
about one-third of pts and is treated with curative intent by surgery or
CHAPTER 76 
433
Lung Cancer
radiation therapy. Radiation therapy is preferred for localized larynx 
cancer to preserve organ function; surgery is used more commonly for 
oral cavity lesions. Overall 5-year survival is 60–90%, and most recur-
rences occur within 2 years. Locally advanced disease is the most com-
mon presentation (>50%). Combined-modality therapy using induction 
chemotherapy, then surgery followed by concomitant chemotherapy 
and radiation therapy, is most effective. The use of three cycles of cis-
platin (75 mg/m2 IV day 1) and docetaxel (75 mg/m2 IV day 1) plus 
5-fluorouracil (5FU) [750 (mg/m2)/d by 96- to 120-h continuous infu-
sion] before or during radiation therapy is more effective than surgery 
plus radiation therapy, although mucositis is also more severe; 5-year 
survival is 34–50%. Cetuximab plus radiation therapy may be more 
effective than radiation therapy alone. Head and neck cancer pts are 
frequently malnourished and often have intercurrent illness. Pts with 
recurrent or metastatic disease (about 10% of pts) are treated palliatively 
with cisplatin plus 5FU or paclitaxel (200–250 mg/m2 with granulocyte 
colony-stimulating factor support) or with single-agent chemotherapy 
(a taxane, methotrexate, cisplatin, or carboplatin). Response rates are 
usually 30–50% and median survival about 3 months.
� PREVENTION
The most important intervention is to get the pts to stop smoking. 
Long-term survival is significantly better in those who stop smoking. 
Chemopreventive therapy with cis-retinoic acid [3 months of 1.5 (mg/kg)/d 
followed by 9 months of 0.5 (mg/kg)/d PO] may cause regression of leuko-
plakia but has no consistent effect on development of cancer.
For a more detailed discussion, see Vokes EE: Head and 
Neck Cancer, Chap. 88, p. 733, in HPIM-18.
CHAPTER 76
Lung Cancer
� INCIDENCE
Lung cancer has been diagnosed in about 116,470 men and 109,690 women 
in the United States in 2012, and 86% of pts die within 5 years. Lung cancer, 
the leading cause of cancer death, accounts for 28% of all cancer deaths in 
men and 26% in women. Peak incidence occurs between ages 55 and 65 
years. Incidence is decreasing in men and increasing in women.
� HISTOLOGIC CLASSIFICATION
Four major types account for 88% of primary lung cancers: epidermoid 
(squamous), 29%; adenocarcinoma (including bronchioloalveolar), 35%; 
SECTION 6
434
Hematology and Oncology
large cell, 9%; and small cell (or oat cell), 18%. Histology (small cell versus 
non-small cell types) is a major determinant of treatment approach. Small 
cell is usually widely disseminated at presentation, while non-small cell may 
be localized. Epidermoid and small cell typically present as central masses, 
while adenocarcinomas and large cell usually present as peripheral nodules 
or masses. Epidermoid and large cell cavitate in 20–30% of pts.
� ETIOLOGY
The major cause of lung cancer is tobacco use, particularly cigarette smok-
ing. Lung cancer cells may have ≥10 acquired genetic lesions, most com-
monly point mutations in ras oncogenes; amplification, rearrangement, or 
transcriptional activation of myc family oncogenes; overexpression of bcl-2, 
Her2/neu, and telomerase; and deletions involving chromosomes 1p, 1q, 
3p12-13, 3p14 (FHIT gene region), 3p21, 3p24-25, 3q, 5q, 9p (p16 and p15 
cyclin-dependent kinase inhibitors), 11p13, 11p15, 13q14 (rb gene), 16q, 
and 17p13 (p53 gene). Loss of 3p and 9p are the earliest events, detectable 
even in hyperplastic bronchial epithelium; p53 abnormalities and ras point 
mutations are usually found only in invasive cancers. A small but significant 
subset of pts with adenocarcinoma have activating mutations in the gene for 
the EGF receptor, or activating fusion events involving the alk or ros gene.
� CLINICAL MANIFESTATIONS
Only 5–15% are detected while asymptomatic. Central endobronchial 
tumors cause cough, hemoptysis, wheeze, stridor, dyspnea, pneumonitis. 
Peripheral lesions cause pain, cough, dyspnea, symptoms of lung abscess 
resulting from cavitation. Metastatic spread of primary lung cancer may 
cause tracheal obstruction, dysphagia, hoarseness, Horner’s syndrome. 
Other problems of regional spread include superior vena cava syndrome, 
pleural effusion, respiratory failure. Extrathoracic metastatic disease affects 
50% of pts with epidermoid cancer, 80% with adenocarcinoma and large 
cell, and >95% with small cell. Clinical problems result from brain metas-
tases, pathologic fractures, liver invasion, and spinal cord compression. 
Paraneoplastic syndromes may be a presenting finding of lung cancer or 
first sign of recurrence (Chap. 83). Systemic symptoms occur in 30% and 
include weight loss, anorexia, fever. Endocrine syndromes occur in 12% and 
include hypercalcemia (epidermoid), syndrome of inappropriate antidi-
uretic hormone secretion (small cell), gynecomastia (large cell). Skeletal 
connective tissue syndromes include clubbing in 30% (most often non-
small cell) and hypertrophic pulmonary osteoarthropathy in 1–10% (most 
often adenocarcinomas), with clubbing, pain, and swelling.
� STAGING (SEE TABLE 76-1)
Two parts to staging are (1) determination of location (anatomic staging) 
and (2) assessment of pt’s ability to withstand antitumor treatment (physi-
ologic staging). Non-small cell tumors are staged by the TNM/International 
Staging System (ISS). The T (tumor), N (regional node involvement), and 
M (presence or absence of distant metastasis) factors are taken together 
to define different stage groups. Small cell tumors are staged by two-stage 
system: limited stage disease—confined to one hemithorax and regional 
lymph nodes; extensive disease—involvement beyond this. General staging 
procedures include careful ear, nose, and throat examination; chest x-ray 
CHAPTER 76 
435
Lung Cancer
TABLE 76-1  TUMOR, NODE, METASTASIS INTERNATIONAL STAGING 
SYSTEM FOR LUNG CANCER
Comparison of Survival by Stage in TNM Sixth and Seventh Editions
Stage
TNM Sixth Edition
TNM Seventh Edition
5-Year
Survival, %*
IA
T1N0M0
T1a-T1bN0M0
73
IB
T2N0M0
T2aN0M0
58
IIA
T1N1M0
T1a-T2aN1M0 or
46
T2bN0M0
IIB
T2N1M0 or
T2bN1M0 or
36
T3N0M0
T3N0M0
IIIA
T3N1M0 or
T1a-T3N2M0 or
24
T1-3N2M0
T3N1M0 or
T4N0-1M0
IIIB
Any T N3M0
T4N2M0 or
9
T4 Any N M0
T1a-T4N3M0
IV
Any T Any N M1
Any T Any N M1a or
M1b
13
Sixth Edition
Seventh Edition
Tumor (T)
T1
Tumor ≤3 cm diameter 
without invasion more 
proximal than lobar 
bronchus
Tumor ≤3 cm diameter, sur-
rounded by lung or visceral 
pleura, without invasion more 
proximal than lobar bronchus
T1a
Tumor ≤2 cm in diameter
T1b
Tumor >2 cm but ≤3 cm in 
diameter
T2
Tumor >3 cm diameter or
tumor of any size with any of 
the following:
Tumor >3 cm but ≤7 cm with 
any of the following:
 Visceral pleural invasion
  Involves main bronchus, 
≥2 cm distal to carina
  Atelectasis of less than 
entire lung
  Invades visceral pleura
  Proximal extent at least 
2 cm from carina
  Associated with atelectasis 
or obstructive pneumonitis 
extending to hilar region 
but not involving the entire 
lung
T2a
Tumor >3 cm but ≤5 cm in 
diameter
T2b
Tumor >5 cm but ≤7 cm in 
diameter
(continued)
SECTION 6
436
Hematology and Oncology
TABLE 76-1  TUMOR, NODE, METASTASIS INTERNATIONAL STAGING 
SYSTEM FOR LUNG CANCER (CONTINUED)
Sixth Edition
Seventh Edition
Tumor (T)
T3
Tumor of any size that 
invades any of the follow-
ing: chest wall, diaphragm, 
mediastinal pleura, parietal 
pericardium
Tumor >7 cm or directly 
invades any of the following: 
chest wall (including supe-
rior sulcus tumors), phrenic 
nerve, mediastinal pleura, 
parietal pericardium
Tumor <2 cm distal to carina
Tumor <2 cm distal to carina 
but without involvement of 
carina
Tumor with associated 
atelectasis or obstructive 
pneumonitis of entire lung
Separate tumor nodule(s) in 
same lobe
T4
Tumor of any size that 
invades any of the following: 
mediastinum, heart or great 
vessels, trachea, esophagus, 
vertebral body, carina
Tumor of any size that 
invades any of the following: 
mediastinum, heart or great 
vessels, trachea, recurrent 
laryngeal nerve, esophagus, 
vertebral body, carina
Tumor with malignant pleural 
or pericardial effusion
Separate tumor nodule(s) in 
a different ipsilateral lobe
Separate tumor nodules in 
same lobe
Nodes (N)
N0
No regional lymph node 
metastasis
No regional lymph node 
metastasis
N1
Metastasis in ipsilateral 
peribronchial and/or hilar 
lymph node(s)
Metastasis in ipsilateral 
peribronchial and/or hilar 
lymph node(s) and intrapul-
monary node(s), including 
involvement by direct 
extensions
N2
Metastasis in ipsilateral 
mediastinal and/or subcarinal 
lymph node(s)
Metastasis in ipsilateral 
mediastinal and/or subcarinal 
lymph node(s)
N3
Metastasis in contralateral 
mediastinal, contralateral 
hilar, ipsilateral or contralat-
eral scalene or supraclavicu-
lar lymph node(s)
Metastasis in contralateral 
mediastinal, hilar, ipsilateral 
or contralateral scalene 
or supraclavicular lymph 
node(s)
CHAPTER 76 
437
Lung Cancer
TABLE 76-1  TUMOR, NODE, METASTASIS INTERNATIONAL STAGING 
SYSTEM FOR LUNG CANCER (CONTINUED)
Sixth Edition
Seventh Edition
Metastasis (M)
M0
No distant metastasis
No distant metastasis
M1
Distant metastasis (includes 
tumor nodules in different 
lobe from primary)
Distant metastasis
M1a
Separate tumor nodules in a 
contralateral lobe
Tumor with pleural nodules 
or malignant pleural or 
pericardial effusion
M1b
Distant metastasis
*Survival according to the seventh edition.
Source: Bottom portion of table reproduced with permission from P Goldstraw et al: J Thorac 
Oncol 2:706, 2007.
(CXR); chest and abdominal CT scanning; and positron emission tomogra-
phy scan. CT scans may suggest mediastinal lymph node involvement and 
pleural extension in non-small cell lung cancer, but definitive evaluation of 
mediastinal spread requires histologic examination. Routine radionuclide 
scans are not obtained in asymptomatic pts. If a mass lesion is on CXR and 
no obvious contraindications to curative surgical approach are noted, the 
mediastinum should be investigated. Major contraindications to curative 
surgery include extrathoracic metastases, superior vena cava syndrome, 
vocal cord and phrenic nerve paralysis, malignant pleural effusions, metas-
tases to contralateral lung, and histologic diagnosis of small cell cancer.
Lung Cancer (See Table 76-2)
TREATMENT
1. Surgery in pts with localized disease and non-small cell cancer; how-
ever, majority initially thought to have curative resection ultimately 
succumb to metastatic disease. Adjuvant chemotherapy [cisplatin, 
four cycles at 100 mg/m2 plus a second active agent (etoposide, vin-
blastine, vinorelbine, vindesine, a taxane)] in pts with total resection 
of stage IIA and IIB disease may modestly extend survival.
2. Solitary pulmonary nodule: factors suggesting resection include 
cigarette smoking, age ≥35, relatively large (>2 cm) lesion, lack of 
calcification, chest symptoms, and growth of lesion compared with 
old CXR. See Fig. 76-1.
3. For unresectable stage II non-small cell lung cancer, combined tho-
racic radiation therapy and cisplatin-based chemotherapy reduces 
mortality by about 25% at 1 year.
SECTION 6
438
Hematology and Oncology
TABLE 76-2  SUMMARY OF TREATMENT APPROACH TO PATIENTS WITH 
LUNG CANCER
Non-Small Cell Lung Cancer
Stages IA, IB, IIA, IIB, and some IIIA:
 Surgical resection for stages IA, IB, IIA, and IIB
  Surgical resection with complete-mediastinal lymph node dissection and 
consideration of neoadjuvant CRx for stage IIIA disease with “minimal N2 
involvement” (discovered at thoracotomy or mediastinoscopy)
 Consider postoperative RT for pts found to have N2 disease
 Stage IB: discussion of risk/benefits of adjuvant CRx; not routinely given
 Stage II: Adjuvant CRx
Curative potential RT for “nonoperable” pts
Stage IIIA with selected types of stage T3 tumors:
  Tumors with chest wall invasion (T3): en bloc resection of tumor with 
involved chest wall and consideration of postoperative RT
  Superior sulcus (Pancoast’s) (T3) tumors: preoperative RT (30–45 Gy) and 
CRx followed by en bloc resection of involved lung and chest wall with 
postoperative RT
  Proximal airway involvement (<2 cm from carina) without mediastinal 
nodes: sleeve resection if possible preserving distal normal lung or 
pneumonectomy
Stages IIIA “advanced, bulky, clinically evident N2 disease” (discovered 
preoperatively) and IIIB disease that can be included in a tolerable RT port:
  Curative potential concurrent RT + CRx if performance status and general 
medical condition are reasonable; otherwise, sequential CRx followed by 
RT, or RT alone
Stage IIIB disease with carinal invasion (T4) but without N2 involvement:
  Consider pneumonectomy with tracheal sleeve resection with direct 
reanastomosis to contralateral mainstem bronchus
Stage IV and more advanced IIIB disease:
 RT to symptomatic local sites
 CRx for ambulatory pts; consider CRx and bevacizumab for selected pts
 Chest tube drainage of large malignant pleural effusions
  Consider resection of primary tumor and metastasis for isolated brain or 
adrenal metastases
Small Cell Lung Cancer
Limited stage (good performance status): combination CRx + concurrent 
chest RT
Extensive stage (good performance status): combination CRx
Complete tumor responders (all stages): consider prophylactic cranial RT
Poor-performance-status pts (all stages):
CHAPTER 76 
439
Lung Cancer
TABLE 76-2  SUMMARY OF TREATMENT APPROACH TO PATIENTS WITH 
LUNG CANCER (CONTINUED)
Small Cell Lung Cancer
Modified-dose combination CRx
Palliative RT
Bronchioloalveolar or Adenocarcinoma with EGF Receptor Mutations 
or ALK rearrangements
Gefitinib or erlotinib, inhibitors of EGF receptor kinase activity
Crizotinib, an alk inhibitor
All Patients
RT for brain metastases, spinal cord compression, weight-bearing lytic 
bony lesions, symptomatic local lesions (nerve paralyses, obstructed airway, 
hemoptysis, intrathoracic large venous obstruction, in non-small cell lung 
cancer and in small cell cancer not responding to CRx)
Appropriate diagnosis and treatment of other medical problems and 
supportive care during CRx
Encouragement to stop smoking
Entrance into clinical trial, if eligible
Abbreviations: CRx, chemotherapy; EGF, epidermal growth factor; RT, radiotherapy.
4. For unresectable non-small cell cancer, metastatic disease, or refusal 
of surgery: consider for radiation therapy; addition of cisplatin/
taxane-based chemotherapy may reduce death risk by 13% at 2 years 
and improve quality of life. Pemetrexed has activity in pts with pro-
gressive disease.
5. Small cell cancer: combination chemotherapy is standard mode of 
therapy; response after 6–12 weeks predicts median- and long-term 
survival.
6. Addition of radiation therapy to chemotherapy in limited-stage small 
cell lung cancer can increase 5-year survival from about 11% to 20%.
7. Prophylactic cranial irradiation improves survival of limited-stage 
small cell lung cancer by another 5%.
8. Laser obliteration of tumor through bronchoscopy in presence of 
bronchial obstruction.
9. Radiation therapy for brain metastases, spinal cord compression, 
symptomatic masses, bone lesions.
10. Encourage cessation of smoking.
11. Pts with adenocarcinoma carcinoma (3% of all pts with lung cancer): 
7% of these have activating mutations in the epidermal growth factor 
(EGF) receptor. These pts often respond to gefitinib or erlotinib, EGF 
receptor inhibitors. About 5% of these have activating rearrange-
ments of the alk gene and may respond to crizotinib.
Moderate probability of
cancer (10–60%)
Low probability of
cancer
No further testing
Risk factor
surgery
Video-assisted thoracoscopic surgery;
examination of mediastinal lymph nodes
and frozen section followed by
lobectomy if nodule is malignant
New nodule identified on
standard CT scanning
Does probability of cancer
warrant further
investigation?
No
Serial high-resolution
CT 3, 6, 12, and 24 mo
Yes
No
No
Negative
tests
Positive
tests
Benign calcification pattern
on CT or stability for 2 yr
on archival films
Additional testing
• PET if nodule ≥ 1 cm in diameter
• Contrast-enhanced CT, depending on institutional expertise
• Transthoracic fine-needle aspiration biopsy if nodule is peripherally located
• Bronchoscopy if air–bronchus sign present
APPROACH TO SOLITARY PULMONARY NODULE
Yes
FIGURE 76-1 Approach to solitary pulmonary nodule.
440
CHAPTER 77 
441
Breast Cancer
� PROGNOSIS
At time of diagnosis, only 20% of pts have localized disease. Overall 5-year 
survival is 30% for males and 50% for females with localized disease and 5% 
for pts with advanced disease.
� SCREENING 
The National Cancer Institute study of lung cancer screening of high risk 
pts (age 55 to 74 years with 30+ pack-year smoking history) with low-dose 
helical CT scan reduced lung cancer mortality by 20% but had only a small 
effect on overall mortality.
For a more detailed discussion, see Horn L, Pao W, Johnson 
DH: Neoplasms of the Lung, Chap. 89, p. 737, in HPIM-18.
CHAPTER 77
Breast Cancer
� INCIDENCE AND EPIDEMIOLOGY
The most common tumor in women; 229,060 women in the United States 
have been diagnosed in 2012 and 40,000 died with breast cancer. Men 
also get breast cancer; F:M is 150:1. Breast cancer is hormone-dependent. 
Women with late menarche, early menopause, and first full-term pregnancy 
by age 18 have a significantly reduced risk. The average American woman 
has about a 1 in 9 lifetime risk of developing breast cancer. Dietary fat is a 
controversial risk factor. Oral contraceptives have little, if any, effect on risk 
and lower the risk of endometrial and ovarian cancer. Voluntary interrup-
tion of pregnancy does not increase risk. Estrogen replacement therapy may 
slightly increase the risk, but the beneficial effects of estrogen on quality of 
life, bone mineral density, and decreased risk of colorectal cancer appear to 
be somewhat outnumbered by increases in cardiovascular and thrombotic 
disease. Women who received therapeutic radiation before age 30 are at 
increased risk. Breast cancer risk is increased when a sister and mother also 
had the disease.
� GENETICS
Perhaps 8–10% of breast cancer is familial. BRCA-1 mutations account for 
about 5%. BRCA-1 maps to chromosome 17q21 and appears to be involved 
in transcription-coupled DNA repair. Ashkenazi Jewish women have a 1% 
chance of having a common mutation (deletion of adenine and guanine at 
position 185). The BRCA-1 syndrome includes an increased risk of ovarian 
cancer in women and prostate cancer in men. BRCA-2 on chromosome 11 
may account for 2–3% of breast cancer. Mutations are associated with an 
increased risk of breast cancer in men and women. Germ-line mutations in 
p53 (Li-Fraumeni syndrome) are very rare, but breast cancer, sarcomas, and 
SECTION 6
442
Hematology and Oncology
other malignancies occur in such families. Germ-line mutations in hCHK2 
and PTEN may account for some familial breast cancer. Sporadic breast can-
cers show many genetic alterations, including overexpression of HER2/neu in 
25% of cases, p53 mutations in 40%, and loss of heterozygosity at other loci.
� DIAGNOSIS
Breast cancer is usually diagnosed by biopsy of a nodule detected by 
mammogram or by palpation. Women should be strongly encouraged 
to examine their breasts monthly. In premenopausal women, question-
able or nonsuspicious (small) masses should be reexamined in 2–4 weeks 
(Fig. 77-1). A mass in a premenopausal woman that persists throughout 
her cycle and any mass in a postmenopausal woman should be aspirated. If 
the mass is a cyst filled with non-bloody fluid that goes away with aspira-
tion, the pt is returned to routine screening. If the cyst aspiration leaves a 
residual mass or reveals bloody fluid, the pt should have a mammogram and 
excisional biopsy. If the mass is solid, the pt should undergo a mammogram 
and excisional biopsy. Screening mammograms performed every other year 
beginning at age 50 have been shown to save lives. The controversy regard-
ing screening mammograms beginning at age 40 relates to the following 
Questionable mass
“thickening”
Reexamine follicular
phase menstrual cycle
Biopsy
Mammogram
Solid mass
Postmenopausal Patient
 (with dominant mass)
Management by “triple 
diagnosis” or biopsy
Premenopausal Patient
Routine screening
Mass gone
Cyst (see
Fig. 90-3 in HPIM-18)
Mass persists
Suspicious
Aspiration
Dominant mass
ALGORITHM FOR BREAST MASS PALPATION
“Benign”
FIGURE 77-1 Approach to a palpable breast mass. 
CHAPTER 77 
443
Breast Cancer
facts: (1) the disease is much less common in the 40-to 49-year age group, 
and screening is generally less successful for less common problems; (2) 
workup of mammographic abnormalities in the 40- to 49-year age group 
less commonly diagnoses cancer; and (3) about 50% of women who are 
screened annually during their forties have an abnormality at some point 
that requires a diagnostic procedure (usually a biopsy), yet very few evalua-
tions reveal cancer. However, many believe in the value of screening mam-
mography beginning at age 40. After 13–15 years of follow-up, women who 
start screening at age 40 have a small survival benefit. Women with familial 
breast cancer more often have false-negative mammograms. MRI is a better 
screening tool in these women.
� STAGING
Therapy and prognosis are dictated by stage of disease (Table 77-1). Unless 
the breast mass is large or fixed to the chest wall, staging of the ipsilateral 
axilla is performed at the time of lumpectomy (see below). Within pts of a 
given stage, individual characteristics of the tumor may influence prognosis: 
expression of estrogen receptor improves prognosis, while overexpression 
of HER2/neu, mutations in p53, high growth fraction, and aneuploidy 
worsen the prognosis. Breast cancer can spread almost anywhere but com-
monly goes to bone, lungs, liver, soft tissue, and brain.
Breast Cancer
TREATMENT
Five-year survival rate by stage is shown in Table 77-2. Treatment varies 
with stage of disease.
Ductal carcinoma in situ is noninvasive tumor present in the breast 
ducts. Treatment of choice is wide excision with breast radiation therapy. 
In one study, adjuvant tamoxifen further reduced the risk of recurrence.
Invasive breast cancer can be classified as operable, locally advanced, 
and metastatic. In operable breast cancer, outcome of primary therapy 
is the same with modified radical mastectomy or lumpectomy followed 
by breast radiation therapy. Axillary dissection may be replaced with 
sentinel node biopsy to evaluate node involvement. The sentinel node is 
identified by injecting a dye in the tumor site at surgery; the first node 
in which dye appears is the sentinel node. Women with tumors <1 cm 
and negative axillary nodes require no additional therapy beyond their 
primary lumpectomy and breast radiation. Adjuvant combination che-
motherapy for 6 months appears to benefit premenopausal women with 
positive lymph nodes, pre- and postmenopausal women with negative 
lymph nodes but with large tumors or poor prognostic features, and 
postmenopausal women with positive lymph nodes whose tumors do 
not express estrogen receptors. Estrogen receptor–positive tumors >1 cm 
with or without involvement of lymph nodes are treated with aromatase 
inhibitors. Women who began treatment with tamoxifen before aroma-
tase inhibitors were approved should switch to an aromatase inhibitor 
after 5 years of tamoxifen and continue for another 5 years.
Adjuvant chemotherapy is added to hormonal therapy in estrogen 
receptor–positive, node-positive women and is used without hormonal
SECTION 6
444
Hematology and Oncology
TABLE 77-1 STAGING OF BREAST CANCER
Primary Tumor (T)
T0
No evidence of primary tumor
TIS
Carcinoma in situ
T1
Tumor ≤2 cm
T1a
Tumor >0.1 cm but ≤0.5 cm
T1b
Tumor >0.5 but ≤1 cm
T1c
Tumor >1 cm but ≤2 cm 
T2
Tumor >2 cm but ≤5 cm
T3
Tumor >5 cm
T4
Extension to chest wall, inflammation, satellite lesions, 
ulcerations
Regional Lymph Nodes (N)
PN0(i–)
No regional lymph node metastasis histologically, negative IHC
PN0(i+)
No regional lymph node metastasis histologically, positive 
IHC, no IHC cluster greater than 0.2 mm
PN0(mol–)
No regional lymph node metastasis histologically, negative 
molecular findings (RT-PCR)
PN0(mol+)
No regional lymph node metastasis histologically, positive 
molecular findings (RT-PCR)
PN1
Metastasis in one to three axillary lymph nodes, or in inter-
nal mammary nodes with microscopic disease detected by 
sentinel lymph node dissection but not clinically apparent
PN1mi
Micrometastasis (>0.2 mm, none >2 mm)
PN1a
Metastasis in one to three axillary lymph nodes
PN1b
Metastasis in internal mammary nodes with microscopic 
disease detected by sentinel lymph node dissection but not 
clinically apparent a
PN1c
Metastasis in one to three axillary lymph nodes and in 
internal mammary lymph nodes with microscopic disease 
detected by sentinel lymph node dissection but not clinically 
apparent.a (If associated with greater than three positive 
axillary lymph nodes, the internal mammary nodes are 
classified as pN3b to reflect increased tumor burden.)
pN2
Metastasis in four to nine axillary lymph nodes, or in 
clinically apparent internal mammary lymph nodes in the 
absence of axillary lymph node metastasis
pN3
Metastasis in 10 or more axillary lymph nodes, or in infra-
clavicular lymph nodes, or in clinically apparenta ipsilateral 
internal mammary lymph nodes in the presence of 1 or more 
positive axillary lymph nodes; or in more than 3 axillary 
lymph nodes with clinically negative microscopic metastasis 
in internal mammary lymph nodes; or in ipsilateral subcarinal 
lymph nodes
CHAPTER 77 
445
Breast Cancer
TABLE 77-1 STAGING OF BREAST CANCER (CONTINUED)
Distant Metastasis (M)
M0
No distant metastasis
M1
Distant metastasis (includes spread to ipsilateral 
supraclavicular nodes)
Stage Grouping
Stage 0
TIS
N0
M0
Stage I
T1
N0
M0
Stage IIA 
T0
N1
M0
T1
N1
M0
T2
N0
M0
Stage IIB
T2
N1
M0
T3
N0
M0
Stage IIIA
T0
N2
M0
T1
N2
M0
T2
N2
M0
T3
N1, N2
M0
Stage IIIB
T4
Any N
M0
Any T
N3
M0
Stage IIIC
Any T
N3
M0
Stage IV
Any T
Any N
M1
aClinically apparent is defined as detected by imaging studies (excluding lymphoscintigraphy) 
or by clinical examination.
Abbreviations: IHC, immunohistochemistry; RT-PCR, reverse transcriptase/polymerase chain 
reaction.
Source: Used with permission of the American Joint Committee on Cancer (AJCC), Chicago, 
Illinois. The original source for this material is the AJCC Cancer Staging Manual, 7th ed. New 
York, Springer, 2010; www.springeronline.com.
therapy in estrogen receptor–negative node-positive women, whether 
they are pre- or postmenopausal. Various regimens have been used. The 
most effective regimen appears to be four cycles of doxorubicin, 60 mg/m2, 
plus cyclophosphamide, 600 mg/m2, IV on day 1 of each 3-week cycle 
followed by four cycles of paclitaxel, 175 mg/m2, by 3-h infusion on day 1 
of each 3-week cycle. In women with HER2+ tumors, trastuzumab aug-
ments the ability of chemotherapy to prevent recurrence. The activity of 
other combinations is being explored. In premenopausal women, ovarian 
ablation [e.g., with the luteinizing hormone–releasing hormone (LHRH) 
inhibitor goserelin] may be as effective as adjuvant chemotherapy.
Tamoxifen adjuvant therapy (20 mg/d for 5 years) or an aromatase 
inhibitor (anastrozole, letrozole, exemestane) is used for postmenopausal 
women with tumors expressing estrogen receptors whose nodes are
SECTION 6
446
Hematology and Oncology
positive or whose nodes are negative but with large tumors or poor prog-
nostic features. Breast cancer will recur in about half of pts with local-
ized disease. High-dose adjuvant therapy with marrow support does not 
appear to benefit even women with high risk of recurrence.
Pts with locally advanced breast cancer benefit from neoadjuvant 
combination chemotherapy (e.g., CAF: cyclophosphamide 500 mg/m2, 
doxorubicin 50 mg/m2, and 5-fluorouracil 500 mg/m2 all given IV on 
days 1 and 8 of a monthly cycle for 6 cycles) followed by surgery plus 
breast radiation therapy.
Treatment for metastatic disease depends on estrogen receptor status 
and treatment philosophy. No therapy is known to cure pts with meta-
static disease. Randomized trials do not show that the use of high-dose 
therapy with hematopoietic stem cell support improves survival. Median 
survival is about 16 months with conventional treatment: aromatase 
inhibitors for estrogen receptor–positive tumors and combination 
chemotherapy for receptor-negative tumors. Pts whose tumors express 
HER2/neu have higher response rates by adding trastuzumab (anti-
HER2/neu) to chemotherapy. Some advocate sequential use of active 
single agents in the setting of metastatic disease. Active agents in anthra-
cycline- and taxane-resistant disease include capecitabine, vinorelbine, 
gemcitabine, irinotecan, and platinum agents. Pts progressing on adju-
vant tamoxifen may benefit from an aromatase inhibitor such as letro-
zole or anastrozole. Half of pts who respond to one endocrine therapy 
will respond to another. Bisphosphonates reduce skeletal complications 
and may promote antitumor effects of other therapy. Radiation therapy 
is useful for palliation of symptoms.
� PREVENTION
Women with breast cancer have a 0.5% per year risk of developing a second 
breast cancer. Women at increased risk of breast cancer can reduce their risk 
by 49% by taking tamoxifen for 5 years. Aromatase inhibitors are probably 
TABLE 77-2 5-YEAR SURVIVAL RATE FOR BREAST CANCER BY STAGE
Stage
5-Year Survival (Percentage of Patients)
0
99
I
92
IIA
82
IIB
65
IIIA
47
IIIB
44
IV
14
Source: Modified from data of the National Cancer Institute—Surveillance, Epidemiology, and 
End Results (SEER).
CHAPTER 78 
447
Tumors of the Gastrointestinal Tract 
at least as effective as tamoxifen and are under study. Women with BRCA-1 
mutations can reduce the risk by 90% with simple mastectomy.
For a more detailed discussion, see Lippman ME: Breast 
Cancer, Chap. 90, p. 754, in HPIM-18.
CHAPTER 78
Tumors of the 
Gastrointestinal Tract
ESOPHAGEAL CARCINOMA
In 2012 in the United States, 17,460 cases and 15,070 deaths; less frequent 
in women than men. Highest incidence in focal regions of China, Iran, 
Afghanistan, Siberia, Mongolia. In the United States, blacks more frequently 
affected than whites; usually presents sixth decade or later; 5-year survival 
<5% because most pts present with advanced disease.
Pathology 
60% squamous cell carcinoma, most commonly in upper two-thirds; <40% 
adenocarcinoma, usually in distal third, arising in region of columnar 
metaplasia (Barrett’s esophagus), glandular tissue, or as direct extension of 
proximal gastric adenocarcinoma; lymphoma and melanoma rare. 10% of 
all esophageal cancers occur in the upper third, 35% in the middle third, 
and 55% in the lower third.
Risk Factors 
Major risk factors for squamous cell carcinoma: ethanol abuse, smoking 
(combination is synergistic); other risks: lye ingestion and esophageal stric-
ture, radiation exposure, head and neck cancer, achalasia, smoked opiates, 
Plummer-Vinson syndrome, tylosis, chronic ingestion of extremely hot tea, 
deficiency of vitamin A, zinc, molybdenum. Barrett’s esophagus is a risk for 
adenocarcinoma.
Clinical Features 
Progressive dysphagia (first with solids, then liquids), rapid weight loss 
common, chest pain (from mediastinal spread), odynophagia, pulmonary 
aspiration (obstruction, tracheoesophageal fistula), hoarseness (laryngeal 
nerve palsy), hypercalcemia (parathyroid hormone–related peptide hyper-
secretion by squamous carcinomas); bleeding infrequent, occasionally 
severe; examination often unremarkable.
Diagnosis
Double-contrast barium swallow useful as initial test in dysphagia; flexible 
esophagogastroscopy most sensitive and specific test; pathologic confirmation 
SECTION 6
448
Hematology and Oncology
by combining endoscopic biopsy and cytologic examination of mucosal 
brushings (neither alone sufficiently sensitive); CT and endoscopic ultraso-
nography valuable to assess local and nodal spread.
Esophageal Carcinoma
TREATMENT
Surgical resection feasible in only 40% of pts; associated with high 
complication rate (fistula, abscess, aspiration). Squamous cell carcinoma: 
Surgical resection after chemotherapy [5-fluorouracil (5FU), cisplatin] 
plus radiation therapy prolongs survival and may provide improved cure 
rate. Adenocarcinoma: Curative resection rarely possible; <20% of pts 
with resectable tumors survive 5 years. Palliative measures include laser 
ablation, mechanical dilatation, radiotherapy, and a luminal prosthesis to 
bypass the tumor. Gastrostomy or jejunostomy are frequently required 
for nutritional support. Preoperative chemotherapy with concurrent 
radiation therapy is somewhat more effective but more toxic therapy.
GASTRIC CARCINOMA
Highest incidence in Japan, China, Chile, Ireland; incidence decreasing 
worldwide, eightfold in the United States over past 60 years; in 2012, 21,320 
new cases and 10,540 deaths. Male:female = 2:1; peak incidence sixth and 
seventh decades; overall 5-year survival <15%.
Risk Factors 
Increased incidence in lower socioeconomic groups; environmental com-
ponent is suggested by studies of migrants and their offspring. Several 
dietary factors correlated with increased incidence: nitrates, smoked foods, 
heavily salted foods; genetic component suggested by increased incidence 
in first-degree relatives of affected pts; other risk factors: atrophic gastritis, 
Helicobacter pylori infection, Billroth II gastrectomy, gastrojejunostomy, 
adenomatous gastric polyps, pernicious anemia, hyperplastic gastric polyps 
(latter two associated with atrophic gastritis), Ménétrier’s disease, slight 
increased risk with blood group A.
Pathology 
Adenocarcinoma in 85%; usually focal (polypoid, ulcerative), two-thirds 
arising in antrum or lesser curvature, frequently ulcerative (“intestinal 
type”); less commonly diffuse infiltrative (linitis plastica) or superficial 
spreading (diffuse lesions more prevalent in younger pts; exhibit less geo-
graphic variation; have extremely poor prognosis); spreads primarily to 
local nodes, liver, peritoneum; systemic spread uncommon; lymphoma 
accounts for 15% (most frequent extranodal site in immunocompetent pts), 
either low-grade tumor of mucosa-associated lymphoid tissue (MALT) or 
aggressive diffuse large B cell lymphoma; leiomyosarcoma or gastrointesti-
nal stromal tumor (GIST) is rare.
Clinical Features 
Most commonly presents with progressive upper abdominal discomfort, 
frequently with weight loss, anorexia, nausea; acute or chronic GI bleeding 
CHAPTER 78 
449
Tumors of the Gastrointestinal Tract 
(mucosal ulceration) common; dysphagia (location in cardia); vomiting 
(pyloric and widespread disease); early satiety; examination often unre-
vealing early in course; later, abdominal tenderness, pallor, and cachexia 
most common signs; palpable mass uncommon; metastatic spread may be 
manifest by hepatomegaly, ascites, left supraclavicular or scalene adenopa-
thy, periumbilical, ovarian, or prerectal mass (Blumer’s shelf), low-grade 
fever, skin abnormalities (nodules, dermatomyositis, acanthosis nigricans, 
or multiple seborrheic keratoses). Laboratory findings: iron-deficiency 
anemia in two-thirds of pts; fecal occult blood in 80%; rarely associated 
with pancytopenia and microangiopathic hemolytic anemia (from marrow 
infiltration), leukemoid reaction, migratory thrombophlebitis, or acanthosis 
nigricans.
Diagnosis
Double-contrast barium swallow useful; gastroscopy most sensitive and 
specific test; pathologic confirmation by biopsy and cytologic examination 
of mucosal brushings; superficial biopsies less sensitive for lymphomas 
(frequently submucosal); important to differentiate benign from malignant 
gastric ulcers with multiple biopsies and follow-up examinations to dem-
onstrate ulcer healing.
Gastric Carcinoma
TREATMENT
Adenocarcinoma: Gastrectomy offers only chance of cure (only possible 
in less than one-third); the rare tumors limited to mucosa are resectable 
for cure in 80%; deeper invasion, nodal metastases decrease 5-year sur-
vival to 20% of pts with resectable tumors in absence of obvious meta-
static spread (Table 78-1); CT and endoscopic ultrasonography may aid 
in determining tumor resectability. Subtotal gastrectomy has similar 
efficacy to total gastrectomy for distal stomach lesions, but with less 
morbidity; no clear benefit for resection of spleen and a portion of the 
pancreas, or for radical lymph node removal. Adjuvant chemotherapy 
(5FU/leucovorin) plus radiation therapy following primary surgery 
leads to a 7-month increase in median survival. Neoadjuvant chemo-
therapy with epirubicin, cisplatin, and 5FU may downstage tumors and 
increase the efficacy of surgery. Palliative therapy for pain, obstruction, 
and bleeding includes surgery, endoscopic dilatation, radiation therapy, 
chemotherapy.
Lymphoma: Low-grade MALT lymphoma is caused by H. pylori infec-
tion, and eradication of the infection causes complete remissions in 
50% of pts; rest are responsive to combination chemotherapy including 
cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) plus 
rituximab. Diffuse large B cell lymphoma may be treated with either 
CHOP plus rituximab or subtotal gastrectomy followed by chemotherapy; 
50–60% 5-year survival.
Leiomyosarcoma: Surgical resection curative in most pts. Tumors 
expressing the c-kit tyrosine kinase (CD117)—GIST—respond to ima-
tinib mesylate in a substantial fraction of cases.
SECTION 6
450
Hematology and Oncology
BENIGN GASTRIC TUMORS
Much less common than malignant gastric tumors; hyperplastic polyps 
most common, with adenomas, hamartomas, and leiomyomas rare; 30% 
of adenomas and occasional hyperplastic polyps are associated with gastric 
malignancy; polyposis syndromes include Peutz-Jeghers and familial polyp-
osis (hamartomas and adenomas), Gardner’s (adenomas), and Cronkhite-
Canada (cystic polyps). See “Colonic Polyps,” below.
TABLE 78-1 STAGING SYSTEM FOR GASTRIC CARCINOMA
Data from ACS
Stage
TNM
Features
No. of 
Cases, %
5-Year 
Survival, %
0
TisN0M0
Node negative; limited to 
mucosa
1
90
IA
T1N0M0
Node negative; invasion 
of lamina propria or 
submucosa
7
59
IB
T2N0M0
T1N1M0
Node negative; invasion of 
muscularis propria
10
44
II
T1N2M0
T2N1M0
Node positive; invasion 
beyond mucosa but within 
wall
17
29
or
T3N0M0
Node negative; extension 
through wall
IIIA
T2N2M0
T3N1-2M0
Node positive; invasion 
of muscularis propria or 
through wall
21
15
IIIB
T4N0-1M0
Node negative; adherence 
to surrounding tissue
14
9
IIIC
T4N2-3M0
>3 nodes positive; 
invasion of serosa or 
adjacent structures
T3N3M0
7 or more positive nodes; 
penetrates wall without 
invading serosa or 
adjacent structures
IV
T4N2M0
Node positive; adherence 
to surrounding tissue
30
3
or
T1-4N0-2-M1
Distant metastases
Abbreviations: ACS, American Cancer Society; TNM, tumor, node, metastasis.
CHAPTER 78 
451
Tumors of the Gastrointestinal Tract 
Clinical Features 
Usually asymptomatic; occasionally present with bleeding or vague epigastric 
discomfort.
Benign Gastric Tumors
TREATMENT
Endoscopic or surgical excision.
SMALL-BOWEL TUMORS
Clinical Features 
Uncommon tumors (~5% of all GI neoplasms); usually present with bleed-
ing, abdominal pain, weight loss, fever, or intestinal obstruction (intermit-
tent or fixed); increased incidence of lymphomas in pts with gluten-sensitive 
enteropathy, Crohn’s disease involving small bowel, AIDS, prior organ 
transplantation, autoimmune disorders.
Pathology 
Usually benign; most common are adenomas (usually duodenal), leiomyo-
mas (intramural), and lipomas (usually ileal); 50% of malignant tumors are 
adenocarcinoma, usually in duodenum (at or near ampulla of Vater) or 
proximal jejunum, commonly coexisting with benign adenomas; primary 
intestinal lymphomas (non-Hodgkin’s) account for 25% and occur as focal 
mass (Western type), which is usually a T cell lymphoma associated with 
prior celiac disease, or diffuse infiltration (Mediterranean type), which is 
usually immunoproliferative small-intestinal disease (IPSID; α-heavy chain 
disease), a B-cell MALT lymphoma associated with Campylobacter jejuni 
infection, which can present as intestinal malabsorption; carcinoid tumors 
(usually asymptomatic) occasionally produce bleeding or intussusception 
(see below). 
Diagnosis
Endoscopy and biopsy most useful for tumors of duodenum and proximal 
jejunum; otherwise barium x-ray examination best diagnostic test; direct 
small-bowel instillation of contrast (enteroclysis) occasionally reveals 
tumors not seen with routine small-bowel radiography; angiography (to 
detect plexus of tumor vessels) or laparotomy often required for diagnosis; 
CT useful to evaluate extent of tumor (esp. lymphomas).
Small-Bowel Tumors
TREATMENT
Surgical excision; adjuvant chemotherapy appears helpful for focal lym-
phoma; IPSID appears to be curable with combination chemotherapy 
used in aggressive lymphoma plus oral antibiotics (e.g., tetracycline); 
no proven role for chemotherapy or radiation therapy for other small-
bowel tumors.
SECTION 6
452
Hematology and Oncology
COLONIC POLYPS
� TUBULAR ADENOMAS
Present in ~30% of adults; pedunculated or sessile; usually asymptomatic; 
~5% cause occult blood in stool; may cause obstruction; overall risk of 
malignant degeneration correlates with size (<2% if <1.5 cm diam; >10% 
if >2.5 cm diam) and is higher in sessile polyps; 65% found in rectosig-
moid colon; diagnosis by barium enema, sigmoidoscopy, or colonoscopy. 
Treatment: Full colonoscopy to detect synchronous lesions (present in 30%); 
endoscopic resection (surgery if polyp large or inaccessible by colonos-
copy); follow-up surveillance by colonoscopy every 2–3 years.
� VILLOUS ADENOMAS
Generally larger than tubular adenomas at diagnosis; often sessile; high 
risk of malignancy (up to 30% when >2 cm); more prevalent in left colon; 
occasionally associated with potassium-rich secretory diarrhea. Treatment: 
As for tubular adenomas.
� HYPERPLASTIC POLYPS
Asymptomatic; usually incidental finding at colonoscopy; rarely >5 mm; no 
malignant potential. No treatment required.
� HEREDITARY POLYPOSIS SYNDROMES
See Table 78-2.
1. Familial polyposis coli (FPC): Diffuse pancolonic adenomatous pol-
yposis (up to several thousand polyps); autosomal dominant inheritance 
associated with deletion in adenomatous polyposis coli (APC) gene on 
chromosome 5; colon carcinoma from malignant degeneration of polyp 
in 100% by age 40. Treatment: Prophylactic total colectomy or subtotal 
colectomy with ileoproctostomy before age 30; subtotal resection avoids 
ileostomy but necessitates frequent proctoscopic surveillance; periodic 
colonoscopic or annual radiologic screening of siblings and offspring 
of pts with FPC until age 35; sulindac and other nonsteroidal anti-
inflammatory drugs (NSAIDs) cause regression of polyps and inhibit 
their development.
2. Gardner’s syndrome: Variant of FPC with associated soft tissue tumors 
(epidermoid cysts, osteomas, lipomas, fibromas, desmoids); higher inci-
dence of gastroduodenal polyps, ampullary adenocarcinoma. Treatment: 
As for FPC; surveillance for small-bowel disease with fecal occult blood 
testing after colectomy.
3. Turcot’s syndrome: Rare variant of FPC with associated malignant brain 
tumors. Treatment: As for FPC.
4. Nonpolyposis syndrome: Familial syndrome with up to 50% risk of colon 
carcinoma; peak incidence in fifth decade; associated with multiple pri-
mary cancers (esp. endometrial); autosomal dominant; due to defective 
DNA mismatch repair.
5. Juvenile polyposis: Multiple benign colonic and small-bowel hamartomas; 
intestinal bleeding common. Other symptoms: abdominal pain, diar-
rhea; occasional intussusception. Rarely recur after excision; low risk of 
CHAPTER 78 
453
Tumors of the Gastrointestinal Tract 
colon cancer from malignant degeneration of interspersed adenomatous 
polyps. Prophylactic colectomy controversial.
6. Peutz-Jeghers syndrome: Numerous hamartomatous polyps of entire GI 
tract, though denser in small bowel than colon; GI bleeding common; 
somewhat increased risk for the development of cancer at GI and non-GI 
sites. Prophylactic surgery not recommended.
COLORECTAL CANCER
Second most common internal cancer in humans; accounts for 10% of cancer-
related deaths in United States; incidence increases dramatically above age 50, 
nearly equal in men and women. In 2012, 143,460 new cases, 51,690 deaths.
Etiology and Risk Factors
Most colon cancers arise from adenomatous polyps. Genetic steps from 
polyp to dysplasia to carcinoma in situ to invasive cancer have been defined, 
TABLE 78-2 HEREDITABLE (AUTOSOMAL DOMINANT)
Gastrointestinal Polyposis Syndromes
Syndrome
Distribution
of Polyps
Histologic
Type
Malignant
Potential
Associated Lesions
Familial 
adenomatous 
polyposis
Large
intestine
Adenoma
Common
None
Gardner’s 
syndrome
Large
and small 
intestines
Adenoma
Common
Osteomas, fibromas, 
lipomas, epidermoid 
cysts, ampullary 
cancers, congenital 
hypertrophy of 
retinal pigment 
epithelium
Turcot’s 
syndrome
Large
intestine
Adenoma
Common
Brain tumors
Nonpolyposis
syndrome
(Lynch 
syndrome)
Large
intestine
(often
proximal)
Adenoma
Common
Endometrial and 
ovarian tumors
Peutz-Jeghers 
syndrome
Small
and large 
intestines, 
stomach
Hamartoma
Rare
Mucocutaneous 
pigmentation; 
tumors of the ovary, 
breast, pancreas, 
endometrium
Juvenile
polyposis
Large
and small 
intestines, 
stomach
Hamartoma, 
rarely
progressing
to adenoma
Rare
Various congenital 
abnormalities
SECTION 6
454
Hematology and Oncology
including point mutation in K-ras proto-oncogene, hypomethylation of 
DNA leading to enhanced gene expression, allelic loss at the APC gene (a 
tumor suppressor), allelic loss at the DCC (deleted in colon cancer) gene 
on chromosome 18, and loss and mutation of p53 on chromosome 17. 
Hereditary nonpolyposis colon cancer arises from mutations in the DNA 
mismatch repair genes, hMSH2 gene on chromosome 2 and hMLH1 gene 
on chromosome 3. Mutations lead to colon and other cancers. Diagnosis 
requires three or more relatives with colon cancer, one of whom is a first-
degree relative; one or more cases diagnosed before age 50; and involvement 
of at least two generations. Environmental factors also play a role; increased 
prevalence in developed countries, urban areas, advantaged socioeconomic 
groups; increased risk in pts with hypercholesterolemia, coronary artery 
disease; correlation of risk with low-fiber, high-animal-fat diets, although 
direct effect of diet remains unproven; decreased risk with long-term 
dietary calcium supplementation and, possibly, daily aspirin ingestion. Risk 
increased in first-degree relatives of pts; families with increased prevalence 
of cancer; and pts with history of breast or gynecologic cancer, familial 
polyposis syndromes, >10-year history of ulcerative colitis or Crohn’s colitis, 
>15-year history of ureterosigmoidostomy. Tumors in pts with strong fam-
ily history of malignancy are frequently located in right colon and com-
monly present before age 50; high prevalence in pts with Streptococcus bovis 
bacteremia.
Pathology 
Nearly always adenocarcinoma; 75% located distal to the splenic flexure 
(except in association with polyposis or hereditary cancer syndromes); may 
be polypoid, sessile, fungating, or constricting; subtype and degree of dif-
ferentiation do not correlate with course. Degree of invasiveness at surgery 
(Dukes’ classification) is single best predictor of prognosis (Fig. 78-1). 
Rectosigmoid tumors may spread to lungs early because of systemic para-
vertebral venous drainage of this area. Other predictors of poor prognosis: 
preoperative serum carcinoembryonic antigen (CEA) >5 ng/mL (>5 μg/L), 
poorly differentiated histology, bowel perforation, venous invasion, adher-
ence to adjacent organs, aneuploidy, specific deletions in chromosomes 5, 
17, 18, and mutation of ras proto-oncogene. 15% have defects in DNA repair.
Clinical Features 
Left-sided colon cancers present most commonly with rectal bleeding, 
altered bowel habits (narrowing, constipation, intermittent diarrhea, tenes-
mus), and abdominal or back pain; cecal and ascending colon cancers 
more frequently present with symptoms of anemia, occult blood in stool, 
or weight loss; other complications: perforation, fistula, volvulus, inguinal 
hernia; laboratory findings: anemia in 50% of right-sided lesions.
Diagnosis
Early diagnosis aided by screening asymptomatic persons with fecal occult 
blood testing (see below); >50% of all colon cancers are within reach of a 
60-cm flexible sigmoidoscope; air-contrast barium enema will diagnose 
~85% of colon cancers not within reach of sigmoidoscope; colonoscopy 
Staging of colorectal cancer
Stage at
presentation
Mucosa
Serosa
Fat
Lymph nodes
Muscularis
mucosa
Muscularis
propria
Submucosa
Stage
I
II
T3
Through
muscularis
70–85%
31%
25%
IV
M
Distant
metastases
<5%
20%
15%
T2
Not through
muscularis
>90%
T1
No deeper
than
submucosa
>95%
23%
34%
III
N2
 ≥4 lymph node
metastases
25–60%
N1
1–3 lymph node
metastases
50–70%
26%
26%
Colon
Rectal
Extent of tumor
5-year survival
FIGURE 78-1 Staging and prognosis for pts with colorectal cancer. 
455
SECTION 6
456
Hematology and Oncology
most sensitive and specific, permits tumor biopsy and removal of synchro-
nous polyps (thus preventing neoplastic conversion), but is more expensive. 
Radiographic or virtual colonoscopy has not been shown to be a better 
diagnostic method than colonoscopy.
Colorectal Cancer
TREATMENT
Local disease: Surgical resection of colonic segment containing tumor; 
preoperative evaluation to assess prognosis and surgical approach 
includes full colonoscopy, chest films, biochemical liver tests, plasma 
CEA level, and possible abdominal CT. Resection of isolated hepatic 
metastases possible in selected cases. Adjuvant radiation therapy to pelvis 
(with or without concomitant 5FU chemotherapy) decreases local recur-
rence rate of rectal carcinoma (no apparent effect on survival); radiation 
therapy without benefit on colon tumors; preoperative radiation therapy 
may improve resectability and local control in pts with rectal cancer. Total 
mesorectal excision is more effective than conventional anteroposterior 
resection in rectal cancer. Adjuvant chemotherapy (5FU/leucovorin 
plus oxaliplatin, or FOLFOX plus bevacizumab, or 5FU/leucovorin plus 
irinotecan, or FOLFIRI) decreases recurrence rate and improves survival 
of stage C (III); survival benefit from adjuvant therapy is not so clear in 
stage B (II) tumors; periodic determination of serum CEA level useful 
to follow therapy and assess recurrence. Follow-up after curative resec-
tion: Yearly liver tests, complete blood count, follow-up radiologic or 
colonoscopic evaluation at 1 year—if normal, repeat every 3 years, with 
routine screening interim (see below); if polyps detected, repeat 1 year 
after resection. Advanced tumor (locally unresectable or metastatic): 
Systemic chemotherapy (5FU/leucovorin plus oxaliplatin plus bevaci-
zumab), irinotecan usually used in second treatment; antibodies to the 
EGF receptor (cetuximab, panitumumab) appear to enhance the effect of 
chemotherapy; intraarterial chemotherapy [floxuridine (FUDR)] and/or 
radiation therapy may palliate symptoms from hepatic metastases.
Prevention
Early detection of colon carcinoma may be facilitated by routine screening 
of stool for occult blood (Hemoccult II, ColonCare, Hemosure); however, 
sensitivity only ~50% for carcinoma; specificity for tumor or polyp ~25–40%. 
False positives: ingestion of red meat, iron, aspirin; upper GI bleeding. 
False negatives: vitamin C ingestion, intermittent bleeding. Annual digital 
rectal exam and fecal occult blood testing recommended for pts over age 40, 
screening by flexible sigmoidoscopy every 3 years after age 50, earlier in pts 
at increased risk (see above); careful evaluation of all pts with positive fecal 
occult blood tests (flexible sigmoidoscopy and air-contrast barium enema 
or colonoscopy alone) reveals polyps in 20–40% and carcinoma in ~5%; 
screening of asymptomatic persons allows earlier detection of colon cancer 
(i.e., earlier Dukes’ stage) and achieves greater resectability rate; decreased 
overall mortality from colon carcinoma seen only after 13 years of follow-
up. More intensive evaluation of first-degree relatives of pts with colon 
carcinoma frequently includes screening air-contrast barium enema or 
CHAPTER 78 
457
Tumors of the Gastrointestinal Tract 
colonoscopy after age 40. NSAIDs and cyclooxygenase 2 inhibitors appear 
to prevent polyp development and induce regression in high-risk groups, 
but have not been recommended for average-risk pts at this time.
� ANAL CANCER
Accounts for 1–2% of large-bowel cancer, 6230 cases and 780 deaths in 
2012; associated with chronic irritation, e.g., from condyloma acumi-
nata, perianal fissures/fistulas, chronic hemorrhoids, leukoplakia, trauma 
from anal intercourse. Women are more commonly affected than men. 
Homosexual men are at increased risk. Human papillomavirus is etiologic. 
Presents with bleeding, pain, and perianal mass. Radiation therapy plus 
chemotherapy (5FU and mitomycin) leads to complete response in 80% 
when the primary lesion is <3 cm. Abdominoperineal resection with per-
manent colostomy is reserved for those with large lesions or whose disease 
recurs after chemoradiotherapy.
BENIGN LIVER TUMORS
Hepatocellular adenomas occur most commonly in women in the third or 
fourth decades who take birth control pills. Most are found incidentally but 
may cause pain; intratumoral hemorrhage may cause circulatory collapse. 
10% may become malignant. Women with these adenomas should stop tak-
ing birth control pills. Large tumors near the liver surface may be resected. 
Focal nodular hyperplasia is also more common in women but seems not 
to be caused by birth control pills. Lesions are vascular on angiography and 
have septae and are usually asymptomatic.
HEPATOCELLULAR CARCINOMA
About 28,720 cases in the United States in 2012, but worldwide this may 
be the most common tumor; 20,550 deaths in 2012 in US. Male:female = 
4:1; tumor usually develops in cirrhotic liver in persons in fifth or sixth 
decade. High incidence in Asia and Africa is related to etiologic relationship 
between this cancer and hepatitis B and C infections. Aflatoxin exposure 
contributes to etiology and leaves a molecular signature, a mutation in 
codon 249 of the gene for p53.
Modes of Presentation 
A pt with known liver disease develops an abnormality on ultrasound or rising α 
fetoprotein (AFP) or des-gamma-carboxy prothrombin (DCP) due to absence of 
vitamin K; abnormal liver function tests; cachexia, abdominal pain, fever.
Physical Findings 
Jaundice, asthenia, itching, tremors, disorientation, hepatomegaly, spleno-
megaly, ascites, peripheral edema.
Hepatocellular Carcinoma
TREATMENT
Surgical resection or liver transplantation is therapeutic option but 
rarely successful. Radiofrequency ablation can cause regression of small 
tumors. Sorafenib may produce partial responses lasting a few months.
SECTION 6
458
Hematology and Oncology
Screening and Prevention 
Screening populations at risk has given conflicting results. Hepatitis B vaccine 
prevents the disease. Interferon α (IFN-α) may prevent liver cancer in persons 
with chronic active hepatitis C disease and possibly in those with hepatitis 
B. Ribavirin ± IFN-α is most effective treatment of chronic hepatitis C. 
Teleprevir, a protease inhibitor, is also active.
PANCREATIC CANCER
In 2012 in the United States, about 43,920 new cases and 27,390 deaths. The 
incidence is decreasing somewhat, but nearly all diagnosed cases are fatal. 
The tumors are ductal adenocarcinomas and are not usually detected until 
the disease has spread. About 70% of tumors are in the pancreatic head, 20% 
in the body, and 10% in the tail. Mutations in K-ras have been found in 85% 
of tumors, and the p16 cyclin-dependent kinase inhibitor on chromosome 
9 may also be implicated. Long-standing diabetes, chronic pancreatitis, and 
smoking increase the risk; coffee-drinking, alcoholism, and cholelithiasis do 
not. Pts present with pain and weight loss, the pain often relieved by bending 
forward. Jaundice commonly complicates tumors of the head, due to biliary 
obstruction. Curative surgical resections are feasible in about 10%. Adjuvant 
chemotherapy (5FU) may benefit some pts after resection. Gemcitabine plus 
erlotinib or capecitabine may palliate symptoms in pts with advanced disease.
ENDOCRINE TUMORS OF THE GI TRACT AND PANCREAS
� CARCINOID TUMOR
Carcinoid tumor accounts for 75% of GI endocrine tumors; incidence is 
about 15 cases per million population. 90% originate in Kulchitsky cells of 
the GI tract, most commonly the appendix, ileum, and rectum. Carcinoid 
tumors of the small bowel and bronchus have a more malignant course 
than tumors of other sites. About 5% of pts with carcinoid tumors develop 
symptoms of the carcinoid syndrome, the classic triad being cutaneous 
flushing, diarrhea, and valvular heart disease. For tumors of GI tract origin, 
symptoms imply metastases to liver.
Diagnosis can be made by detecting the site of tumor or documenting 
production of >15 mg/d of the serotonin metabolite 5-hydroxyindoleacetic 
acid (5-HIAA) in the urine. Octreotide scintigraphy identifies sites of pri-
mary and metastatic tumor in about two-thirds of cases.
Carcinoid Tumor
TREATMENT
Surgical resection where feasible. Symptoms may be controlled with his-
tamine blockers and octreotide, 150–1500 mg/d in three doses. Hepatic 
artery embolization and chemotherapy (5FU plus streptozocin or doxo-
rubicin) have been used for metastatic disease. IFN-α at 3–10 million 
units SC three times a week may relieve symptoms. Prognosis ranges 
from 95% 5-year survival for localized disease to 20% 5-year survival 
for those with liver metastases. Median survival of pts with carcinoid 
syndrome is 2.5 years from the first episode of flushing.
CHAPTER 78 
459
Tumors of the Gastrointestinal Tract 
� PANCREATIC ISLET-CELL TUMORS
Gastrinoma, insulinoma, VIPoma, glucagonoma, and somatostatinoma 
account for the vast majority of pancreatic islet-cell tumors; their charac-
teristics are shown in Table 78-3. The tumors are named for the dominant 
hormone they produce. They are generally slow-growing and produce 
symptoms related to hormone production. Gastrinomas and peptic ulcer 
disease constitute the Zollinger-Ellison syndrome. Gastrinomas are rare 
(4 cases per 10 million population), and in 25–50%, the tumor is a com-
ponent of a multiple endocrine neoplasia type 1 (MEN 1) syndrome 
(Chap. 186). 
Insulinoma may present with Whipple’s triad: fasting hypoglycemia, 
symptoms of hypoglycemia, and relief after IV glucose. Normal or elevated 
serum insulin levels in the presence of fasting hypoglycemia are diagnostic. 
Insulinomas may also be associated with MEN 1.
Verner and Morrison described a syndrome of watery diarrhea, hypoka-
lemia, achlorhydria, and renal failure associated with pancreatic islet tumors 
that produce vasoactive intestinal polypeptide (VIP). VIPomas are rare (1 case 
per 10 million) but often grow to a large size before producing symptoms.
TABLE 78-3 GASTROINTESTINAL ENDOCRINE TUMOR SYNDROMES
Syndrome
Cell Type
Clinical
Features
Percentage 
Malignant
Major
Products
Carcinoid
syndrome
Enterochromaffin, 
enterochromaffin-
like
Flushing, 
diarrhea, 
wheezing, 
hypotension
~100
Serotonin, 
histamine, 
miscel-
laneous
peptides
Zollinger-Ellison, 
gastrinoma
Non-β islet cell, 
duodenal G cell
Peptic ulcers, 
diarrhea
~70
Gastrin
Insulinoma
Islet β cell
Hypoglycemia ~10
Insulin
VIPoma (Verner-
Morrison, WDHA)
Islet D1 cell
Diarrhea, 
hypokalemia, 
hypochlorhy-
dria
~60
Vasoactive 
intestinal
peptide
Glucagonoma
Islet A cell
Mild diabetes 
mellitus, 
erythema 
necrolytica
migrans, 
glossitis
>75
Glucagon
Somatostatinoma Islet D cell
Diabetes 
mellitus, 
diarrhea, 
steatorrhea, 
gallstones
~70
Somatostatin
Abbreviation: WDHA, watery diarrhea, hypokalemia, achlorhydria.
SECTION 6
460
Hematology and Oncology
Glucagonoma is associated with diabetes mellitus and necrolytic migra-
tory erythema, a characteristic red, raised, scaly rash usually located on the 
face, abdomen, perineum, and distal extremities. Glucagon levels >1000 
ng/L not suppressed by glucose are diagnostic.
The classic triad of somatostatinoma is diabetes mellitus, steatorrhea, and 
cholelithiasis.
Provocative tests may facilitate diagnosis of functional endocrine tumors: 
tolbutamide enhances somatostatin secretion by somatostatinomas; pen-
tagastrin enhances calcitonin secretion from medullary thyroid (C cell) 
tumors; secretin enhances gastrin secretion from gastrinomas. If imaging 
techniques fail to detect tumor masses, angiography or selective venous 
sampling for hormone determination may reveal the site of tumor. 
Metastases to nodes and liver should be sought by CT or MRI.
Pancreatic Islet-Cell Tumors
TREATMENT
Tumor is surgically removed, if possible. Everolimus 10 mg PO qd or 
sunitinib 37.5 mg PO qd may produce meaningful delay (~12 months) 
in progressive disease and prolong survival in pts with metastatic disease. 
Octreotide inhibits hormone secretion in the majority of cases. IFN-α 
may reduce symptoms. Streptozotocin plus doxorubicin combination 
chemotherapy may produce responses in 60–90% of cases. Embolization 
or chemoembolization of hepatic metastases may be palliative.
CHAPTER 79
Genitourinary Tract Cancer
BLADDER CANCER
� INCIDENCE AND EPIDEMIOLOGY 
Annual incidence in the United States is about 73,510 cases with 14,880 
deaths. Median age is 65 years. Smoking accounts for 50% of the risk. 
Exposure to polycyclic aromatic hydrocarbons increases the risk, especially 
in slow acetylators. Risk is increased in chimney sweeps, dry cleaners, and 
those involved in aluminum manufacturing. Chronic cyclophosphamide 
exposure increases risk ninefold. Schistosoma haematobium infection also 
increases risk, especially of squamous histology.
For a more detailed discussion, see Mayer RJ: Gastrointestinal 
Tract Cancer, Chap. 91, p. 764; Carr BI: Tumors of the Liver 
and Biliary Tree, Chap. 92, p. 777; Chong I, Cunningham 
D: Pancreatic Cancer, Chap. 93, p. 786; and Jensen RT: 
Endocrine Tumors of the Gastrointestinal Tract and Pancreas, 
Chap. 350, p. 3056, in HPIM-18.
CHAPTER 79 
461
Genitourinary Tract Cancer
� ETIOLOGY 
Lesions involving chromosome 9q are an early event. Deletions in 17p 
(p53), 18q (the DCC locus), 13q (RB), 3p, and 5q are characteristic of 
invasive lesions. Overexpression of epidermal growth factor receptors and 
HER2/neu receptors is common.
� PATHOLOGY 
Over 90% of tumors are derived from transitional epithelium; 3% are 
squamous, 2% are adenocarcinomas, and <1% are neuroendocrine small 
cell tumors. Field effects are seen that place all sites lined by transitional 
epithelium at risk, including the renal pelvis, ureter, bladder, and proximal 
two-thirds of the urethra; 90% of tumors are in the bladder, 8% in the renal 
pelvis, and 2% in the ureter or urethra. Histologic grade influences survival. 
Lesion recurrence is influenced by size, number, and growth pattern of the 
primary tumor.
� CLINICAL PRESENTATION 
Hematuria is the initial sign in 80–90%; however, cystitis is a more common 
cause of hematuria (22% of all hematuria) than is bladder cancer (15%). 
Pts are initially staged and treated by endoscopy. Superficial tumors are 
removed at endoscopy; muscle invasion requires more extensive surgery.
Bladder Cancer
TREATMENT
Management is based on extent of disease: superficial, invasive, or meta-
static. Frequency of presentation is 75% superficial, 20% invasive, and 
5% metastatic. Superficial lesions are resected at endoscopy. Although 
complete resection is possible in 80%, 30–80% of cases recur; grade 
and stage progression occur in 30%. Intravesical instillation of bacille 
Calmette-Guérin (BCG) reduces the risk of recurrence by 40–45%. 
Recurrence is monitored every 3 months.
The standard management of muscle-invasive disease is radical cys-
tectomy. 5-year survival is 70% for those without invasion of perivesicu-
lar fat or lymph nodes, 50% for those with invasion of fat but not lymph 
nodes, 35% for those with one node involved, and 10% for those with 
six or more involved nodes. Pts who cannot withstand radical surgery 
may have 30–35% 5-year survival with 5000- to 7000-cGy external beam 
radiation therapy. Bladder sparing may be possible in up to 45% of pts 
with two cycles of chemotherapy with CMV (methotrexate, 30 mg/m2 
days 1 and 8, vinblastine, 4 mg/m2 days 1 and 8, cisplatin, 100 mg/m2 
day 2, q21d) followed by 4000-cGy radiation therapy given concurrently 
with cisplatin.
Metastatic disease is treated with combination chemotherapy. Useful 
regimens include CMV (see above), M-VAC (methotrexate, 30 mg/m2 
days 1, 15, 22; vinblastine, 3 mg/m2 days 2, 15, 22; doxorubicin, 30 mg/
m2 day 2; cisplatin, 70 mg/m2 day 2; q28d) or cisplatin (70 mg/m2 day 2) 
plus gemcitabine (1000 mg/m2 days 1, 8, 15 of a 28-day cycle) or carbo-
platin plus paclitaxel. About 70% of pts respond to treatment, and 20% 
have a complete response; 10–15% have long-term disease-free survival.
SECTION 6
462
Hematology and Oncology
RENAL CANCER
� INCIDENCE AND EPIDEMIOLOGY 
Annual incidence in the United States is about 65,000 cases with 13,500 
deaths. Cigarette smoking accounts for 20–30% of cases. Risk is increased in 
acquired renal cystic disease. There are two familial forms: a rare autosomal 
dominant syndrome and von Hippel–Lindau disease. About 35% of pts with 
von Hippel–Lindau disease develop renal cancer. Incidence is also increased 
in those with tuberous sclerosis and polycystic kidney disease.
� ETIOLOGY 
Most cases are sporadic; however, the most frequent chromosomal abnormal-
ity (occurs in 60%) is deletion or rearrangement of 3p21-26. The von Hippel–
Lindau gene has been mapped to that region and appears to have ubiquitin 
ligase activities that influence regulation of speed of transcription and turn-
over of damaged proteins. It is unclear how lesions in the gene lead to cancer.
� PATHOLOGY 
Five variants are recognized: clear cell tumors (75%), chromophilic tumors 
(15%), chromophobic tumors (5%), oncocytic tumors (3%), and collecting 
duct tumors (2%). Clear cell tumors arise from cells of the proximal convoluted 
tubules. Chromophilic tumors tend to be bilateral and multifocal and often 
show trisomy 7 and/or trisomy 17. Chromophobic and eosinophilic tumors less 
frequently have chromosomal aberrations and follow a more indolent course.
� CLINICAL PRESENTATION 
The classic triad of hematuria, flank pain, and flank mass is seen in only 
10–20% of pts; hematuria (40%), flank pain (40%), palpable mass (33%), and 
weight loss (33%) are the most common individual symptoms. Paraneoplastic 
syndromes of erythrocytosis (3%), hypercalcemia (5%), and nonmetastatic 
hepatic dysfunction (Stauffer’s syndrome) (15%) may also occur. Workup 
should include IV pyelography, renal ultrasonography, CT of abdomen and 
pelvis, chest x-ray (CXR), urinalysis, and urine cytology. Stage I is disease 
restricted to the kidney, stage II is disease contained within Gerota’s fascia, 
stage III is locally invasive disease involving nodes and/or inferior vena cava, 
stage IV is invasion of adjacent organs or metastatic sites. Prognosis is related 
to stage: 66% 5-year survival for I, 64% for II, 42% for III, and 11% for IV.
Renal Cancer
TREATMENT
Radical nephrectomy is standard for stage I, II, and most stage III pts. 
Surgery may also be indicated in the setting of metastatic disease for 
intractable local symptoms (bleeding, pain). Response rates of 40–48% 
have been noted with three different single agents, sunitinib (50 mg/d 
4 weeks out of 6), sorafenib (400 mg bid), and temsirolimus (25 mg 
IV weekly). Sunitinib and sorafenib are thought to be antiangiogenic 
through inhibition of kinases in tumor cells. Temsirolimus is an inhibi-
tor of mTOR. About 10–15% of pts with advanced-stage disease may 
benefit from interleukin 2 and/or interferon α (IFN-α). Addition of 
bevacizumab to IFN-α improves the response rate. Some remissions are 
durable. Chemotherapy is of little or no benefit.
CHAPTER 79 
463
Genitourinary Tract Cancer
TESTICULAR CANCER
� INCIDENCE AND EPIDEMIOLOGY 
Annual incidence is about 8590 cases with 360 deaths. Peak age incidence 
is 20–40. Occurs 4–5 times more frequently in white than black men. 
Cryptorchid testes are at increased risk. Early orchiopexy may protect 
against testis cancer. Risk is also increased in testicular feminization syn-
dromes, and Klinefelter syndrome is associated with mediastinal germ cell 
tumor.
� ETIOLOGY 
The cause is unknown. Disease is associated with a characteristic cytoge-
netic defect, isochromosome 12p.
� PATHOLOGY 
Two main subtypes are noted: seminoma and nonseminoma. Each accounts 
for ~50% of cases. Seminoma has a more indolent natural history and is 
highly sensitive to radiation therapy. Four subtypes of nonseminoma are 
defined: embryonal carcinoma, teratoma, choriocarcinoma, and endoder-
mal sinus (yolk sac) tumor.
� CLINICAL PRESENTATION 
Painless testicular mass is the classic initial sign. In the presence of pain, dif-
ferential diagnosis includes epididymitis or orchitis; a brief trial of antibiot-
ics may be undertaken. Staging evaluation includes measurement of serum 
tumor markers α fetoprotein (AFP) and β-human chorionic gonadotropin 
(hCG), CXR, and CT scan of abdomen and pelvis. Lymph nodes are staged 
at resection of the primary tumor through an inguinal approach. Stage I dis-
ease is limited to the testis, epididymis, or spermatic cord; stage II involves 
retroperitoneal nodes; and stage III is disease outside the retroperitoneum. 
Among seminoma pts, 70% are stage I, 20% are stage II, and 10% are stage 
III. Among nonseminoma germ cell tumor pts, 33% are found in each 
stage. hCG may be elevated in either seminoma or nonseminoma, but AFP 
is elevated only in nonseminoma. 95% of pts are cured if treated appropri-
ately. Primary nonseminoma in the mediastinum is associated with acute 
leukemia or other hematologic disorders and has a poorer prognosis than 
testicular primaries (~33%).
Testicular Cancer (Table 79-1)
TREATMENT
For stages I and II seminoma, inguinal orchiectomy followed by retro-
peritoneal radiation therapy to 2500–3000 cGy is effective. For stages I 
and II nonseminoma germ cell tumors, inguinal orchiectomy followed 
by retroperitoneal lymph node dissection is effective. For pts of either 
histology with bulky nodes or stage III disease, chemotherapy is given. 
Cisplatin (20 mg/m2 days 1–5), etoposide (100 mg/m2 days 1–5), and 
bleomycin (30 U days 2, 9, 16) given every 21 days for four cycles is the 
standard therapy. If tumor markers return to zero, residual masses are 
resected. Most are necrotic debris or teratomas. Salvage therapy rescues 
about 25% of those not cured with primary therapy.
SECTION 6
464
Hematology and Oncology
CHAPTER 80
Gynecologic Cancer
OVARIAN CANCER
� INCIDENCE AND EPIDEMIOLOGY 
Annually in the United States, about 22,000 new cases are found and 15,500 
women die of ovarian cancer. Incidence begins to rise in the fifth decade, 
peaking in the eighth decade. Risk is increased in nulliparous women and 
reduced by pregnancy (risk decreased about 10% per pregnancy) and oral 
contraceptives. About 5% of cases are familial.
For a more detailed discussion, see Scher HI, Motzer RJ: 
Bladder and Renal Cell Carcinomas, Chap. 94, p. 790; and 
Motzer RJ, Bosl GJ: Testicular Cancer, Chap. 96, p. 806, in 
HPIM-18.
TABLE 79-1 GERM CELL TUMOR STAGING AND TREATMENT
Stage
Extent of Disease
Treatment
Seminoma
Nonseminoma
IA
Testis only, no vascular/
lymphatic invasion (T1)
Radiation therapy
RPLND or 
observation
IB
Testis only, with vascular/
lymphatic invasion (T2), 
or extension through 
tunica albuginea (T2), or 
involvement of spermatic 
cord (T3) or scrotum (T4)
Radiation therapy
RPLND or 
chemotherapy
IIA
Nodes <2 cm
Radiation therapy
RPLND ± adjuvant 
chemotherapy or 
chemotherapy 
followed by RPLND
IIB
Nodes 2–5 cm
Radiation therapy 
or chemotherapy
Chemotherapy, often 
followed by RPLND
IIC
Nodes >5 cm
Chemotherapy
Chemotherapy, often 
followed by RPLND
III
Distant metastases
Chemotherapy
Chemotherapy, often 
followed by surgery 
(biopsy or resection)
Abbreviation: RPLND, retroperitoneal lymph node dissection.
CHAPTER 80 
465
Gynecologic Cancer
� GENETICS 
Mutations in BRCA-1 predispose women to both breast and ovarian cancer. 
Cytogenetic analysis of epithelial ovarian cancers that are not familial often 
reveals complex karyotypic abnormalities, including structural lesions on 
chromosomes 1 and 11 and loss of heterozygosity for loci on chromosomes 
3q, 6q, 11q, 13q, and 17. C-myc, H-ras, K-ras, and HER2/neu are often 
mutated or overexpressed. Unlike in colon cancer, a stepwise pathway to 
ovarian carcinoma is not apparent. Ovarian cancers may also occur in the 
setting of Lynch syndrome, inherited nonpolyposis colorectal cancer, due to 
mutations in the genes that repair DNA mismatches. The subset of women 
with endometrioid histology often have a mutation in ARID1A, a DNA 
repair complex component.
� SCREENING 
No benefit has been seen from screening women of average risk. Hereditary 
ovarian cancer accounts for 10% of all cases. Women with BRCA-1 or -2 
mutations should consider prophylactic bilateral salpingo-oophorectomy 
by age 40.
� CLINICAL PRESENTATION 
Most pts present with abdominal pain, bloating, urinary symptoms, and 
weight gain indicative of disease spread beyond the true pelvis. Localized 
ovarian cancer is usually asymptomatic and detected on routine pelvic 
examination as a palpable nontender adnexal mass. Most ovarian masses 
detected incidentally in ovulating women are ovarian cysts that resolve over 
one to three menstrual cycles. Adnexal masses in postmenopausal women 
are more often pathologic and should be surgically removed. CA-125 serum 
levels are ≥35 U/mL in 80–85% of women with ovarian cancer, but other 
conditions may also cause elevations.
� PATHOLOGY 
Half of ovarian tumors are benign, one-third are malignant, and the rest are 
tumors of low malignant potential. These borderline lesions have cytologic 
features of malignancy but do not invade. Malignant epithelial tumors may 
be of five different types: serous (50%), mucinous (25%), endometrioid 
(15%), clear cell (5%), and Brenner tumors (1%, derived from urothelial 
or transitional epithelium). The remaining 4% of ovarian tumors are 
stromal or germ cell tumors, which are managed like testicular cancer in 
men (Chap. 79). Histologic grade is an important prognostic factor for the 
epithelial varieties.
� STAGING 
Extent of disease is ascertained by a surgical procedure that permits visual 
and manual inspection of all peritoneal surfaces and the diaphragm. 
Total abdominal hysterectomy, bilateral salpingo-oophorectomy, partial 
omentectomy, pelvic and paraaortic lymph node sampling, and peritoneal 
washings should be performed. The staging system and its influence on 
survival are shown in Table 80-1. About 23% of pts are stage I, 13% are stage 
II, 47% are stage III, and 16% are stage IV.
TABLE 80-1 STAGING AND SURVIVAL IN GYNECOLOGIC MALIGNANCIES
Stage
Ovarian
5-Year Survival, %
Endometrial
5-Year Survival, % Cervical
5-Year Survival, %
0
—
—
Carcinoma in situ
100
I
Confined to ovary
90–95
Confined to corpus
89
Confined to uterus
  85
II
Confined to pelvis
70–80
Involves corpus and 
cervix
73
Invades beyond uterus but 
not pelvic wall
  65
III
Intraabdominal 
spread
25–50
Extends outside the 
uterus but not outside 
the true pelvis
52
Extends to pelvic wall and/
or lower third of vagina, or 
hydronephrosis
  35
IV
Spread outside 
abdomen
1–5
Extends outside the 
true pelvis or involves 
the bladder or rectum
17
Invades mucosa of blad-
der or rectum or extends 
beyond the true pelvis
    7
466
CHAPTER 80 
467
Gynecologic Cancer
Ovarian Cancer
TREATMENT
Pts with stage I disease, no residual tumor after surgery, and well- or 
moderately differentiated tumors need no further treatment after 
surgery and have a 5-year survival of >95%. For stage II pts totally 
resected and stage I pts with poor histologic grade, adjuvant therapy 
with single-agent cisplatin or cisplatin plus paclitaxel produces 5-year 
survival of 80%. Advanced-stage pts should receive paclitaxel, 175 mg/
m2 by 3-h infusion, followed by carboplatin dosed to an area under the 
curve (AUC) of 7.5 every 3 or 4 weeks. Carboplatin dose is calculated 
by the Calvert formula: dose = target AUC × (glomerular filtration rate 
+ 25). The complete response rate is about 55%, and median survival is 
38 months.
ENDOMETRIAL CANCER
� INCIDENCE AND EPIDEMIOLOGY 
The most common gynecologic cancer—47,000 cases are diagnosed in the 
United States and 8010 pts die annually. It is primarily a disease of post-
menopausal women. Obesity, altered menstrual cycles, infertility, late meno-
pause, and postmenopausal bleeding are commonly encountered in women 
with endometrial cancer. Women taking tamoxifen to prevent breast cancer 
recurrence and those taking estrogen replacement therapy are at a modestly 
increased risk. Peak incidence is in the sixth and seventh decades.
� CLINICAL PRESENTATION 
Abnormal vaginal discharge (90%), abnormal vaginal bleeding (80%), and 
leukorrhea (10%) are the most common symptoms.
� PATHOLOGY 
Endometrial cancers are adenocarcinomas in 75–80% of cases. The remain-
ing cases include mucinous carcinoma; papillary serous carcinoma; and 
secretory, ciliate, and clear cell varieties. Prognosis depends on stage, histo-
logic grade, and degree of myometrial invasion.
� STAGING 
Total abdominal hysterectomy and bilateral salpingo-oophorectomy con-
stitute both the staging procedure and the treatment of choice. The staging 
scheme and its influence on prognosis are shown in Table 80-1. About 75% 
of pts are stage I, 13% are stage II, 9% are stage III, and 3% are stage IV.
Endometrial Cancer
TREATMENT
In women with poor histologic grade, deep myometrial invasion, or exten-
sive involvement of the lower uterine segment or cervix, intracavitary 
or external-beam radiation therapy is given. If cervical invasion is deep, 
preoperative radiation therapy may improve the resectability of the tumor. 
Stage III disease is managed with surgery and radiation therapy. Stage IV
SECTION 6
468
Hematology and Oncology
disease is usually treated palliatively. Progestational agents such as hydroxy-
progesterone or megestrol and the antiestrogen tamoxifen may produce 
responses in 20% of pts. Doxorubicin, 60 mg/m2 IV day 1, and cisplatin, 50 
mg/m2 IV day 1, every 3 weeks for 8 cycles produces a 45% response rate.
CERVICAL CANCER
� INCIDENCE AND EPIDEMIOLOGY 
In the United States about 12,120 cases of invasive cervical cancer are diag-
nosed each year and 50,000 cases of carcinoma in situ are detected by Pap 
smear. Cervical cancer kills 4220 women a year, 85% of whom never had a 
Pap smear. It is a major cause of disease in underdeveloped countries and is 
more common in lower socioeconomic groups, in women with early sexual 
activity and/or multiple sexual partners, and in smokers. Human papilloma 
virus (HPV) types 16 and 18 are the major types associated with cervical 
cancer. The virus attacks the G1 checkpoint of the cell cycle; its E7 protein 
binds and inactivates Rb protein, and E6 induces the degradation of p53.
� SCREENING 
Women should begin screening when they begin sexual activity or at age 
20. After two consecutive negative annual Pap smears, the test should be 
repeated every 3 years. Abnormal smears dictate the need for a cervical 
biopsy, usually under colposcopy, with the cervix painted with 3% acetic 
acid, which shows abnormal areas as white patches. If there is evidence of 
carcinoma in situ, a cone biopsy is performed, which is therapeutic.
� PREVENTION 
Women and children age 9–26 should consider vaccination with Gardasil 
to prevent infection with two serotypes of virus (16 and 18) that cause 70% 
of the cervical cancer in the United States.
� CLINICAL PRESENTATION 
Pts present with abnormal bleeding or postcoital spotting or menometror-
rhagia or intermenstrual bleeding. Vaginal discharge, low back pain, and 
urinary symptoms also may be present.
� STAGING 
Staging is clinical and consists of a pelvic exam under anesthesia with cys-
toscopy and proctoscopy. Chest x-ray, IV pyelography, and abdominal CT 
are used to search for metastases. The staging system and its influence on 
prognosis are shown in Table 80-1. At presentation, 47% of pts are stage I, 
28% are stage II, 21% are stage III, and 4% are stage IV.
Cervical Cancer
TREATMENT
Carcinoma in situ is cured with cone biopsy. Stage I disease may be 
treated with radical hysterectomy or radiation therapy. Stages II–IV 
disease are usually treated with radiation therapy, often with both
CHAPTER 81 
469
Prostate Hyperplasia and Carcinoma 
brachytherapy and teletherapy, or combined-modality therapy. Pelvic 
exenteration is used uncommonly to control the disease, especially in 
the setting of centrally recurrent or persistent disease. Women with 
locally advanced (stage IIB to IVA) disease usually receive concur-
rent chemotherapy and radiation therapy. The chemotherapy acts as a 
radiosensitizer. Hydroxyurea, 5-fluorouracil (5FU), and cisplatin have 
all shown promising results given concurrently with radiation therapy. 
Cisplatin, 75 mg/m2 IV over 4 h on day 1, and 5FU, 4 g given by 96-h 
infusion on days 1–5 of radiation therapy, is a common regimen. 
Relapse rates are reduced 30–50% by such therapy. Advanced-stage 
disease is treated palliatively with single agents (cisplatin, irinotecan, 
ifosfamide).
For a more detailed discussion, see Seiden MV: Gynecologic 
Malignancies, Chap. 97, p. 810, in HPIM-18.
CHAPTER 81
Prostate Hyperplasia 
and Carcinoma
PROSTATE HYPERPLASIA
Enlargement of the prostate is nearly universal in aging men. Hyperplasia 
usually begins by age 45 years, occurs in the area of the prostate gland 
surrounding the urethra, and produces urinary outflow obstruction. 
Symptoms develop on average by age 65 in whites and 60 in blacks. 
Symptoms develop late because hypertrophy of the bladder detrusor 
compensates for ureteral compression. As obstruction progresses, urinary 
stream caliber and force diminish, hesitancy in stream initiation develops, 
and postvoid dribbling occurs. Dysuria and urgency are signs of bladder 
irritation (perhaps due to inflammation or tumor) and are usually not seen 
in prostate hyperplasia. As the postvoid residual increases, nocturia and 
overflow incontinence may develop. Common medications such as tran-
quilizing drugs and decongestants, infections, or alcohol may precipitate 
urinary retention. Because of the prevalence of hyperplasia, the relation-
ship to neoplasia is unclear.
On digital rectal exam (DRE), a hyperplastic prostate is smooth, firm, 
and rubbery in consistency; the median groove may be lost. Prostate-
specific antigen (PSA) levels may be elevated but are ≤10 ng/mL unless 
cancer is also present (see below). Cancer may also be present at lower 
levels of PSA.
SECTION 6
470
Hematology and Oncology
Prostate Hyperplasia
TREATMENT
Asymptomatic pts do not require treatment, and those with complica-
tions of urethral obstruction such as inability to urinate, renal failure, 
recurrent urinary tract infection, hematuria, or bladder stones clearly 
require surgical extirpation of the prostate, usually by transurethral 
resection (TURP). However, the approach to the remaining pts should 
be based on the degree of incapacity or discomfort from the disease and 
the likely side effects of any intervention. If the pt has only mild symp-
toms, watchful waiting is not harmful and permits an assessment of the 
rate of symptom progression. If therapy is desired by the pt, two medical 
approaches may be helpful: terazosin, an α1-adrenergic blocker (1 mg at 
bedtime, titrated to symptoms up to 20 mg/d), relaxes the smooth mus-
cle of the bladder neck and increases urine flow; finasteride (5 mg/d) or 
dutasteride (2.5 mg/d), inhibitors of 5α-reductase, block the conversion 
of testosterone to dihydrotestosterone and cause an average decrease in 
prostate size of ~24%. TURP has the greatest success rate but also the 
greatest risk of complications. Transurethral microwave thermotherapy 
(TUMT) may be comparably effective to TURP. Direct comparison has 
not been made between medical and surgical management.
PROSTATE CARCINOMA
Prostate cancer has been diagnosed in 241,740 men in 2012 in the United 
States—an incidence comparable to that of breast cancer. About 28,170 
men have died of prostate cancer in 2012. The early diagnosis of cancers in 
mildly symptomatic men found on screening to have elevated serum levels 
of PSA has complicated management. Like most other cancers, incidence is 
age-related. The disease is more common in blacks than whites. Symptoms 
are generally similar to and indistinguishable from those of prostate hyper-
plasia, but those with cancer more often have dysuria and back or hip pain. 
On histology, 95% are adenocarcinomas. Biologic behavior is affected by 
histologic grade (Gleason score).
In contrast to hyperplasia, prostate cancer generally originates in the 
periphery of the gland and may be detectable on DRE as one or more nod-
ules on the posterior surface of the gland, hard in consistency and irregular 
in shape. An approach to diagnosis is shown in Fig. 81-1. Those with a 
negative DRE and PSA ≤4 ng/mL may be followed annually. Those with an 
abnormal DRE or a PSA >10 ng/mL should undergo transrectal ultrasound 
(TRUS)-guided biopsy. Those with normal DRE and PSA of 4.1–10 ng/mL 
may be handled differently in different centers. Some would perform TRUS 
and biopsy any abnormality or follow if no abnormality were found. Some 
would repeat the PSA in a year and biopsy if the increase over that period 
were >0.75 ng/mL. Other methods of using PSA to distinguish early cancer 
from hyperplasia include quantitating bound and free PSA and relating the 
PSA to the size of the prostate (PSA density). Perhaps one-third of persons 
with prostate cancer do not have PSA elevations.
Lymphatic spread is assessed surgically; it is present in only 10% of those 
with Gleason grade 5 or lower and in 70% of those with grade 9 or 10. PSA 
DIAGNOSTIC EVALUATION OF MEN
Men >50 or African Americans >45 or
positive family history
DRE
  and PSA
DRE normal
DRE
Abnormal
PSA
Normal
  Positive
  Borderline
TRUS
  guided
  biopsy
Normal
>4
Staging
PSA
Repeat annually
Repeat biopsy in 3–6 months
PSA
Total <4
PSA velocity <0.75
PSA <2
PSA 2–4
TRUS-guided biopsy
DRE annually PSA
Annual DRE +PSA
Total <4
PSA velocity >0.75
Staging
Repeat annually
TRUS-guided biopsy
% Free PSA
PSA 4–10
PSA >10
Staging
Check % free PSA in 6–12 months
TRUS-guided biopsy
Staging
Consider repeat
Biopsy
Low
Staging
+
–
+
+
–
–
+
–
+
–
FIGURE 81-1 The use of the annual digital rectal examination (DRE) and measurement of prostate-specific antigen (PSA) as guides for deciding which men 
should have transrectal ultrasound (TRUS)-guided prostate biopsy. There are at least three schools of thought about what to do if the DRE is negative and the PSA 
is equivocal (4.1 to 10 ng/mL).
471
SECTION 6
472
Hematology and Oncology
level also correlates with spread; only 10% of those with PSA <10 ng/mL 
have lymphatic spread. Bone is the most common site of distant metastasis. 
Whitmore-Jewett staging includes A: tumor not palpable but detected at 
TURP; B: palpable tumor in one (B1) or both (B2) lobes; C: palpable tumor 
outside capsule; and D: metastatic disease.
Prostate Carcinoma
TREATMENT
For pts with stages A through C disease, surgery (radical retropubic pros-
tatectomy) and radiation therapy (conformal 3-dimensional fields) are 
said to have similar outcomes; however, most pts are treated surgically. 
Both modalities are associated with impotence. Surgery is more likely to 
lead to incontinence. Radiation therapy is more likely to produce proc-
titis, perhaps with bleeding or stricture. Addition of hormonal therapy 
(goserelin) to radiation therapy of pts with localized disease appears 
to improve results. Pts usually must have a 5-year life expectancy to 
undergo radical prostatectomy. Stage A pts have survival identical to 
age-matched controls without cancer. Stage B and C pts have a 10-year 
survival of 82% and 42%, respectively.
Pts treated surgically for localized disease who develop rising PSA 
may undergo Prostascint scanning (antibody to a prostate-specific 
membrane antigen). If no uptake is seen, the pt is observed. If uptake is 
seen in the prostate bed, local recurrence is implied and external beam 
radiation therapy is delivered to the site. (If the pt was initially treated 
with radiation therapy, this local recurrence may be treated with sur-
gery.) However, in most cases, a rising PSA after local therapy indicates 
systemic disease. It is not clear when to intervene in such pts.
For pts with metastatic disease, androgen deprivation is the treatment 
of choice. Surgical castration is effective, but most pts prefer to take 
leuprolide, 7.5 mg depot form IM monthly (to inhibit pituitary gonado-
tropin production), plus flutamide, 250 mg PO tid (an androgen receptor 
blocker). The value of added flutamide is debated. Alternative approaches 
include adrenalectomy, hypophysectomy, estrogen administration, and 
medical adrenalectomy with aminoglutethimide. The median survival 
of stage D pts is 33 months. Pts occasionally respond to withdrawal of 
hormonal therapy with tumor shrinkage. Second hormonal manipula-
tions act by blocking androgen production in the tumor; abiraterone, 
a CYP17 inhibitor that blocks androgen synthesis and MDV3100, an 
antiandrogen, improve overall survival. Many pts who progress on 
hormonal therapy have androgen-independent tumors, often associated 
with genetic changes in the androgen receptor and new expression of 
bcl-2, which may contribute to chemotherapy resistance. Chemotherapy 
is used for palliation in prostate cancer. Mitoxantrone, estramustine, 
and taxanes, particularly cabazitaxel, appear to be active single agents, 
and combinations of drugs are being tested. Chemotherapy-treated pts 
are more likely to have pain relief than those receiving supportive care 
alone. Sipuleucel-T, an active specific immunotherapy, improves survival 
by about 4 months in hormone-refractory disease without producing
CHAPTER 82 
473
Cancer of Unknown Primary Site 
For a more detailed discussion, see Scher HI: Benign and 
Malignant Diseases of the Prostate, Chap. 95, p. 796, in 
HPIM-18.
any measureable change in the tumor. Bone pain from metastases may 
be palliated with strontium-89 or samarium-153. Bisphosphonates 
decrease the incidence of skeletal events. 
� PROSTATE CANCER PREVENTION
Finasteride and dutasteride have been shown to reduce the incidence of pros-
tate cancer by 25%, but no effect on overall survival has been seen with limited 
follow-up. In addition, the cancers that do occur appear to be shifted to higher 
Gleason grades, although follow-up is limited to assess the natural history.
CHAPTER 82
Cancer of Unknown 
Primary Site
Cancer of unknown primary site (CUPS) is defined as follows: biopsy-
proven malignancy; primary site unapparent after history, physical exam, 
chest x-ray, abdominal and pelvic CT, complete blood count, chemistry sur-
vey, mammography (women), β-human chorionic gonadotropin (hCG) lev-
els (men), α-fetoprotein (AFP) levels (men), and prostate-specific antigen 
(PSA) levels (men); and histologic evaluation not consistent with a primary 
tumor at the biopsy site. CUPS incidence is declining, probably because of 
better pathology diagnostic criteria; it accounts for about 3% of all cancers 
today, down from 10–15% 15 years ago. Most pts are over age 60. The tumors 
are often aneuploid. Cell lines derived from such tumors frequently have 
abnormalities in chromosome 1.
Clinical Presentation 
Pts may present with fatigue, weight loss, pain, bleeding, abdominal swell-
ing, subcutaneous masses, and lymphadenopathy. Once metastatic malig-
nancy is confirmed, diagnostic efforts should be confined to evaluating the 
presence of potentially curable tumors, such as lymphoma, Hodgkin’s dis-
ease, germ cell tumor, ovarian cancer, head and neck cancer, and primitive 
neuroectodermal tumor, or tumors for which therapy may be of significant 
palliative value such as breast cancer or prostate cancer. In general, efforts 
to evaluate the presence of these tumor types depend more on the patholo-
gist than on expensive clinical diagnostic testing. Localizing symptoms, a 
history of carcinogen exposure, or a history of fulguration of skin lesion 
SECTION 6
474
Hematology and Oncology
TABLE 82-1  POSSIBLE PATHOLOGIC EVALUATION OF BIOPSY SPECIMENS 
FROM PATIENTS WITH METASTATIC CANCER OF UNKNOWN 
PRIMARY SITE
Evaluation/Findings
Suggested Primary Site or 
Neoplasm
Histology (hematoxylin and eosin staining)
Psammoma bodies, papillary 
configuration
Ovary, thyroid
Signet ring cells
Stomach
Immunohistology
Leukocyte common antigen (LCA, 
CD45)
Lymphoid neoplasm
Leu-M1
Hodgkin’s disease
Epithelial membrane antigen
Carcinoma
Cytokeratin
Carcinoma
CEA
Carcinoma
HMB45
Melanoma
Desmin
Sarcoma
Thyroglobulin
Thyroid carcinoma
Calcitonin
Medullary carcinoma of the thyroid
Myoglobin
Rhabdomyosarcoma
PSA/prostatic acid phosphatase
Prostate
AFP
Liver, stomach, germ cell
Placental alkaline phosphatase
Germ cell
β-human chorionic gonadotropin
Germ cell
B, T cell markers
Lymphoid neoplasm
S-100 protein
Neuroendocrine tumor, melanoma
Gross cystic fluid protein
Breast, sweat gland
Estrogen and progesterone receptors
Breast
Factor VIII
Kaposi’s sarcoma, angiosarcoma
Thyroid transcription factor 1 (TTF-1)
Lung adenocarcinoma, thyroid
Calretinin, mesothelin
Mesothelioma
URO-III, thrombomodulin
Bladder
Flow Cytometry
B, T cell markers
Lymphoid neoplasm
Ultrastructure
Actin-myosin filaments
Rhabdomyosarcoma
Secretory granules
Neuroendocrine tumors
Desmosomes
Carcinoma
Premelanosomes
Melanoma
CHAPTER 82 
475
Cancer of Unknown Primary Site 
TABLE 82-1  POSSIBLE PATHOLOGIC EVALUATION OF BIOPSY SPECIMENS 
FROM PATIENTS WITH METASTATIC CANCER OF UNKNOWN 
PRIMARY SITE (CONTINUED)
Cytogenetics
Isochromosome 12p; 12q(–)
Germ cell
t(11;22)
Ewing’s sarcoma, primitive 
neuroectodermal tumor
t(8;14)a
Lymphoid neoplasm
3p(–)
Small cell lung carcinoma; renal 
cell carcinoma, mesothelioma
t(X;18)
Synovial sarcoma
t(12;16)
Myxoid liposarcoma
t(12;22)
Clear cell sarcoma (melanoma of 
soft parts)
t(2;13)
Alveolar rhabdomyosarcoma
1p(–)
Neuroblastoma
Receptor Analysis
Estrogen/progesterone receptor
Breast
Molecular Biologic Studies
Immunoglobulin, bcl-2, T cell receptor 
gene rearrangement
Lymphoid neoplasm
aOr any other rearrangement involving an antigen-receptor gene.
Abbreviations: AFP, α-fetoprotein; CEA, carcinoembryonic antigen; PSA, prostate-specific antigen.
may direct some clinical testing; however, the careful light microscopic, 
ultrastructural, immunologic, karyotypic, and molecular biologic examina-
tion of adequate volumes of tumor tissue is the most important feature of 
the diagnostic workup in the absence of suspicious findings on history and 
physical exam (Table 82-1).
Histology 
About 60% of CUPS tumors are adenocarcinomas, 5% are squamous cell 
carcinomas, and 30% are poorly differentiated neoplasms not further clas-
sified on light microscopy. Expression of cytokeratin subtypes may narrow 
the range of possible diagnoses (Fig. 82-1).
Prognosis
Pts with squamous cell carcinoma have a median survival of 9 months; 
those with adenocarcinoma or unclassifiable tumors have a median survival 
of 4–6 months. Pts in whom a primary site is identified usually have a bet-
ter prognosis. Limited sites of involvement and neuroendocrine histology 
are favorable prognostic factors. Pts without a primary diagnosis should 
be treated palliatively with radiation therapy to symptomatic lesions. 
All-purpose chemotherapy regimens rarely produce responses but always 
SECTION 6
476
Hematology and Oncology
produce toxicity. Certain clinical features may permit individualized 
therapy.
� SYNDROME OF UNRECOGNIZED EXTRAGONADAL GERM CELL CANCER
In pts <50 years with tumor involving midline structures, lung parenchyma, 
or lymph nodes and evidence of rapid tumor growth, germ cell tumor is 
a possible diagnosis. Serum tumor markers may or may not be elevated. 
Cisplatin, etoposide, and bleomycin (Chap. 79) chemotherapy may induce 
complete responses in ≥25%, and ~15% may be cured. A trial of such 
therapy should probably also be undertaken in pts whose tumors have 
abnormalities in chromosome 12.
� PERITONEAL CARCINOMATOSIS IN WOMEN
Women who present with pelvic mass or pain and an adenocarcinoma dif-
fusely throughout the peritoneal cavity, but without a clear site of origin, 
have primary peritoneal papillary serous carcinoma. The presence of psam-
moma bodies in the tumor or elevated CA-125 levels may favor ovarian 
origin. Such pts should undergo debulking surgery followed by paclitaxel 
plus cisplatin or carboplatin combination chemotherapy (Chap. 80). About 
20% of pts will respond, and 10% will survive at least 2 years.
� CARCINOMA IN AN AXILLARY LYMPH NODE IN WOMEN
Such women should receive adjuvant breast cancer therapy appropriate for 
their menopausal status even in the absence of a breast mass on physical 
examination or mammography and undetermined or negative estrogen 
and progesterone receptors on the tumor (Chap. 77). Unless the ipsilateral 
breast is radiated, up to 50% of these pts will later develop a breast mass. 
Although this is a rare clinical situation, long-term survival similar to 
women with stage II breast cancer is possible.
� OSTEOBLASTIC BONE METASTASES IN MEN
The probability of prostate cancer is high; a trial of empirical hormonal 
therapy (leuprolide and flutamide) is warranted (Chap. 81).
� CERVICAL LYMPH NODE METASTASES
Even if panendoscopy fails to reveal a head and neck primary, treatment 
of such pts with cisplatin and 5-fluorouracil chemotherapy may produce a 
response; some responses are long-lived (Chap. 75).
CK7     CK20
CK7+     CK20+
CK7+     CK20–
CK7–     CK20+
CK7–     CK20–
Urothelial tumors 
Ovarian mucinous 
 adenocarcinoma
Pancreatic
 adenocarcinoma
Cholangiocarcinoma
Lung adenocarcinoma
Breast carcinoma
Thyroid carcinoma
Endometrial carcinoma
Cervical carcinoma 
Salivary gland carcinoma
Cholangiocarcinoma
Pancreatic carcinoma
Colorectal carcinoma 
Merkel cell carcinoma
Hepatocellular carcinoma
Renal cell carcinoma
Prostate carcinoma
Squamous cell and small 
 cell lung carcinoma
Head and neck carcinoma
FIGURE 82-1 Approach to cytokeratin (CK7 and CK20) markers used in CUP. 
CHAPTER 83 
477
Paraneoplastic Endocrine Syndromes 
For a more detailed discussion, see Varadhachary GR, 
Abbruzzese JL: Carcinoma of Unknown Primary, Chap. 99, 
p. 821, in HPIM-18.
CHAPTER 83
Paraneoplastic 
Endocrine Syndromes
Both benign and malignant tumors of nonendocrine tissue can secrete 
a variety of hormones, principally peptide hormones, and many tumors 
produce more than one hormone (Table 83-1). At the clinical level, ectopic 
hormone production is important for two reasons.
First, endocrine syndromes that result may either be the presenting mani-
festations of the neoplasm or occur late in the course. The endocrine manifes-
tations in some instances are of greater significance than the tumor itself, as 
in pts with benign or slowly growing malignancies that secrete corticotropin-
releasing hormone and cause fulminant Cushing’s syndrome. The frequency 
with which ectopic hormone production is recognized varies with the criteria 
used for diagnosis. The most common syndromes of clinical import are those 
of adrenocorticotropic hormone (ACTH) hypersecretion, hypercalcemia, and 
hypoglycemia. Indeed, ectopic ACTH secretion is responsible for 15–20% of 
pts with Cushing’s syndrome, and ~50% of pts with persistent hypercalcemia 
have a malignancy rather than hyperparathyroidism. Because of the rapid-
ity of development of hormone secretion in some rapidly growing tumors, 
diagnosis may require a high index of suspicion, and hormone levels may be 
elevated out of proportion to the manifestations.
Second, ectopic hormones serve as valuable peripheral markers for neopla-
sia. Because of the broad spectrum of ectopic hormone secretion, screening 
measurements of plasma hormone levels for diagnostic purposes are not cost-
effective. However, in pts with malignancies that are known to secrete hor-
mones, serial measurements of circulating hormone levels can serve as markers 
for completeness of tumor excision and for effectiveness of radiation therapy or 
chemotherapy. Likewise, tumor recurrence may be heralded by reappearance 
of elevated plasma hormone levels before mass effects of the tumor are evident. 
However, some tumors at recurrence do not secrete hormones, so hormone 
measurements cannot be relied on as the sole evidence of tumor activity.
Paraneoplastic Endocrine Syndromes
TREATMENT
Therapy of ectopic hormone-secreting tumors should be directed when 
possible toward removal of the tumor. When the tumor cannot be 
removed or is incurable, specific therapy can be directed toward inhibiting 
SECTION 6
478
Hematology and Oncology
TABLE 83-1  PARANEOPLASTIC SYNDROMES CAUSED BY ECTOPIC 
HORMONE PRODUCTION
Paraneoplastic 
Syndrome
Ectopic Hormone
Typical Tumor Typesa
Common
Hypercalcemia of 
malignancy
Parathyroid hormone–
related protein (PTHrP)
Squamous cell (head 
and neck, lung, skin), 
breast, genitourinary, 
gastrointestinal
1,25 dihydroxyvitamin D
Lymphomas
Parathyroid hormone 
(PTH) (rare)
Lung, ovary
Prostaglandin E2 (PGE2) 
(rare)
Renal, lung
Syndrome of inap-
propriate antidi-
uretic hormone 
secretion (SIADH)
Vasopressin
Lung (squamous, small 
cell), gastrointestinal, 
genitourinary, ovary
Cushing’s 
syndrome
Adrenocorticotropic
hormone (ACTH)
Lung (small cell, bron-
chial carcinoid, adeno-
carcinoma, squamous), 
thymus, pancreatic 
islet, medullary thyroid 
carcinoma
Corticotropin-releasing
hormone (CRH) (rare)
Pancreatic islet, carci-
noid, lung, prostate
Ectopic expression of 
gastric inhibitory peptide 
(GIP), luteinizing 
hormone (LH)/human 
chorionic gonadotropin 
(hCG), other G protein–
coupled receptors 
(rare)
Macronodular adrenal 
hyperplasia
Less common
Non-islet cell 
hypoglycemia
Insulin-like growth factor 
(IGF-II)
Mesenchymal tumors, 
sarcomas, adrenal, 
hepatic, gastrointestinal, 
kidney, prostate
Insulin (rare)
Cervix (small cell 
carcinoma)
Male feminization
hCGb
Testis (embryonal, semi-
nomas), germinomas, 
choriocarcinoma, lung, 
hepatic, pancreatic islet
CHAPTER 83 
479
Paraneoplastic Endocrine Syndromes 
hormone secretion (octreotide for ectopic acromegaly or mitotane to 
inhibit adrenal steroidogenesis in the ectopic ACTH syndrome) or 
blocking the action of the hormone at the tissue level (demeclocycline 
for inappropriate vasopressin secretion).
� HYPERCALCEMIA
The most common paraneoplastic syndrome, hypercalcemia of malignancy 
accounts for 40% of all hypercalcemia. Of cancer pts with hypercalcemia, 
80% have humoral hypercalcemia mediated by parathyroid hormone–
related peptide; 20% have local osteolytic hypercalcemia mediated by cyto-
kines such as interleukin 1 and tumor necrosis factor. Many tumor types 
may produce hypercalcemia (Table 83-1). Pts may have malaise, fatigue, 
TABLE 83-1  PARANEOPLASTIC SYNDROMES CAUSED BY ECTOPIC 
HORMONE PRODUCTION (CONTINUED)
Paraneoplastic 
Syndrome
Ectopic Hormone
Typical Tumor Typesa
Less common
Diarrhea or intesti-
nal hypermotility
Calcitoninc
Lung, colon, breast, med-
ullary thyroid carcinoma
Vasoactive intestinal 
peptide (VIP)
Pancreas, pheochromo-
cytoma, esophagus
Rare
Oncogenic osteo-
malacia
Phosphatonin [fibro-
blast growth factor 23 
(FGF23)]
Hemangiopericytomas, 
osteoblastomas, fibro-
mas, sarcomas, giant cell 
tumors, prostate, lung
Acromegaly
Growth hormone–
releasing hormone 
(GHRH)
Pancreatic islet, bronchial 
and other carcinoids
Growth hormone (GH)
Lung, pancreatic islet
Hyperthyroidism
Thyroid-stimulating 
hormone (TSH)
Hydatidiform mole, 
embryonal tumors, 
struma ovarii
Hypertension
Renin
Juxtaglomerular tumors, 
kidney, lung, pancreas, 
ovary
aOnly the most common tumor types are listed. For most ectopic hormone syndromes, an 
extensive list of tumors has been reported to produce one or more hormones.
bhCG is produced eutopically by trophoblastic tumors. Certain tumors produce disproportion-
ate amounts of the hCG α or hCG β subunit. High levels of hCG rarely cause hyperthyroid-
ism because of weak binding to the TSH receptor.
cCalcitonin is produced eutopically by medullary thyroid carcinoma and is used as a tumor 
marker.
SECTION 6
480
Hematology and Oncology
confusion, anorexia, bone pain, polyuria, weakness, constipation, nausea, 
and vomiting. At high calcium levels, confusion, lethargy, coma, and death 
may ensue. Median survival of hypercalcemic cancer pts is 1–3 months. 
Treatment with saline hydration, furosemide diuresis, and pamidronate 
(60–90 mg IV) or zoledronate (4–8 mg IV) controls calcium levels within 
2 days and suppresses calcium release for several weeks. Oral bisphos-
phonates can be used for chronic treatment. In the setting of hematologic 
malignancies, hypercalcemia may respond to glucocorticoids.
� HYPONATREMIA
Most commonly discovered in asymptomatic individuals as a result of serum 
electrolyte measurements, hyponatremia is usually due to tumor secretion of 
arginine vasopressin, a condition called syndrome of inappropriate antidiuretic 
hormone secretion (SIADH). Atrial natriuretic hormone also may produce 
hyponatremia. SIADH occurs most commonly in small cell lung cancer 
(15%) and head and neck cancer (3%). A number of drugs may produce 
the syndrome. Symptoms of fatigue, poor attention span, nausea, weakness, 
anorexia, and headache may be controlled by restricting fluid intake to 500 
mL/d or blocking the effects of the hormone with 600–1200 mg demeclocy-
cline a day. With severe hyponatremia (<115 meq/L) or in the setting of men-
tal status changes, normal saline infusion plus furosemide may be required; 
rate of correction should be <1 meq/L per hour to prevent complications.
� ECTOPIC ACTH SYNDROME
When pro-opiomelanocortin mRNA in the tumor is processed into ACTH, 
excessive secretion of glucocorticoids and mineralocorticoids may ensue. Pts 
develop Cushing’s syndrome with hypokalemic alkalosis, weakness, hyperten-
sion, and hyperglycemia. About half the cases occur in small cell lung cancer. 
ACTH production adversely affects prognosis. Ketoconazole (400–1200 mg/d) 
or metyrapone (1–4 g/d) may be used to inhibit adrenal steroid synthesis.
CHAPTER 84
Neurologic Paraneoplastic 
Syndromes
Paraneoplastic neurologic disorders (PNDs) are cancer-related syndromes 
that can affect any part of the nervous system; caused by mechanisms other 
than metastasis or by complications of cancer such as coagulopathy, stroke, 
metabolic and nutritional conditions, infections, and side effects of cancer 
therapy. In 60% of pts the neurologic symptoms precede cancer diagnosis. 
For a more detailed discussion, see Jameson JL, Longo, 
DL: Paraneoplastic Syndromes: Endocrinologic/Hematologic, 
Chap. 100, p. 826, in HPIM-18.
CHAPTER 84 
481
Neurologic Paraneoplastic Syndromes 
PNDs occur in 0.5–1% of all cancer pts, but they occur in 2–3% of pts with 
neuroblastoma or small cell lung cancer (SCLC), and in 30–50% of pts with 
thymoma or sclerotic myeloma.
� CLINICAL FEATURES
Recognition of a distinctive paraneoplastic syndrome (Table 84-1); should 
prompt a search for cancer, as prompt treatment of tumor may improve 
the course of PNDs; many of these disorders also occur without cancer. 
Diagnosis is based on the clinical pattern, exclusion of other cancer-
related disorders, confirmatory serum or CSF antibodies, or electrodiag-
nostic testing. Most PNDs are mediated by immune responses triggered 
by neuronal proteins expressed by tumors. PNDs associated with immune 
responses against intracellular antigens often respond poorly to treatment 
(Table 84-2), whereas those associated with antibodies to antigens on the 
neuronal cell surface of the CNS or at neuromuscular synapses are more 
responsive to immunotherapy (Table 84-3). For any type of PND, if antineu-
ronal antibodies are negative, the diagnosis rests on the demonstration of 
cancer and the exclusion of other cancer-related or independent disorders. 
Combined whole-body CT and PET scans often uncover tumors undetected 
by other tests.
TABLE 84-1 PARANEOPLASTIC SYNDROMES OF THE NERVOUS SYSTEM
Classic Syndromes: Usually Occur 
With Cancer Association
Nonclassic Syndromes: May 
Occur With and Without Cancer 
Association
Encephalomyelitis
Brainstem encephalitis
Limbic encephalitis
Stiff-person syndrome
Cerebellar degeneration (adults)
Necrotizing myelopathy
Opsoclonus-myoclonus
Motor neuron disease
Subacute sensory neuronopathy
Guillain-Barré syndrome
Gastrointestinal paresis or pseudo-
obstruction
Subacute and chronic mixed 
sensory-motor neuropathies
Dermatomyositis (adults)
Neuropathy associated with plasma 
cell dyscrasias and lymphoma
Lambert-Eaton myasthenic syndrome
Vasculitis of nerve
Cancer or melanoma associated 
retinopathy
Pure autonomic neuropathy
Acute necrotizing myopathy
Polymyositis
Vasculitis of muscle
Optic neuropathy
BDUMP
Abbreviation: BDUMP, bilateral diffuse uveal melanocytic proliferation.
SECTION 6
482
Hematology and Oncology
TABLE 84-2  ANTIBODIES TO INTRACELLULAR ANTIGENS, SYNDROMES, 
AND ASSOCIATED CANCERS
Antibody
Associated Neurologic 
Syndrome(s)
Tumors
Anti-Hu
Encephalomyelitis, subacute 
sensory neuronopathy
SCLC
Anti-Yo
Cerebellar degeneration
Ovary, breast
Anti-Ri
Cerebellar degeneration, opsoclonus Breast, gyneco-
logic, SCLC
Anti-Tr
Cerebellar degeneration
Hodgkin lymphoma
Anti-CV2/CRMP5
Encephalomyelitis, chorea, 
optic neuritis, uveitis, peripheral 
neuropathy 
SCLC, thymoma, 
other
Anti-Ma proteins
Limbic, hypothalamic, brainstem 
encephalitis
Testicular (Ma2), 
other (Ma)
Anti-amphiphysin Stiff-person syndrome, 
encephalomyelitis
Breast, SCLC
Recoverin, bipo-
lar cell antibod-
ies, othersa
Cancer-associated retinopathy 
(CAR)
SCLC (CAR), 
melanoma (MAR)
Melanoma-associated retinopathy 
(MAR)
Anti-GAD
Stiff-person, cerebellar syndromes
Infrequent tumor 
association 
(thymoma)
aA variety of target antigens have been identified.
Abbreviations: CRMP, collapsing response-mediator protein; SCLC, small cell lung cancer.
PNDs of the Central Nervous System and Dorsal Root Ganglia 
MRI and CSF studies are important to rule out neurologic complications 
due to the direct spread of cancer. In most PNDs the MRI findings are 
nonspecific. CSF findings typically consist of mild to moderate pleocytosis 
(<200 mononuclear cells, predominantly lymphocytes), an increase in the 
protein concentration, intrathecal synthesis of IgG, and a variable presence 
of oligoclonal bands. 
• Limbic encephalitis is characterized by confusion, depression, agitation, 
anxiety, severe short-term memory deficits, partial complex seizures, and 
dementia; MRI usually shows unilateral or bilateral medial temporal lobe 
abnormalities.
• Paraneoplastic cerebellar degeneration begins as dizziness, oscillopsia, 
blurry or double vision, nausea, and vomiting; a few days or weeks later, 
dysarthria, gait and limb ataxia, and variable dysphagia can appear.
• Opsoclonus-myoclonus syndrome consists of involuntary, chaotic eye 
movements in all directions of gaze plus myoclonus; it is frequently asso-
ciated with ataxia.
CHAPTER 84 
483
Neurologic Paraneoplastic Syndromes 
• Acute necrotizing myelopathy. Reports of paraneoplastic spinal cord 
syndromes have decreased in recent years; it is unclear if this is due to 
improved oncologic interventions or better detection of nonparaneoplastic 
etiologies.
• Paraneoplastic retinopathies involve cone and rod dysfunction character-
ized by photosensitivity, progressive loss of vision and color perception, 
central or ring scotomas, night blindness, and attenuation of photopic 
and scotopic responses in the electroretinogram (ERG).
• Dorsal root ganglionopathy (sensory neuronopathy) is characterized by 
sensory deficits that may be symmetric or asymmetric, painful dyses-
thesias, radicular pain, and decreased or absent reflexes; all modalities of 
sensation can be involved.
PNDs of Nerve and Muscle 
These disorders may develop anytime during the course of the neoplastic 
disease. Serum and urine immunofixation studies should be considered in 
TABLE 84-3  ANTIBODIES TO CELL SURFACE OR SYNAPTIC ANTIGENS, 
SYNDROMES, AND ASSOCIATED TUMORS
Antibody
Neurologic Syndrome
Tumor Type When 
Associated
Anti-AChR (muscle)a
Myasthenia gravis
Thymoma 
Anti-AChR (neuronal)a
Autonomic neuropathy
SCLC
Anti-VGKC–related pro-
teinsb (LGI1, Caspr2)
Neuromyotonia, limbic 
encephalitis
Thymoma, SCLC
Anti-VGCCc
LEMS, cerebellar 
degeneration
SCLC
Anti-NMDARd
Anti-NMDAR
encephalitis
Teratoma
Anti-AMPARd
Limbic encephalitis 
with relapses
SCLC, thymoma, 
breast
Anti-GABABRd
Limbic encephalitis, 
seizures
SCLC, neuroendocrine
Glycine receptord
Encephalomyelitis
with rigidity, stiff-
person syndrome
Lung cancer
aA direct pathogenic role of these antibodies has been demonstrated.
bAnti-VGKC-related proteins are pathogenic for some types of neuromyotonia.
cAnti-VGCC antibodies are pathogenic for LEMS.
dThese antibodies are strongly suspected to be pathogenic.
Abbreviations: AChR, acetylcholine receptor; AMPAR, α-amino-3-hydroxy-5-methylisoxazole-
4-propionic acid receptor; GABABR, Gamma-amino-butyric acid B receptor; GAD, glutamic 
acid decarboxylase; LEMS, Lambert-Eaton myasthenic syndrome; NMDAR, N-methyl-d-
aspartate receptor; SCLC, small cell lung cancer; VGCC, voltage-gated calcium channel; 
VGKC, voltage-gated potassium channel.
SECTION 6
484
Hematology and Oncology
pts with peripheral neuropathy of unknown cause; detection of a monoclo-
nal gammopathy suggests the need for additional studies to uncover a B cell 
or plasma cell malignancy. In paraneoplastic neuropathies, diagnostically 
useful antineuronal antibodies are limited to anti-CV2/CRMP5 and anti-Hu.
Myasthenia gravis is discussed in Chap. 206, and dermatomyositis in 
Chap. 207.
Paraneoplastic Neurologic Disorders
TREATMENT
• Treatment of PNDs focuses mainly on recognition and control of the 
underlying malignancy; a stabilization or improvement of symptoms 
has been reported in some pts with successful tumor control. 
• Variable responses have been described following treatment with glu-
cocorticoids and other immunosuppressive agents as well as IVIg and 
plasma exchange.
• Those PNDs caused by antibodies to cell surface or synaptic antigens 
have a much more favorable response to therapy.
For a more detailed discussion, see Dalmau J, Rosenfeld 
MR: Paraneoplastic Neurologic Syndromes, Chap. 101, 
p. 833, in HPIM-18.
485
CHAPTER 85
Diagnosis of Infectious 
Diseases
The laboratory diagnosis of infection requires the demonstration—either 
direct or indirect—of viral, bacterial, fungal, or parasitic agents in tissues, 
fluids, or excreta of the host. The traditional detection methods of micros-
copy and phenotypic characterization are time-consuming and are increas-
ingly being replaced by nucleic acid probe assays.
� MICROSCOPY
• Wet mounts: the simplest method for microscopic evaluation and useful 
for certain large and/or motile organisms. For example, combining wet 
mounts with dark-field illumination permits detection of spirochetes in 
genital lesions or of Borrelia and Leptospira in blood. 
– Fungal elements may be identified in skin scrapings with 10% KOH 
wet mount preparations. 
– Some wet mounts use staining to enhance detection and morphologic 
identification—e.g., india ink for visualization of encapsulated crypto-
cocci in CSF and lactophenol cotton blue for morphologic identifica-
tion of fungal elements.
• Stains: Staining techniques permit organisms to be seen more clearly. 
– Gram’s stain: differentiates between organisms with thick peptido-
glycan cell walls (gram-positive) and those with thin peptidoglycan 
cell walls and outer membranes that can be dissolved with alcohol or 
acetone (gram-negative). 
• This stain is particularly useful for examining sputum samples for 
PMNs and bacteria. The presence of >10 epithelial cells per low-
power field and multiple bacterial types suggests contamination 
with oral flora.
• In normally sterile fluids (e.g., CSF, pleural and joint fluid), the 
detection of bacteria suggests an infectious etiology (Fig. 85-1) and 
correlates with the presence of >104 bacteria/mL. 
• Sensitivity is increased by centrifugation of the sample. 
– Acid-fast stains: identify organisms that retain carbol fuchsin dye after 
acid/organic solvation (e.g., Mycobacterium spp.). Modification of 
this procedure permits detection of weakly acid-fast organisms (e.g., 
Nocardia). 
– Immunofluorescent stains: utilize antibodies—either labeled directly 
with a fluorescent compound or detected indirectly by a secondary 
immunofluorescent antibody—to detect viral antigens (e.g., CMV, 
SECTION 7
Infectious Diseases
SECTION 7
486
Infectious Diseases
GRx only
Oxidase +
Oxidase –
Fastidious
Anaerobic
Curved
Pseudomonas
Aeromonas
Pasteurella
Others
Neisseria
Branhamella
Veillonella
Acidaminococcus
Megasphaera
Enterobacteriaceae
Others
Haemophilus
Legionella
Bordetella
Brucella
Francisella
Others
Bacteroides
Prevotella
Fusobacterium
Others
Vibrio
Campylobacter
Rod
Coccus
Branching
Spores
Acid-Fast
Catalase +
Catalase –
Clostridium
Bacillus
Nocardia
Actinomyces
Bifidobacterium
Staphylococcus
Micrococcus
Others
Mycobacterium
Corynebacterium
Listeria
Others
Lactobacillus
Others
Rod
Coccus
Gram-Negative Organisms
Gram-Positive Organisms
Streptococcus
FIGURE 85-1 Interpretation of Gram’s stain.
CHAPTER 85
487
Diagnosis of Infectious Diseases 
HSV, and respiratory viruses) within cultured cells and difficult-to-
grow bacteria (e.g., Legionella pneumophila).
� MACROSCOPIC ANTIGEN DETECTION
• Latex agglutination assays and EIAs are rapid and inexpensive tests that 
identify bacteria, viruses, or extracellular bacterial toxins by means of 
their protein or polysaccharide antigens. 
• The assays may be performed either directly on clinical specimens or 
after growth of the organisms in the laboratory.
� CULTURE
• The success of efforts to culture a specific pathogen often depends on use 
of appropriate collection and transport procedures in conjunction with a 
laboratory-processing algorithm suitable for the specimen. Instructions 
for collection and transport are listed in Table 85-1. 
• Bacterial isolation relies on the use of artificial media that support bacte-
rial growth in vitro. Once bacteria are isolated, different methods are used 
to characterize specific isolates (e.g., phenotyping based on enzymatic and 
metabolic functions, gas-liquid chromatography, nucleic acid tests). 
• Viruses are grown on a monolayer of cultured cells sensitive to infection 
with the suspected virus. After incubation, cells are examined for cyto-
pathic effects or immunofluorescent studies are performed to detect viral 
antigens.
� SEROLOGY
• Measurement of serum antibody provides an indirect marker for past or 
current infection with a specific pathogen. 
• Quantitative assays detect increases in antibody titers, most often with 
paired serum samples obtained at illness onset and 10–14 days later (i.e., 
acute- and convalescent-phase samples). A 4-fold increase is regarded as 
evidence for acute infection.
• Serology can also be used to document protective levels of antibody, par-
ticularly in diseases for which vaccines are available (e.g., rubella, VZV 
infections).
� NUCLEIC ACID PROBES
• Techniques for the detection and quantitation of specific DNA and RNA 
base sequences in clinical specimens have become powerful tools for the 
diagnosis of infection and are useful in four settings:
1. To detect and/or quantify specific pathogens in clinical specimens 
(e.g., Neisseria gonorrhoeae, HIV)
2. To identify organisms that are difficult to grow or identify by conven-
tional methods (e.g., Tropheryma whipplei, Legionella)
3. To determine whether two or more isolates belong to the same clone 
or strain
4. To predict sensitivity (typically of viruses) to chemotherapeutic agents 
(e.g., HIV, Mycobacterium tuberculosis)
• The sensitivity and specificity of probe assays for direct detection are 
comparable to those of more traditional assays, including EIA and 
culture. 
TABLE 85-1  INSTRUCTIONS FOR COLLECTION AND TRANSPORT OF SPECIMENS FOR CULTURE 
Note: It is absolutely essential that the microbiology laboratory be informed of the site of origin of the sample to be cultured and the infections that are suspected. This information 
determines the selection of culture media and the length of culture time.
Type of Culture 
(Synonyms)
Specimen
Minimal Volume
Container
Other Considerations
Blood
Blood, routine 
(blood culture for 
aerobes, anaer-
obes, and yeasts)
Whole blood
10 mL in each of 2 bottles for 
adults and children; 5 mL, if 
possible, in aerobic bottles for 
infants; less for neonates
See below.a
See below.b
Blood for fungi/
Mycobacterium
spp.
Whole blood
10 mL in each of 2 bottles, 
as for routine blood cultures, 
or in Isolator tube requested 
from laboratory
Same as for routine blood 
culture
Specify “hold for extended incubation,” 
since fungal agents may require 
4 weeks to grow.
Blood, 
Isolator (lysis 
centrifugation)
Whole blood
10 mL
Isolator tubes
Use mainly for isolation of fungi, 
Mycobacterium, and other fastidious 
aerobes and for elimination of antibiotics 
from cultured blood in which organisms 
are concentrated by centrifugation.
Respiratory tract
Nose
Swab from nares
1 swab
Sterile culturette or similar 
transport system containing 
holding medium
Swabs made of calcium alginate may 
be used.
488
Throat
Swab of posterior pharynx, 
ulcerations, or areas of 
suspected purulence
1 swab
Sterile culturette or similar swab 
specimen collection system 
containing holding medium
See below.c
Sputum
Fresh sputum (not saliva)
2 mL
Commercially available 
sputum collection system or 
similar sterile container with 
screw cap
Cause for rejection: Care must be taken 
to ensure that the specimen is sputum 
and not saliva. Examination of Gram’s 
stain, with number of epithelial cells and 
polymorphonuclear leukocytes (PMNs) 
noted, can be an important part of the 
evaluation process. Induced sputum 
specimens should not be rejected.
Bronchial
aspirates
Transtracheal aspirate, 
bronchoscopy specimen, 
or bronchial aspirate
1 mL of aspirate or brush in 
transport medium
Sterile aspirate or bronchos-
copy tube, bronchoscopy brush 
in a separate sterile container
Special precautions may be required, 
depending on diagnostic considerations 
(e.g., Pneumocystis).
Stool
Stool for routine 
culture; stool 
for Salmonella,
Shigella, and 
Campylobacter
Rectal swab or (preferably) 
fresh, randomly collected 
stool
1 g of stool or 2 rectal swabs
Plastic-coated cardboard cup 
or plastic cup with tight-fitting 
lid. Other leakproof containers 
are also acceptable.
If Vibrio spp. are suspected, the labora-
tory must be notified, and appropriate 
collection/transport methods should 
be used.
Stool for Yersinia, 
Escherichia coli 
O157
Fresh, randomly collected 
stool
1 g
Plastic-coated cardboard 
cup or plastic cup with 
tight-fitting lid
Limitations: Procedure requires enrich-
ment techniques.
Stool for 
Aeromonas and 
Plesiomonas
Fresh, randomly collected 
stool
1 g
Plastic-coated cardboard 
cup or plastic cup with 
tight-fitting lid
Limitations: Stool should not be cul-
tured for these organisms unless also 
cultured for other enteric pathogens.
(continued)
489
TABLE 85-1  INSTRUCTIONS FOR COLLECTION AND TRANSPORT OF SPECIMENS FOR CULTURE (CONTINUED)
Type of Culture 
(Synonyms)
Specimen
Minimal Volume
Container
Other Considerations
Urogenital tract
Urine
Clean-voided urine speci-
men or urine collected by 
catheter
0.5 mL
Sterile, leak-proof container 
with screw cap or special 
urine transfer tube
See below.d
Urogenital
secretions
Vaginal or urethral 
secretions, cervical swabs, 
uterine fluid, prostatic fluid, 
etc.
1 swab or 0.5 mL of fluid
Vaginal and rectal swabs 
transported in Amies transport 
medium or similar hold-
ing medium for group B 
Streptococcus; direct inocula-
tion preferred for Neisseria 
gonorrhoeae
Vaginal swab samples for “routine cul-
ture” should be discouraged whenever 
possible unless a particular pathogen 
is suspected. For detection of multiple 
organisms (e.g., group B Streptococcus,
Trichomonas, Chlamydia, or Candida
spp.), 1 swab per test should be 
obtained.
Body fluids, aspirates, and tissues
Cerebrospinal fluid 
(lumbar puncture)
Spinal fluid
1 mL for routine cultures; ≥5
mL for Mycobacterium
Sterile tube with tight-fitting 
cap
Do not refrigerate; transfer to 
laboratory as soon as possible.
Body fluids
Aseptically aspirated body 
fluids
1 mL for routine cultures
Sterile tube with tight-fitting 
cap. Specimen may be left in 
syringe used for collection if 
the syringe is capped before 
transport.
For some body fluids (e.g., peritoneal 
lavage samples), increased volumes 
are helpful for isolation of small num-
bers of bacteria.
490
Biopsy and aspi-
rated materials
Tissue removed at surgery, 
bone, anticoagulated bone 
marrow, biopsy samples, 
or other specimens from 
normally sterile areas
1 mL of fluid or a 1-g piece 
of tissue
Sterile “culturette”-type swab 
or similar transport system 
containing holding medium. 
Sterile bottle or jar should be 
used for tissue specimens.
Accurate identification of specimen and 
source is critical. Enough tissue should 
be collected for both microbiologic and 
histopathologic evaluations.
Wounds
Purulent material or 
abscess contents obtained 
from wound or abscess 
without contamination by 
normal microflora
2 swabs or 0.5 mL of 
aspirated pus
Culturette swab or similar 
transport system or sterile 
tube with tight-fitting screw 
cap. For simultaneous anaer-
obic cultures, send specimen 
in anaerobic transport device 
or closed syringe.
Collection: When possible, abscess 
contents or other fluids should be 
collected in a syringe (rather than with 
a swab) to provide an adequate sample 
volume and an anaerobic environment.
Special recommendations
Fungi
Specimen types listed above 
may be used. When urine or 
sputum is cultured for fungi, 
a first morning specimen 
usually is preferred.
1 mL or as specified above 
for individual listing of speci-
mens. Large volumes may be 
useful for urinary fungi.
Sterile, leakproof container 
with tight-fitting cap
Collection: Specimen should be transported 
to microbiology laboratory within 1 h of 
collection. Contamination with normal flora 
from skin, rectum, vaginal tract, or other 
body surfaces should be avoided.
Mycobacterium 
(acid-fast bacilli)
Sputum, tissue, urine, body 
fluids
10 mL of fluid or small piece 
of tissue. Swabs should not 
be used.
Sterile container with tight-
fitting cap
Detection of Mycobacterium spp. is 
improved by use of concentration tech-
niques. Smears and cultures of pleural, 
peritoneal, and pericardial fluids often 
have low yields. Multiple cultures from 
the same pt are encouraged. Culturing in 
liquid media shortens time to detection.
(continued)
491
TABLE 85-1  INSTRUCTIONS FOR COLLECTION AND TRANSPORT OF SPECIMENS FOR CULTURE (CONTINUED)
Type of Culture 
(Synonyms)
Specimen
Minimal Volume
Container
Other Considerations
Special recommendations (continued)
Legionella
Pleural fluid, lung biopsy, 
bronchoalveolar lavage fluid, 
bronchial/transbronchial
biopsy. Rapid transport to 
laboratory is critical.
1 mL of fluid; any size tissue 
sample, although a 0.5-g 
sample should be obtained 
when possible
—
—
Anaerobic
organisms
Aspirated specimens from 
abscesses or body fluids
1 mL of aspirated fluid, 1 g of 
tissue, or 2 swabs
An appropriate anaerobic 
transport device is required.e
Specimens cultured for obligate anaer-
obes should be cultured for facultative 
bacteria as well. Fluid or tissue is pre-
ferred to swabs.
Virusesf
Respiratory secretions, 
wash aspirates from 
respiratory tract, nasal 
swabs, blood samples 
(including buffy coats), 
vaginal and rectal swabs, 
swab specimens from 
suspicious skin lesions, 
stool samples (in some 
cases)
1 mL of fluid, 1 swab, or 1 g 
of stool in each appropriate 
transport medium
Fluid or stool samples in ster-
ile containers or swab sam-
ples in viral culturette devices 
(kept on ice but not frozen) 
are generally suitable. Plasma 
samples and buffy coats in 
sterile collection tubes should 
be kept at 4–8°C. If speci-
mens are to be shipped or 
kept for a long time, freezing 
at −80°C is usually adequate.
Most samples for culture are transported 
in holding medium containing antibiotics 
to prevent bacterial overgrowth and viral 
inactivation. Many specimens should be 
kept cool but not frozen, provided they 
are transported promptly to the laboratory. 
Procedures and transport media vary with 
the agent to be cultured and the duration 
of transport.
492
aFor samples from adults, two bottles (smaller for pediatric samples) should be used: one with dextrose phosphate, tryptic soy, or another appropriate broth and the other with 
thioglycollate or another broth containing reducing agents appropriate for isolation of obligate anaerobes. For children, from whom only limited volumes of blood can be obtained, only 
an aerobic culture should be done unless there is specific concern about anaerobic sepsis (e.g., with abdominal infections). For special situations (e.g., suspected fungal infection, 
culture-negative endocarditis, or mycobacteremia), different blood collection systems may be used (Isolator systems; see table).
bCollection: An appropriate disinfecting technique should be used on both the bottle septum and the pt. Do not allow air bubbles to get into anaerobic broth bottles. Special consider-
ations: There is no more important clinical microbiology test than the detection of bloodborne pathogens. The rapid identification of bacterial and fungal agents is a major determinant 
of pts’ survival. Bacteria may be present in blood either continuously (as in endocarditis, overwhelming sepsis, and the early stages of salmonellosis and brucellosis) or intermittently (as 
in most other bacterial infections, in which bacteria are shed into the blood on a sporadic basis). Most blood culture systems employ two separate bottles containing broth medium: one 
that is vented in the laboratory for the growth of facultative and aerobic organisms and one that is maintained under anaerobic conditions. In cases of suspected continuous bacteremia/
fungemia, two or three samples should be drawn before the start of therapy, with additional sets obtained if fastidious organisms are thought to be involved. For intermittent bacteremia, 
two or three samples should be obtained at least 1 h apart during the first 24 h.
cNormal microflora includes α-hemolytic streptococci, saprophytic Neisseria spp., diphtheroids, and Staphylococcus spp. Aerobic culture of the throat (“routine”) includes screening 
for and identification of β-hemolytic Streptococcus spp. and other potentially pathogenic organisms. Although considered components of the normal microflora, organisms such as 
Staphylococcus aureus, Haemophilus influenzae, and Streptococcus pneumoniae will be identified by most laboratories, if requested. When Neisseria gonorrhoeae or Corynebacterium 
diphtheriae is suspected, a special culture request is recommended.
d(1) Clean-voided specimens, midvoid specimens, and Foley or indwelling catheter specimens that yield 50,000 organisms/mL and from which no more than three species are isolated 
should have organisms identified. Neither indwelling catheter tips nor urine from the bag of a catheterized pt should be cultured. (2) Straight-catheterized, bladder-tap, and similar urine 
specimens should undergo a complete workup (identification and susceptibility testing) for all potentially pathogenic organisms regardless of colony count. (3) Certain clinical problems 
(e.g., acute dysuria in women) may warrant identification and susceptibility testing of isolates present at concentrations of <50,000 organisms/mL.
eAspirated specimens in capped syringes or other transport devices designed to limit oxygen exposure are suitable for the cultivation of obligate anaerobes. A variety of commercially 
available transport devices may be used. Contamination of specimens with normal microflora from the skin, rectum, vaginal vault, or another body site should be avoided. Collection 
containers for aerobic culture (such as dry swabs) and inappropriate specimens (such as refrigerated samples; expectorated sputum; stool; gastric aspirates; and vaginal, throat, nose, 
and rectal swabs) should be rejected as unsuitable.
fLaboratories generally use diverse methods to detect viral agents, and the specific requirements for each specimen should be checked before a sample is sent.
493
SECTION 7
494
Infectious Diseases
• Amplification strategies (e.g., PCR) enhance the sensitivity of RNA or 
DNA assays, but false-positive findings can result from even low levels of 
contamination.
� SUSCEPTIBILITY TESTING
• Susceptibility testing allows the clinician to choose the optimal antimi-
crobial agents and to identify potential infection-control problems (e.g., 
the level of methicillin-resistant Staphylococcus aureus in a hospital). 
• Qualitative measures (e.g., disk/agar diffusion and breakpoint) and quan-
titative measures [e.g., broth dilution, epsilometer (E-test)] are available.
• Antifungal susceptibility testing is becoming more commonplace; how-
ever, testing of some species (e.g., Aspergillus) remains technically dif-
ficult and is performed primarily in reference labs.
� CONSIDERATIONS FOR DIAGNOSIS OF PARASITIC INFECTIONS 
The cornerstone for the diagnosis of parasitic diseases, as for that of many 
other infections, is the elicitation of a thorough history of the illness and of 
epidemiologic factors such as travel, recreational activities, and occupation. 
Table 85-2 summarizes the diagnosis of some common parasitic infections.
� INTESTINAL PARASITES
• Most helminths and protozoa can be detected by examination of fecal 
samples; contamination with urine or water should be avoided. 
• Fecal samples should be collected before the ingestion of contrast agents 
and before treatment with antidiarrheal agents or antacids; these substances 
alter fecal consistency and interfere with microscopic detection of parasites. 
• The collection of three samples on alternate days is recommended 
because of the cyclic shedding of most parasites in the feces; examination 
of a single sample can be up to 50% less sensitive. 
• Analysis of fecal samples entails macroscopic examination for adult worms 
or tapeworm segments and microscopic examination that includes direct 
wet mounts, concentration techniques, and application of permanent stains. 
• Alternative diagnostic methods such as sampling of duodenal contents 
(e.g., for Giardia lamblia, Cryptosporidium, and Strongyloides larvae) and 
the “cellophane tape” method (e.g., for pinworm ova or Taenia saginata) 
may be required.
� BLOOD AND TISSUE PARASITES
• Diagnosis of tissue-invasive parasites requires an understanding of the 
pathophysiology of the parasite in question (e.g., examination of urine 
sediment to detect Schistosoma haematobium). 
• The laboratory procedures for detection of parasites in other body fluids 
are similar to those used for examination of feces. 
• The parasites most commonly detected in Giemsa-stained blood smears 
are plasmodia, microfilariae, and African trypanosomes; however, wet 
mounts may be more sensitive for microfilariae and African trypano-
somes, given their motility.
• The timing of blood collection is crucial—e.g., to diagnose Wuchereria 
bancrofti infection, blood must be drawn near midnight, when the 
nocturnal microfilariae are active. 
TABLE 85-2  DIAGNOSIS OF SOME COMMON PARASITIC INFECTIONS
Parasite
Geographic Distribution
Parasite
Stage
Diagnosis
Body Fluid or 
Tissue
Serologic Tests
Other
Blood flukes
 Schistosoma mansoni
Africa, Central and South 
America, West Indies
Ova, adults
Feces
EIA, WB
Rectal snips, liver biopsy
 S. haematobium
Africa
Ova, adults
Urine
WB
Liver, urine, or bladder biopsy
 S. japonicum
Far East
Ova, adults
Feces
WB
Liver biopsy
Intestinal roundworms
 Strongyloides stercoralis 
(strongyloidiasis)
Moist tropics and subtropics
Larvae
Feces, sputum, 
duodenal fluid
EIA
Dissemination in 
immunodeficiency
Intestinal protozoans
 Entamoeba histolytica (amebiasis) Worldwide, especially tropics
Troph, cyst
Feces, liver
EIA, antigen detection
Ultrasound, liver CT, PCR
 Giardia lamblia (giardiasis)
Worldwide
Troph, cyst
Feces
Antigen detection
String test, DFA, PCR
 Isospora belli
Worldwide
Oocyst
Feces
—
Acid-fasta
 Cryptosporidium
Worldwide
Oocyst
Feces
Antigen detection
Acid-fast,a DFA, biopsy, PCR
Blood and tissue protozoans
 Plasmodium species (malaria)
Subtropics and tropics
Asexual
Blood
Limited use
PCR
 Babesia microti (babesiosis)
U.S., especially New England
Asexual
Blood
IIF
Animal species in asplenia, PCR
 Toxoplasma gondii 
(toxoplasmosis)
Worldwide
Cyst, troph
CNS, eye, 
muscles, other
EIA, IIF
PCR
aAcid-fastness is best demonstrated by auramine fluorescence or modified acid-fast stain.
Abbreviations: DFA, direct fluorescent antibody; IIF, indirect immunofluorescence; troph, trophozoite; WB, western blot.
Source: Adapted from Reed SL, Davis CE: Chap. e25, HPIM-18.
495
SECTION 7
496
Infectious Diseases
For a more detailed discussion, see McAdam AJ, Onderdonk 
AB: Laboratory Diagnosis of Infectious Diseases, Chap. e22; and 
Reed SL, Davis CE: Laboratory Diagnosis of Parasitic Diseases, 
Chap. e25, in HPIM-18.
CHAPTER 86
Antibacterial Therapy
Antibacterial agents are among the most commonly prescribed drugs world-
wide and can be lifesaving when used appropriately. However, their indiscrimi-
nate use (estimated at ~50% of all antibiotic use)  drives up the cost of health 
care, leads to a plethora of side effects and drug interactions, and fosters the 
emergence of bacterial resistance, rendering previously valuable drugs useless. 
MECHANISMS OF DRUG ACTION
Antibacterial agents act on unique targets not found in mammalian cells. 
Bactericidal drugs kill bacteria within their spectrum of activity; bacterio-
static drugs inhibit bacterial growth. Table 86-1 summarizes the mecha-
nisms of action of commonly used antibacterial drugs.
• Inhibition of cell-wall synthesis: Drugs that inhibit cell-wall synthesis are 
almost always bactericidal. The cell wall is broken down by bacterial 
autolysins (cell wall–remodeling enzymes) during normal growth, and 
this class of antibacterial agents prevents the synthesis of a repaired cell 
wall. Examples include β-lactam antibiotics (e.g., penicillins, cephalo-
sporins, carbapenems), glycopeptides (vancomycin, teicoplanin), and 
lipoglycopeptides (telavancin).
• Inhibition of protein synthesis: Typically, inhibition takes place through 
interaction with bacterial ribosomes, which differ in composition from 
mammalian ribosomes. Except for aminoglycosides, these drugs are 
bacteriostatic. Examples include aminoglycosides (e.g., gentamicin, 
tobramycin, streptomycin), macrolides (erythromycin, clarithromycin, 
azithromycin), ketolides (telithromycin), lincosamides (clindamycin), 
streptogramins [quinupristin/dalfopristin (Synercid)], chloramphenicol, 
oxazolidinone (linezolid), tetracyclines (tetracycline, doxycycline, mino-
cycline), and glycylcyclines (tigecycline).
• Inhibition of bacterial metabolism: Antimetabolites interfere with bacte-
rial folic acid production, thereby preventing synthesis of thymidine, all 
purines, and several amino acids. These drugs are generally bacterio-
static, although in some cases they may be bactericidal. Examples include 
sulfonamides and trimethoprim.
• Inhibition of nucleic acid synthesis or activity: Several antibacterial agents 
have disparate effects on nucleic acids. Examples include fluoroquinolones 
(ciprofloxacin, levofloxacin, moxifloxacin), rifampin, nitrofurantoin, and 
metronidazole.
CHAPTER 86
497
Antibacterial Therapy
TABLE 86-1  MECHANISMS OF ACTION OF AND RESISTANCE TO MAJOR 
CLASSES OF ANTIBACTERIAL AGENTS
Antibacterial
Agenta
Major
Cellular
Target
Mechanism of 
Action
Major Mechanisms of 
Resistance
β-Lactams
(penicillins, 
cephalosporins, 
carbapenems)
Cell wall
Inhibit cell-wall 
cross-linking
1.  Drug inactivation 
(β-lactamase)
2.  Insensitivity of target 
(altered penicillin-
binding proteins)
3.  Decreased 
permeability (altered 
gram-negative outer-
membrane porins)
4.  Active efflux
Vancomycin
Cell wall
Interferes with 
addition of 
new cell-wall 
subunits (muramyl 
pentapeptides)
Alteration of target 
(substitution of 
terminal amino acid of 
peptidoglycan subunit)
Bacitracin
Cell wall
Prevents addition 
of cell-wall sub-
units by inhibiting 
recycling of mem-
brane lipid carrier
Not defined
Macrolides
(erythromycin)
Protein
synthesis
Bind to 50S 
ribosomal subunit
1.  Alteration of target 
(ribosomal methyla-
tion and mutation of 
23S rRNA)
2.  Active efflux
Lincosamides
(clindamycin)
Protein
synthesis
Bind to 50S ribo-
somal subunit
Block peptide 
chain elongation
1.  Alteration of 
target (ribosomal
methylation)
2. Active efflux
Chloramphenicol
Protein 
synthesis
Binds to 50S ribo-
somal subunit
Blocks aminoacyl 
tRNA attachment
1.  Drug inactivation 
(chloramphenicol
acetyltransferase)
2.  Active efflux
Tetracycline
Protein 
synthesis
Binds reversibly 
to 30S ribosomal 
subunit
1.  Decreased intracel-
lular drug accumu-
lation (active efflux)
Blocks binding of 
aminoacyl tRNA
2.  Insensitivity of target
(continued)
SECTION 7
498
Infectious Diseases
TABLE 86-1  MECHANISMS OF ACTION OF AND RESISTANCE TO MAJOR 
CLASSES OF ANTIBACTERIAL AGENTS (CONTINUED)
Antibacterial
Agenta
Major
Cellular
Target
Mechanism 
of Action
Major Mechanisms 
of Resistance
Aminoglycosides
(gentamicin)
Protein
synthesis
Bind irreversibly 
to 30S ribosomal 
subunit
1.  Drug inactivation 
(aminoglycoside-
modifying enzyme)
Inhibit
translocation of 
peptidyl-tRNA
2.  Decreased 
permeability
through gram-
negative outer 
membrane
3. Active efflux
4.  Ribosomal 
methylation
Mupirocin
Protein 
synthesis
Inhibits isoleucine 
tRNA synthetase
Mutation of gene 
for target protein 
or acquisition of 
new gene for drug-
insensitive target
Streptogramins
[quinupristin/
dalfopristin
(Synercid)]
Protein
synthesis
Bind to 50S ribo-
somal subunit
Block peptide 
chain elongation
1.  Alteration of target 
(ribosomal methyla-
tion: dalfopristin)
2.  Active efflux 
(quinupristin)
3.  Drug inactivation 
(quinupristin and 
dalfopristin)
Linezolid
Protein 
synthesis
Binds to 50S 
ribosomal subunit
Alteration of target 
(mutation of 23S rRNA)
Inhibits initiation of 
protein synthesis
Sulfonamides
and trimethoprim
Cell
metabolism
Competitively
inhibit enzymes 
involved in two 
steps of folic acid 
biosynthesis
Production of insensi-
tive targets [dihydrop-
teroate synthetase 
(sulfonamides) and 
dihydrofolate reduc-
tase (trimethoprim)] 
that bypass metabolic 
block
Rifampin
Nucleic 
acid
synthesis
Inhibits DNA-
dependent RNA 
polymerase
Insensitivity of 
target (mutation of 
polymerase gene)
CHAPTER 86
499
Antibacterial Therapy
• Alteration of cell-membrane permeability: Agents of this class interact 
with bacterial membranes and are generally bactericidal. Examples 
include polymyxins (polymyxin B, colistin) and daptomycin.
MECHANISMS OF ANTIBACTERIAL RESISTANCE
• Bacteria can either be intrinsically resistant to an agent (e.g., obligate 
anaerobic bacteria are resistant to aminoglycosides) or acquire resistance 
through mutation of resident genes or acquisition of new genes. 
• The major mechanisms of resistance used by bacteria are drug inactiva-
tion, alteration or overproduction of the antibacterial target, acquisition 
of a new gene encoding a drug-insensitive target, decreased permeability 
TABLE 86-1  MECHANISMS OF ACTION OF AND RESISTANCE TO MAJOR 
CLASSES OF ANTIBACTERIAL AGENTS (CONTINUED)
Antibacterial
Agenta
Major
Cellular
Target
Mechanism of 
Action
Major Mechanisms of 
Resistance
Metronidazole
Nucleic 
acid
synthesis
Intracellularly gen-
erates short-lived 
reactive intermedi-
ates that damage 
DNA by electron 
transfer system
Not defined
Quinolones
(ciprofloxacin)
DNA
synthesis
Inhibit activity 
of DNA gyrase 
(A subunit) and 
topoisomerase IV
1.  Insensitivity of 
target (mutation of 
gyrase genes)
2.  Decreased 
intracellular drug 
accumulation 
(active efflux)
Novobiocin
DNA 
synthesis
Inhibits activity 
of DNA gyrase 
(B subunit)
Not defined
Polymyxins 
(polymyxin B)
Cell
membrane
Disrupt membrane 
permeability by 
charge alteration
Not defined
Gramicidin
Cell 
membrane
Forms pores
Not defined
Daptomycin
Cell 
membrane
Forms channels 
that disrupt mem-
brane potential
Alteration of membrane 
charge
aCompounds in parentheses are major representatives for the class.
SECTION 7
500
Infectious Diseases
to the agent, failure to convert an inactive prodrug to its active derivative, 
and active efflux of the agent. 
• Table 86-1 summarizes specific mechanisms of bacterial resistance to 
commonly used antibacterial agents.
PHARMACOKINETICS OF ANTIBIOTICS
The pharmacokinetic profile refers to drug concentrations in serum and 
tissue versus time and reflects the processes of absorption, distribution, 
metabolism, and elimination.
• Absorption: systemic bioavailability after PO, IM, or IV administration 
– The IM and IV routes offer 100% bioavailability.
– Bioavailability after PO administration ranges from 10% (e.g., penicil-
lin G) to nearly 100% (e.g., amoxicillin, clindamycin, metronidazole, 
fluoroquinolones).
• Distribution: The concentration of an antibiotic must exceed the patho-
gen’s minimal inhibitory concentration (MIC) at the site of infection to 
be effective.
• Metabolism and elimination: Antibacterial agents are disposed of by 
hepatic elimination (metabolism or biliary elimination), renal excretion 
of the unchanged or metabolized form, or a combination of the two. 
Understanding the mode of elimination is important in adjusting dosage 
if elimination is impaired.
PRINCIPLES OF ANTIBACTERIAL CHEMOTHERAPY
• When possible, obtain specimens to identify the etiologic agent (by micro-
scopic examination and culture) before treatment.
• Standard in vitro susceptibility testing assesses only bacteriostasis and is 
essential to devising a chemotherapeutic regimen. Use local susceptibil-
ity patterns to help direct empirical treatment.
• The pharmacokinetic-pharmacodynamic (PK-PD) profile of an antibiotic 
refers to the quantitative relationships among (1) the time course of 
antibiotic concentrations in serum and tissue, (2) the MIC, and (3) the 
microbial response (inhibition of growth or rate of killing). Profiles can 
be categorized as either concentration or time dependent.
– Concentration-dependent antibiotics (e.g., fluoroquinolones, aminogly-
cosides): Increasing the ratio of the maximal serum concentration to 
the MIC (or the ratio of the area under the plasma concentration vs. 
time curve to the MIC) leads to a more rapid rate of bacterial death. 
Administration of larger doses (within the confines of toxicity) with 
longer dosing intervals is the practical application of these relationships.
– Time-dependent antibiotics (e.g., β-lactam antibiotics): The reduction 
in bacterial density is proportional to the amount of time that drug 
concentrations exceed the MIC. While the optimal dosing strategy is 
continuous infusion, more convenient dosing intervals can be used, 
with maintenance of the serum drug concentration above the MIC for 
30–50% of the dosing interval.
• Once etiology and susceptibility are known, the therapeutic regimen 
should be changed to one that has the narrowest effective spectrum 
CHAPTER 86
501
Antibacterial Therapy
TABLE 86-2  MOST CLINICALLY RELEVANT ADVERSE REACTIONS TO 
COMMON ANTIBACTERIAL DRUGS
Drug
Adverse Event
Comments
β-Lactams
Allergies in ~1–4% 
of treatment courses
Cephalosporins cause allergy in 
2–4% of penicillin-allergic pts. 
Aztreonam is safe in 
β-lactam-allergic pts.
Nonallergic skin 
reactions
Ampicillin “rash” is common 
among pts with EBV infection.
Diarrhea, including 
Clostridium difficile 
colitis
—
Vancomycin
Anaphylactoid reaction 
(“red man syndrome”)
Give as a 1- to 2-h infusion.
Nephrotoxicity, 
ototoxicity, allergy, 
neutropenia
Thought to be rare, but apparently 
increasing as larger dosages are 
used
Telavancin
Taste disturbance, 
foamy urine, 
gastrointestinal distress
New drug; full spectrum of 
adverse reactions unclear
Aminoglycosides
Nephrotoxicity 
(generally reversible)
Greatest with prolonged therapy 
in the elderly or with preexisting 
renal insufficiency. Monitor serum 
creatinine level every 2–3 days.
Ototoxicity
(often irreversible)
Risk factors similar to those for 
nephrotoxicity; both vestibular and 
hearing toxicities
Macrolides/
ketolides
Gastrointestinal
distress
Most common with erythromycin
Ototoxicity
High-dose IV erythromycin
Cardiac toxicity
QTc prolongation and torsades de 
pointes, especially when inhibitors 
of erythromycin metabolism are 
given simultaneously
Hepatic toxicity 
(telithromycin)
Warning added to prescribing 
information (July 2006)
Respiratory failure in 
pts with myasthenia 
gravis (telithromycin)
Warning added to prescribing 
information (July 2006)
Clindamycin
Diarrhea, including 
C. difficile colitis
—
Sulfonamides
Allergic reactions
Rashes (more common among 
HIV-infected pts); serious dermal 
reactions, including erythema multi-
forme, Stevens-Johnson syndrome, 
toxic epidermal necrolysis
(continued)
SECTION 7
502
Infectious Diseases
TABLE 86-2  MOST CLINICALLY RELEVANT ADVERSE REACTIONS TO 
COMMON ANTIBACTERIAL DRUGS (CONTINUED)
Drug
Adverse Event
Comments
Hematologic 
reactions
Uncommon; include agranulocy-
tosis and granulocytopenia (more 
common in HIV-infected pts), 
hemolytic and megaloblastic ane-
mia, thrombocytopenia
Renal insufficiency
Crystalluria with sulfadiazine 
therapy
Fluoroquinolones
Diarrhea, including 
C. difficile colitis
—
Contraindicated for 
general use in pts 
<18 years old and 
pregnant women
Appear safe in treatment of 
pulmonary infections in children 
with cystic fibrosis
CNS adverse effects 
(e.g., insomnia)
—
Miscellaneous: 
allergies, tendon 
rupture, dysglycemias, 
QTc prolongation
Rare, although warnings for 
tendon rupture have been added 
to prescribing information
Rifampin
Hepatotoxicity
Rare
Orange discoloration 
of urine and body 
fluids
Common
Miscellaneous: flu-like 
symptoms, hemolysis, 
renal insufficiency
Uncommon; usually related to 
intermittent administration
Metronidazole
Metallic taste
Common
Tetracyclines/
glycylcyclines
Gastrointestinal
distress
Up to 20% with tigecycline
Esophageal ulceration
Doxycycline (take in A.M. with 
fluids)
Linezolid
Myelosuppression
Follows long-term treatment
Ocular and peripheral 
neuritis
Follows long-term treatment
Daptomycin
Distal muscle pain or 
weakness
Weekly creatine phosphokinase 
measurements, especially in pts 
also receiving statins
and—all else being equal—is least costly. The status of the host (e.g., 
pregnancy, immunosuppression, hepatic and renal function, other 
required medications), the site of infection (e.g., CNS infection or endo-
carditis), and the adverse reaction profile (including contraindications) 
need to be considered in choosing an appropriate antibacterial agent.
CHAPTER 86
503
Antibacterial Therapy
TABLE 86-3  INTERACTIONS OF ANTIBACTERIAL AGENTS WITH 
OTHER DRUGS
Antibiotic
Interacts with
Potential Consequence 
(Clinical Significancea)
Erythromycin/
clarithromycin/
telithromycin
Theophylline
Theophylline toxicity (1)
Carbamazepine
CNS depression (1)
Digoxin
Digoxin toxicity (2)
Triazolam/midazolam
CNS depression (2)
Ergotamine
Ergotism (1)
Warfarin
Bleeding (2)
Cyclosporine/tacrolimus
Nephrotoxicity (1)
Cisapride
Cardiac arrhythmias (1)
Statinsb
Rhabdomyolysis (2)
Valproate
Valproate toxicity (2)
Vincristine/vinblastine
Excess neurotoxicity (2)
Quinupristin/
dalfopristin
Similar to 
erythromycinc
—
Fluoroquinolones
Theophylline
Theophylline toxicity (2)d
Antacids/sucralfate/
iron
Subtherapeutic antibiotic 
levels (1)
Tetracycline
Antacids/sucralfate/
iron
Subtherapeutic antibiotic 
levels (1)
Trimethoprim-
sulfamethoxazole
Phenytoin
Oral hypoglycemics
Warfarin
Digoxin
Phenytoin toxicity (2)
Hypoglycemia (2)
Bleeding (1)
Digoxin toxicity (2)
Metronidazole
Ethanol
Disulfiram-like 
reactions (2)
Fluorouracil
Bone marrow 
suppression (1)
Warfarin
Bleeding (2)
Rifampin
Warfarin
Clot formation (1)
Oral contraceptives
Pregnancy (1)
Cyclosporine/tacrolimus
Rejection (1)
HIV-1 protease inhibitors
Increased viral load, 
resistance (1)
Nonnucleoside reverse-
transcriptase inhibitors
Increased viral load, 
resistance (1)
Glucocorticoids
Loss of steroid effect (1)
(continued)
SECTION 7
504
Infectious Diseases
TABLE 86-3  INTERACTIONS OF ANTIBACTERIAL AGENTS WITH 
OTHER DRUGS (CONTINUED)
Antibiotic
Interacts with
Potential Consequence 
(Clinical Significancea)
Methadone
Narcotic withdrawal 
symptoms (1)
Digoxin
Subtherapeutic digoxin 
levels (1)
Itraconazole
Subtherapeutic itraconazole 
levels (1)
Phenytoin
Loss of seizure control (1)
Statins
Hypercholesterolemia (1)
Diltiazem
Subtherapeutic diltiazem 
levels (1)
Verapamil
Subtherapeutic verapamil 
levels (1)
a1 = well-documented interaction with clinically important consequences; 2 = interaction of 
uncertain frequency but potential clinical importance.
bLovastatin and simvastatin are most affected; pravastatin and atorvastatin are less likely to 
have clinically important effects.
cThe macrolide antibiotics and quinupristin/dalfopristin inhibit the same human metabolic 
enzyme (CYP3A4), and similar interactions are anticipated.
dCiprofloxacin only. Levofloxacin and moxifloxacin do not inhibit theophylline metabolism.
Note: New interactions are commonly reported after marketing. Consult the most recent 
prescribing information for updates.
• Although combination chemotherapy usually is not indicated, it is 
used occasionally to prevent emergence of resistance (e.g., addition of 
rifampin for staphylococci), for synergistic or additive activity (e.g., 
β-lactam/aminoglycoside combinations against enterococci), and for 
therapy directed against multiple potential pathogens (e.g., intraab-
dominal or brain abscess). Some combination therapies (e.g., penicillin 
plus tetracycline against pneumococci) have antagonistic effects; i.e., the 
combination is worse than either drug alone.
CHOICE OF ANTIBACTERIAL AGENTS
For current and practical information regarding antimicrobial drugs and 
treatment regimens for specific indications, consult relevant chapters in 
HPIM-18. In addition, online references such as the Johns Hopkins anti-
biotic guide (www.Hopkins-abxguide.org) are available. Evidence-based 
practice guidelines for many infections are available from the Infectious 
Diseases Society of America (www.idsociety.org).
ADVERSE REACTIONS
Adverse reactions are classified as either dose-related (e.g., aminoglycoside-
induced nephrotoxicity) or unpredictable. Unpredictable reactions are 
CHAPTER 87
505
Health Care–Associated Infections 
idiosyncratic or allergic. Table 86-2 summarizes the most clinically relevant 
adverse reactions to common antibacterial drugs.
DRUG INTERACTIONS
Antimicrobial agents are a common cause of drug–drug interactions, often 
because of effects on the hepatic P450 system, which is responsible for 
metabolizing many drugs. Table 86-3 lists the most common and best-
documented interactions of antimicrobial agents with other drugs and 
characterizes the clinical relevance of these interactions. This information 
is presented only to heighten awareness of potential interactions; to ensure 
that no drug–drug interactions occur, appropriate sources should be con-
sulted before any antibiotic is prescribed.
For a more detailed discussion, see Archer GL, Polk RE: 
Treatment and Prophylaxis of Bacterial Infections, Chap. 133, 
p. 1133, in HPIM-18. For a discussion of antifungal therapy, 
see Chaps. 115 and 116 in this manual; for antimycobacterial 
therapy, see Chap. 103; for antiviral therapy, see Chaps. 108 
through 114; and for antiparasitic therapy, see Chaps. 117 
and 118.
CHAPTER 87
Health Care–Associated 
Infections
Hospital-acquired or nosocomial infections (defined as those not present or 
incubating at the time of admission to the hospital) and other health care–
associated infections affect an estimated 1.7 million pts, cost $28–33 billion, 
and contribute to 99,000 deaths in U.S. hospitals each year. Although efforts 
to lower infection risks have been challenged by the growing numbers of 
immunocompromised pts, antibiotic-resistant bacteria, fungal and viral 
superinfections, and invasive procedures and devices, the “zero-tolerance” 
viewpoint of consumer advocates holds that nearly all health care–
associated infections should be avoidable. Accordingly, federal legislation 
now exists to prevent U.S. hospitals from upgrading Medicare charges to 
pay for hospital costs resulting from at least 10 specific nosocomial events. 
� PREVENTION OF HOSPITAL-ACQUIRED INFECTIONS
Nosocomial pathogens have reservoirs, are transmitted by largely predict-
able routes, and require susceptible hosts—features that allow the imple-
mentation of monitoring and prevention strategies. 
• Surveillance: review of microbiology laboratory results, surveys of nursing 
wards, and use of other mechanisms to keep track of infections acquired 
after hospital admission. Most hospitals aim surveillance at infections 
SECTION 7
506
Infectious Diseases
associated with high-level morbidity or great expense. Results of surveil-
lance are expressed as rates and should include a denominator indicating 
the number of pts exposed to a specific risk (e.g., pts using a mechanical 
ventilator) or the number of intervention days (e.g., 1000 pt-days on a 
ventilator).
• Prevention and control measures: Hand hygiene is the single most impor-
tant measure to prevent cross-infection.
– Health care workers’ rates of adherence to hand-hygiene recommen-
dations are abysmally low at <50%.
– Other measures include identifying and eradicating reservoirs of 
infection and minimizing use of invasive procedures and catheters.
• Isolation techniques: Isolation of infectious pts is a standard component 
of infection control programs.
– Standard precautions: include hand hygiene and use of gloves when 
there is a potential for contact with blood, other body fluids, nonintact 
skin, or mucous membranes during the care of all pts. In certain cases, 
masks, eye protection, and gowns are used as well.
– Transmission-based guidelines: Airborne, droplet, or contact precautions—
for which personnel don (at a minimum) N95 respirators, surgical 
face masks, or gowns and gloves, respectively—are used to prevent 
transmission of disease from pts with contagious clinical syndromes. 
More than one precaution can be used for diseases that have more 
than one mode of transmission (e.g., contact and airborne isolation for 
varicella). 
� NOSOCOMIAL AND DEVICE-RELATED INFECTIONS
Nosocomial infections are due to the combined effect of the pt’s own flora 
and the presence of invasive devices in 25–50% of cases. Intensive educa-
tion, “bundling” of evidence-based interventions, and use of checklists 
to facilitate adherence can reduce infection rates. Table 87-1 summarizes 
effective interventions to reduce the incidence of the more common noso-
comial infections.
• Urinary Tract Infections Approximately 34% of nosocomial infections 
are UTIs, contributing ~15% to prolongation of hospital stay with an 
attributable cost of ~$1300. 
– Most nosocomial UTIs are associated with prior instrumentation or 
indwelling bladder catheterization. The 3–10% risk of infection for 
each day a catheter remains in place is due to the ascent of bacteria 
from the periurethral area or via intraluminal contamination of the 
catheter. 
– In men, condom catheters may lessen the risk of UTI.
– The most common pathogens are Escherichia coli, nosocomial gram-
negative bacilli, enterococci, and (particularly for pts in the ICU) 
Candida.
– For suspected infection in the setting of chronic catheterization, the 
catheter should be replaced and a freshly voided urine specimen 
obtained for culture to confirm actual infection as opposed to simple 
colonization of the catheter.
CHAPTER 87
507
Health Care–Associated Infections 
TABLE 87-1  EXAMPLES OF “BUNDLED INTERVENTIONS” TO PREVENT 
COMMON HEALTH CARE–ASSOCIATED INFECTIONS AND 
OTHER ADVERSE EVENTS
Prevention of Central Venous Catheter Infections
Educate personnel about catheter insertion and care.
Use chlorhexidine to prepare the insertion site.
Use maximal barrier precautions during catheter insertion.
Consolidate insertion supplies (e.g., in an insertion kit or cart).
Use a checklist to enhance adherence to the bundle.
Empower nurses to halt insertion if asepsis is breached.
Cleanse pts daily with chlorhexidine.
Ask daily: Is the catheter needed? Remove catheter if not needed or used.
Prevention of Ventilator-Associated Pneumonia and Complications
Elevate head of bed to 30–45 degrees.
Decontaminate oropharynx regularly with chlorhexidine.
Give “sedation vacation,” and assess readiness to extubate daily.
Use peptic ulcer disease prophylaxis.
Use deep-vein thrombosis prophylaxis (unless contraindicated).
Prevention of Surgical-Site Infections
Administer prophylactic antibiotics within 1 h before surgery; discontinue 
within 24 h.
Limit hair removal to the time immediately before surgery; use clippers or do 
not remove hair at all.
Prepare surgical site with chlorhexidine-alcohol.
Maintain normal perioperative glucose levels (cardiac surgery pts).a
Maintain perioperative normothermia (colorectal surgery pts).a
Prevention of Urinary Tract Infections
Place bladder catheters only when absolutely needed 
(e.g., to relieve obstruction), not solely for the provider’s convenience.
Use aseptic technique for catheter insertion and urinary tract instrumentation.
Minimize manipulation or opening of drainage systems.
aThese components of care are supported by clinical trials and experimental evidence in the 
specified populations; they may prove valuable for other surgical pts as well.
Source: Adapted from information presented at the following website:
www.cdc.gov/HAI/InfectionTypes.html
– As with all nosocomial infections, it is useful to repeat the culture to 
confirm the persistence of infection at the time therapy is initiated. 
• Pneumonia Accounting for ~13% of nosocomial infections, pneumonia 
increases the duration of hospital stay by 10 days, accounts for ~$23,000 
in extra costs, and is associated with more deaths than are infections at 
any other body site. 
SECTION 7
508
Infectious Diseases
– Bacterial nosocomial pneumonia is caused by aspiration of endog-
enous or hospital-acquired oropharyngeal flora. 
– Risk factors include events that increase colonization with poten-
tial pathogens, such as prior antibiotic use, contaminated ventilator 
equipment, or decreased gastric acidity; events that increase risk of 
aspiration, such as nasogastric or endotracheal intubation or decreased 
level of consciousness; and conditions that compromise host defense 
mechanisms in the lung, such as chronic obstructive pulmonary dis-
ease, extremes of age, or upper abdominal surgery. 
– Etiologic organisms include community-acquired pathogens (e.g., 
Streptococcus pneumoniae, Haemophilus influenzae) early during 
hospitalization and Staphylococcus aureus, Pseudomonas aeruginosa, 
Klebsiella pneumoniae, Enterobacter species, and Acinetobacter species 
later in the hospital stay. 
– Diagnosis can be difficult, as clinical criteria (e.g., fever, leukocytosis, 
purulent secretions, and new or changing pulmonary infiltrates on 
chest x-ray) have high sensitivity but low specificity. 
• An etiology should be sought by studies of lower respiratory tract 
samples protected from upper-tract contamination; quantitative 
cultures have diagnostic sensitivities in the range of 80%. 
• Febrile pts with nasogastric or nasotracheal tubes should also have 
sinusitis or otitis media ruled out. 
• Surgical Wound Infections Making up ~17% of nosocomial infections, 
surgical wound infections increase the length of hospital stay by 7–10 
days and increase costs by $3000–$29,000. 
– These infections often become evident after pts have left the hospital; 
thus it is difficult to assess the true incidence. 
– Risk factors include the pt’s underlying conditions (e.g., diabetes mel-
litus or obesity) and age, inappropriate timing of antibiotic prophylaxis, 
the presence of drains, prolonged preoperative hospital stays, shaving 
of the operative site the day before surgery (rather than just before the 
procedure), long duration of surgery, and infection at remote sites.
– These infections are typically caused by the pt’s endogenous or hos-
pital-acquired flora. S. aureus, coagulase-negative staphylococci, and 
enteric and anaerobic bacteria are the most common pathogens.
• S. aureus, coagulase-negative staphylococci, and enteric and anaer-
obic bacteria are the most common pathogens.
• Group A streptococcal and clostridial infections should be consid-
ered in rapidly progressing postoperative infections (manifesting 
within 24–48 h of a procedure).
– Clinical assessment of the surgical site may reveal obvious cellulitis 
or abscess formation; diagnosis of deeper infections requires a high 
index of suspicion and radiographic imaging.
– Treatment of postoperative wound infections requires source control 
(drainage or surgical excision of infected or necrotic material) and 
antibiotic therapy aimed at the most likely or laboratory-confirmed 
pathogens.
CHAPTER 87
509
Health Care–Associated Infections 
• Intravascular Device Infections Intravascular device–related infections 
cause ~14% of nosocomial infections, increase the duration of hospital 
stay by 12 days, add $3700–$29,000 to hospital costs, and have an attrib-
utable mortality rate of 12–25%. 
– Catheterization of the femoral vessels is associated with a higher risk 
of infection in adults.
• These infections are largely due to the skin flora at the site of 
catheter insertion, with pathogens migrating extraluminally to the 
catheter tip. 
• Contamination of the infusate is rare.
• Coagulase-negative staphylococci, S. aureus (≥50% methicillin-
resistant isolates), enterococci, nosocomial gram-negative bacilli, 
and Candida are the pathogens most frequently associated with these 
bacteremias.
– Infection is suspected on the basis of the catheter site's appearance 
and/or the presence of fever or bacteremia without another source. 
The diagnosis is confirmed by isolation of the same bacteria from 
peripheral-blood cultures and from semiquantitative or quantitative 
cultures of samples from the vascular catheter tip. 
– In addition to the initiation of appropriate antibiotic treatment, other 
considerations include the level of risk for endocarditis (relatively high 
in pts with S. aureus bacteremia) and the decision regarding catheter 
removal, which is often necessary to cure infection. 
• If salvage of the catheter is attempted, the “antibiotic lock” technique 
(allowing a concentrated antibiotic solution to dwell in the catheter 
lumen along with systemic antibiotic administration) should be used. 
• If the catheter is changed over a guidewire and cultures of the removed 
catheter tip are positive, the catheter should be moved to a new site. 
� EPIDEMIC AND EMERGING PROBLEMS
Although outbreaks and emerging pathogens often receive a great deal of 
press, they account for <5% of nosocomial infections.
• Influenza: The main components of infection control—vaccination of 
the general public and health care workers, early use of antiviral agents 
for control of outbreaks, and adherence to surveillance and droplet pre-
cautions for symptomatic pts—have been effective in controlling influ-
enza, including the 2009 H1N1 pandemic.
• Nosocomial diarrhea: Rates of health care–associated diarrhea have been 
increasing in recent years.
– Rates of infection with Clostridium difficile—particularly the more 
virulent BI/NAP1/027 strain—are increasing, especially among older 
pts. Important infection-control components include judicious antibi-
otic use; heightened suspicion in cases with atypical presentations; and 
early diagnosis, treatment, and implementation of contact precautions.
– Outbreaks of norovirus infection should be suspected in bacterial cul-
ture-negative diarrheal syndromes in which nausea and vomiting are 
prominent aspects. Contact precautions may need to be augmented 
SECTION 7
510
Infectious Diseases
by environmental cleaning and active exclusion of ill staff and visitors, 
who often represent index cases.
• Chickenpox: Routine vaccination of children and VZV-susceptible 
employees has made nosocomial spread less common.
– If VZV exposure occurs, postexposure prophylaxis with varicella-
zoster immune globulin (VZIg) is considered for immunocompro-
mised or pregnant contacts. 
– Varicella vaccine or preemptive administration of acyclovir is an alter-
native for other susceptible persons. 
– Susceptible employees are furloughed for 8–21 days (or for 28 days if 
VZIg has been given). 
• Tuberculosis: Prompt recognition and isolation of cases, use of negative-
pressure private rooms with 100% exhaust and at least 6–12 air changes 
per hour, use of approved N95 respirators, and follow-up skin testing of 
susceptible, exposed personnel are required.
• Group A streptococcal infections: A single nosocomial case, usually 
involving surgical wounds and the presence of an asymptomatic carrier 
in the operating room, should trigger an investigation. Health care work-
ers linked to nosocomial transmission of group A streptococci should 
not be permitted to return to pt care settings until eradication of carriage 
via antimicrobial therapy has been documented.
• Fungal infections: Hospital renovations and disturbance of dusty surfaces 
can cause fungal spores to become airborne. Routine surveillance of neutro-
penic pts for infections with filamentous fungi (e.g., Aspergillus, Fusarium) 
helps determine whether there are extensive environmental risks.
• Legionellosis: If nosocomial cases are detected, environmental samples 
(e.g., tap water) should be cultured; eradication measures should be pur-
sued if typing of clinical and environmental isolates reveals a correlation.
• Antibiotic-resistant bacterial infection: Close laboratory surveillance, 
strict infection-control practices, and aggressive antibiotic-control poli-
cies are the cornerstones of resistance-control efforts.
– Molecular typing can help distinguish an outbreak of a single isolate 
(which necessitates an emphasis on hand hygiene and an evaluation of 
common-source exposures) from a polyclonal outbreak (which neces-
sitates re-emphasis on antibiotic prudence and device bundles).
– Organisms that raise concerns include methicillin-resistant S. aureus, 
gram-negative organisms that produce carbapenemases and/or extended-
spectrum β-lactamases, pan-resistant strains of Acinetobacter, and 
vancomycin-resistant enterococci.
• Bioterrorism preparedness: Education, effective systems of internal and 
external communication, and risk assessment capabilities are key features.
For a more detailed discussion, see Weinstein RA: Health 
Care–Associated Infections, Chap. 131, p. 1112, in HPIM-18.
CHAPTER 88
511
Infections in the Immunocompromised Host 
CHAPTER 88
Infections in the 
Immunocompromised Host
The immunocompromised pt is at increased risk for infection with both 
common and opportunistic pathogens.
INFECTIONS IN CANCER PTS
Table 88-1 lists the normal barriers to infection whose disruption may 
permit infections in immunocompromised pts, with particular relevance 
for the noted cancers. Infection-associated mortality rates among cancer 
pts have decreased as a result of an evolving approach entailing early use 
of empirical broad-spectrum antibiotics; empirical antifungal therapy in 
neutropenic pts who, after 4–7 days of antibiotic treatment, remain febrile 
without positive cultures; and use of antibiotics for afebrile neutropenic pts 
as broad-spectrum prophylaxis against infections.
� SYSTEM-SPECIFIC SYNDROMES
• Skin infections Skin lesions of various types are common in pts with 
cancer and may be the first sign of bacterial or fungal sepsis, particularly 
in neutropenic pts (those with <500 functional neutrophils/μL).
– Cellulitis: most often caused by group A Streptococcus and Staphylococcus 
aureus. Unusual organisms (e.g., Escherichia coli, Pseudomonas, fungi) 
may be involved in neutropenic pts.
– Macules or papules: due to bacteria (e.g., Pseudomonas aeruginosa 
causing ecthyma gangrenosum) or fungi (e.g., Candida)
– Sweet’s syndrome or febrile neutrophilic dermatosis: Most often seen in 
neutropenic leukemic pts, it presents as red or bluish-red papules or 
nodules that form sharply bordered plaques; high fever; and an elevated 
ESR. The skin lesions are most common on the face, neck, and arms.
– Erythema multiforme with mucous membrane involvement: Often 
due to HSV infection, it is distinct from Stevens-Johnson syndrome, 
which is associated with drugs and has a more widespread distribu-
tion; both conditions are common in pts with cancer.
– Drug rashes: Rashes associated with drugs, particularly cytokines used 
in cancer therapy, complicate the differential diagnosis of rashes in pts 
with cancer.
• Catheter-related infections Exit-site infections, often with erythema 
around the insertion site, are most common. 
– Infections caused by coagulase-negative staphylococci can often be 
treated medically without catheter removal. 
– Infections caused by other organisms, including S. aureus, P. aeruginosa, 
Candida, Stenotrophomonas, or Bacillus, usually require catheter removal.
TABLE 88-1  DISRUPTION OF NORMAL BARRIERS THAT MAY PREDISPOSE TO INFECTIONS IN PATIENTS WITH CANCER
Type of Defense
Specific Lesion
Cells Involved
Organisms
Cancer Association
Disease
Physical barrier
Breaks in skin
Skin epithelial 
cells
Staphylococci, streptococci
Head and neck, squa-
mous cell carcinoma
Cellulitis, extensive skin 
infection
Emptying of fluid 
collections
Occlusion of orifices: 
ureters, bile duct, 
colon
Luminal epithelial 
cells
Gram-negative bacilli
Renal, ovarian, biliary 
tree, and many 
metastatic cancers
Rapid, overwhelming 
bacteremia; urinary tract 
infection
Lymphatic function
Node dissection
Lymph nodes
Staphylococci, streptococci
Breast cancer surgery
Cellulitis
Splenic clearance 
of microorganisms
Splenectomy
Splenic 
reticuloendothelial
cells
Streptococcus pneumoniae, 
Haemophilus influenzae, 
Neisseria meningitidis, Babesia, 
Capnocytophaga canimorsus
Hodgkin’s disease, 
leukemia, idiopathic 
thrombocytopenic 
purpura
Rapid, overwhelming 
sepsis
Phagocytosis
Lack of granulocytes
Granulocytes 
(neutrophils)
Staphylococci, streptococci, 
enteric organisms, fungi
Hairy cell, acute 
myelocytic, and acute 
lymphocytic leukemias
Bacteremia
Humoral immunity
Lack of antibody
B cells
S. pneumoniae, H. influenzae, 
N. meningitidis
Chronic lymphocytic 
leukemia, multiple 
myeloma
Infections with encapsu-
lated organisms, sinusitis, 
pneumonia
Cellular immunity
Lack of T cells
T cells and 
macrophages
Mycobacterium tuberculosis, 
Listeria, herpesviruses, fungi, 
intracellular parasites
Hodgkin’s disease, 
leukemia, T cell 
lymphoma
Infections with intracellular 
bacteria, fungi, parasites
512
CHAPTER 88
513
Infections in the Immunocompromised Host 
– If a red streak develops over the SC part of a “tunneled” catheter, the 
device must be removed to prevent extensive cellulitis and tissue necrosis. 
• Upper GI infections Breakdown of mucosal surfaces due to chemo-
therapy and infection are common. 
– Oral mucositis is associated with viridans streptococci and HSV.
– Oral candidal infections (thrush) are common.
– Esophagitis can be caused by Candida albicans and HSV.
• Lower GI infections Transmigration of bowel flora across the intestinal 
epithelium can lead to severe conditions.
– Chronic disseminated candidiasis: results from seeding of organs (e.g., 
liver, spleen, kidneys) during neutropenia in pts with hematologic 
malignancy and generally presents symptomatically when neutropenia 
resolves. Pts have persistent fever unresponsive to antibiotics, abdomi-
nal pain, and increased alkaline phosphatase levels. Although biopsies 
may reveal granulomas, yeasts, or pseudohyphae, the diagnosis is 
often made on the basis of radiographic studies (CT, MRI). Treatment 
should be directed to the causative agent; C. albicans is usually 
responsible, but C. tropicalis or other Candida species are sometimes 
involved.
– Typhlitis (necrotizing colitis): more common among children than 
among adults and among pts with acute myelocytic leukemia or acute 
lymphocytic leukemia than among pts with other forms of cancer. Pts 
have fever, RLQ tenderness, and diarrhea that is often bloody. The 
diagnosis is confirmed by documentation of a thickened cecal wall via 
imaging. Treatment should include antibiotics directed against bowel 
flora and surgery (in the case of perforation).
• CNS infections The susceptibility of pts to specific infections depends 
on whether they have prolonged neutropenia, defects in cellular immu-
nity (e.g., high-dose glucocorticoid therapy, cytotoxic chemotherapy), 
or defects in humoral immunity [e.g., pts with chronic lymphocytic 
leukemia, s/p splenectomy, or s/p bone marrow transplantation (BMT)].
– Meningitis: Consider Cryptococcus or Listeria, particularly for pts with 
defects in cellular immunity. Pts with defects in humoral immunity are 
also at risk for infection with encapsulated bacteria such as Streptococcus 
pneumoniae, Haemophilus influenzae, and Neisseria meningitidis.
– Encephalitis: Pts with defects in cellular immunity are particularly 
prone to infection with VZV, JC virus (progressive multifocal leuko-
encephalopathy), CMV, Listeria, HSV, and human herpesvirus type 6.
– Brain masses: most often present as headache with or without fever 
or neurologic abnormalities. Pts with prolonged neutropenia are at 
increased risk for a brain abscess due to Aspergillus, Nocardia, or 
Cryptococcus. Pts with defects in cellular immunity are at increased 
risk for infection with Toxoplasma and EBV (lymphoproliferative 
disease). A definitive diagnosis may require a biopsy.
• Pulmonary infections Pneumonia can be difficult to diagnose in immu-
nocompromised pts, given that many of the conventional findings (e.g., 
purulent sputum, physical findings suggestive of chest consolidation) 
SECTION 7
514
Infectious Diseases
rely on the presence of neutrophils. Radiographic patterns of infiltration 
can help narrow the differential diagnosis.
– Localized infiltrate: Consider bacterial pneumonia (including Legionella 
and mycobacteria), local hemorrhage or embolism, and tumor.
– Nodular infiltrate: Consider fungal infection (e.g., Aspergillus, Mucor), 
Nocardia infection, and recurrent tumor. In pts with Aspergillus infec-
tion, hemoptysis may be an ominous sign. A biopsy performed with 
direct visualization may be required for definitive diagnosis.
– Diffuse infiltrates: Consider infection with viruses (particularly CMV), 
Chlamydia, Pneumocystis, Toxoplasma, or mycobacteria. Viruses that 
cause upper respiratory infections in normal hosts (e.g., influenza, 
respiratory syncytial) may cause fatal pneumonitis in immunocom-
promised pts. Noninfectious causes include radiation pneumonitis, 
CHF, diffuse alveolar hemorrhage (after BMT), and drug-induced 
lung injury (e.g., bleomycin, alkylating agents). 
• Renal and ureteral infections These infections are usually associated 
with obstructing tumor masses. 
– Candida has a predilection for the kidneys, reaching this site via 
either hematogenous seeding or retrograde spread from the bladder. 
Persistent funguria should prompt a search for infection in the kidney 
(e.g., fungus ball).
– BK virus and adenovirus can cause hemorrhagic cystitis.
Febrile Neutropenia
APPROACH TO THE
PATIENT
Approach to Diagnosis and Treatment of Febrile Neutropenic Pts 
Figure 88-1 presents an algorithm for the diagnosis and treatment of pts 
with febrile neutropenia. 
• The initial regimen should be refined on the basis of culture data. 
• Adding antibiotics to the initial regimen is not appropriate unless 
there is a clinical or microbiologic reason to do so. The addition of 
aminoglycosides to β-lactam therapy does not enhance efficacy (but 
does increase toxicity), even for infections involving P. aeruginosa. 
• For empirical antifungal treatment, amphotericin B is being supplant-
ed by liposomal formulations of amphotericin B, newer azoles (e.g., 
voriconazole or posaconazole), and echinocandins (e.g., caspofun-
gin). Echinocandins are useful against infections with azole-resistant 
Candida. Clinical experience related to antiviral therapy is most 
extensive with acyclovir for HSV and VZV infections. Newer agents 
(e.g., cidofovir, foscarnet) with a broader spectrum of action have 
heightened the focus on treatment of viral infections. 
– Prophylactic antibiotics (e.g., fluoroquinolones) in pts expected 
to have prolonged neutropenia or antifungal agents (e.g., flucon-
azole) in pts with hematopoietic stem cell transplants may prevent 
infections. Pneumocystis prophylaxis is mandatory for pts with 
acute lymphocytic leukemia and for those receiving glucocorti-
coid-containing regimens.
CHAPTER 88
515
Infections in the Immunocompromised Host 
Continue treatment until neutropenia resolves (granulocyte count >500/μL).
Add a broad-
  spectrum
  antifungal
  agent.
Febrile
Afebrile
Initial
evaluation
Initial
therapy
Follow-up
Subsequent
therapy
Physical examination: skin lesions, mucous
  membranes, IV catheter sites, perirectal area
Granulocyte count: absolute count < 500/μL; duration
  of expected neutropenia
Blood cultures; chest radiogram; other appropriate
  studies based on history (sputum, urine, skin biopsy)
Treat with antibiotic(s) effective
  against both gram-negative and
  gram-positive aerobes.
Treat the infection with
  the best available
  antibiotics. Do not
  narrow the spectrum
  unnecessarily. Continue
  to treat for both
  gram-positive and
  gram-negative aerobes.
Obvious infectious
  site found
No obvious
  infectious site
Continue
  regimen.
DIAGNOSIS AND TREATMENT FOR PATIENTS WITH FEBRILE NEUTROPENIA
FIGURE 88-1 Algorithm for the diagnosis and treatment of febrile neutropenic pts. 
Several general guidelines are useful in the initial treatment of these pts: (1) The 
agents used should reflect both the epidemiology and the antibiotic resistance pattern 
of the hospital. (2) A single third-generation cephalosporin constitutes an appropriate 
initial regimen in many hospitals (if the pattern of resistance justifies its use). (3) Most 
standard regimens are designed for pts who have not previously received prophylactic 
antibiotics. The development of fever in a pt receiving antibiotics affects the choice of 
subsequent therapy (which should target resistant organisms and organisms known 
to cause infections in pts being treated with the antibiotics already administered). 
(4) Randomized trials have indicated that it is safe to use oral antibiotic regimens to 
treat “low-risk” pts who have fever and neutropenia. Outpatients who are expected 
to remain neutropenic for <10 days and who have no concurrent medical problems 
(such as hypotension, pulmonary compromise, or abdominal pain) can be classified 
as low-risk and treated with a broad-spectrum oral regimen. 
INFECTIONS IN TRANSPLANT RECIPIENTS
Evaluation of infections in transplant recipients must involve consideration 
of infectious agents harbored by the donor organ and the recipient’s immu-
nosuppressive drug regimen, which increases susceptibility to latent infec-
tions (among other infections).
SECTION 7
516
Infectious Diseases
– Pretransplantation evaluation of the donor should include a thorough 
serologic evaluation for viral pathogens (e.g., HSV-1, HSV-2, VZV, 
CMV, EBV, HIV, and hepatitis A, B, and C viruses) and mycobacterial 
disease; other evaluations should be directed by the donor’s history, 
including diet, exposures, and travel.
– Pretransplantation evaluation of the recipient is generally more com-
prehensive than that of the donor and should include assessment for 
respiratory viruses and gastrointestinal pathogens. Given the effects of 
underlying chronic disease and chemotherapy, serologic testing of the 
recipient may not be reliable.
� HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) 
• Pathogenesis The myeloablative processes involved in HSCT result in 
the complete absence of innate and adaptive immune cells. This transient 
state of complete immunologic incompetence and the reconstitution that 
follows make the host extremely susceptible to infections.
• Etiology Most infections occur in a predictable time frame after HSCT 
(Table 88-2).
– Bacterial infections: Neutropenia-related infectious complications are 
most common during the first month. Some centers give prophylactic 
antibiotics (e.g., quinolones) that may decrease the risk of gram-
negative bacteremia but increase the risk of Clostridium difficile colitis.
• Skin and bowel flora (e.g., S. aureus, coagulase-negative staphy-
lococci, E. coli) are responsible for most infections in the first 
few days following HSCT, after which nosocomial pathogens 
and filamentous bacteria (e.g., vancomycin-resistant enterococci, 
Acinetobacter and Nocardia species) become more common. 
– Fungal infections: Fungal infections are increasingly common beyond 
the first week after HSCT, particularly among pts who receive broad-
spectrum antibiotics. Infections with Candida species are most com-
mon, although resistant fungi (e.g., Aspergillus, Fusarium) are becoming 
more common because of the increased use of prophylactic fluconazole. 
• Prolonged treatment with glucocorticoids or other immunosup-
pressive agents increases the risk of infection with Candida or 
Aspergillus and of reactivation of endemic fungi even after resolu-
tion of neutropenia. 
• Maintenance prophylaxis with trimethoprim-sulfamethoxazole 
(TMP-SMX; 160/800 mg/d starting 1 month after engraftment 
and continuing for at least 1 year) is recommended to prevent 
Pneumocystis jiroveci pneumonia.
– Parasitic infections: Prophylaxis with TMP-SMX is also protective 
against disease caused by Toxoplasma as well as against late infections 
caused by certain bacteria, including Nocardia, Listeria monocyto-
genes, S. pneumoniae, and H. influenzae.
• Given increasing international travel, parasitic diseases (e.g., caused 
by Strongyloides, Leishmania, Giardia, Cryptosporidium) that are 
typically restricted to particular environments may be more likely 
to be reactivated in pts after HSCT.
CHAPTER 88
517
Infections in the Immunocompromised Host 
TABLE 88-2  COMMON INFECTIONS AFTER HSCT
Period after Transplantation
Infection Site
Early
 (<1 Month)
Middle
(1–4 Months)
Late
(>6 Months)
Disseminated
Aerobic bacteria 
(gram-negative, 
gram-positive)
Nocardia, 
Candida, 
Aspergillus,
EBV
Encapsulated bacteria 
(Streptococcus 
pneumoniae, 
Haemophilus 
influenzae, Neisseria 
meningitidis)
Skin and 
mucous
membranes
HSV
HHV-6
VZV
Lungs
Aerobic bacteria 
(gram-negative, 
gram-positive), 
Candida, 
Aspergillus, other 
molds, HSV
CMV, seasonal 
respiratory 
viruses, 
Pneumocystis, 
Toxoplasma
Pneumocystis, 
S. pneumoniae
Gastrointestinal
tract
Clostridium 
difficile
CMV, adeno-
virus
EBV, CMV
Kidney
BK virus, 
adenovirus
Brain
HHV-6a
HHV-6 
Toxoplasma
Toxoplasma, JC virus 
(rare)
Bone marrow
HHV-6
aHHV-6, human herpesvirus type 6.
– Viral infections: Prophylactic acyclovir or valacyclovir for HSV-
seropositive pts reduces rates of mucositis and prevents pneumonia 
and other HSV manifestations. 
• Zoster generally occurs several months after HSCT and usually is 
managed readily with acyclovir. 
• Human herpesvirus type 6 delays monocyte and platelet engraft-
ment and may be linked to encephalitis or pneumonitis; the efficacy 
of antiviral treatment has not been well studied. 
• CMV disease (e.g., interstitial pneumonia, bone marrow suppres-
sion, colitis, and graft failure) usually occurs 30–90 days after 
HSCT. Severe disease is more common among allogeneic transplant 
recipients and is often associated with graft-versus-host disease, 
with pneumonia as the foremost cause of death. Preemptive therapy 
(initiation of antiviral therapy only after CMV is detected in blood) 
has supplanted prophylactic therapy (treatment of all transplant 
recipients when either the recipient or the donor is seropositive) 
because of the toxic side effects associated with ganciclovir. 
SECTION 7
518
Infectious Diseases
• EBV lymphoproliferative disease as well as infections caused by 
respiratory viruses (e.g., respiratory syncytial virus, parainfluenza 
virus, metapneumovirus, influenza virus, adenovirus) can occur. 
BK virus (a polyomavirus) has been found in the urine of pts after 
HSCT and may be associated with hemorrhagic cystitis.
� SOLID ORGAN TRANSPLANTATION 
• Pathogenesis After solid organ transplantation, pts do not go through a 
stage of neutropenia like that seen after HSCT; thus the infections in these 
two groups of pts differ. However, solid organ transplant recipients are 
immunosuppressed for longer periods with agents that chronically impair 
T cell immunity. Moreover, the persistent HLA mismatch between recipi-
ent immune cells (e.g., effector T cells) and the donor organ (allograft) 
places the organ at permanently increased risk of infection. 
• Etiology As in HSCT, the infection risk depends on the interval since 
transplantation.
– Early infections (<1 month): Infections are most commonly caused by 
extracellular organisms, which originate in surgical wound or anasto-
motic sites.
– Middle-period infections (1–6 months): The consequences of suppress-
ing cell-mediated immunity become apparent, and infections result 
from acquisition—or reactivation—of viruses, mycobacteria, endemic 
fungi, and parasites. 
• CMV can cause severe systemic disease or infection of transplanted 
organs; the latter increases the risk of organ rejection, prompt-
ing increased immunosuppression that, in turn, increases CMV 
replication. 
• Diagnosis, treatment, and prophylaxis of CMV infection are the 
keys to interrupting this cycle. 
– Late infections (>6 months): Infections of this period are similar to 
those in pts with chronically impaired T cell immunity (e.g., Listeria, 
Nocardia, Rhodococcus, mycobacteria, various fungi, other intracel-
lular organisms). 
• EBV lymphoproliferative disease occurs most commonly in pts 
who receive a heart or lung transplant (as well as the most intense 
immunosuppressive regimens); in these cases, immunosuppression 
should be decreased or discontinued, if possible, and consideration 
should be given to treatment with anti–B cell antibodies.
• Prophylaxis against Pneumocystis pneumonia for at least 1 year is 
generally recommended for all solid organ transplant recipients.
• The incidence of tuberculosis within the first 12 months after solid 
organ transplantation is greater than that after HSCT and reflects 
the prevalence of tuberculosis in the local population.
• Specific issues While the above information is generally valid for all 
organ transplants, there are some organ-specific considerations.
– Kidney transplantation: TMP-SMX prophylaxis for the first 4–6 months 
decreases the incidence of early and middle-period infections, 
particularly UTIs related to anatomic alterations resulting from 
CHAPTER 88
519
Infections in the Immunocompromised Host 
TABLE 88-3  VACCINATION OF CANCER PATIENTS RECEIVING 
CHEMOTHERAPYa
Vaccine
Use in Indicated Patients
Intensive
Chemotherapy
Hodgkin’s 
Disease
HSCT
Diphtheria-
tetanusb
Primary series and 
boosters as 
necessary 
No special 
recommendation
3 doses given 
6–12 months 
after
transplantation
Poliomyelitisc
Complete primary 
series and boosters
No special 
recommendation
3 doses given 
6–12 months 
after
transplantation
Haemophilus 
influenzae type
b conjugate
Primary series and 
booster for children
Immunization 
before treatment 
and booster 
3 months 
afterward
3 doses given 
6–12 months 
after
transplantation
Human
papillomavirus
3 doses for girls and 
women through 
26 years of age
3 doses for girls 
and women 
through 26 years 
of age
3 doses for girls 
and women 
through
26 years of age
Hepatitis A
As indicated for 
normal hosts based 
on occupation and 
lifestyle
As indicated for 
normal hosts 
based on occupa-
tion and lifestyle
As indicated 
for normal 
hosts based on 
occupation and 
lifestyle
Hepatitis B
Same as for normal 
hosts
As indicated for 
normal hosts 
based on occupa-
tion and lifestyle
3 doses given 
6–12 months 
after
transplantation
23-Valent 
pneumococcal
polysaccharided
Every 5 years
Immunization 
before treatment 
and booster 3 
months afterward
1 or 2 doses 
given 6–12 
months after 
transplantation
4-Valent 
meningococcale
Should be adminis-
tered to splenecto-
mized pts and pts 
living in endemic 
areas, including 
college students in 
dormitories
Should be 
administered to 
splenectomized
pts and pts living 
in endemic areas, 
including college 
students in 
dormitories
Should be 
administered to 
splenectomized 
pts and pts 
living in endemic 
areas, including 
college students 
in dormitories
Influenza
Seasonal 
immunization
Seasonal
immunization
Seasonal
immunization
(continued)
SECTION 7
520
Infectious Diseases
TABLE 88-3  VACCINATION OF CANCER PATIENTS RECEIVING 
CHEMOTHERAPYa (CONTINUED)
Vaccine
Use in Indicated Patients
Intensive
Chemotherapy
Hodgkin’s 
Disease
HSCT
Measles/
mumps/rubella
Contraindicated
Contraindicated 
during
chemotherapy
After 24 months 
in pts without 
graft-versus-
host disease
Varicella-zoster 
virusf
Contraindicatedg
Contraindicated
Contraindicated 
aThe latest recommendations by the Advisory Committee on Immunization Practices and the 
CDC guidelines can be found at www.cdc.gov/vaccines.
bThe Td (tetanus-diphtheria) combination was recommended for adults. Pertussis vaccine 
was not recommended for people >6 years of age in the past. However, recent data indicate 
that the Tdap (tetanus–diphtheria–acellular pertussis) product is both safe and efficacious in 
adults. A single Tdap booster is now recommended for adults.
cLive-virus vaccine is contraindicated; inactivated vaccine should be used.
dThe 13-valent pneumococcal conjugate vaccine is currently recommended for children.
eMeningococcal conjugate vaccine (MCV4) is recommended for adults ≤55 years old and me-
ningococcal polysaccharide vaccine (MPSV4) for those ≥56 years old.
fIncludes both varicella vaccine for children and zoster vaccine for adults.
gContact the manufacturer for more information on use in children with acute lymphocytic leukemia.
surgery. CMV is the predominant pathogen in the middle period; 
disease is evident in 50% of renal transplant pts presenting with fever 
1–4 months after transplantation, prompting many centers to use 
valacyclovir prophylaxis for high-risk pts. BK viruria and viremia are 
associated with ureteral strictures, nephropathy, and vasculopathy and 
require a reduction of immunosuppression to lower rates of graft loss.
– Heart transplantation: Mediastinitis, generally caused by typical skin 
flora and rarely caused by Mycoplasma hominis, is an early complica-
tion of heart transplantation. The overall incidence of toxoplasmosis 
(a middle-period infection) is so high in the setting of heart trans-
plantation that serologic screening and some prophylaxis (e.g., TMP-
SMX) are always warranted.
– Lung transplantation: Pts receiving a lung transplant are predisposed to 
pneumonia and mediastinitis in the early period. The high incidence of 
CMV disease (75–100% if either the donor or the recipient is seroposi-
tive) indicates the importance of antiviral prophylaxis; late disease may 
occur once prophylaxis is discontinued, although the pt is generally 
better able to handle it because of reduced immunosuppression.
– Liver transplantation: Bacterial abscesses and peritonitis are common 
early complications and often result from biliary leaks. Pts receiving a 
liver transplant have a high incidence of fungal infections correlated 
with preoperative glucocorticoid use, long-term antimicrobial use, and 
CHAPTER 89
521
Infective Endocarditis
a high degree of immunosuppression. Recurrent (reactivated) hepatitis 
B and C infections are problematic; while hepatitis B immunoglobulin 
administration and prophylaxis with antiviral agents active against 
hepatitis B virus have been successful in preventing reinfection with 
hepatitis B virus, reinfection with hepatitis C virus occurs in all pts.
IMMUNIZATIONS IN IMMUNOSUPPRESSED PTS
Recommendations for vaccination of cancer pts receiving chemotherapy, 
pts with Hodgkin’s disease, and hematopoietic stem cell transplant recipi-
ents are listed in Table 88-3.  In solid organ transplant recipients, the usual 
vaccines and boosters should be given before immunosuppression. Pts with 
continued immunosuppression should have pneumococcal vaccination 
repeated every 5 years and should not receive live vaccines.
For a more detailed discussion, see Finberg R: Infections 
in Patients With Cancer, Chap. 86, p. 712; Madoff LC, 
Kasper DL: Introduction to Infectious Diseases: Host–Pathogen 
Interactions, Chap. 119, p. 1007; and Finberg R, Fingeroth J: 
Infections in Transplant Recipients, Chap. 132, p. 1120, in 
HPIM-18.
CHAPTER 89
Infective Endocarditis
Acute endocarditis is a febrile illness that rapidly damages cardiac struc-
tures, seeds extracardiac sites hematogenously, and can progress to death 
within weeks. Subacute endocarditis follows an indolent course, rarely 
causes metastatic infection, and progresses gradually unless complicated by 
a major embolic event or a ruptured mycotic aneurysm.
• Epidemiology In developed countries, the incidence of endocarditis 
ranges from 2.6 to 7.0 cases per 100,000 population per year, with higher 
rates among the elderly. 
– Predisposing conditions include congenital heart disease, illicit IV 
drug use, degenerative valve disease, and intracardiac devices.
– Chronic rheumatic heart disease is a risk factor in low-income countries. 
– Of endocarditis cases, 16–30% involve prosthetic valves, with the 
greatest risk during the first 6–12 months after valve replacement.
• Etiology Because of their different portals of entry, the causative micro-
organisms vary among clinical types of endocarditis. 
– In native valve endocarditis (NVE), viridans streptococci, staphy-
lococci, and HACEK organisms [Haemophilus spp., Aggregatibacter 
(formerly Actinobacillus) actinomycetemcomitans, Cardiobacterium 
hominis, Eikenella corrodens, and Kingella kingae] enter the blood-
stream from oral, skin, and upper respiratory tract portals. Streptococcus 
SECTION 7
522
Infectious Diseases
gallolyticus (formerly S. bovis) originates from the gut and is associated 
with colon polyps or cancer. Enterococci originate from the genitouri-
nary tract. 
– Health care–associated NVE, frequently due to Staphylococcus aureus, 
coagulase-negative staphylococci (CoNS), and enterococci, can have a 
nosocomial onset (55%) or a community onset (45%) in pts who have 
had extensive contact with the health care system in the preceding 
90 days. 
– Prosthetic valve endocarditis (PVE) developing within 2 months of sur-
gery is due to intraoperative contamination or a bacteremic postoperative 
complication and is typically caused by CoNS, S. aureus, facultative gram-
negative bacilli, diphtheroids, or fungi. Cases beginning >1 year after 
valve surgery are caused by the same organisms that cause community-
acquired NVE. PVE due to CoNS that presents 2–12 months after surgery 
often represents delayed-onset nosocomial infection.
– Endocarditis occurring among IV drug users, especially that involv-
ing the tricuspid valve, is commonly caused by S. aureus (often a 
methicillin-resistant strain). Left-sided valve infections among IV drug 
users are caused by Pseudomonas aeruginosa and Candida, Bacillus, 
Lactobacillus, and Corynebacterium spp. in addition to the usual causes 
of endocarditis.
– About 5–15% of endocarditis cases are culture negative, and one-third 
to one-half of these cases are due to prior antibiotic exposure. The 
remainder of culture-negative cases represent infection by fastidious 
organisms, such as the nutritionally variant bacteria Granulicatella 
and Abiotrophia, HACEK organisms, Bartonella spp., Coxiella bur-
netii, Brucella spp., and Tropheryma whipplei. 
• Pathogenesis Endothelial injury allows direct infection by more virulent 
pathogens (e.g., S. aureus) or the development of an uninfected platelet-
fibrin thrombus [referred to as nonbacterial thrombotic endocarditis 
(NBTE)] that may become infected during transient bacteremia. NBTE 
arises from cardiac conditions (e.g., mitral regurgitation, aortic stenosis, 
aortic regurgitation), hypercoagulable states, and the antiphospholipid 
antibody syndrome. After entering the bloodstream, organisms adhere 
to the endothelium or sites of NBTE via surface adhesin molecules. The 
clinical manifestations of endocarditis arise from cytokine production, 
damage to intracardiac structures, embolization of vegetation fragments, 
hematogenous infection of sites during bacteremia, and tissue injury due 
to the deposition of immune complexes. 
• Clinical manifestations The clinical syndrome is variable and spans 
a continuum between acute and subacute presentations. The temporal 
course of disease is dictated in large part by the causative organism: 
S. aureus, β-hemolytic streptococci, pneumococci, and Staphylococcus 
lugdunensis typically present acutely, whereas viridans streptococci, 
enterococci, CoNS (other than S. lugdunensis), and the HACEK group 
typically present subacutely.
– Constitutional symptoms: generally nonspecific, but may include fever, 
chills, weight loss, myalgias, or arthralgias.
CHAPTER 89
523
Infective Endocarditis
– Cardiac manifestations: Heart murmurs, particularly new or worsened 
regurgitant murmurs, are ultimately heard in 85% of pts with acute NVE. 
• CHF develops in 30–40% of pts and is usually due to valvular 
dysfunction.
• Extension of infection can result in perivalvular abscesses, which in 
turn may cause intracardiac fistulae. Abscesses may burrow from 
the aortic root into the ventricular septum and interrupt the con-
duction system or may burrow through the epicardium and cause 
pericarditis.
– Noncardiac manifestations: Arterial emboli are present in 50% of pts, 
with hematogenously seeded focal infection most often evident in the 
skin, spleen, kidneys, bones, and meninges.
• The risk of embolization increases with endocarditis caused by 
S. aureus, vegetations >10 mm in diameter, and infection involving 
the mitral valve.
• Cerebrovascular emboli presenting as stroke or encephalopathy 
complicate 15–35% of cases, with one-half of these cases preceding 
the diagnosis of endocarditis. 
– The incidence of stroke decreases dramatically with antibiotic 
therapy and does not correlate with change in vegetation size.
– Other neurologic complications include aseptic or purulent 
meningitis, intracranial hemorrhage due to ruptured mycotic 
aneurysms (focal dilations of arteries at points in the artery wall 
that have been weakened by infection or where septic emboli 
have lodged) or hemorrhagic infarcts, seizures, and microab-
scesses (especially with S. aureus).
• Immune complex deposition on the glomerular basement mem-
brane causes glomerulonephritis and renal dysfunction.
• Nonsuppurative peripheral manifestations of subacute endocarditis 
(e.g., Janeway lesions, Roth’s spots) are related to duration of infec-
tion and are now rare because of early diagnosis and treatment.
– Manifestations of specific predisposing conditions: Underlying condi-
tions may affect the presenting signs and symptoms.
• IV drug use: ~50% of endocarditis cases associated with IV drug 
use are limited to the tricuspid valve and present as fever, faint or 
no murmur, and prominent pulmonary findings such as cough, 
pleuritic chest pain, nodular pulmonary infiltrates, or occasional 
pyopneumothorax. Pts with left-sided cardiac infections present 
with the typical clinical features of endocarditis.
• Health care–associated endocarditis: Manifestations are typical in the 
absence of a retained intracardiac device. Endocarditis associated 
with a transvenous pacemaker or an implanted defibrillator may 
be associated with a generator pocket infection and result in fever, 
minimal murmur, and pulmonary symptoms due to septic emboli.
• PVE: In cases of endocarditis occurring within 60 days of valve sur-
gery, typical symptoms may be masked by comorbidity associated 
SECTION 7
524
Infectious Diseases
with recent surgery. Paravalvular infection is common in PVE, 
resulting in partial valve dehiscence, regurgitant murmurs, CHF, or 
disruption of the conduction system.
• Diagnosis A diagnosis of infective endocarditis is established definitively 
only when vegetations are examined histologically and microbiologically. 
– The Duke criteria (Table 89-1) constitute a highly sensitive and spe-
cific diagnostic schema that emphasizes the roles of bacteremia and 
echocardiographic findings.
• A clinical diagnosis of definite endocarditis requires fulfillment of 
2 major, 1 major plus 3 minor, or 5 minor criteria.
• A diagnosis of possible endocarditis requires documentation of 
1 major plus 1 minor criterion or 3 minor criteria.
– For antibiotic-naïve pts, three 2-bottle blood culture sets—separated 
from one another by at least 1 h—should be obtained from different 
sites within the first 24 h. If blood cultures are negative after 48–72 h, 
two or three additional cultures should be performed.
– Serology is helpful in implicating Brucella, Bartonella, Legionella, or C. 
burnetii in endocarditis. Examination of the vegetation by histology, 
culture, direct fluorescent antibody techniques, and/or PCR may be 
helpful in identifying the causative organism in the absence of a posi-
tive blood culture.
– Echocardiography should be performed to confirm the diagnosis, to 
verify the size of vegetations, to detect intracardiac complications, and 
to assess cardiac function. 
• Transthoracic echocardiography (TTE) does not detect vegetations 
<2 mm in diameter and is not adequate for evaluation of prosthetic 
valves or detection of intracardiac complications; however, TTE 
may be used when pts have a low pretest likelihood of endocarditis 
(<5%). 
• Transesophageal echocardiography (TEE) detects vegetations in 
>90% of cases of definite endocarditis and is optimal for evaluation 
of prosthetic valves and detection of abscesses, valve perforation, or 
intracardiac fistulas.
• When endocarditis is likely, a negative TEE result does not exclude 
the diagnosis but warrants repetition of the study in 7–10 days.
Endocarditis
TREATMENT
ANTIMICROBIAL THERAPY
• Antimicrobial therapy must be bactericidal and prolonged. See 
Table 89-2 for organism-specific regimens. Most pts defervesce 
within 5–7 days. 
– Blood cultures should be repeated until sterile, and results should 
be rechecked if there is recrudescent fever and at 4–6 weeks after 
therapy to document cure. 
– If pts are febrile for 7 days despite antibiotic therapy, an evaluation 
for paravalvular or extracardiac abscesses should be performed.
CHAPTER 89
525
Infective Endocarditis
TABLE 89-1  THE DUKE CRITERIA FOR THE CLINICAL DIAGNOSIS OF 
INFECTIVE ENDOCARDITISa
Major Criteria
1. Positive blood culture
Typical microorganism for infective endocarditis from two separate blood 
cultures
  Viridans streptococci, Streptococcus gallolyticus, HACEK group, 
Staphylococcus aureus, or
Community-acquired enterococci in the absence of a primary focus, or
Persistently positive blood culture, defined as recovery of a microorganism 
consistent with infective endocarditis from:
 Blood cultures drawn >12 h apart; or
  All of three or a majority of four or more separate blood cultures, with 
first and last drawn at least 1 h apart
Single positive blood culture for Coxiella burnetii or phase I IgG antibody 
titer of >1:800
2. Evidence of endocardial involvement
Positive echocardiogramb
  Oscillating intracardiac mass on valve or supporting structures or in 
the path of regurgitant jets or in implanted material, in the absence of 
an alternative anatomic explanation, or
 Abscess, or
 New partial dehiscence of prosthetic valve, or
New valvular regurgitation (increase or change in preexisting murmur not 
sufficient)
Minor Criteria
1. Predisposition: predisposing heart condition or injection drug use
2. Fever ≥38.0°C (≥100.4°F)
3.  Vascular phenomena: major arterial emboli, septic pulmonary infarcts, 
mycotic aneurysm, intracranial hemorrhage, conjunctival hemorrhages, 
Janeway lesions
4.  Immunologic phenomena: glomerulonephritis, Osler’s nodes, Roth’s spots, 
rheumatoid factor
5.  Microbiologic evidence: positive blood culture but not meeting major 
criterion as noted previouslyc or serologic evidence of active infection with 
organism consistent with infective endocarditis
aSee text for details.
bTransesophageal echocardiography is recommended for assessing possible prosthetic valve 
endocarditis or complicated endocarditis.
cExcluding single positive cultures for coagulase-negative staphylococci and diphtheroids, 
which are common culture contaminants, and organisms that do not cause endocarditis 
frequently, such as gram-negative bacilli.
Abbreviations: HACEK, Haemophilus spp., Aggregatibacter actinomycetemcomitans,
Cardiobacterium hominis, Eikenella corrodens, Kingella kingae.
Source: Adapted from JS Li et al: Clin Infect Dis 30:633, 2000, with permission from the 
University of Chicago Press.
SECTION 7
526
Infectious Diseases
TABLE 89-2  ANTIBIOTIC TREATMENT FOR INFECTIVE ENDOCARDITIS 
CAUSED BY COMMON ORGANISMSa
Organism
Drug (Dose, Duration)
Comments
Streptococci
Penicillin-
susceptibleb
streptococci, 
Streptococcus 
gallolyticus
•  Penicillin G (2–3 mU IV q4h 
for 4 weeks)
—
•  Ceftriaxone (2 g/d IV as a 
single dose for 4 weeks)
Can use ceftriaxone in 
pts with nonimmediate 
penicillin allergy
•  Vancomycinc (15 mg/kg IV 
q12h for 4 weeks)
Use vancomycin in 
pts with severe or 
immediate β-lactam
allergy
•  Penicillin G (2–3 mU IV q4h) 
or ceftriaxone (2 g IV qd) for
2 weeks plus
Gentamicind (3 mg/kg qd 
IV or IM, as a single dosee
or divided into equal doses 
q8h for 2 weeks)
Avoid 2-week regimen 
when risk of amino-
glycoside toxicity is 
increased and in pros-
thetic valve or compli-
cated endocarditis
Relatively 
penicillin-
resistantf
streptococci
•  Penicillin G (4 mU IV q4h) 
or ceftriaxone (2 g IV qd) 
for 4 weeks plus
Gentamicind (3 mg/kg qd 
IV or IM, as a single dosee
or divided into equal doses 
q8h for 2 weeks)
Penicillin alone at this 
dose for 6 weeks or with 
gentamicin during initial 
2 weeks is preferred for 
prosthetic valve endo-
carditis caused by strep-
tococci with penicillin 
MICs of ≤0.1 μg/mL
•  Vancomycinc as noted 
above for 4 weeks
—
Moderately 
penicillin-
resistantg
streptococci, 
nutritionally
variant organisms, 
or Gemella 
morbillorum
•  Penicillin G (4–5 mU IV q4h) 
or ceftriaxone (2 g IV qd) 
for 6 weeks plus
Gentamicind (3 mg/kg qd 
IV or IM as a single dosee
or divided into equal doses 
q8h for 6 weeks)
Preferred for prosthetic 
valve endocarditis 
caused by streptococci 
with penicillin MICs of 
>0.1 μg/mL
•  Vancomycinc as noted 
above for 4 weeks
—
Enterococcih
•  Penicillin G (4–5 mU IV q4h) 
plus
  Gentamicind (1 mg/kg IV 
q8h), both for 4–6 weeks
Can use streptomycin 
(7.5 mg/kg q12h) in lieu 
of gentamicin if there is 
not high-level resistance 
to streptomycin
CHAPTER 89
527
Infective Endocarditis
TABLE 89-2  ANTIBIOTIC TREATMENT FOR INFECTIVE ENDOCARDITIS 
CAUSED BY COMMON ORGANISMSa (CONTINUED)
Organism
Drug (Dose, Duration)
Comments
Enterococcih (continued)
•  Ampicillin (2 g IV q4h) plus
Gentamicind (1 mg/kg IV 
q8h), both for 4–6 weeks
—
•  Vancomycinc
(15 mg/kg IV q12h) plus
Gentamicind (1 mg/kg IV 
q8h), both for 4–6 weeks
Use vancomycin 
plus gentamicin for 
penicillin-allergic pts, or 
desensitize to penicillin
Staphylococci
Methicillin-
susceptible, 
infecting native 
valves (no foreign 
devices)
•  Nafcillin or oxacillin 
(2 g IV q4h for 4–6 weeks)
Can use penicillin 
(4 mU q4h) if isolate is 
penicillin-susceptible 
(does not produce 
β-lactamase)
•  Cefazolin (2 g IV q8h for 
4–6 weeks)
Can use cefazolin 
regimen for pts with 
nonimmediate penicillin 
allergy
•  Vancomycinc (15 mg/kg IV 
q12h for 4–6 weeks)
Use vancomycin for 
pts with immediate 
(urticarial) or severe 
penicillin allergy
Methicillin-
resistant, 
infecting native 
valves (no foreign 
devices)
•  Vancomycinc (15 mg/kg IV 
q8–12h for 4–6 weeks)
No role for routine use of 
rifampin
Methicillin-
susceptible, 
infecting
prosthetic valves
•  Nafcillin or oxacillin 
(2 g IV q4h for 6–8 weeks) 
plus
Gentamicind (1 mg/kg IM 
or IV q8h for 2 weeks) plus
Rifampini (300 mg PO q8h 
for 6–8 weeks)
Use gentamicin 
during initial 2 weeks; 
determine susceptibility 
to gentamicin before 
initiating rifampin; if 
pt is highly allergic to 
penicillin, use regimen 
for methicillin-resistant 
staphylococci; if 
β-lactam allergy is of 
the minor nonimmediate 
type, can substitute 
cefazolin for oxacillin/
nafcillin
(continued)
SECTION 7
528
Infectious Diseases
TABLE 89-2  ANTIBIOTIC TREATMENT FOR INFECTIVE ENDOCARDITIS 
CAUSED BY COMMON ORGANISMSa (CONTINUED)
Organism
Drug (Dose, Duration)
Comments
Staphylococci (continued)
Methicillin-
resistant,
infecting
prosthetic
valves
•  Vancomycinc (15 mg/kg IV 
q12h for 6–8 weeks) plus
Gentamicind (1 mg/kg IM 
or IV q8h for 2 weeks) plus
Rifampini (300 mg PO q8h 
for 6–8 weeks)
Use gentamicin dur-
ing initial 2 weeks; 
determine gentamicin 
susceptibility before ini-
tiating rifampin
HACEK organisms
•  Ceftriaxone (2 g/d IV as a 
single dose for 4 weeks) 
•  Ampicillin/sulbactam 
(3 g IV q6h for 4 weeks)
Can use another third-
generation cephalosporin 
at comparable dosage
—
aDoses are for adults with normal renal function. Doses of gentamicin, streptomycin, and van-
comycin must be adjusted for reduced renal function. Ideal body weight is used to calculate 
doses of gentamicin and streptomycin per kilogram (men = 50 kg + 2.3 kg per inch over 
5 feet; women = 45.5 kg + 2.3 kg per inch over 5 feet).
bMIC, ≤0.1 μg/mL.
cVancomycin dose is based on actual body weight. Adjust for trough level of 10–15 μg/mL for 
streptococcal and enterococcal infections and 15–20 μg/mL for staphylococcal infections.
dAminoglycosides should not be administered as single daily doses for enterococcal endocar-
ditis and should be introduced as part of the initial treatment. Target peak and trough serum 
concentrations of divided-dose gentamicin 1 h after a 20- to 30-min infusion or IM injection 
are ~3.5 μg/mL and ≤1 μg/mL, respectively; target peak and trough serum concentrations of 
streptomycin (timing as with gentamicin) are 20–35 μg/mL and <10 μg/mL, respectively.
eNetilmicin (4 mg/kg qd, as a single dose) can be used in lieu of gentamicin.
fMIC, >0.1 μg/mL and <0.5 μg/mL.
gMIC, ≥0.5 μg/mL and <8 μg/mL.
hAntimicrobial susceptibility must be evaluated.
iRifampin increases warfarin and dicumarol requirements for anticoagulation.
• Pts with acute endocarditis require antibiotic treatment as soon 
as three sets of blood culture samples are obtained, but pts with 
subacute disease who are clinically stable should have antibiotics 
withheld until a diagnosis is made. 
• Pts treated with vancomycin or an aminoglycoside should have 
serum drug levels monitored. Tests to detect renal, hepatic, and/or 
hematologic toxicity should be performed periodically.
ORGANISM-SPECIFIC THERAPIES
• Endocarditis due to group B, C, or G streptococci should be treated 
with the regimen recommended for relatively penicillin-resistant 
streptococci (Table 89-2).
CHAPTER 89
529
Infective Endocarditis
• Enterococci require the synergistic activity of a cell wall–active 
agent and an aminoglycoside for killing. Enterococci must be 
tested for high-level resistance to streptomycin and gentamicin. If 
such resistance is detected, the addition of an aminoglycoside will 
not produce a synergistic effect; the cell wall–active agent should 
be given alone for periods of 8–12 weeks, or—for Enterococcus 
faecalis—high-dose ampicillin plus ceftriaxone can be given. If 
treatment fails or the isolate is resistant to commonly used agents, 
surgical therapy is advised (see below and Table 89-3). The ami-
noglycoside can be discontinued in those pts who have responded 
satisfactorily to therapy if toxicity develops after 2–3 weeks of 
treatment.
• For staphylococcal endocarditis, the addition of 3–5 days of genta-
micin to a β-lactam antibiotic does not improve survival rates and is 
not recommended.
• Daptomycin [6 mg/kg (or, as some experts prefer, 8–10 mg/kg) IV qd] 
has been recommended for endocarditis caused by S. aureus isolates 
with a vancomycin MIC of ≥2 μg/mL, although this regimen has not 
yet been approved by the U.S. Food and Drug Administration. These 
isolates should be tested to document daptomycin sensitivity.
TABLE 89-3  INDICATIONS FOR CARDIAC SURGICAL INTERVENTION IN 
PATIENTS WITH ENDOCARDITIS
Surgery required for optimal outcome
Moderate to severe CHF due to valve dysfunction
Partially dehisced unstable prosthetic valve
Persistent bacteremia despite optimal antimicrobial therapy
Lack of effective microbicidal therapy (e.g., fungal or Brucella endocarditis)
Staphylococcus aureus PVE with an intracardiac complication
Relapse of PVE after optimal antimicrobial therapy
Surgery to be strongly considered for improved outcomea
Perivalvular extension of infection
Poorly responsive S. aureus endocarditis involving the aortic or mitral valve
Large (>10-mm diameter) hypermobile vegetations with increased risk of 
embolism
Persistent unexplained fever (≥10 days) in culture-negative NVE
Poorly responsive or relapsed endocarditis due to highly antibiotic-resistant 
enterococci or gram-negative bacilli
aSurgery must be carefully considered; findings are often combined with other indications to 
prompt surgery.
Abbreviations: NVE, native valve endocarditis; PVE, prosthetic valve endocarditis.
SECTION 7
530
Infectious Diseases
• Staphylococcal PVE is treated for 6–8 weeks with a multidrug regi-
men. Rifampin is important because it kills organisms adherent to 
foreign material. The inclusion of two other agents in addition to 
rifampin helps prevent the emergence of rifampin resistance in vivo. 
Susceptibility testing for gentamicin should be performed before 
rifampin is given; if the strain is resistant, another aminoglycoside, 
a fluoroquinolone, or another active agent should be substituted.
• Empirical therapy (either before culture results are known or when 
cultures are negative) depends on epidemiologic clues to etiology (e.g., 
endocarditis in an IV drug user, health care–associated endocarditis).
– In the setting of no prior antibiotic therapy and negative 
blood cultures, S. aureus, CoNS, and enterococcal infection are 
unlikely; empirical therapy in this situation should target nutri-
tionally variant organisms, the HACEK group, and Bartonella.
– If negative cultures are confounded by prior antibiotic therapy, 
broader empirical therapy is indicated and should cover patho-
gens inhibited by the prior therapy.
SURGICAL TREATMENT
• Surgery should be considered early in the course of illness in pts 
with the indications listed in Table 89-3; most of these indications 
are not absolute, and recommendations are derived from observa-
tional studies and expert opinion. Moderate or severe refractory 
CHF is the major indication for surgical treatment of endocarditis.
• Pts who develop acute aortic regurgitation with preclosure of the 
mitral valve, a sinus of Valsalva abscess rupture into the right heart, or 
rupture into the pericardial sac require emergent (same-day) surgery. 
• Cardiac surgery should be delayed for 2–3 weeks if possible when 
the pt has had a nonhemorrhagic embolic stroke and for 4 weeks 
when the pt has had a hemorrhagic embolic stroke. Ruptured 
mycotic aneurysms should be treated prior to cardiac surgery.
• The duration of antibiotic therapy after cardiac surgery depends on 
the indication for surgery.
– For cases of uncomplicated NVE caused by susceptible organisms 
with negative valve cultures at surgery, the duration of pre- and 
postoperative treatment should equal the total duration of recom-
mended therapy, with ~2 weeks of treatment given postoperatively.
– For endocarditis with paravalvular abscess, partially treated 
PVE, or culture-positive valves, pts should receive a full course of 
therapy postoperatively.
• Outcome Death and poor outcome are related not to failure of antibiotic 
therapy but rather to interactions of comorbidities and endocarditis-
related end-organ complications.
– Survival rates are 85–90% for NVE due to viridans streptococci, 
HACEK organisms, or enterococci as opposed to 55–70% for NVE 
due to S. aureus in pts who are not IV drug users. 
CHAPTER 89
531
Infective Endocarditis
– PVE beginning within 2 months of valve replacement results in mortal-
ity rates of 40–50%, whereas rates are only 10–20% in later-onset cases.
• Prevention The American Heart Association has reversed earlier recom-
mendations and dramatically restricted recommendations for antibiotic 
prophylaxis. Prophylaxis is now recommended only for pts at highest 
risk of severe morbidity and death from endocarditis. 
– Prophylaxis is recommended only for those dental procedures involv-
ing manipulation of gingival tissue or the periapical region of the teeth 
or perforation of the oral mucosa (including respiratory tract surgery). 
TABLE 89-4  HIGH-RISK CARDIAC LESIONS FOR WHICH ENDOCARDITIS 
PROPHYLAXIS IS ADVISED BEFORE DENTAL PROCEDURES
Prosthetic heart valves
Prior endocarditis
Unrepaired cyanotic congenital heart disease, including palliative shunts 
or conduits
Completely repaired congenital heart defects during the 6 months after repair
Incompletely repaired congenital heart disease with residual defects 
adjacent to prosthetic material
Valvulopathy developing after cardiac transplantation
Source: W Wilson et al: Circulation, published online, 9th April, 2007.
TABLE 89-5  ANTIBIOTIC REGIMENS FOR PROPHYLAXIS OF ENDOCARDITIS 
IN ADULTS WITH HIGH-RISK CARDIAC LESIONSa,b
A.  Standard oral regimen
1. Amoxicillin: 2 g PO 1 h before procedure
B.  Inability to take oral medication
1. Ampicillin: 2 g IV or IM within 1 h before procedure
C.  Penicillin allergy
1. Clarithromycin or azithromycin: 500 mg PO 1 h before procedure
2. Cephalexinc: 2 g PO 1 h before procedure
3. Clindamycin: 600 mg PO 1 h before procedure
D.  Penicillin allergy, inability to take oral medication
1. Cefazolinc or ceftriaxonec: 1 g IV or IM 30 min before procedure
2. Clindamycin: 600 mg IV or IM 1 h before procedure
aDosing for children: for amoxicillin, ampicillin, cephalexin, or cefadroxil, use 50 mg/kg PO; 
cefazolin, 25 mg/kg IV; clindamycin, 20 mg/kg PO, 25 mg/kg IV; clarithromycin, 15 mg/kg 
PO; and vancomycin, 20 mg/kg IV.
bFor high-risk lesions, see Table 89-4 . Prophylaxis is not advised for other lesions.
cDo not use cephalosporins in pts with immediate hypersensitivity (urticaria, angioedema, 
anaphylaxis) to penicillin.
Source: W Wilson et al: Circulation, published online 4/19/2007.
SECTION 7
532
Infectious Diseases
Prophylaxis is not advised for pts undergoing gastrointestinal or geni-
tourinary tract procedures.
– Table 89-4 lists the high-risk cardiac lesions for which prophylaxis is 
advised, and Table 89-5 lists the recommended antibiotic regimens for 
this purpose.
For a more detailed discussion, see Karchmer AW: Infective 
Endocarditis, Chap. 124, p. 1052, in HPIM-18.
CHAPTER 90
Intraabdominal Infections
Intraperitoneal infections result when normal anatomic barriers are dis-
rupted. Organisms contained within the bowel or an intraabdominal organ 
enter the sterile peritoneal cavity, causing peritonitis and—if the infection 
goes untreated and the pt survives—abscesses.
PERITONITIS
Peritonitis is a life-threatening event that is often accompanied by bac-
teremia and sepsis. Primary peritonitis has no apparent source, whereas 
secondary peritonitis is caused by spillage from an intraabdominal viscus; 
the etiologic organisms and the clinical presentation of these two processes 
are different.
� PRIMARY (SPONTANEOUS) BACTERIAL PERITONITIS 
• Epidemiology Primary bacterial peritonitis (PBP) is most common 
among pts with cirrhosis (usually due to alcoholism) and preexisting 
ascites, but ≤10% of these pts develop PBP. PBP is also described in other 
settings (e.g., malignancy, hepatitis).
• Pathogenesis PBP is due to hematogenous spread of organisms to ascitic 
fluid in pts in whom a diseased liver and altered portal circulation com-
promise the liver’s filtration function. 
• Microbiology Enteric gram-negative bacilli such as Escherichia coli or 
gram-positive organisms such as streptococci, enterococci, and pneumo-
cocci are the most common etiologic agents.
– A single organism is typically isolated.
– If a polymicrobial infection including anaerobes is identified, the 
diagnosis of PBP should be reconsidered and a source of secondary 
peritonitis should be sought.
• Clinical manifestations Although some pts experience acute-onset 
abdominal pain or signs of peritoneal irritation, other pts have only 
nonspecific and nonlocalizing manifestations (e.g., malaise, fatigue, 
encephalopathy). Fever is common (~80% of pts).
CHAPTER 90
533
Intraabdominal Infections
• Diagnosis PBP is diagnosed if peritoneal fluid is sampled and contains 
>250 PMNs/μL. 
– Culture yield is improved if a 10-mL volume of peritoneal fluid is 
placed directly into blood culture bottles. 
– Blood cultures should be performed because bacteremia is common.
Primary (Spontaneous) Bacterial Peritonitis
TREATMENT
• A third-generation cephalosporin (e.g., ceftriaxone, 2 g q24h IV; or 
cefotaxime, 2 g q8h IV) or piperacillin/tazobactam (3.375 g qid IV) 
constitutes appropriate empirical treatment. 
• The regimen should be narrowed after the etiology is identified. 
• Treatment should continue for at least 5 days, but longer courses (up 
to 2 weeks) may be needed for pts with coexisting bacteremia or for 
those whose improvement is slow.
• Prevention Up to 70% of pts have a recurrence of PBP within 1 year. 
Prophylaxis with fluoroquinolones (e.g., ciprofloxacin, 750 mg weekly) 
or trimethoprim-sulfamethoxazole (TMP-SMX; one double-strength 
tablet daily) reduces this rate to 20% but increases the risk of serious 
staphylococcal infections over time.
� SECONDARY PERITONITIS
• Pathogenesis Secondary peritonitis develops when bacteria contaminate 
the peritoneum as a result of spillage from an intraabdominal viscus. 
• Microbiology Infection almost always involves a mixed flora in which 
gram-negative bacilli and anaerobes predominate, especially when the 
contaminating source is colonic. The specific organisms depend on the 
flora present at the site of the initial process.
• Clinical manifestations Initial symptoms may be localized or vague 
and depend on the primary organ involved. Once infection has spread 
to the peritoneal cavity, pain increases; pts lie motionless, often with 
knees drawn up to avoid stretching the nerve fibers of the peritoneal 
cavity. Coughing or sneezing causes severe, sharp pain. There is marked 
voluntary and involuntary guarding of anterior abdominal musculature, 
tenderness (often with rebound), and fever.
• Diagnosis Although recovery of organisms from peritoneal fluid is easier 
in secondary than in primary peritonitis, radiographic studies to find the 
source of peritoneal contamination or immediate surgical intervention 
should usually be part of the initial diagnostic evaluation. Abdominal taps 
are done only to exclude hemoperitoneum in trauma cases.
• Treatment Antibiotics aimed at the inciting flora—e.g., penicillin/
β-lactamase inhibitor combinations or a combination of a fluoroquino-
lone or a third-generation cephalosporin plus metronidazole—should be 
administered early.
– For critically ill pts in the ICU, imipenem (500 mg q6h IV) or drug 
combinations such as ampicillin plus metronidazole plus ciprofloxa-
cin should be used. 
– Surgical intervention is often needed.
SECTION 7
534
Infectious Diseases
� PERITONITIS IN PTS UNDERGOING CAPD 
• Pathogenesis In a phenomenon similar to that seen in intravascular 
device–related infections, organisms migrate along the catheter, a foreign 
body that serves as an entry point.
• Microbiology CAPD-associated peritonitis usually involves skin organ-
isms, with Staphylococcus spp. such as coagulase-negative staphylococci 
and Staphylococcus aureus accounting for ~45% of cases; gram-negative 
bacilli and fungi (e.g., Candida) are occasionally identified. 
• Clinical manifestations CAPD-associated peritonitis presents similarly 
to secondary peritonitis, in that diffuse pain and peritoneal signs are 
common.
• Diagnosis Several hundred milliliters of removed dialysis fluid should be 
centrifuged and sent for culture. 
– Use of blood culture bottles improves the diagnostic yield.
– The dialysate is usually cloudy and contains >100 WBCs/μL, with 
>50% neutrophils.
• Treatment Empirical therapy should be directed against staphylococcal 
species and gram-negative bacilli (e.g., cefazolin plus a fluoroquinolone 
or a third-generation cephalosporin such as ceftazidime). Vancomycin 
should be used instead of cefazolin if methicillin resistance is prevalent, 
if the pt has an overt exit-site infection, or if the pt appears toxic. 
– Antibiotics are given by the intraperitoneal route either continuously 
(e.g., with each exchange) or intermittently (e.g., once daily, with the 
dose allowed to remain in the peritoneal cavity for 6 h). Severely ill pts 
should be given the same regimen by the IV route. 
– Catheter removal should be considered if the pt’s condition does not 
improve within 48 h.
INTRAABDOMINAL ABSCESSES
Intraabdominal abscesses are generally diagnosed through radiographic 
studies, of which abdominal CT is typically most useful.
� INTRAPERITONEAL ABSCESSES
• Epidemiology Of intraabdominal abscesses, 74% are intraperitoneal or 
retroperitoneal, not visceral. 
• Pathogenesis Most abscesses arise from colonic sources. Abscesses 
develop in untreated peritonitis as an extension of the disease process 
and represent host defense activity aimed at containing the infection. 
• Microbiology Bacteroides fragilis accounts for only 0.5% of the normal 
colonic flora, but is the anaerobe most frequently isolated from intraab-
dominal abscesses and from blood. 
• Treatment Antimicrobial therapy is adjunctive to drainage and/or surgi-
cal correction of an underlying lesion or process.
– Diverticular abscesses usually wall off locally, and surgical interven-
tion is not routinely needed. 
– Antimicrobial agents with activity against gram-negative bacilli 
and anaerobic organisms are indicated (see “Secondary Peritonitis,” 
above).
CHAPTER 90
535
Intraabdominal Infections
� VISCERAL ABSCESSES
Liver Abscess 
• Epidemiology and Microbiology Liver abscesses account for up to half 
of visceral intraabdominal abscesses and are caused most commonly by 
biliary tract disease (due to aerobic gram-negative bacilli or enterococci) 
and less often by local spread from pelvic and other intraperitoneal 
sources (due to mixed flora including aerobic and anaerobic species, 
among which B. fragilis is most common) or hematogenous seeding 
(infection with a single species, usually S. aureus or streptococci such as 
S. milleri). 
– Amebic liver abscesses are not uncommon.
– Amebic serology has yielded positive results in >95% of affected pts. 
• Clinical manifestations Pts have fever, anorexia, weight loss, nausea, 
and vomiting, but only ~50% have signs localized to the RUQ, such as 
pain, tenderness, hepatomegaly, and jaundice. Serum levels of alkaline 
phosphatase are elevated in ~70% of pts, and leukocytosis is common. 
One-third to one-half of pts are bacteremic. 
• Treatment Drainage is the mainstay of treatment, but medical manage-
ment with long courses of antibiotics can be successful. 
– Empirical therapy is the same as for intraabdominal sepsis and SBP.
– Percutaneous drainage tends to fail in cases with multiple, sizable 
abscesses; with viscous abscess contents that plug the pigtail cath-
eter; with associated disease (e.g., of the biliary tract); or with lack of 
response in 4–7 days.
Splenic Abscess 
• Epidemiology Splenic abscesses are much less common than liver 
abscesses and usually develop via hematogenous spread of infection 
(e.g., due to endocarditis). The diagnosis is often made only after the pt’s 
death; the condition is frequently fatal if left untreated.
• Microbiology Splenic abscesses are most often caused by streptococci; 
S. aureus is the next most common cause. Gram-negative bacilli can cause 
splenic abscess in pts with urinary tract foci, with associated bacteremia, 
or with infection from another intraabdominal source; salmonellae are 
fairly commonly isolated, particularly from pts with sickle cell disease.
• Clinical manifestations Abdominal pain or splenomegaly occurs in 
~50% of cases and pain localized to the LUQ in ~25%. Fever and leuko-
cytosis are common. 
• Treatment Pts with multiple or complex multilocular abscesses should 
undergo splenectomy, receive adjunctive antibiotics, and be vaccinated 
against encapsulated organisms (Streptococcus pneumoniae, Haemophilus 
influenzae, and Neisseria meningitidis). Percutaneous drainage has been 
successful for single, small (<3-cm) abscesses and may also be useful for 
pts at high surgical risk.
Perinephric and Renal Abscesses 
• Epidemiology Perinephric and renal abscesses are uncommon. More 
than 75% of these abscesses are due to ascending infection and are pre-
ceded by pyelonephritis. The most important risk factor is the presence 
SECTION 7
536
Infectious Diseases
of renal calculi that produce local obstruction to urinary flow. 
• Microbiology E. coli, Proteus spp. (associated with struvite stones), and 
Klebsiella spp. are the most common etiologic agents; Candida species 
are sometimes identified. 
• Clinical manifestations Clinical signs are nonspecific and include flank 
pain, abdominal pain, and fever. The diagnosis should be considered if 
pts with pyelonephritis have persistent fever after 4 or 5 days of treat-
ment, if a urine culture yields a polymicrobial flora in pts with known 
renal stone disease, or if fever and pyuria occur in conjunction with a 
sterile urine culture. 
• Treatment Drainage and the administration of antibiotics active against 
the organisms recovered are essential. Percutaneous drainage is usually 
successful for perinephric abscesses.
For a more detailed discussion, see Baron MJ, Kasper DL: 
Intraabdominal Infections and Abscesses, Chap. 127, p. 1077, 
in HPIM-18.
CHAPTER 91
Infectious Diarrheas
Acute diarrheal disease, which has an incidence of ~4.6 billion cases world-
wide per year, is the second most common infectious cause of death worldwide 
(after lower respiratory tract infection). The wide range of clinical manifesta-
tions is matched by the wide variety of infectious agents involved (Table 91-1). 
An approach to pts with infectious diarrhea is presented in Fig. 91-1.
NONINFLAMMATORY DIARRHEA
� TRAVELER’S DIARRHEA
See Chap. 214 for details.
� BACTERIAL FOOD POISONING
If there is evidence of a common-source outbreak, questions concerning the 
ingestion of specific foods and the timing of the diarrhea after a meal can 
provide clues to the bacterial cause of the illness.
• Staphylococcus aureus: Enterotoxin is elaborated in food left at room 
temperature (e.g., at picnics). 
– The incubation period is 1–6 h. Disease lasts <12 h and consists of 
diarrhea, nausea, vomiting, and abdominal cramping, usually without 
fever.
– Most cases are due to contamination from infected human carriers.
• Bacillus cereus: Either an emetic or a diarrheal form of food poisoning 
can occur.
CHAPTER 91
537
Infectious Diarrheas
TABLE 91-1  GASTROINTESTINAL PATHOGENS CAUSING ACUTE DIARRHEA
Mechanism
Location Illness
Stool
Findings
Examples of 
Pathogens Involved
Noninflammatory 
(enterotoxin)
Proximal
small
bowel
Watery 
diarrhea
No fecal 
leukocytes; 
mild or no 
increase
in fecal 
lactoferrin
Vibrio cholerae,
enterotoxigenic 
Escherichia coli 
(LT and/or ST), entero-
aggregative E. coli, 
Clostridium perfrin-
gens, Bacillus cereus, 
Staphylococcus 
aureus, Aeromonas 
hydrophila, 
Plesiomonas shigel-
loides, rotavirus, 
norovirus, enteric 
adenoviruses, 
Giardia lamblia,
Cryptosporidium
spp., Cyclospora spp., 
microsporidia
Inflammatory 
(invasion or 
cytotoxin)
Colon
or distal 
small
bowel
Dysentery 
or inflam-
matory 
diarrhea
Fecal 
polymor-
phonuclear 
leukocytes; 
substantial
increase
in fecal 
lactoferrin
Shigella spp., 
Salmonella spp., 
Campylobacter jejuni,
enterohemorrhagic 
E. coli, enteroinva-
sive E. coli, Yersinia 
enterocolitica, Listeria 
monocytogenes, Vibrio 
parahaemolyticus, 
Clostridium difficile, 
A. hydrophila, 
P. shigelloides, 
Entamoeba histolytica, 
Klebsiella oxytoca
Penetrating
Distal 
small
bowel
Enteric
fever
Fecal 
mononuclear 
leukocytes
Salmonella typhi, Y. 
enterocolitica
Abbreviations: LT, heat-labile enterotoxin; ST, heat-stable enterotoxin.
Source: After Steiner TS, Guerrant RL: Principles and syndromes of enteric infection, in 
Mandell, Douglas, and Bennett’s Principles and Practice of Infectious Diseases, 7th ed, GL 
Mandell et al (eds). Philadelphia, Churchill Livingstone, 2010, pp 1335–1351.
– The emetic form presents like S. aureus food poisoning, is due to a 
staphylococcal type of enterotoxin, has an incubation period of 1–6 h, 
and is associated with contaminated fried rice.
– The diarrheal form has an incubation period of 8–16 h, is caused by 
an enterotoxin resembling Escherichia coli heat-labile toxin (LT), and 
presents with diarrhea and abdominal cramps without vomiting.
SECTION 7
538
Infectious Diseases
Yes
No
Assess:
  Duration (>1 day)
  Severity (see text)
Symptomatic therapy
Oral rehydration therapy
Diarrhea, Nausea, or Vomiting
Resolution
Continued illness
Obtain stool to be examined for WBCs
 (and, if >10 days, for parasites)
and
Obtain history:
  Duration1
  Fever2
  Appearance of stool3
  Frequency of bowel
    movements4
  Abdominal pain5
Tenesmus6
Vomiting7
Common source8
Antibiotic use9
Travel10
Specific antiparasitic
therapy
Examine stool
for parasites
Consider: Empirical
  antimicrobial therapy
Culture for: Shigella,
  Salmonella, C. jejuni
Consider:
  C.difficile cytotoxin
Inflammatory (WBCs)
Continue symptomatic
 therapy; further
 evaluation if no
 resolution
Noninflammatory
  (no WBCs)
FIGURE 91-1 Clinical algorithm for the approach to pts with community-acquired 
infectious diarrhea or bacterial food poisoning. Key to superscripts: 1. Diarrhea lasting 
>2 weeks is generally defined as chronic; in such cases, many of the causes of acute 
diarrhea are much less likely, and a new spectrum of causes needs to be considered. 
2. Fever often implies invasive disease, although fever and diarrhea may also result 
from infection outside the GI tract, as in malaria. 3. Stools that contain blood or mucus 
indicate ulceration of the large bowel. Bloody stools without fecal leukocytes should 
alert the laboratory to the possibility of infection with Shiga toxin–producing entero-
hemorrhagic Escherichia coli. Bulky white stools suggest a small-intestinal process 
that is causing malabsorption. Profuse “rice-water” stools suggest cholera or a similar 
toxigenic process. 4. Frequent stools over a given period can provide the first warning 
CHAPTER 91
539
Infectious Diarrheas
• Clostridium perfringens: Ingestion of heat-resistant spores in undercooked 
meat, poultry, or legumes leads to toxin production in the intestinal tract. 
The incubation period is 8–14 h, after which pts develop ≤24 h of diarrhea 
and abdominal cramps, without vomiting or fever.
� CHOLERA
Microbiology
Cholera is caused by Vibrio cholerae serogroups O1 (classic and El Tor 
biotypes) and O139—highly motile, facultatively anaerobic, curved gram-
negative rods. The natural habitat of V. cholerae is coastal salt water and 
brackish estuaries. Toxin production causes disease manifestations.
Epidemiology 
Currently, >90% of cases reported to the World Health Organization 
(WHO) are from Africa; however, most cases go unreported or do not have 
a specific bacterial etiology identified.
• It is estimated that there are >3 million cases annually, with >100,000 deaths. 
• Spread takes place by fecal contamination of water and food sources. 
Infection requires ingestion of a relatively large inoculum (compared 
with that required for other pathogens) of >105 organisms. 
Clinical Manifestations 
After an incubation period of 24–48 h, pts develop painless watery diarrhea 
and vomiting that can cause profound, rapidly progressive dehydration and 
death within hours. 
• Volume loss can be >250 mL/kg in the first day.
• Stool has a characteristic “rice-water” appearance: gray cloudy fluid with 
flecks of mucus; no blood; and a fishy, inoffensive odor.
of impending dehydration. 5. Abdominal pain may be most severe in inflammatory 
processes like those due to Shigella, Campylobacter, and necrotizing toxins. Painful 
abdominal muscle cramps, caused by electrolyte loss, can develop in severe cases 
of cholera. Bloating is common in giardiasis. An appendicitis-like syndrome should 
prompt a culture for Yersinia enterocolitica with cold enrichment. 6. Tenesmus (painful 
rectal spasms with a strong urge to defecate but little passage of stool) may be a fea-
ture of cases with proctitis, as in shigellosis or amebiasis. 7. Vomiting implies an acute 
infection (e.g., a toxin-mediated illness or food poisoning) but can also be prominent 
in a variety of systemic illnesses (e.g., malaria) and in intestinal obstruction. 8. Asking 
pts whether anyone else they know is sick is a more efficient means of identifying a 
common source than is constructing a list of recently eaten foods. If a common source 
seems likely, specific foods can be investigated. See text for a discussion of bacterial 
food poisoning. 9. Current antibiotic therapy or a recent history of treatment suggests 
Clostridium difficile diarrhea. Stop antibiotic treatment if possible and consider tests 
for C. difficile toxins. Antibiotic use may increase the risk of other infections, such as 
salmonellosis. 10. See Chap. 214 for a discussion of traveler’s diarrhea. [After Steiner 
TS, Guerrant RL: Principles and syndromes of enteric infection, in Mandell, Douglas, 
and Bennett’s Principles and Practice of Infectious Diseases, 7th ed, GL Mandell 
et al (eds). Philadelphia, Churchill Livingstone, 2010, pp 1335–1351; RL Guerrant, DA 
Bobak: N Engl J Med 325:327, 1991; with permission.]
SECTION 7
540
Infectious Diseases
Diagnosis
Stool cultures on selective medium [e.g., thiosulfate–citrate–bile salts–sucrose 
(TCBS) agar] can isolate the organism. A point-of-care antigen-detection 
assay is available for field use.
Cholera
TREATMENT
Rapid fluid replacement is critical, preferably with the WHO’s reduced-
osmolarity oral rehydration solution (ORS), which contains (per liter 
of water) Na+, 75 mmol; K+, 20 mmol; Cl–, 65 mmol; citrate, 10 mmol; 
and glucose, 75 mmol. 
• If available, rice-based ORS is considered superior to standard ORS 
for cholera. 
• If ORS is not available, a substitute can be made by adding 0.5 teaspoon 
of table salt (NaCl; 3.5 g) and 4 tablespoons of table sugar (glucose; 
40 g) to 1 L of safe water.
• Severely dehydrated pts should be managed initially with IV hydra-
tion (preferably with Ringer’s lactate), with the total fluid deficit 
replaced in the first 3–6 h (half within the first hour).
• A single dose of an effective antibiotic diminishes the duration and 
volume of stool: doxycycline (300 mg), ciprofloxacin (30 mg/kg, not 
to exceed 1 g), or azithromycin (1 g).
VIBRIO PARAHAEMOLYTICUS AND NON-O1 V. CHOLERAE
These infections are linked to ingestion of contaminated seawater or 
undercooked seafood. After an incubation period of 4 h to 4 days, watery 
diarrhea, abdominal cramps, nausea, vomiting, and occasionally fever and 
chills develop. The disease lasts <7 days. Dysentery is a less common pre-
sentation. Pts with comorbid disease (e.g., liver disease) sometimes have 
extraintestinal infections that require antibiotic treatment.
� NOROVIRUSES AND RELATED HUMAN CALICIVIRUSES
Microbiology and Epidemiology 
These single-stranded RNA viruses are common causes of traveler’s 
diarrhea and of viral gastroenteritis in pts of all ages as well as of epi-
demics worldwide, with a higher prevalence in cold-weather months. 
In the United States, >90% of outbreaks of nonbacterial gastroenteritis 
are caused by noroviruses. Very small inocula are required for infection. 
Thus, although the fecal-oral route is the primary mode of transmission, 
aerosolization, fomite contact, and person-to-person contact can also 
result in infection.
Clinical Manifestations 
After a 24-h incubation period (range, 12–72 h), pts experience the sudden 
onset of nausea, vomiting, diarrhea, and/or abdominal cramps with con-
stitutional symptoms (e.g., fever, headache, chills). Stools are loose, watery, 
and without blood, mucus, or leukocytes. Disease lasts 12–60 h.
CHAPTER 91
541
Infectious Diarrheas
Diagnosis
PCR assays and enzyme immunoassays (EIAs) have been developed to 
detect these viruses in stool and other body fluids, but these techniques are 
still largely relegated to research and outbreak settings.
Infections with Noroviruses and Related Human 
Caliciviruses
TREATMENT
Only supportive measures are required.
� ROTAVIRUSES
Microbiology and Epidemiology 
Rotavirus is a segmented, double-stranded RNA virus that infects nearly all 
children worldwide by 3–5 years of age; adults can become infected if exposed. 
• Reinfections are progressively less severe. 
• Large quantities of virus are shed in the stool during the first week of 
infection, and transmission takes place both via the fecal-oral route and 
from person to person. 
• Disease incidence peaks in the cooler fall and winter months. 
Clinical Manifestations 
After an incubation period of 1–3 days, disease onset is abrupt. Vomiting 
often precedes diarrhea (loose, watery stools without blood or fecal leu-
kocytes), and about one-third of pts have temperatures >39°C. Symptoms 
resolve within 3–7 days.
Diagnosis
EIAs or viral RNA detection techniques, such as PCR, can identify rotavirus 
in stool samples.
Rotavirus Infections
TREATMENT
Only supportive treatment is needed. Dehydration can be severe, and 
IV hydration may be needed in pts with frequent vomiting. Avoid 
antibiotics and antimotility agents.
Prevention
Rotavirus vaccines, two of which are available, are included in the routine 
vaccination schedule for U.S. infants. Although these vaccines have a lower 
efficacy (50–70%) in low-resource settings, the WHO recommends their 
use in all countries worldwide.
� GIARDIASIS
Microbiology and Epidemiology 
Giardia lamblia (also known as G. intestinalis or G. duodenalis) is a protozoal 
parasite that inhabits the small intestines of humans and other mammals. 
• Cysts are ingested from the environment, excyst in the small intestine, and 
release flagellated trophozoites that remain in the proximal small intestine. 
Some trophozoites encyst, with the resulting cysts excreted in feces. 
SECTION 7
542
Infectious Diseases
• Transmission occurs via the fecal-oral route, by ingestion of contaminated 
food and water, or from person to person in settings with poor fecal 
hygiene (e.g., day-care centers, institutional settings). Infection results 
from as few as 10 cysts.
• Viable cysts can be eradicated from water by either boiling or filtration. 
Standard chlorination techniques used to control bacteria do not destroy 
cysts. 
• Young pts, newly exposed pts, and pts with hypogammaglobulinemia are 
at increased risk—a pattern suggesting a role for humoral immunity in 
resistance.
Clinical Manifestations 
After an incubation period of 5 days to 3 weeks, disease ranges from asymp-
tomatic carriage (most common) to fulminant diarrhea and malabsorption.
• Prominent early symptoms include diarrhea, abdominal pain, bloating, 
belching, flatus, nausea, and vomiting and usually last >1 week. Fever is 
rare, as is blood or mucus in stool.
• Chronic giardiasis can be continual or episodic; diarrhea may not be 
prominent, but increased flatulence, sulfurous belching, and weight loss 
can occur.
• In some cases, disease can be severe, with malabsorption, growth retar-
dation, dehydration, and/or extraintestinal manifestations (e.g., anterior 
uveitis, arthritis).
Diagnosis
Giardiasis can be diagnosed by parasite antigen detection in feces and/or 
identification of cysts (oval, with four nuclei) or trophozoites (pear-shaped, 
flattened parasites with two nuclei and four pairs of flagella) in stool speci-
mens. Given variability in cyst excretion, multiple samples may need to be 
examined.
Giardiasis
TREATMENT
• Cure rates with metronidazole (250 mg tid for 5 days) are >90%; 
tinidazole (2 g PO once) may be more effective. Nitazoxanide (500 
mg bid for 3 days) is an alternative agent.
• If symptoms persist, continued infection should be documented 
before re-treatment and possible sources of reinfection sought. 
Prolonged therapy with metronidazole (750 mg tid for 21 days) has 
been successful.
� CRYPTOSPORIDIOSIS
Microbiology and Epidemiology 
Cryptosporidial infections are caused by Cryptosporidium hominis and 
C. parvum. 
• Oocysts are ingested and subsequently excyst, enter intestinal cells, and 
generate oocysts that are excreted in feces. The 50% infectious dose in 
immunocompetent individuals is ~132 oocysts.
CHAPTER 91
543
Infectious Diarrheas
• Person-to-person transmission of infectious oocysts can occur among 
close contacts and in day-care settings. Waterborne transmission is com-
mon. Oocysts are not killed by routine chlorination.
Clinical Manifestations 
After an incubation period of ~1 week, pts may remain asymptomatic or 
develop watery, nonbloody diarrhea, occasionally with abdominal pain, 
nausea, anorexia, fever, and/or weight loss lasting 1–2 weeks. In immuno-
compromised hosts (particularly those with CD4+ T cell counts <100/μL), 
diarrhea can be profuse and chronic, resulting in severe dehydration, weight 
loss, and wasting; the biliary tract can be involved.
Diagnosis
On multiple days, fecal samples should be examined for oocysts (4–5 μm in 
diameter, smaller than most parasites). Modified acid-fast staining, direct 
immunofluorescent techniques, and EIAs can facilitate diagnosis.
Cryptosporidiosis
TREATMENT
• Nitazoxanide (500 mg bid for 3 days) is effective for immunocom-
petent pts but not for HIV-infected pts; improved immune status 
due to antiretroviral therapy can alleviate symptoms in the latter pts.
• In addition to antiprotozoal agents, supportive measures include 
replacement of fluid and electrolytes and use of antidiarrheal agents.
� CYSTOISOSPORIASIS
Cystoisospora belli (formerly Isospora belli) infection is acquired by oocyst 
ingestion and is most common in tropical and subtropical countries. Acute 
infection can begin suddenly with fever, abdominal pain, and watery, 
nonbloody diarrhea and can last for weeks or months. Eosinophilia may 
occur. Compromised (e.g., HIV-infected) pts may have chronic disease that 
resembles cryptosporidiosis. Detection of large oocysts (~25 μm) in stool by 
modified acid-fast staining confirms the diagnosis.
Cystoisosporiasis
TREATMENT
• Trimethoprim-sulfamethoxazole (TMP-SMX; 160/800 mg bid for 
10 days) is effective therapy for immunocompetent pts.
– HIV-infected pts should receive prolonged therapy with TMP-
SMX (160/800 mg qid for 10 days, followed by 160/800 mg bid, 
tid, or qid for 3–4 weeks, depending on the clinical response).
– Pyrimethamine (50–75 mg/d) can be given to pts intolerant of 
TMP-SMX. 
– Pts with AIDS may need suppressive maintenance therapy 
(TMP-SMX, 160/800 mg 3 times per week) to prevent relapses.
� CYCLOSPORIASIS
Cyclospora cayetanensis can be transmitted through water or food (e.g., 
basil, raspberries). Clinical symptoms include diarrhea, flulike symptoms, 
SECTION 7
544
Infectious Diseases
flatulence, and burping. Disease can be self-limited or can persist for 
>1 month. Diagnosis is made by detection of oocysts (spherical, 8–10 μm) 
in stool; targeted diagnostic studies must be specifically requested.
Cyclosporiasis
TREATMENT
TMP-SMX (160/800 mg bid for 1 week) is effective. Pts with AIDS may 
need suppressive maintenance therapy to prevent relapses.
INFLAMMATORY DIARRHEA
� SALMONELLOSIS
Microbiology and Pathogenesis 
Salmonellae are facultatively anaerobic gram-negative bacilli that cause infec-
tion when 103–106 organisms are ingested. 
• Conditions that reduce gastric acidity or intestinal integrity increase 
susceptibility to infection. 
• Organisms penetrate the small-intestinal mucus layer and traverse the 
intestinal epithelium through M cells overlying Peyer’s patches. 
– S. typhi and S. paratyphi survive within macrophages, then dis-
seminate throughout the body via lymphatics, and ultimately colonize 
reticuloendothelial tissues. 
– Nontyphoidal salmonellae most commonly cause gastroenteritis, 
invading the large- and small-intestinal mucosa and resulting in mas-
sive PMN infiltration (as opposed to the mononuclear-cell infiltration 
seen with typhoid fever).
Epidemiology and Clinical Manifestations 
Depending on the specific species, salmonellosis results in typhoid fever or 
gastroenteritis.
• Typhoid (enteric) fever: Typhoid fever is a systemic disease characterized 
by fever and abdominal pain and caused by dissemination of S. typhi or 
S. paratyphi, for which humans are the only hosts. 
– Disease results from ingestion of food or water contaminated by 
chronic carriers and is rare in developed nations. Worldwide, there are 
~22 million cases, with 200,000 deaths annually.
– After an incubation period of 3–21 days, prolonged fever (>75% of 
cases), headache (80%), chills (35–45%), anorexia (55%), and abdomi-
nal pain (30–40%) are common. Other symptoms may include sweat-
ing, cough, malaise, arthralgias, nausea, vomiting, and diarrhea—or, 
less often, constipation. 
– Physical findings include rose spots (faint, salmon-colored, blanching, 
maculopapular rash), hepatosplenomegaly, epistaxis, and relative bra-
dycardia. 
– Intestinal perforation and/or GI hemorrhage can occur in the third 
and fourth weeks of illness; neurologic manifestations (e.g., meningi-
tis, Guillain-Barré syndrome) occur in 2–40% of pts. 
– Long-term Salmonella carriage (i.e., for >1 year) in urine or stool 
develops in 1–4% of pts.
CHAPTER 91
545
Infectious Diarrheas
• Nontyphoidal salmonellosis (NTS): Most commonly caused by S. typhimurium 
or S. enteritidis, NTS typically presents within 6–48 h of exposure as gastro-
enteritis (nausea, vomiting, nonbloody diarrhea, abdominal cramping, and 
fever) that lasts 3–7 days. 
– In 2009, there were ~14 million cases of NTS in the United States. 
– Disease is acquired from multiple animal reservoirs. The main mode 
of transmission is via contaminated food products, such as eggs 
(S. enteritidis), poultry, undercooked meat, dairy products, manufac-
tured or processed foods, and fresh produce. Infection is also acquired 
during exposure to pets, especially reptiles.
– Stool cultures remain positive for 4–5 weeks and—in rare cases of 
chronic carriage—for >1 year.
– 8% of pts develop bacteremia, usually due to S. choleraesuis and 
S. dublin; of these pts, 5–10% develop localized infections (e.g., hepa-
tosplenic abscesses, meningitis, pneumonia, osteomyelitis).
– Reactive arthritis can follow Salmonella gastroenteritis, particularly in 
persons with the HLA-B27 histocompatibility antigen.
Diagnosis
Positive cultures of blood, stool, or other specimens are required for diagnosis. 
Salmonellosis
TREATMENT
• Typhoid fever: A fluoroquinolone (e.g., ciprofloxacin, 500 mg PO bid) 
is most effective for susceptible organisms.
– Pts infected with nalidixic acid–resistant strains (whose suscepti-
bility to ciprofloxacin is reduced) should be treated with ceftriax-
one (2–3 g/d IV for 7–14 days), azithromycin (1 g/d PO for 5 days), 
or high-dose ciprofloxacin (750 mg PO bid or 400 mg IV q8h for 
10–14 days). 
– Dexamethasone may be of benefit in severe cases.
• NTS: Antibiotic treatment is not recommended in most cases as it 
does not shorten the duration of symptoms and is associated with 
increased rates of relapse, a prolonged carrier state, and adverse 
drug reactions. 
– Antibiotic treatment may be required for infants ≤3 months of 
age; pts >50 years of age with suspected atherosclerosis; pts with 
immunosuppression; pts with cardiac, valvular, or endovascular 
abnormalities; and pts with significant joint disease. 
– Fluoroquinolones or third-generation cephalosporins are given 
for 2–3 days or until defervescence (if the pt is immunocompe-
tent) or for 1–2 weeks (if the pt is immunocompromised). 
– HIV-infected pts are at high risk for Salmonella bacteremia 
and should receive 4 weeks of oral fluoroquinolone therapy after 
1–2 weeks of IV treatment. In cases of relapse, long-term suppres-
sion with a fluoroquinolone or TMP-SMX should be considered. 
– Pts with endovascular infections or endocarditis should receive 6 
weeks of treatment with a third-generation cephalosporin. 
SECTION 7
546
Infectious Diseases
� CAMPYLOBACTERIOSIS
Microbiology 
Campylobacters are motile, curved gram-negative rods that are a common 
bacterial cause of gastroenteritis in the United States. Most cases are caused 
by C. jejuni.
Epidemiology 
Campylobacters are common commensals in the GI tract of many food 
animals and household pets. In the United States, ingestion of contaminated 
poultry accounts for 30–70% of cases. Transmission to humans occurs via 
contact with or ingestion of raw or undercooked food products or direct 
contact with infected animals.
Clinical Manifestations 
An incubation period of 2–4 days (range, 1–7 days) is followed by a pro-
drome of fever, headache, myalgia, and/or malaise. Within the next 12–48 h, 
diarrhea (with stools containing blood, mucus, and leukocytes), cramping 
abdominal pain, and fever develop.
• Most cases are self-limited, but illness persists for >1 week in 10–20% of 
pts and may be confused with inflammatory bowel disease.
• Species other than C. jejuni (e.g., C. fetus) can cause a similar illness or 
prolonged relapsing systemic disease without a primary focus in immu-
nocompromised pts. 
– The course may be fulminant, with bacterial seeding of many organs, 
particularly vascular sites. 
– Fetal death can result from infection in a pregnant pt.
• Three patterns of extraintestinal infection have been noted: (1) transient 
bacteremia in a normal host with enteritis (benign course, no specific treat-
ment needed); (2) sustained bacteremia or focal infection in a normal host; 
and (3) sustained bacteremia or focal infection in a compromised host.
• Complications include reactive arthritis (particularly in persons with the 
HLA-B27 phenotype) and Guillain-Barré syndrome (in which campylo-
bacters are associated with 20–40% of cases).
Diagnosis
The diagnosis is confirmed by cultures of stool, blood, or other specimens 
on special media and/or with selective techniques.
Campylobacteriosis
TREATMENT
• Fluid and electrolyte replacement is the mainstay of therapy. 
• Use of antimotility agents is not recommended, as they are associ-
ated with toxic megacolon.
• Antibiotic treatment (erythromycin, 250 mg PO qid for 5–7 days) 
should be reserved for pts with high fever, bloody or severe diarrhea, 
persistence for >1 week, and worsening of symptoms. Azithromycin 
and fluoroquinolones are alternative regimens, although resistance to 
these drugs is increasing.
CHAPTER 91
547
Infectious Diarrheas
� SHIGELLOSIS AND INFECTION WITH SHIGA TOXIN–PRODUCING/
ENTEROHEMORRHAGIC E. COLI (STEC/EHEC)
Microbiology and Epidemiology 
Shigellae are small, gram-negative, nonmotile bacilli that are very 
closely related to E. coli. The four most common Shigella serotypes are 
S. dysenteriae type 1, S. flexneri, S. boydii, and S. sonnei (which is more 
prevalent in the industrialized world). There are no animal reservoirs other 
than higher primates. 
• These bacteria are transmitted from person to person via the fecal-oral 
route and occasionally via intermediate vectors such as food and water. 
• The ability of as few as 100 organisms to cause infection helps explain the 
high rate of secondary household transmission.
• Shiga toxin and Shiga-like toxins produced by some strains of E. coli 
(including O157:H7) are important factors in disease severity. The toxins 
target endothelial cells and play a significant role in the microangio-
pathic complications of Shigella and E. coli infections, such as hemolytic-
uremic syndrome (HUS) and thrombotic thrombocytopenic purpura. 
• An analysis of cases occurring in 1966–1997 revealed an incidence of 165 mil-
lion cases (of which 69% affected children <5 years of age) with 0.5–1.1 million 
deaths annually; these numbers have likely decreased since then, but 
multidrug-resistant strains have emerged.
Clinical Manifestations 
After an incubation period of 1–4 days, shigellosis evolves through three 
phases: watery diarrhea, dysentery (bloody mucopurulent stools), and the 
postinfectious phase.
• Most episodes resolve in 1 week without treatment; with appropriate 
treatment, recovery takes place within a few days, with no sequelae.
• Complications are largely intestinal (e.g., toxic megacolon, intestinal 
perforation, rectal prolapse) or metabolic (e.g., hypoglycemia, hypona-
tremia). Shiga toxin produced by S. dysenteriae type 1 is linked to HUS 
(Coombs-negative hemolytic anemia; thrombocytopenia; and acute 
renal failure) in developing countries but is rare in industrialized coun-
tries, where E. coli O157:H7 is a more common cause.
Diagnosis
Shigellosis is diagnosed directly by stool culture. STEC/EHEC infection is 
diagnosed by screening of stool cultures for E. coli strains that do not fer-
ment sorbitol, with subsequent serotyping for O157. Tests to detect Shiga 
toxins or toxin genes are sensitive, specific, and rapid; this approach detects 
non-O157 STEC/EHEC and sorbitol-fermenting strains of O157:H7.
Shigellosis and Infection with STEC/EHEC
TREATMENT
• In the United States, because of the ready transmissibility of Shigella, 
antibiotics are recommended. Fluoroquinolones (e.g., ciprofloxacin, 
500 mg bid) are effective, as are ceftriaxone, azithromycin, and 
pivmecillinam. 
SECTION 7
548
Infectious Diseases
– S. dysenteriae infection should be treated for 5 days and non-
dysenteriae Shigella infection for 3 days. 
– Immunocompromised pts should receive 7–10 days of treatment.
• Antibiotic treatment for STEC/EHEC infections should be avoided, 
since antibiotics may increase the incidence of HUS.
• Rehydration usually is not needed; Shigella infection rarely causes 
significant dehydration. If required, rehydration should be oral, and 
nutrition should be started as soon as possible. Use of antimotility 
agents may prolong fever and increase the risk of HUS and toxic 
megacolon.
� YERSINIOSIS
Microbiology and Clinical Manifestations 
Y. enterocolitica and Y. pseudotuberculosis are nonmotile gram-negative 
rods that cause enteritis or enterocolitis with self-limited diarrhea that lasts 
an average of 2 weeks as well as mesenteric adenitis (especially common 
with Y. pseudotuberculosis) and terminal ileitis (especially common with 
Y. enterocolitica) that can resemble acute appendicitis. Septicemia can occur 
in pts with chronic liver disease, malignancy, diabetes mellitus, and other 
underlying illnesses. Infection has been linked to reactive arthritis in HLA-
B27-positive pts.
Diagnosis
Stool culture studies for Yersinia must be specifically requested and require 
the use of special media.
Yersiniosis
TREATMENT
Antibiotics are not indicated for diarrhea caused by yersiniae; support-
ive measures suffice.
� AMEBIASIS
Microbiology and Epidemiology 
Caused by Entamoeba histolytica, amebiasis has a high incidence in develop-
ing countries and among travelers, recent immigrants, men who have sex 
with men, and inmates of institutions in developed nations. Infection follows 
ingestion of cysts from fecally contaminated water, food, or hands. Motile 
trophozoites are released from cysts in the small intestine and then cause 
infection in the large bowel. Trophozoites may be shed in stool (in active dys-
entery) or encyst. Excreted cysts survive for weeks in a moist environment.
Clinical Manifestations 
Most pts harboring Entamoeba species are asymptomatic, but some pts 
develop inflammatory colitis 2–6 weeks after ingestion of amebic cysts.
• Dysentery may develop, with daily passage of 10–12 small stools consisting 
mostly of blood and mucus. Fewer than 40% of pts have fever. 
CHAPTER 91
549
Infectious Diarrheas
• Fulminant amebic colitis—characterized by more profuse diarrhea, severe 
abdominal pain with peritoneal signs, and fever—is more common among 
young children, pregnant women, and pts taking glucocorticoids.
• Liver abscess is the most common type of extraintestinal infection and 
can arise months or years after exposure to E. histolytica. Pts present with 
right-upper-quadrant pain, fever, right-sided pleural effusion, and hepatic 
tenderness and typically do not have active colitis. The abscess can rupture 
through the diaphragm and metastasize elsewhere (e.g., lung, brain).
Diagnosis
Microscopic examination of three stool samples, often combined with sero-
logic testing, remains the standard diagnostic approach. 
• Radiographic demonstration of at least one space-occupying lesion in 
the liver combined with positive serology confirms the diagnosis of ame-
bic liver abscess. In this setting, serology has a sensitivity of >94% and a 
specificity of >95%.
Amebiasis
TREATMENT
• Tinidazole (2 g/d PO for 3 days) or metronidazole (750 mg PO or 
IV tid for 5–10 days) is recommended for amebic colitis and amebic 
liver abscess.
– >90% of pts respond clinically within 3 days of treatment initiation.
– Drainage of liver abscesses is rarely needed. Indications for aspi-
ration include the need to rule out pyogenic abscess, a lack of 
response to treatment after 4 days, an imminent threat of liver-
abscess rupture, or the need to prevent left-lobe abscess rupture 
into the pericardium.
• Pts with either colitis or liver abscesses should also receive a luminal 
agent to ensure eradication of the infection. Paromomycin (10 mg/kg 
PO tid for 5–10 days) is the preferred agent; iodoquinol (650 mg PO 
tid for 20 days) is an alternative.
� CLOSTRIDIUM DIFFICILE INFECTION (CDI)
Microbiology and Epidemiology 
C. difficile is an obligately anaerobic, gram-positive, spore-forming bacillus 
and causes diarrheal illness that is most commonly acquired in the hospital. 
The disease is acquired almost exclusively in association with antimicrobial 
treatment; virtually all antibiotics carry a risk of CDI. 
• After C. difficile colonizes the gut, its spores vegetate, multiply, and secrete 
toxin A (an enterotoxin) and toxin B (a cytotoxin), causing diarrhea and 
pseudomembranous colitis. The rate of fecal colonization is often ≥20% 
among adult pts hospitalized for >1 week; in contrast, the rate is 1–3% 
among community residents.
• Spores can persist on environmental surfaces in the hospital for months 
and on the hands of hospital personnel who do not practice adequate hand 
hygiene. 
SECTION 7
550
Infectious Diseases
• Rates and severity of CDI in the United States, Canada, and Europe have 
increased markedly in the past decade. An epidemic strain accounts for 
much of the increase and is characterized by production of 16–23 times 
as much toxin A and toxin B as is documented for control strains, by the 
presence of a third toxin (binary toxin), and by high-level resistance to 
fluoroquinolones.
Clinical Manifestations 
Most commonly, pts develop diarrhea, with stools that are not grossly 
bloody and are soft to watery, with a characteristic odor. Pts may have up 
to 20 bowel movements per day. Fever, abdominal pain, and leukocytosis 
are common.
• Constipation due to an adynamic ileus can occur. Unexplained leuko-
cytosis (≥15,000 WBCs/μL) in this setting should prompt evaluation for 
CDI. These pts are at high risk for complications such as toxic megacolon 
and sepsis.
• C. difficile diarrhea recurs after treatment in ~15–30% of cases.
Diagnosis
The diagnosis of CDI is made in a pt with diarrhea (≥3 unformed stools per 
24 h for ≥2 days) by detection of the organism, toxin A, or toxin B in stool 
or identification of pseudomembranes in the colon. 
• Most laboratory tests for toxin lack sensitivity, but repeat testing is not 
recommended.
• Testing of asymptomatic pts (including a test of cure for those who have 
completed therapy) is not recommended.
C. difﬁ cile Infection
TREATMENT
• Primary CDI: When feasible, discontinuation of ongoing antimi-
crobial treatment is an effective cure in 15–23% of cases. Prompt 
initiation of specific therapy is recommended.
– For mild to moderate disease, metronidazole (500 mg tid for 10 
days) is recommended, with extension of therapy if the clinical 
response is slow.
– For severe disease (e.g., >15,000 WBCs/μL, serum creatinine lev-
els ≥1.5 times baseline), vancomycin (125 mg qid PO for 10–14 d) 
is the agent of choice.
• Recurrent CDI: The first recurrence should be treated the same as 
the initial episode. 
– For the second recurrence, an extended, tapered vancomycin 
regimen (125 mg qid for 10–14 d, then bid for 1 week, then daily 
for 1 week, then q2–3d for 2–8 weeks) should be used.
– For multiple recurrences, there is no standard treatment course. 
Consider repetition of the tapered vancomycin regimen, 
administration of vancomycin (500 mg qid for 10 days) with 
Saccharomyces boulardii (500 mg bid for 28 d), administration 
of sequential therapy with vancomycin (125 mg qid for 10–14 d)
CHAPTER 92
551
Sexually Transmitted Infections
 
followed by rifaximin (400 mg bid for 2 weeks), treatment with 
nitazoxanide (500 mg bid for 10 d), fecal transplantation, or treat-
ment with IV immunoglobulin (400 mg/kg).
• Fulminant CDI: Medical management is complicated by ineffective 
delivery of oral antibiotics to the intestinal lumen in the setting 
of ileus. Vancomycin (given via nasogastric tube and by retention 
enema) combined with IV metronidazole has been used with some 
success, as has IV tigecycline. Surgical colectomy can be life-saving. 
For a more detailed discussion, see LaRocque RC, Ryan 
ET, Calderwood SB: Acute Infectious Diarrheal Diseases 
and Bacterial Food Poisoning, Chap. 128, p. 1084; Gerding 
DN, Johnson S: Clostridium difficile Infection, Including 
Pseudomembranous Colitis, Chap. 129, p. 1091; Russo 
TA, Johnson JR: Diseases Caused by Gram-Negative 
Enteric Bacilli, Chap. 149, p. 1246; Pegues DA, Miller SI: 
Salmonellosis, Chap. 153, p. 1274; Sansonetti P, Bergounioux 
J: Shigellosis, Chap. 154, p. 1281; Blaser MJ: Infections 
Due to Campylobacter and Related Organisms, Chap. 155, 
p. 1286; Waldor MK, Ryan ET: Cholera and Other Vibrioses, 
Chap. 156, p. 1289; Prentice MB: Plague and Other Yersinia
Infections, Chap. 159, p. 1305; Parashar UD, Glass RI: 
Viral Gastroenteritis, Chap. 190, p. 1588; Stanley SL Jr: 
Amebiasis and Infection With Free-Living Amebas, Chap. 209, 
p. 1683; and Weller PF: Protozoal Intestinal Infections and 
Trichomoniasis, Chap. 215, p. 1729, in HPIM-18.
CHAPTER 92
Sexually Transmitted and 
Reproductive Tract Infections
GENERAL PRINCIPLES
• Worldwide, most adults acquire at least one sexually transmitted infec-
tion (STI).
• Three factors determine the initial rate of spread of any STI within a popu-
lation: rate of sexual exposure of susceptible to infectious people, efficiency 
of transmission per exposure, and duration of infectivity of those infected.
• STI care and management begin with risk assessment and proceed to clini-
cal assessment, diagnostic testing or screening, syndrome-based treatment 
to cover the most likely causes, and prevention and control. The “4 C’s” 
of control are contact tracing, ensuring compliance with treatment, and 
counseling on risk reduction, including condom promotion and provision.
SECTION 7
552
Infectious Diseases
SPECIFIC SYNDROMES
� URETHRITIS IN MEN
Microbiology and Epidemiology 
Most cases are caused by either Neisseria gonorrhoeae or Chlamydia trachomatis. 
Other causative organisms include Mycoplasma genitalium, Ureaplasma 
urealyticum, Trichomonas vaginalis, and herpes simplex virus (HSV). Chlamydia 
causes 30–40% of nongonococcal urethritis (NGU) cases. M. genitalium is the 
probable cause in many Chlamydia-negative cases of NGU.
Clinical Manifestations 
Urethritis in men produces urethral discharge, dysuria, or both, usually 
without frequency of urination. 
Diagnosis
Pts present with a mucopurulent urethral discharge that can usually be 
expressed by milking of the urethra; alternatively, a Gram’s-stained smear of 
urethral exudates containing ≥5 PMNs/1000× field confirms the diagnosis.
• Centrifuged sediment of the day’s first 20–30 mL of voided urine can be 
examined instead.
• N. gonorrhoeae can be presumptively identified if intracellular gram-
negative diplococci are present in Gram’s-stained samples. 
• Early-morning, first-voided urine should be used in “multiplex” nucleic 
acid amplification tests (NAATs) for N. gonorrhoeae and C. trachomatis.
Urethritis in Men
TREATMENT
• Treat urethritis promptly, while test results are pending.
– Unless these diseases have been excluded, treat gonorrhea with a 
single dose of ceftriaxone (250 mg IM), cefpodoxime (400 mg PO), 
or cefixime (400 mg PO) and treat Chlamydia with azithromycin 
(1 g PO once) or doxycycline (100 mg bid for 7 days); azithromycin 
may be more effective for M. genitalium.
– Sexual partners of the index case should receive the same treatment.
• For recurrent symptoms: With re-exposure, re-treat pt and partner. 
Without re-exposure, consider infection with T. vaginalis (with culture 
or NAATs of urethral swab and early-morning, first-voided urine) or 
doxycycline-resistant M. genitalium or Ureaplasma. Consider treatment 
with metronidazole, azithromycin (1 g PO once), or both.
� EPIDIDYMITIS
Microbiology 
In sexually active men <35 years old, epididymitis is caused by C. trachomatis 
and, less commonly, by N. gonorrhoeae.
• In older men or after urinary tract instrumentation, urinary pathogens 
are most common.
• In men who practice insertive rectal intercourse, Enterobacteriaceae may 
be responsible.
CHAPTER 92
553
Clinical Manifestations 
Acute epididymitis—almost always unilateral—produces pain, swelling, and 
tenderness of the epididymis, with or without symptoms or signs of urethritis. 
Epididymitis must be differentiated from testicular torsion, tumor, and 
trauma. If symptoms persist after treatment, a testicular tumor or a chronic 
granulomatous disease (e.g., tuberculosis) should be considered.
Epididymitis
TREATMENT
• Ceftriaxone (250 mg IM once) followed by doxycycline (100 mg PO 
bid for 10 days) is effective for epididymitis due to C. trachomatis 
and N. gonorrhoeae. 
• Fluoroquinolones are no longer recommended because of increas-
ing resistance in N. gonorrhoeae.
� URETHRITIS (THE URETHRAL SYNDROME) IN WOMEN
Microbiology and Clinical Manifestations 
C. trachomatis, N. gonorrhoeae, and occasionally HSV cause symptomatic 
urethritis—known as the urethral syndrome in women—that is character-
ized by “internal” dysuria (usually without urinary urgency or frequency), 
pyuria, and an absence of Escherichia coli and other uropathogens at counts 
of ≥102/mL in urine.
Diagnosis
Evaluate for infection with N. gonorrhoeae or C. trachomatis with specific 
tests (e.g., NAATs on the first 10 mL of voided morning urine).
Urethritis (the Urethral Syndrome) in Women 
TREATMENT
See “Urethritis in Men,” above.
� VULVOVAGINAL INFECTIONS
Microbiology 
A variety of organisms are associated with vulvovaginal infections, including 
N. gonorrhoeae and C. trachomatis (particularly when they cause cervicitis), 
T. vaginalis, Candida albicans, Gardnerella vaginalis, and HSV.
Clinical Manifestations 
Vulvovaginal infections encompass a wide array of specific conditions, each 
of which has different presenting symptoms.
• Unsolicited reporting of abnormal vaginal discharge suggests trichomo-
niasis or bacterial vaginosis (BV).
– Trichomoniasis is characterized by vulvar irritation and a profuse 
white or yellow, homogeneous vaginal discharge with a pH that is 
typically ≥5.
– BV is characterized by vaginal malodor and a slight to moderate increase 
in white or gray, homogeneous vaginal discharge that uniformly coats 
the vaginal walls and typically has a pH >4.5. 
Sexually Transmitted Infections
SECTION 7
554
Infectious Diseases
– Vaginal trichomoniasis and BV early in pregnancy are associated with 
premature onset of labor.
• Vulvar conditions such as genital herpes or vulvovaginal candidiasis can 
cause vulvar pruritus, burning, irritation, or lesions as well as external 
dysuria (as urine passes over the inflamed vulva or areas of epithelial 
disruption) or vulvar dyspareunia.
Diagnosis
Evaluation of vulvovaginal symptoms includes a pelvic examination (with a 
speculum examination) and simple rapid diagnostic tests.
• Examine abnormal vaginal discharge for pH, a fishy odor after mixing 
with 10% KOH (BV), evidence on microscopy of motile trichomonads 
and/or clue cells of BV (vaginal epithelial cells coated with coccobacil-
lary organisms) when mixed with saline, or hyphae or pseudohyphae on 
microscopy when 10% KOH is added (vaginal candidiasis).
• A DNA probe test (the Affirm test) can detect T. vaginalis, C. albicans, 
and increased concentrations of G. vaginalis.
Vulvovaginal Infections
TREATMENT
• Vulvovaginal candidiasis: Miconazole (a single 1200-mg vaginal sup-
pository), clotrimazole (two 100-mg vaginal tablets daily for 3 days), 
or fluconazole (150 mg PO once) are all effective.
• Trichomoniasis: Metronidazole (2 g PO once) or tinidazole is effec-
tive. Treatment of sexual partners with the same regimen is the 
standard of care.
• BV: Metronidazole (500 mg PO bid for 7 days) or 2% clindamycin 
cream (one full applicator vaginally each night for 7 days) is effec-
tive, but recurrence is common with both.
� MUCOPURULENT CERVICITIS
Microbiology 
N. gonorrhoeae, C. trachomatis, and M. genitalium are the primary causative 
agents. Of note, NAATs for these pathogens, HSV, and T. vaginalis have 
been negative in nearly half of cases.
Clinical Manifestations 
Mucopurulent cervicitis represents the “silent partner” of urethritis in men 
and results from inflammation of the columnar epithelium and subepithe-
lium of the endocervix.
Diagnosis
Yellow mucopurulent discharge from the cervical os, with ≥20 PMNs/1000× 
field on Gram’s stain of cervical mucus, indicates endocervicitis. The presence 
of intracellular gram-negative diplococci on Gram’s stain of cervical mucus 
is specific but <50% sensitive for gonorrhea; thus NAATs for N. gonorrhoeae 
and C. trachomatis are always indicated.
CHAPTER 92
555
Mucopurulent Cervicitis
TREATMENT
See “Urethritis in Men,” above.
� PELVIC INFLAMMATORY DISEASE (PID)
Microbiology 
The agents most often implicated in acute PID—infection that ascends from 
the cervix or vagina to the endometrium and/or fallopian tubes—include the 
primary causes of endocervicitis (e.g., N. gonorrhoeae and C. trachomatis); 
other organisms (e.g., M. genitalium, Prevotella spp., peptostreptococci, 
E. coli, Haemophilus influenzae, and group B streptococci) account for 
25–33% of cases.
Epidemiology 
In 2008, there were 104,000 visits to physicians’ offices for PID in the 
United States; there are ~70,000–100,000 hospitalizations related to PID 
annually.
• Risk factors for PID include cervicitis, BV, a history of salpingitis or 
recent vaginal douching, menstruation, and recent insertion of an intra-
uterine contraceptive device (IUD). 
• Oral contraceptive pills decrease risk.
Clinical Manifestations 
The presenting symptoms depend on the extent to which the infection has 
spread.
• Endometritis: Pts present with midline abdominal pain and abnor-
mal vaginal bleeding. Lower quadrant, adnexal, or cervical motion or 
abdominal rebound tenderness is less severe in women with endometri-
tis alone than in women who also have salpingitis.
• Salpingitis: Symptoms evolve from mucopurulent cervicitis to endome-
tritis and then to bilateral lower abdominal and pelvic pain caused by 
salpingitis. Nausea, vomiting, and increased abdominal tenderness may 
occur if peritonitis develops. 
• Perihepatitis (Fitz-Hugh–Curtis syndrome): 3–10% of women present 
with pleuritic upper abdominal pain and tenderness in the right upper 
quadrant due to perihepatic inflammation. Most cases are due to chla-
mydial salpingitis.
• Periappendicitis: ~5% of pts can have appendiceal serositis without 
involvement of the intestinal mucosa as a result of gonococcal or chla-
mydial salpingitis.
Diagnosis
Speculum examination shows evidence of mucopurulent cervicitis in the 
majority of pts with gonococcal or chlamydial PID; cervical motion tender-
ness, uterine fundal tenderness, and/or abnormal adnexal tenderness also 
are usually present. Endocervical swab specimens should be examined by 
NAATs for N. gonorrhoeae and C. trachomatis.
Sexually Transmitted Infections
SECTION 7
556
Infectious Diseases
Pelvic Inﬂ ammatory Disease
TREATMENT
• Empirical treatment for PID should be initiated in sexually active 
young women and in other women who are at risk for PID and who 
have pelvic or lower abdominal pain with no other explanation as 
well as cervical motion, uterine, or adnexal tenderness.
• Hospitalization should be considered when (1) the diagnosis is 
uncertain and surgical emergencies cannot be excluded, (2) the pt 
is pregnant, (3) pelvic abscess is suspected, (4) severe illness pre-
cludes outpatient management, (5) the pt has HIV infection, (6) the 
pt is unable to follow or tolerate an outpatient regimen, or (7) the pt 
has failed to respond to outpatient therapy.
• Outpatient regimen: Ceftriaxone (250 mg IM once) plus doxycycline 
(100 mg PO bid for 14 days) plus metronidazole (500 mg PO bid for 
14 days) is effective. Women treated as outpatients should be clini-
cally reevaluated within 72 h.
• Parenteral regimens: Parenteral treatment with regimens listed 
below should be given for ≥48 h after clinical improvement. A 
14-day course should be completed with doxycycline (100 mg PO 
bid); if the clindamycin-containing regimen is used, oral therapy 
can be given with clindamycin (450 mg PO qid).
– Cefotetan (2 g IV q12h) or cefoxitin (2 g IV q6h) plus doxycycline 
(100 mg IV/PO q12h)
– Clindamycin (900 mg IV q8h) plus gentamicin (loading dose of 
2.0 mg/kg IV/IM followed by 1.5 mg/kg q8h)
• Male sex partners should be evaluated and treated empirically for 
gonorrhea and chlamydial infection.
Prognosis
Late sequelae include infertility (11% after one episode of PID, 23% after 
two, and 54% after three or more); ectopic pregnancy (sevenfold increase in 
risk); chronic pelvic pain; and recurrent salpingitis.
� ULCERATIVE GENITAL LESIONS
The most common etiologies in the United States are genital herpes, syphi-
lis, and chancroid. See Table 92-1 and sections on individual pathogens 
below for specific clinical manifestations. Pts with persistent genital ulcers 
that do not resolve with syndrome-based antimicrobial therapy should have 
their HIV serologic status assessed if such testing has not previously been 
performed. Immediate treatment (before all test results are available) is 
often appropriate to improve response, reduce transmission, and cover pts 
who might not return for follow-up visits.
� PROCTITIS, PROCTOCOLITIS, ENTEROCOLITIS, AND ENTERITIS
Microbiology and Epidemiology 
Acquisition of HSV, N. gonorrhoeae, or C. trachomatis [including lympho-
granuloma venereum (LGV) strains of C. trachomatis] during receptive 
TABLE 92-1  CLINICAL FEATURES OF GENITAL ULCERS
Feature
Syphilis
Herpes
Chancroid
Lymphogranuloma 
Venereum
Donovanosis
Incubation period
9–90 days
2–7 days
1–14 days
3 days–6 weeks
1–4 weeks 
(up to 6 months)
Early primary lesions
Papule
Vesicle
Pustule
Papule, pustule, or 
vesicle
Papule
No. of lesions
Usually one
Multiple
Usually multiple, may 
coalesce
Usually one; often 
not detected, despite 
lymphadenopathy
Variable
Diameter
5–15 mm
1–2 mm
Variable
2–10 mm
Variable
Edges
Sharply demarcated, 
elevated, round, or oval
Erythematous
Undermined, ragged, 
irregular
Elevated, round, or 
oval
Elevated, irregular
Depth
Superficial or deep
Superficial
Excavated
Superficial or deep
Elevated
Base
Smooth, nonpurulent, 
relatively nonvascular
Serous, erythematous, 
nonvascular
Purulent, bleeds easily
Variable, nonvascular
Red and velvety, 
bleeds readily
Induration
Firm
None
Soft
Occasionally firm
Firm
Pain
Uncommon
Frequently tender
Usually very tender
Variable
Uncommon
Lymphadenopathy
Firm, nontender, bilateral
Firm, tender, often 
bilateral with initial 
episode
Tender, may suppurate, 
loculated, usually 
unilateral
Tender, may 
suppurate, loculated, 
usually unilateral
None; pseudobuboes
Source: From RM Ballard, in KK Holmes et al (eds): Sexually Transmitted Diseases, 4th ed. New York, McGraw-Hill, 2008.
557
SECTION 7
558
Infectious Diseases
anorectal intercourse causes most cases of infectious proctitis in women 
and in men who have sex with men (MSM). Sexually acquired proctocolitis 
is most often due to Campylobacter or Shigella species. In MSM without 
HIV infection, enteritis is often attributable to Giardia lamblia.
Clinical Manifestations 
Anorectal pain and mucopurulent, bloody rectal discharge suggest proctitis 
or proctocolitis. Proctitis is more likely to cause tenesmus and constipation, 
but proctocolitis and enteritis more often cause diarrhea.
• HSV proctitis and LGV proctocolitis can cause severe pain, fever, and 
systemic manifestations. 
• Sacral nerve root radiculopathy, with urinary retention or anal 
sphincter dysfunction, is associated with primary HSV infection.
Diagnosis
Pts should undergo anoscopy to examine the rectal mucosa and exudates 
and to obtain specimens for diagnosis.
Proctitis, Proctocolitis, Enterocolitis, Enteritis
TREATMENT
• Pending test results, pts should receive empirical treatment for gon-
orrhea and chlamydial infection with ceftriaxone (125 mg IM once) 
followed by doxycycline (100 mg bid for 7 days); therapy for syphilis 
or herpes should be given as indicated.
INDIVIDUAL PATHOGENS
� GONORRHEA
Microbiology 
N. gonorrhoeae, the causative agent of gonorrhea, is a gram-negative, nonmotile, 
non-spore-forming organism that grows singly and in pairs (i.e., as diplococci).
Epidemiology 
The ~299,000 cases reported in the United States in 2008 probably repre-
sent only half the true number of cases because of underreporting, self-
treatment, and nonspecific treatment without a laboratory diagnosis.
• 40% of reported cases in the U.S. occur in 15- to 19-year-old women and 
20- to 24-year-old men.
• Gonorrhea is transmitted from males to females more efficiently than in 
the opposite direction, with 40–60% of women acquiring gonorrhea dur-
ing a single unprotected sexual encounter with an infected man. Roughly 
two-thirds of all infected men are asymptomatic.
• Drug-resistant strains are widespread. Penicillin, ampicillin, and tetracy-
cline are no longer reliable therapeutic agents, and fluoroquinolones are 
no longer routinely recommended. 
Clinical Manifestations 
Except in disseminated disease, the sites of infection typically reflect areas 
involved in sexual contact. 
CHAPTER 92
559
• Urethritis and cervicitis have an incubation period of 2–7 days and ~10 days, 
respectively. See above for details. 
• Anorectal gonorrhea can cause acute proctitis in women (due to the 
spread of cervical exudate to the rectum) and MSM.
• Pharyngeal gonorrhea is usually mild or asymptomatic and results from 
oral-genital sexual exposure (typically fellatio). Pharyngeal infection 
almost always coexists with genital infection, resolves spontaneously, and 
is rarely transmitted to sexual contacts.
• Ocular gonorrhea is typically caused by autoinoculation and presents 
with a markedly swollen eyelid, hyperemia, chemosis, and profuse puru-
lent discharge.
• Gonorrhea in pregnancy can have serious consequences for both the 
mother and the infant. 
– Salpingitis and PID are associated with fetal loss. 
– Third-trimester disease can cause prolonged rupture of membranes, 
premature delivery, chorioamnionitis, funisitis, and neonatal sepsis.
– Ophthalmia neonatorum, the most common form of gonorrhea 
among neonates, is preventable by prophylactic ophthalmic ointments 
(e.g., containing erythromycin or tetracycline), but treatment requires 
systemic antibiotics.
• Gonococcal arthritis results from dissemination of organisms due to 
gonococcal bacteremia. Pts present during a bacteremic phase (relatively 
uncommon) or with suppurative arthritis involving one or two joints 
(most commonly the knees, wrists, ankles, and elbows), with tenosynovitis 
and skin lesions. Menstruation and complement deficiencies of the mem-
brane attack complex (C5–C9) are risk factors for disseminated disease.
Diagnosis
NAATs, culture, and microscopic examination (for intracellular diplococci) 
of urogenital samples are used to diagnose gonorrhea. A single culture of 
endocervical discharge has a sensitivity of 80–90%.
Gonorrhea
TREATMENT
See Table 92-2.
� INFECTIONS WITH CHLAMYDIA TRACHOMATIS
Microbiology 
C. trachomatis organisms are obligate intracellular bacteria that are divided 
into two biovars: trachoma and LGV. The trachoma biovar causes ocular 
trachoma and urogenital infections; the LGV biovar causes lymphogranu-
loma venereum.
Epidemiology 
The WHO estimates that >89 million cases of C. trachomatis infection occur 
annually worldwide. The estimated 2–3 million cases per year that occur in 
the U.S. make C. trachomatis infection the most commonly reported infectious 
disease in this country.
Sexually Transmitted Infections
SECTION 7
560
Infectious Diseases
TABLE 92-2  RECOMMENDED TREATMENT FOR GONOCOCCAL INFECTIONS: 
2010 GUIDELINES OF THE CENTERS FOR DISEASE CONTROL 
AND PREVENTION
Diagnosis
Treatment of Choicea
Uncomplicated gonococcal infection 
of the cervix, urethra, pharynxb, or 
rectum
 First-line regimens
Ceftriaxone (250 mg IM, single dose)
or
Cefixime (400 mg PO, single dose)
plus
Treatment for Chlamydia if chlamydial 
infection is not ruled out:
Azithromycin (1 g PO, single dose)
or
Doxycycline (100 mg PO bid for 7 days)
 Alternative regimens
Ceftizoxime (500 mg IM, single dose)
or
Cefotaxime (500 mg IM, single dose)
or
Spectinomycin (2 g IM, single dose)c,d
or
Cefotetan (1 g IM, single dose) plus 
probenecid (1 g PO, single dose)c
or
Cefoxitin (2 g IM, single dose) plus 
probenecid (1 g PO, single dose)c
Epididymitis
See text and Chap. 130, HPIM-18
Pelvic inflammatory disease
See text and Chap. 130, HPIM-18
Gonococcal conjunctivitis in an adult Ceftriaxone (1 g IM, single dose)e
Ophthalmia neonatorumf
Ceftriaxone (25–50 mg/kg IV, single 
dose, not to exceed 125 mg)
Disseminated gonococcal infectiong
 Initial therapyh
  Pt tolerant of β-lactam drugs
Ceftriaxone (1 g IM or IV q24h; 
recommended)
or
Cefotaxime (1 g IV q8h)
or
Ceftizoxime (1 g IV q8h)
CHAPTER 92
561
TABLE 92-2  RECOMMENDED TREATMENT FOR GONOCOCCAL INFECTIONS: 
2010 GUIDELINES OF THE CENTERS FOR DISEASE CONTROL 
AND PREVENTION (CONTINUED)
Diagnosis
Treatment of Choicea
  Pts allergic to β-lactam drugs
Spectinomycin (2 g IM q12h)d
 Continuation therapy
Cefixime (400 mg PO bid)
Meningitis or endocarditis
Ceftriaxone (1–2 g IV q12h)i
aTrue failure of treatment with a recommended regimen is rare and should prompt an evalua-
tion for reinfection or consideration of an alternative diagnosis.
bCeftriaxone is the only agent recommended for treatment of pharyngeal infection.
cSpectinomycin, cefotetan, and cefoxitin, which are alternative agents, currently are unavailable 
or in short supply in the United States.
dSpectinomycin may be ineffective for the treatment of pharyngeal gonorrhea.
ePlus lavage of the infected eye with saline solution (once).
fProphylactic regimens are discussed in the text.
gHospitalization is indicated if the diagnosis is uncertain, if the pt has frank arthritis with an 
effusion, or if the pt cannot be relied on to adhere to treatment.
hAll initial regimens should be continued for 24–48 h after clinical improvement begins, at 
which time the switch may be made to one of the continuation regimens to complete a full 
week of antimicrobial treatment. Treatment for chlamydial infection (as above) should be given 
if this infection has not been ruled out. Fluoroquinolones may be an option if antimicrobial 
susceptibility can be documented by culture of the causative organism.
iHospitalization is indicated to exclude suspected meningitis or endocarditis. Treatment should 
be given in the hospital. The durations are 10–14 days for meningitis and at least 4 weeks for 
endocarditis.
Clinical Manifestations 
80–90% of women and >50% of men with C. trachomatis genital infections 
lack symptoms; other pts have very mild symptoms. 
• Urethritis, epididymitis, cervicitis, salpingitis, PID, and proctitis are all 
discussed above.
• Reactive arthritis (conjunctivitis, urethritis or cervicitis, arthritis, and 
mucocutaneous lesions) occurs in 1–2% of NGU cases, many of which are 
due to C. trachomatis. More than 80% of pts have the HLA-B27 phenotype.
• LGV is an invasive, systemic STI that—in heterosexual individuals—
presents most commonly as painful inguinal lymphadenopathy begin-
ning 2–6 weeks after presumed exposure. Progressive periadenitis results 
in fluctuant, suppurative nodes with development of multiple draining 
fistulas. Spontaneous resolution occurs after several months. See Table 92-1 
for additional clinical details.
Diagnosis
NAATs of urine or urogenital swabs are the diagnostic tests of choice. 
Serologic testing may be helpful in the diagnosis of LGV and neonatal 
pneumonia caused by C. trachomatis, but it is not useful in diagnosing 
uncomplicated urogenital infections. 
Sexually Transmitted Infections
SECTION 7
562
Infectious Diseases
Infections with Chlamydia trachomatis
TREATMENT
• See “Specific Syndromes,” above.
• LGV should be treated with doxycycline (100 mg PO bid) or eryth-
romycin base (500 mg PO qid) for at least 3 weeks.
� INFECTIONS DUE TO MYCOPLASMAS
Microbiology and Epidemiology 
Mycoplasmas are the smallest free-living organisms known and lack a cell 
wall. M. hominis, M. genitalium, Ureaplasma parvum, and U. urealyticum 
cause urogenital tract disease. These organisms are commonly present in 
the vagina of asymptomatic women.
Clinical Manifestations 
Ureaplasmas are a common cause of Chlamydia-negative NGU. M. hominis 
and M. genitalium are associated with PID; M. hominis is implicated in 
5–10% of cases of postpartum or postabortal fever.
Diagnosis
PCR is most commonly used for detection of urogenital mycoplasmas; 
culture is possible but can be done primarily at reference laboratories. 
Serologic testing is not helpful.
Infections Due to Mycoplasmas
TREATMENT
Recommendations for treatment of NGU and PID listed above are 
appropriate for genital mycoplasmas.
� SYPHILIS
Microbiology and Epidemiology 
Treponema pallidum subspecies pallidum—the cause of syphilis—is a thin 
spiral organism with a cell body surrounded by a trilaminar cytoplasmic 
membrane. Humans are the only natural host, and the organism cannot be 
cultured in vitro.
• Cases are acquired by sexual contact with infectious lesions (chancre, 
mucous patch, skin rash, condyloma latum); nonsexual acquisition 
through close personal contact, infection in utero, blood transfusion, and 
organ transplantation is less common.
• There are ~12 million new infections per year worldwide. 
– In the United States, 31,575 cases were reported in 2000. 
– The reported cases of primary and secondary syphilis combined 
(which better indicate disease activity) increased from <6000 in 2000 
to 13,500 in 2008, primarily affecting MSM, many of whom were co-
infected with HIV.
• One-third to one-half of sexual contacts of persons with infectious syphi-
lis become infected—a figure that underscores the importance of treating 
all recently exposed sexual contacts.
CHAPTER 92
563
Pathogenesis 
T. pallidum penetrates intact mucous membranes or microscopic abrasions 
and, within hours, enters lymphatics and blood to produce systemic infection 
and metastatic foci. The primary lesion (chancre) appears at the site of inocu-
lation within 4–6 weeks and heals spontaneously. Generalized parenchymal, 
constitutional, and mucocutaneous manifestations of secondary syphilis 
appear 6–8 weeks later despite high antibody titers, subsiding in 2–6 weeks. 
After a latent period, one-third of untreated pts eventually develop tertiary 
disease (syphilitic gummas, cardiovascular disease, neurologic disease).
Clinical Manifestations 
Syphilis progresses through three phases with distinct clinical presentations.
• Primary syphilis: A chancre at the site of inoculation (penis, rectum or 
anal canal, mouth, cervix, labia) is characteristic but often goes unno-
ticed. See Table 92-1 for clinical details. Regional adenopathy can persist 
long after the chancre heals. 
• Secondary syphilis: The protean manifestations of the secondary stage 
usually include mucocutaneous lesions and generalized nontender 
lymphadenopathy.
– Skin lesions can be subtle but are often pale red or pink, nonpruritic 
macules that are widely distributed over the trunk and extremities, 
including the palms and soles.
– In moist intertriginous areas, papules can enlarge and erode to pro-
duce broad, highly infectious lesions called condylomata lata.
– Superficial mucosal erosions (mucous patches) and constitutional 
symptoms (e.g., sore throat, fever, malaise) can occur.
– Less common findings include hepatitis, nephropathy, arthritis, and 
ocular findings (e.g., optic neuritis, anterior uveitis, iritis).
• Latent syphilis: Pts without clinical manifestations but with positive 
syphilis serology have latent disease. Early latent syphilis is limited to the 
first year after infection, whereas late latent syphilis is defined as that of 
≥1 year’s (or unknown) duration.
• Tertiary syphilis: The classic forms of tertiary syphilis include neuro-
syphilis, cardiovascular syphilis, and gummas.
– Neurosyphilis represents a continuum, with asymptomatic disease 
occurring early after infection, potentially progressing to general 
paresis and tabes dorsalis. Symptomatic disease has three main pre-
sentations, all of which are now rare (except in pts with advanced HIV 
infection). Meningeal syphilis presents as headache, nausea, vomiting, 
neck stiffness, cranial nerve involvement, seizures, and changes in 
mental status within 1 year of infection. Meningovascular syphilis 
presents up to 10 years after infection as a subacute encephalitic 
prodrome followed by a gradually progressive vascular syndrome. 
Parenchymatous involvement presents at 20 years for general paresis 
and 25–30 years for tabes dorsalis. A general mnemonic for paresis 
is personality, affect, reflexes (hyperactive), eye (Argyll Robertson 
pupils, which react to accommodation but not to light), sensorium 
(illusions, delusions, hallucinations), intellect (decrease in recent 
Sexually Transmitted Infections
SECTION 7
564
Infectious Diseases
memory and orientation, judgment, calculations, insight), and speech. 
Tabes dorsalis is a demyelination of posterior columns, dorsal roots, 
and dorsal root ganglia, with ataxic, wide-based gait and footslap; 
paresthesia; bladder disturbances; impotence; areflexia; and loss of 
position, deep pain, and temperature sensations.
– Cardiovascular syphilis develops in ~10% of untreated pts 10–40 years 
after infection. Endarteritis obliterans of the vasa vasorum providing 
the blood supply to large vessels results in aortitis, aortic regurgitation, 
saccular aneurysm, and coronary ostial stenosis.
– Gummas are usually solitary lesions showing granulomatous inflam-
mation with central necrosis. Common sites include the skin and skel-
etal system; however, any organ (including the brain) may be involved.
• Congenital syphilis: Syphilis can be transmitted throughout pregnancy, 
but fetal disease does not become manifest until after the fourth month 
of gestation. All pregnant women should be tested for syphilis early in 
pregnancy.
Diagnosis
Serologic tests—both nontreponemal and treponemal—are the main-
stays of diagnosis; changes in antibody titers can also be used to monitor 
response to therapy.
• Nontreponemal serologic tests that measure IgG and IgM antibodies to 
a cardiolipin-lecithin-cholesterol antigen complex [e.g., rapid plasma 
reagin (RPR), Venereal Disease Research Laboratory (VDRL)] are rec-
ommended for screening or for quantitation of serum antibody. After 
therapy for early syphilis, a persistent fall in titer by ≥4-fold is considered 
an adequate response.
• Treponemal tests, including the agglutination assay (e.g., the Serodia 
TP-PA test) and the fluorescent treponemal antibody–absorbed (FTA-
ABS) test, are used to confirm results from nontreponemal tests. Results 
remain positive even after successful treatment.
• Lumbar puncture (LP) is recommended for pts with syphilis and neuro-
logic signs or symptoms, an RPR or VDRL titer ≥1:32, or suspected treat-
ment failure and for HIV-infected pts with a CD4+ T cell count <350/μL.
– CSF exam demonstrates pleocytosis (>5 WBCs/μL) and increased 
protein levels (>45 mg/dL). A positive CSF VDRL test is specific but 
not sensitive; an unabsorbed FTA test is sensitive but not specific. A 
negative unabsorbed FTA test excludes neurosyphilis.
• Pts with syphilis should be evaluated for HIV disease.
Syphilis
TREATMENT
• See Table 92-3 for treatment recommendations.
• The Jarisch-Herxheimer reaction is a dramatic reaction to treatment 
that is most common with initiation of therapy for primary (~50% 
of pts) or secondary (~90%) syphilis. The reaction is associated 
with fever, chills, myalgias, tachycardia, headache, tachypnea, and 
vasodilation. Symptoms subside within 12–24 h without treatment.
CHAPTER 92
565
TABLE 92-3  RECOMMENDATIONS FOR THE TREATMENT OF SYPHILISa
Stage of Syphilis
Patients without 
Penicillin Allergy
Patients with Confirmed 
Penicillin Allergyb
Primary, secondary, 
or early latent
CSF normal or not 
examined: Penicillin 
G benzathine (single 
dose of 2.4 mU IM)
CSF normal or not 
examined: Tetracycline 
HCl (500 mg PO qid) or 
doxycycline (100 mg PO 
bid) for 2 weeks
CSF abnormal: Treat as 
neurosyphilis
CSF abnormal: Treat as 
neurosyphilis
Late latent (or latent 
of uncertain dura-
tion), cardiovascular, 
or benign tertiary
CSF normal or not 
examined: Penicillin 
G benzathine 
(2.4 mU IM weekly for 
3 weeks)
CSF normal and pt 
not infected with HIV:
Tetracycline HCl 
(500 mg PO qid) or 
doxycycline (100 mg 
PO bid) for 4 weeks
CSF normal and pt 
infected with HIV:
Desensitization and 
treatment with penicillin 
if compliance cannot be 
ensured
CSF abnormal: Treat as 
neurosyphilis
CSF abnormal: Treat as 
neurosyphilis
Neurosyphilis
(asymptomatic or 
symptomatic)
Aqueous crystalline peni-
cillin G (18–24 mU/d IV, 
given as 3–4 mU q4h or 
continuous infusion) for 
10–14 days
Desensitization and 
treatment with penicillinc
or
Aqueous procaine penicillin 
G (2.4 mU/d IM) plus oral 
probenecid (500 mg qid), 
both for 10–14 days
Syphilis in pregnancy According to stage
Desensitization and 
treatment with penicillin
aSee Table 169-1 in HPIM-18 and text for indications for CSF examination.
bBecause of documented macrolide resistance in many T. pallidum strains in North America, 
Europe, and China, azithromycin should be used with caution only when treatment with peni-
cillin or doxycycline is not feasible. Azithromycin should not be used for men who have sex 
with men or for pregnant women.
cLimited data suggest that ceftriaxone (2 g/d either IM or IV for 10–14 days) can be used; 
however, cross-reactivity between penicillin and ceftriaxone is possible.
Abbreviation: mU, million units.
Source: Based on the 2010 Sexually Transmitted Diseases Treatment Guidelines from the 
Centers for Disease Control and Prevention.
Sexually Transmitted Infections
SECTION 7
566
Infectious Diseases
• Response to treatment should be monitored by determination of 
RPR or VDRL titers at 6 and 12 months in primary and secondary 
syphilis and at 6, 12, and 24 months in tertiary or latent syphilis. 
– HIV-infected pts should undergo repeat serologic testing at 3, 6, 
9, 12, and 24 months, irrespective of the stage of syphilis.
– Re-treatment should be considered if serologic responses are not 
adequate (a persistent fall by ≥4-fold) or if clinical signs persist 
or recur. For these pts, CSF should be examined, with treatment 
for neurosyphilis if CSF is abnormal and treatment for late latent 
syphilis if CSF is normal.
– In treated neurosyphilis, CSF cell counts should be moni-
tored every 6 months until normal. In adequately treated HIV-
uninfected pts, an elevated CSF cell count falls to normal in 3–12 
months.
� HERPES SIMPLEX VIRUS INFECTIONS
Microbiology and Epidemiology 
HSV is a linear, double-strand DNA virus, with two subtypes (HSV-1 and 
HSV-2).
• Exposure to HSV at mucosal surfaces or abraded skin sites permits viral 
entry into cells of the epidermis and dermis, viral replication, entry into 
neuronal cells, and centrifugal spread throughout the body.
• More than 90% of adults have antibodies to HSV-1 by age 40; 15–20% of 
the U.S. population has antibodies to HSV-2.
• Unrecognized carriage of HSV-2 and frequent asymptomatic reactiva-
tions of virus from the genital tract foster the continued spread of HSV 
disease.
• Genital lesions caused by HSV-1 have lower recurrence rates in the first 
year (~55%) than those caused by HSV-2 (~90%).
Clinical Manifestations 
See Table 92-1 for clinical details. First episodes of genital herpes due 
to HSV-1 and HSV-2 present similarly and can be associated with fever, 
headache, malaise, and myalgias. More than 80% of women with primary 
genital herpes have cervical or urethral involvement. Local symptoms 
include pain, dysuria, vaginal and urethral discharge, and tender inguinal 
lymphadenopathy.
Diagnosis
Isolation of HSV in tissue culture or demonstration of HSV antigens or 
DNA in scrapings from lesions is the most accurate diagnostic method. 
PCR is increasingly being used for detection of HSV DNA and is more sen-
sitive than culture at mucosal sites. Staining of scrapings from the base of 
the lesion with Wright’s, Giemsa’s (Tzanck preparation), or Papanicolaou’s 
stain to detect giant cells or intranuclear inclusions is well described, but 
most clinicians are not skilled in these techniques, which furthermore do 
not differentiate between HSV and VZV.
CHAPTER 92
567
HSV Genital Infections
TREATMENT
• First episodes: Oral acyclovir (400 mg tid), valacyclovir (1 g bid), or 
famciclovir (250 mg bid) for 7–14 days is effective.
• Symptomatic recurrent episodes: Oral acyclovir (800 mg tid for 2 days), 
valacyclovir (500 mg bid for 3 days), or famciclovir (750 or 1000 mg 
bid for 1 day, 1500 mg once, or 500 mg stat followed by 250 mg q12h 
for 3 days) effectively shortens lesion duration.
• Suppression of recurrent episodes: Oral acyclovir (400–800 mg bid) 
or valacyclovir (500 mg qd) is given. Pts with >9 episodes per year 
should take valacyclovir (1 g qd or 500 mg bid) or famciclovir 
(250–500 mg bid). Daily valacyclovir appears to be more effective at 
reducing subclinical shedding than daily famciclovir. 
� CHANCROID (HAEMOPHILUS DUCREYI INFECTION)
H. ducreyi is the etiologic agent of chancroid, an STI characterized by genital 
ulceration and inguinal adenitis. H. ducreyi poses a significant health problem 
in developing countries because of its directly related morbidity and its role 
in increasing the efficiency of transmission of and degree of susceptibility to 
HIV infection. See Table 92-1 for clinical details. Culture of H. ducreyi from 
the lesion confirms the diagnosis; PCR is starting to become available.
Chancroid (Haemophilus ducreyi Infection)
TREATMENT
• Regimens recommended by the CDC include azithromycin (1 g PO 
once), ciprofloxacin (500 mg PO bid for 3 days), ceftriaxone (250 mg 
IM once), and erythromycin base (500 mg tid for 1 week).
• Sexual partners within 10 days preceding the pt’s onset of symptoms 
should be identified and treated, regardless of symptoms.
� DONOVANOSIS (KLEBSIELLA GRANULOMATIS INFECTION)
Microbiology and Epidemiology 
Also known as granuloma inguinale, donovanosis is caused by Klebsiella 
granulomatis. The infection is endemic in Papua New Guinea, parts of 
southern Africa, India, French Guyana, Brazil, and aboriginal communities 
in Australia; few cases are reported in the U.S.
Clinical Manifestations 
See Table 92-1 for clinical details. Four types of lesions have been described: 
(1) the classic ulcerogranulomatous lesion that bleeds readily when 
touched; (2) a hypertrophic or verrucous ulcer with a raised irregular edge; 
(3) a necrotic, offensive-smelling ulcer causing tissue destruction; and (4) 
a sclerotic or cicatricial lesion with fibrous and scar tissue. The genitals are 
affected in 90% of pts and the inguinal region in 10%. 
Diagnosis and Treatment 
Diagnosis is often based on identification of typical Donovan bodies 
(gram-negative intracytoplasmic cysts filled with deeply staining bodies 
Sexually Transmitted Infections
SECTION 7
568
Infectious Diseases
that may have a safety-pin appearance) within large mononuclear cells in 
smears from lesions or biopsy specimens. PCR is also available. Pts should 
be treated with azithromycin (1 g on day 1, then 500 mg qd for 7 days or 
1 g weekly for 4 weeks); alternative therapy consists of a 14-day course of 
doxycycline (100 mg bid), trimethoprim-sulfamethoxazole (960 mg bid), 
erythromycin (500 mg qid), or tetracycline (500 mg qid). If any of the 
14-day treatment regimens are chosen, the pts should be monitored until 
lesions have healed completely.
� HUMAN PAPILLOMAVIRUS (HPV) INFECTIONS
Microbiology 
Papillomaviruses are nonenveloped viruses with a double-strand circular DNA 
genome. More than 100 HPV types are recognized, and individual types are 
associated with specific clinical manifestations. For example, HPV types 16, 
18, 31, 33, and 45 have been most strongly associated with cervical cancers, 
and HPV types 6 and 11 cause anogenital warts (condylomata acuminata). 
Most infections, including those with oncogenic types, are self-limited.
Clinical Manifestations 
The clinical manifestations of HPV infection depend on the location of 
lesions and the type of virus. The incubation period is usually 3–4 months 
but can be as long as 2 years.
• Warts (including plantar warts) appear as flesh-colored to brown and 
exophytic, with hyperkeratotic papules. 
• Anogenital warts are commonly found on the penile shaft (in circumcised 
men), at the urethral meatus, and in the perianal region (in persons who 
practice receptive anal intercourse) and may involve the vagina and cervix.
Diagnosis
Most visible warts are diagnosed correctly by history and physical examina-
tion alone. Colposcopy is invaluable in assessing vaginal and cervical lesions, 
and 3–5% acetic acid solution applied to lesions may aid in the diagnosis.
• Papanicolaou smears from cervical or anal scrapings show cytologic 
evidence of HPV infection.
• Detection of HPV nucleic acids (e.g., PCR, hybrid-capture assay) is the 
most specific and sensitive method of detection.
Human Papillomavirus Infections
TREATMENT
• Many lesions resolve spontaneously. Current treatment is not com-
pletely effective, and some agents have significant side effects. 
– Provider-administered therapy can include cryotherapy, podo-
phyllin resin (10–25%) applied weekly for up to 4 weeks, trichloro-
acetic acid or bichloroacetic acid (80–90%) applied weekly, surgical 
excision, intralesionally administered interferon, or laser surgery. 
– Pt-administered therapy consists of podofilox (0.5% solution or 
gel applied bid for 3 days; this treatment can be repeated up to 4 
times with 4 days between treatment courses) or imiquimod (5% 
cream applied 3 times/week for up to 16 weeks).
CHAPTER 93
569
Infections of the Skin, Soft Tissues, Joints, Bone
Prevention
A quadrivalent vaccine (Gardasil, Merck) containing HPV types 6, 11, 16, 
and 18 and a bivalent vaccine (Cervarix, GlaxoSmithKline) containing HPV 
types 16 and 18 are available. Either vaccine is recommended for admin-
istration to girls and young women 9–26 years of age and may be used in 
males 9–26 years of age. 
• HPV types 6 and 11 cause 90% of anogenital warts, and HPV types 16 
and 18 cause 70% of cervical cancers. 
• Because 30% of cervical cancers are caused by HPV types not included 
in either  vaccine, no changes in clinical cancer-screening programs are 
currently recommended.
For a more detailed discussion, see Marrazzo JM, Holmes 
KK: Sexually Transmitted Infections: Overview and Clinical 
Approach, Chap. 130, p. 1095; Ram S, Rice PA: Gonococcal 
Infections, Chap. 144, p. 1220; Murphy TF: Haemophilus
and Moraxella Infections, Chap. 145, p. 1228; O’Farrell N: 
Donovanosis, Chap. 161, p. 1320; Lukehart SA: Syphilis, Chap. 
169, p. 1380; Hardy RD: Infections Due to Mycoplasmas, 
Chap. 175, p. 1417; Gaydos CA, Quinn TC: Chlamydial 
Infections, Chap. 176, p. 1421; Corey L: Herpes Simplex Virus 
Infections, Chap. 179, p. 1453; and Reichman RC: Human 
Papillomavirus Infections, Chap. 185, p. 1481, in HPIM-18.
CHAPTER 93
Infections of the Skin, 
Soft Tissues, Joints, and Bones
SKIN AND SOFT TISSUE INFECTIONS
Skin and soft tissue infections are diagnosed principally by a careful his-
tory (e.g., temporal progression, travel, animal exposure, bites, trauma, 
underlying medical conditions) and physical examination (appearance of 
lesions and distribution). Treatment of common skin infections is sum-
marized in Table 93-1; parenteral treatment is usually given until systemic 
signs and symptoms have improved. Types of skin lesions include the 
following:
1. Vesicles: due to proliferation of organisms, usually viruses, within the 
epidermis (e.g., VZV, HSV, coxsackievirus, poxviruses, Rickettsia akari) 
 2. Bullae: caused by toxin-producing organisms. Different entities affect 
different skin levels; for example, staphylococcal scalded-skin syndrome 
and toxic epidermal necrolysis cause cleavage of the stratum corneum 
and the stratum germinativum, respectively. Bullae are also seen in nec-
rotizing fasciitis, gas gangrene, and Vibrio vulnificus infections.
SECTION 7
570
Infectious Diseases
TABLE 93-1  TREATMENT OF COMMON INFECTIONS OF THE SKIN
Diagnosis/
Condition
Primary Treatment
Alternative 
Treatment
See Also 
HPIM-18
Chap(s).
Animal bite 
(prophylaxis or 
early infection)a
Amoxicillin/
clavulanate, 
875/125 mg 
PO bid
Doxycycline, 
100 mg PO bid
e24
Animal bitea
(established
infection)
Ampicillin/
sulbactam, 
1.5–3 g IV q6h
Clindamycin, 600–
900 mg IV q8h,
plus
Ciprofloxacin, 
400 mg IV q12h,
or
Cefoxitin, 
2 g IV q6h
e24
Bacillary 
angiomatosis
Erythromycin, 
500 mg PO qid
Doxycycline, 
100 mg PO bid
160
Herpes simplex 
(primary genital)
Acyclovir, 
400 mg PO tid 
for 10 days
Famciclovir, 250 mg 
PO tid for 
5–10 days,
or
Valacyclovir, 
1000 mg PO bid for 
10 days
179
Herpes zoster 
(immunocompe-
tent host 
>50 years of age)
Acyclovir, 
800 mg PO 
5 times daily 
for 7–10 days
Famciclovir, 
500 mg PO tid for 
7–10 days,
or
Valacyclovir, 1000 
mg PO tid for 7 days
180
Cellulitis
(staphylococcal or 
streptococcalb,c)
Nafcillin or 
oxacillin, 
2 g IV q4–6h
Cefazolin, 1–2 g IV 
q8h,
or
Ampicillin/
sulbactam, 
1.5–3 g IV q6h,
or
Erythromycin, 
0.5–1 g IV q6h,
or
Clindamycin, 600–
900 mg IV q8h
135, 136
MRSA skin 
infectiond
Vancomycin, 
1 g IV q12h
Linezolid, 600 mg 
IV q12h
135
CHAPTER 93
571
TABLE 93-1  TREATMENT OF COMMON INFECTIONS OF THE SKIN 
(CONTINUED)
Diagnosis/
Condition
Primary Treatment
Alternative 
Treatment
See Also 
HPIM-18
Chap(s).
Necrotizing
fasciitis (group A 
streptococcalb)
Clindamycin, 
600–900 mg IV 
q6–8h,
plus
Penicillin G, 
4 million units 
IV q4h
Clindamycin, 
600–900 mg IV 
q6–8h,
plus
Cephalosporin
(first- or second-
generation)
136
Necrotizing
fasciitis (mixed 
aerobes and 
anaerobes)
Ampicillin, 
2 g IV q4h,
plus
Clindamycin, 
600–900 mg IV 
q6–8h,
plus
Ciprofloxacin, 
400 mg IV 
q6–8h
Vancomycin, 
1 g IV q6h,
plus
Metronidazole, 500 
mg IV q6h,
plus
Ciprofloxacin, 
400 mg IV q6–8h
164
Gas gangrene
Clindamycin, 
600–900 mg IV 
q6–8h,
plus
Penicillin G, 
4 million units IV 
q4–6h
Clindamycin, 
600–900 mg IV 
q6–8h,
plus
Cefoxitin, 2 g IV q6h
142
Note: Parenteral treatment is usually given until systemic signs and symptoms have improved.
aPasteurella multocida, a species commonly associated with both dog and cat bites, is 
resistant to cephalexin, dicloxacillin, clindamycin, and erythromycin. Eikenella corrodens, a 
bacterium commonly associated with human bites, is resistant to clindamycin, penicillinase-
resistant penicillins, and metronidazole but is sensitive to trimethoprim-sulfamethoxazole and 
fluoroquinolones.
bThe frequency of erythromycin resistance in group A Streptococcus is currently ~5% in 
the United States but has reached 70–100% in some other countries. Most, but not all, 
erythromycin-resistant group A streptococci are susceptible to clindamycin. Approximately 
90–95% of Staphylococcus aureus strains are sensitive to clindamycin.
cSevere hospital-acquired S. aureus infections or community-acquired S. aureus infections 
that are not responding to the β-lactam antibiotics recommended in this table may be caused 
by methicillin-resistant strains, requiring a switch to vancomycin or linezolid.
dSome strains of methicillin-resistant S. aureus (MRSA) remain sensitive to tetracycline and 
trimethoprim-sulfamethoxazole. Daptomycin (4 mg/kg IV q24h) or tigecycline (100-mg loading 
dose followed by 50 mg IV q12h) are alternative treatments for MRSA.
Infections of the Skin, Soft Tissues, Joints, Bone
SECTION 7
572
Infectious Diseases
3. Crusted lesions: Impetigo caused by either Streptococcus pyogenes (impe-
tigo contagiosa) or Staphylococcus aureus (bullous impetigo) usually 
starts with a bullous phase before development of a golden-brown 
crust. Crusted lesions are also seen in some systemic fungal infections, 
dermatophytic infections, and cutaneous mycobacterial infections. It is 
important to recognize impetigo contagiosa because of its relation to 
poststreptococcal glomerulonephritis. 
4. Folliculitis: Localized infection of hair follicles is usually due to S. aureus. 
“Hot-tub folliculitis” is a diffuse condition caused by Pseudomonas aeru-
ginosa. Freshwater avian schistosomes cause an allergic reaction after 
penetrating hair follicles, resulting in “swimmer’s itch.”
5. Papular and nodular lesions: Raised lesions of the skin occur in many 
different forms and can be caused by Bartonella (cat-scratch disease and 
bacillary angiomatosis), Treponema pallidum, human papillomavirus, 
mycobacteria, and helminths.
6. Ulcers, with or without eschars: can be caused by cutaneous anthrax, 
ulceroglandular tularemia, plague, and mycobacterial infection. 
Ulcerated lesions on the genitals can be caused by chancroid (painful) or 
syphilis (painless).
7. Erysipelas: abrupt onset of fiery red swelling of the face or extremities, 
with well-defined indurated margins, intense pain, and rapid progres-
sion. S. pyogenes is the exclusive cause.
� CELLULITIS 
• Pathogenesis Bacteria gain access to the epidermis through breaks in the 
skin, whether accidental (e.g., cuts, scratches, burns) or iatrogenic (e.g., 
surgical incisions, IV catheters). The expanding area of erythema may be 
due to extracellular toxins and/or the host immune response rather than 
to increasing bacterial numbers.
• Microbiology Etiologic causes include commensal flora (e.g., S. aureus, 
S. pyogenes) or a wide variety of exogenous flora. With the latter, a thor-
ough history and epidemiologic data may help identify the cause.
– Examples of exogenous bacteria causing cellulitis include the follow-
ing: Pasteurella multocida after a cat or dog bite; Capnocytophaga 
canimorsus after a dog bite; Eikenella corrodens after a human bite; 
P. aeruginosa in association with ecthyma gangrenosum in neutro-
penic pts, a penetrating injury (stepping on a nail), or hot-tub fol-
liculitis; Aeromonas hydrophila after a laceration sustained in fresh 
water; or Erysipelothrix rhusiopathiae after contact with domestic 
swine and fish.
• Clinical manifestations This acute inflammatory condition of the skin 
is characterized by localized pain, erythema, swelling, and heat.
– Cellulitis due to S. aureus often spreads from a central site of localized 
infection, such as an abscess or an infected foreign body.
– S. pyogenes can cause a rapidly spreading, diffuse process, often with 
fever and lymphangitis.
• Diagnosis If there is drainage, an open wound, or an obvious portal of 
entry, Gram’s staining and culture may identify the etiology. Aspiration 
CHAPTER 93
573
or biopsy of the leading edge of the cellulitic tissue yields a diagnosis in 
only 20% of cases.
• Treatment See Table 93-1.
� NECROTIZING FASCIITIS
• Pathogenesis Infection, either apparent or inapparent, results from a breach 
in integrity of the skin or mucous membrane barriers and can be associated 
with malignancy, a diverticulum, hemorrhoids, or an anal fissure. 
– In the case of infections with no obvious portal of entry, transient bac-
teremia is thought to seed sites of nonpenetrating trauma (e.g., bruise, 
muscle strain). 
– Infection spreads to the deep fascia and along fascial planes through 
venous channels and lymphatics.
• Microbiology Necrotizing fasciitis is caused by S. pyogenes, mixed 
aerobic and anaerobic bacteria, or Clostridium perfringens; methicillin-
resistant S. aureus (MRSA) strains that produce the Panton-Valentine 
leukocidin have also been reported as an occasional cause.
• Clinical manifestations The timing of cutaneous manifestations (e.g., 
violaceous bullae; friable, necrotic skin; induration; brawny edema) 
depends on whether the infection began superficially (rapid onset) or in 
deeper structures (slower onset).
– Early in the disease course, severe pain and unexplained fever may be 
the only findings. 
– Thrombosis of blood vessels in dermal papillae leads to ischemia of 
peripheral nerves and anesthesia of the affected area. 
– In later stages, pts appear toxic and often develop shock and multior-
gan failure.
• Diagnosis Diagnosis is based on clinical presentation. Other findings 
may include gas detected in deep tissues by imaging studies (particularly 
with clostridial species but rarely with S. pyogenes) and markedly elevated 
serum creatine phosphokinase levels (in the case of concomitant myositis).
• Treatment Emergent surgical exploration to deep fascia and muscle, 
with removal of necrotic tissue, is essential. Table 93-1 provides recom-
mendations for adjunctive antibiotic therapy.
� MYOSITIS/MYONECROSIS
• Clinical manifestations and microbiology Infections involving the 
muscle have differing manifestations, depending on the etiology.
– Myositis: can be caused by bacteria (clostridia, streptococci), viruses 
(influenza virus, dengue virus, coxsackievirus), or parasites (Trichinella, 
Taenia solium, Toxoplasma). This condition usually manifests with 
myalgias, but pain can be severe in coxsackievirus, Trichinella, and 
bacterial infections.
– Pyomyositis: a localized muscle infection usually due to S. aureus, 
common in tropical areas, and typically with no known portal of entry.
– Myonecrosis: can be caused by clostridial species (C. perfringens, 
C. septicum, C. histolyticum, C. sordellii) or by mixed aerobic and 
anaerobic bacteria. Myonecrosis is usually related to trauma; however, 
Infections of the Skin, Soft Tissues, Joints, Bone
SECTION 7
574
Infectious Diseases
spontaneous gangrene—usually due to C. septicum—can occur in pts 
with neutropenia, GI malignancy, or diverticulosis. Myonecrosis of 
the uterus, typically due to C. sordellii, occurs in women after spon-
taneous or medically induced abortion and in healthy postpartum 
women; infection is rapidly and almost uniformly fatal as there are few 
or no localizing clinical findings.
• Diagnosis and Treatment Emergent surgical intervention to visual-
ize deep structures, obtain materials for culture and sensitivity testing, 
remove necrotic tissue, and reduce compartment pressure is both diag-
nostic and therapeutic.
– Empirical antibiotic treatment should target likely etiologies—e.g., 
vancomycin (1 g IV q12h) for pyomyositis and ampicillin/sulbactam 
(2–3 g IV q6h) for mixed aerobic-anaerobic infections. 
– For treatment of clostridial myonecrosis (gas gangrene), see Table 93-1.
INFECTIOUS ARTHRITIS
• Pathogenesis Joints become infected by hematogenous seeding (the 
most common route), by spread from a contiguous site of infection, or 
by direct inoculation (e.g., during trauma or surgery). Acute bacterial 
infection can rapidly destroy articular cartilage as a result of increased 
intraarticular pressure and the elicited host immune response.
• Microbiology The predominant etiologic agents differ with the pt’s 
age; S. aureus is the most common nongonococcal isolate in adults of 
all ages.
– In children <5 years old, S. aureus, S. pyogenes, and Kingella kingae 
predominate.
– In young adults, Neisseria gonorrhoeae is the most common etiology.
– In adults, S. aureus predominates, but gram-negative bacilli, pneumo-
cocci, and β-hemolytic streptococci are involved in one-third of cases 
in older adults. 
– Other causes of septic arthritis include Borrelia burgdorferi (Lyme dis-
ease), tuberculosis and other mycobacterial infections, fungal infec-
tions (e.g., coccidioidomycosis, histoplasmosis), and viral infections 
(e.g., rubella, mumps, hepatitis B, parvovirus infection).
• Epidemiology and clinical manifestations The risk factors and presen-
tation differ depending on whether N. gonorrhoeae is the cause.
– Nongonococcal bacterial arthritis: Risk is increased in pts with rheu-
matoid arthritis, diabetes mellitus, glucocorticoid therapy, hemodialy-
sis, malignancy, and IV drug use. 
• In 90% of pts, one joint is involved—most often the knee, which is fol-
lowed in frequency by the hip, shoulder, wrist, and elbow; IV drug users 
often have spinal, sacroiliac, or sternoclavicular joint involvement.
• Pts have moderate to severe pain, effusion, decreased range of 
motion, and fever. 
– Gonococcal arthritis: Women are 2–3 times more likely than men to 
develop disseminated gonococcal infection (DGI) and arthritis, par-
ticularly during menses and during pregnancy (see Chap. 92).
CHAPTER 93
575
• DGI presents as fever, chills, rash, and articular symptoms 
(migratory arthritis). The cutaneous and articular findings result 
from an immune reaction to circulating gonococci and immune-
complex deposition, so that synovial fluid cultures are consistently 
negative.
• In true gonococcal arthritis (which always follows DGI), a single 
joint (hip, knee, ankle, or wrist) is usually involved.
– Prosthetic joint infections: complicate 1–4% of joint replacements and 
are usually acquired intra- or perioperatively.
• Acute presentations are seen in infections caused by S. aureus, pyo-
genic streptococci, and enteric bacilli.
• Indolent presentations are seen in infections caused by coagulase-
negative staphylococci and diphtheroids.
– Reactive arthritis: follows ~1% of cases of nongonococcal urethritis 
and 2% of enteric infections (e.g., Yersinia enterocolitica, Shigella 
flexneri, Campylobacter jejuni, Salmonella spp.). Only a minority of 
pts have the other classic findings associated with reactive arthritis, 
including urethritis, conjunctivitis, uveitis, oral ulcers, and rash.
• Diagnosis If there is concern about joint infection, examination of syno-
vial fluid from the affected joint is essential. There is considerable overlap 
in the cell counts due to different etiologies, but synovial fluid culture 
and examination for crystals (to rule out gout and pseudogout) can help 
narrow the diagnosis.
– Normal synovial fluid contains <180 cells (mostly mononuclear)/μL. 
Acute bacterial infection of joints results in synovial fluid cell counts 
averaging 100,000/μL (range, 25,000–250,000/μL), with >90% PMNs. 
Synovial fluid in gonococcal arthritis contains >50,000 cells/μL, but 
results of Gram’s staining are usually negative, and cultures of syno-
vial fluid are positive in <40% of cases. Other mucosal sites should 
be cultured to diagnose gonorrhea. Pts with septic arthritis due to 
mycobacteria or fungi can have 10,000–30,000 cells/μL in synovial 
fluid, with 50–70% PMNs. Synovial fluid cell counts in noninfectious 
inflammatory arthritides are typically 30,000–50,000/μL.
– Gram’s staining of synovial fluid should be performed, and injection 
directly into blood culture bottles can increase the yield of synovial 
fluid cultures. 
– Blood cultures are positive in 50–70% of cases due to S. aureus but are 
less commonly positive with other organisms. 
– Plain radiographs show soft tissue swelling, joint space widening, and 
displacement of tissue planes by distended capsule. Narrowing of the 
joint space and bony erosions suggest advanced disease.
Infectious Arthritis
TREATMENT
• Drainage of pus and necrotic debris is needed to cure infection 
and to prevent destruction of cartilage, postinfectious degenerative 
arthritis, and joint deformity or instability.
Infections of the Skin, Soft Tissues, Joints, Bone
SECTION 7
576
Infectious Diseases
• A third-generation cephalosporin (cefotaxime, 1 g IV q8h; or 
ceftriaxone, 1–2 g IV q24h) provides adequate empirical coverage 
for most community-acquired infections in adults when smears 
demonstrate no organisms. Vancomycin (1 g IV q12h) should be 
used to cover the possibility of MRSA when there are gram-positive 
cocci on the smear. 
– In IV drug users and other susceptible pts, treatment for gram-
negative organisms such as P. aeruginosa should be considered. 
– If a pathogen is identified by culture, treatment should be adjust-
ed according to the specific bacterial organism and its antibiotic 
susceptibility. 
• Treatment for S. aureus should be given for 4 weeks, that for 
enteric gram-negative bacilli for 3–4 weeks, and that for pneumo-
cocci or streptococci for 2 weeks. Treatment of gonococcal arthri-
tis should commence with ceftriaxone (1 g/d) until improvement; 
the 7-day course can be completed with an oral fluoroquinolone 
(e.g., ciprofloxacin, 500 mg bid). If fluoroquinolone resistance 
is not prevalent, a fluoroquinolone can be given for the entire 
course.
• Prosthetic joint infections should be treated with surgery and high-
dose IV antibiotics for 4–6 weeks. The prosthesis often has to be 
removed; to avoid joint removal, antibiotic suppression of infection 
may be tried. A 3- to 6-month course of ciprofloxacin and rifampin 
has been successful in S. aureus prosthetic joint infections of relative-
ly short duration, although prospective trials confirming the efficacy 
of this regimen are still needed.
OSTEOMYELITIS
• Pathogenesis Osteomyelitis is typically caused either by direct spread 
from a contiguous focus of infection or by hematogenous spread. Areas 
of bone or contiguous surrounding tissue that have abnormal viability, 
blood supply, sensation, or edema are at increased risk for bacterial infec-
tion. Bacteria can colonize and persist in these areas, partly because of 
the decreased immunosurveillance resulting from compromised blood 
flow and—in the case of some organisms, such as S. aureus—elaboration 
of bacterial adhesins and toxins.
• Epidemiology In the U.S., 0.1–1.8% of otherwise healthy adults 
are affected by acute osteomyelitis; 30–40% of adults with diabetes 
develop osteomyelitis after a foot puncture. Orthopedic surgery (par-
ticularly with implantation of hardware), obesity, diabetes, trauma, 
bacteremia, poor circulation, and older age are risk factors for 
osteomyelitis.
• Microbiology Table 93-2 lists organisms that cause osteomyelitis. 
– S. aureus is the most common cause.
– The overlapping circulations of the urinary tract and the spine may be 
a source of vertebral osteomyelitis due to urinary tract pathogens such 
as Escherichia coli and Klebsiella.
CHAPTER 93
577
TABLE 93-2  MICROORGANISMS THAT CAUSE OSTEOMYELITIS
Organism
Comment
Frequently encountered bacteria
Staphylococcus aureus
Most likely bacterial pathogen
Aggressive, invasive
Often metastatic foci with bacteremia
Should consider surgery early
Staphylococci other than 
S. aureus (coagulase-
negative)
Usually associated with foreign material or 
implants
Biofilm production
Streptococci
May spread rapidly through soft tissues 
Enterobacteriaceae
(Escherichia coli, Klebsiella,
others)
Considerable variation in antibiotic 
susceptibility
Increasing antibiotic resistance with overuse
May become resistant to antibiotics during 
therapy
Pseudomonas aeruginosa
Increasingly resistant to antibiotics
Frequent successor to other bacteria when 
initial therapy fails
May be related to contamination
Unusual organisms
Anaerobic bacteria
Usually mixed with aerobic bacteria
May be synergistic
Survival dependent on devitalized tissue
Bartonella henselae
Associated with cat scratches and probably 
with fleas
Brucella spp.
Prominent in developing countries, especially 
with unpasteurized milk
Fungi
Candida the most likely genus
Considerable variation in susceptibility, 
depending on species
Surgery sometimes helpful if infection is invasive
Mycobacterium tuberculosis
May involve any bone
Vertebral osteomyelitis common in some 
countries
Mycobacteria other than 
M. tuberculosis
Need special culture media for recovery
Viruses
Some associated viral infections, including 
varicella and variola
Infections of the Skin, Soft Tissues, Joints, Bone
SECTION 7
578
Infectious Diseases
TABLE 93-3 ANTIBIOTICS FOR THE TREATMENT OF OSTEOMYELITIS
Organism
Antimicrobial
Agent
Dosing
Comments
Methicillin-
susceptible
Staphylococcus 
aureus
Oxacillin or 
nafcillin
2 g IV q6h
May be more active 
than cephalosporins
More difficult than 
cephalosporins to 
administer for long 
periods
Cephalosporins
Cefazolin: 
2 g IV q8h
Ceftriaxone: 
1–2 g IV 
q24h
Ceftriaxone
advantageous with 
OPAT
Clindamycina
600–900 mg 
IV q8h
Not well studied for 
osteomyelitis
Oral form possible 
(300–600 mg q8h)
Resistance significant 
and increasing
Toxicity different 
from that of β-lactam
antibiotics
Methicillin-
resistant S. aureus
Vancomycin
15 mg/kg IV 
q12h
Strains with an MIC 
of ≥2 μg/mL may not 
respond well.
Daptomycina
4–6 mg/kg 
IV q24h
Promising, but con-
cern about adverse 
effects with prolonged 
therapy
Linezolida
600 mg IV or 
PO q12h
Effectiveness and 
adverse effects with 
prolonged therapy 
unclear
Bacteriostatic
Streptococci
Penicillin
5 mU IV q6h 
or 20 mU/d 
by continu-
ous infusion
Not all streptococci 
are susceptible.
Ceftriaxone (1 g/d IV 
or IM) and ampicillin 
(12 g/d IV) are 
alternatives.
Enterococci
Penicillin plus
As above
If strain is susceptible
Gentamicin
5 mg/kg 
daily IV
Vancomycin
As above
If strain is susceptible
CHAPTER 93
579
• Clinical manifestations Pts generally have a febrile illness, with local-
ized pain and tenderness. A history of surgery or trauma in the affected 
region—even in the remote past—should raise suspicion. 
• Diagnosis Radiographic studies and occasionally invasive sampling of 
lesions are needed to confirm the diagnosis.
– X-rays of the affected region may demonstrate bone loss, sequestra, 
periosteal elevation, or swelling, but many of these findings may 
become apparent only after the infection has continued for several 
weeks.
– CT and especially MRI scans offer increased sensitivity in detecting 
osteomyelitis.
– Needle aspiration or biopsy of lesions allows histologic confirmation 
of disease and may permit identification of the etiologic agent.
• Treatment Table 93-3 lists antibiotics for the treatment of osteomyelitis 
due to common pathogens. Empirical antibiotic therapy should target 
staphylococci and often includes cefazolin or an antistaphylococcal peni-
cillin (oxacillin or nafcillin).
– The optimal route and duration of therapy remain controversial, but 
a 4- to 6-week course of IV therapy is the usual recommended mini-
mum; pediatric studies are providing increasing evidence that shorter 
courses and oral agents may be adequate.
– Serial measurement of inflammatory markers (ESR, C-reactive pro-
tein) can serve as a surrogate marker of response to treatment in some 
infections (particularly in cases due to S. aureus).
TABLE 93-3  ANTIBIOTICS FOR THE TREATMENT OF OSTEOMYELITIS 
(CONTINUED)
Organism
Antimicrobial
Agent
Dosing
Comments
Enterobacteriaceae
(Escherichia coli, 
Klebsiella, other)
Ceftriaxone
or another 
cephalosporin
As above
If strain is susceptible
Ciprofloxacin
400 mg IV 
q8–12h
Oral form possible 
(500–750 mg q8–12h)
Pseudomonas 
aeruginosa
Ciprofloxacin 
As above
Resistance may 
develop during 
therapy; if strain is 
resistant, drugs to 
consider include 
cefepime and 
ceftazidime.
aNot approved for use in osteomyelitis by the U.S. Food and Drug Administration.
Abbreviations: MIC, minimal inhibitory concentration; OPAT, outpatient parenteral 
antimicrobial therapy.
Infections of the Skin, Soft Tissues, Joints, Bone
SECTION 7
580
Infectious Diseases
For a more detailed discussion, see Stevens DL: Infections of 
the Skin, Muscles, and Soft Tissues, Chap. 125, p. 1064; Tice 
AD: Osteomyelitis, Chap. 126, p. 1071; Wang F: Molluscum 
Contagiosum, Monkeypox, and Other Poxvirus Infections, 
Chap. 183, p. 1476; and Madoff LC: Infectious Arthritis, 
Chap. 334, p. 2842, in HPIM-18. 
CHAPTER 94
Pneumococcal Infections
� MICROBIOLOGY
• Streptococcus pneumoniae (the pneumococcus) is a gram-positive coccus 
that grows in chains, causes α-hemolysis on blood agar, is bile soluble, 
and is sensitive to optochin. 
• Nearly every clinical isolate has a polysaccharide capsule that protects the 
bacteria from phagocytosis in the absence of type-specific antibody; 92 
distinct capsules have been identified.
� EPIDEMIOLOGY
• In industrialized countries, children serve as the major vectors of pneu-
mococcal transmission: 20–50% of children <5 years old have asymp-
tomatic nasopharyngeal colonization with S. pneumoniae (compared 
with 5–15% of young and middle-aged adults). Colonization rates for all 
age groups are even higher in low-income countries.
• Rates of pneumococcal disease vary by season (higher in winter), gender 
(higher for males), and underlying medical condition (e.g., splenic dys-
function; chronic respiratory, heart, liver, and kidney disease; immuno-
suppression).
• The introduction and widespread use (in industrialized countries) of 
pneumococcal conjugate vaccines have led to dramatic changes in the 
epidemiology of invasive pneumococcal disease; rates have fallen by 
>75% among infants and children in the U.S.
� PATHOGENESIS
• Nasopharyngeal colonization can persist for many months, resulting 
in the development of type-specific serum IgG that ultimately leads to 
pneumococcal clearance from the nasopharynx. Accordingly, pneu-
mococcal disease is usually associated with recent acquisition of a new 
colonizing serotype.
• Once the nasopharynx has been colonized, the bacteria spread either via 
the bloodstream to distant sites (e.g., brain, joint, bones) or locally to 
contiguous areas (e.g., middle ear, lungs). 
– Given the prolonged treatment necessary, outpatient parenteral 
antibiotic therapy is increasingly being used and is both safe and 
effective.
CHAPTER 94
581
Pneumococcal Infections
• Local cytokine production, particularly after intercurrent viral infections, 
facilitates pneumococcal adherence; bacterial factors such as peptido-
glycan and teichoic acid induce inflammation, result in characteristic 
pathology, and permit bacterial invasion.
� CLINICAL MANIFESTATIONS AND DIAGNOSIS
The clinical manifestations of pneumococcal disease depend on the site of 
infection and the duration of illness.
Pneumonia
Pneumococcal pneumonia—the most common serious pneumococcal syn-
drome—is difficult to distinguish from pneumonia of other etiologies on 
the basis of clinical findings. 
• Pts often present with fever, abrupt-onset cough and dyspnea, and sputum 
production.
– Pts may also have pleuritic chest pain, shaking chills, or myalgias.
– Among the elderly, presenting symptoms may be less specific, with 
confusion and malaise but without fever or cough.
• On physical examination, adults may have tachypnea (>30 breaths/min) 
and tachycardia, crackles on chest auscultation, and dullness to percus-
sion of the chest in areas of consolidation.
– In some cases, hypotension, bronchial breathing, a pleural rub, or 
cyanosis may be present.
– Upper abdominal pain may be present if the diaphragmatic pleura is 
involved.
• Pneumococcal pneumonia is generally diagnosed by Gram’s staining and 
culture of sputum.
– While culture results are awaited, chest x-rays—which classically 
demonstrate lobar or segmental consolidation—may provide some 
adjunctive evidence, although they may be normal early in the course 
of illness or with dehydration.
– Blood cultures are positive for pneumococci in <30% of cases.
– Leukocytosis (>15,000/μL) is common; leukopenia is documented in 
<10% of cases and is associated with a fatal outcome.
– A positive pneumococcal urinary antigen test has a high predictive 
value among adults, in whom the prevalence of nasopharyngeal colo-
nization is low.
• Empyema occurs in <5% of cases and should be considered when a pleu-
ral effusion is accompanied by fever and leukocytosis after 4–5 days of 
appropriate antibiotic therapy. Pleural fluid with frank pus, bacteria, or a 
pH of ≤7.1 indicates empyema and requires aggressive drainage.
Meningitis
S. pneumoniae is among the most common causes of meningitis in both 
adults and children. Pneumococcal meningitis can present as a primary 
syndrome or as a complication of other pneumococcal conditions (e.g., oti-
tis media, infected  skull fracture, bacteremia). Pneumococcal meningitis is 
indistinguishable from other causes of pyogenic meningitis.
SECTION 7
582
Infectious Diseases
• Pts have fever, headache, neck stiffness, photophobia, and occasionally 
seizures and confusion. 
• On examination, pts have a toxic appearance, altered consciousness, bra-
dycardia, and hypertension (indicative of increased intracranial pressure). 
Kernig’s or Brudzinski’s sign or cranial nerve palsies (particularly of the 
third and sixth cranial nerves) are noted in a small fraction of adult pts.
• Diagnosis of pneumococcal meningitis relies on examination of CSF, 
which reveals an elevated protein level, elevated WBC count, and 
reduced glucose concentration; the etiologic agent can be specifically 
identified by culture, antigen testing, or PCR. A blood culture positive 
for S. pneumoniae in conjunction with clinical manifestations of menin-
gitis is also considered confirmatory.
Other Invasive Syndromes 
S. pneumoniae can affect virtually any body site and cause invasive syn-
dromes, including bacteremia, osteomyelitis, septic arthritis, endocarditis, 
pericarditis, and peritonitis. The essential diagnostic approach is collection of 
fluid from the site of infection by sterile technique and examination by Gram’s 
staining, culture, and—when relevant—capsular antigen assay or PCR. 
Hemolytic-uremic syndrome can complicate invasive pneumococcal disease.
Noninvasive Syndromes 
Sinusitis and otitis media are the two most common noninvasive syndromes 
caused by S. pneumoniae; the latter is the most common pneumococcal syn-
drome and most often affects young children. See Chap. 64 for more detail. 
Pneumococcal Infections
TREATMENT
• Penicillin remains the cornerstone of treatment for pneumococcal 
disease caused by sensitive isolates, with daily doses ranging from 
50,000 U/kg for minor infections to 300,000 U/kg for meningitis. 
Macrolides and cephalosporins are alternatives for penicillin-
allergic pts but otherwise offer no advantage over penicillin.
• Strains resistant to β-lactam drugs are increasing in frequency, and 
antibiotic recommendations are typically based on the minimal 
inhibitory concentration against the isolate, particularly in cases of 
invasive disease.
PNEUMONIA
• Outpatient treatment: Amoxicillin (1 g PO q8h) is effective for 
virtually all cases of pneumococcal pneumonia. Fluoroquinolones 
(e.g., levofloxacin, 500–750 mg/d; or moxifloxacin, 400 mg/d) are 
also highly likely to be effective in the U.S., although they are much 
more expensive than amoxicillin. Clindamycin and azithromycin 
are effective in 90% and 80% of cases, respectively.
• Inpatient treatment: For pts with noncritical illness, β-lactam 
antibiotics are recommended—e.g., penicillin (3–4 mU IV q4h), 
ampicillin (1–2 g IV q6h), or ceftriaxone (1 g IV q12–24h). For pts 
with critical illness, vancomycin may be added, with its use reviewed 
once susceptibility data are available. 
CHAPTER 94
583
Pneumococcal Infections
• Treatment duration: The optimal duration of treatment is uncer-
tain, but continuation of antibiotics for at least 5 days after the pt 
becomes afebrile seems prudent.
MENINGITIS
• Because of the increased prevalence of resistant pneumococci, first-
line therapy should include vancomycin (1 g IV q12h) plus a third-
generation cephalosporin (ceftriaxone, 2 g IV q12h; or cefotaxime, 
2 g IV q4h). Rifampin (600 mg/d) can be substituted for the third-
generation cephalosporin in pts hypersensitive to β-lactam agents.
• The antibiotic regimen should be adjusted appropriately once sus-
ceptibility data are available. If the isolate is resistant to penicillin and 
cephalosporins, both vancomycin and the cephalosporin should be 
continued.
• A repeat LP should be considered after 48 h if the organism is not 
sensitive to penicillin and information on cephalosporin sensitivity 
is not yet available, if the pt’s clinical condition does not improve or 
deteriorates, or if the pt has received dexamethasone, which may 
compromise clinical evaluation.
• In adults with community-acquired bacterial meningitis, dexa-
methasone should be given before or in conjunction with the first 
dose of antibiotics, as glucocorticoids have been demonstrated to 
significantly reduce rates of mortality, severe hearing loss, and neu-
rologic sequelae; the data are not clear as to whether this practice is 
also beneficial in children.
� PREVENTION
• All persons ≥65 years old and those 2–64 years old who are at increased 
risk of pneumococcal disease should receive the 23-valent pneumococcal 
polysaccharide vaccine (PPV23), which contains capsular polysaccharide 
from the 23 most prevalent serotypes of S. pneumoniae. 
– Persons >2 years old with continuing increased risk should be revac-
cinated every 5 years.
– Persons whose only indication for vaccination is an age of ≥65 years 
do not need to be revaccinated.
• The efficacy of PPV23 is controversial; it appears to be effective against 
invasive pneumococcal disease but less effective or ineffective against 
nonbacteremic pneumococcal pneumonia.
• The duration of protection conferred by PPV23 is ~5 years.
• The poor response of infants and young children to pneumococcal poly-
saccharide vaccines prompted the development of pneumococcal conju-
gate vaccines. In the U.S., the current recommendation is for infants to be 
routinely vaccinated with the conjugate vaccine PCV13, which contains 
the 13 serotypes most associated with disease.
– Pneumococcal conjugate vaccines are highly effective at providing 
protection against vaccine-serotype invasive pneumococcal disease, 
pneumonia, otitis media, nasopharyngeal colonization, and all-cause 
mortality.
SECTION 7
584
Infectious Diseases
– In the U.S., there has been a >90% reduction in vaccine-serotype inva-
sive pneumococcal disease among the whole population, including 
indirect protection of unvaccinated adults.
 For a more detailed discussion, see Goldblatt D, O'Brien KL: 
Pneumococcal Infections, Chap. 134, p. 1151, in HPIM-18.
CHAPTER 95
Staphylococcal Infections
� MICROBIOLOGY
Staphylococci are gram-positive cocci that form grapelike clusters on Gram’s 
stain; they are catalase positive (unlike streptococci), nonmotile, aerobic, and 
facultatively anaerobic. Staphylococcus aureus, which is distinguished from 
other staphylococci by its production of coagulase, is the most virulent species.
� S. AUREUS INFECTIONS
Epidemiology 
S. aureus is an important cause of community-acquired infections and is the 
leading cause of nosocomial infections. 
• S. aureus is a component of the normal human flora, most frequently 
colonizing the anterior nares but also colonizing the skin (particularly 
damaged skin), vagina, axilla, perineum, and oropharynx. These sites of 
colonization are reservoirs for future infection. 
• Of healthy persons, 25–50% may be persistently or transiently colonized 
with S. aureus, and the rate is especially high among insulin-dependent 
diabetic pts, HIV-infected persons, injection drug users, hemodialysis 
pts, and pts with skin damage. 
• Methicillin-resistant S. aureus (MRSA) is common in hospitals, and its 
prevalence is increasing dramatically in community settings among indi-
viduals without prior medical exposure. 
– In the United States, strain USA300 (defined by pulsed-field gel elec-
trophoresis) causes most community-acquired MRSA (CA-MRSA) 
infections and can cause severe disease in immunocompetent pts. 
– Outbreaks of CA-MRSA infection occur among diverse groups, 
including prisoners, athletes, and drug users. 
Pathogenesis 
S. aureus is a pyogenic pathogen known for its capacity to induce abscess 
formation. 
• Invasive Disease For invasive S. aureus infection to occur, some or all of 
the following steps are necessary:
– Colonization/inoculation: Bacteria colonize tissue surfaces or are 
inoculated directly into tissue—e.g., as a result of minor abrasions or 
via IV access catheters. 
CHAPTER 95
585
Staphylococcal Infections
– Invasion: Bacteria replicate at the site of infection and elaborate 
enzymes that facilitate survival and local spread. CA-MRSA isolates 
that produce the Panton-Valentine leukocidin toxin have been linked 
to more serious infections.
– Evasion of host defense mechanisms: S. aureus possesses an antiphago-
cytic polysaccharide microcapsule that facilitates evasion of host 
defenses and plays a role in abscess formation. Organisms can survive 
in a quiescent state in various tissues and then cause recrudescent 
infections when conditions are suitable.
– Metastatic spread: S. aureus can survive in PMNs and may use these 
cells to spread to and seed other tissue sites. 
• Toxin-Mediated Disease S. aureus produces three types of toxin: cyto-
toxins, pyrogenic toxin superantigens, and exfoliative toxins. 
– Antitoxin antibodies are protective against toxin-mediated staphylo-
coccal illness. 
– Enterotoxins and toxic shock syndrome toxin 1 (TSST-1) act as “super-
antigens” or T cell mitogens and cause the release of large amounts of 
inflammatory mediators, producing multisystem disease that includes 
fever, rash, and hypotension.
Diagnosis
S. aureus infections are readily diagnosed by Gram’s stain and microscopic 
examination of infected tissue. 
• Routine cultures of infected material usually yield positive results, and 
blood cultures are sometimes positive even when infections are localized 
to extravascular sites. 
• PCR assays have been developed for rapid testing and are increasingly 
being used.
Clinical Syndromes 
Skin and Soft Tissue Infections S. aureus causes a variety of cutaneous infec-
tions characterized by pus-containing blisters, many of which can also be 
caused by group A streptococci and other streptococcal species. Predisposing 
factors include skin disease (e.g., eczema), skin damage (e.g., minor trauma), 
injections, and poor personal hygiene. 
• Infections can be superficial (e.g., folliculitis, cellulitis, impetigo) or deep 
and painful (e.g., furuncles, carbuncles, hidradenitis suppurativa).
– Carbuncles (often located in the lower neck) are more severe and 
painful than furuncles (boils that extend from hair follicles) and are 
due to coalesced lesions extending to deeper SC tissue. 
– Mastitis in lactating women can range from superficial cellulitis to 
abscess. 
Musculoskeletal Infections See Chap. 93 for additional details.
• S. aureus is the most common cause of osteomyelitis arising from either 
hematogenous dissemination or contiguous spread from a soft tissue site 
(e.g., diabetic or vascular ulcers). 
– Hematogenous osteomyelitis in adults is often vertebral and occurs 
in pts with endocarditis, pts undergoing hemodialysis, injection drug 
SECTION 7
586
Infectious Diseases
users, or diabetics. Intense back pain and fever can occur, but infections 
may also be clinically occult. 
– Epidural abscess is a serious complication that can present as trouble 
voiding or walking or as radicular pain in addition to symptoms of 
osteomyelitis; neurologic compromise can develop in the absence of 
timely treatment, which often requires surgical intervention. 
– Osteomyelitis from contiguous soft tissue infections is suggested by 
exposure of bone, a draining fistulous tract, failure to heal, or contin-
ued drainage. 
• S. aureus is the most common cause of septic arthritis in native joints of 
both adults and children. S. aureus septic arthritis in adults may result 
from trauma, surgery, or hematogenous dissemination.
– The joints most commonly affected are the knees, shoulders, hips, and 
phalanges.
– Examination of synovial fluid reveals >50,000 PMNs/μL and gram-
positive cocci in clusters on Gram’s stain.
• Pyomyositis, an infection of skeletal muscles that is seen in tropical cli-
mates and in seriously compromised pts (including HIV-infected pts), 
causes fever, swelling, and pain overlying involved muscle and is usually 
due to S. aureus.
Respiratory Tract Infections 
• Newborns and infants can develop serious infections characterized by 
fever, dyspnea, and respiratory failure; pneumatoceles (shaggy, thin-
walled cavities), pneumothorax, and empyema are known complications.
• Community-acquired pneumonia usually follows viral infections (e.g., 
after influenza) and manifests as fever, bloody sputum production, and 
midlung-field pneumatoceles or multiple patchy pulmonary infiltrates.
• Nosocomial pneumonia is commonly seen in intubated pts. 
– The clinical presentation resembles that of pneumonia of other bacte-
rial etiologies.
– Pts produce an increased volume of purulent sputum and develop 
fever, new pulmonary infiltrates, and respiratory distress.
Bacteremia and Sepsis The incidence of metastatic seeding during bactere-
mia has been estimated to be as high as 31%. 
• Bones, joints, kidneys, and lungs are most commonly infected. 
• Diabetes, HIV infection, and renal insufficiency are often seen in asso-
ciation with S. aureus bacteremia and increase the risk of complications.
Infective Endocarditis (See also Chap. 89) 
S. aureus is the leading cause of endocarditis worldwide and accounts for 
25–35% of cases. 
• The incidence is increasing as a result of injection drug use, hemodialy-
sis, intravascular prosthetic devices, and immunosuppression.
• Mortality rates range from 20% to 40% despite the availability of effective 
antibiotics. 
• The four clinical settings in which S. aureus endocarditis is encountered 
are (1) right-sided endocarditis in association with injection drug use, 
CHAPTER 95
587
Staphylococcal Infections
(2) left-sided native-valve endocarditis, (3) prosthetic-valve endocarditis, 
and (4) nosocomial endocarditis.
Urinary Tract Infections UTIs due to S. aureus are uncommon and suggest 
hematogenous dissemination.
Prosthetic Device–Related Infections Compared with coagulase-negative 
staphylococci, S. aureus causes more acute disease, with localized and sys-
temic manifestations that tend to be rapidly progressive. Successful treat-
ment usually involves removal of the prosthetic device.
CA-MRSA Infections While the skin and soft tissues are the most common 
sites of infection associated with CA-MRSA, 5–10% of these infections are 
invasive and potentially life-threatening (e.g., necrotizing fasciitis, necrotic 
pneumonia, sepsis, purpura fulminans).
Toxin-Mediated Disease Each class of toxin produced by S. aureus results in 
a characteristic syndrome.
• Food poisoning: results from inoculation of toxin-producing S. aureus 
into food by colonized food handlers, with subsequent toxin elaboration 
in growth-promoting foods (e.g., custard, potato salad, processed meat). 
– The heat-stable toxin is not destroyed even if heating kills the bacteria. 
– Because the disease is caused by preformed toxins, its onset is rapid 
and explosive, occurring within 1–6 h of ingestion of contaminated 
food. 
– The chief signs and symptoms are nausea and vomiting, but diarrhea, 
hypotension, and dehydration may occur. Fever is absent. 
– Symptoms resolve within 8–10 h; treatment is entirely supportive.
• Toxic shock syndrome (TSS): results from elaboration of an enterotoxin 
(many nonmenstrual TSS cases) or TSST-1 (some nonmenstrual cases 
and >90% of menstrual cases).
– Although the specific toxin may differ, the clinical presentation is 
similar in menstrual and nonmenstrual cases.
– Diagnosis is based on a constellation of clinical findings. Table 95-1 
summarizes the case definition for staphylococcal TSS. 
– Menstrual cases occur 2–3 days after menses begin.
– Illness occurs only in people who lack antibody to the toxin.
• Staphylococcal scalded-skin syndrome (SSSS): most often affects new-
borns and children. Fragility of the skin, with tender, thick-walled, fluid-
filled bullae, can lead to exfoliation of most of the skin surface. Nikolsky’s 
sign is positive when gentle pressure on bullae causes rupture of lesions 
and leaves denuded underlying skin.
Prevention
Hand washing and careful attention to appropriate isolation procedures 
prevent the spread of S. aureus infection. Elimination of nasal carriage of 
S. aureus (e.g., with mupirocin) has reduced the incidence of postsurgical 
infection and the rates of infection among hemodialysis and peritoneal 
dialysis pts. 
SECTION 7
588
Infectious Diseases
� INFECTIONS CAUSED BY COAGULASE-NEGATIVE STAPHYLOCOCCI (CoNS)
Microbiology 
CoNS are generally less virulent than S. aureus but are important and common 
causes of prosthetic-device infections. 
• Of CoNS species, S. epidermidis most often causes disease. This organism 
is a normal component of the skin, oropharyngeal, and vaginal flora. 
• S. saprophyticus is a cause of UTIs. 
• S. lugdunensis and S. schleiferi are more virulent than other CoNS spe-
cies and cause serious infections, possibly because they apparently share 
more virulence determinants with S. aureus than do other CoNS species.
Pathogenesis 
CoNS are uniquely adapted to cause prosthetic-device infections because 
they can elaborate an extracellular polysaccharide (glycocalyx or slime) that 
forms a biofilm on the device surface, protecting bacteria from host defenses 
as well as from antibiotic treatment while allowing bacterial survival.
Clinical Syndromes 
CoNS cause diverse prosthetic device–related infections. Signs of local-
ized infection are usually subtle, disease progression is slow, and systemic 
findings are limited. Fever and mild leukocytosis may be documented. 
Infections not associated with prosthetic devices are infrequent, but up to 
5% of native-valve endocarditis cases have been due to CoNS in some series.
TABLE 95-1  CASE DEFINITION OF S. AUREUS TOXIC SHOCK SYNDROME
1.  Fever: temperature of ≥38.9°C (≥102°F)
2.  Hypotension: systolic blood pressure of ≤90 mmHg or orthostatic 
hypotension (orthostatic drop in diastolic blood pressure by ≥15 mmHg, 
orthostatic syncope, or orthostatic dizziness)
3.  Diffuse macular rash, with desquamation 1–2 weeks after onset 
(including palms and soles)
4.  Multisystem involvement (≥3 of the following)
 a.  Hepatic: bilirubin or aminotransferase levels ≥2 times normal
 b.  Hematologic: platelet count ≤100,000/μL
 c.  Renal: blood urea nitrogen or serum creatinine level ≥2 times the 
normal upper limit
 d.  Mucous membranes: vaginal, oropharyngeal, or conjunctival hyperemia
 e.  GI: vomiting or diarrhea at onset of illness
 f.  Muscular: severe myalgias or serum creatine phosphokinase level 
≥2 times the upper limit
 g.  CNS: disorientation or alteration in consciousness without focal 
neurologic signs and in the absence of fever and hypotension
5.  Negative serologic or other tests for measles, leptospirosis, and Rocky 
Mountain spotted fever as well as negative blood or CSF cultures for 
organisms other than S. aureus 
Source: M Wharton et al: Case definitions for public health surveillance. MMWR 39:1, 1990; 
with permission.
CHAPTER 95
589
Staphylococcal Infections
Diagnosis
CoNS are readily detected by standard methods, but distinguishing infec-
tion from colonization is often problematic because CoNS are common 
contaminants of cultures of blood and other sites. Only 10–25% of blood 
cultures positive for CoNS reflect true bacteremia.
Staphylococcal Infections
TREATMENT
• Suppurative collections should be surgically drained. The emer-
gence of CA-MRSA has increased the importance of culturing mate-
rial from all collections to identify the pathogen and determine its 
antimicrobial susceptibility. 
• In most cases of prosthetic-device infection, the device should be 
removed, although some CoNS infections can be managed medically. 
• Antibiotic therapy for S. aureus infection is generally prolonged 
(i.e., 4–8 weeks), particularly if blood cultures remain positive 
48–96 h after initiation of therapy, if the infection was acquired in 
the community, if a removable focus of infection is not removed, 
or if cutaneous or embolic manifestations of infection occur. For 
immunocompetent pts in whom shorter therapy is planned, a trans-
esophageal echocardiogram to rule out endocarditis is warranted.
• Antimicrobial therapy for serious staphylococcal infections is sum-
marized in Table 95-2.
– Penicillinase-resistant β-lactams, such as nafcillin, oxacillin, and 
cephalosporins, are highly effective against penicillin-resistant strains. 
– The incidence of MRSA is high in hospital settings, and strains 
intermediately or fully resistant to vancomycin have been 
described. In general, vancomycin is less reliably bactericidal than 
the β-lactams and should be used only when absolutely indicated. 
– Among newer antistaphylococcal agents, daptomycin is bacteri-
cidal but is not effective in pulmonary infections; quinupristin/
dalfopristin is typically bactericidal but is only bacteriostatic 
against isolates resistant to erythromycin or clindamycin; line-
zolid is bacteriostatic and offers similar bioavailability after oral 
or parenteral administration; and telavancin—a derivative of 
vancomycin—is active against strains with reduced susceptibility 
to vancomycin (VISA). Tigecycline, a broad-spectrum minocy-
cline analogue, is bacteriostatic against MRSA. 
• Other alternatives include the quinolones, but resistance to 
these drugs is increasing, especially among MRSA strains. 
• Trimethoprim-sulfamethoxazole (TMP-SMX) and minocy-
cline have been used successfully to treat MRSA infections in 
cases of vancomycin toxicity or intolerance.
• Although some drugs have been used in combination (e.g., 
rifampin, aminoglycosides, fusidic acid), clinical studies have 
not demonstrated a therapeutic benefit.
Special considerations for treatment include:
• Uncomplicated skin and soft tissue infections: Oral agents are usually 
adequate.
TABLE 95-2  ANTIMICROBIAL THERAPY FOR STAPHYLOCOCCAL INFECTIONSa
Sensitivity/Resistance
of Isolate
Drug of Choice
Alternative(s)
Comments
Parenteral therapy for serious infections
Sensitive to penicillin
Penicillin G 
(4 mU q4h)
Nafcillin or oxacillin (2 g 
q4h), cefazolin (2 g q8h), 
vancomycin (1 g q12hb)
Fewer than 5% of isolates are sensitive to penicillin.
Sensitive to methicillin
Nafcillin or oxacillin 
(2 g q4h)
Cefazolin (2 g q8hb), 
vancomycin
(15–20 mg/kg q8–12hb)
Pts with penicillin allergy can be treated with a cephalosporin if the allergy 
does not involve an anaphylactic or accelerated reaction; desensitization 
to β-lactams may be indicated in selected cases of serious infection when 
maximal bactericidal activity is needed (e.g., prosthetic-valve endocarditisd). 
Type A β-lactamase may rapidly hydrolyze cefazolin and reduce its efficacy 
in endocarditis. Vancomycin is a less effective option.
Resistant to methicillin
Vancomycin (15–20 
mg/kg q8–12hb)
Daptomycin (6 mg/
kg q24hb,c) for bactere-
mia, endocarditis, and 
complicated skin infections; 
linezolid (600 mg q12h 
except: 400 mg q12h 
for uncomplicated skin 
infections); quinupristin/
dalfopristin (7.5 mg/kg q8h)
Sensitivity testing is necessary before an alternative drug is used.
Adjunctive drugs (those that should be used only in combination with other 
antimicrobial agents) include gentamicin (1 mg/kg q8hb), rifampin (300 mg PO 
q8h), and fusidic acid (500 mg q8h; not readily available in the United States). 
For some serious infections, higher doses of daptomycin have been used. 
Quinupristin/dalfopristin is bactericidal against methicillin-resistant isolates 
unless the strain is resistant to erythromycin or clindamycin. The efficacy of 
adjunctive therapy is not well established in many settings. Both linezolid and 
quinupristin/dalfopristin have had in vitro activity against most VISA and VRSA 
strains. See footnote for treatment of prosthetic-valve endocarditis.d
Resistant to methicillin 
with intermediate or 
complete resistance to 
vancomycine
Uncertain
Same as for methicillin-
resistant strains; check 
antibiotic susceptibilities
Same as for methicillin-resistant strains; check antibiotic susceptibilities.
590
Not yet known (i.e., 
empirical therapy)
Vancomycin 
(15–20 mg/kg 
q8–12hb)
–
Empirical therapy is given when the susceptibility of the isolate is not known. 
Vancomycin with or without an aminoglycoside is recommended for sus-
pected community- or hospital-acquired S. aureus infections because of the 
increased frequency of methicillin-resistant strains in the community.
Oral therapy for skin and soft tissue infections
Sensitive to methicillin
Dicloxacillin 
(500 mg qid), 
cephalexin
(500 mg qid)
Minocycline or doxycycline 
(100 mg q12hb), TMP-SMX 
(1 or 2 ds tablets bid), 
clindamycin (300–450 
mg/kg tid)
It is important to know the antibiotic susceptibility of isolates in the specific 
geographic region. All drainage should be cultured.
Resistant to methicillin
Clindamycin (300–450 
mg/kg tid), TMP-SMX 
(1 or 2 ds tablets bid), 
minocycline or doxycy-
cline (100 mg q12hb), 
linezolid (400–600 
mg bid)
It is important to know the antibiotic susceptibility of isolates in the specific 
geographic region. All drainage should be cultured.
aRecommended dosages are for adults with normal renal and hepatic function.
bThe dosage must be adjusted for pts with reduced creatinine clearance.
cDaptomycin cannot be used for pneumonia.
dFor the treatment of prosthetic-valve endocarditis, the addition of gentamicin (1 mg/kg q8h) and rifampin (300 mg PO q8h) is recommended, with adjustment of the gentamicin dosage if 
the creatinine clearance rate is reduced.
eVancomycin-resistant S. aureus isolates from clinical infections have been reported.
Abbreviations: TMP-SMX, trimethoprim-sulfamethoxazole; ds, double-strength; VISA, vancomycin-intermediate S. aureus; VRSA, vancomycin-resistant S. aureus.
Source: Modified with permission from FD Lowy: N Engl J Med 339:520, 1998 (© 1998 Massachusetts Medical Society. All rights reserved.) and from DL Stevens et al: Clin Infect Dis 
41:1373, 2006, and Med Lett 48:13, 2006.
591
SECTION 7
592
Infectious Diseases
• Native-valve endocarditis: A β-lactam is recommended for MSSA 
and vancomycin (1 g q12h) for MRSA. Treatment should continue 
for 4–6 weeks.
• Prosthetic-valve endocarditis: Surgery is often needed in addition to 
antibiotics. A β-lactam drug (or vancomycin if MRSA is involved) 
with gentamicin and rifampin is indicated.
• Hematogenous osteomyelitis or septic arthritis: A 4-week treatment 
course is adequate for children, but adults require longer courses. 
Joint infections require repeated aspiration or arthroscopy to pre-
vent damage from inflammatory cells.
• Chronic osteomyelitis: Surgical debridement—in addition to antibi-
otic therapy—is needed in most cases.
• Prosthetic-joint infections: Ciprofloxacin and rifampin have been 
used successfully in combination, particularly when the prosthesis 
cannot be removed.
• TSS: Supportive therapy and removal of tampons or other packing 
material or debridement of an infected site are most important. 
The role of antibiotics is less clear, but a clindamycin/semisynthetic 
penicillin combination is recommended. 
– Clindamycin is recommended because it is a protein synthesis 
inhibitor and has been shown to decrease toxin synthesis in vitro; 
its efficacy in vivo is less clear . 
– IV immunoglobulin may be helpful.
For a more detailed discussion, see Lowy FD: Staphylococcal 
Infections, Chap. 135, p. 1160, in HPIM-18.
CHAPTER 96
Streptococcal/Enterococcal
Infections, Diphtheria, and 
Other Infections Caused by 
Corynebacteria and Related Species
STREPTOCOCCAL AND ENTEROCOCCAL INFECTIONS
� MICROBIOLOGY
Streptococci and enterococci are gram-positive cocci that form chains when 
grown in liquid media. 
• Culture on blood agar reveals three hemolytic patterns:
– α-Hemolysis results in partial hemolysis that imparts a greenish appear-
ance to agar. This pattern is seen with S. pneumoniae and viridans 
streptococci.
CHAPTER 96
593
Streptococcal/Enterococcal Infections
– β-Hemolysis results in complete hemolysis around a colony. This 
pattern is seen with streptococci of Lancefield groups A, B, C, and G. 
Lancefield grouping is based on cell-wall carbohydrate antigens.
– γ-Hemolysis describes the absence of hemolytic ability. This pattern 
is typical of enterococci, nonenterococcal group D streptococci, and 
anaerobic streptococci.
• Streptococci and enterococci colonize the respiratory, GI, and genitouri-
nary tracts as part of the normal flora. Several of these species are also 
important causes of human diseases.
� GROUP A STREPTOCOCCUS (GAS)
Epidemiology and Pathogenesis 
GAS (S. pyogenes) causes suppurative infections and is associated with 
postinfectious syndromes such as acute rheumatic fever (ARF) and post-
streptococcal glomerulonephritis (PSGN). 
• Up to 20% of people may have asymptomatic pharyngeal colonization 
with GAS. 
– Pharyngitis due to GAS is one of the most common bacterial infec-
tions of childhood.
– GAS accounts for 20–40% of all cases of exudative pharyngitis in 
children >3 years of age. 
• The incidence of all GAS infections is ~10-fold higher in low-income 
than in high-income countries. Worldwide, GAS contributes to ~500,000 
deaths per year. 
• The major surface protein (M protein) and the hyaluronic acid poly-
saccharide capsule protect GAS against phagocytic ingestion and 
killing. 
• GAS makes a large number of extracellular products that may contribute 
to local and systemic toxicity; these include streptolysins S and O, strep-
tokinase, DNases, and the pyrogenic exotoxins that cause the rash of 
scarlet fever and contribute to the pathogenesis of toxic shock syndrome 
(TSS) and necrotizing fasciitis. 
• Respiratory droplets provide the usual route of transmission, although 
other mechanisms have been described. 
Clinical Manifestations 
Pharyngitis After an incubation period of 1–4 days, pts develop sore throat, 
fever, chills, malaise, and GI manifestations. 
• Examination may reveal an erythematous and swollen pharyngeal 
mucosa, purulent exudates over the posterior pharynx and tonsillar 
pillars, and tender anterior cervical adenopathy. 
• Viral pharyngitis is the more likely diagnosis when pts have coryza, 
hoarseness, conjunctivitis, or mucosal ulcers. 
• Throat culture is the gold standard for diagnosis. 
– Latex agglutination or enzyme immunoassay is highly specific (>95%) 
and can be relied on for a rapid, definitive diagnosis. 
– Given a variable sensitivity of 55–90%, a negative rapid-assay result 
should be confirmed with a throat culture. 
SECTION 7
594
Infectious Diseases
GAS Pharyngitis
TREATMENT
• See Table 96-1 for recommended treatments. 
– The primary goal of treatment is to prevent suppurative complica-
tions (e.g., lymphadenitis, abscess, sinusitis, bacteremia, pneumonia) 
and ARF; therapy does not seem to reduce the duration of symptoms 
or prevent PSGN. 
– Follow-up cultures after completion of therapy are not routinely 
recommended.
• Asymptomatic pharyngeal GAS carriage usually is not treated; 
however, when the pt is a potential source of infection in others (e.g., 
health care workers), penicillin V (500 mg PO qid for 10 days) with 
rifampin (600 mg PO bid for the final 4 days) is used.
TABLE 96-1 TREATMENT OF GROUP A STREPTOCOCCAL INFECTIONS
Infection
Treatmenta
Pharyngitis
Benzathine penicillin G, 1.2 mU IM; or penicil-
lin V, 250 mg PO tid or 500 mg PO bid ×
10 days
(Children <27 kg: Benzathine penicillin G, 
600,000 units IM; or penicillin V, 250 mg PO 
bid or tid × 10 days)
Impetigo
Same as pharyngitis
Erysipelas/cellulitis
Severe: Penicillin G, 1–2 mU IV q4h
Mild to moderate: Procaine penicillin, 
1.2 mU IM bid
Necrotizing fasciitis/myositis
Surgical debridement; plus penicillin G, 
2–4 mU IV q4h; plus clindamycin,b
600–900 mg q8h
Pneumonia/empyema
Penicillin G, 2–4 mU IV q4h; plus drainage 
of empyema
Streptococcal toxic shock 
syndrome
Penicillin G, 2–4 mU IV q4h; plus
clindamycin,b 600–900 mg q8h; plus IV 
immunoglobulin,b 2 g/kg as a single dose
aPenicillin allergy: A first-generation cephalosporin, such as cephalexin or cefadroxil, may 
be substituted for penicillin in cases of penicillin allergy if the nature of the allergy is not 
an immediate hypersensitivity reaction (anaphylaxis or urticaria) or another potentially life-
threatening manifestation (e.g., severe rash and fever). Alternative agents for oral therapy are 
erythromycin (10 mg/kg PO qid, up to a maximum of 250 mg per dose) and azithromycin (a 
5-day treatment course at a dose of 12 mg/kg once daily, up to a maximum of 500 mg/d). 
Vancomycin is an alternative for parenteral therapy.
bEfficacy unproven, but recommended by several experts.
CHAPTER 96
595
Scarlet Fever
Scarlet fever is the designation for GAS infection—usually 
pharyngitis—associated with a characteristic rash. It is much less common 
now than in the past.
• The rash typically appears in the first 2 days of illness over the upper 
trunk and spreads to the extremities but not to the palms and soles. The 
skin has a sandpaper feel. 
• Other findings include strawberry tongue (enlarged papillae on a coated 
tongue) and Pastia’s lines (accentuation of rash in skin folds). 
• Rash improves in 6–9 days, with desquamation on palms and soles. 
Skin and Soft Tissue Infections See Chap. 93 for further discussion of clinical 
manifestations and treatment.
• Impetigo: A superficial skin infection, impetigo is most often seen in young 
children in warmer months or climates and under poor hygienic conditions. 
– Red papular lesions evolve into pustules that ultimately form char-
acteristic honeycomb-like crusts, usually affecting the facial areas 
around the nose and mouth and the legs. Pts are usually afebrile. 
– GAS impetigo is associated with PSGN.
– For treatment, see Table 96-1. Given an increasing incidence of impe-
tigo due to Staphylococcus aureus, empirical antibiotic therapy should 
cover GAS and S. aureus. 
• Thus dicloxacillin or cephalexin (250 mg PO qid for 10 days) is used.
• Topical mupirocin ointment is also effective. 
• Cellulitis: GAS cellulitis develops at anatomic sites where normal lym-
phatic drainage has been disrupted (e.g., due to surgery or prior celluli-
tis). When skin integrity is breached, organisms may enter at sites distant 
from the area of cellulitis. 
– GAS may cause rapidly developing postoperative wound infections 
with a thin exudate. 
– Erysipelas is a form of cellulitis characterized by pain, fever, and acute 
onset of bright red swelling that is sharply demarcated from normal skin. 
• It usually involves the malar facial area or the lower extremities and 
is caused almost exclusively by GAS.
• The skin often has a peau d’orange texture, and blebs or bullae may 
form after 2 or 3 days. 
– For treatment of erysipelas or cellulitis known to be due to GAS, see 
Table 96-1; empirical treatment should be directed against GAS and S. 
aureus.
• Necrotizing fasciitis: See Chap. 93 for details. GAS causes ~60% of cases 
of necrotizing fasciitis. For treatment, see Table 96-1.
Pneumonia and Empyema GAS is an occasional cause of pneumonia in pre-
viously healthy pts. 
• Pts have pleuritic chest pain, fever, chills, and dyspnea; ~50% have 
accompanying pleural effusions that—unlike the sterile parapneumonic 
effusions of pneumococcal pneumonia—are almost always infected and 
should be drained quickly to avoid loculation. 
• For treatment, see Table 96-1.
Streptococcal/Enterococcal Infections
SECTION 7
596
Infectious Diseases
Bacteremia In most cases of GAS bacteremia, a focus is readily identifiable. 
Bacteremia occurs occasionally with cellulitis and frequently with necrotiz-
ing fasciitis. 
• If no focus is immediately evident, a diagnosis of endocarditis, occult 
abscess, or osteomyelitis should be considered.
Toxic Shock Syndrome Unlike those with TSS due to S. aureus, pts with strep-
tococcal TSS generally lack a rash, have bacteremia, and have an associated 
soft-tissue infection (cellulitis, necrotizing fasciitis, or myositis). 
• Table 96-2 presents a proposed case definition for streptococcal TSS. 
• The mortality rate for streptococcal TSS is ~30%, with most deaths due 
to shock and respiratory failure. 
• For treatment, see Table 96-1.
Prevention
Although household contacts of individuals with invasive GAS infection are 
at increased risk of infection, the attack rate is low enough that antibiotic 
prophylaxis is not routinely recommended.
� STREPTOCOCCI OF GROUPS C AND G
• Streptococci of groups C and G cause infections similar to those caused 
by GAS, including cellulitis, bacteremia (particularly in elderly or chron-
ically ill pts), pneumonia, and soft tissue infections. 
• Strains that form small colonies (<0.5 mm) on blood agar are generally 
of the S. milleri group (S. intermedius, S. anginosus); large-colony groups 
C and G streptococci are now considered a single species (S. dysgalactiae 
subsp. equisimilis).
TABLE 96-2  PROPOSED CASE DEFINITION FOR STREPTOCOCCAL TOXIC 
SHOCK SYNDROMEa
I. Isolation of group A streptococci (S. pyogenes)
 A. From a normally sterile site
 B. From a nonsterile site
II. Clinical signs of severity
 A. Hypotension and
 B. ≥2 of the following signs:
     1. Renal impairment
     2. Coagulopathy
     3. Liver function impairment
     4. Adult respiratory distress syndrome
     5. Generalized erythematous macular rash that may desquamate
      6.  Soft tissue necrosis, including necrotizing fasciitis or myositis; or
gangrene
aAn illness fulfilling criteria IA, IIA, and IIB is defined as a definite case. An illness fulfilling crite-
ria IB, IIA, and IIB is defined as a probable case if no other etiology for the illness is identified.
Source : Modified from Working Group on Severe Streptococcal Infections, JAMA 269:390, 1993.
CHAPTER 96
597
• Treatment is the same as for similar syndromes due to GAS. 
– Although it has not been shown to be superior, the addition of genta-
micin (1 mg/kg IV q8h) is recommended by some experts for endo-
carditis or septic arthritis due to group C or G streptococci because of 
a poor clinical response to penicillin alone. 
– Joint infections can require repeated aspiration or open drainage for cure.
� GROUP B STREPTOCOCCUS (GBS)
• GBS is a major cause of meningitis and sepsis in neonates and a common 
cause of peripartum fever in women. 
– About half of the infants delivered vaginally to mothers colonized with 
GBS (5–40% of women) become colonized, but only 1–2% develop 
infection. 
– With maternal colonization, the risk of neonatal GBS infection is 
high if delivery is preterm or if the mother has an early rupture 
of membranes (>24 h before delivery), prolonged labor, fever, or 
chorioamnionitis.
• Widespread prenatal screening for GBS has reduced the incidence of 
neonatal infection to 0.8 cases per 1000 live births; adults now account 
for a larger proportion of invasive GBS infections than do newborns.
Neonatal Infections 
• Early-onset infection occurs within the first week of life (median age, 20 h). 
The infection is acquired within the maternal genital tract during birth. 
– Neonates typically have respiratory distress, lethargy, and hypotension.
– Bacteremia is noted in ~100% of cases, pneumonia in one-third to 
one-half, and meningitis in one-third.
• Late-onset infection develops in infants >1 week old and generally ≤3 months 
of age (mean age, 3–4 weeks). The organism is acquired during delivery or 
during later contact with a source. 
– Meningitis is the most common manifestation.
– Infants present with lethargy, fever, irritability, poor feeding, and 
occasionally seizures.
GBS Infections in Neonates
TREATMENT
• Penicillin is the agent of choice for all GBS infections.
– Empirical therapy for suspected bacterial sepsis consists of ampicil-
lin and gentamicin while cultures are pending. 
– Many physicians continue to give gentamicin until the pt improves 
clinically.
Prevention
Identification of high-risk mothers and prophylactic administration of 
ampicillin or penicillin during delivery reduce the risk of neonatal infection. 
• Maternal screening for anogenital colonization with GBS at 35–37 weeks 
of pregnancy is currently recommended.
Streptococcal/Enterococcal Infections
SECTION 7
598
Infectious Diseases
• Women who have previously given birth to an infant with GBS disease, who 
have a history of GBS bacteriuria during pregnancy, or who have an unknown 
culture status but risk factors noted above should receive intrapartum prophy-
laxis (usually 5 mU of penicillin G followed by 2.5 mU q4h until delivery). 
– Cefazolin can be used for pts with a penicillin allergy who are at low 
risk for anaphylaxis. 
– If the mother is at risk for anaphylaxis and the GBS isolate is known to 
be susceptible, clindamycin or erythromycin can be used; otherwise, 
vancomycin is indicated.
Infections in Adults 
Most GBS infections in adults are related to pregnancy and parturition. 
Other GBS infections are seen in the elderly, especially pts with underlying 
conditions such as diabetes mellitus or cancer. 
• Cellulitis and soft tissue infection, urinary tract infection (UTI), 
pneumonia, endocarditis, and septic arthritis are most common. 
• Penicillin (12 mU/d for localized infections and 18–24 mU/d for endo-
carditis or meningitis, in divided doses) is recommended. Vancomycin is 
an acceptable alternative for penicillin-allergic pts. 
• Relapse or recurrent invasive infection occurs in ~4% of cases.
� NONENTEROCOCCAL GROUP D STREPTOCOCCI
The main nonenterococcal group D streptococci that cause human infec-
tions are S. gallolyticus, S. pasteurianus, S. infantarius, and S. lutetiensis 
(previously classified together as S. bovis). 
• These organisms have been associated with GI malignancies and other 
bowel lesions, which are found in ≥60% of pts presenting with group D 
streptococcal endocarditis. 
• Unlike enterococcal endocarditis, group D streptococcal endocarditis 
can be adequately treated with penicillin alone.
� VIRIDANS STREPTOCOCCI
• Many viridans streptococcal species are part of the normal oral flora, 
residing in close association with the teeth and gingiva. Minor trauma 
such as flossing or tooth-brushing can cause transient bacteremia. 
• Viridans streptococci have a predilection to cause endocarditis. Moreover, 
they are often part of a mixed flora in sinus infections and brain and liver 
abscesses. 
• Bacteremia is common in neutropenic pts, who can develop a sepsis 
syndrome with high fever and shock. Risk factors in these pts include 
chemotherapy with high-dose cytosine arabinoside, prior treatment 
with trimethoprim-sulfamethoxazole (TMP-SMX) or a fluoroquinolone, 
mucositis, or therapy with antacids or histamine antagonists. 
• The S. milleri group (including S. intermedius, S. anginosus, and 
S. constellatus) differs from other viridans streptococci in both hemolytic 
pattern (i.e., they may be α-, β-, or γ-hemolytic) and clinical syndromes. 
These organisms commonly cause suppurative infections, especially 
abscesses of brain and viscera, as well as respiratory tract infections such 
as pneumonia, empyema, and lung abscess. 
CHAPTER 96
599
• Neutropenic pts should receive vancomycin pending susceptibility test-
ing; other pts may be treated with penicillin.
� ABIOTROPHIA AND GRANULICATELLA SPECIES (NUTRITIONALLY 
VARIANT STREPTOCOCCI)
• The organisms formerly known as nutritionally variant streptococci 
are now classified as Abiotrophia defectiva and three species within the 
genus Granulicatella. These fastidious organisms require media that are 
enriched (e.g., with vitamin B6) for growth. 
• These organisms are more frequently associated with treatment failure 
and relapse in cases of endocarditis than are viridans streptococci. Thus 
gentamicin (1 mg/kg q8h) must be added to the penicillin regimen. 
� ENTEROCOCCAL INFECTIONS
Microbiology 
Enterococci are gram-positive cocci that are observed as single cells, diplo-
cocci, or short chains. 
• Enterococci share many morphologic and phenotypic characteristics 
with streptococci and thus were previously classified as the latter. 
• Enterococci are generally nonhemolytic when cultured on blood agar 
plates.
• Enterococci are inherently resistant to a variety of commonly used 
antibiotics. E. faecium is the most resistant species, with >80% of U.S. 
isolates resistant to vancomycin (VRE) and >90% resistant to ampicillin. 
In contrast, only ~7% of E. faecalis isolates are resistant to vancomycin 
and ~4% to ampicillin.
Epidemiology 
Although 18 enterococcal species have been isolated from human infec-
tions, E. faecalis and E. faecium cause the overwhelming majority of entero-
coccal infections.
• Enterococci are the second most common cause of nosocomial infection 
(after staphylococci), with roughly equal numbers of cases caused by 
E. faecalis and E. faecium. 
• Colonization with VRE (as opposed to antibiotic-susceptible strains) 
predisposes to enterococcal infection. Risk factors for VRE colonization 
include prolonged hospitalization; long antibiotic courses; hospitaliza-
tion in long-term-care facilities, surgical units, and/or ICUs; organ trans-
plantation; renal failure; high APACHE scores; and physical proximity to 
pts colonized with VRE.
Clinical Manifestations 
Enterococci cause UTIs, especially in pts who have undergone instrumen-
tation; chronic prostatitis; bacteremia related to intravascular catheters; 
bacterial endocarditis of both native and prosthetic valves (usually with a 
subacute presentation); meningitis, particularly in pts who have undergone 
neurosurgery; soft tissue infections, particularly involving surgical wounds; 
and neonatal infections. These organisms can also be a component of mixed 
intraabdominal infections.
Streptococcal/Enterococcal Infections
SECTION 7
600
Infectious Diseases
Enterococcal Infections
TREATMENT
• Given low cure rates with β-lactam monotherapy, combination therapy 
with a β-lactam plus gentamicin or streptomycin is recommended for 
serious enterococcal infections. High-level resistance to aminoglycosides 
(i.e., minimal inhibitory concentrations of >500 and >2000 μg/mL for 
gentamicin and streptomycin, respectively) abolishes the synergism oth-
erwise obtained by adding an aminoglycoside to a cell wall–active agent. 
This phenotype must be assessed in isolates from serious infections.
• For E. faecium isolates resistant to ampicillin: 
– Daptomycin, quinupristin/dalfopristin, or linezolid plus another 
active agent (doxycycline with rifampin, tigecycline, or a fluoro-
quinolone) may be used.
– If daptomycin is used and if high-level resistance is not noted, an 
aminoglycoside should be added to the regimen.
• If high-level aminoglycoside resistance is present, two other active 
agents should be used. 
CORYNEBACTERIAL AND RELATED INFECTIONS
� CORYNEBACTERIUM DIPHTHERIAE
Microbiology 
C. diphtheriae, the causative agent of the nasopharyngeal and skin infec-
tion known as diphtheria, is a club-shaped, gram-positive, unencapsulated, 
nonmotile, nonsporulating rod. 
• The bacteria often form clusters of parallel arrays (palisades) in culture, 
referred to as Chinese characters. 
• Some strains produce diphtheria toxin, which can cause myocarditis, poly-
neuropathy, and other systemic toxicities and is associated with the forma-
tion of pseudomembranes in the pharynx during respiratory infection.
Epidemiology and Pathogenesis
As a result of routine immunization, fewer than five cases of diphtheria are 
diagnosed per year in the United States. 
• Low-income countries in Africa and Asia continue to have significant 
outbreaks; globally, there were ~7000 cases of diphtheria in 2008 and 
~5000 deaths related to diphtheria in 2004.
• C. diphtheriae is transmitted via the aerosol route, primarily during close 
contact. 
• Diphtheria toxin—the primary virulence factor—irreversibly inhibits 
protein synthesis, thereby causing the death of the cell.
Clinical Manifestations 
• Respiratory diphtheria: Upper respiratory tract illness due to C. diphthe-
riae typically has a 2- to 5-day incubation period and is diagnosed on the 
basis of a constellation of sore throat; low-grade fever; and a tonsillar, 
pharyngeal, or nasal pseudomembrane. 
CHAPTER 96
601
– Unlike that of GAS pharyngitis, the pseudomembrane of diphtheria is 
tightly adherent; dislodging the membrane usually causes bleeding. 
– Massive swelling of the tonsils and “bull-neck” diphtheria resulting 
from submandibular and paratracheal edema can develop. This illness 
is further characterized by foul breath, thick speech, and stridorous 
breathing.
– Respiratory tract obstruction due to swelling and sloughing of the 
pseudomembrane can be fatal.
– Neurologic manifestations may appear during the first 2 weeks of 
illness, beginning with dysphagia and nasal dysarthria and progress-
ing to cranial nerve involvement (e.g., weakness of the tongue, facial 
numbness, blurred vision due to ciliary paralysis).
• Several weeks later, a generalized sensorimotor polyneuropathy with 
prominent autonomic dysfunction (including hypotension) may occur.
• Pts who survive the acute phase gradually improve.
• Cutaneous diphtheria: This variable dermatosis is generally characterized 
by punched-out ulcerative lesions with necrotic sloughing or pseudo-
membrane formation. Pts typically present to medical care because of 
nonhealing or enlarging ulcers; the lesions rarely exceed 5 cm in diameter.
Diagnosis
A definitive diagnosis is based on compatible clinical findings and detection 
of C. diphtheriae or toxigenic C. ulcerans (by isolation or histologic identi-
fication) in local lesions. 
• The laboratory should be notified that diphtheria is being considered, 
and appropriate selective media must be used.
• In the U.S., respiratory diphtheria is a notifiable disease; cutaneous diph-
theria is not.
Diphtheria
TREATMENT
• Diphtheria antitoxin is the most important component of treatment 
and should be given as soon as possible. To obtain antitoxin, contact 
the Emergency Operations Center at the CDC (770-488-7100). See 
www.cdc.gov/vaccines/vpd-vac/diphtheria/dat/dat-main.htm for fur-
ther information.
• Antibiotic therapy is administered for 14 days to prevent transmission 
to contacts. The recommended options are (1) procaine penicillin 
G (600,000 U IM q12h in adults; 12,500–25,000 U/kg IM q12h in 
children) until the pt can take oral penicillin V (125–250 mg qid); or 
(2) erythromycin (500 mg IV q6h in adults; 40–50 mg/kg per day IV in 
2–4 divided doses in children) until the pt can take oral erythromycin 
(500 mg qid). 
– Rifampin and clindamycin are other options for pts who cannot 
tolerate penicillin or erythromycin. 
– Cultures should document eradication of the organism 1 and 
14 days after completion of antibiotic therapy. If the organism is not
Streptococcal/Enterococcal Infections
SECTION 7
602
Infectious Diseases
 
eradicated after 2 weeks of therapy, an additional 10-day course 
followed by repeat cultures is recommended.
• Respiratory isolation and close monitoring of cardiac and respiratory 
functions should be instituted.
Prognosis
Risk factors for death include a long interval between onset of local disease 
and antitoxin administration; bull-neck diphtheria; myocarditis with ven-
tricular tachycardia; atrial fibrillation; complete heart block; an age of >60 
years or <6 months; alcoholism; extensive pseudomembrane elongation; 
and laryngeal, tracheal, or bronchial involvement. 
Prevention
DTaP (diphtheria and tetanus toxoids and acellular pertussis vaccine 
adsorbed) is recommended for primary immunization of children up to 
age 7 years; Tdap (tetanus toxoid, reduced diphtheria toxoid, and acellular 
pertussis) is recommended as the booster vaccine for children 11–12 years 
old and as the catch-up vaccine for children 7–10 and 13–18 years old. 
• Td (tetanus and diphtheria toxoids) is recommended for routine booster 
use in adults at 10-year intervals or for tetanus-prone wounds. When 
>10 years have elapsed since the last Td dose, adults 19–64 years old 
should receive a single dose of Tdap. 
• Close contacts of pts with respiratory diphtheria should have throat 
specimens cultured for C. diphtheriae, should receive a 7- to 10-day 
course of oral erythromycin or one dose of benzathine penicillin (1.2 mU 
for persons ≥6 years old; 600,000 U for children <6 years old), and should 
be vaccinated if immunization status is uncertain.
� INFECTIONS WITH OTHER CORYNEBACTERIA AND 
RELATED ORGANISMS
Nondiphtherial Corynebacterium species and related organisms are com-
mon components of the normal human flora. Although frequently consid-
ered contaminants, these bacteria are associated with invasive disease in 
immunocompromised hosts.
• C. ulcerans infection is a zoonosis that causes diphtheria-like illness and 
requires similar treatment.
• C. jeikeium infects pts with cancer or severe immunodeficiency and can 
cause severe sepsis, endocarditis, device-related infections, pneumonia, 
and soft tissue infections. Treatment consists of removal of the source of 
infection and administration of vancomycin.
• C. urealyticum is a cause of sepsis and nosocomial UTI, including 
alkaline-encrusted cystitis (a chronic inflammatory bladder infection 
associated with deposition of ammonium magnesium phosphate on the 
surface and walls of ulcerating lesions in the bladder). Vancomycin is an 
effective therapeutic agent.
• Rhodococcus species appear as spherical to long, curved, clubbed gram-
positive rods that are often acid-fast. The most common presentation—
nodular cavitary pneumonia of the upper lobe (similar to tuberculosis 
CHAPTER 97 
603
Meningococcal and Listerial Infections 
and nocardiosis) in an immunocompromised host—often occurs in 
conjunction with HIV infection. Vancomycin is the drug of choice, but 
macrolides, clindamycin, rifampin, and TMP-SMX have also been used 
to treat these infections.
• Arcanobacterium haemolyticum can cause pharyngitis and chronic skin 
ulcers, often in association with a scarlatiniform rash similar to that 
caused by GAS. The organism is susceptible to β-lactam agents, mac-
rolides, fluoroquinolones, clindamycin, vancomycin, and doxycycline. 
Penicillin resistance has been reported .
For a more detailed discussion, see Wessels MR: 
Streptococcal Infections, Chap. 136, p. 1171; Arias CA, 
Murray BE: Enterococcal Infections, Chap. 137, p. 1180; 
and Bishai WR, Murphy JR: Diphtheria and Other Infections 
Caused by Corynebacteria and Related Species, Chap. 138, 
p. 1188, in HPIM-18.
CHAPTER 97
Meningococcal and Listerial 
Infections
MENINGOCOCCAL INFECTIONS
• Etiology and Microbiology Neisseria meningitidis is a catalase- and 
oxidase-positive, gram-negative aerobic diplococcus with a polysaccha-
ride capsule that colonizes humans only. 
– Of the 13 identified serogroups, only 5—A, B, C, Y, and W135—
account for the majority of cases of invasive disease.
– Serogroups A and W135 cause recurrent epidemics in sub-Saharan 
Africa. Serogroup B can cause hyperendemic disease, and serogroups 
C and Y cause sporadic disease and small outbreaks.
• Epidemiology Up to 500,000 cases of meningococcal disease occur 
worldwide each year, with a mortality rate of ~10%. 
– Most commonly, meningococci asymptomatically colonize the naso-
pharynx; such asymptomatic nasopharyngeal carriage is detected in 
>25% of healthy adolescents and adults.
– Patterns of meningococcal disease include epidemics, outbreaks (e.g., 
in colleges, refugee camps), hyperendemic disease, and sporadic or 
endemic cases.
– Although most countries have predominantly sporadic cases (0.3–5 cases 
per 100,000 population), epidemics in sub-Saharan Africa can have rates 
as high as 1000 cases per 100,000 population.
– Rates of meningococcal disease are highest among infants, with a 
second peak in adolescents and young adults (15–25 years of age).
SECTION 7
604
Infectious Diseases
– Other risk factors for meningococcal disease include complement 
deficiency (C5–C9), close contact with carriers, exposure to tobacco 
smoke, and a recent URI caused by a virus or Mycoplasma species.
• Pathogenesis Meningococci colonizing the upper respiratory tract 
invade the bloodstream through the mucosa only rarely, usually within a 
few days after an invasive strain is acquired.
– The capsule is an important virulence factor, providing resistance to 
phagocytosis and helping prevent desiccation during transmission 
between hosts.
– Severity of disease is related to the degree of endotoxemia and the 
magnitude of the inflammatory response.
– Endothelial injury leads to increased vascular permeability and hypo-
volemia, resulting in vasoconstriction and ultimately in decreased 
cardiac output.
– Intravascular thrombosis caused by activation of procoagulant path-
ways and down-regulation of anticoagulant pathways results in the 
characteristic purpura fulminans often seen in meningococcemia. 
• Clinical Manifestations The most common clinical syndromes are men-
ingitis and meningococcal septicemia, with disease usually developing 
within 4 days of organism acquisition.
– A nonblanching rash (petechial or purpuric) develops in >80% of 
cases; early in the illness, the rash is often absent or may be indistin-
guishable from viral rashes.
– Meningococcal meningitis alone (without septicemia) accounts for 
30–50% of cases. 
• This meningitis is indistinguishable from other forms of bacterial 
meningitis unless there is an associated petechial or purpuric rash.
• Classic signs of meningitis (e.g., headache, neck stiffness, photophobia) 
are often absent or difficult to discern in infants and young children.
– Meningococcal septicemia alone accounts for ~20% of cases and 
initially may present as an influenza-like illness (e.g., fever, headache, 
myalgias, vomiting, abdominal pain).
• May progress to shock (e.g., tachycardia, poor peripheral perfu-
sion, oliguria), decreased level of consciousness due to decreased 
cerebral perfusion, spontaneous hemorrhage (pulmonary, gastric, 
or cerebral), and ultimately multiorgan failure and death.
• Poor prognostic factors include an absence of meningismus, 
hypotension, relatively low temperature (<38°C), leukopenia, and 
thrombocytopenia.
– Chronic meningococcemia presents as repeated episodes of petechial 
rash associated with fever, joint pain, features of arthritis, and spleno-
megaly that may progress to acute meningococcal septicemia if untreated.
• Chronic meningococcemia is rarely recognized.
• This condition is occasionally associated with complement defi-
ciencies or inadequate sulfonamide therapy.
– Postmeningococcal reactive disease is an immune complex–mediated 
disease that occurs 4–10 days after onset of meningococcal disease.
CHAPTER 97 
605
Meningococcal and Listerial Infections 
• Manifestations can include a maculopapular or vasculitic rash (2% 
of cases), arthritis (≤8% of cases), iritis (1% of cases), or serositis. 
These features resolve spontaneously without sequelae.
• Less common clinical manifestations include pneumonia, pyogenic 
arthritis, osteomyelitis, purulent pericarditis, endophthalmitis, 
conjunctivitis, or primary peritonitis.
• Diagnosis Although meningococcal infections are often diagnosed on 
clinical grounds, blood cultures are positive in ~75% of cases and should 
be performed to confirm the diagnosis and to facilitate public health 
investigations.
– In the setting of fever and petechial rash, elevations in the WBC count 
and inflammatory marker levels suggest meningococcal disease.
– With antibiotic pretreatment, blood cultures are generally negative; in 
contrast,  PCR analysis of whole-blood samples is effective for several days 
after initiation of antibiotics and increases the diagnostic yield by >40%.
– Unless contraindicated on clinical grounds, LP should be performed 
in cases of suspected meningococcal meningitis.
• Gram’s staining of CSF is ~80% sensitive, and CSF culture is 90% 
sensitive. Latex agglutination testing of CSF is insensitive and 
should be avoided.
• LP should be avoided in pts with meningococcal septicemia, as posi-
tioning for the procedure may adversely affect circulatory status.
Meningococcal Infections
TREATMENT
• Initial therapy should focus on urgent clinical issues (e.g., hypovo-
lemic shock, increased intracranial pressure, airway patency) and 
administration of antibiotic therapy.
• Empirical antibiotic therapy for suspected meningococcal disease 
consists of a third-generation cephalosporin such as ceftriaxone 
[75–100 mg/kg per day (maximum, 4 g/d) in one or two divided IV 
doses] or cefotaxime [200 mg/kg per day (maximum, 8 g/d) in four 
divided IV doses] to provide coverage both for meningococci and for 
other, potentially penicillin-resistant organisms that may produce an 
indistinguishable clinical syndrome.
• Meningococcal meningitis and meningococcal septicemia are con-
ventionally treated for 7 days.
– A single dose of ceftriaxone has been used successfully in resource-
poor settings.
– Treatment for meningococcal disease at other foci (e.g., pneumo-
nia, arthritis) is usually continued until clinical and laboratory 
evidence of infection has resolved.
• Little evidence supports other adjunctive therapies (e.g., antibody to 
lipopolysaccharide, recombinant bactericidal/permeability-increasing 
protein, activated protein C) in relevant pt populations; these thera-
pies are not currently recommended.
SECTION 7
606
Infectious Diseases
• Prognosis Despite the availability of antibiotics and other intensive 
medical interventions, ~10% of pts die.
– Necrosis of purpuric lesions leads to scarring and potential need for 
skin grafting in ~10% of cases.
– Amputations are required in ~2% of cases. 
• Prevention Polysaccharide-based and conjugate vaccines exist for 
primary prevention; secondary cases can be prevented with antibiotic 
prophylaxis. 
– Meningococcal polysaccharide vaccines are currently formulated 
as bivalent (serogroups A and C) or quadrivalent (serogroups A, 
C, Y, and W135) and provide adults with immunity of 2–10 years’ 
duration. Because the B polysaccharide is the same as a polysaccharide 
expressed in fetuses and is therefore recognized as self, serogroup B 
strains have not been targeted by polysaccharide vaccines.
– A variety of meningococcal conjugate vaccines have been developed 
for administration to children. A quadrivalent formulation (sero-
groups A, C, Y, and W135) is most common in the United States.
– Close contacts (i.e., household and kissing contacts) of pts with 
meningococcal disease should receive prophylaxis with ciprofloxacin, 
ofloxacin, or ceftriaxone to eradicate nasopharyngeal colonization by 
N. meningitidis.
• Rifampin fails to eradicate carriage in 15–20% of cases, and emerg-
ing resistance has been reported.
• Pts with meningococcal disease who receive treatment with an 
antibiotic that does not clear colonization (e.g., penicillin) should 
also be given a prophylactic agent at the end of therapy.
LISTERIAL INFECTIONS
• Etiology and Microbiology Listeria monocytogenes is a food-borne 
pathogen that can cause serious infections, particularly in pregnant 
women and immunocompromised individuals. 
– The organism is a facultatively anaerobic, nonsporulating, gram-
positive rod that demonstrates motility when cultured at low 
temperatures. 
– Listeria is commonly found in processed and unprocessed foods 
such as soft cheeses, delicatessen meats, hot dogs, milk, and cold 
salads.
– After ingestion of food that contains a high bacterial burden, viru-
lence factors expressed by Listeria allow internalization into cells, 
intracellular growth, and cell-to-cell spread.
• Epidemiology 
– Recent annual incidences in the United States range from 2 to 9 cases 
per 1 million population.
– There is no human-to-human transmission (other than vertical trans-
mission from mother to fetus) or waterborne infection.
• Clinical Manifestations Listeria causes several clinical syndromes, of 
which meningitis and septicemia are most common.
CHAPTER 97 
607
Meningococcal and Listerial Infections 
– Gastroenteritis: Can develop within 48 h after ingestion of contami-
nated foods containing a large bacterial inoculum.
• Listeriosis should be considered in outbreaks of gastroenteritis 
when cultures for other likely pathogens are negative.
• Sporadic cases appear to be uncommon.
– Bacteremia: Pts present with fever, chills, myalgias, and arthralgias. 
Endocarditis is uncommon and is associated with fatality rates of 35–50%.
– Meningitis: Listeria causes ~5–10% of cases of community-acquired 
meningitis in adults in the United States, with case–fatality rates of 
15–26%. 
• Listerial meningitis differs from meningitis of other bacterial eti-
ologies in that its presentation is often subacute and the CSF profile 
usually reveals <1000 WBCs/μL with a less marked neutrophil 
predominance. 
• Low glucose levels and a positive Gram’s stain are seen in ~30–40% 
of cases.
– Meningoencephalitis and focal CNS infection: Listeria can directly 
invade the brain parenchyma and cause cerebritis or focal abscess. 
• Of CNS infections, ~10% are macroscopic abscesses, which are 
sometimes misdiagnosed as tumors.
• Brainstem invasion can cause severe rhombencephalitis, with 
asymmetric cranial nerve defects, cerebellar signs, and hemipa-
retic/hemisensory defects.
– Infection in pregnant women and neonates: Listeriosis is a serious 
infection in pregnancy. 
• Pregnant women are usually bacteremic and present with a non-
specific febrile illness that includes myalgias/arthralgias, backache, 
and headache; CNS involvement is rare. Infected women usually do 
well after delivery. 
• Infection develops in 70–90% of fetuses from infected women; 
almost 50% of infected fetuses die. This risk can be reduced with 
prepartum treatment. 
• Overwhelming listerial fetal infection—granulomatosis infantiseptica—
is characterized by miliary microabscesses and granulomas, most often 
in the skin, liver, and spleen.
• Late-onset neonatal disease develops ~10–30 days after delivery by 
mothers with asymptomatic infection.
• Diagnosis Timely diagnosis requires that the illness be considered in 
groups at risk: pregnant women, elderly pts, neonates, immunocom-
promised pts, and pts with chronic underlying medical conditions (e.g., 
alcoholism, diabetes). 
– Listeriosis is diagnosed when the organism is cultured from a usually 
sterile site, such as blood, CSF, or amniotic fluid. 
– Listeriae may be confused with “diphtheroids” or pneumococci in gram-
stained CSF or may be gram-variable and confused with Haemophilus spp.
– Serologic tests and PCR assays are not clinically useful at present.
SECTION 7
608
Infectious Diseases
Listerial Infections
TREATMENT
• Ampicillin (2 g IV q4h) is the drug of choice for the treatment of liste-
rial infections; penicillin is also highly active. 
– Most experts recommend gentamicin (1.0–1.7 mg/kg IV q8h) for 
synergy. 
– For penicillin-allergic pts, trimethoprim-sulfamethoxazole (15–20 
mg of TMP/kg IV daily in divided doses q6–8h) should be given. 
Cephalosporins are not effective.
– Neonates should receive ampicillin and gentamicin, dosed by weight.
• The duration of therapy depends on the syndrome: 2 weeks for bacte-
remia, 3 weeks for meningitis, 6–8 weeks for brain abscess/encephali-
tis, and 4–6 weeks for endocarditis. Early-onset neonatal disease can 
be severe and requires >2 weeks of treatment.
• Prognosis With prompt therapy, many pts recover fully.
– However, permanent neurologic sequelae are common in pts with 
brain abscess or rhombencephalitis.
– Of live-born treated neonates in one series, 60% recovered fully, 24% 
died, and 13% were left with neurologic or other complications.
• Prevention Pregnant women and other persons at risk for listeriosis 
should avoid soft cheeses and should avoid or thoroughly reheat ready-
to-eat and delicatessen foods, even though the absolute risk posed by 
these foods is relatively low. 
For a more detailed discussion, see Pollard AJ: Meningococcal 
Infections, Chap. 143, p. 1211; and Hohmann EL, Portnoy 
DA: Listeria monocytogenes Infections, Chap. 139, p. 1194, 
in HPIM-18.
CHAPTER 98
Infections Caused by 
Haemophilus, Bordetella, 
Moraxella, and HACEK Group Organisms
HAEMOPHILUS INFLUENZAE
� MICROBIOLOGY 
H. influenzae is a small, gram-negative, pleomorphic coccobacillus that 
grows both aerobically and anaerobically. 
• Six major serotypes (designated a through f ) have been identified on the 
basis of antigenically distinct polysaccharide capsules. 
• Unencapsulated strains are referred to as nontypable (NTHi).
CHAPTER 98 
609
Haemophilus, Bordetella, Moraxella, HACEK
� EPIDEMIOLOGY 
H. influenzae, an exclusively human pathogen, is spread by airborne drop-
lets or through direct contact with secretions or fomites. 
• Type b (Hib) strains are most important clinically, causing systemic inva-
sive disease, primarily in infants and children <6 years of age. 
• Widespread use of Hib conjugate vaccine in industrialized countries has 
dramatically decreased rates of Hib colonization and invasive disease, but 
the majority of children worldwide remain unimmunized. 
• Both typable and nontypable strains can asymptomatically colonize the 
nasopharynx.
� PATHOGENESIS 
Hib strains cause systemic disease by invasion and systemic spread from the 
respiratory tract to distant sites (e.g., meninges, bones, joints). In contrast, 
NTHi strains cause disease by spread from the nasopharynx to contiguous 
sites (e.g., middle ear, lower respiratory tract).
• The polysaccharide capsule of encapsulated strains is critical for the 
organism's avoidance of opsonization. 
• Levels of maternally derived antibodies to the capsular polysaccharide 
decline from birth to ~6 months of age and—in the absence of vaccination—
remain low until ~2–3 years of age. 
� CLINICAL MANIFESTATIONS
• Hib infection The most serious Hib infections are associated with men-
ingitis or epiglottitis.
– Meningitis: primarily affects children <2 years old and presents simi-
larly to meningitis due to other bacterial pathogens.
• Mortality rates are ~5%.
• Morbidity rates are high: 6% of pts have sensorineural hearing 
loss; one-fourth have some significant handicap; and one-half have 
some neurologic sequelae.
– Epiglottitis: occurs in children 2–7 years old and occasionally in adults. 
It involves cellulitis of the epiglottis and supraglottic tissues that 
begins with a sore throat and fever and progresses rapidly to dyspha-
gia, drooling, and airway obstruction.
– Other infections: include cellulitis, pneumonia, osteomyelitis, septic 
arthritis, and bacteremia without a source.
• NTHi infection NTHi is a common cause of lower respiratory tract 
disease in adults, particularly those with chronic obstructive pulmonary 
disease (COPD).
– COPD exacerbations: characterized by increased cough, sputum pro-
duction, and shortness of breath.
– Pneumonia: presents similarly to other bacterial pneumonias, includ-
ing pneumococcal pneumonia.
– Other infections: NTHi is one of the three most common causes of 
childhood otitis media and is an important cause of sinusitis (in adults 
and children) and neonatal bacteremia. It is a less common cause of 
invasive infections in adults.
SECTION 7
610
Infectious Diseases
� DIAGNOSIS 
Recovery of the organism in culture is the most reliable method for diagnosis. 
• The presence of gram-negative coccobacilli in gram-stained CSF pro-
vides strong evidence for meningitis due to H. influenzae.
• Detection of polyribitol ribose phosphate (PRP)—polymers of which 
form the type b capsule—in CSF allows rapid diagnosis of Hib meningitis 
before culture results are available.
H. inﬂ uenzae Infections
TREATMENT
• Initial therapy for Hib meningitis consists of a third-generation cephalo-
sporin: ceftriaxone (2 g q12h) or cefotaxime (2 g q4–6h) for adults and cef-
triaxone (75–100 mg/kg q12h) or cefotaxime (50 mg/kg q6h) for children.
– Children >2 months of age should receive adjunctive dexametha-
sone (0.15 mg/kg IV q6h for 2 days) to reduce the incidence of 
neurologic sequelae.
– Antibiotic therapy should continue for 7–14 days.
• Antibiotic treatment for invasive infections other than meningitis (e.g., 
epiglottitis) consists of the same antibiotic but at a dosage different 
from that given for meningitis—e.g., ceftriaxone (2 g q24h) for adults.
– Treatment duration depends on the clinical response.
– A course lasting 1–2 weeks is generally appropriate.
• Most NTHi infections can be treated with oral antibiotics, such as 
amoxicillin/clavulanate, extended-spectrum cephalosporins, newer 
macrolides (azithromycin or clarithromycin), and fluoroquinolones 
(in nonpregnant adults). 
– About 20–35% of NTHi strains produce β-lactamase. 
– The incidence of strains with altered penicillin-binding proteins 
conferring resistance to ampicillin is increasing in Europe and Japan.
� PREVENTION 
Hib vaccine is recommended for all children worldwide; the immunization 
series should be started at ~2 months of age. 
• Secondary attack rates are high among household contacts of pts 
with Hib disease. All children and adults (except pregnant women) in 
households with a case of Hib disease and at least one incompletely 
immunized contact <4 years of age should receive prophylaxis with oral 
rifampin.
• No vaccines against NTHi disease are currently available.
PERTUSSIS
� MICROBIOLOGY AND PATHOGENESIS 
Bordetella pertussis, the etiologic agent of pertussis, is a fastidious gram-
negative pleomorphic aerobic bacillus that attaches to ciliated epithelial 
cells of the nasopharynx, multiplies locally, and produces a wide array of 
toxins and biologically active products. 
CHAPTER 98 
611
• B. parapertussis causes a similar, though typically milder, illness.
• The most important toxin in B. pertussis is pertussis toxin, which has 
ADP ribosylating activity. The absence of this toxin in B. parapertussis 
may explain the milder illness.
� EPIDEMIOLOGY 
Pertussis is highly communicable. In households, attack rates are 80% 
among unimmunized contacts and 20% among immunized contacts. 
• Pertussis remains an important cause of infant morbidity and death in 
developing countries, with ~250,000 childhood deaths worldwide in 2004. 
• In the United States, although the incidence of pertussis has decreased 
by >95% because of universal childhood vaccination, 10,454 cases were 
reported in 2007, with increasing rates among adolescents and adults. 
• Persistent cough of >2 weeks’ duration in an adult may be due to B. pertussis 
in 12–30% of cases. 
• Severe morbidity and mortality are restricted to infants <6 months of age.
� CLINICAL MANIFESTATIONS 
After an incubation period of 7–10 days, a prolonged coughing illness 
begins. Symptoms are usually more severe in infants and young children.
• The initial symptoms (the catarrhal phase) are similar to those of the 
common cold (e.g., coryza, lacrimation, mild cough, low-grade fever, 
malaise) and last 1–2 weeks.
• The paroxysmal phase follows and lasts 2–4 weeks. It is characterized 
by a hallmark cough that occurs in spasmodic fits of 5–10 coughs each. 
Vomiting or a “whoop” may follow a coughing fit. Apnea and cyanosis 
can occur during spasms. Most complications occur during this phase.
• During the subsequent convalescent phase, coughing episodes resolve 
gradually over 1–3 months. For 6–12 months, viral infections may 
induce a recrudescence of paroxysmal cough.
• Disease manifestations are often atypical in adolescents and adults, with 
paroxysmal cough and the “whoop” being less common. Post-tussive emesis 
is the best predictor of pertussis as the cause of prolonged cough in adults.
• Lymphocytosis (an absolute lymphocyte count of >105/μL) suggests per-
tussis in young children, but is not common among affected adolescents 
and adults.
� DIAGNOSIS
• Cultures of nasopharyngeal secretions—the gold standard for diagno-
sis—remain positive in untreated cases of pertussis for a mean of 3 weeks 
after illness onset. Given that the diagnosis often is not considered until 
the pt is in the paroxysmal phase, there is a small window of opportunity 
for culture-proven diagnosis.
– Secretions must be inoculated immediately onto selective media. 
– Results become positive by day 5.
• Compared with culture, PCR of nasopharyngeal specimens is more sen-
sitive and yields positive results longer in both treated and untreated pts. 
– Reporting of pseudo-outbreaks of pertussis based on false-positive 
PCR results indicates the need for greater standardization.
Haemophilus, Bordetella, Moraxella, HACEK
SECTION 7
612
Infectious Diseases
• Although serology can be useful in pts with symptoms lasting >4 weeks, 
interpretation of results is complicated by late presentation for medical 
care and prior immunization.
Pertussis
TREATMENT
• Antibiotic therapy does not substantially alter the clinical course 
unless given early in the catarrhal phase but is effective at eradicating 
the organism from the nasopharynx.
– Macrolides (erythromycin, 1–2 g/d for 1–2 weeks; clarithromycin, 
250 mg bid for 1 week; or azithromycin, 500-mg load on day 1, then 
250 mg/d for 4 days) are the drugs of choice.
– Trimethoprim-sulfamethoxazole (TMP-SMX; one double-strength tab-
let PO bid for 2 weeks) is recommended for macrolide-intolerant pts.
• Cough suppressants are ineffective and have no role in management of 
pertussis.
• Respiratory isolation is required for hospitalized pts until antibiotics 
have been given for 5 days.
� PREVENTION
• Chemoprophylaxis with macrolides is recommended for household 
contacts of pts, especially if there are household members at high risk of 
severe disease (e.g., children <1 year of age, pregnant women); however, 
there is no evidence demonstrating that this regimen leads to a decrease 
in the incidence of clinical disease.
• In addition to the regular childhood immunization schedule, adolescents 
and adults should receive a one-time booster with an acellular vaccine. 
MORAXELLA CATARRHALIS
� MICROBIOLOGY AND EPIDEMIOLOGY 
M. catarrhalis is an unencapsulated gram-negative diplococcus. Part of the 
normal flora of the upper airways, M. catarrhalis colonizes 33–100% of 
infants; the prevalence of colonization decreases steadily with age.
� CLINICAL MANIFESTATIONS
• M. catarrhalis causes 15–20% of cases of acute otitis media in children. 
Acute otitis media caused by M. catarrhalis or NTHi is clinically milder 
than cases caused by S. pneumoniae, with less fever and a lower fre-
quency of an erythematous, bulging tympanic membrane.
• M. catarrhalis accounts for ~20% of cases of acute bacterial sinusitis in 
children and for a smaller proportion in adults. 
• In adults, M. catarrhalis is a common cause of exacerbations of chronic 
obstructive pulmonary disease (COPD), accounting for ~10% of cases.
• M. catarrhalis is an infrequent cause of pneumonia. When it occurs, it 
generally affects elderly pts with underlying cardiopulmonary disease.
� DIAGNOSIS 
Invasive procedures are needed to definitively identify the etiology of 
otitis media or sinusitis and are generally not performed. Isolation of 
CHAPTER 98 
613
M. catarrhalis from sputum samples from pts with COPD is suggestive, but 
not diagnostic, of M. catarrhalis as the cause.
M. catarrhalis Infections
TREATMENT
• Otitis media in children and exacerbations of COPD in adults are gen-
erally managed empirically with antibiotics active against Streptococcus 
pneumoniae, Haemophilus influenzae, and M. catarrhalis. 
• Most strains of M. catarrhalis are susceptible to amoxicillin/clavulanate, 
extended-spectrum cephalosporins, newer macrolides (e.g., azithromycin, 
clarithromycin), TMP-SMX, and fluoroquinolones. 
• More than 90% of M. catarrhalis strains produce a β-lactamase and are 
resistant to ampicillin.
THE HACEK GROUP
� MICROBIOLOGY 
The HACEK group consists of fastidious, slow-growing, gram-negative 
bacteria whose growth requires carbon dioxide. Several Haemophilus 
species, Aggregatibacter (formerly Actinobacillus) actinomycetemcomitans, 
Aggregatibacter (formerly Haemophilus) aphrophilus, Cardiobacterium hom-
inis, Eikenella corrodens, and Kingella kingae make up this group.1 Normal 
residents of the oral cavity, HACEK bacteria can cause both local oral infec-
tions and severe systemic disease, particularly endocarditis. 
� CLINICAL MANIFESTATIONS
• Up to 3% of cases of infective endocarditis are caused by HACEK 
organisms; most of these cases are due to Aggregactibacter species, 
Haemophilus species, or C. hominis. 
• Infection typically occurs in pts with underlying valvular disease, often 
in the setting of a recent dental procedure, nasopharyngeal infection, or 
tongue piercing or scraping. 
• The aortic and mitral valves are most commonly affected. 
• Embolization is common, with 28–71% of pts affected. 
• Blood cultures can take 30 days to become positive, although most cul-
tures that ultimately yield HACEK bacteria become positive in the first 
week, especially with newer detection systems such as BACTEC.
• A. aphrophilus and H. parainfluenzae cause more than half of all cases 
of HACEK endocarditis. Pts usually present within the first 2 months of 
illness, and 19–50% of pts develop CHF.
• A. actinomycetemcomitans is isolated from soft tissue infections in associa-
tion with Actinomyces israelii. It is associated with severe destructive peri-
odontal disease, which also is frequently evident in pts with endocarditis.
• C. hominis most often affects the aortic valve. Long-standing infection 
usually precedes diagnosis. A second species, C. valvarum, has now been 
described in association with endocarditis.
1H. paraphrophilus is now considered to be encompassed by A. aphrophilus as opposed to 
being a separate species.
Haemophilus, Bordetella, Moraxella, HACEK
SECTION 7
614
Infectious Diseases
• E. corrodens is usually a component of mixed infections and is common 
in human bite wounds, head and neck soft-tissue infections, endocardi-
tis, and infections in IV drug users.
• K. kingae is a common cause of skeletal infections in children <3 years 
old. Inoculation of clinical specimens (e.g., synovial fluid) into aerobic 
blood-culture bottles enhances recovery of this organism. Infective 
endocarditis due to K. kingae occurs in older children and adults.
HACEK Group Infections
TREATMENT
• Table 98-1 lists antibiotic regimens used to treat endocarditis and 
other serious infections caused by HACEK organisms. 
• Native-valve endocarditis should be treated for 4 weeks and prosthetic-
valve endocarditis for 6 weeks. 
• Unlike prosthetic-valve endocarditis caused by other gram-negative 
organisms, that due to HACEK bacteria can often be cured with anti-
biotics alone (i.e., without surgery).
TABLE 98-1  TREATMENT OF ENDOCARDITIS AND OTHER SERIOUS 
INFECTIONS CAUSED BY HACEK GROUP ORGANISMSa
Organism
Initial
Therapy
Alternative 
Agents
Comments
Haemophilus
or
Aggregatibacter
species
Ceftriaxone
(2 g/d)
Ampicillin/
sulbactam (3 g of 
ampicillin q6h) or 
fluoroquinolonesb
Ampicillin ± an amino-
glycoside can be used if 
the organism does not 
produce β-lactamase.c
Cardiobacterium
hominis
Ceftriaxone
(2 g/d)
Ampicillin/
sulbactam (3 g of 
ampicillin q6h)
Penicillin (16–18 mU 
q4h) or ampicillin (2 g 
q4h) should be used if 
the organism is sus-
ceptible.
Eikenella
corrodens
Ampicillin
(2 g q4h)
Ceftriaxone
(2 g/d) or 
fluoroquinolonesb
The organism is typi-
cally resistant to clinda-
mycin, metronidazole, 
and aminoglycosides.
Kingella kingae
Ceftriaxone
(2 g/d) or 
ampicillin/
sulbactam
(3 g of 
ampicillin
q6h)
Fluoroquinolonesb
The prevalence of 
β-lactamase-producing
strains is increasing. 
Efficacy for invasive 
infections is best dem-
onstrated for first-line 
treatments.
aSusceptibility testing should be performed in all cases to guide therapy.
bFluoroquinolones are not recommended for treatment of children <18 years of age.
cEuropean guidelines for endocarditis recommend the addition of gentamicin (3 mg/kg per day 
in 3 divided doses for 2–4 weeks).
CHAPTER 99 
615
For a more detailed discussion, see Murphy TF: Haemophilus
and Moraxella Infections, Chap. 145, p. 1228; Barlam 
TF, Kasper DL: Infections Due to the HACEK Group and 
Miscellaneous Gram-Negative Bacteria, Chap. 146, p. 1233; 
and Halperin SA: Pertussis and Other Bordetella Infections, 
Chap. 148, p. 1241, in HPIM-18.
CHAPTER 99 
Diseases Caused by 
Gram-Negative Enteric Bacteria, 
Pseudomonas, and Legionella
INFECTIONS CAUSED BY GRAM-NEGATIVE ENTERIC BACTERIA
� GENERAL CONSIDERATIONS
Gram-negative bacilli (GNB) are normal components of the human colonic 
flora and/or a number of environmental habitats and can colonize mucosal and 
skin surfaces, especially in pts in long-term-care facilities and hospital settings. 
GNB cause a wide variety of infections involving diverse anatomic sites in both 
healthy and compromised hosts; extraintestinal infections due to Escherichia 
coli and, to a lesser degree, Klebsiella and Proteus species are most common. 
Isolation of GNB from any sterile site almost always implies infection, whereas 
isolation from nonsterile sites requires clinical correlation. Early appropriate 
antimicrobial therapy improves outcomes. Given worldwide increases in multi-
drug-resistant GNB [e.g., due to extended-spectrum β-lactamases (ESBLs) and 
AmpC β-lactamases], combination empirical antimicrobial therapy pending 
susceptibility results may be appropriate for critically ill pts.
� INFECTIONS CAUSED BY EXTRAINTESTINAL 
PATHOGENIC E. COLI (ExPEC)
In contrast to intestinal pathogenic E. coli, ExPEC strains are often found in 
the intestinal flora of healthy individuals but cause disease only when they 
enter a normally sterile extraintestinal site (e.g., the urinary tract, peritoneal 
cavity, or lungs). Most ExPEC strains have virulence factor profiles distinct 
from those of other commensal strains and from those of pathogenic strains 
that cause intestinal infections. 
Clinical Manifestations 
The clinical presentation depends in large part on the site of the body 
infected by ExPEC.
• Urinary tract infection: The urinary tract is the site most frequently infected 
by ExPEC; see Chap. 154 for more details. E. coli causes 85–95% of 
~6–8 million episodes of acute uncomplicated UTI in premenopausal women.
Gram-Negative Enteric Bacteria
SECTION 7
616
Infectious Diseases
• Abdominal and pelvic infection: The abdomen and pelvis represent the 
second most common site of infection by ExPEC, which may be isolated 
in the setting of a polymicrobial infection; see Chap. 90 for more details. 
Syndromes include peritonitis, intraabdominal abscesses, and cholangitis.
• Pneumonia: ExPEC is generally the third or fourth most commonly iso-
lated GNB in hospital-acquired pneumonia and can be a common cause 
of pneumonia in pts residing in long-term-care facilities; see Chap. 141 
for more details. 
• Meningitis: E. coli is one of the two leading causes of neonatal meningitis 
(the other being group B Streptococcus). Strains with the K1 capsular 
serotype are generally involved.
• Cellulitis/musculoskeletal infection: E. coli often contributes to infection 
of decubitus ulcers and diabetic lower-extremity ulcers; cellulitis; and 
burn-site or surgical-site infections. Hematogenously acquired osteomy-
elitis, particularly vertebral, is more commonly caused by E. coli than is 
generally appreciated. See Chap. 93 for more details.
• Bacteremia: E. coli is one of the two most common blood isolates of 
clinical significance. E. coli bacteremia can arise from primary infec-
tion at any site, but originates most commonly from the urinary tract 
(50–67% of episodes) and next most commonly from the abdomen 
(25% of episodes). E. coli bacteremia is typically associated with sepsis. 
Endovascular infections are rare but have been described.
Diagnosis
ExPEC grows readily on standard media under either aerobic or anaerobic 
conditions. More than 90% of strains ferment lactose and are indole positive.
Extraintestinal Infections Caused by E. coli
TREATMENT
• Rates of resistance to ampicillin, first-generation cephalosporins, 
trimethoprim-sulfamethoxazole (TMP-SMX), and fluoroquinolones 
are increasing. ESBLs are increasingly common in E. coli. 
• Carbapenems and amikacin are the most predictably active agents 
overall, but carbapenemase-producing strains are on the rise.
• It is important to use the most appropriate narrower-spectrum agent 
whenever possible and to avoid treating colonized but uninfected pts, 
thus combating the increase in antibiotic resistance.
� INFECTIONS CAUSED BY INTESTINAL PATHOGENIC E. COLI
Microbiology and Clinical Manifestations 
At least five distinct pathotypes of intestinal pathogenic E. coli exist; see 
Chap. 91 for more details. As mentioned above, these strains are rarely 
encountered as part of the commensal flora in healthy individuals.
• Shiga toxin–producing E. coli (STEC)/enterohemorrhagic E. coli (EHEC): 
In addition to diarrhea, STEC/EHEC infection results in the hemolytic-
uremic syndrome in 2–8% of pts, particularly those who are very young or 
elderly. 
CHAPTER 99 
617
– STEC/EHEC is associated with ingestion of contaminated food 
(e.g., undercooked ground beef, fresh produce) and water; person-
to-person transmission (e.g., at day-care centers) is an important 
route for secondary spread.
– Disease can be caused by <102 colony-forming units (CFU) of STEC/
EHEC.
– In contrast to the other pathotypes, STEC/EHEC (including E. coli 
O157:H7) causes infection more frequently in industrialized countries 
than in developing countries.
• Enterotoxigenic E. coli (ETEC): These strains are a major cause of 
endemic diarrhea among children residing in tropical and low-income 
countries and are the most common agent of traveler’s diarrhea; 106–1010 
CFU are needed to cause disease.
• Enteropathogenic E. coli (EPEC): EPEC is an important cause of diarrhea 
among infants in developing countries.
• Enteroinvasive E. coli (EIEC): EIEC, an uncommon cause of diarrhea, 
produces inflammatory colitis (stools containing mucus, blood, and 
inflammatory cells) similar to that caused by Shigella and primarily 
affects children and travelers in developing countries; 108–1010 CFU are 
needed to cause disease.
• Enteroaggregative and diffusely adherent E. coli (EAEC): Initially described 
in young children in developing countries, more recent studies indicate 
that EAEC may be a common cause of prolonged, watery diarrhea in all 
age groups in industrialized countries. 
Diagnosis
Specific diagnosis is usually unnecessary except when STEC/EHEC is 
involved. To detect the latter, testing for Shiga toxins or toxin genes is more 
sensitive, specific, and rapid than screening for E. coli strains that do not 
ferment sorbitol followed by serotyping for O157.
Intestinal Infections Caused by E. coli
TREATMENT
• See Chap. 91 for more details. Replacement of water and electrolytes 
and avoidance of antibiotics in STEC/EHEC infection (since antibi-
otic use may increase the incidence of hemolytic-uremic syndrome) 
are indicated.
� KLEBSIELLA INFECTIONS
Epidemiology
K. pneumoniae colonizes the colon in 5–35% of healthy individuals and, 
from a medical standpoint, is the most important Klebsiella species. 
K. oxytoca primarily causes infections in long-term-care and hospital settings. 
K. pneumoniae subspecies rhinoscleromatis, which causes rhinoscleroma, 
and K. pneumoniae subspecies ozaenae, which causes chronic atrophic rhi-
nitis, infect pts in tropical climates.
Gram-Negative Enteric Bacteria
SECTION 7
618
Infectious Diseases
Clinical Manifestations 
As in other GNB infections, the clinical presentation depends on the 
infected anatomic site.
• Pneumonia: Klebsiella is an uncommon cause of community-acquired 
pneumonia, which occurs primarily in pts with underlying disease (e.g., 
alcoholism, diabetes, chronic obstructive pulmonary disease) and among 
residents of long-term-care facilities and hospitalized pts. 
– The presentation is similar to that of pneumonia caused by other 
enteric GNB, with purulent sputum production and pulmonary infil-
trates on CXR. 
– Infection can progress to pulmonary necrosis, pleural effusion, and 
empyema.
• UTI: K. pneumoniae causes 1–2% of cases of uncomplicated cystitis and 
5–17% of cases of complicated UTI.
• Abdominal infections: Klebsiella causes a spectrum of disease similar to 
that of E. coli, but with less frequent occurrence. Hypervirulent variants 
that contain capsular serotype K1 or K2 have become more common in 
the past decade.
• Bacteremia: Bacteremia can arise from a primary infection at any site; 
infections of the urinary tract, respiratory tract, and abdomen (especially 
hepatic abscess) each account for 15–30% of episodes.
• Other infections: Klebsiella cellulitis or soft tissue infection most frequently 
affects devitalized tissue and immunocompromised hosts. Klebsiella can 
also cause endophthalmitis, nosocomial sinusitis, and osteomyelitis.
Diagnosis
Klebsiellae usually ferment lactose, although the subspecies rhinoscleromatis 
and ozaenae are nonfermenters and are indole negative.
Klebsiella Infections
TREATMENT
• Klebsiellae are resistant to ampicillin and ticarcillin. 
– Resistance to third-generation cephalosporins is increasing, as is 
the frequency of ESBL-containing isolates. 
– Fluoroquinolone resistance is increasing, especially among ESBL-
containing strains. 
• Empirical treatment of serious or health care–associated Klebsiella infec-
tions with amikacin or carbapenems is prudent; however, carbapenemase-
producing strains are increasing in frequency. Optimal therapy for 
carbapenemase strains is unclear, but tigecycline, polymyxin B, and colis-
tin are used most frequently on the basis of in vitro susceptibility profiles.
� PROTEUS INFECTIONS
Epidemiology 
P. mirabilis is part of the normal flora in 50% of healthy people and causes 
90% of Proteus infections. P. vulgaris and P. penneri are isolated primarily 
from pts in hospitals and long-term care facilities.
CHAPTER 99 
619
Clinical Manifestations 
Most Proteus infections arise from the urinary tract. Proteus species 
account for 1–2% of uncomplicated UTIs, 5% of hospital-acquired UTIs, 
and 10–15% of complicated UTIs (especially those associated with urinary 
catheters). 
• Proteus produces high levels of urease that result in alkalinization of 
urine and ultimately in formation of struvite and carbonate-apatite 
calculi. 
• Other sites of infection are uncommon but include pneumonia, abdomi-
nal infections, soft tissue infections, and bacteremia.
Diagnosis
Proteus strains are typically lactose negative, produce H2S, and exhibit 
swarming motility on agar plates. P. mirabilis is indole negative, whereas 
P. vulgaris and P. penneri are indole positive.
Proteus Infections
TREATMENT
• P. mirabilis is susceptible to most agents except tetracycline, 
nitrofurantoin, polymyxin B, and tigecycline. Resistance to ampi-
cillin, first-generation cephalosporins, and fluoroquinolones is 
increasing. 
• P. vulgaris and P. penneri are more resistant; ~30% of P. vulgaris isolates 
have an inducible AmpC β-lactamase. Imipenem, fourth-generation 
cephalosporins, amikacin, and TMP-SMX exhibit excellent activity: 
90–100% of Proteus isolates are susceptible.
� INFECTIONS CAUSED BY OTHER GRAM-NEGATIVE ENTERIC PATHOGENS
• Enterobacter (e.g., E. cloacae, E. aerogenes), Acinetobacter (e.g., A. baumannii), 
Serratia (e.g., S. marcescens), and Citrobacter (e.g., C. freundii, C. koseri) 
usually cause nosocomial infections. Risk factors include immunosuppres-
sion, comorbid disease, prior antibiotic use, and ICU stays. 
• Infections caused by Morganella (e.g., M. morganii) and Providencia (e.g., 
P. stuartii, P. rettgeri) resemble Proteus infections in terms of epidemiology, 
pathogenicity, and clinical manifestations but occur almost exclusively 
among persons in long-term-care facilities and, to a lesser degree, in hospi-
talized pts.
Clinical Manifestations 
These organisms generally cause a spectrum of disease similar to that 
caused by other GNB, including pneumonia (particularly ventilator-
associated), UTI (especially catheter-related), intravascular device–related 
infection, surgical-site infection, and abdominal infections.
• Citrobacter, Morganella, and Providencia infections are generally associ-
ated with UTIs.
• Acinetobacter has caused soft tissue and bone infections among soldiers 
with battlefield injuries and is a well-known pathogen in burn units.
Gram-Negative Enteric Bacteria
SECTION 7
620
Infectious Diseases
Infections Caused by Other Gram-Negative Enteric Pathogens
TREATMENT
• Significant antibiotic resistance among these organisms makes therapy 
challenging.
– Many of these organisms (e.g., Serratia, Providencia, Acinetobacter, 
Citrobacter, Enterobacter, Morganella) have a derepressible AmpC 
β-lactamase that results in resistance to third-generation cephalo-
sporins, monobactams, and—in many cases—β-lactam/β-lactamase 
inhibitor combinations. 
• Carbapenems and amikacin are most reliably active, and fourth-
generation cephalosporins are active provided the organism does not 
express an ESBL. Susceptibility testing is essential. Some isolates may 
retain susceptibility only to colistin and polymyxin B.
� AEROMONAS INFECTIONS
A. hydrophila causes >85% of Aeromonas infections. Aeromonas organisms 
proliferate in potable water, freshwater, and soil and are a putative cause 
of gastroenteritis. Aeromonas causes bacteremia and sepsis in infants and 
compromised hosts, especially those with cancer, hepatobiliary disease, 
trauma, or burns. The organisms can produce skin lesions similar to the 
ecthyma gangrenosum caused by Pseudomonas aeruginosa. Aeromonas 
causes nosocomial infections related to catheters, surgical incisions, and 
use of leeches.
Aeromonas Infections
TREATMENT
• Aeromonas is usually susceptible to fluoroquinolones (e.g., cipro-
floxacin at a dosage of 500 mg PO q12h or 400 mg IV q12h), third-
generation cephalosporins, carbapenems, and aminoglycosides. 
• Susceptibility testing is critical to guide therapy since Aeromonas can 
produce various β-lactamases, including carbapenemases.
INFECTIONS DUE TO PSEUDOMONAS AERUGINOSA AND RELATED 
ORGANISMS
The pseudomonads make up a set of gram-negative organisms unable to 
ferment lactose. This group includes three medically important genera—
Pseudomonas, Burkholderia, and Stenotrophomonas—that typically cause 
opportunistic disease.
� P. AERUGINOSA INFECTIONS
Microbiology 
P. aeruginosa is a motile gram-negative rod that commonly produces green 
or bluish pigment and may have a mucoid appearance (which is particularly 
common in isolates from pts with cystic fibrosis). P. aeruginosa differs from 
enteric GNB in that it has a positive reaction in the oxidase test and does 
not ferment lactose.
CHAPTER 99 
621
Epidemiology 
Because P. aeruginosa is found in most moist environments (e.g., in soil, in 
tap water, and on countertops), people routinely come into contact with the 
organism. The many factors that predispose to P. aeruginosa infection include 
disruption of cutaneous or mucosal barriers (e.g., due to burns or trauma), immu-
nosuppression (e.g., due to neutropenia, AIDS, or diabetes), and disruption of the 
normal bacterial flora (e.g., due to broad-spectrum antibiotic therapy). 
• P. aeruginosa is no longer a major cause of life-threatening bacteremia 
among pts with neutropenia or burn injury. 
• P. aeruginosa bacteremia is currently most common among pts in the 
ICU.
Clinical Manifestations 
P. aeruginosa can infect virtually all sites in the body but has a strong pre-
dilection for the lungs.
• Pneumonia: P. aeruginosa is considered a major cause of ventilator-associated 
pneumonia, although colonization may be difficult to distinguish from true 
infection. 
– Clinically, most pts have a slowly progressive infiltrate, although pro-
gression is rapid in some cases. Infiltrates may become necrotic.
– It is unclear whether an invasive procedure (e.g., bronchoalveolar 
lavage, protected-brush sampling of distal airways) is superior to tra-
cheal aspiration in obtaining samples for culture.
– Chronic respiratory infection with P. aeruginosa is associated with 
underlying or predisposing conditions (e.g., cystic fibrosis, bronchi-
ectasis).
• Bacteremia: The presentation of P. aeruginosa bacteremia resembles that 
of sepsis in general. 
– Pathognomonic skin lesions (ecthyma gangrenosum) that at first are pain-
ful, reddish, and maculopapular and later become black and necrotic may 
develop in pts with marked neutropenia or with HIV infection.
– Endovascular infections occur mostly in IV drug users and pts with 
prosthetic valves.
• Bone and joint infections: P. aeruginosa is an infrequent cause of bone and 
joint infections.
– Injection drug use (associated with sternoclavicular joint infections 
and vertebral osteomyelitis) and UTIs in the elderly (associated with 
vertebral osteomyelitis) are risk factors.
– Pseudomonas osteomyelitis of the foot most often follows puncture 
wounds through sneakers and most commonly affects children.
• CNS infections: CNS infections due to P. aeruginosa are relatively rare and 
are almost always secondary to a surgical procedure or head trauma.
• Eye infections: Keratitis and corneal ulcers can occur, usually resulting 
from trauma or surface injury by contact lenses. These infections are 
rapidly progressing entities that demand immediate therapeutic inter-
vention. P. aeruginosa endophthalmitis secondary to bacteremia is a 
fulminant disease with severe pain, chemosis, decreased visual acuity, 
anterior uveitis, vitreous involvement, and panophthalmitis.
Gram-Negative Enteric Bacteria
SECTION 7
622
Infectious Diseases
• Ear infections: In addition to mild swimmer’s ear, Pseudomonas ear infec-
tions can result in malignant otitis externa, a life-threatening infection 
that presents as severe ear pain and decreased hearing.
– Pts may develop cranial-nerve palsies or cavernous venous sinus 
thrombosis. 
– Most ear infections due to P. aeruginosa occur in elderly diabetic pts.
• UTIs: UTIs due to P. aeruginosa usually result from a foreign body in 
the urinary tract, an obstruction in the genitourinary system, or urinary 
tract instrumentation or surgery.
• Skin and soft tissue infections: P. aeruginosa can cause a variety of derma-
titides, including pyoderma gangrenosum in neutropenic pts, folliculitis, 
and other papular or vesicular lesions. Multiple outbreaks have been 
linked to whirlpools, spas, and swimming pools.
• Infections in pts with fever and neutropenia: P. aeruginosa is always tar-
geted in empirical treatment of these pts, given high rates of infection in 
the past and high associated mortality rates.
• Infections in pts with AIDS: P. aeruginosa infections in pts with AIDS can 
be fatal even though the clinical presentation is not particularly severe. 
– Pneumonia is the most common type of infection, with a high fre-
quency of cavitary disease. 
– Since the advent of antiretroviral therapy, P. aeruginosa infection has 
declined in incidence among these pts but still occurs.
P. aeruginosa Infections
TREATMENT
• See Table 99-1 for antibiotic options and schedules. 
• Several observational studies indicate that a single modern antipseudo-
monal β-lactam agent to which the isolate is sensitive is as efficacious as 
combination therapy. However, if—in the local environment—the sus-
ceptibility to first-line agents is <80%, empirical combination therapy 
should be administered until isolate-specific susceptibility data are 
available.
� INFECTIONS CAUSED BY BACTERIA RELATED TO PSEUDOMONAS SPECIES
Stenotrophomonas maltophilia 
S. maltophilia is an opportunistic pathogen. Most infections occur in the 
setting of prior broad-spectrum antimicrobial therapy that has eradicated 
the normal flora in immunocompromised pts. 
• S. maltophilia causes pneumonia, especially ventilator-associated pneu-
monia, with or without bacteremia. 
• Central venous line infection (most often in cancer pts) and ecthyma 
gangrenosum in neutropenic pts have been described.
Burkholderia cepacia 
This organism can colonize airways during broad-spectrum antimicrobial 
treatment and is a cause of ventilator-associated pneumonia, catheter-
associated infection, and wound infection. 
CHAPTER 99 
623
• B. cepacia is recognized as an antibiotic-resistant nosocomial pathogen 
in ICU pts. 
• B. cepacia can cause a rapidly fatal syndrome of respiratory distress and 
septicemia (the “cepacia syndrome”) in pts with cystic fibrosis.
S. maltophilia and B. cepacia Infections
TREATMENT
Intrinsic resistance to many antibiotics limits treatment. See Table 99-1 
for recommended antibiotic regimens. 
Miscellaneous Organisms 
Melioidosis is endemic to Southeast Asia and is caused by B. pseudomallei. 
Glanders is associated with close contact with horses or other equines 
and is caused by B. mallei. These diseases present as acute or chronic 
pulmonary or extrapulmonary suppurative illnesses or as acute 
septicemia.
LEGIONELLA INFECTIONS
Microbiology
Legionellaceae are intracellular aerobic gram-negative bacilli that grow 
on buffered charcoal yeast extract (BCYE) agar. L. pneumophila causes 
80–90% of cases of human Legionella disease and includes 16 serogroups; 
serogroups 1, 4, and 6 are most common. 
Epidemiology 
• Legionella is found in fresh water and human-constructed water sources. 
Outbreaks have been traced to drinking water systems and rarely to cool-
ing towers. 
• The organisms are transmitted to individuals primarily via aspiration but 
can also be transmitted by aerosolization and direct instillation into the 
lungs during respiratory tract manipulations. 
• Legionella is the fourth most common cause of community-acquired 
pneumonia, accounting for 2–9% of cases. It causes 10–50% of cases of 
nosocomial pneumonia if the hospital’s water system is colonized with 
the organism. 
• Pts who have chronic lung disease, who smoke, and/or who are elderly, 
immunosuppressed, or recently discharged from the hospital are at par-
ticularly high risk for disease.
Clinical Manifestations 
Legionellosis manifests as either an acute, febrile, self-limited illness 
(Pontiac fever) or pneumonia (Legionnaires’ disease).
• Pontiac fever is a flulike illness with a 24- to 48-h incubation period. Malaise, 
fatigue, and myalgias occur in 97% of cases. Fever and headaches are also 
very common, but pneumonia does not develop. The disease is self-limited 
and does not require antimicrobial treatment. Recovery takes place in a 
few days.
Gram-Negative Enteric Bacteria
SECTION 7
624
Infectious Diseases
TABLE 99-1 ANTIBIOTIC TREATMENT OF INFECTIONS DUE TO 
PSEUDOMONAS AERUGINOSA AND RELATED SPECIES
Infection
Antibiotics and Dosages
Other Considerations
Bacteremia
  Nonneutropenic 
host
Monotherapy:
Add an aminoglycoside for 
pts in shock and in regions 
or hospitals where rates of 
resistance to the primary 
β-lactam agents are 
high. Tobramycin may be 
used instead of amikacin 
(susceptibility permitting). 
The duration of therapy is 
at least 2 weeks.
Ceftazidime (2 g q8h IV) or 
cefepime (2 g q12h IV)
 Combination therapy:
Piperacillin/tazobac-
tam (3.375 g q4h IV) or 
imipenem (500 mg q6h IV) 
or meropenem (1 g q8h 
IV) or doripenem (500 mg 
q8h IV)
plus
Amikacin (7.5 mg/kg q12h 
or 15 mg/kg q24h IV)
  Neutropenic 
host
Cefepime (2 g q8h IV) or 
any of the other agents 
listed above (except 
doripenem) in the above 
dosages
Endocarditis
Antibiotic regimens as for 
bacteremia for 6–8 weeks
Resistance during therapy 
is common. Surgery is 
required for relapse.
Pneumonia
Drugs and dosages as for 
bacteremia, except that 
the available carbapenems 
should not be the sole 
primary drugs because of 
high rates of resistance 
during therapy
IDSA guidelines recom-
mend the addition of an 
aminoglycoside or cipro-
floxacin. The duration of 
therapy is 10–14 days.
Bone infection, 
malignant otitis 
externa
Cefepime or ceftazidime 
at the same dosages as 
for bacteremia; aminogly-
cosides not a necessary 
component of therapy; 
ciprofloxacin (500–750 
mg q12h PO) may be used
Duration of therapy varies 
with the drug used (e.g., 
6 weeks for a β-lactam
agent; at least 3 months 
for oral therapy except in 
puncture-wound osteomy-
elitis, for which the dura-
tion should be 2–4 weeks).
CNS infection
Ceftazidime or cefepime 
(2 g q8h IV) or meropenem 
(1 g q8h IV)
Abscesses or other 
closed-space infections 
may require drainage. The 
duration of therapy is ≥2
weeks.
CHAPTER 99 
625
TABLE 99-1 ANTIBIOTIC TREATMENT OF INFECTIONS DUE TO 
PSEUDOMONAS AERUGINOSA AND RELATED SPECIES 
(CONTINUED)
Infection
Antibiotics and Dosages
Other Considerations
Eye infection
Keratitis/ulcer
Topical therapy with 
tobramycin/ciprofloxacin/
levofloxacin eyedrops
Use maximal strengths 
available or compounded 
by pharmacy.
 Endophthalmitis
Ceftazidime or cefepime 
as for CNS infection
plus
Topical therapy
UTI
Ciprofloxacin (500 mg 
q12h PO) or levofloxacin 
(750 mg q24h) or any 
aminoglycoside (total daily 
dose given once daily)
Relapse may occur if an 
obstruction or a foreign 
body is present.
Multidrug-resistant
P. aeruginosa
infection
Colistin (100 mg q12h IV) 
for the shortest possible 
period to obtain a clinical 
response
Doses used have varied. 
Dosage adjustment is 
required in renal failure. 
Inhaled colistin may be 
added for pneumonia 
(100 mg q12h).
Stenotrophomonas
maltophilia
infection
TMP-SMX (1600/320 mg 
q12h IV for 14 days)
Resistance to all agents is 
increasing. Levofloxacin 
may be an alternative, but 
there is little published 
clinical experience with 
this agent.
Ticarcillin/clavulanate 
(3.1 g q4h IV for 14 days)
Burkholderia
cepacia infection
Meropenem (1 g q8h IV for 
14 days)
Resistance to both agents 
is increasing. Do not 
use them in combina-
tion because of possible 
antagonism.
TMP-SMX (1600/320 mg 
q12h IV for 14 days)
Melioidosis, 
glanders
Ceftazidime (2 g q6h for 
2 weeks) or meropenem 
(1 g q8h for 2 weeks) or 
imipenem (500 mg q6h for 
2 weeks)
followed by
TMP-SMX (1600/320 mg 
q12h PO for 3 months)
Abbreviations: IDSA, Infectious Diseases Society of America; TMP-SMX, trimethoprim-
sulfamethoxazole.
Gram-Negative Enteric Bacteria
SECTION 7
626
Infectious Diseases
• Legionnaires’ disease is more severe than other atypical pneumonias and 
is more likely to result in ICU admission.
– After a usual incubation period of 2–10 days, nonspecific symptoms (e.g., 
malaise, fatigue, headache, anorexia) develop and are followed by a cough that 
is usually mild and only slightly productive. Chest pain can be prominent.
– Radiologic findings are nonspecific, but pleural effusions are present 
in 28–63% of pts on hospital admission.
– Legionnaires’ disease is not readily distinguishable from pneumonia of 
other etiologies based on clinical manifestations, but diarrhea, confu-
sion, temperatures >39°C, hyponatremia, increased aminotransferase 
levels, hematuria, hypophosphatemia, and elevated creatine phosphoki-
nase levels are documented more frequently than in other pneumonias.
– Extrapulmonary infection results from hematogenous dissemination 
and most commonly affects the heart (e.g., myocarditis, pericarditis).
Diagnosis
The use of Legionella testing—especially the Legionella urinary antigen 
test—is recommended for all pts with community-acquired pneumonia.
• Sputum or bronchoscopy specimens can be subjected to direct fluores-
cent antibody (DFA) staining and culture. 
– DFA testing is rapid and specific but is less sensitive than culture.
– Cultures on BCYE media (with antibiotics to suppress competing 
flora) require 3–5 days to become positive.
• Serologic confirmation requires comparison of acute- and convalescent-phase 
samples. Detection of the necessary 4-fold rise in titers often requires 12 weeks.
• Urinary antigen testing is rapid, inexpensive, easy to perform, second 
only to culture in terms of sensitivity, and highly specific. It is useful only 
for L. pneumophila serogroup 1, which causes 80% of disease cases.
– Urinary antigen is detectable 3 days after disease onset and generally 
disappears over 2 months, although positivity can be prolonged if the 
pt is receiving glucocorticoid therapy.
– The test is not affected by antibiotic administration.
Legionella Infections
TREATMENT
• Newer macrolides (e.g., azithromycin at 500 mg/d PO, with consider-
ation of doubling the first dose; or clarithromycin at 500 mg bid IV or 
PO) or fluoroquinolones (e.g., levofloxacin at 750 mg/d IV or 500 mg/d 
PO or moxifloxacin at 400 mg/d PO) are most effective. 
– Rifampin (100–600 mg bid) combined with either class of drug is 
recommended in severe cases.
– Tetracyclines (doxycycline at 100 mg bid IV or PO) are alternatives.
• Immunocompetent hosts should receive 10–14 days of therapy, but 
immunocompromised hosts and pts with advanced disease should 
receive a 3-week course of treatment. 
– A 5- to 10-day course of azithromycin is adequate because of this 
drug’s long half-life.
– A clinical response usually occurs within 3–5 days after the initiation 
of parenteral therapy, at which point oral therapy can be substituted.
CHAPTER 100
627
Prognosis
Mortality rates approach 80% among immunocompromised pts who do 
not receive timely therapy. Among immunocompetent hosts, mortality can 
approach 31% without treatment but ranges from 0 to 11% with appropri-
ate and timely therapy. Fatigue, weakness, and neurologic symptoms can 
persist for >1 year.
For a more detailed discussion, see Barlam TF, Kasper DL: 
Infections Due to the HACEK Group and Miscellaneous 
Gram-Negative Bacteria, Chap. 146, p. 1233; Sabria M, 
Yu VL: Legionella Infections, Chap. 147, p. 1236; Russo 
TA, Johnson JR: Diseases Caused by Gram-Negative 
Enteric Bacilli, Chap. 149, p. 1246; Paterson DL, Peleg AY: 
Acinetobacter Infections, Chap. 150, p. 1258; and Ramphal 
R: Infections Due to Pseudomonas Species and Related 
Organisms, Chap. 152, p. 1266, in HPIM-18.
CHAPTER 100
Infections Caused by 
Miscellaneous Gram-
Negative Bacilli
BRUCELLOSIS
Microbiology 
Brucellae are small, gram-negative, unencapsulated, nonsporulating, non-
motile rods or coccobacilli that can persist intracellularly. The genus Brucella 
includes four major clinically relevant species: B. melitensis (acquired by 
humans most commonly from sheep, goats, and camels), B. suis (from 
swine), B. abortus (from cattle or buffalo), and B. canis (from dogs). 
Epidemiology 
Brucellosis is transmitted via ingestion, inhalation, or mucosal or percutaneous 
exposure; the disease in humans is usually associated with exposure to infected 
animals or their products in either occupational settings (e.g., slaughterhouse 
work, farming) or domestic settings (e.g., consumption of contaminated foods, 
especially dairy products). The global prevalence of brucellosis is unknown 
because of difficulties in diagnosis and inadequacies in reporting systems.
Clinical Manifestations 
Regardless of the specific infecting species, brucellosis often presents with 
one of three patterns: a febrile illness similar to but less severe than typhoid 
Miscellaneous Gram-Negative Bacilli
SECTION 7
628
Infectious Diseases
fever; fever and acute monarthritis, typically of the hip or knee, in a young 
child (septic arthritis); or long-lasting fever, misery, and low-back or hip 
pain in an older man (vertebral osteomyelitis). 
• An incubation period of 1 week to several months is followed by the 
development of undulating fever; sweats; increasing apathy, fatigue, 
and anorexia; and nonspecific symptoms such as headache, myalgias, 
and chills. 
• Brucella infection can cause lymphadenopathy, hepatosplenomegaly, 
epididymoorchitis, neurologic involvement, and focal abscess.
• Given the persistent fever and similar symptoms, tuberculosis is the most 
important differential diagnosis (Table 100-1).
Diagnosis
Laboratory personnel must be alerted to the potential diagnosis to ensure 
that they take precautions to prevent occupational exposure. 
• The organism is successfully cultured in 50–70% of cases. Cultures using 
the BACTEC systems usually become positive in 7–10 days and can be 
deemed negative at 3 weeks. 
• PCR analysis of blood or tissue samples is more sensitive, faster, and safer 
than culture.
• Agglutination assays for IgM are positive early in infection. Single titers 
of ≥1:160 and ≥1:320 are diagnostic in nonendemic and endemic areas, 
respectively. 
TABLE 100-1  RADIOLOGY OF THE SPINE: DIFFERENTIATION OF 
BRUCELLOSIS FROM TUBERCULOSIS
Brucellosis
Tuberculosis
Site
Lumbar and others
Dorsolumbar
Vertebrae
Multiple or 
contiguous
Contiguous
Discitis
Late
Early
Body
Intact until late
Morphology lost early
Canal compression Rare
Common
Epiphysitis
Anterosuperior 
(Pom’s sign)
General: upper and lower disk 
regions, central, subperiosteal
Osteophyte
Anterolateral (parrot 
beak)
Unusual
Deformity
Wedging uncommon
Anterior wedge, gibbus
Recovery
Sclerosis, whole body Variable
Paravertebral 
abscess
Small, well-localized
Common and discrete loss, 
transverse process
Psoas abscess
Rare
More likely
CHAPTER 100
629
Miscellaneous Gram-Negative Bacilli
Brucellosis
TREATMENT
• The recommended regimen is streptomycin at a dosage of 0.75–1 g/d 
(or gentamicin at 5–6 mg/kg qd) for 14–21 days plus doxycycline at 
a dosage of 100 mg bid for 6 weeks. 
– Rifampin (600–900 mg/d) plus doxycycline (100 mg bid) for 
6 weeks constitute an alternative regimen (the current World 
Health Organization [WHO] recommendation).
– Significant neurologic disease requires at least 3–6 months of treat-
ment, with ceftriaxone supplementation of a standard regimen. 
– Endocarditis requires a four-drug regimen (an aminoglycoside, 
rifampin, a tetracycline, and ceftriaxone or a fluoroquinolone) for 
at least 6 weeks.
– Relapse rates range from 5 to >20% and depend on the specific anti-
biotic regimen used; pts should be monitored for at least 2 years.
TULAREMIA
Microbiology and Epidemiology 
Tularemia is the only disease caused by Francisella tularensis, a small, 
gram-negative, aerobic bacillus that is a potential agent of bioterrorism 
(Chap. 33).
• Human infection occurs via interaction with biting or blood-sucking 
insects (especially ticks and tabanid flies in the spring and sum-
mer), wild or domestic animals (e.g., wild rabbits, squirrels), or the 
environment. 
– The organism gains entry into the skin or mucous membranes through 
bites or inapparent abrasions or is acquired via inhalation or ingestion.
– As few as 10 organisms can result in infection when injected into the 
skin or inhaled.
• More than half of U.S. cases occur in Arkansas, Oklahoma, South Dakota, 
and Missouri. 
Clinical Manifestations 
After an incubation period of 2–10 days, tularemia generally starts with an 
acute onset of fever, chills, headache, and myalgias. The ulceroglandular/
glandular forms of tularemia affect 75–85% of pts, but several other syn-
dromes involving systemic manifestations can occur. 
• Ulceroglandular/glandular tularemia: The hallmark of ulceroglan-
dular tularemia is an indurated, erythematous, nonhealing ulcer 
lasting 1–3 weeks that begins as a pruritic or tender lesion, ulcerates, 
has sharply demarcated edges and a yellow exudate, and develops a 
black base. 
– Inguinal/femoral lymphadenopathy is most common in adults; nodes 
can become fluctuant and drain spontaneously.
– In glandular tularemia (5–10% of cases), no primary skin lesion is 
apparent.
SECTION 7
630
Infectious Diseases
• Oculoglandular tularemia: In 1% of pts, infection of the conjunctiva—
usually by contact with contaminated fingers—results in purulent 
conjunctivitis with regional lymphadenopathy and debilitating pain. 
Painful preauricular lymphadenopathy distinguishes tularemia from 
other diseases.
• Oropharyngeal and GI tularemia: Acquired through oral inoculation (via 
contaminated foods or fingers), the infection can present as pharyngitis 
and cervical adenopathy, intestinal ulcerations, mesenteric lymphade-
nopathy, diarrhea, nausea, vomiting, and abdominal pain.
• Pulmonary tularemia: Infection is acquired via inhalation or via hema-
togenous spread from ulceroglandular or typhoidal tularemia. Pts pres-
ent with signs and symptoms similar to those of pneumonia of other 
etiologies (e.g., nonproductive cough, dyspnea, pleuritic chest pain, CXR 
with bilateral patchy or lobar infiltrates or cavitary lesions).
• Typhoidal tularemia: Due to pharyngeal or GI inoculation or to bacte-
remic disease, typhoidal tularemia consists of fever and signs of sepsis, 
generally without skin lesions or lymphadenopathy. This form is the 
result of a large inoculum or a preexisting compromising condition.
Diagnosis
The diagnosis of tularemia is most frequently confirmed by serology, 
although up to 30% of pts infected for 3 weeks have negative results in 
serologic tests.
• Cultures are positive in only 10% of cases; organisms in culture pose a 
significant risk to laboratory personnel. 
• PCR has been used to detect F. tularensis DNA in clinical specimens, 
mainly for ulceroglandular disease.
Tularemia
TREATMENT
• Gentamicin (2.5 mg/kg IV bid for 7–10 days) is considered the drug of 
choice; pts who defervesce within the first 48–72 h of treatment may 
receive a 5- to 7-day course.
– Streptomycin (1 g IM q12h for 10 days) is also effective, but tobra-
mycin is not. 
– Doxycycline is another alternative, but it must be given for at least 
14 days because it is only bacteriostatic against F. tularensis.
– Healing of skin lesions and lymph nodes may take 1–2 weeks. Late 
lymph-node suppuration can occur, with sterile necrotic tissue.
PLAGUE
Epidemiology 
Yersinia pestis causes plague, a systemic zoonosis that primarily affects small 
rodents in rural areas of Africa (where 80% of all human cases worldwide 
occur), Asia, and the Americas. As the rodent population succumbs to 
disease, fleas (the arthropod vector) search for a new host and can transmit 
the bacteria to humans.
CHAPTER 100
631
• In addition to fleabites, direct contact with infected tissues or air-
borne droplets can cause human infections. Given the possibility of 
airborne transmission, Y. pestis is a potential agent of bioterrorism 
(Chap. 33).
• There are a median of 7 cases per year in the U.S., most of them occur-
ring near the “Four Corners” (the junction point of New Mexico, 
Arizona, Colorado, and Utah) and further west in California, southern 
Oregon, and western Nevada. 
Clinical Manifestations 
Worldwide, bubonic plague accounts for 80–95% of all plague cases, with 
primary septicemic plague occurring in 10–20% of cases and primary pul-
monary plague in only a small minority of cases.
• Bubonic plague: After an incubation period of 2–6 days, the onset of 
bubonic plague is sudden and is characterized by fever (>38°C), malaise, 
myalgia, dizziness, and increasing pain due to progressive lymphadenitis 
in the regional lymph nodes near the fleabite or other inoculation site.
– The tender, swollen lymph node (bubo) has a boggy consistency with 
an underlying hard core when palpated.
– With treatment, fever resolves within 2–5 days; without treatment, 
infection can disseminate and cause serious illness (e.g., secondary 
pneumonic plague, meningitis).
• Primary septicemic plague: Pts present with gram-negative septicemia not 
preceded by lymphadenopathy. Persons >40 years old are at greater risk, 
although this form of the disease can occur in all age groups.
• Pneumonic plague: After a short incubation period averaging a few hours 
to 3 days, pts experience a sudden onset of fever, nonspecific signs and 
symptoms (e.g., headache, myalgias, vomiting), and respiratory manifes-
tations (e.g., cough, chest pain, sputum production with hemoptysis).
– Pneumonitis that is initially segmental can progress to lobar pneumo-
nia and then to bilateral lung involvement.
– The mortality rate is nearly 100% without treatment and is still >50% 
with effective treatment.
Diagnosis
The WHO recommends an initial presumptive diagnosis followed by con-
firmation in a reference laboratory.
• The appropriate specimens for diagnosis of bubonic, pneumonic, and 
septicemic plague are bubo aspirate (after injection of 1 mL of normal 
saline), bronchoalveolar lavage fluid or sputum, and blood, respectively. 
Gram’s, Wayson, or Wright-Giemsa staining of these samples may reveal 
bipolar gram-negative rods.
• Given the potential risk to laboratory workers, culture of Y. pestis 
should be performed only at reference laboratories, which use direct 
immunofluorescence, PCR, and/or specific bacteriophage lysis as con-
firmatory tests for identification. The optimal growth temperature is 
25–29°C.
• In the absence of other positive diagnostic testing, a serologic diagnosis 
can be made.
Miscellaneous Gram-Negative Bacilli
SECTION 7
632
Infectious Diseases
Plague
TREATMENT
• Streptomycin (1g IM q12h) or gentamicin (5 mg/kg IV q24h) is 
the drug of choice. Doxycycline (200 mg/d PO/IV in 1 or 2 doses) 
and chloramphenicol (12.5 mg/kg PO/IV q6h) are alternative 
agents.
• For pts who are hospitalized with pneumonic plague or in whom this 
disease is suspected, respiratory droplet precautions should be imple-
mented until treatment has been given for at least 48 h.
• Postexposure antimicrobial prophylaxis lasting 7 days is recommended 
after household, hospital, or other close (<2 m) contact with persons 
with untreated pneumonic plague. Doxycycline (200 mg/d PO/IV in 1 
or 2 doses), ciprofloxacin (1 g PO q12h), or TMP-SMX (320 mg of the 
TMP component PO q12h) are effective agents for prophylaxis.
BARTONELLA INFECTIONS
• Bartonella species are fastidious, facultative intracellular, gram-negative 
bacteria that cause an array of infectious disease syndromes in humans. 
• Most Bartonella species have successfully adapted to survival in 
specific domestic or wild mammals, creating a reservoir for human 
infection. The exceptions are B. bacilliformis and B. quintana, which 
are not zoonotic. 
• Clinical presentation generally depends on both the infecting Bartonella 
species and the immune status of the infected individual.
• Therapy for syndromes caused by Bartonella is summarized in Table 100-2.
� CAT-SCRATCH DISEASE (CSD)
Microbiology and Epidemiology 
B. henselae is the principal etiologic agent of CSD, although other Bartonella 
species may rarely be involved. Consistent with the disease’s name, contact 
(being scratched, bitten, or licked) with apparently healthy cats, and espe-
cially with kittens, is the primary source of infection. Adults are affected 
nearly as frequently as children. In the U.S., the estimated incidence is ~10 
cases per 100,000 population.
Clinical Manifestations 
Of pts with CSD, 85–90% have typical disease consisting of a localized 
lesion (papule, vesicle, or nodule) at the site of inoculation with subsequent 
painful regional lymphadenopathy ≥1–3 weeks after cat contact. 
• Axillary and epitrochlear nodes are most commonly involved and sup-
purate in 10–15% of cases.
• Low-grade fever, malaise, and anorexia develop in ~50% of pts.
• Atypical disease involves extranodal manifestations (e.g., fever of 
unknown origin, ophthalmologic manifestations, neurologic involve-
ment, osteomyelitis). 
• In immunocompetent pts, the disease resolves spontaneously without 
treatment, although its resolution takes weeks or months.
CHAPTER 100
633
Miscellaneous Gram-Negative Bacilli
TABLE 100-2  ANTIMICROBIAL THERAPY FOR DISEASE CAUSED BY 
BARTONELLA SPECIES IN ADULTS
Disease
Antimicrobial Therapy
Typical cat-scratch disease 
(CSD)
Not routinely indicated; for pts with extensive 
lymphadenopathy, consider azithromycin 
(500 mg PO on day 1, then 250 mg PO qd for 
4 days)
CSD retinitis
Doxycycline (100 mg PO bid) plus rifampin 
(300 mg PO bid) for 4–6 weeks 
Other atypical CSD 
manifestationsa
As per retinitis, with treatment duration 
individualized
Trench fever or chronic 
B. quintana bacteremia 
Gentamicin (3 mg/kg IV qd for 14 days) plus
doxycycline (200 mg PO qd or 100 mg PO bid for 
6 weeks) 
Suspected Bartonella
endocarditis
Gentamicinb (1 mg/kg IV q8h for ≥14 days) plus
doxycycline (100 mg PO/IV bid for 6 weeksc) plus
ceftriaxone (2 g IV qd for 6 weeks)
Confirmed Bartonella
endocarditis
As for suspected Bartonella endocarditis minus
ceftriaxone
Bacillary angiomatosis
Erythromycind (500 mg PO qid for 3 months)
or
Doxycycline (100 mg PO bid for 3 months)
Bacillary peliosis
Erythromycind (500 mg PO qid for 4 months)
or
Doxycycline (100 mg PO bid for 4 months)
Bartonellosis (Carrión’s 
disease)
 Oroya fever
Chloramphenicol (500 mg PO/IV qid for 14 days) 
plus another antibiotic (β-lactam preferred)
or
Ciprofloxacin (500 mg PO bid for 10 days)
 Verruga peruana
Rifampin (10 mg/kg PO qd, to a maximum of 
600 mg/d, for 14 days)
or
Streptomycin (15–20 mg/kg IM qd for 10 days) 
aData on treatment efficacy for encephalitis and hepatosplenic CSD are lacking. Therapy 
similar to that given for retinitis is reasonable.
bSome experts recommend gentamicin at 3 mg/kg IV qd. If gentamicin is contraindicated, 
rifampin (300 mg PO bid) can be added to doxycycline for documented Bartonella endocarditis.
cSome experts recommend extending oral doxycycline therapy for 3–6 months.
dOther macrolides are probably effective and may be substituted for erythromycin or doxycycline.
Source: Recommendations are modified from Rolain JM et al: Recommendations for treatment 
of human infections caused by Bartonella species. Antimicrob Agents Chemother 48:1921, 2004.
SECTION 7
634
Infectious Diseases
Diagnosis
Serologic testing is most commonly used but is variably sensitive and 
specific. It is noteworthy that seroconversion may take a few weeks. 
Bartonella species are difficult to culture, but PCR analysis of lymph 
node tissue, pus, or the primary inoculation lesion is highly sensitive and 
specific.
� BACILLARY ANGIOMATOSIS AND PELIOSIS
Bacillary angiomatosis is caused by B. henselae and B. quintana, while pelio-
sis is caused only by the former species. These diseases occur most often in 
HIV-infected pts with CD4+ T cell counts of <100/μL. 
• Pts with bacillary angiomatosis present with one or more painless skin 
lesions that may be tan, red, or purple in color. Subcutaneous masses 
or nodules, ulcerated plaques, and verrucous growths also occur. B. 
quintana is also associated with lytic bone lesions, primarily in the long 
bones.
• Peliosis is an angioproliferative disorder characterized by blood-filled 
cystic structures that affects primarily the liver but also the spleen 
and lymph nodes. Hypodense hepatic areas are usually evident on 
imaging.
• Both diseases are diagnosed on histologic grounds. Blood cultures may 
be positive.
� TRENCH FEVER
• Trench fever (5-day fever) is caused by B. quintana, which is spread by the 
human body louse among its only animal reservoir: humans. 
• Much less common today than in the trenches of World War I, the dis-
ease now primarily affects homeless people. 
• After a usual incubation period of 15–25 days, disease classically ranges 
from a mild febrile illness to a recurrent or protracted and debilitating 
disease. Fever is often periodic, with episodes of 4–5 days separated by 
~5-day afebrile periods. 
• Diagnosis requires identification of B. quintana in blood cultures.
• Untreated, the disease usually lasts 4–6 weeks. Death is rare. 
� BARTONELLA ENDOCARDITIS
Bartonella species (typically B quintana or B. henselae) are an important 
cause of culture-negative endocarditis. The disease's manifestations are 
similar to those of subacute endocarditis of any etiology (Chap. 89). Even 
if incubated for prolonged periods (up to 6 weeks), blood cultures are 
positive in only ~25% of cases. Serologic or PCR testing for Bartonella in 
cardiac valve tissue can help establish the diagnosis in pts with negative 
blood cultures.
� BARTONELLOSIS (CARRIÓN’S DISEASE)
Bartonellosis is a biphasic disease caused by B. bacilliformis, which is trans-
mitted by a sandfly vector found in the Andes valleys of Peru, Ecuador, and 
Colombia. 
• Oroya fever is the initial, bacteremic, systemic form, and verruga peruana 
is its late-onset, eruptive manifestation. 
CHAPTER 101
635
Anaerobic Infections
• Oroya fever may present as a nonspecific bacteremic febrile illness with-
out anemia or as acute, severe hemolytic anemia with hepatomegaly and 
jaundice of rapid onset.
– In verruga peruana, red, hemangioma-like, cutaneous vascular lesions of 
various sizes appear either weeks to months after systemic illness or with 
no previous suggestive history. The lesions persist for months up to 1 year.
• In systemic illness, Giemsa-stained blood films show typical intraeryth-
rocytic bacilli, and blood and bone marrow cultures are positive. 
Serologic assays may be helpful. Biopsy may be required to confirm the 
diagnosis of verruga peruana.
For a more detailed discussion, see Corbel MJ, Beeching 
NJ: Brucellosis, Chap. 157, p. 1296; Jacobs RF, Schutze GE: 
Tularemia, Chap. 158, p. 1301; Prentice MB: Plague and 
Other Yersinia Infections, Chap. 159, p. 1305; and Giladi 
M, Ephros M: Bartonella Infections, Including Cat-Scratch 
Disease, Chap. 160, p. 1314, in HPIM-18.
CHAPTER 101
Anaerobic Infections
DEFINITIONS
• Anaerobic bacteria: require reduced oxygen tension for growth; do not 
grow on the surface of solid media in 10% Co2 in air
• Microaerophilic bacteria: grow in an atmosphere of 10% Co2 in air or 
under anaerobic or aerobic conditions, but grow best if only a small 
amount of atmospheric oxygen is present
• Facultative bacteria: grow in the presence or absence of oxygen
TETANUS
Microbiology, Epidemiology, and Pathogenesis 
Tetanus is characterized by increased muscle tone and spasms caused by 
tetanospasmin (“tetanus toxin”), a toxin produced by Clostridium tetani. 
• C. tetani is a spore-forming, anaerobic gram-positive rod that is ubiqui-
tous in soil and whose spores are highly resilient.
• Worldwide, tetanus is a common disease because of low rates of vacci-
nation. In 2006, ~290,000 people—most of them in Southeast Asia and 
Africa—died of tetanus; maternal and neonatal infections accounted for 
~60% of these deaths. In contrast, only 28 cases were reported in the 
United States in 2007.
• After spores contaminate wounds (typically puncture wounds or, in the 
case of neonates, the umbilical stump) and reach a suitable anaerobic envi-
ronment (e.g., devitalized tissue), organisms proliferate and release toxin. 
SECTION 7
636
Infectious Diseases
– The toxin blocks release of inhibitory neurotransmitters (glycine and 
γ-aminobutyric acid) in presynaptic terminals, and rigidity results 
from an increased resting firing rate of the α-motor neurons.
– A toxin dose as low as 2.5 mg/kg can be fatal.
Clinical Manifestations 
C. tetani can cause a usually mild local disease confined to the muscles near 
the wound or a more severe generalized disease (e.g., neonatal disease).
• If the cranial nerves are involved in localized cephalic tetanus, the pt may 
aspirate or develop airway obstruction due to pharyngeal or laryngeal 
muscle spasm. This situation is associated with a poor prognosis.
• The early symptoms of generalized tetanus often include trismus (lock-
jaw), muscle pain and stiffness, back pain, and difficulty swallowing. As 
the disease progresses, painful muscle spasms develop and can some-
times be strong enough to cause crush fractures.
– Without ventilatory support, respiratory failure is the commonest 
cause of death in tetanus.
– Autonomic disturbance (e.g., labile blood pressure; GI stasis; increased 
tracheal secretions; acute, high-output renal failure) is maximal dur-
ing the second week of severe tetanus, and death due to cardiovascular 
events becomes the major risk.
Diagnosis
The diagnosis is made on clinical grounds. Culture of C. tetani from a wound 
provides supportive evidence.
Tetanus
TREATMENT
• The mainstays of early treatment are the elimination of ongoing toxin 
production and the neutralization of circulating toxin.
– The entry wound should be identified, cleaned, and debrided of 
necrotic material in order to remove anaerobic foci of infection and 
prevent further toxin production.
– Metronidazole (400 mg rectally or 500 mg IV q6h for 7 days) is the 
preferred antibiotic. Penicillin (100,000–200,000 IU/kg qd) is an 
alternative but theoretically may increase spasms.
– Antitoxin should be given as early as possible. 
– Standard treatment consists of a single IM dose of tetanus immune 
globulin (TIG; 3000–6000 IU) or equine antitoxin (10,000–20,000 
IU). However, there is evidence that intrathecal TIG (50–1500 IU) 
inhibits disease progression and leads to a better outcome than 
IM-administered TIG.
• TIG is preferred as it is less likely to cause an anaphylactoid reaction.
• Monitoring and supportive care in a calm, quiet environment are 
important because light and noise can trigger spasms.
– Spasms are controlled by heavy sedation with benzodiazepines, chlor-
promazine, and/or phenobarbital; magnesium sulfate can also be used 
as a muscle relaxant. The doses required to control spasms also cause
CHAPTER 101
637
Anaerobic Infections
 
respiratory depression; thus it is difficult to control spasms ade-
quately in settings without mechanical ventilation.
– Cardiovascular instability in severe tetanus is notoriously difficult to 
treat; increased sedation (e.g., with magnesium sulfate or morphine) 
or administration of short-acting agents that work specifically on the 
cardiovascular system (e.g., esmolol, calcium antagonists, inotropes) 
may be required.
• Recovery from tetanus may take 4–6 weeks. Because natural disease 
does not induce immunity, recovering pts should be immunized.
Prevention
Vaccination effectively prevents disease.
• “Catch-up” vaccination schedules recommend a three-dose primary 
course followed by two further doses for unimmunized adolescents. For 
persons who have received a complete primary course in childhood but 
no further boosters, two doses at least 4 weeks apart are recommended.
• Individuals sustaining tetanus-prone wounds should be immunized if 
their vaccination status is incomplete or unknown or if their last booster 
was given >10 years earlier. Pts sustaining wounds not classified as clean 
or minor should also undergo passive immunization with TIG.
Prognosis
A shorter incubation period (time from wound to first symptom) or onset 
period (time from first symptom to first generalized spasm) is associated 
with worse outcome.
BOTULISM
Microbiology, Epidemiology, and Pathogenesis 
Botulism is a paralytic disease caused by neurotoxins elaborated by 
Clostridium botulinum, an anaerobic spore-forming gram-positive bacte-
rium, as well as a few other toxigenic Clostridium species. 
• Botulism is caused by the toxin’s inhibition of acetylcholine release at the 
neuromuscular junction through an enzymatic mechanism. 
– C. botulinum toxin types A, B, E, and (rarely) F cause human disease, 
with toxin type A causing the most severe syndrome. 
– Toxin type E is associated with foods of aquatic origin.
• Transmission is usually due to consumption of foods contaminated with 
botulinum toxin, but contamination of wounds with spores also can 
result in disease.
– Most U.S. food-borne cases are associated with home-canned food.
– Infant botulism is the most common form of the disease in the United 
States, with ~80–100 cases reported annually.
• Toxin is heat-labile (inactivated when heated for 10 min at 100°C), and 
spores are heat-resistant (inactivated at 116°–121°C or with steam steril-
izers or pressure cookers); these properties underscore the importance of 
properly heating foods.
SECTION 7
638
Infectious Diseases
• Botulinum toxin is the most toxic substance known and thus is of con-
cern as a potential weapon of bioterrorism (Chap. 33).
Clinical Manifestations 
Botulism occurs naturally as four syndromes: (1) food-borne illness; (2) 
wound infection; (3) infant botulism; and (4) adult intestinal toxemia, 
which is similar to infant botulism. The disease presents as symmetric cra-
nial nerve palsies (diplopia, dysarthria, dysphonia, ptosis, and/or dyspha-
gia) followed by symmetric descending flaccid paralysis that may progress 
to respiratory arrest and death.
• Food-borne botulism occurs 18–36 h after ingestion of food contaminated 
with toxin and ranges in severity from mild to fatal (within 24 h). Nausea, 
vomiting, and abdominal pain may precede or follow the onset of paraly-
sis; constipation due to paralytic ileus is nearly universal. Fever is usually 
absent.
• Wound botulism occurs when spores contaminate wounds (e.g., in black-
tar heroin users) and germinate. The clinical syndrome is indistinguishable 
from food-borne botulism except that GI symptoms are generally absent.
• In infant botulism and adult intestinal toxemia, spores germinate in 
the intestine and produce toxin, which is absorbed and causes illness. 
This form in infants has been associated with contaminated honey; 
thus honey should not be fed to children <12 months of age. Adult pts 
typically have some anatomic or functional bowel abnormality or have a 
bowel flora disrupted by recent antibiotic use.
Diagnosis
The clinical symptoms suggest the diagnosis. The definitive test is the dem-
onstration of the toxin in clinical specimens (serum, stool, gastric aspirates, 
wound material) with a mouse bioassay (i.e., paralysis in a mouse after 
injection with the clinical sample). 
• The results may not be available for up to 48 h, so clinical decisions (e.g., 
to administer botulinum antitoxin) need to be made in their absence. 
• This test may yield a negative result even if the pt has botulism; addi-
tional tests may be necessary to rule out other conditions. 
Botulism
TREATMENT
• The mainstays of treatment are meticulous supportive care and immedi-
ate administration of botulinum antitoxin—the only specific treatment.
– Adults are given an equine antitoxin available through the CDC 
(770-488-7100); infant botulism is treated with a human-origin 
antitoxin (licensed as BabyBIG®) available through the California 
Department of Public Health (510-231-7600).
– In wound botulism, suspect wounds and abscesses should be 
cleaned, debrided, and drained promptly, and antimicrobial therapy 
(e.g., penicillins) should be guided by clinical judgment, as its clini-
cal efficacy has not been established.
CHAPTER 101
639
Anaerobic Infections
Prognosis
Toxin binding is irreversible, but nerve terminals do regenerate. In the United 
States, 95% of pts recover fully, but this process may take many months.
OTHER CLOSTRIDIAL INFECTIONS
Microbiology and Pathogenesis 
Clostridia are pleomorphic, gram-positive, spore-forming organisms. Most 
species are obligate anaerobes; some (e.g., C. septicum, C. tertium) can 
grow—but not sporulate—in air. 
• In humans, clostridia reside in the GI and female genital tracts and on 
the oral mucosa. 
• Clostridial species produce more protein toxins than any other bacterial 
genus; the C. perfringens epsilon toxin is among the most lethal and is 
considered a potential agent of bioterrorism (Chap. 33).
Epidemiology and Clinical Manifestations 
Life-threatening clostridial infections range from intoxications (e.g., food 
poisoning, tetanus) to necrotizing enteritis/colitis, bacteremia, myonecro-
sis, and toxic shock syndrome (TSS).
• Clostridial wound contamination: Of open traumatic wounds, 30–80% 
are contaminated with clostridial species. Diagnosis and treatment of 
clostridial infection should be based on clinical signs and symptoms, 
given that clostridia are isolated with equal frequency from both sup-
purative and well-healing wounds.
• Polymicrobial infections involving clostridia: Clostridial species can be 
involved in infection throughout the body; 66% of intraabdominal 
infections related to compromised mucosal integrity involve clostridia 
(most commonly C. ramosum, C. perfringens, and C. bifermentans).
• Enteric clostridial infections: Disease ranges from food-borne illnesses 
and antibiotic-associated colitis (Chap. 91) to extensive necrosis of 
the intestine (e.g., enteritis necroticans and necrotizing enterocolitis, 
which are due to toxigenic C. perfringens type C and type A, 
respectively).
• Clostridial bacteremia: C. perfringens causes 79% of clostridial bactere-
mias; when associated with myonecrosis, clostridial bacteremia has a 
grave prognosis. 
– C. septicum is also commonly associated with bacteremia (<5% of 
cases). More than 50% of pts with C. septicum bacteremia have a GI 
anomaly or an underlying malignancy. Neutropenia (of any origin) is 
also associated with clostridial bloodstream infection.
• Pts with clostridial bacteremia—particularly that due to C. septi-
cum—require immediate treatment, as infection can metastasize and 
cause spontaneous myonecrosis.
• Clostridial skin and soft-tissue infections: Necrotizing clostridial soft-
tissue infections are rapidly progressive and are characterized by marked 
tissue destruction, gas in the tissues, and shock. Most pts develop severe 
pain, crepitus, brawny induration with rapid progression to skin slough-
ing, violaceous bullae, and marked tachycardia.
SECTION 7
640
Infectious Diseases
– C. perfringens myonecrosis (gas gangrene) is accompanied by bacte-
remia, hypotension, and multiorgan failure and is invariably fatal if 
untreated. 
 
•  If due to trauma, gas gangrene has an incubation period of 6 h 
to <4 days. Disease initially presents as excruciating pain at the 
affected site and the development of a foul-smelling wound con-
taining a thin serosanguineous discharge and gas bubbles.
 
•  Spontaneous gas gangrene results from hematogenous seeding 
of normal muscle with toxigenic clostridia from a GI source. 
Confusion, extreme pain in the absence of trauma, and fever 
should heighten suspicion.
– TSS: Endometrial clostridial infection (particularly with C. sordellii) is 
usually related to pregnancy and proceeds rapidly to TSS and death. 
 
•  Systemic manifestations, including edema, effusions, profound 
leukocytosis (50,000–200,000/μL), and hemoconcentration (Hct 
of 75–80%), are followed by the rapid onset of hypotension and 
multiple-organ failure. 
 
• Fever is usually absent.
– Other clostridial skin and soft-tissue infections include crepitant 
cellulitis (involving subcutaneous or retroperitoneal tissues in dia-
betic pts), cellulitis and abscess formation due to C. histolyticum, 
and endophthalmitis due to C. sordellii or C. perfringens.
Diagnosis
Isolation of clostridia from clinical sites does not in itself indicate severe 
disease. Clinical findings and presentation must also be taken into account.
Other Clostridial Infections 
TREATMENT
Table 101-1 lists treatment regimens for clostridial infections.
MIXED ANAEROBIC INFECTIONS
Microbiology, Epidemiology, and Pathogenesis 
Nonsporulating anaerobic bacteria are important components of the nor-
mal flora of mucosal surfaces of the mouth, lower GI tract, skin, and female 
genital tract and contribute to physiologic, metabolic, and immunologic 
functions of the host. 
• Most clinically relevant anaerobes are relatively aerotolerant and can 
survive for as long as 72 h in the presence of low levels of oxygen. 
– Clinically relevant anaerobes include gram-positive cocci (e.g., 
Peptostreptococcus species), gram-positive rods (e.g., spore-forming 
clostridia and Propionibacterium acnes), and gram-negative bacilli (e.g., 
the B. fragilis group in the normal bowel flora, Fusobacterium species 
in the oral cavity and GI tract, Prevotella species in the oral cavity and 
female genital tract, and Porphyromonas species in the oral flora).
• Infections caused by anaerobes are typically polymicrobial (including at 
least one anaerobic organism and sometimes involving microaerophilic 
CHAPTER 101
641
Anaerobic Infections
TABLE 101-1 TREATMENT OF CLOSTRIDIAL INFECTIONS
Condition
Antibiotic
Treatment
Penicillin Allergy
Adjunctive
Treatment/Note
Wound 
contamination
None
—
—
Polymicrobial 
anaerobic
infections
involving
clostridia 
(e.g., abdom-
inal wall, 
gynecologic)
Ampicillin
(2 g IV q4h)
plus
Clindamycin
(600–900
mg IV 
q6–8h)
plus
Ciprofloxacin
(400 mg IV 
q6–8 h)
Vancomycin 
(1 g IV q12h)
plus
Metronidazole
(500 mg IV q6h)
plus
Ciprofloxacin
(400 mg IV 
q6–8h)
Empirical therapy 
should be initiated.
Therapy should be 
based on Gram’s stain 
and culture results 
and on sensitivity data 
when available. Add 
gram-negative cover-
age if indicated.
Clostridial
sepsis
Penicillin 
(3–4 mU IV 
q4–6h)
plus
Clindamycin
(600–900
mg IV 
q6–8h)
Clindamycin
alone
or
Metronidazole
or
Vancomycin
As for polymi-
crobial anaerobic 
infections (see 
above)
Transient bacteremia 
without signs of sys-
temic toxicity may be 
clinically insignificant.
Gas gangrene
Penicillin G 
(4 mU IV 
q4–6 h)
plus
Clindamycin
(600–900 mg 
IV q6–8h)
Cefoxitin
(2 g IV q6h)
plus
Clindamycin
(600–900 mg IV 
q6–8h)
Emergent surgical 
exploration and thor-
ough debridement are 
extremely important.
Hyperbaric oxygen 
therapy may be con-
sidered after surgery 
and antibiotic treatment 
have been initiated.
and facultative bacteria) and occur when organisms penetrate a previ-
ously sterile site that has a reduced oxidation-reduction potential—e.g., 
from tissue ischemia, trauma, surgery, perforated viscus, shock, or aspira-
tion. Bacterial synergy, bacterial virulence factors, and mechanisms of 
abscess formation are factors involved in the pathogenesis of anaerobic 
infections. 
SECTION 7
642
Infectious Diseases
• Anaerobes account for 0.5–12% of all cases of bacteremia, with B. fragilis 
isolated in 35–80% of these cases.
Clinical Manifestations 
The clinical presentation of anaerobic infections depends, in part, on the 
anatomic location affected.
• Mouth, head, and neck infections: Odontogenic infections (e.g., dental 
caries, periodontal disease, gingivitis) are common, can spread locally, 
and may be life-threatening.
– Acute necrotizing ulcerative gingivitis (trench mouth, Vincent’s stomatitis) 
is associated with bleeding tender gums, foul breath, and ulceration with 
gray exudates, often affecting malnourished children, pts with leukemia, 
or pts with a debilitating illness. Widespread destruction of bone and soft 
tissue can develop. Lesions heal but leave disfiguring defects.
– Acute necrotizing infection of the pharynx is associated with ulcerative 
gingivitis. Pts have a sore throat, foul breath, fever, a choking sensation, 
and tonsillar pillars that are swollen, red, ulcerated, and covered with a 
gray membrane. Aspiration of infected material can lead to a lung abscess.
– Peripharyngeal infections include peritonsillar abscess (quinsy; caused 
by a mixed flora including anaerobes and group A streptococci) and 
submandibular space infection (Ludwig’s angina), which arises from 
the second and third molars in 80% of cases and is associated with 
swelling (which can lead to respiratory obstruction), pain, trismus, 
and displacement of the tongue.
– Chronic sinusitis and otitis (Chap. 64) are commonly due to anaerobes.
– Complications of anaerobic mouth, head, and neck infections include 
Lemierre’s syndrome, osteomyelitis, CNS infections (e.g., brain 
abscess, epidural abscess, subdural empyema), mediastinitis, pleuro-
pulmonary infections, and hematogenous dissemination.
• Lemierre’s syndrome, which is typically due to Fusobacterium nec-
rophorum, is an acute oropharyngeal infection with secondary septic 
thrombophlebitis of the internal jugular vein and frequent metastasis, 
most commonly to the lung.
• Pleuropulmonary infections include aspiration pneumonia (which 
is difficult to distinguish from chemical pneumonitis due to aspi-
ration of gastric juices), necrotizing pneumonitis, lung abscesses, 
and empyema. Bacterial aspiration pneumonia is associated with 
a depressed gag reflex, impaired swallowing, or altered mental 
status; anaerobic lung abscess usually arises from a dental source.
• Intraabdominal infections: See Chap. 90.
• Pelvic infections: See Chap. 92 for more details. Anaerobes, typically in com-
bination with coliforms, are isolated from most women with genital tract 
infections (e.g., Bartholin gland abscess, salpingitis, tuboovarian abscess, 
endometritis) that are not caused by a sexually transmitted pathogen. The 
major anaerobic pathogens are Bacteroides fragilis, Prevotella species (bivia, 
disiens, melaninogenica), anaerobic cocci, and Clostridium species.
• Skin and soft tissue infections: See Chap. 93 for more details. These infec-
tions most frequently occur at sites prone to contamination with feces or 
with upper airway secretions.
CHAPTER 101
643
Anaerobic Infections
• Bone and joint infections: Anaerobic bone and joint infections usually 
occur adjacent to soft tissue infections. Actinomycosis is the leading 
cause of anaerobic bone infections worldwide; Fusobacterium species are 
the most common anaerobic cause of septic arthritis.
Diagnosis
The three critical steps in successfully culturing anaerobic bacteria from clini-
cal samples are (1) proper specimen collection, with avoidance of contamina-
tion by normal flora; (2) rapid specimen transport to the microbiology labora-
tory in anaerobic transport media; and (3) proper specimen handling. A foul 
odor is often indicative (and nearly pathognomonic) of an anaerobic infection.
Mixed Anaerobic Infections
TREATMENT
• Appropriate treatment requires antibiotic administration (Table 101-2), 
surgical resection or debridement of devitalized tissues, and drainage.
– Given that most infections involving anaerobes also include aero-
bic organisms, therapeutic regimens should include agents active 
against both classes of organisms.
– Infections above the diaphragm usually reflect the orodental flora, which 
includes many organisms that produce β-lactamase. Accordingly, the 
recommended regimens include clindamycin, a β-lactam/β-lactamase 
inhibitor combination, or metronidazole in combination with a drug 
active against microaerophilic and aerobic streptococci.
– Infections below the diaphragm must be treated with agents active 
against Bacteroides species, such as metronidazole, β-lactam/
β-lactamase inhibitor combinations, or carbapenems. Treatment 
should also cover the aerobic gram-negative flora, including entero-
cocci (e.g., ampicillin or vancomycin) when indicated.
• Pts with anaerobic infections that fail to respond to treatment or that 
relapse should be reassessed, with consideration of additional surgical 
drainage or debridement. Superinfection with resistant gram-negative 
facultative or aerobic bacteria should also be considered. 
TABLE 101-2  TREATMENT OF SERIOUS INFECTIONS DUE TO COMMONLY 
ENCOUNTERED ANAEROBIC GRAM-NEGATIVE RODS
First-Line Therapy
Dose
Schedulea
Metronidazoleb
500 mg
q6h
Ticarcillin/clavulanic acid
3.1 g
q4h
Piperacillin/tazobactam
3.375 g
q6h
Imipenem
0.5 g
q6h
Meropenem
1.0 g
q8h
aSee disease-specific chapters in HPIM-18 for recommendations on duration of therapy.
bShould generally be used in conjunction with drugs active against aerobic or facultative organisms.
Note: All drugs are given by the IV route.
SECTION 7
644
Infectious Diseases
For a more detailed discussion, see Thwaites CL, Yen LM: 
Tetanus, Chap. 140, p. 1197; Sobel J, Maslanka S: Botulism, 
Chap. 141, p. 1200; Bryant AE, Stevens DL: Gas Gangrene 
and Other Clostridial Infections, Chap. 142, p. 1204; and 
Kasper DL, Cohen-Poradosu R: Infections Due to Mixed 
Anaerobic Organisms, Chap. 164, p. 1331, in HPIM-18.
CHAPTER 102
Nocardiosis and 
Actinomycosis
NOCARDIOSIS
Microbiology 
Nocardiae are branching, beaded, gram-positive filaments that usually give 
positive results with modified acid-fast stains. These saprophytic aerobic 
actinomycetes are common in soil. 
• Nine species or species complexes are most commonly associated with 
human disease. 
• Speciation of nocardiae is precluded in most clinical laboratories because 
it is nearly impossible without molecular phylogenetic techniques. 
• Nocardia brasiliensis is most often associated with localized skin lesions.
Epidemiology 
Nocardiosis occurs worldwide and has an incidence of ~0.375 cases per 
100,000 persons in Western countries. The risk of disease is greater than 
usual among persons who have deficient cell-mediated immunity—e.g., 
that associated with lymphoma, transplantation, glucocorticoid therapy, or 
HIV infection with <250 CD4+ T cells/μL.
Pathogenesis 
Pneumonia and disseminated disease follow inhalation of fragmented bac-
terial mycelia. 
• Nocardiosis causes abscesses with neutrophilic infiltration and necrosis. 
• Organisms have multiple mechanisms for surviving within phagocytes.
Clinical Manifestations
• Respiratory tract disease: Pneumonia is usually subacute, presenting over 
days to weeks, but can be acute in immunocompromised pts.
– A prominent cough productive of small amounts of thick purulent 
sputum, fever, anorexia, weight loss, and malaise are common; dyspnea, 
hemoptysis, and pleuritic chest pain are less common. 
– CXR may demonstrate single or multiple nodular infiltrates of varying 
sizes that tend to cavitate. Empyema is noted in one-quarter of cases. 
– Extrapulmonary disease is documented in >50% of cases. 
CHAPTER 102
645
Nocardiosis and Actinomycosis 
• Extrapulmonary disease: In 20% of cases of disseminated disease, lung 
disease is absent. 
– Nocardial dissemination manifests as subacute abscesses in brain 
(most commonly), skin, kidneys, bone, and/or muscle. 
– Brain abscesses are usually supratentorial, are often multiloculated, 
can be single or multiple, and tend to burrow into ventricles or extend 
into the subarachnoid space.
– Meningitis is uncommon, and nocardiae are difficult to recover from CSF.
• Disease following transcutaneous inoculation: usually presents as celluli-
tis, lymphocutaneous disease, or actinomycetoma
– Cellulitis presents 1–3 weeks after a break in the skin (often with con-
tamination by soil). 
•  The firm, tender, erythematous, warm, and nonfluctuant lesions 
may involve underlying structures, but dissemination is rare.
•  N. brasiliensis and species in the N. otitidiscaviarum complex are 
most common in cellulitis.
– Lymphocutaneous disease resembles sporotrichosis and presents as a 
pyodermatous nodule at the inoculation site, with central ulceration 
and purulent or honey-colored discharge. 
•  Subcutaneous nodules often appear along lymphatics that drain the 
primary lesion.
– Actinomycetoma progresses from a nodular swelling at the site of local 
trauma (typically on the feet or hands, although other sites can be 
affected) to fistula formation; dissemination is rare.
•  The discharge is serous or purulent and can contain granules con-
sisting of masses of mycelia. 
•  Lesions, which spread slowly along fascial planes to involve adja-
cent skin and SC tissue and bone, can cause extensive deformity 
after months or years.
• Eye disease: Endophthalmitis can occur after eye surgery or during dis-
seminated disease.
Diagnosis
• Sputum or pus should be examined microscopically and by culture for 
the presence of nocardiae. In pts with nocardial pneumonia, sputum 
smears are often negative, and bronchoscopy may be needed to obtain 
adequate specimens.
– Cultures take 2–4 weeks to yield the organism. To maximize the like-
lihood of isolation, the laboratory should be alerted if nocardiosis is 
being considered.
– Sputum cultures positive for nocardiae should be assumed to reflect 
disease in immunocompromised hosts, but may represent coloniza-
tion in immunocompetent pts. 
• Discharge from lesions suspected to be an actinomycetoma should be 
examined for granules, the appearance of which can help differentiate 
this diagnosis from eumycetoma (cases involving fungi) and botryomy-
cosis (cases involving cocci or bacilli).
– Granules from actinomycetomas consist of fine filaments (0.5–1 μm 
wide) radiating from a central core.
SECTION 7
646
Infectious Diseases
– In contrast, granules from eumycetoma cases have broader filaments 
(2–5 μm wide) encased in a matrix, and those of botryomycosis are 
loose masses of bacteria.
• Brain imaging should be considered in pts with pulmonary or dissemi-
nated disease.
Nocardiosis
TREATMENT
• Sulfonamides are the empirical drugs of choice, and trimethoprim-
sulfamethoxazole (TMP-SMX; 10–20 mg of TMP/kg qd and 50–100 
mg of SMX/kg qd initially, with later reduction to 5 and 25 mg/kg qd, 
respectively) may be more effective than sulfonamides alone. 
– Susceptibility testing, particularly in severe cases or cases failing to 
improve, can guide alternative treatments and should be performed 
at reference labs (e.g., the Mycobacteria/Nocardia Laboratory at the 
University of Texas Health Science Center; phone, 903-877-7685).
– Alternative oral agents that are often effective include minocycline, 
linezolid (whose long-term use is complicated by side effects), 
amoxicillin/clavulanic acid, and fluoroquinolones. 
– Effective parenteral agents include amikacin, ceftriaxone, cefotaxime, 
and imipenem.
• Pts with severe disease are initially treated with a combination of 
TMP-SMX, amikacin, and either ceftriaxone or imipenem. After defi-
nite clinical improvement, the regimen can usually be simplified to a 
single oral agent.
• Surgical management of nocardial infections is similar to that of other 
bacterial diseases.
– Brain abscesses that are large or unresponsive to antibiotics should 
be aspirated.
– Medical therapy is generally sufficient for actinomycetomas.
• Relapse is common. 
– Long courses of therapy are required (Table 102-1).
– Pts should be followed for at least 6 months after therapy is complete. 
ACTINOMYCOSIS
Microbiology 
Actinomycosis is caused by anaerobic or microaerophilic bacteria, primarily 
of the genus Actinomyces (e.g., A. israelii, A. naeslundii, A. odontolyticus), 
that colonize the mouth, colon, and vagina. Most infections are polymi-
crobial, but the role of other species in the pathogenesis of the disease is 
unclear.
Epidemiology 
Actinomycosis is associated with poor dental hygiene, prolonged use 
of intrauterine contraceptive devices (IUCDs), and treatment with 
bisphosphonates. 
CHAPTER 102
647
Nocardiosis and Actinomycosis 
Pathogenesis 
After disruption of the mucosal barrier, resident Actinomyces can infect 
locally and spread contiguously in a slow progressive manner, ignoring tis-
sue planes. The hallmark of actinomycosis is the development of single or 
multiple indurated lesions with fibrotic walls often described as “wooden.” 
Central necrosis of lesions with neutrophils and sulfur granules is virtually 
diagnostic of the disease. 
Clinical Manifestations
• Oral-cervicofacial disease: Infection starts as a soft-tissue swelling, 
abscess, or mass, often at the angle of the jaw, with occasional contigu-
ous extension to the brain, cervical spine, or thorax. Pain, fever, and 
leukocytosis are variable. Radiation therapy and particularly bisphos-
phonate treatment are associated with actinomycosis of the maxilla and 
mandible.
• Thoracic disease: The pulmonary parenchyma and/or pleural space is 
usually involved. Chest pain, fever, and weight loss are common. 
– Radiographic studies demonstrate a mass lesion or pneumonia. 
Cavitary disease or hilar adenopathy may occur, and >50% of pts have 
pleural thickening, effusion, or empyema. 
– Lesions cross fissures or pleura and may involve the mediastinum, 
contiguous bone, or the chest wall. In the absence of these findings, 
the disease is often mistaken for a neoplasm or for pneumonia.
• Abdominal disease: The diagnosis is challenging given that it may not 
present clinically until months or years after the initial event (e.g., appen-
dicitis, diverticulitis, bowel surgery) and that any abdominal organ or 
region can be involved. 
TABLE 102-1 TREATMENT DURATION FOR NOCARDIOSIS
Disease
Duration
Pulmonary or systemic
 Intact host defenses
6–12 months
 Deficient host defenses
12 monthsa
 CNS disease
12 monthsb
Cellulitis, lymphocutaneous syndrome
2 months
Osteomyelitis, arthritis, laryngitis, sinusitis 4 months
Actinomycetoma
6–12 months after clinical cure
Keratitis
Topical: until apparent cure
Systemic: until 2–4 months after 
apparent cure
aIn some pts with AIDS and CD4+ T lymphocyte counts of <200/μL or with chronic granulo-
matous disease, therapy for pulmonary or systemic disease must be continued indefinitely.
bIf all apparent diseased CNS tissue has been excised, the duration of therapy may be 
reduced to 6 months.
SECTION 7
648
Infectious Diseases
– The disease usually presents as an abscess, mass, or lesion fixed to 
underlying tissue and is often mistaken for cancer. 
– Sinus tracts to the abdominal wall, perianal region, or other organs 
may develop and mimic inflammatory bowel disease. Recurrent 
disease or a wound or fistula that fails to heal suggests actinomycosis.
• Pelvic disease: Pelvic actinomycosis is often associated with IUCDs that 
have been in place for >1 year. The presentation is indolent and may fol-
low removal of the device. 
– Pts have fever, weight loss, abdominal pain, and abnormal vaginal 
bleeding or discharge. Endometritis progresses to pelvic masses or 
tuboovarian abscess. 
– When there are no symptoms and Actinomyces-like organisms are 
identified on Papanicolaou-stained specimens, the pt should undergo 
close follow-up but the IUCD should be not removed.
• Miscellaneous sites: Actinomycosis can involve musculoskeletal tissue, 
soft tissue, or (rarely) the CNS. Hematogenous dissemination, most 
commonly to the lungs and liver, can occur.
Diagnosis
Actinomycosis should be considered when a chronic progressive process 
with mass-like features crosses tissue boundaries, a sinus tract develops, 
and/or the pt has evidence of a refractory or relapsing infection despite 
short courses of antibiotics. 
• Aspirations, biopsies, or surgical excision may be required to obtain 
material for diagnosis. 
• Microscopic identification of sulfur granules (an in vivo matrix of bac-
teria, calcium phosphate, and host material) in pus or tissues establishes 
the diagnosis. 
• Cultures usually require 5–7 days to become positive but may take 2–4 weeks; 
even a single antibiotic dose can affect the yield of cultures. 
Actinomycosis
TREATMENT
• For serious infection and bulky disease, IV therapy for 2–6 weeks (usually 
with penicillin, 18–24 million units IV daily) followed by oral therapy for 
6–12 months (e.g., with penicillin or ampicillin) is suggested. 
– Less extensive disease, particularly that involving the oral-cervicofacial 
region, may be cured with a shorter course. 
– If treatment is extended beyond the point of resolution of measur-
able disease (as quantified by CT or MRI), relapse is minimized. 
• Suitable alternative agents include the tetracyclines (e.g., doxycycline 
or minocycline, 100 mg PO/IV q12h) or clindamycin (900 mg IV q8h 
or 300–450 mg PO q6h).
For a more detailed discussion, see Filice GA: Nocardiosis, 
Chap. 162, p. 1322; and Russo TA: Actinomycosis, Chap. 163, 
p. 1326, in HPIM-18.
CHAPTER 103
649
Tuberculosis and Other Mycobacterial Infections 
CHAPTER 103
Tuberculosis and Other 
Mycobacterial Infections
TUBERCULOSIS
� MICROBIOLOGY 
Tuberculosis (TB) is caused by organisms of the Mycobacterium tuberculosis 
complex, which includes M. tuberculosis, the most common and important 
agent of human mycobacterial disease, and M. bovis, which (like several 
other mycobacterial species) is acquired via ingestion of unpasteurized milk. 
M. tuberculosis is a thin aerobic bacillus that is neutral on Gram’s staining but 
that, once stained, is acid-fast; i.e., it cannot be decolorized by acid alcohol 
because of the cell wall’s high content of mycolic acids and other lipids.
� EPIDEMIOLOGY 
Approximately 9.4 million new cases of TB occurred worldwide in 2009, 
with ~1.7 million TB-related deaths in 2008—mostly in low-income coun-
tries. Globally, TB rates are stable or falling.
• In the United States, TB primarily affects HIV-infected adults, immi-
grants, the elderly, and disadvantaged/marginalized populations.
• Multidrug-resistant (MDR; resistant to at least isoniazid and rifampin) 
and extensively drug-resistant (XDR; resistant to isoniazid, rifampin, fluo-
roquinolones, and either amikacin, kanamycin, or capreomycin) isolates 
of M. tuberculosis are increasing in frequency; ~440,000 cases of MDR-TB 
may have emerged in 2008, of which ~10% were probably XDR.
• Disease from a pt with pulmonary TB is spread by droplet nuclei that are 
aerosolized by coughing, sneezing, or speaking. 
– Droplets <5–10 μm in diameter may be suspended in air for several hours. 
– Transmission is determined by the intimacy and duration of contact 
with a pt with TB, the degree of infectiousness of the pt, and the shared 
environment. 
– Pts with cavitary or laryngeal disease are most infectious, with as 
many as 105–107 acid-fast bacilli (AFB)/mL of sputum.
• Risk factors for development of active disease after M. tuberculosis infec-
tion include recent acquisition (within the preceding year), comorbidity 
(e.g., HIV disease, diabetes, silicosis, immunosuppression, gastrectomy), 
malnutrition, tobacco smoking, and presence of fibrotic lesions.
� PATHOGENESIS 
AFB that reach alveoli are ingested by macrophages. The bacilli impair phago-
some maturation, multiply, lyse the macrophages, and spread to regional 
lymph nodes, from which they may disseminate throughout the body. These 
initial stages of infection are generally asymptomatic and induce cellular and 
humoral immunity.
SECTION 7
650
Infectious Diseases
• About 2–4 weeks after infection, a tissue-damaging response resulting 
from delayed-type hypersensitivity [the basis for tuberculin skin test-
ing (TST)] destroys nonactivated macrophages that contain multiplying 
bacilli, and a macrophage-activating response activates cells capable of 
killing AFB. A granuloma forms at the site of the primary lesion and 
at sites of dissemination. The lesions can then either heal by fibrosis or 
undergo further evolution. Despite “healing,” viable bacilli can remain 
dormant within macrophages or in necrotic material for years. 
• Cell-mediated immunity confers partial protection against TB. Cytokines 
secreted by alveolar macrophages contribute to disease manifestations, 
granuloma formation, and mycobacterial killing.
� CLINICAL MANIFESTATIONS 
TB is classified as pulmonary, extrapulmonary, or both.
Pulmonary TB 
TB is limited to the lungs in >80% of HIV-negative pts. Primary disease 
may cause no or mild symptoms (fever and occasional pleuritic chest pain) 
in contrast to the prolonged disease course that is common in postprimary 
or adult-type disease.
• Primary disease is frequently located in the middle and lower lobes. The 
primary lesion usually heals spontaneously, and a calcified nodule (Ghon 
lesion) remains.
– Transient hilar and paratracheal lymphadenopathy is common. 
– In immunosuppressed pts and children, primary disease may progress 
rapidly to significant clinical disease, with cavitation, pleural effu-
sions, and hematogenous dissemination (miliary disease).
• Adult-type disease presents initially with nonspecific and insidious symp-
toms, such as diurnal fever, night sweats, weight loss, anorexia, malaise, 
and weakness. 
– As the disease progresses, pts develop cough and purulent sputum pro-
duction, often with blood streaking. Extensive cavitation may develop, 
with occasional massive hemoptysis following erosion of a vessel 
located in the wall of a cavity.
– Disease is usually localized to the apical and posterior segments of the 
upper lobes and the superior segments of the lower lobes.
Extrapulmonary TB 
Any site in the body can be involved, but the most commonly affected sites 
are (in order of frequency) the lymph nodes, pleura, genitourinary tract, 
bones and joints, meninges, peritoneum, and pericardium. Up to two-thirds 
of HIV-infected pts with TB have extrapulmonary disease.
• Lymphadenitis occurs in 35% of extrapulmonary TB cases, especially 
among HIV-infected pts. Painless swelling of cervical and supraclavicu-
lar nodes (scrofula) is typical. 
– Nodes are discrete early on but can develop into a matted nontender 
mass with a fistulous tract. 
– Fine-needle aspiration or surgical-excision biopsy of the node is 
required for diagnosis. Cultures are positive in 70–80% of cases.
CHAPTER 103
651
Tuberculosis and Other Mycobacterial Infections 
• Pleural involvement is common and results from a hypersensitivity 
response to mycobacterial antigens or contiguous spread of parenchymal 
inflammation.
– Fluid is straw-colored and exudative, with protein levels >50% of 
those in serum, normal to low glucose levels, a usual pH of ~7.3 
(occasionally <7.2), and pleocytosis (500–6000 cells/μL). The 
pleural concentration of adenosine deaminase, if low, virtually 
excludes TB. 
– Pleural biopsy is often required for diagnosis, with up to 80% of biopsy 
cultures positive. Direct smears and cultures of pleural fluid are less 
sensitive.
– Empyema is an uncommon complication of pulmonary TB and 
results from rupture of a cavity with many bacilli into the pleural 
space. In these cases, direct smears and cultures are often positive, 
and surgical drainage is usually required in addition to chemo-
therapy.
• In genitourinary disease, local symptoms predominate (e.g., frequency, 
dysuria, hematuria, abdominal or flank pain), and up to 75% of pts 
have a CXR demonstrating previous or concomitant pulmonary disease. 
Disease is occasionally identified only after severe destructive lesions of 
the kidneys have developed.
– In >90% of cases, urinalysis shows pyuria and hematuria with negative 
bacterial cultures.
– Mycobacterial culture of three morning urine specimens is diagnostic 
in 90% of cases. 
• Weight-bearing joints (spine, hips, and knees) are the most common sites 
of skeletal disease. 
– Spinal TB (Pott’s disease) often involves two or more adjacent verte-
bral bodies; in adults, lower thoracic/upper lumbar vertebrae are usu-
ally affected. Disease spreads to adjacent vertebral bodies, later affect-
ing the intervertebral disk and causing collapse of vertebral bodies in 
advanced disease (kyphosis, gibbus). Paravertebral cold abscesses may 
form.
• Meningitis occurs most often in young children and HIV-seropositive 
pts. Disease typically evolves over 1–2 weeks and often involves paresis 
of cranial nerves (particularly of ocular nerves). The ultimate evolution 
is toward coma, with hydrocephalus and intracranial hypertension.
– CSF can have a high lymphocyte count, an elevated protein level, and 
a low glucose concentration. Cultures are positive in 80% of cases. 
PCR is ~80% sensitive but gives a false-positive result 10% of the 
time.
– Neurologic sequelae are seen in ~25% of treated pts; adjunctive 
glucocorticoids enhance survival among pts >14 years of age, but do 
not reduce the frequency of neurologic sequelae.
• Gastrointestinal disease can affect any portion of the GI tract (with the 
terminal ileum and cecum most commonly involved), causing abdominal 
pain, obstruction, hematochezia, and often a palpable mass. TB peritonitis 
can occur after spread of the organism from ruptured lymph nodes and 
intraabdominal organs; peritoneal biopsy is usually required for diagnosis.
SECTION 7
652
Infectious Diseases
• Pericarditis is characterized by an acute or subacute onset of fever, dull 
retrosternal pain, and sometimes a friction rub. Effusion is common. 
Chronic constrictive pericarditis is a potentially fatal complication, even 
in treated pts. Adjunctive glucocorticoids remain controversial; no con-
clusive data demonstrate a benefit.
• Miliary disease arises from hematogenous spread of M. tuberculosis 
throughout the body. Symptoms are nonspecific, and small (1- to 2-mm) 
granulomas may develop in many organs. Hepatomegaly, splenomegaly, 
lymphadenopathy, and choroidal tubercles of the eye may occur.
HIV-Associated TB 
The manifestations of TB vary with the stage of HIV infection. When cell-
mediated immunity is only partly compromised, pulmonary TB presents as 
typical upper-lobe cavitary disease. In late HIV infection, a primary TB–like 
pattern may be evident, with diffuse interstitial or miliary infiltrates, little or 
no cavitation, and intrathoracic lymphadenopathy. 
• Extrapulmonary disease occurs frequently; common forms include 
lymphadenitis, meningitis, pleuritis, pericarditis, mycobacteremia, and 
disseminated disease.
• Immune reconstitution inflammatory syndrome (IRIS), which may 
occur 1–3 months after initiation of antiretroviral therapy, may exacer-
bate the signs and symptoms of TB.
� DIAGNOSIS 
The key to diagnosis is a high index of suspicion. 
• AFB microscopy of diagnostic specimens—i.e., light microscopy of 
specimens stained with Ziehl-Neelsen basic fuchsin dyes or fluorescence 
microscopy of samples stained with auramine-rhodamine—can provide 
a presumptive diagnosis. In suspected pulmonary TB, 2 or 3 sputum 
samples should be examined.
• Definitive diagnosis requires growth of M. tuberculosis in culture or 
identification of the organism’s DNA in clinical samples. 
– Liquid media and speciation by molecular methods have decreased the 
time required for diagnostic confirmation to 2–3 weeks (from 4–8 weeks).
– Nucleic acid amplification is useful not only for rapid confirmation of 
TB in AFB-positive specimens but also for diagnosis of AFB-negative 
pulmonary and extrapulmonary TB.
• Drug susceptibility can be assessed via indirect testing on solid media 
(which takes ≥8 weeks), direct testing in liquid media (which takes ~3 
weeks), or PCR (which can provide results within hours).
• TST is of limited value in active disease because of low sensitivity and speci-
ficity but is the most widely used screening test for latent TB infection. 
• Interferon γ release assays (IGRAs) measure the release of interferon γ by 
T cells after stimulation with TB-specific antigens and are more specific 
for M. tuberculosis than is TST. 
– In low-incidence settings, IGRAs may be more sensitive than TST. 
– In high TB- and/or HIV-burden settings, the performance of IGRAs 
has varied greatly.
CHAPTER 103
653
Tuberculosis and Other Mycobacterial Infections 
Tuberculosis
TREATMENT
DRUGS
First-Line Agents
• Rifampin: Rifampin is the most important and potent antituberculous 
agent. The standard dosage in adults is 600 mg/d. 
– The drug distributes well throughout body tissues, including 
inflamed meninges. It turns body fluids (e.g., urine, saliva, tears) red-
orange and is excreted through bile and the enterohepatic circulation. 
– Rifampin is usually well tolerated; adverse events are infrequent and 
generally mild. 
– Of note, rifampin is a potent inducer of the hepatic cytochrome 
P450 system and decreases the half-life of many other drugs.
• Isoniazid: Isoniazid is a critical drug for active and latent TB disease. 
The usual adult dosage is 300 mg/d or 900 mg twice per week. 
– Isoniazid is distributed well throughout the body and infected tis-
sues, including CSF and caseous granulomas. 
– The most important toxicities are hepatotoxicity and peripheral 
neuropathy. 
• Isoniazid-associated hepatitis is idiosyncratic and increases with 
age and alcohol use and in the postpartum period.
• Because peripheral neuropathy can result from interference 
with pyridoxine metabolism, pyridoxine (25–50 mg/d) should 
be given to pts with other risk factors for neuropathy, such as 
diabetes, alcohol abuse, or malnutrition.
• Ethambutol: The least potent first-line agent, ethambutol is synergistic 
with the other drugs in the standard first-line regimen. Ethambutol is 
usually given at a dosage of 15 mg/kg daily. 
– The drug is distributed throughout the body but reaches only low 
levels in CSF.
– This agent can cause dose-dependent optic neuritis, producing central 
scotoma and impairing both visual acuity and the ability to see green.
• Pyrazinamide: The usual dosage is 15–30 mg/kg daily (maximum, 2 g/d). 
The drug distributes well throughout the body, including the CSF. 
• Hyperuricemia that can be managed conservatively is common.
• Clinical gout is rare.
Other Effective Agents
• Streptomycin: The usual adult dose is 0.5–1.0 g IM daily or 5 times per 
week. Streptomycin causes ototoxicity (primarily vestibulotoxicity) 
but is less nephrotoxic than other aminoglycosides.
• Rifabutin: Rifabutin has fewer drug interactions than rifampin and is active 
in vitro against some rifampin-resistant strains of M. tuberculosis. Rifabutin 
reaches tissue concentrations 5 to 10 times higher than those in plasma and 
has a much longer half-life than rifampin. The drug is well tolerated, and its 
adverse effects are dose related.
SECTION 7
654
Infectious Diseases
• Rifapentine: Rifapentine is similar to rifampin but can be given once 
or twice weekly. This drug is not approved for the treatment of HIV-
infected pts because of elevated rates of relapse. 
Second-Line Agents
• Fluoroquinolones: Levofloxacin, gatifloxacin (no longer marketed in 
the United States because of its severe toxicity), and moxifloxacin 
have solid, broad antimycobacterial activity. Ciprofloxacin is no longer 
recommended for treatment of TB because of poor efficacy.
• Other agents are used uncommonly but may be needed in disease 
caused by resistant strains of M. tuberculosis.
REGIMENS
See Table 103-1.
• During the initial phase, the majority of tubercle bacilli are killed, 
symptoms resolve, and usually the pt becomes noninfectious. The 
continuation phase is required to eliminate persisting mycobacteria 
and prevent relapse.
• Nonadherence to the regimen is the most important impediment to cure. 
Directly observed treatment (especially during the initial 2 months) and 
fixed drug-combination products should be used if possible.
• Bacteriologic evaluation is the preferred method of monitoring 
response to treatment. 
– Virtually all pts should have negative sputum cultures after 3 months 
of treatment. If the culture remains positive, treatment failure and 
drug resistance should be suspected.
– With extrapulmonary TB, bacteriologic monitoring may not be 
feasible. In these cases, the response to treatment must be assessed 
clinically and radiographically.
• Drug resistance may be either primary (i.e., present in a strain prior 
to therapy) or acquired (i.e., arising during treatment because of an 
inadequate regimen or noncompliance).
• Close monitoring for drug toxicity should take place during treat-
ment and should include baseline LFTs and monthly questioning 
about possible hepatitis symptoms. High-risk pts (e.g., older pts, pts 
who use alcohol daily) should have LFT values monitored during 
treatment.
 
For pts with symptomatic hepatitis and those with marked (five- to 
sixfold) elevations in serum levels of aspartate aminotransferase, treat-
ment should be stopped and drugs reintroduced one at a time after 
liver function has returned to normal.
• Three important considerations are relevant to TB treatment in 
HIV-infected pts: an increased frequency of paradoxical reactions, 
interactions between antiretroviral agents and rifamycins, and devel-
opment of rifampin monoresistance with widely spaced intermittent 
treatments.
CHAPTER 103
655
Tuberculosis and Other Mycobacterial Infections 
TABLE 103-1 RECOMMENDED REGIMENS FOR TREATMENT OF TB
Initial Phase
Continuation Phase
Indication
Duration, 
Months
Drugs
Duration, 
Months
Drugs
New smear- or 
culture-positive
cases
2
HRZEa,b
4
HRa,c,d
New culture-
negative cases
2
HRZEa
4
HRa
Pregnancy
2
HREe
7
HR
Relapses and 
treatment default 
(pending suscepti-
bility testing)
3
HRZESf
5
HRE
Failuresg
—
—
—
—
Resistance (or 
intolerance) to H
Throughout (6) RZEh
Resistance (or 
intolerance) to R
Throughout
(12–18)
HZEQi
Resistance to 
H + R
Throughout
(at least 20 
months)
ZEQ + S 
(or another 
injectable agentj)
Resistance to all 
first-line drugs
Throughout
(at least 20 
months)
1 injectable agentj
+ 3 of these 
4: ethionamide, 
cycloserine, 
Q, PAS
Intolerance to Z
2
HRE
7
HR
aAll drugs can be given daily or intermittently (three times weekly throughout). A twice-weekly 
regimen after 2–8 weeks of daily therapy during the initial phase is sometimes used, although 
it is not recommended by the WHO.
bStreptomycin can be used in place of ethambutol but is no longer considered a first-line drug 
by the ATS/IDSA/CDC.
cThe continuation phase should be extended to 7 months for pts with cavitary pulmonary TB 
who remain sputum culture–positive after the initial phase of treatment.
dHIV-negative pts with noncavitary pulmonary TB who have negative sputum AFB smears after 
the initial phase of treatment can be given once-weekly rifapentine/isoniazid in the continua-
tion phase.
eThe 6-month regimen with pyrazinamide can probably be used safely during pregnancy 
and is recommended by the WHO and the International Union Against Tuberculosis and Lung 
Disease. If pyrazinamide is not included in the initial treatment regimen, the minimal duration 
of therapy is 9 months.
fStreptomycin should be discontinued after 2 months. Drug susceptibility results will determine 
the best regimen option.
SECTION 7
656
Infectious Diseases
� PREVENTION
• Vaccination: An attenuated strain of M. bovis, bacille Calmette-Guérin 
(BCG), protects infants and young children from serious forms of TB 
(e.g., meningitis and miliary disease) and is recommended for routine 
use in countries with high TB prevalence. 
• Treatment of latent infection: Candidates for chemoprophylaxis are iden-
tified by TST or IGRA. Positive skin tests are determined by reaction size 
and risk group (Table 103-2). Drug treatment should be considered for 
pts with evidence of latent infection (Table 103-3). Isoniazid should not 
be given to persons with active liver disease.
LEPROSY
� MICROBIOLOGY AND EPIDEMIOLOGY 
Leprosy is a nonfatal chronic infectious disease caused by M. leprae, an 
obligate intracellular bacterial species indistinguishable microscopically 
from other mycobacteria. The organism is confined to humans, armadillos 
(in some locales), and sphagnum moss. 
• M. leprae cannot yet be cultured in vitro. The organism has a doubling 
time in mice of 2 weeks (compared with 20 min for Escherichia coli and 
1 day for M. tuberculosis).
• Leprosy, which is associated with poverty and rural residence, is a disease 
of the developing world; its global prevalence is difficult to assess and is 
variously estimated at 0.6–8 million. 
– More than 80% of the world’s cases occur in a few countries: India, 
China, Myanmar, Indonesia, Nepal, Brazil, Nigeria, and Madagascar. 
– In the U.S., ~4000 people have leprosy and 100–200 new cases are 
reported annually.
• The route of transmission is uncertain but may be via nasal droplets, 
contact with infected soil, or insect vectors.
� CLINICAL MANIFESTATIONS 
The spectrum from polar tuberculoid (TT) to polar lepromatous (LL) 
disease is associated with an evolution from asymmetric localized macules 
and plaques to nodular and indurated symmetric generalized skin manifes-
tations, an increasing bacterial load, and loss of M. leprae–specific cellular 
immunity. Prognosis, complications, and intensity of antimicrobial therapy 
depend on where a pt presents on the clinical spectrum. The incubation 
period ranges from 2 to 40 years but is usually 5–7 years.
gThe regimen is tailored according to the results of drug susceptibility tests. The availability 
of rapid molecular methods to identify drug resistance allows initiation of a proper regimen at 
the start of treatment.
hA fluoroquinolone may strengthen the regimen for pts with extensive disease.
iStreptomycin for the initial 2 months may strengthen the regimen for pts with extensive disease.
jAmikacin, kanamycin, or capreomycin. All these agents should be used for at least 6 months 
and for 4 months after culture conversion. If susceptibility is confirmed, streptomycin could be 
used as the injectable agent.
Abbreviations: E, ethambutol; H, isoniazid; PAS, para-aminosalicylic acid; Q, a quinolone anti-
biotic; R, rifampin; S, streptomycin; Z, pyrazinamide.
CHAPTER 103
657
Tuberculosis and Other Mycobacterial Infections 
Tuberculoid Leprosy (TL) 
At the less severe end of the disease spectrum, TL results in symptoms con-
fined to the skin and peripheral nerves. 
• One or several hypopigmented macules or plaques with sharp margins 
that are hypesthetic and have lost sweat glands and hair follicles are pres-
ent. AFB are few or absent.
• There is asymmetric enlargement of one or several peripheral nerves—
most often the ulnar, posterior auricular, peroneal, and posterior tibial 
nerves—associated with hypesthesia and myopathy.
Lepromatous Leprosy (LL) 
Pts develop symmetrically distributed skin nodules, raised plaques, and dif-
fuse dermal infiltration that can cause leonine facies, loss of eyebrows and 
lashes, pendulous earlobes, and dry scaling. 
• Numerous bacilli are present in skin (up to 109/g), nerves, and all organs 
except the lungs and CNS.
• Nerve enlargement and damage are usually symmetric and are due to 
bacillary invasion.
� COMPLICATIONS
• Reactional states: These common, immunologically mediated inflam-
matory states cause considerable morbidity. Erythema nodosum lep-
rosum—characterized by painful erythematous papules that resolve 
spontaneously in ~1 week—occurs in ~50% of pts near the LL end of the 
disease spectrum within 2 years of initiation of therapy.
TABLE 103-2  TUBERCULIN REACTION SIZE AND TREATMENT OF LATENT 
TB INFECTION
Risk Group
Tuberculin Reaction Size, mm
HIV-infected pts or pts receiving 
immunosuppressive therapy
≥5
Close contacts of TB pts
≥5a
Pts with fibrotic lesions on CXR
≥5
Recently infected pts (≤2 years)
≥10
Pts with high-risk medical conditionsb
≥10
Low-risk personsc
≥15
aTuberculin-negative contacts, especially children, should receive prophylaxis for 2–3 months 
after contact ends and should then undergo repeat TST. Those whose results remain negative 
should discontinue prophylaxis. HIV-infected contacts should receive a full course of treatment 
regardless of TST results.
bIncluding diabetes mellitus, some hematologic and reticuloendothelial diseases, injection drug 
use (with HIV seronegativity), end-stage renal disease, and clinical situations associated with 
rapid weight loss.
cExcept for employment purposes where longitudinal TST screening is anticipated, TST is not 
indicated for these low-risk persons. A decision to treat should be based on individual risk/
benefit considerations.
TABLE 103-3  REVISED DRUG REGIMENS FOR TREATMENT OF LATENT TUBERCULOSIS INFECTION (LTBI) IN ADULTS
Ratingb (Evidencec)
Drug
Interval and Duration
Commentsa
HIV-Negative
HIV-Infected
Isoniazid
Daily for 9 monthsd,e
In HIV-infected pts, isoniazid may be administered 
concurrently with nucleoside reverse transcriptase 
inhibitors, protease inhibitors, or NNRTIs.
A (II)
A (II)
Twice weekly for 9 monthsd,e
DOT must be used with twice-weekly dosing.
B (II)
B (II)
Daily for 6 monthse
Regimen is not indicated for HIV-infected pts, those 
with fibrotic lesions on CXR, or children.
B (I)
C (I)
Twice weekly for 6 monthse
DOT must be used with twice-weekly dosing.
B (II)
C (I)
Rifampinf
Daily for 4 months
Regimen is used for contacts of pts with isoniazid-
resistant, rifampin-susceptible TB. In HIV-infected pts, 
most protease inhibitors and delavirdine should not 
be administered concurrently with rifampin. Rifabutin, 
with appropriate dose adjustments, can be used with 
protease inhibitors (saquinavir should be augmented 
with ritonavir) and NNRTIs (except delavirdine). 
Clinicians should consult Web-based updates for the 
latest specific recommendations.
B (II)
B (III)
658
Rifampin plus 
pyrazinamide
Daily for 2 months
Regimen generally should not be offered for treatment 
of LTBI in either HIV-infected or HIV-negative pts.
D (II)
D (II)
Twice weekly for 
2–3 months
D (III)
D (III)
aInformation on interactions with HIV-related drugs is updated frequently and is available at www.aidsinfo.nih.gov/guidelines.
bStrength of the recommendation: A. Both strong evidence of efficacy and substantial clinical benefit support recommendation for use. Should always be offered. B. Moderate 
evidence for efficacy or strong evidence for efficacy but only limited clinical benefit supports recommendation for use. Should generally be offered. C. Evidence for efficacy is 
insufficient to support a recommendation for or against use, or evidence for efficacy might not outweigh adverse consequences (e.g., drug toxicity, drug interactions) or cost of the 
treatment or alternative approaches. Optional. D. Moderate evidence for lack of efficacy or for adverse outcome supports a recommendation against use. Should generally not be 
offered. E. Good evidence for lack of efficacy or for adverse outcome supports a recommendation against use. Should never be offered.
cQuality of evidence supporting the recommendation: I. Evidence from at least one properly randomized controlled trial. II. Evidence from at least one well-designed clinical trial 
without randomization, from cohort or case-controlled analytic studies (preferably from more than one center), from multiple time-series studies, or from dramatic results in 
uncontrolled experiments. III. Evidence from opinions of respected authorities based on clinical experience, descriptive studies, or reports of expert committees.
dRecommended regimen for persons age <18 years.
eRecommended regimen for pregnant women.
fThe substitution of rifapentine for rifampin is not recommended because rifapentine’s safety and effectiveness have not been established for pts with LTBI.
Abbreviations: DOT, directly observed therapy; NNRTIs, nonnucleoside reverse transcriptase inhibitors.
Source: Adapted from CDC: Targeted tuberculin testing and treatment of latent tuberculosis infection. MMWR Recomm Rep 49:RR-6, 2000
659
SECTION 7
660
Infectious Diseases
• Extremities: Neuropathy results in insensitivity and affects fine touch, 
pain, and heat receptors. The loss of distal digits in leprosy is a conse-
quence of insensitivity, trauma, secondary infection, and—in lepromatous 
pts—a poorly understood and sometimes profound osteolytic process.
• Eyes: Owing to cranial nerve palsies, lagophthalmos and corneal insensi-
tivity may complicate leprosy, resulting in trauma, secondary infection, 
and (without treatment) corneal ulcerations and opacities. Leprosy is a 
major cause of blindness in low-income countries.
• Nerve abscesses: Pts with leprosy can develop abscesses of nerves (most 
commonly the ulnar) and require urgent surgical decompression to pre-
vent irreversible sequelae.
� DIAGNOSIS 
In TL, the advancing edge of a skin lesion should be biopsied. In LL, biopsy 
of even normal-appearing skin often yields positive results. Serology, skin 
testing, and PCR of the skin offer little diagnostic assistance.
Leprosy
TREATMENT
DRUGS 
• Rifampin (600 mg daily or monthly) is the only agent bactericidal 
against M. leprae. See the preceding section on M. tuberculosis for more 
details on rifampin.
• Monotherapy with dapsone (50–100 mg/d) results in only a 2.5% 
resistance-related relapse rate.
– A decrease in hemoglobin levels of ~1 g/dL is a common adverse 
effect; the sulfone syndrome (high fever, anemia, exfoliative derma-
titis, and a mononucleosis-type blood picture) occurs rarely. 
– G6PD deficiency must be ruled out before therapy to avoid hemo-
lytic anemia. 
• Clofazimine (50–100 mg/d, 100 mg 3 times per week, or 300 mg 
monthly) is a phenazine iminoquinone dye that is weakly active against 
M. leprae. Adverse effects include red-black skin discoloration.
REGIMENS
Given the unreliability of skin smears and the lack of accessibility to his-
topathology in many countries in which leprosy is endemic, treatment 
regimens are based on the number of lesions present.
• Paucibacillary disease in adults (<6 skin lesions) is treated with dapsone 
(100 mg/d) and rifampin (600 mg monthly, supervised) for 6 months or 
with dapsone (100 mg/d) for 5 years. For a single lesion, a single dose 
of rifampin (600 mg), ofloxacin (400 mg), and minocycline (100 mg) is 
recommended.
• Multibacillary disease in adults (≥6 skin lesions) is treated with 
dapsone (100 mg/d) plus clofazimine (50 mg/d)—unsupervised—in 
addition to rifampin (600 mg monthly) plus clofazimine (300 mg 
monthly)—supervised—for 1–2 years.
CHAPTER 103
661
Tuberculosis and Other Mycobacterial Infections 
– Some experts prefer rifampin (600 mg/d) for 3 years and dapsone 
(100 mg/d) for life.
– Relapse can occur years later; prolonged follow-up is needed.
• Reactional states
– Lesions at risk for ulceration or in cosmetically important areas can 
be treated with glucocorticoids (40–60 mg/d for at least 3 months).
– If erythema nodosum leprosum is present and persists despite two 
short courses of steroids (40–60 mg/d for 1–2 weeks), thalidomide 
(100–300 mg nightly) should be given. Because of thalidomide’s 
teratogenicity, its use is strictly regulated.
INFECTIONS WITH NONTUBERCULOUS MYCOBACTERIA (NTM)
Mycobacteria other than those of the M. tuberculosis complex and M. leprae 
are referred to as nontuberculous or atypical mycobacteria and are ubiquitous 
in soil and water. 
� MICROBIOLOGY 
NTM are broadly differentiated into rapidly and slowly growing forms 
(<7 days and ≥7 days, respectively). M. abscessus, M. fortuitum, and 
M. chelonae are examples of rapid growers; species such as M. avium and 
M. intracellulare (the M. avium complex, or MAC), M. kansasii, M. ulcerans, 
and M. marinum are slow growers.
� EPIDEMIOLOGY 
Most NTM cause disease in humans only rarely unless some aspect of host 
defense is impaired (as in bronchiectasis) or breached (as by inoculation—
e.g., during liposuction or trauma). The bulk of nontuberculous mycobacte-
rial disease in North America is due to M. kansasii, MAC organisms, and 
M. abscessus.
� CLINICAL MANIFESTATIONS 
Although there are many NTM species, the clinical presentations they cause 
can be broadly categorized by the organ system(s) affected.
• Disseminated disease is now quite rare; even pts with advanced HIV 
infection do not often develop disseminated NTM infection, given 
improved treatment of HIV infection and effective antimycobacterial 
prophylaxis.
– Organisms typically spread from the bowel to the bone marrow and 
bloodstream, but disease is indolent, and it can take weeks or months 
for the pt to present for medical attention with malaise, fever, weight 
loss, organomegaly, and lymphadenopathy.
– A child with involvement of ≥2 organ systems and no iatrogenic cause 
should be evaluated for defects in the interferon γ/interleukin-12 
pathway.
• Pulmonary disease represents the most common NTM infection in 
industrialized countries. MAC organisms are most commonly involved 
in North America. Pts present with months or years of throat clearing, 
SECTION 7
662
Infectious Diseases
nagging cough, and slowly progressive fatigue. M. kansasii can cause a 
TB-like syndrome, with hemoptysis, chest pain, and cavitary lung disease.
• Isolated cervical lymphadenopathy is the most common NTM infection 
among young children in North America and is most frequently caused 
by MAC organisms. The nodes are typically firm and painless and 
develop in the absence of systemic symptoms.
• Skin and soft tissue disease usually requires a break in the skin for intro-
duction of the organism. Different NTM species are associated with 
specific exposures.
– M. fortuitum is linked to pedicure bath–associated infections, par-
ticularly if skin abrasion (e.g., during leg shaving) has immediately 
preceded the pedicure.
– Rapidly growing NTM are associated with outbreaks of infection 
acquired via skin contamination from surgical instruments (especially 
in cosmetic surgery), injections, and other procedures. These infections 
are typically accompanied by painful, erythematous, draining subcuta-
neous nodules, usually without associated fever or systemic symptoms.
– M. marinum can be acquired from fish tanks, swimming pools, bar-
nacles, and fish scales. Pts typically develop papules or ulcers (“fish-
tank granuloma”) that can progress to tendonitis and tender nodules 
on the arm in a pattern similar to that caused by Sporothrix schenckii. 
Lesions appear days or weeks after acquisition of the organism.
– M. ulcerans is a waterborne organism found primarily in tropical 
areas, especially in Africa. Skin lesions are typically painless, clean 
ulcers that slough and can cause osteomyelitis.
� DIAGNOSIS 
Similar to M. tuberculosis, NTM can be detected on acid-fast or fluoro-
chrome smears of clinical samples and can be cultured on mycobacterial 
medium. Isolation of NTM from a clinical specimen may reflect coloni-
zation and requires an assessment of the organism’s clinical significance.
• Isolation of NTM from blood specimens is clear evidence of disease; 
many NTM species require special media and will not grow in standard 
blood culture medium.
• The American Thoracic Society has published guidelines for the diag-
nosis of pulmonary NTM disease that require the growth of NTM from 
2 of 3 sputum samples, a positive bronchoalveolar lavage sample, or a 
pulmonary parenchyma biopsy sample with granulomatous inflamma-
tion or mycobacteria found on section and NTM in culture. Although 
these guidelines are specific to MAC, M. abscessus, and M. kansasii, they 
probably apply to other NTM as well.
• The only antibiotic susceptibility assessment indicated is testing of MAC 
organisms for susceptibility to clarithromycin and of M. kansasii for sus-
ceptibility to rifampin.
Infections with NTM
TREATMENT
Since NTM disease evolves over a long period, it is rarely necessary to begin 
treatment on an emergency basis before identifying the infecting species. 
CHAPTER 104 
663
Nonsyphilitic Spirochetal Infections
• MAC infection requires multidrug therapy with a macrolide (clar-
ithromycin or azithromycin), ethambutol, and a rifamycin (rifampin 
or rifabutin). Therapy is prolonged, generally continuing for 12 months 
after culture conversion; typically, a course lasts for at least 18 months.
• M. kansasii lung disease is similar to TB in many ways and is also 
effectively treated with isoniazid (300 mg/d), rifampin (600 mg/d), 
and ethambutol (15 mg/kg per day).
• Extrapulmonary disease due to rapidly growing NTM is often treated 
successfully with a macrolide and another drug (with the choice based 
on in vitro susceptibility). Pulmonary disease due to M. abscessus is 
difficult to cure and often requires repeated courses that include a 
macrolide along with an IV-administered agent such as amikacin, a 
carbapenem, cefoxitin, or tigecycline.
• M. marinum infection is effectively treated with any combination of a 
macrolide, ethambutol, and a rifamycin for 1–2 months after clinical 
resolution of isolated soft-tissue disease; tendon and bone involvement 
may require longer courses in light of clinical evolution.
• Treatment of infections caused by other NTM is less well defined, 
but macrolides and aminoglycosides are usually effective, with other 
agents added as indicated. 
For a more detailed discussion, see Raviglione MC, 
O’Brien RJ: Tuberculosis, Chap. 165, p. 1340; Gelber RH: 
Leprosy, Chap. 166, p. 1359; Holland SM: Nontuberculous 
Mycobacterial Infections, Chap. 167, p. 1367; and O’Donnell 
MR, Saukkonen JJ: Antimycobacterial Agents, Chap. 168, 
p. 1371, in HPIM-18.
Chapter 104
Lyme Disease and Other 
Nonsyphilitic Spirochetal 
Infections
LYME BORRELIOSIS
Microbiology and Epidemiology 
Borrelia burgdorferi, the causative agent of Lyme disease, is a fastidious 
microaerophilic spirochete. The human infection Lyme borreliosis is caused 
primarily by three pathogenic genospecies: B. burgdorferi sensu stricto 
(hereafter referred to as B. burgdorferi), Borrelia garinii, and Borrelia afzelii. 
• B. burgdorferi is the sole cause of Lyme borreliosis in the United States; all 
three genospecies are found in Europe, and the latter two species occur 
in Asia. 
SECTION 7
664
Infectious Diseases
• Lyme disease is the most common vector-borne illness in the United 
States, with >25,000 cases each year. 
– Ixodes ticks transmit the disease.
– I. scapularis, which also transmits babesiosis and anaplasmosis, is 
found in northeastern and midwestern states; I. pacificus is found in 
western states. 
• The white-footed mouse is the preferred host for larval and nymphal 
ticks. Adult ticks prefer the white-tailed deer as host. 
• Nymphal ticks transmit the disease to humans during the early summer 
months after feeding for ≥24 h.
Clinical Manifestations 
Lyme disease usually begins with erythema migrans (EM; stage 1, localized 
infection) before disseminating (stage 2) or causing persistent infection 
(stage 3). 
• Stage 1 (localized infection): After an incubation period of 3–32 days, EM 
develops at the site of the tick bite (commonly the thigh, groin, or axilla) 
in 80% of pts. 
– The classic presentation is a red macule that expands slowly to form 
an annular lesion with a bright red outer border and central clearing. 
Central erythema, induration, necrosis, vesicular changes, or many 
red rings within an outer ring are also possible.
– Most pts do not remember the preceding tick bite.
• Stage 2 (disseminated infection): Given that some pts do not notice EM, 
many pts present within days or weeks after infection with secondary 
annular skin lesions, nonspecific systemic symptoms, neurologic deficits, 
or cardiac manifestations due to hematogenous spread.
– Nonspecific symptoms include severe headache, mild neck stiffness, fever, 
chills, migratory musculoskeletal pain, arthralgias, malaise, and fatigue. 
These symptoms subside within a few weeks, even in untreated pts.
– Neurologic deficits occur in ~15% of pts and may include meningitis; 
encephalitis; cranial neuritis, including bilateral facial palsy; motor 
or sensory radiculoneuropathy; mononeuritis multiplex; ataxia; or 
myelitis. Lymphocytic pleocytosis (~100 cells/μL) is found in CSF, 
often along with elevated protein levels and normal or slightly low 
glucose concentrations.
– Cardiac involvement occurs in ~8% of pts. Atrioventricular (AV) 
block of fluctuating degree is most common, but acute myopericardi-
tis is possible. Cardiac involvement usually lasts for only a few weeks 
but may recur.
• Stage 3 (persistent infection): ~60% of untreated pts in the United States 
develop frank arthritis, usually consisting of intermittent attacks of oligo-
articular arthritis in large joints (especially the knees) that last for weeks 
or months.
– Joint-fluid cell counts range from 500 to 110,000/μL (average, 25,000/
μL); the majority of the cells are neutrophils. 
– Arthritis can persist despite eradication of spirochetes.
CHAPTER 104 
665
– Chronic neurologic involvement (e.g., subtle encephalopathy affecting 
memory, mood, or sleep; peripheral neuropathy) is less common. In 
Europe, severe encephalomyelitis is seen with B. garinii infection.
– Acrodermatitis chronica atrophicans, a late skin manifestation, is seen 
in Europe and Asia and is associated with B. afzelii infection.
• Chronic Lyme disease: For months or years afterward, a small percentage 
of pts have pain, neurocognitive manifestations, or fatigue symptoms—a 
syndrome indistinguishable from chronic fatigue syndrome. There is no 
evidence that these symptoms are caused by active infection. 
Diagnosis
Serologic evidence combined with a compatible clinical picture is the usual 
basis for diagnosis.
• Only 20–30% of pts have positive serologic results in acute-phase samples, 
whereas 70–80% have positive results in convalescent-phase samples 
obtained 2–4 weeks later. Of note, serologic tests do not discriminate 
between active and past disease. 
– Serologic analysis consisting of a two-step approach (ELISA screening 
with western blot confirmation for cases with positive or equivocal 
results) is recommended only for pts with at least an intermediate 
pretest likelihood of having Lyme disease. 
– IgM and IgG testing should be done in the first 2 months of illness, 
after which IgG testing alone is adequate.
– CDC-adopted criteria dictate that the IgM western blot must show at 
least 2 of 3 defined bands and that the IgG western blot must show at 
least 5 of 10 defined bands to be considered positive.
• PCR is most useful for joint fluid, is less sensitive for CSF, and has little 
or no utility for plasma or urine.
• Although culture of the organism is possible, it is reserved primarily for 
research settings.
Lyme Borreliosis
TREATMENT
• Doxycycline (100 mg bid) is the agent of choice for men and non-
pregnant women with localized or disseminated infection and is also 
effective against anaplasmosis (Chap. 105).
– Amoxicillin (500 mg tid), cefuroxime (500 mg bid), erythromycin 
(250 mg qid), and newer macrolides—preferred in that order—are 
alternative agents. 
– Except in cases of neurologic disease and third-degree AV block, 
the drug can usually be taken by mouth.
– More than 90% of pts have good outcomes with a 14-day course 
of treatment for localized infection or a 21-day course for dissemi-
nated infection.
• For pts with objective neurologic abnormalities (with the possible 
exception of isolated facial palsy), IV treatment with ceftriaxone for 
14–28 days should be given. Cefotaxime or penicillin is an alternative.
Nonsyphilitic Spirochetal Infections
SECTION 7
666
Infectious Diseases
• Pts with high-degree AV block (PR interval, >0.3 s) should receive IV 
therapy for at least part of the course; cardiac monitoring is recommended.
• Pts with Lyme arthritis should be treated with 30 days of oral doxycy-
cline or amoxicillin. 
– For pts who do not respond to oral agents, re-treatment with IV 
ceftriaxone for 28 days is appropriate. 
– If joint inflammation persists after therapy but PCR testing for 
B. burgdorferi DNA in joint fluid gives negative results, anti-
inflammatory agents or synovectomy may be successful.
• For pts diagnosed with chronic Lyme disease, no data demonstrate 
that additional antibiotic therapy is helpful. 
Prophylaxis
The risk of infection with B. burgdorferi after a recognized tick bite is so 
low that antibiotic prophylaxis is not routinely indicated. However, if an 
attached, engorged I. scapularis nymph is found or if follow-up will be dif-
ficult, a single 200-mg dose of doxycycline, given within 72 h of the tick bite, 
effectively prevents the disease. 
Prognosis
Early treatment results in an excellent prognosis. Most pts recover with 
minimal or no residual deficits. 
ENDEMIC TREPONEMATOSES
Microbiology and Epidemiology 
The endemic treponematoses—yaws (Treponema pallidum subspecies 
pertenue), endemic syphilis (T. pallidum subspecies endemicum), and 
pinta (T. carateum)—are nonvenereal chronic diseases acquired during 
childhood and caused by organisms closely related to the agent of syphilis, 
T. pallidum subspecies pallidum. 
• Disease is transmitted by direct contact. 
• The most recent WHO estimate (1997) suggested that there are 460,000 
new cases per year and a prevalence of 2.5 million infected persons.
• Disease is limited to people in rural areas of developing nations and 
recent émigrés from these regions.
Clinical Manifestations 
The major clinical distinctions made between venereal syphilis and the 
nonvenereal treponematoses are the apparent lack of congenital transmis-
sion and of CNS involvement in the nonvenereal infections. However, these 
distinctions may not be entirely accurate.
• Yaws is characterized by the development of one or more primary lesions 
(“mother yaw”) followed by multiple disseminated skin lesions. 
– 3–4 weeks after acquisition of the organism, the pt develops a 
papule that ultimately enlarges, is associated with regional lymph-
adenopathy, and heals spontaneously within 6 months. 
CHAPTER 104 
667
– Late gummatous lesions of the skin and long bones affect 10% 
of untreated persons and are similar to the destructive lesions of 
leprosy and leishmaniasis.
• Endemic syphilis is initially localized to mucocutaneous and mucosal 
surfaces. Pts develop an intraoral papule, which is followed by mucous 
patches on the oral mucosa and mucocutaneous lesions resembling the 
condylomata lata of secondary syphilis. Destructive gummas, osteitis, 
and gangosa (destruction of the nose, maxilla, palate, and pharynx) are 
more common in endemic syphilis than in late yaws.
• Pinta is the most benign of the treponemal infections in that it does not 
cause destructive lesions or involve tissues other than the skin. The disease 
has three stages that are characterized by marked changes in skin color.
Diagnosis
Diagnosis is based on clinical presentation, dark-field microscopy of scrap-
ings from lesions, and serologic testing (as for venereal syphilis).
Endemic Treponematoses
TREATMENT
Benzathine penicillin (1.2 million units for adults, 600,000 units for 
children <10 years of age) is the treatment of choice. Doxycycline is 
probably an effective alternative.
LEPTOSPIROSIS
Microbiology and Epidemiology 
Leptospires are spirochetal organisms that cause an important zoonosis 
with a broad spectrum of clinical manifestations. 
• The organisms are small enough to pass through filters used to sterilize 
culture medium.
• The most important sources of transmission to humans are rats, dogs, 
cattle, and pigs. Transmission can occur during contact with urine and 
other excreta (e.g., placenta, products of parturition) from infected ani-
mals or during exposure to contaminated environments. 
• Only ~50–100 cases in the U.S. are passively reported annually to the 
CDC, but these numbers are likely to represent significant underesti-
mates given that leptospirosis is not a notifiable disease. 
Clinical Manifestations 
After an average incubation period of 5–14 days, infection by Leptospira 
results in a subclinical infection, an undifferentiated febrile illness, or Weil’s 
disease (the most severe form).
• Leptospirosis is a biphasic illness. The initial leptospiremic phase lasts 3–10 
days and is characterized by fever. After another 3–10 days (the immune 
phase), some pts experience a return of fever, headache, and other systemic 
symptoms in association with the clearance of leptospires from the blood.
– Only the initial phase is responsive to antibiotic therapy.
– Nonspecific physical findings may include conjunctival suffusion, 
nonexudative pharyngeal erythema, muscle tenderness, rales on 
Nonsyphilitic Spirochetal Infections
SECTION 7
668
Infectious Diseases
lung auscultation, jaundice, meningismus, and hypo- or areflexia 
(particularly in the legs).
• Weil’s disease is characterized by variable combinations of jaundice, acute 
renal injury, hypotension, and hemorrhage—most commonly involv-
ing the lungs. Cardiac involvement (e.g., myocarditis), severe myalgias 
(occasionally mimicking acute abdomen), rash, and neurologic findings 
(e.g., aseptic meningitis) are common.
Diagnosis
A high index of suspicion prompting elicitation of a detailed exposure his-
tory is critical and guides confirmatory testing.
• Serologic assays are the diagnostic mainstay in leptospirosis. The micro-
scopic agglutination test is the gold standard and typically is performed only 
in reference laboratories, such as the CDC. Most other serologic tests use a 
saprophytic leptospire as the antigen and provide nonspecific results.
• Definitive diagnosis rests on demonstration of the organism by culture 
isolation (which takes weeks), detection of nucleic acids or antigen in 
body fluids (a method typically limited to research settings), or immu-
nohistochemical visualization in tissue.
– Leptospires can be cultured from blood and CSF during the first 7–10 days 
of illness.
– Urine cultures are positive in the second week of illness and can remain 
positive for months or years despite antibiotic therapy.
Leptospirosis
TREATMENT
• Prompt initiation of antibiotics probably shortens the course of severe 
leptospirosis and prevents the progression of mild disease.
• For mild disease, oral doxycycline is the drug of choice. Azithromycin 
may also be effective.
• For severe disease, parenteral treatment with penicillin, ceftriaxone, 
or cefotaxime should be given. From a pragmatic viewpoint, severe 
leptospiral disease frequently requires empirical initiation of broad-
spectrum parenteral therapy before the diagnosis is confirmed.
RELAPSING FEVER
Microbiology 
Borrelia recurrentis causes louse-borne relapsing fever (LBRF) and is trans-
mitted from person to person by the body louse. In this disease, spirochetes 
are introduced when the louse is crushed (e.g., by scratching) and the 
insect’s infected hemolymph contaminates the skin. Tick-borne relaps-
ing fever (TBRF), a zoonosis usually transmitted via the bite of various 
Ornithodoros ticks, is caused by multiple Borrelia species. 
Epidemiology 
TBRF is endemic in the western United States, southern British Columbia, the 
plateau regions of Mexico, Central and South America, the Mediterranean, 
Central Asia, and much of Africa. Only 13 counties have accounted for 
CHAPTER 104 
669
~50% of all U.S. cases. Little is known about the epidemiology of LBRF, but 
it is well described in East Africa.
Clinical Manifestations 
Symptoms are similar, although not identical, in the two types of relapsing fever. 
• In addition to fever, pts commonly develop headaches, myalgias, chills, 
nausea/vomiting, and arthralgias.
– Jaundice; CNS involvement; petechiae on the trunk, extremities, and 
mucous membranes; epistaxis; and blood-tinged sputum are more 
likely in LBRF.
– Neurologic findings (e.g., meningitis, focal deficits, paralysis, altered sen-
sorium) may occur in 10–30% of cases and are more common in LBRF.
• For TBRF and LBRF, the mean incubation periods are 7 and 8 days, 
respectively; the average durations of the first episode are 3 and 5.5 days, 
respectively; and the average times between the first episode and the first 
relapse are 7 and 9 days, respectively. Relapsing febrile episodes are typi-
cally of shorter duration than the first episode.
Diagnosis
Laboratory confirmation is made by the detection or isolation of spirochetes from 
blood during a febrile episode. Microscopic examination of Wright- or Giemsa-
stained thick or thin blood smears or buffy coat analysis is most common. 
• PCR techniques offer greater sensitivity but are limited to research settings.
• Serologic confirmation of TBRF is possible but is hampered by lack of 
standardization. An ELISA or an indirect fluorescent antibody assay can 
be performed; if positive, the results of these tests are confirmed with an 
immunoblot.
Relapsing Fever
TREATMENT
• One dose of doxycycline (100 mg) or erythromycin (500 mg) is effec-
tive for LBRF; a 7- to 10-day course of either antibiotic is recommend-
ed for TBRF. Monitoring the pt for a Jarisch-Herxheimer reaction (an 
acute exacerbation of symptoms including hypotension, tachycardia, 
and marked elevation of body temperature) for the first 12 h after the 
first dose of antibiotic is recommended.
• If CSF pleocytosis is detected in the setting of meningitis or encepha-
litis, the pt should be treated with parenteral antibiotics.
Prognosis
LBRF has a fatality rate of 5% for treated pts; the rate is much lower for pts 
with TBRF. 
For a more detailed discussion, see Lukehart SA: Endemic 
Treponematoses, Chap. 170, p. 1389; Vinetz JM: Leptospirosis, 
Chap. 171, p. 1392; Dworkin MS: Relapsing Fever, Chap. 172, 
p. 1397; and Steere AC: Lyme Borreliosis, Chap. 173, p. 1401, 
in HPIM-18. For a discussion of syphilis, see Chap. 92 in this 
manual.
Nonsyphilitic Spirochetal Infections
SECTION 7
670
Infectious Diseases
CHAPTER 105
Rickettsial Diseases
Microbiology 
Rickettsiae are obligate intracellular gram-negative coccobacilli and short 
bacilli usually transmitted by tick, mite, flea, or louse vectors. Except in the 
case of louse-borne typhus, humans are incidental hosts. 
Clinical Manifestations 
The clinical manifestations of all the acute rickettsial presentations are 
similar during the first 5 days and consist of nonspecific symptoms: fever, 
headache, and myalgias with or without nausea, vomiting, and cough. 
As the course progresses, clinical manifestations—including occurrence 
of a macular, maculopapular, or vesicular rash; eschar; pneumonitis; and 
meningoencephalitis—vary from one disease to another. (See Table 105-1 
and details below.)
TICK- AND MITE-BORNE SPOTTED FEVERS
� ROCKY MOUNTAIN SPOTTED FEVER (RMSF)
Epidemiology 
Caused by R. rickettsii, RMSF has the highest case-fatality rate of all rick-
ettsial diseases. 
• In the United States, the prevalence is highest in the south-central and 
southeastern states. Most cases occur between May and September. 
• A rare presentation of fulminant RMSF is seen most often in male black 
pts with G6PD deficiency.
• RMSF is transmitted by different ticks in different geographic areas—
e.g., the American dog tick (Dermacentor variabilis) transmits RMSF 
in the eastern two-thirds of the United States and in California, and 
the Rocky Mountain wood tick (D. andersoni) transmits RMSF in the 
western U.S.
Pathogenesis 
Rickettsiae are inoculated by the tick after ≥6 h of feeding, spread lympho-
hematogenously, and infect numerous foci of contiguous endothelial cells. 
Increased vascular permeability, with edema, hypovolemia, and ischemia, 
causes tissue and organ injury.
Clinical Manifestations 
The incubation period is ~1 week (range, 2–14 days). After 3 days of non-
specific symptoms, half of pts have a rash characterized by macules appear-
ing on the wrists and ankles and subsequently spreading to the rest of the 
extremities and the trunk. 
TABLE 105-1 FEATURES OF SELECTED RICKETTSIAL INFECTIONS
Disease
Organism
Transmission
Geographic Range
Incubation
Period, 
Days
Duration, 
Days
Rash, %
Eschar, 
%
Lymphade-
nopathya
Rocky Mountain 
spotted fever
Rickettsia
rickettsii
Tick bite: Dermacentor andersoni, 
D. variabilis
United States
2–14
10–20
90
<1
+
Amblyomma cajennense, 
A. aureolatum
Central/South America
Rhipicephalus sanguineus
Mexico, Brazil, United 
States
Mediterranean
spotted fever
R. conorii
Tick bite: R. sanguineus, R. pumilio
Southern Europe, Africa, 
Middle East, Central Asia
5–7
7–14
97
50
+
Maculatum 
disease
R. parkeri
A. maculatum
United States, South 
America
2–10
?
88
94
++
African tick-
bite fever
R. africae
Tick bite: A. hebraeum, A. variega-
tum
Sub-Saharan Africa, 
West Indies
4–10
?
50
90
++++ 
Rickettsialpox
R. akari
Mite bite: Liponyssoides sanguineus
United States, Ukraine, 
Turkey, Mexico, Croatia
10–17
3–11
100
90
+++
Tick-borne 
lymphadenopathy
R. slovaca
Tick bite: Dermacentor marginatus, 
D. reticularis
Europe
7–9
17–180
5
100
++++
Flea-borne
spotted fever
R. felis
Flea (mechanism undetermined): 
Ctenocephalides felis
Worldwide
8–16
8–16
80
15
—
671
(continued)
TABLE 105-1 FEATURES OF SELECTED RICKETTSIAL INFECTIONS (CONTINUED)
Disease
Organism
Transmission
Geographic Range
Incubation
Period, 
Days
Duration, 
Days
Rash, %
Eschar, 
%
Lymphade-
nopathya
Epidemic typhus
R. prowazekii Louse feces: Pediculus humanus 
corporis; fleas and lice of flying 
squirrels; or recrudescence
Worldwide
7–14
10–18
80
None
—
Murine typhus
R. typhi
Flea feces: Xenopsylla cheopis, 
C. felis, others
Worldwide
8–16
9–18
80
None
—
Human monocy-
totropic ehrlichio-
sis
Ehrlichia
chaffeensis
Tick bite: Amblyomma americanum, 
D. variabilis
United States
1–21
3–21
26
None
++
Ewingii ehrlichio-
sis
E. ewingii
Tick bite: A. americanum
United States
None
Human granulo-
cytotropic ana-
plasmosis
Anaplasma 
phagocyto-
philum
Tick bite: Ixodes scapularis, I. ricinus, 
I. pacificus, I. persulcatus
United States, Europe, 
Asia
4–8
3–14
Rare
None
—
Scrub typhus
Orientia tsu-
tsugamushi
Mite bite: Leptotrombidium deliense, 
others
Asia, Australia, New 
Guinea, Pacific Islands
9–18
6–21
50
35
+++
Q fever
Coxiella
burnetii
Inhalation of aerosols of infected 
parturition material (sheep, dogs, 
others), ingestion of infected milk or 
milk products
Worldwide
3–30
5–57
<1
None
—
a++++, severe; +++, marked; ++, moderate; +, present in a small portion of cases; —, not a noted feature.
672
CHAPTER 105 
673
Rickettsial Diseases
• Lesions ultimately become petechial in 41–59% of pts, appearing on or 
after day 6 of illness in ~74% of all cases that include a rash. The palms 
and soles become involved after day 5 in 43% of pts but do not become 
involved at all in 18–64%. 
• Pts may develop hypovolemia, prerenal azotemia, hypotension, non-
cardiogenic pulmonary edema, renal failure, hepatic injury, and cardiac 
involvement with dysrhythmias. Bleeding is a rare but potentially life-
threatening consequence of severe vascular damage.
• CNS involvement—manifesting as encephalitis, focal neurologic deficits, or 
meningoencephalitis—is an important determinant of outcome. In menin-
goencephalitis, CSF is notable for pleocytosis with a mononuclear cell or 
neutrophil predominance, increased protein levels, and normal glucose levels. 
• Laboratory findings may include increased plasma levels of acute-phase 
reactants such as C-reactive protein, hypoalbuminemia, hyponatremia, 
and elevated levels of creatine kinase.
Prognosis
Without treatment, the pt usually dies in 8–15 days; fulminant RMSF 
can result in death within 5 days. The mortality rate is 3–5% despite the 
availability of effective antibiotics, mostly because of delayed diagnosis. 
Survivors of RMSF usually return to their previous state of health.
Diagnosis
Within the first 3 days, diagnosis is difficult, since only 3% of pts have the 
classic triad of fever, rash, and known history of tick exposure. When the 
rash appears, the diagnosis should be considered. 
• Immunohistologic examination of a cutaneous biopsy sample from a 
rash lesion is the only useful diagnostic test during acute illness, with a 
sensitivity of 70% and a specificity of 100%.
• Serology, most commonly the indirect immunofluorescence assay (IFA), 
is usually positive 7–10 days after disease onset, and a diagnostic titer of 
≥1:64 is usually documented.
Rocky Mountain Spotted Fever
TREATMENT
• Doxycycline (100 mg bid PO or IV) is the treatment of choice for both 
children and adults but not for pregnant women and pts allergic to this 
drug, who should receive chloramphenicol. 
• Treatment is given until the pt is afebrile and has been improving for 
2 or 3 days.
� OTHER TICK-BORNE SPOTTED FEVERS
• R. conorii causes disease in southern Europe, Africa, and Asia. The name 
for R. conorii infection varies by region (e.g., Mediterranean spotted 
fever, Kenya tick typhus). 
– Disease is characterized by high fever, rash, and—in most locales—an 
inoculation eschar (tâche noire) at the site of the tick bite. 
SECTION 7
674
Infectious Diseases
– A severe form of disease with a mortality rate of ~50% occurs in pts 
with diabetes, alcoholism, or heart failure. 
• R. africae causes African tick-bite fever, which occurs in sub-Saharan 
Africa and the Caribbean and is the rickettsiosis most frequently 
imported into Europe and North America. 
• Tick-borne spotted fever is diagnosed on the basis of clinical and epide-
miologic findings; the diagnosis is confirmed by serology or detection of 
rickettsiae. 
• Doxycycline (100 mg PO bid for 1–5 days), ciprofloxacin (750 mg bid 
PO for 5 days), or chloramphenicol (500 mg qid PO for 7–10 days) is 
effective for treatment.
� RICKETTSIALPOX
Epidemiology 
Rickettsialpox is caused by R. akari and is maintained by mice and their 
mites. Recognized principally in New York City, rickettsialpox has been 
reported in other urban and rural locations in the United States as well as 
in Ukraine, Croatia, Mexico, and Turkey. 
Clinical Manifestations 
A papule forms at the site of the mite bite and develops a central vesicle that 
becomes a painless black-crusted eschar surrounded by an erythematous 
halo. Lymph nodes draining the region of the eschar enlarge. 
• After an incubation period of 10–17 days, malaise, chills, fever, headache, 
and myalgia mark disease onset. 
• A macular rash appears on day 2–6 of illness and evolves sequentially 
into papules, vesicles, and crusts that heal without scarring. 
• If untreated, fever lasts 6–10 days.
Rickettsialpox
TREATMENT
Doxycycline is the drug of choice for treatment.
FLEA- AND LOUSE-BORNE TYPHUS GROUP RICKETTSIOSES
� ENDEMIC MURINE TYPHUS (FLEA-BORNE)
Etiology and Epidemiology 
Caused by R. typhi, endemic murine typhus has a rat reservoir and is trans-
mitted by fleas. 
• Humans become infected when Rickettsia-laden flea feces are scratched 
into pruritic bite lesions; less often, the flea bite itself transmits the 
organisms or aerosolized rickettsiae from flea feces are inhaled. 
• In the United States, endemic typhus occurs mainly in southern Texas 
and southern California; globally, it occurs in warm (often coastal) areas 
throughout the tropics and subtropics. 
• Flea bites often are not recalled by pts, but exposure to animals such as 
cats, opossums, raccoons, skunks, and rats is reported by ~40%. 
CHAPTER 105 
675
Rickettsial Diseases
• Risk factors for severe disease include older age, underlying disease, and 
treatment with a sulfonamide drug.
Clinical Manifestations 
Prodromal symptoms 1–3 days before the abrupt onset of chills and fever 
include headache, myalgia, arthralgia, nausea, and malaise; nausea and 
vomiting are nearly universal early in illness. 
• Rash is apparent at presentation (usually ~4 days after symptom onset) 
in 13% of pts; 2 days later, half of the remaining pts develop a maculo-
papular rash that involves the trunk more than the extremities, is seldom 
petechial, and rarely involves the face, palms, or soles. 
• Pulmonary disease is common, causing a hacking, nonproductive cough 
in 35% of pts. Almost one-fourth of pts who undergo CXR have pul-
monary densities due to interstitial pneumonia, pulmonary edema, and 
pleural effusions. 
• Laboratory abnormalities include anemia, leukopenia early in the course, 
leukocytosis late in the course, thrombocytopenia, hyponatremia, hypo-
albuminemia, mildly increased hepatic aminotransferase levels, and 
prerenal azotemia. 
• Complications may include respiratory failure, hematemesis, cerebral 
hemorrhage, and hemolysis. 
• The duration of untreated disease averages 12 days (range, 9–18 days). 
Diagnosis
The diagnosis can be based on culture, PCR, cross-adsorption serologic 
studies of acute- and convalescent-phase sera, or immunohistology, but 
most pts are treated empirically.
Endemic Murine Typhus (Flea-Borne)
TREATMENT
Doxycycline (100 mg bid for 7–15 days) is effective. Ciprofloxacin 
provides an alternative if doxycycline is contraindicated.
� EPIDEMIC TYPHUS (LOUSE-BORNE)
Etiology and Epidemiology 
Epidemic typhus is caused by R. prowazekii and is transmitted by the 
human body louse. Eastern flying squirrels and their lice and fleas maintain 
R. prowazekii in a zoonotic cycle.
• The louse lives in clothing under poor hygienic conditions, particularly 
in colder climates and classically at times of war or natural disaster. 
• Lice feed on pts with epidemic typhus and then defecate the organism 
into the bite at their next meal. The pt autoinoculates the organism while 
scratching. 
• Brill-Zinsser disease is a recrudescent and mild form of epidemic typhus 
whose occurrence years after acute illness suggests that R. prowazekii 
remains dormant in the host, with reactivation when immunity 
wanes.
SECTION 7
676
Infectious Diseases
Clinical Manifestations 
Epidemic typhus presents abruptly with the onset of high fevers, prostra-
tion, severe headache, cough, and severe myalgias. Photophobia with con-
junctival injection and eye pain is also common.
• A rash appears on the upper trunk around the fifth day of illness and 
spreads to involve all body-surface areas except the face, palms, and soles. 
• Confusion and coma, skin necrosis, and gangrene of the digits are noted 
in severe cases. 
• Untreated, the disease is fatal in 7–40% of cases. Pts develop renal failure, 
multiorgan involvement, and prominent neurologic manifestations.
Diagnosis
Epidemic typhus is sometimes misdiagnosed as typhoid fever. The diagno-
sis can be based on serology, immunohistochemistry, or detection of the 
organism in a louse found on a pt. Cross-adsorption IFA can distinguish 
R. prowazekii from R. typhi.
Epidemic Typhus (Louse-Borne)
TREATMENT
Doxycycline (100 mg bid) is given until 2 or 3 days after the pt has defer-
vesced, although a one-time dose of 200 mg has proved effective under 
epidemic conditions.
� SCRUB TYPHUS
• Orientia tsutsugamushi, the agent of scrub typhus, is transmitted by lar-
val mites or chiggers in environments with heavy scrub vegetation. 
• Disease occurs during the wet season. It is endemic in eastern and south-
ern Asia, northern Australia, and the Pacific islands. 
• The classic case description includes an eschar at the site of chigger feed-
ing, regional lymphadenopathy, and maculopapular rash—signs rarely 
seen in indigenous pts; Westerners commonly do not present with all three 
findings. Severe cases include encephalitis and interstitial pneumonia. 
• Scrub typhus can be diagnosed by serologic assays (IFA, indirect immu-
noperoxidase, and enzyme immunoassays); PCR analysis of eschars and 
blood is also effective.
• A 7- to 15-day course of doxycycline (100 mg bid) or chloramphenicol 
(500 mg qid) or a 3-day course of azithromycin (500 mg qd) is effective.
EHRLICHIOSES AND ANAPLASMOSIS
Two distinct Ehrlichia species and one Anaplasma species—all obligately 
intracellular organisms—are transmitted by ticks to humans and cause 
infections that can be severe and prevalent. 
� HUMAN MONOCYTOTROPIC EHRLICHIOSIS (HME)
Etiology and Epidemiology 
HME is caused by Ehrlichia chaffeensis and, in the United States, generally 
occurs in southeastern, south-central, and mid-Atlantic states. The inci-
dence can be as high as 414 cases per 100,000 population. 
CHAPTER 105 
677
Rickettsial Diseases
• E. chaffeensis is transmitted by the Lone Star tick (A. americanum), and 
white-tailed deer are the major reservoir.
• Most pts are male; the median age of pts is 53 years. 
• E. ewingii causes an illness similar to, but less severe than, that due to 
E. chaffeensis.
Clinical Manifestations 
Clinical findings are nonspecific and include fever (96%), headache (72%), 
myalgia (68%), and malaise (77%). Nausea, vomiting, diarrhea, cough, rash, 
and confusion may be noted. 
• The median incubation period is 8 days. 
• Disease can be severe: up to 62% of pts are hospitalized and ~3% die. 
Complications include a toxic shock–like syndrome, respiratory distress, 
meningoencephalitis, fulminant infection, and hemorrhage. 
• Leukopenia (61%), thrombocytopenia (73%), and elevated serum ami-
notransferase levels (84%) are common. 
Diagnosis
Because HME can be fatal, empirical antibiotic therapy based on clinical 
diagnosis is required. PCR testing before initiation of antibiotic therapy 
or retrospective serodiagnosis to detect increased antibody titers can be 
performed. Morulae are seen in <10% of peripheral-blood smears. 
Treatment 
Treatment with doxycycline (100 mg PO/IV bid) or tetracycline (250–
500 mg PO q6h) is effective and should be continued for 3–5 days after 
defervescence.
� HUMAN GRANULOCYTOTROPIC ANAPLASMOSIS (HGA)
Etiology and Epidemiology 
HGA is caused by Anaplasma phagocytophilum and, in the U.S., occurs 
mainly in northeastern and upper midwestern states. 
• The geographic distribution is similar to that of Lyme disease and 
Babesia microti infection, given the shared I. scapularis tick vector.
• HGA incidence peaks in May through July, but the disease can occur 
year-round.
Clinical Manifestations 
Given high seroprevalence rates in endemic areas, it appears that most 
people develop subclinical infections. 
• After an incubation period of 4–8 days, pts develop fever (91%), myalgia 
(77%), headache (77%), and malaise (94%). 
• Severe complications—respiratory insufficiency, a toxic shock–like 
syndrome, and opportunistic infections—occur most often in elderly pts. 
• On laboratory examination, pts are found to have leukopenia, thrombo-
cytopenia, and elevated serum aminotransferase levels. 
Diagnosis
HGA should be considered in pts with influenza-like illness during May through 
December and in pts with atypical severe presentations of Lyme disease. 
SECTION 7
678
Infectious Diseases
• Peripheral-blood films may reveal morulae in neutrophils in 20–75% of 
infections. 
• PCR testing before antibiotic therapy or retrospective serologic testing 
demonstrating a ≥4-fold rise in antibody titer can confirm the diagnosis. 
Treatment 
Doxycycline (100 mg PO bid) is effective, and most pts defervesce within 
24–48 h. Pregnant women and children <8 years old may be treated with 
rifampin.
� PREVENTION
HME and HGA are prevented by avoidance of ticks in endemic areas, use of 
protective clothing and tick repellents, careful tick searches after exposures, 
and prompt removal of attached ticks.
Q FEVER
Microbiology 
Coxiella burnetii—the etiologic agent of Q fever—is a small, pleomorphic 
coccobacillus with a gram-negative cell wall that exists intracellularly. 
Epidemiology and Pathogenesis 
A worldwide disease, Q fever is a zoonosis. Cattle, sheep, and goats are 
responsible for most cases of human infection; many other animals can 
serve as vectors of transmission or as reservoirs of disease. 
• C. burnetii localizes to the uterus and mammary glands of infected 
female mammals. It is reactivated in pregnancy and is found at high 
concentrations in the placenta. At parturition, the organism is dispersed 
as an aerosol, and infection usually follows inhalation. 
• Abattoir workers, veterinarians, farmers, and other persons who have 
contact with infected animals, and particularly with newborn animals or 
infected products of conception, are at risk. 
• In the U.S., there are 28–54 cases per year; in Australia, there are 30 cases 
per 1 million population per year.
Clinical Manifestations 
The specific presentation of acute Q fever differs geographically (e.g., pneu-
monia in Nova Scotia and granulomatous hepatitis in Marseille); chronic 
Q fever almost always implies endocarditis.
• Acute Q fever: After an incubation period of 3–30 days, pts may present 
with flulike syndromes, prolonged fever, pneumonia, hepatitis, pericar-
ditis, myocarditis, meningoencephalitis, and infection during pregnancy. 
– Symptoms are often nonspecific (e.g., fever, fatigue, headache, chills, 
sweats, nausea, vomiting, diarrhea, cough, and occasionally rash). 
– Multiple rounded opacities on CXR in pts in endemic areas are highly 
suggestive of Q fever pneumonia. 
– The WBC count is usually normal, but thrombocytopenia occurs. 
During recovery, reactive thrombocytosis can develop. 
CHAPTER 105 
679
Rickettsial Diseases
– Prolonged fatigue, along with a constellation of nonspecific symptoms 
(e.g., headaches, myalgias, arthralgias), can follow Q fever (post–Q 
fever fatigue syndrome).
• Chronic Q fever: Pts with C. burnetii endocarditis typically have prior 
valvular heart disease, immunosuppression, or chronic renal failure.
– Fever is absent or low grade; pts may be ill for >1 year before diagnosis. 
– Valvular vegetations are best seen with transesophageal echocardiog-
raphy rather than transthoracic echocardiography, which identifies 
vegetations in only 12% of cases. The vegetations differ from those 
in bacterial endocarditis of other etiologies and manifest as endothe-
lium-covered nodules on the valve. 
– The disease should be suspected in all pts with culture-negative 
endocarditis.
– Although C. burnetii can be isolated by a shell-vial technique, most 
laboratories are not permitted to attempt isolation because of the 
organism’s highly contagious nature. PCR testing of tissue or biopsy 
specimens can be used, but serology is the most common diagnostic 
tool; IFA is the method of choice. 
Q Fever
TREATMENT
• Acute Q fever is treated with doxycycline (100 mg bid for 14 days). 
– Quinolones are also efficacious. 
– If Q fever is diagnosed during pregnancy, trimethoprim-
sulfamethoxazole should be administered up to term. 
• The currently recommended treatment for chronic Q fever is doxy-
cycline (100 mg bid) and hydroxychloroquine (200 mg tid; plasma 
concentrations maintained at 0.8–1.2 μg/mL) for 18 months. 
– In vitro, hydroxychloroquine renders doxycycline bactericidal 
against C. burnetii. 
– The minimal inhibitory concentration (MIC) of doxycycline for the 
pt’s isolate should be determined and serum levels monitored, with 
a goal of a serum level–to–doxycycline MIC ratio of ≥1. 
– Pts should be advised about photosensitivity and retinal toxicity 
risks with treatment. 
– Pts who cannot receive doxycycline-hydroxychloroquine should be 
treated with at least two agents active against C. burnetii. The combi-
nation of rifampin (300 mg once daily) plus doxycycline (100 mg bid) 
or ciprofloxacin (750 mg bid) has been used with success. 
– Treatment should be given for at least 3 years and discontinued 
only if phase I IgA and IgG antibody titers are ≤1:50 and ≤1:200, 
respectively.
For a more detailed discussion, see Walker DH, Dumler 
JS, Marrie T: Rickettsial Diseases, Chap. 174, p. 1407, in 
HPIM-18.
SECTION 7
680
Infectious Diseases
CHAPTER 106 
Mycoplasma Infections 
With a size of only 150–350 nm, mycoplasmas are the smallest free-living 
organisms. Genome sequence data from many different Mycoplasma spe-
cies have helped define the minimal set of genes necessary for cellular life. 
Lacking a cell wall and bounded only by a plasma membrane, mycoplasmas 
colonize mucosal surfaces of the respiratory and urogenital tracts.
� M. PNEUMONIAE
Epidemiology 
M. pneumoniae occurs worldwide with no seasonal pattern. Infection causes 
upper respiratory tract disease ~20 times more frequently than pneumonia. 
• Infection is acquired by inhalation of aerosols, with an incubation period 
of 2–4 weeks.
• M. pneumoniae accounts for ~23% of cases of community-acquired 
pneumonia in adults. 
Clinical Manifestations 
M. pneumoniae is often grouped with Chlamydia pneumoniae and Legionella 
species as the most important causes of “atypical” community-acquired 
pneumonia. The clinical presentation does not help distinguish M. pneu-
moniae pneumonia from that of any other bacterial etiology.
• Acute M. pneumoniae infection manifests as a nonspecific upper respira-
tory syndrome with pharyngitis, tracheobronchitis, and/or wheezing. 
• Pneumonia develops in 3–13% of infected pts. The most common pre-
senting symptom is a nonproductive cough. Headache, malaise, chills, 
and fever are common.
• On physical exam, ~80% of pts have wheezes or rales.
• Symptoms usually resolve in 2–3 weeks, and appropriate antimicrobial 
therapy significantly shortens the duration of clinical illness.
• Infection uncommonly results in critical illness and rarely causes death.
• Extrapulmonary manifestations of M. pneumoniae infection are rela-
tively uncommon but include skin eruptions (e.g., erythema multiforme 
major, rashes), neurologic manifestations (e.g., encephalitis, Guillain-
Barré syndrome, acute demyelinating encephalomyelitis), septic arthritis 
(particularly in pts with hypogammaglobulinemia), and hematologic 
manifestations (e.g., hemolytic anemia, coagulopathies).
Diagnosis
Clinical findings, nonmicrobiologic laboratory tests, and chest radiography 
are not useful in distinguishing M. pneumoniae pneumonia from pneumo-
nia of other etiologies. 
• Acute M. pneumoniae infection can be diagnosed by PCR analysis of respi-
ratory tract secretions, which is 65–90% sensitive and 90–100% specific.
CHAPTER 107 
681
Chlamydial Infections
• M. pneumoniae culture (which requires special medium) is not recom-
mended for routine diagnosis as its sensitivity is ≤60% and growth of the 
organism can take weeks.
• Serologic testing for IgM and IgG antibodies to M. pneumoniae requires 
acute- and convalescent-phase samples and is therefore less useful for 
diagnosis of active infections. Moreover, IgM antibodies to M. pneu-
moniae can persist for up to 1 year after acute infection.
• Measurement of cold agglutinin titers is no longer recommended for the 
diagnosis of M. pneumoniae infection because the findings are nonspecific.
M. pneumoniae Infections
TREATMENT
• Antibiotic options include macrolides (azithromycin, 500 mg PO for 1 day 
followed by 250 mg for 4 days), tetracyclines (doxycycline, 100 mg PO 
bid for 10–14 days), and respiratory fluoroquinolones (levofloxacin, 500–
750 mg PO qd for 10–14 days). 
• Ciprofloxacin and ofloxacin are not recommended because of their 
high minimal inhibitory concentrations against M. pneumoniae.
� UROGENITAL MYCOPLASMAS
See Chap. 92.
For a more detailed discussion, see Hardy RD: Infections Due 
to Mycoplasmas, Chap. 175, p. 1417, in HPIM-18.
CHAPTER 107
Chlamydial Infections
� MICROBIOLOGY
• Chlamydiae are obligate intracellular bacteria, possess both DNA and 
RNA (a characteristic that distinguishes them from viruses), and have a 
cell wall similar to that of gram-negative bacteria. 
• These organisms have a complex reproductive cycle and exist in two forms. 
– The elementary body (the infective form) is adapted for extracellular 
survival, while the reticulate body is adapted for intracellular survival 
and multiplication.
– Within 18–24 h after infection of the cell, reticulate bodies have repli-
cated and begin to condense into elementary bodies that are released 
to infect other cells or people. 
• Three chlamydial species infect humans: Chlamydia trachomatis, C. psittaci, 
and C. pneumoniae. 
SECTION 7
682
Infectious Diseases
– CF tests and enzyme immunoassays that detect lipopolysaccharide 
identify chlamydiae only to the genus level.
– The microimmunofluorescence (MIF) test can differentiate among 
the three species.
C. TRACHOMATIS INFECTIONS
� GENITAL INFECTIONS, INCLUDING LYMPHOGRANULOMA VENEREUM
See Chap. 92.
� TRACHOMA AND ADULT INCLUSION CONJUNCTIVITIS (AIC)
Etiology 
• Trachoma is a chronic conjunctivitis caused by C. trachomatis serovars A, 
B, Ba, and C. Transmission occurs through contact with ocular discharge 
from infected pts, which can also be transferred by flies. 
• AIC is an acute eye infection in adults exposed to infected genital secre-
tions and in their newborns. This infection is caused by sexually trans-
mitted C. trachomatis strains, usually serovars D through K.
Epidemiology 
Trachoma is a leading cause of preventable infectious blindness, with ~6 million 
pts having been affected. In the hyperendemic regions of northern and sub-
Saharan Africa, the Middle East, and parts of Asia, the prevalence of trachoma is 
~100% by the third year of life. Reinfection and persistent infection are common.
Clinical Manifestations 
Both trachoma and AIC present clinically as conjunctivitis characterized 
by small lymphoid follicles in the conjunctiva, although trachoma usually 
starts insidiously before 2 years of age. 
• With progression, there is inflammatory leukocytic infiltration and 
superficial vascularization (pannus formation) of the cornea. 
– Scarring eventually distorts the eyelids, turning lashes inward and 
abrading the eyeball (trichiasis and entropion). 
– The corneal epithelium eventually ulcerates, with subsequent scarring 
and blindness. 
– Destruction of goblet cells, lacrimal ducts, and glands causes dry-eye 
syndrome (xerosis), with resultant corneal opacity and secondary 
bacterial corneal ulcers. 
• AIC is an acute unilateral follicular conjunctivitis with preauricular 
lymphadenopathy and presents similarly to acute conjunctivitis due to 
adenovirus or HSV. 
– Corneal inflammation is evidenced by discrete opacities, punctate 
epithelial erosions, and superficial corneal vascularization.
– Left untreated, the disease may persist for 6 weeks to 2 years.
Diagnosis
Clinical diagnosis is based on the presence of two of the following signs: 
lymphoid follicles on the upper tarsal conjunctiva, typical conjunctival scar-
ring, vascular pannus, or limbal follicles. 
CHAPTER 107 
683
Chlamydial Infections
• Intracytoplasmic chlamydial inclusions are found in 10–60% of Giemsa-
stained conjunctival smears from children with severe inflammation.
• However, chlamydial nucleic acid amplification tests are more sensitive 
in detecting infection.
Trachoma/AIC
TREATMENT
• AIC responds to azithromycin (a single 1-g oral dose) or doxycycline 
(100 mg PO bid for 7 days). Treatment of sexual partners is needed to 
prevent ocular reinfection and chlamydial genital disease.
C. PSITTACI INFECTIONS
Etiology and Epidemiology 
Most avian species can harbor C. psittaci, but psittacine birds (e.g., parrots, 
parakeets) are most often infected; human infections are uncommon and 
occur only as a zoonosis. 
• Exposure is greatest in poultry workers and in owners of pet birds. 
• Present in nasal secretions, excreta, tissues, and feathers of infected birds, 
C. psittaci is transmitted to humans by direct contact with infected birds 
or by inhalation of aerosols. Transmission from person to person has 
never been documented. 
• As a result of quarantine of imported birds and improved veterinary-
hygienic measures, outbreaks and sporadic cases of psittacosis are 
now rare, with fewer than 50 confirmed cases reported in the U.S. 
each year.
Clinical Manifestations 
Psittacosis in humans can range in severity from asymptomatic or mild 
infections to acute primary atypical pneumonia (which can be fatal in 10% 
of untreated cases) to severe chronic pneumonia. 
• After an incubation period of >5–19 days, pts present with fever, chills, 
muscular aches and pains, severe headaches, hepatomegaly and/or sple-
nomegaly, and gastrointestinal symptoms.
• Cardiac complications may include endocarditis and myocarditis.
Diagnosis
This diagnosis is confirmed by serologic studies. 
• The gold standard is the MIF test.
• Any antibody titer >1:16 or a 4-fold rise between paired acute- and 
convalescent-phase serum samples, in combination with a clinically 
compatible syndrome, can be used to diagnose psittacosis.
C. psittaci Infections
TREATMENT
• Tetracycline (250 mg PO qid for 3 weeks) is the antibiotic of choice.
• Erythromycin (500 mg PO qid) is an alternative agent.
SECTION 7
684
Infectious Diseases
C. PNEUMONIAE INFECTIONS
Epidemiology 
C. pneumoniae is a common cause of human respiratory diseases, primarily 
in young adults. 
• Seroprevalence rates of 40–70% demonstrate that C. pneumoniae is wide-
spread worldwide. Seropositivity is first detected at school age and then 
increases by ~10% per decade.
• The role of C. pneumoniae in atherosclerotic disease has long been dis-
cussed, but large-scale treatment studies have cast doubts on the etiologic 
role of this organism in this disease. 
Clinical Manifestations 
The clinical spectrum of C. pneumoniae infection includes acute pharyngi-
tis, sinusitis, bronchitis, and pneumonia. 
• Pneumonia due to C. pneumoniae resembles that due to Mycoplasma 
pneumoniae. Pts have antecedent upper respiratory tract symptoms, 
fever, nonproductive cough, minimal findings on auscultation, small 
segmental infiltrates on chest x-ray, and no leukocytosis. 
– Primary infection is more severe than reinfection.
– Elderly pts can have severe disease.
Diagnosis
Serology is the most clinically useful means for diagnosing C. pneumoniae 
infection.
• The diagnosis of acute C. pneumoniae infection requires demonstra-
tion of a 4-fold rise in titer between acute- and convalescent-phase 
serum samples.
• Culture of the organism is difficult and is not routinely attempted. 
PCR assays for C. pneumoniae are currently available only for research 
purposes.
C. pneumoniae Infections
TREATMENT
• Erythromycin or tetracycline (2 g/d for 10–14 days) is recommended.  
• Other macrolides (e.g., azithromycin) or quinolones (e.g., levofloxa-
cin) are alternative agents.
For a more detailed discussion, see Gaydos CA, Quinn TC: 
Chlamydial Infections, Chap. 176, p. 1421, in HPIM-18.
CHAPTER 108 
685
Herpesvirus Infections
CHAPTER 108
Herpesvirus Infections
HERPES SIMPLEX VIRUSES
� MICROBIOLOGY AND PATHOGENESIS 
The herpes simplex viruses HSV-1 and HSV-2 are linear, double-stranded 
DNA viruses that share ~50% sequence homology. Exposure to HSV at 
mucosal surfaces or abraded skin sites permits viral entry and replication 
in cells of the epidermis and dermis prior to infection of neuronal cells and 
development of a latent infection in ganglia. 
• Reactivation occurs when normal viral gene expression resumes, with 
reappearance of the virus on mucosal surfaces. 
• Both antibody-mediated and cell-mediated immunity (including type-
specific immunity) are clinically important.
� EPIDEMIOLOGY 
HSV-1 is acquired more frequently and at an earlier age than HSV-2. More than 
90% of adults have antibodies to HSV-1 by the fifth decade of life. Antibodies 
to HSV-2 usually are not detected until adolescence and correlate with sexual 
activity; in the United States, 15–20% of the population has antibody to HSV-2.
• HSV is transmitted by contact with active lesions or with virus shed from 
mucocutaneous surfaces by asymptomatic persons. 
• HSV reactivation is very common: HSV-2 is shed on a median of 25% of 
days by infected pts, with 29% of genital reactivation episodes lasting <6 h.
• The large reservoir of unidentified carriers and the frequent asymptom-
atic reactivation of HSV-2 have fostered the continued spread of HSV 
throughout the world.
� CLINICAL MANIFESTATIONS 
Both viral subtypes can cause indistinguishable genital and oral-facial infec-
tions. Overall, genital HSV-2 is twice as likely to reactivate as genital HSV-1, 
and HSV-2 infection recurs 8–10 times more often. In contrast, oral-labial 
HSV-1 infection recurs more frequently than oral-labial HSV-2 infection. 
The incubation period for primary infection with either virus is 1–26 days 
(median, 6–8 days).
Oral-Facial Infections 
Primary HSV-1 infection results in gingivostomatitis, pharyngitis, and up to 
2 weeks of fever, malaise, myalgia, inability to eat, and cervical adenopathy, 
with lesions on the palate, gingiva, tongue, lip, face, posterior pharynx, and/
or tonsillar pillars and occasional exudative pharyngitis.
• Reactivation of HSV from the trigeminal ganglia is associated with 
asymptomatic viral excretion in the saliva, intraoral mucosal ulcerations, 
or ulcers on the vermilion border of the lip or external facial skin. 
SECTION 7
686
Infectious Diseases
– 50–70% of pts undergoing trigeminal nerve-root decompression and 
10–15% of pts undergoing dental extraction develop oral-labial herpes 
a median of 3 days after the procedure.
– Reactivation of HSV-1 or VZV in the mandibular portion of the facial 
nerve causes flaccid paralysis (Bell’s palsy).
• Immunosuppressed pts can have a severe infection that extends into the 
mucosa and skin, causing friability, necrosis, bleeding, pain, and inability 
to eat or drink.
• Pts with atopic dermatitis may also develop severe oral-facial HSV infec-
tion (eczema herpeticum), with extensive skin lesions and occasional 
visceral dissemination.
• HSV infection is the precipitating event in ~75% of cases of erythema 
multiforme.
Genital Infections (see Chap. 92)
First-episode primary genital herpes is characterized by fever, headache, 
malaise, and myalgias. Pain, itching, dysuria, vaginal and urethral dis-
charge, and tender inguinal lymphadenopathy are the predominant local 
symptoms.
• Pts with prior HSV-1 infection have milder cases.
• Reactivation infections are often subclinical or can cause genital lesions 
or urethritis with dysuria. 
• Even without a history of rectal intercourse, perianal lesions can occur as 
a result of latency established in the sacral dermatome from prior genital 
tract infection.
Whitlow
In HSV infection of the finger, pts experience an abrupt onset of edema, 
erythema, pain, and vesicular or pustular lesions of the fingertips that 
are often confused with the lesions of pyogenic bacterial infection. 
Fever, lymphadenitis, and epitrochlear and axillary lymphadenopathy are 
common.
Herpes Gladiatorum 
HSV infection caused by trauma to the skin during wrestling can occur 
anywhere on the body but commonly affects the thorax, ears, face, and 
hands.
Eye Infections 
HSV is the most frequent cause of corneal blindness in the United States.
• HSV keratitis presents with acute onset of pain, blurred vision, chemosis, 
conjunctivitis, and dendritic corneal lesions. Topical glucocorticoids may 
exacerbate disease. Recurrences are common.
• Other manifestations include chorioretinitis and acute necrotizing retinitis.
Central and Peripheral Nervous System Infections 
In the United States, HSV causes 10–20% of all cases of sporadic viral 
encephalitis, and 95% of these cases are due to HSV-1 (either primary 
CHAPTER 108 
687
Herpesvirus Infections
or reactivated infection). The estimated annual incidence is 2.3 cases per 
1 million persons. 
• Pts present with an acute onset of fever and focal neurologic symptoms 
and signs, especially in the temporal lobe. In severe cases, RBCs can be 
found in the CSF as a result of hemorrhagic necrosis.
• Given the potential severity of infection, antiviral treatment should be 
started empirically until the diagnosis is confirmed or an alternative 
diagnosis is made.
• HSV meningitis, which is usually seen in association with primary 
genital HSV infection, is an acute self-limited disease manifested by 
headache, fever, and mild photophobia and lasting 2–7 days.
– Of cases of aseptic meningitis, 3–15% are due to HSV.
– HSV is the most common cause of recurrent lymphocytic meningitis 
(Mollaret’s meningitis).
• Autonomic dysfunction caused by either HSV or VZV most commonly 
affects the sacral region, resulting in numbness, tingling of the buttocks 
or perineal areas, urinary retention, constipation, and impotence. 
– Symptoms take days or weeks to resolve. 
– In rare instances, transverse myelitis or Guillain-Barré syndrome 
follows HSV infection.
Visceral Infections 
HSV infection of visceral organs usually results from viremia; multiple-
organ involvement is common, but occasionally only the esophagus, lung, 
or liver is affected.
• In HSV esophagitis, pts present with odynophagia, dysphagia, substernal 
pain, weight loss, and multiple oval ulcerations on an erythematous base. 
Detection of HSV is necessary to distinguish this entity from esophagitis 
of other etiologies (e.g., Candida esophagitis).
• HSV pneumonitis is rare except among severely immunocompromised 
pts and results in focal necrotizing pneumonitis with a mortality rate 
of >80%.
• Hepatic HSV infection occurs primarily in immunocompromised pts 
and is associated with fever, abrupt elevations of bilirubin and serum 
aminotransferase levels, and leukopenia (<4000 WBCs/μL).
Neonatal Infections 
The frequency of visceral and/or CNS infection is highest among HSV-
infected infants <6 weeks of age; the mortality rate without therapy is 65%. 
• Infection is usually acquired perinatally from contact with infected geni-
tal secretions during delivery. 
• More than two-thirds of cases are due to HSV-2. The risk is elevated by 
10-fold for infants born to a mother who has recently acquired HSV.
� DIAGNOSIS 
Microscopic evaluation, viral culture, serology, and PCR are all clinically 
useful for diagnosing HSV infection.
SECTION 7
688
Infectious Diseases
• Regardless of the detection method, the sensitivity is greater for vesicular 
rather than ulcerative mucosal lesions, in primary rather than recurrent 
disease, and in immunocompromised rather than immunocompetent pts.
• PCR is most sensitive for detection of HSV and should be used whenever 
possible.
• A Tzanck smear (Giemsa-stained scrapings from the base of lesions) to 
detect giant cells or intranuclear inclusions characteristic of both HSV 
and VZV infections has a low level of sensitivity; its use requires clini-
cians skilled in this technique. 
• Serologic tests can be used to demonstrate prior exposure to HSV; no reli-
able IgM detection method for defining acute HSV infection is available.
Infections with Herpes Simplex Viruses
TREATMENT
• Table 108-1 details antiviral chemotherapy for HSV infection. 
– All antiviral agents licensed for use against HSV inhibit the viral 
DNA polymerase.
– Acyclovir can crystallize in the renal parenchyma, causing transient 
renal insufficiency; this drug should be given over the course of 1 h 
to a well-hydrated pt.
– Acyclovir-resistant strains of HSV are rare but have been identified, 
primarily in immunocompromised pts. In general, these isolates are 
also resistant to valacyclovir and famciclovir, which have similar 
mechanisms of action.
� PREVENTION 
The use of barrier forms of contraception, especially condoms, decreases 
the likelihood of HSV transmission, particularly during asymptomatic viral 
excretion. Chronic daily therapy with valacyclovir can also be partially effec-
tive in reducing acquisition of HSV-2, particularly among susceptible women.
VARICELLA-ZOSTER VIRUS
� MICROBIOLOGY AND PATHOGENESIS 
VZV—a double-stranded DNA virus in the family Herpesviridae—has a 
pathogenic cycle similar to that of HSV. Primary infection is transmitted 
by the respiratory route. The virus replicates and causes viremia, which 
is reflected by the diffuse and scattered skin lesions in varicella; it then 
establishes latency in the dorsal root ganglia and can reactivate through 
unknown mechanisms at a later time.
� EPIDEMIOLOGY AND CLINICAL MANIFESTATIONS 
VZV causes two distinct entities: primary infection (varicella or chicken-
pox) and reactivation infection (herpes zoster or shingles). Humans are the 
only known reservoir for VZV. 
Chickenpox
Pts present with fever, malaise, and rash characterized by maculopapules, 
vesicles, and scabs in various stages of evolution. The skin lesions are small, 
CHAPTER 108 
689
Herpesvirus Infections
TABLE 108-1 ANTIVIRAL CHEMOTHERAPY FOR HSV INFECTION
I. Mucocutaneous HSV infections
A. Infections in immunosuppressed pts
   1.  Acute symptomatic first or recurrent episodes: IV acyclovir (5 mg/kg 
q8h) or oral acyclovir (400 mg qid), famciclovir (500 mg bid or tid), or 
valacyclovir (500 mg bid) is effective. Treatment duration may vary 
from 7 to 14 days.
   2.  Suppression of reactivation disease (genital or oral-labial): IV acyclovir 
(5 mg/kg q8h) or oral valacyclovir (500 mg bid) or acyclovir (400–800 
mg 3–5 times per day) prevents recurrences during the 30-day period 
immediately after transplantation. Longer-term HSV suppression is often 
used for pts with continued immunosuppression. In bone marrow and 
renal transplant recipients, oral valacyclovir (2 g/d) is also effective in 
reducing CMV infection. Oral valacyclovir at a dose of 4 g/d has been 
associated with thrombotic thrombocytopenic purpura after extended 
use in HIV-positive pts. In HIV-infected pts, oral acyclovir (400–800 mg 
bid), valacyclovir (500 mg bid), or famciclovir (500 mg bid) is effective in 
reducing clinical and subclinical reactivations of HSV-1 and HSV-2.
B. Infections in immunocompetent pts
   1. Genital herpes
    a.  First episodes: Oral acyclovir (200 mg 5 times per day or 400 mg 
tid), valacyclovir (1 g bid), or famciclovir (250 mg bid) for 7–14 days 
is effective. IV acyclovir (5 mg/kg q8h for 5 days) is given for severe 
disease or neurologic complications such as aseptic meningitis.
    b.  Symptomatic recurrent genital herpes: Short-course (1- to 3-day) 
regimens are preferred because of low cost, likelihood of adher-
ence, and convenience. Oral acyclovir (800 mg tid for 2 days), 
valacyclovir (500 mg bid for 3 days), or famciclovir (750 or 1000 mg 
bid for 1 day, a 1500-mg single dose, or 500 mg stat followed 
by 250 mg q12h for 3 days) effectively shortens lesion duration. 
Other options include oral acyclovir (200 mg 5 times per day), 
valacyclovir (500 mg bid), and famciclovir (125 mg bid for 5 days).
    c.  Suppression of recurrent genital herpes: Oral acyclovir (400–800 mg 
bid) or valacyclovir (500 mg daily) is given. Pts with >9 episodes per 
year should take oral valacyclovir (1 g daily or 500 mg bid) or famci-
clovir (250 mg bid or 500 mg bid).
   2. Oral-labial HSV infections
    a.  First episode: Oral acyclovir (200 mg) is given 4 or 5 times per day; 
an oral acyclovir suspension can be used (600 mg/m2 qid). Oral fam-
ciclovir (250 mg bid) or valacyclovir (1 g bid) has been used clinically.
    b.  Recurrent episodes: If initiated at prodrome onset, single-dose or 1-day 
therapy effectively reduces pain and speeds healing. Regimens include 
oral famciclovir (a 1500-mg single dose or 750 mg bid for 1 day) or 
valacyclovir (a 2-g single dose or 2 g bid for 1 day). Self-initiated therapy 
with 6-times-daily topical penciclovir cream effectively speeds healing of 
oral-labial HSV lesions. Topical acyclovir cream also speeds healing.
(continued)
SECTION 7
690
Infectious Diseases
TABLE 108-1 ANTIVIRAL CHEMOTHERAPY FOR HSV INFECTION (CONTINUED)
I. Mucocutaneous HSV infections (continued)
    c.  Suppression of reactivation of oral-labial HSV: If started before expo-
sure and continued for the duration of exposure (usually 5–10 days), 
oral acyclovir (400 mg bid) prevents reactivation of recurrent oral-
labial HSV infection associated with severe sun exposure.
   3.  Surgical prophylaxis of oral or genital HSV infection: Several surgical 
procedures, such as laser skin resurfacing, trigeminal nerve-root 
decompression, and lumbar disk surgery, have been associated with 
HSV reactivation. IV acyclovir (3–5 mg/kg q8h) or oral acyclovir (800 
mg bid), valacyclovir (500 mg bid), or famciclovir (250 mg bid) effec-
tively reduces reactivation. Therapy should be initiated 48 h before 
surgery and continued for 3–7 days.
   4.  Herpetic whitlow: Oral acyclovir (200 mg) is given 5 times daily for 
7–10 days (alternative: 400 mg tid).
   5.  HSV proctitis: Oral acyclovir (400 mg 5 times per day) is useful in 
shortening the course of infection. In immunosuppressed pts or in pts 
with severe infection, IV acyclovir (5 mg/kg q8h) may be useful.
   6.  Herpetic eye infections: In acute keratitis, topical trifluorothymidine, vida-
rabine, idoxuridine, acyclovir, penciclovir, and interferon are all beneficial. 
Debridement may be required. Topical steroids may worsen disease.
II. CNS HSV infections
A.  HSV encephalitis: IV acyclovir (10 mg/kg q8h; 30 mg/kg per day) is 
given for 10 days or until HSV DNA is no longer detected in CSF.
B.  HSV aseptic meningitis: No studies of systemic antiviral chemotherapy exist. 
If therapy is given, IV acyclovir (15–30 mg/kg per day) should be used.
C.  Autonomic radiculopathy: No studies are available. Most authorities 
recommend a trial of IV acyclovir.
III. Neonatal HSV infections: Oral acyclovir (60 mg/kg per day, divided 
into 3 doses) is given. The recommended duration of treatment is 21 days. 
Monitoring for relapse should be undertaken, and some authorities recom-
mend continued suppression with oral acyclovir suspension for 3–4 months.
IV. Visceral HSV infections
A.  HSV esophagitis: IV acyclovir (15 mg/kg per day) is given. In some pts 
with milder forms of immunosuppression, oral therapy with valacyclovir 
or famciclovir is effective.
B.  HSV pneumonitis: No controlled studies exist. IV acyclovir (15 mg/kg 
per day) should be considered.
V. Disseminated HSV infections: No controlled studies exist. IV acyclovir 
(5 mg/kg q8h) should be tried. Adjustments for renal insufficiency may be needed. 
No definite evidence indicates that therapy will decrease the risk of death.
VI. Erythema multiforme associated with HSV: Anecdotal observations 
suggest that oral acyclovir (400 mg bid or tid) or valacyclovir (500 mg bid) 
will suppress erythema multiforme.
VII. Infections due to acyclovir-resistant HSV: IV foscarnet (40 mg/kg IV q8h) 
should be given until lesions heal. The optimal duration of therapy and the use-
fulness of its continuation to suppress lesions are unclear. Some pts may benefit 
from cutaneous application of trifluorothymidine or 5% cidofovir gel.
CHAPTER 108 
691
Herpesvirus Infections
with an erythematous base of 5–10 mm, and appear in successive crops over 
2–4 days. Severity varies from person to person, but older pts tend to have 
more severe disease.
• In immunocompetent hosts, the disease is benign and lasts 3–5 days. 
In contrast, immunocompromised pts have numerous slower-healing 
lesions (often with a hemorrhagic base) and are more likely to develop 
visceral complications that, if not treated, are fatal in 15% of cases.
• The incubation period ranges from 10 to 21 days but is usually 14–17 days. 
Pts are infectious for 48 h before onset of rash and remain infectious until 
all vesicles have crusted.
• The virus is highly contagious, with an attack rate of 90% among suscep-
tible persons. Historically, children 5–9 years old accounted for half of all 
cases; vaccination has dramatically changed the epidemiology of infec-
tion and has caused a significant decrease in the annualized incidence of 
chickenpox.
• Complications of varicella include bacterial superinfection of the skin, 
CNS involvement, pneumonia, myocarditis, and hepatic involvement.
– Bacterial superinfection is usually caused by Streptococcus pyogenes or 
Staphylococcus aureus.
– CNS involvement, usually manifesting as acute cerebellar ataxia and 
meningeal irritation ~21 days after the onset of rash, runs a benign 
course. Aseptic meningitis, encephalitis, transverse myelitis, Guillain-
Barré syndrome, or Reye’s syndrome (which mandates the avoidance 
of aspirin administration to children) can occur. There is no specific 
therapy other than supportive care.
– VZV pneumonia is the most serious complication and develops more 
frequently among adults (occurring in up to 20% of cases) than among 
children. The onset comes 3–5 days into illness, with tachypnea, 
cough, dyspnea, fever, cyanosis, pleuritic chest pain, and hemop-
tysis. CXR shows nodular infiltrates and interstitial pneumonitis. 
Resolution of pneumonitis parallels improvement of the skin rash.
Herpes Zoster (Shingles) 
Herpes zoster represents a reactivation of VZV from dorsal root ganglia and 
usually manifests as a unilateral vesicular eruption within a dermatome, 
often associated with severe pain.
• Dermatomal pain may precede lesions by 48–72 h, and dermatomes T3 
to L3 are most frequently involved. 
• The usual duration of disease is 7–10 days, but it may take as long as 
2–4 weeks for the skin to return to normal.
• With ~1.2 million cases each year in the U.S., the incidence is highest 
among pts ≥60 years of age.
• Pts with herpes zoster can transmit infection to seronegative individuals, 
with consequent chickenpox.
• Complications include zoster ophthalmicus (which can lead to blind-
ness), Ramsay Hunt syndrome (characterized by pain and vesicles in 
the external auditory canal, loss of taste in the anterior two-thirds of the 
tongue, and ipsilateral facial palsy), and postherpetic neuralgia (pain 
persisting for months after resolution of cutaneous disease).
SECTION 7
692
Infectious Diseases
• Immunocompromised pts—particularly those with Hodgkin’s disease 
and non-Hodgkin’s lymphoma—are at greatest risk for severe zoster and 
progressive disease. Cutaneous dissemination occurs in 40% of these pts 
and increases the risk for other complications (pneumonitis, meningo-
encephalitis, hepatitis).
� DIAGNOSIS 
Definitive diagnosis requires isolation of VZV in culture, detection of VZV 
by molecular means (PCR, immunofluorescent staining of cells from the 
lesion base), or serology (seroconversion or a ≥4-fold rise in antibody titer 
between convalescent- and acute-phase serum specimens).
Varicella-Zoster Virus Infections
TREATMENT
• Chickenpox: Antiviral therapy can be helpful if started within 24 h of 
symptoms. 
– For children <12 years of age, acyclovir (20 mg/kg PO q6h) is 
recommended. 
– For adolescents and adults, acyclovir (800 mg PO five times daily), 
valacyclovir (1 g PO tid), or famciclovir (250 mg PO tid) for 5–7 
days is recommended. 
– Good hygiene, meticulous skin care, and antipruritic drugs are 
important to relieve symptoms and prevent bacterial superinfection 
of skin lesions.
• Zoster: Lesions heal more quickly with antiviral treatment. 
– Acyclovir (800 mg PO five times daily for 7–10 days), famciclovir 
(500 mg PO tid for 7 days), or valacyclovir (1 g PO tid for 5–7 days) 
is recommended.
– One study also showed twofold faster resolution of postherpetic 
neuralgia with famciclovir.
• VZV infection in severely immunocompromised pts: Severely immuno-
compromised pts should receive acyclovir, at least at the outset (10 mg/kg 
IV q8h for 7 days), for chickenpox and herpes zoster to reduce the risk of 
visceral complications, although this regimen does not speed the healing 
or relieve the pain of skin lesions. 
– Low-risk immunocompromised pts can be treated with oral valacy-
clovir or famciclovir.
– If feasible, immunosuppression should be decreased during con-
comitant acyclovir administration.
• Zoster ophthalmicus: Antiviral treatment, analgesics for severe pain, 
and consultation with an ophthalmologist are required.
• Postherpetic neuralgia: Gabapentin, amitriptyline, lidocaine patches, and 
fluphenazine may relieve pain and can be given along with routine anal-
gesic agents. Prednisone (given along with antiviral therapy at a dosage of 
60 mg/d for the first week of zoster, with the dose then tapered by 50% 
weekly over the next 2 weeks) can accelerate quality-of-life improvements, 
including a return to usual activity; prednisone treatment is indicated only 
for healthy elderly persons with moderate or severe pain at presentation.
CHAPTER 108 
693
Herpesvirus Infections
� PREVENTION 
Three methods are used for the prevention of VZV infections.
• Active immunization: For all children and seronegative adults, two doses 
of a live attenuated varicella vaccine are recommended. Irrespective of 
serologic status, pts >60 years old should receive a vaccine with 18 times 
the viral content of varicella vaccine; zoster vaccine reduces the incidence 
of zoster and postherpetic neuralgia.
• Passive immunization: Varicella-zoster immune globulin (VZIg) can be 
given to VZV-susceptible hosts within 96 h of a significant exposure if 
the risk of complications from varicella is high (e.g., immunocompro-
mised pts, pregnant women, premature infants, neonates whose moth-
ers had chickenpox onset within 5 days before or 2 days after delivery). 
VZIg is available under an investigational new drug protocol from FFF 
Enterprises (800-843-7477).
• Antiviral treatment: Seven days after intense exposure, antiviral prophy-
laxis can be given to high-risk pts who are ineligible for vaccine or for 
whom the 96-h window after direct contact has passed. This intervention 
may lessen illness severity.
HUMAN HERPESVIRUS (HHV) TYPES 6, 7, AND 8
• HHV-6 causes exanthem subitum (roseola infantum, a common child-
hood febrile illness with rash) and 20–30% of febrile seizures without 
rash in infancy. 
– In older age groups, HHV-6 has been associated with mononucleosis 
syndromes; focal encephalitis; and (in immunocompromised hosts) 
pneumonitis, syncytial giant-cell hepatitis, and disseminated disease. 
– More than 80% of adults are seropositive for HHV-6.
• HHV-7 is frequently acquired during childhood, and infections typically 
manifest as fever and seizures. The virus is commonly present in saliva.
• HHV-8 infection in healthy children can present as fever and rash; in 
immunocompromised pts, primary infection may present as fever, sple-
nomegaly, pancytopenia, and rapid-onset Kaposi’s sarcoma.
– HHV-8 is associated with Kaposi’s sarcoma, body cavity–based lym-
phoma in AIDS pts, and multicentric Castleman’s disease. 
– Unlike other herpesvirus infections, HHV-8 infection is much more 
common in some geographic areas (e.g., central and southern Africa) 
than in others (North America, Asia, northern Europe). 
– The virus appears to be sexually spread and may also be transmitted 
in saliva, by organ transplantation, and through IV drug use.
For a more detailed discussion, see Baden LR, Dolin R: Antiviral 
Chemotherapy, Excluding Antiretroviral Drugs, Chap. 178, 
p. 1442; Corey L: Herpes Simplex Virus Infections, Chap. 179, 
p. 1453; Whitley RJ: Varicella-Zoster Virus Infections, 
Chap. 180, p. 1462; and Hirsch MS: Cytomegalovirus and Human 
Herpesvirus Types 6, 7, and 8, Chap. 182, p. 1471, in HPIM-18.
SECTION 7
694
Infectious Diseases
CHAPTER 109
Cytomegalovirus and 
Epstein-Barr Virus Infections
� CYTOMEGALOVIRUS (CMV)
Microbiology 
CMV is a herpesvirus, has double-stranded DNA, and renders infected cells 
2–4 times the size of surrounding cells. These cytomegalic cells contain an 
eccentrically placed intranuclear inclusion surrounded by a clear halo, with 
an “owl’s-eye” appearance.
Epidemiology 
CMV disease is found worldwide. Perinatal and early childhood infections 
are common; ~1% of U.S. newborns are infected. 
• The virus can be spread in breast milk, saliva, feces, and urine. 
• Transmission requires repeated or prolonged contact as opposed to 
casual contact. Sexual transmission is common among adolescents and 
adults, and CMV has been identified in semen and cervical secretions. 
• Latent CMV infection persists throughout life unless reactivation is trig-
gered by depressed cell-mediated immunity (e.g., in transplant recipients 
or HIV-infected pts).
Pathogenesis 
Primary CMV infection is associated with a vigorous T lymphocyte 
response; activated CD8+ T cells predominate among atypical lymphocytes. 
• Latent infection occurs in multiple cell types and various organs. 
Chronic antigen stimulation in the presence of immunosuppression (e.g., 
in the transplantation setting) and certain immunosuppressive agents 
(e.g., antithymocyte globulin) promote CMV reactivation. 
• CMV disease increases the risk of infection with opportunistic patho-
gens by depressing T lymphocyte responsiveness.
Clinical Manifestations 
The most common presentation is CMV mononucleosis in immunocom-
petent pts, but disease can be more severe in immunocompromised pts 
(including newborns).
Congenital CMV Infection 
Cytomegalic inclusion disease occurs in ~5% of infected fetuses in the set-
ting of primary maternal CMV infection in pregnancy. 
• Petechiae, hepatosplenomegaly, and jaundice are present in 60–80% of 
cases; microcephaly with or without cerebral calcifications, intrauterine 
growth retardation, prematurity, and chorioretinitis are less common. 
CHAPTER 109 
695
Cytomegalovirus and Epstein-Barr Virus
• Laboratory findings include elevated values in LFTs, thrombocytopenia, 
conjugated hyperbilirubinemia, hemolysis, and increased CSF protein levels. 
• The mortality rate is 20–30% among infants with severe disease; survi-
vors have intellectual or hearing difficulties.
Perinatal CMV Infection 
Perinatal infection with CMV is acquired by breast-feeding or contact with 
infected maternal secretions (e.g., in the birth canal). Although most pts are 
asymptomatic, disease similar to—but less severe than—congenital CMV 
can occur.
CMV Mononucleosis 
Symptoms last 2–6 weeks and include high fevers, profound fatigue and 
malaise, myalgias, headache, and splenomegaly; in contrast to EBV infec-
tion, exudative pharyngitis and cervical lymphadenopathy are rare in CMV 
infection. 
• Laboratory findings include relative lymphocytosis with >10% atypical 
lymphocytes, transaminitis, and immunologic abnormalities (e.g., the 
presence of cryoglobulins, rheumatoid factor, or cold agglutinins). 
• The incubation period ranges from 20 to 60 days. 
• Recovery is generally complete, but postviral asthenia can persist for 
months. 
CMV Infection in the Immunocompromised Host 
CMV is the most common and important viral pathogen complicating 
organ transplantation, with the greatest risk of infection at 1–4 months after 
transplantation. HIV-infected pts with CD4+ T cell counts of <50–100/μL 
also are at risk for severe CMV disease.
• Primary CMV infection (including reinfection with a new, donor-
derived strain) is more likely than reactivation to cause severe disease 
with high viral loads. 
– Reactivation infection is common but less important clinically. 
– The transplanted organ is at particular risk; e.g., CMV pneumonitis 
tends to follow lung transplantation. 
– The risk of severe disease is reduced by antiviral prophylaxis or pre-
emptive therapy.
• Pts present initially with prolonged fever, malaise, anorexia, fatigue, 
night sweats, and arthralgias or myalgias but can ultimately have multi-
organ involvement.
– Respiratory involvement is evidenced by tachypnea, hypoxia, unpro-
ductive cough, and chest radiographs demonstrating bilateral intersti-
tial or reticulonodular infiltrates.
– GI involvement often includes hepatitis and ulcer formation.
– CMV encephalitis, particularly in HIV-infected pts, can occur as 
either progressive dementia or ventriculoencephalitis characterized by 
cranial nerve deficits, disorientation, and lethargy.
– CMV retinitis is an important cause of blindness in pts with advanced 
AIDS.
SECTION 7
696
Infectious Diseases
Diagnosis
Diagnosis requires isolation of CMV or detection of its antigens or DNA 
in appropriate clinical specimens in conjunction with a compatible clinical 
syndrome. Immunofluorescence assays for CMV antigens (pp65), PCR, 
viral culture, and serology are all useful means of detection.
Cytomegalovirus Infections
TREATMENT
• When possible, seronegative donors should be used for seronegative 
transplant recipients.
• Ganciclovir (5 mg/kg IV bid for 14–21 days followed by 5 mg/kg 
IV qd) or valganciclovir (the oral prodrug of ganciclovir; 900 mg PO 
bid for 14–21 days followed by 900 mg PO qd) produces response 
rates of 70–90% among HIV-infected pts with CMV retinitis or colitis. 
– In severe infections, ganciclovir is often combined with CMV 
immune globulin. 
– Neutropenia is an adverse reaction to ganciclovir treatment that 
may require administration of colony-stimulating factors. 
– Prophylactic or suppressive treatment can be given to high-risk 
transplant recipients (those who are seropositive before transplan-
tation or culture positive without symptoms afterward).
– Resistance to ganciclovir is common among pts treated for >3 months 
and is usually related to mutations in the CMV UL97 gene.
– For CMV retinitis, ganciclovir can be administered via a slow-
release pellet sutured into the eye, but this intervention does not 
provide treatment for the contralateral eye or for systemic disease.
• Foscarnet (180 mg/kg qd divided into 2 or 3 doses for 2 weeks, fol-
lowed by 90–120 mg/kg IV qd) inhibits CMV DNA polymerase and 
is active against most ganciclovir-resistant CMV isolates. The primary 
adverse events include electrolyte disturbances and renal dysfunction.
• Cidofovir (5 mg/kg IV per week for 2 weeks followed by 3–5 mg/kg IV 
every 2 weeks) is a nucleotide analogue that is also effective against CMV; 
however, it can cause severe nephrotoxicity by proximal tubular cell injury. 
The use of saline hydration and probenecid reduces this adverse effect.
• CMV immune or hyperimmune globulin may reduce the risk of CMV 
disease in seronegative renal transplant recipients and prevent con-
genital CMV infection in infants born to women with primary CMV 
infection during pregnancy.
� EPSTEIN-BARR VIRUS (EBV)
Epidemiology 
EBV is a DNA virus in the family Herpesviridae that infects >90% of persons 
by adulthood. 
• Infectious mononucleosis (IM) is a disease of young adults and is more 
common in areas with higher standards of hygiene; infection occurs at a 
younger age in areas with deficient standards of hygiene.
CHAPTER 109 
697
• EBV is spread by contact with oral secretions (e.g., by transfer of saliva 
during kissing) and is shed in oropharyngeal secretions by >90% of 
asymptomatic seropositive individuals.
Pathogenesis 
EBV infects the epithelium of the oropharynx and salivary glands as well as 
B cells in tonsillar crypts prior to a period of viremia. 
• There is polyclonal activation of B cells, and memory B cells form the 
reservoir for EBV. Reactive T cells proliferate, with up to 40% of CD8+ 
T cells directed against EBV antigens during acute infection. 
• Cellular immunity is more important than humoral immunity in con-
trolling infection. If T cell immunity is compromised, EBV-infected 
B cells may proliferate—a step toward neoplastic transformation.
Clinical Manifestations 
The nature of disease depends on the pt’s age and immune status: young 
children typically develop asymptomatic infections or mild pharyngitis, 
adolescents and adults develop an IM syndrome, and immunocompro-
mised pts can develop lymphoproliferative disease.
• In IM, a prodrome of fatigue, malaise, and myalgia may last for 1–2 weeks 
before the onset of fever, exudative pharyngitis, and lymphadenopathy 
with tender, symmetric, and movable nodes; splenomegaly is more 
prominent in the second or third week.
– The incubation period is ~4–6 weeks.
– Most pts treated with ampicillin develop a rash that does not represent 
a true penicillin allergy.
– Illness lasts for 2–4 months, but malaise and difficulty with concen-
tration can persist for months longer. EBV is not, however, a cause of 
chronic fatigue syndrome.
– Lymphocytosis occurs in the second or third week, with >10% atypical 
lymphocytes (enlarged cells with abundant cytoplasm and vacuoles); 
abnormal liver function is common.
– Complications include CNS disease (e.g., meningitis, encephalitis), 
Coombs-positive autoimmune hemolytic anemia, splenic rupture, 
and upper airway obstruction due to hypertrophy of lymphoid tissue.
• Lymphoproliferative disease—i.e., infiltration of lymph nodes and 
multiple organs by proliferating EBV-infected B cells—occurs in pts 
with deficient cellular immunity (e.g., pts with AIDS, those with 
severe combined immunodeficiency, and those receiving immuno-
suppressive medications). Pts develop fever and lymphadenopathy or 
GI symptoms.
• Oral hairy leukoplakia—raised, white, corrugated, EBV DNA–contain-
ing lesions on the tongue—is an early manifestation of infection with 
HIV in adults. 
• EBV-associated malignancies include Burkitt’s lymphoma (~90% of 
cases in Africa and ~15% of cases in the U.S.), anaplastic nasopharyngeal 
carcinoma in southern China, Hodgkin’s disease (especially the mixed-
cellularity type), and CNS lymphoma (especially HIV-related). 
Cytomegalovirus and Epstein-Barr Virus
SECTION 7
698
Infectious Diseases
Diagnosis
Serologic testing is the mainstay of diagnostic assessment. PCR analysis can 
be useful in monitoring EBV DNA levels in blood from pts with lympho-
proliferative disease.
• Heterophile antibodies (Table 109-1) form the basis of most rapid test-
ing, which assesses the ability of serum to agglutinate sheep, horse, or 
cow erythrocytes after adsorption with guinea pig kidney. 
– The antibodies can persist for up to 1 year after infection. 
– The monospot test for heterophile antibodies is ~75% sensitive and 
~90% specific in comparison with EBV-specific serologies.
– Pts <5 years old and elderly pts usually do not develop heterophile 
antibodies.
• EBV-specific antibody testing (Table 109-1) can be used in heterophile-
negative pts and pts with atypical disease. Antibodies to viral capsid anti-
gen occur in >90% of cases, with elevated IgM titers present only during 
the first 2–3 months of disease. 
• Antibodies to Epstein-Barr nuclear antigen are not detected until 3–6 weeks 
after symptom onset and then persist for life. 
Epstein-Barr Virus Infections
TREATMENT
• IM is treated with supportive measures, including rest and analgesia. 
– Excessive physical activity should be avoided in the first month of 
illness to reduce the possibility of splenic rupture, which necessi-
tates splenectomy.
TABLE 109-1 SEROLOGIC FEATURES OF EBV-ASSOCIATED DISEASES
Condition
Result in Indicated Test
Anti-VCA
Anti-EA
Heterophile
IgM
IgG
EA-D
EA-R
Anti-EBNA
Acute infectious 
mononucleosis
+
+
++
+
−
−
Convalescence
±
−
+
−
±
+
Past infection
−
−
+
−
−
+
Reactivation with 
immunodeficiency
−
−
++
+
+
±
Burkitt’s lymphoma
−
−
+++
±
++
+
Nasopharyngeal 
carcinoma
−
−
+++
++
±
+
Abbreviations: EA, early antigen; EA-D antibody, antibody to early antigen in diffuse pattern in 
nucleus and cytoplasm of infected cells; EA-R antibody, antibody to early antigen restricted to 
the cytoplasm; EBNA, Epstein-Barr nuclear antigen; VCA, viral capsid antigen.
Source: Adapted from Okano M et al: Clin Microbiol Rev 1:300, 1988.
CHAPTER 110 
699
Influenza and Other Viral Respiratory Diseases 
– Administration of glucocorticoids may be indicated for some com-
plications of IM; e.g., these agents may be given to prevent airway 
obstruction or to treat autoimmune hemolytic anemia. 
– Antiviral therapy (e.g., with acyclovir) is generally not effective for 
IM but is effective for oral hairy leukoplakia. 
• Treatment of posttransplantation EBV lymphoproliferative syndrome is 
generally directed toward reduction of immunosuppression, although 
other treatments—e.g., with interferon α, antibody to CD20 (rituximab), 
and donor lymphocyte infusions—have been used with varying success.
For a more detailed discussion, see Baden LR, Dolin R: Antiviral 
Chemotherapy, Excluding Antiretroviral Drugs, Chap. 178, 
p. 1442; Cohen JI: Epstein-Barr Virus Infections, Including 
Infectious Mononucleosis, Chap. 181, p. 1467; and Hirsch 
MS: Cytomegalovirus and Human Herpesvirus Types 6, 7, and 
8, Chap. 182, p. 1471, in HPIM-18.
CHAPTER 110
Influenza and Other Viral 
Respiratory Diseases
INFLUENZA
Microbiology and Pathogenesis 
Influenza A, B, and C viruses are RNA viruses and members of the fam-
ily Orthomyxoviridae with different nucleoprotein (NP) and matrix (M) 
protein antigens. Influenza A and B viruses are major human pathogens 
and are morphologically similar; influenza B infection is associated with 
less severe disease than influenza A infection, and influenza C virus causes 
subclinical disease.
• Influenza A viruses are subtyped by surface hemagglutinin (H) and 
neuraminidase (N) antigens. 
– Virus attaches to sialic acid cell receptors via the hemagglutinin. 
Neuraminidase degrades the receptor and plays a role in the release of 
virus from infected cells after replication has occurred. 
– Antibodies to the H antigen are the major determinants of immunity, 
while antibodies to the N antigen limit viral spread and contribute to 
reduction of the infection.
• Influenza is acquired from aerosolized respiratory secretions of acutely 
ill individuals and possibly by hand-to-hand contact or other personal 
or fomite contact. Viral shedding usually stops 2–5 days after disease 
onset.
SECTION 7
700
Infectious Diseases
Epidemiology 
Influenza outbreaks occur each year but vary in extent and severity. Influenza 
A epidemics occur almost exclusively during the winter months in temper-
ate climates but occur year-round in the tropics. These epidemics begin 
abruptly, peak over 2–3 weeks, last 2–3 months, and then subside rapidly.
• Global pandemics (the most recent of which took place in 2009 and 
was due to an A/H1N1 virus) occur, by definition, at multiple locations; 
they carry high attack rates (10–20% of the general population), extend 
beyond normal seasonality patterns, and are due in part to the propensity 
of the H and N antigens to undergo periodic antigenic variation. 
– Major changes (which are restricted to influenza A viruses) are called 
antigenic shifts and are associated with pandemics. Minor variations 
are called antigenic drifts. 
– The avian influenza strain A/H5N1, first detected in 1997, has not resulted 
in a pandemic because efficient person-to-person transmission has not 
occurred; infection is linked to direct contact with infected poultry. 
• The segmented genome of influenza A and B viruses allows reassortment 
of strains between different animal species. The pandemic A/H1N1 virus 
of 2009–2010 represented a quadruple reassortment among swine, avian, 
and human influenza viruses.
• Interpandemic outbreaks of influenza are associated with economic costs 
exceeding $87 billion in the U.S. Chronic cardiopulmonary disease and 
old age are the most prominent risk factors for severe illness. 
Clinical Manifestations 
Influenza has a wide spectrum of clinical presentations, ranging from a mild 
illness resembling the common cold to severe prostration with relatively few 
respiratory symptoms. The classic description involves the abrupt onset of 
headache, fever, chills, myalgia, and malaise in the setting of respiratory symp-
toms (e.g., cough, sore throat).
• Pts typically defervesce within 2–3 days, but respiratory symptoms 
accompanied by substernal pain can persist for ≥1 week. Postinfluenzal 
asthenia may persist for weeks, particularly in the elderly.
• Complications of influenza (pneumonia and extrapulmonary manifesta-
tions) are more common among pts >64 years old, pregnant women, and 
pts with chronic disorders (e.g., cardiopulmonary disease, diabetes, renal 
diseases, hemoglobinopathies, or immunosuppression).
– Pneumonia: Primary influenza pneumonia is the least common but 
most severe of the pneumonic complications, most often affecting 
pts with mitral stenosis and pregnant women. Pts have progressive 
pulmonary disease and high titers of virus in respiratory secretions.
• Secondary bacterial pneumonia is usually due to Streptococcus 
pneumoniae, Staphylococcus aureus, or Haemophilus influenzae 
and presents as the reappearance of fever and respiratory symp-
toms after 2–3 days of clinical improvement.
• The most common pneumonic complication involves aspects of 
viral and bacterial pneumonia.
– Extrapulmonary complications: Reye’s syndrome, myositis, rhabdomy-
olysis, myoglobinuria, and CNS disease (e.g., encephalitis, transverse 
CHAPTER 110 
701
Influenza and Other Viral Respiratory Diseases 
myelitis, Guillain-Barré syndrome) can occur as complications of 
influenza infection.
• Reye’s syndrome is a serious complication in children that is asso-
ciated with influenza B virus (and less commonly with influenza A 
virus), varicella-zoster virus, and aspirin therapy for the anteced-
ent viral infection.
Laboratory Findings 
Most commonly, a laboratory diagnosis is made with a rapid test that 
detects viral antigens from throat swabs, nasopharyngeal washes, or spu-
tum. These tests are relatively specific but variably sensitive. 
• Reverse-transcription PCR of respiratory samples is most sensitive and 
specific for detecting influenza. Viral culture is also possible and gives a 
positive result within 48–72 h. 
• Serologic testing requires the availability of acute- and convalescent-
phase sera and is useful only retrospectively.
Inﬂ uenza
TREATMENT
• See Table 110-1 for specific treatment of influenza.
– Antiviral agents have been tested in healthy adults with uncomplicat-
ed influenza but not in the treatment or prevention of complications 
associated with influenza.
– If started within 2 days of illness due to a susceptible virus, the 
neuraminidase inhibitors (oseltamivir and zanamivir) and the ada-
mantane agents (amantadine and rimantadine) reduce the duration 
of signs and symptoms by 1–1.5 days and ~50%, respectively.
– IV formulations of neuraminidase inhibitors (peramivir and zanamivir) 
are currently in clinical trials but may be accessed through the FDA’s 
Emergency Investigational New Drug (E-IND) application procedures.
– Zanamivir may exacerbate bronchospasm in asthmatic pts, while 
oseltamivir has been associated with nausea and vomiting (reac-
tions whose incidence is reduced if the drug is given with food) and 
with neuropsychiatric side effects in children.
– Amantadine causes mild CNS side effects (e.g., jitteriness, anxiety, 
insomnia, difficulty concentrating) in ~5–10% of pts; rimantadine 
has fewer CNS side effects.
• For uncomplicated influenza in individuals at low risk for complica-
tions, symptom-based rather than antiviral therapy may be considered.
Prophylaxis
Annual vaccination with either an inactivated or a live attenuated vaccine is 
the main public health measure for prevention of influenza. 
• Vaccine strains are generated from influenza A and B viruses that have 
circulated during the previous influenza season and whose circulation 
during the upcoming season is predicted.
– For inactivated vaccines, 50–80% protection against influenza is 
expected if the vaccine virus and the currently circulating viruses are 
closely related.
SECTION 7
702
Infectious Diseases
– Influenza vaccination is currently recommended for all individuals 
>6 months of age.
• Chemoprophylaxis against influenza (see Table 110-1 for regimens) should 
be reserved for individuals at high risk of complications who have had 
close contact with a pt sick with influenza. Chemoprophylaxis can be 
administered simultaneously with inactivated—but not with live—vaccine.
TABLE 110-1  ANTIVIRAL MEDICATIONS FOR TREATMENT AND 
PROPHYLAXIS OF INFLUENZA
Age Group (Years)
Antiviral Drug
Children (≤12)
13–64
≥65
Oseltamivir
Treatment, 
influenza A and B
Age 1–12, dose 
varies by weighta
75 mg PO bid
75 mg PO bid
Prophylaxis, 
influenza A and B
Age 1–12, dose 
varies by weightb
75 PO qd
75 mg PO qd
Zanamivir
Treatment, 
influenza A and B
Age 7–12, 10 mg 
bid by inhalation
10 mg bid by 
inhalation
10 mg bid by 
inhalation
Prophylaxis, 
influenza A and B
Age 5–12, 10 mg qd 
by inhalation
10 mg qd by 
inhalation
10 mg qd by 
inhalation
Amantadinec
Treatment, 
influenza A
Age 1–9, 5 mg/kg in 
2 divided doses, up 
to 150 mg/d
Age ≥10, 100 
mg PO bid
≤100 mg/d
Prophylaxis, 
influenza A
Age 1–9, 5 mg/kg in 
2 divided doses, up 
to 150 mg/d
Age ≥10, 100 
mg PO bid
≤100 mg/d
Rimantadinec
Treatment, 
influenza A
Not approved
100 mg PO bid
100–200 mg/d
Prophylaxis, 
influenza A
Age 1–9, 5 mg/kg in 
2 divided doses, up 
to 150 mg/d
Age ≥10, 100 
mg PO bid
100–200 mg/d
a<15 kg: 30 mg bid; >15–23 kg: 45 mg bid; >23–40 kg: 60 mg bid; >40 kg: 75 mg bid. For 
children <1 year of age, see www.cdc.gov/h1n1flu/recommendations.htm.
b<15 kg: 30 mg qd; >15–23 kg: 45 mg qd; >23–40 kg: 60 mg qd; >40 kg: 75 mg qd. For 
children <1 year of age, see www.cdc.gov/h1n1flu/recommendations.htm.
cAmantadine and rimantadine are not currently recommended (2009–2010) because of 
widespread resistance among influenza A viruses. Their use may be reconsidered if viral sus-
ceptibility is reestablished.
CHAPTER 110 
703
Influenza and Other Viral Respiratory Diseases 
OTHER COMMON VIRAL RESPIRATORY INFECTIONS
Acute viral respiratory illnesses account for ≥50% of all acute illnesses; 
adults have 3–4 cases per person per year. Clinical presentations for viral 
infections are generally not specific enough to allow an etiologic diagnosis, 
and viral illnesses are typically grouped into clinical syndromes (e.g., the 
“common cold,” pharyngitis, tracheitis, pneumonia). This section will cover 
the six major groups of respiratory viruses; see Table 110-2 for an overview 
and Chap. 64 for additional details on viral respiratory infections.
� RHINOVIRUSES
Microbiology 
Rhinoviruses are nonenveloped, single-stranded RNA viruses in the family 
Picornaviridae that together are the major cause of the “common cold” (up 
to 50% of cases). 
Epidemiology 
Rhinoviruses are spread by direct contact with infected secretions, usually 
respiratory droplets.
Clinical Manifestations 
After an incubation period of 1–2 days, pts develop rhinorrhea, sneezing, 
nasal congestion, and sore throat that lasts 4–9 days. Fever and other sys-
temic symptoms are unusual.
• Severe disease, including fatal pneumonia, is rare but has been described in 
immunocompromised pts, particularly bone marrow transplant recipients.
Diagnosis
An etiologic diagnosis usually is not attempted, given that the disease is gen-
erally mild and self-limited. PCR and tissue culture methods are available.
Treatment 
Treatment is limited to symptom relief (e.g., with antihistamines, decongestants).
� CORONAVIRUSES
Microbiology 
Coronaviruses are pleomorphic, single-stranded RNA viruses. 
Epidemiology and Clinical Manifestations 
Coronaviruses often result in the common cold (accounting for 10–35% of 
cases) with symptoms similar to those caused by rhinoviruses.
• Compared with rhinoviruses, the incubation period for coronaviruses 
is slightly longer (3 days) and the duration of illness is slightly shorter 
(6–7 days).
• In 2002–2003, a coronavirus-induced severe acute respiratory syndrome 
(SARS) developed in >8000 pts in 28 countries (with 90% of cases in 
China and Hong Kong) and was associated with a ~9.5% case-fatality 
rate; no cases were reported in 2005–2009.
SECTION 7
704
Infectious Diseases
TABLE 110-2 ILLNESSES ASSOCIATED WITH RESPIRATORY VIRUSES
Frequency of Respiratory Syndromes
Virus
Most Frequent
Occasional
Infrequent
Rhinoviruses
Common cold
Exacerbation of 
chronic bronchitis 
and asthma
Pneumonia in 
children
Coronavirusesa Common cold
Exacerbation of 
chronic bronchitis 
and asthma
Pneumonia and 
bronchiolitis
Human
respiratory 
syncytial virus
Pneumonia and 
bronchiolitis in 
young children
Common cold in 
adults
Pneumonia in 
elderly and immu-
nosuppressed pts
Parainfluenza 
viruses
Croup and lower 
respiratory tract 
disease in young 
children
Pharyngitis and 
common cold
Tracheobronchitis 
in adults; lower 
respiratory tract 
disease in immuno-
suppressed pts
Adenoviruses
Common cold 
and pharyngitis in 
children
Outbreaks of 
acute respiratory 
disease in military 
recruitsb
Pneumonia in 
children; lower 
respiratory tract 
and disseminated 
disease in immuno-
suppressed pts
Influenza A 
viruses
Influenzac
Pneumonia and 
excess mortality 
in high-risk pts
Pneumonia in 
healthy individuals
Influenza B 
viruses
Influenzac
Rhinitis or phar-
yngitis alone
Pneumonia
Enteroviruses
Acute undiffer-
entiated febrile 
illnessesd
Rhinitis or phar-
yngitis alone
Pneumonia
Herpes sim-
plex viruses
Gingivostomatitis 
in children; pha-
ryngotonsillitis in 
adults
Tracheitis and 
pneumonia in 
immunocompro-
mised pts
Disseminated 
infection in immu-
nocompromised pts
Human
metapneumo-
viruses
Upper and lower 
respiratory tract 
disease in children
Upper respiratory 
tract illness in 
adults
Pneumonia in 
elderly and immu-
nosuppressed pts
aSARS-associated coronavirus (SARS-CoV) caused epidemics of pneumonia from November 
2002 to July 2003 (see text).
bSerotypes 4 and 7.
cFever, cough, myalgia, malaise.
dMay or may not have a respiratory component.
CHAPTER 110 
705
Influenza and Other Viral Respiratory Diseases 
– SARS has an incubation period of 2–7 days, after which pts develop 
fever, malaise, headache, myalgias, and then (1–2 days later) a nonpro-
ductive cough and dyspnea. 
– Respiratory function may worsen in the second week of illness and 
can progress to ARDS and multiorgan dysfunction.
Diagnosis
Laboratory diagnosis of coronavirus-induced colds is rarely required, but 
ELISA, immunofluorescence, and RT-PCR assays can detect the virus in 
clinical specimens.
• The coronavirus associated with SARS (SARS-CoV) can be detected by 
RT-PCR or viral culture from respiratory samples and serum early in ill-
ness and from urine and stool later on. 
• SARS is also associated with lymphopenia (mostly CD4+ cells) in 50% of 
cases.
Coronaviruses
TREATMENT
• For the common cold, no treatment beyond symptom relief is gener-
ally needed.
• For SARS, aggressive supportive care is most important. No specific 
therapy (e.g., ribavirin, glucocorticoids) has been established as 
efficacious.
� HUMAN RESPIRATORY SYNCYTIAL VIRUS
Microbiology 
Human respiratory syncytial virus (HRSV) is an enveloped, single-stranded 
RNA virus and a member of the family Paramyxoviridae. 
Epidemiology 
With an attack rate approaching 100% among susceptible individuals, 
HRSV is a major respiratory pathogen among young children (particularly 
those 2–3 months of age) and the foremost cause of lower respiratory dis-
ease among infants. 
• HRSV accounts for 20–25% of hospital admissions of young children for 
pneumonia and for up to 75% of cases of bronchiolitis in this age group. 
• The virus is transmitted efficiently via contact with contaminated fingers or 
fomites and by spread of coarse aerosols. The incubation period is ~4–6 days.
Clinical Manifestations 
Infants typically develop rhinorrhea, low-grade fever, cough, and wheezing; 
20–40% of infections result in lower tract disease, including pneumonia, 
bronchiolitis, and tracheobronchitis.
• In adults, HRSV typically presents as the common cold, but it can cause 
lower respiratory tract disease with fever, including severe pneumonia in 
elderly or immunosuppressed pts. HRSV pneumonia has a case-fatality 
rate of 20–80% among transplant pts.
SECTION 7
706
Infectious Diseases
Diagnosis
Rapid viral diagnosis is available by immunofluorescence, ELISA, or 
RT-PCR of nasopharyngeal washes, aspirates, or (less satisfactorily) swabs.
Human Respiratory Syncytial Virus
TREATMENT
• Treatment is symptom-based for upper tract disease and mild lower 
tract disease. 
• For severe lower tract disease, intubation and ventilatory assistance 
should be given as needed.
– Aerosolized ribavirin has a demonstrated modest beneficial effect 
for infants with severe HRSV pneumonia, but its efficacy in older 
children and adults (including immunocompromised pts) has not 
been established.
– No benefit has been found in any pt population for IV immunoglob-
ulin (IVIg), immunoglobulin with high titers of antibody to HRSV 
(RSVIg), or a monoclonal IgG antibody to HRSV (palivizumab).
Prevention
Monthly administration of palivizumab is approved for prophylaxis in children 
<2 years of age who have bronchopulmonary dysplasia or cyanotic heart disease 
or who were born prematurely. In settings with high transmission rates (e.g., 
pediatric wards), contact precautions are useful to limit spread of the virus.
� HUMAN METAPNEUMOVIRUS
Microbiology 
Human metapneumovirus (HMPV) is a pleomorphic, single-stranded RNA 
virus of the family Paramyxoviridae. 
Epidemiology 
HMPV accounts for 1–5% of childhood upper respiratory tract infections 
and for 2–4% of acute respiratory illnesses in ambulatory adults. 
Clinical Manifestations 
Disease manifestations are similar to those caused by HRSV. 
Diagnosis
Diagnosis is made by immunofluorescence, PCR, or tissue culture of nasal 
aspirates or respiratory secretions. 
Treatment 
Treatment is primarily supportive and symptom-based.
� PARAINFLUENZA VIRUS
Microbiology and Epidemiology 
This enveloped, single-stranded RNA virus of the family Paramyxoviridae 
ranks second only to HRSV as a cause of lower respiratory tract disease 
CHAPTER 110 
707
Influenza and Other Viral Respiratory Diseases 
among young children and is the most common cause of croup (laryngo-
tracheobronchitis). 
Clinical Manifestations 
Infections are milder among older children and adults, but severe, pro-
longed, and fatal infection has been reported among pts with severe immu-
nosuppression, including transplant recipients. 
Diagnosis
Tissue culture, rapid testing with immunofluorescence or ELISA (both 
of which are less sensitive), or PCR of respiratory tract secretions, throat 
swabs, or nasopharyngeal washings can detect the virus. 
Treatment 
Treatment of upper respiratory tract disease is symptom-based. Humidified 
air may be helpful for mild cases of croup. 
• For cases of croup with respiratory distress, intermittent racemic 
epinephrine and glucocorticoids are beneficial.
• Anecdotal reports describe the use of ribavirin (particularly in immuno-
suppressed pts), but its clinical utility is still unclear.
� ADENOVIRUSES
Microbiology and Epidemiology 
Adenoviruses are double-stranded DNA viruses that cause ~10% of acute 
respiratory infections among children and <2% of respiratory illnesses 
among civilian adults. Some serotypes are associated with outbreaks among 
military recruits. Transmission takes place primarily from fall to spring via 
inhalation of aerosolized virus, through inoculation of the conjunctival 
sacs, and probably via the fecal-oral route.
Clinical Manifestations 
In children, adenovirus causes acute upper and lower respiratory tract 
infections and outbreaks of pharyngoconjunctival fever (a syndrome of 
fever, bilateral conjunctivitis, sore throat, and cervical adenopathy typically 
due to types 3 and 7).
• In adults, adenovirus types 4 and 7 cause an acute respiratory disease 
consisting of a prominent sore throat, fever on the second or third day of 
illness, cough, coryza, and regional adenopathy. Pharyngeal edema and 
tonsillar hypertrophy with little or no exudate may be seen.
• In addition to respiratory disease, adenovirus can cause diarrheal illness, 
hemorrhagic cystitis, and epidemic keratoconjunctivitis. In pts who have 
received a solid-organ transplant, adenovirus can affect the transplanted 
organ and disseminate to other organs.
Diagnosis
Definitive diagnosis can be made by isolation of the virus in tissue culture; 
by rapid testing (with immunofluorescence or ELISA) of nasopharyngeal 
aspirates, conjunctival or respiratory secretions, urine, or stool; or by PCR 
testing.
SECTION 7
708
Infectious Diseases
Treatment 
Treatment is supportive. Ribavirin and cidofovir exhibit in vitro activity 
against adenovirus and therefore are used occasionally in disseminated 
adenovirus infections, but definitive efficacy data are not available.
 For a more detailed discussion, see Baden LR, Dolin R: Antiviral 
Chemotherapy, Excluding Antiretroviral Drugs, Chap. 178,
p. 1442; Dolin R: Common Viral Respiratory Infections, 
Chap. 186, p. 1485; and Dolin R: Influenza, Chap. 187, p. 1493, 
in HPIM-18.
CHAPTER 111
Rubeola, Rubella, Mumps, 
and Parvovirus Infections
� MEASLES (RUBEOLA)
Definition and Microbiology 
Measles is a highly contagious disease that is characterized by a prodromal 
illness of fever, cough, coryza, and conjunctivitis followed by a generalized 
maculopapular rash. Measles is caused by a nonsegmented, single-stranded, 
negative-sense RNA virus of the genus Morbillivirus and the family 
Paramyxoviridae.
Epidemiology 
Humans are the only reservoir for measles virus; unvaccinated infants who 
have lost maternal antibodies account for the bulk of susceptible individuals. 
However, as measles vaccine coverage increases, the age distribution of the 
disease shifts upward: in the United States, adolescents and adults are the 
most likely age groups to acquire measles. 
• Routine administration of the measles vaccine has markedly reduced 
worldwide mortality due to measles; in 2008, there were ~164,000 deaths. 
• Pts are contagious for several days before and after the rash appears. The 
virus is spread primarily via respiratory droplets over short distances. 
Secondary attack rates among susceptible contacts are >90%.
Clinical Manifestations 
Approximately 10 days after infection with measles virus, pts develop fever 
and malaise, followed by cough, coryza, and conjunctivitis; the characteristic 
rash occurs 14 days after infection.
• An erythematous, nonpruritic, maculopapular rash begins at the hair-
line and behind the ears, spreads down the trunk and limbs to include 
the palms and soles, can become confluent, and begins to fade (in the 
same order of progression) by day 4.
CHAPTER 111 
709
Rubeola, Rubella, Mumps, and Parvovirus
• Koplik’s spots are pathognomonic for measles and consist of bluish-white 
dots ~1 mm in diameter surrounded by erythema. They appear on the buccal 
mucosa ~2 days before the rash appears and fade with the onset of rash.
• Pts with impaired cellular immunity may not develop a rash and have a 
higher case-fatality rate than those with intact immunity.
• Complications include giant-cell pneumonitis, secondary bacterial infec-
tion of the respiratory tract (e.g., otitis media, bronchopneumonia), and 
CNS disorders.
 
–  Postmeasles encephalitis occurs within 2 weeks of rash onset in ~1 
in 1000 cases and is characterized by fever, seizures, and a variety of 
neurologic abnormalities.
 
–  Measles inclusion-body encephalitis (MIBE) and subacute sclerosing 
panencephalitis (SSPE) occur months to years after acute infection 
and are caused by persistent measles virus infection.
• MIBE is a fatal complication that primarily affects pts with defects 
in cellular immunity. 
• SSPE is a progressive disease characterized by seizures and 
deterioration of cognitive and motor functions, with death occurring 
5–15 years after measles virus infection.
Diagnosis
The characteristic rash and pathognomonic Koplik’s spots permit a clinical 
diagnosis. 
• Serologic testing is the most common method of laboratory diagnosis. 
Measles-specific IgM is usually detectable within 1–3 days of rash onset.
• Viral culture and reverse-transcription PCR analysis of clinical speci-
mens are used occasionally to detect measles.
Measles
TREATMENT
• Supportive care is the mainstay of treatment, as there is no specific 
antiviral therapy for measles. Prompt antibiotic therapy for pts with 
secondary bacterial infections helps reduce morbidity and mortality 
risks.
• Vitamin A (for children ≥12 months: 200,000 IU daily for 2 days) 
is recommended by the World Health Organization (WHO) for all 
children with measles. 
Prevention
In the U.S., children are routinely immunized with two doses of a live atten-
uated vaccine containing measles, mumps, and rubella (MMR) antigens. 
• Vaccine-induced immunity lasts for at least several decades; rates of 
secondary vaccine failure 10–15 years after immunization are ~5%. In 
contrast, natural infection leads to life-long immunity.
• Administration of immunoglobulin within 6 days of exposure, which can 
prevent or modify the disease in immunocompetent persons, is recom-
mended for children <1 year old, immunocompromised pts, and pregnant 
SECTION 7
710
Infectious Diseases
women. A dose of 0.25 mL/kg is given to healthy pts and a dose of 0.5 mL/kg 
to immunocompromised hosts, with a maximal dose of 15 mL.
� RUBELLA (GERMAN MEASLES)
Microbiology and Epidemiology 
Rubella is a contagious infectious disease caused by a single-stranded, 
enveloped RNA virus in the family Togaviridae and the genus Rubivirus. 
• In 2007, there were ~165,000 cases of rubella worldwide, although this 
figure is probably an underestimate because of poor reporting. Since 
2004, rubella has not been an endemic disease in the U.S.
• Virus is spread via respiratory droplets, and primary implantation and 
replication occur in the nasopharynx. Placental infection can lead to 
chronic infection of virtually all fetal organs, which sometimes persists 
for up to 1 year after birth. 
Clinical Manifestations 
While acquired rubella infection is generally benign, congenital rubella 
infection can be more severe.
• Acquired infection: With an incubation period of 14 days, acquired 
rubella is characterized by a generalized maculopapular rash that lasts 
for ≤3 days; ~50% of infections are subclinical. 
 
–  Occipital and/or postauricular lymphadenopathy may occur during 
the second week after exposure.
 
–  In older children and adults, the rash may be preceded by a 1- to 5-day 
prodrome consisting of low-grade fever, malaise, and upper respira-
tory symptoms.
 
–  Arthralgias and arthritis are common among adults, particularly women.
• Congenital infection: Congenital rubella infection can lead to a number 
of physical defects, usually involving the eyes (e.g., cataracts), ears 
(e.g., deafness), and heart (e.g., pulmonary arterial stenosis).
 
–  Up to 90% of women infected with rubella virus during the first 
11 weeks of pregnancy will deliver an infant with congenital rubella.
 
–  The congenital rubella rate is 20% for maternal infections acquired 
during the first 20 weeks of pregnancy.
Diagnosis
Given the difficulty of diagnosing rubella clinically, serologic testing (for the 
presence of IgM or a ≥4-fold rise in IgG titer) is generally used for diagnosis. 
• If the IgM sample taken within the first 4 days of rash is negative but 
clinical suspicion remains, testing should be repeated; IgM antibody 
titers are generally positive for up to 6 weeks.
• Congenital rubella can be diagnosed by detection of IgM antibodies, 
although titers may be negative during the first month; by isolation of the 
virus from throat swabs, urine, or CSF; and/or by an IgG titer that does 
not decline at the expected rate of a twofold dilution per month. 
• In the U.S., screening of pregnant women for rubella IgG antibodies is 
part of routine prenatal care; seronegative women should be vaccinated 
postpartum.
CHAPTER 111 
711
Treatment 
Symptom-based treatment for various manifestations, such as fever and 
arthralgia, is appropriate. No rubella-specific therapies are available. 
Prevention
As of 2008, 66% of countries holding membership in the WHO had recom-
mended inclusion of a rubella-containing vaccine in the routine childhood 
vaccination schedule. One dose induces seroconversion in ≥95% of persons 
>1 year of age and provides long-term (potentially life-long) immunity.
• Pregnant women should not receive the vaccine, and pregnancy should 
be avoided for at least 28 days after vaccination. 
• Immunoglobulin does not prevent rubella virus infection after exposure 
and therefore is not recommended as routine postexposure prophylaxis.
� MUMPS
Definition and Microbiology 
Mumps is an acute systemic communicable viral infection whose most 
distinctive feature is swelling of one or both parotid glands. It is caused by 
mumps virus, a negative-strand nonsegmented RNA paramyxovirus.
Epidemiology 
The estimated annual global incidence of mumps is 100–1000 cases per 
100,000 population in countries without national mumps vaccination 
programs. In the U.S., there were <300 cases in 2001 because levels of child-
hood vaccination are high.
• The incubation period of mumps is ~19 days, and humans are the only 
natural hosts.
• Mumps virus is transmitted by respiratory secretions and fomites. Pts are 
contagious from 1 week before to 1 week after symptom onset and are 
most contagious 1–2 days before symptom onset.
Clinical Manifestations 
Up to half of infections are asymptomatic or lead to nonspecific respira-
tory symptoms. Unilateral or bilateral parotitis lasting >2 days is present in 
70–90% of symptomatic infections.
• A prodrome involving low-grade fever, malaise, myalgia, headache, and 
anorexia may precede the development of parotitis and last for 1–7 days.
 
–  Pts with parotitis typically have difficulty eating, swallowing, and/or 
talking and may have an earache.
 
–  Glandular swelling disappears within 1 week.
• Epididymo-orchitis is the second most common manifestation of 
mumps, developing in 15–30% of cases in postpubertal males.
 
–  Orchitis, characterized by a painful, tender, and enlarged testis, is 
bilateral in 10–30% of cases and resolves within 1 week.
 
–  Oophoritis (manifested by lower abdominal pain and vomiting) 
occurs in ~5% of women with mumps.
 
–  Sterility after mumps is rare.
Rubeola, Rubella, Mumps, and Parvovirus
SECTION 7
712
Infectious Diseases
• Symptomatic CNS disease (e.g., aseptic meningitis) occurs in <10% of 
pts and is usually self-limited.
 
–  In CSF pleocytosis, neutrophils often predominate in the first 24 h 
before being replaced by lymphocytes on the second day.
 
–  Cranial nerve palsies occasionally lead to permanent sequelae, par-
ticularly deafness.
• Other, less common manifestations of mumps include pancreatitis, 
myocarditis, thyroiditis, nephritis, and arthritis. Mumps in pregnancy 
does not appear to lead to premature birth, low birth weight, or fetal 
malformations.
Diagnosis
Laboratory diagnosis is generally based on detection of viral antigens or 
RNA in clinical samples (e.g., throat swab, CSF, urine, seminal fluid) via 
immunofluorescence or reverse-transcription PCR. Serologic assays are of 
limited utility since IgM is detected in <20% of cases in immunized pts and 
IgG titers often exhibit little fluctuation between acute- and convalescent-
phase samples.
Treatment 
Mumps is generally a benign, self-resolving illness in which symptom-
based and supportive therapies are most helpful.
Prevention
Current U.S. recommendations are for a two-dose vaccination schedule, with 
the first dose at ≥1 year old and the second dose at least 1 month after the first. 
Outbreaks, such as those occurring in 2006 in the U.S., the United Kingdom, 
and Canada, demonstrate that vaccine-induced immunity is not life-long.
� PARVOVIRUS INFECTION
Microbiology 
Parvovirus B19 (B19V), a nonenveloped single-strand DNA virus of the 
family Parvoviridae, is the only member of this family shown definitively 
to be a human pathogen.
Epidemiology 
B19V exclusively infects humans, is endemic worldwide, and is transmitted 
via the respiratory route. By the age of 15 years, ≥50% of children are sero-
positive. Of elderly pts, >90% have detectable antibody.
Pathogenesis 
B19V replicates in erythroid progenitors, which are among the few cells that 
express the B19V receptor, blood group P antigen (globoside). Infection 
leads to high-titer viremia and arrest of erythropoiesis. When an IgM and 
IgG antibody response is mounted, normal erythropoiesis resumes. 
Clinical Manifestations 
Most B19V infections are asymptomatic or are associated with only a mild 
nonspecific illness.
CHAPTER 111 
713
• Erythema infectiosum (fifth disease): The main manifestation of symptom-
atic B19V disease, erythema infectiosum presents as a low-grade fever 
~7–10 days after exposure and a facial “slapped-cheek” rash (more common 
among children) a few days later. Two or three days after the facial rash 
develops, a lacy, reticular macular rash may spread to the extremities.
• Polyarthropathy syndrome: Arthralgias, typically symmetric and affect-
ing the small joints of the hands and occasionally the ankles, knees, and 
wrists, occur in ~50% of adults (more commonly women). Most cases 
resolve in a few weeks, but some persist for months.
• Transient aplastic crisis (TAC): Pts with chronic hemolytic conditions 
(e.g., hemoglobinopathies, autoimmune hemolytic anemia) can develop 
aplastic crisis with B19V infection that can be life-threatening. Pts dis-
play symptoms associated with severe anemia.
• Pure red-cell aplasia/chronic anemia: Immunosuppressed pts can develop 
persistent anemia with reticulocytopenia, high levels of B19V DNA in 
serum, and absent or low levels of B19V IgG. B19V occasionally causes a 
hemophagocytic syndrome.
• Hydrops fetalis: B19V infection during pregnancy can lead to hydrops 
fetalis and/or fetal loss. The risk of transplacental fetal infection is ~30%, 
and the risk of fetal loss (which occurs predominantly early in the second 
trimester) is ~9%. The risk of congenital infection is <1%.
Diagnosis
Diagnosis in immunocompetent pts generally relies on detection of B19V-
specific IgM antibodies, which can be detected coincident with the rash in 
erythema infectiosum or by day 3 of TAC. 
• B19V-specific IgG is detectable by the seventh day of illness and persists 
for life.
• Detection of B19V DNA via quantitative PCR should be used to diagnose 
early TAC or chronic anemia. In acute infection, the viremia load can 
be >1012 B19V DNA IU/mL of serum; pts with TAC or chronic anemia 
generally have >105 B19V IU/mL. 
Parvovirus Infection
TREATMENT
• Treatment of B19V infection is generally supportive as no specific 
therapy exists. TAC should be treated with transfusions as needed. 
• In pts receiving immunosuppressive agents, treatment should be 
reduced to the extent feasible to allow an immune response. IV immu-
noglobulin (400 mg/kg daily for 5–10 days) may cure or ameliorate 
persistent B19V infection in immunosuppressed pts. 
For a more detailed discussion, see Brown KE: Parvovirus 
Infections, Chap. 184, p. 1478; Moss WJ: Measles (Rubeola), 
Chap. 192, p. 1600; Zimmerman LA, Reef SE: Rubella 
(German Measles), Chap. 193, p. 1605; and Rubin S, 
Carbone KM: Mumps, Chap. 194, p. 1608, in HPIM-18.
Rubeola, Rubella, Mumps, and Parvovirus
SECTION 7
714
Infectious Diseases
CHAPTER 112
Enteroviral Infections
� MICROBIOLOGY
• Enteroviruses are so named because of their ability to multiply in the GI 
tract, but they do not typically cause gastroenteritis. 
• Enteroviruses encompass 96 human serotypes: 3 serotypes of poliovirus, 
21 serotypes of coxsackievirus A, 6 serotypes of coxsackievirus B, 
28 serotypes of echovirus, enteroviruses 68–71, and 34 new enteroviruses 
(beginning with enterovirus 73) that have been identified by molecular 
techniques. In the United States, coxsackievirus B1 and echoviruses 18, 
9, and 6 account for ~50% of all enteroviral infections.
� PATHOGENESIS 
• Studies of poliovirus infection form the basis of our understanding of 
enteroviral pathogenesis. 
• After ingestion, poliovirus infects GI tract mucosal epithelial cells, spreads 
to regional lymph nodes, causes viremia, and replicates in the reticuloen-
dothelial system; in some cases, a second round of viremia occurs. 
• Virus gains access to the CNS either via the bloodstream or via direct 
spread from neural pathways. 
• Virus is present in blood for 3–5 days. It is shed from the oropharynx for 
up to 3 weeks and from the GI tract for up to 12 weeks after infection; 
hypogammaglobulinemic pts can shed virus for up to 20 years. 
• Infection is controlled by humoral and secretory immunity in the GI 
tract.
� EPIDEMIOLOGY
• Enteroviruses cause disease worldwide, especially in areas with crowded 
conditions and poor hygiene. 
• Infants and young children are most often infected and are the most 
frequent shedders. 
• Transmission takes place mainly by the fecal-oral route, but airborne 
transmission and placental transmission have been described. 
• The incubation period ranges from 2 to 14 days but usually is <1 week 
in duration. Pts are most infectious shortly before and after the onset of 
symptoms.
� CLINICAL MANIFESTATIONS
Poliovirus 
After an incubation period of 3–6 days, ~5% of pts present with a minor 
illness (abortive poliomyelitis) characterized by fever, malaise, sore throat, 
myalgias, and headache that usually resolves within 3 days.
• Asymptomatic infection: >90% of all infections 
• Aseptic meningitis (nonparalytic poliomyelitis): occurs in ~1% of pts. 
Examination of CSF reveals normal glucose and protein concentrations and 
lymphocytic pleocytosis (with PMNs sometimes predominating early).
CHAPTER 112
715
Enteroviral Infections
• Paralytic disease: the least common form; presents ≥1 day after aseptic 
meningitis as severe back, neck, and muscle pain as well as a gradual 
development of motor weakness. 
 
–  The weakness is usually asymmetric and proximal and is most com-
mon in the legs; the arms and the abdominal, thoracic, and bulbar 
muscles are other frequently involved sites. 
 
–  Paralysis generally occurs only during the febrile phase. 
 
–  Physical examination reveals weakness, fasciculations, decreased 
muscle tone, and reduced or absent reflexes in affected areas; hyper-
reflexia may precede the loss of reflexes. Bulbar paralysis is associated 
with dysphagia, difficulty handling secretions, or dysphonia. 
 
–  Respiratory insufficiency due to aspiration or neurologic involvement 
may develop. Severe medullary infection may lead to circulatory 
collapse. 
 
–  Most pts recover some function, but around two-thirds have residual 
neurologic sequelae.
• Vaccine-associated poliomyelitis: The risk of acquiring poliomyelitis 
after vaccination with the live oral vaccine is estimated to be 1 case per 
2.5 million doses and is ~2000 times higher among immunodeficient 
persons.
• Postpolio syndrome: new weakness 20–40 years after poliomyelitis. Onset 
is insidious, progression is slow, and plateau periods can last 1–10 years.
Other Enteroviruses 
In the United States, 5–10 million cases of symptomatic enteroviral disease 
other than poliomyelitis occur each year. More than 50% of nonpoliovirus 
enteroviral infections are subclinical.
• Nonspecific febrile illness (summer grippe): Pts present with acute-onset 
fever, malaise, and headache, with occasional upper respiratory symptoms. 
 
–  Disease resolves within a week. 
 
–  Disease frequently occurs during the summer and early fall. 
• Generalized disease of the newborn: Neonates, typically within the first 
week of life, present with an illness resembling bacterial sepsis, with 
fever, irritability, and lethargy. 
 
–  Myocarditis, hypotension, hepatitis, DIC, meningitis, and pneumonia 
are complications. 
 
–  A history of a recent flu-like illness in the mother should prompt con-
sideration of this disease.
• Aseptic meningitis and encephalitis: Enteroviruses cause 90% of cases of 
aseptic meningitis among children and young adults in which an etiologic 
agent can be identified; 10–35% of cases of viral encephalitis are due to 
enteroviruses. 
 
–  Pts have an acute onset of fever, chills, headache, photophobia, nausea, 
and vomiting, with meningismus on examination. Diarrhea, rashes, 
myalgias, pleurodynia, myocarditis, and herpangina may occur. 
Encephalitis is much less common and is usually mild, with an excel-
lent prognosis in healthy hosts.
 
–  CSF examination reveals pleocytosis, with PMNs sometimes predomi-
nating early but a shift to lymphocyte predominance within 24 h. Total 
SECTION 7
716
Infectious Diseases
cell counts usually do not exceed 1000/μL. CSF glucose and protein 
levels are typically normal. 
 
–  Symptoms resolve within 1 week, but CSF abnormalities persist longer. 
• Pleurodynia (Bornholm disease): Pts have an acute onset of fever associ-
ated with spasms of pleuritic chest pain (more common among adults) 
or upper abdominal pain (more common among children) that typically 
last 15–30 min. Fever subsides when pain resolves. 
 
–  Coxsackievirus B is the most common cause. 
 
–  Disease lasts for a few days and can be treated with NSAIDs and heat 
application to the affected muscles.
• Myocarditis and pericarditis: Enteroviruses (e.g., coxsackievirus B) cause 
up to one-third of cases of acute myocarditis. Pts have upper respiratory 
symptoms followed by fever, chest pain, dyspnea, arrhythmias, and occa-
sionally heart failure. 
 
–  Disease occurs most often in newborns (who are most severely ill), 
adolescents, and young adults. 
 
–  A pericardial friction rub, ST-segment and T-wave abnormalities on 
electrocardiography, and elevated serum levels of myocardial enzymes 
can be present. 
 
–  Up to 10% of pts develop chronic dilated cardiomyopathy. 
• Exanthems: Enteroviral infection is the leading cause of exanthems 
among children in the summer and fall. Echoviruses 9 and 16 are com-
mon causes.
• Hand-foot-and-mouth disease: generally due to coxsackievirus A16 and 
enterovirus 71. Pts present with fever, anorexia, and malaise, which are 
followed by sore throat and vesicles on the buccal mucosa, tongue, and 
dorsum or palms of the hands and occasionally on the palate, uvula, 
tonsillar pillars, or feet. 
 
–  The disease is highly infectious, with attack rates of almost 100% 
among young children. Symptoms resolve within a week. 
 
–  A Taiwan epidemic of enterovirus 71 infection in 1998 was associated 
with CNS disease, myocarditis, and pulmonary hemorrhage. Deaths 
occurred primarily among children ≤5 years old.
• Herpangina: usually caused by coxsackievirus A infection. Pts develop 
fever, sore throat, odynophagia, and grayish-white papulovesicular 
lesions on an erythematous base that ulcerate and are concentrated in the 
posterior portion of the mouth. 
 
–  Lesions can persist for weeks. 
 
–  In contrast to herpes simplex stomatitis, enteroviral herpangina is not 
associated with gingivitis.
• Acute hemorrhagic conjunctivitis: associated with enterovirus 70 and 
coxsackievirus A24. Pts experience an acute onset of severe eye pain, 
blurred vision, photophobia, and watery eye discharge; edema, chemosis, 
and subconjunctival hemorrhage are evident. Symptoms resolve within 
10 days.
� DIAGNOSIS
• Enterovirus can be isolated from throat or rectal swabs, stool, and/or 
normally sterile body fluids. 
CHAPTER 112
717
Enteroviral Infections
 
–  Positive results for normally sterile body fluids, such as CSF and 
serum, reflect disease.
 
–  However, stool and throat cultures may simply reflect colonization. 
• In general, serotyping is not clinically useful. 
• PCR detects all serotypes that infect humans, with high sensitivity 
(70–100%) and specificity (>80%). 
 
–  PCR of CSF is less likely to be positive if pts present ≥3 days after 
meningitis onset or with enterovirus 71 infection. 
 
–  PCR of serum is also useful in disseminated disease. 
Enteroviral Infections
TREATMENT
• Most enteroviral illness resolves spontaneously, but immunoglobulin 
may be helpful in pts with γ globulin defects and chronic infection. 
• Glucocorticoids are contraindicated.
� PREVENTION AND ERADICATION
• Hand hygiene, use of gowns and gloves, and enteric precautions (for 
7 days after disease onset) prevent nosocomial transmission of enterovi-
ruses during epidemics. 
• The availability of poliovirus vaccines and the implementation of polio 
eradication programs have largely eliminated disease due to wild-type 
poliovirus; of 1781 cases in 2009, ~80% were from Nigeria, India, Pakistan, 
and Afghanistan. Outbreaks and sporadic disease due to vaccine-derived 
poliovirus occur. 
• Both oral poliovirus vaccine (OPV) and inactivated poliovirus vaccine 
(IPV) induce IgG and IgA antibodies that persist for at least 5 years. 
 
–  Most developing countries, particularly those with persistent wild-
type poliomyelitis, use OPV because of its lower cost and ease of 
administration. 
 
–  The suboptimal seroconversion rate among children in low-income 
countries, even after multiple doses of OPV, contributes to difficulties 
in eradication.
• Most industrialized countries have adopted all-IPV childhood vaccina-
tion programs. 
 
–  Unvaccinated adults in the United States do not need routine polio-
virus vaccination, but should receive three doses of IPV (the second 
dose 1–2 months after the first and the final dose 6–12 months later) 
if they are traveling to polio-endemic areas or might be exposed to 
wild-type poliovirus in their communities or workplaces. 
 
–  Adults at increased risk of exposure who have received their primary 
vaccination series should receive a single dose of IPV.
For a more detailed discussion, see Cohen JI: Enteroviruses 
and Reoviruses, Chap. 191, p. 1593, in HPIM-18.
SECTION 7
718
Infectious Diseases
CHAPTER 113
Insect- and Animal-Borne 
Viral Infections
� RABIES
Microbiology 
Rabies is a zoonosis generally transmitted to humans by the bite of a rabid 
animal and caused by rabies virus—a nonsegmented, negative sense, single-
stranded RNA virus in the family Rhabdoviridae. Each animal reservoir 
harbors distinct rabies virus variants.
Epidemiology 
Worldwide, canine rabies causes ~55,000 human deaths each year, most of 
them in Asia and Africa. 
• Endemic canine rabies has been eliminated in the United States and most 
other resource-rich countries but persists in bats, raccoons, skunks, and 
foxes. In 2008, there were 6841 confirmed animal cases of rabies in the U.S.
• Bats (especially silver-haired and eastern pipistrelle bats) cause most 
human cases in North America, although there may be no known history 
of a bat bite or other bat exposure.
Pathogenesis 
The incubation period can range from a few days to >1 year but is usually 
20–90 days. During most of this period, rabies virus is present at or close 
to the site of the bite. 
• The virus binds to postsynaptic nicotinic acetylcholine receptors and 
spreads centripetally along peripheral nerves toward the CNS at a 
rate up to ~250 mm/d. Establishment of CNS infection is followed by 
centrifugal spread along peripheral nerves to other tissues, including 
salivary glands—hence the excretion of virus in the saliva of rabid 
animals. 
• The most characteristic pathologic CNS finding is the Negri body—an 
eosinophilic cytoplasmic inclusion that is composed of rabies virus pro-
teins and viral RNA and is found primarily within Purkinje cells of the 
cerebellum and in pyramidal neurons of the hippocampus.
Clinical Manifestations 
Rabies usually presents as atypical encephalitis with preservation of con-
sciousness; the disease may be difficult to recognize after the onset of coma. 
This disease, which usually leads to death despite aggressive therapy, has 
three phases.
• Prodrome: Pts have fever, headache, malaise, nausea, vomiting, and 
anxiety or agitation lasting 2–10 days. Paresthesias, pain, or pruritus near 
CHAPTER 113
719
Insect- and Animal-Borne Viral Infections 
the site of exposure (which has usually healed at this point) is found in 
50–80% of cases and strongly suggests rabies.
• Acute neurologic phase: Pts present with the encephalitic (furious) form 
of rabies in 80% of cases and with the paralytic form in 20%.
 
–  Encephalitic form: Pts develop symptoms common to other viral 
encephalitides (e.g., fever, confusion, hallucinations, combativeness, 
and seizures) that last 2–10 days. Autonomic dysfunction is common 
and includes hypersalivation, gooseflesh, cardiac arrhythmia, and/or 
priapism. 
• A distinguishing feature of rabies is prominent early brainstem 
dysfunction resulting in hydrophobia and aerophobia (involuntary, 
painful contraction of the diaphragm and the accessory respiratory, 
laryngeal, and pharyngeal muscles in response to swallowing liquid 
or exposure to a draft of air). 
• Hypersalivation and pharyngeal dysfunction produce characteristic 
foaming at the mouth.
• Death usually occurs within days of brainstem involvement. With 
aggressive supportive care, late complications include cardiopulmo-
nary failure, disturbances of water balance (syndrome of inappro-
priate antidiuretic hormone secretion or diabetes insipidus), and GI 
hemorrhage.
 
–  Paralytic form: For unknown reasons, muscle weakness predominates 
but cardinal features of rabies encephalitis (hyperexcitability, hydro-
phobia, aerophobia) are lacking. Muscle weakness usually begins in 
the bitten extremity and proceeds to quadriparesis.
• Coma and death: Even with aggressive supportive measures, recovery is 
rare. Death usually occurs within 2 weeks.
Diagnosis
In North America, the diagnosis is often considered relatively late in the 
clinical course. Rabies should be considered for pts with acute atypical 
encephalitis or acute flaccid paralysis (including those in whom Guillain-
Barré syndrome is suspected). 
• Most routine laboratory tests in rabies are normal or nonspecific; it is 
important to test for alternative, potentially treatable diagnoses. 
• Negative antemortem rabies-specific laboratory tests never exclude a 
diagnosis of rabies, and tests may need to be repeated after an interval 
for diagnostic confirmation. 
 
–  In a previously unimmunized pt, serum neutralizing antibodies to rabies 
virus are diagnostic, but these antibodies may not be present until late 
in the disease course. The presence of rabies virus–specific antibodies in 
CSF suggests rabies encephalitis, regardless of immunization status.
 
–  Reverse-transcription PCR (RT-PCR) can detect virus in fresh saliva 
samples, CSF, and skin and brain tissues.
 
–  Direct fluorescent antibody testing is highly sensitive and specific and 
can be applied to brain tissue or skin biopsy samples from the nape of 
the neck (where virus is found in cutaneous nerves at the base of hair 
follicles).
SECTION 7
720
Infectious Diseases
Rabies
TREATMENT
Management is palliative and supportive. There is no established treat-
ment for rabies.
Prevention
Rabies is almost uniformly fatal but is nearly always preventable with appro-
priate postexposure prophylaxis during the incubation period. Only 7 pts 
have survived infection with rabies virus, and only 1 of these pts had not 
received rabies vaccine before disease onset.
• An algorithm for rabies postexposure prophylaxis is depicted in Fig. 113-1.
 
–  Local wound care (e.g., thorough washing, debridement of devitalized 
tissue) can greatly reduce the risk of rabies.
 
–  All previously unvaccinated pts should receive human rabies immune 
globulin (RIG, 20 IU/kg; 40 IU/kg for equine RIG) no later than 7 days 
after the first vaccine dose. The entire dose should be infiltrated at the 
site of the bite; if not anatomically feasible, the residual RIG should be 
given IM at a distant site.
 
–  Inactivated rabies vaccine should be given as soon as possible (1 mL 
IM in the deltoid region) and repeated on days 3, 7, and 14 for pre-
viously unvaccinated pts; previously vaccinated pts require booster 
doses only on days 0 and 3.
• Preexposure prophylaxis is occasionally given to persons at high risk 
(including certain travelers to rabies-endemic areas). A primary vaccine 
schedule is given on days 0, 7, and 21 or 28.
� INFECTIONS CAUSED BY ARTHROPOD- AND RODENT-BORNE VIRUSES
Microbiology and Pathogenesis 
Most zoonotic viruses only incidentally infect and produce disease 
in humans; only a few agents are regularly spread among humans by 
arthropods. 
• The Arenaviridae, Bunyaviridae, and Flaviviridae—all RNA viruses—are 
among the major families of arthropod- and rodent-borne viruses. 
• Arthropod-borne viruses infect the vector after a blood meal from a 
viremic vertebrate; after spreading throughout the vector and ultimately 
reaching the salivary glands, the viruses can be transmitted to another 
vertebrate during a blood meal. 
• Humans become infected with rodent-borne viruses by inhalation of 
aerosols containing the viruses and through close contact with chroni-
cally infected rodents and their excreta.
Clinical Manifestations 
Infection is usually subclinical; when disease does occur, it generally does 
so in one of four occasionally overlapping clinical syndromes: fever and 
myalgia, encephalitis, arthritis and rash, or hemorrhagic fever (HF).
Fever and Myalgia This is the most common syndrome associated with 
zoonotic viruses. Typically, pts have an acute onset of fever, severe myalgia, 
CHAPTER 113
721
Insect- and Animal-Borne Viral Infections 
malaise, and headache. Complete recovery after 2–5 days of illness is usual. 
Important examples include the following.
• Lymphocytic choriomeningitis (LCM): This infection is transmitted from 
chronically infected mice and pet hamsters via aerosols of excreta and 
secreta. About one-fourth of infected pts have a 3- to 6-day febrile phase, 
a brief remission, and then recurrent fever, headache, nausea, vomiting, 
and meningeal signs lasting ~1 week. 
 
–  Other manifestations include transient alopecia, arthritis, pharyngitis, 
cough, maculopapular rash, and orchitis. 
 
–  Pregnant women can have mild infection yet pass on the virus to the 
fetus, who can develop hydrocephalus and chorioretinitis. 
FIGURE 113-1 Algorithm for rabies postexposure prophylaxis. RIG, rabies immune 
globulin. [From L Corey, in Harrison’s Principles of Internal Medicine, 15th ed. E 
Braunwald et al (eds): New York, McGraw-Hill, 2001, adapted with permission.]
Did the animal bite the patient
or did saliva contaminate a
scratch, abrasion, open wound,
or mucous membrane?
Rabies Prophylaxis
No
Yes
Is rabies known or suspected 
to be present in the species 
and the geographic area?
None
None
No
Yes
Was the animal captured?
RIG and vaccine
RIG and vaccine
No
Yes
Was the animal a normally
behaving dog, cat, or ferret?
Yes
Yes
No
No
Does laboratory examination of
the brain by fluorescent antibody
staining confirm rabies?
Yes
No
Does the animal
become ill under 
observation over
the next 10 days?
None
SECTION 7
722
Infectious Diseases
 
–  The diagnosis should be considered when an adult has aseptic men-
ingitis and any of the following: autumn seasonality, a well-marked 
febrile prodrome, a low CSF glucose level, or CSF mononuclear cell 
counts >1000/μL. 
 
–  LCM viremia is most likely in the initial febrile phase of illness. LCM 
can also be diagnosed by IgM-capture ELISA of serum or CSF or by 
RT-PCR of CSF.
• Dengue fever: The 4 serotypes of dengue viruses are all transmitted by the 
mosquito Aedes aegypti, which is also a vector for yellow fever. After an 
incubation period of 2–7 days, pts experience the sudden onset of fever, 
headache, retroorbital pain, back pain, severe myalgia (break-bone fever), 
adenopathy, palatal vesicles, and scleral injection. 
 
–  The illness usually lasts 1 week, and a maculopapular rash often 
appears near the time of defervescence. 
 
–  A second infection with a different dengue serotype can lead to dengue 
hemorrhagic fever (DHF; see “Hemorrhagic Fever,” below). 
 
–  The diagnosis is made by IgM ELISA or paired serologic tests during 
recovery or by antigen-detection ELISA or RT-PCR during the acute 
phase. Virus is easily isolated from blood during the acute phase 
by inoculation of mosquitoes or mosquito cell culture. Leukopenia, 
thrombocytopenia, and increased serum aminotransferase levels may 
be documented. 
Encephalitis Depending on the causative virus, there is much variability in 
the ratio of clinical to subclinical disease, the mortality rate, and residua 
(Table 113-1). The pt usually presents with a prodrome of nonspecific 
symptoms that is followed quickly by headache, meningeal signs, photo-
phobia, and vomiting; involvement of deeper structures leads to lethargy, 
cognitive deficits, focal neurologic signs, and coma. Acute encephalitis 
usually lasts from a few days to 2–3 weeks, and recovery may be slow and 
incomplete. Treatable causes of encephalitis (e.g., HSV) should be ruled 
out promptly. Some important examples of arboviral encephalitides follow.
• Japanese encephalitis: This infection is present throughout Asia and the 
western Pacific islands. Spinal and motor neuron disease can be docu-
mented in addition to encephalitis. An effective vaccine (ideally given 
on days 0, 7, and 30) is available and is indicated for summer travelers to 
rural Asia, where the risk can be as high as 2.1 cases per 10,000 per week. 
• West Nile encephalitis: Usually a mild or asymptomatic disease, West Nile 
virus infection can cause aseptic meningitis or encephalitis and is present 
throughout the Western Hemisphere. Encephalitis, serious sequelae, and 
death are more common among elderly pts, diabetic and hypertensive 
pts, and pts with previous CNS disease. Unusual clinical features include 
chorioretinitis and flaccid paralysis.
• Eastern equine encephalitis (EEE): EEE occurs primarily within endemic 
swampy foci along the eastern coast of the United States during the 
summer and early fall. EEE is one of the most severe arboviral diseases 
and is characterized by rapid onset, rapid progression, high mortality 
risk, and frequent residua. PMN-predominant pleocytosis of the CSF 
within the first 3 days of disease is common.
TABLE 113-1 PROMINENT FEATURES OF ARBOVIRAL ENCEPHALITIS
Virus
Natural Cycle
Incubation
Period, Days
Annual No. 
of Cases
Case-to-
Infection Ratio
Age of Cases
Case-Fatality
Rate, %
Residua
La Crosse
Aedes triseriatus–
chipmunk (transovarial 
component in mosquito 
also important)
~3–7
70 (U.S.)
<1:1000
<15 years
<0.5
Recurrent seizures 
in ~10%; severe 
deficits in rare cases; 
decreased school 
performance and 
behavioral change 
suspected in small 
proportion
St. Louis
Culex tarsalis,
C. pipiens, 
C. quinquefasciatus–
birds
4–21
85, with hundreds 
to thousands in 
epidemic years 
(U.S.)
<1:200
Milder cases in 
the young; more 
severe cases in 
adults >40 years 
old, particularly 
the elderly
7
Common in the 
elderly
Japanese
Culex tritaeniorhynchus–
birds
5–15
>25,000
1:200–300
All ages; children 
in highly endemic 
areas
20–50
Common (approxi-
mately half of cases); 
may be severe
West Nile
Culex mosquitoes–birds 3–6
?
Very low
Mainly the elderly
5–10
Uncommon
Central
European
Ixodes ricinus–rodents, 
insectivores
7–14
Thousands
1:12
All ages; milder in 
children
1–5
20%
(continued)
723
TABLE 113-1 PROMINENT FEATURES OF ARBOVIRAL ENCEPHALITIS (CONTINUED)
Virus
Natural Cycle
Incubation
Period, Days
Annual No. 
of Cases
Case-to-
Infection Ratio
Age of Cases
Case-Fatality
Rate, %
Residua
Russian spring-
summer
I. persulcatus–rodents, 
insectivores
7–14
Hundreds
—
All ages; milder in 
children
20
Approximately half of 
cases; often severe; 
limb-girdle paralysis
Powassan
I. cookei–wild mammals ~10
~1 (U.S.)
—
All ages; some 
predilection for 
children
~10
Common (approxi-
mately half of cases)
Eastern equine
Culiseta melanura–birds
~5–10
5 (U.S.)
1:40 (adult)
All ages; predilec-
tion for children
50–75
Common
1:17 (child)
Western equine
Culex tarsalis–birds
~5–10
~20 (U.S.)
1:1000 (adult)
1:50 (child)
1:1 (infant)
All ages; predilec-
tion for children 
<2 years old 
(increased
mortality among 
elderly)
3–7
Common only among 
infants <1 year old
Venezuelan 
equine (epi-
demic)
Unknown (multiple 
mosquito species and 
horses in epidemics)
1–5
?
1:250 (adult)
~1:25 (child)
All ages; predilec-
tion for children
~10
—
724
CHAPTER 113
725
Insect- and Animal-Borne Viral Infections 
Arthritis and Rash Alphaviruses are common causes of true arthritis accom-
panied by a febrile illness and maculopapular rash. Examples include the 
following.
• Sindbis virus: Found in northern Europe and the independent states of 
the former Soviet Union, this virus causes a maculopapular rash that 
often vesiculates on the trunk and extremities. The arthritis of this con-
dition is multiarticular, migratory, and incapacitating, with resolution of 
the acute phase in a few days; joint pains may persist for months or years. 
• Chikungunya virus: Found in rural Africa and Asia, this virus results 
in the abrupt onset of fever, severe arthralgias, migratory polyarthritis 
mainly affecting small joints, and a rash that begins coincident with 
defervescence at day 2–3 of illness. 
• Ross River virus: A cause of epidemic polyarthritis in Australia and the 
eastern Pacific Islands, this virus causes rash and persistent joint involve-
ment, typically in the absence of other constitutional symptoms. Because 
of joint pain, only ~50% and 10% of pts can resume normal activities at 
4 weeks and 3 months, respectively.
Hemorrhagic Fever The viral HF syndrome is a constellation of findings 
based on vascular instability and decreased vascular integrity. All HF syn-
dromes begin with the abrupt onset of fever and myalgia and can progress 
to severe prostration, headache, dizziness, photophobia, abdominal and/or 
chest pain, anorexia, and GI disturbances. On initial physical examination, 
there is conjunctival suffusion, muscular or abdominal tenderness to palpa-
tion, hypotension, petechiae, and periorbital edema. Laboratory examina-
tion usually reveals elevated serum aminotransferase levels, proteinuria, 
and hemoconcentration. Shock, multifocal bleeding, and CNS involvement 
(encephalopathy, coma, convulsions) are poor prognostic signs. Early 
recognition is important; appropriate supportive measures and, in some 
cases, virus-specific therapy can be instituted.
• Lassa fever: Endemic and epidemic in West Africa, Lassa fever, which is 
caused by a rodent-borne virus, has a more gradual onset than other HF 
syndromes. Bleeding is evident in 15–30% of cases. A maculopapular 
rash is often noted in light-skinned pts with Lassa fever.
 
–  Pregnant women have higher mortality rates, and the fetal death rate 
is 92% in the last trimester. 
 
–  Pts with high-level viremia or a serum aspartate aminotransferase 
level of >150 IU/mL are at an elevated risk of death, and the adminis-
tration of ribavirin (32 mg/kg IV × 1 dose, followed by 16 mg/kg q6h 
for 4 days and then 8 mg/kg q8h for 6 days), which appears to reduce 
this risk, should be considered. 
• South American HF syndromes (Argentine, Bolivian, Venezuelan, 
Brazilian): These syndromes resemble Lassa fever; however, thrombocy-
topenia, bleeding, and CNS dysfunction are common. 
 
–  Passive antibody treatment for Argentine HF is effective, and an effec-
tive vaccine exists. 
 
–  Ribavirin is likely to be effective in all South American HF syndromes.
• Rift Valley fever: Although Rift Valley fever virus typically causes fever 
and myalgia, HF can occur with prominent liver involvement, renal 
failure, and probably disseminated intravascular coagulation (DIC). 
SECTION 7
726
Infectious Diseases
 
–  Retinal vasculitis can occur in ~10% of otherwise mild infections, and 
pts’ vision can be permanently impaired. 
 
–  There is no proven therapy for Rift Valley fever. A live attenuated vac-
cine is in trials.
• HF with renal syndrome: This entity is most often caused in Europe by 
Puumala virus (rodent reservoir, the bank vole) and in Asia by Hantaan 
virus (rodent reservoir, the striped field mouse). 
 
–  Severe cases of HF with renal syndrome caused by Hantaan virus 
evolve in identifiable stages: the febrile stage with myalgia, lasting 3 or 
4 days; the hypotensive stage, often associated with shock and lasting 
from a few hours to 48 h; the oliguric stage with renal failure, lasting 
3–10 days; and the polyuric stage with diuresis and hyposthenuria.
 
–  Infections with Puumala virus result in a much-attenuated picture but 
the same general presentation.
 
–  IgM-capture ELISA is positive within 2 days of admission and con-
firms the diagnosis.
 
–  The mainstay of therapy is expectant management of shock and renal 
failure. Ribavirin may reduce rates of mortality and morbidity in 
severe cases if treatment is begun within the first 4 days of illness.
• Hantavirus pulmonary syndrome (HPS): After a prodrome of ~3–4 days, 
pts enter a cardiopulmonary phase marked by tachycardia, tachypnea, 
and mild hypotension. Over the next few hours, the illness may rapidly 
progress to severe hypoxemia and respiratory failure; the mortality rate 
is ~30–40% with good management. Pts surviving the first 2 days of 
hospitalization usually recover with no residua.
 
–  The disease is linked to rodent exposure. Sin Nombre virus infects the 
deer mouse and is the most important virus causing HPS in the United 
States.
 
–  Thrombocytopenia (an important early clue), hemoconcentration, 
proteinuria, and hypoalbuminemia are typical.
 
–  IgM testing of acute-phase serum may give positive results, even dur-
ing the prodromal stage, and can confirm the diagnosis. RT-PCR of 
blood clots or tissue usually gives a positive result in the first 7–9 days 
of illness.
 
–  Treatment is nonspecific and requires intensive respiratory manage-
ment and other supportive measures.
• Yellow fever: A former cause of major epidemics, yellow fever causes a 
typical HF syndrome with prominent hepatic necrosis, most commonly 
in urban South America and Africa . Pts are viremic for 3–4 days and can 
have jaundice, hemorrhage, black vomit, anuria, and terminal delirium. 
Vaccination of visitors to endemic areas and control of the mosquito vec-
tor A. aegypti prevent disease.
• Dengue hemorrhagic fever (DHF)/dengue shock syndrome (DSS): Previous 
infection with a heterologous dengue virus serotype may elicit non-
protective antibodies and enhanced disease if pts are reinfected. In 
mild cases, lethargy, thrombocytopenia, and hemoconcentration occur 
2–5 days after typical dengue fever, usually at the time of defervescence. 
In severe cases, frank shock occurs, with cyanosis, hepatomegaly, ascites 
and pleural effusions, and GI bleeding.
CHAPTER 113
727
Insect- and Animal-Borne Viral Infections 
 
–  The risk decreases considerably after age 12; DHF/DSS is more com-
mon among females than among males, more severe among whites 
than among blacks, and more common among well-nourished than 
among malnourished persons.
 
–  With good care, the overall mortality rate is as low as 1%. Control of 
A. aegypti, the mosquito vector, is the key to control of the disease.
� EBOLA AND MARBURG VIRUS INFECTIONS
Microbiology 
The family Filoviridae contains two genera, Marburgvirus and Ebolavirus, 
that consist of negative-sense, single-stranded RNA viruses. Ebolavirus has 
5 species named for their original site of recognition.
• With the exception of Reston virus (an Ebola virus), all Filoviridae are 
African viruses that cause severe disease with high mortality rates. 
• Both Marburg virus and Ebola virus are biosafety level 4 pathogens 
because of the high mortality rate from infection and the aerosol infec-
tivity of the agents.
Epidemiology 
Marburg virus was first identified in 1967; in 2004–2005, a Marburg virus 
epidemic occurred in Angola, with >250 cases and a case-fatality rate of 
90%. Ebola virus was first identified in 1976 and has been associated with 
several epidemics of severe HF; the mortality rate ranges from 50 to 90%, 
depending on the species. 
• Human-to-human transmission occurs, but epidemiologic studies have 
failed to yield evidence for an important role (like that documented in 
Ebola disease in monkeys) of airborne particles in human Ebola disease. 
• The reservoir is unknown, but speculation currently centers on bats.
Pathogenesis 
Both viruses replicate well in virtually all cell types, and viral replication 
is associated with cellular necrosis. Acute infection is associated with high 
levels of circulating virus and viral antigen. Fatal cases are associated with 
the lack of an antibody response, but clinical recovery is probably mediated 
by the cellular immune response since convalescent-phase plasma is not 
protective. 
Clinical Manifestations 
After a 7- to 10-day incubation period, pts experience an abrupt onset of 
fever, severe headache, myalgia, nausea, vomiting, diarrhea, prostration, 
and depressed mentation. 
• A maculopapular rash may appear at day 5–7 and is followed by des-
quamation. Bleeding may occur at this time and is apparent from any 
mucosal site and into the skin. 
• The fever may break after 10–12 days, and the pt may eventually recover. 
• Recrudescence and secondary bacterial infection may occur.
• Leukopenia is common early on and is followed by neutrophilia. 
Thrombocytopenia, transaminitis, and jaundice are common.
SECTION 7
728
Infectious Diseases
CHAPTER 114
HIV Infection and AIDS
� DEFINITION
AIDS was originally defined empirically by the Centers for Disease Control 
and Prevention (CDC) as “the presence of a reliably diagnosed disease that 
is at least moderately indicative of an underlying defect in cell-mediated 
immunity.” Following the recognition of the causative virus, HIV, and the 
development of sensitive and specific tests for HIV infection, the definition 
of AIDS has undergone substantial revision. The current surveillance defi-
nition categorizes HIV-infected persons on the basis of clinical conditions 
associated with HIV infection and CD4+ T lymphocyte counts (Tables 189-1, 
and 189-2, pp. 1506 and 1507, in HPIM-18). From a practical standpoint, 
the clinician should view HIV disease as a spectrum of disorders ranging 
from primary infection, with or without the acute HIV syndrome, to the 
asymptomatic infected state, to advanced disease.
� ETIOLOGY AND TRANSMISSION
AIDS is caused by infection with the human retroviruses HIV-1 or -2. 
HIV-1 is the most common cause worldwide. These viruses are passed 
through sexual contact; through transfusion of contaminated blood or 
blood products; through sharing of contaminated needles and syringes 
Diagnosis
High concentrations of virus in blood can be documented by antigen-
detection ELISA, virus isolation, or RT-PCR. Antibodies can be detected 
in recovering pts.
Ebola and Marburg Virus Infections
TREATMENT
• No virus-specific therapy is available, and supportive measures may 
not be as useful as had been hoped. 
• Studies in rhesus monkeys suggest that treatment with an inhibitor 
of factor VIIa/tissue factor or with activated protein C may improve 
survival rates.
• Barrier nursing precautions can greatly decrease the spread of 
filoviruses.
For a more detailed discussion, see Jackson AC: Rabies and 
Other Rhabdovirus Infections, Chap. 195, p. 1611; Peters 
CJ: Infections Caused by Arthropod- and Rodent-Borne 
Viruses, Chap. 196, p. 1617; and Peters CJ: Ebola and 
Marburg Viruses, Chap. 197, p. 1633, in HPIM-18.
CHAPTER 114
729
HIV Infection and AIDS
among injection drug users; intrapartum or perinatally from mother to 
infant; or via breast milk. There is no evidence that the virus can be passed 
through casual or family contact or by insects such as mosquitoes. There is a 
definite, though small, occupational risk of infection for health care workers 
and laboratory personnel who work with HIV-infected specimens. The risk 
of transmission of HIV from an infected health care worker to his or her pts 
through invasive procedures is extremely low.
� EPIDEMIOLOGY
As of January 1, 2010, an estimated 1,108,611 cumulative cases of AIDS 
had been diagnosed in the United States; there have been approximately 
600,000 deaths due to AIDS. However, the death rate from AIDS has 
decreased substantially in the past 10 years primarily due to the increased 
use of potent antiretroviral drugs. As of January 1, 2010, an estimated 1.1 
million HIV-infected persons were living in the United States; approxi-
mately 21% of these individuals are unaware that they are infected. An 
estimated 56,000 individuals are newly infected each year in the United 
States; this figure has remained stable for at least 15 years (Fig. 189-12, 
p. 1518, in HPIM-18). Among adults and adolescents newly diagnosed 
with HIV infection in 2009, ~76% were men and ~24% were women. Of 
new HIV/AIDS diagnoses among men, ~75% were due to male-to-male 
sexual contact, ~14% to heterosexual contact, and ~8% to injection drug 
use. Among women, ~85% were due to heterosexual contact and ~15% to 
injection drug use (Figs. 189-13 and 189-14, p. 1519, in HPIM-18). HIV 
infection/AIDS is a global pandemic, especially in developing countries. At 
the end of 2009, the estimated number of cases of HIV infection worldwide 
was ~33.3 million, two-thirds of which were in sub-Saharan Africa; ~50% 
of cases were in women and 2.5 million were in children. In 2009 there 
were 2.6 million new HIV infections worldwide and 1.8 million deaths 
(Fig. 189-10, p. 1517, in HPIM-18). 
� PATHOPHYSIOLOGY AND IMMUNOPATHOGENESIS
The hallmark of HIV disease is a profound immunodeficiency resulting 
from a progressive quantitative and qualitative deficiency of the subset of 
T lymphocytes referred to as helper T cells. This subset of T cells is defined 
phenotypically by the expression on the cell surface of the CD4 molecule, 
which serves as the primary cellular receptor for HIV. A co-receptor must 
be present with CD4 for efficient entry of HIV-1 into target cells. The two 
major co-receptors for HIV-1 are the chemokine receptors CCR5 and 
CXCR4. The CD4+ T lymphocyte and CD4+ monocyte lineage are the 
principal cellular targets of HIV. 
Primary Infection 
Following initial transmission, the virus infects CD4+ cells, probably T lym-
phocytes, monocytes, or bone marrow–derived dendritic cells. Both during 
this initial stage and later in infection, the lymphoid system is a major site 
for the establishment and propagation of HIV infection. The gut-associated 
lymphoid tissue (GALT) plays a major role in the establishment of infection 
and in the early depletion of memory CD4+ T cells.
SECTION 7
730
Infectious Diseases
Essentially all pts undergo a viremic stage during primary infection; 
in some pts this is associated with the “acute retroviral syndrome,” a 
mononucleosis-like illness (see below). This phase is important in dis-
seminating virus to lymphoid and other organs throughout the body, and 
it is ultimately contained partially by the development of an HIV-specific 
immune response.
Establishment of Chronic and Persistent Infection 
Despite the robust immune response that is mounted following primary 
infection, the virus is not cleared from the body. Instead, a chronic infection 
develops that persists for a median time of 10 years before the untreated 
pt becomes clinically ill. During this period of what appears to be clinical 
latency, the number of CD4+ T cells gradually declines, but few, if any, 
clinical signs and symptoms may be evident. However, active viral replica-
tion can almost always be detected by measurable plasma viremia and the 
demonstration of virus replication in lymphoid tissue. The level of steady-
state viremia (referred to as the viral set point) at ~6 months to 1 year post-
infection has important prognostic implications for the progression of HIV 
disease; individuals with a low viral set point at 6 months to 1 year after 
infection progress to AIDS more slowly than do those whose set point is 
very high at this time (Fig. 189-22, p. 1524, in HPIM-18).
Advanced HIV Disease 
In untreated pts or in pts in whom therapy has not controlled viral replica-
tion (see below), after some period of time (often years), CD4+ T cell counts 
will fall below a critical level (~200/μL) and pts become highly susceptible 
to opportunistic disease. The presence of a CD4+ T cell count of <200/μL 
or an AIDS-defining opportunistic disease establishes a diagnosis of AIDS. 
Control of plasma viremia by effective antiretroviral therapy, particularly 
maintaining the plasma viral load consistently at <50 copies of RNA per mL, 
even in individuals with low CD4+ T cell counts, has dramatically increased 
survival in these pts, including those whose CD4+ T cell counts may not 
increase significantly as a result of therapy.
� IMMUNE ABNORMALITIES IN HIV DISEASE
A broad range of immune abnormalities has been documented in HIV-
infected pts, resulting in varying degrees of immunodeficiency. These 
include both quantitative and qualitative defects in lymphocytes, and quali-
tative defects in monocyte/macrophage and natural killer (NK) cell func-
tion. Autoimmune phenomena also have been observed in HIV-infected 
individuals.
� IMMUNE RESPONSE TO HIV INFECTION
Both humoral and cellular immune responses to HIV develop soon after 
primary infection (see summary in Table 189-6, p. 1535, and Fig. 189-
26, p. 1536, in HPIM-18). Humoral responses include antibodies with 
HIV binding and neutralizing activity, as well as antibodies participating 
in antibody-dependent cellular cytotoxicity (ADCC). Cellular immune 
responses include the generation of HIV-specific CD4+ and CD8+ T 
CHAPTER 114
731
HIV Infection and AIDS
lymphocytes, as well as NK cells and mononuclear cells mediating ADCC. 
CD8+ T lymphocytes may also suppress HIV replication in a noncytolytic, 
non-MHC-restricted manner. This effect is mediated by soluble factors 
such as the CC-chemokines RANTES, MIP-1α, and MIP-1β. For the most 
part, the natural immune response to HIV is not adequate. Broadly react-
ing neutralizing antibodies against HIV are not easily generated in infected 
individuals, and eradication of the virus from infected individuals by natu-
rally occurring immune responses has not been reported.
� DIAGNOSIS OF HIV INFECTION
Laboratory diagnosis of HIV infection depends on the demonstration of 
anti-HIV antibodies and/or the detection of HIV or one of its components.
The standard screening test for HIV infection is the detection of anti-
HIV antibodies using an enzyme immunoassay (EIA). This test is highly 
sensitive (>99.5%) and is quite specific. Most commercial EIA kits are able 
to detect antibodies to both HIV-1 and -2. Western blot is the most com-
monly used confirmatory test and detects antibodies to HIV antigens of 
specific molecular weights. Antibodies to HIV begin to appear within 2 
weeks of infection, and the period of time between initial infection and 
the development of detectable antibodies is rarely >3 months. The HIV 
p24 antigen can be measured using an EIA-type capture assay. Plasma p24 
antigen levels rise during the first few weeks following infection, prior to 
the appearance of anti-HIV antibodies. A guideline for the use of these 
serologic tests in the diagnosis of HIV infection is depicted in Fig. 114-1.
FIGURE 114-1 Algorithm for the use of serologic tests in the diagnosis of HIV-1 
or HIV-2 infection. *Stable indeterminate Western blot 4–6 weeks later makes HIV 
infection unlikely. However, it should be repeated twice at 3-month intervals to rule 
out HIV infection. Alternatively, one may test for HIV-1 p24 antigen or HIV RNA. EIA, 
enzyme immunoassay.
Repeat
HIV-1/HIV-2
EIA
HIV-1
Western
blot
Screening
HIV-1/HIV-2
EIA
HIV-2
EIA
HIV-2
Western
blot
Diagnosis
of HIV-1
infection
Diagnosis
of HIV-2
infection
–
–
–
–
–
Retest in
3–6 months
if clinically
indicated
+
+
+
+
+
Indeterminate
Repeat in 4–6 weeks*
Indeterminate
SEROLOGIC TESTS IN THE DIAGNOSIS OF HIV-1 OR
HIV-2 INFECTION
SECTION 7
732
Infectious Diseases
HIV can be cultured directly from tissue, peripheral blood cells, or 
plasma, but this is most commonly done in a research setting. HIV genetic 
material can be detected using reverse transcriptase PCR (RT-PCR), 
branched DNA (bDNA), or nucleic acid sequence–based assay (NASBA). 
These tests are useful in pts with a positive or indeterminate EIA and an 
indeterminate Western blot. They turn positive early in infection and will 
usually be positive in pts in whom serologic testing may be unreliable (such 
as those with hypogammaglobulinemia).
� LABORATORY MONITORING OF PTS WITH HIV INFECTION
Measurement of the CD4+ T cell count and level of plasma HIV RNA are 
important parts of the routine evaluation and monitoring of HIV-infected 
individuals. The CD4+ T cell count is a generally accepted indicator of the 
immunologic competence of the pt with HIV infection, and there is a close 
relationship between the CD4+ T cell count and the clinical manifestations 
of AIDS (Fig. 189-32, p. 1541, in HPIM-18). Pts with CD4+ T cell counts 
<200/μL are at higher risk of infection with Pneumocystis jiroveci. Once the 
count declines to <50/μL, pts are also at higher risk for developing CMV 
disease and infection with Mycobacterium avium intracellulare. Pts should 
have their CD4+ T cell count measured at the time of diagnosis and every 
3–6 months thereafter. (Measurements may be done more frequently in pts 
with declining counts.) According to DHHS practice guidelines, a CD4+ 
T cell count <500/μL is a clear indication to initiate antiretroviral therapy. 
While the CD4+ T cell count provides information on the current immu-
nologic status of the pt, the HIV RNA level predicts what will happen to the 
CD4+ T cell count in the near future. Measurements of plasma HIV RNA 
levels should be made at the time of HIV diagnosis and every 3–4 months 
thereafter in the untreated pt. Measurement of plasma HIV RNA is also use-
ful in making therapeutic decisions about antiretroviral therapy (see below). 
Following the initiation of therapy or any change in therapy, HIV RNA levels 
should be monitored approximately every 4 weeks until the effectiveness of 
the therapeutic regimen is determined by the development of a new steady-
state level of HIV RNA. During therapy, levels of HIV RNA should be moni-
tored every 3–6 months to evaluate the continuing effectiveness of therapy.
The sensitivity of an individual’s HIV virus(es) to different antiretroviral 
agents can be tested by either genotypic or phenotypic assays. In the hands of 
experts, the use of resistance testing to select a new antiretroviral regimen in 
pts failing their current regimen leads to a ~0.5-log greater decline in viral load 
compared with the efficacy of regimens selected solely on the basis of drug his-
tory. HIV resistance testing may also be of value in selecting an initial treatment 
regimen in geographic areas with a high prevalence of baseline resistance.
� CLINICAL MANIFESTATIONS OF HIV INFECTION
A complete discussion is beyond the scope of this chapter. The major clini-
cal features of the various stages of HIV infection are summarized below 
(see also Chap. 189, HPIM-18).
Acute HIV (Retroviral) Syndrome 
Approximately 50–70% of infected individuals experience an acute syn-
drome following primary infection. The acute syndrome follows infection 
CHAPTER 114
733
HIV Infection and AIDS
by 3–6 weeks. It can have multiple clinical features (Table 114-1), lasts 1–2 
weeks, and resolves spontaneously as an immune response to HIV develops 
and the viral load diminishes from its peak levels. Most pts will then enter 
a phase of clinical latency, although an occasional pt will experience rapidly 
progressive immunologic and clinical deterioration.
Asymptomatic Infection 
The length of time between HIV infection and development of disease 
in untreated individuals varies greatly, but the median is estimated to be 
10 years. HIV disease with active viral replication usually progresses during 
this asymptomatic period, and CD4+ T cell counts fall. The rate of disease 
progression is directly correlated with plasma HIV RNA levels. Pts with 
high levels of HIV RNA progress to symptomatic disease faster than do 
those with low levels of HIV RNA.
Symptomatic Disease 
Symptoms of HIV disease can develop at any time during the course of HIV 
infection. In general, the spectrum of illness changes as the CD4+ T cell 
count declines. The more severe and life-threatening complications of HIV 
infection occur in pts with CD4+ T cell counts <200/μL. Overall, the clini-
cal spectrum of HIV disease is constantly changing as pts live longer and 
new and better approaches to treatment and prophylaxis of opportunistic 
infections are developed. In addition, a variety of neurologic, cardiovascu-
lar, renal, metabolic, and hepatic problems are increasingly seen in pts with 
HIV infection and may be a direct consequence of HIV infection. The key 
element to treating symptomatic complications of HIV disease, whether 
primary or secondary, is achieving good control of HIV replication through 
the use of combination antiretroviral therapy and instituting primary and 
secondary prophylaxis as indicated. Major clinical syndromes seen in the 
symptomatic stage of HIV infection are summarized below.
• Persistent generalized lymphadenopathy: Palpable adenopathy at two or 
more extrainguinal sites that persists for >3 months without explanation 
other than HIV infection. Many pts will go on to disease progression.
TABLE 114-1 CLINICAL FINDINGS IN THE ACUTE HIV SYNDROME
General
Neurologic
 Fever
 Meningitis
 Pharyngitis
 Encephalitis
 Lymphadenopathy
 Peripheral neuropathy
 Headache/retroorbital pain
 Myelopathy
 Arthralgias/myalgias
Dermatologic
 Lethargy/malaise
 Erythematous maculopapular rash
 Anorexia/weight loss
 Mucocutaneous ulceration
 Nausea/vomiting/diarrhea
Source: From B Tindall, DA Cooper: AIDS 5:1, 1991.
SECTION 7
734
Infectious Diseases
• Constitutional symptoms: Fever persisting for >1 month, involuntary 
weight loss of >10% of baseline, diarrhea for >1 month in absence of 
explainable cause.
• Neurologic disease: Most common is HIV-associated neurocognitive 
disease (HAND); other neurologic complications include opportunistic 
infections, primary CNS lymphoma, CNS Kaposi’s sarcoma, aseptic 
meningitis, myelopathy, peripheral neuropathy, and myopathy.
• Secondary infectious diseases: Common secondary infectious agents 
include P. jiroveci (pneumonia), CMV (chorioretinitis, colitis, pneumo-
nitis, adrenalitis), Candida albicans (oral thrush, esophagitis), M. avium 
intracellulare (localized or disseminated infection), M. tuberculosis 
(pulmonary or disseminated), Cryptococcus neoformans (meningitis, dis-
seminated disease), Toxoplasma gondii (encephalitis, intracerebral mass 
lesion), herpes simplex virus (severe mucocutaneous lesions, esophagi-
tis), diarrhea due to Cryptosporidium spp. or Isospora belli (diarrhea), JC 
virus (progressive multifocal leukoencephalopathy), bacterial pathogens 
(pneumonia, sinusitis, skin).
• Secondary neoplasms: Kaposi’s sarcoma (cutaneous and visceral, more 
fulminant course than in non-HIV-infected pts), lymphoma (primarily 
B cell, may be CNS or systemic).
• Other diseases: A variety of organ-specific syndromes can be seen in 
HIV-infected pts, either as primary manifestations of the HIV infection 
or as complications of treatment. Diseases commonly associated with 
aging are also seen with an increased frequency in pts with HIV 
infection.
HIV Infection (See also Chap. 189, HPIM-18)
TREATMENT
General principles of pt management include counseling, psychosocial 
support, and screening for infections and other conditions and require 
comprehensive knowledge of the disease processes associated with HIV 
infection.
ANTIRETROVIRAL THERAPY (SEE Table 114-2) The cornerstone of medi-
cal management of HIV infection is combination antiretroviral therapy, 
or cART. Suppression of HIV replication is an important component in 
prolonging life as well as in improving the quality of life of pts with HIV 
infection. However, several important questions related to the treat-
ment of HIV disease lack definitive answers. Among them are questions 
regarding when antiretroviral therapy should be started, what the best 
cART regimen is, when a given regimen should be changed, and which 
drugs in a regimen should be changed when a change is made. The 
drugs that are currently licensed for the treatment of HIV infection are 
listed in Table 114-2. These drugs fall into four main categories: those 
that inhibit the viral reverse transcriptase enzyme, those that inhibit 
the viral protease enzyme, those that inhibit viral entry, and those that 
inhibit the viral integrase. There are numerous drug-drug interactions 
that must be taken into consideration when using these medications.
TABLE 114-2 ANTIRETROVIRAL DRUGS COMMONLY USED IN THE TREATMENT OF HIV INFECTION
Drug
Status
Indication
Dose in Combination
Supporting Data
Toxicity
Nucleoside or nucleotide reverse transcriptase inhibitors
Zidovudine (AZT, 
azidothymidine, 
Retrovir, 3′azido-
3′-deoxythymidine)
Licensed
Treatment of HIV infection 
in combination with other 
antiretroviral agents
200 mg q8h or 
300 mg bid
19 vs 1 death in original placebo-controlled 
trial in 281 pts with AIDS or ARC. Decreased 
progression to AIDS in pts with CD4+ T cell 
counts <500/μL, n = 2051.
Anemia, granulocy-
topenia, myopathy, 
lactic acidosis, 
hepatomegaly with 
steatosis, head-
ache, nausea
Prevention of maternal-
fetal HIV transmission
In pregnant women with CD4+ T cell count 
≥200/μL, AZT PO beginning at weeks 14–34 
of gestation plus IV drug during labor and 
delivery plus PO AZT to infant for 6-week 
decreased transmission of HIV by 67.5% 
(from 25.5% to 8.3%), n = 363
Lamivudine (Epivir, 
2′3′-dideoxy-3′-
thiacytidine, 3TC)
Licensed
In combination with other 
antiretroviral agents for the 
treatment of HIV infection
150 mg bid 300 mg qd Superior to AZT alone with respect to 
changes in CD4 counts in 495 pts who 
were zidovudine-naïve and 477 pts who 
were zidovudine-experienced. Overall CD4+
T cell counts for the zidovudine group were 
at baseline by 24 weeks, while in the group 
treated with zidovudine plus lamivudine, they 
were 10–50 cells/μL above baseline. 54% 
decrease in progression to AIDS/death 
compared with AZT alone.
Hepatotoxicity
(continued)
735
TABLE 114-2 ANTIRETROVIRAL DRUGS COMMONLY USED IN THE TREATMENT OF HIV INFECTION (CONTINUED)
Drug
Status
Indication
Dose in Combination
Supporting Data
Toxicity
Nucleoside or nucleotide reverse transcriptase inhibitors
Emtricitabine (FTC, 
Emtriva)
Licensed
In combination with other 
antiretroviral agents for the 
treatment of HIV infection
200 mg qd
Comparable to d4T in combination with ddI 
and efavirenz in 571 treatment-naïve pts. 
Similar to 3TC in combination with AZT or d4T 
+ NNRT1 or PI in 440 pts doing well for at 
least 12 weeks on a 3TC regimen.
Hepatotoxicity
Abacavir (Ziagen)
Licensed
For treatment of HIV infec-
tion in combination with 
other antiretroviral agents
300 mg bid
Abacavir + AZT + 3TC equivalent to indinavir 
+ AZT + 3TC with regard to viral load sup-
pression (~60% in each group with <400 HIV 
RNA copies/mL plasma) and CD4 cell increase 
(~100/μL in each group) at 24 weeks
Hypersensitivity
reaction (can be 
fatal); fever, rash, 
nausea, vomiting, 
malaise or fatigue, 
and loss of appetite
Tenofovir (Viread)
Licensed
For use in combination with 
other antiretroviral agents 
when treatment is indicated
300 mg qd
Reduction of ~0.6 log in HIV-1 RNA levels 
when added to background regimen in treat-
ment-experienced pts
Potential for renal 
toxicity
Nonnucleoside reverse transcriptase inhibitors
Nevirapine 
(Viramune)
Licensed
In combination with other 
antiretroviral agents for 
treatment of progressive 
HIV infection
200 mg/d × 14 days, 
then 200 mg bid
Increases in CD4+ T cell count, decrease 
in HIV RNA when used in combination with 
nucleosides
Skin rash, hepato-
toxicity
736
Efavirenz (Sustiva)
Licensed
For treatment of HIV infec-
tion in combination with 
other antiretroviral agents
600 mg qhs
Efavirenz + AZT + 3TC comparable 
to indinavir + AZT + 3TC with 
regard to viral load suppression (a higher 
percentage of the efavirenz group achieved 
viral load <50 copies/mL; however, the dis-
continuation rate in the indinavir group was 
unexpectedly high, accounting for most treat-
ment “failures”); CD4 cell increase (~140/μL 
in each group) at 24 weeks.
Rash, dysphoria, 
elevated liver func-
tion tests, 
drowsiness, 
abnormal dreams, 
depression
Etravirine (Intelence) Licensed
In combination with other 
antiretroviral agents in 
treatment-experienced adult 
pts who have evidence of 
viral replication and HIV-1 
strains resistant to an NNRTI 
inhibitor and other antiretro-
viral agents
200 mg bid (or twice 
daily)
At 24 weeks in treatment-experienced pts 
with 1 or more NNRTI mutations and 3 or 
more PI mutations at screening, 74% of 
pts randomized to etravirine + background 
had HIV levels <400 copies/mL compared 
to 51.5% of pts randomized to background 
regimen + placebo. All subjects received 
darunavir/ritonavir as part of their background 
regimen. CD4+ T cell counts increased by 81 
cells/mL in the etravirine arm and 64 cells/mL 
in the placebo arm.
Skin rash
(continued)
737
TABLE 114-2 ANTIRETROVIRAL DRUGS COMMONLY USED IN THE TREATMENT OF HIV INFECTION (CONTINUED)
Drug
Status
Indication
Dose in Combination
Supporting Data
Toxicity
Protease inhibitors
Fosamprenavir 
(Lexiva)
Licensed
In combination with other 
antiretroviral agents for 
treatment of HIV infection
1400 mg bid or
700 mg + 100 mg 
ritonavir bid or
1400 mg + 200 mg 
ritonavir qd
In treatment-naïve pts, amprenavir + AZT +
3TC superior to AZT + 3TC with regard to viral 
load suppression (53% vs 11% with <400
HIV RNA copies/mL plasma at 24 weeks). 
CD4+ T cell responses similar between treat-
ment groups. In treatment-experienced pts, 
amprenavir + NRTIs similar to indinavir +
NRTIs with regard to viral load suppression 
(43% vs 53% with <400 HIV RNA copies/mL 
plasma at 24 weeks). CD4+ T cell responses 
superior in the indinavir + NRTIs group.
Nausea, vomiting, 
diarrhea, rash, 
oral paresthesias, 
elevated liver 
function tests, 
hyperglycemia, 
fat redistribution, 
lipid abnormalities, 
headache, nephro-
lithiasis
Lopinavir/ritonavir 
(Kaletra)
Licensed
For treatment of HIV 
infection in combination with 
other antiretroviral agents
400 mg/100 mg bid
In treatment-naïve pts, lopinavir/ritonavir + d4T 
+ 3TC superior to nelfinavir + d4T + 3TC with 
regard to viral load suppression (79% vs 64% 
with <400 HIV RNA copies/μL at 40 weeks). 
CD4+ T cell increases similar in both groups.
Diarrhea, hyper-
glycemia, fat 
redistribution, lipid 
abnormalities
Atazanavir (Reyataz)
Licensed
For treatment of HIV 
infection in combination with 
other antiretroviral agents
400 mg qd or 
300 mg qd + ritonavir 
100 mg qd when 
given with efavirenz
Comparable to efavirenz when given in com-
bination with AZT + 3TC in a study of 810 
treatment-naïve pts. Comparable to nelfinavir 
when given in combination with d4T + 3TC in 
a study of 467 treatment-naïve pts.
Hyperbilirubinemia, 
PR prolongation, 
nausea, vomiting, 
hyperglycemia, fat 
maldistribution
738
Darunavir (Prezista)
Licensed
In combination with 100 mg 
ritonavir for combination 
therapy in treatment-
experienced adults
600 mg + 100 mg 
ritonavir twice daily 
with food
At 24 weeks, pts with prior extensive expo-
sure to antiretrovirals treated with a new 
combination including darunavir showed a 
–1.89-log change in HIV RNA levels and a 
92-cell increase in CD4+ T cells compared 
with –0.48 log and 17 cells in the control arm.
Diarrhea, nausea, 
headache
Entry inhibitors
Maraviroc 
(Selzentry)
Licensed
In combination with other 
antiretroviral agents in 
treatment-experienced 
adults infected with only 
CCR5-tropic HIV-1 that is 
resistant to multiple 
antiretroviral agents
150–600 mg bid 
depending on con-
comitant medications 
(see text)
At 24 weeks, among 635 pts with CCR5-
tropic virus and HIV-1 RNA >5000 copies/mL 
despite at least 6 months of prior therapy with 
at least one agent from 3 of the 4 antiretro-
viral drug classes, 61% of pts randomized to 
maraviroc achieved HIV RNA levels <400 cop-
ies/mL compared with 28% of pts randomized 
to placebo
Hepatotoxicity, 
nasopharyngitis, 
fever, cough, rash, 
abdominal pain, 
dizziness, fever, 
musculoskeletal
symptoms
Integrase inhibitor
Raltegravir 
(Isentress)
Licensed
In combination with other 
antiretroviral agents in treat-
ment experienced pts with 
evidence of ongoing HIV-1 
replication
400 mg bid
At 24 weeks, among 436 pts with three-class 
drug resistance, 76% of pts randomized to 
receive raltegravir achieved HIV RNA levels 
<400 copies/mL compared with 41% of pts 
randomized to receive placebo
Nausea, rash
Abbreviations: ARC, AIDS-related complex; NRTIs, nonnucleoside reverse transcriptase inhibitors.
739
SECTION 7
740
Infectious Diseases
Nucleoside/Nucleotide Analogues These agents act by causing prema-
ture DNA-chain termination during the reverse transcription of viral 
RNA to proviral DNA and should be used in combination with other 
antiretroviral agents. The most common usage is together with another 
nucleoside/nucleotide analogue and a nonnucleoside reverse transcrip-
tase inhibitor or a protease inhibitor (see below).
Nonnucleoside Reverse Transcriptase Inhibitors These agents interfere 
with the function of HIV-1 reverse transcriptase by binding to regions 
outside the active site and causing conformational changes in the 
enzyme that render it inactive. These agents are very potent; however, 
when they are used as monotherapy, they result in the rapid emergence 
of drug-resistant mutants. Five members of this class, nevirapine, dela-
virdine, efavirenz, etravirine, and rilpivirine are currently available for 
clinical use. These drugs are licensed for use in combination with other 
antiretrovirals. 
Protease Inhibitors These drugs are potent and selective inhibitors 
of the HIV-1 protease enzyme and are active in the nanomolar range. 
Unfortunately, as in the case of the nonnucleoside reverse transcrip-
tase inhibitors, this potency is accompanied by the rapid emergence 
of resistant isolates when these drugs are used as monotherapy. Thus, 
the protease inhibitors should be used only in combination with other 
antiretroviral drugs. 
HIV Entry Inhibitors These agents act by interfering with the binding of 
HIV to its receptor or co-receptor or by interfering with the process of 
fusion. A variety of small molecules that bind to HIV-1 co-receptors are 
currently in clinical trials. The first drugs in this class to be licensed are 
the fusion inhibitor enfuvirtide and the entry inhibitor maraviroc.
HIV Integrase Inhibitors These drugs interfere with the integration of 
proviral DNA into the host cell genome. The first agent in this class, 
raltegravir, was approved in 2007 for use in treatment-experienced pts.
CHOICE OF ANTIRETROVIRAL TREATMENT STRATEGY The large number 
of available antiretroviral agents makes the subject of antiretroviral 
therapy one of the more complicated in the management of HIV-
infected pts.
The principles of therapy for HIV infection have been articulated by a 
panel sponsored by the U.S. Department of Health and Human Services 
(Table 114-3). Treatment decisions must take into account the fact that 
one is dealing with a chronic infection and that complete eradication of 
HIV infection has not been achieved with currently available cART regi-
mens. Thus, therapeutic decisions must take into account the balance 
between risks and benefits. At present a reasonable course of action is to 
initiate antiretroviral therapy in anyone with the acute HIV syndrome; 
pts with symptomatic disease; pts with evidence of renal disease; pts 
with asymptomatic infection and CD4+ counts <500/μL; and pts with 
hepatitis B infection when hepatitis B treatment is indicated, to avoid
CHAPTER 114
741
HIV Infection and AIDS
TABLE 114-3 PRINCIPLES OF THERAPY OF HIV INFECTION
1.  Ongoing HIV replication leads to immune system damage and progres-
sion to AIDS.
2.  Plasma HIV RNA levels indicate the magnitude of HIV replication and the 
rate of CD4+ T cell destruction. CD4+ T cell counts indicate the current 
level of competence of the immune system.
3.  Rates of disease progression differ among individuals, and treatment 
decisions should be individualized based on plasma HIV RNA levels and 
CD4+ T cell counts.
4.  Maximal suppression of viral replication is a goal of therapy; the greater 
the suppression the less likely the appearance of drug-resistant quasi-
species.
5.  The most effective therapeutic strategies involve the simultaneous 
initiation of combinations of effective anti-HIV drugs with which the pt 
has not been previously treated and that are not cross-resistant with 
antiretroviral agents that the pt has already received.
6.  The antiretroviral drugs used in combination regimens should be used 
according to optimum schedules and dosages.
7.  The number of available drugs is limited. Any decisions on antiretroviral 
therapy have a long-term impact on future options for the pt.
8.  Women should receive optimal antiretroviral therapy regardless of 
pregnancy status.
9.  The same principles apply to children and adults. The treatment of 
HIV-infected children involves unique pharmacologic, virologic, and 
immunologic considerations.
10.  Compliance is an important part of ensuring maximal effect from a 
given regimen. The simpler the regimen, the easier it is for the pt to 
be compliant.
Source: Modified from Principles of Therapy of HIV Infection, USPHS, and the Henry J. Kaiser 
Family Foundation.
development of resistant strains of HIV. In addition, one may wish to 
administer a 4-week course of therapy to uninfected individuals imme-
diately following a high-risk exposure to HIV (see below). Some experts 
favor treating all pts with HIV infection with cART while awaiting the 
results of randomized, controlled trials.
When the decision to initiate therapy is made, the physician must 
decide which drugs to use in the initial regimen. The two options for initial 
therapy most commonly in use today are (1) two nucleoside/nucleotide 
analogues (one of which is usually tenofovir or abacavir, and the other 
of which is usually lamivudine or emtricitabine) combined with a 
protease inhibitor; or (2) two nucleoside/nucleotide analogues and a 
nonnucleoside reverse transcriptase inhibitor. There are no clear data at 
present on which to base a distinction between these two approaches. 
SECTION 7
742
Infectious Diseases
Following the initiation of therapy, one should expect a 1-log (tenfold) 
reduction in plasma HIV RNA within 1–2 months; eventually a decline 
in plasma HIV RNA to <50 copies/mL; and a rise in CD4+ T cell count 
of 100–150/μL during the first year. Failure to achieve and maintain an 
HIV RNA level <50 copies/mL is an indication to consider a change in 
therapy. Other reasons for changing therapy are listed in Table 114-4. 
When changing therapy because of treatment failure, it is important to 
attempt to provide a regimen with at least two new drugs. In the pt in 
whom a change is made for reasons of drug toxicity, a simple replace-
ment of one drug is reasonable.
Treatment of Secondary Infections and Neoplasms Specific for each 
infection and neoplasm (see Chap. 189, in HPIM-18).
Prophylaxis against Secondary Infections 
(See also Table 189-10, pp. 1544–1546, in HPIM-18)
Primary prophylaxis is clearly indicated for P. jiroveci pneumonia (espe-
cially when CD4+ T cell counts fall to <200 cells/μL), for M. avium complex 
infections in pts with CD4+ T cell counts <50 cells/μL, and for M. tuber-
culosis infections in pts with a positive PPD or anergy if at high risk of TB. 
Vaccination with the influenza and pneumococcal polysaccharide vaccines 
is generally recommended for all pts and may need to be repeated in pts 
with CD4+ T cell counts <200/μL when their counts increase to >200/μL 
(Table 189-10, pp. 1544–1546, in HPIM-18). Secondary prophylaxis, when 
available, is indicated for virtually every infection experienced by HIV-
infected pts until they have significant immunologic recovery.
� HIV AND THE HEALTH CARE WORKER
There is a small but definite risk to health care workers of acquiring HIV 
infection via needle stick exposures, large mucosal surface exposures, or 
exposure of open wounds to HIV-infected secretions or blood products. 
TABLE 114-4  INDICATIONS FOR CHANGING ANTIRETROVIRAL THERAPY IN 
PTS WITH HIV INFECTIONa
Less than a 1-log drop in plasma HIV RNA by 4 weeks following the initiation 
of therapy
A reproducible significant increase (defined as 3-fold or greater) from the 
nadir of plasma HIV RNA level not attributable to intercurrent infection, 
vaccination, or test methodology
Persistently declining CD4+ T cell numbers
Clinical deterioration
Side effects
aGenerally speaking, a change should involve the initiation of at least 2 drugs felt to be 
effective in the given pt. The exception to this is when change is being made to manage 
toxicity, in which case a single substitution is reasonable.
Source: Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents,
USPHS.
CHAPTER 114
743
HIV Infection and AIDS
For a more detailed discussion, see Fauci AS, Lane HC: 
Human Immunodeficiency Virus Disease: AIDS and Related 
Disorders, Chap. 189, p. 1506, in HPIM-18.
The risk of HIV transmission after a skin puncture by an object contami-
nated with blood from a person with documented HIV infection is ~0.3%, 
compared with a 20–30% risk for hepatitis B infection from a similar 
incident. Postexposure prophylaxis appears to be effective in decreasing 
the likelihood of acquisition of infection through accidental exposure in 
the health care setting. In this regard, a U.S. Public Health Service work-
ing group has recommended that chemoprophylaxis be given as soon as 
possible after occupational exposure. While the precise regimen remains 
a subject of debate, the U.S. Public Health Service guidelines recommend 
(1) a combination of two nucleoside analogue reverse transcriptase inhibi-
tors given for 4 weeks for routine exposures, or (2) a combination of two 
nucleoside analogue reverse transcriptase inhibitors plus a third drug given 
for 4 weeks for high-risk or otherwise complicated exposures. Most clini-
cians administer the latter regimen in all cases in which a decision to treat 
is made. Regardless of which regimen is used, treatment should be initiated 
as soon as possible after exposure.
Prevention of exposure is the best strategy and includes following uni-
versal precautions and proper handling of needles and other potentially 
contaminated objects.
Transmission of TB is another potential risk for all health care workers, 
including those dealing with HIV-infected pts. All workers should know 
their PPD status, which should be checked yearly.
� VACCINES
A recent clinical trial conducted in Thailand demonstrated moderate (31% 
effective) protection against acquisition of HIV infection. However, this mod-
est degree of efficacy does not justify deployment of the vaccine; active inves-
tigation continues in the pursuit of a safe and effective vaccine against HIV. 
� PREVENTION
Education, counseling, and behavior modification along with the consistent 
and correct use of condoms in risk situations  remain the cornerstones of 
HIV prevention efforts. Avoidance of shared needle use by IDUs is criti-
cal. If possible, breast-feeding should be avoided by HIV-positive women, 
as the virus can be transmitted to infants via this route. In societies where 
withholding of breast-feeding is not feasible, treatment of the mother, if 
possible, greatly decreases the chances of transmission. Recent studies have 
demonstrated the important role of medically supervised adult male circum-
cision in the prevention of acquisition of heterosexually transmitted HIV 
infection. In addition, antiretroviral-containing vaginal gels, as well as pre-
exposure prophylaxis in men who have sex with men and in heterosexual 
men and women practicing risk behavior, have proved to be effective means 
of prevention when the regimens are adhered to. Finally, treatment of the 
HIV-infected partner in heterosexual discordant couples has proved highly 
effective in preventing transmission of HIV to the uninfected partner.
SECTION 7
744
Infectious Diseases
CHAPTER 115
Fungal Infections
� GENERAL CONSIDERATIONS
• Yeasts (e.g., Candida, Cryptococcus) appear microscopically as round, 
budding forms; molds (e.g., Aspergillus, Rhizopus) appear as filamentous 
forms called hyphae; and dimorphic fungi (e.g., Histoplasma) are spheri-
cal in tissue but appear as molds in the environment. 
 
–  Endemic fungi (e.g., Coccidioides) are not part of the normal human 
microbial flora and infect hosts preferentially by inhalation. 
 
–  Opportunistic fungi (e.g., Candida and Aspergillus) invade the host from 
normal sites of colonization (e.g., mucous membranes or the GI tract). 
• Definitive diagnosis of any fungal infection requires histopathologic 
identification of the fungus invading tissue and evidence of an accompa-
nying inflammatory response.
� ANTIFUNGAL AGENTS
Amphotericin B (AmB) 
AmB is the broadest-spectrum antifungal agent but has significant toxicities, 
including nephrotoxicity, fever, chills, and nausea.
• AmB has fungicidal activity and is available only for parenteral adminis-
tration.
• Lipid formulations lack nephrotoxicity and infusion reactions; whether 
there is a clinically significant difference in efficacy between the deoxy-
cholate and lipid formulations remains controversial. 
Azoles
The azoles’ mechanism of action is inhibition of ergosterol synthesis in 
the fungal cell wall, resulting in fungistatic activity. Azoles have little or no 
nephrotoxicity and are available in oral preparations. 
• Fluconazole: Fluconazole is available in both oral and IV formulations, 
has a long half-life, and penetrates into most body fluids, including 
ocular fluids and CSF.
 
–  Toxicity is minimal but includes (usually reversible) hepatotoxicity 
and—at high doses—alopecia, muscle weakness, dry mouth, and 
metallic taste.
 
–  Fluconazole is useful for coccidioidal and cryptococcal meningitis 
and for candidemia, but it is notably ineffective against aspergillosis 
or mucormycosis.
 
–  It is effective as fungal prophylaxis in bone-marrow and high-risk liver 
transplant recipients.
• Voriconazole: Available in oral and IV formulations, voriconazole is 
considered the first-line agent against Aspergillus and has a broader spec-
trum than fluconazole against Candida species (including C. glabrata 
and C. krusei). It is also active against Scedosporium and Fusarium.
CHAPTER 115
745
Fungal Infections
 
–  Disadvantages of voriconazole (compared to fluconazole) include 
multiple drug interactions, hepatotoxicity, skin rashes (including pho-
tosensitivity), visual disturbances, and the need to monitor drug levels.
 
–  As it is metabolized completely by the liver, dose adjustments are 
required in pts with liver failure. Dose adjustments for renal insufficiency 
are not required, but the parenteral formulation should be avoided in pts 
with severe renal insufficiency given the presence of cyclodextrin.
• Itraconazole: Available in oral and IV formulations, itraconazole is the 
drug of choice for mild to moderate blastomycosis and histoplasmosis. 
It is approved by the U.S. Food and Drug Administration (FDA) for use 
in febrile neutropenic pts. Disadvantages of itraconazole include its poor 
penetration into CSF, the use of cyclodextrin in both the oral suspension 
and the IV preparation, the variable absorption of the drug in capsule 
form, and the need for monitoring of blood levels in pts taking capsules 
for disseminated mycoses.
• Posaconazole: Approved for prophylaxis of aspergillosis and candidiasis 
in high-risk immunocompromised pts, posaconazole is also effective 
against fluconazole-resistant Candida isolates and may be useful as sal-
vage therapy for some other fungal infections.
Echinocandins
The echinocandins, including caspofungin, anidulafungin, and micafungin, 
act by inhibiting the β-1,3-glucan synthase that is necessary for fungal cell 
wall synthesis. These agents are considered fungicidal for Candida and 
fungistatic for Aspergillus.
• Among the safest antifungal agents, echinocandins offer broad-spectrum 
fungicidal activity against all Candida species, and caspofungin has been 
efficacious as salvage therapy for aspergillosis.
• If anidulafungin or micafungin is used in combination with cyclospo-
rine, no dose adjustment is needed for either drug.
Flucytosine 
Flucytosine has excellent CSF penetration, but development of resistance 
has led to its almost always being used in combination with AmB (e.g., for 
cryptococcal meningitis). Adverse effects include bone marrow suppression.
Griseofulvin and Terbinafine 
Griseofulvin is used primarily for ringworm infection. Terbinafine is used 
for onychomycosis and ringworm and is as effective as itraconazole.
Topical Agents 
Many drug classes are used for topical treatment of common fungal skin 
infections: azoles (e.g., clotrimazole, miconazole), polyene agents (e.g., 
nystatin), and other classes (e.g., ciclopirox olamine, terbinafine).
� CANDIDIASIS
Microbiology and Epidemiology 
Candida is a small, thin-walled, ovoid yeast that reproduces by budding and 
occurs in three forms in tissue: blastospores, pseudohyphae, and hyphae. 
SECTION 7
746
Infectious Diseases
• Candida is ubiquitous in nature and inhabits the GI tract, the female 
genital tract, and the skin. Dissemination probably results from fungal 
entry into the bloodstream from mucosal surfaces after the organisms 
have multiplied to large numbers as a result of bacterial suppression by 
antibacterial drugs.
• C. albicans is common, but non-albicans species (e.g., C. glabrata, 
C. krusei, C. parapsilosis, C. tropicalis) now cause ~50% of all cases of 
candidemia and disseminated candidiasis. 
 
–  Candida species represent the fourth most common blood-culture 
isolate from hospitalized pts in the United States.
 
–  Pts with a compromised immune system, pts with indwelling cath-
eters, pts with severe burns, and neonates of low birth weight are at 
risk for hematogenous dissemination.
Clinical Manifestations 
The severity of candidal infections ranges from mild to life-threatening, 
with deep organ infections being at the more severe end of the spectrum.
• Mucocutaneous candidiasis: Thrush is characterized by white, adherent, 
painless, discrete or confluent patches in the mouth, tongue, or esophagus. 
 
–  Vulvovaginal candidiasis presents with pruritus, pain, and a vaginal 
discharge that may contain whitish “curds.”
 
–  Other cutaneous infections include paronychia, balanitis, and inter-
trigo (erythematous irritation with pustules in skin folds).
 
–  Chronic mucocutaneous candidiasis is a heterogeneous infection of 
hair, nails, skin, and mucous membranes that persists despite therapy 
and is associated with a dysfunctional immune system.
• Deeply invasive candidiasis: These infections are most commonly due to 
hematogenous seeding of organs during candidemia, but they can also 
be due to contiguous spread of organisms after disruption of normal 
anatomic barriers (e.g., kidney infection associated with an indwelling 
urinary catheter).
 
–  Nearly any organ can be infected, but the brain, chorioretina, heart, 
and kidneys are most commonly involved. Except in neutropenic pts, 
the liver and spleen are less often infected.
 
–  Skin involvement manifests as macronodular lesions.
 
–  Chorioretinal or skin involvement predicts a high probability of 
abscess formation in deep organs from generalized hematogenous 
seeding.
Diagnosis
The most challenging aspect of diagnosis is determining which pts have 
hematogenously disseminated disease; recovery of Candida from sputum, 
urine, or peritoneal catheters may reflect colonization rather than deep 
infection.
• The diagnosis of Candida infection is established by visualization of 
pseudohyphae or hyphae in the presence of inflammation in appropriate 
clinical samples.
• The β-glucan test has a negative predictive value of ~90% and can help 
exclude disseminated disease.
CHAPTER 115
747
Fungal Infections
Candidiasis
TREATMENT
• Mucocutaneous Candida infection: Azoles are the preferred agents; 
nystatin is an alternative. 
– Topical applications are appropriate when possible.
– Oral therapy can be used for vulvovaginal infections (fluconazole, 
150 mg PO as a single dose) and esophageal infections (fluconazole, 
100–200 mg/d; or itraconazole, 200 mg/d).
• Candidemia and suspected disseminated candidiasis: All pts with can-
didemia should be treated with a systemic antifungal agent for at least 
2 weeks after the last positive blood culture.
– Lipid formulations of AmB, echinocandins, and fluconazole or 
voriconazole are all effective; no agent within a given class is clearly 
superior to the others.
– The choice of antifungal drug depends on local epidemiology and 
susceptibility profiles. 
– Neutropenic or hemodynamically unstable pts should be treated 
with broader-spectrum agents (e.g., AmB, echinocandins) until 
the pathogen is specifically identified and a clinical response 
assessed.
– Fluconazole is the preferred agent for nonneutropenic, hemody-
namically stable pts when azole resistance is not considered likely.
– When possible, foreign materials (e.g., catheters) should be removed 
or replaced.
– All pts with candidemia should undergo an ophthalmologic exam 
because of high rates of Candida endophthalmitis, which may 
require partial vitrectomy.
– Candida endocarditis should be treated with valve removal and 
long-term antifungal administration (see Chap. 89).
– Candida meningitis is often treated with a polyene plus flucytosine.
– Successful treatment of Candida-infected prosthetic material (e.g., 
an artificial joint) nearly always requires removal of the infected 
material followed by long-term antifungal therapy.
Prevention
Allogeneic stem-cell and high-risk liver transplant recipients typically 
receive prophylaxis with fluconazole (400 mg/d). Some centers also use 
antifungal prophylaxis for neutropenic pts.
� ASPERGILLOSIS
Microbiology and Epidemiology 
Aspergillus is a mold with septate hyphae that branch at 45° angles and have 
vast numbers of conidia (spores). It has a worldwide distribution and typi-
cally grows in decomposing plant materials and in bedding. A. fumigatus 
is responsible for most cases of invasive aspergillosis, almost all cases of 
chronic aspergillosis, and most allergic syndromes.
SECTION 7
748
Infectious Diseases
• Inhalation is common; only intense exposures cause disease in healthy, 
immunocompetent individuals.
• The primary risk factors for invasive aspergillosis are profound neutro-
penia and glucocorticoid use. 
• Pts with chronic pulmonary aspergillosis have a wide spectrum of under-
lying pulmonary diseases (e.g., tuberculosis, sarcoidosis).
Clinical Manifestations 
More than 80% of invasive disease cases involve the lungs; in pts who are 
significantly immunocompromised, virtually any organ can be affected.
• Invasive pulmonary aspergillosis: Pts can be asymptomatic or can present 
with fever, cough, chest discomfort, hemoptysis, and shortness of breath. 
 
–  Acute and subacute forms have courses of ≤1 month and 1–3 months, 
respectively. 
 
–  Early diagnosis requires a high index of suspicion, screening for circu-
lating antigen (in leukemia), and urgent CT of the chest.
• Invasive sinusitis: Pts have fever, nasal or facial discomfort, and nasal 
discharge. The sinuses are involved in 5–10% of cases of invasive 
aspergillosis; sinus involvement is especially likely in leukemic pts and 
hematopoietic stem-cell transplant recipients. 
• Disseminated aspergillosis: Aspergillus disseminates from lung to brain, 
skin, thyroid, bone, and other organs, after which pts develop skin lesions 
and deteriorate clinically over 1–3 days, with fever and signs of mild 
sepsis. Blood cultures are usually negative.
 
–  Cerebral aspergillosis: Single or multiple lesions, hemorrhagic infarc-
tion, and cerebral abscess are common. The presentation can be acute 
or subacute, with mood changes, focal signs, seizures, and a decline in 
mental status. MRI is the most useful investigation.
 
–  Cutaneous aspergillosis: Dissemination of Aspergillus occasionally 
results in cutaneous features, usually an erythematous or purplish 
nontender area that progresses to a necrotic eschar.
• Chronic pulmonary aspergillosis: Pts develop one or more cavities that 
expand over months or years, with pulmonary symptoms, fatigue, and 
weight loss. Pericavitary infiltrates and multiple cavities are typical. 
Without treatment, pulmonary fibrosis can develop.
• Aspergilloma: A fungal ball occurs in up to 20% of residual chest cavities 
≥2.5 cm in diameter. Life-threatening hemoptysis may occur.
• Chronic sinusitis: Pts develop one of three presentations: a sinus asper-
gilloma in the maxillary sinus, chronic invasive sinusitis that is slowly 
destructive, or chronic granulomatous sinusitis.
• Allergic bronchopulmonary aspergillosis (ABPA): A hypersensitivity 
reaction leads to bronchial plugging, coughing fits, and dyspnea, primarily 
affecting asthmatics and pts with cystic fibrosis. Total IgE levels are usually 
>1000 IU/mL.
Diagnosis
Culture, molecular diagnosis, antigen detection, and histopathology usually 
confirm the diagnosis; ~40% of cases of invasive aspergillosis are diagnosed 
only at autopsy.
CHAPTER 115
749
Fungal Infections
• Culture may be falsely positive (e.g., in pts with airway colonization) or 
falsely negative; only 10–30% of pts with invasive Aspergillus have a posi-
tive culture at any time.
• Galactomannan antigen testing of serum from high-risk pts is best done 
prospectively, as positive results precede clinical disease; false-positive 
results can occur (e.g., due to certain β-lactam/β-lactamase inhibitor 
antibiotic combinations).
• A halo sign on high-resolution thoracic CT scan (a localized ground-
glass appearance representing hemorrhagic infarction surrounding a 
nodule) suggests the diagnosis.
Aspergillosis
TREATMENT
• See Table 115-1 for recommended treatments and doses.
– The duration of treatment for pts with invasive aspergillosis varies 
from ~3 months to years, depending on the host and the response.
– Chronic cavitary pulmonary aspergillosis probably requires treat-
ment for life.
• Surgical treatment is important for some forms of aspergillosis (e.g., 
maxillary sinus fungal ball; single aspergilloma; invasive disease of 
bone, heart valve, brain, or sinuses).
Outcome
Invasive aspergillosis is curable if immune reconstitution occurs, whereas 
allergic and chronic forms are not. The overall mortality rate is ~50% with 
treatment, but the disease is uniformly fatal without therapy.
� CRYPTOCOCCOSIS
Microbiology and Epidemiology 
Cryptococcus is a yeast-like fungus. C. neoformans and C. gattii are patho-
genic for humans and can cause cryptococcosis; most clinical laboratories 
do not routinely distinguish between these species.
• Worldwide, there are ~1 million cases of cryptococcosis, with >600,000 
deaths annually.
• Cryptococcosis is rare in the absence of impaired immunity.
• C. neoformans is found in soil contaminated with pigeon droppings, 
whereas C. gattii is associated with eucalyptus trees. Most cases are 
acquired via inhalation, which results in pulmonary infection.
Clinical Manifestations 
The clinical manifestations of cryptococcosis reflect the site of fungal infec-
tion, which usually involves the CNS and/or the lungs.
• CNS involvement most commonly presents as chronic meningoencepha-
litis, with headache, fever, lethargy, sensory and memory deficits, cranial 
nerve paresis, visual deficits, and meningismus (absent in some cases) 
lasting for weeks.
TABLE 115-1 TREATMENT OF ASPERGILLOSIS
Indication
Primary Treatment
Evidence Levela Precautions
Secondary Treatment
Comments
Invasiveb
Voriconazole 
AI
Drug interactions (especially 
with rifampin), renal failure 
(IV only)
AmB, caspofungin, 
posaconazole, 
micafungin
As primary therapy, voriconazole carries 
20% more responses than AmB. If azole 
prophylaxis fails, it is unclear whether a 
class change is required for therapy.
Prophylaxis
Posaconazole, 
itraconazole solution 
AI
Diarrhea and vomiting with itra-
conazole, vincristine interaction
Micafungin, aerosol-
ized AmB
Some centers monitor plasma levels of 
itraconazole and posaconazole.
ABPA
Itraconazole
AI
Some glucocorticoid interac-
tions, including with inhaled 
formulations
Voriconazole, 
posaconazole
Long-term therapy is helpful in most pts. No 
evidence indicates whether therapy modi-
fies progression to bronchiectasis/fibrosis.
Single
aspergilloma
Surgery
BII
Multicavity disease: poor 
outcome of surgery; medical 
therapy preferable
Itraconazole, voricon-
azole, intracavity AmB
Single large cavities with an aspergilloma 
are best resected.
Chronic
pulmonaryb
Itraconazole, 
voriconazole
BII
Poor absorption of capsules 
with proton pump inhibitors 
or H2 blockers
Posaconazole, IV AmB, 
IV micafungin
Resistance may emerge during 
treatment, especially if plasma drug 
levels are subtherapeutic.
aEvidence levels are those used in treatment guidelines [Walsh TJ et al: Treatment of aspergillosis: Clinical practice guidelines of the Infectious Diseases Society of America (IDSA). Clin 
Infect Dis 46:327, 2008].
bAn infectious disease consultation is appropriate for these pts.
Note: The oral dose is usually 200 mg bid for voriconazole and itraconazole and 400 mg bid for posaconazole. The IV dose of voriconazole is 6 mg/kg twice at 12-h intervals (loading 
doses) followed by 4 mg/kg q12h. Plasma monitoring is helpful in optimizing the dosage. Caspofungin is given as a single loading dose of 70 mg and then at 50 mg/d; some authorities 
use 70 mg/d for pts weighing >80 kg, and lower doses are required with hepatic dysfunction. Micafungin is given as 50 mg/d for prophylaxis and as at least 150 mg/d for treatment; 
this drug has not yet been approved by the FDA for this indication. AmB deoxycholate is given at a daily dose of 1 mg/kg if tolerated. Several strategies are available for minimizing renal 
dysfunction. Lipid-associated AmB is given at 3 mg/kg (AmBisome) or 5 mg/kg (Abelcet). Different regimens are available for aerosolized AmB, but none is FDA approved. Other consid-
erations that may alter dose selection or route include age; concomitant medications; renal, hepatic, or intestinal dysfunction; and drug tolerability.
750
CHAPTER 115
751
Fungal Infections
• Pulmonary cryptococcosis is generally asymptomatic but can present as 
cough, increased sputum production, and chest pain. Cryptococcomas are 
granulomatous pulmonary masses associated with C. gattii infections.
• Skin lesions are common in pts with disseminated cryptococcosis and 
can be highly variable, including papules, plaques, purpura, vesicles, 
tumor-like lesions, and rashes.
Diagnosis
Diagnosis requires the demonstration of C. neoformans in normally sterile 
tissue (e.g., positive cultures of CSF or blood).
• India ink smear of CSF is a useful rapid diagnostic technique, but may 
yield negative results in pts with a low fungal burden.
• Cryptococcal antigen testing of CSF and/or serum provides strong pre-
sumptive evidence for cryptococcosis; these tests are often negative in 
pulmonary cryptococcosis.
Cryptococcosis
TREATMENT
• Immunocompetent pts 
– Pulmonary cryptococcosis should be treated with fluconazole 
(200–400 mg/d) for 3–6 months. 
– Extrapulmonary cryptococcosis may initially require AmB (0.5–
1.0 mg/kg daily for 4–6 weeks).
– CNS disease should be treated with an induction phase of AmB 
(0.5–1.0 mg/kg daily) followed by prolonged consolidation therapy 
with fluconazole (400 mg/d).
– Meningoencephalitis is treated with AmB (0.5–1.0 mg/kg) plus flu-
cytosine (100 mg/kg) daily for 6–10 weeks or with the same drugs 
at the same dosages for 2 weeks followed by fluconazole (400 mg/d) 
for 10 weeks.
• Immunosuppressed pts are treated with the same initial regimens 
except that maintenance therapy with fluconazole is given for a pro-
longed period (sometimes throughout life) to prevent relapse.
– HIV-infected pts with CNS involvement are typically treated with 
AmB (0.7–1.0 mg/kg daily) plus flucytosine (100 mg/kg qd) for at 
least 2 weeks followed by fluconazole (400 mg/d) for 10 weeks and 
then by lifelong maintenance therapy with fluconazole (200 mg/d). 
– An alternative regimen involves fluconazole (400–800 mg/d) plus 
flucytosine (100 mg/kg qd) for 6–10 weeks followed by fluconazole 
(200 mg/d) as maintenance therapy.
� MUCORMYCOSIS
Microbiology and Epidemiology 
Mucormycosis is caused by fungi of the order Mucorales, most commonly 
Rhizopus oryzae; despite the name of the disease, Mucor species are only 
rarely the cause. 
SECTION 7
752
Infectious Diseases
• Mucorales have characteristic wide (≥6- to 30-μm), thick-walled, ribbon-
like, aseptate hyphal elements that branch at right angles.
• These ubiquitous environmental fungi primarily affect pts with diabe-
tes, defects in phagocytic function (e.g., associated with neutropenia or 
glucocorticoid therapy), and deferoxamine treatment for iron overload 
syndromes.
Clinical Manifestations 
Mucormycosis is highly invasive and relentlessly progressive, with a mor-
tality rate of >40%. The disease is usually categorized by the anatomic site 
involved.
• Rhinocerebral mucormycosis: In this, the most common form of the dis-
ease, pts initially have nonspecific symptoms that include eye or facial 
pain and facial numbness followed by the onset of conjunctival suffusion, 
blurry vision, and soft tissue swelling. 
 
–  If untreated, the infection can spread from the ethmoid sinus to the 
orbit, affecting extraocular muscle function and being associated with 
proptosis and chemosis.
 
–  The visual appearance of infected tissue may progress from normal to 
erythematous to violaceous to a black necrotic eschar. 
• Pulmonary mucormycosis: In this second most common manifes-
tation, pts typically present with fever, dyspnea, cough, and chest 
pain. Angioinvasion results in necrosis, cavitation, and/or hemoptysis. 
Differentiation from aspergillosis is critical as treatment regimens differ; 
the presence of ≥10 pulmonary nodules, pleural effusion, or concomitant 
sinusitis makes mucormycosis more likely.
• Cutaneous mucormycosis: Caused by external implantation or hematog-
enous dissemination, necrotizing fasciitis due to mucormycosis has a 
mortality rate of ~80%.
• Hematogenously disseminated mucormycosis: Infection can disseminate 
from any primary site of infection to any organ, but most commonly 
metastasizes to the brain (with a mortality rate of ~100%).
Diagnosis
Although definitive diagnosis requires a positive culture from a sterile site, 
a positive culture from a nonsterile site [e.g., sputum or bronchoalveolar 
lavage (BAL) fluid] in a pt with a consistent clinical history should prompt 
treatment pending confirmation of the diagnosis.
• The fact that only ~50% of pts have positive cultures is due, in part, to 
the organisms’ being killed by the tissue homogenization required for 
preparation of culture. 
• The laboratory should be notified that mucormycosis is being considered 
so that tissue sections instead of tissue homogenates can be cultured.
Mucormycosis
TREATMENT
• The successful treatment of mucormycosis requires four steps: 
(1) early diagnosis; (2) reversal of underlying predisposing risk factors, 
if possible; (3) surgical debridement; and (4) prompt antifungal therapy.
CHAPTER 115
753
Fungal Infections
• AmB (AmB deoxycholate, 1–1.5 mg/kg qd; or liposomal AmB, 
5–10 mg/kg qd) is the preferred antifungal agent for treatment of 
mucormycosis.
– Limited retrospective data suggest that combinations of echinocan-
dins and liposomal AmB may be more effective.
– Although posaconazole has in vitro activity against Mucorales, few 
clinical data support its use.
– Initial clinical trials suggest that liposomal AmB combined with 
deferasirox (an iron chelator that is fungicidal for clinical isolates 
of Mucorales; 20 mg/kg PO qd for 2–4 weeks) results in improved 
survival rates.
– Treatment should be continued until (1) resolution of clinical 
signs and symptoms of infection; (2) resolution or stabilization 
of residual radiographic signs of disease on serial imaging; and 
(3) resolution of underlying immunosuppression.
� HISTOPLASMOSIS
Microbiology and Epidemiology 
Histoplasma capsulatum, a dimorphic fungus, causes histoplasmosis.
• Mycelia are infectious and have microconidial and macroconidial 
forms. Microconidia are inhaled, reach the alveoli, and are trans-
formed into yeasts with occasional narrow budding. A granulomatous 
reaction results; in pts with impaired cellular immunity, infection may 
disseminate.
• Histoplasmosis is the most prevalent endemic mycosis in North America 
and is also found in Central and South America, Africa, and Asia. In the 
United States, histoplasmosis is endemic in the Ohio and Mississippi 
river valleys. 
• The fungus is found in soil, particularly that enriched by droppings of 
birds and bats.
Clinical Manifestations 
Depending on the intensity of exposure, the immune status of the exposed 
individual, and the underlying lung architecture of the host, disease can 
range from asymptomatic to life-threatening.
• Immunocompetent pts usually have asymptomatic or mild and self-
limited disease.
 
–  1–4 weeks after exposure, some pts develop a flu-like illness with fever, 
chills, sweats, headache, myalgia, anorexia, cough, dyspnea, and chest 
pain. 5–10% of pts with acute histoplasmosis develop arthralgia or 
arthritis, often associated with erythema nodosum.
 
–  Hilar or mediastinal lymphadenopathy may occur and can cause vas-
cular or tracheoesophageal compression.
• Immunocompromised pts are more likely to develop progressive dis-
seminated histoplasmosis (PDH).
 
–  The clinical spectrum ranges from a rapidly fatal course with diffuse 
interstitial or reticulonodular lung infiltrates, shock, and multiorgan 
SECTION 7
754
Infectious Diseases
failure to a subacute course with focal organ involvement, hepato-
splenomegaly, fever, and weight loss. 
 
–  Meningitis, oral mucosal ulcerations, GI ulcerations, and adrenal 
insufficiency can occur.
• Chronic cavitary histoplasmosis most often affects smokers with struc-
tural lung disease (e.g., emphysema) and presents as productive cough, 
dyspnea, low-grade fever, night sweats, and weight loss.
Diagnosis
Fungal culture remains the gold standard, but cultures are often negative in 
less severe cases and may take up to 1 month to become positive.
• In PDH, the culture yield is highest for BAL fluid, bone marrow aspirate, 
and blood; cultures of sputum or bronchial washings are usually positive 
in chronic pulmonary histoplasmosis.
• Fungal stains of cytopathology or biopsy materials may be helpful in 
diagnosing PDH. 
• Histoplasma antigen assay of body fluids (e.g., blood, urine, CSF, BAL 
fluid) is useful in diagnosing PDH or acute disease and in monitoring 
the response to treatment.
• Serology can be helpful in diagnosis but requires ≥1 month for antibody 
production.
Histoplasmosis
TREATMENT
• See Table 115-2 for treatment recommendations. 
– Fibrosing mediastinitis, which represents a chronic fibrotic reaction 
to past mediastinal histoplasmosis rather than an active infection, 
does not respond to antifungal therapy.
� COCCIDIOIDOMYCOSIS
Microbiology and Epidemiology 
Coccidioidomycosis is caused by the two species of the dimorphic soil-
dwelling fungus Coccidioides: C. immitis and C. posadasii. These organisms 
exist as branching, filamentous molds.
• Coccidioidomycosis is confined to the Western Hemisphere between the 
latitudes of 40°N and 40°S. The disease is highly endemic in California, 
Arizona, and other areas of the southwestern United States; northern 
Mexico and localized regions in Central and South America also account 
for cases of infection.
• Direct exposure to soil harboring Coccidioides increases risk, but infec-
tion, which results from inhalation of airborne arthroconidia, can occur 
without overt soil exposure and may be related to other climatic factors 
(e.g., periods of dryness after rainy seasons).
Clinical Manifestations 
60% of infected pts are asymptomatic; the remaining 40% have primarily 
pulmonary disease characterized by fever, cough, and pleuritic chest pain.
CHAPTER 115
755
Fungal Infections
TABLE 115-2  RECOMMENDATIONS FOR THE TREATMENT OF 
HISTOPLASMOSIS
Type of Histoplasmosis Treatment Recommendations Comments
Acute pulmonary, mod-
erate to severe illness 
with diffuse infiltrates 
and/or hypoxemia
Lipid AmB (3–5 mg/kg per 
day) ± glucocorticoids for 
1–2 weeks; then itraconazole 
(200 mg bid) for 12 weeks. 
Monitor renal and hepatic 
function.
Pts with mild cases 
usually recover 
without therapy, but 
itraconazole should 
be considered if the 
pt’s condition has 
not improved after 
1 month.
Chronic/cavitary 
pulmonary
Itraconazole (200 mg qd or 
bid) for at least 12 months. 
Monitor hepatic function.
Continue treatment 
until radiographic 
findings show no 
further improve-
ment. Monitor for 
relapse after treat-
ment is stopped.
Progressive
disseminated
Lipid AmB (3–5 mg/kg per 
day) for 1–2 weeks; then 
itraconazole (200 mg bid) 
for at least 12 months. 
Monitor renal and hepatic 
function.
Liposomal AmB is 
preferred, but the 
AmB lipid com-
plex may be used 
because of cost. 
Chronic mainte-
nance therapy may 
be necessary if the 
degree of immuno-
suppression cannot 
be reduced.
CNS
Liposomal AmB (5 mg/kg 
per day) for 4–6 weeks; then 
itraconazole (200 mg bid or 
tid) for at least 12 months. 
Monitor renal and hepatic 
function.
A longer course of 
lipid AmB is recom-
mended because 
of the high risk of 
relapse. Itraconazole 
should be continued 
until CSF or CT 
abnormalities clear.
• Primary pulmonary infection is sometimes associated with erythema 
nodosum, erythema multiforme, arthralgias, and arthritis.
 
–  A history of night sweats, profound fatigue, eosinophilia, and hilar or 
mediastinal lymphadenopathy suggests the disease.
 
–  Pneumonic complications include pulmonary nodules (resembling 
pulmonary malignancies) and pulmonary cavities (a thin-walled 
lesion in a bronchus that is associated with cough, hemoptysis, and 
pleuritic chest pain).
• Disseminated infection affects <1% of infected pts, most commonly pts 
with depressed cellular immunity and pregnant women.
SECTION 7
756
Infectious Diseases
 
–  Common sites for dissemination include bone, skin, joint, soft tissue, 
and meninges.
 
–  Pts with meningitis present with persistent headache, lethargy, con-
fusion, mild to moderate nuchal rigidity, and CSF with lymphocytic 
pleocytosis and profound hypoglycorrhachia. The mortality rate is 
~100% without treatment.
Diagnosis
Serology and culture are the primary means of diagnosis. Alert the labora-
tory of the possible diagnosis to avoid exposure.
• Tube-precipitin (TP) and complement-fixation (CF) assays, immunodif-
fusion, and an EIA are available to detect IgM and IgG antibodies. 
 
–  TP antibody does not gauge disease progression and is not found in CSF. 
 
–  Rising CF titers in serum are associated with clinical progression, and 
CF antibody in CSF indicates meningitis. 
 
–  EIA frequently yields false-positive results.
• Examination of sputum or other respiratory fluids after Papanicolaou or 
Gomori methenamine silver staining reveals spherules in many pts with 
pulmonary disease.
Coccidioidomycosis
TREATMENT
• The vast majority of pts with coccidioidomycosis do not require treat-
ment. Exceptions include the following:
– Pts with focal primary pneumonia and underlying cellular immu-
nodeficiency or prolonged symptoms (symptoms persisting for ≥2 
months, night sweats occurring for >3 weeks, weight loss of >10%, 
a serum CF antibody titer of >1:16, and extensive pulmonary 
involvement apparent on CXR) should be treated with fluconazole 
(≥400 mg/d) or itraconazole (400–600 mg/d).
– Pts with diffuse pulmonary disease are often treated initially with 
AmB (deoxycholate, 0.7–1 mg/kg IV qd; liposomal, 5 mg/kg IV 
qd), with a switch to prolonged therapy with a triazole once clinical 
improvement occurs.
– Pts with chronic pulmonary disease or disseminated infection are 
treated with prolonged triazole therapy (i.e., for ≥1 year). Relapse 
occurs in 15–30% of individuals once therapy is discontinued.
– Pts with meningitis require lifelong triazole therapy; fluconazole 
is the drug of choice. If triazole therapy fails, intrathecal or intra-
ventricular AmB may be used. Relapse occurs in 80% of pts when 
therapy is stopped.
� BLASTOMYCOSIS
Microbiology and Epidemiology 
Blastomyces dermatitidis is a dimorphic fungus that is found in the south-
eastern and south-central states bordering the Mississippi and Ohio river 
basins, in areas of the United States and Canada bordering the Great Lakes 
CHAPTER 115
757
Fungal Infections
and the St. Lawrence River, and in Africa. Infection is caused by inhalation 
of Blastomyces from moist soil rich in organic debris. 
Clinical Manifestations 
Acute pulmonary infection can present as abrupt-onset fever, chills, pleuritic 
chest pain, myalgias, and arthralgias. However, most pts with pulmonary 
blastomycosis have chronic indolent pneumonia with fever, weight loss, 
productive cough, and hemoptysis. Skin disease is common and can present 
as verrucous (more common) or ulcerative lesions. Blastomycosis can 
include osteomyelitis in one-fourth of infections and CNS disease in ~40% 
of pts with AIDS.
Diagnosis
Smears of clinical samples or cultures of sputum, pus, or tissue are required 
for diagnosis. Antigen detection in urine and serum may assist in diagnos-
ing infection and in monitoring pts during therapy.
Blastomycosis
TREATMENT
• Every pt should be treated because of the high risk of dissemination. 
– For immunocompetent pts with nonsevere disease that does not 
involve the CNS, itraconazole (200–400 mg/d for 6–12 months) is 
recommended.
– Immunocompetent pts with severe disease or CNS manifestations 
should be treated initially with AmB (deoxycholate, 0.7–1 mg/kg 
IV qd; liposomal, 3–5 mg/kg IV qd); once their clinical condition 
improves, they can be switched to itraconazole (or, for those with 
CNS disease, fluconazole, 800 mg/d).
– Immunocompromised pts with any form of infection should be 
treated initially with AmB, with a switch to a triazole, as above, once 
clinical improvement has occurred.
� MALASSEZIA INFECTION
Malassezia species are components of the normal skin flora and can cause 
tinea (pityriasis) versicolor, round scaly patches of hypo- or hyperpig-
mented skin on the neck, chest, or upper arms. M. furfur causes catheter-
related fungemia in premature neonates receiving IV lipids by central 
venous catheter. Topical creams and lotions for 2 weeks are effective in 
treating superficial Malassezia infections; fungemia caused by Malassezia 
species is treated with AmB or fluconazole, prompt removal of the catheter, 
and discontinuation of the lipid infusion.
� SPOROTRICHOSIS
Microbiology and Epidemiology 
Sporothrix schenckii is a dimorphic fungus found worldwide in soil, on 
plants, and on animals. Infection, which results from inoculation of the 
SECTION 7
758
Infectious Diseases
organism into the skin, is most common among people who participate in 
landscaping, gardening, or tree farming.
Clinical Manifestations 
Lymphocutaneous sporotrichosis involves secondary lesions (papules that 
are not very painful and often ulcerate) developing along lymphatic chan-
nels proximally from the initial site of inoculation. Other presentations 
include a fixed lesion (verrucous or ulcerative) at the initial site of inocula-
tion without lymphatic spread, osteoarticular disease (chronic synovitis or 
septic arthritis in alcoholics), pulmonary disease (most common among 
pts with chronic obstructive pulmonary disease), and disseminated disease 
(numerous skin lesions with occasional spread to visceral organs in immu-
nocompromised pts).
Diagnosis
Culture of material from a skin lesion or histopathologic examination of a 
skin biopsy sample can confirm the diagnosis.
Sporotrichosis
TREATMENT
• Cutaneous and lymphocutaneous sporotrichosis is treated with itra-
conazole (200 mg/d) for 2–4 weeks after the lesions have resolved. 
• For extracutaneous disease, itraconazole (200 mg bid for 12 months) 
can be given, but initial therapy with liposomal AmB (3–5 mg/kg qd) 
is more effective for life-threatening pulmonary disease or dissemi-
nated infection.
� PARACOCCIDIOIDOMYCOSIS
Paracoccidioidomycosis (South American blastomycosis) is caused by 
Paracoccidioides brasiliensis, a dimorphic fungus acquired by inhala-
tion from environmental sources. Acute infection occurs in young or 
immunocompromised pts and manifests as disseminated infection of the 
reticuloendothelial system. Chronic infection accounts for 90% of cases 
and presents primarily as progressive pulmonary disease with occasional 
ulcerative and nodular mucocutaneous lesions in the nose and mouth. 
Diagnosis relies on culture of the organism. Itraconazole (100–200 mg/d 
for 6–12 months) is effective, but AmB may be required for seriously 
ill pts.
� PENICILLIOSIS
Penicillium marneffei is a leading cause of opportunistic infection in pts 
with immunocompromise (e.g., due to AIDS) in Southeast Asia and is 
acquired by spore inhalation. Clinical manifestations are similar to those 
of disseminated histoplasmosis, with fever, fatigue, weight loss, lymph-
adenopathy, hepatomegaly, and skin lesions resembling molluscum conta-
giosum. The organism grows readily in culture and produces a distinctive 
red pigment. AmB is the initial treatment of choice for severely ill pts; less 
severe disease may be treated with itraconazole (400 mg/d for 12 weeks). 
CHAPTER 116
759
Pneumocystis Infections
Suppressive therapy with itraconazole (200 mg/d) may be indicated for pts 
with HIV infection or AIDS.
� FUSARIOSIS
Fusarium species are found worldwide in soil and on plants; inhalation, 
ingestion, and direct inoculation of spores can cause disease, particularly 
disseminated disease in immunocompromised pts. Fusariosis is angioin-
vasive and has clinical manifestations similar to those of aspergillosis. One 
difference is that painful, nodular or necrotic skin lesions are extremely 
common with disseminated fusariosis. Blood cultures are positive in 50% 
of cases; the organism is difficult to differentiate from Aspergillus in tissue. 
Fusarium species are often resistant to antifungal agents; liposomal AmB 
(≥5 mg/kg qd), voriconazole (200–400 mg bid), or posaconazole (400 mg 
bid) is recommended. Even with treatment, mortality rates are ~50%.
� SCEDOSPORIOSIS
Pseudallescheria boydii, Scedosporium apiospermum, and S. prolificans are molds 
that are angioinvasive, causing pneumonia and widespread dissemination with 
abscesses (including brain abscess) in immunocompromised hosts. Most dis-
seminated infections are fatal. These organisms are resistant to AmB, echinocan-
dins, and some azoles, but some infections have been cured with voriconazole. 
� DERMATOPHYTOSIS
See Chap. 66. 
For a more detailed discussion, see Edwards JE Jr: Diagnosis 
and Treatment of Fungal Infections, Chap. 198, p. 1637; Hage 
CA, Wheat LJ: Histoplasmosis, Chap. 199, p. 1640; Ampel 
NM: Coccidioidomycosis, Chap. 200, p. 1643; Chapman SW, 
Sullivan DC: Blastomycosis, Chap. 201, p. 1646; Casadevall A: 
Cryptococcosis, Chap. 202, p. 1648; Edwards JE Jr: Candidiasis, 
Chap. 203, p. 1651; Denning DW: Aspergillosis, Chap. 204, 
p. 1655; Spellberg B, Ibrahim AS: Mucormycosis, Chap. 205, 
p. 1661; and Kauffman CA: Superficial Mycoses and Less 
Common Systemic Mycoses, Chap. 206, p. 1665, in HPIM-18.
CHAPTER 116
Pneumocystis Infections
Pneumocystis, an opportunistic fungal pulmonary pathogen, is an impor-
tant cause of pneumonia in immunocompromised hosts. 
� MICROBIOLOGY
• P. jirovecii infects humans, whereas P. carinii—the original species 
described—infects rats. 
SECTION 7
760
Infectious Diseases
• In contrast to most fungi, Pneumocystis lacks ergosterol and thus is not 
susceptible to antifungal drugs that inhibit ergosterol synthesis. 
• Developmental stages include the small trophic form, the cyst, and the 
intermediate precyst stage.
� EPIDEMIOLOGY
• Pneumocystis is found worldwide, and most healthy children have been 
exposed to the organism by 3–4 years of age. 
• Both airborne transmission and person-to-person transmission have 
been demonstrated; the cyst is the transmissible form. 
• Defects in cellular and humoral immunity (including immunosuppressive 
medications) predispose to Pneumocystis pneumonia. The risk in HIV-
infected pts rises dramatically when CD4+ T cell counts fall below 200/μL.
� PATHOGENESIS
• The organisms are inhaled and attach tightly to type I cells in alveoli, 
although they remain extracellular. 
• On histology, alveoli are seen to be filled with foamy, vacuolated exudates. 
• Severe disease may cause interstitial edema, fibrosis, and hyaline membrane 
formation.
� CLINICAL MANIFESTATIONS
• Pts develop dyspnea, fever, and nonproductive cough. 
 
–  HIV-infected pts are usually ill for several weeks or longer with subtle 
manifestations. 
 
–  Pts without HIV infection often become symptomatic after their 
glucocorticoid dose has been tapered, and their symptoms are of 
shorter duration.
• Physical exam reveals tachypnea, tachycardia, and cyanosis out of pro-
portion to the few abnormalities present on chest auscultation.
• Nonspecific laboratory findings include elevated serum concentrations 
of lactate dehydrogenase and β-D-glucan, a component of the fungal cell 
wall.
• CXR classically reveals bilateral diffuse infiltrates beginning in the perihilar 
regions. Other findings (e.g., nodular densities, cavitary lesions) have 
been described.
• Rare cases of disseminated infection have been described, generally 
involving lymph nodes, spleen, liver, and bone marrow.
� DIAGNOSIS
• Histopathologic staining makes the definitive diagnosis. 
 
–  Cell-wall stains (e.g., methenamine silver) are used for Pneumocystis 
cysts and Wright-Giemsa stains for the nuclei of all developmental 
stages. 
 
–  Immunofluorescence with monoclonal antibodies increases diagnostic 
sensitivity.
• DNA amplification by PCR is most sensitive but may not distinguish 
colonization from infection. 
• Proper specimens are key. 
 
–  Fiberoptic bronchoscopy with bronchoalveolar lavage remains the 
mainstay of diagnosis.
CHAPTER 116
761
 
–  Sputum induction and oral washes are noninvasive options that are 
gaining popularity. 
 
–  Transbronchial biopsy and open lung biopsy are used only when a 
diagnosis cannot be made by bronchoalveolar lavage.
Pneumocystis Infections
TREATMENT
• Trimethoprim-sulfamethoxazole (TMP-SMX) is the drug of choice 
for all pts. For doses and adverse effects of TMP-SMX and alternative 
regimens, see Table 116-1.
• For mild to moderate cases (a Pao2 >70 mmHg or a PAo2 – Pao2 gradi-
ent <35 mmHg on room air), alternatives include TMP plus dapsone 
and clindamycin plus primaquine. Atovaquone is less effective than 
TMP-SMX but is better tolerated.
TABLE 116-1 TREATMENT OF PNEUMOCYSTOSIS
Drug(s), Dose, Route
Adverse Effects
First choicea
TMP-SMX (TMP: 5 mg/kg; SMX: 
25 mg/kgb) q6–8h PO or IV
Fever, rash, cytopenias, hepatitis, hyperka-
lemia, GI disturbances
Other agentsa
TMP, 5 mg/kg q6–8h; plus 
dapsone, 100 mg qd PO
Hemolysis (G6PD deficiency), 
methemoglobinemia, fever, rash, 
GI disturbances
Atovaquone, 750 mg bid PO
Rash, fever, GI and hepatic disturbances
Clindamycin, 300–450 mg q6h 
PO or 600 mg q6–8h IV; plus 
primaquine, 15–30 mg qd PO
Hemolysis (G6PD deficiency), methemo-
globinemia, rash, colitis, neutropenia
Pentamidine, 3–4 mg/kg qd IV
Hypotension, azotemia, cardiac arrhyth-
mias, pancreatitis, dysglycemias, hypocal-
cemia, neutropenia, hepatitis
Trimetrexate, 45 mg/m2 qd IV; 
plus leucovorin,c 20 mg/kg q6h 
PO or IV
Cytopenias, peripheral neuropathy, hepatic 
disturbances
Adjunctive agent
Prednisone, 40 mg bid × 5 d, 
40 mg qd × 5 d, 20 mg qd ×
11 d; PO or IV
Immunosuppression, peptic ulcer, hyper-
glycemia, mood changes, hypertension
aTherapy is administered for 14 days to non-HIV-infected pts and for 21 days to HIV-infected pts.
bEquivalent of 2 double-strength (DS) tablets. (One DS tablet contains 160 mg of TMP and 800 
mg of SMX.)
cLeucovorin prevents bone marrow toxicity from trimetrexate.
Pneumocystis Infections
SECTION 7
762
Infectious Diseases
TABLE 116-2 PROPHYLAXIS OF PNEUMOCYSTOSISa
Drug(s), Dose, Route
Comments
First choice
TMP-SMX, 1 DS tablet or 1 SS tablet 
qd POb
TMP-SMX can be safely reintroduced 
for treatment of some pts who have 
had mild to moderate side effects.
Other agents
Dapsone, 50 mg bid or 100 mg qd PO
—
Dapsone, 50 mg qd PO; plus pyri-
methamine, 50 mg weekly PO; plus 
leucovorin, 25 mg weekly PO
Leucovorin prevents bone marrow 
toxicity from pyrimethamine.
Dapsone, 200 mg weekly PO; plus 
pyrimethamine, 75 mg weekly PO; 
plus leucovorin, 25 mg weekly PO
Leucovorin prevents bone marrow 
toxicity from pyrimethamine.
Pentamidine, 300 mg monthly via 
Respirgard II nebulizer
Adverse reactions include cough and 
bronchospasm.
Atovaquone, 1500 mg qd PO
—
TMP-SMX, 1 DS tablet three times 
weekly PO
TMP-SMX can be safely reintroduced 
for treatment of some pts who have 
had mild to moderate side effects.
aFor list of adverse effects, see Table 116-1.
bOne DS tablet contains 160 mg of TMP and 800 mg of SMX.
Abbreviations: DS, double-strength; SS, single-strength.
• For moderate to severe cases (a Pao2 ≤70 mmHg or a PAo2 – Pao2 
gradient ≥35 mmHg), alternatives include IV pentamidine, IV clinda-
mycin plus primaquine (potentially more effective than pentamidine), 
and trimetrexate plus leucovorin. 
• Adjunctive administration of tapering doses of glucocorticoids to 
HIV-infected pts with moderate to severe disease reduces the risk of 
respiratory function deterioration shortly after initiation of treatment. 
Use of glucocorticoids in other pts remains to be evaluated.
� PROGNOSIS
• Therapy is most effective if started early, before there is extensive alveolar 
damage. 
• The mortality rate among HIV-infected pts is 0–15%. 
• The risk of early death remains high among people who need mechanical 
ventilation (60%) and among non-HIV-infected pts (40%).
� PREVENTION
• Prophylaxis is indicated for HIV-infected pts with CD4+ T cell counts 
<200/μL or a history of oropharyngeal candidiasis and for any pt with a 
CHAPTER 117
763
Protozoal Infections
For a more detailed discussion, see Smulian AG, Walzer PD: 
Pneumocystis Infections, Chap. 207, p. 1671, in HPIM-18.
history of Pneumocystis pneumonia. Guidelines for other compromised 
hosts are less clear. 
• In HIV infection, once CD4+ counts have risen to >200/μL and have 
remained above that cutoff for ≥3 months, prophylaxis may be stopped. 
• For prophylactic regimens, see Table 116-2. TMP-SMX is the drug of 
choice for both primary and secondary prophylaxis and also protects 
against toxoplasmosis and some bacterial infections.
CHAPTER 117
Protozoal Infections
MALARIA
Microbiology 
Five major species of Plasmodium cause nearly all cases of human disease: 
P. falciparum, P. vivax, P. ovale, P. malariae, and P. knowlesi. 
• P. falciparum, the cause of most cases of severe disease and most deaths, 
predominates in Africa, New Guinea, and Hispaniola. 
• P. vivax is more common in Central America. 
• P. falciparum and P. vivax are equally prevalent in South America, the 
Indian subcontinent, eastern Asia, and Oceania. 
• P. ovale is unusual outside of Africa, where it makes up ~1% of isolates. 
• P. malariae is found in most areas (especially throughout sub-Saharan 
Africa) but is less common. 
• P. knowlesi (the monkey malaria parasite) can reliably be identified only 
by molecular techniques and is present in Borneo and Southeast Asia.
Epidemiology 
Malaria is the most important parasitic disease in humans, causing ~1 million 
deaths each year.
Pathogenesis 
After introduction of sporozoites into the bloodstream by female anopheline 
mosquitoes, the parasite travels to the liver and reproduces asexually to 
form merozoites that infect RBCs. The merozoites transform into trophozo-
ites, feed on intracellular proteins (principally hemoglobin), multiply 6- to 
20-fold every 48–72 h, and cause the RBCs to rupture, releasing daughter 
merozoites. The process then repeats.
• Some parasites develop into long-lived sexual forms called gametocytes, 
which can be taken up by another female anopheline mosquito, allowing 
transmission.
SECTION 7
764
Infectious Diseases
• In P. vivax or P. ovale infection, dormant forms called hypnozoites remain 
in liver cells and may cause disease 3 weeks to >1 year later.
• RBCs infected with P. falciparum may exhibit cytoadherence (attachment 
to venular and capillary endothelium), rosetting (adherence to uninfected 
RBCs), and agglutination (adherence to other infected RBCs). The result 
is sequestration of P. falciparum in vital organs, with consequent under-
estimation (through parasitemia determinations) of parasite numbers 
in the body. Sequestration is central to the pathogenesis of falciparum 
malaria but is not evident in the other three “benign” forms. 
• In nonimmune individuals, infection triggers nonspecific host defense 
mechanisms such as increased splenic filtration. 
 
–  With repeated exposure to malaria, pts develop resistance to high-
level parasitemia and disease but not to infection. 
 
–  Hemoglobinopathies (e.g., sickle cell disease, ovalocytosis, thalassemia) 
and G6PD deficiency are more common in endemic areas and protect 
against death from malaria.
Clinical Manifestations 
Pts initially develop nonspecific symptoms (e.g., headache, fatigue, myalgias) 
that are followed by fever.
• Febrile paroxysms at regular intervals are unusual and suggest infection 
with P. vivax or P. ovale.
• Splenomegaly, hepatomegaly, mild anemia, and jaundice may develop.
• The diagnosis of severe falciparum malaria requires ≥1 of the following: 
impaired consciousness/coma, severe normocytic anemia, renal failure, 
pulmonary edema, ARDS, circulatory shock, DIC, spontaneous bleeding, 
acidosis, hemoglobinuria, jaundice, repeated generalized convulsions, 
and a parasitemia level of >5%.
 
–  Cerebral malaria manifests as diffuse symmetric encephalopathy, typi-
cally without focal neurologic signs.
 
–  Coma is an ominous sign associated with mortality rates of ~20%.
• Pregnant women have unusually severe illness. Premature labor, fetal 
distress, stillbirth, and delivery of low-birth-weight infants are common.
• Tropical splenomegaly (hyperreactive malarial splenomegaly) may result 
as a chronic complication of malaria and is characterized by massive 
splenomegaly, hepatomegaly, and an abnormal immunologic response to 
infection. 
Diagnosis
Although antibody-based diagnostic tests are being used with increasing 
frequency, demonstration of asexual forms of the parasite on peripheral-
blood smears is required for diagnosis. 
• Thick and thin smears should be examined; thick smears and the less 
sensitive thin smears detect parasitemia levels as low as  0.001% and 
~0.05%, respectively.
• If the level of clinical suspicion is high and smears are initially negative, 
they should be repeated q12–24h for 2 days.
• Other laboratory findings generally include normochromic, normocytic 
anemia; elevated inflammatory markers; and thrombocytopenia (~105/μL).
CHAPTER 117
765
Protozoal Infections
Malaria
TREATMENT
• See Table 117-1 for treatment regimens. IV artesunate is approved by 
the U.S. Food and Drug Administration for emergency use against 
severe malaria through the CDC [Malaria Hotline: 770-488-7788; 
Emergency Operations Center (after hours): 770-488-7100].
• Pts receiving quinidine should undergo cardiac monitoring; a total 
plasma level of >8 μg/mL, increased QT intervals (>0.6 s), or QRS 
widening by >25% is an indication for slowing the infusion rate.
• Exchange transfusions can be considered for severely ill pts, although 
indications for their use are not yet agreed upon. 
• All pts with severe malaria should receive a continuous infusion of 
dextrose. Unconscious pts should have blood glucose levels measured 
q4–6h. 
• Parasite counts and hematocrits for pts with severe malaria and pts 
with uncomplicated disease should be measured q6–12h and q24h, 
respectively.
• Primaquine (0.5 mg of base/kg for 14 days) eradicates persistent liver 
stages and prevents relapse in P. vivax or P. ovale infection. G6PD 
deficiency must be ruled out before treatment.
Personal Protection Measures 
Measures that can protect persons against infection include avoidance of 
mosquito exposure, with particular caution at peak feeding times (dusk 
and dawn); use of insect repellents containing DEET (10–35%) or (if 
DEET is unacceptable) picaridin (7%); suitable clothing; and insecticide-
impregnated bed nets.
Chemoprophylaxis
See Table 117-2 for prophylaxis options.
• Mefloquine is the only drug advised for pregnant women traveling to 
areas with drug-resistant malaria and is generally considered safe in the 
second and third trimesters; data regarding use in the first trimester, 
although limited, are reassuring.
BABESIOSIS
Microbiology 
Babesiosis is caused by intraerythrocytic protozoa of the genus Babesia. B. 
microti is the etiologic agent in the northeastern United States, and B. duncani 
is responsible for disease on the West Coast. B. divergens causes disease in 
Europe. The deer tick (Ixodes scapularis) transmits B. microti; the vectors of 
transmission for the other Babesia species are unknown.
Epidemiology 
In the United States, infections occur most frequently along the northeastern 
coast. In 2009, >700 cases were reported in the U.S.; this number is probably 
SECTION 7
766
Infectious Diseases
TABLE 117-1 REGIMENS FOR THE TREATMENT OF MALARIA
Type of Disease or Treatment
Regimen(s)
Uncomplicated malaria
Known chloroquine-sensitive 
strains of Plasmodium vivax,
P. malariae, P. ovale, P. knowlesi, 
P. falciparum a
Chloroquine (10 mg of base/kg stat 
followed by 5 mg/kg at 12, 24, and 36 h 
or by 10 mg/kg at 24 h and 5 mg/kg at 
48 h)
or
Amodiaquine (10–12 mg of base/kg qd 
for 3 days)
Radical treatment for P. vivax 
or P. ovale infection
In addition to chloroquine or amodiaquine 
as detailed above, primaquine (0.5 mg 
of base/kg qd) should be given for 
14 days to prevent relapse. In mild G6PD 
deficiency, 0.75 mg of base/kg should 
be given once weekly for 6–8 weeks. 
Primaquine should not be given in severe 
G6PD deficiency.
Sensitive P. falciparum malariab
Artesunatec (4 mg/kg qd for 3 days) plus 
sulfadoxine (25 mg/kg)/pyrimethamine 
(1.25 mg/kg) as a single dose
or
Artesunatec (4 mg/kg qd for 3 days) plus 
amodiaquine (10 mg of base/kg qd for 
3 days)d
Multidrug-resistant
P. falciparum malaria
Either artemether-lumefantrinec (1.5/
9 mg/kg bid for 3 days with food)
or
Artesunatec (4 mg/kg qd for 3 days)
plus
Mefloquine (25 mg of base/kg—either 
8 mg/kg qd for 3 days or 15 mg/kg on 
day 2 and then 10 mg/kg on day 3)d
Second-line treatment/treatment 
of imported malaria
Either artesunatec (2 mg/kg qd for 7 days) 
or quinine (10 mg of salt/kg tid for 7 
days) plus 1 of the following 3:
1.  Tetracyclinee (4 mg/kg qid for 7 days)
2.  Doxycyclinee (3 mg/kg qd for 7 days)
3.  Clindamycin (10 mg/kg bid for 7 days)
or
Atovaquone-proguanil (20/8 mg/kg qd 
for 3 days with food)
CHAPTER 117
767
Protozoal Infections
TABLE 117-1 REGIMENS FOR THE TREATMENT OF MALARIA (CONTINUED)
Type of Disease or Treatment
Regimen(s)
Severe falciparum malariaf
Artesunatec (2.4 mg/kg stat IV followed by 
2.4 mg/kg at 12 and 24 h and then daily 
if necessary)g or, if unavailable, one of the 
following:
Artemetherc (3.2 mg/kg stat IM followed 
by 1.6 mg/kg qd)
or
Quinine dihydrochloride (20 mg of salt/kgh
infused over 4 h, followed by 10 mg of 
salt/kg infused over 2–8 h q8hi)
or
Quinidine (10 mg of base/kgh infused over 
1–2 h, followed by 1.2 mg of base/kg per 
houri with electrocardiographic monitoring)
aVery few areas now have chloroquine-sensitive P. falciparum malaria (see Fig. 210-2 in HPIM-18).
bIn areas where the partner drug to artesunate is known to be effective.
cArtemisinin derivatives are not readily available in some temperate countries.
dFixed-dose coformulated combinations are available. The World Health Organization now 
recommends artemisinin combination regimens as first-line therapy for falciparum malaria 
in all tropical countries and advocates use of fixed-dose combinations.
eTetracycline and doxycycline should not be given to pregnant women or to children <8 years 
of age.
fOral treatment should be substituted as soon as the pt recovers sufficiently to take fluids by 
mouth.
gArtesunate is the drug of choice when available. The data from large studies in Southeast 
Asia showed a 35% lower mortality rate than with quinine, and very large studies in Africa 
showed a 22.5% lower mortality rate than with quinine.
hA loading dose should not be given if therapeutic doses of quinine or quinidine have definitely 
been administered in the previous 24 h. Some authorities recommend a lower dose of quinidine.
iInfusions can be given in 0.9% saline and 5–10% dextrose in water. Infusion rates for quinine 
and quinidine should be carefully controlled.
an underestimate, given that most pts experience a mild and self-limiting 
disease and may not seek medical attention.
Clinical Manifestations 
Most pts develop a mild illness, but immunosuppressed pts may have more 
severe disease. 
• After an incubation period of 1–6 weeks, pts gradually develop fevers, 
fatigue, and weakness. Other symptoms may include chills, sweats, myal-
gias, arthralgias, headache, and—less often—neck stiffness, shortness of 
breath, and abdominal pain.
TABLE 117-2 DRUGS USED IN THE PROPHYLAXIS OF MALARIA
Drug
Usage
Adult Dose
Pediatric Dose
Comments
Atovaquone/
proguanil (Malarone)
Prophylaxis in areas 
with chloroquine- or 
mefloquine-resistant
Plasmodium 
falciparum
1 adult tablet 
POa
5–8 kg: ½ pediatric tabletb daily
≥8–10 kg: ¾ pediatric tablet daily
≥10–20 kg: 1 pediatric tablet 
daily
≥20–30 kg: 2 pediatric tablets 
daily
≥30–40 kg: 3 pediatric tablets 
daily
≥40 kg: 1 adult tablet daily
Begin 1–2 days before travel to malarious areas. 
Take daily at the same time each day while in the 
malarious areas and for 7 days after leaving such 
areas. Atovaquone-proguanil is contraindicated in 
persons with severe renal impairment (creatinine 
clearance rate <30 mL/min). In the absence of 
data, it is not recommended for children weighing 
<5 kg, pregnant women, or women breast-feed-
ing infants weighing <5 kg. Atovaquone/proguanil 
should be taken with food or a milky drink.
Chloroquine
phosphate (Aralen 
and generic)
Prophylaxis, restricted 
to areas with chloro-
quine-sensitive P. falci-
parumc or P. vivax only
300 mg of base 
(500 mg of salt) 
PO once weekly
5 mg/kg of base (8.3 mg of salt/
kg) PO once weekly, up to maxi-
mal adult dose of 300 mg of base
Begin 1–2 weeks before travel to malarious 
areas. Take weekly on the same day of the week 
while in the malarious areas and for 4 weeks 
after leaving such areas. Chloroquine phosphate 
may exacerbate psoriasis.
Doxycycline (many 
brand names and 
generic)
Prophylaxis in areas 
with chloroquine- or 
mefloquine-resistant
P. falciparumc
100 mg PO qd
≥8 years of age: 2 mg/kg, up to 
adult dose
Begin 1–2 days before travel to malarious areas. 
Take daily at the same time each day while in 
the malarious areas and for 4 weeks after leav-
ing such areas. Doxycycline is contraindicated 
for children <8 years of age and for pregnant 
women.
768
Hydroxychloroquine
sulfate (Plaquenil)
An alternative to 
chloroquine for primary 
prophylaxis, restricted to 
areas with chloroquine-
sensitive P. falciparumc
or P. vivax only
310 mg of base 
(400 mg of salt) 
PO once weekly
5 mg of base/kg (6.5 mg of salt/
kg) PO once weekly, up to maxi-
mal adult dose of 310 mg of base
Begin 1–2 weeks before travel to malarious 
areas. Take weekly on the same day of the week 
while in the malarious areas and for 4 weeks 
after leaving such areas. Hydroxychloroquine 
may exacerbate psoriasis.
Mefloquine (Lariam 
and generic)
Prophylaxis in areas 
with chloroquine-
resistant P. falciparumc
228 mg of base 
(250 mg of salt) 
PO once weekly
≤9 kg: 4.6 mg of base/kg (5 mg 
of salt/kg) PO once weekly
10–19 kg: ¼ tablet once weekly
20–30 kg: ½ tablet once weekly
31–45 kg: ¾ tablet once weekly
≥46 kg: 1 tablet once weekly
Begin 1–2 weeks before travel to malarious areas. 
Take weekly on the same day of the week while in 
the malarious areas and for 4 weeks after leaving 
such areas. Mefloquine is contraindicated in persons 
allergic to this drug or related compounds (e.g., 
quinine and quinidine) and in persons with active 
or recent depression, generalized anxiety disorder, 
psychosis, schizophrenia, other major psychiatric 
disorders, or seizures. Use with caution in persons 
with psychiatric disturbances or a history of depres-
sion. Mefloquine is not recommended for persons 
with cardiac conduction abnormalities.
Primaquine
For prevention of 
malaria in areas with 
mainly P. vivax
30 mg of base 
(52.6 mg of 
salt) PO qd
0.5 mg of base/kg (0.8 mg of 
salt/kg) PO qd, up to adult dose; 
should be taken with food
Begin 1–2 days before travel to malarious areas. 
Take daily at the same time each day while in the 
malarious areas and for 7 days after leaving such 
areas. Primaquine is contraindicated in persons 
with G6PD deficiency. It is also contraindicated 
during pregnancy and in lactation unless the 
infant being breast-fed has a documented normal 
G6PD level.
(continued)
769
TABLE 117-2 DRUGS USED IN THE PROPHYLAXIS OF MALARIA (CONTINUED)
Drug
Usage
Adult Dose
Pediatric Dose
Comments
Primaquine
Used for presumptive 
therapy to decrease 
risk of relapses of P. 
vivax and P. ovale (ter-
minal prophylaxis) 
30 mg of base 
(52.6 mg of 
salt) PO qd for 
14 days after 
departure from 
the malarious 
area
0.5 mg of base/kg (0.8 mg of 
salt/kg), up to adult dose, PO qd 
for 14 days after departure from 
the malarious area
This therapy is indicated for persons who have 
had prolonged exposure to P. vivax and/or P. 
ovale. It is contraindicated in persons with G6PD 
deficiency as well as during pregnancy and in 
lactation unless the infant being breast-fed has a 
documented normal G6PD level.
aAn adult tablet contains 250 mg of atovaquone and 100 mg of proguanil hydrochloride.
bA pediatric tablet contains 62.5 mg of atovaquone and 25 mg of proguanil hydrochloride.
cVery few areas now have chloroquine-sensitive malaria (see Fig. 210-2 in HPIM-18).
Source: CDC: wwwnc.cdc.gov/travel/yellowbook/2012/chapter-3-infectious-diseases-related-to-travel/malaria.htm#1939
770
CHAPTER 117
771
Protozoal Infections
• Severe babesiosis is associated with parasitemia levels of >4%. 
 
–  Risk factors include an age of >50 years, male gender, asplenia, HIV 
infection/AIDS, malignancy, and immunosuppression.
 
–  Complications include respiratory failure, DIC, CHF, and renal failure.
 
–  The fatality rate is 5% among all hospitalized pts and 20% among 
immunocompromised pts.
Diagnosis
Giemsa-stained thin smears identify intraerythrocytic Babesia parasites, 
which appear round or pear-shaped. 
• Ring forms resembling P. falciparum but without pigment are most common. 
• Tetrads (“Maltese crosses”)—formed by four budding merozoites—are 
pathognomonic for B. microti and other small Babesia species. 
• PCR and serology can also be used for diagnostic purposes. 
Babesiosis
TREATMENT
• Mild illness should be treated with atovaquone (750 mg PO q12h) plus 
azithromycin (500–1000 mg/d PO on day 1 followed by 250 mg/d PO) 
for 7–10 days.
– Clindamycin plus quinine is equally effective but not as well tolerated.
– Treatment should be given only if Babesia is detected on blood 
smear, regardless of serology or PCR results.
• Severe disease should be treated with clindamycin (300–600 mg q6h 
IV or 600 mg q8h PO) plus quinine (650 mg q6–8h PO) for 7–10 days. 
– Consider exchange transfusion in cases with high-level parasitemia 
(>10%); hemoglobin levels of ≤10 g/dL; or pulmonary, hepatic, or 
renal compromise.
– Immunocompromised pts generally need longer courses of treatment 
(e.g., 6 weeks), with at least 2 weeks of therapy after parasites are no 
longer detected on blood smear.
• B. duncani and B. divergens infections can be treated with IV clinda-
mycin and quinine for 7–10 days.
LEISHMANIASIS
Microbiology 
Leishmania species are extracellular, flagellated promastigotes while dwelling 
in their sandfly vector, but are obligate intracellular, nonflagellated 
amastigotes while living in vertebrate hosts, including humans. 
• Organisms of the L. donovani complex usually cause visceral leish-
maniasis and are present in Asia, the Middle East, the horn of Africa, the 
Mediterranean, and Central and South America. 
• L. tropica, L. major, and L. aethiopica cause Old World cutaneous leish-
maniasis and are present in Asia and in northern and sub-Saharan Africa. 
• The L. mexicana complex causes New World cutaneous leishmaniasis 
and is present in Central America and northern South America.
SECTION 7
772
Infectious Diseases
Epidemiology
Roughly 2 million cases of leishmaniasis occur annually worldwide, of 
which 1–1.5 million are cutaneous and 500,000 are visceral.
Clinical Manifestations
Visceral Leishmaniasis (kala-azar ): Pts most commonly present with an 
abrupt onset of moderate- to high-grade fever associated with rigor and 
chills.
• Splenomegaly, hepatomegaly, and (except in the Indian subcontinent) 
lymphadenopathy are common.
• Leukopenia, anemia, thrombocytopenia, a polyclonal increase in serum 
immunoglobulins, and hepatic transaminitis are common.
• Up to 50% of pts in India, East Africa, and the Sudan may develop 
hypopigmented skin lesions (post–kala-azar dermal leishmaniasis) con-
current with or after cure of visceral leishmaniasis. In some cases, these 
pts may require unusually long treatment courses.
Cutaneous Leishmaniasis: After an incubation period of days or weeks, 
papular lesions progress to nodules that ulcerate over weeks or months. 
Lesions usually heal spontaneously after 2–15 months.
• The margins of the ulcer are raised and indurated, and the base of the 
ulcer is usually painless.
• Disease due to L. tropica may involve leishmaniasis recidivans: develop-
ment of new scaly, erythematous papules in the area of a healed sore.
Mucosal Leishmaniasis: This disfiguring sequela of New World cutaneous 
leishmaniasis results from dissemination of parasites from the skin to the 
naso-oropharyngeal mucosa.
• Disease may occur 1–5 years after the initial cutaneous episode.
• Persistent nasal congestion and bleeding are followed by progressive 
ulcerative destruction.
• These lesions do not resolve spontaneously.
Diagnosis
• Visceral leishmaniasis: Identification of amastigotes in smears of tissue 
aspirates is the gold standard for diagnosis. 
 
–  The sensitivity of splenic smears is >95%, but splenic aspiration may 
be very dangerous; smears of bone marrow and lymph node aspirates 
have sensitivities of 60–85% and 50%, respectively. 
 
–  Several serologic techniques, including a rapid test, are available and 
offer good sensitivity.
• Cutaneous and mucosal leishmaniasis: Diagnosis is made by microscopy, 
culture, or PCR examination of aspirates and biopsy specimens from skin 
lesions and lymph nodes.
Leishmaniasis
TREATMENT
• Visceral leishmaniasis: The pentavalent antimonial (SbV) compounds 
sodium stibogluconate and meglumine antimoniate (20 mg/kg per day 
IV or IM for 28–30 days) are the first-line therapeutic agents.
CHAPTER 117
773
Protozoal Infections
– Amphotericin B (AmB; either deoxycholate or a lipid formulation) 
is recommended in areas with SbV resistance (e.g., northeastern 
India) or if initial SbV therapy fails.
– Paromomycin and the oral agent miltefosine have been approved 
for treatment of visceral leishmaniasis in India. 
– Liposomal AmB is the drug of choice for HIV-infected pts.
• Cutaneous leishmaniasis: Although lesions generally self-resolve, treat-
ment may be needed if lesions spread or persist. 
– Topical agents can be effective for a few small lesions. Systemic 
treatment is needed for multiple lesions; lesions on the face, hands, 
or joints; and lesions of New World cutaneous leishmaniasis. 
– Administration of SbV (20 mg/kg daily for 20 days) constitutes 
the most effective treatment. Exceptions include disease due to 
L. guyanensis (pentamidine isethionate preferred) or L. aethiopica 
(paromomycin preferred).
• Mucosal leishmaniasis: SbV (20 mg/kg for 30 days) is recommended. 
– Pts require long-term follow-up, and neither relapse nor failure of 
therapy is uncommon.
– AmB and potentially miltefosine can be used in cases of relapse or 
therapy failure. 
TRYPANOSOMIASIS
� CHAGAS’ DISEASE
Microbiology and Pathology 
Trypanosoma cruzi causes Chagas’ disease (American trypanosomiasis) and 
is transmitted among mammalian hosts by hematophagous reduviid bugs. 
Organisms disseminate through the lymphatics and the bloodstream, often 
parasitizing muscles particularly heavily.
Epidemiology 
T. cruzi is found exclusively in the Americas and causes disease mostly 
among the poor in rural areas of Mexico and Central and South America. 
An estimated 8 million people are chronically infected, with 14,000 deaths 
annually.
Clinical Manifestations 
An indurated area of erythema and swelling (the chagoma) with local 
lymphadenopathy generally precedes malaise, fever, anorexia, and edema 
of the face and lower extremities.
• Romaña’s sign—unilateral painless edema of the palpebrae and periocu-
lar tissues—occurs when the conjunctiva is the portal of entry.
• Acute disease resolves spontaneously within 4–8 weeks, and pts enter an 
asymptomatic phase of chronic infection.
• Symptomatic chronic disease becomes apparent years or even decades 
after the initial infection.
 
–  Cardiac symptoms are common and include rhythm disturbances, 
segmental or dilated cardiomyopathy, and thromboembolism.
SECTION 7
774
Infectious Diseases
 
–  Pts can develop megaesophagus and suffer from dysphagia, odyno-
phagia, chest pain, and regurgitation.
 
–  Megacolon may develop, leading to abdominal pain, chronic constipa-
tion, fecaloma formation, obstruction, and volvulus.
Diagnosis
Microscopic examination of fresh anticoagulated blood, the buffy coat, or 
blood smears may reveal organisms in cases of acute Chagas’ disease. Serology 
has no diagnostic role in acute disease. Chronic Chagas’ disease is diagnosed 
by detection of specific IgG antibodies. Given the frequency of false-positive 
results, a positive result should be confirmed by at least two assays. 
Chagas’ Disease
TREATMENT
• Only two drugs—nifurtimox and benznidazole—are available to treat 
Chagas’ disease; neither is entirely effective.
– Nifurtimox (8–10 mg/kg qd in 4 divided oral doses for 90–120 days) 
reduces symptom duration, parasitemia level, and mortality rate but 
offers a parasitologic cure in only ~70% of cases.
– Benznidazole (5 mg/kg qd in 2 or 3 divided doses for 60 days) is the 
drug of choice in Latin America and may provide parasitologic cure 
rates as high as 90%.
– Both drugs have a number of side effects.
• Treatment of chronic Chagas’ disease is controversial; no adequate 
studies demonstrate efficacy. However, a panel of experts convened by 
the CDC recommends that pts <50 years old with presumably long-
standing T. cruzi infection be offered treatment. 
� SLEEPING SICKNESS
Microbiology and Epidemiology 
Sleeping sickness (human African trypanosomiasis, HAT) is caused by 
parasites of the T. brucei complex and is transmitted via tsetse flies. 
• T. b. rhodesiense causes the East African form and T. b. gambiense the 
West African form; these two forms are epidemiologically and clinically 
distinct illnesses.
• Humans are the only reservoir for T. b. gambiense; infection occurs 
primarily in rural populations and rarely develops in tourists. T. b. rhod-
esiense has reservoirs in antelope and cattle; tourists can be infected when 
visiting areas where infected game and vectors are present.
• HAT was nearly eradicated in the mid-1960s but resurged in the 1990s. 
There were an estimated 50,000–70,000 new cases in 2004.
Clinical Manifestations 
A trypanosomal chancre develops ~1 week after the bite of an infected 
tsetse fly. A systemic febrile illness without involvement of the CNS (stage I 
disease) then evolves as the parasites disseminate through the bloodstream 
and lymphatics.
CHAPTER 117
775
Protozoal Infections
• Bouts of high-grade fever lasting several days are separated by afebrile 
periods. Malaise, headache, arthralgias, hepatosplenomegaly, and other 
nonspecific manifestations can develop.
• Lymphadenopathy with discrete, rubbery, nontender nodes is prominent 
in T. b. gambiense disease. Enlargement of nodes of the posterior cervical 
triangle (Winterbottom’s sign) is a classic manifestation.
• With CNS invasion (stage II disease), pts develop progressive indiffer-
ence and daytime somnolence, a state that sometimes alternates with 
restlessness and insomnia. Extrapyramidal signs may include choreiform 
movements, tremors, and fasciculations; ataxia is common.
• Disease due to T. b. rhodesiense is more acute and, if untreated, can lead 
to death in weeks to months; in contrast, disease due to T. b. gambiense 
can smolder for months or years.
Diagnosis
Examination of fluid from the chancre, thin or thick blood smears, buffy 
coats, lymph node aspirates, bone marrow biopsy specimens, or CSF 
samples can reveal the parasite. 
• Parasitemia is more likely in stage I disease than in stage II disease and 
in pts infected with T. b. rhodesiense rather than T. b. gambiense.
• CSF should be examined whenever the diagnosis is being considered. 
Increased opening pressure, increased protein level, and increased 
mononuclear cell counts are common. 
Sleeping Sickness
TREATMENT
Stage I disease
• T. b. rhodesiense: suramin (a test dose of 100–200 mg followed by 
20 mg/kg IV on days 1, 5, 12, 18, and 26)
–  Hypersensitivity reactions and renal damage are the most important 
side effects. 
– A urinalysis should be done before each dose. Treatment should be 
discontinued if there is hematuria or increasing proteinuria or if 
casts are present in the sediment.
• T. b. gambiense: pentamidine (4 mg/kg daily IM or IV for 10 days) 
–  Serious adverse reactions include nephrotoxicity, abnormal liver 
function, neutropenia, hypoglycemia, and sterile abscesses.
–  Suramin is an alternative agent.
Stage II disease
• T. b. rhodesiense: melarsoprol (2–3.6 mg/kg daily in 3 divided doses for 
3 days; 1 week later, 3.6 mg/kg per day in 3 divided doses for 3 days; 
1 week later, the latter course repeated). To reduce melarsoprol-induced 
encephalopathy, administer prednisolone (1 mg/kg up to 40 mg daily, 
starting 1–2 days before the first dose of melarsoprol and continuing 
through the last dose).
• T. b. gambiense: Eflornithine (100 mg/kg IV qid for 2 weeks) is the first-
line agent. Melarsoprol (2.2 mg/kg qd IV for 10 days) is an alternative.
SECTION 7
776
Infectious Diseases
TOXOPLASMOSIS
Microbiology and Epidemiology 
Toxoplasmosis is caused by the intracellular parasite Toxoplasma gondii; 
cats and their prey are the definitive hosts. The primary route of transmis-
sion to humans is ingestion of tissue cysts from contaminated soil, food 
(e.g., undercooked meat), or water. 
• Roughly one-third of women who contract T. gondii during pregnancy 
transmit the parasite to the fetus, with a 65% risk of transmission if the 
maternal infection is acquired during the third trimester. 
• In the United States and most European countries, seroconversion rates 
increase with age and exposure; 10–67% of persons >50 years old are 
seropositive.
Pathogenesis 
Both humoral and cellular immunity are important, but subclinical infec-
tion commonly persists for the pt’s lifetime. Immunocompromised hosts 
lack factors required to control infection; the consequences are progressive 
focal destruction and organ failure.
Clinical Manifestations 
Disease in immunocompetent hosts is usually asymptomatic (80–90% of 
cases) and self-limited and does not require therapy. In contrast, immu-
nocompromised pts, including newborns, can develop severe infections 
typically involving the CNS.
• In the minority of immunocompetent pts who develop symptoms of 
acute infection, cervical lymphadenopathy is the most common finding; 
nodes are nontender and discrete. Generalized lymphadenopathy, fever 
<40°C, headache, malaise, and fatigue occur in 20–40% of pts. Clinical 
disease usually resolves within several weeks, although lymphadenopa-
thy may persist for several months.
• Immunocompromised pts develop acute toxoplasmosis through reacti-
vation of latent infection in 95% of cases; the remainder of cases are due 
to new acquisition of parasites.
 
–  CNS findings include encephalopathy, meningoencephalitis, and 
mass lesions. Pts may develop changes in mental status (75%), fever 
(10–72%), seizures (33%), headaches (56%), and focal neurologic 
findings (60%). The brainstem, basal ganglia, pituitary gland, and 
corticomedullary junction are most often involved.
 
–  Multiple organs (e.g., lungs, GI tract, skin, eyes, heart, liver) can be 
affected. Toxoplasma pneumonia is often confused with Pneumocystis 
pneumonia because of an overlapping pt population and similar 
clinical presentations (i.e., fever, dyspnea, and nonproductive cough 
rapidly progressing to respiratory failure).
• Congenital infection, which affects 400–4000 infants each year in the 
U.S., may initially be asymptomatic but can result in reactivation and 
clinical disease (e.g., chorioretinitis) decades later. 
• Toxoplasma causes ~35% of all cases of chorioretinitis in the U.S. and 
Europe, most of which are thought to be due to congenital infection. 
CHAPTER 117
777
Protozoal Infections
Blurred vision, macular involvement with loss of central vision, sco-
toma, photophobia, and eye pain are manifestations of infection. On 
examination, yellow-white cotton-like patches with indistinct margins of 
hyperemia are seen. Older lesions appear as white plaques with distinct 
borders and black spots.
Diagnosis
Culture of the parasite is difficult and can be done only at specialized 
laboratories. However, serology is the primary method of diagnosis.
• Results of IgM, IgG, and antibody avidity levels can be combined to help 
determine when infection may have occurred. (Of note, IgM can persist 
for >1 year.) These tests, along with a more extensive panel of serologic 
tests, can be performed at the Toxoplasma reference lab at the Palo Alto 
Medical Foundation (www.pamf.org/serology/clinicianguide.html).
• In immunocompromised pts, a presumptive clinical diagnosis can be 
based on clinical presentation, history of exposure (e.g., a positive IgG 
result), and radiologic evaluation. Radiologic studies demonstrate bilateral 
contrast-enhancing lesions, typically in the basal ganglia and corticome-
dullary junction. These lesions can be difficult to distinguish from CNS 
lymphoma, although the latter more frequently consists of only a single 
lesion. A brain biopsy may be required for definitive diagnosis.
• Congenital toxoplasmosis is diagnosed by PCR of amniotic fluid (to 
detect the B1 gene of the parasite) and by the persistence of IgG antibody 
or a positive IgM titer after the first week of life; IgG antibody determina-
tions should be repeated every 2 months.
• Ocular toxoplasmosis is diagnosed by the detection of typical lesions on 
ophthalmologic examination and the demonstration of a positive IgG 
titer in serum or ocular fluids.
Toxoplasmosis
TREATMENT
• Immunocompetent pts with only lymphadenopathy do not require 
treatment unless they have persistent, severe symptoms.
• Immunocompromised pts should receive pyrimethamine plus sulfa-
diazine. In resource-poor settings, trimethoprim-sulfamethoxazole 
(TMP-SMX; one double-strength tablet daily) is an effective alternative.
– Either dapsone plus pyrimethamine or atovaquone with or without 
pyrimethamine is an alternative for pts who cannot take TMP-SMX.
• Congenital infection is treated daily for 1 year with oral pyrimeth-
amine (1 mg/kg), sulfadiazine (100 mg/kg), and folinic acid.
• Ocular toxoplasmosis is treated with pyrimethamine and either sulfa-
diazine or clindamycin for 1 month.
Chemoprophylaxis
The risk of disease is very high among AIDS pts who are seropositive for 
T. gondii and have a CD4+ T lymphocyte count of <100/μL. TMP-SMX (one 
double-strength tablet daily) should be given to these pts as prophylaxis 
SECTION 7
778
Infectious Diseases
against both Pneumocystis pneumonia and toxoplasmosis. Primary or 
secondary prophylaxis can be stopped if, after institution of antiretroviral 
treatment, the CD4+ T lymphocyte count is >200/μL for 3 months.
Personal Protection Measures 
Toxoplasma infection can be prevented by the avoidance of undercooked 
meats and oocyst-contaminated materials (e.g., a cat’s litter box).
For a more detailed discussion, see Reed SL, Davis CE: 
Laboratory Diagnosis of Parasitic Infections, Chap. e25; Moore 
TA: Pharmacology of Agents Used to Treat Parasitic Infections, 
Chap. e26; and White NJ, Breman JG: Atlas of Blood Smears 
of Malaria and Babesiosis, Chap. e27; Moore TA: Agents Used 
to Treat Parasitic Infections, Chap. 208, p. 1675; White NJ, 
Breman JG: Malaria, Chap. 210, p. 1688; Vannier E, Gelfand 
JA: Babesiosis, Chap. 211, p. 1706; Sundar S: Leishmaniasis, 
Chap. 212, p. 1709; Kirchhoff LV, Rassi A Jr: Trypanosomiasis, 
Chap. 213, p. 1716; and Kim K, Kasper LH: Toxoplasma
Infections, Chap. 214, p. 1722, in HPIM-18.
CHAPTER 118
Helminthic Infections and 
Ectoparasite Infestations
HELMINTHS
� NEMATODES
The nematodes, or roundworms, that are of medical significance can be 
broadly classified as either tissue or intestinal parasites.
Tissue Nematode Infections
With the exception of trichinellosis, these infections are due to invasive 
larval stages that do not reach maturity in humans.
Trichinellosis
Microbiology and Epidemiology Eight species of Trichinella cause human 
infection; two—T. spiralis and T. pseudospiralis—are found worldwide.
• Infection results when humans ingest meat (usually pork) that contains 
encysted Trichinella larvae. 
 
–  The larvae invade the small-bowel mucosa.
 
–  After 1 week, female worms release new larvae that migrate to striated 
muscle via the circulation and encyst.
• The host immune response has little effect on muscle-dwelling larvae.
• About 12 cases of trichinellosis are reported annually in the United States.
CHAPTER 118
779
Helminths and Ectoparasites
Clinical Manifestations Most light infections (<10 larvae per gram of 
muscle) are asymptomatic. A burden of >50 larvae per gram can cause fatal 
disease.
• In the first week of infection, large numbers of parasites invading the 
gut usually cause diarrhea, abdominal pain, constipation, nausea, and/or 
vomiting.
• In the second week of infection, pts develop symptoms related to larval 
migration and muscle invasion: hypersensitivity reactions with fever and 
hypereosinophilia; periorbital and facial edema; and hemorrhages in 
conjunctivae, retina, and nail beds. Deaths are usually due to myocarditis 
with arrhythmias or heart failure.
• 2–3 weeks after infection, larval encystment in muscle causes myosi-
tis, myalgias, muscle edema, and weakness (especially in extraocular 
muscles; the biceps; and muscles of the jaw, neck, lower back, and 
diaphragm).
• Symptoms peak at 3 weeks; convalescence is prolonged.
Diagnosis Eosinophilia develops in >90% of pts, peaking at a level of >50% 
at 2–4 weeks after infection. 
• An increase in parasite-specific antibody titers after the third week of 
infection confirms the diagnosis.
• Detection of larvae by microscopic examination of ≥1 g of fresh muscle 
tissue (i.e., not routine histopathologic sections) also confirms the 
diagnosis. Yields are highest near tendon insertions.
Trichinellosis
TREATMENT
• Mebendazole (200–400 mg tid for 3 days; then 400 mg tid for 8–14 days) 
or albendazole (400 mg bid for 8–14 days) is active against enteric-
stage parasites; the efficacy of these drugs against encysted larvae is 
inconclusive. 
• Glucocorticoids (e.g., prednisone at 1 mg/kg daily for 5 days) may 
reduce severe myositis and myocarditis.
Prevention Cooking pork until it is no longer pink or freezing it at 
–15˚C for 3 weeks kills larvae and prevents infection by most Trichinella 
species.
Visceral and Ocular Larva Migrans 
Microbiology and Epidemiology Humans are an incidental host for 
nematodes that cause visceral larva migrans. Most cases are caused by the 
canine ascarid Toxocara canis. Infection results when humans—most often 
preschool children—ingest soil contaminated by puppy feces that contain 
infective T. canis eggs. Larvae penetrate the intestinal mucosa and dissemi-
nate hematogenously to a wide variety of organs (e.g., liver, lungs, CNS), 
provoking intense eosinophilic granulomatous responses.
Clinical Manifestations Symptomatic infections result in fever, malaise, 
anorexia, weight loss, cough, wheezing, rashes, hepatosplenomegaly, and 
SECTION 7
780
Infectious Diseases
profound eosinophilia (up to 90%). Ocular disease usually develops in older 
children or young adults and includes an eosinophilic mass that mimics 
retinoblastoma, endophthalmitis, uveitis, and/or chorioretinitis. 
Diagnosis The clinical diagnosis can be confirmed by an ELISA for toxo-
caral antibodies. Stool examination for eggs is ineffective because larvae do 
not develop into adult worms in humans.
Visceral and Ocular Larva Migrans
TREATMENT
• The vast majority of Toxocara infections are self-limited and resolve 
without specific therapy. 
• For pts with severe disease, glucocorticoids can reduce inflammatory 
complications. 
• Antihelminthic drugs, including mebendazole and albendazole, have 
not been shown to alter the course of larva migrans.
• Ocular disease can be treated with albendazole (800 mg bid) and 
glucocorticoids for 5–20 days.
Cutaneous Larva Migrans This disease is caused by larvae of animal hook-
worms, usually the dog and cat hookworm Ancylostoma braziliense. Larvae 
in contaminated soil penetrate human skin; intensely pruritic, erythematous 
lesions form along the tracks of larval migration and advance several centime-
ters each day. Ivermectin (a single dose of 200 μg/kg) or albendazole (200 mg 
bid for 3 days) can relieve the symptoms of this self-limited infestation.
Intestinal Nematode Infections 
Intestinal nematodes infect >1 billion persons worldwide, most commonly 
in regions with poor sanitation and particularly in developing countries in 
the tropics or subtropics. Because most helminthic parasites do not self-
replicate, clinical disease (as opposed to asymptomatic infection) generally 
develops only with prolonged residence in an endemic area and is typically 
related to infection intensity.
Ascariasis
Microbiology Ascariasis is caused by Ascaris lumbricoides, the largest 
intestinal nematode, which reaches lengths up to 40 cm. 
• Humans—primarily younger children—are infected by ingestion of 
fecally contaminated soil that contains ascarid eggs. 
• Larvae hatch in the intestine, invade the mucosa, migrate to the lungs, 
break into the alveoli, ascend the bronchial tree, are swallowed, mature 
in the small intestine, and produce up to 240,000 eggs per day that pass 
in the feces.
Clinical Manifestations Most infections have a low worm burden and are 
asymptomatic. During lung migration of the parasite (~9–12 days after egg 
ingestion), pts may develop a cough and substernal discomfort, occasionally 
with dyspnea or blood-tinged sputum, fever, and eosinophilia. 
CHAPTER 118
781
• Eosinophilic pneumonitis (Löffler’s syndrome) may be evident. 
• Heavy infections with numerous entangled worms can occasionally cause 
pain, small-bowel obstruction, perforation, volvulus, biliary obstruction 
and colic, or pancreatitis.
Laboratory Findings Ascaris eggs (65 by 45 μm) can be found in fecal 
samples. Adult worms can pass in the stool or through the mouth. 
Ascariasis
TREATMENT
A single dose of albendazole (400 mg), mebendazole (500 mg), or 
ivermectin (150–200 μg/kg) is effective. Pyrantel pamoate (a single dose 
of 11 mg/kg; maximal dose, 1 g) is safe in pregnancy.
Hookworm
Microbiology Two hookworm species, Ancylostoma duodenale and 
Necator americanus, cause human infections. Infectious larvae present in 
soil penetrate the skin, reach the lungs via the bloodstream, invade the 
alveoli, ascend the airways, are swallowed, reach the small intestine, mature 
into adult worms, attach to the mucosa, and suck blood (0.2 mL/d per 
Ancylostoma adult) and interstitial fluid.
Clinical Manifestations Most infections are asymptomatic. Chronic 
infection causes iron deficiency and—in marginally nourished persons—
progressive anemia and hypoproteinemia, weakness, and shortness of 
breath. Larvae may cause pruritic rash (“ground itch”) at the site of skin 
penetration as well as serpiginous tracks of subcutaneous migration (similar 
to those of cutaneous larva migrans).
Laboratory Findings Hookworm eggs (40 by 60 μm) can be found in the 
feces. Stool concentration may be needed for the diagnosis of light infections.
Hookworm
TREATMENT
• Albendazole (400 mg once), mebendazole (500 mg once), or pyrantel 
pamoate (11 mg/kg daily for 3 days) is effective. Nutritional support, 
iron replacement, and deworming are undertaken as needed.
Strongyloidiasis
Microbiology and Epidemiology Unlike other helminths, Strongyloides 
stercoralis can replicate in the human host, permitting ongoing cycles of 
autoinfection from endogenously produced larvae. 
• Infection results when filariform larvae in fecally contaminated soil 
penetrate the skin or mucous membranes.
 
–  Larvae travel through the bloodstream to the lungs, break through into 
alveolar spaces, ascend the bronchial tree, are swallowed, reach the 
small intestine, mature into adult worms, and penetrate the mucosa of 
the proximal small bowel; eggs hatch in the intestinal mucosa. 
Helminths and Ectoparasites
SECTION 7
782
Infectious Diseases
 
–  Rhabditiform larvae can pass with the feces into the soil or can 
develop into filariform larvae that penetrate the colonic wall or peri-
anal skin and enter the circulation to establish ongoing autoinfection.
• Autoinfection is constrained by unknown factors of the host immune 
system, disruption of which (e.g., by glucocorticoid therapy) can lead to 
hyperinfection.
Clinical Features Uncomplicated disease is associated with mild cutane-
ous and/or abdominal manifestations such as recurrent urticaria, larva currens 
(a pathognomonic serpiginous, pruritic, erythematous eruption along the 
course of larval migration that may advance up to 10 cm/h), abdominal 
pain, nausea, diarrhea, bleeding, and weight loss. 
• Disseminated disease involves tissues outside the GI tract and lungs, 
including the CNS, peritoneum, liver, and kidney. 
 
–  Gram-negative sepsis, pneumonia, or meningitis can complicate or 
dominate the clinical course.
 
–  Disease can be fatal in pts given glucocorticoids; disseminated infec-
tion is uncommon among pts with HIV-1 infection.
• Fluctuating eosinophilia is common in uncomplicated disease but is 
uncommon in disseminated disease.
Diagnosis A single stool examination detects rhabditiform larvae (~250 
μm long) in about one-third of uncomplicated infections. Duodenojejunal 
contents can be sampled if stool examinations are repeatedly negative. 
• Antibodies can be detected by ELISA. 
• In disseminated infection, filariform larvae can be found in stool or 
at sites of larval migration (e.g., sputum, bronchoalveolar lavage fluid, 
surgical drainage fluid).
Strongyloidiasis
TREATMENT
• Ivermectin (200 μg/kg daily for 2 days) is more effective than alben-
dazole (400 mg daily for 3 days). Asymptomatic pts should be treated, 
given the potential for later fatal hyperinfection.
• Disseminated disease should be treated with ivermectin for ≥5–7 days 
(or until the parasites are eradicated).
Enterobiasis
Microbiology and Epidemiology Enterobiasis (pinworm) is caused by 
Enterobius vermicularis and affects ~40 million people in the U.S. (primar-
ily children).
• Gravid female worms migrate nocturnally from the cecum to the peri-
anal region, each releasing up to 10,000 immature eggs that become 
infective within hours.
• Autoinfection and person-to-person transmission result from perianal 
scratching and transport of infective eggs to the mouth.
Clinical Manifestations Perianal pruritus is the cardinal symptom and is 
often worst at night. Eosinophilia is uncommon.
CHAPTER 118
783
Diagnosis Eggs (55 by 25 μm and flattened on one side) are detected by 
microscopic examination of cellulose acetate tape applied to the perianal 
region in the morning. 
Enterobiasis
TREATMENT
• One dose of mebendazole (100 mg), albendazole (400 mg), or pyrantel 
pamoate (11 mg/kg; maximum, 1 g) is given, with the same treatment 
repeated after 2 weeks. Household members should also be treated to 
avoid reservoirs of potential reinfection.
Filarial and Related Infections 
Filarial worms, which infect more than 170 million people worldwide, are 
nematodes that dwell in the SC tissue and lymphatics. Usually, infection is 
established only with repeated and prolonged exposures to infective larvae; 
however, filarial disease is characteristically more intense and acute in 
newly exposed individuals than in natives of endemic areas.
• Filarial parasites have a complex life cycle, including infective larval 
stages carried by insects and adult worms that reside in humans. 
 
–  The offspring of adults are microfilariae (200–250 μm long, 5–7 μm 
wide) that either circulate in the blood or migrate through the skin. 
 
–  Microfilariae are ingested by the arthropod vector and develop over 
1–2 weeks into new infective larvae. 
• A Rickettsia-like endosymbiont, Wolbachia, is found in all stages of 
Brugia, Wuchereria, Mansonella, and Onchocerca and has become a 
target for antifilarial chemotherapy.
Lymphatic Filariasis 
Microbiology Lymphatic filariasis is caused by Wuchereria bancrofti (most 
commonly), Brugia malayi, or B. timori, which can reside in and cause 
inflammatory damage to lymphatic channels or lymph nodes. 
Clinical Manifestations Subclinical microfilaremia, hydrocele, acute 
adenolymphangitis (ADL), and chronic lymphatic disease are the main 
clinical presentations. 
• ADL is associated with high fever, lymphatic inflammation, and transient 
local edema. Both the upper and lower extremities can be involved in 
both bancroftian and brugian filariasis, but W. bancrofti almost exclu-
sively affects genital lymphatics. 
• ADL may progress to more chronic lymphatic obstruction and elephantiasis 
with brawny edema, thickening of the SC tissues, and hyperkeratosis. 
Superinfection is a problem.
Diagnosis Detection of the parasite is difficult, but microfilariae can be 
found in peripheral blood, hydrocele fluid, and occasionally other body 
fluids. 
• Timing of blood collection is critical and should be based on the peri-
odicity of the microfilariae in the endemic region involved (primarily 
nocturnal in many regions). 
Helminths and Ectoparasites
SECTION 7
784
Infectious Diseases
• Two assays are available to detect W. bancrofti circulating antigens, 
and a PCR has been developed to detect DNA of both W. bancrofti and 
B. malayi in the blood. 
• High-frequency ultrasound (with Doppler techniques) of the scrotum or 
the female breast can identify motile adult worms. 
• The presence of antifilarial antibody supports the diagnosis, but cross-
reactivity with other helminthic infections makes interpretation of this 
finding difficult.
Lymphatic Filariasis
TREATMENT
• Pts with active lymphatic filariasis (defined by microfilaremia, antigen 
positivity, or adult worms on ultrasound) should be treated with dieth-
ylcarbamazine (DEC; 6 mg/kg daily for 12 days). Albendazole (400 mg 
bid for 21 days), albendazole and DEC both given daily for 7 days, and 
doxycycline (100 mg bid for 4–6 weeks) are alternative regimens with 
macrofilaricidal efficacy. 
• A single dose of albendazole (400 mg) combined with DEC (6 mg/kg) 
or ivermectin (200 μg/kg) has sustained microfilaricidal activity and is 
used in lymphatic filariasis eradication campaigns.
• For pts with chronic lymphatic filariasis, treatment regimens should 
focus on hygiene, prevention of secondary bacterial infections, and 
physiotherapy. Drug treatment should be reserved for individuals with 
evidence of active infection.
Onchocerciasis
Microbiology and Epidemiology Onchocerciasis (“river blindness”) is 
caused by Onchocerca volvulus, which infects 37 million people worldwide 
and is transmitted by the bite of an infected blackfly near free-flowing rivers 
and streams.
• Larvae deposited by the blackfly develop into adult worms (females 
and males are ~40–60 cm and ~3–6 cm in length, respectively) that are 
found in SC nodules (onchocercomata). About 7 months to 3 years after 
infection, the gravid female releases microfilariae that migrate out of the 
nodules and concentrate in the dermis.
• In contrast to lymphatic filariasis, onchocerciasis is characterized by 
microfilarial induction of inflammation.
Clinical Manifestations Onchocerciasis most commonly presents as 
dermatologic manifestations (an intensely pruritic papular rash or firm 
nontender onchocercomata), but visual impairment is the most serious 
complication in pts with moderate or heavy infections.
• Conjunctivitis with photophobia is an early ocular finding.
• Sclerosing keratitis (the leading cause of onchocercal blindness in Africa, 
affecting 1–5% of pts), anterior uveitis, iridocyclitis, and secondary glau-
coma due to pupillary deformities are more serious ocular complications.
Diagnosis A definitive diagnosis is based on the finding of an adult worm 
in an excised nodule or of microfilariae in a skin snip. 
CHAPTER 118
785
• Specific antibody assays and PCR to detect onchocercal DNA are avail-
able in reference laboratories. 
• Eosinophilia and elevated serum IgE levels are common but nonspecific.
Onchocerciasis
TREATMENT
• Ivermectin (a single dose of 150 μg/kg), given yearly or semiannually, 
is microfilaricidal and is the mainstay of treatment. 
– In African regions where O. volvulus is co-endemic with Loa loa, 
ivermectin is contraindicated because of the risk of severe post-
treatment encephalopathy. 
– Doxycycline therapy for 6 weeks is macrofilaristatic, rendering 
adult female worms sterile for long periods, and also targets the 
Wolbachia endosymbiont. 
• Nodules on the head should be excised to avoid ocular infection.
� TREMATODES
• The trematodes, or flatworms, may be classified according to the tissues 
invaded by the adult flukes: blood, biliary tree, intestines, and lungs. 
• The life cycle involves a definitive mammalian host (e.g., humans), in 
which adult worms produce eggs through sexual reproduction, and 
an intermediate host (e.g., snails), in which miracidial forms undergo 
asexual reproduction to form cercariae. Worms do not multiply within 
the definitive host. 
• Human infection results from either direct penetration of intact skin or 
ingestion.
• Infections with trematodes that migrate through or reside in host 
tissues are associated with a moderate to high degree of peripheral-blood 
eosinophilia.
Schistosomiasis
Microbiology and Epidemiology Five species cause human schistoso-
miasis: the intestinal species Schistosoma mansoni, S. japonicum, S. mekongi, 
and S. intercalatum and the urinary species S. haematobium. 
• After infective cercariae penetrate intact skin, they mature into schisto-
somula and migrate through venous or lymphatic vessels to the lungs 
and ultimately the liver parenchyma. Sexually mature worms migrate to 
the veins of the bladder and ureters (S. haematobium) or the mesentery 
(S. mansoni, S. japonicum, S. mekongi, S. intercalatum) and deposit eggs. 
 
–  Some mature ova are extruded into the intestinal or urinary lumina, 
from which they may be voided and ultimately may reach water and 
perpetuate the life cycle. 
 
–  The persistence of ova in tissues leads to a granulomatous host 
response and fibrosis. 
• These blood flukes infect 200–300 million persons in South America, the 
Caribbean, Africa, the Middle East, and Southeast Asia. 
Clinical Manifestations Schistosomiasis occurs in three stages that vary 
by species, intensity of infection, and host factors.
Helminths and Ectoparasites
SECTION 7
786
Infectious Diseases
• Cercarial invasion, most often with S. mansoni and S. japonicum infections, 
causes a pruritic maculopapular rash (“swimmers’ itch”) 2–3 days later.
• Acute schistosomiasis (Katayama fever) presents 4–8 weeks after skin inva-
sion as a serum sickness–like illness characterized by fever, generalized 
lymphadenopathy, hepatosplenomegaly, and significant eosinophilia. 
• Chronic schistosomiasis causes manifestations that depend primarily on 
the schistosome species.
 
–  Intestinal species cause colicky abdominal pain, bloody diarrhea, 
anemia, hepatosplenomegaly, portal hypertension, and esophageal 
varices with bleeding.
 
–  Urinary species cause dysuria, frequency, hematuria, obstruction with 
hydroureter and hydronephrosis, fibrosis of bladder granulomas, and 
late development of squamous cell carcinoma of the bladder.
 
–  Pulmonary disease (e.g., endarteritis obliterans, pulmonary hyper-
tension, cor pulmonale) and CNS disease (e.g., Jacksonian epilepsy, 
transverse myelitis) can occur and are due to granulomas and fibrosis.
Diagnosis Diagnosis is based on geographic history, clinical presentation, 
and presence of schistosome ova in excreta. 
• Serologic assays for schistosomal antibodies (available through the CDC 
in the U.S.) may yield positive results before eggs are seen in excreta. 
• Infection may also be diagnosed by examination of tissue samples, 
typically from rectal biopsies. 
Schistosomiasis
TREATMENT
• Because antischistosomal therapy has no significant impact on matur-
ing worms, supportive measures and the consideration of glucocorti-
coid treatment constitute initial management for acute schistosomiasis. 
– After the acute critical phase has resolved, a single day of treatment 
with praziquantel (20 mg/kg bid for S. mansoni, S. intercalatum, 
and S. haematobium infections; 20 mg/kg tid for S. japonicum and 
S. mekongi infections) results in parasitologic cure in ~85% of cases 
and reduces egg counts by >90%. 
– Late established manifestations, such as fibrosis, do not improve 
with treatment.
Prevention Travelers to endemic regions should avoid contact with all 
freshwater bodies.
Liver (Biliary) Flukes
• Clonorchiasis (due to Clonorchis sinensis) and opisthorchiasis (due 
to Opisthorchis viverrini and O. felineus) occur in Southeast Asia and 
Eastern Europe. 
 
–  Infection is acquired by ingestion of contaminated raw freshwater fish; 
larvae travel through the ampulla of Vater and mature in biliary canaliculi. 
 
–  Most infected individuals are asymptomatic; chronic or repeated 
infection causes cholangitis, cholangiohepatitis, and biliary obstruc-
tion and is associated with cholangiocarcinoma. 
CHAPTER 118
787
 
–  Therapy for acute infection consists of praziquantel administration 
(25 mg/kg tid for 1 day).
• Fascioliasis (due to Fasciola hepatica and F. gigantica) is endemic in sheep-
raising countries and has a worldwide prevalence of 17 million cases. 
 
–  Infection is acquired by ingestion of contaminated aquatic plants (e.g., 
watercress). 
 
–  Acute disease develops 1–2 weeks after infection and causes fever, 
right-upper-quadrant pain, hepatomegaly, and eosinophilia. Chronic 
infection is infrequently associated with bile duct obstruction and 
biliary cirrhosis. 
 
–  For treatment, triclabendazole is given as a single dose of 10 mg/kg.
• Stool ova and parasite (O & P) examination diagnoses infection with 
liver flukes.
Lung Flukes Infection with Paragonimus spp. is acquired by ingestion of 
contaminated crayfish and freshwater crabs. 
• Acute infection causes lung hemorrhage, necrosis with cyst forma-
tion, and parenchymal eosinophilic infiltrates. A productive cough 
with brownish or bloody sputum, in association with peripheral-blood 
eosinophilia, is the usual presentation in pts with heavy infection. 
 
–  In chronic cases, bronchitis or bronchiectasis may predominate. 
 
–  CNS disease can also occur and can result in seizures. 
• The diagnosis is made by O & P examination of sputum or stool; serology 
can be helpful. 
• Praziquantel (25 mg/kg tid for 2 days) is the recommended therapy.
� CESTODES
The cestodes, or tapeworms, are segmented worms that can be classified 
into two groups according to whether humans are the definitive or the 
intermediate hosts. The tapeworm attaches to intestinal mucosa via sucking 
cups or hooks located on the scolex. Proglottids (segments) form behind the 
scolex and constitute the bulk of the tapeworm. 
Taeniasis Saginata and Taeniasis Asiatica 
Microbiology Humans are the definitive host for Taenia saginata, the 
beef tapeworm, and T. asiatica, the swine tapeworm, which inhabit the 
upper jejunum. Eggs are excreted in feces and ingested by cattle or other 
herbivores (T. saginata) or pigs (T. asiatica); larvae encyst (cysticerci) in the 
striated muscles of these animals. When humans ingest raw or undercooked 
meat, the cysticerci mature into adult worms in ~2 months.
Clinical Manifestations Pts become aware of the infection by noting 
passage of motile proglottids in their feces. They may experience perianal 
discomfort, mild abdominal pain, nausea, change in appetite, weakness, and 
weight loss.
Diagnosis The diagnosis is made by detection of eggs or proglottids in 
the stool; eggs may be detected in the perianal area by the cellophane-tape 
test (as in pinworm infection). Eosinophilia and elevated IgE levels may 
occur.
Helminths and Ectoparasites
SECTION 7
788
Infectious Diseases
Taeniasis Saginata and Taeniasis Asiatica
TREATMENT
Praziquantel is given in a single dose of 10 mg/kg.
Taeniasis Solium and Cysticercosis 
Microbiology and Pathogenesis Humans are the definitive host and pigs 
the usual intermediate host for T. solium, the pork tapeworm. 
• The disease has two forms, which depend on the form of parasite 
ingested. 
 
–  By ingesting undercooked pork containing cysticerci, humans develop 
intestinal tapeworms and a disease similar to taeniasis saginata. 
 
–  If humans ingest T. solium eggs (e.g., as a result of close contact with a 
tapeworm carrier or via autoinfection), they develop cysticercosis due 
to larvae penetrating the intestinal wall and migrating to many tissues.
Clinical Manifestations Intestinal infections are generally asymptomatic 
except for fecal passage of proglottids. The presentation of cysticercosis 
depends on the number and location of cysticerci as well as the extent of 
associated inflammatory responses or scarring.
• Cysticerci can be found anywhere in the body but most often are 
detected in the brain, skeletal muscle, SC tissue, or eye. 
• Neurologic manifestations are most common and include seizures (due 
to inflammation surrounding cysticerci in the brain), hydrocephalus 
(from obstruction of CSF flow by cysticerci and accompanying inflam-
mation or by arachnoiditis), and signs of increased intracranial pressure 
(e.g., headache, nausea, vomiting, changes in vision).
Diagnosis Intestinal infection is diagnosed by detection of eggs or proglot-
tids in stool. A consensus conference has delineated criteria for the diagnosis 
of cysticercosis (Table 118-1). Findings on neuroimaging include cystic 
lesions with or without enhancement, one or more nodular calcifications, 
or focal enhancing lesions.
Taeniasis Solium and Cysticercosis
TREATMENT
• Intestinal infections respond to a single dose of praziquantel (10 mg/
kg), but this treatment may evoke an inflammatory response in the 
CNS if there is cryptic cysticercosis. 
• Neurocysticercosis can be treated with albendazole (15 mg/kg per day 
for 8–28 days) or praziquantel (50–100 mg/kg daily in 3 divided doses 
for 15–30 days). 
– Given the potential for an inflammatory response to treatment, 
pts should be carefully monitored and high-dose glucocorticoids 
should be used during treatment. 
– Since glucocorticoids induce praziquantel metabolism, cimetidine 
should be given with praziquantel to inhibit this effect. 
– Supportive measures include antiepileptic administration and treat-
ment of hydrocephalus as indicated.
CHAPTER 118
789
TABLE 118-1 DIAGNOSTIC CRITERIA FOR HUMAN CYSTICERCOSISa
1. Absolute criteria
  a.  Demonstration of cysticerci by histologic or microscopic examination 
of biopsy material
  b.  Visualization of the parasite in the eye by funduscopy
  c.  Neuroradiologic demonstration of cystic lesions containing a 
characteristic scolex
2. Major criteria
  a.  Neuroradiologic lesions suggestive of neurocysticercosis
  b.  Demonstration of antibodies to cysticerci in serum by enzyme-linked 
immunoelectrotransfer blot
  c.  Resolution of intracranial cystic lesions spontaneously or after therapy 
with albendazole or praziquantel alone
3. Minor criteria
  a.  Lesions compatible with neurocysticercosis detected by neuroimaging 
studies
  b.  Clinical manifestations suggestive of neurocysticercosis
  c.  Demonstration of antibodies to cysticerci or cysticercal antigen in 
CSF by ELISA
  d.  Evidence of cysticercosis outside the CNS (e.g., cigar-shaped soft 
tissue calcifications)
4. Epidemiologic criteria
  a.  Residence in a cysticercosis-endemic area
  b.  Frequent travel to a cysticercosis-endemic area
  c.  Household contact with an individual infected with Taenia solium
aDiagnosis is confirmed by either one absolute criterion or a combination of two major criteria, 
one minor criterion, and one epidemiologic criterion. A probable diagnosis is supported by 
the fulfillment of (1) one major criterion plus two minor criteria; (2) one major criterion plus 
one minor criterion and one epidemiologic criterion; or (3) three minor criteria plus one 
epidemiologic criterion.
Source: Modified from Del Brutto OH et al: Proposed diagnostic criteria for neurocysticercosis. 
Neurology 57:177, 2001.
Echinococcosis
Microbiology and Epidemiology Humans are an intermediate host for 
Echinococcus larvae and acquire echinococcal disease by ingesting eggs 
spread by canine feces (for E. granulosus).
• After ingestion, embryos escape from the eggs, penetrate the intestinal 
mucosa, enter the portal circulation, and are carried to many organs but 
particularly the liver and lungs. Larvae develop into fluid-filled unilocular 
hydatid cysts within which daughter cysts develop, as do germinating 
cystic structures (brood capsules). Cysts expand over years.
• Disease is prevalent on all continents, particularly in areas where live-
stock is raised in association with dogs. 
Helminths and Ectoparasites
SECTION 7
790
Infectious Diseases
• E. multilocularis, found in arctic or subarctic regions, is similar, but wild 
canines (e.g., foxes) are the definitive hosts and rodents are the interme-
diate hosts. The parasite is multilocular, and vesicles progressively invade 
host tissue.
Clinical Manifestations Expanding cysts exert the effects of space-
occupying lesions, causing symptoms in the affected organ (usually liver 
and lung); the liver is involved in two-thirds of E. granulosus infections and 
~100% of E. multilocularis infections.
• Pts with hepatic disease most commonly present with abdominal pain or 
a palpable mass in the right upper quadrant. Compression of a bile duct 
may mimic biliary disease, and rupture or leakage from a hydatid cyst 
may cause fever, pruritus, urticaria, eosinophilia, or anaphylaxis. 
• Pulmonary cysts may rupture into the bronchial tree or the peritoneal 
cavity and cause cough, salty phlegm, chest pain, or hemoptysis. 
• Rupture of cysts may result in multifocal dissemination. 
• E. multilocularis disease may present as a hepatic tumor, with destruction 
of the liver and extension into adjoining (e.g., lungs, kidneys) or distant 
(e.g., brain, spleen) organs.
Diagnosis Radiographic imaging is important in detecting and evaluating 
echinococcal cysts. 
• Daughter cysts within a larger cyst are pathognomonic of E. granulosus. 
Eggshell or mural calcification on CT is also indicative of E. granulosus 
infections. 
• Serologic testing yields positive results in ~90% of pts with hepatic dis-
ease, but results can be negative in up to half of pts with lung cysts. 
• Aspiration of cysts usually is not attempted because leakage of cyst fluid 
can cause dissemination or anaphylactic reactions.
Echinococcosis
TREATMENT
• Therapy is based on considerations of the size, location, and manifes-
tations of cysts and the overall health of the pt. Ultrasound staging is 
recommended for E. granulosus infection. 
• For some uncomplicated lesions, PAIR [percutaneous aspiration, 
infusion of scolicidal agents (95% ethanol or hypertonic saline), and 
reaspiration] is recommended. 
– Albendazole (7.5 mg/kg bid for 4 days before the procedure and 
for at least 4 weeks afterward) is given for prophylaxis of secondary 
peritoneal echinococcosis due to inadvertent spillage of fluid dur-
ing this treatment.
– PAIR is contraindicated for superficial cysts, for cysts with multiple 
thick internal septal divisions, and for cysts communicating with 
the biliary tree. 
• Surgical resection is the treatment of choice for complicated E. granulosus 
cysts. 
– Albendazole should also be given prophylactically, as just described. 
Praziquantel (50 mg/kg daily for 2 weeks) may hasten the death of 
protoscolices. 
CHAPTER 118
791
– Medical therapy alone with albendazole for 12 weeks to 6 months 
results in cure in ~30% of cases and in clinical improvement in 
another 50%. 
• E. multilocularis infection is treated surgically, and albendazole is 
given for at least 2 years after presumptively curative surgery. If sur-
gery is not curative, albendazole should be continued indefinitely.
Diphyllobothriasis Diphyllobothrium latum, the longest tapeworm (up to 25 m), 
attaches to the ileal and occasionally the jejunal mucosa. Humans are infected 
by consumption of infected raw or smoked fish. Symptoms are rare and usu-
ally mild, but infection, particularly in Scandinavia, can cause vitamin B12 
deficiency because the tapeworm absorbs large amounts of vitamin B12 and 
interferes with ileal B12 absorption. Up to 2% of infected pts, especially the 
elderly, have megaloblastic anemia resembling pernicious anemia and can suffer 
neurologic sequelae due to B12 deficiency. The diagnosis is made by detection 
of eggs in the stool. Praziquantel (5–10 mg/kg once) is highly effective.
ECTOPARASITES
Ectoparasites are arthropods or helminths that infest the skin of other ani-
mals, from which they derive sustenance and shelter. These organisms can 
inflict direct injury, elicit hypersensitivity, or inoculate toxins or pathogens.
Scabies
Etiology and Epidemiology Scabies is caused by the human itch mite 
Sarcoptes scabiei and infests ~300 million people worldwide. 
• Gravid female mites burrow beneath the stratum corneum, deposit eggs 
that mature in 2 weeks, and emerge as adults to reinvade the same or 
another host. 
• Scabies transmission is facilitated by intimate contact with an infested 
person and by crowding, uncleanliness, or contact with multiple sexual 
partners.
Clinical Manifestations Itching, which is due to a sensitization reaction 
against excreta of the mite, is worst at night and after a hot shower. Burrows 
appear as dark wavy lines (≤15 mm in length), with most lesions located 
between the fingers or on the volar wrists, elbows, and penis. Norwegian or 
crusted scabies—hyperinfestation with thousands of mites—is associated 
with glucocorticoid use and immunodeficiency diseases.
Diagnosis Scrapings from unroofed burrows reveal the mite, its eggs, or 
fecal pellets.
Scabies
TREATMENT
• Permethrin cream (5%) should be applied thinly behind the ears and 
from the neck down after bathing and removed 8 h later with soap and 
water. A dose of ivermectin (200 μg/kg) is also effective but has not yet 
been approved by the U.S. Food and Drug Administration for scabies 
treatment. 
Helminths and Ectoparasites
SECTION 7
792
Infectious Diseases
• For crusted scabies, first a keratolytic agent (e.g., 6% salicylic acid) and 
then scabicides are applied to the scalp, face, and ears in addition to 
the rest of the body. Two doses of ivermectin, separated by an interval 
of 1–2 weeks, may be required for pts with crusted scabies. 
• Itching and hypersensitivity may persist for weeks or months in sca-
bies and should be managed with symptom-based treatment. Bedding 
and clothing should be washed in hot water and dried in a heated 
dryer, and close contacts (regardless of symptoms) should be treated 
to prevent reinfestations.
Pediculiasis
Etiology and Epidemiology Nymphs and adults of human lice—Pediculus 
capitis (the head louse), P. humanus (the body louse), and Pthirus pubis (the 
pubic louse)—feed at least once a day and ingest human blood exclusively. 
The saliva of these lice produces an irritating rash in sensitized persons. 
Eggs are cemented firmly to hair or clothing, and empty eggs (nits) remain 
affixed for months after hatching. Lice are generally transmitted from person 
to person. Head lice are transmitted among schoolchildren and body lice 
among disaster victims and indigent people; pubic lice are usually transmitted 
sexually. The body louse is a vector for the transmission of diseases such as 
louse-borne typhus, relapsing fever, and trench fever.
Diagnosis The diagnosis can be suspected if nits are detected, but confir-
matory measures should include the demonstration of a live louse.
Pediculiasis
TREATMENT
• If live lice are found, treatment with 1% permethrin (two 10-min 
applications 10 days apart) is usually adequate. If this course fails, 
treatment for ≤12 h with 0.5% malathion may be indicated. Eyelid 
infestations should be treated with petrolatum applied for 3–4 days. 
• Body lice usually are eliminated by bathing and by changing to laun-
dered clothes. 
– Pediculicides applied from head to foot may be needed in hirsute 
pts to remove body lice.
– Clothes and bedding should be deloused by placement in a hot 
dryer for 30 minutes or by heat pressing.
Myiasis In this infestation, maggots invade living or necrotic tissue or body 
cavities and produce clinical syndromes that vary with the species of fly. 
Certain flies are attracted to blood and pus, and newly hatched larvae enter 
wounds or diseased skin. Treatment consists of maggot removal and tissue 
debridement.
Leech Infestations Medicinal leeches can reduce venous congestion in surgical 
flaps or replanted body parts. Pts occasionally develop sepsis from Aeromonas 
hydrophila, which colonizes the gullets of commercially available leeches.
CHAPTER 118
793
For a more detailed discussion, see Reed SL, Davis CE: 
Laboratory Diagnosis of Parasitic Infections, Chap. e25; 
Moore TA: Pharmacology of Agents Used to Treat Parasitic 
Infections, Chap. e26; and Moore TA: Agents Used to 
Treat Parasitic Infections, Chap. 208, p. 1675; Weller PF: 
Trichinellosis and Other Tissue Nematode Infections, Chap. 
216, p. 1735; Weller PF, Nutman TB: Intestinal Nematode 
Infections, Chap. 217, p. 1739; Nutman TB, Weller PF: Filarial 
and Related Infections, Chap. 218, p. 1745; Mahmoud AAF: 
Schistosomiasis and Other Trematode Infections, Chap. 219, 
p. 1752; White AC Jr, Weller PF: Cestode Infections, Chap. 
220, p. 1759; and Pollack RJ: Ectoparasite Infestations and 
Arthropod Bites and Stings, Chap. 397, p. 3576, in HPIM-18.
Helminths and Ectoparasites
This page intentionally left blank 
795
CHAPTER 119
Physical Examination 
of the Heart
General examination of a pt with suspected heart disease should include 
vital signs (respiratory rate, pulse, blood pressure) and observation of skin 
color (e.g., cyanosis, pallor), clubbing, edema, evidence of decreased perfu-
sion (cool and diaphoretic skin), and hypertensive changes in optic fundi. 
Examine abdomen for evidence of hepatomegaly, ascites, or abdominal 
aortic aneurysm. An ankle-brachial index (systolic bp at ankle divided by 
arm systolic bp) <0.9 indicates lower extremity arterial obstructive disease. 
Important findings on cardiovascular examination include:
CAROTID ARTERY PULSE (FIG. 119-1)
• Pulsus parvus: Weak upstroke due to decreased stroke volume (hypovo-
lemia, LV failure, aortic or mitral stenosis).
• Pulsus tardus: Delayed upstroke (aortic stenosis).
• Bounding (hyperkinetic) pulse: Hyperkinetic circulation, aortic regurgita-
tion, patent ductus arteriosus, marked vasodilatation.
• Pulsus bisferiens: Double systolic pulsation (aortic regurgitation, 
hypertrophic cardiomyopathy).
• Pulsus alternans: Regular alteration in pulse pressure amplitude (severe 
LV dysfunction).
• Pulsus paradoxus: Exaggerated inspiratory fall (>10 mmHg) in systolic 
bp (pericardial tamponade, severe obstructive lung disease).
C. Hyperkinetic Pulse
A. Hypokinetic Pulse
D. Bisferiens Pulse
B. Parvus et Tardus Pulse
S
D
E. Dicrotic Pulse + Alternans
FIGURE 119-1 Carotid artery pulse patterns.
SECTION 8
Cardiology
SECTION 8
796
Cardiology
JUGULAR VENOUS PULSATION (JVP)
Jugular venous distention develops in right-sided heart failure, constrictive 
pericarditis, pericardial tamponade, obstruction of superior vena cava. JVP 
normally falls with inspiration but may rise (Kussmaul sign) in constrictive 
pericarditis. Abnormalities in examination include:
• Large “a” wave: Tricuspid stenosis (TS), pulmonic stenosis, AV dissocia-
tion (right atrium contracts against closed tricuspid valve).
• Large “v” wave: Tricuspid regurgitation, atrial septal defect.
• Steep “y” descent: Constrictive pericarditis.
• Slow “y” descent: Tricuspid stenosis.
PRECORDIAL PALPATION
Cardiac apical impulse is normally localized at the fifth intercostal space, 
midclavicular line. Abnormalities include:
• Forceful apical thrust: Left ventricular hypertrophy.
• Lateral and downward displacement of apex impulse: Left ventricular 
dilatation.
• Prominent presystolic impulse: Hypertension, aortic stenosis, hypertro-
phic cardiomyopathy.
• Double systolic apical impulse: Hypertrophic cardiomyopathy.
• Sustained “lift” at lower left sternal border: Right ventricular hypertrophy.
• Dyskinetic (outward bulge) impulse: Ventricular aneurysm, large dyski-
netic area post MI, cardiomyopathy.
AUSCULTATION
� HEART SOUNDS (FIG. 119-2)
S1
Loud: Mitral stenosis, short PR interval, hyperkinetic heart, thin chest wall. 
Soft: Long PR interval, heart failure, mitral regurgitation, thick chest wall, 
pulmonary emphysema.
S2
Normally A2 precedes P2 and splitting increases with inspiration; abnor-
malities include:
• Widened splitting: Right bundle branch block, pulmonic stenosis, mitral 
regurgitation.
• Fixed splitting (no respiratory change in splitting): Atrial septal defect.
• Narrow splitting: Pulmonary hypertension.
• Paradoxical splitting (splitting narrows with inspiration): Aortic stenosis, 
left bundle branch block, heart failure.
• Loud A2: Systemic hypertension.
• Soft A2: Aortic stenosis (AS).
• Loud P2: Pulmonary arterial hypertension.
• Soft P2: Pulmonic stenosis (PS).
S3
Low-pitched, heard best with bell of stethoscope at apex, following S2; 
normal in children; after age 30–35, indicates LV failure or volume overload.
CHAPTER 119 
797
Physical Examination of the Heart 
S4
Low-pitched, heard best with bell at apex, preceding S1; reflects atrial 
contraction into a noncompliant ventricle; found in AS, hypertension, 
hypertrophic cardiomyopathy, and coronary artery disease (CAD).
Opening Snap (OS) 
High-pitched; follows S2 (by 0.06–0.12 s), heard at lower left sternal border 
and apex in mitral stenosis (MS); the more severe the MS, the shorter the 
S2–OS interval.
Ejection Clicks 
High-pitched sounds following S1; observed in dilatation of aortic root or 
pulmonary artery, congenital AS (loudest at apex) or PS (upper left sternal 
border); the latter decreases with inspiration.
A Normal
EXPIRATION
INSPIRATION
S1
S2
A2 P2
B Atrial septal
defect
C Expiratory splitting
with inspiratory
increase (RBBB,
idiopathic dilatation PA)
D Reversed splitting
(LBBB, aortic
stenosis)
E Close fixed
splitting
(pulmonary
hypertension)
S1
S2
A2 P2
S1
S2
A2 P2
S1
S2
A2 P2
S1
S2
A2 P2
S1
S2
A2 P2
S1
S2
A2
P2
S1
S2
A2
P2
S1
S2
A2
P2
S1
S2
A2 P2
FIGURE 119-2 Heart sounds. A. Normal. S1, first heart sound; S2, second heart 
sound; A2, aortic component of the second heart sound; P2, pulmonic component of 
the second heart sound. B. Atrial septal defect with fixed splitting of S2. C. Physiologic
but wide splitting of S2 with right bundle branch block. D. Reversed or paradoxical 
splitting of S2 with left bundle branch block. E. Narrow splitting of S2 with pulmonary 
hypertension. (From NO Fowler: Diagnosis of Heart Disease. New York, Springer-Verlag, 
1991, p 31.)
SECTION 8
798
Cardiology
Midsystolic Clicks 
At lower left sternal border and apex, often followed by late systolic murmur 
in mitral valve prolapse.
� HEART MURMURS (TABLES 119-1 AND 119-2, FIG. 119-3)
Systolic Murmurs 
May be “crescendo-decrescendo” ejection type, pansystolic, or late systolic; 
right-sided murmurs (e.g., tricuspid regurgitation) typically increase with 
inspiration.
Diastolic Murmurs
• Early diastolic murmurs: Begin immediately after S2, are high-pitched, 
and are usually caused by aortic or pulmonary regurgitation.
• Mid-to-late diastolic murmurs: Low-pitched, heard best with bell of 
stethoscope; observed in MS or TS; less commonly due to atrial myxoma.
• Continuous murmurs: Present in systole and diastole (envelops S2); found 
in patent ductus arteriosus and sometimes in coarctation of aorta; less 
common causes are systemic or coronary AV fistula, aortopulmonary 
septal defect, ruptured aneurysm of sinus of Valsalva.
TABLE 119-1 HEART MURMURS 
Systolic Murmurs
Ejection-type
Aortic outflow tract
 Aortic valve stenosis
 Hypertrophic obstructive cardiomyopathy
 Aortic flow murmur
Pulmonary outflow tract
 Pulmonic valve stenosis
 Pulmonic flow murmur
Holosystolic
Mitral regurgitation
Tricuspid regurgitation
Ventricular septal defect
Late-systolic
Mitral or tricuspid valve prolapse
Diastolic Murmurs
Early diastolic
Aortic valve regurgitation
Pulmonic valve regurgitation
Mid-to-late diastolic
Mitral or tricuspid stenosis
Flow murmur across mitral or tricuspid valves
Continuous
Patent ductus arteriosus
Coronary AV fistula
Ruptured sinus of Valsalva aneurysm
CHAPTER 119 
799
Physical Examination of the Heart 
TABLE 119-2  EFFECTS OF PHYSIOLOGIC AND PHARMACOLOGIC 
INTERVENTIONS ON THE INTENSITY OF HEART MURMURS 
AND SOUNDS
Respiration 
Systolic murmurs due to TR or pulmonic blood flow through a normal or 
stenotic valve and diastolic murmurs of TS or PR generally increase with 
inspiration, as do right-sided S3 and S4. Left-sided murmurs and sounds 
usually are louder during expiration, as is the pulmonic ejection sound.
Valsalva Maneuver 
Most murmurs decrease in length and intensity. Two exceptions are the 
systolic murmur of HCM, which usually becomes much louder, and that 
of MVP, which becomes longer and often louder. Following release of the 
Valsalva maneuver, right-sided murmurs tend to return to control intensity 
earlier than left-sided murmurs.
After VPB or AF 
Murmurs originating at normal or stenotic semilunar valves increase in 
the cardiac cycle following a VPB or in the cycle after a long cycle length 
in AF. By contrast, systolic murmurs due to AV valve regurgitation either 
do not change, diminish (papillary muscle dysfunction), or become shorter 
(MVP).
Positional Changes 
With standing, most murmurs diminish, two exceptions being the murmur of 
HCM, which becomes louder, and that of MVP, which lengthens and often is 
intensified. With squatting, most murmurs become louder, but those of HCM 
and MVP usually soften and may disappear. Passive leg raising usually 
produces the same results.
Exercise 
Murmurs due to blood flow across normal or obstructed valves (e.g., PS, 
MS) become louder with both isotonic and submaximal isometric (handgrip) 
exercise. Murmurs of MR, VSD, and AR also increase with handgrip exercise. 
However, the murmur of HCM often decreases with near maximum handgrip 
exercise. Left-sided S4 and S3 are often accentuated by exercise, particularly 
when due to ischemic heart disease.
Abbreviations: AF, atrial fibrillation; AR, aortic regurgitation; HCM, hypertrophic cardiomy-
opathy; HOCM, hypertrophic obstructive cardiomyopathy; MR, mitral regurgitation; MS, mitral 
stenosis; MVP, mitral valve prolapse; PES, pulmonic ejection sound; PR, pulmonic regurgita-
tion; PS, pulmonic stenosis; TR, tricuspid regurgitation; TS, tricuspid stenosis; VPB, ventricular 
premature beat; VSD, ventricular septal defect.
SECTION 8
800
Cardiology
ECG
LVP
LAP
HSM
S1
S2
ECG
LVP
AOP
MSM
S1
A2
ECG
ECG
LVP
AOP
EDM
S1
A2
S1
S2
LVP
LAP
PSM
MDM
B
A
FIGURE 119-3 A. Schematic representation of ECG, aortic pressure (AOP), left ventricular 
pressure (LVP), and left atrial pressure (LAP). The gray areas indicated a transvalvular 
pressure difference during systole. HSM, holosystolic murmur; MSM, midsystolic murmur. 
B. Graphic representation of ECG, aortic pressure (AOP), left ventricular pressure (LVP), and 
left atrial pressure (LAP) with gray areas indicating transvalvular diastolic pressure differ-
ence. EDM, early diastolic murmur; PSM, presystolic murmur; MDM, middiastolic murmur.
For a more detailed discussion, see O’Gara P, Loscalzo J: 
Physical Examination of the Cardiovascular System, 
Chap. 227, p. 1821, in HPIM-18.
CHAPTER 120
Electrocardiography
STANDARD APPROACH TO THE ECG
Normally, standardization is 1.0 mV per 10 mm, and paper speed is 25 mm/s 
(each horizontal small box = 0.04 s).
Heart Rate 
Beats/min = 300 divided by the number of large boxes (each 5 mm apart) 
between consecutive QRS complexes. For faster heart rates, divide 1500 by 
number of small boxes (1 mm apart) between each QRS.
Rhythm
Sinus rhythm is present if every P wave is followed by a QRS, PR interval 
≥0.12 s, every QRS is preceded by a P wave, and the P wave is upright in leads 
I, II, and III. Arrhythmias are discussed in Chaps. 131 and 132.
CHAPTER 120 
801
Electrocardiography
Mean Axis 
If QRS is primarily positive in limb leads I and II, then axis is normal. 
Otherwise, find limb lead in which QRS is most isoelectric (R = S). The 
mean axis is perpendicular to that lead (Fig. 120-1). If the QRS complex is 
positive in that perpendicular lead, then mean axis is in the direction of that 
lead; if negative, then mean axis points directly away from that lead.
Left-axis deviation (more negative than −30°) occurs in diffuse left ven-
tricular disease, inferior MI; also in left anterior hemiblock (small R, deep 
S in leads II, III, and aVF).
Right-axis deviation (>90°) occurs in right ventricular hypertrophy (R > S 
in V1) and left posterior hemiblock (small Q and tall R in leads II, III, and 
aVF). Mild right-axis deviation is seen in thin, healthy individuals (up 
to 110°).
� INTERVALS (NORMAL VALUES IN PARENTHESES)
PR (0.12–0.20 s)
• Short: (1) preexcitation syndrome (look for slurred QRS upstroke due to 
“delta” wave), (2) nodal rhythm (inverted P in aVF).
• Long: first-degree AV block (Chap. 131).
E
xtr
e
me
axi
s d
ev
ia
ti
o
n
No
rm
al
ax
is
R
ig
ht
ax
is
de
vi
at
io
n
–90°
–aVF
–60°
–III
–30°
+aVL
0°
+I
+30°
–aVR
+60°
+II
+90°
+aVF
+120°
+III
+150°
–aVL
180°
–I
–150°
+aVR
–120°
–II
Le
ft
ax
is
d
ev
ia
ti
on
FIGURE 120-1 Electrocardiographic lead systems: The hexaxial frontal plane refer-
ence system to estimate electrical axis. Determine leads in which QRS deflections 
are maximum and minimum. For example, a maximum positive QRS in I which is 
isoelectric in aVF is oriented to 0°. Normal axis ranges from −30° to +90°. An axis 
> +90° is right-axis deviation and <30° is left-axis deviation.
SECTION 8
802
Cardiology
QRS (0.06–0.10 s) 
Widened: (1) ventricular premature beats, (2) bundle branch blocks: right 
(RsR′ in V1, deep S in V6) and left [RR′ in V6 (Fig. 120-2)], (3) toxic lev-
els of certain drugs (e.g., flecainide, propafenone, quinidine), (4) severe 
hypokalemia.
QT (<50% of RR interval; corrected QT ≤0.44 s) 
Prolonged: congenital, hypokalemia, hypocalcemia, drugs (e.g., class IA and 
class III antiarrhythmics, tricyclics).
� HYPERTROPHY
• Right atrium: P wave ≥2.5 mm in lead II.
• Left atrium: P biphasic (positive, then negative) in V1, with terminal 
negative force wider than 0.04 s.
• Right ventricle: R > S in V1 and R in V1 > 5 mm; deep S in V6; right-axis 
deviation.
• Left ventricle: S in V1 plus R in V5 or V6 ≥35 mm or R in aVL >11 mm.
Infarction (Figs. 120-3 and 120-4)
Following acute ST-segment elevation MI without successful reperfusion: 
Pathologic Q waves (≥0.04 s and ≥25% of total QRS height) in leads shown 
in Table 120-1; acute non-ST-segment elevation MI shows ST-T changes 
in these leads without Q-wave development. A number of conditions (other 
than acute MI) can cause Q waves (Table 120-2).
RBBB
LBBB
LAH
RBBB
+
LAH
RBBB
+
LPH
V1
V2
V3
V4
V5
V6
I
II
III
aVR
aVL
aVF
FIGURE 120-2 Intraventricular conduction abnormalities. Illustrated are right bundle 
branch block (RBBB); left bundle branch block (LBBB); left anterior hemiblock (LAH); 
right bundle branch block with left anterior hemiblock (RBBB + LAH); and right bundle 
branch block with left posterior hemiblock (RBBB + LPH).
CHAPTER 120 
803
Electrocardiography
A
B
ECG sequence with anterior Q-wave infarction
Early
Evolving
Early
Evolving
ECG sequence with inferior Q-wave infarction
V2
V4
V6
V2
V4
V6
I
II
III
I
II
III
aVR
aVL
aVF
aVR
aVL
aVF
FIGURE 120-3 Sequence of depolarization and repolarization changes with A. acute 
anterior and B. acute inferior wall Q-wave infarctions. With anterior infarcts, ST 
elevation in leads I, aVL, and the precordial leads may be accompanied by recipro-
cal ST depressions in leads II, III, and aVF. Conversely, acute inferior (or posterior) 
infarcts may be associated with reciprocal ST depressions in leads V1 to V3. (After
AL Goldberger: Clinical Electrocardiography: A Simplified Approach, 7th ed. St. Louis, 
Mosby/Elsevier, 2006.)
1
2
1
2
3
11/29
12/5
V2
aVF
V1
V2
V3
V4
V5
V6
I
II
III
aVR aVL aVF
FIGURE 120-4 Acute inf erior wall myocardial infarction. The ECG of 11/29 shows minor 
nonspecific ST-segment and T-wave changes. On 12/5 an acute myocardial infarction 
occurred. There are pathologic Q waves 1, ST-segment elevation 2, and terminal T-wave 
inversion 3 in leads II, III, and aVF indicating the location of the infarct on the inferior wall. 
Reciprocal changes in aVL (small arrow). Increasing R-wave voltage with ST depression 
and increased voltage of the T wave in V2 are characteristic of true posterior wall exten-
sion of the inferior infarction. (Reproduced from R.J. Myerburg: HPIM-12.)
� ST-T WAVES
• ST elevation: Acute MI, coronary spasm, pericarditis (concave upward) 
(see Fig. 125-1 and Table 125-2), LV aneurysm, Brugada pattern (RBBB 
with ST elevation in V1–V2).
• ST depression: Digitalis effect, strain (due to ventricular hypertrophy), 
ischemia, or nontransmural MI.
SECTION 8
804
Cardiology
• Tall peaked T: Hyperkalemia; acute MI (“hyperacute T”).
• Inverted T: Non-Q-wave MI, ventricular “strain” pattern, drug effect 
(e.g., digitalis), hypokalemia, hypocalcemia, increased intracranial pres-
sure (e.g., subarachnoid bleed).
TABLE 120-1 LEADS WITH ABNORMAL Q WAVES IN MI
Leads with Abnormal Q Waves
Site of Infarction
V1–V2
Anteroseptal
V3–V4
Apical
I, aVL, V5–V6
Anterolateral
II, III, aVF
Inferior
V1–V2 (tall R, not deep Q)
True posterior
TABLE 120-2  DIFFERENTIAL DIAGNOSIS OF Q WAVES (WITH SELECTED 
EXAMPLES)
Physiologic or positional factors
1. Normal variant “septal” Q waves
2. Normal variant Q waves in V1 to V2, aVL, III, and aVF
3. Left pneumothorax or dextrocardia
Myocardial injury or infiltration
1.  Acute processes: myocardial ischemia or infarction, myocarditis, 
hyperkalemia
2.  Chronic processes: idiopathic cardiomyopathy, amyloid, tumor, sarcoid, 
scleroderma
Ventricular hypertrophy/enlargement
1. Left ventricular (poor R-wave progression)a
2. Right ventricular (reversed R-wave progression)
3. Hypertrophic cardiomyopathy
Conduction abnormalities
1. Left bundle branch block
2. Wolff-Parkinson-White patterns
aSmall or absent R waves in the right to midprecordial leads.
Source: After AL Goldberger: Myocardial Infarction: Electrocardiographic Differential Diagnosis,
4th ed. St. Louis, Mosby-Year Book, 1991.
For a more detailed discussion, see Goldberger AL: 
Electrocardiography, Chap. 228, p. 1831 in HPIM-18.
CHAPTER 121 
805
Noninvasive Examination of the Heart 
CHAPTER 121
Noninvasive Examination 
of the Heart
ECHOCARDIOGRAPHY (TABLE 121-1 AND FIG. 121-1)
Visualizes heart in real time with ultrasound; Doppler recordings noninva-
sively assess hemodynamics and abnormal flow patterns. Imaging may be 
compromised in pts with chronic obstructive lung disease, thick chest wall, 
or narrow intercostal spaces.
Chamber Size and Ventricular Performance 
Assessment of atrial and ventricular dimensions, global and regional 
systolic wall motion abnormalities, ventricular hypertrophy/infiltration, 
evaluation for pulmonary hypertension: RV systolic pressure (RVSP) is 
calculated from maximum velocity of tricuspid regurgitation (TR):
RVSP = 4 × (TR velocity)2 + RA pressure
(RA pressure is same as JVP estimated by physical exam.) In absence of RV 
outflow obstruction, RVSP = pulmonary artery systolic pressure.
LV diastolic function is assessed by transmitral Doppler (see Fig. 229-9, p. 
1844, in HPIM-18) and Doppler tissue imaging, which measures velocity of 
myocardial relaxation.
Valvular Abnormalities 
Thickness, mobility, calcification, and regurgitation of each cardiac valve 
can be assessed. Severity of valvular stenosis is calculated by Doppler 
TABLE 121-1 CLINICAL USES OF ECHOCARDIOGRAPHY
2-D Echo 
Transesophageal Echocardiography 
Cardiac chambers: size, hypertrophy, 
wall motion abnormalities 
Superior to 2-D echo to identify:
 Infective endocarditis
Valves: morphology a nd motion
 Cardiac source of embolism
Pericardium: effusion, tamponade
 Prosthetic valve dysfunction
Aorta: aneurysm, dissection
 Aortic dissection
Assess intracardiac masses 
Doppler Echocardiography 
Stress Echocardiography
Valvular stenosis and regurgitation
Assess myocardial ischemia and viability
Intracardiac shunts
Diastolic filling/dysfunction
Approximate intracardiac pressures 
SECTION 8
806
Cardiology
[peak gradient = 4 × (peak velocity)2]. Structural lesions (e.g., flail leaf-
let, vegetation) resulting in regurgitation may be identified, and Doppler 
(Fig. 121-2) estimates severity of regurgitation.
Pericardial Disease 
Echo is noninvasive modality of choice to rapidly identify pericardial 
effusion and assess its hemodynamic significance; in tamponade there is 
diastolic RA and RV collapse, dilatation of IVC, exaggerated respiratory 
alterations in transvalvular Doppler velocities. Actual thickness of pericar-
dium (e.g., in suspected constrictive pericarditis) is better measured by CT 
or MRI.
Intracardiac Masses 
May visualize atrial or ventricular thrombus, intracardiac tumors, and 
valvular vegetations. Yield of identifying cardiac source of embolism is low 
FIGURE 121-1 Two-dimensional echocardiographic still-frame images of a normal 
heart. Upper: Parasternal long axis view during systole and diastole (left) and systole 
(right). During systole, there is thickening of the myocardium and reduction in the size 
of the left ventricle (LV). The valve leaflets are thin and open widely. Lower: Parasternal 
short axis view during diastole (left) and systole (right) demonstrating a decrease in the 
left ventricular cavity size during systole as well as an increase in wall thickness. LA, 
left atrium; RV, right ventricle; Ao, aorta. (Reproduced from R.J. Myerburg: HPIM-12.)
CHAPTER 121 
807
Noninvasive Examination of the Heart 
in absence of cardiac history or physical findings. Transesophageal echo-
cardiography (TEE) is more sensitive than standard transthoracic study for 
masses <1 cm in diameter.
Aortic Disease 
Aneurysm and dissection of the aorta may be evaluated and complications 
(aortic regurgitation, tamponade) assessed (Chap. 134) by standard trans-
thoracic echo. TEE is more sensitive and specific for aortic dissection.
Congenital Heart Disease (See Chap. 122)
Echo, Doppler, and contrast echo (rapid IV injection of agitated saline) are 
useful to identify congenital lesions and shunts.
Stress Echocardiography 
Echo performed prior to, and after, treadmill or bicycle exercise identi-
fies regions of prior MI and inducible myocardial ischemia (↓ regional 
A
C
2
1
0 m/s
1
2
3
4
B
2
1
0 m/s
1
2
3
D
AS
AR
Vmax = 3.8 m/s
 
MS
MR
FIGURE 121-2 Schematic presentation of normal Doppler flow across the aortic 
A. and mitral valves B. Abnormal continuous wave Doppler profiles: C. Aortic stenosis 
(AS) [peak transaortic gradient = 4 × Vmax
2 = 4 × (3.8)2 = 58 mmHg] and regurgitation 
(AR). D. Mitral stenosis (MS) and regurgitation (MR).
Cardiology
SECTION 8
808
contraction with exercise). Dobutamine pharmacologic stress echo can be 
substituted for pts who cannot exercise.
NUCLEAR CARDIOLOGY
Uses nuclear isotopes to assess LV perfusion and contractile function.
Ventricular Function Assessment 
Blood pool imaging is obtained by injecting IV 99m Tc-labeled albumin or 
RBCs to quantify LV ejection fraction. Contractile function can also be 
assessed during gated single photon emission CT (SPECT) myocardial per-
fusion exercise test imaging (see below).
Nuclear Myocardial Perfusion Assessment 
SPECT imaging using 201Tl or 99m Tc-labeled compounds (sestamibi or tet-
rofosmin) or PET imaging (82Rb or 13NH3), obtained at peak stress and at 
rest, depicts zones of prior infarction as fixed defects and regions of induc-
ible myocardial ischemia as reversible defects. Nuclear imaging is more 
sensitive, but less specific, than stress echocardiography for detection of 
ischemia.
For pts who can’t exercise, pharmacologic perfusion imaging with ade-
nosine, dipyridamole, or dobutamine is used instead (Chap. 130). For pts 
with LBBB, perfusion imaging with adenosine or dipyridamole is preferred 
to avoid artifactual septal defects that are common with exercise imaging.
Pharmacologic PET scanning is especially useful in imaging obese pts 
and to assess myocardial viability.
MAGNETIC RESONANCE IMAGING (MRI)
Delineates cardiac structures with high resolution without ionizing radia-
tion. Excellent technique to characterize intracardiac masses, the pericar-
dium, great vessels, and anatomic relationships in congenital heart disease. 
MRI with delayed gadolinium enhancement (avoid in pts with renal 
insufficiency) differentiates ischemic from nonischemic cardiomyopathy 
and is useful in assessing myocardial viability. Pharmacologic stress testing 
with MR identifies significant CAD and detects subendocardial ischemia 
with higher sensitivity than SPECT imaging.
COMPUTED TOMOGRAPHY (CT)
Provides high-resolution images of cardiac structures and detects coronary 
calcification in atherosclerosis with high sensitivity (but low specificity). 
CT angiography delineates abnormalities of the great vessels, including 
aortic aneurysms and dissection, and pulmonary embolism. It is useful for 
assessment of pericardial thickness and calcification, cardiac masses, and 
arrhythmogenic RV cardiomyopathy. Multislice spiral CT provides high-
resolution images of coronary anatomy. It is most useful in evaluation of 
suspected coronary anatomic anomalies and to exclude high-grade coro-
nary stenoses in pts with chest pain and intermediate pretest probability of 
coronary artery disease. Its greatest accuracy is in detection of left main and 
proximal LAD and circumflex disease. 
TABLE 121-2 SELECTION OF IMAGING TESTS
Echo
Nuclear
CTa
MRIb
LV Size/function
Initial modality of choice
Low cost, portable
Provides ancillary structural and 
hemodynamic information
Available from gated SPECT 
stress imaging
Best resolution
High cost
Best resolution
High cost
Valve disease
Initial modality of choice
Valve motion
Doppler hemodynamics
Visualize valve motion
Delineate abnormal flow
Pericardial disease
Pericardial effusion
Doppler hemodynamics
Pericardial thickening
Pericardial thickening
Aortic disease
TEE rapid diagnosis of acute 
dissectionc
Image entire aorta
Acute aneurysm
Aortic dissection
Image entire aorta
Aortic aneurysm
Chronic dissection
Cardiac masses
TTE—large intracardiac masses
Extracardiac masses
Extracardiac masses
TEE—smaller intracardiac massesc
Myocardial masses
Myocardiac masses
aContrast required.
bRelative contraindication: pacemakers, metallic objects, claustrophobic.
cWhen not seen on TTE.
Abbreviations: Echo, echocardiography; SPECT, single photon emission CT; TEE, transesophageal echocardiography; TTE, transthoracic echocardiogram.
809
SECTION 8
810
Cardiology
Table 121-2 summarizes key diagnostic features of the noninvasive imag-
ing modalities. Figure 121-3 provides an algorithm for diagnostic imaging 
assessment of suspected CAD.
CHOICE OF TEST FOR KNOWN/ SUSPECTED CAD
Exercise imaging
study
Exercise 
ECG
PET
LBBB or PPM
Prev MI?
LBBB or PPM
Prev MI
Patient able to 
exercise?
Previous coronary
revascularization
Resting ECG
interpretable?
Viability
Pharmacologic
imaging study
Dobutamine
echo
Pharmacologic
nuc*
Dobutamine
echo or pharm
nuc*
Exercise echo
Pharmacologic
nuc
Exercise nuc
Either  exercise
nuc or exercise
echo
Need structural
information?
Need structural
information?
No
Yes
No
Yes
No
No
No
No
No
No
Yes
Yes
Yes
Yes
Yes
Yes
FIGURE 121-3 Flow diagram showing selection of initial stress test in a pt with chest 
pain. LBBB, left bundle branch block; Prev MI-Reg ischemia, previous MI with a need 
to detect regional ischemia; Nuc, SPECT nuclear imaging study; Pharm, pharmaco-
logic. *Consider PET if morbidly obese or female with large/dense breasts.
For a more detailed discussion, see Nishimura RA, 
Chareonthaitawee P, Martinez M: Noninvasive Cardiac 
Imaging: Echocardiography, Nuclear Cardiology, and MRI/CT 
Imaging, Chap. 229, p. 1840 in HPIM-18.
CHAPTER 122
811
Congenital Heart Disease in the Adult 
CHAPTER 122
Congenital Heart Disease 
in the Adult
ACYANOTIC CONGENITAL HEART LESIONS WITH LEFT-TO-RIGHT SHUNT
� ATRIAL SEPTAL DEFECT (ASD)
Most common is ostium secundum ASD, located at mid interatrial septum. 
Sinus venosus type ASD involves the high atrial septum and may be associ-
ated with anomalous pulmonary venous drainage to the right heart. Ostium 
primum ASDs (e.g., typical of Down syndrome) appear at lower atrial 
septum, adjacent to atrioventricular (AV) valves.
History 
Usually asymptomatic until third or fourth decades, when exertional 
dyspnea, fatigue, and palpitations may occur. Onset of symptoms may be 
associated with development of pulmonary hypertension (see below).
Physical Examination 
Prominent right ventricular (RV) impulse, wide fixed splitting of S2, 
systolic murmur from flow across pulmonic valve, diastolic flow rumble 
across tricuspid valve, prominent jugular venous v wave.
ECG
Incomplete RBBB (rSR’ in right precordial leads) common. Left axis devia-
tion frequently present with ostium primum defect. Ectopic atrial pacemaker 
or first degree AV block occur in sinus venosus defects.
CXR
Increased pulmonary vascular markings, prominence of right atrium (RA), 
RV, and main pulmonary artery (LA enlargement not usually present).
Echocardiogram
RA, RV, and pulmonary artery enlargement; Doppler shows abnormal 
turbulent transatrial flow. Echo contrast (agitated saline injection into 
peripheral systemic vein) may visualize transatrial shunt. Transesophageal 
echo usually diagnostic if transthoracic echo is ambiguous.
Atrial Septal Defect
TREATMENT
In the absence of contraindications an ASD with pulmonary-to-systemic 
flow ratio (PF:SF) >2.0:1.0 should be repaired surgically or by percuta-
neous transcatheter closure. Surgery is contraindicated with significant 
pulmonary hypertension and PF:SF <1.2:1.0. Medical management 
includes antiarrhythmic therapy for associated atrial fibrillation or 
supraventricular tachycardia (Chap. 132) and standard therapy for 
symptoms of heart failure (Chap. 133).
SECTION 8
812
Cardiology
� VENTRICULAR SEPTAL DEFECT (VSD)
Congenital VSDs may close spontaneously during childhood. Symptoms 
relate to size of the defect and pulmonary vascular resistance.
History 
CHF may develop in infancy. Adults may be asymptomatic or develop 
fatigue and reduced exercise tolerance.
Physical Examination 
Systolic thrill and holosystolic murmur at lower left sternal border, loud P2, 
S3; diastolic flow murmur across mitral valve.
ECG
Normal with small defects. Large shunts result in LA and LV enlargement.
CXR
Enlargement of main pulmonary artery, LA, and LV, with increased pulmo-
nary vascular markings.
Echocardiogram
LA and LV enlargement; defect may be directly visualized. Color Doppler 
demonstrates flow across the defect.
Ventricular Septal Defect
TREATMENT
Fatigue and mild dyspnea are treated with diuretics and afterload reduc-
tion (Chap. 133 ). Surgical closure is indicated if PF:SF >1.5:1 in absence 
of very high pulmonary vascular resistance.
� PATENT DUCTUS ARTERIOSUS (PDA)
Abnormal communication between the descending aorta and pulmonary 
artery; associated with birth at high altitudes and maternal rubella.
History 
Asymptomatic or fatigue and dyspnea on exertion.
Physical Examination 
Hyperactive LV impulse; loud continuous “machinery” murmur at upper 
left sternal border. If pulmonary hypertension develops, diastolic compo-
nent of the murmur may disappear.
ECG
LV hypertrophy is common; RV hypertrophy if pulmonary hypertension 
develops.
CXR
Increased pulmonary vascular markings: enlarged main pulmonary artery, 
LV, ascending aorta; occasionally, calcification of ductus.
CHAPTER 122
813
Congenital Heart Disease in the Adult 
Echocardiography
Hyperdynamic, enlarged LV; the PDA can often be visualized on two-
dimensional echo; Doppler demonstrates abnormal flow through it.
Patent Ductus Arteriosus
TREATMENT
In absence of pulmonary hypertension, PDA should be surgically ligated 
or divided to prevent infective endocarditis, LV dysfunction, and pulmo-
nary hypertension. Transcatheter device closure is frequently possible.
� PROGRESSION TO PULMONARY HYPERTENSION (PHT)
Pts with large, uncorrected left-to-right shunts (e.g., ASD, VSD, or PDA) 
may develop progressive, irreversible PHT with reverse shunting of desatu-
rated blood into the arterial circulation (right-to-left direction), resulting in 
Eisenmenger syndrome. Fatigue, lightheadedness, and chest pain due to RV 
ischemia are common, accompanied by cyanosis, clubbing of digits, loud 
P2, murmur of pulmonary valve regurgitation, and signs of RV failure. ECG 
and echocardiogram show RV hypertrophy. Therapeutic options are limited 
and include pulmonary artery vasodilators and consideration of single lung 
transplant with repair of the cardiac defect, or heart-lung transplantation.
ACYANOTIC CONGENITAL HEART LESIONS WITHOUT A SHUNT
� PULMONIC STENOSIS (PS)
A transpulmonary valve gradient < 30 mmHg indicates mild PS, 30–50 
mmHg is moderate PS, and >50 mmHg is considered severe PS. Mild to 
moderate PS rarely causes symptoms, and progression tends not to occur. 
Pts with higher gradients may manifest dyspnea, fatigue, light-headedness, 
chest pain (RV ischemia).
Physical Examination 
Jugular venous distention with prominent a wave, RV parasternal impulse, 
wide splitting of S2 with soft P2, ejection click followed by “diamond-
shaped” systolic murmur at upper left sternal border, right-sided S4.
ECG
Normal in mild PS; RA and RV enlargement in advanced PS.
CXR
Often shows poststenotic dilatation of the pulmonary artery and RV 
enlargement.
Echocardiography
RV hypertrophy and systolic “doming” of the pulmonic valve. Doppler 
accurately measures transvalvular gradient.
Pulmonic Stenosis
TREATMENT
Symptomatic or severe stenosis requires balloon valvuloplasty or surgi-
cal correction.
SECTION 8
814
Cardiology
� CONGENITALLY BICUSPID AORTIC VALVE
One of the most common congenital heart malformations (up to 1.4% of the 
population); rarely results in childhood aortic stenosis (AS), but is a cause of AS 
and/or regurgitation later in life. May go undetected in early life or suspected 
by the presence of a systolic ejection click; often identified during echocardiog-
raphy that was obtained for another reason. See Chap. 123 for typical history, 
physical findings, and treatment of subsequent clinical aortic valve disease.
� COARCTATION OF THE AORTA
Aortic constriction just distal to the origin of the left subclavian artery is 
a surgically correctable form of hypertension (Chap. 126). Usually asymp-
tomatic, but may cause headache, fatigue, or claudication of lower extremities. 
Often accompanied by bicuspid aortic valve.
Physical Examination 
Hypertension in upper extremities; delayed femoral pulses with decreased 
pressure in lower extremities. Pulsatile collateral arteries can be palpated 
in the intercostal spaces. Systolic (and sometimes also diastolic) murmur is 
best heard over the mid-upper back at left interscapular space.
ECG
LV hypertrophy.
CXR
Notching of the ribs due to collateral arteries; “figure 3” appearance of distal 
aortic arch.
Echocardiography
Can delineate site and length of coarctation, and Doppler determines the 
pressure gradient across it. MR or CT angiography also visualizes the site of 
coarctation and can identify associated collateral vessel formation.
Coarctation of the Aorta
TREATMENT
Surgical correction (or percutaneous transcatheter stent dilation in 
selected pts), although hypertension may persist. Recoarctation after 
surgical repair may be amenable to percutaneous balloon dilatation.
COMPLEX CONGENITAL HEART LESIONS
Such lesions are often accompanied by cyanosis. Examples include:
� TETRALOGY OF FALLOT
The four main components are (1) malaligned VSD, (2) obstruction to RV 
outflow, (3) aorta that overrides the VSD, and (4) RV hypertrophy (RVH). 
Degree of RV outflow obstruction largely determines clinical presentation; 
when severe, the large right-to-left shunt causes cyanosis and systemic 
hypoxemia. ECG shows RVH. CXR demonstrates “boot-shaped” heart with 
prominent RV. Echocardiography delineates VSD, overriding aorta, and 
RVH and quantitates degree of RV outflow obstruction.
CHAPTER 123
815
Valvular Heart Disease
� COMPLETE TRANSPOSITION OF THE GREAT ARTERIES
Accounts for 10% of pts with cyanotic congenital heart disease. Aorta 
and pulmonary artery arise abnormally from the right and left ventricles 
respectively, creating two separate parallel circulations; a communica-
tion must exist between the two sides (ASD, PDA, or VSD) to sustain life. 
Development of RV dysfunction and heart failure are common by the third 
decade. Echocardiography reveals the aberrant anatomy.
� EBSTEIN ANOMALY
Abnormal downward placement of tricuspid valve within the RV; tricuspid 
regurgitation, hypoplasia of RV, and a right-to-left shunt are common. 
Echocardiography shows apical displacement of tricuspid septal leaflet, 
abnormal RV size, and quantitates degree of tricuspid regurgitation.
ENDOCARDITIS PROPHYLAXIS IN CONGENITAL HEART DISEASE
American Heart Association 2007 Guidelines recommend antibiotic pro-
phylaxis only in specific pts with congenital heart disease, i.e., those who 
are to undergo a dental procedure associated with bacteremia who have:
1. Unrepaired cyanotic congenital heart disease (e.g., tetralogy of Fallot)
2. Repaired congenital heart disease with residual defects adjacent to site 
of a prosthetic patch or transcatheter device
3. A history of complete repair of congenital defects with prosthetic mate-
rial or a transcatheter device within the previous 6 months.
For a more detailed discussion, see Child JS, Aboulhosn J: 
Congenital Heart Disease in the Adult, Chap. 236, p. 1920, 
in HPIM-18.
CHAPTER 123
Valvular Heart Disease
� MITRAL STENOSIS (MS)
Etiology 
Most commonly rheumatic, although history of acute rheumatic fever 
is now uncommon; congenital MS is rare cause, observed primarily in 
infants.
History 
Symptoms most commonly begin in the fourth decade, but MS often causes 
severe disability at earlier ages in developing nations. Principal symptoms 
are dyspnea and pulmonary edema precipitated by exertion, excitement, 
fever, anemia, paroxysmal tachycardia, pregnancy, sexual intercourse, etc.
SECTION 8
816
Cardiology
Physical Examination 
Right ventricular lift; palpable S1; opening snap (OS) follows A2 by 0.06–
0.12 s; OS–A2 interval inversely proportional to severity of obstruction. 
Diastolic rumbling murmur with presystolic accentuation in sinus rhythm. 
Duration of murmur correlates with severity of obstruction.
Complications
Hemoptysis, pulmonary embolism, pulmonary infection, systemic emboli-
zation; endocarditis is uncommon in pure MS.
Laboratory ECG 
Typically shows atrial fibrillation (AF) or left atrial (LA) enlargement when 
sinus rhythm is present. Right-axis deviation and RV hypertrophy in the 
presence of pulmonary hypertension.
CXR
Shows LA and RV enlargement and Kerley B lines.
Echocardiogram
Most useful noninvasive test; shows inadequate separation, calcification 
and thickening of valve leaflets and subvalvular apparatus, and LA enlarge-
ment. Doppler flow recordings provide estimation of transvalvular gradi-
ent, mitral valve area, and degree of pulmonary hypertension (Chap. 121).
Mitral Stenosis (See Fig. 123-1)
TREATMENT
At-risk pts should receive prophylaxis for recurrent rheumatic fever 
(penicillin V 250–500 mg PO bid or benzathine penicillin G 1–2 M 
units IM monthly). In the presence of dyspnea, sodium restriction and 
oral diuretic therapy; beta blockers, digitalis, or rate-limiting calcium 
channel antagonists (i.e., verapamil or diltiazem) to slow ventricular rate 
in AF. Warfarin (with target INR 2.0–3.0) for pts with AF and/or his-
tory of systemic and pulmonic emboli. For AF of recent onset, consider 
reversion (chemical or electrical) to sinus rhythm, ideally after ≥3 weeks 
of anticoagulation. Mitral valvotomy in the presence of symptoms and 
mitral orifice ≤ ~1.5 cm2. In uncomplicated MS, percutaneous balloon 
valvuloplasty is the procedure of choice; if not feasible, then open 
surgical valvotomy (Fig. 123-1).
� MITRAL REGURGITATION (MR)
Etiology 
Mitral valve prolapse (see below), rheumatic heart disease, ischemic heart 
disease with papillary muscle dysfunction, LV dilatation of any cause, mitral 
annular calcification, hypertrophic cardiomyopathy, infective endocarditis, 
congenital.
Clinical Manifestations 
Fatigue, weakness, and exertional dyspnea. Physical examination: sharp 
upstroke of arterial pulse, LV lift, S1 diminished: wide splitting of S2; S3; loud 
CHAPTER 123
817
Valvular Heart Disease
holosystolic murmur and often a brief early-mid-diastolic murmur due to 
increased transvalvular flow.
Echocardiogram
Enlarged LA, hyperdynamic LV, identifies mechanism of MR; Doppler 
analysis helpful in diagnosis and assessment of severity of MR and degree 
of pulmonary hypertension.
History, physical exam, CXR, ECG, 2D echo/Doppler
Mild stenosis
MVA > 1.5 cm2
Moderate or
severe stenosis
MVA ≤ 1.5 cm2
Exercise
PASP > 60 mmHg
PAWP ≥ 25 mmHg
MVG > 15 mmHg
Valve morphology
favorable for PMBV?
Valve morphology
favorable for PMBV?
Yearly
follow-up
6-month
follow-up
6-month
follow-up
Class IIb
Class IIa
Class I
Severe PH
PAP > 60 mmHg
Consider
PMBV
† Consider
commissurotomy or MVR
Exclude LA clot,
3+ to 4+ MR
No
No
No
Yes
Yes
Yes
No
Yes
Symptomatic Mitral Stenosis
NYHA functional class II
FIGURE 123-1 Management of mitral stenosis (MS). †There is controversy as to whether 
pts with severe MS (MVA <1.0 cm2) and severe pulmonary hypertension (PH) (PASP >60 
mmHg) should undergo percutaneous mitral balloon valvotomy (PMBV) or mitral valve 
replacement (MVR) to prevent right ventricular failure. CXR, chest x-ray; ECG, electro-
cardiogram; echo, echocardiography; LA, left atrial; MR, mitral regurgitation; MVA, mitral 
valve area; MVG, mean mitral valve pressure gradient; NYHA, New York Heart Association; 
PASP, pulmonary artery systolic pressure; PAWP, pulmonary artery wedge pressure; 2D, 
2-dimensional. (From RO Bonow et al: J Am Coll Cardiol 48:e1, 2006; with permission.)
SECTION 8
818
Cardiology
Mitral Regurgitation (See Fig. 123-2)
TREATMENT
For severe/decompensated MR, treat as for heart failure (Chap. 133). 
IV vasodilators (e.g., nitroprusside) are beneficial for acute, severe MR. 
Anticoagulation is indicated in the presence of atrial fibrillation. Surgical 
treatment, either valve repair or replacement, is appropriate if pt has symp-
toms or evidence of progressive LV dysfunction [LV ejection fraction (LVEF) 
≤60% or end-systolic LV diameter by echo ≥40 mm]. Operation should be 
carried out before development of chronic heart failure symptoms.
� MITRAL VALVE PROLAPSE (MVP)
Etiology 
Most commonly idiopathic; may accompany rheumatic fever, ischemic heart 
disease, atrial septal defect, Marfan syndrome, Ehlers-Danlos syndrome.
Clinical evaluation + Echo
Symptoms
LV function?
LV function?
Normal LV function
EF > 0.60
ESD < 40 mm
EF < 0.30 and/or
ESD > 55 mm
EF > 0.30
ESD ≤ 55 mm
LV dysfunction
EF ≤ 0.60 and/or
ESD ≥ 40 mm
Class I
Class I
Chordal preservation
likely?
New-onset AF?
Pulmonary HT?
MV repair
If not possible,
MVR
Class IIa
Class IIa
MV repair
MV repair
likely?*
Medical
therapy
Clinical eval every 6 mos
Echo every 6 mos
No
No
No
Yes
Yes
Class IIa
No
Yes*
Yes
CHRONIC SEVERE MITRAL REGURGITATION
Reevaluation
FIGURE 123-2 Management of advanced mitral regurgitation. *Mitral valve (MV) 
repair may be performed in asymptomatic pts with normal left ventricular (LV) function 
if performed by an experienced surgical team and if the likelihood of successful MV 
repair is >90%. AF, atrial fibrillation; Echo, echocardiography; EF, ejection fraction; 
ESD, end-systolic dimension; eval, evaluation; HT, hypertension; MVR, mitral valve 
replacement. (From RO Bonow et al: J Am Coll Cardiol 48:e1, 2006; with permission.)
CHAPTER 123
819
Valvular Heart Disease
Pathology 
Redundant mitral valve tissue with myxedematous degeneration and elon-
gated chordae tendineae.
Clinical Manifestations 
More common in females. Most pts are asymptomatic and remain so. Most 
common symptoms are vague chest pain and supraventricular and ven-
tricular arrhythmias. Most important complication is severe MR resulting 
in LV failure. Rarely, systemic emboli from platelet-fibrin deposits on valve. 
Sudden death is a very rare complication.
Physical Examination 
Mid or late systolic click(s) followed by late systolic murmur at the apex; 
exaggeration by Valsalva maneuver, reduced by squatting and isometric 
exercise (Chap. 119).
Echocardiogram
Shows posterior displacement of one or both mitral leaflets late in systole.
Mitral Valve Prolapse
TREATMENT
Asymptomatic pts should be reassured. Beta blockers may lessen chest 
discomfort and palpitations. Prophylaxis for infective endocarditis is 
indicated only if prior history of endocarditis. Valve repair or replace-
ment for pts with severe mitral regurgitation; aspirin or anticoagulants 
for pts with history of TIA or embolization.
� AORTIC STENOSIS (AS)
Etiologies
Most common are (1) degenerative calcification of a congenitally bicuspid 
valve, (2) chronic deterioration of a trileaflet valve, and (3) rheumatic 
disease (almost always associated with rheumatic mitral disease).
Symptoms
Exertional dyspnea, angina, and syncope are cardinal symptoms; they occur 
late, after years of obstruction and aortic valve area ≤1.0 cm2.
Physical Examination 
Weak and delayed (parvus et tardus) arterial pulses with carotid thrill. 
Double apical impulse (palpable S4); A2 soft or absent; S4 common. 
Diamond-shaped systolic murmur ≥ grade 3/6, often with systolic thrill. 
Murmur is typically loudest at second right intercostal space, with radiation 
to carotids and sometimes to the apex (Gallavardin effect).
ECG
Often shows LV hypertrophy, but not useful for predicting gradient.
SECTION 8
820
Cardiology
Echocardiogram
Shows LV hypertrophy, calcification and thickening of aortic valve cusps 
with reduced systolic opening. Dilatation and reduced contraction of LV 
indicate poor prognosis. Doppler quantitates systolic gradient and allows 
calculation of valve area.
Aortic Stenosis (See Fig. 123-3)
TREATMENT
Avoid strenuous activity in severe AS, even in asymptomatic phase. Treat 
heart failure in standard fashion (Chap. 133), but use vasodilators with 
caution in pts with advanced disease. Valve replacement is indicated in 
adults with symptoms resulting from AS and hemodynamic evidence
Symptoms?
Equivocal
Normal
LV ejection
fraction
Normal
Less than 0.50
Symptoms
↓BP
No
No
Yes
Yes
Class IIb
Class I
Class IIb
Class I
Class I
SEVERE AORTIC STENOSIS
Reevaluation
Exercise
test
Aortic valve replacement
Severe valve calcification,
rapid progression, and/or
expected delays in surgery
Preoperative coronary angiography
Clinical follow-up, patient
education, risk factor
modification, annual echo
Vmax > 4 m/s
AVA < 1 cm2
Mean gradient > 40 mmHg
Undergoing CABG or
other heart surgery?
FIGURE 123-3 Algorithm for the management of aortic stenosis (AS). AVA, aortic 
valve area; BP, blood pressure; CABG, coronary artery bypass graft surgery; LV, left 
ventricle; Vmax, maximal velocity across aortic valve by Doppler echocardiography. 
(Modified from CM Otto: J Am Coll Cardiol 47:2141, 2006.)
CHAPTER 123
821
Valvular Heart Disease
of severe obstruction. Transcatheter aortic valve implantation (TAVI) 
is an investigational approach for pts at excessive surgical risk that has 
demonstrated favorable results.
� AORTIC REGURGITATION (AR)
Etiology 
Valvular: Rheumatic (especially if rheumatic mitral disease is present), 
bicuspid valve, endocarditis. Dilated aortic root: dilatation due to cystic 
medial necrosis, aortic dissection, ankylosing spondylitis, syphilis. Three-
fourths of pts are male.
Clinical Manifestations 
Exertional dyspnea and awareness of forceful heartbeat, angina pectoris, 
and signs of LV failure. Wide pulse pressure, water hammer pulse, capil-
lary pulsations (Quincke’s sign), A2 soft or absent, S3 common. Blowing, 
decrescendo diastolic murmur along left sternal border (along right sternal 
border with aortic dilatation). May be accompanied by systolic murmur of 
augmented blood flow.
Laboratory ECG and CXR 
LV enlargement.
Echocardiogram
LA enlargement, LV enlargement, high-frequency diastolic fluttering of 
mitral valve. Failure of coaptation of aortic valve leaflets may be present. 
Doppler studies useful in detection and quantification of AR.
Aortic Regurgitation
TREATMENT
Standard therapy for LV failure (Chap. 133). Vasodilators (long-acting 
nifedipine or ACE inhibitors) are recommended if hypertension present. 
Surgical valve replacement should be carried out in pts with severe AR 
when symptoms develop or in asymptomatic pts with LV dysfunction 
(LVEF <50%, LV end-systolic volume >55 mL/m2, end-systolic diameter 
>55 mm, or LV diastolic dimension >75 mm) by imaging studies.
� TRICUSPID STENOSIS (TS)
Etiology 
Usually rheumatic; most common in females; almost invariably associated 
with MS.
Clinical Manifestations 
Hepatomegaly, ascites, edema, jaundice, jugular venous distention with 
slow y descent (Chap. 119). Diastolic rumbling murmur along left ster-
nal border increased by inspiration with loud presystolic component. 
Right atrial and superior vena caval enlargement on chest x-ray. Doppler 
SECTION 8
822
Cardiology
echocardiography demonstrates thickened valve and impaired separation of 
leaflets and provides estimate of transvalvular gradient.
Tricuspid Stenosis
TREATMENT
In severe TS, surgical relief is indicated, with valvular repair or replacement.
� TRICUSPID REGURGITATION (TR)
Etiology 
Usually functional and secondary to marked RV dilatation of any cause and 
often associated with pulmonary hypertension.
Clinical Manifestations 
Severe RV failure, with edema, hepatomegaly, and prominent v waves in 
jugular venous pulse with rapid y descent (Chap. 119). Systolic murmur 
along lower left sternal edge is increased by inspiration. Doppler echocar-
diography confirms diagnosis and estimates severity.
Tricuspid Regurgitation
TREATMENT
Intensive diuretic therapy when right-sided heart failure signs are present. 
In severe cases (in absence of severe pulmonary hypertension), surgical 
treatment consists of tricuspid annuloplasty or valve replacement.
For a more detailed discussion, see O’Gara P, Loscalzo J: 
Valvular Heart Disease, Chap. 237, p. 1929, in HPIM-18.
CHAPTER 124
Cardiomyopathies and 
Myocarditis
Cardiomyopathies are primary diseases of heart muscle. Table 124-1 
summarizes distinguishing presenting features of the three major types of 
cardiomyopathy. Table 124-2 details the comprehensive initial evaluation of 
suspected cardiomyopathies.
� DILATED CARDIOMYOPATHY (CMP)
Symmetrically dilated left ventricle (LV), with poor systolic contractile 
function; right ventricle (RV) commonly involved.
CHAPTER 124
823
Cardiomyopathies and Myocarditis 
TABLE 124-1 PRESENTATION WITH SYMPTOMATIC CARDIOMYOPATHY
Dilated
Restrictive
Hypertrophic
Ejection fraction 
(normal >55%)
Usually <30% 
when symptoms 
severe
25–50%
>60%
Left ventricular 
diastolic dimen-
sion (normal 
<55 mm)
≥60 mm
<60 mm (may be 
decreased)
Often decreased
Left ventricular 
wall thickness
Decreased
Normal or 
increased
Markedly
increased
Atrial size
Increased
Increased; may 
be massive
Increased; related 
to abnormal 
Valvular 
regurgitation
Related to annular 
dilation; mitral 
appears earlier, 
during decompen-
sation; tricuspid 
regurgitation in 
late stages
Related to 
endocardial
involvement;
frequent mitral 
and tricuspid 
regurgitation, 
rarely severe
Related to 
valve-septum
interaction; mitral 
regurgitation
Common first 
symptoms
Exertional
intolerance
Exertional
intolerance, fluid 
retention early
Exertional
intolerance; may 
have chest pain
Congestive
symptoms*
Left before right, 
except right 
prominent in 
young adults
Right often 
dominates
Left-sided
congestion may 
develop late
Arrhythmia
Ventricular 
tachyarrhythmia; 
conduction block 
in Chagas’ disease, 
and some families. 
Atrial fibrillation.
Ventricular 
uncommon except 
in sarcoidosis 
conduction block 
in sarcoidosis and 
amyloidosis. Atrial 
fibrillation.
Ventricular 
tachyarrhythmias; 
atrial fibrillation
*Left-sided symptoms of pulmonary congestion: dyspnea on exertion, orthopnea, paroxysmal 
nocturnal dyspnea. Right-sided symptoms of systemic versus congestion: discomfort on 
bending, hepatic and abdominal distention, peripheral edema.
Etiology 
Approximately one-third of pts have a familial form, including those cases 
due to mutations in genes encoding sarcomeric proteins. Other causes 
include previous myocarditis, toxins [ethanol, certain antineoplastic agents 
(doxorubicin, trastuzumab, imatinib mesylate)], connective tissue disor-
ders, muscular dystrophies, “peripartum.” Impaired LV function owing to 
severe coronary disease/infarction or chronic aortic/mitral regurgitation 
may behave similarly.
SECTION 8
824
Cardiology
TABLE 124-2 INITIAL EVALUATION OF CARDIOMYOPATHY
Clinical Evaluation
Thorough history and physical examination to identify cardiac and noncardiac 
disordersa
Detailed family history of heart failure, cardiomyopathy, skeletal myopathy, 
conduction disorders and tachyarrhythmias, sudden death
History of alcohol, illicit drugs, chemotherapy or radiation therapya
Assessment of ability to perform routine and desired activitiesa
Assessment of volume status, orthostatic blood pressure, body mass indexa
Laboratory Evaluation
Electrocardiograma
Chest radiographa
Two-dimensional and Doppler echocardiograma
Chemistry:
 Serum sodium,a potassium,a calcium,a magnesiuma
 Fasting glucose (glycohemoglobin in DM) 
 Creatinine, a blood urea nitrogena
 Albumin,a total protein,a liver function testsa
 Lipid profile 
 Thyroid-stimulating hormonea
 Serum iron, transferrin saturation 
 Urinalysis 
 Creatine kinase
H ematology:
 Hemoglobin/hematocrita
 White blood cell count with differential,a including eosinophils 
 Erythrocyte sedimentation rate
Initial Evaluation Only in Pts Selected for Possible Specific Diagnosis 
Titers for infection in presence of clinical suspicion:
 Acute viral (coxsackievirus virus, echovirus, influenza virus) 
 Human immunodeficiency virus, 
 Chagas’ disease, Lyme disease, toxoplasmosis
Catheterization with coronary angiography in pts with angina who are 
candidates for interventiona
Serologies for active rheumatologic disease
Endomyocardial biopsy including sample for electron microscopy when 
suspecting specific diagnosis with therapeutic implications
Screening for sleep-disordered breathing
aLevel I Recommendations from ACC/AHA Practice Guidelines for Chronic Heart Failure in the adult.
Source: From SA Hunt et al: Circulation 112: 2005.
CHAPTER 124
825
Cardiomyopathies and Myocarditis 
Symptoms
Congestive heart failure (Chap. 133); tachyarrhythmias and peripheral 
emboli from LV mural thrombus occur.
Physical Examination 
Jugular venous distention (JVD), rales, diffuse and dyskinetic LV apex, S3, 
hepatomegaly, peripheral edema; murmurs of mitral and tricuspid regurgi-
tation are common.
Laboratory ECG 
Left bundle branch block and ST-T-wave abnormalities common.
CXR
Cardiomegaly, pulmonary vascular redistribution, pulmonary effusions 
common.
Echocardiogram, CT, and Cardiac MRI 
LV and RV enlargement with globally impaired contraction. Regional wall 
motion abnormalities suggest coronary artery disease rather than primary 
cardiomyopathy.
B-Type Natriuretic Peptide (BNP) 
Level elevated in heart failure/cardiomyopathy but not in pts with dyspnea 
due to lung disease.
Dilated Cardiomyopathy
TREATMENT
Standard therapy of heart failure (Chap. 133): Diuretic for volume over-
load, vasodilator therapy with ACE inhibitor (preferred), angiotensin 
receptor blocker or hydralazine-nitrate combination shown to limit 
disease progression and improve longevity. Add beta blocker in most 
pts. Add spironolactone for pts with advanced heart failure. Consider 
chronic anticoagulation with warfarin if accompanying atrial fibrillation 
(AF), prior embolism, or recent large anterior MI. Antiarrhythmic drugs 
(e.g., amiodarone or dofetilide) may be useful to maintain sinus rhythm 
in pts with AF. Consider implanted cardioverter defibrillator for pts 
with ≥ class III heart failure and LVEF <35%. For those with persistent 
class III–IV heart failure, LVEF <35%, and QRS duration >120 ms, con-
sider biventricular pacing. Possible trial of immunosuppressive drugs, 
if active myocarditis present on RV biopsy (controversial as long-term 
efficacy has not been demonstrated). In selected pts, consider cardiac 
transplantation.
� RESTRICTIVE CARDIOMYOPATHY
Increased myocardial stiffness impairs ventricular relaxation; diastolic ven-
tricular pressures are elevated. Etiologies include infiltrative disease (amy-
loid, sarcoid, hemochromatosis, eosinophilic disorders), endomyocardial 
fibrosis, Fabry’s disease, and prior mediastinal irradiation.
SECTION 8
826
Cardiology
Symptoms
Are of heart failure, although right-sided heart failure often predominates, 
with peripheral edema and ascites.
Physical Examination 
Predominantly signs of right-sided heart failure: JVD, hepatomegaly, 
peripheral edema, murmur of tricuspid regurgitation. Left-sided S4 is common.
Laboratory ECG 
Low limb lead voltage, sinus tachycardia, ST-T-wave abnormalities.
CXR
Mild LV enlargement.
Echocardiogram, CT, Cardiac MRI 
Bilateral atrial enlargement; increased ventricular thickness (“speckled 
pattern”) in infiltrative disease, especially amyloidosis. Systolic function is 
usually normal but may be mildly reduced.
Cardiac Catheterization 
Increased LV and RV diastolic pressures with “dip and plateau” pattern; RV 
biopsy useful in detecting infiltrative disease (rectal or fat pad biopsy useful 
in diagnosis of amyloidosis).
Note: Must distinguish restrictive cardiomyopathy from constrictive 
pericarditis, which is surgically correctable. Thickening of pericardium in 
pericarditis usually apparent in CT or MRI.
Restrictive Cardiomyopathy
TREATMENT
Salt restriction and diuretics ameliorate pulmonary and systemic con-
gestion; digitalis is not indicated unless systolic function is impaired or 
atrial arrhythmias are present. Note: Increased sensitivity to digitalis in 
amyloidosis. Anticoagulation often indicated, particularly in pts with 
eosinophilic endomyocarditis. For specific therapy of hemochromatosis 
and sarcoidosis, see Chaps. 357 and 329, respectively, in HPIM-18.
� HYPERTROPHIC CARDIOMYOPATHY
Marked LV hypertrophy; often asymmetric, without underlying hyperten-
sion or valvular disease. Systolic function is usually normal; increased LV 
stiffness results in elevated diastolic filling pressures. Typically results from 
mutations in sarcomeric proteins (autosomal dominant transmission).
Symptoms
Secondary to elevated diastolic pressure, dynamic LV outflow obstruction 
(if present), and arrhythmias; dyspnea on exertion, angina, and presyncope; 
sudden death may occur.
CHAPTER 124
827
Cardiomyopathies and Myocarditis 
Physical Examination 
Brisk carotid upstroke with pulsus bisferiens; S4, harsh systolic murmur 
along left sternal border, blowing murmur of mitral regurgitation at apex; 
murmur changes with Valsalva and other maneuvers (Chap. 119).
Laboratory ECG 
LV hypertrophy with prominent “septal” Q waves in leads I, aVL, V5–6. 
Periods of atrial fibrillation or ventricular tachycardia are often detected by 
Holter monitor.
Echocardiogram
LV hypertrophy, often with asymmetric involvement, especially of the 
septum or apex; LV contractile function typically excellent with small end-
systolic volume. If LV outflow tract obstruction is present, systolic anterior 
motion (SAM) of mitral valve and midsystolic partial closure of aortic valve 
are present. Doppler shows early systolic accelerated blood flow through LV 
outflow tract.
Hypertrophic Cardiomyopathy
TREATMENT
Strenuous exercise should be avoided. Beta blockers, verapamil, or 
disopyramide used individually to reduce symptoms. Digoxin, other 
inotropes, diuretics, and vasodilators are generally contraindicated. 
Endocarditis antibiotic prophylaxis (Chap. 89) is necessary only in pts 
with a prior history of endocarditis. Antiarrhythmic agents, especially 
amiodarone, may suppress atrial and ventricular arrhythmias. However, 
consider implantable cardioverter defibrillator for pts with high-risk 
profile, e.g., history of syncope or aborted cardiac arrest, nonsustained 
ventricular tachycardia, marked LVH (>3 cm), exertional hypotension, 
or family history of sudden death. In selected pts, LV outflow gradient 
can be reduced by controlled septal infarction by ethanol injection into 
the septal artery. Surgical myectomy may be useful in pts refractory to 
medical therapy.
� MYOCARDITIS
Inflammation of the myocardium that may progress to chronic dilated car-
diomyopathy, most commonly due to acute viral infection (e.g., parvovirus 
B19, coxsackievirus, adenovirus, Epstein-Barr virus). Myocarditis may also 
develop in pts with HIV infection, hepatitis C or Lyme disease. Chagas’ dis-
ease is a common cause of myocarditis in endemic areas, typically Central 
and South America.
History 
Fever, fatigue, palpitations; if LV dysfunction develops, symptoms of heart 
failure are present. Viral myocarditis may be preceded by URI.
Physical Examination 
Fever, tachycardia, soft S1; S3 common.
SECTION 8
828
Cardiology
Laboratory 
CK-MB isoenzyme and cardiac troponins may be elevated in absence of MI. 
Convalescent antiviral antibody titers may rise.
ECG
Transient ST-T-wave abnormalities.
CXR
Cardiomegaly
Echocardiogram, Cardiac MRI 
Depressed LV function; pericardial effusion present if accompanying peri-
carditis present. MRI demonstrates mid-wall gadolinium enhancement.
Myocarditis
TREATMENT
Rest; treat as heart failure (Chap. 133); efficacy of immunosuppressive 
therapy (e.g., steroids) has not been demonstrated except in isolated 
conditions such as sarcoidosis and giant cell myocarditis. In fulminant 
cases, cardiac transplantation may be indicated.
For a more detailed discussion, see Stevenson LW, Loscalzo 
J: Cardiomyopathy and Myocarditis, Chap. 238, p. 1951, in 
HPIM-18.
CHAPTER 125
Pericardial Disease
� ACUTE PERICARDITIS
Etiologies (See Table 125-1)
History 
Chest pain, which may be intense, mimicking acute MI, but characteristi-
cally sharp, pleuritic, and positional (relieved by leaning forward); fever and 
palpitations are common. Typical pain may not be present in slowly devel-
oping pericarditis (e.g., tuberculous, post-irradiation, neoplastic, uremic).
Physical Examination 
Rapid or irregular pulse, coarse pericardial friction rub, which may vary in 
intensity and is loudest with pt sitting forward.
Laboratory ECG (See Table 125-2 and Fig. 125-1)
Diffuse ST elevation (concave upward) usually present in all leads except 
aVR and V1; PR-segment depression (and/or PR elevation in lead aVR) 
CHAPTER 125
829
Pericardial Disease
may be present; days later (unlike acute MI), ST returns to baseline and 
T-wave inversion develops. Atrial premature beats and atrial fibrillation 
may appear. Differentiate from ECG of early repolarization (ER) (ratio of ST 
elevation/T wave height <0.25 in ER, but >0.25 in pericarditis).
CXR
Symmetrically increased size of cardiac silhouette if large (>250 mL) peri-
cardial effusion is present.
Echocardiogram
Most readily available test for detection of pericardial effusion, which com-
monly accompanies acute pericarditis.
TABLE 125-1 MOST COMMON CAUSES OF PERICARDITIS
“Idiopathic”
Infections (particularly viral)
Acute myocardial infarction
Neoplasms
Mediastinal radiation therapy
Chronic renal failure
Connective tissue disease (e.g., rheumatoid arthritis, SLE)
Drug reaction (e.g., procainamide, hydralazine)
Post–cardiac injury (i.e., weeks following heart surgery or myocardial 
infarction)
TABLE 125-2 ECG IN ACUTE PERICARDITIS VS ACUTE ST-ELEVATION MI
ST-Segment 
Elevation
ECG Lead 
Involvement
Evolution of ST 
and T Waves
PR-Segment
Depression
Pericarditis
Concave upward All leads involved 
except aVR and V1
ST remains elevated 
for several days; after 
ST returns to base-
line, T waves invert
Yes, in majority
Acute ST elevation MI
Convex upward
ST elevation over 
infarcted region 
only; reciprocal 
ST depression in 
opposite leads
In absence 
of successful 
reperfusion therapies: 
T waves invert within 
hours, while ST still 
elevated; followed by 
Q-wave development
No
ST
III
aVF
V3
V6
II
aVL
V2
V5
PR
I
aVR
V1
V4
FIGURE 125-1 Electrocardiogram in acute pericarditis. Note diffuse ST-segment elevation and PR-segment depression.
830
831
CHAPTER 125
Pericardial Disease
Acute Pericarditis
TREATMENT
Aspirin 650–975 mg qid or other NSAIDs (e.g., ibuprofen 400–600 mg 
tid or indomethacin 25–50 mg tid); addition of colchicine 0.6 mg bid 
may be beneficial and reduces frequency of recurrences. For severe, 
refractory pain, prednisone 40–80 mg/d can be used as last resort. 
Intractable, prolonged pain or frequently recurrent episodes may require 
pericardiectomy. Anticoagulants are relatively contraindicated in acute 
pericarditis because of risk of pericardial hemorrhage.
� CARDIAC TAMPONADE
Life-threatening condition resulting from accumulation of pericardial fluid 
under pressure; impaired filling of cardiac chambers and decreased cardiac 
output.
Etiology 
Previous pericarditis (most commonly metastatic tumor, uremia, viral or 
idiopathic pericarditis), cardiac trauma, or myocardial perforation during 
catheter or pacemaker placement.
History 
Hypotension may develop suddenly; subacute symptoms include dyspnea, 
weakness, confusion.
Physical Examination 
Tachycardia, hypotension, pulsus paradoxus (inspiratory fall in systolic 
blood pressure >10 mmHg), jugular venous distention with preserved x 
descent but loss of y descent; heart sounds distant. If tamponade develops 
subacutely, peripheral edema, hepatomegaly, and ascites may be present.
Laboratory ECG 
Low limb lead voltage; large effusions may cause electrical alternans (alter-
nating size of QRS complex due to swinging of heart).
CXR
Enlarged cardiac silhouette if large (>250 mL) effusion present.
Echocardiogram
Swinging motion of heart within large effusion; prominent respiratory 
alteration of RV dimension with RA and RV collapse during diastole. 
Doppler shows marked respiratory variation of transvalvular flow velocities.
Cardiac Catheterization 
Confirms diagnosis; shows equalization of diastolic pressures in all four 
chambers; pericardial = RA pressure.
Cardiac Tamponade
TREATMENT
Immediate pericardiocentesis and IV volume expansion.
SECTION 8
832
Cardiology
� CONSTRICTIVE PERICARDITIS
Condition in which a rigid pericardium impairs cardiac filling, causing 
elevation of systemic and pulmonary venous pressures, and decreased 
cardiac output. Results from healing and scar formation in some pts with 
previous pericarditis. Viral, tuberculosis (mostly in developing nations), 
previous cardiac surgery, collagen vascular disorders, uremia, neoplastic 
and radiation-associated pericarditis are potential causes.
History 
Gradual onset of dyspnea, fatigue, pedal edema, abdominal swelling; symp-
toms of LV failure uncommon.
Physical Examination 
Tachycardia, jugular venous distention (with prominent y descent) that 
increases further on inspiration (Kussmaul sign); hepatomegaly, ascites, 
peripheral edema are common; sharp diastolic sound, “pericardial knock” 
following S2 sometimes present.
Laboratory ECG 
Low limb lead voltage; atrial arrhythmias are common.
CXR
Rim of pericardial calcification is most common in tuberculous pericarditis.
Echocardiogram
Thickened pericardium, normal ventricular contraction; abrupt halt in 
ventricular filling in early diastole. Dilatation of IVC is common. Dramatic 
Septum
E
RV
RA
LA
LV
DIASTOLE
DIASTOLE
E
A
A
TV
TV
MV
MV
Septum
Doppler
transvalvular
inflow patterns
Thickened
pericardium
Pulmonary
vein
IVC and hepatic veins
Inspiration
Expiration
Apical 4-chamber views
FIGURE 125-2 Constrictive pericarditis. Doppler schema of respirophasic changes 
in mitral and tricuspid inflow. Reciprocal patterns of ventricular filling are assessed 
on pulsed Doppler examination of mitral (MV) and tricuspid (TV) inflow. (Courtesy of 
Bernard E. Bulwer, MD; with permission.)
CHAPTER 125
833
Pericardial Disease
effects of respiration are typical: During inspiration the ventricular septum 
shifts to the left with prominent reduction of blood flow velocity across 
mitral valve; pattern reverses during expiration (Fig 125-2).
CT or MRI 
More precise than echocardiogram for demonstrating thickened pericardium.
Cardiac Catheterization 
Equalization of diastolic pressures in all chambers; ventricular pressure 
tracings show “dip and plateau” appearance. Differentiate from restrictive 
cardiomyopathy (Table 125-3).
Constrictive Pericarditis
TREATMENT
Surgical stripping of the pericardium. Progressive improvement ensues 
over several months.
TABLE 125-3  FEATURES THAT DIFFERENTIATE CONSTRICTIVE 
PERICARDITIS FROM RESTRICTIVE CARDIOMYOPATHY
Constrictive
Pericarditis
Restrictive
Cardiomyopathy
Physical exam
Kussmaul sign
Present
May be present
Pericardial knock
May be present
Absent
Chest X-ray 
Pericardial calcification
May be present
Absent
Echocardiography
Thickened pericardium
Present
Absent
Thickened myocardium
Absent
Present
Exaggerated variation in transvalvular 
velocities
Present
Absent
CT or MRI 
Thickened pericardium
Present
Absent
Cardiac catheterization
Equalized RV and LV diastolic pressures Yes
Often LV > RV
Elevated PA systolic pressure
Uncommon
Usual
Effect of inspiration on systolic 
pressures
Discordant: LV↓,
RV↑
Concordant: LV↓,
RV↓
Endomyocardial biopsy
Normal
Usually abnormal 
(e.g., amyloid)
Abbreviations: LV, left ventricle; PA, pulmonary artery; RV, right ventricle.
SECTION 8
834
Cardiology
Asymptomatic Pericardial Effusion of Unknown Cause
APPROACH TO THE
PATIENT
If careful history and physical exam do not suggest etiology, the following 
may lead to diagnosis:
• Skin test and cultures for tuberculosis (Chap. 103)
• Serum albumin and urine protein measurement (nephrotic syndrome)
• Serum creatinine and BUN (renal failure)
• Thyroid function tests (myxedema)
• Antineutrophil antibodies (SLE and other collagen-vascular disease)
• Search for a primary tumor (especially lung and breast)
For a more detailed discussion, see Braunwald E: Pericardial 
Disease, Chap. 239, p. 1971, in HPIM-18.
CHAPTER 126
Hypertension
Definition
Chronic elevation in bp (systolic ≥140 mmHg or diastolic ≥90 mmHg); 
etiology unknown in 80–95% of pts (“essential hypertension”). Always 
consider a secondary correctable form of hypertension, especially in pts 
under age 30 or those who become hypertensive after 55. Isolated systolic 
hypertension (systolic ≥140, diastolic <90) most common in elderly pts, due 
to reduced vascular compliance.
� SECONDARY HYPERTENSION
Renal Artery Stenosis (Renovascular Hypertension) 
Due to either atherosclerosis (older men) or fibromuscular dysplasia (young 
women). Presents with recent onset of hypertension, refractory to usual 
antihypertensive therapy. Abdominal bruit is present in 50% of cases; often 
audible; mild hypokalemia due to activation of the renin-angiotensin-
aldosterone system may be present.
Renal Parenchymal Disease 
Elevated serum creatinine and/or abnormal urinalysis, containing protein, 
cells, or casts.
Coarctation of Aorta 
Presents in children or young adults; constriction is usually present in aorta 
at origin of left subclavian artery. Exam shows diminished, delayed femoral 
pulsations; late systolic murmur loudest over the midback. CXR shows 
CHAPTER 126
835
Hypertension
indentation of the aorta at the level of the coarctation and rib notching (due 
to development of collateral arterial flow).
Pheochromocytoma 
A catecholamine-secreting tumor, typically of the adrenal medulla or 
extraadrenal paraganglion tissue, that presents as paroxysmal or sustained 
hypertension in young to middle-aged pts. Sudden episodes of headache, 
palpitations, and profuse diaphoresis are common. Associated findings 
include chronic weight loss, orthostatic hypotension, and impaired glu-
cose tolerance. Pheochromocytomas may be localized to the bladder wall 
and may present with micturition-associated symptoms of catecholamine 
excess. Diagnosis is suggested by elevated plasma metanephrine level or 
urinary catecholamine metabolites in a 24-h urine collection (see below); 
the tumor is then localized by CT scan or MRI.
Hyperaldosteronism
Usually due to aldosterone-secreting adenoma or bilateral adrenal hyper-
plasia. Should be suspected when hypokalemia is present in a hypertensive 
pt off diuretics (Chap. 182).
Other Causes 
Oral contraceptive usage, obstructive sleep apnea (Chap. 146), Cushing’s 
and adrenogenital syndromes (Chap. 182), thyroid disease (Chap. 181), 
hyperparathyroidism, and acromegaly (Chap. 179). In pts with systolic 
hypertension and wide pulse pressure, consider thyrotoxicosis, aortic regur-
gitation (Chap. 123), and systemic AV fistula.
Hypertension
APPROACH TO THE
PATIENT
History: Most pts are asymptomatic. Severe hypertension may lead to 
headache, dizziness, or blurred vision.
Clues to specific forms of secondary hypertension: Use of medications 
(e.g., birth control pills, glucocorticoids, decongestants, erythropoietin, 
NSAIDs, cyclosporine); paroxysms of headache, sweating, or tachycardia 
(pheochromocytoma); history of renal disease or abdominal trauma 
(renal hypertension); daytime somnolence and snoring (sleep apnea).
Physical examination: Measure bp with appropriate-sized cuff (large 
cuff for large arm). Measure bp in both arms as well as a leg (to evaluate 
for aortic coarctation). Signs of hypertension include retinal arteriolar 
changes (narrowing/nicking); left ventricular lift, loud A2, S4. Clues to 
secondary forms of hypertension include cushingoid appearance, thyro-
megaly, abdominal bruit (renal artery stenosis), delayed femoral pulses 
(coarctation of aorta).
Laboratory Workup
Screening tests for secondary hypertension: Should be carried out on 
all pts with documented hypertension: (1) serum creatinine, BUN, 
and urinalysis (renal parenchymal disease); (2) serum K measured off 
836
SECTION 8
Cardiology
diuretics (hypokalemia prompts workup for hyperaldosteronism or 
renal artery stenosis); (3) CXR (rib notching or indentation of distal 
aortic arch in coarctation of the aorta); (4) ECG (LV hypertrophy sug-
gests chronicity of hypertension); (5) other useful screening blood tests 
including CBC, glucose, lipid levels, calcium, uric acid; (6) thyroid-
stimulating hormone if thyroid disease suspected.
Further workup: Indicated for specific diagnoses if screening tests are 
abnormal or bp is refractory to antihypertensive therapy: (1) renal artery 
stenosis: magnetic resonance angiography, captopril renogram, renal 
duplex ultrasound, digital subtraction angiography, renal arteriography; 
(2) Cushing’s syndrome: dexamethasone suppression test (Chap. 182); 
(3) pheochromocytoma: 24-h urine collection for catecholamines, meta-
nephrines, and vanillylmandelic acid and/or measurement of plasma 
metanephrine; (4) primary hyperaldosteronism: depressed plasma renin 
activity and hypersecretion of aldosterone, both of which fail to change 
with volume expansion; (5) renal parenchymal disease (Chap. 149).
Hypertension
TREATMENT
Helpful lifestyle modifications include weight reduction (to attain 
BMI <25 kg/m2); sodium restriction; diet rich in fruits, vegetables, and 
low-fat dairy products; regular exercise; and moderation of alcohol 
consumption.
DRUG THERAPY OF ESSENTIAL HYPERTENSION (SEE TABLE 126-1 AND 
FIG. 126-1) Goal is to control hypertension with minimal side effects. 
A combination of medications with complementary actions is often 
required. First-line agents include diuretics, ACE inhibitors, angiotensin 
receptor antagonists, calcium channel antagonists, and beta blockers. 
On-treatment blood pressure goal is <135–140 systolic, <80–85 diastolic 
(<130/80 in pts with diabetes or chronic kidney disease).
Diuretics Should be cornerstone of most antihypertensive regimes. 
Thiazides preferred over loop diuretics because of longer duration 
of action; however, the latter are more potent when serum creatinine 
>2.5 mg/dL. Major side effects include hypokalemia, hyperglycemia, 
and hyperuricemia, which can be minimized by using low dosage 
(e.g., hydrochlorothiazide 6.25–50 mg qd). Diuretics are particularly 
effective in elderly and black pts. Prevention of hypokalemia is especially 
important in pts on digitalis glycosides.
ACE Inhibitors and Angiotensin II Receptor Blockers (ARBs) ACE 
inhibitors and ARBs are well tolerated with low frequency of side 
effects. May be used as monotherapy or in combination with a diuretic, 
calcium antagonist, or beta blocker. Side effects are uncommon and 
include angioedema (more common with ACE inhibitors than ARBs), 
hyperkalemia, and azotemia (particularly in pts with elevated baseline 
serum creatinine). A nonproductive cough may develop in the course of
TABLE 126-1 ORAL DRUGS COMMONLY USED IN TREATMENT OF HYPERTENSION
Drug Class
Examples
Usual Total Daily Dose (Dosing 
Frequency/Day)
Potential Adverse Effects
Diuretics
 Thiazides
Hydrochlorothiazide
6.25–50 mg (1–2)
Hypokalemia, hyperuricemia, hyperglycemia, 
↑ cholesterol, ↑ triglycerides
 Thiazide-like
Chlorthalidone
25–50 mg (1)
same as above
 Loop diuretics
Furosemide
40–80 mg (2–3)
Hypokalemia, hyperuricemia
 K+-retaining
Spironolactone
25–100 mg (1–2)
Hyperkalemia, gynecomastia
Eplerenone
50–100 mg (1–2)
Hyperkalemia
Amiloride
5–10 mg (1–2)
Triamterene
50–100 mg (1–2)
Beta blockers
 β1-selective
Atenolol
25–100 mg (1–2)
Bronchospasm, bradycardia, heart block, fatigue, 
sexual dysfunction, ↑ triglycerides, ↓ HDL
Metoprolol
25–100 mg (1–2)
same as above
 Nonselective
Propranolol
40–160 mg (2)
same as above
Propranolol LA
60–180 mg (1)
same as above
  Combined alpha/beta
Labetolol
200–800 mg (2)
Bronchospasm, bradycardia, heart block
Carvedilol
12.5–50 mg (2)
(continued)
837
TABLE 126-1 ORAL DRUGS COMMONLY USED IN TREATMENT OF HYPERTENSION (CONTINUED)
Drug Class
Examples
Usual Total Daily Dose (Dosing 
Frequency/Day)
Potential Adverse Effects
ACE inhibitors
Captopril
25–200 mg (2)
Cough, hyperkalemia, azotemia, angioedema
Lisinopril
10–40 mg (1)
Ramipril
2.5–20 mg (1–2)
Angiotensin II receptor 
blockers
Losartan
25–100 mg (1–2)
Hyperkalemia, azotemia
Valsartan
80–320 mg (1)
Candesartan
2–32 mg (1–2)
Calcium channel antagonists
 Dihydropyridines
Nifedipine long-acting
30–60 mg (1)
Edema, constipation
 Nondihydropyridines
Verapamil long-acting
120–360 mg (1–2)
Edema, constipation, bradycardia, heart block
Diltiazem long-acting
180–420 mg (1)
838
839
CHAPTER 126
Hypertension
therapy in up to 15% of pts on an ACE inhibitor, prompting substitution 
with an ARB (cough is not common side effect) or alternate antihyper-
tensives. Note that renal function may deteriorate rapidly as a result of 
inhibition of the renin-angiotensin system in pts with bilateral renal 
artery stenosis.
Potassium supplements and potassium-sparing diuretics should be 
used cautiously with ACE inhibitors or ARBs to prevent hyperkalemia. 
If pt is intravascularly volume depleted, hold diuretics for 2–3 days prior 
to initiation of drug, which should then be administered at low dosage.
Calcium Antagonists Direct arteriolar vasodilators; all have negative 
inotropic effects (particularly verapamil) and should be used cautiously if 
LV dysfunction is present. Verapamil and, to a lesser extent, diltiazem can 
result in bradycardia and AV block, so combination with beta blockers is 
generally avoided. Use sustained-release formulations, as short-acting dihy-
dropyridine calcium channel blockers may increase incidence of coronary 
events. Common side effects include peripheral edema and constipation.
Lifestyle Improvements
Increase dose or add additional antihypertensive drugs
bp above goal
bp above goal
Standard therapy
Generally start with thiazide
diuretic (may also consider
one of the following: ACEI, 
ARB, CCB, or BB)
“Compelling” indications
(See Table 126-2)
Start with ACEI, ARB, CCB,
or BB; consider adding
thiazide
FIGURE 126-1 Initiation of therapy in pts with hypertension. ACEI, angiotensin-
converting enzyme inhibitor; ARB, angiotensin receptor blocker; CCB, calcium channel 
blocker; BB, beta blocker.
TABLE 126-2 GUIDELINES FOR SELECTING INITIAL DRUG TREATMENT OF HYPERTENSION
Class of Drug
Compelling Indications
Possible Indications
Compelling Contraindications
Possible Contraindications
Diuretics
Heart failure
Gout
Dyslipidemia
Elderly pts
Systolic hypertension
Beta blockers
Angina
Heart failure
Asthma and COPD
Dyslipidemia
After MI
Pregnancy
Heart blocka
Athletes and physically active pts
Tachyarrhythmias
Peripheral vascular disease
ACE inhibitors
Heart failure
Chronic renal parenchymal 
disease
Pregnancy
LV dysfunction
Hyperkalemia
After MI
Bilateral renal artery stenosis
Diabetic nephropathy
Angiotensin receptor 
blockers
ACE inhibitor cough
Chronic renal parenchymal 
disease
Pregnancy
Heart failure
Bilateral renal artery stenosis
Diabetic nephropathy
Hyperkalemia
Calcium channel 
blockers
Angina
Elderly pts
Systolic hypertension
Peripheral vascular disease
Heart blockb
Congestive heart failurec
aGrade 2 or 3 atrioventricular block.
bGrade 2 or 3 atrioventricular block with verapamil or diltiazem.
cVerapamil or diltiazem.
Abbreviations: ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; COPD, chronic obstructive pulmonary disease; LV, left ventricular; MI, myocardial infarction.
840
841
CHAPTER 126
Hypertension
If bp proves refractory to drug therapy, work up for secondary forms 
of hypertension, especially renal artery stenosis and pheochromocytoma.
Beta Blockers Particularly useful in young pts with “hyperkinetic” 
circulation. Begin with low dosage (e.g., metoprolol succinate 25–50 mg 
daily). Relative contraindications: bronchospasm, CHF, AV block, 
bradycardia, and “brittle” insulin-dependent diabetes.
Table 126-2 lists compelling indications for specific initial drug 
treatment.
SPECIAL CIRCUMSTANCES
Pregnancy Most commonly used antihypertensives include methyldopa 
(250–1000 mg PO bid-tid), labetalol (100–200 mg bid), and hydralazine 
(10–150 mg PO bid-tid). Calcium channel blockers (e.g., nifedipine, long-
acting, 30–60 mg daily) also appear to be safe in pregnancy. Beta blockers 
should be used cautiously; fetal hypoglycemia and low birth weights have 
been reported. ACE inhibitors and ARBs are contraindicated in pregnancy.
Renal Disease Standard thiazide diuretics may not be effective. 
Consider metolazone, furosemide, or bumetanide, alone or in combination.
Diabetes Goal bp <130/80. Consider ACE inhibitors and angiotensin 
receptor blockers as first-line therapy to control bp and slow renal 
deterioration.
TABLE 126-3  USUAL INTRAVENOUS DOSES OF ANTIHYPERTENSIVE 
AGENTS USED IN HYPERTENSIVE EMERGENCIESa
Antihypertensive Agent IV Dose
Nitroprusside
Initial 0.3 (mg/kg)/min; usual 2–4 (mg/kg)/min; 
maximum 10 (mg/kg)/min for 10 min
Nicardipine
Initial 5 mg/h; titrate by 2.5 mg/h at 5–15 min 
intervals; max 15 mg/h
Labetalol
2 mg/min up to 300 mg or 20 mg over 2 min, then 
40–80 mg at 10-min intervals up to 300 mg total
Enalaprilat
Usual 0.625–1.25 mg over 5 min every 6–8 h; 
maximum 5 mg/dose
Esmolol
Initial 80–500 mg/kg over 1 min, then 
50–300 (mg/kg)/min
Phentolamine
5–15 mg bolus
Nitroglycerin
Initial 5 mg/min, then titrate by 5 mg/min at 
3–5 min intervals; if no response is seen at 
20 mg/min, incremental increases of 10–20 mg/min 
may be used
Hydralazine
10–50 mg at 30-min intervals
aConstant blood pressure monitoring is required. Start with the lowest dose. Subsequent doses 
and intervals of administration should be adjusted according to the blood pressure response 
and duration of action of the specific agent.
SECTION 8
842
Cardiology
Malignant Hypertension Defined as an abrupt increase in bp in pt with 
chronic hypertension or sudden onset of severe hypertension; a medi-
cal emergency. Immediate therapy is mandatory if there is evidence of 
cardiac decompensation (CHF, angina), encephalopathy (headache, 
seizures, visual disturbances), or deteriorating renal function. Inquire 
about use of cocaine, amphetamines, or monoamine oxidase inhibitors.  
Drugs to treat hypertensive crisis are listed in Table 126-3. Replace with 
PO antihypertensive as pt becomes asymptomatic and bp improves.
For a more detailed discussion, see Kotchen TA: Hypertensive 
Vascular Disease, Chap. 247, p. 2042, in HPIM-18.
CHAPTER 127
Metabolic Syndrome
The metabolic syndrome (insulin resistance syndrome, syndrome X) is an 
important risk factor for cardiovascular disease and type 2 diabetes; it 
consists of a constellation of metabolic abnormalities that includes central 
obesity, insulin resistance, hypertension, dyslipidemia, and endothelial 
dysfunction. The prevalence of metabolic syndrome varies among ethnic 
groups; it increases with age, degree of obesity and propensity to type 2 dia-
betes. In the United States, 44% of persons over age 50 have the metabolic 
syndrome; women are affected in greater numbers than men.
� ETIOLOGY
Overweight/obesity (especially central adiposity), sedentary lifestyle, 
increasing age, and lipodystrophy are all risk factors for the metabolic 
syndrome. The exact cause is not known and may be multifactorial. 
Insulin resistance is central to the development of the metabolic syndrome. 
Increased intracellular fatty acid metabolites contribute to insulin resistance 
by impairing insulin-signaling pathways and accumulating as triglycerides 
in skeletal and cardiac muscle, while stimulating hepatic glucose and tri-
glyceride production. Excess adipose tissue leads to increased production 
of proinflammatory cytokines.
� CLINICAL FEATURES
There are no specific symptoms of the metabolic syndrome. The major 
features include central obesity, hypertriglyceridemia, low HDL cholesterol, 
hyperglycemia, and hypertension (Table 127-1). Associated conditions 
include cardiovascular disease, type 2 diabetes, nonalcoholic fatty liver 
disease, hyperuricemia/gout, polycystic ovary syndrome, and obstructive 
sleep apnea.
CHAPTER 127
843
Metabolic Syndrome
� DIAGNOSIS
The diagnosis of the metabolic syndrome relies on satisfying the criteria 
listed in Table 127-1. Screening for associated conditions should be under-
taken.
Metabolic Syndrome
TREATMENT
Obesity is the driving force behind the metabolic syndrome. Thus, 
weight reduction is the primary approach to this disorder. In general, 
recommendations for weight loss include a combination of caloric 
restriction, increased physical activity, and behavior modification. 
Weight loss drugs (orlistat) or bariatric surgery are adjuncts that may 
be considered for obesity management (Chap. 183). Metformin or 
thiazolidinedione (pioglitazone) reduce insulin resistance. Hypertension 
(Chap. 126), impaired fasting glucose or diabetes (Chap. 184), and lipid 
abnormalities (Chap. 189) should be managed according to current 
guidelines. The antihypertensive regimen should include an angiotensin-
converting enzyme (ACE) inhibitor or angiotensin receptor blocker 
when possible.
TABLE 127-1  NCEP:ATPIII 2001 AND IDF CRITERIA FOR THE METABOLIC 
SYNDROME
NCEP:ATPIII 2001 Criteria
Three or more of the following:
Central obesity: Waist circumference >102 cm (M), >88 cm (F)
Hypertriglyceridemia: Triglycerides ≥150 mg/dL or specific medication
Low HDL cholesterol: <40 mg/dL (M) and <50 mg/dL (F) or specific 
medication 
Hypertension: Blood pressure ≥130 mm systolic or ≥85 mm diastolic or 
specific medication
Fasting plasma glucose ≥100 mg/dL or specific medication or previously 
diagnosed type 2 diabetes
IDF Criteria
Differ from NCEP: ATPIII 2001 criteria by more stringent and ethnicity-specific 
waist circumference limits. Other criteria are the same.
Waist circumference: Europid, 
≥94 cm (M), ≥80 cm (F)
 
Sub-Saharan African
 
Eastern and Middle Eastern
 
South Asian, Chinese 
≥90 cm (M), ≥80 cm (F)
 
South and Central American
 
Japanese 
≥90 cm (M), ≥80 cm (F)
Abbreviations: HDL, high-density lipoprotein; IDF, International Diabetes Foundation; 
NCEP:ATPIII, National Cholesterol Education Program, Adult Treatment Panel III.
SECTION 8
844
Cardiology
For a more detailed discussion, see Eckel RH: The Metabolic 
Syndrome, Chap. 242, p. 1992, in HPIM-18. 
CHAPTER 128
ST-Segment Elevation 
Myocardial Infarction (STEMI)
Early recognition and immediate treatment of acute MI are essential; diag-
nosis is based on characteristic history, ECG, and serum cardiac markers.
Symptoms
Chest pain similar to angina (Chap. 37) but more intense and persistent; not 
fully relieved by rest or nitroglycerin, often accompanied by nausea, sweat-
ing, apprehension. However, ~25% of MIs are clinically silent.
Physical Examination 
Pallor, diaphoresis, tachycardia, S4, dyskinetic cardiac impulse may be pres-
ent. If CHF exists, rales and S3 are present. Jugular venous distention is 
common in right ventricular infarction.
ECG
ST elevation, followed (if acute reperfusion is not achieved) by T-wave 
inversion, then Q-wave development over several hours (see Figs. 120-3 
and 120-4).
Non-ST Elevation MI, or NSTEMI 
ST depression followed by persistent ST-T-wave changes without Q-wave 
development. Comparison with old ECG helpful (see Chap. 129).
Cardiac Biomarkers 
Cardiac-specific troponins T and I are highly specific for myocardial injury 
and are the preferred biochemical markers for diagnosis of acute MI. They 
remain elevated for 7–10 days. Creatine phosphokinase (CK) level rises 
within 4–8 h, peaks at 24 h, and returns to normal by 48–72 h. CK-MB 
isoenzyme is more specific for MI but may also be elevated with myo-
carditis or after electrical cardioversion. Total CK (but not CK-MB) rises 
(two- to threefold) after IM injection, vigorous exercise, or other skeletal 
muscle trauma. A ratio of CK-MB mass:CK activity ≥2.5 suggests acute MI. 
CK-MB peaks earlier (about 8 h) following acute reperfusion therapy (see 
below). Serum cardiac markers should be measured at presentation, 6–9 h 
later, and then at 12–24 h.
CHAPTER 128
845
ST-Segment Elevation Myocardial Infarction
Noninvasive Imaging Techniques 
Useful when diagnosis of MI is not clear. Echocardiography detects infarct-
associated regional wall motion abnormalities (but cannot distinguish acute 
MI from a previous myocardial scar). Echo is also useful in detecting RV 
infarction, LV aneurysm, and LV thrombus. Myocardial perfusion imag-
ing (thallium 201 or technetium 99m-sestamibi) is sensitive for regions 
of decreased perfusion, but is not specific for acute MI. MRI with delayed 
gadolinium enhancement accurately indicates regions of infarction, but is 
technically difficult to obtain in acutely ill pts.
STEMI
TREATMENT
INITIAL THERAPY Initial goals are to (1) quickly identify if pt is can-
didate for reperfusion therapy, (2) relieve pain, and (3) prevent/treat 
arrhythmias and mechanical complications.
• Aspirin should be administered immediately (162–325 mg chewed at 
presentation, then 162–325 mg PO qd), unless pt is aspirin-intolerant.
• Perform targeted history, exam, and ECG to identify STEMI (>1 mm 
ST elevation in two contiguous limb leads, ≥2 mm ST elevation in 
two contiguous precordial leads, or new LBBB) and appropriateness 
of reperfusion therapy [percutaneous coronary intervention (PCI) or 
IV fibrinolytic agent], which reduces infarct size, LV dysfunction, and 
mortality.
• Primary PCI is generally more effective than fibrinolysis and is pre-
ferred at experienced centers capable of performing the procedure 
rapidly (Fig. 128-1), especially when diagnosis is in doubt, cardiogenic 
shock is present, bleeding risk is increased, or symptoms have been 
present for >3 h.
• Proceed with IV fibrinolysis if PCI is not available or if logistics would 
delay PCI >1 h longer than fibrinolysis could be initiated (Fig. 128-1). 
Door-to-needle time should be <30 min for maximum benefit. Ensure 
absence of contraindications (Fig. 128-2) before administering fibri-
nolytic agent. Those treated within 1–3 h benefit most; can still be 
useful up to 12 h if chest pain is persistent or ST remains elevated in 
leads that have not developed new Q waves. Complications include 
bleeding, reperfusion arrhythmias, and, in case of streptokinase (SK), 
allergic reactions. Enoxaparin or heparin [60 U/kg (maximum 4000 U), 
then 12 (U/kg)/h (maximum 1000 U/h)] should be initiated with fibri-
nolytic agents (Fig. 128-2); maintain activated partial thromboplastin 
time (aPTT) at 1.5–2.0 × control (~50–70 s).
• If chest pain or ST elevation persists >90 min after fibrinolysis, con-
sider referral for rescue PCI. Coronary angiography after fibrinolysis 
should also be considered for pts with recurrent angina or high-risk 
features (Fig. 128-2) including extensive ST elevation, signs of heart 
failure (rales, S3, jugular venous distension, LVEF ≤35%), or systolic 
BP <100 mmHg.
The initial management of NSTEMI (non-Q MI) is different 
(Chap. 129). In particular, fibrinolytic therapy should not be administered.
SECTION 8
846
Cardiology
ADDITIONAL STANDARD TREATMENT (Whether or not reperfusion 
therapy is undertaken):
• Hospitalize in CCU with continuous ECG monitoring.
• IV line for emergency arrhythmia treatment.
• Pain control: (1) Morphine sulfate 2–4 mg IV q5–10 min until pain is 
relieved or side effects develop [nausea, vomiting, respiratory depres-
sion (treat with naloxone 0.4–1.2 mg IV), hypotension (if bradycardic, 
treat with atropine 0.5 mg IV; otherwise use careful volume infusion)]; 
(2) nitroglycerin 0.3 mg SL if systolic bp >100 mmHg; for refractory 
pain: IV nitroglycerin (begin at 10 μg/min, titrate upward to maximum 
of 200 μg/min, monitoring bp closely); do not administer nitrates 
within 24 h of sildenafil or within 48 h of tadalafil (used for erectile 
dysfunction); (3) β-adrenergic antagonists (see below).
• Oxygen: 2–4 L/min by nasal cannula (if needed to maintain O2 
saturation >90%).
• Mild sedation (e.g., diazepam 5 mg, oxazepam 15–30 mg, or lorazepam 
0.5–2 mg PO three to four times daily).
• Soft diet and stool softeners (e.g., docusate sodium 100–200 mg/d).
STEMI patient who
is a candidate for
reperfusion
Initially seen at
a PCI-capable
facility
Initially seen at a
non-PCI-capable
facility
Send to cath lab
for primary PCI
Transfer for
primary PCI
Initial treatment
with
fibrinolytic
NOT HIGH RISK
Transfer to a PCI
facility may be
considered
especially if
ischemic
symptoms
persist and failure
to reperfuse is
suspected
HIGH RISK
Transfer to a PCI
facility is reasonable
for early diagnostic
angio and possible
PCI or CABG
High-risk patients as
defined by 2007
STEMI focused
update should
undergo cath
Preparatory antithrombotic
(anticoagulant plus
antiplatelet) regimen
Medical
therapy only
PCI with
stent
CABG
Diagnostic angiography
*• Time since onset of symptoms
 • Risk of STEMI
 • Risk of fibrinolysis
 • Time required for transport to
  a skilled PCI lab
Selection of reperfusion strategy*
At PCI
facility,
evaluate
for timing of
diagnostic
angio
FIGURE 128-1 Reperfusion strategies in STEMI. [Adapted from Kushner FG et al: 
2009 focused update of the ACC/AHA Guidelines for the Management of Patients with 
ST-Elevation Myoc ardial Infarction (updating the 2004 guideline and 2007 focused 
update): A report of the American College of Cardiology Foundation/American Heart 
Association Task Force on Practice Guidelines. Circulation 120:2271, 2009.]
CHAPTER 128
847
SUBSEQUENT CORONARY ANGIOGRAPHY RESERVED FOR
• Failure of reperfusion (persistent chest pain or ST elevation after 90 min)
• Spontaneous recurrent ischemia during hospitalization
• High risk features: e.g., extensive ST elevation, heart failure, hypotension
SELECTION CRITERIA
1.  Acute chest discomfort characteristic of myocardial infarction
2.  ECG criteria for ST-elevation MI (a, b, or c):
     a.  ST elevation ≥ 0.1 mV (1 mm) in at least 2 leads of either:
   
Inferior group: II, III, aVF
 
Lateral group: I, aVL, V5, V6
     b.  ST elevation ≥ 0.2 mV (1 mm) in at least 2 contiguous anterior 
          leads (V1–V4)
     c.  New LBBB
3.  Primary PCI not available, or delay to PCI would be >1 h
     longer than initiation of fibrinolysis
• Prior intracranial bleeding
• Intracranial malignancy or vascular malformation
• Ischemic stroke or head trauma in previous 3 months
• Aortic dissection
• Active bleeding (with exception of menses)
• Internal bleeding in previous 4 weeks
• Severe hypertension (systolic >180 or diastolic >110)
• Prolonged (>10 min) CPR chest compressions
• INR ≥ 2.0 on warfarin, or known bleeding diathesis
• Pregnancy
ASSESS FOR CONTRAINDICATIONS
FIBRINOLYTIC DRUG
INTRAVENOUS DOSAGE
Streptokinase
Alteplase*
Reteplase*
Tenecteplase*
Single bolus of 0.53 mg/kg over 10 sec.
10 U over 2 min; repeat same dose
30 min later
15-mg bolus, then 0.75 mg/kg (up
to 50 mg) over 30 min, then 0.5 mg/kg
(up to 35 mg) over 60 min
1.5 million U over 60 min
*If alteplase, reteplase, or tenecteplase used, also administer IV heparin 
 60-U/kg bolus (maximum 4000 U) followed by 12 (U/kg)/h (maximum 1000 U/h), 
 then adjusted to maintain aPTT at 1.5–2 x control (∼50–70 s) for 48 h
FIGURE 128-2 Algorithm for fibrinolytic therapy of acute STEMI.
• β-Adrenergic blockers (Chap. 126) reduce myocardial O2 consumption, 
limit infarct size, and reduce mortality. Especially useful in pts with 
hypertension, tachycardia, or persistent ischemic pain; contraindications 
include active CHF, systolic bp <95 mmHg, heart rate <50 beats/min, AV 
block, or history of bronchospasm. Consider IV (e.g., metoprolol 5 mg 
q2–5min to total dose of 15 mg) if pt is hypertensive. Otherwise, begin 
PO regimen (e.g., metoprolol tartrate 25–50 mg four times daily).
ST-Segment Elevation Myocardial Infarction
SECTION 8
848
Cardiology
• Anticoagulation/antiplatelet agents: Pts who receive fibrinolytic therapy 
are begun on heparin and aspirin as indicated above. In absence of 
fibrinolytic therapy, administer aspirin, 160–325 mg qd, and low-dose 
heparin (5000 U SC q12h) or low-molecular-weight heparin (LMWH, 
e.g., enoxaparin 40 mg SC daily) for DVT prevention. Full-dose IV 
heparin (PTT 1.5-2 × control) or LMWH (e.g., enoxaparin 1 mg/kg 
SC q12h) followed by oral anticoagulants is recommended for pts with 
severe CHF, presence of ventricular thrombus by echocardiogram, or 
large dyskinetic region in acute anterior MI. If used, oral anticoagulants 
are continued for 3–6 months, then replaced by aspirin. The addition 
of a P2Y12 platelet receptor antagonist after STEMI (e.g., clopidogrel 
75 mg daily) reduces future adverse cardiac events whether or not 
fibrinolysis or PCI are undertaken.
• ACE inhibitors reduce mortality in pts following acute MI and should 
be prescribed within 24 h of hospitalization for pts with STEMI—e.g., 
captopril (6.25 mg PO test dose advanced to 50 mg PO tid). ACE 
inhibitors should be continued indefinitely after discharge in pts with 
CHF or those with asymptomatic LV dysfunction (ejection fraction 
≤40%); if pt is ACE inhibitor intolerant, use ARB (e.g., valsartan or 
candesartan).
• Aldosterone antagonists (spironolactone or eplerenone 25–50 mg daily) 
further reduce mortality in pts with LVEF ≤40% and either symptom-
atic heart failure or diabetes; do not use in pts with advanced renal 
insufficiency (e.g., creatinine ≥2.5 mg/dL) or hyperkalemia.
• Serum magnesium level should be measured and repleted if necessary 
to reduce risk of arrhythmias.
� COMPLICATIONS
(For arrhythmias, see also Chaps. 131 and 132)
Ventricular Arrhythmias 
Isolated ventricular premature beats (VPBs) occur frequently. Precipitating 
factors should be corrected [hypoxemia, acidosis, hypokalemia (maintain 
serum K+ ~4.5 mmol/L), hypercalcemia, hypomagnesemia, CHF, arrhyth-
mogenic drugs]. Routine beta blocker administration (see above) dimin-
ishes ventricular ectopy. Other in-hospital antiarrhythmic therapy should 
be reserved for pts with sustained ventricular arrhythmias.
Ventricular Tachycardia 
If hemodynamically unstable, perform immediate electrical countershock 
(unsynchronized discharge of 200–300 J or 50% less if using biphasic 
device). If hemodynamically tolerated, use IV amiodarone (bolus of 150 mg 
over 10 min, then infusion of 1.0 mg/min for 6 h, then 0.5 mg/min).
Ventricular Fibrillation (VF) 
VF requires immediate defibrillation (200–400 J). If unsuccessful, initi-
ate cardiopulmonary resuscitation (CPR) and standard resuscitative 
measures (Chap. 11). Ventricular arrhythmias that appear several days or 
CHAPTER 128
849
weeks following MI often reflect pump failure and may warrant invasive 
electrophysiologic study and implantation of a cardioverter defibrillator 
(ICD).
Accelerated Idioventricular Rhythm 
Wide QRS complex, regular rhythm, rate 60–100 beats/min, is common 
and usually benign; if it causes hypotension, treat with atropine 0.6 mg IV.
Supraventricular Arrhythmias 
Sinus tachycardia may result from heart failure, hypoxemia, pain, fever, 
pericarditis, hypovolemia, administered drugs. If no cause is identified, 
suppressive beta blocker therapy may be beneficial to reduce myocardial 
oxygen demand. Other supraventricular arrhythmias (paroxysmal supra-
ventricular tachycardia, atrial flutter, and fibrillation) are often secondary to 
heart failure. If hemodynamically unstable, proceed with electrical cardio-
version. In absence of acute heart failure, suppressive alternatives include 
beta blockers, verapamil, or diltiazem (Chap. 132).
Bradyarrhythmias and AV Block 
(See Chap. 131) In inferior MI, usually represent heightened vagal tone 
or discrete AV nodal ischemia. If hemodynamically compromised (CHF, 
hypotension, emergence of ventricular arrhythmias), treat with atropine 
0.5 mg IV q5min (up to 2 mg). If no response, use temporary external or 
transvenous pacemaker. Isoproterenol should be avoided. In anterior MI, 
AV conduction defects usually reflect extensive tissue necrosis. Consider 
temporary external or transvenous pacemaker for (1) complete heart block, 
(2) Mobitz type II block (Chap. 131), (3) new bifascicular block (LBBB, 
RBBB + left anterior hemiblock, RBBB + left posterior hemiblock), (4) any 
bradyarrhythmia associated with hypotension or CHF.
Heart Failure 
CHF may result from systolic “pump” dysfunction, increased LV diastolic 
“stiffness,” and/or acute mechanical complications.
Symptoms Dyspnea, orthopnea, tachycardia.
Examination Jugular venous distention, S3 and S4 gallop, pulmonary rales; 
systolic murmur if acute mitral regurgitation or ventricular septal defect 
(VSD) has developed.
Heart Failure (See Chaps. 14 and 133)
TREATMENT
Initial therapy includes diuretics (begin with furosemide 10–20 mg IV), 
inhaled O2, and vasodilators, particularly nitrates [PO, topical, or IV 
(Chap. 133) unless pt is hypotensive (systolic bp <100 mmHg)]; digitalis 
is usually of little benefit in acute MI unless supraventricular arrhyth-
mias are present. Diuretic, vasodilator, and inotropic therapy 
(Table 128-1) may be guided by invasive hemodynamic monitoring 
(Swan-Ganz pulmonary artery catheter, arterial line), particularly in pts 
ST-Segment Elevation Myocardial Infarction
SECTION 8
850
Cardiology
with accompanying hypotension (Table 128-2; Fig. 128-3). In acute MI, 
optimal pulmonary capillary wedge pressure (PCW) is 15–20 mmHg; 
in the absence of hypotension, PCW >20 mmHg is treated with diuretic 
plus vasodilator therapy [IV nitroglycerin (begin at 10 μg/min) or nitro-
prusside (begin at 0.5 μg/kg per min)] and titrated to optimize bp, PCW, 
and systemic vascular resistance (SVR).
SVR = (mean arterial pressure − mean RA pressure) × 80
cardiac output
Normal SVR = 900 − 1350 dyne•s/cm5. If PCW >20 mmHg and pt 
is hypotensive (Table 128-2 and Fig. 128-3), evaluate for VSD or acute 
mitral regurgitation, consider dobutamine [begin at 1–2 (μg/kg)/min], 
titrate upward to maximum of 10 (μg/kg)/min; beware of drug-induced 
tachycardia or ventricular ectopy.
After stabilization on parenteral vasodilator therapy, oral therapy 
follows with an ACE inhibitor or an ARB (Chap. 133). Consider addition 
of long-term aldosterone antagonist (spironolactone 25–50 mg daily or 
eplerenone 25–50 mg daily) to ACE inhibitor if LVEF ≤40% or symptom-
atic heart failure or diabetes are present—do not use if renal insufficiency 
or hyperkalemia are present.
TABLE 128-1 IV VASODILATORS AND INOTROPIC DRUGS USED IN ACUTE MI
Drug
Usual Dosage Range Comment
Nitroglycerin
5–100 μg/min
May improve coronary blood flow to 
ischemic myocardium
Nitroprusside
0.5–10 (μg/kg)/min
More potent vasodilator, but improves 
coronary blood flow less than 
nitroglycerin
With therapy >24 h or in renal failure, 
watch for thiocyanate toxicity (blurred 
vision, tinnitus, delirium)
Dobutamine
2–20 (μg/kg)/min
Results in ↑ cardiac output, ↓ PCW, 
but does not raise bp
Dopamine
2–20 (μg/kg)/min
More appropriate than dobutamine if 
hypotensive
Hemodynamic effect depends on 
dose: (μg/kg)/min
 <5: ↑ renal blood flow
 2.5–10: positive inotrope
 >10: vasoconstriction
Milrinone
50 μg/kg over 
10 min, then 0.375–
0.75 (μg/kg)/min
Ventricular arrhythmias may result
CHAPTER 128
851
TABLE 128-2 HEMODYNAMIC COMPLICATIONS IN ACUTE MI
Condition
Cardiac 
Index, 
(L/min)/m2
PCW, 
mmHg
Systolic
bp, mmHg Treatment
Uncomplicated >2.5
≤18
>100
—
Hypovolemia
<2.5
<15
<100
Successive boluses of 
normal saline
In setting of inferior wall 
MI, consider RV infarction 
(esp. if RA pressure >10)
Volume 
overload
>2.5
>20
>100
Diuretic (e.g., furosemide 
10–20 mg IV)
Nitroglycerin, topical 
paste or IV (Table 128-1)
LV failure
<2.5
>20
>100
Diuretic (e.g., furosemide 
10–20 mg IV)
IV nitroglycerin (or if 
hypertensive, use IV 
nitroprusside)
Severe LV 
failure
<2.5
>20
<100
If bp ≥90: IV dobutamine 
± IV nitroglycerin or 
sodium nitroprusside
If bp <90: IV dopamine
If accompanied by 
pulmonary edema: 
attempt diuresis with IV 
furosemide; may be 
limited by hypotension
If new systolic murmur 
present, consider acute 
VSD or mitral regurgitation
Cardiogenic
shock
<2.2
>20
<90 with 
oliguria
and con-
fusion
IV dopamine
Intraaortic balloon pump
Reperfusion by PCI or 
CABG may be life-saving
Abbreviations: CABG, coronary artery bypass graft; LV, left ventricle; PCI, percutaneous 
coronary intervention; PCW, pulmonary capillary wedge pressure; RA, right atrium; RV, right 
ventricle; VSD, ventricular septal defect.
Cardiogenic Shock 
(See Chap. 12) Severe LV failure with hypotension (bp <90 mmHg) and 
elevated PCW (>20 mmHg), accompanied by oliguria (<20 mL/h), peripheral 
vasoconstriction, dulled sensorium, and metabolic acidosis.
ST-Segment Elevation Myocardial Infarction
Clinical signs: Shock, hypoperfusion, congestive heart failure, acute pulmonary edema
Most likely major underlying disturbance?
Acute pulmonary edema
Check blood pressure
Systolic BP
Greater than 100 mm Hg and not
less than 30 mm Hg below baseline
ACE Inhibitors
Short-acting agent such as captopril (1 to 6.25 mg)
Low output- cardiogenic shock
See Section 7.7 in the ACC/AHA
guidelines for patients with
ST-elevation myocardial infarction
Hypovolemia
Bradycardia
Tachycardia
Administer
• Fluids
• Blood transfusions
• Cause-specific
 interventions
Consider vasopressors
Arrhythmia
Systolic BP
Greater than 100 mm Hg
Nitroglycerin
10 to 20 mcg/min IV
Systolic BP
70 to 100 mm Hg
NO signs/symptoms of shock
Dobutamine
2 to 20 mcg/kg per minute IV
Systolic BP
less than 100 mm Hg
signs/symptoms of shock*
*Norepinephrine 0.5 to 30 mcg/min IV or
Dopamine, 5 to 15 mcg/kg per minute IV
Administer
• Furosemide IV 0.5 to 1.0 mg/kg
• Morphine IV 2 to 4 mg
• Oxygen/intubation as needed
• Nitroglycerin SL, then 10 to 20 mcg/min IV if SBP greater than 100 mm Hg
• *Norepinephrine, 0.5 to 30 mcg/min IV or Dopamine, 5 to 15 mcg/kg per minute IV if SBP
 <100 mm Hg and signs/symptoms of shock present
• Dobutamine 2 to 20 mcg/kg per minute IV if SBP 70 to 100 mm Hg and no signs/symptoms of shock
First line of action
Second line of action
Third line of action
Further diagnostic/therapeutic considerations (should be considered in nonhypovolemic shock)
Diagnostic
• Pulmonary artery catheter
• Echocardiography
• Angiography for MI/ischemia
• Additional diagnostic studies
Therapeutic
• Intra-aortic balloon pump
• Reperfusion/revascularization
Check blood
pressure
FIGURE 128-3 Emergency management of cardiogenic shock and pulmonary edema. ACE, angiotensin converting-enzyme; BP, blood pressure; MI, myocardial
infarction. [Modified from Guidelines 2000 for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Part 7: The era of reperfusion: Section 1: Acute 
coronary syndromes (acute myocardial infarction). The American Heart Association in collaboration with the International Liaison Committee on Resuscitation. 
Circulation 102:I172, 2000.]
852
Cardiogenic Shock (Fig. 128-3)
TREATMENT
Swan-Ganz catheter and intraarterial bp monitoring are not always 
essential but may be helpful; aim for mean PCW of 18–20 mmHg with 
adjustment of volume (diuretics or infusion) as needed. Vasopressors 
[e.g., dopamine (Table 128-1)] and/or intraaortic balloon counterpulsa-
tion may be necessary to maintain systolic bp >90 mmHg and reduce 
PCW. Administer high concentration of O2 by mask; if pulmonary 
edema coexists, consider bilateral positive airway pressure (BiPAP) or 
intubation and mechanical ventilation. Acute mechanical complications 
(see below) should be sought and promptly treated.
If cardiogenic shock develops within 36 h of acute STEMI, reperfu-
sion by PCI or coronary artery bypass grafting (CABG) may markedly 
improve LV function.
Hypotension
May also result from right ventricular MI, which should be suspected in 
inferior or posterior MI, if jugular venous distention and elevation of right-
heart pressures predominate (rales are typically absent and PCW may be 
normal); right-sided ECG leads typically show ST elevation, and echocar-
diography may confirm diagnosis. Treatment consists of volume infusion. 
Noncardiac causes of hypotension should be considered: hypovolemia, 
acute arrhythmia, or sepsis.
Acute Mechanical Complications 
Ventricular septal rupture and acute mitral regurgitation due to papil-
lary muscle ischemia/infarct develop during the first week following MI 
and are characterized by sudden onset of CHF and new systolic murmur. 
Echocardiography and Doppler interrogation can confirm presence of these 
complications. PCW tracings may show large v waves in either condition, 
but an oxygen “step-up” as the catheter is advanced from right atrium to 
right ventricle suggests septal rupture.
Acute medical therapy of these conditions includes vasodilator therapy 
(IV nitroprusside: begin at 10 μg/min and titrate to maintain systolic bp 
~100 mmHg); intraaortic balloon pump may be required to maintain cardiac 
output. Mechanical correction is the definitive therapy. Acute ventricular 
free-wall rupture presents with sudden loss of bp, pulse, and consciousness, 
while ECG shows an intact rhythm (pulseless electrical activity); emergent 
surgical repair is crucial, and mortality is high.
Pericarditis 
Characterized by pleuritic, positional pain and pericardial rub (Chap. 125); 
atrial arrhythmias are common; must be distinguished from recurrent 
angina. Often responds to aspirin, 650 mg PO qid. Anticoagulants should be 
avoided when pericarditis is suspected to avoid development of tamponade.
Ventricular Aneurysm 
Localized “bulge” of LV chamber due to infarcted myocardium. True aneu-
rysms consist of scar tissue and do not rupture. However, complications 
853
CHAPTER 128
ST-Segment Elevation Myocardial Infarction
SECTION 8
854
Cardiology
include CHF, ventricular arrhythmias, and thrombus formation. Typically 
an aneurysm is confirmed by echocardiography or by left ventriculography. 
The presence of thrombus within the aneurysm, or a large aneurysmal seg-
ment due to anterior MI, warrants oral anticoagulation with warfarin for 
3–6 months.
Pseudoaneurysm is a form of cardiac rupture contained by a local area of 
pericardium and organized thrombus; direct communication with the LV 
cavity is present; surgical repair usually necessary to prevent rupture.
Recurrent Angina 
Usually associated with transient ST-T wave changes; signals high incidence 
of reinfarction; when it occurs in early post-MI period, proceed directly to 
coronary arteriography, to identify those who would benefit from PCI or 
CABG.
� SECONDARY PREVENTION
For pts who have not already undergone coronary angiography and PCI, 
submaximal exercise testing should be performed prior to or soon after 
discharge. A positive test in certain subgroups (angina at a low workload, a 
large region of provocable ischemia, or provocable ischemia with a reduced 
LVEF) suggests need for cardiac catheterization to evaluate myocardium 
at risk of recurrent infarction. Beta blockers (e.g., metoprolol, 25–200 mg 
daily) should be prescribed routinely for at least 2 years following acute 
MI, unless contraindications present (asthma, CHF, bradycardia, “brittle” 
diabetes). Continue oral antiplatelet agents (e.g., aspirin 81–325 mg daily, 
clopidogrel 75 mg daily) to reduce incidence of reinfarction. If LVEF ≤40%, 
an ACE inhibitor (e.g., captopril 6.25 mg PO tid, advanced to target dose 
of 50 mg PO tid) or ARB (if ACE inhibitor is not tolerated) should be 
used indefinitely. Consider addition of aldosterone antagonist (see “Heart 
Failure,” above).
Modification of cardiac risk factors must be encouraged: discontinue 
smoking; control hypertension, diabetes, and serum lipids (typically 
atorvastatin 80 mg daily in immediate post-MI period—see Chap. 189); 
and pursue graduated exercise.
For a more detailed discussion, see Antman EM, Loscalzo J: 
ST-Segment Elevation Myocardial Infarction, Chap. 245, 
p. 2021; and Hochman JS, Ingbar DH: Cardiogenic Shock 
and Pulmonary Edema, Chap. 272, p. 2232, in HPIM-18.
CHAPTER 129
855
CHAPTER 129
Unstable Angina and 
Non-ST-Elevation Myocardial 
Infarction
Unstable angina (UA) and non-ST-elevation MI (NSTEMI) are acute 
coronary syndromes with similar mechanisms, clinical presentations, and 
treatment strategies.
Clinical Presentation 
UA includes (1) new onset of severe angina, (2) angina at rest or with mini-
mal activity, and (3) recent increase in frequency and intensity of chronic 
angina. NSTEMI is diagnosed when symptoms of UA are accompanied by 
evidence of myocardial necrosis (e.g., elevated cardiac biomarkers). Some 
pts with NSTEMI present with symptoms identical to STEMI—the two are 
differentiated by ECG (Chap. 128).
Physical Examination 
May be normal or include diaphoresis, pale cool skin, tachycardia, S4, 
basilar rales; if large region of ischemia, may demonstrate S3, hypotension.
Electrocardiogram
Most commonly ST depression and/or T-wave inversion; unlike STEMI, 
there is no Q-wave development.
Cardiac Biomarkers 
CK-MB and/or cardiac-specific troponins (more specific and sensitive 
markers of myocardial necrosis) are elevated in NSTEMI. Small troponin 
elevations may also occur in pts with CHF, myocarditis, or pulmonary 
embolism.
Unstable Angina and Non-ST-Elevation Myocardial 
Infarction
TREATMENT
First step is appropriate triage based on likelihood of coronary artery 
disease (CAD) and acute coronary syndrome (Fig. 129-1) as well as 
identification of higher-risk pts (Fig. 129-2). Pts with low likelihood of 
active ischemia are initially monitored by serial ECGs and serum cardiac 
biomarkers, and for recurrent chest discomfort; if these are negative, 
stress testing (or CT angiography if probability of CAD is low) can be 
used for further therapeutic planning.
Therapy of UA/NSTEMI is directed (1) against the inciting intracoro-
nary thrombus, and (2) toward restoration of balance between myocardial 
oxygen supply and demand. Pts with the highest risk scores (Fig. 129-2) 
benefit the most from aggressive interventions.
Unstable Angina and Myocardial Infarction
SECTION 8
856
Cardiology
Clinical finding
ECG
Cardiac markers
Noncardiac
chest pain
Stable
angina
Negative
Negative
Exertional
pain
Atypical
pain
Risk
assessment
Low probability
Discharge
Negative
Positive
Diagnostic
rule out MI/ACS
pathway
ASA, clopidogrel,
anticoagulant,
anti-ischemic therapy
Early conservative Rx
STEMI
Unstable
angina
NSTEMI
Rest pain, Post-MI,
DM, Prior ASA
Positive
ST-T wave changes
ST
elevation
Ongoing
pain
High risk
Primary PCI
Thrombolysis
STEMI
Low risk
ASA+ anticoagulant
+ ADP inhibitor
+ IIb/IIIa inhibitor if unstable
anti-ischemic therapy
Early invasive Rx
FIGURE 129-1 Algorithm for risk stratification and treatment of pts with suspected 
coronary artery disease. ACS, acute coronary syndrome; ASA, aspirin; DM, diabetes 
mellitus; ECG, electrocardiogram; LMWH, low-molecular-weight heparin; MI, myo-
cardial infarction; PCI, percutaneous coronary intervention; Rx, treatment; STEMI, 
ST-segment elevation myocardial infarction. [Adapted from CP Cannon, E Braunwald, 
in Braunwald’s Heart Disease: A Textbook of Cardiovascular Medicine, 8th ed, P Libby 
et al (eds). Philadelphia, Saunders, 2008.]
Age ≥ 65 years
≥ 3 CAD risk factors
Prior stenosis > 50%
ST deviation
≥ 2 anginal events ≤ 24h
ASA in last 7 days
Elev cardiac markers
50
40
0/1
2
3
4
5
6/7
4.7
8.3
13.2
19.9
26.2
40.9
30
20
10
0
D/MI/Urg Revasc, %
Number of Risk Factors
4.3
% Population:
17.3
32.0
29.3
13.0
3.4
FIGURE 129-2 The TIMI Risk Score for UA/NSTEMI. The quantity of listed attributes 
correlates with risk of death, MI, or need for urgent revascularization over 14 days. 
(Modified from E Antman et al: JAMA 284:835, 2000.)
CHAPTER 129
857
ANTITHROMBOTIC THERAPIES
• Aspirin (325 mg initially, then 75–325 mg/d).
• Platelet ADP receptor antagonist: Clopidogrel (300–600 mg PO load, 
then 75 mg/d) unless excessive risk of bleeding or immediate coronary 
artery bypass grafting (CABG) likely; alternatives include ticagrelor 
[180 mg PO, then 90 mg PO bid (chronic aspirin dose should not 
exceed 100 mg daily)] or prasugrel (60 mg PO, then 10 mg daily) if 
PCI is planned.
• Anticoagulant: Unfractionated heparin (UFH) [60 U/kg then 
12 (U/kg)/h (maximum 1000 U/h)] to achieve aPTT 1.5–2.5 × control, 
or low-molecular-weight heparin (e.g., enoxaparin 1 mg/kg SC 
q12h), which is superior to UFH in reduction of future cardiac 
events. Alternatives include (1) the factor Xa inhibitor fondaparinux 
(2.5 mg SC daily), which is associated with lower bleeding risk, or 
(2) the direct thrombin inhibitor bivalirudin [0.1 mg/kg, then 
0.25 (mg/kg)/h], which causes less bleeding in pts undergoing 
catheterization compared with UFH plus a GP IIb/IIIa inhibitor.
• For high-risk unstable pts who undergo PCI, consider an IV GP 
IIb/IIIa antagonist [e.g., tirofiban, 0.4 (μg/kg)/min × 30 min, then 
0.1 (μg/kg)/min for 48–96 h; or eptifibatide, 180-μg/kg bolus, then 
2.0 (μg/kg)/min for 72–96 h].
ANTI-ISCHEMIC THERAPIES
• Nitroglycerin 0.3–0.6 mg sublingually or by buccal spray. If chest 
discomfort persists after three doses given 5 min apart, consider IV 
nitroglycerin (5–10 μg/min, then increase by 10 μg/min every 
3–5 min until symptoms relieved or systolic bp <100 mmHg). Do not 
use nitrates in pts with recent use of phosphodiesterase-5 inhibitors 
for erectile dysfunction (e.g., not within 24 h of sildenafil or within 
48 h of tadalafil).
• Beta blockers (e.g., metoprolol 25–50 mg PO q6h) targeted to a heart 
rate of 50–60 beats/min. In pts with contraindications to beta block-
ers (e.g., bronchospasm), consider long-acting verapamil or diltiazem 
(Table 126-1).
ADDITIONAL RECOMMENDATIONS
• Admit to unit with continuous ECG monitoring, initially with bed 
rest.
• Consider morphine sulfate 2–5 mg IV q5–30min for refractory chest 
discomfort.
• Add HMG-CoA reductase inhibitor (initially at high dose, e.g., atorv-
astatin 80 mg daily) and consider ACE inhibitor (Chap. 128).
INVASIVE VS CONSERVATIVE STRATEGY In highest-risk pts (Table 129-1), 
an early invasive strategy (coronary arteriography within ~48 h followed 
by percutaneous intervention or CABG) improves outcomes. In lower-risk 
pts, angiography can be deferred but should be pursued if myocardial 
ischemia recurs spontaneously (angina or ST deviations at rest or with 
minimal activity) or is provoked by stress testing.
Unstable Angina and Myocardial Infarction
SECTION 8
858
Cardiology
LONG-TERM MANAGEMENT
• Stress importance of smoking cessation, achieving optimal weight, diet 
low in saturated and trans fats, regular exercise; these principles can be 
reinforced by encouraging pt to enter cardiac rehabilitation program.
• Continue aspirin, clopidogrel (or prasugrel or ticagrelor), beta blocker, 
statin, and ACE inhibitor or angiotensin receptor blocker (especially 
if hypertensive, or diabetic, or LV ejection fraction is reduced).
TABLE 129-1  CLASS I RECOMMENDATIONS FOR USE OF AN EARLY 
INVASIVE STRATEGY
Recurrent angina/ischemia at rest or minimal exertion despite anti-ischemic 
therapy
Elevated cardiac TnI or TnT
New ST-segment depression
Recurrent ischemia with CHF or worsening mitral regurgitation
Positive stress test
LVEF <0.40
Hemodynamic instability or hypotension
Sustained ventricular tachycardia
PCI within previous 6 months, or prior CABG
High risk score
Abbreviations: CABG, coronary artery bypass grafting; LVEF, left ventricular ejection fraction; 
PCI, percutaneous coronary intervention; TnI, troponin I; TnT, troponin T.
Source: Modified from Anderson JL et al: J Am Coll Cardiol 50:e1, 2007.
For a more detailed discussion, see Cannon CP, Braunwald E: 
Unstable Angina and Non-ST-Elevation Myocardial Infarction, 
Chap. 244, p. 2015, in HPIM-18
CHAPTER 130
Chronic Stable Angina
� ANGINA
Angina pectoris, the most common clinical manifestation of coronary 
artery disease (CAD), results from an imbalance between myocardial O2 
supply and demand, most often due to atherosclerotic coronary artery 
obstruction. Other major conditions that upset this balance and result in 
angina include aortic valve disease (Chap. 123), hypertrophic cardiomyopathy 
(Chap. 124), and coronary artery spasm (see below).
CHAPTER 130
859
Chronic Stable Angina
Symptoms
Angina is typically associated with exertion or emotional upset; relieved 
quickly by rest or nitroglycerin (Chap. 37). Major risk factors are cigarette 
smoking, hypertension, hypercholesterolemia (↑LDL fraction; ↓HDL), 
diabetes, obesity, and family history of CAD before age 55.
Physical Examination 
Often normal; arterial bruits or retinal vascular abnormalities suggest 
generalized atherosclerosis; S4 is common. During acute anginal episode, 
other signs may appear: loud S3 or S4, diaphoresis, rales, and a transient 
murmur of mitral regurgitation due to papillary muscle ischemia.
Laboratory ECG 
May be normal between anginal episodes or show old infarction (Chap. 120). 
During angina, ST- and T-wave abnormalities typically appear (ST-segment 
depression reflects subendocardial ischemia; ST-segment elevation may 
reflect acute infarction or transient coronary artery spasm). Ventricular 
arrhythmias frequently accompany acute ischemia.
Stress Testing 
Enhances diagnosis of CAD (Fig. 130-1). Exercise is performed on tread-
mill or bicycle until target heart rate is achieved or pt becomes symptomatic 
(chest pain, light-headedness, hypotension, marked dyspnea, ventricular 
tachycardia) or develops diagnostic ST-segment changes. Useful informa-
tion includes duration of exercise achieved; peak heart rate and bp; depth, 
morphology, and persistence of ST-segment depression; and whether and 
at which level of exercise pain, hypotension, or ventricular arrhythmias 
develop. Exercise testing with radionuclide, echocardiographic, or magnetic 
resonance imaging increases sensitivity and specificity and is particularly 
useful if baseline ECG abnormalities prevent interpretation of test. Note: 
Exercise testing should not be performed in pts with acute MI, unstable 
angina, or severe aortic stenosis. If the pt is unable to exercise, pharma-
cologic stress with IV dipyridamole (or adenosine) or dobutamine can be 
performed in conjunction with radionuclide or echocardiographic imaging. 
(Table 130-1). Pts with LBBB on baseline ECG should be referred for 
adenosine or dipyridamole radionuclide imaging, which is most specific for 
diagnosis of CAD in this setting.
The prognostic utility of coronary calcium detection (by electron-beam 
or multidetector CT) in the diagnosis of CAD has not yet been fully 
characterized.
Some pts do not experience chest pain during ischemic episodes with 
exertion (“silent ischemia”) but are identified by transient ST-T-wave abnor-
malities during stress (see below).
Coronary Arteriography 
The definitive test for assessing severity of CAD; major indications are 
(1) angina refractory to medical therapy, (2) markedly positive exercise 
test (≥2-mm ST-segment depression, onset of ischemia at low workload, or 
ventricular tachycardia or hypotension with exercise) suggestive of left 
SECTION 8
860
Cardiology
Symptoms consistent with
angina pectoris
Inactive or
elderly
patient
with mild
symptoms
Consider
alternate
diagnosis
Positive or
nondiagnostic
test
Trial of medical
therapy
Symptoms
controlled
Symptomatic
stable
angina
Refractory
symptoms
Assess LV function
(e.g., by echo)
Consider
coronary
arteriography
Continue medical
therapy
Markedly
positive test
Normal
Stress testing
EF ≤ 40%
EF > 40%
FIGURE 130-1 Role of exercise testing in management of CAD; EF, left ventricular 
ejection fraction. [Modified from LS Lilly, in Textbook of Primary Care Medicine, 3rd 
ed., J Nobel (ed.) St. Louis, Mosby, 2001, p. 552.]
main or three-vessel disease, (3) recurrent angina or positive exercise test 
after MI, (4) to assess for coronary artery spasm, and (5) to evaluate pts with 
perplexing chest pain in whom noninvasive tests are not diagnostic.
The role of newer noninvasive coronary imaging techniques (CT and MR 
angiography) has not yet been defined.
Chronic Stable Angina
TREATMENT
GENERAL
• Identify and treat risk factors: mandatory cessation of smoking; 
treatment of diabetes, hypertension, and lipid disorders (Chap. 189); 
advocate a diet low in saturated fat and trans fats.
CHAPTER 130
861
Chronic Stable Angina
• Correct exacerbating factors contributing to angina: morbid obesity, 
CHF, anemia, hyperthyroidism.
• Reassurance and pt education.
DRUG THERAPY Sublingual nitroglycerin (TNG 0.3–0.6 mg); may be 
repeated at 5-min intervals; warn pts of possible headache or light-
headedness; teach prophylactic use of TNG prior to activity that regu-
larly evokes angina. If chest pain persists for >10 min despite 2–3 TNG, 
pt should report promptly to nearest medical facility for evaluation of 
possible unstable angina or acute MI.
LONG-TERM ANGINA SUPPRESSION The following classes of drugs are 
used, frequently in combination.
Long-Acting Nitrates May be administered by many routes (Table 130-2); 
start at the lowest dose and frequency to limit tolerance and side effects of 
headache, light-headedness, tachycardia.
Beta Blockers (See Table 126-1) All have antianginal properties; 
β1-selective agents are less likely to exacerbate airway or peripheral 
vascular disease. Dosage should be titrated to resting heart rate of 50–
60 beats/min. Contraindications to beta blockers include CHF, AV block, 
bronchospasm, “brittle” diabetes. Side effects include fatigue, broncho-
spasm, depressed LV function, impotence, depression, and masking of 
hypoglycemia in diabetics.
TABLE 130-1 STRESS TESTING RECOMMENDATIONS
Subgroup
Recommended Study
Pt able to exercise
  If baseline ST-T on ECG 
is normal
Standard exercise test (treadmill, bicycle, or 
arm ergometry)
  If baseline ST-T impairs 
test interpretation (e.g., 
LVH with strain, digoxin)
Standard exercise test (above) combined with 
either
Perfusion scintigraphy (thallium-201, 99mTc-
sestamibi) or
Echocardiography
Pt not able to exercise 
(regardless of baseline ST-T 
abnormality)
Pharmacologic stress test (IV dobutamine, 
dipyridamole, or adenosine) combined with 
imaging:
  Perfusion scintigraphy [thallium 201, 
99mTc-sestamibi, or PET (rubidium-82 or 
N-13 ammonia)] or
  Echocardiography or
  Cardiac MRI
  LBBB on baseline ECG
Adenosine (or dipyridamole) 99mTc-sestamibi
or PET scintigraphy
SECTION 8
862
Cardiology
Calcium Antagonists (See Table 126-1) Useful for stable and unstable 
angina, as well coronary vasospasm. Combination with other antiangi-
nal agents is beneficial, but verapamil should be administered cautiously 
to pts on beta blockers (additive effects on slowing heart rate). Use 
sustained-release, not short-acting, calcium antagonists; the latter are 
associated with increased coronary mortality.
Ranolazine
For pts who continue to experience stable angina despite 
the above standard medications, consider addition of ranolazine (500–
1000 mg PO bid), which reduces anginal frequency and improves exer-
cise capacity without affecting blood pressure or heart rate. Ranolazine 
is contraindicated in hepatic impairment, in pts with prolongation of the 
QTc interval, or in combination with drugs that inhibit its metabolism 
(e.g., ketoconazole, macrolide antibiotics, HIV protease inhibitors, 
diltiazem, and verapamil).
Aspirin
75–325 mg/d reduces the incidence of MI in chronic stable 
angina, following MI, and in asymptomatic men. It is recommended 
in pts with CAD in the absence of contraindications (GI bleeding or 
allergy). Consider clopidogrel (75 mg/d) for aspirin-intolerant individuals.
The addition of an ACE inhibitor is recommended in pts with CAD 
and LV ejection fraction <40%, hypertension, diabetes, or chronic kidney 
disease.
TABLE 130-2 EXAMPLES OF COMMONLY USED NITRATES
Usual Dose
Recommended Dosing Frequency
Short-acting agents
Sublingual TNG
0.3–0.6 mg
As needed
Aerosol TNG
0.4 mg (1 inhalation) As needed
Sublingual ISDN
2.5–10 mg
As needed
Long-acting agents
ISDN
 Oral
5–30 mg
tid
  Sustained-action 40 mg
bid (once in the A.M., then 7 h later)
TNG ointment (2%) 0.5–2
qid (with one 7- to 10-h nitrate-
free interval)
TNG skin patches
0.1–0.6 mg/h
Apply in morning, remove at 
bedtime
ISMO
 Oral
20–40 mg
bid (once in the A.M., then 7 h later)
 Sustained-action 30–240 mg
Daily
Abbreviations: TNG, nitroglycerin; ISDN, isosorbide dinitrate; ISMO, isosorbide mononitrate.
CHAPTER 130
863
Chronic Stable Angina
MECHANICAL REVASCULARIZATION Used in conjunction with, not as 
replacement for, risk factor modification and medical therapies.
Percutaneous Coronary Intervention (PCI) Technique of balloon dila-
tation, usually with intracoronary stent implantation. Performed on 
anatomically suitable stenoses of native vessels and bypass grafts; more 
effective than medical therapy for relief of angina. Has not been shown 
to reduce risk of MI or death in chronic stable angina; should not be 
performed on asymptomatic or only mildly symptomatic individuals. 
With PCI initial relief of angina occurs in 95% of pts; however, restenosis 
develops in 30–45% following balloon dilatation alone, in ~20% after 
bare metal stenting, but in only <10% after drug-eluting stent (DES) 
implantation. Late stent thrombosis may occur rarely in pts with DES; 
it is diminished by prolonged antiplatelet therapy [aspirin indefinitely 
and clopidogrel (or alternate platelet ADP receptor antagonist) for a 
minimum of 12 months].
Coronary Artery Bypass Graft (CABG) Appropriately used for angina 
refractory to medical therapy or when the latter is not tolerated (and 
when lesions are not amenable to PCI) or if severe CAD is present (e.g., 
left main, three-vessel disease with impaired LV function). In type 2 
diabetics with multivessel CAD, CABG plus optimal medical therapy 
is superior to medical therapy alone in prevention of major coronary 
events.
The relative advantages of PCI and CABG are summarized in 
Table 130-3.
TABLE 130-3  COMPARISON OF REVASCULARIZATION PROCEDURES IN 
MULTIVESSEL DISEASE
Procedure
Advantages
Disadvantages
Percutaneous coronary 
revascularization
Less invasive
Shorter hospital stay
Lower initial cost
Effective in relieving 
symptoms
Restenosis requiring repeat 
procedure
Possible incomplete 
revascularization
Limited to specific anatomic 
subsets
Coronary artery bypass 
grafting
Lower rate of 
recurrent angina
Ability to achieve 
complete
revascularization
Cost
Risk of a repeat procedure 
due to late graft closure
Morbidity and mortality of 
major surgery
Source: Modified from DP Faxon, in GA Beller (ed), Chronic Ischemic Heart Disease, in 
E Braunwald (series ed), Atlas of Heart Disease, Philadelphia, Current Medicine, 1994.
SECTION 8
864
Cardiology
� PRINZMETAL’S VARIANT ANGINA (CORONARY VASOSPASM)
Intermittent focal spasm of coronary artery; often associated with athero-
sclerotic lesion near site of spasm. Chest discomfort is similar to angina but 
more severe and occurs typically at rest, with transient ST-segment elevation. 
Acute infarction or malignant arrhythmias may develop during spasm-
induced ischemia. Evaluation includes observation of ECG for transient ST 
elevation during discomfort; diagnosis confirmed at coronary angiography 
using provocative (e.g., IV acetylcholine) testing. Primary treatment consists 
of long-acting nitrates and calcium antagonists. Prognosis is better in pts 
with anatomically normal coronary arteries than in those with fixed coro-
nary stenoses.
For a more detailed discussion, see Antman EM, Selwyn AP, 
Loscalzo J: Ischemic Heart Disease, Chap. 243, p. 1998, in 
HPIM-18.
CHAPTER 131
Bradyarrhythmias
Bradyarrhythmias arise from (1) failure of impulse initiation (sinoatrial node 
dysfunction) or (2) impaired electrical conduction (e.g., AV conduction blocks).
� SINOATRIAL (SA) NODE DYSFUNCTION
Etiologies are either intrinsic [degenerative, ischemic, inflammatory, infiltra-
tive (e.g., senile amyloid), or rare mutations in sodium channel or pacemaker 
current genes] or extrinsic [e.g., drugs (beta blockers, Ca++ channel blockers, 
digoxin), autonomic dysfunction, hypothyroidism].
Symptoms are due to bradycardia (fatigue, weakness, lightheadedness, 
syncope) and/or episodes of associated tachycardia (e.g., rapid palpitations, 
angina) in pts with sick sinus syndrome (SSS).
Diagnosis
Examine ECG for evidence of sinus bradycardia (sinus rhythm at <60 beats/
min) or failure of rate to increase with exercise, sinus pauses, or exit block. 
In pts with SSS, periods of tachycardia (i.e., atrial fibrillation/flutter) occur. 
Prolonged ECG monitoring (24-h Holter or 30-day loop event monitor) 
aids in identi fying these abnormalities. Invasive electrophysiologic testing 
is rarely necessary to establish diagnosis.
Sinoatrial Node Dysfunction
TREATMENT
Remove or treat extrinsic causes such as contributing drugs or hypo-
thyroidism. Otherwise, symptoms of bradycardia respond to permanent 
pacemaker placement. In SSS, treat associated atrial fibrillation or flutter 
as indicated in Chap. 132.
CHAPTER 131
865
Bradyarrhythmias
� AV BLOCK
Impaired conduction from atria to ventricles may be structural and 
permanent, or reversible (e.g., autonomic, metabolic, drug-related)—see 
Table 131-1.
TABLE 131-1 ETIOLOGIES OF ATRIOVENTRICULAR BLOCK
Autonomic
Carotid sinus hypersensitivity
Vasovagal
Metabolic/Endocrine
Hyperkalemia
Hypothyroidism
Hypermagnesemia
Adrenal insufficiency
Drug-Related
Beta blockers
Adenosine
Calcium channel blockers
Antiarrhythmics (class I and III)
Digitalis
Lithium
Infectious
Endocarditis
Tuberculosis
Lyme disease
Diphtheria
Chagas’ disease
Toxoplasmosis
Syphilis
Heritable/Congenital
Congenital heart disease
Kearns-Sayre syndrome (OMIM #530000)
Maternal SLE
Myotonic dystrophy
Inflammatory
SLE
MCTD
Rheumatoid arthritis
Scleroderma
Infiltrative
Amyloidosis
Hemochromatosis
Sarcoidosis
Neoplastic/Traumatic
Lymphoma
Radiation
Mesothelioma
Catheter ablation
Melanoma
Degenerative
Lev disease
Lenègre disease
Coronary Artery Disease
Acute MI
Abbreviations: MCTD, mixed connective tissue disease; MI, myocardial infarction; OMIM, 
Online Mendelian Inheritance in Man (database); SLE, systemic lupus erythematosus.
SECTION 8
866
Cardiology
First Degree (See Fig. 131-1A)
Prolonged, constant PR interval (>0.20 s). May be normal or secondary 
to increased vagal tone or drugs (e.g., beta blocker, diltiazem, verapamil, 
digoxin); treatment not usually required.
Second Degree (See Fig. 131-1B)
Mobitz I (Wenckebach) 
Narrow QRS, progressive increase in PR interval until a ventricular beat is 
dropped, then sequence is repeated (Fig. 131-1D). Seen with drug intoxi-
cation (digitalis, beta blockers), increased vagal tone, inferior MI. Usually 
transient, no therapy required; if symptomatic, use atropine (0.6 mg IV, 
repeated × 3–4) or temporary pacemaker.
Mobitz II 
Fixed PR interval with occasional dropped beats, in 2:1, 3:1, or 4:1 pattern; 
the QRS complex is usually wide. Seen with MI or degenerative conduction 
system disease; more serious than Mobitz I—may progress suddenly to 
complete AV block; permanent pacemaker is indicated.
Atrial Rate
  Ventric Rate
Conduction
Disturbances
A. First degree heart block
70 70
B. Second degree heart block
80 40
P
P
P
P
C. Third degree heart block
    (complete H. B.)
80 40
P
P
P       P     P
D. Wenckebach
80 50 P
P
P
P
FIGURE 131-1 Bradyarrhythmias. (Modified from BE Sobel, E Braunwald: HPIM-9, 
p. 1052.)
CHAPTER 132
867
Tachyarrhythmias
Third Degree (Complete AV Block) (See Fig. 131-1C)
Complete failure of conduction from atria to ventricles; atria and ventricles 
depolarize independently. May occur with MI, digitalis toxicity, or degener-
ative conduction system disease. Permanent pacemaker is usually indicated, 
except when reversible (e.g., drug-related or appears only transiently in MI 
without associated bundle branch block).
For a more detailed discussion, see Spragg DD, Tomaselli 
GF: The Bradyarrhythmias, Chap. 232, p. 1867, in HPIM-18.
CHAPTER 132
Tachyarrhythmias
Tachyarrhythmias may appear in the presence or absence of structural 
heart disease; they are more serious in the former. Conditions that provoke 
arrhythmias include (1) myocardial ischemia, (2) heart failure, (3) hypox-
emia, (4) hypercapnia, (5) hypotension, (6) electrolyte disturbances (e.g., 
hypokalemia and/or hypomagnesemia), (7) drug toxicity (digoxin, phar-
macologic agents that prolong the QT interval), (8) caffeine consumption, 
(9) ethanol consumption.
Diagnosis
Examine ECG for evidence of ischemic changes (Chap. 120), prolonged or 
shortened QT interval, characteristics of Wolff-Parkinson-White (WPW) 
syndrome (see below), or ST elevation in leads V1–V3 typical of Brugada 
syndrome. See Fig. 132-1 and Table 132-1 for diagnosis of tachyarrhyth-
mias; always identify atrial activity and relationship between P waves and 
QRS complexes. To aid the diagnosis:
• Obtain long rhythm strip of lead II, aVF, or V1. P waves can be made 
more evident by intentionally doubling the ECG voltage.
• Place accessory ECG leads (e.g., right-sided chest leads) to help identify 
P waves. Record ECG during carotid sinus massage (Table 132-1). Note: 
Do not massage both carotids simultaneously.
• For intermittent symptoms, consider 24-h Holter monitor (if symptoms 
occur daily), a pt-activated or continuously recording event monitor over 
2–4 weeks, or, if symptoms are very infrequent but severely symptomatic, 
an implanted loop monitor. A standard exercise test may be used to pro-
voke arrhythmias for diagnostic purposes.
Tachyarrhythmias with wide QRS complex beats may represent ventricu-
lar tachycardia or supraventricular tachycardia with aberrant conduction. 
Factors favoring ventricular tachycardia include (1) AV dissociation, (2) QRS 
>0.14 s, (3) rightward and superior QRS axis, (4) no response to carotid sinus 
massage, (5) morphology of QRS unlike typical RBBB or LBBB, and similar 
to that of previous ventricular premature beats (Table 132-2).
SECTION 8
868
Cardiology
Atrial Rate
  Ventric Rate
Rhythm & Rate
Disturbances
A. Ectopic atrial contraction
N
B. Sinus tachycardia
100+
100+
P
C. Reentrant AV nodal
     tachycardia
160 160 P
D. Atrial tachycardia
     with block (2:1)
16
P
E. Atrial flutter (2:1 block)
300
F. Atrial fibrillation
500+
G. Ectopic ventricular contractions
I.   Ventricular fibrillation
N
H. Ventricular tachycardia
70 150
150 FF   F
P
Variable
P
P
P
V-1
J.  Wolff-Parkinson-White
     with delta waves
70 70
K. Wolff-Parkinson-White
     without delta waves
70 70
δ
δ
δ
80
II
II
II
II
II
II
II
II
FIGURE 132-1 Tachyarrhythmias. (Modified from BE Sobel, E Braunwald: HPIM-9, 
p. 1052.)
TABLE 132-1 CLINICAL AND ELECTROCARDIOGRAPHIC FEATURES OF COMMON ARRHYTHMIAS
Rhythm
Example
(Fig. 132-1)
Atrial
Rate
Features
Carotid Sinus 
Massage
Precipitating Conditions
Initial Treatment
Narrow QRS complex 
Atrial premature 
beats
A
—
P wave abnormal; 
QRS width normal
—
Can be normal or due to anxiety, 
CHF, hypoxia, caffeine, abnormal 
electrolytes (↓K+, ↓Mg2+)
Remove precipitating cause; if 
symptomatic: beta blocker
Sinus tachycardia B
100–160
Normal P wave 
contour
Rate gradually 
slows
Fever, anxiety, dehydration, pain, 
CHF, hyperthyroidism, COPD
Remove precipitating cause; if 
symptomatic: beta blocker
AV nodal 
tachycardia
(reentrant)
C
120–250
Absent or retrograde 
P wave
Abruptly converts 
to sinus rhythm 
(or no effect)
Can occur in healthy individuals Vagal maneuvers; if unsuccess-
ful: adenosine, verapamil, beta 
blocker, cardioversion (100–200 
J). To prevent recurrence: beta 
blocker, verapamil, diltiazem, 
digoxin, class IC agent, or catheter 
ablation
Atrial tachycardia D
130–200
P contour different 
from sinus P wave; 
AV block may occur; 
automatic form 
shows “warm-up” in 
rate in first several 
beats
AV block may ↑  
Digitalis toxicity; pulmonary 
disease; scars from prior 
cardiac surgery
If digitalis toxic: hold digoxin, 
correct [K+]
In absence of digoxin toxicity: 
slow rate with beta blocker, vera-
pamil, or diltiazem; can attempt 
conversion with IV procainamide 
or amiodarone; if unsuccessful, 
proceed to cardioversion or 
catheter ablation
(continued)
869
TABLE 132-1 CLINICAL AND ELECTROCARDIOGRAPHIC FEATURES OF COMMON ARRHYTHMIAS (CONTINUED)
Rhythm
Example
(Fig. 132-1)
Atrial
Rate
Features
Carotid Sinus 
Massage
Precipitating Conditions
Initial Treatment
Atrial flutter
Atrial fibrillation
E
F
260–300
>350
“Sawtooth” flutter 
waves; 2:1, 4:1 
block
No discrete P; 
irregularly spaced 
QRS
↑ AV block with 
↓ventricular rate 
↓ Ventricular rate
Mitral valve disease, 
hypertension, pulmonary 
embolism, pericarditis, 
post–cardiac surgery, 
hyperthyroidism; obstructive 
lung disease, EtOH, idiopathic
1. Slow the ventricular rate: beta 
blocker, verapamil, diltiazem, or 
digoxin
2. Convert to NSR (after 
anticoagulation if chronic) 
electrically (50–100 J for atrial 
flutter, 100–200 J for atrial 
fibrillation) or chemically with IV 
ibutilide or oral class IC, III, or 
IAa agent
Atrial flutter may respond to 
rapid atrial pacing, and radio 
frequency ablation highly 
effective to prevent recurrences
Multifocal atrial 
tachycardia
100–150
More than 3 
different P wave 
shapes with varying 
PR intervals
No effect
Severe respiratory insufficiency
Treat underlying lung disease; 
verapamil may be used to slow 
ventricular rate; class IC agents 
or amiodarone may ↓ episodes
870
Wide QRS Complex
Ventricular 
premature beats
G
Fully compensatory 
pause between 
normal beats
No effect
CAD, MI, CHF, hypoxia, 
hypokalemia, digitalis toxicity, 
prolonged QT interval 
(congenital or drug-related)
May not require therapy; if needed 
for symptomatic suppression, use 
beta blocker
Ventricular 
tachycardia
H
QRS rate 100–250; 
slightly irregular rate
No effect
If unstable: electrical conversion/
defibrillation (≥200 J monophasic, 
or 100 J biphasic)
Otherwise: acute (IV): amiodarone, 
lidocaine, procainamide; chronic 
management: usually ICD
Pt s without structural heart 
disease (e.g., focal outflow tract 
ventricular tachycardia) may 
respond to beta blockers or 
verapamil
Accelerated 
idioventricular
rhythm (AIVR)
Gradual onset and 
offset; QRS rate 
40–120
Acute MI, cocaine, myocarditis
Usually none; for symptoms, use 
atropine or atrial pacing
Ventricular 
fibrillation
I
Erratic electrical 
activity only
No effect
Immediate defibrillation
(continued)
871
TABLE 132-1 CLINICAL AND ELECTROCARDIOGRAPHIC FEATURES OF COMMON ARRHYTHMIAS (CONTINUED)
Rhythm
Example
(Fig. 132-1)
Atrial
Rate
Features
Carotid Sinus 
Massage
Precipitating Conditions
Initial Treatment
Torsades de 
pointes
Ventricular tachycar-
dia with sinusoidal 
oscillations of QRS 
height
No effect
Prolonged QT interval 
(congenital or drug-related)
IV magnesium (1- to 2-g bolus); 
overdrive pacing; isoproterenol 
for bradycardia-dependent 
torsades (unless CAD present); 
lidocaine
Drugs that prolong QT interval are 
contraindicated
Supraventricular 
tachycardias with 
aberrant ventricu-
lar conduction
P wave typical of 
the supraventricular 
rhythm; wide QRS 
complex due to 
conduction through 
partially refractory 
pathways
Etiologies of the respective 
supraventricular rhythms listed 
above; atrial fibrillation with 
rapid, wide QRS may be due to 
preexcitation (WPW)
Same as treatment of respective 
supraventricular rhythm; if 
ventricular rate rapid (>200), 
treat as WPW (see text)
aAntiarrhythmic drug groups listed in Table 132-3.
Abbreviations: CAD, coronary artery disease; COPD, chronic obstructive pulmonary disease; EtOH, ethyl alcohol; ICD, implantable cardioverter defibrillator; NSR, normal sinus rhythm; 
WPW, Wolff-Parkinson-White.
872
873
CHAPTER 132
Tachyarrhythmias
Tachyarrhythmias (Tables 132-1 and 132-3)
TREATMENT
Precipitating causes (listed above) should be corrected. If pt is hemo-
dynamically compromised (angina, hypotension, CHF), proceed to 
immediate cardioversion.
Do not cardiovert sinus tachycardia; exercise caution if digitalis tox-
icity is suspected. Initiate drugs as indicated in the tables; follow ECG 
intervals (esp. QRS and QT). Reduce dosage for pts with hepatic or renal 
dysfunction as indicated in Table 132-3. Drug efficacy is confirmed
TABLE 132-2  WIDE COMPLEX TACHYCARDIA
ECG Criteria That Favor Ventricular Tachycardia
1. AV dissociation
2. QRS width:  
>0.14 s with RBBB configuration
 
>0.16 s with LBBB configuration
3. QRS axis:  
Left axis deviation with RBBB morphology
 
 Extreme left axis deviation (northwest axis) with LBBB 
morphology
4. Concordance of QRS in precordial leads
5. Morphologic patterns of the QRS complex
  RBBB: Mono-or biphasic complex in V1
  RS (only with left axis deviation) or QS in V6
  LBBB: Broad R wave V1 or V2 ≥ 0.04 s
 
Onset of QRS to nadir of S wave in V1 or V2 of ≥ 0.07 s
 
Notched downslope of S wave in V1 or V2
 
Q wave in V6
Abbreviations: AV, atrioventricular; BBB, bundle branch block.
TABLE 132-3 ANTIARRHYTHMIC DRUGS
Drug
Loading Dose
Maintenance Dose
Side Effects
Excretion
Class IA
Quinidine sulfate
PO: 200–400 mg q6h
Diarrhea, tinnitus, QT prolongation, hypotension, 
anemia, thrombocytopenia
Hepatic
Quinidine gluconate
PO: 324–628 mg q8h
Hepatic
Procainamide
IV: 15 mg/kg over 60 min
IV: 1–4 mg/min
Nausea, lupus-like syndrome, agranulocytosis, QT 
prolongation
Renal and 
hepatic
PO: 500–1000 mg q4h
Sustained-release
PO: 1000–2500 mg q12h
Disopyramide
PO: 100–300 mg q6–8h
Myocardial depression, AV block, QT prolongation 
anticholinergic effects
Renal and 
hepatic
Sustained-release
PO: 200–400 mg q12h
Class IB
Lidocaine
IV: 1-mg/kg bolus followed 
by 0.5-mg/kg bolus q8–10 
min to total 3 mg/kg
IV: 1–4 mg/min
Confusion, seizures, respiratory arrest
Hepatic
Mexiletine
PO: 150–300 mg q8–12h
Nausea, tremor, gait disturbance
Hepatic
874
Class IC
Flecainide
PO: 50–200 mg q12h
Nausea, exacerbation of ventricular arrhythmia, 
prolongation of PR and QRS intervals
Hepatic 
and renal
Propafenone
PO: 150–300 mg q8h
Hepatic
Class II
Metoprolol
IV: 5–10 mg q5min × 3
PO: 25–100 mg q6h
CHF, bradycardia, AV block, bronchospasm
Hepatic
Esmolol
IV: 500 μg/kg over 1 min
IV: 50 (μg/kg)/min
Class III
Amiodarone
PO: 800–1600 mg qd ×
1–2 weeks, then 400–600 
mg/d × 3 weeks
PO: 100–400 mg qd
Thyroid abnormalities, pulmonary fibrosis, hepatitis, 
bluish skin
Hepatic
IV: 150 mg over 10 min
IV: 1 mg/min × 6 h, then 
0.5 mg/min
Ibutilide
IV (≥60 kg): 1 mg over 
10 min, can repeat after 
10 min
—
Torsades de pointes, hypotension, nausea
Hepatic
Dofetilide
PO: 125–500 μg bid
Torsades de pointes, headache, dizziness
Renal
Sotalol
PO: 80–160 mg q12h
Fatigue, bradycardia, exacerbation of ventricular 
arrhythmia
Renal
Dronedarone
PO: 400 mg q12h
Bradycardia, AV block, prolonged QT, exacerbation 
of heart failure, GI discomfort
Hepatic
(continued)
875
TABLE 132-3 ANTIARRHYTHMIC DRUGS (CONTINUED)
Drug
Loading Dose
Maintenance Dose
Side Effects
Excretion
Class IV
Verapamil
IV: 2.5–10 mg over 
3–5 min
IV: 2.5–10 mg/h
AV block, CHF, hypotension, constipation
Hepatic
PO: 80–120 mg q6–8 h
Diltiazem
IV: 0.25 mg/kg over 
3–5 min (maximum 
20 mg)
IV: 5–15 mg/h
Hepatic
PO: 30–60 mg q6h
Other
Digoxin
IV, PO: 0.75–1.5 mg 
over 24 h
IV, PO: 0.125–0.25 mg qd
Nausea, AV block, ventricular and supraventricular 
arrhythmias
Renal
Adenosine
IV: 6-mg rapid bolus; if 
no effect then 12-mg 
bolus
—
Transient hypotension or atrial standstill
—
876
877
CHAPTER 132
Tachyarrhythmias
by ECG (or Holter) monitoring, stress testing, and, in special circum-
stances, invasive electrophysiologic study.
Antiarrhythmic agents all have potential toxic side effects, including 
provocation of ventricular arrhythmias, esp. in pts with LV dysfunc-
tion or history of sustained ventricular arrhythmias. Drug-induced QT 
prolongation and associated torsades de pointes ventricular tachycardia 
(Table 132-1) is most common with class IA and III agents; the drug 
should be discontinued if the QTc interval (QT divided by square root 
of RR interval) increases by >25%. Antiarrhythmic drugs should be 
avoided in pts with asymptomatic ventricular arrhythmias after MI, 
since mortality risk increases.
CHRONIC ATRIAL FIBRILLATION (AF) Evaluate potential underlying 
cause (e.g., thyrotoxicosis, mitral stenosis, excessive ethanol consump-
tion, pulmonary embolism). Pts with risk factors for stroke (e.g., 
rheumatic mitral valve disease, history of cerebrovascular accident or 
transient ischemic attack, hypertension, diabetes, heart failure, age >75, 
left atrial diameter >5.0 cm) should receive anticoagulation with either 
warfarin (INR 2.0–3.0) or, for AF not associated with valvular disease, 
newer agents that do not require prothrombin time monitoring—
e.g., dabigatran 150 mg bid [75 mg bid for creatinine clearance (CrCl) 
30–50 mL/min; avoid if CrCl <30] or rivaroxaban 20 mg daily with the 
evening meal (15 mg daily for CrCl 15–50 mL/min; avoid if CrCl <15). 
Substitute aspirin, 325 mg/d, for pts without these risk factors or if 
contraindication to systemic anticoagulation exists.
Control ventricular rate (60–80 beats/min at rest, <100 beats/min 
with mild exercise) with beta blocker, calcium channel blocker (vera-
pamil, diltiazem), or digoxin.
Consider cardioversion (100–200 J) after ≥3 weeks therapeutic anti-
coagulation, or acutely if no evidence of left atrial thrombus by trans-
esophageal echo, especially if symptomatic despite rate control. Initiation 
of class IC, III, or IA agents prior to electrical cardioversion facilitates 
maintenance of sinus rhythm after successful procedure. Class IC 
(Table 132-3) drugs are preferred in pts without structural heart disease, 
and class III drugs are recommended in presence of left ventricular dys-
function or coronary artery disease (Fig. 132-2). Anticoagulation should 
be continued for a minimum of 3 weeks after successful cardioversion.
Catheter-based ablation (pulmonary vein isolation) can be considered 
for recurrent symptomatic AF refractory to pharmacologic measures.
� PREEXCITATION SYNDROME (WPW)
Conduction occurs through an accessory pathway between atria and ventri-
cles. Baseline ECG typically shows a short PR interval and slurred upstroke 
of the QRS (“delta” wave) (Fig. 132-1J). Associated tachyarrhythmias are 
of two types:
• Narrow QRS complex tachycardia (antegrade conduction through AV 
node). Treat cautiously with IV adenosine or beta blocker, verapamil, or 
diltiazem (Table 132-2).
SECTION 8
878
Cardiology
• Wide QRS complex tachycardia (antegrade conduction through accessory 
pathway); may also be associated with AF with a very rapid (>250/min) 
ventricular rate, which can degenerate into VF. If hemodynamically com-
promised, immediate cardioversion is indicated; otherwise, treat with 
IV procainamide or ibutilide (Table 132-3), not digoxin, beta blocker, or 
verapamil.
Consider catheter ablation of accessory pathway for long-term prevention.
LVEF <40% 
and/or CHF
CAD
Normal EF
No CHF
Amiodarone
Dofetilide
First choice
    Sotalol
    Amiodarone
Second choices
    Sotalol
 Dofetilide
 Dronedarone
 Class 1A agents
 Amiodarone
First choice
Class IC
Second choices
    Dronedarone
    Dofetilide
Third choice
Type IA
Third choices
    Type IA
    Dofetilide
Structural Heart Disease
Yes
No
Hypertension
with LV thickness
≥1.4 cm
Amiodarone
FIGURE 132-2 Recommendations for the selection of antiarrhythmic medications 
to prevent the recurrence of atrial fibrillation. See Table 132-3 for definition of class 
IA and IC drugs. An atrioventricular nodal blocking agent (i.e., beta blocker, calcium 
channel blocker, or digoxin) should be added to all class IC and IA agents as well as 
to dofetilide. LVEF, left ventricular ejection fraction; CHF, congestive heart failure; CAD, 
coronary artery disease; EF, ejection fraction.
For a more detailed discussion, see Marchlinski F: The 
Tachyarrhythmias, Chap. 233, p. 1878, in HPIM-18.
CHAPTER 133
879
Heart Failure and Cor Pulmonale 
CHAPTER 133
Heart Failure and 
Cor Pulmonale
HEART FAILURE
Definition
Abnormality of cardiac structure and/or function resulting in clinical symp-
toms (e.g., dyspnea, fatigue) and signs (e.g., edema, rales), hospitalizations, 
poor quality of life, and shortened survival. It is important to identify the 
underlying nature of the cardiac disease and the factors that precipitate 
acute CHF.
Underlying Cardiac Disease 
Includes (1) states that depress systolic ventricular function and ejection 
fraction (coronary artery disease, hypertension, dilated cardiomyopathy, 
valvular disease, congenital heart disease); and (2) states of heart failure 
with preserved ejection fraction (e.g., restrictive cardiomyopathies, hyper-
trophic cardiomyopathy, fibrosis, endomyocardial disorders), also termed 
diastolic failure.
Acute Precipitating Factors 
Include (1) excessive Na+ intake, (2) noncompliance with heart failure 
medications, (3) acute MI (may be silent), (4) exacerbation of hypertension, 
(5) acute arrhythmias, (6) infections and/or fever, (7) pulmonary embolism, 
(8) anemia, (9) thyrotoxicosis, (10) pregnancy, (11) acute myocarditis or 
infective endocarditis, and (12) certain drugs (e.g., nonsteroidal anti-
inflammatory agents, verapamil).
Symptoms
Due to inadequate perfusion of peripheral tissues (fatigue, dyspnea) and 
elevated intracardiac filling pressures (orthopnea, paroxysmal nocturnal 
dyspnea, peripheral edema).
Physical Examination 
Jugular venous distention, S3, pulmonary congestion (rales, dullness over 
pleural effusion), peripheral edema, hepatomegaly, and ascites. Sinus tachy-
cardia is common.
In pts with diastolic dysfunction, an S4 is often present.
Laboratory 
CXR may reveal cardiomegaly, pulmonary vascular redistribution, Kerley B 
lines, pleural effusions. Left ventricular contraction and diastolic dysfunc-
tion can be assessed by echocardiography with Doppler. In addition, echo 
can identify underlying valvular, pericardial, or congenital heart disease, 
SECTION 8
880
Cardiology
as well as regional wall motion abnormalities typical of coronary artery 
disease. Measurement of B-type natriuretic peptide (BNP) or N-terminal 
pro-BNP differentiates cardiac from pulmonary causes of dyspnea (elevated 
in the former).
Conditions That Mimic CHF 
Pulmonary Disease: Chronic bronchitis, emphysema, and asthma 
(Chaps. 138 and 140); assess for sputum production and abnormalities 
on CXR and pulmonary function tests. Other Causes of Peripheral Edema: 
Liver disease, varicose veins, and cyclic edema, none of which results in 
jugular venous distention. Edema due to renal dysfunction is often accom-
panied by elevated serum creatinine and abnormal urinalysis (Chap. 42).
Heart Failure (See Fig. 133-1)
TREATMENT
Aimed at symptomatic relief, prevention of adverse cardiac remodeling, 
and prolonging survival. Overview of treatment shown in Table 133-1; 
notably, ACE inhibitors and beta blockers are cornerstones of therapy 
in pts with impaired ejection fraction (EF). Once symptoms develop:
• Control excess fluid retention: (1) Dietary sodium restriction (eliminate 
salty foods, e.g., potato chips, canned soups, bacon, salt added at 
table); more stringent requirements (<2 g NaCl/d) in advanced CHF. 
If dilutional hyponatremia present, restrict fluid intake (<1000 mL/d). 
(2) Diuretics: Loop diuretics [e.g., furosemide or torsemide (Table 133-2)] 
are most potent and, unlike thiazides, remain effective when GFR 
ALGORITHM FOR TREATMENT OF CHF
Diagnosis of HF confirmed
Assess for fluid retention
Fluid retention
No fluid retention
Diuretic
ACE inhibitor*
ICD if NYHA class II–III
Beta blocker
CRT if NYHA class III–IV
and QRS >120 ms
*ARB if ACE-intolerant
ARB
Aldosterone antagonist
Hydralazine/isosorbide
digoxin
NYHA I–IV
Persistent 
symptoms 
or special 
populations
FIGURE 133-1 Treatment algorithm for chronic heart failure with reduced ejection 
fraction.
CHAPTER 133
881
Heart Failure and Cor Pulmonale 
TABLE 133-1 THERAPY FOR HEART FAILURE
1. General measures
  a. Restrict salt intake
  b. Avoid antiarrhythmics for asymptomatic arrhythmias
  c. Avoid NSAIDs
  d. Immunize against influenza and pneumococcal pneumonia
2. Diuretics
  a.  Use in volume-overloaded pts to achieve normal JVP and relief of edema
  b. Weigh daily to adjust dose
  c.  For diuretic resistance, administer IV or use 2 diuretics in combination 
(e.g., furosemide plus metolazone)
  d. Low-dose dopamine to enhance renal flow
3. ACE inhibitor or angiotensin receptor blocker
  a. For all pts with LV systolic heart failure or asymptomatic LV dysfunction
  b.  Contraindications: Serum K+ >5.5, advanced renal failure (e.g., creatinine 
>3 mg/dL), bilateral renal artery stenosis, pregnancy
4. Beta blocker
  a.  For pts with symptomatic or asymptomatic heart failure and LVEF 
<40%, combined with ACE inhibitor and diuretics
  b.  Contraindications: Bronchospasm, symptomatic bradycardia or 
advanced heart block, unstable heart failure 
5. Aldosterone antagonist
  a. Consider for class III–IV heart failure and LVEF <35%
  b. Avoid if K+ >5.0 or creatinine >2.5 mg/dL
6. Digitalis
  a.  For persistently symptomatic pts with systolic heart failure (especially if 
atrial fibrillation present) added to ACE inhibitor, diuretics, beta blocker
7. Other measures
  a.  Consider combination of hydralazine and oral nitrate if not tolerant of 
ACE inhibitor/ARB
  b.  Consider ventricular resynchronization (biventricular pacemaker) for 
pts with class III or IV heart failure, LVEF <35%, and QRS >120 ms
  c.  Consider implantable cardioverter-defibrillator in pts with class II–III 
heart failure and ejection fraction <30–35%
 
<25 mL/min. Combine loop diuretic with thiazide or metolazone for 
augmented effect. 
 
During diuresis, obtain daily weights, aiming for loss of 1–1.5 kg/d.
• ACE inhibitors (Table 133-2): Recommended as standard initial CHF 
therapy. They have been shown to prolong life in pts with symptomatic 
CHF. ACE inhibitors have also been shown to delay the onset of CHF
SECTION 8
882
Cardiology
TABLE 133-2  DRUGS FOR THE TREATMENT OF CHRONIC HEART FAILURE 
(EF <40%)
Initiating Dose
Maximal Dose
Diuretics
Furosemide
20–40 mg qd or bid
400 mg/da
Torsemide
10–20 mg qd bid
200 mg/da
Bumetanide
0.5–1.0 mg qd or bid
10 mg/da
Hydrochlorothiazide
25 mg qd
100 mg/da
Metolazone
2.5–5.0 mg qd or bid
20 mg/da
Angiotensin-converting enzyme inhibitors
Captopril
6.25 mg tid
50 mg tid
Enalapril
2.5 mg bid
10 mg bid
Lisinopril
2.5–5.0 mg qd
20–35 mg qd
Ramipril
1.25–2.5 mg bid
2.5–5 mg bid
Trandolapril
0.5 mg qd
4 mg qd
Angiotensin receptor blockers
Valsartan
40 mg bid
160 mg bid
Candesartan
4 mg qd
32 mg qd
Irbesartan
75 mg qd
300 mg qdb
Losartan
12.5 mg qd
50 mg qd
β receptor blockers
Carvedilol
3.125 mg bid
25–50 mg bid
Bisoprolol
1.25 mg qd
10 mg qd
Metoprolol succinate CR
12.5–25 mg qd
Target dose 200 mg qd
Additional therapies
Spironolactone
12.5–25 mg qd
25–50 mg qd
Eplerenone
25 mg qd
50 mg qd
Combination of hydralazine/
isosorbide dinitrate
10–25 mg/10 mg tid
75 mg/40 mg tid
Fixed dose of hydralazine/
isosorbide dinitrate
37.5 mg/20 mg (one 
tablet) tid
75 mg/40 mg (two 
tablets) tid
Digoxin
0.125 mg qd
≤0.375 mg/db
aDose must be titrated to reduce the pt’s congestive symptoms.
bTarget dose not established.
 
in pts with asymptomatic LV dysfunction and to lower mortality when 
begun soon after acute MI. ACE inhibitors may result in significant 
hypotension in pts who are volume depleted, so start at lowest dosage 
(e.g., captopril 6.25 mg PO tid). ARBs (Table 133-2) may be substi-
tuted if pt is intolerant of ACE inhibitor (e.g., because of cough or
CHAPTER 133
883
Heart Failure and Cor Pulmonale 
 
angioedema). Consider hydralazine plus an oral nitrate instead in pts 
who develop hyperkalemia or renal insufficiency on ACE inhibitor.
• Beta blockers (Table 133-2) administered in gradually augmented 
dosage improve symptoms and prolong survival in pts with heart 
failure and reduced EF <40%. After pt stabilized on ACE inhibitor and 
diuretic, begin at low dosage and increase gradually [e.g., carvedilol 
3.125 mg bid, double q2weeks as tolerated to maximum of 25 mg bid 
(for weight <85 kg) or 50 mg bid (weight >85 kg)].
• Aldosterone antagonist therapy (spironolactone or eplerenone 
[Table 133-2]), added to standard therapy in pts with advanced heart 
failure reduces mortality. The diuretic properties may also be symp-
tomatically beneficial, and such therapy should be considered in pts 
with class III/IV heart failure symptoms and LVEF <35%. Should be 
used cautiously when combined with ACE inhibitor or angiotensin 
receptor blocker (ARB) to avoid hyperkalemia.
• Digoxin is useful in heart failure due to (1) marked systolic dysfunc-
tion (LV dilatation, low EF, S3) and (2) heart failure with atrial fibril-
lation (AF) and rapid ventricular rates. Unlike ACE inhibitors and 
beta blockers, digoxin does not prolong survival in heart failure pts 
but reduces hospitalizations. Not indicated in CHF due to pericardial 
disease, restrictive cardiomyopathy, or mitral stenosis (unless AF is 
present). Digoxin is contraindicated in hypertrophic cardiomyopathy 
and in pts with AV conduction blocks.
– Digoxin dosing (0.125–0.25 mg qd) depends on age, weight, and 
renal function and can be guided by measurement of serum digoxin 
level (maintain level <1.0 ng/mL).
– Digitalis toxicity may be precipitated by hypokalemia, hypoxemia, 
hypercalcemia, hypomagnesemia, hypothyroidism, or myocardial 
ischemia. Early signs of toxicity include anorexia, nausea, and leth-
argy. Cardiac toxicity includes ventricular extrasystoles and ven-
tricular tachycardia and fibrillation; atrial tachycardia with block; 
sinus arrest and sinoatrial block; all degrees of AV block. Chronic 
digitalis intoxication may cause cachexia, gynecomastia, “yellow” 
vision, or confusion. At first sign of digitalis toxicity, discontinue 
the drug; maintain serum K+ concentration between 4.0 and 5.0 
mmol/L. Bradyarrhythmias and AV block may respond to atropine 
(0.6 mg IV); otherwise, a temporary pacemaker may be required. 
Antidigoxin antibodies are available for massive overdose.
• The combination of the oral vasodilators hydralazine (10–75 mg tid) 
and isosorbide dinitrate (10–40 mg tid) may be of benefit for chronic 
administration in pts intolerant of ACE inhibitors and ARBs and 
is also beneficial as part of standard therapy, along with ACE inhibi-
tor and beta blocker, in African Americans with class II–IV heart 
failure.
• In sicker, hospitalized pts, IV vasodilator therapy (Table 133-3) is 
often necessary. Nitroprusside is a potent mixed vasodilator for pts 
with markedly elevated systemic vascular resistance. It is metabolized 
to thiocyanate, which is excreted via the kidneys. To avoid thiocyanate
SECTION 8
884
Cardiology
 
toxicity (seizures, altered mental status, nausea), follow thiocyanate 
levels in pts with renal dysfunction or if administered for >2 days. IV 
nesiritide (Table 133-3), a purified preparation of BNP, is a vasodilator 
that reduces pulmonary capillary wedge pressure and dyspnea in pts 
with acutely decompensated CHF. It should be used only in pts with 
refractory heart failure.
• IV inotropic agents (see Table 133-3) are administered to hospitalized 
pts for refractory symptoms or acute exacerbation of CHF to augment 
cardiac output. They are contraindicated in hypertrophic cardiomy-
opathy. Dobutamine augments cardiac output without significant 
peripheral vasoconstriction or tachycardia. Dopamine at low dosage 
[1–5 (μg/kg)/min] facilitates diuresis; at higher dosage [5–10 (μg/kg)/
min] positive inotropic effects predominate; peripheral vasoconstric-
tion is greatest at dosage >10 (μg/kg)/min. Milrinone [0.1–0.75 (μg/
kg)/min after 50-μg/kg loading dose] is a nonsympathetic positive 
inotrope and vasodilator. The above vasodilators and inotropic agents 
may be used together for additive effect.
• The initial approach to treatment of acute decompensated heart failure 
can rely on the pt’s hemodynamic profile (Fig. 133-2) based on clinical 
exam and, if necessary, invasive hemodynamic monitoring:
– Profile A “Warm and dry”: Symptoms due to conditions other than 
heart failure (e.g., acute ischemia). Treat underlying condition.
TABLE 133-3 DRUGS FOR TREATMENT OF ACUTE HEART FAILURE
Initiating Dose
Maximal Dose
Vasodilators
Nitroglycerin
20 μg/min
40–400 μg/min
Nitroprusside
10 μg/min
30–350 μg/min
Nesiritide
Bolus 2 μg/kg
0.01–0.03 μg/kg per mina
Inotropes
Dobutamine
1–2 μg/kg per min
2–10 μg/kg per minb
Milrinone
Bolus 50 μg/kg
0.1–0.75 μg/kg per minb
Dopamine
1–2 μg/kg per min
2–4 μg/kg per minb
Levosimendan
Bolus 12 μg/kg
0.1–0.2 μg/kg per minc
Vasoconstrictors
Dopamine for hypotension 5 μg/kg per min
5–15 μg/kg per min
Epinephrine
0.5 μg/kg per min
50 μg/kg per min
Phenylephrine
0.3 μg/kg per min
3 μg/kg per min
Vasopressin
0.05 units/min
0.1–0.4 units/min
aUsually <4 (μg/kg)/min.
bInotropes will also have vasodilatory properties.
cApproved outside of the United States for the management of acute heart failure.
CHAPTER 133
885
Heart Failure and Cor Pulmonale 
– Profile B “Warm and wet”: Treat with diuretic and vasodilators.
– Profile C “Cold and wet”: Treat with IV vasodilators and inotropic 
agents.
– Profile L “Cold and dry”: If low filling pressure (PCW <12 mmHg) 
confirmed, consider trial of volume repletion.
• Consider implantable cardioverter defibrillator (ICD) prophylactically 
for chronic class II–III heart failure and LVEF <30–35%. Pts with an 
LVEF <35%, refractory CHF (NYHA class III–IV), and QRS >120 ms 
may be candidates for biventricular pacing (cardiac resynchronization 
therapy), typically in combination with an ICD. Pts with severe disease 
and <6 months expected survival, who meet stringent criteria, may be 
candidates for a ventricular assist device or cardiac transplantation.
• Pts with predominantly diastolic heart failure are treated with salt 
restriction and diuretics. Beta blockers and ACE inhibitors may be of 
benefit in blunting neurohormonal activation.
COR PULMONALE
RV enlargement resulting from primary lung disease; leads to RV hypertro-
phy and eventually to RV failure. Etiologies include:
• Pulmonary parenchymal or airway disease leading to hypoxemic vaso-
constriction. Chronic obstructive lung disease (COPD), interstitial lung 
diseases, bronchiectasis, cystic fibrosis (Chaps. 140 and 143).
• Conditions that occlude the pulmonary vasculature. Recurrent pulmonary 
emboli, pulmonary arterial hypertension (PAH) (Chap. 136), vasculitis, 
sickle cell anemia.
• Inadequate mechanical ventilation (chronic hypoventilation). Kyphoscoliosis, 
neuromuscular disorders, marked obesity, sleep apnea (Chap. 146).
Symptoms
Depend on underlying disorder but include dyspnea, cough, fatigue, and 
sputum production (in parenchymal diseases).
Profile A
“Warm and dry”
Profile B
“Warm and wet”
No
Yes
Profile L
“Cold and dry”
No
Yes
Profile C
“Cold and wet”
↓ CO?
↑ SVR?
Elevated LV filling pressures?
FIGURE 133-2 Hemodynamic profiles in pts with acute heart failure. CO, cardiac 
output; LV, left ventricular; SVR, systemic vascular resistance. (Modified from Grady 
et al: Circulation 102:2443, 2000.)
SECTION 8
886
Cardiology
Physical Examination 
Tachypnea, RV impulse along left sternal border, loud P2, right-sided S4; 
cyanosis, clubbing are late findings. If RV failure develops, elevated jugular 
venous pressure, hepatomegaly with ascites, pedal edema; murmur of tri-
cuspid regurgitation (Chap. 119) is common.
Laboratory ECG 
RV hypertrophy and RA enlargement (Chap. 120); tachyarrhythmias are 
common.
Radiologic Studies 
CXR shows RV and pulmonary artery enlargement; if PAH present, taper-
ing of the pulmonary artery branches. Chest CT identifies emphysema, 
interstitial lung disease, and acute pulmonary embolism; V/Q scan is more 
reliable for diagnosis of chronic thromboemboli. Pulmonary function tests 
and ABGs characterize intrinsic pulmonary disease.
Echocardiogram
RV hypertrophy; LV function typically normal. RV systolic pressure can 
be estimated from Doppler measurement of tricuspid regurgitant flow. If 
imaging is difficult because of air in distended lungs, RV volume and wall 
thickness can be evaluated by MRI.
Right-Heart Catheterization 
Can confirm presence of pulmonary hypertension and exclude left-heart 
failure as cause.
Cor Pulmonale
TREATMENT
Aimed at underlying pulmonary disease and may include bronchodila-
tors, antibiotics, oxygen administration, and noninvasive mechanical 
ventilation. For pts with PAH, pulmonary vasodilator therapy may be 
beneficial to reduce RV afterload (Chap. 136). See Chap. 142 for specific 
treatment of pulmonary embolism. 
If RV failure is present, treat as heart failure, instituting low-sodium 
diet and diuretics; digoxin is of uncertain benefit and must be admin-
istered cautiously (toxicity increased due to hypoxemia, hypercapnia, 
acidosis). Loop diuretics must also be used with care to prevent significant 
metabolic alkalosis that blunts respiratory drive.
For a more detailed discussion, see Mann DL, Chakinala M: 
Heart Failure and Cor Pulmonale, Chap. 234, p. 1901, in 
HPIM-18.
CHAPTER 134
887
Diseases of the Aorta
CHAPTER 134
Diseases of the Aorta
AORTIC ANEURYSM
Abnormal dilatation of the abdominal or thoracic aorta; in ascending aorta 
most commonly secondary to cystic medial necrosis (e.g., familial, Marfan 
syndrome, Ehlers-Danlos syndrome type IV); aneurysms of descending 
thoracic and abdominal aorta are primarily atherosclerotic. Rare causes of 
aneurysms are infections (syphilitic, tuberculous, mycotic) and vasculitides 
(e.g., Takayasu’s arteritis, giant cell arteritis).
History 
May be clinically silent, but thoracic aortic aneurysms can result in deep, 
diffuse chest pain, dysphagia, hoarseness, hemoptysis, dry cough; abdomi-
nal aneurysms may result in abdominal pain or thromboemboli to the lower 
extremities.
Physical Examination 
Abdominal aneurysms are often palpable, most commonly in periumbilical 
area. Pts with ascending thoracic aneurysms may show features of Marfan 
syndrome (Chap. 363, HPIM-18).
Laboratory 
Suspect thoracic aneurysm by abnormal CXR (enlarged aortic silhouette) and 
confirm by echocardiography, contrast CT, or MRI. Confirm abdominal aneu-
rysm by abdominal plain film (rim of calcification), ultrasound, CT, MRI, or 
contrast aortography. If clinically suspected, obtain serologic test for syphilis, 
especially if ascending thoracic aneurysm shows thin shell of calcification.
Aortic Aneurysm
TREATMENT
Pharmacologic control of hypertension (Chap. 126) is essential, usually 
including a beta blocker. Preliminary studies suggest inhibition of the 
renin-angiotensin system (e.g., with the ARB losartan) may reduce rate 
of aortic dilation in Marfan syndrome via blockade of TGF-β signaling. 
Surgical resection for large aneurysms (ascending thoracic aortic aneu-
rysms >5.5–6 cm, descending thoracic aortic aneurysms >6.5–7.0 cm, or 
abdominal aortic aneurysm >5.5 cm), for persistent pain despite bp con-
trol, or for evidence of rapid expansion. In pts with Marfan syndrome or 
bicuspid aortic valve, thoracic aortic aneurysms >5 cm usually warrant 
repair. Less invasive endovascular repair is an option for some pts with 
descending thoracic or abdominal aortic aneurysms.
AORTIC DISSECTION (FIG. 134-1)
Potentially life-threatening condition in which disruption or aortic intima 
allows dissection of blood into vessel wall; may involve ascending aorta 
SECTION 8
888
Cardiology
(type II), descending aorta (type III), or both (type I). Alternative classifica-
tion: Type A—dissection involves ascending aorta; type B—limited to trans-
verse and/or descending aorta. Involvement of the ascending aorta is most 
lethal form. Variant acute aortic syndromes include intramural hematoma 
without an intimal flap, and penetrating atherosclerotic ulcer.
Etiology 
Ascending aortic dissection is associated with hypertension, cystic medial 
necrosis, Marfan and Ehlers-Danlos syndromes; descending dissections are 
commonly associated with atherosclerosis or hypertension. Incidence is 
increased in pts with coarctation of aorta, bicuspid aortic valve, and rarely 
in third trimester of pregnancy in otherwise normal women.
Type A
Type B
FIGURE 134-1 Classification of aortic dissections. Stanford classification: Top panels 
illustrate type A dissections that involve the ascending aorta independent of site of 
tear and distal extension; type B dissections (bottom panels) involve transverse and/or 
descending aorta without involvement of the ascending aorta. DeBakey classification: 
Type I dissection involves ascending to descending aorta (top left); type II dissection 
is limited to ascending or transverse aorta, without descending aorta (top center + 
top right); type III dissection involves descending aorta only (bottom left). [From DC
Miller, in RM Doroghazi, EE Slater (eds.), Aortic Dissection. New York, McGraw-Hill, 
1983, with permission.]
CHAPTER 134
889
Diseases of the Aorta
Symptoms
Sudden onset of severe anterior or posterior chest pain, with “ripping” qual-
ity; maximal pain may travel if dissection propagates. Additional symptoms 
relate to obstruction of aortic branches (stroke, MI), dyspnea (acute aortic 
regurgitation), or symptoms of low cardiac output due to cardiac tampon-
ade (dissection into pericardial sac).
Physical Examination 
Sinus tachycardia common; if cardiac tamponade develops, hypotension, 
pulsus paradoxus, and pericardial rub appear. Asymmetry of carotid or bra-
chial pulses, aortic regurgitation, and neurologic abnormalities associated 
with interruption of carotid artery flow are possible findings.
Laboratory 
CXR: Widening of mediastinum; dissection can be confirmed by CT, MRI, 
or transesophageal echocardiography. Aortography is rarely required, as sen-
sitivity of these noninvasive techniques is >90%.
Aortic Dissection
TREATMENT
Reduce cardiac contractility and treat hypertension to maintain sys-
tolic bp between 100 and 120 mmHg using IV agents (Table 134-1), 
e.g., sodium nitroprusside accompanied by a beta blocker (e.g., IV 
metoprolol, labetolol, or esmolol, aiming for heart rate of 60 beats per 
min), followed by oral therapy. If beta blocker contraindicated, consider 
IV verapamil or diltiazem (see Table 132-3). Avoid direct vasodilators 
(e.g., hydralazine) because they may increase shear stress. Ascending 
aortic dissection (type A) requires surgical repair emergently or, if pt 
can be stabilized with medications, semielectively. Descending aortic 
dissections are stabilized medically (maintain systolic bp between 110 
and 120 mmHg) with oral antihypertensive agents (esp. beta blockers); 
surgical repair is not usually indicated unless continued pain or exten-
sion of dissection is observed (by serial MRI or CT performed every 
6–12 months).
TABLE 134-1 TREATMENT OF AORTIC DISSECTION
Preferred Regimen
Dose
Sodium nitroprusside
20–400 μg/min IV
 plus a beta blocker:
 Propranolol or
0.5 mg IV; then 1 mg q5min, to total of 0.15 mg/kg
 Esmolol or
500 μg/kg IV over 1 min; then 50–200 (μg/kg)/min
 Labetalol
20 mg IV over 2 min, then 40–80 mg q10–15min to 
max of 300 mg
SECTION 8
890
Cardiology
OTHER ABNORMALITIES OF THE AORTA
Atherosclerotic Occlusive Disease of Abdominal Aorta 
Particularly common in presence of diabetes mellitus or cigarette smoking. 
Symptoms include intermittent claudication of the buttocks and thighs 
and impotence (Leriche syndrome); femoral and other distal pulses are 
absent. Diagnosis is established by noninvasive leg pressure measurements 
and Doppler velocity analysis, and confirmed by MRI, CT, or aortography. 
Catheter-based endovascular treatment or aortic-femoral bypass surgery is 
required for symptomatic treatment.
Takayasu’s (“Pulseless”) Disease 
Arteritis of aorta and major branches in young women. Anorexia, weight 
loss, fever, and night sweats occur. Localized symptoms relate to occlu-
sion of aortic branches (cerebral ischemia, claudication, and loss of pulses 
in arms). ESR and C-reactive protein are increased; diagnosis confirmed 
by aortography. Glucocorticoid and immunosuppressive therapy may be 
beneficial.
For a more detailed discussion, see Creager MA, Loscalzo J: 
Diseases of the Aorta, Chap. 248, p. 2060, in HPIM-18.
CHAPTER 135
Peripheral Vascular Disease
Occlusive or inflammatory disease that develops within the peripheral 
arteries, veins, or lymphatics.
ARTERIOSCLEROSIS OF PERIPHERAL ARTERIES
History
Intermittent claudication is muscular cramping with exercise; quickly 
relieved by rest. Pain in buttocks and thighs suggests aortoiliac disease; calf 
muscle pain implies femoral or popliteal artery disease. More advanced 
arteriosclerotic obstruction results in pain at rest; painful ulcers of the feet 
(sometimes painless in diabetics) may result.
Physical Examination 
Decreased peripheral pulses (ankle:brachial index <1.0; <0.5 with severe 
ischemia), blanching of affected limb with elevation, dependent rubor (red-
ness). Ischemic ulcers or gangrene of toes may be present.
Laboratory 
Segmental pressure measurements and Doppler ultrasound of peripheral 
pulses before and during exercise localizes stenoses; magnetic resonance 
CHAPTER 135
891
Peripheral Vascular Disease
angiography, computed tomographic angiography (CTA), or conventional 
arteriography is performed if mechanical revascularization (surgical or 
percutaneous) is planned.
Arteriosclerosis
TREATMENT
Most pts can be managed medically with daily exercise program, careful 
foot care (especially in diabetics), treatment of hypercholesterolemia, and 
local debridement of ulcerations. Abstinence from cigarettes is mandatory. 
Antiplatelet therapy is indicated to reduce future cardiovascular events. 
Some, but not all, pts note symptomatic improvement with drug therapy 
(cilostazol or pentoxifylline). Pts with severe claudication, rest pain, or 
gangrene are candidates for revascularization (arterial reconstructive 
surgery or percutaneous transluminal angioplasty/stent placement).
OTHER CONDITIONS THAT IMPAIR PERIPHERAL ARTERIAL FLOW
Arterial Embolism 
Results from thrombus or vegetation within the heart or aorta, or paradoxi-
cally from a venous thrombus through a right-to-left intracardiac shunt.
History 
Sudden pain or numbness in an extremity in the absence of previous history 
of claudication.
Physical Examination 
Absent pulse, pallor, and decreased temperature of limb distal to the occlu-
sion. Lesion is identified by angiography.
Arterial Embolism
TREATMENT
IV heparin is administered to prevent propagation of clot. For acute 
severe ischemia, immediate endovascular or surgical embolectomy is 
indicated. Thrombolytic therapy (e.g., tissue plasminogen activator, 
reteplase, or tenecteplase) may be effective for thrombus within athero-
sclerotic vessel or arterial bypass graft.
Atheroembolism
A subset of acute arterial occlusion due to embolization of fibrin, plate-
lets, and cholesterol debris from more proximal atheromas or aneurysm; 
typically occurs after intraarterial instrumentation. Depending on location, 
may lead to stroke, renal insufficiency, or pain and tenderness in embolized 
tissue. Atheroembolism to lower extremities results in blue toe syndrome, 
which can progress to necrosis and gangrene. Treatment is supportive; for 
recurrent episodes, surgical intervention in the proximal atherosclerotic 
vessel or aneurysm may be required.
Vasospastic Disorders 
Manifest by Raynaud’s phenomenon in which cold exposure results in tri-
phasic color response: blanching of the fingers, followed by cyanosis, then 
SECTION 8
892
Cardiology
rubor. Usually a benign disorder. However, suspect an underlying disease 
(Table 135-1) if tissue necrosis occurs, if disease is unilateral, or if it devel-
ops after age 50.
Vasospastic Disorders
TREATMENT
Keep extremities warm. Tobacco use is contraindicated. Dihydropyridine 
calcium channel blockers (e.g., nifedipine XL 30–90 mg PO qd) or 
α1-adrenergic antagonists (e.g., prazosin 1–5 mg tid) may be effective.
Thromboangiitis Obliterans (Buerger’s Disease) 
Occurs in young men who are heavy smokers and involves both upper and 
lower extremities; nonatheromatous inflammatory reaction develops in 
veins and small arteries, leading to superficial thrombophlebitis and arte-
rial obstruction with ulceration or gangrene of digits. Arteriography shows 
smooth tapering lesions in distal vessels, often without proximal atheroscle-
rotic disease. Abstinence from tobacco is essential.
VENOUS DISEASE
Superficial Thrombophlebitis 
A benign disorder characterized by erythema, tenderness, and edema 
along involved vein. Conservative therapy includes local heat, elevation, 
and anti-inflammatory drugs such as aspirin. More serious conditions such 
as cellulitis or lymphangitis may mimic this, but these are associated with 
fever, chills, lymphadenopathy, and red superficial streaks along inflamed 
lymphatic channels.
TABLE 135-1 CLASSIFICATION OF RAYNAUD’S PHENOMENON
Primary or idiopathic Raynaud’s phenomenon: Raynaud’s disease
Secondary Raynaud’s phenomenon
  Collagen vascular diseases: scleroderma, systemic lupus erythematosus, 
rheumatoid arthritis, dermatomyositis, polymyositis
  Arterial occlusive diseases: atherosclerosis of the extremities, thromboan-
giitis obliterans, acute arterial occlusion, thoracic outlet syndrome
  Pulmonary hypertension
  Neurologic disorders: intervertebral disk disease, syringomyelia, spinal 
cord tumors, stroke, poliomyelitis, carpal tunnel syndrome
  Blood dyscrasias: cold agglutinins, cryoglobulinemia, cryofibrinogenemia, 
myeloproliferative disorders, Waldenström’s macroglobulinemia
  Trauma: vibration injury, hammer hand syndrome, electric shock, cold 
injury, typing, piano playing
  Drugs: ergot derivatives, methysergide, β-adrenergic receptor blockers, 
bleomycin, vinblastine, cisplatin
CHAPTER 135
893
Peripheral Vascular Disease
Deep-Vein Thrombosis (DVT) 
This is a more serious condition that may lead to pulmonary embolism 
(Chap. 142). Particularly common in pts on prolonged bed rest, those with 
chronic debilitating disease, and those with malignancies (Table 135-2).
History 
Pain or tenderness in calf or thigh, usually unilateral; may be asymptomatic, 
with pulmonary embolism as primary presentation.
Physical Examination 
Often normal; local swelling or tenderness to deep palpation may be present 
over affected vein.
Laboratory 
d-Dimer testing is sensitive but not specific for diagnosis. Most helpful 
noninvasive testing is ultrasound imaging of the deep veins with Doppler 
interrogation [most sensitive for proximal (upper leg) DVT, less sensitive 
for calf DVT]. Invasive venography is rarely indicated. MRI may be useful 
for diagnosis of proximal DVT and DVT within the pelvic veins or in the 
superior or inferior vena cavae.
Venous Disease
TREATMENT
Systemic anticoagulation with heparin [5000- to 10,000-U bolus, followed 
by continuous IV infusion to maintain aPTT at 2 × normal (or using a 
nomogram: 80-U/kg bolus followed by initial infusion of 18 (U/kg)/h)] 
or low-molecular-weight heparin (LMWH) (e.g., enoxaparin 1 mg/kg SC 
bid), followed by warfarin PO (overlap with heparin for at least 4–5 days 
and continue for at least 3 months if proximal deep veins involved). Adjust 
warfarin dose to maintain prothrombin time INR 2.0–3.0.
TABLE 135-2  CONDITIONS ASSOCIATED WITH AN INCREASED RISK FOR 
DEVELOPMENT OF VENOUS THROMBOSIS
Surgery: Orthopedic, thoracic, abdominal, and genitourinary procedures
Neoplasms: Pancreas, lung, ovary, testes, urinary tract, breast, stomach
Trauma: Fractures of spine, pelvis, femur, tibia
Immobilization: Acute MI, CHF, stroke, postoperative convalescence
Pregnancy: Estrogen use (for replacement or contraception)
Hypercoagulable states: Resistance to activated protein C; prothrombin 
20210A mutation; deficiencies of antithrombin III, protein C, or protein S; 
antiphospholipid antibodies; myeloproliferative disease; dysfibrinogenemia; 
DIC
Venulitis: Thromboangiitis obliterans, Behçet’s disease, homocystinuria
Previous deep-vein thrombosis
SECTION 8
894
Cardiology
DVT can be prevented by early ambulation following surgery or with 
low-dose unfractionated heparin during prolonged bed rest (5000 U SC 
bid-tid) or LMWH (e.g., enoxaparin 40 mg SC daily), supplemented by 
pneumatic compression boots. Following knee or hip surgery, warfarin 
(INR 2.0–3.0) is an effective regimen. LMWHs are also effective in pre-
venting DVT after general or orthopedic surgery.
Chronic Venous Insufficiency 
Results from prior DVT or venous valvular incompetence and manifests 
as chronic dull ache in leg that worsens with prolonged standing, edema, 
and superficial varicosities. May lead to erythema, hyperpigmentation, 
and recurrent cellulitis; ulcers may appear at medial and lateral malleoli. 
Treatment includes graduated compression stockings and leg elevation.
LYMPHEDEMA
Chronic, painless edema, usually of the lower extremities; may be primary 
(inherited) or secondary to lymphatic damage or obstruction (e.g., recur-
rent lymphangitis, tumor, filariasis).
Physical Examination 
Marked pitting edema in early stages; limb becomes indurated with nonpit-
ting edema chronically. Differentiate from chronic venous insufficiency, 
which displays hyperpigmentation, stasis dermatitis, and superficial venous 
varicosities.
Laboratory 
Abdominal and pelvic ultrasound or CT or MRI to identify obstructing 
lesions. Lymphangiography or lymphoscintigraphy (rarely done) to con-
firm diagnosis. If unilateral edema, differentiate from DVT by noninvasive 
venous studies (above).
Lymphedema
TREATMENT
(1) Meticulous foot hygiene to prevent infection, (2) leg elevation, 
(3) compression stockings and/or pneumatic compression boots. 
Diuretics should be avoided to prevent intravascular volume depletion.
For a more detailed discussion, see Creager MA, Loscalzo 
J: Vascular Diseases of the Extremities, Chap. 249, p. 2066, 
in HPIM-18.
CHAPTER 136
895
Pulmonary Hypertension
CHAPTER 136
Pulmonary Hypertension
Definition
Elevation of pulmonary artery (PA) pressure due to pulmonary vascular or 
parenchymal disease, increased left heart filling pressures, or a combina-
tion. Table 136-1 lists etiologies by underlying categories. 
Symptoms
Exertional dyspnea, fatigue, angina (due to RV ischemia), syncope, peripheral 
edema.
TABLE 136-1 CATEGORIES OF PULMONARY HYPERTENSION
1. Pulmonary Arterial Hypertension
 
 Idiopathic
 
 Collagen vascular diseases (e.g., CREST, scleroderma, SLE, RA)
 
  Congenital systemic to pulmonary shunts (e.g., ventricular septal defect, 
patent ductus arteriosus, atrial septal defect)
 
 Portal hypertension
 
 HIV infection
 
 Drugs or toxins (e.g., fenfluramines)
2. Pulmonary Venous Hypertension
 
 LV systolic or diastolic dysfunction 
 
 Left-sided valvular disease
 
 Pulmonary venous obstruction
3. Hypoxemic Lung Disease
 
 Chronic obstructive lung disease
 
 Interstitial lung disease
 
 Sleep-disordered breathing
 
 Chronic hypoventilation
4. Chronic Pulmonary Thromboembolic Disease
 
 Chronic pulmonary embolism 
 
 Nonthrombotic pulmonary embolism (e.g., tumor or foreign material)
5. Miscellaneous
 
 Sarcoidosis
 
 Histiocytosis X
 
 Schistosomiasis
Abbreviation: CREST, calcinosis, Raynaud’s phenomenon, esophageal involvement, 
sclerodactyly, and telangiectasia (syndrome).
SECTION 8
896
Cardiology
Physical Examination 
Jugular venous distention, RV lift, increased P2, right-sided S4, tricuspid 
regurgitation. Peripheral cyanosis and edema are late manifestations.
Laboratory 
CXR shows enlarged central PA. ECG may demonstrate RV hypertrophy 
and RA enlargement. Echocardiogram shows RV and RA enlargement; RV 
systolic pressure can be estimated from Doppler recording of tricuspid 
regurgitation (Chap. 120). Pulmonary function tests identify underlying 
obstructive or restrictive lung disease; impaired CO diffusion capacity 
is common. Chest CT identifies contributing interstitial lung disease or 
pulmonary thromboembolic disease. ANA titer is elevated in collagen 
vascular diseases. HIV testing should be performed in individuals at risk. 
Cardiac catheterization accurately assesses PA pressures, cardiac output, 
and pulmonary vascular resistance, and it identifies underlying congenital 
vascular shunts; during procedure, response to short-acting vasodilators 
can be assessed.
Figure 136-1 summarizes workup of pt with unexplained pulmonary 
hypertension.
� IDIOPATHIC PULMONARY ARTERIAL HYPERTENSION (PAH)
Uncommon (2 cases/million), very serious form of pulmonary hyperten-
sion. Most pts present in fourth and fifth decades, female » male predomi-
nance; up to 20% of cases are familial. Major symptom is dyspnea, often 
with insidious onset. Mean survival <3 years in absence of therapy.
Physical Examination 
Prominent a wave in jugular venous pulse, right ventricular heave, narrowly 
split S2 with accentuated P2. Terminal course is characterized by signs of 
right-sided heart failure. 
Laboratory 
CXR: RV and central pulmonary arterial prominence. Pulmonary arteries 
taper sharply. PFTs: usually normal or mild restrictive defect. ECG: RV 
enlargement, right axis deviation, and RV hypertrophy. Echocardiogram: 
RA and RV enlargement and tricuspid regurgitation.
Differential Diagnosis 
Other disorders of heart, lungs, and pulmonary vasculature must be consid-
ered. Lung function studies will identify chronic pulmonary disease causing 
pulmonary hypertension and cor pulmonale. Interstitial diseases (PFTs, 
CT scan) and hypoxic pulmonary hypertension (ABGs, Sao2) should be 
excluded. Perfusion lung scan should be considered to exclude chronic pul-
monary embolism (PE). Rarely, pulmonary hypertension is due to parasitic 
disease (schistosomiasis, filariasis). Cardiovascular disorders to be excluded 
include pulmonary artery and pulmonic valve stenosis, ventricular and 
atrial shunts with secondary pulmonary vascular disease (Eisenmenger 
syndrome), and clinically silent mitral stenosis.
CHAPTER 136
897
Pulmonary Hypertension
Echocardiogram
Dilated right
ventricle
Left heart disease
Valvular heart disease
Congenital abnormality
Dilated right
ventricle
Pulmonary function tests
Cardiac catheterization
Normal or
restrictive pattern
Obstructive
pattern
High resolution
chest CT
COLD
Interstitial
lung disease
Normal or enlarged
pulmonary arteries
Measure exercise
capacity
Lab tests:
• CBC  •ANA  • HIV  • TSH  • LFTs
Pulmonary
thromboembolism
Cardiac catheterization
• Vasodilator testing
FIGURE 136-1 An algorithm for the workup of a pt with unexplained pulmonary 
hypertension. All potential etiologies and associated conditions must be investigated 
in a pt with clinical findings consistent with pulmonary hypertension. ANA, antinuclear 
antibodies; CBC, complete blood count; COLD, chronic obstructive lung disease; HIV, 
human immunodeficiency virus; LFTs, liver function tests; TSH, thyroid-stimulating 
hormone. 
SECTION 8
898
Cardiology
Pulmonary Arterial Hypertension
TREATMENT
Limit physical activities, use diuretics for peripheral edema, O2 supple-
mentation if PO2 reduced, and chronic warfarin anticoagulation (target 
INR = 2.0–3.0).
If short-acting vasodilators are beneficial during acute testing in 
catheterization laboratory, pt may benefit from high-dose calcium channel 
blocker (e.g., nifedipine, up to 240 mg/d, or amlodipine up to 20 mg/d); 
must monitor for hypotension or worsening of right heart failure during 
such therapy.
Additional approved therapies for PAH include:
1. Endothelin receptor antagonists: bosentan (62.5 mg PO bid × 1 month, 
then 125 mg PO bid) and ambrisentan (5–10 mg daily) significantly 
improve exercise tolerance. Hepatic transaminases should be moni-
tored. Bosentan is contraindicated in pts taking cyclosporine (which 
greatly increases bosentan plasma levels) or glyburide (combination is 
associated with increased hepatic transaminases).
2. Phosphodiesterase-5 inhibitors: sildenafil (20–80 mg PO tid) and 
tadalafil (40 mg daily) also improve exercise tolerance in PAH. Do not 
prescribe concurrently with nitrovasodilators; the combination could 
result in marked hypotension.
3. Prostaglandins (iloprost by inhalation, epoprostenol by continuous 
IV infusion, and treprostinil by IV, SC, or inhalation routes) improve 
symptoms, exercise tolerance, and, in the case of epoprostenol, 
survival. The most common side effect is flushing.
For selected pts with persistent right heart failure, lung transplantation 
can be considered.
For a more detailed discussion, see Rich S: Pulmonary 
Hypertension, Chap. 250, p. 2076, in HPIM-18.
899
CHAPTER 137
Respiratory Function and 
Pulmonary Diagnostic 
Procedures
RESPIRATORY FUNCTION
The major classes of lung diseases include obstructive lung diseases 
(e.g., asthma, chronic obstructive pulmonary disease, and bronchiectasis), 
restrictive lung diseases (e.g., interstitial lung diseases, chest wall abnor-
malities, and neuromuscular diseases), and vascular abnormalities (e.g., 
pulmonary thromboembolism and pulmonary arterial hypertension). 
The respiratory system includes not only the lungs but also the chest wall, 
pulmonary circulation, and central nervous system. There are three key 
types of respiratory system physiologic disturbances that occur in varying 
combinations in different lung diseases: ventilatory function, pulmonary 
circulation, and gas exchange.
Disturbances in Ventilatory Function 
Ventilation involves the delivery of gas to the alveoli. Pulmonary function 
tests are used to assess ventilatory function. The classification of lung vol-
umes, which are measured with pulmonary function testing, is shown in 
Fig. 137-1. Spirometry involves forced exhalation from total lung capacity 
Tidal
Volume
Total
Lung
Capacity
Functional
Residual
Capacity
Residual
Volume
Vital
Capacity
Expiratory
Reserve
Volume
FIGURE 137-1 Spirogram of a slow vital capacity maneuver demonstrating various 
lung volumes.
SECTION 9
Pulmonology
SECTION 9
900
Pulmonology
(TLC) to residual volume (RV); key measurements from a spirogram are 
the forced expiratory volume in 1 s (FEV1) and the forced vital capacity 
(FVC). Expiratory flow rates may be plotted against lung volumes to yield 
a flow-volume curve. Plateau of the inspiratory curve on the flow-volume 
loop suggests extrathoracic large airway obstruction, while plateau of the 
expiratory curve suggests intrathoracic large airway obstruction. Other 
lung volumes, including TLC and RV, are measured under static conditions 
using either helium dilution or body plethysmography. Lung volumes and 
flow rates are typically compared with population-based normal values that 
adjust for the age, height, sex, and race of the pt. 
There are two major patterns of abnormal ventilatory function detected 
by pulmonary function testing: restrictive and obstructive (Tables 137-1 
and 137-2). The presence of obstruction is determined by a reduced ratio 
TABLE 137-1  COMMON RESPIRATORY DISEASES BY DIAGNOSTIC 
CATEGORIES
Obstructive
Asthma 
Bronchiectasis
Chronic obstructive pulmonary 
disease
Cystic fibrosis
Bronchiolitis
Restrictive—Parenchymal
Sarcoidosis
Pneumoconiosis
Idiopathic pulmonary fibrosis
Desquamative interstitial pneumonitis
Drug- or radiation-induced interstitial 
lung disease
Asbestosis
Restrictive—Extraparenchymal
Neuromuscular
Chest wall
 Diaphragmatic weakness/paralysis
 Kyphoscoliosis
 Myasthenia gravis
 Obesity
 Guillain-Barré syndrome
 Ankylosing spondylitis
 Muscular dystrophies
 Chronic pleural effusions
 Cervical spine injury
 Amyotrophic lateral sclerosis
Pulmonary Vascular Disease
Pulmonary embolism
Pulmonary arterial hypertension
Malignancy
Bronchogenic carcinoma (small cell 
or non-small cell)
Cancer metastatic to lung
Infectious Diseases
Pneumonia
Tracheitis
Bronchitis
CHAPTER 137 
901
Respiratory Function and Diagnostic Procedures
TABLE 137-2  ALTERATIONS IN VENTILATORY FUNCTION IN DIFFERENT 
PULMONARY DISEASE CATEGORIES
TLC
RV
VC
FEV1/FVC
Obstructive
N to ↑
↑
↓
↓
Restrictive
 Pulmonary parenchymal
↓
↓
↓
N to ↑
  Extraparenchymal—neuromus-
cular weakness
↓
Variable
↓
Variable
  Extraparenchymal—chest wall 
deformity
↓
Variable
↓
N
Abbreviation: N, normal; for other abbreviations, see text.
of FEV1/FVC (with abnormal often defined using a threshold of <0.7), and 
the severity of airflow obstruction is determined by the level of reduction of 
FEV1. With airflow obstruction, TLC may be normal or increased, and RV is 
typically elevated. With severe airflow obstruction, the FVC is often reduced.
The presence of a restrictive pattern is determined by a reduction in 
lung volumes, especially TLC. When pulmonary parenchymal processes 
cause restriction, RV is also decreased, but the FEV1/FVC is normal. With 
extraparenchymal etiologies of restrictive ventilatory defects, such as neu-
romuscular weakness or chest wall abnormalities, the impact on RV and 
FEV1/FVC is more variable. Weakness of the respiratory muscles can be 
assessed by measuring maximal inspiratory and expiratory pressures. 
Disturbances in Pulmonary Circulation
The pulmonary vasculature normally handles the right ventricular output 
(~5 L/min) at a low pressure. Normal mean pulmonary artery pressure 
(PAP) is 15 mmHg. When cardiac output increases, pulmonary vascular 
resistance (PVR) normally falls, leading to only small increases in mean PAP.
Assessment of the pulmonary vasculature requires measuring pulmonary 
vascular pressures and cardiac output to derive PVR. PVR rises with hypox-
emia (due to vasoconstriction), intraluminal thrombi (due to diminished 
cross-sectional area from obstruction), or destruction of small pulmonary 
vessels (due to scarring or loss of the alveolar walls).
All diseases of the respiratory system causing hypoxemia are capable of 
causing pulmonary hypertension. However, pts with prolonged hypoxemia 
related to chronic obstructive pulmonary disease, interstitial lung disease, 
chest wall disease, and obesity-hypoventilation/obstructive sleep apnea 
are particularly likely to develop pulmonary hypertension. When pulmo-
nary vessels are directly affected, as with recurrent pulmonary emboli, the 
decrease in cross-sectional area of the pulmonary vasculature is the primary 
mechanism for increased PVR, rather than hypoxemia.
Disturbances in Gas Exchange 
The primary functions of the respiratory system are to remove CO2 from 
blood entering the pulmonary circulation and to provide O2 to blood leaving 
SECTION 9
902
Pulmonology
the pulmonary circulation. Normal tidal volume is approximately 500 mL 
and normal respiratory rate is approximately 15 breaths/min, leading to a 
total minute ventilation of approximately 7.5 L/min. Because of anatomic 
dead space, alveolar ventilation is approximately 5 L/min. Gas exchange 
depends on alveolar ventilation rather than total minute ventilation.
Partial pressure of CO2 in arterial blood (Paco2) is directly proportional 
to the amount of CO2 produced each minute ( ˙Vco2) and inversely propor-
tional to alveolar ventilation ( ˙VA)
Paco2 = 0.863 × ˙Vco2/V˙A
Adequate movement of gas between alveoli and pulmonary capillaries 
by diffusion is required for normal gas exchange. Diffusion can be tested 
by measuring the diffusing capacity of the lung for a low (and safe) con-
centration of carbon monoxide (Dlco) during a 10-second breath-hold. 
Dlco measurement is typically corrected for the pt’s hemoglobin level. 
Diffusion abnormalities rarely result in arterial hypoxemia at rest but can 
cause hypoxemia with exercise. A restrictive ventilatory defect with reduced 
Dlco suggests parenchymal lung disease. The pattern of normal spirom-
etry, normal lung volumes, and reduced Dlco is consistent with pulmonary 
vascular disease. Gas exchange is critically dependent on proper matching 
of ventilation and perfusion.
Assessment of gas exchange is commonly performed with arterial blood 
gases, which provide measurements of the partial pressures of O2 and CO2. 
The actual content of O2 in blood is determined by both Po2 and hemoglo-
bin concentration. The alveolar-arterial O2 difference [(A − a) gradient] can 
provide useful information when assessing abnormalities in gas exchange. 
The normal (A − a) gradient is <15 mmHg under age 30 but increases with 
aging. In order to calculate the (A − a) gradient, the alveolar Po2 (Paco2) 
must be calculated:
Pao2 = Fio2 × (PB − PH2O) − Paco2/R
where Fio2 = fractional concentration of inspired O2 (0.21 while breath-
ing room air), PB = barometric pressure (760 mmHg at sea level), 
PH2O = water vapor pressure (47 mmHg when air is saturated at 37°C), 
and R = respiratory quotient (the ratio of CO2 production to O2 consump-
tion, usually assumed to be 0.8). Severe arterial hypoxemia rarely occurs 
purely due to alveolar hypoventilation while breathing air at sea level. The 
(A − a) gradient is calculated by subtracting the measured Pao2 from the 
calculated Pao2. 
Adequacy of CO2 removal is reflected in the partial pressure of CO2 
measured in an arterial blood gas. Pulse oximetry is a valuable, widely used, 
and noninvasive tool to assess O2 saturation, but it provides no information 
about Paco2. Other limitations of pulse oximetry include relative insen-
sitivity to oxygenation changes when Pao2  is >60 mmHg, problems with 
obtaining an adequate signal when cutaneous perfusion is decreased, and 
inability to distinguish oxyhemoglobin from other forms of hemoglobin, 
such as carboxyhemoglobin and methemoglobin.
CHAPTER 137 
903
Mechanisms of Abnormal Respiratory Function
The four basic mechanisms of hypoxemia are (1) decrease in inspired Po2, 
(2) hypoventilation, (3) shunt, and (4) ventilation/perfusion mismatch. 
Decrease in inspired Po2(e.g., at high altitude) and hypoventilation (charac-
terized by an increased Paco2) both lower arterial oxygenation by reducing 
alveolar oxygenation; thus, the (A − a) gradient is normal. Shunting (e.g., 
intracardiac shunt) causes hypoxemia by bypassing the alveolar capillaries. 
Shunting is characterized by an elevated (A − a) gradient and is relatively 
refractory to oxygenation improvement with supplemental O2. Ventilation/
perfusion mismatch is the most common cause of hypoxemia; it is asso-
ciated with an elevated (A − a) gradient, but supplemental O2 corrects 
the hypoxemia by raising the O2 content of blood from regions with low 
ventilation/perfusion ratios. An algorithm for approaching the hypoxemic 
pt is shown in Fig. 137-2.
Hypercapnia is caused by inadequate alveolar ventilation. Potential 
contributing factors include (1) increased CO2 production, (2) decreased 
ventilatory drive, (3) malfunction of the respiratory pump or increased airway 
resistance, and (4) inefficiency of gas exchange (increased dead space or 
ventilation/perfusion mismatch).
Yes
Yes
Yes
Yes
Is PaCO2 increased?
Is PAO2 – PaO2 increased?
Is PAO2 – PaO2 increased?
No
No
No
Hypoventilation
Hypoventilation
alone
Hypoventilation
plus another
mechanism
Shunt
1.    Respiratory
    drive
1. Alveolar collapse
    (atelectasis)
2. Neuromuscular
    disease
2. Intraalveolar
    filling (pneumonia,
    pulmonary edema)
3. Intracardiac shunt
4. Vascular shunt
    within lungs
1. Airways disease
    (asthma, COPD)
2. Interstitial
    lung disease
3. Alveolar disease
4. Pulmonary vascular
    disease
Is low PO2
correctable
with O2?
Inspired PO2
1. High altitude
2.    FlO2
V/Q Mismatch
•  •
No
FIGURE 137-2 Flow diagram outlining the diagnostic approach to the pt with hypox-
emia. COPD, chronic obstructive pulmonary disease. (From SE Weinberger: Principles
of Pulmonary Medicine, 4th ed. Philadelphia, Saunders, 2004; with permission.)
Respiratory Function and Diagnostic Procedures
SECTION 9
904
Pulmonology
Although diffusion abnormalities rarely cause hypoxemia at rest, assess-
ment of Dlco can be used to determine the functional integrity of the 
alveolar-capillary membrane. Diseases that solely affect the airways typi-
cally do not reduce the Dlco. Dlco is reduced in interstitial lung disease, 
emphysema, and pulmonary vascular disease. Dlco can be elevated in 
alveolar hemorrhage, asthma, and congestive heart failure.
DIAGNOSTIC PROCEDURES
� NONINVASIVE PROCEDURES 
Radiographic Studies 
The chest x-ray (CXR), generally including both posteroanterior and lateral 
views, is often the first diagnostic study in pts presenting with respiratory 
symptoms. With some exceptions (e.g., pneumothorax), the CXR pattern 
is usually not sufficiently specific to establish a diagnosis; instead, the CXR 
serves to detect disease, assess magnitude, and guide further diagnostic 
investigation. With diffuse lung disease, CXR can detect an alveolar, inter-
stitial, or nodular pattern. CXR can also detect pleural effusion and pneu-
mothorax, as well as abnormalities in the hila and mediastinum. Lateral 
decubitus views can be used to estimate the size of freely flowing pleural 
effusions.
Chest CT is widely used to clarify radiographic abnormalities detected 
by CXR. Advantages of chest CT compared with CXR include (1) ability 
to distinguish superimposed structures due to cross-sectional imaging; 
(2) superior assessment of tissue density, permitting accurate assessment 
of the size and density of pulmonary nodules and improved identification 
of abnormalities adjacent to the chest wall, such as pleural disease; (3) with 
the use of IV contrast, ability to distinguish vascular from nonvascular 
structures, which is especially useful in assessing hilar and mediastinal 
abnormalities; (4) with CT angiography, ability to detect pulmonary emboli; 
and (5) due to superior visible detail, improved recognition of parenchymal 
and airway diseases, including emphysema, bronchiectasis, lymphangitic 
carcinoma, and interstitial lung disease.
A variety of other imaging techniques are used less commonly to assess 
respiratory disease. Magnetic resonance imaging (MRI) is generally less 
useful than CT for evaluation of the respiratory system but can be helpful 
as a nonradioactive tool to assist in the evaluation of intrathoracic cardio-
vascular pathology and to distinguish vascular and nonvascular structures 
without IV contrast. Ultrasound is not useful for assessing the pulmonary 
parenchyma, but it can detect pleural abnormalities and guide thoracentesis 
of a pleural effusion. Pulmonary angiography can assess the pulmonary 
arterial system for venous thromboembolism but has largely been replaced 
by CT angiography.
Nuclear Medicine Imaging 
Ventilation-perfusion lung scans can be used to assess for pulmonary 
thromboembolism but have also largely been replaced by CT angiogra-
phy. Positron emission tomographic (PET) scanning assesses the uptake 
and metabolism of a radiolabeled glucose analogue. Because malignant 
CHAPTER 137 
905
lesions usually have increased metabolic activity, PET scanning, especially 
when combined with CT images in PET/CT, is useful to assess pulmonary 
nodules for potential malignancy and to stage lung cancer. PET studies are 
limited in assessing lesions <1 cm in diameter; false-negative screening 
for malignancy can result from lesions with low metabolic activity, such 
as bronchioloalveolar cell carcinoma. False-positive PET signals can be 
observed in inflammatory conditions such as pneumonia. 
Sputum Exam
Sputum can be obtained by spontaneous expectoration or induced by 
inhalation of an irritating aerosol like hypertonic saline. Sputum is dis-
tinguished from saliva by the presence of bronchial epithelial cells and 
alveolar macrophages as opposed to squamous epithelial cells. Sputum 
exam should include gross inspection for blood, color, and odor, as well 
as Gram’s stain and routine bacterial culture. Bacterial culture of expecto-
rated sputum may be misleading due to contamination with oropharyngeal 
flora. Sputum samples can also be assessed for a variety of other pathogens, 
including mycobacteria, fungi, and viruses. Sputum samples induced by 
hypertonic saline can be stained for the presence of Pneumocystis jiroveci. 
Cytologic examination of sputum samples can be used as an initial screen 
for malignancy.
� INVASIVE PROCEDURES 
Bronchoscopy
Bronchoscopy is a procedure that provides direct visualization of the 
tracheobronchial tree, typically to the subsegmental level. The fiberoptic 
bronchoscope is used in most cases, but rigid bronchoscopy is valuable in 
specific circumstances, including massive hemorrhage and foreign body 
removal. Flexible fiberoptic bronchoscopy allows visualization of the air-
ways; identification of endobronchial abnormalities, including tumors and 
sites of bleeding; and collection of diagnostic specimens by washing, brushing, 
biopsy, or lavage. Washing involves instilling sterile saline through the 
bronchoscope channel onto the surface of a lesion; part of the saline is 
suctioned back through the bronchoscope and processed for cytology and 
microorganisms. Bronchial brushings can be obtained from the surface of 
an endobronchial lesion or from a more distal mass or infiltrate (potentially 
with fluoroscopic guidance) for cytologic and microbiologic studies. Biopsy 
forceps can be used to obtain biopsies of endobronchial lesions or passed 
into peribronchial alveolar tissue (often with fluoroscopic guidance) to 
obtain transbronchial biopsies of more distal lung tissue. Transbronchial 
biopsy is particularly useful in diagnosing diffuse infectious processes, lym-
phangitic spread of cancer, and granulomatous diseases. Complications of 
transbronchial biopsy include hemorrhage and pneumothorax.
Bronchoalveolar lavage (BAL) is an adjunct to fiberoptic bronchoscopy, 
permitting collection of cells and fluid from distal air spaces. After wedging 
the bronchoscope in a subsegmental airway, saline is instilled and then 
suctioned back through the bronchoscope for analyses, which can include 
cytology, microbiology, and cell counts. BAL is especially useful in the 
diagnosis of P. jiroveci pneumonia and some other infections.
Respiratory Function and Diagnostic Procedures
SECTION 9
906
Pulmonology
Additional bronchoscopic approaches to obtain tissue samples from loca-
tions adjacent to the trachea or large bronchi for cytologic assessment of 
malignancy include transbronchial needle aspiration (TBNA). TBNA can 
be supplemented with endobronchial ultrasound (EBUS), which can allow 
guided aspiration of hilar and mediastinal lymph nodes. 
Percutaneous Needle Aspiration of the Lung
A needle can be inserted through the chest wall and into a pulmonary lesion to 
aspirate material for cytologic and microbiologic studies. Percutaneous needle 
aspiration is usually performed under CT guidance. Owing to the small size of 
the sample obtained, sampling error is a limitation of the procedure.
Thoracentesis
Thoracentesis should be performed as an early step in the evaluation of a 
pleural effusion of uncertain etiology. Analysis of pleural fluid can deter-
mine the etiology of the effusion (Chap. 144). Large-volume thoracentesis 
can be therapeutic by palliating dyspnea. 
Mediastinoscopy
Tissue biopsy of mediastinal masses or lymph nodes is often required 
for cancer diagnosis and staging. Mediastinoscopy is performed from a 
suprasternal approach, and a rigid mediastinoscope is inserted—from 
which biopsies can be obtained. Lymph nodes in the aortopulmonary 
location typically require a parasternal mediastinotomy to provide access 
for biopsy.
Video-Assisted Thoracic Surgery 
Video-assisted thoracic surgery (VATS), also known as thoracoscopy, is 
widely used for the diagnosis of pleural lesions as well as peripheral paren-
chymal infiltrates and nodules. VATS, which requires that the pt tolerate 
single lung ventilation during the procedure, involves passing a rigid scope 
with a camera through a trocar and into the pleural space; instruments can 
be inserted and manipulated through separate intercostal incisions. VATS 
has largely replaced “open biopsy,” which requires a thoracotomy.
For a more detailed discussion, see Kritek P, Choi AMK: 
Approach to the Patient With Disease of the Respiratory 
System, Chap. 251, p. 2084, in HPIM-18; Naureckas 
ET, Solway J: Disturbances of Respiratory Function, 
Chap. 252, p. 2087, in HPIM-18; and Fuhlbrigge AL, 
Choi AMK: Diagnostic Procedures in Respiratory Disease, 
Chap. 253, p. 2094, in HPIM-18.
CHAPTER 138
907
Asthma
CHAPTER 138
Asthma
Definition and Epidemiology 
Asthma is a syndrome characterized by airflow obstruction that varies both 
spontaneously and with specific treatment. Chronic airway inflammation 
causes airway hyperresponsiveness to a variety of triggers, leading to airflow 
obstruction and respiratory symptoms including dyspnea and wheezing. 
Although asthmatics typically have periods of normal lung function with 
intermittent airflow obstruction, a subset of pts develop chronic airflow 
obstruction.
The prevalence of asthma has increased markedly over the past 30 years. 
In developed countries, approximately 10% of adults and 15% of children 
have asthma. Most asthmatics are atopic, and they often have allergic 
rhinitis and/or eczema. The majority of asthmatics have childhood-onset 
disease. Most asthmatics have atopy, and asthmatics often have atopic 
dermatitis (eczema) and/or allergic rhinitis. A minority of asthmatic pts do 
not have atopy (negative skin prick tests to common allergens and nor-
mal serum total IgE levels). These individuals, occasionally referred to as 
intrinsic asthmatics, often have adult-onset disease. Occupational asthma 
can result from a variety of chemicals, including toluene diisocyanate and 
trimellitic anhydride, and also can have an adult onset.
Asthmatics can develop increased airflow obstruction and respiratory 
symptoms in response to a variety of different triggers. Inhaled allergens 
can be potent asthma triggers for individuals with specific sensitivity to 
those agents. Viral upper respiratory infections (URIs) commonly trigger 
asthma exacerbations. β-Adrenergic blocking medications can markedly 
worsen asthma symptoms and should typically be avoided in asthmatics. 
Exercise often triggers increased asthma symptoms, which usually begin 
after exercise has ended. Other triggers of increased asthma symptoms 
include air pollution, cold air, occupational exposures, and stress.
Clinical Evaluation of the Patient History
Common respiratory symptoms in asthma include wheezing, dyspnea, and 
cough. These symptoms often vary widely within a particular individual, 
and they can change spontaneously or with age, season of the year, and 
treatment. Symptoms may be worse at night, and nocturnal awakenings are 
an indicator of inadequate asthma control. The severity of a pt’s asthmatic 
symptoms, as well as the pt’s need for systemic steroid treatment, hospital-
ization, and intensive care treatment, are important to ascertain. Types of 
asthmatic triggers for the particular pt, and their recent exposure to them, 
should be determined. Approximately 1–5% of asthmatics have sensitivity 
to aspirin and other cyclooxygenase inhibitors; they typically are nonatopic 
and have nasal polyps. Cigarette smoking leads to more hospital admissions 
and more rapid decline in lung function; smoking cessation is essential.
SECTION 9
908
Pulmonology
Physical Exam 
It is important to assess for signs of respiratory distress, including tachy-
pnea, use of accessory respiratory muscles, and cyanosis. On lung exam, 
there may be wheezing and rhonchi throughout the chest, typically more 
prominent in expiration than inspiration. Localized wheezing may indicate 
an endobronchial lesion. Evidence of allergic nasal, sinus, or skin disease 
should be assessed. When asthma is adequately controlled, the physical 
exam may be normal.
Pulmonary Function Tests 
Spirometry often shows airflow obstruction, with a reduction in forced 
expiratory volume in 1 s (FEV1) and FEV1/forced vital capacity (FVC) 
ratio. However, spirometry may be normal, especially if asthma symptoms 
are adequately treated. Bronchodilator reversibility is demonstrated by 
an increase in FEV1 by ≥200 mL and ≥12% from baseline FEV1 15 min 
after a short-acting β agonist (often albuterol metered-dose inhaler two 
puffs or 180 μg). Many but not all asthmatics will demonstrate significant 
bronchodilator reversibility; optimal pharmacologic treatment may reduce 
bronchodilator reversibility. Airway hyperresponsiveness is characteristic 
of asthma; it can be assessed by exposure to direct bronchoconstrictors 
such as methacholine or histamine. Greater airway responsiveness is asso-
ciated with increased asthmatic symptoms. The peak expiratory flow rate 
(PEF) can be used by the pt to track asthma control objectively at home. 
Measurement of lung volumes is not typically performed, but increases in 
total lung capacity and residual volume may be observed. The diffusing 
capacity for carbon monoxide is usually normal.
Other Laboratory Tests
Blood tests are usually not helpful. CBC may demonstrate eosinophilia. 
Specific IgE measurements for inhaled allergens (RAST) or allergy skin test-
ing may assist in determining allergic triggers. Total serum IgE is markedly 
elevated in allergic bronchopulmonary aspergillosis (ABPA). Exhaled nitric 
oxide levels can provide an assessment of eosinophilic airway inflammation.
Radiographic Findings
Chest x-ray is usually normal. In acute exacerbations, pneumothorax may 
be identified. In ABPA, eosinophilic pulmonary infiltrates may be observed. 
Chest CT scan is not typically performed in routine asthma but may show 
central bronchiectasis in ABPA.
Differential Diagnosis
The differential diagnosis of asthma includes other disorders that can cause 
wheezing and dyspnea. Upper airway obstruction by tumor or laryngeal 
edema can mimic asthma, but stridor in the large airways is typically noted 
on physical examination. Localized wheezing in the chest may indicate an 
endobronchial tumor or foreign body. Congestive heart failure can cause 
wheezing but is typically accompanied by bibasilar crackles. Eosinophilic 
pneumonias and Churg-Strauss syndrome may present with wheezing. 
CHAPTER 138
909
Asthma
Vocal cord dysfunction can mimic severe asthma and may require direct 
laryngoscopy to assess. When asthma involves chronic airflow obstruction, 
distinguishing it from chronic obstructive pulmonary disease (COPD) can 
be very difficult.
Chronic Asthma
TREATMENT
If a specific inciting agent for asthmatic symptoms can be identified 
and eliminated, that is an optimal part of treatment. In most cases, 
pharmacologic therapy is required. The two major classes of drugs are 
bronchodilators, which provide rapid symptomatic relief by relaxing 
airway smooth muscle, and controllers, which limit the airway inflam-
matory process. 
BRONCHODILATORS The most widely used class of bronchodilators is 
β2-adrenergic agonists, which relax airway smooth muscle by activating 
β2-adrenergic receptors. Two types of inhaled β2 agonists are widely used 
in asthma treatment: short-acting (SABA) and long-acting (LABA). 
SABAs, which include albuterol, have rapid onset of action and last for 
up to 6 h. SABAs are effective rescue medications, but excessive use indi-
cates inadequate asthma control. SABAs can prevent exercise-induced 
asthma if administered before exercise. LABAs, which include salme-
terol and formoterol, have a slower onset of action but last for >12 h. 
LABAs have replaced regularly scheduled use of SABAs, but they do not 
control airway inflammation and should not be used without inhaled 
corticosteroid (ICS) therapy. Combinations of LABAs with ICS reduce 
asthma exacerbations and provide an excellent long-term treatment 
option for asthma severity of moderate persistent degree or greater. 
Common side effects of β2-adrenergic agonists include muscle trem-
ors and palpitations. These side effects are more prominent with oral 
formulations, which should not generally be used. There have been 
ongoing concerns about mortality risks associated with β2-adrenergic 
agonists, which have not been completely resolved. LABAs taken 
without concomitant inhaled steroid treatment may increase this risk.
Other available bronchodilator medications include anticholinergics 
and theophylline. Anticholinergics, which are available in short-acting 
and long-acting inhaled formulations, are commonly used in COPD. 
They appear to be considerably less effective than β2-adrenergic agonists 
in asthma, and they are typically considered as an additional treat-
ment option only if other asthma medications do not provide adequate 
asthma control. Theophylline may have both bronchodilator and anti-
inflammatory effects; it is not widely used due to the potential toxicities 
associated with high plasma levels. Low doses of theophylline may have 
additive effects with ICS at levels below the standard therapeutic range, 
and this can be a useful treatment option for severe asthma.
CONTROLLER THERAPIES ICS are the most effective controller treat-
ments for asthma. ICS are usually given twice daily; a variety of ICS 
medications are available. Although they do not provide immediate 
symptom relief, respiratory symptoms and lung function often begin to 
SECTION 9
910
Pulmonology
improve within several days of initiating treatment. ICS reduces exercise-
induced symptoms, nocturnal symptoms, and acute exacerbations. ICS 
treatment typically leads to reductions in airway hyperresponsiveness. 
ICS side effects include hoarseness and oral candidiasis; these effects 
may be minimized by use of a spacer device and by rinsing out the 
mouth after taking ICS. 
Other available controller therapies for asthma include systemic cor-
ticosteroids. Although quite helpful in the management of acute asthma 
exacerbations, oral or IV steroid use should be avoided if at all possible 
in the chronic management of asthma due to multiple potential side 
effects. Antileukotrienes, such as montelukast and zafirlukast, may be 
quite beneficial in some pts. Cromolyn sodium and nedocromil sodium 
are not widely used due to their brief durations of action and typically 
modest effects. Omalizumab is a blocking antibody that neutralizes 
IgE; with SC injection, it appears to reduce acute asthma exacerbation 
frequency in severe asthmatics. However, it is expensive and considered 
only for highly selected pts with elevated total serum IgE levels and 
refractory asthma symptoms despite maximal inhaled bronchodilator 
and ICS therapy.
OVERALL TREATMENT APPROACH In addition to limiting exposure to 
their environmental triggers for asthma, pts should receive stepwise 
therapy appropriate for their disease severity (Fig. 138-1). Asthmatics 
with mild intermittent symptoms are typically managed adequately with 
SABAs taken on an as-needed basis. Use of SABAs more than three 
times a week suggests that controller therapy, typically with an ICS twice 
per day, is required. If symptoms are not adequately controlled with ICS, 
LABAs can be added. If symptoms are still not adequately controlled, 
higher doses of ICS and/or alternative controller therapies should be 
considered. 
Short-acting β2-agonist as required for symptom relief
Mild
intermittent
Mild
persistent
Moderate
persistent
Severe
persistent
Very severe
persistent
ICS
Low dose
ICS
Low dose
LABA
ICS
High dose
ICS
High dose
LABA
LABA
OCS
FIGURE 138-1 Step-wise approach to asthma therapy according to the severity of 
asthma and ability to control symptoms. ICS, inhaled corticosteroid; LABA, long-acting 
β2 agonists; OCS, oral corticosteroid.
CHAPTER 139
911
Environmental Lung Diseases
ASTHMA EXACERBATIONS
Clinical Features
Asthma exacerbations are periods of acute worsening of asthma symptoms 
that may be life-threatening. Exacerbations are commonly triggered by 
viral URIs, but other triggers also can be involved. Symptoms often include 
increased dyspnea, wheezing, and chest tightness. Physical examination 
can reveal pulsus paradoxus as well as tachypnea, tachycardia, and lung 
hyperinflation. Pulmonary function testing reveals a reduction in FEV1 and 
PEF. Hypoxemia can result; Pco2 is usually reduced due to hyperventilation. 
Normal or rising 
 
Pco2 can signal impending respiratory failure.
Asthma Exacerbations
TREATMENT
The mainstays of asthma exacerbation treatment are high doses of 
SABAs and systemic corticosteroids. SABAs may be administered by 
nebulizer or metered-dose inhaler with a spacer; very frequent dosing 
(q1h or more often) may be required initially. Inhaled anticholinergic 
bronchodilator medication can be added to the SABAs. IV corticoste-
roids, such as methylprednisolone (e.g., 80 mg IV q8h), may be used, 
although oral corticosteroids also may be used. Supplemental oxygen 
should be provided to maintain adequate oxygen saturation (>90%). If 
respiratory failure occurs, mechanical ventilation should be instituted, 
with care to minimize airway pressures and auto-PEEP. Because bacterial 
infections rarely trigger asthma exacerbations, antibiotics are not 
routinely administered unless there are signs of pneumonia. 
In an effort to treat asthma exacerbations before they become severe, 
asthma pts should receive written action plans with instructions for self-
initiation of treatment based on respiratory symptoms and reductions in PEF.
For a more detailed discussion, see Barnes PJ: 
Asthma, Chap. 254, p. 2102, in HPIM-18.
CHAPTER 139
Environmental Lung Diseases
The susceptibility to develop many pulmonary diseases is influenced 
by environmental factors. This chapter will focus on occupational and 
toxic chemical exposures. However, a variety of nonoccupational indoor 
exposures such as environmental tobacco smoke exposure (lung cancer), 
radon gas (lung cancer), and biomass fuel cooking (chronic obstructive 
pulmonary disease [COPD]) also should be considered. Particle size is an 
important determinant of the impact of environmental exposures on the 
SECTION 9
912
Pulmonology
respiratory system. Particles >10 μm in diameter typically are captured 
by the upper airway. Particles 2.5–10 μm in diameter will likely deposit 
in the upper tracheobronchial tree, while smaller particles (including 
nanoparticles) will reach the alveoli. Water-soluble gases like ammonia are 
absorbed in the upper airways and produce irritative and bronchoconstric-
tive responses, while less water-soluble gases (e.g., phosgene) may reach the 
alveoli and cause a life-threatening acute chemical pneumonitis.
Environmental Lung Diseases
APPROACH TO THE
PATIENT
Because there are many types of occupational lung disease (pneumoconio-
sis) that can mimic diseases not known to relate to environmental factors, 
obtaining a careful occupational history is essential. In addition to the 
types of occupation performed by the pt, the specific environmental 
exposures, use of protective respiratory devices, and ventilation of the 
work environment can provide key information. Assessing the temporal 
development of symptoms relative to the pt’s work schedule also can be 
very useful.
The chest x-ray is helpful in the assessment of environmental lung 
disease, but it may over- or underestimate the functional impact of 
pneumoconioses. Pulmonary function tests should be used to assess 
the severity of impairment, but they typically do not suggest a specific 
diagnosis. Changes in spirometry before and after a work shift can pro-
vide strong evidence for bronchoconstriction in suspected occupational 
asthma. Some radiologic patterns are distinctive for certain occupational 
lung diseases; chest x-rays are widely used, and chest CT scans can pro-
vide more detailed evaluation.
OCCUPATIONAL EXPOSURES AND PULMONARY DISEASE
� INORGANIC DUSTS 
Asbestos-Related Diseases
In addition to exposures to asbestos that may occur during the production 
of asbestos products (from mining to manufacturing), common occupa-
tional asbestos exposures occur in shipbuilding and other construction 
trades (e.g., pipefitting, boilermaking) and in the manufacture of safety 
garments and friction materials (e.g., brake and clutch linings). Along with 
worker exposure in these areas, bystander exposure (e.g., spouses) can be 
responsible for some asbestos-related lung diseases.
A range of respiratory diseases has been associated with asbestos expo-
sure. Pleural plaques indicate that asbestos exposure has occurred, but they 
are typically not symptomatic. Interstitial lung disease, often referred to as 
asbestosis, is pathologically and radiologically similar to idiopathic pulmo-
nary fibrosis; it is typically accompanied by a restrictive ventilatory defect 
with reduced diffusing capacity for carbon monoxide (Dlco) on pulmo-
nary function testing. Asbestosis can develop after 10 years of exposure, and 
no specific therapy is available.
Benign pleural effusions can also occur from asbestos exposure. Lung 
cancer is clearly associated with asbestos exposure, but does not typically 
CHAPTER 139
913
Environmental Lung Diseases
present for at least 15 years after initial exposure. The lung cancer risk 
increases multiplicatively with cigarette smoking. In addition, mesothe-
liomas (both pleural and peritoneal) are strongly associated with asbestos 
exposure, but they are not related to smoking. Relatively brief asbestos 
exposures may lead to mesotheliomas, which typically do not develop 
for decades after the initial exposure. Biopsy of pleural tissue, typically by 
thoracoscopic surgery, is required for diagnosing mesothelioma.
Silicosis
Silicosis results from exposure to free silica (crystalline quartz), which 
occurs in mining, stone cutting, abrasive industries (e.g., stone, clay, glass, 
and cement manufacturing), foundry work, and quarrying. Heavy expo-
sures over relatively brief time periods (as little as 10 months) can cause 
acute silicosis—which is pathologically similar to pulmonary alveolar 
proteinosis and associated with a characteristic chest CT pattern known 
as “crazy paving.” Acute silicosis can be severe and progressive; whole lung 
lavage may be of some therapeutic benefit.
Longer-term exposures can result in simple silicosis, with small rounded 
opacities in the upper lobes of the lungs. Calcification of hilar lymph nodes 
can give a characteristic “eggshell” appearance. Progressive nodular fibrosis 
can result in masses >1 cm in diameter in complicated silicosis. When such 
masses become very large, the term progressive massive fibrosis is used to 
describe the condition. Due to impaired cell-mediated immunity, silicosis 
pts are at increased risk of tuberculosis, atypical mycobacterial infections, 
and fungal infections. Silica may also be a lung carcinogen.
Coal Worker’s Pneumoconiosis 
Occupational exposure to coal dust predisposes to coal worker’s pneumo-
coniosis (CWP), which is less common among coal workers in the western 
United States due to a lower risk from the bituminous coal found in that 
region. Simple CWP is defined radiologically by small nodular opacities 
and is not typically symptomatic; however, an increased risk of COPD may 
occur. The development of larger nodules (>1 cm in diameter), usually 
in the upper lobes, characterizes complicated CWP. Complicated CWP is 
often symptomatic and is associated with reduced pulmonary function and 
increased mortality.
Berylliosis 
Beryllium exposure may occur in the manufacturing of alloys, ceram-
ics, and electronic devices. Although acute beryllium exposure can rarely 
produce acute pneumonitis, a chronic granulomatous disease very similar 
to sarcoidosis is much more common. Radiologically, chronic beryllium 
disease, like sarcoidosis, is characterized by pulmonary nodules along 
septal lines. As in sarcoidosis, either a restrictive or obstructive ventilatory 
pattern with reduced Dlco on pulmonary function testing can be seen. 
Bronchoscopy with transbronchial biopsy is typically required to diagnose 
chronic beryllium disease. The most effective way to distinguish chronic 
beryllium disease from sarcoidosis is to assess for delayed hypersensitivity 
to beryllium by performing a lymphocyte proliferation test using blood 
SECTION 9
914
Pulmonology
or bronchoalveolar lavage lymphocytes. Removal from further beryllium 
exposure is required, and corticosteroids may be beneficial.
� ORGANIC DUSTS 
Cotton Dust (Byssinosis) 
Dust exposures occur in the production of yarns for textiles and rope-
making. At the early stages of byssinosis, chest tightness occurs near the end 
of the first day of the workweek. In progressive cases, symptoms are present 
throughout the workweek. After at least 10 years of exposure, chronic air-
flow obstruction can develop. In symptomatic individuals, limiting further 
exposure is essential.
Grain Dust 
Farmers and grain elevator operators are at risk for grain dust–related lung 
disease, which is similar to COPD. Symptoms include productive cough, 
wheezing, and dyspnea. Pulmonary function tests typically show airflow 
obstruction.
Farmer’s Lung 
Exposure to moldy hay containing spores of thermophilic actinomycetes 
can lead to the development of hypersensitivity pneumonitis. Within 8 h 
after exposure, the acute presentation of farmer’s lung includes fever, cough, 
and dyspnea. With repeated exposures, chronic and patchy interstitial lung 
disease can develop.
Toxic Chemicals 
Many toxic chemicals can affect the lung in the form of vapors and gases. 
For example, smoke inhalation can be lethal to firefighters and fire victims 
through a variety of mechanisms. Carbon monoxide poisoning can cause 
life-threatening hypoxemia. Combustion of plastics and polyurethanes 
can release toxic agents including cyanide. Occupational asthma can result 
from exposure to diisocyanates in polyurethanes and acid anhydrides in 
epoxides. Radon gas, released from earth materials and concentrated within 
buildings, is a risk factor for lung cancer.
PRINCIPLES OF MANAGEMENT
Treatment of environmental lung diseases typically involves limiting 
or avoiding exposures to the toxic substance. Chronic interstitial lung 
diseases (e.g., asbestosis, CWP) are not responsive to glucocorticoids, but 
acute organic dust exposures may respond to corticosteroids. Therapy of 
occupational asthma (e.g., diisocyanates) follows usual asthma guidelines 
(Chap. 138), and therapy of occupational COPD (e.g., byssinosis) follows 
usual COPD guidelines (Chap. 140).
For a more detailed discussion, see Balmes JR, Speizer FE: 
Occupational and Environmental Lung Disease, Chap. 256, 
p. 2121, in HPIM-18. 
CHAPTER 140
915
Chronic Obstructive Pulmonary Disease 
CHAPTER 140
Chronic Obstructive 
Pulmonary Disease
DEFINITION AND EPIDEMIOLOGY
Chronic obstructive pulmonary disease (COPD) is a disease state charac-
terized by chronic airflow obstruction; thus, pulmonary function testing is 
central to its diagnosis. The presence of airflow obstruction is determined 
by a reduced ratio of the forced expiratory volume in 1 s (FEV1) to the 
forced vital capacity (FVC). Among individuals with a reduced FEV1/
FVC ratio, the severity of airflow obstruction is determined by the level of 
reduction in FEV1 (Table 140-1): ≥80% is stage I, 50–80% is stage II, 
30–50% is stage III, and <30% is stage IV. Cigarette smoking is the major 
environmental risk factor for COPD. The risk of COPD increases with 
cigarette smoking intensity, which is typically quantified as pack-years. 
(One pack of cigarettes smoked per day for 1 year equals 1 pack-year.) 
Individuals with airway hyperresponsiveness and certain occupational 
exposures (e.g., coal mining, gold mining, and cotton textiles) are likely 
TABLE 140-1 GOLD CRITERIA FOR COPD SEVERITY
GOLD Stage Severity
Symptoms
Spirometry
0
At risk
Chronic cough, 
sputum production
Normal
I
Mild
With or without 
chronic cough or 
sputum production
FEV1/FVC <0.7 and FEV1
≥80% predicted
IIA
Moderate
With or without 
chronic cough or 
sputum production
FEV1/FVC <0.7 and FEV1
≥50% but <80% predicted
III
Severe
With or without 
chronic cough or 
sputum production
FEV1/FVC <0.7 and FEV1
≥30% but <50% predicted
IV
Very severe
With or without 
chronic cough or 
sputum production
FEV1/FVC <0.7 and FEV1
<30% predicted 
or
FEV1 <50% predicted with 
respiratory failure or signs 
of right heart failure
Abbreviation: GOLD, Global Initiative for Lung Disease.
Source: From RA Pauwels et al: Am J Respir Crit Care Med 163:1256, 2001; with permission.
SECTION 9
916
Pulmonology
also at increased risk for COPD. In countries in which biomass combustion 
with poor ventilation is used for cooking, an increased risk of COPD among 
women has been reported. COPD is a progressive disorder; however, the 
rate of loss of lung function often slows markedly if smoking cessation 
occurs. In normal individuals, FEV1 reaches a lifetime peak at around age 
25 years, enters a plateau phase, and subsequently declines gradually and 
progressively. Subjects can develop COPD by having reduced maximally 
attained lung function, shortened plateau phase, or accelerated decline in 
lung function.
Symptoms often occur only when COPD is advanced; thus, early detec-
tion requires spirometric testing. The Pao2 typically remains near normal 
until the FEV1 falls to <50% of the predicted value. Hypercarbia and pul-
monary hypertension are most common after FEV1 has fallen to <25% of 
predicted. COPD pts with similar FEV1 values can vary markedly in their 
respiratory symptoms and functional impairment. COPD often includes 
periods of increased respiratory symptoms, such as dyspnea, cough, and 
phlegm production, which are known as exacerbations. Exacerbations are 
often triggered by bacterial and/or viral respiratory infections. These exac-
erbations become more common as COPD severity increases, but some 
individuals are much more susceptible to developing exacerbations than 
others with similar degrees of airflow obstruction.
CLINICAL MANIFESTATIONS
History 
Subjects with COPD usually have smoked ≥20 pack-years of cigarettes. 
Common symptoms include cough and phlegm production; individuals 
with chronic productive cough for 3 months per year for the preceding 
2 years have chronic bronchitis. However, chronic bronchitis without airflow 
obstruction is not included within COPD. Exertional dyspnea is a common 
and potentially disabling symptom in COPD pts. Exercise involving upper-
body activity is especially difficult for severe COPD pts. Weight loss and 
cachexia are common in advanced disease. Hypoxemia and hypercarbia 
may result in fluid retention, morning headaches, sleep disruption, eryth-
rocytosis, and cyanosis.
Exacerbations are more frequent as disease progresses and are most 
often triggered by respiratory infections, often with a bacterial compo-
nent. The history of prior exacerbations is a strong predictor of future 
exacerbations.
Physical Findings 
The physical examination may be normal until COPD is fairly advanced. 
As disease progresses, signs of hyperinflation may become more prominent, 
including barrel chest and poor diaphragmatic excursion. Expiratory wheez-
ing may be observed, but it does not predict the severity of obstruction or 
response to therapy. Persistently localized wheezing and digital clubbing 
raise the possibility of lung cancer.
During COPD exacerbations, signs of respiratory distress may be 
prominent, including tachycardia, tachypnea, use of accessory muscles of 
respiration, and cyanosis.
CHAPTER 140
917
Chronic Obstructive Pulmonary Disease 
Radiographic Findings 
Plain chest x-ray may show hyperinflation, emphysema, and pulmonary 
hypertension. It is typically performed to exclude other disease processes 
during routine evaluation and to exclude pneumonia during exacerbations. 
Chest CT scanning has much greater sensitivity for detecting emphysema 
but is typically reserved for the evaluation of advanced disease when surgical 
options such as lung volume reduction and lung transplantation are being 
considered.
Pulmonary Function Tests 
Objective documentation of airflow obstruction is essential for diagnos-
ing COPD. Standardized staging of COPD is based on postbronchodilator 
spirometry. In COPD, the FEV1/FVC ratio is reduced below 0.7. Despite 
prolonged expiratory efforts, subjects may not be able to achieve a plateau 
in their FVC. Increases in total lung capacity and residual volume, as well 
as reduced diffusing capacity for carbon monoxide, are typically seen in 
emphysema.
Laboratory Tests 
α1 Antitrypsin (α1AT) testing, typically by measurement of the protein level 
in the bloodstream, is recommended to exclude severe α1AT deficiency. 
Augmentation therapy (a weekly IV infusion) is available for individuals 
with severe α1AT deficiency (e.g., PI Z). Pulse oximetry can determine the 
O2 saturation. However, arterial blood gases remain useful to assess the 
severity of CO2 retention as well as acid-base disorders. During acute exac-
erbations, arterial blood gases should be considered in pts with mental status 
changes, significant respiratory distress, very severe COPD, or a history of 
hypercarbia. Complete blood counts are useful in advanced disease to assess 
for erythrocytosis, which can occur secondary to hypoxemia, and anemia, 
which can worsen dyspnea.
COPD
TREATMENT
OUTPATIENT MANAGEMENT
Smoking Cessation Elimination of tobacco smoking has been convinc-
ingly shown to reduce decline in pulmonary function and to prolong 
survival in pts with COPD. Although lung function does not typically 
improve substantially after smoking cessation, the rate of decline in 
FEV1 often reverts to that of nonsmokers. Pharmacologic treatment to 
assist with smoking cessation is often beneficial. Use of nicotine replace-
ment therapy (available as a transdermal patch, gum, nasal spray, and 
oral inhaler) can increase rates of smoking cessation; oral bupropion 
(150 mg bid after starting at 150 mg qd for 3 days) also produces 
significant benefit and can be combined successfully with nicotine 
replacement. Varenicline, a partial agonist for nicotinic acetylcholine 
receptors, also can promote smoking cessation. All adult, nonpregnant 
smokers without specific contraindications should be offered pharma-
cologic treatment to assist with smoking cessation. 
SECTION 9
918
Pulmonology
Nonpharmacologic Treatment Pulmonary rehabilitation improves dys-
pnea and functional status and reduces hospitalizations. Annual influ-
enza vaccinations are strongly recommended; in addition, pneumococcal 
vaccination is recommended. 
Bronchodilators Although inhaled bronchodilator medications have 
not been proven to increase longevity in COPD, they may significantly 
reduce respiratory symptoms. Short- and long-acting β-adrenergic ago-
nists, short- and long-acting anticholinergics, and theophylline deriva-
tives all may be used. Although oral medications are associated with 
greater rates of adherence, inhaled medications generally have fewer 
side effects.
Pts with mild disease can usually be managed with an inhaled short-
acting anticholinergic such as ipratropium or a short-acting β agonist 
such as albuterol. Combination therapy and long-acting β agonists 
and/or long-acting anticholinergics should be added in pts with severe 
disease. The narrow toxic-therapeutic ratio of theophylline compounds 
limits their use, and either low doses or regular monitoring of serum 
levels are required.
Corticosteroids Chronic systemic corticosteroid treatment is not rec-
ommended in COPD pts due to the risk of multiple complications, 
including osteoporosis, weight gain, cataracts, and diabetes mellitus. 
Although inhaled steroids have not been proven to reduce the rate 
of decline of FEV1 in COPD, inhaled steroid medications reduce 
the frequency of exacerbations in individuals with severe COPD. 
Combinations of inhaled steroids and long-acting β agonists reduce 
COPD exacerbations and may reduce mortality—although that has not 
been conclusively shown.
Oxygen Long-term supplemental oxygen therapy has been shown to 
reduce symptoms and improve survival in COPD pts who are chroni-
cally hypoxemic. Documentation of the need for O2 requires a measure-
ment of Pao2 or oxygen saturation (Sao2) after a period of stability. Pts 
with a Pao2 ≤55 mmHg or Sao2 ≤88% should receive O2 to raise the 
 
Sao2 to ≥90%. O2 is also indicated for pts with Pao2 of 56–59 mmHg or 
Sao2 ≤89% if associated with signs and symptoms of pulmonary hyper-
tension or cor pulmonale. For individuals who meet these guidelines, 
continuous O2 therapy is recommended because the number of hours 
per day of oxygen use is directly related to the mortality benefit. 
Supplemental oxygen may also be prescribed for selected COPD pts 
who desaturate only with exercise or during sleep, although the evidence 
for benefit is less compelling.
Surgical Options for Severe COPD Two main types of surgical options 
are available for end-stage COPD. Lung volume reduction surgery 
can reduce mortality and improve lung function in selected pts with 
upper lobe–predominant emphysema and low exercise capacity (after 
pulmonary rehabilitation). Individuals who meet the criteria for the 
CHAPTER 140
919
Chronic Obstructive Pulmonary Disease 
high-risk group (FEV1 <20% predicted and either a diffuse distribu-
tion of emphysema or lung carbon monoxide diffusing capacity <20% 
predicted) should not be considered for lung volume reduction surgery. 
Lung transplantation should be considered for COPD pts who have very 
severe chronic airflow obstruction and disability at a relatively young age 
despite maximal medical therapy.
MANAGEMENT OF COPD EXACERBATIONS COPD exacerbations are a 
major cause of morbidity and mortality. Critical decisions in manage-
ment include whether hospitalization is required. Although there are 
no definitive guidelines to determine which COPD pts require hospi-
talization for an exacerbation, the development of respiratory acidosis, 
worsening hypoxemia, severe underlying COPD, pneumonia, or social 
situations without adequate home support for the treatment required 
should prompt consideration of hospitalization.
Key components of exacerbation treatment include bronchodilators, 
antibiotics, and short courses of systemic glucocorticoids. 
Antibiotics Because bacterial infections often trigger COPD exacer-
bations, antibiotic therapy should be strongly considered, especially 
with increased sputum volume or change in sputum color. Common 
pathogens include Streptococcus pneumoniae, Haemophilus influenzae, 
and Moraxella catarrhalis. Antibiotic choice should depend on the local 
antibiotic sensitivity patterns, previous sputum culture results for a par-
ticular pt, and the severity of disease. Trimethoprim-sulfamethoxazole, 
doxycycline, and amoxicillin are reasonable choices for subjects with 
mild to moderate COPD; broader-spectrum antibiotics should be con-
sidered for subjects with more severe underlying COPD and/or more 
severe exacerbations.
Bronchodilators Bronchodilator therapy is essential during COPD 
exacerbations. Short-acting β-adrenergic agonists by inhalation (e.g., 
albuterol q1–2h) are used; addition of anticholinergics is likely of benefit 
(e.g., ipratropium q4–6h). Administration of bronchodilators by nebu-
lizer is often used initially because it is easier to administer to pts in 
respiratory distress. Conversion to metered-dose inhaler administration 
can be successfully achieved with appropriate training of the pt and staff.
Glucocorticoids Systemic steroids hasten resolution of symptoms and 
reduce relapses and subsequent exacerbations for up to 6 months. 
Dosing is not well worked out, but 30–40 mg of prednisone daily (or IV 
equivalent) is standard, with a total course of 10–14 days. Hyperglycemia 
is the most commonly reported complication and should be monitored.
Oxygen Hypoxemia often worsens during COPD exacerbations. 
Supplemental O2 should be administered to maintain Sao2 ≥90%. Very 
high O2 delivery can worsen hypercarbia, primarily due to increasing 
ventilation-perfusion mismatch. However, providing adequate O2 to 
obtain saturation of ~90% is the key goal. Therefore, supplemental O2 
delivery should be focused on providing adequate oxygenation without 
SECTION 9
920
Pulmonology
providing unnecessarily high O2 saturations. Pts may require use of 
supplemental O2 after hospital discharge until the exacerbation com-
pletely resolves.
Ventilatory Support Numerous studies suggest that noninvasive mask 
ventilation [noninvasive ventilation (NIV)] can improve outcomes in 
acute COPD exacerbations with respiratory failure (Paco2 >45 mmHg). 
Contraindications to NIV include cardiovascular instability, impaired 
mental status, inability to cooperate, copious secretions, craniofacial 
abnormalities or facial trauma, extreme obesity, or significant burns. 
Progressive hypercarbia, refractory hypoxemia, or alterations in mental 
status that compromise ability to comply with NIV therapy, hemody-
namic instability, and respiratory arrest may necessitate endotracheal 
intubation for mechanical ventilation. Sufficient expiratory time is 
required to avoid the development of auto-PEEP.
For a more detailed discussion, see Reilly JJ Jr., Silverman 
EK, Shapiro SD: Chronic Obstructive Pulmonary Disease, 
Chap. 260, p. 2151, in HPIM-18.
CHAPTER 141
Pneumonia, Bronchiectasis, 
and Lung Abscess
PNEUMONIA
Pneumonia, an infection of the lung parenchyma, is classified as community-
acquired (CAP) or health care–associated (HCAP). The HCAP category 
is subdivided into hospital-acquired pneumonia (HAP) and ventilator-
associated pneumonia (VAP). HCAP is associated with hospitalization for 
≥48 h, hospitalization for ≥2 days in the prior 3 months, residence in a 
nursing home or extended-care facility, antibiotic therapy in the preceding 
3 months, chronic dialysis, home infusion therapy, home wound care, and 
contact with a family member who has a multidrug-resistant (MDR) infection.
PATHOPHYSIOLOGY
• Microorganisms gain access to the lower respiratory tract via micro-
aspiration from the oropharynx (the most common route), inhalation of 
contaminated droplets, hematogenous spread, or contiguous extension 
from an infected pleural or mediastinal space.
• Before disease manifests, the size of the organism burden must overcome 
the ability of macrophages and other components of innate immunity 
(e.g., surfactant proteins A and D) to clear bacteria. 
CHAPTER 141
921
Pneumonia, Bronchiectasis, and Lung Abscess 
• Classic pneumonia (typified by that due to Streptococcus pneumoniae) 
presents as a lobar pattern and evolves through four phases characterized 
by changes in the alveoli:
– Edema: Proteinaceous exudates are present in the alveoli. 
– Red hepatization: Erythrocytes and neutrophils are present in the 
intraalveolar exudate. 
– Gray hepatization: Neutrophils and fibrin deposition are abundant.
– Resolution: Macrophages are the dominant cell type. 
• In VAP, respiratory bronchiolitis can precede a radiologically apparent 
infiltrate. 
COMMUNITY-ACQUIRED PNEUMONIA
Microbiology 
Although many bacteria, viruses, fungi, and protozoa can cause CAP, most 
cases are caused by relatively few pathogens. In >50% of cases, a specific 
etiology is never determined.
• Typical bacterial pathogens include S. pneumoniae, Haemophilus influen-
zae, Staphylococcus aureus, and gram-negative bacteria such as Klebsiella 
pneumoniae and Pseudomonas aeruginosa.
• Atypical organisms include Mycoplasma pneumoniae, Chlamydia pneu-
moniae, Legionella species, and respiratory viruses (e.g., influenza 
viruses, adenoviruses, respiratory syncytial viruses).
– A virus may be responsible for up to 18% of cases of CAP that require 
hospital admission.
– 10–15% of CAP cases are polymicrobial and involve a combination of 
typical and atypical organisms.
• Involvement of anaerobes, which play a significant role in CAP only 
when aspiration precedes presentation by days or weeks, often results in 
significant empyemas.
Epidemiology 
CAP affects ~4 million adults each year in the United States, 80% of whom 
are treated on an outpatient basis. CAP causes 45,000 deaths annually and 
is associated with an overall yearly cost of $9–10 billion. 
• Incidence rates of CAP are highest at the extremes of age (i.e., <4 and 
>60 years).
• Risk factors for CAP include alcoholism, asthma, immunosuppression, 
institutionalization, and an age of ≥70 years (vs. 60–69 years).
• Many factors—e.g., tobacco smoking, chronic obstructive pulmonary 
disease, colonization with methicillin-resistant S. aureus (MRSA), recent 
hospitalization or antibiotic therapy—influence the types of pathogens 
that should be considered in the etiologic diagnosis. 
Clinical Manifestations 
Pts frequently have fever, chills, sweats, cough (either nonproductive or 
productive of mucoid, purulent, or blood-tinged sputum), pleuritic chest 
pain, and dyspnea.
SECTION 9
922
Pulmonology
• Other common symptoms include nausea, vomiting, diarrhea, fatigue, 
headache, myalgias, and arthralgias. 
• Elderly pts may present atypically, with confusion but few other 
manifestations.
• Physical examination often reveals tachypnea; increased or decreased 
tactile fremitus; dull or flat percussion reflecting consolidation and 
pleural fluid, respectively; crackles; bronchial breath sounds; or a pleural 
friction rub.
Diagnosis
Both confirmation of the diagnosis and assessment of the likely etiology are 
required. Although no data have demonstrated that treatment directed at a 
specific pathogen is superior to empirical treatment, an etiologic diagnosis 
allows narrowing of the empirical regimen, identification of organisms 
with public safety implications (e.g., Mycobacterium tuberculosis, influenza 
virus), and monitoring of antibiotic susceptibility trends.
• Chest radiography is often required to differentiate CAP from other con-
ditions, particularly since the sensitivity and specificity of physical exam 
findings for CAP are only 58% and 67%, respectively. 
– CT of the chest may be helpful for pts with suspected postobstructive 
pneumonia. 
– Some radiographic patterns suggest an etiology; e.g., pneumatoceles 
suggest S. aureus.
• Sputum samples must have >25 WBCs and <10 squamous epithelial cells 
per high-power field to be appropriate for culture. The sensitivity of sputum 
cultures is highly variable; in cases of proven bacteremic pneumococcal 
pneumonia, the yield of positive cultures from sputum samples is ≤50%.
• Blood cultures are positive in 5–14% of cases, most commonly yielding 
S. pneumoniae. Blood cultures are optional for most CAP pts, but should 
be performed for high-risk pts (e.g., pts with chronic liver disease or 
asplenia).
• Urine antigen tests for S. pneumoniae and Legionella pneumophila type 1 
can be helpful.
• Serology: A fourfold rise in titer of specific IgM antibody can assist in 
the diagnosis of pneumonia due to some pathogens; however, the time 
required to obtain a final result makes serology of limited clinical utility.
Community-Acquired Pneumonia
TREATMENT
DECIDING WHETHER TO HOSPITALIZE PTS
• Two sets of criteria identify pts who will benefit from hospital care. It 
is not clear which set is superior, and application of each tool should 
be tempered by a consideration of factors relevant to the individual pt.
– Pneumonia Severity Index (PSI): Points are given for 20 variables, 
including age, coexisting illness, and abnormal physical and labora-
tory findings. On this basis, pts are assigned to one of five classes of 
mortality risk. 
CHAPTER 141
923
Pneumonia, Bronchiectasis, and Lung Abscess 
– CURB-65: Five variables are included: confusion (C); urea 
>7 mmol/L (U); respiratory rate ≥30/min (R); blood pressure, 
systolic ≤90 mmHg or diastolic ≤60 mmHg (B); and age ≥65 years 
(65). Pts with a score of 0 can be treated at home, pts with a score 
of 2 should be hospitalized, and pts with a score of ≥3 may require 
management in the intensive care unit (ICU).
ANTIBIOTIC THERAPY
• For recommendations on empirical antibiotic treatment of CAP, see 
Table 141-1. U.S. guidelines always target S. pneumoniae and atypical 
pathogens. Retrospective data suggest that this approach lowers the 
mortality rate. 
• Pts initially treated with IV antibiotics can be switched to oral agents 
when they can ingest and absorb drugs, are hemodynamically stable, 
and are improving clinically. 
• CAP has historically been treated for 10–14 days, but a 5-day course of 
a fluoroquinolone is sufficient for cases of uncomplicated CAP. A longer 
course is required for pts with bacteremia, metastatic infection, or infec-
tion with a particularly virulent pathogen and in most cases of severe CAP.
• Fever and leukocytosis usually resolve within 2–4 days. Pts who have 
not responded to therapy by day 3 should be reevaluated, with consid-
eration of alternative diagnoses, antibiotic resistance in the pathogen, 
and the possibility that the wrong drug is being given.
Complications
Common complications of severe CAP include respiratory failure, shock 
and multiorgan failure, coagulopathy, and exacerbation of comorbid dis-
ease. Metastatic infection (e.g., brain abscess, endocarditis) occurs rarely 
and requires immediate attention.
• Lung abscess may occur in association with aspiration or infection caused 
by single CAP pathogens [e.g., community-acquired MRSA (CA-MRSA) 
or P. aeruginosa]. Drainage should be established and proper antibiotics 
administered.
• Any significant pleural effusion should be tapped for diagnostic and ther-
apeutic purposes. If the fluid has a pH <7, a glucose level <2.2 mmol/L, 
and a lactate dehydrogenase content >1000 U or if bacteria are seen or 
cultured, fluid should be drained; a chest tube is usually required.
Follow-Up
Chest x-ray abnormalities may require 4–12 weeks to clear. Pts should 
receive influenza and pneumococcal vaccines, as appropriate.
HEALTH CARE–ASSOCIATED PNEUMONIA (SEE ALSO CHAP. 87)
� VENTILATOR-ASSOCIATED PNEUMONIA
Microbiology 
Potential etiologic agents include MDR and non-MDR pathogens; the 
prominence of the various pathogens depends on the length of hospital stay 
at the time of infection.
SECTION 9
924
Pulmonology
TABLE 141-1  EMPIRICAL ANTIBIOTIC TREATMENT OF COMMUNITY-
ACQUIRED PNEUMONIA
Outpatients
Previously healthy and no antibiotics in past 3 months
•  A macrolide [clarithromycin (500 mg PO bid) or azithromycin (500 mg PO 
once, then 250 mg qd)] or
•  Doxycycline (100 mg PO bid)
Comorbidities or antibiotics in past 3 months: select an alternative from a 
different class
•  A respiratory fluoroquinolone [moxifloxacin (400 mg PO qd), gemifloxacin 
(320 mg PO qd), or levofloxacin (750 mg PO qd)] or
•  A β-lactam [preferred: high-dose amoxicillin (1 g tid) or amoxicillin/
clavulanate (2 g bid); alternatives: ceftriaxone (1–2 g IV qd), cefpodoxime 
(200 mg PO bid), or cefuroxime (500 mg PO bid)] plus a macrolidea
In regions with a high rate of “high-level” pneumococcal macrolide 
resistance,b consider alternatives listed above for pts with comorbidities.
Inpatients, Non-ICU
•  A respiratory fluoroquinolone [moxifloxacin (400 mg PO or IV qd), 
gemifloxacin (320 mg PO qd), or levofloxacin (750 mg PO or IV qd)]
•  A β-lactamc [cefotaxime (1–2 g IV q8h), ceftriaxone (1–2 g IV qd), 
ampicillin (1–2 g IV q4–6h), or ertapenem (1 g IV qd in selected pts)] 
plus a macrolided [oral clarithromycin or azithromycin (as listed above 
for previously healthy pts) or IV azithromycin (1 g once, then 500 mg qd)]
Inpatients, ICU
•  A β-lactame [cefotaxime (1–2 g IV q8h), ceftriaxone (2 g IV qd), or 
ampicillin-sulbactam (2 g IV q8h)] plus
• Azithromycin or a fluoroquinolone (as listed above for inpatients, non-ICU)
Special Concerns
If Pseudomonas is a consideration
•  An antipneumococcal, antipseudomonal β-lactam [piperacillin/tazobactam 
(4.5 g IV q6h), cefepime (1–2 g IV q12h), imipenem (500 mg IV q6h), or 
meropenem (1 g IV q8h)] plus either ciprofloxacin (400 mg IV q12h) or 
levofloxacin (750 mg IV qd)
•  A β-lactam (as listed above) plus an aminoglycoside [amikacin (15 mg/kg 
qd) or tobramycin (1.7 mg/kg qd)] plus azithromycin
•  A β-lactam (as listed above)f plus an aminoglycoside plus an
antipneumococcal fluoroquinolone
If CA-MRSA is a consideration
• Add linezolid (600 mg IV q12h) or vancomycin (1 g IV q12h).
aDoxycycline (100 mg PO bid) is an alternative to the macrolide.
bMICs of >16 μg/mL in 25% of isolates.
cA respiratory fluoroquinolone should be used for penicillin-allergic pts.
dDoxycycline (100 mg IV q12h) is an alternative to the macrolide.
eFor penicillin-allergic pts, use a respiratory fluoroquinolone and aztreonam (2 g IV q8h).
fFor penicillin-allergic pts, substitute aztreonam.
Abbreviation: CA-MRSA, community-acquired methicillin-resistant Staphylococcus aureus.
CHAPTER 141
925
Pneumonia, Bronchiectasis, and Lung Abscess 
Epidemiology, Pathogenesis, and Clinical Manifestations 
Prevalence estimates of VAP are 6–52 cases per 100 pts, with the highest 
hazard ratio in the first 5 days of mechanical ventilation. 
• Three factors important in the pathogenesis of VAP are colonization of 
the oropharynx with pathogenic microorganisms, aspiration of these 
organisms to the lower respiratory tract, and compromise of normal host 
defense mechanisms. 
• Clinical manifestations are similar to those in other forms of pneumonia.
Diagnosis
Application of clinical criteria consistently results in overdiagnosis of 
VAP. Use of quantitative cultures to discriminate between colonization 
and true infection by determining bacterial burden may be helpful; the 
more distal in the respiratory tree the diagnostic sampling, the more 
specific the results.
Ventilator-Associated Pneumonia
TREATMENT
• See Table 141-2 for recommended options for empirical therapy for 
HCAP. 
– Higher mortality rates are associated with inappropriate initial 
empirical treatment. 
– Broad-spectrum treatment should be modified when a pathogen is 
identified.
– Clinical improvement, if it occurs, is usually evident within 48–72 h 
of the initiation of antimicrobial treatment.
• Treatment failure in VAP is not uncommon, especially when MDR 
pathogens are involved; MRSA and P. aeruginosa are associated with 
high failure rates. 
• VAP complications include prolongation of mechanical ventilation, 
increased length of ICU stay, and necrotizing pneumonia with pulmo-
nary hemorrhage or bronchiectasis. VAP is associated with significant 
mortality risk. 
• Strategies effective for the prevention of VAP are listed in Table 141-3.
� HOSPITAL-ACQUIRED PNEUMONIA
Less well studied than VAP, HAP more commonly involves non-MDR 
pathogens. Anaerobes may also be more commonly involved in non-VAP pts 
because of the increased risk of macroaspiration in pts who are not intubated.
� BRONCHIECTASIS
Etiology and Epidemiology 
Bronchiectasis is an irreversible airway dilation that involves the lung in either 
a focal (due to obstruction) or a diffuse (due to a systemic or infectious process) 
manner. Bronchiectasis can arise from infectious or noninfectious causes. 
• The epidemiology varies greatly with the underlying etiology; in general, 
the incidence of bronchiectasis increases with age and is higher among 
women than among men.
• 25–50% of pts with bronchiectasis have idiopathic disease.
SECTION 9
926
Pulmonology
Pathogenesis 
The most widely cited mechanism of infectious bronchiectasis is the 
“vicious cycle hypothesis,” in which susceptibility to infection and poor 
mucociliary clearance result in microbial colonization of the bronchial tree. 
Proposed mechanisms for noninfectious bronchiectasis include immune-
mediated reactions that damage the bronchial wall and parenchymal 
distortion as a result of lung fibrosis (e.g., postradiation fibrosis or idiopathic 
pulmonary fibrosis).
Clinical Manifestations 
Presenting pts typically have a persistent productive cough with ongoing 
production of thick, tenacious sputum. 
• Physical exam usually reveals crackles and wheezing on lung auscultation 
and occasionally reveals digital clubbing. 
• Acute exacerbations are associated with increased purulent-sputum 
production.
Diagnosis
The diagnosis of bronchiectasis is based on clinical presentation with con-
sistent radiographic findings, such as parallel “tram tracks,” a “signet-ring 
sign” (a cross-sectional area of the airway with a diameter at least 1.5 times 
that of the adjacent vessel), lack of bronchial tapering, bronchial wall thick-
ening, or cysts emanating from the bronchial wall.
TABLE 141-2  EMPIRICAL ANTIBIOTIC TREATMENT OF HEALTH CARE–
ASSOCIATED PNEUMONIA
Pts without Risk Factors for MDR Pathogens
Ceftriaxone (2 g IV q24h) or
Moxifloxacin (400 mg IV q24h), ciprofloxacin (400 mg IV q8h), or levofloxacin 
(750 mg IV q24h) or
Ampicillin/sulbactam (3 g IV q6h) or
Ertapenem (1 g IV q24h)
Pts with Risk Factors for MDR Pathogens
1. A β-lactam: 
 Ceftazidime (2 g IV q8h) or cefepime (2 g IV q8–12h) or
  Piperacillin/tazobactam (4.5 g IV q6h), imipenem (500 mg IV q6h or 1 g 
IV q8h), or meropenem (1 g IV q8h) plus
2. A second agent active against gram-negative bacterial pathogens:
  Gentamicin or tobramycin (7 mg/kg IV q24h) or amikacin (20 mg/kg IV 
q24h) or
 Ciprofloxacin (400 mg IV q8h) or levofloxacin (750 mg IV q24h) plus
3. An agent active against gram-positive bacterial pathogens:
 Linezolid (600 mg IV q12h) or
 Vancomycin (15 mg/kg, up to 1 g IV q12h)
CHAPTER 141
927
Pneumonia, Bronchiectasis, and Lung Abscess 
TABLE 141-3  PATHOGENIC MECHANISMS AND CORRESPONDING 
PREVENTION STRATEGIES FOR VENTILATOR-ASSOCIATED 
PNEUMONIA
Pathogenic Mechanism
Prevention Strategy
Oropharyngeal colonization with 
pathogenic bacteria
  Elimination of normal flora
Avoidance of prolonged antibiotic courses
  Large-volume oropharyngeal 
aspiration around time of 
intubation
Short course of prophylactic antibiotics 
for comatose ptsa
  Gastroesophageal reflux
Postpyloric enteral feedingb; avoidance 
of high gastric residuals, prokinetic 
agents
  Bacterial overgrowth of stomach Prophylactic agents that raise gastric 
pHb; selective decontamination of 
digestive tract with nonabsorbable 
antibioticsb
Cross-infection from other 
colonized pts
Hand washing, especially with 
alcohol-based hand rub; intensive 
infection-control educationa; isolation; 
proper cleaning of reusable equipment
Large-volume aspiration
Endotracheal intubation; avoidance 
of sedation; decompression of 
small-bowel obstruction
Microaspiration around 
endotracheal tube
  Endotracheal intubation
Noninvasive ventilationa
  Prolonged duration of ventilation Daily awakening from sedation,a
weaning protocolsa
  Abnormal swallowing function
Early percutaneous tracheostomya
  Secretions pooled above 
endotracheal tube
Head of bed elevateda; continuous
aspiration of subglottic secretions with 
specialized endotracheal tubea; avoid-
ance of reintubation; minimization of 
sedation and pt transport
Altered lower respiratory host 
defenses
Tight glycemic controlb; lowering of 
hemoglobin transfusion threshold; 
specialized enteral feeding formula
aStrategies demonstrated to be effective in at least one randomized controlled trial.
bStrategies with negative randomized trials or conflicting results.
SECTION 9
928
Pulmonology
Bronchiectasis
TREATMENT
Treatment of infectious bronchiectasis is directed at the control of active 
infection and at improvements in secretion clearance and bronchial 
hygiene.
• Acute exacerbations should be treated with a 7- to 10-day course of anti-
biotics targeting the causative or presumptive pathogen; H. influenzae 
and P. aeruginosa are isolated commonly.
• Hydration and mucolytic administration, aerosolization of broncho-
dilators and hyperosmolar agents (e.g., hypertonic saline), and chest 
physiotherapy can be used to enhance secretion clearance.
• For pts with ≥3 recurrences per year, suppressive antibiotic treatment 
to minimize the microbial load and reduce the frequency of exacerba-
tions has been proposed.
• In select cases, surgery (including lung transplantation) should be 
considered.
� LUNG ABSCESS
Microbiology
Lung abscess—infection of the lung that results in necrosis of the pulmo-
nary parenchyma—can be caused by a variety of microorganisms. The etiol-
ogy depends, in part, on the characteristics of the host. 
• Previously healthy pts are at risk for infection with bacteria (e.g., S. aureus, 
Streptococcus milleri, K. pneumoniae, group A Streptococcus) and para-
sites (e.g., Entamoeba histolytica, Paragonimus westermani, Strongyloides 
stercoralis).
• Aspiration-prone pts are at risk for infection with anaerobic bacteria; 
S. aureus, P. aeruginosa, and F. necrophorum (embolic lesions); endemic 
fungi; and mycobacteria.
• Immunocompromised pts are susceptible to M. tuberculosis, Nocardia 
asteroides, Rhodococcus equi, Legionella species, Enterobacteriaceae, 
Aspergillus species, and Cryptococcus species.
Clinical Manifestations
Nonspecific lung abscesses—typically presumed to be due to anaerobic 
organisms—present as an indolent infection with fatigue, cough, sputum 
production, fever, weight loss, and anemia. Pts may have foul-smelling 
breath or evidence of periodontal infection with pyorrhea or gingivitis.
Diagnosis
A chest CT is the preferred radiographic study to precisely delineate the 
lesion. 
• Sputum samples can be cultured to detect aerobic bacteria but are unreli-
able for culture of anaerobic bacteria. 
• Pleural fluid or bronchoalveolar lavage specimens may be helpful if they 
are processed promptly and appropriately for anaerobic bacteria.
CHAPTER 142
929
Thromboembolism and Deep-Vein Thrombosis
CHAPTER 142
Pulmonary Thromboembolism 
and Deep-Vein Thrombosis
DEFINITION AND NATURAL HISTORY
Venous thromboembolism includes both deep-vein thrombosis (DVT) 
and pulmonary thromboembolism (PE). DVT results from blood clot 
formation within large veins, usually in the legs. PE results from DVTs that 
have broken off and traveled to the pulmonary arterial circulation. About 
one-half of pts with pelvic vein or proximal leg DVT develop PE, which 
is often asymptomatic. Isolated calf vein thrombi have much lower risk of 
PE. Although DVTs are typically related to thrombus formation in the legs 
and/or pelvis, indwelling venous catheters have increased the occurrence of 
upper extremity DVT. In the absence of PE, the major complication of DVT 
is postphlebitic syndrome, which causes chronic leg swelling and discom-
fort due to damage to the venous valves of the affected leg. In its most severe 
Lung Abscess
TREATMENT
Treatment depends on the presumed or established etiology.
• Most infections caused by anaerobic bacteria should be treated ini-
tially with clindamycin (600 mg IV qid). Any β-lactam/β-lactamase 
inhibitor combination is an alternative.
• A transition from parenteral to oral therapy is appropriate once pts 
become afebrile and improve clinically.
• Although the duration of therapy is arbitrary, continuation of oral 
treatment is recommended until imaging shows that chest lesions have 
cleared or have left a small, stable scar.
• Fever persisting for 5–7 days after antibiotics have been started suggests 
failure of therapy and a need to exclude factors such as obstruction, com-
plicating empyema, and involvement of antibiotic-resistant bacteria.
– Clinical improvement with decreased fever usually occurs within 
3–5 days, with defervescence in 5–10 days.
– Pts with fevers persisting for 7–14 days should undergo bronchos-
copy or other diagnostic tests to better define anatomic changes and 
microbiologic findings.
 For a more detailed discussion, see Mandell LA, Wunderink R: 
Pneumonia, Chap. 257, p. 2130; and Baron RM, Bartlett JG: 
Bronchiectasis and Lung Abscess, Chap. 258, p. 2142, in 
HPIM-18.
SECTION 9
930
Pulmonology
form, postphlebitic syndrome causes skin ulceration. PE is often fatal, usu-
ally due to progressive right ventricular failure. Chronic thromboembolic 
pulmonary hypertension is another long-term complication of PE.
Some genetic risk factors, including factor V Leiden and the prothrombin 
G20210A mutation, have been identified, but they account for only a minority 
of venous thromboembolic disease. A variety of other risk factors have been 
identified, including immobilization during prolonged travel, cancer, obesity, 
smoking, surgery, trauma, pregnancy, oral contraceptives, and postmenopausal 
hormone replacement. Medical conditions that increase the risk of venous 
thromboembolism include cancer and antiphospholipid antibody syndrome.
CLINICAL EVALUATION
History 
DVTs often present with progressive lower calf discomfort. For PE, dyspnea 
is the most common presenting symptom. Chest pain, cough, or hemopty-
sis can indicate pulmonary infarction with pleural irritation. Syncope can 
occur with massive PE.
Physical Examination 
Tachypnea and tachycardia are common in PE. Low-grade fever, neck vein 
distention, and a loud P2 on cardiac examination can be seen. Hypotension 
and cyanosis suggest massive PE. Physical examination with DVT may be 
notable only for mild calf tenderness. However, with massive DVT, marked 
thigh swelling and inguinal tenderness can be observed.
Laboratory Tests 
Normal d-dimer level (<500 μg/mL by enzyme-linked immunosorbent 
assay) essentially rules out PE in pts with low-to-moderate likelihood of PE, 
although hospitalized pts often have elevated d-dimer levels due to other 
disease processes. Although hypoxemia and an increased alveolar-arterial 
O2 gradient may be observed in PE, arterial blood gases are rarely useful 
in diagnosing PE. Elevated serum troponin, plasma heart-type fatty acid-
binding protein, and brain natriuretic peptide levels are associated with 
increased risk of complications and mortality in PE. The electrocardiogram 
can show an S1Q3T3 sign in PE, but that finding is not frequently observed.
Imaging Studies 
Venous ultrasonography can detect DVT by demonstrating loss of normal 
venous compressibility. When combined with Doppler imaging of venous 
flow, the detection of DVT by ultrasonography is excellent. For pts with 
nondiagnostic venous ultrasound studies, CT or MRI can be used to assess 
for DVT. Contrast phlebography is very rarely required. About one-half of 
pts with PE have no imaging evidence for DVT. 
In PE, a normal chest x-ray (CXR) is common. Although not commonly 
observed, focal oligemia and peripheral wedge-shaped densities on CXR are 
well-established findings in PE. Chest CT with IV contrast has become the 
primary diagnostic imaging test for PE. Ventilation-perfusion lung scanning 
is primarily used for subjects unable to tolerate IV contrast. Transthoracic 
echocardiography is valuable to assess for right ventricular hypokinesis 
with moderate to large PE, but it is not typically useful for diagnosing the 
CHAPTER 142
931
presence of a PE. Transesophageal echocardiography can be used to identify 
large central PE when IV contrast chest CT scans are not appropriate (e.g., 
renal failure or severe contrast allergy). With the advent of contrast chest CT 
scans for PE diagnosis, pulmonary angiography studies are rarely performed.
Integrated Diagnostic Approach 
An integrated diagnostic approach that considers the clinical suspicion for 
DVT and PE is required. For individuals with a low clinical likelihood of 
DVT or with a low to moderate clinical likelihood of PE, the d-dimer level 
can be used to determine if further imaging studies are required. An algo-
rithm for imaging studies in both DVT and PE is shown in Fig. 142-1. The 
differential diagnosis of DVT includes a ruptured Baker’s cyst and cellulitis. 
The differential diagnosis of PE is broad and includes pneumonia, acute 
myocardial infarction, and aortic dissection.
FIGURE 142-1 Imaging tests useful to diagnose DVT and PE. ECHO, echocardiogram.
ALGORITHM FOR DVT AND PE DIAGNOSIS
DVT imaging test
Venous ultrasound
Diagnostic
Nondiagnostic
Stop
MR
CT
Phlebography
PE Imaging Test
Chest CT
Diagnostic
Nondiagnostic, unavailable, or unsafe
Stop
Stop
Lung scan
Diagnostic
Nondiagnostic
Venous ultrasound
Positive
Negative
Treat for PE
Transesophageal ECHO or MR or
invasive pulmonary angiography
Thromboembolism and Deep-Vein Thrombosis
SECTION 9
932
Pulmonology
Deep-Vein Thrombosis and Pulmonary Thromboembolism 
TREATMENT
ANTICOAGULATION Although anticoagulants do not dissolve existing 
clots in DVT or PE directly, they limit further thrombus formation and 
allow fibrinolysis to occur. In order to provide effective anticoagulation 
rapidly, parenteral anticoagulation is used for the initial treatment of 
venous thromboembolism. Traditionally, unfractionated heparin (UFH) 
has been used, with a target activated partial thromboplastin time (aPTT) 
of 2–3 times the upper limit of the normal laboratory value. UFH is typi-
cally administered with a bolus of 5000–10,000 U followed by a continu-
ous infusion of approximately 1000 U/h. Frequent dosage adjustments 
are often required to achieve and maintain a therapeutic aPTT with UFH. 
Heparin-induced thrombocytopenia can occur with UFH. However, the 
short half-life of UFH remains a significant advantage.
Alternatives to UFH for acute anticoagulation include low-molecular-
weight heparins (LMWHs) such as enoxaparin and dalteparin. Laboratory 
monitoring is not required, but doses are adjusted for renal impairment or 
obesity. Fondaparinux, a pentasaccharide, is another parenteral alternative 
to UFH that does not require laboratory monitoring but does require dose 
adjustment for body weight and renal insufficiency. In pts with heparin-
induced thrombocytopenia, direct thrombin inhibitors (e.g., argatroban, 
lepirudin, or bivalirudin) should be used.
After initiating treatment with a parenteral agent, warfarin is typically 
used for long-term oral anticoagulation. Warfarin can be initiated soon 
after a parenteral agent is given; however, 5–7 days are required for war-
farin to achieve therapeutic anticoagulation. Warfarin is given to achieve 
a therapeutic international normalized ratio (INR) of the prothrombin 
time, which is typically an INR of 2.0–3.0. Pts vary widely in their 
required warfarin doses; dosing often begins at 5 mg/d, with adjustment 
based on the INR.
The most troublesome adverse event from anticoagulation treatment 
is hemorrhage. For severe hemorrhage while undergoing treatment with 
UFH or LMWH, protamine can be given to reverse anticoagulation. 
Severe bleeding while anticoagulated with warfarin can be treated with 
fresh frozen plasma or cryoprecipitate; milder hemorrhage or markedly 
elevated INR values can be treated with vitamin K. Recombinant human 
coagulation factor VIIa provides an off-label option to manage catastrophic 
bleeding from warfarin. Warfarin should be avoided in pregnant pts.
The duration of anticoagulation for an initial DVT or PE is at least 
3–6 months. Pts with DVT or PE in the setting of trauma, surgery, or 
high estrogen states have a low recurrence rate after 3–6 months of 
anticoagulation. However, recurrence rate is high in pts with cancer or 
with idiopathic, unprovoked DVT or PE, and prolonged anticoagulation 
should be considered. Recurrent DVT or PE typically requires lifelong 
anticoagulation.
OTHER TREATMENT MODALITIES Although anticoagulation is the 
mainstay of therapy for venous thromboembolism, additional thera-
peutic modalities also can be employed, based on risk stratification
CHAPTER 143
933
Interstitial Lung Disease
For a more detailed discussion, see Goldhaber SZ: Deep 
Venous Thrombosis and Pulmonary Thromboembolism, 
Chap. 262, p. 2170, in HPIM-18.
FIGURE 142-2 Acute management of pulmonary thromboembolism. IVC, inferior 
vena cava; RV, right ventricle.
Risk stratify
Normotension
plus normal RV
Normotension
plus RV hypokinesis
Hypotension
Anticoagulation
plus
thrombolysis
IVC filter
Embolectomy:
catheter/surgical
Anticoagulation
alone
Secondary
prevention
Individualize
therapy
Primary
therapy
ALGORITHM FOR PE MANAGEMENT
(Fig. 142-2). Inferior vena cava filters can be used if thrombosis recurs 
despite adequate anticoagulation or if active bleeding precludes antico-
agulation. Fibrinolytic therapy (often with tissue plasminogen activator) 
should be considered for PE causing right heart failure, although the risk 
of hemorrhage is significant. Surgical or catheter embolectomy also can 
be considered for massive PE.
If PE pts develop chronic thromboembolic pulmonary hypertension, 
surgical intervention (pulmonary thromboendarterectomy) can be per-
formed. There is no effective therapy for postphlebitic syndrome.
CHAPTER 143
Interstitial Lung Disease
Interstitial lung diseases (ILDs) are a group of >200 disease entities char-
acterized by diffuse parenchymal abnormalities. ILDs can be classified into 
two major groups: (1) diseases associated with predominant inflammation 
and fibrosis, and (2) diseases with predominantly granulomatous reaction 
in interstitial or vascular areas (Table 143-1). ILDs are nonmalignant and 
noninfectious, and they are typically chronic. The differential diagnosis 
of ILDs often includes infections (e.g., atypical mycobacteria, fungi) and 
SECTION 9
934
Pulmonology
TABLE 143-1  MAJOR CATEGORIES OF ALVEOLAR AND INTERSTITIAL 
INFLAMMATORY LUNG DISEASE
Lung Response: Alveolitis, Interstitial Inflammation, and Fibrosis
Known cause
Asbestos
Radiation
Fumes, gases
Aspiration pneumonia
Drugs (antibiotics, amiodarone, gold) and 
chemotherapy drugs
Residual of adult respiratory 
distress syndrome
Smoking-related
  Desquamative interstitial pneumonia
  Respiratory bronchiolitis-associated 
interstitial lung disease
  Langerhans cell granulomatosis 
(eosinophilic granulomatosis of the 
lung)
Unknown cause
Idiopathic interstitial pneumonias
Pulmonary alveolar proteinosis
  Idiopathic pulmonary fibrosis (usual 
interstitial pneumonia)
Lymphocytic infiltrative disorders 
(lymphocytic interstitial pneumo-
nitis associated with connective 
tissue disease)
Eosinophilic pneumonias
  Acute interstitial pneumonia (diffuse 
alveolar damage)
Lymphangioleiomyomatosis
Amyloidosis
  Cryptogenic organizing pneumonia 
(bronchiolitis obliterans with organizing 
pneumonia)
 Nonspecific interstitial pneumonia
Inherited diseases
  Tuberous sclerosis, neuro-
fibromatosis, Niemann-Pick 
disease, Gaucher’s disease, 
Hermansky-Pudlak syndrome
Connective tissue diseases
Gastrointestinal or liver diseases 
(Crohn’s disease, primary biliary 
cirrhosis, chronic active hepatitis, 
ulcerative colitis)
  Systemic lupus erythematosus, 
rheumatoid arthritis, ankylosing 
spondylitis, systemic sclerosis, 
Sjögren’s syndrome, polymyositis-
dermatomyositis
Graft-versus-host disease (bone 
marrow transplantation; solid 
organ transplantation)
Pulmonary hemorrhage syndromes
  Goodpasture’s syndrome, idiopathic 
pulmonary hemosiderosis, isolated 
pulmonary capillaritis
CHAPTER 143
935
Interstitial Lung Disease
TABLE 143-1  MAJOR CATEGORIES OF ALVEOLAR AND INTERSTITIAL 
INFLAMMATORY LUNG DISEASE (CONTINUED)
Lung Response: Granulomatous
Known cause
Hypersensitivity pneumonitis (organic 
dusts)
Inorganic dusts: beryllium, silica
Unknown cause
Sarcoidosis
Bronchocentric granulomatosis
Granulomatous vasculitides 
Lymphomatoid granulomatosis
Granulomatosis with polyangiitis 
(Wegener’s), allergic granulomatosis of 
Churg-Strauss
malignancy (e.g., bronchioloalveolar cell carcinoma, lymphangitic carcino-
matosis). One of the most common ILDs associated with a granulomatous 
reaction, sarcoidosis, is discussed in Chap. 177. Many ILDs are of unknown 
etiology; however, some ILDs are known to be associated with specific envi-
ronmental exposures including asbestos, radiation therapy, and organic dusts.
Interstitial Lung Disease
APPROACH TO THE
PATIENT
History: Common presenting symptoms for pts with ILDs include 
dyspnea and nonproductive cough. Symptom onset and duration can 
assist in the differential diagnosis. Chronic symptoms (over months 
to years) are typically seen in most ILDs, including idiopathic pulmo-
nary fibrosis (IPF), pneumoconioses, and pulmonary Langerhans cell 
histiocytosis (PLCH or eosinophilic granuloma). Subacute symptoms 
(over weeks to months) can also be observed in many ILDs, especially 
in sarcoidosis, drug-induced ILDs, cryptogenic organizing pneumonitis 
[COP, also known as bronchiolitis obliterans with organizing pneumo-
nia (BOOP)], and alveolar hemorrhage syndromes. Acute presentations 
are uncommon for ILDs but are typically observed with acute interstitial 
pneumonia (AIP), and they can also occur with eosinophilic pneumonia 
and hypersensitivity pneumonitis. Sudden onset of dyspnea can indi-
cate a pneumothorax, which occurs in PLCH and tuberous sclerosis/
lymphangioleiomyomatosis. Fatigue and weight loss are common in all 
ILDs. Episodic presentations also are unusual, but they are more typical 
for eosinophilic pneumonia, hypersensitivity pneumonitis, and COP.
Age at presentation also can guide the differential diagnosis. IPF 
pts typically present at age >60, while sarcoidosis, PLCH, lymphangi-
oleiomyomatosis (LAM), and connective tissue disease–related ILD 
often present between the ages of 20 and 40. LAM occurs exclusively in 
women, while ILD in rheumatoid arthritis (RA) typically occurs in men. 
Cigarette smoking is a risk factor for several ILDs including IPF, PLCH, 
SECTION 9
936
Pulmonology
Goodpasture’s syndrome, and respiratory bronchiolitis. Occupational 
exposures can be important risk factors for many types of hypersensi-
tivity pneumonitis as well as pneumoconioses. Medical treatment with 
radiation and drugs also should be assessed. 
Physical examination: Tachypnea and bibasilar end-inspiratory crackles 
are commonly observed in inflammatory ILDs, but they are less fre-
quent in granulomatous ILDs. Clubbing of the digits is observed in some 
pts with advanced ILD.
Laboratory studies: Antinuclear antibodies and rheumatoid factor at low 
titers are observed in some IPF pts without a connective tissue disorder. 
Specific serum antibodies can confirm exposure to relevant antigens in 
hypersensitivity pneumonitis, but they do not prove causation. 
Chest imaging: Chest x-ray (CXR) does not typically provide a specific 
diagnosis but often raises the possibility of ILD by demonstrating a 
bibasilar reticular pattern. Upper-lung-zone predominance of nodular 
opacities is noted in several ILDs, including PLCH, sarcoidosis, chronic 
hypersensitivity pneumonitis, and silicosis. High-resolution chest CT 
scans provide improved sensitivity for the early detection of ILDs and may 
be sufficiently specific to allow a diagnosis to be made in ILDs such as IPF, 
PLCH, and asbestosis. Honeycombing is indicative of advanced fibrosis.
Pulmonary function testing: Lung function measurements can assess the 
extent of pulmonary involvement in pts with ILD. Most ILDs produce a 
restrictive ventilatory defect with reduced total lung capacity. The forced 
expiratory volume in 1 s (FEV1) and forced vital capacity (FVC) are typi-
cally reduced, but the ratio of FEV1/FVC is usually normal to increased. 
Reduction in the diffusing capacity of the lung for carbon monoxide 
(Dlco) is commonly observed. Cardiopulmonary exercise testing can 
be useful to detect exercise-induced hypoxemia.
Tissue and cellular examination: In order to provide a specific diagnosis 
and assess disease activity, lung biopsy is often required. Bronchoscopy 
with transbronchial biopsies can be diagnostic in some ILDs, including 
sarcoidosis and eosinophilic pneumonia. In addition, bronchoscopy can 
assist by excluding chronic infections or lymphangitic carcinomatosis. 
However, the more extensive tissue samples provided by open lung biop-
sies, often obtained by video-assisted thoracic surgery, are often required 
to establish a specific diagnosis. Evidence for diffuse end-stage disease, 
such as widespread honeycombing, or other major operative risks are 
relative contraindications to lung biopsy procedures.
PRINCIPLES OF MANAGEMENT
If a causative agent can be identified (e.g., thermophilic actinomyces in 
hypersensitivity pneumonitis), cessation of exposure to that agent is imper-
ative. Because the response to treatment among different ILDs is so variable, 
identification of treatable causes is essential. Glucocorticoids can be highly 
effective for eosinophilic pneumonias, COP, hypersensitivity pneumonitis 
(HP), radiation pneumonitis, and drug-induced ILD. Prednisone at 
CHAPTER 143
937
Interstitial Lung Disease
0.5–1.0 mg/kg qd is commonly given for 4–12 weeks, followed by a gradual 
tapering dose. On the other hand, glucocorticoids are typically not benefi-
cial in IPF. Smoking cessation is essential, especially for smoking-related 
ILDs such as PLCH and respiratory bronchiolitis.
Supportive therapeutic measures include providing supplemental O2 for 
pts with significant hypoxemia (Pao2 <55 mmHg at rest and/or with exer-
cise). Pulmonary rehabilitation may also be beneficial. For young pts with 
end-stage ILD, lung transplantation should be considered.
SELECTED INDIVIDUAL ILDS
Idiopathic Pulmonary Fibrosis
IPF, which is also known as usual interstitial pneumonia (UIP), is the most 
common idiopathic interstitial pneumonia. Cigarette smoking is a risk factor 
for IPF. Common respiratory symptoms include exertional dyspnea and a 
nonproductive cough. Physical examination is notable for inspiratory crack-
les at the lung bases. Clubbing may occur. High-resolution chest CT scans 
show subpleural reticular opacities predominantly in the lower lung fields, 
which are associated with honeycombing in advanced disease. Pulmonary 
function tests reveal a restrictive ventilatory defect with reduced Dlco. 
Surgical lung biopsy is usually required to confirm the diagnosis, although 
classic presentations may not require a biopsy. IPF can include acute exac-
erbations characterized by accelerated clinical deterioration over days to 
weeks. IPF is poorly responsive to available pharmacologic treatment.
Nonspecific Interstitial Pneumonia
Nonspecific interstitial pneumonia (NSIP) is a histologic pattern that can 
be observed in connective tissue disease, drug-induced ILD, and chronic 
HP. NSIP is a subacute restrictive process with similar presentation to IPF. 
High-resolution CT (HRCT) shows bilateral ground-glass opacities, and 
honeycombing is rare. Unlike IPF, NSIP pts have a good prognosis and typi-
cally respond well to systemic glucocorticoid treatment. 
ILD Associated with Connective Tissue Disorders 
Pulmonary manifestations may precede systemic manifestations of a 
connective tissue disorder. In addition to direct pulmonary involvement, it 
is necessary to consider complications of therapy (e.g., opportunistic infec-
tions), respiratory muscle weakness, esophageal dysfunction, and associated 
malignancies as contributors to pulmonary parenchymal abnormalities in 
pts with connective tissue disorders.
Progressive systemic sclerosis (scleroderma) commonly includes ILD as 
well as pulmonary vascular disease. Lung involvement tends to be highly 
resistant to available treatment.
In addition to pulmonary fibrosis (ILD), RA can involve a range of pul-
monary complications, including pleural effusions, pulmonary nodules, 
and pulmonary vasculitis. ILD in RA pts is more common in men.
Systemic lupus erythematosus (SLE) also can involve a range of pul-
monary complications, including pleural effusions, pulmonary vascular 
disease, pulmonary hemorrhage, and BOOP. Chronic, progressive ILD is 
not commonly observed.
SECTION 9
938
Pulmonology
Cryptogenic Organizing Pneumonia 
When the BOOP pathologic pattern occurs without another primary pul-
monary disorder, the term cryptogenic organizing pneumonia (COP) is used. 
COP may present with a flulike illness. Recurrent and migratory pulmonary 
opacities are common. Glucocorticoid therapy is often effective.
Desquamative Interstitial Pneumonia and Respiratory Bronchiolitis-
Associated ILD
Desquamative interstitial pneumonia (DIP) includes extensive macrophage 
accumulation in intraalveolar spaces with minimal fibrosis. It is seen almost 
exclusively in cigarette smokers and improves with smoking cessation. 
Respiratory bronchiolitis-associated ILD is a subset of DIP that includes 
bronchial wall thickening, ground-glass opacities, and air trapping on 
HRCT; it also resolves in most pts after smoking cessation.
Pulmonary Alveolar Proteinosis 
Pulmonary alveolar proteinosis (PAP) is a rare diffuse lung disease, with a 
male predominance, that involves the accumulation of lipoproteinaceous 
material in the distal airspaces, rather than a classic ILD. More common in 
males, PAP usually presents insidiously, with dyspnea, fatigue, weight loss, 
cough, and low-grade fever. Whole-lung lavage is often of therapeutic benefit.
Pulmonary Infiltrates with Eosinophilia 
Several disorders are characterized by pulmonary infiltrates and peripheral 
blood eosinophilia. Tropical eosinophilia relates to parasitic infection; drug-
induced eosinophilic pneumonias are more common in the United States. 
Löffler’s syndrome typically includes migratory pulmonary infiltrates and 
minimal clinical symptoms. Acute eosinophilic pneumonia involves pulmo-
nary infiltrates with severe hypoxemia. Chronic eosinophilic pneumonia is 
often in the differential diagnosis with other ILDs; it includes fever, cough, 
and weight loss, with a CXR notable for peripheral infiltrates. Eosinophilic 
pneumonias tend to be rapidly responsive to glucocorticoid therapy.
Alveolar Hemorrhage Syndromes 
A variety of diseases can cause diffuse alveolar hemorrhage, including systemic 
vasculitic syndromes [e.g., granulomatosis with polyangiitis (Wegener’s)], con-
nective tissue diseases (e.g., SLE), and Goodpasture’s syndrome. Although 
typically an acute process, recurrent episodes can lead to pulmonary fibrosis. 
Hemoptysis may not occur initially in one-third of cases. CXR typically shows 
patchy or diffuse alveolar opacities. The Dlco may be increased. High doses of 
IV methylprednisolone are typically required, followed by gradual tapering of sys-
temic steroid doses. Plasmapheresis may be effective for Goodpasture’s syndrome.
Pulmonary Langerhans Cell Histiocytosis 
PLCH is a smoking-related diffuse lung disease that typically affects men 
20 to 40 years of age. Presenting symptoms often include cough, dyspnea, 
chest pain, weight loss, and fever. Pneumothorax occurs in 25% of pts. 
High-resolution chest CT scan reveals upper-zone-predominant nodular 
opacities and thin-walled cysts, which are virtually diagnostic of this disor-
der. Smoking cessation is the key therapeutic intervention.
CHAPTER 144
939
Diseases of the Pleura and Mediastinum
Hypersensitivity Pneumonitis 
HP is an inflammatory lung disorder caused by repeated inhalation of an 
organic agent in a susceptible individual. Many organic agents have been 
implicated. Clinical presentations can be acute, with cough, fever, mal-
aise, and dyspnea developing within 6–8 h after exposure; subacute, with 
cough and dyspnea that can become progressively worse over weeks; and 
chronic, which can appear similar to IPF. Peripheral blood eosinophilia 
is not observed. Serum precipitins can be measured as an indicator of an 
environmental exposure. Although helpful in implicating specific agents, the 
presence of a specific serum precipitin is not diagnostic since many exposed 
individuals without HP will have such precipitins; false-negative results can 
also occur. Diagnosis is made based on symptoms, physical findings, pul-
monary function tests (restrictive or obstructive pattern), and radiographic 
studies (chest CT scans typically show ground-glass opacification in acute 
and subacute forms) that are consistent with HP; history of exposure to a 
recognized antigen; and presence of an antibody to that antigen. In some 
cases, lung biopsy (transbronchial or open lung) may be required to confirm 
the diagnosis. Treatment involves avoiding exposure to the causative antigen; 
systemic corticosteroids may be required in subacute or chronic HP.
For a more detailed discussion, see King TE Jr: Interstitial 
Lung Diseases, Chap. 261, p. 2160; Gerke AK, Hunninghake 
GW: Hypersensitivity Pneumonitis and Pulmonary Infiltrates 
With Eosinophilia, Chap. 255, p. 2116, in HPIM-18.
CHAPTER 144
Diseases of the Pleura and 
Mediastinum
PLEURAL EFFUSION
Etiology and Diagnostic Approach 
Pleural effusion is defined as excess fluid accumulation in the pleural space. 
It can result from increased pleural fluid formation in the lung interstitium, 
parietal pleura, or peritoneal cavity, or from decreased pleural fluid removal 
by the parietal pleural lymphatics.
The two major classes of pleural effusions are transudates, which are 
caused by systemic influences on pleural fluid formation or resorption, and 
exudates, which are caused by local influences on pleural fluid formation 
and resorption. Common causes of transudative effusions are left ventricu-
lar heart failure, cirrhosis, and nephrotic syndrome. Common causes of 
exudative effusions are bacterial pneumonia, malignancy, viral infection, 
and pulmonary embolism. A more comprehensive list of the etiologies of 
SECTION 9
940
Pulmonology
transudative and exudative pleural effusions is provided in Table 144-1. 
Additional diagnostic procedures are indicated with exudative effusions to 
define the cause of the local disease.
Exudates fulfill at least one of the following three criteria: high pleural 
fluid/serum protein ratio (>0.5), pleural fluid lactate dehydrogenase (LDH) 
greater than two-thirds of the laboratory normal upper limit for serum 
LDH, or pleural/serum LDH ratio >0.6. Transudative effusions typically 
do not meet any of these criteria. However, these criteria misidentify about 
25% of transudates as exudates. For exudative effusions, pleural fluid should 
also be tested for pH, glucose, white blood cell count with differential, 
microbiologic studies, cytology, and amylase. An algorithm for determining 
the etiology of a pleural effusion is presented in Fig. 144-1.
A subset of the most common types of pleural effusions is described in 
the following sections.
Transudative Pleural Effusions 
Transudative pleural effusions related to left ventricular failure are often 
bilateral; if unilateral, right-sided effusions are more common than left-sided 
effusions. Thoracentesis is not always required to confirm the transudative 
nature of the pleural effusions if congestive heart failure is present; however, 
if the effusions are not comparable in size, if the pt is febrile, or if pleuritic 
chest pain is present, thoracentesis should be strongly considered. A pleural 
fluid N-terminal pro-brain natriuretic peptide (NT-proBNP) >1500 pg/mL is 
highly suggestive of an effusion related to congestive heart failure.
Parapneumonic Effusion/Empyema 
Parapneumonic effusions are exudates that are associated with contiguous 
bacterial lung infections, including pneumonia and lung abscess. In the 
setting of pulmonary infections, the presence of free pleural fluid can be 
demonstrated with a lateral decubitus x-ray, chest CT scan, or ultrasound. If 
the pleural fluid is grossly purulent, it is referred to as an empyema.
Tube thoracostomy (i.e., chest tube) for management of parapneumonic 
effusions is likely indicated if any of the following applies (in descending 
order of importance): (1) gross pus is present, (2) Gram’s stain or culture 
of pleural fluid is positive, (3) pleural fluid glucose is <3.3 mmol/L (<60 
mg/dL), (4) pleural fluid pH is <7.20, or (5) there is loculated pleural fluid.
If chest tube drainage does not result in complete removal of pleural fluid, 
a fibrinolytic agent (e.g., tissue plasminogen activator 10 mg) can be instilled 
through the tube, or thoracoscopy can be performed to lyse adhesions. If 
these approaches are not effective, surgical decortication may be required.
Malignant Pleural Effusions 
Metastatic cancer is a common cause of exudative pleural effusions. Tumors 
that frequently cause malignant effusions include lung cancer, breast cancer, 
and lymphoma. The pleural fluid glucose level may be markedly reduced. 
Cytologic examination of the pleural fluid is usually diagnostic. If cytologic 
examination of thoracentesis fluid is negative, thoracoscopy should be 
considered. Symptomatic relief of dyspnea can be provided by therapeutic 
thoracentesis. If the pleural fluid recurs, pleural sclerosis can be performed 
CHAPTER 144
941
Diseases of the Pleura and Mediastinum
TABLE 144-1 DIFFERENTIAL DIAGNOSES OF PLEURAL EFFUSIONS
Transudative Pleural Effusions
1. Congestive heart failure
2. Cirrhosis
3. Pulmonary embolism
4. Nephrotic syndrome
5. Peritoneal dialysis
6. Superior vena cava obstruction
7. Myxedema
8. Urinothorax
Exudative Pleural Effusions
1. Neoplastic diseases
a. Metastatic disease
b. Mesothelioma
2. Infectious diseases
a. Bacterial infections
b. Tuberculosis
c. Fungal infections
d. Viral infections
e. Parasitic infections
3. Pulmonary embolism
4. Gastrointestinal disease
a. Esophageal perforation
b. Pancreatic disease
c. Intraabdominal abscess
d. Diaphragmatic hernia
e.  After abdominal surgery
f.  Endoscopic variceal sclerotherapy
g. After liver transplant
5. Collagen-vascular diseases
a. Rheumatoid pleuritis
b. Systemic lupus erythematosus
c. Drug-induced lupus
d. Immunoblastic lymphadenopathy
e. Sjögren’s syndrome
f.  Granulomatosis with polyangiitis (Wegener’s)
g. Churg-Strauss syndrome
6. Post–coronary artery bypass surgery
(continued)
SECTION 9
942
Pulmonology
TABLE 144-1  DIFFERENTIAL DIAGNOSES OF PLEURAL EFFUSIONS 
(CONTINUED)
Exudative Pleural Effusions
  7. Asbestos exposure
  8. Sarcoidosis
  9. Uremia
10. Meigs’ syndrome
11. Yellow nail syndrome
12. Drug-induced pleural disease
a. Nitrofurantoin
b. Dantrolene
c. Methysergide
d. Bromocriptine
e. Procarbazine
f.  Amiodarone
g. Dasatinib 
13. Trapped lung
14. Radiation therapy
15. Post–cardiac injury syndrome
16. Hemothorax
17. Iatrogenic injury
18. Ovarian hyperstimulation syndrome
19. Pericardial disease
20. Chylothorax
with pleural abrasion via thoracoscopy or with instillation of a scleros-
ing agent, such as doxycycline, through a chest tube; alternatively, a small 
indwelling catheter can be placed.
Effusions Related to Pulmonary Thromboembolism 
Pleural effusions in pulmonary thromboembolism are usually exudative but 
can be transudative. The presence of a pleural effusion does not alter the 
standard treatment for pulmonary embolism (Chap. 142). If the effusion 
increases in size during anticoagulation treatment, possible explanations 
include recurrent embolism, hemothorax, or empyema.
Tuberculous Pleuritis 
Usually associated with primary tuberculosis (Tb) infection, tuberculous 
pleural effusions are exudative with predominant lymphocytosis. High levels 
of Tb markers in the pleural fluid, such as adenosine deaminase and inter-
feron γ, are present. Mycobacterial cultures obtained from pleural fluid (low 
positive culture rate) or pleural biopsy (high positive culture rate with needle 
biopsy or thoracoscopy) can definitively confirm the diagnosis. Although 
CHAPTER 144
943
Diseases of the Pleura and Mediastinum
Perform diagnostic thoracentesis
Measure pleural fluid protein and LDH
Exudate
Further diagnostic procedures
Transudate
Treat CHF, cirrhosis, nephrosis
Measure PF glucose, amylase
Obtain PF cytology
Obtain differential cell count
Culture, stain PF
PF marker for TB
Consider: Esophageal rupture
Pancreatic pleural
effusion
Malignancy
Amylase elevated
Consider: Malignancy
Bacterial infections
Rheumatoid
pleuritis
Glucose < 60 mg/dL
No diagnosis
Consider pulmonary
embolus (spiral CT
or lung scan)
Treat for PE
Treat for TB
PF marker for TB
Observe
Consider thoracoscopy
or open pleural biopsy
Any of following met?
PF/serum protein > 0.5
PF/serum LDH > 0.6
PF LDH > 2/3 upper normal serum limit
Pleural Effusion
Yes
No
Yes
Yes
Yes
No
No
No
SYMPTOMS IMPROVING
DIAGNOSTIC ALGORITHM OF PLEURAL EFFUSION
FIGURE 144-1 Approach to the diagnosis of pleural effusions. CHF, congestive 
heart failure; CT, computed tomography; LDH, lactate dehydrogenase; PE, pulmonary 
embolism; PF, pleural fluid; TB, tuberculosis. 
SECTION 9
944
Pulmonology
tuberculous pleuritis often resolves without treatment, active tuberculosis 
can develop years later if antimycobacterial treatment is not given.
Effusion Secondary to Viral Infection
No diagnosis is established for approximately 20% of exudative effusions, 
and viral infections likely account for many of these cases. Pleural effusions 
related to viral infection resolve spontaneously.
Rheumatoid Arthritis (RA) 
RA can cause pleural effusions that are exudative. Effusions may pre-
cede particular symptoms. Pleural fluid shows very low glucose and pH. 
Rheumatoid pleural effusions are usually seen in males.
Chylothorax
Chylothorax is an exudative pleural effusion with milky fluid and an ele-
vated triglyceride level (>1.2 mmol/L or >110 mg/dL). The most common 
etiologies are trauma to the thoracic duct and mediastinal tumors. Chest 
tube placement is often required, and octreotide administration may be 
beneficial. Prolonged chest tube drainage can lead to malnutrition.
Hemothorax
Hemothorax commonly results from trauma; blood vessel rupture and 
tumor are other potential etiologies. When frankly bloody pleural fluid is 
noted at thoracentesis, the hematocrit should be tested. If the hematocrit of 
the pleural fluid is >50% of the bloodstream hematocrit, a hemothorax is 
present. Chest tube placement is typically required. If pleural blood loss 
is >200 mL/h, thoracic surgical intervention should be pursued.
PNEUMOTHORAX
Pneumothorax (Ptx) is defined as gas in the pleural space. Spontaneous 
Ptx occurs without trauma to the thorax. Primary spontaneous Ptx occurs 
in the absence of underlying lung disease and typically results from apical 
pleural blebs. Simple aspiration may be adequate treatment for an initial 
primary spontaneous Ptx, but recurrence typically requires thoracoscopic 
intervention. Secondary spontaneous Ptx occurs in the setting of underly-
ing lung disease, most commonly chronic obstructive pulmonary disease. 
Chest tube placement is typically required for secondary spontaneous Ptx; 
thoracoscopy and/or pleurodesis (with pleural abrasion or a sclerosing 
agent) should also be considered.
Traumatic Ptx, resulting from either penetrating or nonpenetrating chest 
trauma, usually requires chest tube placement. Iatrogenic Ptx can occur from 
transthoracic needle biopsy, thoracentesis, placement of a central venous 
catheter, or transbronchial biopsy. Treatment with O2 or aspiration is often 
adequate for iatrogenic Ptx, but chest tube placement may be required. 
Tension Ptx can result from trauma or mechanical ventilation. Positive pleu-
ral pressure in mechanical ventilation can rapidly lead to a tension Ptx with 
reduced cardiac output. Urgent treatment is required, either with a chest 
tube or, if not immediately available, with a large-bore needle inserted into 
the pleural space through the second anterior intercostal space.
CHAPTER 145
945
Disorders of Ventilation
MEDIASTINAL DISEASE
Mediastinitis
Mediastinitis can be an acute or chronic process. Acute mediastinitis can result 
from esophageal perforation or after cardiac surgery with median sternotomy. 
Esophageal perforation can occur spontaneously or iatrogenically; surgical 
exploration of the mediastinum, repair of the esophageal perforation, and 
drainage of the pleural space and mediastinum are required. Mediastinitis after 
median sternotomy typically presents with wound drainage and is diagnosed 
by mediastinal needle aspiration. Treatment requires immediate drainage, 
debridement, and IV antibiotics.
Chronic mediastinitis can cause a spectrum of disease ranging from granu-
lomatous inflammation of lymph nodes to fibrosing mediastinitis. Chronic 
mediastinitis is commonly caused by Tb and histoplasmosis; other etiologies 
are also possible, including sarcoidosis and silicosis. Granulomatous mediastinal 
inflammation is usually asymptomatic. Fibrosing mediastinitis causes symptoms 
related to compression of mediastinal structures, such as the superior vena cava, 
esophagus, or large airways. Fibrosing mediastinitis is very difficult to treat.
Mediastinal Masses 
Different types of mediastinal masses are found in the anterior, middle, 
and posterior mediastinal compartments. The most common mass lesions 
in the anterior mediastinum are thymomas, lymphomas, teratomas, and 
thyroid lesions. In the middle mediastinum, vascular masses, enlarged 
lymph nodes (e.g., metastatic cancer or granulomatous disease), and bron-
chogenic or pleuropericardial cysts are found. Posterior mediastinal masses 
include neurogenic tumors, gastroenteric cysts, and esophageal diverticula.
CT scans are invaluable for evaluating mediastinal masses. Barium swal-
low studies can assist in evaluating posterior mediastinal masses. Biopsy 
procedures are typically required to diagnose mediastinal masses; needle 
biopsy procedures (e.g., percutaneous or bronchoscopy), mediastinoscopy, 
and thoracoscopy are potential options.
For a more detailed discussion, see Light RW: Disorders of the 
Pleura and Mediastinum, Chap. 263, p. 2178, in HPIM-18.
CHAPTER 145
Disorders of Ventilation
DEFINITION
Ventilatory disorders, reflected by abnormalities in Paco2, include alterations 
in CO2 production, minute ventilation, or respiratory system dead space. Many 
diseases can cause acute elevations in CO2 production; chronic ventilatory dis-
orders relate to inappropriate minute ventilation or dead space fraction. 
SECTION 9
946
Pulmonology
HYPOVENTILATION
� ETIOLOGY
Chronic hypoventilation can result from parenchymal lung diseases, chest wall 
abnormalities (e.g., severe kyphoscoliosis), sleep-disordered breathing, neuro-
muscular diseases, and abnormal respiratory drive. Obesity-hypoventilation 
syndrome includes body mass index ≥30 kg/m2; sleep-disordered breathing 
(typically obstructive sleep apnea); Paco2 >45 mmHg; and Pao2 <70 mmHg. 
Central hypoventilation syndrome is a rare disorder that includes a failure of 
the normal respiratory response to hypoxemia and/or hypercapnia. 
� CLINICAL ASSESSMENT
Key symptoms of hypoventilation can include exertional dyspnea, orthopnea, 
daytime somnolence, morning headache, and anxiety. Parenchymal lung 
diseases, such as chronic obstructive pulmonary disease and interstitial lung 
disease, often include dyspnea and cough. Sleep-disordered breathing includes 
daytime somnolence, snoring, and fragmented sleep. Orthopnea is common in 
neuromuscular disorders, although weakness of the extremities or other muscle 
groups often precedes respiratory system muscular weakness. Hypoventilation 
related to neuromuscular and chest wall disorders progresses from asymptom-
atic to nocturnal hypoventilation to daytime hypercapnia. Chronic narcotic use 
and hypothyroidism can lead to reduced respiratory drive. 
Physical examination, chest radiographic studies (chest x-ray and pos-
sibly chest CT), and pulmonary function tests reveal most lung parenchy-
mal and chest wall causes of hypoventilation. Measurement of maximal 
inspiratory and expiratory pressures can assess respiratory muscle strength. 
Polysomnography to assess for obstructive sleep apnea should also be 
considered. When pts have hypercapnia with normal pulmonary function, 
normal respiratory muscle strength, and normal alveolar-arterial Po2 differ-
ence, respiratory drive abnormalities may be present, which can be revealed 
by polysomnography. Laboratory findings include increased Paco2 and often 
reduced Pao2 as well. Compensatory increases in plasma bicarbonate levels 
and normal pH are seen in chronic hypoventilation. Eventually, pulmonary 
hypertension and cor pulmonale can develop. In central hypoventilation 
syndrome, hypercapnia worsens substantially during sleep. 
Hypoventilation
TREATMENT
In all forms of hypoventilation, supplemental oxygen should be given 
to correct hypoxemia. Obesity-hypoventilation is treated with weight 
reduction and continuous positive airway pressure (CPAP) during sleep. 
Some pts may require bilevel positive airway pressure (BiPAP). 
Noninvasive positive pressure ventilation during sleep can provide 
ventilatory support and treat sleep apnea associated with neuromus-
cular disorders, chest wall disorders, and central hypoventilation. With 
progressive neuromuscular disorders, full-time mechanical ventilatory 
support is often required. 
Pts with respiratory drive disorders may benefit from phrenic nerve 
pacing
CHAPTER 146
947
Sleep Apnea
HYPERVENTILATION
� ETIOLOGY
Hyperventilation is caused by ventilation in excess of requirements based 
on CO2  production, leading to a reduced Paco2 . Although anxiety can 
contribute to the initiation and progression of hyperventilation, hyper-
ventilation is not always related to anxiety. Hyperventilation can precede 
systemic illnesses such as diabetic ketoacidosis. 
� CLINICAL ASSESSMENT
Symptoms of chronic hyperventilation can include dyspnea, paresthesias, 
headache, tetany, and atypical chest pain. Laboratory findings of chronic 
hyperventilation include a reduced Paco2, but low serum bicarbonate level 
and near normal pH on arterial blood gas analysis. 
Hyperventilation
TREATMENT
Treatment of chronic hyperventilation is problematic. Identification of 
initiating factors and excluding alternative diagnoses can be helpful.
For a more detailed discussion, see McConville JF, Solway J: 
Disorders of Ventilation, Chap. 264, p. 2182, in HPIM-18.
CHAPTER 146
Sleep Apnea
� DEFINITION AND ETIOLOGY
Sleep apnea is defined by the presence of at least five episodes per hour of apnea 
(no airflow for ≥10 seconds) and/or hypopnea (reduction in airflow by at least 
50% from baseline for ≥10 seconds). Obstructive sleep apnea/hypopnea syn-
drome (OSAHS) is the most common medical cause of daytime somnolence. 
OSAHS is caused by upper airway closure during inspiration, punctuated by 
brief arousals that terminate apneic episodes. Risk factors for OSAHS include 
obesity and anatomic shortening of the mandible or maxilla. Hypothyroidism 
and acromegaly are systemic diseases associated with OSAHS.
Central sleep apnea (CSA) is characterized by respiratory pauses during 
sleep related to absence of respiratory effort. CSA is commonly found in 
heart failure and stroke pts; spontaneous CSA is rare.
� CLINICAL ASSESSMENT
Symptoms of OSAHS include daytime somnolence, impaired cognitive 
performance and driving skills, nocturnal choking, nocturia, and decreased 
libido. Loud snoring is typically reported by sleeping partners. Depression 
SECTION 9
948
Pulmonology
and hypertension are associated with OSAHS, and cardiovascular disease 
risk may be increased. Differential diagnosis of OSAHS includes insufficient 
amount of sleep, somnolence related to shift work, depression, drug effects 
(both stimulants and sedatives), narcolepsy, and idiopathic hypersomnolence. 
Severity of somnolence can be assessed with the Epworth Sleepiness 
Score, although somnolent pts who don’t fall asleep at inappropriate times 
may be missed with this questionnaire. Obtaining the sleep history from the 
pt’s partner can be very helpful. Daytime somnolence may be seen in CSA 
as well as OSAHS. 
Physical examination should include assessment of body mass index, jaw 
and upper airway structure, and blood pressure. Potentially related systemic 
illnesses, including acromegaly and hypothyroidism, should be considered. 
Diagnostic testing often includes a polysomnogram in a sleep laboratory. 
However, limited sleep studies without neurophysiologic monitoring may be 
used for screening. Significant daytime somnolence with a negative limited 
screening study should be followed by a full polysomnogram. Many apneic 
events previously labeled as central apneas in polysomnographic studies may 
have been obstructive events despite lack of thoracoabdominal movement. 
Sleep Apnea
TREATMENT
Pts with significant daytime somnolence and >15 apneic and/or hypop-
neic events per hour clearly benefit from treatment; benefits are less 
compelling with milder degrees of OSAHS. Efforts to reduce weight in 
obese pts, to limit alcohol use, and to carefully withdraw sedative medi-
cations should be pursued. 
The primary therapy for OSAHS is continuous positive airway pres-
sure (CPAP). Selecting a comfortable mask delivery system and titrating 
the appropriate amount of CPAP are essential. Airway drying related to 
CPAP can be reduced by including a heated humidification component 
in the CPAP system. Alternative OSAHS therapies include mandibular 
repositioning splints (oral devices), which hold the jaw and tongue 
forward to widen the pharyngeal airway. Several types of surgical pro-
cedures have been used in OSAHS, including bariatric surgery in obese 
pts, tonsillectomy, jaw advancement surgery, and pharyngeal surgery. 
Tracheostomy is curative since it bypasses the upper airway obstruction 
site, but it is rarely used. No drugs have been proven to reduce apneic 
events; however, modafinil may reduce sleepiness. 
Treatment of CSA involves managing any predisposing conditions, 
such as congestive heart failure. CPAP may be effective in some CSA pts.
For a more detailed discussion, see Douglas NJ: Sleep 
Apnea, Chap. 265, p. 2186, in HPIM-18.
949
CHAPTER 147
Approach to the Patient 
With Renal Disease
The approach to renal disease begins with recognition of particular 
syndromes on the basis of findings such as presence or absence of azotemia, 
proteinuria, hypertension, edema, abnormal urinalysis, electrolyte disorders, 
abnormal urine volumes, or infection (Table 147-1).
ACUTE RENAL INJURY (SEE CHAP. 148)
Clinical syndrome is characterized by a rapid, severe decrease in glomeru-
lar filtration rate (GFR) [rise in serum creatinine and blood urea nitrogen 
(BUN)], usually with reduced urine output. Extracellular fluid expansion 
leads to edema, hypertension, and occasionally acute pulmonary edema. 
Hyperkalemia, hyponatremia, and acidosis are common. Etiologies include 
ischemia; nephrotoxic injury due to drugs, toxins, or endogenous pigments; 
sepsis; severe renovascular disease; glomerulonephritis (GN); interstitial 
nephritis, particularly allergic interstitial nephritis due to medications; 
thrombotic microangiopathy; or conditions related to pregnancy. Prerenal 
failure and postrenal failure are potentially reversible causes.
Rapidly Progressive Glomerulonephritis 
Defined as a >50% reduction in renal function, occurring over weeks to 
months. Broadly classified into three major subtypes on the basis of renal 
biopsy findings and pathophysiology: (1) immune complex–associated, 
e.g., in systemic lupus erythematosus (SLE); (2) “pauci-immune,” associated 
with antineutrophil cytoplasmic antibodies (ANCA) specific for myeloper-
oxidase or proteinase-3; and (3) associated with anti–glomerular basement 
membrane (anti-GBM) antibodies, e.g., in Goodpasture’s syndrome.
Pts are initially nonoliguric and may have recent flulike symptoms (myal-
gias, low-grade fevers, etc.); later, oliguric renal failure with uremic symptoms 
supervenes. Hypertension is common, particularly in poststreptococcal 
GN. Symptoms of associated disorders may be prominent, e.g., arthritis/
arthralgias in SLE or vasculitis. Pulmonary manifestations in ANCA- and 
anti-GBM-associated rapidly progressive GN range from asymptomatic infil-
trates to life-threatening pulmonary hemorrhage. Urinalysis typically shows 
hematuria, proteinuria, and red blood cell (RBC) casts; however, while highly 
specific for GN, RBC casts are not a particularly sensitive finding.
Acute Glomerulonephritis (See Chap. 152)
Often called nephritic syndrome, classically caused by poststreptococcal 
GN. An acute illness with sudden onset of hematuria, edema, hypertension, 
oliguria, and elevated BUN and creatinine. Mild pulmonary congestion 
SECTION 10
Nephrology
SECTION 10
950
Nephrology
TABLE 147-1  INITIAL CLINICAL AND LABORATORY DATABASE FOR 
DEFINING MAJOR SYNDROMES IN NEPHROLOGY
Syndromes
Important Clues to 
Diagnosis
Common Findings
Acute or rapidly 
progressive renal 
failure
Anuria
Hypertension, pulmonary 
edema, peripheral edema, 
hematuria, proteinuria, 
pyuria
Oliguria
Documented recent 
decline in GFR
Acute nephritis
Hematuria, RBC casts
Proteinuria
Azotemia, oliguria
Pyuria
Edema, hypertension
Circulatory congestion
Chronic renal failure
Azotemia for >3 months
Hematuria, proteinuria
Symptoms or signs of 
uremia
Edema, hypertension
Shrunken, echogenic 
kidneys on ultrasound
Hyperkalemia, acidosis, 
hypocalcemia, anemia
Anemia, 
hyperparathyroidism
Nephrotic syndrome
Proteinuria >3.5 g per 
1.73 m2 per 24 h
Edema
Hypoalbuminemia
Hyperlipidemia
Lipiduria
Asymptomatic urinary 
abnormalities
Hematuria
Proteinuria (below 
nephrotic range)
Sterile pyuria, casts
Urinary tract infection
Bacteriuria >105 colonies 
per mL
Hematuria
Other infectious agent 
documented in urine
Mild azotemia
Pyuria, leukocyte casts
Mild proteinuria
Frequency, urgency
Fever
Bladder tenderness, flank 
tenderness
Renal tubule defects
Electrolyte (Na+, K+, Mg2+,
phosphate, or Ca2+) or 
solute (glucose, uric acid, 
amino acid) disorders
Hematuria
“Tubular” proteinuria
Enuresis
Electrolyte or acid-base 
disorders
Polyuria, nocturia
CHAPTER 147 
951
Approach to the Patient With Renal Disease 
may be present. An antecedent or concurrent infection or multisystem dis-
ease may be causative, or glomerular disease may exist alone. Hematuria, 
proteinuria, and pyuria are usually present, and RBC casts confirm the 
diagnosis. Serum complement may be decreased in certain conditions.
CHRONIC RENAL FAILURE (SEE CHAP. 149)
Progressive permanent loss of renal function over months to years does not 
cause symptoms of uremia until GFR is reduced to about 10–15% of normal. 
Hypertension and/or edema may occur early. Later, manifestations include 
anorexia, nausea, vomiting, dysgeusia, insomnia, weight loss, weakness, 
paresthesia, pruritus, bleeding, serositis (typically pericarditis), anemia, 
acidosis, hypocalcemia, hyperphosphatemia, and hyperkalemia. Common 
causes include diabetes mellitus, severe hypertension, glomerular disease, 
urinary tract obstruction, vascular disease, polycystic kidney disease, and 
interstitial nephritis. Indications of chronicity include longstanding azote-
mia, anemia, hyperphosphatemia, hypocalcemia, shrunken kidneys, renal 
TABLE 147-1  INITIAL CLINICAL AND LABORATORY DATABASE FOR 
DEFINING MAJOR SYNDROMES IN NEPHROLOGY 
(CONTINUED)
Syndromes
Important Clues to 
Diagnosis
Common Findings
Symptoms or signs of 
renal osteodystrophy
Structurally abnormal 
kidneys, e.g., cysts
Hypertension
Systolic/diastolic 
hypertension
Moderate proteinuria
Azotemia
Nephrolithiasis
Previous history of stone 
passage or removal
Hematuria
Pyuria
Previous history of stone 
seen by x-ray
Frequency, urgency
Renal colic
Urinary tract 
obstruction
Azotemia, oliguria, anuria
Hematuria
Polyuria, nocturia, urinary 
retention
Pyuria
Slowing of urinary stream Enuresis, dysuria
Large prostate, large 
kidneys
Flank tenderness, full 
bladder after voiding
Abbreviations: GFR, glomerular filtration rate; RBC, red blood cell.
Source: Modified from FL Coe, BM Brenner: HPIM-14.
SECTION 10
952
Nephrology
osteodystrophy by x-ray, or findings on renal biopsy (extensive glomerular 
sclerosis, arteriosclerosis, and/or tubulointerstitial fibrosis).
NEPHROTIC SYNDROME (SEE CHAP. 152)
Defined as heavy albuminuria (>3.5 g/d in the adult) with or without 
edema, hypoalbuminemia, hyperlipidemia, and varying degrees of renal 
insufficiency. Can be idiopathic or due to drugs, infections, neoplasms, or 
multisystem or hereditary diseases. Complications include severe edema, 
thromboembolic events, infection, and protein malnutrition.
ASYMPTOMATIC URINARY ABNORMALITIES
Hematuria may be due to neoplasms, stones, infection at any level of the urinary 
tract, sickle cell disease, or analgesic abuse. Renal parenchymal causes are sug-
gested by RBC casts, proteinuria, and/or dysmorphic RBCs in urine. Pattern 
of gross hematuria may be helpful in localizing site. Hematuria with minimal 
or low-grade proteinuria is most commonly due to thin basement membrane 
nephropathy or IgA nephropathy. Modest proteinuria may be an isolated find-
ing due to fever, exertion, congestive heart failure (CHF), or upright posture; 
renal causes include early stages of diabetes nephropathy, amyloidosis, or other 
causes of glomerular disease. Pyuria can be caused by urinary tract infection 
(UTI), interstitial nephritis, GN, or renal transplant rejection. “Sterile” pyuria 
can be associated with UTI treated with antibiotics, cyclophosphamide therapy, 
pregnancy, genitourinary trauma, prostatitis, cystourethritis, tuberculosis and 
other mycobacterial infections, and fungal infection.
URINARY TRACT INFECTION (SEE CHAP. 154)
Generally defined as >105 bacteria per mL of urine. Levels between 102 and 
105/mL may indicate infection but are usually due to poor sample collection, 
especially if mixed flora are present. Adults at risk are sexually active women 
or anyone with urinary tract obstruction, vesicoureteral reflux, bladder 
catheterization, neurogenic bladder (associated with diabetes mellitus), or 
primary neurologic diseases. Prostatitis, urethritis, and vaginitis may be 
distinguished by quantitative urine culture. Flank pain, nausea, vomiting, 
fever, and chills indicate kidney infection, i.e., pyelonephritis. UTI is a 
common cause of sepsis, especially in the elderly and institutionalized.
RENAL TUBULAR DEFECTS (SEE CHAP. 153)
Generally inherited, these include anatomic defects (polycystic kidneys, 
medullary cystic disease, medullary sponge kidney) detected in the evalua-
tion of hematuria, flank pain, infection, or renal failure of unknown cause. 
Isolated or generalized defects of renal tubular salt, solute, acid, and water 
transport can also occur. The Fanconi syndrome is characterized by mul-
tiple defects in proximal tubular solute transport; cardinal features include 
generalized aminoaciduria, glycosuria with a normal serum glucose, and 
phosphaturia. The Fanconi syndrome can also encompass a proximal renal 
tubular acidosis, hypouricemia, hypokalemia, polyuria, hypovitaminosis D 
and hypocalcemia, and low-molecular-weight proteinuria. This syndrome 
can be hereditary (e.g., in Dent’s disease and cystinosis) or acquired, the 
latter due to drugs (ifosfamide, tenofovir, valproic acid), toxins (aristolochic 
CHAPTER 147 
953
Approach to the Patient With Renal Disease 
acid), heavy metals, multiple myeloma, or amyloidosis. Hereditary hypo-
kalemic alkalosis is typically caused by defects in ion transport by 
the thick ascending limb (Bartter’s syndrome) or the distal convoluted 
tubule (Gitelman’s syndrome); similar acquired defects can occur after 
exposure to aminoglycosides or cisplatin. Nephrogenic diabetes insipidus 
and renal tubular acidosis are caused by defects in distal tubular water and 
acid transport, respectively; these also have both hereditary and acquired 
forms. Lithium, prescribed for bipolar disease and related psychiatric disorders, 
is a very common cause of acquired nephrogenic diabetes insipidus.
HYPERTENSION (SEE CHAP. 126)
Blood pressure >140/90 mmHg affects 20% of the U.S. adult population; 
when inadequately controlled, it is an important cause of cerebrovascular 
accident, myocardial infarction, and CHF, and can contribute to the devel-
opment of renal failure. Hypertension is usually asymptomatic until cardiac, 
renal, or neurologic symptoms appear; retinopathy or left ventricular 
hypertrophy (S4 heart sound, electrocardiographic or echocardiographic 
evidence) may be the only clinical sequelae. In most cases, hypertension 
is idiopathic and becomes evident between ages 25 and 45. Secondary 
hypertension is generally suggested by the following clinical scenarios: 
(1) severe or refractory hypertension, (2) a sudden increase in blood pressure 
over prior values, (3) onset prior to puberty, or (4) age <30 in a nonobese, 
non-African-American pt with a negative family history. Clinical clues may 
suggest specific causes. Hypokalemia suggests renovascular hypertension 
or primary hyperaldosteronism; paroxysmal hypertension with headache, 
diaphoresis, and palpitations can occur in pheochromocytoma.
NEPHROLITHIASIS (SEE CHAP. 156)
Causes colicky pain, UTI, hematuria, dysuria, or unexplained pyuria. Stones 
may be found on routine x-ray of kidneys, ureter, and bladder (KUB); 
however, noncontrast helical CT, with 5-mm CT cuts, will pick up stones 
not detected by KUB x-ray and will furthermore assess for the presence of 
obstruction. Most are radiopaque Ca stones and are associated with high 
levels of urinary Ca, and/or oxalate excretion, and/or low levels of urinary 
citrate excretion. Staghorn calculi are large, branching, radiopaque stones 
within the renal pelvis due to recurrent infection. Uric acid stones are 
radiolucent. Urinalysis may reveal hematuria, pyuria, or pathologic crystals.
URINARY TRACT OBSTRUCTION (SEE CHAP. 157)
Causes variable symptoms depending on the underlying etiology and 
whether obstruction is acute or chronic, unilateral or bilateral, and complete 
or partial. It is an important, reversible cause of unexplained renal failure. 
Upper tract obstruction may be silent or produce flank pain, hematuria, and 
renal infection. Bladder symptoms or prostatism may be present in lower 
tract obstruction. Functional consequences include polyuria, anuria, noctu-
ria, acidosis, hyperkalemia, and hypertension. A flank or suprapubic mass 
may be found on physical exam; an obstructed, enlarged bladder is typically 
dull to percussion. An increased post-void residual urine volume can be 
confirmed with bedside bladder scan or by ultrasound.
SECTION 10
954
Nephrology
For a more detailed discussion, see Part 13: Disorders of the 
Kidney and Urinary Tract, p. 2279, in HPIM-18. 
CHAPTER 148
Acute Renal Failure
DEFINITION
Acute renal failure (ARF) or acute kidney injury (AKI), defined as a mea-
surable increase in the serum creatinine (Cr) concentration [usually relative 
increase of 50% or absolute increase by 44–88 μmol/L (0.5–1.0 mg/dL)], 
occurs in ~5–7% of hospitalized pts. It is associated with a substantial 
increase in in-hospital mortality and morbidity. AKI can be anticipated in 
some clinical circumstances (e.g., after radiocontrast exposure or major 
surgery), and there are no specific pharmacologic therapies proven helpful 
at preventing or reversing the condition. Maintaining optimal renal perfu-
sion and intravascular volume appears to be important in most clinical 
circumstances; important cofactors in AKI include hypovolemia and drugs 
that interfere with renal perfusion and/or glomerular filtration [nonsteroidal 
anti-inflammatory drugs (NSAIDs), angiotensin-converting enzyme (ACE) 
inhibitors, and angiotensin receptor blockers].
DIFFERENTIAL DIAGNOSIS
The separation into three broad categories (prerenal, intrinsic renal, and 
postrenal failure) is of considerable clinical utility (Table 148-1). Prerenal 
failure is most common among hospitalized pts. It may result from true 
volume depletion [e.g., diarrhea, vomiting, gastrointestinal (GI) or other 
hemorrhage] or “effective circulatory volume” depletion or “arterial under-
filling,” i.e., reduced renal perfusion in the setting of adequate or excess 
blood volume. Reduced renal perfusion may be seen in congestive heart 
failure (CHF) (due to reduced cardiac output and/or potent vasodilator 
therapy), hepatic cirrhosis (due most likely to peripheral vasodilation and 
arteriovenous shunting), nephrotic syndrome and other states of severe 
hypoproteinemia [total serum protein <54 g/L (<5.4 g/dL)], and renovascu-
lar disease (because of fixed stenosis at the level of the main renal artery 
or large branch vessels). Several drugs can reduce renal perfusion, most 
notably NSAIDs. ACE inhibitors and angiotensin II receptor antagonists 
may reduce glomerular filtration rate but do not tend to reduce renal 
perfusion.
Causes of intrinsic renal failure depend on the clinical setting. Among 
hospitalized pts, especially on surgical services or in intensive care units, 
acute tubular necrosis (ATN) is the most common diagnosis. A well-
defined ischemic event or toxic exposure (e.g., aminoglycoside therapy) 
CHAPTER 148
955
Acute Renal Failure
TABLE 148-1 COMMON CAUSES OF ACUTE KIDNEY INJURY
Prerenal
Volume depletion
 Blood loss
 GI fluid loss (e.g., vomiting, diarrhea)
 Overzealous diuretic use
Volume overload with reduced renal perfusion
 Congestive heart failure
  Low-output with systolic dysfunction
  “High-output” (e.g., anemia, thyrotoxicosis)
 Hepatic cirrhosis
 Severe hypoproteinemia
Renovascular disease
Drugs
 NSAIDs, cyclosporine, ACE inhibitors, ARBs, cisplatin, aminoglycosides
Other
  Hypercalcemia, “third spacing” (e.g., pancreatitis, systemic inflammatory 
response), hepatorenal syndrome
Intrinsic
Acute tubular necrosis (ATN)
  Hypotension or shock, prolonged prerenal azotemia, postoperative sepsis 
syndrome, rhabdomyolysis, hemolysis, drugs
  Radiocontrast, aminoglycosides, cisplatin
Other tubulointerstitial disease
  Allergic interstitial nephritis
  Pyelonephritis (bilateral, or unilateral in single functional kidney)
  Heavy metal poisoning
Atheroembolic disease—after vascular procedures, thrombolysis, or 
anticoagulation
Glomerulonephritis
 1.   ANCA-associated: granulomatosis with polyangiitis (Wegener’s), 
idiopathic pauci-immune GN, PAN
 2.  Anti-GBM disease; isolated or with pulmonary involvement 
(Goodpasture’s syndrome)
 3.  Immune complex–mediated
  Subacute bacterial endocarditis, SLE, cryoglobulinemia (with or without 
hepatitis C infection), postinfectious GN (classically poststreptococcal)
IgA nephropathy and Henoch-Schönlein purpura
Glomerular endotheliopathies
  Thrombotic microangiopathy, malignant hypertension, scleroderma, 
antiphospholipid syndrome, preeclampsia
(continued)
SECTION 10
956
Nephrology
may lead to in-hospital ATN. Alternatively, pts may be admitted to the 
hospital with ATN associated with rhabdomyolysis; common predisposing 
factors include alcoholism, hypokalemia, and various drugs (e.g., statins). 
Allergic interstitial nephritis, usually due to antibiotics (e.g., penicillins, 
cephalosporins, sulfa drugs, quinolones, and rifampin), or NSAIDs, may 
also be responsible. Radiographic contrast dyes may cause AKI in pts with 
preexisting kidney disease; the risk is substantially higher in diabetics with 
chronic kidney disease. Coronary angiography, other vascular procedures, 
thrombolysis, or anticoagulation may lead to atheroemboli, which cause 
AKI due to both hemodynamic and inflammatory effects; livedo reticularis, 
embolic phenomena with preserved peripheral pulses, and eosinophilia are 
important clues to this diagnosis. Acute glomerulonephritis (Chap. 152) 
and thrombotic microangiopathies (Chap. 155) may also cause AKI. 
Thrombotic microangiopathies can be clinically subdivided into renal-
limited forms [e.g., Escherichia coli–associated hemolytic uremic syndrome 
(HUS)] and systemic forms [e.g., thrombotic thrombocytopenic purpura 
(TTP)]. A variety of drugs can cause thrombotic microangiopathies, including 
calcineurin inhibitors (cyclosporine and tacrolimus), quinine, antiplatelet 
agents (e.g., ticlopidine), and chemotherapeutics (e.g., mitomycin C and 
gemcitabine). Important associated disorders in TTP include HIV infec-
tion, bone marrow transplantation, systemic lupus erythematosus (SLE), 
and antiphospholipid syndrome.
Postrenal failure is due to urinary tract obstruction, which is also more 
common among ambulatory rather than hospitalized pts. More common in 
men than women, it is most often caused by ureteral or urethral blockade. 
Occasionally, stones, sloughed renal papillae, or malignancy (primary or 
metastatic) may cause more proximal obstruction.
CHARACTERISTIC FINDINGS AND DIAGNOSTIC WORKUP
All pts with AKI manifest some degree of azotemia [increased blood urea 
nitrogen (BUN) and Cr]. Other clinical features depend on the etiol-
ogy of renal disease. Pts with prerenal azotemia due to volume depletion 
TABLE 148-1 COMMON CAUSES OF ACUTE KIDNEY INJURY (CONTINUED)
Postrenal (urinary tract obstruction)
Bladder neck obstruction, bladder calculi
Prostatic hypertrophy
Ureteral obstruction due to compression
  Pelvic or abdominal malignancy, retroperitoneal fibrosis
Nephrolithiasis
Papillary necrosis with obstruction
Abbreviations: ACE, angiotensin-converting enzyme; ANCA, antineutrophil cytoplasmic 
antibody; ARBs, angiotensin receptor blockers; GBM, glomerular basement membrane; 
GI, gastrointestinal; GN, glomerulonephritis; NSAIDs, nonsteroidal anti-inflammatory drugs; 
PAN, polyarteritis nodosa; SLE, systemic lupus erythematosus.
CHAPTER 148
957
Acute Renal Failure
usually demonstrate orthostatic hypotension, tachycardia, low jugular venous 
pressure, and dry mucous membranes. Pts with prerenal azotemia and CHF 
(“cardiorenal syndrome”) may show jugular venous distention, an S3 gallop, 
and peripheral and pulmonary edema. Therefore, the physical exam is critical 
in the workup of pts with prerenal AKI. In general, the BUN/Cr ratio tends 
to be high (>20:1), more so with volume depletion and CHF than with cir-
rhosis. The uric acid may also be disproportionately elevated in noncirrhotic 
prerenal states (due to increased proximal tubular absorption). Urine chem-
istries tend to show low urine [Na+] (<10–20 mmol/L, <10 with hepatorenal 
syndrome) and a fractional excretion of sodium (FENa) of <1% (Table 148-2). 
The urinalysis (UA) typically shows hyaline and a few granular casts, without 
cells or cellular casts. Renal ultrasonography is usually normal.
Pts with intrinsic renal disease present with varying complaints. 
Glomerulonephritis (GN) is often accompanied by hypertension and mild 
to moderate edema (associated with Na retention and proteinuria, and 
sometimes with gross hematuria). An antecedent prodromal illness and/or 
prominent extrarenal symptoms and signs may occur if GN occurs in 
the context of a systemic illness, e.g., vasculitis or SLE; these may include 
hemoptysis or pulmonary hemorrhage (vasculitis and Goodpasture’s 
syndrome), arthralgias/arthritis (vasculitis or SLE), serositis (SLE), and 
unexplained sinusitis (vasculitis). The urine chemistries may be indistin-
guishable from those in pts with prerenal failure; in fact, some pts with GN 
have renal hypoperfusion (due to glomerular inflammation and ischemia) 
TABLE 148-2  URINE DIAGNOSTIC INDICES IN DIFFERENTIATION OF 
PRERENAL VERSUS INTRINSIC RENAL AZOTEMIA 
Typical Findings
Diagnostic Index
Prerenal 
Azotemia
Intrinsic Renal 
Azotemia
Fractional excretion of sodium (%)a UNa ×
PCr/PNa × UCr × 100
<1
>1
Urine sodium concentration (mmol/L)
<10
>20
Urine creatinine to plasma creatinine ratio
>40
>20
Urine urea nitrogen to plasma urea 
nitrogen ratio
>8
<3
Urine specific gravity
>1.018
<1.015
Urine osmolality (mosmol/kg H2O)
>500
<300
Plasma BUN/creatinine ratio
>20
<10–15
Renal failure index UNa/UCr/PCr
<1
>1
Urinary sediment
Hyaline 
casts
Muddy brown 
granular casts
aMost sensitive indices
Abbreviations: BUN, blood urea nitrogen; PCr, plasma creatinine concentration; PNa, plasma 
sodium concentration; UCr, urine creatinine concentration; UNa, urine sodium concentration.
SECTION 10
958
Nephrology
with resultant hyperreninemia leading to acute volume expansion and 
hypertension. The urine sediment can be very helpful in these cases. Red 
blood cell (RBC), white blood cell (WBC), and cellular casts are charac-
teristic of GN; RBC casts are rarely seen in other conditions (i.e., they are 
highly specific). In the setting of inflammatory nephritis (GN or interstitial 
nephritis, see below), there may be increased renal echogenicity on ultraso-
nography. Unlike pts with GN, pts with interstitial diseases are less likely to 
have hypertension or proteinuria; a notable exception is NSAID-associated 
acute interstitial nephritis, which can be accompanied by proteinuria due 
to an associated minimal-change glomerular lesion. Hematuria and pyuria 
may present on UA. The classic sediment finding in allergic interstitial 
nephritis is a predominance (>10%) of urinary eosinophils with Wright’s 
or Hansel’s stain; however, urinary eosinophils can be increased in several 
other causes of AKI. WBC casts may also be seen, particularly in cases of 
pyelonephritis.
The urinary sediment of pts with ischemic or toxic ATN will charac-
teristically contain pigmented “muddy-brown” granular casts and casts 
containing tubular epithelial cells; free tubular epithelial cells can also be 
seen. The FENa is typically >1% in ATN, but may be <1% in pts with milder, 
nonoliguric ATN (e.g., from rhabdomyolysis) and in pts with underlying 
“prerenal” disorders, such as CHF or cirrhosis.
Pts with postrenal AKI due to urinary tract obstruction are usually 
less severely ill than pts with prerenal or intrinsic renal disease, and 
their presentation may be delayed until azotemia is markedly advanced 
[BUN >54 μmol/L (150 mg/dL), Cr >1060–1325 μmol/L (12–15 mg/dL)]. 
An associated impairment of urinary concentrating ability often “protects” 
the pt from complications of volume overload. Urinary electrolytes typically 
show a FENa >1%, and microscopic examination of the urinary sediment is 
usually bland. Ultrasonography is the key diagnostic tool. More than 90% 
of pts with postrenal AKI show obstruction of the urinary collection system 
on ultrasound (e.g., dilated ureter, calyces); false negatives include hyper-
acute obstruction and encasement of the ureter and/or kidney by tumor or 
of the ureter by retroperitoneal fibrosis, functionally obstructing urinary 
outflow without structural dilation. 
Acute Renal Failure
TREATMENT
Treatment should focus on providing etiology-specific supportive care. 
For example, pts with prerenal failure due to GI fluid loss may experi-
ence relatively rapid correction of AKI after the administration of IV 
fluid to expand volume. The same treatment in prerenal pts with CHF 
would be counterproductive; in this case, treatment of the underlying 
disease with vasodilators and/or inotropic agents would more likely be 
of benefit.
There are relatively few intrinsic renal causes of AKI for which there 
is safe and effective therapy. GN associated with vasculitis or SLE may 
respond to high-dose glucocorticoids and cytotoxic agents (e.g., cyclo-
phosphamide); plasmapheresis and plasma exchange may be useful in
CHAPTER 148
959
Acute Renal Failure
other selected circumstances (e.g., Goodpasture’s syndrome and HUS/
TTP, respectively). Antibiotic therapy may be sufficient for the treat-
ment of AKI associated with pyelonephritis or endocarditis. There 
are conflicting data regarding the utility of glucocorticoids in allergic 
interstitial nephritis. Many practitioners advocate their use with clini-
cal evidence of progressive renal insufficiency despite discontinuation 
of the offending drug, or with biopsy evidence of potentially reversible, 
severe disease.
The treatment of urinary tract obstruction often involves consultation 
with a urologist. Interventions as simple as Foley catheter placement or 
as complicated as multiple ureteral stents and/or nephrostomy tubes 
may be required.
DIALYSIS FOR AKI AND RECOVERY OF RENAL FUNCTION Most cases of 
community- and hospital-acquired AKI resolve with conservative sup-
portive measures, time, and patience. If nonprerenal AKI continues to 
progress, dialysis must be considered. The traditional indications for 
dialysis—volume overload refractory to diuretic agents; hyperkalemia; 
encephalopathy not otherwise explained; pericarditis, pleuritis, or other 
inflammatory serositis; and severe metabolic acidosis, compromising 
respiratory or circulatory function—can seriously compromise recov-
ery from acute nonrenal illness. Therefore, dialysis should generally be 
provided in advance of these complications. The inability to provide req-
uisite fluids for antibiotics, inotropes and other drugs, and/or nutrition 
should also be considered an indication for acute dialysis.
Dialytic options for AKI include (1) intermittent hemodialysis (IHD), 
(2) peritoneal dialysis (PD), and (3) continuous renal replacement 
therapy (CRRT, i.e., continuous arteriovenous or venovenous hemo-
diafiltration). Most pts are treated with IHD. It is unknown whether 
conventional thrice-weekly hemodialysis is sufficient or more frequent 
treatments are required. Few centers rely on PD for management of 
AKI (risks include infection associated with intraperitoneal catheter 
insertion and respiratory compromise due to abdominal distention). At 
some centers, CRRT is prescribed only in pts intolerant of IHD, usually 
because of hypotension; other centers use it as the modality of choice for 
pts in intensive care units. Hybrid hemodialysis techniques, such as slow 
low-efficiency dialysis (SLED), may be used in centers in which CRRT 
is not employed.
For a more detailed discussion, see Liu KD, Chertow GM: 
Dialysis in the Treatment of Acute Renal Failure, Chap. 281, 
p. 2322, in HPIM-18.
SECTION 10
960
Nephrology
CHAPTER 149
Chronic Kidney Disease 
and Uremia
EPIDEMIOLOGY
The prevalence of chronic kidney disease (CKD), generally defined as a long-
standing, irreversible impairment of kidney function, is substantially greater 
than the number of pts with end-stage renal disease (ESRD), now ≥500,000 
in the United States. There is a spectrum of disease related to decrements in 
renal function; clinical and therapeutic issues differ greatly depending on 
whether the glomerular filtration rate (GFR) reduction is moderate (stage 3 
CKD, 30–59 mL/min per 1.73 m2) (Table 52-1), severe (stage 4 CKD, 
15–29 mL/min per 1.73 m2), or “end-stage renal disease” (stage 5 CKD, 
<15 mL/min per 1.73 m2). Dialysis is usually required once GFR <10 mL/min 
per 1.73 m2. Common causes of CKD are outlined in Table 149-1.
DIFFERENTIAL DIAGNOSIS
The first step in the differential diagnosis of CKD is establishing its chronic-
ity, i.e., disproving a major acute component. The two most common means 
of determining disease chronicity are the history and prior laboratory data 
(if available) and the renal ultrasound, which is used to measure kidney size. 
In general, kidneys that have shrunk (<10–11.5 cm, depending on body size) 
are more likely affected by chronic disease. While reasonably specific (few 
false positives), reduced kidney size is only a moderately sensitive marker 
for CKD, i.e., there are several relatively common conditions in which 
kidney disease may be chronic without any reduction in renal size. Diabetic 
nephropathy, HIV-associated nephropathy, and infiltrative diseases such as 
TABLE 149-1 COMMON CAUSES OF CHRONIC RENAL FAILURE 
Diabetic nephropathy
Hypertensive nephropathya
Glomerulonephritis
Renovascular disease (ischemic nephropathy) 
Polycystic kidney disease
Reflux nephropathy and other congenital renal diseases 
Interstitial nephritis, including analgesic nephropathy
HIV-associated nephropathy
Transplant allograft failure (“chronic rejection”)
aOften diagnosis of exclusion; very few pts undergo renal biopsy; may be occult renal disease 
with hypertension.
CHAPTER 149 
961
Chronic Kidney Disease and Uremia 
multiple myeloma may in fact be associated with relatively large kidneys 
despite chronicity. Renal biopsy, although rarely performed in pts with 
CKD, is a more reliable means of proving chronicity; a predominance 
of glomerulosclerosis or interstitial fibrosis argues strongly for chronic 
disease. Hyperphosphatemia, anemia, and other laboratory abnormalities 
are not reliable indicators in distinguishing acute from chronic disease.
Once chronicity has been established, clues from the physical exam, labora-
tory panel, and urine sediment evaluation can be used to determine etiology. 
A detailed history (Hx) will identify important comorbid conditions, such 
as diabetes, HIV seropositivity, or peripheral vascular disease. The family 
Hx is paramount in the workup of autosomal dominant polycystic kidney 
disease or hereditary nephritis (Alport’s syndrome). An occupational Hx 
may reveal exposure to environmental toxins or culprit drugs (including 
over-the-counter agents, such as analgesics or Chinese herbs).
Physical exam may demonstrate abdominal masses (i.e., polycystic 
kidneys), diminished pulses or femoral/carotid bruits (i.e., atherosclerotic 
peripheral vascular disease), or abdominal or femoral bruits (i.e., renovas-
cular disease). The Hx and exam may also yield important data regarding 
severity of disease. Excoriations (uremic pruritus), pallor (anemia), muscle 
wasting, and a nitrogenous fetor are all signs of advanced CKD, as are peri-
carditis, pleuritis, and asterixis, complications of particular concern that 
usually prompt the initiation of dialysis.
Laboratory Findings 
Serum and urine laboratory findings typically provide additional information 
useful in determining the etiology and severity of CKD; serial studies deter-
mine the pace of progression and/or whether the renal failure is in fact acute. 
Heavy proteinuria (>3.5 g/d), hypoalbuminemia, hypercholesterolemia, 
and edema suggest nephrotic syndrome (Chap. 152). Diabetic nephropathy, 
membranous nephropathy, focal segmental glomerulosclerosis, minimal 
change disease, amyloid, and HIV-associated nephropathy are principal 
causes. Proteinuria may decrease slightly with decreasing GFR, but rarely 
to normal levels. Hyperkalemia and metabolic acidosis may complicate all 
forms of CKD eventually, but can be more prominent in pts with interstitial 
renal diseases. Serum and urine protein electrophoresis, in addition to serum 
free light chains, should be obtained in all pts >35 years of age with CKD to 
exclude paraproteinemia-associated renal disease. If underlying glomerulo-
nephritis is suspected, autoimmune disorders such as lupus and infectious 
etiologies such as hepatitis B and C should be assessed. Serum concentrations 
of calcium, phosphate, vitamin D, and PTH should be measured to evaluate 
metabolic bone disease. Hemoglobin, vitamin B12, folate, and iron studies 
should be measured to evaluate anemia.
THE UREMIC SYNDROME
The culprit toxin(s) responsible for the uremic syndrome remain elusive. 
The serum creatinine (Cr) is the most common laboratory surrogate 
of renal function. GFR can be estimated using serum Cr–based equa-
tions derived from the Modification of Diet in Renal Disease Study. This 
“eGFR” is now reported with serum Cr by most clinical laboratories in the 
SECTION 10
962
Nephrology
United States and is the basis for the National Kidney Foundation classifica-
tion of chronic kidney disease (Table 52-1).
Uremic symptoms tend to develop with serum Cr >530–710 μmol/L 
(>6–8 mg/dL) or CrCl <10 mL/min, although these values vary widely. 
Uremia is thus a clinical diagnosis made in pts with CKD. Symptoms of 
advanced uremia include anorexia, weight loss, dyspnea, fatigue, pruritus, 
sleep and taste disturbance, and confusion and other forms of encephalopathy. 
Key findings on physical exam include hypertension, jugular venous 
distention, pericardial and/or pleural friction rub, muscle wasting, asterixis, 
excoriations, and ecchymoses. Laboratory abnormalities may include hyper-
kalemia, hyperphosphatemia, metabolic acidosis, hypocalcemia, hyperurice-
mia, anemia, and hypoalbuminemia. Most of these abnormalities eventually 
resolve with initiation of dialysis or renal transplantation (Chaps. 150 and 
151) or with appropriate drug therapies (see below). 
Chronic Kidney Disease and Uremia
TREATMENT
Hypertension complicates many forms of CKD and warrants aggressive 
treatment to reduce the risk of stroke and potentially to slow the pro-
gression of CKD (see below). Volume overload contributes to hyperten-
sion in many cases, and potent diuretic agents are frequently required. 
Anemia can be ameliorated with recombinant human erythropoietin 
(rHuEPO); current practice is to target a hemoglobin concentration of 
100–110 g/L. Iron deficiency and/or other causes of anemia can reduce 
the response to rHuEPO and should be investigated if present. Iron 
supplementation is often required; many pts require parenteral iron 
therapy, since intestinal iron absorption is reduced in CKD.
Hyperphosphatemia can be controlled with judicious restriction of 
dietary phosphorus and the use of postprandial phosphate binders, 
either calcium-based salts (calcium carbonate or acetate) or nonabsorbed 
agents (e.g., sevelamer). Hyperkalemia should be controlled with dietary 
potassium restriction. Dialysis should be considered if the potassium is 
>6 mmol/L on repeated occasions. If these conditions cannot be conser-
vatively controlled, dialysis should be instituted (Chap. 150). It is also 
advisable to begin dialysis if severe anorexia, weight loss, and/or hypoal-
buminemia develop, as it has been definitively shown that outcomes for 
dialysis pts with malnutrition are particularly poor.
SLOWING PROGRESSION OF RENAL DISEASE Prospective clinical trials 
have explored the roles of blood pressure control and dietary protein 
restriction on the rate of progression of renal failure. Control of hyper-
tension is of benefit, although angiotensin-converting enzyme (ACE) 
inhibitors and angiotensin receptor blockers (ARBs) may exert unique 
beneficial effects, most likely due to their effects on intrarenal hemody-
namics. The effects of ACE inhibitors and ARBs are most pronounced 
in pts with diabetic nephropathy and in those without diabetes but with 
significant proteinuria (>1 g/d). Diuretics and other antihypertensive 
agents are often required, in addition to ACE inhibitors and ARBs, to 
optimize hypertension control and attenuate disease progression; diuret-
ics may also help control serum [K+]. 
CHAPTER 150
963
Dialysis
For a more detailed discussion, see Bargman JM, Skorecki K: 
Chronic Kidney Disease, Chap. 280, p. 2308, in HPIM-18.
CHAPTER 150
Dialysis
OVERVIEW
The decision to initiate dialysis usually depends on a combination of the 
pt’s symptoms, comorbid conditions, and laboratory parameters. Unless a 
living donor is identified, transplantation is deferred by necessity, due to the 
scarcity of cadaveric donor organs (median waiting time, 3–6 years at most 
transplant centers). Dialytic options include hemodialysis and peritoneal 
dialysis (PD). Roughly 85% of U.S. pts are started on hemodialysis.
Absolute indications for dialysis include severe volume overload refrac-
tory to diuretic agents, severe hyperkalemia and/or acidosis, encephalopathy 
not otherwise explained, and pericarditis or other serositis. Additional 
indications for dialysis include symptomatic uremia (Chap. 149) (e.g., 
intractable fatigue, anorexia, dysgeusia, nausea, vomiting, pruritus, difficulty 
maintaining attention and concentration) and protein-energy malnutrition/
failure to thrive without other overt cause. No absolute serum creatinine, 
blood urea nitrogen, creatinine or urea clearance, or glomerular filtration 
rate (GFR) is used as an absolute cutoff for requiring dialysis, although most 
individuals experience, or will soon develop, symptoms and complications 
when the GFR is below ~10 mL/min. However, the “pre-emptive” initiation 
of dialysis in such pts, prior to the onset of clinical indications, does not 
improve outcomes in ESRD.
HEMODIALYSIS
This requires direct access to the circulation, either via a native arteriove-
nous fistula (the preferred method of vascular access), usually at the wrist 
(a “Brescia-Cimino” fistula); an arteriovenous graft, usually made of polytet-
rafluoroethylene; a large-bore intravenous catheter; or a subcutaneous 
device attached to intravascular catheters. Blood is pumped though hollow 
fibers of an artificial kidney (the “dialyzer”) and bathed with a solution of 
favorable chemical composition (isotonic, free of urea and other nitrogenous 
compounds, and generally low in potassium). Dialysate [K+] is varied from 
0 to 4 mM, depending on predialysis [K+] and the clinical setting. Dialysate 
[Ca2+] is typically 2.5 mg/dL (1.25 mM), [HCO3
−] typically 35 meq/L, and 
dialysate [Na+] 140 mM; these can also be modified, depending on the clini-
cal situation. Most pts undergo dialysis thrice weekly, usually for 3–4 h. The 
efficiency of dialysis is largely dependent on the duration of dialysis, blood 
flow rate, dialysate flow rate, and surface area of the dialyzer.
SECTION 10
964
Nephrology
Complications of hemodialysis are outlined in Table 150-1. Many of these 
relate to the process of hemodialysis as an intense, intermittent therapy. 
In contrast to the native kidney or to PD, both major dialytic functions 
(i.e., clearance of solutes and fluid removal, or “ultrafiltration”) are accom-
plished over relatively short time periods. The rapid flux of fluid can cause 
hypotension, even without a pt reaching “dry weight.” Hemodialysis-related 
hypotension is common in diabetic pts whose neuropathy prevents the 
compensatory responses (vasoconstriction and tachycardia) to intravascular 
volume depletion. Occasionally, confusion or other central nervous system 
symptoms will occur. The dialysis “disequilibrium syndrome” refers to the 
development of headache, confusion, and rarely seizures, in association with 
rapid solute removal early in the pt’s dialysis history, before adaptation to the 
procedure; this complication is largely avoided by an incremental induction 
of chronic dialytic therapy in uremic pts, starting with treatments of short 
duration, lower blood flows, and lower dialysate flow rates.
PERITONEAL DIALYSIS
PD does not require direct access to the circulation; rather, it obligates place-
ment of a peritoneal catheter that allows infusion of a dialysate solution into 
the abdominal cavity; this allows transfer of solutes (i.e., urea, potassium, 
other uremic molecules) across the peritoneal membrane, which serves as 
the “artificial kidney.” This solution is similar to that used for hemodialysis, 
except that it must be sterile, and it uses lactate, rather than bicarbonate, to 
provide base equivalents. PD is far less efficient at cleansing the bloodstream 
than hemodialysis and therefore requires a much longer duration of therapy. 
Pts generally have the choice of performing their own “exchanges” (2–3 L 
of dialysate, 4–5 times during daytime hours) or using an automated device 
at night. Compared with hemodialysis, PD offers the major advantages of 
(1) independence and flexibility, and (2) a more gentle hemodynamic profile.
Complications are outlined in Table 150-2. Peritonitis is the most impor-
tant complication. The clinical presentation typically consists of abdominal 
pain and cloudy dialysate; peritoneal fluid leukocyte count is typically 
>100/μL, 50% neutrophils. In addition to the negative effects of the systemic 
inflammatory response, protein loss is magnified severalfold during the 
peritonitis episode. If severe or prolonged, an episode of peritonitis may 
prompt removal of the peritoneal catheter or even discontinuation of the 
modality (i.e., switch to hemodialysis). Gram-positive organisms (espe-
cially Staphylococcus aureus and other Staphylococcus spp.) predominate; 
TABLE 150-1 COMPLICATIONS OF HEMODIALYSIS
Hypotension 
Dialysis-related amyloidosis 
Accelerated vascular disease
Protein-energy malnutrition
Rapid loss of residual renal function
Hemorrhage
Access thrombosis
Anaphylactoid reactiona
Access or catheter sepsis
aPrimarily with first use of “bioincompatible” modified cellulosic dialyzer membranes.
CHAPTER 151
965
Renal Transplantation
Pseudomonas or fungal (usually Candida) infections tend to be more resis-
tant to medical therapy and typically obligate catheter removal. Antibiotic 
administration may be intravenous or intraperitoneal when intensive therapy 
is required.
TABLE 150-2 COMPLICATIONS OF PERITONEAL DIALYSIS
Peritonitis
Dialysis-related amyloidosis
Hyperglycemia
Insufficient clearance due to vascular disease or 
other factors 
Uremia secondary to loss of residual renal function 
Hypertriglyceridemia
Obesity
Hypoproteinemia
For a more detailed discussion, see Liu KD, Chertow GM: 
Dialysis in the Treatment of Renal Failure: Chap. 281, 
p. 2322, in HPIM-18.
CHAPTER 151
Renal Transplantation
With the advent of more potent and well-tolerated immunosuppressive 
regimens and further improvements in short-term graft survival, renal 
transplantation remains the treatment of choice for most pts with end-stage 
renal disease. Results are best with living-related transplantation, in part 
because of optimized tissue matching and in part because waiting time can 
be minimized; ideally, these pts are transplanted prior to the onset of symp-
tomatic uremia or indications for dialysis. Many centers now perform living-
unrelated donor (e.g., spousal) transplants. Graft survival in these cases is far 
superior to that observed with cadaveric transplants, although less favorable 
than with living-related transplants. Factors that influence graft survival are 
outlined in Table 151-1. Pretransplant blood transfusion should be avoided, 
so as to reduce the likelihood of sensitization to incompatible HLA antigens; 
if transfusion is necessary, leukocyte-reduced irradiated blood is preferred. 
Contraindications to renal transplantation are outlined in Table 151-2. 
Overall, the current standard of care is that the pt should have >5 years 
of life expectancy to be eligible for a renal transplant, since the benefits of 
transplantation are only realized after a perioperative period in which the 
mortality rate is higher than in comparable pts on dialysis.
REJECTION
Immunologic rejection is the major hazard to the short-term success of 
renal transplantation. Rejection may be (1) hyperacute (immediate graft 
SECTION 10
966
Nephrology
TABLE 151-1  SOME FACTORS THAT INFLUENCE GRAFT SURVIVAL IN 
RENAL TRANSPLANTATION
HLA mismatch
↓
Presensitization (preformed antibodies)
↓
Very young or older donor age
↓
Female donor sex
↓
African-American donor race (compared with white)
↓
Older recipient age
↑
African-American recipient race (compared with white)
↓
Recipient diabetes as the cause of end-stage renal disease
↓
Prolonged cold ischemia time
↓
Hepatitis C infection
↓
Large recipient body size
↓
TABLE 151-2 CONTRAINDICATIONS TO RENAL TRANSPLANTATION
Absolute contraindications
Active glomerulonephritis 
Active bacterial or other infection
Active or very recent malignancy
Overt AIDSa
Active hepatitis
Severe degrees of comorbidity (e.g., advanced atherosclerotic vascular disease)
Relative contraindications
Severe psychiatric disease
Moderately severe degrees of comorbidity
Hepatitis C infection with chronic hepatitis or cirrhosis
Noncompliance with dialysis or other medical therapy
Primary renal diseases
 Primary focal sclerosis with prior recurrence in transplant
 Multiple myeloma
 Amyloid
 Oxalosis
aMost centers consider overt AIDS a contraindication to transplantation; however, transplanta-
tion of HIV-positive pts is increasing in frequency.
dysfunction due to presensitization) or (2) acute (sudden change in renal 
function occurring within weeks to months). Rejection is usually detected 
by a rise in serum creatinine but may also lead to hypertension, fever, 
reduced urine output, and occasionally graft tenderness. A percutaneous 
renal transplant biopsy confirms the diagnosis. Treatment usually consists 
CHAPTER 151
967
Renal Transplantation
of a “pulse” of methylprednisolone (500–1000 mg/d for 3 days). In refrac-
tory or particularly severe cases, 7–10 days of a monoclonal antibody 
directed at human T lymphocytes may be given.
IMMUNOSUPPRESSION
Maintenance immunosuppressive therapy usually consists of a three-
drug regimen, with each drug targeted at a different stage in the immune 
response. The calcineurin inhibitors cyclosporine and tacrolimus are the 
cornerstones of immunosuppressive therapy. The most potent of orally 
available agents, calcineurin inhibitors have vastly improved short-term 
graft survival. Side effects of cyclosporine include hypertension, hyper-
kalemia, resting tremor, hirsutism, gingival hypertrophy, hyperlipidemia, 
hyperuricemia and gout, and a slowly progressive loss of renal func-
tion with characteristic histopathologic patterns (also seen in exposed 
recipients of heart and liver transplants). While the side effect profile of 
tacrolimus is generally similar to cyclosporine, there is a higher risk of 
hyperglycemia, a lower risk of hypertension, and occasional hair loss rather 
than hirsutism.
Prednisone is frequently used in conjunction with cyclosporine, at least 
for the first several months following successful graft function. Side effects 
of prednisone include hypertension, glucose intolerance, cushingoid fea-
tures, osteoporosis, hyperlipidemia, acne, and depression and other mood 
disturbances.
Mycophenolate mofetil has proved more effective than azathioprine in 
combination therapy with calcineurin inhibitors and prednisone. The major 
side effects of mycophenolate mofetil are gastrointestinal (diarrhea is most 
common); leukopenia (and thrombocytopenia to a lesser extent) develops 
in a fraction of pts.
Sirolimus is a newer immunosuppressive agent often used in combina-
tion with other drugs, particularly when calcineurin inhibitors are reduced 
or eliminated. Side effects include hyperlipidemia and oral ulcers.
OTHER COMPLICATIONS
Infection and neoplasia are important complications of renal transplanta-
tion. Infection is common in the heavily immunosuppressed host (e.g., 
cadaveric transplant recipient with multiple episodes of rejection requiring 
steroid pulses or monoclonal antibody treatment). The culprit organism 
depends in part on characteristics of the donor and recipient and timing 
following transplantation (Table 151-3). In the first month, bacterial organ-
isms predominate. After 1 month, there is a significant risk of systemic 
infection with cytomegalovirus (CMV), particularly in recipients without 
prior exposure whose donor was CMV positive. Prophylactic use of ganci-
clovir or valacyclovir can reduce the risk of CMV disease. Later on, there is 
a substantial risk of fungal and related infections, especially in pts who are 
unable to taper prednisone to <20–30 mg/d. Daily low-dose trimethoprim-
sulfamethoxazole is effective at reducing the risk of Pneumocystis carinii 
infection.
The polyoma group of DNA viruses (BK, JC, SV40) can be activated 
by immunosuppression. Reactivation of BK is associated with a typical 
SECTION 10
968
Nephrology
pattern of renal inflammation, BK nephropathy, which can lead to loss of 
the allograft; therapy typically involves reduction of immunosuppression to 
aid in clearance of the reactivated virus.
Epstein-Barr virus–associated lymphoproliferative disease is the most 
important neoplastic complication of renal transplantation, especially in 
pts who receive polyclonal (antilymphocyte globulin, used at some centers 
for induction of immunosuppression) or monoclonal antibody therapy. 
Non-Hodgkin’s lymphoma and squamous cell carcinoma of the skin are also 
more common in this population.
TABLE 151-3  THE MOST COMMON OPPORTUNISTIC INFECTIONS IN 
RENAL TRANSPLANT RECIPIENTS
Peritransplant (<1 month)
Late (>6 months)
 Wound infections
 Aspergillus
 Herpesvirus
 Nocardia
 Oral candidiasis
 BK virus (polyoma)
 Urinary tract infection
 Herpes zoster
Early (1–6 months)
 Hepatitis B
Pneumocystis carinii
 Hepatitis C
 Cytomegalovirus
Legionella
Listeria
 Hepatitis B
 Hepatitis C
For a more detailed discussion, see Chandraker A, Milford 
EL, Sayegh MH: Transplantation in the Treatment of Renal 
Failure, Chap. 282, p. 2327, in HPIM-18.
CHAPTER 152
Glomerular Diseases
ACUTE GLOMERULONEPHRITIS (GN)
Often called the “nephritic syndrome.” Characterized by development, 
over days, of azotemia, hypertension, edema, hematuria, proteinuria, and 
sometimes oliguria. Salt and water retention are due to reduced glomerular 
filtration rate (GFR) and may result in circulatory congestion. Red blood 
cell (RBC) casts on urinalysis confirm diagnosis (Dx). Proteinuria is 
CHAPTER 152
969
Glomerular Diseases
usually <3 g/d. Most forms of acute GN are mediated by humoral immune 
mechanisms. Clinical course depends on underlying lesion (Table 152-1).
Acute Poststreptococcal GN 
This is the prototype and most common cause in childhood. Nephritis 
develops 1–3 weeks after pharyngeal or cutaneous infection with “nephrito-
genic” strains of group A β-hemolytic streptococci. Dx depends on a positive 
pharyngeal or skin culture (if available), positive titers for antistreptococcal 
antigens (ASO, anti-DNAse, or antihyaluronidase), and hypocomplement-
emia. Renal biopsy reveals diffuse proliferative GN. Treatment consists of 
correction of fluid and electrolyte imbalance. In most cases the disease is 
self-limited, although the prognosis is less favorable and urinary abnormalities 
are more likely to persist in adults.
Postinfectious GN 
May follow other bacterial, viral, and parasitic infections. Examples are 
bacterial endocarditis, sepsis, hepatitis B, and pneumococcal pneumonia. 
Features are milder than with poststreptococcal GN. Control of primary 
infection usually produces resolution of GN.
RAPIDLY PROGRESSIVE GLOMERULONEPHRITIS
Defined as a subacute reduction in GFR of >50%, with evidence of a 
proliferative GN; causes overlap with those of acute GN (Table 152-2). 
Broadly classified into three major subtypes on the basis of renal biopsy 
TABLE 152-1 CAUSES OF ACUTE GLOMERULONEPHRITIS
I. Infectious diseases
 A. Poststreptococcal glomerulonephritisa
 B. Nonstreptococcal postinfectious glomerulonephritis
1.  Bacterial: infective endocarditis, “shunt nephritis,” sepsis, 
pneumococcal pneumonia, typhoid fever, secondary syphilis, 
meningococcemia
2.  Viral: hepatitis B, infectious mononucleosis, mumps, measles, 
varicella, vaccinia, echovirus, and coxsackievirus
3. Parasitic: malaria, toxoplasmosis 
II.  Multisystem diseases: SLE, vasculitis, Henoch-Schönlein purpura, 
Goodpasture’s syndrome
III.  Primary glomerular diseases: mesangiocapillary glomerulonephritis, 
Berger’s disease (IgA nephropathy), “pure” mesangial proliferative 
glomerulonephritis
IV.  Miscellaneous: Guillain-Barré syndrome, irradiation of Wilms’ tumor, 
self-administered diphtheria-pertussis-tetanus vaccine, serum sickness
aMost common cause.
Abbreviation: SLE, systemic lupus erythematosus.
Source: RJ Glassock, BM Brenner: HPIM-13.
SECTION 10
970
Nephrology
TABLE 152-2  CAUSES OF RAPIDLY PROGRESSIVE GLOMERULONEPHRITIS
I. Infectious diseases
 A. Poststreptococcal glomerulonephritisa
 B. Infective endocarditis
 C. Occult visceral sepsis
 D. Hepatitis B infection (with vasculitis and/or cryoglobulinemia)
 E. HIV infection 
 F.   Hepatitis C infection (with cryoglobulinemia, membranoproliferative 
glomerulonephritis)
II. Multisystem diseases
 A. Systemic lupus erythematosus
 B. Henoch-Schönlein purpura
 C. Systemic necrotizing vasculitis [including granulomatosis with polyangiitis 
(Wegener’s)]
 D. Goodpasture’s syndrome
 E. Essential mixed (IgG/IgM) cryoglobulinemia
 F.  Malignancy
 G. Relapsing polychondritis
 H. Rheumatoid arthritis (with vasculitis)
III. Drugs
 A. Penicillamine
 B. Hydralazine
 C. Allopurinol (with vasculitis)
 D. Rifampin
IV. Idiopathic or primary glomerular disease
 A. Idiopathic crescentic glomerulonephritis
1. Type I—with linear deposits of Ig (anti-GBM antibody–mediated)
2. Type II—with granular deposits of Ig (immune complex–mediated)
3. Type III—with few or no immune deposits of Ig (“pauci-immune”)
4.  Antineutrophil cytoplasmic antibody–induced, forme fruste of 
vasculitis
5. Immunotactoid glomerulonephritis
6. Fibrillary glomerulonephritis
 B. Superimposed on another primary glomerular disease
1.  Mesangiocapillary (membranoproliferative) glomerulonephritis 
(especially type II)
2. Membranous glomerulonephritis
3. Berger’s disease (IgA nephropathy)
aMost common cause.
Abbreviation: GBM, glomerular basement membrane.
Source: RJ Glassock, BM Brenner: HPIM-13. 
CHAPTER 152
971
Glomerular Diseases
findings and pathophysiology: (1) immune complex–associated, e.g., in 
systemic lupus erythematosus (SLE); (2) “pauci-immune,” associated with 
antineutrophil cytoplasmic antibodies (ANCA); and (3) associated with 
anti–glomerular basement (anti-GBM) antibodies, e.g., in Goodpasture’s 
syndrome. All three forms will typically have a proliferative, crescentic GN 
by light microscopy but differ in the results of the immunofluorescence and 
electron microscopy components of the renal biopsy.
SLE (Lupus) 
Renal involvement is due to deposition of circulating immune complexes. 
Clinical features of SLE with or without renal involvement include arthral-
gias, “butterfly” skin rash, serositis, alopecia (hair loss), and central nervous 
system disease. Nephrotic syndrome with renal insufficiency is common. 
Renal biopsy reveals mesangial, focal, or diffuse GN and/or membranous 
nephropathy. Diffuse GN, the most common finding in renal biopsy series, 
is characterized by an active sediment, severe proteinuria, and progressive 
renal insufficiency and may have an ominous prognosis. Pts have a positive 
antinuclear antibody test, anti-dsDNA antibodies, and hypocomplement-
emia. Treatment includes glucocorticoids and cytotoxic agents. Oral or IV 
monthly cyclophosphamide is most commonly employed, typically for a 
period of 6 months; pts of childbearing age should first bank sperm and 
eggs. Mycophenolate mofetil is an alternative.
Antineutrophil Cytoplasmic Antibody (ANCA)–Associated, Pauci-Immune GN
May be renal-limited (idiopathic pauci-immune GN) or associated with sys-
temic vasculitis [granulomatosis with polyangiitis (Wegener’s) or microscopic 
polyarteritis nodosa]. Defining characteristic is the presence of circulating 
ANCA. These are detected by immunofluorescence of alcohol-fixed neutro-
phils; a “perinuclear” pattern (pANCA) is usually due to antibodies against 
myeloperoxidase (MPO), whereas a “cytoplasmic” pattern (cANCA) is almost 
always due to reactivity against proteinase-3 (PR3). Confirmatory enzyme-
linked immunosorbent assay testing against the MPO and PR3 antigens is 
mandatory, since the pANCA pattern can be caused by antibodies against 
other neutrophil components, e.g., lactoferrin; these do not have the same 
consistent relationship to vasculitis and pauci-immune GN. The anti-MPO 
or anti-PR3 titer does not always correlate with disease activity.
Pts typically have a prodromal, “flulike” syndrome, which may encompass 
myalgias, fever, arthralgias, anorexia, and weight loss. There may be asso-
ciated cutaneous, pulmonary, upper respiratory (sinusitis), or neurologic 
(mononeuritis monoplex) complications of associated systemic vasculitis. 
In particular, pulmonary necrotizing capillaritis can lead to hemoptysis and 
pulmonary hemorrhage.
Standard initial therapy for ANCA-associated rapidly progressive GN 
includes methylprednisolone and cyclophosphamide; more specific deple-
tion of B cells by anti-CD20 antibody therapy with rituximab is an alterna-
tive. Some centers will also utilize plasmapheresis in the initial management 
of pts with a severe pulmonary-renal syndrome or to stave off dialysis in 
pts with severe renal impairment. Steroids are quickly tapered soon after 
the acute inflammation subsides; cyclophosphamide is continued until a 
SECTION 10
972
Nephrology
stable remission is achieved, typically within 3–6 months. Pts must receive 
prophylaxis for Pneumocystis carinii (jiroveci) pneumonia (PCP) with 
trimethoprim-sulfamethoxazole, atovaquone, or dapsone. Some form of 
maintenance immunosuppression is standard, typically for 12–18 months 
after achievement of a stable remission; drugs include methotrexate, myco-
phenolate mofetil, and azathioprine. 
Anti–Glomerular Basement Membrane Disease 
Caused by antibodies against the α3 NCI (noncollagenous) domain of type 
IV collagen; circulating anti-GBM antibody and linear immunofluorescence 
on renal biopsy establish the Dx. Pts may have isolated GN; Goodpasture’s 
syndrome encompasses GN and lung hemorrhage. Plasma exchange may 
produce remission; renal prognosis is worse in those who require dialytic 
support, with >50% crescents on renal biopsy, or creatinine >5–6 mg/dL. 
Severe lung hemorrhage is treated with IV glucocorticoids (e.g., 1 g/d × 
3 days). Approximately 10–15% will also have ANCA against MPO, some 
with evidence of vasculitis, e.g., leukocytoclastic vasculitis in the skin.
Henoch-Schönlein Purpura 
A generalized vasculitis causing IgA nephropathy, purpura, arthralgias, and 
abdominal pain; occurs mainly in children. Renal involvement is mani-
fested by hematuria and proteinuria. Serum IgA is increased in half of pts. 
Renal biopsy is useful for prognosis. Treatment is symptomatic.
NEPHROTIC SYNDROME (NS)
Characterized by albuminuria (>3.5 g/d) and hypoalbuminemia (<30 g/L) 
and accompanied by edema, hyperlipidemia, and lipiduria. Protein excre-
tion can be quantified by 24-h urine collection or by measurement of the 
urine protein:creatinine ratio or albumin:creatinine ratio on a random 
spot urine. The measurement of creatinine excretion helps define the 
adequacy of 24-h urine collections: daily creatinine excretion should be 
20–25 mg/kg lean body weight in men and 15–20 mg/kg lean body weight 
in women. For random urine samples, the ratio of protein or albumin to 
creatinine in mg/dL approximates the 24-h urine protein excretion, since 
creatinine excretion is only slightly greater than 1000 mg/d per 1.73 m2. 
A urine protein:creatinine ratio of 5 is thus consistent with 5 g/d per 1.73 m2. 
Quantification of urine protein excretion on spot urines has largely sup-
planted formal 24-h urine collections, due to the greater ease and the need 
to verify a complete 24-h collection. The total protein:creatinine ratio 
does not detect microalbuminuria, a level of albumin excretion that is 
below the level of detection by tests for total protein; urine albumin:
creatinine measurement is therefore preferred as a screening tool for lesser 
proteinuria. 
In addition to edema, the complications of NS can include renal vein 
thrombosis and other thromboembolic events, infection, vitamin D defi-
ciency, protein malnutrition, and drug toxicities due to decreased protein 
binding.
In adults, the most common cause of NS is diabetes. A minority of cases 
are secondary to SLE, amyloidosis, drugs, neoplasia, or other disorders 
CHAPTER 152
973
Glomerular Diseases
(Table 152-3). By exclusion, the remainder are idiopathic. With the 
exception of diabetic nephropathy, a renal biopsy is required to make the 
diagnosis and determine therapy in NS.
Minimal Change Disease 
Causes about 10–15% of idiopathic NS in adults, but 70–90% of NS in chil-
dren. Blood pressure is normal; GFR is normal or slightly reduced; urinary 
sediment is benign or may show few RBCs. Protein selectivity is variable 
in adults. Recent upper respiratory infection, allergies, or immunizations 
are present in some cases; nonsteroidal anti-inflammatory drugs can cause 
minimal change disease with interstitial nephritis. Acute renal failure may 
rarely occur, particularly among elderly persons. Renal biopsy shows only 
foot process fusion on electron microscopy. Remission of proteinuria with 
glucocorticoids carries a good prognosis; cytotoxic therapy may be required 
for relapse. Progression to renal failure is uncommon. Focal sclerosis has 
been suspected in some cases refractory to steroid therapy.
Membranous GN 
Characterized by subepithelial IgG deposits; accounts for ~30% of idio-
pathic adult NS. Pts present with edema and nephrotic proteinuria. Blood 
pressure, GFR, and urine sediment are usually normal at initial presenta-
tion. Hypertension, mild renal insufficiency, and abnormal urine sediment 
develop later. Renal vein thrombosis is relatively common, more so than 
with other forms of NS. Underlying diseases such as SLE, hepatitis B, and 
solid tumors and exposure to such drugs as high-dose captopril or penicil-
lamine should be sought. The majority of pts with idiopathic membranous 
GN have detectable circulating autoantibodies to the M-type phospholipase 
TABLE 152-3 CAUSES OF NEPHROTIC SYNDROME (NS)
Systemic Causes 
Glomerular Disease
Diabetes mellitus, SLE, amyloidosis, 
HIV-associated nephropathy
Membranous
Minimal change disease
Drugs: gold, penicillamine, probenecid, 
street heroin, NSAIDs, pamidronate, 
interferons
Focal glomerulosclerosis
Infections: bacterial endocarditis, 
hepatitis B, shunt infections, syphilis, 
malaria, hepatic schistosomiasis
Membranoproliferative GN
Malignancy: multiple myeloma, light chain 
deposition disease, Hodgkin’s and other 
lymphomas, leukemia, carcinoma of breast 
and GI tract
Mesangioproliferative GN
Immunotactoid and fibrillary GN
Abbreviations: GI, gastrointestinal; GN, glomerulonephritis; NSAIDs, nonsteroidal anti-
inflammatory drugs; SLE, systemic lupus erythematosus.
Source: Modified from RJ Glassock, BM Brenner: HPIM-13.
SECTION 10
974
Nephrology
A2 (PLA2R), which is expressed in glomerular podocytes. Some pts progress 
to end-stage renal disease (ESRD); however, 20–33% may experience a 
spontaneous remission. Male gender, older age, hypertension, and persis-
tence of significant proteinuria (>6 g/d) are associated with a higher risk of 
progressive disease. Optimal immunosuppressive therapy is controversial. 
Glucocorticoids alone are ineffective. Cytotoxic agents may promote com-
plete or partial remission in some pts, as may cyclosporine. Anti-CD20 
antibody therapy with rituximab has recently shown considerable promise, 
consistent with a role for B cells and anti-PLA2R antibodies  in the patho-
physiology. Reduction of proteinuria with angiotensin-converting enzyme 
(ACE) inhibitors and/or angiotensin receptor blockers (ARBs) is also an 
important mainstay of therapy.
Focal Glomerulosclerosis (FGS) 
Can be primary or secondary. Primary tends to be more acute, similar 
to minimal change disease in abruptness of NS, but with added features 
of hypertension, renal insufficiency, and hematuria. Involves fibrosis of 
portions of some (primarily juxtamedullary) glomeruli and is found in 
~35% of pts with NS. There are several different pathologic subtypes of 
idiopathic FGS, with prognostic implications. In particular, the “collaps-
ing glomerulopathy” variant has pathologic similarity to HIV-associated 
nephropathy (HIVAN); both nephropathies cause rapidly progressive 
disease.  
African Americans are disproportionately affected by FGS, HIVAN, and 
other nondiabetic renal disease, with higher incidence, greater susceptibility 
(HIVAN), and a much higher risk of developing ESRD. “African-specific” 
variants in the APOL1 gene, which encodes apolipoprotein L1 expressed 
in glomerular podocytes, have recently been implicated in this enhanced 
genetic risk.
Treatment of primary FGS typically begins with an extended course 
of steroids; fewer than half of pts undergo remission. Cyclosporine is an 
alternative therapy for maintenance of remission and for steroid-resistant 
pts. As in other glomerulopathies, reduction of proteinuria with ACE 
inhibitors and/or ARBs is also an important component of therapy. Finally, 
primary FGS may recur after renal transplant, when it may lead to loss of 
the allograft.
Secondary FGS can occur in the late stages of any form of kidney disease 
associated with nephron loss (e.g., remote GN, pyelonephritis, sickle cell 
disease, vesicoureteral reflux). Treatment includes anti-proteinuric therapy 
with ACE inhibition and blood pressure control. There is no benefit of 
glucocorticoids in secondary FGS. Clinical history, kidney size, biopsy 
findings, and associated conditions usually allow differentiation of primary 
versus secondary causes.
Membranoproliferative Glomerulonephritis (MPGN) 
Mesangial expansion and proliferation extend into the capillary loop. Two 
ultrastructural variants exist. In MPGN I, subendothelial electron-dense 
deposits are present, C3 is deposited in a granular pattern indicative of 
immune-complex pathogenesis, and IgG and the early components of 
CHAPTER 152
975
Glomerular Diseases
complement may or may not be present. In MPGN II, the lamina densa 
of the GBM is transformed into an electron-dense character, as is the base-
ment membrane in Bowman’s capsule and tubules. C3 is found irregularly 
in the GBM. Small amounts of Ig (usually IgM) are present, but early com-
ponents of complement are absent. Serum complement levels are decreased. 
MPGN affects young adults. Blood pressure and GFR are abnormal, and the 
urine sediment is active. Some have acute nephritis or hematuria. Similar 
lesions occur in SLE and hemolytic-uremic syndrome. Infection with hepati-
tis C virus (HCV) has been linked to MPGN, often with associated cryoglob-
ulinemia. Treatment with interferon α and ribavirin has resulted in remission 
of renal disease in some cases, depending on HCV serotype; however, renal 
insufficiency typically precludes ribavirin therapy. Glucocorticoids, cytotoxic 
agents, antiplatelet agents, and plasmapheresis have been used with limited 
success; rituximab is a newer therapy with greater evident efficacy. MPGN 
may recur in allografts.
Diabetic Nephropathy 
The most common cause of NS. Although prior duration of diabetes mel-
litus (DM) is variable, in type 1 DM proteinuria may develop 10–15 years 
after onset of diabetes, progress to NS, and then lead to renal failure over 
3–5 years. Retinopathy is nearly universal in type 1 diabetics with nephrop-
athy, so much so that the absence of retinopathy should prompt consid-
eration of another glomerular lesion (e.g., membranous nephropathy). In 
contrast, only ~60% of type 2 diabetics with diabetic nephropathy have 
retinopathy. Clinical features include proteinuria, progressive hypertension, 
and progressive renal insufficiency. Pathologic changes include mesangial 
sclerosis, diffuse, and/or nodular (Kimmelstiel-Wilson) glomerulosclerosis. 
However, pts rarely undergo renal biopsy; to the extent that yearly mea-
surement of microalbuminuria is routine management for all diabetics, the 
natural history is an important component of the diagnosis. Pts typically 
demonstrate progression from microalbuminuria (30–300 mg/24 h) to 
dipstick-positive proteinuria (>300 mg albuminuria) and then progressively 
overt proteinuria and chronic kidney disease. However, proteinuria can be 
quite variable in diabetic nephropathy, with as much as 25 g/24 h in the 
absence of profound renal insufficiency or alternatively with progressive 
renal insufficiency and stable, modest proteinuria.
Treatment with ACE inhibitors delays the onset of nephropathy and of 
ESRD in type 1 diabetics with microalbuminuria and/or declining renal 
function and should be instituted in all pts tolerant to that class of drug. 
If a cough develops in a pt treated with an ACE inhibitor, an ARB is the 
next best choice. Type 2 diabetics with microalbuminuria or proteinuria 
can be treated with ACE inhibitors or ARBs. Although long-term stud-
ies are lacking, many authorities advocate combining inhibitors of the 
renin-angiotensin-aldosterone system (RAAS), i.e., ARBs, ACE inhibitors, 
mineralocorticoid receptor blockers, and/or renin inhibitors, in pts with 
persistent, significant proteinuria. Hyperkalemia, hypotension, and/or 
worsening GFR can limit single or combined therapy with RAAS inhibitors. 
If hyperkalemia develops and cannot be controlled with (1) optimizing glu-
cose control, (2) loop diuretics (if otherwise appropriate), or (3) treatment 
Nephrology
SECTION 10
976
TABLE 152-4 EVALUATION OF NEPHROTIC SYNDROME
Random spot urine for protein and creatinine
Serum albumin, cholesterol, complement
Urine protein electrophoresis
Rule out SLE, diabetes mellitus
Review drug exposure
Renal biopsy
Consider malignancy (in elderly pt with membranous GN or minimal change 
disease)
Consider renal vein thrombosis (if membranous GN or symptoms of 
pulmonary embolism are present)
Abbreviations: GN, glomerulonephritis; SLE, systemic lupus erythematosus.
TABLE 152-5  GLOMERULAR CAUSES OF ASYMPTOMATIC URINARY 
ABNORMALITIES
I. Hematuria with or without proteinuria
 A. Primary glomerular diseases
1. Berger’s disease (IgA nephropathy)a
2. Mesangiocapillary glomerulonephritis
3.  Other primary glomerular hematurias accompanied by “pure” 
mesangial proliferation, focal and segmental proliferative 
glomerulonephritis, or other lesions
4.  “Thin basement membrane” disease (? forme fruste of Alport’s 
syndrome)
 B. Associated with multisystem or hereditary diseases
1. Alport’s syndrome and other “benign” familial hematurias
2. Fabry’s disease
3. Sickle cell disease
 C. Associated with infections
1. Resolving poststreptococcal glomerulonephritis
2. Other postinfectious glomerulonephritides
II. Isolated nonnephrotic proteinuria
 A. Primary glomerular diseases
1. “Orthostatic” proteinuria
2. Focal and segmental glomerulosclerosis
3. Membranous glomerulonephritis
 B. Associated with multisystem or heredofamilial diseases
1. Diabetes mellitus
2. Amyloidosis
3. Nail-patella syndrome
aMost common.
Source: RJ Glassock, BM Brenner: HPIM-13. 
TABLE 152-6  SEROLOGIC FINDINGS IN SELECTED MULTISYSTEM DISEASES CAUSING GLOMERULAR DISEASE
Disease
C3
Ig
FANA
Anti-dsDNA
Anti-GBM
Cryo-Ig
CIC
ANCA
SLE
↓
↑ IgG
+++
++
−
++
+++
±
Goodpasture’s syndrome
−
−
−
−
+++
−
±
+ (10−15%)
Henoch-Schönlein purpura
−
↑ IgA
−
−
−
±
++
−
Polyarteritis
↓↑
IgG
+
±
−
++
+++
+++
Granulomatosis with polyangiitis (Wegener’s)
↓↑
↑ IgA, IgE
−
−
−
±
++
+++
Cryoglobulinemia
↓
±
−
−
+++
++
−
↓↑ IgG
IgA, IgD
Multiple myeloma
−
IgE
−
−
+
−
−
Waldenström’s macroglobulinemia
−
↑ IgM
−
−
−
−
−
−
Amyloidosis
−
± Ig
−
−
−
−
−
−
Abbreviations: ANCA, antineutrophil cytoplasmic antibody; anti-dsDNA, antibody to double-stranded (native) DNA; anti-GBM, antibody to glomerular basement membrane antigens; 
CIC, circulating immune complexes; cryo-Ig, cryoimmunoglobulin; C3, complement component 3; FANA, fluorescent antinuclear antibody assay; Ig, immunoglobulin levels; SLE, 
systemic lupus erythematosus; −, normal; +, occasionally slightly abnormal; ++, often abnormal; +++, severely abnormal.
Source: RJ Glassock, BM Brenner: HPIM-13.
977
SECTION 10
978
Nephrology
of metabolic acidosis (if present), then tight control of blood pressure with 
alternative agents is warranted. 
Evaluation of NS is shown in Table 152-4.
ASYMPTOMATIC URINARY ABNORMALITIES
Proteinuria in the nonnephrotic range and/or hematuria unaccompanied 
by edema, reduced GFR, or hypertension can be due to multiple causes 
(Table 152-5).
Thin Basement Membrane Nephropathy 
Also known as benign familial hematuria, may cause up to 25% of isolated, 
sustained hematuria without proteinuria. Diffuse thinning of the glomeru-
lar basement membrane on renal biopsy, with minimal other changes. May 
be hereditary, caused in some instances by defects in type IV collagen. Pts 
have persistent glomerular hematuria, with minimal proteinuria. The renal 
prognosis is controversial but appears to be relatively benign.
IgA Nephropathy 
Another very common cause of recurrent hematuria of glomerular origin; is 
most frequent in young men. Episodes of macroscopic hematuria are present 
with flulike symptoms, without skin rash, abdominal pain, or arthritis. Renal 
biopsy shows diffuse mesangial deposition of IgA, often with lesser amounts 
of IgG, nearly always by C3 and properdin but not by C1q or C4. Prognosis 
is variable; 50% develop ESRD within 25 years; men with hypertension and 
heavy proteinuria are at highest risk. Glucocorticoids and other immuno-
suppressive agents have not proved successful, except in pts who present with 
rapidly progressive GN. A randomized clinical trial of fish oil supplementa-
tion suggested a modest therapeutic benefit. Rarely recurs in allografts.
Glomerulopathies Associated with Multisystem Disease (Table 152-6)
For a more detailed discussion, see Lewis JB, Neilson EG: 
Glomerular Diseases, Chap. 283, p. 2334, in HPIM-18. 
CHAPTER 153
Renal Tubular Disease
Tubulointerstitial diseases constitute a diverse group of acute and chronic, 
hereditary and acquired disorders involving the renal tubules and support-
ing structures (Table 153-1). Functionally, they may result in a wide variety 
of physiologic phenotypes, including nephrogenic diabetes insipidus (DI) 
with polyuria, non-anion-gap metabolic acidosis, salt wasting, and hypo- 
or hyperkalemia. Azotemia is common, owing to associated glomerular 
fibrosis and/or ischemia. Compared with glomerulopathies, proteinuria 
CHAPTER 153
979
Renal Tubular Disease
TABLE 153-1  PRINCIPAL CAUSES OF TUBULOINTERSTITIAL DISEASE OF 
THE KIDNEY
Toxins
Exogenous toxins
Metabolic toxins
 Analgesic nephropathya
 Acute uric acid nephropathy
 Lead nephropathy
 Gouty nephropathya
 Chinese herb nephropathy
 Hypercalcemic nephropathy
 Balkan endemic nephropathy
 Hypokalemic nephropathy
  Miscellaneous nephrotoxins 
(e.g., antibiotics, cyclosporine, 
radiographic contrast media, 
heavy metals)a,b
  Miscellaneous metabolic toxins 
(e.g., hyperoxaluria, cystinosis, 
Fabry’s disease)
Neoplasia
Lymphoma
Leukemia
Multiple myeloma (cast nephropathy, 
AL amyloidosis)
Immune disorders
Acute (allergic) interstitial nephritisa,b
Transplant rejection
Sjögren’s syndrome
HIV-associated nephropathy
Amyloidosis
Vascular disorders
Arteriolar nephrosclerosisa
Sickle cell nephropathy
Atheroembolic disease
Acute tubular necrosisa,b
Hereditary renal diseases
Disorders associated with renal 
failure
Hereditary tubular disorders
  Autosomal dominant polycystic 
kidney disease
Bartter’s syndrome (hereditary 
hypokalemic alkalosis)
  Autosomal recessive polycystic 
kidney disease
Gitelman’s syndrome (hereditary 
hypokalemic alkalosis)
 Medullary cystic kidney disease
Pseudohypoaldosteronism type I 
(hypotension/salt wasting and 
hyperkalemia)
  Hereditary nephritis (Alport’s 
syndrome)
Pseudohypoaldosteronism type II 
(hereditary hypertension and 
hyperkalemia)
Liddle’s syndrome (hypertension and 
hypokalemia)
Hereditary hypomagnesemia
(continued)
SECTION 10
980
Nephrology
and hematuria are less dramatic, and hypertension is less common. The 
functional consequences of tubular dysfunction are outlined in Table 153-2.
ACUTE INTERSTITIAL NEPHRITIS (AIN)
Drugs are a leading cause of this type of renal failure, usually identified by 
a gradual rise in the serum creatinine at least several days after the institu-
tion of therapy, occasionally accompanied by fever, eosinophilia, rash, and 
arthralgias. The onset of renal dysfunction may be very rapid in pts who 
have previously been sensitized to the offending agent; this is particularly 
true for rifampin, for which intermittent or interrupted therapy appears to 
be associated with the development of AIN. In addition to azotemia, there 
may be evidence of tubular dysfunction (e.g., hyperkalemia, metabolic 
acidosis). Urinalysis may show hematuria, pyuria, white cell casts, and 
eosinophiluria on Hansel’s or Wright’s stain; notably, however, eosin-
ophiluria is not specific for AIN, occurring in other causes of acute kidney 
injury (AKI), including atheroemboli.
Drugs that commonly cause AIN are listed in Table 153-3. Some drugs 
have a particular predilection for causing AIN, e.g., nafcillin; however, less 
frequent causes may be apparent only from case reports, such that a detailed 
history and literature review may be required to make the association 
with AIN. Many drugs, nonsteroidal anti-inflammatory drugs (NSAIDs) 
in particular, may elicit a glomerular lesion with similarity to minimal 
change disease, in addition to AIN; these pts typically have nephrotic-range 
proteinuria, versus the modest proteinuria typically associated with 
tubulointerstitial disease.
Renal dysfunction in drug-associated AIN usually improves after with-
drawal of the offending drug, but complete recovery may be delayed and 
TABLE 153-1  PRINCIPAL CAUSES OF TUBULOINTERSTITIAL DISEASE OF 
THE KIDNEY (CONTINUED)
Hereditary renal diseases
Hereditary nephrogenic diabetes 
insipidus
  X-linked (AVP receptor dysfunction)
  Autosomal (aquaporin-2 dysfunction)
Infectious injury
Acute pyelonephritisa,b
Chronic pyelonephritis
Miscellaneous disorders
Chronic urinary tract obstructiona
Vesicoureteral refluxa
Radiation nephritis
aCommon.
bTypically acute.
CHAPTER 153
981
Renal Tubular Disease
incomplete. In uncontrolled studies, glucocorticoids have been shown to 
promote earlier recovery of renal function and reduce fibrosis; this therapy 
is generally reserved to avoid or reduce the duration of dialytic therapy in 
pts who fail to respond to medication withdrawal.
AIN may also occur in the context of systemic infections, classically 
leptospirosis, Legionella infection, and streptococcal bacterial infection. 
Interstitial nephritis characterized by a dense infiltrate of IgG4-expressing 
plasma cells can occur as part of IgG4-related systemic disease; pancreatitis, 
retroperitoneal fibrosis, and a chronic sclerosing sialadenitis may variably 
be present. Finally, the tubulointerstitial nephritis and uveitis syndrome 
(TINU) is another increasingly recognized form of AIN. In addition to 
uveitis, which may precede or follow the AIN in pts with TINU, systemic 
symptoms and signs are common, e.g., weight loss, fever, malaise, arthral-
gias, and an elevated erythrocyte sedimentation rate. The renal disease is 
typically self-limited; those with progressive disease are often treated with 
prednisone.
TABLE 153-2  TRANSPORT DYSFUNCTION IN TUBULOINTERSTITIAL 
DISEASE
Defect
Cause(s)
Reduced GFRa
Obliteration of microvasculature and obstruction 
of tubules 
Fanconi syndrome
Damage to proximal tubular reabsorption of 
solutes, primarily glucose, amino acids, and 
phosphate; may also exhibit hypouricemia, 
proximal tubular acidosis, low-molecular-weight 
proteinuria
Hyperchloremic acidosisa
1.  Reduced ammonia production (CKD) or 
excretion (hyperkalemia)
2.  Inability to acidify the collecting duct fluid 
(distal renal tubular acidosis)
3. Proximal bicarbonate wasting (proximal RTA)
Polyuria, isothenuriaa
Damage to medullary tubules (thick ascending 
limb and/or collecting duct) and vasculature
Hypokalemic alkalosis
Damage or hereditary dysfunction of the thick 
ascending limb or distal convoluted tubule 
(Bartter’s and Gitelman’s syndromes)
Magnesium wasting
Damage or hereditary dysfunction of the thick 
ascending limb or distal convoluted tubules
Hyperkalemiaa
Potassium secretory defects including aldosterone 
resistance
Salt wasting
Distal tubular damage with impaired sodium 
reabsorption
aCommon.
Abbreviations: CKD, chronic kidney disease; GFR, glomerular filtration rate; RTA, renal tubular 
acidosis.
SECTION 10
982
Nephrology
CHRONIC INTERSTITIAL NEPHRITIS (IN)
Analgesic nephropathy is an important cause of chronic kidney disease that 
results from the cumulative (in quantity and duration) effects of combina-
tion analgesic agents, usually phenacetin and aspirin. It is thought to be a 
more common cause of end-stage renal disease (ESRD) in Australia/New 
Zealand than elsewhere owing to the larger per capita ingestion of analgesic 
agents in that region of the world. Transitional cell carcinoma may develop. 
Analgesic nephropathy should be suspected in pts with a history of chronic 
headache or back pain with chronic kidney disease (CKD) that is other-
wise unexplained. Manifestations include papillary necrosis, calculi, sterile 
pyuria, and azotemia.
A severe form of chronic tubulointerstitial fibrosis has been associated 
with the ingestion of Chinese herbal medicines, typically employed as part 
of a dieting regimen; Balkan endemic nephropathy (BEN), geographically 
restricted to pts from this region of southeastern Europe, shares many 
similarities with Chinese herbal nephropathy. These disorders are thought 
to be caused by exposure to aristolochic acid and/or other plant, endemic 
(in BEN), and medical toxins (the appetite suppressants fenfluramine and 
diethylpropion, in Chinese herbal nephropathy). Like analgesic nephropa-
thies, these syndromes are both characterized by a high incidence of 
genitourinary malignancy.
TABLE 153-3 CAUSES OF ACUTE INTERSTITIAL NEPHRITIS
Drugs (70%, antibiotics in one-third)
 Antibiotics
  Methicillin, nafcillin, oxacillin
  Rifampin
  Penicillins, cephalosporins
  Ciprofloxacin
  Sulfamethoxazole and other sulfonamides
 Proton pump inhibitors, e.g., omeprazole
 H2 blockers, e.g., cimetidine
 Allopurinol
 5-Aminosalicylates
 NSAIDs, including COX-2 inhibitors
Infections (16%)
 Leptospirosis, Legionella, streptococcal, tuberculosis
Tubulointerstitial nephritis and uveitis syndrome (TINU) (5%)
Idiopathic (8%)
Sarcoidosis (1%)
IgG4-related systemic disease
Abbreviations: COX-2, cyclooxygenase 2; NSAIDs, nonsteroidal anti-inflammatory drugs.
CHAPTER 153
983
Renal Tubular Disease
Chronic therapy with lithium can also cause a chronic tubulointerstitial 
nephritis, often accompanied by nephrogenic DI that persists following 
discontinuation of the medication. If at all feasible, lithium-treated pts with 
evolving CKD should be transitioned to alternative medications for their 
psychiatric disease (e.g., valproic acid).
Metabolic causes of chronic IN include hypercalcemia (with nephrocal-
cinosis), oxalosis (primary or secondary, e.g., with intestinal disease and 
hyperabsorption of dietary oxalate), hypokalemia, and hyperuricemia or 
hyperuricosuria. The renal pathology associated with chronic hypokalemia 
includes a relatively specific proximal tubular vacuolization, interstitial 
nephritis, and renal cysts; both chronic and acute renal failure have been 
described. Chronic IN can occur in association with several systemic 
diseases, including sarcoidosis, Sjögren’s syndrome, and following radiation 
or chemotherapy exposure (e.g., ifosfamide, cisplatin).
MONOCLONAL IMMUNOGLOBULINS AND RENAL DISEASE
Monoclonal immunoglobulins are associated with a wide variety of renal 
manifestations (Table 153-4), of which myeloma-associated cast nephropathy 
is the most common. The physiochemical characteristics of the monoclonal 
immunoglobulin light or heavy chains determine the clinical phenotype in 
individual pts, most commonly cast nephropathy, light chain deposition dis-
ease, and AL amyloidosis. In cast nephropathy, filtered light chains aggregate 
and cause tubular obstruction, tubular damage, and interstitial inflammation. 
TABLE 153-4  RENAL DISEASES ASSOCIATED WITH MONOCLONAL 
IMMUNOGLOBULINS
Disease
Notes
Cast nephropathy
Most common cause of CKD in myeloma
Tubular obstruction with light chains
Interstitial inflammation
Acute or chronic renal failure
Light chain deposition disease Nephrotic syndrome, chronic renal failure, 
~40% have associated myeloma
Heavy chain deposition disease Nephrotic syndrome, chronic renal failure
AL amyloidosis
Nephrotic syndrome, cardiac/endocrine/
neuropathic involvement
~10% have associated myeloma
Renal tubular dysfunction (RTA, nephrogenic 
DI, etc.)
Hypercalcemia
With myeloma
Hyperviscosity syndrome
With Waldenström’s macroglobulinemia
Fanconi syndrome
Glucosuria, aminoaciduria, phosphaturia, 
± hypouricemia, proximal RTA, etc.
Abbreviations: CKD, chronic kidney disease; DI, diabetes insipidus; RTA, renal tubular acidosis.
SECTION 10
984
Nephrology
Pts can present with CKD or with AKI; important predisposing factors in 
acute cast nephropathy include hypercalcemia and volume depletion.
Diagnosis of cast nephropathy relies on the detection of monoclonal 
light chains in serum and/or urine, typically by protein electrophoresis and 
immunofixation. Dipstick analysis of the urine for protein is classically 
negative in cast nephropathy, despite the excretion of up to several grams 
a day of light chain protein; light chains are not detected by this screening 
test, which tests only for albuminuria. In contrast, the glomerular deposi-
tion of light chains in light chain deposition disease or AL amyloidosis can 
result in nephrotic-range proteinuria (Table 153-4), with strongly positive 
urine dipstick for protein.
Management of cast nephropathy encompasses aggressive hydration, 
treatment of hypercalcemia if present, and chemotherapy for the associated 
multiple myeloma. Some experts advocate the use of plasmapheresis for pts 
with severe AKI, high levels of serum monoclonal light chains, and a renal 
biopsy demonstrating cast nephropathy.  
Filtered light chains and multiple other low-molecular-weight proteins 
are also endocytosed and metabolized by the proximal tubule. Rarely, 
specific light chains generate crystalline depositions within proximal tubule 
cells, causing a Fanconi syndrome; again, this property appears to be caused 
by the specific physicochemical characteristics of the associated light chains. 
Fanconi syndrome or dysfunction of the distal nephron (hyperkalemic 
acidosis or nephrogenic DI) may also complicate renal amyloidosis.
POLYCYSTIC KIDNEY DISEASE
Autosomal dominant polycystic kidney disease (ADPKD) is the most com-
mon life-threatening monogenic genetic disorder, caused by autosomal 
dominant mutations in the PKD1 and PKD2 genes; it is a quantitatively 
important cause of ESRD. Autosomal recessive polycystic disease is a less 
much common cause of renal failure, typically presenting in infancy; hepatic 
involvement is much more prominent. The massive renal cysts in ADPKD 
can lead to progressive CKD, episodic flank pain, hematuria (often gross), 
hypertension, and/or urinary tract infection. The kidneys are often palpable 
and occasionally of very large size. Hepatic cysts and intracranial aneurysms 
may also be present; pts with ADPKD and a family history of ruptured 
intracranial aneurysms should undergo presymptomatic screening. Other 
common extrarenal features include diverticulosis and mitral valve prolapse.
The expression of ADPKD is highly variable, with the age of onset of 
ESRD ranging from childhood to old age. The renal phenotype is much 
milder in pts with mutations in PKD1, who on average develop ESRD 
approximately 15 years earlier than those with PKD2 mutations. Indeed, 
some pts with ADPKD discover the disease incidentally in late adult life, 
having had mild to moderate hypertension earlier.
The diagnosis is usually made by ultrasonography. In a 15- to 29-year-old 
at-risk individual from a family with ADPKD, the presence of at least 
two renal cysts (unilateral or bilateral) is sufficient for diagnosis. Notably, 
however, renal cysts are a common ultrasound finding in older pts without 
ADPKD, particularly those with CKD. Therefore, in at-risk individuals 
30–59 years of age, the presence of at least two cysts in each kidney is 
CHAPTER 153
985
Renal Tubular Disease
required for the diagnosis; this increases to four cysts in each kidney for 
those older than 60. Conversely, the absence of at least two cysts in each 
kidney excludes the diagnosis of ADPKD in at-risk individuals between the 
ages of 30 and 59.
Hypertension is common in ADPKD, often in the absence of an apparent 
reduction in glomerular filtration rate. Activation of the renin-angiotensin 
system appears to play a dominant role; angiotensin-converting enzyme 
inhibitors or angiotensin receptor blockers are the recommended antihy-
pertensive agents, with a target blood pressure of 120/80 mmHg. Promising 
treatment modalities for halting progression of CKD in ADPKD include 
vasopressin antagonists, which dramatically reduce cyst enlargement and 
renal progression in animal models.
Urinary tract infections are also common in ADPKD. In particular, pts 
may develop cyst infections, often with negative urine cultures and an 
absence of pyuria. Pts with an infected cyst may have a discrete area of 
tenderness, as opposed to the more diffuse discomfort of pyelonephritis; 
however, clinical distinction between these two possibilities can be prob-
lematic. Many commonly used antibiotics, including penicillins and ami-
noglycosides, fail to penetrate cysts and are ineffective; therapy of kidney 
infections in ADPKD should use an antibiotic that is known to penetrate 
cysts (e.g., quinolones), guided initially by local antimicrobial susceptibility 
patterns.
RENAL TUBULAR ACIDOSIS (RTA)
This describes a number of pathophysiologically distinct entities of tubular 
function whose common feature is the presence of a non-anion-gap meta-
bolic acidosis. Diarrhea, CKD, and RTA together constitute the vast major-
ity of cases of non-anion-gap metabolic acidosis. Pts with earlier stages 
of CKD (Table 52-1) typically develop a non-anion-gap acidosis, with a 
superimposed increase in the anion gap at later stages (Chap. 2). Acidosis 
may develop at an earlier stage of CKD in those with prominent injury to 
the distal nephron, as for example in reflux nephropathy.
Distal Hypokalemic (Type I) RTA 
Pts are unable to acidify the urine despite systemic acidosis; the urinary 
anion gap is positive, reflective of a decrease in ammonium excretion 
(Chap. 2). Distal hypokalemic RTA may be inherited (both autosomal 
dominant and autosomal recessive) or acquired due to autoimmune and 
inflammatory diseases (e.g., Sjögren’s syndrome, sarcoidosis), urinary tract 
obstruction, or amphotericin B therapy. Chronic type I RTA is typically 
associated with hypercalciuria and osteomalacia, a consequence of the long-
term buffering of acidosis by bone.
Proximal (Type II) RTA 
There is a defect in bicarbonate reabsorption, usually associated with 
features of Fanconi syndrome, including glycosuria, aminoaciduria, phos-
phaturia, and uricosuria (indicating proximal tubular dysfunction). Isolated 
proximal RTA is caused by hereditary dysfunction of the basolateral 
sodium-bicarbonate cotransporter. Fanconi syndrome may be inherited or 
SECTION 10
986
Nephrology
acquired due to myeloma, chronic IN (e.g., Chinese herbal nephropathy), 
or drugs (e.g., ifosfamide, tenofovir). Treatment requires large doses of 
bicarbonate (5–15 mmol/kg per day), which may aggravate hypokalemia.
Type IV RTA 
This may be due to hyporeninemic hypoaldosteronism or to resistance of the 
distal nephron to aldosterone. Hyporeninemic hypoaldosteronism is typically 
associated with volume expansion and most commonly seen in elderly and/
or diabetic pts with CKD. The hyperkalemia associated with NSAIDs and 
cyclosporine is at least partially due to hyporeninemic hypoaldosteronism. Pts 
with hyporeninemic hypoaldosteronism are typically hyperkalemic; they may 
also exhibit a mild non-anion-gap acidosis, with urine pH <5.5 and a positive 
urinary anion gap. Acidosis often improves with reduction in serum [K+]; 
hyperkalemia appears to interfere with medullary concentration of ammo-
nium by the renal countercurrent mechanism. Should reduction in serum [K+] 
not improve acidosis, pts should be treated with oral bicarbonate or citrate. 
Finally, various forms of distal tubular injury and tubulointerstitial disease, 
e.g., interstitial nephritis, are associated with distal insensitivity to aldosterone; 
urine pH is classically >5.5, again with a positive urinary anion gap.
For a more detailed discussion, see Beck LH, Salant DJ: 
Tubulointerstitial Diseases of the Kidney, Chap. 285, p. 2367, 
in HPIM-18.  
CHAPTER 154
Urinary Tract Infections 
and Interstitial Cystitis
URINARY TRACT INFECTIONS
Definitions
The term urinary tract infection (UTI) encompasses a variety of clini-
cal entities: cystitis (symptomatic disease of the bladder), pyelonephritis 
(symptomatic disease of the kidney), prostatitis (symptomatic disease of 
the prostate), and asymptomatic bacteriuria (ABU). Uncomplicated UTI 
refers to acute disease in nonpregnant outpatient women without anatomic 
abnormalities or instrumentation of the urinary tract; complicated UTI 
refers to all other types of UTI.
Epidemiology 
UTI occurs far more commonly in females than in males, although obstruc-
tion from prostatic hypertrophy causes men >50 years old to have an 
incidence of UTI comparable to that among women of the same age. 
CHAPTER 154
987
Urinary Tract Infections and Interstitial Cystitis 
• 50–80% of women have at least one UTI during their lifetime, and 
20–30% of women have recurrent episodes.
• Risk factors for acute cystitis include recent use of a diaphragm with 
spermicide, frequent sexual intercourse, a history of UTI, diabetes 
mellitus, and incontinence; many of these factors also increase the risk 
of pyelonephritis.
Microbiology 
In the United States, Escherichia coli accounts for 75–90% of cystitis isolates; 
Staphylococcus saprophyticus for 5–15%; and Klebsiella species, Proteus spe-
cies, Enterococcus species, Citrobacter species, and other organisms for 5–10%. 
• The spectrum of organisms causing uncomplicated pyelonephritis is 
similar, with E. coli predominating.
• Gram-positive bacteria (e.g., enterococci and Staphylococcus aureus) and 
yeasts are also important pathogens in complicated UTI.
Pathogenesis 
In the majority of UTIs, bacteria establish infection by ascending from the 
urethra to the bladder. Continuing ascent up the ureter to the kidney is the 
pathway for most renal parenchymal infections.
• The pathogenesis of candiduria is distinct in that the hematogenous 
route is common.
• The presence of Candida in the urine of a noninstrumented immu-
nocompetent pt implies either genital contamination or potentially 
widespread visceral dissemination.
Clinical Manifestations 
When a UTI is suspected, the most important issue is to classify it as ABU; as 
uncomplicated cystitis, pyelonephritis, or prostatitis; or as complicated UTI.
• Asymptomatic bacteriuria is diagnosed when a screening urine culture 
performed for a reason unrelated to the genitourinary tract is inciden-
tally found to contain bacteria, but the pt has no local or systemic symp-
toms referable to the urinary tract.
• Cystitis presents with dysuria, urinary frequency, and urgency; nocturia, 
hesitancy, suprapubic discomfort, and gross hematuria are often noted 
as well. Unilateral back or flank pain and fever are signs that the upper 
urinary tract is involved.
• Pyelonephritis presents with fever, lower-back or costovertebral-angle 
pain, nausea, and vomiting. Bacteremia develops in 20–30% of cases. 
– Papillary necrosis can occur in pts with obstruction, diabetes, sickle 
cell disease, or analgesic nephropathy.
– Emphysematous pyelonephritis is particularly severe, is associated with 
the production of gas in renal and perinephric tissues, and occurs 
almost exclusively in diabetic pts.
– Xanthogranulomatous pyelonephritis occurs when chronic urinary 
obstruction (often by staghorn calculi), together with chronic infec-
tion, leads to suppurative destruction of renal tissue.
• Prostatitis can be either infectious or noninfectious; noninfectious cases 
are far more common. Acute bacterial prostatitis presents with dysuria, 
SECTION 10
988
Nephrology
urinary frequency, fever, chills, symptoms of bladder outlet obstruction, 
and pain in the prostatic, pelvic, or perineal area.
• Complicated UTI presents as symptomatic disease in a man or woman with 
an anatomic predisposition to infection, with a foreign body in the urinary 
tract, or with factors predisposing to a delayed response to therapy.
Diagnosis
The clinical history itself has a high predictive value in diagnosing uncom-
plicated cystitis; in a pt presenting with both dysuria and urinary frequency 
in the absence of vaginal discharge, the likelihood of UTI is 96%.
• A urine dipstick test positive for nitrite or leukocyte esterase can confirm 
the diagnosis of uncomplicated cystitis in pts with a high pretest prob-
ability of disease.
• The detection of bacteria in a urine culture is the diagnostic gold stan-
dard for UTI. A colony count threshold of >102 bacteria/mL is more 
sensitive (95%) and specific (85%) than a threshold of 105/mL for the 
diagnosis of acute cystitis in women with symptoms of cystitis.
Urinary Tract Infections
TREATMENT
• Uncomplicated cystitis in women See Table 154-1 for effective the ra-
peutic regimens.
– Trimethoprim-sulfamethoxazole (TMP-SMX) has been recom-
mended as first-line treatment for acute cystitis, but should be 
avoided in regions with resistance rates >20%.
– Nitrofurantoin is another first-line agent with low rates of resistance.
– Fluoroquinolones should be used only when other antibiotics are 
not suitable because of increasing resistance or their role in prompt-
ing nosocomial outbreaks of Clostridium difficile infection.
– Except for pivmecillinam, β-lactam agents are associated with lower 
rates of pathogen eradication and higher rates of relapse.
• Pyelonephritis Given high rates of TMP-SMX-resistant E. coli, fluoro-
quinolones (e.g., ciprofloxacin, 500 mg PO bid for 7 days) are first-line 
agents for the treatment of acute uncomplicated pyelonephritis. Oral 
TMP-SMX (one double-strength tablet bid for 14 days) is effective 
against susceptible uropathogens. 
• UTI in pregnant women Nitrofurantoin, ampicillin, and the cephalo-
sporins are considered relatively safe in early pregnancy. 
• UTI in men In men with apparently uncomplicated UTI, a 7- to 
14-day course of a fluoroquinolone or TMP-SMX is recommended.
– If acute bacterial prostatitis is suspected, antibiotics should be 
initiated after urine and blood are obtained for cultures. 
– Therapy can be tailored to urine culture results and should be con-
tinued for 2–4 weeks; a 4- to 6-week course is often necessary for 
chronic bacterial prostatitis.
• Asymptomatic bacteriuria ABU should be treated only in pregnant 
women, in pts undergoing urologic surgery, and perhaps in neutro-
penic pts and renal transplant recipients; antibiotic choice is guided 
by culture results.
CHAPTER 154
989
Urinary Tract Infections and Interstitial Cystitis 
• Catheter-associated UTI Urine culture results are essential to guide 
therapy. 
– Replacing the catheter during treatment is generally necessary. 
Candiduria, a common complication of indwelling catheterization, 
resolves in ~1/3 of cases with catheter removal. 
– Treatment (fluconazole, 200–400 mg/d for 14 days) is recommended 
for pts who have symptomatic cystitis or pyelonephritis and for 
those who are at high risk for disseminated disease.
Prevention of Recurrent UTI
Women experiencing symptomatic UTIs ≥2 times a year are candidates 
for prophylaxis—either continuous or postcoital—or pt-initiated therapy. 
Continuous prophylaxis and postcoital prophylaxis usually entail low doses 
of TMP-SMX, a fluoroquinolone, or nitrofurantoin. Pt-initiated therapy 
involves supplying the pt with materials for urine culture and for self-
medication with a course of antibiotics at the first symptoms of infection. 
Prognosis
In the absence of anatomic abnormalities, recurrent infection in children 
and adults does not lead to chronic pyelonephritis or to renal failure.
TABLE 154-1  TREATMENT STRATEGIES FOR ACUTE UNCOMPLICATED 
CYSTITIS
Drug and Dose
Estimated
Clinical
Efficacy (%)
Estimated
Bacterial
Efficacy (%)
Common
Side Effects
Nitrofurantoin, 
100 mg bid × 5–7 d
84–95
86–92
Nausea, headache
TMP-SMX, 
1 DS tablet bid × 3 d
90–100
91–100
Rash, urticaria, nausea, 
vomiting, hematologic 
abnormalities
Fosfomycin, 3-g 
single-dose sachet
70–91
78–83
Diarrhea, nausea, 
headache
Pivmecillinam, 
400 mg bid × 3–7 d
55–82
74–84
Nausea, vomiting, 
diarrhea
Fluoroquinolones, 
dose varies by agent; 
3-d regimen
85–95
81–98
Nausea, vomiting, 
diarrhea, headache, 
drowsiness, insomnia
β-Lactams, dose 
varies by agent; 5- 
to 7-d regimen
79–98
74–98
Diarrhea, nausea, 
vomiting, rash, 
urticaria
Note: Efficacy rates are averages or ranges calculated from the data and studies included in 
the 2010 Infectious Diseases Society of America/European Society of Clinical Microbiology and 
Infectious Diseases guidelines for treatment of uncomplicated UTI. 
Abbreviations: DS, double-strength; TMP-SMX, trimethoprim-sulfamethoxazole. 
SECTION 10
990
Nephrology
INTERSTITIAL CYSTITIS
Interstitial cystitis (painful bladder syndrome) is a chronic condition char-
acterized by pain perceived to be from the urinary bladder, urinary urgency 
and frequency, and nocturia.
Epidemiology 
In the United States, 2–3% of women and 1–2% of men have interstitial 
cystitis. Among women, the average age at onset is the early forties, but the 
range is from childhood through the early sixties.
Etiology 
The etiology remains unknown.
• Theoretical possibilities include chronic bladder infection, inflammatory 
factors such as mast cells, autoimmunity, increased permeability of the 
bladder mucosa, and abnormal pain sensitivity. 
• However, few data support any of these factors as an inciting cause.
Clinical Manifestations 
The cardinal symptoms of pain (often at ≥2 sites), urinary urgency and 
frequency, and nocturia occur in no consistent order. Symptoms can begin 
acutely or gradually.
• Unlike pelvic pain arising from other sources, pain caused by interstitial 
cystitis is exacerbated by bladder filling and relieved by bladder emptying.
• 85% of pts void >10 times per day; some do so as often as 60 times per day.
• Many pts with interstitial cystitis have comorbid functional somatic 
syndromes (e.g., fibromyalgia, chronic fatigue syndrome, irritable bowel 
syndrome, vulvodynia, migraine).
Diagnosis
The diagnosis is based on the presence of appropriate symptoms and the 
exclusion of diseases with a similar presentation (e.g., diseases that manifest 
with pelvic pain and/or urinary symptoms, functional somatic syndromes 
with urinary symptoms); physical exam and laboratory findings are insensitive 
and/or nonspecific. Cystoscopy may reveal an ulcer (10% of pts) or petechial 
hemorrhages after bladder distension, but neither of these findings is specific.
Interstitial Cystitis
TREATMENT
The goal of therapy is the relief of symptoms, which often requires a mul-
tifaceted approach (e.g., education, dietary changes, medications such as 
nonsteroidal anti-inflammatory drugs or amitriptyline, pelvic-floor physi-
cal therapy, and treatment of associated functional somatic syndromes).
For a more detailed discussion, see Gupta K, Trautner 
BW: Urinary Tract Infections, Pyelonephritis, and Prostatitis, 
Chap. 288, p. 2387, in HPIM-18.
CHAPTER 155
991
Renovascular Disease
CHAPTER 155
Renovascular Disease
Ischemic injury to the kidney depends on the rate, site, severity, and dura-
tion of vascular compromise. Manifestations range from painful infarction 
to acute kidney injury (AKI), impaired glomerular filtration rate (GFR), 
hematuria, or tubular dysfunction. Renal ischemia of any etiology may 
cause renin-mediated hypertension.
ACUTE OCCLUSION OF A RENAL ARTERY
Can be due to thrombosis or embolism (from valvular disease, endocarditis, 
mural thrombi, or atrial arrhythmias) or to intraoperative occlusion, e.g., 
during endovascular repair of abdominal aortic aneurysms.
Thrombosis of Renal Arteries 
Large renal infarcts cause pain, vomiting, nausea, hypertension, fever, pro-
teinuria, hematuria, and elevated lactate dehydrogenase (LDH) and aspartate 
aminotransferase. In unilateral lesion, renal functional loss depends on 
contralateral function. IV pyelogram or radionuclide scan shows unilateral 
hypofunction; ultrasound is typically normal until scarring develops. Renal 
arteriography establishes diagnosis. With occlusions of large arteries, surgery 
may be required; anticoagulation should be used for occlusions of small arter-
ies. Pts should be evaluated for a thrombotic diathesis, e.g., antiphospholipid 
syndrome. Occlusion of one or both of the renal arteries can also rarely occur 
in pts treated with angiotensin-converting enzyme (ACE) inhibitors, typically 
in association with significant underlying renal artery stenosis.
Renal Atheroembolism 
Usually arises when aortic or coronary angiography or surgery causes cho-
lesterol embolization of small renal vessels in a pt with diffuse atheroscle-
rosis. May also be spontaneous or associated with thrombolysis, or rarely 
may occur after the initiation of anticoagulation (e.g., with warfarin). Renal 
insufficiency may develop suddenly, a few days or weeks after a procedure 
or intervention, or gradually; the pace may alternatively be progressive or 
“stuttering,” with punctuated drops in GFR. Associated findings can include 
retinal ischemia with cholesterol emboli visible on funduscopic examination, 
pancreatitis, neurologic deficits (especially confusion), livedo reticularis, 
peripheral embolic phenomena (e.g., gangrenous toes with palpable pedal 
pulses), abdominal pain from mesenteric emboli, and hypertension (some-
times malignant). Systemic symptoms may also occur, including fever, 
myalgias, headache, and weight loss. Peripheral eosinophilia, eosinophi-
luria, and hypocomplementemia may be observed, mimicking other forms 
of acute and subacute renal injury. Indeed, atheroembolic renal disease is 
the “great imitator” of clinical nephrology, presenting in rare instances with 
malignant hypertension, with nephrotic syndrome, or with what looks like 
rapidly progressive glomerulonephritis with an “active” urinary sediment; 
the diagnosis is made by history, clinical findings, and/or the renal biopsy.
SECTION 10
992
Nephrology
Renal biopsy is usually successful in detecting the cholesterol emboli in 
the renal microvasculature, which are seen as needle-shaped clefts after 
solvent fixation of the biopsy specimen; these emboli are typically associated 
with an exuberant intravascular inflammatory response.
There is no specific therapy, and pts have a poor overall prognosis due to 
the associated burden of atherosclerotic vascular disease. However, there is 
often a partial improvement in renal function several months after the onset 
of renal impairment.
RENAL VEIN THROMBOSIS
This occurs in a variety of settings, including pregnancy, oral contraceptive 
use, trauma, nephrotic syndrome (especially membranous nephropathy; 
see Chap. 152), dehydration (in infants), extrinsic compression of the renal 
vein (lymph nodes, aortic aneurysm, tumor), and invasion of the renal vein 
by renal cell carcinoma. Definitive diagnosis is established by selective renal 
renography. Thrombolytic therapy may be effective. Oral anticoagulants 
(warfarin) are usually prescribed for longer-term therapy.
RENAL ARTERY STENOSIS AND ISCHEMIC NEPHROPATHY 
(SEE TABLE 155-1)
Main cause of renovascular hypertension. Due to (1) atherosclerosis (two-
thirds of cases; usually men age >60 years, advanced retinopathy, history or 
findings of generalized atherosclerosis, e.g., femoral bruits) or (2) fibromus-
cular dysplasia (one-third of cases; usually white women age <45 years, brief 
history of hypertension). Renal hypoperfusion due to renal artery stenosis 
(RAS) activates the renin-angiotensin-aldosterone (RAA) axis. Suggestive 
clinical features include onset of hypertension <30 or >50 years of age, 
abdominal or femoral bruits, hypokalemic alkalosis, moderate to severe 
retinopathy, acute onset of hypertension or malignant hypertension, recur-
rent episodes of acute, otherwise unexplained pulmonary edema (typically 
with bilateral RAS or RAS in a solitary kidney), and hypertension resistant 
to medical therapy. Malignant hypertension (Chap. 126) may also be caused 
by renal vascular occlusion. Pts, particularly those with bilateral atheroscle-
rotic disease, may develop chronic kidney disease (ischemic nephropathy). 
Although the incidence is difficult to assess, ischemic nephropathy is clearly 
a major cause of end-stage renal disease (ESRD) in those over 50.
Nitroprusside, labetalol, or calcium antagonists are generally effective in 
lowering blood pressure (bp) acutely; inhibitors of the RAA axis (e.g., ACE 
inhibitors, angiotensin II receptor blockers) are the most effective long-
term treatment.
The “gold standard” in diagnosis of renal artery stenosis is conventional 
arteriography. Magnetic resonance angiography (MRA) has been used in 
many centers, given the risk of radiographic contrast nephropathy in pts 
with renal insufficiency; however, the newly appreciated risk of nephro-
genic systemic fibrosis (NSF) in pts with renal insufficiency, attributed to 
gadolinium-containing MRI contrast agents, has dramatically restricted 
this practice in most institutions. Duplex ultrasonography is an alternative, 
but only if experienced operators are available. In pts with normal renal 
function and hypertension, the captopril (or enalaprilat) renogram may be 
CHAPTER 155
993
Renovascular Disease
used as a screening test. Lateralization of renal function [accentuation of 
the difference between affected and unaffected (or “less affected”) sides] is 
suggestive of significant vascular disease. Test results may be falsely negative 
in the presence of bilateral disease.
Medical therapy is advocated for most pts with renal artery stenosis, such 
that investigation of suspected RAS should be reserved for those in whom 
an intervention is anticipated. Medical management of atherosclerotic RAS 
should include lifestyle modification and management of dyslipidemia 
(Fig. 155-1). Intervention, i.e., revascularization, should be considered in 
the following scenarios: (1) progressive, otherwise-unexplained reduction in 
GFR during treatment of systemic hypertension; (2) poorly controlled hyper-
tension despite multiple agents at maximally tolerated dosages; (3) rapid or 
recurrent decline in GFR in association with reduction in systemic pressure; 
and/or (4) recurrent episodes of acute, otherwise unexplained pulmo-
nary edema. Notably, pts should always be re-evaluated frequently (every 
3–6 months) for the progression of RAS and the development of an indication 
for revascularization (Fig. 155-1).
The choice of nonmedical management options depends on the type of 
lesion (atherosclerotic vs fibromuscular), the location of the lesion (ostial 
vs. nonostial), localized surgical and/or interventional expertise, and the 
presence of other localized comorbidities (i.e., aortic aneurysm or severe 
TABLE 155-1  CLINICAL FINDINGS ASSOCIATED WITH RENAL ARTERY 
STENOSIS
Hypertension
  Abrupt onset of hypertension before the age of 50 years (suggestive of 
fibromuscular dysplasia)
  Abrupt onset of hypertension at or after the age of 50 years (suggestive of 
atherosclerotic renal artery stenosis)
  Accelerated or malignant hypertension; can sometimes be associated with 
polydipsia and hyponatremia
  Refractory hypertension (not responsive to therapy with ≥3 drugs)
Renal abnormalities
  Unexplained azotemia (suggestive of atherosclerotic renal artery stenosis)
  Azotemia induced by treatment with an angiotensin-converting enzyme 
inhibitor
  Unilateral small kidney
  Unexplained hypokalemia
Other findings
  Abdominal bruit, flank bruit, or both
  Severe retinopathy
  Carotid, coronary, or peripheral vascular disease
  Unexplained congestive heart failure or acute pulmonary edema
Source: From RD Safian, SC Textor: New Engl J Med 344:431, 2001, reprinted with permission.
SECTION 10
994
Nephrology
aortoiliac disease). Thus fibromuscular lesions, typically located at a dis-
tance away from the renal artery ostium, are generally amenable to percu-
taneous angioplasty; ostial atherosclerotic lesions require stenting. Surgery 
is more commonly reserved for those who require aortic surgery, but it 
may be appropriate for those with severe bilateral disease. Again, periodic 
Hypertension ± Reduced GFR
Initiate therapy: antihypertensive medications
         Lifestyle, risk factor and
         dyslipidemia management
Suspicion of renovascular disease
       ? Age, associated vascular disease
       ? Diminishing GFR/proteinuria
       ? Clinical features/abrupt onset (see text)
Stable renal function
Excellent blood pressure
Noninvasive imaging: RAS present
    ? Comorbid disease risk
    ? Indications for revascularization
              -Circulatory congestion
              -Deteriorating kidney function
 
    ACE inhibitor
 
    Advanced renal failure
              -Bilateral high-grade RAS
              -Solitary functioning kidney
              -Uncontrolled hypertension
Optimize antihypertensive 
   and medical therapy
Low
High
Low
Repeat assessment: 3–6 months ?
Significant disease progression ?
Stable renal function
Excellent blood pressure
Stable
Moderate
Progression
Renal Intervention
   PTRA/stent
   Surgical revascularization  
   Nephrectomy (non-salvageable
      pressor kidney)
Repeat assessment: 6–12 weeks
? Excellent blood pressure control
? Stable renal function
Optimize antihypertensive
  and medical therapy
? Recheck for vessel patency
? Restenosis
? Technical failure
? De-novo/contralateral lesions
? Atheroemboli
May need 
repeat
procedure
High:
RX failure
No
No
Yes
FIGURE 155-1 Management of pts with renal artery stenosis and/or ischemic ne-
phropathy. ACE, angiotensin-converting enzyme; GFR, glomerular filtration rate; PTRA, 
percutaneous transluminal renal angioplasty; RAS, renal artery stenosis. [From Textor 
SC: Renovascular hypertension and ischemic nephropathy, in Brenner BM (ed). The
Kidney, 8th ed. Philadelphia, Saunders 2008; with permission.]
CHAPTER 155
995
Renovascular Disease
re-evaluation is needed to follow the response to intervention and, if neces-
sary, investigate for restenosis (Fig. 155-1).
Pts who respond to vascularization will typically have a reduction in 
bp of 25–30 mmHg systolic, generally within the first 48 h or so after the 
procedure. For those with renal dysfunction, only ~25% are expected to 
demonstrate renal improvement, with deterioration in renal function in 
another 25% and stable function in ~50%. Small kidneys (<8 cm by ultra-
sound) are much less likely to respond favorably to revascularization.
SCLERODERMA
Scleroderma commonly affects the kidney; 52% of pts with widespread 
scleroderma have renal involvement. Scleroderma renal crisis can 
cause sudden oliguric renal failure and severe hypertension due to small-
vessel occlusion in previously stable pts. Aggressive control of bp with ACE 
inhibitors and dialysis, if necessary, improve survival and may restore renal 
function.
ARTERIOLAR NEPHROSCLEROSIS
Persistent hypertension causes arteriosclerosis of the renal arterioles and 
loss of renal function (nephrosclerosis). “Benign” nephrosclerosis is asso-
ciated with loss of cortical kidney mass and thickened afferent arterioles 
and mild to moderate impairment of renal function. Renal biopsy will also 
demonstrate glomerulosclerosis and interstitial nephritis; pts will typically 
exhibit moderate proteinuria, i.e., <1 g/d. Malignant nephrosclerosis is 
characterized by accelerated rise in bp and the clinical features of malignant 
hypertension, including renal failure (Chap. 126). Malignant nephrosclero-
sis may be seen in association with cocaine use, which also increases the risk 
of renal progression in pts with “benign” arteriolar nephrosclerosis.
Aggressive control of bp can usually but not always halt or reverse the 
deterioration of renal function, and some pts have a return of renal function 
to near normal. Risk factors for progressive renal injury include a history 
of severe, longstanding hypertension; however, African Americans are at 
particularly high risk of progressive renal injury (Chap. 152). The African 
American Study of Kidney Disease and Hypertension (AASK) established 
the superiority of ACE inhibitors over beta blockers or calcium channel 
blockers, with respect to progression of kidney disease.
THROMBOTIC MICROANGIOPATHIES
The thrombotic microangiopathies (TMAs) are classically subdivided into 
two general syndromes: thrombotic thrombocytopenic purpura (TTP) and 
hemolytic uremic syndrome (HUS). TMAs are thus broadly characterized 
by the presence of AKI, microangiopathic hemolytic anemia, thrombocy-
topenia, and neurologic dysfunction. Pts with TTP may suffer from the 
classic pentad of microangiopathic hemolytic anemia, fever, thrombocyto-
penia, neurologic symptoms and signs, and renal dysfunction. Extrarenal 
symptoms are in contrast less prominent or common, but not unheard of, 
in postdiarrheal HUS.
The major causes of TMA are listed in Table 155-2; the common patho-
genic pathway is endothelial injury. In idiopathic and familial TTP, pts have 
SECTION 10
996
Nephrology
TABLE 155-2 CAUSES OF THROMBOTIC MICROANGIOPATHY
Genetic
  TTP: deficiency of ADAMTS13 (vWF protease)
  HUS: deficiency of complement regulatory proteins: factor H, complement 
factor I, complement factor B, complement factor H-related protein 1 
(CHFR1, CHFR3, CHFR5, membrane cofactor protein
Idiopathic
  TTP: acquired antibodies to ADAMTS13 (vWF protease)
  HUS: acquired antibodies to complement factor H, typically in pts with 
genetic deficiency of this and other complement regulatory proteins
Infectious
  Bacterial: Escherichia coli O157:H7 and other strains, Shigella, Salmonella,
Campylobacter, etc.
  Viral: HIV, CMV, EBV, etc.
Drug-related
  Calcineurin inhibitors: tacrolimus and cyclosporine
  Antiplatelet agents: ticlopidine, clopidogrel
  Quinine
  Chemotherapy: mitomycin C, gemcitabine, cisplatin
  OKT3 monoclonal antibody
  Angiogenesis/VEGF inhibitors: bevacizumab, sunitinib, sorafenib
Autoimmune
  Antiphospholipid antibody syndrome
  SLE, vasculitis
Miscellaneous
  Post–bone marrow transplantation
  Disseminated malignancy
  Pregnancy
Abbreviations: ADAMTS13, a disintegrin-like and metalloprotease with thrombospondin type I 
motif-13; CMV, cytomegalovirus; EBV, Epstein-Barr virus; HUS, hemolytic uremic syndrome; 
SLE, systemic lupus erythematosus; TTP, thrombotic thrombocytopenic purpura; VEGF, vascular 
endothelial growth factor; vWF, von Willebrand factor.
a marked deficiency in the ADAMTS13 protease, leading to accumulation 
of ultra-large, unprocessed von Willebrand factor (vWF) polymers, plate-
let aggregation, and TMA. In contrast, postdiarrheal HUS is associated 
with presence of a bacterial toxin (Shiga toxin or verotoxin) that causes 
endothelial injury; children and the elderly are particularly susceptible. Pts 
with atypical or nondiarrheal HUS may in turn have inherited or acquired 
deficiencies in membrane-associated regulatory proteins of the alternative 
complement pathway, enhancing endothelial sensitivity to complement.
CHAPTER 155
997
Renovascular Disease
Laboratory evaluation will usually reveal evidence of a microangiopathic 
hemolytic anemia, although this may be absent in certain causes, e.g., 
antiphospholipid antibody syndrome. The reticulocyte count should be ele-
vated, along with an increase in the red cell distribution width. Hemolysis 
should increase levels of LDH and decrease circulating haptoglobin, with a 
negative Coombs’ test. Examination of the peripheral smear is key, since the 
presence of schistocytes will help establish the diagnosis. Specific diagnostic 
tests—e.g., HIV testing, antiphospholipid antibody screens—may be useful 
in the differential diagnosis. Measurement of vWF protease activity prom-
ises considerable diagnostic and therapeutic utility; however, at this point, 
this is not routinely available in a time frame suitable for routine clinical 
use. Renal biopsy will classically demonstrate fibrin- and/or vWF-positive 
thrombi in arterioles and glomeruli, endothelial injury, and widening of 
the subendothelial space leading to a “double contour” appearance of the 
glomerular capillaries.
Treatment of TMA depends on the underlying pathogenesis. Idiopathic 
TTP is due to the presence of circulating antibody inhibitors of ADAMTS13 
and thus responds to plasma exchange, combining plasmapheresis (removal 
of antibody) and infusion of fresh-frozen plasma (repletion with native 
ADAMTS13/vWF protease). Pts with atypical HUS due to deficiencies in 
complement regulatory proteins respond to therapy with eculizumab, a 
monoclonal antibody to C5 that prevents the production of the terminal 
complement components C5a and the membrane attack complex C5b-9. 
TOXEMIAS OF PREGNANCY
Preeclampsia is characterized by hypertension, proteinuria, edema, con-
sumptive coagulopathy, sodium retention, hyperuricemia, and hyperreflexia; 
eclampsia is the further development of seizures. Glomerular swelling and/or 
ischemia causes renal insufficiency. Coagulation abnormalities and AKI may 
occur. Treatment consists of bed rest, sedation, control of neurologic mani-
festations with magnesium sulfate, control of hypertension with vasodilators 
and other antihypertensive agents proven safe in pregnancy, and delivery of 
the infant.
VASCULITIS
Renal complications are frequent and severe in polyarteritis nodosa, hyper-
sensitivity angiitis, granulomatosis with polyangiitis (Wegener’s), and other 
forms of vasculitis (Chap. 170). Therapy is directed toward the underlying 
disease.
SICKLE CELL NEPHROPATHY
The hypertonic and relatively hypoxic renal medulla coupled with slow blood 
flow in the vasa recta favors sickling. Papillary necrosis, cortical infarcts, 
functional tubule abnormalities (nephrogenic diabetes insipidus), glomeru-
lopathy, nephrotic syndrome, and, rarely, ESRD may be complications.
For a more detailed discussion, see Textor SC, Leung N: 
Vascular Injury to the Kidney, Chap. 286, p. 2375, in HPIM-18.
SECTION 10
998
Nephrology
CHAPTER 156
Nephrolithiasis
Renal calculi are common, affecting ~1% of the population, and recurrent in 
more than half of pts. Stone formation begins when urine becomes supersatu-
rated with insoluble components due to (1) low urinary volume, (2) excessive or 
insufficient excretion of selected compounds, or (3) other factors (e.g., urinary
pH) that diminish solubility. Approximately 75% of stones are Ca-based (the 
majority Ca oxalate; also Ca phosphate and other mixed stones), 15% struvite 
(magnesium-ammonium-phosphate), 5% uric acid, and 1% cystine, reflect-
ing the metabolic disturbance(s) from which they arise.
SIGNS AND SYMPTOMS
Stones in the renal pelvis may be asymptomatic or cause hematuria alone; 
with passage, obstruction may occur at any site along the collecting system. 
Obstruction related to the passing of a stone leads to severe pain, often radi-
ating to the groin, sometimes accompanied by intense visceral symptoms 
(i.e., nausea, vomiting, diaphoresis, light-headedness), hematuria, pyuria, 
urinary tract infection (UTI), and, rarely, hydronephrosis. In contrast, stag-
horn calculi, associated with recurrent UTI with urea-splitting organisms 
(Proteus, Klebsiella, Providencia, Morganella, and others), may be completely 
asymptomatic, presenting with loss of renal function.
STONE COMPOSITION
Most stones are composed of Ca oxalate. These may be associated with 
hypercalciuria and/or hyperoxaluria. Hypercalciuria can be seen in asso-
ciation with a very high-Na diet, loop diuretic therapy, distal (type I) renal 
tubular acidosis (RTA), sarcoidosis, Cushing’s syndrome, aldosterone excess, 
or conditions associated with hypercalcemia (e.g., primary hyperparathy-
roidism, vitamin D excess, milk-alkali syndrome), or it may be idiopathic.
Hyperoxaluria may be seen with intestinal (especially ileal) malabsorption 
syndromes (e.g., inflammatory bowel disease, pancreatitis), due to reduced 
intestinal secretion of oxalate and/or the binding of intestinal Ca by fatty acids 
within the bowel lumen, with enhanced absorption of free oxalate and hyp-
eroxaluria. Ca oxalate stones may also form due to (1) a deficiency of urinary 
citrate, an inhibitor of stone formation that is underexcreted with metabolic 
acidosis; and (2) hyperuricosuria (see below). Ca phosphate stones are much 
less common and tend to occur in the setting of an abnormally high urinary 
pH (7–8), usually in association with a complete or partial distal RTA.
Struvite stones form in the collecting system when infection with urea-
splitting organisms is present. Struvite is the most common component 
of staghorn calculi and obstruction. Risk factors include previous UTI, 
nonstruvite stone disease, urinary catheters, neurogenic bladder (e.g., with 
diabetes or multiple sclerosis), and instrumentation.
Uric acid stones develop when the urine is saturated with uric acid in 
the presence of an acid urine pH; pts typically have underlying metabolic 
CHAPTER 156
999
Nephrolithiasis
syndrome and insulin resistance, often with clinical gout, associated with 
a relative defect in ammoniagenesis and urine pH that is <5.4 and often 
<5.0. Pts with myeloproliferative disorders and other causes of secondary 
hyperuricemia and hyperuricosuria due to increased purine biosynthesis 
and/or urate production are at risk for stones if the urine volume dimin-
ishes. Hyperuricosuria without hyperuricemia may be seen in association 
with certain drugs (e.g., probenecid, high-dose salicylates).
Cystine stones are the result of a rare inherited defect in renal and intes-
tinal transport of several dibasic amino acids; the overexcretion of cystine 
(cysteine disulfide), which is relatively insoluble, leads to nephrolithiasis. 
Stones begin in childhood and are a rare cause of staghorn calculi; they 
occasionally lead to end-stage renal disease. Cystine stones are more likely 
to form in acidic urinary pH.
WORKUP
Although some have advocated a complete workup after a first stone 
episode, others would defer that evaluation until there has been evidence 
of recurrence or if there is no obvious cause (e.g., low fluid intake dur-
ing the summer months with obvious dehydration). Table 156-1 outlines 
a reasonable workup for an outpatient with an uncomplicated kidney 
stone. On occasion, a stone is recovered and can be analyzed for content, 
yielding important clues to pathogenesis and management. For example, 
a predominance of Ca phosphate suggests underlying distal RTA or 
hyperparathyroidism.
Nephrolithiasis
TREATMENT
Treatment of renal calculi is often empirical, based on odds (Ca oxalate 
stones most common), clinical history, and/or the metabolic workup. 
An increase in fluid intake to at least 2.5–3 L/d is perhaps the single 
most effective intervention, regardless of the type of stone. Conservative 
recommendations for pts with Ca oxalate stones (i.e., low-salt, low-fat,
TABLE 156-1 WORKUP FOR AN OUTPATIENT WITH A RENAL STONE
1. Dietary and fluid intake history
2.  Careful medical history and physical examination, focusing on systemic 
diseases
3. Noncontrast helical CT, with 5-mm CT cuts
4. Routine UA; presence of crystals, hematuria, measurement of urine pH
5.  Serum chemistries: BUN, Cr, uric acid, calcium, phosphate, chloride, 
bicarbonate, PTH
6.  Timed urine collections (at least 1 day during week, 1 day on weekend): 
Cr, Na, K, urea nitrogen, uric acid, calcium, phosphate, oxalate, citrate, pH
Abbreviations: BUN, blood urea nitrogen; Cr, creatinine; PTH, parathyroid hormone; UA, 
urinalysis.
SECTION 10
1000
Nephrology
moderate-protein diet) are thought to be healthful in general and 
therefore advisable in pts whose condition is otherwise uncomplicated. 
In contrast to prior assumptions, dietary calcium intake does not con-
tribute to stone risk; rather, dietary calcium may help to reduce oxalate 
absorption and reduce stone risk. Table 156-2 outlines stone-specific 
therapies for pts with complex or recurrent nephrolithiasis.
TABLE 156-2 SPECIFIC THERAPIES FOR NEPHROLITHIASIS
Stone Type
Dietary Modifications
Other
Calcium oxalate
Increase fluid intake
Citrate supplementation 
(calcium or potassium salts 
> sodium)
Moderate sodium intake
Moderate oxalate intake
Cholestyramine or other 
therapy for fat malabsorption
Moderate protein intake
Moderate fat intake
Thiazides if hypercalciuric
Allopurinol if hyperuricosuric
Calcium phosphate Increase fluid intake
Thiazides if hypercalciuric
Moderate sodium intake
Treat hyperparathyroidism if 
present
Alkali for distal renal tubular 
acidosis
Struvite
Increase fluid intake; 
same as calcium oxalate 
if evidence of calcium 
oxalate nidus for struvite
Methenamine and vitamin C 
or daily suppressive antibiotic 
therapy (e.g., trimethoprim-
sulfamethoxazole)
Uric acid
Increase fluid intake
Allopurinol
Moderate dietary protein 
intake
Alkali therapy (K+ citrate) to 
raise urine pH to 6.0–6.5
Cystine
Increase fluid intake
Alkali therapy
Penicillamine
Note: Sodium excretion correlates with calcium excretion.
For a more detailed discussion, see Asplin JR, Coe FL, Favus 
MJ: Nephrolithiasis, Chap. 287, p. 2382, in HPIM-18.
CHAPTER 157
1001
Urinary Tract Obstruction
CHAPTER 157
Urinary Tract Obstruction
Urinary tract obstruction (UTO), a potentially reversible cause of renal 
failure (RF), should be considered in all cases of acute or abrupt worsening 
of chronic RF. Consequences depend on duration and severity and whether 
the obstruction is unilateral or bilateral. UTO may occur at any level from 
collecting tubule to urethra. It is preponderant in women (pelvic tumors), 
elderly men (prostatic disease), diabetic pts (papillary necrosis), pts with 
neurologic diseases (spinal cord injury or multiple sclerosis, with neuro-
genic bladder), and individuals with retroperitoneal lymphadenopathy or 
fibrosis, vesicoureteral reflux, nephrolithiasis, or other causes of functional 
urinary retention (e.g., anticholinergic drugs).
CLINICAL MANIFESTATIONS
Pain can occur in some settings (obstruction due to stones) but is not common. 
In men, there is frequently a history of prostatism. Physical exam may reveal 
an enlarged bladder by percussion over the lower abdominal wall; bedside 
ultrasound assessment (“bladder scan”) can be helpful to assess the post-void 
bladder volume. Other findings depend on the clinical scenario. Prostatic 
hypertrophy can be determined by digital rectal examination. A bimanual 
examination in women may show a pelvic or rectal mass. The workup of pts 
with RF suspected of having UTO is shown in Fig. 157-1. Laboratory stud-
ies may show marked elevations of blood urea nitrogen and creatinine; if the 
obstruction has been of sufficient duration, there may be evidence of tubuloin-
terstitial disease (e.g., hyperkalemia, non-anion-gap metabolic acidosis, mild 
hypernatremia). Urinalysis is most often benign or with a small number of cells; 
heavy proteinuria is rare. An obstructing stone may be visualized on abdominal 
radiography or helical noncontrast CT with 5-mm cuts.
Ultrasonography can be used to assess the degree of hydronephrosis and 
the integrity of the renal parenchyma; CT or IV urography may be required 
to localize the level of obstruction. Calyceal dilation is commonly seen; 
it may be absent with hyperacute obstruction, upper tract encasement by 
tumor or retroperitoneal fibrosis, or indwelling staghorn calculi. Imaging 
in retroperitoneal fibrosis with associated periaortitis classically reveals 
a periaortic, confluent mass encasing the anterior and lateral sides of the 
aorta. Kidney size may indicate the duration of obstruction. It should be 
noted that unilateral obstruction may be prolonged and severe (ultimately 
leading to loss of renal function in the obstructed kidney), with no hint of 
abnormality on physical exam and laboratory survey.
Urinary Tract Obstruction
TREATMENT
Management of acute RF associated with UTO is dictated by (1) the level 
of obstruction (upper vs. lower tract), and (2) the acuity of the obstruc-
tion and its clinical consequences, including renal dysfunction and
SECTION 10
1002
Nephrology
infection. Benign causes of UTO, including bladder outlet obstruction 
and nephrolithiasis, should be ruled out because conservative manage-
ment, including Foley catheter placement and IV fluids, respectively, 
will usually relieve the obstruction in most cases.
Among more seriously ill pts, ureteral obstruction due to tumor is 
the most common and concerning cause of UTO. If technically fea-
sible, ureteral obstruction due to tumor is best managed by cystoscopic 
placement of a ureteral stent. Otherwise, the placement of nephrostomy 
tubes with external drainage may be required. IV antibiotics should also 
be given if there are signs of pyelonephritis or urosepsis. In addition to 
ureteral stenting, pts with idiopathic retroperitoneal fibrosis are typically 
treated with immunosuppression (prednisone, mycophenolate mofetil, 
and/or tamoxifen).
No further
workup for
obstruction
Identify specific cause of
obstruction (consider
CT evaluation)
Obstruction
below bladder
neck
High clinical
suspicion
Diuresis
No diuresis;
 do renal
ultrasound
Insert bladder catheter
No hydronephrosis
Hydronephrosis;
  obstruction above
  bladder neck
Low clinical
suspicion of
obstruction
Antegrade
urogram
Retrograde
urogram
Identify site and
relieve obstruction
  (suspect obstruction if bladder or prostate
  enlarged, evidence of tumor, or urinalysis
  nondiagnostic)
Unexplained Renal Failure
FIGURE 157-1 Diagnostic approach for urinary tract obstruction in unexplained 
renal failure. Circles represent diagnostic procedures and squares indicate clinical 
decisions based on available data.
CHAPTER 157
1003
Urinary Tract Obstruction
Fluid and electrolyte status should be carefully monitored after 
obstruction is relieved. There may be a physiologic natriuresis/diuresis 
related to volume overload. However, there may be an “inappropriate” 
natriuresis/diuresis related to (1) elevated urea nitrogen, leading to 
an osmotic diuresis; and (2) acquired nephrogenic diabetes insipidus. 
Hypernatremia, sometimes of a severe degree, may develop.
For a more detailed discussion, see Seifter JL: Urinary Tract 
Obstruction, Chap. 289, p. 2396, in HPIM-18.
This page intentionally left blank 
1005
SECTION 11
Gastroenterology
CHAPTER 158
Peptic Ulcer and Related 
Disorders
PEPTIC ULCER DISEASE (PUD)
PUD occurs most commonly in duodenal bulb (duodenal ulcer, DU) and 
stomach (gastric ulcer, GU). It may also occur in esophagus, pyloric channel, 
duodenal loop, jejunum, Meckel’s diverticulum. PUD results when “aggressive” 
factors (gastric acid, pepsin) overwhelm “defensive” factors involved in mucosal 
resistance (gastric mucus, bicarbonate, microcirculation, prostaglandins, muco-
sal “barrier”), and from effects of Helicobacter pylori.
� CAUSES AND RISK FACTORS 
General
H. pylori is a spiral urease-producing organism that colonizes gastric antral 
mucosa in up to 100% of persons with DU and 80% with GU. It is also found 
in normals (increasing prevalence with age) and in those of low socioeco-
nomic status. H. pylori is invariably associated with histologic evidence of 
active chronic gastritis, which over years can lead to atrophic gastritis and 
gastric cancer. The other major cause of ulcers (those not due to H. pylori) 
is nonsteroidal anti-inflammatory drugs (NSAIDs). Fewer than 1% are due 
to gastrinoma (Zollinger-Ellison syndrome). Other risk factors and associa-
tions: hereditary (? increased parietal cell number), smoking, hypercalce-
mia, mastocytosis, blood group O (antigens may bind H. pylori). Unproven: 
stress, coffee, alcohol.
Duodenal Ulcer 
Mild gastric acid hypersecretion resulting from (1) increased release of 
gastrin, presumably due to (a) stimulation of antral G cells by cytokines 
released by inflammatory cells and (b) diminished production of soma-
tostatin by D cells, both resulting from H. pylori infection; and (2) an 
exaggerated acid response to gastrin due to an increased parietal cell mass 
resulting from gastrin stimulation. These abnormalities reverse rapidly 
with eradication of H. pylori. However, a mildly elevated maximum gastric 
acid output in response to exogenous gastrin persists in some pts long after 
eradication of H. pylori, suggesting that gastric acid hypersecretion may be, 
in part, genetically determined. H. pylori may also result in elevated serum 
pepsinogen levels. Mucosal defense in duodenum is compromised by toxic 
effects of H. pylori infection on patches of gastric metaplasia that result from 
gastric acid hypersecretion or rapid gastric emptying. Other risk factors 
include glucocorticoids, NSAIDs, chronic renal failure, renal transplanta-
tion, cirrhosis, chronic lung disease.
SECTION 11
1006
Gastroenterology
Gastric Ulcer 
H. pylori is also principal cause. Gastric acid secretory rates are usually 
normal or reduced, possibly reflecting earlier age of infection by H. pylori 
than in DU pts. Gastritis due to reflux of duodenal contents (including bile) 
may play a role. Chronic salicylate or NSAID use may account for 15–30% 
of GUs and increase risk of associated bleeding, perforation.
� CLINICAL FEATURES 
Duodenal Ulcer 
Burning epigastric pain 90 min to 3 h after meals, often nocturnal, relieved 
by food.
Gastric Ulcer 
Burning epigastric pain made worse by or unrelated to food; anorexia, food 
aversion, weight loss (in 40%). Great individual variation. Similar symp-
toms may occur in persons without demonstrated peptic ulcers (“nonulcer 
dyspepsia”); less responsive to standard therapy.
� COMPLICATIONS 
Bleeding, obstruction, penetration causing acute pancreatitis, perforation, 
intractability.
� DIAGNOSIS 
Duodenal Ulcer 
Upper endoscopy or upper GI barium radiography.
Gastric Ulcer 
Upper endoscopy preferable to exclude possibility that ulcer is malignant 
(brush cytology, ≥6 pinch biopsies of ulcer margin). Radiographic features 
suggesting malignancy: ulcer within a mass, folds that do not radiate from 
ulcer margin, a large ulcer (>2.5–3 cm).
� DETECTION OF H. PYLORI
Detection of antibodies in serum (inexpensive, preferred when endoscopy is 
not required); rapid urease test of antral biopsy (when endoscopy is required). 
Urea breath test generally used to confirm eradication of H. pylori, if neces-
sary. The fecal antigen test is sensitive, specific, and inexpensive (Table 158-1).
Peptic Ulcer Disease
TREATMENT
MEDICAL Objectives: pain relief, healing, prevention of complications, 
prevention of recurrences. For GU, exclude malignancy (follow endo-
scopically to healing). Dietary restriction unnecessary with contem-
porary drugs; discontinue NSAIDs; smoking may prevent healing and 
should be stopped. Eradication of H. pylori markedly reduces rate of ulcer 
relapse and is indicated for all DUs and GUs associated with H. pylori 
(Table 158-2). Acid suppression is generally included in regimen. 
Reinfection rates are <1%/year.  Standard drugs (H2 receptor blockers, 
CHAPTER 158
1007
Peptic Ulcer and Related Disorders 
1007
sucralfate, antacids) heal 80–90% of DUs and 60% of GUs in 6 weeks; 
healing is more rapid with omeprazole (20 mg/d).
SURGERY Used for complications (persistent or recurrent bleeding, 
obstruction, perforation) or, uncommonly, intractability (first screen for 
surreptitious NSAID use and gastrinoma). For DU, see Table 158-3. For 
GU, perform subtotal gastrectomy.
COMPLICATIONS OF SURGERY (1) Obstructed afferent loop (Billroth II), 
(2) bile reflux gastritis, (3) dumping syndrome (rapid gastric emptying 
with abdominal distress + postprandial vasomotor symptoms), (4) post-
vagotomy diarrhea, (5) bezoar, (6) anemia (iron, B12, folate malabsorption), 
(7) malabsorption (poor mixing of gastric contents, pancreatic juices, 
bile; bacterial overgrowth), (8) osteomalacia and osteoporosis (vitamin 
D and Ca malabsorption), (9) gastric remnant carcinoma.
Peptic Ulcer Disease
APPROACH TO THE
PATIENT
Optimal approach is uncertain. Serologic testing for H. pylori and 
treating, if present, may be cost-effective. Other options include trial of 
acid-suppressive therapy, endoscopy only in treatment failures, or initial 
endoscopy in all cases.
TABLE 158-1 TESTS FOR DETECTION OF H. PYLORI
Test
Sensitivity/
Specificity, %
Comments
Invasive (endoscopy/biopsy required)
Rapid urease
80–95/95–100
Simple, false negative with recent use of 
PPIs, antibiotics, or bismuth compounds
Histology
80–90/>95
Requires pathology processing and 
staining; provides histologic information
Culture
—/—
Time-consuming, expensive, dependent 
on experience; allows determination of 
antibiotic susceptibility
Noninvasive
Serology
>80/>90
Inexpensive, convenient; not useful for 
early follow-up
Urea breath 
test
>90/>90
Simple, rapid; useful for early follow-up; 
false negatives with recent therapy (see 
rapid urease test); exposure to low-dose 
radiation with 14C test
Stool antigen
>90/>90
Inexpensive, convenient; not established 
for eradication but promising
Abbreviation: PPIs, proton pump inhibitors.
SECTION 11
1008
Gastroenterology
GASTROPATHIES
� EROSIVE GASTROPATHIES 
Hemorrhagic gastritis, multiple gastric erosions may be caused by aspirin 
and other NSAIDs (lower risk with newer agents, e.g., nabumetone and 
etodolac, which do not inhibit gastric mucosal prostaglandins) or severe 
stress (burns, sepsis, trauma, surgery, shock, or respiratory, renal, or liver 
failure). Pt may be asymptomatic or experience epigastric discomfort, nau-
sea, hematemesis, or melena. Diagnosis is made by upper endoscopy.
TABLE 158-2  REGIMENS RECOMMENDED FOR ERADICATION OF 
H. PYLORI INFECTION
Drug
Dose
Triple therapy
1. Bismuth subsalicylate plus
2 tablets qid
Metronidazole plus
250 mg qid
Tetracyclinea
500 mg qid
2. Ranitidine bismuth citrate plus
400 mg bid
Tetracycline plus
500 mg bid
Clarithromycin or metronidazole
500 mg bid
3. Omeprazole (lansoprazole) plus
20 mg bid (30 mg bid)
Clarithromycin plus
250 or 500 mg bid
Metronidazoleb or
500 mg bid
Amoxicillinc
1 g bid
Quadruple therapy
Omeprazole (lansoprazole)
20 mg (30 mg) daily
Bismuth subsalicylate
2 tablets qid
Metronidazole
250 mg qid
Tetracycline
500 mg qid
aAlternative: use prepacked Helidac.
bAlternative: use prepacked Prevpac.
cUse either metronidazole or amoxicillin, not both.
TABLE 158-3 SURGICAL TREATMENT OF DUODENAL ULCER
Operation
Recurrence 
Rate
Complication
Rate
Vagotomy + antrectomy (Billroth I or II)a
1%
Highest
Vagotomy and pyloroplasty
10%
Intermediate
Parietal cell (proximal gastric, 
superselective) vagotomy
≥10%
Lowest
aBillroth I, gastroduodenostomy; Billroth II, gastrojejunostomy.
CHAPTER 158
1009
Peptic Ulcer and Related Disorders 
Erosive Gastropathies
TREATMENT
Removal of offending agent and maintenance of O2 and blood volume 
as required. For prevention of stress ulcers in critically ill pts, hourly 
oral administration of liquid antacids (e.g., Maalox 30 mL), IV H2 
receptor antagonist (e.g., cimetidine, 300-mg bolus + 37.5–50 mg/h 
IV), or both is recommended to maintain gastric pH > 4. Alternatively, 
sucralfate slurry, 1 g PO q6h, can be given; does not raise gastric pH 
and may thus avoid increased risk of aspiration pneumonia associated 
with liquid antacids. Pantoprazole can be administered IV to suppress 
gastric acid in the critically ill. Misoprostol, 200 μg PO qid, or pro-
found acid suppression (e.g., famotidine, 40 mg PO bid) can be used 
with NSAIDs to prevent NSAID-induced ulcers.
� CHRONIC GASTRITIS 
Identified histologically by an inflammatory cell infiltrate dominated by 
lymphocytes and plasma cells with scant neutrophils. In its early stage, 
the changes are limited to the lamina propria (superficial gastritis). When 
the disease progresses to destroy glands, it becomes atrophic gastritis. The 
final stage is gastric atrophy, in which the mucosa is thin and the infiltrate 
sparse. Chronic gastritis can be classified based on predominant site of 
involvement.
Type A Gastritis 
This is the body-predominant and less common form. Generally asymptom-
atic, common in elderly; autoimmune mechanism may be associated with 
achlorhydria, pernicious anemia, and increased risk of gastric cancer (value of 
screening endoscopy uncertain). Antibodies to parietal cells present in >90%.
Type B Gastritis 
This is antral-predominant disease and caused by H. pylori. Often asymp-
tomatic but may be associated with dyspepsia. Atrophic gastritis, gastric 
atrophy, gastric lymphoid follicles, and gastric B cell lymphomas may occur. 
Infection early in life or in setting of malnutrition or low gastric acid output 
is associated with gastritis of entire stomach (including body) and increased 
risk of gastric cancer. Eradication of H. pylori (Table 158-2) not routinely 
recommended unless PUD or gastric mucosa-associated lymphoid tissue 
(MALT) lymphoma is present.
� SPECIFIC TYPES OF GASTROPATHY OR GASTRITIS 
Alcoholic gastropathy (submucosal hemorrhages), Ménétrier’s disease 
(hypertrophic gastropathy), eosinophilic gastritis, granulomatous gastri-
tis, Crohn’s disease, sarcoidosis, infections (tuberculosis, syphilis, fungi, 
viruses, parasites), pseudolymphoma, radiation, corrosive gastritis.
ZOLLINGER-ELLISON (Z-E) SYNDROME (GASTRINOMA)
Consider when ulcer disease is severe, refractory to therapy, associated with 
ulcers in atypical locations, or associated with diarrhea. Tumors are usually 
pancreatic or in duodenum (submucosal, often small), may be multiple, 
SECTION 11
1010
Gastroenterology
slowly growing; >60% malignant; 25% associated with MEN 1, i.e., multiple 
endocrine neoplasia type 1 (gastrinoma, hyperparathyroidism, pituitary 
neoplasm), often duodenal, small, multicentric, less likely to metastasize 
to liver than pancreatic gastrinomas but often metastasize to local lymph 
nodes.
� DIAGNOSIS 
Suggestive
Basal acid output >15 mmol/h; basal/maximal acid output >60%; large 
mucosal folds on endoscopy or upper GI radiograph.
Confirmatory 
Serum gastrin > 1000 ng/L or rise in gastrin of 200 ng/L following IV secre-
tin and, if necessary, rise of 400 ng/L following IV calcium (Table 158-4).
� DIFFERENTIAL DIAGNOSIS 
Increased Gastric Acid Secretion 
Z-E syndrome, antral G cell hyperplasia or hyperfunction (? due to H. pylori), 
postgastrectomy retained antrum, renal failure, massive small bowel resec-
tion, chronic gastric outlet obstruction.
Normal or Decreased Gastric Acid Secretion 
Pernicious anemia, chronic gastritis, gastric cancer, vagotomy, pheochro-
mocytoma.
Zollinger-Ellison Syndrome
TREATMENT
Omeprazole (or lansoprazole), beginning at 60 mg PO q a.m. and 
increasing until maximal gastric acid output is <10 mmol/h before 
next dose, is drug of choice during evaluation and in pts who are not 
surgical candidates; dose can often be reduced over time. Radiolabeled 
octreotide scanning has emerged as the most sensitive test for detecting 
primary tumors and metastases; may be supplemented by endoscopic 
ultrasonography. Exploratory laparotomy with resection of primary 
tumor and solitary metastases is done when possible. In pts with MEN 1, 
tumor is often multifocal and unresectable; treat hyperparathyroidism
TABLE 158-4 DIFFERENTIAL DIAGNOSTIC TESTS
Gastrin Response to
Condition
Fasting Gastrin
IV Secretin
Food
DU
N (≤150 ng/L)
NC
Slight ↑
Z-E
↑↑↑
↑↑↑
NC
Antral G (gastrin) cell 
hyperplasia
↑
↑, NC
↑↑↑
Abbreviations: DU, duodenal ulcer; N, normal; NC, no change; Z-E, Zollinger-Ellison syndrome.
CHAPTER 159
1011
Inflammatory Bowel Diseases
first (hypergastrinemia may improve). For unresectable tumors, pari-
etal cell vagotomy may enhance control of ulcer disease by drugs. 
Chemotherapy is used for metastatic tumor to control symptoms (e.g., 
streptozocin, 5-fluorouracil, doxorubicin, or interferon α); 40% partial 
response rate. Newer agents effective in pancreatic neuroendocrine 
tumors have not been evaluated.
For a more detailed discussion, see Del Valle J: Peptic Ulcer 
Disease and Related Disorders, Chap. 293, p. 2438, in 
HPIM-18.
CHAPTER 159
Inflammatory Bowel Diseases
Inflammatory bowel diseases (IBD) are chronic inflammatory disorders 
of unknown etiology involving the GI tract. Peak occurrence is between 
ages 15 and 30 and between ages 60 and 80, but onset may occur at any 
age. Epidemiologic features are shown in Table 159-1. Pathogenesis of IBD 
involves activation of immune cells by unknown inciting agent (? microor-
ganism, dietary component, bacterial or self-antigen) leading to release of 
cytokines and inflammatory mediators. Genetic component suggested by 
increased risk in first-degree relatives of pts with IBD and concurrence of 
type of IBD, location of Crohn’s disease (CD), and clinical course. Reported 
associations include HLA-DR2 in Japanese pts with ulcerative colitis 
and a CD-related gene called CARD15 on chromosome 16p. CARD15 
TABLE 159-1 EPIDEMIOLOGY OF IBD
Ulcerative Colitis
Crohn’s Disease
Incidence (North America) 
per person-years
2.2–14.3:100,000
3.1–14.6:100,000
Age of onset
15–30 and 60–80
15–30 and 60–80
Ethnicity
Jewish > non-Jewish white > African American 
> Hispanic > Asian
Male/female ratio
1:1
1.1–1.8:1
Smoking
May prevent disease
May cause disease
Oral contraceptives
No increased risk
Odds ratio 1.4
Appendectomy
Protective
Not protective
Monozygotic twins
6% concordance
58% concordance
Dizygotic twins
0% concordance
4% concordance
SECTION 11
1012
Gastroenterology
mutations may account for 10% of CD risk. Other potential pathogenic 
factors include serum antineutrophil cytoplasmic antibodies (ANCA) in 
70% of pts with ulcerative colitis (also in 5–10% of CD pts) and antibodies 
to Saccharomyces cerevisiae (ASCA) in 60–70% of CD pts (also in 10–15% 
of ulcerative colitis pts and 5% of normal controls). Granulomatous angiitis 
(vasculitis) may occur in CD. Acute flares may be precipitated by infec-
tions, nonsteroidal anti-inflammatory drugs (NSAIDs), stress. Onset of 
ulcerative colitis often follows cessation of smoking.
ULCERATIVE COLITIS (UC)
� PATHOLOGY 
Colonic mucosal inflammation; rectum almost always involved, with 
inflammation extending continuously (no skip areas) proximally for a vari-
able extent; histologic features include epithelial damage, inflammation, 
crypt abscesses, loss of goblet cells.
� CLINICAL MANIFESTATIONS 
Bloody diarrhea, mucus, fever, abdominal pain, tenesmus, weight loss; 
spectrum of severity (majority of cases are mild, limited to rectosigmoid). 
In severe cases dehydration, anemia, hypokalemia, hypoalbuminemia.
� COMPLICATIONS 
Toxic megacolon, colonic perforation; cancer risk related to extent and 
duration of colitis; often preceded by or coincident with dysplasia, which 
may be detected on surveillance colonoscopic biopsies.
� DIAGNOSIS 
Sigmoidoscopy/colonoscopy: mucosal erythema, granularity, friability, 
exudate, hemorrhage, ulcers, inflammatory polyps (pseudopolyps). Barium 
enema: loss of haustrations, mucosal irregularity, ulcerations.
CROHN’S DISEASE (CD)
� PATHOLOGY 
Any part of GI tract, usually terminal ileum and/or colon; transmural inflam-
mation, bowel wall thickening, linear ulcerations, and submucosal thickening 
leading to cobblestone pattern; discontinuous (skip areas); histologic features 
include transmural inflammation, granulomas (often absent), fissures, fistulas.
� CLINICAL MANIFESTATIONS 
Fever, abdominal pain, diarrhea (often without blood), fatigue, weight loss, 
growth retardation in children; acute ileitis mimicking appendicitis; anorec-
tal fissures, fistulas, abscesses. Clinical course falls into three broad patterns: 
(1) inflammatory, (2) stricturing, and (3) fistulizing.
� COMPLICATIONS 
Intestinal obstruction (edema vs. fibrosis); rarely toxic megacolon or 
perforation; intestinal fistulas to bowel, bladder, vagina, skin, soft tissue, 
often with abscess formation; bile salt malabsorption leading to cholesterol 
gallstones and/or oxalate kidney stones; intestinal malignancy; amyloidosis.
CHAPTER 159
1013
Inflammatory Bowel Diseases
� DIAGNOSIS 
Sigmoidoscopy/colonoscopy, barium enema, upper GI and small-bowel 
series: nodularity, rigidity, ulcers that may be deep or longitudinal, cobble-
stoning, skip areas, strictures, fistulas. CT may show thickened, matted 
bowel loops or an abscess.
DIFFERENTIAL DIAGNOSIS
� INFECTIOUS ENTEROCOLITIS 
Shigella, Salmonella, Campylobacter, Yersinia (acute ileitis), Plesiomonas 
shigelloides, Aeromonas hydrophila, Escherichia coli serotype O157:H7, 
Gonorrhea, Lymphogranuloma venereum, Clostridium difficile (pseudo-
membranous colitis), tuberculosis, amebiasis, cytomegalovirus, AIDS.
� OTHERS 
Ischemic bowel disease, appendicitis, diverticulitis, radiation enterocoli-
tis, bile salt–induced diarrhea (ileal resection), drug-induced colitis (e.g., 
NSAIDs), bleeding colonic lesion (e.g., neoplasm), irritable bowel syndrome 
(no bleeding), microscopic (lymphocytic) or collagenous colitis (chronic 
watery diarrhea)—normal colonoscopy, but biopsies show superficial colonic 
epithelial inflammation and, in collagenous colitis, a thick subepithelial layer 
of collagen; response to aminosalicylates and glucocorticoids variable.
EXTRAINTESTINAL MANIFESTATIONS OF UC AND CD
1. Joint: Peripheral arthritis—parallels activity of bowel disease; ankylosing 
spondylitis and sacroiliitis (associated with HLA-B27)—activity inde-
pendent of bowel disease.
2. Skin: Erythema nodosum, aphthous ulcers, pyoderma gangrenosum, 
cutaneous Crohn’s disease.
3. Eye: Conjunctivitis, episcleritis, iritis, uveitis.
4. Liver: Fatty liver, “pericholangitis” (intrahepatic sclerosing cholangitis), 
primary sclerosing cholangitis, cholangiocarcinoma, chronic hepatitis.
5. Others: Autoimmune hemolytic anemia, phlebitis, pulmonary embolus 
(hypercoagulable state), kidney stones, metabolic bone disease.
Inﬂ ammatory Bowel Diseases (See Fig. 159-1)
TREATMENT
SUPPORTIVE Antidiarrheal agents (diphenoxylate and atropine, loper-
amide) in mild disease; IV hydration and blood transfusions in severe 
disease; parenteral nutrition or defined enteral formulas—effective as 
primary therapy in CD, although high relapse rate when oral feeding is 
resumed; should not replace drug therapy; important role in preopera-
tive preparation of malnourished pt; emotional support.
SULFASALAZINE AND AMINOSALICYLATES Active component of sul-
fasalazine is 5-aminosalicylic acid (5-ASA) linked to sulfapyridine 
carrier; useful in colonic disease of mild to moderate severity (1–1.5 g 
PO qid); efficacy in maintaining remission demonstrated only for UC 
(500 mg PO qid). Toxicity (generally due to sulfapyridine component):
5-ASA rectal or oral
Glucocorticoid rectal
Glucocorticoid oral
Glucocorticoid IV
6-Mercaptopurine
or azathioprine
IV
cyclosporine
or infliximab
Sulfasalazine antibiotics
Prednisone
Glucocorticoid IV
Infliximab/adalimumab/
certolizumab pegol
IV
cyclosporine
or tacrolimus
natalizumab
Antibiotics
6-Mercaptopurine or
azathioprine/methotrexate
Infliximab/adalimumab/
certolizumab pegol
IV cyclosporine or
tacrolimus natalizumab
Total
parenteral
nutrition
Budesonide (Ileal and R colon)
5-ASA rectal or oral
Glucocorticoid rectal
Glucocorticoid oral
Glucocorticoid IV
6-Mercaptopurine
or azathioprine
IV
cyclosporine
or infliximab
6-Mercaptopurine or
azathioprine/methotrexate
Distal UC
Extensive UC
Inflammatory CD
Fistulizing CD
FIGURE 159-1 Medical management of IBD. 5-ASA, 5-aminosalicylic acid; CD, Crohn’s disease; UC, ulcerative colitis.
1014
CHAPTER 159
1015
Inflammatory Bowel Diseases
dose-related—nausea, headache, rarely hemolytic anemia—may resolve 
when drug dose is lowered; idiosyncratic—fever, rash, neutropenia, 
pancreatitis, hepatitis, etc.; miscellaneous—oligospermia. Newer ami-
nosalicylates are as effective as sulfasalazine but with fewer side effects. 
Enemas containing 4 g of 5-ASA (mesalamine) may be used in distal UC, 
1 nightly retained qhs until remission, then q2hs or q3hs. Suppositories 
containing 500 mg of 5-ASA may be used in proctitis.
GLUCOCORTICOIDS Useful in severe disease and ileal or ileocolonic CD. 
Prednisone, 40–60 mg PO qd, then taper; IV hydrocortisone, 100 mg 
tid or equivalent, in hospitalized pts; IV adrenocorticotropic hormone 
drip (120 U qd) may be preferable in first attacks of UC. Nightly hydro-
cortisone retention enemas in proctosigmoiditis. Numerous side effects 
make long-term use problematic.
IMMUNOSUPPRESSIVE AGENTS Azathioprine, 6-mercaptopurine—
50 mg PO qd up to 2.0 or 1.5 mg/kg qd, respectively. Useful as steroid-
sparing agents and in intractable or fistulous CD (may require 2- to 
6-month trial before efficacy seen). Toxicity—immunosuppression, 
pancreatitis, ?carcinogenicity. Avoid in pregnancy.
METRONIDAZOLE Appears effective in colonic CD (500 mg PO bid) and 
refractory perineal CD (10–20 mg/kg PO qd). Toxicity—peripheral neu-
ropathy, metallic taste, ?carcinogenicity. Avoid in pregnancy. Other anti-
biotics (e.g., ciprofloxacin 500 mg PO bid) may be of value in terminal 
ileal and perianal CD, and broad-spectrum IV antibiotics are indicated 
for fulminant colitis and abscesses.
OTHERS Cyclosporine [potential value in a dose of 4 (mg/kg)/d IV for 
7–14 days in severe UC and possibly intractable Crohn’s fistulas]; experi-
mental—tacrolimus, methotrexate, chloroquine, fish oil, nicotine, others. 
Infliximab [monoclonal antibody to tumor necrosis factor (TNF)] 5 mg/kg IV 
induces responses in 65% (complete in 33%) of CD pts refractory to 5-ASA, 
glucocorticoids, and 6-mercaptopurine. In UC, 27–49% of pts respond.
Adalimumab is a humanized version of the anti-TNF antibody that is 
less likely to elicit neutralizing antibodies in the pt. Pegylated versions of 
anti-TNF antibody may be used once monthly.
Natalizumab is an anti-integrin antibody with activity against Crohn’s 
disease, but some pts develop progressive multifocal leukoencephalopathy.
SURGERY UC: Colectomy (curative) for intractability, toxic megacolon 
(if no improvement with aggressive medical therapy in 24–48 h), cancer, 
dysplasia. Ileal pouch—anal anastomosis is operation of choice in UC, but 
contraindicated in CD and in elderly. CD: Resection for fixed obstruction 
(or stricturoplasty), abscesses, persistent symptomatic fistulas, intractability.
For a more detailed discussion, see Friedman S, Blumberg 
RS: Inflammatory Bowel Disease, Chap. 295, p. 2477, in 
HPIM-18.
SECTION 11
1016
Gastroenterology
CHAPTER 160
Colonic and Anorectal 
Diseases
IRRITABLE BOWEL SYNDROME (IBS)
Characterized by altered bowel habits, abdominal pain, and absence of 
detectable organic pathology. Most common GI disease in clinical practice. 
Three types of clinical presentations: (1) spastic colon (chronic abdominal 
pain and constipation), (2) alternating constipation and diarrhea, or 
(3) chronic, painless diarrhea.
� PATHOPHYSIOLOGY 
Visceral hyperalgesia to mechanoreceptor stimuli is common. Reported 
abnormalities include altered colonic motility at rest and in response to stress, 
cholinergic drugs, cholecystokinin; altered small-intestinal motility; enhanced 
visceral sensation (lower pain threshold in response to gut distention); and 
abnormal extrinsic innervation of the gut. Pts presenting with IBS to a physi-
cian have an increased frequency of psychological disturbances—depression, 
hysteria, obsessive-compulsive disorder. Specific food intolerances and malab-
sorption of bile acids by the terminal ileum may account for a few cases.
� CLINICAL MANIFESTATIONS 
Onset often before age 30; females:males = 2:1. Abdominal pain and irregu-
lar bowel habits. Additional symptoms often include abdominal disten-
tion, relief of abdominal pain with bowel movement, increased frequency 
of stools with pain, loose stools with pain, mucus in stools, and sense of 
incomplete evacuation. Associated findings include pasty stools, ribbony 
TABLE 160-1 DIAGNOSTIC CRITERIA FOR IRRITABLE BOWEL SYNDROMEa
Recurrent abdominal pain or discomfortb at least 3 days per month in the 
last 3 months associated with two or more of the following:
1. Improvement with defecation
2. Onset associated with a change in frequency of stool
3. Onset associated with a change in form (appearance) of stool
aCriteria fulfilled for the last 3 months with symptom onset at least 6 months prior to 
diagnosis.
bDiscomfort means an uncomfortable sensation not described as pain. In pathophysiology 
research and clinical trials, a pain/discomfort frequency of at least 2 days a week during 
screening evaluation is required for subject eligibility.
Source: Adapted from Longstreth GF et al: Functional bowel disorders. Gastroenterology 
130:1480, 2006.
CHAPTER 160
1017
Colonic and Anorectal Diseases 
TABLE 160-2 POSSIBLE DRUGS FOR A DOMINANT SYMPTOM IN IBS
Symptom
Drug
Dose
Diarrhea
Loperamide
2–4 mg when necessary/
maximum 12 g/d
Cholestyramine resin
4 g with meals
Alosetrona
0.5–1 mg bid (for severe IBS, 
women)
Constipation
Psyllium husk
3–4 g bid with meals, then 
adjust
Methylcellulose
2 g bid with meals, then adjust
Calcium polycarbophil
1 g qd to qid
Lactulose syrup
10–20 g bid
70% sorbitol
15 mL bid
Polyethylene glycol 3350
17 g in 250 mL water qd
Lubiprostone (Amitiza)
24 mg bid
Magnesium hydroxide
30–60 mL qd
Abdominal pain
Smooth-muscle relaxant
qd to qid ac
Tricyclic antidepressants
Start 25–50 mg hs, then 
adjust
Selective serotonin 
reuptake inhibitors
Begin small dose, increase as 
needed
aAvailable only in the United States.
Source: Adapted from Longstreth GF et al:Functional bowel disorders. Gastroenterology 
130:1480, 2006.
or pencil-thin stools, heartburn, bloating, back pain, weakness, faintness, 
palpitations, urinary frequency.
� DIAGNOSIS 
IBS is a diagnosis of exclusion. Rome criteria for diagnosis are shown in 
Table 160-1. Consider sigmoidoscopy and barium radiographs to exclude 
inflammatory bowel disease or malignancy; consider excluding giardiasis, 
intestinal lactase deficiency, hyperthyroidism.
Irritable Bowel Syndrome (Table 160-2)
TREATMENT
Reassurance and supportive physician-pt relationship, avoidance of 
stress or precipitating factors, dietary bulk (fiber, psyllium extract, 
e.g., Metamucil 1 tbsp daily or bid); for diarrhea, trials of loperamide 
(2-mg tabs PO q a.m. then 1 PO after each loose stool to a maximum 
of 8/d, then titrate), diphenoxylate (Lomotil) (up to 2-mg tabs PO qid), 
or cholestyramine (up to 1-g packet mixed in water PO qid); for 
pain, anticholinergics (e.g., dicyclomine HCl 10–40 mg PO qid) or
SECTION 11
1018
Gastroenterology
hyoscyamine as Levsin 1–2 PO q4h prn. Amitriptyline 25–50 mg PO 
qhs or other antidepressants in low doses may relieve pain. Selective 
serotonin reuptake inhibitors such as paroxetine are being evaluated in 
constipation-dominant pts, and serotonin receptor antagonists such as 
alosetron are being evaluated in diarrhea-dominant pts. Altering gut 
flora with probiotics (Bifidobacterium infantis 35624) or oral nonab-
sorbable antibiotics (rifaximin) is being evaluated with some promising 
early results. Psychotherapy, hypnotherapy of possible benefit in severe 
refractory cases.
DIVERTICULAR DISEASE
Herniations or saclike protrusions of the mucosa through the muscularis at 
points of nutrient artery penetration; possibly due to increased intraluminal 
pressure, low-fiber diet; most common in sigmoid colon.
� CLINICAL PRESENTATION
1. Asymptomatic (detected by barium enema or colonoscopy).
2. Pain: Recurrent left lower quadrant pain relieved by defecation; alternat-
ing constipation and diarrhea. Diagnosis by barium enema.
3. Diverticulitis: Pain, fever, altered bowel habits, tender colon, leukocytosis. 
Best confirmed and staged by CT after opacification of bowel. (In pts 
who recover with medical therapy, perform elective barium enema or 
colonoscopy in 4–6 weeks to exclude cancer.) Complications: pericolic 
abscess, perforation, fistula (to bladder, vagina, skin, soft tissue), liver 
abscess, stricture. Frequently require surgery or, for abscesses, percutaneous 
drainage.
4. Hemorrhage: Usually in absence of diverticulitis, often from ascend-
ing colon and self-limited. If persistent, manage with mesenteric 
arteriography and intraarterial infusion of vasopressin, or surgery 
(Chap. 47).
Diverticular Disease
TREATMENT
PAIN High-fiber diet, psyllium extract (e.g., Metamucil 1 tbsp PO qd or 
bid), anticholinergics (e.g., dicyclomine HCl 10–40 mg PO qid).
DIVERTICULITIS NPO, IV fluids, antibiotics for 7–10 d (e.g., trimethoprim/
sulfamethoxazole or ciprofloxacin and metronidazole; add ampicillin 
to cover enterococci in nonresponders); for ambulatory pts, ampicillin/
clavulanate (clear liquid diet); surgical resection in refractory or frequently 
recurrent cases, young persons (<age 50), immunosuppressed pts, or when 
there is inability to exclude cancer.
Pts who have had at least two documented episodes and those who 
respond slowly to medical therapy should be offered surgical options 
to achieve removal of the diseased colonic segment, controlling sepsis, 
eliminating obstructions or fistulas, and restoring intestinal continuity.
CHAPTER 160
1019
Colonic and Anorectal Diseases 
INTESTINAL PSEUDOOBSTRUCTION
Recurrent attacks of nausea, vomiting, and abdominal pain and distention 
mimicking mechanical obstruction; may be complicated by steatorrhea due 
to bacterial overgrowth.
� CAUSES 
Primary: Familial visceral neuropathy, familial visceral myopathy, idiopathic. 
Secondary: Scleroderma, amyloidosis, diabetes, celiac disease, parkinson-
ism, muscular dystrophy, drugs, electrolyte imbalance, postsurgical.
Intestinal Pseudoobstruction
TREATMENT
For acute attacks: intestinal decompression with long tube. Oral anti-
biotics for bacterial overgrowth (e.g., metronidazole 250 mg PO tid, 
tetracycline 500 mg PO qid, or ciprofloxacin 500 mg bid 1 week out of 
each month, usually in an alternating rotation of at least two antibiot-
ics). Avoid surgery. In refractory cases, consider long-term parenteral 
hyperalimentation.
VASCULAR DISORDERS (SMALL AND LARGE INTESTINE)
� MECHANISMS OF MESENTERIC ISCHEMIA 
(1) Occlusive: embolus (atrial fibrillation, valvular heart disease); arterial 
thrombus (atherosclerosis); venous thrombosis (trauma, neoplasm, infec-
tion, cirrhosis, oral contraceptives, antithrombin-III deficiency, protein S 
or C deficiency, lupus anticoagulant, factor V Leiden mutation, idiopathic); 
vasculitis (systemic lupus erythematosus, polyarteritis, rheumatoid arthri-
tis, Henoch-Schönlein purpura); (2) nonocclusive: hypotension, heart fail-
ure, arrhythmia, digitalis (vasoconstrictor).
� ACUTE MESENTERIC ISCHEMIA 
Periumbilical pain out of proportion to tenderness; nausea, vomiting, 
distention, GI bleeding, altered bowel habits. Abdominal x-ray shows 
bowel distention, air-fluid levels, thumbprinting (submucosal edema), but 
may be normal early in course. Peritoneal signs indicate infarcted bowel 
requiring surgical resection. Early celiac and mesenteric arteriography is 
recommended in all cases following hemodynamic resuscitation (avoid 
vasopressors, digitalis). Intraarterial vasodilators (e.g., papaverine) can be 
administered to reverse vasoconstriction. Laparotomy indicated to restore 
intestinal blood flow obstructed by embolus or thrombosis or to resect 
necrotic bowel. Postoperative anticoagulation indicated in mesenteric 
venous thrombosis, controversial in arterial occlusion.
� CHRONIC MESENTERIC INSUFFICIENCY 
“Abdominal angina”: dull, crampy periumbilical pain 15–30 min after 
a meal and lasting for several hours; weight loss; occasionally diarrhea. 
Evaluate with mesenteric arteriography for possible bypass graft surgery.
SECTION 11
1020
Gastroenterology
� ISCHEMIC COLITIS 
Usually due to nonocclusive disease in pts with atherosclerosis. Severe 
lower abdominal pain, rectal bleeding, hypotension. Abdominal x-ray 
shows colonic dilatation, thumbprinting. Sigmoidoscopy shows submuco-
sal hemorrhage, friability, ulcerations; rectum often spared. Conservative 
management (NPO, IV fluids); surgical resection for infarction or 
postischemic stricture.
COLONIC ANGIODYSPLASIA
In persons over age 60, vascular ectasias, usually in right colon, account for 
up to 40% of cases of chronic or recurrent lower GI bleeding. May be asso-
ciated with aortic stenosis. Diagnosis is by arteriography (clusters of small 
vessels, early and prolonged opacification of draining vein) or colonoscopy 
(flat, bright red, fernlike lesions). For bleeding, treat by colonoscopic 
electro- or laser coagulation, band ligation, arteriographic embolization, or, 
if necessary, right hemicolectomy (Chap. 47).
ANORECTAL DISEASES
� HEMORRHOIDS 
Due to increased hydrostatic pressure in hemorrhoidal venous plexus (asso-
ciated with straining at stool, pregnancy). May be external, internal, throm-
bosed, acute (prolapsed or strangulated), or bleeding. Treat pain with bulk 
laxative and stool softeners (psyllium extract, dioctyl sodium sulfosuccinate 
100–200 mg/d), sitz baths 1–4 per day, witch hazel compresses, analgesics 
as needed. Bleeding may require rubber band ligation or injection sclero-
therapy. Operative hemorrhoidectomy in severe or refractory cases.
� ANAL FISSURES 
Medical therapy as for hemorrhoids. Relaxation of the anal canal with nitro-
glycerin ointment (0.2%) applied tid or botulinum toxin type A up to 20 U 
injected into the internal sphincter on each side of the fissure. Internal anal 
sphincterotomy in refractory cases.
� PRURITUS ANI 
Often of unclear cause; may be due to poor hygiene, fungal or parasitic 
infection. Treat with thorough cleansing after bowel movement, topical 
glucocorticoid, antifungal agent if indicated.
� ANAL CONDYLOMAS (GENITAL WARTS) 
Wartlike papillomas due to sexually transmitted papillomavirus. Treat with 
cautious application of liquid nitrogen or podophyllotoxin or with intral-
esional interferon α. Tend to recur. May be prevented by vaccination with 
HPV vaccine.
For a more detailed discussion, see Owyang C: Irritable Bowel 
Syndrome, Chap. 296, p. 2496; Gearhart SL: Diverticular 
Disease and Common Anorectal Disorders, Chap. 297, 
p. 2502; and Gearhart SL: Mesenteric Vascular Insufficiency, 
Chap. 298, p. 2510, in HPIM-18.
CHAPTER 161
1021
Cholelithiasis, Cholecystitis, and Cholangitis 
CHAPTER 161
Cholelithiasis, Cholecystitis, 
and Cholangitis
CHOLELITHIASIS
There are two major types of gallstones: cholesterol and pigment stones. 
Cholesterol gallstones contain >50% cholesterol monohydrate. Pigment 
stones have <20% cholesterol and are composed primarily of calcium bilirubi-
nate. In the United States, 80% of stones are cholesterol and 20% are pigment.
� EPIDEMIOLOGY 
One million new cases of cholelithiasis per year in the United States. 
Predisposing factors include demographic/genetics (increased prevalence 
in North American Indians), obesity, weight loss, female sex hormones, age, 
ileal disease, pregnancy, type IV hyperlipidemia, and cirrhosis.
� SYMPTOMS AND SIGNS 
Many gallstones are “silent,” i.e., present in asymptomatic pts. Symptoms 
occur when stones trigger inflammation or cause obstruction of the cystic 
or common bile ducts. Major symptoms: (1) biliary colic—a severe steady 
ache in the RUQ or epigastrium that begins suddenly; often occurs 30–90 
min after meals, lasts for several hours, and occasionally radiates to the 
right scapula or back; (2) nausea, vomiting. Physical exam may be normal 
or show epigastric or RUQ tenderness.
� LABORATORY 
Occasionally, mild and transient elevations in bilirubin [<85 μmol/L 
(<5 mg/dL)] accompany biliary colic.
� IMAGING 
Only 10% of cholesterol gallstones are radiopaque. Ultrasonography is 
best diagnostic test. The oral cholecystogram has been largely replaced by 
ultrasound, but may be used to assess the patency of the cystic duct and 
gallbladder emptying function (Table 161-1).
� DIFFERENTIAL DIAGNOSIS 
Includes peptic ulcer disease (PUD), gastroesophageal reflux, irritable 
bowel syndrome, and hepatitis.
� COMPLICATIONS 
Cholecystitis, pancreatitis, cholangitis.
Cholelithiasis
TREATMENT
In asymptomatic pts, risk of developing complications requiring surgery 
is small. Elective cholecystectomy should be reserved for: (1) symptomatic
SECTION 11
1022
Gastroenterology
TABLE 161-1 DIAGNOSTIC EVALUATION OF THE BILE DUCTS
Diagnostic Advantages
Diagnostic Limitations
Hepatobiliary ultrasound
Rapid
Bowel gas
Simultaneous scanning of GB, liver, bile ducts, 
pancreas
Massive obesity
Ascites
Accurate identification of dilated bile ducts
Barium
Not limited by jaundice, pregnancy
Partial bile duct obstruction
Guidance for fine-needle biopsy
Poor visualization of distal CBD
Computed tomography
Simultaneous scanning of GB, liver, bile ducts, 
pancreas
Extreme cachexia
Movement artifact
Accurate identification of dilated bile ducts, 
masses
Ileus
Partial bile duct obstruction
Not limited by jaundice, gas, obesity, ascites
High-resolution image
Guidance for fine-needle biopsy
Magnetic resonance cholangiopancreatography
Useful modality for visualizing pancreatic and 
biliary ducts
Cannot offer therapeutic 
intervention
Has excellent sensitivity for bile duct dilatation, 
biliary stricture, and intraductal abnormalities
High cost
Can identify pancreatic duct dilatation or 
stricture, pancreatic duct stenosis, and 
pancreas divisum
Endoscopic retrograde cholangiopancreatography
Simultaneous pancreatography
Gastroduodenal obstruction
Best visualization of distal biliary tract
?Roux-en-Y biliary-enteric 
anastomosis
Bile or pancreatic cytology
Endoscopic sphincterotomy and stone removal
Biliary manometry
Percutaneous transhepatic cholangiogram
Extremely successful when bile ducts dilated
Nondilated or sclerosed ducts
Best visualization of proximal biliary tract
Bile cytology/culture
Percutaneous transhepatic drainage
Endoscopic ultrasound
Most sensitive method to detect ampullary stones
CHAPTER 161
1023
Cholelithiasis, Cholecystitis, and Cholangitis 
pts (i.e., biliary colic despite low-fat diet); (2) persons with previous 
complications of cholelithiasis (see below); and (3) presence of an 
underlying condition predisposing to an increased risk of complications 
(calcified or porcelain gallbladder). Pts with gallstones >3 cm or with 
an anomalous gallbladder containing stones should also be considered 
for surgery. Laparoscopic cholecystectomy is minimally invasive and is 
the procedure of choice for most pts undergoing elective cholecystec-
tomy. Oral dissolution agents (ursodeoxycholic acid) partially or com-
pletely dissolve small radiolucent stones in 50% of selected pts within 
6–24 months. Because of the frequency of stone recurrence and the 
effectiveness of laparoscopic surgery, the role of oral dissolution therapy 
has been largely confined to pts who are not candidates for elective 
cholecystectomy.
ACUTE CHOLECYSTITIS
Acute inflammation of the gallbladder is usually caused by cystic duct 
obstruction by an impacted stone. Inflammatory response is evoked by: (1) 
mechanical inflammation from increased intraluminal pressure; (2) chemi-
cal inflammation from release of lysolecithin; (3) bacterial inflammation, 
which plays a role in 50–85% of pts with acute cholecystitis.
� ETIOLOGY 
90% calculous; 10% acalculous. Acalculous cholecystitis is associated with 
higher complication rate and acute illness (i.e., burns, trauma, major sur-
gery), fasting, hyperalimentation leading to gallbladder stasis, vasculitis, 
carcinoma of gallbladder or common bile duct, some gallbladder infections 
(Leptospira, Streptococcus, Salmonella, or Vibrio cholerae), but in >50% of 
cases an underlying explanation is not found.
� SYMPTOMS AND SIGNS 
(1) Biliary colic (RUQ or epigastric pain) that progressively worsens; (2) 
nausea, vomiting, anorexia; and (3) fever. Examination typically reveals 
RUQ tenderness; palpable RUQ mass found in 20% of pts. Murphy’s sign 
is present when deep inspiration or cough during palpation of the RUQ 
produces increased pain or inspiratory arrest.
� LABORATORY 
Mild leukocytosis; serum bilirubin, alkaline phosphatase, and AST may be 
mildly elevated.
� IMAGING 
Ultrasonography is useful for demonstrating gallstones and occasionally 
a phlegmonous mass surrounding the gallbladder. Radionuclide scans 
(HIDA, DIDA, DISIDA, etc.) may identify cystic duct obstruction.
� DIFFERENTIAL DIAGNOSIS 
Includes acute pancreatitis, appendicitis, pyelonephritis, peptic ulcer dis-
ease, hepatitis, and hepatic abscess.
SECTION 11
1024
Gastroenterology
� COMPLICATIONS 
Empyema, hydrops, gangrene, perforation, fistulization, gallstone ileus, 
porcelain gallbladder.
Acute Cholecystitis
TREATMENT
No oral intake, nasogastric suction, IV fluids and electrolytes, analgesia 
(meperidine or NSAIDs), and antibiotics (ureidopenicillins, ampicillin 
sulbactam, ciprofloxacin, third-generation cephalosporins; anaerobic 
coverage should be added if gangrenous or emphysematous cholecysti-
tis is suspected; imipenem/meropenem cover the spectrum of bacteria 
causing ascending cholangitis but should be reserved for the most 
life-threatening infections when other antibiotics have failed). Acute 
symptoms will resolve in 70% of pts. Optimal timing of surgery depends 
on pt stabilization and should be performed as soon as feasible. Urgent 
cholecystectomy is appropriate in most pts with a suspected or con-
firmed complication. Delayed surgery is reserved for pts with high risk 
of emergent surgery and where the diagnosis is in doubt.
CHRONIC CHOLECYSTITIS
� ETIOLOGY 
Chronic inflammation of the gallbladder; almost always associated with 
gallstones. Results from repeated acute/subacute cholecystitis or prolonged 
mechanical irritation of gallbladder wall.
� SYMPTOMS AND SIGNS 
May be asymptomatic for years, may progress to symptomatic gallbladder 
disease or to acute cholecystitis, or present with complications.
� LABORATORY 
Tests are usually normal.
� IMAGING 
Ultrasonography preferred; usually shows gallstones within a contracted 
gallbladder (Table 161-1).
� DIFFERENTIAL DIAGNOSIS 
Peptic ulcer disease, esophagitis, irritable bowel syndrome.
Chronic Cholecystitis
TREATMENT
Surgery indicated if pt is symptomatic.
CHOLEDOCHOLITHIASIS/CHOLANGITIS
� ETIOLOGY 
In pts with cholelithiasis, passage of gallstones into common bile duct 
(CBD) occurs in 10–15%; increases with age. At cholecystectomy, unde-
tected stones are left behind in 1–5% of pts.
CHAPTER 161
1025
Cholelithiasis, Cholecystitis, and Cholangitis 
� SYMPTOMS AND SIGNS 
Choledocholithiasis may present as an incidental finding, biliary colic, 
obstructive jaundice, cholangitis, or pancreatitis. Cholangitis usually pres-
ents as fever, RUQ pain, and jaundice (Charcot’s triad).
� LABORATORY 
Elevations in serum bilirubin, alkaline phosphatase, and aminotransferases. 
Leukocytosis usually accompanies cholangitis; blood cultures are frequently 
positive. Amylase is elevated in 15% of cases.
� IMAGING 
Diagnosis usually made by cholangiography either preoperatively by endo-
scopic retrograde cholangiopancreatography (ERCP) or intraoperatively at 
the time of cholecystectomy. Ultrasonography may reveal dilated bile ducts 
but is not sensitive for detecting CBD stones (Table 161-1).
� DIFFERENTIAL DIAGNOSIS 
Acute cholecystitis, renal colic, perforated viscus, pancreatitis.
� COMPLICATIONS 
Cholangitis, obstructive jaundice, gallstone-induced pancreatitis, and sec-
ondary biliary cirrhosis.
Choledocholithiasis/Cholangitis
TREATMENT
Laparoscopic cholecystectomy and ERCP have decreased the need for 
choledocholithotomy and T-tube drainage of the bile ducts. When CBD 
stones are suspected prior to laparoscopic cholecystectomy, preop-
erative ERCP with endoscopic papillotomy and stone extraction is the 
preferred approach. CBD stones should be suspected in gallstone pts 
with (1) history of jaundice or pancreatitis, (2) abnormal LFT, and (3) 
ultrasound evidence of a dilated common bile duct or stones in the duct. 
Cholangitis treated like acute cholecystitis; no oral intake, hydration, 
analgesia, and antibiotics are the mainstays; stones should be removed 
surgically or endoscopically.
PRIMARY SCLEROSING CHOLANGITIS (PSC)
PSC is a sclerosing, inflammatory, and obliterative process involving the 
biliary tree.
� ETIOLOGY 
Associations: inflammatory bowel disease (75% of cases of PSC—especially 
ulcerative colitis), AIDS, rarely retroperitoneal fibrosis.
� SYMPTOMS AND SIGNS 
Pruritus, RUQ pain, jaundice, fever, weight loss, and malaise. 44% may be 
asymptomatic at diagnosis. May progress to cirrhosis with portal hypertension.
� LABORATORY 
Evidence of cholestasis (elevated bilirubin and alkaline phosphatase) common.
SECTION 11
1026
Gastroenterology
� RADIOLOGY/ENDOSCOPY 
Transhepatic or endoscopic cholangiograms reveal stenosis and dilation of 
the intra- and extrahepatic bile ducts.
� DIFFERENTIAL DIAGNOSIS 
Cholangiocarcinoma, Caroli disease (cystic dilation of bile ducts), Fasciola 
hepatica infection, echinococcosis, and ascariasis.
Primary Sclerosing Cholangitis
TREATMENT
No satisfactory therapy. Cholangitis should be treated as outlined above. 
Cholestyramine may control pruritus. Supplemental vitamin D and calcium 
may retard bone loss. Glucocorticoids, methotrexate, and cyclosporine 
have not been shown to be effective. Ursodeoxycholic acid improves liver 
tests but has not been shown to affect survival. Surgical relief of biliary 
obstruction may be appropriate but has a high complication rate. Liver 
transplantation should be considered in pts with end-stage cirrhosis. 
Median survival: 9–12 years after diagnosis, with age, bilirubin level, 
histologic stage, and splenomegaly being predictors of survival.
For a more detailed discussion, see Greenberger NJ, 
Paumgartner G: Diseases of the Gallbladder and Bile Ducts, 
Chap. 311, p. 2615, in HPIM-18.
CHAPTER 162
Pancreatitis
ACUTE PANCREATITIS
The pathologic spectrum of acute pancreatitis varies from interstitial pan-
creatitis, which is usually a mild and self-limited disorder, to necrotizing 
pancreatitis, in which the degree of pancreatic necrosis correlates with the 
severity of the attack and its systemic manifestations.
� ETIOLOGY 
Most common causes in the United States are cholelithiasis and alcohol. 
Others are listed in Table 162-1.
� CLINICAL FEATURES 
Can vary from mild abdominal pain to shock. Common symptoms: 
(1) steady, boring midepigastric pain radiating to the back that is frequently 
increased in the supine position; (2) nausea, vomiting.
Physical exam: (1) low-grade fever, tachycardia, hypotension; (2) ery-
thematous skin nodules due to subcutaneous fat necrosis; (3) basilar rales, 
pleural effusion (often on the left); (4) abdominal tenderness and rigidity, 
CHAPTER 162
1027
Pancreatitis
TABLE 162-1 CAUSES OF ACUTE PANCREATITIS
Common Causes
Gallstones (including microlithiasis)
Alcohol (acute and chronic alcoholism)
Hypertriglyceridemia
Complication of endoscopic retrograde cholangiopancreatography (ERCP),
especially after biliary manometry
Trauma (especially blunt abdominal trauma)
Postoperative (abdominal and nonabdominal operations)
Drugs (azathioprine, 6-mercaptopurine, sulfonamides, estrogens, tetracycline,
valproic acid, anti-HIV medications)
Sphincter of Oddi dysfunction
Uncommon Causes
Vascular causes and vasculitis (ischemic-hypoperfusion states after cardiac 
surgery)
Connective tissue disorders and thrombotic thrombocytopenic purpura 
(TTP)
Cancer of the pancreas
Hypercalcemia
Periampullary diverticulum
Pancreas divisum
Hereditary pancreatitis
Cystic fibrosis
Renal failure
Rare Causes
Infections (mumps, coxsackievirus, cytomegalovirus, echovirus, parasites) 
Autoimmune (e.g., Sjögren’s syndrome)
Causes to Consider in Patients with Recurrent Bouts of Acute Pancreatitis 
without an Obvious Etiology
Occult disease of the biliary tree or pancreatic ducts, especially 
microlithiasis, sludge
Drugs
Hypertriglyceridemia
Pancreas divisum
Pancreatic cancer
Sphincter of Oddi dysfunction
Cystic fibrosis
Idiopathic
SECTION 11
1028
Gastroenterology
diminished bowel sounds, palpable upper abdominal mass; (5) Cullen’s 
sign: blue discoloration in the periumbilical area due to hemoperitoneum; 
(6) Turner’s sign: blue-red-purple or green-brown discoloration of the 
flanks due to tissue catabolism of hemoglobin.
� LABORATORY
1. Serum amylase: Large elevations (>3 × normal) virtually assure the diag-
nosis if salivary gland disease and intestinal perforation/infarction are 
excluded. However, normal serum amylase does not exclude the diagnosis 
of acute pancreatitis, and the degree of elevation does not predict severity 
of pancreatitis. Amylase levels typically return to normal in 48–72 h.
2. Urinary amylase–creatinine clearance ratio: no more sensitive or specific 
than blood amylase levels.
3. Serum lipase level: increases in parallel with amylase level and measure-
ment of both tests increases the diagnostic yield.
4. Other tests: Hypocalcemia occurs in ~25% of pts. Leukocytosis (15,000–
20,000/μL) occurs frequently. Hypertriglyceridemia occurs in 15–20% 
of cases and can cause a spuriously normal serum amylase level. 
Hyperglycemia is common. Serum bilirubin, alkaline phosphatase, and 
aspartame aminotransferase can be transiently elevated. Hypoalbuminemia 
and marked elevations of serum lactic dehydrogenase (LDH) are associ-
ated with an increased mortality rate. Hypoxemia is present in 25% of pts. 
Arterial pH <7.32 may spuriously elevate serum amylase.
� IMAGING
1. Abdominal radiographs are abnormal in 30–50% of pts but are not spe-
cific for pancreatitis. Common findings include total or partial ileus 
(“sentinel loop”) and the “colon cut-off sign,” which results from isolated 
distention of the transverse colon. Useful for excluding diagnoses such as 
intestinal perforation with free air.
2. Ultrasound often fails to visualize the pancreas because of overlying 
intestinal gas but may detect gallstones, pseudocysts, mass lesions, or 
edema or enlargement of the pancreas.
3. CT can confirm the clinical impression of acute pancreatitis. It can also be 
helpful in indicating the severity of acute pancreatitis via the CT severity 
index (CTSI—see Table 313-3, p. 2637, HPIM-18), assessing the risk of mor-
bidity and mortality and in evaluating the complications of acute pancreatitis.
� DIFFERENTIAL DIAGNOSIS 
Intestinal perforation (especially peptic ulcer), cholecystitis, acute intestinal 
obstruction, mesenteric ischemia, renal colic, myocardial ischemia, aortic 
dissection, connective tissue disorders, pneumonia, and diabetic ketoacidosis.
Acute Pancreatitis
TREATMENT
Most (90%) cases subside over a period of 3–7 days. Conventional mea-
sures: (1) analgesics, such as meperidine; (2) IV fluids and colloids; (3) 
no oral alimentation. The benefit of antibiotic prophylaxis in necrotizing
CHAPTER 162
1029
Pancreatitis
acute pancreatitis remains controversial. Current recommendation is 
use of an antibiotic such as imipenem-cilastatin, 500 mg tid for 2 weeks. 
Not effective: cimetidine (or related agents), H2 blockers, protease 
inhibitors, glucocorticoids, nasogastric suction, glucagon, peritoneal 
lavage, and anticholinergic medications. Precipitating factors (alcohol, 
medications) must be eliminated. In mild or moderate pancreatitis, 
a clear liquid diet can usually be started after 3–6 days. pts with severe 
gallstone-induced pancreatitis often benefit from early (<3 days) 
papillotomy.
� COMPLICATIONS 
It is important to identify pts who are at risk of poor outcome. Risk factors 
and markers of severe acute pancreatitis are listed in Table 162-2. Fulminant 
pancreatitis requires aggressive fluid support and meticulous management. 
Mortality is largely due to infection.
TABLE 162-2 SEVERE ACUTE PANCREATITIS
Risk Factors for Severity
• Age >60 years
• Obesity, BMI >30
• Comorbid disease
Markers of Severity within 24 Hours
•  SIRS [temperature >38° or <36°C (>100.4° or 96.8°F), Pulse >90, 
Tachypnea >24, ↑ WBC >12,000]
• Hemoconcentration (Hct >44%)
• BISAP
 – (B) Blood urea nitrogen (BUN) >22 mg%
 – (I) Impaired mental status
 – (S) SIRS: 2/4 present
 – (A) Age >60 years
 – (P) Pleural effusion
• Organ Failure
 – Cardiovascular: systolic BP <90 mmHg, heart rate >130
 – Pulmonary: Pao2 <60 mmHg 
 – Renal serum creatinine >2.0 mg% 
Markers of Severity during Hospitalization
• Persistent organ failure
• Pancreatic necrosis
• Hospital-acquired infection
Abbreviations:  BISAP, bedside index of severity in acute pancreatitis.
SECTION 11
1030
Gastroenterology
Systemic
Shock, GI bleeding, common duct obstruction, ileus, splenic infarction or 
rupture, disseminated intravascular coagulation, subcutaneous fat necrosis, 
acute respiratory distress syndrome, pleural effusion, acute renal failure, 
sudden blindness.
Local
1. Sterile or infected pancreatic necrosis—necrosis may become secondarily 
infected in 40–60% of pts, typically within 1–2 weeks after the onset 
of pancreatitis. Most frequent organisms: gram-negative bacteria of 
alimentary origin, but intraabdominal Candida infection increasing in 
frequency. Necrosis can be visualized by contrast-enhanced dynamic CT, 
with infection diagnosed by CT-guided needle aspiration. Laparotomy 
with removal of necrotic material and adequate drainage should be 
considered for pts with sterile acute necrotic pancreatitis, if  pt continues 
to deteriorate despite conventional therapy. Infected pancreatic necrosis 
requires aggressive surgical debridement and antibiotics.
2. Pancreatic pseudocysts develop over 1–4 weeks in 15% of pts. Abdominal 
pain is the usual complaint, and a tender upper abdominal mass may 
be present. Can be detected by abdominal ultrasound or CT. In pts who 
are stable and uncomplicated, treatment is supportive; pseudocysts that 
are >5 cm in diameter and persist for >6 weeks should be considered for 
drainage. In pts with an expanding pseudocyst or one complicated by 
hemorrhage, rupture, or abscess, surgery should be performed.
3. Pancreatic abscess—ill-defined liquid collection of pus that evolves over 
4–6 weeks. Can be treated surgically or in selected cases by percutaneous 
drainage.
4. Pancreatic ascites and pleural effusions are usually due to disruption of 
the main pancreatic duct. Treatment involves nasogastric suction and 
parenteral alimentation for 2–3 weeks. If medical management fails, 
pancreatography followed by surgery should be performed.
CHRONIC PANCREATITIS
Chronic pancreatitis may occur as recurrent episodes of acute inflamma-
tion superimposed upon a previously injured pancreas or as chronic dam-
age with pain and malabsorption.
� ETIOLOGY 
Chronic alcoholism is most frequent cause of pancreatic exocrine insuf-
ficiency in U.S. adults; in 25% of adults, etiology is unknown. Other causes 
are listed in Table 162-3.
� SYMPTOMS AND SIGNS 
Pain is cardinal symptom. Weight loss, steatorrhea, and other signs and 
symptoms of malabsorption common. Physical exam often unremarkable.
� LABORATORY 
No specific laboratory test for chronic pancreatitis. Serum amylase and 
lipase levels are often normal. Serum bilirubin and alkaline phosphatase 
CHAPTER 162
1031
Pancreatitis
TABLE 162-3  CHRONIC PANCREATITIS AND PANCREATIC EXOCRINE 
INSUFFICIENCY: TIGAR-O CLASSIFICATION SYSTEM
Toxic-Metabolic
Autoimmune
Alcoholic
 Isolated autoimmune CP
Tobacco smoking
 Autoimmune CP associated with
Hypercalcemia
  Sjögren’s syndrome
Hyperlipidemia
  Inflammatory bowel disease
Chronic renal failure
  Primary biliary cirrhosis
Medications—phenacetin 
abuse
Recurrent and severe acute pancreatitis
 Postnecrotic (severe acute pancreatitis)
 Recurrent acute pancreatitis
 Vascular diseases/ischemia
 Postirradiation
Toxins—organotin compounds 
(e.g., DBTC)
Idiopathic
 Early onset
 Late onset
 Tropical
Obstructive
 Pancreas divisum
Genetic
 Sphincter of Oddi disorders (controversial)
 Duct obstruction (e.g., tumor)
 Preampullary duodenal wall cysts
 Posttraumatic pancreatic duct scars
 Hereditary pancreatitis
 Cationic trypsinogen
 CFTR mutations
 SPINK1 mutations
Abbreviations: CP, chronic pancreatitis; TIGAR-O, toxic-metabolic, idiopathic, genetic, 
autoimmune, recurrent and severe acute pancreatitis, obstructive.
may be elevated. Steatorrhea (fecal fat concentration ≥9.5%) late in the 
course. The bentiromide test, a simple, effective test of pancreatic exo-
crine function, may be helpful. d-Xylose urinary excretion test is usually 
normal. Impaired glucose tolerance is present in >50% of pts. Secretin 
stimulation test is a relatively sensitive test for pancreatic exocrine 
deficiency.
� IMAGING 
Plain films of the abdomen reveal pancreatic calcifications in 30–60%. 
Ultrasound and CT scans may show dilation of the pancreatic duct. ERCP 
and endoscopic ultrasound (EUS) provide information about the main 
pancreatic and smaller ducts.
� DIFFERENTIAL DIAGNOSIS 
Important to distinguish from pancreatic carcinoma; may require radio-
graphically guided biopsy.
SECTION 11
1032
Gastroenterology
Chronic Pancreatitis
TREATMENT
Aimed at controlling pain and malabsorption. Intermittent attacks 
treated like acute pancreatitis. Alcohol and large, fatty meals must be 
avoided. Narcotics for severe pain, but subsequent addiction is com-
mon. pts unable to maintain adequate hydration should be hospitalized, 
while those with milder symptoms can be managed on an ambulatory 
basis. Surgery may control pain if there is a ductal stricture. Subtotal 
pancreatectomy may also control pain but at the cost of exocrine insuf-
ficiency and diabetes. Malabsorption is managed with a low-fat diet 
and pancreatic enzyme replacement. Because pancreatic enzymes are 
inactivated by acid, agents that reduce acid production (e.g., omeprazole 
or sodium bicarbonate) may improve their efficacy (but should not be 
given with enteric-coated preparations). Insulin may be necessary to 
control serum glucose.
� COMPLICATIONS 
Vitamin B12 malabsorption in 40% of alcohol-induced and all cystic fibrosis 
cases. Impaired glucose tolerance. Nondiabetic retinopathy due to vitamin A 
and/or zinc deficiency. GI bleeding, icterus, effusions, subcutaneous fat 
necrosis, and bone pain occasionally occur. Increased risk for pancreatic 
carcinoma. Narcotic addiction common.
For a more detailed discussion, see Greenberger NJ, Conwell 
DL, Banks PA: Approach to the Patient With Pancreatic 
Disease, Chap. 312, p. 2629; Greenberger NJ, Conwell 
DL, Wu BU, Banks PA: Acute and Chronic Pancreatitis, 
Chap. 313, p. 2634, in HPIM-18.
CHAPTER 163
Acute Hepatitis
VIRAL HEPATITIS
Acute viral hepatitis is a systemic infection predominantly affecting the 
liver. Clinically characterized by malaise, nausea, vomiting, diarrhea, and 
low-grade fever followed by dark urine, jaundice, and tender hepatomegaly; 
may be subclinical and detected on basis of elevated aspartate and alanine 
aminotransferase (AST and ALT) levels. Hepatitis B may be associated with 
immune-complex phenomena, including arthritis, serum sickness-like illness, 
glomerulonephritis, and a polyarteritis nodosa–like vasculitis. Hepatitis-like 
illnesses may be caused not only by hepatotropic viruses (A, B, C, D, E) but 
also by other viruses (Epstein-Barr, CMV, coxsackievirus, etc.), alcohol, drugs, 
hypotension and ischemia, and biliary tract disease (Table 163-1).
TABLE 163-1 THE HEPATITIS VIRUSES
HAV
HBV
HCV
HDV
HEV
Viral Properties
 Size, nm
27
42
~55
~36
~32
 Nucleic acid
RNA
DNA
RNA
RNA
RNA
 Genome length, kb
7.5
3.2
9.4
1.7
7.5
 Classification
Picornavirus
Hepadnavirus
Flavivirus-like
—
Calicivirus-like or alpha-virus-like
Incubation, days
15–45
30–180
15–160
21–140
14–63
Transmission
 Fecal-oral
+++
—
—
—
+++
 Percutaneous
Rare
+++
+++
+++
—
 Sexual
?
++
Uncommon
++
—
 Perinatal
—
+++
Uncommon
+
—
Clinical Features
 Severity
Usually mild
Moderate
Mild
May be severe
Usually mild
 Chronic infection
No
1–10%; up to 90% in 
neonates
80–90%
Common
No
 Carrier state
No
Yes
Yes
Yes
No
 Fulminant hepatitis
0.1%
1%
Rare
Up to 20% in superinfection
10–20% in pregnant women
 Hepatocellular carcinoma No
Yes
Yes
?
No
Prophylaxis
Ig; vaccine
HBIg; vaccine
None
None (HBV vaccine for susceptibles)
None
Note: HAV, hepatitis A virus; HBV, hepatitis B virus; HCV, hepatitis C virus; HDV, hepatitis D virus; HEV, hepatitis E virus; Ig, immune globulin; + +, sometimes; + + +, often; ?, possibly.
1033
SECTION 11
1034
Gastroenterology
� HEPATITIS A (HAV) 
27-nm picornavirus (hepatovirus) with single-stranded RNA genome.
Clinical Course See Fig. 163-1.
Outcome
Recovery within 6–12 months, usually with no clinical sequelae; a small 
proportion will have one or two apparent clinical and serologic relapses; 
in some cases, pronounced cholestasis suggesting biliary obstruction may 
occur; rare fatalities (fulminant hepatitis), no chronic carrier state.
Diagnosis
IgM anti-HAV in acute or early convalescent serum sample.
Epidemiology 
Fecal-oral transmission; endemic in underdeveloped countries; food-borne 
and waterborne epidemics; outbreaks in day-care centers, residential 
institutions.
Prevention
After exposure: immune globulin 0.02 mL/kg IM within 2 weeks to house-
hold and institutional contacts (not casual contacts at work). Before expo-
sure: inactivated HAV vaccine 1 mL IM (unit dose depends on formulation); 
half dose to children; repeat at 6–12 months; target travelers, military 
recruits, animal handlers, day-care personnel, laboratory workers, and pts 
with chronic liver disease (especially hepatitis C).
� HEPATITIS B (HBV) 
42-nm hepadnavirus with outer surface coat (HBsAg), inner nucleocap-
sid core (HBcAg), DNA polymerase, and partially double-stranded DNA 
genome of 3200 nucleotides. Circulating form of HBcAg is HBeAg, a 
marker of viral replication and infectivity. Multiple serotypes and genetic 
heterogeneity.
IgG Anti-HAV
IgM Anti-HAV
Jaundice
ALT
Fecal HAV
0
4
8
12
16
20
Weeks after exposure
FIGURE 163-1 Scheme of typical clinical and laboratory features of HAV. 
CHAPTER 163
1035
Acute Hepatitis
100
0
Jaundice
ALT
HBeAg
Anti-HBe
IgG Anti-HBc
HBsAg
IgM Anti-HBc
Anti-HBs
4
8
12
16
20
24
28
32
36
52
Weeks after exposure
FIGURE 163-2 Scheme of typical clinical and laboratory features of HBV.
Clinical Course See Fig. 163-2.
Outcome
Recovery >90%, fulminant hepatitis (<1%), chronic hepatitis or carrier 
state (only 1–2% of immunocompetent adults; higher in neonates, elderly, 
immunocompromised), cirrhosis, and hepatocellular carcinoma (especially 
following chronic infection beginning in infancy or early childhood) 
(Chap. 165). Reactivation of HBV has been observed with immunosuppres-
sion, particularly with rituximab.
Diagnosis
HBsAg in serum (acute or chronic infection); IgM anti-HBc (early anti-
HBc indicative of acute or recent infection). Most sensitive test is detection 
of HBV DNA in serum; not generally required for routine diagnosis.
Epidemiology 
Percutaneous (needle stick), sexual, or perinatal transmission. Endemic 
in sub-Saharan Africa and Southeast Asia, where up to 20% of population 
acquire infection, usually early in life.
Prevention
After exposure in unvaccinated persons: hepatitis B immune globulin 
(HBIg) 0.06 mL/kg IM immediately after needle stick to within 14 days of 
sexual exposure in combination with vaccine series. For perinatal exposure 
(HbsAg+ mother) HBIg 0.05 mL in the thigh immediately after birth with 
the vaccine series started within the first 12 h of life. Before exposure: recom-
binant hepatitis B vaccine IM (dose depends on formulation as well as adult 
or pediatric and hemodialysis); at 0, 1, and 6 months; deltoid, not gluteal 
injection. Has been targeted to high-risk groups (e.g., health workers, persons 
SECTION 11
1036
Gastroenterology
with multiple sexual partners, IV drug users, hemodialysis pts, hemophili-
acs, household and sexual contacts of HBsAg carriers, persons traveling 
in endemic areas, unvaccinated children <18). Universal vaccination of all 
children is now recommended in the United States.
� HEPATITIS C (HCV) 
Caused by flavi-like virus with RNA genome of >9000 nucleotides (simi-
lar to yellow fever virus, dengue virus); genetic heterogeneity. Incubation 
period 7–8 weeks.
Clinical Course 
Often clinically mild and marked by fluctuating elevations of serum ami-
notransferase levels; >50% likelihood of chronicity, leading to cirrhosis in 
>20%.
Diagnosis
Anti-HCV in serum. Current third-generation immunoassay incorporates 
proteins from the core, NS3, and NS5 regions. The most sensitive indicator 
of HCV infection is HCV RNA (Fig. 163-3).
Epidemiology 
HCV accounts for >90% of transfusion-associated hepatitis cases. IV drug 
use accounts >50% of reported cases of hepatitis C. Little evidence for fre-
quent sexual or perinatal transmission.
Prevention
Exclusion of paid blood donors, testing of donated blood for anti-HCV. 
Anti-HCV detected by enzyme immunoassay in blood donors with normal 
ALT is often falsely positive (30%); result should be confirmed by HCV 
RNA in serum.
0 1 2 3 4 5 6
12
24
48
60
120
36
Anti-HCV
HCV  RNA
ALT
Months after exposure
FIGURE 163-3 Scheme of typical laboratory features during acute hepatitis C 
progressing to chronicity. HCV RNA is the first detectable event, preceding alanine 
aminotransferase (ALT) elevation and the appearance of anti-HCV.
CHAPTER 163
1037
Acute Hepatitis
� HEPATITIS D (HDV, DELTA AGENT) 
Defective 37-nm RNA virus that requires HBV for its replication; either co-
infects with HBV or superinfects a chronic HBV carrier. Enhances severity 
of HBV infection (acceleration of chronic hepatitis to cirrhosis, occasionally 
fulminant acute hepatitis).
Diagnosis
Anti-HDV in serum (acute hepatitis D—often in low titer, is transient; 
chronic hepatitis D—in higher titer, is sustained).
Epidemiology 
Endemic among HBV carriers in Mediterranean Basin, where it is spread 
predominantly by nonpercutaneous means. In nonendemic areas (e.g., 
northern Europe, United States) HDV is spread percutaneously among 
HbsAg+ IV drug users or by transfusion in hemophiliacs and to a lesser 
extent among HbsAg+ men who have sex with men.
Prevention
Hepatitis B vaccine (noncarriers only).
� HEPATITIS E (HEV) 
Caused by 29- to 32-nm agent thought to be related to caliciviruses. 
Enterically transmitted and responsible for waterborne epidemics of hepa-
titis in India, parts of Asia and Africa, and Central America. Self-limited 
illness with high (10–20%) mortality rate in pregnant women.
Viral Hepatitis
TREATMENT
Activity as tolerated, high-calorie diet (often tolerated best in morn-
ing), IV hydration for severe vomiting, cholestyramine up to 4 g PO 
four times daily for severe pruritus, avoid hepatically metabolized 
drugs; no role for glucocorticoids. Liver transplantation for fulminant 
hepatic failure and grades III–IV encephalopathy. In rare instances 
of severe acute HBV, lamivudine has been used successfully. Most 
authorities would recommend antiviral therapy for severe acute HBV 
(Chap. 164). Meta-analyses and small clinical trials suggest that treat-
ment of acute HCV infection with interferon α may be effective at 
reducing the rate of chronicity. Based on these data, many experts feel 
that acute HCV infection should be treated with a 24-week course of 
the best available regimens currently used to treat chronic HCV infec-
tion (Chap. 164).
TOXIC AND DRUG-INDUCED HEPATITIS
� DOSE-DEPENDENT (DIRECT HEPATOTOXINS) 
Onset is within 48 h, predictable, necrosis around terminal hepatic venule–
e.g., carbon tetrachloride, benzene derivatives, mushroom poisoning, acet-
aminophen, or microvesicular steatosis (e.g., tetracyclines, valproic acid).
SECTION 11
1038
Gastroenterology
� IDIOSYNCRATIC 
Variable dose and time of onset; small number of exposed persons affected; 
may be associated with fever, rash, arthralgias, eosinophilia. In many cases, 
mechanism may actually involve toxic metabolite, possibly determined on 
genetic basis—e.g., isoniazid, halothane, phenytoin, methyldopa, carbam-
azepine, diclofenac, oxacillin, sulfonamides.
Toxic and Drug-Induced Hepatitis
TREATMENT
Supportive as for viral hepatitis; withdraw suspected agent, and include use 
of gastric lavage and oral administration of charcoal or cholestyramine. 
Liver transplantation if necessary. In acetaminophen overdose, more 
specific therapy is available in the form of sulfhydryl compounds (e.g., 
N-acetylcysteine). These agents appear to act by providing a reservoir of 
sulfhydryl groups to bind the toxic metabolites or by stimulating synthesis 
of hepatic glutathione. Therapy should be begun within 8 h of ingestion but 
may be effective even if given as late as 24–36 h after overdose.
ACUTE HEPATIC FAILURE
Massive hepatic necrosis with impaired consciousness occurring within 8 
weeks of the onset of illness.
� CAUSES 
Infections [viral, including HAV, HBV, HCV (rarely), HDV, HEV; bacterial, 
rickettsial, parasitic], drugs and toxins, ischemia (shock), Budd-Chiari syn-
drome, idiopathic chronic active hepatitis, acute Wilson’s disease, microve-
sicular fat syndromes (Reye’s syndrome, acute fatty liver of pregnancy).
� CLINICAL MANIFESTATIONS 
Neuropsychiatric changes—delirium, personality change, stupor, coma; 
cerebral edema—suggested by profuse sweating, hemodynamic instabil-
ity, tachyarrhythmias, tachypnea, fever, papilledema, decerebrate rigidity 
(though all may be absent); deep jaundice, coagulopathy, bleeding, renal 
failure, acid-base disturbance, hypoglycemia, acute pancreatitis, cardiore-
spiratory failure, infections (bacterial, fungal).
� ADVERSE PROGNOSTIC INDICATORS 
Age <10 or >40, certain causes (e.g., halothane, hepatitis C), duration of 
jaundice >7 d before onset of encephalopathy, serum bilirubin > 300 μmol/L 
(>18 mg/dL), coma (survival <20%), rapid reduction in liver size, respira-
tory failure, marked prolongation of PT, factor V level < 20%. In acetamino-
phen overdose, adverse prognosis is suggested by blood pH <7.30, serum 
creatinine >266 μmol/L (>3 mg/dL), markedly prolonged PT.
Acute Hepatic Failure
TREATMENT
Endotracheal intubation often required. Monitor serum glucose—
IV D10 or D20 as necessary. Prevent GI bleeding with H2 receptor 
antagonists and antacids (maintain gastric pH ≥3.5). In many centers
CHAPTER 164
1039
Chronic Hepatitis
intracranial pressure is monitored—more sensitive than CT in detecting 
cerebral edema. Value of dexamethasone for cerebral edema unclear; IV 
mannitol may be beneficial. Liver transplantation should be considered 
in pts with grades III–IV encephalopathy and other adverse prognostic 
indicators.
For a more detailed discussion, see Dienstag JL: Acute Viral 
Hepatitis, Chap. 304, p.2537, and Dienstag JL: Toxic and 
Drug-Induced Hepatitis, Chap. 305, p. 2558, in HPIM-18.
CHAPTER 164
Chronic Hepatitis
A group of disorders characterized by a chronic inflammatory reaction in 
the liver for at least 6 months.
OVERVIEW
� ETIOLOGY 
Hepatitis B virus (HBV), hepatitis C virus (HCV), hepatitis D virus (HDV, 
delta agent), drugs (methyldopa, nitrofurantoin, isoniazid, dantrolene), 
autoimmune hepatitis, Wilson’s disease, hemochromatosis, α1-antitrypsin 
deficiency.
� HISTOLOGIC CLASSIFICATION 
Chronic hepatitis can be classified by grade and stage. The grade is a his-
tologic assessment of necrosis and inflammatory activity and is based on 
examination of the liver biopsy. The stage of chronic hepatitis reflects the 
level of disease progression and is based on the degree of fibrosis (see Table 
306-2, p. 2568, HPIM-18).
� PRESENTATION 
Wide clinical spectrum ranging from asymptomatic serum aminotrans-
ferase elevations to apparently acute, even fulminant, hepatitis. Common 
symptoms include fatigue, malaise, anorexia, low-grade fever; jaundice is 
frequent in severe disease. Some pts may present with complications of cir-
rhosis: ascites, variceal bleeding, encephalopathy, coagulopathy, and hyper-
splenism. In chronic HBV or HCV and autoimmune hepatitis, extrahepatic 
features may predominate.
CHRONIC HEPATITIS B
Follows up to 1–2% of cases of acute hepatitis B in immunocompetent 
hosts; more frequent in immunocompromised hosts. Spectrum of disease: 
asymptomatic antigenemia, chronic hepatitis, cirrhosis, hepatocellular 
cancer; early phase often associated with continued symptoms of hepatitis, 
SECTION 11
1040
Gastroenterology
elevated aminotransferase levels, presence in serum of HBeAg and HBV 
DNA, and presence in liver of replicative form of HBV; later phase in 
some pts may be associated with clinical and biochemical improvement, 
disappearance of HBeAg and HBV DNA and appearance of anti-HBeAg 
in serum, and integration of HBV DNA into host hepatocyte genome. In 
Mediterranean and European countries as well as in Asia, a frequent vari-
ant is characterized by readily detectable HBV DNA, but without HBeAg 
(anti-HBeAg-reactive). Most of these cases are due to a mutation in the 
pre-C region of the HBV genome that prevents HBeAg synthesis (may 
appear during course of chronic wild-type HBV infection as a result of 
immune pressure and may also account for some cases of fulminant hepa-
titis B). Chronic hepatitis B ultimately leads to cirrhosis in 25–40% of cases 
(particularly in pts with HDV superinfection or the pre-C mutation) and 
hepatocellular carcinoma in many of these pts (particularly when chronic 
infection is acquired early in life). 
� EXTRAHEPATIC MANIFESTATIONS (IMMUNE COMPLEX–MEDIATED) 
Rash, urticaria, arthritis, polyarteritis nodosa–like vasculitis, polyneuropa-
thy, glomerulonephritis.
Chronic Hepatitis B
TREATMENT
There are currently seven approved drugs for the treatment of chronic 
HBV: interferon α (IFN-α), pegylated interferon (PEG IFN), lamivudine, 
adefovir dipivoxil, entecavir, telbivudine, and tenofovir (see Table 164-1).
Use of IFN-α has been supplanted by PEG-IFN. Table 164-2 summarizes 
recommendations for treatment of chronic HBV.
CHRONIC HEPATITIS C
Follows 50–70% of cases of transfusion-associated and sporadic hepatitis C. 
Clinically mild, often waxing and waning aminotransferase elevations; mild 
chronic hepatitis on liver biopsy. Extrahepatic manifestations include cryo-
globulinemia, porphyria cutanea tarda, membranoproliferative glomerulo-
nephritis, and lymphocytic sialadenitis. Diagnosis confirmed by detecting 
anti-HCV in serum. May lead to cirrhosis in ≥20% of cases after 20 years.
Chronic Hepatitis C
TREATMENT
Therapy should be considered in pts with detectable HCV RNA in serum 
and biopsy evidence of at least moderate chronic hepatitis (portal or 
bridging fibrosis). The current agents used in the treatment of chronic 
HCV, as well as their dosage and duration, depend on HCV genotype 
(see Tables 164-3 and Table 164-4). For pts with genotype 1, PEG IFN/
ribavirin should be combined with a protease inhibitor (boceprevir, tela-
previr) where available. Protease inhibitors should never be used alone 
due to development of resistance. Since the presently available HCV 
protease inhibitors have not been studied on pts with genotypes other than I, 
their use in these populations is not recommended (see Table 164-3).
TABLE 164-1  COMPARISON OF PEGYLATED INTERFERON (PEG IFN), LAMIVUDINE, ADEFOVIR, ENTECAVIR, TELBIVUDINE, AND TENOFOVIR 
THERAPY FOR CHRONIC HEPATITIS Ba
Feature
PEG IFNb
Lamivudine
Adefovir
Entecavir
Telbivudine
Tenofovir
Route of administration
Subcutaneous 
injection
Oral
Oral
Oral
Oral
Oral
Duration of therapyc
48–52 weeks
≥52 weeks
≥48 weeks
≥48 weeks
≥52 weeks
≥48 weeks
Tolerability
Poorly tolerated
Well tolerated
Well tolerated; 
creatinine 
monitoring
recommended
Well tolerated
Well tolerated
Well tolerated; cre-
atinine monitoring 
recommended
HBeAg seroconversion
 1 yr Rx
18–20%
16–21%
12%
21%
22%
21%
 >1 yr Rx
NA
up to 50% @ 
5 yrs
43% @ 3 yrsd
31% @ 2 yrs
39% @ 3 yrs
30% @ 2 yrs
27% @ 2 yrs
Log10 HBV DNA reduction (mean 
copies/mL)
 HBeAg-reactive
4.5
5.5
median 3.5–5
6.9
6.4
6.2
 HBeAg-negative
4.1
4.4–4.7
median 3.5–3.9
5.0
5.2
4.6
(continued)
1041
TABLE 164-1  COMPARISON OF PEGYLATED INTERFERON (PEG IFN), LAMIVUDINE, ADEFOVIR, ENTECAVIR, TELBIVUDINE, AND TENOFOVIR 
THERAPY FOR CHRONIC HEPATITIS Ba (CONTINUED)
Feature
PEG IFNb
Lamivudine
Adefovir
Entecavir
Telbivudine
Tenofovir
HBV DNA PCR negative 
(<300–400 copies/mL; <1000 
copies/mL for adefovir) end of yr 1
 HBeAg-reactive
10–25%
36–44%
13–21%
67%(91%@ 4 
yrs)
60%
76%
 HBeAg-negative
63%
60–73%
48–77%
90%
88%
93%
ALT normalization at end of yr 1
 HBeAg-reactive
39%
41–75%
48–61%
68%
77%
68%
 HBeAg-negative
34–38%
62–79%
48–77%
78%
74%
76%
HBsAg loss yr 1
3–4%
≤1%
0%
2%
<1%
3%
       yr 2
12% 5 yr after 
1 yr of Rx
no data
5% at yr 5
5%
No data
6%
Histologic improvement (≥2-point
reduction in HAI) at yr 1
 HBeAg-reactive
38% 6 months 
after
49–62%
53–68%
72%
65%
74%
 HBeAg-negative
48% 6 months 
after
61–66%
64%
70%
67%
72%
1042
Viral resistance
None
15-30% @ 1 yr None @ 1 yr
≤1% @ 1 yre
up to 5% @ yr 1
0% @ yr 1
70% @ 5 yrs
29% at 5 yrs
1.2% @ 5 yre
up to 22% @ 
yr 2
0% through yr 3
Cost (US $) for 1 yr
~$18,000
~$2500
~$6500
~$8700f
~$6000
~$6000
aGenerally, these comparisons are based on data on each drug tested individually versus placebo in registration clinical trials; because, with rare exception, these comparisons are 
not based on head-to-head testing of these drugs, relative advantages and disadvantages should be interpreted cautiously.
bAlthough standard IFN-α administered daily or three times a week is approved as therapy for chronic hepatitis B, it has been supplanted by PEG IFN, which is administered once a 
week and is more effective. Standard IFN has no advantages over PEG IFN.
cDuration of therapy in clinical efficacy trials; use in clinical practice may vary.
dBecause of a computer-generated randomization error that resulted in misallocation of drug versus placebo during the second year of clinical-trial treatment, the frequency of 
HBeAg seroconversion beyond the first year is an estimate (Kaplan-Meier analysis) based on the small subset in whom adefovir was administered correctly.
e7% during a year of therapy (43% at year 4) in lamivudine-resistant pts.
f~17,400 for lamivudine-refractory pts.
Abbreviations: ALT, alanine aminotransferase; HAI, histologic activity index; HBeAg, hepatitis B e antigen; HBsAg, hepatitis B surface antigen; HBV, hepatitis B virus; NA, not 
applicable; PEG IFN, pegylated interferon; PCR, polymerase chain reaction; Rx, therapy; yr, year.
1043
TABLE 164-2 RECOMMENDATIONS FOR TREATMENT OF CHRONIC HEPATITIS Ba
HBeAg Status
Clinical
HBV DNA (IU/mL)
ALT
Recommendation
HBeAg-reactive
b
>2 × 104
≤2 × ULNd
No treatment; monitor. In pts >40, with family his-
tory of hepatocellular carcinoma, and/or ALT per-
sistently at the high end of the twofold range, liver 
biopsy may help in decision to treat
Chronic hepatitis
>2 × 104 d
>2 × ULNd
Treate
Cirrhosis compensated
>2 × 103
< or > ULN
Treate with oral agents, not PEG IFN
<2 × 103
>ULN
Consider treatmentf
Cirrhosis decompensated
Detectable
< or > ULN
Treate with oral agentsg, not PEG IFN; refer for liver 
transplantation
Undetectable
< or > ULN
Observe; refer for liver transplantation
HBeAg-negative
b
≤2 × 103
≤ULN
Inactive carrier; treatment not necessary
Chronic hepatitis
>103
1–>2 × ULNd
Consider liver biopsy; treath if biopsy shows moder-
ate to severe inflammation or fibrosis
Chronic hepatitis
>104
>2 × ULNd
Treath,i
1044
Cirrhosis compensated
>2 × 103
< or > ULN
Treate with oral agents, not PEG IFN
<2 × 103
>ULN
Consider treatmentf
Cirrhosis decompensated
Detectable
< or > ULN
Treath with oral agentsg, not PEG IFN; refer for liver 
transplantation
Undetectable
< or > ULN
Observe; refer for liver transplantation
aBased on practice guidelines of the American Association for the Study of Liver Diseases (AASLD). Except as indicated in footnotes, these guidelines are similar to those issued by 
the European Association for the Study of the Liver (EASL).
bLiver disease tends to be mild or inactive clinically; most such pts do not undergo liver biopsy.
cThis pattern is common during early decades of life in Asian pts infected at birth.
dAccording to the EASL guidelines, treat if HBV DNA is >2 × 103 IU/mL and ALT >ULN.
eOne of the potent oral drugs with a high barrier to resistance (entecavir or tenofovir) or PEG IFN can be used as first-line therapy (see text). These oral agents, but not PEG IFN, 
should be used for IFN-refractory/intolerant and immunocompromised pts. PEG IFN is administered weekly by SC injection for a year; the oral agents are administered daily for at 
least a year and continued indefinitely or until at least 6 months after HBeAg seroconversion.
fAccording to EASL guidelines, pts with compensated cirrhosis and detectable HBV DNA at any level, even with normal ALT, are candidates for therapy. Most authorities would treat 
indefinitely, even in HBeAg-positive disease after HBeAg seroconversion.
gBecause the emergence of resistance can lead to loss of antiviral benefit and further deterioration in decompensated cirrhosis, a low-resistance regimen is recommended—
entecavir or tenofovir monotherapy or combination therapy with the more resistance-prone lamivudine (or telbivudine) plus adefovir. Therapy should be instituted urgently.
hBecause HBeAg seroconversion is not an option, the goal of therapy is to suppress HBV DNA and maintain a normal ALT. PEG IFN is administered by SC injection weekly for a year; 
caution is warranted in relying on a 6-month posttreatment interval to define a sustained response, because the majority of such responses are lost thereafter. Oral agents, enteca-
vir or tenofovir, are administered daily, usually indefinitely or, until as very rarely occurs, virologic and biochemical responses are accompanied by HBsAg seroconversion.
iFor older pts and those with advanced fibrosis, consider lowering the HBV DNA threshold to >2 × 103 IU/mL.
Abbreviations: ALT, alanine aminotransferase; AASLD, American Association for the Study of Liver Diseases; EASL, European Association for the Study of the Liver; HBeAg, 
hepatitis B e antigen; HBsAg, hepatitis B surface antigen; HBV, hepatitis B virus; PEG IFN, pegylated interferon; ULN, upper limits of normal.
1045
SECTION 11
1046
Gastroenterology
TABLE 164-3  PEGYLATED INTERFERON α-2A AND α-2B FOR CHRONIC 
HEPATITIS C
PEG IFN α-2b
PEG IFN α-2a
PEG size
12 kDa linear
40 kDa branched
Elimination half-life
54 h
65 h
Clearance
725 mL/h
60 mL/h
Dose
1.5 μg/kg (weight-based)
180 μg
Storage
Room temperature
Refrigerated
Ribavirin dose
 Genotype 1
 Genotype 2/3
800–1400 mga
800 mg
1000–1200 mgb
800 mg
Duration of therapy
 Genotype 1c
 Genotype 2/3
48 weeks
48 weeksd
48 weeks
24 weeks
Efficacy of combination Rxe
54%
56%
 Genotype 1c
 Genotype 2/3
40–42%
82%
41–51%
76–78%
aIn the registration trial for PEG IFN α-2b plus ribavirin, the optimal regimen was 1.5 μg of PEG IFN 
plus 800 mg of ribavirin; however, a post-hoc analysis of this study suggested that higher ribavirin 
doses are better. In subsequent trials of PEG IFN α-2b with ribavirin in pts with genotype 1, the fol-
lowing daily ribavirin doses have been validated: 800 mg for pts weighing <65 kg, 1000 mg for pts 
weighing >65–85 kg, 1200 for pts weighing >85–105 kg, and 1400 mg for pts weighing >105 kg.
b1000 mg for pts weighing <75 kg; 1200 mg for pts weighing ≥75 kg.
cBased on PEG IFN/ribavirin-based regimens without protease inhibitors. 
dIn the registration trial for PEG IFN α-2b plus ribavirin, all pts were treated for 48 weeks; 
however, data from other trials of standard IFNs and the other PEG IFN demonstrated that 24 
weeks suffices for pts with genotypes 2 and 3. For pts with genotype 3 who have advanced 
fibrosis/cirrhosis and/or high-level HCV RNA, a full 48 weeks is preferable.
eAttempts to compare the two PEG IFN preparations based on the results of registration clini-
cal trials are confounded by differences between trials of the two agents in methodologic details 
(different ribavirin doses, different methods for recording depression, and other side effects) and 
study-population composition (different proportion with bridging fibrosis/cirrhosis, proportion from 
the United States versus international, mean weight, proportion with genotype 1, and proportion 
with high-level HCV RNA). In the head-to-head comparison of the two PEG IFN preparations in the 
IDEAL trial reported in 2009, the two drugs were comparable in tolerability and efficacy. PEG IFN 
α-2b was administered at a weekly weight-based dose of 1.0 μg/kg or 1.5 μg/kg, and PEG IFN 
α-2a was administered at a weekly fixed dose of 180 μg. For PEG IFN α-2b, daily ribavirin weight-
based doses ranged between 800–1400 mg based on weight criteria,a while for PEG IFN α-2a, 
daily ribavirin weight-based doses ranged between 1000 and 1200 mg.b For the two PEG IFN α-2b 
study arms, ribavirin dose reductions for ribavirin-associated adverse effects were done in 200- to 
400-mg decrements; for PEG IFN α-2a, the ribavirin dose was reduced to 600 mg for intolerability. 
Sustained virologic responses occurred in 38.0% of the low-dose PEG IFN α-2b group; 39.8% of 
the standard, full-dose PEG IFN α-2b group; and 40.9% of the PEG IFN α-2a group.
Abbreviations: PEG, polyethylene glycol; PEG IFN, pegylated interferon; HCV RNA, hepatitis C 
virus RNA.
CHAPTER 164
1047
Chronic Hepatitis
TABLE 164-4  INDICATIONS AND RECOMMENDATIONS FOR ANTIVIRAL 
THERAPY OF CHRONIC HEPATITIS C
Standard Indications for Therapy
Detectable HCV RNA (with or without elevated ALT)
Portal/bridging fibrosis or moderate to severe hepatitis on liver biopsy
Re-Treatment Recommended
Genotype 1
Relapsers, partial responders, or nonresponders after a previous course of 
standard IFN monotherapy or combination standard IFN/ribavirin therapy or 
PEG IFN/ribavirin
 A course of PEG-IFN/ribavirin plus protease inhibitor as below
Genotype 2, 3, 4
 Relapsers after a previous course of standard IFN monotherapy or combina-
tion standard IFN/ribavirin therapy
 A course of PEG IFN plus ribavirin
 Nonresponders to a previous course of standard IFN monotherapy or combi-
nation standard IFN/ribavirin therapy
  A course of PEG IFN plus ribavirin—more likely to achieve a sustained 
virologic response in Caucasian pts without previous ribavirin therapy, 
with low baseline HCV RNA levels, with a 2-log10 reduction in HCV RNA 
during previous therapy, with genotypes 2 and 3, and without reduction in 
ribavirin dose.
Antiviral Therapy Management Decisions Made on an Individual Basis
Children (age <18 years)—protease inhibitors not recommended
Age >60
Mild hepatitis on liver biopsy 
Persons with severe renal insufficiency
Long-Term Maintenance Therapy Recommended
Cryoglobulinemic vasculitis associated with chronic hepatitis C
Long-Term Maintenance Therapy in Nonresponders Not Recommended
Antiviral Therapy Not Recommended
Decompensated cirrhosis
Pregnancy (teratogenicity of ribavirin)
Contraindications to medications
Therapeutic Regimens
HCV genotype 1
  PEG IFN-α2a 180 μg weekly plus ribavirin 1000 mg/d (weight <75 kg) to 
1200 mg/d (weight ≥75 kg) or
  PEG IFN-α2b 1.5 μg/kg weekly plus ribavirin 800 mg/d (the dose used 
in registration clinical trials, but the higher, weight-based ribavirin doses 
above are recommended for both types of PEG IFN)
(continued)
SECTION 11
1048
Gastroenterology
TABLE 164-4  INDICATIONS AND RECOMMENDATIONS FOR ANTIVIRAL 
THERAPY OF CHRONIC HEPATITIS C (CONTINUED)
Therapeutic Regimens
 Plus a protease inhibitor consisting of one of the following two:
  Boceprevir 800 mg three times daily started after a lead in treatment of 
4 weeks with PEG IFN/ribavirin
 •  Pts with undetectable HCV RNA at 8 and 24 weeks should receive triple 
therapy (PEG-IFN/ribavirin, boceprevir) through week 28 (4 weeks of 
PEG IFN/ribavirin then 24 weeks of triple therapy). If there is detectable 
HCV RNA at 4 weeks, continuing therapy through 48 weeks (4 weeks 
of PEG IFN/ribavirin then 44 weeks of triple therapy) may increase the 
sustained response rate.
 •  Pts with detectable HCV RNA at 8 weeks and undetectable at 24 weeks 
should receive triple therapy (PEG-IFN/ribavirin, boceprevir) through 
week 36 (4 weeks of PEG IFN/ribavirin then 32 weeks of triple therapy) 
followed by a return to PEG IFN/ribavirin for 12 more weeks, making a 
total treatment duration of 48 weeks.
 •  Pts with cirrhosis who are treatment naïve and have undetectable HCV 
RNA at week 8 and 24 should continue triple therapy (PEG IFN/ribavirin, 
boceprevir) through 48 weeks (4 weeks of PEG IFN/ribavirin then 44 
weeks of triple therapy).
  Telaprevir 750 mg three times daily started at the beginning of therapy 
without a PEG IFN/ribavirin lead-in.
 •  Pts with undetectable HCV RNA at 4 and 12 weeks should receive triple 
therapy (PEG IFN/ribavirin, telaprevir) for 12 weeks then PEG-IFN and 
ribavirin for another 12 weeks for a total of 24 weeks.
 •  Pts with cirrhosis who are treatment naïve and have undetectable HCV 
RNA at 4 and 12 weeks should receive triple therapy for 12 weeks then 
PEG-FN, ribavirin for another 36 weeks to total 48 weeks.
 HCV genotype 1 where protease inhibitors unavailable or contraindicated—
48 weeks of therapy
  PEG IFN-α2a 180 μg weekly plus ribavirin 1000 mg/d (weight <75 kg) to 
1200 mg/d (weight ≥75 kg) or
  PEG IFN-α2b 1.5 μg/kg weekly plus ribavirin 800 mg/d (the dose used 
in registration clinical trials, but the higher, weight-based ribavirin doses 
above are recommended for both types of PEG IFN)
HCV genotype 4—48 weeks of therapy
  PEG IFN-α2a 180 μg weekly plus ribavirin 1000 mg/d (weight <75 kg) to 
1200 mg/d (weight ≥75 kg) or
  PEG IFN-α2b 1.5 μg/kg weekly plus ribavirin 800 mg/d (the dose used 
in registration clinical trials, but the higher, weight-based ribavirin doses 
above are recommended for both types of PEG IFN)
 •  Treatment should be discontinued in pts who do not achieve an early 
virologic response at week 12.
CHAPTER 164
1049
Chronic Hepatitis
TABLE 164-4  INDICATIONS AND RECOMMENDATIONS FOR ANTIVIRAL 
THERAPY OF CHRONIC HEPATITIS C (CONTINUED)
Therapeutic Regimens
 •  Pts who do achieve an early virologic response should be retested at 
week 24 and treatment should be discontinued if HCV RNA remains 
positive.
HCV genotypes 2 and 3–24 weeks of therapy
 PEG IFN-α2a 180 μg weekly plus ribavirin 800 mg/d or
  PEG IFN-α2b 1.5 μg/kg weekly plus ribavirin 800 mg/d (for pts with 
genotype 3 who have advanced fibrosis and/or high-level HCV RNA, a full 
48 weeks of therapy may be preferable)
 For HCV-HIV co-infected pts: 48 weeks, regardless of genotype, of weekly 
PEG IFN-α2a (180 μg) or PEG IFN-α2b (1.5 μg/kg) plus a daily ribavirin 
dose of at least 600–800 mg, up to full weight-based 1000- to 1200-mg 
dosing if tolerated. Protease inhibitors for genotype I are not recommended 
in this population at the current time due to potential interaction with 
anti-HIV drugs.
Features Associated with Reduced Responsiveness
Single-nucleotide polymorphism (SNP) T allele (as opposed to C allele) at 
IL28B locus
Genotype 1
High-level HCV RNA (>2 million copies/mL or >800,000 IU/mL)
Advanced fibrosis (bridging fibrosis, cirrhosis)
Long-duration disease
Age >40
High HCV quasispecies diversity
Immunosuppression
African-American ethnicity
Latino ethnicity
Obesity
Hepatic steatosis
Insulin resistance, type 2 diabetes mellitus
Reduced adherence (lower drug doses and reduced duration of therapy)
Abbreviations: ALT, alanine aminotransferase; HCV, hepatitis C virus; IFN, interferon; PEG IFN, 
pegylated interferon; IU, international units (1 IU/mL is equivalent to ~2.5 copies/mL).
Monitoring of HCV plasma RNA is useful in assessing response 
to therapy. The goal of treatment is to eradicate HCV RNA, which is 
predicted by the absence of HCV RNA by polymerase chain reaction 
6 months after stopping treatment (“sustained viral response”). The fail-
ure to achieve a 2-log drop in HCV RNA by week 12 of therapy (“early
SECTION 11
1050
Gastroenterology
virologic response”) makes it unlikely that further therapy will result in 
a sustained virologic response. Thus, it is recommended that HCV RNA 
be measured at baseline and at weeks 4, 12, and 24 to assess response to 
treatment and to aid in decisions regarding treatment duration as well 
as after 12 weeks of therapy. Pts with genotype I receiving boceprevir 
should additionally have HCV RNA measured at week 8, as this may 
influence the duration of therapy. The current consensus view is that 
therapy can be stopped if an early virologic response is not achieved.
HEPATITIS A
Although hepatitis A rarely causes fulminant hepatic failure, it may do so more 
frequently in pts with chronic liver disease—especially those with chronic 
hepatitis B or C. The hepatitis A vaccine is immunogenic and well tolerated in 
pts with chronic hepatitis. Thus, pts with chronic liver disease, especially those 
with chronic hepatitis B or C, should be vaccinated against hepatitis A.
AUTOIMMUNE HEPATITIS
� CLASSIFICATION 
Type I: classic autoimmune hepatitis, anti–smooth-muscle and/or anti-
nuclear antibodies (ANA). Type II: associated with anti-liver/kidney 
microsomal (anti-LKM) antibodies, which are directed against cytochrome 
P450IID6 (seen primarily in southern Europe). Type III pts lack ANA and 
anti-LKM, have antibodies reactive with hepatocyte cytokeratins; clinically 
similar to type I. Criteria have been suggested by an international group for 
establishing a diagnosis of autoimmune hepatitis.
� CLINICAL MANIFESTATIONS 
Classic autoimmune hepatitis (type I): 80% women, third to fifth decades. 
Abrupt onset (acute hepatitis) in a third. Insidious onset in two-thirds: pro-
gressive jaundice, anorexia, hepatomegaly, abdominal pain, epistaxis, fever, 
fatigue, amenorrhea. Leads to cirrhosis; >50% 5-year mortality if untreated.
� EXTRAHEPATIC MANIFESTATIONS 
Rash, arthralgias, keratoconjunctivitis sicca, thyroiditis, hemolytic anemia, 
nephritis.
� SEROLOGIC ABNORMALITIES 
Hypergammaglobulinemia, positive rheumatoid factor, smooth-muscle 
antibody (40–80%), ANA (20–50%), antimitochondrial antibody (10–20%), 
false-positive anti-HCV enzyme immunoassay but usually not HCV RNA, 
atypical p-ANCA. Type II: anti-LKM antibody.
Autoimmune Hepatitis
TREATMENT
Indicated for symptomatic disease with biopsy evidence of severe 
chronic hepatitis (bridging necrosis), marked aminotransferase eleva-
tions (5- to 10-fold), and hypergammaglobulinemia. Prednisone or 
prednisolone 30–60 mg/d PO tapered to 10–15 mg/d over several weeks; 
often azathioprine 50 mg/d PO is also administered to permit lower
CHAPTER 165
1051
Cirrhosis and Alcoholic Liver Disease 
For a more detailed discussion, see Dienstag JL: Chronic 
Hepatitis, Chap. 306, p. 2567, in HPIM-18.
CHAPTER 165
Cirrhosis and Alcoholic 
Liver Disease
CIRRHOSIS
Cirrhosis is defined histopathologically and has a variety of causes, clinical 
features, and complications. In cirrhosis, there is the development of liver 
fibrosis to the point that there is architectural distortion with the formation 
of regenerative nodules, which results in decreased liver function.
� CAUSES (SEE TABLE 165-1)
� CLINICAL MANIFESTATIONS 
May be absent, with cirrhosis being incidentally found at surgery.
glucocorticoid doses and avoid steroid side effects. Monitor liver func-
tion tests monthly. Symptoms may improve rapidly, but biochemical 
improvement may take weeks or months and subsequent histologic 
improvement (to lesion of mild chronic hepatitis or normal biopsy) 
up to 18–24 months. Therapy should be continued for at least 12–18 
months. Relapse occurs in at least 50% of cases (re-treat). For frequent 
relapses, consider maintenance therapy with low-dose glucocorticoids 
or azathioprine 2 (mg/kg)/d.
TABLE 165-1 CAUSES OF CIRRHOSIS
Alcoholism
Cardiac cirrhosis
Chronic viral hepatitis
Inherited metabolic liver disease
 Hepatitis B
 Hemochromatosis
 Hepatitis C
 Wilson’s disease
Autoimmune hepatitis
 α1-Antitrypsin deficiency
Nonalcoholic steatohepatitis
 Cystic fibrosis
Biliary cirrhosis
Cryptogenic cirrhosis
 Primary biliary cirrhosis
 Primary sclerosing cholangitis
Autoimmune cholangiopathy
SECTION 11
1052
Gastroenterology
Symptoms
Anorexia, nausea, vomiting, diarrhea, vague RUQ pain, fatigue, weakness, 
fever, jaundice, amenorrhea, impotence, infertility.
Signs
Spider telangiectases, palmar erythema, jaundice, scleral icterus, parotid 
and lacrimal gland enlargement, clubbing, Dupuytren’s contracture, gyne-
comastia, testicular atrophy, hepatosplenomegaly, ascites, gastrointestinal 
bleeding (e.g., varices), hepatic encephalopathy.
Laboratory Findings 
Anemia (microcytic due to blood loss, macrocytic due to folate deficiency; 
hemolytic called Zieve’s syndrome), pancytopenia (hypersplenism), pro-
longed PT, rarely overt DIC; hyponatremia, hypokalemic alkalosis, glucose 
disturbances, hypoalbuminemia.
� DIAGNOSTIC STUDIES 
Depend on clinical setting. Serum: HBsAg, anti-HBc, anti-HBs, anti-HCV, 
anti-HDV, Fe, total iron-binding capacity, ferritin, antimitochondrial anti-
body (AMA), smooth-muscle antibody (SMA), anti-liver/kidney micro-
somal (anti-LKM) antibody, ANA, ceruloplasmin, α1 antitrypsin (and 
phenotyping); abdominal ultrasound with Doppler study, CT or MRI 
(may show cirrhotic liver, splenomegaly, collaterals, venous thrombosis). 
Definitive diagnosis often depends on liver biopsy (percutaneous, transjugular, 
or open).
� COMPLICATIONS (SEE TABLE 165-2 AND CHAPS. 48, 49, AND 166)
The Child-Pugh scoring system has been used to predict the severity of 
cirrhosis and the risk of complications (Table 165-3).
TABLE 165-2 COMPLICATIONS OF CIRRHOSIS
Portal hypertension
Coagulopathy
 Gastroesophageal varices
 Factor deficiency
 Portal hypertensive gastropathy
 Fibrinolysis
 Splenomegaly, hypersplenism
 Thrombocytopenia
 Ascites
Bone disease
  Spontaneous bacterial peritonitis
 Osteopenia
Hepatorenal syndrome
 Osteoporosis
 Type 1
 Osteomalacia
 Type 2
Hematologic abnormalities
Hepatic encephalopathy
 Anemia
Hepatopulmonary syndrome
 Hemolysis
Portopulmonary hypertension
 Thrombocytopenia
Malnutrition
 Neutropenia
CHAPTER 165
1053
Cirrhosis and Alcoholic Liver Disease 
ALCOHOLIC LIVER DISEASE
Excessive alcohol use can cause fatty liver, alcoholic hepatitis, cirrhosis. 
Alcoholic cirrhosis accounts for about 40% of the deaths due to cirrhosis. 
History of excessive alcohol use often denied. Severe forms (hepatitis, cir-
rhosis) associated with ingestion of 160 g/d for 10–20 years; women more 
susceptible than men and develop advanced liver disease with less alcohol 
intake. Hepatitis B and C may be cofactors in the development of liver dis-
ease. Malnutrition may contribute to development of cirrhosis.
� FATTY LIVER 
Often presents as asymptomatic hepatomegaly and mild elevations in biochem-
ical liver tests. Reverses on withdrawal of ethanol; does not lead to cirrhosis.
� ALCOHOLIC HEPATITIS 
Clinical presentation ranges from asymptomatic to severe liver failure with 
jaundice, ascites, GI bleeding, and encephalopathy. Typically anorexia, nau-
sea, vomiting, fever, jaundice, tender hepatomegaly. Occasional cholestatic 
picture mimicking biliary obstruction. Aspartate aminotransferase (AST) 
usually <400 U/L and more than twofold higher than alanine aminotransfer-
ase (ALT). Bilirubin and WBC may be elevated. Diagnosis defined by liver 
biopsy findings: hepatocyte swelling, alcoholic hyaline (Mallory bodies), 
infiltration of PMNs, necrosis of hepatocytes, pericentral venular fibrosis.
� OTHER METABOLIC CONSEQUENCES OF ALCOHOLISM 
Increased NADH/NAD ratio leads to lactic acidemia, ketoacidosis, hyper-
uricemia, hypoglycemia, hypomagnesemia, hypophosphatemia. Also mito-
chondrial dysfunction, induction of microsomal enzymes resulting in 
TABLE 165-3 CHILD-PUGH CLASSIFICATION OF CIRRHOSIS
Factor
Units
1
2
3
Serum bilirubin
μmol/L
<34
34–51
>51
mg/dL
<2.0
2.0–3.0
>3.0
Serum albumin
g/L
>35
30–35
<30
g/dL
>3.5
3.0–3.5
<3.0
Prothrombin time
Seconds 
prolonged
0–4
4–6
>6
INR
<1.7
1.7–2.3
>2.3
Ascites
None
Easily 
controlled
Poorly 
controlled
Hepatic encephalopathy
None
Minimal
Advanced
Note: The Child-Pugh score is calculated by adding the scores of the five factors and can 
range from 5–15. Child-Pugh class is either A (a score of 5–6), B (7–9), or C (10 or above). 
Decompensation indicates cirrhosis with a Child-Pugh score of 7 or more (class B). This level 
has been the accepted criterion for listing for liver transplantation.
SECTION 11
1054
Gastroenterology
altered drug metabolism, lipid peroxidation leading to membrane damage, 
hypermetabolic state; many features of alcoholic hepatitis are attributable to 
toxic effects of acetaldehyde and cytokines (interleukins 1 and 6, and TNF, 
released because of impaired detoxification of endotoxin).
� ADVERSE PROGNOSTIC FACTORS 
Critically ill pts with alcoholic hepatitis have 30-day mortality rates >50%. 
Severe alcoholic hepatitis characterized by PT >5 × above control, bilirubin 
>137 μmol/L (>8 mg/dL), hypoalbuminemia, azotemia. A discriminant 
function can be calculated as 4.6 × (pt’s PT in seconds) (control PT in 
seconds) + serum bilirubin (mg/dL). Values ≥32 are associated with poor 
prognosis. Ascites, variceal hemorrhage, encephalopathy, hepatorenal syn-
drome predict a poor prognosis.
Alcoholic Liver Disease
TREATMENT
Abstinence is essential; 8500- to 12,500-kJ (2000- to 3000-kcal) diet with 
1 g/kg protein (less if encephalopathy). Daily multivitamin, thiamine 100 
mg, folic acid 1 mg. Correct potassium, magnesium, and phosphate defi-
ciencies. Transfusions of packed red cells, plasma as necessary. Monitor 
glucose (hypoglycemia in severe liver disease). Prednisone 40 mg/d or 
prednisolone 32 mg/d PO for 1 month may be beneficial in severe alco-
holic hepatitis with encephalopathy (in absence of GI bleeding, renal fail-
ure, infection). Pentoxifylline demonstrated improved survival and led to 
the inclusion of this agent as an alternative to glucocorticoids in the treat-
ment of severe alcoholic hepatitis. Liver transplantation may be an option 
in carefully selected cirrhotic pts who have been abstinent >6 months.
PRIMARY BILIARY CIRRHOSIS (PBC)
PBC is a progressive nonsuppurative destructive intrahepatic cholangitis. 
Strong female predominance, median age of 50 years. Presents as asymp-
tomatic elevation in alkaline phosphatase (better prognosis) or with pru-
ritus, progressive jaundice, consequences of impaired bile excretion, and 
ultimately cirrhosis and liver failure.
� CLINICAL MANIFESTATIONS 
Pruritus, fatigue, jaundice, xanthelasma, xanthomata, osteoporosis, steator-
rhea, skin pigmentation, hepatosplenomegaly, portal hypertension; eleva-
tions in serum alkaline phosphatase, bilirubin, cholesterol, and IgM levels.
� ASSOCIATED DISEASES 
Sjögren’s syndrome, collagen vascular diseases, thyroiditis, glomerulone-
phritis, pernicious anemia, renal tubular acidosis.
� DIAGNOSIS 
Antimitochondrial antibodies (AMA) in 90% (directed against enzymes of 
the pyruvate dehydrogenase complex and other 2-oxo-acid dehydrogenase 
mitochondrial enzymes). Liver biopsy most important in AMA-negative PBC. 
Biopsies identify 4 stages: stage 1—destruction of interlobular bile ducts, granu-
lomas; stage 2—ductular proliferation; stage 3—fibrosis; stage 4—cirrhosis.
CHAPTER 165
1055
Cirrhosis and Alcoholic Liver Disease 
� PROGNOSIS 
Correlates with age, serum bilirubin, serum albumin, prothrombin time, edema.
Primary Biliary Cirrhosis
TREATMENT
Ursodeoxycholic acid 13–15 mg/kg per day has been shown to improve 
the biochemical and histologic features of disease. Response is great-
est when given early. Cholestyramine 4 g PO with meals for pruritus; 
in refractory cases consider rifampin, naltrexone, plasmapheresis. 
Calcium, vitamin D, and bisphosphonates are given for osteoporosis. 
Liver transplantation for end-stage disease.
LIVER TRANSPLANTATION
Consider in the absence of contraindications for chronic, irreversible, 
progressive liver disease or fulminant hepatic failure when no alternative 
therapy is available (Table 165-4).
� CONTRAINDICATIONS (SEE TABLE 165-5)
TABLE 165-4 INDICATIONS FOR LIVER TRANSPLANTATION
Children
Adults
Biliary atresia
Primary biliary cirrhosis
Neonatal hepatitis
Secondary biliary cirrhosis
Congenital hepatic fibrosis
Primary sclerosing cholangitis
Alagille syndromea
Autoimmune hepatitis
Byler diseaseb
Caroli diseasec
α1-Antitrypsin deficiency
Cryptogenic cirrhosis
Inherited disorders of metabolism
Chronic hepatitis with cirrhosis
 Wilson’s disease
Hepatic vein thrombosis
Tyrosinemia
Fulminant hepatitis
Glycogen storage diseases
Alcoholic cirrhosis
Lysosomal storage diseases
Chronic viral hepatitis
Protoporphyria
Primary hepatocellular malignancies
Crigler-Najjar disease type I
Hepatic adenomas
Familial hypercholesterolemia
Nonalcoholic steatohepatitis
Primary hyperoxaluria type I
Familial amyloid polyneuropathy
Hemophilia
aArteriohepatic dysplasia, with paucity of bile ducts, and congenital malformations, including 
pulmonary stenosis.
bIntrahepatic cholestasis, progressive liver failure, mental and growth retardation.
cMultiple cystic dilatations of the intrahepatic biliary tree.
SECTION 11
1056
Gastroenterology
� SELECTION OF DONOR 
Matched for ABO blood group compatibility and liver size (reduced-size grafts 
may be used, esp. in children). Should be negative for HIV, HBV, and HCV. 
Living-donor transplant has gained increased popularity with transplantation of 
the right hepatic lobe from a healthy adult donor to an adult. Living-donor trans-
plant of the left lobe accounts for one-third of all liver transplants in children.
� IMMUNOSUPPRESSION 
Various combinations of tacrolimus or cyclosporine and glucocorticoids, siro-
limus, mycophenolate mofetil, or OKT3 (monoclonal antithymocyte globulin).
� MEDICAL COMPLICATIONS AFTER TRANSPLANTATION 
Liver graft dysfunction (primary nonfunction, acute or chronic rejection, 
ischemia, hepatic artery thrombosis, biliary obstruction or leak, recurrence 
of primary disease); infections (bacterial, viral, fungal, opportunistic); renal 
dysfunction; neuropsychiatric disorders, cardiovascular instability, pulmo-
nary compromise.
� SUCCESS RATE 
Currently, 5-year survival rates exceed 60%; less for certain conditions (e.g., 
chronic hepatitis B, hepatocellular carcinoma).
TABLE 165-5 CONTRAINDICATIONS TO LIVER TRANSPLANTATION
Absolute
Relative
Uncontrolled extrahepatobiliary 
infection
Age >70
Active, untreated sepsis
Prior extensive hepatobiliary surgery
Uncorrectable, life-limiting 
congenital anomalies
Portal vein thrombosis
Active substance or alcohol 
abuse
Renal failure not attributable to liver 
disease
Advanced cardiopulmonary 
disease
Previous extrahepatic malignancy (not 
including nonmelanoma skin cancer)
Extrahepatobiliary malignancy (not 
including nonmelanoma skin cancer)
Severe obesity
Metastatic malignancy to the liver
Severe malnutrition/wasting
Cholangiocarcinoma
Medical noncompliance
AIDS
HIV seropositivity with failure to 
control HIV viremia or CD4 <100/μL
Life-threatening systemic 
diseases
Intrahepatic sepsis 
Severe hypoxemia secondary to 
right-to-left intrapulmonary shunts 
(Po2<50 mmHg) 
Severe pulmonary hypertension 
(mean pulmonary
artery pressure >35 mmHg)
Uncontrolled psychiatric disorder
CHAPTER 166
1057
Portal Hypertension
For a more detailed discussion, see Bacon BR: Cirrhosis and Its 
Complications, Chap. 308, p. 2592; Mailliard ME, Sorrell MF: 
Alcoholic Liver Disease, Chap. 307, p. 2589; Dienstag JL, Chung 
RT: Liver Transplantation, Chap. 310, p. 2606, in HPIM-18.
CHAPTER 166
Portal Hypertension
Portal hypertension is defined as elevation of the hepatic venous pressure gra-
dient to >5 mmHg, which occurs as a consequence of cirrhosis (Chap. 165).
 It is caused by increased intrahepatic resistance to the passage of blood flow 
through the liver due to cirrhosis together with increased splanchnic blood 
flow due to vasodilatation within the splanchnic vascular bed.
� CLASSIFICATION (SEE TABLE 166-1)
TABLE 166-1 CLASSIFICATION OF PORTAL HYPERTENSION
Prehepatic
 Portal vein thrombosis
 Splenic vein thrombosis
 Massive splenomegaly (Banti’s syndrome)
Hepatic
 Presinusoidal
 Schistosomiasis
 Congenital hepatic fibrosis
Sinusoidal
 Cirrhosis—many causes
 Alcoholic hepatitis
Postsinusoidal
 Hepatic sinusoidal obstruction (venoocclusive syndrome)
Posthepatic
 Budd-Chiari syndrome
 Inferior vena caval webs
 Cardiac causes
  Restrictive cardiomyopathy
  Constrictive pericarditis
  Severe congestive heart failure
SECTION 11
1058
Gastroenterology
� CONSEQUENCES 
The primary complications of portal hypertension are gastroesophageal 
varices with hemorrhage, ascites (Chap. 49), hypersplenism, hepatic 
encephalopathy, spontaneous bacterial peritonitis (Chap. 49), hepatorenal 
syndrome (Chap. 49), hepatocellular carcinoma (Chap. 78).
ESOPHAGOGASTRIC VARICES
About one-third of pts with cirrhosis have varices, and one-third of pts with 
varices will develop bleeding. Bleeding is a life-threatening complication; 
risk of bleeding correlates with variceal size and location, the degree of 
portal hypertension (portal venous pressure >12 mmHg), and the severity 
of cirrhosis, e.g., Child-Pugh classification (see Table 165-3).
� DIAGNOSIS 
Esophagogastroscopy: procedure of choice for evaluation of upper GI hem-
orrhage in pts with known or suspected portal hypertension. Celiac and 
mesenteric arteriography are alternatives when massive bleeding prevents 
endoscopy and to evaluate portal vein patency (portal vein may also be 
studied by ultrasound with Doppler and MRI).
Esophagogastric Varices
TREATMENT
See Chap. 47 for general measures to treat GI bleeding.
CONTROL OF ACUTE BLEEDING
Choice of approach depends on clinical setting and availability.
1.  Endoscopic intervention is employed as first-line treatment to control 
bleeding acutely. Endoscopic variceal ligation (EVL) is used to control 
acute bleeding in >90% of cases. EVL is less successful when varices extend 
into proximal stomach. Some endoscopists will use variceal injection 
(sclerotherapy) as initial therapy, particularly when bleeding is vigorous.
2.  Vasoconstricting agents: somatostatin or octreotide (50–100 μg/h by 
continuous infusion).
3.  Balloon tamponade (Blakemore-Sengstaken or Minnesota tube). Can 
be used when endoscopic therapy is not immediately available or in pts 
who need stabilization prior to endoscopic therapy. Complications—
obstruction of pharynx, asphyxiation, aspiration, esophageal ulcer-
ation. Generally reserved for massive bleeding, failure of vasopressin 
and/or endoscopic therapy.
4.  Transjugular intrahepatic portosystemic shunt (TIPS)—portacaval 
shunt placed by interventional radiologic technique, reserved for 
failure of other approaches; risk of hepatic encephalopathy (20–30%), 
shunt stenosis or occlusion (30–60%), infection.
PREVENTION OF RECURRENT BLEEDING
1.  EVL should be repeated until obliteration of all varices is accomplished.
2.  Propranolol or nadolol—nonselective beta blockers that act as portal 
venous antihypertensives; may decrease the risk of variceal hemor-
rhage and mortality due to hemorrhage.
CHAPTER 166
1059
Portal Hypertension
3.  TIPS—regarded as useful “bridge” to liver transplantation in pt who 
has failed pharmacologic therapy and is awaiting a donor liver.
4.  Portosystemic shunt surgery used less commonly with the advent of 
TIPS; could be considered for pts with good hepatic synthetic function.
PREVENTION OF INITIAL BLEED
For pts at high risk of variceal bleeding, consider prophylaxis with EVL 
and/or nonselective beta blockers.
HEPATIC ENCEPHALOPATHY
An alteration in mental status and cognitive function occurring in the pres-
ence of liver failure; may be acute and reversible or chronic and progressive.
� CLINICAL FEATURES 
Confusion, slurred speech, change in personality that can include being 
violent and hard to manage, being sleepy and difficult to arouse, asterixis 
(flapping tremor). Can progress to coma; initially responsive to noxious 
stimuli, later unresponsive.
� PATHOPHYSIOLOGY 
Gut-derived neurotoxins that are not removed by the liver because of vas-
cular shunting and decreased hepatic mass reach the brain and cause the 
symptoms of hepatic encephalopathy. Ammonia levels are typically elevated 
in encephalopathy, but the correlation between the severity of liver disease 
and height of ammonia levels is often poor. Other compounds that may 
contribute include false neurotransmitters and mercaptans.
� PRECIPITANTS 
GI bleeding, azotemia, constipation, high-protein meal, hypokalemic 
alkalosis, CNS depressant drugs (e.g., benzodiazepines and barbiturates), 
hypoxia, hypercarbia, sepsis.
Hepatic Encephalopathy
TREATMENT
Remove precipitants; correct electrolyte imbalances. Lactulose (nonab-
sorbable disaccharide) results in colonic acidification and diarrhea and 
is the mainstay of treatment; goal is to produce 2–3 soft stools per day. 
Poorly absorbed antibiotics are often used in pts who do not tolerate 
lactulose, with alternating administration of neomycin and metronida-
zole being used to reduce the individual side effects of each. Rifaximin 
has recently also been used; zinc supplementation is sometimes helpful. 
Liver transplantation when otherwise indicated.
For a more detailed discussion, see Bacon BR: Cirrhosis and 
Its Complications, Chap. 308, p. 2592; in HPIM-18.
This page intentionally left blank 
1061
CHAPTER 167
Diseases of Immediate-Type 
Hypersensitivity
� DEFINITION 
These diseases result from IgE-dependent release of mediators from sensitized 
basophils and mast cells upon contact with an offending antigen (allergen). 
Associated disorders include anaphylaxis, allergic rhinitis, urticaria, asthma, 
and eczematous (atopic) dermatitis. Atopic allergy implies a familial tendency 
to the development of these disorders singly or in combination.
� PATHOPHYSIOLOGY 
IgE binds to the surface of mast cells and basophils through a high-affinity 
receptor. Cross-linking of this IgE by antigen causes cellular activation with 
subsequent release of preformed and newly synthesized mediators including 
histamine, prostaglandins, leukotrienes (C4, D4, and E4, collectively known as 
slow-reacting substance of anaphylaxis—SRS-A), acid hydrolases, neutral pro-
teases, proteoglycans, and cytokines (Fig. 167-1). These mediators have been 
SECTION 12
Allergy, Clinical Immunology, 
and Rheumatology
FIGURE 167-1 Bioactive mediators of three categories generated by IgE-dependent 
activation of murine mast cells can elicit common but sequential target cell effects 
leading to acute and sustained inflammatory responses. LT, leukotriene; PAF, platelet-
activating factor; PGD2, prostaglandin D2; IL, interleukin; GM-CSF, granulocyte-
macrophage colony-stimulating factor; INF, interferon; TNF, tumor necrosis factor.
Lipid mediators
Secretory granule
preformed mediators
Cytokines
Leukocyte responses
Fibroblast responses
Substrate responses
Microvascular responses
• LTB4
• LTC4
• PAF
• PGD2
• Histamine
• Proteoglycans
• Tryptase and chymase
• Carboxypeptidase A
• IL-3
• IL-4
• IL-5
• IL-6
• GM-CSF
• IL-13
• IL-1
• INF−γ
• TNF−α
• Adherence
• Chemotaxis
• IgE production
• Mast cell proliferation
• Eosinophil activation
• Proliferation
• Vacuolation
• Globopentaosylceramide production
• Collagen production
• Activation of matrix
   metalloproteases
• Activation of coagulation cascade
• Augmented venular permeability
• Leukocyte adherence
• Constriction
• Dilatation
Activated mast cell
SECTION 12
1062
Allergy, Clinical Immunology, and Rheumatology
implicated in many pathophysiologic events associated with immediate-type 
hypersensitivity, such as vasodilatation, increased vasopermeability, smooth-
muscle contraction, and chemotaxis of neutrophils and other inflammatory 
cells. The clinical manifestations of each allergic reaction depend largely on the 
anatomic site(s) and time course of mediator release.
URTICARIA AND ANGIOEDEMA
� DEFINITION 
May occur together or separately. Urticaria involves only the superficial 
dermis and presents as circumscribed wheals with raised serpiginous 
borders and blanched centers; wheals may coalesce. Angioedema involves 
deeper layers of skin and may include subcutaneous tissue. The classifica-
tion of urticaria-angioedema focuses on mechanisms that elicit clinical 
disease and can be useful for differential diagnosis (see Table 167-1).
� PATHOPHYSIOLOGY 
Characterized by massive edema formation in the dermis (and subcuta-
neous tissue in angioedema). Presumably the edema is due to increased 
vasopermeability caused by mediator release from mast cells or other cell 
populations.
TABLE 167-1  CLASSIFICATION OF URTICARIA AND/OR ANGIOEDEMA
1. IgE-dependent
 
a.  Specific antigen sensitivity (pollens, foods, drugs, fungi, molds, 
Hymenoptera venom, helminths)
 
b.  Physical: dermographism, cold, solar
 
c.  Autoimmune
2.  Bradykinin-mediated
 
a.  Hereditary angioedema: C1 inhibitor deficiency: null (type 1) and 
dysfunctional (type 2)
 
b.  Acquired angioedema: C1 inhibitor deficiency: anti-idiotype and anti-C1 
inhibitor
 
c.  Angiotensin-converting enzyme inhibitors
3.  Complement-mediated
 
a.  Necrotizing vasculitis
 
b.  Serum sickness
 
c.  Reactions to blood products
4.  Nonimmunologic
 
a.  Direct mast cell–releasing agents (opiates, antibiotics, curare, 
D-tubocurarine, radiocontrast media)
 
b.  Agents that alter arachidonic acid metabolism (aspirin and nonsteroidal 
anti-inflammatory agents, azo dyes, and benzoates)
5.  Idiopathic
CHAPTER 167
1063
Diseases of Immediate-Type Hypersensitivity
� DIAGNOSIS 
History, with special attention to possible offending exposures and/or inges-
tion as well as the duration of lesions. Vasculitic urticaria typically persists 
>72 h, whereas conventional urticaria often lasts <48 h.
• Skin testing to food and/or inhalant antigens.
• Physical provocation, e.g., challenge with vibratory or cold stimuli.
• Laboratory exam: complement levels, ESR (neither an elevated ESR nor 
hypocomplementemia is observed in IgE-mediated urticaria or angioedema); 
C1 inhibitor (C1INH) testing for deficiency of C1INH antigen (type 1) or a 
nonfunctional protein (type 2) if history suggests hereditary angioedema; 
cryoglobulins, hepatitis B antigen, and antibody studies; autoantibody screen.
• Skin biopsy may be necessary.
� DIFFERENTIAL DIAGNOSIS 
Atopic dermatitis, contact sensitivity, cutaneous mastocytosis (urticaria 
pigmentosa), systemic mastocytosis.
� PREVENTION 
Identification and avoidance of offending agent(s), if possible.
Urticaria and Angioedema
TREATMENT
• H1 antihistamines may be helpful: e.g., chlorpheniramine up to 
24 mg PO daily; diphenhydramine 25–50 mg PO qid; hydroxyzine 
40–200 mg PO daily; cyproheptadine 8–32 mg PO daily; or the low 
or nonsedating class, e.g., loratidine 10 mg PO daily; desloratidine 
5mg PO daily; fexofenadine up to 180 mg PO daily; cetirizine 
5–10 mg PO daily; levocetirizine 5 mg PO daily.
• H2 antihistamines: e.g., ranitidine 150 mg PO bid may add benefit.
• Leukotriene receptor antagonists can be add-on therapy: e.g., 
montelukast 10 mg daily or zafirlukast 20 mg bid.
• Topical glucocorticoids are of no value in the management of urti-
caria and/or angioedema. Systemic glucocorticoids should not be 
used in the treatment of idiopathic, allergen-induced, or physical 
urticaria because of their long-term toxicity.
ALLERGIC RHINITIS
� DEFINITION 
An inflammatory condition of the nose characterized by sneezing, rhinor-
rhea, and obstruction of nasal passages; may be associated with conjunctival 
and pharyngeal itching, lacrimation, and sinusitis. Seasonal allergic rhinitis 
is commonly caused by exposure to pollens, especially from grasses, trees, 
weeds, and molds. Perennial allergic rhinitis is frequently due to contact 
with house dust (containing dust mite antigens) and animal danders.
� PATHOPHYSIOLOGY 
Deposition of pollens and other allergens on nasal mucosa of sensitized 
individuals results in IgE-dependent triggering of mast cells with subsequent 
SECTION 12
1064
Allergy, Clinical Immunology, and Rheumatology
release of mediators that cause development of mucosal hyperemia, swell-
ing, and fluid transudation. Inflammation of nasal mucosal surface probably 
allows penetration of allergens deeper into tissue, where they contact peri-
venular mast cells. Obstruction of sinus ostia may result in development of 
secondary sinusitis, with or without bacterial infection.
� DIAGNOSIS 
Accurate history of symptoms correlated with time of seasonal pollination 
of plants in a given locale; special attention must be paid to other potentially 
sensitizing antigens such as materials associated with pets, e.g., dander.
• Physical examination: nasal mucosa may be boggy or erythematous; 
nasal polyps may be present; conjunctivae may be inflamed or edema-
tous; manifestations of other allergic conditions (e.g., asthma, eczema) 
may be present.
• Skin tests to inhalant and/or food antigens.
• Nasal smear may reveal large numbers of eosinophils; presence of neu-
trophils may suggest infection.
• Total and specific serum IgE (as assessed by immunoassay) may be 
elevated.
� DIFFERENTIAL DIAGNOSIS 
Vasomotor rhinitis, URI, irritant exposure, pregnancy with nasal mucosal 
edema, rhinitis medicamentosa, non-allergic rhinitis with eosinophilia, 
rhinitis due to α-adrenergic agents.
� PREVENTION 
Identification and avoidance of offending antigen(s).
Allergic Rhinitis
TREATMENT
• Older antihistamines (e.g., chlorpheniramine, diphenhydramine) are 
effective but cause sedation and psychomotor impairment including 
reduced hand-eye coordination and impaired automobile driving 
skills. Newer anti-histamines (e.g., fexofenadine, loratadine, deslo-
ratadine, cetirizine, levocetirizine, olopatadine, bilastine, and azelas-
tine) are equally effective but are less sedating and more H1 specific.
• Oral sympathomimetics, e.g., pseudoephedrine 30–60 mg PO qid; 
may aggravate hypertension; combination antihistamine/deconges-
tant preparations may balance side effects and provide improved pt 
convenience.
• Topical vasoconstrictors—should be used sparingly due to rebound 
congestion and chronic rhinitis associated with prolonged use.
• Topical nasal glucocorticoids, e.g., beclomethasone, 2 sprays in each 
nostril bid, or fluticasone, 2 sprays in each nostril once daily.
• Topical nasal cromolyn sodium, 1–2 sprays in each nostril qid.
• Montelukast 10 mg PO daily is approved for seasonal and perennial 
rhinitis.
• Hyposensitization therapy, if more conservative therapy is 
unsuccessful.
CHAPTER 167
1065
Diseases of Immediate-Type Hypersensitivity
SYSTEMIC MASTOCYTOSIS
� DEFINITION 
A systemic disorder characterized by mast cell hyperplasia; generally involves 
bone marrow, skin, GI mucosa, liver, and spleen. Classified as (1) indolent, 
(2) associated with concomitant hematologic disorder, (3) aggressive, 
(4) mastocytic leukemia, and (5) mast cell sarcoma.
� PATHOPHYSIOLOGY AND CLINICAL MANIFESTATIONS 
The clinical manifestations of systemic mastocytosis are due to tissue occu-
pancy by the mast cell mass, the tissue response to that mass (fibrosis), and 
the release of bioactive substances acting both locally (urticaria pigmentosa, 
crampy abdominal pain, gastritis, peptic ulcer) and at distal sites (headache, 
pruritus, flushing, vascular collapse). Clinical manifestations may be aggra-
vated by alcohol, use of narcotics (e.g., codeine), ingestion of NSAIDs.
� DIAGNOSIS 
Although the diagnosis of mastocytosis may be suspected on the basis of clini-
cal and laboratory findings, it can be established only by tissue biopsy (usually 
bone marrow biopsy). The diagnostic criteria for systemic mastocytosis are 
shown in Table 167-2. Laboratory studies that can help support a diagnosis 
of systemic mastocytosis include measurement of urinary or blood levels of 
mast cell products such as histamine, histamine metabolites, prostaglandin D2 
(PGD2) metabolites, or mast cell tryptase. Other studies including bone scan, 
skeletal survey, GI contrast studies may be helpful. Other flushing disorders 
(e.g., carcinoid syndrome, pheochromocytoma) should be excluded.
Systemic Mastocystosis
TREATMENT
• H1 and H2 antihistamines.
• Proton pump inhibitors for gastric hypersecretion.
• Oral cromolyn sodium for diarrhea and abdominal pain.
• NSAIDs (in nonsensitive pts) may help by blocking PGD2 production.
TABLE 167-2  DIAGNOSTIC CRITERIA FOR SYSTEMIC MASTOCYTOSISa
Major: Multifocal dense infiltrates of mast cells in bone marrow or other 
extracutaneous tissues with confirmation by immunodetection of tryptase or 
metachromasia
Minor: Abnormal mast cell morphology with a spindle shape and/or multilobed 
or eccentric nucleus
Aberrant mast cell surface phenotype with expression of CD25 and CD2 
(IL-2 receptor) in addition to C117 (c-kit)
Detection of codon 816 mutation in peripheral blood cells, bone marrow cells, 
or lesional tissue
Total serum tryptase (mostly alpha) >20 ng/mL
aDiagnosis requires either major and one minor or three minor criteria.
SECTION 12
1066
Allergy, Clinical Immunology, and Rheumatology
• Systemic glucocorticoids may help, but frequently are associated 
with complications.
• Hydroxyurea to reduce mast cell lineage progenitors may have merit 
in aggressive systemic mastocytosis.
• Chemotherapy for frank leukemias.
For a more detailed discussion, see Austen KF: Allergies, 
Anaphylaxis, and Systemic Mastocytosis, Chap. 317, p. 2707, 
in HPIM-18.
CHAPTER 168
Primary Immune Deficiency 
Diseases
DEFINITION
Primary immunodeficiencies are genetic diseases that can involve all pos-
sible aspects of immune responses, from innate through adaptive, as well as 
cell differentiation, effector function, and immune regulation (Table 168-1). 
The consequences of primary immunodeficiencies vary widely as a function 
of the molecules that are defective and include vulnerability to infection by 
pathogenic and opportunistic infection, immunopathologic responses such 
as allergy, lymphoproliferations, and autoimmunity, and increased risk of 
cancers. The locations and sites of infection and the causal microorganisms 
often aid the physician in diagnosis.
DIAGNOSIS (SEE TABLE 168-2)
CLASSIFICATION (TABLE 168-1) 
� DEFICIENCIES OF THE INNATE IMMUNE SYSTEM
Account for ~10% of all primary immunodeficiencies (Table 168-1).
� DEFICIENCES OF THE ADAPTIVE IMMUNE SYSTEM
T Lymphocyte Deficiency Syndromes
Severe Combined Immunodeficiency (SCID) Group of rare primary immu-
nodeficiencies characterized by a profound block in T cell development 
as a consequence of an intrinsic deficiency. Clinical consequences occur 
within 3–6 months following birth. The most frequent clinical manifesta-
tions are recurrent oral candidiasis, failure to thrive, protracted diarrhea, 
Pneumocystis jiroveci infections. Six distinct causative mechanisms have 
been identified: 
CHAPTER 168
1067
Primary Immune Deficiency Diseases 
TABLE 168-1  CLASSIFICATION OF PRIMARY IMMUNE DEFICIENCY 
DISEASES
Deficiencies of the Innate Immune System
• Phagocytic cells
–  Impaired production: severe congenital neutropenia (SCN)
–  Asplenia
–  Impaired adhesion: leukocyte adhesion deficiency (LAD)
–  Impaired killing: chronic granulomatous disease (CGD)
• Innate immunity receptors and signal transduction
–  Defects in Toll-like receptor signaling
–  Mendelian susceptibility to mycobacterial disease
• Complement deficiencies
–  Classic, alternative, and lectin pathways
–  Lytic phase
Deficiencies of the Adaptive Immune System
• T lymphocytes
–  Impaired 
development
–  Impaired survival, 
migration, function
Severe combined immune deficiencies (SCIDs) 
DiGeorge syndrome
Severe combined immunodeficiencies
Hyper-IgE syndrome (autosomal dominant)
CD40 ligand deficiency
Wiskott-Aldrich syndrome
Ataxia-telangiectasia and other DNA repair 
deficiencies
• B lymphocytes
–  Impaired 
development
–  Impaired function
XL and AR agammaglobulinemia
Hyper-IgM syndrome
Common variable immunodeficiency (CVID)
IgA deficiency
Regulatory Defects
• Innate immunity
• Adaptive immunity
Autoinflammatory syndromes (outside the scope 
of this chapter)
Severe colitis
Hemophagocytic lymphohistiocytosis (HLH)
Autoimmune lymphoproliferation syndrome (ALPS)
Autoimmunity and inflammatory diseases 
(IPEX, APECED)
Abbreviations: APECED, autoimmune polyendocrinopathy candidiasis ectodermal dysplasia; 
AR, autosomal recessive; IPEX, immunodysregulation polyendocrinopathy enteropathy X-linked 
syndrome; XL, X-linked.
SECTION 12
1068
Allergy, Clinical Immunology, and Rheumatology
TABLE 168-2  TEST MOST FREQUENTLY USED TO DIAGNOSE A PRIMARY 
IMMUNE DEFICIENCY (PID)
Test
Information
PID Disease
Blood cell counts and 
cell morphology
Neutrophil counts
Lymphocyte counts*
Eosinophilia
Howell-Jolly bodies
↓Severe congenital 
neutropenia, ↑↑ LAD
T cell ID
WAS, Hyper-IgE 
syndrome
Asplenia
Chest x-ray
Thymic shadow
Costochondral junctions
SCID, DiGeorge 
syndrome
Adenosine deaminase 
deficiency
Bone x-ray
Metaphyseal ends
Cartilage hair hypoplasia
Immunoglobulin serum 
levels
IgG, IgA, IgM
IgE
B cell ID
Hyper-IgE syndrome, 
WAS, T cell ID
Lymphocyte phenotype
T, B lymphocyte counts
T cell ID, 
agammaglobulinemia
Dihydrorhodamine
fluorescence (DHR) 
assay
Nitroblue tetrazolium 
(NBT) assay
Reactive oxygen species 
production by PMN
Chronic granulomatous 
disease
CH50, AP50
Classic and alternative 
complement pathways
Complement
deficiencies
Ultrasonography of the 
abdomen
Spleen size
Asplenia
*Normal counts vary with age. For example, the lymphocyte count is between 3000 and 
9000/μL of blood below the age of 3 months and between 1500 and 2500/μL in adults.
Abbreviations: ID, immunodeficiency; LAD, leukocyte adhesion deficiency; PMNs, 
polymorphonuclear leukocytes; SCID, severe combined immunodeficiency; WAS, Wiskott-
Aldrich syndrome.
• Cytokine signaling deficiency: Most frequent SCID accounting for 40–50% 
of cases with the absence of T and NK cells. These pts have a deficiency 
in the gamma chain receptor shared by several cytokine receptors (inter-
leukins 2, 4, 7, 9, 15, 21). The same phenotype seen in X-linked SCID 
can be inherited as an autosomal recessive disease due to mutations in 
the JAK3 protein kinase gene. 
• Purine metabolism deficiency: About 20% of SCID pts are deficient in 
adenosine deaminase (ADA) due to mutations in the ADA gene.
• Defective rearrangements of T and B cell receptors: Account for ~20–30% 
of SCID cases. Main deficiencies involve recombinase activating genes 
CHAPTER 168
1069
Primary Immune Deficiency Diseases 
(RAG-1, RAG-2) DNA dependent protein kinase, DNA ligase 4, and 
Cernunnos deficiencies.
• Defective (pre-) T cell receptor signaling in the thymus: Rare deficiencies in 
CD3 subunits associated with the (pre) TCR and CD45.
• Reticular dysgenesis: Extremely rare. Results from adenylate kinase 2 
deficiency.
• Defective egress of lymphocytes: Defective egress of T cells from the thy-
mus resulting from deficiency in coronin-1A.
Severe Combined Immunodeﬁ ciency
TREATMENT
Curative treatment relies on hematopoietic stem cell transplant (HSCT).
Other T cell–Related Primary Immunodefi ciencies
• DiGeorge syndrome: Maldevelopment of the thymus.
• Hyper-IgE syndrome
• CD40 ligand deficiency
• Wiskott-Aldrich syndrome
• Ataxia-telangiectasia and other DNA repair deficiencies
Other T Cell Immunodeﬁ ciencies
TREATMENT
Treatment is complex and largely investigational. HSCT plays a role 
in some diseases. Live vaccines and blood transfusions containing 
viable T cells should be strictly avoided. Prophylaxis for Pneumocystis 
jiroveci pneumonia should be considered in selected pts with severe 
T cell deficiency.
B Lymphocyte Deficiency Syndromes
Deficiencies that affect B cells are the most common primary immuno-
deficiencies and account for ~60–70% of all cases. Defective antibody 
production predisposes to invasive pyogenic bacterial infections as well 
as recurrent sinus and pulmonary infections. Complete lack of antibody 
production (agammaglobulinemia) predisposes to disseminated enteroviral 
infections causing meningoencephalitis, hepatitis, and a dermatomyositis-
like disease. Diagnosis relies on the determination of serum Ig level.
• Agammaglobulinemia: Due to an X-linked mutation in the Bruton’s tyro-
sine kinase (Btk) gene in 85% of cases. 
• Hyper IgM: In most pts this syndrome results from an X linked defect in 
the gene encoding CD40 ligand. Pts exhibit normal or increased serum 
IgM with low or absent IgG and IgA.
• Common variable immunodeficiency (CVID): Heterogeneous group of 
syndromes characterized by low serum levels of one or more Ig isotypes. 
Prevalence estimated to be 1 in 20,000. Besides infections, pts may 
develop lymphoproliferation, granulomatous lesions, colitis, antibody-
mediated autoimmune diseases, and lymphomas.
• Isolated IgA deficiency: Most common immunodeficiency; affects 1 in 
600 people. The majority of affected individuals do not have increased 
SECTION 12
1070
Allergy, Clinical Immunology, and Rheumatology
infections; antibodies against IgA may lead to anaphylaxis during trans-
fusion of blood or plasma; may progress to CVID.
• Selective antibody deficiency to polysaccharide antigens. 
B Cell/Immunoglobulin Deﬁ ciency Syndromes
TREATMENT
IV immunoglobulin administration (only for pts who have recurrent 
bacterial infections and are deficient in IgG):
• Starting dose 400–500 mg/kg given every 3–4 weeks
• Adjust dose to keep trough IgG level 800 mg/dL
• SC administration usually once a week can be considered in selected pts. 
� REGULATORY DEFECTS
Rare but increasingly described primary immunodeficiencies that cause 
homeostatic dysregulation of the immune system either alone or in associa-
tion with increased vulnerability to infection (Table 168-1). 
For a more detailed discussion, see Fischer A: Primary Immune 
Deficiency Diseases, Chap. 316, p. 2695, in HPIM-18.
CHAPTER 169
SLE, RA, and Other Connective 
Tissue Diseases
CONNECTIVE TISSUE DISEASE
� DEFINITION 
Heterogeneous disorders that share certain common features, including 
inflammation of skin, joints, and other structures rich in connective tissue; 
as well as altered patterns of immunoregulation, including production of 
autoantibodies and abnormalities of cell-mediated immunity. While dis-
tinct clinical entities can be defined, manifestations may vary considerably 
from one pt to the next, and overlap of clinical features between and among 
specific diseases can occur.
SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
� DEFINITION AND PATHOGENESIS 
Disease of unknown etiology in which tissues and cells undergo damage 
mediated by tissue-binding autoantibodies and immune complexes. Genetic, 
environmental, and sex hormonal factors are likely of pathogenic importance. 
T and B cell hyperactivity, production of autoantibodies with specificity for 
nuclear antigenic determinants, and abnormalities of T cell function occur.
CHAPTER 169
1071
SLE, RA, and Other Connective Tissue Diseases 
� CLINICAL MANIFESTATIONS 
90% of pts are women, usually of child-bearing age; more common in blacks 
than whites. Course of disease is often characterized by periods of exacer-
bation and relative quiescence. May involve virtually any organ system and 
have a wide range of disease severity. Common features include:
• Constitutional—fatigue, fever, malaise, weight loss
• Cutaneous—rashes (especially malar “butterfly” rash), photosensitivity, 
vasculitis, alopecia, oral ulcers
• Arthritis—inflammatory, symmetric, nonerosive
• Hematologic—anemia (may be hemolytic), neutropenia, thrombocyto-
penia, lymphadenopathy, splenomegaly, venous or arterial thrombosis
• Cardiopulmonary—pleuritis, pericarditis, myocarditis, endocarditis. Pts 
are also at increased risk of myocardial infarction usually due to acceler-
ated atherosclerosis.
• Nephritis—classification is primarily histologic (Table 319-2, p. 2727, in 
HPIM-18)
• GI—peritonitis, vasculitis
• Neurologic—organic brain syndromes, seizures, psychosis, cerebritis
Drug-Induced Lupus
A clinical and immunologic picture similar to spontaneous SLE may be 
induced by drugs; in particular: procainamide, hydralazine, isoniazid, 
chlorpromazine, methyldopa, minocycline, anti-TNF agents. Features are 
predominantly constitutional, joint, and pleuropericardial; CNS and renal 
disease are rare. All pts have antinuclear antibodies (ANA); antihistone 
antibodies may be present, but antibodies to dsDNA and hypocomplement-
emia are uncommon. Most pts improve following withdrawal of offend-
ing drug.
� EVALUATION
• Hx and physical exam
• Presence of ANA is a cardinal feature, but a (+) ANA is not specific for 
SLE. Laboratory assessment should include: CBC, ESR, ANA and ANA 
subtypes (antibodies to dsDNA, ssDNA, Sm, Ro, La, histone), comple-
ment levels (C3, C4, CH50), serum immunoglobulins, VDRL, PT, PTT, 
anticardiolipin antibody, lupus anticoagulant, urinalysis.
• Appropriate radiographic studies
• ECG
• Consideration of renal biopsy if evidence of glomerulonephritis
� DIAGNOSIS 
Made in the presence of four or more published criteria (Table 319-3, p. 2728, 
in HPIM-18).
Systemic Lupus Erythematosus
TREATMENT
Choice of therapy is based on type and severity of disease manifesta-
tions. Goals are to control acute, severe flares and to develop mainte-
nance strategies whereby symptoms are suppressed to an acceptable
SECTION 12
1072
Allergy, Clinical Immunology, and Rheumatology
level. Treatment choices depend on (1) whether disease is life-threatening 
or likely to cause organ damage; (2) whether manifestations are 
reversible; and (3) the best approach to prevent complications of dis-
ease and treatment (Fig. 319-2, p. 2729, and Table 319-5, p. 2732, in 
HPIM-18).
CONSERVATIVE THERAPIES FOR NON-LIFE-THREATENING DISEASE
• NSAIDs (e.g., ibuprofen 400–800 mg three to four times a day). 
Must consider renal, GI, and cardiovascular complications.
• Antimalarials (hydroxychloroquine 400 mg/d)—may improve con-
stitutional, cutaneous, articular manifestations. Ophthalmologic 
evaluation required before and during Rx to rule out ocular toxicity.
• Belimumab (10 mg/kg IV at weeks 0, 2, 4 then monthly). B lym-
phocyte stimulator (BLyS)-specific inhibitor. Should not be used in 
severe SLE such as nephritis or CNS disease and limited to pts with 
mild to moderate active disease.
TREATMENTS FOR LIFE-THREATENING SLE
• Systemic glucocorticoids.
• Cytotoxic/immunosuppressive agents—added to glucocorticoids to 
treat serious SLE.
1. Cyclophosphamide—administered as IV pulse 500–750 mg/M2 
IV × 6 months followed by maintenance with mycophenolate 
mofetil or azathioprine. European studies have found cyclophos-
phamide 500 mg every 2 weeks for 6 doses may be effective, but it 
remains unclear whether these data will apply to U.S. populations.
2. Mycophenolate mofetil—2–3 g/d; efficacy data limited to nephri-
tis. A higher proportion of black pts appear to respond to myco-
phenolate mofetil compared with cyclophosphamide.
3. Azathioprine—may be effective but is slower in inducing thera-
peutic response.
RHEUMATOID ARTHRITIS (RA)
� DEFINITION AND PATHOGENESIS 
A chronic multisystem disease of unknown etiology characterized by persis-
tent inflammatory synovitis, usually involving peripheral joints symmetri-
cally. Although cartilaginous destruction, bony erosions, and joint deformity 
are hallmarks, the course of RA can be quite variable. An association with 
HLA-DR4 has been noted; both genetic and environmental factors may play 
a role in initiating disease. The propagation of RA is an immunologically 
mediated event in which joint injury occurs from synovial hyperplasia; 
lymphocytic infiltration of synovium; and local production of cytokines and 
chemokines by activated lymphocytes, macrophages, and fibroblasts.
� CLINICAL MANIFESTATIONS 
RA occurs in 0.5–1.0% of the population; women affected three times more 
often than men; prevalence increases with age, onset most frequent in 
fourth and fifth decades.
CHAPTER 169
1073
SLE, RA, and Other Connective Tissue Diseases 
Articular Manifestations
Typically a symmetric polyarthritis of peripheral joints with pain, tender-
ness, and swelling of affected joints; morning stiffness is common; PIP 
and MCP joints frequently involved; joint deformities may develop after 
persistent inflammation.
Extraarticular Manifestations
Cutaneous—rheumatoid nodules, vasculitis
Pulmonary—nodules, interstitial disease, bronchiolitis obliterans–organizing 
pneumonia (BOOP), pleural disease, Caplan’s syndrome [sero (+) RA asso-
ciated with pneumoconiosis]
Ocular—keratoconjunctivitis sicca, episcleritis, scleritis
Hematologic—anemia, Felty’s syndrome (splenomegaly and neutropenia)
Cardiac—pericarditis, myocarditis
Neurologic—myelopathies secondary to cervical spine disease, entrapment, 
vasculitis
� EVALUATION
• Hx and physical exam with careful examination of all joints.
• Rheumatoid factor (RF) is present in >66% of pts; its presence correlates 
with severe disease, nodules, extraarticular features.
• Antibodies to cyclic citrullinated protein (anti-CCP) have similar sen-
sitivity but higher specificity than RF; may be most useful in early RA; 
presence most common in pts with aggressive disease with a tendency 
for developing bone erosions.
• Other laboratory data: CBC, ESR.
• Synovial fluid analysis—useful to rule out crystalline disease, infection.
• Radiographs—juxta-articular osteopenia, joint space narrowing, mar-
ginal erosions. Chest x-ray should be obtained.
� DIAGNOSIS
Not difficult in pts with typical established disease. May be confusing 
early. Classification criteria were updated in 2010 (Table 321-1, p. 2745, in 
HPIM-18).
� DIFFERENTIAL DIAGNOSIS 
Gout, SLE, psoriatic arthritis, infectious arthritis, osteoarthritis, sarcoid.
Rheumatoid Arthritis
TREATMENT
Goals: lessen pain, reduce inflammation, improve/maintain function, 
prevent long-term joint damage, control of systemic involvement. 
Increasing trend to treat RA more aggressively earlier in disease 
course (Table 321-2, HPIM-18, pp. 2748–2749). All RA therapies have 
individual toxicities, with many requiring pretreatment screening and 
monitoring. 
• Pt education on disease, joint protection.
• Physical and occupational therapy—strengthen periarticular mus-
cles, consider assistive devices.
SECTION 12
1074
Allergy, Clinical Immunology, and Rheumatology
• Aspirin or NSAIDs.
• Intra-articular glucocorticoids.
• Systemic glucocorticoids.
• Disease-modifying antirheumatic drugs (DMARDs)—e.g., metho-
trexate, hydroxychloroquine, sulfasalazine, leflunomide.
• Biologic therapies.
• TNF modulatory agents (etanercept, infliximab, adalimumab, goli-
mumab, certolizumab)—effective at controlling RA in many pts and 
can slow the rate of progression of radiographic joint damage and 
decrease disability; carry potential for serious infection and indi-
vidual toxicities. 
• Abatacept (CTLA4-Ig)—inhibits T cell activation, can be given with 
or without methotrexate.
• Rituximab—a chimeric antibody directed to CD20 that depletes 
mature B cells, is approved for refractory RA.
• Tocilizumab—humanized monoclonal antibody directed against 
the IL-6 receptor.
• Anakinra—an IL-1 receptor antagonist approved for RA but rarely 
used in RA due to only modest clinical efficacy. 
• Surgery—may be considered for severe functional impairment due 
to deformity.
SYSTEMIC SCLEROSIS (SCLERODERMA, SSC)
� DEFINITION AND PATHOGENESIS 
Systemic sclerosis (SSc) is a multisystem disorder characterized by thicken-
ing of the skin (scleroderma) and distinctive involvement of multiple inter-
nal organs (chiefly GI tract, lungs, heart, and kidney). Pathogenesis unclear; 
involves immunologic mechanisms leading to vascular endothelial damage 
and activation of fibroblasts.
� CLINICAL MANIFESTATIONS
• Cutaneous—edema followed by fibrosis of the skin (chiefly extremities, 
face, trunk); telangiectasis; calcinosis; Raynaud’s phenomenon
• Arthralgias and/or arthritis
• GI—esophageal hypomotility; intestinal hypofunction
• Pulmonary—fibrosis, pulmonary hypertension, alveolitis
• Cardiac—pericarditis, cardiomyopathy, conduction abnormalities
• Renal—hypertension; renal crisis/failure
Two distinct subsets can be identified:
1. Diffuse cutaneous SSc—rapid development of symmetric skin thickening 
of proximal and distal extremity, face, and trunk. At high risk for devel-
opment of visceral disease early in course.
2. Limited cutaneous SSc—often have long-standing Raynaud’s phenomenon 
before other features appear; skin involvement limited to fingers (sclero-
dactyly), extremity distal to elbows, and face; associated with better prog-
nosis; a subset of limited SSc has features of CREST syndrome (calcinosis, 
Raynaud’s, esophageal dysmotility, sclerodactyly, telangiectasias).
CHAPTER 169
1075
SLE, RA, and Other Connective Tissue Diseases 
� EVALUATION
• Hx and physical exam with particular attention to blood pressure (her-
alding feature of renal disease).
• Laboratories: ESR, ANA (anticentromere pattern associated with limited 
SSc), specific antibodies may include antitopoisomerase I (Scl-70), UA. 
An increased range of autoantibodies correlating with specific clinical 
features have become recognized (Table 323-3, HPIM-18, p. 2760) 
• Radiographs: CXR, barium swallow if indicated, hand x-rays may show 
distal tuft resorption and calcinosis.
• Additional studies: ECG, echo, PFT, consider skin biopsy.
Systemic Sclerosis
TREATMENT
• Education regarding warm clothing, smoking cessation, antireflux 
measures.
• Calcium channel blockers (e.g., nifedipine) useful for Raynaud’s phe-
nomenon. Other agents with potential benefit include sildenafil, losar-
tan, nitroglycerin paste, fluoxetine, bosentan, digital sympathectomy.
• ACE inhibitors—particularly important for controlling hyperten-
sion and limiting progression of renal disease.
• Antacids, H2 antagonists, omeprazole, and metoclopramide may be 
useful for esophageal reflux.
• d-Penicillamine—controversial benefit to reduce skin thicken-
ing and prevent organ involvement; no advantages to using doses 
>125 mg every other day.
• Glucocorticoids—no efficacy in slowing progression of SSc; indi-
cated for inflammatory myositis or pericarditis; high doses early in 
disease may be associated with development of renal crisis.
• Cyclophosphamide—improves lung function and survival in pts 
with alveolitis.
• Epoprostenol (prostacyclin) and bosentan (endothelin-1 receptor 
antagonist)—may improve cardiopulmonary hemodynamics in pts 
with pulmonary hypertension.
MIXED CONNECTIVE TISSUE DISEASE (MCTD)
� DEFINITION 
Syndrome characterized by a combination of clinical features similar to 
those of SLE, SSc, polymyositis, and RA; unusually high titers of circulating 
antibodies to a nuclear ribonucleoprotein (RNP) are found. It is controver-
sial whether MCTD is a truly distinct entity or a subset of SLE or SSc.
� CLINICAL MANIFESTATIONS
Raynaud’s phenomenon, polyarthritis, swollen hands or sclerodactyly, 
esophageal dysfunction, pulmonary fibrosis, inflammatory myopathy. 
Renal involvement occurs in about 25%. Laboratory abnormalities include 
high-titer ANAs, very high titers of antibody to RNP, positive RF in 50% 
of pts.
SECTION 12
1076
Allergy, Clinical Immunology, and Rheumatology
� EVALUATION
Similar to that for SLE and SSc.
Mixed Connective Tissue Disease
TREATMENT
Few published data. Treat based on manifestations with similar 
approach to that used if feature occurred in SLE/SSc/polymyositis/RA.
SJÖGREN’S SYNDROME
� DEFINITION
An immunologic disorder characterized by progressive lymphocytic 
destruction of exocrine glands most frequently resulting in symptomatic 
eye and mouth dryness; can be associated with extraglandular manifesta-
tions; predominantly affects middle-age females; may be primary or sec-
ondary when it occurs in association with other autoimmune diseases.
� CLINICAL MANIFESTATIONS
• Constitutional—fatigue
• Sicca symptoms—keratoconjunctivitis sicca (KCS) and xerostomia
• Dryness of other surfaces—nose, vagina, trachea, skin
• Extraglandular features—arthralgia/arthritis, Raynaud’s, lymphadenopathy, 
interstitial pneumonitis, vasculitis (usually cutaneous), nephritis, lym-
phoma
� EVALUATION
• Hx and physical exam—with special attention to oral, ocular, lymphatic 
exam and presence of other autoimmune disorders.
• Presence of autoantibodies is a hallmark of disease (ANA, RF, anti-Ro, 
anti-La).
• Other laboratory tests—ESR; CBC; renal, liver, and thyroid function 
tests; serum protein electrophoresis (SPEP) (hypergammaglobulinemia 
or monoclonal gammopathy common); UA.
• Ocular studies—to diagnose and quantitate KCS; Schirmer’s test, Rose 
bengal staining.
• Oral exam—unstimulated salivary flow, dental exam.
• Labial salivary gland biopsy—demonstrates lymphocytic infiltration and 
destruction of glandular tissue.
� DIAGNOSIS 
International classification criteria based on clinical and laboratory features 
have been established (Table 324-5, HPIM-18, p. 2772). 
Sjögren’s Syndrome 
TREATMENT
• Regular follow-up with dentist and ophthalmologist.
• Dry eyes—artificial tears, ophthalmic lubricating ointments, local 
stimulation with cyclic adenosine monophosphate or cyclosporine 
drops.
CHAPTER 169
1077
SLE, RA, and Other Connective Tissue Diseases 
• Xerostomia—frequent sips of water, sugarless candy.
• Pilocarpine or cevimeline—may help sicca manifestations.
• Hydroxychloroquine—may help arthralgias.
• Glucocorticoids—not effective for sicca Sx but may have role in 
treatment of extraglandular manifestations.
ANTIPHOSPHOLIPID ANTIBODY SYNDROME (APS)
� DEFINITION 
Autoantibody-mediated acquired thrombophilia characterized by recurrent 
arterial or venous thromboses and/or pregnancy morbidity in the presence 
of autoantibodies against phospholipid (PL)-binding plasma proteins. Can 
occur alone (primary) or in association with another autoimmune disease 
(secondary). 
� CLINICAL MANIFESTATIONS 
Consist of vascular thrombotic features and pregnancy morbidity 
(Table 320-2 in HPIM-18, p. 2737). Catastrophic APS (CAPS) is rapidly 
progressive thromboembolic disease involving three or more organ systems 
that can be life-threatening. 
� EVALUATION
Laboratory examination of clotting parameters to include partial thrombo-
plastin time, kaolin clotting time, dilute Russell viper venom test, antibod-
ies directed against cardiolipin, β2 glycoprotein, prothrombin. Antibodies 
should be measured on two occasions 12 weeks apart.
� DIAGNOSIS 
Suggested by the presence of at least one clinical and one laboratory feature. 
Antiphospholipid Antibody Syndrome
TREATMENT
• After first thrombotic event, warfarin for life to achieve an INR 
2.5–3.5.
• Pregnancy morbidity prevented by heparin with aspirin 80 mg 
daily. IV immunoglobulins (IVIG) may also prevent pregnancy loss. 
Glucocorticoids are ineffective. 
• For CAPS, consider IVIG, anti-CD20 and use of antithrombotics 
such as fondaparinux or rivaroxaban. 
For a more detailed discussion, see Hahn BH: Systemic Lupus 
Erythematosus, Chap. 319, p. 2724; Shah A, St. Clair EW: 
Rheumatoid Arthritis, Chap. 321, p. 2738; Varga J: Systemic 
Sclerosis (Scleroderma) and Related Disorders, Chap. 323, 
p. 2757; Moutsopoulos HM, Tzioufas AG: Sjögren’s Syndrome, 
Chap. 324, p. 2770; and Moutsopoulos HM, Vlachoyiannopoulos 
PG: Antiphospholipid Antibody Syndrome, Chap. 320, p. 2736, 
in HPIM-18.
SECTION 12
1078
Allergy, Clinical Immunology, and Rheumatology
CHAPTER 170
Vasculitis
� DEFINITION AND PATHOGENESIS
A clinicopathologic process characterized by inflammation of and dam-
age to blood vessels, compromise of vessel lumen, and resulting isch-
emia. Clinical manifestations depend on size and location of affected 
vessel. Most vasculitic syndromes appear to be mediated by immune 
mechanisms. May be primary or sole manifestation of a disease or 
secondary to another disease process. Unique vasculitic syndromes can 
differ greatly with regards to clinical features, disease severity, histology, 
and treatment.
� PRIMARY VASCULITIS SYNDROMES
Granulomatosis with Polyangiitis (Wegener’s) 
Granulomatous vasculitis of upper and lower respiratory tracts together 
with glomerulonephritis; upper airway lesions affecting the nose and 
sinuses can cause purulent or bloody nasal discharge, mucosal ulceration, 
septal perforation, and cartilaginous destruction (saddlenose deformity). 
Lung involvement may be asymptomatic or cause cough, hemoptysis, 
dyspnea; eye involvement may occur; glomerulonephritis can be rapidly 
progressive and asymptomatic and can lead to renal failure.
Churg-Strauss Syndrome 
Granulomatous vasculitis of multiple organ systems, particularly the lung; 
characterized by asthma, peripheral eosinophilia, eosinophilic tissue infil-
tration; glomerulonephritis can occur.
Polyarteritis Nodosa (PAN) 
Medium-sized muscular arteries involved; frequently associated with 
arteriographic aneurysms; commonly affects renal arteries, liver, GI tract, 
peripheral nerves, skin, heart; can be associated with hepatitis B.
Microscopic Polyangiitis 
Small-vessel vasculitis that can affect the glomerulus and lungs; medium-
sized vessels also may be affected.
Giant Cell Arteritis 
Inflammation of medium- and large-sized arteries; primarily involves tem-
poral artery but systemic and large vessel involvement may occur; symp-
toms include headache, jaw/tongue claudication, scalp tenderness, fever, 
musculoskeletal symptoms (polymyalgia rheumatica); sudden blindness 
from involvement of optic vessels is a dreaded complication.
CHAPTER 170
1079
Vasculitis
Takayasu’s Arteritis 
Vasculitis of the large arteries with strong predilection for aortic arch and 
its branches; most common in young women; presents with inflammatory 
or ischemic symptoms in arms and neck, systemic inflammatory symptoms, 
aortic regurgitation.
Henoch-Schönlein Purpura 
Characterized by involvement of skin, GI tract, kidneys; more common in 
children; may recur after initial remission.
Cryoglobulinemic Vasculitis 
Majority of cases are associated with hepatitis C where an aberrant immune 
response leads to formation of cryoglobulin; characterized by cutaneous 
vasculitis, arthritis, peripheral neuropathy, and glomerulonephritis.
Idiopathic Cutaneous Vasculitis 
Cutaneous vasculitis is defined broadly as inflammation of the blood vessels 
of the dermis; due to underlying disease in >70% of cases (see “Secondary 
Vasculitis Syndromes,” below) with 30% occurring idiopathically.
Miscellaneous Vasculitic Syndromes
• Kawasaki disease (mucocutaneous lymph node syndrome)
• Isolated vasculitis of the central nervous system
• Behçet’s syndrome
• Cogan’s syndrome
• Polyangiitis overlap syndrome
� SECONDARY VASCULITIS SYNDROMES
• Drug-induced vasculitis
• Serum sickness
• Vasculitis associated with infection, malignancy, rheumatic disease
� EVALUATION (SEE FIG. 170-1)
• Thorough Hx and physical exam—special reference to ischemic manifes-
tations and systemic inflammatory signs/symptoms.
• Laboratories—important in assessing organ involvement: CBC with dif-
ferential, ESR, renal function tests, UA. Should also be obtained to rule 
out other diseases: ANA, rheumatoid factor, anti-GBM, hepatitis B/C 
serologies, HIV.
• Antineutrophil cytoplasmic autoantibodies (ANCA)—associated with 
granulomatosis with polyangiitis (Wegener’s), microscopic polyangi-
itis, and some pts with Churg-Strauss syndrome; presence of ANCA 
is adjunctive and should not be used in place of biopsy as a means of 
diagnosis or to guide treatment decisions.
• Radiographs—CXR should be performed even in the absence of symptoms.
• Diagnosis—can usually be made only by arteriogram or biopsy of 
affected organ(s).
� DIFFERENTIAL DIAGNOSIS
Guided by organ manifestations. In many instances includes infections and 
neoplasms, which must be ruled out prior to beginning immunosuppressive 
SECTION 12
1080
Allergy, Clinical Immunology, and Rheumatology
Properly categorize to a
specific vasculitis syndrome
Determine pattern and
extent of disease
Presentation of patient
with suspected vasculitis
Clinical findings
Laboratory workup
Establish diagnosis
Biopsy
Angiogram where
appropriate
Look for
offending antigen
Look for
underlying disease
Characteristic
syndrome [i.e.,
granulomatosis
with polyangiitis
(Wegener’s)
PAN, Takayasu’s
arteritis]
Treat vasculitis
Remove antigen
Syndrome
resolves
Treat underlying
disease
No further action
Treat vasculitis
Yes
No
Yes
No
Yes
No
SUSPECTED VASCULITIS
FIGURE 170-1 Algorithm for the approach to a pt with suspected diagnosis of 
vasculitis. PAN, polyarteritis nodosa. 
therapy. Consideration must also be given for diseases that can mimic vas-
culitis (Table 170-1).
Vasculitis
TREATMENT
Therapy is based on the specific vasculitic syndrome and the severity 
of its manifestations. Immunosuppressive therapy should be avoided in 
disease that rarely results in irreversible organ system dysfunction or 
that usually does not respond to such agents (e.g., isolated cutaneous 
vasculitis). Antiviral agents play an important role in treating vasculitis
CHAPTER 170
1081
Vasculitis
TABLE 170-1  CONDITIONS THAT CAN MIMIC VASCULITIS
Infectious diseases
Bacterial endocarditis
Disseminated gonococcal infection
Pulmonary histoplasmosis
Coccidioidomycosis
Syphilis
Lyme disease
Rocky Mountain spotted fever
Whipple’s disease
Coagulopathies/thrombotic microangiopathies
Antiphospholipid antibody syndrome
Thrombotic thrombocytopenic purpura
Neoplasms
Atrial myxoma
Lymphoma
Carcinomatosis
Drug toxicity
Cocaine
Amphetamines
Ergot alkaloids
Methysergide
Arsenic
Sarcoidosis
Atheroembolic disease
Anti–glomerular basement membrane antibody disease (Goodpasture’s 
syndrome)
Amyloidosis
Migraine
occurring with hepatitis B or C. Glucocorticoids alone may control 
giant cell arteritis and Takayasu’s arteritis. Therapy that combines 
glucocorticoids with another immunosuppressive agent is particularly 
important in syndromes with life-threatening organ system involve-
ment, especially active glomerulonephritis. Frequently used agents:
• Prednisone 1 (mg/kg)/d initially, then tapered.
• Cyclophosphamide 2 (mg/kg)/d, adjusted to avoid severe leukope-
nia. Morning administration with a large amount of fluid is impor-
tant in minimizing bladder toxicity. IV cyclophosphamide (15 mg/kg
SECTION 12
1082
Allergy, Clinical Immunology, and Rheumatology
 
every 2 weeks for 3 doses then every 3 weeks thereafter) can also 
induce remission but may be associated with a higher relapse rate. 
Treatment should be limited to 3–6 months followed by transition 
to maintenance therapy with methotrexate or azathioprine.
• Rituximab 375 (mg/m2)/week for 4 weeks. As effective as cyclophos-
phamide to induce remission of granulomatosis with polyangiitis 
(Wegener’s) or microscopic polyangiitis. Relapse rate, long-term 
safety, repeat dosing frequency are unclear. 
• Methotrexate in weekly doses up to 25 mg/week may be used to 
induce remission in granulomatosis with polyangiitis (Wegener’s) 
or microscopic polyangiitis pts who do not have immediately life-
threatening disease or cannot tolerate cyclophosphamide. It may 
also be used for maintaining remission after induction with cyclo-
phosphamide. Cannot be used in renal insufficiency or chronic 
liver disease.
• Azathioprine 2 (mg/kg)/d. Less effective in treating active disease 
but useful in maintaining remission after induction with 
cyclophosphamide.
• Mycophenolate mofetil 1000 mg bid. Less effective than azathio-
prine to maintain remission but an option in pts who cannot take or 
who have relapsed with methotrexate and azathioprine.
• Plasmapheresis may have an adjunctive role in rapidly progressive 
glomerulonephritis.
For a more detailed discussion, see Langford CA, Fauci AS: The 
Vasculitis Syndromes, Chap. 326, p. 2785; in HPIM-18.
CHAPTER 171
Ankylosing Spondylitis
� DEFINITION
Chronic and progressive inflammatory disease of the axial skeleton with 
sacroiliitis (usually bilateral) as its hallmark. Peripheral joints and extraar-
ticular structures may also be affected. Most frequently presents in young 
men in second or third decade; strong association with histocompatibility 
antigen HLA-B27.
� CLINICAL MANIFESTATIONS
• Back pain and stiffness—not relieved by lying down, often present at 
night forcing pt to leave bed, worse in the morning, improves with 
activity, insidious onset, duration >3 months (often called symptoms of 
“inflammatory” back pain).
CHAPTER 171
1083
Ankylosing Spondylitis
• Extraaxial arthritis—hip and shoulders 25–35%, other peripheral joint 
involvement up to 30%, usually asymmetric.
• Chest pain—from involvement of thoracic skeleton and muscular insertions.
• Extra/juxtaarticular pain—due to “enthesitis”: inflammation at insertion 
of tendons and ligaments into bone; frequently affects greater trochanter, 
iliac crests, ischial tuberosities, tibial tubercles, heels.
• Extraarticular findings—include acute anterior uveitis in about 20% of 
pts, aortitis, aortic insufficiency, GI inflammation, cardiac conduction 
defects, amyloidosis, bilateral upper lobe pulmonary fibrosis.
• Constitutional symptoms—fever, fatigue, weight loss may occur.
• Neurologic complications—related to spinal fracture/dislocation (can 
occur with even minor trauma), atlantoaxial subluxation (can lead to 
spinal cord compression), cauda equina syndrome.
� PHYSICAL EXAMINATION
• Tenderness over involved joints
• Diminished chest expansion
• Diminished anterior flexion of lumbar spine (Schober test)
� EVALUATION
• Erythrocyte sedimentation rate (ESR) and C-reactive protein elevated in 
majority.
• Mild anemia.
• Rheumatoid factor and ANA negative.
• HLA-B27 may be helpful in pts with inflammatory back Sx but negative 
x-rays.
• Radiographs: early may be normal. Sacroiliac joints: usually symmetric; 
bony erosions with “pseudowidening” followed by fibrosis and ankylosis. 
Spine: squaring of vertebrae; syndesmophytes; ossification of annulus 
fibrosis and anterior longitudinal ligament causing “bamboo spine.” Sites 
of enthesitis may ossify and be visible on x-ray. MRI is procedure of 
choice when plain radiographs do not reveal sacroiliac abnormalities and 
can show early intraarticular inflammation, cartilage changes, and bone 
marrow edema.
� DIAGNOSIS (TABLE 171-1)
Differential Diagnosis
Spondyloarthropathy associated with reactive arthritis, psoriatic arthritis, 
enteropathic arthritis (Table 171-2). Diffuse idiopathic skeletal hyperostosis.
Ankylosing Spondylitis
TREATMENT
• Exercise program to maintain posture and mobility is important.
• TNF modulatory agents (etanercept, infliximab, adalimumab, 
golimumab) have been found to suppress disease activity and 
improve function.
• NSAIDs (e.g., indomethacin 75 mg slow-release daily or bid) useful 
in most pts.
SECTION 12
1084
Allergy, Clinical Immunology, and Rheumatology
TABLE 171-1  ASAS CRITERIA FOR CLASSIFICATION OF AXIAL 
SPONDYLOARTHRITIS (TO BE APPLIED FOR PATIENTS WITH 
BACK PAIN ≥3 MONTHS AND AGE OF ONSET <45 YEARS)a
Sacroiliitis on Imaging Plus 
≥1 SpA Feature
or
HLA-B27 Plus ≥ 2 Other SpA 
Features
Sacroiliitis on imaging
SpA features
•  Active (acute) inflammation on 
MRI highly suggestive of SpA-
associated sacroiliitisb
• Inflammatory back paind
• Arthritise
• Enthesitis (heel)f
and/or
• Anterior uveitisg
•  Definite radiographic sacroili-
itis according to modified New 
York criteriac
• Dactylitise
• Psoriasise
•  Crohn’s disease or ulcerative colitise
• Good response to NSAIDsh
• Family history of SpAi
• HLA-B27
• Elevated CRPj
aSensitivity 83%, specificity 84%. The imaging arm (sacroiliitis) alone has a sensitivity of 66% 
and a specificity of 97%.
bBone marrow edema and/or osteitis on short tau inversion recovery (STIR) or gadolinium-
enhanced T1 image.
cBilateral grade ≥2 or unilateral grade 3 or 4.
dSee text for criteria.
ePast or present, diagnosed by a physician.
fPast or present pain or tenderness on examination at calcaneus insertion of Achilles tendon 
or plantar fascia.
gPast or present, confirmed by an ophthalmologist.
hSubstantial relief of back pain at 24–48 h after a full dose of NSAID.
iFirst- or second-degree relatives with ankylosing spondylitis (AS), psoriasis, uveitis, reactive 
arthritis (ReA), or inflammatory bowel disease (IBD).
jAfter exclusion of other causes of elevated CRP.
Abbreviations: ASAS, Assessment of Spondyloarthritis International Society; CRP, C-reactive 
protein; NSAIDs, nonsteroidal anti-inflammatory drugs; SpA, spondyloarthritis.
Source: From M Rudwaleit et al: Ann Rheum Dis 68:777, 2009. Copyright 2009, with permis-
sion from BMJ Publishing Group Ltd.
• Sulfasalazine 2–3 g/d is of modest benefit, primarily for peripheral 
arthritis.
• Methotrexate, widely used but has not been of proven benefit.
• No documented therapeutic role for systemic glucocorticoids.
• Intraarticular glucocorticoids for persistent enthesitis or peripheral 
synovitis; ocular glucocorticoids for uveitis with systemic immuno-
suppression required in some cases; surgery for severely affected or 
deformed joints.
CHAPTER 172
1085
Psoriatic Arthritis
TABLE 171-2  EUROPEAN SPONDYLOARTHROPATHY STUDY GROUP (ESSG) 
CRITERIA FOR SPONDYLOARTHRITISa
Inflammatory 
Back Painb
or
Synovitis 
• Asymmetric or
• Predominantly in Lower Extremities
and
One or more of the following: 
• Family history of SpAb
• Psoriasisb
• Crohn’s disease or ulcerative colitisc
•  Nongonococcal urethritis, cervicitis, or acute diarrhea within 1 month before 
arthritis
• Alternating buttock paind
• Enthesitisb
• Radiographic sacroiliitisb
aSensitivity >85%, specificity >85%.
bSee definition in Table 171-1.
cPast or present, diagnosed by a physician and confirmed by endoscopy or radiography.
dPast or present pain alternating between the right and left gluteal regions. SpA, 
spondyloarthritis.
Sources: From M Dougados et al; J Sieper J et al. Copyright 2009, with permission from BMJ 
Publishing Group Ltd.
For a more detailed discussion, see Taurog JD: The 
Spondyloarthritides, Chap. 325, p. 2774, in HPIM-18.
CHAPTER 172
Psoriatic Arthritis
� DEFINITION
Psoriatic arthritis is a chronic inflammatory arthritis that affects 5–30% of per-
sons with psoriasis. Some pts, especially those with spondylitis, will carry the 
HLA-B27 histocompatibility antigen. Onset of psoriasis usually precedes devel-
opment of joint disease; approximately 15–20% of pts develop arthritis prior to 
onset of skin disease. Nail changes are seen in 90% of pts with psoriatic arthritis.
� PATTERNS OF JOINT INVOLVEMENT
There are 5 patterns of joint involvement in psoriatic arthritis.
• Asymmetric oligoarthritis: often involves distal interphalangeal/
proximal interphalangeal (DIP/PIP) joints of hands and feet, knees, 
SECTION 12
1086
Allergy, Clinical Immunology, and Rheumatology
wrists, ankles; “sausage digits” may be present, reflecting tendon sheath 
inflammation.
• Symmetric polyarthritis (40%): resembles rheumatoid arthritis except 
rheumatoid factor is negative, absence of rheumatoid nodules.
• Predominantly DIP joint involvement (15%): high frequency of associa-
tion with psoriatic nail changes.
• “Arthritis mutilans” (3–5%): aggressive, destructive form of arthritis with 
severe joint deformities and bony dissolution.
• Spondylitis and/or sacroiliitis: axial involvement is present in 20–40% of 
pts with psoriatic arthritis; may occur in absence of peripheral arthritis.
� EVALUATION
• Negative tests for rheumatoid factor.
• Hypoproliferative anemia, elevated erythrocyte sedimentation rate (ESR).
• Hyperuricemia may be present.
• HIV infection should be suspected in fulminant disease.
• Inflammatory synovial fluid and biopsy without specific findings.
• Radiographic features include erosion at joint margin, bony ankylosis, tuft 
resorption of terminal phalanges, “pencil-in-cup” deformity (bone prolifera-
tion at base of distal phalanx with tapering of proximal phalanx), axial skel-
eton with asymmetric sacroiliitis, asymmetric nonmarginal syndesmophytes.
TABLE 172-1  THE CASPAR (CLASSIFICATION CRITERIA FOR PSORIATIC 
ARTHRITIS) CRITERIAa
To meet the CASPAR criteria, a pt must have inflammatory articular 
disease (joint, spine, or entheseal) with ≥3 points from any of the 
following five categories:
1. Evidence of current psoriasis,b, c a personal history of psoriasis, or a 
family history of psoriasisd
2. Typical psoriatic nail dystrophye observed on current physical 
examination
3. A negative test result for rheumatoid factor
4. Either current dactylitisf or a history of dactylitis recorded by a 
rheumatologist
5. Radiographic evidence of juxtaarticular new bone formationg in the 
hand or foot
aSpecificity of 99% and sensitivity of 91%.
bCurrent psoriasis is assigned 2 points; all other features are assigned 1 point.
cPsoriatic skin or scalp disease present at the time of examination, as judged by a rheumatolo-
gist or dermatologist.
dHistory of psoriasis in a first- or second-degree relative.
eOnycholysis, pitting, or hyperkeratosis.
fSwelling of an entire digit.
gIll-defined ossification near joint margins, excluding osteophyte formation.
Source: From Taylor W et al: Classification criteria for psoriatic arthritis. Development of new 
criteria from a large international study. Arthritis Rheum, 54:2665, 2006.
CHAPTER 173
1087
Reactive Arthritis
� DIAGNOSIS (TABLE 172-1)
Psoriatic Arthritis
TREATMENT
• Coordinated therapy is directed at the skin and joints.
• Pt education, physical and occupational therapy.
• TNF modulatory agents (etanercept, infliximab, adalimumab, goli-
mumab) can improve skin and joint disease and delay radiographic 
progression.
• Alefacept in combination with methotrexate can benefit skin and 
joint disease.
• NSAIDs.
• Intraarticular steroid injections—useful in some settings. Systemic 
glucocorticoids should rarely be used as may induce rebound flare 
of skin disease upon tapering.
• Efficacy of gold salts and antimalarials controversial.
• Methotrexate 15–25 mg/week and sulfasalazine 2–3 g/d have clini-
cal efficacy but do not halt joint erosion.
• Leflunomide may be of benefit for skin and joint disease.
For a more detailed discussion, see Taurog JD: The 
Spondyloarthritides, Chap. 325, p. 2774, in HPIM-18.
CHAPTER 173
Reactive Arthritis
� DEFINITION
Reactive arthritis refers to acute nonpurulent arthritis complicating an 
infection elsewhere in the body. The term has been used primarily to refer 
to spondyloarthritides following enteric or urogenital infections occurring 
predominantly in HLA-B27-positive individuals. 
� PATHOGENESIS
Up to 85% of pts possess the HLA-B27 alloantigen. It is thought that in 
individuals with appropriate genetic background, reactive arthritis may be 
triggered by an enteric infection with any of several Shigella, Salmonella, 
Yersinia, and Campylobacter species; by genitourinary infection with 
Chlamydia trachomatis; and possibly by other agents.
� CLINICAL MANIFESTATIONS
The male:female ratio following enteric infection is 1:1; however, genito
 urinary-acquired reactive arthritis is predominantly seen in young males. 
SECTION 12
1088
Allergy, Clinical Immunology, and Rheumatology
In a majority of cases, Hx will elicit Sx of genitourinary or enteric infection 
1–4 weeks prior to onset of other features.
Constitutional—fatigue, malaise, fever, weight loss.
Arthritis—usually acute, asymmetric, oligoarticular, involving predomi-
nantly lower extremities; sacroiliitis may occur.
Enthesitis—inflammation at insertion of tendons and ligaments into bone; dac-
tylitis or “sausage digit,” plantar fasciitis, and Achilles tendinitis are common.
Ocular features—conjunctivitis, usually minimal; uveitis, keratitis, and optic 
neuritis rarely present.
Urethritis—discharge intermittent and may be asymptomatic.
Other urogenital manifestations—prostatitis, cervicitis, salpingitis.
Mucocutaneous lesions—painless lesions on glans penis (circinate balanitis) and 
oral mucosa in approximately a third of pts; keratoderma blennorrhagica: cuta-
neous vesicles that become hyperkeratotic, most common on soles and palms.
Uncommon manifestations—pleuropericarditis, aortic regurgitation, neuro-
logic manifestations, secondary amyloidosis.
Reactive arthritis is associated with and may be the presenting sign and 
Sx of HIV.
� EVALUATION
• Pursuit of triggering infection by culture, serology, or molecular meth-
ods as clinically suggested.
• Rheumatoid factor and ANA negative.
• Mild anemia, leukocytosis, elevated ESR may be seen.
• HLA-B27 may be helpful in atypical cases.
• HIV screening should be performed in all pts.
• Synovial fluid analysis—often very inflammatory; negative for crystals or 
infection.
• Radiographs—erosions may be seen with new periosteal bone formation, 
ossification of entheses, sacroiliitis (often unilateral).
� DIFFERENTIAL DIAGNOSIS
Includes septic arthritis (gram +/−), gonococcal arthritis, crystalline arthri-
tis, psoriatic arthritis.
Reactive Arthritis
TREATMENT
• Controlled trials have failed to demonstrate any benefit of antibiot-
ics in reactive arthritis. Prompt antibiotic treatment of acute chla-
mydial urethritis may prevent subsequent reactive arthritis.
• NSAIDs (e.g., indomethacin 25–50 mg PO tid) benefit most pts.
• Intra-articular glucocorticoids.
• Sulfasalazine up to 3 g/d in divided doses may help some pts with 
persistent arthritis.
• Cytotoxic therapy, such as azathioprine [1–2 (mg/kg)/d] or metho-
trexate (7.5–15 mg/week) may be considered for debilitating disease 
refractory to other modalities; contraindicated in HIV disease.
CHAPTER 174
1089
Osteoarthritis
• Anti-TNF agents can be considered in severe chronic cases.
• Uveitis may require therapy with ocular or systemic glucocorticoids.
� OUTCOME
Prognosis is variable; 30–60% will have recurrent or sustained disease, with 
15–25% developing permanent disability.
For a more detailed discussion, see Taurog JD: The 
Spondyloarthritides, Chap. 325, p. 2774, in HPIM-18.
CHAPTER 174
Osteoarthritis
� DEFINITION
Osteoarthritis (OA) is a disorder characterized by progressive joint failure 
in which all structures of the joint have undergone pathologic change. The 
pathologic sine qua non of OA is hyaline articular cartilage loss accompa-
nied by increasing thickness and sclerosis of the subchondral bone plate, 
outgrowth of osteophytes at the joint margin, stretching of the articular 
capsule, and weakness of the muscles bridging the joint. There are numer-
ous pathways that lead to OA, but the initial step is often joint injury in the 
setting of a failure of protective mechanisms.
� EPIDEMIOLOGY
OA is the most common type of arthritis. The prevalence of OA correlates 
strikingly with age, and it is much more common in women than in men. 
Joint vulnerability and joint loading are the two major risk factors contrib-
uting to OA. These are influenced by factors that include age, female sex, 
race, genetic factors, nutritional factors, joint trauma, previous damage, 
malalignment, proprioceptive deficiencies, and obesity.
� PATHOGENESIS
The earliest changes of OA may begin in cartilage. The two major compo-
nents of cartilage are type 2 collagen, which provides tensile strength, and 
aggrecan, a proteoglycan. OA cartilage is characterized by gradual depletion 
of aggrecan, unfurling of the collagen matrix, and loss of type 2 collagen, 
which leads to increased vulnerability.
� CLINICAL MANIFESTATIONS
OA can affect almost any joint but usually occurs in weight-bearing and fre-
quently used joints such as the knee, hip, spine, and hands. The hand joints 
that are typically affected are the DIP, PIP, or first carpometacarpal (thumb 
base); metacarpophalangeal joint involvement is rare.
SECTION 12
1090
Allergy, Clinical Immunology, and Rheumatology
Symptoms
• Use-related pain affecting one or a few joints (rest and nocturnal pain 
less common)
• Stiffness after rest or in morning may occur but is usually brief (<30 min)
• Loss of joint movement or functional limitation
• Joint instability
• Joint deformity
• Joint crepitation (“crackling”)
Physical Examination
• Chronic monarthritis or asymmetric oligo/polyarthritis
• Firm or “bony” swellings of the joint margins, e.g., Heberden’s nodes 
(hand DIP) or Bouchard’s nodes (hand PIP)
• Mild synovitis with a cool effusion can occur but is uncommon
• Crepitance—audible creaking or crackling of joint on passive or active 
movement
• Deformity, e.g., OA of knee may involve medial, lateral, or patellofemoral 
compartments resulting in varus or valgus deformities
• Restriction of movement, e.g., limitation of internal rotation of hip
• Objective neurologic abnormalities may be seen with spine involvement 
(may affect intervertebral disks, apophyseal joints, and paraspinal ligaments)
� EVALUATION
• Routine lab work usually normal.
• ESR usually normal but may be elevated in pts who have synovitis.
• Rheumatoid factor, ANA studies negative.
• Joint fluid is straw-colored with good viscosity; fluid WBCs <1000/μL; 
of value in ruling out crystal-induced arthritis, inflammatory arthritis, or 
infection.
• Radiographs may be normal at first but as disease progresses may show joint 
space narrowing, subchondral bone sclerosis, subchondral cysts, and osteo-
phytes. Erosions are distinct from those of rheumatoid and psoriatic arthritis 
as they occur subchondrally along the central portion of the joint surface.
� DIAGNOSIS
Usually established on basis of pattern of joint involvement. Radiographic 
features, normal laboratory tests, and synovial fluid findings can be helpful 
if signs suggest an inflammatory arthritis.
Differential Diagnosis 
Osteonecrosis, Charcot joint, rheumatoid arthritis, psoriatic arthritis, 
crystal-induced arthritides.
Osteoarthritis
TREATMENT
• Treatment goal—alleviate pain and minimize loss of physical function.
• Nonpharmacotherapy strategies aimed at altering loading across the 
painful joint—include pt education, weight reduction, appropriate use 
of cane and other supports, isometric exercises to strengthen muscles 
around affected joints, bracing/orthotics to correct malalignment.
• Topical capsaicin cream may help relieve hand or knee pain.
CHAPTER 175
1091
Gout, Pseudogout, and Related Diseases 
• Acetaminophen, salicylates, NSAIDs, COX-2 inhibitors—must 
weigh individual risks and benefits.
• Tramadol—may be considered in pts whose symptoms are inad-
equately controlled with NSAIDs; as it is a synthetic opioid agonist, 
habituation is a potential concern.
• Intraarticular glucocorticoids—may provide symptomatic relief but 
typically short-lived.
• Intraarticular hyaluronan—can be given for symptomatic knee and 
hip OA, but it is controversial whether it has efficacy beyond placebo.
• Glucosamine and chondroitin—although widely sold, is not FDA 
approved for use in OA. Proof of efficacy has not been established.
• Systemic glucocorticoids have no place in the treatment of OA.
• Arthroscopic debridement and lavage—can be helpful in the sub-
group of pts with knee OA in whom disruption of the meniscus 
causes mechanical symptoms such as locking or buckling. In pts 
who do not have mechanical symptoms, this modality appears to be 
of no greater benefit than placebo.
• Joint replacement surgery may be considered in pts with advanced 
OA who have intractable pain and loss of function in whom aggres-
sive medical management has failed.
For a more detailed discussion, see Felson DT: Osteoarthritis, 
Chap. 332, p. 2828, in HPIM-18.
CHAPTER 175
Gout, Pseudogout, and 
Related Diseases
GOUT
� DEFINITION
Gout is a metabolic disease most often affecting middle-aged to elderly men 
and postmenopausal women. Hyperuricemia is the biologic hallmark of gout. 
When present, plasma and extracellular fluids become supersaturated with 
uric acid, which, under the right conditions, may crystallize and result in a 
spectrum of clinical manifestations that may occur singly or in combination.
� PATHOGENESIS
Uric acid is the end product of purine nucleotide degradation; its production 
is closely linked to pathways of purine metabolism, with the intracellular 
concentration of 5-phosphoribosyl-1-pyrophosphate (PRPP) being the 
major determinant of the rate of uric acid biosynthesis. Uric acid is excreted 
SECTION 12
1092
Allergy, Clinical Immunology, and Rheumatology
primarily by the kidney through mechanisms of glomerular filtration, tubu-
lar secretion, and reabsorption. Hyperuricemia may thus arise in a wide 
range of settings that cause overproduction or reduced excretion of uric acid 
or a combination of the two (Table 359-2, p. 3183, HPIM-18).
Acute Gouty Arthritis 
Monosodium urate (MSU) crystals present in the joint are phagocytosed 
by leukocytes; release of inflammatory mediators and lysosomal enzymes 
leads to recruitment of additional phagocytes into the joint and to synovial 
inflammation.
� CLINICAL MANIFESTATIONS
Acute arthritis—most frequent early clinical manifestation of gout. Usually 
initially affects one joint, but may be polyarticular in later episodes. The 
first metatarsophalangeal joint (podagra) is often involved. Acute gout 
frequently begins at night with dramatic pain, swelling, warmth, and 
tenderness. Attack will generally subside spontaneously after 3–10 days. 
Although some pts may have a single attack, most pts have recurrent 
episodes with intervals of varying length with no symptoms between 
attacks. Acute gout may be precipitated by dietary excess, trauma, surgery, 
excessive ethanol ingestion, hypouricemic therapy, and serious medical 
illnesses such as myocardial infarction and stroke.
Chronic arthritis—a proportion of gout pts may have a chronic nonsymmet-
ric synovitis; may rarely be the only manifestation. Can also present with 
periarticular tophi (aggregates of MSU crystals surrounded by a giant cell 
inflammatory reaction). Occurs in the setting of long-standing gout.
Extraarticular tophi—often occur in olecranon bursa, helix and anthelix of 
ears, ulnar surface of forearm, Achilles tendon.
Tenosynovitis
Urate nephropathy—deposition of MSU crystals in renal interstitium and 
pyramids. Can cause chronic renal insufficiency.
Acute uric acid nephropathy—reversible cause of acute renal failure due to 
precipitation of urate in the tubules; pts receiving cytotoxic treatment for 
neoplastic disease are at risk.
Uric acid nephrolithiasis—responsible for 10% of renal stones in the United 
States.
� DIAGNOSIS
• Synovial fluid analysis—should be performed to confirm gout even when 
clinical appearance is strongly suggestive; joint aspiration and demonstra-
tion of both intracellular and extracellular needle-shaped negatively bire-
fringent MSU crystals by polarizing microscopy. Gram stain and culture 
should be performed on all fluid to rule out infection. MSU crystals can 
also be demonstrated in chronically involved joints or tophaceous deposits.
• Serum uric acid—normal levels do not rule out gout.
• Urine uric acid—excretion of >800 mg/d on regular diet in the absence 
of drugs suggests overproduction.
• Screening for risk factors or sequelae—urinalysis; serum creatinine, liver 
function tests, glucose and lipids; complete blood counts.
CHAPTER 175
1093
Gout, Pseudogout, and Related Diseases 
• If overproduction is suspected, measurement of erythrocyte hypoxan-
thine guanine phosphoribosyl transferase (HGPRT) and PRPP levels 
may be indicated.
• Joint x-rays—may demonstrate cystic changes, erosions with sclerotic 
margins in advanced chronic arthritis.
• If renal stones suspected, abdominal flat plate (stones often radiolucent), 
possibly IVP.
• Chemical analysis of renal stones.
Differential Diagnosis
Septic arthritis, reactive arthritis, calcium pyrophosphate dihydrate (CPPD)
deposition disease, rheumatoid arthritis.
Gout
TREATMENT
ASYMPTOMATIC HYPERURICEMIA As only ~5% of hyperuricemic pts 
develop gout, treatment of asymptomatic hyperuricemia is not indicated. 
Exceptions are pts about to receive cytotoxic therapy for neoplasms.
ACUTE GOUTY ARTHRITIS Treatment is given for symptomatic relief 
only since attacks are self-limited and will resolve spontaneously. 
Toxicity of therapy must be considered in each pt.
• Analgesia
• NSAIDs—Rx of choice when not contraindicated.
• Colchicine—generally only effective within first 24 h of attack; 
overdose has potentially life-threatening side effects; use is con-
traindicated in pts with renal insufficiency, cytopenias, LFTs >2 × 
normal, sepsis. PO—0.6 mg qh until pt improves, has GI side effects, 
or maximal dose of 4 mg is reached. 
• Intraarticular glucocorticoids—septic arthritis must be ruled out 
prior to injection.
• Systemic glucocorticoids—brief taper may be considered in pts with 
a polyarticular gouty attack for whom other modalities are contrain-
dicated and where articular or systemic infection has been ruled out.
URIC ACID–LOWERING AGENTS Indications for initiating uric acid–
lowering therapy include recurrent frequent acute gouty arthritis, polyar-
ticular gouty arthritis, tophaceous gout, renal stones, prophylaxis during 
cytotoxic therapy. Should not start during an acute attack. Initiation of 
such therapy can precipitate an acute flare; consider concomitant PO 
colchicine 0.6 mg qd until uric acid <5.0 mg/dL, then discontinue.
1. Xanthine oxidase inhibitors (allopurinol, febuxostat): Decrease uric 
acid synthesis. Allopurinol must be dose-reduced in renal insuf-
ficiency. Both have side effects and drug interactions.
2. Uricosuric drugs (probenecid, sulfinpyrazone): Increases uric acid 
excretion by inhibiting its tubular reabsorption; ineffective in renal 
insufficiency; should not be used in these settings: age >60, renal 
stones, tophi, increased urinary uric acid excretion, prophylaxis 
during cytotoxic therapy.
SECTION 12
1094
Allergy, Clinical Immunology, and Rheumatology
3. Pegloticase: Recombinant uricase that lowers uric acid by oxidizing 
urate to allantoin. Risk of severe infusion reactions. Should be used 
only in selected pts with chronic tophaceous gout refractory to 
conventional therapy. 
CALCIUM PYROPHOSPHATE DIHYDRATE (CPPD) DEPOSITION DISEASE 
(PSEUDOGOUT)
� DEFINITION AND PATHOGENESIS
CPPD disease is characterized by acute and chronic inflammatory joint disease, 
usually affecting older individuals. The knee and other large joints are most 
commonly affected. Calcium deposits in articular cartilage (chondrocalcinosis) 
may be seen radiographically; these are not always associated with symptoms.
CPPD is most often idiopathic but can be associated with other condi-
tions (Table 175-1).
Crystals are thought not to form in synovial fluid but are probably shed 
from articular cartilage into joint space, where they are phagocytosed by 
neutrophils and incite an inflammatory response.
� CLINICAL MANIFESTATIONS
• Acute CPPD arthritis (“pseudogout”)—knee is most frequently involved, 
but polyarticular in two-thirds of cases; involved joint is erythematous, 
swollen, warm, and painful. Most pts have evidence of chondrocalcinosis.
• Chronic arthropathy—progressive degenerative changes in multiple joints; 
can resemble osteoarthritis (OA). Joint distribution may suggest CPPD 
with common sites including knee, wrist, MCP, hips, and shoulders.
• Symmetric proliferative synovitis—seen in familial forms with early onset; 
clinically similar to RA.
TABLE 175-1  CONDITIONS ASSOCIATED WITH CPPD DEPOSITION DISEASE
Aging
Disease-associated
Primary hyperparathyroidism
Hemochromatosis
Hypophosphatasia
Hypomagnesemia
Chronic gout
Postmeniscectomy
Epiphyseal dysplasias
Hereditary: Slovakian-Hungarian, Spanish, Spanish-American (Argentinian,a
Colombian, and Chilean), French,a Swedish, Dutch, Canadian, Mexican-American, 
Italian-American,a German-American, Japanese, Tunisian, Jewish, Englisha
aMutations in the ANKH gene.
CHAPTER 175
1095
Gout, Pseudogout, and Related Diseases 
• Intervertebral disk and ligament calcification
• Spinal stenosis
� DIAGNOSIS
• Synovial fluid analysis—demonstration of CPPD crystals that appear as 
short blunt rods, rhomboids, and cuboids with weak positive birefrin-
gence by polarizing microscopy
• Radiographs may demonstrate chondrocalcinosis and degenerative 
changes (joint space narrowing, subchondral sclerosis/cysts).
• Secondary causes of CPPD deposition disease should be considered in 
pts <50 years old.
Differential Diagnosis 
OA, RA, gout, septic arthritis.
Pseudogout
TREATMENT
• NSAIDs
• Intraarticular injection of glucocorticoids
• Colchicine (variably effective)
CALCIUM APATITE DEPOSITION DISEASE
Apatite is the primary mineral of normal bone and teeth. Abnormal accu-
mulation can occur in a wide range of clinical settings (Table 175-2). Apatite 
TABLE 175-2  CONDITIONS ASSOCIATED WITH CALCIUM APATITE 
DEPOSITION DISEASE
Aging
Osteoarthritis
Hemorrhagic shoulder effusions in the elderly (Milwaukee shoulder)
Destructive arthropathy
Tendinitis, bursitis
Tumoral calcinosis (sporadic cases)
Disease-associated
 Hyperparathyroidism
 Milk-alkali syndrome
 Renal failure/long-term dialysis
  Connective tissue diseases (e.g., systemic sclerosis, idiopathic myositis, SLE)
  Heterotopic calcification following neurologic catastrophes (e.g., stroke, 
spinal cord injury)
Heredity
Bursitis, arthritis
Tumoral calcinosis
Fibrodysplasia ossificans progressiva
Abbreviation: SLE, systemic lupus erythematosus.
SECTION 12
1096
Allergy, Clinical Immunology, and Rheumatology
is an important factor in Milwaukee shoulder, a destructive arthropathy of 
the elderly that occurs in the shoulders and knees. Apatite crystals are small; 
clumps may stain purplish on Wright’s stain and bright red with alizarin red S.
Definitive identification requires electron microscopy or x-ray diffraction 
studies. Radiographic appearance resembles CPPD disease. Treatment: 
NSAIDs, repeated aspiration, and rest of affected joint.
CALCIUM OXALATE DEPOSITION DISEASE
CaOx crystals may be deposited in joints in primary oxalosis (rare) or 
secondary oxalosis (a complication of end-stage renal disease). Clinical syn-
drome similar to gout and CPPD disease. Treatment: marginally effective.
For a more detailed discussion, see Burns CM, Wortmann 
RL: Disorders of Purine and Pyrimidine Metabolism, Chap. 
359, p. 3181; and Schumacher HR, Chen LX: Gout and 
Other Crystal-Associated Arthropathies, Chap. 333, p. 2837, 
in HPIM-18.
CHAPTER 176
Other Musculoskeletal 
Disorders
ENTEROPATHIC ARTHRITIS
Both peripheral and axial arthritis may be associated with the inflammatory 
bowel diseases (IBD) of ulcerative colitis or Crohn’s disease. The arthritis 
can occur after or before the onset of intestinal symptoms. Peripheral 
arthritis is episodic and asymmetric; it most frequently affects knee and 
ankle. Attacks usually subside within several weeks and characteristically 
resolve completely without residual joint damage. Enthesitis (inflammation 
at insertion of tendons and ligaments into bone) can occur with manifesta-
tions of “sausage digit,” Achilles tendinitis, plantar fasciitis. Axial involve-
ment can manifest as spondylitis and/or sacroiliitis (often symmetric). 
Laboratory findings are nonspecific; rheumatoid factor (RF) absent; only 
30–70% HLA-B27 positive; radiographs of peripheral joints usually normal; 
axial involvement is often indistinguishable from ankylosing spondylitis.
Enteropathic Arthritis 
TREATMENT
Directed at underlying IBD; NSAIDs may alleviate joint symptoms 
but can precipitate flares of IBD; sulfasalazine may benefit peripheral 
arthritis; treatment of Crohn’s disease with infliximab or adalimumab 
has improved arthritis.
CHAPTER 176
1097
Other Musculoskeletal Disorders 
� WHIPPLE’S DISEASE 
Characterized by arthritis in up to 75% of pts that usually precedes appear-
ance of other symptoms. Usually oligo- or polyarticular, symmetric, transient 
but may become chronic. Joint manifestations respond to antibiotic therapy.
NEUROPATHIC JOINT DISEASE
Also known as Charcot’s joint, this is a severe destructive arthropathy that 
occurs in joints deprived of pain and position sense; may occur in diabetic 
neuropathy, tabes dorsalis, syringomyelia, amyloidosis, spinal cord or 
peripheral nerve injury. Distribution depends on the underlying joint dis-
ease. Joint effusions are usually noninflammatory but can be hemorrhagic. 
Radiographs can reveal either bone resorption or new bone formation with 
bone dislocation and fragmentation.
Neuropathic Joint Disease
TREATMENT
Stabilization of joint; surgical fusion may improve function.
RELAPSING POLYCHONDRITIS
An idiopathic disorder characterized by recurrent inflammation of cartilag-
inous structures. Cardinal manifestations include ear and nose involvement 
with floppy ear and saddlenose deformities, inflammation and collapse of 
tracheal and bronchial cartilaginous rings, asymmetric episodic nonde-
forming polyarthritis. Other features can include scleritis, conjunctivitis, 
iritis, keratitis, aortic regurgitation, glomerulonephritis, and other features 
of systemic vasculitis. Onset is frequently abrupt, with the appearance of 
1–2 sites of cartilaginous inflammation. Diagnosis is made clinically and 
may be confirmed by biopsy of affected cartilage.
Relapsing Polychondritis
TREATMENT
Glucocorticoids (prednisone 40–60 mg/d with subsequent taper) may 
suppress acute features and reduce the severity/frequency of recur-
rences. Cytotoxic agents should be reserved for unresponsive disease or 
for pts who require high glucocorticoid doses. When airway obstruc-
tion is severe, tracheostomy is required.
HYPERTROPHIC OSTEOARTHROPATHY
Syndrome consisting of periosteal new bone formation, digital clubbing, and 
arthritis. Most commonly seen in association with lung carcinoma but, also 
occurs with chronic lung or liver disease; congenital heart, lung, or liver dis-
ease in children; and idiopathic and familial forms. Symptoms include burning 
and aching pain most pronounced in distal extremities. Radiographs show 
periosteal thickening with new bone formation of distal ends of long bones.
Hypertrophic Osteoarthropathy 
TREATMENT
Identify and treat associated disorder; aspirin, NSAIDs, other analgesics, 
vagotomy, or percutaneous nerve block may help to relieve symptoms.
SECTION 12
1098
Allergy, Clinical Immunology, and Rheumatology
FIBROMYALGIA
A common disorder characterized by chronic widespread musculo-
skeletal pain, aching, stiffness, paresthesia, disturbed sleep, and easy 
fatigability along with multiple tender points. More common in women 
than in men. Diagnosis is made clinically; evaluation reveals soft tissue 
tender points but no objective joint abnormalities by exam, laboratory, 
or radiograph.
Fibromyalgia
TREATMENT
Pregabalin, duloxetine, and milnacipran have shown benefit for fibro-
myalgia. Benzodiazepines or tricyclics for sleep disorder, local mea-
sures (heat, massage, injection of tender points), NSAIDs.
POLYMYALGIA RHEUMATICA (PMR)
Clinical syndrome characterized by aching and morning stiffness in the 
shoulder girdle, hip girdle, or neck for >1 month, elevated ESR, and rapid 
response to low-dose prednisone (15 mg qd). Rarely occurs before age 50; 
more common in women. PMR can occur in association with giant cell 
(temporal) arteritis, which requires treatment with higher doses of predni-
sone. Evaluation should include a careful history to elicit Sx suggestive of 
giant cell arteritis (Chap. 170); ESR; labs to rule out other processes usually 
include RF, ANA, CBC, CPK, serum protein electrophoresis; and renal, 
hepatic, and thyroid function tests.
PMR
TREATMENT
Pts rapidly improve on prednisone, 10–20 mg qd, but may require 
treatment over months to years.
OSTEONECROSIS (AVASCULAR NECROSIS)
Caused by death of cellular elements of bone, believed to be due to impair-
ment in blood supply. Frequent associations include glucocorticoid treat-
ment, connective tissue disease, trauma, sickle cell disease, embolization, 
alcohol use, and HIV disease. Commonly involved sites include femoral and 
humeral heads, femoral condyles, proximal tibia. Hip disease is bilateral in 
>50% of cases. Clinical presentation is usually the abrupt onset of articular 
pain. Early changes are not visible on plain radiograph and are best seen by 
MRI; later stages demonstrate bone collapse (“crescent sign”), flattening of 
articular surface with joint space loss.
Osteonecrosis
TREATMENT
Limited weight-bearing of unclear benefit; NSAIDs for Sx. Surgical 
procedures to enhance blood flow may be considered in early-stage 
disease but are of controversial efficacy; joint replacement may be nec-
essary in late-stage disease for pain unresponsive to other measures.
CHAPTER 176
1099
Other Musculoskeletal Disorders 
PERIARTICULAR DISORDERS
� BURSITIS 
Inflammation of the thin-walled bursal sac surrounding tendons and 
muscles over bony prominences. The subacromial and greater trochanteric 
bursae are most commonly involved.
Bursitis
TREATMENT
Prevention of aggravating conditions, rest, NSAIDs, and local gluco-
corticoid injections.
� TENDINITIS 
May involve virtually any tendon but frequently affects tendons of the 
rotator cuff around shoulder, especially the supraspinatus. Pain is dull 
and aching but becomes acute and sharp when tendon is squeezed below 
acromion.
Tendinitis
TREATMENT
NSAIDs, glucocorticoid injection, and physical therapy may be ben-
eficial. The rotator cuff tendons or biceps tendon may rupture acutely, 
frequently requiring surgical repair.
� CALCIFIC TENDINITIS 
Results from deposition of calcium salts in tendon, usually supraspinatus. 
The resulting pain may be sudden and severe.
� ADHESIVE CAPSULITIS (“FROZEN SHOULDER”) 
Results from conditions that enforce prolonged immobility of shoulder 
joint. Shoulder is painful and tender to palpation, and both active and pas-
sive range of motion is restricted.
Adhesive Capsulitis
TREATMENT
Spontaneous improvement may occur; NSAIDs, local injections of 
glucocorticoids, and physical therapy may be helpful.
For a more detailed discussion, see Taurog JD: The 
Spondyloarthritides, Chap. 325, p. 2774; Crofford LJ: 
Fibromyalgia, Chap. 335, p. 2849; Langford CA, Mandell 
BF: Arthritis Associated With Systemic Disease, and Other 
Arthritides, Chap. 336, p. 2852; Langford CA, Gilliland BC: 
Periarticular Disorders of the Extremities, Chap. 337, p. 2860; 
and Langford CA: Relapsing Polychondritis, Chap. 328, p. 2802, 
in HPIM-18.
SECTION 12
1100
Allergy, Clinical Immunology, and Rheumatology
CHAPTER 177
Sarcoidosis
� DEFINITION
An inflammatory multisystem disease characterized by the presence of 
noncaseating granulomas of unknown etiology.
� PATHOPHYSIOLOGY
The cause of sarcoid is unknown, and current evidence suggests that the 
triggering of an inflammatory response by an unidentified antigen in a 
genetically susceptible host is involved. The granuloma is the pathologic 
hallmark of sarcoidosis. The initial inflammatory response is an influx of 
CD4+ (helper) T cells and an accumulation of activated monocytes. This 
leads to an increased release of cytokines and the formation of a granuloma. 
The granuloma may resolve or lead to chronic disease, including fibrosis.
� CLINICAL MANIFESTATIONS
In 10–20% of cases, sarcoidosis may first be detected as asymptomatic hilar 
adenopathy. Sarcoid manifests clinically in organs where it affects function 
or where it is readily observed. Löfgren’s syndrome consists of hilar adenopa-
thy, erythema nodosum, acute arthritis presenting in one or both ankles 
spreading to involve other joints, and uveitis.
Disease manifestations of sarcoid include:
• Lung—most commonly involved organ; >90% of pts with sarcoidosis 
will have abnormal CXR sometime during course. Features include hilar 
adenopathy, alveolitis, interstitial pneumonitis; airways may be involved and 
cause obstruction to airflow; pleural disease and hemoptysis are uncommon.
• Lymph nodes—intrathoracic nodes enlarged in 75–90% of pts. Extrathoracic 
lymph nodes affected in 15%.
• Skin—25% will have skin involvement; lesions include erythema nodo-
sum, plaques, maculopapular eruptions, subcutaneous nodules, and lupus 
pernio (indurated blue-purple shiny lesions on face, fingers, and knees).
• Eye—uveitis in 30%; may progress to blindness.
• Upper respiratory tract—nasal mucosa involved in up to 20%, larynx 5%.
• Bone marrow and spleen—mild anemia and thrombocytopenia may occur.
• Liver—involved on biopsy in 60–90%; rarely important clinically.
• Kidney—parenchymal disease <5%, nephrolithiasis secondary to abnor-
malities of calcium metabolism.
• Nervous system—occurs in 5–10%; cranial/peripheral neuropathy, chronic 
meningitis, pituitary involvement, space-occupying lesions, seizures.
• Heart—disturbances of rhythm and/or contractility, pericarditis.
• Musculoskeletal—bone lesions involving cortical bone seen in 3–13%, 
consisting of cysts in areas of expanded bone or lattice-like changes; 
dactylitis; joint involvement occurs in 25–50% with chronic mono- or 
oligoarthritis of knee, ankle, proximal interphalangeal joints.
• Constitutional symptoms—fever, weight loss, anorexia, fatigue.
• Other organ systems—endocrine/reproductive, exocrine glands, GI.
CHAPTER 177
1101
Sarcoidosis
� EVALUATION
• Hx and physical exam to rule out exposures and other causes of intersti-
tial lung disease.
• CBC, Ca2+, LFTs, ACE, PPD, and control skin tests.
• CXR and/or chest CT, ECG, PFTs.
• Biopsy of lung or other affected organ.
• Bronchoalveolar lavage and gallium scan of lungs may help decide when 
treatment is indicated and may help to follow therapy; however, these are 
not uniformly accepted.
� DIAGNOSIS
Made on basis of clinical, radiographic, and histologic findings. Biopsy of 
lung or other affected organs is mandatory to establish diagnosis before 
starting therapy. Transbronchial lung biopsy usually adequate to make the 
diagnosis. No blood findings are diagnostic. Differential diagnosis includes 
neoplasms, infections including HIV, other granulomatous processes.
Sarcoidosis
TREATMENT
As sarcoidosis may remit spontaneously, treatment is based largely on 
the level of symptoms and extent of organ involvement (Figs. 177-1 and 
177-2). When systemic therapy is indicated, glucocorticoids are the 
mainstay of therapy. Other immunomodulatory agents have been used 
in refractory or severe cases or when prednisone cannot be tapered.
� OUTCOME
Sarcoidosis is usually a self-limited, non-life-threatening disease. Overall, 
50% of pts with sarcoidosis have some permanent organ dysfunction; death 
directly due to disease occurs in 5% of cases usually related to lung, cardiac, 
neurologic, or liver involvement. Respiratory tract abnormalities cause 
most of the morbidity and mortality related to sarcoid.
Acute disease
Minimal to no symptoms
Single organ disease
Symptomatic multiple organs
Abnormalities of 
neurologic, cardiac, 
ocular, calcium
Affecting only: 
anterior eye, localized 
skin, cough
Systemic therapy: 
Glucocorticoids (e.g., 
prednisone)
Yes: consider 
systemic therapy
No: no therapy 
and observe
Yes: try topical 
steroids
No: systemic 
therapy
Taper to <10 mg in less than 6 
months: continue prednisone
Cannot taper to <10 mg in 6 
months or glucocorticoid toxicity
Consider methotrexate, 
hydroxychloroquine, azathioprine
ALGORITHM FOR MANAGEMENT OF SARCOIDOSIS
FIGURE 177-1 The management of acute sarcoidosis is based on level of symptoms 
and extent of organ involvement. In pts with mild symptoms, no therapy may be 
needed unless specified manifestations are noted.
SECTION 12
1102
Allergy, Clinical Immunology, and Rheumatology
MANAGEMENT ALGORITHM OF CHRONIC DISEASE
Chronic disease
Glucocorticoids
tolerated
Glucocorticoids
not tolerated
Glucocorticoids
not effective
Dose <10 mg/d
Continue therapy
Seek alternative
agents
Alternative agents
Methotrexate
Hydroxychloroquine
Azathioprine
Leflunomide
Minocycline
Try alternative agents
If effective, taper off 
glucocorticoids
If not effective, 
consider:
Multiple agents
Infliximab
Cyclophosphamide
Thalidomide
No
Yes
FIGURE 177-2 Approach to chronic disease is based on whether glucocorticoid 
therapy is tolerated.
For a more detailed discussion, see Baughman RP, Lower EE: 
Sarcoidosis, Chap. 329, p. 2805, in HPIM-18.
CHAPTER 178
Amyloidosis
� DEFINITION
Amyloidosis is a term for a group of diseases that are due to the extracel-
lular deposition of insoluble polymeric protein fibrils in organs and tissues. 
Clinical manifestations depend on anatomic distribution and intensity of 
amyloid protein deposition; they range from local deposition with little 
significance to involvement of virtually any organ system with severe patho-
physiologic consequences.
� CLASSIFICATION
Amyloid diseases are defined by the biochemical nature of the protein in 
the fibril deposits and are classified according to whether they are systemic 
or localized, acquired or inherited; they are also classified by their clinical 
patterns. The accepted nomenclature is AX where A indicates amyloidosis 
and X is the protein in the fibril (Table 112-1, p. 945, in HPIM-18).
• AL (immunoglobulin light chains): Primary amyloidosis; most common 
form of systemic amyloidosis; arises from a clonal B cell disorder, usually 
multiple myeloma.
CHAPTER 178
1103
Amyloidosis
• AA (serum amyloid A): Secondary amyloidosis; can occur in associa-
tion with almost any chronic inflammatory state [e.g., RA, SLE, familial 
Mediterranean fever (FMF), Crohn’s disease] or chronic infections.
• AF (familial amyloidoses): number of different types that are dominantly 
transmitted in association with a mutation that enhances protein mis-
folding and fibril formation; most commonly due to transthyretin.
• Aβ2M: composed of β2 microglobulin; occurs in end-stage renal disease 
of long duration.
• Localized or organ-limited amyloidoses: most common form is Aβ 
found in Alzheimer’s disease derived from abnormal proteolytic process-
ing of the amyloid precursor protein.
� CLINICAL MANIFESTATIONS
Clinical features are varied and depend entirely on biochemical nature of 
the fibril protein. Frequent sites of involvement:
• Kidney—seen with AA and AL; proteinuria, nephrosis, azotemia.
• Liver—occurs in AA, AL, and AF; hepatomegaly.
• Skin—characteristic of AL but can be seen in AA; raised waxy papules.
• Heart—common in AL and AF; CHF, cardiomegaly, arrhythmias.
• GI—common in all types; GI obstruction or ulceration, hemorrhage, 
protein loss, diarrhea, macroglossia, disordered esophageal motility.
• Joints—usually AL, frequently with myeloma; periarticular amyloid 
deposits, “shoulder pad sign”: firm amyloid deposits in soft tissue around 
the shoulder, symmetric arthritis of shoulders, wrists, knees, hands.
• Nervous system—prominent in AF; peripheral neuropathy, postural 
hypotension, dementia. Carpal tunnel syndrome may occur in AL 
and Aβ2M.
• Respiratory—lower airways can be affected in AL; localized amyloid can 
cause obstruction along upper airways.
� DIAGNOSIS
Diagnosis relies on the identification of fibrillar deposits in tissues and typ-
ing of the amyloid (Fig. 178-1). Congo red staining of abdominal fat will 
demonstrate amyloid deposits in >80% of pts with systemic amyloid.
� PROGNOSIS
Outcome is variable and depends on type of amyloidosis and organ involve-
ment. Average survival of AL amyloid is ~12 months; prognosis is poor 
when associated with myeloma. Cardiac dysfunction associated with death 
in 75% of pts.
Amyloidosis
TREATMENT
For AL most effective treatment is high-dose IV melphalan followed 
by autologous stem-cell transplantation. Only 50% are eligible for such 
aggressive treatment, and peritransplant mortality is higher than for other 
hematologic diseases because of impaired organ function. In pts who are 
not candidates for hematopoietic cell transplant, cyclic melphalan and glu-
cocorticoids can decrease the plasma cell burden but produce remission
SECTION 12
1104
Allergy, Clinical Immunology, and Rheumatology
in only a few percent of pts with a minimal improvement in survival 
(median, 2 years). Treatment of AA is directed toward controlling the 
underlying inflammatory condition. Colchicine (1–2 mg/d) may pre-
vent acute attacks in FMF and thus may block amyloid deposition. 
Eprodisate slowed the decline of renal function in AA, but had no 
significant effect on progression to end-stage renal disease or risk of 
death. In certain forms of AF, genetic counseling is important and liver 
transplantation is a successful form of therapy.
CLINICAL SUSPICION OF AMYLOIDOSIS
Tissue Biopsy
(Congo red staining of abdominal fat or other tissue)
More invasive biopsy of 
other affected organ
No further work-up
Immunohistochemical 
staining of biopsy
Identify
Diagnosis
Kappa or 
lambda light 
chain
Monoclonal protein in 
serum or urine 
Plasma cell dyscrasia 
in bone marrow 
AL amyloidosis 
(Screen for cardiac, renal, 
hepatic, autonomic 
involvement, and factor X 
deficiency)
Amyloid A 
protein
Underlying chronic 
inflammatory disease
AA amyloidosis
(Screen for renal, 
hepatic involvement)
Transthyretin
Mutant transthyretin 
+/- family history 
Familial ATTR amyloidosis
(Screen for neuropathy, 
cardiomyopathy; screen 
relatives)
Wild-type transthyretin 
(usually males >65, cardiac)
Age-related or senile 
systemic amyloidosis
Negative
Mutant ApoAI, ApoAII, 
fibrinogen, lysozyme, 
gelsolin
Familial amyloidosis of rare type
(Screen for renal, hepatic, GI 
involvement)
+
–
+
–
FIGURE 178-1 Algorithm for the diagnosis of amyloidosis and determination of type: 
Clinical suspicion: unexplained nephropathy, cardiomyopathy, neuropathy, enteropa-
thy, arthropathy, and macroglossia. ApoAI, apolipoprotein AI, ApoAII, apolipoprotein 
AII, GI, gastrointestinal.
For a more detailed discussion, see Seldin DC, Skinner M: 
Amyloidosis, Chap. 112, p. 945, in HPIM-18.
1105
CHAPTER 179
Disorders of the Anterior 
Pituitary and Hypothalamus
The anterior pituitary is often referred to as the “master gland” because, 
together with the hypothalamus, it orchestrates the complex regulatory 
functions of multiple other glands (Fig. 179-1). The anterior pituitary pro-
duces six major hormones: (1) prolactin (PRL); (2) growth hormone (GH); 
(3) adrenocorticotropin hormone (ACTH); (4) luteinizing hormone (LH); 
(5) follicle-stimulating hormone (FSH); and (6) thyroid-stimulating hor-
mone (TSH). Pituitary hormones are secreted in a pulsatile manner, reflect-
ing intermittent stimulation by specific hypothalamic-releasing factors. 
Each of these pituitary hormones elicits specific responses in peripheral tar-
get glands. The hormonal products of these peripheral glands, in turn, exert 
feedback control at the level of the hypothalamus and pituitary to modulate 
pituitary function. Disorders of the pituitary include neoplasms or other 
lesions (granulomas, hemorrhage) that lead to mass effects and clinical 
syndromes due to excess or deficiency of one or more pituitary hormones.
PITUITARY TUMORS
Pituitary adenomas are benign monoclonal tumors that arise from one of 
the five anterior pituitary cell types and may cause clinical effects from 
either overproduction of a pituitary hormone or compressive/destructive 
effects on surrounding structures, including the hypothalamus, pituitary, 
optic chiasm, and cavernous sinus. About one-third of all adenomas are 
clinically nonfunctioning and produce no distinct clinical hypersecretory 
syndrome. Among hormonally functioning neoplasms, tumors secreting 
prolactin are most common (~50%); they have a greater prevalence in 
women than in men. GH- and ACTH-secreting tumors each account for 
about 10–15% of functioning pituitary tumors. Adenomas are classified 
as microadenomas (<10 mm) or macroadenomas (≥10 mm). Pituitary 
adenomas (especially PRL- and GH-producing tumors) may be part of 
genetic familial syndromes such as MEN 1, Carney syndrome, or mutant 
aryl hydrocarbon receptor inhibitor protein (AIP) syndrome. Other entities 
that can present as a sellar mass include craniopharyngiomas, Rathke’s cleft 
cysts, sella chordomas, meningiomas, pituitary metastases, gliomas, and 
granulomatous disease (e.g., histiocytosis X, sarcoidosis).
Clinical Features 
Symptoms from mass effects include headache; visual loss through compres-
sion of the optic chiasm superiorly (classically a bitemporal hemianopia); 
and diplopia, ptosis, ophthalmoplegia, and decreased facial sensation from 
SECTION 13
Endocrinology and Metabolism
SECTION 13
1106
Endocrinology and Metabolism
FIGURE 179-1 Diagram of pituitary axes. Hypothalamic hormones regulate anterior 
pituitary tropic hormones that, in turn, determine target gland secretion. Peripheral 
hormones feed back to regulate hypothalamic and pituitary hormones. GHRH, growth 
hormone-releasing hormone; SRIF, Somatostatin, somatotropin release-inhibiting 
factor; TRH, thyrotropin-releasing hormone; for other abbreviations, see text.
Hypothalamus
Pituitary
Cortisol
ACTH
PRL
IGF-1
Target
organs
+
+
+
+
+
+
+
+
–
–
– – +
–
Adrenal
glands
Lactation
Liver,
other tissues
Chondrocytes
Linear and
organ growth
Thyroid
glands
Testes
Ovaries
Cell homeostasis
and function
T4/T3
Thermogenesis
metabolism
Testosterone
Inhibin
Spermatogenesis
Estradiol
Progesterone
Inhibin
Ovulation
Secondary sex
characteristics
GnRH
TRH
CRH
Somatostatin
+
TSH
LH
FSH
Dopamine
GHRH
GH
CHAPTER 179
1107
Disorders of the Anterior Pituitary and Hypothalamus 
cranial nerve compression laterally. Pituitary stalk compression from the 
tumor may also result in mild hyperprolactinemia. Symptoms of hypopitu-
itarism or hormonal excess may be present as well (see below).
Pituitary apoplexy, typically resulting from hemorrhage into a pre-existing 
adenoma or post-partum as Sheehan’s syndrome, is an endocrine emergency 
that typically presents with features that include severe headache, bilat-
eral visual changes, ophthalmoplegia, and, in severe cases, cardiovascular 
collapse and loss of consciousness. It may result in hypotension, severe 
hypoglycemia, CNS hemorrhage, and death. Pts with no evident visual loss 
or impaired consciousness can usually be observed and managed conser-
vatively with high-dose glucocorticoids; surgical decompression should be 
considered when visual or neurologic symptoms/signs are present.
Diagnosis
Sagittal and coronal T1-weighted MRI images with specific pituitary cuts 
should be obtained before and after administration of gadolinium. In pts 
with lesions close to the optic chiasm, visual field assessment that uses 
perimetry techniques should be performed. Initial hormonal evaluation is 
listed in Table 179-1.
In pituitary apoplexy, CT or MRI of the pituitary may reveal signs of 
sellar hemorrhage, with deviation of the pituitary stalk and compression of 
pituitary tissue.
Pituitary Tumors
TREATMENT
Pituitary surgery is indicated for mass lesions that impinge on sur-
rounding structures or to correct hormonal hypersecretion, except in 
the case of prolactinoma, where medical treatment is usually effective 
(see below). Transsphenoidal surgery, rather than transfrontal resection, 
TABLE 179-1 INITIAL HORMONAL EVALUATION OF PITUITARY ADENOMAS
Pituitary 
Hormone
Test for Hyperfunction
Test for Deficiency
Prolactin
Prolactin
Growth hormone
Insulin-like growth 
factor I (IGF-I)
IGF-I, GH stimulation tests
ACTH
24-h urinary free cortisol or
1-mg overnight dexameth-
asone suppression test
8 A.M. serum cortisol or 
ACTH stimulation test
Gonadotropins
FSH, LH
Testosterone in men
Menstrual history in women
TSH
TSH, free T4
TSH, free T4
Other
α-subunit
SECTION 13
1108
Endocrinology and Metabolism
is the desired surgical approach for most pts. The goal is selective 
resection of the pituitary mass lesion without damage to the nor-
mal pituitary tissue, to decrease the likelihood of hypopituitarism. 
Transient or permanent diabetes insipidus, hypopituitarism, CSF rhi-
norrhea, visual loss, and oculomotor palsy may occur postoperatively. 
Tumor invasion outside of the sella is rarely amenable to surgical cure, 
but debulking procedures may relieve tumor mass effects and reduce 
hormonal hypersecretion. Radiation may be used as an adjunct to 
surgery, but efficacy is delayed and >50% of pts develop hormonal 
deficiencies within 10 years, usually due to hypothalamic damage. 
GH-, and TSH-secreting tumors may also be amenable to medical 
therapy; in PRL-secreting tumors medical therapy is the initial treat-
ment of choice.
PITUITARY HORMONE HYPERSECRETION SYNDROMES
� HYPERPROLACTINEMIA
Prolactin is unique among the pituitary hormones in that the predominant 
central control mechanism is inhibitory, reflecting dopamine-mediated 
suppression of prolactin release. Prolactin acts to induce and maintain 
lactation and decrease reproductive function and drive [via suppression 
of gonadotropin-releasing hormone (GnRH), gonadotropins, and gonadal 
steroidogenesis].
Etiology 
Physiologic elevation of prolactin occurs in pregnancy and lactation. 
Otherwise, prolactin-secreting pituitary adenomas (prolactinomas) are 
the most common cause of prolactin levels >100 μg/L. Less pronounced 
hyperprolactinemia is commonly caused by medications [risperidone, 
chlorpromazine, perphenazine, haloperidol, metoclopramide, opiates, H2 
antagonists, amitriptyline, selective serotonin reuptake inhibitors (SSRIs), 
verapamil, estrogens], pituitary stalk damage (tumors, lymphocytic 
hypophysitis, granulomas, trauma, irradiation), primary hypothyroid-
ism, or renal failure. Nipple stimulation may also cause acute prolactin 
increases.
Clinical Features 
In women, amenorrhea, galactorrhea, and infertility are the hallmarks of 
hyperprolactinemia. In men, symptoms of hypogonadism (Chap. 185) 
or mass effects are the usual presenting symptoms, and galactorrhea 
is rare.
Diagnosis
Fasting, morning prolactin levels should be measured; when clinical suspi-
cion is high, measurement of levels on several different occasions may be 
required. If hyperprolactinemia is present, nonneoplastic causes should be 
excluded (e.g., pregnancy test, hypothyroidism, medications).
CHAPTER 179
1109
Disorders of the Anterior Pituitary and Hypothalamus 
Hyperprolactinemia
TREATMENT
If the pt is taking a medication that is known to cause hyperprolactinemia, 
the drug should be withdrawn, if possible. A pituitary MRI should be per-
formed if the underlying cause of prolactin elevation is unknown. Resection 
of hypothalamic or sellar mass lesions can reverse hyperprolactinemia due 
to stalk compression. Medical therapy with a dopamine agonist is indi-
cated in microprolactinomas for control of symptomatic galactorrhea, for 
restoration of gonadal function, or when fertility is desired. Alternatively, 
estrogen replacement may be indicated if fertility is not desired, but tumor 
size should be carefully monitored. Dopamine agonist therapy for macro-
prolactinomas generally results in both adenoma shrinkage and reduction 
of prolactin levels. Cabergoline (initial dose 0.5 mg a week, usual dose 
0.5–1 mg twice a week) or bromocriptine (initial dose 0.625–1.25 mg qhs, 
usual dose 2.5 PO three times a day) are the two most frequently used 
dopamine agonists. Cabergoline is the more effective and better-tolerated 
drug. These medications should initially be taken at bedtime with food, 
followed by gradual dose increases, to reduce the side effects of nausea and 
postural hypotension. Other side effects include constipation, nasal stuffi-
ness, dry mouth, nightmares, insomnia, or vertigo; decreasing the dose 
usually alleviates these symptoms. Dopamine agonists may also precipitate 
or worsen underlying psychiatric conditions. Cabergoline in high doses 
can cause cardiac valvular disease. At doses typically used for prolactinoma 
treatment the risk for valvulopathy is small. Nevertheless, cardiac echo-
cardiography should be performed before and 6–12 months after starting 
cabergoline therapy. In pts with microadenomas successfully treated (nor-
mal PRL, full tumors shrinkage), therapy may be withdrawn after 2 years, 
followed by careful monitoring for tumor recurrence. Spontaneous remis-
sion of microadenomas, presumably caused by infarction, occurs in some 
pts. Surgical debulking may be required for macroprolactinomas that do 
not adequately respond to medical therapy.
Women with microprolactinomas who become pregnant should dis-
continue dopaminergic therapy, as the risk for significant tumor growth 
during pregnancy is low. In those with macroprolactinomas, visual field 
testing should be performed at each trimester. A pituitary MRI should 
be performed if severe headache and/or visual defects occur.
� ACROMEGALY
Etiology 
GH hypersecretion is primarily the result of pituitary somatotrope adenomas, 
mostly sporadic, but also in conjunction with MEN 1, Carney syndrome, 
McCune-Albright syndrome, and familial AIP mutations. Extrapituitary 
causes of acromegaly (ectopic GHRH production) are very rare.
Clinical Features 
The peak occurrence of acromegaly is at age 40–45. In children, GH 
hypersecretion prior to long bone epiphyseal closure results in gigantism. 
SECTION 13
1110
Endocrinology and Metabolism
The presentation of acromegaly in adults is usually indolent, and diag-
nosis is typically delayed by up to a decade. Pts may note a change in 
facial features, widened teeth spacing, deepening of the voice, snoring, 
increased shoe or glove size, ring tightening, hyperhidrosis, oily skin, 
arthropathy, and carpal tunnel syndrome. Frontal bossing, mandibular 
enlargement with prognathism, macroglossia, an enlarged thyroid, skin 
tags, thick heel pads, and hypertension may be present on examination. 
Associated conditions include cardiomyopathy, left ventricular hypertro-
phy, diastolic dysfunction, sleep apnea, glucose intolerance, diabetes mel-
litus, colon polyps, and colonic malignancy. Overall mortality is increased 
approximately threefold.
Diagnosis
Insulin-like growth factor type I (IGF-I) levels are a useful screening mea-
sure, with elevation suggesting acromegaly. Due to the pulsatility of GH, 
measurement of a single random GH level is not useful for screening. The 
diagnosis of acromegaly is confirmed by demonstrating the failure of GH 
suppression to <1 μg/L within 1–2 h of a 75-g oral glucose load. MRI of the 
pituitary usually reveals a macroadenoma.
Acromegaly
TREATMENT
The primary treatment modality for acromegaly is transsphenoidal 
surgery. GH levels are not normalized by surgery alone in many pts 
with macroadenomas; in those, somatostatin analogues provide adjunc-
tive medical therapy that suppresses GH secretion with modest to no 
effect on tumor size. Octreotide (50 μg SC three times a day) is used 
for initial therapy to determine response. Once a positive response and 
tolerance of side effects (nausea, abdominal discomfort, diarrhea, flatu-
lence) is established, pts are changed to long-acting depot formulations 
(octreotide LAR 20–30 mg IM every 2–4 weeks or lanreotide autogel 
90–120 mg IM once a month). Dopamine agonists (bromocriptine, 
cabergoline) can be used as adjunctive therapy but are generally not very 
effective. The GH receptor antagonist pegvisomant (10–30 mg SC daily) 
can be added in pts who do not respond to somatostatin analogues. 
Pegvisomant is highly effective in lowering IGF-I levels but does not 
lower GH levels or decrease tumor size. Pituitary irradiation may also 
be required as adjuvant therapy but has a slow therapeutic onset and a 
high rate of late hypopituitarism.
� CUSHING’S DISEASE (SEE CHAP. 182)
� NONFUNCTIONING AND GONADOTROPIN-PRODUCING ADENOMAS
These tumors are the most common type of pituitary neoplasm and usu-
ally present with symptoms of one or more hormonal deficiencies or mass 
effect. They typically produce small amounts of intact gonadotropins (usu-
ally FSH) as well as uncombined α-subunit and LHβ and FSHβ subunits. 
Surgery is indicated for mass effects or hypopituitarism; asymptomatic 
CHAPTER 179
1111
Disorders of the Anterior Pituitary and Hypothalamus 
small adenomas may be followed with regular MRI and visual field testing. 
Diagnosis is based on immunohistochemical analysis of resected tumor tis-
sue. Medical therapy is usually ineffective in shrinking these tumors.
� TSH-SECRETING ADENOMAS
TSH-producing adenomas are rare but often large and locally invasive when 
they occur. Pts present with goiter and hyperthyroidism, and/or sella mass 
effects. Diagnosis is based on elevated serum free T4 levels in the setting of 
inappropriately normal or high TSH secretion and MRI evidence of a pitu-
itary adenoma. Surgery is indicated and is usually followed by somatostatin 
analogue therapy to treat residual tumor. Somatostatin analogue therapy 
leads to normalization of TSH and euthyroidism in most and tumor shrink-
age in 50–75% of pts. If necessary, thyroid ablation or antithyroid drugs can 
be used to reduce thyroid hormone levels.
HYPOPITUITARISM
Etiology 
A variety of disorders may cause deficiencies of one or more pituitary 
hormones. These disorders may be genetic, congenital, traumatic (pitu-
itary surgery, cranial irradiation, head injury), neoplastic (large pituitary 
adenoma, parasellar mass, craniopharyngioma, metastases, meningioma), 
infiltrative (hemochromatosis, lymphocytic hypophysitis, sarcoidosis, 
histiocytosis X), vascular (pituitary apoplexy, postpartum necrosis, sickle 
cell disease), or infectious (tuberculous, fungal, parasitic). The most com-
mon cause of hypopituitarism is neoplastic in origin (macroadenomatous 
destruction, or following hypophysectomy or radiation therapy). Pituitary 
hormone failure due to compression, destruction, or radiation ther-
apy typically follows a sequential pattern: GH>FSH>LH>TSH>ACTH. 
Genetic causes of hypopituitarism may affect several hormones (e.g., 
pituitary dysplasia, PROP-1 and PIT-1 mutations) or be restricted to 
single pituitary hormones or axes (e.g., isolated GH deficiency, Kallmann 
syndrome, isolated ACTH deficiency). Hypopituitarism following cra-
nial irradiation develops over 5–15 years. Varying degrees of partial 
to complete hormone deficiencies occur during evolution of pituitary 
destruction.
Clinical Features 
Each hormone deficiency is associated with specific findings:
• GH: growth disorders in children; increased intraabdominal fat, reduced 
lean body mass, hyperlipidemia, reduced bone mineral density, decreased 
stamina, and social isolation in adults
• FSH/LH: menstrual disorders and infertility in women (Chap. 186); 
hypogonadism in men (Chap. 185)
• ACTH: features of hypocortisolism (Chap. 182) without mineralocorti-
coid deficiency
• TSH: growth retardation in children, features of hypothyroidism in chil-
dren and adults (Chap. 181)
• PRL: failure to lactate post-partum
SECTION 13
1112
Endocrinology and Metabolism
TABLE 179-2  HORMONE REPLACEMENT THERAPY FOR ADULT 
HYPOPITUITARISMa
Trophic Hormone 
Deficit
Hormone Replacement
ACTH
Hydrocortisone (10–20 mg A.M.; 5–10 mg P.M.)
Cortisone acetate (25 mg A.M.; 12.5 mg P.M.)
Prednisone (5 mg A.M.)
TSH
L-Thyroxine (0.075–0.15 mg daily)
FSH/LH
Males
 Testosterone enanthate (200 mg IM every 2 weeks)
 Testosterone gel (5–10 g/d applied to skin)
Females
  Conjugated estrogen (0.625–1.25 mg qd for 25 days)
 Progesterone (5–10 mg qd) on days 16–25
 Estradiol skin patch (0.5 mg, every other day)
For fertility: Menopausal or biosynthetic gonadotropins, 
human chorionic gonadotropins
GH
Adults: Somatotropin (0.1–1.25 mg SC qd)
Children: Somatotropin [0.02–0.05 (mg/kg per day)]
Vasopressin
Intranasal desmopressin (5–20 μg twice daily)
Oral desmopressin (300–600 μg qd) 
aAll doses shown should be individualized for specific pts and should be reassessed during 
stress, surgery, or pregnancy. Male and female fertility requirements should be managed as 
discussed in Chaps. 185 and 186.
Note: For abbreviations, see text.
Diagnosis
Biochemical diagnosis of pituitary insufficiency is made by demonstrating 
low or inappropriately normal levels of pituitary hormones in the setting of 
low target hormone levels. Initial testing should include an 8 a.m. cortisol 
level, TSH and free T4, IGF-I, testosterone in men, assessment of menstrual 
cycles in women, and prolactin level. Provocative tests are required for 
definitive diagnosis of GH and ACTH deficiency. Adult GH deficiency 
is diagnosed by demonstrating a subnormal GH response to a standard 
provocative test (insulin tolerance test, l-arginine + GHRH). Acute ACTH 
deficiency may be diagnosed by a subnormal response in an insulin toler-
ance test, metyrapone test, or corticotropin-releasing hormone (CRH) stim-
ulation test. Standard ACTH (cosyntropin) stimulation tests may be normal 
in acute ACTH deficiency; with adrenal atrophy, the cortisol response to 
cosyntropin is blunted.
CHAPTER 180
1113
Diabetes Insipidus and SIADH 
Hypopituitarism
TREATMENT
Hormonal replacement should aim to mimic physiologic hormone 
production. Effective dose schedules are outlined in Table 179-2. 
Doses should be individualized, particularly for GH, glucocorticoids 
and l-thyroxine. GH therapy, particularly when excessive, may be 
associated with fluid retention, joint pain, and carpal tunnel syn-
drome. Glucocorticoid replacement should always precede l-thyroxine 
therapy to avoid precipitation of adrenal crisis. Pts requiring glucocor-
ticoid replacement should wear a medical alert bracelet and should be 
instructed to take additional doses during stressful events such as acute 
illness, dental procedures, trauma, and acute hospitalization.
For a more detailed discussion, see Melmed S, Jameson JL: 
Disorders of the Anterior Pituitary and Hypothalamus, Chap. 
339, p. 2876, in HPIM-18. 
CHAPTER 180
Diabetes Insipidus 
and SIADH
The neurohypophysis, or posterior pituitary gland, produces two hor-
mones: (1) arginine vasopressin (AVP), also known as antidiuretic hormone 
(ADH), and (2) oxytocin. AVP acts on the renal tubules to induce water 
retention, leading to concentration of the urine. Oxytocin stimulates post-
partum milk letdown in response to suckling. Its physiologic role in partu-
rition is not established. Clinical syndromes may result from deficiency or 
excess of AVP.
� DIABETES INSIPIDUS
Etiology 
Diabetes insipidus (DI) results from insufficient AVP production by the 
hypothalamus or from impaired AVP action in the kidney. AVP defi-
ciency is characterized by production of large amounts of dilute urine. In 
central DI, insufficient AVP is released in response to physiologic stimuli. 
Causes include acquired (head trauma; neoplastic or inflammatory con-
ditions affecting the hypothalamus/posterior pituitary), congenital, and 
genetic disorders, but almost half of cases are idiopathic. In gestational DI, 
increased metabolism of plasma AVP by an aminopeptidase (vasopressi-
nase) produced by the placenta leads to a relative deficiency of AVP during 
pregnancy. Primary polydipsia results in secondary insufficiency of AVP 
SECTION 13
1114
Endocrinology and Metabolism
due to physiologic inhibition of AVP secretion by excessive fluid intake. 
Nephrogenic DI is caused by AVP resistance in the kidney; it can be genetic 
or acquired from drug exposure (lithium, demeclocycline, amphotericin 
B), metabolic conditions (hypercalcemia, hypokalemia), or renal damage.
Clinical Features 
Symptoms include polyuria, excessive thirst, and polydipsia, with a 24-h 
urine output of >50 mL/kg/day and a urine osmolality that is less than 
that of serum (<300 mosmol/kg; specific gravity <1.010). DI can be 
partial or complete; in the latter case the urine is maximally diluted 
(<100 mosmol/kg) and the daily urine output can reach 10–20 L. Clinical 
or laboratory signs of dehydration, including hypernatremia, occur only if 
the pt simultaneously has a thirst defect (not uncommon in pts with CNS 
disease) or does not have access to water. Other etiologies of hypernatremia 
are described in Chap. 2.
Diagnosis
DI must be differentiated from other etiologies of polyuria (Chap. 52). 
Unless an inappropriately dilute urine is present in the setting of serum 
hyperosmolality, a fluid deprivation test is used to make the diagnosis of 
DI. This test should be started in the morning, and body weight, plasma 
osmolality, serum sodium, and urine volume and osmolality should be 
measured hourly. The test should be stopped when body weight decreases 
by 5% or plasma osmolality/sodium exceed the upper limit of normal. 
If the urine osmolality is <300 mosmol/kg with serum hyperosmolality, 
desmopressin (0.03 μg/kg SC) should be administered with repeat measure-
ment of urine osmolality 1–2 h later. An increase of >50% indicates severe 
pituitary DI, whereas a smaller or absent response suggests nephrogenic 
DI. Measurement of AVP levels before and after fluid deprivation may be 
required to diagnose partial DI. Occasionally, hypertonic saline infusion 
may be required if fluid deprivation does not achieve the requisite level of 
hypertonic dehydration, but this should be administered with caution.
Diabetes Insipidus
TREATMENT
Pituitary DI can be treated with desmopressin (DDAVP) subcutane-
ously (1–2 μg once or twice per day), via nasal spray (10–20 μg two or 
three times a day), or orally (100–400 μg two or three times a day), with 
recommendations to drink to thirst. Symptoms of nephrogenic DI may 
be ameliorated by treatment with a thiazide diuretic and/or amiloride 
in conjunction with a low-sodium diet, or with prostaglandin synthesis 
inhibitors (e.g., indomethacin).
� SYNDROME OF INAPPROPRIATE ANTIDIURETIC HORMONE (SIADH)
Etiology 
Excessive or inappropriate production of AVP predisposes to hyponatre-
mia, reflecting water retention. The evaluation of hyponatremia is described 
CHAPTER 180
1115
Diabetes Insipidus and SIADH 
in Chap. 2. Etiologies of SIADH include neoplasms, lung infections, CNS 
disorders, and drugs (Table 180-1).
Clinical Features 
If hyponatremia develops gradually, it may be asymptomatic until it reaches a 
severe stage. However, if it develops acutely, symptoms of water intoxication 
TABLE 180-1  CAUSES OF SYNDROME OF INAPPROPRIATE ANTIDIURETIC 
HORMONE (SIADH)
Neoplasms
Neurologic
 Carcinomas
 Guillain-Barré syndrome
  Lung
 Multiple sclerosis
  Duodenum
 Delirium tremens
  Pancreas
 Amyotrophic lateral sclerosis
  Ovary
 Hydrocephalus
  Bladder, ureter
 Psychosis
 Other neoplasms
 Peripheral neuropathy
  Thymoma
Congenital malformations
  Mesothelioma
 Agenesis corpus callosum
  Bronchial adenoma
 Cleft lip/palate
  Carcinoid
 Other midline defects
  Gangliocytoma
Metabolic
  Ewing’s sarcoma
 Acute intermittent porphyria
Head trauma
Pulmonary 
Infections
 Asthma 
 Pneumonia, bacterial or viral
 Pneumothorax 
 Abscess, lung or brain
 Positive-pressure respiration 
 Cavitation (aspergillosis)
Drugs
 Tuberculosis, lung or brain
 Vasopressin or desmopressin
 Meningitis, bacterial or viral
 Chlorpropamide
 Encephalitis
 Oxytocin, high dose
 AIDS
 Vincristine
Vascular
 Carbamazepine
  Cerebrovascular occlusions, 
hemorrhage
 Cavernous sinus thrombosis
Genetic
 X-linked recessive
 (V2 receptor gene)
 Nicotine
 Phenothiazines
 Cyclophosphamide
 Tricyclic antidepressants
 Monoamine oxidase inhibitors
 Serotonin reuptake inhibitors
SECTION 13
1116
Endocrinology and Metabolism
may include mild headache, confusion, anorexia, nausea, vomiting, 
coma, and convulsions. Laboratory findings include low BUN, creatinine, 
uric acid, and albumin; serum Na <130 meq/L and plasma osmolality 
<270 mosmol/kg; urine is not maximally diluted and frequently hypertonic 
to plasma, and urinary Na+ is usually >20 mmol/L.
SIADH
TREATMENT
Fluid intake should be restricted to 500 mL less than urinary output. In 
pts with severe symptoms or signs, hypertonic (3%) saline can be infused 
at ≤0.05 mL/kg body weight IV per minute, with hourly sodium levels 
measured until Na increases by 12 meq/L or to 130 meq/L, whichever 
occurs first. However, if the hyponatremia has been present for >24–48 h 
and is corrected too rapidly, saline infusion has the potential to produce 
central pontine myelinolysis, a serious, potentially fatal neurologic com-
plication caused by osmotic fluid shifts. Demeclocycline (150–300 mg 
PO three or four times a day) or fludrocortisone (0.05–0.2 mg PO twice 
a day) may be required to manage chronic SIADH. Vasopressin antago-
nists (conivaptan, tolvaptan) are available, but experience with these 
agents in SIADH treatment is limited.
For a more detailed discussion, see Robertson GL: Disorders 
of the Neurohypophysis, Chap. 340, p. 2902, in HPIM-18.
CHAPTER 181
Thyroid Gland Disorders
Disorders of the thyroid gland result primarily from autoimmune processes 
that stimulate the overproduction of thyroid hormones (thyrotoxicosis) or 
cause glandular destruction and underproduction of thyroid hormones 
(hypothyroidism). Neoplastic processes in the thyroid gland can lead to 
benign nodules or thyroid cancer.
Thyroidal production of the hormones thyroxine (T4) and triiodothyro-
nine (T3) is controlled via a classic endocrine feedback loop (see Fig. 179-1). 
Some T3 is secreted by the thyroid, but most is produced by deiodination 
of T4 in peripheral tissues. Both T4 and T3 are bound to carrier proteins 
[thyroid-binding globulin (TBG), transthyretin (binds T4 only), and albu-
min] in the circulation. Increased levels of total T4 and T3 with normal free 
levels are seen in states of increased carrier proteins (pregnancy, estrogens, 
cirrhosis, hepatitis, and inherited disorders). Conversely, decreased total 
T4 and T3 levels with normal free levels are seen in severe systemic illness, 
chronic liver disease, and nephrosis.
CHAPTER 181
1117
Thyroid Gland Disorders
HYPOTHYROIDISM
Etiology 
Deficient thyroid hormone secretion can be due to thyroid failure (primary 
hypothyroidism) or, less commonly, pituitary or hypothalamic disease 
(secondary hypothyroidism) (Table 181-1). Transient hypothyroidism may 
occur in silent or subacute thyroiditis. Subclinical (or mild) hypothyroidism 
is a state of normal free thyroid hormone levels and mild elevation of TSH; 
despite the name, some pts may have minor symptoms. With higher TSH 
levels and low free T4 levels, symptoms become more readily apparent in 
clinical (or overt) hypothyroidism. In areas of iodine sufficiency, autoim-
mune disease and iatrogenic causes are the most common causes of hypo-
thyroidism. The peak age of occurrence is around 60 years, and prevalence 
increases with age. Congenital hypothyroidism is present in 1 of 4000 
newborns; the importance of its recognition and prompt treatment for child 
development has led to the adoption of neonatal screening programs. 
Clinical Features 
Symptoms of hypothyroidism include lethargy, dry hair and skin, cold 
intolerance, hair loss, difficulty concentrating, poor memory, constipa-
tion, mild weight gain with poor appetite, dyspnea, hoarse voice, muscle 
cramping, and menorrhagia. Cardinal features on examination include 
bradycardia, mild diastolic hypertension, prolongation of the relaxation 
phase of deep tendon reflexes, and cool peripheral extremities. Goiter may 
be palpated, or the thyroid may be atrophic and nonpalpable. Carpal tunnel 
syndrome may be present. Cardiomegaly may be present due to pericardial 
FIGURE 181-1 Evaluation of hypothyroidism. TPOAb+, thyroid peroxidase antibodies 
present; TPOAb–, thyroid peroxidase antibodies not present; TSH, thyroid-stimulating 
hormone.
Measure unbound T4
Measure unbound T4
Mild
  hypothyroidism
Measure TSH
Elevated
Normal
Normal
Primary
  hypothyroidism
Low
Autoimmune
  hypothyroidism
Rule out other
  causes of
  hypothyroidism
T4 treatment
TPOAb+ or
  symptomatic
TPOAb–, no
symptoms
Annual follow-up
T4 treatment
TPOAb+
TPOAb–
Pituitary disease suspected?
No further
  tests
Normal
Yes
Rule out drug effects,
  sick euthyroid
  syndrome, then
  evaluate anterior
  pituitary function
No further
  tests
No
Low
EVALUATION OF HYPOTHYROIDISM
SECTION 13
1118
Endocrinology and Metabolism
TABLE 181-1 CAUSES OF HYPOTHYROIDISM
Primary
Autoimmune hypothyroidism: Hashimoto’s thyroiditis, atrophic thyroiditis
Iatrogenic: 131I treatment, subtotal or total thyroidectomy, external irradiation of 
neck for lymphoma or cancer
Drugs: iodine excess (including iodine-containing contrast media and amioda-
rone), lithium, antithyroid drugs, p-aminosalicylic acid, interferon α and other 
cytokines, aminoglutethimide, sunitinib
Congenital hypothyroidism: absent or ectopic thyroid gland, dyshormonogen-
esis, TSH-R mutation
Iodine deficiency
Infiltrative disorders: amyloidosis, sarcoidosis, hemochromatosis, scleroderma, 
cystinosis, Riedel’s thyroiditis
Overexpression of type 3 deiodinase in infantile hemangioma
Transient
Silent thyroiditis, including postpartum thyroiditis
Subacute thyroiditis
Withdrawal of thyroxine treatment in individuals with an intact thyroid
After 131I treatment or subtotal thyroidectomy for Graves’ disease
Secondary
Hypopituitarism: tumors, pituitary surgery or irradiation, infiltrative disorders, 
Sheehan’s syndrome, trauma, genetic forms of combined pituitary hormone 
deficiencies
Isolated TSH deficiency or inactivity
Bexarotene treatment
Hypothalamic disease: tumors, trauma, infiltrative disorders, idiopathic
Abbreviations: TSH, thyroid-stimulating hormone; TSH-R, TSH receptor.
effusion. The most extreme presentation is a dull, expressionless face, sparse 
hair, periorbital puffiness, large tongue, and pale, doughy, cool skin. The 
condition may progress into a hypothermic, stuporous state (myxedema 
coma) with respiratory depression. Factors that predispose to myxedema 
coma include cold exposure, trauma, infection, and administration of nar-
cotics. In mild hypothyroidism, the classic findings of overt hypothyroidism 
may not be present, and the clinical picture may be dominated by fatigue 
and ill-defined symptoms.
Diagnosis
Decreased serum free T4 is common to all varieties of hypothyroidism. An 
elevated serum TSH is a sensitive marker of primary hypothyroidism but is 
not found in secondary hypothyroidism. A summary of the investigations 
used to determine the existence and cause of hypothyroidism is provided 
in Fig. 181-1. Thyroid peroxidase (TPO) antibodies are increased in >90% 
CHAPTER 181
1119
Thyroid Gland Disorders
of pts with autoimmune-mediated hypothyroidism. Elevated cholesterol, 
increased creatine phosphokinase, and anemia may be present; bradycardia, 
low-amplitude QRS complexes, and flattened or inverted T waves may be 
present on ECG. 
Hypothyroidism
TREATMENT
Adult pts <60 years without evidence of heart disease may be started 
on 50–100 μg of levothyroxine (T4) daily. In the elderly or in pts with 
known coronary artery disease, the starting dose of levothyroxine is 
12.5–25 μg/d. The dose should be adjusted in 12.5- to 25-μg increments 
every 6–8 weeks on the basis of TSH levels, until a normal TSH level is 
achieved. The average daily replacement dose is 1.6 μg/kg/d, but dosing 
should be individualized and guided by TSH measurement. In second-
ary hypothyroidism, TSH levels cannot be used, and therapy needs to be 
guided by free T4 measurement. Women on levothyroxine replacement 
should have a TSH level checked as soon as pregnancy is diagnosed, as 
the replacement dose typically increases by 30–50% during pregnancy. 
Failure to recognize and treat maternal hypothyroidism may adversely 
affect fetal neural development. Therapy for myxedema coma should 
include levothyroxine (500 μg) as a single IV bolus followed by daily 
treatment with levothyroxine (50–100 μg/d), along with hydrocortisone 
(50 mg every 6 h) for impaired adrenal reserve, ventilatory support, 
space blankets, and treatment of precipitating factors.
THYROTOXICOSIS
Etiology 
Causes of thyroid hormone excess include primary hyperthyroidism 
(Graves’ disease, toxic multinodular goiter, toxic adenoma, iodine excess); 
thyroid destruction (subacute thyroiditis, silent thyroiditis, amiodarone, 
radiation); extrathyroidal sources of thyroid hormone (thyrotoxicosis facti-
tia, struma ovarii, functioning follicular carcinoma); and secondary hyper-
thyroidism [TSH-secreting pituitary adenoma, thyroid hormone resistance 
syndrome, human chorionic gonadotropin (hCG)-secreting tumors, gesta-
tional thyrotoxicosis]. Graves’ disease, caused by activating TSH-receptor 
antibodies, is the most common cause of thyrotoxicosis and accounts for 
60–80% of cases. Its prevalence in women is 10-fold higher than in men; its 
peak occurrence is at age 20–50 years. 
Clinical Features 
Symptoms include nervousness, irritability, heat intolerance, excessive 
sweating, palpitations, fatigue and weakness, weight loss with increased 
appetite, frequent bowel movements, and oligomenorrhea. Pts are anxious, 
restless, and fidgety. Skin is warm and moist, and fingernails may separate 
from the nail bed (Plummer’s nails). Eyelid retraction and lid lag may be 
present. Cardiovascular findings include tachycardia, systolic hypertension, 
systolic murmur, and atrial fibrillation. A fine tremor, hyperreflexia, and 
SECTION 13
1120
Endocrinology and Metabolism
proximal muscle weakness also may be present. Long-standing thyrotoxico-
sis may lead to osteopenia. In the elderly, the classic signs of thyrotoxicosis 
may not be apparent, the main manifestations being weight loss and fatigue 
(“apathetic thyrotoxicosis”).
In Graves’ disease, the thyroid is usually diffusely enlarged to two to 
three times its normal size, and a bruit or thrill may be present. Infiltrative 
ophthalmopathy (with variable degrees of proptosis, periorbital swelling, 
and ophthalmoplegia) and dermopathy (pretibial myxedema) also may be 
found; these are extrathyroidal manifestations of the autoimmune process. 
In subacute thyroiditis, the thyroid is exquisitely tender and enlarged with 
referred pain to the jaw or ear, and sometimes accompanied by fever and 
preceded by an upper respiratory tract infection. Solitary or multiple nod-
ules may be present in toxic adenoma or toxic multinodular goiter.
Thyrotoxic crisis, or thyroid storm, is rare, presents as a life-threatening 
exacerbation of hyperthyroidism, and can be accompanied by fever, delir-
ium, seizures, arrhythmias, coma, vomiting, diarrhea, and jaundice.
Diagnosis
Investigations used to determine the existence and causes of thyrotoxi-
cosis are summarized in Fig. 181-2. Serum TSH is a sensitive marker of 
thyrotoxicosis caused by Graves’ disease, autonomous thyroid nodules, 
thyroiditis, and exogenous levothyroxine treatment. Associated laboratory 
abnormalities include elevation of bilirubin, liver enzymes, and ferritin. 
Thyroid radioiodine uptake may be required to distinguish the various eti-
ologies: high uptake in Graves’ disease and nodular disease vs. low uptake 
in thyroid destruction, iodine excess, and extrathyroidal sources of thyroid 
hormone. (Note: Radioiodine is the nuclide required for quantitative thy-
roid uptake, whereas technetium is sufficient for imaging purposes.) The 
ESR is elevated in subacute thyroiditis.
Thyrotoxicosis
TREATMENT
Graves’ disease may be treated with antithyroid drugs or radioiodine; 
subtotal thyroidectomy is rarely indicated. The main antithyroid drugs 
are methimazole or carbimazole (10–20 mg two to three times a day 
initially, titrated to 2.5–10 mg/d) and propylthiouracil (100–200 mg 
every 8 h initially, titrated to 50 mg once or twice a day). Methimazole 
is preferred in most pts because of easier dosing. Thyroid function tests 
should be checked 3–4 weeks after initiation of treatment, with adjust-
ments to maintain a normal free T4 level. Since TSH recovery from 
suppression is delayed, serum TSH levels should not be used for dose 
adjustment in the first few months. The common side effects are rash, 
urticaria, fever, and arthralgia (1–5% of pts). Uncommon but major 
side effects include hepatitis, an SLE-like syndrome, and, rarely, agran-
ulocytosis (<1%). All pts should be given written instructions regarding 
the symptoms of possible agranulocytosis (sore throat, fever, mouth 
ulcers) and the need to stop treatment pending a complete blood count 
to confirm that agranulocytosis is not present. Propranolol (20–40 mg
CHAPTER 181
1121
Thyroid Gland Disorders
FIGURE 181-2 Evaluation of thyrotoxicosis. aDiffuse goiter, positive TPO antibodies, 
ophthalmopathy, dermopathy; bcan be confirmed by radionuclide scan. TSH, thyroid-
stimulating hormone.
Primary
  thyrotoxicosis
Features of
  Graves’ diseasea?
T3 toxicosis
Subclinical
  hyperthyroidism
TSH low, unbound
  T4 high
Measure TSH, unbound T4
Yes
No
Normal
Measure
  unbound T3
TSH normal or increased,
  high unbound T4
TSH-secreting
  pituitary adenoma
  or thyroid hormone
  resistance syndrome
Follow up in
  6-12 weeks
High
Graves’ disease
Multinodular goiter or toxic adenomab?
Yes
No
Toxic nodular
  hyperthyroidism
Low radioiodine uptake?
Yes
No
Destructive thyroiditis, iodine excess
  or excess thyroid hormone
Rule out other causes including stimulation
  by chorionic gonadotropin
TSH low, unbound
  T4 normal
TSH and unbound
  T4 normal
No further tests
EVALUATION OF THYROTOXICOSIS
every 6 h) or longer-acting beta blockers such as atenolol (50 mg/d) 
may be useful at the start of treatment to control adrenergic symptoms 
until euthyroidism is reached. Anticoagulation with warfarin should be 
considered in all pts with atrial fibrillation. Radioiodine can also be used 
as initial treatment or in pts who do not undergo remission after a 1- to 
2-year trial of antithyroid drugs. Antecedent treatment with antithyroid 
drugs should be considered in elderly pts and those with cardiac prob-
lems, with cessation of antithyroid drugs 3–5 days prior to radioiodine 
administration. Radioiodine treatment is contraindicated in pregnancy; 
instead, symptoms should be controlled with the lowest effective dose 
of propylthiouracil (PTU). (Methimazole is not recommended in preg-
nancy because of reports of fetal agenesis cutis.) Corneal drying may 
be relieved with artificial tears and taping the eyelids shut during sleep. 
Progressive exophthalmos with chemosis, ophthalmoplegia, or vision 
loss is treated with large doses of prednisone (40–80 mg/d) and ophthal-
mologic referral; orbital decompression may be required.
SECTION 13
1122
Endocrinology and Metabolism
In thyroid storm, large doses of PTU (600-mg loading dose) should 
be administered orally, per nasogastric tube, or per rectum, followed 1 h 
later by 5 drops saturated solution of KI (SSKI) q6h. PTU (200–300 mg 
every 6 h) should be continued, along with propranolol (40–60 mg PO 
q4h or 2 mg IV every 4 h) and dexamethasone (2 mg every 6 h). Any 
underlying precipitating cause should be identified and treated.
Radioiodine is the treatment of choice for toxic nodules. Subacute 
thyroiditis in its thyrotoxic phase should be treated with NSAIDs and 
beta blockade to control symptoms, with monitoring of the TSH and 
free T4 levels every 4 weeks. Antithyroid drugs are not effective in thy-
roiditis. The clinical course of subacute thyroiditis is summarized in 
Fig. 181-3. Transient levothyroxine replacement (50–100 μg/d) may 
be required if the hypothyroid phase is prolonged. Silent thyroiditis 
(or postpartum thyroiditis if within 3–6 months of delivery) should be 
treated with beta blockade during the thyrotoxic phase and levothy-
roxine in the hypothyroid phase, with withdrawal after 6–9 months to 
assess recovery.
SICK EUTHYROID SYNDROME
Any acute, severe illness can cause abnormalities of circulating thyroid 
hormone levels or TSH, even in the absence of underlying thyroid disease. 
Therefore, the routine testing of thyroid function should be avoided in 
acutely ill pts unless a thyroid disorder is strongly suspected. The most 
FIGURE 181-3 Clinical course of subacute thyroiditis. The release of thyroid hor-
mones is initially associated with a thyrotoxic phase and suppressed TSH levels. 
A hypothyroid phase then ensues, with T4 and TSH levels that are initially low but 
gradually increase. During the recovery phase, increased TSH levels combined with 
resolution of thyroid follicular injury leads to normalization of thyroid function, often 
several months after the beginning of the illness. ESR, erythrocyte sedimentation rate; 
UT4, unbound T4.
Clinical Phases
0
Time (weeks)
50
ESR
TSH (mU/L)
UT4 (pmol/L)
5
0.5
0.01
6
Thyrotoxic
Hypothyroid
Recovery
12
18
40
30
10
0
20
ESR (mm/h)
100
0
50
UT4
TSH
CHAPTER 181
1123
Thyroid Gland Disorders
common pattern in sick euthyroid syndrome is a decrease in total and free 
T3 levels, with normal levels of TSH and T4. This is considered an adaptive 
response to a catabolic state. More ill pts may additionally have a fall in 
total T4 levels, with normal free T4 levels. TSH levels may range from <0.1 
to >20 mU/L, with normalization after recovery from illness. The patho-
genesis of this condition is not fully understood but may involve altered 
binding of T4 to TBG and effects of high glucocorticoid and cytokine levels. 
Unless there is historic or unequivocal clinical evidence of hypothyroidism, 
thyroid hormone should not be administered and thyroid function tests 
should be repeated after recovery.
AMIODARONE
Amiodarone is a type III antiarrhythmic agent that has some structural 
similarity to thyroid hormone and has a high iodine content. Amiodarone 
treatment leads to substantial iodine overload and is associated with (1) 
acute, transient suppression of thyroid function, (2) hypothyroidism, or 
(3) thyrotoxicosis. These effects are only partially attributable to iodine 
overload. Hypothyroidism can occur in pts with preexisting thyroid disease, 
with an inability to escape from the suppressive effect of excess iodine. Pts 
with hypothyroidism can be easily managed with levothyroxine replacement 
therapy, without a need to stop amiodarone. There are two major forms of 
amiodarone-induced thyrotoxicosis (AIT). Type 1 AIT is associated with an 
underlying thyroid abnormality (preclinical Graves’ disease or nodular goi-
ter). Thyroid hormone synthesis becomes excessive as a result of increased 
iodine exposure. Type 2 AIT occurs in pts with no intrinsic thyroid abnor-
malities and is the result of destructive thyroiditis. Differentiation between 
type 1 and type 2 AIT may be difficult as the high iodine load interferes with 
thyroid scans. The drug should be stopped, if possible, although this is often 
difficult to achieve without compromising the arrhythmia management. 
Amiodarone has a long biologic half-life, and its effects persist for weeks 
following discontinuation. Therapy of type 1 AIT consists of high-dose anti-
thyroid drugs, but efficacy may be limited. In type 2 AIT, sodium ipodate 
(500 mg/d) or sodium tyropanoate (500 mg, 1–2 doses/d) can be used to 
rapidly lower thyroid hormone levels. Potassium perchlorate (200 mg every 
6 h) can be used to deplete the thyroid of iodine, but long-term use carries 
a risk of agranulocytosis. Glucocorticoids in high doses are partially effec-
tive. Lithium can be used to block thyroid hormone release. In some cases, 
subacute thyroidectomy may be necessary to control thyrotoxicosis.
NONTOXIC GOITER
Goiter refers to an enlarged thyroid gland (>20–25 g), which can be dif-
fuse or nodular. Goiter is more common in women than men. Biosynthetic 
defects, iodine deficiency, autoimmune disease, dietary goitrogens (cab-
bage, cassava root), and nodular diseases can lead to goiter. Worldwide, 
iodine deficiency is the most common etiology of goiter. Nontoxic mul-
tinodular goiter is common in both iodine-deficient and iodine-replete 
populations, with a prevalence of up to 12%. The etiology, other than iodine 
deficiency, is usually not known and may be multifactorial. If thyroid func-
tion is preserved, most goiters are asymptomatic. Substernal goiter may 
SECTION 13
1124
Endocrinology and Metabolism
obstruct the thoracic inlet and should be evaluated with respiratory flow 
measurements and CT or MRI in pts with obstructive signs or symptoms 
(difficulty swallowing, tracheal compression, or plethora). Thyroid function 
tests should be performed in all pts with goiter to exclude thyrotoxicosis or 
hypothyroidism. Ultrasound is not generally indicated in the evaluation of 
diffuse goiter, unless a nodule is palpable on physical exam.
Iodine or thyroid hormone replacement induces variable regression of 
goiter in iodine deficiency. Thyroid hormone replacement is rarely effec-
tive in significantly shrinking a nontoxic goiter that is not due to iodine 
deficiency or a biosynthetic defect. Radioiodine reduces goiter size by 
about 50% in the majority of pts. Surgery is rarely indicated for diffuse 
goiter but may be required to alleviate compression in pts with nontoxic 
multinodular goiter.
TOXIC MULTINODULAR GOITER AND TOXIC ADENOMA
� TOXIC MULTINODULAR GOITER (MNG)
In addition to features of goiter, the clinical presentation of toxic MNG 
includes subclinical hyperthyroidism or mild thyrotoxicosis. The pt is usu-
ally elderly and may present with atrial fibrillation or palpitations, tachycar-
dia, nervousness, tremor, or weight loss. Recent exposure to iodine, from 
contrast dyes or other sources, may precipitate or exacerbate thyrotoxicosis; 
this may be prevented by prior administration of an antithyroid drug. The 
TSH level is low. T4 may be normal or minimally increased; T3 is often 
elevated to a greater degree than T4. Thyroid scan shows heterogeneous 
uptake with multiple regions of increased and decreased uptake; 24-h 
uptake of radioiodine may not be increased. Cold nodules in a multinodular 
goiter should be evaluated in the same way as solitary nodules (see below). 
Antithyroid drugs, often in combination with beta blockers, can normalize 
thyroid function and improve clinical features of thyrotoxicosis but do not 
induce remission. A trial of radioiodine should be considered before sub-
jecting pts, many of whom are elderly, to surgery. Subtotal thyroidectomy 
provides definitive treatment of goiter and thyrotoxicosis. Pts should be 
rendered euthyroid with antithyroid drugs before surgical intervention.
� TOXIC ADENOMA
A solitary, autonomously functioning thyroid nodule is referred to as toxic 
adenoma. Most cases are cause by somatic activating mutations of the TSH 
receptor. Thyrotoxicosis is typically mild. A thyroid scan provides a defini-
tive diagnostic test, demonstrating focal uptake in the hyperfunctioning 
nodule and diminished uptake in the remainder of the gland, as activity of 
the normal thyroid is suppressed. Radioiodine ablation with relatively large 
doses (e.g., 10–29.9 mCi 131I) is usually the treatment of choice. 
THYROID NEOPLASMS
Etiology 
Thyroid neoplasms may be benign (adenomas) or malignant (carcinomas). 
Carcinomas of the follicular epithelium include papillary, follicular, and 
anaplastic thyroid cancer. Thyroid cancer incidence is ~9/100,000 per year. 
CHAPTER 181
1125
Thyroid Gland Disorders
Papillary thyroid cancer is the most common type of thyroid cancer 
(70–90%). It tends to be multifocal and to invade locally. Follicular thyroid 
cancer is difficult to diagnose via fine-needle aspiration (FNA) because the 
distinction between benign and malignant follicular neoplasms rests largely 
on evidence of invasion into vessels, nerves, or adjacent structures. It tends 
to spread hematogenously, leading to bone, lung, and CNS metastases. 
Anaplastic carcinoma is rare, highly malignant, and rapidly fatal. Thyroid 
lymphoma often arises in the background of Hashimoto’s thyroiditis and 
occurs in the setting of a rapidly expanding thyroid mass. Medullary thyroid 
carcinoma arises from parafollicular (C) cells producing calcitonin and may 
occur sporadically or as a familial disorder, sometimes in association with 
multiple endocrine neoplasia type 2.
Clinical Features 
Features suggesting carcinoma include recent or rapid growth of a nodule 
or mass, history of neck irradiation, lymph node involvement, hoarseness, 
and fixation to surrounding tissues. Glandular enlargement may result in 
compression and displacement of the trachea or esophagus and obstructive 
symptoms. Age <20 or >45, male sex, and larger nodule size are associated 
with a worse prognosis.
Diagnosis
An approach to the evaluation of a solitary nodule is outlined in Fig. 181-4.
FIGURE 181-4 Approach to the pt with a thyroid nodule. *About one-third of nodules 
are cystic or mixed solid-cystic. FNA, fine-needle aspiration; TSH, thyroid-stimulating 
hormone; US, ultrasound.
Solitary or Suspicious
  Nodule*
Thyroid scan
FNA, consider
US-guided
Benign
Monitor by US
Surgery if further growth or suspicious cytology
Malignant
Surgery
“Hot” nodule
“Cold” or
indeterminate
Nondiagnostic
Suspicious or
  follicular neoplasm
Repeat bx
inadequate
Consider
thyroid scan
Cytopathology
Ablate, resect,
  or Rx medically
Low TSH
Normal TSH
“Hot” nodule
“Cold” or
   indeterminate
17%
10%
4%
69%
APPROACH TO PATIENT WITH THYROID NODULE
SECTION 13
1126
Endocrinology and Metabolism
Thyroid Neoplasms
TREATMENT
Benign nodules should be monitored via serial examination. TSH sup-
pression with levothyroxine results in decreased nodule size in about 30% 
of pts. Suppressive therapy should not exceed 6–12 months if unsuccessful.
Follicular adenomas cannot be distinguished from follicular carcino-
mas on the basis of cytologic analysis of FNA specimens. The extent of 
surgical resection (lobectomy vs. near-total thyroidectomy) should be 
discussed prior to surgery.
Near-total thyroidectomy is required for papillary and follicular carci-
noma and should be performed by a surgeon who is highly experienced 
in the procedure. If risk factors and pathologic features indicate the need 
for radioiodine treatment, the pt should be treated for several weeks 
postoperatively with liothyronine (T3, 25 μg two to three times a day), 
followed by withdrawal for an additional 2 weeks, in preparation for 
postsurgical radioablation of remnant tissue. A therapeutic dose of 131I 
is administered when the TSH level is >50 IU/L. Alternatively, recombi-
nant TSH can be used to raise the preablation TSH level. This appears 
to be equally effective as thyroid hormone withdrawal for radioablation 
therapy. Subsequent levothyroxine suppression of TSH to a low, but 
detectable, level (0.1–0.5 IU/L) should be attempted in pts with a low 
risk of recurrence, and to a completely suppressed level in those with a 
high risk of recurrence. In the latter case, free T4 should be monitored 
to avoid overtreatment. Follow-up scans and serum thyroglobulin levels 
(acting as a tumor marker in an athyreotic pt) should be performed at 
regular intervals after either thyroid hormone withdrawal or administra-
tion of recombinant human TSH.
The management of medullary thyroid carcinoma is surgical, as these 
tumors do not take up radioiodine. Testing for RET mutations should 
be performed to assess for the presence of MEN-2, and the family should 
be screened if testing is positive. Following surgery, serum calcitonin 
provides a marker of residual or recurrent disease.
For a more detailed discussion, see Jameson JL, Weetman 
AP: Disorders of the Thyroid Gland, Chap. 341, p. 2911, in 
HPIM-18.
CHAPTER 182
Adrenal Gland Disorders
The adrenal cortex produces three major classes of steroids: (1) gluco-
corticoids, (2) mineralocorticoids, and (3) adrenal androgens. Clinical 
syndromes may result from deficiencies or excesses of these hormones. 
CHAPTER 182
1127
Adrenal Gland Disorders
The adrenal medulla produces catecholamines, with excess leading to 
pheochromocytoma (Chap. 126).
HYPERFUNCTION OF THE ADRENAL GLAND
� CUSHING’S SYNDROME
Etiology 
The most common cause of Cushing’s syndrome is iatrogenic, due to 
administration of glucocorticoids for therapeutic reasons. Endogenous 
Cushing’s syndrome results from production of excess cortisol (and other 
steroid hormones) by the adrenal cortex. The major cause is bilateral adre-
nal hyperplasia secondary to hypersecretion of adrenocorticotropic hor-
mone (ACTH) by the pituitary (Cushing’s disease) or from ectopic sources 
such as small cell carcinoma of the lung; carcinoids of the bronchus, thymus, 
gut and ovary, medullary carcinoma of the thyroid; or pheochromocytoma. 
Adenomas or carcinoma of the adrenal gland account for about 15–20% of 
endogenous Cushing’s syndrome cases. There is a female preponderance in 
endogenous Cushing’s syndrome except for the ectopic ACTH syndrome.
Clinical Features 
Some common manifestations (central obesity, hypertension, osteoporo-
sis, psychological disturbances, acne, hirsutism, amenorrhea, and diabetes 
mellitus) are relatively nonspecific. More specific findings include easy bruis-
ing, purple striae, proximal myopathy, fat deposition in the face and nuchal 
areas (moon facies and buffalo hump), and rarely virilization. Thin, fragile 
skin and plethoric moon facies also may be found. Hypokalemia and meta-
bolic alkalosis are prominent, particularly with ectopic production of ACTH.
Diagnosis
The diagnosis of Cushing’s syndrome requires demonstration of increased 
cortisol production and abnormal cortisol suppression in response to dexa-
methasone. For initial screening, measurement of 24-h urinary free cortisol, 
the 1-mg overnight dexamethasone test [8 a.m. plasma cortisol <1.8 μg/dL 
(50 nmol/L)], or late-night salivary cortisol measurement is appropriate. 
Repeat testing or performance of more than one screening test may be 
required. Definitive diagnosis is established in equivocal cases by inad-
equate suppression of urinary cortisol [<10 μg/d (25 nmol/d)] or plasma 
cortisol [<5 μg/dL (140 nmol/L)] after 0.5 mg dexamethasone every 6 h 
for 48 h. Once the diagnosis of Cushing’s syndrome is established, further 
biochemical testing is required to localize the source. This evaluation is best 
performed by an experienced endocrinologist. Low levels of plasma ACTH 
levels suggest an adrenal adenoma or carcinoma; inappropriately normal 
or high plasma ACTH levels suggest a pituitary or ectopic source. In 95% 
of ACTH-producing pituitary microadenomas, cortisol production is sup-
pressed by high-dose dexamethasone (2 mg every 6 h for 48 h). MRI of the 
pituitary should be obtained but may not reveal a microadenoma because 
these tumors are typically very small. Furthermore, because up to 10% of 
ectopic sources of ACTH may also suppress after high-dose dexamethasone 
testing, inferior petrosal sinus sampling may be required to distinguish 
SECTION 13
1128
Endocrinology and Metabolism
pituitary from peripheral sources of ACTH. Testing with corticotropin-
releasing hormone (CRH) also may be helpful in determining the source 
of ACTH. Imaging of the chest and abdomen is required to localize the 
source of ectopic ACTH production; small bronchial carcinoids may escape 
detection by conventional CT. Pts with chronic alcoholism, depression, or 
obesity may have false-positive results in testing for Cushing’s syndrome—a 
condition named pseudo-Cushing’s syndrome. Similarly, pts with acute ill-
ness may have abnormal laboratory test results, since major stress alters the 
normal regulation of ACTH secretion.
Cushing’s Syndrome
TREATMENT
Uncontrolled hypercorticism carries a poor prognosis, and treatment of 
Cushing’s syndrome is therefore necessary. Transsphenoidal surgery for 
pituitary ACTH-secreting microadenomas is curative in 70–80% when 
performed by a highly experienced surgeon, but long-term follow-up 
is required because these tumors may recur. Radiation therapy may 
be used when a surgical cure is not achieved (Chap. 179). Therapy of 
adrenal adenoma or carcinoma requires surgical excision; stress doses 
of glucocorticoids must be given pre- and postoperatively. Metastatic 
and unresectable adrenal carcinomas are treated with mitotane in doses 
gradually increased to 6 g/d in three or four divided doses. On occasion, 
debulking of lung carcinoma or resection of carcinoid tumors can result 
in remission of ectopic Cushing’s syndrome. If the source of ACTH 
cannot be resected, medical management with ketoconazole (600–1200 
mg/d), metyrapone (2–3 g/d), or mitotane (2–3 mg/d) may relieve mani-
festations of cortisol excess. In some cases, bilateral total adrenalectomy 
is required to control hypercorticism. Pts with unresectable pituitary 
adenomas who have had bilateral adrenalectomy are at risk for Nelson’s 
syndrome (aggressive pituitary adenoma enlargement).
� HYPERALDOSTERONISM
Etiology 
Aldosteronism is caused by hypersecretion of the adrenal mineralocorticoid 
aldosterone. Primary hyperaldosteronism refers to an adrenal cause and can 
be due to either an adrenal adenoma or bilateral adrenal hyperplasia. Rare 
causes include glucocorticoid-remediable hyperaldosteronism, some forms 
of congenital adrenal hyperplasia, and other disorders of true or apparent 
mineralocorticoid excess (see Table 342-3, HPIM-18). The term secondary 
hyperaldosteronism is used when an extraadrenal stimulus for renin secre-
tion is present, as in renal artery stenosis, decompensated liver cirrhosis, or 
diuretic therapy.
Clinical Features 
Most pts with primary hyperaldosteronism have difficult to control hyperten-
sion (especially diastolic) and hypokalemia. Headaches are common. Edema 
is characteristically absent, unless congestive heart failure or renal disease is 
CHAPTER 182
1129
Adrenal Gland Disorders
present. Hypokalemia, caused by urinary potassium losses, may cause muscle 
weakness, fatigue, and polyuria, although potassium levels may be normal 
in mild primary hyperaldosteronism. Metabolic alkalosis is a typical feature.
Diagnosis
The diagnosis is suggested by treatment-resistant hypertension that is associ-
ated with persistent hypokalemia in a nonedematous pt who is not receiving 
potassium-wasting diuretics. In pts receiving potassium-wasting diuretics, 
the diuretic should be discontinued and potassium supplements should be 
administered for 1–2 weeks. If hypokalemia persists after supplementation, 
screening using a serum aldosterone and plasma renin activity should be per-
formed. Ideally, antihypertensives should be stopped before testing, but that 
is often impractical. Aldosterone receptor antagonists, beta-adrenergic block-
ers, ACE inhibitors, and angiotensin receptor blockers interfere with testing 
and should be substituted for other antihypertensives if possible. A ratio of 
serum aldosterone (in ng/dL) to plasma renin activity (in ng/mL per hour) 
>30 and an absolute level of aldosterone >15 ng/dL suggest primary aldoste-
ronism. Failure to suppress plasma aldosterone (to <5 ng/dL after 500 mL/h 
of normal saline × 4 h) or urinary aldosterone after saline or sodium loading 
(to <10 μg/d on day 3 of 200 mmol/d oral NaCl + fludrocortisone 0.2 mg 
twice daily × 3 days) confirms primary hyperaldosteronism. Caution should 
be used with sodium loading in a hypertensive pt. Localization should then 
be undertaken with a high-resolution CT scan of the adrenal glands. If the CT 
scan is negative, bilateral adrenal vein sampling may be required to diagnose 
a unilateral aldosterone-producing adenoma. Secondary hyperaldosteronism 
is associated with elevated plasma renin activity.
Hyperaldosteronism
TREATMENT
Surgery can be curative in pts with adrenal adenoma but is not effective 
for adrenal hyperplasia, which is managed with sodium restriction and 
spironolactone (25–100 mg twice daily) or eplerenone (25–50 mg twice 
daily). The sodium channel blocker amiloride (5–10 mg twice a day) 
also can be used. Secondary hyperaldosteronism is treated with salt 
restriction and correction of the underlying cause.
� SYNDROMES OF ADRENAL ANDROGEN EXCESS
See Chap. 186 for discussion of hirsutism and virilization.
HYPOFUNCTION OF THE ADRENAL GLAND
Primary adrenal insufficiency is due to failure of the adrenal gland, whereas 
secondary adrenal insufficiency is due to failure of ACTH production or release.
� ADDISON’S DISEASE
Etiology 
Addison’s disease occurs when >90% of adrenal tissue is destroyed. The 
most common cause is autoimmune destruction (alone, or as part of type I 
SECTION 13
1130
Endocrinology and Metabolism
or type II polyglandular autoimmune syndromes). Tuberculosis used to be 
the leading etiology. Other granulomatous diseases (histoplasmosis, coccid-
ioidomycosis, cryptococcosis, sarcoidosis), bilateral adrenalectomy, bilat-
eral tumor metastases, bilateral hemorrhage, CMV, HIV, amyloidosis, and 
congenital diseases (some types of congenital adrenal hypoplasia, adrenal 
hypoplasia congenita, and adrenoleukodystrophy) are additional etiologies.
Clinical Features 
Manifestations include fatigue, weakness, anorexia, nausea and vomiting, 
weight loss, abdominal pain, cutaneous and mucosal pigmentation, salt 
craving, hypotension (especially orthostatic), and, occasionally, hypogly-
cemia. Routine laboratory parameters may be normal, but typically serum 
Na is reduced and serum K increased. Extracellular fluid depletion accen-
tuates hypotension. In secondary adrenal insufficiency, pigmentation is 
diminished and serum potassium is not elevated. Serum Na tends to be low 
because of hemodilution stemming from excess vasopressin secreted in the 
setting of cortisol deficiency.
Diagnosis
The best screening test is the cortisol response 60 min after 250 μg ACTH 
(cosyntropin) IV or IM. Cortisol levels should exceed 18 μg/dL 30–60 min 
after the ACTH. If the response is abnormal, then primary and secondary 
deficiency may be distinguished by measurement of aldosterone from the 
same blood samples. In secondary, but not primary, adrenal insufficiency, 
the aldosterone increment from baseline will be normal (≥5 ng/dL). 
Furthermore, in primary adrenal insufficiency, plasma ACTH is elevated, 
whereas in secondary adrenal insufficiency, plasma ACTH values are low 
or inappropriately normal. Pts with recent onset or partial pituitary insuf-
ficiency may have a normal response to the rapid ACTH stimulation test. In 
these pts, alternative testing (metyrapone test or insulin tolerance testing) 
can be used for diagnosis.
Addison’s Disease
TREATMENT
Hydrocortisone, at 15–25 mg/d divided into ⅔ in the morning and ⅓ 
in the afternoon, is the mainstay of glucocorticoid replacement. Some 
pts benefit from doses administered three times daily, and other gluco-
corticoids may be given at equivalent doses. Mineralocorticoid supple-
mentation is usually needed for primary adrenal insufficiency, with 
administration of 0.05–0.1 mg fludrocortisone PO qd and maintenance 
of adequate Na intake. Doses should be titrated to normalize Na and K 
levels and to maintain normal blood pressure without postural changes. 
Measurement of plasma renin levels may also be useful in titrating the 
dose. Mineralocorticoid replacement is not needed in pts with second-
ary adrenal insufficiency. All pts with adrenal insufficiency should be 
instructed in the parenteral self-administration of steroids and should 
be registered with a medical alert system. During periods of intercurrent 
illness, the dose of hydrocortisone should be doubled. During adrenal
CHAPTER 182
1131
Adrenal Gland Disorders
crisis, high-dose hydrocortisone (10 mg/h continuous IV or 100-mg 
bolus IV three times a day) should be administered along with normal 
saline. Thereafter, if the pt is improving and is afebrile, the dose can be 
tapered by 20–30% daily to usual replacement doses.
� HYPOALDOSTERONISM
Isolated aldosterone deficiency accompanied by normal cortisol production 
occurs with hyporeninism, as an inherited aldosterone synthase deficiency, 
postoperatively following removal of aldosterone-secreting adenomas 
(transient), and during protracted heparin therapy. Hyporeninemic hypoal-
dosteronism is seen most commonly in adults with diabetes mellitus and 
mild renal failure; it is characterized by mild to moderate hyperkalemia. 
This is usually a benign condition that can be managed by observation. If 
needed, oral fludrocortisone (0.05–0.15 mg/d PO) restores electrolyte bal-
ance if salt intake is adequate. In pts with hypertension, mild renal insuf-
ficiency, or congestive heart failure, an alternative approach is to reduce salt 
intake and to administer furosemide.
INCIDENTAL ADRENAL MASSES
Adrenal masses are common findings on abdominal CT or MRI scans 
(1–7% prevalence with increasing age). The majority (70–80%) of such 
“incidentalomas” are clinically nonfunctional, and the probability of an 
adrenal carcinoma is low (<0.01%). Genetic syndromes such as MEN 1, 
MEN 2, Carney syndrome, and McCune-Albright syndrome are all associ-
ated with adrenal masses. The first step in evaluation is to determine the 
functional status by measurement of plasma free metanephrines to screen 
for pheochromocytoma (Fig. 182-1). In a pt with a known extraadrenal 
malignancy, there is a 30–50% chance that the incidentaloma is a metas-
tasis. Additional hormonal evaluation should include overnight 1-mg 
dexamethasone suppression testing in all pts, plasma renin activity/
aldosterone ratio in hypertensives, DHEAS in women with signs of andro-
gen excess, and estradiol in males with feminization. Fine-needle aspiration 
is rarely indicated and absolutely contraindicated if a pheochromocytoma 
is suspected. Adrenocortical cancer is suggested by large size (>4–6 cm), 
irregular margins, tumor inhomogeneity, soft tissue calcifications, and high 
unenhanced CT attenuation values (>10 HU).
CLINICAL USES OF GLUCOCORTICOIDS
Glucocorticoids are pharmacologic agents used for a variety of disorders 
such as asthma, rheumatoid arthritis, and psoriasis. The almost certain 
development of complications (weight gain, hypertension, Cushingoid 
facies, diabetes mellitus, osteoporosis, myopathy, increased intraocular 
pressure, ischemic bone necrosis, infection, and hyperlipidemia) must be 
weighed against the potential therapeutic benefits of glucocorticoid therapy. 
These side effects can be minimized by a careful choice of steroid prepara-
tions (Table 182-1), dose minimization, and alternate-day or interrupted 
therapy; the use of topical steroids, i.e., inhaled, intranasal, or dermal, 
whenever possible; the judicious use of nonsteroid therapies; monitoring of 
SECTION 13
1132
Endocrinology and Metabolism
FIGURE 182-1 Incidentaloma. *Adrenocortical hormonal evaluation: Dexamethasone 
suppression test in all pts; plasma renin activity/aldosterone ratio for hypertensives; 
sex steroid (DHEA sulfate, estradiol) for clinical signs in females and males, respec-
tively. †Hounsfield units (HU): a measurement of x-ray attenuation or lipid content of 
neoplasms. A lipid-rich mass (<10 HU) is diagnostic of a benign cortical adenoma. 
‡Benign characteristics: homogeneous mass, smooth borders, HU <10. ¶Benign ad-
renal adenomas are also characterized by earlier washout of contrast enhancement 
than other neoplasms.
  Resect
Fine-needle aspiration
>6 cm
Resect
? Hx of prior malignancy
Incidentaloma (adrenal mass ≥1 cm) 
+
–
+
–
+
–
Plasma metanephrines
Adrenocortical hormonal
evaluation∗
Consider
resection
Benign characteristics:¶
Early washout
Radiographic
evaluation (unenhanced CT)
assess size; characteristics (HU)†
>20 HU 
Delayed washout
(contrast enhanced)¶
Heterogeneous mass;
irregular borders
Repeat scan in 6 mo
to assess change
in size
Consider resection
No change.
Repeat scan in 1 year
<6 cm, >3 cm
<3 cm
Benign characteristics‡
INCIDENTALOMA
CHAPTER 182
1133
Adrenal Gland Disorders
caloric intake; and instituting measures to minimize bone loss. Pts should 
be evaluated for the risk of complications before the initiation of gluco-
corticoid therapy (Table 182-2). Higher doses of glucocorticoids may be 
required during periods of stress, since the hypothalamo-pituitary-adrenal 
axis is suppressed and the adrenal gland may atrophy in the setting of exog-
enous glucocorticoids. In addition, following long-term use, glucocorti-
coids should be tapered with the dual goals of allowing the pituitary-adrenal 
axis to recover and the avoidance of underlying disease flare.
For a more detailed discussion, see Arlt W: Disorders of the 
Adrenal Cortex, Chap. 342, p. 2940, in HPIM-18.
TABLE 182-1 GLUCOCORTICOID PREPARATIONS
Relative Potency
Generic Name
Glucocorticoid Mineralocorticoid Dose Equivalent
Short-acting
 Hydrocortisone
1.0
1.0
20.0
 Cortisone
0.8
0.8
25.0
Intermediate-acting
 Prednisone
4.0
0.25
5.0
 Methylprednisolone 5.0
0
4.0
 Triamcinolone
5.0
0
4.0
Long-acting
 Dexamethasone
30.0
0
0.75
 Betamethasone
25.0
0
0.8
TABLE 182-2  A CHECKLIST FOR USE PRIOR TO THE ADMINISTRATION OF 
GLUCOCORTICOIDS IN PHARMACOLOGIC DOSES
Presence of tuberculosis or other chronic infection (chest x-ray, tuberculin test)
Evidence of glucose intolerance, history of gestational diabetes mellitus, or 
high risk for type 2 diabetes mellitus
Evidence of preexisting osteoporosis (bone density assessment in organ 
transplant recipients or postmenopausal pts)
History of peptic ulcer, gastritis, or esophagitis (stool guaiac test)
Evidence of hypertension, cardiovascular disease, or hypertriglyceridemia
History of psychological disorders
SECTION 13
1134
Endocrinology and Metabolism
CHAPTER 183
Obesity
Obesity is a state of excess adipose tissue mass. Obesity should not be 
defined by body weight alone, as muscular individuals may be overweight 
by arbitrary standards without having increased adiposity. The most widely 
used method to classify weight status and risk of disease is the body mass 
index (BMI), which is equal to weight/height2 in kg/m2 (Table 183-1). At a 
similar BMI, women have more body fat than men. Furthermore, regional 
fat distribution may influence the risks associated with obesity. Central 
(primarily visceral) obesity [high ratio of the circumference of the waist to 
the circumference of the hips (waist-to-hip ratio), >0.9 in women and 1.0 
in men] is independently associated with a higher risk for metabolic syn-
drome, diabetes mellitus, hyperandrogenism in women, and cardiovascular 
disease. The prevalence of obesity has increased dramatically over the past 
3 decades. In the United States in 2008, 34% of adults age >20 were obese 
(BMI >30), and another 34% were overweight (BMI 25–30). Most alarming 
is the same trend among children, where 17% between ages 2 and 19 were 
obese, and another 18% were overweight. This has led to an epidemic of 
type 2 diabetes in children, a condition almost never seen until recently. 
These trends to increased obesity are not limited to Western societies but 
are occurring worldwide.
� ETIOLOGY
Obesity can result from increased energy intake, decreased energy expen-
diture, or a combination of the two. Excess accumulation of body fat is the 
consequence of environmental and genetic factors; social factors and eco-
nomic conditions also represent important influences. The recent increase 
in obesity can be attributed to a combination of excess caloric intake and 
decreasing physical activity. Poorly understood reasons for increased food 
TABLE 183-1 CLASSIFICATION OF WEIGHT STATUS AND RISK OF DISEASE
BMI (kg/m2)
Obesity Class
Risk of Disease
Underweight
<18.5
Healthy weight
18.5–24.9
Overweight
25.0–29.9
Increased
Obesity
30.0–34.9
I
High
Obesity
35.0–39.9
II
Very high
Extreme obesity ≥40
III
Extremely high
Source: Adapted from National Institutes of Health, National Heart, Lung, and Blood Institute: 
Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity 
in Adults. U.S. Department of Health and Human Services, Public Health Service, 1998.
CHAPTER 183
1135
Obesity
assimilation due to dietary composition have also been postulated, as have 
sleep deprivation and an unfavorable gut flora. The susceptibility to obesity 
is polygenic in nature, and 30–50% of the variability in total fat stores is 
believed to be genetically determined. Among monogenic causes, muta-
tions in the melanocortin receptor 4 are most common and account for 
~1% of obesity in the general population and ~6% in severe, early-onset 
obesity. Syndromic obesity forms include Prader-Willi syndrome and 
Laurence-Moon-Biedl syndrome. Other monogenetic or syndromic causes 
are extremely rare. Secondary causes of obesity include hypothalamic 
injury, hypothyroidism, Cushing’s syndrome, and hypogonadism. Drug-
induced weight gain is also common in those who use antidiabetes agents 
(insulin, sulfonylureas, thiazolidinediones), glucocorticoids, psychotropic 
agents, mood stabilizers (lithium), antidepressants (tricyclics, monoamine 
oxidase inhibitors, paroxetine, mirtazapine), or antiepileptic drugs (valpro-
ate, gabapentin, carbamazepine). Insulin-secreting tumors can cause over-
eating and weight gain.
� CLINICAL FEATURES
Obesity has major adverse effects on health. Increased mortality from obe-
sity is primarily due to cardiovascular disease, hypertension, gall bladder 
disease, diabetes mellitus, and several types of cancer, such as cancer of 
the esophagus, colon, rectum, pancreas, liver, and prostate, and gallblad-
der, bile ducts, breasts, endometrium, cervix, and ovaries in women. Sleep 
apnea in severely obese individuals poses serious health risks. Obesity is 
also associated with an increased incidence of steatohepatitis, gastroesopha-
geal reflux, osteoarthritis, gout, back pain, skin infections, and depression. 
Hypogonadism in men and infertility in both sexes are prevalent in obesity; 
in women this may be associated with hyperandrogenism (polycystic ovar-
ian syndrome).
Obesity
TREATMENT
Obesity is a chronic medical condition that requires ongoing treatment 
and lifestyle modifications. Treatment is important because of the asso-
ciated health risks, but is made difficult by a limited repertoire of effec-
tive therapeutic options. Weight regain after weight loss is common with 
all forms of therapy. The urgency and selection of treatment modalities 
should be based on BMI and a risk assessment.
Diet, exercise, and behavior therapy are recommended for all pts with 
a BMI ≥25 kg/m2. Behavior modification including group counseling, 
diet diaries, and changes in eating patterns should be initiated. Food-
related behaviors should be monitored carefully (avoid cafeteria-style 
settings, eat small and frequent meals, eat breakfast). A deficit of 7500 
kcal will produce a weight loss of approximately 1 kg. Therefore, eating 
100 kcal/d less for a year should cause a 5-kg weight loss, and a deficit 
of 1000 kcal/d should cause a loss of ~1 kg per week. Physical activity 
should be increased to a minimum of 150 min of moderate intensity 
physical activity per week.
SECTION 13
1136
Endocrinology and Metabolism
Pharmacotherapy may be added to a lifestyle program for pts with a 
BMI ≥30 kg/m2 or ≥27 kg/m2 with concomitant obesity-related diseases. 
Orlistat is the only pharmacologic agent currently approved by the 
U.S. Food and Drug Administration for treatment of obesity; several 
others have been withdrawn from the market because of significant 
adverse effects. Orlistat, an inhibitor of intestinal lipase, causes modest 
weight loss (9–10% at 12 months with lifestyle measures) due to drug-
induced fat malabsorption. Metformin, exenatide, and liraglutide tend 
to decrease body weight in pts with obesity and type 2 diabetes mellitus, 
but they are not indicated for pts without diabetes.
x
x
y
y
z
z
100 cm
150 cm
A
B
C
D
FIGURE 183-1 Bariatric surgical procedures. Examples of operative interventions 
used for surgical manipulation of the gastrointestinal tract. A. Laparoscopic gastric 
band (LAGB). B. The Roux-en-Y gastric bypass. C. Biliopancreatic diversion with 
duodenal switch. D. Biliopancreatic diversion. (From ML Kendrick, GF Dakin, Surgical 
approaches to obesity. Mayo Clinic Proc 815:518, 2006; with permission.)
CHAPTER 184
1137
Diabetes Mellitus
Bariatric surgery should be considered for pts with severe obesity (BMI 
≥40 kg/m2) or moderate obesity (BMI ≥35 kg/m2) associated with a serious 
medical condition, with repeated failures of other therapeutic approaches, 
at eligible weight for >3 years, capable of tolerating surgery, and without 
addictions or major psychopathology. Weight-loss surgeries are either 
restrictive (limiting the amount of food the stomach can hold and slow-
ing gastric emptying), such as laparoscopic adjustable silicone gastric 
banding, or restrictive-malabsorptive, such as Roux-en-Y gastric bypass 
(Fig. 183-1). These procedures generally produce a 30–35% weight loss 
that is maintained in about 40% of pts at 4 years. Complications include 
stomal stenosis, marginal ulcers, and dumping syndrome. Procedures 
with a malabsorptive component require lifelong supplementation of 
micronutrients (iron, folate, calcium, vitamins B12 and D) and are associ-
ated with a risk of islet cell hyperplasia and hypoglycemia.
For a more detailed discussion, see Flier JS, Maratos-Flier 
E: Biology of Obesity, Chap. 77, p. 622 and Kushner RF: 
Evaluation and Management of Obesity, Chap. 78, p. 629, 
in HPIM-18. 
CHAPTER 184
Diabetes Mellitus
� ETIOLOGY AND PREVALENCE
Diabetes mellitus (DM) comprises a group of metabolic disorders that share 
the common phenotype of hyperglycemia. DM is currently classified on 
the basis of the pathogenic process that leads to hyperglycemia. Type 1 DM 
is characterized by insulin deficiency and a tendency to develop ketosis, 
whereas type 2 DM is a heterogeneous group of disorders characterized by 
variable degrees of insulin resistance, impaired insulin secretion, and exces-
sive hepatic glucose production. Other specific types include DM caused by 
genetic defects [maturity-onset diabetes of the young (MODY) and other 
rare monogenic disorders], diseases of the exocrine pancreas (chronic pan-
creatitis, cystic fibrosis, hemochromatosis), endocrinopathies (acromegaly, 
Cushing’s syndrome, glucagonoma, pheochromocytoma, hyperthyroidism), 
drugs (nicotinic acid, glucocorticoids, thiazides, protease inhibitors), and 
pregnancy (gestational DM). The phenotype of these monogenetic and sec-
ondary types of DM typically resembles type 2 DM; its severity depends on 
the degree of beta cell dysfunction and prevailing insulin resistance. Type 1 
DM usually results from autoimmune destruction of pancreatic beta cells; 
it is also known as juvenile-onset diabetes because its peak incidence is in 
children and adolescents. 
The prevalence of DM is increasing rapidly; type 2 DM frequency in 
particular is rising in parallel with the epidemic of obesity (Chap. 183). 
SECTION 13
1138
Endocrinology and Metabolism
Between 1985 and 2010, the worldwide prevalence of DM has risen almost 
10-fold, from 30 million to 285 million cases. In the United States, DM 
prevalence in 2010 is estimated at 26 million, or 8.4% of the population. A 
significant portion of persons with DM are undiagnosed.
DM is attended by serious morbidity and significant mortality; it is the 
fifth leading cause of death worldwide.
� DIAGNOSIS
Criteria for the diagnosis of DM include one of the following:
• Fasting plasma glucose ≥7.0 mmol/L (≥126 mg/dL)
• Symptoms of diabetes plus a random blood glucose concentration ≥11.1 
mmol/L (≥200 mg/dL)
• 2-h plasma glucose ≥11.1 mmol/L (≥200 mg/dL) during a 75-g oral glu-
cose tolerance test.
• Hemoglobin A1c >6.5%
These criteria should be confirmed by repeat testing on a different day, 
unless unequivocal hyperglycemia is present.
Two intermediate categories also have been designated:
• Impaired fasting glucose (IFG) for a fasting plasma glucose level of 
5.6–6.9 mmol/L (100–125 mg/dL)
• Impaired glucose tolerance (IGT) for plasma glucose levels of 7.8–11.1 
mmol/L (140–199 mg/dL) 2 h after a 75-g oral glucose load
Individuals with IFG or IGT do not have DM but are at substantial risk 
for developing type 2 DM and cardiovascular disease in the future. 
Screening with a fasting plasma glucose level is recommended every 3 
years for individuals over the age of 45, as well as for younger individuals 
who are overweight (body mass index ≥25 kg/m2) and have one or more 
additional risk factors (Table 184-1).
The metabolic syndrome (also known as insulin resistance syndrome or 
syndrome X) is a term used to describe a commonly found constellation 
of metabolic derangements that includes insulin resistance (with or with-
out diabetes), hypertension, dyslipidemia, central or visceral obesity, and 
endothelial dysfunction and is associated with accelerated cardiovascular 
disease (Chap. 127).
� CLINICAL FEATURES
Common presenting symptoms of DM include polyuria, polydipsia, 
weight loss, fatigue, weakness, blurred vision, frequent superficial infec-
tions, and poor wound healing. In early type 2 DM, symptoms may be 
more subtle and consist of fatigue, poor wound healing, and paresthesias. 
The lack of symptoms is the main reason for the delayed diagnosis of 
type 2 DM. A complete medical history should be obtained with special 
emphasis on weight, exercise, smoking, ethanol use, family history of DM, 
and risk factors for cardiovascular disease. In a pt with established DM, 
assessment of prior diabetes care, HbA1c levels, self-monitoring blood 
glucose results, frequency of hypoglycemia, and pt’s knowledge about DM 
CHAPTER 184
1139
Diabetes Mellitus
should be obtained. Special attention should be given on physical exam 
to retinal exam, orthostatic bp, foot exam (including vibratory sensation 
and monofilament testing), peripheral pulses, and insulin injection sites. 
Acute complications of DM that may be seen on presentation include dia-
betic ketoacidosis (DKA) (type 1 DM) and hyperglycemic hyperosmolar 
state (type 2 DM) (Chap. 24).
The chronic complications of DM are listed below:
• Ophthalmologic: nonproliferative or proliferative diabetic retinopathy, 
macular edema, rubeosis of iris, glaucoma, cataracts
• Renal: proteinuria, end-stage renal disease (ESRD), type IV renal tubular 
acidosis
• Neurologic: distal symmetric polyneuropathy, polyradiculopathy, mono-
neuropathy, autonomic neuropathy
• Gastrointestinal: gastroparesis, diarrhea, constipation
• Genitourinary: cystopathy, erectile dysfunction, female sexual dysfunc-
tion, vaginal candidiasis
• Cardiovascular: coronary artery disease, congestive heart failure, periph-
eral vascular disease, stroke
• Lower extremity: foot deformity (hammer toe, claw toe, Charcot foot), 
ulceration, amputation
• Dermatologic: Infections (folliculitis, furunculosis, cellulitis), necrobio-
sis, poor healing, ulcers, gangrene
• Dental: Periodontal disease
TABLE 184-1  CRITERIA FOR TESTING FOR PRE-DIABETES AND DIABETES 
IN ASYMPTOMATIC INDIVIDUALSa
Risk Factors
• First-degree relative with diabetes
• Physical inactivity
•  Race/ethnicity (e.g., African American, Latino, Native American, Asian 
American, Pacific Islander)
• Previously identified IFG, IGT, or a hemoglobin A1C of 5.7–6.4%
• History of GDM or delivery of baby >4 kg (>9 lb)
• Hypertension (blood pressure ≥140/90 mmHg)
•  HDL cholesterol level ≤0.90 mmol/L (35 mg/dL) and/or a triglyceride level 
≥2.82 mmol/L (250 mg/dL)
• Polycystic ovary syndrome or acanthosis nigricans
• History of vascular disease
aTesting should be considered in all adults at age 45 and adults <45 y with BMI ≥25 kg/m2
and one or more of the following risk factors for diabetes.
Abbreviations: BMI, body mass index; GDM, gestational diabetes mellitus; HDL, high-density 
lipoprotein; IFG, impaired fasting glucose; IGT, impaired glucose tolerance.
Source: Adapted from American Diabetes Association, 2011.
SECTION 13
1140
Endocrinology and Metabolism
Diabetes Mellitus
TREATMENT
Optimal treatment of DM requires more than plasma glucose manage-
ment. Comprehensive diabetes care should also detect and manage 
DM-specific complications and modify risk factors for DM-associated 
diseases. The pt with type 1 or type 2 DM should receive education 
about nutrition, exercise, care of diabetes during illness, and medica-
tions to lower the plasma glucose. In general, the target HbA1c level 
should be <7.0%, although individual considerations (age, ability to 
implement a complex treatment regimen, and presence of other medical 
conditions) should also be taken into account. Intensive therapy reduces 
long-term complications but is associated with more frequent and more 
severe hypoglycemic episodes. Goal preprandial capillary plasma glu-
cose levels should be 3.9–7.2 mmol/L (70–130 mg/dL) and postprandial 
levels should be <10.0 mmol/L (<180 mg/dL) 1–2 h after a meal.
In general, pts with type 1 DM require 0.5–1.0 U/kg per day of insu-
lin divided into multiple doses. Combinations of insulin preparations 
with different times of onset and duration of action should be used 
(Table 184-2). Preferred regimens include injection of glargine at bedtime 
with preprandial lispro, glulisine, or insulin aspart or continuous SC insu-
lin using an infusion device. Pramlintide, an injectable amylin analogue, 
can be used as adjunct therapy to control postprandial glucose excursions.
Pts with type 2 DM may be managed with diet and exercise alone or 
in conjunction with oral glucose-lowering agents, insulin, or a combi-
nation of oral agents and insulin. The classes of oral glucose-lowering 
agents and dosing regimens are listed in Table 184-3. In addition, 
exenatide and liraglutide are injectable glucagon-like peptide 1 (GLP-1, 
an incretin) analogues that may be used in combination with metformin 
or sulfonylureas. A reasonable treatment algorithm for initial therapy 
proposes metformin as initial therapy because of its efficacy (1–2% 
decrease in HbA1c), known side-effect profile, and relatively low cost 
(Fig. 184-1). Metformin has the advantage that it promotes mild weight 
loss, lowers insulin levels, improves the lipid profile slightly, lowers can-
cer risk, and does not cause hypoglycemia when used as monotherapy, 
although it is contraindicated in renal insufficiency, congestive heart 
failure, any form of acidosis, liver disease, or severe hypoxia, and should 
be temporarily discontinued in pts who are seriously ill or receiving 
radiographic contrast material. Metformin therapy can be followed by 
addition of a second oral agent (insulin secretagogue, DPP-IV inhibitor, 
thiazolidinedione, or α-glucosidase inhibitor). Combinations of two oral 
agents may be used with additive effects, with stepwise addition of bed-
time insulin or a third oral agent if adequate control is not achieved. As 
endogenous insulin production falls, multiple injections of long-acting 
and short-acting insulin may be required, as in type 1 DM. Individuals 
who require >1 U/kg per day of long-acting insulin should be consid-
ered for combination therapy with an insulin-sensitizing agent such as 
metformin or a thiazolidinedione. Insulin-requiring type 2 DM pts may 
also benefit from addition of pramlintide.
CHAPTER 184
1141
Diabetes Mellitus
The morbidity and mortality of DM-related complications can 
be greatly reduced by timely and consistent surveillance procedures 
(Table 184-4). A routine urinalysis may be performed as an initial screen 
for diabetic nephropathy. If it is positive for protein, quantification of 
protein on a 24-h urine collection should be performed. If the urinalysis 
is negative for protein, a spot collection for microalbuminuria should 
be performed (present if 30–300 μg/mg creatinine on two of three tests 
within a 3- to 6-month period). A resting ECG should be performed in 
adults, with more extensive cardiac testing for high-risk pts. Therapeutic 
goals to prevent complications of DM include management of protein-
uria with ACE inhibitor or angiotensin receptor blocker therapy, bp 
control (<130/80 mmHg if no proteinuria, <125/75 if proteinuria), and 
dyslipidemia management [LDL <2.6 mmol/L (<100 mg/dL), HDL >1.1 
mmol/L (>40 mg/dL) in men and >1.38 mmol/L (50 mg/dL) in women, 
triglycerides <1.7 mmol/L (<150 mg/dL)]. In addition, any diabetic pt 
>40 years should take a statin, regardless of the LDL cholesterol, and in
TABLE 184-2 PROPERTIES OF INSULIN PREPARATIONS
Time of Action
Preparation
Onset, h
Peak, h 
Effective Duration, h
Short-acting
Aspart
<0.25
0.5–1.5
3–4
 Glulisine
<0.25
0.5–1.5
3–4
 Lispro
<0.25
0.5–1.5
3–4
 Regular
0.5–1.0
2–3
4–6
Long-acting
 Detemir
1–4
—a
Up to 24
 Glargine
1–4
—a
Up to 24
 NPH
1–4
6–10
10–16
Insulin combinations
  75/25–75% protamine 
lispro, 25% lispro
<0.25
1.5 h
Up to 10–16
  70/30–70% protamine 
aspart, 30% aspart
<0.25
1.5 h
Up to 10–16
  50/50–50% protamine 
lispro, 50% lispro
<0.25
1.5 h
Up to 10–16
  70/30–70% NPH, 30% 
regular
0.5–1
Dualb
10–16
aGlargine and detemir have minimal peak activity.
bDual: two peaks—one at 2–3 h and the second one several hours later.
Source: Adapted from JS Skyler: Therapy for Diabetes Mellitus and Related Disorders,
American Diabetes Association, Alexandria, VA, 2004.
SECTION 13
1142
Endocrinology and Metabolism
TABLE 184-3 ORAL GLUCOSE-LOWERING AGENTS
Agent
Daily
Dose, mg
Doses/d
Contraindications
Biguanide
Creatinine >133 μmol/L (1.5 
mg/dL) (men); >124 μmol/L
(1.4 mg/dL) (women); CHF; 
liver disease
 Metformin
500–2500
1–3
Sulfonylureas
Renal/liver disease
 Glimepiride
1–8
1
 Glipizide
2.5–40
1–2
  Glipizide (ext. 
release)
5–10
1
 Glyburide
1.25–20
1–2
  Glyburide 
(micronized)
0.75–12
1–2
Non-sulfonylurea 
secretagogue
Renal/liver disease
 Repaglinide
0.5–16
1–4
 Nateglinide
180–360
1–3
α-Glucosidase
inhibitor
IBD, liver disease, or Cr 
>177 μmol/L (2.0 mg/dL)
 Acarbose
25–300
1–3
 Miglitol
25–300
1–3
Thiazolidinedione
Liver disease, CHF
 Pioglitazone
15–45
1
DPP-IV inhibitor
↓ Dose with renal failure
 Sitagliptin
100
1
 Saxagliptin
2.5–5
1
 Linagliptin
5
1
 Vildagliptin
50–100
1
those with existing cardiovascular disease, the LDL target should be <1.8 
mmol/L (70 mg/dL).
MANAGEMENT OF THE HOSPITALIZED PATIENT
The goals of diabetes management during hospitalization are near-
normal glycemic control, avoidance of hypoglycemia, and transition 
back to the outpatient diabetes treatment regimen. Pts with type 1 DM 
undergoing general anesthesia and surgery, or with serious illness, should 
receive continuous insulin, either through an IV insulin infusion or by
CHAPTER 184
1143
Diabetes Mellitus
FIGURE 184-1 Glycemic management of type 2 diabetes. Agents that can be com-
bined with metformin include insulin secretagogues, thiazolidinediones, α-glucosidase 
inhibitors, DPP-IV inhibitors, and GLP-1 receptor agonists. A1c, hemoglobin A1c.
Insulin + metformin
Reassess A1C
Reassess A1C
Reassess A1C
Patient with type 2 diabetes
Medical nutrition therapy,
increased physical activity,
weight loss
+
metformin
Combination therapy
-metformin + second agent
Combination therapy
-metformin + two
other agents
TABLE 184-4  GUIDELINES FOR ONGOING MEDICAL CARE FOR PATIENTS 
WITH DIABETES
• Self-monitoring of blood glucose (individualized frequency)
• A1c testing (2–4 times/year)
• Pt education in diabetes management (annual)
• Medical nutrition therapy and education (annual)
• Eye examination (annual)
• Foot examination (1–2 times/year by physician; daily by pt)
• Screening for diabetic nephropathy (annual; see Fig. 344-11 )
• Blood pressure measurement (quarterly)
• Lipid profile and serum creatinine (estimate GFR) (annual)
• Influenza/pneumococcal immunizations
• Consider antiplatelet therapy (see text)
Abbreviation: A1c, hemoglobin A1c.
SECTION 13
1144
Endocrinology and Metabolism
SC administration of a reduced dose of long-acting insulin. Short-
acting insulin alone is insufficient to prevent the onset of diabetic 
ketoacidosis. Oral hypoglycemic agents should be discontinued in pts 
with type 2 DM at the time of hospitalization. Either regular insulin 
infusion (0.05–0.15 U/kg per hour) or a reduced dose (by 30–50%) 
of long-acting insulin and short-acting insulin (held, or reduced 
by 30–50%), with infusion of a solution of 5% dextrose, should be 
administered when pts are NPO for a procedure. A regimen of long- 
and short-acting SC insulin should be used in type 2 pts who are 
eating. The glycemic goal for hospitalized pts with DM should be a 
preprandial glucose of <7.8 mmol/L (<140 mg/dL) and <10 mmol/L 
(<180 mg/dL) at post-meal times. For critically ill pts, glucose levels 
of 7.8–10.0 mmol/L (140–180 mg/dL) are recommended. Those with 
DM undergoing radiographic procedures with contrast dye should be 
well hydrated before and after dye exposure, and the serum creatinine 
should be monitored after the procedure.
For a more detailed discussion, see Powers AC: Diabetes 
Mellitus, Chap. 344, p. 2968, in HPIM-18. 
CHAPTER 185
Disorders of the Male 
Reproductive System
The testes produce sperm and testosterone. Inadequate production of 
sperm can occur in isolation or in the presence of androgen deficiency, 
which impairs spermatogenesis secondarily.
� ANDROGEN DEFICIENCY
Etiology 
Androgen deficiency can be due to either testicular failure (primary hypo-
gonadism) or hypothalamic-pituitary defects (secondary hypogonadism).
Primary hypogonadism is diagnosed when testosterone levels are 
low and gonadotropin levels [luteinizing hormone (LH) and follicle-
stimulating hormone (FSH)] are high. Klinefelter’s syndrome is the most 
common cause (~1 in 1000 male births) and is due to the presence of 
one or more extra X chromosomes, usually a 47,XXY karyotype. Other 
genetic causes of testicular development, androgen biosynthesis, or 
androgen action are uncommon. Acquired primary testicular failure 
usually results from viral orchitis but may be due to trauma, testicular 
torsion, cryptorchidism, radiation damage, or systemic diseases such as 
CHAPTER 185
1145
Disorders of the Male Reproductive System 
amyloidosis, Hodgkin’s disease, sickle cell disease, or granulomatous dis-
eases. Testicular failure can occur as a part of polyglandular autoimmune 
failure syndrome. Malnutrition, AIDS, renal failure, liver cirrhosis, 
myotonic dystrophy, paraplegia, and toxins such as alcohol, marijuana, 
heroin, methadone, lead, and antineoplastic and chemotherapeutic agents 
also can cause testicular failure. Testosterone synthesis may be blocked 
by ketoconazole, and testosterone action may be blocked at the androgen 
receptor level by spironolactone or cimetidine.
Secondary hypogonadism is diagnosed when levels of both testosterone 
and gonadotropins are low (hypogonadotropic hypogonadism). Kallmann 
syndrome is due to maldevelopment of neurons producing gonadotropin-
releasing hormone (GnRH) and is characterized by GnRH deficiency, 
low levels of LH and FSH, and anosmia. Several other types of GnRH 
deficiency or gonadotropin deficiency present without anosmia. Acquired 
causes of isolated hypogonadotropic hypogonadism include critical 
illness, excessive stress, obesity, Cushing’s syndrome, opioid and mari-
juana use, hemochromatosis, and hyperprolactinemia (due to pituitary 
adenomas or drugs such as phenothiazines). Destruction of the pituitary 
gland by tumors, infection, trauma, or metastatic disease causes hypo-
gonadism in conjunction with deficiency of other pituitary hormones 
(see Chap. 179). Normal aging is associated with a progressive decline 
of testosterone production, which is due to downregulation of the entire 
hypothalamo-pituitary-testicular axis. 
Clinical Features
The history should focus on developmental stages such as puberty and 
growth spurts, as well as androgen-dependent events such as early morn-
ing erections, frequency and intensity of sexual thoughts, and frequency 
of masturbation or intercourse. The physical examination should focus 
on secondary sex characteristics such as hair growth in the face, axilla, 
chest, and pubic regions; gynecomastia; testicular volume; prostate; and 
height and body proportions. Eunuchoidal proportions are defined as an 
arm span >2 cm greater than height and suggest that androgen deficiency 
occurred prior to epiphyseal fusion. Normal testicular size ranges from 
3.5–5.5 cm in length, which corresponds to a volume of 12–25 mL. The 
presence of varicocele should be sought by palpation of the testicular 
veins with the pt standing. Pts with Klinefelter’s syndrome have small 
(1–2 mL), firm testes.
A morning total testosterone level <10.4 nmol/L (<300 ng/dL), in 
association with symptoms, suggests testosterone deficiency. A level of 
>12.1 nmol/L (>350 ng/dL) makes the diagnosis of androgen deficiency 
unlikely. In men with testosterone levels between 6.9 and 12.1 nmol/L 
(200 and 350 ng/dL), the total testosterone level should be repeated and a 
free testosterone level should be measured by a reliable method. In older 
men and in pts with other clinical states that are associated with altera-
tions in sex hormone–binding globulin levels, a direct measurement of 
free testosterone by equilibrium dialysis can be useful in unmasking tes-
tosterone deficiency. When androgen deficiency has been confirmed by 
low testosterone concentrations, LH should be measured to classify the pt 
SECTION 13
1146
Endocrinology and Metabolism
as having primary (high LH) or secondary (low or inappropriately normal 
LH) hypogonadism. In men with primary hypogonadism of unknown 
cause, a karyotype should be performed to exclude Klinefelter’s syndrome. 
Measurement of a prolactin level and MRI of the hypothalamic-pituitary 
region should be considered in men with secondary hypogonadism. 
Gynecomastia in the absence of androgen deficiency should be further 
evaluated (Fig. 185-1).
FIGURE 185-1 Evaluation of gynecomastia. T, testosterone; LH, luteinizing hormone; 
FSH, follicle-stimulating hormone; hCGβ, human chorionic gonadotropin β; E2, 
17β-estradiol.
Increased aromatization of
  androgen to estrogen (obesity,
  feminizing adrenal tumors,
  Sertoli cell tumors, inherited
  dysregulation of aromatase)
Breast Enlargement
True glandular enlargement
Breast mass hard or fixed to
  the underlying tissue
Recent onset and rapid growth
Mammography and/or
  biopsy to exclude
  malignancy
Follow-up with serial
  examinations
Increased E2,
  normal T, altered
  E2/T ratio
Increased hCGβ
Exclude hCG
  secreting tumors 
Low T, high
  E2/T ratio
Androgen deficiency
  syndrome
Serum T, LH, FSH,
  estradiol, and hCGβ
Onset in neonatal or
  peripubertal period
Causative drugs
Known liver disease
Size <4 cm
Clinical evidence of androgen
  deficiency
Breast tenderness
Very small testes
Glandular tissue >4 cm in diameter
Absence of causative drugs or
  liver disease 
Increased adipose tissue
CHAPTER 185
1147
Disorders of the Male Reproductive System 
Androgen Deﬁ ciency
TREATMENT
Treatment of hypogonadal men with androgens restores normal male 
secondary sexual characteristics (beard, body hair, external genitalia), 
male sexual drive, and masculine somatic development (hemoglobin, 
muscle mass), but not fertility. Administration of gradually increasing 
doses of testosterone is recommended for disorders in which hypogo-
nadism occurred prior to puberty. Testosterone levels in the normal 
range may be achieved through daily application of transdermal testos-
terone patches (5–10 mg/d) or gel (50–100 mg/d), parenteral adminis-
tration of a long-acting testosterone ester (e.g., 100–200 mg testosterone 
enanthate at 1- to 3-week intervals) or buccal testosterone tablets (30 
mg/d). Hematocrit should be monitored initially during testosterone 
therapy and the dose lowered if Hct is >54%. Prostate cancer, severe 
symptoms of lower urinary tract obstruction, baseline hematocrit >50%, 
severe sleep apnea, and class IV congestive heart failure are contraindi-
cations for androgen replacement. Gonadotropin therapy for secondary 
hypogonadism should be reserved for fertility induction.
� MALE INFERTILITY
Etiology
Male infertility plays a role in 25% of infertile couples (couples who fail to 
conceive after 1 year of unprotected intercourse). Known causes of male 
infertility include primary hypogonadism (30–40%), disorders of sperm 
transport (10–20%), and secondary hypogonadism (2%), with an unknown 
etiology in up to half of men with suspected male factor infertility (see 
Fig. 186-3). Impaired spermatogenesis occurs with testosterone deficiency 
but may also be present without testosterone deficiency. Y chromosome 
microdeletions and substitutions, viral orchitis, tuberculosis, STDs, radia-
tion, chemotherapeutic agents, and environmental toxins have all been 
associated with isolated impaired spermatogenesis. Prolonged elevations 
of testicular temperature, as in varicocele, in cryptorchidism, or after an 
acute febrile illness, may impair spermatogenesis. Ejaculatory obstruction 
can be a congenital (cystic fibrosis, in utero diethylstilbestrol exposure, or 
idiopathic) or acquired (vasectomy, accidental ligation of the vas deferens, 
or obstruction of the epididymis) etiology of male infertility. Androgen 
abuse by male athletes can lead to testicular atrophy and a low sperm count.
Clinical Features 
Evidence of hypogonadism may or may not be present. Testicular size and 
consistency may be abnormal, and a varicocele may be apparent on palpa-
tion. When the seminiferous tubules are damaged prior to puberty, the 
testes are small (usually <12 mL) and firm, whereas postpubertal damage 
causes the testes to be soft (the capsule, once enlarged, does not contract 
to its previous size). The key diagnostic test is a semen analysis. Sperm 
counts of <13 million/mL, motility of <32%, and <9% normal morphology 
are associated with subfertility. Testosterone levels should be measured if 
SECTION 13
1148
Endocrinology and Metabolism
the sperm count is low on repeated exam or if there is clinical evidence of 
hypogonadism.
Male Infertility
TREATMENT
Men with primary hypogonadism occasionally respond to androgen 
therapy if there is minimal damage to the seminiferous tubules, whereas 
those with secondary hypogonadism require gonadotropin therapy to 
achieve fertility. Fertility occurs in about half of men with varicocele 
who undergo surgical repair. In vitro fertilization is an option for men 
with mild to moderate defects in sperm quality; intracytoplasmic sperm 
injection (ICSI) has been a major advance for men with severe defects 
in sperm quality.
� ERECTILE DYSFUNCTION
Etiology 
Erectile dysfunction (ED) is the failure to achieve erection, ejaculation, or 
both. It affects 10–25% of middle-aged and elderly men. ED may result 
from three basic mechanisms: (1) failure to initiate (psychogenic, endo-
crinologic, or neurogenic); (2) failure to fill (arteriogenic); or (3) failure 
to store adequate blood volume within the lacunar network (venooc-
clusive dysfunction). Diabetic, atherosclerotic, and drug-related causes 
account for >80% of cases of ED in older men. The most common organic 
cause of ED is vasculogenic; 35–75% of men with diabetes have ED due 
to a combination of vascular and neurologic complications. Psychogenic 
causes of ED include performance anxiety, depression, relationship con-
flict, sexual inhibition, history of sexual abuse in childhood, and fear of 
pregnancy or sexually transmitted disease. Among the antihypertensive 
agents, the thiazide diuretics and beta blockers have been implicated most 
frequently. Estrogens, GnRH agonists and antagonists, H2 antagonists, 
and spironolactone suppress gonadotropin production or block androgen 
action. Antidepressant and antipsychotic agents—particularly neuroleptics, 
tricyclics, and selective serotonin reuptake inhibitors—are associated with 
erectile, ejaculatory, orgasmic, and sexual desire difficulties. Recreational 
drugs, including ethanol, cocaine, and marijuana, also may cause ED. Any 
disorder that affects the sacral spinal cord or the sensory nerves or auto-
nomic fibers innervating the penis may lead to ED.
Clinical Features 
Men with sexual dysfunction may complain of loss of libido, inability to 
initiate or maintain an erection, ejaculatory failure, premature ejaculation, 
or inability to achieve orgasm, but frequently are too embarrassed to bring 
up the subject unless specifically asked by the physician. Initial questions 
should focus on the onset of symptoms, the presence and duration of par-
tial erections, the progression of ED, and ejaculation. Psychosocial history, 
libido, relationship issues, sexual orientation and sexual practices should 
be part of the clinical assessment. A history of nocturnal or early morning 
CHAPTER 185
1149
Disorders of the Male Reproductive System 
erections is useful for distinguishing physiologic from psychogenic ED. 
Relevant risk factors should be identified, such as diabetes mellitus, coro-
nary artery disease, lipid disorders, hypertension, peripheral vascular dis-
ease, smoking, alcoholism, and endocrine or neurologic disorders. The pt’s 
surgical history should be explored, with an emphasis on bowel, bladder, 
prostate, or vascular procedures. Evaluation includes a detailed general 
as well as genital physical exam. Penile abnormalities (Peyronie’s disease), 
testicular size, and gynecomastia should be noted. Peripheral pulses should 
be palpated, and bruits should be sought. Neurologic exam should assess 
anal sphincter tone, perineal sensation, and bulbocavernosus reflex. Serum 
testosterone and prolactin should be measured. Penile arteriography, elec-
tromyography, or penile Doppler ultrasound is occasionally performed.
Erectile Dysfunction
TREATMENT
An approach to the evaluation and treatment of ED is summarized 
in Fig. 185-2. Correction of the underlying disorders or discontinua-
tion of responsible medications should be attempted. Oral inhibitors of 
phosphodiesterase-5 (sildenafil, tadalafil, and vardenafil) enhance erec-
tions after sexual stimulation, with an onset of approximately 60–120 min. 
They are contraindicated in men receiving any form of nitrate therapy 
and should be avoided in those with congestive heart failure. Vacuum
FIGURE 185-2 Algorithm for the evaluation and management of pts with ED. PDE, 
phosphodiesterase.
Patient/partner education
Goal-directed therapy planning
Sex therapy
Special testing
Treatment
  success
Treatment
  success
Oral PDE-inhibitors
Vacuum device
Implantation/
  vascular surgery
Intraurethral or injection therapy
Problem resolved
Problem persists
History: Medical, sexual, and psychosocial
Physical examination
Serum: Testosterone and prolactin levels
Lifestyle risk management
Medication review
PATIENT EVALUATION AND MANAGEMENT
SECTION 13
1150
Endocrinology and Metabolism
constriction devices or injection of alprostadil into the urethra or cor-
pora cavernosa may also be effective. The insertion of a penile prosthesis 
is reserved for pts with refractory ED.
For a more detailed discussion, see Bhasin S, Jameson 
JL: Disorders of the Testes and Male Reproductive System, 
Chap. 346, p. 3010; Hall JE: The Female Reproductive 
System, Infertility, and Contraception, Chap. 347, p. 3028; and 
McVary KT: Sexual Dysfunction, Chap. 48, p. 374, in HPIM-18. 
CHAPTER 186
Disorders of the Female 
Reproductive System
The pituitary hormones, luteinizing hormone (LH) and follicle-stimulating 
hormone (FSH), stimulate ovarian follicular development and result in 
ovulation at about day 14 of the 28-day menstrual cycle.
� AMENORRHEA
Etiology
Amenorrhea refers to the absence of menstrual periods. It is classified as 
primary, if menstrual bleeding has never occurred by age 15 in the absence 
of hormonal treatment, or secondary, if menstrual periods are absent for 
>3 months in a woman with previous periodic menses. Pregnancy should 
be excluded in women of childbearing age with amenorrhea, even when 
history and physical exam are not suggestive. Oligomenorrhea is defined 
as a cycle length of >35 days or <10 menses per year. Both the frequency 
and amount of bleeding are irregular in oligomenorrhea. Frequent or heavy 
irregular bleeding is termed dysfunctional uterine bleeding if anatomic uter-
ine lesions or a bleeding diathesis have been excluded.
The causes of primary and secondary amenorrhea overlap, and it is gen-
erally more useful to classify disorders of menstrual function into disorders 
of the uterus and outflow tract and disorders of ovulation (Fig. 186-1).
Anatomic defects of the outflow tract that prevent vaginal bleeding 
include absence of vagina or uterus, imperforate hymen, transverse vaginal 
septae, and cervical stenosis.
Women with amenorrhea and low FSH and LH levels have hypogo-
nadotropic hypogonadism due to disease of either the hypothalamus or 
the pituitary. Hypothalamic causes include congenital idiopathic hypo-
gonadotropic hypogonadism, hypothalamic lesions (craniopharyngiomas 
and other tumors, tuberculosis, sarcoidosis, metastatic tumors), hypotha-
lamic trauma or irradiation, vigorous exercise, eating disorders, stress, 
1151
FIGURE 186-1 Algorithm for evaluation of amenorrhea. β-hCG, human chorionic gonadotropin; FSH, follicle-stimulating hormone; PRL, 
prolactin; TSH, thyroid-stimulating hormone.
Neuroanatomic abnormality or idiopathic 
hypogonadotropic hypogonadism
Hypothalamic
amenorrhea
1° amenorrhea, 
short stature or 
clinical suspicion
Hyperandrogenism
↑ testosterone, 
hirsutism, acne
R/O tumor
R/O 21 hydroxylase 
deficiency
Polycystic ovarian 
syndrome
Increased
MRI
Normal
PRL
Ovarian
insufficiency
Normal or low
Increased (x2)
GYN referral
GYN referral
Asherman’s
syndrome
FSH
β-hCG
Normal
Abnormal
Normal PRL, 
FSH
Negative trial of 
estrogen/ 
progesterone
Müllerian 
agenesis, cervical 
stenosis, vaginal 
septum, 
imperforate hymen
Uterine
instrumentation
Androgen
insensitivity
syndrome
Uterus and outflow tract
AMENORRHEA/OLIGOMENORRHEA
–
+
R/O discuss diet, exercise, stress
Pregnancy
R/O drugs, ↑ TSH
2° amenorrhea
SECTION 13
1152
Endocrinology and Metabolism
and chronic debilitating diseases (end-stage renal disease, malignancy, 
malabsorption). The most common form of hypothalamic amenorrhea is 
functional, reversible GnRH deficiency due to psychological or physical 
stress, including excess exercise and anorexia nervosa. Disorders of the 
pituitary include rare developmental defects, pituitary adenomas, granu-
lomas, post-radiation hypopituitarism, and Sheehan’s syndrome. They can 
lead to amenorrhea by two mechanisms: direct interference with gonado-
tropin production, or inhibition of GnRH secretion via excess prolactin 
production (Chap. 179).
Women with amenorrhea and high FSH levels have ovarian failure, 
which may be due to Turner’s syndrome, pure gonadal dysgenesis, pre-
mature ovarian failure, the resistant-ovary syndrome, and chemotherapy 
or radiation therapy for malignancy. The diagnosis of premature ovarian 
failure is applied to women who cease menstruating before age 40.
Polycystic ovarian syndrome (PCOS) is characterized by the presence of 
clinical or biochemical hyperandrogenism (hirsutism, acne, male pattern 
baldness) in association with amenorrhea or oligomenorrhea. The metabolic 
syndrome and infertility are often present; these features are worsened with 
coexistent obesity. Additional disorders with a similar presentation include 
excess androgen production from adrenal or ovarian tumors and adult-onset 
congenital adrenal hyperplasia. Hyperthyroidism may be associated with 
oligo- or amenorrhea; hypothyroidism more typically with metrorrhagia.
Diagnosis
The initial evaluation involves careful physical exam including assessment 
of hyperandrogenism, serum or urine human chorionic gonadotropin 
(hCG), and serum FSH levels (Fig. 186-1). Anatomic defects are usually 
diagnosed by physical exam, though hysterosalpingography or direct visual 
examination by hysteroscopy may be required. A karyotype should be per-
formed when gonadal dysgenesis is suspected. The diagnosis of PCOS is 
based on the coexistence of chronic anovulation and androgen excess, after 
ruling out other etiologies for these features. The evaluation of pituitary 
function and hyperprolactinemia is described in Chap. 179. In the absence 
of a known etiology for hypogonadotropic hypogonadism, MRI of the 
pituitary-hypothalamic region should be performed when gonadotropins 
are low or inappropriately normal.
Amenorrhea
TREATMENT
Disorders of the outflow tract are managed surgically. Decreased estro-
gen production, whether from ovarian failure or hypothalamic/pituitary 
disease, should be treated with cyclic estrogens, either in the form of 
oral contraceptives or conjugated estrogens (0.625–1.25 mg/d PO) and 
medroxyprogesterone acetate (2.5 mg/d PO or 5–10 mg during the last 
5 days of the month). PCOS may be treated with medications to induce 
periodic withdrawal menses (medroxyprogesterone acetate 5–10 mg or 
progesterone 200 mg daily for 10–14 days of each month, or oral contra-
ceptive agents) and weight reduction, along with treatment of hirsutism
CHAPTER 186
1153
Disorders of the Female Reproductive System 
and, if desired, ovulation induction (see below). Individuals with PCOS 
may benefit from insulin-sensitizing drugs, such as metformin, and 
should be screened for diabetes mellitus.
� PELVIC PAIN
Etiology 
Pelvic pain may be associated with normal or abnormal menstrual cycles 
and may originate in the pelvis or be referred from another region of the 
body. A high index of suspicion must be entertained for extrapelvic disor-
ders that refer to the pelvis, such as appendicitis, diverticulitis, cholecystitis, 
intestinal obstruction, and urinary tract infections. A thorough history 
including the type, location, radiation, and status with respect to increasing 
or decreasing severity can help to identify the cause of acute pelvic pain. 
Associations with vaginal bleeding, sexual activity, defecation, urination, 
movement, or eating should be sought. Determination of whether the pain 
is acute versus chronic, constant versus spasmodic, and cyclic versus non-
cyclic will direct further investigation (Table 186-1).
Acute Pelvic Pain 
Pelvic inflammatory disease most commonly presents with bilateral lower 
abdominal pain. Unilateral pain suggests adnexal pathology from rupture, 
bleeding, or torsion of ovarian cysts, or, less commonly, neoplasms of the 
ovary, fallopian tubes, or paraovarian areas. Ectopic pregnancy is associated 
with right- or left-sided lower abdominal pain, vaginal bleeding, and men-
strual cycle abnormalities, with clinical signs appearing 6–8 weeks after the 
last normal menstrual period. Orthostatic signs and fever may be present. 
Uterine pathology includes endometritis and degenerating leiomyomas.
TABLE 186-1 CAUSES OF PELVIC PAIN
Acute
Chronic
Cyclic pelvic pain
Premenstrual symptoms
Mittelschmerz
Dysmenorrhea
Endometriosis
Noncyclic pelvic pain Pelvic inflammatory 
disease
Ruptured or hemorrhagic 
ovarian cyst or ovarian 
torsion
Ectopic pregnancy
Endometritis
Acute growth or degenera-
tion of uterine myoma
Pelvic congestion 
syndrome
Adhesions and retrover-
sion of the uterus
Pelvic malignancy
Vulvodynia
History of sexual abuse
SECTION 13
1154
Endocrinology and Metabolism
Chronic Pelvic Pain 
Many women experience lower abdominal discomfort with ovulation 
(mittelschmerz), characterized as a dull, aching pain at midcycle that 
lasts minutes to hours. In addition, ovulatory women may experience 
somatic symptoms during the few days prior to menses, including edema, 
breast engorgement, and abdominal bloating or discomfort. A symp-
tom complex of cyclic irritability, depression, and lethargy is known as 
premenstrual syndrome (PMS). Severe or incapacitating cramping with 
ovulatory menses in the absence of demonstrable disorders of the pelvis 
is termed primary dysmenorrhea. Secondary dysmenorrhea is caused by 
underlying pelvic pathology such as endometriosis, adenomyosis, or 
cervical stenosis.
Diagnosis
Evaluation includes a history, pelvic exam, hCG measurement, tests 
for chlamydial and gonococcal infections, and pelvic ultrasound. 
Laparoscopy or laparotomy is indicated in some cases of pelvic pain of 
undetermined cause.
Pelvic Pain
TREATMENT
Primary dysmenorrhea is best treated with NSAIDs or oral contra-
ceptive agents. Secondary dysmenorrhea not responding to NSAIDs 
suggests pelvic pathology, such as endometriosis. Infections should 
be treated with the appropriate antibiotics. Symptoms from PMS may 
improve with selective serotonin reuptake inhibitor (SSRI) therapy. The 
majority of unruptured ectopic pregnancies are treated with methotrex-
ate, which has an 85–95% success rate. Surgery may be required for 
structural abnormalities.
� HIRSUTISM
Etiology
Hirsutism, defined as excessive male-pattern hair growth, affects ~10% of 
women. It may be familial or caused by PCOS, ovarian or adrenal neo-
plasms, congenital adrenal hyperplasia, Cushing’s syndrome, pregnancy, 
and drugs (androgens, oral contraceptives containing androgenic proges-
tins). Other drugs, such as minoxidil, phenytoin, diazoxide, and cyclospo-
rine, can cause excessive growth of non-androgen-dependent vellus hair, 
leading to hypertrichosis. 
Clinical Features 
An objective clinical assessment of hair distribution and quantity is central 
to the evaluation. A commonly used method to grade hair growth is the 
Ferriman-Gallwey score (see Fig. 49-1, p. 382, in HPIM-18). Associated 
manifestations of androgen excess include acne and male-pattern balding 
(androgenic alopecia). Virilization, on the other hand, refers to the state 
CHAPTER 186
1155
Disorders of the Female Reproductive System 
in which androgen levels are sufficiently high to cause deepening of the 
voice, breast atrophy, increased muscle bulk, clitoromegaly, and increased 
libido. Historic elements include menstrual history and the age of onset, 
rate of progression, and distribution of hair growth. Sudden development of 
hirsutism, rapid progression, and virilization suggest an ovarian or adrenal 
neoplasm.
Diagnosis
An approach to testing for androgen excess is depicted in Fig. 186-2. PCOS 
is a relatively common cause of hirsutism. The dexamethasone androgen-
suppression test (0.5 mg PO every 6 h × 4 days, with free testosterone 
levels obtained before and after administration of dexamethasone) may 
distinguish ovarian from adrenal overproduction. Incomplete suppression 
suggests ovarian androgen excess. Congenital adrenal hyperplasia due to 
21-hydroxylase deficiency can be excluded by a 17-hydroxyprogesterone 
level that is <6 nmol/L (<2 μg/L) either in the morning during the follicular 
phase or 1 h after administration of 250 μg of cosyntropin. CT may localize 
an adrenal mass, and ultrasound may identify an ovarian mass, if evaluation 
suggests these possibilities.
FIGURE 186-2 Algorithm for the evaluation and differential diagnosis of hirsutism. 
ACTH, adrenocorticotropic hormone; CAH, congenital adrenal hyperplasia; DHEAS, 
sulfated form of dehydroepiandrosterone; PCOS, polycystic ovarian syndrome.
CLINICAL EVALUATION OF HIRSUTISM
Idiopathic
Other causes
see Table 49-1
in HPIM-18
• Nonclassic CAH
• Functional adrenal
  hyperandrogenism
Laboratory Evaluation
• Total, free testosterone
• DHEAS
Reassurance
Nonpharmacologic 
approaches
Hirsutism
significant
Virilization
Rapid progression
Rule out ovarian or
adrenal neoplasm
Normal
Increased
Final diagnosis
• PCOS
• Functional ovarian
  hyperandrogenism
Treat empirically
   or
Consider further testing
• Dexamethasone suppression → adrenal vs ovarian causes; R/O Cushing’s
• ACTH stimulation → assess nonclassic CAH
Marked elevation
Total testosterone > 7 nmol/L
(>2 ng/mL)
DHEAS > 18.5 μmol/L (> 7000 μg/L)
Yes
No
SECTION 13
1156
Endocrinology and Metabolism
Hirsutism
TREATMENT
Treatment of a remediable underlying cause (e.g., Cushing’s syndrome, 
adrenal or ovarian tumor) also improves hirsutism. In idiopathic hir-
sutism or PCOS, symptomatic physical or pharmacologic treatment 
is indicated. Nonpharmacologic treatments include (1) bleaching; (2) 
depilatory such as shaving and chemical treatments; and (3) epilatory 
such as plucking, waxing, electrolysis, and laser therapy. Pharmacologic 
therapy includes oral contraceptives with a low androgenic proges-
tin and spironolactone (100–200 mg/d PO), often in combination. 
Flutamide is also effective as an antiandrogen, but its use is limited by 
hepatotoxicity. Glucocorticoids (dexamethasone, 0.25–0.5 mg at bed-
time, or prednisone, 5–10 mg at bedtime) are the mainstay of treatment 
in pts with congenital adrenal hyperplasia. Attenuation of hair growth 
with pharmacologic therapy is typically not evident until 6 months after 
initiation of medical treatment and therefore should be used in conjunc-
tion with nonpharmacologic treatments.
� MENOPAUSE
Etiology
Menopause is defined as the final episode of menstrual bleeding and occurs 
at a median age of 51 years. It is the consequence of depletion of ovarian fol-
licles or of oophorectomy. The onset of perimenopause, when fertility wanes 
and menstrual irregularity increases, precedes the final menses by 2–8 years.
Clinical Features 
The most common menopausal symptoms are vasomotor instability (hot 
flashes and night sweats), mood changes (nervousness, anxiety, irritability, 
and depression), insomnia, and atrophy of the urogenital epithelium and skin. 
FSH levels are elevated to ≥40 IU/L with estradiol levels that are <30 pg/mL.
Menopause
TREATMENT
During perimenopause, low-dose combined oral contraceptives may 
be of benefit. The rational use of postmenopausal hormone therapy 
requires balancing the potential benefits and risks. Concerns include 
increased risks of endometrial cancer, breast cancer, thromboembolic 
disease, and gallbladder disease, as well as probably increased risks 
of stroke, cardiovascular events, and ovarian cancer. Benefits include 
a delay in postmenopausal bone loss and probably decreased risks of 
colorectal cancer and diabetes mellitus. Short-term therapy (<5 years) 
may be beneficial in controlling intolerable symptoms of menopause, 
as long as no contraindications exist. These include unexplained vagi-
nal bleeding, active liver disease, venous thromboembolism, history of 
endometrial cancer (except stage I without deep invasion), breast cancer, 
preexisting cardiovascular disease, and diabetes. Hypertriglyceridemia
CHAPTER 186
1157
Disorders of the Female Reproductive System 
(>400 mg/dL) and active gallbladder disease are relative contrain-
dications. Alternative therapies for symptoms include venlafaxine, 
fluoxetine, paroxetine, gabapentin, clonidine, vitamin E, or soy-based 
products. Vaginal estradiol tablets may be used for genitourinary symp-
toms. Long-term therapy (≥5 years) should be undertaken only after 
careful consideration , particularly in light of alternative therapies for 
osteoporosis (bisphosphonates, raloxifene) and of the risks of venous 
thromboembolism and breast cancer. Estrogens should be given in the 
minimal effective doses (conjugated estrogen, 0.625 mg/d PO; micron-
ized estradiol, 1.0 mg/d PO; or transdermal estradiol, 0.05–1.0 mg once 
or twice a week). Women with an intact uterus should be given estrogen 
in combination with a progestin (medroxyprogesterone either cyclically, 
5–10 mg/d PO for days 15–25 each month, or continuously, 2.5 mg/d 
PO) to avoid the increased risk of endometrial carcinoma seen with 
unopposed estrogen use.
� CONTRACEPTION
The most widely used methods for fertility control include (1) barrier 
methods, (2) oral contraceptives, (3) intrauterine devices, (4) long-acting 
progestins, (5) sterilization, and (6) abortion.
Oral contraceptive agents are widely used for both prevention of preg-
nancy and control of dysmenorrhea and anovulatory bleeding. Combination 
oral contraceptive agents contain synthetic estrogen (ethinyl estradiol or 
mestranol) and synthetic progestins. Some progestins possess an inherent 
androgenic action. Low-dose norgestimate and third-generation proges-
tins (desogestrel, gestodene, drospirenone) have a less androgenic profile; 
levonorgestrel appears to be the most androgenic of the progestins and 
should be avoided in pts with hyperandrogenic symptoms. The three major 
formulation types include fixed-dose estrogen-progestin, phasic estrogen-
progestin, and progestin only.
Despite overall safety, oral contraceptive users are at risk for venous 
thromboembolism, hypertension, and cholelithiasis. Risks for myocardial 
infarction and stroke are increased with smoking and aging. Side effects, 
including breakthrough bleeding, amenorrhea, breast tenderness, and 
weight gain, are often responsive to a change in formulation.
Absolute contraindications to the use of oral contraceptives include 
previous thromboembolic disorders, cerebrovascular or coronary artery 
disease, carcinoma of the breasts or other estrogen-dependent neopla-
sia, liver disease, hypertriglyceridemia, heavy smoking with age over 35, 
undiagnosed uterine bleeding, or known or suspected pregnancy. Relative 
contraindications include hypertension and anticonvulsant drug therapy.
New methods include a weekly contraceptive patch, a monthly contracep-
tive injection, and a monthly vaginal ring. Long-term progestins may be 
administered in the form of Depo-Provera or a subdermal progestin implant.
Emergency contraceptive pills, containing progestin only or estrogen and 
progestin, can be used within 72 h of unprotected intercourse for preven-
tion of pregnancy. Both Plan B and Preven are emergency contraceptive kits 
specifically designed for postcoital contraception. In addition, certain oral 
SECTION 13
1158
Endocrinology and Metabolism
contraceptive pills may be dosed within 72 h for emergency contraception 
(Ovral, 2 tabs, 12 h apart; Lo/Ovral, 4 tabs, 12 h apart). Side effects include 
nausea, vomiting, and breast soreness. Mifepristone (RU486) also may be 
used, with fewer side effects.
� INFERTILITY
Etiology
Infertility is defined as the inability to conceive after 12 months of unpro-
tected sexual intercourse. The causes of infertility are outlined in Fig. 186-3. 
Male infertility is discussed in Chap. 185.
Clinical Features 
The initial evaluation includes discussion of the appropriate timing of inter-
course, semen analysis in the male, confirmation of ovulation in the female, 
and, in the majority of situations, documentation of tubal patency in the 
female. Abnormalities in menstrual function constitute the most common 
cause of female infertility (Fig. 186-1). A history of regular, cyclic, predict-
able, spontaneous menses usually indicates ovulatory cycles, which may 
be confirmed by urinary ovulation predictor kits, basal body temperature 
graphs, or plasma progesterone measurements during the luteal phase of 
FIGURE 186-3 Causes of infertility. FSH, follicle-stimulating hormone; LH, luteinizing 
hormone.
Infertility
14% of reproductive aged women
5 million couples in the U.S.
Female causes
58%
Male causes
25%
Unexplained
17%
Amenorrhea/
ovulatory
dysfunction
46%
Hypothalamic/
pituitary
causes
51%
Polycystic
ovary
syndrome
30%
Premature
ovarian
failure
12%
Tubal
defect
38%
Primary
hypogonadism
(   FSH)
30–40%
Secondary
hypogonadism
(   FSH,    LH)
2%
Disordered
sperm
transport
10–20%
Unknown
40–50%
Endometriosis
9%
Other
7%
Uterine or
outflow tract
disorders
7%
CHAPTER 187
1159
Hypercalcemia and Hypocalcemia 
the cycle. An FSH level <10 IU/mL on day 3 of the cycle predicts adequate 
ovarian oocyte reserve. Tubal disease can be evaluated by obtaining a 
hysterosalpingogram or by diagnostic laparoscopy. Endometriosis may be 
suggested by history and exam, but is often clinically silent and can only be 
excluded definitively by laparoscopy.
Infertility
TREATMENT
The treatment of infertility should be tailored to the problems unique 
to each couple. Treatment options include expectant management, 
clomiphene citrate with or without intrauterine insemination (IUI), 
gonadotropins with or without IUI, and in vitro fertilization (IVF). In 
specific situations, surgery, pulsatile GnRH therapy, intracytoplasmic 
sperm injection (ICSI), or assisted reproductive technologies with donor 
egg or sperm may be required.
For a more detailed discussion, see Ehrmann DA: Hirsutism 
and Virilization, Chap. 49, p. 380; Hall JE: Menstrual 
Disorders and Pelvic Pain, Chap. 50, p. 384; Hall JE: The 
Female Reproductive System: Infertility and Contraception, 
Chap. 347, p. 3028; and Manson JE, Bassuk SS: The 
Menopause Transition and Postmenopausal Hormone 
Therapy, Chap. 348, p. 3040, in HPIM-18.
CHAPTER 187
Hypercalcemia and 
Hypocalcemia
� HYPERCALCEMIA
Hypercalcemia from any cause can result in fatigue, depression, mental 
confusion, anorexia, nausea, constipation, renal tubular defects, polyuria, 
a short QT interval, and arrhythmias. CNS and GI symptoms can occur 
at levels of serum calcium >2.9 mmol/L (>11.5 mg/dL), and nephrocal-
cinosis and impairment of renal function occur when serum calcium 
is >3.2 mmol/L (>13 mg/dL). Severe hypercalcemia, usually defined as 
>3.7 mmol/L (>15 mg/dL), can be a medical emergency, leading to coma 
and cardiac arrest.
Etiology 
The regulation of the calcium homeostasis is depicted in Fig. 187-1. The 
causes of hypercalcemia are listed in Table 187-1. Hyperparathyroidism and 
malignancy account for 90% of cases.
SECTION 13
1160
Endocrinology and Metabolism
Primary hyperparathyroidism is a generalized disorder of bone 
metabolism due to increased secretion of parathyroid hormone (PTH) 
by an adenoma (81%) or rarely a carcinoma in a single gland, or by 
parathyroid hyperplasia (15%). Familial hyperparathyroidism may 
be part of multiple endocrine neoplasia type 1 (MEN 1), which also 
includes pituitary and pancreatic islet tumors, or of MEN 2A, in which 
hyperparathyroidism occurs with pheochromocytoma and medullary 
carcinoma of the thyroid.
Hypercalcemia associated with malignancy is often severe and difficult 
to manage. Mechanisms for this include excess production and release of 
PTH-related protein (PTHrP) in lung, kidney, and squamous cell carci-
noma (humoral hypercalcemia of malignancy); local bone destruction in 
FIGURE 187-1 Feedback mechanisms maintaining extracellular calcium concentra-
tions within a narrow, physiologic range [8.9–10.1 mg/dL (2.2–2.5 mM)]. A decrease 
in extracellular (ECF) ionized calcium (Ca2+) triggers an increase in parathyroid hor-
mone (PTH) secretion (1) via activation of the calcium sensor receptor on parathyroid 
cells. PTH, in turn, results in increased tubular reabsorption of calcium by the kidney
(2) and resorption of calcium from bone (2) and also stimulates renal 1,25(OH)2D
production (3). 1,25(OH)2D, in turn, acts principally on the intestine to increase 
calcium absorption (4). Collectively, these homeostatic mechanisms serve to restore 
serum calcium levels to normal.
Parathyroid glands
Kidney
Bone
Intestine
PTH
1,25 (OH)2D
ECF Ca2+
1
2
2
3
4
CHAPTER 187
1161
Hypercalcemia and Hypocalcemia 
myeloma and breast carcinoma; activation of lymphocytes leading to release 
of IL-1 and TNF in myeloma and lymphoma; or an increased synthesis of 
1,25(OH)2D in lymphoma.
Several other conditions have been associated with hypercalcemia. 
These include sarcoidosis and other granulomatous diseases, which lead 
to increased synthesis of 1,25(OH)2D; vitamin D intoxication from chronic 
ingestion of large vitamin doses (50–100 × physiologic requirements); 
lithium therapy, which results in hyperfunctioning of the parathyroid 
glands; and familial hypocalciuric hypercalcemia (FHH) due autosomal 
dominant inheritance of an inactivating mutation in the calcium-sensing 
receptor, which results in inappropriately normal or even high secretion of 
PTH, despite hypercalcemia and enhanced renal calcium resorption. Severe 
secondary hyperparathyroidism associated with end-stage renal disease 
TABLE 187-1 CLASSIFICATION OF CAUSES OF HYPERCALCEMIA
I. Parathyroid-related
 A. Primary hyperparathyroidism
  1. Solitary adenomas or rarely carcinoma
  2. Multiple endocrine neoplasia
 B. Lithium therapy
 C. Familial hypocalciuric hypercalcemia
II. Malignancy-related
 A.  Solid tumor with humoral mediation of hypercalcemia (lung, kidney, 
squamous cell carcinoma)
 B. Solid tumor with metastases (breast)
 C. Hematologic malignancies (multiple myeloma, lymphoma, leukemia)
III. Vitamin D–related
 A. Vitamin D intoxication
 B. ↑ 1,25(OH)2D; sarcoidosis and other granulomatous diseases
 C. Idiopathic hypercalcemia of infancy
IV. Associated with high bone turnover
 A. Hyperthyroidism
 B. Immobilization
 C. Thiazides
 D. Vitamin A intoxication
V. Associated with renal failure
 A. Severe secondary or tertiary hyperparathyroidism
 B. Aluminum intoxication
 C. Milk-alkali syndrome
SECTION 13
1162
Endocrinology and Metabolism
may progress to tertiary hyperthyroidism, in which PTH hypersecretion 
becomes autonomous, causes hypercalcemia, and is no longer responsive 
to medical therapy.
Clinical Features 
Most pts with mild to moderate hyperparathyroidism are asymptomatic, 
even when the disease involves the kidneys and the skeletal system. Pts 
frequently have hypercalciuria and polyuria, and calcium can be deposited 
in the renal parenchyma (nephrocalcinosis) or form calcium oxalate stones. 
The characteristic skeletal lesion is osteopenia or osteoporosis; rarely, the 
more severe disorder osteitis fibrosa cystica occurs as a manifestation of 
long-standing, more severe hyperparathyroidism. Increased bone resorp-
tion primarily involves cortical rather than trabecular bone. Hypercalcemia 
may be intermittent or sustained, and serum phosphate is usually low but 
may be normal.
Diagnosis
Primary hyperparathyroidism is confirmed by demonstration of an inap-
propriately high PTH level for the degree of hypercalcemia. Hypercalciuria 
helps to distinguish this disorder from FHH, in which PTH levels are usu-
ally in the normal range and the urine calcium level is low. Differentiation 
between primary hyperparathyroidism and FHH is important because the 
latter does not respond to parathyroid surgery. Levels of PTH are low in 
hypercalcemia of malignancy (Table 187-2). 
Total serum calcium should be corrected when serum albumin is abnor-
mal [addition of 0.2 mM (0.8 mg/dL) to calcium value for every 1.0-g/dL 
decrement in albumin below 4.1 g/dL, or the converse for an increase 
in albumin]. Alternatively, ionized calcium can be measured. Third-
generation PTH assays should be used for PTH measurement, especially in 
pts with renal impairment.
TABLE 187-2  DIFFERENTIAL DIAGNOSIS OF HYPERCALCEMIA: 
LABORATORY CRITERIA
Blooda
Ca
Pi
1,25(OH)2D
iPTH
Primary hyperparathyroidism
↑
↓
↑↔
↑(↔)
Malignancy-associated 
hypercalcemia:
Humoral hypercalcemia
↑↑
↓
↓↔
↓
Local destruction (osteolytic 
metastases)
↑
↔
↓↔
↓
aSymbols in parentheses refer to values rarely seen in the particular disease.
Abbreviations: Pi, inorganic phosphate; iPTH, immunoreactive parathyroid hormone.
Source: JT Potts Jr: HPIM-12, p. 1911.
CHAPTER 187
1163
Hypercalcemia and Hypocalcemia 
Hypercalcemia
TREATMENT
The type of treatment is based on the severity of the hypercalcemia and 
the nature of the associated symptoms. Table 187-3 shows general rec-
ommendations that apply to therapy of severe hypercalcemia [levels of 
>3.2 mmol/L (>13 mg/dL)] from any cause.
In pts with severe primary hyperparathyroidism, surgical parathy-
roidectomy should be performed promptly. Asymptomatic disease may 
not require surgery; usual surgical indications include age <50, neph-
rolithiasis, creatinine clearance <60 mL/min, reduction in bone mass 
(T score <–2.5), or serum calcium >0.25 mmol/L (>1 mg/dL) above the 
normal range. A minimally invasive approach may be used if preopera-
tive localization via sestamibi scans with SPECT or neck ultrasound 
demonstrates a solitary adenoma and intraoperative PTH assays are
TABLE 187-3 THERAPIES FOR SEVERE HYPERCALCEMIA
Treatment
Onset of 
Action
Duration 
of Action Advantages
Disadvantages
Hydration with 
saline (≤6 L/d)
Hours
During 
infusion
Rehydrates; 
rapid action
Volume overload; 
electrolyte
disturbance
Forced diuresis 
(furosemide along 
with aggressive 
hydration)
Hours
During 
treatment
Rapid action
Monitoring 
required to avoid 
dehydration
Pamidronate 
30–90 mg IV 
over 4 h
1–2 days 10–14 
days
High potency; 
intermediate 
onset of action
Fever in 20%, ↓
Ca, ↓ phosphate, 
↓ Mg, rarely jaw 
necrosis
Zoledronate 
4–8 mg IV over 
15 min
1–2 days >3
weeks
High potency; 
prolonged
action; rapid 
infusion
Minor: Fever; 
rare ↓ Ca, ↓
phosphate, jaw 
necrosis
Calcitonin (2–8 U/
kg SC q6-12h)
Hours
1–2 days Rapid onset
Limited 
effect; rapid 
tachyphylaxis
Glucocorticoids
(prednisone
10–25 mg 
PO qid)
Days
Days-
weeks
Useful in 
myeloma, lym-
phoma, breast 
CA, sarcoid, 
vitamin D intox
Effects limited to 
certain disorders; 
glucocorticoid
side effects
Dialysis
Hours
During 
use–2
days
Useful in renal 
failure; immedi-
ate effect
Complex
procedure
SECTION 13
1164
Endocrinology and Metabolism
available. Otherwise, neck exploration is required. Surgery in a center 
experienced in parathyroid interventions is recommended. Postoperative 
management requires close monitoring of calcium and phosphorus, as 
transient hypocalcemia is common. Calcium supplementation is given 
for symptomatic hypocalcemia.
Hypercalcemia of malignancy is managed by treating the underlying 
tumor. Adequate hydration and parenteral bisphosphonates can be used 
to reduce calcium levels. Long-term control of hypercalcemia is difficult 
unless the underlying cause can be eliminated.
No therapy is recommended for FHH. Secondary hyperparathyroid-
ism should be treated with phosphate restriction, the use of nonabsorb-
able antacids or sevelamer, and calcitriol. Tertiary hyperparathyroidism 
requires parathyroidectomy.
� HYPOCALCEMIA
Chronic hypocalcemia is less common than hypercalcemia, but is usually 
symptomatic and requires treatment. Symptoms include peripheral and 
perioral paresthesia, muscle spasms, carpopedal spasm, tetany, laryngeal 
spasm, seizure, and respiratory arrest. Increased intracranial pressure and 
papilledema may occur with long-standing hypocalcemia, and other mani-
festations may include irritability, depression, psychosis, intestinal cramps, 
and chronic malabsorption. Chvostek’s and Trousseau’s signs are frequently 
positive, and the QT interval is prolonged. Both hypomagnesemia and alka-
losis lower the threshold for tetany.
Etiology 
Transient hypocalcemia often occurs in critically ill pts with burns, sep-
sis, and acute renal failure; following transfusion with citrated blood; or 
with medications such as protamine and heparin. Hypoalbuminemia can 
reduce serum calcium below normal, although ionized calcium levels 
remain normal. The above-mentioned correction (see “Hypercalcemia”) 
can be used to assess whether the serum calcium concentration is 
abnormal when serum proteins are low. Alkalosis increases calcium 
binding to proteins, and in this setting direct measurements of ionized 
calcium should be used.
The causes of hypocalcemia can be divided into those in which PTH is 
absent (hereditary or acquired hypoparathyroidism, hypomagnesemia), 
PTH is ineffective (chronic renal failure, vitamin D deficiency, anticon-
vulsant therapy, intestinal malabsorption, pseudohypoparathyroidism), 
or PTH is overwhelmed (severe, acute hyperphosphatemia in tumor 
lysis, acute renal failure, or rhabdomyolysis; hungry bone syndrome fol-
lowing parathyroidectomy). The most common forms of chronic severe 
hypocalcemia are autoimmune hypoparathyroidism and postoperative 
hypoparathyroidism following neck surgery. Chronic renal insufficiency 
is associated with mild hypocalcemia compensated for by secondary 
hyperparathyroidism. The cause of hypocalcemia associated with acute 
pancreatitis is unclear.
CHAPTER 187
1165
Hypercalcemia and Hypocalcemia 
Hypocalcemia
TREATMENT
Symptomatic hypocalcemia may be treated with IV calcium gluconate (bolus 
of 1–2 g IV over 10–20 min followed by infusion of 10 ampoules of 10% cal-
cium gluconate diluted in 1 L D5W infused at 30–100 mL/h). Management 
of chronic hypocalcemia requires a high oral calcium intake, usually with 
vitamin D supplementation (Chap. 188). Hypoparathyroidism requires 
administration of calcium (1–3 g/d) and calcitriol (0.25–1 μg/d), adjusted 
according to serum calcium levels and urinary excretion. Restoration of 
magnesium stores may be required to reverse hypocalcemia in the setting 
of severe hypomagnesemia.
� HYPOPHOSPHATEMIA
Mild hypophosphatemia is not usually associated with clinical symptoms. 
In severe hypophosphatemia, pts may have muscle weakness, numbness, 
paresthesia, and confusion. Rhabdomyolysis may develop during rapidly 
progressive hypophosphatemia. Respiratory insufficiency can result from 
diaphragm muscle weakness.
Etiology 
The causes of hypophosphatemia include: decreased intestinal absorption 
(vitamin D deficiency, phosphorus-binding antacids, malabsorption); uri-
nary losses (hyperparathyroidism, hyperglycemic states, X-linked hypophos-
phatemic rickets, oncogenic osteomalacia, alcoholism, or certain toxins); 
and shifts of phosphorus from extracellular to intracellular compartments 
(administration of insulin in diabetic ketoacidosis or by hyperalimentation 
or refeeding in a malnourished pt). In syndromes of severe primary renal 
phosphate wasting (X-linked hypophosphatemic rickets, autosomal domi-
nant hypophosphatemic rickets, oncogenic osteomalacia), the phosphatonin 
hormone FGF23 (fibroblast growth factor 23) plays a key pathogenetic role. 
Hypophosphatemia
TREATMENT
Mild hypophosphatemia can be replaced orally with milk, carbonated 
beverages, or Neutra-Phos or K-Phos (up to 2 g/d in divided doses). For 
severe hypophosphatemia [0.75 mmol/L; (<2.0 mg/dL)], IV phosphate 
may be administered at initial doses of 0.2–0.8 mmol/kg of elemental 
phosphorus over 6 h. The total body phosphate depletion cannot be 
predicted from the serum phosphate level; careful monitoring of therapy 
is therefore required. Hypocalcemia should be corrected first, and the 
dose reduced 50% in hypercalcemia. Serum calcium and phosphate 
levels should be measured every 6–12 h; a serum calcium × phosphate 
product of >50 must be avoided.
� HYPERPHOSPHATEMIA
In adults, hyperphosphatemia is defined as a level >1.8 mmol/L (>5.5 mg/dL). 
The most common causes are acute and chronic renal failure, but it may 
SECTION 13
1166
Endocrinology and Metabolism
also be seen in hypoparathyroidism, vitamin D intoxication, acromegaly, 
acidosis, rhabdomyolysis, and hemolysis. The clinical consequences of 
severe hyperphosphatemia are hypocalcemia and calcium phosphate depo-
sition in tissues. Depending on the location of tissue calcifications, serious 
chronic or acute complications may ensue (e.g., nephrocalcinosis, cardiac 
arrhythmias). Therapy consists of treating the underlying disorder and lim-
iting dietary phosphorus intake and absorption. Oral aluminum phosphate 
binders or sevelamer may be used, and hemodialysis should be considered 
in severe cases.
� HYPOMAGNESEMIA
Hypomagnesemia usually indicates significant whole body magnesium 
depletion. Muscle weakness, prolonged PR and QT intervals, and cardiac 
arrhythmias are the most common manifestations of hypomagnesemia. 
Magnesium is important for effective PTH secretion as well as the renal 
and skeletal responsiveness to PTH. Therefore, hypomagnesemia is often 
associated with hypocalcemia.
Etiology 
Hypomagnesemia generally results from a derangement in renal or intes-
tinal handling of magnesium and is classified as primary (hereditary) or 
secondary (acquired). Hereditary causes include both disorders of absorp-
tion (rare) and those of renal loss (e.g., Bartter’s and Gitelman syndromes). 
Secondary causes are much more common, with renal losses being due to 
volume expansion, hypercalcemia, osmotic diuresis, loop diuretics, alcohol, 
aminoglycosides, cisplatin, cyclosporine, and amphotericin B, and gastroin-
testinal losses most commonly resulting from vomiting and diarrhea.
Hypomagnesemia
TREATMENT
For mild deficiency, oral replacement in divided doses totaling 20–30 
mmol/d (40–60 meq/d) is effective, although diarrhea may result. 
Parenteral magnesium administration is usually needed for serum levels 
<0.5 mmol/L (<1.2 mg/dL), with a continuous infusion of magnesium 
chloride IV to deliver 50 mmol/d over a 24-h period (dose reduced by 
50–75% in renal failure). Therapy may be required for several days in 
order to replete tissue magnesium stores; serum Mg should be moni-
tored every 12–24 h during treatment. Other electrolyte disturbances 
should be treated simultaneously. Pts with associated seizures or acute 
arrhythmias can be given 1–2 g of magnesium sulfate IV over 5–10 min.
� HYPERMAGNESEMIA
Hypermagnesemia is rare but can be seen in renal failure when pts are tak-
ing magnesium-containing antacids, laxatives, enemas, or infusions, or in 
acute rhabdomyolysis. The most readily detectable clinical sign of hyperma-
gnesemia is the disappearance of deep tendon reflexes, but hypocalcemia, 
hypotension, paralysis of respiratory muscles, complete heart block, and 
cardiac arrest can occur. Treatment includes stopping the preparation, 
CHAPTER 188
1167
Osteoporosis and Osteomalacia 
clearing the intestines of residual offending laxatives or antacids with 
magnesium-free enemas or cathartics, dialysis against a low magnesium 
bath, or, if associated with life-threatening complications, 100–200 mg of 
elemental calcium IV over 1–2 h.
For a more detailed discussion, see Bringhurst FR, Demay MB, 
Krane SM, Kronenberg HM: Bone and Mineral Metabolism 
in Health and Disease, Chap. 352, p. 3082; Khosla S: 
Hypercalcemia and Hypocalcemia, Chap. 46, p. 360; and 
Potts JT Jr, Jüppner H: Disorders of the Parathyroid Gland and 
Calcium Homeostasis, Chap. 353, p. 3096, in HPIM-18. 
CHAPTER 188
Osteoporosis and 
Osteomalacia
� OSTEOPOROSIS
Osteoporosis is defined as a reduction in bone mass [or bone mineral den-
sity (BMD)] or the presence of fragility fracture. It is defined operationally 
as a bone density that falls 2.5 SD below the mean for a young normal 
individual (a T-score of <–2.5). Those with a T-score of <1.0 (osteopenia) 
have low bone density and are at increased risk for osteoporosis. The most 
common sites for osteoporosis-related fractures are the vertebrae, hip, and 
distal radius.
Osteoporosis is a common condition in the elderly; women are at par-
ticularly high risk. In the United States, 8 million women and 2 million men 
have osteoporosis; an additional 18 million have osteopenia. The annual 
incidence of osteoporosis-related fractures is at least 1.5 million; almost half 
of them are vertebral crush fractures, followed in frequency by hip and wrist 
fractures. Hip fractures are associated with significant morbidity (thrombo-
embolism) and a 5–20% mortality within a year.
Etiology 
Low bone density may result from low peak bone mass or increased bone 
loss. Risk factors for an osteoporotic fracture are listed in Table 188-1, and 
diseases associated with osteoporosis are listed in Table 188-2. Certain 
drugs, primarily glucocorticoids, cyclosporine, cytotoxic drugs, thiazoli-
dinediones, anticonvulsants, aluminum, heparin, excessive levothyroxine, 
GnRH agonists, and aromatase inhibitors also have detrimental effects on 
the skeleton.
Clinical Features 
Pts with multiple vertebral crush fractures may have height loss, kypho-
sis, and secondary pain from altered biomechanics of the back. Thoracic 
SECTION 13
1168
Endocrinology and Metabolism
TABLE 188-1 RISK FACTORS FOR OSTEOPOROSIS FRACTURE
Nonmodifiable
Estrogen deficiency
  Personal history of fracture as 
an adult
  Early menopause (<45 years) or 
bilateral ovariectomy 
  History of fracture in first-
degree relative
  Prolonged premenopausal amenor-
rhea (>1 year)
  Female sex
Low calcium intake
  Advanced age
Alcoholism
  White race
  Impaired eyesight despite adequate 
correction
  Dementia
Potentially modifiable
Recurrent falls
  Current cigarette smoking
Inadequate physical activity
  Low body weight [<58 kg 
(127 lb)]
Poor health/frailty
fractures can be associated with restrictive lung disease, whereas lumbar 
fractures are sometimes associated with abdominal symptoms or nerve 
compression leading to sciatica. Dual-energy x-ray absorptiometry (DEXA) 
has become the standard for measuring bone density. The U.S. Preventive 
Health Services Task Force recommends that women age 65 and older be 
screened routinely for osteoporosis, and screening should begin at age 60 
for women with increased risk. Criteria approved for Medicare reimburse-
ment of bone mass measurement are summarized in Table 188-3. A gen-
eral laboratory evaluation includes complete blood count, serum and 24-h 
urine calcium, 25(OH)D level, and renal and hepatic function tests. Further 
testing is based on clinical suspicion and may include thyroid-stimulating 
hormone (TSH), urinary free cortisol, parathyroid hormone (PTH), serum 
and urine electrophoresis, and testosterone levels (in men). Tissue transglu-
taminase Ab testing may identify asymptomatic celiac disease. Markers of 
bone resorption (e.g., urine cross-linked N-telopeptide) may be helpful in 
detecting an early response to antiresorptive therapy if measured prior to 
and 4–6 months after initiating therapy.
Osteoporosis
TREATMENT
Treatment involves the management of acute fractures, modifying risk 
factors, and treating any underlying disorders that lead to reduced bone 
mass. Treatment decisions are based on an individual’s risk factors, but 
active treatment is generally recommended if the T-score is ≤2.5. Risk 
factor reduction is a key part of management; smoking cessation and 
reduced alcohol intake should be encouraged; offending drugs should 
be discontinued or doses minimized (e.g., glucocorticoids), an exercise 
program should be instituted, and fall prevention strategies should be 
put in place. Oral calcium (1–1.5 g/d of elemental calcium in divided
CHAPTER 188
1169
Osteoporosis and Osteomalacia 
TABLE 188-2  DISEASES ASSOCIATED WITH AN INCREASED RISK OF 
GENERALIZED OSTEOPOROSIS IN ADULTS
Hypogonadal states
 Turner’s syndrome
 Klinefelter’s syndrome
 Anorexia nervosa
 Hypothalamic amenorrhea
 Hyperprolactinemia
  Other primary or secondary 
hypogonadal states
Endocrine disorders
 Cushing’s syndrome
 Hyperparathyroidism
 Thyrotoxicosis
 Type 1 diabetes mellitus
 Acromegaly
 Adrenal insufficiency
Nutritional and gastrointestinal 
disorders
 Malnutrition
 Parenteral nutrition
 Malabsorption syndromes
 Gastrectomy
  Severe liver disease, 
especially biliary cirrhosis
 Pernicious anemia
Rheumatologic disorders
 Rheumatoid arthritis
 Ankylosing spondylitis
Hematologic disorders/malignancy
 Multiple myeloma
 Lymphoma and leukemia
  Malignancy-associated parathyroid 
hormone–related (PTHrP) production
 Mastocytosis
 Hemophilia
 Thalassemia
Selected inherited disorders
 Osteogenesis imperfecta
 Marfan syndrome
 Hemochromatosis
 Hypophosphatasia
 Glycogen storage diseases
 Homocystinuria
 Ehlers-Danlos syndrome
 Porphyria
 Menkes’ syndrome
 Epidermolysis bullosa
Other disorders
 Immobilization
 Chronic obstructive pulmonary disease
 Pregnancy and lactation
 Scoliosis
 Multiple sclerosis
 Sarcoidosis
Amyloidosis
doses) and vitamin D (400–800 IU/d) should be initiated in all pts with 
osteoporosis. Adequate vitamin D status should be verified by measur-
ing serum 25(OH)D, the value of which should be at least 75 nmol/L (30 
ng/mL). Some pts may require higher vitamin D supplements than those 
recommended above. Moderate sun exposure also generates vitamin 
D, although recommending outdoor exposure is controversial because 
of concerns about skin cancer. Bisphosphonates (alendronate, 70 mg 
PO weekly; risedronate, 35 mg PO weekly; ibandronate, 150 mg PO 
monthly or 3 mg IV every 3 mo; zoledronic acid, 5 mg IV annually)
SECTION 13
1170
Endocrinology and Metabolism
TABLE 188-3 FDA-APPROVED INDICATIONS FOR BMD TESTSa
Estrogen-deficient women at clinical risk of osteoporosis
  Vertebral abnormalities on x-ray suggestive of osteoporosis (osteopenia, 
vertebral fracture)
  Glucocorticoid treatment equivalent to ≥7.5 mg of prednisone, or duration 
of therapy >3 months
Primary hyperparathyroidism
Monitoring response to an FDA-approved medication for osteoporosis
  Repeat BMD evaluations at >23-month intervals, or more frequently, if 
medically justified
aCriteria adapted from the 1998 Bone Mass Measurement Act.
Abbreviations: BMD, bone mineral density; FDA, U.S. Food and Drug Administration
inhibit bone resorption, augment bone density, and decrease fracture 
rates. Oral bisphosphonates are poorly absorbed and should be taken 
in the morning on an empty stomach with 0.25 L (8 oz) of tap water. 
Long-term bisphosphonate treatment may be associated with atypi-
cal femur fractures; a tentative recommendation is to limit therapy to 
5 years. Osteonecrosis of the jaw is a rare complication of bisphospho-
nate treatment mainly seen with high-dose IV zoledronic acid or pami-
dronate administered in cancer pts. Estrogen decreases the rate of bone 
reabsorption, but therapy should be carefully weighed in the context of 
increased risks of cardiovascular disease and breast cancer. Raloxifene 
(60 mg/d PO), a selective estrogen receptor modulator (SERM), is an 
alternative antiresorptive agent that can be used in lieu of estrogen. It 
increases bone density and decreases total and LDL cholesterol without 
stimulating endometrial hyperplasia, although it may precipitate hot 
flashes. A new antiresorptive agent is denosumab, a monoclonal anti-
body against RANKL, an osteoclast differentiation factor. It is approved 
for pts at high risk for fracture and is given as an injection twice a year 
(60 mg SC every 6 months). Clinical experience with denosumab is 
still limited.
The only available drug that induces bone formation is teriparatide 
[PTH(1-34)]. It is indicated for treatment of severe osteoporosis and is 
administered as a daily injection for a maximum of 2 years. Teriparatide 
therapy must be followed by antiresorptive agent therapy to prevent 
rapid loss of the newly formed bone. 
� OSTEOMALACIA
Etiology 
Defective mineralization of the organic matrix of bone results in osteoma-
lacia. The childhood form of osteomalacia is called rickets. Osteomalacia 
is caused by inadequate intake or malabsorption of vitamin D (chronic 
CHAPTER 188
1171
Osteoporosis and Osteomalacia 
pancreatic insufficiency, gastrectomy, malabsorption) and disorders of 
vitamin D metabolism (anticonvulsant therapy, chronic renal failure, 
genetic disorders of vitamin D activation or action). Osteomalacia can also 
be caused by long-standing hypophosphatemia, which can be due to renal 
phosphate wasting (e.g., X-linked hypophosphatemic rickets or oncogenic 
osteomalacia) or excessive use of phosphate binders. 
Clinical Features 
Skeletal deformities may be overlooked until fractures occur after minimal 
trauma. Symptoms include diffuse skeletal pain and bony tenderness and may 
be subtle. Proximal muscle weakness is a feature of vitamin D deficiency and 
may mimic primary muscle disorders. A decrease in bone density is usually 
associated with loss of trabeculae and thinning of the cortices. Characteristic 
x-ray findings are radiolucent bands (Looser’s zones or pseudofractures) 
ranging from a few millimeters to several centimeters in length, usually per-
pendicular to the surface of the femur, pelvis, and scapula. Changes in serum 
calcium, phosphorus, 25(OH)D, and 1,25(OH)2D levels vary depending on 
the cause. The most specific test for vitamin D deficiency in an otherwise 
healthy individual is a low serum 25(OH)D level. Even modest vitamin D 
deficiency leads to compensatory secondary hyperparathyroidism character-
ized by increased levels of PTH and alkaline phosphatase, hyperphosphaturia, 
and low serum phosphate. With advancing osteomalacia, hypocalcemia may 
develop due to impaired calcium mobilization from undermineralized bone. 
1,25-Dihydroxyvitamin D levels may be preserved, reflecting upregulation of 
1α-hydroxylase activity.
Osteomalacia
TREATMENT
In osteomalacia due to vitamin D deficiency [serum 25(OH)D 
<50 nmol/L (<20 ng/mL)], vitamin D2 (ergocalciferol) is given orally in 
doses of 50,000 IU weekly for 8 weeks, followed by maintenance therapy 
with 800 IU daily. Osteomalacia due to malabsorption requires larger 
doses of vitamin D (up to 50,000 IU/d orally or 250,000 IU IM biannu-
ally). In pts taking anticonvulsants or those with disorders of abnormal 
vitamin D activation, vitamin D should be administered in doses that 
maintain the serum calcium and 25(OH)D levels in the normal range. 
Calcitriol (0.25–0.5 μg/d PO) is effective in treating hypocalcemia or 
osteodystrophy caused by chronic renal failure. Vitamin D deficiency 
should always be repleted in conjunction with calcium supplementation 
(1.5–2.0 g of elemental calcium daily). Serum and urinary calcium mea-
surements are efficacious for monitoring resolution of vitamin D defi-
ciency, with a goal 24-h urinary calcium excretion of 100–250 mg/24 h.
For a more detailed discussion, see Bringhurst FR, Demay MB, 
Krane SM, Kronenberg HM: Bone and Mineral Metabolism in 
Health and Disease, Chap. 352, p. 3082; and Lindsay R, 
Cosman F: Osteoporosis, Chap. 354, p. 3120, in HPIM-18. 
SECTION 13
1172
Endocrinology and Metabolism
CHAPTER 189
Hypercholesterolemia and 
Hypertriglyceridemia
Hyperlipoproteinemia may be characterized by hypercholesterolemia, 
isolated hypertriglyceridemia, or both (Table 189-1). Diabetes mellitus, 
obesity, ethanol consumption, oral contraceptives, glucocorticoids, renal 
disease, hepatic disease, and hypothyroidism can cause secondary hyperli-
poproteinemias or worsen underlying hyperlipoproteinemic states.
Standard lipoprotein analysis assesses total cholesterol, HDL cholesterol, 
and triglycerides with a calculation of LDL cholesterol levels using the fol-
lowing equation: LDL cholesterol = total cholesterol – HDL cholesterol – 
(triglycerides/5). The LDL cholesterol concentration can be estimated using 
this method only if triglycerides are <4.0 mmol/L (<350 mg/dL). Both LDL 
and HDL cholesterol levels are temporarily decreased for several weeks after 
myocardial infarction or acute inflammatory states, but can be accurately 
measured if blood is obtained within 8 h of the event.
ISOLATED HYPERCHOLESTEROLEMIA
Elevated levels of fasting plasma total cholesterol [>5.2 mmol/L (>200 mg/dL)] 
in the presence of normal levels of triglycerides are almost always associated 
with increased concentrations of plasma LDL cholesterol. A rare individual 
with markedly elevated HDL cholesterol may also have increased plasma 
total cholesterol levels. Elevations of LDL cholesterol can result from single-
gene defects, from polygenic disorders, or from the secondary effects of 
other disease states.
� FAMILIAL HYPERCHOLESTEROLEMIA (FH)
FH is a codominant genetic disorder due to mutations in the gene for 
the LDL receptor. Plasma LDL levels are elevated at birth and remain 
so throughout life. In untreated heterozygous adults, total cholesterol 
levels range from 7.1 to 12.9 mmol/L (275–500 mg/dL). Plasma triglyc-
eride levels are typically normal, and HDL cholesterol levels are normal 
or reduced. Heterozygotes, especially men, are prone to accelerated 
atherosclerosis and premature coronary artery disease (CAD). Tendon 
xanthomas (most commonly of the Achilles tendons and the extensor 
tendons of the knuckles), tuberous xanthomas (softer, painless nodules 
on the ankles and buttocks), and xanthelasmas (deposits on the eyelids) 
are common. In its homozygous form, FH leads to severe atherosclerosis 
during childhood.
� FAMILIAL DEFECTIVE APO B-100
This autosomal dominant disorder impairs the synthesis and/or function of 
apo B-100, thereby reducing the affinity for the LDL receptor, slowing LDL 
catabolism, and causing a phenocopy of FH.
1173
TABLE 189-1 CHARACTERISTICS OF CLASSIC HYPERLIPIDEMIAS
Lipoproteins
Lipid Phenotype
Plasma Lipid Levels, 
mmol/L (mg/dL)
Elevated
Phenotype
Clinical Signs
Isolated Hypercholesterolemia
Familial hypercholesterolemia
Heterozygotes: total chol = 7–13 
(275–500)
LDL
IIa
Usually develop xanthomas in adulthood 
and vascular disease at 30–50 years
Homozygotes: total chol >13 (>500)
LDL
IIa
Usually develop xanthomas and vascular 
disease in childhood
Familial defective apo B-100
Heterozygotes: total chol = 7–13 
(275–500)
LDL
IIa
Polygenic hypercholesterolemia
Total chol = 6.5–9.0 (250–350)
LDL
IIa
Usually asymptomatic until vascular 
disease develops; no xanthomas
Isolated Hypertriglyceridemia
Familial hypertriglyceridemia
TG = 2.8–8.5 (250–750) (plasma may 
be cloudy)
VLDL
IV
Asymptomatic; may be associated with 
increased risk of vascular disease
Familial lipoprotein lipase deficiency
TG >8.5 (>750) (plasma may be milky 
postprandially)
Chylomicrons I, V
May be asymptomatic; may be associ-
ated with pancreatitis, abdominal pain, 
hepatosplenomegaly
Familial apo CII deficiency
TG >8.5 (>750) (plasma may be milky 
postprandially)
Chylomicrons I, V
As above
(continued)
1174
TABLE 189-1 CHARACTERISTICS OF CLASSIC HYPERLIPIDEMIAS
Lipoproteins
Lipid Phenotype
Plasma Lipid Levels, 
mmol/L (mg/dL)
Elevated
Phenotype
Clinical Signs
Hypertriglyceridemia and Hypercholesterolemia
Combined hyperlipidemia
TG = 2.8–8.5 (250–750)
Total chol = 6.5–13.0 (250–500)
VLDL, LDL
IIb
Usually asymptomatic until vascular 
disease develops; familial form may also 
present as isolated high TG or an isolated 
high LDL cholesterol
Dysbetalipoproteinemia
TG = 2.8–5.6 (250–500)
Total chol = 6.5–13.0 (250–500)
VLDL, IDL; 
LDL normal
III
Usually asymptomatic until vascular 
disease develops; may have palmar or 
tuberoeruptive xanthomas
Note: Total chol, the sum of free and esterified cholesterol. The lipoprotein phenotype is designated according to the Fredrickson classification.
Abbreviations: IDL, intermediate-density lipoprotein; LDL, low-density lipoprotein; TG, triglycerides; VLDL, very low-density lipoprotein. 
Source: From HN Ginsberg, IJ Goldberg: HPIM-15, p. 2250.
(CONTINUED)
CHAPTER 189
1175
Hypercholesterolemia and Hypertriglyceridemia
� POLYGENIC HYPERCHOLESTEROLEMIA
Most moderate hypercholesterolemia [<9.1 mmol/L (<350 mg/dL)] arises 
from an interaction of multiple genetic defects and environmental factors 
such as diet, age, and exercise. Plasma HDL and triglyceride levels are nor-
mal, and xanthomas are not present.
Isolated Hypercholesterolemia
TREATMENT
An algorithm for the evaluation and treatment of hypercholesterolemia 
is displayed in Fig. 189-1. Therapy for all of these disorders includes 
restriction of dietary cholesterol and HMG-CoA reductase inhibitors 
(statins). Cholesterol absorption inhibitors and bile acid sequestrants or 
nicotinic acid may also be required (Table 189-2).
ISOLATED HYPERTRIGLYCERIDEMIA
The diagnosis of hypertriglyceridemia is made by measuring plasma lipid 
levels after an overnight fast (≥12 h). Hypertriglyceridemia in adults is 
defined as a triglyceride level >2.3 mmol/L (>200 mg/dL). An isolated 
increase in plasma triglycerides indicates that chylomicrons and/or very 
low-density lipoprotein (VLDL) are increased. Plasma is usually clear when 
triglyceride levels are <4.5 mmol/L (<400 mg/dL) and cloudy when levels 
are higher due to VLDL (and/or chylomicron) particles becoming large 
enough to scatter light. When chylomicrons are present, a creamy layer 
floats to the top of plasma after refrigeration for several hours. Tendon 
xanthomas and xanthelasmas do not occur with isolated hypertriglyceride-
mia, but eruptive xanthomas (small orange-red papules) can appear on the 
trunk and extremities and lipemia retinalis (orange-yellow retinal vessels) 
may be seen when the triglyceride levels are >11.3 mmol/L (>1000 mg/dL). 
Pancreatitis is associated with these high concentrations.
� FAMILIAL HYPERTRIGLYCERIDEMIA
In this relatively common (~1 in 500) autosomal dominant disorder, 
increased plasma VLDL causes elevated plasma triglyceride concentrations. 
Obesity, hyperglycemia, and hyperinsulinemia are characteristic, and diabetes 
mellitus, ethanol consumption, oral contraceptives, and hypothyroidism may 
exacerbate the condition. The diagnosis is suggested by the triad of elevated 
plasma triglycerides [2.8–11.3 mmol/L (250–1000 mg/dL)], normal or only 
mildly increased cholesterol levels [<6.5 mmol/L (<250 mg/dL)], and reduced 
plasma HDL. Secondary forms of hypertriglyceridemia due to the conditions 
listed above should be ruled out before making the diagnosis of familial 
hypertriglyceridemia. The identification of other first-degree relatives with 
hypertriglyceridemia is useful in making the diagnosis. Familial dysbetalipo-
proteinemia and familial combined hyperlipidemia should be ruled out, as 
these two conditions are associated with accelerated atherosclerosis.
� LIPOPROTEIN LIPASE DEFICIENCY
This rare autosomal recessive disorder results from the absence or defi-
ciency of lipoprotein lipase, which in turn impairs the metabolism of 
SECTION 13
1176
Endocrinology and Metabolism
FIGURE 189-1 Algorithms for the evaluation and treatment of hypercholesterolemia 
A and hypertriglyceridemia B. Statin, HMG-CoA reductase inhibitor; Chol, cholesterol; 
HDL, high-density lipoprotein; LDL, low-density lipoprotein; TG, triglyceride; TSH, 
thyroid-stimulating hormone; CHD, coronary heart disease.
Evaluation
  •Lipoprotein profile (Chol, TG, HDL, LDL)
  •Risk factor assessment (family, personal history)
Exclude secondary causes
  •Glucose, TSH
  •Liver and renal
   function tests
Low risk (0 or 1 risk factors)
LDL≥160
 Diet therapy
LDL≥190
 Diet therapy
 drug therapy
High risk (existing CHD or
atherosclerosis ≥2 risk
factors and 10-y risk ≥20%,
or diabetes mellitus)
LDL≥100
 Diet therapy
 + drug therapy
Moderate risk (≥2 risk factors and 10-y risk 20%)
LDL≥130
 Diet therapy + drug therapy
   for 10-y risk 10–20% 
Treatment
A
B
→
→
→
→
LDL≥160 
 Drug therapy for 10-y risk < 10%
→
Evaluation
  •History of eruptive xanthomas or abdominal pain (pancreatitis)
  •Exercise, weight gain, estrogen treatment, alcohol intake, diabetes
  •Lipoprotein profile, (Chol, TG, HDL, LDL)
  •Blood sugar, TSH, liver and renal function tests
  •Consider dysbetalipoproteinemia if 
 LDL and  TG
  •Risk factor assessment (family, personal history)
<2 risk factors 
 follow
≥2 risk factors
High-dose statin
Add Chol absorption
  inhibitor, niacin, or 
  fibrate if needed
Fibric acid or fish oils
Add niacin if needed
  to lower TG <500 
>500 mg/dL
200–500 mg/dL
without CHD
Lifestyle modification
  •Diet
  •Exercise
  •Reduce alcohol intake
  •Control diabetes, if present
Treatment
200–500 mg/dL
with CHD
→
→
→
LDL≥130 mg/dL
CHAPTER 189
1177
Hypercholesterolemia and Hypertriglyceridemia
TABLE 189-2 HYPOLIPIDEMIC DRUGS
Drugs and dosing
Lipoprotein
Class Affected
Common Side 
Effects
Contraindications
HMG-CoA reductase 
inhibitors
↓ LDL 18–55% Myalgias, 
arthralgias, ↑
transaminases, 
dyspepsia
Acute or chronic 
liver disease; 
risk of myositis 
increased by 
impaired renal 
function and in 
combination with 
a fibrate
  Lovastatin 
20–80 mg/d
↓ TG 7–30%
  Pravastatin 
40–80 mg qhs
↑ HDL 5–15%
  Simvastatin 
20–80 mg qhs
  Fluvastatin 
20–80 mg/d
  Atorvastatin 
10–80 mg qhs
  Rosuvastatin 
10–40 mg qhs
Cholesterol absorption 
inhibitors
↓ LDL 18%
↑ Transaminases
  Ezetimibe 
10 mg qd
↓ TG 8%
Bile acid sequestrant
↓ LDL 15–30% Constipation, 
gastric discom-
fort, nausea
Biliary tract 
obstruction, 
gastric outlet 
obstruction
  Cholestyramine 
4–32 g/d
↑ TG 10%
  Colestipol 5–40 g/d
↑ HDL 3–5%
  Colesevelam 
3750–4375 mg/d
Nicotinic acid
↓ LDL 5–25%
↓ TG 20–50%
↑ HDL 15–35%
Flushing (may 
be relieved by 
aspirin), hepatic 
dysfunction, 
nausea, diar-
rhea, glucose 
intolerance, 
hyperuricemia
Peptic ulcer 
disease, hepatic 
disease, gout
  Immediate release 
100 mg tid, gradual 
increase to 1 g tid
  Sustained release 
250 mg–1.5 g bid
(continued)
SECTION 13
1178
Endocrinology and Metabolism
TABLE 189-2 HYPOLIPIDEMIC DRUGS
Drugs and dosing
Lipoprotein
Class Affected
Common Side 
Effects
Contraindications
  Extended release 
500 mg–2 g qhs
Fibric acid derivatives
↑ or ↓ LDL
↓ Absorption of 
other drugs
Hepatic or biliary 
disease, renal 
insufficiency 
associated with ↑
risk of myositis
  Gemfibrozil 
600 mg bid
↓ TG 20–50%
↑ Gallstones, 
dyspepsia, 
hepatic dysfunc-
tion, myalgia
  Fenofibrate 
145 mg qd
↑ HDL 10–20%
Fish oils 3–6 g qd
↓ TG 5–10%
Dyspepsia, 
diarrhea, fishy 
odor to breath
Abbreviations: HDL, high-density lipoprotein; LDL, low-density lipoprotein; LPL, lipoprotein 
lipase; TG, triglycerides; VLDL, very low density lipoprotein.
(CONTINUED)
chylomicrons. Accumulation of chylomicrons in plasma causes recurrent 
bouts of pancreatitis, usually beginning in childhood, and hepatospleno-
megaly is present. Accelerated atherosclerosis is not a feature.
� APO CII DEFICIENCY
This rare autosomal recessive disorder is due to the absence of apo CII, 
an essential cofactor for lipoprotein lipase. As a result, chylomicrons and 
triglycerides accumulate and cause manifestations similar to those in lipo-
protein lipase deficiency.
Isolated Hypertriglyceridemia
TREATMENT
An algorithm for the evaluation and treatment of hypertriglyceridemia 
is displayed in Fig. 189-1. Pts with severe hypertriglyceridemia should 
be placed on a fat-free diet with fat-soluble vitamin supplementation. 
Pts with moderate hypertriglyceridemia should restrict fat, carbohy-
drate, and alcohol intake. In those with familial hypertriglyceridemia, 
fibric acid derivatives should be administered if dietary measures fail 
(Table 189-2).
HYPERCHOLESTEROLEMIA AND HYPERTRIGLYCERIDEMIA
Elevations of both triglycerides and cholesterol are caused by elevations in 
both VLDL and LDL or in VLDL remnant particles.
� FAMILIAL COMBINED HYPERLIPIDEMIA (FCHL)
This inherited disorder, present in 1/200 persons, can cause different lipopro-
tein abnormalities in affected individuals, including hypercholesterolemia 
CHAPTER 189
1179
Hypercholesterolemia and Hypertriglyceridemia
(elevated LDL), hypertriglyceridemia (elevated triglycerides and VLDL), 
or both. Atherosclerosis is accelerated. A mixed dyslipidemia [plasma 
triglycerides 2.3–9.0 mmol/L (200–800 mg/dL), cholesterol levels 5.2–10.3 
mmol/L (200–400 mg/dL), and HDL levels <10.3 mmol/L (<40 mg/dL) 
in men and <12.9 mmol/L (<50 mg/dL) in women] and a family history 
of hyperlipidemia and/or premature cardiovascular disease suggest the 
diagnosis of FCHL. Many of these pts also have the metabolic syndrome 
(Chap. 127), and it may be difficult to differentiate familial from second-
ary causes of hyperlipidemia. All pts should restrict dietary cholesterol and 
fat and avoid alcohol and oral contraceptives; pts with diabetes should be 
treated aggressively. An HMG-CoA reductase inhibitor is usually required, 
and many pts will require a second drug (cholesterol absorption inhibitor, 
niacin, or fibrate) for optimal control.
� DYSBETALIPOPROTEINEMIA
This rare genetic disorder is associated with homozygosity for an apo-
protein variant (apoE2) that has reduced affinity for the LDL receptor. 
Development of disease requires additional environmental and/or genetic 
factors. Plasma cholesterol [6.5–13.0 mmol/L (250–500 mg/dL)] and tri-
glycerides [2.8–5.6 mmol/L (250–500 mg/dL)] are increased due to accu-
mulation of VLDL and chylomicron remnant particles. Pts usually present 
in adulthood with xanthomas and premature coronary and peripheral 
vascular disease. Cutaneous xanthomas are distinctive, in the form of 
palmar and tuberoeruptive xanthomas. Triglycerides and cholesterol are 
both elevated. Diagnosis is established by lipoprotein electrophoresis 
(showing a broad beta band) or a ratio of VLDL (by ultracentrifugation) 
to total plasma triglycerides of >0.3. The disorder is associated with accel-
erated atherosclerosis. Dietary modifications should be instituted, and 
HMG-CoA reductase inhibitors, fibrates, and/or niacin may be necessary. 
Comorbidities, such as diabetes mellitus, obesity, or hypothyroidism, 
should be optimally managed.
PREVENTION OF THE COMPLICATIONS OF ATHEROSCLEROSIS
The National Cholesterol Education Program guidelines (Fig. 189-1) are 
based on plasma LDL levels and estimations of other risk factors. The goal 
in pts with the highest risk (known coronary heart or other atheroscle-
rotic disease, 10-year Framingham Study risk for coronary heart disease 
>20%, or diabetes mellitus) is to lower LDL cholesterol to <2.6 mmol/L 
(<100 mg/dL). In pts with very high risk, clinical trials suggest additional 
benefit by reducing LDL cholesterol to <1.8 mmol/L (<70 mg/dL). The 
goal is an LDL cholesterol <3.4 mmol/L (<130 mg/dL) in pts with two or 
more risk factors for atherosclerotic heart disease and a 10-year absolute 
risk of 10–20%, although a treatment goal of <2.6 mmol/L (<100 mg/
dL) can be considered. The intensity of LDL-lowering drug treatment in 
high- and moderately high-risk pts should achieve at least a 30% reduc-
tion in LDL levels. Risk factors include (1) men age >45, women age >55 
or after menopause; (2) family history of early CAD (<55 years in a male 
parent or sibling and <65 years in a female parent or sibling); (3) hyper-
tension (even if it is controlled with medications); (4) cigarette smoking 
SECTION 13
1180
Endocrinology and Metabolism
(>10 cigarettes/day); and (5) HDL cholesterol <1.0 mmol/L (<40 mg/
dL). Therapy begins with a low-fat diet and lifestyle modification, but 
pharmacologic intervention is often required (Table 189-2).
For a more detailed discussion, see Rader DJ, Hobbs HH: 
Disorders of Lipoprotein Metabolism, Chap. 356, p. 3145; 
in HPIM-18. 
CHAPTER 190
Hemochromatosis, 
Porphyrias, and Wilson’s Disease
HEMOCHROMATOSIS
Hemochromatosis is a disorder of iron storage that results in increased 
intestinal iron absorption with Fe deposition and damage to many tissues. 
The classic clinical constellation of hemochromatosis is a pt presenting 
with bronze skin, liver disease, diabetes, arthropathy, cardiac conduction 
abnormalities, and hypogonadism. Two major causes of hemochromatosis 
exist: hereditary (due to inheritance of mutant HFE genes) and secondary 
iron overload (usually the result of ineffective erythropoiesis, such as thal-
assemia or sideroblastic anemia). HFE encodes a protein that is involved 
in cellular iron sensing and in regulating intestinal iron absorption. HFE 
mutations are very common in populations of Northern European origin 
(1 in 10 is a carrier). Heterozygotes are asymptomatic; homozygotes show a 
disease penetrance of ~30%. There is progressive iron overload, with clini-
cal manifestations appearing after age 30–40, typically earlier in men than 
in women. Alcoholic liver disease and chronic excessive Fe ingestion may 
also be associated with a moderate increase in hepatic Fe and elevated body 
Fe stores.
Clinical Features 
Early symptoms include weakness, lassitude, weight loss, a bronze pig-
mentation or darkening of skin, abdominal pain, and loss of libido. 
Hepatomegaly occurs in 95% of pts, sometimes in the presence of normal 
LFTs. If untreated, liver disease progresses to cirrhosis, and further to 
hepatocellular carcinoma in ~30% of pts with cirrhosis. Other manifesta-
tions include skin pigmentation (bronzing), diabetes mellitus (65% of pts), 
arthropathy (25–59%), cardiac arrhythmias and CHF (15%), and hypogo-
nadotropic hypogonadism. Diabetes mellitus is more common in pts with 
a family history of diabetes, and hypogonadism may be an isolated early 
manifestation. Typical signs of portal hypertension and decompensated 
CHAPTER 190
1181
Hemochromatosis, Porphyrias, and Wilson’s Disease 
hepatic cirrhosis may appear late in the clinical course. Adrenal insuffi-
ciency, hypothyroidism, and hypoparathyroidism rarely occur.
Diagnosis
Serum Fe, percent transferrin saturation, and serum ferritin levels are 
increased. In an otherwise-healthy person, a fasting serum transferrin satu-
ration >50% is abnormal and suggests homozygosity for hemochromatosis. 
In most untreated pts with hemochromatosis, the serum ferritin level is also 
greatly increased. If either the percent transferrin saturation or the serum 
ferritin level is abnormal, genetic testing for hemochromatosis should be 
performed. All first-degree relatives of pts with hemochromatosis should 
be tested for the C282Y and H63D mutations in HFE. Liver biopsy may 
be required in affected individuals to evaluate possible cirrhosis and to 
quantify tissue iron. An algorithm for evaluating pts with possible hemo-
chromatosis is shown in Fig. 190-1. Death in untreated pts results from 
cardiac failure (30%), cirrhosis (25%), and hepatocellular carcinoma (30%); 
the latter may develop despite adequate Fe removal.
FIGURE 190-1 Algorithm for screening for HFE-associated hemochromatosis. LFT, 
liver function tests; TS, transferrin saturation. (From EJ Eijkelkamp et al: Can J
Gastroenterol 14:2, 2000; with permission.)
Family
  member
General
  population
Individual
Transferrin saturation or
  unsaturated iron-binding capacity
TS < 45%
TS ≥ 45%
Reassure,
  retest later?
HFE Genotype
Phlebotomy
Normal and
other genotypes
Counsel and
  consider non-HFE
  hemochromatosis
C282Y Homozygote
C282Y/H63D Heterozygote
Confirmed
  iron overload
Serum ferritin, LFTs
  Transferrin saturation
Serum
ferritin
LFTs normal
<300 mg/L
Observe,
  retest in 1–2 years
Serum ferritin >1000 mg/L
  and/or LFTs abnormal
Serum ferritin =
  300–1000 mg/L,
  LFTs normal
Liver biopsy
No iron
overload
Investigate and
  treat as
  appropriate
SECTION 13
1182
Endocrinology and Metabolism
Hemochromatosis
TREATMENT
Therapy involves removal of excess body Fe, usually by intermittent 
phlebotomy, and supportive treatment of damaged organs. Since 1 
unit of blood contains ~250 mg Fe, and since up to 25 g of Fe must be 
removed, phlebotomy is performed weekly for 1–2 years. Less frequent 
phlebotomy is then used to maintain serum Fe at 9–18 μmol/L (50–100 
μg/dL). Chelating agents such as deferoxamine (infused subcutaneously 
using a portable pump) remove 10–20 mg iron per day, a fraction of 
that mobilized by weekly phlebotomy. Chelation therapy is indicated, 
however, when phlebotomy is inappropriate, such as with anemia or 
hypoproteinemia. Alcohol consumption should be eliminated. End-
stage liver disease may require liver transplantation.
PORPHYRIAS
The porphyrias are inherited disturbances in heme biosynthesis. Each of 
the nine disorders causes a unique pattern of overproduction, accumula-
tion, and excretion of intermediates of heme synthesis. These disorders are 
classified as either hepatic or erythropoietic, depending on the primary 
site of overproduction and accumulation of the porphyrin precursor or 
porphyrin. The major manifestations of the hepatic porphyrias are neuro-
logic (neuropathic abdominal pain, neuropathy, and mental disturbances), 
whereas the erythropoietic porphyrias characteristically cause cutaneous 
photosensitivity. Laboratory testing is required to confirm or exclude the 
various types of porphyria. However, a definite diagnosis requires demon-
stration of the specific enzyme deficiency or gene defect. Only the three 
most common porphyrias are discussed here.
� ACUTE INTERMITTENT PORPHYRIA
This is an autosomal dominant disorder with variable expressivity caused 
by partial (50%) deficiency in hydroxymethylbilane synthase. It has a 
prevalence of 1–3 in 100,000 but is much more common in certain parts 
of the world (Northern Sweden, Great Britain). Manifestations include 
colicky abdominal pain, vomiting, constipation, port wine–colored urine, 
and neurologic and psychiatric disturbances. Acute attacks rarely occur 
before puberty and may last from days to months. Photosensitivity does 
not occur. Clinical and biochemical manifestations may be precipitated 
by barbiturates, anticonvulsants, estrogens, oral contraceptives, the luteal 
phase of the menstrual cycle, alcohol, or low-calorie diets. Diagnosis is 
established by demonstrating elevation of urinary porphobilinogen (PBG) 
and γ-aminolevulinic acid (ALA) during an acute attack.
Acute Intermittent Porphyria
TREATMENT
As soon as possible after the onset of an attack, 3–4 mg of heme, in the 
form of heme arginate, heme albumin, or hematin, should be infused 
daily for 4 days. Heme acts by inhibiting ALA synthase, thereby restraining
CHAPTER 190
1183
Hemochromatosis, Porphyrias, and Wilson’s Disease 
ALA and PBG production. Administration of IV glucose at rates up to 
20 g/h or parenteral nutrition, if oral feeding is not possible for long 
periods, can be effective in acute attacks. Narcotic analgesics may be 
required during acute attacks for abdominal pain, and phenothiazines 
are useful for nausea, vomiting, anxiety, and restlessness. Treatment 
between attacks involves adequate nutritional intake, avoidance of drugs 
known to exacerbate the disease, and prompt treatment of other inter-
current diseases or infections.
� PORPHYRIA CUTANEA TARDA
This is the most common porphyria (2–4 in 100,000) and is character-
ized by cutaneous photosensitivity and, usually, hepatic disease. It is due 
to partial deficiency (familial, sporadic, or acquired) of hepatic uropor-
phyrinogen decarboxylase. Photosensitivity causes facial pigmentation, 
increased fragility of skin, erythema, and vesicular and ulcerative lesions, 
typically involving face, forehead, and forearms. Neurologic manifestations 
are not observed. Contributing factors include excess alcohol, iron, and 
estrogens. Pts with liver disease are at risk for cirrhosis and hepatocellular 
carcinoma. Plasma and urine uroporphyrin and 7-carboxylate porphyrin 
are increased.
Porphyria Cutanea Tarda
TREATMENT
Avoidance of precipitating factors, including abstinence from alcohol, 
estrogens, iron supplements, and other exacerbating drugs, is the first 
line of therapy. A complete response can almost always be achieved by 
repeated phlebotomy (every 1–2 weeks) until hepatic iron is reduced. 
Chloroquine or hydroxychloroquine may be used in low doses (e.g., 
125 mg chloroquine phosphate twice weekly) to promote porphyrin 
excretion in pts unable to undergo or unresponsive to phlebotomy.
� ERYTHROPOIETIC PROTOPORPHYRIA
Erythropoietic protoporphyria is an autosomal dominant disorder due to 
partial deficiency of ferrochelatase, the last enzyme in the heme biosyn-
thetic pathway. Its prevalence is 1 in 100,000. Porphyrins (primarily proto-
porphyrin IX) from bone marrow erythrocytes and plasma are deposited 
in the skin and lead to cutaneous photosensitivity. Skin photosensitivity 
usually begins in childhood. The skin manifestations differ from those of 
other porphyrias, in that vesicular lesions are uncommon. Redness, swell-
ing, burning, and itching can develop within minutes of sun exposure and 
resemble angioedema. Symptoms may seem out of proportion to the visible 
skin lesions. Chronic skin changes may include lichenification, leathery 
pseudovesicles, labial grooving, and nail changes. Liver function is usually 
normal, but liver disease and gallstones may occur. Protoporphyrin levels 
are increased in bone marrow, circulating erythrocytes, plasma, bile, and 
feces; protoporphyrin in erythrocytes is free rather than zinc-complexed 
as it is in other types of porphyria or hematologic disorders. Urinary 
SECTION 13
1184
Endocrinology and Metabolism
porphyrin levels are normal. Diagnosis is confirmed by identifying a muta-
tion in the ferrochelatase gene.
Erythropoietic Protoporphyria
TREATMENT
Avoidance of sun exposure is essential. Oral β-carotene (120–180 mg/d) 
improves tolerance to sunlight in many pts. The dosage may be adjusted 
to maintain serum carotene levels between 10 and 15 μmol/L (600–800 
μg/dL). Cholestyramine or activated charcoal may promote fecal excre-
tion of protoporphyrin. Plasmapheresis or IV heme therapy may be 
beneficial.
WILSON’S DISEASE
Wilson’s disease is a rare inherited disorder of copper metabolism, resulting 
in the toxic accumulation of copper in the liver, brain, and other organs. 
Individuals with Wilson’s disease have mutations in the ATP7B gene, which 
encodes a membrane-bound copper-transporting ATPase. Deficiency of 
this protein impairs copper excretion into the bile and copper incorporation 
into ceruloplasmin, leading to its rapid degradation.
Clinical Features 
Clinical manifestations typically appear in the mid- to late-teen years but 
may occur later. Hepatic disease may present as hepatitis, cirrhosis, or 
hepatic decompensation. In other pts, neurologic or psychiatric distur-
bances are the first clinical sign and are always accompanied by Kayser-
Fleischer rings (corneal deposits of copper). Dystonia, incoordination, 
or tremor may be present, and dysarthria and dysphagia are common. 
Autonomic disturbances also may be present. Microscopic hematuria is 
common. In about 5% of pts, the first manifestation may be primary or 
secondary amenorrhea or repeated spontaneous abortions.
Diagnosis
Serum ceruloplasmin levels are often low but may be normal in up to 10% 
of pts. Urine copper levels are elevated. The “gold standard” for diagnosis 
is an elevated copper level on liver biopsy. Genetic testing is not currently 
practical because of the large number of mutations that can be responsible.
Wilson’s Disease
TREATMENT
Hepatitis or cirrhosis without decompensation should be treated with 
zinc acetate (50 mg elemental Zn PO three times a day). Zinc is effective 
by blocking intestinal copper absorption and inducing metallothionein, 
which sequesters copper in an nontoxic complex. For pts with hepatic 
decompensation, the chelator trientene (500 mg PO twice a day) plus zinc 
(separated by at least 1 h to avoid zinc chelation in the intestinal lumen) 
is recommended, although liver transplantation should be considered
CHAPTER 190
1185
Hemochromatosis, Porphyrias, and Wilson’s Disease 
for severe hepatic decompensation. For initial neurologic therapy, 
trientine and zinc are recommended for 8 weeks, followed by therapy 
with zinc alone. Tetrathiomolybdate is an alternative therapeutic option 
available in the future. Penicillamine is no longer first-line therapy. Zinc 
treatment does not require monitoring for toxicity, and 24-h urine cop-
per can be followed for a therapeutic response. Trientine may induce 
bone marrow suppression and proteinuria. With chelation therapy, 
measuring free serum copper levels (adjusting total serum copper for 
ceruloplasmin copper) rather than urine copper is used to monitor 
therapeutic response. Anticopper therapy must be lifelong.
For a more detailed discussion, see Powell LW: 
Hemochromatosis, Chap. 357, p. 3162; Desnick RJ, Balwani 
M: The Porphyrias, Chap. 358, p. 3167; and Brewer GJ: 
Wilson’s Disease, Chap. 360, p. 3188, in HPIM-18. 
This page intentionally left blank 
1187
CHAPTER 191
The Neurologic Examination
MENTAL STATUS EXAM
• The bare minimum: During the interview, look for difficulties with com-
munication and determine whether the pt has recall and insight into recent 
and past events.
The mental status examination is underway as soon as the physician begins 
observing and talking with the pt. The goal of the mental status exam is to 
evaluate attention, orientation, memory, insight, judgment, and grasp of 
general information. Attention is tested by asking the pt to respond every 
time a specific item recurs in a list. Orientation is evaluated by asking 
about the day, date, and location. Memory can be tested by asking pt to 
immediately recall a sequence of numbers and by testing recall of a series 
of objects after defined times (e.g., 5 and 15 min). More remote memory is 
evaluated by assessing pt’s ability to provide a cogent chronologic history 
of the illness or personal life events. Recall of historic events or dates of 
current events can be used to assess knowledge. Evaluation of language 
function should include assessment of spontaneous speech, naming, 
repetition, reading, writing, and comprehension. Additional tests such as 
ability to draw and copy, perform calculations, interpret proverbs or logic 
problems, identify right vs. left, name and identify body parts, etc., are also 
important.
A useful screening examination of cognitive function is the mini-mental 
status examination (MMSE) (Table 191-1).
CRANIAL NERVE (CN) EXAM
• The bare minimum: Check the fundi, visual fields, pupil size and reactivity, 
extraocular movements, and facial movements.
CN I 
Occlude each nostril sequentially and ask pt to gently sniff and identify a 
mild test stimulus, such as soap, toothpaste, coffee, or lemon oil.
CN II 
Check visual acuity with eyeglasses or contact lens correction using a 
Snellen chart or similar tool. Map visual fields (VFs) by confrontation 
testing in each quadrant of visual field for each eye individually. The best 
method is to sit facing pt (2–3 ft apart) and then have pt cover one eye 
gently and fix uncovered eye on examiner’s nose. A small white object (e.g., 
a cotton-tipped applicator) is then moved slowly from periphery of field 
toward center until seen. Pt’s VF should be mapped against examiner’s for 
SECTION 14
Neurology
SECTION 14
1188
Neurology
comparison. Formal perimetry and tangent screen exam are essential to 
identify and delineate small defects. Optic fundi should be examined with 
an ophthalmoscope, and the color, size, and degree of swelling or elevation 
of the optic disc recorded. The retinal vessels should be checked for size, 
regularity, AV nicking at crossing points, hemorrhage, exudates, and aneu-
rysms. The retina, including the macula, should be examined for abnormal 
pigmentation and other lesions.
CN III, IV, VI 
Describe size, regularity, and shape of pupils; reaction (direct and consen-
sual) to light; and convergence (pt follows an object as it moves closer). 
Check for lid drooping, lag, or retraction. Ask pt to follow your finger as you 
move it horizontally to left and right and vertically with each eye first fully 
adducted then fully abducted. Check for failure to move fully in particular 
directions and for presence of regular, rhythmic, involuntary oscillations of 
eyes (nystagmus). Test quick voluntary eye movements (saccades) as well as 
pursuit (e.g., follow the finger).
TABLE 191-1  THE MINI-MENTAL STATUS EXAMINATION
Points
Orientation
 Name: season/date/day/month/year
5 (1 for each name)
 Name: hospital floor/town/state/country
5 (1 for each name)
Registration
  Identify three objects by name and ask pt to 
repeat
3 (1 for each object)
Attention and calculation
  Serial 7s; subtract from 100 (e.g., 93–86–79–
72–65)
5 (1 for each subtraction)
Recall
 Recall the three objects presented earlier
3 (1 for each object)
Language
 Name pencil and watch
2 (1 for each object)
 Repeat “No ifs, ands, or buts”
1
  Follow a 3-step command (e.g., “Take this 
paper, fold it in half, and place it on the table”)
3 (1 for each command)
  Write “close your eyes” and ask pt to obey 
written command
1
 Ask pt to write a sentence
1
  Ask pt to copy a design (e.g., intersecting 
pentagons)
1
TOTAL
30
CHAPTER 191 1189
The Neurologic Examination
CN V 
Feel the masseter and temporalis muscles as pt bites down and test jaw opening, 
protrusion, and lateral motion against resistance. Examine sensation over entire 
face. Testing of the corneal reflex is indicated when suggested by the history. 
CN VII 
Look for asymmetry of face at rest and with spontaneous movements. 
Test eyebrow elevation, forehead wrinkling, eye closure, smiling, frown-
ing; check puff, whistle, lip pursing, and chin muscle contraction. Observe 
for differences in strength of lower and upper facial muscles. Taste on the 
anterior two-thirds of tongue can be affected by lesions of the seventh CN 
proximal to the chorda tympani.
CN VIII 
Check ability to hear tuning fork, finger rub, watch tick, and whispered 
voice at specified distances with each ear. Check for air vs. mastoid bone 
conduction (Rinne) and lateralization of a tuning fork placed on center of 
forehead (Weber). Accurate, quantitative testing of hearing requires formal 
audiometry. Remember to examine tympanic membranes.
CN IX, X 
Check for symmetric elevation of palate-uvula with phonation (“ahh”), 
as well as position of uvula and palatal arch at rest. Sensation in region of 
tonsils, posterior pharynx, and tongue may also require testing. Pharyngeal 
(“gag”) reflex is evaluated by stimulating posterior pharyngeal wall on each 
side with a blunt object (e.g., tongue blade). Direct examination of vocal 
cords by laryngoscopy is necessary in some situations.
CN XI 
Check shoulder shrug (trapezius muscle) and head rotation to each side 
(sternocleidomastoid muscle) against resistance.
CN XII 
Examine bulk and power of tongue. Look for atrophy, deviation from mid-
line with protrusion, tremor, and small flickering or twitching movements 
(fibrillations, fasciculations).
MOTOR EXAM
• The bare minimum: Look for muscle atrophy and check limb tone. Assess 
upper limb strength by checking for pronator drift and strength of wrist or 
finger reflexes. Test for lower limb strength by asking pt to walk normally 
and on heels and toes.
Power should be systematically tested for major movements at each joint 
(Table 191-2). Strength should be recorded using a reproducible scale (e.g., 
0 = no movement, 1 = flicker or trace of contraction with no associated 
movement at a joint, 2 = movement present but cannot be sustained against 
gravity, 3 = movement against gravity but not against applied resistance, 
TABLE 191-2 MUSCLES THAT MOVE JOINTS
Muscle
Nerve
Segmental
Innervation
Function
Shoulder
Supraspinatus
Suprascapular n.
C5,6
Abduction of upper arm
Deltoid
Axillary n.
C5,6
Abduction of upper arm
Forearm
Biceps
Musculocutaneous n.
C5,6
Flexion of the supinated forearm
Brachioradialis
Radial n.
C5,6
Forearm flexion with arm between pronation and supination
Triceps
Radial n.
C6,7,8
Extension of forearm
Ext. carpi 
radialis
Radial n.
C5,6
Extension and abduction of hand at the wrist
Ext. carpi ulnaris P. interosseous n.
C7,8
Extension and adduction of hand at the wrist
Ext. digitorum
P. interosseous n.
C7,8
Extension of fingers at the MCP joints
Supinator
P. interosseous n.
C6,7
Supination of the extended forearm
Flex. carpi 
radialis
Median n.
C6,7
Flexion and abduction of hand at the wrist
Flex. carpi 
ulnaris
Ulnar n.
C7,8,T1
Flexion and adduction of hand at the wrist
Pronator teres
Median n.
C6,7
Pronation of the forearm
Wrist
Ext. carpi ulnaris Ulnar n.
C7,8,T1
Extension/adduction at the wrist
Flex. carpi 
radialis
Median n.
C6,7
Flexion/abduction at the wrist
1190
Hand
Lumbricals
Median + ulnar n.
C8,T1
Extension of fingers at PIP joint with the MCP joint extended and fixed
Interossei
Ulnar n.
C8,T1
Abduction/adduction of the fingers
Flex. digitorum
Median + A. interos-
seous n.
C7,C8,T1
Flexion of the fingers
Thumb
Opponens pol-
licis
Median n.
C8,T1
Touching the base of the 5th finger with thumb
Ext. pollicis
P. interosseous n.
C7,8
Extension of the thumb
Add. pollicis
Median n.
C8,T1
Adduction of the thumb
Abd. pollicis
Ulnar n.
C8,T1
Abduction of the thumb
Flex. pollicis br.
Ulnar n.
C8,T1
Flexion of the thumb
Thigh
Iliopsoas
Femoral n.
L1,2,3
Flexion of the thigh
Glutei
Sup. + inf. gluteal n.
L4,L5,S1,S2
Abduction, extension, and internal rotation of the leg
Quadriceps
Femoral n.
L2,3,4
Extension of the leg at the knee
Adductors
Obturator n.
L2,3,4
Adduction of the leg
Hamstrings
Sciatic n.
L5,S1,S2
Flexion of the leg at the knee
Foot
Gastrocnemius
Tibial n.
S1,S2
Plantar flexion of the foot
Tibialis ant.
Deep peroneal n.
L4,5
Dorsiflexion of the foot
Peronei
Deep peroneal n.
L5,S1
Eversion of the foot
Tibialis post.
Tibial n.
L4,5
Inversion of the foot
Toes
Ext. hallucis l.
Deep peroneal n.
L5,S1
Dorsiflexion of the great toe
1191
SECTION 14
1192
Neurology
4 = movement against some degree of resistance, and 5 = full power; 4 
values can be supplemented with + and − signs to provide additional gra-
dations). Speed of movement, ability to relax contractions promptly, and 
fatigue with repetition should all be noted. Loss in bulk and size of muscle 
(atrophy) should be noted, as well as the presence of irregular involuntary 
contraction (twitching) of groups of muscle fibers (fasciculations). Any 
involuntary movements should be noted at rest, during maintained posture, 
and with voluntary action.
REFLEXES
• The bare minimum: Tap the biceps, patellar, and Achilles reflexes.
Important muscle-stretch reflexes to test routinely and the spinal cord seg-
ments involved in their reflex arcs include biceps (C5, 6); brachioradialis 
(C5, 6); triceps (C7, 8); patellar (L3, 4); and Achilles (S1, 2). A common 
grading scale is 0 = absent, 1 = present but diminished, 2 = normal, 3 = 
hyperactive, and 4 = hyperactive with clonus (repetitive rhythmic con-
tractions with maintained stretch). The plantar reflex should be tested by 
using a blunt-ended object such as the point of a key to stroke the outer 
border of the sole of the foot from the heel toward the base of the great 
toe. An abnormal response (Babinski sign) is extension (dorsiflexion) of 
the great toe at the metatarsophalangeal joint. In some cases this may be 
associated with abduction (fanning) of other toes and variable degrees of 
flexion at ankle, knee, and hip. Normal response is plantar flexion of the 
toes. Superficial abdominal and anal reflexes are important in certain situ-
ations; unlike muscle stretch reflexes, these cutaneous reflexes disappear 
with CNS lesions.
SENSORY EXAM
• The bare minimum: Ask whether the pt can feel light touch and the tem-
perature of a cool object in each distal extremity. Check double simultane-
ous stimulation using light touch on the hands.
For most purposes it is sufficient to test sensation to pinprick, touch, posi-
tion, and vibration in each of the four extremities (Figs. 191-1 and 191-2). 
Specific problems often require more thorough evaluation. Pts with cerebral 
lesions may have abnormalities in “discriminative sensation” such as the 
ability to perceive double simultaneous stimuli, to localize stimuli accu-
rately, to identify closely approximated stimuli as separate (two-point dis-
crimination), to identify objects by touch alone (stereognosis), or to judge 
weights, evaluate texture, or identify letters or numbers written on the skin 
surface (graphesthesia).
COORDINATION AND GAIT
• The bare minimum: Test rapid alternating movements of the fingers and 
feet, and the finger-to-nose maneuver. Observe the pt while he or she is 
walking along a straight line.
The ability to move the index finger accurately from the nose to the exam-
iner’s outstretched finger and the ability to slide the heel of each foot from 
the knee down the shin are tests of coordination. Additional tests (drawing 
CHAPTER 191 1193
The Neurologic Examination
Great auricular n.
Ant. cut. n. of neck
Ant.
cut.
rami
of
  thor.
  n’s.
T2
3
4
5
6
7
8
9
10
11
12
Lat.
   cut.
  rami
Supraclavicular n’s.
Med. cut. n. of arm
 & intercostobrachial n.
Med. cut. n. 
  of forearm
Iliohypo-
gastric n.
Genital
branch of
genitofem.
n.
Dorsal n. of penis
Scrotal branch of perineal n.
Obturator n.
Lat.cut. n. of calf
(from common peroneal n.)
Superﬁcial peroneal n.
   (from common peroneal n.)
Deep peroneal n.
(from common peroneal n.)
Intermed. & med. cut. n’s.
of thigh (from femoral n.)
Lat. cut. n. of thigh
Lat. cut. of forearm
(from musculocut. n.)
Lower lat.cut. n. of arm
(from radial n.)
Axillary n.
(circumflex)
I
II
III
Ilio-
inguinal n.
Femoral
branch
of genito- 
femoral n.
(lumbo-inguinal n.)     
Saphenous n.
(from femoral n.)
Med. & lat. plantar n’s.
(from posttibial n.)
Sural n.
(from tibial n.)
Radial n.
Median n.
Ulnar n.
FIGURE 191-1 The cutaneous fields of peripheral nerves. (Reproduced by permis-
sion from W Haymaker, B Woodhall: Peripheral Nerve Injuries, 2nd ed. Philadelphia, 
Saunders, 1953.)
objects in the air, following a moving finger, tapping with index finger 
against thumb or alternately against each individual finger) may also be 
useful. The ability to stand with feet together and eyes closed (Romberg 
test), to walk a straight line (tandem walk), and to turn should all be 
observed.
SECTION 14
1194
Neurology
Great auricular n.
Greater
Lesser n.}  occipital nerves
Ant. cut. n. of neck
T2
3
4
  5
   6
   7
    8
    9
     10
          11
          12
T1
L1
S1
Post. rami of
lumbar sacral
& coccygeal n’s.
Lat.
cut.   
rami         
Post.
cut.
rami
of
thor.
n’s.
C5
C6
Supraclavicular n’s.
Med. cut. n. of arm
 & intercostobrachial n.
Post. cut. n. of forearm
 (from radial n.)
Lat. cut. n. of forearm
 (from musculocut n.)
Med. 
 cut. n. 
  of 
   forearm
Obturator n.
Superficial peroneal n.
(from common peroneal n.)
Lat. cut. n.of calf
(from common femoral n.)
Inf. med.
cluneal n.
Inf. lat.
      cluneal n’s.
Lat. plantar n.
Saphenous n.
Sural n.
Calcanean branches
of tibial & sural n’s.
Med.
plantar n.
Lat. 
  plantar n.
Superficial
peroneal
n.
Inf. med. n. of thigh
Post cut. n. of thigh
Lower
Lat. cut. of arm
(from radial n.)
Post cut. n. of arm
(from radial n.)
Axillary n.
(circumflex)
Iliohypo-
gastric n.
Saphenous n.
(from femoral n.)
Med. cut. n. of thigh
(from femoral n.)
Calcanean branches of
sural & tibial n’s.
Sural n. (from tibial n.)
Radial n.
Median n.
Ulnar n.
FIGURE 191-1 (Continued)
THE NEUROLOGIC METHOD AND LOCALIZATION
The clinical data obtained from the neurologic examination coupled with a 
careful history are interpreted to arrive at an anatomic localization that best 
explains the clinical findings (Table 191-3) and to select the diagnostic tests 
most likely to be informative in order to define the pathophysiology of the 
anatomic lesion.
CHAPTER 191 1195
The Neurologic Examination
T2
T2
T2
T1
T1
C3
C3
C4
C4
C5
C5
C5
C6
C6
C8
C6
C7
C8
T3
T3
T4
T4
T5
T5
T6
T6
T7
T7
T8
T8
T9
T9
T10
T10
T11
T11
T12
T12
L1
L2
L3
L3
L4
L4
L5
L5
L5
L1
L3
S1
S2
S2
S1
S1
S3
S4
S5
L2
FIGURE 191-2 Distribution of the sensory spinal roots on the surface of the body 
(dermatomes). (From D Sinclair: Mechanisms of Cutaneous Sensation. Oxford, UK, 
Oxford University Press, 1981; with permission from Dr. David Sinclair.)
SECTION 14
1196
Neurology
For a more detailed discussion, see Lowenstein DH, Martin JB, 
Hauser SL: Approach to the Patient With Neurologic Disease, 
Chap. 367, p. 3233, in HPIM-18 
TABLE 191-3  FINDINGS HELPFUL FOR LOCALIZATION WITHIN THE 
NERVOUS SYSTEM
Signs
Cerebrum
Abnormal mental status or cognitive impairment
Seizures
Unilateral weaknessa and sensory abnormalities including 
head and limbs
Visual field abnormalities
Movement abnormalities (e.g., diffuse incoordination, 
tremor, chorea)
Brainstem
Isolated cranial nerve abnormalities (single or multiple)
“Crossed” weaknessa and sensory abnormalities of head 
and limbs (e.g., weakness of right face and left arm and leg)
Spinal cord
Back pain or tenderness
Weaknessa and sensory abnormalities sparing the head
Mixed upper and lower motor neuron findings
Sensory level
Sphincter dysfunction
Spinal roots
Radiating limb pain
Weaknessb or sensory abnormalities following root distri-
bution (Figs. 191-1 and 191-2)
Loss of reflexes
Peripheral nerve Mid or distal limb pain
Weaknessb or sensory abnormalities following nerve 
distribution (Figs. 191-1 and 191-2 )
“Stocking or glove” distribution of sensory loss
Loss of reflexes
Neuromuscular
junction
Bilateral weakness including face (ptosis, diplopia, 
dysphagia) and proximal limbs
Increasing weakness with exertion
Sparing of sensation
Muscle
Bilateral proximal or distal weakness
Sparing of sensation
aWeakness along with other abnormalities having an “upper motor neuron” pattern, i.e., 
spasticity, weakness of extensors > flexors in the upper extremity and flexors > extensors in 
the lower extremity, hyperreflexia.
bWeakness along with other abnormalities having a “lower motor neuron” pattern, i.e., 
flaccidity and hyporeflexia.
CHAPTER 192 1197
Neuroimaging
CHAPTER 192
Neuroimaging
The clinician caring for pts with neurologic symptoms is faced with an 
expanding number of imaging options. MRI is more sensitive than CT for 
detection of many lesions affecting the nervous system, particularly those 
of the spinal cord, cranial nerves, and posterior fossa  structures. Diffusion 
MR, a sequence that detects reduction of microscopic motion of water, 
is the most sensitive technique for detecting acute ischemic stroke and 
is useful in the detection of encephalitis, abscesses, and prion diseases. 
CT, however, can be quickly obtained and is widely available, making it a 
pragmatic choice for initial evaluation of pts with suspected acute stroke 
(especially when coupled with CT angiography and perfusion CT), hemor-
rhage, and intracranial or spinal trauma. CT is also more sensitive than MRI 
for visualizing fine osseous detail and is indicated in the initial evaluation 
of conductive hearing loss as well as lesions affecting the skull base and 
calvarium. MRI and CT-myelography have replaced conventional myelog-
raphy for evaluation of disease of the spinal cord and canal. An increasing 
number of interventional neuroradiologic techniques are available includ-
ing embolization, coiling, and stenting of vascular structures as well as spine 
interventions such as discography, selective nerve root injection, and epi-
dural injection. Conventional angiography is now reserved for pts in whom 
small-vessel detail is essential for diagnosis or for whom interventional 
therapies are planned. Guidelines for initial selection of neuroimaging stud-
ies are shown in Table 192-1.
TABLE 192-1 GUIDELINES FOR THE USE OF CT, ULTRASOUND, AND MRI
Condition
Recommended Technique
Hemorrhage
 Acute parenchymal
CT, MR
 Subacute/chronic
MRI
 Subarachnoid hemorrhage 
CT, CTA, lumbar puncture →
angiography
Aneurysm
Angiography > CTA, MRA 
Ischemic infarction 
 Hemorrhagic infarction 
CT or MRI
 Bland infarction
MRI > CT, CTA, angiography
 Carotid or vertebral dissection
MRI/MRA 
 Vertebral basilar insufficiency
CTA, MRI/MRA
 Carotid stenosis
CTA > Doppler ultrasound, MRA
(continued)
SECTION 14
1198
Neurology
For a more detailed discussion, see Dillon WP: Neuroimaging in 
Neurologic Disorders, Chap. 368, p. 3240, in HPIM-18.
TABLE 192-1  GUIDELINES FOR THE USE OF CT, ULTRASOUND, AND MRI 
(CONTINUED)
Condition
Recommended Technique
Suspected mass lesion
 Neoplasm, primary or metastatic
MRI + contrast
 Infection/abscess
MRI + contrast
  Immunosuppressed with focal findings
MRI + contrast
Vascular malformation
MRI ± angiography
White matter disorders
MRI
 Demyelinating disease
MRI ± contrast
Dementia
MRI > CT
Trauma
 Acute trauma
CT (noncontrast)
  Shear injury/chronic hemorrhage
MRI + gradient echo imaging
Headache/migraine
CT (noncontrast)/MRI
Seizure
 First time, no focal neurologic deficits
?CT as screen ± contrast
 Partial complex/refractory 
MRI with coronal T2W imaging
Cranial neuropathy
MRI with contrast
Meningeal disease
MRI with contrast
Spine
Low back pain
 No neurologic deficits
MRI or CT after 4 weeks
 With focal deficits
MRI > CT
Spinal stenosis 
MRI or CT
Cervical spondylosis
MRI or CT myelography
Infection
MRI + contrast, CT
Myelopathy
MRI + contrast 
Arteriovenous malformation
MRI, angiography
Abbreviations: CT, computed tomography; CTA, CT angiography; MRA, MR angiography; MRI, 
magnetic resonance imaging; T2W, T2-weighted.
CHAPTER 193 1199
Seizures and Epilepsy
CHAPTER 193
Seizures and Epilepsy
A seizure is a paroxysmal event due to abnormal excessive or synchronous 
neuronal activity in the brain. Epilepsy is diagnosed when there are recur-
rent seizures due to a chronic, underlying process.
Seizure
APPROACH TO THE
PATIENT
Seizure classification: This is essential for diagnosis, therapy, and prog-
nosis (Table 193-1). Seizures are focal or generalized: focal seizures 
originate in networks limited to one cerebral hemisphere, and general-
ized seizures involve networks distributed across both hemispheres. 
Focal seizures can be described as with or without dyscognitive features 
depending on the presence of cognitive impairment.
Generalized seizures may occur as a primary disorder or result from 
secondary generalization of a focal seizure. Tonic-clonic seizures (grand 
mal) cause sudden loss of consciousness, loss of postural control, and 
tonic muscular contraction producing teeth-clenching and rigidity in 
extension (tonic phase), followed by rhythmic muscular jerking (clonic 
phase). Tongue-biting and incontinence may occur during the seizure. 
Recovery of consciousness is typically gradual over many minutes to 
hours. Headache and confusion are common postictal phenomena. In 
absence seizures (petit mal) there is sudden, brief impairment of con-
sciousness without loss of postural control. Events rarely last longer than 
5–10 s but can recur many times per day. Minor motor symptoms are 
common, while complex automatisms and clonic activity are not. Other 
types of generalized seizures include tonic, atonic, and myoclonic seizures.
Etiology: Seizure type and age of pt provide important clues to etiology 
(Table 193-2).
� CLINICAL EVALUATION
Careful history is essential since diagnosis of seizures and epilepsy is often 
based solely on clinical grounds. Differential diagnosis (Table 193-3) 
includes syncope or psychogenic seizures (“pseudoseizures”). General exam 
includes search for infection, trauma, toxins, systemic illness, neurocuta-
neous abnormalities, and vascular disease. A number of drugs lower the 
seizure threshold (Table 193-4). Asymmetries in neurologic exam suggest 
brain tumor, stroke, trauma, or other focal lesions. An algorithmic approach 
is shown in Fig. 193-1. 
� LABORATORY EVALUATION
Routine blood studies are indicated to identify the more common metabolic 
causes of seizures such as abnormalities in electrolytes, glucose, calcium, or 
magnesium, and hepatic or renal disease. A screen for toxins in blood and 
SECTION 14
1200
Neurology
urine should be obtained especially when no clear precipitating factor has 
been identified. A lumbar puncture is indicated if there is any suspicion of 
CNS infection such as meningitis or encephalitis; it is mandatory in HIV-
infected pts even in the absence of symptoms or signs suggesting infection.
Electroencephalography (EEG) 
All pts should be evaluated as soon as possible with an EEG, which measures 
electrical activity of the brain by recording from electrodes placed on the 
scalp. The presence of electrographic seizure activity during the clinically 
evident event, i.e., abnormal, repetitive, rhythmic activity having an abrupt 
onset and termination, clearly establishes the diagnosis. The absence of elec-
trographic seizure activity does not exclude a seizure disorder, however. The 
EEG is always abnormal during generalized tonic-clonic seizures. Continuous 
monitoring for prolonged periods may be required to capture the EEG abnor-
malities. The EEG can show abnormal discharges during the interictal period 
that support the diagnosis of epilepsy and is useful for classifying seizure 
disorders, selecting anticonvulsant medications, and determining prognosis.
Brain Imaging 
All pts with unexplained new-onset seizures should have a brain imaging 
study (MRI or CT) to search for an underlying structural abnormality; the 
only exception may be children who have an unambiguous history and 
examination suggestive of a benign, generalized seizure disorder such as 
absence epilepsy. Newer MRI methods have increased the sensitivity for 
detection of abnormalities of cortical architecture, including hippocampal 
atrophy associated with mesial temporal sclerosis, and abnormalities of 
cortical neuronal migration.
TABLE 193-1 CLASSIFICATION OF SEIZURES
1. Focal seizures
(Can be further described as having motor, sensory, autonomic, cognitive, or 
other features)
2. Generalized seizures
   a. Absence
 
Typical
 
Atypical
   b. Tonic clonic
   c. Clonic
   d. Tonic
   e. Atonic
    f. Myoclonic
3. May be focal, generalized, or unclear
 
Epileptic spasms
CHAPTER 193 1201
Seizures and Epilepsy
TABLE 193-2 CAUSES OF SEIZURES
Neonates (<1 month)
Perinatal hypoxia and ischemia
Intracranial hemorrhage and trauma
Acute CNS infection
Metabolic disturbances (hypoglycemia, hypocal-
cemia, hypomagnesemia, pyridoxine deficiency)
Drug withdrawal
Developmental disorders
Genetic disorders
Infants and children 
(>1 month and <12 years)
Febrile seizures
Genetic disorders (metabolic, degenerative, 
primary epilepsy syndromes)
CNS infection
Developmental disorders
Trauma
Idiopathic
Adolescents (12–18 years)
Trauma
Genetic disorders
Infection
Brain tumor
Illicit drug use
Idiopathic
Young adults (18–35 years) Trauma
Alcohol withdrawal
Illicit drug use
Brain tumor
Idiopathic
Older adults (>35 years)
Cerebrovascular disease
Brain tumor
Alcohol withdrawal
Metabolic disorders (uremia, hepatic failure, 
electrolyte abnormalities, hypoglycemia, hyper-
glycemia)
Alzheimer’s disease and other degenerative CNS 
diseases
Idiopathic
Abbreviation: CNS, central nervous system.
SECTION 14
1202
Neurology
Seizures and Epilepsy
TREATMENT
• Acute management of seizures
– Pt should be placed in semiprone position with head to the side to 
avoid aspiration. 
– Tongue blades or other objects should not be forced between 
clenched teeth. 
– Oxygen should be given via face mask. 
– Reversible metabolic disorders (e.g., hypoglycemia, hyponatremia, 
hypocalcemia, drug or alcohol withdrawal) should be promptly 
corrected. 
– Treatment of status epilepticus is discussed in Chap. 23.
• Longer-term therapy includes treatment of underlying conditions, 
avoidance of precipitating factors, prophylactic therapy with anti-
epileptic medications or surgery, and addressing various psychological 
and social issues. 
• Choice of antiepileptic drug therapy depends on a variety of factors 
including seizure type, dosing schedule, and potential side effects 
(Tables 193-5  and 193-6).
TABLE 193-3 DIFFERENTIAL DIAGNOSIS OF SEIZURES
Syncope
 Vasovagal syncope
 Cardiac arrhythmia
 Valvular heart disease
 Cardiac failure
 Orthostatic hypotension
Psychological disorders
 Psychogenic seizure
 Hyperventilation
 Panic attack
Metabolic disturbances
 Alcoholic blackouts
 Delirium tremens
 Hypoglycemia
 Hypoxia
  Psychoactive drugs 
(e.g., hallucinogens)
Migraine
 Confusional migraine
 Basilar migraine
Transient ischemic attack (TIA)
 Basilar artery TIA
Sleep disorders
 Narcolepsy/cataplexy
 Benign sleep myoclonus
Movement disorders
 Tics
 Nonepileptic myoclonus
 Paroxysmal choreoathetosis
Special considerations in children
 Breath-holding spells
  Migraine with recurrent abdominal 
pain and cyclic vomiting
 Benign paroxysmal vertigo
 Apnea
 Night terrors
 Sleepwalking
CHAPTER 193 1203
Seizures and Epilepsy
• Therapeutic goal is complete cessation of seizures without side effects 
using a single drug (monotherapy) and a dosing schedule that is easy 
for the pt to follow. 
– If ineffective, medication should be increased to maximal tolerated 
dose based primarily on clinical response rather than serum levels. 
– If still unsuccessful, a second drug should be added, and when 
control is obtained, the first drug can be slowly tapered. Some pts 
will require polytherapy with two or more drugs, although mono-
therapy should be the goal.
– Pts with certain epilepsy syndromes (e.g., temporal lobe epilepsy) 
are often refractory to medical therapy and benefit from surgical 
excision of the seizure focus.
TABLE 193-4  DRUGS AND OTHER SUBSTANCES THAT CAN CAUSE 
SEIZURES
Alkylating agents 
(e.g., busulfan, chlorambucil)
Psychotropics
 Antidepressants
Antimalarials (chloroquine, mefloquine)
Antimicrobials/antivirals
  β-Lactam and related compounds
 Quinolones
 Acyclovir
 Isoniazid
 Ganciclovir
Anesthetics and analgesics
 Meperidine
 Tramadol
 Local anesthetics
Dietary supplements
 Ephedra (ma huang)
 Gingko
Immunomodulatory drugs
 Cyclosporine
 Muromonab-(CD3)
 Tacrolimus
 Interferons
 Antipsychotics
 Lithium
Radiographic contrast agents
 Theophylline
Sedative-hypnotic drug withdrawal
 Alcohol
 Barbiturates (short-acting)
 Benzodiazepines (short-acting)
Drugs of abuse
 Amphetamine
 Cocaine
 Phencyclidine
 Methylphenidate
 Flumazenila
aIn benzodiazepine-dependent pts.
SECTION 14
1204
Neurology
Normal
Adult Patient with a Seizure
History of epilepsy; currently treated
  with antiepileptics
Assess: adequacy of antiepileptic therapy
  Side effects
  Serum levels
No history of epilepsy
Laboratory studies
  CBC
  Electrolytes, calcium, magnesium
  Serum glucose
  Liver and renal function tests
  Urinalysis
  Toxicology screen
Negative
metabolic screen
Positive metabolic screen
or symptoms/signs
suggesting a metabolic
or infectious disorder
Abnormal or change in
neurologic exam
  Treat identifiable
  metabolic abnormalities
Assess cause of
  neurologic change
  Lumbar puncture
  Cultures
  Endocrine studies
  CT
  MRI if focal
   features present
MRI scan
  and EEG
Subtherapeutic
antiepileptic
levels
Appropriate
increase or
resumption
of dose
Increase antiepileptic
therapy to maximum
tolerated dose;
consider alternative
antiepileptic drugs
Therapeutic
antiepileptic
levels
Focal features of 
seizures
Focal abnormalities
on clinical or lab
examination
Other evidence of
neurologic
dysfunction
Treat underlying
metabolic abnormality
Idiopathic seizures
Treat underlying disorder
Yes
No
Consider: Mass lesion; stroke; CNS infection;
  trauma; degenerative disease
Consider: Antiepileptic therapy
Further workup
Other causes of episodic cerebral dysfunction
Syncope
Transient ischemic attack
Migraine
Acute psychosis
History
Physical examination
Exclude
Consider: Antiepileptic therapy
Consider: Antiepileptic therapy
ALGORITHM FOR THE ADULT PATIENT WITH A SEIZURE
Consider
 CBC
 Electrolytes, calcium, magnesium
 Serum glucose
 Liver and renal function tests
 Urinalysis
 Toxicology screen
FIGURE 193-1 Evaluation of the adult pt with a seizure. CBC, complete blood count; 
CNS, central nervous system; CT, computed tomography; EEG, electroencephalo-
gram; MRI, magnetic resonance imaging.
TABLE 193-5 DOSAGE AND ADVERSE EFFECTS OF COMMONLY USED ANTIEPILEPTIC DRUGS
Adverse Effects
Generic Name
Trade 
Name
Principal
Uses
Typical Dose; 
Dose Interval
Half-Life
Therapeutic 
Range
Neurologic
Systemic
Drug Interactions
Phenytoin 
(diphenylhy-
dantoin)
Dilantin
Tonic-clonic
300–400 mg/d 
(3–6 mg/kg, 
adult; 4–8 mg/
kg, child); qd-bid
24 h (wide 
variation, 
dose-
dependent)
10–20 μg/mL
Dizziness
Gum hyperplasia
Level increased by 
isoniazid, sulfonamides, 
fluoxetine
Focal-onset
Diplopia
Lymphadenopathy
Ataxia
Hirsutism
Level decreased by 
enzyme-inducing
drugsa
Incoordination
Osteomalacia
Confusion
Facial coarsening
Altered folate 
metabolism
Skin rash
Carbamazepine Tegretolb
Tonic-clonic
600–1800 mg/d 
(15–35 mg/kg, 
child); bid-qid
10–17 h
6–12 μg/mL
Ataxia
Aplastic anemia
Level decreased by 
enzyme-inducing
drugsa
Carbatrol
Focal-onset
Dizziness
Leukopenia
Diplopia
Gastrointestinal 
irritation
Level increased by 
erythromycin, pro-
poxyphene, isoniazid, 
cimetidine, fluoxetine
Vertigo
Hepatotoxicity
Hyponatremia
(continued)
1205
TABLE 193-5 DOSAGE AND ADVERSE EFFECTS OF COMMONLY USED ANTIEPILEPTIC DRUGS (CONTINUED)
Adverse Effects
Generic Name
Trade 
Name
Principal
Uses
Typical Dose; 
Dose Interval
Half-Life
Therapeutic 
Range
Neurologic
Systemic
Drug Interactions
Valproic acid 
Depakene
Tonic-clonic
750–2000 mg/d 
(20–60 mg/kg); 
bid-qid
15 h
50–125 μg/mL Ataxia
Hepatotoxicity
Level decreased by 
enzyme-inducing
drugsa
Depakoteb
Absence
Sedation
Thrombocytopenia
Atypical
absence
Tremor
Gastrointestinal 
irritation
Myoclonic
Weight gain
Focal-onset
Transient alopecia
Atonic
Hyperammonemia
Lamotrigine
Lamictalb
Focal-onset
150–500 mg/d; 
bid
25 h
Not established Dizziness
Skin rash
Level decreased by 
enzyme-inducing
drugsa and oral 
contraceptives
Tonic-clonic
14 h (with 
enzyme-
inducers) 59 h 
(with valproic 
acid)
Diplopia
Stevens-Johnson 
syndrome
Atypical
absence
Sedation
Myoclonic
Ataxia
Level increased by 
valproic acid
Lennox-
Gastaut
syndrome
Headache
1206
Ethosuximide 
Zarontin
Absence
750–1250 mg/d 
(20-40 mg/kg); 
qd-bid
60 h, adult
40–100 μg/mL
Ataxia
Gastrointestinal 
irritation
Level decreased by 
enzyme-inducing
drugsa
30 h, child
Lethargy
Skin rash
Headache
Bone marrow 
suppression
Level increased by 
valproic acid
Gabapentin 
Neurontin 
Focal-onset
900–2400 mg/d; 
tid-qid
5–9 h
Not established Sedation
Gastrointestinal 
irritation
No known significant 
interactions
Dizziness
Weight gain
Ataxia
Edema
Fatigue
Topiramate 
Topamax
Focal-onset
200–400 mg/d; 
bid
20–30 h
Not established Psychomotor 
slowing
Renal stones 
(avoid use with 
other carbonic 
anhydrase
inhibitors)
Level decreased by 
enzyme-inducing
drugsa
Tonic-clonic
Sedation
Lennox-
Gastaut
syndrome
Speech or 
language 
problems
Glaucoma
Fatigue
Weight loss
Paresthesias
Hypohidrosis
(continued)
1207
TABLE 193-5 DOSAGE AND ADVERSE EFFECTS OF COMMONLY USED ANTIEPILEPTIC DRUGS (CONTINUED)
Adverse Effects
Generic Name
Trade 
Name
Principal
Uses
Typical Dose; 
Dose Interval
Half-Life
Therapeutic 
Range
Neurologic
Systemic
Drug Interactions
Tiagabine 
Gabitril
Focal-onset
32–56 mg/d; 
bid-qid
7–9 h
Not established Confusion
Gastrointestinal 
irritation
Level decreased by 
enzyme-inducing drugsa
Sedation
Depression
Dizziness
Speech or 
language 
problems
Paresthesias
Psychosis
Phenobarbital 
Luminal
Tonic-clonic
60–180 mg/d; 
qd
90 h 
10–40 μg/mL
Sedation
Skin rash
Level increased by 
valproic acid, phenytoin 
Focal-onset
Ataxia
Confusion
Dizziness
Decreased
libido
Depression
1208
Primidone 
Mysoline 
Tonic-clonic
750–1000 mg/d; 
bid-tid
Primidone, 
8–15 h
Primidone, 
4–12 μg/mL
Same as 
phenobarbital
Level increased by 
valproic acid, phenytoin
Focal-onset
Phenobarbital, 
90 h
Phenobarbital, 
10–40 μg/mL
Clonazepam
Klonopin
Absence
1–12 mg/d; 
qd-tid
24–48 h
10–70 ng/mL
Ataxia
Anorexia
Level decreased by 
enzyme-inducing
drugsa
Atypical
absence
Sedation
Myoclonic
Lethargy
Felbamate
Felbatol
Focal-onset
2400–3600 
mg/d, tid-qid
16–22 h
Not established Insomnia
Aplastic anemia
Increases phenytoin, 
valproic acid, active 
carbamazepine
metabolite
Lennox-
Gastaut
syndrome
Dizziness
Hepatic failure
Sedation
Weight loss
Tonic-clonic
Headache
Gastrointestinal 
irritation
Levetiracetam
Kepprab
Focal-onset
1000–3000 
mg/d; qd-bid
6–8 h
Not established Sedation
Anemia
No known significant 
interactions
Fatigue
Leukopenia
Incoordination
Mood
changes
(continued)
1209
TABLE 193-5 DOSAGE AND ADVERSE EFFECTS OF COMMONLY USED ANTIEPILEPTIC DRUGS (CONTINUED)
Adverse Effects
Generic Name
Trade 
Name
Principal
Uses
Typical Dose; 
Dose Interval
Half-Life
Therapeutic 
Range
Neurologic
Systemic
Drug Interactions
Zonisamide 
Zonegran
Focal-onset
200–400 mg/d; 
qd-bid
50–68 h
Not established Sedation
Anorexia
Level decreased by 
enzyme-inducing
drugsa
Tonic-clonic
Dizziness
Renal stones
Confusion
Hypohidrosis
Headache
Psychosis
Oxcarbazepine
Trileptal
Focal-onset
900–2400 mg/d 
(30–45 mg/kg, 
child); bid
10–17 h 
(for active 
metabolite)
Not established Fatigue
See carba-
mazepine
Level decreased by 
enzyme-inducing
drugsa
Tonic-clonic
Ataxia
Dizziness
May increase phenytoin
Diplopia
Vertigo
Headache
1210
Lacosamide
Vimpat
Focal-onset
200–400 mg/d; 
bid
13 h
Not established Dizziness
GI irritation
Level decreased by 
enzyme-inducing drugsa
Ataxia
Cardiac conduc-
tion (PR interval 
prolongation)
Diplopia
Vertigo
Rufinamide
Banzel
Lennox-
Gastaut
syndrome
3200 mg/d 
(45 mg/kg, child); 
bid
6–10 h
Not established Sedation
GI irritation
Level decreased by 
enzyme-inducing drugsa
Fatigue
Leukopenia
Dizziness
Cardiac conduction 
(QT interval pro-
longation)
Level increased by 
valproic acid
Ataxia
May increase phenytoin
Headache
Diplopia
aPhenytoin, carbamazepine, phenobarbital.
bExtended-release product available.
1211
SECTION 14
1212
Neurology
For a more detailed discussion, see Lowenstein DH: Seizures 
and Epilepsy, Chap. 369, p. 3251, in HPIM-18.
CHAPTER 194
Dementia
Dementia
Dementia is an acquired deterioration in cognitive ability that impairs 
the successful performance of activities of daily living. Memory is the 
most common cognitive ability lost with dementia; 10% of persons over 
age 70 and 20–40% of individuals over age 85 have clinically identifiable 
memory loss. Other mental faculties are also affected in dementia, such as 
language, visuospatial ability, calculation, judgment, and problem solving. 
Neuropsychiatric and social deficits develop in many dementia syndromes, 
resulting in depression, withdrawal, hallucinations, delusions, agitation, 
insomnia, and disinhibition. Dementia is usually chronic and progressive.
TABLE 193-6 SELECTION OF ANTIEPILEPTIC DRUGS
Generalized-onset 
Tonic-Clonic
Focal
Typical Absence
Atypical Absence, 
Myoclonic, Atonic
First-line
Valproic acid
Lamotrigine
Valproic acid
Valproic acid
Lamotrigine
Carbamazepine
Ethosuximide
Lamotrigine
Topiramate
Oxcarbazepine
Topiramate
Phenytoin
Levetiracetam
Alternatives
Zonisamidea
Topiramate
Lamotrigine
Clonazepam
Phenytoin
Zonisamidea
Clonazepam
Felbamate
Carbamazepine
Valproic acid
Oxcarbazepine
Tiagabinea
Phenobarbital
Gabapentina
Primidone
Lacosamidea
Felbamate
Phenobarbital
Primidone
Felbamate
aAs adjunctive therapy.
CHAPTER 194 1213
Dementia
Diagnosis
The mini-mental status examination (MMSE) is a useful screening test for 
dementia (Table 191-1). A score of <24 points (out of 30) indicates a need 
for more detailed cognitive and physical assessment. In some pts with early 
cognitive disorders, the MMSE may be normal and more detailed neuro-
psychological testing will be required.
Dementia
APPROACH TO THE
PATIENT
Differential Diagnosis: Dementia has many causes (Table 194-1). It is 
essential to exclude treatable etiologies; the most common potentially 
reversible diagnoses are depression, hydrocephalus, and alcohol depen-
dence. The major degenerative dementias can usually be distinguished 
by distinctive symptoms, signs, and neuroimaging features (Table 194-2).
History: A subacute onset of confusion may represent delirium and should 
trigger the search for intoxication, infection, or metabolic derangement 
(Chap. 17). An elderly person with slowly progressive memory loss over 
several years is likely to have Alzheimer’s disease (AD). A change in person-
ality, disinhibition, gain of weight, or compulsive eating suggests frontotem-
poral dementia (FTD), not AD; apathy, loss of executive function, progres-
sive abnormalities in speech, or relative sparing of memory or visuospatial 
abilities also suggests FTD. Dementia with Lewy bodies (DLB) is suggested 
by the early presence of visual hallucinations, parkinsonism, tendency to 
delirium, sensitivity to psychoactive medications, or an REM behavior dis-
order (RBD, the loss of skeletal muscle paralysis during dreaming).
A history of stroke suggests vascular dementia, which may also 
occur with hypertension, atrial fibrillation, peripheral vascular disease, 
and diabetes. Rapid progression of dementia with myoclonus sug-
gests a prion disease such as Creutzfeldt-Jakob disease (CJD). Gait 
disturbance is prominent with vascular dementia, Parkinson’s disease, 
DLB, or normal-pressure hydrocephalus. Multiple sex partners or 
IV drug use should trigger search for an infection, especially HIV or 
syphilis. A history of head trauma could indicate chronic subdural 
hematoma, dementia pugilistica, or normal-pressure hydrocephalus. 
Alcoholism may suggest malnutrition and thiamine deficiency. A 
history of gastric surgery may result in loss of intrinsic factor and 
vitamin B12 deficiency. A careful review of medications, especially of 
sedatives and tranquilizers, may raise the issue of drug intoxication. 
A family history of dementia is found in Huntington’s disease and 
in familial forms of AD, FTD, DLB, or prion disorders. Insomnia or 
weight loss is often seen with depression-related cognitive impair-
ments, which can also be caused by the recent death of a loved one.
Examination: It is essential to document the dementia, look for other 
signs of nervous system involvement, and search for clues of a systemic 
disease that might be responsible for the cognitive disorder. AD does 
not affect motor systems until late in the course. In contrast, FTD 
pts often develop axial rigidity, supranuclear gaze palsy, or features of
SECTION 14
1214
Neurology
TABLE 194-1 DIFFERENTIAL DIAGNOSIS OF DEMENTIA
Most Common Causes of Dementia
Alzheimer’s disease
Alcoholisma
Vascular dementia
Parkinson’s disease
 Multi-infarct
Drug/medication intoxicationa
  Diffuse white matter dis-
ease  (Binswanger’s)
Less Common Causes of Dementia
Vitamin deficiencies
Thiamine (B1): Wernicke’s 
encephalopathya
B12 (subacute combined 
degeneration)a
Nicotinic acid (pellagra)a
Endocrine and other organ failure
Hypothyroidisma
Adrenal insufficiency and 
Cushing’s syndromea
Hypo- and hyperparathyroidisma
Renal failurea
Liver failurea
Pulmonary failurea
Chronic infections
HIV
Neurosyphilisa
Papovavirus (JC virus) (progres-
sive multifocal leukoencepha-
lopathy)
Tuberculosis, fungal, and 
protozoala
Whipple’s diseasea
Head trauma and diffuse brain 
damage
Dementia pugilistica
Chronic subdural hematomaa
Postanoxia
Postencephalitis
Normal-pressure hydrocephalusa
Neoplastic
Primary brain tumora
Toxic disorders
Drug, medication, and narcotic 
poisoninga
Heavy metal intoxicationa
Dialysis dementia (aluminum)
Organic toxins
Psychiatric
Depression (pseudodementia)a
Schizophreniaa
Conversion reactiona
Degenerative disorders
Huntington’s disease
Dementia with Lewy bodies
Progressive supranuclear palsy
Multisystem atrophy
Hereditary ataxias (some forms)
Motor neuron disease [amyotrophic 
lateral sclerosis (ALS); some forms]
Frontotemporal dementia
Corticobasal degeneration
Multiple sclerosis
Adult Down syndrome with Alzheimer’s 
disease
ALS–Parkinson’s–dementia complex of 
Guam
Prion (Creutzfeldt-Jakob and Gerstmann-
Sträussler-Scheinker diseases)
Miscellaneous
Sarcoidosisa
Vasculitisa
CADASIL, etc.
Acute intermittent porphyriaa
CHAPTER 194 1215
Dementia
TABLE 194-1 DIFFERENTIAL DIAGNOSIS OF DEMENTIA (CONTINUED)
Less Common Causes of Dementia
Metastatic brain tumora
Paraneoplastic limbic 
encephalitis
Recurrent nonconvulsive seizuresa
Additional conditions in children or 
adolescents
Pantothenate kinase–associated 
neurodegeneration
Subacute sclerosing panencephalitis
Metabolic disorders (e.g., Wilson’s and 
Leigh’s diseases, leukodystrophies, lipid 
storage diseases, mitochondrial 
mutations)
aPotentially reversible dementia.
Abbreviation: CADASIL, Cerebral autosomal dominant arteriopathy with subcortical infarcts 
and leukoencephalopathy.
amyotrophic lateral sclerosis. In DLB, initial symptoms may be the new 
onset of a parkinsonian syndrome (resting tremor, cogwheel rigidity, 
bradykinesia, and festinating gait). Unexplained falls, axial rigidity, dys-
phagia, and gaze deficits suggest progressive supranuclear palsy (PSP).
Focal neurologic deficits may occur in vascular dementia or brain 
tumor. Dementia with a myelopathy and peripheral neuropathy suggests 
vitamin B12 deficiency. A peripheral neuropathy could also indicate an 
underlying vitamin deficiency or heavy metal intoxication. Dry cool 
skin, hair loss, and bradycardia suggest hypothyroidism. Confusion 
associated with repetitive stereotyped movements may indicate ongo-
ing seizure activity. Hearing impairment or visual loss may produce 
confusion and disorientation misinterpreted as dementia. Such sensory 
deficits are common in the elderly.
Choice of Diagnostic Studies: A reversible or treatable cause must not be 
missed, yet no single etiology is common; thus a screen must employ 
multiple tests, each of which has a low yield. Table 194-3 lists most 
screening tests for dementia. Guidelines recommend the routine mea-
surement of thyroid function, a vitamin B12 level, and a neuroimaging 
study (CT or MRI). Lumbar puncture need not be done routinely but 
is indicated if infection is a consideration; CSF levels of tau protein and 
amyloid β42 show differing patterns with the various dementias although 
their sensitivity and specificity are not yet sufficiently high to warrant 
routine use. An EEG is rarely helpful except to suggest a prion disease 
or an underlying nonconvulsive seizure disorder. The role of functional-
metabolic imaging in the diagnosis of dementia is still under study; amy-
loid imaging has recently shown promise for the diagnosis of AD. Brain 
biopsy is not advised except to diagnose vasculitis, potentially treatable 
neoplasms, unusual infections, or systemic disorders such as sarcoid.
TABLE 194-2 CLINICAL DIFFERENTIATION OF THE MAJOR DEMENTIAS
Disease
First Symptom
Mental Status
Neuropsychiatry
Neurology
Imaging
AD
Memory loss
Episodic memory loss
Initially normal
Initially normal
Entorhinal cortex and 
hippocampal atrophy
FTD
Apathy; poor judgment/
insight, speech/language; 
hyperorality
Frontal/executive, lan-
guage; spares drawing
Apathy, disinhibition, 
hyperorality, euphoria, 
depression
May have vertical gaze 
palsy, axial rigidity, 
dystonia, alien hand, 
or MND
Frontal, insular, and/or 
temporal atrophy; spares 
posterior parietal lobe
DLB
Visual hallucinations, REM 
sleep disorder, delirium, 
Capgras syndrome, 
parkinsonism
Drawing and frontal/
executive; spares 
memory; delirium prone
Visual hallucinations, 
depression, sleep 
disorder, delusions
Parkinsonism
Posterior parietal atro-
phy; hippocampi larger 
than in AD
CJD
Dementia, mood, anxiety, 
movement disorders
Variable, frontal/executive, 
focal cortical, memory
Depression, anxiety
Myoclonus, rigidity, 
parkinsonism
Cortical ribboning and 
basal ganglia or thala-
mus hyperintensity on 
diffusion/FLAIR MRI
Vascular 
Often but not always sud-
den; variable; apathy, falls, 
focal weakness 
Frontal/executive, cogni-
tive slowing; can spare 
memory
Apathy, delusions, 
anxiety
Usually motor slow-
ing, spasticity; can be 
normal
Cortical and/or subcorti-
cal infarctions, confluent 
white matter disease
Abbreviations: AD, Alzheimer’s disease; CBD, cortical basal degeneration; CJD, Creutzfeldt-Jakob disease; DLB, dementia with Lewy bodies; FTD, frontotemporal dementia; 
MND, motor neuron disease; PSP, progressive supranuclear palsy.
1216
CHAPTER 194 1217
Dementia
ALZHEIMER’S DISEASE
Most common cause of dementia; 10% of all persons over age 70 have signifi-
cant memory loss, and in more than half the cause is AD. Cost is >$50 billion/
year.
TABLE 194-3 EVALUATION OF THE PATIENT WITH DEMENTIA
Routine Evaluation
Optional Focused Tests
Occasionally Helpful Tests
History
Physical examination
Laboratory tests
  Thyroid function 
(TSH)
 Vitamin B12
  Complete blood 
count
 Electrolytes
 CT/MRI
Psychometric testing
Chest x-ray
Lumbar puncture
Liver function
Renal function
Urine toxin screen
HIV
Apolipoprotein E
RPR or VDRL
EEG
Parathyroid function
Adrenal function
Urine heavy metals
RBC sedimentation rate
Angiogram
Brain biopsy
SPECT
PET
Diagnostic Categories
Reversible causes
Irreversible/
degenerative dementias 
Psychiatric disorders
Examples
 Hypothyroidism 
Thiamine deficiency
Vitamin B12
deficiency 
Normal-pressure
hydrocephalus
Subdural hematoma
Chronic infection
Brain tumor
Drug intoxication
Examples
Alzheimer’s
Frontotemporal dementia
Huntington’s
Dementia with Lewy 
bodies
Vascular
Leukoencephalopathies
Parkinson’s
Depression
Schizophrenia
Conversion reaction
Associated Treatable Conditions
Depression
Seizures
Insomnia
Agitation
Caregiver “burnout”
Drug side effects
Abbreviations: PET, positron emission tomography; RPR, rapid plasma reagin (test); SPECT, 
single-photon emission CT; VDRL, Venereal Disease Research Laboratory (test for syphilis).
SECTION 14
1218
Neurology
Clinical Manifestations 
Cognitive changes follow a characteristic pattern beginning with memory 
impairment and spreading to language and visuospatial deficits. Memory 
loss is often not recognized initially, in part due to preservation of social 
graces until later phases; impaired activities of daily living (keeping track of 
finances, appointments) draw attention of friends/family. Once the memory 
loss becomes noticeable to the pt and spouse and falls 1.5 standard deviations 
below normal on standardized memory tests, the term mild cognitive impair-
ment (MCI) is applied; Roughly 12% per year will progress to AD over 4 years. 
Disorientation, poor judgment, poor concentration, aphasia, and apraxia 
are increasingly evident as the disease progresses. Pts may be frustrated or 
unaware of deficit. In end-stage AD, pts become rigid, mute, incontinent, and 
bedridden. Help may be needed with the simplest tasks, such as eating, dress-
ing, and toilet function. Often, death results from malnutrition, secondary 
infections, pulmonary emboli, heart disease, or, most commonly, aspiration. 
Typical duration is 8–10 years, but the course can range from 1 to 25 years.
Pathogenesis 
Risk factors for AD are old age, positive family history. Pathology: neuritic 
plaques composed in part of Aβ amyloid, derived from amyloid precursor pro-
tein (APP); neurofibrillary tangles composed of abnormally phosphorylated 
tau protein. The apolipoprotein E (apo E) ε4 allele accelerates age of onset of 
AD and is associated with sporadic and late-onset familial cases. Apo E testing 
is not indicated as a predictive test. Rare genetic causes of AD are Down syn-
drome and mutations in APP, presenilin I, and presenilin II genes; all appear 
to increase production of Aβ amyloid. Genetic testing available for presenilin 
mutations; likely to be revealing only in early-age-of-onset familial AD.
Alzheimer’s Disease
TREATMENT
• AD cannot be cured, and no highly effective drug exists. The focus 
is on judicious use of cholinesterase inhibitor drugs; symptomatic 
management of behavioral problems; and building rapport with the 
pt, family members, and other caregivers.
• Donepezil, rivastigmine, galantamine, tacrine (tetrahydroaminoacri-
dine), and memantine are approved by the FDA for treatment of AD. 
Due to hepatotoxicity, tacrine is no longer used. With the exception of 
memantine, their action is inhibition of cholinesterase, with a result-
ing increase in cerebral levels of acetylcholine. Memantine appears to 
act by blocking overexcited N-methyl-D-aspartate (NMDA) channels. 
– These compounds are only modestly efficacious and offer little or no 
benefit in the late stages of AD; they are associated with improved 
caregiver ratings of pts ’ functioning and with an apparent decreased 
rate of decline in cognitive test scores over periods of up to 3 years. 
– Donepezil (Aricept), 5–10 mg/d PO, has the advantages of few side 
effects and single daily dosage. 
– Dosing of memantine begins at 5 mg/d with gradual increases (over 
1 month) to 10 mg twice a day.
CHAPTER 194 1219
Dementia
• There is no role for hormone replacement therapy in prevention of 
AD in women, and no benefit has been found in the treatment of 
established AD with estrogen. 
• Randomized trials of Ginkgo biloba have found it to be ineffective. 
Prospective studies are examining the role of NSAIDs and statin medi-
cations as well as lowering of serum homocysteine in order to slow the 
progression to dementia. 
• Other experimental approaches target amyloid either through dimin-
ishing its production or promoting clearance by passive immunization 
with monoclonal antibodies.
• Depression, common in early stages of AD, may respond to antide-
pressants or cholinesterase inhibitors. Selective serotonin reuptake 
inhibitors (SSRIs) are often used due to their low anticholinergic side 
effects. Management of behavioral problems in conjunction with fam-
ily and caregivers is essential. Mild sedation may help insomnia. 
• Control of agitation usually involves low doses of atypical antipsy-
chotic medications, but recent trials have questioned the efficacy of 
this approach; in addition, all of the antipsychotics carry a black box 
warning in the elderly, increasing the risk of cardiovascular complica-
tions and death, and therefore should be used with caution. 
• Notebooks and posted daily reminders can function as memory aids 
in early stages. Kitchens, bathrooms, and bedrooms need evalua-
tion for safety. Pts must eventually stop driving. Caregiver burnout 
is common; nursing home placement may be necessary. Local and 
national support groups (Alzheimer’s Disease and Related Disorders 
Association) are valuable resources.
OTHER CAUSES OF DEMENTIA
Vascular Dementia 
Typically follows a pattern of either multiple strokelike episodes (multi-
infarct dementia) or diffuse white matter disease (leukoaraiosis, subcortical 
arteriosclerotic encephalopathy, Binswanger’s disease) (Fig. 194-1). Unlike 
AD, focal neurologic signs (e.g., hemiparesis) may be apparent at presenta-
tion. Treatment focuses on underlying causes of atherosclerosis.
Frontotemporal Dementia 
Often begins in the fifth to seventh decades; in this age group it is nearly 
as prevalent as AD. Unlike in AD, behavioral symptoms predominate in 
the early stages of FTD. Extremely heterogeneous; presents with combina-
tions of disinhibition, dementia, apraxia, parkinsonism, and motor neuron 
disease. May be sporadic or inherited; some familial cases due to mutations 
of tau or progranulin genes. Treatment is symptomatic; no therapies known 
to slow progression or improve cognitive symptoms. Many of the behaviors 
that accompany FTD such as depression, hyperorality, compulsions, and 
irritability may be helped with SSRIs.
SECTION 14
1220
Neurology
FIGURE 194-1 Diffuse white matter disease (Binswanger’s disease). Axial T2-
weighted MR image through the lateral ventricles reveals multiple areas of abnormal 
high signal intensity involving the periventricular white matter as well as the corona 
radiata and lentiform nuclei (arrows). While seen in some individuals with normal cog-
nition, this appearance is more pronounced in pts with dementia of a vascular etiology.
Dementia with Lewy Bodies 
Characterized by visual hallucinations, parkinsonism, fluctuating alertness, 
and falls. Dementia can precede or follow the appearance of parkinsonism; 
when it occurs after an established diagnosis of Parkinson’s disease, many 
use the term Parkinson’s disease dementia (PDD). Lewy bodies are intra-
neuronal cytoplasmic inclusions. Anticholinesterase compounds often pro-
vide significant benefit due to a severe cholinergic deficit in DLB. Exercise 
programs to maximize motor function, antidepressants to treat depressive 
syndromes, and possibly antipsychotics in low doses to alleviate psychosis 
may also be helpful.
Normal-Pressure Hydrocephalus (NPH) 
Uncommon; presents as a gait disorder (ataxic or apractic), dementia, and 
urinary incontinence. Gait improves in some pts following ventricular 
shunting; dementia and incontinence do not improve. The diagnosis is 
CHAPTER 195 1221
Parkinson’s Disease
difficult to make, and the clinical picture may overlap with several other 
causes of dementia including AD; historically many individuals treated for 
NPH have suffered from other dementias.
Huntington’s Disease 
Chorea, behavioral disturbance, and a frontal/executive disorder (Chap. 59). 
Typical onset fourth to fifth decade but can present at almost any age. 
Autosomal dominant inheritance due to expanded trinucleotide repeat in 
gene encoding the protein huntingtin. Diagnosis confirmed with genetic 
testing coupled with genetic counseling. Symptomatic treatment of move-
ments and behaviors; SSRIs may help depression.
Creutzfeldt-Jakob Disease (CJD) 
Prion disorders such as CJD are rare (~1 per million). CJD is a rapidly 
progressive disorder with dementia, focal cortical signs, rigidity, and 
myoclonus; death in <1 year from first symptom. The markedly abnormal 
periodic discharges on EEG and cortical and basal ganglia abnormalities 
on diffusion-weighted MR are unique diagnostic features. No proven treat-
ments exist.
For a more detailed discussion, see Seeley WW, Miller BL: 
Dementia, Chap. 371, p. 3300, in HPIM-18.
CHAPTER 195
Parkinson’s Disease
� CLINICAL FEATURES
Parkinsonism is a general term used to define a symptom complex 
manifest by bradykinesia (slowness of voluntary movements) with rigid-
ity and/or tremor; it has a wide differential diagnosis (Table 195-1). 
Parkinson’s disease (PD) is idiopathic parkinsonism without evidence of 
more widespread neurologic involvement. PD afflicts >1 million indi-
viduals in the United States. Peak age of onset in the 60s; course progres-
sive over 10–25 years. Tremor (“pill rolling” of hands) at rest (4–6 Hz). 
Presentation with tremor confined to one limb or one side of body is 
common. Other findings: rigidity (“cogwheeling”—increased ratchet-like 
resistance to passive limb movements), bradykinesia, fixed expressionless 
face (facial masking) with reduced frequency of blinking, hypophonic 
voice, drooling, impaired rapid alternating movements, micrographia 
(small handwriting), reduced arm swing, and flexed “stooped” posture 
with walking, shuffling gait, difficulty initiating or stopping walking, 
en-bloc turning (multiple small steps required to turn), retropulsion 
SECTION 14
1222
Neurology
(tendency to fall backwards). Nonmotor aspects of PD include depres-
sion and anxiety, cognitive impairment, sleep disturbances, sensation 
of inner restlessness, loss of smell (anosmia), and disturbances of auto-
nomic function. Normal muscular strength, deep tendon reflexes, and 
sensory exam. Diagnosis based on history and examination; neuroimag-
ing, EEG, and CSF studies usually normal for age. 
� PATHOPHYSIOLOGY
Most PD cases occur sporadically and are of unknown cause. Degeneration 
of pigmented pars compacta neurons of the substantia nigra in the mid-
brain resulting in lack of dopaminergic input to striatum; accumulation 
of cytoplasmic intraneural inclusion granules (Lewy bodies). Cause of 
cell death is unknown, but it may result from generation of free radicals 
and oxidative stress; no environmental factor has yet been conclusively 
determined to cause PD. Rare genetic forms of parkinsonism exist (~5% of 
cases); most common are mutations in α-synuclein or parkin genes. Early 
TABLE 195-1 DIFFERENTIAL DIAGNOSIS OF PARKINSONISM
Parkinson’s 
Disease
Atypical
Parkinsonisms
Secondary 
Parkinsonism
Other
Neurodegenerative 
Disorders
Genetic
Multiple-system 
atrophy
Drug-induced
Wilson’s disease
Sporadic
Cerebellar type 
(MSA-c)
Tumor
Huntington’s disease
Dementia
with Lewy 
bodies
Parkinson type 
(MSA-p)
Infection
Neurodegeneration 
with brain iron 
accumulation
Progressive supra-
nuclear palsy
Vascular 
Corticobasal gangli-
onic degeneration
Normal-pressure
hydrocephalus
SCA 3 (spinocer-
ebellar ataxia)
Trauma
Fragile X–associ-
ated ataxia-tremor-
parkinsonism
Frontotemporal 
dementia
Liver failure
Toxins (e.g., car-
bon monoxide, 
manganese, 
MPTP, cyanide, 
hexane, methanol, 
carbon disulfide)
Prion disease
Dystonia-
parkinsonism (DYT3)
Alzheimer’s disease 
with parkinsonism
Abbreviation: MPTP, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
CHAPTER 195 1223
Parkinson’s Disease
age of onset suggests a possible genetic cause of PD, although one genetic 
form (LLRK2) causes PD in the same age range as sporadic PD and may 
be responsible for as much as 1% of all sporadic cases. Mutations in the 
glucocerebrosidase (GBA) gene are also associated with an increased risk 
of idiopathic PD.
� DIFFERENTIAL DIAGNOSIS 
Atypical parkinsonism refers to a group of neurodegenerative condi-
tions that usually are associated with more widespread neurodegen-
eration than is found in PD including multiple-system atrophy (MSA), 
progressive supranuclear palsy (PSP), and corticobasal ganglionic 
degeneration (CBGD). Secondary parkinsonism can be associated 
with drugs (neuroleptics as well as GI medications such as meto-
clopramide, all of which block dopamine), infection, or exposure to 
toxins such as carbon monoxide or manganese. Some features to sug-
gest that parkinsonism might be due to a condition other than PD are 
shown in Table 195-2.
TABLE 195-2 FEATURES SUGGESTING DIAGNOSIS OTHER THAN PD
Symptoms/Signs
Alternate Diagnosis to Consider
History
Early speech and gait impairment
Atypical parkinsonism
Exposure to neuroleptics
Drug-induced parkinsonism
Onset prior to age 40
Genetic form of PD
Liver disease
Wilson’s disease, non-Wilsonian 
hepatolenticular degeneration
Early hallucinations
Dementia with Lewy bodies
Diplopia
PSP
Poor or no response to an adequate trial 
of levodopa
Atypical or secondary parkinsonism
Physical Exam
Dementia as first symptom
Dementia with Lewy bodies
Prominent orthostatic hypotension
MSA-p
Prominent cerebellar signs
MSA-c
Impairment of down gaze
PSP
High-frequency (8–10 Hz) symmetric 
postural tremor with a prominent kinetic 
component
Essential tremor
Abbreviations: MSA-c, multiple-system atrophy–cerebellar type; MSA-p, multiple-system 
atrophy–Parkinson type; PSP, progressive supranuclear palsy.
SECTION 14
1224
Neurology
Parkinson’s Disease (see Fig. 195-1, Table 195-3)
TREATMENT
Goals are to maintain function and avoid drug-induced complications; 
start therapy when symptoms interfere with quality of life. Bradykinesia, 
tremor, rigidity, and abnormal posture respond early in illness; cognitive 
symptoms, hypophonia, autonomic dysfunction, and balance difficulties 
respond poorly.
LEVODOPA
• Routinely administered in combination with a decarboxylase inhibitor 
to prevent its peripheral metabolism to dopamine and the develop-
ment of nausea and vomiting. In the United States, levodopa is com-
bined with carbidopa (Sinemet). 
• Levodopa is also available in controlled-release formulations and in 
combination (e.g., as Stalevo) with a COMT inhibitor (see below). 
• Levodopa remains the most effective symptomatic treatment for PD, 
and lack of response to the medication despite an adequate trial should 
cause the diagnosis to be questioned. 
• Side effects include nausea, vomiting, and orthostatic hypotension that 
can be avoided by gradual titration.
• Levodopa-induced motor complications consist of fluctuations in 
motor response and involuntary movements known as dyskinesias. 
• When pts initially take the drug, the benefits are long-lasting; with 
continued treatment, the duration of benefit following an individual 
dose becomes progressively shorter (“wearing-off effect”).
DOPAMINE AGONISTS
• A diverse group of drugs that act directly on dopamine receptors. 
Second-generation non-ergot dopamine agonists are commonly used 
(e.g., pramipexole, ropinirole, rotigotine). 
• Compared with levodopa, dopamine agonists are longer acting and 
thus provide a more uniform stimulation of dopamine receptors; less 
prone to induce dyskinesias compared with levodopa. 
• They are effective as monotherapeutic agents and as adjuncts to carbi-
dopa/levodopa therapy. 
• Side effects include nausea, vomiting, and postural hypotension. 
Hallucinations and cognitive impairment are more common than with 
levodopa, so caution is urged in those older than 70.
• Recently, it has become recognized that dopamine agonists are associ-
ated with impulse-control disorders including pathologic gambling, 
hypersexuality, and compulsive eating and shopping. 
MAO-B INHIBITORS
• Block central dopamine metabolism and increase synaptic concentra-
tions of the neurotransmitter; generally safe and well tolerated. 
• Provide modest antiparkinson benefits when used as monotherapy in 
early disease. 
• Recent work has examined whether these drugs could have a disease-
modifying effect; however, long-term significance is uncertain.
CHAPTER 195 1225
Parkinson’s Disease
Functional disability
Parkinson’s Disease
Surgery/CDS
Combination therapy
Levodopa/dopamine
agonist/COMT
Inhibitor/MAO-B Inhibitor
Nonpharmacologic intervention
Pharmacologic intervention
Neuroprotection —? Rasagiline
Yes
Levodopa
No
Dopamine agonists
TREATMENT ALGORITHM FOR THE MANAGEMENT OF
PARKINSON’S DISEASE
FIGURE 195-1 Treatment options for the management of PD. Decision points include:
a. Introduction of a neuroprotective therapy: No drug has been established to have or is cur-
rently approved for neuroprotection or disease modification, but there are several agents that 
have this potential based on laboratory and preliminary clinical studies (e.g., rasagiline 1 mg/d, 
coenzyme Q10 1200 mg/d, the dopamine agonists ropinirole and pramipexole).
b. When to initiate symptomatic therapy: There is a trend toward initiating therapy at the time 
of diagnosis or early in the course of the disease because pts may have some disability even 
at an early stage, and there is the possibility that early treatment may preserve beneficial 
compensatory mechanisms; however, some experts recommend waiting until there is func-
tional disability before initiating therapy.
c. What therapy to initiate: Many experts favor starting with an MAO-B inhibitor in mildly af-
fected pts because of the potential for a disease-modifying effect; dopamine agonists for 
younger pts with functionally significant disability to reduce the risk of motor complications; and 
levodopa for pts with more advanced disease, the elderly, or those with cognitive impairment.
d. Management of motor complications: Motor complications are typically approached with 
combination therapy to try and reduce dyskinesia and enhance the “on” time. When medical 
therapies cannot provide satisfactory control, surgical therapies can be considered.
e. Nonpharmacologic approaches: Interventions such as exercise, education, and support 
should be considered throughout the course of the disease. (Adapted from CW Olanow et al: 
Neurology 72:S1, 2009.)
SECTION 14
1226
Neurology
TABLE 195-3 DRUGS COMMONLY USED FOR TREATMENT OF PD*
Agent
Available Dosages
Typical Dosing
Levodopa*
  Carbidopa/
levodopa
10/100, 25/100, 25/250
200–1000 mg 
levodopa/d 2–4 times/d 
  Benserazide/
levodopa
25/100, 50/200
  Carbidopa/
levodopa CR
25/100, 50/200
  Benserazide/
levodopa MDS
25/200, 25/250
 Parcopa 
10/100, 25/100, 25/250
  Carbidopa/
levodopa/
entacapone
12.5/50/200, 
18.75/75/200, 25/100/200, 
31.25/125/200, 
37.5/150/200, 50/200/200
Dopamine agonists
 Pramipexole
0.125, 0.25, 0.5, 1.0, 1.5 
mg
0.25–1.0 mg tid
 Pramipexole ER
0.375, 0.75, 1.5. 3.0, 4.5 
mg
1–3 mg/d
 Ropinirole
0.25, 0.5, 1.0, 3.0 mg
6–24 mg/d
 Ropinirole XL
2, 4, 6, 8
6–24 mg/d
 Rotigotine patch
2-, 4-, 6-mg patches
4–10 mg/d
 Apomorphine SC
2–8 mg
COMT Inhibitors
 Entacapone
200 mg
200 mg with each 
levodopa dose
 Tolcapone
100, 200 mg
100–200 mg tid
MAO-B Inhibitors
 Selegiline
5 mg
5 mg bid
 Rasagiline
0.5, 1.0 mg
1.0 mg QAM
*Treatment should be individualized. Generally, drugs should be started in low doses and 
titrated to optimal dose.
Note: Drugs should not be withdrawn abruptly but should be gradually lowered or removed as 
appropriate.
Abbreviations: COMT, catechol-O-methyltransferase; MAO-B, monoamine oxidase type B.
CHAPTER 196 1227
Ataxic Disorders
COMT INHIBITORS
• When levodopa is administered with a decarboxylase inhibitor, it is 
primarily metabolized by COMT; inhibitors of COMT increase the 
elimination half-life of levodopa and enhance its brain availability. 
• Combining levodopa with a COMT inhibitor reduces wearing-off 
time.
OTHER MEDICAL T HERAPIES
• Anticholinergics (trihexyphenidyl, benztropine) have their major 
clinical effect on tremor. Use in the elderly is limited due to propensity 
for inducing urinary dysfunction, glaucoma, and particularly cogni-
tive impairment. 
• The mechanism of action of amantadine is unknown; it has NMDA 
antagonist properties; it is most commonly used as an antidyskinesia 
agent in pts with advanced PD. Side effects include livedo reticularis, 
weight gain, and impaired cognitive function; discontinue slowly as 
pts can experience withdrawal symptoms.
SURGICAL TREATMENTS
• In refractory cases, surgical treatment of PD should be considered. 
• The use of ablation (e.g., pallidotomy or thalamotomy) has decreased 
greatly since the introduction of deep-brain stimulation (DBS) of the 
subthalamic nucleus (STN) or globus pallidus interna (GPi). 
• DBS is primarily indicated for pts who suffer disability resulting from 
levodopa-induced motor complications; the procedure is profoundly 
beneficial to many pts.
• Contraindications to surgery include atypical PD, cognitive impair-
ment, major psychiatric illness, substantial medical comorbidities, and 
advanced age (a relative factor). 
• Experimental surgical procedures including cell-based therapies, gene 
therapies, and trophic factors are under investigation.
For a more detailed discussion, see Olanow CW, Schapira AHV: 
Parkinson’s Disease and Other Extrapyramidal Movement 
Disorders, Chap. 372, p. 3317, in HPIM-18.
CHAPTER 196
Ataxic Disorders
� CLINICAL PRESENTATION
Symptoms and signs may include gait impairment, visual blurring due to 
nystagmus, unclear (“scanning”) speech, hand incoordination, intention 
tremor (i.e., with movement). Differential diagnosis: Unsteady gait associ-
ated with vertigo from vestibular nerve or labyrinthine disease can resemble 
SECTION 14
1228
Neurology
gait instability of cerebellar disease but produces a sensation of movement, 
dizziness, or light-headedness. Sensory disturbances also can simulate cer-
ebellar disease; with sensory ataxia, imbalance dramatically worsens when 
visual input is removed (Romberg sign). Bilateral proximal leg weakness 
also can rarely mimic cerebellar ataxia.
Ataxia
APPROACH TO THE
PATIENT
Causes are best grouped by determining whether ataxia is symmetric 
or focal and by the time course (Table 196-1). Also important to distin-
guish whether ataxia is present in isolation or is part of a multisystem 
neurologic disorder. Acute symmetric ataxia is usually due to medica-
tions, toxins, viral infection, or a postinfectious syndrome (especially 
varicella). Subacute or chronic symmetric ataxia can result from hypo-
thyroidism, vitamin deficiencies, infections (Lyme disease, tabes dorsa-
lis, prions), alcohol, other toxins, or an inherited condition (see below). 
An immune-mediated progressive ataxia is associated with antigliadin 
antibodies; biopsy of the small intestine may reveal villous atrophy of 
gluten enteropathy. Elevated serum anti–glutamic acid decarboxylase 
(GAD) antibodies have been associated with a progressive ataxic syn-
drome affecting speech and gait. Progressive nonfamilial cerebellar 
ataxia after age 45 suggests a paraneoplastic syndrome, either subacute 
cortical cerebellar degeneration (ovarian, breast, lung, Hodgkin’s) or 
opsoclonus-myoclonus (neuroblastoma, breast, lung).
Unilateral ataxia suggests a focal lesion in the ipsilateral cerebellar 
hemisphere or its connections. An important cause of acute unilateral 
ataxia is stroke. Mass effect from cerebellar hemorrhage or swelling 
from cerebellar infarction can compress brainstem structures, produc-
ing altered consciousness and ipsilateral pontine signs (small pupils, 
sixth or seventh nerve palsies); limb ataxia may not be prominent. Other 
diseases producing asymmetric or unilateral ataxia include tumors, 
multiple sclerosis, progressive multifocal leukoencephalopathy (immu-
nodeficiency states), and congenital malformations.
� INHERITED ATAXIAS
May be autosomal dominant, autosomal recessive, or mitochondrial 
(maternal inheritance); more than 30 disorders recognized (see Table 373-2, 
pp. 3337–3340, in HPIM-18). Friedreich’s ataxia is most common; autosomal 
recessive, onset before age 25; ataxia with areflexia, upgoing toes, vibration 
and position sense deficits, cardiomyopathy, hammer toes, scoliosis; linked 
to expanded trinucleotide repeat in the intron of gene encoding frataxin; a 
second form is associated with genetically determined vitamin E deficiency 
syndrome. Common dominantly inherited ataxias are spinocerebellar ataxia 
(SCA)1 (olivopontocerebellar atrophy; “ataxin-1” gene) (Fig. 196-1), SCA2 
(ataxin-2; pts from Cuba and India) and SCA3 (Machado-Joseph disease); 
all may manifest as ataxia with brainstem and/or extrapyramidal signs; SCA3 
may also have dystonia and amyotrophy; genes for each disorder contain 
unstable trinucleotide repeats in coding region.
TABLE 196-1 ETIOLOGY OF CEREBELLAR ATAXIA
Symmetric and Progressive Signs
Focal and Ipsilateral Cerebellar Signs
Acute (Hours to 
Days)
Subacute (Days to 
Weeks)
Chronic (Months 
to Years)
Acute (Hours to 
Days)
Subacute (Days to 
Weeks)
Chronic (Months 
to Years)
Intoxication: alcohol, 
lithium, phenytoin, 
barbiturates (posi-
tive history and 
toxicology screen)
Acute viral cerebel-
litis (CSF supportive 
of acute viral 
infection)
Postinfection 
syndrome
Intoxication: mercury, 
solvents, gasoline, 
glue; cytotoxic 
chemotherapeutic, 
hemotherapeutic drugs
Alcoholic-nutritional
(vitamin B1 and B12
deficiency)
Lyme disease
Paraneoplastic 
syndrome
Antigliadin anti-
body syndrome
Hypothyroidism
Inherited diseases
Tabes dorsalis 
(tertiary syphilis)
Phenytoin toxicity
Amiodarone
Vascular: cerebellar infarc-
tion, hemorrhage, or subdu-
ral hematoma 
Infectious: cerebellar 
abscess (mass lesion on 
MRI/CT, history in support 
of lesion)
Neoplastic: cerebellar 
glioma or metastatic 
tumor (positive for 
neoplasm on MRI/CT) 
Demyelinating: mul-
tiple sclerosis (history, 
CSF, and MRI are 
consistent)
AIDS-related multifocal 
leukoencephalopathy 
(positive HIV test and 
CD4+ cell count for 
AIDS)
Stable gliosis secondary 
to vascular lesion or demy-
elinating plaque (stable 
lesion on MRI/CT older than 
several months)
Congenital lesion: Chiari 
or Dandy-Walker 
malformations 
(malformation noted 
on MRI/CT)
Abbreviations: CSF, cerebrospinal fluid; CT, computed tomography; MRI, magnetic resonance imaging.
1229
SECTION 14
1230
Neurology
� EVALUATION
Diagnostic approach is determined by the nature of the ataxia (Table 196-1). 
For symmetric ataxias, drug and toxicology screens; vitamin B1, B12, and E 
levels; thyroid function tests; antibody tests for syphilis and Lyme infection; 
antigliadin and anti-GAD antibodies; paraneoplastic antibodies (Chap. 84); 
and CSF studies often indicated. Genetic testing is available for many inherited 
ataxias. For unilateral or asymmetric ataxias, brain MRI or CT scan is the initial 
test of choice; CT is insensitive for nonhemorrhagic lesions of the cerebellum.
Ataxia
TREATMENT
• The most important goal is to identify treatable entities including 
hypothyroidism, vitamin deficiency, and infectious causes. 
• Parainfectious ataxia can be treated with glucocorticoids. 
• Ataxia with antigliadin antibodies and gluten enteropathy may 
improve with a gluten-free diet. 
• Paraneoplastic disorders are often refractory to therapy, but some pts 
improve following removal of the tumor or immunotherapy (Chap. 84). 
FIGURE 196-1 Sagittal MRI of the brain of a 60-year-old-man with gait ataxia and 
dysarthria due to SCA1, illustrating cerebellar atrophy (arrows). MRI, magnetic reso-
nance imaging; SCA1, spinocerebellar ataxia type 1.
CHAPTER 197 1231
ALS and Other Motor Neuron Diseases 
• Vitamins B1, B12, and E should be administered to pts with deficient 
levels. 
• The deleterious effects of phenytoin and alcohol on the cerebellum are 
well known, and these exposures should be avoided in pts with ataxia 
of any cause. 
• There is no proven therapy for any of the autosomal dominant ataxias; 
family and genetic counseling are important. 
• There is preliminary evidence that idebenone, a free-radical scaven-
ger, can improve myocardial hypertrophy in Friedreich’s ataxia; there 
is no evidence that it improves neurologic function. 
• Cerebellar hemorrhage and other mass lesions of the posterior fossa 
may require emergent surgical treatment to prevent fatal brainstem 
compression.
For a more detailed discussion, see Rosenberg RN: Ataxic 
Disorders, Chap. 373, p. 3335, in HPIM-18.
CHAPTER 197
ALS and Other Motor 
Neuron Diseases
Amyotrophic lateral sclerosis (ALS) is the most common form of progres-
sive motor neuron disease (Table 197-1). ALS is caused by degeneration 
of motor neurons at all levels of the CNS, including anterior horns of the 
spinal cord, brainstem motor nuclei, and motor cortex. Familial ALS (FALS) 
represents 5–10% of the total and is inherited usually as an autosomal 
dominant disorder.
� CLINICAL FEATURES
Onset is usually midlife, with most cases progressing to death in 3–5 years. 
In most societies there is an incidence of 1–3 per 100,000 and a prevalence 
of 3–5 per 100,000. Presentation is variable depending on whether upper 
motor or lower motor neurons are more prominently involved initially.
Common initial symptoms are weakness, muscle wasting, stiffness and 
cramping, and twitching in muscles of hands and arms, often first in the 
intrinsic hand muscles. Legs are less severely involved than arms, with 
complaints of leg stiffness, cramping, and weakness common. Symptoms 
of brainstem involvement include dysphagia, which may lead to aspiration 
pneumonia and compromised energy intake; there may be prominent wast-
ing of the tongue leading to difficulty in articulation (dysarthria), phona-
tion, and deglutition. Weakness of ventilatory muscles leads to respiratory 
insufficiency. Additional features that characterize ALS are lack of sensory 
SECTION 14
1232
Neurology
abnormalities, pseudobulbar palsy (e.g., involuntary laughter, crying), and 
absence of bowel or bladder dysfunction. Dementia is not a component of spo-
radic ALS; in some families ALS is co-inherited with frontotemporal dementia 
characterized by behavioral abnormalities due to frontal lobe dysfunction.
� PATHOPHYSIOLOGY
Pathologic hallmark is death of lower motor neurons (consisting of anterior 
horn cells in the spinal cord and their brainstem homologues innervating 
bulbar muscles) and upper, or corticospinal, motor neurons (originating 
in layer five of the motor cortex and descending via the pyramidal tract to 
synapse with lower motor neurons). Although at onset ALS may involve 
selective loss of function of only upper or lower motor neurons, it ultimately 
causes progressive loss of both; the absence of clear involvement of both 
motor neuron types should call into question the diagnosis of ALS.
� LABORATORY EVALUATION
EMG provides objective evidence of extensive muscle denervation not con-
fined to the territory of individual peripheral nerves and nerve roots. CSF is 
usually normal. Muscle enzymes (e.g., CK) may be elevated.
Several types of secondary motor neuron disorders that resemble ALS are 
treatable (Table 197-2); therefore all pts should have a careful search for 
these disorders.
MRI or CT myelography is often required to exclude compressive 
lesions of the foramen magnum or cervical spine. When involvement is 
TABLE 197-1 SPORADIC MOTOR NEURON DISEASES
Chronic
Entity
Upper and lower motor neuron
Amyotrophic lateral sclerosis
Predominantly upper motor neuron
Primary lateral sclerosis
Predominantly lower motor neuron
Multifocal motor neuropathy with 
conduction block
Motor neuropathy with parapro-
teinemia or cancer
Motor predominant peripheral 
neuropathies
Other
Associated with other neurodegenera-
tive disorders
Secondary motor neuron disorders 
(see Table 197-2)
Acute
Poliomyelitis
Herpes zoster
Coxsackie virus
CHAPTER 197 1233
ALS and Other Motor Neuron Diseases 
TABLE 197-2 ETIOLOGY OF MOTOR NEURON DISORDERS
Diagnostic Category
Investigation
Structural lesions
MRI scan of head (including fora-
men magnum and cervical spine)
  Parasagittal or foramen magnum 
tumors
 Cervical spondylosis
 Chiari malformation of syrinx
  Spinal cord arteriovenous malformation
Infections
CSF exam, culture
 Bacterial—tetanus, Lyme
Lyme titer
 Viral—poliomyelitis, herpes zoster
Antiviral antibody
 Retroviral—myelopathy
HTLV-1 titers
Intoxications, physical agents
24-h urine for heavy metals
 Toxins—lead, aluminum, others
Serum lead level
 Drugs—strychnine, phenytoin
 Electric shock, x-irradiation
Immunologic mechanisms
Complete blood counta
 Plasma cell dyscrasias
Sedimentation ratea
 Autoimmune polyradiculopathy
Total proteina
  Motor neuropathy with conduction block Anti-GM1 antibodiesa
 Paraneoplastic
Anti-Hu antibody
 Paracarcinomatous
MRI scan, bone marrow biopsy
Metabolic
Fasting blood sugara
 Hypoglycemia
Routine chemistries including 
calciuma
 Hyperparathyroidism
PTH
 Hyperthyroidism
Thyroid functiona
  Deficiency of folate, vitamin B12,
vitamin E
Vitamin B12, vitamin E, folatea
 Deficiency of copper, zinc
Serum zinc, coppera
 Malabsorption
24-h stool fat, carotene, 
prothrombin time
 Mitochondrial dysfunction
Fasting lactate, pyruvate, 
ammonia
Consider mtDNA
Hyperlipidemia
Lipid electrophoresis
Hyperglycinuria
Urine and serum amino acids
CSF amino acids
Hereditary disorders
WBC DNA for mutational analysis
(continued)
SECTION 14
1234
Neurology
TABLE 197-2 ETIOLOGY OF MOTOR NEURON DISORDERS (CONTINUED)
Diagnostic Category
Investigation
 Superoxide dismutase
 TDP43
 FUS/TLS
  Androgen receptor defect (Kennedy’s 
disease)
 Hexosaminidase deficiency
  Infantile α-glucosidase deficiency 
(Pompe’s disease)
aDenotes studies that should be obtained in all cases.
Abbreviations: CSF, cerebrospinal fluid; FUS/TLS, fused in sarcoma/translocated in liposar-
coma; HTLV-1, human T cell lymphotropic virus; PTH, parathyroid; WBC, white blood cell.
restricted to lower motor neurons only, another important entity is multi-
focal motor neuropathy with conduction block (MMCB). A diffuse, lower 
motor axonal neuropathy mimicking ALS sometimes evolves in association 
with hematopoietic disorders such as lymphoma or multiple myeloma; an 
M-component in serum should prompt consideration of a bone marrow 
biopsy. Lyme disease may also cause an axonal, lower motor neuropathy, 
typically with intense proximal limb pain and a CSF pleocytosis. Other 
treatable disorders that occasionally mimic ALS are chronic lead poisoning 
and thyrotoxicosis.
Pulmonary function studies may aid in management of ventilation. 
Swallowing evaluation identifies those at risk for aspiration. Genetic testing 
is available for superoxide dismutase 1 (SOD1) (20% of FALS) and for rare 
mutations in other genes.
Amyotrophic Lateral Sclerosis
TREATMENT
• There is no treatment that arrests the underlying pathologic process 
in ALS. 
• The drug riluzole produces modest lengthening of survival; in one trial 
the survival rate at 18 months with riluzole (100 mg/d) was similar to 
placebo at 15 months. It may act by diminishing glutamate release and 
thereby decreasing excitotoxic neuronal cell death. Side effects of riluzole 
include nausea, dizziness, weight loss, and elevation of liver enzymes. 
• Multiple therapies are presently in clinical trials for ALS including cef-
triaxone, pramipexole, and tamoxifen; interventions such as antisense 
oligonucleotides that diminish expression of mutant SOD1 protein 
are in trial for SOD1-mediated ALS.
• A variety of rehabilitative aids may substantially assist ALS pts . Foot-
drop splints facilitate ambulation, and finger extension splints can 
potentiate grip. 
CHAPTER 198 1235
Autonomic Nervous System Disorders 
• Respiratory support may be life-sustaining. For pts electing against 
long-term ventilation by tracheostomy, positive-pressure ventila-
tion by mouth or nose provides transient (several weeks) relief from 
hypercarbia and hypoxia. Also beneficial are respiratory devices that 
produce an artificial cough; these help to clear airways and prevent 
aspiration pneumonia. 
• When bulbar disease prevents normal chewing and swallowing, gas-
trostomy is helpful in restoring normal nutrition and hydration. 
• Speech synthesizers can augment speech when there is advanced bul-
bar palsy.
• Web-based information on ALS is offered by the Muscular Dystrophy 
Association (www.mdausa.org) and the Amyotrophic Lateral Sclerosis 
Association (www.alsa.org).
For a more detailed discussion, see Brown RH Jr: Amyotrophic 
Lateral Sclerosis and Other Motor Neuron Diseases, Chap. 374, 
p. 3345, in HPIM-18.
CHAPTER 198
Autonomic Nervous 
System Disorders
The autonomic nervous system (ANS) (Fig. 198-1) innervates the entire 
neuraxis and permeates all organ systems. It regulates blood pressure (bp), 
heart rate, sleep, and bladder and bowel function. It operates automatically, 
so that its full importance becomes recognized only when ANS function is 
compromised, resulting in dysautonomia.
Key features of the ANS are summarized in Table 198-1. Responses to 
sympathetic or parasympathetic activation often have opposite effects; 
partial activation of both systems allows for simultaneous integration of 
multiple body functions.
Consider disorders of autonomic function in the differential diagnosis 
of pts with unexplained orthostatic hypotension, sleep dysfunction, impo-
tence, bladder dysfunction (urinary frequency, hesitancy, or incontinence), 
diarrhea, constipation, upper gastrointestinal symptoms (bloating, nausea, 
vomiting of old food), impaired lacrimation, or altered sweating (hyperhi-
drosis or hypohidrosis).
Orthostatic hypotension (OH) is perhaps the most disabling feature of 
autonomic dysfunction. Syncope results when the drop in bp impairs cere-
bral perfusion (Chap. 56). Other manifestations of impaired baroreflexes 
are supine hypertension, a heart rate that is fixed regardless of posture, 
postprandial hypotension, and an excessively high nocturnal bp. Many pts 
SECTION 14
1236
Neurology
A Ciliary ganglion
B Sphenopalatine
(pterygopalatine) ganglion
C Submandibular ganglion
D Otic ganglion
E Vagal ganglion cells
in the heart wall
F Vagal ganglion cells in
bowel wall
G Pelvic ganglia
H Superior cervical ganglion
J
Middle cervical ganglion and
inferior cervical (stellate)
ganglion including T1
ganglion
K Coeliac and other
abdominal ganglia
L Lower abdominal
sympathetic ganglia
Parasympathetic system
from cranial nerves III, VII, IX, X
and from sacral nerves 2 and 3
Sympathetic system
from T1-L2
Preganglionic fibers
Postganglionic fibers
T1
2
3
4
5
6
7
8
9
10
11
12
L1
2
Parasympathetic 
Sympathetic 
A
B
C
Heart
E
Arm
Heart
Leg
G
D
Terminal ganglion
(coccygeal)
Sympathetic
chain
H
Bowel
Adrenal medulla
(preganglionic
supply)
Viscera
F
J
L
S2
3
K
III
VII IX
X
FIGURE 198-1 Schematic representation of the autonomic nervous system. (From
M. Moskowitz: Clin Endocrinol Metab 6:745, 1977.)
CHAPTER 198 1237
Autonomic Nervous System Disorders 
with OH have a preceding diagnosis of hypertension. The most common 
causes of OH are not neurologic in origin; these must be distinguished from 
the neurogenic causes.
Autonomic Nervous System Disorders
APPROACH TO THE
PATIENT
The first step in the evaluation of symptomatic OH is the exclusion of 
treatable causes. The history should include a review of medications 
that may cause OH (e.g., diuretics, antihypertensives, antidepressants, 
phenothiazines, ethanol, narcotics, insulin, dopamine agonists, barbi-
turates, and calcium channel blocking agents); the precipitation of OH 
by medications may also be the first sign of an underlying autonomic 
disorder. The history may reveal an underlying cause for symptoms (e.g., 
diabetes, Parkinson’s disease) or specific underlying mechanisms (e.g., 
cardiac pump failure, reduced intravascular volume). The relationship of 
symptoms to meals (splanchnic pooling), standing on awakening in the 
morning (intravascular volume depletion), ambient warming (vasodila-
tation), or exercise (muscle arteriolar vasodilatation) should be sought.
Physical exam includes measurement of supine and standing pulse and 
bp. OH is defined as a sustained drop in systolic (≥20 mmHg) or diastolic 
(≥10 mmHg) bp within 3 min of standing. In nonneurogenic causes of OH 
(such as hypovolemia), the bp drop is accompanied by a compensatory 
increase in heart rate of >15 beats/min. A clue to neurogenic OH is aggra-
vation or precipitation of OH by autonomic stressors (such as a meal, hot 
tub/hot bath, and exercise). Neurologic evaluation should include a mental 
status exam (to exclude neurodegenerative disorders), cranial nerve exam 
(impaired downgaze in progressive supranuclear palsy), pupils (Horner’s 
or Adie’s pupils), motor tone (Parkinson’s), and sensory exam (polyneu-
ropathies). In pts without a clear initial diagnosis, follow-up exams and 
laboratory evaluations over 1 to 2 years may reveal the underlying cause.
TABLE 198-1 FUNCTIONAL CONSEQUENCES OF NORMAL ANS ACTIVATION
Sympathetic
Parasympathetic
Heart rate
Increased
Decreased
Blood pressure
Increased
Mildly decreased
Bladder
Increased sphincter tone
Voiding (decreased tone)
Bowel motility
Decreased motility
Increased
Lung
Bronchodilation
Bronchoconstriction
Sweat glands
Sweating
—
Pupils
Dilation
Constriction
Adrenal glands
Catecholamine release
—
Sexual function
Ejaculation, orgasm
Erection
Lacrimal glands
—
Tearing
Parotid glands
—
Salivation
SECTION 14
1238
Neurology
Autonomic Testing : Autonomic function tests are helpful when the his-
tory and physical exam findings are inconclusive; to detect subclinical 
involvement; or to follow the course of an autonomic disorder. Heart 
rate variation with deep breathing is a measure of vagal function. The 
Valsalva maneuver measures changes in heart rate and bp while a 
constant expiratory pressure of 40 mmHg is maintained for 15 s. The 
Valsalva ratio is the maximum heart rate during the maneuver divided 
by the minimum heart rate following the maneuver; the ratio reflects 
cardiovagal function. Tilt-table beat-to-beat bp measurements in the 
supine, 70° tilt, and tilt-back positions can be used to evaluate ortho-
static failure in bp control in pts with unexplained syncope. Most pts 
with syncope do not have autonomic failure; the tilt-table test can be 
used to diagnose vasovagal syncope with high sensitivity, specificity, and 
reproducibility.
Other tests of autonomic function include the quantitative sudomotor 
axon reflex test (QSART) and the thermoregulatory sweat test (TST). 
The QSART provides quantitative measure of regional autonomic func-
tion mediated by ACh-induced sweating. The TST provides a qualitative 
measure of sweating in response to a standardized elevation of body 
temperature. For a more complete discussion of autonomic function 
tests, see Chap. 375, HPIM-18.
� DISORDERS OF THE AUTONOMIC NERVOUS SYSTEM
Autonomic disorders may occur with a large number of disorders of the 
central and/or peripheral nervous systems (Table 198-2). Diseases of the 
CNS may cause ANS dysfunction at many levels, including hypothalamus, 
brainstem, or spinal cord.
Multiple system atrophy (MSA) is a progressive neurodegenerative dis-
order comprising autonomic failure (OH and/or a neurogenic bladder) 
combined with either parkinsonism (MSA-p) or cerebellar signs (MSA-c), 
often along with progressive cognitive dysfunction. Dysautonomia is also 
common in advanced Parkinson’s disease and dementia with Lewy bodies.
Spinal cord injury may be accompanied by autonomic hyperreflexia 
affecting bowel, bladder, sexual, temperature-regulation, or cardiovascular 
functions. Markedly increased autonomic discharge (autonomic dysre-
flexia) can be elicited by stimulation of the bladder, skin, or muscles with 
spinal cord lesions above the C6 level. Bladder distention from palpation, 
catheter insertion, catheter obstruction, or urinary infection is a common 
and correctable trigger of autonomic dysreflexia. Dangerous increases or 
decreases in body temperature may result from the inability to experience 
the sensory accompaniments of heat or cold exposure below the level of 
the injury.
Peripheral neuropathies affecting the small myelinated and unmyelinated 
fibers of the sympathetic and parasympathetic nerves are the most com-
mon cause of chronic autonomic insufficiency (Chap. 205). Autonomic 
involvement in diabetes mellitus typically begins ~10 years after the onset of 
diabetes and slowly progresses. Diabetic enteric neuropathy may result in 
CHAPTER 198 1239
Autonomic Nervous System Disorders 
TABLE 198-2 CLASSIFICATION OF CLINICAL AUTONOMIC DISORDERS
I. Autonomic disorders with brain involvement
  A. Associated with multisystem degeneration
 
1. Multisystem degeneration: autonomic failure clinically prominent
 
a. Multiple system atrophy (MSA)
 
b. Parkinson’s disease with autonomic failure
 
c. Diffuse Lewy body disease (some cases)
 
2.  Multisystem degeneration: autonomic failure clinically not usually 
prominent
 
a. Parkinson’s disease
 
b.  Other extrapyramidal disorders [inherited spinocerebellar atrophies, 
progressive supranuclear palsy, corticobasal degeneration, Machado-
Joseph disease, fragile X–associated tremor/ataxia syndrome 
(FXTAS)]
  B. Unassociated with multisystem degeneration (focal CNS disorders)
 
1. Disorders mainly due to cerebral cortex involvement
 
a. Frontal cortex lesions causing urinary/bowel incontinence
 
b. Partial complex seizures (temporal lobe or anterior cingulate)
 
c. Cerebral infarction of the insula
 
2. Disorders of the limbic and paralimbic circuits
 
a.  Shapiro’s syndrome (agenesis of corpus callosum, hyperhidrosis, 
hypothermia)
 
b. Autonomic seizures
 
c. Limbic encephalitis
 
3. Disorders of the hypothalamus
 
a. Wernicke-Korsakoff syndrome
 
b. Diencephalic syndrome
 
c. Neuroleptic malignant syndrome
 
d. Serotonin syndrome
 
e. Fatal familial insomnia
 
 f.  Antidiuretic hormone syndromes (diabetes insipidus, inappropriate 
ADH secretion)
 
g. Disturbances of temperature regulation (hyperthermia, hypothermia)
 
h. Disturbances of sexual function
 
 i. Disturbances of appetite
 
 j. Disturbances of BP/HR and gastric function
 
k. Horner’s syndrome
 
4. Disorders of the brainstem and cerebellum
 
a. Posterior fossa tumors
 
b. Syringobulbia and Arnold-Chiari malformation
(continued)
SECTION 14
1240
Neurology
TABLE 198-2  CLASSIFICATION OF CLINICAL AUTONOMIC DISORDERS 
(CONTINUED)
 
c. Disorders of BP control (hypertension, hypotension)
 
d. Cardiac arrhythmias
 
e. Central sleep apnea
 
 f. Baroreflex failure
 
g. Horner’s syndrome
 
h. Vertebrobasilar and Wallenberg syndromes
 
 i. Brainstem encephalitis
II. Autonomic disorders with spinal cord involvement
  A. Traumatic quadriplegia
  B. Syringomyelia
  C. Subacute combined degeneration
  D.  Multiple sclerosis and Devic disease 
  E.  Amyotrophic lateral sclerosis
  F.  Tetanus
  G. Stiff-man syndrome
  H. Spinal cord tumors
III. Autonomic neuropathies
  A. Acute/subacute autonomic neuropathies
 
1. Subacute autoimmune autonomic ganglionopathy (AAG)
 
a. Subacute paraneoplastic autonomic neuropathy
 
b. Guillain-Barré syndrome
 
c. Botulism
 
d. Porphyria
 
e.  Drug-induced autonomic neuropathies—stimulants, drug with-
drawal, vasoconstrictors, vasodilators, beta receptor antagonists, 
beta agonists
 
 f. Toxic autonomic neuropathies
 
g. Subacute cholinergic neuropathy
  B. Chronic peripheral autonomic neuropathies
 
1. Distal small fiber neuropathy
 
2. Combined sympathetic and parasympathetic failure
 
a. Amyloid
 
b. Diabetic autonomic neuropathy
 
c.  Autoimmune autonomic ganglionopathy (paraneoplastic and 
idiopathic)
 
d. Sensory neuronopathy with autonomic failure
 
e. Familial dysautonomia (Riley-Day syndrome)
CHAPTER 198 1241
Autonomic Nervous System Disorders 
gastroparesis, nausea and vomiting, malnutrition, achlorhydria, and bowel 
incontinence. Impotence, urinary incontinence, pupillary abnormalities, and 
OH may occur as well. Prolongation of the QT interval increases the risk of 
sudden death. Autonomic neuropathy occurs in both sporadic and familial 
forms of amyloidosis. Pts typically present with distal, painful polyneuropa-
thy. Alcoholic polyneuropathy produces symptoms of autonomic failure only 
when the neuropathy is severe. Attacks of acute intermittent porphyria (AIP) 
are associated with tachycardia, sweating, urinary retention, and hyperten-
sion; other prominent symptoms include anxiety, abdominal pain, nausea, 
and vomiting. Blood pressure fluctuation and cardiac arrhythmias can be 
severe in Guillain-Barré syndrome. Autoimmune autonomic neuropathy pres-
ents as the subacute development of autonomic failure featuring OH, enteric 
neuropathy (gastroparesis, ileus, constipation/diarrhea), loss of sweating, 
sicca complex, and a tonic pupil. Onset may follow a viral infection; serum 
antibodies to the ganglionic ACh receptor (A3 AChR) are diagnostic, and 
some pts appear to respond to immunotherapy. Rare pts develop dysautono-
mia as a paraneoplastic disorder (Chap. 84). There are five known hereditary 
sensory and autonomic neuropathies (HSAN I–V).
Botulism is associated with blurred vision, dry mouth, nausea, unreactive 
or sluggishly reactive pupils, urinary retention, and constipation. Postural 
orthostatic tachycardia syndrome (POTS) presents with symptoms of ortho-
static intolerance (not OH), including shortness of breath, light-headed-
ness, and exercise intolerance accompanied by an increase in heart rate but 
no drop in bp. Primary hyperhidrosis affects 0.6–1.0% of the population; 
the usual symptoms are excessive sweating of the palms and soles. Onset 
is in adolescence, and symptoms tend to improve with age. Although not 
dangerous, this condition is socially embarrassing; treatment with either 
sympathectomy or local injection of botulinum toxin is often effective.
� COMPLEX REGIONAL PAIN SYNDROME (REFLEX SYMPATHETIC 
DYSTROPHY AND CAUSALGIA)
Complex regional pain syndrome (CRPS) type I is a regional pain syndrome 
that usually develops after tissue trauma. Allodynia (the perception of a 
nonpainful stimulus as painful), hyperpathia (an exaggerated pain response 
to a painful stimulus), and spontaneous pain occur. The symptoms are 
unrelated to the severity of the initial trauma and are not confined to the 
distribution of a single peripheral nerve. CRPS type II is a regional pain 
TABLE 198-2  CLASSIFICATION OF CLINICAL AUTONOMIC DISORDERS 
(CONTINUED)
 
 f. Diabetic, uremic, or nutritional deficiency
 
g. Dysautonomia of old age
 
3.  Disorders of reduced orthostatic intolerance—reflex syncope, POTS, 
associated with prolonged bed rest, associated with space flight, 
chronic fatigue
Abbreviations: BP, blood pressure; HR, heart rate; POTS, postural orthostatic tachycardia 
syndrome.
SECTION 14
1242
Neurology
syndrome that develops after injury to a peripheral nerve, usually a major 
nerve trunk. Spontaneous pain initially develops within the territory of the 
affected nerve but eventually may spread outside the nerve distribution.
• Early mobilization with physical therapy or a brief course of glucocorti-
coids may be helpful for CRPS type I. 
• Other treatments include the use of adrenergic blockers, NSAIDs, cal-
cium channel blockers, phenytoin, opioids, and calcitonin. 
• Stellate ganglion blockade is a commonly used invasive therapeutic 
technique that often provides temporary pain relief, but the efficacy of 
repetitive blocks is uncertain.
Autonomic Nervous System Disorders
TREATMENT
• Of particular importance is the removal of drugs or amelioration 
of underlying conditions that cause or aggravate the autonomic 
symptom. For instance, OH can be related to angiotensin-converting 
enzyme inhibitors, calcium channel blocking agents, tricyclic antide-
pressants, levodopa, alcohol, or insulin. 
• Nonpharmacologic approaches are summarized in Table 198-3. 
Adequate intake of salt and fluids to produce a voiding volume 
between 1.5 and 2.5 L of urine (containing >170 meq of Na+) each 
24 h is essential. Sleeping with the head of the bed elevated will mini-
mize the effects of supine nocturnal hypertension. 
• Prolonged recumbency should be avoided. Pts are advised to sit with 
legs dangling over the edge of the bed for several minutes before 
attempting to stand in the morning. Compressive garments such 
as compression stockings and abdominal binders may be helpful 
if they can be tolerated. Anemia should be corrected, if necessary, 
with erythropoietin; the increased intravascular volume that accom-
panies the rise in hematocrit can exacerbate supine hypertension. 
Postprandial OH may respond to frequent, small, low-carbohydrate 
meals.
• If these measures are not sufficient, drug treatment might be 
necessary. 
• Midodrine is a directly acting α1 agonist that does not cross the blood-
brain barrier. The dose is 5–10 mg orally three times a day, but some 
pts respond best to a decremental dose (e.g., 15 mg on awakening, 
10 mg at noon, and 5 mg in the afternoon). Midodrine should not be 
taken after 6 p.m. Side effects include pruritus, uncomfortable pilo-
erection, and supine hypertension.
• Pyridostigmine appears to improve OH without aggravating supine 
hypertension by enhancing ganglionic transmission (maximal when 
orthostatic, minimal supine). 
• Fludrocortisone (0.1–0.3 mg PO twice daily) will reduce OH, but it 
aggravates supine hypertension. Susceptible pts may develop fluid over-
load, congestive heart failure, supine hypertension, or hypokalemia.
CHAPTER 199 1243
Cranial Nerve Disorders
TABLE 198-3 INITIAL TREATMENT OF ORTHOSTATIC HYPOTENSION (OH)
Educate pt: mechanisms and stressors of OH
Implement high-salt diet (10–20 g/d)
Implement high fluid intake (2 L/d)
Elevate head of bed 10 cm (4 in.)
Maintain postural stimuli
Learn physical countermaneuvers
Wear compression garments
Correct anemia
For a more detailed discussion, see Low PA, Engstrom JW: 
Disorders of the Autonomic Nervous System, Chap. 375, 
p. 3351, in HPIM-18.
CHAPTER 199
Trigeminal Neuralgia, 
Bell’s Palsy, and Other 
Cranial Nerve Disorders
Disorders of vision and ocular movement are discussed in Chaps. 58 and 63, 
dizziness and vertigo in Chap. 57, and disorders of hearing in Chap. 63.
� FACIAL PAIN OR NUMBNESS [TRIGEMINAL NERVE (V)]
(See Fig. 199-1)
Trigeminal Neuralgia (Tic Douloureux) 
Frequent, excruciating paroxysms of pain in lips, gums, cheek, or chin 
(rarely in ophthalmic division of fifth nerve) lasting seconds to minutes. 
Typically presents in middle or old age. Pain is often stimulated at trigger 
points. Sensory deficit cannot be demonstrated. Must be distinguished from 
other forms of facial pain arising from diseases of jaw, teeth, or sinuses. Rare 
causes are herpes zoster or a tumor. Onset in young adulthood or if bilateral 
raises the possibility of multiple sclerosis (Chap. 202).
Trigeminal Neuralgia
TREATMENT
• Carbamazepine is effective in 50–75% of cases. Begin at 100-mg single 
daily dose taken with food and advance by 100 mg every 1–2 days until 
substantial (50%) pain relief occurs. Most pts require 200 mg four times 
a day; doses >1200 mg daily usually provide no additional benefit. 
SECTION 14
1244
Neurology
• Oxcarbazepine (300–1200 mg bid) is an alternative with less bone 
marrow toxicity and probably similar efficacy.
• For nonresponders, lamotrigine (400 mg daily) or phenytoin (300–
400 mg/d) can be tried. 
• When medications fail, surgical microvascular decompression to 
relieve pressure on the trigeminal nerve can be offered. 
• Other options include gamma knife radiosurgery and radiofrequency 
thermal rhizotomy.
Trigeminal Neuropathy 
Usually presents as facial sensory loss or weakness of jaw muscles. Causes 
are varied (Table 199-1), including tumors of middle cranial fossa or tri-
geminal nerve, metastases to base of skull, or lesions in cavernous sinus 
(affecting first and second divisions of fifth nerve) or superior orbital fissure 
(affecting first division of fifth nerve).
� FACIAL WEAKNESS [FACIAL NERVE (VII)] (SEE FIG. 199-2)
Look for hemifacial weakness that includes muscles of forehead and orbi-
cularis oculi. If lesion is in middle ear portion, taste is lost over the anterior 
two-thirds of tongue and there may be hyperacusis; if lesion is at internal 
auditory meatus, there may be involvement of auditory and vestibular 
nerves; pontine lesions usually affect abducens nerve and often cortico-
spinal tract. Peripheral nerve lesions with incomplete recovery may pro-
duce continuous contractions of affected musculature (facial myokymia); 
contraction of all facial muscles on attempts to move one group selectively 
(synkinesis); hemifacial spasms; or anomalous tears when facial muscles 
activated as in eating (crocodile tears).
M
a
xillar
y (
V2)
 
C2
C3
C4
O
phth
a
l
m
i
c
 (
V1
)
 
Mand
i
b
u
l
ar 
(V3) 
FIGURE 199-1 The three major sensory divisions of the trigeminal nerve consist of 
the ophthalmic, maxillary, and mandibular nerves.
CHAPTER 199 1245
Cranial Nerve Disorders
Lacrimal gland
Sublingual gland
Submandibular gland
Submandibular
ganglion
Nucleus
fasciculus
solitarius
Motor nucleus
VII n.
Motor nucleus
VI n.
Superior
salivatory
nucleus
Fasciculus
solitarius
Geniculate
ganglion
Trigeminal
ganglion
Major superficial
petrosal nerve
Pterygopalatine
ganglion
Lingual
nerve
Chorda
tympani
To nasal and
palatine glands
VII n.
V n.
1
2
3
B
C
A
FIGURE 199-2 The facial nerve. A, B, and C denote lesions of the facial nerve at the 
stylomastoid foramen, distal and proximal to the geniculate ganglion, respectively. 
Green lines indicate the parasympathetic fibers, red lines indicate motor fibers, and 
purple lines indicate visceral afferent fibers (taste). (Adapted from MB Carpenter: Core
Text of Neuroanatomy, 2nd ed. Baltimore, Williams & Wilkins, 1978.)
TABLE 199-1 TRIGEMINAL NERVE DISORDERS
Nuclear (brainstem) lesions
Peripheral nerve lesions
 Multiple sclerosis
 Nasopharyngeal carcinoma
 Stroke
 Trauma
 Syringobulbia
 Guillain-Barré syndrome
 Glioma
 Sjögren’s syndrome
 Lymphoma
 Collagen-vascular diseases
Preganglionic lesions
 Sarcoidosis
 Acoustic neuroma
 Leprosy
 Meningioma
 Drugs (stilbamidine, trichloroethylene)
 Metastasis
 Idiopathic trigeminal neuropathy
 Chronic meningitis
 Cavernous carotid aneurysm
Gasserian ganglion lesions
 Trigeminal neuroma
 Herpes zoster
  Infection (spread from otitis 
media or mastoiditis)
SECTION 14
1246
Neurology
Bell’s Palsy 
Most common form of idiopathic facial paralysis; affects 1 in 60 persons over 
a lifetime. Association with herpes simplex virus type 1. Weakness evolves 
with maximal weakness by 48 h, sometimes preceded by retroaural pain. 
Hyperacusis may be present. Full recovery within several weeks or months in 
80%; incomplete paralysis in first week is the most favorable prognostic sign.
Diagnosis can be made clinically in pts with (1) a typical presentation, (2) no 
risk factors or preexisting symptoms for other causes of facial paralysis, (3) no 
lesions of herpes zoster in the external ear canal, and (4) a normal neurologic 
examination with the exception of the facial nerve. In uncertain cases, an ESR, 
testing for diabetes mellitus, a Lyme titer, angiotensin-converting enzyme level 
and chest imaging study for possible sarcoidosis, a lumbar puncture for pos-
sible Guillain-Barré syndrome, or MRI scanning may be indicated.
Bell’s Palsy
TREATMENT
• Protect the eye with paper tape to depress the upper eyelid during 
sleep and prevent corneal drying.
• Massage of the weakened muscle may help symptomatically as well
• Prednisone (60–80 mg/d over 5 days, tapered off over the next 
5 days) modestly shortens the recovery period and improves func-
tional outcome.
• Two large randomized trials found no added benefit for valacyclovir 
or acyclovir compared with glucocorticoids alone 
Other Facial Nerve Disorders 
Ramsay Hunt syndrome is caused by herpes zoster infection of geniculate 
ganglion; distinguished from Bell’s palsy by a vesicular eruption in pharynx 
and external auditory canal, and by frequent involvement of eighth cra-
nial nerve. Acoustic neuromas often compress the seventh nerve. Infarcts, 
demyelinating lesions of multiple sclerosis, and tumors are common pontine 
causes. Bilateral facial weakness may occur in Guillain-Barré syndrome, sar-
coidosis, Lyme disease, and leprosy. Hemifacial spasm may occur with Bell’s 
palsy, irritative lesions (e.g., acoustic neuroma, basilar artery aneurysm, 
an aberrant vessel compressing the nerve), or as an idiopathic disorder. 
Blepharospasm consists of involuntary recurrent spasms of both eyelids, 
usually occurring in the elderly and sometimes with associated facial spasm; 
may subside spontaneously. Hemifacial spasm or blepharospasm can be 
treated by injection of botulinum toxin into the orbicularis oculi.
� OTHER CRANIAL NERVE DISORDERS
Disorders of the Sense of Smell 
Olfactory nerve (I) disorders are due to interference with access of the 
odorant to the olfactory neuroepithelium (transport loss), injury to recep-
tor region (sensory loss), or damage to central olfactory pathways (neural 
loss). The causes of olfactory disorders are summarized in Table 199-2); 
most common other than aging are severe upper respiratory infections, 
CHAPTER 199 1247
Cranial Nerve Disorders
TABLE 199-2  DISORDERS AND CONDITIONS ASSOCIATED WITH 
COMPROMISED OLFACTORY FUNCTION AS MEASURED BY 
OLFACTORY TESTING
22q11 deletion syndrome
Liver disease
AIDS/HIV infection
Lubag disease
Adenoid hypertrophy
Medications
Adrenal cortical insufficiency
Migraine
Age
Multiple sclerosis
Alcoholism
Multi-infarct dementia
Allergies
Narcolepsy with cataplexy
Alzheimer’s disease
Neoplasms, cranial/nasal
Amyotrophic lateral sclerosis
Nutritional deficiencies
Anorexia nervosa
Obesity
Asperger’s syndrome
Obsessive-compulsive disorder
Ataxias
Obstructive pulmonary disease
Attention deficit/hyperactivity disorder
Orthostatic tremor
Bardet-Biedl syndrome
Panic disorder
Chemical exposure
Parkinson’s disease
Chronic obstructive pulmonary disease
Pick’s disease
Congenital
Posttraumatic stress disorder
Cushing’s syndrome
Pregnancy
Cystic fibrosis
Pseudohypoparathyroidism
Degenerative ataxias
Psychopathy
Diabetes
Radiation (therapeutic, cranial)
Down syndrome
Refsum disease
Epilepsy
REM behavior disorder
Facial paralysis
Renal failure/end-stage kidney 
disease
Frontotemporal lobe degeneration
Restless leg syndrome
Gonadal dysgenesis (Turner syndrome)
Rhinosinusitis/polyposis
Guamanian ALS/PD/dementia syndrome
Schizophrenia
Head trauma
Seasonal affective disorder
Herpes simplex encephalitis
Sjögren’s syndrome
Huntington’s disease
Stroke
Hypothyroidism
Tobacco smoking
Iatrogenesis
Toxic chemical exposure
Kallmann syndrome
Upper respiratory infections
Korsakoff’s psychosis
Usher syndrome
Leprosy
Vitamin B12 deficiency
SECTION 14
1248
Neurology
head trauma, and chronic rhinosinusitis. More than half of people between 
65 and 80 years of age suffer from olfactory dysfunction that is idiopathic 
(presbyosmia). Pts often present with a complaint of loss of the sense of taste 
even though their taste thresholds may be within normal limits.
Disorders of the Sense of Smell
TREATMENT
• Therapy for allergic rhinitis, bacterial rhinitis and sinusitis, polyps, 
neoplasms, and structural abnormalities of the nasal cavities is usu-
ally successful in restoring the sense of smell. 
• There is no proven treatment for sensorineural olfactory losses; for-
tunately, spontaneous recovery can occur. 
• Cases due to exposure to cigarette smoke and other airborne toxic 
chemicals can recover if the insult is discontinued.
• A nonblinded study reported that pts with hyposmia may benefit 
from smelling strong odors before going to bed and upon awakening 
over the course of several months
Glossopharyngeal Neuralgia 
This form of neuralgia involves the ninth (glossopharyngeal) and some-
times portions of the tenth (vagus) cranial nerves. Paroxysmal, intense pain 
in tonsillar fossa of throat that may be precipitated by swallowing. There is 
no demonstrable sensory and motor deficit. Other diseases affecting this 
nerve include herpes zoster or compressive neuropathy due to tumor or 
aneurysm in region of jugular foramen (when associated with vagus and 
accessory nerve palsies).
Glossopharyngeal Neuralgia
TREATMENT
• Medical therapy is similar to that for trigeminal neuralgia, and carba-
mazepine is generally the first choice. 
• If drug therapy is unsuccessful, surgical procedures (including 
microvascular decompression, if vascular compression is evident, or 
rhizotomy of glossopharyngeal and vagal fibers in the jugular bulb) 
are frequently successful.
Dysphagia and Dysphonia 
Lesions of the vagus nerve (X) may be responsible. Unilateral lesions pro-
duce drooping of soft palate, loss of gag reflex, and “curtain movement” 
of lateral wall of pharynx with hoarse, nasal voice. Etiologies include 
neoplastic and infectious processes of the meninges, tumors and vascular 
lesions in the medulla, motor neuron disease (e.g., ALS), or compression 
of the recurrent laryngeal nerve by intrathoracic processes. Aneurysm of 
the aortic arch, an enlarged left atrium, and tumors of the mediastinum 
and bronchi are much more frequent causes of an isolated vocal cord palsy 
than are intracranial disorders. A substantial number of cases of recurrent 
laryngeal palsy remain idiopathic.
CHAPTER 199 1249
Cranial Nerve Disorders
With laryngeal palsy, first determine the site of the lesion. If intramedul-
lary, there are usually other brainstem or cerebellar signs. If extramedullary, 
the glossopharyngeal (IX) and spinal accessory (XI) nerves are frequently 
involved (jugular foramen syndrome). If extracranial in the posterior lat-
erocondylar or retroparotid space, there may be combinations of ninth, 
tenth, eleventh, and twelfth cranial nerve palsies and a Horner syndrome. 
If there is no sensory loss over the palate and pharynx and no palatal weak-
ness or dysphagia, lesion is below the origin of the pharyngeal branches, 
which leave the vagus nerve high in the cervical region; the usual site of 
disease is then the mediastinum.
Neck Weakness 
Isolated involvement of the accessory (XI) nerve can occur anywhere along 
its route, resulting in paralysis of the sternocleidomastoid and trapezius 
muscles. More commonly, involvement occurs in combination with defi-
cits of the ninth and tenth cranial nerves in the jugular foramen or after 
exit from the skull. An idiopathic form of accessory neuropathy, akin to 
Bell’s palsy, has been described; most pts recover but it may be recurrent 
in some cases.
Tongue Paralysis 
The hypoglossal (XII) nerve supplies the ipsilateral muscles of the 
tongue. The nucleus of the nerve or its fibers of exit may be involved 
by intramedullary lesions such as tumor, poliomyelitis, or most often 
motor neuron disease. Lesions of the basal meninges and the occipital 
bones (platybasia, invagination of occipital condyles, Paget’s disease) 
may compress the nerve in its extramedullary course or in the hypo-
glossal canal. Isolated lesions of unknown cause can occur. Atrophy and 
fasciculation of the tongue develop weeks to months after interruption 
of the nerve.
� MULTIPLE CRANIAL NERVE PALSIES
Multiple Cranial Nerve Palsies
APPROACH TO THE
PATIENT
First determine whether the process is within the brainstem or outside it. 
Lesions on the surface of the brainstem tend to involve adjacent cranial 
nerves in succession with only late and slight involvement of long sensory 
and motor pathways. The opposite is true of processes within the brain-
stem. Involvement of multiple cranial nerves outside of the brainstem 
may be due to trauma, localized infections including varicella zoster 
virus, infectious and noninfectious (especially carcinomatous) causes of 
meningitis; granulomatous diseases such as Wagener’s, Behçet’s disease, 
vascular disorders including those associated with diabetes, enlarging sac-
cular aneurysms, or locally infiltrating tumors. A purely motor disorder 
without atrophy raises the question of myasthenia gravis. Facial diplegia 
is common in Guillain-Barré syndrome. Ophthalmoplegia may occur with 
Guillain-Barré syndrome (Fisher variant) or Wernicke’s encephalopathy.
SECTION 14
1250
Neurology
The cavernous sinus syndrome (Fig. 199-3) is frequently life-threat-
ening. It often presents as orbital or facial pain; orbital swelling and 
chemosis; fever; oculomotor neuropathy; and trigeminal neuropathy 
affecting the ophthalmic (V1) and occasionally maxillary (V2) divi-
sions. Cavernous sinus thrombosis, often secondary to infection from 
orbital cellulitis, a cutaneous source on the face, or sinusitis, is the most 
frequent cause; other etiologies include aneurysm of the carotid artery, 
a carotid-cavernous fistula (orbital bruit may be present), meningioma, 
nasopharyngeal carcinoma, other tumors, or an idiopathic granulo-
matous disorder (Tolosa-Hunt syndrome). In infectious cases, prompt 
administration of broad-spectrum antibiotics, drainage of any abscess 
cavities, and identification of the offending organism are essential. 
Anticoagulant therapy may benefit cases of primary thrombosis. Repair 
or occlusion of the carotid artery may be required for treatment of 
fistulas or aneurysms. Tolosa-Hunt syndrome generally responds to 
glucocorticoids.
Ant. cerebral a.
Int. carotid a.
Ant. clinoid process
Subarachnoid
space
Oculomotor (III) n.
Trochlear (IV) n.
Ophthalmic (VI) n.
Abducens (VI) n.
Maxillary (V2) n.
Pia
Dura
Arachnoid
Sphenoid
  sinus
Optic
  chiasma
Hypophysis
FIGURE 199-3 Anatomy of the cavernous sinus in coronal section, illustrating the 
location of the cranial nerves in relation to the vascular sinus, internal carotid artery 
(which loops anteriorly to the section), and surrounding structures.
For a more detailed discussion, see Beal MF, Hauser SL: 
Trigeminal Neuralgia, Bell’s Palsy, and Other Cranial Nerve 
Disorders, Chap. 376, p. 3360; and Doty RL, Bromley 
SM: Disorders of Smell and Taste, Chap. 29, p. 241, in 
HPIM-18.
CHAPTER 200 1251
Spinal Cord Diseases
CHAPTER 200
Spinal Cord Diseases
Spinal cord disorders can be devastating, but many are treatable if recog-
nized early (Table 200-1). Knowledge of relevant spinal cord anatomy is 
often the key to correct diagnosis (Fig. 200-1). 
� SYMPTOMS AND SIGNS
Sensory symptoms often include paresthesias; may begin in one or both 
feet and ascend. Sensory level to pin sensation or vibration often cor-
relates well with location of transverse lesions. May have isolated pain/
temperature sensation loss over the shoulders (“cape” or “syringomyelic” 
pattern) or loss of sensation to vibration/position on one side of the 
body and pain/temperature loss on the other (Brown-Séquard hemicord 
syndrome).
Motor symptoms are caused by disruption of corticospinal tracts that 
leads to quadriplegia or paraplegia with increased muscle tone, hyperactive 
deep tendon reflexes, and extensor plantar responses. With acute severe 
lesions there may be initial flaccidity and areflexia (spinal shock).
Autonomic dysfunction includes primarily urinary retention; should 
raise suspicion of spinal cord disease when associated with back or neck 
pain, weakness, and/or a sensory level.
Pain may be present. Midline back pain is of localizing value; interscapu-
lar pain may be first sign of midthoracic cord compression; radicular pain 
may mark site of more laterally placed spinal lesion; pain from lower cord 
(conus medullaris) lesion may be referred to low back.
� SPECIFIC SIGNS BY SPINAL CORD LEVEL
Approximate indicators of level of lesion include the location of a sensory 
level, a band of hyperalgesia/hyperpathia at the upper end of the sensory 
disturbance, identification of isolated atrophy or fasciculations, or lost ten-
don reflex at a specific spinal cord segment.
Lesions Near the Foramen Magnum 
Weakness of the ipsilateral shoulder and arm, followed by weakness of 
ipsilateral leg, then contralateral leg, then contralateral arm, with respira-
tory paralysis.
Cervical Cord 
Best localized by noting pattern of motor weakness and areflexia; shoulder 
(C5), biceps (C5–6), brachioradialis (C6), triceps/finger and wrist extensors 
(C7), finger and wrist flexors (C8).
Thoracic Cord 
Localized by identification of a sensory level on the trunk. Useful markers 
are the nipples (T4) and umbilicus (T10). 
SECTION 14
1252
Neurology
TABLE 200-1 TREATABLE SPINAL CORD DISORDERS
Compressive
Epidural, intradural, or intramedullary neoplasm
Epidural abscess
Epidural hemorrhage
Cervical spondylosis
Herniated disk
Posttraumatic compression by fractured or displaced vertebra or hemorrhage
Vascular
Arteriovenous malformation
Antiphospholipid syndrome and other hypercoagulable states
Inflammatory
Multiple sclerosis
Neuromyelitis optica
Transverse myelitis
Sarcoidosis
Sjögren’s syndrome myelopathy
Systemic lupus erythematosus
Vasculitis
Infectious
Viral: VZV, HSV-1 and -2, CMV, HIV, HTLV-I, others
Bacterial and mycobacterial: Borrelia, Listeria, syphilis, others
Mycoplasma pneumoniae
Parasitic: schistosomiasis, toxoplasmosis
Developmental
Syringomyelia
Meningomyelocele
Tethered cord syndrome
Metabolic
Vitamin B12 deficiency (subacute combined degeneration)
Copper deficiency
Abbreviations: CMV, cytomegalovirus; HSV, herpes simplex virus; HTLV, human T cell lympho-
tropic virus; VZV, varicella-zoster virus.
Lumbar Cord 
Upper lumbar cord lesions paralyze hip flexion and knee extension and 
abolish the patella reflex, whereas lower lumbar lesions affect foot and 
ankle movements, knee flexion, and thigh extension, and abolish the 
ankle jerks.
CHAPTER 200 1253
Spinal Cord Diseases
Sacral Cord (Conus Medullaris) 
Saddle anesthesia, early bladder/bowel dysfunction, impotence; muscle 
strength is largely preserved.
Cauda Equina (Cluster of Nerve Roots Derived from Lower Cord) 
Lesions below spinal cord termination at the L1 vertebral level produce a flac-
cid, areflexic, asymmetric paraparesis with bladder/bowel dysfunction and 
sensory loss below L1; pain is common and projected to perineum or thighs.
� INTRAMEDULLARY AND EXTRAMEDULLARY SYNDROMES
Spinal cord disorders may be intramedullary (arising from within the substance 
of the cord) or extramedullary (compressing the cord or its blood supply). 
Extramedullary lesions often produce radicular pain, early corticospinal signs, 
and sacral sensory loss. Intramedullary lesions produce poorly localized burning 
pain, less prominent corticospinal signs, and often spare perineal/sacral sensation.
� ACUTE AND SUBACUTE SPINAL CORD DISEASES (SEE CHAP. 21)
Neoplastic spinal cord compression (Chap. 21): Most are epidural in origin, 
resulting from metastases to the adjacent spinal bones (Fig. 200-2). Almost 
any tumor can be responsible: breast, lung, prostate, lymphoma, and plasma 
Anterior horn
(motor neurons)
Lateral
corticospinal
(pyramidal) tract
Dorsal root
Dorsal 
spinocerebellar
tract
Ventral
spinocerebellar
tract
Lateral
spinothalamic
tract
C
T
L S
Ventral
spinothalamic
tract
Pressure, touch
(minor role)
Ventral
(uncrossed)
corticospinal
tract
Tectospinal
tract
S L T C
C
T
L
S
Fasciculus
cuneatus
Rubrospinal
tract
Lateral
reticulospinal
tract
Vestibulospinal
tract
Ventral 
root
Axial and 
proximal
limb 
movements
(Joint Position, Vibration, Pressure)
Posterior Columns
Distal limb
movements
(minor role)
Pain, 
temperature
Ventral
reticulospinal
tract
Fasciculus
gracilis
S
L T C
Distal limb
movements
L/
S
L/
S
P
E
D
F
FIGURE 200-1 Transverse section through the spinal cord, composite representa-
tion, illustrating the principal ascending (left) and descending (right) pathways. The 
lateral and ventral spinothalamic tracts ascend contralateral to the side of the body 
that is innervated. C, cervical; D, distal; E, extensors; F, flexors; L, lumbar; P, proximal; 
S, sacral; T, thoracic.
SECTION 14
1254
Neurology
cell dyscrasias most frequent. Thoracic cord most commonly involved. 
Initial symptom is usually back pain, worse when recumbent, with local 
tenderness preceding other symptoms by many weeks. Spinal cord com-
pression due to metastases is a medical emergency; in general, therapy will 
not reverse paralysis of >48 h duration.
Spinal epidural abscess: Triad of fever, localized midline dorsal spinal 
pain, and progressive limb weakness; once neurologic signs appear, cord 
compression rapidly progresses.
Spinal epidural hematoma: Presents as focal or radicular pain followed by 
variable signs of a spinal cord or conus medullaris disorder.
Acute disk herniation: Cervical and thoracic disk herniations are less 
common than lumbar.
Spinal cord infarction: Anterior spinal artery infarction produces paraple-
gia or quadriplegia, sensory loss affecting pain/temperature but sparing 
vibration/position sensation (supplied by posterior spinal arteries), and 
loss of sphincter control. Onset sudden or evolving over minutes or a few 
hours. Associated conditions: aortic atherosclerosis, dissecting aortic aneu-
rysm, vertebral artery occlusion or dissection in the neck, aortic surgery, or 
profound hypotension. Therapy is directed at the predisposing condition.
Immune-mediated myelopathies: Acute transverse myelopathy (ATM) 
occurs in 1% of pts with SLE; associated with antiphospholipid antibod-
ies. Sjögren’s and Behçet’s syndromes, mixed connective tissue disease, 
and p-ANCA vasculitis are other causes. Sarcoid can produce ATM with 
FIGURE 200-2 Epidural spinal cord compression due to breast carcinoma. Sagittal 
T1-weighted A. and T2-weighted B. MRI scans through the cervicothoracic junction 
reveal an infiltrated and collapsed second thoracic vertebral body with posterior dis-
placement and compression of the upper thoracic spinal cord. The low-intensity bone 
marrow signal in (A ) signifies replacement by tumor.
CHAPTER 200 1255
Spinal Cord Diseases
large edematous swelling of the spinal cord. Demyelinating diseases, either 
neuromyelitis optica (NMO) or multiple sclerosis, also can present as ATM; 
glucocorticoids, consisting of IV methylprednisolone followed by oral pred-
nisone, are indicated for moderate to severe symptoms and refractory cases 
may respond to plasma exchange (Chap. 202). Treatment with mycopheno-
late mofetil (250 mg bid gradually increasing to 1000 mg bid) or anti-CD20 
monoclonal antibody may protect against relapses in NMO. Other cases of 
ATM are idiopathic.
Infectious myelopathies: Herpes zoster is the most common viral agent, 
but herpes simplex virus types 1 and 2, EBV, CMV, and rabies virus are 
also well described; in cases of suspected viral myelitis, antivirals may 
be appropriately started pending laboratory confirmation. Bacterial and 
mycobacterial causes are less common. Schistosomiasis is an important 
cause worldwide.
� CHRONIC MYELOPATHIES
Spondylitic myelopathies: One of the most common causes of gait difficulty 
in the elderly. Presents as neck and shoulder pain with stiffness, radicular 
arm pain, and progressive spastic paraparesis with paresthesias and loss of 
vibration sense; in advanced cases, urinary incontinence may occur. A ten-
don reflex in the arms is often diminished at some level. Diagnosis is best 
made by MRI. Treatment is surgical (Chap. 54).
Vascular malformations: An important treatable cause of progressive or 
episodic myelopathy. May occur at any level; diagnosis is often suggested by 
contrast-enhanced MRI (Fig. 200-3), but is confirmed by selective spinal 
angiography. Treatment is embolization with occlusion of the major feed-
ing vessels.
Retrovirus-associated myelopathies: Infection with HTLV-I may produce 
a slowly progressive spastic paraparesis with variable pain, sensory loss, and 
bladder disturbance; diagnosis is made by demonstration of specific serum 
antibody. Treatment is symptomatic. A progressive vacuolar myelopathy 
may also result from HIV infection.
Syringomyelia: Cavitary expansion of the spinal cord resulting in progres-
sive myelopathy; may be an isolated finding or associated with protrusion of 
cerebellar tonsils into cervical spinal canal (Chiari type 1). Classic presentation 
is loss of pain/temperature sensation in the neck, shoulders, forearms, or hands 
with areflexic weakness in the upper limbs and progressive spastic parapare-
sis; cough headache, facial numbness, or thoracic kyphoscoliosis may occur. 
Diagnosis is made by MRI; treatment is surgical and often unsatisfactory.
Multiple sclerosis: Spinal cord involvement is common and is a major 
cause of disability in progressive forms of MS (Chap. 202).
Subacute combined degeneration (vitamin B12 deficiency): Paresthesias in 
hands and feet, early loss of vibration/position sense, progressive spastic/
ataxic weakness, and areflexia due to associated peripheral neuropathy; 
mental changes (“megaloblastic madness”) and optic atrophy may be pres-
ent along with a serum macrocytic anemia. Diagnosis is confirmed by a low 
serum B12 level, elevated levels of homocysteine and methylmalonic acid. 
Treatment is vitamin replacement beginning with 1 mg of IM vitamin B12 
repeated at regular intervals or by subsequent oral treatment.
SECTION 14
1256
Neurology
Hypocupric myelopathy: Clinically nearly identical to subacute combined 
degeneration (above). Low levels of serum copper and usually ceruloplas-
min make the diagnosis. Some cases idiopathic and others follow GI pro-
cedures that hinder absorption. Treatment is oral copper supplementation.
Tabes dorsalis (tertiary syphilis): May present as lancinating pains, gait 
ataxia, bladder disturbances, and visceral crises. Cardinal signs are areflexia 
in the legs, impaired vibration/position sense, Romberg sign, and Argyll 
Robertson pupils, which fail to constrict to light but accommodate.
Familial spastic paraplegia: Progressive spasticity and weakness in the 
legs occurring on a familial basis; may be autosomal dominant, recessive, 
or X-linked. More than 20 different loci identified.
Adrenomyeloneuropathy: X-linked disorder that is a variant of adrenoleu-
kodystrophy. Usually affected males have a history of adrenal insufficiency 
and then develop a progressive spastic paraparesis. Female heterozygotes 
may develop a slower progressive myelopathy without adrenal insuffi-
ciency. Diagnosis made by elevated very long chain fatty acids in serum. 
FIGURE 200-3  Arteriovenous malformation. Sagittal MR scans of the thoracic spinal 
cord: T2 fast spin-echo technique (left) and T1 post-contrast image (right). On the 
T2-weighted image (left), abnormally high signal intensity is noted in the central 
aspect of the spinal cord (arrowheads). Numerous punctate flow voids indent the 
dorsal and ventral spinal cord (arrow). These represent the abnormally dilated venous 
plexus supplied by the dural arteriovenous fistula. After contrast administration (right), 
multiple, serpentine, enhancing veins (arrows) on the ventral and dorsal aspect of the 
thoracic spinal cord are visualized, diagnostic of arteriovenous malformation. This pt 
was a 54-year-old man with a 4-year history of progressive paraparesis.
CHAPTER 201 1257
Tumors of the Nervous System 
No therapy is clearly effective although bone marrow transplantation and 
nutritional supplements have been tried.
� COMPLICATIONS
Bladder dysfunction with risk of urinary tract infection; bowel dysmotility; 
pressure sores; in high cervical cord lesions, mechanical respiratory failure; 
paroxysmal hypertension or hypotension with volume changes; severe 
hypertension and bradycardia in response to noxious stimuli or bladder or 
bowel distention; venous thrombosis and pulmonary embolism.
For a more detailed discussion, see Hauser SL, Ropper 
AH: Diseases of the Spinal Cord, Chap. 377, p. 3366, in 
HPIM-18.
CHAPTER 201
Tumors of the 
Nervous System
Tumor of the Nervous System
APPROACH TO THE
PATIENT
Clinical Presentation: Brain tumors of any type can present with 
general and/or focal symptoms and signs. General nonspecific symptoms 
include headache, cognitive difficulties, personality change, and gait 
disorder. The classic headache associated with a brain tumor is most 
evident in the morning and improves during the day, but this pattern 
is actually seen in only a minority of pts. Papilledema may suggest 
elevated intracranial pressure. Focal symptoms and signs include 
hemiparesis, aphasia, or visual field deficit that are typically subacute 
and progressive. Seizures are a common presentation, occurring 
in about 25% of pts with brain metastases or malignant glioma. 
Evaluation: Primary brain tumors have no serologic features of 
malignancy such as an elevated ESR or tumor-specific antigens, unlike 
metastases. Cranial MRI with contrast is the preferred diagnostic test 
for any pt suspected of having a brain tumor; CT should be reserved 
for those pts unable to undergo MRI. Malignant brain tumors typically 
enhance with contrast and may have central areas of necrosis; they are 
characteristically surrounded by edema of the neighboring white matter. 
Low-grade gliomas typically do not enhance. Additional testing such 
as cerebral angiogram, EEG, or lumbar puncture is rarely indicated or 
helpful.
SECTION 14
1258
Neurology
Tumors of the Nervous System
TREATMENT
SYMPTOMATIC TREATMENT
• Glucocorticoids (dexamethasone 12–16 mg/d in divided doses PO or 
IV) to temporarily reduce edema 
• Anticonvulsants (levetiracetam, topiramate, lamotrigine, valproic 
acid, or lacosamide) for pts who present with seizures; there is no role 
for prophylactic anticonvulsant drugs
• Low-dose SC heparin for immobile pts
DEFINITIVE TREATMENT
• Based on the specific tumor types and includes surgery, radiotherapy 
(RT), and chemotherapy
� PRIMARY INTRACRANIAL TUMORS
Astrocytomas 
Infiltrative tumors with a presumptive glial cell of origin. Most common 
primary intracranial neoplasm. Only known risk factors are ionizing radiation 
and uncommon hereditary syndromes (neurofibromatosis, tuberous sclero-
sis). Infiltration along white matter pathways often prevents total resection. 
Imaging studies (Fig. 201-1) fail to indicate full tumor extent. Grade I tumors 
(pilocytic astrocytomas) are the most common tumor of childhood, typically 
in the cerebellum; can be cured if completely resected. Grade II astrocytomas 
usually present with seizures in young adults; if feasible should be surgically 
resected. RT and chemotherapeutic agents such as temozolomide are increas-
ingly used and may be helpful. Grade III (anaplastic astrocytoma) and grade 
IV (glioblastoma) astrocytomas are treated similarly with maximal safe surgi-
cal resection followed by RT with concurrent and adjuvant temozolomide or 
with RT and adjuvant temozolomide alone. Median survival in glioblastoma 
is 12–15 months. Glioblastomas invariably recur and treatment options 
include reoperation, carmustine wafer implantation, and chemotherapeutic 
regimens including bevacizumab. The most important adverse prognos-
tic factors in high-grade astrocytomas are older age, histologic features of 
glioblastoma, poor performance status, and unresectable tumor. 
Oligodendrogliomas
Generally more responsive to therapy and have a better prognosis than pure 
astrocytic tumors. Usually nonenhancing; often partially calcified. Treated 
with surgery and, if necessary, RT and chemotherapy. Median survival in 
excess of 10 years. Chemotherapy response improved when deletions of 
chromosomes 1p and 19q present.
Ependymomas
Derived from ependymal cells; highly cellular. Location—spinal canal 
more than intracranial in adults. If total excision possible, may be curable. 
Partially resected tumors will recur and require irradiation.
Primary CNS Lymphomas 
B cell malignancy; most occur in immunosuppressed pts (organ trans-
plantation, AIDS). May present as a single mass lesion or as multiple mass 
CHAPTER 201 1259
Tumors of the Nervous System 
lesions or meningeal disease. Dramatic, transient responses occur with 
glucocorticoids; therefore whenever possible steroids should be withheld 
until after biopsy has been obtained. Pts should be tested for HIV and the 
extent of disease assessed by performing PET or CT of the body, MRI of 
the spine, CSF analysis, and slit-lamp examination of the eye. In immuno-
competent pts, high-dose methotrexate therapy produces median survival 
up to 50 months, which may be increased with concurrent whole-brain 
RT and additional combinations of other chemotherapeutic agents such as 
cytarabine or rituximab. In immunocompromised pts, prognosis is worse 
and treatment is with high-dose methotrexate, whole-brain RT, and, in HIV, 
antiretroviral therapy. 
Medulloblastomas
Most common malignant brain tumor of childhood. Half in posterior fossa; 
highly cellular; derived from neural precursor cells. Treat with surgery, RT, 
and chemotherapy. Approximately 70% of pts have long-term survival but 
usually at the cost of significant neurocognitive impairment. 
FIGURE 201-1 Postgadolinium T1 MRI of a large cystic left frontal glioblastoma.
SECTION 14
1260
Neurology
FIGURE 201-2 Postgadolinium T1 MRI demonstrating multiple meningiomas along 
the falx and left parietal cortex.
Meningiomas
The most common primary brain tumor. Extraaxial mass attached to dura; 
dense and uniform contrast enhancement is diagnostic (Fig. 201-2). Total 
surgical resection of large, symptomatic benign meningiomas is curative. 
With subtotal resection, local RT reduces recurrence. Small, asymptomatic 
meningiomas may be followed radiologically without surgery. Treat rare 
aggressive meningiomas with excision and RT.
Schwannomas
Vestibular schwannomas present as progressive, unexplained unilateral 
hearing loss. MRI reveals dense, uniformly enhancing tumor at the cerebel-
lopontine angle. Surgical excision may preserve hearing.
� TUMORS METASTATIC TO THE NERVOUS SYSTEM
Hematogenous spread most common. Skull metastases rarely invade CNS; 
may compress adjacent brain or cranial nerves or obstruct intracranial 
venous sinuses. Primary tumors that commonly metastasize to the nervous 
system are listed in Table 201-1. Brain metastases are well demarcated 
CHAPTER 201 1261
Tumors of the Nervous System 
TABLE 201-1  FREQUENCY OF NERVOUS SYSTEM METASTASES BY 
COMMON PRIMARY TUMORS
Brain %
LM %
ESCC %
Lung
41
17
15
Breast
19
57
22
Melanoma
10
12
 4
Prostate
 1
 1
10
GIT
 7
—
 5
Renal
 3
 2
 7
Lymphoma
<1
10
10
Sarcoma
 7
 1
 9
Other
11
—
18
Abbreviations: ESCC, epidural spinal cord compression; GIT, gastrointestinal tract; LM, 
leptomeningeal metastases.
by MRI and enhance with gadolinium. Ring enhancement is nonspecific; 
differential diagnosis includes brain abscess, radiation necrosis, toxo-
plasmosis, granulomas, tuberculosis, sarcoidosis, demyelinating lesions, 
primary brain tumors, CNS lymphoma, stroke, hemorrhage, and trauma. 
Screen for occult cancer: examine skin and thyroid gland; blood carcino-
embryonic antigen (CEA) and liver function tests; CT of chest, abdomen, 
and pelvis. In approximately 10% of pts, a systemic cancer may present with 
brain metastases; biopsy of primary tumor or accessible brain metastasis is 
needed to plan treatment. Treatment with glucocorticoids, anticonvulsants, 
RT, or surgery. Whole-brain RT is often given because multiple microscopic 
tumor deposits are likely throughout the brain; stereotaxic radiosurgery is 
of benefit in pts with three or fewer metastases demonstrated by MRI. If a 
single metastasis is found, it may be surgically excised followed by whole-
brain RT. Systemic chemotherapy may produce dramatic responses in rare 
cases of a highly chemosensitive tumor type such as germ cell tumors.
Leptomeningeal Metastases 
Presents as headache, encephalopathy, cranial nerve or polyradicular 
symptoms. Diagnosis by CSF cytology, MRI (nodular meningeal tumor 
deposits or diffuse meningeal enhancement), or meningeal biopsy. 
Associated with hydrocephalus due to CSF pathway obstruction. Treatment 
is palliative, often with RT or chemotherapy. 
Spinal Cord Compression from Metastases 
(See Chap. 21) Expansion of vertebral body metastasis posteriorly into 
epidural space compresses cord. Most common primary tumors are lung, 
breast, or prostate primary. Back pain (>90%) precedes development 
of weakness, sensory level, or incontinence. Medical emergency; early 
recognition of impending spinal cord compression essential to avoid devas-
tating sequelae. Diagnosis is by spine MRI.
SECTION 14
1262
Neurology
� COMPLICATIONS OF RADIATION THERAPY
Three patterns of radiation injury after CNS RT:
1. Acute—headache, sleepiness, worse neurologic deficits during or immedi-
ately after RT. Rarely seen with current protocols. Can be both prevented 
and treated with glucocorticoids.
2. Early delayed—somnolence (children), Lhermitte’s sign; within weeks to 
months of RT. Increased T2 signal and sometimes enhancement on MRI. 
Self-limited and improves with glucocorticoids.
3. Late delayed—dementia or other progressive neurologic deficits; 
typically months to years after RT. White matter abnormalities on MRI 
(leukoencephalopathy) or ring-enhancing mass (radiation necrosis). 
PET can distinguish delayed necrosis from tumor recurrence. Progressive 
radiation necrosis is best treated palliatively with surgical resection unless 
it can be managed with glucocorticoids. Radiation injury of large arteries 
accelerates the development of atherosclerosis, increasing the risk of 
stroke years after RT. Endocrine dysfunction due to hypothalamus or 
pituitary gland injury can be due to delayed effects of RT. Development 
of a second neoplasm after RT also is a risk years after exposure.
For a more detailed discussion, see DeAngelis LM, Wen 
PY: Primary and Metastatic Tumors of the Nervous System, 
Chap. 379, p. 3382, in HPIM-18.
CHAPTER 202
Multiple Sclerosis (MS)
Characterized by chronic inflammation and selective destruction of CNS 
myelin; peripheral nervous system is spared. Pathologically, the multifocal 
scarred lesions of MS are termed plaques. Etiology is thought to be autoim-
mune, with susceptibility determined by genetic and environmental factors. 
MS affects 350,000 Americans; onset is most often in early to middle 
adulthood, and women are affected approximately three times as often as men.
� CLINICAL FEATURES
Onset may be abrupt or insidious. Some pts have symptoms that are so trivial 
that they may not seek medical attention for months or years. Most com-
mon are recurrent attacks of focal neurologic dysfunction, typically lasting 
weeks or months, and followed by variable recovery; some pts initially 
present with slowly progressive neurologic deterioration. Symptoms often 
transiently worsen with fatigue, stress, exercise, or heat. Manifestations of 
MS are protean but commonly include weakness and/or sensory symptoms 
involving a limb, visual difficulties, abnormalities of gait and coordination, 
urinary urgency or frequency, and abnormal fatigue. Motor involvement 
can present as a heavy, stiff, weak, or clumsy limb. Localized tingling, “pins 
CHAPTER 202 1263
Multiple Sclerosis (MS)
and needles,” and “dead” sensations are common. Optic neuritis can result 
in blurring of vision, especially in the central visual field, often with associ-
ated retroorbital pain accentuated by eye movement. Involvement of the 
brainstem may result in diplopia, nystagmus, vertigo, or facial pain, numb-
ness, weakness, hemispasm, or myokymia (rippling muscular contractions). 
Ataxia, tremor, and dysarthria may reflect disease of cerebellar pathways. 
Lhermitte’s symptom, a momentary electric shock–like sensation evoked by 
neck flexion, indicates disease in the cervical spinal cord. Diagnostic criteria 
are listed in Table 202-1; MS mimics are summarized in Table 202-2.
� PHYSICAL EXAMINATION
Abnormal signs usually more widespread than expected from the history. 
Check for abnormalities in visual fields, loss of visual acuity, disturbed color 
perception, optic pallor or papillitis, afferent pupillary defect (paradoxical 
dilation to direct light following constriction to consensual light), nystagmus, 
internuclear ophthalmoplegia (slowness or loss of adduction in one eye 
with nystagmus in the abducting eye on lateral gaze), facial numbness or 
weakness, dysarthria, weakness and spasticity, hyperreflexia, ankle clonus, 
upgoing toes, ataxia, sensory abnormalities.
� DISEASE COURSE
Four general categories:
• Relapsing-remitting MS (RRMS) is characterized by recurrent attacks of 
neurologic dysfunction with or without recovery; between attacks, no 
progression of neurologic impairment is noted. Accounts for 85% of 
new-onset MS cases.
• Secondary progressive MS (SPMS) always initially presents as RRMS but 
evolves to be gradually progressive. The majority of RRMS eventually 
evolves into SPMS (~2% each year).
• Primary progressive MS (PPMS) is characterized by gradual progression of 
disability from onset without discrete attacks; 15% of new-onset MS cases.
• Progressive-relapsing MS (PRMS) is a rare form that begins with a 
primary progressive course, but later superimposed relapses occur.
MS is a chronic illness; 15 years after diagnosis, only 20% of pts have no 
functional limitation; one-third to one-half will have progressed to SPMS 
and will require assistance with ambulation.
� LABORATORY EVALUATION
MRI reveals multifocal bright areas on T2-weighted sequences in >95% of 
pts, often in periventricular location; gadolinium enhancement indicates 
acute lesions with disruption of blood-brain barrier (Fig. 202-1). MRI also 
useful to exclude MS mimics, although findings in MS are not completely 
specific for the disorder. CSF findings include mild lymphocytic pleocytosis 
(5–75 cells in 25%), oligoclonal bands (75–90%), elevated IgG (80%), and 
normal total protein level. Visual, auditory, and somatosensory evoked 
response tests can identify lesions that are clinically silent; one or more 
evoked response tests abnormal in 80–90% of pts. Urodynamic studies 
aid in management of bladder symptoms.
SECTION 14
1264
Neurology
TABLE 202-1 DIAGNOSTIC CRITERIA FOR MS
Clinical Presentation
Additional Data Needed for MS Diagnosis
2 or more attacks; objec-
tive clinical evidence of 2 
or more lesions or objective 
clinical evidence of 1 lesion 
with reasonable historical 
evidence of a prior attack
None
2 or more attacks; objective 
clinical evidence of 1 lesion
Dissemination in space, demonstrated by
• ≥1 T2 lesion on MRI in at least two out of four 
MS-typical regions of the CNS (periventricular, 
juxtacortical, infratentorial, or spinal cord)
or
•  Await a further clinical attack implicating a 
different CNS site
1 attack; objective 
clinical evidence of 2 or 
more lesions
Dissemination in time, demonstrated by
•  Simultaneous presence of asymptomatic 
gadolinium-enhancing and -nonenhancing 
lesions at any time
or
•  A new T2 and/or gadolinium-enhancing 
lesion(s) on follow-up MRI, irrespective of 
its timing with reference to a baseline scan
or
•  Await a second clinical attack
1 attack; objective clinical 
evidence of 1 lesion 
(clinically isolated syndrome)
Dissemination in space and time, demonstrated by:
For dissemination in space
• ≥1 T2 lesion in at least two out of four MS-
typical regions of the CNS (periventricular, 
juxtacortical, infratentorial, or spinal cord)
or
•  Await a second clinical attack implicating 
a different CNS site
and
For dissemination in time
•  Simultaneous presence of asymptomatic 
gadolinium-enhancing and -nonenhancing 
lesions at any time
or
•  A new T2 and/or gadolinium-enhancing 
lesion(s) on follow-up MRI, irrespective of its 
timing with reference to a baseline scan
or
•  Await a second clinical attack
(continued)
1265
CHAPTER 202
TABLE 202-1 DIAGNOSTIC CRITERIA FOR MS (CONTINUED)
Clinical Presentation
Additional Data Needed for MS Diagnosis
Insidious neurologic 
progression suggestive of 
MS (PPMS)
1 year of disease progression (retrospectively 
or prospectively determined)
plus
2 out of the 3 following criteria
Evidence for dissemination in space in 
the brain based on ≥1 T2+ lesions in the 
MS-characteristic periventricular, juxtacortical, 
or infratentorial regions
Evidence for dissemination in space in the 
spinal cord based on ≥2 T2+ lesions in the cord
Positive CSF (isoelectric focusing evidence of 
oligoclonal bands and/or elevated IgG index)
Source: From Polman CH et al: Diagnostic criteria for multiple sclerosis: 2010 revisions to 
the “McDonald Criteria.” Ann Neurol 69:292, 2011
TABLE 202-2 DISORDERS THAT CAN MIMIC MS
Acute disseminated encephalomyelitis (ADEM)
Antiphospholipid antibody syndrome
Behçet’s disease
Cerebral autosomal dominant arteriopathy, subcortical infarcts, and 
leukoencephalopathy (CADASIL)
Congenital leukodystrophies (e.g., adrenoleukodystrophy, metachromatic 
leukodystrophy)
Human immunodeficiency virus (HIV) infection
Ischemic optic neuropathy (arteritic and nonarteritic)
Lyme disease
Mitochondrial encephalopathy with lactic acidosis and stroke (MELAS)
Neoplasms (e.g., lymphoma, glioma, meningioma)
Sarcoid
Sjögren’s syndrome
Stroke and ischemic cerebrovascular disease
Syphilis
Systemic lupus erythematosus and related collagen vascular disorders
Tropical spastic paraparesis (HTLV I/II infection)
Vascular malformations (especially spinal dural AV fistulas)
Vasculitis (primary CNS or other)
Vitamin B12 deficiency
Abbreviations: AV, arteriovenous; CNS, central nervous system; HTLV, human T cell 
lymphotropic virus.
Multiple Sclerosis (MS)
SECTION 14
1266
Neurology
Multiple Sclerosis (See Fig. 202-2)
TREATMENT
DISEASE-MODIFYING THERAPIES FOR RELAPSING FORMS OF MS (RRMS, 
SPMS WITH EXACERBATIONS)
• Seven treatments are available in the U.S.: interferon (IFN)-β1a (Avonex; 
30 μg IM once a week), IFN-β1a (Rebif; 44 μg SC thrice weekly), IFN-β1b 
(Betaseron; 250 μg SC every other day), glatiramer acetate (Copaxone; 
A
B
C
D
FIGURE 202-1 MRI findings in MS. A. Axial first-echo image from T2-weighted 
sequence demonstrates multiple bright signal abnormalities in white matter, typical for 
MS. B. Sagittal T2-weighted FLAIR (fluid attenuated inversion recovery) image in which 
the high signal of CSF has been suppressed. CSF appears dark, while areas of brain 
edema or demyelination appear high in signal as shown here in the corpus callosum 
(arrows). Lesions in the anterior corpus callosum are frequent in MS and rare in vascular 
disease. C. Sagittal T2-weighted fast spin echo image of the thoracic spine demonstrates 
a fusiform high-signal-intensity lesion in the midthoracic spinal cord. D. Sagittal T1-
weighted image obtained after the IV administration of gadolinium DPTA reveals focal 
areas of blood-brain barrier disruption, identified as high-signal-intensity regions (arrows).
DECISION-MAKING ALGORITHM FOR RELAPSING-REMITTING MS 
Continue
therapy
Good
response
Intolerant or
poor response
Continue periodic
clinical/ MRI
assessments
No
change
Intolerant or poor response
Natalizumab
Successive trials
of alternatives
Prophylaxis
1. IFN-β1a, or
2. IFN-β1b, or
3. Glatiramer acetate or
4. Fingolimod
Methylprednisolone/
prednisone
Identify and treat any
underlying infection or trauma
Symptomatic
therapy
Exacerbation
Pseudoexacerbation
Acute neurologic change
Stable
Relapsing-Remitting MS
Functional
impairment
No functional
impairment
?- Low attack frequency or
    single attack
?- Normal neurologic exam
?- Low disease burden by MRI
No
Yes
Repeat clinical exam
and MRI in 6 months
A
Clinical or
MRI change
Secondary
progressive MS
With relapses
Without relapses
Consider
1. IFN-β1a, or
2. IFN-β1b
Intolerant or
poor response
1. Mitoxantrone
2. Azathioprine
3. Methotrexate
4. Pulse cyclophosphamide
5. IVIg
6. Pulse methylprednisolone
No proven treatment
Primary
progressive MS
Symptomatic therapy
Progressive MS
Consider Rx with one of the following:
B
DECISION-MAKING ALGORITHM FOR PROGRESSIVE MS
FIGURE 202-2 Therapeutic decision-making for MS.
1267
SECTION 14
1268
Neurology
12 mg/d SC), natalizumab (Tysabri; 300 mg IV every 4 weeks), fin-
golimod (Gilenya; 0.5 mg PO daily), and mitoxantrone (Novantrone; 
12 mg/m2 IV every 3 months). An eighth, cladribine (Leustatin; 
3.5 mg/kg PO every year), has not been approved by the FDA or 
European Medicines Agency but is used in some parts of the world. 
Each of the first four therapies reduces annual exacerbation rates by 
~30% and also reduces the development of new MRI lesions. 
• IFN preparations that are given multiple times weekly (e.g., Rebif or 
Betaseron) appear to have slightly greater efficacy compared with 
once-weekly agents (e.g., Avonex), but are also more likely to induce 
neutralizing antibodies, which may reduce the clinical benefit. 
• Fingolimod is generally well tolerated, and the oral dosing schedule 
makes it convenient for pts; however, as with any new therapy, long-
term safety remains to be established. First-degree heart block and 
bradycardia can occur with fingolimod, necessitating the prolonged 
(6-h) observation of pts receiving their first dose. 
• Natalizumab is the most effective MS agent available. It dramatically 
reduces the attack rate and significantly improves all measures of disease 
severity in MS; however, because of the development of progressive 
multifocal leukoencephalopathy (PML) in 0.2% of pts treated for 
more than 2 years, it is currently used only for pts who have failed 
other therapies or who have particularly aggressive presentations. 
Recently, a blood test to detect antibodies against the PML (JC) virus 
has shown promise in identifying individuals who are at risk for 
this complication. 
• Most pts with relapsing forms of MS receive (IFN)-β or glatiramer 
acetate as first-line therapy. Although approved for first-line use, the 
role of fingolimod in this situation has yet to be defined. Regardless of 
which agent is chosen first, treatment should probably be altered in pts 
who continue to have frequent attacks (Fig. 202-2). 
• Side effects of IFN include flulike symptoms, local injection-site 
reactions (with SC dosing), and mild abnormalities on routine labo-
ratory evaluation (e.g., elevated liver function tests or lymphopenia). 
Rarely, more severe hepatotoxicity may occur. Side effects of IFN often 
subside with time. Injection-site reactions also occur with glatiramer 
acetate but are less severe than with IFN. Approximately 15% of pts 
receiving glatiramer acetate experience one or more episodes of flushing, 
chest tightness, dyspnea, palpitations, and anxiety.
• Several recent studies suggest that these agents can improve the long-term 
outcome of MS. Thus, early treatment with a disease-modifying drug is 
appropriate for most pts. It is reasonable to delay initiating treatment in 
pts with (1) normal neurologic exams, (2) a single attack or a low attack 
frequency, and (3) a low burden of disease as assessed by brain MRI.
• Untreated pts need to be followed closely with periodic brain MRI 
scans; the need for therapy is reassessed if the scans reveal evidence of 
ongoing disease.
CHAPTER 202 1269
Multiple Sclerosis (MS)
ACUTE RELAPSES
• Acute relapses that produce functional impairment may be treated 
with a short course of IV methylprednisolone (1 g IV q a.m. × 3–5 
days) followed by oral prednisone (60 mg q a.m. × 4; 40 mg q a.m. × 
4; 20 mg q a.m. × 3). This regimen modestly reduces the severity and 
shortens the duration of attacks.
• Plasma exchange (7 exchanges: 40–60 mL/kg, every other day for 
14 days) may benefit pts with fulminant attacks of demyelination (not 
only MS) that are unresponsive to glucocorticoids; cost is high and 
conclusive evidence of efficacy is lacking.
PROGRESSIVE SYMPTOMS
• For pts with secondary progressive MS who continue to experience 
relapses, treatment with one of the IFNs is reasonable; however, the 
IFNs are ineffective against purely progressive MS symptoms. 
• The immunosuppressant/immunomodulatory drug mitoxantrone 
is approved in the U.S. for treatment of secondary progressive MS; 
however, the evidence for efficacy is relatively weak, and dose-related 
cardiac toxicity is an important concern. 
• Methotrexate (7.5–20 mg PO once each week) or azathioprine 
(2–3 mg/kg per day PO) is sometimes tried, but efficacy is modest. 
• Pulse therapy with cyclophosphamide is employed in some centers for 
young adults with aggressive forms of MS. 
• Other smaller studies have examined monthly pulses of IV immuno-
globulin (IVIg) or IV methylprednisolone. 
• For pts with PPMS, symptomatic therapy only is recommended, 
although a preplanned secondary analysis of a negative rituximab 
trial was promising and a follow-up trial with a related agent is 
ongoing. 
SYMPTOMATIC THERAPY
• Spasticity may respond to physical therapy, baclofen (20–120 mg/d), 
diazepam (2–40 mg/d), tizanidine (8–32 mg/d), dantrolene (25–400 
mg/d), and cyclobenzaprine hydrochloride (10–60 mg/d). 
• Dysesthesia may respond to carbamazepine (100–1000 mg/d in divided 
doses), phenytoin (300–600 mg/d), gabapentin (300–3600 mg/d), 
pregabalin (50–300 mg/d), or amitriptyline (25–150 mg/d). 
• Treatment of bladder symptoms is based on the underlying patho-
physiology investigated with urodynamic testing: bladder hyperre-
flexia is treated with evening fluid restriction and frequent voiding; 
if this fails, anticholinergics such as oxybutynin (5–15 mg/d) may be 
tried; hyporeflexia is treated with the cholinergic drug bethanechol 
(30–150 mg a day), and dyssynergia due to loss of coordination 
between bladder wall and sphincter muscles is treated with anticho-
linergics and intermittent catheterization. 
• Depression should be treated aggressively.
SECTION 14
1270
Neurology
� CLINICAL VARIANTS OF MS
Neuromyelitis optica (NMO), or Devic’s syndrome, consists of separate 
attacks of acute optic neuritis (bilateral or unilateral) and myelitis. In 
contrast to MS, the brain MRI is typically, but not always, normal. A 
focal enhancing region of swelling and cavitation, extending over three 
or more spinal cord segments, is typically seen on spinal MRI. A highly 
specific autoantibody directed against the water channel aquaporin-4 is 
present in the sera of more than half of pts with a clinical diagnosis of 
NMO. Acute attacks are usually treated with high-dose glucocorticoids as 
for MS exacerbations. Plasma exchange has also been used empirically for 
acute episodes that fail to respond to glucocorticoids. Prophylaxis against 
relapses can be achieved with mycophenolate mofetil, rituximab, or a 
combination of glucocorticoids plus azathioprine. Acute MS (Marburg’s 
variant) is a fulminant demyelinating process that progresses to death 
within 1–2 years. No controlled trials of therapy exist; high-dose gluco-
corticoids, plasma exchange, and cyclophosphamide have been tried, with 
uncertain benefit.
� ACUTE DISSEMINATED ENCEPHALOMYELITIS (ADEM)
A fulminant, often devastating, demyelinating disease that has a mono-
phasic course and may be associated with antecedent immunization 
or infection. Signs of disseminated neurologic disease are consistently 
present (e.g., hemiparesis or quadriparesis, extensor plantar responses, 
lost or hyperactive tendon reflexes, sensory loss, and brainstem involve-
ment). Fever, headache, meningismus, lethargy progressing to coma, and 
seizures may occur. CSF pleocytosis, generally 200 cells/μL, is common. 
MRI may reveal extensive gadolinium enhancement of white matter in 
brain and spinal cord. Initial treatment is with high-dose glucocorticoids. 
Pts who fail to respond may benefit from a course of plasma exchange 
or IVIg.
For a more detailed discussion, see Hauser SL, Goodin DS: 
Multiple Sclerosis and Other Demyelinating Diseases, Chap. 
380, p. 3395, in HPIM-18.
CHAPTER 203
Acute Meningitis and 
Encephalitis
Acute infections of the nervous system include bacterial meningitis, viral 
meningitis, encephalitis, focal infections such as brain abscess and sub-
dural empyema, and infectious thrombophlebitis. Key goals: emergently 
distinguish between these conditions, identify the pathogen, and initiate 
appropriate antimicrobial therapy.
CHAPTER 203 1271
Acute Meningitis and Encephalitis 
Acute Infection of the Nervous System
APPROACH TO THE
PATIENT
(Fig. 203-1) First identify whether infection predominantly involves 
the subarachnoid space (meningitis) or brain tissue (termed encephalitis 
when viral, cerebritis or abscess if bacterial, fungal, or parasitic). Nuchal 
rigidity is the pathognomonic sign of meningeal irritation and is present 
when the neck resists passive flexion.
Principles of management:
• Initiate empirical therapy whenever bacterial meningitis is considered.
• All pts with head trauma, immunocompromised states, known 
malignancies, or focal neurologic findings (including papilledema or 
stupor/coma) should undergo a neuroimaging study of the brain prior 
to LP. If bacterial meningitis is suspected, begin empirical antibiotic 
therapy prior to neuroimaging and LP.
• Stupor/coma, seizures, or focal neurologic deficits do not occur in 
viral meningitis; pts with these symptoms should be hospitalized and 
treated empirically for bacterial and viral meningoencephalitis.
• Immunocompetent pts with a normal level of consciousness, no 
prior antimicrobial treatment, and a CSF profile consistent with viral 
meningitis (lymphocytic pleocytosis and a normal glucose concentra-
tion) can often be treated as outpatients. Failure of a pt with suspected 
viral meningitis to improve within 48 h should prompt a reevaluation 
including follow-up exam, repeat imaging, and laboratory studies, 
often including a second LP.
ACUTE BACTERIAL MENINGITIS
Pathogens most frequently involved in immunocompetent adults are 
Streptococcus pneumoniae (“pneumococcus,” ~50%) and Neisseria men-
ingitidis (“meningococcus,” ~25%). Predisposing factors for pneumococ-
cal meningitis include infection (pneumonia, otitis, sinusitis), asplenia, 
hypogammaglobulinemia, complement deficiency, alcoholism, diabetes, 
and head trauma with CSF leak. Listeria monocytogenes is an important 
consideration in pregnant women, individuals >60 years, alcoholics, and 
immunocompromised individuals of all ages. Enteric gram-negative bacilli 
and group B streptococcus are increasingly common causes of meningitis 
in individuals with chronic medical conditions. Staphylococcus aureus and 
coagulase-negative staphylococci are important causes following invasive 
neurosurgical procedures, especially shunting procedures for hydrocephalus.
Clinical Features 
Presents as an acute fulminant illness that progresses rapidly in a few 
hours or as a subacute infection that progressively worsens over several 
days. The classic clinical triad of meningitis is fever, headache, and nuchal 
rigidity (“stiff neck”). Alteration in mental status occurs in >75% of pts 
and can vary from lethargy to coma. Nausea, vomiting, and photophobia 
are also common. Seizures occur in 20–40% of pts. Raised intracranial 
pressure (ICP) is the major cause of obtundation and coma. The rash of 
SECTION 14
1272
Neurology
ADEM
Encephalitis
Bacterial process
Appropriate medical
and/or surgical
interventions
Pleocytosis with PMNs
  Elevated protein
  Decreased glucose
  Gram’s stain positive
Tier 1 Eval (no unusual historic points or exposures):
Viral: CSF PCR for enterovirus, HSV, VZV
 
CSF IgM for WNV
 
Viral culture: CSF, throat, stool
 
If skin lesions DFA for HSV, VZV
 
HIV serology
 
Serology for enteroviruses and
 
arthropod-borne viruses
Fungal: CSF cryptococcal Ag, fungal cultures
Bacterial: VDRL and bacterial culture, PCR
Mycobacterial: CSF AFB stain and TB PCR, TB 
culture, CXR, PPD
Pleocytosis with MNCs
Normal or increased protein
Normal or decreased glucose
Gram’s stain negative
Abscess
or tumor
White matter
abnormalities
Focal or
  generalized
  gray matter
  abnormalities
  or normal
No mass lesion
Yes
Yes
No
No
Headache, Fever, éNuchal Rigidity
Altered mental status?
Immediate blood culture
and lumbar puncture
Meningoencephalitis, ADEM, 
encephalopathy, or mass lesion
Imaging: Head CT or MRI (preferred)
Mass lesion
Obtain blood culture and start
empirical antimicrobial therapy
Meningitis
Papilledema and/or focal neurologic deficit?
Immunocompromised?
History of recent head trauma, known
  cancer, sinusitis?
A
FIGURE 203-1 The management of pts with suspected CNS infection. ADEM, acute 
disseminated encephalomyelitis; AFB, acid-fast bacillus; Ag, antigen; CSF, cerebrospinal 
fluid; CT, computed tomography; CTFV, Colorado tick fever virus; CXR, chest x-ray; DFA, 
direct fluorescent antibody; EBV, Epstein-Barr virus; HHV, human herpesvirus; HSV, 
herpes simplex virus; LCMV, lymphocytic choriomeningitis virus; MNCs, mononuclear 
cells; MRI, magnetic resonance imaging; PCR, polymerase chain reaction; PMNs, 
polymorphonuclear leukocytes; PPD, purified protein derivative; TB, tuberculosis; VDRL, 
Venereal Disease Research Laboratory; VZV, varicella-zoster virus; WNV, West Nile virus.
CHAPTER 203 1273
Acute Meningitis and Encephalitis 
Hepatitis C
Rotavirus
Rabies
Tier 2 Evaluation (if above negative):
EBV: Serum serology, CSF PCR
Mycoplasma: Serum serology, CSF PCR
Influenza A, B: Serology, respiratory culture, CSF PCR
Adenovirus: Serology, throat swab. CSF PCR
Fungal: CSF & serum coccidioidal antibody, Histoplasma
antigen & antibody
Tier 3 Evaluation
(based on epidemiology)
Diarrhea
(infant/child)
Recent
exanthemal
illness
Measles
Rubella
HHV-6
Raccoon
exposure or
Hx of pica
Baylisascaris
procyonis
Pet bird
(Psittacine)
exposure
Chlamydia psittaci
(Psittacosis)
Exposure to
cattle or
unpasteurized
dairy products
Brucella spp. (Brucellosis)
Coxiella burnetii (Q fever)
Wild rodent
or hamster
exposure
Bat exposure
Animal bite
Cat
exposure
Mosquito or
tick exposure
CTFV
Arbovirus
Rickettsial
Borrelia
Ehrlichia
LCMV
Swimming in
lakes or ponds or
nonchlorinated water
Acanthamoeba or
Naegleria fowleri
(amebic
meningoencephalitis)
Bartonella spp.
(cat scratch fever)
B
Hepatitis
FIGURE 203-1 (Continued)
meningococcemia begins as a diffuse maculopapular rash resembling a 
viral exanthem but rapidly becomes petechial on trunk and lower extremi-
ties, mucous membranes and conjunctiva, and occasionally palms and soles.
Laboratory Evaluation 
The CSF profile is shown in Table 203-1. CSF bacterial cultures are positive 
in >80% of pts, and CSF Gram’s stain demonstrates organisms in >60%. 
A 16S rRNA conserved sequence broad-based bacterial PCR can detect 
small numbers of viable and nonviable organisms in the CSF and is useful 
for making a diagnosis in pts who have been pretreated with antibiotics 
and in whom Gram’s stain and CSF cultures are negative. When positive, 
more specific PCR tests for individual organisms can be obtained. The latex 
agglutination (LA) test for detection of bacterial antigens of S. pneumoniae, 
N. meningitidis, Haemophilus influenzae type b, group B streptococcus, and 
Escherichia coli K1 strains in the CSF is being replaced by the CSF bacte-
rial PCR assay. The Limulus amebocyte lysate assay rapidly detects gram-
negative endotoxin in CSF and thus is useful in diagnosis of gram-negative 
SECTION 14
1274
Neurology
TABLE 203-1  CEREBROSPINAL FLUID (CSF) ABNORMALITIES IN 
BACTERIAL MENINGITIS
Opening pressure
>180 mmH2O
White blood cells
10/μL to 10,000/μL; neutrophils predominate
Red blood cells
Absent in nontraumatic tap
Glucose 
<2.2 mmol/L (<40 mg/dL)
CSF/serum glucose 
<0.4
Protein
>0.45 g/L (>45 mg/dL)
Gram’s stain
Positive in >60%
Culture
Positive in >80%
Latex agglutination
May be positive in pts with meningitis due to 
S. pneumoniae, N. meningitidis, H. influenzae type b, 
E. coli, group B streptococci
Limulus lysate
Positive in cases of gram-negative meningitis
PCR
Detects bacterial DNA
Abbreviation: PCR, polymerase chain reaction
bacterial meningitis; false-positives may occur but sensitivity approaches 
100%. Petechial skin lesions, if present, should be biopsied. Blood cultures 
should always be obtained.
Differential Diagnosis 
Includes viral meningoencephalitis, especially herpes simplex virus (HSV) 
encephalitis (see below); rickettsial diseases such as Rocky Mountain 
spotted fever (immunofluorescent staining of skin lesions); focal suppura-
tive CNS infections including subdural and epidural empyema and brain 
abscess (see below); subarachnoid hemorrhage (Chap. 19); and the demye-
linating disease acute disseminated encephalomyelitis (ADEM, Chap. 202).
Acute Bacterial Meningitis
TREATMENT
• Recommendations for empirical therapy are summarized in 
Table 203-2. Therapy is then modified based on results of CSF 
culture (Table 203-3). 
• In general, the treatment course is 7 days for meningococcus, 14 days 
for pneumococcus, 21 days for gram-negative meningitis, and at least 
21 days for L. monocytogenes.
• Adjunctive therapy with dexamethasone (10 mg IV), administered 
15–20 min before the first dose of an antimicrobial agent and 
repeated every 6 h for 4 days, improves outcome from bacterial 
meningitis; benefits most striking in pneumococcal meningitis. 
Dexamethasone may decrease the penetration of vancomycin into 
CSF, and thus its potential benefit should be carefully weighed 
when vancomycin is the antibiotic of choice.
CHAPTER 203 1275
Acute Meningitis and Encephalitis 
TABLE 203-2  ANTIBIOTICS USED IN EMPIRICAL THERAPY OF BACTERIAL 
MENINGITIS AND FOCAL CNS INFECTIONSa
Indication
Antibiotic
Preterm infants to infants 
<1 month
Ampicillin + cefotaxime 
Infants 1–3 months
Ampicillin + cefotaxime or ceftriaxone 
Immunocompetent children 
>3 months and adults <55
Cefotaxime, ceftriaxone or cefepime +
vancomycin
Adults >55 and adults of any 
age with alcoholism or other 
debilitating illnesses
Ampicillin + cefotaxime, ceftriaxone or 
cefepime + vancomycin
Hospital-acquired meningitis, 
posttraumatic or postneurosur-
gery meningitis, neutropenic 
pts, or pts with impaired 
cell-mediated immunity
Ampicillin + ceftazidime or meropenem +
vancomycin
Antimicrobial Agent
Total Daily Dose and Dosing Interval
Child (>1 month)
Adult
Ampicillin
200 (mg/kg)/d, q4h
12 g/d, q4h
Cefepime
150 (mg/kg)/d, q8h
6 g/d, q8h
Cefotaxime
200 (mg/kg)/d, q6h
12 g/d, q4h
Ceftriaxone
100 (mg/kg)/d, q12h
4 g/d, q12h
Ceftazidime
150 (mg/kg)/d, q8h
6 g/d, q8h
Gentamicin 
7.5 (mg/kg)/d, q8hb
7.5 (mg/kg)/d, q8h
Meropenem
120 (mg/kg)/d, q8h
3 g/d, q8h
Metronidazole
30 (mg/kg)/d, q6h
1500–2000 mg/d, q6h
Nafcillin
100–200 (mg/kg)/d, q6h
9–12 g/d, q4h
Penicillin G
400,000 (U/kg)/d, q4h
20–24 million U/d, q4h
Vancomycin
60 (mg/kg)/d, q6h
2 g/d, q12hb
aAll antibiotics are administered intravenously; doses indicated assume normal renal and 
hepatic function.
bDoses should be adjusted based on serum peak and trough levels: gentamicin therapeutic 
level: peak: 5–8 μg/mL; trough: <2 μg/mL; vancomycin therapeutic level: peak: 25–40 μg/mL; 
trough: 5–15 μg/mL.
• In meningococcal meningitis, all close contacts should receive 
prophylaxis with rifampin [600 mg in adults (10 mg/kg in children 
> 1 year)] every 12 h for 2 days; rifampin is not recommended 
in pregnant women. Alternatively, adults can be treated with one 
dose of azithromycin (500 mg), or one IM dose of ceftriaxone 
(250 mg).
SECTION 14
1276
Neurology
Prognosis
Moderate or severe sequelae occur in ~25% of survivors; outcome varies 
with the infecting organism. Common sequelae include decreased intel-
lectual function, memory impairment, seizures, hearing loss and dizziness, 
and gait disturbances.
VIRAL MENINGITIS
Presents as fever, headache, and meningeal irritation associated with a CSF 
lymphocytic pleocytosis. Fever may be accompanied by malaise, myalgia, 
anorexia, nausea and vomiting, abdominal pain, and/or diarrhea. A mild 
degree of lethargy or drowsiness may occur; however, a more profound 
alteration in consciousness should prompt consideration of alternative 
diagnoses, including encephalitis.
Etiology 
Using a variety of diagnostic techniques, including CSF PCR, culture, and 
serology, a specific viral cause can be found in 75–90% of cases. The most 
important agents are enteroviruses, HSV type 2, HIV, and arboviruses 
(Table 203-4). The incidence of enteroviral and arboviral infections is 
greatly increased during the summer.
TABLE 203-3  ANTIMICROBIAL THERAPY OF CNS BACTERIAL INFECTIONS 
BASED ON PATHOGENa
Organism
Antibiotic
Neisseria meningitides
 Penicillin-sensitive
Penicillin G or ampicillin
 Penicillin-resistant
Ceftriaxone or cefotaxime
Streptococcus pneumoniae
 Penicillin-sensitive
Penicillin G
 Penicillin-intermediate
Ceftriaxone or cefotaxime or cefepime 
 Penicillin-resistant
(Ceftriaxone or cefotaxime or cefepime) +
vancomycin
Gram-negative bacilli (except 
Pseudomonas spp.)
Ceftriaxone or cefotaxime
Pseudomonas aeruginosa
Ceftazidime or cefepime or meropenem
Staphylococci spp.
 Methicillin-sensitive
Nafcillin
 Methicillin-resistant
Vancomycin
Listeria monocytogenes
Ampicillin + gentamicin
Haemophilus influenzae
Ceftriaxone or cefotaxime or cefepime
Streptococcus agalactiae
Penicillin G or ampicillin
Bacteroides fragilis
Metronidazole
Fusobacterium spp.
Metronidazole
aDoses are as indicated in Table 203-2.
CHAPTER 203 1277
Acute Meningitis and Encephalitis 
TABLE 203-4  VIRUSES CAUSING ACUTE MENINGITIS AND ENCEPHALITIS 
IN NORTH AMERICA
Acute Meningitis
Common
Less common
Enteroviruses (coxsackieviruses, 
echoviruses, and human enteroviruses 
68–71)
Varicella zoster virus
Epstein-Barr virus
Lymphocytic choriomeningitis virus
Herpes simplex virus 2
Arthropod-borne viruses
HIV
Acute Encephalitis
Common
Less common
Herpesviruses
Rabies
 Herpes simplex virus 1
Eastern equine encephalitis virus 
 Varicella zoster virus
Western equine encephalitis virus
 Epstein-Barr virus
Powassan virus
Arthropod-borne viruses
Cytomegalovirusa
 La Crosse virus
Enterovirusesa
 West Nile virus
Colorado tick fever
 St. Louis encephalitis virus
Mumps
aImmunocompromised host.
Diagnosis
Most important test is examination of the CSF. The typical profile is a lym-
phocytic pleocytosis (25–500 cells/μL), a normal or slightly elevated protein 
concentration [0.2–0.8 g/L (20–80 mg/dL)], a normal glucose concentration, 
and a normal or mildly elevated opening pressure (100–350 mmH2O). 
Organisms are not seen on Gram or acid-fast stained smears or india ink 
preparations of CSF. Rarely, polymorphonuclear leukocytes (PMN) pre-
dominate in the first 48 h of illness, especially with echovirus 9, West Nile 
virus (WNV), eastern equine encephalitis virus, or mumps. The total CSF 
cell count in viral meningitis is typically 25–500/μL. As a general rule, a 
lymphocytic pleocytosis with a low glucose concentration should suggest 
fungal, listerial, or tuberculous meningitis or noninfectious disorders (e.g., 
sarcoid, neoplastic meningitis).
CSF PCR testing is the procedure of choice for rapid, sensitive, and spe-
cific identification of enteroviruses, HSV, EBV, varicella zoster virus (VZV), 
human herpes virus 6 (HHV-6), and CMV. Attempts should also be made 
to culture virus from CSF and other sites and body fluids including blood, 
throat swabs, stool, and urine, although sensitivity of cultures is generally 
poor. Serologic studies, including those utilizing paired CSF and serum 
specimens, may be helpful for retrospective diagnosis; they are particularly 
important for diagnosis of WNV and other arbovirus etiologies.
SECTION 14
1278
Neurology
Differential Diagnosis 
Consider bacterial, fungal, tuberculous, spirochetal, and other infectious 
causes of meningitis; parameningeal infections; partially treated bacterial 
meningitis; neoplastic meningitis; noninfectious inflammatory diseases 
including sarcoid and Behçet’s disease.
Viral Meningitis
TREATMENT
• Supportive or symptomatic therapy is usually sufficient, and hospi-
talization is not required.
• The elderly and immunocompromised pts should be hospitalized, as 
should individuals in whom the diagnosis is uncertain or those with 
significant alterations in consciousness, seizures, or focal neurologic 
signs or symptoms. 
• Severe cases of meningitis due to HSV, EBV, and VZV can be 
treated with IV acyclovir (5–10 mg/kg every 8 h), followed by an 
oral drug (acyclovir (800 mg, five times daily; famciclovir 500 mg 
tid; or valacyclovir 1000 mg tid) for a total course of 7–14 days; 
for mildly affected pts, a 7–14 day course of oral antivirals may be 
appropriate. 
• Additional supportive or symptomatic therapy can include analgesics 
and antipyretics. 
• Prognosis for full recovery is excellent. 
• Vaccination is an effective method of preventing the development 
of meningitis and other neurologic complications associated with 
poliovirus, mumps, measles, and VZV infection.
VIRAL ENCEPHALITIS
An infection of the brain parenchyma commonly associated with meningi-
tis (“meningoencephalitis”). Clinical features are those of viral meningitis 
plus evidence of brain tissue involvement, commonly including altered 
consciousness such as behavioral changes and hallucinations; seizures; and 
focal neurologic findings such as aphasia, hemiparesis, involuntary move-
ments, and cranial nerve deficits.
Etiology 
The same organisms responsible for aseptic meningitis are also responsible 
for encephalitis, although relative frequencies differ. The most common 
causes of sporadic encephalitis in immunocompetent adults are herpes-
viruses (HSV, VZV, EBV) (Table 203-4). HSV encephalitis should be 
considered when focal findings are present and when involvement of 
the inferomedial frontotemporal regions of the brain is likely (olfactory 
hallucinations, anosmia, bizarre behavior, or memory disturbance). 
Epidemics of encephalitis are usually caused by arboviruses. WNV has been 
responsible for the majority of arbovirus meningitis and encephalitis cases 
in the United States. Since 2002, prominent motor manifestations, including 
acute poliomyelitis-like paralysis, may occur with WNV.
CHAPTER 203 1279
Acute Meningitis and Encephalitis 
Diagnosis
CSF studies are essential; typical CSF profile is similar to viral meningitis. 
CSF PCR tests allow for rapid and reliable diagnosis of HSV, EBV, 
VZV, CMV, HHV-6, and enteroviruses. CSF virus cultures are generally 
negative. Serologic studies also have a role for some viruses. Demonstration 
of WNV IgM antibodies is diagnostic of WNV encephalitis.
MRI is the neuroimaging procedure of choice and demonstrates areas of 
increased T2 signal. Bitemporal and orbitofrontal areas of increased signal 
are seen in HSV encephalitis, but are not diagnostic (Fig. 203-2). The EEG 
may suggest seizures or show temporally predominant periodic spikes on a 
slow, low-amplitude background suggestive of HSV encephalitis.
Brain biopsy is now used only when CSF PCR studies fail to identify 
the cause, focal abnormalities on MRI are present, and progressive clinical 
deterioration occurs despite treatment with acyclovir and supportive 
therapy.
FIGURE 203-2 Coronal FLAIR magnetic resonance image from a pt with herpes 
simplex encephalitis. Note the area of increased signal in the right temporal lobe (left 
side of image) confined predominantly to the gray matter. This pt had predominantly 
unilateral disease; bilateral lesions are more common, but may be quite asymmetric 
in their intensity.
SECTION 14
1280
Neurology
Differential Diagnosis 
Includes both infectious and noninfectious causes of encephalitis, including 
vascular diseases; abscess and empyema; fungal (Cryptococcus and Mucor), 
spirochetal (Leptospira), rickettsial, bacterial (Listeria), tuberculous, and 
mycoplasmal infections; tumors; toxic encephalopathy; SLE; and acute dis-
seminated encephalomyelitis.
Viral Encephalitis
TREATMENT
• All pts with suspected HSV encephalitis should be treated with IV 
acyclovir (10 mg/kg every 8 h) while awaiting diagnostic studies. 
• Pts with a PCR-confirmed diagnosis of HSV encephalitis should receive 
a 14- to 21-day course of therapy. Consider repeat CSF PCR after 
completion of acyclovir therapy; pts with a persistently positive CSF 
PCR for HSV after completing a standard course of acyclovir therapy 
should receive additional treatment, followed by a repeat CSF PCR test. 
• Acyclovir treatment may also be of benefit in severe encephalitis 
due to EBV and VZV. No therapy currently available for enteroviral, 
mumps, or measles encephalitis. 
• IV ribavirin (15–25 mg/kg per day given in 3 divided doses) may 
benefit severe encephalitis due to California encephalitis (LaCrosse) 
virus. 
• CMV encephalitis should be treated with ganciclovir (5 mg/kg 
every 12 h IV over 1 h, followed by maintenance therapy of 5 mg/kg 
every day), foscarnet (60 mg/kg every 8 h IV over 1 h, followed by 
maintenance therapy (60–120 mg/kg per day), or a combination of 
the two drugs; cidofovir (5 mg/kg IV once weekly for 2 weeks, then 
biweekly for two or more additional doses, depending on response; 
prehydrate with normal saline and pretreat with probenecid) may 
provide an alternative for nonresponders. 
• No proven therapy is available for WNV encephalitis; small 
groups of pts have been treated with interferon, ribavirin, WNV-
specific antisense oligonucleotides, IV immunoglobulin prepara-
tions of Israeli origin containing high-titer anti-WNV antibody, 
and humanized monoclonal antibodies directed against the viral 
envelope glycoprotein.
Prognosis
In HSV encephalitis treated with acyclovir, 81% survival in one series; neuro-
logic sequelae were mild or absent in 46%, moderate in 12%, and severe in 42%.
BRAIN ABSCESS
A focal, suppurative infection within the brain parenchyma, typically sur-
rounded by a vascularized capsule. The term cerebritis is used to describe 
a nonencapsulated brain abscess. Predisposing conditions include otitis 
media and mastoiditis, paranasal sinusitis, pyogenic infections in the chest 
or other body sites, head trauma, neurosurgical procedures, and dental 
infections. Many brain abscesses occur in immunocompromised hosts 
CHAPTER 203 1281
Acute Meningitis and Encephalitis 
and are caused less often by bacteria than by fungi and parasites including 
Toxoplasma gondii, Aspergillus spp., Nocardia spp., Candida spp., and 
Cryptococcus neoformans. In Latin America and in immigrants from Latin 
America, the most common cause of brain abscess is Taenia solium (neuro-
cysticercosis). In India and the Far East, mycobacterial infection (tubercu-
loma) remains a major cause of focal CNS mass lesions.
Clinical Features 
Brain abscess typically presents as an expanding intracranial mass lesion, 
rather than as an infectious process. The classic triad of headache, fever, and 
a focal neurologic deficit is present in <50% of cases.
Diagnosis
MRI is better than CT for demonstrating abscesses in the early (cerebritis) 
stages and is superior to CT for identifying abscesses in the posterior fossa. 
A mature brain abscess appears on CT as a focal area of hypodensity sur-
rounded by ring enhancement. The CT and MRI appearance, particularly of 
the capsule, may be altered by treatment with glucocorticoids. The distinc-
tion between a brain abscess and other focal lesions such as tumors may 
be facilitated with diffusion-weighted imaging (DWI) sequences in which 
brain abscesses typically show increased signal due to restricted diffusion.
Microbiologic diagnosis best determined by Gram’s stain and culture of 
abscess material obtained by stereotactic needle aspiration. Up to 10% of pts 
will also have positive blood cultures. CSF analysis contributes nothing to 
diagnosis or therapy, and LP increases the risk of herniation.
Brain Abscess
TREATMENT
• Optimal therapy involves a combination of high-dose parenteral 
antibiotics and neurosurgical drainage.
• Empirical therapy of community-acquired brain abscess in an 
immunocompetent pt  typically includes a third or fourth-generation 
cephalosporin (e.g., cefotaxime, ceftriaxone, or cefepime) and 
metronidazole (see Table 203-2 for antibiotic dosages).
• In pts with penetrating head trauma or recent neurosurgical proce-
dures, treatment should include ceftazidime as the third-generation 
cephalosporin to enhance coverage of Pseudomonas spp. and 
vancomycin for coverage of resistant staphylococci. Meropenem 
plus vancomycin also provides good coverage in this setting.
• Aspiration and drainage essential in most cases. Empirical antibiotic 
coverage is modified based on the results of Gram’s stain and culture 
of the abscess contents. 
• Medical therapy alone is reserved for pts whose abscesses are 
neurosurgically inaccessible and for pts with small (<2–3 cm) or 
nonencapsulated abscesses (cerebritis). 
• All pts should receive a minimum of 6–8 weeks of parenteral antibiotic 
therapy. 
• Pts should receive prophylactic anticonvulsant therapy. 
• Glucocorticoids should not be given routinely.
SECTION 14
1282
Neurology
Prognosis
In modern series the mortality is typically <15%. Significant sequelae 
including seizures, persisting weakness, aphasia, or mental impairment 
occur in ≥20% of survivors.
PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY (PML)
Clinical Features 
A progressive disorder due to infection with the JC virus, a human polyoma 
virus; characterized pathologically by multifocal areas of demyelination of 
varying size distributed throughout the CNS but sparing the spinal cord 
and optic nerves. In addition, there are characteristic cytologic alterations in 
both astrocytes and oligodendrocytes. Pts often present with visual deficits 
(45%), typically a homonymous hemianopia, and mental impairment (38%) 
(dementia, confusion, personality change), weakness, and ataxia. Almost 
all pts have an underlying immunosuppressive disorder. More than 80% 
of currently diagnosed PML cases occur in pts with AIDS; it has been esti-
mated that nearly 5% of AIDS pts will develop PML. Immunosuppressant 
drugs such as natalizumab have also been associated with PML. 
Diagnostic Studies 
MRI reveals multifocal asymmetric, coalescing white matter lesions located 
periventricularly, in the centrum semiovale, in the parietal-occipital region, 
and in the cerebellum. These lesions have increased T2 and decreased T1 
signal, are generally nonenhancing (rarely they may show ring enhance-
ment), and are not associated with edema or mass effect. CT scans, which 
are less sensitive than MRI for the diagnosis of PML, often show hypodense 
nonenhancing white matter lesions.
The CSF is typically normal, although mild elevation in protein and/or 
IgG may be found. Pleocytosis occurs in <25% of cases, is predominantly 
mononuclear, and rarely exceeds 25 cells/μL. PCR amplification of JC 
virus DNA from CSF has become an important diagnostic tool. A positive 
CSF PCR for JC virus DNA in association with typical MRI lesions in the 
appropriate clinical setting is diagnostic of PML. Pts with negative CSF 
PCR studies may require brain biopsy for definitive diagnosis as sensitivity 
of this test is variable; JC virus antigen and nucleic acid can be detected 
by immunocytochemistry, in situ hybridization, or PCR amplification on 
tissue. Detection of JC virus antigen or genomic material should be con-
sidered diagnostic of PML only if accompanied by characteristic pathologic 
changes, since both antigen and genomic material have been found in the 
brains of normal pts. Serologic studies are of no utility given high basal 
seroprevalence level (>80%).
Progressive Multifocal Leukoencephalopathy
TREATMENT
• No effective therapy is available.
• Some pts with HIV-associated PML have shown dramatic clinical 
gains associated with improvement in immune status following 
institution of highly active antiretroviral therapy (HAART).
CHAPTER 204 1283
Chronic Meningitis
For a more detailed discussion, see Roos KL, Tyler KL: 
Meningitis, Encephalitis, Brain Abscess, and Empyema, 
Chap. 381, p. 3410, in HPIM-18; and HPIM-18 chapters 
covering specific organisms or infections.
CHAPTER 204
Chronic Meningitis
Chronic inflammation of the meninges (pia, arachnoid, and dura) can 
produce profound neurologic disability and may be fatal if not successfully 
treated. The causes are varied. Five categories of disease account for most 
cases of chronic meningitis:
• Meningeal infections
• Malignancy
• Noninfectious inflammatory disorders
• Chemical meningitis
• Parameningeal infections
� CLINICAL FEATURES
Neurologic manifestations consist of persistent headache with or without 
stiff neck and hydrocephalus; cranial neuropathies; radiculopathies; and/
or cognitive or personality changes (Table 204-1). The diagnosis is usually 
TABLE 204-1 SYMPTOMS AND SIGNS OF CHRONIC MENINGITIS
Symptom
Sign
Chronic headache
+/− Papilledema
Neck or back pain
Brudzinski’s or Kernig’s sign of meningeal irritation
Change in personality
Altered mental status—drowsiness, inatten-
tion, disorientation, memory loss, frontal release 
signs (grasp, suck, snout), perseveration
Facial weakness
Peripheral seventh CN palsy
Double vision
Palsy of CNs III, IV, VI
Visual loss
Papilledema, optic atrophy
Hearing loss
Eighth CN palsy
Arm or leg weakness
Myelopathy or radiculopathy
Numbness in arms or legs Myelopathy or radiculopathy 
Sphincter dysfunction 
Myelopathy or radiculopathy Frontal lobe 
dysfunction (hydrocephalus)
Clumsiness
Ataxia
Abbreviation: CN, cranial nerve.
SECTION 14
1284
Neurology
made when clinical presentation leads the physician to examine CSF for 
signs of inflammation; on occasion the diagnosis is made when a neuroim-
aging study shows contrast enhancement of the meninges.
Two clinical forms of chronic meningitis exist. In the first, symptoms are 
chronic and persistent, whereas in the second there are recurrent, discrete 
episodes with complete resolution of meningeal inflammation between 
episodes without specific therapy. In the latter group, likely etiologies are 
herpes simplex virus type 2, chemical meningitis due to leakage from a 
tumor, a primary inflammatory condition, or drug hypersensitivity.
Chronic Meningitis
APPROACH TO THE
PATIENT
Once chronic meningitis is confirmed by CSF examination, effort is 
focused on identifying the cause (Tables 204-2 and 204-3) by (1) further 
analysis of the CSF, (2) diagnosis of an underlying systemic infection or 
noninfectious inflammatory condition, or (3) examination of meningeal 
biopsy tissue.
Proper analysis of the CSF is essential; if the possibility of raised intra-
cranial pressure (ICP) exists, a brain imaging study should be performed 
before LP. In pts with communicating hydrocephalus caused by impaired 
resorption of CSF, LP is safe and may lead to temporary improvement. 
However, if ICP is elevated because of a mass lesion, brain swelling, or a 
block in ventricular CSF outflow (obstructive hydrocephalus), then LP 
carries the potential risk of brain herniation. Obstructive hydrocephalus 
usually requires direct ventricular drainage of CSF.
Contrast-enhanced MRI or CT studies of the brain and spinal cord 
can identify meningeal enhancement, parameningeal infections (includ-
ing brain abscess), encasement of the spinal cord (malignancy or inflam-
mation and infection), or nodular deposits on the meninges or nerve 
roots (malignancy or sarcoidosis). Imaging studies are also useful to 
localize areas of meningeal disease prior to meningeal biopsy. Cerebral 
angiography may identify arteritis. 
A meningeal biopsy should be considered in pts who are disabled, 
who need chronic ventricular decompression, or whose illness is 
progressing rapidly. The diagnostic yield of meningeal biopsy can be 
increased by targeting regions that enhance with contrast on MRI or CT; 
in one series, diagnostic biopsies most often identified sarcoid (31%) or 
metastatic adenocarcinoma (25%). Tuberculosis is the most common 
condition identified in many reports outside of the United States.
In approximately one-third of cases, the diagnosis is not known 
despite careful evaluation. A number of the organisms that cause 
chronic meningitis may take weeks to be identified by culture. It is 
reasonable to wait until cultures are finalized if symptoms are mild 
and not progressive. However, in many cases progressive neurologic 
deterioration occurs, and rapid treatment is required. Empirical therapy 
in the United States consists of antimycobacterial agents, amphotericin 
for fungal infection, or glucocorticoids for noninfectious inflammatory 
causes (most common). It is important to direct empirical therapy of
TABLE 204-2 INFECTIOUS CAUSES OF CHRONIC MENINGITIS
Causative Agent
CSF Formula
Helpful Diagnostic Tests
Risk Factors and Systemic Manifestations
Common bacterial causes
Partially treated suppurative 
meningitis
Mononuclear or mixed mononu-
clear-polymorphonuclear cells
CSF culture and Gram’s stain
History consistent with acute bacterial meningitis 
and incomplete treatment
Parameningeal infection
Mononuclear or mixed polymor-
phonuclear-mononuclear cells
Contrast-enhanced CT or MRI to 
detect parenchymal, subdural, 
epidural, or sinus infection
Otitis media, pleuropulmonary infection, right-
to-left cardiopulmonary shunt for brain abscess; 
focal neurologic signs; neck, back, ear, or sinus 
tenderness
Mycobacterium tuberculosis
Mononuclear cells except 
polymorphonuclear cells in 
early infection (commonly 
<500 WBC/μL); low CSF 
glucose, high protein
Tuberculin skin test may be negative; 
AFB culture of CSF (sputum, urine, 
gastric contents if indicated); tuber-
culostearic acid detection in CSF; 
identify tubercle bacillus on acid-fast 
stain of CSF or protein pellicle; PCR
Exposure history; previous tuberculous illness; 
immunosuppressed or AIDS; young children; 
fever, meningismus, night sweats, miliary TB on 
x-ray or liver biopsy; stroke due to arteritis
Lyme disease (Bannwarth’s 
syndrome) Borrelia burgdorferi 
Mononuclear cells; elevated 
protein
Serum Lyme antibody titer; Western 
blot confirmation; (pts with syphilis 
may have false-positive Lyme titer)
History of tick bite or appropriate exposure 
history; erythema chronicum migrans skin rash; 
arthritis, radiculopathy, Bell’s palsy, meningoen-
cephalitis–multiple sclerosis-like syndrome
Syphilis (secondary, tertiary) 
Treponema pallidum
Mononuclear cells; elevated 
protein
CSF VDRL; serum VDRL (or RPR); fluo-
rescent treponemal antibody-absorbed 
(FTA) or MHA-TP; serum VDRL may be 
negative in tertiary syphilis
Appropriate exposure history; HIV- seropositive 
individuals at increased risk of aggressive 
infection; “dementia”; cerebral infarction due 
to endarteritis
(continued)
1285
TABLE 204-2 INFECTIOUS CAUSES OF CHRONIC MENINGITIS (CONTINUED)
Causative Agent
CSF Formula
Helpful Diagnostic Tests
Risk Factors and Systemic Manifestations
Uncommon bacterial causes
Actinomyces
Polymorphonuclear cells
Anaerobic culture
Parameningeal abscess or sinus tract (oral or 
dental focus); pneumonitis
Nocardia
Polymorphonuclear; occasion-
ally mononuclear cells; often 
low glucose 
Isolation may require weeks; weakly 
acid fast
Associated brain abscess may be present
Brucella
Mononuclear cells (rarely 
polymorphonuclear); elevated 
protein; often low glucose 
CSF antibody detection; serum 
antibody detection
Intake of unpasteurized dairy products; exposure 
to goats, sheep, cows; fever, arthralgia, myalgia, 
vertebral osteomyelitis
Whipple’s disease Tropheryma 
whipplei 
Mononuclear cells
Biopsy of small bowel or lymph node; 
CSF PCR for T. whipplei; brain and 
meningeal biopsy (with PAS stain and 
EM examination)
Diarrhea, weight loss, arthralgias, fever; demen-
tia, ataxia, paresis, ophthalmoplegia, oculomasti-
catory myoclonus
Rare bacterial causes
Leptospirosis (occasionally if left untreated may last 3–4 weeks)
Fungal causes
Cryptococcus neoformans
Mononuclear cells; count not 
elevated in some pts with AIDS
India ink or fungal wet mount of CSF 
(budding yeast); blood and urine 
cultures; antigen detection in CSF
AIDS and immune suppression; pigeon exposure; 
skin and other organ involvement due to 
disseminated infection
1286
Coccidioides immitis
Mononuclear cells (sometimes 
10–20% eosinophils); often low 
glucose
Antibody detection in CSF and serum
Exposure history—southwestern U.S.; increased 
virulence in dark-skinned races
Candida sp.
Polymorphonuclear or 
mononuclear
Fungal stain and culture of CSF
IV drug abuse; post surgery; prolonged IV therapy; 
disseminated candidiasis
Histoplasma capsulatum
Mononuclear cells; low glucose Fungal stain and culture of large 
volumes of CSF; antigen detection 
in CSF, serum, and urine; antibody 
detection in serum, CSF
Exposure history—Ohio and central Mississippi 
River Valley; AIDS; mucosal lesions
Blastomyces dermatitidis
Mononuclear cells
Fungal stain and culture of CSF; 
biopsy and culture of skin, lung 
lesions; antibody detection in serum
Midwestern and southeastern U.S.; usually 
systemic infection; abscesses, draining sinus, 
ulcers
Aspergillus sp.
Mononuclear or polymorpho-
nuclear
CSF culture
Sinusitis; granulocytopenia or immunosuppression
Sporothrix schenckii
Mononuclear cells
Antibody detection in CSF and serum; 
CSF culture
Traumatic inoculation; IV drug use; ulcerated skin 
lesion
Rare fungal causes
Xylohypha (formerly Cladosporium) trichoides and other dark-walled (dematiaceous) fungi such as Curvularia, Drechslera; Mucor, and, after water aspiration, 
Pseudallescheria boydii
Protozoal causes
Toxoplasma gondii
Mononuclear cells
Biopsy or response to empirical therapy 
in clinically appropriate context 
(including presence of antibody in serum)
Usually with intracerebral abscesses; common
in HIV-seropositive pts
(continued)
1287
TABLE 204-2 INFECTIOUS CAUSES OF CHRONIC MENINGITIS (CONTINUED)
Causative Agent
CSF Formula
Helpful Diagnostic Tests
Risk Factors and Systemic Manifestations
Protozoal causes
Trypanosomiasis Trypanosoma 
gambiense, T. rhodesiense
Mononuclear cells, elevated 
protein
Elevated CSF IgM; identification of 
trypanosomes in CSF and blood smear
Endemic in Africa; chancre, lymphadenopathy; 
prominent sleep disorder
Rare protozoal causes
Acanthamoeba sp. causing granulomatous amebic encephalitis and meningoencephalitis in immunocompromised and debilitated individuals. Balamuthia
mandrillaris causing chronic meningoencephalitis in immunocompetent hosts. 
Helminthic causes
Cysticercosis (infection with 
cysts of Taenia solium)
Mononuclear cells; may have 
eosinophils; glucose level may 
be low
Indirect hemagglutination assay in CSF; 
ELISA immunoblotting in serum
Usually with multiple cysts in basal meninges 
and hydrocephalus; cerebral cysts, muscle 
calcification
Gnathostoma spinigerum
Eosinophils, mononuclear cells
Peripheral eosinophilia
History of eating raw fish; common in Thailand 
and Japan; subarachnoid hemorrhage; painful 
radiculopathy
Angiostrongylus cantonensis
Eosinophils, mononuclear cells
Recovery of worms from CSF
History of eating raw shellfish; common in 
tropical Pacific regions; often benign
Baylisascaris procyonis
(raccoon ascarid)
Eosinophils, mononuclear cells
Infection follows accidental ingestion of 
B. procyonis eggs from raccoon feces; fatal 
meningoencephalitis
1288
Rare helminthic causes
Trichinella spiralis (trichinosis); Fasciola hepatica (liver fluke), Echinococcus cysts; Schistosoma sp. The former may produce a lymphocytic pleocytosis 
whereas the latter two may produce an eosinophilic response in CSF associated with cerebral cysts (Echinococcus) or granulomatous lesions of brain or 
spinal cord
Viral causes
Mumps
Mononuclear cells
Antibody in serum
No prior mumps or immunization; may 
produce meningoencephalitis; may persist for 
3–4 weeks
Lymphocytic choriomeningitis
Mononuclear cells
Antibody in serum
Contact with rodents or their excreta; may 
persist for 3–4 weeks
Echovirus 
Mononuclear cells; may have 
low glucose 
Virus isolation from CSF
Congenital hypogammaglobulinemia; history 
of recurrent meningitis
HIV (acute retroviral syndrome) Mononuclear cells
p24 antigen in serum and CSF; high 
level of HIV viremia
HIV risk factors; rash, fever, lymphadenopathy; 
lymphopenia in peripheral blood; syndrome 
may persist long enough to be considered as 
“chronic meningitis”; or chronic meningitis 
may develop in later stages (AIDS) due to HIV
Herpes simplex (HSV)
Mononuclear cells
PCR for HSV, CMV DNA; CSF antibody 
for HSV, EBV
Recurrent meningitis due to HSV-2 (rarely 
HSV-1) often associated with genital 
recurrences; EBV associated with myeloradicu-
lopathy, CMV with polyradiculopathy
Abbreviations: AFB, acid-fast bacillus; CMV, cytomegalovirus; CSF, cerebrospinal fluid; CT, computed tomography; EBV, Epstein-Barr virus; ELISA, enzyme-linked immunosorbent assay; 
EM, electron microscopy; FTA, fluorescent treponemal antibody absorption test; HSV, herpes simplex virus; MHA-TP, microhemagglutination assay–T. pallidum; MRI, magnetic resonance 
imaging; PAS, periodic acid–Schiff; PCR, polymerase chain reaction; RPR, rapid plasma reagin test; TB, tuberculosis; VDRL, Venereal Disease Research Laboratories test.
1289
TABLE 204-3 NONINFECTIOUS CAUSES OF CHRONIC MENINGITIS
Causative Agents
CSF Formula
Helpful Diagnostic Tests
Risk Factors and Systemic Manifestations
Malignancy 
Mononuclear cells, elevated 
protein, low glucose
Repeated cytologic examination of large 
volumes of CSF; CSF exam by polarizing 
microscopy; clonal lymphocyte markers; 
deposits on nerve roots or meninges seen 
on myelogram or contrast-enhanced MRI; 
meningeal biopsy
Metastatic cancer of breast, lung, stomach, 
or pancreas; melanoma, lymphoma, leukemia; 
meningeal gliomatosis; meningeal sarcoma; 
cerebral dysgerminoma; meningeal melanoma 
or B cell lymphoma
Chemical compounds 
(may cause recurrent 
meningitis)
Mononuclear or PMNs, low 
glucose, elevated protein; 
xanthochromia from sub-
arachnoid hemorrhage in 
week prior to presentation 
with “meningitis”
Contrast-enhanced CT scan or MRI 
Cerebral angiogram to detect aneurysm
History of recent injection into the subarachnoid 
space; history of sudden onset of headache; 
recent resection of acoustic neuroma or 
craniopharyngioma; epidermoid tumor of brain 
or spine, sometimes with dermoid sinus tract; 
pituitary apoplexy
Primary Inflammation
CNS sarcoidosis
Mononuclear cells; elevated 
protein; often low glucose
Serum and CSF angiotensin-converting 
enzyme levels; biopsy of extraneural 
affected tissues or brain lesion/meningeal 
biopsy
CN palsy, especially of CN VII; hypothalamic 
dysfunction, especially diabetes insipidus; 
abnormal chest radiograph; peripheral 
neuropathy or myopathy
Vogt-Koyanagi-Harada 
syndrome (recurrent 
meningitis)
Mononuclear cells
Recurrent meningoencephalitis with uveitis, 
retinal detachment, alopecia, lightening of 
eyebrows and lashes, dysacousia, cataracts, 
glaucoma
1290
Isolated granulomatous 
angiitis of the nervous 
system
Mononuclear cells, elevated 
protein
Angiography or meningeal biopsy
Subacute dementia; multiple cerebral 
infarctions; recent zoster ophthalmicus
Systemic lupus 
erythematosus
Mononuclear or PMNs
Anti-DNA antibody, antinuclear antibodies
Encephalopathy; seizures; stroke; transverse 
myelopathy; rash; arthritis
Behçet’s syndrome 
(recurrent meningitis)
Mononuclear or PMNs, 
elevated protein
Oral and genital aphthous ulcers; iridocyclitis; 
retinal hemorrhages; pathergic lesions at site 
of skin puncture 
Chronic benign 
lymphocytic meningitis
Mononuclear cells
Recovery in 2–6 months, diagnosis by exclusion
Mollaret’s meningitis 
(recurrent meningitis)
Large endothelial cells and 
PMNs in first hours, followed 
by mononuclear cells
PCR for herpes; MRI/CT to rule out 
epidermoid tumor or dural cyst
Recurrent meningitis; exclude HSV-2; rare 
cases due to HSV-1; occasional case associated 
with dural cyst
Drug hypersensitivity
PMNs; occasionally 
mononuclear cells or 
eosinophils
Complete blood count (eosinophilia)
Exposure to non steroidal anti-inflammatory 
agents, sulfonamides, isoniazid, tolmetin, cipro-
floxacin, penicillin, carbamazepine, lamotrigine, 
IV immunoglobulin, OKT3 antibodies, phenazo-
pyridine; improvement after discontinuation of 
drug; recurrence with repeat exposure
Granulomatosis with 
polyangiitis (Wegener’s)
Mononuclear cells
Chest and sinus radiographs; urinalysis; 
ANCA antibodies in serum
Associated sinus, pulmonary, or renal lesions; 
CN palsies; skin lesions; peripheral neuropathy
Other: multiple sclerosis, Sjögren’s syndrome, neonatal-onset multisystemic inflammatory disease (NOMID), and rarer forms of vasculitis
(e.g., Cogan’s syndrome)
Abbreviations: ANCA, anti-neutrophil cytoplasmic antibodies; CN, cranial nerve; CSF, cerebrospinal fluid; CT, computed tomography; HSV, herpes simplex virus; MRI, magnetic 
resonance imaging; PCR, polymerase chain reaction; PMNs, polymorphonuclear cells.
1291
SECTION 14
1292
Neurology
CHAPTER 205
Peripheral Neuropathies 
Including Guillain-Barré 
Syndrome (GBS)
Peripheral Neuropathy
APPROACH TO THE
PATIENT
Peripheral neuropathy (PN) refers to a peripheral nerve disorder of any 
cause. Nerve involvement may be single (mononeuropathy) or mul-
tiple (polyneuropathy); pathology may be axonal or demyelinating. An 
approach to pts with suspected neuropathy appears in Fig. 205-1.
Address the following seven  initial questions:
1. What systems are involved? It is important to determine if the pt’s 
symptoms and signs are motor, sensory, autonomic, or a combination 
of these. If only weakness is present without any evidence of sensory or 
autonomic dysfunction, consider a motor neuropathy, neuromuscular 
junction disorder, or myopathy; myopathies usually have a proximal, 
symmetric pattern of weakness.
2. What is the distribution of weakness? Polyneuropathy involves wide-
spread and symmetric dysfunction of the peripheral nerves that is 
usually distal more than proximal; mononeuropathy involves a single 
nerve usually due to trauma or compression; multiple mononeuropa-
thies (mononeuropathy multiplex) can be a result of multiple entrap-
ments, vasculitis, or infiltration.
3. What is the nature of the sensory involvement? Temperature loss or 
burning/stabbing pain suggests small fiber involvement. Vibratory or 
proprioceptive loss implicates large fibers.
lymphocytic meningitis at tuberculosis, particularly if the condition is 
associated with hypoglycorrhachia and sixth and other cranial nerve 
palsies, since untreated disease can be fatal in 4–8 weeks. Carcinomatous 
or lymphomatous meningitis may be difficult to diagnose initially, but 
the diagnosis becomes evident with time. Important causes of chronic 
meningitis in AIDS pts include infection with Toxoplasma (usually 
presents as intracranial abscesses), Cryptococcus, Nocardia, Candida, or 
other fungi; syphilis; and lymphoma.
For a more detailed discussion, see Koroshetz WJ, Swartz 
MN: Chronic and Recurrent Meningitis, Chap. 382, p. 3435, 
in HPIM-18.
Patient Complaint: ? Neuropathy
History and examination compatible with neuropathy?
Mononeuropathy
Mononeuropathy multiplex
Polyneuropathy
Evaluation of other
 disorder or
 reassurance and
 follow-up
EDx
Is the lesion axonal
 or demyelinating?
Is entrapment or
 compression present?
Is a contributing systemic 
  disorder present?
Axonal
Demyelinating
 with focal
 conduction block
Axonal
Demyelinating
Consider
 vasculitis or 
 other multifocal
 process
Consider multifocal
 form of CIDP
Subacute
 course (months)
Chronic
 course (years)
Uniform slowing,
 chronic
Nonuniform slowing,
conduction block
Decision on need
 for surgery (nerve repair,
 transposition, or release
 procedure)
Possible
 nerve biopsy
Test for paraprotein,
 HIV, Lyme disease
Review history for toxins;
 test for associated
 systemic disease or
 intoxication
Test for paraprotein,
   if negative
Review family
 history; examine
 family members;
 genetic testing
If chronic or
 subacute: CIDP
If acute: GBS
Treatment appropriate
 for specific diagnosis
If tests are
 negative, consider
 treatment for
 CIDP
Treatment appropriate
 for specific diagnosis
Genetic counseling if appropriate
Treatment
  for CIDP; see
  Ch.385 in HPIM-18
IVIg or
 plasmapheresis;
 supportive care
 including respiratory
  assistance
EDx
EDx
No
Yes
FIGURE 205-1 Approach to evaluation of peripheral neuropathies. CIDP, chronic inflammatory demyelinating polyradiculoneuropathy; EDX, electrodiagnostic
studies; GBS, Guillain-Barré syndrome; IVIg, intravenous immunoglobulin.
1293
SECTION 14
1294
Neurology
4. Is there evidence of upper motor neuron involvement? The most com-
mon cause is combined system degeneration with B12 deficiency, but 
should also consider copper deficiency, HIV infection, severe hepatic 
disease, and adrenomyeloneuropathy.
5. What is the temporal evolution? Most neuropathies are insidious and 
slowly progressive. Rapidly evolving neuropathies are often inflam-
matory, including acute inflammatory demyelinating polyneuropathy 
(AIDP) or Guillain-Barré syndrome (GBS); subacute evolution sug-
gests an inflammatory, toxic, or nutritional cause; chronic neuropa-
thies that are long-standing over years may be hereditary.
6. Is there evidence for a hereditary neuropathy? Consider in pts with a 
slowly progressive distal weakness over many years with few sensory 
symptoms but significant sensory deficits on clinical examination. 
Most common is Charcot-Marie-Tooth disease (CMT; look for foot 
abnormalities such as high or flat arches, hammer toes).
7. Does the pt have any other medical conditions? Inquire about associat-
ed medical conditions (e.g., diabetes, systemic lupus erythematosus); 
preceding or concurrent infections (e.g., diarrheal illness preceding 
GBS); surgeries (e.g., gastric bypass and nutritional neuropathies); 
medications (toxic neuropathy); over-the-counter vitamin prepara-
tions (B6); alcohol, dietary habits; and use of dentures (because fixa-
tives contain zinc that can lead to copper deficiency). 
Based on the answers to these seven key questions, neuropathic dis-
orders can be classified into several patterns based on the distribution 
or pattern of sensory, motor, and autonomic involvement (Table 205-1).
� POLYNEUROPATHY
Diagnostic Evaluation 
Screening laboratory studies in a distal, symmetric polyneuropathy may include 
a complete blood count, basic chemistries including serum electrolytes and tests 
of renal and hepatic function, fasting blood glucose, HbA1c, urinalysis, thyroid 
function tests, B12, folate, ESR, rheumatoid factor, ASA, SPEP, and urine for 
Bence Jones protein. An oral glucose tolerance test is indicated in pts with pain-
ful sensory neuropathies even if other screens for diabetes are negative.
Diagnostic tests to further characterize the neuropathy include nerve 
conduction studies (NCS), electromyography (EMG), sural nerve biopsy, 
muscle biopsy, and quantitative sensory testing. Diagnostic tests are more 
likely to be informative in pts with asymmetric, motor-predominant, rapid-
onset, or demyelinating neuropathies.
Electrodiagnosis
NCS are carried out by stimulating motor or sensory nerves electrically. 
Demyelination is characterized by slowing of nerve conduction velocity (NCV), 
dispersion of evoked compound action potentials, conduction block (decreased 
amplitude of muscle compound action potentials on proximal, as compared to 
distal, stimulation of the nerve), and prolongation of distal latencies. In contrast, 
axonal neuropathies exhibit reduced amplitude of evoked compound action 
potentials with relative preservation of NCV. EMG records electrical potentials 
CHAPTER 205 1295
Peripheral Neuropathies
TABLE 205-1 PATTERNS OF NEUROPATHIC DISORDERS
Pattern 1: Symmetric proximal and distal weakness with sensory loss
 Consider: inflammatory demyelinating polyneuropathy (GBS and CIDP)
Pattern 2: Symmetric distal sensory loss with or without distal weakness
  Consider: cryptogenic or idiopathic sensory polyneuropathy (CSPN), 
diabetes mellitus and other metabolic disorders, drugs, toxins, hereditary 
(Charcot-Marie-Tooth, amyloidosis, and others)
Pattern 3: Asymmetric distal weakness with sensory loss
With involvement of multiple nerves
  Consider: multifocal CIDP, vasculitis, cryoglobulinemia, amyloidosis, 
sarcoid, infectious (leprosy, Lyme, hepatitis B or C, HIV, CMV), hereditary 
neuropathy with liability to pressure palsies (HNPP), tumor infiltration
With involvement of single nerves/regions
  Consider: may be any of the above but also could be compressive 
mononeuropathy, plexopathy, or radiculopathy
Pattern 4: Asymmetric proximal and distal weakness with sensory loss
  Consider: polyradiculopathy or plexopathy due to diabetes mellitus, 
meningeal carcinomatosis or lymphomatosis, hereditary plexopathy (HNPP, 
HNA), idiopathic
Pattern 5: Asymmetric distal weakness without sensory loss
With upper motor neuron findings
 Consider: motor neuron disease
Without upper motor neuron findings
  Consider: progressive muscular atrophy, juvenile monomelic amyotrophy 
(Hirayama disease), multifocal motor neuropathy, multifocal acquired 
motor axonopathy
Pattern 6: Symmetric sensory loss and distal areflexia with upper motor 
neuron findings
  Consider: Vitamin B12, vitamin E, and copper deficiency with combined 
system degeneration with peripheral neuropathy, hereditary leukodystro-
phies (e.g., adrenomyeloneuropathy)
Pattern 7: Symmetric weakness without sensory loss
With proximal and distal weakness
 Consider: spinal muscular atrophy
With distal weakness
 Consider: hereditary motor neuropathy (“distal” SMA) or atypical CMT
Pattern 8: Asymmetric proprioceptive sensory loss without weakness
 Consider causes of a sensory neuronopathy (ganglionopathy):
 Cancer (paraneoplastic)
 Sjögren’s syndrome
 Idiopathic sensory neuronopathy (possible GBS variant)
(continued)
SECTION 14
1296
Neurology
from a needle electrode in muscle, at rest and during voluntary contraction; 
it is most useful for distinguishing myopathic from neuropathic disorders. 
Myopathic disorders are marked by small, short-duration, polyphasic muscle 
action potentials; by contrast, neuropathic disorders are characterized by 
muscle denervation. Denervation decreases the number of motor units (e.g., 
an anterior horn cell, its axon, and the motor end plates and muscle fibers it 
innervates). In long-standing denervation, motor unit potentials become large 
and polyphasic due to collateral reinnervation of denervated muscle fibers by 
axonal sprouts from surviving motor axons. Other EMG features of denerva-
tion include fibrillations (random, unregulated firing of individual muscle 
fibers) and fasciculations (random, spontaneous firing of motor units).
Polyneuropathy
TREATMENT
• Treatment of the underlying disorder, pain management, and sup-
portive care to protect and rehabilitate damaged tissue all need to 
be considered. 
• Examples of specific therapies include tight glycemic control in 
diabetic neuropathy, vitamin replacement for B12 deficiency, IV 
immune globulin (IVIg) or plasmapheresis for GBS, and immuno-
suppression for vasculitis.
• Painful sensory neuropathies can be difficult to treat. Pain manage-
ment usually begins with tricyclic antidepressants (TCAs), duloxetine 
hydrochloride, lidocaine patches, or anticonvulsants such as gabap-
entin (Table 205-2). Topical anesthetic agents including EMLA (lido-
caine/prilocaine) and capsaicin cream can provide additional relief.
TABLE 205-1 PATTERNS OF NEUROPATHIC DISORDERS (CONTINUED)
Pattern 8: Asymmetric proprioceptive sensory loss without weakness
 Cisplatin and other chemotherapeutic agents
 Vitamin B6 toxicity
 HIV-related sensory neuronopathy
Pattern 9: Autonomic symptoms and signs
 Consider neuropathies associated with prominent autonomic dysfunction:
 Hereditary sensory and autonomic neuropathy
 Amyloidosis (familial and acquired)
 Diabetes mellitus
 Idiopathic pandysautonomia (may be a variant of Guillain-Barré syndrome)
 Porphyria
 HIV-related autonomic neuropathy
 Vincristine and other chemotherapeutic agents
Abbreviations: CIDP, chronic inflammatory demyelinating polyneuropathy; CMT, Charcot-
Marie-Tooth disease; CMV, cytomegalovirus; GBS, Guillain-Barré syndrome; HIV, human 
immunodeficiency virus; HNA, hereditary neuralgic amyotrophy; SMA, spinal muscular atrophy.
CHAPTER 205 1297
Peripheral Neuropathies
TABLE 205-2 TREATMENT OF PAINFUL SENSORY NEUROPATHIES
Therapy
Route
Dose
Side Effects
First-line
Lidocaine 5% 
patch
Apply to 
painful area
Up to 3 
patches qd
Skin irritation
Tricyclic antide-
pressants (e.g., 
amitriptyline, 
nortriptyline)
PO
10–100 mg 
qhs
Cognitive changes, sedation, 
dry eyes and mouth, urinary 
retention, constipation
Gabapentin
PO
300–1200 
mg tid
Cognitive changes, sedation, 
peripheral edema
Pregabalin
PO
50–100 mg 
tid
Cognitive changes, sedation, 
peripheral edema
Duloxetine
PO
30–60 mg 
qd
Cognitive changes, sedation, 
dry eyes, diaphoresis, nau-
sea, diarrhea, constipation
Second-line
Carbamazepine
PO
200–400 
mg q 6–8 h
Cognitive changes, dizziness, 
leukopenia, liver dysfunction
Phenytoin
PO
200–400 
mg qhs
Cognitive changes, dizziness, 
liver dysfunction
Venlafaxine
PO
37.5–150 
mg/d
Asthenia, sweating, nausea, 
constipation, anorexia, 
vomiting, somnolence, dry 
mouth, dizziness, nervous-
ness, anxiety, tremor, and 
blurred vision as well as 
abnormal ejaculation/orgasm 
and impotence
Tramadol
PO
50 mg qid
Cognitive changes, GI upset
Third-line
Mexiletine
PO
200–300 
mg tid
Arrhythmias
Other agents
EMLA cream 
Cutaneous
qid
Local erythema
  2.5% 
lidocaine
  2.5% 
prilocaine
Capsaicin 
0.025%–
0.075% cream
Cutaneous
qid
Painful burning skin
Source: Modified from Amato AA, Russell J: Neuromuscular Disease. New York, McGraw-Hill, 
2008.
SECTION 14
1298
Neurology
• Physical and occupational therapy is important. Proper care of dener-
vated areas prevents skin ulceration, which can lead to poor wound 
healing, tissue resorption, arthropathy, and ultimately amputation.
Specific Polyneuropathies
AIDP or GBS: an ascending, usually demyelinating, motor > sensory polyneu-
ropathy accompanied by areflexia, motor paralysis, and elevated CSF total pro-
tein without pleocytosis. Over two-thirds are preceded by an acute respiratory 
or gastrointestinal infection. Maximum weakness is usually reached within 
2 weeks; demyelination by EMG. Most pts are hospitalized; one-third require 
ventilatory assistance. 85% make a complete or near-complete recovery 
with supportive care. Variants of GBS include Fisher syndrome (ophthalmo-
paresis, facial diplegia, ataxia, areflexia; associated with serum antibodies to 
ganglioside GQ1b) and acute motor axonal neuropathy (more severe course 
than demyelinating GBS; antibodies to GM1 in some cases).
• IVIg (2 g/kg divided over 5 days) or plasmapheresis (40–50 mL/kg daily 
for 4–5 days) significantly shortens the course. 
• Glucocorticoids are ineffective. 
Chronic inflammatory demyelinating polyneuropathy (CIDP): a slowly pro-
gressive or relapsing polyneuropathy characterized by diffuse hyporeflexia 
or areflexia, diffuse weakness, elevated CSF protein without pleocytosis, and 
demyelination by EMG. 
• Begin treatment when progression is rapid or walking is compromised.
• Initial treatment is usually IVIg; most pts require periodic re-treatment 
at 4- to 6-week intervals.
• Other first-line treatment options include plasmapheresis or glucocorticoids 
• Immunosuppressants (azathioprine, methotrexate, cyclosporine, cyclo-
phosphamide) used in refractory cases.
Diabetic neuropathy: typically a distal symmetric, sensorimotor, axonal poly-
neuropathy. A mixture of demyelination and axonal loss is frequent. Other 
variants include: isolated sixth or third cranial nerve palsies, asymmetric 
proximal motor neuropathy in the legs, truncal neuropathy, autonomic neu-
ropathy, and an increased frequency of entrapment neuropathy (see below). 
Mononeuropathy multiplex (MM): defined as involvement of multiple 
individual peripheral nerves. When an inflammatory disorder is the cause, 
mononeuritis multiplex is the term used. Both systemic (67%) and nonsys-
temic (33%) vasculitis may present as MM. Immunosuppressive treatment 
of the underlying disease (usually with glucocorticoids and cyclophos-
phamide) is indicated. A tissue diagnosis of vasculitis should be obtained 
before initiating treatment; a positive biopsy helps to justify the necessary 
long-term treatment with immunosuppressive medications, and pathologic 
confirmation is difficult after treatment has commenced.
� MONONEUROPATHY
Clinical Features 
Mononeuropathies are usually caused by trauma, compression, or entrap-
ment. Sensory and motor symptoms are in the distribution of a single 
TABLE 205-3 MONONEUROPATHIES
Symptoms
Precipitating Activities
Examination
Electro-Diagnosis
Differential 
Diagnosis
Treatment
Carpal tunnel 
syndrome
Numbness, pain 
or paresthesias in 
fingers
Sleep or repetitive hand 
activity
Sensory loss in thumb, 
second, and third 
fingers
Slowing of sensory 
and motor conduc-
tion across carpal 
tunnel
C6 radiculopathy
Splint
Surgery definitive 
treatment
Weakness in thenar 
muscles; inability to 
make a circle with 
thumb and index finger
Tinel sign, Phalen 
maneuver
Ulnar nerve 
entrapment 
at the elbow 
(UNE)
Numbness or 
paresthesias in 
ulnar aspect of 
hand
Elbow flexion during 
sleep; elbow resting on 
desk
Sensory loss in the 
little finger and ulnar 
half of ring finger
Focal slowing of 
nerve conduction 
velocity at the 
elbow
Thoracic outlet 
syndrome
C8-T1 radiculopa-
thy
Elbow pads
Avoid further injury
Surgery when 
conservative treatment 
fails
Weakness of the 
interossei and thumb 
adductor; claw-hand
Ulnar nerve 
entrapment at 
the wrist
Numbness or 
weakness in the 
ulnar distribution 
in the hand
Unusual hand activities 
with tools, bicycling
Like UNE but sensory 
examination spares 
dorsum of the hand, 
and selected hand 
muscles affected
Prolongation of 
distal motor latency 
in the hand
UNE
Avoid precipitating 
activities
(continued)
1299
TABLE 205-3 MONONEUROPATHIES (CONTINUED)
Symptoms
Precipitating Activities
Examination
Electro-Diagnosis
Differential 
Diagnosis
Treatment
Radial neuropa-
thy at the spiral 
groove
Wrist drop
Sleeping on arm 
after inebriation with 
alcohol—“Saturday 
night palsy”
Wrist drop with spar-
ing of elbow extension 
(triceps sparing); finger 
and thumb extensors 
paralyzed; sensory loss 
in radial region of wrist
Early—conduction
block along the 
spiral groove
Posterior cord 
lesion; deltoid also 
weak
Splint
Spontaneous recovery 
provided no ongoing 
injury
Late—denervation 
in radial muscles; 
reduced radial 
SNAP
Posterior interos-
seous nerve (PIN); 
isolated finger drop
C7 radiculopathy
Thoracic outlet 
syndrome
Numbness, 
paresthesias in 
medial arm, fore-
arm, hand, and 
fingers
Lifting heavy objects 
with the hand
Sensory loss resem-
bles ulnar nerve and 
motor loss resembles 
median nerve
Absent ulnar 
sensory response 
and reduced 
median motor 
response
UNE
Surgery if correctable 
lesion present
Femoral neu-
ropathy
Buckling of knee, 
numbness or 
tingling in thigh/
medial leg
Abdominal hysterec-
tomy; lithotomy position; 
hematoma, diabetes
Wasting and weakness 
of quadriceps; absent 
knee jerk; sensory loss 
in medial thigh and 
lower leg
EMG of quadriceps, 
iliopsoas, para-
spinal muscles, 
adductor muscles
L2-4 radiculopathy
Lumbar plexopathy
Physiotherapy to 
strengthen quadriceps 
and mobilize hip joint
Surgery if needed
Obturator 
neuropathy
Weakness of 
the leg, thigh 
numbness
Stretch during hip 
surgery; pelvic fracture; 
childbirth
Weakness of hip 
adductors; sensory loss 
in upper medial thigh
EMG—denerva-
tion limited to hip 
adductors sparing 
the quadriceps
L3-4 radiculopathy
Lumbar plexopathy
Conservative 
management
Surgery if needed
1300
Meralgia
paresthetica
Pain or numbness 
in the anterior 
lateral thigh
Standing or walking
Sensory loss in the 
pocket of the pant 
distribution
Sometimes slow-
ing of sensory 
response can be 
demonstrated 
across the inguinal 
ligament
L2 radiculopathy
Usually resolves 
spontaneously
Recent weight gain
Peroneal nerve 
entrapment at 
the fibular head
Footdrop
Usually an acute com-
pressive episode identi-
fiable; weight loss
Weak dorsiflexion, 
eversion of the foot
Focal slowing of 
nerve conduction 
across fibular head
L5 radiculopathy
Foot brace; remove 
external source of 
compression
Sensory loss in the 
anterolateral leg and 
dorsum of the foot
Denervation in 
tibialis anterior and 
peroneus longus 
muscles
Sciatic 
neuropathy
Flail foot and 
numbness in foot
Injection injury; fracture/
dislocation of hip; pro-
longed pressure on hip 
(comatose pt)
Weakness of ham-
string, plantar and 
dorsiflexion of foot; 
sensory loss in tibial 
and peroneal nerve 
distribution
NCS—abnormal
sural, peroneal, and 
tibial amplitudes
L5-S1 radiculopa-
thies
Common peroneal 
neuropathy (partial 
sciatic nerve injury)
LS plexopathies
Conservative follow up 
for partial sciatic nerve 
injuries
Brace and physio-
therapy
Surgical exploration 
if needed
EMG—denervation 
in sciatic nerve 
distribution sparing 
glutei and para-
spinal
Tarsal tunnel 
syndrome
Pain and par-
esthesias in the 
sole of the foot 
but not in the 
heel
At the end of the day 
after standing or walk-
ing; nocturnal
Sensory loss in the 
sole of the foot
Tinel sign at tarsal 
tunnel
Reduced amplitude 
in sensory or motor 
components of 
medial and planter 
nerves
Polyneuropathy, 
foot deformity, poor 
circulation
Surgery if no external 
cause identified
1301
SECTION 14
1302
Neurology
nerve—most commonly the ulnar or median nerve in the arm or peroneal 
nerve in the leg. Intrinsic factors making pts more susceptible to entrap-
ment include arthritis, fluid retention (pregnancy), amyloid, tumors, and 
diabetes mellitus. Clinical features favoring conservative management 
of median neuropathy at the wrist (carpal tunnel syndrome) or ulnar 
neuropathy at the elbow include sudden onset, no motor deficit, few or no 
sensory findings (pain or paresthesias may be present), and no evidence 
of axonal loss by EMG. Surgical decompression is considered for chronic 
mononeuropathies that are unresponsive to conservative treatment, if the 
site of entrapment is clearly defined. The most frequently encountered 
mononeuropathies are summarized in Table 205-3. 
For a more detailed discussion, see Amato AA, Barohn RJ: 
Peripheral Neuropathy, Chap. 384, p. 3448; and Hauser SL, 
Amato AA: Guillain-Barré Syndrome and Other Immune-
Mediated Neuropathies, Chap. 385, p. 3473, in HPIM-18.
CHAPTER 206
Myasthenia Gravis (MG)
An autoimmune neuromuscular disorder resulting in weakness and 
fatigability of skeletal muscles, due to autoantibodies directed against 
acetylcholine receptors (AChRs) at neuromuscular junctions (NMJs).
� CLINICAL FEATURES
May present at any age. Symptoms fluctuate throughout the day and are 
provoked by exertion. Characteristic distribution: cranial muscles (eyelids, 
extraocular muscles, facial weakness, “nasal” or slurred speech, dysphagia); 
in 85%, limb muscles (often proximal and asymmetric) become involved. 
Reflexes and sensation normal. May be limited to extraocular muscles 
only. Complications: aspiration pneumonia (weak bulbar muscles), respi-
ratory failure (weak chest wall muscles), exacerbation of myasthenia due 
to administration of drugs with neuromuscular junction blocking effects 
(quinolones, macrolides, aminoglycosides, procainamide, propranolol, 
nondepolarizing muscle relaxants).
� PATHOPHYSIOLOGY
Anti-AChR antibodies reduce the number of available AChRs at the NMJ. 
Postsynaptic folds are flattened or “simplified,” with resulting inefficient 
neuromuscular transmission. During repeated or sustained muscle contrac-
tion, decrease in amount of ACh released per nerve impulse (“presynaptic 
rundown,” a normal occurrence), combined with disease-specific decrease 
in postsynaptic AChRs, results in pathologic fatigue. Thymus is abnormal 
in 75% of pts (65% hyperplasia, 10% thymoma). Other autoimmune 
diseases may coexist: Hashimoto’s thyroiditis, Graves’ disease, rheumatoid 
arthritis, systemic lupus erythematosus.
CHAPTER 206 1303
Myasthenia Gravis (MG)
� DIFFERENTIAL DIAGNOSIS
Lambert-Eaton syndrome (autoantibodies to calcium channels in presynaptic 
motor nerve terminals)—reduced ACh release; may be associated with 
malignancy
Neurasthenia—weakness/fatigue without underlying organic disorder
Drug-induced myasthenia—penicillamine may cause MG; resolves weeks to 
months after discontinuing drug
Botulism—toxin inhibits presynaptic ACh release; most common form is 
food-borne.
Diplopia from an intracranial mass lesion—compression of nerves to extra-
ocular muscles or brainstem lesions affecting cranial nerve nuclei
Hyperthyroidism
Progressive external ophthalmoplegia—seen in rare mitochondrial disorders 
that can be detected with muscle biopsy
� LABORATORY EVALUATION
• AChR antibodies—levels do not correlate with disease severity; 85% of all 
MG pts are positive; only 50% with pure ocular findings are positive; posi-
tive antibodies are diagnostic. Muscle-specific kinase (MuSK) antibodies 
present in 40% of AChR antibody–negative pts with generalized MG.
• Tensilon (edrophonium) test—a short-acting anticholinesterase—look 
for rapid and transient improvement of strength; false-positive (placebo 
response, motor neuron disease) and false-negative tests occur. Atropine IV 
should be on hand if symptoms such as bradycardia occur.
• EMG—low-frequency (2–4 Hz) repetitive stimulation produces rapid 
decrement in amplitude (>10–15%) of evoked motor responses.
• Chest CT/MRI—search for thymoma.
• Consider thyroid and other studies (e.g., ANA) for associated autoimmune 
disease.
• Measurements of baseline respiratory function are useful.
Myasthenia Gravis (See Fig. 206-1)
TREATMENT
• The anticholinesterase drug pyridostigmine (Mestinon) titrated to 
assist pt with functional activities (chewing, swallowing, strength 
during exertion); usual initial dose of 30–60 mg 3–4 times daily; 
long-acting tablets help at night but have variable absorption so 
are not reliable during the day. Muscarinic side effects (diarrhea, 
abdominal cramps, salivation, nausea) blocked with atropine/
diphenoxylate or loperamide if required. 
• Plasmapheresis or IV immune globulin (IVIg; 400 mg/kg per day for 
5 days) provides temporary boost for seriously ill pts; used to improve 
condition prior to surgery or during myasthenic crisis (see below).
• Thymectomy improves likelihood of long-term remission in adult 
pts (~85% improve; of these, ~35% achieve drug-free remission); 
benefit is usually delayed by months to years; whether it helps those 
with pure ocular disease, children, or those age >55 remains unclear. 
SECTION 14
1304
Neurology
Establish diagnosis unequivocally (see Table 386-1 in HPIM-18)
Search for associated conditions (see Table 386-3 in HPIM-18)
Ocular only
MRI of brain
  (if positive,
   reassess)
Anticholinesterase
  (pyridostigmine)
Anticholinesterase
  (pyridostigmine)
Evaluate for thymectomy
  (indications: thymoma or
  generalized MG);
  evaluate surgical risk, FVC
Crisis
Intensive care
  (tx respiratory
 infection; fluids)
Generalized
If unsatisfactory
Thymectomy
Good risk
  (good FVC)
Poor risk
  (low FVC)
If not
  improved
Immunosuppression
Evaluate clinical status; if indicated,
  go to immunosuppression
Improved
See text for short-term, intermediate,
and long-term treatments
Plasmapheresis
 or intravenous Ig
then
MANAGEMENT OF MG
FIGURE 206-1 Algorithm for the management of myasthenia gravis. FVC, forced 
vital capacity.
CHAPTER 206 1305
Myasthenia Gravis (MG)
TABLE 206-1 DRUGS WITH INTERACTIONS IN MYASTHENIA GRAVIS (MG) 
Drugs That May Exacerbate MG
Antibiotics
Aminoglycosides: e.g., streptomycin, tobramycin, kanamycin
Quinolones: e.g., ciprofloxacin, levofloxacin, ofloxacin, gatifloxacin
Macrolides: e.g., erythromycin, azithromycin
Nondepolarizing muscle relaxants for surgery
D-Tubocurarine (curare), pancuronium, vecuronium, atracurium
Beta-blocking agents
Propranolol, atenolol, metoprolol
Local anesthetics and related agents
Procaine, lidocaine in large amounts
Procainamide (for arrhythmias)
Botulinum toxin
Botulinum toxin exacerbates weakness
Quinine derivatives
Quinine, quinidine, chloroquine, mefloquine (Lariam)
Magnesium
Decreases ACh release
Penicillamine
May cause MG
Drugs with Important Interactions in MG
Cyclosporine
Broad range of drug interactions, which may raise or lower cyclosporine 
levels
Azathioprine
Avoid allopurinol—combination may result in myelosuppression
• Glucocorticoids are a mainstay of chronic immunosuppressive treat-
ment; begin prednisone at low dose (15–25 mg/d), increase by 5 mg/d 
every 2–3 days until marked clinical improvement or dose of 50–60 
mg/d is reached. Maintain high dose for 1–3 months, then decrease 
to alternate-day regimen. Immunosuppressive drugs (mycophenolate 
mofetil, azathioprine, cyclosporine, tacrolimus, cyclophosphamide) 
may spare dose of prednisone required long-term to control symptoms. 
• Myasthenic crisis is defined as an exacerbation of weakness, usually 
with respiratory failure, sufficient to endanger life; expert manage-
ment in an intensive care setting essential as is prompt treatment 
with IVIg or plasmapheresis to hasten recovery.
• A number of drugs may exacerbate MG, potentially leading to crisis, 
and therefore should be avoided (Table 206-1).
SECTION 14
1306
Neurology
CHAPTER 207
Muscle Diseases
Muscle Disease
APPROACH TO THE
PATIENT
Muscle diseases (myopathies) may be intermittent or persistent and usu-
ally present with proximal, symmetric weakness with preserved reflexes 
and sensation. An associated sensory loss suggests injury to peripheral 
nerve or the central nervous system rather than myopathy; on occasion, 
disorders affecting the anterior horn cells, the neuromuscular junction, 
or peripheral nerves can mimic myopathy. Any disorder causing muscle 
weakness may be accompanied by fatigue, referring to an inability to 
maintain or sustain a force; this must be distinguished from asthenia, 
a type of fatigue caused by excess tiredness or lack of energy. Fatigue 
without abnormal clinical or laboratory findings almost never indicates 
a true myopathy.
Muscle disorders are usually painless; however, myalgias, or muscle 
pains, may occur. Myalgias must be distinguished from muscle cramps, 
i.e., painful, involuntary muscle contractions, usually due to neurogenic 
disorders. A muscle contracture due to an inability to relax after an active 
muscle contraction is associated with energy failure in glycolytic disor-
ders. Myotonia is a condition of prolonged muscle contraction followed 
by slow muscle relaxation.
A limited battery of tests can be used to evaluate a suspected myopathy. 
CK is the preferred muscle enzyme to measure in the evaluation of 
myopathies. Electrodiagnostic studies (nerve conduction studies and 
electromyography, NCS-EMG) are usually necessary to distinguish 
myopathies from neuropathies and neuromuscular junction disorders. 
An approach to muscle weakness is presented in Figs. 207-1 and 207-2. 
MUSCULAR DYSTROPHIES
A varied group of inherited, progressive degenerations of muscle, each with 
unique features.
� DUCHENNE’S MUSCULAR DYSTROPHY
X-linked recessive mutation of the dystrophin gene that affects males 
almost exclusively. Progressive weakness in hip and shoulder girdle muscles 
beginning by age 5; by age 12, the majority are nonambulatory. Survival 
beyond age 25 is rare. Associated problems include tendon and muscle 
For a more detailed discussion, see Drachman DB: 
Myasthenia Gravis and Other Diseases of the Neuromuscular 
Junction, Chap. 386, p. 3480, in HPIM-18.
1307
Intermittent Weakness
DIAGNOSTIC EVALUATION OF INTERMITTENT WEAKNESS
Myoglobinuria
Variable weakness includes
  EOMs, ptosis, bulbar and limb muscles
Repetitive nerve
  stimulation decrement
AChR AB or Musk
AB positive
Acquired MG
AChR AB and Musk
AB negative
Congenital MG
Acquired MG
Lambert-Eaton
myasthenic syndrome
Yes
No
Exam normal between attacks
Proximal > distal weakness during attacks
Exam usually normal between attacks
Proximal > distal weakness during attacks
Forearm exercise
Myotonia on exam
DNA test confirms diagnosis
Low potassium
level
Normal or elevated
  potassium level
Hypokalemic PP
Hyperkalemic PP
Paramyotonia congenita
Muscle biopsy
  defines specific defect
Reduced lactic acid rise
Consider glycolytic defect
Normal lactic acid rise
Consider CPT deficiency
or other fatty acid
metabolism disorders
No
Yes
No
Yes
FIGURE 207-1 Diagnostic evaluation of intermittent weakness. AChR AB, acetylcholine receptor antibody; CPT, carnitine palmityl transferase; EOMs,
extraocular muscles; MG, myasthenia gravis; PP, periodic paralysis.
1308
Persistent Weakness
DIAGNOSTIC EVALUATION OF PERSISTENT WEAKNESS
Patterns of Weakness on Neurologic Exam
Myopathic EMG confirms muscle disease and excludes ALS
Repetitive nerve stimulation indicates MG
CK elevation supports myopathy
May need DNA testing for further distinction of inherited myopathies
Muscle biopsy will help distinguish many disorders
Proximal > distal
  PM; DM; muscular
    dystrophies;
 
mitochondrial
 
and metabolic
 
myopathies;
 
toxic, endocrine
 
myopathies
Facial, distal, 
  quadriceps;
  handgrip myotonia
  Myotonic muscular
    dystrophy
Proximal & distal
(hand grip), &
quadriceps
 IBM
Ptosis, EOMs
  OPMD;
  mitochondrial
  myopathy;
  myotubular
  myopathy
Facial and
scapular winging
 (FSHD)
Dropped head
  MG; PM; ALS;
 hyperpara-
 thyroid
Distal
Distal myopathy
FIGURE 207-2 Diagnostic evaluation of persistent weakness. ALS, amyotrophic lateral sclerosis; CK, creatinine kinase; DM, dermatomyositis; EOM, extraocular 
muscle; FSHD, facioscapulohumeral muscular dystrophy; IBM, inclusion body myositis; MG, myasthenia gravis; OPMD, oculopharyngeal muscular dystrophy; 
PM, polymyositis.
CHAPTER 207 1309
Muscle Diseases
contractures, progressive kyphoscoliosis, impaired pulmonary function, 
cardiomyopathy, and intellectual impairment. Palpable enlargement and 
firmness of some muscles. Becker dystrophy is a less severe form, with a 
slower course and later age of onset (5–15 yrs) but similar clinical, labora-
tory, and genetic features.
Laboratory findings include massive elevations (20–100 × normal) of 
serum CK, a myopathic pattern on EMG testing, and evidence of groups of 
necrotic muscle fibers with regeneration, phagocytosis, and fatty replacement 
of muscle on biopsy. Diagnosis is established by determination of dystrophin 
deficiency in muscle tissue or mutation analysis on peripheral blood 
leukocytes. Testing is available for detecting carriers and prenatal diagnosis.
Duchenne’s Muscular Dystrophy
TREATMENT
• Treatment is with glucocorticoids [prednisone (0.75 mg/kg)/d]. 
These slow progression of disease for up to 3 years; some pts cannot 
tolerate this therapy due to weight gain and increased risk of 
fractures.
� LIMB-GIRDLE DYSTROPHY
A constellation of diseases with proximal weakness involving the pelvic 
and shoulder girdle musculature. Age of onset, rate of progression, severity 
of manifestations, inheritance pattern (autosomal dominant or autosomal 
recessive), and associated complications (e.g., cardiac, respiratory) vary 
with the specific subtype of disease.
� MYOTONIC DYSTROPHY
Type 1 is an autosomal dominant disorder with genetic anticipation. 
Weakness typically becomes obvious in the second to third decade and 
initially involves the muscles of the face, neck, and distal extremities. This 
results in a distinctive facial appearance (“hatchet face”) characterized by 
ptosis, temporal wasting, drooping of the lower lip, and sagging of the jaw. 
Myotonia manifests as a peculiar inability to relax muscles rapidly following 
a strong exertion (e.g., after tight hand grip) usually by the age of 5, as well 
as by sustained contraction of muscles following percussion (e.g., of tongue 
or thenar eminence).
Associated problems can include frontal baldness, posterior subcapsular 
cataracts, gonadal atrophy, respiratory and cardiac problems, endocrine 
abnormalities, intellectual impairment, and hypersomnia. Cardiac distur-
bances, including complete heart block, may be life-threatening. Respiratory 
function should be carefully followed, as chronic hypoxia may lead to cor 
pulmonale.
Laboratory studies show normal or mildly elevated CK, characteristic 
myotonia and myopathic features on EMG, and a typical pattern of muscle 
fiber injury on biopsy, including selective type I fiber atrophy in 50% of 
cases. Pts with myotonic dystrophy type 1 have an unstable region of DNA 
with an increased number of trinucleotide CTG repeats on chromosome 
19q13.3 in a protein kinase gene. Genetic testing for early detection and 
prenatal diagnosis is possible.
SECTION 14
1310
Neurology
Myotonic Dystrophy
TREATMENT
• Phenytoin or mexiletine may help alleviate myotonia, although pts  
are rarely bothered by this symptom. 
• Pacemaker insertion may be required for syncope or heart block. 
• Orthoses may control foot drop, stabilize the ankle, and decrease 
falling. 
• Excessive daytime somnolence with or without sleep apnea is not 
uncommon; sleep studies, noninvasive respiratory support (BiPAP), 
and treatment with modafinil may be beneficial.
� FACIOSCAPULOHUMERAL (FSH) DYSTROPHY
An autosomal dominant, slowly progressive disorder with onset in child-
hood or young adulthood. Weakness involves facial (usually the initial 
manifestation), shoulder girdle, and proximal arm muscles and can result 
in atrophy of biceps, triceps, and scapular winging. Facial weakness results 
in inability to smile, whistle, or fully close the eyes with loss of facial expres-
sivity. Foot drop and leg weakness may cause falls and progressive difficulty 
with ambulation.
Laboratory studies reveal normal or slightly elevated CK and usually 
myopathic features on EMG and muscle biopsy. Pts have deletions at 
chromosome 4q35. Genetic testing is available for carrier detection and 
prenatal diagnosis.
Facioscapulohumeral Dystrophy
TREATMENT
• Ankle-foot orthoses are helpful for foot drop. 
• Scapular stabilization procedures may help scapular winging but 
may not improve function.
� OCULOPHARYNGEAL DYSTROPHY 
Onset in the fourth to sixth decade of ptosis, limitation of extraocular 
movements, and facial and cricopharyngeal weakness. One of sev-
eral disorders characterized by progressive external ophthalmoplegia. 
Dysphagia may be life-threatening. Most pts are of French-Canadian 
or Spanish-American descent. Mutation in a poly-RNA binding protein 
responsible.
INFLAMMATORY MYOPATHIES
The most common group of acquired and potentially treatable skeletal 
muscle disorders. Three major forms: polymyositis (PM), dermatomyositis 
(DM), and inclusion body myositis (IBM). Usually present as progressive 
and symmetric muscle weakness; extraocular muscles spared but pharyn-
geal weakness (dysphagia) and head drop from neck muscle weakness 
common. Respiratory muscles may be affected in advanced cases. IBM 
is characterized by early involvement of quadriceps (leading to falls) and 
CHAPTER 207 1311
Muscle Diseases
TABLE 207-1 FEATURES ASSOCIATED WITH INFLAMMATORY MYOPATHIES
Characteristic
Polymyositis
Dermatomyositis
Inclusion Body 
Myositis
Age at onset
>18 years
Adulthood and 
childhood
>50 years
Familial association
No
No
Yes, in some 
cases
Extramuscular
manifestations
Yes
Yes
Yes
Associated conditions
  Connective tissue 
diseases
Yesa
Scleroderma and 
mixed connective 
tissue disease 
(overlap syndromes)
Yes, in up to 20% 
of casesa
  Systemic autoim-
mune diseasesb
Frequent
Infrequent
Infrequent
 Malignancy
No
Yes, in up to 15% 
of cases
No
 Viruses
Yesc
Unproven
Yesc
 Drugsd
Yes
Yes, rarely
No
  Parasites and 
bacteriae
Yes
No
No
aSystemic lupus erythematosus, rheumatoid arthritis, Sjögren’s syndrome, systemic sclerosis, 
mixed connective tissue disease.
bCrohn’s disease, vasculitis, sarcoidosis, primary biliary cirrhosis, adult celiac disease, 
chronic graft-versus-host disease, discoid lupus, ankylosing spondylitis, Behçet’s syndrome, 
myasthenia gravis, acne fulminans, dermatitis herpetiformis, psoriasis, Hashimoto’s disease, 
granulomatous diseases, agammaglobulinemia, monoclonal gammopathy, hypereosinophilic 
syndrome, Lyme disease, Kawasaki disease, autoimmune thrombocytopenia, hypergamma-
globulinemic purpura, hereditary complement deficiency, IgA deficiency.
cHIV and HTLV-I (human T cell lymphotropic virus type I).
dDrugs include penicillamine (dermatomyositis and polymyositis), zidovudine (polymyositis), 
and contaminated tryptophan (dermatomyositis-like illness). Other myotoxic drugs may cause 
myopathy but not an inflammatory myopathy (see text for details).
eParasites (protozoa, cestodes, nematodes), tropical and bacterial myositis (pyomyositis).
distal muscles; IBM may have an asymmetric pattern. Progression is over 
weeks or months in PM and DM, but typically over years in IBM. Skin 
involvement in DM may consist of a heliotrope rash (blue-purple dis-
coloration) on the upper eyelids with edema, a flat red rash on the face 
and upper trunk, or erythema over knuckles (Gottron’s sign). A variety of 
cancers are associated with DM. Features of each disorder are summarized 
in Table 207-1. 
SECTION 14
1312
Neurology
Inﬂ ammatory Myopathies
TREATMENT
Often effective for PM and DM but not for IBM.
• Step 1: Glucocorticoids (prednisone, 1 mg/kg per day for 3–4 weeks, 
then tapered very gradually)
• Step 2: Approximately 75% of pts require additional therapy with 
other immunosuppressive drugs. Azathioprine (up to 3 mg/kg per 
day), mycophenolate mofetil (up to 2.5–3 g/day in 2 divided doses), 
or methotrexate (7.5 mg/week gradually increasing to 25 mg/week), 
commonly used.
• Step 3: IV immunoglobulin (2 g/kg divided over 2–5 days)
• Step 4: A trial of one of the following agents: rituximab, cyclospo-
rine, cyclophosphamide, or tacrolimus.
DISORDERS OF MUSCLE ENERGY METABOLISM
There are two principal sources of energy for skeletal muscle: fatty acids 
and glucose. Abnormalities in either glucose or lipid utilization can be 
associated with distinct clinical presentations that can range from an 
acute, painful syndrome that mimics polymyositis to a chronic, progressive 
muscle weakness simulating muscular dystrophy. Definitive diagnosis 
usually requires biochemical-enzymatic studies of biopsied muscle. 
However, muscle enzymes, EMG, and muscle biopsy all might be abnormal 
and may suggest specific disorders.
Progressive muscle weakness beginning usually in the third or fourth 
decade can be due to the adult form of acid maltase deficiency (Pompe’s 
disease). Respiratory failure is often the initial manifestation; treatment with 
enzyme replacement may be of benefit. Progressive weakness beginning 
after puberty occurs with debranching enzyme deficiency. Glycolytic defects, 
including myophosphorylase deficiency (McArdle’s disease) or phosphofruc-
tokinase deficiency, present as exercise intolerance with myalgias. Disorders 
of fatty acid metabolism present with a similar picture. In adults, the most 
common cause is carnitine palmitoyltransferase deficiency. Exercise-induced 
cramps and myoglobinuria are common; strength is normal between the 
attacks. Dietary approaches (frequent meals and a low-fat high-carbohydrate 
diet, or a diet rich in medium-chain triglycerides) are of uncertain value.
MITOCHONDRIAL MYOPATHIES
More accurately referred to as mitochondrial cytopathies because multiple 
tissues are usually affected, these disorders result from defects in mitochon-
drial DNA. The clinical presentations vary greatly: muscle symptoms may 
include weakness, ophthalmoparesis, pain, or stiffness, or they may even 
be absent; age of onset ranges from infancy to adulthood; associated clini-
cal presentations include ataxia, encephalopathy, seizures, strokelike epi-
sodes, and recurrent vomiting. Three groups: chronic progressive external 
ophthalmoplegia (CPEO), skeletal muscle–central nervous system syn-
dromes, and pure myopathy syndromes simulating muscular dystrophy. 
The characteristic finding on muscle biopsy is “ragged red fibers,” which 
are muscle fibers with accumulations of abnormal mitochondria. Genetics 
CHAPTER 207 1313
Muscle Diseases
often show a maternal pattern of inheritance because mitochondrial genes 
are inherited almost exclusively from the oocyte.
PERIODIC PARALYSES
Muscle membrane excitability is affected in a group of disorders referred to 
as channelopathies. Onset is usually in childhood or adolescence. Episodes 
typically occur after rest or sleep, often following earlier exercise. May be 
TABLE 207-2 DRUG-INDUCED MYOPATHIES
Drugs
Major Toxic Reaction
Lipid-lowering agents
Drugs belonging to all three of the major 
classes of lipid-lowering agents can produce 
a spectrum of toxicity: asymptomatic 
serum creatine kinase elevation, myalgias, 
exercise-induced pain, rhabdomyolysis, and 
myoglobinuria.
 Fibric acid derivatives
  HMG-CoA reductase 
inhibitors
 Niacin (nicotinic acid)
Glucocorticoids
Acute, high-dose glucocorticoid treatment 
can cause acute quadriplegic myopathy. These 
high doses of steroids are often combined 
with nondepolarizing neuromuscular blocking 
agents but the weakness can occur without 
their use. Chronic steroid administration 
produces predominantly proximal weakness.
Nondepolarizing neuromus-
cular blocking agents
Acute quadriplegic myopathy can occur with 
or without concomitant glucocorticoids.
Zidovudine 
Mitochondrial myopathy with ragged red 
fibers.
Drugs of abuse
All drugs in this group can lead to widespread 
muscle breakdown, rhabdomyolysis, and 
myoglobinuria.
 Alcohol
 Amphetamines
 Cocaine
Local injections cause muscle necrosis, skin 
induration, and limb contractures.
 Heroin
 Phencyclidine
 Meperidine
Autoimmune toxic myopathy
Use of this drug may cause polymyositis and 
myasthenia gravis.
D-Penicillamine
Amphophilic cationic drugs
All amphophilic drugs have the potential to 
produce painless, proximal weakness 
associated with autophagic vacuoles in 
the muscle biopsy.
 Amiodarone
 Chloroquine
 Hydroxychloroquine
Antimicrotubular drugs
 Colchicine
This drug produces painless, proximal weak-
ness especially in the setting of renal failure. 
Muscle biopsy shows autophagic vacuoles.
SECTION 14
1314
Neurology
For a more detailed discussion, see Amato AA, Brown RH Jr.,: 
Muscular Dystrophies and Other Muscle Diseases, Chap. 387, 
p. 3487; Dalakas MC: Polymyositis, Dermatomyositis, and 
Inclusion Body Myositis, Chap. 388, p. 3509, in HPIM-18.
due to genetic disorders of calcium [hypokalemic periodic paralysis 
(hypoKPP)], sodium (hyperkalemic periodic paralysis), chloride, or potas-
sium channels. 
• Attacks of hypoKPP are treated with potassium chloride (usually oral), 
and prophylaxis with acetazolamide (125–1000 mg/d in divided doses) 
is usually effective in hypoKPP type 1. 
• Attacks of thyrotoxic periodic paralysis (usually in Asian men) resemble 
those of hypoKPP; attacks abate with treatment of the underlying thyroid 
condition.
ENDOCRINE AND METABOLIC MYOPATHIES
Abnormalities of thyroid function can cause a wide array of muscle disorders. 
Hypothyroidism is associated with muscle cramps, pain, and stiffness, and 
proximal muscle weakness occurs in one-third of pts; the relaxation phase 
of muscle stretch reflexes is characteristically prolonged, and serum CK is 
often elevated (up to 10 times normal).
Hyperthyroidism can produce proximal muscle weakness and atrophy; 
bulbar, respiratory, and even esophageal muscles are occasionally involved, 
causing dysphagia, dysphonia, and aspiration. Other neuromuscular 
disorders associated with hyperthyroidism include hypoKPP, myasthenia 
gravis, and a progressive ocular myopathy associated with proptosis (Graves’ 
ophthalmopathy). Other endocrine conditions, including parathyroid, adrenal, 
and pituitary disorders, as well as diabetes mellitus, can also produce 
myopathy. Deficiencies of vitamins D and E are additional causes of muscle 
weakness.
DRUG-INDUCED MYOPATHIES
Drugs (including glucocorticoids and lipid-lowering agents) and toxins 
(e.g., alcohol) are associated with myopathies (Table 207-2). In most 
cases, weakness is symmetric and involves proximal limb girdle muscles. 
Weakness, myalgia, and cramps are common symptoms. An elevated CK is 
often an important indication of toxicity. Diagnosis often depends on reso-
lution of signs and symptoms with removal of offending agent.
1315
CHAPTER 208
Psychiatric Disorders
Mental disorders are common in medical practice and may present either 
as a primary disorder or as a comorbid condition. The prevalence of mental 
or substance use disorders in the United States is ~30%, but only one-third 
of those individuals are currently receiving treatment.
Disorders of mood, thinking, and behavior may be due to a primary 
psychiatric diagnosis [DSM-IV (Diagnostic and Statistical Manual, 4th edi-
tion, American Psychiatric Association) Axis I major psychiatric disorders] 
or a personality disorder (DSM-IV Axis II disorders) or may be secondary 
to metabolic abnormalities, drug toxicities, focal cerebral lesions, seizure 
disorders, or degenerative neurologic disease (DSM-IV Axis III disor-
ders). Any pt presenting with new onset of psychiatric symptoms must be 
evaluated for underlying psychoactive substance abuse and/or medical or 
neurologic illness. Psychiatric medications are discussed in Chap. 209. The 
DSM-IV-PC (Primary Care) Manual provides a synopsis of mental disor-
ders commonly seen in medical practice.
MAJOR PSYCHIATRIC DISORDERS (AXIS I DIAGNOSES)
� MOOD DISORDERS (MAJOR AFFECTIVE DISORDERS)
Mood disorders are characterized by a disturbance in the regulation of 
mood, behavior, and affect; subdivided into (1) depressive disorders, 
(2) bipolar disorders (depression plus manic or hypomanic episodes), and 
(3) depression in association with medical illness or alcohol and substance 
abuse (see Chaps. 211 and 212).
Major Depression 
Clinical Features Affects 15% of the general population at some point in life; 
6–8% of all outpatients in primary care settings satisfy diagnostic criteria. 
Diagnosis is made when five (or more) of the following symptoms have been 
present for 2 weeks (at least one of the symptoms must be #1 or #2 below):
1. Depressed mood
2. Loss of interest or pleasure
3. Change in appetite or weight
4. Insomnia or hypersomnia
5. Fatigue or loss of energy
6. Psychomotor agitation or retardation
7. Feelings of worthlessness or inappropriate guilt
8. Decreased ability to concentrate and make decisions
9. Recurrent thoughts of death or suicide.
SECTION 15
Psychiatry and Substance Abuse
SECTION 15
1316
Psychiatry and Substance Abuse
A small number of pts with major depression will have psychotic symp-
toms (hallucinations and delusions) with their depressed mood. Negative 
life events can precipitate depression, but genetic factors influence the 
sensitivity to these events.
Onset of a first depressive episode is typically in early adulthood, 
although major depression can occur at any age. Untreated episodes gen-
erally resolve spontaneously in a few months to a year; however, a sizable 
number of pts suffer from chronic, unremitting depression or from partial 
treatment response. Half of all pts experiencing a first depressive episode 
will go on to a recurrent course. Untreated or partially treated episodes put 
the pt at risk for future problems with mood disorders. Within an indi-
vidual, the nature of episodes may be similar over time. A family history of 
mood disorder is common and tends to predict a recurrent course. Major 
depression can also be the initial presentation of bipolar disorder (manic 
depressive illness).
Suicide Approximately 4–5% of all depressed pts will commit suicide, and 
most will have sought help from a physician within 1 month of their death. 
Physicians must always inquire about suicide when evaluating a pt with 
depression.
Depression with Medical Illness Virtually every class of medication can 
potentially induce or worsen depression. Antihypertensive drugs, anti-
cholesterolemic agents, and antiarrhythmic agents are common triggers 
of depressive symptoms. Among the antihypertensive agents, β-adrenergic 
blockers and, to a lesser extent, calcium channel blockers are the most likely 
to cause depressed mood. Iatrogenic depression should also be considered 
in pts receiving glucocorticoids, antimicrobials, systemic analgesics, anti-
parkinsonian medications, and anticonvulsants.
Between 20–30% of cardiac pts manifest a depressive disorder. Tricyclic 
antidepressants (TCAs) are contraindicated in pts with bundle branch 
block, and TCA-induced tachycardia is an additional concern in pts with 
congestive heart failure. Selective serotonin reuptake inhibitors (SSRIs) 
appear not to induce ECG changes or adverse cardiac events, and thus, are 
reasonable first-line drugs for pts at risk for TCA-related complications. 
SSRIs may interfere with hepatic metabolism of anticoagulants, however, 
causing increased anticoagulation.
In cancer, the prevalence of depression is 25%, but it occurs in 40–50% 
of pts with cancers of the pancreas or oropharynx. Extreme cachexia from 
cancer may be misinterpreted as depression. Antidepressant medications in 
cancer pts improve quality of life as well as mood.
Diabetes mellitus is another consideration; the severity of the mood state 
correlates with the level of hyperglycemia and the presence of diabetic 
complications. Monoamine oxidase inhibitors (MAOIs) can induce hypogly-
cemia and weight gain. TCAs can produce hyperglycemia and carbohydrate 
craving. SSRIs, like MAOIs, may reduce fasting plasma glucose, but they 
are easier to use and may also improve dietary and medication compliance.
Depression may also occur with hypothyroidism or hyperthyroidism, in 
neurologic disorders, in HIV-positive individuals, and in chronic hepatitis 
C infection (depression worsens with interferon treatment). Some chronic 
CHAPTER 208 1317
Psychiatric Disorders
disorders of uncertain etiology, such as chronic fatigue syndrome and fibro-
myalgia, are strongly associated with depression.
Major Depression
TREATMENT
• Pts with suicidal ideation require treatment by a psychiatrist and may 
require hospitalization. 
• Most other pts with an uncomplicated unipolar major depression (a 
major depression that is not part of a cyclical mood disorder, such 
as a bipolar disorder) can be successfully treated by a nonpsychiatric 
physician. 
• Vigorous intervention and successful treatment appear to decrease the 
risk of future relapse. 
• Pts who do not respond fully to standard treatment should be referred 
to a psychiatrist.
• Antidepressant medications are the mainstay of treatment, although 
combined treatment with psychotherapy improves outcome. Symptoms 
are ameliorated after 6–8 weeks at a therapeutic dose in 60–70% of pts. 
• A guideline for the medical management of depression is shown in 
Fig. 208-1.
• Once remission is achieved, antidepressants should be continued for 
6–9 months. Pts must be monitored carefully after termination of 
treatment since relapse is common. 
• Pts with two or more episodes of depression should be considered for 
indefinite maintenance treatment. 
• Electroconvulsive therapy is generally reserved for treatment-resistant 
depression unresponsive to medication or for pts in whom the use of 
antidepressants is medically contraindicated. 
• Transcranial magnetic stimulation (TMS) is approved for treatment-
resistant depression. 
• Vagus nerve stimulation (VNS) has been approved for treatment-
resistant depression as well, but its degree of efficacy is controversial.
Bipolar Disorder (Manic Depressive Illness) 
Clinical Features A cyclical mood disorder in which episodes of major 
depression are interspersed with episodes of mania or hypomania; 1.5% of 
the population is affected. Most pts initially present with a manic episode 
in adolescence or young adulthood. Antidepressant therapy may provoke 
a manic episode; pts with a major depressive episode and a prior history of 
“highs” (mania or hypomania—which can be pleasant/euphoric or irritable/
impulsive) and/or a family history of bipolar disorder should not be treated 
with antidepressants, but instead referred promptly to a psychiatrist.
With mania, an elevated, expansive mood, irritability, angry outbursts, 
and impulsivity are characteristic. Specific symptoms include: (1) unusual 
talkativeness; (2) flight of ideas and racing thoughts; (3) inflated self-
esteem that can become delusional; (4) decreased need for sleep (often the 
SECTION 15
1318
Psychiatry and Substance Abuse
first feature of an incipient manic episode); (5) increase in goal-directed 
activity or psychomotor agitation; (6) distractibility; (7) excessive involve-
ment in risky activities (buying sprees, sexual indiscretions). Pts with 
full-blown mania can become psychotic. Hypomania is characterized by 
attenuated manic symptoms and is greatly underdiagnosed, as are “mixed 
episodes,” where both depressive and manic or hypomanic symptoms 
coexist simultaneously.
Untreated, a manic or depressive episode typically lasts for several weeks 
but can last for 8–12 months. Variants of bipolar disorder include rapid and 
ultrarapid cycling (manic and depressed episodes occurring at cycles of 
weeks, days, or hours). In many pts, especially females, antidepressants trigger 
rapid cycling and worsen the course of illness. Pts with bipolar disorder are at 
risk for substance use, especially alcohol abuse, and for medical consequences 
Determine whether there is a history of good response to a medication 
in the patient or a first-degree relative; if yes, consider treatment with 
this agent if compatible with considerations in step 2.
Evaluate patient characteristics and match to drug; consider health 
status, side effect profile, convenience, cost, patient preference, drug 
interaction risk, suicide potential, and medication compliance history.
Begin new medication at 1/3 to 1/2 target dose if drug is a TCA, 
bupropion, venlafaxine, or mirtazapine, or full dose as tolerated if drug 
is an SSRI. 
If problem side effects occur, evaluate possibility of tolerance; consider 
temporary decrease in dose or adjunctive treatment.
If unacceptable side effects continue, taper drug over 1 week and 
initiate new trial; consider potential drug interactions in choice. 
Evaluate response after 6 weeks at target dose; if response is 
inadequate, increase dose in stepwise fashion as tolerated.
If inadequate response after maximal dose, consider tapering and 
switching to a new drug vs adjunctive treatment; if drug is a TCA, obtain 
plasma level to guide further treatment.
MEDICAL MANAGEMENT OF MAJOR DEPRESSIVE DISORDER
ALGORITHM
FIGURE 208-1 A guideline for the medical management of major depressive disor-
der. SSRI, selective serotonin reuptake inhibitor; TCA, tricyclic antidepressant.
CHAPTER 208 1319
Psychiatric Disorders
of risky sexual behavior (STDs). Bipolar disorder has a strong genetic compo-
nent; the concordance rate for monozygotic twins approaches 80%.
Bipolar Disorder
TREATMENT
• Bipolar disorder is a serious, chronic illness that requires lifelong 
monitoring by a psychiatrist. 
• Acutely manic pts often require hospitalization to reduce environ-
mental stimulation and to protect themselves and others from the 
consequences of their reckless behavior. 
• The recurrent nature of bipolar disorder necessitates maintenance 
treatment. 
• Mood stabilizers (lithium, valproic acid, second-generation antipsy-
chotic drugs, carbamazepine, lamotrigine) are effective for the resolu-
tion of acute episodes and for prophylaxis of future episodes.
� SCHIZOPHRENIA AND OTHER PSYCHOTIC DISORDERS
Schizophrenia
Clinical Features Occurs in 0.85% of the population worldwide; lifetime 
prevalence is ~1–1.5%. Characterized by perturbations of language, per-
ception, thinking, social activity, affect, and volition. Pts usually present 
in late adolescence, often after an insidious premorbid course of subtle 
psychosocial difficulties. Core psychotic features last ≥6 months and 
include positive symptoms (such as conceptual disorganization, delusions, 
or hallucinations) and negative symptoms (loss of function, anhedonia, 
decreased emotional expression, impaired concentration, and diminished 
social engagement). Negative symptoms predominate in one-third and are 
associated with a poor long-term outcome and poor response to treatment.
Prognosis depends not on symptom severity but on the response to 
antipsychotic medication. A permanent remission without recurrence 
does occasionally occur. About 10% of schizophrenic pts commit suicide. 
Comorbid substance abuse is common.
Schizophrenia
TREATMENT
• Hospitalization is required for acutely psychotic pts who may be dan-
gerous to themselves or others. 
• Conventional antipsychotic medications are effective against halluci-
nations, delusions, and thought disorder. 
• The novel antipsychotic medications—clozapine, risperidone, olan-
zapine, quetiapine, ziprasidone, and aripiprazole—are helpful in pts 
unresponsive to conventional neuroleptics and may also be more 
useful for negative and cognitive symptoms. 
• Drug treatment by itself is insufficient, and educational efforts direct-
ed toward families and relevant community resources are necessary to 
maintain stability and optimize outcomes.
SECTION 15
1320
Psychiatry and Substance Abuse
Other Psychotic Disorders 
These include schizoaffective disorder (where symptoms of schizophrenia 
are interspersed with major mood episodes) and schizophreniform disorder 
(pts who meet the symptom requirements but not the duration require-
ments for schizophrenia).
� ANXIETY DISORDERS
Characterized by severe, persistent anxiety or sense of dread or foreboding. 
Most prevalent group of psychiatric illnesses seen in the community; present 
in 15–20% of medical clinic pts.
Panic Disorder 
Occurs in 1–3% of the population; familial aggregation may occur. Onset in 
late adolescence or early adulthood. Initial presentation is almost always to 
a nonpsychiatric physician, frequently in the ER, as a possible heart attack 
or serious respiratory problem. The disorder is often initially unrecognized 
or misdiagnosed. Three-quarters of pts with panic disorder will also satisfy 
criteria for major depression at some point.
Clinical Features Characterized by panic attacks, which are sudden, unexpected, 
overwhelming paroxysms of terror and apprehension with multiple associated 
somatic symptoms. Attacks usually reach a peak within 10 min, then slowly 
resolve spontaneously, occurring in an unexpected fashion. Diagnostic criteria 
for panic disorder include recurrent panic attacks and at least 1 month of 
concern or worry about the attacks or a change in behavior related to them. 
Panic attacks must be accompanied by at least four of the following: palpita-
tions, sweating, trembling or shaking, dyspnea, choking, chest pain, nausea or 
abdominal distress, dizziness or faintness, derealization or depersonalization, 
fear of losing control, fear of death, paresthesias, and chills or hot flashes.
When the disorder goes unrecognized and untreated, pts often experience 
significant morbidity: they become afraid of leaving home and may develop 
anticipatory anxiety, agoraphobia, and other spreading phobias; many turn 
to self-medication with alcohol or benzodiazepines.
Panic disorder must be differentiated from cardiovascular and respira-
tory disorders. Conditions that may mimic or worsen panic attacks include 
hyperthyroidism, pheochromocytoma, hypoglycemia, drug ingestions 
(amphetamines, cocaine, caffeine, sympathomimetic nasal decongestants), 
and drug withdrawal (alcohol, barbiturates, opiates, minor tranquilizers).
Panic Disorder
TREATMENT
• The cornerstone of drug therapy is antidepressant medication. 
• SSRIs benefit the majority of panic disorder pts and do not have the 
adverse effects of the TCAs. 
• Benzodiazepines may be used in the short term while waiting for anti-
depressants to take effect.
• Early psychotherapeutic intervention and education aimed at symptom 
control enhances the effectiveness of drug treatment. 
• Psychotherapy (identifying and aborting panic attacks through relax-
ation and breathing techniques) can be effective.
CHAPTER 208 1321
Psychiatric Disorders
Generalized Anxiety Disorder (GAD) 
Characterized by persistent, chronic anxiety; occurs in 5–6% of the population.
Clinical Features Pts experience persistent, excessive, and/or unrealistic 
worry associated with muscle tension, impaired concentration, autonomic 
arousal, feeling “on edge” or restless, and insomnia. Pts worry excessively 
over minor matters, with life-disrupting effects; unlike panic disorder, com-
plaints of shortness of breath, palpitations, and tachycardia are relatively 
rare. Secondary depression is common, as is social phobia and comorbid 
substance abuse.
Generalized Anxiety Disorder
TREATMENT
• A combination of pharmacologic and psychotherapeutic interventions 
is most effective; complete symptom relief is rare. 
• Benzodiazepines are the initial agents of choice when generalized 
anxiety is severe and acute enough to warrant drug therapy; physi-
cians must be alert to psychological and physical dependence on 
benzodiazepines. 
• A subgroup of pts respond to buspirone, a nonbenzodiazepine anxiolytic. 
• Some SSRIs also are effective at doses comparable to their efficacy in 
major depression.
• Anticonvulsants with GABA-ergic properties (gabapentin, oxcarbaze-
pine, tiagabine, pregabalin, divalproex) may also be effective against 
anxiety.
Obsessive-Compulsive Disorder (OCD) 
A severe disorder present in 2–3% of the population and characterized by 
recurrent obsessions (persistent intrusive thoughts) and compulsions (repet-
itive behaviors) that impair everyday functioning. Pts are often ashamed of 
their symptoms; physicians must ask specific questions to screen for this 
disorder including asking about recurrent thoughts and behaviors.
Clinical Features Common obsessive thoughts and compulsive behaviors 
include fears of germs or contamination, handwashing, counting behaviors, 
and having to check and recheck such actions as whether a door is locked. 
Onset is usually in adolescence (childhood onset is not rare); more common 
in males and first-born children. Comorbid conditions are common, the most 
frequent being depression, other anxiety disorders, eating disorders, and tics. 
The course of OCD is usually episodic with periods of incomplete remission; 
some cases may show a steady deterioration in psychosocial functioning.
Obsessive-Compulsive Disorder
TREATMENT
• Clomipramine and the SSRIs (fluoxetine, fluvoxamine, sertraline) are 
effective, but only 50–60% of pts show adequate improvement with 
pharmacotherapy alone.
• A combination of drug therapy and cognitive-behavioral psycho-
therapy is most effective for the majority of pts.
SECTION 15
1322
Psychiatry and Substance Abuse
Posttraumatic Stress Disorder (PTSD) 
Occurs in a subgroup of individuals exposed to a severe life-threatening 
trauma. If the reaction occurs shortly after the event, it is termed acute 
stress disorder, but if the reaction is delayed and subject to recurrence, PTSD 
is diagnosed. Predisposing factors include a past psychiatric history and 
personality characteristics of extroversion and high neuroticism.
Clinical Features Individuals experience associated symptoms of detach-
ment and loss of emotional responsivity. The pt may feel depersonalized 
and unable to recall specific events of the trauma, although it is reexpe-
rienced through intrusions in thought, dreams, or flashbacks. Comorbid 
substance abuse and other mood and anxiety disorders are common. This 
disorder is extremely debilitating; most pts require referral to a psychiatrist 
for ongoing care.
Posttraumatic Stress Disorder
TREATMENT
• TCAs, phenelzine (an MAOI), and the SSRIs all are somewhat effective. 
• Trazodone is frequently used at night to help with insomnia. 
• Psychotherapeutic strategies help the pt overcome avoidance behav-
iors and master fear of recurrence of the trauma.
Phobic Disorders 
Clinical Features Recurring, irrational fears of specific objects, activities, 
or situations, with subsequent avoidance behavior of the phobic stimulus. 
Diagnosis is made only when the avoidance behavior interferes with social 
or occupational functioning. Affects ~10% of the population. Common 
phobias include fear of closed places, (claustrophobia), fear of blood, and 
fear of flying. Social phobia is distinguished by a specific fear of social or 
performance situations in which the individual is exposed to unfamiliar 
individuals or to possible examination and evaluation by others (e.g., having 
to converse at a party, use of public restrooms, meeting strangers).
Phobic Disorders
TREATMENT
• Agoraphobia is treated as for panic disorder. 
• Beta blockers (e.g., propranolol, 20–40 mg PO 2 h before the event) are 
particularly effective in the treatment of “performance anxiety.” 
• SSRIs are very helpful in treating social phobias. Social and simple 
phobias respond well to behaviorally focused psychotherapy.
Somatoform Disorders 
Clinical Features 
Pts with multiple somatic complaints that cannot be explained by a known 
medical condition or by the effects of substances; seen commonly in primary 
care practice (prevalence of 5%). In somatization disorder, the pt presents 
with multiple physical complaints referable to different organ systems. 
CHAPTER 208 1323
Psychiatric Disorders
Onset is before age 30, and the disorder is persistent; pts with somatiza-
tion disorder can be impulsive and demanding. In conversion disorder, the 
symptoms involve voluntary motor or sensory function. In hypochondriasis, 
the pt believes there is a serious medical illness, despite reassurance and 
appropriate medical evaluation. As with somatization disorder, these pts 
have a history of poor relationships with physicians due to their sense 
that they have not received adequate evaluation. Hypochondriasis can 
be disabling and show a waxing and waning course. In factitious illnesses, 
the pt consciously and voluntarily produces physical symptoms; the sick 
role is gratifying. Munchausen’s syndrome refers to individuals with dramatic, 
chronic, or severe factitious illness. A variety of signs, symptoms, and 
diseases have been simulated in factitious illnesses; most common are 
chronic diarrhea, fever of unknown origin, intestinal bleeding, hematuria, 
seizures, hypoglycemia. In malingering, the fabrication of illness derives 
from a desire for an external gain (narcotics, disability).
Somatoform Disorders
TREATMENT
• Pts with somatoform disorders are usually subjected to multiple diag-
nostic tests and exploratory surgeries in an attempt to find their “real” 
illness. This approach is doomed to failure.
• Successful treatment is achieved through behavior modification, in 
which access to the physician is adjusted to provide a consistent, sus-
tained, and predictable level of support that is not contingent on the 
pt’s level of presenting symptoms or distress. 
• Visits are brief, supportive, and structured and are not associated with 
a need for diagnostic or treatment action.
• Pts may benefit from antidepressant treatment. 
• Consultation with a psychiatrist is essential.
PERSONALITY DISORDERS (AXIS II DIAGNOSES)
Characteristic patterns of thinking, feeling, and interpersonal behavior that 
are relatively inflexible and cause significant functional impairment or sub-
jective distress for the individual. Individuals with personality disorders are 
often regarded as “difficult pts.”
DSM-IV describes three major categories of personality disorders; pts 
usually present with a combination of features.
� CLUSTER A PERSONALITY DISORDERS
Includes individuals who are odd and eccentric and who maintain an emo-
tional distance from others. The paranoid personality has pervasive m istrust 
and suspiciousness of others. The schizoid personality is interpersonally iso-
lated, cold, and indifferent, while the schizotypal personality is eccentric and 
superstitious, with magical thinking and unusual perceptual experiences.
� CLUSTER B PERSONALITY DISORDERS
Describes individuals whose behavior is impulsive, excessively emotional, 
and erratic. The borderline personality is impulsive and manipulative, with 
SECTION 15
1324
Psychiatry and Substance Abuse
unpredictable and fluctuating intense moods and unstable relationships, 
a fear of abandonment, and occasional rage episodes. The histrionic pt is 
dramatic, engaging, seductive, and attention-seeking. The narcissistic pt 
is self-centered and has an inflated sense of self-importance combined with 
a tendency to devalue or de-mean others, while pts with antisocial personality 
disorder use other people to achieve their own ends and engage in exploit-
ative and manipulative behavior with no sense of remorse.
� CLUSTER C PERSONALITY DISORDERS
Enduring traits are anxiety and fear. The dependent pt fears separation, 
tries to engage others to assume responsibility, and often has a help-
rejecting style. Pts with compulsive personality disorder are meticulous and 
perfectionistic but also inflexible and indecisive. Avoidant pts are anxious 
about social contact and have difficulty assuming responsibility for their 
isolation.
CHAPTER 209
Psychiatric Medications
Four major classes are commonly used in adults: (1) antidepressants, (2) anx-
iolytics, (3) antipsychotics, and (4) mood stabilizing agents. Nonpsychiatric 
physicians should become familiar with one or two drugs in each of the 
first three classes so that the indications, dose range, efficacy, potential side 
effects, and interactions with other medications are well known.
GENERAL PRINCIPLES OF USE
1. Most treatment failures are due to undermedication and impatience. For 
a proper medication trial to take place, an effective dose must be taken 
for an adequate amount of time. For antidepressants, antipsychotics, and 
mood stabilizers, full effects may take weeks or months to occur.
2. History of a positive response to a medication usually indicates that a 
response to the same drug will occur again. A family history of a positive 
response to a specific medication is also useful.
3. Pts who fail to respond to one drug will often respond to another in the 
same class; one should attempt another trial with a drug that has a dif-
ferent mechanism of action or a different chemical structure. Treatment 
failures should be referred to a psychiatrist, as should all pts with 
psychotic symptoms or who require mood stabilizers.
4. Avoid polypharmacy; a pt who is not responding to standard mono-
therapy requires referral to a psychiatrist.
For a more detailed discussion, see Reus VI: Mental 
Disorders, Chap. 391, p. 3529, in HPIM-18.
CHAPTER 209
1325
Psychiatric Medications
5. Pharmacokinetics may be altered in the elderly, with smaller volumes of 
distribution, reduced renal and hepatic clearance, longer biologic half-
lives, and greater potential for CNS toxicity. The rule with elderly pts is 
to “start low and go slow.”
6. Never stop treatment abruptly; especially true for antidepressants and 
anxiolytics. In general, medications should be slowly tapered and discon-
tinued over 2–4 weeks.
7. Review possible side effects each time a drug is prescribed; educate pts 
and family members about side effects and need for patience in awaiting 
a response.
ANTIDEPRESSANTS (ADs)
Useful to group according to known actions on CNS monoaminergic systems 
(Table 209-1). The selective serotonin reuptake inhibitors (SSRIs) have 
predominant effects on serotonergic neurotransmission, also reflected in 
side-effect profile. The TCAs, or tricyclic antidepressants, affect noradren-
ergic and, to a lesser extent, serotonergic neurotransmission but also have 
anticholinergic and antihistaminic effects. Venlafaxine, desvenlafaxine, 
duloxetine, and mirtazapine have mixed noradrenergic and serotonergic 
effects. Bupropion is a novel antidepressant that enhances noradrenergic 
function. Trazodone, nefazodone, and amoxapine have mixed effects on 
serotonin receptors and on other neurotransmitter systems. The MAOIs 
inhibit monoamine oxidase, the primary enzyme responsible for the degra-
dation of monoamines in the synaptic cleft.
ADs are effective against major depression, particularly when neuro-
vegetative symptoms and signs are present. Despite the widespread use of 
SSRIs, there is no convincing evidence that they are more efficacious than 
TCAs, although their safety profile in overdose is more favorable than 
that of the TCAs. ADs are also useful in treatment of panic disorder, post-
traumatic stress disorder, chronic pain syndromes, and generalized anxiety 
disorder. The TCA clomipramine and the SSRIs successfully treat obsessive-
compulsive disorder.
All ADs require at least 2 weeks at a therapeutic dose before clinical 
improvement is observed. All ADs also have the potential to trigger a 
manic episode or rapid cycling when given to a pt with bipolar disorder. 
The MAOIs must not be prescribed concurrently with other ADs or with 
narcotics, as potentially fatal reactions may occur. “Withdrawal syndromes” 
usually consisting of malaise can occur when ADs are stopped abruptly.
ANXIOLYTICS
Benzodiazepines bind to sites on the γ-aminobutyric acid receptor and are 
cross-tolerant with alcohol and with barbiturates. Four clinical properties: 
(1) sedative, (2) anxiolytic, (3) skeletal muscle relaxant, and (4) antiepileptic. 
Individual drugs differ in terms of potency, onset of action, duration of action 
(related to half-life and presence of active metabolites), and metabolism 
(Table 209-2). Benzodiazepines have additive effects with alcohol; like alco-
hol, they can produce tolerance and physiologic dependence, with serious 
withdrawal syndromes (tremors, seizures, delirium, and autonomic hyper-
activity) if discontinued too quickly, especially for those with short half-lives.
TABLE 209-1 ANTIDEPRESSANTS
Name
Usual Daily 
Dose, mg
Side Effects
Comments
SSRIs
Fluoxetine (Prozac)
Sertraline (Zoloft)
Paroxetine (Paxil)
Fluvoxamine (Luvox)
Citalopram (Celexa)
Escitalopram (Lexapro)
10–80
50–200
20–60
100–300
20–60
10–30
Headache; nausea and other GI effects; jitteriness; 
insomnia; sexual dysfunction; can affect plasma levels 
of other medicines (except sertraline); akathisia rare
Once-daily dosing, usually in the morning; 
fluoxetine has very long half-life; must not 
be combined with MAOIs 
TCAs
Amitriptyline (Elavil)
Nortriptyline (Pamelor)
Imipramine (Tofranil)
Desipramine (Norpramin)
Doxepin (Sinequan)
Clomipramine (Anafranil)
150–300
50–200
150–300
150–300
150–300
150–300
Anticholinergic (dry mouth, tachycardia, constipation, 
urinary retention, blurred vision); sweating; tremor; 
postural hypotension; cardiac conduction delay; 
sedation; weight gain
Once-daily dosing, usually qhs; blood levels 
of most TCAs available; can be lethal in O.D. 
(lethal dose = 2 g); nortriptyline best 
tolerated, especially by elderly
Mixed Norepinephrine/Serotonin reuptake inhibitors and receptor blockers
Venlafaxine (Effexor)
75–375
Nausea; dizziness; dry mouth; headaches; increased 
blood pressure; anxiety and insomnia
Bid-tid dosing (extended release available); 
lower potential for drug interactions than 
SSRIs; contraindicated with MAOIs
1326
Desvenlafaxine (Pristiq)
50–400
Nausea, dizziness, insomnia
Primary metabolite of venlafaxine. No 
increased efficacy with higher dosing
Duloxetine (Cymbalta)
40–60
Nausea, dizziness, headache, insomnia, constipation
May have utility in treatment of neuropathic 
pain and stress incontinence
Mirtazapine (Remeron)
15–45
Somnolence; weight gain; neutropenia rare
Once daily dosing
Mixed-action drugs
Bupropion (Wellbutrin)
250–450
Jitteriness; flushing; seizures in at-risk pts; anorexia; 
tachycardia; psychosis
Tid dosing, but sustained release also 
available; fewer sexual side effects than 
SSRIs or TCAs; may be useful for adult ADD
Trazodone (Desyrel)
200–600
Sedation; dry mouth; ventricular irritability; postural 
hypotension; priapism rare
Useful in low doses for sleep because of 
sedating effects with no anticholinergic side 
effects
Nefazodone (Serzone)
300–600
Sedation; headache; dry mouth; nausea; constipation
Discontinued sale in United States and sev-
eral other countries due to risk of liver failure
Amoxapine (Asendin)
200–600
Sexual dysfunction
Lethality in overdose; EPS possible
MAOIs
Phenelzine (Nardil)
45–90
Insomnia; hypotension; anorgasmia; weight gain; 
hypertensive crisis; toxic reactions with SSRIs; narcotics
May be more effective in pts with atypical 
features or treatment-refractory depression
Tranylcypromine (Parnate)
20–50
Isocarboxazid (Marplan)
20–60
Transdermal selegiline (Emsam)
6–12
Local skin reaction hypertension
No dietary restrictions with 6 mg dose
Abbreviations: ADD, attention deficit disorder; EPS, extrapyramidal symptoms; MAOIs, monoamine oxidase inhibitors; SSRIs, selective serotonin reuptake inhibitors; TCAs, tricyclic 
antidepressants. 
1327
TABLE 209-2 ANXIOLYTICS
Name
Equivalent 
PO Dose, mg
Onset of Action
Half-Life, h
Comments
Benzodiazepines
 Diazepam (Valium)
5
Fast
20–70
Active metabolites; quite sedating
 Flurazepam (Dalmane)
15
Fast
30–100
Flurazepam is a prodrug; metabolites are active; quite sedating
 Triazolam (Halcion)
0.25
Intermediate
1.5–5
No active metabolites; can induce confusion and delirium, especially 
in elderly
 Lorazepam (Ativan)
1
Intermediate
10–20
No active metabolites; direct hepatic glucuronide conjugation; quite 
sedating
 Alprazolam (Xanax)
0.5
Intermediate
12–15
Active metabolites; not too sedating; may have specific antidepressant 
and antipanic activity; tolerance and dependence develop easily
 Chlordiazepoxide (Librium)
10
Intermediate
5–30
Active metabolites; moderately sedating
 Oxazepam (Serax)
15
Slow
5–15
No active metabolites; direct glucuronide conjugation; not too 
sedating 
 Temazepam (Restoril)
15
Slow
9–12
No active metabolites; moderately sedating
 Clonazepam (Klonopin)
0.5
Slow
18–50
No active metabolites; moderately sedating
Nonbenzodiazepines
 Buspirone (BuSpar)
7.5
2 weeks
2–3
Active metabolites; tid dosing—usual daily dose 10–20 mg tid; 
nonsedating; no additive effects with alcohol; useful for controlling 
agitation in demented or brain-injured pts
1328
CHAPTER 209
1329
Psychiatric Medications
Buspirone is a nonbenzodiazepine anxiolytic that is nonsedating, is not 
cross-tolerant with alcohol, and does not induce tolerance or dependence. It 
requires at least 2 weeks at therapeutic doses to achieve full effects.
ANTIPSYCHOTIC MEDICATIONS
These include the first-generation (typical) neuroleptics, which act by 
blocking dopamine D2 receptors, and the second-generation (atypical) neu-
roleptics, which act on dopamine, serotonin, and other neurotransmitter 
systems. Some antipsychotic effect may occur within hours or days of ini-
tiating treatment, but full effects usually require 6 weeks to several months 
of daily, therapeutic dosing.
� FIRST-GENERATION ANTIPSYCHOTICS 
Useful to group into high-, mid-, and low-potency neuroleptics (Table 209-3). 
High-potency neuroleptics are least sedating, have almost no anticholinergic 
side effects, and have a strong tendency to induce extrapyramidal side effects 
(EPSEs). The EPSEs occur within several hours to several weeks of beginning 
treatment and include acute dystonias, akathisia, and pseudo-parkinsonism. 
Extrapyramidal symptoms respond well to trihexyphenidyl, 2 mg twice daily, 
or benztropine mesylate, 1 to 2 mg twice daily. Akathisia may respond to beta 
blockers. Low-potency neuroleptics are very sedating, may cause orthostatic 
hypotension, are anticholinergic, and tend not to induce EPSEs frequently.
Up to 20% of pts treated with conventional antipsychotic agents for 
>1 year develop tardive dyskinesia (probably due to dopamine receptor 
supersensitivity), an abnormal involuntary movement disorder most often 
observed in the face and distal extremities. Treatment includes gradual 
withdrawal of the neuroleptic, with possible switch to a novel neuroleptic; 
anticholinergic agents can worsen the disorder.
Rarely, pts exposed to neuroleptics develop neuroleptic malignant syndrome 
(NMS), a life-threatening complication with a mortality rate as high as 25%; 
hyperpyrexia, autonomic hyperactivity, muscle rigidity, obtundation, and agi-
tation are characteristic, associated with increased WBC, increased creatine 
phosphokinase, and myoglobinuria. Treatment involves immediate discontinu-
ation of neuroleptics, supportive care, and use of dantrolene and bromocriptine.
� SECOND-GENERATION ANTIPSYCHOTICS 
A new class of agents that has become the first line of treatment 
(Table 209-3); efficacious in treatment-resistant pts, tend not to induce 
EPSEs or tardive dyskinesia, and appear to have uniquely beneficial proper-
ties on negative symptoms and cognitive dysfunction. Main problem is side 
effect of weight gain (most prominent in clozapine and in olanzapine; can 
induce diabetes). The CATIE study, a large-scale investigation of antipsy-
chotic agents in the “real world,” revealed a high rate of discontinuation of 
all medications over 18 months; olanzapine was modestly more effective 
than other agents but with a higher discontinuation rate due to side effects.
MOOD-STABILIZING AGENTS
Four mood stabilizers in common use: lithium, valproic acid, carbamaze-
pine/oxcarbazepine, and lamotrigine (Table 209-4). Lithium is the gold 
standard and the best studied, and along with carbamazepine and valproic 
TABLE 209-3 ANTIPSYCHOTIC AGENTS
Name
Usual PO Daily 
Dose, mg
Side Effects
Sedation
Comments
First-generation antipsychotics
Low potency
 Chlorpromazine (Thorazine)
100–1000
Anticholinergic effects; orthostasis; pho-
tosensitivity; cholestasis; QT prolongation
+++
EPSEs usually not prominent; can cause 
anticholinergic delirium in elderly pts
 Thioridazine (Mellaril)
100–600
Midpotency
 Trifluoperazine (Stelazine)
2–50
Fewer anticholinergic side effects
++
Well tolerated by most pts
 Perphenazine (Trilafon)
4–64
Fewer EPSEs than with higher potency 
agents
++
 Loxapine (Loxitane)
30–100
Frequent EPSEs
++
 Molindone (Moban)
30–100
Frequent EPSEs
0
Little weight gain
High potency
 Haloperidol (Haldol)
5–20
No anticholinergic side effects; EPSEs 
often prominent
0/+
Often prescribed in doses that are too 
high; long-acting injectable forms of 
haloperidol and fluphenazine available
 Fluphenazine (Prolixin)
1–20
Frequent EPSEs
0/+
 Thiothixene (Navane)
2–50
Frequent EPSEs
0/+
1330
Second-generation antipsychotics
Clozapine (Clozaril)
150–600
Agranulocytosis (1%); weight gain; sei-
zures; drooling; hyperthermia
+ +
Requires weekly WBC count for first 6 
months, then biweekly if stable
Risperidone (Risperdal)
2–8
Orthostasis
+
Requires slow titration; EPSEs observed 
with doses >6 mg qd
Olanzapine (Zyprexa)
10–30
Weight gain
++
Mild prolactin elevation
Quetiapine (Seroquel)
350–800
Sedation; weight gain; anxiety
+++
Bid dosing
Ziprasidone (Geodon)
120–200
Orthostatic hypotension
+/++
Minimal weight gain; increases QT interval
Aripiprazole (Abilify)
10–30
Nausea, anxiety, insomnia
0/+
Mixed agonist/antagonist
Paliperidone (Invega)
3–12
Restlessness, EPSEs
+
Active metabolite of risperidone
Iloperidone (Fanapt)
12–24
Dizziness, hypotension
0/+
Requires dose titration
Asenapine (Saphris)
10–20
Dizziness, EPSEs, weight gain
++
Sublingual tablets; bid dosing
Lurasidone (Latuda)
40–80
Nausea, EPSEs
++
Uses CYP3A4
Abbreviations: EPSEs, extrapyramidal side effects; WBC, white blood cell.
1331
SECTION 15
1332
Psychiatry and Substance Abuse
TABLE 209-4 CLINICAL PHARMACOLOGY OF MOOD STABILIZERS
Agent and Dosing
Side Effects and Other Effects
Lithium
Common side effects
Starting dose: 300 mg 
bid or tid
Nausea/anorexia/diarrhea, fine tremor, thirst, 
polyuria, fatigue, weight gain, acne, folliculitis, 
neutrophilia, hypothyroidism
Therapeutic blood level: 
0.8–1.2 meq/L
Blood level is increased by thiazides, tetracyclines, 
and NSAIDs
Blood level is decreased by bronchodilators, 
verapamil, and carbonic anhydrase inhibitors
Rare side effects: Neurotoxicity, renal toxicity, 
hypercalcemia, ECG changes
Valproic acid
Common side effects
Starting dose: 250 mg 
tid
Nausea/anorexia, weight gain, sedation, tremor, 
rash, alopecia
Therapeutic blood level: 
50–125 μg/mL
Inhibits hepatic metabolism of other medications
Rare side effects: Pancreatitis, hepatotoxicity, 
Stevens-Johnson syndrome
Carbamazepine/
Oxcarbazepine
Common side effects
Starting dose: 200 mg 
bid for carbamazepine, 
150 mg bid for 
oxcarbazepine
Nausea/anorexia, sedation, rash, dizziness/ataxia
Therapeutic blood level: 
4–12 μg/mL for 
carbamazepine
Carbamazepine, but not oxcarbazepine, induces 
hepatic metabolism of other medications
Rare side effects: Hyponatremia, agranulocytosis, 
Stevens-Johnson syndrome
Lamotrigine
Common side effects
Starting dose: 25 mg/d
Rash, dizziness, headache, tremor, sedation, 
nausea
Rare side effect: Stevens-Johnson syndrome
Abbreviations: ECG, electrocardiogram; NSAIDs, nonsteroidal anti-inflammatory drugs.
acid, is used for treatment of acute manic episodes; 1–2 weeks to reach 
full effect. As prophylaxis, the mood stabilizers reduce frequency and 
severity of both manic and depressed episodes in cyclical mood disorders. 
In refractory bipolar disorder, combinations of mood stabilizers may be 
beneficial.
CHAPTER 210
1333
Eating Disorders
For a more detailed discussion, see Reus VI: Mental 
Disorders, Chap. 391, p. 3529, in HPIM-18.
CHAPTER 210
Eating Disorders
� DEFINITIONS AND EPIDEMIOLOGY
Anorexia nervosa is characterized by refusal to maintain normal body 
weight, resulting in a body weight <85% of the expected weight for age 
and height. Bulimia nervosa is characterized by recurrent episodes of binge 
eating followed by abnormal compensatory behaviors, such as self-induced 
vomiting, laxative abuse, or excessive exercise. Weight is in the normal 
range or above. Binge eating disorder is similar to bulimia nervosa but lacks 
the compensatory behavior element. As a result, binge eating disorder is 
typically associated with obesity. 
Both anorexia nervosa and bulimia nervosa occur primarily among 
previously healthy young women who become overly concerned with body 
shape and weight. Binge eating and purging behavior may be present in 
both conditions, with the critical distinction between the two resting on the 
weight of the individual. The lifetime prevalence of anorexia nervosa is 1%, 
that of bulimia nervosa 1–3%, but mild forms of occasional bulimia may 
occur in up to 5–10% of women. Binge eating disorder has a 4% prevalence. 
There is a 10:1 female to male ratio for both conditions; binge eating disor-
der is more evenly divided between women and men (2:1). The typical time 
of onset of anorexia is mid-adolescence, that of bulimia in early adulthood. 
Both can occur later, but onset is uncommon after age 40. 
Anorexia and bulimia nervosa are disorders of the affluent, well-educated 
societies in Western cultures. Affected pts frequently exhibit perfectionist 
and obsessional tendencies. Pursuit of activities that emphasize thinness 
(ballet, modeling, distance running) are prevalent, as is a drive for high scho-
lastic achievement. Risk factors are a family history of mood disturbance, 
childhood obesity, and psychological or physical abuse during childhood.
The diagnostic features of anorexia and bulimia nervosa are shown in 
Tables 210-1 and 210-2. 
� CLINICAL FEATURES
Anorexia Nervosa
• General: feeling cold
• Skin, hair, nails: alopecia, lanugo hair, acrocyanosis, edema
• Cardiovascular: bradycardia, hypotension
• Gastrointestinal: salivary gland enlargement, slow gastric emptying, con-
stipation, elevated liver enzymes
SECTION 15
1334
Psychiatry and Substance Abuse
• Hematopoietic: normochromic, normocytic anemia; leukopenia
• Fluid/electrolyte: increased blood urea nitrogen, increased creatinine, 
hyponatremia, hypokalemia. Hypokalemia can become life-threatening.
• Endocrine: low luteinizing hormone and follicle-stimulating hormone 
with secondary amenorrhea, hypoglycemia, normal thyroid-stimulating 
hormone with low normal thyroxine, increased plasma cortisol, osteopenia
Bulimia Nervosa
• Gastrointestinal: salivary gland enlargement, dental erosion from gastric 
acid exposure
• Fluid/electrolyte: hypokalemia, hypochloremia, alkalosis (from vomiting) 
or acidosis (from laxative abuse)
• Other: callus or scar on dorsum of hand (from repeated scraping against 
teeth during induced vomiting)
Eating Disorders
TREATMENT
ANOREXIA NERVOSA Weight restoration to 90% of predicted weight 
(BMI >18.5 kg/m2) is the primary goal in the treatment of anorexia 
nervosa. The intensity of the initial treatment, including the need for 
hospitalization, is determined by the pt’s current weight, the rapidity 
of recent weight loss, and the severity of medical and psychological 
complications (Fig. 210-1). Severe electrolyte imbalances should be 
identified and corrected. Nutritional restoration can almost always be 
successfully accomplished by oral feeding. For severely underweight pts, 
sufficient calories should be provided initially in divided meals as food 
or liquid supplements to maintain weight and to permit stabilization of 
fluid and electrolyte balance (1200–1800 kcal/d intake). Calories can be 
gradually increased to achieve a weight gain of 1–2 kg per week (3000–
4000 kcal/d intake). Meals must be supervised. Intake of vitamin D 
(400 IU/d) and calcium (1500 mg/d) should be sufficient to minimize 
bone loss. The assistance of psychiatrists or psychologists experienced in 
the treatment of anorexia nervosa is usually necessary. No psychotropic 
medications are of established value in the treatment of anorexia ner-
vosa. Medical complications occasionally occur during refeeding; most
TABLE 210-1 DIAGNOSTIC FEATURES OF ANOREXIA NERVOSA
Refusal to maintain body weight at or above a minimally normal weight for 
age and height. (This includes a failure to achieve weight gain expected 
during a period of growth leading to an abnormally low body weight.)
Intense fear of weight gain or becoming fat.
Distortion of body image (e.g., feeling fat despite an objectively low weight 
or minimizing the seriousness of low weight).
Amenorrhea. (This criterion is met if menstrual periods occur only following 
hormone—e.g., estrogen—administration.)
CHAPTER 210
1335
Eating Disorders
TABLE 210-2 DIAGNOSTIC FEATURES OF BULIMIA NERVOSA
Recurrent episodes of binge eating, which is characterized by the consump-
tion of a large amount of food in a short period of time and a feeling that the 
eating is out of control.
Recurrent inappropriate behavior to compensate for the binge eating, such 
as self-induced vomiting.
The occurrence of both the binge eating and the inappropriate compensatory 
behavior at least twice weekly, on average, for 3 months.
Overconcern with body shape and weight.
Note: If the diagnostic criteria for anorexia nervosa are simultaneously met, only the diagnosis 
of anorexia nervosa is given.
Meets criteria for anorexia nervosa or bulimia nervosa?
Weight <75% of
  expected body weight
  for age and height?*
Medically unstable?
  (e.g., heart rate <40 bpm,
  potassium <2.5 mmol/L)
Other psychiatric problems
  requiring intensive treatment?
  (e.g., serious suicidal
  ideation, substance abuse)
Yes
Yes
Yes
Yes
No
No
Outpatient Treatment
Inpatient
Treatment
or
Partial
Hospitalization
No
If unsuccessful
TREATMENT ALGORITHM FOR EATING DISORDERS
FIGURE 210-1 An algorithm for basic treatment decisions regarding pts with 
anorexia nervosa or bulimia nervosa. Based on the American Psychiatric Association 
practice guidelines for the treatment of pts with eating disorders. *Although outpatient 
management may be considered for pts with anorexia nervosa weighing more than 
75% of expected, there should be a low threshold for using more intensive interven-
tions if the weight loss has been rapid or if current weight is <80% of expected.
SECTION 15
1336
Psychiatry and Substance Abuse
pts transiently retain excess fluid, occasionally resulting in peripheral 
edema. Congestive heart failure and acute gastric dilatation have been 
described when refeeding is rapid. Transient modest elevations in serum 
levels of liver enzymes occasionally occur. Low levels of magnesium and 
phosphate should be replaced. Mortality is 5% per decade, from either 
chronic starvation or suicide.
BULIMIA NERVOSA Bulimia nervosa can usually be treated on an out-
patient basis (Fig. 210-1). Cognitive behavioral therapy and fluoxetine 
(Prozac) are first-line therapies. The recommended treatment dose for 
fluoxetine (60 mg/d) is higher than that typically used to treat depression.
� PROGNOSIS
The prognosis of anorexia nervosa is variable. Full recovery is seen in 
25–50% of pts, but many have persistent difficulties with weight maint-
enance, depression, and eating disturbances, including bulimia. Mortality 
is 5% per decade, from starvation, electrolyte abnormalities, or suicide. 
Bulimia nervosa has a more benign outcome. Full recovery occurs in 
~50% of pts within 10 years; 25% have persistent bulimia, but mortality 
is low.
CHAPTER 211
Alcoholism
Alcoholism is a multifactorial disorder in which genetic, biologic, and 
sociocultural factors interact.
• Alcohol dependence: defined in DSM-IV as repeated alcohol-related diffi-
culties in at least three of seven areas of functioning that cluster together 
over the same 12-month period; tolerance and withdrawal are two of 
these seven areas and are associated with a more severe course.
• Alcohol abuse: defined as repetitive problems with alcohol in any one 
of four life areas—social, interpersonal, legal, and occupational—or 
repeated use in hazardous situations such as driving while intoxicated. 
� CLINICAL FEATURES
Lifetime risk for alcohol dependence is 10–15% for men and 5–8% for 
women. Typically, the first major life problem from excessive alcohol use 
appears in early adulthood, followed by periods of exacerbation and remis-
sion. The course is not hopeless; following treatment, between half and 
two-thirds of pts maintain abstinence for years and often permanently. If the 
For a more detailed discussion, see Walsh TB, Attia E: Eating 
Disorders, Chap. 79, p. 636, in HPIM-18.
CHAPTER 211
1337
Alcoholism
alcoholic continues to drink, life span is shortened by an average of 10 years 
due to increased risk of death from heart disease, cancer, accidents, or suicide.
Screening for alcoholism is important given its high prevalence. Probe 
for marital or job problems, legal difficulties, history of accidents, medical 
problems, and evidence of tolerance to alcohol. Standardized questionnaires 
can be helpful in busy clinical practices including the 10-item Alcohol Use 
Disorders Identification Test (AUDIT) (see Table 211-1).
Routine medical care requires attention to potential alcohol-related illness 
and to alcoholism itself:
1. Neurologic—blackouts, seizures, delirium tremens, cerebellar degenera-
tion, neuropathy, myopathy
2. Gastrointestinal—esophagitis, gastritis, pancreatitis, hepatitis, cirrhosis, 
GI hemorrhage
3. Cardiovascular—hypertension, cardiomyopathy
4. Hematologic—macrocytosis, folate deficiency, thrombocytopenia, 
leukopenia
5. Endocrine—gynecomastia, testicular atrophy, amenorrhea, infertility
6. Skeletal—fractures, osteonecrosis
7. Cancer—breast cancer, oral and esophageal cancers, rectal cancers
Alcohol Intoxication 
Alcohol is a CNS depressant that acts on receptors for γ-aminobutyric acid 
(GABA), the major inhibitory neurotransmitter in the nervous system. 
Behavioral, cognitive, and psychomotor changes can occur at blood alcohol 
levels as low as 0.02–0.03 g/dL, a level achieved after the ingestion of one 
or two typical drinks. “Legal intoxication” in most states requires a blood 
alcohol concentration of 0.08 g/dL; levels twice this can lead to deep but 
disturbed sleep. Incoordination, tremor, ataxia, confusion, stupor, coma, 
and even death occur at progressively higher blood alcohol levels.
Alcohol Withdrawal 
Chronic alcohol use produces CNS dependence, and the earliest sign of 
alcohol withdrawal is tremulousness (“shakes” or “jitters”), occurring 
5–10 h after decreasing ethanol intake. This may be followed by generalized 
seizures in the first 24–48 h; these do not require initiation of antiseizure 
medications. With severe withdrawal, autonomic hyperactivity ensues 
(sweating, hypertension, tachycardia, tachypnea, fever), accompanied by 
insomnia, nightmares, anxiety, and GI symptoms.
Delirium Tremens (DTs) 
A very severe withdrawal syndrome characterized by profound autonomic 
hyperactivity, extreme confusion, agitation, vivid delusions, and hallucina-
tions (often visual and tactile) that begins 3–5 days after the last drink. 
Mortality is 5–15%.
Wernicke’s Encephalopathy 
An alcohol-related syndrome characterized by ataxia, ophthalmoplegia, 
and confusion, often with associated nystagmus, peripheral neuropathy, 
SECTION 15
1338
Psychiatry and Substance Abuse
TABLE 211-1  THE ALCOHOL USE DISORDERS IDENTIFICATION TEST 
(AUDIT)a
Item
5-Point Scale (Least to Most)
1.  How often do you have a drink 
containing alcohol?
Never (0) to 4+ per week (4)
2.  How many drinks containing 
alcohol do you have on a typical 
day?
1 or 2 (0) to 10+ (4)
3.  How often do you have six or 
more drinks on one occasion?
Never (0) to daily or almost daily (4)
4.  How often during the last year 
have you found that you were 
not able to stop drinking once 
you had started?
Never (0) to daily or almost daily (4)
5.  How often during the last 
year have you failed to do 
what was normally expected 
from you because of drinking?
Never (0) to daily or almost daily (4)
6.  How often during the last year 
have you needed a first drink 
in the morning to get yourself 
going after a heavy drinking 
session?
Never (0) to daily or almost daily (4)
7.  How often during the last year 
have you had a feeling of guilt 
or remorse after drinking?
Never (0) to daily or almost daily (4)
8.  How often during the last year 
have you been unable to 
remember what happened the 
night before because you had 
been drinking?
Never (0) to daily or almost daily (4)
9.  Have you or someone else 
been injured as a result of your 
drinking?
No (0) to yes, during the last year (4)
10.  Has a relative, friend, doctor 
or other health worker been 
concerned about your drinking 
or suggested that you should 
cut down?
No (0) to yes, during the last year (4)
aTotal score > 8 indicates harmful alcohol use and possible alcohol dependence.
Source: Adapted from DF Reinert, GP Allen: Alcoholism: Clinical & Experimental Research
26:272, 2002, and from MA Schuckit, Drug and Alcohol Abuse: Clinical Guide to Diagnosis & 
Treatment, 6th ed, New York: Springer, 2006.
CHAPTER 211
1339
Alcoholism
cerebellar signs, and hypotension; there is impaired short-term memory, 
inattention, and emotional lability. Wernicke-Korsakoff’s syndrome fol-
lows, characterized by anterograde and retrograde amnesia and con-
fabulation. Wernicke-Korsakoff’s syndrome is caused by chronic thiamine 
deficiency, resulting in damage to thalamic nuclei, mamillary bodies, and 
brainstem and cerebellar structures.
� LABORATORY FINDINGS
Include mild anemia with macrocytosis, folate deficiency, thrombocytope-
nia, granulocytopenia, abnormal liver function tests, hyperuricemia, and 
elevated triglycerides. Two blood tests with ≥60% sensitivity and specificity 
are γ-glutamyl transferase (GGT) (>35 U) and carbohydrate-deficient trans-
ferrin (CDT) (>20 U/L or >2.6%); the combination of the two is likely to be 
more accurate than either alone. A variety of diagnostic studies may show 
evidence of alcohol-related organ dysfunction.
Alcoholism
TREATMENT
ACUTE WITHDRAWAL
• Acute alcohol withdrawal is treated with multiple B vitamins includ-
ing thiamine (50–100 mg IV or PO daily for ≥1 week) to replenish 
depleted stores; use the IV route if Wernicke-Korsakoff’s syndrome is 
suspected since intestinal absorption is unreliable in alcoholics.
• CNS depressant drugs are used when seizures or autonomic hyper-
activity is present to halt the rapid state of withdrawal in the CNS 
and allow for a slower, more controlled reduction of the substance. 
Low-potency benzodiazepines with long half-lives are the medica-
tion of choice (e.g., diazepam 10 mg PO q4–6 h, chlordiazepoxide 
25–50 mg PO q 4–6 h) because they produce fairly steady blood levels 
of drug with a wide dose range within which to work. Risks include 
overmedication and oversedation, which occur less commonly with 
shorter-acting agents (e.g., oxazepam, lorazepam). 
• In severe withdrawal or DTs, high doses of benzodiazepines are usu-
ally required. Fluid and electrolyte status and blood glucose levels 
should be closely followed. Cardiovascular and hemodynamic moni-
toring are crucial, as hemodynamic collapse and cardiac arrhythmia 
are not uncommon. 
• Generalized withdrawal seizures rarely require aggressive pharma-
cologic intervention beyond that given to the usual pt undergoing 
withdrawal, i.e., adequate doses of benzodiazepines.
RECOVERY AND SOBRIETY
Counseling, Education, and Cognitive Approaches
• First, attempts should be made to help the alcoholic achieve and 
maintain a high level of motivation toward abstinence. These include 
education about alcoholism and instructing family and/or friends to 
stop protecting the person from the problems caused by alcohol.
SECTION 15
1340
Psychiatry and Substance Abuse
• A second goal is to help the pt to readjust to life without alcohol and to 
reestablish a functional lifestyle through counseling, vocational reha-
bilitation, and self-help groups such as Alcoholics Anonymous (AA).
• A third component, called relapse prevention, helps the person to iden-
tify situations in which a return to drinking is likely, formulate ways of 
managing these risks, and develop coping strategies that increase the 
chances of a return to abstinence if a slip occurs. 
• There is no convincing evidence that inpatient rehabilitation is more 
effective than outpatient care.
Drug Therapy Several medications may be useful in alcoholic reha-
bilitation; usually medications are continued for 6 months if a positive 
response is seen.
• The opioid-antagonist drug naltrexone, (50–150 mg/d PO or monthly 
380 mg injection) decreases the probability of a return to drinking and 
shortens periods of relapse.
• A second medication, acamprosate (2 g/d divided into three oral 
doses), an N-methyl-d-aspartate receptor inhibitor, may be used; 
efficacy appears to be similar to naltrexone.
• A combination of naltrexone and acamprosate may be superior to 
either drug alone, although not all studies agree.
• Disulfiram (250 mg/d), an aldehyde dehydrogenase inhibitor, pro-
duces an unpleasant and potentially dangerous reaction in the 
presence of alcohol.
CHAPTER 212
Narcotic Abuse
Narcotics, or opiates, bind to specific opioid receptors in the CNS and else-
where in the body. These receptors mediate the opiate effects of analgesia, 
euphoria, respiratory depression, and constipation. Endogenous opiate 
peptides (enkephalins and endorphins) are natural ligands for the opioid 
receptors and play a role in analgesia, memory, learning, reward, mood 
regulation, and stress tolerance.
The prototypic opiates, morphine and codeine, are derived from the juice 
of the opium poppy. The semisynthetic drugs produced from morphine 
include hydromorphone (Dilaudid), diacetylmorphine (heroin), and oxyco-
done (OxyContin). The purely synthetic opioids and their cousins include 
meperidine, propoxyphene, diphenoxylate, fentanyl, buprenorphine, tra-
madol, methadone, and pentazocine. All of these substances produce 
For a more detailed discussion, see Schuckit MA: Alcohol 
and Alcoholism, Chap. 392, p. 3546, in HPIM-18.
CHAPTER 212
1341
Narcotic Abuse
analgesia and euphoria as well as physical dependence when taken in high 
enough doses for prolonged periods of time.
� CLINICAL FEATURES
The 0.14% annual prevalence of heroin dependence in the United States is 
only about one-third the rate of prescription opiate abuse and is substan-
tially lower than the 2% rate of morphine dependence in parts of Asia. Since 
2007, prescription opiates have surpassed marijuana as the most common 
illicit drug that adolescents initially abuse.
Acute Effects 
All opiates have the following CNS effects: sedation, euphoria, decreased 
pain perception, decreased respiratory drive, and vomiting. In larger doses, 
markedly decreased respirations, bradycardia, pupillary miosis, stupor, 
and coma ensue. Additionally, the adulterants used to “cut” street drugs 
(quinine, phenacetin, strychnine, antipyrine, caffeine, powdered milk) can 
produce permanent neurologic damage, including peripheral neuropathy, 
amblyopia, myelopathy, and leukoencephalopathy; adulterants can also pro-
duce an “allergic-like” reaction characterized by decreased alertness, frothy 
pulmonary edema, and an elevation in blood eosinophil count.
Chronic Effects 
Tolerance and withdrawal commonly occur with chronic daily use after 
6–8 weeks depending on the dose and frequency; the ever-increasing 
amounts of drug needed to sustain euphoriant effects and avoid discomfort 
of withdrawal strongly reinforce dependence once it has started. 
Withdrawal 
Withdrawal produces nausea and diarrhea, coughing, lacrimation, mydriasis, 
rhinorrhea, diaphoresis, twitching muscles, piloerection, fever, tachypnea, 
hypertension, diffuse body pain, insomnia, and yawning. 
With shorter-acting opiates such as heroin, morphine, or oxycodone, 
withdrawal signs begin 8–16 h after the last dose, peak at 36–72 h, and 
subside over 5–8 days. With longer-acting opiates such as methadone, with-
drawal begins several days after the last dose, peaks at 7–10 days in some 
cases, and lasts several weeks.
Narcotic Abuse
TREATMENT
OVERDOSE
• High doses of opiates, whether taken in a suicide attempt or acciden-
tally when potency is misjudged, are potentially lethal. Toxicity occurs 
immediately after IV administration and with a variable delay after 
oral ingestion. Symptoms include miosis, shallow respirations, brady-
cardia, hypothermia, and stupor or coma.
• Managing overdose requires support of vital functions, including 
intubation if needed.
SECTION 15
1342
Psychiatry and Substance Abuse
• The opiate antagonist naloxone is given at 0.4–2 mg IV or IM with an 
expected response within 1–2 min; repeated doses may be needed for 
24–72 h depending on the opiate used in overdose
WITHDRAWAL
• Long-acting opiates such as methadone or buprenorphine can be used 
to treat withdrawal and achieve detoxification by slowly tapering the 
dose over weeks to months. Buprenorphine produces fewer with-
drawal symptoms compared with methadone but does not appear to 
result in better outcomes.
• Several α-2-adrenergic agonists have relieved opioid withdrawal and 
achieved detoxification by suppressing central noradrenergic activity. 
Clonidine and lofexidine are commonly used orally in three to four 
doses per day. Completion rates of managed withdrawal are similar to 
methadone.
• Rapid opiate detoxification can be accomplished with naltrexone com-
bined with an α-2-adrenergic agonist. Completion rates are high, but 
the approach is highly controversial due to the medical risks and even 
mortality associated with this approach.
OPIOID MAINTENANCE
• Methadone maintenance is a widely used treatment strategy in the 
management of opiate addiction. Methadone is a long-acting opioid 
optimally dosed at 80–150 mg/d (gradually increased over time). 
• The partial agonist buprenorphine can also be used; it has several 
advantages, including low overdose danger, potentially easier detoxi-
fication than with methadone, and a probable ceiling effect in which 
higher doses do not increase euphoria. In the U.S. primary care 
physicians can prescribe buprenorphine; this may improve access and 
quality of treatment.
OPIATE ANTAGONISTS FOR OPIOID DEPENDENCE
• Rationale is that blocking the action of self-administered opioids 
should eventually extinguish the habit; poorly accepted by many pts.
• Naltrexone can be given three times a week (100- to 150-mg dose); a 
depot form for monthly injection is available and improves adherence, 
retention, and decreases opioid use. 
DRUG-FREE PROGRAMS
• Medication-free treatments in inpatient, residential, or outpatient 
settings have poor 1- to 5-year outcomes compared with pharma-
cotherapy; exceptions are residential programs lasting 6–18 months, 
which require full immersion in a regimented system.
� PREVENTION
Preventing opiate abuse is a critically important challenge for physicians. 
Sources of opiates for the 9000 adolescents in the United States that become 
abusers daily are most commonly family members, not drug dealers or the 
CHAPTER 212
1343
Narcotic Abuse
Internet. Except for the terminally ill, physicians should carefully monitor 
opioid drug use in their pts, keeping doses as low as is practical and admin-
istering them over as short a period as the level of pain would warrant in the 
average person. Pts must dispose of any remaining opiates after treatment. 
Physicians must be vigilant regarding their own risk for opioid abuse and 
dependence, never prescribing these drugs for themselves.
For a more detailed discussion, see Kosten TR: Opioid Drug 
Abuse and Dependence, Chap. 393, p. 3552, in HPIM-18.
This page intentionally left blank 
1345
CHAPTER 213
Routine Disease Screening
A primary goal of health care is to prevent disease or to detect it early 
enough that interventions will be more effective. In general, screening is 
most effective when applied to relatively common disorders that carry a 
large disease burden and have a long latency period. Early detection of 
disease has the potential to reduce both morbidity and mortality; however, 
screening asymptomatic individuals carries some risk. False-positive results 
can lead to unnecessary lab tests and invasive procedures and can increase 
pt anxiety. Several measurements have been derived to better assess the 
potential gain from screening and prevention interventions:
• Number of subjects needed to be screened to alter the outcome in one 
individual
• Absolute impact of screening on disease (e.g., lives saved per thousand 
screened)
• Relative impact of screening on disease outcome (e.g., the % reduction in 
deaths)
• The cost per year of life saved
• The increase in average life expectancy for a population
Current recommendations include performance of a routine health care 
examination every 1–3 years before age 50 and every year thereafter. 
History should include medication use, allergies, vaccination history, 
dietary history, use of alcohol and tobacco, sexual practices, safety practices 
(seat belt and helmet use, gun possession), and a thorough family history. 
Routine measurements should include assessments of height, weight, body-
mass index, and blood pressure. Screening should also be considered for 
domestic violence and depression.
Counseling by health care providers should be performed at health care 
visits. Tobacco and alcohol use, diet, and exercise represent the vast majority 
of factors that influence preventable deaths. While behavioral changes are 
frequently difficult to achieve, it should be emphasized that studies show even 
brief (<5 min) tobacco counseling by physicians results in a significant rate of 
long-term smoking cessation. Instruction about self-examination (e.g., skin, 
breast, testicular) should also be provided during preventative visits.
The top causes of age-specific mortality and corresponding preventative 
strategies are listed in Table 213-1. Formal recommendations from the U.S. 
Preventive Services Task Force are listed in Table 213-2.
In addition to the general recommendations applicable to all per-
sons, screening for specific diseases and preventive measures need to be 
individualized based on family history, travel history, or occupational 
SECTION 16
Disease Prevention and 
Health Maintenance
SECTION 16
1346
Disease Prevention and Health Maintenance
TABLE 213-1  AGE-SPECIFIC CAUSES OF MORTALITY AND 
CORRESPONDING PREVENTATIVE OPTIONS
Age Group
Leading Causes of 
Age-Specific Mortality
Screening Prevention 
Interventions to Consider for Each 
Specific Population
15–24
1. Accident
2. Homicide
3. Suicide
4. Malignancy
5. Heart disease
• Counseling on routine seat 
belt use, bicycle/motorcycle/all 
terrain vehicle helmets (1)
• Counseling on diet and 
exercise (5)
• Discuss dangers of alcohol use 
while driving, swimming, 
boating (1)
• Ask about vaccination status 
(tetanus, diphtheria, pertussis, 
hepatitis B, MMR, varicella, 
meningitis, HPV)
• Ask about gun use and/or gun 
possession (2,3)
• Assess for substance abuse 
history including alcohol (2,3)
• Screen for domestic 
violence (2,3)
• Screen for depression and/or 
suicidal/homicidal ideation (2,3)
• Pap smear for cervical cancer 
screening, discuss STD 
prevention (4)
• Recommend skin, breast, and 
testicular self-exams (4)
• Recommend UV light avoidance 
and regular sun screen use (4)
• Measurement of blood pres-
sure, height, weight and body 
mass index (5)
• Discuss health risks of tobacco 
use, consider emphasis of cos-
metic and economic issues to 
improve quit rates for younger 
smokers (4,5)
• Chlamydia screening and con-
traceptive counseling for sexu-
ally active females
• HIV, hepatitis B, and syphilis test-
ing if there is high-risk sexual 
behavior(s) or any prior history of 
sexually transmitted disease
CHAPTER 213
1347
Routine Disease Screening
TABLE 213-1  AGE-SPECIFIC CAUSES OF MORTALITY AND 
CORRESPONDING PREVENTATIVE OPTIONS
Age Group
Leading Causes of 
Age-Specific Mortality
Screening Prevention 
Interventions to Consider for Each 
Specific Population
25–44
1. Accident
2. Malignancy
3. Heart disease
4. Suicide
5. Homicide
6. HIV
As above plus consider the following:
• Readdress smoking status, 
encourage cessation at every 
visit (2,3)
• Obtain detailed family history of 
malignancies and begin early 
screening/prevention program 
if pt is at significant increased 
risk (2)
• Assess all cardiac risk factors 
(including screening for dia-
betes and hyperlipidemia) and 
consider primary prevention 
with aspirin for pts at >3%
5-year risk of a vascular 
event (3)
• Assess for chronic alcohol 
abuse, risk factors for viral hep-
atitis, or other risks for develop-
ment of chronic liver disease
• Begin breast cancer screening 
with mammography at 
age 40 (2)
45–64
1. Malignancy
• Consider prostate cancer 
screen with annual PSA and 
digital rectal exam at age 50 
(or possibly earlier in African 
Americans or pts with family 
history) (1)
• Begin colorectal cancer 
screening at age 50 with 
either fecal occult blood testing, 
flexible sigmoidoscopy, or 
colonoscopy (1)
• Reassess vaccination status at 
age 50 and give special con-
sideration to vaccines against 
Streptococcus pneumoniae,
influenza, tetanus, and viral 
hepatitis
2. Heart disease
3. Accident
4. Diabetes mellitus
5.  Cerebrovascular 
disease
6.  Chronic lower 
respiratory disease
7.  Chronic liver disease 
and cirrhosis
8. Suicide
• Consider screening for coronary 
disease in higher risk pts (2,5)
(CONTINUED)
(continued)
SECTION 16
1348
Disease Prevention and Health Maintenance
TABLE 213-1  AGE-SPECIFIC CAUSES OF MORTALITY AND 
CORRESPONDING PREVENTATIVE OPTIONS
Age Group
Leading Causes of 
Age-Specific Mortality
Screening Prevention 
Interventions to Consider for Each 
Specific Population
≥65
1. Heart disease
2. Malignancy
3.  Cerebrovascular 
disease
4.  Chronic lower 
respiratory disease
5.   Alzheimer’s 
disease
6.  Influenza and 
pneumonia
7. Diabetes mellitus
8. Kidney disease
9.  Accidents
10. Septicemia
As above plus consider the following:
• Readdress smoking status, 
encourage cessation at every 
visit (1,2,3)
• One-time ultrasound for AAA 
in men 65–75 who have ever 
smoked
• Consider pulmonary func-
tion testing for all long-term 
smokers to assess for develop-
ment of chronic obstructive 
pulmonary disease (4,6)
• Vaccinate all smokers against 
influenza and S. pneumoniae at 
age 50 (6)
• Screen all postmenopausal 
women (and all men with risk 
factors) for osteoporosis
• Reassess vaccination status at 
age 65, emphasis on influenza 
and S. pneumoniae (4,6)
• Screen for dementia and 
depression (5)
• Screen for visual and hearing 
problems, home safety issues, 
and elder abuse (9)
Note: The numbers in parentheses refer to areas of risk in the mortality column affected by 
the specified intervention.
Abbreviations: AAA, abdominal aortic aneurysm; HPV, human papilloma virus; MMR, 
measles-mumps-rubella; PSA, prostate-specific antigen; STD, sexually transmitted disease; 
UV, ultraviolet.
(CONTINUED)
history. For example, when there is a significant family history of breast, 
colon, or prostate cancer, it is prudent to initiate screening about 10 years 
before the age at which the youngest family member developed cancer. 
Specific recommendations for disease prevention can also be found in 
subsequent chapters on “Immunization and Advice to Travelers” (Chap. 214), 
“Cardiovascular Disease Prevention” (Chap. 215), “Prevention and Early 
Detection of Cancer” (Chap. 216), “Smoking Cessation” (Chap. 217), and 
“Women’s Health” (Chap. 218).
CHAPTER 213
1349
Routine Disease Screening
TABLE 213-2  CLINICAL PREVENTIVE SERVICES FOR NORMAL-RISK 
ADULTS RECOMMENDED BY THE U.S. PREVENTIVE 
SERVICES TASK FORCE
Test or Disorder
Population,a Years
Frequency
Blood pressure, height 
and weight
>18
Periodically
Cholesterol
Men >35
Every 5 years
Women >45
Every 5 years
Depression
>18
Periodicallyb
Diabetes
>45 or earlier, if there 
are additional risk factors
Every 3 years
Pap smearc
Within 3 years of onset 
of sexual activity or 
21–65
Every 1–3 years
Chlamydia
Women 18–25
Every 1–2 years
Mammographya
Women > 50d
Every 1–2 years
Colorectal cancera
>50
fecal occult blood and/or
Every year
sigmoidoscopy or
Every 5 years
colonoscopy
Every 10 years
Osteoporosis
Women >65; >60 at risk
Periodically
Abdominal aortic aneu-
rysm (ultrasound)
Men 65–75 who have 
ever smoked
Once
Alcohol use
>18
Periodically
Vision, hearing
>65
Periodically
Adult immunization
 Tetanus-diphtheria (Td) >18
Every 10 years
 Varicella (VZV)
Susceptibles only, >18
Two doses
 Zoster
>60
One dose
  Measles, mumps, 
rubella (MMR)
Women, childbearing age One dose
 Pneumococcal
>65
One dose
 Influenza
>50
Yearly
  Human papillomavirus 
(HPV)
Up to age 26
If not done prior
aScreening is performed earlier and more frequently when there is a strong family history. 
Randomized, controlled trials have documented that fecal occult blood testing (FOBT) confers 
a 15–30% reduction in colon cancer mortality. Although randomized trials have not been per-
formed for sigmoidoscopy or colonoscopy, well-designed case-control studies suggest similar 
or greater efficacy relative to FOBT.
bIf staff support is available.
cIn the future, Pap smear frequency may be influenced by HPV testing and the HPV vaccine.
SECTION 16
1350
Disease Prevention and Health Maintenance
For a more detailed discussion, see Martin GJ: Screening 
and Prevention of Disease, Chap. 4, p. 29, in HPIM-18. 
CHAPTER 214
Immunization and 
Recommendations for Travelers
IMMUNIZATION
Few medical interventions of the past century can rival the effect that 
immunization has had on longevity, economic savings, and quality of life.
� VACCINE IMPACT
• Vaccines have both a direct impact (protecting the vaccinated individual 
against infection) and indirect effects (reducing transmission of infec-
tious agents from immunized people to others).
• Vaccine programs attempt to control, eliminate, or eradicate a disease.
 
–  Control programs: limit the disruptive impacts associated with out-
breaks in a defined geographic area
 
–  Elimination programs: require a blockage in the indigenous sustained 
transmission of an infection in a defined geographic area, with pos-
sible importation of sporadic cases from other areas requiring ongoing 
interventions
 
–  Eradication programs: considered successful if elimination of a disease 
can be sustained without ongoing interventions. Smallpox is the only 
vaccine-preventable disease that has been globally eradicated; consid-
erable effort is ongoing in attempts to eradicate polio.
� IMMUNIZATION PRACTICE STANDARDS
• Figure 214-1 summarizes the adult immunization schedules for 2011.
• Before vaccination, pts must be screened for contraindications (condi-
tions that substantially increase the risk of a serious adverse reaction) 
and precautions (conditions that may increase the risk of an adverse 
dSome authorities advocate starting mammography at age 40.
Note: Prostate-specific antigen (PSA) testing is capable of enhancing the detection of early-
stage prostate cancer, but evidence is inconclusive that it improves health outcomes. PSA 
testing is recommended by several professional organizations and is widely used in clinical 
practice, but it is not currently recommended by the U.S. Preventive Services Task Force.
Source: Adapted from the U.S. Preventive Services Task Force, Guide to Clinical Prevention 
Services, 2010–2011. www.ahrq.gov/clinic/pocketgd.htm.
CHAPTER 214
1351
Immunization and Recommendations for Travelers 
event or that may compromise the ability of the vaccine to evoke immu-
nity). Table 214-1 summarizes the contraindications and precautions for 
vaccines used commonly in adults.
• A vaccine information statement must be provided to all vaccine recipi-
ents; current VISs are available online at www.cdc.gov/vaccines and 
www.immunize.org/vis/. (The latter website includes translations.)
• Any adverse event that occurs after immunization and that may or may 
not be related to the vaccine should be reported to the Vaccine Adverse 
Event Reporting System (www.vaers.hhs.gov).
RECOMMENDATIONS FOR TRAVELERS
Travelers should be aware of various health risks that might be associated 
with given destinations. Information regarding country-specific risks can 
be obtained from the CDC publication Health Information for International 
Travel, which is available at www.cdc.gov/travel. Travelers should be 
encouraged to see a travel medicine practitioner before departure. Although 
infections contribute substantially to morbidity among travelers, they 
account for only ~1% of deaths; in contrast, injuries (e.g., motor vehicle, 
drowning, or aircraft accidents) account for 22% of deaths.
� IMMUNIZATIONS FOR TRAVEL
There are three categories of immunization for travel.
• Routine immunizations (see Fig. 214-1) are needed regardless of travel. 
However, travelers from the United States should be certain that their 
routine immunizations are up to date because certain diseases (e.g., diph-
theria, tetanus, polio, measles) are more likely to be acquired outside the 
United States than at home.
• Required immunizations (e.g., yellow fever vaccination) are mandated by 
international regulations for entry into certain areas.
• Recommended immunizations (e.g., hepatitis A, typhoid) are advisable because 
they protect travelers against illnesses for whose acquisition they are at 
increased risk. Table 214-2 lists vaccines required or recommended for travel.
� PREVENTION OF MALARIA AND OTHER INSECT-BORNE DISEASES
• Chemoprophylaxis against malaria and other preventive measures are 
recommended for travel to malaria-endemic regions, particularly since 
fewer than 50% of travelers adhere to basic recommendations for malaria 
prevention.
• Chemoprophylactic regimens consist of chloroquine, doxycycline, 
atovaquone-proguanil, or mefloquine.
• In the United States, 90% of cases of Plasmodium falciparum infection 
occur in persons returning or immigrating from Africa and Oceania. 
• The destination helps determine the particular medication chosen (e.g., 
whether chloroquine-resistant P. falciparum is present), as does the trav-
eler’s preference and medical history. 
• Personal protective measures against mosquito bites [e.g., the use of DEET-
containing insect repellents (25–50%), permethrin-impregnated bed nets, 
and screened sleeping areas], especially between dusk and dawn, can pre-
vent malaria and other insect-borne diseases (e.g., dengue fever).
*Covered by the Vaccine Injury Compensation Program.
Recommended Adult Immunization Schedule
UNITED STATES · 2011
Note: These recommendations must be read with the footnotes that follow containing number of doses, intervals between doses, and other important information.
Recommended adult immunization schedule, by vaccine and age group
Report all clinically significant postvaccination reactions to the Vaccine Adverse Event Reporting System (VAERS). Reporting forms and instructions on filing a VAERS report are available at http://www.vaers.hhs.gov or by telephone, 800-822-7967.
Information on how to file a Vaccine Injury Compensation Program claim is available at http://www.hrsa.gov/vaccinecompensation or by telephone, 800-338-2382. Information about filing a claim for vaccine injury is available through the
U.S. Court of Federal Claims, 717 Madison Place, N.W., Washington, D.C. 20005; telephone, 202-357-6400.
Additional information about the vaccines in this schedule, extent of available data, and contraindications for vaccination also is available at http://www.cdc.gov/vaccines or from the CDC-INFO Contact Center at 800-CDC- INFO (800-232-4636) in English
and Spanish, 24 hours a day, 7 days a week.
For all persons in this category who meet the age requirements and
who lack evidence of immunity (e.g., lack documentation of
vaccination or have no evidence of previous infection)
No recommendation 
Recommended if some other risk factor is present (e.g., based on
medical, occupational, lifestyle, or other indications)
VACCINE
AGE GROUP
19–26 years
27–49 years
50–59 years
60–64 years
≥65 years
Hepatitis B11,* 
3 doses
Meningococcal9,*
1 or more doses
Varicella3,*
2 doses
Measles, mumps, rubella (MMR)6,*
1 or 2 doses
1 dose
Human papillomavirus (PHV)4,*
3 doses (females)
Hepatitis A10,*
2 doses
Pneumococcal (polysaccharide)7,8
1 or 2 doses
1 dose
Zoster5
1 dose
Influenza1,*
1 dose annually
Tetanus, diphtheria, pertussis (Td/Tdap)2,*
Substitute 1-time dose of Tdap for Td booster; then boost with Td every 10 yrs
Td booster every 10 yrs
1352
FIGURE 214-1 Recommended adult immunization schedules, United States, 2011. For complete statements by the Advisory Committee on Immunization
Practices (ACIP), visit www.cdc.gov/vaccines/pubs/ACIP-list.htm.
Human papillomavirus (HPV)4,*
3 doses through age 26 yrs
Tetanus, diphtheria, pertussis (Td/Tdap)2,*
Substitute 1-time dose of Tdap for Td booster; then boost with Td every 10 yrs
Td
Measles, mumps, rubella (MMR)6,*
Contraindicated
1 or 2 doses
Varicella3,*
Contraindicated
2 doses
Zoster5
1 dose
Contraindicated
Influenza1,*
1 dose TIV annually
1 dose TIV or
LAIV annually
Pneumococcal (polysaccharide)7,8
1 or 2 doses
Hepatitis A10,* 
2 doses
Hepatitis B11,*
3 doses
Meningococcal9,*
1 or more doses 
Recommended if some other risk factor is present
(e.g., on the basis of medical, occupational, lifestyle,
or other indications)
No recommendation 
For all persons in this category who meet the age requirements
and who lack evidence of immunity (e.g., lack documentation of
vaccination or have no evidence of previous infection) 
Vaccines that might be indicated for adults based on medical and other indications
U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
CENTERS FOR DISEASE CONTROL AND PREVENTION
The recommendations in this schedule were approved by the Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP),
the American Academy of Family Physicians (AAFP), the American College of Obstetricians and Gynecologists (ACOG), and the American College of Physicians (ACP).
Healthcare
personnel
<200
cells/μL
≥200
cells/μL
CD4 + T lympho -
cyte count
HIV 
infection3,6,12,13
Kidney failure,
end-stage renal
disease,
receipt of
hemodialysis 
Asplenia12
(including elective
splenectomy)
and persistent
complement
component
deficiencies
Chronic liver
disease
Diabetes,
heart disease,
chronic
lung disease,
chronic
alcoholism
Immuno-
compromising 
conditions
(excluding human 
immunodeficiency
virus
[HIV])3,5,6,13
Pregnancy
*Covered by the Vaccine Injury Compensation Program.
INDICATION
VACCINE
These schedules indicate the recommended age groups and medical indications for which administration of currently licensed vaccines is commonly indicated for adults ages 19 years and older, as of February 4, 2011. For all vaccines being recommended
on the adult immunization schedule, a vaccine series does not need to be restarted, regardless of the time that has elapsed between doses. Licensed combination vaccines may be used whenever any components of the combination are indicated and when
the vaccine’s other components are not contraindicated. For detailed recommendations on all vaccines, including those used primarily for travelers or  that are issued during the year, consult the manufacturers’ package inserts and the complete statements
from the Advisory Committee on Immunization Practices (http:// www.cdc.gov/vaccines/pubs/acip-list.htm).
1353
SECTION 16
1354
Disease Prevention and Health Maintenance
Footnotes
Recommended Adult Immunization Schedule—UNITED STATES · 2011
For complete statements by the Advisory Committee on Immunization Practices (ACIP), visit www.cdc.gov/vaccines/pubs/ACIP-list.htm.
1. Influenza vaccination
 
Annual vaccination against influenza is recommended for all persons aged 6 months and older, including all adults. Healthy,
nonpregnant adults aged less than 50 years without high-risk medical conditions can receive either intranasally administered live,
attenuated influenza vaccine (FluMist), or inactivated vaccine. Other persons should receive the inactivated vaccine. Adults aged 65
years and older can receive the standard influenza vaccine or the high-dose (Fluzone) influenza vaccine. Additional information about
influenza vaccination is available at http://www.cdc.gov/vaccines/vpd-vac/flu/default.htm.
2. Tetanus, diphtheria, and acellular pertussis (Td/Tdap) vaccination
 
Administer a one-time dose of Tdap to adults aged less than 65 years who have not received Tdap previously or for whom vaccine
status is unknown to replace one of the 10-year Td boosters, and as soon as feasible to all 1) postpartum women, 2) close contacts of
infants younger than age 12 months (e.g., grandparents and child-care providers), and 3) healthcare personnel with direct patient
contact. Adults aged 65 years and older who have not previously received Tdap and who have close contact with an infant aged
less than 12 months also should be vaccinated. Other adults aged 65 years and older may receive Tdap. Tdap can be administered
regardless of interval since the most recent tetanus or diphtheria-containing vaccine.
 
Adults with uncertain or incomplete history of completing a 3-dose primary vaccination series with Td-containing vaccines should
begin or complete a primary vaccination series. For unvaccinated adults, administer the first 2 doses at least 4 weeks apart and the third
dose 6–12 months after the second. If incompletely vaccinated (i.e., less than 3 doses), administer remaining doses. Substitute a
one-time dose of Tdap for one of the doses of Td, either in the primary series or for the routine booster, whichever comes first.
 
If a woman is pregnant and received the most recent Td vaccination 10 or more years previously, administer Td during the second
or third trimester. If the woman received the most recent Td vaccination less than 10 years previously, administer Tdap during the
immediate postpartum period. At the clinician’s discretion, Td may be deferred during pregnancy and Tdap substituted in the immediate
postpartum period, or Tdap may be administered instead of Td to a pregnant woman after an informed discussion with the woman.
 
The ACIP statement for recommendations for administering Td as prophylaxis in wound management is available at
http://www.cdc.gov/vaccines/pubs/acip-list.htm.
3. Varicella vaccination
 
All adults without evidence of immunity to varicella should receive 2 doses of single-antigen varicella vaccine if not previously
vaccinated or a second dose if they have received only 1 dose, unless they have a medical contraindication. Special consideration should
be given to those who 1) have close contact with persons at high risk for severe disease (e.g., healthcare personnel and family contacts
of persons with immunocompromising conditions) or 2) are at high risk for exposure or transmission (e.g., teachers; child-care
employees; residents and staff members of institutional settings, including correctional institutions; college students; military personnel;
adolescents and adults living in households with children; nonpregnant women of childbearing age; and international travelers).
 
Evidence of immunity to varicella in adults includes any of the following: 1) documentation of 2 doses of varicella vaccine at least
4 weeks apart; 2) U.S.-born before 1980 (although for healthcare personnel and pregnant women, birth before 1980 should not be
considered evidence of immunity); 3) history of varicella based on diagnosis or verification of varicella by a healthcare provider (for a
patient reporting a history of or having an atypical case, a mild case, or both, healthcare providers should seek either an epidemiologic
link with a typical varicella case or to a laboratory-confirmed case or evidence of laboratory confirmation, if it was performed at the time
of acute disease); 4) history of herpes zoster based on diagnosis or verification of herpes zoster by a healthcare provider; or 5)
laboratory evidence of immunity or laboratory confirmation of disease.
 
Pregnant women should be assessed for evidence of varicella immunity. Women who do not have evidence of immunity should
receive the first dose of varicella vaccine upon completion or termination of pregnancy and before discharge from the healthcare facility.
The second dose should be administered 4–8 weeks after the first dose.
4. Human papillomavirus (HPV) vaccination
 
HPV vaccination with either quadrivalent (HPV4) vaccine or bivalent vaccine (HPV2) is recommended for females at age 11 or 12
years and catch-up vaccination for females aged 13 through 26 years.
 
Ideally, vaccine should be administered before potential exposure to HPV through sexual activity; however, females who are sexually
active should still be vaccinated consistent with age-based recommendations. Sexually active females who have not been infected with
any of the four HPV vaccine types (types 6, 11, 16, and 18, all of which HPV4 prevents) or any of the two HPV vaccine types (types 16
and 18, both of which HPV2 prevents) receive the full benefit of the vaccination. Vaccination is less beneficial for females who have
already been infected with one or more of the HPV vaccine types. HPV4 or HPV2 can be administered to persons with a history of genital
warts, abnormal Papanicolaou test, or positive HPV DNA test, because these conditions are not evidence of previous infection with all
vaccine HPV types.
 
HPV4 may be administered to males aged 9 through 26 years to reduce their likelihood of genital warts. HPV4 would be most
effective when administered before exposure to HPV through sexual contact.
 
A complete series for either HPV4 or HPV2 consists of 3 doses. The second dose should be administered 1–2 months after the first
dose; the third dose should be administered 6 months after the first dose.
 
Although HPV vaccination is not specifically recommended for persons with the medical indications described in Figure 2, “Vaccines
that might be indicated for adults based on medical and other indications,” it may be administered to these persons because the HPV
vaccine is not a live-virus vaccine. However, the immune response and vaccine efficacy might be less for persons with the medical
indications described in Figure 2 than in persons who do not have the medical indications described or who are immunocompetent.
5. Herpes zoster vaccination
 
A single dose of zoster vaccine is recommended for adults aged 60 years and older regardless of whether they report a previous
episode of herpes zoster. Persons with chronic medical conditions may be vaccinated unless their condition constitutes a
contraindication.
6. Measles, mumps, rubella (MMR) vaccination
 
Adults born before 1957 generally are considered immune to measles and mumps. All adults born in 1957 or later should have
documentation of 1 or more doses of MMR vaccine unless they have a medical contraindication to the vaccine, laboratory evidence of
immunity to each of the three diseases, or documentation of provider-diagnosed measles or mumps disease. For rubella, documentation
of provider-diagnosed disease is not considered acceptable evidence of immunity.
 
Measles component: A second dose of MMR vaccine, administered a minimum of 28 days after the first dose, is recommended for
adults who 1) have been recently exposed to measles or are in an outbreak setting; 2) are students in postsecondary educational
institutions; 3) work in a healthcare facility; or 4) plan to travel internationally. Persons who received inactivated (killed) measles vaccine
or measles vaccine of unknown type during 1963–1967 should be revaccinated with 2 doses of MMR vaccine.
 
Mumps component: A second dose of MMR vaccine, administered a minimum of 28 days after the first dose, is recommended for
adults who 1) live in a community experiencing a mumps outbreak and are in an affected age group; 2) are students in postsecondary
educational institutions; 3) work in a healthcare facility; or 4) plan to travel internationally. Persons vaccinated before 1979 with either
killed mumps vaccine or mumps vaccine of unknown type who are at high risk for mumps infection (e.g. persons who are working in a
healthcare facility) should be revaccinated with 2 doses of MMR vaccine.
 
Rubella component: For women of childbearing age, regardless of birth year, rubella immunity should be determined. If there is no
evidence of immunity, women who are not pregnant should be vaccinated. Pregnant women who do not have evidence of immunity
should receive MMR vaccine upon completion or termination of pregnancy and before discharge from the healthcare facility.
CHAPTER 214
1355
Immunization and Recommendations for Travelers 
 
Healthcare personnel born before 1957: For unvaccinated healthcare personnel born before 1957 who lack laboratory evidence of
measles, mumps, and/or rubella immunity or laboratory confirmation of disease, healthcare facilities should 1) consider routinely
vaccinating personnel with 2 doses of MMR vaccine at the appropriate interval (for measles and mumps) and 1 dose of MMR vaccine
(for rubella), and 2) recommend 2 doses of MMR vaccine at the appropriate interval during an outbreak of measles or mumps, and
1 dose during an outbreak of rubella. Complete information about evidence of immunity is available at
http://www.cdc.gov/vaccines/recs/provisional/default.htm.
7. Pneumococcal polysaccharide (PPSV) vaccination
 Vaccinate all persons with the following indications:
 Medical: Chronic lung disease (including asthma); chronic cardiovascular diseases; diabetes mellitus; chronic liver diseases; cirrhosis;
chronic alcoholism; functional or anatomic asplenia (e.g., sickle cell disease or splenectomy [if elective splenectomy is planned,
vaccinate at least 2 weeks before surgery]); immunocompromising conditions (including chronic renal failure or nephrotic syndrome);
and cochlear implants and cerebrospinal fluid leaks. Vaccinate as close to HIV diagnosis as possible.
 Other: Residents of nursing homes or long-term care facilities and persons who smoke cigarettes. Routine use of PPSV is not
recommended for American Indians/Alaska Natives or persons aged less than 65 years unless they have underlying medical conditions
that are PPSV indications. However, public health authorities may consider recommending PPSV for American Indians/Alaska Natives
and persons aged 50 through 64 years who are living in areas where the risk for invasive pneumococcal disease is increased 
8. Revaccination with PPSV
 One-time revaccination after 5 years is recommended for persons aged 19 through 64 years with chronic renal failure or nephrotic
syndrome; functional or anatomic asplenia (e.g., sickle cell disease or splenectomy); and for persons with immunocompromising
conditions. For persons aged 65 years and older, one-time revaccination is recommended if they were vaccinated 5 or more years
previously and were aged less than 65 years at the time of primary vaccination.
9. Meningococcal vaccination
 Meningococcal vaccine should be administered to persons with the following indications:
 Medical: A 2-dose series of meningococcal conjugate vaccine is recommended for adults with anatomic or functional asplenia, or
persistent complement component deficiencies. Adults with HIV infection who are vaccinated should also receive a routine 2-dose series.
The 2 doses should be administered at 0 and 2 months.
 Other: A single dose of meningococcal vaccine is recommended for unvaccinated first-year college students living in dormitories;
microbiologists routinely exposed to isolates of Neisseria meningitidis; military recruits; and persons who travel to or live in countries
in which meningococcal disease is hyperendemic or epidemic (e.g., the “meningitis belt” of sub-Saharan Africa during the dry season
[December through June]), particularly if their contact with local populations will be prolonged. Vaccination is required by the
government of Saudi Arabia for all travelers to Mecca during the annual Hajj.
 Meningococcal conjugate vaccine, quadrivalent (MCV4) is preferred for adults with any of the preceding indications who are aged 55
years and younger; meningococcal polysaccharide vaccine (MPSV4) is preferred for adults aged 56 years and older. Revaccination with
MCV4 every 5 years is recommended for adults previously vaccinated with MCV4 or MPSV4 who remain at increased risk for infection
(e.g., adults with anatomic or functional asplenia, or persistent complement component deficiencies).
10. Hepatitis A vaccination
 Vaccinate persons with any of the following indications and any person seeking protection from hepatitis A virus (HAV) infection:
 Behavioral: Men who have sex with men and persons who use injection drugs.
 Occupational: Persons working with HAV-infected primates or with HAV in a research laboratory setting.
 Medical: Persons with chronic liver disease and persons who receive clotting factor concentrates.
 Other: Persons traveling to or working in countries that have high or intermediate endemicity of hepatitis A (a list of countries is
available at http://wwwn.cdc.gov/travel/contentdiseases.aspx).
 Unvaccinated persons who anticipate close personal contact (e.g., household or regular babysitting) with an international adoptee
during the first 60 days after arrival in the United States from a country with high or intermediate endemicity should be vaccinated.
The first dose of the 2-dose hepatitis A vaccine series should be administered as soon as adoption is planned, ideally 2 or more weeks
before the arrival of the adoptee.
 Single-antigen vaccine formulations should be administered in a 2-dose schedule at either 0 and 6–12 months (Havrix), or 0 and
6–18 months (Vaqta). If the combined hepatitis A and hepatitis B vaccine (Twinrix) is used, administer 3 doses at 0, 1, and 6 months;
alternatively, a 4-dose schedule may be used, administered on days 0, 7, and 21–30, followed by a booster dose at month 12.
11. Hepatitis B vaccination
 Vaccinate persons with any of the following indications and any person seeking protection from hepatitis B virus (HBV) infection:
Behavioral: Sexually active persons who are not in a long-term, mutually monogamous relationship (e.g., persons with more than one
sex partner during the previous 6 months); persons seeking evaluation or treatment for a sexually transmitted disease (STD); current or
recent injection-drug users; and men who have sex with men.
 Occupational: Healthcare personnel and public-safety workers who are exposed to blood or other potentially infectious body fluids.
 Medical: Persons with end-stage renal disease, including patients receiving hemodialysis; persons with HIV infection; and persons
with chronic liver disease.
 Other: Household contacts and sex partners of persons with chronic HBV infection; clients and staff members of institutions for
persons with developmental disabilities; and international travelers to countries with high or intermediate prevalence of chronic HBV
infection (a list of countries is available at http://wwwn.cdc.gov/travel/contentdiseases.aspx).
 Hepatitis B vaccination is recommended for all adults in the following settings: STD treatment facilities; HIV testing and treatment
facilities; facilities providing drug-abuse treatment and prevention services; healthcare settings targeting services to injection-drug users
or men who have sex with men; correctional facilities; end-stage renal disease programs and facilities for chronic hemodialysis patients;
and institutions and nonresidential day-care facilities for persons with developmental disabilities.
 Administer missing doses to complete a 3-dose series of hepatitis B vaccine to those persons not vaccinated or not completely
vaccinated. The second dose should be administered 1 month after the first dose; the third dose should be given at least 2 months after
the second dose (and at least 4 months after the first dose). If the combined hepatitis A and hepatitis B vaccine (Twinrix) is used,
administer 3 doses at 0, 1, and 6 months; alternatively, a 4-dose Twinrix schedule, administered on days 0, 7, and 21 to 30, followed by
a booster dose at month 12 may be used.
 Adult patients receiving hemodialysis or with other immunocompromising conditions should receive 1 dose of 40 μg/mL
(Recombivax HB) administered on a 3-dose schedule or 2 doses of 20 μg/mL (Engerix-B) administered simultaneously on a 4-dose
schedule at 0, 1, 2, and 6 months.
12. Selected conditions for which Haemophilus influenzae type b (Hib) vaccine may be used
 1 dose of Hib vaccine should be considered for persons who have sickle cell disease, leukemia, or HIV infection, or who have had a
splenectomy, if they have not previously received Hib vaccine.
13. Immunocompromising conditions
 Inactivated vaccines generally are acceptable (e.g., pneumococcal, meningococcal, influenza [inactivated influenza vaccine]) and live
vaccines generally are avoided in persons with immune deficiencies or immunocompromising conditions. Information on specific
conditions is available at http://www.cdc.gov/vaccines/pubs/acip-list.htm.
SECTION 16
1356
Disease Prevention and Health Maintenance
TABLE 214-1  CONTRAINDICATIONS AND PRECAUTIONS FOR COMMONLY 
USED VACCINES IN ADULTS
Vaccine 
Formulation
Contraindications and Precautions
All vaccines
Contraindication
Severe allergic reaction (e.g., anaphylaxis) after a previous 
vaccine dose or to a vaccine component
Precaution
Moderate or severe acute illness with or without fever; 
defer vaccination until illness resolves
Td
Precautions
GBS within 6 weeks after a previous dose of TT-containing 
vaccine
History of Arthus-type hypersensitivity reactions after a pre-
vious dose of TT-containing vaccine; defer vaccination until 
at least 10 years have elapsed since the last dose
Tdap
Contraindication
History of encephalopathy (e.g., coma or prolonged sei-
zures) not attributable to another identifiable cause within 
7 days of administration of a vaccine with pertussis compo-
nents, such as DTaP or Tdap
Precautions
GBS within 6 weeks after a previous dose of TT-containing 
vaccine
Unstable neurologic condition (e.g., cerebrovascular events 
and acute encephalopathic conditions)
History of Arthus-type hypersensitivity reactions after a pre-
vious dose of TT-containing and/or DT-containing vaccine, 
including MCV4; defer vaccination until at least 10 years 
have elapsed since the last dose
Pregnancy
HPV
Contraindication
History of immediate hypersensitivity to yeast (for Gardasil)
Precaution
Pregnancy. If a woman is found to be pregnant after initiation 
of the vaccination series, the remainder of the 3-dose regimen 
should be delayed until after completion of the pregnancy. If 
a vaccine dose has been administered during pregnancy, no 
intervention is needed. A vaccine-in-pregnancy registry has 
been established for Gardasil; pts and health care providers 
should report any exposure to quadrivalent HPV vaccine during 
pregnancy (telephone: 800-986-8999). 
MMR
Contraindications
History of immediate hypersensitivity reaction to gelatina or 
neomycin
CHAPTER 214
1357
Immunization and Recommendations for Travelers 
(continued)
TABLE 214-1  CONTRAINDICATIONS AND PRECAUTIONS FOR COMMONLY 
USED VACCINES IN ADULTS
Vaccine 
Formulation
Contraindications and Precautions
MMR
(continued)
Pregnancy
Known severe immunodeficiency (e.g., hematologic and 
solid tumors; chemotherapy; congenital immunodeficiency; 
long-term immunosuppressive therapy; severe immuno-
compromise due to HIV infection)
Precaution
Recent (within 11 months) receipt of antibody-containing 
blood product 
Varicella
Contraindications
Pregnancy
Known severe immunodeficiency
History of immediate hypersensitivity reaction to gelatina or 
neomycin
Precaution
Recent (within 11 months) receipt of antibody-containing 
blood product 
Influenza, 
injectable, 
trivalent
Contraindication
History of immediate hypersensitivity reaction to eggsb
Precautions
History of GBS within 6 weeks after a previous influenza 
vaccine dose
Pregnancy is not a contraindication or precaution. This vac-
cine is recommended for women who will be pregnant dur-
ing the influenza season.
Influenza, live 
attenuated
Contraindications
History of immediate hypersensitivity reaction to eggsb
Age ≥50 years
Pregnancy
Immunosuppression, including that caused by medications 
or by HIV infection; known severe immunodeficiency (e.g., 
hematologic and solid tumors; chemotherapy; congenital 
immunodeficiency; long-term immunosuppressive therapy; 
severe immunocompromise due to HIV infection)
Certain chronic medical conditions, such as diabetes 
mellitus; chronic pulmonary disease (including asthma); 
chronic cardiovascular disease (except hypertension); 
renal, hepatic, neurologic/neuromuscular, hematologic, or 
metabolic disorders
Close contact with severely immunosuppressed persons 
who require a protected environment (e.g., isolation in a 
bone marrow transplantation unit)
(CONTINUED)
SECTION 16
1358
Disease Prevention and Health Maintenance
TABLE 214-1  CONTRAINDICATIONS AND PRECAUTIONS FOR COMMONLY 
USED VACCINES IN ADULTS
Vaccine 
Formulation
Contraindications and Precautions
Influenza, live 
attenuated 
(continued)
Close contact with persons with lesser degrees of immu-
nosuppression (e.g., persons receiving chemotherapy or 
radiation therapy who are not being cared for in a protective 
environment; persons with HIV infection) is not a contraindi-
cation or precaution.
Precaution
History of GBS within 6 weeks of a previous influenza vac-
cine dose
Pneumococcal
polysaccharide
None
Hepatitis A
Precaution
Pregnancy
Hepatitis B
Contraindication
History of immediate hypersensitivity to yeast
Meningococcal
conjugate
Contraindications
Age >55 years (licensed for use only among persons 2–55 
years of age)
History of severe allergic reaction to dry natural rubber 
(latex) or to DT-containing vaccines
Precaution
History of GBS
Meningococcal
polysaccharide
Contraindication
History of severe allergic reaction to dry natural rubber 
(latex)
Zoster
Contraindications
Age <60 years
Pregnancy
Known severe immunodeficiency
History of immediate hypersensitivity reaction to gelatina or 
neomycin
aExtreme caution must be exercised in administering MMR, varicella, or zoster vaccine to per-
sons with a history of an anaphylactic reaction to gelatin or gelatin-containing products. Before 
administration, skin testing for sensitivity to gelatin can be considered. However, no specific 
protocols for this purpose have been published.
bProtocols have been published for safely administering influenza vaccine to persons with egg 
allergies. See references 222–224 in Fiore AE et al: MMWR Recomm Rep 57:1, 2008.
Abbreviations: DT, diphtheria toxoid; DTaP, diphtheria, tetanus, and pertussis; GBS, Guillain-Barré 
syndrome; HPV, human papillomavirus; MMR, measles, mumps, and rubella; Td, tetanus and diph-
theria toxoids; Tdap, tetanus and diphtheria toxoids and acellular pertussis; TT, tetanus toxoid.
(CONTINUED)
CHAPTER 214
1359
Immunization and Recommendations for Travelers 
TABLE 214-2 VACCINES COMMONLY USED FOR TRAVEL
Vaccine
Primary Series
Booster Interval
Cholera, live oral (CVD 
103 HgR)
1 dose
6 months
Hepatitis A (Havrix), 
1440 enzyme 
immunoassay U/mL
2 doses, 6–12 months 
apart, IM
None required
Hepatitis A (VAQTA, 
AVAXIM, EPAXAL)
2 doses, 6–12 months 
apart, IM
None required
Hepatitis A/B combined 
(Twinrix)
3 doses at 0, 1, and 6–12 
months or 0, 7, and 21 
days plus booster at 1 
year, IM
None required except
12 months (once 
only, for accelerated 
schedule)
Hepatitis B (Engerix B): 
accelerated schedule
3 doses at 0, 1, and 
2 months or 0, 7, and 
21 days plus booster at 
1 year, IM
12 months, once only
Hepatitis B (Engerix 
B or Recombivax): 
standard schedule
3 doses at 0, 1, and 
6 months, IM
None required
Immune globulin 
(hepatitis A prevention)
1 dose IM
Intervals of 3–5 
months, depending 
on initial dose
Japanese encephalitis 
(JE-VAX)
3 doses, 1 week apart, 
SC
12–18 months (first 
booster), then 4 years
Japanese encephalitis 
(Ixiaro)
2 doses, 1 month apart, 
SC
Optimal booster sched-
ule not yet determined
Meningococcus, 
quadrivalent
[Menimmune
(polysaccharide), 
Menactra, Menveo 
(conjugate)]
1 dose SC
>3 years (optimal 
booster schedule not 
yet determined)
Rabies (HDCV), rabies 
vaccine absorbed 
(RVA), or purified chick 
embryo cell vaccine 
(PCEC)
3 doses at 0, 7, and 21 
or 28 days, IM
None required except 
with exposure
Typhoid Ty21a, oral 
live attenuated 
(Vivotif)
1 capsule every other 
day × 4 doses
5 years
Typhoid Vi capsular 
polysaccharide, 
injectable (Typhim Vi)
1 dose IM
2 years
Yellow fever
1 dose SC
10 years
SECTION 16
1360
Disease Prevention and Health Maintenance
� PREVENTION OF GASTROINTESTINAL ILLNESS
• Diarrhea, the leading cause of illness in travelers, is usually a short-lived, 
self-limited condition, although 20% of pts are confined to bed.
• Incidence rates per 2-week stay approach 55% in parts of Africa, Central 
and South America, and Southeast Asia. 
• Travelers should eat only well-cooked hot foods, peeled or cooked fruits 
and vegetables, and bottled or boiled liquids (i.e., “boil it, cook it, peel it, 
or forget it!”). 
• The most common etiologies of travelers’ diarrhea are toxigenic and 
enteroaggregative strains of Escherichia coli, although Campylobacter and 
norovirus are common in certain circumstances. 
• Travelers should carry medications for self-treatment. 
 
–  Mild to moderate diarrhea can be treated with loperamide and fluids. 
 
–  Moderate to severe diarrhea should be treated with a 3-day course or 
a single double dose of a fluoroquinolone. 
• High rates of quinolone-resistant Campylobacter in Thailand make 
azithromycin a better choice for that country. 
• If fever and hematochezia are both absent, loperamide should be 
taken in combination with the antibiotic.
• Prophylaxis with bismuth subsalicylate is ~60% effective; for some pts 
(athletes, pts with repeated travelers’ diarrhea, and persons with chronic 
diseases), a single daily dose of a quinolone, azithromycin, or rifaximin 
during travel of <1 month’s duration is 75–90% effective.
� PREVENTION OF OTHER TRAVEL-RELATED PROBLEMS
• Travelers are at high risk for sexually transmitted diseases preventable by 
condom use.
• Schistosomiasis can be prevented by avoidance of swimming or bath-
ing in freshwater lakes, streams, or rivers in parts of northeastern South 
America, the Caribbean, Africa, and Southeast Asia.
• Travel-associated injury can be prevented with common-sense precau-
tions: not riding on motorcycles and in overcrowded public vehicles, not 
traveling by road in rural areas of developing countries after dark, and 
not drinking excessive amounts of alcohol.
• Walking barefoot should be avoided given the risk of hookworm and 
Strongyloides infections and snakebites. 
� TRAVEL DURING PREGNANCY
• The safest part of pregnancy in which to travel is between 18 and 24 
weeks, when the risk of spontaneous abortion or premature labor is low. 
• Relative contraindications to international travel during pregnancy 
include a history of miscarriage, premature labor, incompetent cervix, or 
toxemia or the presence of other general medical problems (e.g., heart 
failure, severe anemia). 
• Areas of excessive risk (e.g., where live virus vaccines are required 
for travel or where multidrug-resistant malaria is endemic) should be 
avoided throughout pregnancy.
• Malaria during pregnancy carries a significant risk of morbidity and 
death for both the mother and the fetus.
1361
Cardiovascular Disease Prevention 
� THE HIV-INFECTED TRAVELER
• HIV-seropositive persons with depressed CD4+ T cell counts should 
seek counseling from a travel medicine practitioner before departure, 
particularly when traveling to the developing world. 
• Several countries routinely deny entry to HIV-positive persons for pro-
longed stay, even though these restrictions do not appear to decrease 
rates of transmission of the virus.
• Ensuring that HIV-infected pts’ immunizations are up to date is criti-
cal, as many vaccine-preventable diseases are particularly severe in this 
population.
• Malaria is especially severe in pts with AIDS; the HIV load doubles dur-
ing malaria, with subsidence in 8–9 weeks.
� PROBLEMS AFTER RETURN FROM TRAVEL
• Diarrhea: After travelers’ diarrhea, symptoms may persist because of the 
continued presence of pathogens (e.g., Giardia lamblia) or, more often, 
because of postinfectious sequelae such as lactose intolerance or irritable 
bowel syndrome. A trial of metronidazole for giardiasis, a lactose-free 
diet, or a several-week trial of high-dose hydrophilic mucilloid (plus an 
osmotic laxative such as lactulose or PEG 3350) may relieve symptoms.
• Fever: Malaria is the first diagnosis that should be considered when a trav-
eler returns from an endemic area with fever. Malaria is acquired most 
often in Africa, dengue in Southeast Asia and the Caribbean, typhoid 
fever in southern Asia, and rickettsial infections in southern Africa.
• Skin conditions: Pyodermas, sunburn, insect bites, skin ulcers, and cuta-
neous larva migrans are the most common skin conditions in returning 
travelers; if persistent, a diagnosis of cutaneous leishmaniasis, mycobac-
terial infection, or fungal infection should be considered.
For a more detailed discussion, see Schuchat A, Jackson LA: 
Immunization Principles and Vaccine Use, Chap. 122, p. 1031; 
and Keystone JS, Kozarsky PE: Health Recommendations for 
International Travel, Chap. 123, p. 1042, in HPIM-18.
CHAPTER 215
Cardiovascular Disease 
Prevention
Cardiovascular disease is the leading cause of death in developed 
nations; prevention is targeted at modifiable atherosclerosis risk factors 
(Table 215-1). Identification and control of these attributes reduce subse-
quent cardiovascular event rates.
CHAPTER 215
SECTION 16
1362
Disease Prevention and Health Maintenance
� ESTABLISHED RISK FACTORS
Cigarette Smoking
Cigarette smoking increases the incidence of, and mortality associated with, 
coronary heart disease (CHD). Observational studies show that smoking 
cessation reduces excess risk of coronary events within months; after 3–5 
years, the risk falls to that of individuals who never smoked. Pts should be 
asked regularly about tobacco use, followed by counseling and, as needed, 
antismoking pharmacologic therapy to assist cessation.
Lipid Disorders
(See Chap. 189) Both elevated LDL and low HDL cholesterol are associ-
ated with cardiovascular events. Each 1-mg/dL increase in serum LDL 
correlates with a 2–3% rise in CHD risk; each 1-mg/dL decrease in HDL 
heightens risk by 3–4%. ATP III guidelines advise a fasting lipid profile 
[total cholesterol, triglycerides, HDL, LDL (calculated or directly mea-
sured)] in all adults, repeated every 5 years. Recommended dietary and/or 
pharmacologic approach depends on presence or risk of coronary artery 
disease (CAD) and the LDL level (Table 215-2); treatment should be most 
aggressive in pts with established CAD and in those with “equivalent 
risk” (e.g., presence of peripheral arterial disease or diabetes mellitus). 
Drug therapy is indicated when LDL level exceeds goal in Table 215-2 
by 30 mg/dL (0.8 mmol/L). If elevated triglyceride level [>200 mg/dL 
(> 2.6 mmol/L)] persists after control of LDL, secondary goal is to achieve 
non-HDL level (calculated as total cholesterol minus HDL) ≤30 mg/dL 
(0.8 mmol/L) above the target values listed in Table 215-2. In pts with 
isolated low HDL, encourage beneficial lifestyle measures: smoking ces-
sation, weight loss, and increased physical activity. Consider addition of 
fibric acid derivative or niacin to raise HDL in pts with established CAD 
(see Chap. 189).
TABLE 215-1 ESTABLISHED ATHEROSCLEROTIC RISK FACTORS 
Modifiable Risk Factors
 Cigarette smoking
 Dyslipidemias (↑LDL or ↓HDL)
 Hypertension
 Diabetes mellitus
 Obesity
 Sedentary lifestyle
Unmodifiable Risk Factors
  Premature coronary heart disease in first-degree relatives (age <55 in 
men, <65 in women)
 Age (men ≥45 years; women ≥55 years)
 Male sex
1363
Cardiovascular Disease Prevention CHAPTER 215
Hypertension
(See Chap. 126) Systolic or diastolic bp > “optimal” level of 115/75 mmHg is 
associated with increased risk of cardiovascular disease; each augmentation 
of 20 mmHg systolic, or 10 mmHg diastolic, above this value doubles the 
risk. Treatment of elevated blood pressure reduces the rate of stroke, conges-
tive heart failure, and CHD events, with general goal of bp <140/85 mmHg 
or <130/80 in pts with diabetes or chronic kidney disease. Cardiovascular 
event rates in elderly pts with isolated systolic hypertension (systolic ≥140 
but diastolic <90) are also reduced by antihypertensive therapy.
See Chap. 126 for antihypertensive treatment recommendations. Pts 
with “prehypertension” (systolic bp 120–139 mmHg or diastolic bp 80–89 
mmHg) should receive counseling about beneficial lifestyle modifications 
such as those listed below (e.g., low-fat diet replete with vegetables and fruit, 
weight loss if overweight, increased physical activity, reduction of excessive 
alcohol consumption).
TABLE 215-2  LDL CHOLESTEROL GOALS AND CUTPOINTS FOR 
THERAPEUTIC LIFESTYLE CHANGES (TLC) AND DRUG 
THERAPY IN DIFFERENT RISK CATEGORIES
LDL Level, mmol/L (mg/dL)
Risk Category
Goal
Initiate TLC
Consider Drug 
Therapy
Very high
<1.8 (<70)
≥1.8 (≥70)
≥1.8 (≥70)
ACS, or CHD 
w/DM, or 
multiple CRF
High
<2.6 (<100)
[optional goal: 
<1.8 (<70)]
≥2.6 (≥100)
≥2.6 (≥100)
[<2.6 (<100): 
consider
drug Rx]
CHD or CHD risk 
equivalents (10-
year risk > 20%)
If LDL < 2.6 
(<100)
<1.8 (<70)
Moderately high
<2.6 (<100)
≥3.4 (≥130)
≥3.4 (≥130)
[2.6–3.3 (100–
129): consider 
drug Rx]
2+ risk factors 
(10-year risk, 
10–20%)
Moderate
<3.4 (<130)
≥3.4 (≥130)
≥4.1 (≥160)
2+ risk factors 
(risk < 10%)
Lower
<4.1 (<160)
≥4.1 (≥160)
≥4.9 (≥190)
0–1 risk factor
Abbreviations: ACS, acute coronary syndrome; CHD, coronary heart disease; DM, diabetes 
mellitus; CRF, coronary risk factors; LDL, low-density lipoprotein.
Source: Adapted from S Grundy et al: Circulation 110:227, 2004.
SECTION 16
1364
Disease Prevention and Health Maintenance
Diabetes Mellitus/Insulin Resistance/Metabolic Syndrome
(See Chaps. 127 and 184) Pts with diabetes most often succumb to car-
diovascular disease. LDL levels are typically near average in diabetic pts, 
but LDL particles are smaller, denser, and more atherogenic; low HDL and 
elevated triglyceride levels are common. Tight control of serum glucose in 
type 2 diabetics reduces microvascular diabetic complications (retinopathy, 
renal disease), but a decrease in macrovascular events (CAD, stroke) has not 
been shown. Conversely, successful management of associated risk factors 
in diabetics (e.g., dyslipidemia and hypertension) does reduce cardiovas-
cular events and should be vigorously pursued. Antilipidemic (i.e., statin) 
therapy should be used to lower LDL to <100 mg/dL in diabetics, even if pt 
has no symptoms of CAD.
Individuals without overt diabetes but who have “metabolic syndrome” 
(constellation of insulin resistance, central obesity, hypertension, hypertri-
glyceridemia, low HDL—see Chap. 127) are also at high risk of cardiovas-
cular events. Dietary counseling, weight loss, and increased physical activity 
are important in reducing the prevalence of this syndrome.
Male Sex/Postmenopausal State
Coronary risk is greater in men compared to that of premenopausal 
women of same age, but female risk accelerates after menopause. 
Estrogen-replacement therapy lowers LDL and raises HDL in postmeno-
pausal women and in observational studies has been associated with 
reduced coronary events. However, prospective clinical trials do not 
support such a benefit and hormone-replacement therapy should not be 
prescribed for the purpose of cardiovascular risk reduction, especially in 
older women.
� EMERGING RISK FACTORS
May be assessed selectively in pts without above traditional risk factors 
who have premature vascular disease or strong family history of premature 
vascular disease.
Homocysteine 
There is a graded correlation between serum homocysteine levels and risk 
of cardiovascular events and stroke. Supplemental folic acid and other 
B vitamins lower serum levels, but prospective clinical trials have not shown 
that such therapy reduces cardiac events.
Inflammation
Inflammatory serum markers, such as high-sensitivity C-reactive protein 
(CRP), correlate with the risk of coronary events. CRP prospectively pre-
dicts risk of MI and outcomes after acute coronary syndromes; its useful-
ness and role in prevention as an independent risk factor is currently being 
defined. 
Potential benefits of assessing other emerging risk factors [e.g., 
lipoprotein(a), fibrinogen] remain unproven and controversial.
1365
Prevention and Early Detection of Cancer CHAPTER 216
� PREVENTION
Antithrombotic Therapy in Primary Prevention 
Thrombosis at the site of disrupted atherosclerotic plaque is the most 
common cause of acute coronary events. In primary prevention trials, 
chronic low-dose aspirin therapy has reduced the risk of a first MI in men 
and the risk of stroke in women. The American Heart Association recom-
mends aspirin (75–160 mg daily) for men and women who are at high 
cardiovascular risk (i.e., by Framingham Study criteria, for men with ≥10% 
10-year risk, or women with ≥20% 10-year risk).
Lifestyle Modifications 
Encourage beneficial exercise habits (>30 min moderate intensity physical 
activity daily) and sensible diet (low in saturated and trans fat; 2–3 serv-
ings of fish/week to ensure adequate intake of omega-3 fatty acids; balance 
caloric consumption with energy expenditure). Advise moderation in etha-
nol intake (no more than 1–2 drinks/day).
For a more detailed discussion, see Libby P: The Pathogenesis, 
Prevention, and Treatment of Atherosclerosis, Chap. 241, 
p. 1983; Gaziano TA and Gaziano JM: Epidemiology of 
Cardiovascular Disease, Chap. 225, p. 1811; and Martin 
GJ: Screening and Prevention of Disease, Chap. 4, p. 29; 
in HPIM-18.
CHAPTER 216
Prevention and Early 
Detection of Cancer
One of the most important functions of medical care is to prevent disease 
or discover it early enough that treatment might be more effective. All risk 
factors for cancer have not yet been defined. However, a substantial num-
ber of factors that elevate risk are within a person’s control. Some of these 
factors are listed in Table 216-1. Every physician visit is an opportunity to 
teach and reinforce the elements of a healthy lifestyle. Cancer screening in 
the asymptomatic population at average risk is a complex issue. To be of 
value, screening must detect disease at a stage that is more readily curable 
than disease that is treated after symptoms appear. For cervix cancer and 
colon cancer, screening has been shown to save lives. For other tumors, 
benefit is less clear. Screening can cause harm; complications may ensue 
from the screening test or the tests done to validate a positive screening 
test or from treatments for the underlying disease. Furthermore, quality of 
life can be adversely affected by false-positive tests. Evaluation of screening 
SECTION 16
1366
Disease Prevention and Health Maintenance
tools can be biased and needs to rely on prospective randomized studies. 
Lead-time bias occurs when the natural history of disease is unaffected by 
the diagnosis, but the pt is diagnosed earlier in the course of disease than 
normal; thus, the pt spends more of his/her life span knowing the diagnosis. 
Length bias occurs when slow-growing cancers that might never have come 
to medical attention are detected during screening. Overdiagnosis is a form 
of length bias in which a cancer is detected when it is not growing and is not 
an influence on length of survival. Selection bias is the term for the fact that 
people who volunteer for screening trials may be different from the general 
population. Volunteers might have family history concerns that actually 
elevate their risk, or they may be generally more health-conscious, which 
can affect outcome.
The various groups that evaluate and recommend screening practice 
guidelines have used varying criteria to make their recommendations 
(Table 216-2). The absence of data on survival for a number of diseases has 
led to a lack of consensus. In particular, four areas are worth noting.
1. Prostate cancer: Prostate-specific antigen (PSA) levels are elevated 
in prostate cancer, but a substantial number of the cancers detected 
appear to be non-life-threatening. PSA screening has not been shown to 
improve survival. Efforts are underway to develop better tests (predomi-
nantly using bound vs. free and rate of increase of PSA) to distinguish 
lethal and nonlethal cancers.
2. Breast cancer: The data on annual mammography support its use in 
women age >50 years. However, the benefit for women age 40–49 
years is quite small. One study shows some advantage for women who 
are screened starting at age 40 that appears 15 years later; however, it 
is unclear if this benefit would not have also been derived by starting 
screening at age 50 years. Women age 40–49 years have a much lower 
incidence of breast cancer and a higher false-positive rate on mammog-
raphy. Nearly half of women screened during their forties will have a 
false-positive test. Refined methods of screening are in development.
3. Colon cancer: Annual fecal occult blood testing after age 50 years is 
felt to be useful. Colonoscopy is the gold standard in colorectal cancer 
TABLE 216-1 LIFESTYLE FACTORS THAT REDUCE CANCER RISK
Do not use any tobacco products
Maintain a healthy weight; eat a well-balanced dieta; maintain caloric 
balance
Exercise at least 3 times a week
Prevent sun exposure
Avoid excessive alcohol intake
Practice safe sex; use condoms
aNot precisely defined, but current recommendations include 5 servings of fruits and veg-
etables per day, 25 g fiber, and <30% of calories coming from fat.
CHAPTER 216
1367
Prevention and Early Detection of Cancer 
TABLE 216-2  SCREENING RECOMMENDATIONS FOR ASYMPTOMATIC 
NORMAL-RISK SUBJECTSa
Test or 
Procedure
USPSTF
ACS
Sigmoidoscopy Adults 50–75 years: every 
5 years (“A”)b
Adults 76–85 years: “C”
Adults ≥85 years: “D”
Adults ≥50 years: Screen 
every 5 years
Fecal occult 
blood testing 
(FOBT)
Adults 50–75 years: 
Annually (“A”)
Adults 76–85 years: “C”
Adults ≥85 years: “D”
Adults ≥50 years: Screen 
every year
Colonoscopy
Adults 50–75 years: every 
10 years (“A”)
Adults 76–85 years: “C”
Adults ≥85 years: “D”
Adults ≥50 years: Screen 
every 10 years
Fecal DNA 
testing
“I”
Adults ≥50 years: Screen, but 
interval uncertain
Fecal immu-
nochemical
testing (FIT)
“I”
Adults ≥50 years: Screen 
every year
CT
colonography
“I”
Adults ≥50 years: Screen 
every 5 years
Digital rectal 
examination 
(DRE)
No recommendation
Men ≥50 years, with a 
10-year life expectancy; 
men ≥45 years, if African 
American, or men with a 
first-degree relative diag-
nosed with prostate cancer 
<65 years; ≥40, if has 
several relatives with prostate 
cancer <65 years: Discuss 
and offer (with PSA testing) 
annually
Prostate-
specific
antigen (PSA)
Men <75 years: “I”
Men ≥75 years: “D”
As for DRE
Pap test
Women <65 years: 
Beginning 3 years after 
first intercourse or by 
age 21, screen at least 
every 3 years (“A”)
Women ≥65 years, with 
adequate, normal recent 
Pap screenings: “D”
Women <30 years: Beginning 
3 years after first intercourse 
or by age 21. Yearly for stan-
dard Pap; every 2 years with 
liquid test.
Women 30–70 years: Every 
2–3 years if last 3 tests 
normal
(continued)
SECTION 16
1368
Disease Prevention and Health Maintenance
TABLE 216-2  SCREENING RECOMMENDATIONS FOR ASYMPTOMATIC 
NORMAL-RISK SUBJECTSa
Test or 
Procedure
USPSTF
ACS
Women after total hyster-
ectomy for noncancerous 
causes: “D”
Women ≥70 years: May stop 
screening if no abnormal Pap 
in past 10 years
Women after total hyster-
ectomy for noncancerous 
causes: Do not screen
Breast self-
examination
“D”
Women ≥20 years: Breast 
self-exam is an option
Breast clinical 
examination
Women ≥40 years: “I” 
(as a stand-alone without 
mammography)
Women 20–40 years: Perform 
every 3 years
Women ≥40 years: Perform 
annually
Mammography Women 40–49 years: The 
decision should be an 
individual one, and take pt 
context into account (“C”)
Women 50–74 years: every 
2 years (“B”)
Women ≥75 years: (“I”)
Women ≥40 years: Screen 
annually
Magnetic reso-
nance imaging 
(MRI)
“I”
Women >20% lifetime risk of 
breast cancer: Screen with MRI 
plus mammography annually
Women 15–20% lifetime risk 
of breast cancer: Discuss 
option of MRI plus mammog-
raphy annually
Women <15% lifetime risk of 
breast cancer: Do not screen 
annually with MRI
Complete skin 
examination
“I”
Self-examination monthly; 
clinical exam as part of rou-
tine cancer-related checkup
aSummary of the screening procedures recommended for the general population by the U.S. 
Preventive Services Task Force and the American Cancer Society. These recommendations refer to 
asymptomatic persons who have no risk factors, other than age or gender, for the targeted condition.
bUSPSTF lettered recommendations are defined as follows: “A”: The USPSTF strongly recom-
mends that clinicians provide (the service) to eligible pts; “B”: The USPSTF recommends that 
clinicians provide (this service) to eligible pts; “C”: The USPSTF makes no recommendation for 
or against routine provision of (the service); “D”: The USPSTF recommends against routinely 
providing [the service] to asymptomatic pts; “I”: The USPSTF concludes that the evidence is 
insufficient to recommend for or against routinely providing (the service).
Abbreviations: ACS, American Cancer Society; USPSTF, U.S. Preventive Services Task Force.
(CONTINUED)
CHAPTER 216
1369
Prevention and Early Detection of Cancer 
detection, but it is expensive and has not been shown to be cost-effective 
in asymptomatic people.
4. Lung cancer: Chest radiographs and sputum cytology in smokers appear 
to identify more early-stage tumors, but paradoxically, the screened pts 
do not have improved survival. Low-dose spiral CT scanning performed 
annually for 3 years reduces lung cancer death in older smokers by 20% 
compared with annual chest x-ray. However, 96% of the positive tests are 
false-positives and overall survival is improved by only 6.7%.
CANCER PREVENTION IN HIGH-RISK GROUPS
� BREAST CANCER
Risk factors include age, early menarche, nulliparity or late first pregnancy, 
high body-mass index, radiation exposure before age 30 years, hormone-
replacement therapy (HRT), alcohol consumption, family history, presence 
of mutations in BRCA1 or BRCA2, and prior history of breast neoplasia. 
Risk assessment models have been developed to predict an individual’s like-
lihood of developing breast cancer (see www.cancer.gov/cancertopics/pdq/
treatment/breast/healthprofessional#Section_627). 
Diagnosis
MRI scanning is a more effective screening tool than mammography in 
women with a familial breast cancer risk.
Interventions 
Women whose risk exceeds 1.66% in the next 5 years have been shown to 
have a 50% reduction in breast cancer from taking tamoxifen or raloxifene. 
Aromatase inhibitors have generally been superior to tamoxifen in the 
adjuvant treatment of hormone-sensitive breast cancer, and one of them 
(exemestane) reduces the risk of breast cancer by 65% in postmenopausal 
women at increased risk. Women with strong family histories should 
undergo testing for mutations in BRCA1 and BRCA2. Mutations in these 
genes carry a lifetime probability of >80% for developing breast cancer. 
Bilateral prophylactic mastectomy prevents at least 90% of these cancers 
but is a more radical prevention than the usual treatment for the disease. 
In addition, bilateral salpingo-oophorectomy reduces ovarian and fallopian 
tube cancer risk by about 96% in women with BRCA1 or BRCA2 mutations.
� COLORECTAL CANCER
Risk factors include diets high in saturated fats and low in fruits and veg-
etables, smoking, and alcohol consumption. Stronger but less prevalent risk 
factors are the presence of inflammatory bowel disease or genetic disorders 
such as familial polyposis (autosomal dominant germline mutation in 
APC) and hereditary nonpolyposis colorectal cancer (mutations in DNA 
mismatch repair genes hMSH2 and hMLH1).
Interventions 
Pts with ulcerative colitis and familial polyposis generally undergo total 
colectomy. In familial polyposis, nonsteroidal anti-inflammatory drugs 
SECTION 16
1370
Disease Prevention and Health Maintenance
(NSAIDs) reduce the number and size of polyps. Celecoxib, sulindac, and 
even aspirin appear to be effective, and celecoxib is approved by the U.S. 
Food and Drug Administration for this indication. Calcium supplementa-
tion can lead to a decrease in the recurrence of adenomas, but it is not yet 
clear that the risk of colorectal cancer is decreased and survival increased. 
The Women’s Health Study noted a significant reduction in the risk of 
colorectal cancer in women taking HRT, but the increase in thrombotic 
events and breast cancers counterbalanced this benefit. Studies are under-
way to assess NSAIDs with and without inhibitors of the epidermal growth 
factor (EGF) receptor in other risk groups.
� LUNG CANCER
Risk factors include smoking, exposure to radiation, asbestos, radon.
Interventions 
Smoking cessation is the only effective prevention (Chap. 217) . NSAIDs 
and EGF receptor inhibitors are being evaluated. Carotenoids, selenium, 
retinoids, and α-tocopherol do not work.
� PROSTATE CANCER
Risk factors include age, family history, and possibly dietary fat intake. 
African Americans are at increased risk. The disease is highly prevalent, 
with autopsy studies finding prostate cancer in 70–80% of men over 
age 70.
Interventions 
In a group of men age ≥55 years with normal rectal examinations and 
PSA levels <3 ng/mL, daily finasteride reduced the incidence of prostate 
cancer by 25%. Finasteride also prevents the progression of benign pros-
tate hyperplasia. However, some men experience decreased libido as a 
side effect. The Gleason grade of tumors seen in men taking finasteride 
prevention was somewhat higher than the controls; however, androgen 
deprivation alters the morphology of the cells and it is not yet clear that 
the Gleason grade is a reliable indicator of tumor aggressiveness in the set-
ting of androgen deprivation. Dutasteride, another 5α-reductase inhibitor, 
had similar effects. The FDA has reviewed the data and concluded that the 
reduction in risk is primarily in the group of pts with low-grade tumors 
whose risk from prostate cancer is unclear. One additional high-grade 
tumor emerges for every 3–4 low-grade tumors averted. More follow-up 
is necessary to see if higher-grade tumors emerging on preventive therapy 
have the same aggressive behavior as those occurring in the absence of 
preventive hormone blockade. 
� CERVICAL CANCER
Risk factors include early age at first intercourse, multiple sexual partners, 
smoking, and infection with human papillomavirus (HPV) types 16, 18, 
45, and 56.
CHAPTER 216
1371
Prevention and Early Detection of Cancer 
Interventions 
Regular Pap testing can detect nearly all cases of the premalignant lesion 
called cervical intraepithelial neoplasia. Untreated, the lesion can prog-
ress to carcinoma in situ and invasive cervical cancer. Surgical removal, 
cryotherapy, or laser therapy is used to treat the disease and is effective in 
80%. Risk of recurrence is highest in women over age 30, those with prior 
HPV infection, and those who have had prior treatment for the same condi-
tion. A vaccine (Gardasil) containing antigens of strains 6, 11, 16, and 18 
has been shown to be 100% effective in preventing HPV infections from 
those strains. The vaccine is recommended for all females age 9–16 years 
and could prevent up to 70% of all cervical cancer. The vaccine is not effec-
tive after infection has been established.
� HEAD AND NECK CANCER
Risk factors include smoking, alcohol consumption, and possibly HPV 
infection.
Interventions 
Oral leukoplakia, white lesions of the oral mucosa, occur in 1–2 persons 
in 1000, and 2–3% of these pts go on to develop head and neck cancer. 
Spontaneous regression of oral leukoplakia is seen in 30–40% of pts. 
Retinoid treatment (13-cis retinoid acid) can increase the regression 
rate. Vitamin A induces complete remission in ~50% of pts. The use of 
retinoids in pts who have been diagnosed with head and neck cancer 
and received definitive local therapy has not produced consistent results. 
Initial studies claimed that retinoids prevented the development of second 
primary tumors, a common feature of head and neck cancer. However, 
large randomized studies did not confirm this benefit. Other studies are 
underway combining retinoids and NSAIDs with and without EGF recep-
tor inhibitors.
PATIENT EDUCATION IN EARLY DETECTION
Pts can be taught to look for early warning signals. The American Cancer 
Society has identified seven major warning signs of cancer:
• A change in bowel or bladder habits
• A sore that does not heal
• Unusual bleeding or discharge
• A lump in the breast or other parts of the body
• Chronic indigestion or difficulty in swallowing
• Obvious changes in a wart or mole
• Persistent coughing or hoarseness
For a more detailed discussion, see Crosswell JM, Brawley 
OW, Kramer BS: Prevention and Early Detection of Cancer, 
Chap. 82, p. 655, in HPIM-18.
SECTION 16
1372
Disease Prevention and Health Maintenance
CHAPTER 217
Smoking Cessation
Over 400,000 individuals die each year in the United States from cigarette 
use: one out of every five deaths nationwide. Approximately 40% of smokers 
will die prematurely unless they are able to quit; major diseases caused by 
cigarette smoking are listed in Table 217-1.
Nicotine Addiction
APPROACH TO THE
PATIENT
All pts should be asked whether they smoke, their past experience with 
quitting, and whether they are currently interested in quitting; those who 
are not interested should be encouraged and motivated to quit. Provide 
a clear, strong, and personalized physician message that smoking is an 
important health concern. A quit date should be negotiated within a few 
weeks of the visit, and a follow-up contact by office staff around the time 
of the quit date should be provided. Incorporation of cessation assistance 
into a practice requires a change of the care delivery infrastructure. 
Simple changes include:
• Adding questions about smoking and interest in cessation on pt-intake 
questionnaires
• Asking pts whether they smoke as part of the initial vital sign measure-
ments made by office staff
• Listing smoking as a problem in the medical record
• Automating follow-up contact with the pt on the quit date
Nicotine Addiction
TREATMENT
• Clinical practice guidelines suggest a variety of pharmacologic 
and nonpharmacologic interventions to aid in smoking cessation 
(Table 217-2).
• Numerous nicotine-replacement products exist , including over-the-
counter nicotine patches, gum, and lozenges, as well as nicotine nasal 
and oral inhalers available by prescription; these products can be used 
for 3–6 months with a gradual step-down in dosage with increasing 
duration of abstinence. 
• Prescription medications that have been shown to be effective include 
antidepressants such as bupropion (300 mg/d in divided doses for up 
to 6 months) and varenicline, a partial agonist for the nicotinic ace-
tylcholine receptor (initial dose 0.5 mg daily increasing to 1 mg twice 
daily at day 8; treatment duration up to 6 months). Antidepressants are 
more effective in pts with a history of depressive symptoms.
CHAPTER 217
1373
Smoking Cessation
TABLE 217-1 RELATIVE RISKS FOR CURRENT SMOKERS OF CIGARETTES
Current Smokers
Disease or Condition
Males
Females
Coronary heart disease
 Age 35–64
2.8
3.1
 Age ≥65 
1.5
1.6
Cerebrovascular disease
 Age 35–64 
3.3
4
 Age ≥65 
1.6
1.5
Aortic aneurysm
6.2
7.1
Chronic airway obstruction
10.6
13.1
Cancer
 Lung
23.3
12.7
 Larynx 
14.6
13
 Lip, oral cavity, pharynx 
10.9
5.1
 Esophagus 
6.8
7.8
 Bladder, other urinary organs 
3.3
2.2
 Kidney
2.7
1.3
 Pancreas 
2.3
2.3
 Stomach
2
1.4
 Cervix
1.6
 Acute myeloid leukemia
1.4
1.4
Sudden infant death syndrome
2.3
Infant respiratory distress syndrome
1.3
Low birth weight at delivery
1.8
• Clonidine or nortriptyline may be useful for pts who have failed first-
line therapies. 
• Current recommendations are to offer pharmacologic treatment, usu-
ally with nicotine replacement therapy or varenicline, to all who will 
accept it and to provide counseling and other support as a part of the 
cessation attempt.
� PREVENTION
Approximately 90% of individuals who will become cigarette smokers initi-
ate the behavior during adolescence; prevention must begin early, preferably 
in the elementary school years. Physicians who treat adolescents should 
be sensitive to the prevalence of this problem and screen for tobacco use, 
reinforcing the fact that most adolescents and adults do not smoke, and 
explaining that all forms of tobacco are both addictive and harmful.
SECTION 16
1374
Disease Prevention and Health Maintenance
For a more detailed discussion, see Burns DM: Nicotine 
Addiction, Chap. 395, p. 3560, in HPIM-18.
TABLE 217-2 CLINICAL PRACTICE GUIDELINES
Physician Actions
Ask: Systematically identify all tobacco users at every visit
Advise: Strongly urge all smokers to quit
Identify smokers willing to quit
Assist the pt in quitting
Arrange follow-up contact
Effective Pharmacologic Interventionsa
First-line therapies
 Nicotine gum (1.5)
 Nicotine patch (1.9)
 Nicotine nasal inhaler (2.7)
 Nicotine oral inhaler (2.5)
 Nicotine lozenge (2.0)
 Bupropion (2.1)
 Varenicline (2.7)
Second-line therapies
 Clonidine (2.1)
 Nortriptyline (3.2)
Other Effective Interventionsa
Physician or other medical personnel counseling (10 min) (1.3)
Intensive smoking cessation programs (at least 4–7 sessions of 20- to 
30-min duration lasting at least 2 and preferably 8 weeks) (2.3)
Clinic-based smoking status identification system (3.1)
Counseling by nonclinicians and social support by family and friends
Telephone counseling (1.2)
aNumeric value following the intervention is the multiple for cessation success compared 
with no intervention.
CHAPTER 218
1375
Women’s Health
CHAPTER 218
Women’s Health
The most common causes of death in both men and women are heart 
disease and cancer, with lung cancer the top cause of cancer death, despite 
common misperceptions that breast cancer is the most common cause of 
death in women. These misconceptions perpetuate inadequate attention to 
modifiable risk factors in women, such as dyslipidemia, hypertension, and 
cigarette smoking. Furthermore, since women in the Unites States live on 
average 5.1 years longer than men, the majority of the disease burden for 
many age-related disorders (e.g., hypertension, Alzheimer’s disease) rests in 
women. For a discussion of the menopause transition and postmenopausal 
hormone therapy, see Chap. 186.
SEX DIFFERENCES IN HEALTH AND DISEASE
� ALZHEIMER’S DISEASE (SEE ALSO CHAP. 194)
Alzheimer’s disease (AD) affects approximately twice as many women 
as men, due to larger numbers of women surviving to older ages and 
to sex differences in brain size, structure, and functional organization. 
Postmenopausal hormone therapy may worsen cognitive function and the 
development of AD.
� CORONARY HEART DISEASE (SEE ALSO CHAPS. 128–130)
Coronary heart disease (CHD) presents differently in women, who are 
usually 10–15 years older than men with CHD and are more likely to have 
comorbidities, such as hypertension, congestive heart failure, and diabetes. 
Women more often have atypical symptoms, such as nausea, vomiting, 
indigestion, and upper back pain. Physicians are less likely to suspect heart 
disease in women with chest pain and are less likely to perform diagnos-
tic and therapeutic cardiac procedures in women. The conventional risk 
factors for CHD are the same in both men and women, though women 
receive fewer interventions for modifiable risk factors than do men. The 
marked increase in CHD occurring after menopause or oophorectomy sug-
gests that endogenous estrogens are cardioprotective. However, hormone 
replacement therapy in postmenopausal women was not shown to be car-
dioprotective in controlled trials such as the Women’s Health Initiative and 
other randomized trials. Therapy with estrogen plus progestin therapy was 
associated with increased cardiovascular events. The discrepancy between 
endogenous and exogenous estrogen effects is poorly understood but may 
be related to deleterious effects of late re-exposure to estrogen after a period 
of estrogen deficiency.
� DIABETES MELLITUS (SEE ALSO CHAP. 184)
The prevalence of type 2 diabetes mellitus (DM) is similar between men and 
women. Polycystic ovary syndrome and gestational diabetes mellitus are 
both common conditions in premenopausal women that carry an increased 
SECTION 16
1376
Disease Prevention and Health Maintenance
risk for type 2 DM. Premenopausal women with DM have identical rates of 
CHD to those of males.
� HYPERTENSION (SEE ALSO CHAP. 126)
Hypertension, as an age-related disorder, is more common in women than 
in men after age 60. Antihypertensive drugs appear to be equally effective 
in women and men; however, women may experience more side effects.
� AUTOIMMUNE DISORDERS (SEE ALSO CHAP. 169)
Most autoimmune disorders occur more commonly in women than in men; 
these include autoimmune thyroid and liver diseases, lupus, rheumatoid 
arthritis, scleroderma, multiple sclerosis, and idiopathic thrombocytopenic 
purpura. The mechanism for these sex differences remains obscure.
� HIV INFECTION (SEE ALSO CHAP. 114)
Heterosexual contact with an at-risk partner is the fastest-growing trans-
mission category of HIV, and women are more susceptible to HIV infection 
than men. Women with HIV have more rapid decreases in their CD4 cell 
counts than men do. Other sexually transmitted diseases, such as chlamyd-
ial infection and gonorrhea, are important causes of infertility in women, 
and papilloma virus infection predisposes to cervical cancer.
� OBESITY (SEE ALSO CHAP. 183)
The prevalence of obesity is higher in women than in men, in part due 
to the unique risk factors of pregnancy and menopause. In addition, the 
distribution of body fat differs by sex, with a gluteal and femoral (gynoid) 
pattern in women and a central and upper body (android) pattern in men. 
The android distribution of fat carries a higher risk for metabolic syndrome, 
diabetes mellitus, and cardiovascular disease. Obesity increases a woman’s 
risk for postmenopausal breast and endometrial cancer, in part because of 
adipose tissue aromatization of androgens to estrone.
� OSTEOPOROSIS (SEE ALSO CHAP. 188)
Osteoporosis is much more prevalent in postmenopausal women than in 
age-matched men, since men accumulate more bone mass in their youth 
and lose bone more slowly than do women, in particular after age 50, when 
accelerated postmenopausal bone loss occurs in women. In addition, dif-
ferences in calcium intake, vitamin D, and estrogen levels contribute to sex 
differences in bone formation and bone loss. Vitamin D insufficiency is 
present in a large proportion of elderly women living in Northern latitudes. 
Osteoporotic hip fracture is a major cause of morbidity and an important 
cause of mortality in elderly women.
� PHARMACOLOGY
On average, women have lower body weights, smaller organs, higher per-
cent body fat, and lower total-body water than men do. Gonadal steroids, 
menstrual cycle phase, and pregnancy can all affect drug metabolism and 
action. Women also take more medications than men do, including over-
the-counter formulations and supplements. The greater use of medications, 
CHAPTER 218
1377
Women’s Health
combined with biologic differences, may account for the reported higher 
frequency of adverse drug reactions in women.
� PSYCHOLOGICAL DISORDERS (SEE ALSO CHAPS. 208 AND 210)
Depression, anxiety, and eating disorders (bulimia and anorexia nervosa) 
are more common in women than in men. Depression occurs in 10% of 
women during pregnancy and 10–15% of women during the postpartum 
period. 
� SLEEP DISORDERS (SEE ALSO CHAP. 62)
During sleep, women have an increased amount of slow-wave activity, dif-
ferences in timing of delta activity, and an increase in the number of sleep 
spindles. They have a decreased prevalence of sleep apnea compared to 
men, a feature that may be related to lower androgen levels.
� SUBSTANCE ABUSE AND TOBACCO (SEE ALSO CHAPS. 211 AND 217)
Substance abuse is more common in men than women. However, women 
alcoholics are less likely to be diagnosed than men and are less likely to seek 
help. When they do seek help, it is more likely to be from a physician than 
from a treatment facility. Alcoholic women drink less than alcoholic men 
but exhibit the same degree of impairment. Alcohol abuse poses special 
risks to a woman, adversely affecting fertility and the health of the baby 
(fetal alcohol syndrome). Even moderate alcohol use increases the risk of 
breast cancer, hypertension, and stroke in women. More men than women 
smoke tobacco, but the prevalence of smoking is declining faster in men 
than women. The effects of smoking on pulmonary disease (COPD and 
cancer) are more pronounced in women than in men.
� VIOLENCE AGAINST WOMEN
Domestic violence is the most common cause of physical injury in women. 
Women may present with symptoms of chronic abdominal pain, headaches, 
substance abuse, and eating disorders, in addition to obvious manifestations 
such as trauma. Sexual assault is one of the most common crimes against 
women (reported by one in five women in the U.S.) and is more likely com-
mitted by a spouse, ex-spouse, or acquaintance than by a stranger.
For a more detailed discussion, see Dunaif A: Women’s 
Health, Chap. 6, p. 50, HPIM-18. 
This page intentionally left blank 
1379
CHAPTER 219
Adverse Drug Reactions
Adverse drug reactions are among the most frequent problems encountered 
clinically and represent a common cause for hospitalization. They occur 
most frequently in pts receiving multiple drugs and are caused by:
• Errors in self-administration of prescribed drugs (quite common in the 
elderly);
• Exaggeration of intended pharmacologic effect (e.g., hypotension in a pt 
given antihypertensive drugs);
• Concomitant administration of drugs with synergistic effects (e.g., aspi-
rin and warfarin);
• Cytotoxic reactions (e.g., hepatic necrosis due to acetaminophen);
• Immunologic mechanisms (e.g., quinidine-induced thrombocytopenia, 
hydralazine-induced SLE);
• Genetically determined enzymatic defects (e.g., primaquine-induced 
hemolytic anemia in G6PD deficiency); or
• Idiosyncratic reactions (e.g., chloramphenicol-induced aplastic anemia).
Recognition
History is of prime importance. Consider the following:
• Nonprescription drugs and topical agents as potential offenders
• Previous reaction to identical drugs
• Temporal association between drug administration and development of 
clinical manifestations
• Subsidence of manifestations when the agent is discontinued or reduced 
in dose
• Recurrence of manifestations with cautious readministration (for less 
hazardous reactions)
• Rare: (1) biochemical abnormalities, e.g., red cell G6PD deficiency as 
cause of drug-induced hemolytic anemia; (2) abnormal serum antibody 
in pts with agranulocytosis, thrombocytopenia, or hemolytic anemia.
Table 219-1 lists a number of clinical manifestations of adverse effects of 
drugs. It is not designed to be complete or exhaustive.
TABLE 219-1  CLINICAL MANIFESTATIONS OF ADVERSE REACTIONS TO DRUGS
Multisystem manifestations
Anaphylaxis
Angioedema
Cephalosporins
ACE inhibitors
Dextran
Drug-induced lupus erythematosus
Insulin
Cephalosporins
(continued)
SECTION 17
Adverse Drug Reactions
SECTION 17
1380
Adverse Drug Reactions
TABLE 219-1  CLINICAL MANIFESTATIONS OF ADVERSE REACTIONS TO DRUGS 
(CONTINUED)
Multisystem manifestations
Iodinated drugs or contrast media
Hydralazine
Lidocaine
Iodides
Penicillins
Isoniazid
Procaine
Methyldopa
Phenytoin
Hyperpyrexia
Procainamide
Antipsychotics
Quinidine
Serum sickness
Sulfonamides
Aspirin
Thiouracil
Penicillins
Fever
Propylthiouracil
Aminosalicylic acid
Sulfonamides
Amphotericin B
Antihistamines
Penicillins
Endocrine manifestations
Addisonian-like syndrome
Guanethidine
Busulfan
Lithium
Ketoconazole
Major tranquilizers
Galactorrhea (may also cause 
amenorrhea)
Methyldopa
Phenothiazines
Tricyclic antidepressants
Methyldopa
Oral contraceptives
Sedatives
Thyroid function tests, disorders of
Acetazolamide
Amiodarone
Chlorpropamide
Clofibrate
Colestipol and nicotinic acid
Gold salts
Iodides
Lithium
Oral contraceptives
Phenothiazines
Phenylbutazone
Phenytoin
Sulfonamides
Tolbutamide
Gynecomastia
Calcium channel antagonists
Digitalis
Estrogens
Griseofulvin
Isoniazid
Methyldopa
Phenytoin
Spironolactone
Testosterone
Sexual dysfunction
Beta blockers
Clonidine
Diuretics
CHAPTER 219
1381
Adverse Drug Reactions
1381
TABLE 219-1  CLINICAL MANIFESTATIONS OF ADVERSE REACTIONS TO DRUGS 
(CONTINUED)
Metabolic manifestations
Hyperbilirubinemia
Oral contraceptives
Rifampin
Thiazides
Hypercalcemia
Hypoglycemia
Antacids with absorbable alkali
Insulin
Thiazides
Oral hypoglycemics
Vitamin D
Quinine
Hyperglycemia
Hyperkalemia
Chlorthalidone
ACE inhibitors
Diazoxide
Amiloride
Encainide
Cytotoxics
Ethacrynic acid
Digitalis overdose
Furosemide
Heparin
Glucocorticoids
Lithium
Growth hormone
Ethacrynic acid
Potassium preparations including 
salt substitute
Furosemide
Hyperalimentation
Potassium salts of drugs
Thiazides
Spironolactone
Hyponatremia
Succinylcholine
1. Dilutional
Triamterene
Carbamazepine
Hypokalemia
Chlorpropamide
Alkali-induced alkalosis
Cyclophosphamide
Amphotericin B
Diuretics
Diuretics
Vincristine
Gentamicin
2. Salt wasting
Insulin
Diuretics
Laxative abuse
Enemas
Mineralocorticoids, some 
glucocorticoids
Mannitol
Metabolic acidosis
Osmotic diuretics
Acetazolamide
Sympathomimetics
Paraldehyde
Tetracycline
Salicylates
Theophylline
Spironolactone
Vitamin B12
Hyperuricemia
Aspirin
Cytotoxics
(continued)
SECTION 17
1382
Adverse Drug Reactions
TABLE 219-1  CLINICAL MANIFESTATIONS OF ADVERSE REACTIONS TO DRUGS 
(CONTINUED)
Dermatologic manifestations
Acne
Salicylates
Anabolic and androgenic steroids
Sulfonamides
Bromides
Sulfones
Glucocorticoids
Tetracyclines
Iodides
Thiazides
Isoniazid
Erythema nodosum
Oral contraceptives
Oral contraceptives
Alopecia
Penicillins
Cytotoxics
Sulfonamides
Ethionamide
Exfoliative dermatitis
Heparin
Barbiturates
Oral contraceptives (withdrawal)
Gold salts
Eczema
Penicillins
Captopril
Phenylbutazone
Cream and lotion preservatives
Phenytoin
Lanolin
Quinidine
Topical antihistamines
Sulfonamides
Topical antimicrobials
Fixed drug eruptions
Topical local anesthetics
Barbiturates
Erythema multiforme or Stevens-
Johnson syndrome
Captopril
Phenylbutazone
Barbiturates
Quinine
Chlorpropamide
Salicylates
Codeine
Sulfonamides
Penicillins
Hyperpigmentation
Phenylbutazone
Bleomycin
Phenytoin
Busulfan
Chloroquine and other antimalarials
Aspirin
Corticotropin
Glucocorticoids
Cyclophosphamide
Rashes (nonspecific)
Gold salts
Allopurinol
Hypervitaminosis A
Ampicillin
Oral contraceptives
Barbiturates
Phenothiazines
Indapamide
Lichenoid eruptions
Methyldopa
Aminosalicylic acid
Phenytoin
CHAPTER 219
1383
Adverse Drug Reactions
TABLE 219-1  CLINICAL MANIFESTATIONS OF ADVERSE REACTIONS TO DRUGS 
(CONTINUED)
Dermatologic manifestations
Antimalarials
Skin necrosis
Chlorpropamide
Warfarin
Gold salts
Toxic epidermal necrolysis (bullous)
Methyldopa
Allopurinol
Phenothiazines
Barbiturates
Photodermatitis
Bromides
Captopril
Iodides
Chlordiazepoxide
Nalidixic acid
Furosemide
Penicillins
Griseofulvin
Phenylbutazone
Nalidixic acid
Phenytoin
Oral contraceptives
Sulfonamides
Phenothiazines
Urticaria
Sulfonamides
Aspirin
Sulfonylureas
Barbiturates
Tetracyclines, particularly 
demeclocycline
Thiazides
Purpura (see also 
Thrombocytopenia)
Allopurinol
Ampicillin
Captopril
Enalapril
Penicillins
Sulfonamides
Hematologic manifestations
Agranulocytosis (see also 
Pancytopenia)
Clotting abnormalities/
hypothrombinemia
Captopril
Cefamandole
Carbimazole
Cefoperazone
Chloramphenicol
Moxalactam
Cytotoxics
Eosinophilia
Gold salts
Aminosalicylic acid
Indomethacin
Chlorpropamide
Methimazole
Erythromycin estolate
Oxyphenbutazone
Imipramine
Phenothiazines
L-Tryptophan
Phenylbutazone
Methotrexate
Propylthiouracil
(continued)
SECTION 17
1384
Adverse Drug Reactions
TABLE 219-1  CLINICAL MANIFESTATIONS OF ADVERSE REACTIONS TO DRUGS 
(CONTINUED)
Hematologic manifestations
Sulfonamides
Nitrofurantoin
Tolbutamide
Procarbazine
Tricyclic antidepressants
Sulfonamides
Hemolytic anemia
Cytotoxics
Aminosalicylic acid
Gold salts
Cephalosporins
Mephenytoin
Chlorpromazine
Phenylbutazone
Dapsone
Phenytoin
Insulin
Quinacrine
Isoniazid
Sulfonamides
Levodopa
Trimethadione
Mefenamic acid
Zidovudine (AZT)
Melphalan
Pure red cell aplasia
Methyldopa
Azathioprine
Penicillins
Chlorpropamide
Phenacetin
Isoniazid
Procainamide
Phenytoin
Quinidine
Thrombocytopenia (see also 
Pancytopenia)
Rifampin
Sulfonamides
Acetazolamine
Aspirin
Carbamazepine
Carbenicillin
Chlorpropamide
Chlorthalidone
Furosemide
Gold salts
Heparin
Indomethacin
Isoniazid
Methyldopa
Moxalactam
Phenylbutazone
Phenytoin and other hydantoins
Quinidine
Hemolytic anemias in G6PD 
deficiency
See Table 68-3
Leukocytosis
Glucocorticoids
Lithium
Lymphadenopathy
Phenytoin
Primidone
Megaloblastic anemia
Folate antagonists
Nitrous oxide
Oral contraceptives
Phenobarbital
Phenytoin
Primidone
CHAPTER 219
1385
Adverse Drug Reactions
TABLE 219-1  CLINICAL MANIFESTATIONS OF ADVERSE REACTIONS TO DRUGS 
(CONTINUED)
Hematologic manifestations
Triamterene
Quinine
Trimethroprim
Thiazides
Pancytopenia (aplastic anemia)
Ticarcillin
Carbamazepine
Chloramphenicol
Cardiovascular manifestations
Angina exacerbation
Arrhythmias
Alpha blockers
Adriamycin
Beta blocker withdrawal
Antiarrhythmic drugs
Ergotamine
Atropine
Excessive thyroxine
Anticholinesterases
Hydralazine
Beta blockers
Methysergide
Digitalis
Minoxidil
Emetine
Nifedipine
Lithium
Oxytocin
Phenothiazines
Vasopressin
Sympathomimetics
Thyroid hormone
Diuretics
Tricyclic antidepressants
Levodopa
Verapamil
Morphine
AV block
Nitroglycerin
Clonidine
Phenothiazines
Methyldopa
Protamine
Verapamil
Quinidine
Cardiomyopathy
Hypertension
Adriamycin
Clonidine withdrawal
Daunorubicin
Corticotropin
Emetine
Cyclosporine
Lithium
Glucocorticoids
Phenothiazines
Monoamine oxidase inhibitors with 
sympathomimetics
Sulfonamides
Sympathomimetics
NSAIDs
Fluid retention or congestive 
heart failure
Oral contraceptives
Sympathomimetics
Beta blockers
Tricyclic antidepressants with 
Sympathomimetics
Calcium antagonists
(continued)
SECTION 17
1386
Adverse Drug Reactions
TABLE 219-1  CLINICAL MANIFESTATIONS OF ADVERSE REACTIONS TO DRUGS 
(CONTINUED)
Cardiovascular manifestations
Estrogens
Pericarditis
Indomethacin
Emetine
Mannitol
Hydralazine
Minoxidil
Methysergide
Phenylbutazone
Procainamide
Steroids
Thromboembolism
Hypotension
Oral contraceptives
Calcium antagonists
Citrated blood
Respiratory manifestations
Airway obstruction
Pulmonary infiltrates
Beta blockers
Acyclovir
Cephalosporins
Amiodarone
Cholinergic drugs
Azathioprine
NSAIDs
Bleomycin
Penicillins
Busulfan
Pentazocine
Carmustine (BCNU)
Streptomycin
Chlorambucil
Tartrazine (drugs with yellow dye)
Cyclophosphamide
Cough
Melphalan
ACE inhibitors
Methotrexate
Pulmonary edema
Methysergide
Contrast media
Mitomycin C
Heroin
Nitrofurantoin
Methadone
Procarbazine
Propoxyphene
Sulfonamides
Gastrointestinal manifestations
Cholestatic jaundice
Sodium valproate
Anabolic steroids
Sulfonamides
Androgens
Tetracyclines
Chlorpropamide
Verapamil
Erythromycin estolate
Zidovudine (AZT)
Gold salts
Intestinal ulceration
Methimazole
Solid KCl preparations
CHAPTER 219
1387
Adverse Drug Reactions
TABLE 219-1  CLINICAL MANIFESTATIONS OF ADVERSE REACTIONS TO DRUGS 
(CONTINUED)
Gastrointestinal manifestations
Nitrofurantoin
Malabsorption
Oral contraceptives
Aminosalicylic acid
Phenothiazines
Antibiotics (broad-spectrum)
Constipation or ileus
Cholestyramine
Aluminum hydroxide
Colchicine
Barium sulfate
Colestipol
Calcium carbonate
Cytotoxics
Ferrous sulfate
Neomycin
Ion exchange resins
Phenobarbital
Opiates
Phenytoin
Phenothiazines
Nausea or vomiting
Tricyclic antidepressants
Digitalis
Verapamil
Estrogens
Diarrhea or colitis
Ferrous sulfate
Antibiotics (broad-spectrum)
Levodopa
Colchicine
Opiates
Digitalis
Potassium chloride
Magnesium in antacids
Tetracyclines
Methyldopa
Theophylline
Diffuse hepatocellular damage
Oral conditions
Acetaminophen (paracetamol)
1. Gingival hyperplasia
Allopurinol
Calcium antagonists
Aminosalicylic acid
Cyclosporine
Dapsone
Phenytoin
Erythromycin estolate
2. Salivary gland swelling
Ethionamide
Bretylium
Glyburide
Clonidine
Halothane
Guanethidine
Isoniazid
Iodides
Ketoconazole
Phenylbutazone
Methimazole
3. Taste disturbances
Methotrexate
Biguanides
Methoxyflurane
Captopril
Methyldopa
Griseofulvin
Monoamine oxidase inhibitors
Lithium
(continued)
SECTION 17
1388
Adverse Drug Reactions
TABLE 219-1  CLINICAL MANIFESTATIONS OF ADVERSE REACTIONS TO DRUGS 
(CONTINUED)
Gastrointestinal manifestations
Niacin
Metronidazole
Nifedipine
Penicillamine
Nitrofurantoin
Rifampin
Phenytoin
4. Ulceration
Propoxyphene
Aspirin
Propylthiouracil
Cytotoxics
Pyridium
Gentian violet
Rifampin
Isoproterenol (sublingual)
Salicylates
Pancreatin
Pancreatitis
Sulfonamides
Azathioprine
Thiazides
Ethacrynic acid
Peptic ulceration or hemorrhage
Furosemide
Aspirin
Glucocorticoids
Ethacrynic acid
Opiates
Glucocorticoids
Oral contraceptives
NSAIDs
Renal/urinary manifestations
Bladder dysfunction
Nephrotic syndrome
Anticholinergics
Captopril
Disopyramide
Gold salts
Monoamine oxidase inhibitors
Penicillamine
Tricyclic antidepressants
Phenindione
Calculi
Probenecid
Acetazolamide
Obstructive uropathy
Vitamin D
Extrarenal: methysergide
Concentrating defect with 
polyuria (or nephrogenic 
diabetes insipidus)
Demeclocycline
Lithium
Methoxyflurane
Vitamin D
Hemorrhagic cystitis
Cyclophosphamide
Interstitial nephritis
Allopurinol
Furosemide
Penicillins, esp. methicillin
Intrarenal: cytotoxics
Renal dysfunction
Cyclosporine
NSAIDS
Triamterene
Renal tubular acidosis
Acetazolamide
Amphotericin B
Degraded tetracycline
Tubular necrosis
Aminoglycosides
Amphotericin B
CHAPTER 219
1389
Adverse Drug Reactions
TABLE 219-1  CLINICAL MANIFESTATIONS OF ADVERSE REACTIONS TO DRUGS 
(CONTINUED)
Renal/urinary manifestations
Phenindione
Colistin
Sulfonamides
Cyclosporine
Thiazides
Methoxyflurane
Nephropathies
Polymyxins
Due to analgesics 
(e.g., phenacetin)
Radioiodinated contrast medium
Sulfonamides
Tetracyclines
Neurologic manifestations
Exacerbation of myasthenia
Headache
Aminoglycosides
Ergotamine (withdrawal)
Polymyxins
Glyceryl trinitrate
Extrapyramidal effects
Hydralazine
Butyrophenones, e.g., haloperidol
Indomethacin
Disopyramide
Peripheral neuropathy
Ethambutol
Amiodarone
Ethionamide
Chloramphenicol
Glutethimide
Chloroquine
Hydralazine
Chlorpropamide
Isoniazid
Clofibrate
Levodopa
Demeclocycline
Methyldopa
Hypervitaminosis A
Methysergide
Oral contraceptives
Metoclopramide
Tetracyclines
Metronidazole
Seizures
Nalidixic acid
Amphetamines
Nitrofurantoin
Analeptics
Oral contraceptives
Isoniazid
Phenothiazines
Lidocaine
Phenytoin
Lithium
Polymyxin, colistin
Nalidixic acid
Procarbazine
Penicillins
Streptomycin
Phenothiazines
Tolbutamide
Physostigmine
Tricyclic antidepressants
Theophylline
Tricyclic antidepressants
Tricyclic antidepressants
Vincristine
Vincristine
(continued)
SECTION 17
1390
Adverse Drug Reactions
TABLE 219-1  CLINICAL MANIFESTATIONS OF ADVERSE REACTIONS TO DRUGS 
(CONTINUED)
Neurologic manifestations
Pseudotumor cerebri 
(or intracranial hypertension)
Stroke
Oral contraceptives
Amiodarone
Glucocorticoids, mineralocorticoids
Ocular manifestations
Cataracts
Glaucoma
Busulfan
Mydriatics
Chlorambucil
Sympathomimetics
Glucocorticoids
Optic neuritis
Phenothiazines
Aminosalicylic acid
Color vision alteration
Chloramphenicol
Barbiturates
Ethambutol
Digitalis
Isoniazid
Methaqualone
Penicillamine
Streptomycin
Phenothiazines
Thiazides
Phenylbutazone
Corneal edema
Quinine
Oral contraceptives
Streptomycin
Corneal opacities
Retinopathy
Chloroquine
Chloroquine
Indomethacin
Phenothiazines
Vitamin D
Ear manifestations
Deafness
Furosemide
Aminoglycosides
Nortriptyline
Aspirin
Quinine
Bleomycin
Vestibular disorders
Chloroquine
Aminoglycosides
Erythromycin
Quinine
Ethacrynic acid
Musculoskeletal manifestations
Bone disorders
Chloroquine
1. Osteoporosis
Clofibrate
Glucocorticoids
Glucocorticoids
Heparin
Oral contraceptives
CHAPTER 219
1391
Adverse Drug Reactions
TABLE 219-1  CLINICAL MANIFESTATIONS OF ADVERSE REACTIONS TO DRUGS 
(CONTINUED)
Musculoskeletal manifestations
2. Osteomalacia
Aluminum hydroxide
Anticonvulsants
Glutethimide
Myopathy or myalgia
Amphotericin B
Myositis
Gemfibrozil
Lovastatin
Psychiatric manifestations
Delirious or confusional states
Amantadine
Aminophylline
Anticholinergics
Antidepressants
Cimetidine
Digitalis
Glucocorticoids
Isoniazid
Levodopa
Methyldopa
Penicillins
Phenothiazines
Sedatives and hypnotics
Depression
Amphetamine withdrawal
Beta blockers
Centrally acting antihypertensives 
(reserpine, methyldopa, clonidine)
Glucocorticoids
Levodopa
Drowsiness
Antihistamines
Anxiolytic drugs
Clonidine
Major tranquilizers
Methyldopa
Tricyclic antidepressants
Hallucinatory states
Amantadine
Beta blockers
Levodopa
Meperidine
Narcotics
Pentazocine
Tricyclic antidepressants
Hypomania, mania, or excited 
reactions
Glucocorticoids
Levodopa
Monoamine oxidase inhibitors
Sympathomimetics
Tricyclic antidepressants
Schizophrenic-like or paranoid 
reactions
Amphetamines
Bromides
Glucocorticoids
Levodopa
Lysergic acid
Monoamine oxidase inhibitors
Tricyclic antidepressants
Sleep disturbances
Anorexiants
Levodopa
Monoamine oxidase inhibitors
Sympathomimetics
Source: Adapted from AJJ Wood: HPIM-15, pp. 432–436.
For a more detailed discussion, see Roden DM: Principles of 
Clinical Pharmacology, Chap. 5, p. 33, in HPIM-18; Wood AJJ: 
Adverse Reactions to Drugs, Chap. 71, p. 430, in HPIM-15.
This page intentionally left blank 
1393
CHAPTER 220
Laboratory Values of 
Clinical Importance
INTRODUCTORY COMMENTS
In preparing for the Appendix, the authors have taken into account the fact 
that the system of international units (SI, système international d’unités) 
is used in most countries and in some medical journals. However, clinical 
laboratories may continue to report values in “conventional” units. 
Therefore, both systems are provided in the Appendix.
For many analytes, the reference ranges given here are meant as general 
guidelines rather than absolute normative ranges. Because of differences in 
methodology, assay reagents, and collection methods, reference values may 
differ among clinical laboratories. Therefore, for diagnostic pt management 
purposes, reference ranges provided by the laboratory performing the test 
should be used for interpretation of a given result.
REFERENCE VALUES FOR LABORATORY TESTS
(Tables 220-1 through 220-5)
SECTION 18
Laboratory Values
TABLE 220-1 HEMATOLOGY AND COAGULATION
Analyte
Specimen
SI Units
Conventional Units
Activated clotting time
WB
70–180 s
70–180 s
Activated protein C resistance (factor V Leiden)
P
Not applicable
Ratio >2.1
ADAMTS13 activity
P
≥0.67
≥67%
ADAMTS13 inhibitor activity
P
Not applicable
≤0.4 U
ADAMTS13 antibody
P
Not applicable
≤18 U
Alpha2 antiplasmin
P
0.87–1.55
87–155%
Antiphospholipid antibody panel
  PTT-LA (lupus anticoagulant screen)
P
Negative
Negative
  Platelet neutralization procedure
P
Negative
Negative
  Dilute viper venom screen
P
Negative
Negative
  Anticardiolipin antibody
S
   IgG
0–15 arbitrary units
0–15 GPL
   IgM
0–15 arbitrary units
0–15 MPL
Antithrombin III
P
  Antigenic
220–390 mg/L
22–39 mg/dL
  Functional
0.7–1.30 U/L
70–130 %
1394
Anti-Xa assay (heparin assay)
P
  Unfractionated heparin
0.3–0.7 kIU/L
0.3–0.7 IU/mL
  Low-molecular-weight heparin
0.5–1.0 kIU/L
0.5–1.0 IU/mL
  Danaparoid (Orgaran)
0.5–0.8 kIU/L
0.5–0.8 IU/mL
Autohemolysis test
WB
0.004–0.045
0.4–4.50%
Autohemolysis test with glucose
WB
0.003–0.007
0.3–0.7%
Bleeding time (adult)
<7.1 min
<7.1 min
Bone marrow: See Table 220-8
Clot retraction
WB
0.50–1.00/2 h
50–100%/2 h
Cryofibrinogen
P
Negative
Negative
D-dimer
P
220–740 ng/mL FEU
220–740 ng/mL FEU
Differential blood count
WB
Relative counts
  Neutrophils
0.40–0.70
40–70%
  Bands
0.0–0.05
0–5%
  Lymphocytes
0.20–0.50
20–50%
  Monocytes
0.04–0.08
4–8%
  Eosinophils
0.0–0.6
0–6%
  Basophils
0.0–0.02
0–2%
(continued)
1395
TABLE 220-1 HEMATOLOGY AND COAGULATION (CONTINUED)
Analyte
Specimen
SI Units
Conventional Units
Absolute counts
  Neutrophils
1.42–6.34 × 109/L
1420–6340/mm3
  Bands
0–0.45 × 109/L
0–450/mm3
  Lymphocytes
0.71–4.53 × 109/L
710–4530/mm3
  Monocytes
0.14–0.72 × 109/L
140–720/mm3
  Eosinophils
0–0.54 × 109/L
0–540/mm3
  Basophils
0–0.18 × 109/L
0–180/mm3
Erythrocyte count
WB
  Adult males
4.30–5.60 × 1012/L
4.30–5.60 × 106/mm3
  Adult females
4.00–5.20 × 1012/L
4.00–5.20 × 106/mm3
Erythrocyte life span
WB
  Normal survival
120 days
120 days
  Chromium labeled, half-life (t1/2)
25–35 days
25–35 days
Erythrocyte sedimentation rate
WB
  Females
0–20 mm/h
0–20 mm/h
  Males
0–15 mm/h
0–15 mm/h
Euglobulin lysis time
P
7200–14,400 s
120–240 min
Factor II, prothrombin
P
0.50–1.50
50–150%
1396
Factor V
P
0.50–1.50
50–150%
Factor VII
P
0.50–1.50
50–150%
Factor VIII
P
0.50–1.50
50–150%
Factor IX
P
0.50–1.50
50–150%
Factor X
P
0.50–1.50
50–150%
Factor XI
P
0.50–1.50
50–150%
Factor XII
P
0.50–1.50
50–150%
Factor XIII screen
P
Not applicable
Present
Factor inhibitor assay
P
<0.5 Bethesda Units
<0.5 Bethesda Units
Fibrin(ogen) degradation products
P
0–1 mg/L
0–1 μg/mL
Fibrinogen
P
2.33–4.96 g/L
233–496 mg/dL
Glucose-6-phosphate dehydrogenase (erythrocyte)
WB
<2400 s
<40 min
Ham’s test (acid serum)
WB
Negative
Negative
Hematocrit
 Adult males
 Adult females
WB
0.388–0.464
0.354–0.444
38.8–46.4
35.4–44.4
Hemoglobin
 Plasma
 Whole blood
  Adult males
  Adult females
P
WB
6–50 mg/L
133–162 g/L
120–158 g/L
0.6–5.0 mg/dL
13.3–16.2 g/dL
12.0–15.8 g/dL
(continued)
1397
TABLE 220-1 HEMATOLOGY AND COAGULATION (CONTINUED)
Analyte
Specimen
SI Units
Conventional Units
Hemoglobin electrophoresis
WB
 Hemoglobin A
0.95–0.98
95–98%
 Hemoglobin A2
0.015–0.031
1.5–3.1%
 Hemoglobin F
0–0.02
0–2.0%
  Hemoglobins other than A, A2, or F
Absent
Absent
Heparin-induced thrombocytopenia antibody
P
Negative
Negative
Immature platelet fraction (IPF)
WB
0.011–0.061
1.1–6.1%
Joint fluid crystal
JF
Not applicable
No crystals seen
Joint fluid mucin
JF
Not applicable
Only type I mucin present
Leukocytes
 Alkaline phosphatase (LAP)
WB
0.2–1.6 μkat/L
13–100 μ/L
 Count (WBC)
WB
3.54–9.06 × 109/L
3.54–9.06 × 103/mm3
Mean corpuscular hemoglobin (MCH)
WB
26.7–31.9 pg/cell
26.7–31.9 pg/cell
Mean corpuscular hemoglobin concentration (MCHC)
WB
323–359 g/L
32.3–35.9 g/dL
Mean corpuscular hemoglobin of reticulocytes (CH)
WB
24–36 pg
24–36 pg
Mean corpuscular volume (MCV)
WB
79–93.3 fL
79–93.3 μm3
Mean platelet volume (MPV)
WB
9.00–12.95 fL
9.00–12.95 fL
1398
Osmotic fragility of erythrocytes
WB
 Direct
0.0035–0.0045
0.35–0.45%
 Indirect
0.0030–0.0065
0.30–0.65%
Partial thromboplastin time, activated
P
26.3–39.4 s
26.3–39.4 s
Plasminogen
P
 Antigen
84–140 mg/L
8.4–14.0 mg/dL
 Functional
0.70–1.30
70–130%
Plasminogen activator inhibitor 1
P
4–43 μg/L
4–43 ng/mL
Platelet aggregation
PRP
Not applicable
>65% aggregation in 
response to adenosine 
diphosphate, epinephrine, 
collagen, ristocetin, and 
arachidonic acid
Platelet count
WB
165–415 × 109/L
165–415 × 103/mm3
Platelet, mean volume
WB
6.4–11 fL
6.4–11.0 μm3
Prekallikrein assay
P
0.50–1.5
50–150%
Prekallikrein screen
P
No deficiency detected
Protein C
P
 Total antigen
0.70–1.40
70–140%
 Functional
0.70–1.30
70–130%
(continued)
1399
TABLE 220-1 HEMATOLOGY AND COAGULATION (CONTINUED)
Analyte
Specimen
SI Units
Conventional Units
Protein S
P
 Total antigen
0.70–1.40
70–140%
 Functional
0.65–1.40
65–140%
 Free antigen
0.70–1.40
70–140%
Prothrombin gene mutation G20210A
WB
Not applicable
Not present
Prothrombin time
P
12.7–15.4 s
12.7–15.4 s
Protoporphyrin, free erythrocyte
WB
0.28–0.64 μmol/L of red 
blood cells
16–36 μg/dL of red 
blood cells
Red cell distribution width
WB
<0.145
<14.5%
Reptilase time
P
16–23.6 s
16–23.6 s
Reticulocyte count
WB
 Adult males
0.008–0.023 red cells
0.8–2.3% red cells
 Adult females
0.008–0.020 red cells
0.8–2.0% red cells
Reticulocyte hemoglobin content
WB
>26 pg/cell
>26 pg/cell
Ristocetin cofactor (functional von Willebrand factor)
P
 Blood group O
0.75 mean of normal
75% mean of normal
 Blood group A
1.05 mean of normal
105% mean of normal
 Blood group B
1.15 mean of normal
115% mean of normal
 Blood group AB
1.25 mean of normal
125% mean of normal
1400
Serotonin release assay
S
<0.2 release
<20% release
Sickle cell test
WB
Negative
Negative
Sucrose hemolysis
WB
<0.1
<10% hemolysis
Thrombin time
P
15.3–18.5 s
15.3–18.5 s
Total eosinophils
WB
150–300 × 106/L
150–300/mm3
Transferrin receptor
S, P
9.6–29.6 nmol/L
9.6–29.6 nmol/L
Viscosity
 Plasma
P
1.7–2.1
1.7–2.1
 Serum
S
1.4–1.8
1.4–1.8
von Willebrand factor (vWF) antigen 
(factor VIII:R antigen)
P
 Blood group O
0.75 mean of normal
75% mean of normal
 Blood group A
1.05 mean of normal
105% mean of normal
 Blood group B
1.15 mean of normal
115% mean of normal
 Blood group AB
1.25 mean of normal
125% mean of normal
von Willebrand factor multimers
P
Normal distribution
Normal distribution
White blood cells: see “Leukocytes”
Abbreviations: JF, joint fluid; P, plasma; PRP, platelet-rich plasma; S, serum; WB, whole blood.
1401
TABLE 220-2 CLINICAL CHEMISTRY AND IMMUNOLOGY
Analyte
Specimen
SI Units
Conventional Units
Acetoacetate
P
49–294 μmol/L
0.5–3.0 mg/dL
Adrenocorticotropin (ACTH)
P
1.3–16.7 pmol/L
6.0–76.0 pg/mL
Alanine aminotransferase (ALT, SGPT )
S
0.12–0.70 μkat/L
7–41 U/L
Albumin
S
40–50 g/L
4.0–5.0 mg/dL
Aldolase
S
26–138 nkat/L
1.5–8.1 U/L
Aldosterone (adult)
  Supine, normal sodium diet
S, P
<443 pmol/L
<16 ng/dL
 Upright, normal
S, P
111–858 pmol/L
4–31 ng/dL
Alpha fetoprotein (adult)
S
0–8.5 μg/L
0–8.5 ng/mL
Alpha1 antitrypsin
S
1.0–2.0 g/L
100–200 mg/dL
Ammonia, as NH3
P
11–35 μmol/L
19–60 μg/dL
Amylase (method dependent)
S
0.34–1.6 μkat/L
20–96 U/L
Androstenedione (adult)
S
 Males
0.81–3.1 nmol/L
23–89 ng/dL
 Females
  Premenopausal
0.91–7.5 nmol/L
26–214 ng/dL
  Postmenopausal
0.46–2.9 nmol/L
13–82 ng/dL
Angiotensin-converting enzyme (ACE)
S
0.15–1.1 μkat/L
9–67 U/L
1402
Anion gap
S
7–16 mmol/L
7–16 mmol/L
Apolipoprotein A-1
S
 Male
0.94–1.78 g/L
94–178 mg/dL
 Female
1.01–1.99 g/L
101–199 mg/dL
Apolipoprotein B
S
 Male
0.55–1.40 g/L
55–140 mg/dL
 Female
0.55–1.25 g/L
55–125 mg/dL
Arterial blood gases
WB
 [HCO3
–]
22–30 mmol/L
22–30 meq/L
 PCO2
4.3–6.0 kPa
32–45 mmHg
 pH
7.35–7.45
7.35–7.45
 PO2
9.6–13.8 kPa
72–104 mmHg
Aspartate aminotransferase (AST, SGOT)
S
0.20–0.65 μkat/L
12–38 U/L
Autoantibodies
S
  Anticentromere antibody IgG
≤29 AU/mL
≤29 AU/mL
  Anti-double-strand (native) DNA
<25 IU/L
<25 IU/L
  Anti–glomerular basement membrane antibodies
   Qualitative IgG, IgA
Negative
Negative
   Quantitative IgG antibody
≤19 AU/mL
≤19 AU/mL
  Antihistone antibodies
<1.0 U
<1.0 U
(continued)
1403
TABLE 220-2 CLINICAL CHEMISTRY AND IMMUNOLOGY (CONTINUED)
Analyte
Specimen
SI Units
Conventional Units
  Anti-Jo-1 antibody
≤29 AU/mL
≤29 AU/mL
  Antimitochondrial antibody
Not applicable
<20 Units
   Antineutrophil cytoplasmic autoantibodies
Not applicable
<1:20
   Serine proteinase 3 antibodies
≤19 AU/mL
≤19 AU/mL
   Myeloperoxidase antibodies
≤19 AU/mL
≤19 AU/mL
  Antinuclear antibody
Not applicable
Negative at 1:40
  Anti-parietal cell antibody
Not applicable
None detected
  Anti-RNP antibody
Not applicable
<1.0 U
  Anti-Scl 70 antibody
Not applicable
<1.0 U
  Anti-Smith antibody
Not applicable
<1.0 U
  Anti-smooth muscle antibody
Not applicable
<1.0 U
  Anti-SSA antibody
Not applicable
<1.0 U
  Anti-SSB antibody
Not applicable
Negative
  Antithyroglobulin antibody
<40 KIU/mL
<40 IU/mL
  Anti-thyroid peroxidase antibody
<35 KIU/L
<35 IU/L
B-type natriuretic peptide (BNP)
P
Age and gender specific: <100 ng/L
Age and gender specific: <100 pg/mL
Bence Jones protein, serum qualitative
S
Not applicable
None detected
1404
Bence Jones protein, serum quantitative
S
 Free kappa
3.3–19.4 mg/L
0.33–1.94 mg/dL
 Free lambda
5.7–26.3 mg/L
0.57–2.63 mg/dL
K/L ratio
0.26–1.65 
0.26–1.65
Beta-2-microglobulin
S
1.1–2.4 mg/L
1.1–2.4 mg/L
Bilirubin
S
 Total
5.1–22 μmol/L
0.3–1.3 mg/dL
 Direct
1.7–6.8 μmol/L
0.1–0.4 mg/dL
 Indirect
3.4–15.2 μmol/L
0.2–0.9 mg/dL
C peptide
S
0.27–1.19 nmol/L
0.8–3.5 ng/mL
C1-esterase-inhibitor protein
S
210–390 mg/L
21–39 mg/dL
CA 125
S
<35 kU/L
<35 U/mL
CA 19-9
S
<37 kU/L
<37 U/mL
CA 15-3
S
<33 kU/L
<33 U/mL
CA 27-29
S
0–40 kU/L
0–40 U/mL
Calcitonin
S
 Male
0–7.5 ng/L
0–7.5 pg/mL
 Female
0–5.1 ng/L
0–5.1 pg/mL
Calcium
S
2.2–2.6 mmol/L
8.7–10.2 mg/dL
(continued)
1405
TABLE 220-2 CLINICAL CHEMISTRY AND IMMUNOLOGY (CONTINUED)
Analyte
Specimen
SI Units
Conventional Units
Calcium, ionized
WB
1.12–1.32 mmol/L
4.5–5.3 mg/dL
Carbon dioxide content (TCO2)
P (sea level)
22–30 mmol/L
22–30 meq/L
Carboxyhemoglobin (carbon monoxide content)
WB
 Nonsmokers
0.0–0.015
0–1.5%
 Smokers
0.04–0.09
4–9%
  Loss of consciousness and death
>0.50
>50%
Carcinoembryonic antigen (CEA)
S
 Nonsmokers
0.0–3.0 μg/L
0.0–3.0 ng/mL
 Smokers
0.0–5.0 μg/L
0.0–5.0 ng/mL
Ceruloplasmin
S
250–630 mg/L
25–63 mg/dL
Chloride
S
102–109 mmol/L
102–109 meq/L
Cholesterol: see Table 220-5
Cholinesterase
S
5–12 kU/L
5–12 U/mL
Chromogranin A
S
0–50 μg/L
0–50 ng/mL
Complement
S
 C3
0.83–1.77 g/L
83–177 mg/dL
 C4
0.16–0.47 g/L
16–47 mg/dL
 Complement total
60–144 CAE units
60–144 CAE units
1406
Cortisol
  Fasting, 8 A.M.–12 noon
S
138–690 nmol/L
5–25 μg/dL
 12 noon–8 P.M.
138–414 nmol/L
5–15 μg/dL
 8 P.M.–8 A.M.
0–276 nmol/L
0–10 μg/dL
C-reactive protein
S
<10 mg/L
<10 mg/L
C-reactive protein, high sensitivity
S
Cardiac risk
Cardiac risk
  Low: <1.0 mg/L
Low: <1.0 mg/L
  Average: 1.0–3.0 mg/L
Average: 1.0–3.0 mg/L
  High: >3.0 mg/L
High: >3.0 mg/L 
Creatine kinase (total)
S
 Females
0.66–4.0 μkat/L
39–238 U/L
 Males
0.87−5.0 μkat/L
51–294 U/L
Creatine kinase-MB
S
 Mass
0.0–5.5 μg/L
0.0–5.5 ng/mL
  Fraction of total activity (by electrophoresis)
0–0.04
0–4.0%
Creatinine
S
 Female
44–80 μmol/L
0.5–0.9 mg/dL
 Male
53–106 μmol/L
0.6–1.2 mg/dL
Cryoglobulins
S
Not applicable
None detected
(continued)
1407
TABLE 220-2 CLINICAL CHEMISTRY AND IMMUNOLOGY (CONTINUED)
Analyte
Specimen
SI Units
Conventional Units
Cystatin C
S
0.5–1.0 mg/L
0.5–1.0 mg/L
Dehydroepiandrosterone (DHEA) (adult)
 Male
S
6.2–43.4 nmol/L
180–1250 ng/dL
 Female
4.5–34.0 nmol/L
130–980 ng/dL
Dehydroepiandrosterone (DHEA) sulfate
S
 Male (adult)
100–6190 μg/L
10–619 μg/dL
  Female (adult, premenopausal)
120–5350 μg/L
12–535 μg/dL
  Female (adult, postmenopausal)
300–2600 μg/L
30–260 μg/dL
11-Deoxycortisol (adult)(compound S) 
S
0.34–4.56 nmol/L
12–158 ng/dL
Dihydrotestosterone
 Male
S, P
1.03–2.92 nmol/L
30–85 ng/dL
 Female
0.14–0.76 nmol/L
4–22 ng/dL
Dopamine
P
0–130 pmol/L
0–20 pg/mL
Epinephrine
P
 Supine (30 min)
<273 pmol/L
<50 pg/mL
 Sitting
<328 pmol/L
<60 pg/mL
 Standing (30 min)
<491pmol/L
<90 pg/mL
Erythropoietin
S
4–27 U/L
4–27 U/L
1408
Estradiol
S, P
 Female
  Menstruating
   Follicular phase
74–532 pmol/L
<20–145 pg/mL
   Midcycle peak
411–1626 pmol/L
112–443 pg/mL
   Luteal phase
74–885 pmol/L
<20–241 pg/mL
  Postmenopausal
217 pmol/L
<59 pg/mL
 Male
74 pmol/L
<20 pg/mL
Estrone
S, P
 Female
  Menstruating
   Follicular phase
<555 pmol/L
<150 pg/mL
   Luteal phase
<740 pmol/L
<200 pg/mL
  Postmenopausal
11–118 pmol/L
3–32 pg/mL
 Male
33–133 pmol/L
9–36 pg/mL
Fatty acids, free (nonesterified)
P
0.1–0.6 mmol/L
2.8–16.8 mg/dL
Ferritin
S
 Female
10–150 μg/L
10–150 ng/mL
 Male
29−248 μg/L
29–248 ng/mL
(continued)
1409
TABLE 220-2 CLINICAL CHEMISTRY AND IMMUNOLOGY (CONTINUED)
Analyte
Specimen
SI Units
Conventional Units
Follicle-stimulating hormone (FSH)
S, P
 Female
  Menstruating
   Follicular phase
3.0–20.0 IU/L
3.0–20.0 mIU/mL
   Ovulatory phase
9.0–26.0 IU/L
9.0–26.0 mIU/mL
   Luteal phase
1.0–12.0 IU/L
1.0–12.0 mIU/mL
  Postmenopausal
18.0–153.0 IU/L
18.0–153.0 mIU/mL
 Male
1.0–12.0 IU/L
1.0–12.0 mIU/mL
Fructosamine
S
<285 umol/L 
<285 umol/L 
Gamma glutamyltransferase
S
0.15–0.99 μkat/L
9–58 U/L
Gastrin
S
<100 ng/L
<100 pg/mL
Glucagon
P
40–130 ng/L
40–130 pg/mL
Glucose
WB
3.6–5.3 mmol/L
65–95 mg/dL
Glucose (fasting)
P
 Normal
4.2–5.6 mmol/L
75–100 mg/dL
  Increased risk for diabetes
5.6–6.9 mmol/L
100–125 mg/dL
1410
 Diabetes mellitus
Fasting ≥7.0 mmol/L
Fasting ≥126 mg/dL
A 2-hour level of ≥11.1 mmol/L 
during an oral glucose tolerance test
A 2-hour level of ≥200 mg/dL during 
an oral glucose tolerance test
A random glucose level of 
≥11.1 mmol/L in pts with symptoms 
of hyperglycemia
A random glucose level of ≥200 mg/dL 
in pts with symptoms of hyperglycemia
Growth hormone
S
0–5 μg/L
0–5 ng/mL
Hemoglobin Alc
WB
0.04–0.06 Hgb fraction
4.0–5.6%
 Pre-diabetes
0.057–0.064 Hgb fraction
5.7–6.4%
 Diabetes mellitus
A hemoglobin A1c level of ≥0.065 Hgb 
fraction as suggested by the American 
Diabetes Association
A hemoglobin A1c level of ≥6.5% as 
suggested by the American Diabetes 
Association
Hemoglobin A1c with estimated average 
glucose (eAg)
WB
eAg mmol/L = 1.59 × HbA1c − 2.59
eAg (mg/dL) = 28.7 × HbA1c − 46.7
High-density lipoprotein (HDL) (see Table 220-5)
Homocysteine
P
4.4–10.8 μmol/L
4.4–10.8 μmol/L
Human chorionic gonadotropin (HCG)
S
 Nonpregnant female
<5 IU/L
<5 mIU/mL
  1–2 weeks postconception
9–130 IU/L
9–130 mIU/mL
  2–3 weeks postconception
75–2600 IU/L
75–2600 mIU/mL
(continued)
1411
TABLE 220-2 CLINICAL CHEMISTRY AND IMMUNOLOGY (CONTINUED)
Analyte
Specimen
SI Units
Conventional Units
  3–4 weeks postconception
850–20,800 IU/L
850–20,800 mIU/mL
  4–5 weeks postconception
4000–100,200 IU/L
4000–100,200 mIU/mL
  5–10 weeks postconception
11,500–289,000 IU/L
11,500–289,000 mIU/mL
  10–14 weeks post conception
18,300–137,000 IU/L
18,300–137,000 mIU/mL
  Second trimester
1400–53,000 IU/L
1400–53,000 mIU/mL
  Third trimester
940–60,000 IU/L
940–60,000 mIU/mL
β−Hydroxybutyrate
P
60–170 μmol/L
0.6–1.8 mg/dL
17-Hydroxyprogesterone (adult)
S
  Male
<4.17 nmol/L
<139 ng/dL
  Female
  Follicular phase
0.45–2.1 nmol/L
15–70 ng/dL
  Luteal phase
1.05–8.7 nmol/L
35–290 ng/dL
Immunofixation
S
Not applicable
No bands detected 
Immunoglobulin, quantitation (adult)
 IgA
S
0.70–3.50 g/L
70–350 mg/dL
 IgD
S
0–140 mg/L
0–14 mg/dL
 IgE
S
1–87 KIU/L
1–87 IU/mL
1412
 IgG
S
7.0–17.0 g/L
700–1700 mg/dL
  IgG1
S
2.7–17.4 g/L
270–1740 mg/dL
  IgG2
S
0.3–6.3 g/L
30–630 mg/dL
  IgG3
S
0.13–3.2 g/L
13–320 mg/dL
  IgG4
S
0.11–6.2 g/L
11–620 mg/dL
 IgM
S
0.50–3.0 g/L
50–300 mg/dL
Insulin
S, P
14.35–143.5 pmol/L
2–20 μU/mL
Iron
S
7–25 μmol/L
41–141 μg/dL
Iron-binding capacity
S
45–73 μmol/L
251–406 μg/dL
Iron-binding capacity saturation
S
0.16–0.35
16–35%
Ischemia modified albumin
S
<85 KU/L
<85 U/mL
Joint fluid crystal
JF
Not applicable
No crystals seen
Joint fluid mucin
JF
Not applicable
Only type I mucin present
Ketone (acetone)
S
Negative
Negative
Lactate
P, arterial
0.5–1.6 mmol/L
4.5–14.4 mg/dL
P, venous
0.5–2.2 mmol/L
4.5–19.8 mg/dL
Lactate dehydrogenase
S
2.0–3.8 μkat/L
115–221 U/L
Lipase
S
0.51–0.73 μkat/L
3–43 U/L
(continued)
1413
TABLE 220-2 CLINICAL CHEMISTRY AND IMMUNOLOGY (CONTINUED)
Analyte
Specimen
SI Units
Conventional Units
Lipids: see Table 220-5
Lipoprotein (a)
S
0–300 mg/L
0–30 mg/dL
Low-density lipoprotein (LDL) (see Table 220-5)
Luteinizing hormone (LH)
S, P
 Female
  Menstruating
   Follicular phase
2.0–15.0 U/L
2.0–15.0 mIU/mL
   Ovulatory phase
22.0–105.0 U/L
22.0–105.0 mIU/mL
   Luteal phase
0.6–19.0 U/L
0.6–19.0 mIU/mL
   Postmenopausal
16.0–64.0 U/L
16.0–64.0 mIU/mL
 Male 
2.0–12.0 U/L
2.0–12.0 mIU/mL
Magnesium
S
0.62–0.95 mmol/L
1.5–2.3 mg/dL
Metanephrine
P
<0.5 nmol/L
<100 pg/mL
Methemoglobin
WB
0.0–0.01
0–1%
Myoglobin
S
 Male
20–71 μg/L
20–71 μg/L
 Female
25–58 μg/L
25–58 μg/L
1414
Norepinephrine
P
 Supine (30 min)
650–2423 pmol/L
110–410 pg/mL
 Sitting
709–4019 pmol/L
120–680 pg/mL
 Standing (30 min)
739–4137 pmol/L
125–700 pg/mL
N-telopeptide (cross-linked), NTx
S
  Female, premenopausal
6.2–19.0 nmol BCE
6.2–19.0 nmol BCE
 Male
5.4–24.2 nmol BCE
5.4–24.2 nmol BCE
  BCE = bone collagen equivalent
NT-Pro BNP
S, P
<125 ng/L up to 75 years
<125 pg/mL up to 75 years
<450 ng/L >75 years
<450 pg/mL >75 years
5′ Nucleotidase
S
0.00–0.19 μkat/L
0–11 U/L
Osmolality
P
275–295 mosmol/kg serum water
275–295 kg/kg serum water
Osteocalcin
S
11–50 μg/L
11–50 ng/mL
Oxygen content
WB
 Arterial (sea level)
17–21
17–21 vol%
 Venous (sea level)
10–16
10–16 vol%
Oxygen saturation (sea level)
WB
Fraction:
Percent:
 Arterial
0.94–1.0
94–100%
 Venous, arm
0.60–0.85
60–85%
Parathyroid hormone (intact)
S
8–51 ng/L
8–51 pg/mL
(continued)
1415
TABLE 220-2 CLINICAL CHEMISTRY AND IMMUNOLOGY (CONTINUED)
Analyte
Specimen
SI Units
Conventional Units
Phosphatase, alkaline 
S
0.56–1.63 μkat/L
33–96 U/L
Phosphorus, inorganic
S
0.81–1.4 mmol/L
2.5–4.3 mg/dL
Potassium
S
3.5–5.0 mmol/L
3.5–5.0 meq/L
Prealbumin
S
170–340 mg/L
17–34 mg/dL
Procalcitonin
S
<0.1 μg/L
<0.1 ng/mL
Progesterone
S, P
 Female: Follicular
<3.18 nmol/L
<1.0 ng/mL
 Midluteal
9.54–63.6 nmol/L
3–20 ng/mL
 Male
<3.18 nmol/L
<1.0 ng/mL
Prolactin
S
 Male
53–360 μg/L
2.5–17 ng/mL
 Female
40–530 μg/L
1.9–25 ng/mL
Prostate-specific antigen (PSA) 
S
0.0–4.0 μg/L
0.0–4.0 ng/mL
Prostate-specific antigen, free
S
With total PSA between 4 and 
10 μg/L and when the free PSA is:
With total PSA between 4 and 
10 ng/mL and when the free PSA is:
>0.25 decreased risk of prostate 
cancer
>25% decreased risk of prostate 
cancer
<0.10 increased risk of prostate 
cancer
<10% increased risk of prostate 
cancer
1416
Protein fractions:
S
 Albumin
35–55 g/L
3.5–5.5 g/dL (50–60%)
 Globulin
20–35 g/L
2.0–3.5 g/dL (40–50%)
 Alpha1
2–4 g/L
0.2–0.4 g/dL (4.2–7.2%)
 Alpha2
5–9 g/L
0.5–0.9 g/dL (6.8–12%)
 Beta
6–11 g/L
0.6–1.1 g/dL (9.3–15%)
 Gamma
7–17 g/L
0.7–1.7 g/dL (13–23%)
Protein, total
S
67–86 g/L
6.7–8.6 g/dL
Pyruvate
P
40–130 μmol/L
0.35–1.14 mg/dL
Rheumatoid factor
S
<15 kIU/L
<15 IU/mL
Serotonin
WB
0.28–1.14 umol/L
50–200 ng/mL
Serum protein electrophoresis
S
Not applicable
Normal pattern
Sex hormone–binding globulin (adult)
S
 Male
11–80 nmol/L
11–80 nmol/L
 Female
30–135 nmol/L
30–135 nmol/L
Sodium
S
136–146 mmol/L
136–146 meq/L
Somatomedin-C (IGF-1)(adult)
S
 16 years
226–903 μg/L
226–903 ng/mL
 17 years
193–731 μg/L
193–731 ng/mL
(continued)
1417
TABLE 220-2 CLINICAL CHEMISTRY AND IMMUNOLOGY (CONTINUED)
Analyte
Specimen
SI Units
Conventional Units
 18 years
163–584 μg/L
163–584 ng/mL
 19 years
141–483 μg/L
141–483 ng/mL
 20 years
127–424 μg/L
127–424 ng/mL
 21–25 years
116–358 μg/L
116–358 ng/mL
 26–30 years
117–329 μg/L
117–329 ng/mL
 31–35 years
115–307 μg/L
115–307 ng/mL
 36–40 years
119–204 μg/L
119–204 ng/mL
 41–45 years
101–267 μg/L
101–267 ng/mL
 46–50 years
94–252 μg/L
94–252 ng/mL
 51–55 years
87–238 μg/L
87–238 ng/mL
 56–60 years
81–225 μg/L
81–225 ng/mL
 61–65 years
75–212 μg/L
75–212 ng/mL
 66–70 years
69–200 μg/L
69–200 ng/mL
 71–75 years
64–188 μg/L
64–188 ng/mL
 76–80 years
59–177 μg/L
59–177 ng/mL
 81–85 years
55–166 μg/L
55–166 ng/mL
1418
Somatostatin
P
<25 ng/L
<25 pg/mL
Testosterone, free
 Female, adult
S
10.4–65.9 pmol/L
3–19 pg/mL
 Male, adult
312–1041 pmol/L
90–300 pg/mL
Testosterone, total
S
 Female
0.21–2.98 nmol/L
6–86 ng/dL
 Male
9.36–37.10 nmol/L
270–1070 ng/dL
Thyroglobulin
S
13–318 μg/L
1.3–31.8 ng/mL
Thyroid-binding globulin
S
13–30 mg/L
1.3–3.0 mg/dL
Thyroid-stimulating hormone
S
0.34–4.25 mIU/L
0.34–4.25 μIU/mL
Thyroxine, free (fT4)
S
9.0–16 pmol/L
0.7–1.24 ng/dL
Thyroxine, total (T4)
S
70–151 nmol/L
5.4–11.7 μg/dL
Thyroxine index (free)
S
6.7–10.9
6.7–10.9 
Transferrin
S
2.0–4.0 g/L
200–400 mg/dL
Triglycerides (see Table 220-5)
S
0.34–2.26 mmol/L
30–200 mg/dL
Triiodothyronine, free (fT3)
S
3.7–6.5 pmol/L
2.4–4.2 pg/mL
Triiodothyronine, total (T3)
S
1.2–2.1 nmol/L
77–135 ng/dL
(continued)
1419
TABLE 220-2 CLINICAL CHEMISTRY AND IMMUNOLOGY (CONTINUED)
Analyte
Specimen
SI Units
Conventional Units
Troponin I (method dependent)
S,P
  99th percentile of a healthy population
0–0.04 μg/L
0–0.04 ng/mL
Troponin T
S,P
  99th percentile of a healthy population
0–0.01 μg/L
0–0.01 ng/mL
Urea nitrogen
S
2.5–7.1 mmol/L
7–20 mg/dL
Uric acid
S
 Females
0.15–0.33 mmol/L
2.5–5.6 mg/dL
 Males
0.18–0.41 mmol/L
3.1–7.0 mg/dL
Vasoactive intestinal polypeptide
P
0–60 ng/L
0–60 pg/mL
Zinc protoporphyrin
WB
0–400 μg/L
0–40 μg/dL
Zinc protoporphyrin (ZPP)-to-heme ratio
WB
0–69 μmol ZPP/mol heme
0–69 μmol ZPP/mol heme
Abbreviations: P, plasma; S, serum; WB, whole blood.
1420
TABLE 220-3 TOXICOLOGY AND THERAPEUTIC DRUG MONITORING
Therapeutic Range
Toxic Level
Drug
SI Units
Conventional Units
SI Units
Conventional Units
Acetaminophen
66–199 μmol/L
10–30 μg/mL
>1320 μmol/L
>200 μg/mL
Amikacin
 Peak
34–51 μmol/L
20–30 μg/mL
>60 μmol/L
>35 μg/mL
 Trough
0–17 μmol/L
0–10 μg/mL
>17 μmol/L
>10 μg/mL
Amitriptyline/nortriptyline (total drug)
430–900 nmol/L
120–250 ng/mL
>1800 nmol/L
>500 ng/mL
Amphetamine
150–220 nmol/L
20–30 ng/mL 
>1500 nmol/L
>200 ng/mL
Bromide
9.4–18.7 mmol/L
75–150 mg/dL
>18.8 mmol/L
>150 mg/dL
 Mild toxicity
6.4–18.8 mmol/L
51–150 mg/dL
 Severe toxicity
>18.8 mmol/L
>150 mg/dL
 Lethal
>37.5 mmol/L
>300 mg/dL
Caffeine
25.8–103 μmol/L
5–20 μg/mL
>206 μmol/L
>40 μg/mL
Carbamazepine
17–42 μmol/L
4–10 μg/mL
>85 μmol/L
>20 μg/mL
Chloramphenicol
 Peak
31–62 μmol/L
10–20 μg/mL
>77 μmol/L
>25 μg/mL
 Trough
15–31 μmol/L
5–10 μg/mL
>46 μmol/L
>15 μg/mL
(continued)
1421
TABLE 220-3 TOXICOLOGY AND THERAPEUTIC DRUG MONITORING (CONTINUED)
Therapeutic Range
Toxic Level
Drug
SI Units
Conventional Units
SI Units
Conventional Units
Chlordiazepoxide
1.7–10 μmol/L
0.5–3.0 μg/mL
>17 μmol/L
>5.0 μg/mL
Clonazepam
32–240 nmol/L
10–75 ng/mL
>320 nmol/L
>100 ng/mL
Clozapine
0.6–2.1 μmol/L
200–700 ng/mL
>3.7 μmol/L
>1200 ng/mL
Cocaine
>3.3 μmol/L
>1.0 μg/mL
Codeine
43–110 nmol/mL
13–33 ng/mL
>3700 nmol/mL
>1100 ng/mL (lethal)
Cyclosporine
 Renal transplant
  0–6 months
208–312 nmol/L
250–375 ng/mL
>312 nmol/L
>375 ng/mL
  6–12 months after transplant
166–250 nmol/L
200–300 ng/mL
>250 nmol/L
>300 ng/mL
  >12 months
83–125 nmol/L
100–150 ng/mL
>125 nmol/L
>150 ng/mL
 Cardiac transplant
  0–6 months
208–291 nmol/L
250–350 ng/mL
>291 nmol/L
>350 ng/mL
  6–12 months after transplant
125–208 nmol/L
150–250 ng/mL
>208 nmol/L
>250 ng/mL
  >12 months
83–125 nmol/L
100–150 ng/mL
>125 nmol/L
150 ng/mL
 Lung transplant
  0–6 months
250–374 nmol/L
300–450 ng/mL
>374 nmol/L
>450 ng/mL
1422
 Liver transplant
  Initiation
208–291 nmol/L
250–350 ng/mL
>291 nmol/L
>350 ng/mL
  Maintenance
83–166 nmol/L
100–200 ng/mL
>166 nmol/L
>200 ng/mL
Desipramine
375–1130 nmol/L
100–300 ng/mL
>1880 nmol/L
>500 ng/mL
Diazepam (and metabolite)
 Diazepam
0.7 –3.5 μmol/L
0.2–1.0 μg/mL
>7.0 μmol/L
>2.0 μg/mL
 Nordiazepam
0.4– 6.6 μmol/L
0.1–1.8 μg/mL
>9.2 μmol/L
>2.5 μg/mL
Digoxin
0.64–2.6 nmol/L
0.5–2.0 ng/mL
>5.0 nmol/L
>3.9 ng/mL
Disopyramide
5.3–14.7 μmol/L
2–5 μg/mL
>20.6 μmol/L
>7 μg/mL
Doxepin and nordoxepin
 Doxepin
0.36–0.98 μmol/L
101–274 ng/mL
>1.8 μmol/L
>503 ng/mL
 Nordoxepin
0.38–1.04 μmol/L
106–291 ng/mL
>1.9 μmol/L
>531 ng/mL
Ethanol
 Behavioral changes
>4.3 mmol/L
>20 mg/dL
 Legal limit
≥17 mmol/L
≥80 mg/dL
 Critical with acute exposure
>54 mmol/L
>250 mg/dL
Ethylene glycol
 Toxic
>2 mmol/L
>12 mg/dL
 Lethal
>20 mmol/L
>120 mg/dL
(continued)
1423
TABLE 220-3 TOXICOLOGY AND THERAPEUTIC DRUG MONITORING (CONTINUED)
Therapeutic Range
Toxic Level
Drug
SI Units
Conventional Units
SI Units
Conventional Units
Ethosuximide
280–700 μmol/L
40–100 μg/mL
>700 μmol/L
>100 μg/mL
Everolimus
3.13–8.35 nmol/L
3–8 ng/mL
>12.5 nmol/L
>12 ng/mL
Flecainide
0.5–2.4 μmol/L
0.2–1.0 μg/mL
>3.6 μmol/L
>1.5 μg/mL
Gentamicin
 Peak
10–21 μmol/mL
5–10 μg/mL
>25 μmol/mL
>12 μg/mL
 Trough
0–4.2 μmol/mL
0–2 μg/mL
>42 μmol/mL
>2 μg/mL
Heroin (diacetyl morphine)
>700 μmol/L
>200 ng/mL (as morphine)
Ibuprofen
49–243 μmol/L
10–50 μg/mL
>970 μmol/L
>200 μg/mL
Imipramine (and metabolite)
 Desimipramine
375–1130 nmol/L
100–300 ng/mL
>1880 nmol/L
>500 ng/mL
 Total imipramine + desimipramine
563–1130 nmol/L
150–300 ng/mL
>1880 nmol/L
>500 ng/mL
Lamotrigine
11.7–54.7 μmol/L
3–14 μg/mL
>58.7 μmol/L
>15 μg/mL
Lidocaine
5.1–21.3 μmol/L
1.2–5.0 μg/mL
>38.4 μmol/L
>9.0 μg/mL
Lithium
0.5–1.3 mmol/L
0.5–1.3 meq/L
>2 mmol/L
>2 meq/L
Methadone
1.0–3.2 μmol/L
0.3–1.0 μg/mL
>6.5 μmol/L
>2 μg/mL
1424
Methamphetamine
0.07–0.34 μmol/L
0.01–0.05 μg/mL
>3.35 μmol/L
>0.5 μg/mL
Methanol
>6 mmol/L
>20 mg/dL
Methotrexate
 Low-dose
0.01–0.1 μmol/L
0.01–0.1 μmol/L
>0.1 mmol/L
>0.1 mmol/L
 High-dose (24h)
<5.0 μmol/L
<5.0 μmol/L
>5.0 μmol/L
>5.0 μmol/L
 High-dose (48h)
<0.50 μmol/L
<0.50 μmol/L
>0.5 μmol/L
>0.5 μmol/L
 High-dose (72h)
<0.10 μmol/L
<0.10 μmol/L
>0.1 μmol/L
>0.1 μmol/L
Morphine
232–286 μmol/L
65–80 ng/mL
>720 μmol/L
>200 ng/mL
Mycophenolic acid
3.1–10.9 μmol/L
1.0–3.5 ng/mL
>37 μmol/L
>12 ng/mL
Nitroprusside (as thiocyanate)
103–499 μmol/L
6–29 μg/mL
860 μmol/L
>50 μg/mL
Nortriptyline
190–569 nmol/L
50–150 ng/mL
>1900 nmol/L
>500 ng/mL
Phenobarbital
65–172 μmol/L
15–40 μg/mL
>258 μmol/L
>60 μg/mL
Phenytoin
40–79 μmol/L
10–20 μg/mL
>158 μmol/L
>40 μg/mL
Phenytoin, free
4.0–7.9 μg/mL
1–2 μg/mL
>13.9 μg/mL
>3.5 μg/mL
 % Free
0.08–0.14
8–14%
Primidone and metabolite
 Primidone
23–55 μmol/L
5–12 μg/mL
>69 μmol/L
>15 μg/mL
 Phenobarbital
65–172 μmol/L
15–40 μg/mL
>215 μmol/L
>50 μg/mL
(continued)
1425
TABLE 220-3 TOXICOLOGY AND THERAPEUTIC DRUG MONITORING (CONTINUED)
Therapeutic Range
Toxic Level
Drug
SI Units
Conventional Units
SI Units
Conventional Units
Procainamide
Procainamide
17–42 μmol/L
4–10 μg/mL
>43 μmol/L
>10 μg/mL
 NAPA (N-acetylprocainamide)
22–72 μmol/L
6–20 μg/mL
>126 μmol/L
>35 μg/mL
Quinidine
6.2–15.4 μmol/L
2.0–5.0 μg/mL
>19 μmol/L
>6 μg/mL
Salicylates
145–2100 μmol/L
2–29 mg/dL
>2900 μmol/L
>40 mg/dL
Sirolimus (trough level)
 Kidney transplant
4.4–15.4 nmol/L
4–14 ng/mL
>16 nmol/L
>15 ng/mL
Tacrolimus
(FK506) (trough)
 Kidney and liver
 Initiation
12–19 nmol/L
10–15 ng/mL
>25 nmol/L
>20 ng/mL
 Maintenance
6–12 nmol/L
5–10 ng/mL
>25 nmol/L
>20 ng/mL
 Heart
 Initiation
19–25 nmol/L
15–20 ng/mL
 Maintenance
6–12 nmol/L
5–10 ng/mL
1426
Theophylline
56–111 μg/mL
10–20 μg/mL
>168 μg/mL
>30 μg/mL
Thiocyanate
 After nitroprusside infusion
103–499 μmol/L
6–29 μg/mL
860 μmol/L
>50 μg/mL
 Nonsmoker
17–69 μmol/L
1–4 μg/mL
 Smoker
52–206 μmol/L
3–12 μg/mL
Tobramycin
 Peak
11–22 μg/L
5–10 μg/mL
>26 μg/L
>12 μg/mL
 Trough
0–4.3 μg/L
0–2 μg/mL
>4.3 μg/L
>2 μg/mL
Valproic acid
346–693 μmol/L
50–100 μg/mL
>693 μmol/L
>100 μg/mL
Vancomycin
 Peak
14–28 μmol/L
20–40 μg/mL
>55 μmol/L
>80 μg/mL
 Trough
3.5–10.4 μmol/L
5–15 μg/mL
>14 μmol/L
>20 μg/mL
1427
SECTION 18
1428
Laboratory Values
TABLE 220-4 VITAMINS AND SELECTED TRACE MINERALS
Reference Range
Specimen
Analyte
SI Units
Conventional Units
Aluminum
S
<0.2 μmol/L
<5.41 μg/L
Arsenic
WB
0.03–0.31 μmol/L
2–23 μg/L
Cadmium
WB
<44.5 nmol/L
<5.0 μg/L
Coenzyme Q10 
(ubiquinone)
P
433–1532 μg/L
433–1532 μg/L
β-Carotene
S
0.07–1.43 μmol/L
4–77 μg/dL
Copper
S
11–22 μmol/L
70–140 μg/dL
Folic acid
RC
340–1020 nmol/L 
cells
150–450 ng/mL 
cells
Folic acid
S
12.2–40.8 nmol/L
5.4–18.0 ng/mL
Lead (adult)
S
<0.5 μmol/L
<10 μg/dL
Mercury
WB
3.0–294 nmol/L
0.6–59 μg/L
Selenium
S
0.8–2.0 umol/L
63–160 μg/L
Vitamin A
S
0.7–3.5 μmol/L
20–100 μg/dL
Vitamin B1 (thiamine)
S
0–75 nmol/L
0–2 μg/dL
Vitamin B2 (riboflavin)
S
106–638 nmol/L
4–24 μg/dL
Vitamin B6
P
20–121 nmol/L
5–30 ng/mL
Vitamin B12
S
206–735 pmol/L
279–996 pg/mL
Vitamin C (ascorbic acid)
S
23–57 μmol/L
0.4–1.0 mg/dL
Vitamin D3,1,25-
dihydroxy, total
S, P
36–180 pmol/L
15–75 pg/mL
Vitamin D3,25-hydroxy, 
total
P
75–250 nmol/L
30–100 ng/mL
Vitamin E
S
12–42 μmol/L
5–18 μg/mL
Vitamin K
S
0.29–2.64 nmol/L
0.13–1.19 ng/mL
Zinc
S
11.5–18.4 μmol/L
75–120 μg/dL
Abbreviations: P, plasma; RC, red cells; S, serum; WB, whole blood.
CHAPTER 220 1429
Laboratory Values of Clinical Importance 
TABLE 220-5 CLASSIFICATION OF LDL, TOTAL, AND HDL CHOLESTEROL
LDL Cholesterol
<70 mg/dL
Therapeutic option for very high-risk pts
<100 mg/dL
Optimal
100–129 mg/dL
Near optimal/above optimal
130–159 mg/dL
Borderline high
160–189 mg/dL
High
≥190 mg/dL
Very high
Total Cholesterol
<200 mg/dL
Desirable
200–239 mg/dL
Borderline high
≥240 mg/dL
High
HDL Cholesterol
<40 mg/dL
Low
≥60 mg/dL
High
Abbreviations: LDL, low-density lipoprotein; HDL, high-density lipoprotein.
Sources: Executive summary of the third report of the National Cholesterol Education Program 
(NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults 
(adult treatment panel III). JAMA 2001; 285:2486–97. Implications of Recent Clinical Trials for 
the National Cholesterol Education Program Adult Treatment Panel III Guidelines. SM Grundy et al 
for the Coordinating Committee of the National Cholesterol Education Program: Circulation 
110:227, 2004.
REFERENCE VALUES FOR SPECIFIC ANALYTES
(Tables 220-6 through 220-9)
SECTION 18
1430
Laboratory Values
TABLE 220-6 CEREBROSPINAL FLUIDa
Reference Range
Constituent
SI Units
Conventional Units
Osmolarity
292–297 mmol/kg water
292–297 mosmol/L
Electrolytes
 Sodium
137–145 mmol/L
137–145 meq/L
 Potassium
2.7–3.9 mmol/L
2.7–3.9 meq/L
 Calcium
1.0–1.5 mmol/L
2.1–3.0 meq/L
 Magnesium
1.0–1.2 mmol/L
2.0–2.5 meq/L
 Chloride
116–122 mmol/L
116–122 meq/L
 CO2 content
20–24 mmol/L
20–24 meq/L
PCO2
6–7 kPa
45–49 mmHg
pH
7.31–7.34
Glucose
2.22–3.89 mmol/L
40–70 mg/dL
Lactate
1–2 mmol/L
10–20 mg/dL
Total protein:
 Lumbar
0.15–0.5 g/L
15–50 mg/dL
 Cisternal
0.15–0.25 g/L
15–25 mg/dL
 Ventricular
0.06–0.15 g/L
6–15 mg/dL
 Albumin
0.066–0.442 g/L
6.6–44.2 mg/dL
 IgG
0.009–0.057 g/L
0.9–5.7 mg/dL
 IgG indexb
0.29–0.59
  Oligoclonal bands 
(OGB)
<2 bands not present in 
matched serum sample
Ammonia
15–47 μmol/L
25–80 μg/dL
Creatinine
44–168 μmol/L
0.5–1.9 mg/dL
Myelin basic protein
<4 μg/L
CSF pressure
50–180 mmH2O
CSF volume (adult)
~150 mL
Red blood cells
0
0
Leukocytes
 Total
0–5 mononuclear cells per μL
 Differential
  Lymphocytes
60–70%
  Monocytes
30–50%
  Neutrophils
None
aSince cerebrospinal fluid concentrations are equilibrium values, measurements of the same pa-
rameters in blood plasma obtained at the same time are recommended. However, there is a time 
lag in attainment of equilibrium, and cerebrospinal levels of plasma constituents that can fluctuate 
rapidly (such as plasma glucose) may not achieve stable values until after a significant lag phase.
bIgG index = CSF IgG (mg/dL) × serum albumin (g/dL)/serum IgG (g/dL) × CSF albumin (mg/dL).
CHAPTER 220 1431
Laboratory Values of Clinical Importance 
TABLE 220-7 URINE ANALYSIS AND RENAL FUNCTION TESTS
Reference Range
SI Units
Conventional Units
Acidity, titratable
20–40 mmol/d
20–40 meq/d
Aldosterone
Normal diet: 6–25 μg/d
Normal diet: 6–25 μg/d
Low-salt diet: 17–44 μg/d Low-salt diet: 17–44 μg/d
High-salt diet: 0–6 μg/d
High-salt diet: 0–6 μg/d
Aluminum
0.19–1.11 μmol/L
5–30 μg/L
Ammonia
30–50 mmol/d
30–50 meq/d
Amylase
4–400 U/L
Amylase/creatinine 
clearance ratio [(Clam/
Clcr) × 100]
1–5
1–5
Arsenic
0.07–0.67 μmol/d
5–50 μg/d
Bence Jones protein, 
urine, qualitative
Not applicable
None detected
Bence Jones protein, 
urine, quantitative
 Free Kappa
1.4–24.2 mg/L
0.14–2.42 mg/dL
 Free Lambda
0.2–6.7 mg/L
0.02–0.67 mg/dL
 K/L ratio
2.04–10.37
2.04–10.37
Calcium (10 meq/d 
or 200 mg/d dietary 
calcium)
<7.5 mmol/d
<300 mg/d
Chloride
140–250 mmol/d
140–250 mmol/d
Citrate
320–1240 mg/d
320–1240 mg/d
Copper
<0.95 μmol/d
<60 μg/d
Coproporphyrins
(types I and III)
0–20 μmol/mol creatinine 0–20 μmol/mol 
creatinine
Cortisol, free
55–193 nmol/d
20–70 μg/d
Creatine, as creatinine
 Female
<760 μmol/d
<100 mg/d
 Male
<380 μmol/d
<50 mg/d
Creatinine
8.8–14 mmol/d
1.0–1.6 g/d
Dopamine
392–2876 nmol/d
60–440 μg/d
Eosinophils
<100 eosinophils/mL
<100 eosinophils/mL
Epinephrine 
0–109 nmol/day
0–20 μg/day
Glomerular filtration rate >60 mL/min/1.73 m2
>60 mL/min/1.73 m2
For African Americans 
multiply the result by 1.21
For African Americans 
multiply the result by 1.21
Glucose (glucose 
oxidase method)
0.3–1.7 mmol/d
50–300 mg/d
(continued)
SECTION 18
1432
Laboratory Values
TABLE 220-7 URINE ANALYSIS AND RENAL FUNCTION TESTS (CONTINUED)
Reference Range
SI Units
Conventional Units
5-Hydroindoleacetic
acid [5-HIAA]
0–78.8 μmol/d
0–15 mg/d
Hydroxyproline
53–328 μmol/d
53–328 μmol/d
Iodine, spot urine
  WHO classification 
of iodine deficiency:
   Not iodine 
deficient
>100 μg/L
>100 μg/L
   Mild iodine 
deficiency
50–100 μg/L
50–100 μg/L
   Moderate iodine 
deficiency
20–49 μg/L
20–49 μg/L
   Severe iodine 
deficiency
<20 μg/L
<20 μg/L
Ketone (acetone)
Negative
Negative
17 Ketosteroids
3–12 mg/d
3–12 mg/d
Metanephrines
 Metanephrine
30–350 μg/d
30–350 μg/d
 Normetanephrine
50–650 μg/d
50–650 μg/d
Microalbumin
 Normal
0.0–0.03 g/d
0–30 mg/d
 Microalbuminuria
0.03–0.30 g/d
30–300 mg/d
 Clinical albuminuria
>0.3 g/d
>300 mg/d
Microalbumin/
creatinine ratio
 Normal
0–3.4 g/mol creatinine
0–30 μg/mg creatinine
 Microalbuminuria
3.4–34 g/mol creatinine
30–300 μg/mg creatinine
 Clinical albuminuria
>34 g/mol creatinine
>300 μg/mg creatinine
β2-Microglobulin
0–160 μg/L
0–160 μg/L
Norepinephrine
89–473 nmol/d
15–80 μg/d
N-telopeptide
(cross-linked), NTx
  Female, 
premenopausal
17–94 nmol BCE/mmol 
creatinine
17–94 nmol BCE/mmol 
creatinine
  Female, 
postmenopausal
26–124 nmol BCE/mmol 
creatinine
26–124 nmol BCE/mmol 
creatinine
 Male
21–83 nmol BCE/mmol 
creatinine
21–83 nmol BCE/mmol 
creatinine
CHAPTER 220 1433
Laboratory Values of Clinical Importance 
TABLE 220-7 URINE ANALYSIS AND RENAL FUNCTION TESTS (CONTINUED)
Reference Range
SI Units
Conventional Units
  BCE = bone colla-
gen equivalent
Osmolality
500–800 kg/kg water
500–800 kg/kg water
Oxalate
 Male
80–500 μmol/d
7–44 mg/d
 Female
45–350 μmol/d
4–31 mg/d
pH
5.0–9.0
5.0–9.0
Phosphate 
(phosphorus) (varies 
with intake)
12.9–42.0 mmol/d
400–1300 mg/d
Porphobilinogen
None
None
Potassium (varies with 
intake)
25–100 mmol/d
25–100 meq/d
Protein
<0.15 g/d
<150 mg/d
Protein/creatinine ratio
Male: 15–68 mg/g
Male: 15–68 mg/g
Female: 10–107 mg/g
Female: 10–107 mg/g
Sediment
 Red blood cells
0–2/high-power field
 White blood cells
0–2/high-power field
 Bacteria
None
 Crystals
None
 Bladder cells
None
 Squamous cells
None
 Tubular cells
None
 Broad casts
None
 Epithelial cell casts
None
 Granular casts
None
 Hyaline casts
0–5/low-power field
  Red blood cell casts
None
 Waxy casts
None
 White cell casts
None
Sodium (varies with 
intake)
100–260 mmol/d
100–260 meq/d
Specific gravity
  After 12-h fluid 
restriction
>1.025
>1.025
  After 12-h deliberate 
water intake
≤1.003
≤1.003
(continued)
SECTION 18
1434
Laboratory Values
TABLE 220-7 URINE ANALYSIS AND RENAL FUNCTION TESTS (CONTINUED)
Reference Range
SI Units
Conventional Units
Tubular reabsorption, 
phosphorus
0.79–0.94 of filtered load
79–94% of filtered load
Urea nitrogen
214–607 mmol/d
6–17 g/d
Uric acid (normal diet)
1.49–4.76 mmol/d
250–800 mg/d
Vanillylmandelic acid 
(VMA)
<30 μmol/d
<6 mg/d
TABLE 220-8A  DIFFERENTIAL NUCLEATED CELL COUNTS OF BONE 
MARROW ASPIRATESa (SEE HPIM-18 CHAPS. 57, E17)
Observed Range (%) 95% Range (%) Mean (%)
Blast cells
0–3.2
0–3.0
1.4
Promyelocytes
3.6–13.2
3.2–12.4
7.8
Neutrophil myelocytes
4–21.4
3.7–10.0
7.6
Eosinophil myelocytes
0–5.0
0–2.8
1.3
Metamyelocytes
1–7.0
2.3–5.9
4.1
Neutrophils
 Males
21.0–45.6
21.9–42.3
32.1
 Females
29.6–46.6
28.8–45.9
37.4
Eosinophils
0.4–4.2
0.3–4.2
2.2
Eosinophils plus 
eosinophil myelocytes
0.9–7.4
0.7–6.3
3.5
Basophils
0–0.8
0–0.4
0.1
Erythroblasts
 Male
18.0–39.4
16.2–40.1
28.1
 Females
14.0–31.8
13.0–32.0
22.5
Lymphocytes
4.6–22.6
6.0–20.0
13.1
Plasma cells
0–1.4
0–1.2
0.6
Monocytes
0–3.2
0–2.6
1.3
Macrophages
0–1.8
0–1.3
0.4
M:E ratio
 Males
1.1–4.0
1.1–4.1
2.1
 Females
1.6–5.4
1.6–5.2
2.8
aBased on bone marrow aspirate from 50 healthy volunteers (30 men, 20 women).
Abbreviation: M:E, myeloid to erythroid ratio.
Source: BJ Bain: Br J Haematol 94:206, 1996.
CHAPTER 220 1435
Laboratory Values of Clinical Importance 
TABLE 220-8B BONE MARROW CELLULARITY
Age
Observed Range
95% Range
Mean
Under 10 years
59.0–95.1%
72.9–84.7%
78.8%
10–19 years
41.5–86.6%
59.2–69.4%
64.3%
20–29 years
32.0–83.7%
54.1–61.9%
58.0%
30–39 years
30.3–81.3%
41.1–54.1%
47.6%
40–49 years
16.3–75.1%
43.5–52.9%
48.2%
50–59 years
19.7–73.6%
41.2–51.4%
46.3%
60–69 years
16.3–65.7%
40.8–50.6%
45.7%
70–79 years
11.3–47.1%
22.6–35.2%
28.9%
Source: From RJ Hartsock et al: Am J Clin Pathol 1965; 43:326, 1965.
TABLE 220-9 STOOL ANALYSIS
Reference Range
SI Units
Conventional Units
Alpha-1-antitrypsin
≤540 mg/L
≤54 mg/dL
Amount
0.1–0.2 kg/d
100–200 g/24 h
Coproporphyrin
611–1832 nmol/d
400–1200 μg/24 h
Fat
 Adult
<7 g/d
 Adult on fat-free diet
<4 g/d
Fatty acids
0–21 mmol/d
0–6 g/24 h
Leukocytes
None
None
Nitrogen
<178 mmol/d
<2.5 g/24 h
pH
7.0–7.5
Potassium
14–102 mmol/L
14–102 mmol/L
Occult blood
Negative
Negative
Osmolality
280–325 mosmol/kg
280–325 mosmol/kg
Sodium
7–72 mmol/L
7–72 mmol/L
Trypsin
20–95 U/g
Urobilinogen
85–510 μmol/d
50–300 mg/24 h
Uroporphyrins
12–48 nmol/d
10–40 μg/24 h
Water
<0.75
<75%
Source: Modified from: FT Fishbach, MB Dunning III: A Manual of Laboratory and Diagnostic 
Tests, 7th ed. Philadelphia, Lippincott Williams & Wilkins, 2004.
SECTION 18
1436
Laboratory Values
� SPECIAL FUNCTION TESTS (TABLES 220-10 THROUGH 220-14)
TABLE 220-10 URINE ANALYSIS AND RENAL FUNCTION TESTS
Reference Range
SI Units
Conventional Units
Acidity, titratable
20–40 mmol/d
20–40 meq/d
Aldosterone
Normal diet: 6–25 μg/d Normal diet: 6–25 μg/d
Low-salt diet: 17–44 
μg/d
Low-salt diet: 17–44 
μg/d
High-salt diet: 0–6 
μg/d
High-salt diet: 0–6 
μg/d
Aluminum
0.19–1.11 μmol/L
5–30 μg/L
Ammonia
30–50 mmol/d
30–50 meq/d
Amylase
4–400 U/L
Amylase/creatinine clear-
ance ratio [(Clam/Clcr) ×
100]
1–5
1–5
Arsenic
0.07–0.67 μmol/d
5–50 μg/d
Bence Jones protein, urine, 
qualitative
Not applicable
None detected
Bence Jones protein, urine, 
quantitative
 Free Kappa
1.4–24.2 mg/L
0.14–2.42 mg/dL
 Free Lambda
0.2–6.7 mg/L
0.02–0.67 mg/dL
 K/L ratio
2.04–10.37
2.04–10.37
Calcium (10 meq/d or 200 
mg/d dietary calcium)
<7.5 mmol/d
<300 mg/d
Chloride
140–250 mmol/d
140–250 mmol/d
Citrate
320–1240 mg/d
320–1240 mg/d
Copper
<0.95 μmol/d
<60 μg/d
Coproporphyrins (types 
I and III)
0–20 μmol/mol 
creatinine
0–20 μmol/mol 
creatinine
Cortisol, free
55–193 nmol/d
20–70 μg/d
Creatine, as creatinine
 Female
<760 μmol/d
<100 mg/d
 Male
<380 μmol/d
<50 mg/d
Creatinine
8.8–14 mmol/d
1.0–1.6 g/d
Dopamine
392–2876 nmol/d
60–440 μg/d
Eosinophils
<100 eosinophils/mL
<100 eosinophils/mL
CHAPTER 220 1437
Laboratory Values of Clinical Importance 
TABLE 220-10 URINE ANALYSIS AND RENAL FUNCTION TESTS (CONTINUED)
Reference Range
SI Units
Conventional Units
Epinephrine 
0–109 nmol/day
0–20 μg/day
Glomerular filtration rate
>60 mL/min/1.73 m2
>60 mL/min/1.73 m2
For African Americans 
multiply the result by 
1.21
For African Americans 
multiply the result by 
1.21
Glucose (glucose oxidase 
method)
0.3–1.7 mmol/d
50–300 mg/d
5-Hydroindoleacetic acid 
[5-HIAA]
0–78.8 μmol/d
0–15 mg/d
Hydroxyproline
53–328 μmol/d
53–328 μmol/d
Iodine, spot urine
  WHO classification of 
iodine deficiency:
  Not iodine deficient
>100 μg/L
>100 μg/L
  Mild iodine deficiency
50–100 μg/L
50–100 μg/L
   Moderate iodine 
deficiency
20–49 μg/L
20–49 μg/L
   Severe iodine 
deficiency
<20 μg/L
<20 μg/L
Ketone (acetone)
Negative
Negative
17 Ketosteroids
3–12 mg/d
3–12 mg/d
Metanephrines
 Metanephrine
30–350 μg/d
30–350 μg/d
 Normetanephrine
50–650 μg/d
50–650 μg/d
Microalbumin
 Normal
0.0–0.03 g/d
0–30 mg/d
 Microalbuminuria
0.03–0.30 g/d
30–300 mg/d
 Clinical albuminuria
>0.3 g/d
>300 mg/d
Microalbumin/creatinine 
ratio
 Normal
0–3.4 g/mol creatinine
0–30 μg/mg creatinine
 Microalbuminuria
3.4–34 g/mol 
creatinine
30–300 μg/mg 
creatinine
 Clinical albuminuria
>34 g/mol creatinine
>300 μg/mg creatinine
β2-Microglobulin
0–160 μg/L
0–160 μg/L
Norepinephrine
89–473 nmol/d
15–80 μg/d
(continued)
SECTION 18
1438
Laboratory Values
TABLE 220-10 URINE ANALYSIS AND RENAL FUNCTION TESTS (CONTINUED)
Reference Range
SI Units
Conventional Units
N-telopeptide (cross-
linked), NTx
 Female, premenopausal
17–94 nmol BCE/mmol 
creatinine
17–94 nmol BCE/
mmol creatinine
 Female, postmenopausal 26–124 nmol BCE/
mmol creatinine
26–124 nmol BCE/
mmol creatinine
 Male
21–83 nmol BCE/mmol 
creatinine
21–83 nmol BCE/
mmol creatinine
  BCE = bone collagen 
equivalent
Osmolality
100-800 mosm/kg
100-800 mosm/kg
Oxalate
 Male
80–500 μmol/d
7–44 mg/d
 Female
45–350 μmol/d
4–31 mg/d
pH
5.0–9.0
5.0–9.0
Phosphate (phosphorus) 
(varies with intake)
12.9–42.0 mmol/d
400–1300 mg/d
Porphobilinogen
None
None
Potassium (varies with 
intake)
25–100 mmol/d
25–100 meq/d
Protein
<0.15 g/d
<150 mg/d
Protein/creatinine ratio
Male: 15–68 mg/g
Male: 15–68 mg/g
Female: 10–107 mg/g
Female: 10–107 mg/g
Sediment
 Red blood cells
0–2/high-power field
 White blood cells
0–2/high-power field
 Bacteria
None
 Crystals
None
 Bladder cells
None
 Squamous cells
None
 Tubular cells
None
 Broad casts
None
 Epithelial cell casts
None
 Granular casts
None
 Hyaline casts
0–5/low-power field
 Red blood cell casts
None
 Waxy casts
None
CHAPTER 220 1439
Laboratory Values of Clinical Importance 
TABLE 220-10 URINE ANALYSIS AND RENAL FUNCTION TESTS (CONTINUED)
Reference Range
SI Units
Conventional Units
 White cell casts
None
Sodium (varies with intake)
100–260 mmol/d
100–260 meq/d
Specific gravity
  After 12-h fluid 
restriction
>1.025
>1.025
  After 12-h deliberate 
water intake
≤1.003
≤1.003
Tubular reabsorption, 
phosphorus
0.79–0.94 of filtered 
load
79–94% of filtered 
load
Urea nitrogen
214–607 mmol/d
6–17 g/d
Uric acid (normal diet)
1.49–4.76 mmol/d
250–800 mg/d
Vanillylmandelic acid (VMA) <30 μmol/d
<6 mg/d
SECTION 18
1440
Laboratory Values
TABLE 220-11 CIRCULATORY FUNCTION TESTS
Results: Reference Range
Test
SI Units (Range)
Conventional Units 
(Range)
Arteriovenous oxygen difference 30–50 mL/L
30–50 mL/L
Cardiac output (Fick)
2.5–3.6 L/m2 of body 
surface area per min
2.5–3.6 L/m2 of body 
surface area per min
Contractility indexes
  Max. left ventricular dp/dt
(dp/dt)
220 kPa/s (176–250 
kPa/s)
1650 mmHg/s 
(1320–1880 mmHg/s)
DP when DP = 5.3 kPa
(37.6 ± 12.2)/s
(37.6 ± 12.2)/s
(40 mmHg) (DP, developed 
LV pressure)
3.32 ± 0.84 end-
diastolic volumes per 
second
3.32 ± 0.84 end-
diastolic volumes per 
second
  Mean normalized systolic 
ejection rate (angiography)
1.83 ± 0.56 circum-
ferences per second
1.83 ± 0.56 circum-
ferences per second
  Mean velocity of circum-
ferential fiber shortening 
(angiography)
Ejection fraction: stroke 
volume/end-diastolic volume 
(SV/EDV)
0.67 ± 0.08 
(0.55–0.78)
0.67 ± 0.08 
(0.55–0.78)
End-diastolic volume
70 ± 20.0 mL/m2
(60–88 mL/m2)
70 ± 20.0 mL/m2
(60–88 mL/m2)
End-systolic volume
25 ± 5.0 mL/m2
(20–33 mL/m2)
25 ± 5.0 mL/m2
(20–33 mL/m2)
Left ventricular work
 Stroke work index
50 ± 20.0 (g·m)/m2
(30–110)
50 ± 20.0 (g·m)/m2
(30–110)
  Left ventricular minute 
work index
1.8–6.6 [(kg·m)/m2]/
min
1.8–6.6 [(kg·m)/m2]/
min
 Oxygen consumption index
110–150 mL
110–150 mL
Maximum oxygen uptake
35 mL/min (20–60 
mL/min)
35 mL/min (20–60 
mL/min)
Pulmonary vascular resistance 2–12 (kPa·s)/L
20–130 (dyn·s)/cm5
Systemic vascular resistance
77–150 (kPa·s)/L
770–1600 (dyn·s)/cm5
Source: E Braunwald et al: Heart Disease, 6th ed. Philadelphia, W.B. Saunders Co., 2001.
CHAPTER 220 1441
Laboratory Values of Clinical Importance 
TABLE 220-12 GASTROINTESTINAL TESTS
Results
Test
SI Units
Conventional Units
Absorption tests
D-Xylose: after overnight 
fast, 25 g xylose given 
in oral aqueous solution
   Urine, collected for 
following 5 h
25% of ingested dose
25% of ingested dose
  Serum, 2 h after dose
2.0–3.5 mmol/L
30–52 mg/dL
  Vitamin A: a fasting 
blood specimen is 
obtained and 200,000 
units of vitamin A in oil 
is given orally
Serum level should rise 
to twice fasting level 
in 3–5 h
Serum level should 
rise to twice fasting 
level in 3–5 h
 Plasma
>3.6 (±1.1) μg/mL at 
90 min
 Urine
>50% recovered in 6 h >50% recovered in 6 h
Gastric juice
 Volume
  24 h
2–3 L
2–3 L
  Nocturnal
600–700 mL
600–700 mL
  Basal, fasting
30–70 mL/h
30–70 mL/h
 Reaction
  pH
1.6–1.8
1.6–1.8
   Titratable acidity 
of fasting juice
4–9 μmol/s
15–35 meq/h
Acid output
 Basal
  Females (mean ± 1 SD) 0.6 ± 0.5 μmol/s
2.0 ± 1.8 meq/h
  Males (mean ± 1 SD)
0.8 ± 0.6 μmol/s
3.0 ± 2.0 meq/h
  Maximal (after SC his-
tamine acid phosphate, 
0.004 mg/kg body 
weight, and preceded by 
50 mg promethazine, or 
after betazole, 1.7 mg/
kg body weight, or 
pentagastrin, 6 μg/kg 
body weight)
  Females (mean ± 1 SD) 4.4 ± 1.4 μmol/s
16 ± 5 meq/h
  Males (mean ± 1 SD)
6.4 ± 1.4 μmol/s
23 ± 5 meq/h
(continued)
SECTION 18
1442
Laboratory Values
TABLE 220-12 GASTROINTESTINAL TESTS (CONTINUED)
Results
Test
SI Units
Conventional Units
  Basal acid output/maxi-
mal acid output ratio
≤0.6
≤0.6
Gastrin, serum
0–200 μg/L
0–200 pg/mL
Secretin test (pancreatic 
exocrine function): 1 unit/kg 
body weight, IV
  Volume (pancreatic 
juice) in 80 min
>2.0 mL/kg
>2.0 mL/kg
  Bicarbonate 
concentration
>80 mmol/L
>80 meq/L
  Bicarbonate output in 
30 min
>10 mmol
>10 meq
TABLE 220-13 NORMAL ECHOCARDIOGRAPHIC REFERENCE LIMITS AND PARTITION VALUES IN ADULTS
Women 
Reference Range
Mildly
Abnormal
Moderately 
Abnormal
Severely 
Abnormal
Men Reference 
Range
Mildly
Abnormal
Moderately 
Abnormal
Severely 
Abnormal
Left ventricular dimensions
 Septal thickness, cm
0.6–0.9
1.0–1.2
1.3–1.5
≥1.6
0.6–1.0
1.1–1.3
1.4–1.6
≥1.7
 Posterior wall thickness, cm
0.6–0.9
1.0–1.2
1.3–1.5
≥1.6
0.6–1.0
1.1–1.3
1.4–1.6
≥1.7
 Diastolic diameter, cm
3.9–5.3
5.4–5.7
5.8–6.1
≥6.2
4.2–5.9
6.0–6.3
6.4–6.8
≥6.9
 Diastolic diameter/BSA, cm/m2
2.4–3.2
3.3–3.4
3.5–3.7
≥3.8
2.2–3.1
3.2–3.4
3.5–3.6
≥3.7
 Diastolic diameter/height, cm/m
2.5–3.2
3.3–3.4
3.5–3.6
≥3.7
2.4–3.3
3.4–3.5
3.6–3.7
≥3.8
Left ventricular volumes
 Diastolic, mL
56–104
105–117
118–130
≥131
67–155
156–178
179–201
≥202
 Diastolic/BSA, mL/m2
35–75
76–86
87–96
≥97
35–75
76–86
87–96
≥97
 Systolic, mL
19–49
50–59
60–69
≥70
22–58
59–70
71–82
≥83
 Systolic/BSA, mL/m2
12–30
31–36
37–42
≥43
12–30
31–36
37–42
≥43
Left ventricular mass, 2D method
 Mass, g
66–150
151–171
172–182
≥183
96–200
201–227
228–254
≥255
 Mass/BSA, g/m2
44–88
89–100
101–112
≥113
50–102
103–116
117–130
≥131
Left ventricular function
  Endocardial fractional shorten-
ing (%)
27–45
22–26
17–21
≤16
25–43
20–24
15–19
≤14
(continued)
1443
TABLE 220-13 NORMAL ECHOCARDIOGRAPHIC REFERENCE LIMITS AND PARTITION VALUES IN ADULTS (CONTINUED)
Women 
Reference Range
Mildly
Abnormal
Moderately 
Abnormal
Severely 
Abnormal
Men Reference 
Range
Mildly
Abnormal
Moderately 
Abnormal
Severely 
Abnormal
 Midwall fractional shortening (%)
15–23
13–14
11–12
≤10
14–22
12–13
10–11
≤9
 Ejection fraction, 2D method (%)
≥55
45–54
30–44
≤29
≥55
45–54
30–44
≤29
Right heart dimensions (cm)
 Basal RV diameter
2.0–2.8
2.9–3.3
3.4–3.8
≥3.9
2.0–2.8
2.9–3.3
3.4–3.8
≥3.9
 Mid-RV diameter
2.7–3.3
3.4–3.7
3.8–4.1
≥4.2
2.7–3.3
3.4–3.7
3.8–4.1
≥4.2
 Base-to-apex length
7.1–7.9
8.0–8.5
8.6–9.1
≥9.2
7.1–7.9
8.0–8.5
8.6–9.1
≥9.2
 RVOT diameter above aortic valve
2.5–2.9
3.0–3.2
3.3–3.5
≥3.6
2.5–2.9
3.0–3.2
3.3–3.5
≥3.6
  RVOT diameter above pulmonic 
valve
1.7–2.3
2.4–2.7
2.8–3.1
≥3.2
1.7–2.3
2.4–2.7
2.8–3.1
≥3.2
  Pulmonary artery diameter below 
pulmonic valve
1.5–2.1
2.2–2.5
2.6–2.9
≥3.0
1.5–2.1
2.2–2.5
2.6–2.9
≥3.0
Right ventricular size and function in 
4-chamber view
 Diastolic area, cm2
11–28
29–32
33–37
≥38
11–28
29–32
33–37
≥38
 Systolic area, cm2
7.5–16
17–19
20–22
≥23
7.5–16
17–19
20–22
≥23
 Fractional area change, %
32–60
25–31
18–24
≤17
32–60
25–31
18–24
≤17
1444
Atrial sizes
 LA diameter, cm
2.7–3.8
3.9–4.2
4.3–4.6
≥4.7
3.0–4.0
4.1–4.6
4.7–5.2
≥5.3
 LA diameter/BSA, cm/m2
1.5–2.3
2.4–2.6
2.7–2.9
≥3.0
1.5–2.3
2.4–2.6
2.7–2.9
≥3.0
 RA minor axis, cm
2.9–4.5
4.6–4.9
5.0–5.4
≥5.5
2.9–4.5
4.6–4.9
5.0–5.4
≥5.5
 RA minor axis/BSA, cm/m2
1.7–2.5
2.6–2.8
2.9–3.1
≥3.2
1.7–2.5
2.6–2.8
2.9–3.1
≥3.2
 LA area, cm2
<20
20–30
30–40
≥41
<20
20–30
30–40
≥41
 LA volume, mL
22–52
53–62
63–72
≥73
18–58
59–68
69–78
≥79
 LA volume/BSA, mL/m2
16–28
29–33
34–39
≥40
16–28
29–33
34–39
≥40
Aortic stenosis, classification of 
severity
 Aortic jet velocity, m/s
2.6–2.9
3.0–4.0
>4.0
2.6–2.9
3.0–4.0
>4.0
 Mean gradient, mmHg
<20
20–40
>40
<20
20–40
>40
 Valve area, cm2
>1.5
1.0–1.5
<1.0
>1.5
1.0–1.5
<1.0
 Indexed valve area, cm2/m2
>0.85
0.60–0.85
<0.6
>0.85
0.60–0.85
<0.6
 Velocity ratio
>0.50
0.25–0.50
<0.25
>0.50
0.25–0.50
<0.25
Mitral stenosis, classification of 
severity
 Valve area, cm2
>1.5
1.0–1.5
<1.0
>1.5
1.0–1.5
<1.0
 Mean gradient, mmHg
<5
5–10
>10
<5
5–10
>10
 Pulmonary artery pressure, mmHg
<30
30–50
>50
<30
30–50
>50
(continued)
1445
TABLE 220-13 NORMAL ECHOCARDIOGRAPHIC REFERENCE LIMITS AND PARTITION VALUES IN ADULTS (CONTINUED)
Women 
Reference Range
Mildly
Abnormal
Moderately 
Abnormal
Severely 
Abnormal
Men Reference 
Range
Mildly
Abnormal
Moderately 
Abnormal
Severely 
Abnormal
Aortic regurgitation, indices of 
severity
 Vena contracta width, cm
<0.30
0.30–0.60
≥0.60
<0.30
0.30–0.60
≥0.60
 Jet width/LVOT width, %
<25
25–64
≥65
<25
25–64
≥65
 Jet CSA/LVOT CSA, %
<5
5–59
≥60
<5
5–59
≥60
 Regurgitant volume, mL/beat
<30
30–59
≥60
<30
30–59
≥60
 Regurgitant fraction, %
<30
30–49
≥50
<30
30–49
≥50
  Effective regurgitant orifice 
area, cm2
<0.10
0.10–0.29
≥0.30
<0.10
0.10–0.29
≥0.30
Mitral regurgitation, indices of severity
 Vena contracta width, cm
<0.30
0.30–0.69
≥0.70
<0.30
0.30–0.69
≥0.70
 Regurgitant volume, mL/beat
<30
30–59
≥60
<30
30–59
≥60
 Regurgitant fraction, %
<30
30–49
≥50
<30
30–49
≥50
  Effective regurgitant orifice 
area, cm2
<0.20
0.20–0.39
≥0.40
<0.20
0.20–0.39
≥0.40
Abbreviations: BSA, body surface area; CSA, cross-sectional area; LA, left atrium; LVOT, left ventricular outflow tract; RA, right atrium; RV, right ventricle; RVOT, right ventricular 
outflow tract; 2D, 2-dimensional.
Source: Values adapted from: American Society of Echocardiography, Guidelines and Standards. www.asecho.org/i4a/pages/index.cfm?pageid=3317. Accessed Feb 23, 2010.
1446
TABLE 220-14 SUMMARY OF VALUES USEFUL IN PULMONARY PHYSIOLOGY
Typical Values
Symbol
Man Age 40, 75 kg, 175 cm Tall
Woman Age 40, 60 kg, 160 cm Tall
Pulmonary mechanics
Spirometry—volume-time curves
 Forced vital capacity
FVC
5.0 L
3.4 L
 Forced expiratory volume in 1 s
FEV1
4.0 L
2.8 L
 FEV1/FVC
FEV1%
80%
78%
 Maximal midexpiratory flow rate
MMEF (FEF 25–75)
4.1 L/s
3.2 L/s
 Maximal expiratory flow rate
MEFR (FEF 200–1200)
9.0 L/s
6.1 L/s
Spirometry—flow-volume curves
  Maximal expiratory flow at 50% of expired 
vital capacity
Vmax 50 (FEF 50%)
5.0 L/s
4.0 L/s
  Maximal expiratory flow at 75% of expired 
vital capacity
Vmax 75 (FEF 75%)
2.1 L/s
2.0 L/s
Resistance to airflow
 Pulmonary resistance
RL (RL)
<3.0 (cmH2O/s)/L
 Airway resistance
Raw
<2.5 (cmH2O/s)/L
 Specific conductance
SGaw
>0.13 cmH2O/s
(continued)
1447
TABLE 220-14 SUMMARY OF VALUES USEFUL IN PULMONARY PHYSIOLOGY (CONTINUED)
Typical Values
Symbol
Man Age 40, 75 kg, 175 cm Tall
Woman Age 40, 60 kg, 160 cm Tall
Pulmonary compliance
 Static recoil pressure at total lung capacity
Pst TLC
25 ± 5 cmH2O
 Compliance of lungs (static)
CL
0.2 L cmH2O
 Compliance of lungs and thorax
C(L + T)
0.1 L cmH2O
  Dynamic compliance of 20 breaths per minute C dyn 20
0.25 ± 0.05 L/cmH2O
Maximal static respiratory pressures
 Maximal inspiratory pressure
MIP
>110 cmH2O
>70 cmH2O
 Maximal expiratory pressure
MEP
>200 cmH2O
>140 cmH2O
Lung volumes
Total lung capacity
TLC
6.9 L
4.9 L
Functional residual capacity
FRC
3.3 L
2.6 L
Residual volume
RV
1.9 L
1.5 L
Inspiratory capacity
IC
3.7 L
2.3 L
Expiratory reserve volume
ERV
1.4 L
1.1 L
Vital capacity
VC
5.0 L
3.4 L
1448
Gas exchange (sea level)
Arterial O2 tension
Pao2
12.7 ± 0.7 kPa (95 ± 5 mmHg)
Arterial CO2 tension
Paco2
5.3 ± 0.3 kPa (40 ± 2 mmHg)
Arterial O2 saturation
Sao2
0.97 ± 0.02 (97 ± 2%)
Arterial blood pH
pH
7.40 ± 0.02
Arterial bicarbonate
HCO3
–
24 + 2 meq/L
Base excess
BE
0 ± 2 meq/L
Diffusing capacity for carbon monoxide (single 
breath)
DLCO
37 mL CO/min/mmHg 27 mL CO/min/mmHg
Dead space volume
VD
2 mL/kg body wt
Physiologic dead space; dead space-tidal volume 
ratio
 Rest
VD/VT
≤35% VT
 Exercise
≤20% VT
Alveolar-arterial difference for O2
P(A – a)AO2
≤2.7 kPa ≤20 kPa (≤24 mmHg)
Source: Based on: AH Morris et al: Clinical Pulmonary Function Testing. A Manual of Uniform Laboratory Procedures, 2nd ed. Salt Lake City, Utah, Intermountain Thoracic 
Society, 1984.
1449
SECTION 18
1450
Laboratory Values
� MISCELLANEOUS (TABLE 220-15)
TABLE 220-15 BODY FLUIDS AND OTHER MASS DATA
Reference Range
SI Units
Conventional Units
Ascitic fluid: See Chap. 49
Body fluid
  Total volume (lean) of 
body weight
50% (in obese) to 70%
 Intracellular
30–40% of body weight
 Extracellular
20–30% of body weight
Blood
 Total volume
  Males
69 mL/kg body weight
  Females
65 mL/kg body weight
 Plasma volume
  Males
39 mL/kg body weight
  Females
40 mL/kg body weight
Red blood cell volume
 Males
30 mL/kg body weight
1.15–1.21 L/m2 of 
body surface area
 Females
25 mL/kg body weight
0.95–1.00 L/m2 of 
body surface area
Body mass index
18.5–24.9 kg/m2
18.5–24.9 kg/m2
A
abacavir, for HIV/AIDS, 736t, 741
abatacept, for rheumatoid arthritis, 1074
abciximab, for thrombotic disorders, 394
abdominal angina, 1019
abdominal infection, actinomycosis, 
647–648
abdominal pain, 239–244
acute, catastrophic, 242–244
approach to, 240–242
causes of, 240t
features of, 241
abdominal radiography, 26, 28
in pancreatitis, 1028, 1030
abdominal wall disorders, pain in, 240t
abdominoperineal resection, for anal 
cancer, 457
ABG. See arterial blood gases
Abiotrophia infection, 599
abiraterone, for prostate cancer, 472
abortion, 1157
abscess. See also specific sites
E. coli, 616
epidural, S. aureus, 586
intraabdominal, 534–536
in leprosy, 660
nocardiosis, 645–646
peritonsillar, 642
streptococcal, 598
ABU. See asymptomatic bacteriuria
ABVD regimen, for Hodgkin’s disease, 428
acamprosate, for alcoholic rehabilitation, 
1340
acanthocytes, 292, 375
acarbose, for diabetes mellitus, 1142t
accelerated idioventricular rhythm (AIVR)
clinical and ECG features of, 871t
in myocardial infarction, 849
accessory nerve, 1189
disorders of, 1249
accident prevention, 1346t–1347t
ACE inhibitors. See angiotensin-
converting enzyme inhibitors
acebutolol poisoning, 170t
acetaminophen
for back pain, 303
for fever, 211
for migraine, 310t–312t
for osteoarthritis, 1091
for pain, 43, 44t–45t
for tension headache, 314
toxicity of, 159, 1037
acetazolamide
for AMS, 156, 156t
for glaucoma, 345
for periodic paralysis, 1314
N-acetylcysteine, for acetaminophen 
overdose, 1038
acetylsalicylic acid, for pain, 44t–45t
achalasia, 251
acid maltase deficiency, 1312
acid-base balance, 4
acid-base disorders, 17–25
metabolic acidosis, 20–23, 21t
metabolic alkalosis, 23–24, 23f
mixed disorders, 25
nomogram for, 19f
respiratory acidosis, 24
respiratory alkalosis, 25
acid-fast bacilli, 649
acid-fast stains, 485
acidosis, 17
Acinetobacter infection, 619–620
acitretin, for psoriasis, 367
ACMV. See assist-control mandatory 
ventilation
acne, 371
drug-induced, 1382t
acne rosacea, 364f, 371
acne vulgaris, 364f, 371
acoustic neuroma, 322, 1246
acrodermatitis chronica atrophicans, 665
acromegaly, 1109–1110
paraneoplastic, 479, 479t
ACS. See acute coronary syndrome
ACTH. See adrenocorticotropic hormone
actinic keratosis, 364f
Actinobacillus actinomycetemcomitans 
infection. See HACEK group 
infection
actinomycetoma, 645–646, 647t
actinomycosis, 646–648
action tremor, 1221
activated charcoal
for erythropoietic porphyria, 1184
for heavy metal poisoning, 184t
for methylxanthine poisoning, 167t
for paralytic shellfish poisoning, 147
for poisoning, 165
for toxic and drug-induced hepatitis, 1038
activated protein C therapy
for Ebola and Marburg virus infections, 728
for sepsis/septic shock, 76
acupuncture, for chronic back pain, 304
acute, catastrophic abdominal pain, 242–244
approach to, 242–243
diagnosis of, 243
treatment for, 244
INDEX
1451
1452
INDEX
acute coronary syndrome (ACS), 855, 856f
acute disseminated encephalomyelitis 
(ADEM), 1270
acute intermittent porphyria (AIP), 
1182–1183, 1241
acute interstitial nephritis (AIN), 
980–981, 982t
acute interstitial pneumonia (AIP), 935
acute kidney injury (AKI), 980
acute low back pain (ALBP), 300t
acute lymphoid leukemia/lymphoma 
(ALL), 415t, 417f, 422–423
acute mountain sickness (AMS), 
155–157, 156t
acute myeloid leukemia (AML), 403–406
classification of, 404t–405t
treatment for, 406, 407f
acute otitis media (AOM), 350
acute promyelocytic leukemia, 403, 404t
acute radiation sickness (ARS), 205
clinical features of, 205–206
treatment of casualties of, 206–207, 206f
acute respiratory distress syndrome 
(ARDS), 80–83
clinical course and pathophysiology 
of, 80–81
definition and etiology of, 80
outcomes of, 82–83
treatment of, 81–82, 82f
acute retroviral syndrome, 730, 
732–733, 733t
acute stress disorder, 1322
acute uric acid nephropathy, 1092
acyclovir
for Bell’s palsy, 1246
for Epstein-Barr virus infections, 699
for herpes keratitis, 345
for herpes zoster infections, 570t
for HSCT patients, 517
for HSV infections, 567, 570t, 688, 
689t–690t
for viral encephalitis, 1279–1280
for viral esophagitis, 252
for viral meningitis, 1278
for VZV infection, 692
AD. See Alzheimer’s disease
adalimumab
for ankylosing spondylitis, 1083
for inflammatory bowel disease, 
1015, 1096
for psoriasis, 367
for psoriatic arthritis, 1087
for rheumatoid arthritis, 1074
adamantane agents, for influenza, 701, 702t
adaptive immune system, deficiencies of, 
1066–1070, 1067t
Addison’s disease, 1129–1131
drug-induced, 1380t
adefovir, for chronic hepatitis B, 1040, 
1041t–1043t
ADEM. See acute disseminated 
encephalomyelitis
adenoma
adrenal, 1127–1128
colonic, 452
gastric, 450
hepatocellular, 457
pituitary. See pituitary adenoma
small-bowel, 451
thyroid, 1124–1126, 1125f
adenosine
for arrhythmias, 876t
for tachyarrhythmias, 869t
for Wolff-Parkinson-White 
syndrome, 877
adenosine deaminase deficiency, 1068
adenovirus, 344
adenovirus infection, 704t, 707–708
adenylate kinase 2 deficiency, 1069
ADH. See antidiuretic hormone
admission orders, 2–3
ADMIT VITALS AND PHYSICAL EXAM 
(admissions mnemonic), 2
adnexal mass, 465
ADPKD. See autosomal dominant 
polycystic kidney disease
adrenal adenoma, 1127–1128
adrenal carcinoma, 1127–1128
adrenal gland disease, 1126–1133
hyperfunction, 1127–1129
hypofunction, 1129–1131
adrenal insufficiency
paraneoplastic, 136
primary, 1129
secondary, 1129
adrenal mass, incidental, 1131, 1132f
adrenalectomy, for prostate cancer, 472
adrenocorticotropic hormone (ACTH), 
1105, 1106f
deficiency of, 1107t, 1111, 1112t, 1129
ectopic ACTH syndrome, 477, 478t, 
479–480
hypersecretion of, 1107t, 1127–1128
therapy for inflammatory bowel disease, 
1015
adrenomyeloneuropathy, 1256–1257
adult inclusion conjunctivitis (AIC), 
682–683
adult T cell leukemia/lymphoma 
(ATL), 423
advance directives, 55
advanced sleep phase syndrome, 342
adverse drug reactions, 1379–1391, 
1379t–1391t. See also drug-
induced illness
AED. See automated external defibrillator
Aeromonas infection, 620
affective disorder, major, 1315–1319
aflatoxin, hepatocellular carcinoma 
with, 457
INDEX
1453
African tick-bite fever, 671t, 674
agammaglobulinemia, 1069
agglutination, 764
Aggregatibacter actinomycetemcomitans 
infection, 613–614, 614t
Aggregatibacter aphrophilus infection, 
613–614, 614t
aggressive lymphoma, 415t, 418, 420–421
agitation, in terminally ill patient, 63t
AGMA inducers. See anion-gap metabolic 
acidosis inducers
agoraphobia, 1320, 1322
agranulocytosis, drug-induced, 
1383t–1384t
AIC. See adult inclusion conjunctivitis
AIDS. See also HIV/AIDS
definition of, 728
AIN. See acute interstitial nephritis
AIP. See acute intermittent porphyria; 
acute interstitial pneumonia
airborne precautions, 506
airway obstruction
drug-induced, 1386t
dyspnea in, 226–227
AIVR. See accelerated idioventricular 
rhythm
AKI. See acute kidney injury
alanine aminotransferase (ALT), 270, 272t
albendazole
for ascariasis, 781
for echinococcosis, 790
for enterobiasis, 783
for hookworm infection, 781
for larva migrans, 780
for lymphatic filariasis, 784
for strongyloidiasis, 782
for taeniasis solium and 
cysticercosis, 788
for trichinellosis, 779
ALBP. See acute low back pain
albumin
intravenous, for hepatorenal syndrome, 
278
serum, in liver disease, 273, 273t
serum-ascites gradient, 276f
urine, 290
albuterol
for anaphylaxis, 139
for COPD, 918–919
for hyperkalemia, 18t
poisoning, 166t
alcohol abuse, 1336
alcohol dependence, 1336
alcohol intoxication, 1337
Alcohol Use Disorder Screening Test 
(AUDIT), 1337, 1338t
alcohol withdrawal, 1337, 1339
alcoholic ketoacidosis, 20, 21t
alcoholic liver disease, 1053–1054
alcoholic polyneuropathy, 1241
alcoholism, 1336–1340, 1346t–1347t
chronic, 1030
dementia in, 1213, 1214t
metabolic consequences of, 1053–1054
treatment of
acute withdrawal, 1339
drug therapy, 1340
recovery and sobriety, 1339–1340
relapse prevention, 1340
alefacept
for psoriasis, 367
for psoriatic arthritis, 1087
alemtuzumab, for CLL, 419
alendronate, for osteoporosis, 1169
alkali therapy, for nephrolithiasis, 1000t
alkaline diuresis, for poisoning, 179t
alkaline phosphatase, 270, 273t, 1028
alkaline-encrusted cystitis, 602
alkalosis, 17
alkylating agents, toxicities of, 398t
ALL. See acute lymphoid leukemia/
lymphoma
allergic bronchopulmonary aspergillosis, 
748, 750t
allergic disease, immediate type 
hypersensitivity, 1061–1066
allergy
anaphylaxis, 138–139
to insect sting, 150–151
leukocytosis in, 386
allodynia, 40, 1241
alloimmunization, 52
allopurinol
for CML, 409
for gout, 1093
for nephrolithiasis, 1000t
allylamines, for dermatophyte 
infections, 370
almotriptan, for migraine, 310t, 312t
alopecia, drug-induced, 398t, 1382t
alosetron, for irritable bowel syndrome, 
1017t, 1018
alpha radiation, 204
alpha-adrenergic agonists, for glaucoma, 345
alpha-adrenergic antagonists, for 
vasospastic disorders, 892
alpha-tocopherol, for lung cancer 
prevention, 1370
alphavirus infection, 725
alprazolam
dosage and action of, 1328t
poisoning, 174t
alprostadil injection, for erectile 
dysfunction, 1150
ALS. See amyotrophic lateral sclerosis
ALT. See alanine aminotransferase
alteplase, for thrombotic disorders, 394
altitude illness, 155–159
AMS, 155–157
DCS, 158–159 
1454
INDEX
altitude illness (Cont.):
HACE, 155–157
HAPE, 157
preexisting medical conditions with, 158
treatment of, 156t
aluminum phosphate binders, for 
hyperphosphatemia, 1166
alveolar hemorrhage syndrome, 935, 938
alveolar ventilation, 902
alveolar-arterial oxygen gradient, 902
Alzheimer’s disease (AD), 1213, 1214t, 
1215, 1217–1219
differentiation of major dementias, 1216t
familial, 1213
in women, 1375
amantadine
for influenza, 701, 702t
for neuroleptic malignant syndrome, 214
for Parkinson’s disease, 1227
poisoning, 168t, 182t–183t
amaurosis fugax, 94, 326
AmB, for leishmaniasis, 773
ambrisentan, for pulmonary 
hypertension, 898
amebiasis, 495t
diarrhea, 548–549
amenorrhea, 1150–1153, 1151f
primary, 1150
secondary, 1150
amikacin
for enteric GNB infection, 620
for extraintestinal E. coli infection, 616
for Klebsiella infections, 618
for nocardiosis, 646
for nontuberculous mycobacterial 
infections, 663
for P. aeruginosa infection, 624t
for pneumonia, 924t, 926t
for Proteus infection, 619
amiloride
for diabetes insipidus, 9
for edema, 238t
for hyperaldosteronism, 1129
for hypertension, 837t
for Liddle’s syndrome, 24
aminoglutethimide, for prostate 
cancer, 472
aminoglycoside, for otitis externa, 359
aminoglycosides
adverse reactions to, 501t
for Aeromonas infection, 620
for brucellosis, 629
for enterococcal infections, 600
for HACEK group infections, 614t
for infective endocarditis, 526t–528t, 
528–530
mechanism of/resistance to, 496, 498t
for nontuberculous mycobacterial 
infections, 663
for P. aeruginosa infections, 624t–625t
aminophylline, for anaphylaxis, 139
aminosalicylates, for inflammatory bowel 
disease, 1013–1015
5-aminosalicylic acid (5-ASA), for 
inflammatory bowel disease, 1013
aminotransferases, 270, 272t
amiodarone
for arrhythmias, 875t
for dilated cardiomyopathy, 825
for hypertrophic cardiomyopathy, 827
for tachyarrhythmias, 870t–871t
for ventricular tachycardia, 848
amiodarone-induced thyrotoxicosis, 1123
amitriptyline
for ciguatera poisoning, 147
dosage and adverse effects of, 168t, 
172t, 1326t
for irritable bowel syndrome, 1018
for migraine prevention, 313t
for multiple sclerosis, 1269
for pain, 44t–45t
for postherpetic neuralgia, 692
for tension headache, 314
AML. See acute myeloid leukemia
amlodipine, for pulmonary 
hypertension, 898
ammonia, blood, in liver disease, 274
amodiaquine, for malaria, 766t
amoxapine, 1325, 1327t
amoxicillin
for anthrax, 195t
during COPD exacerbations, 919
for H. pylori eradication, 1008t
for Lyme borreliosis, 665–666
for otitis media, 356t
for pharyngitis, 357t
for pneumococcal infections, 582
for pneumonia, 924t
for sinusitis, 356t
amoxicillin-clavulanate
for animal bite infections, 141t, 570t
for H. influenzae infection, 610
for M. catarrhalis, 613
for nocardiosis, 646
for otitis media, 356t
for pneumonia, 924t
for sinusitis, 356t
amphetamine poisoning, 166t, 182t
amphotericin B, 744
for aspergillosis, 750t
for blastomycosis, 757
for candidiasis, 253, 747
for coccidioidomycosis, 756
for cryptococcosis, 751
for febrile neutropenia in cancer 
patient, 137
for fusariosis, 759
for histoplasmosis, 755t
for leishmaniasis, 773
for Malassezia infection, 757
for mucormycosis, 753
for paracoccidioidomycosis, 758
INDEX
1455
for penicilliosis, 758
for scedosporiosis, 759
for sporotrichosis, 758
ampicillin
for actinomycosis, 648
for bacterial meningitis, 1275t, 1276t
for clostridial infection, 641t
for diverticulitis, 1018
for enterococcal infections, 599–600
for Epstein-Barr virus, 697
for extraintestinal E. coli infection, 616
for H. influenzae infection, 610
for HACEK group infections, 614t
for infective endocarditis, 527t, 529
for Klebsiella infections, 618
for listerial infections, 608
for M. catarrhalis, 613
for mixed anaerobic infections, 643
for necrotizing fasciitis, 571t
for osteomyelitis, 578t
for peritonitis, 533
for pneumococcal infections, 582
for pneumonia, 924t
for streptococcal infection, 597
for urinary tract infections, 988
ampicillin-clavulanate, for diverticulitis, 1018
ampicillin-sulbactam
for animal bite infections, 141t, 570t
for cellulitis, 570t
for cholecystitis, 1024
for epiglottitis, 362
for HACEK group infections, 614t
for human bite infections, 141t
for infective endocarditis, 528t
for myositis/myonecrosis, 574
for pneumonia, 926t
for snakebite, 142t
amrinone
for beta blocker poisoning, 170t
for calcium channel blocker 
poisoning, 170t
AMS. See acute mountain sickness
amyl nitrite, for cytochrome oxidase 
inhibitor poisoning, 176t
amylase, serum, 1028
amylase-creatinine clearance ratio, 
urinary, 1028
amyloid angiopathy, 96t
amyloidosis, 1102–1104
AA (secondary), 1103–1104, 1103f
AL (primary), 983, 983t, 1102–1104, 1103f
autonomic involvement in, 1241
clinical features of, 1103
diagnosis of, 1103, 1104f
familial, 1103–1104, 1103f
glomerular disease in, 977t
treatment of, 1103–1104
amyotrophic lateral sclerosis (ALS), 
1231–1235
familial, 1231
treatment of, 1234–1235
ANA. See antinuclear antibodies
anaerobic bacteria, 635
anaerobic infection, 635–644
bone and joint, 643
clostridial infection, 635–640, 641t
botulism, 637–639
food poisoning, 539
tetanus, 635–637
mixed, 640–643, 643t
of mouth, head, and neck, 642
pelvic, 642
skin/soft tissue, 642
specimen collection and transport, 492t
anagrelide, for essential 
thrombocytosis, 414
anakinra, for rheumatoid arthritis, 1074
anal cancer, 457
anal condylomas, 1020
anal fissure, 1020
analgesia, 40
analgesics, 43, 44t–45t
analgesic nephropathy, 982
anaphylaxis, 138–139
drug-induced, 1379t
prevention of, 139
related to hymenoptera sting, 151
anaplasmosis, 148
human granulocytotropic, 672t, 
677–678
anaplastic large cell lymphoma, 416, 417f
anastrozole
for breast cancer, 445–446
toxicity of, 399t
ANCA. See antineutrophil cytoplasmic 
autoantibodies
Ancylostoma braziliense infection, 780
Ancylostoma duodenale infection. See 
hookworm infection
androgens, adrenal, 1126
androgen abuse, 1147
androgen deficiency, 1144–1147
androgen deprivation, for prostate 
cancer, 472
androgen excess, in female, 1154–1156
anemia, 39, 283–284. See also specific 
types
blood loss, 380–384
drug-induced, 379–380, 380–381, 382t, 
401, 1384t–1385t
in hypometabolic states, 379t
hypoproliferative, 284, 377–379, 379t
in inflammation, 379t, 380t
microcytic, 378f, 379–380, 380t
parvovirus infection, 713
physiologic classification of, 284, 285f
refractory, 379–380, 410t
with excess blasts, 410t
with ringed sideroblasts, 410t
in renal failure, 379t
treatment of, 383–384
anemia of chronic disease, 379, 383
1456
INDEX
anesthetics, for delirium, 59t
aneurysm. See specific types
angina pectoris, 224, 858–864
chronic stable, 858
drug-induced, 1385t
Prinzmetal’s variant, 864
recurrent, 854, 860
treatment of
drug therapy, 861–862, 862t
long-term suppression, 861–862
mechanical revascularization, 863, 863t
unstable, 855–858
angiodysplasia, 264, 266
colonic, 1020
angioedema, 235, 1062–1063
classification of, 1062, 1062t
drug-induced, 1379t
treatment of, 1063
angiography, hepatobiliary, 275
angioma, senile, 364f
angiotensin receptor blockers (ARBs)
for diabetic nephropathy, 975
for dilated cardiomyopathy, 825
for glomerulosclerosis, 974
for heart failure, 881t, 882–883, 882t
for hypertension, 836, 838t, 839, 840t, 
841, 962
metabolic syndrome, 843
for myocardial infarction, 848, 850, 
857–858
preventive treatment, 854
for renal artery stenosis, 992
for unstable angina, 857–858
angiotensin-converting enzyme (ACE) 
inhibitors
for aortic regurgitation, 821
for coronary artery disease, 862
for diabetic nephropathy, 975
for dilated cardiomyopathy, 825
for focal glomerulosclerosis, 974
for glomerulonephritis, 974
for heart failure, 880–883, 881t, 882t, 885
for hypertension, 836, 838t, 839, 840t, 
841, 962
metabolic syndrome, 843
for myocardial infarction, 848, 850, 
857–858
preventive treatment, 854
for renal artery stenosis, 992
for systemic sclerosis, 1075
for unstable angina, 857–858
anidulafungin, 745
anilines, 177t
animal bite, 570t, 572
animal-borne viral infection, 718
rabies, 718–720, 721f
anion gap, 19–20, 21t, 25
calculation of, 22
anion-gap metabolic acidosis (AGMA) 
inducers, 160t–161t
poisoning, 178t–179t
anisocytosis, 375
anistreplase, for thrombotic disorders, 394
ankle-brachial index, 795, 890
ankylosing spondylitis, 900t, 1082–1085
diagnosis of, 1083, 1084t, 1085t
treatment of, 1083–1084
Ann Arbor staging system, for Hodgkin’s 
disease, 427, 427t
annular skin lesion, 363
anomia, 336t
anorectal disease, 1020
anorectal gonorrhea, 559
anorexia, in terminally ill patient, 61t
anorexia nervosa, 220, 1333–1335, 1334t, 
1335f
anosmia, 1222
anosognosia, 93–94
ANS. See autonomic nervous system
antacids
for erosive gastropathies, 1009
for indigestion, 247
for peptic ulcer disease, 1006–1007
for systemic sclerosis, 1075
anterior ischemic optic neuropathy 
(AION), 325f, 327
anthrax, 193, 211
as bioweapon, 193, 195t
cutaneous, 193
gastrointestinal, 193
inhalation, 133, 193
prevention of, 194
treatment of, 194, 195t
antiarrhythmics, 874t–876t, 877
for dilated cardiomyopathy, 825
for hypertrophic cardiomyopathy, 827
for pain, 43, 44t–45t
poisoning, 182t–183t
selection of, 878f
for tachyarrhythmia, 877
antibacterial resistance
control of, 510
emerging problems, 496
mechanisms of, 497t–499t, 499–500
antibacterial therapy, 496–505
for acute renal failure, 959
adverse reactions to, 501t–502t, 
504–505
for bronchiectasis, 928
for campylobacteriosis, 546
choice of antibacterial agents, 504
for cholera, 540
for Clostridium difficile infection, 
550–551
for cor pulmonale, 886
for diverticular disease, 1018
drug interactions with, 503t–504t, 505
for epididymitis, 553
for febrile neutropenic patients, 514, 515f
for HSCT patients, 516
for infective endocarditis, 524, 
526t–528t, 528–532, 531t
INDEX
1457
for intestinal pseudoobstruction, 1019
for intraabdominal abscess, 534–536
for irritable bowel syndrome, 1018
for lung abscess, 928–929
mechanisms of drug action, 496, 
497t–499t, 499
for pancreatitis, 1028–1029
for peritonitis, 533–534
pharmacokinetics of, 500
principles of, 500, 502, 504
for salmonellosis, 545
for shigellosis, 547–548
susceptibility testing, 487
toxicity of, 399t
for transplant recipients, 518, 520
for urethritis in men, 552
anticholinergics
for asthma, 909–911
for COPD, 918–919
for diverticular disease, 1018
for dystonia, 333
for glaucoma, 347
for irritable bowel syndrome, 1017–1018
for nausea and vomiting, 246
for Parkinson’s disease, 1227
poisoning, 160t–161t, 168t
for vertigo, 323t
anticholinesterase drugs
for myasthenia gravis, 1303
poisoning, 172t
anticoagulants
for deep venous thrombosis, 932–933
for dilated cardiomyopathy, 825
for myocardial infarction, 848, 857
for pulmonary embolism, 932–933
for restrictive cardiomyopathy, 826
for stroke, 99
preventive treatment, 102
for thrombotic disorders, 392–394, 393t
for unstable angina, 857
for venous thromboembolism, 932
anticonvulsants
for brain tumor, 1258
for generalized anxiety disorder, 1321
for migraine prevention, 313t
for pain, 43, 44t–45t
poisoning, 173t
for polyneuropathy, 1296
for status epilepticus, 117f, 118
for subarachnoid hemorrhage, 104
antidepressants, 1325
for Alzheimer’s disease, 1219
for chronic fatigue syndrome, 217–218
for daytime sleepiness, 342
for depression, 1317
for fibromyalgia, 1098
for irritable bowel syndrome, 1017t, 
1018
for pain, 42–43, 44t–45t
for panic disorder, 1320
poisoning, 168t, 180t
for PTSD, 1322
for smoking cessation, 1372
for tinnitus, 353
withdrawal syndromes, 1325
antidiuretic hormone (ADH), 1113
antidotes, 163
antiepileptic drugs, 1205t–1212t
antifungal agents, 744–745
antigen detection, bacterial and viral 
infections, 487
antigenic drift, 700
antigenic shift, 700
anti-glomerular basement membrane 
disease, 971–972
antihistamines
for allergic rhinitis, 1064
for antivenom reaction, 144
for carcinoid tumor, 458
for chronic fatigue syndrome, 217
for cough, 232
for erythema multiforme, 372
for hymenoptera sting, 151
for nausea and vomiting, 246
for pityriasis rosea, 367
poisoning, 168t, 180t, 182t–183t
for scombroid poisoning, 148
for systemic mastocytosis, 1065
for urticaria/angioedema, 1063
for vertigo, 323t
antihypertensives
for aortic dissection, 889
for hypertension, 841
metabolic syndrome, 843
for renal disease, 962
antileukotrienes, for asthma, 910
anti-LKM antibodies, 1050
antimalarials, 766t, 768t–770t
poisoning, 177t, 182t–183t
for psoriatic arthritis, 1087
for SLE, 1072
antimetabolites
mechanism of, 496
toxicities of, 398t
antimonial compounds, for leishmaniasis, 
772–773
antineuronal antibodies, paraneoplastic, 
481, 482t, 483t
antineutrophil cytoplasmic autoantibodies 
(ANCA), 1079
glomerulonephritis, 971
antinuclear antibodies (ANA), 896, 936, 
1050
antiphospholipid antibody syndrome 
(APS), 1077
antiplatelet agents
for membranoproliferative 
glomerulonephritis, 975
for myocardial infarction, 848
preventive treatment, 854
for stroke, 99
preventive treatment, 102
1458
INDEX
antiplatelet agents (Cont.):
for thrombotic disorders, 394
antiprotozoal agents
for cryptosporidiosis, 543
for cyclosporiasis, 544
for cystoisosporiasis, 543
for giardiasis, 542
antipseudomonal agents, 622, 624t–625t
antipsychotics, 1329, 1330t–1331t
for Alzheimer’s disease, 1219
for bipolar disorder, 1319
for ergot alkaloid poisoning, 166t
first-generation, 1329, 1330t
poisoning, 168t, 180t, 182t–183t
for schizophrenia, 1319
second-generation, 1329, 1331t
antipyretics, 211
antiretroviral therapy, 734, 740–742
entry inhibitors, 739t, 740
initiation of, 732
integrase inhibitor, 739t, 740
nucleoside analogues, 735t–736t, 
740–741
nucleotide analogues, 735t–736t, 740–741
protease inhibitors, 738t–739t, 740–741
resistance testing for, 732
reverse transcriptase inhibitors, 
735t–737t, 740–741
selection of, 740–742, 741t, 742t
antisocial personality disorder, 1324
antithrombotic drugs
for antiphospholipid antibody 
syndrome, 1077
for myocardial infarction, 857
for unstable angina, 857
antithymocyte globulin, for aplastic 
anemia, 384
antitoxin
botulism, 638
for diphtheria, 601
for tetanus, 636
α1-antitrypsin deficiency, 917
antitussive agents, 232
antivenom
for snakebite, 143–144
sources of, 146
antiviral agents
for herpes keratitis, 345
for HSCT patients, 517
for transplant recipients, 518, 520–521
for vasculitis, 1080
for viral hepatitis, 1037
antrectomy, 1008t
anuria, 288
anxiety attack, 319
anxiety disorder, 1320–1321
anxiolytics, 1325, 1328t, 1329
for delirium, 59t
for dyspnea, 58t
AOM. See acute otitis media
aorta
abdominal, occlusive disease of, 890
coarctation of, 814, 834–835
diseases of, 887–890
echocardiography in, 807, 809t
aortic aneurysm, 887
aortic dissection, 887–889, 889t
chest pain in, 223f, 224
classification of, 887–888, 888f
aortic regurgitation (AR), 798t, 821
echocardiography in, 807f, 821
aortic stenosis (AS), 798t, 819–821
echocardiography in, 807f, 820
treatment of, 820–821, 820f
aortography, 887, 889
aphasia, 335–337, 336t
aphthous stomatitis, 364f
apixaban, for thrombotic disorders, 393
aplastic anemia, 378, 387
aplastic crisis, parvovirus infections, 713
apnea, 947
in terminally ill patient, 62t
apo B-100, familial defective, 1172, 1173t
apo CII deficiency, 1173t, 1178
apomorphine, for Parkinson’s disease, 1226t
apraxia, 331
aprepitant, for nausea and vomiting, 56, 
246, 401
APS. See antiphospholipid antibody 
syndrome
AR. See aortic regurgitation
arachnoiditis, lumbar, pain in, 302
arbovirus infection, 721, 723t–724t
ARBs. See angiotensin receptor blockers
Arcanobacterium haemolyticum 
infection, 603
ARDS. See acute respiratory distress 
syndrome
argatroban
for heparin-induced 
thrombocytopenia, 390
for thrombotic disorders, 393
Argentine hemorrhagic fever, 725
arginine vasopressin (AVP), 3, 1113
aripiprazole
dosage and adverse effects of, 1331t
for schizophrenia, 1319
aromatase inhibitors, for breast cancer, 
443, 446
arrhythmia
bradyarrhythmia, 864–867
drug-induced, 1385t
in myocardial infarction, 848
serum magnesium and, 848
syncope in, 316, 319t
tachyarrhythmias, 867–879
ARS. See acute radiation sickness
arsenic poisoning, 184t
arsenic trioxide, for AML, 406
artemether, for malaria, 767t
artemether-lumefantrine, for 
malaria, 766t
INDEX
1459
artemisinin derivatives, for malaria, 765, 766t
arterial blood gases (ABG), 902
in acid-base disorders, 19, 24
analysis of, in ICU, 38
arterial embolism, 891
arteriography
for colonic angiodysplasia, 1020
coronary, 857, 859–860
mesenteric, 264
arteriosclerosis, of peripheral arteries, 
890–891
arteriovenous fistula, dural, 96t
arteriovenous malformation, 1255, 1256f
intracranial hemorrhage in, 96t
subarachnoid hemorrhage in, 103
arteritis, 1078–1079
artesunate, for malaria, 128t, 765, 766t–767t
arthritis. See also specific types
acute, 1092
chronic, 1092
gonococcal, 559, 574–576
infectious, 574–576, 586
Lyme borreliosis, 664, 666
rash and, alphavirus infection, 725
S. aureus, 586, 592
arthritis mutilans, 1086
arthropathy, chronic, 1094
arthropod bite/sting, 148–149
arthropod ectoparasites, 791–792
arthropod-borne disease, viral infections, 
720–727, 723t–724t
arthroscopic therapy, for osteoarthritis, 1091
AS. See aortic stenosis
5-ASA. See 5-aminosalicylic acid
asbestosis, 900t, 912–913
asbestos-related disease, 912–913
ascariasis, 780–781
ascites, 235–236, 275–278
chylous, 276, 276f
cirrhotic, 276f, 277
complications of, 277–278
fluid characteristics, 276f
pancreatic, 1030
paracentesis, 34–35
primary bacterial peritonitis and, 532
refractory, 277
serum-ascites albumin gradient, 276f
ASD. See atrial septal defect
asenapine, 1331t
L-asparaginase, for acute lymphoblastic 
leukemia and lymphoblastic 
lymphoma, 423
aspartate aminotransferase (AST), 270, 
272t, 1028
aspergilloma, 748, 750t
aspergillosis, 747–749, 750t
allergic bronchopulmonary, 748, 750t
disseminated, 748
pulmonary, 748, 750t
sinusitis, 748
treatment of, 749, 750t
asphyxiants, poisoning, 160t–161t, 176t
aspirates, specimen collection and 
transport, 489t–491t
aspiration, of bone marrow, 376
aspirin
for angina pectoris, 862
for antiphospholipid antibody 
syndrome, 1077
for atrial fibrillation, 877
for cardiovascular disease 
prevention, 1365
for colon cancer prevention, 1370
for fever, 211
low-dose, 1365
for migraine, 310t
for myocardial infarction, 846, 848, 
857–858
preventive treatment, 854
for pain, 43, 44t–45t
for pericarditis, 831
Reye’s syndrome, 701
for rheumatoid arthritis, 1074
for stroke, 99
preventive treatment, 102, 102t
for superficial thrombophlebitis, 892
for tension headache, 314
for thrombotic disorders, 394
for unstable angina, 857–858
assist-control mandatory ventilation 
(ACMV), 84, 85t
assisted reproductive technology, 1159
AST. See aspartate aminotransferase
asterixis, 335
asthma, 900t, 907–911
chronic, 909–910
clinical evaluation of, 907–908
cough in, 231–232
dyspnea in, 226–227
high altitude and, 158
intrinsic, 907
occupational, 907, 912–914
pulmonary function tests in, 908
sleep disorders in, 339, 341t
treatment for, 909–910, 910f
asthma exacerbations, 911
astrocytoma, 1258, 1259f
asymptomatic bacteriuria (ABU), 986–989
asystole, 68, 68f
ataxia, 1227–1231
acute, 1229t
approach to, 1228, 1229t
chronic, 1229t
inherited, 1228
subacute, 1229t
ataxia-telangiectasia, 1069
atazanavir, for HIV/AIDS, 738t
atenolol
for hypertension, 837t
poisoning, 170t
for syncope, 320
for thyrotoxicosis, 1121
1460
INDEX
atheroembolism, 891
renal, 991–992
atherosclerosis
C. pneumoniae infection and, 684
prevention of complications of, 
1179–1180
risk factors for, 1362–1364, 1362t
athetosis, 333–334
ATL. See adult T cell leukemia/lymphoma
atorvastatin
for hyperlipidemia, 1177t
for myocardial infarction, 857
preventive treatment, 854
for unstable angina, 857
atovaquone
for ANCA-associated 
glomerulonephritis, 972
for babesiosis, 126t, 771
for Pneumocystis infections, 761, 761t, 762t
for toxoplasmosis, 777
atovaquone-proguanil, for malaria, 766t
preventive treatment, 768t
atrial fibrillation, 868f, 870t
antithrombotic prophylaxis in, 102, 102t
chronic, 877
stroke and, 101t
atrial flutter, 868f, 870t
atrial premature beats, 869t
atrial septal defect (ASD), 811
ostium primum, 811
ostium secundum, 811
sinus venosus, 811
atrial tachycardia, 869t
with block, 868f
multifocal, 870t
atrioventricular (AV) block, 865–867
causes of, 865t
drug-induced, 865t, 1385t
first degree, 866, 866f
in myocardial infarction, 849
second degree
Mobitz I, 866, 866f
Mobitz II, 866, 866f
third degree (complete), 866f, 867
atrophy (skin lesion), 366t
atropine
for beta blocker poisoning, 170t
for bradycardia, 846
for calcium channel blocker 
poisoning, 170t
for cardiac glycoside poisoning, 171t
for cholinergic poisoning, 172t
exposure, 202, 203t
for inflammatory bowel disease, 1013
poisoning, 168t
for sympatholytic poisoning, 169t
for tachyarrhythmias, 871t
audiologic assessment, 349–350
AUDIT. See Alcohol Use Disorder 
Screening Test
Auer rods, 376
auscultation, 796–798
autoantibody disorders, 54
autoimmune autonomic neuropathy, 1241
autoimmune disease
leukopenia in, 386
thrombocytopenia in, 389
in women, 1376
autoimmune hemolysis, 384
autologous transfusion, 52
automated external defibrillator (AED), 66
autonomic nervous system (ANS)
activation of, 1237t
anatomy of, 1236f
disease, 1235–1243
approach to, 1237–1238
autoimmune, 1241
with brain involvement, 1239t–1240t
classification of, 1239t–1241t
drug-induced, 1237
with spinal cord involvement, 1240t
treatment of, 1242, 1243t
function tests, 1238
autosomal dominant polycystic kidney 
disease (ADPKD), 984–985
AV block. See atrioventricular block
avascular necrosis, 1098
avoidant personality disorder, 1324
AVP. See Arginine vasopressin
axillary lymph node, carcinoma in, 476
5-azacytidine, for myelodysplastic 
syndromes, 412
azathioprine
for ANCA-associated 
glomerulonephritis, 972
for autoimmune hepatitis, 1050–1051
immunosuppression for renal 
transplant, 967
for inflammatory bowel disease, 1015
for inflammatory myopathy, 1312
for multiple sclerosis, 1269
for myasthenia gravis, 1305
for polyneuropathy, 1298
for reactive arthritis, 1088
for SLE, 1072
toxicity of, 398t
for vasculitis, 1082
azelastine, for allergic rhinitis, 1064
azidothymidine. See zidovudine
azithromycin
for adult inclusion conjunctivitis, 683
for babesiosis, 126t, 771
for Bartonella infections, 633t
for C. pneumoniae infections, 684
for campylobacteriosis, 546
for chancroid, 567
for cholera, 540
for diarrhea, 1360
for donovanosis, 568
for gonococcal infections, 560t
INDEX
1461
for H. influenzae infection, 610
for Legionella infection, 626
for leptospirosis, 668
for M. catarrhalis, 613
for M. pneumoniae infections, 681
for meningococcal infections, 
preventive treatment, 1275
for nontuberculous mycobacterial 
infections, 663
for otitis media, 356t
for pertussis, 612
for pneumococcal infections, 582
for pneumonia, 924t
for salmonellosis, 545
for scrub typhus, 676
for shigellosis, 547
for urethritis in men, 552
azoles, 744–745
for candidiasis, 371, 747
for scedosporiosis, 759
azotemia, 287–288
approach to, 289f
classification of, 287, 288t
intrinsic renal, 957, 957t
prerenal, 288, 956–957, 957t
AZT. See zidovudine
aztreonam, for sepsis/septic shock, 77t
B
B cells, 278
deficiency syndromes of, 1069
B cell receptors, defective rearrangements 
of, 1068–1069
babesiosis, 126t, 130, 148, 495t, 765, 771
Babinski sign, 329t, 1196
bacillary angiomatosis, 570t
Bartonella, 633t, 634
bacillary peliosis, 633t, 634
bacille Calmette-Guérin (BCG), 656
intravesical instillation of, 461
Bacillus anthracis infection. See anthrax
Bacillus cereus infection, 536–537
bacitracin, mechanism of/resistance 
to, 497t
back pain, 298. See also low back pain
in ankylosing spondylitis, 1082
approach to, 135f
cancer patient with, 135f
baclofen
for dystonia, 333
for multiple sclerosis, 1269
poisoning, 175t
bacteremia
clostridial, 639
E. coli, 616
Klebsiella, 618
listerial, 607–608
P. aeruginosa, 621, 624t
S. aureus, 586
streptococcal, 596, 598
bacterial food poisoning, 536–539, 
538f–539f
bacterial infection
in chronic meningitis, 1285t–1286t
diagnosis of, 485, 487, 494
antigen detection, 487
culture, 487, 488t–493t
microscopy, 485, 486f, 487
nucleic acid probes, 487, 494
serology, 487
in HSCT patients, 516
lymphadenopathy and, 279t
bacterial vaginosis, 553–554
bacteriuria, asymptomatic, 986–989
Bacteroides fragilis infection, 640, 642
BAER. See brainstem auditory evoked 
responses
BAL. See bronchoalveolar lavage
Balkan endemic nephropathy (BEN), 982
balloon dilatation, for esophageal 
disorders, 251
balloon tamponade, for esophageal 
varices, 1058
barbiturates
for isoniazid poisoning, 180t
poisoning, 174t
for sedative-hypnotic poisoning, 173t
barbiturate coma, 107t
bariatric surgery, 1136f, 1137
metabolic syndrome, 843
barium contrast x-ray study, 257
barium enema
air-contrast, 454, 456
for colonic polyps, 452
barium radiography, for GI bleeding, 264
barium swallow, 249, 251, 448–449
barotrauma, 86
Barrett’s esophagus, 247, 447
barrier contraception, 1157
Bartonella infection, 632–635
bacillary angiomatosis, 633t, 634
bacillary peliosis, 633t, 634
bartonellosis, 633t, 634–635
cat-scratch disease, 632, 633t, 634
endocarditis, 633t, 634
trench fever, 633t, 634
bartonellosis, 633t, 634–635
Bartter’s syndrome, 953
basal cell carcinoma (BCC), 364f, 430–431
keratotic, 430
morpheaform, 430
noduloulcerative, 430
pigmented, 430
superficial, 430
basal energy expenditure (BEE), 46, 46f
basic life support (BLS), 66–68, 66f, 67f, 68f
basophilia, 386
basophilic stippling, 375
BCC. See basal cell carcinoma
BCG. See bacille Calmette-Guérin
1462
INDEX
Bechterew’s disease. See ankylosing 
spondylitis
beclomethasone, for allergic rhinitis, 1064
bed nets, 1351
bee sting, 150–151
beer potomania, 3
Behçet’s syndrome, 1079
in chronic meningitis, 1291t
belimumab, for SLE, 1072
belladonna alkaloid poisoning, 168t
Bell’s palsy, 686, 1246
Belsey procedure, 247
BEN. See Balkan endemic nephropathy
bendamustine, toxicity of, 398t
benign paroxysmal positional vertigo 
(BPPV), 322, 322t, 323t, 324
benserazide/levodopa, for Parkinson’s 
disease, 1226t
bentiromide test, 257, 1031
benzathine penicillin
for diphtheria, 602
for endemic treponematosis, 667
for pharyngitis, 357t
for rheumatic fever prevention, 816
for streptococcal infection, 594t
for syphilis, 565t
benzene derivative poisoning, 1037
benznidazole, for Chagas’ disease, 774
benzodiazepines, 1325
for alcohol withdrawal, 1339
dosage and action of, 1328t
for fibromyalgia, 1098
for generalized anxiety disorder, 1321
for panic disorder, 1320
poisoning, 174t
for sedative-hypnotic poisoning, 173t
sleep disorders with, 338–339
for sympathomimetic poisoning, 166t
for tetanus, 636
for vertigo, 323t
benzonatate, for cough, 232
benzoyl peroxide, for acne, 371
benztropine, for extrapyramidal 
reactions, 180t
berylliosis, 913–914
beta agonists
for asthma, 909–911
for COPD, 918–919
beta blockers
for angina pectoris, 861
for aortic dissection, 889, 889t
for atrial fibrillation, 877
for dilated cardiomyopathy, 825
for esophageal varices, 1058
for glaucoma, 345
for heart failure, 880, 881t, 882t, 883, 885
for hypertension, 836, 837t, 840t
for hypertrophic cardiomyopathy, 827
for migraine prevention, 313t
for mitral stenosis, 816
for mitral valve prolapse, 819
for myocardial infarction, 846–848, 
857–858
preventive treatment, 854
poisoning, 170t, 182t–183t
for sinus tachycardia, 849
for supraventricular arrhythmias, 849
for tachyarrhythmias, 869t–871t
for thyrotoxicosis, 1121–1122
for toxic multinodular goiter, 1124
for unstable angina, 857–858
for Wolff-Parkinson-White syndrome, 877
beta radiation, 204
beta-carotene, for erythropoietic 
porphyria, 1184
beta-lactams
adverse reactions to, 501t
for Corynebacterium infection, 603
for enterococcal infections, 600
for HACEK group infections, 614t
for lung abscess, 928
mechanism of/resistance to, 496, 497t
for mixed anaerobic infections, 643
for P. aeruginosa infections, 622, 624t
for pneumococcal infections, 582–583
for staphylococcal infection, 589, 590t, 592
for urinary tract infections, 988, 989t
betamethasone, 1131, 1131t, 1133
bethanechol
for multiple sclerosis, 1269
poisoning, 173t
bevacizumab
for colorectal cancer, 456
for kidney cancer, 462
toxicity of, 400t
bexarotene, toxicity of, 399t
BFM regimen, for Burkitt’s lymphoma/
leukemia, 423
bicarbonate, renal retention of, 23
bicarbonate therapy
for metabolic acidosis, 22–23, 72
for renal tubular acidosis, 985–986
for tumor lysis syndrome, 137
bichloroacetic acid, for HPV infection, 568
bicuspid aortic valve, congenital, 814
biguanide, for diabetes mellitus, 1142t
bilastine, for allergic rhinitis, 1064
bile ducts, diagnostic evaluation of, 1022t
bile salt deficiency, 260t
biliary colic, 1023
biliary disease, infections in cancer 
patients, 512t
bilirubin, serum, 1028
conjugated fraction (direct), 267, 
267t, 269
unconjugated fraction (indirect), 267, 
267t, 269
binge eating, 1333
Binswanger’s disease. See diffuse white 
matter disease
INDEX
1463
biopsy. See also specific organs
of bone marrow, 376–377
collection and transport of, 491t
bioterrorism, 191–207
chemical, 200–202
microbial, 191–200, 510
radiation, 204–207
bioweapons, botulism, 638
bipolar disorder, 1317–1319
bisacodyl, for constipation, 56t
bismuth subsalicylate
for diarrhea, 1360
for H. pylori eradication, 1008t
bisoprolol, for heart failure, 882t
bisphosphonates
actinomycosis and, 646–647
for breast cancer, 446
for hypercalcemia, 480
for osteoporosis, 1169–1170
for primary biliary cirrhosis, 1055
prostate cancer and, 473
bite
arthropod, 148–149
mammalian, 139–140
treatment of, 141t, 143
management of wound infections, 
141t–142t
snakebite, 142t, 143
bivalirudin
for myocardial infarction, 857
for unstable angina, 857
bladder cancer, 460–461
Blakemore-Sengstaken tube, for 
esophageal varices, 1058
blastomycosis, 756–757
South American, 758
bleeding disorders, 387–391
blood vessel wall defects, 389–390
coagulation disorders, 390
gastrointestinal, 261
platelet disorders, 388–389
treatment of, 390–391
bleomycin
for germ cell tumor, 476
for testicular cancer, 463
toxicity of, 399t
blepharoconjunctivitis, 344–345
blepharospasm, 1247
blocking agents, for radionuclide 
contamination, 207
blood
reference ranges for volumes of, 1450t
specimen collection and transport, 488t
toxicologic analysis of, 160, 1421t–1427t
blood loss
anemia in, 283–284, 380–384
symptoms of, 262
blood parasites, diagnosis of, 494, 495t
blood smear, 375–376
erythrocyte abnormalities, 375–376
leukocyte abnormalities, 376
platelet abnormalities, 376
blood urea nitrogen (BUN), 287
blood vessel wall defects, 389–390
blood volume, disorders of, 319t
BLS. See basic life support
blue toe syndrome, 891
BMI. See body mass index
BNP. See B-type natriuretic peptide
body fluids
reference ranges for volumes of, 1450t
specimen collection and transport, 
490t–491t
body louse, 792
body mass index (BMI), 47, 1134, 1450t
body temperature, 209
Bolivian hemorrhagic fever, 725
bone disease
drug-induced, 1390t–1391t
neck pain in, 306
osteoporosis, 1167–1170
bone infection
anaerobic, 643
arthritis, 574–576, 586, 592
osteomyelitis, 576, 579–580
Klebsiella, 618
microbiology of, 576, 577t
S. aureus, 585–586, 592
treatment of, 578t–579t, 579–580
P. aeruginosa, 621, 624t
tuberculosis, 651
bone marrow
cellularity of, 377
damage causing anemia, 378–379
erythroid:granulocytic ratio, 377
examination of, 284, 376–377
bone marrow aspirate, 376–377
reference values for specific analytes, 
1434t
bone marrow cellularity, 1435t
bone marrow failure, 387
bone marrow transplant
for acute lymphoblastic leukemia and 
lymphoblastic lymphoma, 423
for AML, 406
for CLL, 419
for CML, 406, 409
for myelodysplastic syndromes, 412
bone metastasis, osteoblastic, in men, 476
BOOP. See bronchiolitis obliterans with 
organizing pneumonia
borderline personality disorder, 1323–1324
Bordetella infection. See pertussis
Bordetella pertussis infection. See pertussis
Bornholm disease, 716
Borrelia burgdorferi. See Lyme borreliosis
Borrelia recurrentis infection, 668–669
bortezomib
for multiple myeloma, 426
toxicity of, 400t
1464
INDEX
bosentan
for pulmonary hypertension, 898
for systemic sclerosis, 1075
botulinum toxin
for achalasia, 251
for anal fissures, 1020
as bioweapon, 197t, 199
for dystonia, 333
for hemifacial spasm or 
blepharospasm, 1246
botulism, 637–639, 1241
as bioweapon, 638
treatment of, 197t
bounding pulse, 795, 795f
Bowen’s disease, 431
BPPV. See benign paroxysmal positional 
vertigo
brachial neuritis, acute, 306
brachial plexus, injury to, 306
bradyarrhythmia, 864–867
approach to, 68, 68f
in myocardial infarction, 849
bradycardia, 864
bradykinesia, 331, 332
brain abscess, 128t, 132, 1270, 1280–1282
nocardiosis, 645–646
brain death, 92–93
brain herniation, 106, 106f
brain mass, in cancer patients, 513
brain metastasis, 1260–1261, 1261t
brain tumor, 1215
approach to, 1257
headache in, 308t
intracranial, 1258–1260
metastatic, 96t
treatment of, 1258
brainstem auditory evoked responses 
(BAER), 350
brainstem lesion, 329t, 330t
Brazilian hemorrhagic fever, 725
BRCA genes, 441, 447, 465, 1369
break-bone fever, 722
breast cancer, 441–447
carcinoma in axillary lymph node, 476
diagnosis of, 442–443
estrogen receptor status of, 443, 445–446
genetic factors in, 441–442
infections in cancer patients, 512t
locally advanced, 443
metastatic, 443, 446
oncologic emergencies, 134–135
operable, 443
paraneoplastic, 479t
paraneoplastic syndromes in, 482t, 483t
prevention of, 446–447, 1369
prognosis by stage, 443, 446t
risk factors for, 1369
screening for, 1346t–1347t, 1366, 
1367t–1368t
staging of, 442, 444t–445t
treatment of, 443–446
breast mass, approach to, 442, 442f
breast self-examination, 1367t–1368t
Brenner tumor, 465
brentuximab vedotin, toxicity of, 400t
Brill-Zinsser disease, 675
Broca’s aphasia, 336, 336t
bromocriptine
for acromegaly, 1110
for hyperprolactinemia, 1109
for neuroleptic malignant syndrome, 214
poisoning, 166t
bronchial aspirate, 489t
bronchiectasis, 900t, 925–928
bronchiolitis, 900t
human RSV, 705
respiratory, 936–937
bronchiolitis obliterans with organizing 
pneumonia (BOOP), 935
bronchitis, 900t
hemoptysis in, 233
bronchoalveolar lavage (BAL), 905
bronchodilators
for asthma, 909–910
for bronchiectasis, 928
for COPD, 918–919
for cor pulmonale, 886
poisoning, 166t
bronchoscopy, 233, 234f, 905–906, 936
Brown-Séquard syndrome, 330t, 1251
brucellosis, 627–629, 628t
tuberculosis vs., 628, 628t
Brugada syndrome, 867
brugia infection. See filariasis
Bruton’s tyrosine kinase gene, 1069
B-type natriuretic peptide (BNP)
in cardiomyopathy, 825
in heart failure, 880
bubonic plague, 631
Budd-Chiari syndrome, 276, 276f
bulimia nervosa, 1333–1336, 1334t, 1335f
bullae (skin lesion), 365t, 569
bumetanide
for edema, 238t
for heart failure, 882t
for hypertension, 841
BUN. See blood urea nitrogen
bundle branch block
left, 802f, 804t, 867, 873t
right, 802f, 867, 873t
bundled interventions, 506, 507t
buprenorphine
narcotic abuse, 1340
for opioid maintenance, 1342
bupropion, 1325
dosage and adverse effects of, 1327t
for smoking cessation, 1372
for syncope, 320
Burkholderia cepacia infection, 622–623, 625t
Burkholderia mallei infection, 623, 625t
Burkholderia pseudomallei infection, 623, 625t
Burkitt’s lymphoma, 416, 417f, 423, 697, 698t
INDEX
1465
burn patient
hypothermia in, 152t
neutrophilia in, 385
bursitis, 1099
buspirone, 1329
dosage and action of, 1328t
for generalized anxiety disorder, 1321
busulfan, 398t
butabarbital poisoning, 174t
butorphanol
for migraine, 311t
for pain, 44t–45t
byssinosis, 914
C
cabazitaxel
for prostate cancer, 472
toxicity of, 398t
cabergoline
for acromegaly, 1110
for hyperprolactinemia, 1109
CABG. See coronary artery bypass grafting
CAD. See coronary artery disease
cadmium poisoning, 185t
CaEDTA, for lead poisoning, 186t
caffeine
for migraine, 310t
poisoning, 167t
calamine lotion, for insect stings, 151
calcipotriol, for psoriasis, 367
calcitonin, for hypercalcemia, 1163t
calcitriol
for hypoparathyroidism, 1165
for osteomalacia, 1171
calcium antagonists, for tetanus, 637
calcium apatite deposition disease, 1095–1096
conditions associated with, 1095t
calcium carbonate, for 
hyperphosphatemia, 962
calcium channel blockers
for angina pectoris, 862
for atrial fibrillation, 877
for hypertension, 836, 838t, 839, 840t, 841
for mitral stenosis, 816
poisoning, 170t
for pulmonary hypertension, 898
for renal artery stenosis, 992
for systemic sclerosis, 1075
for vasospastic disorders, 892
calcium docusate, for constipation, 56t
calcium gluconate
for GI bleeding, 266
for hypocalcemia, 1164
for muscle spasms, 145
calcium oxalate deposition disease, 1096
calcium oxalate stones, 998, 1000t
calcium phosphate stones, 998, 1000t
calcium polycarbophil, for irritable bowel 
syndrome, 1017t
calcium pyrophosphate dihydrate (CPPD) 
deposition disease, 1094–1095
calcium therapy
for beta blocker poisoning, 170t
for calcium channel blocker 
poisoning, 170t
for colon cancer prevention, 1370
for hyperkalemia, 18t
for hypermagnesemia, 1167
for hypocalcemia, 1165
for hypoparathyroidism, 1165
for lead poisoning, 186t–187t
for osteoporosis, 1168–1169
for primary biliary cirrhosis, 1055
for primary sclerosing cholangitis, 1026
calicivirus infection, diarrhea, 540–541
Calvert formula, 467
campylobacteriosis
diarrhea, 546
proctocolitis, 558
cancer. See also specific types and sites
depression in, 1316
detection of, 1365–1371
fatigue in, 215t
hemoptysis in, 233
infections in patients with, 511–514, 
512t, 515f
leukocytosis in, 385–386
lifestyle factors that reduce risk of, 1366t
oncologic emergencies, 133–138
paraneoplastic syndromes
endocrine, 477–480
neurologic, 480–484, 481t
prevention of, 1346t–1348t, 1365–1371
in high-risk groups, 1369–1371
screening for, 1346t–1348t, 1365–1366
lead-time bias, 1366
length bias, 1366
overdiagnosis, 1366
selection bias, 1366
spinal cord compression in, 112
tumor growth, 395
vaccination of patients with, 
519t–520t, 521
warning signs of, 1371
weight loss with, 219–220
cancer chemotherapy, 395–403
categories of agents, 397
complications of, 400–401
curability of cancers with, 396t–397t
development of drug resistance, 395, 397
leukopenia in, 386
nausea and vomiting in, 246
toxicities of agents, 397, 398t–400t
management of, 401
cancer of unknown primary site (CUPS), 
473–476
cytogenetics in, 475t
cytokeratin markers, 475, 476f
histology of, 474t, 475
pathologic evaluation of biopsy 
specimens from, 474t–475t
prognosis for, 475–476
1466
INDEX
candesartan
for heart failure, 882t
for hypertension, 838t
for myocardial infarction, 848
candidiasis, 370–371, 745–747
in cancer patients, 513–514
cutaneous, 365
deeply invasive, 746–747
disseminated, 211
esophageal, 252
mucocutaneous, 746–747
vulvovaginal, 371, 553–554, 746–747
CAP. See community-acquired pneumonia
CAPD-associated peritonitis, 534
capecitabine
for breast cancer, 446
for pancreatic cancer, 458
toxicity of, 398t
capillary telangiectasia, 96t
Capnocytophaga canimorsus infection, 
139–140, 141t
capsaicin cream
for osteoarthritis, 1090
for polyneuropathy, 1296, 1297t
capsulitis, adhesive, 1099
captopril
for ergot alkaloid poisoning, 166t
for heart failure, 882, 882t
for hypertension, 838t
for myocardial infarction, 848
preventive treatment, 854
carbamazepine
for bipolar disorder, 1319
dosage and adverse effects of, 173t, 
182t–183t, 1332t
for glossopharyngeal neuralgia, 1248
for multiple sclerosis, 1269
for pain, 43, 44t–45t
for polyneuropathy, 1297t
for seizures, 1205t, 1212t
for trigeminal neuralgia, 1243
carbapenems
for Aeromonas infection, 620
for enteric GNB infection, 620
for extraintestinal E. coli infection, 616
for Klebsiella infections, 618
mechanism of/resistance to, 496, 497t
for mixed anaerobic infections, 643
for nontuberculous mycobacterial 
infections, 663
for P. aeruginosa infection, 624t
carbidopa/levodopa, for Parkinson’s 
disease, 1224, 1226t
carbidopa/levodopa/entacapone, for 
Parkinson’s disease, 1226t
carbimazole, for thyrotoxicosis, 1120
carbohydrate requirements, 46
carbon monoxide poisoning, 114, 116, 
159, 176t, 914
carbon tetrachloride poisoning, 1037
carbonic anhydrase inhibitors, for 
glaucoma, 347
carboplatin
for bladder cancer, 461
for head and neck cancer, 433
for ovarian cancer, 467
toxicity of, 399t
carbuncle, S. aureus, 585
carcinoid syndrome, 458, 459t
carcinoid tumor, 458
paraneoplastic syndromes in, 478t
carcinomatosis, peritoneal, in women, 476
cardiac arrest, 65–69
follow-up of, 68–69
management of, 66–69, 66f, 67f, 68f
cardiac biomarkers, in myocardial 
infarction, 844, 855
cardiac catheterization
in cardiac tamponade, 831
in cardiomyopathy, 824t, 826
in constrictive pericarditis, 833
in pulmonary hypertension, 896
cardiac disease. See heart disease
cardiac glycoside poisoning, 171t
cardiac tamponade, 71t, 831
cardiac toxicity, 883
Cardiobacterium hominis infection, 
613–614, 614t
cardiogenic shock, 36, 37f, 70t, 71t, 72, 
851, 851t, 852f, 853
cardiomyopathy (CMP), 823–828
dilated, 823–825
laboratory evaluation of, 824t, 825
presentation of, 823t
drug-induced, 1385t
hypertrophic, 798t, 826–827
ECG in, 802, 804t
laboratory evaluation of, 824t, 827
presentation of, 823t
restrictive, 825–826, 833t
laboratory evaluation of, 824t, 826
presentation of, 823t
cardiopulmonary resuscitation, 66–67, 66f
for hypothermia, 153
cardiorenal syndrome, 957
cardiovascular collapse, 65–69, 65t
cardiovascular disease
drug-induced, 1385t–1386t
prevention of, 1361–1365
antithrombotic therapy, 1365
lifestyle modifications, 1365
risk factors for, 1362–1364
syncope in, 316, 319t
syphilis, 564, 565t
carisoprodol poisoning, 175t
carnitine palmitoyltransferase 
deficiency, 1312
carotene, serum, 266
carotene, supplementation, for macular 
degeneration, 347
INDEX
1467
carotid artery pulse, 795, 795f
carotid endarterectomy, 102
carotid sinus hypersensitivity, 318t
carotid stenosis
asymptomatic, 101t, 102
symptomatic, 101t, 102
carpal tunnel syndrome, 1299t, 1302
Carrion’s disease. See bartonellosis
carvedilol
for heart failure, 882t, 883
for hypertension, 837t
poisoning, 170t
CASPAR criteria, for psoriatic arthritis, 
1086, 1086t
caspofungin, 745
for aspergillosis, 750t
cast nephropathy, 983–984, 983t
Castleman’s disease, 693
lymphadenopathy and, 279t
cat bite, 140, 141t, 572
cataplexy, 340, 341t, 342, 342t
syncope compared with, 319
cataract, 345–346
drug-induced, 1390t
catecholamines, 1127
catfish envenomation, 145
catheter-related infection, in cancer 
patients, 511, 513
cat-scratch disease, 140, 632, 633t, 634
cauda equina syndrome, 300, 1253
causalgia, 40, 1241–1242
cavernous angioma, 96t
cavernous sinus, anatomy of, 1250f
cavernous sinus syndrome, 1250
CBT. See cognitive behavioral therapy
CD. See Crohn’s disease
CD40 ligand deficiency, 1069
CDI. See Clostridium difficile infection
cefazolin
for cellulitis, 570t
for infective endocarditis, 527t
for osteomyelitis, 578t, 579
for peritonitis, 534
for staphylococcal infection, 590t
for streptococcal infection, 598
cefdinir, for otitis media, 356t
cefepime
for bacterial meningitis, 1275t, 1276t
for brain abscess, 1281
for osteomyelitis, 579t
for P. aeruginosa infections, 624t–625t
for pneumonia, 924t, 926t
for sepsis/septic shock, 77t, 126t
cefixime
for gonococcal infections, 560t–561t
for urethritis in men, 552
cefotaxime
for bacterial meningitis, 1275t, 1276t
for bacterial peritonitis, 277
for brain abscess, 1281
for gonococcal infections, 560t
for H. influenzae infection, 610
for infectious arthritis, 576
for leptospirosis, 668
for Lyme borreliosis, 665
for meningococcal infection, 605
for nocardiosis, 646
for peritonitis, 533
for pneumococcal infections, 583
for pneumonia, 924t
for sepsis/septic shock, 77t
cefotetan
for gonococcal infections, 560t
for pelvic inflammatory disease, 556
cefoxitin
for animal bite infections, 570t
for clostridial infection, 641t
for gas gangrene, 571t
for gonococcal infections, 560t
for human bite infections, 141t
for nontuberculous mycobacterial 
infections, 663
for pelvic inflammatory disease, 556
cefpodoxime
for pneumonia, 924t
for urethritis in men, 552
ceftazidime
for bacterial meningitis, 1275t, 1276t
for brain abscess, 1281
for febrile neutropenia in cancer 
patient, 137
for glanders, 625t
for melioidosis, 625t
for neutropenia, 406
for osteomyelitis, 579t
for otitis externa, 359
for P. aeruginosa infections, 624t–625t
for peritonitis, 534
for pneumonia, 926t
ceftizoxime, for gonococcal infections, 560t
ceftriaxone
for acute bacterial endocarditis, 129t
for bacterial meningitis, 127t, 1275t, 
1276t
for Bartonella infections, 633t
for brain abscess, 128t, 1281
for brucellosis, 629
for chancroid, 567
for epididymitis, 553
for epidural abscess, 129t
for gonococcal infections, 560t
for H. influenzae infection, 610
for HACEK group infections, 614t
for infectious arthritis, 576
for infective endocarditis, 129t, 526t, 
528t, 529
for leptospirosis, 668
for Lyme borreliosis, 665–666
for meningococcal infections, 605–606
preventive treatment, 1275
1468
INDEX
ceftriaxone (Cont.):
for meningococcemia, 126t
for nocardiosis, 646
for osteomyelitis, 578t–579t
for otitis media, 356t–357t
for pelvic inflammatory disease, 556
for peritonitis, 533
for pneumococcal infections, 582–583
for pneumonia, 924t, 926t
for post-splenectomy sepsis, 126t
for proctitis, proctocolitis, enterocolitis, 
and enteritis, 558
for purpura fulminans, 127t
for salmonellosis, 545
for sepsis/septic shock, 77t
for shigellosis, 547
for urethritis in men, 552
cefuroxime
for Lyme borreliosis, 665
for otitis media, 356t
for pneumonia, 924t
celecoxib
for colon cancer prevention, 1370
for pain, 44t–45t
celiac arteriography, 1058
cellophane tape methods, 494
cellulitis, 570t, 572–573
auricular, 358
in cancer patients, 511, 512t
clostridial, 640
E. coli, 616
Klebsiella, 618
nocardiosis, 645, 647t
streptococcal, 594t, 595
central catheter, clotted, 134
central European encephalitis, 723t
central nervous system (CNS) disease
cryptococcal, 749
infections in immunocompromised 
patients, 513, 517t
listerial, 607
measles virus, 709
mumps, 712
P. aeruginosa infection, 621, 624t
paraneoplastic, 481t, 482–483, 482t, 483t
toxoplasmosis, 776
vasculitis of, 1079
central pontine myelinolysis, 7
central sleep apnea (CSA), 340, 948
central venous catheter infection, 507t, 509
cepacia syndrome, 623
cephalexin
for staphylococcal infection, 591t
for streptococcal infection, 595
cephalosporins
for Aeromonas infection, 620
for cholecystitis, 1024
for enteric GNB infection, 620
for epiglottitis, 362
for extraintestinal E. coli infection, 616
for H. influenzae infection, 610
for infectious arthritis, 576
for Klebsiella infections, 618
for M. catarrhalis, 613
mechanism of/resistance to, 496, 497t
for meningococcal infection, 605
for necrotizing fasciitis, 571t
for osteomyelitis, 578t–579t
for peritonitis, 533–534
for pneumococcal infections, 582–583
for Proteus infection, 619
for salmonellosis, 545
for staphylococcal infection, 589, 590t
for urinary tract infections, 988
cerebellar degeneration, paraneoplastic, 
481t, 482, 482t
cerebral angiography, 103
cerebral aspergillosis, 748
cerebral edema, 1039
cerebral herniation, 106, 106f
cerebral palsy, 334
cerebral perfusion pressure (CPP), 105–106
cerebral salt wasting, 104
cerebritis, 1271, 1280
cerebrospinal fluid analysis
in bacterial meningitis, 1273–1274, 1274t
in chronic meningitis, 1284
lumbar puncture, 32–34, 33f
reference values for specific 
analytes, 1430t
specimen collection and transport, 490t
in viral meningitis, 1276–1277
Cernunnos gene, 1067
certolizumab, for rheumatoid arthritis, 1074
ceruloplasmin, serum, 1184
cerumen impaction, 349–350
cervical angina syndrome, 306
cervical cancer, 468–469
paraneoplastic, 478t
prevention of, 468, 569, 1371
risk factors for, 1370
screening for, 468, 1367t–1368t
staging and prognosis in, 466t, 468
cervical intraepithelial neoplasia, 1371
cervical lymph node metastasis, 476
cervical spine disease, pain in, 222f, 225, 304
cervicitis, mucopurulent, 554, 559
cestode infection, 787–791
cetirizine
for allergic rhinitis, 1064
for urticaria/angioedema, 1063
cetuximab
for colorectal cancer, 456
for head and neck cancer, 433
toxicity of, 400t
cevimeline, for Sjögren’s syndrome, 1077
CFS. See chronic fatigue syndrome
Chagas’ disease, 773–774
chagoma, 773
chancre, syphilitic, 563
INDEX
1469
chancroid, 567
features of genital ulcers, 557t
channelopathy, 1313
charcoal, activated. See activated charcoal
Charcot’s joint, 1097
Charcot’s triad, 1025
chelation therapy
for hemochromatosis, 1182
for lead poisoning, 186t
for mercury poisoning, 187t
for radionuclide contamination, 207
for Wilson’s disease, 1184–1185
chemical bioterrorism, 200–202
chemotherapy, cancer. See cancer 
chemotherapy
chest pain, 221–225
in ankylosing spondylitis, 1083
approach to, 225
causes of, 220–225, 221t
differential diagnosis of, 222f, 223f
in myocardial infarction, 844
noncardiac, 249
chest tube, 940, 942
chest wall disease, 226, 900t, 901t, 946–947
chest wall pain, 221t, 222f, 224
chest x-ray (CXR)
in aortic disease, 887, 889
in cardiac tamponade, 831
in cardiomyopathy, 824t, 825–827
in congenital heart disease, 811–814
in cor pulmonale, 886
in heart failure, 879
in hemoptysis, 233, 234f
indications for, 26
in interstitial lung disease, 936
in myocarditis, 828
normal radiograph, 27f
in pericarditis, 829, 832
in pneumonia, 922
in poisoning, 160
in pulmonary edema, 228–229
in pulmonary embolism, 930
in pulmonary hypertension, 896
in respiratory disease, 904
in superior vena cava syndrome, 134
utility of, 26
in valvular heart disease, 816
Cheyne-Stokes respiration, 62t
chickenpox, 688, 691–692
nosocomial, 510
Chikungunya virus infection, 725
Child-Pugh classification, of cirrhosis, 1053t
Chinese herbal nephropathy, 982
chlamydial infection, 559, 561–562, 681–684
adult inclusion conjunctivitis, 682–683
C. pneumoniae, 684
cervicitis, 554
epididymitis, 552–553
lymphadenopathy and, 279t
pelvic inflammatory disease, 555
proctitis, proctocolitis, enterocolitis, 
and enteritis, 556, 558
psittacosis, 683
trachoma, 559, 682–683
urethritis, 552–553
vulvovaginal infection, 553
chloral hydrate poisoning, 175t
chlorambucil, 398t
chloramphenicol
for Bartonella infections, 633t
mechanism of/resistance to, 496, 497t
for plague, 196t, 632
for Rocky Mountain spotted fever, 673
for scrub typhus, 676
for tick-borne spotted fevers, 674
for tularemia, 196t
chlordiazepoxide
for alcohol withdrawal, 1339
dosage and action of, 1328t
poisoning, 174t
chloroquine
for inflammatory bowel disease, 1015
for malaria, 766t
preventive treatment, 768t
poisoning, 182t–183t
for porphyria cutanea tarda, 1183
chlorpheniramine
for allergic rhinitis, 1064
for urticaria/angioedema, 1063
chlorpromazine
for delirium, 59t
dosage and adverse effects of, 168t, 
169t, 1330t
for migraine, 311t
for tetanus, 636
chlorthalidone, for hypertension, 837t
cholangiography, 275
percutaneous transhepatic, 1022t
cholangiopancreatography, 1022t, 1025
cholangitis, 1024–1025
E. coli, 616
primary sclerosing, 1025–1026
cholecystectomy, 1021, 1023–1025
cholecystitis
acute, 1023–1024
chronic, 1024
choledocholithiasis, 1024–1025
cholelithiasis, 1021, 1022t, 1023
cholera, 539–540
cholera vaccine, 1359t
cholestasis, liver function tests in, 272t
cholesteatoma, 350
cholesterol
blood
cardiovascular disease and, 1362, 1363t
goals and cutpoints for therapeutic 
intervention, 1363t
reference values for laboratory 
tests, 1429t
HDL, 1172, 1173t–1174t, 1175
1470
INDEX
cholesterol (Cont.):
LDL, 1172, 1173t–1174t, 1175
total, 1172, 1173t–1174t, 1175
cholesterol emboli, 991
cholesterol gallstones, 1021, 1023
cholestyramine
for erythropoietic porphyria, 1184
for hyperlipidemia, 1177t
for irritable bowel syndrome, 1017, 1017t
for nephrolithiasis, 1000t
for primary biliary cirrhosis, 1055
for primary sclerosing cholangitis, 1026
for toxic and drug-induced hepatitis, 1038
for viral hepatitis, 1037
cholinergic crisis, 201
cholinergic poisoning, 160t–161t, 
172t–173t
cholinesterase inhibitors, for Alzheimer’s 
disease, 1218
chondrocalcinosis, 1094
CHOP regimen
for aggressive lymphoma, 421
for follicular lymphoma, 420
for gastric cancer, 449
choreoathetosis, 333–334
choriocarcinoma, 463, 478t
chronic fatigue syndrome (CFS), 217–218, 
1317
CDC criteria for diagnosis of, 218t
chronic kidney disease (CKD), 960–962
chronic low back pain (CLBP), 303–304
chronic lymphocytic leukemia (CLL), 
418–419
staging of, 418, 419t
treatment of, 419
chronic lymphoid leukemia/lymphoma, 
415t, 417f
chronic myeloid leukemia (CML), 407–409
response criteria for, 408t
treatment of, 408–409
chronic obstructive pulmonary disease 
(COPD), 900t, 915–920
cyanosis in, 230
dyspnea in, 226–227
H. influenzae in, 609
M. catarrhalis in, 612–613
pulmonary function tests in, 
915–917, 915t
sleep disorders in, 339
treatment of
exacerbations of, 919–920
outpatient therapy, 917–919
surgery, 918–919
chronic progressive external 
ophthalmoplegia (CPEO), 
1310, 1312
chronic pulmonary aspergillosis, 748
Churg-Strauss syndrome, 1078
Chvostek’s sign, 1164
chylothorax, 944
ciclopirox olamine, for dermatophyte 
infections, 370
cidofovir
for adenovirus infections, 708
for cytomegalovirus infections, 696
for HSV infections, 690t
for smallpox, 196t
for viral encephalitis, 1280
ciguatera poisoning, 146–147
cilostazol, for arteriosclerosis, 891
cimetidine
for antivenom reaction, 144
for erosive gastropathies, 1009
ciprofloxacin
for Aeromonas infection, 620
for animal bite infections, 141t, 570t
for anthrax, 195t
for Bartonella infections, 633t
for chancroid, 567
for cholecystitis, 1024
for cholera, 540
for clostridial infection, 641t
for diverticulitis, 1018
for infectious arthritis, 576
for inflammatory bowel disease, 1015
for intestinal pseudoobstruction, 1019
for M. pneumoniae infections, 681
mechanism of/resistance to, 496, 499t
for meningococcal infection, 606
for murine typhus, 675
for necrotizing fasciitis, 571t
for osteomyelitis, 579t
for P. aeruginosa infections, 624t–625t
for perichondritis, 358
for peritonitis, 533
for plague, 632
for pneumonia, 924t, 926t
for Q fever, 679
for salmonellosis, 545
for sepsis/septic shock, 77t
for shigellosis, 547
for staphylococcal infection, 592
for tick-borne spotted fevers, 674
for tuberculosis, 654
for tularemia, 196t
for urinary tract infections, 988
circadian rhythm disorder, 337, 342
circulatory function tests, reference values 
for, 1440t
circulatory overload, 52
cirrhosis, 1051–1052
ascites in, 276, 276f
causes of, 1051t
Child-Pugh classification of, 1053t
complications of, 1052, 1052t
edema in, 236, 238–239
liver function tests in, 272t
primary bacterial peritonitis in, 532
primary biliary, 1054–1055
cisplatin
INDEX
1471
for bladder cancer, 461
for cervical cancer, 469
for endometrial cancer, 468
for esophageal cancer, 448
for extragonadal germ cell tumor, 476
for gastric cancer, 449
for head and neck cancer, 433
for lung cancer, 437, 439
for ovarian cancer, 467
for testicular cancer, 463
toxicity of, 399t
citalopram
for depression, 59
dosage and adverse effects of, 1326t
citrate therapy
for nephrolithiasis, 1000t
for renal tubular acidosis, 986
Citrobacter infection, 619–620
CJD. See Creutzfeldt-Jakob disease
CKD. See chronic kidney disease
cladribine
for follicular lymphoma, 420
for multiple sclerosis, 1267
toxicity of, 398t
clarithromycin
drug interactions with, 503t
for H. influenzae infection, 610
for H. pylori eradication, 1008t
for Legionella infection, 626
for M. catarrhalis, 613
for nontuberculous mycobacterial 
infections, 663
for pertussis, 612
for pneumonia, 924t
claudication, intermittent, 890
claustrophobia, 1322
CLBP. See chronic low back pain
clenched-fist injury, 140, 141t
clidinium, poisoning, 168t
clindamycin
for actinomycosis, 648
adverse reactions to, 501t
for animal bite infections, 141t, 570t
for anthrax, 195t
for babesiosis, 126t, 771
for bacterial vaginosis, 554
for cellulitis, 570t
for clostridial infection, 641t
for clostridial infections, 128t
for Corynebacterium infection, 603
for diphtheria, 601
for erythroderma, 127t
for gas gangrene, 571t
for lung abscess, 928
for malaria, 766t
mechanism of/resistance to, 496, 497t
for mixed anaerobic infections, 643
for necrotizing fasciitis, 127t, 571t
for osteomyelitis, 578t
for otitis media, 356t–357t
for pelvic inflammatory disease, 556
for pneumococcal infections, 582
for Pneumocystis infections, 761–762, 761t
for sepsis/septic shock, 77t
for snakebite, 142t
for staphylococcal infection, 591t, 592
for streptococcal infection, 594t, 598
for toxic shock syndrome, 127t
for toxoplasmosis, 777
clinical chemistry, reference values for 
laboratory tests, 1402t–1420t
CLL. See chronic lymphocytic leukemia
clofazimine, for leprosy, 660
clomiphene citrate, for female 
infertility, 1159
clomipramine, 1325
for daytime sleepiness, 342
dosage and adverse effects of, 1326t
for OCD, 1321
clonazepam
dosage and action of, 1328t
for dyspnea, 58t
for myoclonus, 335
for pain, 44t–45t
poisoning, 174t
for posthypoxic myoclonus, 116
for seizures, 1209t
for vertigo, 323t
clonidine
for menopausal symptoms, 1157
for migraine prevention, 314t
for narcotic withdrawal, 1342
poisoning, 169t
for smoking cessation, 1373, 1374t
for tics, 334
clonorchiasis, 786–787
clopidogrel
for angina pectoris, 862
for myocardial infarction, 848, 857–858
preventive treatment, 854
for stroke prevention, 102
for thrombotic disorders, 394
for unstable angina, 857–858
clostridial infection, 635–640
botulism, 637–639
food poisoning, 539
myonecrosis. See gas gangrene
tetanus, 635–637
treatment of, 641t
Clostridium botulinum infection. See 
botulism
Clostridium difficile infection (CDI)
diarrhea, 549–551
nosocomial, 509
Clostridium tetani infection. See tetanus
clotrimazole, for candidiasis, 252, 554
clozapine
dosage and adverse effects of, 169t, 1331t
for schizophrenia, 1319
clubbing, 230–231, 233, 434
1472
INDEX
cluster headache, 307, 308t, 314–315
CML. See chronic myeloid leukemia
CMP. See cardiomyopathy
CMV infection. See cytomegalovirus 
infection
CMV regimen, for bladder cancer, 461
CNS disease. See central nervous system 
disease
coagulase-negative staphylococci (CoNS), 
588–589
treatment of, 589, 590t–591t, 592
coagulation disorders, 390
dilutional, 390
drug-induced, 1383t
intracranial hemorrhage in, 96t
in liver disease, 273
reference values for laboratory tests, 
1394t–1402t
coal tar shampoo, 369
coal worker’s pneumoconiosis, 913
coarctation of aorta, 814
hypertension in, 834–835
cocaine, 166t, 182t–183t
coccidioidomycosis, 754–756
primary pulmonary, 755–756
cochlear implant, 353
Cockcroft-Gault formula, 287
codeine
for cough, 232
for dyspnea, 58t
narcotic abuse, 1340
for pain, 44t–45t
CODOX-M regimen, for Burkitt’s 
lymphoma, 423
Cogan’s syndrome, 1079
cognitive behavioral therapy (CBT)
for chronic back pain, 303
for chronic fatigue syndrome, 218
for insomnia, 339–340
cognitive-behavioral psychotherapy, 1321
cogwheeling, 1221
colchicine
for amyloidosis, 1104
for gout, 1093
for pericarditis, 831
for pseudogout, 1095
colectomy, 452, 1015, 1369
colesevelam, for hyperlipidemia, 1177t
colestipol, for hyperlipidemia, 1177t
colistin
for enteric GNB infection, 620
for Klebsiella infections, 618
for P. aeruginosa infections, 625t
colitis
amebic, 548–549
drug-induced, 1387t
ischemic, 1020
ulcerative. See ulcerative colitis
collagen vascular disease
eosinophilia in, 386
monocytosis in, 385
colon cut-off sign, 1028
colonic angiodysplasia, 1020
colonic disease, 1016
colonic polyps, 452–453
hereditary syndromes, 452–453, 453t
colonoscopy, 1366, 1367t–1368t, 1369
for colonic angiodysplasia, 1020
for colonic polyps, 452
for colorectal cancer, 454, 456–457
in diarrhea, 257
for GI bleeding, 264
color vision, drug-induced abnormalities, 
1390t
colorectal cancer, 453–457
advanced tumor, 456
local disease, 456
pathology of, 454, 455f
prevention of, 456–457, 1369–1370
risk factors for, 1369
screening for, 456–457, 1347t, 1366, 
1367t–1368t, 1369
staging and prognosis for, 455f
colostomy, for anal cancer, 457
Colyte, 190
coma, 86, 88–92
approach to, 88–91
differential diagnosis of, 90t
eye movements in, 91–92
in head trauma, 111
hyperosmolar, 118, 121
myxedema, 1118–1119
pupillary signs in, 91
respiratory patterns in, 92
responsiveness in, 91
commission, errors of, 1
common cold, 354
coronavirus, 703, 704t, 705
human RSV, 704t, 705–706
rhinovirus, 703, 704t
common variable immunodeficiency 
(CVID), 1069
community-acquired pneumonia (CAP), 
920–923
antibiotic therapy, 923, 924t
complications of, 923
laboratory features of, 922
site of care, 922–923, 924t
complete transposition of great 
arteries, 815
complex regional pain syndrome, 
1241–1242
complications, prevention of, 39
compression stockings, 104
for orthostatic hypotension, 1242
for peripheral vascular disease, 894
compulsive personality disorder, 1324
computed tomography (CT)
in acute, catastrophic abdominal pain, 243
in coma, 92
for hearing loss, 350
in heart disease, 808, 809t
INDEX
1473
hepatobiliary, 274, 1022t
in increased intracranial pressure, 108
indications for, 28–29
neuroimaging, 1197, 1197t–1198t
in pancreatitis, 1029
in poisoning, 160
in respiratory disease, 904
in stroke, 95–96, 99, 101
in subarachnoid hemorrhage, 103
utility of, 29
computerized order entry systems, 2
COMT inhibitors, for Parkinson’s disease, 
1227
concussion, 109, 111
management in sports, 110t, 111
conduction aphasia, 336t, 337
condyloma acuminatum, 364f
condylomata acuminata, 568
condylomata lata, 563
confusion, 86
congenital heart disease, 811–815
acyanotic lesions with left-to-right 
shunt, 811–813
acyanotic lesions without shunt, 
813–814
complex heart lesions, 814–815
echocardiography in, 807
endocarditis prophylaxis in, 815
pulmonary hypertension in, 813
congenital rubella syndrome, 710
conivaptan, for SIADH, 1116
conjunctivitis
acute hemorrhagic, enterovirus, 716
adult inclusion, 682–683
trachoma, 559, 682–683
connective tissue disease, 1070
antiphospholipid antibody 
syndrome, 1077
interstitial lung disease in, 937
mixed, 1075–1076
rheumatoid arthritis, 1072–1074
Sjögren’s syndrome, 1076–1077
SLE, 1070–1072
systemic sclerosis, 1074–1075
CoNS. See coagulase-negative 
staphylococci
consciousness, disorders of, 86–93, 109
constipation, 258–260
causes of, 259–260
drug-induced, 259–260, 1387t
irritable bowel syndrome, 1016, 1017t
in terminally ill patient, 55
treatment of, 55, 56t, 260, 261f
contact precautions, 506
continuous positive airway pressure 
(CPAP), 948
continuous renal replacement therapy 
(CRRT), 959
contraception, 1157–1158
controller therapy, for asthma, 909–911
conversion disorder, 1323
coordination, testing of, 1196
COP. See cryptogenic organizing 
pneumonia
COPD. See chronic obstructive pulmonary 
disease
copper metabolism, 1184
coprolalia, 334
cor pulmonale, 885–886
corneal abrasion, 343
coronary arteriography, 857, 859–860
coronary artery bypass grafting (CABG), 
851t, 853, 857, 858t, 863, 863t
coronary artery disease (CAD), 855, 
856f, 858
approach to, 810f
laboratory features of, 859, 860f, 861t
stress testing in, 859, 860f, 861t
treatment of
drug therapy, 861–862, 862t
long-term suppression, 861–862
mechanical revascularization, 863, 863t
coronary artery spasm, 859
coronary vasospasm, 864
coronavirus infection, 703, 704t, 705
corrosive ingestion, 165
corticosteroid therapy
for asthma, 909–911
for COPD, 918
for cough, 232
cortisol, excess of, 1127
cortisone
for hypopituitarism, 1112t
steroid preparations, 1131, 1131t, 1133
Corynebacterium diphtheriae infection. See 
diphtheria
Corynebacterium infection, 600–603
diphtheria, 600–602
nondiphtherial species, 602–603
costochondral pain, 224
cotton dust, 914
cough, 231–232
assessment of, 232
drug-induced, 1386t
etiology of, 231
with high altitude, 157
treatment of, 232
cough headache, 315
cover test, 327
COX-2 inhibitors, for osteoarthritis, 1091
Coxiella burnetii. See Q fever
coxsackievirus infection, 714, 716. See also 
enteroviral infection
pharyngitis with, 361
CPAP. See continuous positive airway 
pressure
CPEO. See chronic progressive external 
ophthalmoplegia
CPP. See cerebral perfusion pressure
CPPD deposition disease. See calcium 
pyrophosphate dihydrate 
deposition disease
1474
INDEX
cranial nerves
CN I. See olfactory nerve
CN II, 1187–1188
CN III, 1188
CN IV, 1188
CN IX, 1189
CN V. See trigeminal nerve
CN VI, 1188
CN VII. See facial nerve
CN VIII, 1189
CN X. See vagus nerve
CN XI. See accessory nerve
CN XII. See hypoglossal nerve
disorders of, 1243–1250
multiple cranial nerve palsies, 
1249–1250
examination of, 1187–1189
C-reactive protein (CRP), 1364
creatinine, serum, 961–962
creatinine clearance, 287
crescent sign, 1098
CREST syndrome, 1074
Creutzfeldt-Jakob disease (CJD), 1213, 
1216t, 1221
critical care medicine, 35–40
critically ill patient, 35–40
initial evaluation of, 35–36
limitation or withdrawal of care, 40
mechanical ventilation, 36–38
monitoring in ICU, 38–39
multiorgan system failure, 38
neurologic dysfunction, 40
prevention of complications, 39
shock, 36, 37f
crizotinib, for lung cancer, 439
crocodile tears, 1244
Crohn’s disease (CD), 1012–1013
epidemiology of, 1011, 1011t
extraintestinal manifestations 
of, 1013
treatment of, 1013, 1014f, 1015
cromolyn sodium
for allergic rhinitis, 1064
for asthma, 910
for systemic mastocytosis, 1065
Cronkhite-Canada, 450
crossed SLR sign, 299
croup, 706–707
CRP. See C-reactive protein
CRRT. See continuous renal replacement 
therapy
crust (skin lesion), 366t, 572
cryoglobulinemia, 977t
cryoglobulinemic vasculitis, 1079
cryoprecipitate, 53, 391, 932
cryotherapy
for HPV infection, 568
for warts, 371
cryptococcosis, 749, 751
cryptococcus, in cancer patients, 513
cryptogenic organizing pneumonia (COP), 
935, 938
cryptosporidiosis, 495t
diarrhea, 542–543
CSA. See central sleep apnea
CT. See computed tomography
Cullen’s sign, 1028
culture
diagnosis of infectious disease, 487
specimen collection and transport for, 
488t–493t
CUPS. See cancer of unknown primary site
CURB-65, 923
Cushing’s syndrome, 1127–1128
hypertension in, 836
paraneoplastic, 477, 478t, 480
CVID. See common variable 
immunodeficiency
CXR. See chest x-ray
cyanide poisoning, 116, 176t
cyanosis, 229
approach to, 230–231
causes of, 230t
central, 229, 230t
peripheral, 229–230, 230t
cyclic adenosine monophosphate 
eyedrops, 1076
cyclic vomiting syndrome, 245t
cyclobenzaprine
for back pain, 303
for multiple sclerosis, 1269
poisoning, 168t, 175t
cyclopentolate, for corneal abrasion, 343
cyclophosphamide
for acute renal failure, 958
for ANCA-associated 
glomerulonephritis, 971–972
for breast cancer, 445–446
for Burkitt’s lymphoma/leukemia, 423
for CLL, 419
for gastric cancer, 449
for idiopathic thrombocytopenic 
purpura, 390
for inflammatory myopathy, 1312
for lymphoma, 420–421
for multiple sclerosis, 1269
for myasthenia gravis, 1305
for polyneuropathy, 1298
for SLE, 971, 1072
for systemic sclerosis, 1075
toxicity of, 398t
for vasculitis, 1081–1082
cycloplegics, for herpes keratitis, 345
cyclosarin, 201–202
cyclosporiasis, diarrhea, 543–544
cyclosporine
for aplastic anemia, 384
for focal glomerulosclerosis, 974
immunosuppression for renal 
transplant, 967
INDEX
1475
for inflammatory bowel disease, 1015
for inflammatory myopathy, 1312
for membranous glomerulonephritis, 974
for myasthenia gravis, 1305
for polyneuropathy, 1298
for primary sclerosing cholangitis, 1026
for psoriasis, 367
cyclosporine eyedrops, 1076
cyproheptadine
for ergot alkaloid poisoning, 166t
for serotonin syndrome, 182t
for urticaria/angioedema, 1063
cystectomy, 461
cystic fibrosis, 900t
sleep disorders in, 339
cysticercosis, 788, 789t
cystine stones, 998–999, 1000t
cystitis, 986–988
hemorrhagic, drug-induced, 398t, 1388t
interstitial, 990
cystoisosporiasis, diarrhea, 543
cytarabine
for acute lymphoblastic leukemia and 
lymphoblastic lymphoma, 423
for AML, 406, 407f
toxicity of, 398t
cytoadherence, 764
cytokeratin, in cancer of unknown 
primary, 475, 476f
cytokines
leukemoid reaction and, 385
neutropenia and, 385
cytokine signaling deficiency, 1068
cytomegalovirus immune globulin, 696
cytomegalovirus (CMV) infection, 694–696
congenital, 694–695
in immunocompromised host, 967
mononucleosis, 695
perinatal, 695
pharyngitis with, 361
in transplant recipients, 517–518, 520, 
695–696
cytopenia, refractory
with multilineage dysplasia, 410t
with unilineage dysplasia, 410t
D
dabigatran
for atrial fibrillation, 877
for thrombotic disorders, 393
dacarbazine
for melanoma, 430
toxicity of, 398t
dactinomycin, 399t
DAH. See diffuse alveolar hemorrhage
dalteparin
for thrombotic disorders, 392
for venous thromboembolism, 932
danazol
for autoimmune hemolysis, 384
for idiopathic thrombocytopenic 
purpura, 390
dantrolene
for malignant hyperthermia, 214
for multiple sclerosis, 1269
dapsone
for ANCA-associated 
glomerulonephritis, 972
for leprosy, 660–661
for Pneumocystis infections, 761, 761t, 762t
poisoning, 177t
for toxoplasmosis, 777
daptomycin
adverse reactions to, 502t
for enterococcal infections, 600
for infective endocarditis, 529
mechanism of/resistance to, 499, 499t
for osteomyelitis, 578t
for staphylococcal infection, 589, 590t
darunavir, for HIV/AIDS, 739t
dasatinib
for CML, 409
toxicity of, 400t
daunorubicin
for acute lymphoblastic leukemia and 
lymphoblastic lymphoma, 423
for AML, 406, 407f
toxicity of, 399t
daytime sleepiness, excessive, 337, 
340–342, 341t, 342t, 948
DBS. See deep-brain stimulation
DCS. See decompression sickness
DDAVP. See desmopressin
death and dying, 54–55
brain death, 92–93
leading causes of death by age, 1345, 
1346t–1348t
death rattle, 62t
debranching enzyme deficiency, 1312
decerebration, 91
decitabine, for myelodysplastic 
syndromes, 412
decompression sickness (DCS), 158–159
decongestants
for chronic fatigue syndrome, 217
for nonspecific URI, 354
poisoning, 166t, 169t
for sinusitis, 355
decontamination, after nerve agent 
exposure, 201
decortication, 91
deep venous thrombosis (DVT), 39, 
893–894, 929–933
causes of, 893, 893t
imaging for, 930–931, 931f
laboratory evaluation of, 930
prevention of, 894
thrombotic disorders, 391–392
treatment of, 392–394, 393t, 893–894, 
932–933, 933f
1476
INDEX
deep-brain stimulation (DBS), 333
for Parkinson’s disease, 1227
defecation, 254
deferasirox
for mucormycosis, 753
for thalassemia, 383–384
deferoxamine
for hemochromatosis, 1182
for iron poisoning, 178t
for thalassemia, 383–384
dehydration, in terminally ill patient, 61t
delavirdine, for HIV/AIDS, 740
delayed sleep phase syndrome, 337, 342
delirium, 86–88
common etiologies of, 87t–88t
drug-induced, 87t, 1391t
step-wise evaluation of, 88, 89t
in terminally ill patient, 59, 63t
treatment of, 59, 59t, 88
delirium tremens (DTs), 1337
demeclocycline
for hyponatremia, 480
for SIADH, 136, 480, 1116
dementia, 1212–1220. See also 
specific types
diagnosis of, 1213, 1214t–1215t, 1216t, 
1217t
differentiation of major types, 1216t
sleep disorders in, 339
dementia with Lewy bodies (DLB), 1213, 
1216t, 1220, 1238
dengue fever, 722, 1351
dengue hemorrhagic fever/dengue shock 
syndrome, 726–727
dengue hemorrhagic fever/dengue toxic 
shock syndrome, 130
denileukin diftitox, 400t
denosumab, for osteoporosis, 1170
dental caries, 642
dental procedures, endocarditis 
prophylaxis before, 531, 531t
dependent personality disorder, 1324
depression
drug-induced, 1316, 1391t
major, 1315–1317
with medical illness, 1316–1317
in terminally ill patient, 58–59
treatment of, 59, 1317, 1318f, 1325
weight loss in, 219
dermatitis, 368–369
allergic contact, 368
atopic, 364f, 368
contact, 364f
drug-induced, 1382t
irritant contact, 368–369
seborrheic, 364f, 369
stasis, 364f
dermatofibroma, 364f
dermatomes, 1192f–1194f
dermatomyositis (DM), 1310, 1311t
dermatopathic lymphadenitis, 
lymphadenopathy and, 279t
dermatophyte infections, 365, 370
desipramine
dosage and adverse effects of, 1326t
for pain, 44t–45t
desloratadine
for allergic rhinitis, 1064
for urticaria/angioedema, 1063
desmopressin (DDAVP)
for diabetes insipidus, 9, 1114
for hypernatremia, 8–9
for hyponatremia, 6, 8
for hypopituitarism, 1112t
for von Willebrand disease, 391
desquamative interstitial pneumonia 
(DIP), 900t, 938
desvenlafaxine, 1325, 1327t
device-related infections, 506–509, 507t
devic’s syndrome, 1270
DEXA. See dual-energy x-ray absorptiometry
dexamethasone
for AMS, 156, 156t
for bacterial meningitis, 1274
for brain tumor, 1258
for H. influenzae infection, 610
for hirsutism, 1155, 1156
for increased intracranial pressure, 107t
for multiple myeloma, 426
for nausea and vomiting, 401
for pneumococcal infections, 583
for salmonellosis, 545
for spinal cord compression, 113, 135
steroid preparations, 1131, 1131t, 1133
for thyrotoxicosis, 1122
dexamethasone test, 1127
dextroamphetamine
for daytime sleepiness, 340
for depression, 59
for fatigue, 58
dextromethorphan
for cough, 232
poisoning, 182t
DGI. See disseminated gonococcal infection
diabetes insipidus, 1113–1114
central, 8, 289, 290t, 1113
drug-induced, 8, 1388t
gestational, 1113
nephrogenic, 8, 289, 290t, 953, 1114
treatment of, 8–9, 1114
diabetes mellitus (DM), 1137–1144
cardiovascular disease and, 1364
clinical features of, 1138–1139
depression in, 1316
diagnosis of, 1138, 1139t
high altitude and, 158
hypertension in, 841
nephropathy, 1141
neuropathy in, 1238, 1241, 1298
pancreatic cancer and, 458
INDEX
1477
retinopathy in, 348, 348f
risk factors for, 1139t
treatment of, 1140–1144, 1141t, 1142t, 
1143t, 1364
hospitalized patient, 1142, 
1143t, 1144
type 1, 1137–1138
type 2, 1137–1138
weight loss in, 220
in women, 1375–1376
diabetic ketoacidosis (DKA), 21t, 25, 
118–120, 1139, 1144
laboratory values in, 119–120, 119f
treatment of, 22, 120, 120t
diabetic nephropathy, 975, 978
diacetylmorphine, 1340
diagnostic imaging, 26
dialysis, 963–965
for acute renal failure, 959
hemodialysis, 963–964, 964t. See also 
hemodialysis
for hypercalcemia, 1163t
peritoneal, 190, 959, 963–965
for renal disease, 962
slow low-efficiency, 959
diarrhea, 254–257
from altered intestinal motility, 255
chronic, physical examination in, 256t
from decreased absorptive state, 255, 260t
drug-induced, 1387t
exudative, 255
infectious, 254–255, 536–551, 538f–539f
inflammatory, 537t, 544–551
noninflammatory, 536–544, 537t
pathogens causing, 537t
penetrating, 537t
irritable bowel syndrome, 1016, 1017t
metabolic acidosis in, 21t, 22
nosocomial, 509–510
osmotic, 254, 257
in patients with AIDS, 256t
in returned traveler, 1361
secretory, 254–255
stool examination, 257
treatment of, 257, 258f, 259f
diascopy, 366
diastolic failure, 879
diazepam
for alcohol withdrawal, 1339
dosage and action of, 1328t
for isoniazid poisoning, 180t
for multiple sclerosis, 1269
for muscle spasms, 145
for myocardial infarction, 846
for nerve agent exposure, 202, 203t
poisoning, 174t
for vertigo, 323t
diazoxide therapy, for hypoglycemia, 124
DIC. See disseminated intravascular 
coagulation
dichloralphenazone, for migraine, 311t
dicloxacillin
for auricular cellulitis, 358
for staphylococcal infection, 591t
for streptococcal infection, 595
dicyclomine
for diverticular disease, 1018
for irritable bowel syndrome, 1017
poisoning, 168t
dietary reference intake (DRI), 46
diethylcarbamazine, for filariasis, 784
diethylstilbestrol, 399t
diffuse alveolar hemorrhage (DAH), 233
diffuse large B cell lymphoma, 421, 
448–449
diffuse white matter disease, 1214t, 
1219, 1220f
DiGeorge’s syndrome, 1069
digital rectal exam, 471f, 1367t–1368t
digital rectal exam (DRE), 456, 469–
470, 1370
digitalis
for heart failure, 881t
for mitral stenosis, 816
digitalis toxicity, 869t, 883
digoxin
for arrhythmias, 876t
for atrial fibrillation, 877
for cor pulmonale, 886
for heart failure, 883
poisoning, 171t
for supraventricular arrhythmias, 849
for tachyarrhythmias, 869t–870t
digoxin-specific antibody fragments, 171t
dihydroergotamine, for migraine, 
310t–312t
dihydropyridine, for vasospastic 
disorders, 892
diltiazem
for aortic dissection, 889
for arrhythmias, 876t
for atrial fibrillation, 877
for hypertension, 838t
for mitral stenosis, 816
for myocardial infarction, 857
poisoning, 170t
for supraventricular arrhythmias, 849
for tachyarrhythmias, 869t–870t
for unstable angina, 857
for Wolff-Parkinson-White 
syndrome, 877
diluting agent, for radionuclide 
contamination, 207
dimenhydrinate
for nausea and vomiting, 246
for vertigo, 323t
dimercaprol
for arsenic poisoning, 184t
for lead poisoning, 186t
for mercury poisoning, 187t
1478
INDEX
dioctyl sodium sulfosuccinate, for 
hemorrhoids, 1020
DIP. See desquamative interstitial 
pneumonia
diphenhydramine
for allergic rhinitis, 1064
for anaphylaxis, 139
for antivenom reaction, 144
for extrapyramidal reactions, 180t
poisoning, 168t, 182t–183t
for urticaria/angioedema, 1063
diphenoxylate
for diarrhea, 257
for inflammatory bowel disease, 1013
for irritable bowel syndrome, 1017
narcotic abuse, 1340
diphtheria, 600–602
diphtheria antitoxin, 601
diphtheria toxin, 600
diphtheria vaccine, 602
diphtheria-tetanus vaccine, 519t
diphyllobothriasis, 791
diplopia. See double vision
dipyridamole
for stroke prevention, 102
for thrombotic disorders, 394
disease prevention, 1345
immunization, 1350–1351
U.S. Preventive Services Task Force 
recommendations, 1349t
disease-modifying antirheumatic drugs 
(DMARDs), for rheumatoid 
arthritis, 1074
disequilibrium syndrome, dialysis, 964
disopyramide
for arrhythmias, 874t
for hypertrophic cardiomyopathy, 827
disseminated gonococcal infection (DGI), 
574–575
disseminated intravascular coagulation 
(DIC), 389–391
distributive shock, 70t, 71t
disulfiram, for alcoholic rehabilitation, 
1340
diuresis, osmotic, 290t
diuretics
for ascites, 277
complications of, 13, 238, 239t
for cor pulmonale, 886
for diabetic nephropathy, 975
for dilated cardiomyopathy, 825
for edema, 238
for heart failure, 880–881, 881t, 882t
for hypernatremia, 8–9
for hypertension, 836, 837t, 840t, 841, 962
for mitral stenosis, 816
for myocardial infarction, 849–850, 851t
for nephrolithiasis, 1000t
for pulmonary hypertension, 898
for restrictive cardiomyopathy, 826
for tricuspid regurgitation, 822
divalproex, for generalized anxiety 
disorder, 1321
diverticular disease, 1018
diverticulitis, 1018
diverticulosis, 264, 266
Dix-Hallpike maneuver, 321
dizziness, 320
DKA. See diabetic ketoacidosis
DLB. See dementia with Lewy bodies
DLCO (diffusing capacity of lung), 902
DM. See dermatomyositis; diabetes mellitus
DMARDs. See disease-modifying 
antirheumatic drugs
DNA repair deficiencies, 1069
DNA-dependent protein kinase gene 
deficiency, 1067
dobutamine
for beta blocker poisoning, 170t
for heart failure, 884, 884t
for myocardial infarction, 850, 850t, 851t
for pulmonary edema, 80
for shock, 72, 72t
docetaxel, 398t
for head and neck cancer, 433
docusate salts
for constipation, 56t, 260
for myocardial infarction, 846
dofetilide
for arrhythmias, 875t
for dilated cardiomyopathy, 825
dog bite, 139–140, 141t, 572
Döhle bodies, 376
domestic violence, 1377
donepezil, for Alzheimer’s disease, 1218
donovanosis, 557t, 567–568
dopamine
for anaphylaxis, 138
for beta blocker poisoning, 170t
for calcium channel blocker 
poisoning, 170t
for cardiac glycoside poisoning, 171t
for heart failure, 881t, 884, 884t
for increased intracranial pressure, 107t
for myocardial infarction, 850t, 851t
for pulmonary edema, 80
for shock, 71, 73t, 853
for sympatholytic poisoning, 169t
dopamine agonists
for acromegaly, 1110
for hyperprolactinemia, 1109
for Parkinson’s disease, 1224, 1226t
doripenem, for P. aeruginosa 
infections, 624t
dorsal root ganglionopathy, paraneoplastic, 
481t, 482–483, 482t, 483t
dothiepin, for migraine prevention, 313t
double vision, 327–328, 328t, 343
doxepin
dosage and adverse effects of, 168t, 
172t, 1326t
for pain, 44t–45t
INDEX
1479
doxorubicin
for bladder cancer, 461
for breast cancer, 445–446
for Burkitt’s lymphoma/leukemia, 423
for carcinoid tumor, 458
for endometrial cancer, 468
for gastric cancer, 449
for islet-cell tumors, 460
for lymphoma, 420–421
for multiple myeloma, 426
toxicity of, 399t
for Zollinger-Ellison syndrome, 1011
doxycycline
for actinomycosis, 648
for adult inclusion conjunctivitis, 683
for animal bite infections, 570t
for anthrax, 195t
for bacillary angiomatosis, 570t
for Bartonella infections, 633t
for brucellosis, 629
for cholera, 540
during COPD exacerbations, 919
for Corynebacterium infection, 603
for donovanosis, 568
for endemic treponematosis, 667
for enterococcal infections, 600
for epidemic typhus, 676
for epididymitis, 553
for gonococcal infections, 560t
for human granulocytotropic 
anaplasmosis, 678
for human monocytotropic 
ehrlichiosis, 677
for Legionella infection, 626
for leptospirosis, 668
for Lyme borreliosis, 665–666
for lymphatic filariasis, 784
for lymphogranuloma venereum, 562
for M. pneumoniae infections, 681
for malaria, 128t, 766t
preventive treatment, 768t
for murine typhus, 675
for onchocerciasis, 785
for pelvic inflammatory disease, 556
for plague, 196t, 632
for pneumonia, 924t
for proctitis, proctocolitis, enterocolitis, 
and enteritis, 558
for Q fever, 679
for relapsing fever, 669
for rickettsialpox, 674
for Rocky Mountain spotted fever, 
127t, 673
for rodent bite infections, 142t
for scrub typhus, 676
for staphylococcal infection, 591t
for syphilis, 565t
for tick-borne spotted fevers, 674
for tularemia, 196t, 630
for urethritis in men, 552
doxylamine poisoning, 168t
DRE. See digital rectal exam
DRI. See dietary reference intake
dronabinol, for weight loss, 221
dronedarone, for arrhythmias, 875t
droplet precautions, 506
drowsiness, drug-induced, 1391t
drug monitoring, therapeutic, reference 
values for laboratory tests, 
1421t–1427t
drug overdose, 159–190. See also 
poisoning
diagnosis of, 160t–161t
reference values for laboratory tests, 
1421t–1427t
treatment of, 163–165, 164t, 
166t–189t, 190
prevention of absorption, 165, 190
supportive care, 163–165
drug-induced illness
acne, 1382t
Addison’s disease, 1380t
agranulocytosis, 1383t–1384t
airway obstruction, 1386t
alopecia, 398t, 1382t
anaphylaxis, 1379t
anemia, 379–380, 380–381, 382t, 401, 
1384t–1385t
angina, 1385t
angioedema, 1379t
arrhythmia, 1385t
autonomic nervous system disease, 1237
AV block, 865t, 1385t
bladder dysfunction, 1388t
bone disease, 1390t–1391t
cardiomyopathy, 1385t
cataract, 1390t
coagulation disorders, 1383t
colitis, 1387t
color vision disturbance, 1390t
constipation/ileus, 259–260, 1387t
cough, 1386t
delirium, 87t, 1391t
depression, 1316, 1391t
dermatitis, 1382t–1383t
diabetes insipidus, 8
diarrhea, 1387t
drowsiness, 1391t
eczema, 1382t
edema, 236t, 237, 400t
eosinophilia, 386, 1383t–1384t
erythema multiforme, 1382t
erythema nodosum, 1382t
extrapyramidal effects, 1389t
fatigue, 215, 215t
fever, 1380t
fluid retention, 1385t–1386t
galactorrhea, 1380t
glaucoma, 1390t
gynecomastia, 399t, 1380t
hallucinations, 1391t
headache, 1389t
1480
INDEX
drug-induced illness (Cont.):
hearing loss, 350, 352, 1390t
heart disease, 399t–400t
heat stroke, 213
hemorrhagic cystitis, 398t, 1388t
hepatitis, 1037–1038
hirsutism, 1154
hyperbilirubinemia, 1381t
hypercalcemia, 1381t
hyperglycemia, 1381t
hyperkalemia, 10, 10t–11t, 16f, 1381t
hyperpigmentation, 1382t
hyperprolactinemia, 1108
hyperpyrexia, 1380t
hypertension, 1385t
hyperuricemia, 1381t
hypocalcemia, 399t
hypoglycemia, 122, 1381t
hypokalemia, 10, 1381t
hypomania, 1391t
hyponatremia, 1381t
hypotension, 1386t
hypothermia, 152t
hypothrombinemia, 1383t
insomnia, 338–339
interstitial lung disease, 935
intracranial hemorrhage in, 96t
jaundice, 270t, 1386t–1387t
leukemia, 398t–399t
leukocytosis, 1384t
leukopenia, 386
lichenoid eruptions, 1382t–1383t
liver disease, 1387t–1388t
lupus, 1071, 1379t
lymphadenopathy, 1384t
malabsorption, 1387t
mania, 1391t
metabolic acidosis, 21t, 1381t
myalgia, 1391t–1392t
myelosuppression, 398t–400t
myopathy, 1313t, 1314, 1391t–1392t
myositis, 1391t
nausea and vomiting, 245t, 398t–400t, 
401, 1387t
nephritis, 980–982, 982t, 1388t–1389t
nephropathy, 1389t
nephrotic syndrome, 1388t
neutropenia, 385, 401
obesity, 1135
optic neuritis, 1390t
oral conditions, 1387t–1388t
pancreatitis, 1388t
pancytopenia, 1385t
peptic ulcer disease, 1388t
pericarditis, 1386t
peripheral neuropathy, 398t, 1389t
pill-related esophagitis, 253
pseudotumor cerebri, 1390t
pulmonary edema, 1386t
pulmonary fibrosis, 398t–400t
pulmonary infiltrate, 1386t
pure red cell aplasia, 1384t
purpura, 1383t
renal tubular acidosis, 1388t
retinopathy, 1390t
schizophrenic-like reactions, 1391t
seizure, 1203t, 1389t
serum sickness, 1380t
sexual dysfunction, 1380t
SIADH, 398t
skin disorders, 372–373, 1383t
sleep disorders, 1391t
stroke, 1390t
thrombocytopenia, 388, 390, 401, 
1384t–1385t
thromboembolism, 1386t
thyroid disease, 1380t
toxic epidermal necrolysis, 1383t
treatment of, 401
urinary calculi, 1388t
urinary tract obstruction, 1388t
urticaria, 1383t
vestibular disorders, 1390t
weight loss, 219t
drusen, 347, 347f
DTaP vaccine, 602
DTs. See delirium tremens
dual-energy x-ray absorptiometry 
(DEXA), 1168
Duchenne’s muscular dystrophy, 1306, 1309
ductal carcinoma in situ, 443
Duke criteria, for infective endocarditis, 
524, 525t
duloxetine, 1325
dosage and adverse effects of, 1327t
for fibromyalgia, 1098
for pain, 44t–45t
for polyneuropathy, 1296, 1297t
duodenal ulcer, 1005–1007, 1008t, 1010t
durable attorney for health care, 55
Durie-Salmon staging, for multiple 
myeloma, 425t
dutasteride
for prostate cancer, 473
prevention, 1370
for prostate hyperplasia, 470
DVT. See deep venous thrombosis
dynamic visual acuity, for vertigo, 321
dysarthria, 95
dysautonomia, 1235, 1241
dysbetalipoproteinemia, 1174t, 1179
dysentery, 537t, 540
amebic, 548–549
dysesthesia, 40
dysfunctional uterine bleeding, 1150
dyskinesia, 1224
dyslipidemia, 1172
in diabetes mellitus, 1141–1142
metabolic syndrome, 842, 843t
dysmenorrhea
INDEX
1481
primary, 1154
secondary, 1154
dyspepsia, 246–247
functional, 247
peptic ulcer disease, 247
dysphagia, 248–249, 1248–1249
approach to, 248–249, 250f
esophageal, 249
oropharyngeal, 249
in terminally ill patient, 61t
dysphonia, 1248–1249
dyspnea, 226–229
approach to, 227, 228f
ARDS, 80
cardiac vs. pulmonary, 228t
paroxysmal nocturnal, 339
pulmonary edema, 228–229
in terminally ill patient, 56–57, 62t
treatment of, 22, 57, 58t
dystonia, 333
focal, 333
generalized, 333
idiopathic torsional, 333
E
EAEC infection. See enteroaggregative and 
diffusely adherent E. coli infection
ear disease
drug-induced, 1390t
external ear infections, 358–359
hearing loss, 349–353
middle ear infections, 359–360
ear infection
anaerobic, 642
otitis media
M. catarrhalis, 612–613
pneumococcal, 582
P. aeruginosa, 622, 624t
eastern equine encephalitis (EEE), 722, 724t
eating disorder, 1333–1335
clinical features of, 1333–1334
treatment of, 1334–1336, 1335f
in women, 1376
Ebola virus infection, 130, 727–728
Ebstein anomaly, 815
EBV infection. See Epstein-Barr virus infection
ECG. See electrocardiography
echinocandins, 745
for candidiasis, 747
for mucormycosis, 753
for scedosporiosis, 759
echinococcosis, 789–791
echinocytes, 375
echocardiography, 805–808
in aortic disease, 807, 809t, 887, 889
in cardiac mass, 806–807, 809t
in cardiac tamponade, 831
in cardiomyopathy, 824t, 825–827
chamber size and ventricular 
performance, 805
clinical uses of, 805–807, 805t, 807f
in congenital heart disease, 807, 
811–814
in cor pulmonale, 886
in coronary artery disease, 859, 861t
Doppler, 805t
normal values in adults, 
1443t–1446t
in endocarditis, 524
in heart failure, 879–880
in myocardial infarction, 845
in myocarditis, 828
in palpitations, 226
in pericardial disease, 806, 809t
in pericardial effusion/tamponade, 134
in pericarditis, 829, 832–833, 832f
in pulmonary embolism, 930
in pulmonary hypertension, 896
stress, 805t, 807–808
in stroke, 101
transesophageal, 805t
2-D echo, 805t, 806f
in valvular heart disease, 805–806, 807f, 
809t, 816–817, 820–821
echolalia, 334
echovirus infection, 714, 716. See also 
enteroviral infection
ecstasy (MDMA), 7
ecthyma gangrenosum, 131, 621
ectoparasites, 791–792
ectopic atrial contractions, 868f
ectopic ventricular contractions, 868f
eczema, 368
asteatotic, 364f
drug-induced, 1382t
dyshidrotic, 364f
hand, 364f
eczema herpeticum, 686
edema, 235–239, 237f
drug-induced, 236t, 237, 400t
generalized, 235–237
in heart failure, 879
idiopathic, 237
localized, 235
lymphedema, 894
in pneumonia, 921
treatment of, 237–239, 238t
EEE. See eastern equine encephalitis
EEG. See electroencephalography
efavirenz, for HIV/AIDS, 737t, 740
effective circulating volume, 4, 4t
eflornithine, for sleeping sickness, 775
E:G ratio. See erythroid:granulocytic ratio
ehrlichiosis, 148
human monocytotropic, 672t, 676–677
EIA. See enzyme immunoassay
EIEC infection. See enteroinvasive E. coli 
infection
Eikenella corrodens infection, 613–614, 614t
Eisenmenger syndrome, 813
1482
INDEX
elderly, joint pain in, 297–298
electrical nerve stimulation, for chronic 
back pain, 304
electrocardiography (ECG), 800–805
in bradyarrhythmias, 864
in cardiac hypertrophy, 802, 804t
in cardiac tamponade, 831
in cardiomyopathy, 824t, 825–827
in congenital heart disease, 811–814
in cor pulmonale, 886
in coronary artery disease, 859
heart rate, 800
in hyperkalemia, 13, 15, 16f, 17f
in hypothermia, 152
lead system, 801f
mean axis in, 801
in myocardial infarction, 225, 802, 803f, 
804t, 829t, 844, 855
in myocarditis, 828
in palpitations, 225–226
in pericarditis, 828–829, 829t, 830f, 832
in poisoning, 160
PR interval, 801
in pulmonary hypertension, 896
QRS interval, 802
QT interval, 802
rhythm, 800
ST-T waves, 803–804
in subarachnoid hemorrhage, 103
in tachyarrhythmias, 867, 868f, 869t–872t
in valvular heart disease, 816
in variant angina, 864
electrocochleography, 350
electroconvulsive therapy, 1317
electrodiagnosis
of mononeuropathy, 1299t–1301t
of muscle disease, 1306
of peripheral neuropathy, 1294–1296
electroencephalography (EEG)
in brain death, 93
in coma, 92
in seizure, 1200
in status epilepticus, 117
electrolyte balance, 4, 216t
electronic records, 1
elephantiasis, 783
eletriptan, for migraine, 310t, 312t
elliptocytes, 375
eltrombopag, for idiopathic 
thrombocytopenic purpura, 390
embolectomy, 933
embryonal carcinoma, 463
emergencies, medical, 65–207
altitude illness, 155–159
anaphylaxis, 138–139
ARDS, 80–83
bioterrorism, 191–207
bites, venoms, and stings, 139–151
cardiovascular collapse, 65–69
diabetic ketoacidosis, 118–120
drug overdose, 159–190
frostbite, 153–154
head trauma, 108–111
hyperosmolar coma, 118, 121
hypoglycemia, 122–124
hypothermia, 151–153
hypoxic-ischemic encephalopathy, 
114–116
increased intracranial pressure, 105–108
infectious disease, 125–133
oncologic, 133–138
poisoning, 139–151, 159–190
pulmonary edema, acute, 78–80
respiratory failure, 83–86
septic shock, 74–78
shock, 69–71
spinal cord compression, 112–114
status epilepticus, 116–118
stroke, 93–102
stupor and coma, 86–93
subarachnoid hemorrhage, 103–105
emergency contraceptive pills, 1157–1158
emerging disease, 509–510
emphysema
dyspnea in, 227
mediastinal, chest pain in, 224
empyema, 581, 940
anaerobic, 642
streptococcal, 594t, 595
emtricitabine, for HIV/AIDS, 736t, 741
enalapril/enalaprilat
for heart failure, 882t
for hypertensive emergencies, 841t
encephalitis. See also specific types
acute, 1270–1282
approach to, 1271, 1272f–1273f
arboviral, 721, 723t–724t
in cancer patients, 513
cytomegalovirus, 695
enterovirus, 715–716
HSV, 690t
measles, 709
paraneoplastic, 481t, 482, 482t, 483t
rabies, 719
viral, 1277t, 1278–1280
diagnosis of, 1279–1280, 1279f
pathogens, 1278
treatment of, 1280
encephalopathy
hepatic, 1059
hypoxic-ischemic, 114–116, 115f
endocarditis
bacterial, 210
Bartonella, 633t, 634
infective, 521–532
acute, 129t, 132–133, 521
clinical manifestations of, 522–524
diagnosis of, 524, 525t
epidemiology of, 521
etiology of, 521–522
INDEX
1483
HACEK group, 613–614, 614t
outcome of, 530–531
P. aeruginosa, 624t
pathogenesis of, 522
prevention of, 531–532, 531t
prophylaxis in congenital heart 
disease, 815
staphylococcal, 586–587, 592
streptococcal, 598–599
subacute, 521
treatment of, 524, 526t–528t, 
528–530, 529t
endocrine disease
adrenal, 1126–1133
diabetes mellitus, 1137–1144
drug-induced, 1380t
hypothalamus, 1105–1113
hypothermia in, 152t
leukocytosis in, 385
lymphadenopathy and, 279t
muscle disorders in, 1314
nausea and vomiting in, 245t
paraneoplastic, 477–480
pituitary
anterior, 1105–1113
posterior, 1113–1116
reproductive system disorders
female, 1150–1159
male, 1144–1150
shock in, 70t
thyroid, 1114–1116
tumors of GI tract and pancreas, 458–460
weight loss in, 219t
endodermal sinus tumor, 463
end-of-life care, 54–63. See also terminally 
ill patient
endometrial cancer, 466t, 467–468
endometritis, 555
endophthalmitis
Klebsiella, 618
P. aeruginosa, 625t
endoscopic retrograde cholangiopancreato-
graphy (ERCP), 1022t, 1025, 1031
endoscopic variceal ligation (EVL), 1058
endoscopy
in gastropathies, 1008–1009
in GI bleeding, 264
in peptic ulcer disease, 1006
end-stage renal disease (ESRD), 960
renal transplant in, 965
enfuvirtide, for HIV/AIDS, 740
enoxaparin
for deep venous thrombosis 
prevention, 893
for myocardial infarction, 845, 848, 857
for thrombotic disorders, 392
for unstable angina, 857
for venous disease, 893
for venous thromboembolism, 932
for venous thrombosis prevention, 894
entacapone, for Parkinson’s disease, 1226t
entecavir, for chronic hepatitis B, 1040, 
1041t–1043t
enteral nutrition, 49–50
decision tree for initiating, 49f
formulas for, 50
enteric bacilli, gram-negative, 615–620
Aeromonas, 620
extraintestinal E. coli, 615–616
intestinal pathogenic E. coli, 616–617
Klebsiella, 617–618
other pathogens, 619–620
Proteus, 618–619
enteric clostridial infection, 639
enteric fever, 537t
salmonellosis, 544–545
enteritis, 556, 558
enteroaggregative and diffusely adherent 
E. coli (EAEC) infection, 617
Enterobacter infection, 619–620
osteomyelitis, 577t, 579t
enterobiasis, 782–783
enteroclysis, 451
enterococcal infection, 592–593, 599–600
endocarditis, 522, 526t–527t, 529
microbiology of, 592–593
osteomyelitis, 578t
enterocolitis, 556, 558
infectious, 1013
enteroinvasive E. coli (EIEC) infection, 617
enteropathic arthritis, 1096–1097
enteropathogenic E. coli (EPEC) 
infection, 617
enterotoxigenic E. coli (ETEC) 
infection, 617
enteroviral infection, 704t, 714–717
entry inhibitors, for HIV/AIDS, 739t, 740
envenomations
marine, 144–145
snakebites, 143–144
enzyme immunoassay (EIA), 487
eosinopenia, 387
eosinophilia, 386
drug-induced, 1383t–1384t
pulmonary infiltrates with, 938
eosinophilic pneumonia, 935–936, 938
EPEC infection. See enteropathogenic 
E. coli infection
ependymoma, 1258
ephedrine, poisoning, 166t
epidemic disease, 509–510
epidemic (louse-borne) typhus, 
672t, 675–676
epidermal inclusion cyst, 364f
epididymitis, 552–553
epididymo-orchitis, mumps, 711
epidural abscess
neck pain in, 306
S. aureus, 586
spinal, 113, 129t, 1254
1484
INDEX
epidural hematoma, 109, 111
spinal, 114, 1254
epiglottitis, 362
H. influenzae, 609–610
epilepsy, 1199–1203
sleep disorders in, 339
status epilepticus, 116–118
treatment of, 1202–1203, 1205t–1212t
epinephrine
for anaphylaxis, 138–139
for antivenom reaction, 144
for beta blocker poisoning, 170t
for calcium channel blocker 
poisoning, 170t
for cardiac glycoside poisoning, 171t
for croup, 707
for heart failure, 884t
for hymenoptera sting, 151
for MAO inhibitor poisoning, 167t
epirubicin
for gastric cancer, 449
toxicity of, 399t
episcleritis, 345
eplerenone
for edema, 238t
for heart failure, 881t, 882t, 883
for hyperaldosteronism, 24, 1129
for hypertension, 837t
for myocardial infarction, 848, 850
Epley procedure, 324
epoprostenol
for pulmonary hypertension, 898
for systemic sclerosis, 1075
eprodisate, for amyloidosis, 1104
EPSEs. See extrapyramidal side effects
Epstein-Barr virus (EBV) infection, 
696–699, 698t
cancer associated with, 416, 697, 698t
pharyngitis with, 361
in transplant recipients, 967
eptifibatide
for myocardial infarction, 857
for thrombotic disorders, 394
for unstable angina, 857
Epworth Sleepiness Score, 948
ERCP. See endoscopic retrograde 
cholangiopancreatography
erectile dysfunction, 1148–1150, 1149f
ergot alkaloid poisoning, 166t
ergotamine
for cluster headache prevention, 314
for migraine, 310t, 312t
poisoning, 166t
erlotinib
for lung cancer, 439
for pancreatic cancer, 458
toxicity of, 400t
erosion (skin lesion), 366t
errors of commission, 1
ertapenem, for pneumonia, 924t, 926t
eruptive xanthoma, 1175
erysipelas, 369, 572
streptococcal, 594t, 595
erythema infectiosum, 713
erythema migrans, 664
erythema multiforme, 372
in cancer patients, 511
drug-induced, 1382t
in HSV, 686, 690t
erythema nodosum, 210, 372
drug-induced, 1382t
erythema nodosum leprosum, 657, 661
erythrocytosis. See polycythemia
erythroderma, 127t, 131
erythroid:granulocytic (E:G) ratio, bone 
marrow, 377
erythroleukemia, 405t
erythromycin
for acne, 371
for bacillary angiomatosis, 570t
for Bartonella infections, 633t
for C. pneumoniae infections, 684
for C. psittaci infection, 683
for campylobacteriosis, 546
for cellulitis, 570t
for chancroid, 567
for diphtheria, 601–602
for donovanosis, 568
drug interactions with, 503t
for H. pylori eradication, 247
for human bite infections, 141t
for Lyme borreliosis, 665
for lymphogranuloma venereum, 562
mechanism of/resistance to, 496, 497t
for nausea and vomiting, 246
for pertussis, 612
for pharyngitis, 357t
for relapsing fever, 669
for streptococcal infection, 598
erythroplakia, 432
erythropoiesis, 284
erythropoietin, decreased level of, 379
erythropoietin therapy
for anemia, 383, 401
for chronic kidney disease, 962
eschar, 211, 572
Escherichia coli infection
enteroaggregative and diffusely 
adherent, 617
enteroinvasive, 617
enteropathogenic, 617
enterotoxigenic, 617
extraintestinal, 615–616
intestinal pathogenic, 616–617
osteomyelitis, 577t, 579t
Shiga toxin-producing/entero-
hemorrhagic, 547–548, 616–617
escitalopram, 1326t
esmolol
for aortic dissection, 889, 889t
INDEX
1485
for arrhythmias, 875t
for hypertensive emergencies, 841t
for MAO inhibitor poisoning, 167t
poisoning, 170t
for sympathomimetic poisoning, 166t
for tetanus, 637
esophageal cancer, 447–448
adenocarcinoma, 447–448
paraneoplastic, 479t
squamous cell carcinoma, 447–448
esophageal inflammation, 252–253
esophageal manometry, 249
esophageal motility disorders, 249–252
esophageal pain, 221t, 222f, 224
esophageal spasm, 251–252
esophageal ulcer, 253
esophageal varices, 1058–1059
prevention of initial bleed, 1059
treatment of
acute bleeding, 1058
prevention of recurrent bleeds, 
1058–1059
esophagitis, 252–253
Candida, 252–253
eosinophilic, 253
in HIV/AIDS, 253
HSV infections, 687, 690t
pill-related, 253
viral, 252
esophagogastroscopy, 249, 447–448, 1058
esophagus, rupture of, 223f
ESRD. See end-stage renal disease
essential thrombocytosis, 412
essential tremor (ET), 332–333, 332t
estazolam poisoning, 174t
estramustine
for prostate cancer, 472
toxicity of, 398t
estrogen therapy
for amenorrhea, 1152
for hypopituitarism, 1112t
for menopausal symptoms, 1157
oral contraceptives, 1157
for osteoporosis, 1170
eszopiclone, for insomnia, 340
ET. See essential tremor
etanercept
for ankylosing spondylitis, 1083
for psoriasis, 367
for psoriatic arthritis, 1087
for rheumatoid arthritis, 1074
ETEC infection. See enterotoxigenic E. coli 
infection
ethambutol
for nontuberculous mycobacterial 
infections, 663
for tuberculosis, 653, 655t
ethanol
for AGMA inducer poisoning, 178t–179t
for hypertrophic cardiomyopathy, 827
ethchlorvynol poisoning, 175t
ethinylestradiol/norethisterone, for GI 
telangiectasis, 266
ethosuximide
poisoning, 173t
for seizures, 1207t, 1212t
ethylene glycol poisoning, 20, 21t, 22, 178t
etomidate poisoning, 175t
etoposide
for AML, 406, 407f
for extragonadal germ cell tumor, 476
for lung cancer, 437
for testicular cancer, 463
toxicity of, 399t
etravirine, for HIV/AIDS, 737t, 740
eustachian tube dysfunction, 350, 359–360
everolimus
for islet-cell tumors, 460
toxicity of, 400t
EVL. See endoscopic variceal ligation
Ewingii ehrlichiosis, 672t
exanthem subitum, 693
exanthems, enterovirus, 716
exchange transfusion, 52, 190
excoriation, 366t
exemestane
for breast cancer, 445–446
toxicity of, 399t
exenatide
for diabetes mellitus, 1140
for obesity, 1136
exercise habits, 1365
exercise testing
in coronary artery disease, 859, 860f, 861t
for palpitations, 225–226
exertional headache, 308t, 315
ExPEC infection. See extraintestinal E. coli 
infection
extensively drug-resistant (XDR) 
tuberculosis, 649
external contamination, radiation, 204
extraarticular tophi, 1092
extraintestinal E. coli (ExPEC) infection, 
615–616
extrapyramidal side effects (EPSEs), 180t, 
1329, 1389t
eye disease, 343–349
chlamydial infection, 682–683
drug-induced, 1390t
HSV infections, 686, 690t
infections, 344–345
inflammation, 345
larva migrans, 779–780
in leprosy, 660
in malnutrition, 48
nocardiosis, 645
P. aeruginosa infection, 621, 625t
paraneoplastic, 481t, 482t
red or painful eye, 343–345, 344t
toxoplasmosis, 777
1486
INDEX
eye disease (Cont.):
tumors, 348–349
eye movements, in coma, 91–92
eye trauma, 343
ezetimibe, for hyperlipidemia, 1177t
F
FAB classification
of AML, 404t–405t
of lymphoid malignancy, 414
facial diplegia, 1249
facial masking, 1221
facial myokymia, 1244
facial nerve, 1189, 1245f
disorders of, 1244, 1246
facial numbness, 1243–1244
facial pain, 315, 1243–1244
facial weakness, 1244, 1246
bilateral, 1246
facioscapulohumeral dystrophy, 1310
factitious illness, 1323
factor VIIa/tissue factor inhibitor, 
for Ebola and Marburg virus 
infections, 728
facultative bacteria, 635
faintness, 316, 320–321
FALS. See familial amyotrophic lateral 
sclerosis
famciclovir
for herpes zoster infections, 570t
for HSV infections, 567, 570t, 688, 
689t–690t
for viral meningitis, 1278
for VZV infection, 692
familial amyotrophic lateral sclerosis 
(FALS), 1231
familial combined hyperlipidemia 
(FCHL), 1174t, 1178–1179
familial hypercholesterolemia (FH), 1172
familial hypocalciuric hypercalcemia 
(FHH), 1161
familial Mediterranean fever, 
lymphadenopathy and, 280t
familial polyposis coli (FPC), 452, 453t
familial spastic paraplegia, 1256
famotidine, for erosive gastropathies, 1009
Fanconi syndrome, 952, 983t, 984
Fanconi’s anemia, 378
farmer’s lung, 914
fasciculations, 329t, 330t, 1189
fascioliasis, 787
fat requirements, 46
fatigability, 331
fatigue
chronic fatigue syndrome, 217–218
daytime, 337
drug-induced, 215, 215t
generalized, 214–217, 215t
in muscle disease, 1306
in terminally ill patient, 57–58, 61t
treatment of, 58, 217
fatty liver, 1053
FCHL. See familial combined hyperlipidemia
febrile neutrophilic dermatosis, in cancer 
patients, 511
febuxostat, for gout, 1093
fecal antigen test, H. pylori, 1006, 1007t
fecal incontinence, 62t, 255
fecal occult blood test, 262, 454, 456, 1366, 
1367t–1368t
felbamate
poisoning, 173t
for seizures, 1209t
fenofibrate, for hyperlipidemia, 1178t
fenoprofen, for pain, 44t–45t
fentanyl
narcotic abuse, 1340
for pain, 43, 44t–45t
fever, 209
approach to, 210–211, 514, 515f
in cancer patient, 137
causes of, 210
drug-induced, 1380t
myalgia with, viral disease, 720–722
with rash, 210–211
in returned traveler, 1361
treatment of, 211
fever of unknown origin (FUO)
approach to, 212, 212f
classic, 209
HIV-associated, 209, 211
neutropenic, 209, 211
nosocomial, 209, 211
treatment of, 213
fexofenadine
for allergic rhinitis, 1064
for urticaria/angioedema, 1063
FFP. See fresh-frozen plasma
FGS. See focal glomerulosclerosis
FH. See familial hypercholesterolemia
FHH. See familial hypocalciuric 
hypercalcemia
fiber, dietary, 260, 1017–1018
fibrinogen deficiency, 390
fibrinolytic therapy
for myocardial infarction, 845, 847f
for thrombotic disorders, 394
for venous thromboembolism, 933
fibromyalgia, 1098, 1317
fibrosing mediastinitis, 754
fifth disease, 713
filariasis, lymphatic, 783–784
finasteride
prostate cancer and, 473
for prostate cancer prevention, 1370
for prostate hyperplasia, 470
fingolimod, for multiple sclerosis, 1268
fire coral, 145
fish oil supplementation
for hyperlipidemia, 1178t
for IgA nephropathy, 978
for inflammatory bowel disease, 1015
INDEX
1487
Fisher syndrome, 1298
Fitz-Hugh-Curtis syndrome, 555
fixed drug eruption, 1382t
flatworm infection, 785–787
flea-borne murine typhus, 672t, 674–675
flea-borne spotted fever, 671t
flecainide, for arrhythmias, 875t
floxuridine (FUDR), for colorectal cancer, 456
fluconazole, 744
for blastomycosis, 757
for candidiasis, 252–253, 371, 554, 747
for coccidioidomycosis, 756
for cryptococcosis, 751
for Malassezia infection, 757
for urinary tract infections, 989
flucytosine, 745
for candidiasis, 747
for cryptococcosis, 751
fludarabine
for CLL, 419
for follicular lymphoma, 420
for idiopathic thrombocytopenic 
purpura, 390
toxicity of, 398t
fludrocortisone
for Addison’s disease, 1130
for adrenal insufficiency, 136
for hypoaldosteronism, 1131
for orthostatic hypotension, 1242
for SIADH, 1116
for syncope, 320
fluid absorption, in GI tract, 253–254
fluid replacement, for cholera, 540
fluid restriction
for heart failure, 880
for hyponatremia, 480
for SIADH, 136, 1116
fluid retention, drug-induced, 1385t–1386t
fluke infection
blood flukes, 495t
liver (biliary) flukes, 786–787
lung flukes, 787
flunarizine, for migraine prevention, 313t
flunitrazepam poisoning, 174t
fluoroquinolones
adverse reactions to, 502t
for Aeromonas infection, 620
for brucellosis, 629
for C. pneumoniae infections, 684
for campylobacteriosis, 546
for Corynebacterium infection, 603
for diarrhea, 1360
drug interactions with, 503t
for enterococcal infections, 600
for extraintestinal E. coli infection, 616
for H. influenzae infection, 610
for HACEK group infections, 614t
for infectious arthritis, 576
for Klebsiella infections, 618
for Legionella infection, 626
for M. catarrhalis, 613
for M. pneumoniae infections, 681
mechanism of/resistance to, 496, 499t
for nocardiosis, 646
for otitis externa, 359
for peritonitis, 533–534
for pneumococcal infections, 582
for Q fever, 679
for salmonellosis, 545
for shigellosis, 547
for sinusitis, 356t
for staphylococcal infection, 589
for tuberculosis, 654, 655t
for urinary tract infection, 988, 989t
prevention, 989
5-fluorouracil (5-FU)
for anal cancer, 457
for breast cancer, 446
for carcinoid tumor, 458
for cervical cancer, 469
for colorectal cancer, 456
for esophageal cancer, 448
for gastric cancer, 449
for head and neck cancer, 433
for pancreatic cancer, 458
toxicity of, 398t
for Zollinger-Ellison syndrome, 1011
fluoxetine
for daytime sleepiness, 342
for depression, 59
dosage and adverse effects of, 1326t
for menopausal symptoms, 1157
for migraine prevention, 314t
for OCD, 1321
for systemic sclerosis, 1075
fluphenazine, 1330t
for postherpetic neuralgia, 692
flurazepam
dosage and action of, 1328t
poisoning, 174t
flutamide
for hirsutism, 1156
for prostate cancer, 472
toxicity of, 399t
fluticasone
for allergic rhinitis, 1064
for esophagitis, 253
fluvastatin, for hyperlipidemia, 1177t
fluvoxamine
dosage and adverse effects of, 1326t
for OCD, 1321
focal glomerulosclerosis (FGS), 974
folate
for alcoholic liver disease, 1054
deficiency
anemia in, 379–380, 383
leukopenia in, 386
for methanol poisoning, 179t
FOLFIRI regimen, for colorectal cancer, 456
FOLFOX regimen, for colorectal 
cancer, 456
folinic acid, for methanol poisoning, 179t
1488
INDEX
follicle-stimulating hormone (FSH), 
1105, 1105f
deficiency of, 1111, 1112t
follicular lymphoma, 416, 417f, 419–420
folliculitis, 364f, 572
fomepizole, for AGMA inducer poisoning, 
178t–179t
fondaparinux
for antiphospholipid antibody 
syndrome, 1077
for myocardial infarction, 857
for thrombotic disorders, 393
for unstable angina, 857
for venous thromboembolism, 932
food metabolism, 46
food poisoning
bacterial, 536–539, 538f–539f
S. aureus, 587
food-borne botulism, 638
foot, muscles and innervation of, 1190t–1191t
for ANCA-associated 
glomerulonephritis, 971
foramen magnum, lesions near, 1251
forearm, muscles and innervation of, 
1190t–1191t
formoterol, for asthma, 909
fosamprenavir, for HIV/AIDS, 738t
foscarnet
for cytomegalovirus infections, 696
for HSV infections, 690t
for viral encephalitis, 1280
for viral esophagitis, 252
fosfomycin, for urinary tract infections, 989t
fosphenytoin, for status epilepticus, 117f
foxglove, 171t
FPC. See familial polyposis coli
fracture, osteoporotic, 1167–1168, 1168t
Francisella tularensis. See tularemia
fresh-frozen plasma (FFP), 52–53
for bleeding disorders, 391
for thrombotic microangiopathy, 997
for warfarin reversal, 392, 932
Friedreich’s ataxia, 1228
frontotemporal dementia (FTD), 1213, 
1216t, 1219
frostbite, 153–154, 154t
frovatriptan, for migraine, 310t, 312t
frozen shoulder, 1099
FSH. See follicle-stimulating hormone
FTD. See frontotemporal dementia
5-FU. See 5-fluorouracil
FUDR. See floxuridine
fungal infection, 744–759
antifungal agents, 744–745
aspergillosis, 747–749, 750t
allergic bronchopulmonary, 748
disseminated, 748
pulmonary, 748
sinusitis, 748
treatment of, 749, 750t
blastomycosis, 756–757
candidiasis, 745–747
in cancer patients, 513–514
deeply invasive, 746–747
mucocutaneous, 746–747
vulvovaginal, 553–554, 746–747
in chronic meningitis, 1286t–1287t
coccidioidomycosis, 754–756
diagnosis of, 485
fusariosis, 759
histoplasmosis, 753–754, 755t
in HSCT patients, 516
lymphadenopathy and, 279t
Malassezia infection, 757
mucormycosis, 751–753
nosocomial, 510
paracoccidioidomycosis, 758
penicilliosis, 758
scedosporiosis, 759
specimen collection and transport, 491t
sporotrichosis, 757–758
fungus ball, 358
FUO. See fever of unknown origin
furosemide
for ascites, 277
for edema, 238t
for heart failure, 880–881, 882t
for hypercalcemia, 480, 1163t
for hyperkalemia, 18t
for hypertension, 837t, 841
for hyponatremia, 480
for myocardial infarction, 849, 851t
for pulmonary edema, 79
for SIADH, 136
furuncle, S. aureus, 585
furunculosis, 369
fusariosis, 759
fusidic acid, for staphylococcal infection, 
590t
Fusobacterium infection, 640, 642
G
gabapentin
for generalized anxiety disorder, 1321
for menopausal symptoms, 1157
for migraine prevention, 313t
for multiple sclerosis, 1269
for pain, 43, 44t–45t
poisoning, 173t
for polyneuropathy, 1296, 1297t
for postherpetic neuralgia, 692
for seizures, 1207t
GAD. See generalized anxiety disorder
gait analysis, 1196
galactorrhea, drug-induced, 1380t
galantamine, for Alzheimer’s disease, 1218
gallstones, 221t
gametocyte, 763
gamma knife radiosurgery, 1244
gamma radiation, 204
INDEX
1489
gamma-glutamyltranspeptidase 
(GGT), 272
gamma-hydroxybutyrate (GHB), for 
daytime sleepiness, 342
ganciclovir
for cytomegalovirus infections, 696
for viral encephalitis, 1280
for viral esophagitis, 252
Gardasil, 468
Gardnerella vaginalis infection, 
vulvovaginal infection, 553–554
Gardner’s syndrome, 450, 452, 453t
GAS. See group A Streptococcus
gas exchange, disturbances of, 901–902
gas gangrene, 131, 571t, 573–574
clostridial, 640, 641t
gastrectomy, 449, 1007
gastric aspiration, 179t
gastric atrophy, 1009
gastric cancer, 448–449
adenocarcinoma, 448–449
diffuse infiltrative, 448
intestinal type, 448
staging of, 449, 450t
superficial spreading, 448
gastric lavage, 165, 1038
gastric tumor, benign, 450–451
gastric ulcer, 1005–1007
gastrinoma, 459–460, 459t, 1009–1011
gastritis, 1009
atrophic, 1009
chronic, 1009
superficial, 1009
treatment of, 266
types A and B, 1009
gastroesophageal reflux disease (GERD), 
246–247
cough in, 231–232
sleep disorders in, 339
gastroesophageal varices, 262, 266
gastrointestinal bleeding, 39, 261–266
anemia in, 380
drug-induced, 1388t
lower GI tract, 264–266, 265f
upper GI tract, 262–264, 263f
gastrointestinal cancer, 447–460
paraneoplastic, 478t
gastrointestinal decontamination, 165
gastrointestinal disease
cholecystitis
acute, 1023–1024
chronic, 1024
choledocholithiasis/cholangitis, 
1024–1025
cholelithiasis, 1021, 1023
cirrhosis, 1051–1052
colonic angiodysplasia, 1020
colonic polyps, 452–453
diverticular disease, 1018
drug-induced, 1386t–1388t
endocrine tumors, 458–460
esophageal varices, 1058–1059
gastric cancer, 448–449
gastric tumors, 450–451
gastropathies, 1008–1009
hepatic failure, 1038–1039
hepatitis
acute, 1032–1039
chronic, 1039–1051
infections in immunocompromised 
patients, 513, 517t
infectious diarrhea, 536–551, 537t, 
538f–539f
noninflammatory, 536–544
inflammatory bowel disease, 
1011–1015
intestinal pseudoobstruction, 1019
irritable bowel syndrome, 1016–1018
listerial, 607
liver tumors, 457
nausea and vomiting in, 245t
pain in, 221t, 222f, 240t
pancreatitis, 1026–1032
peptic ulcer disease, 1005–1007
portal hypertension, 1057–1059
primary sclerosing cholangitis, 
1025–1026
small-bowel tumors, 451
in travelers, 1360
tuberculosis, 651
vascular, 1019–1020
weight loss in, 219–220, 219t
Zollinger-Ellison syndrome, 
1009–1011
gastrointestinal function, normal, 
253–254, 1441t–1442t
gastrointestinal stromal cell tumor (GIST), 
448–449
gastrointestinal telangiectasis, 266
gastrointestinal tularemia, 630
gastropathies, 1008–1009
erosive, 1008–1009
gastroscopy, 449
gatifloxacin, for tuberculosis, 654
GBS. See group B Streptococcus; Guillain-
Barré syndrome
GCSE. See generalized convulsive status 
epilepticus
gefitinib
for lung cancer, 439
toxicity of, 400t
gemcitabine
for bladder cancer, 461
for breast cancer, 446
for pancreatic cancer, 458
gemfibrozil, for hyperlipidemia, 1178t
gemifloxacin, for pneumonia, 924t
gemtuzumab ozogamicin, 400t
generalized anxiety disorder (GAD), 
1321, 1325
1490
INDEX
generalized convulsive status epilepticus 
(GCSE), 116–118
generalized disease of newborn, 715
genital herpes, 566–567, 686, 689t–690t 
features of genital ulcers, 557t
proctitis, proctocolitis, enterocolitis, 
and enteritis, 556, 558 
urethritis, in women, 553
vulvovaginal infection, 553–554
genital lesion, ulcerative, 556, 557t
genital warts, 568–569, 1020
genitourinary tract cancer, 460–463
paraneoplastic, 478t
gentamicin
for bacterial meningitis, 1275t, 1276t
for Bartonella infections, 633t
for brucellosis, 629
for enterococcal infections, 600
for infective endocarditis, 526t–528t, 
529–530
for listerial infections, 608
mechanism of/resistance to, 496, 498t
for necrotizing fasciitis, 127t
for osteomyelitis, 578t
for pelvic inflammatory disease, 556
for plague, 196t, 632
for pneumonia, 926t
for sepsis/septic shock, 126t
for staphylococcal infection, 590t, 592
for streptococcal infection, 597, 599
for tularemia, 196t, 630
geographic tongue, 364f
GERD. See gastroesophageal reflux disease
germ cell tumor, 465
extragonadal, unrecognized, 476
paraneoplastic syndromes in, 482t
German measles. See rubella
GET. See graded exercise therapy
GFR. See glomerular filtration rate
GGT. See gamma-glutamyltranspeptidase
GH. See growth hormone
GHB. See gamma-hydroxybutyrate
giant cell arteritis, 327, 1078
giant platelets, 376
giardiasis, 495t
diarrhea, 541–542
enteritis, 558
Gilbert’s syndrome, 268f, 269, 272t
gingivitis, 642
necrotizing ulcerative, 642
gingivostomatitis, HSV, 685
GIST. See gastrointestinal stromal cell tumor
Gitelman’s syndrome, 953
glanders, 623, 625t
glatiramer acetate, for multiple sclerosis, 
1267–1268
glaucoma, 325f, 346–347, 346f
acute angle-closure, 345
drug-induced, 1390t
open-angle, 346–347
glimepiride, for diabetes mellitus, 1142t
glioma, 1257
glipizide, for diabetes mellitus, 1142t
global aphasia, 336–337, 336t
globulin, in liver disease, 273
globus pharyngeus, 248
glomerular disease, 968–978
serologic findings in multisystem 
diseases causing, 977t
glomerular filtration rate (GFR), 287, 288t, 
960, 963
eGFR, 961
estimation of, 287, 961
glomerulonephritis (GN)
acute, 949–951, 968–969, 969t
ANCA-associated, 971
membranoproliferative, 974–975
membranous, 973–974
postinfectious, 969
poststreptococcal, 292, 969
rapidly progressive, 949, 969–972
with ant-GBM antibodies, 971–972
causes of, 970t
immune complex-associated, 971–972
pauci-immune, 971–972
in SLE, 971
glomerulosclerosis, focal, 974
glossopharyngeal neuralgia, 1248
glucagon
for beta blocker poisoning, 170t
for calcium channel blocker 
poisoning, 170t
for hypoglycemia, 124
glucagonoma, 459–460, 459t
glucocorticoid therapy
for acne, 371
for acute disseminated 
encephalomyelitis, 1270
for acute renal failure, 959
for adhesive capsulitis, 1099
for adult T cell leukemia/lymphoma, 423
for alcoholic liver disease, 1054
for amiodarone-induced 
thyrotoxicosis, 1123
for amyloidosis, 1103–1104
for anaphylaxis, 139
for ankylosing spondylitis, 1084
for ataxia, 1230
for autoimmune hemolysis, 384
for autoimmune hepatitis, 1051
for back pain, 303–304
for brain tumor, 1258
for bursitis, 1099
clinical uses of, 1131, 1131t, 1133
for CLL, 419
for cough, 232
for croup, 707
for dermatitis, 368–369
for eczema, 368
for enterovirus, 717
for Epstein-Barr virus infections, 699
for erythema nodosum, 372
INDEX
1491
for fatigue, 58
for fever, 211
for glomerulonephritis, 974, 975
for gout, 1093
for hirsutism, 1156
for histoplasmosis, 755t
for hymenoptera sting, 151
for hypercalcemia, 136, 480, 1163t
for increased intracranial pressure, 107t
for inflammatory bowel disease, 1015
for inflammatory myopathy, 1312
for interstitial lung disease, 937
for larva migrans, 780
for leprosy, 661
for lichen planus, 368
lymphopenia with, 387
for minimal change disease, 973
monocytopenia with, 387
for multiple myeloma, 426
for muscular dystrophy, 1309
for myasthenia gravis, 1305
nasal, for allergic rhinitis, 1064
for nausea and vomiting, 246
for optic neuritis, 326–327
for osteoarthritis, 1091
for otitis externa, 359
for pityriasis rosea, 367
for Pneumocystis infections, 761t, 762
for polyneuropathy, 1298
for primary sclerosing cholangitis, 1026
for pseudogout, 1095
for psoriasis, 367
for psoriatic arthritis, 1087
for reactive arthritis, 1088
for rheumatoid arthritis, 1074
for sarcoidosis, 1101
for schistosomiasis, 786
for Sjögren’s syndrome, 1077
for SLE, 971, 1072
for spinal cord compression, 113
steroid preparations, 1131, 1131t, 1133
for Stevens-Johnson syndrome, 372
for systemic mastocytosis, 1066
for systemic sclerosis, 1075
for taeniasis solium and cysticercosis, 788
for tendinitis, 1099
topical, for inflamed eye, 345
for trichinellosis, 779
tuberculosis, 651–652
for vasculitis, 1081
for vertigo, 324
glucocorticoids, adrenal, 1126
gluconate, for hyperkalemia, 18t
glucosamine and chondroitin, for 
osteoarthritis, 1091
glucose therapy
for hypoglycemia, 124
for salicylate poisoning, 179t
glucose-6-phosphate dehydrogenase 
deficiency, 380–381, 382t, 384
glucose-lowering agents, oral, 1140, 1142t
glulisine, for diabetes mellitus, 1140
gluten-free diet, 1230
glutethimide poisoning, 175t
glyburide, for diabetes mellitus, 1142t
glycocholic breath test, 257
glycolytic defects, 1312
glycopeptides, mechanism of, 496
glycylcyclines
adverse reactions to, 502t
mechanism of, 496
GN. See glomerulonephritis
GNB. See gram-negative bacilli
goiter, 1117, 1123
nontoxic, 1123–1124
toxic multinodular, 1120, 1124
gold salts, for psoriatic arthritis, 1087
golimumab
for ankylosing spondylitis, 1083
for psoriatic arthritis, 1087
for rheumatoid arthritis, 1074
Golytely, 190
gonadotropins
deficiency of, 1107t, 1111, 1112t
hypersecretion of, 1107t, 1110–1111
gonadotropin-releasing hormone 
deficiency, 1144
gonococcemia, 210
gonorrhea, 558–559, 560t–561t
arthritis, 559, 574–576
cervicitis, 554, 559
epididymitis, 552–553
pelvic inflammatory disease, 555
proctitis, proctocolitis, enterocolitis, 
and enteritis, 556, 558
urethritis, 552–553, 559
vulvovaginal infection, 553
Goodpasture’s syndrome, 972, 977t
goserelin, for prostate cancer, 472
Gottron’s sign, 1311
gout, 1091–1094
gouty arthritis, acute, 1092–1093
GP IIb/IIIa antagonists
for myocardial infarction, 857
for unstable angina, 857
graded exercise therapy (GET), for chronic 
fatigue syndrome, 218
graft-versus-host disease, 52
grain dust, 914
gramicidin, mechanism of/resistance to, 499t
gram-negative bacilli (GNB)
Bartonella infection, 632–635, 633t
brucellosis, 627–629, 628t
enteric, 615–620
Aeromonas, 620
extraintestinal E. coli, 615–616
intestinal pathogenic E. coli, 616–617
Klebsiella, 617–618
other pathogens, 619–620
Proteus, 618–619
plague, 630–632
tularemia, 629–630
1492
INDEX
Gram’s stain, 485, 486f
granisetron, for nausea and vomiting, 246
granules
actinomycosis, 647–648
nocardiosis, 645–646
Granulicatella infection, 599
granulocyte colony-stimulating factor, 401, 
402t–403t, 433
granulocyte-macrophage colony-
stimulating factor, 401, 402t–403t
granuloma inguinale, 557t, 567–568
granulomatosis, with polyangiitis, 1078, 1291t
granulomatosis infantiseptica, 607
granulomatous angiitis, isolated, 1291t
granulomatous disease, leukocytosis in, 385
graphesthesia, 1196
Graves’ disease, 1119–1122
Graves’ ophthalmopathy, 1314
gray (radiation unit), 204
gray hepatization, 921
griseofulvin, 745
for dermatophyte infections, 370
group A Streptococcus (GAS), 593–596
bacteremia, 596
nosocomial infection, 510
pharyngitis, 593–594, 594t
pneumonia and empyema, 594t, 595
scarlet fever, 595
skin and soft tissue infections, 594t, 595
toxic shock syndrome, 594t, 596, 596t
group B Streptococcus (GBS), 597–598
group C Streptococcus, 596–597
group D Streptococcus, 598
group G Streptococcus, 596–597
growth hormone (GH), 1105, 1106f
deficiency of, 1107t, 1111, 1112t
hypersecretion of, 1107t, 1109–1110
therapy for weight loss, 221
guanabenz poisoning, 169t
guanfacine, for tics, 334
Guillain-Barré syndrome (GBS), 900t, 
1241, 1298
gumma, 564
gynecologic cancer, 464–469
gynecomastia
drug-induced, 399t, 1380t
evaluation of, 1146, 1146f
paraneoplastic, 478t
H
H2 receptor antagonists
for erosive gastropathies, 1009
for peptic ulcer disease, 1006–1007
for systemic sclerosis, 1075
HACE. See high-altitude cerebral edema
HACEK group infection, 613–614, 614t
endocarditis, 521–522, 528t
Haemophilus infection
H. ducreyi, 557t, 567
H. influenzae, 608–610
Hib strains, 519t, 609–610
NTHi strains, 608–610
HACEK group, 613–614, 614t
hallucinations
drug-induced, 1391t
hypnagogic, 341t, 342, 342t
hallucinogens, 160t–161t
halo sign, 749
haloperidol
for delirium, 59t
dosage and adverse effects of, 
169t, 1330t
for nausea and vomiting, 56, 246
haloprogin, for dermatophyte 
infections, 370
hamartoma, gastric, 450
hand
hygiene, 506, 717
muscles and innervation of, 
1190t–1191t
hand-foot-and-mouth disease, 716
Hantaan virus infection, 726
Hantavirus hemorrhagic fever with renal 
syndrome, 130
Hantavirus pulmonary syndrome, 
133, 726
HAPE. See high-altitude pulmonary 
edema
Harris and Benedict formula, 46, 46f
Haverhill fever, 140
HCAP. See health care-associated 
pneumonia
HD. See Hodgkin’s disease
head and neck infection
actinomycosis, 647
anaerobic, 642
head cancer, 432–433
infections in cancer patients, 512t
localized disease, 432–433
locally advanced disease, 433
oncologic emergencies, 134–135
paraneoplastic syndromes in, 478t, 480
prevention of, 433, 1371
recurrent or metastatic, 433
head impulse test, for vertigo, 321
head louse, 792
head trauma, 108–111, 1213, 1214t
approach to, 109, 111
concussion management in sports, 
110t, 111
hearing loss in, 349
increased intracranial pressure in, 106
intracranial hemorrhage in, 96t
post-concussion headache, 308t, 315
subarachnoid hemorrhage in, 103
headache, 307–308. See also specific types
causes of, 308t
drug-induced, 1389t
symptoms suggesting serious 
underlying disorder, 308t
INDEX
1493
health care worker, HIV/AIDS in, 742–743
health care–associated infections, 505–510
endocarditis, 522–523
epidemic and emerging problems, 509–510
nosocomial and device-related 
infections, 506–509, 507t
prevention of, 505–506, 507t
health care-associated pneumonia 
(HCAP), 920
hearing aid, 349–350, 352–353
hearing loss, 321–322, 349–353
approach to, 349, 351f
causes of, 350–352
conductive, 349–350, 353
drug-induced, 350, 352, 1390t
noise-induced, 349, 353
prevention of, 353
sensorineural, 349–350, 352
treatment of, 352–353
heart
chamber size and ventricular 
performance, 805
noninvasive examination of, 805–810
physical examination of, 795–800
heart disease. See also cardiovascular disease
cardiac mass, 806–807, 809t
chest pain in, 221t
computed tomography in, 808, 809t
congenital. See congenital heart disease
cyanosis in, 229–230, 230t
depression in, 1316
drug-induced, 399t–400t, 1385t–1386t
dyspnea in, 227–229, 228t
echocardiography in, 805–808
edema in, 235–236, 238–239
endocarditis prophylaxis, 531–532, 531t
fatigue in, 215t
high altitude and, 158
Lyme borreliosis, 664, 666
MRI in, 808, 809t
nausea and vomiting in, 245t
prevention of, 1346t–1348t, 1361
risk factors for, 854, 1362–1364
screening for, 1347t–1348t
valvular. See valvular heart disease
weight loss in, 219t
in women, 1375
heart failure, 879–885
ascites in, 275, 276f
conditions that mimic, 880
drug-induced, 1385t–1386t
edema in, 235–236, 238–239, 879
hemodynamic profiles in, 884–885, 885f
lymphadenopathy and, 280t
myocardial infarction and, 849, 850t, 851t
precipitating factors, 879
treatment of, 393t, 849–850, 850t, 851t, 
880–885, 880f, 881t, 882t, 884t
heart murmur, 798, 798t
diastolic, 797f, 798, 798t
effects of physiologic and 
pharmacologic interventions, 799t
systolic, 797f, 798, 798t
heart rate, 800
heart sounds, 796–798, 796f
effects of physiologic and 
pharmacologic interventions, 
799t
ejection click, 797
midsystolic click, 798
opening snap, 797
S1 through S4, 796–797
heart transplant
for dilated cardiomyopathy, 825
infections in recipients, 520
heartburn, 246–247
heat stroke, 213
drug-induced, 213
exertional, 213
nonexertional, 213
heavy chain deposition disease, 983t
heavy metal poisoning, 184t–189t
height, ideal weight for height, 47t
Heinz bodies, 376
Helicobacter pylori infection
detection of, 1006, 1007t
eradication of, 247, 1006–1007, 1008t
indigestion, 247
lymphoid malignancies and, 416
peptic ulcer disease, 1005–1007
helminth ectoparasites, 791–792
helminth infection, 778–791
in chronic meningitis, 1288t–1289t
diagnosis of, 494, 495t
hemapheresis, 53–54
hematemesis, 261
hematin, for porphyria, 1182–1183
hematochezia, 262
hematocrit, 283
hematologic disease
bleeding disorders, 387–391
blood smear, 375–376
bone marrow examination, 376–377
drug-induced, 1383t–1385t
fatigue in, 215t
leukocytosis, 384–386
leukopenia, 386–387
monocytosis in, 385
red cell disorders, 378–384
reference values for laboratory tests, 
1394t–1402t
thrombotic disorders, 391–394
hematopoietic stem cell transplant (HSCT)
for amyloidosis, 1103
for CLL, 419
for follicular lymphoma, 420
infections in recipients, 516–518, 517t
for severe combined immunodeficiency, 
1069
vaccination of recipients, 519t–520t, 521
1494
INDEX
hematuria, 292, 462, 952, 978
approach to, 293f
causes of, 292, 292t
gross, 292
microscopic, 292
heme preparations
for acute intermittent porphyria, 
1182–1183
for erythropoietic porphyria, 1184
hemianopia
bitemporal, 325, 325f
homonymous, 325f, 326, 330t
hemiballismus, 334
hemiblock, 802f
hemicrania, paroxysmal, 315
hemicrania continua, 315
hemifacial spasm, 1246
hemiparesis, 95, 111, 330t, 331f
hemochromatosis, 52, 1180–1182
HFE-associated, 1180–1181, 1181f
screening for, 1180f
hemodialysis
complications of, 964, 964t
for hyperkalemia, 18t
intermittent, 959
for poisoning, 167t, 173t, 178t, 179t, 
181t, 190
for tumor lysis syndrome, 137–138
hemoglobin
abnormal, 229, 231, 379–380, 381t
blood concentration, 283
unstable variants, 380
hemolysis, 283–284
leukemoid reaction in, 385
leukoerythroblastic reaction in, 385
hemolytic anemia, 283, 380–383
classification of, 381t
drug-induced, 1384t–1385t
microangiopathic, 996
hemolytic pattern
β-hemolysis, 593
γ-hemolysis, 593
α-hemolysis, 592
hemolytic uremic syndrome (HUS), 381t, 
995–997
hemoperfusion
for methylxanthine poisoning, 167t
for sedative-hypnotic poisoning, 173t
hemophilia A, 390–391
hemophilia B, 390–391
hemoptysis, 232–235, 234f
hemorrhage. See also specific types and sites
in diverticular disease, 1018
with extensive transfusion, 389
leukoerythroblastic reaction in, 385
hemorrhagic fever
with renal syndrome, 726
viral, 130, 725–727
hemorrhoidectomy, 1020
hemorrhoids, 364f, 1020
hemostatic disorders, 391
hemothorax, 944
henbane, 168t
Henderson-Hasselbalch equation, 17
Henoch-Schönlein purpura, 972, 977t, 1079
heparin
for antiphospholipid antibody 
syndrome, 1077
for arterial embolism, 891
for deep venous thrombosis 
prevention, 893
for DIC, 391
for myocardial infarction, 845, 848, 857
for thrombotic disorders, 392, 393t, 394
for unstable angina, 857
for venous disease, 893
for venous thromboembolism, 932
preventive treatment, 894
heparin-induced thrombocytopenia, 
388–390, 932
hepatic artery embolization, 458
hepatic disease. See liver disease
hepatic encephalopathy, 1059
hepatitis
acute, 1032–1039
alcoholic, 272t, 1053
autoimmune, 273, 1050
treatment of, 1050–1051
type I, 1050
type II, 1050
type III, 1050
chronic, 1039–1051
depression in, 1316
grading of, 1039
staging of, 1039
marrow damage in, 378
toxic/drug-induced, 1037–1038
viral, 1032–1037, 1033t
hepatitis A
acute, 1033t, 1034, 1034f
chronic, 1050
prevention of, 1034
hepatitis A vaccine, 519t, 1034, 1050, 
1352t–1353t, 1354f–3155f, 
1358t, 1359t
hepatitis B
acute, 1033t, 1034–1036, 1035f
chronic, 1039–1040, 1041t–1045t
hepatocellular carcinoma with, 457–458
prevention of, 1035–1036
hepatitis B immune globulin, 1035
hepatitis B vaccine, 519t, 1035–1036, 
1352t–1353t, 1354f–3155f, 1358t, 
1359t
hepatitis C
acute, 1033t, 1036, 1036f
chronic, 1040, 1047t–1049t, 1049–1050
hepatocellular carcinoma with, 457–458
prevention of, 1036
hepatitis D, 1033t, 1037
INDEX
1495
hepatitis E, 1033t, 1037
hepatobiliary disorders
imaging in, 274–275, 1022t
liver function tests in, 272t
hepatocellular carcinoma, 457–458
hepatocellular disorders, liver function 
tests in, 272t
hepatorenal syndrome (HS), 277–278
hepatotoxins, 1037–1038
hereditary elliptocytosis, 381
hereditary spherocytosis, 381, 383
heroin abuse, 1340
herpangina, 716
herpes gladiatorum, 686
herpes simplex virus (HSV) infection, 
364f, 366, 566–567, 685–688, 704t
acyclovir-resistant, 690t
Bell’s palsy, 1246
eye infection, 686, 690t
genital herpes, 566–567, 686, 689t–690t
features of genital ulcers, 557t
proctitis, proctocolitis, enterocolitis, 
and enteritis, 556, 558
urethritis, in women, 553
vulvovaginal infection, 553–554
neonatal, 687, 690t
neurologic disease, 686–687, 690t
oral-facial, 685–686, 689t–690t
pharyngitis with, 361
reactivation of, 685–686, 689t–690t
skin disease, 369–370
skin lesions, 570t
treatment of, 370, 688, 689t–690t
visceral infections, 687, 690t
whitlow, 686, 690t
herpes zoster, 364f, 366, 370, 691–692
neck pain in, 306
skin lesions, 570t
treatment of, 370
herpes zoster vaccine, 1352t–1353t, 
1354f–3155f, 1358t
herpetiform lesion, 363
heterophile test, 698, 698t
HGA. See human granulocytotropic 
anaplasmosis
HHS. See hyperglycemic hyperosmolar 
coma
5-HIAA. See 5-hydroxyindoleacetic acid
high cardiac output/low systemic vascular 
resistance shock, 36, 37f
high-altitude cerebral edema (HACE), 
155–157, 156t
high-altitude cough, sleep impairment, 157
high-altitude illness, 155–159
AMS, 155–157, 156t
HACE, 155–157, 156t
HAPE, 157
preexisting medical conditions with, 158
treatment of, 156t
high-altitude pulmonary edema (HAPE), 157
hirsutism, 1154–1156
drug-induced, 1154
evaluation of, 1155, 1155f
treatment of, 1156
histone deacetylase inhibitors, toxicity 
of, 399t
histoplasmosis, 753–754
chronic cavitary, 754, 755t
progressive disseminated, 753–754, 755t
histotoxic hypoxia, 114
histrionic personality disorder, 1324
HIV vaccine, 743
HIV/AIDS, 728–734, 740–743
acute retroviral syndrome, 730, 732–
733, 733t
advanced HIV disease, 730
asymptomatic infection, 733
chronic and persistent infection, 730
clinical features of, 732–734, 733t
cytomegalovirus infections in, 695–696
depression in, 1316
diagnosis of, 731–732, 731f
diarrhea in patients with, 256t
epidemiology of, 729
esophagitis in, 253
etiology and transmission of, 728–729
fever of unknown origin in, 209, 211
health care workers and, 742–743
immune abnormalities in, 730
immune response to HIV, 730–731
infected travelers, 1361
laboratory monitoring of, 732
neoplasms in, 734
P. aeruginosa infection, 622
pathophysiology and 
immunopathogenesis of, 729–730
pharyngitis with, 361
Pneumocystis infections in, 760–763, 762t
postexposure prophylaxis, 743
prevention of, 743, 1347t
primary infection, 729–730
secondary infectious diseases in, 734, 742
symptomatic disease, 733–734
treatment of, 734, 735t–793t, 740–742, 
741t, 742t
antiretroviral therapy, 732, 734, 
735t–739t, 740–742, 741t, 742t
prevention of secondary infections, 742
tuberculosis and, 649–652, 658t–659t
vacuolar myelopathy, 1255
in women, 1376
HIV-associated nephropathy (HIVAN), 974
HME. See human monocytotropic 
ehrlichiosis
Hodgkin’s disease (HD), 414, 415t, 426–428
Epstein-Barr virus in, 697
infections in, 512t
paraneoplastic syndromes in, 482t
staging of, 427, 427t
vaccination in, 519t–520t
1496
INDEX
homocysteine, 1364
hookworm infection, 780, 781, 1360
hormone therapy, for prostate cancer, 472
hormones, ectopic production of, 477
hornet sting, 150–151
hospital admittance, 1
hospitalized patient. See also nosocomial 
infections
care of
acid-base balance, 4–25
admission orders, 2–3
critical care medicine, 35–40
electrolyte balance, 4–25
end-of-life care, 54–63
enteral nutrition, 49–50
imaging, 26–30
nutritional status, 46–48
pain and its management, 40–46
palliative care, 54–63
parenteral nutrition, 49–50
procedures performed by internists, 
30–35
transfusion and pheresis therapy, 51–54
hot-tub folliculitis, 572
Howell-Jolly bodies, 375
HPV. See human papillomavirus
HRSV infection. See human respiratory 
syncytial virus infection
HS. See hepatorenal syndrome
HSCT. See hematopoietic stem cell 
transplant
HSV infection. See herpes simplex virus 
infection
human bite, 140, 141t, 572
human granulocytotropic anaplasmosis 
(HGA), 672t, 677–678
human herpesvirus 6 infection, 693
human herpesvirus 7 infection, 693
human herpesvirus 8 infection, 416, 693
human metapneumovirus infection, 
704t, 706
human monocytotropic ehrlichiosis 
(HME), 672t, 676–677
human papillomavirus (HPV)
infection, 568–569
cervical cancer and, 468
warts, 371
vaccine, 468, 519t, 569, 1352t–1353t, 
1354f–3155f, 1356t, 1371
human respiratory syncytial virus (HRSV) 
infection, 704t, 705–706
human T-lymphotropic virus infection, 416
Hunt-Hess Scale, for subarachnoid 
hemorrhage, 104t
Huntington’s disease, 333, 1216, 1221
HUS. See hemolytic uremic syndrome
hyaluronan, for osteoarthritis, 1091
hydralazine
for heart failure, 882t, 883
for hypertension, 841, 841t
hydralazine-nitrate, for dilated 
cardiomyopathy, 825
hydrocephalus
normal-pressure, 1213, 1220–1221
in subarachnoid hemorrhage, 105
hydrochlorothiazide
for diabetes insipidus, 9
for edema, 238t
for heart failure, 882t
for hypertension, 836, 837t
hydrocodone, for dyspnea, 58t
hydrocortisone
for Addison’s disease, 1130–1131
for adrenal insufficiency, 136
for hypopituitarism, 1112t
for inflammatory bowel disease, 1015
for myxedema coma, 1119
for sepsis/septic shock, 76
steroid preparations, 1131, 1131t, 1133
hydrogen sulfide, 176t
hydroids, 145
hydromorphone
for dyspnea, 58t
narcotic abuse, 1340
for pain, 44t–45t
hydrops fetalis, 713
hydrothorax, 235
hydroxychloroquine
for malaria prevention, 768t
poisoning, 182t–183t
for porphyria cutanea tarda, 1183
for Q fever, 679
for rheumatoid arthritis, 1074
for Sjögren’s syndrome, 1077
for SLE, 1072
5-hydroxyindoleacetic acid (5-HIAA), 
urinary, 458
hydroxyprogesterone, for endometrial 
cancer, 468
hydroxyurea
for cervical cancer, 469
for essential thrombocytosis, 414
for sickle cell anemia, 383
for systemic mastocytosis, 1066
toxicity of, 398t
hydroxyzine
for ciguatera poisoning, 147
for urticaria/angioedema, 1063
hymenoptera sting, 150–151
hyoscyamine
for irritable bowel syndrome, 1018
poisoning, 168t
hypalgesia, 40
hyperaldosteronism, 1128–1129
hypertension in, 835–836
primary, 1128
secondary, 1128
treatment of, 24
hyperalgesia, 40
hyperalimentation, 21t
INDEX
1497
hyperbaric oxygen
for AMS, 156t
for cytochrome oxidase inhibitor 
poisoning, 176t
for DCS, 159
for HAPE, 156t
for methemoglobin inducer 
poisoning, 177t
hyperbilirubinemia, 267, 267t
conjugated (direct), 267, 267t, 269
drug-induced, 1381t
unconjugated (indirect), 267, 267t, 269
hypercalcemia, 983t, 1159–1164, 1160f
causes of, 1159–1162, 1161t
diagnosis of, 1162, 1162t
drug-induced, 1381t
familial hypocalciuric, 1161, 1161t, 1164
paraneoplastic, 135–136, 477, 478t, 
479–480, 1159, 1164
treatment of, 136, 1163–1164, 1163t
hypercalciuria, 998, 1162
hypercapnia, 24, 903, 946
hypercarbia, 83
hypercholesterolemia, 1172, 1175
approach to, 1176f
cardiovascular disease and, 1362, 1363t
familial, 1172, 1173t
with hypertriglyceridemia, 1174t, 
1178–1179
isolated, 1172, 1173t, 1175
polygenic, 1173t, 1175
treatment of, 1174, 1176f, 1177t–1178t
hypereosinophilic syndromes, 386
hyperesthesia, 40
hyperglobulinemia, 273
hyperglycemia, 39
drug-induced, 1381t
hyperglycemic hyperosmolar coma (HHS), 
118, 121
hyperglycemic hyperosmolar state, 119f, 1139
hypergranular promyelocytic leukemia, 403
hyperhidrosis, 1235
primary, 1241
hyper-IgE syndrome, 1069
hyperkalemia, 10, 13–17
approach to, 16f
causes of, 10t–11t
drug-induced, 10, 10t–11t, 16f, 1381t
ECG in, 13, 15, 16f, 17f
treatment of, 15, 17, 18t, 962
hyperlipidemia, 1172, 1174t
familial combined, 1174t, 1178–1179
hyperlipoproteinemia, 1172
hypermagnesemia, 1166–1167
hypernatremia, 8–9, 9t
hyperoxaluria, 998
hyperparathyroidism
primary, 1160, 1161t, 1163
secondary, 1161t, 1162, 1164
hyperpathia, 1241
hyperphosphatemia, 1165
treatment of, 962
hyperpigmentation, drug-induced, 1382t
hyperprolactinemia, 1108–1109
drug-induced, 1108
hyperpyrexia, 209
drug-induced, 1380t
hypersegmentation, 376
hypersensitivity disorder, immediate type, 
1061–1066
allergic rhinitis, 1063–1064
angioedema, 1062–1063
pathophysiology of, 1061–1062, 1061f
systemic mastocytosis, 1065–1066
urticaria, 1062–1063
hypersomnia, 341t, 342
hypersplenism, 281, 383, 386
hypertension, 834–842
approach to, 835
cardiovascular disease and, 1363
in coarctation of aorta, 834–835
cyanosis with, 230
in diabetes, 841
drug-induced, 1385t
essential, 834
in hyperaldosteronism, 835, 1129
malignant, 97, 326, 841t, 842, 992
metabolic syndrome, 842, 843t
in pheochromocytoma, 835
portal. See portal hypertension
in pregnancy, 841
pulmonary. See pulmonary 
hypertension
in renal disease, 834, 841, 951t, 953, 962
renovascular, 834, 992–995
secondary, 834
stroke and, 101t
supine nocturnal, 1242
treatment of, 836, 837t–838t, 839, 839f, 
840t, 841–842, 841t, 1363
blood pressure goals, 836, 1363
in women, 1376
hypertensive emergency, 841t, 842
hyperthermia, 209, 213
malignant, 213
hyperthyroidism
depression in, 1316
muscle disorders in, 1314
primary, 1119–1120
secondary, 1119–1120
sleep disorders in, 339
subclinical, 1124
weight loss in, 220
hypertonic saline, for hyponatremia, 7–8
hypertransfusion therapy, 52
hypertriglyceridemia, 1172
approach to, 1176f
familial, 1173t, 1175
with hypercholesterolemia, 1174t, 
1178–1179
1498
INDEX
hypertriglyceridemia (Cont.):
isolated, 1173t, 1174, 1178
lymphadenopathy and, 280t 
treatment of, 1176f, 1177t–1178t, 1178
hypertrophic osteoarthropathy, 1097
hyperuricemia, 1091
asymptomatic, 1093
drug-induced, 1381t
hyperventilation, 947
faintness with, 321
treatment for increased intracranial 
pressure, 107t, 108
hyperviscosity syndrome, 54, 286, 983t
hypervolemia, 3
hypnozoite, 764
hypoalbuminemia, 236–237, 273, 276–277, 
1164
hypoaldosteronism, 1131
hypocalcemia, 1164–1165
drug-induced, 399t
hypochondriasis, 1323
hypocuric myelopathy, 1256
hypoglossal nerve, 1189
disorders of, 1249
paraneoplastic, 477
hypoglycemia, 122–124. See also insulinoma
approach to, 123f
diagnosis of, 123–124
drug-induced, 122
diagnosis of, 124t
drug-induced, 1381t
faintness with, 321
syncope compared with, 319
treatment of, 124
hypoglycemic unawareness, 122, 124
hypogonadism, 1152
hypogonadotropic, 1145
primary, 1144–1148
secondary, 1144–1148
treatment of, 1147
hypohidrosis, 1235
hypokalemia, 10–13
approach to, 12f
causes of, 10, 10t–11t
drug-induced, 10, 1381t
hypokalemic alkalosis, 480
hypomagnesemia, 1164, 1166
hypomania, 1317–1319
drug-induced, 1391t
hyponatremia, 3–8
acute symptomatic, 7–8
approach to, 5f
chronic, 6–8
drug-induced, 1381t
euvolemic, 3, 5f, 6–7
hypervolemic, 3, 5f, 6, 8
hypovolemic, 3–6, 5f
paraneoplastic, 480
in subarachnoid hemorrhage, 104
treatment of, 7–8
hypoparathyroidism, 1164–1165
hypopharyngeal cancer, 432
hypophysectomy, for prostate cancer, 472
hypopituitarism, 1111–1113, 1112t
hypopnea, 947
hyposegmentation, 376
hyposensitization therapy, for allergic 
rhinitis, 1064
hypotension
drug-induced, 1386t
in myocardial infarction, 849–851, 853
orthostatic. See orthostatic hypotension
hypothalamic hormones, 1106f
hypothermia, 151–153
clinical features of, 152
diagnosis of, 152–153
drug-induced, 152t
risk factors for, 151, 152t
therapeutic, 68
for hypoxic-ischemic 
encephalopathy, 116
for increased intracranial pressure, 107t
for stroke, 99
treatment of, 153
hypothrombinemia, drug-induced, 1383t
hypothyroidism, 1116–1119
clinical or overt, 1117
depression in, 1316
diagnosis of, 1117f, 1118–1119
edema in, 237
muscle disorders in, 1314
primary, 1117, 1117t
secondary, 1117, 1117t
subclinical or mild, 1117
transient, 1117, 1117t
hypoventilation, 946–947
hypovolemia, 3–6
in myocardial infarction, 851t
hypovolemic shock, 36, 37f
hypoxemia, 83, 895t, 901, 946–947
approach to, 903f
ARDS, 80
mechanisms of, 903
in pulmonary edema, 228–229
hypoxia, 114
histotoxic, 114
hypoxic-ischemic encephalopathy, 
114–116
hysterectomy, 468
I
ibandronate, for osteoporosis, 1169
IBD. See inflammatory bowel disease
IBM. See inclusion body myositis
ibritumomab tiuxetan
for follicular lymphoma, 420
toxicity of, 400t
IBS. See irritable bowel syndrome
ibuprofen
for frostbite, 154, 154t
INDEX
1499
for migraine, 310t
for pain, 44t–45t
for pericarditis, 831
for SLE, 1072
ibutilide
for arrhythmias, 875t
for Wolff-Parkinson-White 
syndrome, 878
ICD. See implantable cardioverter 
defibrillator
ICP. See intracranial pressure
ICSI. See intracytoplasmic sperm 
injection
icterus. See jaundice
ICU. See intensive care unit
ICU patient. See critically ill patient
idarubicin
for AML, 406
toxicity of, 399t
idebenone, for ataxia, 1231
idiopathic myelofibrosis, 412
idiopathic pulmonary fibrosis (IPF), 900t, 
935, 937
idiopathic thrombocytopenic purpura 
(ITP), 389–390
idoxuridine, for HSV infections, 690t
ifosfamide
for cervical cancer, 469
toxicity of, 398t
IgA deficiency, isolated, 1069–1070
IgA nephropathy, 978
IHD. See intermittent hemodialysis
ILD. See interstitial lung disease
ileal pouch–anal anastomosis, 1015
ileoproctostomy, 452
ileus, drug-induced, 1387t
iloperidone, 1331t
iloprost, for pulmonary hypertension, 
898
imaging, diagnostic, 26–30
imatinib
for CML, 408–409
for gastric cancer, 449
toxicity of, 400t
imidazoles, for dermatophyte infections, 
370
imipenem
for cholecystitis, 1024
for glanders, 625t
for human bite infections, 141t
for melioidosis, 625t
for mixed anaerobic infections, 643t
for nocardiosis, 646
for P. aeruginosa infections, 624t
for peritonitis, 533
for pneumonia, 924t, 926t
for Proteus infection, 619
imipenem-cilastatin
for pancreatitis, 1029
for sepsis/septic shock, 77t
imipramine
dosage and adverse effects of, 168t, 
172t, 1326t
for noncardiac chest pain, 249
for pain, 44t–45t
imiquimod
for HPV infections, 568
for warts, 371
immune globulin, intramuscular, for 
hepatitis A, 1034
immune-complex disorders, 54
immune-mediated myelopathy, 1254–1255
immunization, 1350–1351
DTaP, 602
Hib, 519t, 609–610
HIV, 743
HPV, 519t, 569
of immunosuppressed patients, 
519t–520t, 521
influenza, 519t, 701–702
measles, 520t, 708–709
meningococcal, 519t, 606
mumps, 520t, 709, 712
pertussis, 611–612
pneumococcal, 519t, 580, 583–584
poliovirus, 715, 717
rabies, 720, 721f
recommendations for, 1346t–1348t
rotavirus, 541
rubella, 520t, 709, 711
schedule, for adults, 1352t–1353t, 
1356t–1358t
Td, 602
tetanus, 602, 637
for travelers, 1351, 1359t
tuberculosis, 656
VZV, 520t, 693
immunocompromised host
cytomegalovirus infections in, 694–696
HSV infections in, 686–688, 689t–690t
immunization of, 519t–520t, 521
infections in, 511–521
cancer patients, 511–514, 512t, 515f
transplant recipients, 515–521, 517t
Pneumocystis infections in, 759–763, 
762t
VZV infections in, 691–692
immunodeficiency disease
of adaptive immune system, 1066–1070, 
1067t
classification of, 1066–1070, 1067t
definition of, 1066
diagnosis of, 1068t
immunoglobulin deficiency syndromes, 
1069–1070
of innate immune system, 1066, 1067t
leukopenia in, 387
primary, 1066
regulatory defects, 1067t, 1070
T cell immunodeficiency, 1066–1069
1500
INDEX
immunofluorescent stains, 485, 487
immunoglobulin deficiency syndromes, 
1069–1070
immunohemolytic anemia, 381
cold antibody, 381
warm antibody, 381
immunology, reference values for 
laboratory tests, 1402t–1420t
immunoproliferative small-intestinal 
disease (IPSID), 451
immunosuppressive agents
for dilated cardiomyopathy, 825
for inflammatory bowel disease, 1015
for liver transplant, 1056
for renal transplant, 967
for SLE, 1072
for vasculitis, 1080
impetigo, 369, 572
bullous, 369
streptococcal, 594t, 595
implantable cardioverter defibrillator 
(ICD)
for dilated cardiomyopathy, 825
for heart failure, 885
for hypertrophic cardiomyopathy, 827
in vitro fertilization (IVF), 1159
inactivated poliovirus vaccine (IPV), 717
incidentaloma, 1131, 1132f
inclusion body myositis (IBM), 1310, 1311t
india ink, 485
indigestion, 246–247
indolent lymphoma, 415t, 418, 419–420
indomethacin
for ankylosing spondylitis, 1083
for pain, 44t–45t
for pericarditis, 831
for reactive arthritis, 1088
indomethacin-responsive headache, 315
infant botulism, 637–638
infections
delirium, 87t
diarrhea with, 254–255
headache in, 308t
leukemoid reaction in, 385
leukopenia in, 386
lymphadenopathy and, 279t
lymphocytosis in, 385
monocytosis in, 385
neck pain in, 306
nephritis with, 981
neutrophilia in, 385
sepsis, 74
skin disease, 369–371
with transfusion, 52
weight loss in, 219t, 220
infectious disease. See also antibacterial 
therapy; specific diseases and 
pathogens
diagnosis of, 485–496
antigen detection, 487
culture, 487, 488t–493t
microscopy, 485, 486f, 487
nucleic acid probes, 487, 494
parasitic infection considerations, 
494, 495t
serology, 487
fatigue in, 215t
focal infections with fulminant course, 
129t, 132–133
health care–associated infections, 
505–510
endocarditis, 522–523
epidemic and emerging problems, 
509–510
nosocomial and device-related 
infections, 506–509, 507t
prevention of, 505–506, 507t
in immunocompromised host, 511–521, 
967, 968t
cancer patients, 511–514, 512t, 515f
immunization and, 519t–520t, 521
transplant recipients, 515–521, 517t
medical emergencies, 125–133
treatment of, 125, 126t–129t
infectious mononucleosis
cytomegalovirus, 695
Epstein-Barr virus, 696–699, 698t
infectious myelopathy, 1255
inferior vena cava filter, 933
infertility
female, 1158–1159, 1158f
male, 1147–1148
inflammation
basophilia in, 386
neutropenia in, 385
inflammatory bowel disease (IBD), 
1011–1015
Crohn’s disease, 1012–1013
diagnosis of, 1013
enteropathic arthritis, 1096
epidemiology of, 1011, 1011t
extraintestinal manifestations of, 1013
treatment of, 1013, 1014f, 1015
ulcerative colitis, 1012
inflammatory infectious diarrhea, 537t, 
544–551
amebiasis, 548–549
campylobacteriosis, 546
Clostridium difficile infection, 549–551
salmonellosis, 544–545
shigellosis and STEC/EHEC infection, 
547–548
yersiniosis, 548
infliximab
for ankylosing spondylitis, 1083
for inflammatory bowel disease, 
1015, 1096
for psoriasis, 367
for psoriatic arthritis, 1087
for rheumatoid arthritis, 1074
INDEX
1501
influenza, 699–702, 702t, 704t
antigenic variation, 700
avian, 133
complications of, 700–701
epidemic and emerging problems, 509
H. influenzae infection, 608–610
Hib strains, 519t, 609–610
NTHi strains, 608–610
treatment of, 701–702, 702t
influenza vaccine, 519t, 701–702, 
1352t–1353t, 1354f–3155f, 
1357t–1358t
influenza virus, as bioweapon, 199
innate immune system, deficiencies of, 
1066, 1067t
inotropes, for tetanus, 637
inpatient medicine, 1
insect-borne disease
protozoan infections, 763–778
viral infections, 720–727, 723t–724t
insecticide poisoning, 172t
insomnia, 337–340, 341t
adjustment (acute), 338
drug-induced, 338–339
long-term (chronic), 338
psychophysiologic, 338
rebound, 338
short-term, 338
sleep maintenance, 338
sleep offset, 338
sleep onset, 338
transient, 338
treatment of, 339–340
insulin
combinations, 1140t
long-acting preparations, 1140t
short-acting preparations, 1140t
insulin resistance syndrome. See metabolic 
syndrome
insulin therapy
for beta blocker poisoning, 170t
for calcium channel blocker poisoning, 
170t
for diabetes mellitus, 1140–1144, 1140t, 
1143f
for diabetic ketoacidosis, 120t
for hyperglycemic hyperosmolar 
state, 121
for hyperkalemia, 18t
insulinoma, 122, 123f, 124t, 459, 459t
integrase inhibitor, for HIV/AIDS, 
739t, 740
intensive care unit (ICU), critically ill 
patient monitoring in, 38–39
intercostal neuritis, 225
interferon therapy
for adult T cell leukemia/lymphoma, 423
for HSV infections, 690t
for squamous cell carcinoma, 431
toxicity of, 400t
interferon-alpha therapy
for carcinoid tumor, 458
for chronic hepatitis B, 1040
for essential thrombocytosis, 414
for follicular lymphoma, 420
for hepatocellular carcinoma, 458
for islet-cell tumors, 460
for kidney cancer, 462
for melanoma, 430
for membranoproliferative 
glomerulonephritis, 975
for viral hepatitis, 1037
for Zollinger-Ellison syndrome, 1011
interferon-beta therapy, for multiple 
sclerosis, 1267–1268
interleukin-2 therapy
for kidney cancer, 462
for melanoma, 430
toxicity of, 400t
intermittent hemodialysis (IHD), 959
internal contamination, radiation, 204–205
international travel. See travelers
internist, procedures commonly 
performed by, 30
lumbar puncture, 32–34, 33f
paracentesis, 34–35
thoracentesis, 31–32, 31f
interstitial lung disease (ILD), 900t, 933–939
with alveolitis, inflammation, and 
fibrosis, 933, 934t
approach to, 935–936
in connective tissue disorders, 937–938
drug-induced, 935
with granulomatous reaction, 933, 934t
intestinal decompression, 1019
intestinal infection
botulism, 638
pathogenic E. coli, 616–617
intestinal motility, 254
altered, 255
intestinal parasites, diagnosis of, 494, 495t
intestinal pseudoobstruction, 1019
intraabdominal abscess, E. coli, 616
intraabdominal infection, 532–536
abscess, 534–536
clostridial, 639
peritonitis, 532–534
intra-arterial pressure monitoring, 38
intracerebral hemorrhage, 103
in head trauma, 111
intracranial pressure in, 106
treatment of, 99
intracranial aneurysm, 96t, 103
intracranial hemorrhage, 93, 95, 96t
intracranial infection, 128t
intracranial pressure (ICP)
increased, 105–108
clinical features of, 106–107
treatment of, 107–108, 107t
monitoring of, 107t, 108, 108f
1502
INDEX
intracranial tumor, 1258–1260
intracytoplasmic sperm injection (ICSI), 
1148, 1159
intraocular pressure, 346
intraperitoneal abscess, 534
intrauterine contraceptive device, 1157
actinomycosis and, 646–648
intrauterine insemination (IUI), 1159
intravascular device infection, 507t, 509
intravenous immunoglobulin
for antiphospholipid antibody 
syndrome, 1077
for CLL, 419
for Clostridium difficile infection, 551
for enterovirus, 717
for idiopathic thrombocytopenic 
purpura, 390
for immunoglobulin deficiency 
syndromes, 1070
for inflammatory myopathy, 1312
for multiple sclerosis, 1269
for myasthenia gravis, 1303
for parvovirus infections, 713
for polyneuropathy, 1296, 1298
for RSV infections, 706
for staphylococcal infection, 592
for streptococcal infection, 594t
invasive pulmonary aspergillosis, 748
iodine, radioactive, bioterrorism, 207
iodine deficiency, 1117t, 1123
iodine excess, 1119
iodoquinol, for amebiasis, 549
ipecac, syrup of, 165
IPF. See idiopathic pulmonary fibrosis
ipilimumab, for melanoma, 430
ipratropium, for COPD, 918–919
IPSID. See immunoproliferative small-
intestinal disease
IPV. See inactivated poliovirus vaccine
irbesartan, for heart failure, 882t
iridocyclitis, 345
irinotecan
for breast cancer, 446
for cervical cancer, 469
for colorectal cancer, 456
toxicity of, 399t
iris lesion, 363
iritis, 345
iron
hemochromatosis, 1180
overload, 52
poisoning, 178t
supplementation, for hypertension, 
962
iron-deficiency anemia, 378f, 379–380, 
379t, 383
irritable bowel syndrome (IBS), 1016–
1018, 1017t, 1018t
ischemia, hypoxic-ischemic 
encephalopathy, 114–116
ischemic stroke, 93–94
causes of, 99–101, 100f
treatment of, 96–99, 98t
ISDN. See isosorbide dinitrate
islet-cell tumor
pancreatic, 459–460, 459t
paraneoplastic syndromes in, 478t
ISMO. See isosorbide mononitrate
isocarboxazid, 1327t
isolation techniques, 506
isometheptene, for migraine, 311t
isoniazid
for nontuberculous mycobacterial 
infections, 663
poisoning, 180t
for tuberculosis, 653, 655t, 656, 658t
isoproterenol
for antipsychotic poisoning, 169t
for beta blocker poisoning, 170t
for calcium channel blocker 
poisoning, 170t
for membrane-active agent poisoning, 
182t–183t
for tachyarrhythmias, 872t
isosorbide dinitrate (ISDN)
for achalasia, 251
for angina pectoris, 862t
for esophageal spasm, 252
for heart failure, 882t, 883
isosorbide mononitrate (ISMO), for 
angina pectoris, 862t
isosporiasis, 495t
isotretinoin, for acne, 371
itch mite, 791
ITP. See idiopathic thrombocytopenic purpura
itraconazole, 745
for aspergillosis, 750t
for blastomycosis, 757
for candidiasis, 252–253, 747
for coccidioidomycosis, 756
for dermatophyte infections, 370
for histoplasmosis, 755t
for paracoccidioidomycosis, 758
for penicilliosis, 758
for sporotrichosis, 758
IUI. See intrauterine insemination
IV drug use, endocarditis cases, 523
ivermectin
for ascariasis, 781
for larva migrans, 780
for lymphatic filariasis, 784
for onchocerciasis, 785
for scabies, 791–792
for strongyloidiasis, 782
ixabepilone, toxicity of, 398t
J
J waves. See Osborn waves
Japanese encephalitis, 722, 723t
Japanese encephalitis vaccine, 1359t
INDEX
1503
Jarisch-Herxheimer reaction, 564
jaundice, 266–269, 458
approach to, 268f
causes of, 267, 267t
cholestatic conditions that produce, 
271t–272t
drug-induced, 270t, 1386t–1387t
hepatocellular conditions that produce, 
270t
obstructive, 272t
JC virus, 1282
jellyfish sting, 145
jet-lag disorder, 337, 342
jimson weed, 168t
joints, muscles and innervation of, 
1190t–1191t
joint disease, neuropathic, 1097
joint infection
anaerobic, 643
arthritis, 574–576, 586, 592
osteomyelitis, 576, 579–580
Klebsiella, 618
microbiology of, 576, 577t
S. aureus, 585–586, 592
treatment of, 578t–579t, 579–580
P. aeruginosa, 621, 624t
tuberculosis, 651
joint pain, 294
assessment of, 294, 295f
diagnostic imaging in, 297, 297t
in elderly, 297–298
historic features in, 294
laboratory features in, 297
physical examination in, 294–297
joint replacement surgery, 1091
for osteonecrosis, 1098
jugular foramen syndrome, 1249
jugular venous pulsation (JVP), 796
juvenile polyposis, 452, 453t
JVP. See jugular venous pulsation
K
kaolin-pectin, for diarrhea, 257
Kaposi’s sarcoma, 693
in HIV/AIDS, 734
Katayama fever, 786
Kawasaki’s disease, 1079
lymphadenopathy and, 280t
kayexalate, for hyperkalemia, 18t
KCS. See keratoconjunctivitis sicca
Kenya tick typhus, 673
keratinolytic agents, for warts, 371
keratitis, 344–345
keratoconjunctivitis sicca (KCS), 1076
keratosis pilaris, 364f
ketoacidosis. See specific types
ketoconazole
for adrenal carcinoma, 1128
for Candida esophagitis, 253
for ectopic ACTH syndrome, 480
ketolides
adverse reactions to, 501t
mechanism of, 496
ketorolac
for frostbite, 154t
for pain, 43, 44t–45t
kidney cancer, 462
infections in cancer patients, 512t
oncologic emergencies, 135–136
paraneoplastic, 462, 478t
kidney disease. See renal disease
kidney stones, 536
Kikuchi’s disease, lymphadenopathy 
and, 280t
Kingella kingae infection, 613–614, 614t
Klebsiella infection
enteric, 617–618
K. granulomatosis, 557t, 567–568
Klinefelter’s syndrome, 1144
Koplik’s spots, 709
Korsakoff’s syndrome, 1339
Kussmaul’s sign, 796
kwashiorkor, 47
kyphoscoliosis, 226, 900t
L
La Crosse encephalitis, 723t
labetalol
for aortic dissection, 889, 889t
for hypertension, 837t, 841, 841t
poisoning, 170t
for renal artery stenosis, 992
for sympathomimetic poisoning, 166t
laboratory tests, reference values for, 
1393–1450
labyrinthine dysfunction
acute bilateral, 322
acute unilateral, 322
recurrent, 322
labyrinthitis, 245t, 322, 322t
lacosamide, for seizures, 1211t
lactic acidosis, 20, 21t, 22
D-Lactic acidosis, 20, 21t
lactose hydrogen breath test, 257
lactulose
for constipation, 56t, 260
for hepatic encephalopathy, 1059
for irritable bowel syndrome, 1017t
lacunar syndromes, 95, 101
Lambert-Eaton myasthenic syndrome 
(LEMS), 481t, 483t
laminectomy, decompressive, 113
lamivudine
for chronic hepatitis B, 1037, 1040, 
1041t–1043t
for HIV/AIDS, 735t, 741
lamotrigine
for bipolar disorder, 1319
dosage and adverse effects of, 173t, 
1332t
1504
INDEX
lamotrigine (Cont.):
for seizures, 1206t, 1212t
for trigeminal neuralgia, 1244
lanreotide autogel, for acromegaly, 1110
lansoprazole
for H. pylori eradication, 1008t
for Zollinger-Ellison syndrome, 1010
larva migrans
cutaneous, 780
ocular, 779–780
visceral, 779–780
laryngeal cancer, 432
laryngeal palsy, 1249
laryngitis, 361–362
laser therapy
for diabetic retinopathy, 348
for esophageal cancer, 448
for glaucoma, 347
Lassa fever, 130, 725
lateral sclerosis, amyotrophic, 900t
latex agglutination assay, 487
Laurence-Moon-Biedl syndrome, 1135
laxatives, 56t
for constipation, 260
for hemorrhoids, 1020
LBP. See low back pain
LCM. See lymphocytic choriomeningitis
lead poisoning, 185t–187t
leech infestation, 792
leflunomide
for psoriatic arthritis, 1087
for rheumatoid arthritis, 1074
left ventricular function, assessment by 
nuclear cardiology, 808, 809t
Legionella infection, 623, 626–627
nosocomial, 510, 623
specimen collection and 
transport, 492t
Legionnaires’ disease, 623, 626
leiomyoma
gastric, 450
small-bowel, 451
leiomyosarcoma, gastric, 448–449
leishmaniasis, 771–773
cutaneous, 772–773
mucosal, 772–773
visceral, 772–773
Lemierre’s syndrome, 642
LEMS. See Lambert-Eaton myasthenic 
syndrome
lenalidomide
for multiple myeloma, 426
for myelodysplastic syndromes, 412
lepirudin
for heparin-induced 
thrombocytopenia, 390
for thrombotic disorders, 393
leprosy, 656–657, 660–661
complications of, 657, 660
lepromatous, 656–657
treatment of, 660–661
tuberculoid, 656–657
leptomeningeal metastasis, 1261, 1261t
leptospirosis, 667–668
Leriche syndrome, 890
letrozole
for breast cancer, 445–446
toxicity of, 399t
leucovorin
for colorectal cancer, 456
for gastric cancer, 449
for Pneumocystis infections, 
761t, 762t
leukapheresis, 54
leukemia, 378. See also specific types
acute lymphoblastic, 422–423
adult T cell, 423
definition of, 414
drug-induced, 398t–399t
infections in cancer patients, 512t
megakaryoblastic, 405t
monocytic, 405t
monocytopenia in, 387
myeloblastic, 404t–405t
myelomonocytic, 405t
oligoblastic, 409
leukemoid reaction, 385
leukocytes
inclusion and nuclear 
abnormalities, 376
normal values in blood, 384t
leukocytosis, 384–386
drug-induced, 1384t
leukoerythroblastic reaction, 385
leukopenia, 386–387
drug-induced, 386
leukoplakia, 364f, 432
oral, 1371
oral hairy, 364f
leuprolide
for prostate cancer, 472
toxicity of, 399t
levetiracetam
for myoclonus, 335
poisoning, 173t
for seizures, 1209t, 1212t
levocetirizine
for allergic rhinitis, 1064
for urticaria/angioedema, 1063
levodopa
for neuroleptic malignant 
syndrome, 214
for Parkinson’s disease, 1224, 1226t
levofloxacin
for C. pneumoniae infections, 684
for Legionella infection, 626
for M. pneumoniae infections, 681
for P. aeruginosa infections, 625t
for pneumococcal infections, 582
for pneumonia, 924t, 926t
INDEX
1505
for S. maltophilia infection, 625t
for sepsis/septic shock, 77t
for sinusitis, 356t
for tuberculosis, 654
levorphanol, for pain, 43, 44t–45t
levosimendan, for heart failure, 884t
levothyroxine
for hypothyroidism, 1119
for thyroid neoplasms, 1126
for thyrotoxicosis, 1122
lewisite, 200
LH. See luteinizing hormone
Lhermitte’s symptom, 1263
lice, human, 792
lichen planus, 364f, 368
lichen simplex chronicus, 364f
lichenification, 366t
lichenoid eruption, drug-induced, 
1382t–1383t
Liddle’s syndrome, 24
lidocaine
for antidepressant poisoning, 172t
for antipsychotic poisoning, 169t
for arrhythmias, 874t
for cardiac glycoside poisoning, 171t
for membrane-active agent poisoning, 
182t–183t
for polyneuropathy, 1296, 1297t
for postherpetic neuralgia, 692
for tachyarrhythmias, 871t–872t
Li-Fraumeni syndrome, 441
light chain deposition disease, 983–
984, 983t
lightheadedness, 321
limb dystonia, 333
limb-girdle dystrophy, 1309
limbic encephalitis, paraneoplastic, 481t, 
482, 482t, 483t
linagliptin, for diabetes mellitus, 1142t
lincosamides, mechanism of/resistance to, 
496, 497t
linear skin lesion, 363
linezolid
adverse reactions to, 502t
for enterococcal infections, 600
mechanism of/resistance to, 496, 498t
for MRSA infections, 570t
for nocardiosis, 646
for osteomyelitis, 578t
for pneumonia, 924t, 926t
for staphylococcal infection, 589, 
590t–591t
linitis plastica, 448
liothyronine, for thyroid neoplasms, 1126
lipase, serum, 1028
lipemia retinalis, 1175
lipoglycopeptides, mechanism of, 496
lipoma, small-bowel, 451
lipoprotein analysis, 1172, 
1173t–1174t, 1175
lipoprotein lipase deficiency, 1173t–1174t, 
1175, 1178
liquid nitrogen, for warts, 371
liraglutide
for diabetes mellitus, 1140
for obesity, 1136
lisinopril
for heart failure, 882t
for hypertension, 838t
listerial infection, 606–608
lithium, 1329, 1332
for amiodarone-induced thyrotoxicosis, 
1123
for bipolar disorder, 1319
for cluster headache prevention, 314
dosage and adverse effects of, 9, 181t, 
1332t
in nephrogenic diabetes insipidus, 953
liver abscess, 535
amebic, 549
liver biopsy, percutaneous, 275
liver disease
alcoholic, 1053–1054
benign tumors, 457
coagulation disorders in, 390–391
drug-induced, 1387t–1388t
hepatobiliary imaging in, 274–275
jaundice in, 266
liver failure
acute, 1038–1039
adverse prognostic indicators, 1038
sleep disorders in, 339
liver flap, 335
liver function tests, 269–274, 269f, 272t
liver transplant, 1055–1056
for acute hepatic failure, 1038–1039
for alcoholic liver disease, 1054
for amyloidosis, 1104
for ascites, 277
for chronic hepatitis B, 1044–1045tt
contraindications to, 1056t
for hepatic encephalopathy, 1060
immunosuppressive agents for, 1056
indications for, 1055t
infections in recipients, 520–521
medical complications after, 1056
for primary biliary cirrhosis, 1055
for primary sclerosing cholangitis, 1026
for toxic and drug-induced hepatitis, 
1038
for viral hepatitis, 1037
for Wilson’s disease, 1184–1185
LMWH. See low-molecular-weight 
heparin
lobeline, 173t
local anesthetics, 177t, 182t–183t
lockjaw, 636
lofexidine, for narcotic withdrawal, 1342
Löffler’s syndrome, 781
Löfgren’s syndrome, 1100
1506
INDEX
loperamide
for diarrhea, 257, 1360
for inflammatory bowel disease, 1013
for irritable bowel syndrome, 1017, 1017t
lopinavir/ritonavir, for HIV/AIDS, 738t
loratadine
for allergic rhinitis, 1064
for urticaria/angioedema, 1063
lorazepam
for delirium, 59t
dosage and action of, 1328t
for dyspnea, 58t
for myocardial infarction, 846
for nausea, 56
poisoning, 174t
for status epilepticus, 117f
losartan
for heart failure, 882t
for hypertension, 838t
for systemic sclerosis, 1075
louse-borne epidemic typhus, 672t, 675–676
louse-borne relapsing fever, 668–669
lovastatin, for hyperlipidemia, 1177t
low back pain (LBP), 298–304
acute, 300t, 302
causes of, 300–303
visceral, 302, 302t
chronic, 303–304
examination in, 298–299, 299t
risk factors for structural cause, 300t
treatment of, 303–304
types of, 298
low back strain/sprain, 301
lower esophageal sphincter, disorders 
of, 251
low-molecular-weight heparin (LMWH)
for deep venous thrombosis 
prevention, 893
for myocardial infarction, 848, 857
for thrombotic disorders, 392, 393t
for unstable angina, 857
for venous disease, 893
preventive treatment, 894
for venous thromboembolism, 932
loxapine, 1330t
lubiprostone, for irritable bowel syndrome, 
1017t
Ludwig’s angina, 642
lumbar disk disease, back pain in, 300–301
lumbar puncture, 32–34, 33f, 490t
for meningococcal infection, 605
lumbar puncture headache, 315
lumpectomy, 443
lung abscess, 923, 928–929
lung biopsy, 936
lung cancer, 433–441
adenocarcinoma, 433, 439, 439t
bronchoalveolar, 433, 439t
causes of, 433–434, 912–914
chest pain in, 221t
diagnosis of, 904–905
epidermoid (squamous), 433
large cell, 434
non-small cell, 437, 438t, 439
oncologic emergencies, 134–135
paraneoplastic syndromes in, 434, 
478t–479t, 480, 482t, 483t
prevention of, 1370
screening for, 1369
small cell (oat cell), 434, 438t–439t, 439
staging of, 434, 435t–437t, 437
treatment of, 437, 438t–439t, 439
lung disease
actinomycosis, 647
anaerobic infections, 642
aspergillosis, 748, 750t
coccidioidomycosis, 755–756
cor pulmonale, 885–886
cryptococcal, 751
cyanosis in, 229, 230t
diffuse parenchymal, 226
dyspnea, 226–229, 228t
environmental, 911–914
inorganic dusts, 912–914
occupational exposures, 912–914
organic dusts, 914
toxic chemicals, 914
fatigue in, 215t
high altitude and, 158
interstitial, 900t, 933–939, 934t
mucormycosis, 752
nocardiosis, 644, 647t
nontuberculous mycobacterial 
infections, 661–662
pulmonary hypertension in, 895t
tuberculosis, 650
lung transplant
for COPD, 919
infections in recipients, 520
for interstitial lung disease, 937
lung volumes, 899f
lung volume reduction surgery, 918–919
lupus, drug-induced, 1071, 1379t
lurasidone, 1331t
luteinizing hormone (LH), 1105, 1106f
deficiency of, 1111, 1112t
Lyme borreliosis, 148, 663–666
chronic disease, 665
disseminated infection, 664
localized infection, 664
persistent infection, 664–665
lymphadenitis, in tuberculosis, 650
lymphadenopathy, 278–281
approach to, 280
diseases associated with, 279t–280t
drug-induced, 1384t
due to hyperplasia, 279
due to infiltration, 279
in HIV/AIDS, 733
nontuberculous mycobacterial, 662
INDEX
1507
for toxoplasmosis, 777
treatment of, 280–281
lymphangiectasia, intestinal, 387
lymphedema, 894
lymphoblastic leukemia, 422–423
lymphoblastic lymphoma, 422–423
lymphocutaneous disease, nocardiosis, 
645, 647t
lymphocytes, defective egress of, 1069
lymphocytic choriomeningitis (LCM), 
721–722
lymphocytic leukemia, chronic, 418–419
staging of, 418, 419t
treatment of, 419
lymphocytic meningitis, chronic benign, 
1291t
lymphocytosis, 385
lymphoepithelioma, 432
lymphogranuloma venereum, 556, 558–
559, 561–562
features of genital ulcers, 557t
lymphoid leukemia/lymphoma
acute, 415t, 417f, 422–423
adult T cell leukemia/lymphoma, 423
lymphoblastic leukemia and 
lymphoblastic lymphoma, 422–423
chronic, 415t, 417f, 418–419
lymphoid malignancy, 414–428
classification of, 414, 415t
diagnosis and staging of, 416, 418
incidence and etiology of, 416, 417f
lymphoma, 414, 693. See also specific types
adult T cell, 423
aggressive, 415t, 418, 420–421
anaplastic large cell, 416, 417f
Burkitt’s, 416, 417f, 423
definition of, 414
diffuse large B cell, 421
Epstein-Barr virus in, 697
follicular, 416, 417f
indolent, 415t, 418, 419–420
infections in patients, 512t
lymphoblastic, 422–423
lymphopenia with, 387
MALT, 416, 417f
mantle cell, 416
non-Hodgkin’s, 417f, 418, 421, 422t
oncologic emergencies, 134–135
primary CNS, 1258–1259
lymphomatoid granulomatosis, 
lymphadenopathy and, 279t
lymphopenia, 387
lymphoproliferative disease, Epstein-Barr 
virus, 697, 699
Lynch syndrome, 452, 453t, 465
M
M component, 423–424
MAC infection. See Mycobacterium avium 
complex infection
macrolides
adverse reactions to, 501t
for C. pneumoniae infections, 684
for Corynebacterium infection, 603
for H. influenzae infection, 610
for Legionella infection, 626
for Lyme borreliosis, 665
for M. catarrhalis, 613
for M. pneumoniae infections, 681
mechanism of/resistance to, 496, 497t
for nontuberculous mycobacterial 
infections, 663
for pertussis, 612
for pneumococcal infections, 582
macronodular adrenal hyperplasia, 478t
macular degeneration, 325f, 326, 
347–348, 347f
dry, 347
wet, 347
maculatum disease, 671t
macules, 365t
in cancer patients, 511
maculopapular rash, 130, 210
magnesium, serum, arrhythmias and, 848
magnesium citrate
for constipation, 56t
for poisoning, 190
magnesium hydroxide (Milk of 
Magnesia)
for constipation, 56t
for irritable bowel syndrome, 1017t
magnesium sulfate, for tetanus, 636–637
magnesium therapy
for alcoholic liver disease, 1054
for antipsychotic poisoning, 169t
for cardiac glycoside poisoning, 171t
for hypomagnesemia, 1166
for membrane-active agent poisoning, 
182t–183t
for torsades de pointes, 872t
magnetic resonance angiography (MRA), 
in stroke, 95–96, 99, 101
magnetic resonance imaging (MRI)
in coma, 92
for hearing loss, 350
in heart disease, 808, 809t
hepatobiliary, 274, 1022t
indications for, 29
in myocardial infarction, 845
neuroimaging, 1197, 1197t–1198t
in optic neuritis, 327
in poisoning, 160
in respiratory disease, 904
in spinal cord disorders, 112–113
in stroke, 96, 99
utility of, 29
in vertigo, 321
malabsorption syndromes, 258
causes of, 260t
drug-induced, 1387t
1508
INDEX
malaria, 763–765
cerebral, 128t, 764
diagnosis of, 495t
in pregnancy, 764
prevention of, 765, 768t–770t, 1351
transfusion, 765 
treatment of, 765, 766t–767t
Malassezia infection, 757
malathion, for pediculiasis, 792
maldigestion, 260t
male gender, cardiovascular disease 
and, 1364
malingering, 1323
malnutrition, 46–48
ascites in, 276
eye disease in, 344
MALT lymphoma. See mucosa-associated 
lymphoid tissue lymphoma
mammography, 442
screening, 442–443, 1366, 1367t–1368t
mandibular positioning device, 948
mania, 1317–1319
drug-induced, 1391t
manic depressive illness. See bipolar 
disorder
mannitol therapy
for increased intracranial pressure, 
107t, 108
for poisoning, 190
for stroke, 97
mantle cell lymphoma, 416
MAOIs. See monoamine oxidase inhibitors
marasmus, 47
maraviroc, for HIV/AIDS, 739t, 740
Marburg virus infection, 130, 727–728
march hemoglobinuria, 382
Marie-Strumpell disease. See ankylosing 
spondylitis
marine envenomations, 144–145
invertebrate, 145
vertebrate, 145–146
marine poisoning, 146–148
massage, for chronic back pain, 304
mastectomy
bilateral prophylactic, 1369
for breast cancer, 443
mastitis, S. aureus, 585
mastocytosis, systemic, 1065–1066, 1065t
mastoiditis, 360
McArdle’s disease, 1312
MCTD. See mixed connective tissue 
disease
MDMA. See ecstasy
MDR tuberculosis. See multidrug-resistant 
tuberculosis
MDS. See myelodysplastic syndrome
MDV3100, for prostate cancer, 472
measles, mumps, and rubella (MMR) 
vaccine, 520t, 709, 1352t–1353t, 
1354f–3155f, 1356t–1357t
measles inclusion-body encephalitis 
(MIBE), 709
measles vaccine, 520t, 708–709
measles virus infection, 708–710
mebendazole
for ascariasis, 781
for enterobiasis, 783
for hookworm, 781
for trichinellosis, 779
mechanical ventilation. See ventilatory 
support
mechlorethamine, 398t
meclizine
for nausea and vomiting, 56, 246
for vertigo, 323t
mediastinal mass, 945
mediastinitis, 945
mediastinoscopy, 906
medical emergencies. See emergencies, 
medical
medicinal leech, 792
Mediterranean spotted fever, 131, 671t, 
673
medrol, for anaphylaxis, 139
medroxyprogesterone
for amenorrhea, 1152
for menopausal symptoms, 1157
toxicity of, 399t
medulloblastomas, 1259
mefloquine, for malaria, 766t
preventive treatment, 765, 769t–770t
megakaryoblastic leukemia, 405t
megestrol
for endometrial cancer, 468
for weight loss, 221
meglumine antimonate, for leishmaniasis, 
772
melanoma, 428–430
acral lentiginous, 429
of eye, 348
lentigo maligna, 429
metastatic, 428–430
nodular, 429
paraneoplastic syndromes in, 482t
risk factors for, 428–429, 429t
superficial spreading, 429
melarsoprol, for sleeping sickness, 775
melasma, 364f
melena, 261–262
melioidosis, 623, 625t
melphalan
for amyloidosis, 1103
for multiple myeloma, 426
toxicity of, 398t
memantine, for Alzheimer’s disease, 1218
membranoproliferative glomerulonephritis 
(MPGN), 974–975
MEN 1. See multiple endocrine neoplasia 
type 1
Ménière’s disease, 322, 322t, 323t, 324, 352
INDEX
1509
meningeal syphilis, 563
meningioma, 325f, 1260, 1260f
meningitis
acute, 1270–1282
approach to, 1271, 1272f–1273f
acute bacterial, 1271–1276
clinical features of, 1271, 1273
laboratory features of, 1273–1274, 
1274t
pathogens, 1271, 1276t
treatment of, 1274–1275, 1275t, 1276t
bacterial, 128t, 132
in cancer patients, 513
chronic, 1283–1292
approach to, 1284, 1292
causes of, 1284, 1285t–1289t, 
1290t–1291t
clinical features of, 1283–1284, 1283t
coccidioidomycosis, 756
E. coli, 616
enterovirus, 715–716
H. influenzae, 609–610
HSV, 687, 690t
listerial, 606–608
lumbar puncture, 32–34, 33f
meningococcal, 604–605
pneumococcal, 581–583
poliovirus, 714
streptococcal, 597
tuberculosis, 651
viral, 1276–1278
pathogens, 1277t
treatment of, 1278
meningococcal infection, 603–606
meningococcal vaccine, 519t, 606, 
1352t–1353t, 1354f–3155f, 1358t, 
1359t
meningococcemia, 127t, 130, 210, 604
meningoencephalitis, listerial, 607
meningovascular syphilis, 563
menopause, 1156–1157
sleep disorders in, 339
mental status exam, 1187, 1187t
meperidine
for cholecystitis, 1024
narcotic abuse, 1340
for pain, 44t–45t
for pancreatitis, 1028
poisoning, 182t–183t
meprobamate poisoning, 175t
meralgia paresthetica, 1301t
6-mercaptopurine
for Burkitt’s lymphoma, 423
for inflammatory bowel disease, 1015
mercury poisoning, 187t–189t
meropenem
for B. cepacia infection, 625t
for bacterial meningitis, 1275t, 1276t
for brain abscess, 1281
for cholecystitis, 1024
for glanders, 625t
for melioidosis, 625t
for mixed anaerobic infections, 643t
for P. aeruginosa infections, 624t
for pneumonia, 924t, 926t
for sepsis/septic shock, 77t
merozoite, 763
mesalamine enema, for inflammatory 
bowel disease, 1015
mesenchymal tumors, paraneoplastic, 478t
mesenteric arteriography, 264, 1058
mesenteric insufficiency, chronic, 1019
mesenteric ischemia, acute, 1019
mesothelioma, 913
metabolic acidosis, 20–23, 21t
anion-gap, 20, 21t, 22, 25
causes of, 20–22, 21t
drug-induced, 21t, 1381t
hyperchloremic, 22
non-anion-gap, 21t, 22, 25
metabolic alkalosis, 23–24
approach to, 23f
chloride-resistant, 23–24, 23f
chloride-responsive, 23–24, 23f
metabolic disease
abdominal pain in, 240t
drug-induced, 1381t
fatigue with, 216t
muscle disorders in, 1314
nausea and vomiting in, 245t
neutropenia and, 385
weight loss in, 219t
metabolic syndrome, 842–843, 1138
NCEP:ATPIII 2001 and IDF criteria 
for, 843t
metabolism, of food, 46
metabolism disruptors, 160t–161t
metapneumovirus infection, 704t, 706
metaxalone, poisoning, 175t
metformin
for amenorrhea, 1153
for diabetes mellitus, 1140, 1142t
metabolic syndrome, 843
for obesity, 1136
methadone
narcotic abuse, 1340
for narcotic withdrawal, 1342
for opioid maintenance, 1342
for pain, 43, 44t–45t
methanol poisoning, 20, 21t, 22, 179t
methaqualone, poisoning, 175t
methemoglobin inducers, 177t
methemoglobinemia, 229
methenamine, for nephrolithiasis, 1000t
methicillin-resistant S. aureus (MRSA) 
infection, 77t, 584, 587
osteomyelitis, 578t
skin, 570t
treatment of, 589, 590t–591t, 592
methimazole, for thyrotoxicosis, 1120
1510
INDEX
methocarbamol, poisoning, 175t
methotrexate
for ANCA-associated 
glomerulonephritis, 972
for ankylosing spondylitis, 1084
for bladder cancer, 461 
for head and neck cancer, 433
for inflammatory bowel disease, 1015
for inflammatory myopathy, 1312
for multiple sclerosis, 1269
for polyneuropathy, 1298
for primary sclerosing cholangitis, 1026
for psoriasis, 367
for psoriatic arthritis, 1087
for reactive arthritis, 1088
for rheumatoid arthritis, 1074
toxicity of, 398t
for vasculitis, 1082
methylcellulose, for irritable bowel 
syndrome, 1017t
methyldopa, for hypertension, 841
methylene blue, for methemoglobin, 177t
methylphenidate
for daytime sleepiness, 340, 340t
for depression, 59
for fatigue, 58
methylprednisolone
for ANCA-associated 
glomerulonephritis, 971
for asthma, 911
for multiple sclerosis, 1269
for optic neuritis, 326
for renal transplant rejection, 967
steroid preparations, 1131, 1131t, 1133
for vertigo, 323t
methylxanthine poisoning, 167t
methyprylon, poisoning, 175t
methysergide
for migraine prevention, 313t
poisoning, 166t
metoclopramide
for H. pylori eradication, 247
for migraine, 311t
for nausea and vomiting, 56, 246
for systemic sclerosis, 1075
metolazone
for edema, 238, 238t
for heart failure, 880–881, 882t
for hypertension, 841
metoprolol
for aortic dissection, 889
for arrhythmias, 875t
for heart failure, 882t
for hypertension, 837t, 841
for myocardial infarction, 847, 857
preventive treatment, 854
poisoning, 170t
for sympathomimetic poisoning, 166t
for syncope, 320
for unstable angina, 857
metronidazole
for acne, 371
adverse reactions to, 502t
for amebiasis, 549
for bacterial meningitis, 1275t, 1276t
for bacterial vaginosis, 554
for brain abscess, 128t, 1281
for clostridial infection, 641t
for Clostridium difficile infection, 550–551
for diverticulitis, 1018
drug interactions with, 503t
for giardiasis, 542
for H. pylori eradication, 1008t
for hepatic encephalopathy, 1059
for inflammatory bowel disease, 1015
for intestinal pseudoobstruction, 1019
mechanism of/resistance to, 496, 499t
for mixed anaerobic infections, 643, 643t
for necrotizing fasciitis, 571t
for pelvic inflammatory disease, 556
for peritonitis, 533
for tetanus, 636
for trichomoniasis, 554
for urethritis in men, 552
metyrapone
for adrenal carcinoma, 1128
for ectopic ACTH syndrome, 480
mexiletine
for arrhythmias, 874t
for myotonic dystrophy, 1310
for polyneuropathy, 1297t
MG. See myasthenia gravis
MGUS. See monoclonal gammopathy of 
uncertain significance
MI. See myocardial infarction
MIBE. See measles inclusion-body 
encephalitis
micafungin, 745
for aspergillosis, 750t
miconazole, for candidiasis, 554
microaerophilic bacteria, 635
microbial bioterrorism, 191–200, 510
CDC category A agents, 192t, 193–199
CDC category B agents, 192t, 199
CDC category C agents, 192t, 199
features of bioweapons, 191t
prevention and preparedness, 200
micrographia, 1221
micronutrient deficiency, 50, 51t
microscopic polyangiitis, 1078
microscopy, diagnostic, 485, 486f, 487
midazolam
for delirium, 59t
for dyspnea, 58t
for increased intracranial pressure, 107t
poisoning, 174t
for scorpion sting, 150
for status epilepticus, 117f
midodrine
for hepatorenal syndrome, 278
INDEX
1511
for orthostatic hypotension, 1242
for syncope, 320
mifepristone, for emergency 
contraception, 1158
miglitol, for diabetes mellitus, 1142t
migraine, 308–315, 308t
diagnosis of, 309t
prevention of, 313t–314t
sleep disorders and, 339
treatment of, 309, 310t–312t, 314
vertigo in, 323t, 324
visual loss and, 326
migrating motor complex, 254
miliary disease, 652
milk alkali syndrome, 23
milnacipran, for fibromyalgia, 1098
milrinone
for heart failure, 884, 884t
for myocardial infarction, 850t
for pulmonary edema, 80
miltefosine, for leishmaniasis, 773
Milwaukee shoulder, 1096
minerals
therapy for mineral deficiencies, 51t
trace, reference values for laboratory 
tests, 1428t
mineral oil, for constipation, 260
mineralocorticoids, 1126
for Addison’s disease, 1130
minimal change disease, 973
mini-mental status examination, 1187t, 1213
mini-transplant, 419–420
Minnesota tube, for esophageal varices, 1058
minocycline
for actinomycosis, 648
for leprosy, 660
for nocardiosis, 646
for staphylococcal infection, 589, 591t
mirtazapine, 1325, 1327t
misoprostol, for erosive gastropathies, 1009
mite-borne spotted fever, 670–674, 671t
mithramycin, 399t
mitochondrial myopathies, 1312–1313
mitomycin
for anal cancer, 457
toxicity of, 399t
mitotane
for adrenal carcinoma, 1128
for ectopic ACTH syndrome, 479
mitoxantrone
for multiple sclerosis, 1267, 1269
for prostate cancer, 472
toxicity of, 399t
mitral regurgitation (MR), 798t, 816–818
echocardiography in, 807f, 817
in myocardial infarction, 853
treatment of, 818, 818f
mitral stenosis (MS), 798t, 815–816
echocardiography in, 807f, 816
treatment of, 816, 817f
mitral valve prolapse (MVP), 798t, 
818–819
mittelschmerz, 1154
mixed anaerobic infections, 640–643, 
643t
mixed connective tissue disease (MCTD), 
1075–1076
MM. See mononeuropathy multiplex
MMCB. See multifocal motor neuropathy 
with conduction block
MMR vaccine. See measles, mumps, and 
rubella vaccine
mobilizing agent, for radionuclide 
contamination, 207
modafinil
for circadian rhythm disorders, 342
for daytime sleepiness, 340, 340t
for depression, 59
Moh’s micrographic surgery, 431
molindone, 1330t
Mollaret’s meningitis, 1291t
monkey bite, 140, 141t
monoamine oxidase inhibitors (MAOIs), 
1325, 1327t
for Parkinson’s disease, 1224
poisoning, 167t, 182t
monoclonal gammopathy of uncertain 
significance (MGUS), 424
monoclonal immunoglobulins, renal 
disease and, 983–984
monocytic leukemia, 405t
monocytopenia, 387
monocytosis, 385
mononeuritis multiplex, 1298
mononeuropathy, 1292, 1298, 
1299t–1301t, 1302
mononeuropathy multiplex (MM), 1298
monoparesis, 331f
montelukast
for allergic rhinitis, 1064
for asthma, 910
for urticaria/angioedema, 1063
mood disorders, 1315–1319
mood stabilizers, 1329, 1332, 1332t
MOPP regimen, for Hodgkin’s disease, 
428
MOPP-ABV regimen, for Hodgkin’s 
disease, 428
Moraxella catarrhalis infection, 612–613
morbilliform lesion, 363
Morganella infection, 619–620
morphine
for dyspnea, 58t
for increased intracranial pressure, 107t
for myocardial infarction, 846, 857
narcotic abuse, 1340
for pain, 43, 44t–45t
for pulmonary edema, 79
for tetanus, 637
for unstable angina, 857
1512
INDEX
mortality, age-specific, 1345, 1346t–1348t
mosquito-borne viral infection, Dengue 
fever, 722
motion sickness, 245t, 246, 323t
motor exam, 1189, 1192
motor fluctuations, 1224, 1227
motor neuron disease, 1231–1235
etiology and investigation of, 
1233t–1234t
lower motor neurons, 329t, 330t, 331, 
1232t
secondary, 1232t
sporadic, 1232t
upper motor neurons, 329t, 330t, 331, 
1232t
motor unit disorders, 330t, 331
movement disorders, 332–335
insomnia and, 339
moxifloxacin
for Legionella infection, 626
for pneumococcal infections, 582
for pneumonia, 924t, 926t
for sepsis/septic shock, 77t
for tuberculosis, 654
MPGN. See membranoproliferative 
glomerulonephritis
MR. See mitral regurgitation
MRA. See magnetic resonance 
angiography
MRI. See magnetic resonance imaging
MRSA infection. See methicillin-resistant 
S. aureus infection
MS. See mitral stenosis
MSA. See multiple system atrophy
MSLT. See multiple sleep latency test
mucocutaneous candidiasis, 746–747
mucopurulent cervicitis, 554, 559
mucormycosis, 751–753
cutaneous, 752
pulmonary, 752
rhinocerebral, 132, 752
mucosa-associated lymphoid tissue 
(MALT) lymphoma, 416, 417f, 
448–449, 451, 1009
mucous membranes
dry, in terminally ill patient, 63t
in malnutrition, 48
mucous patch, 563
multidrug-resistant (MDR) 
tuberculosis, 649
multifocal motor neuropathy with 
conduction block (MMCB), 
1232t, 1234
multi-infarct dementia, 1219
multiorgan system failure, 38
multiple cranial nerve palsies, 1249–1250
multiple endocrine neoplasia type 1 
(MEN 1), 459, 1009–1010, 1160
multiple myeloma, 415t, 418, 424–426
glomerular disease in, 977t
infections in patients, 512t
oncologic emergencies, 134–135
staging of, 424, 425t
multiple sclerosis (MS), 1262–1270
acute (Marburg’s variant), 1270
clinical features of, 1262–1263
clinical variants of, 1270
diagnostic criteria for, 1263, 
1264t–1265t
disorders that mimic, 1265t
facial nerve involvement in, 1246
laboratory features of, 1263, 1266f
primary progressive, 1263, 1267f
progressive-relapsing, 1263
relapsing-remitting, 1263, 1266–1268, 
1267f
secondary progressive, 1263, 1266–
1269, 1267f
spinal cord involvement in, 1255
treatment of, 1266–1269, 1267f
acute relapses, 1269
disease-modifying therapies, 
1266–1268
progressive symptoms, 1269
symptomatic therapy, 1269
multiple sleep latency test (MSLT), 340, 
341t
multiple system atrophy (MSA), 1238
mumps vaccine, 520t, 709, 712
mumps virus infection, 711–712
Munchausen’s syndrome, 1323
mupirocin
mechanism of/resistance to, 498t
for streptococcal infection, 595
murine (flea-borne) typhus, 672t, 
674–675
murmur. See heart murmur
Murphy’s sign, 1023
muscle contracture, 1306
muscle cramp, 1306
muscle disease, 1306–1314
approach to, 1306, 1307f–1308f
disorders of energy metabolism, 1312
drug-induced, 1313t, 1314, 1390t–1391t
endocrine and metabolic myopathies, 
1314
inflammatory myopathies, 1310–1312, 
1311t
mitochondrial myopathies, 1312–1313
muscular dystrophies, 1306, 1309
paraneoplastic, 481t, 483–484, 483t
periodic paralysis, 1313–1314
muscle relaxant poisoning, 168t, 169t, 175t
muscular dystrophy, 900t, 1306, 1309
Duchenne’s, 1306, 1309
facioscapulohumeral, 1310
limb-girdle, 1309
myotonic dystrophy, 1309–1310
oculopharyngeal, 1310
musculoskeletal complaints, 294
INDEX
1513
musculoskeletal infection
E. coli, 616
S. aureus, 585–586
mushrooms, poisonous, 168t, 173t, 1037
M-VAC regimen, for bladder cancer, 461
MVP. See mitral valve prolapse
myalgia, 1306
drug-induced, 1391t–1392t
fever with, viral disease, 720–722
myasthenia gravis (MG), 900t, 1302–1305
differential diagnosis of, 1303
diplopia in, 327
drug interactions with, 1305t
paraneoplastic, 481t, 483t
treatment of, 1303–1305, 1304f
myasthenic crisis, 1303, 1305
mycetoma, 358
Mycobacterium abscessus infection, 
661–663
Mycobacterium avium complex (MAC) 
infection, 661–663
Mycobacterium chelonae infection, 661
Mycobacterium fortuitum infection, 
661–662
Mycobacterium infection, 491t
leprosy, 656–657, 660–661
complications of, 657, 660
lepromatous, 656–657
treatment of, 660–661
tuberculoid, 656–657
nontuberculous, 661–663
tuberculosis, 649–656
brucellosis vs., 628, 628t
extensively drug-resistant, 649
extrapulmonary, 650–652
gastrointestinal disease in, 651
genitourinary, 651
HIV/AIDS and, 649–652, 658t–659t
latent, 656, 657t, 658t–659t
meningitis in, 651
miliary disease, 652
multidrug-resistant, 649
nosocomial, 510
pericarditis in, 652
pleural involvement in, 651
prevention of, 656, 657t, 658t–659t
pulmonary, 650
skeletal disease in, 651
treatment of, 653–656, 655t, 658t–659t
Mycobacterium kansasii infection, 661–663
Mycobacterium leprae infection. See 
leprosy
Mycobacterium marinum infection, 
661–663
Mycobacterium tuberculosis infection. See 
tuberculosis
Mycobacterium ulcerans infection, 661–662
mycophenolate mofetil
for ANCA-associated 
glomerulonephritis, 972
immunosuppression for renal 
transplant, 967
for inflammatory myopathy, 1312
for myasthenia gravis, 1305
for SLE, 971, 1072
for vasculitis, 1082
Mycoplasma genitalium infection, 562
cervicitis, 554
urethritis in men, 552
Mycoplasma pneumoniae infection, 
680–681
mycoplasmal infection, urogenital, 552, 
554, 562
mycotic aneurysm, 103
mydriatic agents, for inflamed eye, 345
myelitis, paraneoplastic, 481t, 482t, 483t
myeloblastic leukemia, 404t–405t
myelodysplastic syndrome (MDS), 379–
380, 404t, 409, 412
classification of, 410t–411t
with isolated Del(5q), 411t
prognostic scoring system for, 
412, 413t
unclassified, 411t
myelofibrosis, 378, 385
idiopathic, 412
myelography, 1197
myeloid leukemia
acute, 403–406, 404t–405t, 407f
chronic, 407–409, 408t
myelomonocytic leukemia, 405t
myelopathy. See also specific types
hypocuric, 1256
immune-mediated, 1254–1255
infectious, 1255
retrovirus-associated, 1255
myelophthisis, 378, 385
myeloproliferative syndrome, 412–414
basophilia in, 386
neutropenia in, 385
myelosuppression, drug-induced, 
398t–400t
myiasis, 792
myocardial infarction (MI)
anterior, 848–849
arrhythmias in, 848–849
cardiogenic shock in, 851, 851t, 
852f, 853
chest pain in, 223f, 224
complications of, 848–849
acute mechanical complications, 853
hemodynamic, 851t
ECG in, 225, 802, 803f, 804t, 829t
heart failure and, 849–850, 850t, 851t
hypotension in, 849–851, 853
hypovolemia in, 851t
laboratory features of, 844–845, 855
non-ST-elevation (non-Q-wave), 802–
803, 803f, 804t, 829t, 844, 855–858
treatment of, 855–858, 856f
1514
INDEX
myocardial infarction (MI) (Cont.):
pericarditis in, 853
secondary prevention of, 854
ST-segment elevation (Q-wave), 
802–803, 803f, 804t, 829t, 844–855
treatment of, 845–848, 846f, 847f
syncope in, 316
TIMI Risk Score for, 855, 856f
treatment of, 393t, 394
ventricular aneurysm and, 853–854
myocardial ischemia
chest pain in, 221t, 222f, 224
sleep disruption in, 339
myocarditis, 827–828
enterovirus, 716
myoclonus, 334–335
posthypoxic, 116
myonecrosis. See gas gangrene
myopathy, 1306. See also specific types
drug-induced, 1313t, 1314, 1391t–1392t
inflammatory, 1310–1312, 1311t
weakness in, 329t, 330t
myophosphorylase deficiency, 1312
myositis, 573–574. See also specific types
drug-induced, 1391t
streptococcal, 594t, 595
myotonia, 1306
myotonic dystrophy, 1309–1310
myxedema coma, 1118–1119
N
nadolol
for esophageal varices, 1058
poisoning, 170t
for syncope, 320
for variceal bleeding, 266
nafcillin
for bacterial meningitis, 1275t, 1276t
for cellulitis, 570t
for infective endocarditis, 527t
for osteomyelitis, 578t, 579
for perichondritis, 358
for staphylococcal infection, 589, 590t
nail lesions, 365
nailbed, in cyanosis, 229
naloxone
for bradycardia, 846
for membrane-active agent poisoning, 
182t–183t
for opiate overdose, 1342
for sympatholytic poisoning, 169t
naltrexone
for alcoholic rehabilitation, 1340
for narcotic withdrawal, 1342
as opiate antagonist, 1342
for primary biliary cirrhosis, 1055
naproxen
for migraine, 310t
for pain, 44t–45t
naratriptan, for migraine, 310t, 312t
narcissistic personality disorder, 1324
narcolepsy, 338, 340, 341t, 342t
narcotics, 42–43, 44t–45t
for abdominal pain, 244
for frostbite, 154, 154t
for hemoptysis, 235
for migraine, 311t
narcotic abuse, 1340–1343
clinical features of, 1341
prevention of, 1342–1343
treatment of, 1341–1342
drug-free programs, 1342
opiate antagonists, 1342
opioid maintenance, 1342
overdose, 1341–1342
withdrawal, 1341–1342
nasal swab, 488t
nasopharyngeal cancer, 432
Epstein-Barr virus in, 697, 698t
natalizumab
for inflammatory bowel disease, 1015
for multiple sclerosis, 1268
nateglinide, for diabetes mellitus, 1142t
native valve endocarditis (NVE), 521–523, 
530, 592
HACEK group, 613–614, 614t
nausea and vomiting, 244–246
causes of, 244–245, 245t
drug-induced, 245t, 398t–400t, 401, 1387t
in terminally ill patient, 56
treatment of, 56, 246, 401
NBTE. See nonbacterial thrombotic 
endocarditis
Necator americanus infection. See 
hookworm infection
neck cancer, 432–433
infections in cancer patients, 512t
localized disease, 432–433
locally advanced disease, 433
paraneoplastic syndromes in, 478t, 480
prevention of, 433, 1371
recurrent or metastatic, 433
neck pain, 304–307
causes of, 304–306
treatment of, 306–307
neck weakness, 1249
necrotizing fasciitis, 127t, 131, 571t, 573
streptococcal, 594t, 595
necrotizing myelopathy, acute, 483
nedocromil sodium, for asthma, 910
nefazodone, 1325, 1327t
Negri bodies, 718
Neisseria gonorrhoeae infection. See 
gonorrhea
Neisseria meningitidis infection, 603–606
nematocysts, 145
nematode infection, 778–785
filarial worms, 783–785
intestinal, 780–783
tissue nematodes, 778–780
INDEX
1515
neomycin, for hepatic encephalopathy, 1059
neonatal disease
cytomegalovirus infections, 694–695
generalized disease of newborn, 715
HSV infection, 687, 690t
listerial infection, 607–608
streptococcal infections, 597–598
neoplasm, neck pain in, 306
neostigmine poisoning, 172t
nephrectomy, 462
nephritic syndrome, 292, 950t, 968
nephritis
acute interstitial, 980–981, 982t
chronic interstitial, 982–983
drug-induced, 980–981, 982t, 
1388t–1389t
nephrolithiasis, 951t, 953, 998–1000, 1000t
stone composition, 998–999
treatment for, 999–1000, 1000t
uric acid, 1092
workup for, 999, 999t
nephropathy. See also specific types
acute uric acid, 1092
drug-induced, 1389t
HIV-associated, 974
IgA, 978
ischemic, 992–995, 994f
thin basement membrane, 978
urate, 1092
nephrosclerosis, arteriolar, 995
nephrostomy tube, 1002
nephrotic syndrome (NS), 290, 950t, 952, 
972–978
ascites in, 276f
causes of, 972–973, 973t
drug-induced, 1388t
evaluation of, 976t
nerve abscess, in leprosy, 660
nerve agents, 201–202
clinical features of exposure, 201
treatment of, 202, 203t
nerve gas, 172t
nervous system tumor, 1257–1262
metastasis to nervous system, 1260–
1261, 1261t
nesiritide
for heart failure, 884, 884t
for pulmonary edema, 80
neuralgia, 40. See also specific types
neuraminidase inhibitors, for influenza, 
701, 702t
neuritis. See specific types
neurocysticercosis, 788
neurogenic shock, 70t
neuroimaging, 1197–1198, 1197t–1198t
in seizures, 1200
neuroleptic malignant syndrome (NMS), 
213, 1329
neuroleptics, for delirium, 59t
neurologic disease
abdominal pain in, 240t
ataxia, 1227–1231
autonomic nervous system disorders, 
1235–1243
brain abscess, 1280–1282
cranial nerve disorders, 1243–1250
in critically ill patient, 40
dementia, 1212–1220
depression in, 1316
drug-induced, 398t, 1389t–1390t
encephalitis, acute, 1270–1282
epilepsy, 1199–1203
fatigue in, 215t
in HIV/AIDS, 734
HSV infections, 686–687, 690t
hypothermia in, 152t
infections, 128t–129t, 132
in leprosy, 660
Lyme borreliosis, 664–665
in malnutrition, 48
meningitis
acute, 1270–1282
chronic, 1283–1292
motor neuron disease, 1231–1235
multiple sclerosis, 1262–1270
myasthenia gravis, 1302–1305
paraneoplastic, 480–484, 482t, 483t
Parkinson’s disease, 1221–1227
peripheral neuropathy, 1292–1302
progressive multifocal 
leukoencephalopathy, 1282
rabies, 719
seizure, 1199–1203
sleep disorders in, 339
spinal cord disease, 1251–1257
tumors of nervous system, 1257–1262
varicella-zoster virus infections, 691
weakness and paralysis in, 331
weight loss in, 219t
neurologic examination, 1187–1196
anatomic localization of problem, 
1195t, 1196
coordination and gait, 1196
cranial nerve exam, 1187–1189
in head trauma, 111
in low back pain, 299, 299t
mental status exam, 1187, 1187t
motor exam, 1189, 1192
reflexes, 1193, 1196
sensory exam, 1196
neuromuscular blockers, 37–38
neuromuscular junction disorders, 
329t, 330t
neuromyelitis optica (NMO), 327, 1270
neuropathic pain, 40–41, 41t
neuropathy. See also specific types
paraneoplastic, 481t, 482t, 483t
neuroprotection, for stroke, 99
neurosyphilis, 563–564, 565t, 566
neutron particles, 204
1516
INDEX
neutropenia, 386
in cancer patient, 137
drug-induced, 385, 401
febrile, 386 
approach to, 514, 515f
P. aeruginosa infection, 622, 624t
treatment of, 386
refractory, 410t
treatment of, 137, 386
neutrophilia, 384–385
nevirapine, for HIV/AIDS, 736t, 740
niacin deficiency, 51t
nicardipine, for hypertensive 
emergencies, 841t
nicotine, 173t
for inflammatory bowel disease, 1015
nicotine addiction, 1372–1373. See also 
smoking cessation
in women, 1377
nicotine-replacement products, 1372, 
1374t
nicotinic acid, for hyperlipidemia, 1177t
nifedipine
for achalasia, 251
for aortic regurgitation, 821
for ergot alkaloid poisoning, 166t
for esophageal spasm, 252
for HAPE, 156t
for hypertension, 838t, 841
for neuroleptic malignant 
syndrome, 214
poisoning, 170t
for pulmonary hypertension, 898
for systemic sclerosis, 1075
for vasospastic disorders, 892
nifurtimox, for Chagas’ disease, 774
nightshade, 168t
nilotinib
for CML, 409
toxicity of, 400t
nimodipine
for migraine prevention, 314t
for subarachnoid hemorrhage with 
vasospasm, 105
Nissen fundoplication, 247
nits, 792
nitazoxanide
for Clostridium difficile infection, 551
for cryptosporidiosis, 543
for giardiasis, 542
nitrates
for angina pectoris, 861, 862t
for heart failure, 882t, 883
poisoning, 177t
nitrite poisoning, 177t
nitrofurantoin
mechanism of, 496
for urinary tract infections, 988, 989t
prevention, 989
nitrogen mustard, 200
nitrogen oxides, poisoning, 177t
nitroglycerin
for anal fissures, 1020
for angina pectoris, 861, 862t
for ergot alkaloid poisoning, 166t
for heart failure, 884t
for hypertensive emergencies, 841t
for myocardial infarction, 846, 850, 
850t, 851t, 857
for pulmonary edema, 79
for systemic sclerosis, 1075
for unstable angina, 857
nitroprusside
for aortic dissection, 889, 889t
for ergot alkaloid poisoning, 166t
for heart failure, 883–884, 884t
for hypertension, 841t
for MAO inhibitor poisoning, 167t
for mitral regurgitation, 818
for myocardial infarction, 850, 850t, 
851t, 853
for renal artery stenosis, 992
nitrosourea, 398t
NIV. See noninvasive ventilation
NMO. See neuromyelitis optica
NMS. See neuroleptic malignant 
syndrome
nocardiosis, 644–646, 647t
nodule (skin lesion), 210, 365t, 572
nonbacterial thrombotic endocarditis 
(NBTE), 522
non-Hodgkin’s lymphoma, 417f, 418
international prognostic index for, 
421, 422t
noninvasive ventilation (NIV), 83–84, 85t
nonpolyposis syndrome, 452, 453t
nonsteroidal anti-inflammatory drugs 
(NSAIDs)
for adhesive capsulitis, 1099
for ankylosing spondylitis, 1083
for bursitis, 1099
for calcium apatite deposition 
disease, 1096
for cholecystitis, 1024
for chronic fatigue syndrome, 217
for colon cancer prevention, 1369–1370
for colonic polyps, 452
for diabetes insipidus, 9
for enteropathic arthritis, 1096
for erythema multiforme, 372
for erythema nodosum, 372
for fever, 211
for fibromyalgia, 1098
for gout, 1093
for inflamed eye, 345
for low back pain, 303
for migraine, 309, 310t, 312t
for neck and back pain, 307
for osteoarthritis, 1091
for osteonecrosis, 1098
for pain, 42–43, 44t–45t
for pelvic pain, 1154
INDEX
1517
for pericarditis, 831
for pseudogout, 1095
for psoriatic arthritis, 1087
for reactive arthritis, 1088
for rheumatoid arthritis, 1074
for SLE, 1072
for systemic mastocytosis, 1065
for tendinitis, 1099
for tension headache, 314
for thyrotoxicosis, 1122
nontuberculous mycobacterial (NTM) 
infection, 661–663
disseminated disease, 661
lymphadenopathy in, 662
pulmonary disease, 661–662
skin and soft tissue disease, 662
norepinephrine
for beta blocker poisoning, 170t
for calcium channel blocker 
poisoning, 170t
for increased intracranial pressure, 107t
for MAO inhibitor poisoning, 167t
for shock, 71, 73t
for subarachnoid hemorrhage with 
vasospasm, 105
for sympatholytic poisoning, 169t
normal-pressure hydrocephalus (NPH), 
1213, 1220–1221
norovirus infection
diarrhea, 540–541
nosocomial, 509
nortriptyline
dosage and adverse effects of, 1326t
for migraine prevention, 313t
for pain, 44t–45t
for smoking cessation, 1373, 1374t
nosocomial infections, 505–510
diarrhea, 509–510
endocarditis, 522–523
intravascular device infection, 507t, 509
pneumonia, 507–508, 507t, 623
prevention of, 505–506, 507t
surgical-site infection, 507t, 508
urinary tract infection, 506–507, 507t
novobiocin, mechanism of/resistance to, 
499t
NPH. See normal-pressure hydrocephalus
NS. See nephrotic syndrome
NSAIDs. See nonsteroidal anti-
inflammatory drugs
5´-NT. See 5´-nucleotidase
NTM infection. See nontuberculous 
mycobacterial infection
nuclear cardiology, 808, 809t, 824t
nuclear medicine imaging, in respiratory 
disease, 904–905
nuclear myocardial perfusion assessment, 
808, 845, 861t
nucleic acid probes, 487, 494
nucleoside analogues, for HIV/AIDS, 
735t–736t, 740–741
5´-nucleotidase (5´-NT), 270, 272
nucleotide analogues, for HIV/AIDS, 
735t–736t, 740–741
nummular lesion, 363
nutcracker esophagus, 251
nutrients, absorption in GI tract, 254
nutrition
fatigue and, 216t
inadequate, 39
leukopenia and, 386
nutritional status, assessment of, 46
nutritional support, 49
decision tree for initiating, 49f
enteral nutrition, 50
parenteral nutrition, 50
nutritionally variant streptococci, 599
NVE. See native valve endocarditis
nystagmus, 321–323
nystatin, for candidiasis, 
252, 371, 747
O
OAE. See otoacoustic emissions
obesity, 900t, 1134–1137, 1134t
central, 1134
drug-induced, 1135
extreme, 1134t
metabolic syndrome, 842, 843t
sleep disorders in, 341t
treatment of, 1135–1137, 1136f
in women, 1376
obsessive-compulsive disorder (OCD), 
1321, 1325
obstructive shock, extracardiac, 70t
obstructive sleep apnea/hypopnea 
syndrome (OSAHS), 947–948
obturator neuropathy, 1300t
occipital cortex lesions, 326
occipital neuralgia, 315
occlusional injury, 140, 141t
octreotide
for acromegaly, 479, 1110
for carcinoid tumor, 458
for esophageal varices, 1058
for hepatorenal syndrome, 278
for islet-cell tumors, 460
octreotide scintigraphy, 458
for Zollinger-Ellison syndrome, 1010
octreotide therapy, for hypoglycemia, 
124
ocular gonorrhea, 559
ocular motor nerve palsy, 327–328
oculoglandular tularemia, 630
oculopharyngeal dystrophy, 1310
oculopharyngeal tularemia, 630
odynophagia, 248
ofloxacin
for leprosy, 660
for M. pneumoniae infections, 681
for meningococcal infection, 606
OH. See orthostatic hypotension
1518
INDEX
olanzapine
for delirium, 59t
dosage and adverse effects of, 168t, 
1331t
for schizophrenia, 1319
olfactory nerve, 1187
disorders of, 1246, 1247t, 1248
oligemic shock, 70t, 71t
oligoanuria, 288
oligoblastic leukemia, 409
oligodendroglioma, 1258
oligomenorrhea, 1150
oliguria, 288
olopatadine, for allergic rhinitis, 1064
omalizumab, for asthma, 910
omeprazole
for H. pylori eradication, 1008t
for indigestion, 247
for noncardiac chest pain, 249
for peptic ulcer disease, 1007
for systemic sclerosis, 1075
for Zollinger-Ellison syndrome, 1010
onchocerciasis, 784–785
onchocercomata, 784
oncologic emergencies, 133–138
paraneoplastic syndromes, 135–136
structural/obstructive, 133–135
treatment complications, 137–138
ondansetron, for nausea and vomiting, 
246, 401
oophoritis, mumps, 711
ophthalmia neonatorum, 559
ophthalmoplegia, 1249
chronic progressive external, 1310, 1312
diffuse, 327
ophthalmoscopic examination, 324
opiates, narcotic abuse, 1340
opioids
for back pain, 303
for dyspnea, 58t
for pain, 43
poisoning, 160t–161t, 182t–183t
opisthorchiasis, 786–787
opsoclonus-myoclonus syndrome, 
481t, 482
optic chiasm compression, 325f
optic neuritis, 325f, 326–327
drug-induced, 1390t
optic neuropathy, 325f
OPV. See oral poliovirus vaccine
oral contraceptives, 1154, 1157
for hirsutism, 1156
oral disease
actinomycosis, 647
drug-induced, 1387t–1388t
infections, 360–361
anaerobic, 642
in malnutrition, 48
oral cavity cancer, 432
oral dissolution therapy, for gallstones, 1023
oral hairy leukoplakia, 697, 699
oral poliovirus vaccine (OPV), 717
oral rehydration solution (ORS), for 
cholera, 540
oral-facial HSV infection, 685–686, 
689t–690t
orchiectomy, 463
orchitis, mumps, 711
Orientia tsutsugamushi infection, 672t, 676
orlistat
for metabolic syndrome, 843
for obesity, 1136
oropharyngeal cancer, 432
Oroya fever, 633t, 634–635
orphenadrine poisoning, 168t, 175t, 
182t–183t
ORS. See oral rehydration solution
orthostatic hypotension (OH), 317, 318t, 
319, 1235, 1237
neurogenic, 1237
in pheochromocytoma, 835
treatment of, 1242, 1243t
OSAHS. See obstructive sleep apnea/
hypopnea syndrome
Osborn (J) waves, 152
oseltamivir, for influenza, 701, 702t
osmolar gap, 20, 22
osmoregulation, 4t
osmotic demyelination syndrome, 7–8
osteoarthritis, 1089–1091
low back pain in, 301
osteoblastoma, 479t
osteomalacia, 1170–1171
drug-induced, 1391t
osteomyelitis, 576, 579–580
Klebsiella, 618
microbiology of, 576, 577t
neck pain in, 306
S. aureus, 585–586, 592
treatment of, 578t–579t, 579–580
vertebral, low back pain in, 302
osteonecrosis, 1098, 1170
osteoporosis, 1157, 1167–1170
diseases associated with, 1169t
drug-induced, 1390t
fracture risk in, 1167–1168, 1168t
low back pain in, 302
screening for, 1168, 1170t, 1348t
in women, 1376
otitis externa
acute diffuse, 358
acute localized, 358
chronic, 359
malignant or necrotizing, 359
P. aeruginosa, 622, 624t
otitis media, 350
acute, 350, 356t–357t, 359–360
chronic, 350, 360
M. catarrhalis, 612–613
pneumococcal, 582
INDEX
1519
serous, 350, 360
treatment of, 356t–357t
otoacoustic emissions (OAE), 350
otosclerosis, 350
otoscopy, 350
ovarian cancer, 464–467
infections in cancer patients, 512t
paraneoplastic, 478t, 482t
staging and prognosis in, 465, 466t
ovarian cyst, 465
ovarian tumor, 465
overdosage, 159
oxacillin
for cellulitis, 570t
for infective endocarditis, 527t
for osteomyelitis, 578t, 579
for staphylococcal infection, 589, 590t
oxaliplatin
for colorectal cancer, 456
toxicity of, 399t
oxazepam
dosage and action of, 1328t
for myocardial infarction, 846
poisoning, 174t
oxazolidinone, mechanism of, 496
oxcarbazepine
dosage and adverse effects of, 173t, 1332t
for generalized anxiety disorder, 1321
for pain, 44t–45t
for seizures, 1210t, 1212t
for trigeminal neuralgia, 1244
5-oxoprolinuria, 20, 21t, 22
oxybutynin, for multiple sclerosis, 1269
oxycodone
for dyspnea, 58t
narcotic abuse, 1340
for pain, 44t–45t
oxygen therapy
for AMS, 156t
for anaphylaxis, 139
for asthma, 911
for cluster headache, 314
for COPD, 919–920
for cor pulmonale, 886
for cytochrome oxidase inhibitor 
poisoning, 176t
for DCS, 159
for HAPE, 156t
for interstitial lung disease, 937
for methemoglobin inducer 
poisoning, 177t
for myocardial infarction, 846, 849
for pulmonary edema, 79
for pulmonary hypertension, 898
for shock, 72, 853
oxytocin, 1113
P
packed red blood cell transfusion, 52
for alcoholic liver disease, 1054
paclitaxel
for bladder cancer, 461
for breast cancer, 445
for head and neck cancer, 433
for ovarian cancer, 467
toxicity of, 398t
pain. See also specific types and sites
approach to, 40–41
chronic, 41
treatment of, 43, 1325
in diverticular disease, 1018
drugs for relief of, 42–43, 44t–45t
management of, 40–45, 44t–45t
terminally ill patient, 55
neuropathic, 40–41, 41t, 43
organization of pain pathways, 41–43, 41f
somatic, 40, 41t, 43, 241
spontaneous, 1241
visceral, 40, 41t, 241
painful bladder syndrome, 990
paliperidone, 1331t
palivizumab, for human RSV infections, 706
palliative care, 54–63
palmar xanthoma, 1179
palpations, precordial, 796
palpitations, 225–226
2-PAM. See 2-pralidoxime chloride
pamidronate, for hypercalcemia, 136, 480, 
1163t
PAN. See polyarteritis nodosa
pancreatectomy, 1032
pancreatic abscess, 1030
pancreatic cancer, 458
paraneoplastic, 478t–479t
pancreatic endocrine tumors, 458–460
pancreatic enzyme replacement, 1032
pancreatic exocrine insufficiency, 1030–
1032, 1031t
pancreatic islet-cell tumor, 459–460
paraneoplastic, 478t
pancreatic necrosis, 1030
pancreatic pseudocyst, 1030
pancreatitis, 1026–1032
acute, 1026–1030
causes of, 1027t
complications of, 1029–1030
risk factors that adversely affect 
survival, 1029t
treatment of, 1028–1029
ascites in, 276f
chronic, 1030–1032
complications of, 1032
TIGAR-O classification of, 1031t
treatment of, 1032
drug-induced, 1388t
interstitial, 1026
necrotizing, 1026
pancreatic cancer and, 458
pancytopenia, drug-induced, 1385t
panic disorder, 1320, 1325
1520
INDEX
panitumumab
for colorectal cancer, 456
toxicity of, 400t
pantoprazole
for erosive gastropathies, 1009
for H. pylori eradication, 1008t
PAP. See pulmonary alveolar proteinosis; 
pulmonary artery pressure
pap smear, 468, 1367t–1368t, 1371
papillary necrosis, 987
papilledema, 325f, 326
Pappenheimer bodies, 376
papule (skin lesion), 365t, 572
papules, in cancer patients, 511
papulosquamous disorder, 367–368
paracentesis, 34–35, 276–277
paracoccidioidomycosis, 758
paragonimiasis, 233
paragonimus infection. See fluke infection, 
lung flukes
parainfluenza virus infection, 704t, 706–707
paralysis, 328–332
approach to, 328, 331
periodic, 1313–1314
site of responsible lesion, 329t, 331
paralytic disease, poliovirus infection, 715
paralytic shellfish poisoning, 147
paraneoplastic syndromes
emergent, 135–136
endocrine, 477–480
in kidney cancer, 462
in lung cancer, 434
neurologic, 480–484, 481t
paranoid personality disorder, 1323
paraparesis, 330t, 331f
parasitic infection
blood, 376
diagnosis of, 494, 495t
eosinophilia in, 386
in HSCT patients, 516
lymphadenopathy and, 279t
parasympathetic system, 1236f, 1237t
parathyroidectomy, for 
hyperparathyroidism, 1163
parcopa, for Parkinson’s disease, 1226t
parenchymatous syphilis, 563
parenteral nutrition, 49–50
decision tree for initiating, 49f
paresis, 328
Parkinsonism, 332, 1221
Parkinson’s disease (PD), 1221–1227, 1238
dementia in, 1213, 1214t
differential diagnosis of, 1222t, 1223, 1223t
sleep disorders in, 339
treatment of, 1224, 1225f, 1226t, 1227
tremor in, 332
paromomycin
for amebiasis, 549
for leishmaniasis, 773
parotitis, mumps, 711–712
paroxetine
for depression, 59
dosage and adverse effects of, 1326t
for irritable bowel syndrome, 1018
for menopausal symptoms, 1157
for syncope, 320
paroxysmal nocturnal dyspnea, 879
paroxysmal nocturnal hemoglobinuria 
(PNH), 378, 381, 381t
parvovirus B19 infection, 712–713
patch (skin lesion), 365t
patch tests, 366
patent ductus arteriosus, 798t, 812–813
patient admittance, 1
patient-controlled analgesia (PCA), 43
PBP. See primary (spontaneous) bacterial 
peritonitis
PCA. See patient-controlled analgesia
PCI. See percutaneous coronary 
intervention
PCOS. See polycystic ovarian syndrome
PD. See Parkinson’s disease
PE. See pulmonary embolism
peau d’orange appearance, 369
pediculiasis, 792
PEEP. See positive end-expiratory pressure
PEG IFN. See pegylated interferon
pegloticase, for gout, 1094
pegvisomant, for acromegaly, 1110
pegylated interferon (PEG IFN)
for chronic hepatitis B, 1040, 
1041t–1043t
for chronic hepatitis C, 1040, 
1047t–1049t
Pelger-Hüet anomaly, 376
pelvic infection
actinomycosis, 648
anaerobic, 642
pelvic inflammatory disease (PID), 555–556
pain in, 1153
pelvic pain, 1153–1154
acute, 1153
causes of, 1153, 1153t
chronic, 1154
cyclic, 1153, 1153t
noncyclic, 1153, 1153t
pemetrexed
for lung cancer, 439
toxicity of, 398t
pemoline, for depression, 59
penciclovir, for HSV infections, 689t–690t
penetrating infectious diarrhea, 537t
penetrating radiation, 204
penicillamine
for lead poisoning, 187t–188t
for nephrolithiasis, 1000t
for systemic sclerosis, 1075
penicillins, mechanism of/resistance to, 
496, 497t
penicillin/penicillin G/penicillin V
INDEX
1521
for actinomycosis, 648
for bacterial meningitis, 1275t, 1276t
for clostridial infection, 641t
for clostridial infections, 128t
for diphtheria, 601–602
for gas gangrene, 571t
for HACEK group infections, 614t
for infective endocarditis, 526t–527t
for leptospirosis, 668
for listerial infections, 608
for Lyme borreliosis, 665
for meningococcal infections, 127t, 606
for necrotizing fasciitis, 127t, 571t
for osteomyelitis, 578t
for perichondritis, 358
for peritonitis, 533
for pharyngitis, 357t
for pneumococcal infections, 582–583
for rheumatic fever prevention, 816
for rodent bite infections, 142t
for staphylococcal infection, 590t, 592
for streptococcal infection, 594, 594t, 
597–599
for syphilis, 565t
for tetanus, 636
penicilliosis, 758
pentamidine
for Pneumocystis infections, 761t, 762, 762t
for sleeping sickness, 775
pentamidine isethionate, for 
leishmaniasis, 773
pentazocine abuse, 1340
pentobarb coma, 107t
pentobarbital
poisoning, 174t
for status epilepticus, 117f
pentostatin, 398t
pentoxifylline
for alcoholic liver disease, 1054
for arteriosclerosis, 891
peptic ulcer disease (PUD), 459, 
1005–1007
bleeding in, 262
causes and risk factors for, 1005–1006
diagnosis of, 1010t
drug-induced, 1388t
duodenal, 1005–1007
gastric, 1005–1007
treatment of, 1006–1007, 1008t
Peptostreptococcus infection, 640
peramivir, for influenza, 701
percutaneous coronary intervention (PCI), 
845, 846f, 851t, 853–854, 857, 
858t, 863, 863t
percutaneous needle aspiration, of lung, 906
percutaneous transhepatic cholangiogram, 
1022t
pergolide, poisoning, 166t
periappendicitis, 555
periarticular disorder, 1099
pericardial disease, 828–834
echocardiography in, 806, 809t
pericardial effusion
approach to, 834
oncologic emergency, 134
treatment of, 134
pericardial stripping/window, 134
pericardial tamponade, oncologic 
emergency, 134
pericardiectomy, for pericarditis, 831
pericardiocentesis, for cardiac 
tamponade, 831
pericarditis
acute, 828–831
causes of, 829t
chest pain in, 221t, 223f, 224
laboratory features of, 828–829, 
829t, 830f
constrictive, 134, 832–834, 833t
laboratory features of, 832–833, 832f
drug-induced, 1386t
enterovirus, 716
in myocardial infarction, 853
in tuberculosis, 652
perichondritis, 358
perihepatitis, 555
perimenopause, 1156
perinephric abscess, 535–536
periodic leg movements of sleep, 337
periodic limb movements of sleep 
(PLMS), 339
periodic paralysis, 1313–1314
hyperkalemic, 1314
hypokalemic, 1314
periodontal disease, 642
periorbital edema, 235
peripheral edema, 879
peripheral nerves, cutaneous areas 
supplied by, 1192f–1194f
peripheral neuropathy (PN), 1292–1302
approach to, 1292–1294, 1293f
autonomic involvement in, 1238, 
1240t–1241t, 1241
diagnosis of, 1294–1296
drug-induced, 398t, 1389t
mononeuropathy, 1292, 1298, 
1299t–1301t, 1302
motor-predominant, 1232t
paraneoplastic, 481t, 482t, 484
patterns of, 1295t–1296t
polyneuropathy, 1292, 1294–1298
weakness in, 329t, 330t
peripheral vascular disease, 890–894
arterial embolism, 891
arteriosclerosis of arteries, 890–891
atheroembolism, 891
superficial thrombophlebitis, 892
vasospastic disorders, 891–892
venous disease, 892–894
venous insufficiency, chronic, 894
1522
INDEX
peristalsis, 254
peritoneal carcinomatosis, 276f
in women, 476
peritoneal dialysis, 190, 959, 963–965
complications of, 964–965, 964t
peritoneal disease
ascites in, 275
pain in, 240t
peritoneal fluid, paracentesis, 34–35
peritonitis, 532–534
bacterial, 277
CAPD-associated, 534
E. coli, 616
primary bacterial, 532–533
secondary, 533
peritonsillar abscess, 642
perleche, 364f
permethrin cream
for pediculiasis, 792
for scabies, 791
peroneal nerve entrapment, 1301t
perphenazine, 1330t
personality disorder, 1323–1324
cluster A, 1323
cluster B, 1323–1324
cluster C, 1324
pertussis, 610–612
catarrhal phase of, 611
convalescent phase of, 611
paroxysmal phase of, 611
vaccine, 611–612
PET. See positron emission tomography
petechiae, 130
Peutz-Jeghers syndrome, 450, 453, 453t
phagocytic cells, deficiencies of, 1067t
pharmacologic stress testing, 859, 861t
pharyngeal gonorrhea, 559
pharyngitis
acute, 360–361
HSV, 685
streptococcal, 593–594, 594t
treatment of, 357t
pharyngoconjunctival fever, 707
phenazopyridine, 177t
phenelzine, 167t, 1327t
phenobarbital
poisoning, 174t
for seizures, 1208t
for status epilepticus, 117f
for tetanus, 636
phentolamine
for hypertensive emergencies, 841t
for sympathomimetic poisoning, 166t
phenylephrine
for heart failure, 884t
for increased intracranial pressure, 107t
poisoning, 166t
for shock, 71, 73t
for subarachnoid hemorrhage with 
vasospasm, 105
phenylpropanolamine, 166t
phenytoin
adenopathy with, 280
for antidepressant poisoning, 172t
for cardiac glycoside poisoning, 171t
for multiple sclerosis, 1269
for myotonic dystrophy, 1310
for pain, 44t–45t
poisoning, 173t
for polyneuropathy, 1297t
for seizures, 1205t, 1212t
for status epilepticus, 117f
for trigeminal neuralgia, 1244
pheochromocytoma, 1127
hypertension in, 835–836
paraneoplastic, 479t
pheresis therapy, 51–54
phlebotomy, 286, 413, 1182–1183
phobic disorder, 1322
phosphofructokinase deficiency, 1312
phosphorus therapy, for alcoholic liver 
disease, 1054
photodermatitis, drug-induced, 1383t
physical activity, 46
physical therapy
for adhesive capsulitis, 1099
for tendinitis, 1099
for vertigo, 323t
physostigmine
for anticholinergic poisoning, 168t
for membrane-active agent poisoning, 
182t–183t
poisoning, 172t
PID. See pelvic inflammatory disease
pigment gallstones, 1021, 1023
pill rolling, 1221
pilocarpine
for glaucoma, 345
poisoning, 173t
for Sjögren’s syndrome, 1077
pindolol, 170t
pink eye, 344
pinta, 666–667
pinworm. See enterobiasis
pioglitazone
for diabetes mellitus, 1142t
metabolic syndrome, 843
piperacillin, for otitis externa, 359
piperacillin-tazobactam
for mixed anaerobic infections, 643t
for P. aeruginosa infections, 624t
for peritonitis, 533
for pneumonia, 924t, 926t
for sepsis/septic shock, 77t, 126t
piracetam, for myoclonus, 335
pitting, 281
pituitary adenoma, 1105–1108
ACTH-secreting, 1105, 1107t, 
1127–1128
gonadotropin-secreting, 1107t, 1110–1111
INDEX
1523
growth hormone-secreting, 1105, 1107t, 
1109–1110
hormonal evaluation of, 1107t
macroadenoma, 1105
microadenoma, 1105
prolactin-secreting, 1105, 1107t, 
1108–1109
thyroid-stimulating hormone-secreting, 
1107t, 1111, 1119
pituitary apoplexy, 1107
pituitary disease
anterior, 1105–1113
hormone hypersecretion syndromes, 
1107t, 1108–1113
posterior, 1113–1116
pituitary hormones, 1105, 1106f
pituitary tumor, 325f, 348–349, 1105
pityriasis rosea, 364f, 367
pivmecillinam
for shigellosis, 547
for urinary tract infections, 989t
pizotifen, for migraine prevention, 313t
plague, 130, 630–632
as bioweapon, 194, 196t
pneumonic, 194, 196t
treatment of, 196t
plantar reflex, 1193, 1196
plaque (lesion of MS), 1262
plaque (skin lesion), 365t
plasma cell disorders, 415t, 417f, 
423–428
plasma exchange
for acute renal failure, 958
for multiple sclerosis, 1269
plasmacytoma, 424
plasmapheresis, 54
for acute renal failure, 958
for ANCA-associated 
glomerulonephritis, 971
for autoimmune hemolysis, 384
for erythropoietic porphyria, 1184
for myasthenia gravis, 1303
for polyneuropathy, 1296
for primary biliary cirrhosis, 1055
for thrombotic microangiopathy, 997
for thrombotic thrombocytopenic 
purpura, 391
for vasculitis, 1082
plasmodium infection. See malaria
platelet clumping, 376
platelet disorders, 388–389
platelet function disorders, 389
platelet transfusion, 52
for thrombocytopenia, 401
plateletpheresis, 54
platinum compounds, 399t
for breast cancer, 446
PLCH. See pulmonary Langerhans cell 
histiocytosis
pleural biopsy, 905
pleural effusion, 923, 940–944
approach to, 940, 943f
causes of, 940, 941t–942t
chronic, 900t
chylothorax, 944
exudative, 939–940, 941t–942t
hemothorax, 944
malignant, 942
in pancreatitis, 1030
parapneumonic, 940
related to pulmonary embolism, 942, 944
secondary to viral infection, 944
thoracentesis for, 31–32, 31f
transudative, 939–940, 941t–942t
tuberculous pleuritis, 944
pleurisy, 224
pleuritis, tuberculous, 944
pleurodesis, 944
pleurodynia, enterovirus, 716
pleuropulmonary infection, anaerobic, 642
PLMS. See periodic limb movements of sleep
Plummer’s nails, 1119
PM. See polymyositis
PML. See progressive multifocal 
leukoencephalopathy
PMR. See polymyalgia rheumatica
PMS. See premenstrual syndrome
PN. See peripheral neuropathy
pneumococcal infection, 580–584
meningitis, 581–583
pneumonia, 581–583
prevention of, 583–584
pneumococcal vaccine, 519t, 580, 583–584, 
1352t–1353t, 1354f–3155f, 1358t
pneumoconiosis, 900t
Pneumocystis infection, 759–763, 761t, 762t
pneumonia, 900t, 920
acute interstitial, 935
aspiration, 642
C. pneumoniae, 684
in cancer patients, 513–514
causes of, 920–921
community-acquired, 920–923, 924t
cryptogenic organizing, 935, 938
cyanosis in, 230
desquamative interstitial, 900t, 938
E. coli, 616
eosinophilic, 935–936, 938
H. influenzae, 609
health care-associated, 920, 923–929
hemoptysis in, 233
hospital-acquired, 925
human RSV, 705–706
influenza virus, 700
Klebsiella, 618
Legionella infection, 623, 626
M. catarrhalis, 612
M. pneumoniae, 680–681
measles virus, 709
nocardiosis, 644
1524
INDEX
pneumonia (Cont.):
nosocomial, 507–508, 507t, 623
P. aeruginosa, 621, 624t
pain in, 225
pathophysiology of, 920–921 
pneumococcal, 581–583
Pneumocystis infection, 759–763, 
761t, 762t
S. aureus, 586
secondary bacterial, 700
streptococcal, 594t, 595
toxoplasmosis, 776
varicella-zoster virus, 691
ventilator-associated, 86, 621, 923, 925, 
926t, 927t
Pneumonia Severity Index (PSI), 922
pneumonic plague, 631
pneumonitis
HSV infections, 687, 690t
hypersensitivity, 935–936, 939
necrotizing, 642
pneumothorax (Ptx), 223f, 935, 944–945
PNH. See paroxysmal nocturnal 
hemoglobinuria
podagra, 1092
podofilox, for HPV infections, 568
podophyllin
for HPV infections, 568
for warts, 371
poikilocytosis, 375
poison control center, 146, 190
poisoning, 159–190
diagnosis of, 159–163, 160t–161t
heavy metals, 184t–189t
marine, 146–148
reference values for laboratory tests, 
1421t–1427t
treatment of, 163–165, 164t, 
166t–189t, 190
enhancement of elimination, 190
prevention of absorption, 165, 190
supportive care, 163–165
poliomyelitis vaccine, 519t
poliovirus infection, 714–715
meningitis, 714
paralytic disease, 715
postpolio syndrome, 715
poliovirus vaccine, 715, 717
polyangiitis
granulomatosis with, 1078
microscopic, 1078
polyangiitis overlap syndrome, 1079
polyarteritis, glomerular disease in, 977t
polyarteritis nodosa (PAN), 1078
polyarthropathy, parvovirus, 713
polychondritis, relapsing, 1097
polycystic kidney disease, 984–985
autosomal dominant, 984–985
polycystic ovarian syndrome (PCOS), 
1152, 1154
polycythemia, 284–286
causes of, 285, 286f
complications of, 286
treatment of, 286
polycythemia vera, 285, 412–413
polydipsia, 7
primary, 1113–1114
polyene, for candidiasis, 747
polyethylene glycol–containing solution
for constipation, 260
for irritable bowel syndrome, 1017t
polymyalgia rheumatica (PMR), 1098
polymyositis (PM), 1310, 1311t
polymyxins, mechanism of/resistance to, 
499, 499t
polymyxin B
for enteric GNB infection, 620
for Klebsiella infections, 618
polymyxin-bacitracin-neomycin, for eye 
infections, 345
polyneuropathy, 1292, 1294–1298
acute inflammatory demyelinating, 1298
chronic inflammatory demyelinating, 
1298
patterns of, 1295t–1296t
treatment of, 1296–1298, 1297t
polyps
colonic, 452–453
gastric, 450
polyposis syndromes, 450
hereditary, 452–453, 453t
polysomnography, 341t
polyuria, 288–289, 290t, 291f, 1162
Pompe’s disease, 1312
Pontiac fever, 623
porphyria, 1182–1184
acute intermittent, 1182–1183, 1241
erythropoietic, 1182–1184
hepatic, 1183
porphyria cutanea tarda, 1183
Porphyromonas infection, 640
portal hypertension, 281, 1057–1059
classification of, 1057t
complications of, 1058
Portuguese man-of-war injury, 145
posaconazole, 745
for aspergillosis, 750t
for fusariosis, 759
for mucormycosis, 753
positive end-expiratory pressure (PEEP), 
81–82, 86
positron emission tomography (PET), 29
post-concussion headache, 308t, 315
postherpetic neuralgia, 370, 691–692
postmeningococcal reactive disease, 
604–605
postmenopausal hormone therapy, 
1156–1157
postmenopausal state, 1364
postpolio syndrome, 715
INDEX
1525
postradiation fibrosis, 306
posttraumatic stress disorder (PTSD), 
1322, 1325
postural hypotension. See orthostatic 
hypotension
postural orthostatic tachycardia syndrome 
(POTS), 1241
potassium, disorders of, 9–17
hyperkalemia, 10, 10t–11t, 13–17, 16f, 17f
hypokalemia, 10–13, 10t–11t, 12f
potassium chloride
for hypokalemia, 13
for periodic paralysis, 1314
potassium hydroxide preparation, 365, 485
potassium iodide, for radioactive iodine 
exposure, 207
potassium perchlorate, for amiodarone-
induced thyrotoxicosis, 1123
potassium restriction, for hyperkalemia, 962
potassium therapy, for alcoholic liver 
disease, 1054
POTS. See postural orthostatic tachycardia 
syndrome
Pott’s disease, 651
Pott’s puffy tumor, 355
Powassan encephalitis, 724t
PPMS. See primary progressive multiple 
sclerosis
Prader-Willi syndrome, 1135
2-pralidoxime chloride (2-PAM)
for cholinergic poisoning, 172t
for nerve agent exposure, 202, 203t
pramipexole
for Parkinson’s disease, 1226t
for restless legs syndrome, 339, 341t
pramlintide, for diabetes mellitus, 1140
pravastatin, for hyperlipidemia, 1177t
praziquantel
for echinococcosis, 790
for fluke infection, 787
for schistosomiasis, 786
for taeniasis solium and 
cysticercosis, 788
for tapeworm infection, 788
prazosin
for ergot alkaloid poisoning, 166t
for vasospastic disorders, 892
precordial palpation, 796
prednisolone
for alcoholic liver disease, 1054
for autoimmune hepatitis, 1050
prednisone
for acute lymphoblastic leukemia and 
lymphoblastic lymphoma, 423
for alcoholic liver disease, 1054
for autoimmune hepatitis, 1050
for Bell’s palsy, 1246
for Burkitt’s lymphoma/leukemia, 423
for cluster headache prevention, 314
for gastric cancer, 449
for hirsutism, 1156
for hypercalcemia, 1163t
for hypopituitarism, 1112t
for idiopathic thrombocytopenic 
purpura, 390
immunosuppression for renal 
transplant, 967
for inflammatory bowel disease, 1015
for inflammatory myopathy, 1312
for interstitial lung disease, 937
for lymphoma, 420–421
for multiple myeloma, 426
for multiple sclerosis, 1269
for muscular dystrophy, 1309
for myasthenia gravis, 1305
for optic neuritis, 326
for pericarditis, 831
for Pneumocystis infections, 761t, 762
for polymyalgia rheumatica, 1098
for postherpetic neuralgia, 692
for relapsing polychondritis, 1097
for sarcoidosis, 1101
steroid preparations, 1131, 1131t, 1133
for thyrotoxicosis, 1121
for vasculitis, 1081
preexcitation syndrome. See Wolff-
Parkinson-White syndrome
pregabalin, 44t–45t
for fibromyalgia, 1098
for generalized anxiety disorder, 1321
for multiple sclerosis, 1269
for polyneuropathy, 1297t
pregnancy
ectopic, 1153–1154
gonorrhea in, 559
high altitude and, 158
hypertension in, 841
listerial infections in, 606–608
malaria in, 764
streptococcal infections in, 597–598
syphilis in, 565t
toxemia of, 997
toxoplasmosis in, 776
travel during, 1360
prehypertension, 1363
preleukemia, 409
premenstrual syndrome (PMS), 1154
presbycusis, 352
pressure-control ventilation, 84
pressure-support ventilation (PSV), 84, 85t
preventive medicine, 1345
Preventive Services Task Force, U.S., 
recommendations of, 1349t
Prevotella infection, 640
prilocaine, for polyneuropathy, 1297t
primaquine
for malaria, 765, 766t
preventive treatment, 770t
for Pneumocystis infections, 761–762, 
761t
1526
INDEX
primary (spontaneous) bacterial 
peritonitis (PBP), 532–533
primary biliary cirrhosis, 1054–1055
primary lateral sclerosis, 1232t
primary progressive multiple sclerosis 
(PPMS), 1263
primary sclerosing cholangitis (PSC), 
1025–1026
primidone
for myoclonus, 335
poisoning, 174t
for seizures, 1209t
for tremor, 333
Prinzmetal’s variant angina, 864
PRL. See prolactin
PRMS. See progressive-relapsing multiple 
sclerosis
probenecid
for gonococcal infections, 560t
for gout, 1093
for syphilis, 565t
procainamide
for arrhythmias, 874t
for tachyarrhythmias, 871t
for Wolff-Parkinson-White 
syndrome, 878
procaine penicillin
for diphtheria, 601
for streptococcal infection, 594t
for syphilis, 565t
prochlorperazine
for migraine, 311t
for nausea and vomiting, 246, 401
proctitis, 556, 558
HSV, 690t
proctocolitis, 556, 558
progressive disseminated histoplasmosis, 
753–754, 755t
progressive multifocal 
leukoencephalopathy (PML), 1282
progressive systemic sclerosis, 937
progressive-relapsing multiple sclerosis 
(PRMS), 1263
prolactin (PRL), 1105, 1105f
deficiency of, 1107t, 1111
hypersecretion of, 1107t, 1108–1109
prolactinoma, 349, 1108–1109
promethazine, for vertigo, 323t
promyelocytic leukemia
acute, 403, 404t
hypergranular, 403
propafenone, for arrhythmias, 875t
Propionibacterium acnes infection, 640
propofol
for delirium, 59t
for increased intracranial pressure, 107t
poisoning, 175t
for sedative-hypnotic poisoning, 173t
for status epilepticus, 117f
for sympathomimetic poisoning, 166t
propoxyphene
narcotic abuse, 1340
poisoning, 182t–183t
propranolol
for aortic dissection, 889t
for esophageal varices, 1058
for hypertension, 837t
for methylxanthine poisoning, 167t
for migraine prevention, 313t
poisoning, 170t
for sympathomimetic poisoning, 166t
for thyrotoxicosis, 1120, 1122
for tremor, 333
for variceal bleeding, 266
propylene glycol poisoning, 20, 21t
propylthiouracil (PTU), for thyrotoxicosis, 
1120–1122
prostaglandin analogues, for glaucoma, 345
Prostascint scanning, 472
prostate biopsy, transrectal ultrasound, 
470, 471f
prostate cancer, 470–473
oncologic emergencies, 135
osteoblastic bone metastasis, 476
paraneoplastic, 478t
prevention of, 473, 1370
risk factors for, 1370
screening for, 1347t–1348t, 1366, 
1367t–1368t
treatment of, 472–473
prostate hyperplasia, 469–470
prostatectomy, radical retropubic, 472
prostate-specific antigen (PSA), 469, 471f, 
472, 1366, 1367t–1368t, 1370
bound, 470
free, 470
prostatitis, 986–988
prosthetic device-related infection, 575–576
coagulase-negative staphylococci, 588
S. aureus, 587
treatment of, 589, 592
prosthetic valve endocarditis (PVE), 
522–524, 530–531, 592
HACEK group, 613–614, 614t
protamine, to reverse anticoagulation, 
392, 932
protease inhibitors, for HIV/AIDS, 
738t–739t, 740–741
protein malnutrition, 47–48
protein requirements, 46
protein restriction, in renal failure, 962
protein-losing enteropathy, 276
proteinuria, 290–292, 952, 978
nephrotic range, 290
Proteus infection, 618–619
prothrombin time, 273t
proto-oncogenes, 395
protozoal infection, 763–778
in chronic meningitis, 1287t–1288t
diagnosis of, 494, 495t
INDEX
1527
protriptyline, for daytime sleepiness, 340t
Providencia infection, 619–620
prune juice, 56t
pruritus ani, 1020
PS. See pulmonic stenosis
PSA. See prostate-specific antigen
PSC. See primary sclerosing cholangitis
pseudocyst, pancreatic, 1030
pseudodementia, 1213
pseudoephedrine
for allergic rhinitis, 1064
for syncope, 320
pseudogout, 1094–1095
conditions associated with, 1094t
pseudohyponatremia, 4
pseudomelena, 261–262
Pseudomonas aeruginosa infection, 
620–622
infections by related bacteria, 
622–623, 625t
osteomyelitis, 577t, 579t
treatment of, 622, 624t–625t
pseudoseizures, 1199
pseudothrombocytopenia, 389
pseudotumor cerebri, 326
drug-induced, 1390t
PSI. See Pneumonia Severity Index
psittacosis, 683
psoralens, for polycythemia vera, 412
psoriasis, 364f, 367
psoriatic arthritis, 1085–1087
CASPAR criteria for, 1086, 1086t
patterns of joint involvement in, 
1085–1086
PSV. See pressure-support ventilation
psychiatric disorders, 1315–1324
anxiety disorders, 1320
diagnosis of, 1217t
drug-induced, 1391t
DSM-IV Axis I, 1315–1323
DSM-IV Axis II, 1315, 1323–1324
eating disorders, 1333–1336
fatigue in, 215t
mood disorders, 1315–1319
nausea and vomiting in, 245t
personality disorders, 1323–1324
psychotic disorders, 1319–1320
schizophrenia, 1319–1320
sleep disorders and, 339
syncope compared with, 319–320
treatment of, 1324–1332
weight loss in, 219t
in women, 1377
psychiatric medication, 1324–1332
antidepressants, 1325, 1326t–1327t
antipsychotics, 1329
anxiolytics, 1325, 1328t, 1329
mood stabilizers, 1329, 1332, 1332t
principles of use of, 1324–1325
psychotic disorder, 1319–1320
psyllium
for diverticular disease, 1018
for hemorrhoids, 1020
for irritable bowel syndrome, 1017, 1017t
PTH(1-34), for osteoporosis, 1170
PTSD. See posttraumatic stress disorder
PTU. See propylthiouracil
Ptx. See pneumothorax
pubic louse, 792
PUD. See peptic ulcer disease
puddle sign, 275
pulmonary alveolar proteinosis 
(PAP), 938
pulmonary angiography, 904
pulmonary artery catheters, 38–39
pulmonary artery pressure (PAP), 901
pulmonary circulation
cor pulmonale, 885
disturbances of, 901
pulmonary disease. See lung disease
pulmonary edema, 235, 238
acute, 78–80
cardiogenic, 79
causes of, 79t
cyanosis in, 230–231
drug-induced, 1386t
dyspnea in, 228–229
noncardiogenic, 78, 79t
precipitants of, 78t
treatment of, 79–80
pulmonary embolism (PE), 900t, 929–933
chest pain in, 221t, 223f, 224
dyspnea in, 227
hemodynamic profiles in, 71t
hemoptysis in, 233
imaging for, 930–931, 931f
laboratory evaluation of, 930
pleural effusion related to, 942, 944
pulmonary hypertension in, 895t
thrombotic disorders, 391–392
treatment of, 392–394, 393t, 
932–933, 933f
pulmonary fibrosis
drug-induced, 398t–400t
idiopathic, 900t, 935, 937
progressive massive, 913
pulmonary function tests, 899, 904–906
in asthma, 908
in COPD, 915–917, 915t
in pulmonary hypertension, 896
reference values for, 1447t–1449t
pulmonary hypertension, 895–898, 901
approach to, 897f
arterial, 895t
categories of, 895t
in congenital heart disease, 813
differential diagnosis of, 896
laboratory features of, 896
treatment of, 898
venous, 895t
1528
INDEX
pulmonary infiltrate
drug-induced, 1386t
with eosinophilia, 938
pulmonary Langerhans cell histiocytosis 
(PLCH), 935, 939
pulmonary nodule, solitary, 437, 440f
pulmonary rehabilitation, 918, 937
pulmonary thromboendarterectomy, for 
venous thromboembolism, 933
pulmonary tularemia, 630
pulmonary vascular resistance (PVR), 901
pulmonic stenosis (PS), 798t, 813
pulmonic valve regurgitation, 798t
pulse oximetry, 902
pulseless disease, 890
pulseless electrical activity, 68, 68f
pulsus alternans, 795, 795f
pulsus biferiens, 795, 795f
pulsus paradoxus, 795, 795f
pulsus parvus, 795, 795f
pulsus tardus, 795, 795f
pupillary signs, in coma, 91
pure alexia, 336t
pure red cell aplasia
drug-induced, 1384t
parvovirus infections, 713
pure tone audiometry, 349–350
pure word deafness, 336t
purging behavior, 1333
purine metabolism deficiency, 1068
purpura, 210. See also specific types
drug-induced, 1383t
palpable, 373
purpura fulminans, 127t, 131
pustule, 365t
Puumala virus infection, 726
PUVA, for psoriasis, 367
PVE. See prosthetic valve endocarditis
PVR. See pulmonary vascular resistance
pyelonephritis, 535–536, 986–988
emphysematous, 987
xanthogranulomatous, 987
pyloroplasty, 1008t
pyomyositis, 573–574
S. aureus, 586
pyrantel pamoate
for ascariasis, 781
for enterobiasis, 783
for hookworm infection, 781
pyrazinamide, for tuberculosis, 653, 
655t, 659t
pyridostigmine
for myasthenia gravis, 1303
for orthostatic hypotension, 1242
pyridoxine, for isoniazid poisoning, 180t
pyridoxine deficiency, 51t
pyrilamine, 168t
pyrimethamine
for cystoisosporiasis, 543
for malaria, 766t
for Pneumocystis infections, 762t
for toxoplasmosis, 777
pyrogen, 209
pyroglutamic aciduria, 20, 21t
pyruvate kinase deficiency, 380
pyuria, 293, 952
sterile, 952
Q
Q fever, 672t, 678–679
acute, 678–679
chronic, 679
QSART. See quantitative sudomotor axon 
reflex test
quadrantanopia, 330t
quadrantopia, 325f
quadriparesis, 330t, 331f
quantitative sudomotor axon reflex test 
(QSART), 1238
quetiapine
dosage and adverse effects of, 168t, 1331t
for schizophrenia, 1319
quinidine
for arrhythmias, 874t
for malaria, 765, 767t
quinine
for babesiosis, 126t, 771
for malaria, 128t, 766t–767t
poisoning, 182t–183t
quinolones. See fluoroquinolones
quinsy, 642
quinupristin-dalfopristin
drug interactions with, 503t
for enterococcal infections, 600
mechanism of/resistance to, 496, 498t
for staphylococcal infection, 589, 590t
R
RA. See refractory anemia; rheumatoid 
arthritis
rabies, 139–140, 718–720
encephalitic form, 719
paralytic form, 719
postexposure prophylaxis, 143, 720, 721f
preexposure prophylaxis, 720
prodrome, 718–719
rabies immune globulin, 143, 720, 721f
rabies vaccine, 143, 720, 721f, 1359t
rad, 204
radial neuropathy at spiral groove, 1300t
radiation bioterrorism, 204–207
acute radiation sickness, 205
treatment of casualties, 206–207, 206f
types of exposure, 204–205
types of radiation, 204
radiation sickness, acute, 205, 206f
radiation therapy
for adrenal carcinoma, 1128
for anal cancer, 457
for bladder cancer, 461
INDEX
1529
for brain tumor, 1258
for breast cancer, 443, 446
for cervical cancer, 468–469
for colorectal cancer, 456
complications of, 400t, 1262
for endometrial cancer, 467
for esophageal cancer, 448
for follicular lymphoma, 420
for gastric cancer, 449
for head and neck cancer, 432–433
for Hodgkin’s disease, 428
leukopenia in, 387
for lung cancer, 437, 439
for multiple myeloma, 424
for prostate cancer, 472
for spinal cord compression, 113, 135
for testicular cancer, 463, 463t
radiculopathy
cervical, 304, 305t, 306–307
lumbosacral, 299t
subacute, 304
radiography
in joint pain, 297, 297t
in spinal cord compression, 135
radioiodine
for nontoxic goiter, 1124
for thyroid neoplasms, 1126
for thyrotoxicosis, 1120–1122
for toxic adenoma, 1124
for toxic multinodular goiter, 1124
radionuclide contamination, 207
radionuclide scan
hepatobiliary imaging, 274
utility of, 29–30
RAEB. See refractory anemia with excess 
blasts
ragged red fibers, 1312
raloxifene
for breast cancer prevention, 1369
for osteoporosis, 1170
toxicity of, 399t
raltegravir, for HIV/AIDS, 739t, 740
ramipril
for heart failure, 882t
for hypertension, 838t
Ramsay Hunt syndrome, 691, 1246
ranitidine
for H. pylori eradication, 1008t
for indigestion, 247
for urticaria/angioedema, 1063
ranolazine, for angina pectoris, 862
rapid eye movement (REM) behavioral 
disorder, 337
rapid shallow breathing index (RSBI), 38
rapid urease test, 1006, 1007t
RARS. See refractory anemia with ringed 
sideroblasts
rasagiline, for Parkinson’s disease, 1226t
rasburicase, for tumor lysis syndrome, 
137–138
rashes
arthritis and, alphavirus infection, 725
drug, 511
measles infection, 708–709
rubella, 710
rat-bite fever, 140
Raynaud’s disease, 892t
Raynaud’s phenomenon, 891, 892t
RBCs. See red blood cells
RCMD. See refractory cytopenia with 
multilineage dysplasia
RCUD. See refractory cytopenia with 
unilineage dysplasia
RDA. See recommended dietary allowance
reactive arthritis, 575, 1087–1089
recluse spider bite, 148–149
recombinase activating gene deficiency, 
1068–1069
recommended dietary allowance (RDA), 46
rectal cancer, 456
red blood cells (RBCs)
disorders of, 377–384
anemia, 283, 377–381
intracellular abnormalities, 380
maturation disorders, 379–380
membrane abnormalities, 381
polycythemia, 284–286
inclusions, 375–376
increased RBC mass, 412
morphology of, 375
RBC indices, 284–285
reference ranges for volumes of, 1450t
transfusion, 52
red eye, 343–345, 344t
red hepatization, 921
REE. See resting energy expenditure
reentrant AV nodal tachycardia, 868f, 869t
referred pain, 41
abdominal pain, 240t
low back pain, 298
neck pain, 306
shoulder pain, 306
reflex sympathetic dystrophy, 1241–1242
reflexes, testing of, 1193, 1196
refractory anemia (RA), 410t
refractory anemia with excess blasts 
(RAEB), 410t
refractory anemia with ringed sideroblasts 
(RARS), 410t
refractory cytopenia with multilineage 
dysplasia (RCMD), 410t
refractory cytopenia with unilineage 
dysplasia (RCUD), 410t
refractory neutropenia (RN), 410t
refractory thrombocytopenia (RT), 410t
regurgitation, 244, 246
rehydration, in diarrhea, 257
relapse prevention, 1340
relapsing fever, 668–669
relapsing polychondritis, 1097
1530
INDEX
relapsing-remitting multiple sclerosis 
(RRMS), 1263
REM behavioral disorder. See rapid eye 
movement behavioral disorder
renal abscess, 535–536
renal artery occlusion, 991–997
renal artery stenosis, 992–995
approach to, 994f
clinical features of, 992, 993t
hypertension in, 834, 836, 992
renal artery thrombosis, 991
renal atheroembolism, 991–992
renal cancer. See kidney cancer
renal disease
approach to, 949–954
azotemia, 287
chronic
classification of, 288t
treatment of, 962
clinical and laboratory database for, 
950t–951t
dialysis in, 962
drug-induced, 398t, 1388t–1389t
end-stage, 960
renal transplant in, 965–968
fatigue in, 215t
glomerular, 949–951, 968–978
high altitude and, 158
hypertension in, 834, 836, 841, 951t, 
953, 962
infections in immunocompromised 
patients, 514, 517t
metabolic acidosis in, 20, 21t
monoclonal immunoglobulins and, 
983–984, 983t
nephritic syndrome, 950t
nephrolithiasis, 951t, 953, 998–1000
nephrotic syndrome, 950t, 952
reference values for renal function tests, 
1436t–1439t
renal tubular disease, 950t, 952–953, 
978–986
renovascular disease, 991–997
urinary abnormalities in, 288–289
urinary tract infection, 950t, 952
urinary tract obstruction, 951t, 953, 
1001–1003
renal failure
acute, 39, 949–951, 950t, 954–959
approach to, 956–958, 957t
causes of, 954, 955t–956t
dialysis for, 959
intrinsic, 954, 955t, 956–958, 957t
postrenal, 954, 956, 956t, 958
prerenal, 954, 955t, 957t
treatment for, 958–959
chronic, 950t, 951–952, 960–962
causes of, 960–961, 960t
sleep disorders in, 339
slowing progression of, 962
edema in, 236–237
renal parenchymal disease, hypertension 
in, 834, 836
renal transplant, 21t, 962, 965–968
complications of, 967–968
contraindications to, 966t
drug-induced, 1388t
factors influencing graft survival, 966t
FGS and, 974
immunosuppressive therapy for, 967
infections in recipients, 518, 520
rejection of, 965–967
renal tubular acidosis (RTA), 985–986
distal (type I), 985
drug-induced, 1388t
proximal (type II), 985–986
type IV, 986
renal tubular disease, 950t, 952–953, 
978–986
causes of, 979t–980t
drug-induced, 1388t
transport dysfunction in, 981t
renovascular disease, 991–997
arteriolar nephrosclerosis, 995
renal artery occlusion, 991–992
renal artery stenosis, 992–995
renal vein thrombosis, 992
in scleroderma, 995
sickle cell nephropathy, 997
thrombotic microangiopathy, 995–997
toxemia of pregnancy, 997
repaglinide, for diabetes mellitus, 1142t
repositioning exercises, for vertigo, 
323t, 324
reproductive system disease
female, 1150–1159
male, 1144–1150
reproductive tract infection, 551
chancroid, 557t, 567
chlamydial infection, 552–556, 559, 
561–562
donovanosis, 557t, 567–568
epididymitis, 552–553
genital herpes, 553–554, 556, 557t, 558, 
566–567
gonorrhea, 552–556, 558–559, 
560t–561t, 574–576
HPV infection, 568–569
mucopurulent cervicitis, 554, 559
mycoplasmal infection, 552, 554, 562
pelvic inflammatory disease, 555–556
proctitis, proctocolitis, enterocolitis, 
and enteritis, 556, 558
syphilis, 557t, 558, 562–566, 565t
ulcerative genital lesions, 556, 557t
urethritis
in men, 552, 559
in women, 553, 559
vulvovaginal infection, 553–554
resistance. See antibacterial resistance
respiratory acidosis, 24
respiratory alkalosis, 25
INDEX
1531
respiratory bronchiolitis, 936–937
respiratory disease. See also lung disease
bronchoalveolar lavage in, 905
bronchoscopy in, 905–906
C. pneumoniae infection, 684
chest x-ray in, 904
computed tomography in, 904
diagnosis of, 904–906
drug-induced, 1386t
extraparenchymal, 900t, 901, 901t
infections in immunocompromised 
patients, 513–514, 517t
M. pneumoniae infection, 680–681
MRI in, 904
nuclear medicine imaging in, 904–905
obstructive, 899–901, 900t, 901t
parenchymal, 900t, 901, 901t
pulmonary function tests in, 904–906
restrictive, 899–901, 900t, 901t
sputum exam in, 905
upper respiratory infections, 353–362
weight loss in, 219t
respiratory failure, 83–86, 85t
hypercarbic, 83
hypoxemic, 83
respiratory function, 899–904
in coma, 92
disturbances of, 903–904
gas exchange disturbances, 901–902
pulmonary circulation disturbances, 
901
ventilatory function disturbances, 
899–901
respiratory muscle dysfunction, 226
respiratory rate, 902
respiratory syncytial virus, human. See 
human respiratory syncytial virus 
infection
respiratory tract, specimen collection and 
transport, 488t–489t
respiratory tract infection
diphtheria, 600–601
S. aureus, 586
respiratory viruses, 703
adenovirus infection, 704t, 707–708
coronavirus, 703, 704t, 705
human metapneumovirus infection, 
704t, 706
human RSV, 704t, 705–706
influenza, 699–702, 702t, 704t
antigenic variation, 700
complications of, 700–701
epidemic and emerging problems, 
509
H. influenzae infection, 519t, 
608–610
treatment of, 701–702
parainfluenza virus infection, 704t, 
706–707
rhinovirus, 703, 704t
resting energy expenditure (REE), 46
restless legs syndrome (RLS), 339, 341t
resuscitation, 71–72, 72f
retching, 244
reteplase, for thrombotic disorders, 394
reticular dysgenesis, 1069
reticulocytes, 375
reticulocyte index (RI), 284
retinal artery occlusion, 325f
retinal detachment, 326
retinal vein occlusion, 325f, 326
retinitis, cytomegalovirus, 695–696
retinitis pigmentosa, 325f
retinoic acid
for acne, 371
for head and neck cancer, 433
prevention, 1371
for squamous cell carcinoma, 431
trans-retinoic acid, for AML, 406
retinoid, for psoriasis, 367
retinopathy
diabetic, 348, 348f
drug-induced, 1390t
paraneoplastic, 481t, 482t, 483
reverse SLR sign, 299
reverse transcriptase inhibitors, for HIV/
AIDS, 735t–737t, 740–741
rewarming
active, 153
external, 153
internal, 153
passive, 153
Reye’s syndrome, 700–701
rhabdomyolysis, 292
rheumatic (Sydenham’s) chorea, 333
rheumatic fever, prophylaxis for, 816
rheumatic heart disease, 816
rheumatoid arthritis (RA), 935, 944, 
1072–1074
neck pain in, 306
treatment of, 1073–1074
rheumatoid factor, 936, 1079, 1083
rhinitis, allergic, 1063–1064
rhinocerebral mucormycosis, 752
rhinophyma, 371
rhinosinusitis. See sinusitis
rhinovirus infection, 703, 704t
Rhizomucor infection. See mucormycosis
Rhizopus oryzae. See mucormycosis
Rhodococcus infection, 602–603
RI. See reticulocyte index
ribavirin
for adenovirus infections, 708
for chronic hepatitis C, 1040, 
1047t–1049t
for croup, 707
for hemorrhagic fever with renal 
syndrome, 726
for hepatocellular carcinoma, 458
for human RSV infections, 706
for membranoproliferative 
glomerulonephritis, 975
1532
INDEX
ribavirin (Cont.):
for South American hemorrhagic 
fevers, 725
for viral encephalitis, 1280
for viral hemorrhagic fevers, 197t
Richter’s syndrome, 418
Rickettsia africae infection, 671t, 674
Rickettsia conorii infection, 671t, 673–674
Rickettsia prowazekii infection. See typhus, 
epidemic
Rickettsia rickettsii infection. See Rocky 
Mountain spotted fever
Rickettsia typhi infection. See typhus, 
murine
rickettsial disease, 127t, 130–131, 211, 
670–679, 671t–672t
flea- and louse-borne typhus, 672t, 
674–678
lymphadenopathy and, 279t
Q fever, 672t, 678–679
tick- and mite-borne spotted fever, 
670–674, 671t
rickettsialpox, 671t, 674
rifabutin
for nontuberculous mycobacterial 
infections, 663
for tuberculosis, 653, 658t
rifampin
adverse reactions to, 502t
for anthrax, 195t
for Bartonella infections, 633t
for brucellosis, 629
for Corynebacterium infection, 603
for diphtheria, 601
drug interactions with, 503t–504t
for enterococcal infections, 600
for human granulocytotropic 
anaplasmosis, 678
for infectious arthritis, 576
for infective endocarditis, 527t–528t, 530
for Legionella infection, 626
for leprosy, 660–661
mechanism of/resistance to, 496, 498t
for meningococcal disease prevention, 
1275
for meningococcal infection, 606
for nontuberculous mycobacterial 
infections, 663
for pneumococcal infections, 583
for primary biliary cirrhosis, 1055
for Q fever, 679
for staphylococcal infection, 590t, 592
for streptococcal infection, 594
for tuberculosis, 653, 655t, 656, 658t–659t
rifapentine, for tuberculosis, 654, 655t
rifaximin
for Clostridium difficile infection, 551
for diarrhea, 1360
for hepatic encephalopathy, 1060
for irritable bowel syndrome, 1018
Rift Valley fever, 725–726
right ventricular systolic pressure 
(RVSP), 805
rilpivirine, for HIV/AIDS, 740
riluzole, for ALS, 1234
rimantadine, for influenza, 701, 702t
Ringer’s lactate, for cholera, 540
ringworm, 370
Rinne test, 349
risedronate, for osteoporosis, 1169
risperidone
for delirium, 59t
dosage and adverse effects of, 169t, 
1331t
for schizophrenia, 1319
ritonavir, for HIV/AIDS, 738t
rituximab
for ANCA-associated 
glomerulonephritis, 971
for autoimmune hemolysis, 384
for CLL, 419
for focal glomerulosclerosis, 975
for gastric cancer, 449
for glomerulonephritis, 974–975
for idiopathic thrombocytopenic 
purpura, 390
for inflammatory myopathy, 1312
for lymphoma, 420–421
for multiple sclerosis, 1269
for posttransplantation 
lymphoproliferative disease, 699
for rheumatoid arthritis, 1074
toxicity of, 400t
for vasculitis, 1082
rivaroxaban
for antiphospholipid antibody 
syndrome, 1077
for atrial fibrillation, 877
for thrombotic disorders, 393
rivastigmine, for Alzheimer’s disease, 1218
river blindness, 784
rizatriptan, for migraine, 310t, 312t
RLS. See restless legs syndrome
RN. See refractory neutropenia
Rocky Mountain spotted fever, 127t, 
130–131, 210, 670, 671t, 673
rodent bite, 140, 142t
rodent-borne viral infection, 720–727, 
723t–724t
Romaña’s sign, 773
Romberg test, 1196
romidepsin, toxicity of, 399t
ropinirole
for Parkinson’s disease, 1226t
for restless legs syndrome, 339, 341t
rosacea. See acne rosacea
Rosai-Dorfman disease, lymphadenopathy 
and, 280t
rose spots, 544
roseola infantum, 693
INDEX
1533
rosetting, 764
Ross River virus infection, 725
rosuvastatin, for hyperlipidemia, 1177t
rotavirus infection, diarrhea, 541
rotavirus vaccine, 541
rotigotine, for Parkinson’s disease, 1226t
rouleaux formation, 375
roundworm infection. See also nematode 
infection
intestinal, 495t
RRMS. See relapsing-remitting multiple 
sclerosis
RSBI. See rapid shallow breathing index
RT. See refractory thrombocytopenia
RTA. See renal tubular acidosis
rubella, 710–711
rubella vaccine, 520t, 709, 711
rubeola. See measles virus infection
rufinamide, for seizures, 1211t
rumination, 244
Russian spring-summer encephalitis, 724t
RVSP. See right ventricular systolic pressure
S
SAAG. See serum-ascites albumin gradient
Saccharomyces boulardii therapy, for 
Clostridium difficile infection, 550
SAH. See subarachnoid hemorrhage
salicylates, 20
metabolic acidosis with, 21t
for osteoarthritis, 1091
poisoning, 179t
for seborrheic dermatitis, 369
for warts, 371
saline therapy
for diabetic ketoacidosis, 120t
for hypercalcemia, 136, 480, 1163t
for hyperglycemic hyperosmolar 
state, 121
for hypernatremia, 8
for hyponatremia, 7, 480
for increased intracranial pressure, 107t
for membrane-active agent poisoning, 
182t–183t
for metabolic alkalosis, 24
for SIADH, 136
for tumor lysis syndrome, 137
salmeterol, for asthma, 909
salmonellosis, 544–545
nontyphoidal, 545
typhoid fever, 544–545
salpingitis, 555
samarium-153 EDTMP, 400t
samarium-153 therapy, 473
sarcoidosis, 900t, 935, 1100–1101
in chronic meningitis, 1290t
lymphadenopathy and, 279t
treatment of, 1101, 1101f, 1102f
sarcoma, paraneoplastic syndromes in, 
479t
Sarcoptes scabiei infestation. See scabies
sarin, 172t, 201–202
SARS. See severe acute respiratory 
infection
SARS coronavirus, as bioweapon, 199
sausage digits, 1085–1086
saxagliptin, for diabetes mellitus, 
1142t
scabies, 791–792
scale (skin lesion), 366t
scar, 366t
scar carcinoma, 431
scarlet fever, 595
SCC. See squamous cell carcinoma
scedosporiosis, 759
Schilling test, 257
schistocytes, 375
schistosomiasis, 460, 495t, 785–786, 
1360
schizoaffective disorder, 1320
schizoid personality disorder, 1323
schizophrenia, 1319–1320
drug-induced schizophrenic reactions, 
1391t
schizophreniform disorder, 1320
schizotypal personality disorder, 1323
schwannoma, 1260
vestibular, 352
sciatic neuropathy, 1301t
SCID. See severe combined 
immunodeficiency
scleritis, 345
sclerodactyly, 1074
scleroderma. See systemic sclerosis
scombroid poisoning, 147–148
scopolamine
for nausea and vomiting, 56, 246
poisoning, 168t
for vertigo, 323t
scorpion sting, 150
scorpionfish envenomation, 145
scotoma, 325, 325f, 346
screening recommendations, 1345
scrub typhus, 672t, 676
sea anemone injury, 145
seborrheic keratosis, 364f
secobarbital, 174t
secondary progressive multiple sclerosis 
(SPMS), 1263
secretin stimulation test, 257, 1031
sedative-hypnotics, poisoning, 
160t–161t, 173t
seizure, 1199–1203. See also epilepsy
absence (petit mal), 1199, 1200t, 
1205t–1212t
approach to, 1199, 1204f
causes of, 1199, 1201t, 1202t
differential diagnosis of, 1202t
drug-induced, 1203t, 1389t
EEG in, 1200
1534
INDEX
seizure (Cont.):
focal, 1199, 1200t, 1205t–1212t
generalized, 1199, 1200t, 1205t–1212t
neuroimaging in, 1200
in poisoning, 165
syncope compared with, 317
tonic-clonic (grand mal), 1199, 1200t, 
1205t–1212t, 1208t–1210t
treatment of, 1202–1203, 1205t–1212t
selective antibody deficiency to 
polysaccharide antigens, 1070
selective serotonin reuptake inhibitors 
(SSRIs), 1325, 1326t
selegiline
dosage and adverse effects of, 167t, 1327t
for Parkinson’s disease, 1226t
selenium, for lung cancer prevention, 1370
selenium sulfide, for seborrheic 
dermatitis, 369
semen analysis, 1147
seminoma, 463, 463t
senna, for constipation, 56t
sensitization, 40–41
sensory exam, 1196
sensory level, 135
sensory loss, 330t
proprioceptive, 331
sentinel loop, 1028
sentinel node biopsy, in breast cancer, 443
sepsis, 39, 74–78
without clear focus of primary 
infection, 126t, 130
clinical features of, 75–76
clostridial, 639, 641t
complications of, 75
epidemiology of, 74
infectious disease emergencies, 130
pathophysiology of, 74–75
post-splenectomy, 126t, 130
S. aureus, 586
severe, 74
with skin manifestations, 127t, 130–131
with soft tissue/muscle findings, 
127t–128t, 131
streptococcal, 597
treatment of, 76, 77t
septal panniculitis, 372
septic shock, 36, 37f, 70, 70t, 74–78, 126t, 130
clinical features of, 75–76
complications of, 75
epidemiology of, 74
infectious disease emergencies, 130
pathophysiology of, 74–75
treatment of, 76, 77t
septicemia
listerial, 606–608
meningococcal, 604–605
septicemic plague, 631
serology, diagnosis of infectious disease, 487
serotonin syndrome, 182t, 213
serous otitis media (SOM), 350
Serratia infection, 619–620
sertraline
dosage and adverse effects of, 1326t
for OCD, 1321
for syncope, 320
serum sickness, 210
drug-induced, 1380t
serum-ascites albumin gradient (SAAG), 
276, 276f
sevelamer, for hyperphosphatemia, 1166
severe acute respiratory infection (SARS), 
703, 705
severe combined immunodeficiency 
(SCID), 1066–1069
sexual assault, 1377
sexual dysfunction, drug-induced, 1380t
sexually transmitted infection (STI), 551
chancroid, 557t, 567
chlamydial infection, 552–556, 559, 
561–562
donovanosis, 557t, 567–568
epididymitis, 552–553
genital herpes, 553–554, 556, 557t, 558, 
566–567
gonorrhea, 552–556, 558–559, 
560t–561t, 574–576
HPV infection, 568–569
mucopurulent cervicitis, 554, 559
mycoplasmal infection, 552, 554, 562
pelvic inflammatory disease, 555–556
proctitis, proctocolitis, enterocolitis, 
and enteritis, 556, 558
syphilis, 557t, 558, 562–566, 565t
in travelers, 1360
ulcerative genital lesions, 556, 557t
urethritis
in men, 552, 559
in women, 553, 559
vulvovaginal infection, 553–554
shift work, 337, 342
Shiga toxin-producing/enterohemorrhagic 
E. coli (STEC/EHEC), 616–617
diarrhea, 547–548
shigellosis
diarrhea, 547–548
proctocolitis, 558
shingles, 370, 691–692
shock, 36, 37f, 69–71. See also specific types
approach to, 37f, 69
cardiogenic, 36
forms of, 70t
in GI bleeding, 262
hemodynamic profiles in, 71t, 72f
high cardiac output/low systemic 
vascular resistance, 36, 37f
hypovolemic, 36, 37f
treatment of, 71–72, 73t
shoulder
adhesive capsulitis, 1099
INDEX
1535
muscles and innervation of, 
1190t–1191t
shoulder pain, 304–307
causes of, 304–306
mechanical, 306
treatment of, 306–307
shunting, hypoxemia in, 903
SIADH. See syndrome of inappropriate ADH
sick euthyroid syndrome, 1122–1123
sick sinus syndrome (SSS), 864
sickle cell anemia, 380–381, 383
pathophysiology of sickle cell 
crisis, 382f
sickle cell disease, high altitude and, 158
sickle cell nephropathy, 997
sickled cells, 375
sideroblastic anemia, 379–380, 380t
sigmoidoscopy, 456, 1367t–1368t
in colonic polyps, 452
in diarrhea, 257
in GI bleeding, 264
sildenafil
for achalasia, 251
for erectile dysfunction, 1149
for pulmonary hypertension, 898
for systemic sclerosis, 1075
silent ischemia, 859
silicosis, 913
simple phobia, 1322
SIMV. See synchronized intermittent 
mandatory ventilation
simvastatin, for hyperlipidemia, 1177t
Sindbis virus infection, 725
single photon emission computed 
tomography (SPECT), 29
sinoatrial node dysfunction, 864
extrinsic, 864
intrinsic, 864
sinus rhythm, 800
sinus tachycardia, 849, 868f, 869t
sinusitis, 354–355, 358
acute, 354–355
anaerobic, 642
aspergillosis, 748
bacterial, 354–355
chronic, 355, 358
fungal, 354–355
Klebsiella, 618
M. catarrhalis, 612
nosocomial, 354
pneumococcal, 582
treatment of, 354, 356t
viral, 354–355
sinusoidal obstruction syndrome, 276f
sipuleucel-T, for prostate cancer, 472
sirolimus, immunosuppression for renal 
transplant, 967
SIRS. See systemic inflammatory response 
syndrome
Sister Mary Joseph’s nodule, 276
sitagliptin, for diabetes mellitus, 1142t
Sjögren’s syndrome, 1076–1077
SK. See streptokinase
skin, examination of, 363–366
skin biopsy, 365
skin cancer, 428–432
basal cell carcinoma, 430–431
melanoma. See melanoma
paraneoplastic syndromes in, 478t
prevention of, 429, 431, 1346t–1347t
screening for, 1367t–1368t
squamous cell carcinoma, 431
skin disease
acne, 371
arrangement and shape of lesions, 
363, 364f
in cancer patients, 511
diagnosis of, 365–366
distribution of lesions, 363
drug-induced, 372–373, 400t, 1382t–1383t
eczematous, 368–369
history in, 364–365
lesion characteristics, 363–364, 364f
in malnutrition, 48
papulosquamous, 367–368
primary lesions, 363, 365t
in returned traveler, 1361
secondary lesions, 363, 366t
sepsis-associated, 130–131
vascular disorders, 372–373
skin infection, 369–371, 569, 570t–571t, 
572–574
anaerobic, 642
aspergillosis, 748
cellulitis, 570t, 572–573
in cancer patients, 511, 512t
clostridial, 639
cryptococcal, 751
diphtheria, 601
group A Streptococcus, 594t, 595
mucormycosis, 752
necrotizing fasciitis, 571t, 573
nontuberculous mycobacterial, 662
P. aeruginosa, 622
S. aureus, 585, 589, 591t
in transplant recipients, 517t
treatment of, 570t–571t
skin tag, 364f
skull fracture, 109
SLE. See systemic lupus erythematosus
SLED. See slow low-efficiency dialysis
sleep, nonrestorative, 338
sleep apnea, 338, 340, 947–948
central, 340, 948
mixed, 340
obstructive, 340, 341t, 947–948
sleep disorder, 215t, 337–342
approach to, 337–338
drug-induced, 1391t
in women, 1377
1536
INDEX
sleep hygiene, 338
inadequate, 338
sleep impairment, with high altitude, 157
sleep paralysis, 340, 341t, 342, 342t
sleeping sickness, 774–775
sleepwalking, 337
slit-lamp examination, 324, 344–345
slow low-efficiency dialysis (SLED), 959
slow-reacting substance of anaphylaxis 
(SRS-A), 1061, 1061f
SLR sign. See straight leg raising sign
small-bowel tumor, 451
smallpox
as bioweapon, 194, 196t
hemorrhagic, 198
malignant, 198
microbiology and clinical features of, 
194, 198
treatment of, 196t, 198
vaccination and prevention, 198
smell, disorders of sense of, 1246, 
1247t, 1248
smoke inhalation, 914
smoking
bladder cancer and, 460–461
cough and, 231–232
lung cancer and, 434
for myocardial infarction, 854
pancreatic cancer and, 458
prevention of, 1373
relative risks for current smokers, 1373t
smoking cessation, 433, 439, 1345, 1372–1374
approach to, 1372
for arteriosclerosis, 891
clinical practice guidelines, 1371, 1374t
COPD and, 916–917
for disease prevention, 1346t–1348t, 
1362, 1370
for interstitial lung disease, 937
methods of, 1372–1373, 1374t
for osteoporosis, 1168
quit date, 1372
for vasospastic disorders, 892
snakebite, 142t, 143–145
field management of, 143–144
hospital management of, 144–145
snoring, 341t
SNS. See specialized nutrition support
social phobia, 1322
sodium, disorders of, 3–9
hypernatremia, 8–9, 9t
hyponatremia, 3–8, 5f
sodium bicarbonate
for AGMA inducer poisoning, 178t
for antidepressant poisoning, 172t
for antipsychotic poisoning, 169t
for iron poisoning, 178t
for membrane-active agent poisoning, 
182t–183t
for metabolic acidosis, 22–23
for methanol poisoning, 179t
for poisoning, 190
for salicylate poisoning, 179t
sodium citrate, for metabolic acidosis, 22–23
sodium deficit, 8
sodium docusate, for constipation, 56t
sodium ipodate, for amiodarone-induced 
thyrotoxicosis, 1123
sodium nitrite, for cytochrome oxidase 
inhibitor poisoning, 176t
sodium phosphate enema, for 
constipation, 56t
sodium restriction
for aldosteronism, 1129
for ascites, 277
for cor pulmonale, 886
for edema, 238
for heart failure, 880, 881t
for hypertension, 836
for restrictive cardiomyopathy, 826
for vertigo, 323t, 324
sodium stibogluconate, for 
leishmaniasis, 772
sodium thiosulfate, for cytochrome 
oxidase inhibitor poisoning, 176t
sodium tyropanoate, for amiodarone-
induced thyrotoxicosis, 1123
soft tissue infection, 569, 570t–571t, 572–574
anaerobic, 642
cellulitis, 570t, 572–573
in cancer patients, 511, 512t
clostridial, 639
group A Streptococcus, 594t, 595
Klebsiella, 618
myositis and myonecrosis, 573–574
necrotizing fasciitis, 571t, 573
nontuberculous mycobacterial, 662
P. aeruginosa, 622
S. aureus, 585–586, 589, 591t
solid organ transplant
infections in recipients, 518, 520–521
vaccination of recipients, 521
SOM. See serous otitis media
soman, 172t
somatic pain, 40, 41t
somatization disorder, 1322
somatoform disorder, 1322–1323
somatostatin therapy
for acromegaly, 1110
for esophageal varices, 1058
somatostatinoma, 459–460, 459t
somatotropin, for hypopituitarism, 1112t
sorafenib
for hepatocellular carcinoma, 457
for kidney cancer, 462
toxicity of, 400t
sorbitol
for irritable bowel syndrome, 1017t
for paralytic shellfish poisoning, 147
for poisoning, 190
INDEX
1537
sotalol
for arrhythmias, 875t
poisoning, 170t
South American blastomycosis, 758
South American hemorrhagic fevers, 725
soy-based products, 1157
spastic colon, 1016
specialized nutrition support (SNS), 
49, 49f
specimen collection, 488t–493t
specimen transport, 488t–493t
SPECT. See single photon emission 
computed tomography
spectinomycin, for gonococcal infections, 
560t–561t
speech audiometry, 350
spermatogenesis, 1147
spherocytes, 375
spider bite, 148–149
spinal cord, anatomy of, 1253f
spinal cord compression, 112–114
approach to, 112
epidural abscess, 113
epidural hematoma, 114
from metastases, 1261t, 1262
neoplastic, 112–113, 1253, 1254f
oncologic emergency, 134–135
treatment of, 113, 135, 135f
spinal cord disease, 1251–1257
acute, 1253–1255
autonomic dysfunction in, 1238, 1251
cauda equina, 1253
cervical cord, 1251
chronic, 1255–1257
complications of, 1257
extramedullary, 1253
foramen magnum lesions, 1251
intramedullary, 1253
lumbar cord, 1252
sacral cord, 1253
subacute, 1253–1255
thoracic cord, 1251
treatable, 1252t
weakness in, 329t, 330t
spinal cord infarction, 1254
spinal manipulation, for chronic back 
pain, 304
spinal radiology, brucellosis vs. 
tuberculosis, 628, 628t
spinal stenosis, 1095
back pain in, 301
spinocerebellar ataxia, 1228, 1230f
Spirillum minor infection, 140
spirochetal infection
endemic treponematosis, 666–667
leptospirosis, 667–668
Lyme borreliosis, 663–666
relapsing fever, 668–669
spirometry, 899–900, 916
for cough, 232
spironolactone
for ascites, 277
for dilated cardiomyopathy, 825
for edema, 238t, 239
for heart failure, 881t, 882t, 883
for hirsutism, 1156
for hyperaldosteronism, 25, 1129
for hypertension, 837t
for myocardial infarction, 848, 850
splenectomy, 281, 419, 535
for idiopathic thrombocytopenic 
purpura, 390
post-splenectomy infections, 126t, 130
for thalassemia, 383–384
splenic abscess, 535
splenomegaly, 281–283
diseases associated with, 282t–283t
mechanism of, 281, 282t–283t
tropical, 764
SPMS. See secondary progressive multiple 
sclerosis
spondylitic myelopathy, 307, 1255
spondyloarthropathy, 1083, 1085t
spondylolisthesis, 301
spondylosis
cervical, 304, 307
low back pain in, 301
spontaneous breathing trial, 38
sporotrichosis, 757–758
sporozoite, 763
spotted fever
flea-borne, 671t
tick- and mite-borne, 670–674, 671t
spur cell anemia, 381
sputum analysis
in pneumonia, 921
in respiratory disease, 905
specimen collection and transport, 489t
sputum cytology, for cough, 232
squamous cell carcinoma (SCC), 364f, 431
infections in cancer patients, 512t
SRS-A. See slow-reacting substance of 
anaphylaxis
SSPE. See subacute sclerosing 
panencephalitis
SSRIs. See selective serotonin reuptake 
inhibitors
SSS. See sick sinus syndrome
SSSS. See staphylococcal scalded-skin 
syndrome
St. Louis encephalitis, 723t
stabbing headache, primary, 308t, 315
stains, 485, 486f, 487
standard precautions, 506
staphylococcal infection, 584–592
arthritis, 574–576, 586
coagulase-negative staphylococci, 588–589
treatment of, 589, 590t–591t, 592
endocarditis, 521–523, 527t–528t, 
529–530
1538
INDEX
staphylococcal infection (Cont.):
food poisoning, 536
osteomyelitis, 576, 577t, 578t, 579, 
585–586
S. aureus, 584–587, 588t
bacteremia and sepsis, 586
endocarditis, 586–587, 592
invasive disease, 584–585
MRSA, 570t, 578t, 584, 587, 589, 
590t–591t, 592
musculoskeletal, 585–586
osteomyelitis, 585–586, 592
prevention of, 587
prosthetic device-related, 587
respiratory tract, 586
skin, 585, 589, 591t
soft tissue, 585–586, 589, 591t
toxin-mediated disease, 585, 587, 
588t, 592
treatment of, 589, 590t–591t, 592
urinary tract infection, 587
skin, 570t, 572
staphylococcal scalded-skin syndrome 
(SSSS), 587
Staphylococcus aureus infection
impetigo, 369
methicillin-resistant, 77t
spinal epidural abscess, 113
Staphylococcus moniliformis infection, 140
starvation, 47–48
stasis ulcer, 364f
Stat DRIP (medication pneumonic), 3
statins
for hyperlipidemia, 1177t
for myocardial infarction, 857–858
for unstable angina, 857–858
status epilepticus, 116–118, 117f
GCSE, 116–118
after hypoxic-ischemic insult, 116
nonconvulsive, 117
Stauffer’s syndrome, 462
steatorrhea, 258
STEC/EHEC. See Shiga toxin-producing/
enterohemorrhagic E. coli
stellate ganglion blockade, 1242
Stenotrophomonas maltophilia infection, 
622–623, 625t
stenting, vascular
for angina pectoris, 863, 863t
for superior vena cava syndrome, 134
stereognosis, 1196
sterilization, 1157
steroid therapy
for ANCA-associated 
glomerulonephritis, 971
for focal glomerulosclerosis, 974
for psoriatic arthritis, 1087
Stevens-Johnson syndrome, 372, 1382t
STI. See sexually transmitted infection
stiff-person syndrome, 481t, 482t, 483t
stingray envenomation, 145
stonefish envenomation, 145
stool analysis, 257
parasites, 494
reference values for specific 
analytes, 1435t
specimen collection and transport, 489t
stool softeners, 56t, 1020
straight leg raising (SLR) sign, 298–299
Streptobacillus moniliformis infection, 140
streptococcal infection, 592–599
arthritis, 574–576
endocarditis, 521–522, 526t, 528
erysipelas, 369
group A, 369, 593–596, 594t, 596t
bacteremia, 596
nosocomial infection, 510
pharyngitis, 593–594, 594t
pneumonia and empyema, 594t, 595
scarlet fever, 595
skin and soft tissue infections, 
594t, 595
toxic shock syndrome, 594t, 596, 
596t
group B, 597–598
group D, 598
groups C and G, 596–597
hemolytic patterns, 592–593
microbiology of, 592–593
nutritionally variant streptococci, 599
osteomyelitis, 577t, 578t
pharyngitis with, 361
pneumococcal infection, 580–584
poststreptococcal 
glomerulonephritis, 969
skin, 570t–571t, 572
viridans streptococci, 598–599
Streptococcus pneumoniae infection. See 
pneumococcal infection
streptogramins, mechanism of/resistance 
to, 496, 498t
streptokinase (SK)
for myocardial infarction, 845
for thrombotic disorders, 394
streptomycin
for Bartonella infections, 633t
for brucellosis, 629
for enterococcal infections, 600
for infective endocarditis, 526t, 529
for plague, 196t, 632
for tuberculosis, 653, 655t
for tularemia, 196t, 630
streptozotocin
for carcinoid tumor, 458
for islet-cell tumors, 460
for Zollinger-Ellison syndrome, 1011
stress testing, in coronary artery disease, 
859, 860f, 861t
stroke, 93–102
anatomic localization in, 94t–95t
INDEX
1539
causes of, 99–101
drug-induced, 1390t
embolic, prevention of, 102, 102t
hemorrhagic, 93, 95
ischemic, 93–94
causes of, 99–101, 100t
treatment of, 96–99, 98t
pathophysiology of, 93
prevention of, 101–102, 102t
risk factors for, 101, 101t
small-vessel, 93, 95
treatment of, 95–98, 97f
stromal tumor, 465
strongyloidiasis, 495t, 781–782, 1360
strontium-89 therapy, 400t, 473
struvite stones, 998, 1000t
stupor, 86
subacute sclerosing panencephalitis 
(SSPE), 709
subarachnoid hemorrhage (SAH), 
103–105
grading scales for, 103, 104t
headache in, 308t
with hydrocephalus, 105
lumbar puncture, 32–34, 33f
treatment for, 104–105
vasospasm in, 105
subdural hematoma, 111
substance abuse, 1346t–1347t
alcoholism, 1336–1340
narcotic abuse, 1340–1343
in women, 1377
succimer, for heavy metal poisoning, 
185t–187t
sucralfate
for erosive gastropathies, 1009
for peptic ulcer disease, 1006–1007
sudden death, 65–69
differential diagnosis of, 65t
suicide, 1316, 1319
prevention of, 1346t–1347t
suicide attempt, 159
sulfacetamide, for eye infections, 345
sulfadiazine, for toxoplasmosis, 777
sulfadoxine-pyrimethamine, for malaria, 766t
sulfasalazine
for ankylosing spondylitis, 1084
for enteropathic arthritis, 1096
for inflammatory bowel disease, 
1013–1015
for psoriatic arthritis, 1087
for reactive arthritis, 1088
for rheumatoid arthritis, 1074
sulfhemoglobinemia, 229
sulfinpyrazone, for gout, 1093
sulfonamides
adverse reactions to, 501t–502t
mechanism of/resistance to, 496, 498t
for nocardiosis, 646
poisoning, 177t
sulfonylurea, for diabetes mellitus, 
1140, 1142t
sulfur granules, 647–648
sulfur mustard, 200–201
sulindac
for colon cancer prevention, 1370
for colonic polyps, 452
sumatriptan
for cluster headache, 314
for migraine, 310t–312t
summer grippe, 715
sunitinib
for islet-cell tumors, 460
for kidney cancer, 462
toxicity of, 400t
superior vena cava syndrome, 134
supraventricular arrhythmia, in 
myocardial infarction, 849
supraventricular tachycardia (SVT), 
867, 872t
in poisoning, 164
suramin, for sleeping sickness, 775
surgical-site infection, 507t, 508
surveillance, of nosocomial pathogens, 
505–506
susceptibility testing, antibacterial 
therapy, 487
SVR. See systemic vascular resistance
SVT. See supraventricular tachycardia
swallowing studies, 249
Sweet’s syndrome, 210, 511
swimmer’s ear, 358, 622
swimmer’s itch, 572, 786
swinging flashlight test, 325
symmetric proliferative synovitis, 1094
sympathectomy, digital, for systemic 
sclerosis, 1075
sympathetic poisoning, 160t–161t
sympathetic system, 1236f, 1237t
sympatholytic poisoning, 160t–161t, 169t
sympathomimetics
for allergic rhinitis, 1064
poisoning, 160t–161t, 166t
synchronized intermittent mandatory 
ventilation (SIMV), 84, 85t
syncope, 316–320
approach to, 316, 317f
cardiac, 319t
causes of, 318t–319t
differential diagnosis of, 317–320
cataplexy, 319
hypoglycemia, 319
psychiatric disorders, 319–320
seizures, 317
etiology of, 316–317
neurocardiogenic, 316, 318t
orthostatic hypotension, 317, 318t–319t
treatment of, 320
vasodepressor, 316
vasovagal, 316
1540
INDEX
syndrome of inappropriate ADH 
(SIADH), 1114–1116
causes of, 1115t
drug-induced, 398t
hyponatremia in, 6–8
paraneoplastic, 136, 478t, 480
treatment of, 136, 480, 1116
syndrome X. See metabolic syndrome
synkinesis, 1244
synovial fluid analysis, 296f, 297, 575, 
1092, 1095
syphilis, 558, 562–566
congenital, 564
endemic, 666–667
features of genital ulcers, 557t
latent, 563, 565t
in pregnancy, 565t
primary, 563, 565t
secondary, 210, 563, 565t
tertiary, 563–564, 565t, 1256
syringomyelia, 1255
systemic inflammatory response syndrome 
(SIRS), 74
systemic lupus erythematosus (SLE), 938, 
1070–1072
in chorea, 333–334
in chronic meningitis, 1291t
glomerular disease in, 971, 977t
treatment of, 1071–1072
systemic sclerosis, 1074–1075
diffuse cutaneous, 1074
esophageal disorders in, 252
limited cutaneous, 1074
renovascular disease in, 995
systemic vascular resistance (SVR), 850
T
T cells, 278
deficiency syndromes of, 1066–1069, 
1067t
T cell receptors
defective rearrangements of, 1068–1069
defective signaling of, 1069
T3. See triiodothyronine
T4. See thyroxine
tabes dorsalis, 563–564, 1256
tabun, 172t, 201–202
TAC. See transient aplastic crisis
tache noire, 673
tachyarrhythmia, 867–878
clinical and ECG features of, 868f, 
869t–872t, 873t
treatment of, 873, 877
tachycardia, 864
tacrine
for Alzheimer’s disease, 1218
poisoning, 172t
tacrolimus
immunosuppression for renal 
transplant, 967
for inflammatory bowel disease, 1015
for inflammatory myopathy, 1312
for myasthenia gravis, 1305
tadalafil
for erectile dysfunction, 1149
for pulmonary hypertension, 898
taeniasis asiatica, 787–788
taeniasis saginata, 787–788
taeniasis solium, 788
Takayasu’s arteritis, 890, 1079
tamoxifen
for breast cancer, 443, 445–446
preventive treatment, 1369
for endometrial cancer, 468
for melanoma, 430
toxicity of, 399t
tapeworm infection, 787–791
tardive dyskinesia, 334, 1329
target cells, 375
target lesion, 363
tarsal tunnel syndrome, 1301t
TAVI. See transcatheter aortic valve 
implantation
taxanes, for prostate cancer, 472
tazarotene, for psoriasis, 367
TB. See tuberculosis
TCAs. See tricyclic antidepressants
Td vaccine. See tetanus and diphtheria 
toxoid vaccine
Tdap vaccine, 1352t–1353t, 1354f–3155f, 
1356t
teardrop cells, 375
telangiectasia, 365t
telavancin
adverse reactions to, 501t
for staphylococcal infection, 589
telbivudine, for chronic hepatitis B, 1040, 
1041t–1043t
telithromycin, drug interactions with, 503t
temazepam, 1328t
poisoning, 174t
temozolomide, for melanoma, 430
temperature, 209
temporal arteritis. See giant cell arteritis
temsirolimus
for kidney cancer, 462
toxicity of, 400t
tendinitis, 1099
calcific, 1099
tendon reflexes, 329t
tendon xanthoma, 1175
tenecteplase, for thrombotic disorders, 394
tenofovir
for chronic hepatitis B, 1040, 
1041t–1043t
for HIV/AIDS, 736t, 741
tenosynovitis, 1092
tension headache, 308t, 314
teratogenesis, of cancer chemotherapy, 401
teratoma, 463
INDEX
1541
terazosin, for prostate hyperplasia, 470
terbinafine, 745
for dermatophyte infections, 370
terbutaline poisoning, 166t
teriparatide, for osteoporosis, 1170
terminally ill patient, 54–55
anorexia in, 61t
apnea in, 62t
care during last hours, 59–60, 61t–63t
clinical courses in last days, 60f
constipation in, 55
death rattle in, 62t
dehydration in, 61t
delirium in, 59, 63t
depression in, 58–59
dysphagia in, 61t
dyspnea in, 56–57, 62t
fatigue in, 57–58, 61t
incontinence in, 62t
mucosal membranes in, 63t
nausea and vomiting in, 56
pain management in, 55
physical symptoms of, 55, 55t
psychological symptoms of, 55, 55t
withdrawal of care, 40
testicular cancer, 463, 463t
testosterone deficiency, 1144–1146
testosterone therapy
for androgen deficiency, 1147
for hypopituitarism, 1112t
tetanus, 635–637
tetanus and diphtheria toxoid (Td) 
vaccine, 602
tetanus booster, 143
tetanus immune globulin, 636
tetracyclines
for acne, 371
for actinomycosis, 648
adverse reactions to, 502t
for brucellosis, 629
for C. pneumoniae infections, 684
for C. psittaci infection, 683
for donovanosis, 568
drug interactions with, 503t
for H. pylori eradication, 1008t
for human monocytotropic 
ehrlichiosis, 677
for intestinal pseudoobstruction, 1019
for Legionella infection, 626
for M. pneumoniae infections, 681
for malaria, 766t
mechanism of/resistance to, 496, 497t
for syphilis, 565t
tetrahydrozoline, poisoning, 169t
Tetralogy of Fallot, 814
tetrathiomolybdate, for Wilson’s disease, 1185
thalassemia, 379–380, 380t, 383–384
thalidomide
for leprosy, 661
for multiple myeloma, 426
theophylline
for asthma, 909
for COPD, 918
poisoning, 167t
therapeutic hypothermia, 68
thermoregulatory sweat test (TST), 
1238
thiamine deficiency, 51t
thiamine therapy, for alcohol 
withdrawal, 1339
thiazides
for heart failure, 880–881
for hypertension, 836, 837t, 841
for nephrolithiasis, 1000t
thiazolidinedione
for diabetes mellitus, 1140, 1142t
for metabolic syndrome, 843
thienopyridines, for thrombotic 
disorders, 394
thigh, muscles and innervation of, 
1190t–1191t
thin basement membrane 
nephropathy, 978
thiocyanate toxicity, 883–884
thioguanine, 398t
thioridazine
for delirium, 59t
dosage and adverse effects of, 168t, 
169t, 1330t
thiothixene, 1330t
thoracentesis, 31–32, 31f, 905
thoracic outlet syndrome, 1300t
arterial, 306
disputed, 306
true neurogenic, 306
thoracic spine disease, chest pain in, 
222f, 225
thoracic surgery, video-assisted (VATS), 
905, 936
thoracoscopy, 944
throat specimen, collection and transport 
of, 488t
thrombin inhibitors, for venous 
thromboembolism, 932
thrombocytopenia, 388–389, 388f
drug-induced, 388, 390, 401, 
1384t–1385t
heparin-induced, 388–390
refractory, 410t
treatment of, 391
thrombocytopenic purpura
idiopathic, 389–390
thrombotic, 53–54, 389, 391, 995–997
thrombocytosis, 389
essential, 412
thrombolytic therapy
for arterial embolism, 891
for renal vein thrombosis, 992
for stroke, 97
thrombophlebitis, superficial, 892
1542
INDEX
thrombotic disorders, 391–394
treatment of, 392–394, 393t
thrombotic microangiopathy (TMA), 
995–997, 996t
thrombotic thrombocytopenic purpura 
(TTP), 53–54, 389, 391, 995–997
thrush, 746
thumb, muscles and innervation of, 
1190t–1191t
thymectomy, for myasthenia gravis, 1303
thymoma, 482t
thymus, myasthenia gravis, 1302
thyroid adenoma, 1124–1126, 1125f
thyroid carcinoma, 1124–1126, 1125f
paraneoplastic, 479t
thyroid disease, 1116–1126
drug-induced, 1380t
hypothyroidism, 1117–1119
neoplasms, 1124–1126, 1125f
nontoxic goiter, 1123–1124
sick euthyroid syndrome, 1122–1123
thyrotoxicosis, 1119–1122
toxic adenoma, 1124
toxic multinodular goiter, 1124
thyroid function tests, 1120
thyroid nodule, 1125f
thyroid storm, 1120, 1122
thyroidectomy
for thyroid neoplasms, 1126
for thyrotoxicosis, 1120
for toxic multinodular goiter, 1124
thyroiditis
silent, 1119–1120
subacute, 1119–1120, 1122, 1122f
thyroid-stimulating hormone (TSH), 1105, 
1106f
deficiency of, 1107t, 1111, 1112t
hypersecretion of, 1107t, 1111
thyrotoxic crisis, 1120, 1122
thyrotoxicosis, 1116, 1119–1122, 1121f
amiodarone-induced, 1123
thyroxine (T4), 1116
for hypopituitarism, 1112t
TIA. See transient ischemic attack
tiagabine
for generalized anxiety disorder, 1321
poisoning, 173t
for seizures, 1208t
TIBC. See total iron-binding capacity
tics, 334
tic douloureux. See trigeminal neuralgia
ticarcillin, for Klebsiella infections, 618
ticarcillin-clavulanate
for mixed anaerobic infections, 643t
for S. maltophilia infection, 625t
tick, removal of, 148
tick bite, 148
tick paralysis, 148
tick-borne relapsing fever, 668–669
tick-borne spotted fever, 670–674, 671t
ticlopidine, for thrombotic disorders, 394
TIGAR-O classification, of pancreatic 
disease, 1031t
tigecycline
for Clostridium difficile infection, 551
for enterococcal infections, 600
for Klebsiella infections, 618
for nontuberculous mycobacterial 
infections, 663
for staphylococcal infection, 589
tilt-table test, 1238
TIMI Risk Score, 855, 856f
timolol, poisoning, 170t
tinea capitis, 370
tinea corporis, 370
tinea cruris, 364f, 370
tinea pedis, 364f, 370
tinea unguium, 370
tinea (pityriasis) versicolor, 365
tinidazole
for amebiasis, 549
for giardiasis, 542
for trichomoniasis, 554
tinnitus, 321–322, 349, 352–353
TINU. See tubulointerstitial nephritis and 
uveitis syndrome
TIPS. See transjugular intrahepatic 
portosystemic shunt
tirofiban
for myocardial infarction, 857
for thrombotic disorders, 394
for unstable angina, 857
tissues, specimen collection and transport, 
490t–491t
tissue necrosis, 385
tissue parasites, diagnosis of, 494, 495t
tissue plasminogen activator (tPA)
for frostbite, 154
for stroke, 98, 98t
for thrombotic disorders, 394
for venous thromboembolism, 933
tizanidine
for multiple sclerosis, 1269
poisoning, 169t, 175t
TMA. See thrombotic microangiopathy
TMP-SMX. See 
trimethoprim-sulfamethoxazole
TMS. See transcranial magnetic stimulation
TNM staging
for breast cancer, 443, 444t–445t
for gastric cancer, 449, 450t
for lung cancer, 434, 435t–437t
toad skin secretions, 171t
tobramycin
for P. aeruginosa infections, 624t–625t
for pneumonia, 924t, 926t
for sepsis/septic shock, 77t
tocilizumab, for rheumatoid arthritis, 1074
toes, muscles and innervation of, 
1190t–1191t
INDEX
1543
tolcapone, for Parkinson’s disease, 1226t
tolfenamic acid, for migraine, 310t
tolnaftate, for dermatophyte infections, 
370
Tolosa-Hunt syndrome, 1250
tolvaptan, for SIADH, 1116
tongue paralysis, 1249
topical antifungal agents, 745
topiramate
for migraine prevention, 313t
poisoning, 173t
for seizures, 1207t, 1212t
topoisomerase inhibitors, 399t
topotecan, 399t
torsades de pointes, 872t
torsemide
for edema, 238t
for heart failure, 880–881, 882t
torticollis, 333
tositumomab
for follicular lymphoma, 420
toxicity of, 400t
total iron-binding capacity (TIBC), 
378–379, 378f, 379t
Tourette syndrome (TS), 334
toxemia of pregnancy, 997
toxic adenoma, 1124
toxic chemicals, 914
toxic epidermal necrolysis, drug-induced, 
1383t
toxic granulations, 376
toxic shock syndrome (TSS), 127t, 131, 
210
clostridial, 640
staphylococcal, 585, 587, 588t, 592
streptococcal, 594t, 596, 596t
toxicology, reference values for laboratory 
tests, 1421t–1427t
Toxocara canis infection. See larva 
migrans
toxoplasmosis, 776–778
CNS disease, 776
congenital, 776–777
diagnosis of, 495t
ocular, 777
pneumonia, 776
in pregnancy, 776
prevention of, 777–778
tPA. See tissue plasminogen activator
TR. See tricuspid regurgitation
trabeculectomy, for glaucoma, 347
tracheitis, 900t
tracheobronchitis, 225
human RSV, 705
tracheostomy, 948
trachoma, 344, 559, 682–683
tramadol
narcotic abuse, 1340
for osteoarthritis, 1091
for pain, 44t–45t
poisoning, 182t
for polyneuropathy, 1297t
trandolapril, for heart failure, 882t
transaminases, 270, 272t
transcatheter aortic valve implantation 
(TAVI), for aortic stenosis, 821
transcranial magnetic stimulation (TMS), 
for depression, 1317
transfusion therapy, 51–54
for AML, 406
autologous transfusion, 52
complications of, 52, 53t
plasma components, 53
platelet transfusion, 52
red blood cell transfusion, 52
whole blood, 51
transient aplastic crisis (TAC), 713
transient ischemic attack (TIA), 93, 97f
transient monocular blindness, 326
transjugular intrahepatic portosystemic 
shunt (TIPS), 266, 277, 1058–1059
transplant recipient
infections in, 515–521, 517t, 695–696, 
967, 968t
transfusion for, 52
vaccination of, 519t–520t, 521
transsphenoidal surgery, 1128
for acromegaly, 1110
for pituitary adenomas, 1107–1108
transtubular potassium gradient (TTKG), 
10, 12f, 13, 15, 16f
transurethral microwave thermotherapy 
(TUMT), 470
transurethral resection of prostate 
(TURP), 470
tranylcypromine, 167t, 1327t
trastuzumab
for breast cancer, 446
toxicity of, 400t
travelers
gastrointestinal illness, 1360
HIV-infected, 1361
immunizations for, 1351, 1359t
insect-borne disease prevention, 1351
malaria prevention, 1351
pregnant, 1360
problems after return, 1361
sexually transmitted diseases in, 1360
traveler’s diarrhea, 536, 540
prevention of, 1360
trazodone, 1325
dosage and adverse effects of, 1327t
for PTSD, 1322
trematode infection, 785–787
tremor, 332–335
coarse, 332
essential, 332–333, 332t
intention, 332
Parkinsonian, 332, 332t
postural, 332
1544
INDEX
trench fever, 633t, 634
trench mouth, 642
Treponema pallidum infection. See syphilis
treponematosis, endemic, 666–667
treprostinil, for pulmonary hypertension, 
898
tretinoin, 399t
triamcinolone, steroid preparations, 1131, 
1131t, 1133
triamterene
for edema, 238t
for hypertension, 837t
triazolam
for insomnia, 340
poisoning, 174t
triazoles
for coccidioidomycosis, 756
for dermatophyte infections, 370
trichinellosis, 778–779
trichloroacetic acid, for HPV 
infection, 568
Trichomonas vaginalis infection
urethritis in men, 552
vulvovaginal infection, 553–554
trichomoniasis, 553–554
triclabendazole, for liver flukes, 787
tricuspid regurgitation (TR), 798t, 822
tricuspid stenosis (TS), 798t, 821
tricuspid valve endocarditis, 523
tricuspid valve prolapse, 798t
tricyclic antidepressants (TCAs), 
1325, 1326t
for irritable bowel syndrome, 1017t
for migraine prevention, 313t, 314
poisoning, 172t, 180t, 182t–183t
for polyneuropathy, 1296, 1297t
trientine, for Wilson’s disease, 1184–1185
trifluoperazine, 1330t
trifluorothymidine, for HSV infections, 
690t
trigeminal nerve, 1189
sensory divisions of, 1244f
trigeminal neuralgia, 315, 1243–1244
trigeminal neuropathy, 1244, 1245t
trigger points, 1243
triglycerides, 1172
trihexyphenidyl
for dystonia, 333
poisoning, 168t
triiodothyronine (T3), 1116
trimethoprim
mechanism of/resistance to, 496, 498t
for Pneumocystis infections, 761, 761t
trimethoprim-polymyxin
for ANCA-associated 
glomerulonephritis, 972
for eye infections, 345
trimethoprim-sulfamethoxazole 
(TMP-SMX)
for animal bite infections, 141t
for B. cepacia infection, 625t
during COPD exacerbations, 919
for Corynebacterium infection, 603
for cyclosporiasis, 544
for cystoisosporiasis, 543
for diverticulitis, 1018
for donovanosis, 568
drug interactions with, 503t
for extraintestinal E. coli infection, 616
for glanders, 625t
for HSCT patients, 516
for listerial infections, 608
for M. catarrhalis, 613
for melioidosis, 625t
for nephrolithiasis, 1000t
for nocardiosis, 646
for peritonitis prevention, 533
for pertussis, 612
for plague, 632
for Pneumocystis infections, 761, 761t, 
762t, 763
for Proteus infection, 619
for Q fever, 679
for S. maltophilia infection, 625t
for salmonellosis, 545
for sinusitis, 356t
for snakebite, 142t
for staphylococcal infection, 589, 591t
for toxoplasmosis, 777
for transplant recipients, 518
for urinary tract infections, 988, 989t
preventive treatment, 989
trimetrexate, for Pneumocystis infections, 
761t
triolein breath test, 257
triple-H therapy, for subarachnoid 
hemorrhage with vasospasm, 105
triptans
for migraine, 310t, 312t
prevention, 309
poisoning, 182t
tritium contamination, 207
trophozoite, 763
troponins, cardiac-specific, 855
Trousseau’s sign, 1164
trypanosomiasis, 773–775
tryptophan poisoning, 182t
TS. See Tourette syndrome; tricuspid 
stenosis
TSH. See thyroid-stimulating hormone
TSS. See toxic shock syndrome
TST. See thermoregulatory sweat test
TTKG. See transtubular potassium 
gradient
TTP. See thrombotic thrombocytopenic 
purpura
tube thoracostomy, 940
tuberculin skin test, 650, 657t
tuberculosis (TB), 649–656
ascites in, 276, 276f
INDEX
1545
brucellosis vs., 628, 628t
extensively drug-resistant, 649
extrapulmonary, 650–652
gastrointestinal disease in, 651
genitourinary, 651
HIV/AIDS and, 649–652, 658t–659t
latent, 656, 657t, 658t–659t
meningitis in, 651
miliary disease, 652
multidrug-resistant, 649
nosocomial, 510
pericarditis in, 652
pleural involvement in, 651, 944
prevention of, 656, 657t, 658t–659t
pulmonary, 650
skeletal disease in, 651
treatment of, 653–656, 655t, 658t–659t
tuberoeruptive xanthoma, 1179
tuberous sclerosis/
lymphangioleiomyomatosis, 935
tuberous xanthoma, 1175
tubulin poisons, 398t
tubulointerstitial disease. See renal tubular 
disease
tubulointerstitial nephritis and uveitis 
syndrome (TINU), 981
tularemia, 130, 139–140, 211, 629–630
as bioweapon, 196t, 198–199
treatment of, 196t
tumor (skin lesion), 365t
tumor lysis syndrome, 137, 423
tumor-suppressor genes, 395
TUMT. See transurethral microwave 
thermotherapy
Turcot’s syndrome, 452, 453t
Turner’s sign, 1028
TURP. See transurethral resection of prostate
twitching, 1189
two-point discrimination, 1196
tympanic membrane perforation, 350
tympanocentesis, 357t
tympanometry, 350
typhlitis
in cancer patients, 513
Kenya tick, 673
typhoid fever. See enteric fever
typhoid vaccine, 1359t
typhoidal tularemia, 630
typhus
epidemic (louse-borne), 131, 672t, 
675–676
murine (flea-borne), 672t, 674–675
scrub, 131, 210, 672t, 676
Tzanck preparation, 366
U
UC. See ulcerative colitis
UFH. See unfractionated heparin
ulcer, 366t
cutaneous, 211, 572
genital, 556, 557t
skin lesion, 366t
ulcerative colitis (UC), 1012
epidemiology of, 1011, 1011t
extraintestinal manifestations of, 
1013
treatment of, 1013, 1014f, 1015
ulceroglandular/glandular tularemia, 629
ulnar nerve entrapment, 1299t
ultrasonography (US)
diagnostic, 28
endoscopic, 448, 1022t, 1031
hepatobiliary, 274, 1022t
neuroimaging, 1197t–1198t
in pancreatitis, 1029
renal, 960
in stroke, 101
venous, 930
undecylenic acid, for dermatophyte 
infections, 370
underweight, 1134t
undulating fever, brucellosis, 628
unfractionated heparin (UFH)
for myocardial infarction, 857
for thrombotic disorders, 392
for unstable angina, 857
for venous thromboembolism, 932
preventive treatment, 894
unstable angina, 855–858
TIMI Risk Score for, 855, 856f
treatment of, 855–858, 856f
upper respiratory infections (URIs), 
353–362
nonspecific, 354
sinusitis, 354–355, 358
treatment of, 356t–357t
urate nephropathy, 1092
urea breath test, 1006, 1007t
Ureaplasma infection, 562
urethritis in men, 552
ureidopenicillin, for cholecystitis, 1024
uremia, 288, 960–962
uremic syndrome, 961–962
ureteral obstruction, 1002
ureterosigmoidostomy, 21t
urethral syndrome, 553
urethritis
in men, 552
in women, 553, 559
uric acid nephrolithiasis, 1092
uric acid stones, 998–999, 1000t, 1092
uric-acid lowering agents, 1093
uricosuric drugs, for gout, 1093
urinalysis, 949, 988–989
reference values for specific analytes, 
1431t–1434t
urinary incontinence, in terminally ill 
patient, 62t
urinary retention, 469
urinary stones, drug-induced, 1388t
1546
INDEX
urinary tract infection (UTI), 950t, 952, 
986–990
acute, 986
in cancer patients, 514
catheter-associated, 989
causes of, 986–987
complicated, 986, 988–989
Corynebacterium, 602 
E. coli, 615
enteric GNB, 620
Klebsiella, 618
nosocomial, 506–507, 507t
P. aeruginosa, 622, 625t
prevention of, 989
Proteus, 619
S. aureus, 587
treatment of, 988–989, 989t
urinary tract obstruction (UTO), 951t, 
953, 1001–1003, 1002f
drug-induced, 1388t–1389t
urine
abnormalities
asymptomatic, 950t–951t, 952, 
976t, 978
of composition, 290–293
of volume, 288–289
specimen collection and transport, 490t
toxicologic analysis of, 160
URIs. See upper respiratory infections
urogenital tract, specimen collection and 
transport, 490t
urokinase, for thrombotic disorders, 394
ursodeoxycholic acid
for gallstones, 1023
for primary biliary cirrhosis, 1055
for primary sclerosing cholangitis, 1026
urticaria, 210, 372–373, 1062–1063
classification of, 1062, 1062t
drug-induced, 1383t
treatment of, 1063
US. See ultrasonography
ustekinumab, for psoriasis, 367
UTI. See urinary tract infection
UTO. See urinary tract obstruction
UV-B phototherapy, for pityriasis rosea, 367
uveitis, 345
V
vaccination. See immunization
Vaccine Adverse Event Reporting System 
(VAERS), 1351
vaccine-associated poliomyelitis, 715
VAERS. See Vaccine Adverse Event 
Reporting System
vagotomy, for peptic ulcer disease, 1008t
vagus nerve, 1189
disorders of, 1248–1249
stimulation of, 1317
valacyclovir
for Bell’s palsy, 1246
for herpes zoster infections, 570t
for HSCT patients, 517
for HSV infections, 567, 570t, 688, 
689t–690t
for transplant recipients, 520
for viral esophagitis, 252
for viral meningitis, 1278
for VZV infection, 692
valdecoxib, for pain, 44t–45t
valganciclovir
for cytomegalovirus infections, 696
for viral esophagitis, 252
valproate/valproic acid
for bipolar disorder, 1319
dosage and adverse effects of, 1332t
for migraine prevention, 313t
for myoclonus, 335
poisoning, 173t
for posthypoxic myoclonus, 116
for seizures, 1206t, 1212t
for status epilepticus, 117f
Valsalva maneuver, 799t, 1238
Valsalva ratio, 1238
valsartan
for heart failure, 882t
for hypertension, 838t
for myocardial infarction, 848
valvotomy, for mitral stenosis, 816
valvular heart disease, 815–822
echocardiography in, 805–806, 
807f, 809t
murmurs in, 798t
valvuloplasty, for mitral stenosis, 816
vancomycin
for acute bacterial endocarditis, 129t
adverse reactions to, 501t
for bacterial meningitis, 128t, 1275t, 
1276t
for brain abscess, 128t, 1281
for clostridial infection, 641t
for Clostridium difficile infection, 
550–551
for Corynebacterium infection, 602–603
for epidural abscess, 129t
for erythroderma, 127t
for infectious arthritis, 576
for infective endocarditis, 526t–528t, 
528–529
mechanism of/resistance to, 497t
for mixed anaerobic infections, 643
for MRSA infections, 570t
for necrotizing fasciitis, 571t
for osteomyelitis, 578t
for peritonitis, 534
for pneumococcal infections, 582–583
for pneumonia, 924t, 926t
for post-splenectomy sepsis, 126t
for purpura fulminans, 127t
for pyomyositis, 574
for sepsis/septic shock, 77t, 126t
INDEX
1547
for staphylococcal infection, 589, 
590t–591t, 592
for streptococcal infection, 598–599
for toxic shock syndrome, 127t
vancomycin-resistant enterococci 
(VRE), 599
VAP. See ventilator-associated pneumonia
vardenafil, for erectile dysfunction, 1149
varenicline, for smoking cessation, 1372
varicella vaccine, 1352t–1353t, 
1354f–3155f, 1357t
varicella-zoster immune globulin, 693
varicella-zoster vaccine, 520t, 693
varicella-zoster virus (VZV) infection, 
688, 691–693
chickenpox, 688, 691–692
nosocomial, 510
shingles, 691–692
varicocele, 1147–1148
variola major, 194–198, 196t
variola minor, 194–198
vascular dementia, 1213, 1214t, 1216t, 1219
vascular disease
abdominal pain in, 240t
gastrointestinal, 1019
headache in, 308t
malabsorption in, 260t
peripheral, 890–894
skin diseases, 372–373
vascular malformation, myelopathy in, 
1255, 1256f
vascular shunting, anatomic, 229
vascular tone, disorders of, 316
vasculitis, 373, 1078–1082
approach to, 1079–1080, 1080f
of central nervous system, 1079
conditions that mimic, 1081t
cryoglobulinemic, 1079
cutaneous, 373
idiopathic cutaneous, 1079
neuropathy in, 1298
primary vasculitis syndromes, 
1078–1079
renal complications of, 997
secondary vasculitis syndromes, 1079
treatment of, 373, 1080–1082
urticarial, 372–373
vasoconstrictors
for allergic rhinitis, 1064
for heart failure, 884t
vasodilators
for acute renal failure, 958
for aortic regurgitation, 821
for dilated cardiomyopathy, 825
for heart failure, 883–884, 884t
for myocardial infarction, 849–850, 
850t, 853
for pulmonary hypertension, 898
vasopressin
deficiency of, 1112t
for heart failure, 884t
intraarterial, for diverticulosis, 266
for shock, 71, 73t
vasopressin antagonists, for 
hyponatremia, 6–7
vasospasm, in subarachnoid 
hemorrhage, 105
vasospastic disorders, 891–892
VATS. See thoracic surgery, video-assisted
vemurafenib, for melanoma, 430
Venezuelan equine encephalitis, 724t
Venezuelan hemorrhagic fever, 725
venlafaxine, 1325
dosage and adverse effects of, 1326t
for menopausal symptoms, 1157
for pain, 44t–45t
for polyneuropathy, 1297t
venous disease, 892–894
superficial thrombophlebitis, 892
venous insufficiency, chronic, 894
venous insufficiency, chronic, 894
venous thromboembolism, 929
drug-induced, 1386t
ventilation, disorders of, 946–947
ventilation/perfusion lung scan, 896, 930
ventilation/perfusion mismatch, 903
ventilator-associated pneumonia (VAP), 86, 
507–508, 507t, 621, 920, 923, 925
pathogenic mechanisms, 927t
prevention of, 927t
treatment of, 925, 926t
ventilatory function, disturbances in, 
899–901
extraparenchymal, 900t, 901, 901t
obstructive, 899–901, 900t, 901t
parenchymal, 900t, 901, 901t
restrictive, 899–901, 900t, 901t
ventilatory support
in ALS, 1235
in ARDS, 81–82, 82f
for asthma, 911
care of ventilated patient, 37–38
complications of, 86
during COPD exacerbations, 920
for cor pulmonale, 886
for critically ill patient, 36
for hemoptysis, 235
management of mechanically ventilated 
patients, 86
mechanical ventilation, 36
modes of mechanical ventilation, 
83–85, 85t
after nerve agent exposure, 202
in respiratory failure, 83–86, 85t
for shock, 853
weaning from mechanical ventilation, 38
ventricular aneurysm
in myocardial infarction, 853–854
pseudoaneurysm, 854
true, 853
1548
INDEX
ventricular arrhythmia, in myocardial 
infarction, 848
ventricular fibrillation (VF), 868f, 871t
management of, 67–68, 67f
in myocardial infarction, 848–849
ventricular premature beats, 871t
ventricular septal defect (VSD), 798t, 812
ventricular septal rupture, 853
ventricular tachycardia (VT), 867, 868f, 
871t, 873t
hypotensive, 67–68, 67f
in myocardial infarction, 848
in poisoning, 165
verapamil
for angina pectoris, 862
for aortic dissection, 889
for arrhythmias, 876t
for atrial fibrillation, 877
for cluster headache prevention, 314
for hypertension, 838t, 839
for hypertrophic cardiomyopathy, 827
for migraine prevention, 314, 314t
for mitral stenosis, 816
for myocardial infarction, 857
poisoning, 170t
for supraventricular arrhythmias, 849
for tachyarrhythmias, 869t–871t
for unstable angina, 857
for Wolff-Parkinson-White 
syndrome, 877
verruca plana, 364f
verruca vulgaris, 364f
verrucous carcinoma, 431
verruga peruana, 633t, 634–635
vertebral disk herniation
acute, 1254
cervical disk, 304, 307
lumbar disk, 300
vertebral fracture, 301
vertebral metastasis, 301
vertigo, 320, 349
acute prolonged, 322
benign positional, 321
central, 322t, 323–324
pathologic, 321
peripheral, 321–322, 322t
physiologic, 321
provocative tests to reproduce, 320
psychogenic, 322
treatment of, 323t, 324
vesicants, 200–201
vesicle (skin lesion), 365t, 569
vesiculobullous eruptions, 210
vestibular disorder
drug-induced, 1390t
vertigo, 321
vestibular function tests, 321
vestibular neuritis, 322, 322t, 323t, 324
vestibular schwannomas, 322
VF. See ventricular fibrillation
Vibrio cholerae infection, 539–540
Vibrio parahaemolyticus infection, 540
Vibrio vulnificus infection, 130
vidarabine, for HSV infections, 690t
videonystagmography, 321
vildagliptin, for diabetes mellitus, 1142t
vinblastine
for bladder cancer, 461
for lung cancer, 437
toxicity of, 398t
Vincent’s stomatitis, 642
vincristine
for acute lymphoblastic leukemia and 
lymphoblastic lymphoma, 423
for Burkitt’s lymphoma/leukemia, 423
for gastric cancer, 449
for idiopathic thrombocytopenic 
purpura, 390
for lymphoma, 420–421
for multiple myeloma, 426
toxicity of, 398t
vindesine, for lung cancer, 437
vinorelbine
for breast cancer, 446
for lung cancer, 437
toxicity of, 398t
VIPoma, 459–460, 459t
viral disease
animal-borne, rabies, 718–720, 721f
arthropod-borne, 720–727, 723t–724t
diagnosis of, 485, 487, 494
antigen detection, 487
culture, 487, 488t–493t
microscopy, 485, 486f, 487
nucleic acid probes, 487, 494
serology, 487
in HSCT patients, 517–518
rodent-borne, 720–727, 723t–724t
specimen collection and transport, 492t
viral gastroenteritis, diarrhea, 540–541
viral hemorrhagic fevers, 211
as bioweapon, 197t, 199
treatment of, 197t
viral infection
in chronic meningitis, 1289t
lymphadenopathy and, 279t
pleural effusion secondary to, 944
viral respiratory disease, 703
adenovirus infection, 704t, 707–708
coronavirus, 703, 704t, 705
human metapneumovirus infection, 
704t, 706
human RSV, 704t, 705–706
influenza, 699–702, 702t, 704t
antigenic variation, 700
complications of, 700–701
epidemic and emerging problems, 
509
H. influenzae infection, 519t, 608–610
treatment of, 701–702, 702t
INDEX
1549
parainfluenza virus infection, 704t, 
706–707
rhinovirus, 703, 704t
viridans streptococci, 598–599
virilization, 1154–1155
visceral abscess, 535–536
visceral disease, back pain in, 302, 302t
visceral pain, 40, 41t
visceral spasm, 240t
visual acuity, 324
visual field mapping, 324–325, 325f
visual loss, 343
acute, approach to, 324–326
chronic, progressive, 346–349, 346t
transient or sudden, 326–327
vitamins
for alcohol withdrawal, 1339
for alcoholic liver disease, 1054
for ataxia, 1231
reference values for laboratory tests, 
1428t
for vitamin deficiencies, 51t
vitamin A deficiency, 51t
eye disease in, 344
vitamin A supplementation
for head and neck cancer prevention, 
1371
for measles virus infection, 709
vitamin B12 deficiency, 791, 1215, 1255, 1296
anemia in, 379–380, 383
leukopenia in, 386
vitamin C, for lead poisoning, 186t
vitamin C deficiency, 51t
vitamin C supplementation
for macular degeneration, 347
for nephrolithiasis, 1000t
vitamin D, for cadmium poisoning, 185t
vitamin D deficiency, 51t, 1164, 
1170–1171
vitamin D supplementation
for hypocalcemia, 1165
for osteomalacia, 1171
for osteoporosis, 1169
for primary biliary cirrhosis, 1055
for primary sclerosing cholangitis, 
1026
for psoriasis, 367
vitamin E deficiency, 51t, 1228
vitamin E supplementation
for macular degeneration, 347
for menopausal symptoms, 1157
vitamin K deficiency, 51t, 390–391
vitamin K supplementation
for vitamin K deficiency, 391
for warfarin reversal, 392
vitiligo, 364f
vitreous detachment, 326
vitreous hemorrhage, 326
Vogt-Koyanagi-Harada syndrome, 1290t
volume regulation, 4t
volume status, assessment of, 5f
vomiting. See nausea and vomiting
von Hippel–Lindau disease, 462
von Willebrand disease, 390–391
voriconazole, 744–745
for aspergillosis, 750t
for candidiasis, 747
for fusariosis, 759
for scedosporiosis, 759
vorinostat, toxicity of, 399t
VRE. See vancomycin-resistant 
enterococci
VSD. See ventricular septal defect
VT. See ventricular tachycardia
vulvovaginal infection, candidiasis, 553–
554, 746–747
VX gas, 172t, 201–202
VZV infection. See varicella-zoster virus 
infection
W
Waldenström’s macroglobulinemia, 977t
warfarin
for antiphospholipid antibody 
syndrome, 1077
for atrial fibrillation, 877, 1121
for deep venous thrombosis prevention, 
893
for dilated cardiomyopathy, 825
for mitral stenosis, 816
for pulmonary hypertension, 898
for renal vein thrombosis, 992
for stroke prevention, 102, 102t
for thrombotic disorders, 392, 394
for venous disease, 893
for venous thromboembolism, 932
warts, 371
genital, 568–569
wasp sting, 150–151
water requirements, 46
watery diarrhea, 537t
weakness, 214, 328–332
approach to, 328, 331, 331f
causes of, 329t
diagnostic evaluation of, 1307f–1308f
site of responsible lesion, 329t, 331
weaning, from mechanical ventilation, 38
weaponization, 191
Weber test, 349
Wegener’s granulomatosis, 977t, 1078
weight, ideal weight for height, 47t
weight loss, 218–221, 220t
causes of, 219t, 220
drug-induced, 219t
for hypertension, 836
in malnutrition, 47–48
for metabolic syndrome, 843
for obesity, 1135–1137
for sleep apnea, 948
treatment for, 221
1550
INDEX
Weil’s syndrome, 667–668
Wenckebach, 866, 866f
Wernicke’s aphasia, 335, 336t
Wernicke’s encephalopathy, 1337, 1339
West Nile virus (WNV) encephalitis, 722, 
723t, 1278–1279
western equine encephalitis, 724t
wet mount, 485
WFNS Scale. See World Federation of 
Neurosurgical Societies Scale
wheal, 365t
whiplash injury, 304
Whipple’s disease, 1097
Whipple’s triad, 122, 123f, 459
whitlow, herpetic, 686, 690t
WHO classification
of AML, 404t
of lymphoid malignancy, 414
whole blood transfusion, 51
whole-body radiation exposure, 204, 206
whole-bowel irrigation, 178t, 181t, 190
whooping cough. See pertussis
widow spider bite, 149
Wilson’s disease, 1184–1185
winking owl sign, 134
Winterbottom’s sign, 775
Winter’s formula, 19
Wiskott-Aldrich syndrome, 1069
withdrawal of care, 40
withdrawal syndrome, 160t–161t, 1325
WNV encephalitis. See West Nile virus 
encephalitis
Wolbachia endosymbiont, 785
Wolff-Parkinson-White (WPW) syndrome, 
804t, 867, 868f, 877–878
women’s health, 1375–1377
Alzheimer’s disease, 1375
autoimmune disease, 1376
coronary heart disease, 1375
diabetes mellitus, 1375–1376
HIV infection, 1376
hypertension, 1376
nicotine addiction, 1377
obesity, 1376
osteoporosis, 1376
pharmacology, 1376–1377
psychiatric disease, 1377
sleep disorders, 1377
substance abuse, 1377
violence, 1377
Wood’s light examination, 366
World Federation of Neurosurgical 
Societies (WFNS) Scale, for 
subarachnoid hemorrhage, 104t
wound infection
botulism, 638
clostridial, 639
specimen collection and transport, 491t
surgical, 507t, 508
WPW syndrome. See Wolff-Parkinson-
White syndrome
wrist, muscles and innervation of, 
1190t–1191t
Wuchereria bancrofti infection. See 
filariasis
X
xanthelasma, 364f, 1175
xanthoma, 1175, 1179
XDR tuberculosis. See extensively drug-
resistant tuberculosis
xerostomia, 1077
D-Xylose absorption test, 257
D-Xylose urinary excretion test, 1030
Y
yaws, 666–667
yellow fever, 130, 726
yellow fever vaccine, 1359t
yellow jacket sting, 150–151
Yersinia pestis. See plague
yersiniosis, diarrhea, 548
Z
zafirlukast
for asthma, 910
for urticaria/angioedema, 1063
zaleplon
for insomnia, 340
poisoning, 175t
zanamivir, for influenza, 701, 702t
zidovudine (AZT, azidothymidine)
for adult T cell leukemia/lymphoma, 
423
for HIV/AIDS, 735t
Zieve’s syndrome, 1052
zinc deficiency, 51t
zinc supplementation
for hepatic encephalopathy, 1060
for macular degeneration, 347
for Wilson’s disease, 1184–1185
ziprasidone
dosage and adverse effects of, 
1331t
for schizophrenia, 1319
zoledronate
for hypercalcemia, 136, 480, 1163t
for osteoporosis, 1169
Zollinger-Ellison syndrome, 459, 459t, 
1009–1011, 1010t
zolmitriptan, for migraine, 310t, 312t
zolpidem
for insomnia, 340
poisoning, 175t
zonisamide
poisoning, 173t
for seizures, 1210t
zoster ophthalmicus, 691–692
GLOSSARY
JVP
jugular venous pressure
LA
left atrium
LAD
left axis deviation
LBBB
left bundle branch block
LDH
lactate dehydrogenase
LDL
low-density lipoprotein
LFT
liver function test
LLQ
left lower quadrant
LP
lumbar puncture
LUQ
left upper quadrant
LV
left ventricle
MI
myocardial infarction
MRI
magnetic resonance 
imaging
NPO
nothing by mouth
NSAIDs
nonsteroidal
antiinflammatory
drugs
P2
pulmonic second sound
PaO2
partial pressure of O2 in 
arterial blood
PAO2
partial pressure of O2 in 
alveolar blood 
PCR
polymerase chain 
reaction
PFTs
pulmonary function tests
PMNs
polymorphonuclear cells 
or leukocytes
PO
by mouth
PPD
purified protein 
derivative, skin test 
for tuberculosis
prn
as needed
pt/pts
patient/patients
PT
prothrombin time
PTT
partial thromboplastin 
time
qAM
every morning
qd
every day
qh
every hour
qhs
every bedtime
qid
four times daily
qod
every other day
R
respiratory rate
RA
rheumatoid arthritis
RBBB
right bundle branch 
block
RBC
red blood (cell) count
RLQ
right lower quadrant
RUQ
right upper quadrant
RV
right ventricle
S1 . . . S4
heart sounds, 1st to 4th
SARS
severe acute respiratory 
syndrome
SC
subcutaneous
SL
sublingual
SLE
systemic lupus 
erythematosus
Sx
signs and symptoms
SVC
superior vena cava
TIA
transient ischemic attack
tid
three times daily
tiw
thrice a week
TLC
total lung capacity
TNF
tumor necrosis factor
UA
urinalysis
URI
upper respiratory 
infection
UTI
urinary tract infection
UV
ultraviolet
VDRL
test for syphilis
VPC
ventricular premature 
contractions
VZV
varicella-zoster virus
WBC
white blood (cell) count
